data_1l3n_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1l3n _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.444 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.5 t -166.22 -41.08 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 127.159 2.184 . . . . 10.0 112.938 178.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -119.37 137.29 53.83 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.244 -1.761 . . . . 10.0 106.244 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -136.73 145.21 44.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -134.99 150.04 29.59 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.236 0 N-CA-C 107.003 -1.481 . . . . 10.0 107.003 174.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.03 129.19 47.56 Favored 'General case' 0 CA--C 1.512 -0.499 0 C-N-CA 126.938 2.095 . . . . 10.0 105.457 168.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.1 m -98.78 121.89 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 168.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -97.16 149.23 22.23 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 119.095 0.861 . . . . 10.0 109.046 177.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.1 tttt -159.29 160.35 35.08 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 108.432 -0.951 . . . . 10.0 108.432 169.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.35 -53.68 0.06 OUTLIER Glycine 0 C--N 1.332 0.35 0 N-CA-C 111.684 -0.566 . . . . 10.0 111.684 170.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -74.1 -45.86 46.44 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.36 -67.75 0.54 Allowed Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.031 -1.441 . . . . 10.0 110.568 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -57.11 -42.94 58.13 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.451 2.101 . . . . 10.0 110.41 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.2 t -63.94 97.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 106.522 -1.658 . . . . 10.0 106.522 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -116.28 118.6 33.21 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.129 -1.434 . . . . 10.0 107.129 169.415 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -99.17 152.95 19.68 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 109.931 -1.268 . . . . 10.0 109.931 174.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -156.47 83.69 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 -172.166 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 tp -85.35 157.21 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 C-N-CA 125.166 1.387 . . . . 10.0 111.016 176.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.406 ' HB2' ' CD1' ' A' ' 32' ' ' TRP . 5.1 m120 -139.1 99.5 3.78 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 127.567 2.347 . . . . 10.0 106.621 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 m-30 -99.07 102.85 14.68 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 105.194 -2.15 . . . . 10.0 105.194 174.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -117.67 132.48 56.48 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 120.409 -0.516 . . . . 10.0 111.591 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -104.36 107.99 19.18 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.701 -1.222 . . . . 10.0 107.701 172.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.2 pttp -54.53 -40.84 69.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 122.955 0.502 . . . . 10.0 110.65 174.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -146.37 172.92 12.78 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 104.937 -2.246 . . . . 10.0 104.937 168.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 86.8 p -69.12 -20.8 64.05 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 124.13 0.972 . . . . 10.0 109.576 174.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -93.89 -3.06 52.42 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.822 -0.627 . . . . 10.0 111.119 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.18 144.8 18.18 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 173.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -61.36 149.7 88.29 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 N-CA-C 106.902 -1.999 . . . . 10.0 106.902 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.7 t -79.0 120.96 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 N-CA-C 104.754 -2.313 . . . . 10.0 104.754 176.178 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.6 tttt -83.24 113.26 20.56 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 105.558 -2.015 . . . . 10.0 105.558 169.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.7 m -97.31 59.14 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 C-N-CA 125.774 1.63 . . . . 10.0 107.975 -170.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.406 ' CD1' ' HB2' ' A' ' 19' ' ' ASN . 14.8 p90 -84.7 171.85 12.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.167 -0.679 . . . . 10.0 109.167 -171.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.12 175.25 38.3 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 119.823 -1.179 . . . . 10.0 112.489 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.3 p -149.03 85.18 1.46 Allowed 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 121.066 0.46 . . . . 10.0 111.972 -169.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -76.83 147.19 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 107.664 -1.235 . . . . 10.0 107.664 174.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.99 156.14 46.77 Favored 'General case' 0 C--O 1.232 0.157 0 O-C-N 124.102 0.876 . . . . 10.0 110.015 167.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.22 2.86 48.16 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 124.043 0.83 . . . . 10.0 114.52 177.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.3 mp -87.75 176.64 7.3 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.542 1.137 . . . . 10.0 108.778 -177.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -91.06 172.71 8.38 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 165.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -64.33 176.02 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.226 1.01 . . . . 10.0 110.889 -172.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.63 175.46 48.42 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 124.137 0.875 . . . . 10.0 111.581 167.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.7 mt -62.24 147.58 47.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.332 -0.511 . . . . 10.0 110.173 171.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -133.59 147.03 51.48 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.637 0.775 . . . . 10.0 110.678 176.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -36.14 112.89 0.14 Allowed Glycine 0 CA--C 1.526 0.736 0 CA-C-O 116.105 -2.497 . . . . 10.0 113.445 164.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -137.08 107.65 6.53 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 121.522 2.661 . . . . 10.0 111.916 170.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.453 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -148.17 -178.99 6.6 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 113.783 1.031 . . . . 10.0 113.783 -175.442 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.7 p -91.5 -47.59 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 127.554 2.342 . . . . 10.0 114.506 -169.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 57.1 161.96 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 125.498 1.519 . . . . 10.0 112.431 -169.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -78.01 -67.85 0.69 Allowed 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.944 -0.571 . . . . 10.0 109.862 -176.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -78.63 146.27 34.21 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 119.954 -0.699 . . . . 10.0 109.432 -171.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -75.74 -28.42 61.09 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 108.905 -1.678 . . . . 10.0 108.905 169.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.3 145.68 1.62 Allowed 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.746 1.26 . . . . 10.0 113.995 -175.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -135.8 16.06 3.33 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 113.679 -1.6 . . . . 10.0 110.453 -178.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -58.08 -36.45 72.86 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 119.181 0.901 . . . . 10.0 112.477 -169.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.07 -17.71 58.54 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 111.778 0.288 . . . . 10.0 111.778 178.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 97.85 84.18 1.74 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.107 -1.597 . . . . 10.0 109.107 -173.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 94.2 m 48.81 57.13 6.71 Favored 'General case' 0 N--CA 1.464 0.228 0 C-N-CA 124.305 1.042 . . . . 10.0 111.391 175.268 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -157.66 -54.61 0.07 Allowed 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.6 p -54.73 -30.26 55.73 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 124.121 0.968 . . . . 10.0 111.023 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.26 -38.47 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 127.977 2.511 . . . . 10.0 113.995 167.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.75 170.06 20.17 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -79.29 -167.13 0.47 Allowed 'Trans proline' 0 N--CA 1.439 -1.679 0 N-CA-C 106.377 -2.201 . . . . 10.0 106.377 166.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.452 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.4 m170 -83.32 59.07 4.82 Favored 'General case' 0 CA--C 1.537 0.457 0 O-C-N 120.561 -1.337 . . . . 10.0 110.097 -175.763 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -76.61 51.66 0.76 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.6 1.191 . . . . 10.0 112.587 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -56.94 149.72 42.7 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 125.601 1.561 . . . . 10.0 111.008 168.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -67.96 -48.04 1.56 Allowed 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.652 2.235 . . . . 10.0 111.401 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.92 54.09 0.98 Allowed 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.743 -0.598 . . . . 10.0 111.103 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.6 t -58.63 100.85 0.07 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.048 0.939 . . . . 10.0 110.111 -174.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtt-85 -113.78 -90.47 0.52 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 105.857 -1.905 . . . . 10.0 105.857 -177.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -149.42 144.59 26.46 Favored 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 109.334 -0.617 . . . . 10.0 109.334 168.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -51.5 119.78 4.48 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 119.714 -0.794 . . . . 10.0 109.929 168.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.0 -129.48 1.97 Allowed Glycine 0 N--CA 1.451 -0.359 0 N-CA-C 107.513 -2.235 . . . . 10.0 107.513 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.53 -143.29 5.84 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 118.182 0.991 . . . . 10.0 111.03 169.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -68.83 1.26 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 CA-C-N 120.075 1.937 . . . . 10.0 110.228 168.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 31.2 mmtp -93.9 -15.96 24.47 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-O 117.844 -1.074 . . . . 10.0 110.494 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -127.61 161.38 28.98 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 119.255 0.934 . . . . 10.0 109.5 -171.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -84.28 -28.91 26.83 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -78.94 -11.52 60.0 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 124.465 1.106 . . . . 10.0 112.059 -169.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.4 ptp180 -33.45 138.46 0.07 Allowed 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 126.415 1.886 . . . . 10.0 114.596 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.4 m170 -69.5 177.17 3.03 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.562 -0.533 . . . . 10.0 109.562 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 p -72.85 39.32 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 125.525 1.53 . . . . 10.0 114.228 -172.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 48.03 0.04 OUTLIER Glycine 0 CA--C 1.524 0.655 0 O-C-N 120.597 -1.315 . . . . 10.0 111.526 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -85.0 102.81 13.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 104.92 -2.252 . . . . 10.0 104.92 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.7 mt -74.62 -32.19 62.23 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 107.073 -1.454 . . . . 10.0 107.073 169.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.82 -104.35 3.04 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 109.586 -1.406 . . . . 10.0 109.586 168.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 39.9 m-20 -126.4 105.79 9.02 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 126.743 2.017 . . . . 10.0 106.511 -167.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.63 134.67 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 123.411 0.684 . . . . 10.0 109.566 173.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.58 122.43 26.49 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.524 2.73 . . . . 10.0 112.809 -167.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.01 133.99 34.86 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.49 0.716 . . . . 10.0 109.255 169.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -60.76 171.53 1.15 Allowed 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.459 0.703 . . . . 10.0 110.001 168.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 pttt -47.54 -34.22 7.37 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.741 1.617 . . . . 10.0 111.311 171.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.8 -7.25 59.36 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 123.655 0.782 . . . . 10.0 111.166 -176.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.86 1.22 77.09 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.77 -0.932 . . . . 10.0 110.77 -175.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -77.19 103.87 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 -176.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.43 114.37 28.32 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 107.809 -1.182 . . . . 10.0 107.809 169.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -85.44 127.96 34.57 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 107.539 -1.282 . . . . 10.0 107.539 169.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 56.9 t -110.11 132.04 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 106.389 -1.708 . . . . 10.0 106.389 170.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -154.52 71.28 0.82 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.994 0.918 . . . . 10.0 108.955 170.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -114.62 159.01 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 105.603 -1.999 . . . . 10.0 105.603 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -130.95 142.44 50.35 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.854 0.861 . . . . 10.0 110.074 172.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -131.25 133.66 45.65 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.266 1.027 . . . . 10.0 109.683 -172.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 62.3 p -110.96 57.09 0.62 Allowed 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.373 1.869 . . . . 10.0 108.63 174.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 96.0 t -141.77 -61.73 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.14 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 -177.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.279 0.0 OUTLIER -60.68 170.94 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 N-CA-C 113.229 0.826 . . . . 10.0 113.229 174.83 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.6 m -145.5 111.97 5.8 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 121.498 -0.751 . . . . 10.0 109.286 175.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.2 tt -49.05 -44.89 42.11 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 126.09 1.756 . . . . 10.0 109.955 177.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -143.72 160.8 40.08 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 106.465 -1.679 . . . . 10.0 106.465 169.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.32 -95.96 0.2 Allowed Glycine 0 C--N 1.334 0.418 0 N-CA-C 109.349 -1.5 . . . . 10.0 109.349 -177.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -119.54 -51.69 2.28 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.265 1.826 . . . . 10.0 107.886 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -73.51 -37.31 65.72 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.681 -1.229 . . . . 10.0 107.681 -171.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 t 47.47 59.27 4.22 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.773 1.629 . . . . 10.0 108.078 169.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.2 pt -74.86 65.77 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 O-C-N 124.622 1.201 . . . . 10.0 110.121 -172.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.7 mm -110.64 -68.34 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 127.808 2.443 . . . . 10.0 108.33 -176.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.68 51.8 4.06 Favored Glycine 0 CA--C 1.531 1.092 0 O-C-N 121.221 -0.925 . . . . 10.0 112.086 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.4 ptm180 -112.36 162.16 15.85 Favored 'General case' 0 CA--C 1.53 0.173 0 C-N-CA 127.213 2.205 . . . . 10.0 107.168 176.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -109.61 104.72 13.79 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 118.565 0.621 . . . . 10.0 109.513 -179.116 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -64.47 131.02 45.94 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 106.695 -1.594 . . . . 10.0 106.695 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.2 t -122.5 132.59 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.7 p -94.56 122.35 45.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 105.829 -1.915 . . . . 10.0 105.829 166.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 6.9 m-70 -100.92 162.78 12.66 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.711 0.767 . . . . 10.0 112.631 174.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -64.58 -56.16 15.76 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.48 -0.782 . . . . 10.0 109.316 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -98.8 165.49 11.75 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 119.474 -0.89 . . . . 10.0 112.076 -168.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.7 147.15 53.04 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.801 -1.545 . . . . 10.0 107.792 169.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.453 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 6.7 m-20 -78.45 163.49 25.57 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.86 -0.793 . . . . 10.0 108.86 172.499 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.15 -10.38 59.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 113.736 -1.575 . . . . 10.0 110.781 168.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.5 mt 43.02 45.92 4.61 Favored 'General case' 0 C--N 1.343 0.32 0 C-N-CA 124.826 1.25 . . . . 10.0 109.856 -168.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.19 -21.83 44.01 Favored Glycine 0 CA--C 1.529 0.968 0 CA-C-N 113.713 -1.585 . . . . 10.0 113.728 170.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -77.48 0.78 21.45 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 115.543 1.682 . . . . 10.0 115.543 -165.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.89 -36.59 88.23 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.831 -0.907 . . . . 10.0 110.831 177.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.23 39.82 98.34 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 108.31 -1.916 . . . . 10.0 108.31 -169.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -128.39 164.46 22.64 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -54.79 -47.98 73.3 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.131 -0.941 . . . . 10.0 108.62 174.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -55.08 -39.61 69.47 Favored 'General case' 0 C--N 1.344 0.347 0 C-N-CA 123.283 0.633 . . . . 10.0 111.387 171.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.305 1.8 p -58.73 -36.06 73.7 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-O 118.138 -0.934 . . . . 10.0 111.733 -173.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.1 t -83.06 3.31 30.94 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.315 0.962 . . . . 10.0 112.541 178.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -118.6 -81.17 0.62 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.669 1.588 . . . . 10.0 110.511 -174.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.8 p -108.52 9.71 27.38 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 121.067 1.758 . . . . 10.0 111.43 175.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.1 -79.83 1.87 Allowed Glycine 0 C--N 1.342 0.891 0 O-C-N 120.708 -1.245 . . . . 10.0 110.0 176.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 178.71 36.87 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.684 1.993 . . . . 10.0 109.347 178.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.75 -14.29 61.96 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 123.832 0.853 . . . . 10.0 111.978 -169.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.02 -170.05 54.44 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 109.146 -1.582 . . . . 10.0 109.146 -169.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.4 m -55.06 165.0 0.74 Allowed 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 124.295 1.038 . . . . 10.0 112.667 -177.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -80.96 114.32 19.76 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 167.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.413 ' N ' ' CD2' ' A' ' 144' ' ' LEU . 1.1 mm? -84.5 -45.29 12.78 Favored 'General case' 0 C--N 1.333 -0.149 0 N-CA-C 108.396 -0.965 . . . . 10.0 108.396 -176.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -147.29 157.04 43.44 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 p -154.28 164.1 39.11 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 116.44 -0.345 . . . . 10.0 110.762 -176.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.86 150.8 22.43 Favored Glycine 0 C--N 1.336 0.531 0 C-N-CA 124.246 0.927 . . . . 10.0 110.916 -173.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.73 148.4 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 104.34 -2.467 . . . . 10.0 104.34 175.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 83.9 mt -76.66 -86.79 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 122.649 1.214 . . . . 10.0 109.169 -171.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.18 25.4 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.744 1.64 . . . . 10.0 115.257 170.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER 63.8 152.64 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 C-N-CA 124.283 1.033 . . . . 10.0 111.413 -173.335 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -113.36 -49.05 2.92 Favored 'General case' 0 CA--C 1.51 -0.592 0 O-C-N 120.456 -1.403 . . . . 10.0 110.316 169.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.433 -1.316 0 N-CA-C 106.047 -1.834 . . . . 10.0 106.047 -178.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.941 0 CA-C-O 118.01 -0.995 . . . . 10.0 108.886 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.5 t -95.15 -45.27 7.27 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.967 0.907 . . . . 10.0 111.952 -175.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.7 tttp -111.09 133.83 53.16 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.328 1.051 . . . . 10.0 109.011 176.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 166.82 23.73 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.12 1.368 . . . . 10.0 108.408 171.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.49 175.19 10.59 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 123.046 0.538 . . . . 10.0 109.767 175.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -149.45 103.85 3.32 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 106.346 -1.724 . . . . 10.0 106.346 166.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 22.7 m -83.13 111.84 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 108.834 -0.802 . . . . 10.0 108.834 170.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.96 143.45 26.85 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.056 -1.09 . . . . 10.0 108.056 175.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 46.5 tttt -163.73 163.76 24.01 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 108.097 -1.075 . . . . 10.0 108.097 170.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.61 -50.76 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 111.803 -0.519 . . . . 10.0 111.803 169.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.24 -47.16 20.9 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.106 -1.442 . . . . 10.0 107.106 -169.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.18 -61.1 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.919 -1.491 . . . . 10.0 111.785 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -62.74 -39.15 44.65 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 122.642 2.228 . . . . 10.0 110.89 170.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 68.1 t -77.6 115.03 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.553 1.141 . . . . 10.0 108.255 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -147.46 139.05 23.95 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 123.208 0.318 . . . . 10.0 110.605 166.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.66 153.53 16.79 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 110.15 -1.18 . . . . 10.0 110.15 169.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 4.0 mt -138.93 59.41 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 106.179 -1.786 . . . . 10.0 106.179 -176.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.1 mm -78.86 136.72 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-N 115.221 -0.9 . . . . 10.0 109.205 -169.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -108.71 117.13 33.39 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 127.329 2.252 . . . . 10.0 108.076 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -101.15 111.18 23.32 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.256 -1.387 . . . . 10.0 107.256 175.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -118.03 133.26 56.08 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-O 121.358 0.599 . . . . 10.0 112.068 172.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -121.72 113.15 19.31 Favored 'General case' 0 N--CA 1.446 -0.646 0 N-CA-C 105.519 -2.03 . . . . 10.0 105.519 170.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 39.2 pttt . . . . . 0 CA--C 1.531 0.223 0 C-N-CA 124.3 1.04 . . . . 10.0 110.725 -175.114 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.038 0 N-CA-C 109.893 -1.283 . . . . 10.0 109.893 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -60.88 136.63 67.19 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 CA-C-N 119.735 1.767 . . . . 10.0 109.537 169.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.7 t -79.86 97.41 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 104.038 -2.579 . . . . 10.0 104.038 168.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . 0.266 71.2 tttt -82.84 112.63 19.83 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 172.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -95.48 101.45 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 C-N-CA 126.952 2.101 . . . . 10.0 105.855 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -121.23 160.94 22.82 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 112.325 0.491 . . . . 10.0 112.325 173.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.87 -152.48 24.14 Favored Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 170.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 40.1 t -155.72 151.49 27.41 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 120.211 -0.596 . . . . 10.0 110.321 177.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -100.99 122.98 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 N-CA-C 107.433 -1.321 . . . . 10.0 107.433 165.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 20.9 ptmt -105.38 139.89 39.32 Favored 'General case' 0 N--CA 1.453 -0.296 0 O-C-N 123.891 0.744 . . . . 10.0 108.995 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.18 -5.52 15.48 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.417 1.008 . . . . 10.0 113.269 176.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -68.21 176.76 2.57 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 118.366 1.083 . . . . 10.0 111.09 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -108.54 161.03 15.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.28 -2.118 . . . . 10.0 105.28 165.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -52.03 160.43 0.73 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.636 1.174 . . . . 10.0 111.725 -169.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.84 -179.98 34.38 Favored Glycine 0 N--CA 1.447 -0.602 0 O-C-N 121.549 -0.719 . . . . 10.0 111.486 168.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.9 mp -68.62 149.01 49.64 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.735 1.614 . . . . 10.0 110.446 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -148.75 148.63 30.21 Favored 'General case' 0 C--O 1.233 0.198 0 C-N-CA 123.42 0.688 . . . . 10.0 112.432 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.4 121.29 0.2 Allowed Glycine 0 C--N 1.339 0.748 0 C-N-CA 127.941 2.686 . . . . 10.0 113.038 165.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -151.64 110.92 3.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 119.088 1.444 . . . . 10.0 110.044 167.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.516 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.2 OUTLIER -144.24 174.3 11.01 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-O 121.373 0.606 . . . . 10.0 111.888 178.131 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 3.2 t -114.42 86.75 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 CA-C-N 112.599 -2.091 . . . . 10.0 107.981 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -67.66 149.99 49.31 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 124.876 1.27 . . . . 10.0 109.898 174.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -71.65 -59.6 2.67 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.136 -1.393 . . . . 10.0 110.412 -170.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -79.09 136.59 37.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 120.891 -0.323 . . . . 10.0 110.237 -171.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -54.75 -50.42 57.99 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 108.304 -1.918 . . . . 10.0 108.304 169.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -24.12 124.0 0.04 OUTLIER 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 128.069 2.547 . . . . 10.0 113.737 -173.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.92 11.99 2.65 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.63 -175.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.41 -40.35 59.13 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 126.049 1.74 . . . . 10.0 111.389 -170.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.51 -20.73 46.51 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 124.703 1.201 . . . . 10.0 113.209 178.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.92 82.83 1.67 Allowed Glycine 0 CA--C 1.528 0.864 0 C-N-CA 124.67 1.129 . . . . 10.0 110.624 -178.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.9 m 53.22 21.1 2.09 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.382 1.473 . . . . 10.0 112.733 176.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -111.56 -42.29 3.89 Favored 'General case' 0 N--CA 1.437 -1.089 0 O-C-N 120.613 -1.304 . . . . 10.0 108.092 -168.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 70.3 m -92.14 -11.05 36.67 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 117.831 -1.08 . . . . 10.0 113.541 -168.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.35 2.01 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 128.597 2.759 . . . . 10.0 117.14 -174.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.2 119.24 2.25 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 109.482 -1.447 . . . . 10.0 109.482 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -76.52 64.12 7.31 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.483 2.789 . . . . 10.0 111.02 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 22.5 m170 69.53 53.62 0.41 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 128.752 2.821 . . . . 10.0 110.132 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -73.95 52.08 0.42 Allowed 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.306 1.042 . . . . 10.0 112.997 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -65.49 153.91 89.2 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 126.823 2.049 . . . . 10.0 111.62 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.8 -43.94 2.34 Favored 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 123.079 2.519 . . . . 10.0 111.955 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 67.3 mt -78.85 53.77 1.44 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.718 0.807 . . . . 10.0 110.363 -177.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.6 p -58.39 102.41 0.11 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.823 1.249 . . . . 10.0 110.337 -172.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 mtp85 -132.48 -87.88 0.44 Allowed 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 -171.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -145.13 155.61 43.41 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 121.689 0.757 . . . . 10.0 109.444 168.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -63.05 120.7 11.93 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 105.592 -2.003 . . . . 10.0 105.592 163.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -140.29 -136.44 3.34 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 107.602 -2.199 . . . . 10.0 107.602 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.446 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -175.36 -166.37 32.91 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 177.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.11 10.12 0.42 Allowed 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.607 1.538 . . . . 10.0 109.938 166.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.446 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.0 mmtt -97.28 -25.67 15.18 Favored 'General case' 0 N--CA 1.44 -0.927 0 C-N-CA 124.75 1.22 . . . . 10.0 107.818 173.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . 0.415 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 23.1 m-20 -120.69 158.12 28.15 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.488 -1.671 . . . . 10.0 106.488 -169.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -80.66 -34.11 35.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.776 -1.194 . . . . 10.0 107.776 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -78.31 1.6 21.24 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 125.939 1.696 . . . . 10.0 113.311 -165.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -40.24 144.18 0.24 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.037 1.735 . . . . 10.0 111.694 174.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.4 m170 -61.52 -58.03 9.76 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-O 120.989 0.424 . . . . 10.0 110.425 -175.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.2 p -174.2 -69.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.457 -0.104 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 172.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.7 62.22 0.37 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 109.478 -1.449 . . . . 10.0 109.478 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -100.5 95.52 6.78 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 103.878 -2.638 . . . . 10.0 103.878 168.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.54 -17.87 64.81 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.694 0.679 . . . . 10.0 111.454 -171.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 107.24 -103.08 1.92 Allowed Glycine 0 N--CA 1.438 -1.228 0 N-CA-C 106.08 -2.808 . . . . 10.0 106.08 -176.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -147.65 139.11 23.78 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 -178.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 28.5 m -106.82 134.45 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.243 0 N-CA-C 105.914 -1.884 . . . . 10.0 105.914 169.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.2 t -109.13 126.21 52.99 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.527 -0.546 . . . . 10.0 109.527 -173.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.42 132.09 37.05 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 122.9 0.48 . . . . 10.0 110.773 -176.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -60.69 168.86 2.05 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 166.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -50.3 -29.26 9.35 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 126.387 1.875 . . . . 10.0 111.414 173.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -78.06 -11.88 59.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.967 0.507 . . . . 10.0 110.701 -177.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.29 20.59 48.34 Favored Glycine 0 C--N 1.338 0.694 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -103.66 107.31 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.838 0 C-N-CA 127.13 2.172 . . . . 10.0 106.115 -178.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.95 125.29 50.79 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 108.883 -0.784 . . . . 10.0 108.883 171.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -79.37 135.0 36.59 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.612 1.165 . . . . 10.0 109.807 175.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.26 129.83 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 127.145 2.178 . . . . 10.0 106.436 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.2 p -158.69 57.4 0.44 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.277 0.944 . . . . 10.0 112.726 176.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.4 152.38 12.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.954 0.902 . . . . 10.0 109.554 -169.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -99.27 112.21 24.42 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 10.0 109.708 167.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -79.13 71.41 5.62 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 104.89 -2.263 . . . . 10.0 104.89 169.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.09 54.37 2.75 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 127.011 2.124 . . . . 10.0 105.416 -174.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.5 t -148.0 -51.99 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 125.817 1.647 . . . . 10.0 109.393 -168.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.322 1.2 pp -113.37 -178.8 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 126.203 1.801 . . . . 10.0 112.683 -172.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 61.2 m -146.94 151.84 37.67 Favored 'General case' 0 C--O 1.232 0.172 0 O-C-N 121.052 -1.03 . . . . 10.0 110.78 -178.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 81.9 mt -70.39 -33.85 71.88 Favored 'General case' 0 N--CA 1.458 -0.047 0 C-N-CA 124.271 1.028 . . . . 10.0 110.891 -177.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 108.866 -0.79 . . . . 10.0 108.866 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 39.8 t . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 113.581 0.956 . . . . 10.0 113.581 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -71.19 -7.1 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 113.789 1.033 . . . . 10.0 113.789 -174.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.7 mm -52.14 127.71 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 109.17 -0.678 . . . . 10.0 109.17 173.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.78 -25.5 11.74 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.383 -0.687 . . . . 10.0 111.383 -175.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 13.3 mtp-105 -72.05 161.8 30.37 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 119.094 1.447 . . . . 10.0 109.526 -169.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -111.03 131.77 54.78 Favored 'General case' 0 CA--C 1.514 -0.412 0 C-N-CA 124.53 1.132 . . . . 10.0 109.652 -167.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 26.4 mt -104.64 140.38 38.11 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.674 -0.861 . . . . 10.0 108.674 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 85.5 t -134.41 125.81 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.884 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 -175.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.3 p -90.35 129.02 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.772 -1.566 . . . . 10.0 106.772 167.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.8 m170 -106.54 157.12 17.91 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.076 1.139 . . . . 10.0 114.076 179.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -50.63 -51.84 45.18 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.667 1.587 . . . . 10.0 110.906 176.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -115.67 167.87 10.53 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-N 118.581 0.628 . . . . 10.0 111.593 -169.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.13 150.17 49.52 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.744 -1.116 . . . . 10.0 110.022 177.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.516 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.6 OUTLIER -79.16 135.16 36.73 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.204 1.002 . . . . 10.0 110.903 171.9 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -79.39 -15.83 57.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 124.621 1.201 . . . . 10.0 110.541 167.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 80.0 mt 58.86 46.11 14.37 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.234 1.014 . . . . 10.0 111.667 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.34 -51.76 1.24 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 110.22 -1.152 . . . . 10.0 110.22 173.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . 0.415 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -82.21 48.77 1.3 Allowed 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 117.583 0.691 . . . . 10.0 112.099 -175.7 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.13 -38.52 5.67 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 108.648 -1.781 . . . . 10.0 108.648 169.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.54 33.26 16.95 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 178.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -130.61 165.08 23.55 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 105.83 -1.915 . . . . 10.0 105.83 168.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -50.38 -43.9 54.64 Favored 'General case' 0 N--CA 1.425 -1.724 0 CA-C-O 121.863 0.84 . . . . 10.0 108.796 171.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -65.7 -35.36 80.54 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-O 117.903 -1.046 . . . . 10.0 112.929 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 44.0 p -54.49 -46.28 73.39 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 120.987 1.721 . . . . 10.0 110.037 171.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -78.47 -13.65 59.74 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 118.11 -0.948 . . . . 10.0 113.162 -174.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.1 ttmm -103.92 -50.85 3.29 Favored 'General case' 0 N--CA 1.443 -0.778 0 C-N-CA 126.518 1.927 . . . . 10.0 112.51 -174.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 19.3 p -137.21 8.41 2.93 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 119.683 1.128 . . . . 10.0 113.658 174.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 88.23 20.56 48.65 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-O 118.577 -1.124 . . . . 10.0 113.215 174.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 6.9 m120 56.09 17.35 2.64 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 119.108 1.454 . . . . 10.0 112.244 -176.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.43 -11.69 58.43 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.007 0.923 . . . . 10.0 112.128 -174.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.97 -160.46 48.41 Favored Glycine 0 N--CA 1.441 -0.973 0 N-CA-C 111.104 -0.798 . . . . 10.0 111.104 168.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.8 m -51.6 125.27 14.26 Favored 'General case' 0 N--CA 1.439 -1.015 0 C-N-CA 124.622 1.169 . . . . 10.0 113.31 -168.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.5 mtm-85 -72.01 75.69 0.92 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 125.412 1.485 . . . . 10.0 109.595 176.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 70.2 mt -43.73 -49.08 8.02 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.997 0.919 . . . . 10.0 112.26 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.99 153.62 32.29 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.796 -0.816 . . . . 10.0 108.796 -168.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.06 166.12 34.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.58 -0.282 . . . . 10.0 110.805 -174.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.63 163.29 30.73 Favored Glycine 0 CA--C 1.523 0.563 0 C-N-CA 125.096 1.331 . . . . 10.0 109.856 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 37.6 t -120.94 136.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 106.088 -1.819 . . . . 10.0 106.088 -173.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 64.2 mt -70.52 130.42 34.71 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-N 118.175 0.443 . . . . 10.0 110.617 -177.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.64 141.98 13.24 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 124.254 0.93 . . . . 10.0 110.794 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -71.26 151.9 8.73 Favored 'Isoleucine or valine' 0 C--N 1.342 0.278 0 CA-C-N 118.44 1.12 . . . . 10.0 111.587 -178.323 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.3 -33.59 2.13 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 124.768 1.227 . . . . 10.0 113.267 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.063 0 CA-C-O 116.856 -1.545 . . . . 10.0 107.424 171.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.601 0 CA-C-O 118.863 -0.589 . . . . 10.0 110.059 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.9 t 125.01 -23.95 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 1 C-N-CA 131.942 4.097 . . . . 10.0 108.523 -174.309 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp -131.0 132.31 44.91 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 126.071 1.748 . . . . 10.0 108.124 169.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.54 168.75 18.66 Favored 'General case' 0 N--CA 1.462 0.149 0 C-N-CA 124.747 1.219 . . . . 10.0 109.443 169.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.2 m -127.65 179.24 3.84 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.357 0 C-N-CA 124.177 0.991 . . . . 10.0 110.766 -174.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.81 114.77 2.64 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 106.879 -1.526 . . . . 10.0 106.879 164.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -98.66 96.26 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 C-N-CA 124.018 0.927 . . . . 10.0 110.21 172.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 mp -84.57 142.67 29.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.416 1.086 . . . . 10.0 110.023 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -153.2 165.06 36.85 Favored 'General case' 0 C--N 1.338 0.074 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 169.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.48 -59.65 0.04 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.391 -0.368 . . . . 10.0 113.268 169.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.19 -42.92 62.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -170.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.25 -66.51 0.53 Allowed Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 113.728 -1.578 . . . . 10.0 109.708 176.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -58.33 -39.95 79.77 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.62 2.213 . . . . 10.0 110.808 171.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.9 t -63.73 110.63 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 N-CA-C 108.134 -1.062 . . . . 10.0 108.134 178.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.18 132.01 51.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 168.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -114.28 134.03 11.49 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 109.47 -1.452 . . . . 10.0 109.47 174.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.41 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 9.9 mt -136.19 97.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 -170.298 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -102.52 152.24 5.74 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 C-N-CA 124.464 1.106 . . . . 10.0 110.979 -176.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -126.53 113.94 17.45 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 126.294 1.838 . . . . 10.0 107.714 169.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -96.94 100.01 11.54 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 172.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -110.65 118.73 36.99 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 120.436 -0.506 . . . . 10.0 111.594 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -90.73 103.61 16.29 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 105.752 -1.944 . . . . 10.0 105.752 172.222 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 27.1 mmmt -48.31 -57.56 5.82 Favored 'General case' 0 C--O 1.228 -0.071 0 C-N-CA 125.433 1.493 . . . . 10.0 110.811 -177.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.14 178.96 6.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 104.258 -2.497 . . . . 10.0 104.258 169.464 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -66.32 -26.98 67.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.594 0.712 . . . . 10.0 109.733 175.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -77.89 -22.68 49.39 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.507 -0.77 . . . . 10.0 109.815 177.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.8 144.75 22.24 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 110.779 -0.928 . . . . 10.0 110.779 -173.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -63.54 153.9 72.06 Favored 'Trans proline' 0 N--CA 1.449 -1.122 0 N-CA-C 107.237 -1.871 . . . . 10.0 107.237 168.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.4 p -77.21 117.24 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 N-CA-C 106.174 -1.787 . . . . 10.0 106.174 173.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 48.4 tttp -85.11 108.8 17.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 106.361 -1.718 . . . . 10.0 106.361 169.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -88.41 93.84 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.112 -1.811 . . . . 10.0 106.112 171.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.3 p90 -106.27 165.77 11.0 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 108.901 -0.777 . . . . 10.0 108.901 168.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.84 163.77 30.54 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -140.23 94.51 2.76 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.209 -1.034 . . . . 10.0 108.209 -175.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.7 pt -77.83 172.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 118.754 -1.179 . . . . 10.0 109.157 171.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -155.58 151.47 27.6 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 167.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.69 -18.97 19.38 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-O 118.83 -0.984 . . . . 10.0 114.036 174.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.8 mp -71.86 179.24 3.26 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 119.34 1.57 . . . . 10.0 111.672 -178.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -95.53 164.89 12.6 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.085 -1.08 . . . . 10.0 108.085 167.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -60.08 171.85 0.91 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.934 1.294 . . . . 10.0 112.892 -169.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.67 -173.08 43.33 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 123.879 0.752 . . . . 10.0 112.462 167.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -70.49 142.62 51.88 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.151 1.381 . . . . 10.0 110.017 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -144.13 147.46 33.75 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 123.64 0.776 . . . . 10.0 112.62 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.05 128.19 0.25 Allowed Glycine 0 C--N 1.341 0.853 0 C-N-CA 127.378 2.418 . . . . 10.0 111.589 165.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -153.79 106.32 2.86 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 118.904 1.352 . . . . 10.0 109.984 167.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.46 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -150.34 174.04 13.31 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 122.303 1.049 . . . . 10.0 113.686 -179.754 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.16 144.57 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 111.694 -2.503 . . . . 10.0 107.873 169.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.7 m-70 -128.14 138.95 52.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.085 -1.45 . . . . 10.0 107.085 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -50.64 -62.79 1.39 Allowed 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.974 1.31 . . . . 10.0 112.143 -169.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -80.22 130.24 35.08 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 119.624 -0.83 . . . . 10.0 109.294 -175.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.57 -13.74 71.63 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.313 -1.115 . . . . 10.0 110.313 167.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -46.37 144.84 1.94 Allowed 'General case' 0 C--N 1.345 0.387 0 CA-C-O 122.45 1.119 . . . . 10.0 109.697 168.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -153.82 15.6 0.49 Allowed 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.309 -1.314 . . . . 10.0 111.724 177.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.42 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -58.77 -34.29 71.26 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.331 0.969 . . . . 10.0 110.671 -174.044 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.67 -20.9 45.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.846 1.258 . . . . 10.0 113.062 175.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.22 97.59 1.36 Allowed Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.392 -1.083 . . . . 10.0 110.392 -170.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.288 20.9 p 15.36 60.27 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 128.597 2.759 . . . . 10.0 116.685 176.055 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 40.9 m -132.18 -61.77 0.86 Allowed 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 128.021 2.528 . . . . 10.0 105.172 174.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.6 m -57.25 -24.75 56.81 Favored 'General case' 0 C--N 1.34 0.156 0 C-N-CA 125.606 1.563 . . . . 10.0 111.667 176.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -41.89 -30.3 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 126.208 1.803 . . . . 10.0 112.502 168.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.93 125.66 5.62 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 109.845 -1.302 . . . . 10.0 109.845 169.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.6 66.95 3.78 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 124.096 3.197 . . . . 10.0 112.28 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 64.16 46.27 3.7 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 129.438 3.095 . . . . 10.0 111.227 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -70.85 69.79 0.47 Allowed 'General case' 0 CA--C 1.531 0.244 0 CA-C-O 121.759 0.79 . . . . 10.0 111.402 178.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.8 p-10 -68.61 152.1 96.86 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.306 -0.871 . . . . 10.0 109.206 169.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.19 -58.68 0.4 Allowed 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 122.26 1.974 . . . . 10.0 111.571 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -76.09 72.27 2.9 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 121.439 -0.788 . . . . 10.0 110.447 174.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.4 m -40.34 112.65 0.29 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.016 0.926 . . . . 10.0 110.699 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.92 -96.27 0.47 Allowed 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 176.348 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -149.39 155.86 41.13 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.988 0.899 . . . . 10.0 109.271 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 63.5 t60 -60.81 115.2 3.49 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 118.364 -1.334 . . . . 10.0 109.096 166.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.69 -137.4 3.49 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 107.935 -2.066 . . . . 10.0 107.935 176.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.26 -162.3 23.36 Favored Glycine 0 N--CA 1.45 -0.368 0 N-CA-C 109.03 -1.628 . . . . 10.0 109.03 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -61.56 -4.8 4.76 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 CA-C-N 119.585 1.692 . . . . 10.0 111.271 168.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -89.29 -26.81 20.94 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.724 1.21 . . . . 10.0 110.401 175.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 34.0 t0 -102.61 157.48 16.91 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 107.227 -1.398 . . . . 10.0 107.227 -178.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -80.6 -30.25 36.86 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.048 -1.093 . . . . 10.0 108.048 167.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -91.05 6.65 44.03 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.07 1.348 . . . . 10.0 113.419 -168.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -42.33 140.35 1.21 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.145 0.978 . . . . 10.0 110.835 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -60.27 -65.09 0.74 Allowed 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.852 0.835 . . . . 10.0 110.453 -171.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.408 ' CG1' ' H ' ' A' ' 82' ' ' GLY . 7.7 p -160.48 -87.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.336 -2.098 . . . . 10.0 105.336 171.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.408 ' H ' ' CG1' ' A' ' 81' ' ' VAL . . . -88.38 59.95 4.06 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.311 -1.116 . . . . 10.0 110.311 178.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -96.15 91.53 5.97 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 104.916 -2.253 . . . . 10.0 104.916 168.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -66.88 -32.8 74.3 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 108.704 -0.85 . . . . 10.0 108.704 -175.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.45 -85.66 0.38 Allowed Glycine 0 N--CA 1.439 -1.13 0 N-CA-C 108.277 -1.929 . . . . 10.0 108.277 168.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 -150.76 135.78 17.56 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.161 -1.422 . . . . 10.0 107.161 -178.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -106.93 133.11 52.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 169.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -87.57 131.76 34.29 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 108.208 -1.034 . . . . 10.0 108.208 176.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -107.11 135.9 47.86 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.029 0.932 . . . . 10.0 109.012 173.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -59.63 172.09 0.75 Allowed 'General case' 0 C--O 1.232 0.135 0 O-C-N 124.243 0.965 . . . . 10.0 109.912 167.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -47.39 -35.87 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 125.732 1.613 . . . . 10.0 110.387 170.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -79.69 -5.95 56.21 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.634 1.173 . . . . 10.0 110.723 -173.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 3.71 89.07 Favored Glycine 0 C--N 1.338 0.684 0 N-CA-C 111.101 -0.799 . . . . 10.0 111.101 -176.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.6 t -79.66 107.83 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 N-CA-C 106.465 -1.68 . . . . 10.0 106.465 179.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.39 120.93 42.83 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 108.829 -0.804 . . . . 10.0 108.829 169.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -79.81 114.8 19.0 Favored 'General case' 0 N--CA 1.434 -1.27 0 C-N-CA 125.849 1.659 . . . . 10.0 109.442 170.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.0 t -101.46 133.76 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 105.417 -2.068 . . . . 10.0 105.417 169.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 7.0 m -158.05 58.85 0.47 Allowed 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 118.969 0.804 . . . . 10.0 110.878 176.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.16 153.61 6.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 C-N-CA 124.001 0.92 . . . . 10.0 108.581 -174.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -123.08 136.27 54.74 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.395 1.478 . . . . 10.0 109.409 172.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -143.75 153.22 42.2 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.7 p -107.95 -26.47 10.69 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 127.148 2.179 . . . . 10.0 111.914 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.2 p -77.91 -45.15 28.08 Favored 'Isoleucine or valine' 0 C--N 1.342 0.27 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -73.72 134.46 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 105.09 -2.189 . . . . 10.0 105.09 165.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -166.28 158.48 14.07 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 125.422 1.489 . . . . 10.0 108.117 -177.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.1 mt -60.59 -50.77 72.18 Favored 'General case' 0 N--CA 1.457 -0.08 0 CA-C-N 116.152 -0.477 . . . . 10.0 110.825 -171.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -120.1 -165.58 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.592 1.157 . . . . 10.0 108.28 172.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 97.77 62.65 0.89 Allowed Glycine 0 CA--C 1.524 0.608 0 C-N-CA 124.394 0.997 . . . . 10.0 111.198 169.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 t70 71.07 -57.54 0.6 Allowed 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 129.469 3.108 . . . . 10.0 109.334 -178.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -74.33 -39.96 62.5 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 -169.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.2 t 39.84 85.05 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 126.111 1.764 . . . . 10.0 113.012 167.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 35.7 pt -58.69 -22.7 21.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -177.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.5 mm -47.26 131.11 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 O-C-N 121.799 -0.563 . . . . 10.0 110.365 174.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.64 1.6 82.92 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 118.408 -1.218 . . . . 10.0 113.987 175.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mmt-85 -81.34 165.76 21.07 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.8 1.3 . . . . 10.0 111.348 171.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -100.7 130.51 46.75 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 105.309 -2.108 . . . . 10.0 105.309 169.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.7 mp -108.66 149.58 28.76 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.416 -0.957 . . . . 10.0 108.416 170.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 96.7 t -135.98 137.09 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.945 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 -173.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.6 p -108.19 138.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 168.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.6 m170 -116.22 161.16 19.4 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 115.641 1.719 . . . . 10.0 115.641 -170.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -43.33 -55.36 4.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 128.621 2.768 . . . . 10.0 110.046 177.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -124.21 174.41 7.7 Favored 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 125.065 1.346 . . . . 10.0 111.34 -169.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.25 148.86 45.06 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.667 1.187 . . . . 10.0 110.401 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.46 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.2 m-20 -78.59 147.33 33.74 Favored 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 124.145 0.978 . . . . 10.0 111.702 174.186 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -75.44 -30.23 59.93 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 114.372 -1.285 . . . . 10.0 109.675 169.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 29.9 mt 57.45 52.67 8.28 Favored 'General case' 0 C--N 1.339 0.13 0 N-CA-C 107.688 -1.227 . . . . 10.0 107.688 -167.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.42 -24.7 12.97 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-N 113.521 -1.672 . . . . 10.0 112.99 173.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -75.11 6.5 4.18 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 114.543 1.312 . . . . 10.0 114.543 -167.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.83 -16.6 79.27 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.057 0.836 . . . . 10.0 112.097 171.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.82 43.77 48.28 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 118.082 0.941 . . . . 10.0 111.801 -176.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -130.88 163.4 27.52 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 106.943 -1.503 . . . . 10.0 106.943 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -54.07 -49.54 68.8 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.16 -0.927 . . . . 10.0 108.502 169.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -56.95 -44.21 82.32 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 122.775 0.43 . . . . 10.0 110.519 173.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.3 p -56.3 -43.74 79.21 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 120.635 -1.29 . . . . 10.0 110.576 -178.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -82.24 2.12 33.37 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 118.848 -0.596 . . . . 10.0 112.071 -178.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.5 -75.84 0.61 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.328 1.851 . . . . 10.0 110.196 176.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 6.6 p -120.96 27.06 8.69 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 120.786 1.63 . . . . 10.0 113.371 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.2 27.99 70.01 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 121.811 -0.556 . . . . 10.0 113.771 167.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 47.65 30.06 1.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.816 0.808 . . . . 10.0 112.177 -173.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.18 -5.33 13.2 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.723 -0.61 . . . . 10.0 110.855 175.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.59 -156.06 36.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 109.806 -1.318 . . . . 10.0 109.806 168.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.3 m -59.86 131.95 52.45 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 109.497 -0.557 . . . . 10.0 109.497 -171.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.46 68.01 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 168.1 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.77 -27.45 67.99 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 -169.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.35 145.83 24.08 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-O 121.475 0.655 . . . . 10.0 109.278 -178.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 15.8 p -162.46 163.65 27.48 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-N 115.849 -0.614 . . . . 10.0 109.641 -167.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 179.6 36.23 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 110.588 -1.005 . . . . 10.0 110.588 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.88 148.12 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.675 0 N-CA-C 103.72 -2.696 . . . . 10.0 103.72 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 3.9 mt -65.81 -87.7 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 C-N-CA 123.222 0.609 . . . . 10.0 111.203 -168.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.57 135.29 7.05 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.426 -0.669 . . . . 10.0 111.426 -178.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 62.3 mt -76.37 150.44 6.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 C-N-CA 125.132 1.373 . . . . 10.0 108.166 -176.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.14 -45.44 3.29 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 120.974 1.716 . . . . 10.0 112.006 169.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.3 tp60 . . . . . 0 C--O 1.252 1.219 0 C-N-CA 124.14 0.976 . . . . 10.0 109.772 -174.526 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.673 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.4 t -166.38 -46.88 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 124.486 1.114 . . . . 10.0 108.788 173.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -123.95 136.53 54.38 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.232 1.413 . . . . 10.0 109.165 -175.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 167.43 22.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 125.942 1.697 . . . . 10.0 107.803 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.49 168.88 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 118.488 0.585 . . . . 10.0 112.314 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.99 104.28 4.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 106.899 -1.519 . . . . 10.0 106.899 167.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 10.9 m -92.09 76.38 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 123.476 0.71 . . . . 10.0 109.212 175.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.5 mp -74.69 145.82 42.81 Favored 'General case' 0 N--CA 1.449 -0.521 0 O-C-N 121.299 -0.876 . . . . 10.0 109.263 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 161.4 19.77 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 107.992 -1.114 . . . . 10.0 107.992 -175.263 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.56 -58.37 0.04 OUTLIER Glycine 0 C--N 1.329 0.175 0 CA-C-N 115.628 -0.714 . . . . 10.0 111.579 169.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.21 -46.49 33.62 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 106.645 -1.613 . . . . 10.0 106.645 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.82 -68.37 0.51 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 113.383 -1.735 . . . . 10.0 110.729 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -59.89 -35.95 92.08 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.957 2.438 . . . . 10.0 111.424 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 96.5 t -68.71 99.74 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.141 0 N-CA-C 107.063 -1.458 . . . . 10.0 107.063 176.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -121.95 111.9 17.63 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.37 138.71 14.16 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 109.133 -1.587 . . . . 10.0 109.133 169.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . 0.42 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 6.5 mt -139.31 78.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 106.681 -1.6 . . . . 10.0 106.681 -177.022 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -102.59 148.88 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.143 -0.935 . . . . 10.0 109.59 -175.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -118.37 114.04 22.32 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.831 1.652 . . . . 10.0 108.223 171.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -86.09 99.28 11.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 175.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.37 153.3 21.85 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 123.964 0.79 . . . . 10.0 109.883 -178.145 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -158.84 86.9 0.85 Allowed 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.254 -0.647 . . . . 10.0 109.254 -173.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 2.0 ttpm? . . . . . 0 N--CA 1.424 -1.755 0 CA-C-O 122.257 1.027 . . . . 10.0 109.74 -174.506 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.126 0 CA-C-O 117.838 -1.534 . . . . 10.0 114.723 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -67.0 151.44 82.03 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.371 2.048 . . . . 10.0 108.34 169.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.49 92.38 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 105.842 -1.91 . . . . 10.0 105.842 169.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttp -83.76 98.43 9.69 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -97.58 99.69 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.95 0 C-N-CA 125.628 1.571 . . . . 10.0 106.819 -174.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 13.3 p90 -117.16 165.54 13.29 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.528 0.68 . . . . 10.0 112.605 171.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.76 -150.04 21.97 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 106.922 -2.471 . . . . 10.0 106.922 169.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 28.6 p -156.04 166.41 33.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 119.352 -0.939 . . . . 10.0 110.931 173.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.7 pt -106.43 174.75 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.843 -1.071 . . . . 10.0 110.491 167.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt -140.4 152.15 45.51 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.552 2.341 . . . . 10.0 105.893 169.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.12 -25.09 14.66 Favored Glycine 0 C--N 1.338 0.653 0 N-CA-C 116.007 1.163 . . . . 10.0 116.007 167.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -78.47 177.6 8.4 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 119.207 1.504 . . . . 10.0 110.945 -169.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.0 t -93.1 165.1 13.0 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 108.973 -0.751 . . . . 10.0 108.973 168.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.99 160.04 6.45 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.576 1.15 . . . . 10.0 111.45 -172.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.87 -170.24 29.06 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.626 -0.59 . . . . 10.0 111.626 169.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.77 148.6 42.39 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.405 1.082 . . . . 10.0 111.783 -172.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -144.42 141.74 29.84 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.215 1.006 . . . . 10.0 113.42 -177.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.2 126.48 1.6 Allowed Glycine 0 C--N 1.342 0.903 0 C-N-CA 126.803 2.144 . . . . 10.0 110.511 165.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -151.36 111.43 4.1 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.887 1.343 . . . . 10.0 108.295 168.083 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -153.76 168.33 26.66 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.978 0.894 . . . . 10.0 112.459 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 18.7 m -88.78 149.34 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 111.869 -2.423 . . . . 10.0 105.812 166.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -124.83 169.72 11.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.691 0.757 . . . . 10.0 109.309 169.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . 0.646 ' CG ' ' H ' ' B' ' 50' ' ' PHE . 0.8 OUTLIER 4.0 -113.68 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 130.503 3.521 . . . . 10.0 117.624 167.727 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . 0.646 ' H ' ' CG ' ' B' ' 49' ' ' GLU . 51.9 m-85 -95.29 -141.88 0.26 Allowed 'General case' 0 N--CA 1.434 -1.231 0 C-N-CA 127.96 2.504 . . . . 10.0 106.024 172.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.43 31.5 4.82 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 125.171 1.367 . . . . 10.0 110.875 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -70.5 158.55 35.88 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 119.685 1.742 . . . . 10.0 108.273 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -163.45 12.07 0.06 Allowed 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 126.288 1.835 . . . . 10.0 111.899 173.085 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.41 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -60.48 -31.63 70.65 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 119.904 1.229 . . . . 10.0 110.954 -173.048 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.03 -18.37 58.18 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.26 1.024 . . . . 10.0 111.887 176.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.83 -171.58 13.78 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 107.539 -2.225 . . . . 10.0 107.539 -169.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 84.7 m -70.43 70.04 0.41 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.826 -1.176 . . . . 10.0 107.826 169.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.14 -51.05 0.08 Allowed 'General case' 0 N--CA 1.448 -0.544 0 O-C-N 120.706 -1.246 . . . . 10.0 110.911 -169.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 10.7 t -98.96 -0.15 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.711 0.804 . . . . 10.0 110.076 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -70.46 60.02 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.821 1.648 . . . . 10.0 109.461 171.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.24 130.42 0.89 Allowed Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 124.612 1.101 . . . . 10.0 115.227 164.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -87.84 42.49 0.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 123.279 2.653 . . . . 10.0 108.168 165.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 15.1 m170 65.47 54.28 1.16 Allowed 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.993 2.517 . . . . 10.0 110.964 -172.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -69.37 70.27 0.26 Allowed 'General case' 0 N--CA 1.47 0.554 0 O-C-N 121.794 -0.566 . . . . 10.0 110.638 171.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -80.01 152.13 73.91 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.521 -0.737 . . . . 10.0 110.333 175.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.05 -48.57 1.29 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.601 2.201 . . . . 10.0 111.298 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 86.0 mt -77.5 59.49 1.92 Allowed 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -56.24 99.51 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 124.761 1.224 . . . . 10.0 110.172 -176.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.48 -89.89 0.53 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 105.517 -2.031 . . . . 10.0 105.517 -177.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -142.87 153.59 43.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.091 0.948 . . . . 10.0 110.286 168.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -64.85 123.24 18.88 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 165.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.41 -144.2 4.08 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 107.857 -2.097 . . . . 10.0 107.857 179.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.432 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -176.05 -153.37 10.42 Favored Glycine 0 N--CA 1.452 -0.296 0 N-CA-C 108.565 -1.814 . . . . 10.0 108.565 170.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -69.12 15.26 0.19 Allowed 'Trans proline' 0 CA--C 1.54 0.802 0 CA-C-N 119.519 1.66 . . . . 10.0 111.404 169.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.432 ' H ' ' C ' ' B' ' 73' ' ' GLY . 72.3 mttt -119.49 0.46 11.05 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.177 1.391 . . . . 10.0 110.791 169.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.4 t0 -118.03 156.48 28.51 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.264 -1.384 . . . . 10.0 107.264 172.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -79.3 -31.61 43.33 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 171.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -118.59 36.94 4.22 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 123.861 0.864 . . . . 10.0 112.466 -165.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.74 148.96 3.61 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 125.257 1.423 . . . . 10.0 110.66 169.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 26.0 m170 -55.26 -62.35 1.73 Allowed 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.161 0.584 . . . . 10.0 112.192 -171.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -172.35 -60.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.181 0 C-N-CA 124.32 1.048 . . . . 10.0 108.332 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.71 51.98 0.82 Allowed Glycine 0 C--N 1.337 0.613 0 N-CA-C 109.319 -1.513 . . . . 10.0 109.319 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -84.77 92.28 8.19 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.447 -2.797 . . . . 10.0 103.447 167.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.5 mt -63.06 -30.4 71.57 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 -173.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.55 -89.8 0.48 Allowed Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.607 -1.397 . . . . 10.0 109.607 166.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -151.79 100.73 2.7 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.332 -0.988 . . . . 10.0 108.332 -171.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -86.37 141.86 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 172.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -99.47 129.87 45.69 Favored 'General case' 0 C--O 1.224 -0.257 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.56 134.81 40.99 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.916 -0.772 . . . . 10.0 108.916 172.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -59.84 169.59 1.39 Allowed 'General case' 0 N--CA 1.451 -0.382 0 O-C-N 124.526 1.141 . . . . 10.0 110.045 167.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 61.8 pttt -50.41 -33.19 19.94 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 124.229 1.011 . . . . 10.0 110.876 169.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -78.53 -1.25 33.0 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 122.87 0.468 . . . . 10.0 111.409 -178.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.36 17.86 75.2 Favored Glycine 0 C--N 1.34 0.781 0 O-C-N 120.746 -1.221 . . . . 10.0 110.49 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.69 103.61 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 C-N-CA 126.439 1.896 . . . . 10.0 106.789 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.35 121.64 40.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 167.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.46 117.79 20.74 Favored 'General case' 0 N--CA 1.436 -1.161 0 C-N-CA 126.579 1.951 . . . . 10.0 108.665 170.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 56.6 t -101.73 134.57 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 107.185 -1.413 . . . . 10.0 107.185 175.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -158.62 57.11 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.409 0.684 . . . . 10.0 111.263 175.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.71 158.2 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -172.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -130.73 90.72 2.95 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 126.762 2.025 . . . . 10.0 108.925 -176.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -84.46 83.78 7.88 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 63.1 p -78.73 60.31 2.74 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 169.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.3 t -143.22 -51.16 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 125.174 1.39 . . . . 10.0 107.704 -168.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.326 0.0 OUTLIER -118.91 165.12 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 113.656 0.984 . . . . 10.0 113.656 175.91 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.0 p -108.17 132.1 53.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.641 1.176 . . . . 10.0 109.646 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -69.83 -41.16 75.31 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.3 t . . . . . 0 N--CA 1.447 -0.623 0 N-CA-C 105.985 -1.857 . . . . 10.0 105.985 174.906 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.9 t . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 121.434 0.635 . . . . 10.0 112.25 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.9 pt -75.01 44.38 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 C-N-CA 123.752 0.821 . . . . 10.0 111.841 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 17.7 mm -78.25 -68.52 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 C-N-CA 125.685 1.594 . . . . 10.0 109.981 -174.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.42 52.31 3.05 Favored Glycine 0 CA--C 1.533 1.198 0 O-C-N 120.8 -1.187 . . . . 10.0 112.302 176.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.1 mmt85 -121.09 153.55 37.3 Favored 'General case' 0 C--O 1.233 0.192 0 C-N-CA 126.147 1.779 . . . . 10.0 110.614 -178.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 53.9 m -97.75 121.26 39.44 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.121 0.968 . . . . 10.0 109.587 177.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -98.24 144.33 27.79 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 125.916 1.686 . . . . 10.0 107.743 169.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 53.1 t -128.8 140.67 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 108.409 -0.96 . . . . 10.0 108.409 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 p -113.39 128.75 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 C-N-CA 125.666 1.586 . . . . 10.0 106.932 169.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 3.4 m170 -114.09 163.74 14.78 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 116.082 1.882 . . . . 10.0 116.082 -169.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -45.02 -59.1 2.76 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.602 2.761 . . . . 10.0 112.628 174.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -122.81 176.29 6.06 Favored 'General case' 0 CA--C 1.522 -0.134 0 C-N-CA 124.366 1.067 . . . . 10.0 113.317 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.58 155.59 38.78 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.827 1.651 . . . . 10.0 111.094 176.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.5 146.86 24.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 124.8 1.24 . . . . 10.0 110.795 172.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -74.9 -32.88 61.94 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 114.849 -1.068 . . . . 10.0 109.321 170.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 52.2 mt 62.94 65.34 0.81 Allowed 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 123.265 1.507 . . . . 10.0 108.237 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.77 -51.11 4.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 112.945 -1.934 . . . . 10.0 111.726 170.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 38.3 mtmt -80.32 53.21 1.74 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.371 1.468 . . . . 10.0 111.591 -169.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.94 -3.71 23.11 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.208 1.861 . . . . 10.0 112.462 177.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.54 42.55 27.16 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.244 0.926 . . . . 10.0 112.797 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -135.98 158.32 44.69 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 107.577 -1.268 . . . . 10.0 107.577 176.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -54.15 -42.94 70.14 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 169.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -58.91 -44.39 91.26 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.983 -0.553 . . . . 10.0 112.175 170.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 10.1 p -56.19 -43.25 78.26 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 119.581 1.082 . . . . 10.0 111.22 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -71.24 -7.85 49.65 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-O 118.083 -0.961 . . . . 10.0 113.091 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -119.7 -65.65 1.14 Allowed 'General case' 0 N--CA 1.439 -1.008 0 C-N-CA 127.677 2.391 . . . . 10.0 113.141 -168.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.5 p -130.16 26.2 5.18 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.274 1.397 . . . . 10.0 109.908 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 68.32 -104.45 1.2 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 107.375 -2.29 . . . . 10.0 107.375 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -154.93 39.06 0.42 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 107.551 -1.278 . . . . 10.0 107.551 170.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.62 -12.48 23.38 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 123.527 0.731 . . . . 10.0 112.512 -171.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.96 -167.55 51.19 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 109.734 -1.346 . . . . 10.0 109.734 175.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 53.1 m -56.03 133.41 51.81 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 121.602 0.715 . . . . 10.0 111.729 -169.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 19.7 mtt180 -65.15 75.32 0.05 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.457 -0.792 . . . . 10.0 109.177 168.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.9 mt -47.56 -48.73 27.69 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.96 0.409 . . . . 10.0 109.986 177.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.15 152.54 37.46 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.414 0.626 . . . . 10.0 110.566 -172.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -148.42 167.71 24.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.595 -0.73 . . . . 10.0 109.308 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.0 148.66 19.75 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 109.592 -1.403 . . . . 10.0 109.592 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 75.1 t -101.35 124.26 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 N-CA-C 104.365 -2.457 . . . . 10.0 104.365 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 21.0 mt -67.75 157.74 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 CA-C-N 118.969 0.804 . . . . 10.0 110.454 -178.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -159.97 147.24 14.07 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.594 1.568 . . . . 10.0 110.423 -170.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 62.0 mt -69.15 135.41 28.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 C-N-CA 126.476 1.91 . . . . 10.0 110.452 -169.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -125.8 -48.4 1.64 Allowed 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.624 -0.673 . . . . 10.0 112.199 -178.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.254 1.294 0 C-N-CA 125.437 1.495 . . . . 10.0 110.517 -168.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 116.164 -1.874 . . . . 10.0 106.571 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -96.55 -33.77 11.69 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.773 1.169 . . . . 10.0 112.79 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -137.54 133.32 34.38 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 123.958 0.903 . . . . 10.0 111.615 -177.327 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.92 162.31 28.88 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.185 1.394 . . . . 10.0 109.457 173.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.2 t -124.31 154.89 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 125.784 1.634 . . . . 10.0 108.272 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.46 111.9 6.35 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 168.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.9 m -101.26 113.47 37.51 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.28 0.632 . . . . 10.0 110.945 -178.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -90.05 139.24 30.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 121.743 -0.598 . . . . 10.0 111.945 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -151.84 159.95 43.71 Favored 'General case' 0 N--CA 1.455 -0.197 0 N-CA-C 107.25 -1.389 . . . . 10.0 107.25 167.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.73 -56.68 0.06 OUTLIER Glycine 0 N--CA 1.461 0.351 0 C-N-CA 120.247 -0.978 . . . . 10.0 112.389 169.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -71.42 -44.5 64.76 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -178.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.3 -70.6 0.43 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.328 -1.305 . . . . 10.0 110.37 169.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -58.28 -33.12 97.35 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 123.528 2.819 . . . . 10.0 111.554 173.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.61 94.24 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 173.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -114.09 126.62 55.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.508 -1.293 . . . . 10.0 107.508 175.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -121.17 145.23 17.08 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 124.294 0.949 . . . . 10.0 111.045 -177.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.429 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 4.9 mt -146.42 84.22 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 106.555 -1.646 . . . . 10.0 106.555 -170.397 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.8 mm -95.46 142.74 13.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 C-N-CA 124.439 1.096 . . . . 10.0 108.571 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -124.3 127.63 47.93 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 125.957 1.703 . . . . 10.0 108.559 172.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -106.43 112.92 26.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.424 -1.324 . . . . 10.0 107.424 176.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -105.26 127.42 52.93 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.601 0.637 . . . . 10.0 111.195 168.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -114.93 88.68 2.92 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.526 1.531 . . . . 10.0 107.288 169.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.531 ' HZ1' ' CD ' ' A' ' 24' ' ' GLU . 12.5 pttp -59.58 -44.0 93.47 Favored 'General case' 0 N--CA 1.457 -0.09 0 C-N-CA 124.199 1.0 . . . . 10.0 110.279 -171.15 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.531 ' CD ' ' HZ1' ' A' ' 23' ' ' LYS . 2.9 mt-10 -133.1 161.58 34.01 Favored 'General case' 0 N--CA 1.425 -1.704 0 N-CA-C 104.301 -2.481 . . . . 10.0 104.301 174.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.9 p -66.18 -18.96 65.68 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 121.505 0.669 . . . . 10.0 109.691 169.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 29.9 m120 -79.1 -21.52 46.56 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 124.828 1.251 . . . . 10.0 110.708 177.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.48 127.52 8.03 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 109.802 -1.319 . . . . 10.0 109.802 -174.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.63 131.39 29.36 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 N-CA-C 106.93 -1.988 . . . . 10.0 106.93 169.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.3 t -78.47 101.95 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -169.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -69.7 106.82 3.21 Favored 'General case' 0 N--CA 1.446 -0.667 0 N-CA-C 107.828 -1.175 . . . . 10.0 107.828 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.7 m -82.8 111.73 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 N-CA-C 106.265 -1.754 . . . . 10.0 106.265 169.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.8 p90 -122.38 168.0 12.61 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.245 0.545 . . . . 10.0 112.304 170.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.33 -152.51 24.57 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 107.738 -2.145 . . . . 10.0 107.738 169.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.3 p -156.17 155.54 32.65 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 119.306 -0.958 . . . . 10.0 112.527 -176.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -117.76 129.14 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 125.489 1.516 . . . . 10.0 107.92 168.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 48.1 tttp -110.08 148.32 31.95 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.73 1.612 . . . . 10.0 107.138 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.61 -10.02 25.92 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 123.796 0.712 . . . . 10.0 113.891 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.0 mt -73.04 179.25 3.87 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.335 1.054 . . . . 10.0 110.522 178.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.3 t -104.86 165.31 11.16 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 167.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -55.38 156.16 4.64 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.489 1.116 . . . . 10.0 113.195 -169.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.98 177.38 51.97 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.429 1.014 . . . . 10.0 112.669 169.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 84.9 mt -40.88 137.88 1.14 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.625 1.97 . . . . 10.0 114.74 175.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.21 150.68 44.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.631 1.572 . . . . 10.0 110.661 170.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -35.95 123.44 0.73 Allowed Glycine 0 C--N 1.338 0.651 0 CA-C-O 116.855 -2.08 . . . . 10.0 109.39 163.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -149.88 108.11 3.76 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 120.207 2.003 . . . . 10.0 109.205 167.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.411 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -154.22 175.47 13.45 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.503 0.668 . . . . 10.0 110.763 -176.807 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.97 156.63 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.639 0 CA-C-N 112.425 -2.171 . . . . 10.0 108.297 168.319 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -132.99 130.81 39.99 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 104.259 -2.497 . . . . 10.0 104.259 174.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -58.25 -53.08 62.37 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.162 0.914 . . . . 10.0 111.321 -168.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -77.04 135.93 38.66 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 118.388 -1.325 . . . . 10.0 107.71 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.07 -31.79 72.5 Favored Glycine 0 N--CA 1.441 -0.97 0 N-CA-C 109.59 -1.404 . . . . 10.0 109.59 169.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -36.35 126.86 0.8 Allowed 'General case' 0 C--N 1.341 0.216 0 C-N-CA 126.352 1.861 . . . . 10.0 112.761 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -130.48 9.94 5.17 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 114.445 -1.252 . . . . 10.0 110.894 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.413 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -54.61 -35.68 63.67 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.312 1.045 . . . . 10.0 112.112 -169.618 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.35 -17.17 58.47 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.197 0.599 . . . . 10.0 112.241 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.89 76.31 0.88 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 108.865 -1.694 . . . . 10.0 108.865 -177.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.84 6.52 0.91 Allowed 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.086 1.354 . . . . 10.0 113.312 176.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 45.1 m -98.72 -42.11 7.37 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 107.774 -1.195 . . . . 10.0 107.774 -169.029 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.93 -39.62 71.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 123.771 0.828 . . . . 10.0 111.022 -169.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.78 -25.2 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.754 3.621 . . . . 10.0 116.863 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.92 121.98 3.95 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.437 -1.465 . . . . 10.0 109.437 172.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.4 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 72.9 Cg_endo -69.16 73.25 1.1 Allowed 'Trans proline' 0 CA--C 1.54 0.792 0 C-N-CA 123.596 2.864 . . . . 10.0 111.759 177.279 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 25.4 m170 61.09 46.84 7.79 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.624 3.17 . . . . 10.0 111.305 176.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.4 ' CZ ' ' HD2' ' A' ' 62' ' ' PRO . 19.5 m-85 -74.29 48.66 0.34 Allowed 'General case' 0 N--CA 1.467 0.39 0 O-C-N 121.799 -0.563 . . . . 10.0 111.993 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -63.62 149.45 92.42 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 121.36 -0.837 . . . . 10.0 108.804 178.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -54.23 -60.03 0.73 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 122.977 2.451 . . . . 10.0 111.879 -172.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.01 66.5 2.22 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.743 -0.598 . . . . 10.0 109.665 169.705 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t -59.1 102.5 0.13 Allowed 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.5 mtp85 -105.36 -89.9 0.42 Allowed 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 106.063 -1.828 . . . . 10.0 106.063 -176.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.2 mmtt -143.32 146.62 33.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.244 0.545 . . . . 10.0 109.664 168.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.0 t60 -55.99 121.57 9.64 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 117.976 -1.489 . . . . 10.0 107.6 165.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.71 -149.99 5.48 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.09 -150.97 8.17 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.265 -1.297 . . . . 10.0 110.675 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -70.05 17.37 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.849 1.699 . . . . 10.0 111.285 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.17 -19.33 16.49 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 108.017 -1.105 . . . . 10.0 108.017 168.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.28 -178.59 4.91 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.895 -1.15 . . . . 10.0 107.895 -168.204 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -116.39 -5.4 11.76 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 123.424 0.69 . . . . 10.0 110.734 170.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.407 ' CD ' ' N ' ' A' ' 78' ' ' GLU . 0.8 OUTLIER -98.11 -2.88 39.04 Favored 'General case' 0 CA--C 1.517 -0.323 0 O-C-N 121.02 -1.05 . . . . 10.0 111.536 -174.258 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 9.6 ptt85 -28.76 129.83 0.07 Allowed 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.408 2.283 . . . . 10.0 111.019 167.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -59.52 151.99 22.95 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.968 -0.753 . . . . 10.0 108.968 172.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 94.5 t -59.5 89.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.955 -1.128 . . . . 10.0 107.955 171.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.64 28.58 3.42 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 125.724 1.631 . . . . 10.0 113.496 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -85.92 101.04 12.52 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 105.055 -2.202 . . . . 10.0 105.055 164.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.65 16.48 1.75 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 119.286 0.948 . . . . 10.0 110.83 173.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.03 -107.98 2.49 Favored Glycine 0 N--CA 1.434 -1.499 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 -179.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -155.94 144.59 20.27 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 106.646 -1.613 . . . . 10.0 106.646 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -120.77 135.99 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 C-N-CA 123.062 0.545 . . . . 10.0 109.867 -171.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -82.72 131.85 35.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 125.134 1.374 . . . . 10.0 109.616 -174.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.76 142.24 31.5 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 123.918 0.887 . . . . 10.0 110.897 170.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -60.93 167.43 2.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.473 1.109 . . . . 10.0 109.744 166.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.4 ptmt -54.1 -26.77 28.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.149 1.379 . . . . 10.0 112.184 173.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -75.9 -29.94 58.61 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 109.75 -0.463 . . . . 10.0 109.75 177.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 112.05 4.71 25.7 Favored Glycine 0 N--CA 1.446 -0.68 0 CA-C-O 118.626 -1.097 . . . . 10.0 111.216 -169.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.7 t -78.61 99.1 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 C-N-CA 125.069 1.347 . . . . 10.0 108.279 177.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 117.47 33.38 Favored 'General case' 0 CA--C 1.518 -0.264 0 N-CA-C 106.886 -1.524 . . . . 10.0 106.886 166.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -89.03 119.78 29.86 Favored 'General case' 0 N--CA 1.436 -1.142 0 C-N-CA 127.879 2.472 . . . . 10.0 109.106 177.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.6 t -105.15 135.06 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 C-N-CA 125.127 1.371 . . . . 10.0 107.787 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 88.9 p -159.72 69.74 0.43 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.309 0.855 . . . . 10.0 113.309 172.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -123.96 143.19 38.08 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 124.53 1.132 . . . . 10.0 110.38 -170.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -116.28 149.84 38.57 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.942 2.097 . . . . 10.0 110.128 173.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -149.87 153.39 36.63 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 106.744 -1.576 . . . . 10.0 106.744 167.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 78.1 p -95.47 56.04 1.78 Allowed 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 125.395 1.478 . . . . 10.0 108.528 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 58.4 t -144.12 -53.18 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -176.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.7 mm -54.48 139.08 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 C-N-CA 124.022 0.929 . . . . 10.0 109.488 173.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.9 m -155.15 134.94 12.78 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 169.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.6 mt -55.85 -52.04 65.42 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.645 1.178 . . . . 10.0 110.436 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.0 t -140.52 -179.27 5.93 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.313 0.645 . . . . 10.0 109.514 176.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.85 -100.3 0.56 Allowed Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 106.22 -2.752 . . . . 10.0 106.22 -170.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -128.92 -49.77 1.23 Allowed 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 125.356 1.462 . . . . 10.0 108.356 -169.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.5 -41.07 48.32 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.888 -1.051 . . . . 10.0 108.867 -176.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t 38.71 89.81 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.391 2.276 . . . . 10.0 113.796 172.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pp -73.63 -15.31 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 112.534 0.568 . . . . 10.0 112.534 178.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.3 mm -50.12 122.63 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 O-C-N 121.188 -0.945 . . . . 10.0 110.412 174.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.44 5.43 56.94 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.466 1.032 . . . . 10.0 112.968 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.6 mpt_? -75.66 179.38 5.41 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.017 0.927 . . . . 10.0 109.533 169.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -129.72 141.56 50.87 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 173.284 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 6.1 mp -107.94 157.43 18.22 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.75 -0.833 . . . . 10.0 108.75 168.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -140.04 137.86 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 O-C-N 123.934 0.771 . . . . 10.0 109.206 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.4 m -103.25 134.56 44.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 O-C-N 124.473 1.108 . . . . 10.0 108.912 164.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.7 m170 -110.83 159.21 17.88 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 114.497 1.295 . . . . 10.0 114.497 -174.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.73 -50.05 73.37 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.973 1.309 . . . . 10.0 110.46 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -113.03 172.17 7.1 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.629 0.728 . . . . 10.0 112.366 -177.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.22 151.24 33.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.138 1.375 . . . . 10.0 109.503 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.411 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 3.4 m-20 -79.49 147.04 32.38 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.207 0.447 . . . . 10.0 112.207 176.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -86.49 3.02 45.81 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.506 1.129 . . . . 10.0 111.637 168.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.4 mt 48.06 51.89 13.94 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 125.247 1.419 . . . . 10.0 111.859 170.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.38 -7.87 64.13 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 113.756 -1.565 . . . . 10.0 112.187 173.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -114.23 35.16 4.29 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.25 1.02 . . . . 10.0 110.691 -168.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -82.89 -23.55 55.3 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 126.124 1.821 . . . . 10.0 111.697 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.44 48.1 81.48 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-N 118.184 0.992 . . . . 10.0 111.547 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -158.13 167.4 29.93 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 127.746 2.418 . . . . 10.0 105.734 -175.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.456 ' CD ' ' HZ2' ' A' ' 136' ' ' LYS . 4.1 tm-20 -57.49 -44.51 85.01 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.627 0.727 . . . . 10.0 109.645 175.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -52.89 -31.15 38.16 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.788 0.835 . . . . 10.0 112.327 175.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.0 t -46.77 -47.14 20.86 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 124.054 0.942 . . . . 10.0 109.035 178.24 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.6 t -83.67 0.56 46.45 Favored 'General case' 0 CA--C 1.539 0.556 0 CA-C-O 118.35 -0.833 . . . . 10.0 112.714 -173.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.456 ' HZ2' ' CD ' ' A' ' 132' ' ' GLU . 91.0 mttt -121.55 -83.02 0.66 Allowed 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.464 1.906 . . . . 10.0 111.897 -174.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.36 24.46 13.06 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 121.759 2.072 . . . . 10.0 110.662 174.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.89 -87.3 0.29 Allowed Glycine 0 C--N 1.34 0.793 0 C-N-CA 125.151 1.358 . . . . 10.0 110.027 175.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.22 34.08 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 125.233 1.413 . . . . 10.0 110.477 172.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.98 -9.76 56.28 Favored 'General case' 0 C--N 1.341 0.212 0 O-C-N 121.041 -1.037 . . . . 10.0 112.192 -172.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.77 -163.62 52.66 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 169.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -49.73 123.79 8.53 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.161 1.384 . . . . 10.0 113.428 -168.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -63.54 74.18 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.259 1.824 . . . . 10.0 110.734 173.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 52.7 mt -49.68 -36.81 26.3 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 113.189 0.811 . . . . 10.0 113.189 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.31 144.44 23.0 Favored 'General case' 0 CA--C 1.513 -0.442 0 O-C-N 121.711 -0.618 . . . . 10.0 109.418 178.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.9 p -132.37 152.16 51.56 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 124.206 0.941 . . . . 10.0 109.876 176.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.39 141.98 11.26 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.297 -1.121 . . . . 10.0 110.297 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.5 t -97.11 142.71 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 105.971 -1.863 . . . . 10.0 105.971 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 14.1 mt -79.29 136.7 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 N-CA-C 110.038 -0.356 . . . . 10.0 110.038 -176.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.84 145.49 17.34 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.75 1.167 . . . . 10.0 111.877 -175.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.3 mt -67.83 139.57 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 124.4 1.08 . . . . 10.0 108.362 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.9 -26.92 2.59 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 114.805 1.409 . . . . 10.0 114.805 -176.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.025 0 CA-C-O 117.61 -1.186 . . . . 10.0 111.84 -178.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.789 0 CA-C-O 116.73 -1.605 . . . . 10.0 107.134 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t -68.99 -18.83 64.11 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-N 120.533 1.515 . . . . 10.0 108.615 169.098 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.6 ptpt -144.39 162.27 36.9 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 120.831 0.348 . . . . 10.0 110.88 165.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -152.95 166.87 31.03 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 127.139 2.175 . . . . 10.0 107.645 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.71 162.79 36.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 C-N-CA 123.419 0.688 . . . . 10.0 111.014 -176.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.39 108.51 5.48 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.931 0.892 . . . . 10.0 109.307 168.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.1 m -82.5 81.81 1.53 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.485 0.714 . . . . 10.0 110.294 171.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -73.13 127.18 31.86 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.714 -0.847 . . . . 10.0 108.714 -171.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.6 mtmp? -147.54 160.36 42.71 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.324 -0.991 . . . . 10.0 108.324 -177.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.17 -57.51 0.06 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 120.479 -0.867 . . . . 10.0 112.928 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -72.65 -43.85 62.63 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 -175.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.02 -70.97 0.43 Allowed Glycine 0 CA--C 1.524 0.596 0 CA-C-N 114.273 -1.33 . . . . 10.0 110.078 171.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -56.46 -34.26 94.27 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.056 2.504 . . . . 10.0 111.28 172.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.8 t -66.83 100.63 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 176.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -122.35 109.52 14.52 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 174.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.56 134.86 11.98 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.751 -1.34 . . . . 10.0 109.751 169.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . 0.413 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 17.7 mt -129.55 67.66 0.34 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.153 0 N-CA-C 107.255 -1.387 . . . . 10.0 107.255 -174.273 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -89.25 137.92 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 114.611 -1.177 . . . . 10.0 109.735 -171.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -120.68 116.03 24.49 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.051 2.14 . . . . 10.0 107.97 -173.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -98.72 109.62 22.35 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 116.986 -1.483 . . . . 10.0 107.672 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -104.18 138.87 40.03 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 119.856 1.207 . . . . 10.0 112.592 169.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 40.2 tp60 -124.21 91.89 3.55 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 129.719 3.208 . . . . 10.0 107.288 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 59.0 tttt . . . . . 0 N--CA 1.426 -1.646 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 177.477 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.039 0 CA-C-O 117.21 -1.883 . . . . 10.0 116.279 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -68.26 128.27 17.17 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 CA-C-N 121.362 2.581 . . . . 10.0 106.174 168.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 1.3 p -76.92 112.39 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.547 0 N-CA-C 105.968 -1.864 . . . . 10.0 105.968 169.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.5 tttt -85.77 107.19 17.5 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.994 -2.225 . . . . 10.0 104.994 172.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 p -95.48 96.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 C-N-CA 126.816 2.046 . . . . 10.0 105.733 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.0 p90 -117.65 169.04 9.89 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 121.827 0.822 . . . . 10.0 112.228 173.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.9 -157.26 27.2 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 106.959 -2.456 . . . . 10.0 106.959 169.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 p -149.24 160.3 43.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 176.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pp -111.52 175.61 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 CA-C-N 114.69 -1.141 . . . . 10.0 109.393 167.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ptmt -143.83 141.43 30.35 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 106.185 -1.783 . . . . 10.0 106.185 166.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.02 -5.43 20.14 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.122 0.867 . . . . 10.0 114.734 170.731 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -70.07 178.13 2.89 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 118.712 1.256 . . . . 10.0 111.502 -179.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.6 t -111.76 156.14 22.41 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 167.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -50.26 156.67 0.79 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.362 1.465 . . . . 10.0 113.073 -169.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.57 -169.24 32.61 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 123.422 0.534 . . . . 10.0 111.784 168.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.49 146.33 44.99 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 124.61 1.164 . . . . 10.0 111.135 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -143.2 151.19 40.34 Favored 'General case' 0 C--N 1.34 0.19 0 N-CA-C 113.684 0.994 . . . . 10.0 113.684 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.05 119.68 0.16 Allowed Glycine 0 C--N 1.339 0.714 0 C-N-CA 129.337 3.351 . . . . 10.0 113.662 166.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -152.4 112.48 4.02 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 120.047 1.923 . . . . 10.0 112.785 168.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.557 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 1.0 OUTLIER -142.22 173.1 11.83 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.645 0.736 . . . . 10.0 111.532 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 46.1 t -106.43 117.77 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 CA-C-N 111.927 -2.397 . . . . 10.0 104.691 168.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -92.81 148.61 21.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 172.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -60.1 -57.16 14.03 Favored 'General case' 0 N--CA 1.45 -0.475 0 CA-C-N 115.113 -0.949 . . . . 10.0 109.979 -171.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -77.67 148.49 34.98 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 108.91 -0.774 . . . . 10.0 108.91 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.55 -5.33 69.33 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 125.022 1.296 . . . . 10.0 110.15 166.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -40.7 143.03 0.38 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.805 1.242 . . . . 10.0 111.422 169.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -153.29 23.56 0.55 Allowed 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 113.89 -1.505 . . . . 10.0 111.359 168.309 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.429 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.83 -36.15 71.86 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 118.685 0.675 . . . . 10.0 110.865 -172.361 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.92 -22.98 39.23 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.673 1.189 . . . . 10.0 112.966 175.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.24 107.42 1.46 Allowed Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.251 0.929 . . . . 10.0 111.45 -174.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 28.7 m 33.45 55.55 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 127.557 2.343 . . . . 10.0 113.537 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.3 -54.81 0.08 Allowed 'General case' 0 N--CA 1.448 -0.568 0 O-C-N 121.439 -0.788 . . . . 10.0 108.955 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 59' ' ' SER . . . . . 0.427 ' C ' ' H ' ' B' ' 61' ' ' GLY . 52.5 m -79.77 -5.52 55.47 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.251 0.621 . . . . 10.0 112.43 -174.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.37 8.31 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.365 1.866 . . . . 10.0 114.829 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . 0.427 ' H ' ' C ' ' B' ' 59' ' ' SER . . . 87.26 113.21 0.99 Allowed Glycine 0 CA--C 1.528 0.862 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 175.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.02 69.17 3.12 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.909 2.406 . . . . 10.0 111.299 175.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.44 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 11.8 m170 70.52 43.29 0.79 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.605 2.762 . . . . 10.0 110.231 170.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -73.95 45.89 0.22 Allowed 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.738 1.215 . . . . 10.0 114.183 -175.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -51.76 155.81 2.73 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.19 1.396 . . . . 10.0 111.54 169.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.47 -51.21 0.76 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.538 2.158 . . . . 10.0 111.866 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -74.97 53.63 0.61 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.954 0.902 . . . . 10.0 112.7 -177.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -54.2 108.82 0.41 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 122.793 0.437 . . . . 10.0 110.133 -171.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 mtt180 -120.61 -91.74 0.55 Allowed 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 105.892 -1.892 . . . . 10.0 105.892 -174.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -148.23 157.11 43.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 168.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -62.02 116.78 5.2 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 117.869 -1.533 . . . . 10.0 107.643 164.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.56 -145.99 6.44 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 107.695 -2.162 . . . . 10.0 107.695 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.4 -164.76 18.09 Favored Glycine 0 C--N 1.33 0.225 0 N-CA-C 108.771 -1.732 . . . . 10.0 108.771 173.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.89 -1.19 3.9 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.983 1.788 . . . . 10.0 110.951 167.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -84.29 -29.35 26.48 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 123.803 0.841 . . . . 10.0 109.279 171.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -107.46 161.72 14.58 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 123.161 0.584 . . . . 10.0 109.483 -170.054 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -92.49 -9.11 42.59 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.512 0.725 . . . . 10.0 109.293 167.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -97.04 0.23 48.34 Favored 'General case' 0 N--CA 1.438 -1.05 0 CA-C-O 116.035 -1.936 . . . . 10.0 113.521 -176.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.8 137.32 0.65 Allowed 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 120.101 1.319 . . . . 10.0 110.57 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -59.32 -37.23 77.27 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 120.159 -0.616 . . . . 10.0 111.341 -170.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.1 -61.23 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 106.61 -1.626 . . . . 10.0 106.61 172.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.46 -56.04 0.32 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 173.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 39.29 85.5 0.02 OUTLIER 'General case' 0 C--N 1.346 0.429 0 C-N-CA 126.325 1.85 . . . . 10.0 108.618 -167.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -49.79 -33.14 15.63 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.349 1.06 . . . . 10.0 112.749 -166.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.03 -89.13 0.42 Allowed Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 168.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -155.06 101.14 2.23 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.639 -0.875 . . . . 10.0 108.639 -170.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -83.6 128.83 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.137 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 174.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.3 t -90.83 130.33 36.8 Favored 'General case' 0 C--O 1.225 -0.2 0 N-CA-C 108.733 -0.84 . . . . 10.0 108.733 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.15 131.86 48.4 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.407 -0.961 . . . . 10.0 108.407 171.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -58.88 168.31 1.31 Allowed 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 124.246 0.966 . . . . 10.0 109.832 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -30.2 18.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.083 0.953 . . . . 10.0 111.3 170.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.71 -7.09 56.01 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 120.958 -0.297 . . . . 10.0 111.091 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.56 28.14 55.82 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.566 -1.413 . . . . 10.0 109.566 -178.197 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 34.9 t -107.7 115.48 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.862 0 N-CA-C 104.617 -2.364 . . . . 10.0 104.617 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -113.53 123.27 49.61 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 107.544 -1.28 . . . . 10.0 107.544 174.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -85.15 119.66 25.78 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 127.32 2.248 . . . . 10.0 109.044 174.14 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 93.9 t -105.12 133.76 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 C-N-CA 124.636 1.174 . . . . 10.0 107.848 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 84.5 p -158.91 72.29 0.56 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 123.564 0.746 . . . . 10.0 111.015 169.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -104.6 153.47 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -117.91 81.74 1.72 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 128.43 2.692 . . . . 10.0 108.103 -176.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -75.84 113.74 13.66 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.768 -1.938 . . . . 10.0 105.768 -176.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 15.1 m -108.48 35.58 3.13 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.819 -1.082 . . . . 10.0 109.963 -174.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.5 p -126.02 -43.07 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-O 118.538 -0.744 . . . . 10.0 110.622 171.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.361 0.0 OUTLIER -91.83 176.11 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 N-CA-C 113.707 1.002 . . . . 10.0 113.707 178.422 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 34.0 m -152.69 145.9 24.7 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 121.615 -0.678 . . . . 10.0 109.972 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -66.23 -18.14 65.17 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 124.159 0.984 . . . . 10.0 112.464 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.9 t . . . . . 0 N--CA 1.451 -0.421 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.467 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.531 0.23 0 N-CA-C 109.89 -0.411 . . . . 10.0 109.89 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.32 0.2 OUTLIER 78.68 -40.22 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 125.264 1.426 . . . . 10.0 112.075 168.817 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.9 mm -24.23 127.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 128.086 2.554 . . . . 10.0 111.342 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 90.2 28.6 17.06 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-O 119.054 -0.859 . . . . 10.0 112.588 -170.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -81.03 176.31 9.93 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.705 -1.22 . . . . 10.0 107.705 166.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -128.66 123.3 32.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.554 -2.017 . . . . 10.0 105.554 167.044 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 mp -96.0 149.75 21.23 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.251 -1.389 . . . . 10.0 107.251 169.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 84.3 t -132.01 133.74 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.703 -1.591 . . . . 10.0 106.703 -174.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -104.34 122.95 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 N-CA-C 107.078 -1.453 . . . . 10.0 107.078 171.155 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -105.43 157.44 17.35 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 115.893 1.812 . . . . 10.0 115.893 -171.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.1 tt0 -43.26 -57.5 2.96 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 128.279 2.632 . . . . 10.0 111.009 173.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -111.42 162.49 15.02 Favored 'General case' 0 CA--C 1.515 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.664 -170.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.13 140.41 58.79 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.888 1.275 . . . . 10.0 107.586 174.012 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.557 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 69.2 m-20 -77.34 132.79 38.76 Favored 'General case' 0 N--CA 1.441 -0.919 0 N-CA-C 108.579 -0.897 . . . . 10.0 108.579 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -81.56 -4.22 55.42 Favored 'General case' 0 N--CA 1.448 -0.574 0 O-C-N 123.483 0.489 . . . . 10.0 110.81 174.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 37.6 mt 53.59 41.11 32.15 Favored 'General case' 0 N--CA 1.463 0.188 0 O-C-N 120.455 -1.403 . . . . 10.0 110.629 172.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.99 -29.87 9.35 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-O 119.072 -0.849 . . . . 10.0 113.089 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.59 10.1 3.49 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 120.054 1.927 . . . . 10.0 113.617 -169.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.41 -16.91 69.96 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.009 0.814 . . . . 10.0 112.003 173.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.88 31.55 76.48 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.52 0.581 . . . . 10.0 112.505 174.004 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -142.37 176.01 9.33 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 108.165 -1.05 . . . . 10.0 108.165 171.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -59.01 -45.93 89.46 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 116.219 -0.446 . . . . 10.0 110.637 -175.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -67.05 -26.01 66.54 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 120.937 -1.102 . . . . 10.0 110.324 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -52.09 -48.38 64.76 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 119.546 1.066 . . . . 10.0 110.301 168.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -86.8 -15.26 39.81 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 124.073 0.858 . . . . 10.0 111.851 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.8 ttmm -89.82 -48.56 7.17 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 125.416 1.486 . . . . 10.0 111.666 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.421 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 8.9 p -133.88 -14.49 2.41 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 114.98 1.474 . . . . 10.0 114.98 176.154 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.37 30.93 8.73 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 119.668 1.122 . . . . 10.0 112.797 -171.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 32.8 m120 50.82 34.74 10.73 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 119.21 1.505 . . . . 10.0 111.918 -177.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.94 -11.71 61.08 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.764 1.226 . . . . 10.0 111.982 -173.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.91 -158.43 53.06 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 109.633 -1.387 . . . . 10.0 109.633 174.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 128.11 35.42 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.61 0.719 . . . . 10.0 110.643 -169.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.01 73.02 0.07 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 123.997 0.919 . . . . 10.0 109.663 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 79.2 mt -45.8 -41.83 11.46 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 124.726 1.211 . . . . 10.0 112.78 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.56 154.17 22.31 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 -171.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.01 164.53 38.33 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.834 -0.621 . . . . 10.0 109.907 -175.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.32 -176.09 14.34 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 -179.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.4 t -131.95 141.67 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 173.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 8.2 mt -70.78 115.52 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.441 0.564 . . . . 10.0 110.464 -177.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.71 136.72 13.7 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.696 1.141 . . . . 10.0 111.197 -178.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 83.1 mt -65.87 142.15 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 124.516 1.126 . . . . 10.0 109.993 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.03 -52.63 1.31 Allowed 'General case' 0 C--O 1.225 -0.204 0 C-N-CA 123.277 0.631 . . . . 10.0 110.957 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 13.3 tt0 . . . . . 0 C--O 1.25 1.114 0 CA-C-O 116.356 -1.783 . . . . 10.0 112.937 -172.489 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.757 0 N-CA-C 108.266 -1.013 . . . . 10.0 108.266 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -166.84 -42.97 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.77 1.228 . . . . 10.0 110.039 175.382 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.9 mtpm? -114.13 148.73 36.72 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 171.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.33 163.25 38.8 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.396 1.479 . . . . 10.0 107.725 177.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -139.94 167.13 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 122.88 0.472 . . . . 10.0 110.718 -177.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.39 114.72 7.95 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 124.14 0.976 . . . . 10.0 108.393 167.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -94.1 118.74 40.75 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 123.832 0.853 . . . . 10.0 108.705 171.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt -104.9 140.89 37.47 Favored 'General case' 0 C--O 1.224 -0.237 0 CA-C-O 118.089 -0.957 . . . . 10.0 109.308 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt -148.42 162.13 40.2 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-N 120.312 1.415 . . . . 10.0 107.866 168.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.29 -72.44 0.02 OUTLIER Glycine 0 C--O 1.228 -0.237 0 CA-C-N 115.117 -0.947 . . . . 10.0 112.295 169.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.73 -41.48 62.48 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 106.972 -1.492 . . . . 10.0 106.972 -170.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.64 -61.39 0.56 Allowed Glycine 0 N--CA 1.441 -0.99 0 CA-C-N 113.697 -1.592 . . . . 10.0 112.401 175.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -55.3 -43.18 61.21 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 CA-C-N 119.12 1.46 . . . . 10.0 110.68 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -64.63 117.51 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.985 0 N-CA-C 108.486 -0.931 . . . . 10.0 108.486 177.219 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.16 109.52 12.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.731 -2.322 . . . . 10.0 104.731 168.437 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.39 143.29 17.82 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 109.181 -1.568 . . . . 10.0 109.181 175.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.434 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 2.9 mt -143.11 86.87 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 -178.31 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -97.95 145.46 9.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 C-N-CA 123.874 0.87 . . . . 10.0 109.599 177.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -126.13 143.38 51.15 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 125.321 1.448 . . . . 10.0 109.271 170.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -125.57 106.17 9.56 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 107.457 -1.312 . . . . 10.0 107.457 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -103.54 111.57 24.09 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 114.074 1.139 . . . . 10.0 114.074 176.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -78.75 95.06 5.23 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.297 -2.112 . . . . 10.0 105.297 165.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -56.14 -53.7 53.9 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 126.285 1.834 . . . . 10.0 109.741 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.78 -156.88 0.71 Allowed 'General case' 0 N--CA 1.434 -1.236 0 N-CA-C 104.111 -2.551 . . . . 10.0 104.111 168.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.36 -27.48 25.83 Favored 'General case' 0 N--CA 1.443 -0.789 0 O-C-N 122.131 -0.356 . . . . 10.0 110.06 169.141 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -108.23 -6.33 16.41 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.953 1.301 . . . . 10.0 111.314 -171.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.57 149.29 49.52 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.597 -1.001 . . . . 10.0 110.597 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -62.98 125.31 15.62 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 N-CA-C 107.392 -1.811 . . . . 10.0 107.392 169.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.8 t -79.34 103.15 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 106.647 -1.612 . . . . 10.0 106.647 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -67.97 112.49 5.0 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 105.858 -1.905 . . . . 10.0 105.858 167.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -95.62 104.99 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 105.61 -1.996 . . . . 10.0 105.61 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 19.9 p90 -112.48 164.18 13.59 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.238 0.542 . . . . 10.0 109.671 177.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -177.44 157.51 22.21 Favored Glycine 0 N--CA 1.434 -1.464 0 C-N-CA 119.946 -1.121 . . . . 10.0 110.506 176.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.6 p -128.54 86.37 2.44 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 106.853 -1.536 . . . . 10.0 106.853 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.2 pt -76.99 154.21 5.58 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 C-N-CA 117.736 -1.585 . . . . 10.0 107.271 168.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.1 ptmm? -145.79 119.77 9.38 Favored 'General case' 0 N--CA 1.446 -0.638 0 O-C-N 124.192 0.932 . . . . 10.0 109.242 172.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.28 8.43 4.98 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-O 118.802 -0.999 . . . . 10.0 114.442 166.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.403 ' CD1' ' N ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -83.07 179.0 7.87 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 107.201 -1.407 . . . . 10.0 107.201 168.795 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -77.9 167.06 22.1 Favored 'General case' 0 N--CA 1.453 -0.317 0 O-C-N 121.04 -1.038 . . . . 10.0 109.174 169.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -65.67 179.09 0.88 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.813 0.845 . . . . 10.0 112.051 -175.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.9 -171.01 44.32 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.211 -0.756 . . . . 10.0 111.211 169.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -76.24 140.46 41.61 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.184 1.394 . . . . 10.0 110.736 -177.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -140.92 139.64 34.36 Favored 'General case' 0 C--N 1.341 0.228 0 N-CA-C 113.907 1.076 . . . . 10.0 113.907 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -37.4 117.13 0.46 Allowed Glycine 0 C--N 1.341 0.852 0 C-N-CA 128.646 3.022 . . . . 10.0 111.945 166.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -135.65 109.18 7.93 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 120.005 1.903 . . . . 10.0 110.324 170.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.426 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -151.12 170.07 20.32 Favored 'General case' 0 CA--C 1.513 -0.462 0 C-N-CA 123.413 0.685 . . . . 10.0 110.372 176.679 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 34.2 m -105.39 -27.11 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 C-N-CA 127.048 2.139 . . . . 10.0 113.171 -169.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 24.9 m-70 61.09 165.18 0.08 Allowed 'General case' 0 C--N 1.342 0.244 0 C-N-CA 124.436 1.095 . . . . 10.0 112.92 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -75.99 -56.53 4.58 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 121.726 -0.609 . . . . 10.0 111.121 171.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -75.98 111.26 11.18 Favored 'General case' 0 C--N 1.341 0.216 0 C-N-CA 119.888 -0.725 . . . . 10.0 110.881 -169.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.3 -39.32 95.92 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 108.852 -1.699 . . . . 10.0 108.852 166.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -34.65 122.82 0.53 Allowed 'General case' 0 C--N 1.341 0.223 0 C-N-CA 125.638 1.575 . . . . 10.0 112.219 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -129.06 18.13 6.07 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 124.529 1.132 . . . . 10.0 111.354 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.467 HG22 ' CG2' ' B' ' 17' ' ' ILE . 2.8 m -54.21 -36.75 63.82 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 119.49 1.041 . . . . 10.0 111.036 -175.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.01 -22.04 53.69 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.386 0.674 . . . . 10.0 112.106 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.61 -163.15 18.61 Favored Glycine 0 N--CA 1.443 -0.891 0 N-CA-C 107.328 -2.309 . . . . 10.0 107.328 -169.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 90.5 m -74.69 49.56 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.202 1.401 . . . . 10.0 111.052 176.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -137.58 -45.83 0.55 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 126.493 1.917 . . . . 10.0 109.574 -177.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -47.99 -31.44 5.32 Favored 'General case' 0 C--N 1.341 0.239 0 C-N-CA 123.146 0.578 . . . . 10.0 111.219 171.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.89 -42.01 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 128.132 2.573 . . . . 10.0 114.639 169.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.43 150.33 26.76 Favored Glycine 0 C--N 1.339 0.7 0 N-CA-C 110.64 -0.984 . . . . 10.0 110.64 168.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -80.54 54.43 5.22 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.192 1.928 . . . . 10.0 111.079 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.426 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 19.6 m170 65.6 -65.93 0.16 Allowed 'General case' 0 C--O 1.226 -0.183 0 C-N-CA 128.502 2.721 . . . . 10.0 111.468 -177.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.265 10.7 p90 36.08 23.4 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 130.594 3.558 . . . . 10.0 118.944 174.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -49.72 158.13 0.9 Allowed Pre-proline 0 CA--C 1.541 0.628 0 C-N-CA 125.98 1.712 . . . . 10.0 114.634 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -57.07 -45.01 38.77 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.583 2.855 . . . . 10.0 112.473 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 78.1 mt -75.1 58.21 0.88 Allowed 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.887 -0.782 . . . . 10.0 108.887 172.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -66.3 72.7 0.08 Allowed 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 128.748 2.819 . . . . 10.0 108.798 -176.697 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 mtt180 -92.16 -91.37 0.16 Allowed 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 105.231 -2.137 . . . . 10.0 105.231 -173.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.1 mttp -149.83 144.48 26.01 Favored 'General case' 0 N--CA 1.425 -1.7 0 N-CA-C 104.21 -2.515 . . . . 10.0 104.21 164.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -52.64 117.59 3.01 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 118.871 -1.131 . . . . 10.0 109.672 167.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.4 -154.72 7.9 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 107.037 -2.425 . . . . 10.0 107.037 175.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.43 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -162.92 -160.87 11.6 Favored Glycine 0 C--O 1.225 -0.413 0 N-CA-C 108.755 -1.738 . . . . 10.0 108.755 174.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -65.51 10.08 0.17 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 CA-C-N 120.864 2.332 . . . . 10.0 111.318 169.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.43 ' H ' ' C ' ' A' ' 73' ' ' GLY . 26.1 mmtp -107.36 -13.6 15.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 119.204 0.911 . . . . 10.0 109.065 175.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -140.82 140.5 34.69 Favored 'General case' 0 C--N 1.348 0.526 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 -169.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -76.13 -20.08 57.93 Favored 'General case' 0 C--N 1.332 -0.167 0 O-C-N 121.106 -0.996 . . . . 10.0 108.819 -169.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -77.18 -5.91 50.95 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 124.412 1.085 . . . . 10.0 111.962 -173.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -35.54 133.92 0.35 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.038 1.335 . . . . 10.0 112.862 -179.163 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -61.5 -79.7 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.246 0.545 . . . . 10.0 110.028 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -130.45 -91.42 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -108.93 52.39 0.65 Allowed Glycine 0 CA--C 1.521 0.421 0 N-CA-C 109.899 -1.28 . . . . 10.0 109.899 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.3 m-20 -72.37 93.64 1.54 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 105.759 -1.941 . . . . 10.0 105.759 168.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 26.6 mt -75.32 -29.42 60.01 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.73 -104.29 2.82 Favored Glycine 0 N--CA 1.439 -1.105 0 N-CA-C 110.559 -1.016 . . . . 10.0 110.559 168.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -125.67 101.02 6.69 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 125.713 1.605 . . . . 10.0 110.54 -167.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 5.0 m -110.04 140.19 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.616 0.766 . . . . 10.0 111.334 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.32 129.73 34.74 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 128.079 2.552 . . . . 10.0 112.416 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -110.16 134.48 52.16 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.342 1.457 . . . . 10.0 109.591 169.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -59.46 169.13 1.33 Allowed 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.015 1.326 . . . . 10.0 111.133 169.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 7.0 ptmt -47.52 -33.19 6.06 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.751 2.02 . . . . 10.0 111.348 172.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.69 -14.05 59.04 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 122.64 0.376 . . . . 10.0 111.13 -176.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.03 17.42 51.29 Favored Glycine 0 C--N 1.341 0.839 0 N-CA-C 110.44 -1.064 . . . . 10.0 110.44 -175.215 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.94 109.57 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 C-N-CA 126.645 1.978 . . . . 10.0 106.962 -179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.34 118.28 36.16 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.071 -0.715 . . . . 10.0 109.071 169.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -85.01 84.38 7.74 Favored 'General case' 0 N--CA 1.437 -1.119 0 C-N-CA 127.416 2.286 . . . . 10.0 109.327 174.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -75.86 129.57 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.307 0 N-CA-C 105.136 -2.172 . . . . 10.0 105.136 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -156.93 59.72 0.52 Allowed 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 122.869 0.467 . . . . 10.0 109.948 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.51 164.02 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -176.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -134.31 135.41 42.78 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.558 0.743 . . . . 10.0 111.215 169.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -131.1 131.11 43.94 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.973 1.309 . . . . 10.0 108.554 -175.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.5 p -98.31 24.2 7.52 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.851 0.86 . . . . 10.0 110.107 169.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.3 p -149.27 20.41 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.032 0.933 . . . . 10.0 110.722 -172.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -122.28 134.52 65.27 Favored 'Isoleucine or valine' 0 C--N 1.34 0.158 0 N-CA-C 102.591 -3.115 . . . . 10.0 102.591 169.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.5 m -146.73 125.77 12.85 Favored 'General case' 0 CA--C 1.527 0.074 0 CA-C-N 118.451 0.569 . . . . 10.0 109.699 -176.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.9 mp -54.53 -48.42 71.98 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.699 1.199 . . . . 10.0 110.52 177.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -137.02 176.35 8.79 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.549 1.54 . . . . 10.0 106.925 169.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.66 -97.25 0.4 Allowed Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 108.15 -1.98 . . . . 10.0 108.15 -176.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -121.96 -50.98 2.03 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 125.758 1.623 . . . . 10.0 108.461 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -73.5 -42.76 61.42 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.249 -1.389 . . . . 10.0 107.249 -171.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.4 t 47.19 54.88 8.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 126.004 1.722 . . . . 10.0 111.94 169.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.1 pt -60.01 -3.9 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 127.746 2.418 . . . . 10.0 115.222 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.3 mp -52.13 144.16 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 O-C-N 121.26 -0.9 . . . . 10.0 111.258 169.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.82 7.52 87.9 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.163 -0.798 . . . . 10.0 113.064 173.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -85.62 172.72 10.69 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.817 0.809 . . . . 10.0 109.123 170.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -122.43 104.64 9.53 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.908 0.883 . . . . 10.0 110.56 -175.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -62.42 130.14 43.88 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 108.261 -1.014 . . . . 10.0 108.261 172.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 51.2 t -119.64 132.65 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 169.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -100.99 121.86 52.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.245 -1.761 . . . . 10.0 106.245 169.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -106.32 164.16 12.25 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.364 1.246 . . . . 10.0 114.364 -173.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -45.13 -57.43 3.91 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 129.354 3.061 . . . . 10.0 111.476 174.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 61.2 mttt -126.17 175.32 7.86 Favored 'General case' 0 CA--C 1.522 -0.116 0 C-N-CA 124.552 1.141 . . . . 10.0 112.581 -169.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.89 152.57 41.4 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.051 1.341 . . . . 10.0 110.878 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -82.77 145.47 29.52 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 116.031 -0.531 . . . . 10.0 111.183 169.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -81.41 -16.07 53.24 Favored 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 125.025 1.453 . . . . 10.0 110.257 166.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 84.4 mt 57.37 64.14 1.68 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 122.721 1.248 . . . . 10.0 109.447 176.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.64 -41.41 3.07 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 114.714 -1.13 . . . . 10.0 110.937 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 29.1 mtmm -78.75 36.09 0.26 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.488 1.515 . . . . 10.0 112.341 -174.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.23 -7.27 52.45 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 127.252 2.358 . . . . 10.0 110.892 170.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 42.38 49.53 5.65 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.98 1.752 . . . . 10.0 114.009 177.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -153.29 172.56 16.83 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 169.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.0 mp0 -44.77 -50.64 10.02 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 123.021 0.528 . . . . 10.0 111.104 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.63 -28.36 66.83 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 118.694 -0.67 . . . . 10.0 111.035 -177.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.8 p -54.95 -37.6 66.66 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 119.902 1.228 . . . . 10.0 112.255 175.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -85.98 -0.26 55.03 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 123.348 0.405 . . . . 10.0 111.73 -178.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.1 mttt -111.71 -66.46 1.08 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.834 1.254 . . . . 10.0 111.125 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -128.99 23.07 5.69 Favored 'General case' 0 CA--C 1.543 0.698 0 CA-C-N 119.434 1.015 . . . . 10.0 112.042 -175.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.6 -87.26 0.35 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -172.34 37.93 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 125.164 1.386 . . . . 10.0 109.073 169.055 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.09 -13.92 62.58 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -168.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.23 54.81 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.275 -1.13 . . . . 10.0 110.275 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -56.08 128.75 36.95 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 123.976 0.91 . . . . 10.0 112.038 -168.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.9 mtm105 -66.68 74.79 0.1 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 124.956 1.302 . . . . 10.0 110.44 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 71.0 mt -46.88 -49.78 19.75 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.447 0.699 . . . . 10.0 111.881 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.65 155.63 38.75 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -169.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.17 165.07 37.47 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 122.564 0.346 . . . . 10.0 111.436 -175.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.78 170.16 38.23 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 125.339 1.447 . . . . 10.0 109.931 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 7.7 t -116.96 142.99 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 118.16 0.98 . . . . 10.0 108.693 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 41.2 mt -83.06 119.63 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.717 0 C-N-CA 123.728 0.811 . . . . 10.0 109.303 -176.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.17 159.75 24.13 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.775 -0.53 . . . . 10.0 111.775 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 55.6 mt -74.4 150.9 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 125.086 1.354 . . . . 10.0 110.415 -169.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.95 -106.59 0.38 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 167.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.922 1 C-N-CA 132.302 4.241 . . . . 10.0 102.72 -169.554 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.624 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.9 t -145.4 -51.81 0.26 Allowed 'General case' 0 CA--C 1.514 -0.418 0 C-N-CA 125.194 1.398 . . . . 10.0 108.482 176.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -110.24 145.81 36.71 Favored 'General case' 0 N--CA 1.44 -0.941 0 C-N-CA 126.567 1.947 . . . . 10.0 106.159 -172.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.57 149.6 30.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 172.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.5 m -129.69 161.31 39.51 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 O-C-N 123.718 0.636 . . . . 10.0 110.388 -176.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.16 105.11 4.03 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.418 -0.956 . . . . 10.0 108.418 170.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.02 91.85 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 170.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -77.36 143.59 38.61 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 108.309 -0.997 . . . . 10.0 108.309 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.14 165.14 32.23 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 107.959 -1.126 . . . . 10.0 107.959 173.027 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -168.67 -58.5 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 115.583 -0.735 . . . . 10.0 111.665 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.52 -45.23 47.17 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 -173.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.04 -68.28 0.52 Allowed Glycine 0 N--CA 1.445 -0.754 0 CA-C-N 113.75 -1.568 . . . . 10.0 110.288 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -57.84 -37.49 96.16 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.852 2.368 . . . . 10.0 111.068 174.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.26 102.76 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 N-CA-C 107.083 -1.451 . . . . 10.0 107.083 175.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -118.97 117.99 30.29 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -99.17 132.05 10.78 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 172.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . 0.467 ' CG2' HG22 ' A' ' 54' ' ' THR . 6.5 mt -135.15 88.62 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 N-CA-C 107.01 -1.478 . . . . 10.0 107.01 -174.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -103.05 140.92 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 125.258 1.423 . . . . 10.0 109.659 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -124.87 112.47 16.68 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.047 1.739 . . . . 10.0 108.109 169.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -93.03 119.24 32.07 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.489 -1.301 . . . . 10.0 107.489 171.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -111.26 143.24 42.36 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 118.926 0.785 . . . . 10.0 111.447 168.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -92.6 118.14 30.7 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 103.909 -2.626 . . . . 10.0 103.909 166.359 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 79.3 mttt . . . . . 0 C--N 1.33 -0.262 0 CA-C-O 121.742 0.782 . . . . 10.0 109.412 171.955 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.686 0 N-CA-C 108.932 -1.667 . . . . 10.0 108.932 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -65.48 135.73 43.71 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.637 1.558 . . . . 10.0 108.446 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -78.23 107.22 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -77.11 108.91 10.53 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 106.284 -1.747 . . . . 10.0 106.284 170.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -85.85 105.99 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 25.3 p90 -113.99 163.81 14.64 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.444 0.64 . . . . 10.0 110.969 170.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 177.63 170.12 39.51 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.224 -0.75 . . . . 10.0 111.224 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.1 p -140.03 100.55 3.95 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.997 -1.483 . . . . 10.0 106.997 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 6.6 pt -78.12 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 C-N-CA 118.64 -1.224 . . . . 10.0 109.247 170.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -152.91 155.01 36.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 168.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.4 34.1 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 119.033 -0.87 . . . . 10.0 115.011 169.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.5 mp -72.45 177.79 4.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 118.934 1.367 . . . . 10.0 110.649 -177.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.25 161.56 15.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.295 -1.002 . . . . 10.0 108.295 168.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -55.74 163.34 1.42 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.227 1.011 . . . . 10.0 112.249 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.98 -175.37 33.66 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-O 121.863 0.702 . . . . 10.0 112.501 168.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -68.2 143.91 55.15 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.409 1.484 . . . . 10.0 109.999 -178.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -142.05 147.78 37.39 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 113.394 0.887 . . . . 10.0 113.394 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.38 125.5 0.27 Allowed Glycine 0 C--N 1.341 0.823 0 C-N-CA 127.738 2.59 . . . . 10.0 111.878 165.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -151.69 108.64 3.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 119.104 1.452 . . . . 10.0 110.473 166.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.503 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -147.66 172.29 14.29 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 122.407 1.099 . . . . 10.0 113.046 179.043 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.96 134.75 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.671 0 CA-C-N 111.191 -2.731 . . . . 10.0 106.418 169.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 47.1 m-70 -116.77 141.44 48.2 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 106.214 -1.773 . . . . 10.0 106.214 171.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -54.68 -52.23 63.03 Favored 'General case' 0 N--CA 1.451 -0.399 0 O-C-N 124.144 0.903 . . . . 10.0 111.915 -168.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -76.92 137.78 39.3 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 -175.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.62 12.51 51.78 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 124.381 0.991 . . . . 10.0 111.649 167.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -79.69 174.76 11.26 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-O 121.864 0.84 . . . . 10.0 110.123 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -165.3 30.56 0.06 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.552 -1.204 . . . . 10.0 112.641 168.625 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.434 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.41 -35.24 79.75 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 119.696 1.134 . . . . 10.0 112.423 -168.923 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.46 -20.75 50.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 118.06 0.391 . . . . 10.0 111.737 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.73 -160.43 13.2 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 105.852 -2.899 . . . . 10.0 105.852 -167.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 59.9 m -70.21 65.75 0.27 Allowed 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 126.321 1.848 . . . . 10.0 111.547 -175.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -153.38 -52.53 0.1 Allowed 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 124.446 1.098 . . . . 10.0 108.727 177.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 18.4 m -51.38 -34.94 36.52 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.205 1.002 . . . . 10.0 111.809 -177.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -26.8 -38.88 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.848 2.859 . . . . 10.0 114.47 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 110.39 139.69 8.3 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 110.285 -1.126 . . . . 10.0 110.285 169.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.27 55.54 4.65 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.61 3.54 . . . . 10.0 113.266 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 18.2 m170 62.88 48.58 3.94 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.418 2.287 . . . . 10.0 109.197 178.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -66.84 71.78 0.09 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.296 1.038 . . . . 10.0 111.68 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.0 p-10 -84.1 153.33 63.05 Favored Pre-proline 0 C--N 1.326 -0.45 0 O-C-N 121.212 -0.93 . . . . 10.0 111.84 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.66 -43.9 1.7 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.685 2.256 . . . . 10.0 111.447 176.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.0 mt -75.98 62.27 1.61 Allowed 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.711 0.805 . . . . 10.0 109.94 -178.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.2 p -40.28 99.87 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.423 1.889 . . . . 10.0 112.796 -173.087 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 14.2 mtp180 -140.26 177.71 7.8 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 126.058 1.743 . . . . 10.0 107.961 -175.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.5 mttt -110.66 82.47 1.6 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 112.218 0.451 . . . . 10.0 112.218 -168.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.439 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 69.1 t60 18.0 93.4 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 116.275 1.954 . . . . 10.0 116.275 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.07 -157.45 16.41 Favored Glycine 0 N--CA 1.441 -0.983 0 C-N-CA 125.223 1.392 . . . . 10.0 110.766 177.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.46 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -165.86 -159.21 11.56 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 106.351 -2.699 . . . . 10.0 106.351 169.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -63.88 6.45 0.28 Allowed 'Trans proline' 0 CA--C 1.543 0.967 0 CA-C-N 120.665 2.233 . . . . 10.0 111.546 168.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.46 ' H ' ' C ' ' B' ' 73' ' ' GLY . 11.7 mmmt -114.15 5.88 16.1 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 125.59 1.556 . . . . 10.0 110.064 176.108 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -141.32 169.13 18.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 119.729 1.15 . . . . 10.0 109.342 167.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.71 -27.05 29.27 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 166.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.87 33.51 0.33 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 124.621 1.168 . . . . 10.0 113.217 -171.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.02 138.76 11.3 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 167.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . 0.439 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 30.9 m80 -66.48 -62.45 1.46 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 118.16 -1.416 . . . . 10.0 108.611 169.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.4 p -164.45 -58.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 108.679 -0.86 . . . . 10.0 108.679 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.8 66.5 0.35 Allowed Glycine 0 C--N 1.334 0.471 0 N-CA-C 109.067 -1.613 . . . . 10.0 109.067 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -112.07 101.62 9.89 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.822 -1.918 . . . . 10.0 105.822 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 19.4 mt -72.65 -18.37 61.58 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.27 0.486 . . . . 10.0 112.195 -169.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 112.73 -95.44 0.78 Allowed Glycine 0 N--CA 1.443 -0.866 0 N-CA-C 106.781 -2.528 . . . . 10.0 106.781 -173.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -155.12 150.61 27.35 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.099 -1.075 . . . . 10.0 108.099 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.05 131.39 62.41 Favored 'Isoleucine or valine' 0 C--O 1.232 0.143 0 N-CA-C 107.332 -1.359 . . . . 10.0 107.332 168.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -95.22 119.12 33.18 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.006 0.522 . . . . 10.0 109.594 -176.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.96 133.54 38.61 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.707 1.203 . . . . 10.0 110.261 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -61.31 168.99 2.38 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.572 1.149 . . . . 10.0 109.215 166.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.18 -29.41 45.66 Favored 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 123.357 0.663 . . . . 10.0 111.385 172.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -77.63 -5.04 48.98 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 121.204 0.526 . . . . 10.0 111.423 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.0 3.17 88.0 Favored Glycine 0 C--N 1.338 0.694 0 O-C-N 120.785 -1.197 . . . . 10.0 111.067 -176.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.47 106.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.16 -1.422 . . . . 10.0 107.16 179.251 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.46 126.01 50.36 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 109.18 -0.674 . . . . 10.0 109.18 170.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -79.43 126.33 30.7 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 168.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 54.1 t -107.23 131.16 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 168.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.1 p -157.92 56.2 0.48 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 118.316 0.507 . . . . 10.0 111.152 176.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.93 152.05 4.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 C-N-CA 124.301 1.04 . . . . 10.0 109.055 -171.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -102.86 106.8 17.44 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 125.766 1.626 . . . . 10.0 108.865 174.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -80.11 77.58 6.81 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.103 -1.443 . . . . 10.0 107.103 175.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.1 m -80.61 50.03 1.26 Allowed 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -155.38 -48.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 C-N-CA 122.606 0.362 . . . . 10.0 110.994 -168.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.343 1.1 pp -104.22 177.09 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 C-N-CA 123.6 0.76 . . . . 10.0 112.24 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -138.12 138.92 39.15 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.848 -1.167 . . . . 10.0 107.848 171.209 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.88 -24.68 26.56 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 104.149 -2.538 . . . . 10.0 104.149 168.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 32.2 t . . . . . 0 N--CA 1.445 -0.693 0 CA-C-O 120.342 0.115 . . . . 10.0 111.306 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 8.1 pt -69.83 49.69 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 C-N-CA 125.783 1.633 . . . . 10.0 111.848 176.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -97.95 151.4 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 C-N-CA 126.5 1.92 . . . . 10.0 107.052 171.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 59.52 32.27 72.78 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.319 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 mmt-85 -105.34 170.44 7.88 Favored 'General case' 0 CA--C 1.536 0.424 0 N-CA-C 106.612 -1.625 . . . . 10.0 106.612 168.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.6 m -112.95 129.38 56.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 177.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 64.6 mt -102.07 141.57 34.71 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 107.806 -1.183 . . . . 10.0 107.806 173.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 67.8 t -129.39 133.32 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.084 -1.45 . . . . 10.0 107.084 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -106.51 134.09 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 105.963 -1.866 . . . . 10.0 105.963 169.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 6.1 m170 -112.13 157.6 20.64 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 123.589 1.661 . . . . 10.0 114.63 -170.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 52.1 tt0 -45.79 -53.24 9.9 Favored 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 128.102 2.561 . . . . 10.0 110.041 179.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -119.58 175.56 5.79 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 125.084 1.354 . . . . 10.0 111.234 -172.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.91 149.68 37.69 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 124.667 1.187 . . . . 10.0 110.48 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.503 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.3 m-20 -77.13 135.62 38.57 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 123.325 0.65 . . . . 10.0 110.238 170.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.3 m-20 -77.13 -21.29 54.41 Favored 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 124.891 1.369 . . . . 10.0 109.72 168.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 76.9 mt 60.71 58.5 2.39 Favored 'General case' 0 C--N 1.342 0.253 0 CA-C-O 123.279 1.514 . . . . 10.0 109.387 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.36 -43.23 3.11 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 112.737 -2.029 . . . . 10.0 110.158 169.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 17.9 mtmm -78.24 44.28 0.49 Allowed 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.625 1.57 . . . . 10.0 111.821 -175.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.21 -33.82 7.47 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.574 2.035 . . . . 10.0 110.12 172.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.17 33.69 48.74 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 123.473 0.559 . . . . 10.0 112.278 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -145.11 165.5 28.08 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 105.905 -1.887 . . . . 10.0 105.905 174.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -55.08 -48.42 73.56 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-O 121.246 0.546 . . . . 10.0 110.068 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -59.86 -30.35 68.92 Favored 'General case' 0 N--CA 1.453 -0.312 0 O-C-N 121.69 -0.631 . . . . 10.0 111.726 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -51.84 -51.91 53.2 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 121.358 -0.838 . . . . 10.0 110.174 169.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.9 t -82.19 -10.74 59.05 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.841 -0.618 . . . . 10.0 112.105 -173.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.4 ttmm -100.17 -52.73 3.32 Favored 'General case' 0 N--CA 1.436 -1.143 0 C-N-CA 125.417 1.487 . . . . 10.0 111.506 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.0 p -140.05 31.18 1.99 Allowed 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.65 0.78 . . . . 10.0 112.2 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.23 19.65 64.28 Favored Glycine 0 C--N 1.339 0.706 0 CA-C-N 119.246 0.93 . . . . 10.0 112.29 174.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 53.62 26.14 5.52 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 117.915 0.858 . . . . 10.0 112.325 -173.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.37 0.78 3.53 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.698 -0.626 . . . . 10.0 112.455 -178.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.75 -165.18 47.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 109.918 -1.273 . . . . 10.0 109.918 168.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -54.19 134.11 44.5 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.61 0.719 . . . . 10.0 110.084 -172.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.04 67.59 0.07 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 169.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -61.71 -25.18 67.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.815 0.672 . . . . 10.0 112.815 -168.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -154.33 148.68 26.08 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.133 0.492 . . . . 10.0 109.793 177.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 21.2 p -158.13 168.78 26.13 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.947 0.499 . . . . 10.0 109.958 -175.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -165.53 167.51 39.02 Favored Glycine 0 CA--C 1.528 0.844 0 N-CA-C 110.704 -0.959 . . . . 10.0 110.704 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 74.0 t -109.64 142.85 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.38 0 C-N-CA 125.48 1.512 . . . . 10.0 107.139 -169.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 67.7 mt -80.35 112.88 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 C-N-CA 122.492 0.317 . . . . 10.0 110.793 -172.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.05 145.39 17.66 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 124.691 1.138 . . . . 10.0 110.745 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 44.9 mt -62.89 148.52 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 124.473 1.109 . . . . 10.0 109.661 174.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.34 170.13 17.43 Favored 'General case' 0 N--CA 1.439 -0.983 0 CA-C-O 122.619 1.2 . . . . 10.0 110.84 168.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 . . . . . 0 C--O 1.25 1.082 0 C-N-CA 129.585 3.154 . . . . 10.0 103.097 165.132 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.803 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -156.35 -44.29 0.07 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 118.47 0.577 . . . . 10.0 110.955 172.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.5 ttpp -113.78 142.87 45.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 106.918 -1.512 . . . . 10.0 106.918 167.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.74 171.06 14.77 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.477 -1.305 . . . . 10.0 107.477 171.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -140.42 166.59 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 123.897 0.879 . . . . 10.0 110.235 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.68 112.37 5.36 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 168.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.4 m -97.59 114.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 173.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -103.51 137.2 41.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 -174.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -146.33 165.39 29.44 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.924 1.238 . . . . 10.0 107.998 170.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.71 -58.81 0.04 OUTLIER Glycine 0 C--O 1.23 -0.096 0 CA-C-N 115.024 -0.989 . . . . 10.0 112.791 169.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.41 -44.91 49.82 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -171.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.48 -65.7 0.57 Allowed Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 113.601 -1.636 . . . . 10.0 110.659 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -59.0 -37.1 95.24 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.737 2.291 . . . . 10.0 111.315 174.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -67.33 106.58 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.007 0 N-CA-C 107.017 -1.475 . . . . 10.0 107.017 175.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -121.78 106.81 11.63 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.03 -1.841 . . . . 10.0 106.03 170.007 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.43 143.39 17.26 Favored Glycine 0 N--CA 1.434 -1.491 0 N-CA-C 109.66 -1.376 . . . . 10.0 109.66 173.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.1 mt -150.22 84.56 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.207 -1.405 . . . . 10.0 107.207 -169.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -96.19 145.43 8.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 C-N-CA 125.273 1.429 . . . . 10.0 110.963 175.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -128.95 117.49 21.05 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.942 2.097 . . . . 10.0 109.126 169.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -95.52 125.45 40.13 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.72 1.208 . . . . 10.0 108.862 178.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.53 132.99 53.62 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 125.121 1.368 . . . . 10.0 111.456 175.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -132.64 79.71 1.86 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 127.971 2.508 . . . . 10.0 106.045 168.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -56.12 -45.63 79.47 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 127.873 2.469 . . . . 10.0 110.658 -172.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -122.75 161.71 23.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 102.305 -3.22 . . . . 10.0 102.305 167.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -58.51 -30.27 66.92 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.473 -0.785 . . . . 10.0 109.073 174.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 m-80 -90.26 -9.13 49.1 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 124.892 1.277 . . . . 10.0 111.037 -174.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.29 138.8 27.01 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -59.82 135.46 63.68 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 N-CA-C 106.044 -2.329 . . . . 10.0 106.044 168.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 t -78.73 129.06 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.016 -1.476 . . . . 10.0 107.016 -170.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt -101.01 118.15 36.44 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -103.03 96.74 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 172.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -103.4 167.14 10.0 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 121.932 0.872 . . . . 10.0 110.613 168.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.03 -177.74 47.61 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.616 -0.802 . . . . 10.0 111.211 175.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.8 m -154.5 91.77 1.43 Allowed 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 -175.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.5 pt -78.96 151.68 4.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 CA-C-O 118.327 -0.844 . . . . 10.0 108.775 169.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.408 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -135.6 156.4 48.92 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 165.614 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.33 -10.13 39.21 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 123.836 0.731 . . . . 10.0 112.887 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -68.68 176.26 3.08 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 118.172 0.986 . . . . 10.0 109.641 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.1 t -105.32 150.41 25.21 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.451 -1.314 . . . . 10.0 107.451 167.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -50.86 146.11 6.34 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.115 0.966 . . . . 10.0 112.276 -169.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.3 -179.26 29.51 Favored Glycine 0 CA--C 1.528 0.85 0 C-N-CA 124.279 0.942 . . . . 10.0 112.128 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mt -57.85 148.72 24.5 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.133 2.173 . . . . 10.0 112.87 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -150.88 147.92 27.81 Favored 'General case' 0 CA--C 1.518 -0.254 0 C-N-CA 125.78 1.632 . . . . 10.0 112.18 176.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -33.17 125.36 0.33 Allowed Glycine 0 C--N 1.338 0.68 0 C-N-CA 126.462 1.982 . . . . 10.0 112.2 164.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -153.13 107.52 3.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 119.158 1.479 . . . . 10.0 110.279 166.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -154.93 169.52 23.85 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.67 0.748 . . . . 10.0 112.021 -179.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.1 m -84.72 153.18 3.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 112.663 -2.062 . . . . 10.0 107.715 168.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.91 148.43 50.49 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 107.536 -1.283 . . . . 10.0 107.536 171.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -35.91 -60.94 0.51 Allowed 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 126.576 1.95 . . . . 10.0 113.736 -170.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -98.8 161.14 13.8 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-O 121.925 0.869 . . . . 10.0 111.368 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.34 -22.88 28.25 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 126.46 1.981 . . . . 10.0 109.866 168.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -44.41 136.93 3.9 Favored 'General case' 0 C--N 1.342 0.243 0 C-N-CA 123.669 0.788 . . . . 10.0 110.275 169.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -141.51 21.1 2.2 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 10.0 111.439 -178.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.6 p -52.06 -39.01 59.03 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 113.961 1.096 . . . . 10.0 113.961 -174.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.04 -11.29 59.92 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.244 0.618 . . . . 10.0 111.619 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 118.66 -64.02 0.42 Allowed Glycine 0 C--O 1.225 -0.425 0 C-N-CA 126.052 1.787 . . . . 10.0 109.253 179.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.5 t -155.19 55.23 0.64 Allowed 'General case' 0 C--O 1.234 0.277 0 CA-C-O 121.789 0.804 . . . . 10.0 109.732 172.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -134.62 -46.47 0.74 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.7 0.8 . . . . 10.0 109.229 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.1 m -51.75 -29.34 18.34 Favored 'General case' 0 C--N 1.344 0.367 0 C-N-CA 123.886 0.874 . . . . 10.0 111.235 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.89 -42.27 0.08 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.748 2.419 . . . . 10.0 112.878 167.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.28 165.93 39.08 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -79.39 -164.86 0.3 Allowed 'Trans proline' 0 N--CA 1.444 -1.409 0 N-CA-C 107.353 -1.826 . . . . 10.0 107.353 169.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -80.25 46.54 0.83 Allowed 'General case' 0 CA--C 1.542 0.657 0 O-C-N 120.69 -1.256 . . . . 10.0 110.634 -176.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -75.31 70.08 2.19 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 119.352 0.978 . . . . 10.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -71.15 149.19 94.42 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 169.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -58.77 -47.12 19.7 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.407 2.071 . . . . 10.0 111.147 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.32 60.82 2.06 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 108.731 -0.841 . . . . 10.0 108.731 174.155 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.5 t -61.19 112.46 2.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 108.664 -0.865 . . . . 10.0 108.664 -178.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 75.4 mtt180 -105.82 -98.66 0.34 Allowed 'General case' 0 CA--C 1.512 -0.491 0 N-CA-C 106.157 -1.794 . . . . 10.0 106.157 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.9 pttt -158.81 144.97 16.84 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 104.982 -2.229 . . . . 10.0 104.982 169.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -47.33 121.78 4.12 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.366 0.603 . . . . 10.0 111.526 174.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.13 -156.13 6.69 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 106.235 -2.746 . . . . 10.0 106.235 169.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.474 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -148.34 -168.84 14.73 Favored Glycine 0 C--O 1.225 -0.43 0 CA-C-N 118.477 1.139 . . . . 10.0 113.464 -178.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -69.73 16.27 0.22 Allowed 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 123.416 2.744 . . . . 10.0 112.303 175.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.474 ' H ' ' C ' ' A' ' 73' ' ' GLY . 0.5 OUTLIER -105.53 -29.24 10.3 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 126.4 1.88 . . . . 10.0 108.999 168.786 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -107.9 172.19 6.97 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -89.41 -26.76 20.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 122.065 0.936 . . . . 10.0 109.351 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -78.6 -11.18 59.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 125.965 1.706 . . . . 10.0 114.692 -167.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.444 HH21 ' CG ' ' A' ' 101' ' ' ASP . 0.0 OUTLIER -34.69 129.17 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.699 1.2 . . . . 10.0 112.186 176.915 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -65.59 169.76 5.84 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 107.81 -1.182 . . . . 10.0 107.81 175.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.2 p -63.55 15.04 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 N-CA-C 115.864 1.801 . . . . 10.0 115.864 -169.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.51 55.91 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.621 0 N-CA-C 108.997 -1.641 . . . . 10.0 108.997 170.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -97.37 102.5 14.28 Favored 'General case' 0 N--CA 1.457 -0.109 0 N-CA-C 106.746 -1.575 . . . . 10.0 106.746 168.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -83.03 9.7 9.66 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.956 0.344 . . . . 10.0 111.49 -177.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 84.55 -100.18 2.35 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 107.536 -2.226 . . . . 10.0 107.536 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -145.57 157.57 43.96 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 107.287 -1.375 . . . . 10.0 107.287 174.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.3 m -112.48 126.12 69.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 109.02 -0.733 . . . . 10.0 109.02 169.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 70.1 m -94.72 101.53 13.38 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 127.518 2.327 . . . . 10.0 109.254 -170.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.7 141.64 37.75 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 122.373 -0.204 . . . . 10.0 111.113 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -69.5 173.77 5.61 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.343 2.257 . . . . 10.0 109.267 167.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -23.91 67.56 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.028 0.381 . . . . 10.0 112.028 174.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.408 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 32.7 t70 -78.21 -1.47 32.99 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 120.993 0.425 . . . . 10.0 111.226 173.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.23 1.11 89.58 Favored Glycine 0 C--N 1.339 0.732 0 O-C-N 120.679 -1.263 . . . . 10.0 110.51 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -77.41 105.66 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 -176.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.64 113.26 26.49 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.389 -0.967 . . . . 10.0 108.389 169.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.29 117.97 20.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 126.603 1.961 . . . . 10.0 107.91 173.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 26.4 t -105.89 135.86 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 N-CA-C 106.399 -1.704 . . . . 10.0 106.399 177.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -158.64 62.41 0.43 Allowed 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 123.649 0.779 . . . . 10.0 110.22 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -107.46 161.63 6.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -139.64 151.76 46.23 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.263 1.025 . . . . 10.0 109.404 167.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.444 ' CG ' HH21 ' A' ' 79' ' ' ARG . 25.0 t0 -146.97 152.43 38.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.645 -1.243 . . . . 10.0 107.645 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.9 p -105.66 -13.26 15.62 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.862 2.465 . . . . 10.0 112.154 -176.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -102.27 16.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 119.603 1.092 . . . . 10.0 110.315 179.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -118.05 142.79 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 104.714 -2.328 . . . . 10.0 104.714 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 91.8 p -142.44 149.8 39.74 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 172.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.2 mt -62.34 -41.17 98.35 Favored 'General case' 0 C--O 1.231 0.105 0 CA-C-N 119.025 0.83 . . . . 10.0 109.485 170.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.3 p -146.95 164.56 32.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.176 1.39 . . . . 10.0 108.947 -178.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 122.87 -105.0 0.91 Allowed Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 106.431 -2.668 . . . . 10.0 106.431 -169.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -126.68 -43.61 1.71 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.368 1.067 . . . . 10.0 110.362 -168.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 20.8 m-70 -73.7 -48.53 31.44 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 105.116 -2.179 . . . . 10.0 105.116 174.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.3 t 45.12 60.7 2.86 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 124.771 1.228 . . . . 10.0 113.214 167.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.8 pt -63.97 -11.43 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 113.339 0.866 . . . . 10.0 113.339 -175.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.1 mm -48.13 141.08 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 119.976 1.262 . . . . 10.0 110.923 170.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.44 16.98 75.9 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 125.074 1.321 . . . . 10.0 115.609 169.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 24.9 mmt-85 -84.65 165.61 17.79 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.917 1.358 . . . . 10.0 108.003 166.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 74.1 m -90.48 127.9 36.37 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 107.572 -1.27 . . . . 10.0 107.572 166.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.08 136.81 32.8 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 165.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.48 136.56 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.743 0 N-CA-C 107.075 -1.454 . . . . 10.0 107.075 171.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -105.25 134.53 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.166 -2.161 . . . . 10.0 105.166 167.038 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -114.11 158.13 21.68 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -170.32 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.67 -48.91 79.46 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 112.883 -1.962 . . . . 10.0 109.08 -174.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.9 mttm -110.76 175.05 5.57 Favored 'General case' 0 C--N 1.34 0.191 0 CA-C-O 121.492 0.663 . . . . 10.0 111.934 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.37 152.81 24.88 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.615 -1.175 . . . . 10.0 110.092 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -76.75 149.11 36.34 Favored 'General case' 0 N--CA 1.443 -0.775 0 C-N-CA 123.782 0.833 . . . . 10.0 112.175 -179.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -79.06 -28.3 43.16 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 112.534 -2.121 . . . . 10.0 110.425 172.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 50.7 mt 50.57 48.47 22.53 Favored 'General case' 0 C--N 1.341 0.219 0 CA-C-O 122.349 1.071 . . . . 10.0 109.812 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.3 -11.06 70.9 Favored Glycine 0 CA--C 1.53 1.011 0 CA-C-N 113.907 -1.497 . . . . 10.0 114.086 169.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -81.57 -0.63 43.1 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.07 1.435 . . . . 10.0 114.078 -168.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.64 -22.44 79.01 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.75 38.86 65.33 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.345 -0.702 . . . . 10.0 111.345 -177.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -135.39 172.37 13.11 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 107.613 -1.254 . . . . 10.0 107.613 174.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -54.63 -47.89 72.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.424 0.631 . . . . 10.0 109.809 -178.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.27 -39.77 80.1 Favored 'General case' 0 C--O 1.236 0.353 0 O-C-N 121.516 -0.74 . . . . 10.0 111.707 176.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.3 p -53.28 -38.76 63.38 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 118.655 -0.688 . . . . 10.0 110.375 177.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.9 t -87.24 -7.83 57.46 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 123.703 0.627 . . . . 10.0 112.333 -177.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.9 mttt -103.17 -60.88 1.48 Allowed 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.215 -0.928 . . . . 10.0 111.277 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 14.3 p -135.55 17.4 3.35 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 118.677 0.671 . . . . 10.0 111.16 -177.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 75.93 -102.43 1.55 Allowed Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 107.453 -2.259 . . . . 10.0 107.453 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.7 m-20 -165.38 40.21 0.07 Allowed 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 124.933 1.293 . . . . 10.0 107.962 173.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.12 -11.95 61.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.519 0.728 . . . . 10.0 111.639 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.32 -163.33 54.63 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.61 -1.396 . . . . 10.0 109.61 174.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -51.05 133.98 26.87 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 124.258 1.023 . . . . 10.0 112.788 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.5 mtt180 -67.95 64.11 0.09 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.518 1.927 . . . . 10.0 108.592 171.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -60.59 -22.92 64.25 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -168.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.12 148.5 22.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 109.323 -0.621 . . . . 10.0 109.323 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 17.7 p -163.25 168.97 19.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 110.109 -0.33 . . . . 10.0 110.109 -171.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.99 169.75 42.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.325 -0.71 . . . . 10.0 111.325 -176.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 96.6 t -109.87 145.55 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 106.271 -1.752 . . . . 10.0 106.271 -171.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 89.0 mt -74.6 138.22 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 110.403 -0.221 . . . . 10.0 110.403 -175.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.8 146.7 16.66 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.035 1.302 . . . . 10.0 110.308 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 80.4 mt -80.32 154.06 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.607 1.203 . . . . 10.0 109.17 177.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.88 -109.15 0.33 Allowed 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.326 -1.361 . . . . 10.0 107.326 167.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 1 C-N-CA 132.795 4.438 . . . . 10.0 102.843 -174.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 119.085 -0.483 . . . . 10.0 110.783 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.0 t -113.6 -13.19 12.76 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 124.105 0.962 . . . . 10.0 112.796 170.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -141.57 147.85 38.35 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 118.525 0.602 . . . . 10.0 109.718 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.99 156.55 47.11 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 123.984 0.914 . . . . 10.0 109.828 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -116.83 153.58 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 126.239 1.815 . . . . 10.0 109.044 172.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.86 97.99 3.55 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.924 -1.51 . . . . 10.0 106.924 166.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 m -77.86 121.63 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.111 -1.07 . . . . 10.0 108.111 170.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mt -103.16 130.32 50.3 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 117.85 -1.072 . . . . 10.0 108.769 -174.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 45.0 mtpt -145.46 160.01 42.23 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 120.236 1.38 . . . . 10.0 109.467 170.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.81 -71.26 0.01 OUTLIER Glycine 0 C--O 1.229 -0.177 0 CA-C-N 114.845 -1.07 . . . . 10.0 111.808 173.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.61 -43.64 54.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 106.865 -1.531 . . . . 10.0 106.865 -171.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.57 -65.5 0.57 Allowed Glycine 0 N--CA 1.443 -0.871 0 CA-C-N 113.299 -1.773 . . . . 10.0 111.27 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -54.57 -39.78 86.92 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.6 2.2 . . . . 10.0 111.019 173.262 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 64.9 t -66.33 99.49 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 107.729 -1.212 . . . . 10.0 107.729 173.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -124.61 123.0 39.11 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 125.169 1.388 . . . . 10.0 108.593 173.385 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.01 156.7 15.52 Favored Glycine 0 C--N 1.333 0.402 0 N-CA-C 111.872 -0.491 . . . . 10.0 111.872 171.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.2 mt -141.12 63.45 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 C-N-CA 124.466 1.106 . . . . 10.0 108.609 -172.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -78.22 141.09 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.073 0 O-C-N 121.502 -0.748 . . . . 10.0 110.138 -170.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.6 115.79 24.08 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 128.812 2.845 . . . . 10.0 108.156 -175.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -108.97 107.17 17.44 Favored 'General case' 0 C--N 1.333 -0.128 0 C-N-CA 124.411 1.084 . . . . 10.0 108.098 173.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -99.22 130.62 45.54 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 119.211 0.914 . . . . 10.0 112.064 169.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 tp60 -79.79 110.48 15.18 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 105.146 -2.168 . . . . 10.0 105.146 168.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mmmt . . . . . 0 CA--C 1.514 -0.423 0 C-N-CA 126.801 2.04 . . . . 10.0 110.0 -177.53 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.09 0 N-CA-C 108.699 -1.76 . . . . 10.0 108.699 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -60.51 140.04 89.31 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.297 1.998 . . . . 10.0 109.643 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.3 t -79.27 108.22 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.048 0 N-CA-C 105.569 -2.012 . . . . 10.0 105.569 175.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 56.1 mttm -83.52 119.05 24.22 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 105.126 -2.176 . . . . 10.0 105.126 168.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -105.79 111.15 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 177.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -129.15 170.9 12.97 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 120.79 0.329 . . . . 10.0 111.72 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.63 -153.25 25.17 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 107.787 -2.125 . . . . 10.0 107.787 172.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.7 156.52 35.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 117.656 0.728 . . . . 10.0 110.286 177.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.29 113.79 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 127.479 2.312 . . . . 10.0 106.894 167.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 1.3 pttt -96.58 136.43 37.11 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 108.413 -0.958 . . . . 10.0 108.413 168.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.95 0.27 9.03 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 124.892 1.234 . . . . 10.0 113.679 173.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -75.12 177.17 6.63 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 118.74 1.27 . . . . 10.0 110.785 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.0 t -107.76 149.75 27.81 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.706 -1.59 . . . . 10.0 106.706 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -44.87 140.72 2.45 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.811 1.644 . . . . 10.0 112.156 -172.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.75 -175.28 19.28 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 123.583 0.611 . . . . 10.0 112.18 171.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -70.91 147.59 48.61 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.305 1.442 . . . . 10.0 110.803 -174.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 81.9 m-70 -144.29 145.02 31.76 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.162 0.801 . . . . 10.0 113.162 178.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -27.7 125.0 0.06 OUTLIER Glycine 0 C--N 1.344 0.996 0 C-N-CA 127.039 2.257 . . . . 10.0 111.973 164.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -150.1 105.36 3.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 119.317 1.559 . . . . 10.0 112.085 168.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.08 171.25 18.16 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 122.054 0.931 . . . . 10.0 111.966 -178.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 8.0 m -92.31 149.0 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.789 -2.46 . . . . 10.0 106.694 167.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -120.64 131.44 54.61 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.069 -2.567 . . . . 10.0 104.069 169.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -60.47 -46.5 89.87 Favored 'General case' 0 N--CA 1.452 -0.334 0 O-C-N 124.315 1.009 . . . . 10.0 113.128 -165.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 11.5 m-30 -78.67 135.31 37.16 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 118.619 -1.232 . . . . 10.0 107.758 175.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.51 -41.26 98.0 Favored Glycine 0 CA--C 1.533 1.164 0 N-CA-C 107.918 -2.073 . . . . 10.0 107.918 166.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -29.48 101.31 0.02 OUTLIER 'General case' 0 C--N 1.344 0.369 0 C-N-CA 128.098 2.559 . . . . 10.0 113.933 -169.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -107.67 14.54 25.52 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 113.836 -1.529 . . . . 10.0 111.297 173.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -57.7 -33.05 67.98 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 120.453 1.479 . . . . 10.0 110.587 -176.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -20.0 51.19 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.049 1.34 . . . . 10.0 113.076 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.89 95.81 1.87 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.74 1.162 . . . . 10.0 110.439 -176.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 26.6 t 19.55 66.85 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.617 2.367 . . . . 10.0 114.219 -174.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.2 m -151.38 -52.09 0.13 Allowed 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 124.946 1.299 . . . . 10.0 107.741 -174.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 13.8 t -73.89 4.57 5.13 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.718 -0.614 . . . . 10.0 112.131 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.05 -22.36 66.8 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.938 1.295 . . . . 10.0 111.37 177.056 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.2 140.32 11.0 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 169.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -75.89 62.31 6.53 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.576 2.851 . . . . 10.0 111.102 176.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.0 m170 58.58 61.89 2.1 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 126.347 1.859 . . . . 10.0 109.123 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -68.66 71.47 0.21 Allowed 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 122.502 1.144 . . . . 10.0 111.843 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -74.96 152.88 86.7 Favored Pre-proline 0 C--N 1.32 -0.693 0 C-N-CA 127.664 2.385 . . . . 10.0 111.443 -178.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.74 163.49 38.05 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.564 2.176 . . . . 10.0 110.534 177.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . 0.29 0.2 OUTLIER 49.52 -96.5 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.745 1.618 . . . . 10.0 110.747 -169.676 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.3 m 172.59 94.8 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 128.079 2.552 . . . . 10.0 108.138 173.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -103.73 156.92 17.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 107.744 -1.206 . . . . 10.0 107.744 169.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 97.06 7.81 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.362 -0.352 . . . . 10.0 110.091 -172.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.476 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.6 t60 -10.17 96.1 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 C-N-CA 126.975 2.11 . . . . 10.0 114.072 -173.488 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -117.97 -162.14 12.25 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 108.971 -1.652 . . . . 10.0 108.971 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.29 -168.92 13.27 Favored Glycine 0 N--CA 1.449 -0.482 0 N-CA-C 110.521 -1.032 . . . . 10.0 110.521 175.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -67.45 11.39 0.22 Allowed 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.155 1.903 . . . . 10.0 112.302 175.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -101.24 -25.03 14.14 Favored 'General case' 0 N--CA 1.443 -0.814 0 C-N-CA 124.563 1.145 . . . . 10.0 108.896 169.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -107.85 170.88 7.72 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -169.284 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -86.03 -31.17 22.13 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 169.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -86.82 21.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 125.563 1.545 . . . . 10.0 113.062 -167.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.54 128.09 34.5 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.104 -1.443 . . . . 10.0 107.104 167.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . 0.476 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 18.4 m170 -58.17 -68.09 0.28 Allowed 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.054 0.454 . . . . 10.0 111.096 -172.042 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.9 p -162.98 -51.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.456 -0.942 . . . . 10.0 108.456 -171.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -138.48 62.94 0.56 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 109.327 -1.509 . . . . 10.0 109.327 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -99.93 104.0 15.61 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 104.626 -2.361 . . . . 10.0 104.626 168.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -78.76 -2.97 42.02 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 119.235 0.925 . . . . 10.0 111.138 -175.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.77 -98.92 2.36 Favored Glycine 0 N--CA 1.44 -1.039 0 N-CA-C 106.584 -2.606 . . . . 10.0 106.584 -173.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -144.78 160.57 41.03 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 123.587 0.755 . . . . 10.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.55 132.03 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 105.495 -2.039 . . . . 10.0 105.495 166.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -94.83 118.12 31.25 Favored 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 108.656 -0.868 . . . . 10.0 108.656 -178.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.03 127.98 34.44 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 123.468 0.707 . . . . 10.0 109.135 175.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.412 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 18.6 t70 -61.94 167.06 4.04 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 124.453 1.096 . . . . 10.0 109.118 168.298 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.412 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 16.0 mtmt -52.54 -28.88 22.61 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 126.022 1.729 . . . . 10.0 111.53 171.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -77.23 -10.86 59.69 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 118.115 0.416 . . . . 10.0 111.597 178.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.09 15.84 60.26 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 121.037 -1.04 . . . . 10.0 111.034 -177.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.0 t -97.43 106.82 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.889 2.076 . . . . 10.0 106.497 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.92 123.93 42.13 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.84 -1.17 . . . . 10.0 107.84 169.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -91.72 132.0 36.7 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 175.312 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -101.64 126.45 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 105.686 -1.968 . . . . 10.0 105.686 168.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 63.4 m -155.15 66.94 0.65 Allowed 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 125.001 1.32 . . . . 10.0 107.749 172.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -113.3 162.47 11.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 106.322 -1.733 . . . . 10.0 106.322 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -141.62 147.69 38.0 Favored 'General case' 0 N--CA 1.446 -0.672 0 O-C-N 121.36 -0.838 . . . . 10.0 111.06 168.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -132.75 137.11 46.74 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.92 1.288 . . . . 10.0 108.988 -175.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 1.7 p -108.79 56.75 0.62 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 125.615 1.566 . . . . 10.0 108.088 171.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.57 -61.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 N-CA-C 109.018 -0.734 . . . . 10.0 109.018 178.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.333 0.0 OUTLIER -70.41 169.55 1.41 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 112.74 0.644 . . . . 10.0 112.74 176.874 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 12.3 m -158.57 138.76 12.34 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 174.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 pp -81.75 -18.64 43.53 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.859 0.464 . . . . 10.0 110.232 172.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t . . . . . 0 N--CA 1.452 -0.351 0 N-CA-C 106.569 -1.641 . . . . 10.0 106.569 168.196 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 14.2 t . . . . . 0 N--CA 1.452 -0.368 0 CA-C-O 120.62 0.248 . . . . 10.0 110.943 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 44.5 pt -56.45 -14.78 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 N-CA-C 113.526 0.936 . . . . 10.0 113.526 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.5 mm -44.79 128.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 O-C-N 121.366 -0.834 . . . . 10.0 109.619 169.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.26 0.17 80.51 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.038 -0.868 . . . . 10.0 112.889 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -79.31 168.13 19.95 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.896 1.348 . . . . 10.0 109.152 168.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -112.31 124.81 53.28 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.72 0.808 . . . . 10.0 109.581 176.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -82.24 147.25 29.05 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.026 -1.101 . . . . 10.0 108.026 168.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 95.7 t -133.12 134.83 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.901 0 N-CA-C 108.217 -1.031 . . . . 10.0 108.217 168.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -103.47 129.95 54.61 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 105.754 -1.943 . . . . 10.0 105.754 167.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.9 m-70 -106.15 157.13 17.78 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 115.42 1.637 . . . . 10.0 115.42 -170.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -39.98 -56.62 1.79 Allowed 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 129.264 3.026 . . . . 10.0 110.623 173.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -119.79 168.35 11.17 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.176 0.991 . . . . 10.0 112.546 -169.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.81 129.13 38.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 113.98 -1.464 . . . . 10.0 109.129 170.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -77.77 108.26 10.87 Favored 'General case' 0 N--CA 1.442 -0.859 0 N-CA-C 107.347 -1.353 . . . . 10.0 107.347 171.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -78.97 3.38 17.33 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 111.676 0.251 . . . . 10.0 111.676 175.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 22.2 mt 59.79 -146.42 0.49 Allowed 'General case' 0 N--CA 1.419 -2.004 0 N-CA-C 105.97 -1.863 . . . . 10.0 105.97 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 -14.28 77.26 Favored Glycine 0 C--N 1.304 -1.221 0 CA-C-N 114.351 -1.295 . . . . 10.0 112.244 -168.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -75.07 -1.27 22.13 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.413 1.107 . . . . 10.0 111.966 -169.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.36 -32.56 77.6 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 108.595 -1.802 . . . . 10.0 108.595 168.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 62.13 37.63 94.8 Favored Glycine 0 C--N 1.341 0.818 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.66 175.34 9.26 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 105.176 -2.157 . . . . 10.0 105.176 170.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -45.82 -54.17 8.49 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 115.044 -0.98 . . . . 10.0 111.23 172.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -64.5 -34.68 78.78 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 119.777 -0.769 . . . . 10.0 111.162 -172.116 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -47.7 -40.0 18.99 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 124.116 0.967 . . . . 10.0 111.702 169.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 t -93.08 -4.04 53.11 Favored 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 119.658 1.117 . . . . 10.0 110.362 -170.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -110.44 -57.82 2.16 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 125.698 1.599 . . . . 10.0 110.922 -171.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.4 p -137.13 5.84 2.8 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.616 0.644 . . . . 10.0 112.563 175.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.69 32.18 57.6 Favored Glycine 0 C--N 1.341 0.848 0 CA-C-N 118.675 0.67 . . . . 10.0 114.37 172.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 63.2 m-20 57.78 19.61 5.78 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.794 0.838 . . . . 10.0 113.175 179.106 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.38 -4.04 20.42 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.128 -0.982 . . . . 10.0 112.945 -176.325 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.54 -164.14 53.99 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.679 -0.968 . . . . 10.0 110.679 172.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.78 141.73 43.28 Favored 'General case' 0 N--CA 1.445 -0.714 0 C-N-CA 123.696 0.798 . . . . 10.0 111.987 -168.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 25.7 mtm-85 -67.22 71.14 0.1 Allowed 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.62 1.568 . . . . 10.0 109.414 172.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 6.8 tp -43.54 -45.56 6.64 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 126.5 1.92 . . . . 10.0 112.212 -174.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -159.48 147.41 17.37 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 -173.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 9.5 m -141.09 157.27 45.53 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 -168.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.6 164.96 30.42 Favored Glycine 0 C--N 1.332 0.346 0 N-CA-C 110.219 -1.152 . . . . 10.0 110.219 175.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.02 135.94 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 108.045 -1.095 . . . . 10.0 108.045 -174.514 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 9.3 mt -75.33 107.13 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 N-CA-C 109.291 -0.633 . . . . 10.0 109.291 -174.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.12 154.97 16.38 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 125.799 1.666 . . . . 10.0 110.976 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 90.4 mt -73.27 140.3 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 124.301 1.04 . . . . 10.0 109.937 -175.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.98 -45.99 2.65 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.84 0.456 . . . . 10.0 111.567 169.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 mm100 . . . . . 0 N--CA 1.445 -0.683 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 179.381 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.974 0 CA-C-O 118.158 -0.925 . . . . 10.0 109.398 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.2 t -84.29 -13.46 52.42 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 119.661 1.119 . . . . 10.0 111.893 -176.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.5 ptpp? -152.6 157.86 41.62 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.499 0.666 . . . . 10.0 112.351 167.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.91 170.62 15.4 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 125.855 1.662 . . . . 10.0 109.635 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.5 150.12 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 C-N-CA 126.462 1.905 . . . . 10.0 110.302 -177.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.62 100.91 4.77 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.005 -1.48 . . . . 10.0 107.005 166.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -82.12 118.91 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 107.821 -1.177 . . . . 10.0 107.821 169.385 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -97.43 138.89 34.18 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.873 -1.158 . . . . 10.0 107.873 177.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.9 ttmt -156.76 162.85 39.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.34 -50.21 0.07 OUTLIER Glycine 0 C--O 1.228 -0.256 0 C-N-CA 120.303 -0.951 . . . . 10.0 112.963 169.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -73.31 -45.73 53.75 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.35 -71.48 0.4 Allowed Glycine 0 CA--C 1.524 0.599 0 CA-C-N 114.46 -1.245 . . . . 10.0 110.021 171.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -57.95 -33.82 97.61 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.496 2.798 . . . . 10.0 111.192 173.059 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.1 t -64.91 105.58 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 N-CA-C 107.915 -1.143 . . . . 10.0 107.915 174.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -124.01 110.64 15.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 106.167 -1.79 . . . . 10.0 106.167 173.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.59 144.38 17.14 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 169.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.45 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 4.9 mt -140.1 80.46 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 106.26 -1.755 . . . . 10.0 106.26 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.7 mm -101.97 123.4 55.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 N-CA-C 109.557 -0.534 . . . . 10.0 109.557 -175.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 9.4 m-20 -85.63 151.29 24.01 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 109.268 -0.642 . . . . 10.0 109.268 169.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -126.33 91.53 3.39 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.231 -1.766 . . . . 10.0 106.231 169.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -84.27 138.72 32.78 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.175 0.99 . . . . 10.0 109.812 171.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -127.76 112.05 14.35 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 168.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.06 -56.4 11.72 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 122.7 1.238 . . . . 10.0 111.64 -170.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -139.97 170.39 15.95 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 103.657 -2.72 . . . . 10.0 103.657 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 91.8 p -65.0 -22.71 67.04 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.02 -0.536 . . . . 10.0 110.237 170.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -81.73 -11.75 58.9 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.763 0.825 . . . . 10.0 111.03 177.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.27 159.08 30.71 Favored Glycine 0 CA--C 1.532 1.116 0 O-C-N 121.929 -0.482 . . . . 10.0 112.073 -172.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -78.87 149.03 22.72 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 122.79 2.327 . . . . 10.0 107.889 167.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -76.6 94.38 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 171.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 mtpm? -73.95 97.7 2.88 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.538 -1.282 . . . . 10.0 107.538 169.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.6 m -85.45 115.01 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 107.261 -1.385 . . . . 10.0 107.261 173.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 23.8 p90 -129.9 160.26 34.08 Favored 'General case' 0 CA--C 1.516 -0.36 0 CA-C-O 121.756 0.789 . . . . 10.0 111.952 168.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.57 -173.45 45.41 Favored Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 173.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.8 t -142.43 118.75 10.84 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.683 -1.599 . . . . 10.0 106.683 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pp -80.86 175.07 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 109.095 -0.706 . . . . 10.0 109.095 169.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -146.32 136.58 23.75 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 167.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.33 -5.12 15.31 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.937 0.779 . . . . 10.0 114.656 172.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.09 176.46 3.19 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 119.147 1.473 . . . . 10.0 111.198 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -108.24 159.47 16.6 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.703 -1.962 . . . . 10.0 105.703 166.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -53.49 163.14 0.67 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.531 1.132 . . . . 10.0 112.935 -169.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.17 -174.39 50.84 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 123.962 0.791 . . . . 10.0 112.104 168.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 mp -63.26 144.48 56.9 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 125.233 1.413 . . . . 10.0 110.819 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -146.72 144.02 29.13 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 123.82 0.848 . . . . 10.0 111.352 174.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -24.87 121.98 0.03 OUTLIER Glycine 0 C--N 1.343 0.956 0 C-N-CA 128.242 2.829 . . . . 10.0 111.864 166.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.96 106.71 3.95 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 120.046 1.923 . . . . 10.0 109.728 171.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.461 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -156.46 172.39 18.62 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.56 0.695 . . . . 10.0 112.855 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.15 152.54 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-N 112.581 -2.099 . . . . 10.0 108.078 168.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 79.9 m-70 -126.2 152.69 45.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 170.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -49.31 -60.75 2.54 Favored 'General case' 0 N--CA 1.447 -0.576 0 O-C-N 124.202 0.938 . . . . 10.0 111.379 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -82.38 162.09 22.3 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 121.41 0.624 . . . . 10.0 110.141 -174.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.77 -6.59 52.26 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 167.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.41 172.52 9.31 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-O 122.588 1.185 . . . . 10.0 111.461 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.49 18.15 0.04 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 114.057 1.132 . . . . 10.0 114.057 -169.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -50.41 -36.92 35.08 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.983 1.313 . . . . 10.0 113.713 -169.002 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.26 -21.38 49.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.393 0.677 . . . . 10.0 112.492 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.98 102.28 2.44 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 109.396 -1.481 . . . . 10.0 109.396 -172.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 37.27 60.78 1.01 Allowed 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 126.273 1.829 . . . . 10.0 112.161 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -157.76 -48.06 0.06 Allowed 'General case' 0 N--CA 1.443 -0.821 0 O-C-N 122.023 -0.423 . . . . 10.0 111.401 176.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -50.63 -35.76 32.03 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 125.092 1.357 . . . . 10.0 110.918 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.28 -36.31 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 128.347 2.659 . . . . 10.0 113.768 169.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.51 166.27 26.43 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 107.641 -2.183 . . . . 10.0 107.641 173.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -79.91 -162.77 0.19 Allowed 'Trans proline' 0 N--CA 1.441 -1.599 0 N-CA-C 105.476 -2.548 . . . . 10.0 105.476 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 44.4 m170 -81.49 53.88 2.2 Favored 'General case' 0 CA--C 1.541 0.609 0 O-C-N 120.38 -1.45 . . . . 10.0 110.716 -176.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.6 m-30 -73.09 71.59 1.13 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 123.273 1.511 . . . . 10.0 111.265 -178.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -78.44 141.51 61.28 Favored Pre-proline 0 N--CA 1.447 -0.583 0 C-N-CA 126.158 1.783 . . . . 10.0 109.642 169.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -79.21 47.77 2.61 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.874 2.383 . . . . 10.0 111.213 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -163.79 49.66 0.14 Allowed 'General case' 0 C--O 1.236 0.361 0 C-N-CA 124.761 1.224 . . . . 10.0 107.871 178.206 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.0 p -52.98 108.37 0.31 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.204 1.802 . . . . 10.0 111.57 -169.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -133.32 -173.2 3.14 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.107 -2.183 . . . . 10.0 105.107 169.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.401 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 6.9 mtmp? -85.71 136.63 33.28 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 118.549 -1.26 . . . . 10.0 107.804 -172.373 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.9 t60 -36.05 116.29 0.39 Allowed 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.336 173.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.71 -134.2 4.92 Favored Glycine 0 N--CA 1.441 -1.015 0 N-CA-C 108.139 -1.984 . . . . 10.0 108.139 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.8 -165.81 31.74 Favored Glycine 0 N--CA 1.444 -0.804 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 169.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -57.52 -11.99 10.02 Favored 'Trans proline' 0 N--CA 1.451 -0.976 0 CA-C-N 119.345 1.572 . . . . 10.0 110.849 167.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.87 -33.98 18.35 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 125.223 1.409 . . . . 10.0 110.076 -177.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -107.45 168.54 9.17 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 108.677 -0.861 . . . . 10.0 108.677 -169.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -94.67 -18.88 20.91 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 124.346 1.058 . . . . 10.0 109.761 178.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.401 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -92.02 3.9 54.23 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.395 0.887 . . . . 10.0 113.395 -175.511 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 19.9 ptp180 -34.94 139.0 0.1 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 128.118 2.567 . . . . 10.0 112.272 171.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -71.22 -100.63 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.351 0.66 . . . . 10.0 111.96 -176.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.9 p -148.3 30.13 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.032 0.92 . . . . 10.0 110.228 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.5 47.83 0.02 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.479 -1.448 . . . . 10.0 109.479 -179.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -84.05 88.97 7.19 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 103.203 -2.888 . . . . 10.0 103.203 168.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 42.5 mt -71.3 -33.38 69.65 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 106.451 -1.685 . . . . 10.0 106.451 176.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.66 -97.19 1.34 Allowed Glycine 0 N--CA 1.44 -1.057 0 N-CA-C 108.815 -1.714 . . . . 10.0 108.815 167.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -132.67 129.06 38.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.655 1.182 . . . . 10.0 108.571 -172.195 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.8 m -113.52 141.65 28.7 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.573 -1.64 . . . . 10.0 106.573 168.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -93.13 133.65 36.1 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.738 -0.467 . . . . 10.0 109.738 -177.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.82 133.23 43.41 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.084 0.954 . . . . 10.0 108.848 172.053 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.416 ' OD2' ' NZ ' ' A' ' 91' ' ' LYS . 45.4 t0 -62.03 168.81 3.01 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.678 1.191 . . . . 10.0 108.438 167.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.416 ' NZ ' ' OD2' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -63.38 -19.16 64.41 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.047 0.451 . . . . 10.0 111.816 -179.22 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -77.45 -12.15 59.93 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 123.73 0.812 . . . . 10.0 110.589 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.87 26.88 43.58 Favored Glycine 0 C--N 1.344 0.979 0 N-CA-C 109.766 -1.334 . . . . 10.0 109.766 -178.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 37.7 t -109.08 116.31 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.007 2.523 . . . . 10.0 105.045 178.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -113.49 120.84 42.38 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 107.918 -1.141 . . . . 10.0 107.918 174.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -84.31 117.41 23.55 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 127.141 2.176 . . . . 10.0 108.767 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -102.4 131.88 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 p -159.53 75.91 0.66 Allowed 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 123.88 0.872 . . . . 10.0 110.804 171.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -116.37 147.23 19.89 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.037 0.935 . . . . 10.0 109.146 -176.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -107.14 104.71 14.42 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 126.449 1.9 . . . . 10.0 110.13 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -87.9 123.32 32.53 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 108.746 -0.835 . . . . 10.0 108.746 172.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.7 p -113.13 43.41 1.72 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.209 1.003 . . . . 10.0 110.21 177.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -138.62 -44.57 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 C-N-CA 123.289 0.636 . . . . 10.0 111.255 175.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.365 0.7 OUTLIER -87.85 175.19 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-N 119.342 0.973 . . . . 10.0 112.749 174.103 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.2 m -159.34 138.43 11.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 123.955 0.902 . . . . 10.0 109.007 172.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 pp -82.49 -14.75 54.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.552 0.741 . . . . 10.0 111.944 177.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.1 m -143.46 124.0 14.01 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.662 -1.607 . . . . 10.0 106.662 167.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.96 -59.63 0.2 Allowed Glycine 0 C--N 1.334 0.44 0 N-CA-C 109.638 -1.385 . . . . 10.0 109.638 175.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -166.89 -50.9 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 126.084 1.753 . . . . 10.0 107.465 -177.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -74.98 -36.02 62.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.669 -1.151 . . . . 10.0 108.879 -169.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t 42.41 61.93 1.86 Allowed 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 126.056 1.743 . . . . 10.0 110.99 169.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.57 32.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 113.194 0.812 . . . . 10.0 113.194 -175.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.0 mm -64.5 150.45 10.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 C-N-CA 125.969 1.708 . . . . 10.0 107.424 168.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.25 33.26 86.31 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 121.523 -0.736 . . . . 10.0 113.804 178.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -100.65 163.96 12.1 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 166.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -103.55 127.55 50.95 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-N 118.587 0.63 . . . . 10.0 111.106 170.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.14 139.64 30.26 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.498 -1.668 . . . . 10.0 106.498 166.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 93.0 t -122.88 138.67 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 172.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.1 p -105.69 134.72 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 104.96 -2.237 . . . . 10.0 104.96 166.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 6.5 m170 -113.67 161.36 17.57 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 114.506 1.298 . . . . 10.0 114.506 -172.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -57.73 -49.16 77.47 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 113.694 -1.594 . . . . 10.0 109.548 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -116.09 176.48 5.08 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.47 1.108 . . . . 10.0 111.812 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.1 146.55 23.57 Favored 'General case' 0 N--CA 1.451 -0.425 0 C-N-CA 125.375 1.47 . . . . 10.0 110.271 -177.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.461 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 3.9 m-20 -76.77 151.39 36.01 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.108 0.563 . . . . 10.0 110.612 178.114 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -89.54 16.58 7.48 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 114.836 -1.075 . . . . 10.0 109.878 166.227 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 69.9 mt 36.43 47.57 0.51 Allowed 'General case' 0 C--N 1.344 0.338 0 C-N-CA 127.19 2.196 . . . . 10.0 112.383 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.74 -47.37 1.05 Allowed Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 124.582 1.087 . . . . 10.0 111.851 176.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -83.23 44.27 0.93 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 124.999 1.32 . . . . 10.0 111.844 -168.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -81.98 -38.68 12.93 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.515 -1.434 . . . . 10.0 109.515 169.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.45 48.61 56.53 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 109.37 -1.492 . . . . 10.0 109.37 -170.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.7 m-80 -138.36 166.57 23.9 Favored 'General case' 0 CA--C 1.508 -0.652 0 N-CA-C 106.689 -1.597 . . . . 10.0 106.689 175.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 2.7 tm-20 -52.99 -46.52 68.36 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 114.712 -1.131 . . . . 10.0 108.843 171.042 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -57.1 -43.2 82.0 Favored 'General case' 0 C--N 1.343 0.305 0 CA-C-N 116.332 -0.395 . . . . 10.0 110.889 171.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.297 2.1 p -59.21 -32.95 70.41 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -167.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -78.89 -8.05 58.5 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 118.592 -1.243 . . . . 10.0 112.276 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 89.5 mttt -116.68 -59.46 1.97 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.638 1.575 . . . . 10.0 111.834 -171.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.1 p -123.48 -4.66 8.26 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 119.318 0.963 . . . . 10.0 112.675 179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.19 -82.97 0.45 Allowed Glycine 0 CA--C 1.531 1.039 0 CA-C-N 119.386 0.994 . . . . 10.0 112.762 169.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.12 32.88 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 123.186 1.47 . . . . 10.0 108.343 177.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.64 -26.6 57.89 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.963 -1.471 . . . . 10.0 109.771 -167.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.13 -159.69 51.22 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 109.53 -1.428 . . . . 10.0 109.53 -177.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.0 t -58.49 139.26 55.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 113.136 0.791 . . . . 10.0 113.136 -168.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -65.05 65.72 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 126.764 2.025 . . . . 10.0 109.754 168.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.48 -19.2 61.77 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 113.904 1.076 . . . . 10.0 113.904 -172.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.22 150.89 25.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 122.81 0.444 . . . . 10.0 110.409 169.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.6 p -154.17 165.6 35.74 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.057 0.543 . . . . 10.0 110.049 -176.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -141.0 -172.0 12.82 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 123.434 0.54 . . . . 10.0 112.675 -177.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.7 t -136.79 136.52 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 107.648 -1.241 . . . . 10.0 107.648 172.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.0 mt -73.93 114.63 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 122.887 0.475 . . . . 10.0 110.402 -177.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.46 151.35 18.46 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 125.762 1.649 . . . . 10.0 111.461 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.8 mt -73.32 140.34 17.97 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 124.902 1.281 . . . . 10.0 109.855 -173.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.72 -45.47 2.89 Favored 'General case' 0 C--O 1.225 -0.222 0 O-C-N 121.069 -1.02 . . . . 10.0 111.74 173.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.25 1.09 0 C-N-CA 127.81 2.444 . . . . 10.0 109.203 -168.575 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.886 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -70.93 -31.03 67.5 Favored 'General case' 0 C--O 1.226 -0.142 0 CA-C-N 119.27 0.941 . . . . 10.0 109.847 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . 0.448 ' HZ2' ' CD ' ' B' ' 21' ' ' GLU . 34.9 tttt -144.37 134.12 23.67 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.769 0.828 . . . . 10.0 109.395 -174.19 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 165.41 27.65 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.865 1.666 . . . . 10.0 107.768 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -126.13 171.1 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 118.339 0.518 . . . . 10.0 109.84 174.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.78 112.86 9.73 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.413 -1.328 . . . . 10.0 107.413 166.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 30.8 m -92.01 114.89 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 168.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.6 mt -100.56 135.65 41.67 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -158.13 157.43 32.73 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.862 1.21 . . . . 10.0 108.705 170.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.3 -52.17 0.04 OUTLIER Glycine 0 C--O 1.228 -0.269 0 C-N-CA 121.414 -0.422 . . . . 10.0 112.148 172.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.8 -45.95 40.1 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.609 -1.626 . . . . 10.0 106.609 -171.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.29 -67.06 0.55 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 113.711 -1.586 . . . . 10.0 110.461 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -56.97 -41.07 79.2 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.646 2.231 . . . . 10.0 110.68 172.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.8 t -65.94 105.83 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -123.02 117.98 26.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 169.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.83 141.63 15.36 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.358 -1.097 . . . . 10.0 110.358 172.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 mt -143.13 81.13 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 106.476 -1.676 . . . . 10.0 106.476 -175.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.6 mm -102.72 151.37 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.324 1.049 . . . . 10.0 109.715 -173.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -121.48 119.93 33.43 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.939 2.095 . . . . 10.0 108.164 174.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -102.89 108.92 20.3 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.783 -1.562 . . . . 10.0 106.783 176.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.448 ' CD ' ' HZ2' ' B' ' 3' ' ' LYS . 36.8 mt-10 -119.49 141.05 49.52 Favored 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.247 0.832 . . . . 10.0 113.247 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -118.39 119.18 33.82 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.332 -1.729 . . . . 10.0 106.332 166.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 57.6 pttt . . . . . 0 CA--C 1.529 0.166 0 N-CA-C 112.842 0.682 . . . . 10.0 112.842 -172.969 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.182 0 CA-C-O 118.398 -1.223 . . . . 10.0 114.509 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -65.63 136.59 46.72 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 107.191 -1.888 . . . . 10.0 107.191 172.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.49 105.19 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 106.028 -1.842 . . . . 10.0 106.028 174.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -97.49 112.85 24.52 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 173.412 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -111.99 113.59 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 125.126 1.37 . . . . 10.0 108.776 -173.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.5 p90 -132.65 170.82 14.67 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.874 0.368 . . . . 10.0 110.804 173.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.88 -147.92 18.84 Favored Glycine 0 N--CA 1.448 -0.52 0 N-CA-C 106.955 -2.458 . . . . 10.0 106.955 170.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.2 t -155.86 156.61 34.98 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 119.306 -0.958 . . . . 10.0 111.192 177.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.9 pt -117.08 153.68 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 N-CA-C 108.032 -1.099 . . . . 10.0 108.032 166.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -127.62 151.41 48.96 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 106.801 -1.555 . . . . 10.0 106.801 167.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.24 -14.44 15.93 Favored Glycine 0 C--N 1.336 0.542 0 CA-C-O 119.002 -0.888 . . . . 10.0 113.322 169.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.6 mp -76.4 176.84 7.84 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 118.652 1.226 . . . . 10.0 110.388 -177.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.59 152.76 20.13 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.596 -0.729 . . . . 10.0 109.348 169.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -45.34 143.98 1.58 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.109 1.764 . . . . 10.0 111.87 -176.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.72 -177.31 22.66 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 123.927 0.775 . . . . 10.0 112.159 171.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -71.69 153.55 41.97 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 125.347 1.459 . . . . 10.0 110.921 -177.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -149.34 146.93 27.77 Favored 'General case' 0 C--N 1.343 0.319 0 N-CA-C 113.959 1.096 . . . . 10.0 113.959 -177.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -31.48 114.26 0.07 OUTLIER Glycine 0 C--N 1.34 0.803 0 C-N-CA 128.379 2.895 . . . . 10.0 113.215 164.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -141.48 101.43 3.99 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 120.519 2.16 . . . . 10.0 109.353 173.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.516 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -151.17 170.15 20.16 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-O 121.749 0.785 . . . . 10.0 111.938 178.603 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.2 m -93.08 154.86 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.223 -2.262 . . . . 10.0 106.788 168.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 61.2 m-70 -126.58 135.87 51.81 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 170.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -50.92 -50.57 57.29 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 118.445 -0.788 . . . . 10.0 112.186 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -82.6 137.29 34.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 117.714 -1.594 . . . . 10.0 109.501 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.58 3.01 87.41 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 126.29 1.9 . . . . 10.0 112.147 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 p-10 -76.3 81.82 3.07 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-O 123.613 1.673 . . . . 10.0 110.181 -173.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.31 9.75 1.94 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.488 -1.233 . . . . 10.0 113.732 -175.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.45 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -44.96 -45.94 10.79 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 127.734 2.414 . . . . 10.0 112.634 -170.818 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.86 -20.72 41.68 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.7 87.82 2.02 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 107.955 -2.058 . . . . 10.0 107.955 -168.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 16.88 54.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 127.987 2.515 . . . . 10.0 116.108 -169.221 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 17.0 m -125.97 -56.25 1.46 Allowed 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 105.69 -1.967 . . . . 10.0 105.69 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -47.74 -37.4 13.18 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.403 1.481 . . . . 10.0 110.708 169.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.14 -31.5 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 127.864 2.466 . . . . 10.0 115.257 169.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.27 148.64 18.98 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 109.517 -1.433 . . . . 10.0 109.517 169.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.51 -179.27 0.85 Allowed 'Trans proline' 0 N--CA 1.446 -1.305 0 N-CA-C 107.674 -1.702 . . . . 10.0 107.674 166.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.413 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 37.8 m170 -76.24 76.57 3.04 Favored 'General case' 0 CA--C 1.543 0.685 0 O-C-N 120.422 -1.424 . . . . 10.0 110.501 -169.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -71.46 69.44 0.59 Allowed 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 123.182 1.468 . . . . 10.0 112.417 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 1.7 p30 -56.15 145.51 55.46 Favored Pre-proline 0 C--N 1.321 -0.649 0 C-N-CA 127.326 2.251 . . . . 10.0 112.155 168.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -74.79 167.74 26.41 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 122.106 1.871 . . . . 10.0 108.296 167.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 tp 62.46 -101.06 0.1 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 125.09 1.356 . . . . 10.0 108.041 -174.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.2 p 171.59 97.45 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.753 1.621 . . . . 10.0 110.263 -174.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 75.9 mtt180 -130.02 163.64 26.04 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 119.651 1.114 . . . . 10.0 110.346 176.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -113.44 55.32 0.71 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 124.648 1.179 . . . . 10.0 111.422 -168.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 65.3 t60 47.05 88.2 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 125.091 1.356 . . . . 10.0 114.646 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.06 -145.18 11.07 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.262 -1.336 . . . . 10.0 110.067 178.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.78 -173.96 32.1 Favored Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 109.152 -1.579 . . . . 10.0 109.152 176.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -55.22 -13.15 6.49 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 123.025 2.483 . . . . 10.0 112.434 173.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -94.27 -30.25 14.65 Favored 'General case' 0 N--CA 1.444 -0.754 0 C-N-CA 125.189 1.396 . . . . 10.0 110.607 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -103.18 169.0 8.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -169.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -78.77 -33.52 46.33 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -77.14 18.14 0.41 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.309 1.043 . . . . 10.0 113.421 -165.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 20.2 ptp180 -64.55 117.22 7.05 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.106 -1.072 . . . . 10.0 108.106 -177.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 11.1 m170 -57.98 -60.96 2.92 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 120.824 0.345 . . . . 10.0 111.846 -170.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p -165.5 -47.09 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 -169.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -152.99 71.49 0.28 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 108.551 -1.82 . . . . 10.0 108.551 172.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -102.57 106.61 17.33 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 105.73 -1.952 . . . . 10.0 105.73 171.092 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.22 -12.07 60.03 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 111.7 -172.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.78 -98.26 1.56 Allowed Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 107.924 -2.071 . . . . 10.0 107.924 -178.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -156.28 146.96 21.82 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 107.099 -1.445 . . . . 10.0 107.099 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.7 m -122.08 131.95 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 107.208 -1.405 . . . . 10.0 107.208 169.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 63.0 m -90.89 107.26 19.07 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 126.298 1.839 . . . . 10.0 109.228 -172.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -77.82 130.33 36.54 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 110.172 -0.307 . . . . 10.0 110.172 172.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.406 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 17.5 t70 -61.85 170.1 2.22 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 124.274 1.03 . . . . 10.0 109.295 167.324 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.406 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 16.5 mtmt -55.79 -29.08 59.09 Favored 'General case' 0 N--CA 1.433 -1.294 0 C-N-CA 125.884 1.674 . . . . 10.0 111.647 171.352 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -78.38 -1.67 34.55 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-O 121.163 0.506 . . . . 10.0 111.371 175.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.09 1.46 90.33 Favored Glycine 0 C--N 1.339 0.746 0 O-C-N 120.376 -1.452 . . . . 10.0 111.179 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 44.8 t -78.43 105.98 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 C-N-CA 126.929 2.092 . . . . 10.0 107.03 178.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.78 124.62 49.23 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 169.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.56 122.74 26.86 Favored 'General case' 0 N--CA 1.432 -1.338 0 C-N-CA 125.832 1.653 . . . . 10.0 107.816 169.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.4 t -101.92 128.85 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.208 0 N-CA-C 106.851 -1.537 . . . . 10.0 106.851 173.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.9 t -156.85 92.67 1.3 Allowed 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 169.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.3 mp -135.94 164.29 32.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 125.96 1.704 . . . . 10.0 106.542 -177.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -148.64 159.63 43.91 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.74 116.21 7.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.023 -0.732 . . . . 10.0 109.023 171.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 52.0 p -90.41 61.6 5.05 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 106.909 -1.515 . . . . 10.0 106.909 -171.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.16 -50.53 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 123.731 0.644 . . . . 10.0 110.068 -176.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -79.91 142.42 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.592 -1.262 . . . . 10.0 107.592 169.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 22.9 m -128.22 114.22 16.68 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.697 -1.594 . . . . 10.0 106.697 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mt -59.23 -4.34 0.53 Allowed 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 114.411 1.263 . . . . 10.0 114.411 -173.049 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.7 m . . . . . 0 N--CA 1.448 -0.567 0 C-N-CA 126.582 1.953 . . . . 10.0 107.558 177.165 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.1 t . . . . . 0 N--CA 1.441 -0.893 0 N-CA-C 107.963 -1.125 . . . . 10.0 107.963 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.6 pt -83.98 23.42 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 122.957 0.503 . . . . 10.0 111.997 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.49 -73.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 CA-C-N 118.8 0.727 . . . . 10.0 111.268 -177.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.66 50.33 3.55 Favored Glycine 0 CA--C 1.532 1.133 0 O-C-N 120.642 -1.286 . . . . 10.0 112.546 -177.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.4 mmt-85 -110.3 152.38 26.24 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 124.832 1.253 . . . . 10.0 109.697 176.386 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.9 m -88.88 125.14 34.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.975 -0.75 . . . . 10.0 108.975 171.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -96.13 138.76 33.29 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 126.42 1.888 . . . . 10.0 107.7 170.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -126.44 135.67 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 N-CA-C 108.517 -0.919 . . . . 10.0 108.517 -177.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -106.16 121.87 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 106.807 -1.553 . . . . 10.0 106.807 171.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.3 m-70 -105.63 158.12 16.93 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 123.75 1.738 . . . . 10.0 115.605 -171.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -43.82 -61.48 1.41 Allowed 'General case' 0 N--CA 1.442 -0.862 0 C-N-CA 129.738 3.215 . . . . 10.0 110.551 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.3 mttp -112.77 172.86 6.67 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.061 0.944 . . . . 10.0 111.395 -175.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.13 154.64 40.96 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.016 1.326 . . . . 10.0 110.571 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.516 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.0 OUTLIER -78.49 144.98 35.22 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 123.98 0.912 . . . . 10.0 111.578 174.083 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -76.27 -32.89 59.07 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 124.781 1.301 . . . . 10.0 109.349 168.057 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt 63.5 56.42 1.62 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 123.491 1.615 . . . . 10.0 109.572 -168.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.92 -47.96 3.44 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 113.582 -1.645 . . . . 10.0 111.341 165.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.19 44.97 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.8 1.64 . . . . 10.0 112.012 -173.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -10.83 50.08 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 126.263 1.887 . . . . 10.0 111.892 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.88 32.43 18.63 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.448 -0.64 . . . . 10.0 112.071 -174.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -113.66 152.34 30.56 Favored 'General case' 0 CA--C 1.506 -0.716 0 N-CA-C 105.65 -1.982 . . . . 10.0 105.65 171.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.8 tm-20 -50.54 -37.57 40.08 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 114.921 -1.036 . . . . 10.0 108.695 169.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 16.8 tp10 -70.81 -38.5 73.29 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 113.889 1.07 . . . . 10.0 113.889 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 76.7 p -57.67 -42.63 83.95 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 120.642 1.565 . . . . 10.0 110.456 -175.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 6.3 t -69.17 -10.3 57.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 113.109 0.781 . . . . 10.0 113.109 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 20.5 ttmt -113.71 -47.97 2.95 Favored 'General case' 0 N--CA 1.435 -1.204 0 C-N-CA 125.43 1.492 . . . . 10.0 112.347 -168.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.413 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 32.0 p -130.78 -2.87 4.14 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.016 0.747 . . . . 10.0 113.016 172.173 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.2 19.7 60.33 Favored Glycine 0 C--N 1.34 0.803 0 N-CA-C 110.809 -0.917 . . . . 10.0 110.809 -175.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 54.45 31.7 15.22 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 117.837 0.819 . . . . 10.0 111.718 176.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.47 7.26 4.62 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 123.906 0.882 . . . . 10.0 111.673 -176.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.85 -168.23 53.48 Favored Glycine 0 N--CA 1.444 -0.798 0 N-CA-C 110.065 -1.214 . . . . 10.0 110.065 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.8 t -67.4 158.32 32.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 122.582 1.182 . . . . 10.0 111.273 -169.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.94 112.37 4.91 Favored 'General case' 0 N--CA 1.442 -0.857 0 C-N-CA 125.075 1.35 . . . . 10.0 107.966 170.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 29.0 mt -72.68 -55.71 6.4 Favored 'General case' 0 N--CA 1.458 -0.054 0 N-CA-C 109.098 -0.704 . . . . 10.0 109.098 170.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.34 156.6 47.47 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.858 -0.61 . . . . 10.0 110.273 -170.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.5 m -129.29 147.63 51.14 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.31 1.444 . . . . 10.0 108.805 -168.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -150.7 156.89 26.93 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.456 -1.458 . . . . 10.0 109.456 169.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 70.1 t -116.1 128.54 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 105.133 -2.173 . . . . 10.0 105.133 177.059 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 16.8 mt -69.03 156.93 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 CA-C-N 119.266 0.939 . . . . 10.0 110.06 176.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.02 160.91 32.47 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 124.995 1.283 . . . . 10.0 110.156 -176.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 96.0 mt -69.75 135.46 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.976 1.31 . . . . 10.0 109.478 -171.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.63 -47.1 2.44 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 123.366 0.666 . . . . 10.0 110.899 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 . . . . . 0 C--O 1.254 1.291 0 CA-C-O 117.809 -1.091 . . . . 10.0 111.031 -169.4 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.463 0 N-CA-C 110.161 -0.311 . . . . 10.0 110.161 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER 169.26 -41.06 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 129.861 3.264 . . . . 10.0 103.891 -167.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.407 ' NZ ' ' OE2' ' A' ' 21' ' ' GLU . 29.3 mtpp -106.39 132.35 52.52 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.243 -2.132 . . . . 10.0 105.243 166.119 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 163.05 33.97 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 107.526 -1.286 . . . . 10.0 107.526 169.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -124.28 176.51 5.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 C-N-CA 123.037 0.535 . . . . 10.0 109.998 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.77 117.13 5.68 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 118.504 0.593 . . . . 10.0 109.887 166.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -97.99 104.27 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 C-N-CA 124.609 1.164 . . . . 10.0 110.519 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mt -98.41 122.74 41.97 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.862 1.665 . . . . 10.0 109.517 -177.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -143.53 157.23 44.59 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 120.034 1.288 . . . . 10.0 108.513 173.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.26 -59.3 0.03 OUTLIER Glycine 0 N--CA 1.464 0.518 0 C-N-CA 120.317 -0.944 . . . . 10.0 113.005 169.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -70.93 -43.91 67.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.86 -71.45 0.38 Allowed Glycine 0 CA--C 1.521 0.451 0 CA-C-N 114.186 -1.37 . . . . 10.0 110.644 168.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -57.39 -33.36 96.13 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.786 2.99 . . . . 10.0 111.369 172.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 57.9 t -64.75 95.89 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.547 -1.279 . . . . 10.0 107.547 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 -120.58 111.27 17.45 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 125.684 1.594 . . . . 10.0 107.775 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -100.81 133.98 11.52 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-O 119.521 -0.6 . . . . 10.0 111.955 171.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.433 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 8.7 mt -136.08 85.93 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 -172.39 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.55 152.8 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 C-N-CA 124.404 1.081 . . . . 10.0 111.136 -171.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -120.68 116.8 26.01 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 126.504 1.922 . . . . 10.0 108.905 170.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -91.5 99.34 12.3 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 174.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.407 ' OE2' ' NZ ' ' A' ' 3' ' ' LYS . 16.4 mm-40 -97.39 117.86 32.58 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.775 0.798 . . . . 10.0 111.025 178.512 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.1 tp60 -117.61 97.31 5.8 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 127.895 2.478 . . . . 10.0 105.788 178.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 4.8 mtmp? -59.08 -52.76 64.33 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 123.004 0.522 . . . . 10.0 110.377 -173.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -131.09 172.31 12.25 Favored 'General case' 0 N--CA 1.424 -1.748 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 173.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.9 t -71.49 -20.28 62.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 108.879 -0.785 . . . . 10.0 108.879 170.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . 0.306 0.0 OUTLIER -89.13 -5.43 57.78 Favored 'General case' 0 C--N 1.344 0.359 0 N-CA-C 113.401 0.889 . . . . 10.0 113.401 173.446 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.72 160.11 35.34 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 109.619 -1.393 . . . . 10.0 109.619 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -71.55 148.2 53.25 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 N-CA-C 107.592 -1.734 . . . . 10.0 107.592 168.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.3 t -78.39 110.92 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 105.39 -2.078 . . . . 10.0 105.39 173.275 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.2 102.86 15.58 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 171.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -98.92 99.7 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.415 -1.328 . . . . 10.0 107.415 179.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.8 p90 -118.15 166.87 12.06 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.566 0.698 . . . . 10.0 112.267 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.79 -150.3 21.81 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.07 -2.412 . . . . 10.0 107.07 171.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.7 t -155.23 152.87 29.84 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 119.773 -0.771 . . . . 10.0 110.914 -178.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pt -110.63 142.85 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 115.215 -0.902 . . . . 10.0 108.616 166.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -118.81 148.85 42.41 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 169.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.71 -5.35 40.18 Favored Glycine 0 CA--C 1.525 0.664 0 CA-C-O 119.235 -0.759 . . . . 10.0 113.499 174.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -69.62 176.78 3.31 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 118.805 1.302 . . . . 10.0 110.122 177.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.1 t -104.75 167.83 9.46 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.319 -2.104 . . . . 10.0 105.319 165.232 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -57.07 166.38 1.07 Allowed 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.373 0.669 . . . . 10.0 111.254 -171.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.98 -177.17 42.94 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.286 -0.884 . . . . 10.0 112.375 168.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.0 mp -74.21 145.42 44.14 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 124.851 1.26 . . . . 10.0 110.093 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -144.91 145.36 31.53 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 124.177 0.991 . . . . 10.0 112.685 -175.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.48 125.97 0.28 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 126.695 2.093 . . . . 10.0 113.398 166.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -150.11 108.55 3.8 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.098 1.449 . . . . 10.0 108.253 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.25 173.0 12.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 122.732 1.253 . . . . 10.0 113.481 177.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 85.8 t -98.19 129.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 CA-C-N 111.03 -2.805 . . . . 10.0 105.487 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -105.8 139.72 39.93 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.194 -1.409 . . . . 10.0 107.194 170.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -58.1 -58.04 10.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 O-C-N 124.094 0.871 . . . . 10.0 110.214 -169.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -76.86 119.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.653 -1.61 . . . . 10.0 106.653 -171.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.74 46.81 2.94 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.523 -1.031 . . . . 10.0 110.523 171.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -108.89 118.72 37.53 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.929 1.291 . . . . 10.0 108.153 176.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -117.94 5.78 12.16 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.218 1.807 . . . . 10.0 109.988 178.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.401 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 1.3 m -57.07 -37.1 71.37 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 120.096 1.316 . . . . 10.0 111.667 -169.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -21.83 45.68 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.079 0.952 . . . . 10.0 112.682 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 143.85 -86.46 0.18 Allowed Glycine 0 CA--C 1.527 0.797 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 -172.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 24.1 p -170.78 43.29 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.152 0.981 . . . . 10.0 110.989 172.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 m -104.92 -49.31 3.52 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 m -50.18 -27.63 6.18 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 126.372 1.869 . . . . 10.0 111.641 174.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -37.16 -32.1 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 128.02 2.528 . . . . 10.0 113.848 168.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.32 126.64 5.2 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.277 -1.291 . . . . 10.0 109.95 170.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -72.4 65.34 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.81 0 C-N-CA 123.729 2.953 . . . . 10.0 112.268 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.7 m170 68.87 42.8 1.29 Allowed 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 129.773 3.229 . . . . 10.0 111.505 172.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -72.51 57.96 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.728 1.01 . . . . 10.0 113.728 -173.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.0 p-10 -68.3 159.57 79.95 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 118.968 0.804 . . . . 10.0 110.931 175.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -61.28 -47.68 11.55 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.216 1.944 . . . . 10.0 111.218 176.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 94.8 mt -78.1 59.05 2.12 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 109.301 -0.629 . . . . 10.0 109.301 177.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.0 t -58.97 95.64 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.417 1.087 . . . . 10.0 108.77 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.59 -96.57 0.41 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.796 -1.557 . . . . 10.0 106.796 -177.172 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.5 mttp -151.67 139.92 20.34 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 106.397 -1.705 . . . . 10.0 106.397 173.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.6 t60 -40.91 124.15 2.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 O-C-N 123.776 0.673 . . . . 10.0 110.903 170.401 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.15 -138.12 3.66 Favored Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 108.367 -1.893 . . . . 10.0 108.367 177.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -177.37 -165.94 33.35 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 107.342 -2.303 . . . . 10.0 107.342 169.297 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -62.54 -0.72 2.06 Favored 'Trans proline' 0 CA--C 1.542 0.878 0 CA-C-N 120.305 2.053 . . . . 10.0 110.948 167.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.403 ' H ' ' C ' ' A' ' 73' ' ' GLY . 61.0 mmtt -91.07 -24.62 19.98 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 124.409 1.084 . . . . 10.0 110.625 173.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.77 174.8 5.72 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -176.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -87.82 -32.15 19.19 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 170.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -82.25 2.0 33.99 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 115.032 1.493 . . . . 10.0 115.032 -165.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -41.54 137.36 1.59 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 125.639 1.575 . . . . 10.0 112.172 -177.12 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -71.88 -77.64 0.09 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.704 -0.798 . . . . 10.0 112.185 -170.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 p -161.41 58.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 121.324 -0.86 . . . . 10.0 109.46 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 106.94 50.55 0.83 Allowed Glycine 0 CA--C 1.523 0.533 0 N-CA-C 109.943 -1.263 . . . . 10.0 109.943 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -87.05 90.97 8.54 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 104.026 -2.583 . . . . 10.0 104.026 167.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.3 mt -70.3 -31.63 69.06 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 107.316 -1.364 . . . . 10.0 107.316 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 101.08 -106.43 3.08 Favored Glycine 0 N--CA 1.434 -1.44 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 168.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -109.23 119.41 39.42 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.506 1.122 . . . . 10.0 110.388 -168.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.1 m -104.89 135.36 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 168.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 50.0 m -99.64 108.8 21.26 Favored 'General case' 0 N--CA 1.442 -0.858 0 C-N-CA 126.316 1.846 . . . . 10.0 109.641 -168.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.44 130.24 35.24 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.229 1.011 . . . . 10.0 110.748 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 45.4 t0 -66.26 170.71 5.52 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 123.956 0.902 . . . . 10.0 109.455 168.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -52.96 -26.99 16.91 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.872 1.669 . . . . 10.0 111.599 177.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -79.03 -15.52 58.11 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.349 1.059 . . . . 10.0 110.065 -175.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.81 74.21 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 110.991 -0.844 . . . . 10.0 110.991 -173.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.0 t -87.64 113.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 C-N-CA 126.338 1.855 . . . . 10.0 106.265 173.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.9 121.38 44.87 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.461 -0.94 . . . . 10.0 108.461 171.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -78.17 130.55 36.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 172.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 75.0 t -104.91 129.39 57.59 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.369 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 169.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -156.93 66.95 0.53 Allowed 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 175.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.35 155.02 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.37 138.36 38.2 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.929 0.492 . . . . 10.0 110.727 169.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.95 131.14 51.15 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.858 1.263 . . . . 10.0 108.789 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.4 p -95.96 42.75 1.09 Allowed 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.626 1.971 . . . . 10.0 108.424 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.3 -49.88 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 123.337 0.655 . . . . 10.0 109.644 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 33.7 mm -57.57 134.55 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 169.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.5 m -164.66 94.22 0.68 Allowed 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.668 0.787 . . . . 10.0 109.441 -176.218 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -68.61 27.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.644 1.177 . . . . 10.0 113.839 175.328 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.9 p -157.8 113.4 2.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 121.275 -0.891 . . . . 10.0 110.32 -176.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 162.26 -54.1 0.31 Allowed Glycine 0 C--N 1.335 0.481 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 169.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.75 -50.14 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 126.337 1.855 . . . . 10.0 107.475 -173.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 -74.42 -38.53 63.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.944 -1.025 . . . . 10.0 108.623 -169.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 40.53 62.2 1.42 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.154 1.782 . . . . 10.0 110.01 172.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 24.3 pt -74.62 46.77 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.745 2.018 . . . . 10.0 111.77 -175.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.3 mm -72.49 -65.17 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 128.971 2.908 . . . . 10.0 108.207 172.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.75 47.52 3.07 Favored Glycine 0 CA--C 1.529 0.953 0 O-C-N 121.343 -0.848 . . . . 10.0 113.808 -169.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -89.65 174.63 7.64 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 125.105 1.362 . . . . 10.0 108.68 172.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 20.2 m -109.87 115.11 29.22 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.787 -2.301 . . . . 10.0 104.787 168.127 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.6 mp -97.94 151.78 19.92 Favored 'General case' 0 CA--C 1.512 -0.511 0 N-CA-C 108.296 -1.001 . . . . 10.0 108.296 175.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.7 t -143.16 136.89 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 O-C-N 123.837 0.711 . . . . 10.0 109.803 -170.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.8 m -105.89 140.35 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.952 1.301 . . . . 10.0 108.887 167.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.0 m170 -120.66 159.13 25.94 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.49 2.033 . . . . 10.0 116.49 -172.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -39.46 -58.61 1.23 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 130.289 3.436 . . . . 10.0 111.886 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -123.17 168.34 12.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 124.679 1.192 . . . . 10.0 110.48 -171.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.76 137.66 55.61 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 108.308 -0.997 . . . . 10.0 108.308 169.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.421 ' C ' ' H ' ' A' ' 126' ' ' LEU . 0.0 OUTLIER -77.84 144.12 37.27 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.191 -1.04 . . . . 10.0 108.191 168.193 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -78.14 25.04 0.23 Allowed 'General case' 0 CA--C 1.539 0.519 0 CA-C-O 121.133 0.492 . . . . 10.0 111.126 177.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.421 ' H ' ' C ' ' A' ' 124' ' ' ASP . 18.8 mt 30.53 45.82 0.03 OUTLIER 'General case' 0 C--N 1.34 0.162 0 C-N-CA 128.23 2.612 . . . . 10.0 112.629 -170.161 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.6 -45.53 1.3 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 124.623 1.106 . . . . 10.0 112.488 177.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -83.34 50.6 1.8 Allowed 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.092 0.957 . . . . 10.0 111.452 -169.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -87.45 -35.89 9.14 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 125.969 1.747 . . . . 10.0 110.022 172.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.27 38.7 71.56 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.865 -0.894 . . . . 10.0 110.865 -178.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 56.1 m-80 -130.8 163.74 26.7 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 169.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -53.31 -39.35 63.96 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.718 0.771 . . . . 10.0 109.592 173.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -67.14 -35.16 79.12 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.448 1.099 . . . . 10.0 112.934 173.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 60.0 p -56.31 -34.01 66.12 Favored 'General case' 0 N--CA 1.443 -0.776 0 O-C-N 120.029 -1.669 . . . . 10.0 112.033 -175.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -81.35 -1.98 47.44 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 118.738 -0.649 . . . . 10.0 112.139 -178.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -112.69 -82.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.263 1.825 . . . . 10.0 110.545 -177.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -109.6 25.45 11.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 120.725 1.602 . . . . 10.0 111.974 174.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.1 18.03 66.42 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.602 167.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 m120 62.24 23.54 13.93 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 118.085 0.943 . . . . 10.0 112.224 -171.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.03 -11.91 33.65 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.24 -0.913 . . . . 10.0 113.097 177.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.62 -161.2 46.1 Favored Glycine 0 CA--C 1.523 0.553 0 O-C-N 121.151 -0.968 . . . . 10.0 111.128 170.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.9 t -57.07 129.68 42.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 124.327 1.051 . . . . 10.0 113.135 -167.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.1 mtt85 -65.94 71.97 0.06 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.454 1.902 . . . . 10.0 111.404 175.152 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 51.7 mt -52.05 -33.4 38.68 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.286 1.034 . . . . 10.0 113.733 -177.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.81 147.18 26.96 Favored 'General case' 0 CA--C 1.512 -0.495 0 O-C-N 121.727 -0.608 . . . . 10.0 110.055 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.8 m -140.9 149.85 42.45 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 107.627 -1.249 . . . . 10.0 107.627 -170.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.58 36.42 Favored Glycine 0 CA--C 1.521 0.416 0 N-CA-C 111.397 -0.681 . . . . 10.0 111.397 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 52.9 t -115.23 154.68 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 103.145 -2.909 . . . . 10.0 103.145 171.082 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 8.3 mt -71.45 -90.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 123.51 0.724 . . . . 10.0 109.306 -169.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 108.06 125.61 5.3 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 81.2 mt -61.18 140.47 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 C-N-CA 125.686 1.594 . . . . 10.0 108.721 175.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.36 -38.84 4.57 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-N 119.525 1.057 . . . . 10.0 111.495 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? . . . . . 0 C--O 1.249 1.038 0 CA-C-O 117.308 -1.33 . . . . 10.0 109.899 178.22 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 106.458 -1.682 . . . . 10.0 106.458 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -88.1 -56.17 3.44 Favored 'General case' 0 N--CA 1.458 -0.027 0 O-C-N 124.293 0.995 . . . . 10.0 110.853 -174.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.07 138.79 49.73 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.415 1.086 . . . . 10.0 110.155 -176.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.48 162.64 33.99 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.63 0.772 . . . . 10.0 110.653 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 m -121.04 160.89 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.557 1.143 . . . . 10.0 109.617 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 95.82 2.9 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.556 -1.275 . . . . 10.0 107.556 166.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 2.7 m -82.15 108.48 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 169.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -93.99 137.8 32.8 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 178.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 tttt -156.58 159.03 38.12 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 119.912 1.233 . . . . 10.0 107.87 171.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.89 -47.91 0.04 OUTLIER Glycine 0 C--O 1.229 -0.2 0 C-N-CA 120.684 -0.769 . . . . 10.0 111.481 169.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.52 -46.43 26.59 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 -171.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.72 -69.0 0.52 Allowed Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 113.905 -1.498 . . . . 10.0 110.145 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -56.28 -44.04 50.23 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.311 2.007 . . . . 10.0 110.539 171.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.96 101.2 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.13 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 -175.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -120.81 110.75 16.72 Favored 'General case' 0 N--CA 1.441 -0.921 0 N-CA-C 106.103 -1.814 . . . . 10.0 106.103 173.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.05 140.38 15.48 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.615 -1.794 . . . . 10.0 108.615 171.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . 0.401 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 4.0 mt -141.53 88.84 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 -173.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -101.3 144.13 13.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 C-N-CA 123.576 0.75 . . . . 10.0 110.362 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -121.19 114.26 21.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 126.499 1.92 . . . . 10.0 108.266 168.639 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -98.19 106.4 18.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 mt-10 -107.54 123.86 49.07 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 112.789 0.662 . . . . 10.0 112.789 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -81.62 115.16 20.76 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 104.112 -2.551 . . . . 10.0 104.112 166.286 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt . . . . . 0 N--CA 1.449 -0.475 0 C-N-CA 123.954 0.902 . . . . 10.0 109.92 169.826 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.929 0 N-CA-C 108.862 -1.695 . . . . 10.0 108.862 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -65.7 132.18 29.94 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.5 1.467 . . . . 10.0 108.497 171.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.9 t -78.07 108.34 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 104.778 -2.305 . . . . 10.0 104.778 169.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -79.62 109.74 14.29 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 105.275 -2.12 . . . . 10.0 105.275 169.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -96.67 97.07 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 106.328 -1.73 . . . . 10.0 106.328 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 20.5 p90 -108.76 164.37 12.44 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.163 0.506 . . . . 10.0 110.595 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.88 178.86 48.45 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 110.391 -1.084 . . . . 10.0 110.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -150.88 106.07 3.34 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.663 -0.866 . . . . 10.0 108.663 178.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 6.2 pt -79.9 173.15 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 119.55 -0.86 . . . . 10.0 109.738 173.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.0 pttt -150.85 153.36 35.22 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 168.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.82 -15.36 40.86 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-O 118.993 -0.893 . . . . 10.0 115.274 169.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.6 mp -75.33 179.66 5.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.943 1.372 . . . . 10.0 110.362 -177.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -91.56 174.95 7.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 166.018 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -62.25 175.09 0.78 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 124.391 1.076 . . . . 10.0 111.435 -173.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.44 -172.74 47.23 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 123.885 0.755 . . . . 10.0 112.588 166.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -75.89 142.78 42.02 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.425 1.49 . . . . 10.0 110.093 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -137.39 143.25 41.84 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 114.753 1.39 . . . . 10.0 114.753 -175.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.04 124.95 0.24 Allowed Glycine 0 C--N 1.343 0.917 0 C-N-CA 127.262 2.363 . . . . 10.0 111.711 162.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.35 103.42 2.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.343 1.572 . . . . 10.0 109.949 170.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.518 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.79 173.98 15.7 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 113.806 1.039 . . . . 10.0 113.806 -176.91 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 m -85.26 151.99 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 CA-C-N 113.006 -1.906 . . . . 10.0 109.385 169.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -132.89 84.9 2.17 Favored 'General case' 0 C--O 1.221 -0.428 0 C-N-CA 124.756 1.222 . . . . 10.0 108.365 174.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 22.5 -83.96 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 128.046 2.539 . . . . 10.0 116.129 -176.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -76.76 179.06 6.31 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-O 121.555 0.693 . . . . 10.0 109.594 -169.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.69 -26.17 10.98 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.508 -1.037 . . . . 10.0 110.508 169.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -37.47 130.24 0.98 Allowed 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 125.502 1.521 . . . . 10.0 110.317 176.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -138.38 18.61 2.75 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 114.944 -1.026 . . . . 10.0 111.398 175.159 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.433 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -56.92 -35.76 69.41 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 118.362 0.528 . . . . 10.0 110.223 -178.197 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.95 -20.25 42.4 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 125.42 1.488 . . . . 10.0 113.515 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.29 99.12 1.04 Allowed Glycine 0 CA--C 1.531 1.065 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 -169.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.9 p 3.94 61.6 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 128.555 2.742 . . . . 10.0 117.508 -169.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.1 m -135.33 -60.03 0.76 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.013 -1.847 . . . . 10.0 106.013 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 41.6 t -50.93 -34.52 28.92 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.736 0.814 . . . . 10.0 110.002 169.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.07 -47.52 0.28 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 126.29 1.836 . . . . 10.0 112.64 168.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 131.63 140.6 4.59 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.082 -0.844 . . . . 10.0 111.998 171.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -73.13 64.68 4.26 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.824 3.016 . . . . 10.0 110.501 169.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 30.3 m170 75.57 -44.31 0.52 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 129.781 3.232 . . . . 10.0 111.05 175.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 31.13 59.4 0.26 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 127.75 2.42 . . . . 10.0 113.252 -174.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -55.34 146.23 43.32 Favored Pre-proline 0 C--N 1.324 -0.519 0 N-CA-C 113.441 0.904 . . . . 10.0 113.441 175.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.84 -47.54 0.34 Allowed 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.762 2.308 . . . . 10.0 110.832 177.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -81.71 56.57 3.07 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.821 0.848 . . . . 10.0 109.879 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -18.35 77.31 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.278 3.031 . . . . 10.0 116.48 -169.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt85 -116.53 -179.86 3.8 Favored 'General case' 0 CA--C 1.509 -0.598 0 C-N-CA 125.499 1.52 . . . . 10.0 109.84 173.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -114.59 89.4 3.09 Favored 'General case' 0 N--CA 1.439 -1.014 0 O-C-N 124.238 0.962 . . . . 10.0 112.755 -171.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.465 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 75.1 t60 12.83 89.19 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.174 2.19 . . . . 10.0 115.084 176.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -106.42 -141.69 10.45 Favored Glycine 0 C--N 1.318 -0.435 0 N-CA-C 108.721 -1.752 . . . . 10.0 108.721 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.417 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -177.67 -168.23 37.0 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 109.896 -1.281 . . . . 10.0 109.896 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -66.72 12.13 0.16 Allowed 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.224 1.95 . . . . 10.0 111.662 169.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.417 ' H ' ' C ' ' B' ' 73' ' ' GLY . 62.7 mmtt -107.55 -18.84 13.74 Favored 'General case' 0 N--CA 1.438 -1.025 0 C-N-CA 124.731 1.213 . . . . 10.0 109.541 173.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -135.54 162.75 31.8 Favored 'General case' 0 C--N 1.348 0.513 0 CA-C-N 118.766 0.712 . . . . 10.0 109.822 -167.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -82.62 -18.76 40.05 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 107.969 -1.123 . . . . 10.0 107.969 173.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -84.27 21.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.219 0 O-C-N 119.908 -1.745 . . . . 10.0 112.854 -169.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.01 138.04 5.4 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.54 1.136 . . . . 10.0 109.196 170.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . 0.465 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 11.6 m170 -70.41 -65.61 0.71 Allowed 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 173.812 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.8 p -174.42 -69.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.117 1.367 . . . . 10.0 108.248 -178.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.84 63.12 0.31 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 109.602 -1.399 . . . . 10.0 109.602 -175.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.8 95.3 5.51 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 26.1 mt -75.33 2.43 11.24 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 120.295 -0.562 . . . . 10.0 110.906 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 89.16 -95.63 2.12 Favored Glycine 0 N--CA 1.437 -1.25 0 N-CA-C 108.174 -1.97 . . . . 10.0 108.174 171.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.3 m-20 -156.17 113.56 3.23 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 118.622 -0.704 . . . . 10.0 109.258 -172.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.3 m -96.72 131.08 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 118.524 0.602 . . . . 10.0 110.215 177.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 14.4 m -87.21 108.64 19.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 127.85 2.46 . . . . 10.0 110.424 -173.218 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.8 133.17 34.34 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.156 0.583 . . . . 10.0 109.752 171.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -61.86 174.05 0.91 Allowed 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.939 0.876 . . . . 10.0 109.591 167.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -51.57 -29.88 18.83 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 125.244 1.418 . . . . 10.0 110.961 173.134 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.01 -9.55 59.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 123.35 0.66 . . . . 10.0 110.501 -175.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.07 7.14 83.98 Favored Glycine 0 C--N 1.339 0.745 0 N-CA-C 111.33 -0.708 . . . . 10.0 111.33 -177.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 47.5 t -90.02 114.18 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 126.144 1.778 . . . . 10.0 106.366 178.301 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.81 118.57 36.5 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 169.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -80.09 121.69 25.85 Favored 'General case' 0 N--CA 1.451 -0.393 0 O-C-N 124.886 1.366 . . . . 10.0 107.547 169.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 99.1 t -105.81 131.07 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 C-N-CA 125.928 1.691 . . . . 10.0 106.625 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.5 p -155.46 74.58 0.9 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 174.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.69 159.01 7.41 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -142.68 133.66 25.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 O-C-N 121.77 -0.581 . . . . 10.0 110.738 173.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -142.88 135.34 27.57 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.976 0.91 . . . . 10.0 109.543 -172.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 3.8 p -93.92 -10.52 33.52 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.17 1.388 . . . . 10.0 111.188 169.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -85.07 -15.75 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.916 0.886 . . . . 10.0 110.28 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -98.15 149.84 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 106.659 -1.608 . . . . 10.0 106.659 169.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.6 m -153.34 141.16 20.11 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 169.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -56.14 -50.04 72.24 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.886 0.874 . . . . 10.0 109.558 -178.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.455 -0.184 0 C-N-CA 124.862 1.265 . . . . 10.0 108.688 -178.771 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t . . . . . 0 N--CA 1.448 -0.571 0 N-CA-C 114.514 1.302 . . . . 10.0 114.514 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 28.1 pt -70.64 -12.16 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 N-CA-C 113.168 0.803 . . . . 10.0 113.168 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.4 mm -57.66 115.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 119.847 1.203 . . . . 10.0 110.208 171.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 102.69 2.6 49.79 Favored Glycine 0 C--N 1.336 0.546 0 C-N-CA 124.496 1.046 . . . . 10.0 111.804 173.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.77 148.8 31.32 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 117.845 0.822 . . . . 10.0 110.605 173.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 31.3 m -80.66 126.69 31.59 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.838 1.255 . . . . 10.0 108.091 168.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -103.48 145.47 29.95 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.305 1.442 . . . . 10.0 107.825 169.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 68.9 t -135.54 143.5 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 4.4 p -110.89 139.8 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 O-C-N 124.535 1.147 . . . . 10.0 108.679 169.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.6 m-70 -117.2 162.41 17.91 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 114.729 1.381 . . . . 10.0 114.729 -174.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -61.72 -51.11 69.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 114.888 -1.051 . . . . 10.0 109.789 178.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -109.65 170.18 8.23 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.51 0.671 . . . . 10.0 111.613 -168.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.21 148.77 45.23 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 114.278 -1.328 . . . . 10.0 109.078 178.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.518 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.7 OUTLIER -74.93 151.14 38.91 Favored 'General case' 0 N--CA 1.443 -0.775 0 N-CA-C 109.226 -0.657 . . . . 10.0 109.226 172.686 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -76.0 -38.35 57.45 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 112.713 -2.039 . . . . 10.0 108.936 172.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 62.8 mt 62.45 64.54 0.93 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 123.97 1.843 . . . . 10.0 108.061 -176.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 76.21 -38.49 1.38 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 112.136 -2.302 . . . . 10.0 116.14 167.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 11.9 mtmt -75.35 5.09 6.1 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.099 1.148 . . . . 10.0 114.099 -167.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.45 -34.93 90.14 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 108.388 -1.885 . . . . 10.0 108.388 166.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.71 25.61 51.77 Favored Glycine 0 C--N 1.341 0.827 0 N-CA-C 111.191 -0.764 . . . . 10.0 111.191 -176.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -108.2 172.88 6.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 170.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -57.1 -45.6 83.27 Favored 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 123.957 0.903 . . . . 10.0 109.277 -177.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 mp0 -52.96 -42.76 65.79 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.456 1.102 . . . . 10.0 109.992 173.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.12 -9.21 20.92 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 117.341 -1.314 . . . . 10.0 113.362 179.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.2 t -108.73 7.57 26.44 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 121.009 1.731 . . . . 10.0 110.627 173.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -127.05 -59.44 1.25 Allowed 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 124.909 1.284 . . . . 10.0 110.94 -170.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.7 p -140.63 22.42 2.33 Favored 'General case' 0 CA--C 1.544 0.736 0 CA-C-N 119.016 0.826 . . . . 10.0 112.008 176.37 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 78.03 -100.23 1.6 Allowed Glycine 0 C--N 1.341 0.857 0 N-CA-C 107.533 -2.227 . . . . 10.0 107.533 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -163.62 42.19 0.1 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 125.696 1.598 . . . . 10.0 107.6 169.075 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.43 -8.98 45.46 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.296 1.038 . . . . 10.0 113.009 -174.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.01 -171.34 55.13 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.669 -1.372 . . . . 10.0 109.669 -173.228 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -53.32 164.11 0.51 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 124.822 1.249 . . . . 10.0 112.004 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.25 114.25 19.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 168.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.425 ' N ' ' CD2' ' B' ' 144' ' ' LEU . 0.7 OUTLIER -84.63 -48.13 9.81 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 108.315 -0.994 . . . . 10.0 108.315 -177.716 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.64 141.17 39.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 116.208 -0.451 . . . . 10.0 110.121 -175.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 m -118.6 145.37 45.46 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 126.491 1.916 . . . . 10.0 108.297 -169.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.19 155.46 26.49 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.859 -1.296 . . . . 10.0 109.859 168.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 18.1 t -116.24 129.51 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 103.946 -2.613 . . . . 10.0 103.946 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.7 mt -65.93 133.65 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 119.188 0.904 . . . . 10.0 111.255 -177.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.04 143.38 16.15 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.338 -1.505 . . . . 10.0 109.338 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -80.94 128.21 38.89 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.346 0 CA-C-N 118.442 1.121 . . . . 10.0 108.622 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.33 -49.23 17.42 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 -175.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.8 tp60 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 117.218 -1.373 . . . . 10.0 109.527 175.195 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 108.466 -0.938 . . . . 10.0 108.466 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t -133.81 -49.09 0.82 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 124.061 0.944 . . . . 10.0 111.439 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -120.93 139.54 53.08 Favored 'General case' 0 C--O 1.235 0.31 0 C-N-CA 125.462 1.505 . . . . 10.0 109.371 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.87 164.12 36.23 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 173.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 m -123.72 179.57 2.7 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 O-C-N 123.469 0.481 . . . . 10.0 109.9 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.89 118.25 8.45 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 126.683 1.993 . . . . 10.0 107.631 164.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 m -97.23 86.81 1.6 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 124.211 1.005 . . . . 10.0 111.007 173.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -79.47 140.15 37.42 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 121.789 -0.569 . . . . 10.0 109.609 -179.007 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.8 mtmt -152.35 163.65 39.06 Favored 'General case' 0 N--CA 1.456 -0.168 0 N-CA-C 106.622 -1.621 . . . . 10.0 106.622 170.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -166.4 -65.71 0.03 OUTLIER Glycine 0 C--N 1.33 0.249 0 C-N-CA 120.606 -0.806 . . . . 10.0 112.249 169.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -74.11 -42.1 60.59 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.08 -66.45 0.5 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 114.885 -1.052 . . . . 10.0 111.959 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.81 -41.24 71.76 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.89 1.727 . . . . 10.0 110.621 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -68.0 109.47 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.331 -1.359 . . . . 10.0 107.331 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -120.46 122.37 40.54 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.161 -2.163 . . . . 10.0 105.161 171.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.94 133.64 11.78 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 109.649 -1.38 . . . . 10.0 109.649 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mt -138.17 86.38 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -173.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.5 mm -95.57 143.33 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 C-N-CA 123.948 0.899 . . . . 10.0 109.111 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 32.7 m-80 -115.54 121.68 43.4 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 126.13 1.772 . . . . 10.0 108.721 168.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -102.28 98.11 8.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 125.862 1.665 . . . . 10.0 107.025 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -117.89 121.31 40.39 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.072 0.851 . . . . 10.0 113.109 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -94.05 105.49 17.49 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 125.867 1.667 . . . . 10.0 107.831 168.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.47 -42.76 61.83 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.795 0.838 . . . . 10.0 110.174 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -135.98 158.53 44.17 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 102.193 -3.262 . . . . 10.0 102.193 165.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 t -77.32 -3.87 42.19 Favored 'General case' 0 C--O 1.226 -0.135 0 CA-C-N 119.37 0.986 . . . . 10.0 109.817 173.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m120 -85.02 -24.6 28.12 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 125.182 1.393 . . . . 10.0 109.361 168.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.62 156.84 45.06 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 109.43 -1.468 . . . . 10.0 109.43 174.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -64.55 153.16 78.71 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 N-CA-C 108.006 -1.575 . . . . 10.0 108.006 169.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.8 p -79.14 121.14 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 N-CA-C 106.69 -1.596 . . . . 10.0 106.69 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -88.79 113.73 24.66 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.16 -1.793 . . . . 10.0 106.16 168.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 m -92.31 95.97 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.824 0 N-CA-C 105.555 -2.017 . . . . 10.0 105.555 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.7 p90 -106.97 161.8 14.4 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.178 0.513 . . . . 10.0 110.538 171.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.16 169.29 39.48 Favored Glycine 0 N--CA 1.438 -1.187 0 C-N-CA 120.055 -1.069 . . . . 10.0 110.63 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.0 t -139.37 95.75 2.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.992 -1.485 . . . . 10.0 106.992 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.4 pt -77.07 166.33 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.124 -1.065 . . . . 10.0 108.124 169.093 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -149.29 146.53 27.6 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 106.58 -1.637 . . . . 10.0 106.58 166.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.53 -4.93 24.73 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 123.921 0.772 . . . . 10.0 113.567 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -73.23 177.93 4.8 Favored 'General case' 0 N--CA 1.444 -0.752 0 CA-C-N 118.117 0.959 . . . . 10.0 109.245 173.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 7.9 t -90.39 172.29 8.85 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.632 -0.877 . . . . 10.0 108.632 166.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.91 169.88 2.37 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.43 1.092 . . . . 10.0 110.837 -173.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.73 -178.92 41.26 Favored Glycine 0 N--CA 1.448 -0.503 0 O-C-N 121.428 -0.795 . . . . 10.0 112.843 167.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.6 mp -69.4 143.83 53.54 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.612 1.165 . . . . 10.0 109.779 176.04 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -142.61 139.49 31.31 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 123.381 0.672 . . . . 10.0 112.662 -176.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -26.84 117.94 0.04 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.106 2.289 . . . . 10.0 113.036 164.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.03 106.23 4.56 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 120.2 2.0 . . . . 10.0 110.095 170.03 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.48 172.06 15.09 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-O 121.174 0.512 . . . . 10.0 112.075 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.43 -44.57 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 C-N-CA 126.249 1.819 . . . . 10.0 113.429 -168.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 63.64 144.45 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 126.887 2.075 . . . . 10.0 112.074 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -67.0 -47.7 70.68 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.694 -0.854 . . . . 10.0 108.694 177.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -74.88 129.98 38.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 107.788 -1.19 . . . . 10.0 107.788 -169.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -88.75 -28.43 21.47 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 126.572 2.034 . . . . 10.0 110.695 175.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.59 176.43 0.65 Allowed 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 125.144 1.378 . . . . 10.0 112.819 -176.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -146.34 -64.41 0.3 Allowed 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.078 -1.419 . . . . 10.0 110.021 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER 46.54 -57.17 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.652 1 C-N-CA 133.211 4.604 . . . . 10.0 115.134 179.546 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . 0.293 . . -69.66 -37.05 76.57 Favored 'General case' 0 N--CA 1.437 -1.081 0 C-N-CA 127.763 2.425 . . . . 10.0 108.216 169.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.29 -143.76 14.96 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.233 -2.747 . . . . 10.0 106.233 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.3 t -78.8 39.35 0.35 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 122.178 0.99 . . . . 10.0 112.066 -172.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.4 m -111.27 -49.33 3.02 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 127.826 2.451 . . . . 10.0 106.811 -169.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.402 ' C ' ' H ' ' A' ' 61' ' ' GLY . 16.1 m -91.0 16.92 8.64 Favored 'General case' 0 N--CA 1.435 -1.224 0 C-N-CA 126.488 1.915 . . . . 10.0 110.113 -171.292 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.69 61.44 1.37 Allowed 'General case' 0 C--O 1.236 0.379 0 C-N-CA 124.101 0.96 . . . . 10.0 109.365 169.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.402 ' H ' ' C ' ' A' ' 59' ' ' SER . . . 0.26 103.92 0.01 OUTLIER Glycine 0 C--N 1.335 0.488 1 C-N-CA 131.62 4.438 . . . . 10.0 111.087 166.705 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -73.04 73.5 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 122.752 2.301 . . . . 10.0 113.129 -168.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 11.1 m170 71.82 36.2 1.24 Allowed 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 129.592 3.157 . . . . 10.0 110.749 170.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -73.62 60.02 0.66 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.451 1.1 . . . . 10.0 110.709 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -75.03 156.96 85.85 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 123.673 0.789 . . . . 10.0 110.181 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -65.43 -65.36 0.05 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.441 2.094 . . . . 10.0 111.5 -175.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.99 66.81 1.22 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.661 0.743 . . . . 10.0 109.975 172.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 113.74 3.3 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.401 -0.812 . . . . 10.0 109.557 178.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.6 mtt180 -116.8 -87.91 0.6 Allowed 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 103.298 -2.852 . . . . 10.0 103.298 -173.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtm -145.72 160.12 42.18 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 122.627 1.203 . . . . 10.0 108.702 167.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 42.7 t60 -62.2 127.27 30.59 Favored 'General case' 0 N--CA 1.439 -1.022 0 N-CA-C 105.364 -2.088 . . . . 10.0 105.364 163.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.89 -138.26 3.27 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 107.79 -2.124 . . . . 10.0 107.79 177.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.469 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.42 -158.39 22.26 Favored Glycine 0 N--CA 1.449 -0.444 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 169.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -65.98 10.58 0.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 CA-C-N 119.869 1.835 . . . . 10.0 110.945 168.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.469 ' H ' ' C ' ' A' ' 73' ' ' GLY . 1.9 mmmp? -108.68 -15.83 14.32 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.621 1.168 . . . . 10.0 109.257 177.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.419 ' OD2' ' NZ ' ' A' ' 128' ' ' LYS . 2.3 m-20 -141.32 132.13 25.85 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.617 -1.623 . . . . 10.0 106.617 -168.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -73.46 -22.58 60.14 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 -171.372 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -79.57 1.82 24.55 Favored 'General case' 0 N--CA 1.433 -1.313 0 C-N-CA 124.737 1.215 . . . . 10.0 111.579 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -42.15 142.97 0.65 Allowed 'General case' 0 C--N 1.346 0.445 0 C-N-CA 124.956 1.302 . . . . 10.0 112.436 177.305 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -59.49 -62.28 2.0 Allowed 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 121.238 0.542 . . . . 10.0 111.132 -173.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.8 p -167.37 -64.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 179.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -122.04 60.26 0.56 Allowed Glycine 0 CA--C 1.522 0.503 0 N-CA-C 109.637 -1.385 . . . . 10.0 109.637 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -92.37 90.97 7.45 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.672 -2.344 . . . . 10.0 104.672 168.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 40.4 mt -70.07 -31.49 69.11 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 173.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.1 -102.73 2.27 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 108.536 -1.825 . . . . 10.0 108.536 168.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 52.4 m-20 -124.51 124.22 41.81 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.686 1.194 . . . . 10.0 110.631 -168.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 16.2 m -111.1 137.71 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 108.057 -1.09 . . . . 10.0 108.057 168.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 54.1 m -92.22 120.18 32.55 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.897 1.679 . . . . 10.0 108.667 -175.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.62 133.2 44.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 123.901 0.88 . . . . 10.0 110.508 176.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -59.38 170.97 0.87 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 123.589 0.755 . . . . 10.0 109.834 167.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.6 pttp -47.37 -34.89 7.51 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.787 1.635 . . . . 10.0 110.403 171.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -79.48 -0.74 34.43 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 124.683 1.193 . . . . 10.0 111.438 -174.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.45 8.55 87.69 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 110.671 -0.972 . . . . 10.0 110.671 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.5 t -88.0 106.92 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 125.95 1.7 . . . . 10.0 106.614 -178.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.9 117.84 35.28 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 168.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.26 114.37 18.14 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 126.038 1.735 . . . . 10.0 108.654 172.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.2 t -107.24 133.43 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 178.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 94.9 p -156.62 59.21 0.55 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.264 0.625 . . . . 10.0 110.088 172.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.6 mt -96.43 157.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -174.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -133.06 143.0 49.06 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.805 0.729 . . . . 10.0 111.057 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -127.09 124.14 38.52 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.274 1.43 . . . . 10.0 108.861 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 p -89.99 -8.89 50.57 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.352 1.461 . . . . 10.0 111.147 169.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.4 p -95.91 -39.23 9.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 124.331 1.052 . . . . 10.0 109.929 -174.081 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -97.03 155.89 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 125.347 1.459 . . . . 10.0 108.514 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.6 m -157.63 156.39 31.74 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 108.281 -1.007 . . . . 10.0 108.281 -173.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -74.53 -23.04 58.75 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 120.919 0.39 . . . . 10.0 110.478 174.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.8 m -150.47 142.57 24.05 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.051 -1.462 . . . . 10.0 107.051 -177.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.73 -67.2 0.29 Allowed Glycine 0 C--N 1.334 0.427 0 N-CA-C 109.014 -1.634 . . . . 10.0 109.014 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -163.37 -51.36 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 126.398 1.879 . . . . 10.0 107.287 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.19 -28.29 59.97 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 114.755 -1.111 . . . . 10.0 110.241 -169.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.1 t 22.86 81.47 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 129.028 2.931 . . . . 10.0 111.814 172.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.8 pt -75.93 39.23 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 112.213 0.449 . . . . 10.0 112.213 -173.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -83.39 -48.61 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 124.899 1.28 . . . . 10.0 111.268 -171.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.79 46.02 1.32 Allowed Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.816 -0.914 . . . . 10.0 110.816 -175.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -111.13 162.02 15.35 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 125.201 1.4 . . . . 10.0 108.881 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -110.22 102.56 11.23 Favored 'General case' 0 C--N 1.347 0.476 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 179.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.82 134.98 40.24 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.514 -0.921 . . . . 10.0 108.514 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 61.9 t -124.11 131.74 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 O-C-N 123.911 0.757 . . . . 10.0 110.407 -172.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.8 t -98.19 123.37 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 128.416 2.686 . . . . 10.0 107.639 168.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -109.94 157.54 19.15 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 115.868 1.803 . . . . 10.0 115.868 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -41.34 -65.13 0.47 Allowed 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 129.767 3.227 . . . . 10.0 111.73 171.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.1 mttp -112.28 175.41 5.44 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.861 0.865 . . . . 10.0 111.74 -172.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.61 147.91 37.29 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 114.005 -1.452 . . . . 10.0 109.72 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -78.77 142.75 36.73 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 123.62 0.768 . . . . 10.0 110.659 171.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -78.53 -13.59 59.76 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.512 -1.222 . . . . 10.0 110.563 167.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 76.5 mt 61.62 42.86 10.56 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 125.474 1.51 . . . . 10.0 110.949 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.14 -5.94 56.12 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 124.262 0.934 . . . . 10.0 112.611 173.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . 0.419 ' NZ ' ' OD2' ' A' ' 76' ' ' ASP . 11.9 mttt -110.65 35.79 3.35 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.752 0.821 . . . . 10.0 110.628 -167.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -84.09 -31.18 26.51 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.861 2.172 . . . . 10.0 111.901 178.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.61 48.41 84.7 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -176.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -150.29 165.62 32.46 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.781 2.432 . . . . 10.0 106.289 -175.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -58.41 -47.65 83.23 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-O 121.588 0.709 . . . . 10.0 109.139 174.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -54.02 -30.92 49.54 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.979 1.312 . . . . 10.0 112.695 175.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.0 t -47.22 -47.46 24.43 Favored 'General case' 0 C--O 1.223 -0.307 0 C-N-CA 124.395 1.078 . . . . 10.0 108.412 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -88.24 10.19 20.46 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 118.751 -0.642 . . . . 10.0 112.55 -173.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -122.38 -94.39 0.5 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.455 1.902 . . . . 10.0 109.875 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.85 25.04 9.08 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 121.353 1.888 . . . . 10.0 110.158 177.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.07 -91.32 0.44 Allowed Glycine 0 C--N 1.339 0.743 0 N-CA-C 108.886 -1.686 . . . . 10.0 108.886 177.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 m-80 -162.27 35.97 0.12 Allowed 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 126.428 1.891 . . . . 10.0 108.246 172.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.55 -9.92 55.95 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 121.219 -0.926 . . . . 10.0 112.116 -173.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.96 -167.92 53.82 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.862 -0.895 . . . . 10.0 110.862 174.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 58.4 p -59.12 139.34 56.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 122.308 1.051 . . . . 10.0 112.277 -168.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 40.2 mtt85 -66.76 74.84 0.11 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.526 1.131 . . . . 10.0 110.838 173.173 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.3 mt -47.31 -38.7 13.22 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 123.506 0.722 . . . . 10.0 112.09 176.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.8 157.17 40.38 Favored 'General case' 0 CA--C 1.514 -0.43 0 O-C-N 121.827 -0.546 . . . . 10.0 111.121 176.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -159.01 167.32 29.63 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.458 -0.337 . . . . 10.0 110.218 171.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.63 165.42 36.23 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 109.331 -1.508 . . . . 10.0 109.331 -176.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 92.9 t -105.53 146.95 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 103.018 -2.956 . . . . 10.0 103.018 -175.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . 0.3 5.0 mt -68.36 -86.88 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 CA-C-O 121.469 0.652 . . . . 10.0 112.46 -168.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 93.49 135.44 7.5 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.775 1.179 . . . . 10.0 112.699 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.1 mt -70.46 142.15 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 125.057 1.343 . . . . 10.0 109.357 -176.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.77 -45.22 2.29 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.077 0.951 . . . . 10.0 111.383 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.537 1.935 . . . . 10.0 113.266 -178.505 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 107.166 -1.42 . . . . 10.0 107.166 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -78.14 -50.44 11.99 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-O 122.299 1.047 . . . . 10.0 109.743 171.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -156.04 153.97 30.29 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.692 -1.14 . . . . 10.0 109.76 -169.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.4 151.47 48.58 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.074 0.949 . . . . 10.0 108.629 169.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.6 t -109.56 159.31 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 125.044 1.338 . . . . 10.0 110.099 174.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.99 97.17 3.01 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 124.31 1.044 . . . . 10.0 108.562 166.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.1 m -82.29 126.36 39.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -106.11 149.74 26.46 Favored 'General case' 0 CA--C 1.529 0.136 0 CA-C-O 117.914 -1.041 . . . . 10.0 108.351 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 47.0 tttt -165.13 161.73 19.72 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 120.083 1.31 . . . . 10.0 108.679 170.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.42 -50.26 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 116.204 -0.453 . . . . 10.0 112.208 169.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -77.62 -46.34 22.41 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 -170.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 131.79 -61.7 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.928 -1.487 . . . . 10.0 111.303 -175.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -63.02 -39.68 38.6 Favored 'Trans proline' 0 N--CA 1.454 -0.811 0 C-N-CA 122.586 2.191 . . . . 10.0 110.79 169.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.97 115.34 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.114 -1.069 . . . . 10.0 108.114 -178.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.43 140.05 27.33 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-O 121.014 0.435 . . . . 10.0 110.091 165.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.07 157.28 15.43 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 125.256 1.408 . . . . 10.0 112.388 178.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -147.19 85.0 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 N-CA-C 106.29 -1.745 . . . . 10.0 106.29 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.78 145.09 9.38 Favored 'Isoleucine or valine' 0 C--O 1.231 0.093 0 C-N-CA 124.062 0.945 . . . . 10.0 110.778 178.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -123.19 111.74 16.85 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 129.854 3.261 . . . . 10.0 106.928 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -101.09 103.22 14.3 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 79.0 mt-10 -96.38 137.1 35.95 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.139 0.881 . . . . 10.0 110.843 170.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -106.15 100.95 10.47 Favored 'General case' 0 CA--C 1.53 0.186 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 24.0 tttp . . . . . 0 N--CA 1.441 -0.903 0 C-N-CA 125.959 1.704 . . . . 10.0 110.297 -176.735 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.868 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -62.83 130.15 28.47 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 N-CA-C 107.966 -1.59 . . . . 10.0 107.966 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.4 t -79.99 99.73 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 105.98 -1.859 . . . . 10.0 105.98 174.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -77.04 119.34 20.63 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 104.67 -2.344 . . . . 10.0 104.67 167.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -105.16 114.15 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 106.323 -1.732 . . . . 10.0 106.323 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -135.8 172.6 12.78 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 121.166 0.508 . . . . 10.0 111.831 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.59 -149.15 21.21 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 106.334 -2.706 . . . . 10.0 106.334 169.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.0 m -155.53 159.43 39.71 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 119.079 -1.048 . . . . 10.0 111.25 177.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pt -117.28 147.1 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.772 -1.104 . . . . 10.0 108.565 166.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -126.07 138.72 53.73 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 124.38 1.05 . . . . 10.0 109.226 168.539 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.27 -8.05 10.47 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.972 1.272 . . . . 10.0 113.29 175.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -62.44 178.55 0.4 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.288 1.044 . . . . 10.0 112.237 177.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.2 t -115.0 156.72 24.57 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 106.897 -1.52 . . . . 10.0 106.897 167.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -46.95 143.95 2.71 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.583 1.553 . . . . 10.0 112.902 -169.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.24 -178.42 31.71 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 124.222 0.915 . . . . 10.0 111.887 171.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 10.6 mt -64.0 150.48 45.15 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.657 1.583 . . . . 10.0 112.71 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -146.11 148.57 32.75 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.681 1.192 . . . . 10.0 112.764 177.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -25.7 124.31 0.04 OUTLIER Glycine 0 C--N 1.341 0.852 0 C-N-CA 126.668 2.08 . . . . 10.0 112.616 166.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -148.91 98.9 2.91 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 119.888 1.844 . . . . 10.0 111.46 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.52 172.59 14.74 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 122.807 0.443 . . . . 10.0 111.151 -178.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.3 m -105.43 -24.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 115.826 1.787 . . . . 10.0 115.826 -167.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 62.39 175.22 0.14 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 121.529 0.68 . . . . 10.0 112.568 177.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -81.09 -56.32 4.17 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.985 -0.552 . . . . 10.0 110.195 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -87.25 156.14 19.78 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.161 0.437 . . . . 10.0 110.158 -172.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.01 -19.26 22.23 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.036 -1.226 . . . . 10.0 110.036 169.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -63.38 160.43 16.11 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 122.556 1.17 . . . . 10.0 111.688 -176.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -153.79 16.66 0.51 Allowed 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.242 -0.89 . . . . 10.0 113.001 -171.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -45.53 -40.86 9.08 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 127.141 2.177 . . . . 10.0 112.707 -177.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.1 -18.56 57.88 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 111.915 0.339 . . . . 10.0 111.915 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.88 -66.2 0.56 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 109.474 -1.45 . . . . 10.0 109.474 -179.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 48.2 t -157.84 18.31 0.25 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.645 1.178 . . . . 10.0 110.584 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -98.87 -45.3 6.04 Favored 'General case' 0 N--CA 1.44 -0.931 0 O-C-N 120.184 -1.572 . . . . 10.0 108.695 -177.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -49.11 -39.71 29.44 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.438 1.495 . . . . 10.0 111.792 -169.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.46 -42.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 129.027 2.931 . . . . 10.0 114.205 168.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.33 163.24 28.43 Favored Glycine 0 N--CA 1.439 -1.113 0 N-CA-C 107.87 -2.092 . . . . 10.0 107.87 172.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -74.42 -169.29 0.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.547 0 N-CA-C 106.734 -2.064 . . . . 10.0 106.734 167.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.425 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 31.7 m170 -82.12 58.41 3.96 Favored 'General case' 0 CA--C 1.539 0.52 0 O-C-N 120.109 -1.62 . . . . 10.0 110.314 -174.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -76.51 59.66 1.51 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 123.06 1.41 . . . . 10.0 111.733 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -60.35 153.67 57.74 Favored Pre-proline 0 C--N 1.324 -0.516 0 C-N-CA 126.44 1.896 . . . . 10.0 110.965 169.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.77 -43.95 0.55 Allowed 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.686 2.257 . . . . 10.0 111.377 175.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 tt -79.3 62.77 3.75 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.175 0.99 . . . . 10.0 109.743 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 10.1 t -39.36 107.61 0.07 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.142 1.777 . . . . 10.0 113.368 -169.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.4 mtt180 -136.5 -174.07 3.59 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.422 1.489 . . . . 10.0 109.708 175.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.5 mmpt? -117.64 57.88 0.81 Allowed 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 113.975 1.102 . . . . 10.0 113.975 -167.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.402 ' CD2' ' CA ' ' B' ' 138' ' ' GLY . 63.5 t60 38.03 94.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 116.209 1.929 . . . . 10.0 116.209 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.6 -164.64 12.51 Favored Glycine 0 C--N 1.315 -0.61 0 N-CA-C 108.524 -1.83 . . . . 10.0 108.524 168.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.408 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -139.53 -162.4 9.1 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.143 -0.783 . . . . 10.0 111.143 171.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -69.81 10.32 0.51 Allowed 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.324 2.016 . . . . 10.0 111.569 176.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.408 ' H ' ' C ' ' B' ' 73' ' ' GLY . 84.3 mttt -101.28 -19.74 15.53 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.657 0.783 . . . . 10.0 109.174 170.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -125.67 -178.64 4.33 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 107.945 -1.132 . . . . 10.0 107.945 -167.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . 0.273 0.6 OUTLIER -110.43 -1.6 17.0 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 112.752 0.649 . . . . 10.0 112.752 167.918 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -77.61 -1.82 32.72 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 121.815 -0.553 . . . . 10.0 109.945 175.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 21.0 ptt-85 -42.25 124.43 2.8 Favored 'General case' 0 C--N 1.344 0.335 0 C-N-CA 124.965 1.306 . . . . 10.0 109.148 169.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -74.67 -54.3 7.67 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.574 -0.528 . . . . 10.0 109.574 -172.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 6.6 p -165.02 -66.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.537 0.735 . . . . 10.0 109.157 176.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -118.7 77.01 0.3 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.663 -2.175 . . . . 10.0 107.663 178.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -119.54 97.97 5.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.99 -2.226 . . . . 10.0 104.99 178.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -83.13 23.06 0.9 Allowed 'General case' 0 CA--C 1.526 0.048 0 CA-C-O 120.962 0.41 . . . . 10.0 110.553 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.4 -109.93 2.91 Favored Glycine 0 N--CA 1.432 -1.615 0 N-CA-C 105.653 -2.979 . . . . 10.0 105.653 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -158.93 139.12 12.2 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.857 -1.164 . . . . 10.0 107.857 -178.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.3 m -108.46 130.49 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 123.535 0.734 . . . . 10.0 111.867 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -80.95 101.52 9.54 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.973 2.909 . . . . 10.0 111.488 -170.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.99 134.34 35.36 Favored 'General case' 0 N--CA 1.451 -0.398 0 O-C-N 121.866 -0.521 . . . . 10.0 109.733 170.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.405 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 16.8 t70 -61.9 167.57 3.68 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 122.033 0.921 . . . . 10.0 108.75 167.09 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.405 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 30.6 ttpt -49.87 -31.13 11.34 Favored 'General case' 0 N--CA 1.432 -1.358 0 C-N-CA 125.934 1.694 . . . . 10.0 111.964 169.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -77.03 -10.29 59.27 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.188 0.449 . . . . 10.0 111.258 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.2 12.11 66.03 Favored Glycine 0 C--N 1.34 0.797 0 O-C-N 120.993 -1.067 . . . . 10.0 110.798 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -92.6 111.48 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 C-N-CA 126.66 1.984 . . . . 10.0 106.311 176.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -108.53 121.6 45.31 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -82.64 123.06 28.91 Favored 'General case' 0 N--CA 1.434 -1.253 0 C-N-CA 126.893 2.077 . . . . 10.0 107.989 170.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.94 131.85 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.935 -1.505 . . . . 10.0 106.935 175.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.85 75.8 0.71 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.991 0.916 . . . . 10.0 109.583 169.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.9 164.31 3.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.589 -1.634 . . . . 10.0 106.589 179.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -137.49 138.9 40.19 Favored 'General case' 0 N--CA 1.451 -0.383 0 O-C-N 121.459 -0.776 . . . . 10.0 110.868 171.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.99 145.53 49.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 124.454 1.096 . . . . 10.0 108.558 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.2 p -120.1 16.71 12.44 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.12 1.368 . . . . 10.0 110.7 172.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -107.65 -49.23 7.93 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 124.362 1.065 . . . . 10.0 109.634 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.329 0.7 OUTLIER -67.82 170.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-O 121.206 0.527 . . . . 10.0 112.094 171.544 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 52.1 p -151.91 140.25 20.46 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.151 -1.055 . . . . 10.0 108.151 174.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.4 pp -85.85 -24.68 26.63 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 108.27 -1.011 . . . . 10.0 108.27 167.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m . . . . . 0 N--CA 1.451 -0.396 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 166.292 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t . . . . . 0 CA--C 1.531 0.229 0 CA-C-O 122.171 0.986 . . . . 10.0 111.981 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 41.1 pt -66.4 1.53 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 113.619 0.97 . . . . 10.0 113.619 -178.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.8 mm -41.42 -40.88 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.302 0 C-N-CA 125.113 1.365 . . . . 10.0 113.783 177.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -105.5 25.59 24.1 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.82 1.2 . . . . 10.0 113.198 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.58 175.94 6.03 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.44 1.096 . . . . 10.0 110.439 174.31 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -123.71 107.98 12.04 Favored 'General case' 0 C--N 1.344 0.355 0 C-N-CA 124.554 1.142 . . . . 10.0 111.168 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -61.94 130.76 47.15 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 167.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.03 131.21 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 N-CA-C 107.504 -1.295 . . . . 10.0 107.504 173.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -100.72 126.35 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.4 m170 -104.26 157.0 17.44 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 115.248 1.573 . . . . 10.0 115.248 -174.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -47.48 -57.06 5.82 Favored 'General case' 0 N--CA 1.447 -0.614 0 C-N-CA 127.784 2.434 . . . . 10.0 110.657 177.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -107.53 170.84 7.73 Favored 'General case' 0 N--CA 1.463 0.199 0 C-N-CA 124.493 1.117 . . . . 10.0 112.478 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.28 149.93 38.67 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.558 1.543 . . . . 10.0 109.804 171.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.01 144.85 38.39 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 112.924 0.713 . . . . 10.0 112.924 177.101 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -78.32 -23.87 46.86 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.755 1.622 . . . . 10.0 109.259 167.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 48.9 mt 54.76 58.28 4.97 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 122.611 1.196 . . . . 10.0 109.693 -174.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.96 -47.31 3.82 Favored Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 113.996 -1.456 . . . . 10.0 112.505 167.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.91 42.39 0.38 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 118.026 0.913 . . . . 10.0 112.649 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.2 -22.82 26.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 127.122 2.296 . . . . 10.0 109.442 168.096 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.78 32.95 83.57 Favored Glycine 0 C--N 1.337 0.6 0 N-CA-C 110.975 -0.85 . . . . 10.0 110.975 176.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -135.67 162.94 31.32 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.132 -1.062 . . . . 10.0 108.132 172.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -45.87 -48.77 15.95 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 124.409 1.083 . . . . 10.0 110.02 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -70.46 -33.6 71.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.671 -0.643 . . . . 10.0 112.143 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.9 p -53.3 -44.26 68.2 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 119.374 0.988 . . . . 10.0 110.331 174.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.6 t -80.71 -19.18 45.66 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 112.852 0.686 . . . . 10.0 112.852 -173.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -101.41 -45.37 5.34 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 125.304 1.442 . . . . 10.0 112.666 -172.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.425 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 30.8 p -132.18 -1.97 3.59 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 119.211 0.914 . . . . 10.0 113.128 174.278 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . 0.402 ' CA ' ' CD2' ' B' ' 71' ' ' HIS . . . 88.89 22.97 36.95 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-O 118.601 -1.11 . . . . 10.0 112.241 -176.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 60.48 15.65 5.75 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 119.567 1.683 . . . . 10.0 112.056 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.98 3.13 5.7 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.103 -0.998 . . . . 10.0 112.438 -170.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.94 -168.55 54.76 Favored Glycine 0 N--CA 1.444 -0.813 0 N-CA-C 110.586 -1.006 . . . . 10.0 110.586 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.4 t -58.04 143.86 41.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 115.05 -0.575 . . . . 10.0 111.755 -169.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.9 mtm-85 -64.02 78.86 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.042 0.937 . . . . 10.0 110.02 168.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 5.7 tp -39.87 -55.37 2.0 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.234 1.813 . . . . 10.0 110.847 176.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.81 149.67 29.27 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.153 -0.684 . . . . 10.0 109.153 -173.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 12.6 m -128.48 153.78 46.79 Favored 'General case' 0 CA--C 1.522 -0.132 0 C-N-CA 125.477 1.511 . . . . 10.0 109.101 -173.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -133.57 169.95 22.56 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 108.964 -1.654 . . . . 10.0 108.964 167.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 17.2 t -117.83 132.44 67.64 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 169.363 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 71.4 mt -69.24 157.99 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.382 -0.97 . . . . 10.0 108.382 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.88 156.16 27.26 Favored Glycine 0 CA--C 1.528 0.891 0 O-C-N 121.249 -0.907 . . . . 10.0 111.731 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.7 mp -55.52 133.38 19.3 Favored 'Isoleucine or valine' 0 C--N 1.341 0.22 0 C-N-CA 125.618 1.567 . . . . 10.0 109.765 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -120.21 165.6 14.59 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.38 -1.341 . . . . 10.0 107.38 166.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 . . . . . 0 C--O 1.25 1.084 0 C-N-CA 125.939 1.695 . . . . 10.0 106.834 169.831 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 106.205 -1.776 . . . . 10.0 106.205 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.7 t -69.4 -14.34 62.85 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.496 1.044 . . . . 10.0 109.171 168.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.67 155.12 50.29 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 125.406 1.483 . . . . 10.0 107.481 168.253 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.04 158.24 44.03 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 125.483 1.513 . . . . 10.0 106.952 169.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -122.05 152.61 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 C-N-CA 123.529 0.732 . . . . 10.0 110.106 -178.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.8 97.23 4.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 125.099 1.359 . . . . 10.0 108.502 168.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -79.64 109.25 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.13 -1.433 . . . . 10.0 107.13 167.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.3 mt -90.07 139.85 30.22 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 18.9 tttt -162.18 161.09 27.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 120.01 1.277 . . . . 10.0 108.388 170.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.42 -53.32 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.206 0 N-CA-C 111.66 -0.576 . . . . 10.0 111.66 170.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -75.72 -47.31 26.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 106.713 -1.588 . . . . 10.0 106.713 -171.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.53 -61.26 0.66 Allowed Glycine 0 CA--C 1.53 0.993 0 CA-C-N 113.822 -1.536 . . . . 10.0 111.807 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.14 -34.92 67.27 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 122.63 2.22 . . . . 10.0 111.23 172.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.0 t -75.58 110.1 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.176 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 176.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.21 129.69 38.08 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 123.448 0.699 . . . . 10.0 109.326 166.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -105.75 147.11 16.18 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 125.595 1.569 . . . . 10.0 109.559 171.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.9 mt -140.82 59.68 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 -176.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm -78.95 140.27 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 N-CA-C 109.095 -0.705 . . . . 10.0 109.095 -172.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -116.61 110.52 18.63 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 126.939 2.096 . . . . 10.0 107.271 178.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -94.45 109.73 21.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 176.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.54 158.64 16.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.572 0.624 . . . . 10.0 112.127 170.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -155.61 83.23 1.04 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.818 2.047 . . . . 10.0 106.646 166.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 6.5 mmtp -52.13 -55.72 19.11 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 125.294 1.437 . . . . 10.0 110.503 -173.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -123.62 167.22 14.24 Favored 'General case' 0 N--CA 1.434 -1.264 0 N-CA-C 103.992 -2.595 . . . . 10.0 103.992 169.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -71.73 -14.58 62.06 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.885 -0.598 . . . . 10.0 109.917 173.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -79.8 -17.03 54.34 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 123.304 0.642 . . . . 10.0 109.314 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.67 140.98 23.17 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 178.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -62.06 153.35 69.74 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.118 1.879 . . . . 10.0 107.543 169.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -76.81 89.82 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.167 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 170.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.6 tmtp? -85.45 114.16 22.28 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 106.075 -1.824 . . . . 10.0 106.075 170.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.2 m -110.31 125.21 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 107.173 -1.417 . . . . 10.0 107.173 -174.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.7 p90 -134.46 164.78 26.69 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.118 0.485 . . . . 10.0 111.878 173.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.2 -148.67 19.52 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 107.827 -2.109 . . . . 10.0 107.827 170.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.5 t -155.31 150.77 27.22 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 116.973 0.387 . . . . 10.0 110.143 -176.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.49 111.51 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.268 0 C-N-CA 125.836 1.654 . . . . 10.0 106.611 165.551 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -95.93 137.33 35.15 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 108.073 -1.084 . . . . 10.0 108.073 170.151 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.78 -0.94 9.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 125.137 1.351 . . . . 10.0 112.585 173.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.04 174.96 7.89 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 118.453 1.126 . . . . 10.0 109.285 176.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -100.58 156.89 17.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.077 -1.823 . . . . 10.0 106.077 165.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -55.03 151.59 8.78 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.373 0.669 . . . . 10.0 111.834 -169.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.54 -178.93 26.56 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.115 0.864 . . . . 10.0 112.081 175.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -67.23 151.08 48.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.899 1.28 . . . . 10.0 111.355 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -151.02 153.77 35.77 Favored 'General case' 0 C--N 1.342 0.265 0 N-CA-C 113.577 0.955 . . . . 10.0 113.577 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.23 125.93 1.57 Allowed Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.693 2.568 . . . . 10.0 113.057 165.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -155.2 114.13 3.58 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.525 -1.287 . . . . 10.0 107.525 165.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 170.44 18.46 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.843 0.83 . . . . 10.0 111.582 174.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -115.33 127.28 72.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 104.251 -2.5 . . . . 10.0 104.251 168.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -167.52 175.16 7.31 Favored 'General case' 0 N--CA 1.451 -0.38 0 O-C-N 121.908 -0.495 . . . . 10.0 110.891 -168.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . 0.28 14.0 pt-20 50.3 -157.51 0.09 Allowed 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 126.279 2.237 . . . . 10.0 113.281 167.116 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.8 m-30 -82.64 -167.37 1.59 Allowed 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 109.247 -0.649 . . . . 10.0 109.247 177.086 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.37 -0.35 24.99 Favored Glycine 0 CA--C 1.536 1.347 0 C-N-CA 126.256 1.884 . . . . 10.0 112.975 174.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -75.0 83.0 2.24 Favored 'General case' 0 C--N 1.342 0.258 0 CA-C-N 119.737 1.768 . . . . 10.0 110.637 -176.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -79.51 8.41 6.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-N 115.282 -0.872 . . . . 10.0 113.077 177.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -42.53 -48.07 5.25 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 127.992 2.517 . . . . 10.0 113.376 -171.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.08 -26.74 39.49 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 123.206 0.602 . . . . 10.0 112.348 -179.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 137.99 -150.69 21.03 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 106.727 -2.549 . . . . 10.0 106.727 -169.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.8 m -80.23 33.16 0.28 Allowed 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 124.668 1.187 . . . . 10.0 112.273 -179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.8 m -125.24 -57.72 1.48 Allowed 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 108.646 -0.872 . . . . 10.0 108.646 -168.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 t -58.61 -39.79 81.46 Favored 'General case' 0 C--N 1.341 0.204 0 O-C-N 123.416 0.448 . . . . 10.0 110.935 -168.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.03 -41.69 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 127.387 2.275 . . . . 10.0 113.997 169.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.5 -162.93 19.65 Favored Glycine 0 C--N 1.34 0.779 0 N-CA-C 109.597 -1.401 . . . . 10.0 109.597 169.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -110.44 178.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.935 1 C-N-CA 125.558 4.172 . . . . 10.0 106.354 164.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.6 m170 -66.87 79.86 0.11 Allowed 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 120.088 1.313 . . . . 10.0 110.927 -176.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -105.85 53.93 0.7 Allowed 'General case' 0 N--CA 1.462 0.138 0 C-N-CA 127.262 2.225 . . . . 10.0 108.802 172.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -52.99 145.41 23.21 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 125.502 1.521 . . . . 10.0 110.772 168.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -64.98 -43.46 11.78 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 123.338 2.692 . . . . 10.0 111.243 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.4 68.68 0.55 Allowed 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.528 -0.915 . . . . 10.0 108.528 170.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.5 p -58.74 104.79 0.25 Allowed 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.381 1.073 . . . . 10.0 109.893 -175.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.1 mtt180 -141.55 -176.56 4.79 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 105.722 -1.955 . . . . 10.0 105.722 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.37 129.48 35.89 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 -177.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.1 t60 -44.92 112.13 0.4 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 122.558 0.343 . . . . 10.0 111.749 178.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.49 -147.66 6.52 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.442 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -156.03 -167.93 18.18 Favored Glycine 0 C--O 1.225 -0.451 0 CA-C-N 117.98 0.89 . . . . 10.0 111.567 179.411 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -68.36 16.09 0.16 Allowed 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.518 2.145 . . . . 10.0 112.398 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.442 ' H ' ' C ' ' A' ' 73' ' ' GLY . 6.2 mtpm? -110.39 -20.6 12.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 124.934 1.294 . . . . 10.0 110.25 169.403 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.67 162.65 16.94 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.754 -1.572 . . . . 10.0 106.754 -167.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -88.98 -21.85 23.31 Favored 'General case' 0 C--N 1.329 -0.32 0 O-C-N 121.629 -0.669 . . . . 10.0 109.877 178.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -83.4 -6.37 59.44 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 124.538 1.135 . . . . 10.0 111.474 -169.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -35.65 118.95 0.51 Allowed 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 126.145 1.778 . . . . 10.0 111.108 171.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m170 -50.37 -50.66 50.75 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 115.828 1.788 . . . . 10.0 115.828 -167.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -178.25 -46.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 106.945 -1.502 . . . . 10.0 106.945 -174.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -153.45 62.33 0.38 Allowed Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -85.84 95.96 9.61 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 103.705 -2.702 . . . . 10.0 103.705 166.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -70.47 -10.42 59.1 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.578 0.626 . . . . 10.0 111.833 -171.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.85 -93.96 0.93 Allowed Glycine 0 N--CA 1.445 -0.744 0 N-CA-C 107.69 -2.164 . . . . 10.0 107.69 176.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -150.54 147.11 27.06 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 124.871 1.268 . . . . 10.0 107.79 -174.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.1 m -117.98 128.04 75.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 118.606 0.639 . . . . 10.0 109.755 169.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.7 m -90.19 95.11 10.04 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 127.267 2.227 . . . . 10.0 111.506 -169.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -69.63 128.5 36.68 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.778 -0.576 . . . . 10.0 111.654 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.1 171.8 5.25 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.123 1.369 . . . . 10.0 109.888 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 pttm -54.89 -29.35 55.62 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.218 1.007 . . . . 10.0 111.088 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -78.25 0.21 26.11 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.031 0.444 . . . . 10.0 111.213 178.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.45 17.59 79.81 Favored Glycine 0 C--N 1.339 0.734 0 O-C-N 120.654 -1.279 . . . . 10.0 110.766 178.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 18.3 t -97.68 103.34 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.734 0 C-N-CA 127.812 2.445 . . . . 10.0 106.356 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.33 118.42 33.77 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 168.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -79.42 141.87 36.45 Favored 'General case' 0 N--CA 1.425 -1.679 0 C-N-CA 124.643 1.177 . . . . 10.0 108.718 178.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 86.8 t -111.63 133.22 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 106.509 -1.663 . . . . 10.0 106.509 169.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.6 p -158.88 58.4 0.43 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.501 0.72 . . . . 10.0 111.512 170.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -101.3 152.73 5.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.897 0.879 . . . . 10.0 109.085 -171.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -112.01 127.94 56.03 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 126.568 1.947 . . . . 10.0 108.448 172.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -130.22 145.72 51.77 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-O 121.378 0.609 . . . . 10.0 111.001 169.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.8 t -133.07 64.66 1.61 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.089 2.156 . . . . 10.0 106.652 -178.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.01 -52.73 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.077 0 C-N-CA 123.672 0.789 . . . . 10.0 109.225 175.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.328 0.0 OUTLIER -78.84 174.82 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.145 0.497 . . . . 10.0 112.19 172.048 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 m -153.99 153.72 32.49 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.372 -1.714 . . . . 10.0 106.372 169.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 95.7 mt -68.45 -14.52 63.06 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.109 0.564 . . . . 10.0 111.602 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.4 m -151.75 157.21 41.7 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.056 -1.831 . . . . 10.0 106.056 169.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 151.84 -66.95 0.33 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 178.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -161.02 -51.74 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 126.298 1.839 . . . . 10.0 107.239 -178.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -73.79 -39.44 64.13 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.513 -1.222 . . . . 10.0 108.165 -169.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 17.8 t 35.53 74.86 0.06 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 127.559 2.344 . . . . 10.0 110.31 169.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 pt -76.36 46.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.986 0.914 . . . . 10.0 111.422 -173.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 35.1 mm -92.31 -86.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 124.936 1.295 . . . . 10.0 108.613 -171.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.23 50.57 2.76 Favored Glycine 0 CA--C 1.537 1.468 0 O-C-N 120.291 -1.506 . . . . 10.0 113.669 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 13.4 mmt-85 -101.05 175.63 5.53 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 126.195 1.798 . . . . 10.0 108.006 169.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 17.2 m -102.46 104.34 14.78 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.362 1.465 . . . . 10.0 107.086 172.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.02 144.65 40.74 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 105.428 -2.064 . . . . 10.0 105.428 168.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.7 t -134.69 139.03 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 N-CA-C 108.645 -0.872 . . . . 10.0 108.645 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -107.39 131.72 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 N-CA-C 106.039 -1.837 . . . . 10.0 106.039 167.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.8 m170 -114.8 158.89 21.27 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 115.693 1.738 . . . . 10.0 115.693 -169.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.2 tt0 -43.84 -57.31 3.34 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 129.035 2.934 . . . . 10.0 111.835 174.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -116.84 169.17 9.59 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 113.835 1.05 . . . . 10.0 113.835 -168.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.05 132.24 37.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.557 1.543 . . . . 10.0 109.829 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 125.956 1.702 . . . . 10.0 110.563 -175.058 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.6 -37.42 50.39 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 124.388 1.075 . . . . 10.0 109.859 174.252 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.0 mt 76.07 53.62 0.06 Allowed 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.916 2.086 . . . . 10.0 112.755 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.92 -25.2 22.87 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 115.509 0.964 . . . . 10.0 115.509 167.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mptt -75.82 -4.13 38.98 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 119.313 1.557 . . . . 10.0 112.56 -172.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.84 -29.41 64.66 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 109.076 -1.609 . . . . 10.0 109.076 168.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.29 41.02 99.39 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.273 -1.131 . . . . 10.0 110.273 -176.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -130.78 171.98 12.51 Favored 'General case' 0 CA--C 1.501 -0.94 0 N-CA-C 106.731 -1.581 . . . . 10.0 106.731 170.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.1 mp0 -40.22 -58.78 1.41 Allowed 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 10.0 110.109 168.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -50.1 -54.52 19.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 116.072 -0.513 . . . . 10.0 109.999 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.4 p -55.29 -44.46 75.73 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 120.022 -0.671 . . . . 10.0 110.313 -177.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -78.24 -7.75 57.52 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.622 1.169 . . . . 10.0 111.16 -173.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -109.36 -68.38 0.92 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.911 1.684 . . . . 10.0 111.38 -178.473 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -114.55 -6.95 12.82 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 121.456 1.934 . . . . 10.0 112.326 179.276 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.55 33.64 47.04 Favored Glycine 0 C--O 1.222 -0.606 0 CA-C-O 118.976 -0.902 . . . . 10.0 111.837 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 61.21 24.91 14.97 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 119.74 1.77 . . . . 10.0 112.189 176.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.7 -9.08 58.29 Favored 'General case' 0 CA--C 1.527 0.082 0 C-N-CA 123.544 0.738 . . . . 10.0 112.31 -177.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.21 -166.12 54.76 Favored Glycine 0 N--CA 1.447 -0.607 0 O-C-N 121.269 -0.894 . . . . 10.0 111.409 172.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.1 m -58.13 136.36 57.21 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.064 0.946 . . . . 10.0 113.078 -167.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -64.03 89.11 0.05 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.123 0.969 . . . . 10.0 109.191 168.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 62.0 mt -58.07 -51.46 69.61 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.848 -0.427 . . . . 10.0 109.848 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -147.97 152.05 36.83 Favored 'General case' 0 N--CA 1.454 -0.261 0 O-C-N 122.273 -0.267 . . . . 10.0 110.371 -169.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 88.2 m -130.49 154.13 48.09 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 124.756 1.222 . . . . 10.0 109.539 -173.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.43 154.58 25.2 Favored Glycine 0 CA--C 1.519 0.328 0 N-CA-C 110.156 -1.178 . . . . 10.0 110.156 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 58.4 t -115.09 126.36 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 105.098 -2.186 . . . . 10.0 105.098 178.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 49.2 mt -78.71 147.7 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 108.895 -0.78 . . . . 10.0 108.895 -177.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -153.43 178.5 30.41 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.337 -1.105 . . . . 10.0 110.337 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -64.31 122.68 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 C-N-CA 124.477 1.111 . . . . 10.0 108.941 -177.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -116.89 148.84 40.96 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 168.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.016 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 167.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 119.111 -0.471 . . . . 10.0 110.174 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 t -81.77 -40.85 22.04 Favored 'General case' 0 C--O 1.226 -0.149 0 C-N-CA 124.217 1.007 . . . . 10.0 110.511 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 49.1 mttp -134.24 140.56 46.55 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 125.221 1.408 . . . . 10.0 109.192 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.43 152.89 47.42 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.017 0.927 . . . . 10.0 108.858 171.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -120.77 158.22 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 123.931 0.892 . . . . 10.0 110.153 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.47 101.94 4.49 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.427 -0.953 . . . . 10.0 108.427 168.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -79.64 105.97 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 108.692 -0.855 . . . . 10.0 108.692 169.666 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -91.86 128.13 37.58 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.364 -0.976 . . . . 10.0 108.364 -178.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -143.38 162.32 36.06 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 120.098 1.317 . . . . 10.0 108.494 170.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.67 -56.89 0.07 OUTLIER Glycine 0 N--CA 1.461 0.319 0 CA-C-N 115.077 -0.965 . . . . 10.0 113.146 169.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.47 -44.27 65.08 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 -177.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.4 -70.68 0.41 Allowed Glycine 0 CA--C 1.523 0.569 0 CA-C-N 114.319 -1.309 . . . . 10.0 110.323 169.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -59.13 -33.08 98.28 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 123.643 2.895 . . . . 10.0 111.515 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 65.2 t -67.06 95.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 177.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -117.69 101.15 8.1 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.522 -2.029 . . . . 10.0 105.522 178.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.415 ' HA2' ' CG2' ' B' ' 35' ' ' ILE . . . -85.47 142.04 19.28 Favored Glycine 0 N--CA 1.435 -1.401 0 N-CA-C 109.577 -1.409 . . . . 10.0 109.577 172.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mt -140.37 81.29 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 105.949 -1.871 . . . . 10.0 105.949 -179.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -90.9 140.7 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 C-N-CA 123.892 0.877 . . . . 10.0 109.05 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 13.5 m-80 -126.44 114.7 18.52 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.044 1.338 . . . . 10.0 109.234 171.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -91.42 132.48 36.19 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 124.882 1.273 . . . . 10.0 108.248 174.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.6 156.38 24.8 Favored 'General case' 0 C--N 1.339 0.151 0 O-C-N 123.519 0.512 . . . . 10.0 111.874 169.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.59 135.0 55.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 102.519 -3.141 . . . . 10.0 102.519 162.063 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 10.6 mptt . . . . . 0 N--CA 1.451 -0.415 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 170.639 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.949 0 N-CA-C 110.136 -1.186 . . . . 10.0 110.136 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -66.29 125.22 13.64 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 123.021 2.48 . . . . 10.0 108.831 175.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 m -79.96 64.51 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 122.774 0.43 . . . . 10.0 110.382 -175.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.8 tttt -54.42 111.95 0.9 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.139 -0.689 . . . . 10.0 109.139 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -103.9 112.28 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 C-N-CA 127.412 2.285 . . . . 10.0 106.556 -176.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -106.14 171.43 7.35 Favored 'General case' 0 CA--C 1.511 -0.532 0 CA-C-O 121.847 0.832 . . . . 10.0 110.507 173.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.59 173.88 45.09 Favored Glycine 0 N--CA 1.436 -1.306 0 N-CA-C 110.124 -1.19 . . . . 10.0 110.124 174.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 19.5 m -145.75 90.19 1.97 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.565 -0.902 . . . . 10.0 108.565 -179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . 0.415 ' CG2' ' HA2' ' B' ' 16' ' ' GLY . 3.4 pt -79.93 146.93 6.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.497 0 N-CA-C 108.661 -0.866 . . . . 10.0 108.661 175.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -126.7 149.74 49.41 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.39 -5.87 49.18 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.665 174.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -63.47 177.69 0.65 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.445 1.123 . . . . 10.0 110.599 173.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.1 t -115.25 168.09 10.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 105.687 -1.968 . . . . 10.0 105.687 165.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -46.57 156.84 0.16 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.785 1.634 . . . . 10.0 113.406 -170.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.14 -162.47 46.29 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-O 122.139 0.855 . . . . 10.0 113.376 166.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -79.7 141.32 36.51 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 125.873 1.669 . . . . 10.0 111.342 -170.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -139.72 145.39 38.26 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 114.504 1.298 . . . . 10.0 114.504 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -34.61 117.94 0.25 Allowed Glycine 0 C--N 1.343 0.95 0 C-N-CA 129.556 3.455 . . . . 10.0 114.569 167.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -141.37 109.23 5.71 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 120.012 1.906 . . . . 10.0 110.931 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.497 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -148.15 170.43 17.86 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 112.708 0.632 . . . . 10.0 112.708 178.66 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 m -116.69 79.1 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 C-N-CA 128.625 2.77 . . . . 10.0 111.247 -168.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 38.4 m-70 -79.23 142.69 36.02 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 124.802 1.241 . . . . 10.0 112.056 -171.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -62.47 -46.31 89.08 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 114.605 1.335 . . . . 10.0 114.605 -169.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -75.7 92.43 2.98 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.798 -2.667 . . . . 10.0 103.798 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.88 -27.13 74.14 Favored Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 128.103 2.764 . . . . 10.0 109.99 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -52.57 175.88 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.777 0 CA-C-O 122.752 1.263 . . . . 10.0 110.78 167.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -149.99 31.82 0.69 Allowed 'General case' 0 N--CA 1.431 -1.378 0 CA-C-N 114.603 -1.18 . . . . 10.0 112.809 168.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -51.78 -38.91 57.52 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.958 0.903 . . . . 10.0 111.084 -177.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.01 -18.08 54.24 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.84 1.256 . . . . 10.0 113.217 -179.425 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.09 85.56 0.62 Allowed Glycine 0 CA--C 1.533 1.161 0 N-CA-C 111.478 -0.649 . . . . 10.0 111.478 -176.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 71.4 m 44.11 39.36 2.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 128.008 2.523 . . . . 10.0 112.634 173.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -134.3 -54.32 0.85 Allowed 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 108.156 -1.053 . . . . 10.0 108.156 -169.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.7 m -90.56 34.31 0.89 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.109 0.563 . . . . 10.0 109.844 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -67.04 -23.18 65.86 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.401 1.08 . . . . 10.0 109.868 177.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.76 141.2 11.61 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 110.911 -0.876 . . . . 10.0 110.911 172.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -76.23 63.01 6.97 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.213 3.275 . . . . 10.0 113.202 -174.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 22.6 m170 63.26 44.04 5.87 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 126.697 1.999 . . . . 10.0 109.939 171.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -67.89 79.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 124.863 2.268 . . . . 10.0 111.351 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -81.89 147.15 57.54 Favored Pre-proline 0 C--N 1.318 -0.772 0 C-N-CA 126.396 1.878 . . . . 10.0 108.316 168.142 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -79.56 40.3 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 122.484 2.123 . . . . 10.0 111.775 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -162.84 37.68 0.1 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.787 0.835 . . . . 10.0 109.996 -176.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -42.31 100.05 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.599 1.56 . . . . 10.0 112.719 -170.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.57 -78.85 0.6 Allowed 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.284 -1.006 . . . . 10.0 108.284 -171.139 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -154.24 144.35 21.97 Favored 'General case' 0 N--CA 1.425 -1.678 0 CA-C-N 115.484 -0.78 . . . . 10.0 109.223 171.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -61.76 118.64 7.41 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 106.711 -1.589 . . . . 10.0 106.711 165.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.06 -146.19 6.25 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 107.743 -2.143 . . . . 10.0 107.743 175.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.423 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -166.53 -165.71 24.37 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 107.813 -2.115 . . . . 10.0 107.813 169.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -64.19 6.36 0.31 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.151 1.9 . . . . 10.0 112.207 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.423 ' H ' ' C ' ' B' ' 73' ' ' GLY . 0.0 OUTLIER -96.86 -29.99 13.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 118.997 0.817 . . . . 10.0 110.35 168.812 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -86.83 166.23 15.37 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 109.347 -0.612 . . . . 10.0 109.347 -174.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -86.18 -24.57 26.08 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.346 -1.297 . . . . 10.0 108.492 167.062 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -76.41 -93.78 0.02 OUTLIER 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 107.667 -1.234 . . . . 10.0 107.667 -173.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 28.5 mtm180 72.43 159.74 0.22 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 127.144 2.178 . . . . 10.0 108.644 -167.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.9 m170 -78.18 -48.63 15.45 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 118.965 -1.094 . . . . 10.0 110.093 169.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.3 p -166.26 -51.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 178.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.29 -76.28 0.9 Allowed Glycine 0 C--N 1.336 0.552 0 N-CA-C 109.019 -1.633 . . . . 10.0 109.019 171.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 41.42 78.58 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.792 1.237 . . . . 10.0 109.654 -169.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -20.97 64.96 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.939 0.348 . . . . 10.0 111.939 -168.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.91 -94.93 0.67 Allowed Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.027 -1.229 . . . . 10.0 110.027 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 33.2 m120 -155.61 106.45 2.51 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -168.647 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -99.24 130.6 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 119.773 1.17 . . . . 10.0 110.708 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -86.93 107.94 18.59 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 128.795 2.838 . . . . 10.0 110.945 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.88 131.51 36.47 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 122.857 0.463 . . . . 10.0 109.908 172.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -59.23 170.98 0.82 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.282 1.033 . . . . 10.0 109.806 168.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 12.4 pttm -51.36 -32.19 24.91 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 125.988 1.715 . . . . 10.0 110.584 175.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.36 -8.36 59.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 124.177 0.991 . . . . 10.0 110.963 -175.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.82 8.19 87.06 Favored Glycine 0 C--N 1.338 0.692 0 O-C-N 121.532 -0.73 . . . . 10.0 111.286 -177.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 50.0 t -80.18 114.92 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 N-CA-C 105.726 -1.953 . . . . 10.0 105.726 170.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.27 121.43 42.0 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 118.87 0.759 . . . . 10.0 109.006 170.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -83.0 121.78 27.45 Favored 'General case' 0 N--CA 1.433 -1.288 0 C-N-CA 126.404 1.881 . . . . 10.0 108.334 173.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 94.0 t -110.49 136.48 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 N-CA-C 106.543 -1.651 . . . . 10.0 106.543 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 18.7 m -157.77 64.97 0.47 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.071 1.349 . . . . 10.0 109.379 169.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 61.9 mt -101.97 156.35 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.859 1.263 . . . . 10.0 108.719 -171.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -144.81 140.48 28.46 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.645 1.578 . . . . 10.0 108.6 175.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -152.4 135.08 15.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 106.667 -1.605 . . . . 10.0 106.667 169.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.4 p -87.53 58.59 5.02 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.745 1.618 . . . . 10.0 107.916 -171.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 p -145.35 -46.53 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.918 -0.583 . . . . 10.0 109.677 -172.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 36.7 mm -66.8 143.04 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 N-CA-C 109.178 -0.675 . . . . 10.0 109.178 171.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 74.3 m -138.38 134.44 34.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 173.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -110.29 17.37 20.97 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.737 0.815 . . . . 10.0 110.59 172.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 107.131 -1.433 . . . . 10.0 107.131 173.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t . . . . . 0 N--CA 1.441 -0.885 0 N-CA-C 107.983 -1.117 . . . . 10.0 107.983 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -69.73 13.87 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 114.095 1.146 . . . . 10.0 114.095 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 33.2 mm -55.74 135.12 19.22 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 O-C-N 120.627 -1.296 . . . . 10.0 108.063 172.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.74 11.66 73.62 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-O 118.132 -1.371 . . . . 10.0 113.855 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mmt-85 -79.38 161.84 25.93 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.242 1.521 . . . . 10.0 108.866 167.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.4 121.25 41.94 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 123.529 0.732 . . . . 10.0 109.99 171.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -84.37 132.37 34.6 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 107.218 -1.401 . . . . 10.0 107.218 167.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.1 t -116.51 137.43 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.792 -1.188 . . . . 10.0 107.792 169.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -104.76 123.99 59.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.2 m170 -107.69 159.09 16.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 116.582 2.067 . . . . 10.0 116.582 -172.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -41.45 -65.61 0.42 Allowed 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 129.631 3.173 . . . . 10.0 111.67 170.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.1 mttp -109.89 175.38 5.46 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.658 1.183 . . . . 10.0 111.559 -173.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.03 151.73 35.43 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 125.75 1.62 . . . . 10.0 109.903 175.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.497 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -77.53 154.64 32.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 122.901 0.48 . . . . 10.0 110.889 169.928 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 53.4 m-20 -76.27 -36.65 58.32 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.289 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 63.5 mt 64.26 56.32 1.35 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.99 1.376 . . . . 10.0 109.27 -170.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.15 -44.34 3.29 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-N 113.376 -1.738 . . . . 10.0 110.918 171.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -76.64 41.06 0.25 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.088 1.755 . . . . 10.0 112.919 -173.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -99.85 -17.83 24.46 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 125.838 1.685 . . . . 10.0 110.65 169.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.26 44.89 65.0 Favored Glycine 0 C--N 1.339 0.696 0 C-N-CA 123.861 0.743 . . . . 10.0 111.443 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -146.02 168.02 21.93 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 172.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.1 -42.55 76.97 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 116.144 -0.48 . . . . 10.0 109.88 -176.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -64.78 -40.37 95.15 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.502 -0.748 . . . . 10.0 110.825 175.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -50.8 -44.02 58.88 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 118.704 0.684 . . . . 10.0 110.449 -179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -76.94 -8.26 57.06 Favored 'General case' 0 CA--C 1.542 0.662 0 CA-C-O 117.759 -1.115 . . . . 10.0 113.79 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 ttmm -114.87 -58.0 2.2 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 127.728 2.411 . . . . 10.0 113.072 -170.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 14.6 p -134.86 17.75 3.52 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.774 1.17 . . . . 10.0 110.784 175.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.12 -110.09 2.95 Favored Glycine 0 C--O 1.219 -0.81 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 -171.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -160.61 43.79 0.19 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 171.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.45 -14.76 62.66 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.787 -1.097 . . . . 10.0 112.194 -170.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.2 -163.5 54.53 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 110.48 -1.048 . . . . 10.0 110.48 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.7 m -56.94 130.41 45.85 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 123.929 0.891 . . . . 10.0 112.43 -168.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.58 73.36 0.06 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.809 1.644 . . . . 10.0 109.91 171.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 61.8 mt -50.96 -36.45 38.96 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.52 0.728 . . . . 10.0 112.116 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.31 159.59 28.7 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.971 -0.752 . . . . 10.0 108.971 -176.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -159.8 165.38 32.51 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.637 -0.505 . . . . 10.0 109.637 -177.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.31 167.73 35.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.421 -1.071 . . . . 10.0 110.421 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 15.9 t -115.41 138.67 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 107.233 -1.395 . . . . 10.0 107.233 -169.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.8 mt -73.18 109.82 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 110.212 -0.292 . . . . 10.0 110.212 -174.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.86 154.65 17.32 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 125.737 1.637 . . . . 10.0 110.373 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.1 mt -86.23 139.4 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 124.894 1.278 . . . . 10.0 108.815 -174.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -91.71 -114.71 0.08 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 167.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 . . . . . 0 C--O 1.248 1.006 0 C-N-CA 127.332 2.253 . . . . 10.0 105.014 166.937 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 107.416 -1.327 . . . . 10.0 107.416 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.2 t -158.45 -44.24 0.06 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.926 0.784 . . . . 10.0 111.328 177.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 11.7 tmtt? -131.78 134.04 45.39 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 123.68 0.792 . . . . 10.0 108.863 178.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.33 169.55 18.05 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 125.281 1.432 . . . . 10.0 109.936 -175.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -129.32 172.72 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 123.159 0.584 . . . . 10.0 112.236 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.72 107.47 4.46 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.826 1.25 . . . . 10.0 107.869 166.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -87.0 89.61 3.07 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-O 121.946 0.879 . . . . 10.0 109.111 172.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mt -80.52 116.22 20.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.573 1.549 . . . . 10.0 109.443 -175.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -142.27 159.35 42.41 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.702 1.137 . . . . 10.0 108.35 173.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.62 -65.02 0.02 OUTLIER Glycine 0 N--CA 1.461 0.365 0 CA-C-N 115.249 -0.887 . . . . 10.0 112.216 169.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -72.15 -41.66 66.85 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 106.891 -1.522 . . . . 10.0 106.891 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.44 -64.26 0.55 Allowed Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.695 -1.059 . . . . 10.0 111.368 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -58.14 -37.91 93.61 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.056 1.837 . . . . 10.0 110.492 174.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 80.3 t -62.85 105.55 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 N-CA-C 107.644 -1.243 . . . . 10.0 107.644 174.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -124.02 118.98 28.22 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.089 -1.819 . . . . 10.0 106.089 171.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.87 130.53 10.15 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 109.725 -1.35 . . . . 10.0 109.725 170.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.494 ' CG2' HG22 ' B' ' 54' ' ' THR . 16.4 mt -128.29 72.04 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.15 -1.796 . . . . 10.0 106.15 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.14 147.19 6.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.288 -0.869 . . . . 10.0 110.447 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.03 106.24 8.74 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 126.78 2.032 . . . . 10.0 107.804 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -86.37 125.11 33.43 Favored 'General case' 0 N--CA 1.451 -0.425 0 CA-C-O 117.73 -1.129 . . . . 10.0 108.012 175.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -120.19 145.27 47.14 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 123.922 0.763 . . . . 10.0 110.963 167.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 tp60 -125.89 105.18 8.74 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 126.858 2.063 . . . . 10.0 107.036 169.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.77 -61.24 2.44 Favored 'General case' 0 C--N 1.339 0.15 0 C-N-CA 124.767 1.227 . . . . 10.0 110.24 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -134.01 167.48 20.53 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 104.552 -2.388 . . . . 10.0 104.552 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.7 t -69.41 -14.94 63.17 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 119.71 -0.186 . . . . 10.0 110.573 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -79.89 -18.02 51.68 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 123.386 0.675 . . . . 10.0 110.171 174.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.6 151.68 39.97 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.23 -0.748 . . . . 10.0 111.23 -176.097 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.23 146.66 40.94 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 N-CA-C 105.493 -2.541 . . . . 10.0 105.493 165.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -76.65 119.35 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 N-CA-C 106.166 -1.791 . . . . 10.0 106.166 -179.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.454 ' HZ2' ' CD ' ' A' ' 100' ' ' GLU . 18.0 mttp -90.97 110.57 21.83 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 106.432 -1.692 . . . . 10.0 106.432 176.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.13 106.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -128.85 169.96 13.95 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.744 0.783 . . . . 10.0 112.214 171.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.05 -153.09 24.77 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 106.592 -2.603 . . . . 10.0 106.592 169.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 27.5 t -156.06 155.98 33.58 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.54 -0.864 . . . . 10.0 109.464 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 pt -108.01 175.63 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 CA-C-N 115.153 -0.931 . . . . 10.0 110.082 167.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.2 ptmt -152.37 150.66 29.94 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.86 -15.57 33.99 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-O 118.985 -0.897 . . . . 10.0 114.566 171.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.1 mp -72.95 -179.67 3.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 118.948 1.374 . . . . 10.0 109.609 177.119 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -96.0 175.55 6.44 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.402 -0.962 . . . . 10.0 108.402 166.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -58.65 168.95 1.04 Allowed 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.676 1.19 . . . . 10.0 112.025 -172.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.37 -168.01 49.65 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-O 122.019 0.788 . . . . 10.0 112.909 167.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -71.26 146.13 49.15 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.762 1.625 . . . . 10.0 110.397 -176.363 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.07 152.69 35.21 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 113.125 0.787 . . . . 10.0 113.125 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -37.3 121.43 0.83 Allowed Glycine 0 C--N 1.339 0.727 0 C-N-CA 128.274 2.845 . . . . 10.0 111.069 165.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -155.68 106.21 2.48 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 106.558 -1.645 . . . . 10.0 106.558 169.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.42 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -148.07 170.6 17.42 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.876 0.846 . . . . 10.0 112.904 178.561 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.36 132.54 60.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 104.336 -2.468 . . . . 10.0 104.336 168.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 1.7 p80 -168.4 177.47 5.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 107.737 -1.208 . . . . 10.0 107.737 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 52.71 -167.75 0.05 Allowed 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 125.984 2.052 . . . . 10.0 116.157 162.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.75 159.42 19.77 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-O 121.593 0.711 . . . . 10.0 110.893 -175.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.01 -18.44 77.76 Favored Glycine 0 CA--C 1.523 0.565 0 C-N-CA 125.443 1.497 . . . . 10.0 110.308 168.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -50.61 140.6 14.03 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 122.723 1.249 . . . . 10.0 108.259 166.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -151.79 8.86 0.51 Allowed 'General case' 0 N--CA 1.412 -2.342 0 CA-C-N 113.5 -1.682 . . . . 10.0 109.889 -168.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -41.45 -55.24 2.87 Favored 'General case' 0 C--N 1.343 0.29 0 C-N-CA 125.842 1.657 . . . . 10.0 114.425 -167.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.18 -18.37 57.84 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.836 0.454 . . . . 10.0 111.554 -173.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.72 78.63 1.38 Allowed Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.312 -1.115 . . . . 10.0 110.312 -175.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.2 m 70.24 35.3 2.12 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.989 1.315 . . . . 10.0 111.752 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -131.8 -57.51 0.98 Allowed 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 107.184 -1.413 . . . . 10.0 107.184 175.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.3 m -52.05 -43.14 63.64 Favored 'General case' 0 C--N 1.343 0.289 0 C-N-CA 123.913 0.885 . . . . 10.0 111.331 -170.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.11 -55.31 0.03 OUTLIER 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 128.35 2.66 . . . . 10.0 113.645 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 139.92 -154.18 23.68 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 110.533 -1.027 . . . . 10.0 110.533 175.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -122.21 -155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.54 0.811 1 C-N-CA 126.865 5.043 . . . . 10.0 105.85 165.049 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -77.93 46.85 0.6 Allowed 'General case' 0 CA--C 1.548 0.896 0 O-C-N 118.587 -2.571 . . . . 10.0 112.113 177.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -77.51 60.9 2.18 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.923 1.289 . . . . 10.0 109.566 169.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -71.74 157.13 90.29 Favored Pre-proline 0 C--N 1.325 -0.457 0 C-N-CA 124.002 0.921 . . . . 10.0 108.67 171.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -56.17 -43.42 56.4 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 121.347 1.365 . . . . 10.0 109.478 169.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 68.2 mt -84.23 47.47 1.34 Allowed 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.831 -0.543 . . . . 10.0 111.232 173.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 p -61.29 91.39 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 107.407 -1.331 . . . . 10.0 107.407 166.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -113.36 -69.06 0.89 Allowed 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 104.183 -2.525 . . . . 10.0 104.183 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -154.64 161.33 41.63 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 106.171 -1.788 . . . . 10.0 106.171 167.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.8 t60 -72.48 129.07 37.48 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 105.194 -2.151 . . . . 10.0 105.194 163.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -150.03 -140.81 3.29 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 108.316 -1.913 . . . . 10.0 108.316 176.004 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.422 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.33 -157.99 21.59 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.812 -2.115 . . . . 10.0 107.812 170.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -69.38 18.3 0.17 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 119.627 1.713 . . . . 10.0 111.326 169.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.422 ' H ' ' C ' ' A' ' 73' ' ' GLY . 30.4 mmtm -104.96 -21.03 13.36 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 124.753 1.221 . . . . 10.0 108.643 169.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -120.9 166.51 13.7 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.121 -1.807 . . . . 10.0 106.121 -171.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -79.32 -42.15 26.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 107.667 -1.235 . . . . 10.0 107.667 173.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -96.2 34.88 1.51 Allowed 'General case' 0 N--CA 1.441 -0.921 0 C-N-CA 127.53 2.332 . . . . 10.0 114.974 -161.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ptp180 -57.28 153.79 11.55 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.521 1.129 . . . . 10.0 110.867 174.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -72.97 159.21 34.03 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 118.9 -1.12 . . . . 10.0 108.497 168.064 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -38.91 -40.09 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 125.974 1.71 . . . . 10.0 114.397 -172.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.6 42.88 1.32 Allowed Glycine 0 C--N 1.338 0.664 0 CA-C-N 118.178 0.445 . . . . 10.0 112.641 179.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.0 89.48 5.34 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 106.619 -1.623 . . . . 10.0 106.619 167.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 21.4 mt -67.97 -37.71 81.86 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.15 -86.08 0.41 Allowed Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 114.873 -1.058 . . . . 10.0 110.537 167.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -140.72 131.03 25.07 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 -172.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.0 m -115.24 137.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.944 -0.762 . . . . 10.0 108.944 169.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -85.19 131.92 34.36 Favored 'General case' 0 C--O 1.226 -0.168 0 C-N-CA 124.761 1.224 . . . . 10.0 109.485 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.05 138.47 45.35 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.37 1.468 . . . . 10.0 109.625 171.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -58.92 171.6 0.66 Allowed 'General case' 0 N--CA 1.456 -0.135 0 O-C-N 124.181 0.926 . . . . 10.0 109.191 167.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 27.5 pttt -45.91 -34.96 4.23 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 127.225 2.21 . . . . 10.0 110.852 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -82.53 -3.04 55.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.861 1.264 . . . . 10.0 110.83 -173.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.52 8.48 83.08 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.556 -1.017 . . . . 10.0 110.556 -177.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 73.5 t -87.83 98.82 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 107.289 -1.374 . . . . 10.0 107.289 -177.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.53 121.66 38.59 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 107.523 -1.288 . . . . 10.0 107.523 168.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -84.47 114.41 21.9 Favored 'General case' 0 N--CA 1.439 -1.003 0 C-N-CA 126.955 2.102 . . . . 10.0 108.202 169.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 87.9 t -102.05 131.36 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.672 -1.233 . . . . 10.0 107.672 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.6 p -157.97 88.95 0.98 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.392 1.077 . . . . 10.0 109.067 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -129.17 163.51 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 106.818 -1.549 . . . . 10.0 106.818 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.454 ' CD ' ' HZ2' ' A' ' 30' ' ' LYS . 12.4 pt-20 -136.67 150.39 48.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 121.471 -0.768 . . . . 10.0 110.407 170.176 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -147.0 155.6 42.37 Favored 'General case' 0 N--CA 1.447 -0.608 0 O-C-N 124.551 1.157 . . . . 10.0 108.761 178.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.3 p -113.27 44.57 1.53 Allowed 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 127.583 2.353 . . . . 10.0 110.39 -173.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.8 p -142.59 -46.24 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 C-N-CA 123.624 0.77 . . . . 10.0 109.557 177.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 39.8 mm -54.73 110.33 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 169.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.4 m -120.82 105.16 10.45 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 124.386 1.074 . . . . 10.0 109.217 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 37.2 mt -58.15 -28.8 65.06 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.984 0.514 . . . . 10.0 111.935 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 m -150.29 160.79 43.45 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.869 -1.53 . . . . 10.0 106.869 174.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 66.1 0.4 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.333 -1.107 . . . . 10.0 110.333 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t70 71.53 -59.67 0.54 Allowed 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 129.557 3.143 . . . . 10.0 109.519 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.9 m-70 -76.49 -22.03 55.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.637 -0.71 . . . . 10.0 111.165 -169.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.1 t 26.43 78.26 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 128.358 2.663 . . . . 10.0 112.213 168.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -67.76 -6.36 5.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 112.599 0.592 . . . . 10.0 112.599 -174.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.5 mm -51.46 132.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 O-C-N 120.952 -1.092 . . . . 10.0 108.309 168.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.428 ' HA3' ' CG2' ' B' ' 113' ' ' ILE . . . 93.38 11.81 57.94 Favored Glycine 0 CA--C 1.523 0.577 0 CA-C-O 117.701 -1.611 . . . . 10.0 115.952 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -80.0 176.29 9.87 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 119.594 1.697 . . . . 10.0 108.554 167.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 99.7 m -106.54 121.46 44.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 125.095 1.358 . . . . 10.0 107.637 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -76.88 144.37 39.01 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 106.498 -1.667 . . . . 10.0 106.498 167.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.2 t -131.88 123.76 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 107.696 -1.224 . . . . 10.0 107.696 -176.021 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 11.7 t -104.49 137.83 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.9 m170 -124.89 157.65 35.44 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 114.553 1.316 . . . . 10.0 114.553 -174.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 68.7 tt0 -45.61 -55.92 5.78 Favored 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 128.833 2.853 . . . . 10.0 109.183 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 63.6 mttt -123.6 175.11 7.0 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.586 1.154 . . . . 10.0 110.751 -170.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.33 143.35 28.72 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 108.715 -0.846 . . . . 10.0 108.715 176.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.42 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.1 OUTLIER -73.64 151.66 40.75 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.435 -0.58 . . . . 10.0 109.435 175.572 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -83.28 13.49 4.24 Favored 'General case' 0 N--CA 1.448 -0.529 0 O-C-N 124.355 1.034 . . . . 10.0 111.168 167.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 75.7 mt 45.58 46.6 11.21 Favored 'General case' 0 C--N 1.343 0.307 0 C-N-CA 125.513 1.525 . . . . 10.0 112.779 171.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 107.79 -21.88 29.08 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-N 115.724 -0.671 . . . . 10.0 112.119 173.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.2 mtmm -112.26 43.89 1.53 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.056 1.343 . . . . 10.0 111.598 -168.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.49 -16.42 64.19 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.343 1.925 . . . . 10.0 112.435 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.33 47.9 88.31 Favored Glycine 0 CA--C 1.532 1.104 0 O-C-N 121.473 -1.016 . . . . 10.0 112.554 173.45 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -165.77 173.81 10.3 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 126.682 1.993 . . . . 10.0 106.094 177.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.416 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 23.7 tt0 -56.9 -42.54 80.08 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 119.802 1.183 . . . . 10.0 111.24 -174.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -70.18 -18.32 63.19 Favored 'General case' 0 N--CA 1.454 -0.273 0 O-C-N 121.29 -0.881 . . . . 10.0 111.916 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.3 t -44.54 -43.53 8.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 C-N-CA 124.836 1.254 . . . . 10.0 109.549 170.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -93.79 5.95 49.96 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 112.411 0.523 . . . . 10.0 112.411 -174.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.416 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 87.1 mttt -117.87 -73.77 0.63 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.203 1.401 . . . . 10.0 110.286 179.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.4 p -111.87 7.81 20.2 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 120.213 1.369 . . . . 10.0 110.943 178.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.78 -90.15 1.06 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 108.413 -1.875 . . . . 10.0 108.413 -173.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.76 39.55 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 124.721 1.208 . . . . 10.0 109.872 176.229 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.35 -10.37 32.53 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 124.217 1.007 . . . . 10.0 112.745 -176.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.67 -168.01 53.34 Favored Glycine 0 N--CA 1.445 -0.743 0 O-C-N 121.059 -1.026 . . . . 10.0 110.736 178.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -59.68 138.99 57.58 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 123.781 0.832 . . . . 10.0 112.354 -168.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.8 mtm180 -68.18 69.32 0.14 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.714 1.206 . . . . 10.0 110.464 169.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.62 -9.16 32.77 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 113.654 0.983 . . . . 10.0 113.654 -178.024 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.38 143.4 17.68 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.47 0.708 . . . . 10.0 111.858 168.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 5.4 p -144.28 166.31 25.41 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.148 -0.686 . . . . 10.0 109.148 171.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.1 150.95 21.15 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 109.74 -1.344 . . . . 10.0 109.74 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.8 139.68 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 106.212 -1.773 . . . . 10.0 106.212 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 58.8 mt -76.84 127.34 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-O 119.555 -0.26 . . . . 10.0 110.937 -173.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -125.31 140.78 12.54 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 123.79 0.71 . . . . 10.0 111.882 -177.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 94.1 mt -68.29 140.96 18.2 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 C-N-CA 124.632 1.173 . . . . 10.0 108.699 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.21 -46.33 1.51 Allowed 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 112.348 0.499 . . . . 10.0 112.348 -176.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 . . . . . 0 C--O 1.248 0.986 0 CA-C-O 117.277 -1.344 . . . . 10.0 110.24 -167.896 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.556 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -88.26 -15.74 35.04 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.865 1.266 . . . . 10.0 111.469 -175.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 31.2 tttp -130.18 135.44 48.17 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.142 1.377 . . . . 10.0 108.645 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.74 161.47 35.47 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.769 1.628 . . . . 10.0 108.843 169.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.1 t -117.98 152.86 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 C-N-CA 125.489 1.516 . . . . 10.0 110.163 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.47 94.96 3.28 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.416 1.887 . . . . 10.0 108.739 171.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.1 m -88.29 111.3 22.18 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 N-CA-C 109.368 -0.604 . . . . 10.0 109.368 172.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.4 mt -94.61 145.68 24.66 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 109.179 -0.674 . . . . 10.0 109.179 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.5 mtmt -166.72 159.28 13.76 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.533 1.133 . . . . 10.0 108.397 172.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.28 -48.7 0.11 Allowed Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.351 -0.928 . . . . 10.0 113.112 169.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -72.94 -45.96 55.15 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 107.548 -1.278 . . . . 10.0 107.548 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.04 -71.36 0.4 Allowed Glycine 0 CA--C 1.523 0.537 0 CA-C-N 114.323 -1.308 . . . . 10.0 109.909 170.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -58.18 -35.72 98.47 Favored 'Trans proline' 0 N--CA 1.453 -0.862 0 C-N-CA 123.156 2.57 . . . . 10.0 111.249 173.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.6 t -64.59 107.59 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 107.573 -1.269 . . . . 10.0 107.573 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.47 124.16 39.48 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 108.608 -0.886 . . . . 10.0 108.608 169.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -104.17 149.4 17.11 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 109.879 -1.289 . . . . 10.0 109.879 170.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 mt -146.75 56.89 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 N-CA-C 107.251 -1.388 . . . . 10.0 107.251 -176.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mm -86.35 135.6 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.09 -0.707 . . . . 10.0 109.09 -169.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -103.23 115.76 31.18 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.249 1.82 . . . . 10.0 107.126 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -96.4 115.01 26.74 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.721 -1.585 . . . . 10.0 106.721 175.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -122.79 151.46 41.62 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 119.321 0.964 . . . . 10.0 112.699 172.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.6 tt0 -139.6 95.83 2.98 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.148 1.379 . . . . 10.0 108.733 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 68.6 tttt . . . . . 0 N--CA 1.426 -1.626 0 C-N-CA 124.15 0.98 . . . . 10.0 109.3 178.847 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.222 0 CA-C-O 118.91 -0.939 . . . . 10.0 114.621 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -68.57 116.33 4.36 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 107.3 -1.846 . . . . 10.0 107.3 169.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.8 t -79.37 99.94 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 104.272 -2.492 . . . . 10.0 104.272 169.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -92.08 112.03 23.8 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 175.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -101.73 102.73 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.908 0 C-N-CA 126.631 1.972 . . . . 10.0 105.98 -174.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.1 p90 -125.14 160.76 28.37 Favored 'General case' 0 C--N 1.339 0.126 0 N-CA-C 112.683 0.623 . . . . 10.0 112.683 177.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.28 -157.64 27.38 Favored Glycine 0 N--CA 1.449 -0.44 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -143.48 127.96 17.96 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 109.613 -0.514 . . . . 10.0 109.613 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.4 pt -90.14 139.84 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 N-CA-C 106.611 -1.626 . . . . 10.0 106.611 166.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.0 142.34 50.42 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 123.8 0.688 . . . . 10.0 109.437 171.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.98 -4.64 25.65 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.221 -0.766 . . . . 10.0 112.888 178.196 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -60.44 176.8 0.33 Allowed 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 118.676 1.238 . . . . 10.0 110.918 170.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -109.65 164.35 12.62 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 105.406 -2.072 . . . . 10.0 105.406 165.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -52.72 163.09 0.5 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.863 0.865 . . . . 10.0 112.974 -169.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.74 -171.59 47.26 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 123.745 0.688 . . . . 10.0 112.297 169.128 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -71.5 144.39 49.66 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.624 1.969 . . . . 10.0 110.961 -177.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -148.48 138.59 22.44 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 113.638 0.977 . . . . 10.0 113.638 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -20.26 120.87 0.01 OUTLIER Glycine 0 C--N 1.341 0.841 0 C-N-CA 129.134 3.254 . . . . 10.0 115.084 165.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.27 108.09 4.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 119.518 1.659 . . . . 10.0 109.827 168.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.561 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 2.0 m80 -139.5 179.88 6.3 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.607 0.718 . . . . 10.0 112.288 177.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 76.1 t -112.43 128.33 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 C-N-CA 127.173 2.189 . . . . 10.0 106.368 169.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 67.0 m-70 -109.42 138.42 45.8 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 125.589 1.555 . . . . 10.0 107.299 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -53.76 -57.73 9.79 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 124.189 0.996 . . . . 10.0 111.844 -169.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -80.06 135.2 36.29 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 118.109 -1.437 . . . . 10.0 109.59 -177.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.86 -19.76 79.56 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 109.827 -1.309 . . . . 10.0 109.827 168.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t0 -39.57 148.63 0.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.008 1.323 . . . . 10.0 112.48 175.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -153.88 20.06 0.52 Allowed 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.424 -1.262 . . . . 10.0 113.214 174.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.494 HG22 ' CG2' ' A' ' 17' ' ' ILE . 1.8 m -52.74 -38.04 60.27 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 119.389 0.995 . . . . 10.0 111.978 -171.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.41 -22.87 47.12 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.025 0.93 . . . . 10.0 113.007 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.05 111.39 2.65 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.056 -1.218 . . . . 10.0 110.056 -169.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.8 m 34.1 51.73 0.43 Allowed 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 127.816 2.446 . . . . 10.0 115.515 170.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.97 -46.18 0.05 Allowed 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.423 0.689 . . . . 10.0 110.032 173.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.8 t -57.09 -26.69 60.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.546 0.738 . . . . 10.0 111.333 -178.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.02 -32.52 0.09 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.032 2.133 . . . . 10.0 112.958 167.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.59 162.66 15.91 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 108.72 -1.752 . . . . 10.0 108.72 173.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . 0.4 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 44.5 Cg_endo -73.94 -134.05 0.01 OUTLIER 'Trans proline' 0 N--CA 1.437 -1.822 0 N-CA-C 103.986 -3.121 . . . . 10.0 103.986 165.321 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.489 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 16.4 m170 -110.18 40.18 2.0 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 120.322 -1.486 . . . . 10.0 109.42 -177.301 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . 0.4 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 0.0 OUTLIER -78.04 57.36 1.77 Allowed 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.061 0.846 . . . . 10.0 112.494 -179.506 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -54.38 167.04 0.61 Allowed Pre-proline 0 CA--C 1.541 0.597 0 C-N-CA 129.782 3.233 . . . . 10.0 112.175 173.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -93.87 19.53 0.76 Allowed 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.738 2.292 . . . . 10.0 111.744 -173.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -144.48 48.73 1.34 Allowed 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.156 1.383 . . . . 10.0 107.444 -171.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.3 p -40.61 107.17 0.07 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 126.716 2.006 . . . . 10.0 112.03 -169.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 45.3 mtp180 -147.56 177.96 8.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 104.98 -2.23 . . . . 10.0 104.98 -175.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -73.41 143.09 46.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 117.395 -1.722 . . . . 10.0 110.257 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.5 t60 -52.53 116.96 2.54 Favored 'General case' 0 CA--C 1.519 -0.216 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 167.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.07 -178.84 22.69 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 106.659 -2.576 . . . . 10.0 106.659 178.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -151.77 -148.34 4.8 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 -174.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -65.58 -0.13 3.43 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 CA-C-N 119.386 1.593 . . . . 10.0 110.591 167.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -87.86 -27.17 22.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 118.798 0.726 . . . . 10.0 109.784 172.018 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -115.05 164.69 13.81 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.71 0.766 . . . . 10.0 111.315 -169.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -96.12 -9.0 31.78 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 124.855 1.262 . . . . 10.0 109.216 168.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 50.0 mm-40 -78.2 -81.32 0.1 Allowed 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 124.874 1.269 . . . . 10.0 109.953 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? 59.76 175.69 0.08 Allowed 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 114.634 -1.166 . . . . 10.0 110.722 -167.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -102.43 -59.81 1.64 Allowed 'General case' 0 CA--C 1.529 0.142 0 O-C-N 121.468 -0.77 . . . . 10.0 110.443 168.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.1 p -157.41 -55.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.146 0 C-N-CA 122.991 0.516 . . . . 10.0 109.698 -178.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.19 50.47 0.69 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.104 -1.598 . . . . 10.0 109.104 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -76.22 97.25 4.1 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 169.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 18.7 mt -75.26 -31.22 60.71 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 102.46 -95.94 1.35 Allowed Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 108.063 -2.015 . . . . 10.0 108.063 171.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -135.72 137.0 41.28 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 112.115 0.413 . . . . 10.0 112.115 -168.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.0 m -119.46 143.83 29.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 108.423 -0.955 . . . . 10.0 108.423 168.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.06 134.75 34.55 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.828 1.651 . . . . 10.0 109.473 -178.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.43 134.38 49.67 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.721 1.208 . . . . 10.0 111.515 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -63.6 169.8 3.67 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.893 -0.78 . . . . 10.0 108.893 165.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.01 -25.48 30.43 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.592 1.157 . . . . 10.0 111.79 175.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -75.55 -11.06 59.95 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.838 0.351 . . . . 10.0 110.286 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.66 12.07 75.87 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 110.138 -1.185 . . . . 10.0 110.138 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.0 t -85.45 107.87 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 106.37 -1.715 . . . . 10.0 106.37 175.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.65 119.5 39.47 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 168.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -78.41 131.01 36.76 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.727 2.011 . . . . 10.0 108.432 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 38.6 t -117.65 131.46 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 126.671 1.988 . . . . 10.0 106.64 -179.318 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 m -158.47 68.06 0.47 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 125.33 1.452 . . . . 10.0 109.196 170.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.1 mt -107.38 166.13 4.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 124.632 1.173 . . . . 10.0 108.283 -176.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -152.68 125.27 8.28 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.714 1.606 . . . . 10.0 109.415 -169.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -140.29 136.24 33.08 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 170.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 68.5 p -105.4 60.33 0.67 Allowed 'General case' 0 N--CA 1.457 -0.124 0 N-CA-C 107.003 -1.48 . . . . 10.0 107.003 174.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 99.9 t -127.92 -56.71 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -177.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . 0.425 ' CD1' ' H ' ' B' ' 104' ' ' ILE 0.301 0.0 OUTLIER -81.31 173.18 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 124.378 1.071 . . . . 10.0 112.226 170.555 . . . . . . . . 4 4 . 1 . 010 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.9 m -147.65 171.35 15.75 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.229 -0.919 . . . . 10.0 108.744 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 61.1 mt -105.81 -18.65 13.99 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 124.796 1.238 . . . . 10.0 110.343 175.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 73.0 m . . . . . 0 N--CA 1.453 -0.314 0 C-N-CA 125.269 1.427 . . . . 10.0 107.243 174.778 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 43.3 t . . . . . 0 N--CA 1.447 -0.599 0 N-CA-C 108.862 -0.792 . . . . 10.0 108.862 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 4.6 pt -78.35 45.76 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 O-C-N 121.349 -0.845 . . . . 10.0 112.618 -176.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . 0.428 ' CG2' ' HA3' ' A' ' 114' ' ' GLY . 1.3 mp -72.71 -63.83 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 O-C-N 121.599 -0.688 . . . . 10.0 110.299 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.76 48.71 3.54 Favored Glycine 0 CA--C 1.532 1.105 0 O-C-N 120.744 -1.223 . . . . 10.0 112.458 -178.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.04 166.17 10.81 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 127.064 2.146 . . . . 10.0 106.985 172.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -121.03 136.75 54.91 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.113 -1.069 . . . . 10.0 108.113 174.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mp -103.07 147.3 27.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 173.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -123.69 134.82 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 106.884 -1.525 . . . . 10.0 106.884 174.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -101.29 121.29 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 169.111 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 9.6 m-70 -101.3 154.08 19.09 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 115.677 1.732 . . . . 10.0 115.677 -169.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -38.49 -61.03 0.74 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 128.715 2.806 . . . . 10.0 111.124 171.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 66.0 mttt -117.0 175.3 5.65 Favored 'General case' 0 CA--C 1.517 -0.322 0 C-N-CA 124.973 1.309 . . . . 10.0 109.916 -173.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.3 140.11 35.02 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 108.131 -1.062 . . . . 10.0 108.131 174.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.561 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -77.81 160.85 28.08 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 122.077 0.941 . . . . 10.0 111.592 170.477 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -74.78 -27.68 60.42 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 113.804 -1.544 . . . . 10.0 109.863 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 3.9 mm? 61.05 63.29 1.28 Allowed 'General case' 0 CA--C 1.521 -0.149 0 C-N-CA 125.711 1.605 . . . . 10.0 107.782 -167.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.74 -52.49 3.64 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.299 168.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.8 pttp -78.62 55.71 1.7 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.315 1.046 . . . . 10.0 112.421 -171.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.36 -34.22 4.85 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 125.387 1.47 . . . . 10.0 110.379 169.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 73.71 35.01 55.71 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.345 -1.102 . . . . 10.0 110.345 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -125.75 156.38 39.51 Favored 'General case' 0 CA--C 1.506 -0.717 0 N-CA-C 105.418 -2.068 . . . . 10.0 105.418 169.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.4 tt0 -49.23 -48.86 45.24 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 107.555 -1.276 . . . . 10.0 107.555 169.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -55.95 -41.73 75.14 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 114.648 -1.16 . . . . 10.0 111.959 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 23.2 p -58.61 -42.41 88.09 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 120.368 1.44 . . . . 10.0 111.183 178.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.9 t -78.5 -16.1 57.88 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 113.079 0.77 . . . . 10.0 113.079 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -102.21 -46.01 4.96 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 126.129 1.772 . . . . 10.0 112.889 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.489 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 29.4 p -127.07 -12.33 5.82 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.375 -0.828 . . . . 10.0 112.669 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 1.68 82.64 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.234 -1.314 . . . . 10.0 112.65 -169.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 69.24 29.71 4.51 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 119.95 1.875 . . . . 10.0 111.907 172.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.81 0.9 11.77 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 124.522 1.129 . . . . 10.0 112.552 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.93 -163.09 53.19 Favored Glycine 0 N--CA 1.445 -0.744 0 O-C-N 120.948 -1.095 . . . . 10.0 111.439 173.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -59.3 136.61 58.02 Favored 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.585 1.154 . . . . 10.0 114.005 -166.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -64.43 75.52 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.227 1.411 . . . . 10.0 109.822 168.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 47.8 mt -54.51 -37.88 65.87 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 118.655 0.661 . . . . 10.0 111.548 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.86 158.84 35.88 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -177.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -151.63 167.6 27.63 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.127 0.571 . . . . 10.0 109.543 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.26 147.43 16.92 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-O 118.446 -1.197 . . . . 10.0 110.361 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.2 t -96.64 127.5 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 N-CA-C 104.358 -2.46 . . . . 10.0 104.358 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.9 mt -70.16 158.02 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.055 0.843 . . . . 10.0 109.936 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -155.57 145.63 12.74 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.201 -1.16 . . . . 10.0 110.201 -172.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 98.6 mt -57.41 131.71 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 C-N-CA 126.335 1.854 . . . . 10.0 109.612 176.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -110.05 -44.37 3.79 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 118.85 0.75 . . . . 10.0 111.942 173.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.584 -2.151 . . . . 10.0 110.908 176.136 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.859 0 CA-C-O 118.698 -0.668 . . . . 10.0 109.276 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.8 t -165.11 -45.85 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.349 1.06 . . . . 10.0 109.919 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 20.0 ttmm -104.27 138.8 40.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.223 -1.769 . . . . 10.0 106.223 168.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.22 163.4 37.12 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 169.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -137.62 166.09 25.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-N 118.286 0.494 . . . . 10.0 110.171 -177.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.89 106.89 4.93 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 167.332 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.4 m -80.94 101.02 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 168.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mt -78.88 138.73 38.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.707 -0.849 . . . . 10.0 108.707 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.93 160.94 34.09 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.61 -0.885 . . . . 10.0 108.61 168.243 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.45 -60.73 0.03 OUTLIER Glycine 0 C--O 1.23 -0.144 0 N-CA-C 110.592 -1.003 . . . . 10.0 110.592 173.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -74.71 -45.14 46.25 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.53 -69.45 0.48 Allowed Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 114.731 -1.122 . . . . 10.0 111.331 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -55.58 -39.28 91.98 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 122.236 1.957 . . . . 10.0 111.062 -179.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.0 t -63.26 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 C-N-CA 129.064 2.946 . . . . 10.0 109.094 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -95.45 47.75 1.13 Allowed 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.92 1.288 . . . . 10.0 110.173 -167.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -58.77 150.73 34.87 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 121.142 -0.551 . . . . 10.0 114.041 -168.146 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.543 ' CG2' HG22 ' B' ' 54' ' ' THR . 9.4 mt -136.63 89.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 106.31 -1.737 . . . . 10.0 106.31 -171.446 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.9 mm -96.24 136.74 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.139 0.576 . . . . 10.0 109.455 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -122.7 111.45 16.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 126.027 1.731 . . . . 10.0 107.522 172.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -92.85 118.74 31.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.2 1.4 . . . . 10.0 107.343 175.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -124.0 117.84 25.66 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 123.62 0.575 . . . . 10.0 111.161 175.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -101.13 102.57 13.53 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 105.876 -1.898 . . . . 10.0 105.876 168.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.3 mmmp? -54.32 -53.6 51.65 Favored 'General case' 0 C--N 1.338 0.108 0 C-N-CA 124.738 1.215 . . . . 10.0 110.821 -169.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.67 178.45 6.99 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 104.798 -2.297 . . . . 10.0 104.798 169.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -70.04 -20.37 63.25 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 110.311 -0.255 . . . . 10.0 110.311 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.8 m-80 -79.5 -21.88 44.72 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 123.742 0.817 . . . . 10.0 109.68 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.47 149.64 33.9 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.096 -0.802 . . . . 10.0 111.096 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -66.82 159.81 49.7 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 122.353 2.035 . . . . 10.0 107.597 168.176 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.29 96.33 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 105.93 -1.878 . . . . 10.0 105.93 174.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.9 mtpm? -71.98 100.6 2.51 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 106.42 -1.696 . . . . 10.0 106.42 172.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.54 97.7 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 125.52 1.528 . . . . 10.0 107.28 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.2 p90 -108.79 169.06 8.9 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 121.017 0.437 . . . . 10.0 110.606 169.299 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.57 -168.43 36.74 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.804 -0.518 . . . . 10.0 111.804 173.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 11.7 m -147.79 122.84 10.11 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.753 -0.223 . . . . 10.0 111.565 -177.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -99.53 95.42 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 C-N-CA 126.64 1.976 . . . . 10.0 107.449 169.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -106.0 102.45 11.88 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.009 0.524 . . . . 10.0 110.243 176.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.61 29.5 0.06 OUTLIER Glycine 0 C--N 1.334 0.463 0 CA-C-O 118.819 -0.989 . . . . 10.0 114.847 171.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -126.23 175.87 7.49 Favored 'General case' 0 C--O 1.223 -0.302 0 CA-C-N 118.329 1.065 . . . . 10.0 109.022 -177.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.3 t -75.52 160.42 30.2 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 109.325 171.437 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -62.24 -176.4 0.1 Allowed 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.029 1.332 . . . . 10.0 112.74 -176.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.9 -177.65 46.48 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.059 -0.816 . . . . 10.0 111.059 171.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.27 150.29 46.54 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.904 0.882 . . . . 10.0 109.216 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 -144.55 149.05 35.2 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.359 0.664 . . . . 10.0 112.484 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -30.09 121.77 0.11 Allowed Glycine 0 C--N 1.34 0.774 0 C-N-CA 128.34 2.876 . . . . 10.0 112.215 165.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -149.56 107.53 3.72 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 120.045 1.923 . . . . 10.0 113.412 168.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.509 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -149.29 168.78 22.38 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 122.18 0.99 . . . . 10.0 112.747 177.777 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 43.5 t -95.36 143.34 12.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 111.186 -2.734 . . . . 10.0 105.964 168.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -125.58 152.24 45.36 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 125.022 1.329 . . . . 10.0 108.889 177.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -62.35 -55.82 24.34 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 123.621 0.768 . . . . 10.0 109.87 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -76.55 104.89 7.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.154 -1.795 . . . . 10.0 106.154 -170.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.57 -36.54 92.59 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 108.844 -1.702 . . . . 10.0 108.844 173.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -54.11 160.99 1.39 Allowed 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 122.735 1.255 . . . . 10.0 113.254 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -156.33 22.39 0.36 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.206 -1.361 . . . . 10.0 114.506 -172.027 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -48.94 -36.95 18.59 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.366 1.066 . . . . 10.0 111.387 174.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.6 -18.14 57.12 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.556 1.142 . . . . 10.0 112.854 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.52 84.15 0.57 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 123.686 0.66 . . . . 10.0 112.03 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.1 m 47.13 35.51 3.61 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.152 1.781 . . . . 10.0 112.378 174.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.5 m -129.44 -52.39 1.17 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 124.176 0.991 . . . . 10.0 108.396 -169.106 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.1 t -104.32 24.38 11.65 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.525 0.73 . . . . 10.0 109.394 178.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.29 46.51 0.62 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 123.607 0.763 . . . . 10.0 110.68 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.15 100.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.1 0 C-N-CA 126.263 1.887 . . . . 10.0 113.919 168.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -68.61 73.79 0.89 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 123.523 2.815 . . . . 10.0 113.086 179.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.436 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 20.0 m170 60.64 44.24 11.67 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.365 3.466 . . . . 10.0 110.6 172.384 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -68.96 68.84 0.17 Allowed 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.917 1.287 . . . . 10.0 111.659 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -84.77 154.97 61.84 Favored Pre-proline 0 C--N 1.322 -0.621 0 C-N-CA 125.512 1.525 . . . . 10.0 109.593 177.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.23 -44.19 5.24 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 122.433 2.089 . . . . 10.0 111.564 178.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.14 53.55 0.99 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.753 0.821 . . . . 10.0 111.021 -178.113 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.6 t -47.34 114.23 0.83 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.086 0.954 . . . . 10.0 111.009 -169.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 54.6 mtt180 -151.69 178.0 9.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 105.458 -2.053 . . . . 10.0 105.458 -169.645 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.5 ' HZ1' ' CD ' ' A' ' 78' ' ' GLU . 0.0 OUTLIER -78.72 141.47 37.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 118.614 -1.235 . . . . 10.0 108.892 -177.766 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -44.98 118.04 1.53 Allowed 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 121.002 -0.279 . . . . 10.0 111.514 168.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.54 -141.64 4.32 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.461 -1.055 . . . . 10.0 110.461 179.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.436 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -162.32 -175.49 33.4 Favored Glycine 0 C--O 1.223 -0.591 0 CA-C-N 118.426 1.113 . . . . 10.0 113.562 -173.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -66.58 7.6 0.39 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.176 1.917 . . . . 10.0 111.09 168.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.436 ' H ' ' C ' ' A' ' 73' ' ' GLY . 71.7 mmtt -96.57 -22.47 17.04 Favored 'General case' 0 N--CA 1.435 -1.183 0 C-N-CA 124.422 1.089 . . . . 10.0 108.407 173.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -126.56 -172.61 2.67 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 112.476 0.547 . . . . 10.0 112.476 -168.301 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -115.1 -6.21 12.48 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.967 1.307 . . . . 10.0 111.071 -174.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.5 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 2.8 mt-10 -100.74 -14.34 18.1 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 124.646 1.178 . . . . 10.0 112.143 -178.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -26.09 114.65 0.06 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 125.929 1.691 . . . . 10.0 111.331 167.707 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -53.62 -53.11 56.53 Favored 'General case' 0 C--O 1.226 -0.14 0 CA-C-O 121.419 0.628 . . . . 10.0 111.718 -167.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.5 p -165.38 -103.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 104.376 -2.453 . . . . 10.0 104.376 170.192 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -76.49 59.39 3.31 Favored Glycine 0 CA--C 1.53 1.018 0 CA-C-N 119.098 0.863 . . . . 10.0 112.476 176.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -91.11 108.18 19.69 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 103.77 -2.678 . . . . 10.0 103.77 166.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -81.59 -19.9 40.96 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 118.446 0.566 . . . . 10.0 111.34 -172.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.03 -92.46 0.59 Allowed Glycine 0 C--O 1.217 -0.937 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -155.19 159.52 40.18 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 -178.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.6 m -126.13 126.6 69.83 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 123.665 0.786 . . . . 10.0 110.283 170.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -80.11 124.47 28.79 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 127.025 2.13 . . . . 10.0 111.773 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.82 129.55 49.53 Favored 'General case' 0 C--O 1.234 0.243 0 C-N-CA 126.051 1.74 . . . . 10.0 109.58 170.031 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -64.98 172.14 3.09 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 123.985 0.803 . . . . 10.0 109.958 169.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -48.59 -34.61 11.86 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 126.586 1.954 . . . . 10.0 109.983 173.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -78.99 -6.53 56.55 Favored 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 123.943 0.897 . . . . 10.0 110.146 -172.452 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.13 21.18 71.23 Favored Glycine 0 C--N 1.339 0.738 0 N-CA-C 110.27 -1.132 . . . . 10.0 110.27 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.5 t -101.79 106.7 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 127.501 2.32 . . . . 10.0 105.266 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.9 120.39 40.32 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.092 -1.077 . . . . 10.0 108.092 169.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -88.77 134.72 33.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 169.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 90.1 t -109.68 131.78 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 104.705 -2.331 . . . . 10.0 104.705 168.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.9 m -154.79 68.5 0.71 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 124.158 0.983 . . . . 10.0 108.795 174.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -117.22 160.82 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 106.736 -1.579 . . . . 10.0 106.736 -174.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -132.01 123.91 28.25 Favored 'General case' 0 N--CA 1.446 -0.626 0 O-C-N 121.842 -0.536 . . . . 10.0 110.139 168.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -104.47 128.0 52.28 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.783 1.233 . . . . 10.0 109.403 -172.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.9 p -113.42 38.25 2.95 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.047 1.339 . . . . 10.0 110.867 177.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.53 -39.73 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 C-N-CA 123.644 0.778 . . . . 10.0 111.47 173.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.369 0.8 OUTLIER -90.27 175.66 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 119.566 1.076 . . . . 10.0 112.106 170.173 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 83.7 p -146.39 158.74 43.92 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.402 -0.811 . . . . 10.0 109.107 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.8 mp -89.82 -26.56 20.49 Favored 'General case' 0 N--CA 1.457 -0.077 0 C-N-CA 122.756 0.422 . . . . 10.0 110.493 170.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -155.9 46.51 0.47 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.188 0.449 . . . . 10.0 110.853 -172.035 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -151.92 70.44 0.3 Allowed Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.549 -1.82 . . . . 10.0 108.549 -178.001 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.8 t70 73.94 -52.32 0.69 Allowed 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 128.711 2.804 . . . . 10.0 111.21 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -75.3 -36.7 61.09 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -167.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.5 t 37.79 75.48 0.07 Allowed 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.694 1.598 . . . . 10.0 113.731 166.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.8 pt -61.98 -9.37 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 N-CA-C 114.133 1.16 . . . . 10.0 114.133 -177.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 39.1 mm -45.28 129.45 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 O-C-N 121.066 -1.022 . . . . 10.0 110.263 170.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.74 -3.41 86.89 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.5 -1.167 . . . . 10.0 114.116 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -78.26 175.67 9.99 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 119.101 1.451 . . . . 10.0 108.04 168.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -123.4 135.2 54.01 Favored 'General case' 0 C--N 1.338 0.105 0 C-N-CA 123.308 0.643 . . . . 10.0 110.151 171.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -89.53 147.22 24.09 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 107.64 -1.245 . . . . 10.0 107.64 168.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.4 t -129.27 131.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.2 -1.407 . . . . 10.0 107.2 169.254 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -102.97 133.18 47.46 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 N-CA-C 105.787 -1.931 . . . . 10.0 105.787 168.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -111.52 157.67 20.07 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.839 1.422 . . . . 10.0 114.839 -170.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 52.0 tt0 -43.52 -52.46 6.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 128.598 2.759 . . . . 10.0 110.332 176.274 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -118.21 165.28 14.0 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 123.584 0.754 . . . . 10.0 110.915 -169.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -58.58 147.16 33.27 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.002 -0.999 . . . . 10.0 109.698 169.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.509 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 26.1 m-20 -79.49 130.56 35.52 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 124.459 1.104 . . . . 10.0 109.829 171.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.51 -16.66 59.59 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 123.876 0.735 . . . . 10.0 111.014 173.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.2 mt 55.6 49.74 15.89 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-O 122.251 1.024 . . . . 10.0 109.386 -173.105 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.52 -29.49 9.61 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.069 -1.423 . . . . 10.0 112.399 169.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt -77.06 9.94 2.68 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.731 1.011 . . . . 10.0 113.731 -168.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.07 -19.98 74.36 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 124.378 0.99 . . . . 10.0 111.86 172.469 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.79 42.51 68.9 Favored Glycine 0 C--N 1.343 0.944 0 N-CA-C 111.031 -0.828 . . . . 10.0 111.031 -176.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -131.51 159.09 39.16 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 106.139 -1.8 . . . . 10.0 106.139 177.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -50.68 -49.0 58.36 Favored 'General case' 0 N--CA 1.442 -0.841 0 CA-C-N 114.522 -1.217 . . . . 10.0 107.82 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -63.28 -33.67 76.02 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 115.376 -0.829 . . . . 10.0 112.41 175.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.9 p -59.43 -43.23 93.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 120.153 -1.592 . . . . 10.0 111.06 174.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -81.47 -21.04 39.02 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 122.973 0.171 . . . . 10.0 111.187 -174.115 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 15.6 mmtp -89.11 -49.3 6.83 Favored 'General case' 0 C--N 1.339 0.129 0 C-N-CA 124.781 1.232 . . . . 10.0 113.099 179.223 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.436 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 34.7 p -128.81 -18.08 3.89 Favored 'General case' 0 C--O 1.227 -0.125 0 N-CA-C 114.734 1.383 . . . . 10.0 114.734 177.709 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 106.55 26.26 5.97 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 119.452 1.024 . . . . 10.0 112.96 -176.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 58.64 21.6 8.93 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 118.349 1.074 . . . . 10.0 111.033 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.4 -5.36 35.93 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 123.965 0.906 . . . . 10.0 111.8 -169.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.84 -165.58 53.66 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.808 -1.317 . . . . 10.0 109.808 168.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 60.2 m -52.01 129.62 27.67 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-O 121.362 0.601 . . . . 10.0 110.037 -171.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.71 72.95 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.004 1.322 . . . . 10.0 110.414 171.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 6.5 tp -47.75 -35.2 9.48 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 128.202 2.601 . . . . 10.0 113.122 -172.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.93 157.09 25.87 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.73 -0.841 . . . . 10.0 108.73 172.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -145.31 163.32 34.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.047 -0.524 . . . . 10.0 109.714 177.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.18 147.32 15.39 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.495 -1.442 . . . . 10.0 109.495 -174.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 69.9 t -105.88 131.88 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 C-N-CA 126.142 1.777 . . . . 10.0 106.771 -169.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 8.2 mt -77.14 117.62 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.735 0 CA-C-N 117.884 0.311 . . . . 10.0 110.398 -174.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.45 158.87 14.1 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.572 1.082 . . . . 10.0 112.036 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.1 mt -64.74 142.56 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 125.309 1.444 . . . . 10.0 109.803 177.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.77 165.11 28.16 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.575 -1.269 . . . . 10.0 107.575 167.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.12 0 N-CA-C 105.023 -2.214 . . . . 10.0 105.023 167.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.551 0 N-CA-C 106.815 -1.55 . . . . 10.0 106.815 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.1 t -94.9 -35.1 12.17 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.558 1.143 . . . . 10.0 109.539 175.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -134.23 160.32 38.22 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 124.486 1.114 . . . . 10.0 110.467 -171.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.99 166.18 34.41 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 169.161 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -128.4 175.78 9.25 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 N-CA-C 107.739 -1.208 . . . . 10.0 107.739 171.175 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.04 122.61 13.24 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 124.064 0.946 . . . . 10.0 109.076 168.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -102.65 100.41 10.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 C-N-CA 124.482 1.113 . . . . 10.0 110.43 174.179 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.65 130.41 35.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.742 0.817 . . . . 10.0 109.188 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -144.62 162.68 36.04 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 119.529 1.059 . . . . 10.0 108.423 170.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -167.22 -61.37 0.03 OUTLIER Glycine 0 C--O 1.229 -0.208 0 CA-C-N 115.331 -0.85 . . . . 10.0 112.057 171.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -73.81 -44.64 55.19 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 106.544 -1.65 . . . . 10.0 106.544 -171.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.07 -65.57 0.59 Allowed Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 113.614 -1.63 . . . . 10.0 110.404 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -55.44 -38.75 93.67 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 122.644 2.23 . . . . 10.0 111.148 171.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 98.6 t -67.91 107.47 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 N-CA-C 108.058 -1.09 . . . . 10.0 108.058 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.04 107.7 10.67 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 125.662 1.585 . . . . 10.0 107.266 172.676 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -95.67 136.57 12.94 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.181 -0.768 . . . . 10.0 111.181 173.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.9 mt -140.75 89.58 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -102.39 149.77 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.087 0 C-N-CA 124.819 1.248 . . . . 10.0 110.753 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -119.57 133.39 55.68 Favored 'General case' 0 C--O 1.232 0.155 0 C-N-CA 127.639 2.376 . . . . 10.0 107.417 174.148 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -119.32 113.62 21.11 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 171.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -110.74 137.46 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 118.714 0.688 . . . . 10.0 111.478 167.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -96.93 113.92 25.5 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.655 -1.98 . . . . 10.0 105.655 167.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.7 tttt . . . . . 0 N--CA 1.443 -0.775 0 C-N-CA 125.804 1.642 . . . . 10.0 109.672 -175.008 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.949 0 N-CA-C 108.164 -1.974 . . . . 10.0 108.164 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -59.59 149.18 83.92 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 122.63 2.22 . . . . 10.0 110.269 -177.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -88.99 108.1 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 105.913 -1.884 . . . . 10.0 105.913 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 40.4 tttt -88.39 116.86 26.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 105.886 -1.894 . . . . 10.0 105.886 168.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -92.56 103.22 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -123.28 152.41 41.4 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 112.63 0.604 . . . . 10.0 112.63 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.42 -150.86 22.07 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 106.556 -2.618 . . . . 10.0 106.556 172.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.98 154.62 31.38 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 118.86 -1.136 . . . . 10.0 110.733 -176.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 pt -113.89 141.38 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 114.91 -1.041 . . . . 10.0 109.614 167.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 tttm -118.81 141.28 48.78 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.81 -8.76 31.96 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 119.517 -0.602 . . . . 10.0 113.95 174.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.39 176.7 0.59 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 118.303 1.052 . . . . 10.0 111.601 175.121 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -112.7 154.04 26.75 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 105.656 -1.979 . . . . 10.0 105.656 165.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -48.95 154.38 0.74 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.869 1.267 . . . . 10.0 113.3 -168.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -171.11 22.29 Favored Glycine 0 C--N 1.337 0.61 0 C-N-CA 123.84 0.733 . . . . 10.0 112.212 168.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -73.3 144.13 46.71 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.293 1.437 . . . . 10.0 109.782 -178.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -148.03 150.03 33.2 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 113.504 0.928 . . . . 10.0 113.504 -177.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -29.73 119.87 0.08 OUTLIER Glycine 0 C--N 1.339 0.731 0 C-N-CA 128.409 2.909 . . . . 10.0 113.847 165.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -153.77 110.92 3.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 118.72 1.26 . . . . 10.0 111.029 168.493 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -146.86 175.01 10.97 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 121.436 0.636 . . . . 10.0 110.382 177.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.9 m -103.1 155.62 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 104.903 -2.258 . . . . 10.0 104.903 166.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -138.58 154.98 48.73 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.845 1.258 . . . . 10.0 109.835 -173.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.7 tt0 -57.48 -64.62 0.83 Allowed 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.387 2.275 . . . . 10.0 112.387 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -77.06 105.92 8.44 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 -172.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.15 -23.9 66.61 Favored Glycine 0 CA--C 1.532 1.116 0 N-CA-C 108.995 -1.642 . . . . 10.0 108.995 167.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.38 152.43 0.44 Allowed 'General case' 0 N--CA 1.445 -0.699 0 C-N-CA 124.928 1.291 . . . . 10.0 111.682 168.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -152.21 24.46 0.63 Allowed 'General case' 0 N--CA 1.439 -1.007 0 CA-C-N 114.629 -1.169 . . . . 10.0 112.49 168.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.543 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -60.6 -25.41 66.22 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 121.783 -0.573 . . . . 10.0 110.292 176.878 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.57 -17.18 60.13 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.632 0.773 . . . . 10.0 111.149 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.05 73.71 0.9 Allowed Glycine 0 CA--C 1.527 0.795 0 N-CA-C 110.709 -0.956 . . . . 10.0 110.709 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 53.72 32.5 14.83 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.092 0.957 . . . . 10.0 112.534 170.201 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -122.4 -48.63 2.07 Favored 'General case' 0 N--CA 1.441 -0.923 0 C-N-CA 124.943 1.297 . . . . 10.0 108.317 -169.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.8 t -125.37 48.94 1.96 Allowed 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.58 -0.896 . . . . 10.0 108.58 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.81 50.62 0.72 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.603 0.761 . . . . 10.0 110.265 176.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 69.78 120.07 0.04 OUTLIER Glycine 0 CA--C 1.537 1.42 0 C-N-CA 124.947 1.261 . . . . 10.0 113.093 173.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -80.98 50.77 3.69 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 122.729 2.286 . . . . 10.0 112.817 -173.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.412 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 17.5 m170 62.33 100.33 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 127.966 2.507 . . . . 10.0 109.631 -175.718 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -27.38 -47.01 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 128.279 2.632 . . . . 10.0 115.725 -175.19 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 19.39 76.75 0.19 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 128.047 2.539 . . . . 10.0 116.011 -174.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.26 -50.63 2.61 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 121.128 1.218 . . . . 10.0 109.576 172.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 23.3 tp -77.58 75.9 4.12 Favored 'General case' 0 N--CA 1.453 -0.285 0 O-C-N 121.677 -0.64 . . . . 10.0 109.322 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.2 t -17.3 90.25 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 128.051 2.54 . . . . 10.0 114.241 174.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -135.34 164.77 26.99 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 126.721 2.008 . . . . 10.0 107.981 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -105.62 95.33 5.74 Favored 'General case' 0 C--O 1.224 -0.247 0 C-N-CA 122.897 0.479 . . . . 10.0 109.853 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.477 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 84.6 t60 2.16 94.84 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.406 0 C-N-CA 127.56 2.344 . . . . 10.0 115.254 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -100.91 -144.82 16.06 Favored Glycine 0 C--N 1.316 -0.582 0 N-CA-C 109.836 -1.306 . . . . 10.0 109.836 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.455 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 179.14 -165.82 34.95 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 106.749 -2.54 . . . . 10.0 106.749 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -65.28 7.25 0.31 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 CA-C-N 119.887 1.843 . . . . 10.0 111.169 167.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.455 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.8 mmmt -119.94 1.56 10.95 Favored 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 126.509 1.923 . . . . 10.0 110.775 178.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -143.34 159.68 41.92 Favored 'General case' 0 C--N 1.348 0.533 0 CA-C-N 120.709 1.595 . . . . 10.0 108.92 168.183 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.2 mm-40 -78.73 -22.0 47.2 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.588 -0.893 . . . . 10.0 108.588 177.09 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -87.14 34.13 0.68 Allowed 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.433 1.093 . . . . 10.0 111.713 -170.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.0 mtm180 -49.12 142.27 7.13 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.591 1.156 . . . . 10.0 108.254 169.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . 0.477 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 24.4 m170 -75.74 -50.35 15.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.639 0.654 . . . . 10.0 110.367 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER 175.46 -19.88 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 126.949 2.1 . . . . 10.0 111.675 174.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -161.46 68.98 0.23 Allowed Glycine 0 C--N 1.338 0.642 0 N-CA-C 108.469 -1.852 . . . . 10.0 108.469 -169.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -127.58 94.79 4.06 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -168.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.1 mp -64.5 -35.9 82.44 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.468 -0.568 . . . . 10.0 109.468 -172.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.74 -88.14 0.41 Allowed Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 107.19 -2.364 . . . . 10.0 107.19 176.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.6 m120 -149.82 141.46 23.54 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.731 -1.211 . . . . 10.0 107.731 -172.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.5 m -116.52 135.5 56.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 118.443 0.565 . . . . 10.0 110.425 169.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 19.8 m -94.92 100.9 12.68 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 128.173 2.589 . . . . 10.0 110.584 -170.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.92 131.23 35.8 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.066 0.547 . . . . 10.0 110.645 174.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -64.92 168.92 5.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.919 1.688 . . . . 10.0 109.139 167.438 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.15 -32.03 33.93 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.488 1.115 . . . . 10.0 111.039 175.77 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -80.68 -2.0 44.88 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 124.445 1.098 . . . . 10.0 110.794 -176.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.83 82.72 Favored Glycine 0 C--N 1.34 0.762 0 O-C-N 121.158 -0.964 . . . . 10.0 110.86 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 62.8 t -90.37 104.12 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 106.069 -1.826 . . . . 10.0 106.069 176.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.61 122.68 44.88 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 107.61 -1.256 . . . . 10.0 107.61 169.531 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -89.7 124.75 34.88 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.305 1.042 . . . . 10.0 108.25 174.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 51.9 t -110.07 131.53 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.937 1.695 . . . . 10.0 107.529 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 95.2 p -156.53 60.8 0.55 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.174 0.589 . . . . 10.0 109.901 174.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.49 155.02 5.13 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 -173.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -131.56 142.37 49.9 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.575 0.75 . . . . 10.0 111.067 177.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -140.37 161.8 36.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.552 -1.648 . . . . 10.0 106.552 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 11.1 t -136.98 10.33 3.06 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 125.398 1.479 . . . . 10.0 112.893 175.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -89.19 -15.46 8.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 120.077 1.308 . . . . 10.0 109.628 174.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.29 1.0 OUTLIER -111.79 162.57 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 125.333 1.453 . . . . 10.0 112.05 175.578 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.2 m -148.66 147.5 29.0 Favored 'General case' 0 C--N 1.34 0.171 0 C-N-CA 124.087 0.955 . . . . 10.0 109.355 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.45 -21.25 66.2 Favored 'General case' 0 C--O 1.227 -0.113 0 C-N-CA 125.208 1.403 . . . . 10.0 111.35 176.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.7 t . . . . . 0 N--CA 1.453 -0.299 0 O-C-N 121.293 -0.879 . . . . 10.0 109.674 171.957 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.445 -0.717 0 N-CA-C 111.899 0.333 . . . . 10.0 111.899 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 pt -74.29 55.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 123.834 0.854 . . . . 10.0 111.281 176.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 43.5 mm -108.46 -49.3 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 125.848 1.659 . . . . 10.0 109.956 179.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -90.19 18.68 47.22 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.372 -0.682 . . . . 10.0 113.074 -174.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.7 mtt85 -99.64 179.73 4.45 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.115 1.366 . . . . 10.0 110.556 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -133.87 147.62 51.18 Favored 'General case' 0 CA--C 1.507 -0.688 0 C-N-CA 125.789 1.636 . . . . 10.0 106.726 -175.484 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 7.7 mp -113.49 153.81 28.09 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.331 -0.988 . . . . 10.0 108.331 173.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.0 t -131.97 130.46 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -97.82 123.92 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.349 -1.723 . . . . 10.0 106.349 169.125 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -105.06 155.04 19.35 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 115.857 1.799 . . . . 10.0 115.857 -172.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 59.3 tt0 -44.79 -53.35 7.51 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 128.139 2.576 . . . . 10.0 111.726 175.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -113.08 167.19 10.73 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.952 0.723 . . . . 10.0 112.952 -168.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -70.49 147.28 49.57 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 113.967 -1.469 . . . . 10.0 108.424 170.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -94.84 131.34 40.82 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -173.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -76.51 -17.42 59.28 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.36 1.064 . . . . 10.0 110.19 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 22.6 mt 57.74 56.6 4.72 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 122.513 1.149 . . . . 10.0 108.969 -179.363 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.1 -40.83 3.06 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.745 -1.57 . . . . 10.0 110.722 168.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 30.7 mtmt -79.01 48.99 0.89 Allowed 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.637 1.175 . . . . 10.0 110.81 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -112.07 -9.21 20.73 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 127.203 2.335 . . . . 10.0 112.377 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.7 37.73 43.1 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 123.951 0.786 . . . . 10.0 112.973 176.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 -134.0 157.87 44.97 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 106.359 -1.719 . . . . 10.0 106.359 174.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -54.86 -45.94 74.63 Favored 'General case' 0 N--CA 1.439 -0.999 0 CA-C-O 122.305 1.05 . . . . 10.0 108.207 170.207 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 24.0 tp10 -58.48 -33.83 70.23 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 121.185 -0.947 . . . . 10.0 112.978 173.084 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.0 p -56.51 -42.09 77.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 120.606 1.548 . . . . 10.0 111.074 172.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.3 t -82.78 -19.65 37.36 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 118.485 -0.769 . . . . 10.0 112.421 -178.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -90.86 -46.46 8.18 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 124.448 1.099 . . . . 10.0 112.128 -176.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.412 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 26.9 p -133.51 -9.26 2.86 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.098 1.147 . . . . 10.0 114.098 176.504 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.42 23.61 12.31 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 119.289 0.95 . . . . 10.0 112.546 -173.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 61.67 21.83 12.46 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.769 1.284 . . . . 10.0 111.248 -176.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.33 -7.76 20.99 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 125.592 1.557 . . . . 10.0 112.285 -171.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.18 -167.97 54.84 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.069 -1.212 . . . . 10.0 110.069 170.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 12.6 t -53.96 129.1 32.94 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 121.819 0.819 . . . . 10.0 110.862 -169.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.45 73.23 0.08 Allowed 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 124.049 0.94 . . . . 10.0 108.961 169.449 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 66.3 mt -47.14 -45.56 22.6 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.868 0.867 . . . . 10.0 111.676 -177.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.24 152.38 27.69 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -169.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -161.42 165.26 29.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.855 -0.611 . . . . 10.0 109.485 -172.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.44 163.24 30.22 Favored Glycine 0 C--N 1.331 0.255 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -174.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -101.91 156.05 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 N-CA-C 104.05 -2.574 . . . . 10.0 104.05 169.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 77.9 mt -74.75 -94.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 109.765 -0.457 . . . . 10.0 109.765 -169.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 112.92 135.95 6.48 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.626 1.108 . . . . 10.0 112.049 175.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -62.48 138.63 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.106 1.363 . . . . 10.0 110.096 179.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.87 146.59 49.37 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.434 -1.321 . . . . 10.0 107.434 169.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 . . . . . 0 C--O 1.248 0.99 0 N-CA-C 106.195 -1.779 . . . . 10.0 106.195 169.295 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 t -172.37 -36.44 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.703 1.201 . . . . 10.0 112.077 -179.109 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 48.0 tttt -137.98 134.46 34.9 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 123.267 0.627 . . . . 10.0 110.357 -179.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.5 167.85 26.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.012 1.325 . . . . 10.0 108.849 -175.21 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -126.89 164.15 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 118.746 0.703 . . . . 10.0 110.519 170.071 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.74 112.31 11.27 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.285 1.434 . . . . 10.0 107.711 167.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.0 m -95.88 103.14 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 123.666 0.787 . . . . 10.0 110.216 177.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mt -87.77 107.83 18.84 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 118.637 -0.697 . . . . 10.0 110.038 -173.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -133.24 158.69 42.26 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 120.644 1.565 . . . . 10.0 108.453 175.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.71 -68.82 0.02 OUTLIER Glycine 0 N--CA 1.462 0.372 0 CA-C-N 114.818 -1.083 . . . . 10.0 112.342 170.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -72.37 -39.5 68.0 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.064 -1.458 . . . . 10.0 107.064 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.24 -60.48 0.56 Allowed Glycine 0 N--CA 1.443 -0.86 0 CA-C-O 118.476 -1.18 . . . . 10.0 112.608 170.241 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -60.62 -39.62 62.7 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 CA-C-N 119.198 1.499 . . . . 10.0 110.848 -177.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -70.66 115.32 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 177.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.84 103.95 7.78 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.413 -2.44 . . . . 10.0 104.413 170.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.38 145.79 19.19 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 108.445 -1.862 . . . . 10.0 108.445 174.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.3 mt -144.85 74.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -168.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 mm -87.45 128.8 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 N-CA-C 109.741 -0.466 . . . . 10.0 109.741 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -99.6 112.15 24.4 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 126.41 1.884 . . . . 10.0 107.752 173.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -88.06 113.43 23.69 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 107.211 -1.403 . . . . 10.0 107.211 173.081 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -121.28 111.39 17.3 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 118.797 0.726 . . . . 10.0 111.272 168.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -99.53 91.54 4.95 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.129 -1.804 . . . . 10.0 106.129 168.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.48 -36.71 66.91 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.972 0.909 . . . . 10.0 112.939 -168.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.05 171.2 14.76 Favored 'General case' 0 N--CA 1.432 -1.362 0 N-CA-C 104.834 -2.284 . . . . 10.0 104.834 167.398 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.4 p -64.81 -24.65 67.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.235 0.54 . . . . 10.0 110.248 179.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -81.58 -19.29 42.29 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 115.221 -0.9 . . . . 10.0 110.259 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -82.02 154.48 33.71 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.617 -0.593 . . . . 10.0 111.617 -173.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_endo -67.36 146.8 76.37 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.71 2.274 . . . . 10.0 106.876 167.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.9 p -80.29 110.05 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 174.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.474 ' HZ3' ' CD ' ' A' ' 100' ' ' GLU . 20.0 tttt -84.3 115.91 22.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.431 -0.952 . . . . 10.0 108.431 176.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 30.2 m -98.48 57.91 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 124.233 1.013 . . . . 10.0 108.73 -170.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 9.3 p90 -77.78 144.88 36.79 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 118.921 -1.112 . . . . 10.0 110.963 -175.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -175.88 172.04 45.06 Favored Glycine 0 N--CA 1.441 -0.976 0 O-C-N 121.24 -0.913 . . . . 10.0 110.89 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.8 t -128.58 107.91 10.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 178.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.7 pt -81.76 142.18 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 108.396 -0.964 . . . . 10.0 108.396 169.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.7 ptmm? -127.13 137.03 52.9 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.192 -1.04 . . . . 10.0 108.192 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.71 -1.92 27.52 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.075 0.845 . . . . 10.0 113.399 176.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -62.53 174.05 1.09 Allowed 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 122.132 0.968 . . . . 10.0 110.467 169.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -103.61 164.49 11.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.18 -1.785 . . . . 10.0 106.18 164.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -54.61 162.87 1.04 Allowed 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.576 0.751 . . . . 10.0 112.062 -172.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.72 -179.78 43.12 Favored Glycine 0 C--N 1.334 0.469 0 O-C-N 121.248 -0.908 . . . . 10.0 112.29 168.144 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.1 mt -66.55 142.22 57.58 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.059 0.943 . . . . 10.0 110.65 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -138.02 128.82 26.91 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 117.729 -1.129 . . . . 10.0 111.103 176.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -15.2 113.46 0.01 OUTLIER Glycine 0 C--N 1.347 1.148 0 CA-C-O 115.949 -2.584 . . . . 10.0 112.49 167.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -137.73 100.15 4.11 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 120.989 2.394 . . . . 10.0 109.91 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.413 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -156.73 169.84 23.79 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-O 122.04 0.924 . . . . 10.0 112.79 -174.075 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.8 t -96.81 141.14 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 111.566 -2.561 . . . . 10.0 107.729 177.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -116.28 168.58 10.0 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.178 0.991 . . . . 10.0 109.397 178.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -67.23 -72.51 0.16 Allowed 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.697 -0.683 . . . . 10.0 111.246 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.55 136.98 34.71 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 120.161 -0.616 . . . . 10.0 110.132 -169.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -66.87 -31.59 78.63 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 109.278 -1.529 . . . . 10.0 109.278 168.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -45.14 155.34 0.12 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 122.837 1.303 . . . . 10.0 114.353 -175.32 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.17 15.37 0.82 Allowed 'General case' 0 N--CA 1.439 -0.985 0 CA-C-N 113.446 -1.707 . . . . 10.0 111.037 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -53.76 -43.07 68.88 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 120.266 1.394 . . . . 10.0 112.352 -167.676 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.59 -17.94 52.74 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.98 0.912 . . . . 10.0 112.65 -179.331 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.05 60.77 0.37 Allowed Glycine 0 CA--C 1.528 0.862 0 C-N-CA 124.468 1.033 . . . . 10.0 111.139 -177.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 61.24 18.65 9.35 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 114.513 1.301 . . . . 10.0 114.513 171.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 p -93.81 -57.53 2.53 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 176.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.4 m -49.91 -34.44 20.42 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.363 2.265 . . . . 10.0 111.853 -178.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -39.25 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.849 2.46 . . . . 10.0 112.078 168.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.74 154.02 28.63 Favored Glycine 0 N--CA 1.436 -1.339 0 N-CA-C 108.28 -1.928 . . . . 10.0 108.28 168.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -71.44 -164.95 0.17 Allowed 'Trans proline' 0 N--CA 1.442 -1.552 0 N-CA-C 107.269 -1.858 . . . . 10.0 107.269 167.295 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.413 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 50.4 m170 -79.84 62.75 4.17 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 120.596 -1.315 . . . . 10.0 109.951 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -75.28 67.28 1.86 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 123.702 1.715 . . . . 10.0 111.18 178.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -72.65 153.6 91.53 Favored Pre-proline 0 N--CA 1.448 -0.54 0 C-N-CA 128.205 2.602 . . . . 10.0 110.181 169.295 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.85 -40.2 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.767 2.312 . . . . 10.0 111.37 177.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mt -78.09 49.18 0.79 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.284 1.034 . . . . 10.0 110.442 -177.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.4 p -57.14 106.55 0.33 Allowed 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.417 1.087 . . . . 10.0 109.826 -170.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.4 mtt180 -134.7 -88.02 0.37 Allowed 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 106.562 -1.644 . . . . 10.0 106.562 -171.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.5 mmtp -140.71 155.39 46.48 Favored 'General case' 0 N--CA 1.438 -1.074 0 CA-C-O 122.695 1.236 . . . . 10.0 110.273 169.184 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 69.2 t60 -69.03 119.31 13.12 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 164.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.9 -138.24 3.81 Favored Glycine 0 N--CA 1.442 -0.919 0 N-CA-C 109.38 -1.488 . . . . 10.0 109.38 -175.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.475 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -176.94 -157.5 18.14 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 109.558 -1.417 . . . . 10.0 109.558 169.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -67.79 14.72 0.15 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.158 1.905 . . . . 10.0 111.424 168.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.475 ' H ' ' C ' ' A' ' 73' ' ' GLY . 4.5 mtpm? -120.91 -6.93 9.54 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.626 1.571 . . . . 10.0 110.677 174.542 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -110.89 162.39 14.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 177.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.4 pm0 -98.74 -16.16 19.06 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 126.319 1.847 . . . . 10.0 109.866 169.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -105.39 6.9 32.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.852 1.661 . . . . 10.0 112.324 -174.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -35.52 149.81 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.575 1.95 . . . . 10.0 112.924 171.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -70.06 -100.42 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 112.47 0.545 . . . . 10.0 112.47 -178.312 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 p -151.64 25.06 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 O-C-N 120.606 -1.309 . . . . 10.0 110.392 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 157.36 51.33 0.01 OUTLIER Glycine 0 CA--C 1.522 0.483 0 N-CA-C 108.814 -1.715 . . . . 10.0 108.814 -173.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.55 99.74 11.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 105.346 -2.094 . . . . 10.0 105.346 169.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.7 mt -94.49 33.02 1.47 Allowed 'General case' 0 N--CA 1.461 0.122 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 172.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 46.09 -106.38 0.13 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 126.514 2.006 . . . . 10.0 111.025 -178.351 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -151.92 117.66 5.43 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 123.557 0.743 . . . . 10.0 110.439 -168.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -92.86 138.69 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 122.731 0.412 . . . . 10.0 110.83 -171.111 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.31 118.56 24.28 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 125.035 1.334 . . . . 10.0 110.493 -172.391 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.59 134.74 38.12 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 123.225 0.61 . . . . 10.0 109.847 173.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -57.92 167.57 1.16 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.856 0.862 . . . . 10.0 109.025 167.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.11 -23.69 62.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.104 -0.498 . . . . 10.0 112.157 177.644 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -78.4 -13.09 60.0 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.266 0.627 . . . . 10.0 110.958 179.121 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.74 6.27 67.8 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.952 -0.859 . . . . 10.0 110.952 -176.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.9 t -81.49 108.1 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.516 1.927 . . . . 10.0 106.978 174.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -112.99 121.12 43.68 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 108.831 -0.803 . . . . 10.0 108.831 173.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -83.08 131.4 35.16 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.719 -0.845 . . . . 10.0 108.719 173.18 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.7 t -119.23 130.79 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 N-CA-C 104.815 -2.291 . . . . 10.0 104.815 168.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -155.75 57.78 0.61 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 118.655 0.661 . . . . 10.0 111.18 -177.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 71.6 mt -116.55 138.77 46.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.208 1.403 . . . . 10.0 109.824 -170.156 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.474 ' CD ' ' HZ3' ' A' ' 30' ' ' LYS . 2.3 pm0 -91.35 104.12 16.68 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 127.843 2.457 . . . . 10.0 109.121 172.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -81.34 116.48 21.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.009 -0.738 . . . . 10.0 109.009 175.256 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.8 p -111.3 46.46 1.09 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 125.448 1.499 . . . . 10.0 109.68 174.081 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.23 -41.06 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.168 0 CA-C-O 118.157 -0.925 . . . . 10.0 110.543 175.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.407 0.0 OUTLIER -106.27 177.21 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-N 119.553 1.069 . . . . 10.0 113.549 169.501 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.6 t -146.23 153.71 40.92 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 108.112 -1.07 . . . . 10.0 108.112 -176.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 93.1 mt -69.77 -17.53 63.43 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.318 0.647 . . . . 10.0 110.801 173.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.3 t -151.15 150.55 30.79 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.536 0.607 . . . . 10.0 109.533 177.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.6 68.09 0.43 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.017 -1.233 . . . . 10.0 110.017 -179.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.8 t70 71.61 -56.67 0.63 Allowed 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 129.536 3.134 . . . . 10.0 109.847 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -78.15 -2.46 37.61 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 113.011 0.745 . . . . 10.0 113.011 -168.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.9 t -17.76 96.41 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 129.025 2.93 . . . . 10.0 112.523 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 29.2 pt -72.84 -3.58 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 112.776 0.658 . . . . 10.0 112.776 -175.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.8 mm -52.54 130.28 13.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 O-C-N 121.092 -1.005 . . . . 10.0 108.493 169.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.92 8.71 87.67 Favored Glycine 0 CA--C 1.533 1.205 0 CA-C-O 118.67 -1.072 . . . . 10.0 114.22 -176.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -78.36 176.43 9.34 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 166.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -127.96 136.82 51.84 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 106.854 -1.535 . . . . 10.0 106.854 171.179 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.9 mp -107.61 158.07 17.55 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.183 -1.414 . . . . 10.0 107.183 168.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.1 t -132.27 136.79 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 107.487 -1.301 . . . . 10.0 107.487 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.3 125.19 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 103.674 -2.713 . . . . 10.0 103.674 167.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 7.0 m170 -106.37 164.37 12.08 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 120.207 1.367 . . . . 10.0 114.37 -171.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.39 -49.79 73.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 114.036 -1.438 . . . . 10.0 109.438 -175.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -117.97 173.05 6.99 Favored 'General case' 0 N--CA 1.456 -0.131 0 CA-C-O 122.425 1.107 . . . . 10.0 113.355 -174.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -73.57 143.28 46.5 Favored 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 113.475 -1.693 . . . . 10.0 109.646 169.454 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.13 156.3 36.11 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 123.851 0.861 . . . . 10.0 110.637 174.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 -85.35 8.92 16.98 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.414 -0.812 . . . . 10.0 109.968 166.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.4 mt 39.32 52.79 2.24 Favored 'General case' 0 C--N 1.344 0.369 0 C-N-CA 126.148 1.779 . . . . 10.0 110.782 -172.478 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.55 -26.24 24.68 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 113.642 -1.617 . . . . 10.0 112.59 173.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -78.97 24.37 0.31 Allowed 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 114.29 1.219 . . . . 10.0 114.29 -167.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.48 -38.41 38.29 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 108.49 -1.844 . . . . 10.0 108.49 169.034 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.84 47.8 58.7 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 109.431 -1.468 . . . . 10.0 109.431 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -152.17 164.08 38.06 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.544 -2.021 . . . . 10.0 105.544 176.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -44.74 -47.15 10.77 Favored 'General case' 0 N--CA 1.438 -1.055 0 C-N-CA 123.031 0.532 . . . . 10.0 111.344 -175.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.77 -34.56 71.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.453 -0.34 . . . . 10.0 110.176 -177.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -51.45 -44.44 62.36 Favored 'General case' 0 N--CA 1.446 -0.651 0 O-C-N 121.725 -0.61 . . . . 10.0 110.677 172.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -84.38 6.75 22.0 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.382 0.512 . . . . 10.0 112.382 -176.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -118.91 -75.62 0.58 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 125.594 1.557 . . . . 10.0 109.619 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 p -111.16 13.64 21.83 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 120.419 1.463 . . . . 10.0 113.689 175.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.66 -21.2 11.5 Favored Glycine 0 C--N 1.338 0.674 0 O-C-N 120.819 -1.176 . . . . 10.0 115.455 168.265 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 90.74 28.02 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 128.183 2.593 . . . . 10.0 110.097 -168.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.18 -2.2 1.28 Allowed 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.767 0.827 . . . . 10.0 112.686 169.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.11 -171.84 55.16 Favored Glycine 0 N--CA 1.443 -0.867 0 N-CA-C 109.882 -1.287 . . . . 10.0 109.882 174.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -60.88 144.92 51.9 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.881 0.848 . . . . 10.0 112.153 -169.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mtm-85 -63.71 63.29 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 127.305 2.242 . . . . 10.0 110.806 169.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.46 -14.86 59.21 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.941 1.089 . . . . 10.0 113.941 -173.021 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.86 146.3 17.63 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 123.303 0.641 . . . . 10.0 109.738 169.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.0 p -155.07 156.48 35.95 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.79 -0.818 . . . . 10.0 108.79 -171.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.22 145.39 12.38 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.412 -1.075 . . . . 10.0 110.412 -169.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.86 140.85 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 125.903 1.681 . . . . 10.0 106.838 -172.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.8 mt -80.56 120.1 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-O 118.716 -0.659 . . . . 10.0 110.575 -174.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -128.51 154.37 20.01 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 124.263 0.935 . . . . 10.0 113.085 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 mm -64.75 146.21 13.37 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 C-N-CA 124.292 1.037 . . . . 10.0 112.254 -169.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.57 -17.47 1.73 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 116.231 1.937 . . . . 10.0 116.231 178.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.252 1.206 0 CA-C-O 117.693 -1.146 . . . . 10.0 110.683 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 108.383 -0.969 . . . . 10.0 108.383 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -170.13 -47.2 0.02 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 124.099 0.96 . . . . 10.0 109.785 178.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -138.51 125.76 21.59 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 125.256 1.422 . . . . 10.0 107.973 -169.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.02 162.58 35.09 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 124.545 1.138 . . . . 10.0 109.053 -172.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 m -115.74 172.94 3.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-O 121.611 0.719 . . . . 10.0 110.086 171.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.44 102.56 3.85 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 104.425 -2.435 . . . . 10.0 104.425 165.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 m -90.03 120.02 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 170.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.16 136.22 39.44 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 108.326 -0.99 . . . . 10.0 108.326 -177.011 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 39.4 mtpt -145.45 160.26 41.86 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.659 -1.237 . . . . 10.0 107.659 169.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.07 -54.56 0.07 OUTLIER Glycine 0 N--CA 1.461 0.323 0 C-N-CA 120.522 -0.846 . . . . 10.0 113.669 169.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -72.06 -43.58 64.67 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 -174.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.84 -70.95 0.4 Allowed Glycine 0 CA--C 1.521 0.425 0 CA-C-N 114.223 -1.353 . . . . 10.0 109.86 169.656 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -57.62 -36.16 98.62 Favored 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 123.381 2.721 . . . . 10.0 111.389 172.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.95 101.69 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -117.79 106.91 13.52 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 124.633 1.173 . . . . 10.0 107.957 172.001 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -86.83 147.75 21.3 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 109.912 -1.275 . . . . 10.0 109.912 169.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.56 76.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 N-CA-C 104.761 -2.311 . . . . 10.0 104.761 -175.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -97.44 146.15 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 124.744 1.218 . . . . 10.0 108.85 -178.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -126.11 125.17 42.1 Favored 'General case' 0 C--O 1.232 0.133 0 C-N-CA 126.669 1.988 . . . . 10.0 107.864 -175.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -112.69 105.57 13.76 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.406 1.482 . . . . 10.0 107.805 178.137 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -113.13 123.78 51.05 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 123.823 0.702 . . . . 10.0 111.486 175.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -95.18 97.78 10.15 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.332 1.453 . . . . 10.0 108.003 174.274 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? . . . . . 0 N--CA 1.448 -0.56 0 C-N-CA 126.275 1.83 . . . . 10.0 110.955 -175.001 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.852 0 N-CA-C 110.458 -1.057 . . . . 10.0 110.458 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.57 161.0 45.43 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.122 1.881 . . . . 10.0 109.073 171.487 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 14.1 t -87.44 112.28 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 N-CA-C 105.208 -2.145 . . . . 10.0 105.208 169.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -92.98 121.12 33.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.599 -1.63 . . . . 10.0 106.599 169.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.69 106.38 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.307 1.843 . . . . 10.0 106.495 177.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -127.64 152.87 47.13 Favored 'General case' 0 CA--C 1.522 -0.133 0 N-CA-C 113.461 0.912 . . . . 10.0 113.461 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.26 -150.31 21.54 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 108.2 -1.96 . . . . 10.0 108.2 172.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 22.6 t -155.14 158.31 38.79 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 119.598 -0.841 . . . . 10.0 112.299 -177.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -118.88 114.21 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 127.147 2.179 . . . . 10.0 108.76 169.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -100.27 142.87 31.16 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 168.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.43 -1.17 14.21 Favored Glycine 0 C--N 1.337 0.599 0 C-N-CA 124.597 1.094 . . . . 10.0 112.932 169.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 31.7 mt -80.78 175.98 10.21 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.875 0.845 . . . . 10.0 110.491 -178.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -93.11 150.77 20.28 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 68.9 tt0 -53.77 145.32 16.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.4 1.08 . . . . 10.0 110.824 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.4 -176.64 21.8 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.799 0.714 . . . . 10.0 111.882 176.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.8 mp -70.83 150.33 45.93 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.485 1.514 . . . . 10.0 111.87 -172.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -143.22 144.15 32.04 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 112.969 0.729 . . . . 10.0 112.969 178.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -37.19 115.82 0.34 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.405 2.431 . . . . 10.0 112.211 166.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -135.66 106.6 6.65 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.754 1.777 . . . . 10.0 110.592 172.179 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.506 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -152.75 171.35 18.37 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-N 115.376 -0.829 . . . . 10.0 109.885 178.142 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 12.3 m -99.93 147.16 7.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 112.952 -1.931 . . . . 10.0 107.106 167.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 22.7 m-70 -116.14 131.19 57.01 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 103.949 -2.612 . . . . 10.0 103.949 173.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -59.73 -48.78 80.32 Favored 'General case' 0 N--CA 1.45 -0.443 0 O-C-N 124.206 0.941 . . . . 10.0 111.643 -167.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.7 m-30 -80.01 148.28 31.18 Favored 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 118.386 -1.326 . . . . 10.0 108.324 175.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.72 35.89 4.29 Favored Glycine 0 N--CA 1.441 -1.021 0 N-CA-C 108.083 -2.007 . . . . 10.0 108.083 166.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.7 74.73 6.38 Favored 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 126.895 3.236 . . . . 10.0 107.318 171.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -76.63 -0.37 23.16 Favored 'General case' 0 N--CA 1.416 -2.133 0 CA-C-N 109.63 -3.441 . . . . 10.0 111.029 -173.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -32.08 -52.38 0.26 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 130.194 3.397 . . . . 10.0 112.932 175.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -21.97 47.45 Favored 'General case' 0 CA--C 1.529 0.147 0 N-CA-C 112.871 0.693 . . . . 10.0 112.871 -176.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.24 75.85 1.3 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -174.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 19.9 m 63.75 56.82 1.47 Allowed 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 123.716 0.806 . . . . 10.0 112.208 168.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -155.14 -58.19 0.1 Allowed 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 108.239 -1.023 . . . . 10.0 108.239 175.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.5 m -61.42 -26.63 67.99 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 122.376 0.27 . . . . 10.0 111.578 -173.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.02 -34.56 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.977 2.511 . . . . 10.0 112.734 168.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.97 155.97 9.24 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.144 -0.783 . . . . 10.0 111.144 166.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -75.92 58.83 5.6 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 123.566 2.844 . . . . 10.0 108.494 166.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.293 26.1 m170 75.2 -44.3 0.53 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 127.181 2.192 . . . . 10.0 109.519 -177.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 51.61 47.62 24.45 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 126.461 1.904 . . . . 10.0 111.57 172.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -72.01 142.73 85.57 Favored Pre-proline 0 C--N 1.321 -0.638 0 C-N-CA 125.571 1.548 . . . . 10.0 112.987 178.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.92 -44.43 0.35 Allowed 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 123.623 2.882 . . . . 10.0 110.843 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 14.4 mt -68.96 88.13 0.38 Allowed 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.223 -1.399 . . . . 10.0 107.223 171.544 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -57.7 82.13 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.658 1.983 . . . . 10.0 111.25 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.68 -179.83 4.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 127.19 2.196 . . . . 10.0 108.126 177.588 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -111.1 107.89 17.41 Favored 'General case' 0 C--O 1.224 -0.244 0 N-CA-C 108.263 -1.014 . . . . 10.0 108.263 -177.155 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.46 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 83.1 t60 -12.09 98.23 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.439 0 C-N-CA 126.783 2.033 . . . . 10.0 113.892 -178.336 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.44 -175.54 14.11 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 106.916 -2.474 . . . . 10.0 106.916 176.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.32 -155.89 7.26 Favored Glycine 0 C--O 1.226 -0.376 0 N-CA-C 107.061 -2.416 . . . . 10.0 107.061 -177.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -67.22 1.45 2.95 Favored 'Trans proline' 0 CA--C 1.544 0.99 0 CA-C-N 119.69 1.745 . . . . 10.0 110.287 165.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 56.3 mmtt -89.8 -15.57 32.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.834 1.653 . . . . 10.0 110.416 171.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -133.81 178.53 6.87 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 119.832 1.196 . . . . 10.0 109.826 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -90.3 -32.41 16.53 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 169.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -95.14 43.52 1.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 122.299 1.047 . . . . 10.0 111.909 -169.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.58 144.31 17.72 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 115.849 -0.614 . . . . 10.0 110.48 168.47 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . 0.46 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.2 m170 -68.95 -56.86 6.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 -173.175 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.4 p -173.74 -38.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 123.715 0.806 . . . . 10.0 111.429 -174.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -158.56 69.61 0.26 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 108.072 -2.011 . . . . 10.0 108.072 -169.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -122.92 94.4 4.26 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.401 -2.074 . . . . 10.0 105.401 -171.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 5.0 mt -72.07 -28.3 63.24 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 88.39 -94.58 2.01 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 108.007 -2.037 . . . . 10.0 108.007 176.117 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -128.98 124.18 34.38 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.092 0.557 . . . . 10.0 110.531 -168.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 6.6 m -121.48 145.52 27.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.2 m -94.17 113.72 25.71 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 127.172 2.189 . . . . 10.0 111.97 -167.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.45 130.48 36.12 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 109.457 -0.571 . . . . 10.0 109.457 169.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -59.51 169.71 1.21 Allowed 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 125.098 1.359 . . . . 10.0 110.311 168.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.06 -32.29 34.03 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.035 1.334 . . . . 10.0 112.115 169.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -77.34 -1.4 29.75 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.3 0.64 . . . . 10.0 110.987 178.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.37 20.41 69.42 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 120.584 -1.323 . . . . 10.0 110.178 175.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.37 105.5 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 128.529 2.732 . . . . 10.0 106.604 -177.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.88 125.13 44.21 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 168.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 p-10 -88.52 122.7 32.27 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 127.052 2.141 . . . . 10.0 109.045 175.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 96.6 t -107.72 134.25 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 174.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.6 m -158.13 66.56 0.46 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.607 1.163 . . . . 10.0 109.695 169.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.59 156.07 5.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.277 -1.379 . . . . 10.0 107.277 -177.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -133.42 139.95 47.04 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.893 1.277 . . . . 10.0 109.946 175.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -147.29 159.14 44.01 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.071 -1.455 . . . . 10.0 107.071 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.66 14.49 4.04 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.423 1.889 . . . . 10.0 111.857 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -89.44 1.69 7.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 119.19 0.905 . . . . 10.0 109.523 169.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.264 0.0 OUTLIER -129.08 171.28 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 126.313 1.845 . . . . 10.0 111.612 -179.328 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 6.2 m -163.56 147.13 10.31 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 107.462 -1.31 . . . . 10.0 107.462 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -62.38 -48.22 80.71 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 123.303 0.641 . . . . 10.0 109.706 -176.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.4 t . . . . . 0 N--CA 1.453 -0.296 0 C-N-CA 125.347 1.459 . . . . 10.0 107.469 169.66 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 22.3 t . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 115.809 1.781 . . . . 10.0 115.809 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 29.7 pt -71.67 -15.11 18.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 114.048 1.129 . . . . 10.0 114.048 -178.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.5 mm -46.51 127.65 2.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 CA-C-N 119.051 0.841 . . . . 10.0 110.173 172.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.27 -0.11 83.22 Favored Glycine 0 CA--C 1.532 1.137 0 CA-C-O 118.969 -0.906 . . . . 10.0 114.583 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -76.22 175.41 9.05 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 119.243 1.521 . . . . 10.0 108.507 169.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -121.7 125.99 47.9 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.362 0.665 . . . . 10.0 111.002 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -80.93 139.98 35.55 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 170.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 98.9 t -124.72 132.49 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 108.025 -1.102 . . . . 10.0 108.025 171.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -98.78 125.81 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.189 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 168.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.0 m170 -102.11 161.0 14.02 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 122.954 1.359 . . . . 10.0 114.022 -176.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.7 tt0 -46.79 -56.73 5.76 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 128.031 2.532 . . . . 10.0 109.288 176.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -124.49 177.03 6.13 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.655 1.582 . . . . 10.0 110.355 -173.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.21 145.38 35.58 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 125.615 1.566 . . . . 10.0 110.401 176.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.506 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.1 OUTLIER -85.38 157.39 20.53 Favored 'General case' 0 N--CA 1.457 -0.098 0 CA-C-O 121.392 0.615 . . . . 10.0 112.156 169.277 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -78.99 -11.31 60.0 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 115.078 -0.964 . . . . 10.0 111.278 174.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 52.93 57.04 6.76 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.887 1.275 . . . . 10.0 108.841 -174.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.93 -42.32 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 113.706 -1.588 . . . . 10.0 111.161 168.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.7 mtmt -80.53 42.57 0.61 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.684 0.794 . . . . 10.0 112.179 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -94.75 -20.04 30.03 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 127.922 2.677 . . . . 10.0 110.101 168.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.56 49.77 38.57 Favored Glycine 0 C--N 1.34 0.778 0 C-N-CA 124.314 0.959 . . . . 10.0 111.802 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -155.28 172.79 17.6 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 117.784 0.792 . . . . 10.0 108.875 176.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . 0.511 ' CD ' ' HZ1' ' B' ' 136' ' ' LYS . 8.6 tm-20 -52.19 -46.24 65.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 C-N-CA 123.351 0.66 . . . . 10.0 111.269 -177.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -70.06 -30.97 68.35 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.825 -0.607 . . . . 10.0 109.756 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.9 p -50.66 -41.36 55.43 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 119.287 0.949 . . . . 10.0 111.258 -177.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.7 t -86.91 -3.28 59.06 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 113.285 0.846 . . . . 10.0 113.285 -177.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.511 ' HZ1' ' CD ' ' B' ' 132' ' ' GLU . 32.1 tttt -114.48 -57.26 2.29 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 127.424 2.29 . . . . 10.0 111.952 -166.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 6.1 p -132.31 7.19 4.21 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 118.453 -0.784 . . . . 10.0 111.041 168.184 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.23 -105.1 2.95 Favored Glycine 0 C--N 1.344 1.009 0 N-CA-C 108.91 -1.676 . . . . 10.0 108.91 -169.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.15 34.17 0.14 Allowed 'General case' 0 C--N 1.321 -0.65 0 O-C-N 121.095 -1.238 . . . . 10.0 108.342 177.453 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.63 -9.21 58.33 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.899 -1.046 . . . . 10.0 111.467 -169.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.31 -158.39 41.78 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 109.261 -1.535 . . . . 10.0 109.261 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.6 m -57.43 128.9 39.36 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-O 121.45 0.643 . . . . 10.0 109.822 -174.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.2 72.78 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 124.711 1.204 . . . . 10.0 111.132 169.463 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 10.0 tp -44.61 -38.0 3.99 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 128.036 2.535 . . . . 10.0 114.517 -174.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -162.32 158.98 24.9 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 178.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.8 165.29 36.63 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 122.471 -0.143 . . . . 10.0 110.906 -178.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.88 146.47 14.16 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 110.374 -1.091 . . . . 10.0 110.374 -172.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 64.4 t -100.46 138.76 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 N-CA-C 105.851 -1.907 . . . . 10.0 105.851 -174.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 38.5 mt -73.33 120.71 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 C-N-CA 122.524 0.33 . . . . 10.0 110.172 -173.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.56 134.35 10.85 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.095 1.331 . . . . 10.0 112.103 -172.482 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.71 137.0 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 125.604 1.562 . . . . 10.0 109.463 179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.21 -48.15 1.1 Allowed 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 113.305 0.854 . . . . 10.0 113.305 -174.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 44.7 tt0 . . . . . 0 C--O 1.253 1.282 0 N-CA-C 108.782 -0.821 . . . . 10.0 108.782 -165.944 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 108.635 -0.876 . . . . 10.0 108.635 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.9 -6.77 55.44 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 118.52 0.6 . . . . 10.0 109.825 -174.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.93 156.66 42.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.028 0.531 . . . . 10.0 109.986 168.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.41 156.26 35.03 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 m -126.82 160.44 35.17 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 109.552 -0.536 . . . . 10.0 109.552 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.27 107.77 7.85 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 107.578 -1.268 . . . . 10.0 107.578 169.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.4 m -84.37 109.06 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 170.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mt -93.23 146.39 23.73 Favored 'General case' 0 C--O 1.224 -0.246 0 CA-C-O 117.97 -1.014 . . . . 10.0 108.434 -174.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.2 mtmt -164.78 158.93 18.04 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 120.081 1.31 . . . . 10.0 108.351 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.74 -51.05 0.1 OUTLIER Glycine 0 N--CA 1.461 0.365 0 C-N-CA 120.013 -1.089 . . . . 10.0 113.768 168.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -73.35 -44.17 59.27 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.975 -1.12 . . . . 10.0 107.975 -173.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.01 -71.44 0.35 Allowed Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 114.086 -1.416 . . . . 10.0 110.536 169.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -55.0 -39.91 88.55 Favored 'Trans proline' 0 N--CA 1.451 -1.028 0 C-N-CA 122.703 2.269 . . . . 10.0 110.72 172.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.7 t -58.52 112.91 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 C-N-CA 123.862 0.865 . . . . 10.0 109.83 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -131.0 109.23 10.37 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 122.752 0.421 . . . . 10.0 110.062 167.295 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.05 154.77 32.26 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.837 -0.905 . . . . 10.0 110.837 168.161 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.22 56.44 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 126.024 1.73 . . . . 10.0 106.858 -179.122 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 tp -67.25 145.46 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 O-C-N 121.473 -0.767 . . . . 10.0 109.494 -179.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -138.04 101.14 4.34 Favored 'General case' 0 CA--C 1.519 -0.22 0 C-N-CA 126.319 1.847 . . . . 10.0 109.429 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 15.7 m-30 -100.48 129.69 46.47 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.561 -1.274 . . . . 10.0 107.561 -177.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.527 ' CD ' ' HZ2' ' A' ' 23' ' ' LYS . 4.8 tt0 -129.38 152.22 49.18 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.574 0.749 . . . . 10.0 110.752 176.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -125.77 114.65 18.89 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.603 -1.629 . . . . 10.0 106.603 166.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.527 ' HZ2' ' CD ' ' A' ' 21' ' ' GLU . 47.0 mmtt -61.34 -60.26 4.01 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 109.07 -0.715 . . . . 10.0 109.07 169.509 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -126.79 165.84 18.54 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.312 -2.107 . . . . 10.0 105.312 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.4 t -73.52 -10.96 60.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-O 121.516 0.674 . . . . 10.0 109.32 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.8 m120 -78.45 -19.65 52.7 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.194 0.998 . . . . 10.0 110.228 173.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.89 150.76 41.61 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.582 -1.007 . . . . 10.0 110.582 178.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -76.16 148.53 31.03 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 N-CA-C 106.078 -2.316 . . . . 10.0 106.078 166.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.6 t -75.22 100.13 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.9 mtpp -68.48 93.87 0.52 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 106.755 -1.572 . . . . 10.0 106.755 170.138 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.3 m -82.06 59.87 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 124.772 1.229 . . . . 10.0 108.853 -172.373 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -82.7 174.25 11.17 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 119.119 -1.032 . . . . 10.0 111.471 -168.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.11 -159.44 28.35 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.427 -1.469 . . . . 10.0 109.427 167.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 15.2 m -155.99 124.72 5.97 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 109.138 -0.69 . . . . 10.0 109.138 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 pt -93.1 143.5 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 106.505 -1.665 . . . . 10.0 106.505 165.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.16 119.1 17.37 Favored 'General case' 0 N--CA 1.45 -0.435 0 O-C-N 123.803 0.689 . . . . 10.0 110.91 171.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.27 14.24 1.81 Allowed Glycine 0 C--N 1.341 0.839 0 CA-C-O 118.849 -0.973 . . . . 10.0 114.967 168.37 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.421 ' N ' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -97.03 179.49 4.92 Favored 'General case' 0 C--O 1.224 -0.269 0 CA-C-N 118.808 1.304 . . . . 10.0 108.397 174.245 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -75.55 174.26 9.93 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 119.6 -0.84 . . . . 10.0 110.885 170.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -63.85 177.29 0.77 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.078 1.751 . . . . 10.0 110.167 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.8 -174.35 40.89 Favored Glycine 0 N--CA 1.448 -0.55 0 O-C-N 121.32 -0.862 . . . . 10.0 112.987 167.323 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.08 147.77 49.59 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.672 1.189 . . . . 10.0 109.273 175.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -144.38 141.9 29.99 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 114.009 1.115 . . . . 10.0 114.009 -176.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -27.48 122.17 0.06 OUTLIER Glycine 0 C--N 1.343 0.925 0 C-N-CA 128.291 2.853 . . . . 10.0 114.0 166.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.75 107.06 3.13 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 119.575 1.687 . . . . 10.0 113.185 169.082 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.457 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -146.28 173.13 12.52 Favored 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 123.368 0.667 . . . . 10.0 110.903 178.505 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.0 t -89.97 -41.99 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 113.624 -1.625 . . . . 10.0 113.107 -168.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 61.29 157.56 0.04 OUTLIER 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 126.145 1.778 . . . . 10.0 114.24 -174.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -72.64 -64.89 0.87 Allowed 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 113.996 -1.456 . . . . 10.0 111.176 -177.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -77.79 149.76 34.4 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.025 0.441 . . . . 10.0 110.214 -173.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.18 -11.47 54.34 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.124 -1.591 . . . . 10.0 109.124 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.92 158.04 0.74 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.58 1.181 . . . . 10.0 111.992 171.601 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -151.17 28.78 0.66 Allowed 'General case' 0 N--CA 1.434 -1.262 0 CA-C-N 113.745 -1.571 . . . . 10.0 112.026 166.158 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -59.12 -29.58 67.5 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 122.527 0.331 . . . . 10.0 110.425 173.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.56 -18.92 59.61 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 122.563 0.345 . . . . 10.0 111.302 176.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.42 82.08 0.27 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 110.923 -0.871 . . . . 10.0 110.923 -177.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m 33.56 58.18 0.53 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 127.499 2.32 . . . . 10.0 111.649 -177.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -136.06 -56.34 0.77 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 -170.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 t -126.3 43.78 3.01 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.015 -1.476 . . . . 10.0 107.015 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.82 65.15 1.34 Allowed 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 174.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.28 92.8 0.01 OUTLIER Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.816 1.198 . . . . 10.0 113.487 169.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -74.62 68.01 5.49 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 123.938 3.092 . . . . 10.0 113.374 -169.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.457 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 34.3 m170 65.34 77.13 0.31 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 128.52 2.728 . . . . 10.0 111.196 173.083 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -18.42 -60.72 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 128.504 2.722 . . . . 10.0 114.578 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.1 t30 4.49 86.55 0.04 OUTLIER Pre-proline 0 CA--C 1.54 0.577 0 C-N-CA 128.664 2.786 . . . . 10.0 114.676 -169.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -66.43 -35.9 28.9 Favored 'Trans proline' 0 N--CA 1.456 -0.701 0 C-N-CA 122.538 2.159 . . . . 10.0 111.551 -175.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.3 tt -74.25 66.74 1.32 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 108.181 -1.044 . . . . 10.0 108.181 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.7 t -31.86 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 127.467 2.307 . . . . 10.0 112.346 -174.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -131.06 170.0 15.11 Favored 'General case' 0 N--CA 1.444 -0.744 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -89.87 123.4 33.79 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 108.419 -0.956 . . . . 10.0 108.419 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 68.2 t60 -29.55 104.04 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 174.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.34 -170.33 12.68 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 108.503 -1.839 . . . . 10.0 108.503 176.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -135.08 -164.84 10.59 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-O 119.406 -0.664 . . . . 10.0 111.638 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -67.2 7.49 0.47 Allowed 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.042 1.828 . . . . 10.0 111.958 170.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -89.94 -29.27 18.61 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.787 -1.19 . . . . 10.0 107.787 169.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.67 177.69 4.57 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.396 1.079 . . . . 10.0 108.334 -168.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -110.99 -12.34 14.23 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.74 -1.118 . . . . 10.0 110.697 169.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -86.86 -0.67 56.87 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.051 0.94 . . . . 10.0 111.245 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -36.81 138.1 0.27 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 127.367 2.267 . . . . 10.0 112.217 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -82.13 60.86 5.11 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.073 -0.392 . . . . 10.0 110.05 -178.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.283 11.7 p 10.46 64.33 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 129.284 3.034 . . . . 10.0 114.507 -176.091 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.36 49.06 0.06 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 126.028 1.775 . . . . 10.0 109.583 -173.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -131.7 105.87 7.78 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 103.889 -2.634 . . . . 10.0 103.889 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -75.88 -13.32 60.26 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -166.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.37 -97.91 1.46 Allowed Glycine 0 C--O 1.219 -0.802 0 N-CA-C 108.006 -2.038 . . . . 10.0 108.006 -175.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -155.09 151.03 27.85 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 124.917 1.287 . . . . 10.0 108.599 -176.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.9 m -120.97 135.62 60.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 108.917 -0.771 . . . . 10.0 108.917 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -88.11 119.19 28.25 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 127.691 2.397 . . . . 10.0 110.594 -177.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.23 133.44 43.52 Favored 'General case' 0 CA--C 1.523 -0.095 0 C-N-CA 124.772 1.229 . . . . 10.0 111.064 176.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -61.02 169.57 1.93 Allowed 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.354 0.662 . . . . 10.0 110.146 168.243 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 -23.25 16.8 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.459 1.104 . . . . 10.0 112.898 170.055 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -17.69 60.8 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 110.29 -0.263 . . . . 10.0 110.29 177.215 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.8 13.89 66.14 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 110.524 -1.03 . . . . 10.0 110.524 -171.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.6 t -91.25 110.38 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.91 0 C-N-CA 126.973 2.109 . . . . 10.0 106.217 175.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.26 116.01 30.72 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 168.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -79.83 123.18 27.5 Favored 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 127.003 2.121 . . . . 10.0 108.09 171.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 29.6 t -108.41 129.06 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 106.86 -1.533 . . . . 10.0 106.86 178.39 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -155.97 64.09 0.58 Allowed 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.142 -1.058 . . . . 10.0 108.142 173.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 49.8 mt -102.13 153.47 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 N-CA-C 106.623 -1.621 . . . . 10.0 106.623 176.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -122.25 110.11 15.3 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.856 0.862 . . . . 10.0 110.75 176.246 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.23 129.18 37.25 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.212 1.005 . . . . 10.0 108.615 -177.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.2 t -119.05 44.83 2.23 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.134 0.974 . . . . 10.0 109.399 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -135.74 -43.09 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 124.05 0.94 . . . . 10.0 111.269 172.208 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.379 0.9 OUTLIER -87.46 161.01 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 CA-C-N 119.477 1.035 . . . . 10.0 111.956 169.948 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.0 m -151.93 106.83 3.25 Favored 'General case' 0 C--N 1.341 0.214 0 C-N-CA 123.997 0.919 . . . . 10.0 109.413 -172.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 36.4 mt -37.79 -38.02 0.27 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.141 2.176 . . . . 10.0 115.326 -174.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 57.3 m -144.83 56.31 1.26 Allowed 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.229 -1.026 . . . . 10.0 108.229 170.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.32 -63.11 1.67 Allowed Glycine 0 C--N 1.335 0.483 0 N-CA-C 109.099 -1.6 . . . . 10.0 109.099 174.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -167.67 -53.38 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.434 1.894 . . . . 10.0 107.141 -178.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.61 -45.6 36.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.266 -1.334 . . . . 10.0 107.896 -173.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.0 t 53.77 173.64 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 125.844 1.658 . . . . 10.0 112.443 -175.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.7 pt -130.54 20.44 2.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 126.008 1.723 . . . . 10.0 108.961 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.9 mm -70.37 140.13 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.268 0.627 . . . . 10.0 109.593 169.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.37 32.42 84.12 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.298 0.952 . . . . 10.0 113.177 173.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -106.25 176.08 5.29 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.968 1.707 . . . . 10.0 107.919 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -124.52 108.52 12.2 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.285 -1.006 . . . . 10.0 108.285 -178.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.7 mp -80.75 138.18 36.29 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 107.36 -1.348 . . . . 10.0 107.36 177.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 64.5 t -117.62 129.59 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.975 0 N-CA-C 105.939 -1.875 . . . . 10.0 105.939 -178.357 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -99.35 110.35 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 102.851 -3.018 . . . . 10.0 102.851 169.455 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 6.4 m170 -91.41 156.66 17.57 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 122.591 1.186 . . . . 10.0 113.492 -170.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.59 -52.92 20.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 126.688 1.995 . . . . 10.0 109.957 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -110.1 170.85 7.81 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 124.183 0.993 . . . . 10.0 112.306 -172.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.22 140.9 57.44 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 114.113 -1.403 . . . . 10.0 109.3 173.089 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.86 125.41 29.25 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 107.483 -1.302 . . . . 10.0 107.483 176.53 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -76.0 -9.74 58.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.761 0.425 . . . . 10.0 111.13 -177.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.6 mt 48.24 38.72 10.65 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.007 0.908 . . . . 10.0 109.924 -176.22 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.28 -15.29 63.6 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.707 1.622 . . . . 10.0 112.554 172.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ptpt -75.7 3.08 10.42 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.239 1.519 . . . . 10.0 112.716 -171.076 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.56 -22.13 76.48 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 169.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.1 35.9 50.49 Favored Glycine 0 CA--C 1.526 0.765 0 C-N-CA 123.89 0.757 . . . . 10.0 112.487 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -136.84 173.72 11.39 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 122.1 0.953 . . . . 10.0 110.058 175.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.6 tm-20 -46.08 -51.98 12.83 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.996 1.719 . . . . 10.0 111.221 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -73.05 -37.14 66.96 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.743 -0.598 . . . . 10.0 110.75 179.463 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -48.84 -43.5 38.67 Favored 'General case' 0 C--N 1.344 0.357 0 O-C-N 121.357 -0.84 . . . . 10.0 110.272 175.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -81.38 -5.3 57.73 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 119.147 -0.454 . . . . 10.0 111.65 -169.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.6 mtmt -114.15 -76.8 0.58 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.593 1.557 . . . . 10.0 110.726 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . 0.26 17.2 p -104.2 12.99 33.13 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 120.157 1.344 . . . . 10.0 113.042 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 28.9 69.12 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 119.351 0.978 . . . . 10.0 113.243 169.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 35.2 m120 49.57 21.25 0.59 Allowed 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 118.203 1.002 . . . . 10.0 113.003 -176.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.75 -6.34 36.82 Favored 'General case' 0 C--O 1.221 -0.43 0 O-C-N 121.491 -0.756 . . . . 10.0 111.542 -171.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.45 162.71 15.05 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 109.919 -1.272 . . . . 10.0 109.919 174.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.6 t -81.41 58.78 3.76 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.688 0.795 . . . . 10.0 111.094 -169.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 45.72 58.81 4.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.311 1.445 . . . . 10.0 112.941 169.571 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -69.15 -10.48 57.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 113.601 0.963 . . . . 10.0 113.601 -169.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -164.98 143.27 6.41 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.226 1.01 . . . . 10.0 108.584 172.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -157.01 166.3 33.72 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 122.83 0.452 . . . . 10.0 110.016 -172.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.53 158.25 29.7 Favored Glycine 0 C--N 1.332 0.34 0 N-CA-C 109.207 -1.557 . . . . 10.0 109.207 -178.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 30.5 t -105.91 137.5 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 106.823 -1.547 . . . . 10.0 106.823 -167.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.3 mt -75.85 125.35 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 118.161 0.437 . . . . 10.0 110.607 -176.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.06 149.52 18.13 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.59 1.09 . . . . 10.0 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.1 mt -56.35 137.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 124.305 1.042 . . . . 10.0 109.594 176.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.81 165.69 19.64 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 107.505 -1.295 . . . . 10.0 107.505 167.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 . . . . . 0 C--O 1.251 1.165 0 C-N-CA 124.997 1.319 . . . . 10.0 107.59 167.731 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 107.162 -1.421 . . . . 10.0 107.162 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.6 t -77.2 -48.52 17.39 Favored 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 119.137 0.88 . . . . 10.0 109.168 174.11 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.66 121.87 40.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 126.109 1.763 . . . . 10.0 107.441 -170.137 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -127.61 159.57 34.27 Favored 'General case' 0 CA--C 1.519 -0.249 0 C-N-CA 124.526 1.13 . . . . 10.0 109.239 177.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.1 t -117.41 156.15 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 123.761 0.824 . . . . 10.0 109.726 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.47 112.14 9.4 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.595 1.558 . . . . 10.0 108.514 169.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -94.11 106.11 17.68 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 C-N-CA 122.857 0.463 . . . . 10.0 110.845 171.443 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mt -86.82 127.67 35.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.396 1.079 . . . . 10.0 110.015 177.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -147.55 162.47 39.02 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.469 -1.308 . . . . 10.0 107.469 169.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.73 -53.71 0.08 OUTLIER Glycine 0 N--CA 1.461 0.303 0 C-N-CA 120.664 -0.779 . . . . 10.0 113.521 169.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -72.26 -44.04 63.43 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.461 -1.311 . . . . 10.0 107.461 -174.328 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.51 -70.88 0.4 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.149 -1.387 . . . . 10.0 110.073 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -57.34 -34.54 98.06 Favored 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 123.436 2.757 . . . . 10.0 111.366 172.078 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 73.8 t -64.58 109.78 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 108.386 -0.968 . . . . 10.0 108.386 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -129.03 118.21 22.17 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.33 1.052 . . . . 10.0 108.376 169.461 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.02 140.05 15.31 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 124.166 0.889 . . . . 10.0 111.373 173.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 9.4 mt -137.03 72.41 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 N-CA-C 106.4 -1.704 . . . . 10.0 106.4 -169.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mm -95.55 138.55 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 115.749 -0.659 . . . . 10.0 109.74 -170.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -114.48 117.89 32.26 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.139 1.775 . . . . 10.0 108.338 -179.289 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -102.51 107.45 18.42 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.872 -1.159 . . . . 10.0 107.872 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -108.12 122.49 47.0 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 114.949 1.463 . . . . 10.0 114.949 173.568 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -82.52 115.61 21.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 101.715 -3.439 . . . . 10.0 101.715 162.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mtpm? . . . . . 0 N--CA 1.45 -0.455 0 N-CA-C 109.979 -0.378 . . . . 10.0 109.979 -178.644 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.894 0 N-CA-C 108.93 -1.668 . . . . 10.0 108.93 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -68.28 145.05 64.66 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 N-CA-C 108.131 -1.527 . . . . 10.0 108.131 169.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.78 108.67 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 N-CA-C 104.966 -2.235 . . . . 10.0 104.966 169.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.7 mtpp -90.2 113.56 25.37 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 169.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -101.64 111.26 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 106.977 -1.49 . . . . 10.0 106.977 179.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.1 p90 -126.38 167.63 15.28 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.323 0.582 . . . . 10.0 112.069 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.64 -151.37 23.12 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 107.159 -2.377 . . . . 10.0 107.159 169.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 33.5 t -155.18 158.72 39.38 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 120.222 -0.591 . . . . 10.0 110.222 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pt -117.14 136.74 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 114.866 -1.061 . . . . 10.0 108.816 167.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 27.5 tptt -108.83 146.44 33.67 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 105.938 -1.875 . . . . 10.0 105.938 170.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.56 -7.07 39.07 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.421 -0.655 . . . . 10.0 113.71 169.524 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.07 175.04 2.22 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 118.348 1.074 . . . . 10.0 110.079 173.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -104.55 167.08 9.97 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 105.693 -1.965 . . . . 10.0 105.693 165.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 7.9 tm-20 -54.88 163.6 0.96 Allowed 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.904 0.881 . . . . 10.0 112.103 -169.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.36 -168.68 46.62 Favored Glycine 0 N--CA 1.445 -0.731 0 CA-C-O 122.012 0.785 . . . . 10.0 112.831 167.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -74.5 143.4 44.6 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.471 1.908 . . . . 10.0 110.606 -173.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -147.07 143.41 28.31 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 124.319 1.048 . . . . 10.0 112.27 -177.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -33.43 128.32 0.39 Allowed Glycine 0 C--N 1.339 0.73 0 C-N-CA 127.669 2.557 . . . . 10.0 112.351 168.279 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -149.74 110.86 4.38 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.09 -1.078 . . . . 10.0 108.09 166.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.04 170.82 16.93 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.437 0.637 . . . . 10.0 112.589 175.491 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 t -91.89 146.11 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 CA-C-N 112.143 -2.299 . . . . 10.0 106.966 169.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -129.41 147.1 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.29 1.436 . . . . 10.0 107.586 176.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.28 -68.06 0.22 Allowed 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.013 0.925 . . . . 10.0 110.6 -172.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -77.63 132.23 38.15 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.914 -1.143 . . . . 10.0 107.914 -169.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.07 -24.94 76.21 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 172.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.29 162.16 0.36 Allowed 'General case' 0 N--CA 1.447 -0.597 0 CA-C-O 123.031 1.396 . . . . 10.0 113.044 177.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.71 30.08 0.47 Allowed 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 114.185 -1.37 . . . . 10.0 111.759 172.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.4 -37.57 72.92 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.288 1.035 . . . . 10.0 112.535 -168.779 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.14 -21.17 54.53 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.014 0.525 . . . . 10.0 111.687 176.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.59 -155.83 16.06 Favored Glycine 0 N--CA 1.435 -1.372 0 N-CA-C 106.189 -2.765 . . . . 10.0 106.189 -166.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.43 54.33 0.44 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 127.214 2.206 . . . . 10.0 113.461 -168.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -161.24 -39.35 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 O-C-N 120.79 -1.194 . . . . 10.0 111.82 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 9.5 t -50.71 -30.28 13.43 Favored 'General case' 0 C--N 1.343 0.319 0 C-N-CA 124.307 1.043 . . . . 10.0 111.137 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.27 -36.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 127.247 2.219 . . . . 10.0 114.194 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.17 143.31 10.98 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 110.694 -0.962 . . . . 10.0 110.694 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -77.06 58.6 6.22 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 124.425 3.417 . . . . 10.0 112.882 -175.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.455 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 17.5 m170 61.0 48.85 6.16 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.738 2.415 . . . . 10.0 109.854 177.059 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -69.7 74.65 0.42 Allowed 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.931 0.872 . . . . 10.0 111.046 178.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -74.99 150.8 86.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 O-C-N 121.343 -0.848 . . . . 10.0 110.832 171.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -67.12 -45.11 4.21 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.631 2.221 . . . . 10.0 111.159 178.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.96 57.29 1.05 Allowed 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.53 0.732 . . . . 10.0 110.038 178.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 39.5 p -42.48 108.73 0.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.629 1.572 . . . . 10.0 110.935 -172.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 58.7 mtt180 -148.6 -172.08 4.01 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.792 -2.299 . . . . 10.0 104.792 -171.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -83.98 146.38 28.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 118.42 -1.312 . . . . 10.0 107.6 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -50.81 119.74 4.16 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 166.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.87 -134.66 4.34 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 108.103 -1.999 . . . . 10.0 108.103 177.051 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.53 -161.36 32.03 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 107.537 -2.225 . . . . 10.0 107.537 169.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -66.02 5.02 0.72 Allowed 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.519 1.479 . . . . 10.0 111.053 168.062 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.8 mtpm? -114.99 8.23 15.75 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.591 1.156 . . . . 10.0 111.412 172.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -126.04 169.16 13.03 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.018 -1.105 . . . . 10.0 108.018 165.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -89.45 -24.8 21.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.724 -0.843 . . . . 10.0 108.724 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -105.48 13.48 30.08 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 115.363 1.616 . . . . 10.0 115.363 -165.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -28.1 130.73 0.05 Allowed 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 127.547 2.339 . . . . 10.0 111.866 168.687 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -47.08 -68.38 0.2 Allowed 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.115 0.966 . . . . 10.0 110.83 -175.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.0 p -168.18 -50.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.193 0 N-CA-C 107.456 -1.313 . . . . 10.0 107.456 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.32 53.3 0.68 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.907 1.241 . . . . 10.0 110.504 179.279 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -91.84 92.91 8.58 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 105.817 -1.92 . . . . 10.0 105.817 169.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -73.67 -37.26 65.32 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.308 -1.738 . . . . 10.0 106.308 174.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.83 -104.28 2.73 Favored Glycine 0 N--CA 1.436 -1.328 0 N-CA-C 108.433 -1.867 . . . . 10.0 108.433 169.349 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -114.48 131.62 56.56 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.239 0.616 . . . . 10.0 110.191 -169.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -115.2 139.34 42.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 107.756 -1.202 . . . . 10.0 107.756 167.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -100.53 123.05 44.23 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 125.017 1.327 . . . . 10.0 110.244 -173.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.08 135.1 43.09 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 124.17 0.988 . . . . 10.0 110.514 179.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -58.99 168.8 1.18 Allowed 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.593 0.757 . . . . 10.0 110.213 167.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -50.58 -34.02 24.2 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.812 0.845 . . . . 10.0 110.767 169.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.0 t0 -79.37 0.71 28.03 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 120.859 0.361 . . . . 10.0 111.761 -178.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.25 13.83 82.36 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 120.733 -1.229 . . . . 10.0 110.695 177.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 45.2 t -89.73 103.33 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 C-N-CA 127.039 2.136 . . . . 10.0 106.29 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.66 120.92 41.1 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 168.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -81.45 117.64 22.05 Favored 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 126.479 1.911 . . . . 10.0 108.494 172.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 67.8 t -98.9 129.14 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.081 0 N-CA-C 106.553 -1.647 . . . . 10.0 106.553 175.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.8 p -157.91 68.29 0.5 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.678 0.791 . . . . 10.0 109.326 170.539 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.13 160.27 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.274 -1.75 . . . . 10.0 106.274 -177.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -135.7 148.01 48.72 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 121.755 -0.591 . . . . 10.0 111.055 169.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -133.14 160.98 35.65 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 125.408 1.483 . . . . 10.0 108.506 179.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.5 t -134.64 41.61 2.89 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.116 1.366 . . . . 10.0 111.933 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.8 p -132.43 -45.04 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 123.352 0.661 . . . . 10.0 110.315 167.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.06 154.16 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 121.843 0.83 . . . . 10.0 109.762 169.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.8 m -154.01 152.87 31.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.533 1.133 . . . . 10.0 108.458 168.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.87 -25.43 62.8 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.013 0.925 . . . . 10.0 110.137 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 16.2 t . . . . . 0 N--CA 1.453 -0.282 0 C-N-CA 124.456 1.102 . . . . 10.0 108.122 169.218 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t . . . . . 0 C--O 1.232 0.155 0 CA-C-O 121.484 0.659 . . . . 10.0 112.67 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 27.1 pt -63.17 -10.59 6.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 N-CA-C 113.984 1.105 . . . . 10.0 113.984 -169.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.7 mm -34.51 -45.71 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.271 0 C-N-CA 126.741 2.016 . . . . 10.0 114.833 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.78 14.43 57.53 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.363 0.982 . . . . 10.0 113.629 -173.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -90.68 175.89 6.86 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.688 1.195 . . . . 10.0 110.497 178.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -122.19 142.28 50.58 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 124.419 1.088 . . . . 10.0 109.747 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -101.5 154.96 18.37 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.248 -1.39 . . . . 10.0 107.248 168.032 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.11 137.54 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -106.2 138.22 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.269 -2.123 . . . . 10.0 105.269 168.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 5.0 m170 -117.83 160.33 21.57 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 114.763 1.394 . . . . 10.0 114.763 -169.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 68.1 tt0 -45.19 -53.72 7.84 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.597 2.759 . . . . 10.0 109.949 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.5 mttt -124.52 175.35 7.21 Favored 'General case' 0 CA--C 1.518 -0.27 0 C-N-CA 125.286 1.434 . . . . 10.0 110.273 -170.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.28 139.03 35.67 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.513 0.725 . . . . 10.0 109.168 175.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -78.12 148.1 34.33 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 123.326 0.65 . . . . 10.0 110.484 169.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -78.1 10.12 3.18 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 124.986 1.314 . . . . 10.0 111.196 174.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 16.5 mt 46.16 41.27 8.4 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.223 1.409 . . . . 10.0 110.829 -179.073 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 104.59 -39.76 2.71 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 125.233 1.397 . . . . 10.0 112.538 177.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.9 37.34 0.36 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.176 1.39 . . . . 10.0 111.769 -167.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -95.57 -12.07 54.35 Favored Glycine 0 CA--C 1.523 0.564 0 C-N-CA 125.568 1.556 . . . . 10.0 111.671 177.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.99 38.18 23.88 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 123.892 0.758 . . . . 10.0 111.779 -175.369 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -124.75 155.58 39.09 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.3 tm-20 -52.58 -44.24 65.79 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 114.123 -1.399 . . . . 10.0 108.353 169.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -65.05 -40.01 94.11 Favored 'General case' 0 CA--C 1.541 0.606 0 O-C-N 121.608 -0.683 . . . . 10.0 112.049 171.056 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 9.1 p -57.2 -40.67 77.91 Favored 'General case' 0 C--N 1.347 0.467 0 CA-C-N 121.141 1.791 . . . . 10.0 111.249 -179.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.1 t -72.97 -18.27 61.38 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 119.953 -0.699 . . . . 10.0 112.515 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -103.74 -50.65 3.36 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.14 1.776 . . . . 10.0 112.799 -168.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.455 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 24.1 p -120.92 -10.92 9.02 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 118.584 -0.722 . . . . 10.0 112.896 171.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 92.94 -1.57 71.0 Favored Glycine 0 C--N 1.337 0.636 0 CA-C-O 118.784 -1.009 . . . . 10.0 112.388 -172.13 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 71.12 31.76 2.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.596 1.198 . . . . 10.0 111.297 177.388 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.11 6.32 2.24 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.43 1.092 . . . . 10.0 112.209 174.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.87 -162.38 53.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.279 -1.128 . . . . 10.0 110.279 172.045 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.3 m -56.83 129.16 40.2 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-O 121.571 0.7 . . . . 10.0 111.388 -168.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.62 73.73 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.881 1.273 . . . . 10.0 109.259 169.751 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -74.09 -12.71 60.68 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 113.79 1.033 . . . . 10.0 113.79 -169.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.98 144.45 13.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.09 0.471 . . . . 10.0 111.795 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -138.28 151.43 47.6 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 126.507 1.923 . . . . 10.0 108.327 -169.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.36 142.28 9.07 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 179.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.3 t -102.87 137.12 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 105.672 -1.973 . . . . 10.0 105.672 -175.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 5.5 mt -72.19 158.06 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 108.939 -0.763 . . . . 10.0 108.939 -179.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -166.97 154.84 25.55 Favored Glycine 0 CA--C 1.528 0.888 0 O-C-N 122.007 -0.433 . . . . 10.0 112.247 -173.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 92.1 mt -68.19 131.41 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 124.882 1.273 . . . . 10.0 109.432 -174.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.81 -12.24 1.13 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 115.993 1.849 . . . . 10.0 115.993 -173.159 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.274 0.0 OUTLIER . . . . . 0 C--O 1.254 1.3 0 C-N-CA 128.774 2.83 . . . . 10.0 116.471 -170.171 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.829 0 N-CA-C 108.03 -1.1 . . . . 10.0 108.03 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -155.99 -43.73 0.08 Allowed 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.525 0.602 . . . . 10.0 111.247 171.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -118.79 130.49 55.81 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 169.076 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.89 163.24 26.78 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.751 1.221 . . . . 10.0 108.422 176.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 m -143.24 163.71 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 118.235 0.471 . . . . 10.0 109.873 -177.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.5 110.43 6.83 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.707 1.254 . . . . 10.0 108.048 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -82.61 119.88 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 N-CA-C 106.445 -1.687 . . . . 10.0 106.445 167.427 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.5 mt -98.52 135.51 39.97 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -157.54 159.72 37.45 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 120.564 1.529 . . . . 10.0 108.217 172.101 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 173.54 -40.32 0.14 Allowed Glycine 0 N--CA 1.461 0.304 0 C-N-CA 119.858 -1.163 . . . . 10.0 113.312 169.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -73.96 -47.3 38.44 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 107.589 -1.264 . . . . 10.0 107.589 -177.392 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.65 -73.08 0.31 Allowed Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.691 -1.364 . . . . 10.0 109.691 170.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -58.6 -39.6 81.35 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 123.126 2.551 . . . . 10.0 111.119 173.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.49 101.8 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 107.808 -1.182 . . . . 10.0 107.808 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -118.4 108.08 14.61 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 108.116 -1.068 . . . . 10.0 108.116 170.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.92 147.04 22.45 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 123.995 0.807 . . . . 10.0 111.556 169.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mt -140.72 82.2 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 N-CA-C 105.946 -1.872 . . . . 10.0 105.946 177.013 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.0 mm -89.92 138.96 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 C-N-CA 124.002 0.921 . . . . 10.0 108.956 177.161 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -130.47 126.65 37.46 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 125.693 1.597 . . . . 10.0 109.552 175.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -109.87 105.21 14.31 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.267 1.427 . . . . 10.0 109.368 177.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -86.26 134.32 33.77 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 120.034 -0.666 . . . . 10.0 110.81 167.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -135.07 82.84 1.98 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.642 2.377 . . . . 10.0 106.136 168.074 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.4 tttp -53.01 -51.03 62.97 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 125.793 1.637 . . . . 10.0 109.454 179.404 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 58.8 mt-10 -135.95 169.17 18.02 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 105.932 -1.877 . . . . 10.0 105.932 169.279 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.2 p -72.41 -10.0 59.24 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.992 -0.374 . . . . 10.0 109.992 170.098 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.5 m-80 -75.41 -24.79 57.17 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.519 -0.549 . . . . 10.0 109.519 170.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.33 129.0 9.3 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.29 -1.124 . . . . 10.0 110.29 -173.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -63.2 131.06 30.8 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 N-CA-C 105.957 -2.363 . . . . 10.0 105.957 168.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.2 t -78.0 107.88 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.154 -1.054 . . . . 10.0 108.154 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.62 96.39 3.55 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 170.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -83.6 106.61 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 N-CA-C 106.494 -1.669 . . . . 10.0 106.494 170.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.1 p90 -113.91 171.12 7.79 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.47 0.653 . . . . 10.0 109.901 172.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.94 170.11 41.09 Favored Glycine 0 N--CA 1.437 -1.256 0 C-N-CA 120.088 -1.053 . . . . 10.0 110.564 174.119 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.3 p -137.98 107.97 6.36 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 pt -90.8 145.22 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 167.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -140.05 147.58 40.54 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.37 -1.344 . . . . 10.0 107.37 175.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.25 -14.13 25.81 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.287 -0.729 . . . . 10.0 114.108 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.6 mp -74.27 179.48 4.49 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 118.692 1.246 . . . . 10.0 110.475 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -95.97 169.02 10.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 165.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -58.21 168.29 1.09 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.981 1.312 . . . . 10.0 111.532 -172.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.93 -176.61 36.31 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-O 122.039 0.8 . . . . 10.0 112.671 167.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.65 142.49 51.6 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 124.539 1.136 . . . . 10.0 109.681 177.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -142.05 150.42 41.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 112.896 0.702 . . . . 10.0 112.896 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -37.78 123.85 1.21 Allowed Glycine 0 C--N 1.34 0.786 0 C-N-CA 127.382 2.42 . . . . 10.0 112.061 166.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -151.88 108.5 3.47 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 118.563 1.181 . . . . 10.0 108.997 168.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 174.59 12.21 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 120.876 0.37 . . . . 10.0 111.354 177.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 11.1 m -104.77 -18.38 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 O-C-N 125.658 1.849 . . . . 10.0 114.676 -168.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 57.29 175.76 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 125.322 1.449 . . . . 10.0 112.861 -177.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -72.62 -69.45 0.41 Allowed 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.561 -0.745 . . . . 10.0 109.855 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -92.02 176.92 6.33 Favored 'General case' 0 N--CA 1.454 -0.256 0 O-C-N 123.534 0.521 . . . . 10.0 111.279 -168.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.12 -22.75 11.36 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 125.477 1.513 . . . . 10.0 111.556 170.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -50.81 117.9 2.79 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-O 122.343 1.068 . . . . 10.0 111.935 -177.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -123.14 17.84 9.96 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.988 -1.006 . . . . 10.0 111.552 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -48.42 -41.77 30.2 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.176 1.79 . . . . 10.0 111.562 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.11 -21.62 46.38 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.225 1.01 . . . . 10.0 112.763 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.0 102.31 0.92 Allowed Glycine 0 CA--C 1.527 0.825 0 N-CA-C 108.392 -1.883 . . . . 10.0 108.392 -169.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.276 1.5 p 15.75 80.42 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 127.031 2.132 . . . . 10.0 113.819 -173.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -161.38 -54.99 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 107.541 -1.281 . . . . 10.0 107.541 179.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -65.59 -31.38 72.38 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 123.8 0.84 . . . . 10.0 110.99 -177.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.97 -6.76 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 129.024 2.93 . . . . 10.0 118.012 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.36 123.26 3.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.212 -1.155 . . . . 10.0 110.212 176.183 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.7 60.49 6.67 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.582 2.855 . . . . 10.0 110.765 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.7 m170 72.12 38.28 0.9 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 129.716 3.206 . . . . 10.0 112.584 172.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -74.53 67.94 1.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.386 0.994 . . . . 10.0 111.671 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.7 p-10 -58.97 154.71 36.92 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 123.947 0.899 . . . . 10.0 111.108 169.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.36 -46.15 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 122.656 2.238 . . . . 10.0 111.602 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 86.8 mt -75.53 59.79 1.15 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.266 0.627 . . . . 10.0 109.696 176.134 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -45.95 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.771 1.628 . . . . 10.0 111.558 -171.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -132.21 -176.54 4.11 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 107.237 -1.394 . . . . 10.0 107.237 -176.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -93.78 123.74 37.33 Favored 'General case' 0 N--CA 1.438 -1.068 0 C-N-CA 118.224 -1.39 . . . . 10.0 108.622 -169.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -35.2 112.53 0.16 Allowed 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 113.316 0.858 . . . . 10.0 113.316 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.03 -136.98 4.33 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 108.058 -2.017 . . . . 10.0 108.058 -178.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.06 -168.77 30.66 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 173.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -63.26 -2.8 4.25 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.025 1.817 . . . . 10.0 111.603 168.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -94.97 -19.92 19.81 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.265 1.026 . . . . 10.0 110.746 173.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -103.11 167.58 9.73 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -86.49 -31.99 21.02 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 107.322 -1.362 . . . . 10.0 107.322 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.257 7.1 pt-20 -100.49 24.55 8.78 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 114.435 1.272 . . . . 10.0 114.435 -165.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.5 ptm180 -42.83 145.3 0.48 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 127.218 2.207 . . . . 10.0 110.346 168.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.9 m170 -67.61 -64.58 0.83 Allowed 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.52 0.676 . . . . 10.0 109.66 178.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.5 p -169.33 -91.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 105.472 -2.048 . . . . 10.0 105.472 173.358 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -80.51 56.32 4.7 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 111.04 -0.824 . . . . 10.0 111.04 174.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -90.9 83.16 5.64 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 103.342 -2.836 . . . . 10.0 103.342 166.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -65.26 -26.45 68.1 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 118.391 0.541 . . . . 10.0 109.821 -173.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 114.41 -89.08 0.5 Allowed Glycine 0 N--CA 1.44 -1.044 0 N-CA-C 108.082 -2.007 . . . . 10.0 108.082 169.428 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -155.52 124.82 6.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 -171.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.39 125.89 66.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 118.193 0.452 . . . . 10.0 110.84 178.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -78.82 112.01 15.54 Favored 'General case' 0 N--CA 1.444 -0.761 0 C-N-CA 127.554 2.341 . . . . 10.0 111.116 -177.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.74 134.79 34.16 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.863 0.465 . . . . 10.0 109.938 171.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -60.1 172.27 0.83 Allowed 'General case' 0 C--O 1.232 0.154 0 O-C-N 123.82 0.7 . . . . 10.0 109.441 168.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.5 pttm -48.67 -33.2 9.59 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.745 1.618 . . . . 10.0 109.793 173.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -79.1 -8.19 58.77 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 124.486 1.115 . . . . 10.0 110.812 -173.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.02 -0.26 86.01 Favored Glycine 0 C--N 1.338 0.678 0 N-CA-C 111.234 -0.746 . . . . 10.0 111.234 -174.247 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.5 t -78.43 105.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 106.776 -1.564 . . . . 10.0 106.776 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.23 117.47 34.12 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 169.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -80.37 118.05 21.67 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 127.123 2.169 . . . . 10.0 108.892 172.481 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.2 t -108.32 131.0 59.98 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.964 0 N-CA-C 106.862 -1.532 . . . . 10.0 106.862 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.2 p -157.36 86.81 0.95 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.455 0.702 . . . . 10.0 109.49 171.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.99 143.09 28.11 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 N-CA-C 107.991 -1.115 . . . . 10.0 107.991 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -111.61 129.5 56.06 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.816 -1.92 . . . . 10.0 105.816 167.069 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -140.54 117.69 11.26 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.5 p -87.15 49.42 1.81 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.891 1.676 . . . . 10.0 108.256 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 p -145.24 -51.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.478 -0.783 . . . . 10.0 109.433 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -51.11 132.36 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 122.926 0.49 . . . . 10.0 110.016 175.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.9 p -131.92 136.12 47.14 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.214 1.406 . . . . 10.0 108.551 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 50.1 mt -56.63 -42.69 79.3 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 169.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.8 t -146.07 128.88 16.3 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 149.54 69.4 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.771 -1.332 . . . . 10.0 109.771 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.7 t70 72.41 -60.25 0.53 Allowed 'General case' 0 CA--C 1.509 -0.633 0 C-N-CA 129.742 3.217 . . . . 10.0 109.482 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.7 m-70 -74.19 -44.71 52.3 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t 54.96 82.05 0.1 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.051 1.34 . . . . 10.0 111.714 173.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.5 pt -71.65 -18.16 19.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 O-C-N 120.999 -1.063 . . . . 10.0 112.699 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 16.2 mm -52.65 129.89 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 118.202 0.456 . . . . 10.0 110.156 172.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.58 22.57 77.06 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.684 -1.064 . . . . 10.0 113.644 175.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.9 mtt85 -89.08 175.75 7.26 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 118.235 1.018 . . . . 10.0 110.602 167.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -118.47 110.63 17.64 Favored 'General case' 0 C--N 1.347 0.486 0 N-CA-C 106.844 -1.539 . . . . 10.0 106.844 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mp -87.18 138.88 31.11 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.548 -0.908 . . . . 10.0 108.548 176.313 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 49.1 t -132.04 132.34 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.615 -1.254 . . . . 10.0 107.615 -173.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -105.67 128.11 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 106.081 -1.822 . . . . 10.0 106.081 174.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.6 m170 -111.78 157.55 20.42 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 114.554 1.316 . . . . 10.0 114.554 -171.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -46.64 -59.52 2.97 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 127.572 2.349 . . . . 10.0 110.488 176.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 51.3 mttp -112.21 169.86 8.57 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.702 0.763 . . . . 10.0 112.042 -170.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.5 151.08 47.95 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 114.034 -1.439 . . . . 10.0 109.291 172.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -77.03 150.04 35.81 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 122.296 1.046 . . . . 10.0 110.944 172.649 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . 0.436 ' HB3' ' CA ' ' A' ' 138' ' ' GLY . 4.4 t70 -79.04 -37.75 38.26 Favored 'General case' 0 N--CA 1.443 -0.824 0 C-N-CA 130.103 3.361 . . . . 10.0 110.596 172.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 48.5 mt 63.53 46.53 4.2 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.924 1.29 . . . . 10.0 111.656 178.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 79.64 10.24 86.0 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-N 115.23 -0.895 . . . . 10.0 114.703 167.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 26.8 mttm -97.06 -11.81 23.98 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 117.999 0.899 . . . . 10.0 112.18 -174.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.98 -21.45 69.68 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 125.124 1.345 . . . . 10.0 112.384 176.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.08 35.75 65.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.247 -0.741 . . . . 10.0 111.247 -177.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -129.89 169.94 14.56 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 173.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.444 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 40.9 tt0 -52.43 -48.0 66.03 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 123.654 0.781 . . . . 10.0 109.628 -178.413 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -58.98 -45.5 90.41 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 118.669 -0.682 . . . . 10.0 111.712 175.731 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.9 p -49.87 -43.59 49.32 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 109.206 -0.665 . . . . 10.0 109.206 177.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.1 t -84.3 -3.56 58.32 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -174.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.444 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 92.5 mttt -110.71 -69.58 0.86 Allowed 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.692 1.597 . . . . 10.0 111.85 -179.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -127.3 28.91 5.64 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 119.437 1.017 . . . . 10.0 109.935 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.436 ' CA ' ' HB3' ' A' ' 125' ' ' ASP . . . 66.84 -105.31 1.29 Allowed Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 107.519 -2.232 . . . . 10.0 107.519 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -157.3 42.6 0.33 Allowed 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 107.059 -1.46 . . . . 10.0 107.059 169.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.84 -12.38 53.87 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.606 0.762 . . . . 10.0 111.616 -175.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.81 -158.7 48.81 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.618 -1.393 . . . . 10.0 109.618 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.0 m -61.76 129.27 40.2 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 123.129 0.572 . . . . 10.0 111.599 -169.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -59.03 92.03 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.991 0.916 . . . . 10.0 109.661 169.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.4 mt -64.44 -41.58 96.49 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.444 -0.785 . . . . 10.0 111.309 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.0 148.89 28.26 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.731 0.301 . . . . 10.0 110.391 -172.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -124.24 146.68 48.58 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.679 1.591 . . . . 10.0 107.801 -169.426 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.85 156.65 27.03 Favored Glycine 0 CA--C 1.52 0.362 0 N-CA-C 108.545 -1.822 . . . . 10.0 108.545 168.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.8 t -119.69 134.91 61.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 -175.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.1 mt -75.66 138.44 20.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 CA-C-N 118.679 0.672 . . . . 10.0 111.014 -177.005 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -150.55 172.7 30.27 Favored Glycine 0 CA--C 1.53 0.984 0 N-CA-C 112.313 -0.315 . . . . 10.0 112.313 170.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 64.7 mt -72.79 142.4 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 125.194 1.397 . . . . 10.0 109.08 -169.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.98 -48.22 2.36 Favored 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 123.4 0.68 . . . . 10.0 111.301 172.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 . . . . . 0 C--O 1.248 1.009 0 CA-C-O 116.685 -1.626 . . . . 10.0 110.026 -167.969 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.694 0 N-CA-C 105.631 -1.989 . . . . 10.0 105.631 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.24 76.88 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 120.055 1.298 . . . . 10.0 108.278 168.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.37 158.0 32.09 Favored 'General case' 0 C--O 1.242 0.667 0 C-N-CA 124.481 1.112 . . . . 10.0 109.576 168.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.14 158.51 41.93 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 127.04 2.136 . . . . 10.0 106.078 169.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 m -111.44 178.67 1.25 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 CA-C-N 118.365 0.53 . . . . 10.0 109.601 174.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.24 101.63 2.4 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 165.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 32.2 m -92.33 130.75 40.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 N-CA-C 107.863 -1.162 . . . . 10.0 107.863 172.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -110.05 155.7 21.51 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.32 1.048 . . . . 10.0 108.641 176.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.0 tttt -164.2 167.99 19.41 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 169.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.2 -48.42 0.1 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.047 -1.549 . . . . 10.0 112.29 168.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -76.08 -46.63 28.04 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 107.893 -1.151 . . . . 10.0 107.893 -177.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.76 -67.2 0.52 Allowed Glycine 0 CA--C 1.526 0.775 0 CA-C-N 114.483 -1.235 . . . . 10.0 110.604 178.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -62.5 -36.2 66.84 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 122.794 2.329 . . . . 10.0 110.68 171.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 89.2 t -72.82 113.91 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.93 134.13 27.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.764 -0.458 . . . . 10.0 109.764 166.199 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.96 154.38 18.71 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 124.635 1.112 . . . . 10.0 111.269 175.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -153.31 81.5 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 -172.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -105.67 151.96 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 C-N-CA 125.216 1.407 . . . . 10.0 109.657 -175.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -126.17 118.4 25.13 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 127.199 2.199 . . . . 10.0 107.295 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -98.41 116.46 30.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 170.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -117.25 125.61 51.41 Favored 'General case' 0 N--CA 1.465 0.308 0 O-C-N 123.716 0.635 . . . . 10.0 112.61 169.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -81.34 106.49 13.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.404 -2.072 . . . . 10.0 105.404 169.079 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.0 tttt . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 124.869 1.268 . . . . 10.0 109.214 -171.497 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.995 0 N-CA-C 109.593 -1.403 . . . . 10.0 109.593 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -59.61 140.96 96.23 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.451 2.101 . . . . 10.0 108.292 174.085 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 p -79.89 103.56 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.537 0 N-CA-C 106.482 -1.673 . . . . 10.0 106.482 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.1 tttp -80.13 122.16 26.46 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 172.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.13 100.47 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 C-N-CA 127.566 2.346 . . . . 10.0 105.726 -178.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.8 p90 -125.56 155.71 40.24 Favored 'General case' 0 C--N 1.339 0.149 0 N-CA-C 112.986 0.735 . . . . 10.0 112.986 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.34 -145.86 13.68 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 106.383 -2.687 . . . . 10.0 106.383 173.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.5 p -157.35 168.16 28.18 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 118.798 -1.161 . . . . 10.0 111.998 177.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pt -117.72 146.46 22.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 114.379 -1.282 . . . . 10.0 109.44 166.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.7 tptt -115.11 146.51 41.27 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 106.464 -1.68 . . . . 10.0 106.464 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.96 -10.1 37.27 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-O 119.538 -0.59 . . . . 10.0 114.073 168.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -62.0 174.45 0.87 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 118.181 0.99 . . . . 10.0 110.561 175.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -108.72 160.7 15.75 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 106.595 -1.631 . . . . 10.0 106.595 167.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -53.72 150.57 7.12 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.61 0.764 . . . . 10.0 111.962 -169.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.51 -172.64 23.19 Favored Glycine 0 CA--C 1.524 0.629 0 C-N-CA 123.496 0.569 . . . . 10.0 111.922 169.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -74.95 149.93 39.23 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.272 1.429 . . . . 10.0 111.594 -173.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -150.97 143.62 24.4 Favored 'General case' 0 C--N 1.342 0.24 0 N-CA-C 113.912 1.079 . . . . 10.0 113.912 -175.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -31.72 126.21 0.23 Allowed Glycine 0 C--N 1.341 0.808 0 C-N-CA 128.247 2.832 . . . . 10.0 112.38 166.019 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.32 107.62 4.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 119.646 1.723 . . . . 10.0 109.887 167.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 176.54 9.75 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 109.718 -0.475 . . . . 10.0 109.718 174.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.4 m -117.71 -15.48 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 125.134 1.521 . . . . 10.0 113.662 -173.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 58.15 171.7 0.05 Allowed 'General case' 0 C--N 1.345 0.412 0 CA-C-O 122.437 1.113 . . . . 10.0 111.661 175.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -72.37 -59.39 2.75 Favored 'General case' 0 N--CA 1.441 -0.885 0 O-C-N 121.507 -0.746 . . . . 10.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -87.04 156.62 19.68 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 121.831 -0.543 . . . . 10.0 109.546 -171.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.72 14.42 29.53 Favored Glycine 0 CA--C 1.524 0.62 0 C-N-CA 125.179 1.371 . . . . 10.0 110.754 177.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.77 175.23 6.81 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 121.918 0.866 . . . . 10.0 110.03 179.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -151.81 33.02 0.55 Allowed 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.055 -0.975 . . . . 10.0 111.165 169.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.23 -37.2 79.6 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.593 -0.692 . . . . 10.0 112.763 -168.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.57 -20.55 46.73 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 117.766 0.257 . . . . 10.0 111.146 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 123.72 -157.59 18.17 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 105.727 -2.949 . . . . 10.0 105.727 -167.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 2.8 t -65.27 7.72 0.19 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.06 1.744 . . . . 10.0 115.189 -169.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 62.2 m -97.74 -49.09 4.96 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 125.93 1.692 . . . . 10.0 108.544 -171.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.1 m -47.41 -39.96 16.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 126.326 1.85 . . . . 10.0 113.061 -166.482 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.89 -39.92 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 128.067 2.547 . . . . 10.0 113.929 168.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.3 162.84 15.23 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 121.44 -0.787 . . . . 10.0 111.951 167.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -86.7 37.94 0.54 Allowed 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.375 2.717 . . . . 10.0 111.885 -172.418 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 71.31 116.38 0.05 OUTLIER 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.38 2.272 . . . . 10.0 110.834 -170.271 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . 0.462 ' N ' ' CD1' ' B' ' 64' ' ' PHE . 0.0 OUTLIER -33.8 94.06 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 127.089 2.156 . . . . 10.0 113.268 165.922 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -105.69 32.71 0.05 OUTLIER Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 116.948 2.203 . . . . 10.0 116.948 -177.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -62.82 -55.88 0.73 Allowed 'Trans proline' 0 C--N 1.35 0.658 0 CA-C-N 122.951 2.09 . . . . 10.0 112.585 -172.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.03 41.88 0.45 Allowed 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.236 -0.915 . . . . 10.0 112.86 -176.308 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 88.0 p 17.41 69.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 128.48 2.712 . . . . 10.0 114.868 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.72 149.17 43.64 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 105.801 -1.926 . . . . 10.0 105.801 172.634 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 30.6 mttm -101.64 106.23 17.26 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 118.746 -0.645 . . . . 10.0 109.637 -168.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -2.33 87.46 0.0 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 126.596 1.959 . . . . 10.0 115.193 -178.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.49 -135.33 8.72 Favored Glycine 0 C--N 1.318 -0.465 0 N-CA-C 109.045 -1.622 . . . . 10.0 109.045 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.68 -168.82 37.88 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 107.467 -2.253 . . . . 10.0 107.467 173.039 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -65.25 -0.72 3.7 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 CA-C-N 119.561 1.68 . . . . 10.0 110.749 167.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.7 mtpm? -109.24 6.79 24.96 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 125.924 1.689 . . . . 10.0 111.0 175.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.99 174.14 10.95 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 165.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.3 -37.01 38.76 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.1 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -81.71 28.59 0.41 Allowed 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 125.433 1.493 . . . . 10.0 114.626 -165.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.67 134.89 41.61 Favored 'General case' 0 N--CA 1.456 -0.141 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 168.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -56.17 -66.43 0.43 Allowed 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.664 -0.495 . . . . 10.0 109.664 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 3.9 p -169.23 -46.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 O-C-N 124.262 0.976 . . . . 10.0 109.132 -176.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.79 53.67 0.79 Allowed Glycine 0 CA--C 1.536 1.379 0 CA-C-N 118.909 0.777 . . . . 10.0 111.865 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -89.38 99.35 12.36 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.655 -1.239 . . . . 10.0 107.655 172.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -70.49 -40.96 73.29 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.289 -1.375 . . . . 10.0 107.289 174.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.02 -93.42 1.03 Allowed Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 124.409 1.004 . . . . 10.0 112.266 168.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -127.66 123.69 36.14 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 123.779 0.832 . . . . 10.0 109.992 -168.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.3 m -119.95 150.31 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 N-CA-C 108.536 -0.913 . . . . 10.0 108.536 167.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -98.24 125.34 43.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.859 1.663 . . . . 10.0 109.204 -177.285 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.27 134.45 38.03 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 108.804 -0.813 . . . . 10.0 108.804 171.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.42 ' CG ' ' HZ3' ' B' ' 91' ' ' LYS . 31.8 t0 -62.05 170.1 2.35 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 124.188 0.93 . . . . 10.0 109.565 167.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.42 ' HZ3' ' CG ' ' B' ' 90' ' ' ASP . 9.4 pttm -52.19 -31.26 30.9 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 125.213 1.405 . . . . 10.0 111.246 173.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -81.91 -1.76 48.97 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.218 0.607 . . . . 10.0 111.386 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.37 9.32 86.65 Favored Glycine 0 C--N 1.339 0.717 0 O-C-N 120.787 -1.195 . . . . 10.0 111.216 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.3 t -80.62 106.11 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 126.2 1.8 . . . . 10.0 106.32 172.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -107.39 120.15 41.36 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.096 -1.076 . . . . 10.0 108.096 169.119 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -80.96 125.5 30.22 Favored 'General case' 0 N--CA 1.437 -1.112 0 C-N-CA 127.233 2.213 . . . . 10.0 109.762 176.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.2 t -111.03 133.71 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.957 0 C-N-CA 125.645 1.578 . . . . 10.0 108.105 175.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 96.9 p -157.63 57.61 0.49 Allowed 'General case' 0 C--O 1.235 0.303 0 C-N-CA 123.141 0.576 . . . . 10.0 111.207 169.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -93.38 144.52 9.3 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.287 0 N-CA-C 107.395 -1.335 . . . . 10.0 107.395 -172.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -90.98 128.13 36.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 167.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -107.06 100.93 10.38 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.278 -1.749 . . . . 10.0 106.278 166.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.77 24.14 4.33 Favored 'General case' 0 N--CA 1.44 -0.957 0 C-N-CA 126.688 1.995 . . . . 10.0 109.948 176.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 38.9 t -120.74 -55.86 3.31 Favored 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 -178.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.348 0.6 OUTLIER -94.3 178.03 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 C-N-CA 123.839 0.856 . . . . 10.0 113.266 -179.039 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 27.1 m -155.4 161.4 41.02 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 123.785 0.834 . . . . 10.0 110.109 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 92.5 mt -81.25 3.92 22.25 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 125.721 1.608 . . . . 10.0 112.456 -175.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 107.845 -1.168 . . . . 10.0 107.845 168.937 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 42.3 t . . . . . 0 N--CA 1.442 -0.868 0 N-CA-C 110.503 -0.184 . . . . 10.0 110.503 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 1.3 pt -79.04 57.53 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 122.372 1.082 . . . . 10.0 110.806 -171.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 19.4 mm -96.21 -37.8 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 C-N-CA 127.725 2.41 . . . . 10.0 110.474 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.75 49.92 0.81 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.563 -1.015 . . . . 10.0 110.563 -175.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.57 169.52 8.65 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.864 2.065 . . . . 10.0 108.746 175.108 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -122.91 103.37 8.57 Favored 'General case' 0 C--N 1.344 0.353 0 C-N-CA 124.837 1.255 . . . . 10.0 109.955 -177.026 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -61.85 134.57 56.86 Favored 'General case' 0 CA--C 1.52 -0.183 0 N-CA-C 108.152 -1.055 . . . . 10.0 108.152 169.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.45 132.78 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 107.924 -1.139 . . . . 10.0 107.924 176.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 m -108.27 134.43 50.15 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 O-C-N 124.282 0.989 . . . . 10.0 110.366 167.415 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 6.3 m170 -110.54 158.0 19.03 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -171.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -40.22 -57.18 1.77 Allowed 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 129.272 3.029 . . . . 10.0 111.192 173.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 mttm -123.85 175.18 7.06 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.902 1.281 . . . . 10.0 109.495 -175.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.17 149.56 33.72 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.766 0.826 . . . . 10.0 109.708 175.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -74.92 152.84 38.81 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.78 -1.193 . . . . 10.0 107.78 168.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -76.15 -5.79 48.28 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 124.591 1.182 . . . . 10.0 110.719 171.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 50.5 mt 51.03 58.15 5.87 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 124.32 1.048 . . . . 10.0 108.798 -177.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.42 -39.44 3.12 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 124.93 1.252 . . . . 10.0 111.261 169.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.8 mtmt -79.13 47.19 0.76 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.211 1.004 . . . . 10.0 111.373 -178.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.57 -22.31 10.48 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 126.891 2.186 . . . . 10.0 111.298 174.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.18 44.41 43.06 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.055 0.836 . . . . 10.0 112.784 176.58 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -151.49 172.84 15.35 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 108.797 -0.816 . . . . 10.0 108.797 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -51.75 -41.53 61.65 Favored 'General case' 0 N--CA 1.445 -0.72 0 C-N-CA 122.96 0.504 . . . . 10.0 111.652 -176.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -71.59 -25.0 62.0 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.33 -0.856 . . . . 10.0 111.891 178.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 36.8 p -59.96 -20.8 59.54 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 113.61 0.967 . . . . 10.0 113.61 -177.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.4 t -94.75 -12.81 26.47 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.622 0.646 . . . . 10.0 110.258 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -109.32 -65.96 1.1 Allowed 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 126.7 2.0 . . . . 10.0 111.514 -171.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.02 31.4 3.87 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 120.266 1.394 . . . . 10.0 110.857 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 65.04 -93.57 0.16 Allowed Glycine 0 C--N 1.343 0.933 0 N-CA-C 108.859 -1.696 . . . . 10.0 108.859 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -164.43 39.73 0.08 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.709 1.204 . . . . 10.0 108.402 167.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.04 -11.84 58.21 Favored 'General case' 0 N--CA 1.456 -0.167 0 N-CA-C 113.637 0.977 . . . . 10.0 113.637 -168.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.44 -165.22 53.64 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.427 -1.069 . . . . 10.0 110.427 177.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.3 t -57.02 130.9 48.1 Favored 'General case' 0 N--CA 1.447 -0.611 0 C-N-CA 123.812 0.845 . . . . 10.0 112.217 -168.082 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -64.21 76.61 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.107 1.363 . . . . 10.0 110.171 170.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.8 mt -53.78 -36.9 62.91 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 112.735 0.643 . . . . 10.0 112.735 -177.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 148.4 28.29 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 109.884 -0.413 . . . . 10.0 109.884 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 p -155.54 132.85 10.93 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.2 1.0 . . . . 10.0 108.911 -169.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.88 -162.02 10.82 Favored Glycine 0 CA--C 1.52 0.382 0 C-N-CA 123.84 0.733 . . . . 10.0 111.973 -173.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 7.1 t -138.9 153.18 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 104.684 -2.339 . . . . 10.0 104.684 168.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.3 mt -67.49 -88.17 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 123.784 0.834 . . . . 10.0 110.409 -169.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.33 134.02 8.07 Favored Glycine 0 CA--C 1.534 1.235 0 O-C-N 121.64 -0.662 . . . . 10.0 112.326 178.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 88.5 mt -72.31 144.97 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 125.143 1.377 . . . . 10.0 109.529 -176.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -124.21 -50.53 1.79 Allowed 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.974 0.909 . . . . 10.0 110.633 176.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 . . . . . 0 C--O 1.25 1.104 0 C-N-CA 125.011 1.324 . . . . 10.0 112.688 -171.931 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.1 t -104.55 -11.11 17.16 Favored 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.921 1.288 . . . . 10.0 110.605 -178.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 15.5 ptmt -155.22 160.77 41.1 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.76 168.44 22.93 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 126.871 2.068 . . . . 10.0 108.778 -177.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 m -126.37 169.23 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 C-N-CA 123.038 0.535 . . . . 10.0 110.825 175.261 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.51 107.68 6.07 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 107.132 -1.433 . . . . 10.0 107.132 165.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -87.26 95.13 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 C-N-CA 123.549 0.74 . . . . 10.0 109.008 173.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -78.76 126.18 30.37 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 107.888 -1.153 . . . . 10.0 107.888 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.4 mptt -146.87 155.15 42.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 168.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.18 -65.91 0.03 OUTLIER Glycine 0 N--CA 1.46 0.272 0 C-N-CA 118.842 -1.646 . . . . 10.0 112.925 169.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -71.66 -43.74 65.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 107.205 -1.406 . . . . 10.0 107.205 -177.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 148.37 -71.1 0.32 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 114.324 -1.307 . . . . 10.0 111.351 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -56.71 -37.69 97.27 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 122.87 2.38 . . . . 10.0 112.078 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 m -72.23 87.19 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 108.529 -0.915 . . . . 10.0 108.529 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -104.19 108.36 19.69 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.097 -1.816 . . . . 10.0 106.097 -178.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.47 141.13 15.43 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.036 -0.826 . . . . 10.0 111.036 172.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.515 ' CG2' HG21 ' B' ' 54' ' ' THR . 9.0 mt -139.37 81.83 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 -177.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -90.87 146.83 5.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 C-N-CA 123.529 0.732 . . . . 10.0 109.509 175.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -129.0 114.42 16.39 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.6 2.36 . . . . 10.0 107.331 177.199 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -93.74 115.65 28.08 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 172.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -117.87 137.8 52.54 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.804 0.729 . . . . 10.0 111.507 168.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -134.19 91.79 2.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.266 2.226 . . . . 10.0 106.235 -178.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -51.26 -38.66 53.86 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 125.581 1.552 . . . . 10.0 112.473 -168.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -152.23 -179.22 7.34 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 105.803 -1.925 . . . . 10.0 105.803 171.426 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.9 p -72.18 -18.96 61.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 118.14 0.427 . . . . 10.0 110.074 -178.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -83.81 -17.31 41.46 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 124.224 1.01 . . . . 10.0 109.438 175.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.63 147.84 30.01 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.647 -0.981 . . . . 10.0 110.647 175.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.26 170.99 15.85 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.443 2.095 . . . . 10.0 108.682 168.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.1 t -87.33 104.92 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 106.197 -1.779 . . . . 10.0 106.197 170.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -84.88 113.99 21.78 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 104.784 -2.302 . . . . 10.0 104.784 168.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.17 98.78 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.023 -1.473 . . . . 10.0 107.023 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.3 p90 -113.16 179.9 3.83 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.893 0.378 . . . . 10.0 110.705 174.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.74 -154.53 22.68 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.701 -2.16 . . . . 10.0 107.701 168.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 61.3 p -155.36 155.41 33.61 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 118.678 -1.209 . . . . 10.0 112.304 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.69 135.8 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 C-N-CA 126.229 1.812 . . . . 10.0 107.031 171.474 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -121.3 150.04 42.01 Favored 'General case' 0 CA--C 1.528 0.105 0 N-CA-C 107.354 -1.35 . . . . 10.0 107.354 170.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.77 -21.54 18.41 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-N 119.146 0.884 . . . . 10.0 114.161 175.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.5 mt -62.94 179.52 0.37 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 125.29 1.436 . . . . 10.0 111.652 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -103.75 175.54 5.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.777 -1.102 . . . . 10.0 108.107 166.092 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -64.28 169.73 4.36 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.054 0.942 . . . . 10.0 111.765 -171.054 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.76 -173.73 28.48 Favored Glycine 0 C--O 1.223 -0.583 0 C-N-CA 124.347 0.975 . . . . 10.0 111.841 167.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.88 148.73 47.48 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.854 0.862 . . . . 10.0 109.107 169.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.1 m-70 -141.53 143.46 33.78 Favored 'General case' 0 C--N 1.34 0.18 0 N-CA-C 113.718 1.007 . . . . 10.0 113.718 -177.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -18.14 116.41 0.01 OUTLIER Glycine 0 C--N 1.339 0.721 0 C-N-CA 129.104 3.24 . . . . 10.0 115.061 163.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -149.41 98.32 2.77 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 120.208 2.004 . . . . 10.0 114.609 174.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.464 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -144.85 170.85 15.34 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.649 0.78 . . . . 10.0 112.16 178.664 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.4 t -105.5 -28.09 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 128.355 2.662 . . . . 10.0 112.827 -168.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.5 m-70 63.03 176.08 0.15 Allowed 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.586 1.154 . . . . 10.0 112.451 178.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -92.47 -64.83 1.06 Allowed 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.582 -0.736 . . . . 10.0 110.855 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -79.21 148.92 32.08 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 119.174 -1.01 . . . . 10.0 109.615 -176.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.0 -25.71 33.56 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 109.797 -1.321 . . . . 10.0 109.797 169.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -62.06 166.57 4.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 123.093 1.425 . . . . 10.0 112.897 -176.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.56 21.55 0.1 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.482 -1.235 . . . . 10.0 113.137 -169.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -52.44 -35.23 51.78 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 124.797 1.239 . . . . 10.0 111.823 -176.556 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.05 -19.79 53.62 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 122.892 0.477 . . . . 10.0 112.138 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.84 107.0 1.22 Allowed Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.741 -1.343 . . . . 10.0 109.741 -172.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.1 m 34.75 59.91 0.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.357 1.863 . . . . 10.0 112.046 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.5 m -153.77 -54.24 0.11 Allowed 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.577 -0.897 . . . . 10.0 108.577 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -51.19 -39.5 56.62 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.857 1.263 . . . . 10.0 110.768 -173.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -29.67 -38.51 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 128.526 2.73 . . . . 10.0 114.786 168.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.49 131.63 6.65 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.125 -1.19 . . . . 10.0 110.125 172.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.94 64.78 3.29 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.531 2.821 . . . . 10.0 112.36 174.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.491 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 11.6 m170 69.86 38.09 1.68 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 128.527 2.731 . . . . 10.0 111.926 168.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -73.19 26.64 0.06 Allowed 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 115.372 1.619 . . . . 10.0 115.372 -170.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -46.22 150.72 1.05 Allowed Pre-proline 0 CA--C 1.54 0.558 0 C-N-CA 125.0 1.32 . . . . 10.0 112.703 -170.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -52.88 -52.86 7.87 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.087 2.524 . . . . 10.0 112.348 -173.28 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -77.06 61.14 1.97 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.9 -0.778 . . . . 10.0 108.9 169.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.4 t -60.02 113.99 2.61 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 106.877 -1.527 . . . . 10.0 106.877 178.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.68 -81.13 0.41 Allowed 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 109.41 -0.589 . . . . 10.0 109.41 -175.227 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -145.53 150.67 36.85 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-O 122.31 1.053 . . . . 10.0 110.91 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 52.8 t60 -64.69 117.88 8.1 Favored 'General case' 0 N--CA 1.447 -0.623 0 C-N-CA 119.146 -1.021 . . . . 10.0 108.642 166.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.97 -132.45 2.58 Favored Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 107.465 -2.254 . . . . 10.0 107.465 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.1 -160.79 24.62 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 109.13 -1.588 . . . . 10.0 109.13 177.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -60.75 -6.91 6.52 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.767 1.645 . . . . 10.0 110.973 167.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -85.21 -27.54 26.03 Favored 'General case' 0 N--CA 1.445 -0.68 0 C-N-CA 124.529 1.132 . . . . 10.0 109.942 175.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -106.63 154.83 20.34 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.938 -1.134 . . . . 10.0 107.938 -173.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -85.37 -24.69 27.47 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 115.073 -0.967 . . . . 10.0 109.052 169.039 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -101.39 14.39 32.12 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.585 0.587 . . . . 10.0 112.585 -173.37 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -43.1 149.72 0.2 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.19 2.196 . . . . 10.0 110.181 171.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -77.46 48.86 0.68 Allowed 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.2 -0.937 . . . . 10.0 112.61 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 26.0 t 33.66 49.38 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 126.099 1.759 . . . . 10.0 110.561 -177.375 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.47 42.55 0.03 OUTLIER Glycine 0 CA--C 1.532 1.156 0 CA-C-N 116.11 -0.495 . . . . 10.0 114.014 -169.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -118.01 111.87 19.51 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 104.466 -2.42 . . . . 10.0 104.466 168.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.8 mt -79.51 -29.92 41.7 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 119.75 1.159 . . . . 10.0 108.783 174.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.49 -83.82 0.36 Allowed Glycine 0 C--O 1.221 -0.683 0 N-CA-C 111.22 -0.752 . . . . 10.0 111.22 167.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -155.64 143.5 19.78 Favored 'General case' 0 CA--C 1.517 -0.318 0 N-CA-C 107.909 -1.145 . . . . 10.0 107.909 -176.125 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -130.93 135.24 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 O-C-N 123.68 0.612 . . . . 10.0 110.299 174.353 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -79.31 108.46 12.84 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 127.232 2.213 . . . . 10.0 111.849 -175.024 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.54 130.17 35.3 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.21 1.404 . . . . 10.0 111.036 173.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -59.6 168.53 1.61 Allowed 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 124.311 1.007 . . . . 10.0 109.984 167.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -53.97 -29.83 44.5 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.754 0.821 . . . . 10.0 112.023 171.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.79 -3.57 42.03 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.033 0.382 . . . . 10.0 112.033 177.366 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.18 3.88 88.59 Favored Glycine 0 C--N 1.337 0.601 0 O-C-N 120.971 -1.08 . . . . 10.0 111.53 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.83 97.73 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 106.673 -1.603 . . . . 10.0 106.673 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.23 121.94 42.77 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 169.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -96.13 127.37 42.08 Favored 'General case' 0 C--N 1.329 -0.292 0 O-C-N 124.118 0.886 . . . . 10.0 109.377 174.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.7 t -108.81 139.53 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 C-N-CA 126.789 2.035 . . . . 10.0 108.934 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 95.4 p -156.39 70.35 0.66 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.694 1.198 . . . . 10.0 110.204 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 8.6 mm -106.53 167.45 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 C-N-CA 125.143 1.377 . . . . 10.0 109.303 -174.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 66.3 tt0 -155.35 123.16 5.71 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 127.224 2.21 . . . . 10.0 108.487 -170.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -155.74 158.23 37.85 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 104.37 -2.456 . . . . 10.0 104.37 173.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 15.1 p -106.14 -19.56 13.68 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 126.301 1.841 . . . . 10.0 111.751 -177.311 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 70.4 t -77.05 -38.68 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 -169.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.292 0.0 OUTLIER -76.19 54.43 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 C-N-CA 124.356 1.063 . . . . 10.0 112.3 178.677 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.93 145.03 52.21 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.229 1.012 . . . . 10.0 111.329 -169.774 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 76.0 mt -47.62 -52.84 16.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.352 0.596 . . . . 10.0 110.478 176.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.3 m -150.44 158.43 44.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 125.28 1.432 . . . . 10.0 107.354 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.9 -67.8 0.25 Allowed Glycine 0 C--N 1.335 0.492 0 N-CA-C 109.609 -1.396 . . . . 10.0 109.609 -176.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -155.82 -53.16 0.09 Allowed 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 126.904 2.082 . . . . 10.0 106.315 178.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.1 -37.62 64.09 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 114.197 -1.365 . . . . 10.0 108.771 -173.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.6 t 47.57 91.6 0.01 OUTLIER 'General case' 0 C--O 1.232 0.182 0 C-N-CA 127.112 2.165 . . . . 10.0 113.872 168.123 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 17.6 pt -68.13 -27.34 36.87 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 119.956 -0.697 . . . . 10.0 111.78 174.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -49.79 126.32 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 119.584 1.084 . . . . 10.0 109.911 175.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.74 14.68 79.35 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-O 118.457 -1.191 . . . . 10.0 114.424 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.8 mmt-85 -84.27 -179.46 7.2 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.092 1.357 . . . . 10.0 109.084 166.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -136.9 104.23 5.41 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -179.451 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.434 ' CD1' HD11 ' A' ' 149' ' ' ILE . 8.9 mp -72.82 146.08 46.53 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 108.3 -1.0 . . . . 10.0 108.3 173.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.2 t -129.04 131.89 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.18 0 N-CA-C 107.17 -1.419 . . . . 10.0 107.17 175.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.7 p -99.69 136.93 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 106.837 -1.542 . . . . 10.0 106.837 168.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 14.4 m-70 -114.74 160.7 19.09 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 114.516 1.302 . . . . 10.0 114.516 -173.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -60.39 -60.12 4.32 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 114.847 -1.07 . . . . 10.0 108.638 173.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -90.38 164.76 14.19 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.735 -0.786 . . . . 10.0 112.007 -170.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.47 147.76 37.66 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 106.951 -1.499 . . . . 10.0 106.951 169.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -98.41 141.22 31.56 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 123.546 0.739 . . . . 10.0 109.441 -169.314 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 -72.32 -20.86 61.42 Favored 'General case' 0 N--CA 1.46 0.061 0 CA-C-O 120.822 0.344 . . . . 10.0 110.705 -173.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.5 mt 55.21 42.54 30.43 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 -167.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.98 -15.46 62.96 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 126.494 1.997 . . . . 10.0 113.194 171.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -76.88 -2.24 32.52 Favored 'General case' 0 CA--C 1.535 0.381 0 N-CA-C 114.443 1.275 . . . . 10.0 114.443 -167.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.17 -16.25 64.28 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 118.562 0.619 . . . . 10.0 111.983 174.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.01 40.89 67.2 Favored Glycine 0 CA--C 1.527 0.824 0 CA-C-N 117.981 0.89 . . . . 10.0 110.983 -178.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -128.3 161.91 28.29 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.477 -1.675 . . . . 10.0 106.477 177.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -53.34 -50.14 65.62 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.269 -1.382 . . . . 10.0 107.269 169.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -52.95 -44.25 66.95 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 115.382 -0.827 . . . . 10.0 112.11 172.494 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 23.1 p -57.4 -39.14 75.5 Favored 'General case' 0 N--CA 1.445 -0.677 0 O-C-N 120.449 -1.407 . . . . 10.0 110.763 -178.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.1 t -85.98 6.26 29.53 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 111.731 0.271 . . . . 10.0 111.731 -179.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 27.7 mmtp -106.75 -84.86 0.51 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.708 1.603 . . . . 10.0 109.241 171.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.491 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 2.9 p -95.47 -12.22 26.23 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 121.242 1.837 . . . . 10.0 112.841 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 80.58 32.97 32.34 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -168.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 53.69 44.69 29.33 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.376 1.088 . . . . 10.0 111.103 -178.06 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.13 -2.49 13.14 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.38 0.672 . . . . 10.0 112.256 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 94.95 -67.01 1.28 Allowed Glycine 0 C--N 1.336 0.556 0 O-C-N 120.921 -1.112 . . . . 10.0 111.215 169.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -166.89 175.21 7.86 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 -178.375 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -105.86 98.93 8.56 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.414 1.886 . . . . 10.0 106.981 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.437 ' N ' ' CD2' ' A' ' 144' ' ' LEU . 0.6 OUTLIER -84.93 -25.22 28.0 Favored 'General case' 0 C--O 1.232 0.178 0 C-N-CA 122.956 0.502 . . . . 10.0 110.963 -167.856 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 139.29 10.96 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.582 -0.896 . . . . 10.0 108.582 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 97.1 m -118.99 144.79 46.3 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.472 1.509 . . . . 10.0 107.657 -177.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.64 134.27 5.39 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.695 -0.962 . . . . 10.0 110.695 173.409 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -95.63 134.0 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 106.958 -1.497 . . . . 10.0 106.958 -170.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.434 HD11 ' CD1' ' A' ' 117' ' ' LEU . 9.4 mt -76.49 115.84 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 N-CA-C 110.517 -0.179 . . . . 10.0 110.517 -168.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.89 136.91 13.83 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.033 0.825 . . . . 10.0 111.515 -175.336 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 68.8 mt -54.7 138.44 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 C-N-CA 125.67 1.588 . . . . 10.0 108.433 173.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.57 -47.75 1.96 Allowed 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 123.265 0.626 . . . . 10.0 111.02 176.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.952 -1.975 . . . . 10.0 113.148 -174.245 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.923 0 CA-C-O 116.423 -1.751 . . . . 10.0 107.306 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . 0.254 1.9 t -141.0 -49.46 0.43 Allowed 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 120.493 1.497 . . . . 10.0 113.072 174.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -103.4 129.56 50.52 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 107.833 -1.173 . . . . 10.0 107.833 169.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.3 158.12 44.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 169.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.8 m -121.02 172.66 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.159 0 CA-C-N 117.89 0.314 . . . . 10.0 110.168 175.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.2 98.56 3.76 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.342 -1.355 . . . . 10.0 107.342 167.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 13.2 m -83.39 104.89 12.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.256 -1.016 . . . . 10.0 108.256 169.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.5 mt -92.71 145.2 24.6 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.011 -0.737 . . . . 10.0 109.011 -177.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 46.0 tttt -160.46 161.07 32.79 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 173.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.27 -51.01 0.05 OUTLIER Glycine 0 C--O 1.228 -0.271 0 CA-C-N 116.347 -0.388 . . . . 10.0 112.272 169.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.7 -45.78 34.87 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 -170.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.08 -67.85 0.54 Allowed Glycine 0 N--CA 1.442 -0.934 0 CA-C-N 113.672 -1.603 . . . . 10.0 110.292 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -56.25 -42.87 61.64 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.547 2.165 . . . . 10.0 110.543 171.117 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -63.66 114.13 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 -179.351 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.0 121.01 28.75 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.665 -1.605 . . . . 10.0 106.665 168.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -97.65 144.08 17.09 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 168.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 mt -144.2 71.29 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.097 -1.446 . . . . 10.0 107.097 -176.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -94.1 141.58 14.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 O-C-N 122.042 -0.411 . . . . 10.0 109.938 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.7 m-80 -110.46 128.05 55.42 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 126.034 1.733 . . . . 10.0 109.48 171.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -109.4 98.01 7.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 174.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -105.24 124.18 49.09 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.599 0.714 . . . . 10.0 112.34 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 tt0 -91.36 99.18 12.19 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.201 1.801 . . . . 10.0 108.241 176.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.3 tttt . . . . . 0 N--CA 1.441 -0.887 0 C-N-CA 126.956 2.102 . . . . 10.0 110.17 179.857 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.68 0 N-CA-C 108.78 -1.728 . . . . 10.0 108.78 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -62.71 141.04 83.9 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 N-CA-C 108.097 -1.54 . . . . 10.0 108.097 170.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.4 t -87.19 109.39 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 105.322 -2.103 . . . . 10.0 105.322 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -76.93 113.18 14.35 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.645 -1.983 . . . . 10.0 105.645 168.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.47 102.19 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 171.088 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -120.73 154.71 35.25 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.202 0.525 . . . . 10.0 112.039 176.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.28 -168.59 36.58 Favored Glycine 0 N--CA 1.444 -0.831 0 N-CA-C 109.616 -1.393 . . . . 10.0 109.616 169.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.8 p -144.78 113.26 6.62 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 109.061 -0.718 . . . . 10.0 109.061 -169.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.4 pt -78.79 170.7 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.063 -1.088 . . . . 10.0 108.063 167.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -154.13 154.35 33.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.343 -0.984 . . . . 10.0 108.343 166.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.35 -15.62 32.6 Favored Glycine 0 CA--C 1.525 0.677 0 CA-C-O 119.139 -0.812 . . . . 10.0 114.08 177.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.7 mp -71.91 -179.21 2.62 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 118.757 1.278 . . . . 10.0 110.918 177.064 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -101.51 175.34 5.6 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.54 -0.911 . . . . 10.0 108.54 166.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -51.07 164.57 0.15 Allowed 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.23 2.212 . . . . 10.0 113.214 -173.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.76 -170.68 55.04 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 124.16 0.886 . . . . 10.0 114.008 165.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.96 141.76 54.86 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.127 1.771 . . . . 10.0 111.798 -175.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.4 m-70 -138.58 123.89 19.31 Favored 'General case' 0 C--N 1.339 0.115 0 C-N-CA 125.013 1.325 . . . . 10.0 109.847 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.42 127.83 1.75 Allowed Glycine 0 C--N 1.346 1.086 0 C-N-CA 126.839 2.161 . . . . 10.0 109.637 171.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.414 ' CZ ' ' HB3' ' B' ' 84' ' ' LEU 0.274 0.3 OUTLIER -145.67 123.82 12.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 119.041 1.42 . . . . 10.0 112.406 168.139 . . . . . . . . 4 4 . 1 . 015 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.429 ' NE2' ' OD2' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -160.33 175.64 12.6 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.573 -0.74 . . . . 10.0 111.719 -174.264 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.2 m -88.72 153.43 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 O-C-N 125.697 1.873 . . . . 10.0 107.807 167.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 64.6 m-70 -134.72 95.04 3.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 108.329 -0.989 . . . . 10.0 108.329 177.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 24.43 -87.54 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 127.228 2.211 . . . . 10.0 114.24 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -78.87 161.76 26.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 122.734 1.254 . . . . 10.0 111.883 -169.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.44 -32.53 57.68 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 108.261 -1.936 . . . . 10.0 108.261 169.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -39.48 150.74 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 125.978 1.711 . . . . 10.0 113.929 176.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -157.17 21.17 0.3 Allowed 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 113.882 -1.508 . . . . 10.0 113.081 178.527 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.515 HG21 ' CG2' ' A' ' 17' ' ' ILE . 6.0 m -41.69 -48.7 4.2 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.512 1.125 . . . . 10.0 113.093 -167.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.09 -25.36 47.53 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.891 0.876 . . . . 10.0 112.859 -176.393 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.17 104.15 2.6 Favored Glycine 0 CA--C 1.528 0.905 0 N-CA-C 109.544 -1.422 . . . . 10.0 109.544 -169.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 17.9 m 49.72 48.51 21.49 Favored 'General case' 0 N--CA 1.462 0.165 0 C-N-CA 125.474 1.51 . . . . 10.0 112.757 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -154.51 -55.86 0.1 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.6 m -50.56 -43.62 56.3 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.496 1.118 . . . . 10.0 111.45 -171.045 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.84 -51.47 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 128.005 2.522 . . . . 10.0 114.033 168.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.08 162.74 11.52 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.603 -1.399 . . . . 10.0 109.603 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -71.71 -164.68 0.17 Allowed 'Trans proline' 0 N--CA 1.447 -1.232 0 N-CA-C 105.019 -2.723 . . . . 10.0 105.019 163.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.43 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 34.1 m170 -81.47 53.55 2.12 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 119.288 -2.132 . . . . 10.0 109.72 -176.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -69.91 88.22 0.56 Allowed 'General case' 0 C--O 1.225 -0.225 0 CA-C-O 122.984 1.373 . . . . 10.0 109.383 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.9 p30 -96.34 151.2 37.95 Favored Pre-proline 0 C--N 1.325 -0.463 0 C-N-CA 127.236 2.214 . . . . 10.0 110.605 -176.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.4 -42.88 4.82 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.803 2.335 . . . . 10.0 111.282 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 77.0 mt -77.89 55.03 1.35 Allowed 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.829 0.852 . . . . 10.0 110.587 -178.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -38.28 101.77 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 126.752 2.021 . . . . 10.0 112.063 -171.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -140.38 -175.79 4.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.361 -1.348 . . . . 10.0 107.361 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -94.26 127.67 40.26 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -178.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -36.87 113.26 0.23 Allowed 'General case' 0 C--O 1.225 -0.207 0 O-C-N 123.639 0.587 . . . . 10.0 112.035 176.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.09 -137.09 5.65 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 177.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 168.44 -153.72 22.98 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.487 -2.245 . . . . 10.0 107.487 169.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -64.27 6.64 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.939 0 CA-C-N 120.635 2.217 . . . . 10.0 112.346 169.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.413 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.0 mmmt -121.4 12.26 10.84 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 126.978 2.111 . . . . 10.0 110.287 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . 0.406 ' CG ' ' HZ1' ' B' ' 128' ' ' LYS . 2.1 m-20 -151.73 158.01 42.8 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 118.945 0.793 . . . . 10.0 108.919 168.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -79.39 -26.69 41.9 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 173.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -79.81 5.79 12.71 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 124.671 1.189 . . . . 10.0 112.82 -169.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt180 -35.23 120.75 0.55 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.796 1.639 . . . . 10.0 110.571 168.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.8 m170 -52.32 -53.55 43.0 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.506 1.122 . . . . 10.0 112.566 -170.057 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -178.03 -47.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 C-N-CA 125.667 1.587 . . . . 10.0 107.74 178.129 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.19 56.0 0.74 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.511 -1.435 . . . . 10.0 109.511 178.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -91.98 86.69 5.93 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 105.0 -2.222 . . . . 10.0 105.0 168.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . 0.414 ' HB3' ' CZ ' ' B' ' 45' ' ' PHE . 5.4 mp -72.98 -30.54 63.9 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 106.908 -1.516 . . . . 10.0 106.908 176.098 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.95 -93.18 0.86 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 124.687 1.137 . . . . 10.0 110.439 165.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 p30 -151.88 141.22 21.49 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.084 0.554 . . . . 10.0 110.021 -173.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.6 138.87 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 C-N-CA 124.451 1.1 . . . . 10.0 111.677 179.219 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.4 m -79.17 115.05 18.6 Favored 'General case' 0 N--CA 1.437 -1.116 0 C-N-CA 128.821 2.849 . . . . 10.0 110.635 -177.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.7 134.17 38.94 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 123.855 0.862 . . . . 10.0 110.154 171.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -57.51 171.2 0.46 Allowed 'General case' 0 C--O 1.233 0.192 0 O-C-N 123.982 0.801 . . . . 10.0 109.634 167.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.63 -29.6 38.78 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 123.874 0.87 . . . . 10.0 110.955 173.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -79.08 -7.6 58.27 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.126 0.489 . . . . 10.0 111.203 -178.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.04 -0.24 72.25 Favored Glycine 0 C--N 1.338 0.684 0 O-C-N 121.195 -0.94 . . . . 10.0 111.001 -175.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 55.7 t -78.95 101.35 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 107.518 -1.289 . . . . 10.0 107.518 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -99.4 118.09 35.25 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.825 -1.176 . . . . 10.0 107.825 168.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.49 125.59 29.58 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 106.829 -1.545 . . . . 10.0 106.829 169.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 59.3 t -107.97 128.95 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 N-CA-C 105.385 -2.079 . . . . 10.0 105.385 169.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 73.0 m -152.72 59.85 0.8 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.798 0.839 . . . . 10.0 108.783 175.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.6 151.24 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 N-CA-C 108.138 -1.06 . . . . 10.0 108.138 -173.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -130.18 141.3 50.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.417 1.087 . . . . 10.0 109.155 170.292 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -149.27 161.03 42.84 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 29.7 p -122.6 4.89 9.55 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 127.237 2.215 . . . . 10.0 111.894 -172.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -84.14 -42.53 17.13 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 N-CA-C 107.699 -1.222 . . . . 10.0 107.699 177.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.283 0.0 OUTLIER -71.31 159.37 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 123.959 0.904 . . . . 10.0 113.228 172.378 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -160.04 155.0 24.59 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.202 -1.407 . . . . 10.0 107.202 170.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -82.14 55.88 2.98 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 108.129 -1.063 . . . . 10.0 108.129 169.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.5 t . . . . . 0 CA--C 1.542 0.648 0 C-N-CA 126.598 1.959 . . . . 10.0 108.666 177.246 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.3 t . . . . . 0 N--CA 1.455 -0.222 0 N-CA-C 115.575 1.694 . . . . 10.0 115.575 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 34.8 pt -73.51 6.2 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 N-CA-C 112.823 0.675 . . . . 10.0 112.823 171.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 9.1 mm -56.95 -67.13 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.311 0 CA-C-N 119.352 0.978 . . . . 10.0 111.458 -176.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -81.63 56.1 4.89 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 120.856 -1.152 . . . . 10.0 111.924 -175.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.1 mmt-85 -122.4 150.57 42.27 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.929 1.291 . . . . 10.0 107.957 176.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -92.24 129.26 38.23 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 104.065 -2.569 . . . . 10.0 104.065 168.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 10.9 mp -112.16 145.42 39.86 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.415 -0.957 . . . . 10.0 108.415 169.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 94.1 t -122.93 145.81 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 -171.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.5 p -117.2 122.74 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 C-N-CA 126.769 2.027 . . . . 10.0 106.473 169.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 10.2 m170 -105.29 167.22 9.87 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 115.722 1.749 . . . . 10.0 115.722 -168.463 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -59.29 -66.06 0.57 Allowed 'General case' 0 C--O 1.223 -0.29 0 C-N-CA 125.887 1.675 . . . . 10.0 110.186 174.155 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -107.06 177.71 4.77 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 118.817 0.735 . . . . 10.0 112.137 -169.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.08 144.13 48.81 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.683 1.193 . . . . 10.0 110.567 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.429 ' OD2' ' NE2' ' B' ' 46' ' ' HIS . 19.5 m-20 -89.59 149.36 22.88 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 109.091 -0.707 . . . . 10.0 109.091 168.039 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -76.76 -11.23 59.81 Favored 'General case' 0 N--CA 1.453 -0.289 0 O-C-N 124.73 1.269 . . . . 10.0 111.01 176.202 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 18.0 mt 57.37 40.05 27.8 Favored 'General case' 0 N--CA 1.457 -0.105 0 CA-C-N 118.26 0.482 . . . . 10.0 109.757 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 106.98 -33.41 6.43 Favored Glycine 0 CA--C 1.525 0.664 0 C-N-CA 125.325 1.44 . . . . 10.0 112.29 173.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . 0.406 ' HZ1' ' CG ' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -83.49 42.63 0.84 Allowed 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 118.471 1.135 . . . . 10.0 110.674 -169.29 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.71 -20.83 12.15 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.142 1.83 . . . . 10.0 111.743 -176.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.34 45.73 44.73 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 123.972 0.796 . . . . 10.0 112.554 178.477 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -152.03 172.43 16.29 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.444 0.622 . . . . 10.0 109.74 175.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 12.8 tm-20 -52.2 -43.78 64.37 Favored 'General case' 0 N--CA 1.443 -0.807 0 C-N-CA 123.699 0.799 . . . . 10.0 111.834 -176.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -72.43 -30.02 64.23 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.397 -0.815 . . . . 10.0 111.097 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 30.0 p -50.44 -40.42 50.4 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 119.419 1.009 . . . . 10.0 111.341 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -85.03 -13.79 49.4 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 123.793 0.683 . . . . 10.0 112.405 -175.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.2 ttmt -107.86 -48.75 3.34 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 126.841 2.056 . . . . 10.0 112.431 -166.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.43 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 8.9 p -131.93 -9.85 3.45 Favored 'General case' 0 C--O 1.224 -0.274 0 CA-C-O 116.794 -1.574 . . . . 10.0 112.258 169.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.0 -105.98 3.08 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 107.089 -2.404 . . . . 10.0 107.089 -166.394 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -171.81 21.53 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 115.187 1.551 . . . . 10.0 115.187 -176.702 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.09 -14.91 62.56 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 120.853 -1.154 . . . . 10.0 111.976 -178.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.53 -117.58 5.0 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.348 -1.901 . . . . 10.0 108.348 169.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 112.11 6.33 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 112.575 0.583 . . . . 10.0 112.575 -167.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.84 73.84 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.405 1.082 . . . . 10.0 109.938 166.172 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.9 mt -51.59 -45.2 63.07 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.783 0.66 . . . . 10.0 112.783 -175.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.27 156.82 41.62 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -168.047 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.0 p -163.4 170.13 17.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.951 -0.388 . . . . 10.0 109.951 -173.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.89 162.33 33.0 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.343 -1.503 . . . . 10.0 109.343 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.91 129.46 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 105.644 -1.984 . . . . 10.0 105.644 -176.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 22.6 mt -69.55 160.98 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 CA-C-N 118.773 0.715 . . . . 10.0 110.03 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.01 166.27 39.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 125.529 1.538 . . . . 10.0 109.919 -173.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 95.5 mt -74.29 134.56 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 C-N-CA 124.858 1.263 . . . . 10.0 109.785 -169.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.57 -35.25 3.59 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 112.795 0.665 . . . . 10.0 112.795 176.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.252 1.186 0 CA-C-O 116.953 -1.498 . . . . 10.0 108.893 174.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t -162.34 -43.77 0.04 OUTLIER 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 118.904 0.774 . . . . 10.0 110.795 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -118.41 138.52 52.39 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.34 155.68 49.13 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 124.148 0.905 . . . . 10.0 109.482 175.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -121.8 148.82 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 C-N-CA 125.618 1.567 . . . . 10.0 109.183 -176.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.33 100.85 4.36 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 108.022 -1.103 . . . . 10.0 108.022 167.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.2 m -79.51 100.99 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 109.055 -0.72 . . . . 10.0 109.055 171.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.9 mt -81.17 142.76 32.91 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -158.23 160.27 36.96 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 173.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -165.25 -60.68 0.02 OUTLIER Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.41 -0.424 . . . . 10.0 112.153 171.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -74.72 -45.86 41.39 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 106.644 -1.613 . . . . 10.0 106.644 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.69 -64.46 0.61 Allowed Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 114.021 -1.445 . . . . 10.0 111.203 -176.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -52.45 -42.74 59.33 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.06 1.84 . . . . 10.0 111.058 173.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 m -72.16 113.78 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.269 -1.011 . . . . 10.0 108.269 177.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -119.49 120.99 38.41 Favored 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 104.783 -2.303 . . . . 10.0 104.783 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.22 141.46 15.34 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.275 -1.93 . . . . 10.0 108.275 169.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.7 mt -137.16 67.26 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.069 -1.086 . . . . 10.0 108.069 -173.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.1 mm -77.06 133.86 29.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 109.4 -0.593 . . . . 10.0 109.4 -178.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -121.25 98.58 6.04 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.517 1.927 . . . . 10.0 107.6 -178.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -81.27 128.79 34.19 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 118.155 -0.926 . . . . 10.0 108.616 177.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.77 122.21 43.81 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.619 0.768 . . . . 10.0 110.723 171.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -122.27 103.17 8.58 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.793 2.037 . . . . 10.0 106.483 168.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -61.77 -60.96 2.88 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 122.709 0.403 . . . . 10.0 110.467 -174.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -128.43 177.51 6.93 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 104.31 -2.478 . . . . 10.0 104.31 169.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.5 p -73.87 -17.17 61.08 Favored 'General case' 0 C--N 1.322 -0.594 0 O-C-N 122.114 -0.367 . . . . 10.0 110.578 -175.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.2 m-80 -79.2 -22.37 45.0 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.984 0.914 . . . . 10.0 109.461 172.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.64 124.73 18.83 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 109.91 -1.276 . . . . 10.0 109.91 179.325 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.92 141.95 86.34 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 N-CA-C 107.097 -1.924 . . . . 10.0 107.097 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 71.0 t -79.54 116.93 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 107.786 -1.19 . . . . 10.0 107.786 -169.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -88.91 108.4 19.53 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.122 -1.807 . . . . 10.0 106.122 177.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 18.6 m -101.32 90.59 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 125.328 1.451 . . . . 10.0 108.122 -177.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -101.49 167.5 10.11 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 122.03 0.919 . . . . 10.0 110.777 168.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.19 162.2 28.05 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.578 -1.409 . . . . 10.0 109.578 171.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.3 m -128.28 102.39 6.66 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 176.099 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.8 pt -77.08 176.32 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 N-CA-C 108.133 -1.062 . . . . 10.0 108.133 170.037 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.9 pttt -153.89 149.1 26.97 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 106.942 -1.503 . . . . 10.0 106.942 169.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.35 -24.24 12.7 Favored Glycine 0 C--N 1.338 0.654 0 CA-C-O 119.248 -0.751 . . . . 10.0 114.438 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.8 mp -65.56 175.92 1.66 Allowed 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 118.414 1.107 . . . . 10.0 111.063 -175.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -89.77 148.12 23.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.378 -0.828 . . . . 10.0 110.284 171.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -39.59 125.47 1.78 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.867 2.467 . . . . 10.0 110.938 174.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 121.42 -174.64 15.99 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 123.602 0.62 . . . . 10.0 112.961 171.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.64 151.91 44.45 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.806 1.642 . . . . 10.0 111.234 -178.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -148.27 143.3 26.86 Favored 'General case' 0 C--N 1.343 0.31 0 N-CA-C 113.524 0.935 . . . . 10.0 113.524 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -30.86 122.75 0.14 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.853 2.644 . . . . 10.0 110.917 165.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.92 106.41 4.42 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 119.989 1.894 . . . . 10.0 110.259 172.557 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.447 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -158.06 172.54 18.25 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-O 121.797 0.808 . . . . 10.0 111.764 -177.922 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 9.8 p -100.05 152.62 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-N 112.418 -2.174 . . . . 10.0 109.366 171.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -128.08 135.47 49.87 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 176.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -51.31 -61.77 2.03 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.318 1.447 . . . . 10.0 112.309 -168.323 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -83.9 147.79 27.31 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 119.539 -0.865 . . . . 10.0 109.516 -178.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.06 9.12 58.36 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 124.919 1.247 . . . . 10.0 111.321 170.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -67.56 98.45 0.68 Allowed 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 123.547 1.642 . . . . 10.0 110.907 -178.184 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.34 14.73 30.85 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 111.516 -2.584 . . . . 10.0 110.588 167.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.427 HG21 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -71.45 -40.95 70.0 Favored 'General case' 0 C--N 1.339 0.152 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 168.516 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -20.22 48.79 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.414 0.524 . . . . 10.0 112.414 170.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.02 78.83 1.37 Allowed Glycine 0 CA--C 1.529 0.909 0 N-CA-C 111.322 -0.711 . . . . 10.0 111.322 178.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.4 p 37.39 43.17 0.37 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 126.841 2.057 . . . . 10.0 114.292 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.2 m -133.14 -57.74 0.91 Allowed 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 105.682 -1.97 . . . . 10.0 105.682 -178.301 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -55.99 -29.05 59.7 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 122.823 0.449 . . . . 10.0 109.934 169.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.03 -27.7 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.564 1.545 . . . . 10.0 113.382 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.54 124.26 5.38 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-O 117.751 -1.583 . . . . 10.0 109.57 168.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -72.31 65.46 3.58 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.066 3.177 . . . . 10.0 111.69 176.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.6 m170 67.09 46.58 1.51 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 130.338 3.455 . . . . 10.0 111.868 176.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -70.48 64.68 0.28 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.194 0.597 . . . . 10.0 111.595 178.533 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -73.31 142.19 81.49 Favored Pre-proline 0 CA--C 1.533 0.292 0 O-C-N 120.154 -1.591 . . . . 10.0 109.102 172.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -57.94 -34.28 98.16 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.563 2.175 . . . . 10.0 111.591 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.45 -17.48 63.86 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.201 0.815 . . . . 10.0 113.201 177.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.4 t 20.75 81.93 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 127.495 2.318 . . . . 10.0 114.726 175.276 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.0 mtt180 -111.32 -84.73 0.57 Allowed 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 105.546 -2.02 . . . . 10.0 105.546 -177.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.09 160.56 41.07 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 109.131 -0.692 . . . . 10.0 109.131 167.557 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.0 t60 -56.74 126.68 27.94 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.316 -1.735 . . . . 10.0 106.316 165.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.39 -136.32 3.13 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 107.343 -2.303 . . . . 10.0 107.343 176.09 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 164.68 -150.64 18.98 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 108.982 -1.647 . . . . 10.0 108.982 169.569 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -68.11 19.22 0.13 Allowed 'Trans proline' 0 N--CA 1.453 -0.911 0 CA-C-N 119.77 1.785 . . . . 10.0 112.307 173.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.403 ' H ' ' C ' ' A' ' 73' ' ' GLY . 59.9 mttt -120.87 -11.66 8.92 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 118.161 -0.923 . . . . 10.0 111.243 169.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -143.6 118.44 9.93 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 104.856 -2.276 . . . . 10.0 104.856 -168.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 36.2 tp10 -75.11 -16.5 60.55 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 107.68 -1.23 . . . . 10.0 107.68 -171.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -82.56 11.11 6.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 C-N-CA 125.803 1.641 . . . . 10.0 111.991 175.656 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.8 ptt-85 -43.86 153.13 0.14 Allowed 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.76 1.624 . . . . 10.0 113.674 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -72.09 160.73 31.98 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 107.334 -1.358 . . . . 10.0 107.334 166.082 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.6 p -38.38 -47.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 125.358 1.463 . . . . 10.0 114.259 -172.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.74 55.0 0.76 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 123.396 0.522 . . . . 10.0 111.975 -177.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -82.47 93.5 7.26 Favored 'General case' 0 CA--C 1.528 0.126 0 N-CA-C 105.38 -2.082 . . . . 10.0 105.38 166.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -71.61 -28.94 64.14 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 106.79 -1.559 . . . . 10.0 106.79 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.63 -104.01 2.7 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 106.867 -2.493 . . . . 10.0 106.867 168.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -126.4 131.09 51.82 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.883 -1.155 . . . . 10.0 107.883 -169.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.98 135.58 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 119.076 0.853 . . . . 10.0 110.834 170.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.74 110.83 15.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.429 2.692 . . . . 10.0 110.51 -177.288 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.9 132.31 37.15 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.182 -0.673 . . . . 10.0 109.182 169.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.403 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 19.5 t70 -53.97 168.43 0.21 Allowed 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 125.047 1.339 . . . . 10.0 110.635 168.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.403 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 22.2 tttp -47.7 -35.43 9.64 Favored 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 125.654 1.582 . . . . 10.0 112.231 169.109 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -78.27 -9.84 59.4 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 121.203 0.525 . . . . 10.0 111.896 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.35 11.86 60.51 Favored Glycine 0 C--N 1.337 0.621 0 O-C-N 120.887 -1.133 . . . . 10.0 110.891 -177.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.3 t -92.19 103.92 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 125.749 1.62 . . . . 10.0 107.705 -178.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.88 121.72 41.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 109.052 -0.722 . . . . 10.0 109.052 169.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -84.6 86.16 7.34 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 127.528 2.331 . . . . 10.0 109.884 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.46 129.82 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.251 0 N-CA-C 105.67 -1.974 . . . . 10.0 105.67 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -158.18 72.06 0.61 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 122.986 0.514 . . . . 10.0 110.728 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -116.71 163.71 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.161 -1.792 . . . . 10.0 106.161 -178.016 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.66 144.85 39.83 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.571 0.623 . . . . 10.0 110.475 167.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -129.56 125.9 37.32 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 125.074 1.349 . . . . 10.0 110.205 -169.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 69.3 p -98.4 53.25 1.04 Allowed 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 107.172 -1.418 . . . . 10.0 107.172 169.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -157.24 -45.25 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 C-N-CA 124.085 0.954 . . . . 10.0 109.29 -175.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -74.23 145.09 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 167.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -133.08 157.15 46.0 Favored 'General case' 0 CA--C 1.528 0.124 0 N-CA-C 107.782 -1.192 . . . . 10.0 107.782 168.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.1 mt -95.39 -34.1 12.25 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 108.429 -0.952 . . . . 10.0 108.429 167.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.0 m -156.73 67.25 0.55 Allowed 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 124.486 1.114 . . . . 10.0 108.614 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -165.05 63.24 0.23 Allowed Glycine 0 C--N 1.333 0.365 0 N-CA-C 108.037 -2.025 . . . . 10.0 108.037 -179.313 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 69.75 -57.89 0.54 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 129.712 3.205 . . . . 10.0 109.532 -174.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -82.48 33.23 0.41 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 123.43 0.692 . . . . 10.0 111.416 -168.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.2 t -52.43 104.1 0.08 Allowed 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 126.618 1.967 . . . . 10.0 110.524 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 30.3 pt -86.06 23.55 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 C-N-CA 123.352 0.661 . . . . 10.0 111.787 171.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 20.8 mm -64.45 143.44 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 O-C-N 120.407 -1.433 . . . . 10.0 108.394 173.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.89 19.01 67.17 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-O 119.198 -0.779 . . . . 10.0 114.509 177.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.3 mmt-85 -88.29 176.4 7.24 Favored 'General case' 0 C--O 1.232 0.18 0 N-CA-C 107.76 -1.2 . . . . 10.0 107.76 167.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -121.08 132.66 55.01 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 106.841 -1.541 . . . . 10.0 106.841 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.9 mp -99.41 147.56 25.12 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.343 -1.354 . . . . 10.0 107.343 169.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 90.4 t -127.23 133.63 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.795 -1.557 . . . . 10.0 106.795 170.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.8 p -103.77 125.33 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.581 0 N-CA-C 103.913 -2.625 . . . . 10.0 103.913 167.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 7.2 m170 -105.56 160.6 15.05 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.052 1.406 . . . . 10.0 114.365 -168.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 -41.48 -58.15 1.99 Allowed 'General case' 0 N--CA 1.444 -0.773 0 C-N-CA 128.088 2.555 . . . . 10.0 109.702 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -124.81 176.96 6.26 Favored 'General case' 0 C--N 1.338 0.093 0 C-N-CA 125.791 1.636 . . . . 10.0 110.85 -174.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.69 135.92 33.34 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.143 0.977 . . . . 10.0 109.891 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.447 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.2 OUTLIER -78.55 143.3 36.64 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.433 1.893 . . . . 10.0 111.897 177.787 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.75 19.95 0.26 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.986 1.314 . . . . 10.0 112.132 178.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 40.1 48.08 2.13 Favored 'General case' 0 C--O 1.226 -0.137 0 C-N-CA 126.25 1.82 . . . . 10.0 112.622 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 105.93 -11.31 45.09 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-O 118.781 -1.011 . . . . 10.0 113.437 173.113 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -120.96 40.6 3.52 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.743 0.771 . . . . 10.0 112.185 -166.276 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.28 -15.34 66.86 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 126.035 1.779 . . . . 10.0 112.323 173.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.7 49.19 78.88 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 118.417 1.109 . . . . 10.0 113.023 175.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -161.12 167.63 25.88 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 127.35 2.26 . . . . 10.0 105.095 -177.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -46.31 -47.89 18.33 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.791 0.805 . . . . 10.0 111.026 172.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -56.74 -33.24 66.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.253 -0.885 . . . . 10.0 111.715 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.0 t -45.65 -46.59 14.71 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 125.064 1.346 . . . . 10.0 109.346 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.6 t -91.68 0.92 57.46 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 112.395 0.517 . . . . 10.0 112.395 -173.177 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -113.18 -81.64 0.59 Allowed 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 126.054 1.741 . . . . 10.0 110.537 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.4 p -111.23 22.82 14.78 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 121.176 1.807 . . . . 10.0 111.02 172.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 -88.51 0.41 Allowed Glycine 0 C--N 1.341 0.816 0 N-CA-C 109.932 -1.267 . . . . 10.0 109.932 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -173.77 40.17 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 125.895 1.678 . . . . 10.0 109.069 172.036 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.21 -4.18 9.73 Favored 'General case' 0 C--N 1.34 0.164 0 O-C-N 121.543 -0.723 . . . . 10.0 112.224 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.56 -166.99 53.85 Favored Glycine 0 N--CA 1.441 -0.987 0 N-CA-C 109.259 -1.537 . . . . 10.0 109.259 179.174 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.6 t -62.41 146.15 52.15 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 122.457 1.122 . . . . 10.0 111.324 -168.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.07 64.22 0.06 Allowed 'General case' 0 N--CA 1.444 -0.743 0 C-N-CA 126.837 2.055 . . . . 10.0 109.145 171.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.63 -19.16 64.64 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 113.206 0.817 . . . . 10.0 113.206 -168.721 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.36 145.7 21.91 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.398 0.544 . . . . 10.0 110.129 172.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.9 m -146.85 158.51 43.93 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 123.852 0.861 . . . . 10.0 109.492 -167.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.92 167.09 36.5 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.472 -1.051 . . . . 10.0 110.472 175.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.8 t -116.28 142.01 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 107.398 -1.334 . . . . 10.0 107.398 -169.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 11.0 mt -80.03 113.68 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 123.291 0.636 . . . . 10.0 110.52 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.07 152.32 17.59 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.244 1.402 . . . . 10.0 111.728 -178.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 84.0 mt -73.55 141.32 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 124.562 1.145 . . . . 10.0 109.179 -178.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.69 -48.16 2.59 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 123.35 0.66 . . . . 10.0 110.764 176.28 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.1 tt0 . . . . . 0 C--O 1.25 1.125 0 C-N-CA 127.268 2.227 . . . . 10.0 112.146 -172.114 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 108.684 -0.858 . . . . 10.0 108.684 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -91.46 -30.19 16.61 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 123.169 0.587 . . . . 10.0 111.149 -179.073 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 12.4 mtpt -124.44 127.9 48.21 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 124.882 1.273 . . . . 10.0 111.1 -175.527 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.01 155.47 49.93 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.957 0.503 . . . . 10.0 110.751 171.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.2 m -114.55 165.05 10.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.421 1.088 . . . . 10.0 109.346 171.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -153.69 104.59 2.72 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 106.417 -1.697 . . . . 10.0 106.417 166.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -106.4 125.23 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 109.217 -0.66 . . . . 10.0 109.217 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -104.44 152.07 22.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.919 1.288 . . . . 10.0 109.352 -172.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.8 tttt -160.0 162.64 34.34 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 169.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 175.0 -43.25 0.12 Allowed Glycine 0 C--O 1.228 -0.242 0 C-N-CA 119.768 -1.206 . . . . 10.0 113.682 168.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -74.22 -46.19 43.4 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.9 -72.37 0.33 Allowed Glycine 0 CA--C 1.52 0.348 0 N-CA-C 109.679 -1.368 . . . . 10.0 109.679 171.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -58.9 -39.23 83.17 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 123.211 2.607 . . . . 10.0 110.834 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.4 t -59.72 110.59 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -121.03 113.62 20.33 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 104.495 -2.409 . . . . 10.0 104.495 168.674 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.04 143.53 16.68 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 108.236 -1.946 . . . . 10.0 108.236 172.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . 0.427 ' CG2' HG21 ' A' ' 54' ' ' THR . 3.0 mt -143.04 91.43 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 -176.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -104.31 138.66 28.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 C-N-CA 124.785 1.234 . . . . 10.0 109.29 178.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -122.84 122.35 38.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 126.38 1.872 . . . . 10.0 108.769 169.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -102.75 126.2 49.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 107.363 -1.347 . . . . 10.0 107.363 176.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -116.53 135.95 53.39 Favored 'General case' 0 C--O 1.233 0.203 0 O-C-N 123.759 0.662 . . . . 10.0 110.986 167.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.2 tt0 -119.52 114.15 21.83 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 106.095 -1.817 . . . . 10.0 106.095 168.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.4 mmpt? . . . . . 0 N--CA 1.453 -0.313 0 C-N-CA 123.912 0.885 . . . . 10.0 110.028 -169.828 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.21 0 N-CA-C 111.437 -0.665 . . . . 10.0 111.437 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_endo -62.63 159.45 36.8 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.874 2.383 . . . . 10.0 108.737 170.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 41.1 t -86.74 115.99 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.22 0 N-CA-C 105.325 -2.102 . . . . 10.0 105.325 169.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.484 ' HZ2' ' CD ' ' B' ' 100' ' ' GLU . 38.8 tttp -92.07 112.45 24.39 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 168.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -94.44 100.66 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 C-N-CA 127.32 2.248 . . . . 10.0 106.484 176.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 23.3 p90 -112.77 171.32 7.6 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.304 0.573 . . . . 10.0 111.11 169.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.66 170.24 38.28 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.869 -0.892 . . . . 10.0 110.869 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.6 m -148.94 95.14 2.36 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.666 -1.605 . . . . 10.0 106.666 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.9 pt -75.8 176.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 108.725 -0.842 . . . . 10.0 108.725 173.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 17.1 ptmt -156.57 164.8 37.77 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 163.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.69 -13.73 59.3 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 119.341 -0.7 . . . . 10.0 113.168 172.065 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.8 mp -69.71 176.69 3.42 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 118.568 1.184 . . . . 10.0 110.211 172.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.0 t -94.06 166.66 12.03 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 107.427 -1.324 . . . . 10.0 107.427 165.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.27 171.46 1.03 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.475 1.11 . . . . 10.0 112.21 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.18 179.89 39.64 Favored Glycine 0 C--N 1.334 0.428 0 C-N-CA 123.943 0.783 . . . . 10.0 112.074 168.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -66.99 142.6 57.19 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.632 0.773 . . . . 10.0 109.083 176.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.4 m-70 -139.68 151.79 46.19 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 123.087 0.555 . . . . 10.0 112.476 177.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -36.44 121.47 0.68 Allowed Glycine 0 C--N 1.341 0.822 0 C-N-CA 129.323 3.344 . . . . 10.0 110.883 166.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -149.59 115.21 5.58 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 119.335 1.567 . . . . 10.0 110.022 168.727 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.535 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.59 168.34 27.1 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-O 121.601 0.715 . . . . 10.0 111.406 176.401 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 7.7 m -93.28 148.88 4.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 111.957 -2.383 . . . . 10.0 105.389 166.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -121.91 153.55 38.3 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 174.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -40.1 -43.42 1.61 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 127.719 2.408 . . . . 10.0 115.403 -175.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -115.21 159.03 21.45 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 124.793 1.237 . . . . 10.0 109.264 -170.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.01 -7.71 63.96 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 126.009 1.766 . . . . 10.0 110.983 169.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -42.86 151.21 0.13 Allowed 'General case' 0 C--O 1.239 0.515 0 CA-C-O 123.174 1.464 . . . . 10.0 112.494 169.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -162.46 21.68 0.1 Allowed 'General case' 0 N--CA 1.437 -1.096 0 CA-C-N 112.485 -2.143 . . . . 10.0 111.997 167.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.83 -35.54 76.81 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.736 0.698 . . . . 10.0 110.821 -169.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.75 -17.6 55.54 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.602 1.161 . . . . 10.0 112.254 175.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.85 -173.2 17.25 Favored Glycine 0 N--CA 1.442 -0.909 0 N-CA-C 106.844 -2.502 . . . . 10.0 106.844 -167.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 60.1 m -66.53 69.96 0.07 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.311 1.444 . . . . 10.0 108.424 172.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -153.53 -53.04 0.1 Allowed 'General case' 0 N--CA 1.444 -0.774 0 O-C-N 120.693 -1.254 . . . . 10.0 109.617 -168.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.4 t -96.22 -1.26 48.55 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.874 0.87 . . . . 10.0 110.203 -178.069 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.31 47.3 0.37 Allowed 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.811 1.244 . . . . 10.0 112.225 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.05 131.57 2.43 Favored Glycine 0 N--CA 1.44 -1.097 0 N-CA-C 117.479 1.752 . . . . 10.0 117.479 162.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -92.69 23.88 0.51 Allowed 'Trans proline' 0 CA--C 1.545 1.069 0 C-N-CA 123.135 2.557 . . . . 10.0 113.282 168.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 21.1 m170 86.77 35.16 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 129.231 3.012 . . . . 10.0 112.352 176.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.24 70.34 0.16 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.319 1.048 . . . . 10.0 111.588 173.182 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -70.13 155.61 93.18 Favored Pre-proline 0 CA--C 1.536 0.413 0 C-N-CA 123.12 0.568 . . . . 10.0 109.965 170.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.57 -48.24 2.39 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 121.965 1.777 . . . . 10.0 110.815 176.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 tt -75.67 63.8 1.63 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.265 1.426 . . . . 10.0 109.205 -175.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -45.06 102.02 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 128.042 2.537 . . . . 10.0 113.143 -168.381 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.3 mtp85 -129.1 178.06 6.68 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 126.049 1.74 . . . . 10.0 108.027 175.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -111.94 56.98 0.64 Allowed 'General case' 0 C--O 1.226 -0.171 0 N-CA-C 113.12 0.785 . . . . 10.0 113.12 -167.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 67.8 t60 44.98 85.81 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 122.959 1.361 . . . . 10.0 114.069 175.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.65 -161.11 25.9 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 168.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.409 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -171.21 -152.99 8.6 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 107.043 -2.423 . . . . 10.0 107.043 173.662 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.42 8.44 0.12 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 120.15 1.975 . . . . 10.0 112.631 169.179 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.409 ' H ' ' C ' ' B' ' 73' ' ' GLY . 70.4 mttt -123.69 -0.49 8.58 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 117.419 -1.277 . . . . 10.0 113.066 175.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.32 163.55 32.71 Favored 'General case' 0 C--N 1.346 0.439 0 CA-C-N 120.629 1.559 . . . . 10.0 108.602 174.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -77.03 -30.29 55.67 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 177.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -76.58 26.07 0.13 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.651 1.58 . . . . 10.0 113.077 -166.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 18.1 mtm180 -47.58 129.5 13.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 107.392 -1.336 . . . . 10.0 107.392 168.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.1 m170 -67.67 -57.59 6.13 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 121.237 0.541 . . . . 10.0 109.932 176.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.8 p -163.82 -58.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 109.072 -0.714 . . . . 10.0 109.072 -176.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -137.23 62.91 0.58 Allowed Glycine 0 C--N 1.337 0.6 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 178.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -90.78 90.74 8.07 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.371 -1.344 . . . . 10.0 107.371 171.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.39 -25.5 57.68 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 121.352 0.596 . . . . 10.0 109.551 177.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.98 -66.98 3.68 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 115.161 0.825 . . . . 10.0 115.161 167.676 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -137.93 109.29 6.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 118.677 -0.678 . . . . 10.0 109.249 -167.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -115.84 125.77 73.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 118.789 0.722 . . . . 10.0 110.451 169.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 10.9 m -81.35 97.51 7.74 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 128.325 2.65 . . . . 10.0 112.134 -171.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.64 132.77 39.6 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 123.824 0.849 . . . . 10.0 112.236 176.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -63.13 173.44 1.45 Allowed 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 125.308 1.443 . . . . 10.0 110.312 167.1 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.3 pttm -55.03 -30.5 59.68 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 123.766 0.827 . . . . 10.0 111.95 170.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.88 3.25 20.37 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.069 0.938 . . . . 10.0 110.953 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.47 -0.26 89.71 Favored Glycine 0 N--CA 1.441 -1.013 0 O-C-N 120.572 -1.33 . . . . 10.0 110.033 -174.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 67.0 t -78.33 94.79 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 108.414 -0.958 . . . . 10.0 108.414 -169.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -88.15 119.11 28.22 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 167.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -77.34 123.59 26.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.951 -1.5 . . . . 10.0 106.951 169.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 65.8 t -104.65 131.69 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 105.292 -2.114 . . . . 10.0 105.292 169.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -158.01 57.84 0.47 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 118.917 0.78 . . . . 10.0 111.815 177.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.6 151.61 12.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.166 0.986 . . . . 10.0 109.631 -169.279 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . 0.484 ' CD ' ' HZ2' ' B' ' 30' ' ' LYS . 2.4 pm0 -109.1 141.99 40.48 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 126.068 1.747 . . . . 10.0 109.601 170.318 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -137.67 155.35 49.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 O-C-N 124.093 0.871 . . . . 10.0 109.413 173.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.5 p -128.07 58.37 1.52 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 126.86 2.064 . . . . 10.0 108.526 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -155.01 -44.5 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 C-N-CA 124.643 1.177 . . . . 10.0 108.888 174.096 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 33.6 mm -55.91 147.66 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 168.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.0 m -153.85 135.3 14.24 Favored 'General case' 0 C--O 1.233 0.22 0 N-CA-C 109.048 -0.723 . . . . 10.0 109.048 169.511 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -79.18 57.42 2.26 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.367 1.467 . . . . 10.0 108.492 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 15.5 t . . . . . 0 CA--C 1.536 0.432 0 C-N-CA 126.913 2.085 . . . . 10.0 110.416 -171.783 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.4 t . . . . . 0 C--O 1.238 0.492 0 N-CA-C 113.966 1.099 . . . . 10.0 113.966 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.2 pp -56.0 -30.29 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 166.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.7 mm -31.12 -36.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 C-N-CA 128.306 2.642 . . . . 10.0 115.234 169.495 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -104.56 28.95 12.86 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-O 118.711 -1.049 . . . . 10.0 112.784 -175.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -104.87 169.85 8.21 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 125.106 1.362 . . . . 10.0 110.176 177.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 18.4 m -108.26 127.7 54.08 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.696 1.598 . . . . 10.0 109.104 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -84.9 141.23 30.55 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 106.71 -1.589 . . . . 10.0 106.71 167.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.5 t -125.46 136.7 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 170.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 p -105.65 130.9 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 125.083 1.353 . . . . 10.0 107.583 169.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 3.3 m170 -114.68 157.84 22.59 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 115.75 1.759 . . . . 10.0 115.75 -171.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -37.11 -63.76 0.41 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 129.301 3.04 . . . . 10.0 111.078 169.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.5 mttt -117.93 175.32 5.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 C-N-CA 124.231 1.012 . . . . 10.0 110.131 -173.077 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -91.72 148.19 22.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.894 1.278 . . . . 10.0 109.478 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.535 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -75.04 143.35 43.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 112.053 0.39 . . . . 10.0 112.053 -178.786 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -80.64 -3.62 51.21 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 124.394 1.059 . . . . 10.0 110.791 166.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 71.1 mt 51.24 50.73 18.4 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 125.426 1.49 . . . . 10.0 111.218 170.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.37 -36.08 4.3 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-N 114.525 -1.216 . . . . 10.0 110.935 174.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.31 35.22 0.49 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 121.025 -1.279 . . . . 10.0 110.847 -173.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.92 -36.11 6.51 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 109.51 -1.436 . . . . 10.0 109.51 179.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.62 51.21 59.26 Favored Glycine 0 CA--C 1.529 0.938 0 N-CA-C 111.39 -0.684 . . . . 10.0 111.39 -171.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -142.66 171.7 13.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 104.605 -2.368 . . . . 10.0 104.605 170.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 24.4 mp0 -51.78 -48.11 63.91 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 120.726 -0.39 . . . . 10.0 110.379 174.328 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -53.08 -38.17 62.32 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.451 -0.34 . . . . 10.0 110.282 177.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.8 p -57.72 -30.01 65.19 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 118.013 -0.994 . . . . 10.0 112.513 -176.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -98.2 17.47 18.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.412 1.005 . . . . 10.0 109.834 -177.551 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -142.19 -69.74 0.35 Allowed 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 124.822 1.249 . . . . 10.0 110.38 -169.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.4 p -126.73 21.61 6.99 Favored 'General case' 0 CA--C 1.547 0.859 0 CA-C-N 119.653 1.115 . . . . 10.0 112.29 177.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 79.07 -88.07 1.18 Allowed Glycine 0 C--N 1.343 0.958 0 O-C-N 121.111 -0.993 . . . . 10.0 111.01 170.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.09 38.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 122.989 1.376 . . . . 10.0 107.934 174.34 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.76 -29.05 61.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 125.169 1.388 . . . . 10.0 109.607 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.95 -157.61 53.09 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 109.847 -1.301 . . . . 10.0 109.847 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 56.7 m -56.84 130.57 46.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 113.59 0.959 . . . . 10.0 113.59 -167.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.9 mtt85 -66.68 75.22 0.11 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.934 1.294 . . . . 10.0 110.654 172.695 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 55.1 mt -50.58 -40.19 51.77 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 118.349 0.522 . . . . 10.0 112.226 179.535 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.31 160.41 40.73 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 121.943 -0.473 . . . . 10.0 109.867 -177.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 p -159.42 166.46 30.99 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 109.982 -0.377 . . . . 10.0 109.982 -177.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.56 165.55 36.24 Favored Glycine 0 C--N 1.334 0.433 0 N-CA-C 110.689 -0.965 . . . . 10.0 110.689 -177.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.68 137.53 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 106.002 -1.851 . . . . 10.0 106.002 -171.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 16.7 mt -68.42 157.3 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 108.491 -0.929 . . . . 10.0 108.491 177.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -163.83 155.38 26.72 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 109.732 -1.347 . . . . 10.0 109.732 -176.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -90.32 125.84 43.16 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-N 118.475 1.138 . . . . 10.0 111.368 -173.1 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.75 -25.96 27.92 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.126 -0.984 . . . . 10.0 111.245 177.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.251 1.133 0 C-N-CA 125.837 1.655 . . . . 10.0 107.676 178.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.835 0 CA-C-O 118.253 -0.88 . . . . 10.0 108.636 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.31 -53.61 1.91 Allowed 'General case' 0 N--CA 1.463 0.175 0 C-N-CA 124.274 1.029 . . . . 10.0 110.828 -175.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -105.51 128.36 53.53 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.32 161.74 35.45 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.132 0.573 . . . . 10.0 109.665 172.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -125.94 153.45 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 125.71 1.604 . . . . 10.0 109.782 -179.202 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.73 127.53 21.98 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 108.251 -1.018 . . . . 10.0 108.251 165.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.9 m -115.36 83.7 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 C-N-CA 124.783 1.233 . . . . 10.0 110.772 -174.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.7 mp -76.02 150.01 37.44 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.144 -0.972 . . . . 10.0 109.856 -169.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.96 155.24 11.81 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 -179.206 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.19 -46.2 0.18 Allowed Glycine 0 N--CA 1.463 0.477 0 C-N-CA 119.505 -1.331 . . . . 10.0 114.136 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -73.33 -45.35 55.74 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -175.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.71 -73.13 0.32 Allowed Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 170.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -56.75 -39.55 90.55 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.835 2.357 . . . . 10.0 110.996 172.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 98.4 t -62.97 106.54 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 CA-C-N 119.245 0.93 . . . . 10.0 108.507 -177.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.63 112.44 20.53 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 169.679 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.17 142.57 16.2 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 109.576 -1.41 . . . . 10.0 109.576 174.293 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -147.12 93.32 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 -172.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.4 mm -111.88 139.82 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 C-N-CA 125.582 1.553 . . . . 10.0 110.111 -175.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -118.32 122.45 42.9 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.943 1.697 . . . . 10.0 109.157 168.247 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -101.74 114.11 27.89 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 125.255 1.422 . . . . 10.0 107.259 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -120.6 112.68 19.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 122.154 0.978 . . . . 10.0 113.084 -179.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -82.29 104.8 12.86 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 106.307 -1.738 . . . . 10.0 106.307 168.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.3 -24.44 67.3 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 118.97 -0.538 . . . . 10.0 110.405 177.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -135.75 -161.22 1.13 Allowed 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.419 -0.586 . . . . 10.0 109.419 178.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 23.1 t -99.87 -7.68 25.02 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 119.363 -0.351 . . . . 10.0 110.355 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.9 m-80 -139.63 21.34 2.52 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.819 1.248 . . . . 10.0 108.969 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.98 161.8 42.09 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.278 -1.129 . . . . 10.0 110.278 -172.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -67.69 117.28 4.76 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 104.226 -3.029 . . . . 10.0 104.226 165.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.77 131.56 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 -174.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.1 mttt -101.53 122.74 44.37 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 106.541 -1.651 . . . . 10.0 106.541 174.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.1 m -119.73 111.93 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.82 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 -175.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -128.99 167.96 16.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 121.209 0.528 . . . . 10.0 109.988 -179.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.77 171.17 38.68 Favored Glycine 0 N--CA 1.437 -1.295 0 N-CA-C 110.009 -1.236 . . . . 10.0 110.009 -176.353 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.5 t -142.55 99.04 3.41 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 177.663 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.9 pt -79.51 156.26 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 C-N-CA 118.514 -1.275 . . . . 10.0 107.642 167.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.5 ptmt -141.9 164.6 29.76 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.519 -0.919 . . . . 10.0 108.519 164.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.66 -14.23 46.2 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-O 119.105 -0.831 . . . . 10.0 113.08 177.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.4 mp -70.77 176.9 3.88 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 118.566 1.183 . . . . 10.0 110.482 178.08 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -95.9 149.82 21.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.397 -0.82 . . . . 10.0 109.309 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -43.61 137.53 2.91 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.685 1.994 . . . . 10.0 111.58 -176.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 114.62 -172.87 14.49 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.881 0.753 . . . . 10.0 112.585 170.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.89 145.32 50.28 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 125.024 1.33 . . . . 10.0 110.908 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -147.9 143.58 27.48 Favored 'General case' 0 C--N 1.34 0.189 0 N-CA-C 113.099 0.777 . . . . 10.0 113.099 177.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -28.55 117.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 C-N-CA 127.842 2.639 . . . . 10.0 113.078 165.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -143.1 109.18 5.24 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 120.207 2.004 . . . . 10.0 110.873 169.046 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.484 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -156.78 171.79 19.77 Favored 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 115.438 -0.801 . . . . 10.0 110.765 178.573 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.9 m -89.45 163.39 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.514 -2.13 . . . . 10.0 106.895 166.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -124.47 158.23 33.32 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 124.857 1.263 . . . . 10.0 107.859 172.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -58.04 -41.3 82.95 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 123.994 0.918 . . . . 10.0 112.935 -169.794 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -107.41 174.65 5.79 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.034 0.934 . . . . 10.0 109.82 176.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.39 -9.96 14.14 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.236 1.874 . . . . 10.0 112.449 175.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -65.81 161.34 21.18 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 122.379 1.085 . . . . 10.0 110.949 -178.138 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -158.0 28.98 0.26 Allowed 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.445 -0.798 . . . . 10.0 112.289 -170.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -59.19 -36.43 75.35 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.569 -0.707 . . . . 10.0 112.368 -171.622 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.44 -17.54 56.2 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.178 0.591 . . . . 10.0 111.499 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.37 -156.25 15.73 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 104.664 -3.374 . . . . 10.0 104.664 -167.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 93.6 m -68.23 72.33 0.19 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 125.133 1.373 . . . . 10.0 110.174 177.033 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -158.56 -47.92 0.06 Allowed 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 123.564 0.746 . . . . 10.0 111.128 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -56.0 -35.17 66.5 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.27 1.028 . . . . 10.0 111.476 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.09 -28.86 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.482 3.113 . . . . 10.0 116.395 174.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.04 165.87 29.03 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 107.84 -2.104 . . . . 10.0 107.84 175.46 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -72.81 -141.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.347 0 N-CA-C 106.635 -2.102 . . . . 10.0 106.635 166.249 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -105.04 38.03 2.03 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 120.515 1.507 . . . . 10.0 111.556 179.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -72.18 73.17 0.93 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.848 1.658 . . . . 10.0 112.181 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 7.2 p-10 -61.12 151.43 75.44 Favored Pre-proline 0 CA--C 1.537 0.456 0 O-C-N 121.557 -0.715 . . . . 10.0 110.524 169.146 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -62.02 -43.55 24.22 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 122.571 2.181 . . . . 10.0 111.459 -178.338 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -77.06 60.4 1.84 Allowed 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 175.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 p -42.23 108.95 0.11 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 126.238 1.815 . . . . 10.0 111.762 -169.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -124.67 176.23 6.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 108.393 -0.965 . . . . 10.0 108.393 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -98.42 113.81 25.93 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -174.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.2 t60 -25.52 102.48 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 124.856 1.262 . . . . 10.0 113.894 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.81 -136.94 7.6 Favored Glycine 0 N--CA 1.443 -0.885 0 N-CA-C 107.975 -2.05 . . . . 10.0 107.975 178.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.03 -164.5 24.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 107.554 -2.219 . . . . 10.0 107.554 168.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -52.67 -18.27 8.44 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.14 1.894 . . . . 10.0 112.237 170.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.477 ' HZ3' ' CG ' ' A' ' 76' ' ' ASP . 0.0 OUTLIER -83.45 -33.36 25.66 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.025 0.93 . . . . 10.0 110.828 -177.424 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.477 ' CG ' ' HZ3' ' A' ' 75' ' ' LYS . 1.4 m-20 -98.04 175.14 6.22 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -171.597 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -89.42 -28.39 19.77 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 167.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -86.79 16.8 4.46 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 125.518 1.527 . . . . 10.0 113.156 -168.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.38 136.05 13.07 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.779 0.831 . . . . 10.0 109.729 168.399 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -71.77 -176.7 1.72 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 107.906 -1.146 . . . . 10.0 107.906 168.262 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.49 41.19 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 N-CA-C 113.754 1.02 . . . . 10.0 113.754 -175.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.82 56.71 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.237 -1.545 . . . . 10.0 109.237 172.166 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -98.01 95.89 7.78 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 169.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -80.16 -30.14 38.87 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.99 -102.02 1.89 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 107.954 -2.058 . . . . 10.0 107.954 168.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -132.34 114.0 13.87 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.998 1.319 . . . . 10.0 109.586 -167.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.5 m -103.6 137.2 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 C-N-CA 122.709 0.403 . . . . 10.0 110.192 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 92.1 m -83.27 105.47 14.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 127.13 2.172 . . . . 10.0 109.681 -177.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.75 131.07 35.21 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.253 0.621 . . . . 10.0 109.945 170.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -59.33 170.63 0.93 Allowed 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.13 1.372 . . . . 10.0 110.182 168.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 66.6 tttt -51.49 -35.27 39.42 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 125.925 1.69 . . . . 10.0 111.845 169.084 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -79.81 2.11 24.29 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 121.556 0.693 . . . . 10.0 111.292 177.293 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.34 -2.81 87.95 Favored Glycine 0 N--CA 1.445 -0.74 0 O-C-N 120.322 -1.487 . . . . 10.0 110.435 -178.312 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 69.5 t -75.67 103.99 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -170.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.23 115.25 30.06 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 108.43 -0.952 . . . . 10.0 108.43 173.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -79.16 125.44 29.45 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 114.44 -1.254 . . . . 10.0 108.107 173.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -106.28 128.67 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.397 0 N-CA-C 104.442 -2.429 . . . . 10.0 104.442 168.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.9 m -155.13 73.88 0.89 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 123.474 0.709 . . . . 10.0 110.028 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 15.8 mm -112.24 161.17 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 124.311 1.044 . . . . 10.0 111.29 -174.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -123.73 134.86 53.61 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 129.733 3.213 . . . . 10.0 107.047 169.092 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -145.68 144.17 30.24 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.505 -0.554 . . . . 10.0 109.505 175.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 5.1 p -109.57 18.72 20.02 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.311 1.844 . . . . 10.0 112.701 -174.24 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.8 t -126.38 -54.26 1.84 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.2 0 C-N-CA 125.595 1.558 . . . . 10.0 107.507 -177.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 10.9 mm -48.92 115.47 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 124.575 1.15 . . . . 10.0 109.086 172.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -114.51 116.78 29.37 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.897 0.879 . . . . 10.0 108.952 -176.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.97 -47.72 32.75 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 125.309 1.444 . . . . 10.0 109.647 176.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.4 m -149.13 164.39 34.83 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.137 -1.431 . . . . 10.0 107.137 174.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 134.27 -99.52 0.35 Allowed Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 107.211 -2.356 . . . . 10.0 107.211 -172.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -120.13 -49.2 2.3 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 124.653 1.181 . . . . 10.0 109.216 -168.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.03 -44.49 39.04 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 -177.315 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.1 t 46.97 76.14 0.11 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.994 1.717 . . . . 10.0 112.559 169.452 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 26.3 pt -59.77 -25.72 33.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 112.146 0.424 . . . . 10.0 112.146 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.1 mm -42.8 122.25 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 CA-C-N 119.068 0.849 . . . . 10.0 111.291 175.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.99 8.59 78.82 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 119.013 -0.881 . . . . 10.0 113.029 175.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.13 169.51 11.86 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.421 1.11 . . . . 10.0 108.499 168.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.92 141.37 36.67 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.862 0.865 . . . . 10.0 111.287 174.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -95.64 141.46 29.12 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.427 -1.323 . . . . 10.0 107.427 168.503 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 72.4 t -123.48 138.96 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 108.604 -0.887 . . . . 10.0 108.604 172.395 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -102.7 122.14 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 167.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 6.3 m-70 -104.88 160.29 15.12 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 115.207 1.558 . . . . 10.0 115.207 -173.036 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.34 -56.23 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 113.818 -1.537 . . . . 10.0 110.657 176.355 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 41.0 mttm -113.8 175.65 5.37 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-O 121.789 0.804 . . . . 10.0 111.918 -179.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.12 139.34 35.68 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.936 1.694 . . . . 10.0 109.051 172.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.484 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -78.14 164.63 24.81 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 121.843 0.83 . . . . 10.0 111.601 174.227 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -73.99 -16.56 61.07 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 114.618 -1.174 . . . . 10.0 110.54 -178.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 10.1 mt 52.13 46.68 26.19 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 -168.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.62 -13.29 67.05 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.65 2.072 . . . . 10.0 113.785 171.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.3 mtmp? -79.31 3.94 16.65 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 115.376 1.621 . . . . 10.0 115.376 -167.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.97 -33.15 51.26 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.493 1.042 . . . . 10.0 110.891 178.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.22 41.99 93.14 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 111.846 -0.502 . . . . 10.0 111.846 -173.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -132.96 170.34 15.49 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 124.684 1.194 . . . . 10.0 108.138 173.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -41.46 -55.66 2.76 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 125.497 1.519 . . . . 10.0 110.479 175.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 49.1 mp0 -56.43 -51.85 66.85 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 125.096 1.359 . . . . 10.0 110.311 176.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.6 p -51.46 -38.26 52.92 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 123.138 0.575 . . . . 10.0 111.009 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.91 -11.65 56.6 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 123.999 0.812 . . . . 10.0 111.307 -170.709 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -112.57 -48.84 2.98 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.829 1.251 . . . . 10.0 112.081 -172.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.7 p -137.05 23.65 3.03 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 120.289 1.404 . . . . 10.0 110.634 174.087 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.81 -113.79 6.19 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 106.065 -2.814 . . . . 10.0 106.065 -171.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 19.3 m-80 -157.95 44.05 0.32 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 107.258 -1.386 . . . . 10.0 107.258 174.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.84 -13.34 55.65 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 124.205 1.002 . . . . 10.0 112.313 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.6 -164.96 54.86 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 110.355 -1.098 . . . . 10.0 110.355 176.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.2 t -54.84 134.14 48.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 113.396 0.888 . . . . 10.0 113.396 -168.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -64.55 73.3 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.967 1.707 . . . . 10.0 109.432 168.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 39.8 mt -49.83 -39.3 38.31 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 118.383 0.538 . . . . 10.0 111.927 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.98 157.42 36.17 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.135 -0.691 . . . . 10.0 109.135 -177.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -157.08 162.3 39.47 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.415 -0.357 . . . . 10.0 110.531 -173.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.62 175.6 26.87 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.847 1.213 . . . . 10.0 110.088 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 13.6 t -122.04 140.81 44.82 Favored 'Isoleucine or valine' 0 C--N 1.343 0.298 0 CA-C-N 118.882 1.341 . . . . 10.0 107.422 -177.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.5 mt -75.82 119.56 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 123.76 0.824 . . . . 10.0 109.836 -176.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.97 148.9 17.89 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 125.428 1.49 . . . . 10.0 111.737 -178.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 89.0 mt -69.16 135.16 28.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.58 1.552 . . . . 10.0 110.163 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.02 -7.13 4.41 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 115.45 1.648 . . . . 10.0 115.45 -173.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.253 1.269 0 CA-C-O 117.528 -1.225 . . . . 10.0 110.199 -179.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.669 0 CA-C-O 118.272 -0.871 . . . . 10.0 109.043 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -78.19 -26.83 47.72 Favored 'General case' 0 C--O 1.224 -0.24 0 C-N-CA 123.345 0.658 . . . . 10.0 110.895 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 62.5 tttt -130.05 137.3 50.16 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.093 0.473 . . . . 10.0 111.068 176.257 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.29 161.17 36.17 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 125.129 1.372 . . . . 10.0 107.964 171.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -126.91 156.26 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 C-N-CA 125.184 1.394 . . . . 10.0 109.735 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.85 112.31 8.2 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 168.589 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 11.6 m -100.41 128.65 52.22 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 108.31 -0.996 . . . . 10.0 108.31 171.004 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.18 145.35 31.64 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 123.917 0.887 . . . . 10.0 110.534 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -161.19 160.45 30.12 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.921 -1.141 . . . . 10.0 107.921 168.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.1 -45.58 0.12 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.982 -1.104 . . . . 10.0 113.285 169.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 -45.04 53.12 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.604 -1.258 . . . . 10.0 107.604 -175.588 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.37 -71.19 0.39 Allowed Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.644 -1.382 . . . . 10.0 109.644 170.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -57.86 -38.88 90.87 Favored 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 123.076 2.518 . . . . 10.0 111.095 171.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 92.2 t -61.47 103.05 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.035 0 N-CA-C 107.824 -1.176 . . . . 10.0 107.824 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -118.1 128.86 55.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.339 -1.356 . . . . 10.0 107.339 169.641 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.15 146.29 18.54 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 110.953 -0.859 . . . . 10.0 110.953 175.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 mt -146.57 89.55 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 C-N-CA 125.634 1.573 . . . . 10.0 107.657 -176.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -102.5 139.25 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.744 1.618 . . . . 10.0 110.082 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -115.9 110.73 19.41 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 129.314 3.046 . . . . 10.0 107.366 176.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -95.02 114.64 26.47 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -112.47 122.34 47.42 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 118.64 0.655 . . . . 10.0 112.721 169.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 5.0 tp-100 -82.55 110.11 17.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.145 -2.168 . . . . 10.0 105.145 166.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt . . . . . 0 N--CA 1.442 -0.836 0 C-N-CA 130.429 3.492 . . . . 10.0 111.456 -179.963 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.04 151.05 86.97 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.458 1.439 . . . . 10.0 108.744 171.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 t -79.76 124.07 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.984 -2.599 . . . . 10.0 103.984 168.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -99.66 112.53 24.75 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.496 -1.668 . . . . 10.0 106.496 169.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -95.99 103.99 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.959 0 C-N-CA 127.08 2.152 . . . . 10.0 106.135 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -124.75 165.17 18.44 Favored 'General case' 0 C--O 1.223 -0.323 0 N-CA-C 112.648 0.61 . . . . 10.0 112.648 173.285 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.8 -156.63 27.1 Favored Glycine 0 N--CA 1.449 -0.494 0 N-CA-C 107.216 -2.354 . . . . 10.0 107.216 172.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 50.8 p -156.25 160.52 39.87 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.565 -1.254 . . . . 10.0 112.52 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.18 136.56 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 C-N-CA 126.197 1.799 . . . . 10.0 107.519 167.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.82 159.38 37.52 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.289 0.368 . . . . 10.0 110.452 167.276 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.14 -0.19 44.31 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.779 0.704 . . . . 10.0 113.22 -178.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.9 mp -85.02 175.62 8.93 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 118.0 0.9 . . . . 10.0 109.703 -178.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.5 t -90.89 154.45 19.47 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.913 -0.773 . . . . 10.0 108.913 168.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -51.22 145.32 8.14 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 126.536 1.935 . . . . 10.0 111.324 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.92 -170.49 21.84 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-O 121.593 0.552 . . . . 10.0 111.95 172.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -73.88 147.56 43.1 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.296 1.438 . . . . 10.0 112.535 -170.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -147.94 127.49 13.24 Favored 'General case' 0 C--N 1.341 0.218 0 N-CA-C 114.395 1.257 . . . . 10.0 114.395 -178.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -17.75 124.41 0.01 OUTLIER Glycine 0 C--N 1.342 0.89 0 C-N-CA 127.473 2.463 . . . . 10.0 114.489 164.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -147.18 106.17 3.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 119.863 1.832 . . . . 10.0 111.339 167.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.45 172.49 15.87 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.417 0.627 . . . . 10.0 111.165 175.206 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 19.5 m -96.91 153.92 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 112.632 -2.076 . . . . 10.0 108.479 168.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -134.49 135.47 42.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.005 2.122 . . . . 10.0 105.349 177.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -56.7 -48.36 77.87 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.896 0.748 . . . . 10.0 112.84 -168.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -78.42 112.66 15.68 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 118.126 -1.43 . . . . 10.0 108.486 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.74 -26.37 62.56 Favored Glycine 0 N--CA 1.44 -1.068 0 N-CA-C 109.534 -1.426 . . . . 10.0 109.534 167.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -34.37 109.12 0.07 Allowed 'General case' 0 CA--C 1.516 -0.364 0 C-N-CA 125.237 1.415 . . . . 10.0 111.343 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.97 13.13 13.9 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 113.417 -1.719 . . . . 10.0 110.672 174.307 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.23 -39.84 67.14 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 119.102 0.864 . . . . 10.0 111.999 -168.314 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.88 -17.98 54.68 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.313 1.045 . . . . 10.0 113.027 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.23 76.07 1.11 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 108.269 -1.932 . . . . 10.0 108.269 -169.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.6 p 30.55 37.5 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 128.338 2.655 . . . . 10.0 116.177 -177.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.4 m -100.33 -50.25 3.99 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 -178.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.1 m -67.04 -14.73 63.18 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 126.378 1.871 . . . . 10.0 112.201 177.698 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.26 -26.74 0.35 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 127.228 2.211 . . . . 10.0 114.334 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 156.26 26.59 Favored Glycine 0 N--CA 1.438 -1.213 0 N-CA-C 109.002 -1.639 . . . . 10.0 109.002 169.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -69.31 -170.92 0.39 Allowed 'Trans proline' 0 N--CA 1.44 -1.65 0 N-CA-C 106.756 -2.055 . . . . 10.0 106.756 167.003 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.417 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 31.2 m170 -81.61 60.33 4.53 Favored 'General case' 0 CA--C 1.542 0.647 0 O-C-N 120.325 -1.485 . . . . 10.0 109.99 -172.398 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -70.85 75.52 0.62 Allowed 'General case' 0 C--O 1.223 -0.328 0 CA-C-N 118.917 0.781 . . . . 10.0 110.584 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -75.26 148.01 83.36 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.336 -0.853 . . . . 10.0 110.933 172.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.14 -42.97 12.32 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.57 2.18 . . . . 10.0 110.661 176.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.2 mt -75.87 54.77 0.84 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 123.806 0.843 . . . . 10.0 109.86 176.253 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.5 p -40.29 112.01 0.24 Allowed 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 125.787 1.635 . . . . 10.0 111.571 -172.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -142.34 178.4 7.6 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.42 -2.437 . . . . 10.0 104.42 -176.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -65.92 156.74 32.61 Favored 'General case' 0 N--CA 1.439 -0.977 0 C-N-CA 116.606 -2.038 . . . . 10.0 108.917 168.386 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -66.43 126.32 28.47 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 104.976 -2.231 . . . . 10.0 104.976 161.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.27 -133.21 3.07 Favored Glycine 0 N--CA 1.451 -0.35 0 N-CA-C 109.226 -1.55 . . . . 10.0 109.226 172.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.84 -155.08 23.19 Favored Glycine 0 C--O 1.226 -0.405 0 CA-C-O 118.028 -1.429 . . . . 10.0 109.53 174.64 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -64.88 2.37 1.37 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 CA-C-N 119.803 1.801 . . . . 10.0 112.155 172.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -95.18 -21.57 18.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 117.65 -1.167 . . . . 10.0 110.862 172.319 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -126.72 156.14 41.6 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 119.318 0.963 . . . . 10.0 109.817 -170.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -78.17 -32.79 50.31 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 106.885 -1.524 . . . . 10.0 106.885 167.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -88.01 57.17 4.18 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 125.553 1.541 . . . . 10.0 108.167 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 14.3 ptm180 -83.78 147.81 27.39 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 106.259 -1.756 . . . . 10.0 106.259 165.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -63.55 -57.95 8.52 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.481 1.037 . . . . 10.0 110.548 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.1 p 179.78 -99.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 104.883 -2.265 . . . . 10.0 104.883 -179.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -74.68 54.15 2.48 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.45 1.023 . . . . 10.0 112.417 172.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 70.0 m-20 -95.76 92.56 6.62 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.223 -2.51 . . . . 10.0 104.223 167.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 80.7 mt -89.44 38.84 0.92 Allowed 'General case' 0 CA--C 1.531 0.214 0 N-CA-C 107.983 -1.117 . . . . 10.0 107.983 177.195 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 32.91 -103.08 0.01 OUTLIER Glycine 0 C--N 1.341 0.84 0 C-N-CA 128.124 2.773 . . . . 10.0 112.206 -175.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -143.85 147.11 33.6 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.11 0.964 . . . . 10.0 109.769 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 32.4 m -113.15 139.04 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 125.095 1.358 . . . . 10.0 108.355 -174.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -83.41 122.47 28.54 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.273 0.629 . . . . 10.0 109.917 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.75 131.31 37.92 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.581 1.153 . . . . 10.0 109.255 171.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -56.15 169.36 0.41 Allowed 'General case' 0 N--CA 1.451 -0.41 0 O-C-N 124.486 1.116 . . . . 10.0 110.007 168.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 11.3 tttp -49.99 -35.46 24.56 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.284 1.434 . . . . 10.0 112.185 169.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -79.47 0.31 30.04 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.275 0.559 . . . . 10.0 112.202 177.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.03 -1.0 86.54 Favored Glycine 0 C--N 1.337 0.623 0 O-C-N 120.394 -1.441 . . . . 10.0 110.698 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 56.0 t -77.15 97.71 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 107.443 -1.317 . . . . 10.0 107.443 -174.639 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.3 116.98 29.44 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 168.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -88.19 130.35 35.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.839 -1.171 . . . . 10.0 107.839 174.014 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.0 t -107.7 129.89 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.257 -2.127 . . . . 10.0 105.257 168.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -157.77 55.88 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 118.696 0.68 . . . . 10.0 110.957 175.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.58 143.68 17.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.466 -0.771 . . . . 10.0 110.222 -169.084 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -97.85 129.21 44.83 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 128.638 2.775 . . . . 10.0 107.049 168.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -143.23 134.0 25.26 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 109.454 -0.573 . . . . 10.0 109.454 -176.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.6 p -115.64 45.78 1.63 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.559 1.544 . . . . 10.0 110.011 -169.337 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.9 p -142.98 -46.79 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 122.634 0.374 . . . . 10.0 111.219 177.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.31 0.0 OUTLIER -65.12 161.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 119.787 -0.765 . . . . 10.0 111.441 169.517 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 20.3 m -146.32 165.47 29.17 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 169.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 83.4 mt -100.55 -18.52 16.59 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 123.138 0.575 . . . . 10.0 110.061 175.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 44.7 m . . . . . 0 N--CA 1.452 -0.344 0 C-N-CA 125.443 1.497 . . . . 10.0 107.189 174.358 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.7 t . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.481 -0.563 . . . . 10.0 109.481 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 24.5 pt -75.41 34.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.519 -0.738 . . . . 10.0 112.746 -177.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 38.2 mm -85.25 146.54 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 O-C-N 120.281 -1.512 . . . . 10.0 109.395 -175.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.85 24.21 69.78 Favored Glycine 0 CA--C 1.531 1.079 0 O-C-N 121.976 -0.452 . . . . 10.0 112.677 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -93.3 149.49 21.19 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 125.172 1.389 . . . . 10.0 107.347 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -87.47 139.96 30.01 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 168.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -116.61 159.01 22.79 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 108.135 -1.061 . . . . 10.0 108.135 168.704 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 74.5 t -137.94 129.51 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 107.981 -1.118 . . . . 10.0 107.981 -172.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 3.0 p -94.52 122.65 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 105.929 -1.878 . . . . 10.0 105.929 167.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -105.98 160.24 15.43 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 115.303 1.594 . . . . 10.0 115.303 -171.329 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -41.38 -60.94 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.069 2.948 . . . . 10.0 111.968 171.108 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -120.16 172.16 7.97 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.71 1.204 . . . . 10.0 113.166 -168.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.54 154.47 38.61 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 114.186 -1.37 . . . . 10.0 108.187 168.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -92.74 168.73 11.0 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 124.337 1.055 . . . . 10.0 111.034 -176.061 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.58 -20.99 59.72 Favored 'General case' 0 C--O 1.223 -0.336 0 C-N-CA 125.11 1.364 . . . . 10.0 108.278 175.049 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 49.8 mt 49.45 43.31 23.52 Favored 'General case' 0 C--N 1.341 0.237 0 C-N-CA 124.457 1.103 . . . . 10.0 109.998 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.51 33.17 80.48 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.087 -1.415 . . . . 10.0 113.174 178.142 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -75.4 0.08 18.18 Favored 'General case' 0 C--N 1.339 0.142 0 CA-C-N 118.913 1.357 . . . . 10.0 112.337 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.82 17.97 78.63 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.45 -1.46 . . . . 10.0 109.45 178.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.25 -26.08 74.32 Favored Glycine 0 N--CA 1.443 -0.834 0 N-CA-C 110.352 -1.099 . . . . 10.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 34.3 m-80 -156.07 163.14 40.03 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 118.067 0.933 . . . . 10.0 108.925 -168.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -56.23 -42.21 76.92 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 109.546 -0.539 . . . . 10.0 109.546 171.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -61.38 -23.96 66.15 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 112.635 0.606 . . . . 10.0 112.635 175.174 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.3 p -52.42 -39.32 60.83 Favored 'General case' 0 CA--C 1.512 -0.519 0 CA-C-N 118.556 0.617 . . . . 10.0 110.393 -172.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.7 t -90.17 -1.76 57.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 O-C-N 124.671 1.232 . . . . 10.0 111.67 -173.593 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -116.82 -48.93 2.64 Favored 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 126.769 2.028 . . . . 10.0 111.367 -168.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.417 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 1.7 p -135.43 -2.61 2.45 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 118.653 -0.689 . . . . 10.0 111.543 168.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 -106.38 3.19 Favored Glycine 0 N--CA 1.433 -1.52 0 N-CA-C 105.693 -2.963 . . . . 10.0 105.693 -166.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -168.79 30.55 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.22 1.01 . . . . 10.0 110.07 -173.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.19 -20.27 66.37 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.971 0.909 . . . . 10.0 113.277 -167.267 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.45 -160.69 53.25 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 110.394 -1.083 . . . . 10.0 110.394 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.5 m -55.57 130.8 44.38 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.074 0.94 . . . . 10.0 113.151 -167.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 60.6 mtt180 -69.23 68.25 0.19 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.129 1.771 . . . . 10.0 110.415 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 37.8 mt -54.41 -31.9 56.08 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 113.141 0.793 . . . . 10.0 113.141 -173.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.22 153.15 25.19 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 109.129 -0.693 . . . . 10.0 109.129 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.5 m -146.19 161.55 39.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 115.548 -0.751 . . . . 10.0 109.934 -166.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.36 172.78 34.81 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.089 -1.204 . . . . 10.0 110.089 176.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -122.4 135.32 62.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 9.1 mt -69.23 116.66 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 C-N-CA 122.983 0.513 . . . . 10.0 110.034 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.05 144.47 17.72 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 124.812 1.196 . . . . 10.0 110.526 -178.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 59.8 mt -65.77 144.56 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 N-CA-C 108.045 -1.094 . . . . 10.0 108.045 176.114 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.55 -43.05 3.06 Favored 'General case' 0 C--O 1.227 -0.124 0 CA-C-N 119.268 0.94 . . . . 10.0 111.923 170.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 117.088 -1.434 . . . . 10.0 110.854 179.029 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.656 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.6 t -154.77 -49.31 0.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 123.479 0.712 . . . . 10.0 109.501 173.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 ttmt -106.41 155.84 19.14 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.222 -1.77 . . . . 10.0 106.222 169.317 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.77 164.82 38.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 107.093 -1.447 . . . . 10.0 107.093 170.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -136.17 164.4 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 O-C-N 123.325 0.391 . . . . 10.0 110.854 -176.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.37 101.85 4.09 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.123 -1.065 . . . . 10.0 108.123 168.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.5 m -85.84 88.26 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 170.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -81.67 126.38 31.71 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.087 -0.708 . . . . 10.0 109.087 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 46.8 mtpt -140.8 160.41 40.11 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.05 -1.463 . . . . 10.0 107.05 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.07 -60.93 0.04 OUTLIER Glycine 0 C--O 1.229 -0.199 0 C-N-CA 120.808 -0.71 . . . . 10.0 112.745 169.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.99 -43.94 64.3 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 -176.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.82 -70.75 0.41 Allowed Glycine 0 CA--C 1.523 0.581 0 CA-C-N 114.23 -1.35 . . . . 10.0 110.446 169.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -58.16 -32.61 96.08 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 123.511 2.807 . . . . 10.0 111.665 173.483 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.0 t -67.22 93.75 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 N-CA-C 107.094 -1.447 . . . . 10.0 107.094 177.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -117.96 106.94 13.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.65 142.18 15.91 Favored Glycine 0 N--CA 1.441 -1.017 0 N-CA-C 109.171 -1.572 . . . . 10.0 109.171 169.204 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.4 mt -143.77 58.66 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 -169.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.0 mm -79.74 137.28 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 115.688 -0.687 . . . . 10.0 109.328 -173.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -115.33 117.04 29.33 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.433 1.493 . . . . 10.0 108.024 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -102.74 122.88 45.36 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 177.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -118.37 144.61 45.77 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.675 0.671 . . . . 10.0 112.405 173.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -125.31 102.01 7.24 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 127.85 2.46 . . . . 10.0 106.594 167.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -49.74 -56.14 11.34 Favored 'General case' 0 C--N 1.338 0.098 0 C-N-CA 124.415 1.086 . . . . 10.0 109.931 172.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.56 178.54 6.99 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 105.128 -2.175 . . . . 10.0 105.128 171.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.0 t -72.31 -18.79 61.75 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.455 -0.202 . . . . 10.0 110.455 177.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -79.68 -19.38 49.15 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 123.673 0.789 . . . . 10.0 109.765 177.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.61 143.46 45.55 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.531 -1.028 . . . . 10.0 110.531 179.217 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.48 149.03 43.73 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.466 2.11 . . . . 10.0 107.648 168.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 t -79.58 100.34 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -81.91 108.0 15.07 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.927 -1.508 . . . . 10.0 106.927 168.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.3 m -90.11 103.41 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 107.108 -1.441 . . . . 10.0 107.108 173.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.4 p90 -112.73 153.95 26.93 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-O 121.481 0.657 . . . . 10.0 112.61 173.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.47 179.37 41.28 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.637 -0.792 . . . . 10.0 111.274 169.156 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.4 p -131.67 103.94 6.65 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 -175.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 pt -79.8 140.99 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 169.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -118.28 149.84 40.46 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 169.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.55 -8.15 37.22 Favored Glycine 0 C--N 1.336 0.569 0 CA-C-O 119.534 -0.592 . . . . 10.0 113.354 170.071 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -60.97 176.68 0.39 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.915 0.864 . . . . 10.0 109.75 170.648 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -110.61 171.65 7.34 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 166.111 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -48.93 156.27 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.858 1.263 . . . . 10.0 112.816 -172.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.01 -169.93 46.84 Favored Glycine 0 N--CA 1.443 -0.858 0 CA-C-O 122.667 1.149 . . . . 10.0 113.848 166.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mp -69.86 141.78 53.16 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 126.246 1.818 . . . . 10.0 110.139 -177.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -142.54 151.98 42.15 Favored 'General case' 0 C--N 1.341 0.203 0 N-CA-C 114.132 1.16 . . . . 10.0 114.132 178.085 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -30.71 122.39 0.13 Allowed Glycine 0 C--N 1.34 0.783 0 C-N-CA 128.533 2.968 . . . . 10.0 112.709 164.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -156.14 107.22 2.46 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.206 1.503 . . . . 10.0 111.72 168.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.463 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -157.55 169.75 23.96 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 113.2 0.815 . . . . 10.0 113.2 -179.764 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.4 m -84.13 157.79 3.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 CA-C-N 112.694 -2.048 . . . . 10.0 109.929 169.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -142.14 140.15 32.35 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 126.58 1.952 . . . . 10.0 107.366 179.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -58.55 -59.72 4.94 Favored 'General case' 0 N--CA 1.446 -0.645 0 O-C-N 124.212 0.945 . . . . 10.0 111.249 -172.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -76.95 123.02 25.7 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 117.932 -1.507 . . . . 10.0 108.984 -169.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.05 -9.25 63.0 Favored Glycine 0 CA--C 1.535 1.317 0 N-CA-C 110.336 -1.106 . . . . 10.0 110.336 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -59.07 99.84 0.06 Allowed 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 122.371 1.081 . . . . 10.0 111.453 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -107.53 14.39 25.84 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 113.506 -1.679 . . . . 10.0 110.432 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.1 m -54.71 -35.51 63.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 120.065 1.302 . . . . 10.0 110.776 -177.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.72 -19.99 57.05 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.769 0.828 . . . . 10.0 112.392 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 133.05 -87.74 0.27 Allowed Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.432 1.492 . . . . 10.0 109.533 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 15.7 t -155.17 62.04 0.64 Allowed 'General case' 0 CA--C 1.529 0.162 0 O-C-N 122.067 -0.666 . . . . 10.0 109.705 -172.233 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -162.5 -49.92 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.557 -0.714 . . . . 10.0 110.175 -175.239 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.7 t -57.47 -19.98 27.77 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 123.941 0.896 . . . . 10.0 111.149 -178.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.82 -27.36 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.822 2.049 . . . . 10.0 113.589 168.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.48 170.69 33.17 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 108.071 -2.012 . . . . 10.0 108.071 168.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -81.5 -166.38 0.4 Allowed 'Trans proline' 0 N--CA 1.441 -1.582 0 N-CA-C 107.077 -1.932 . . . . 10.0 107.077 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.437 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.6 m170 -82.85 58.94 4.57 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 120.893 -1.129 . . . . 10.0 110.629 -174.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -71.99 74.18 0.9 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.949 0.88 . . . . 10.0 111.257 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 -74.92 153.11 86.84 Favored Pre-proline 0 CA--C 1.537 0.444 0 C-N-CA 124.292 1.037 . . . . 10.0 110.302 171.336 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.12 -43.54 11.23 Favored 'Trans proline' 0 N--CA 1.456 -0.712 0 C-N-CA 122.322 2.015 . . . . 10.0 111.019 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.6 51.21 0.73 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.401 0.68 . . . . 10.0 110.579 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 35.0 p -52.48 112.51 0.83 Allowed 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.247 1.019 . . . . 10.0 109.907 -174.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 30.1 mtt85 -136.93 -85.71 0.32 Allowed 'General case' 0 CA--C 1.511 -0.545 0 N-CA-C 106.953 -1.499 . . . . 10.0 106.953 -170.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -144.7 158.2 43.88 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-O 122.402 1.096 . . . . 10.0 109.361 167.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 67.3 t60 -73.13 120.46 18.79 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 162.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.5 -131.75 2.45 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 108.148 -1.981 . . . . 10.0 108.148 175.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.09 -149.2 7.87 Favored Glycine 0 C--O 1.226 -0.351 0 N-CA-C 109.106 -1.598 . . . . 10.0 109.106 169.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -64.92 3.71 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.863 0 CA-C-N 120.344 2.072 . . . . 10.0 111.656 169.112 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -92.35 -22.48 19.67 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 124.901 1.28 . . . . 10.0 110.611 172.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 59.6 t0 -117.18 152.77 34.09 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.118 -1.067 . . . . 10.0 108.118 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -79.2 -33.43 43.87 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.403 -1.271 . . . . 10.0 108.078 169.188 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -91.02 8.1 37.08 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.415 1.486 . . . . 10.0 111.606 -170.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.21 142.1 3.04 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.456 1.103 . . . . 10.0 110.478 176.109 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.7 m170 -59.73 -59.37 5.54 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.447 0.641 . . . . 10.0 110.342 -169.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.3 p -173.5 -98.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 104.586 -2.376 . . . . 10.0 104.586 177.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -79.1 58.38 4.34 Favored Glycine 0 CA--C 1.529 0.954 0 CA-C-N 118.776 0.716 . . . . 10.0 111.457 174.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -90.59 90.59 8.05 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 104.309 -2.478 . . . . 10.0 104.309 167.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 8.6 mt -70.79 -33.28 70.57 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.28 -76.53 0.51 Allowed Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 10.0 111.32 167.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -135.43 118.58 16.52 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 117.938 0.869 . . . . 10.0 109.45 -175.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.2 m -103.98 122.44 56.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 168.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 m -82.67 101.75 11.04 Favored 'General case' 0 N--CA 1.437 -1.107 0 C-N-CA 127.402 2.281 . . . . 10.0 109.507 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.64 130.24 35.33 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.251 0.62 . . . . 10.0 110.561 175.587 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -58.94 169.03 1.1 Allowed 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 124.215 0.947 . . . . 10.0 109.277 167.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 ptmm? -50.78 -32.4 19.76 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.539 1.535 . . . . 10.0 111.565 169.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.8 m-20 -78.28 -5.16 51.2 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.933 0.893 . . . . 10.0 111.321 -178.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.78 6.91 88.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 111.071 -0.811 . . . . 10.0 111.071 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.0 t -79.95 107.2 12.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.926 0 C-N-CA 126.532 1.933 . . . . 10.0 106.043 176.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.12 118.58 36.78 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 169.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -81.68 123.97 29.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 O-C-N 124.408 1.068 . . . . 10.0 108.461 172.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 99.4 t -112.38 130.44 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.238 0 C-N-CA 127.097 2.159 . . . . 10.0 106.365 177.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.3 p -156.11 65.34 0.57 Allowed 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.477 0.711 . . . . 10.0 109.458 174.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -96.63 156.9 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 -177.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -136.02 121.86 19.87 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 125.465 1.506 . . . . 10.0 109.38 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -125.66 117.78 24.24 Favored 'General case' 0 C--O 1.232 0.174 0 C-N-CA 124.623 1.169 . . . . 10.0 108.6 -177.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -89.14 54.64 3.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 171.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.02 -53.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 C-N-CA 122.932 0.493 . . . . 10.0 110.245 -176.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -58.27 147.52 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 172.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.1 p -137.48 136.19 37.5 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.365 -0.379 . . . . 10.0 110.402 170.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -77.79 -35.08 51.91 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 107.862 -1.162 . . . . 10.0 107.862 168.511 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.7 m -151.39 130.58 12.73 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 103.534 -2.765 . . . . 10.0 103.534 168.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.33 -79.7 0.1 Allowed Glycine 0 C--N 1.331 0.302 0 N-CA-C 109.219 -1.552 . . . . 10.0 109.219 -169.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -147.22 -54.29 0.22 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.09 -1.055 . . . . 10.0 108.68 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -75.84 -36.99 59.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.372 -1.286 . . . . 10.0 108.633 -173.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.7 t 45.69 61.12 2.77 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.317 1.047 . . . . 10.0 110.326 169.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 25.5 pt -74.53 31.77 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.89 0.852 . . . . 10.0 112.956 -169.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.7 mm -81.76 123.82 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 C-N-CA 125.627 1.571 . . . . 10.0 107.912 -176.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.14 4.66 64.5 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 123.947 0.785 . . . . 10.0 111.541 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -83.58 171.05 13.71 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 168.189 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 2.4 m -119.12 140.7 49.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 108.245 -1.021 . . . . 10.0 108.245 -177.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.43 164.25 13.85 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.61 0.641 . . . . 10.0 109.631 168.174 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -140.56 134.22 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 O-C-N 123.953 0.783 . . . . 10.0 109.345 -172.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.9 m -96.95 133.0 40.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 106.554 -1.647 . . . . 10.0 106.554 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -114.01 158.3 21.37 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 114.948 1.462 . . . . 10.0 114.948 -175.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -55.78 -47.16 77.55 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.246 1.819 . . . . 10.0 111.35 -179.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 79.3 mttt -112.46 163.39 14.51 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 119.121 0.873 . . . . 10.0 112.903 -175.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.76 152.78 30.32 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 124.697 1.199 . . . . 10.0 108.755 169.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.463 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.5 OUTLIER -78.96 151.4 31.64 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-O 122.746 1.26 . . . . 10.0 112.292 -179.378 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.82 -29.54 44.83 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 112.133 -2.303 . . . . 10.0 109.448 170.633 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.0 mt 58.55 34.68 24.08 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 124.694 1.198 . . . . 10.0 111.893 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.1 -18.48 57.27 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 123.969 0.795 . . . . 10.0 111.768 170.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -74.77 -5.98 46.4 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 124.344 1.058 . . . . 10.0 111.941 -168.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.54 -28.99 70.59 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.362 -1.095 . . . . 10.0 110.362 168.217 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.76 43.46 54.15 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.512 -1.035 . . . . 10.0 110.512 -170.274 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -128.28 168.16 15.89 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.115 -1.069 . . . . 10.0 108.115 175.058 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -48.52 -50.24 32.69 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.076 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 58.8 mp0 -55.85 -54.13 48.26 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 125.805 1.642 . . . . 10.0 111.811 171.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.8 p -49.74 -44.98 48.87 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 109.389 -0.596 . . . . 10.0 109.389 -173.118 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.7 t -81.19 -1.64 45.51 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.503 0.557 . . . . 10.0 112.503 -171.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.7 mttt -112.68 -50.37 2.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 125.653 1.581 . . . . 10.0 112.128 -176.627 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.1 p -139.09 17.17 2.62 Favored 'General case' 0 C--N 1.34 0.174 0 CA-C-N 119.545 1.066 . . . . 10.0 111.817 173.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.07 -116.45 5.56 Favored Glycine 0 N--CA 1.436 -1.311 0 N-CA-C 103.794 -3.722 . . . . 10.0 103.794 -169.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -163.88 40.42 0.09 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.582 -1.636 . . . . 10.0 106.582 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.71 -4.47 37.65 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 124.06 0.944 . . . . 10.0 112.193 -170.539 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.72 -164.3 53.09 Favored Glycine 0 N--CA 1.446 -0.679 0 O-C-N 121.415 -0.803 . . . . 10.0 111.527 169.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.6 m -53.86 131.37 39.76 Favored 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 124.711 1.204 . . . . 10.0 114.019 -168.117 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 34.0 mtt180 -64.95 73.47 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.519 1.928 . . . . 10.0 111.168 174.248 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 43.1 mt -51.03 -35.67 35.5 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 112.642 0.608 . . . . 10.0 112.642 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.49 153.09 32.78 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 121.901 -0.5 . . . . 10.0 109.722 176.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.6 p -149.98 156.51 41.85 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 109.38 -0.6 . . . . 10.0 109.38 178.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.85 153.95 25.17 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.063 -0.815 . . . . 10.0 111.063 -176.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 84.6 t -102.88 139.86 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 105.967 -1.864 . . . . 10.0 105.967 -173.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 18.0 mt -74.91 110.31 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 122.843 0.457 . . . . 10.0 109.894 -175.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.61 141.92 15.38 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 124.237 0.922 . . . . 10.0 110.972 -177.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.8 mt -64.83 146.38 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.401 1.48 . . . . 10.0 110.523 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.59 165.57 29.97 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-O 122.564 1.173 . . . . 10.0 110.506 167.814 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 . . . . . 0 C--O 1.255 1.384 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 166.15 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 105.885 -1.894 . . . . 10.0 105.885 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.7 t -76.81 -46.62 24.21 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 119.996 1.271 . . . . 10.0 110.351 -168.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -127.36 128.3 45.64 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 124.321 1.048 . . . . 10.0 111.317 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.04 160.88 38.73 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 123.348 0.659 . . . . 10.0 109.591 168.742 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.13 162.09 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 124.129 0.972 . . . . 10.0 109.291 -178.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.41 102.75 3.88 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.703 -1.221 . . . . 10.0 107.703 169.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -85.12 111.88 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 N-CA-C 108.851 -0.796 . . . . 10.0 108.851 169.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mt -88.16 141.12 28.82 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.481 -0.933 . . . . 10.0 108.481 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -157.8 161.72 38.41 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.696 1.135 . . . . 10.0 108.14 171.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.59 -55.98 0.04 OUTLIER Glycine 0 C--N 1.329 0.166 0 N-CA-C 111.937 -0.465 . . . . 10.0 111.937 170.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.75 -45.78 41.65 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 -170.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.48 -66.19 0.57 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 113.676 -1.602 . . . . 10.0 110.786 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -57.81 -36.9 98.07 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.763 2.308 . . . . 10.0 111.071 172.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -67.52 109.9 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 108.472 -0.936 . . . . 10.0 108.472 174.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -126.57 112.25 15.3 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 106.381 -1.711 . . . . 10.0 106.381 168.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.39 145.28 17.75 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.718 -1.353 . . . . 10.0 109.718 171.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -145.62 87.63 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -169.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -105.99 145.33 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.204 0 C-N-CA 124.446 1.098 . . . . 10.0 110.253 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -121.06 126.33 49.57 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 127.078 2.151 . . . . 10.0 109.564 168.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -103.68 114.07 28.07 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 170.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -109.27 126.97 53.89 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 123.502 0.501 . . . . 10.0 111.333 169.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 -94.08 99.41 11.71 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 106.811 -1.552 . . . . 10.0 106.811 174.065 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.454 -0.243 0 C-N-CA 124.83 1.252 . . . . 10.0 109.928 -177.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.822 0 N-CA-C 110.073 -1.211 . . . . 10.0 110.073 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -66.12 150.54 85.06 Favored 'Trans proline' 0 N--CA 1.451 -1.029 0 C-N-CA 121.811 1.674 . . . . 10.0 108.426 169.648 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.11 121.0 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 N-CA-C 105.723 -1.954 . . . . 10.0 105.723 169.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.5 ttmp? -95.81 120.57 36.31 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 107.124 -1.436 . . . . 10.0 107.124 169.142 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -100.17 103.94 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 C-N-CA 126.824 2.049 . . . . 10.0 106.147 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -126.84 166.35 17.63 Favored 'General case' 0 CA--C 1.52 -0.198 0 N-CA-C 112.355 0.502 . . . . 10.0 112.355 177.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.18 -150.57 22.44 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 106.928 -2.469 . . . . 10.0 106.928 169.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.0 p -156.38 165.38 36.5 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.88 175.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pp -113.67 173.19 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-N 115.298 -0.864 . . . . 10.0 108.868 167.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.8 tttt -144.03 142.04 30.44 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 106.492 -1.67 . . . . 10.0 106.492 164.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.03 -8.32 11.57 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 113.05 170.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -67.37 177.73 1.79 Allowed 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.181 0.993 . . . . 10.0 111.037 177.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.1 t -110.77 152.85 26.13 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.724 -1.584 . . . . 10.0 106.724 168.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -53.52 150.78 6.41 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.437 0.695 . . . . 10.0 112.216 -168.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.67 -168.49 20.59 Favored Glycine 0 CA--C 1.523 0.567 0 C-N-CA 123.828 0.728 . . . . 10.0 111.295 173.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mp -78.16 138.87 38.92 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.335 1.454 . . . . 10.0 110.892 -172.192 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -142.02 131.91 24.39 Favored 'General case' 0 CA--C 1.521 -0.165 0 C-N-CA 124.376 1.07 . . . . 10.0 112.254 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -17.75 122.92 0.01 OUTLIER Glycine 0 C--N 1.343 0.918 0 C-N-CA 128.001 2.715 . . . . 10.0 113.161 167.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -148.76 106.3 3.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 119.198 1.499 . . . . 10.0 110.633 171.459 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.84 169.95 21.0 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.596 0.712 . . . . 10.0 111.393 177.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 9.3 p -90.6 145.88 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 CA-C-N 111.946 -2.388 . . . . 10.0 107.274 166.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -125.69 146.16 49.86 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.019 -1.845 . . . . 10.0 106.019 170.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . 0.424 ' CD ' ' HE ' ' B' ' 115' ' ' ARG . 29.7 tp10 -76.42 -31.5 57.94 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.295 -0.866 . . . . 10.0 111.887 -166.639 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -78.95 113.94 17.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.081 -1.081 . . . . 10.0 108.081 174.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.34 -15.6 68.18 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 167.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -42.89 148.47 0.25 Allowed 'General case' 0 C--N 1.343 0.305 0 C-N-CA 124.735 1.214 . . . . 10.0 111.716 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -158.24 16.54 0.22 Allowed 'General case' 0 N--CA 1.441 -0.925 0 C-N-CA 125.519 1.528 . . . . 10.0 111.564 169.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 3.1 m -54.95 -37.4 66.42 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 119.458 1.026 . . . . 10.0 111.469 -169.147 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.8 -22.23 46.57 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.409 1.084 . . . . 10.0 112.528 177.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 126.89 -167.01 19.46 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 106.246 -2.742 . . . . 10.0 106.246 -169.308 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m -72.65 53.28 0.32 Allowed 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 125.005 1.322 . . . . 10.0 107.877 169.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 88.9 m -120.83 -50.22 2.18 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 127.638 2.375 . . . . 10.0 108.245 -165.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 14.4 m -114.11 10.61 17.44 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.935 1.294 . . . . 10.0 112.226 -169.174 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -72.49 32.09 0.06 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.434 1.094 . . . . 10.0 113.721 -175.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.67 122.67 0.31 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.151 0.882 . . . . 10.0 112.667 168.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -77.33 60.79 7.14 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.13 2.553 . . . . 10.0 111.492 174.682 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 62.62 48.27 4.44 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.95 1.7 . . . . 10.0 110.235 173.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -71.03 62.21 0.29 Allowed 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.766 0.712 . . . . 10.0 111.373 179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -65.58 142.36 98.25 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.291 -0.881 . . . . 10.0 111.303 -172.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.35 -41.61 6.52 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.723 2.282 . . . . 10.0 110.249 -177.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.75 55.16 1.04 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.166 0.986 . . . . 10.0 108.771 175.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.9 p -34.15 104.95 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 126.539 1.936 . . . . 10.0 111.859 -169.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.11 176.97 8.18 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 104.319 -2.475 . . . . 10.0 104.319 -173.166 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -69.78 154.28 42.2 Favored 'General case' 0 N--CA 1.435 -1.185 0 C-N-CA 117.148 -1.821 . . . . 10.0 107.994 169.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -65.72 118.29 9.38 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 104.717 -2.327 . . . . 10.0 104.717 159.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.79 -177.3 22.09 Favored Glycine 0 N--CA 1.435 -1.409 0 N-CA-C 106.699 -2.561 . . . . 10.0 106.699 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.65 -156.59 6.93 Favored Glycine 0 C--O 1.227 -0.294 0 N-CA-C 109.35 -1.5 . . . . 10.0 109.35 -177.423 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -65.48 1.66 2.0 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.323 1.349 . . . . 10.0 110.613 166.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -109.16 0.86 19.97 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 117.754 -1.117 . . . . 10.0 112.007 173.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -116.22 162.78 16.95 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 169.235 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -79.1 -39.79 32.8 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 167.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -110.55 63.53 0.61 Allowed 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 124.697 1.199 . . . . 10.0 111.65 -168.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -60.65 161.81 7.33 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.359 1.064 . . . . 10.0 109.728 166.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 15.5 m170 -66.49 -71.54 0.19 Allowed 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 113.062 0.764 . . . . 10.0 113.062 -174.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -166.79 -53.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 O-C-N 121.638 -0.664 . . . . 10.0 109.689 -173.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -131.48 60.47 0.68 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 171.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -112.15 90.5 3.36 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.074 -2.195 . . . . 10.0 105.074 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -82.22 -30.38 30.83 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 106.362 -1.718 . . . . 10.0 106.362 -178.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.92 -83.96 0.36 Allowed Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 168.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -156.88 156.35 32.99 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 122.839 0.456 . . . . 10.0 111.101 -177.628 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.5 m -124.48 142.08 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 C-N-CA 125.289 1.435 . . . . 10.0 109.766 -174.339 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -85.71 103.1 14.19 Favored 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 129.433 3.093 . . . . 10.0 110.927 -172.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.48 136.12 36.25 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.861 -0.524 . . . . 10.0 109.844 169.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.402 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 23.8 t70 -65.93 172.49 3.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.733 1.613 . . . . 10.0 110.23 167.546 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.402 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -62.23 -23.48 66.69 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 122.771 0.428 . . . . 10.0 112.091 173.534 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -75.83 -3.05 33.0 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 120.864 0.364 . . . . 10.0 110.252 174.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.48 24.73 60.23 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 108.719 -1.752 . . . . 10.0 108.719 176.327 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.6 t -110.13 109.51 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 127.081 2.152 . . . . 10.0 106.904 -174.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.17 120.19 40.04 Favored 'General case' 0 CA--C 1.513 -0.467 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 169.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -79.97 119.21 22.5 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 127.415 2.286 . . . . 10.0 108.8 170.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -103.68 130.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 C-N-CA 124.839 1.256 . . . . 10.0 107.754 177.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.9 p -158.42 83.02 0.83 Allowed 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 118.646 -0.693 . . . . 10.0 109.227 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.68 152.59 20.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 N-CA-C 107.553 -1.277 . . . . 10.0 107.553 179.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -126.81 137.01 53.13 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 126.014 1.726 . . . . 10.0 110.31 174.055 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.27 141.08 39.86 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.829 0.852 . . . . 10.0 109.513 177.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 18.6 p -106.3 22.91 14.97 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.363 1.465 . . . . 10.0 109.924 169.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 51.0 t -94.88 -15.21 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 C-N-CA 124.859 1.264 . . . . 10.0 109.479 -177.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -134.53 175.17 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 125.461 1.504 . . . . 10.0 112.42 -169.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -158.85 147.0 18.1 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 107.631 -1.248 . . . . 10.0 107.631 169.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -60.03 -50.61 73.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.727 -0.842 . . . . 10.0 108.727 -178.238 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 49.8 p . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 172.866 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.44 -0.956 0 CA-C-O 118.995 -0.526 . . . . 10.0 110.921 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 20.6 pt -67.75 -10.05 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 113.606 0.965 . . . . 10.0 113.606 -172.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 21.2 mm -53.41 139.58 11.18 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 O-C-N 120.854 -1.153 . . . . 10.0 110.159 169.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.41 4.5 84.44 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.556 -1.136 . . . . 10.0 113.986 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . 0.424 ' HE ' ' CD ' ' B' ' 49' ' ' GLU . 27.7 mmt-85 -79.55 178.57 8.04 Favored 'General case' 0 C--N 1.342 0.239 0 CA-C-N 119.223 1.512 . . . . 10.0 109.542 168.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -124.69 135.54 53.13 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 106.454 -1.684 . . . . 10.0 106.454 178.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 7.9 mp -105.08 148.57 26.67 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.406 -1.331 . . . . 10.0 107.406 169.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.5 t -126.88 135.22 64.29 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 N-CA-C 107.429 -1.323 . . . . 10.0 107.429 178.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -102.91 121.0 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.883 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 169.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -106.12 162.6 13.48 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -169.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -47.95 -50.05 28.41 Favored 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 128.425 2.69 . . . . 10.0 112.477 174.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -128.49 171.97 11.58 Favored 'General case' 0 C--N 1.334 -0.086 0 C-N-CA 124.141 0.976 . . . . 10.0 112.225 -168.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.02 165.7 24.68 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.304 -0.862 . . . . 10.0 109.798 170.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.76 155.85 17.15 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.97 1.308 . . . . 10.0 111.637 -176.049 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -77.85 -15.3 59.15 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 114.731 -1.122 . . . . 10.0 110.254 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 73.2 mt 51.65 45.42 28.14 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 124.538 1.135 . . . . 10.0 110.335 172.179 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.19 27.85 73.26 Favored Glycine 0 N--CA 1.437 -1.246 0 CA-C-N 113.797 -1.547 . . . . 10.0 113.378 173.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -74.78 -3.84 34.06 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.295 1.548 . . . . 10.0 112.356 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.22 25.27 73.63 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 108.791 -1.724 . . . . 10.0 108.791 175.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -56.03 -30.15 56.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 170.601 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -155.87 167.84 29.12 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.59 -0.892 . . . . 10.0 108.59 -168.365 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.2 tm-20 -56.29 -46.27 79.83 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 108.511 -0.922 . . . . 10.0 108.511 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -59.04 -24.48 62.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 115.96 -0.564 . . . . 10.0 111.997 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 51.9 m -56.13 -32.63 64.41 Favored 'General case' 0 N--CA 1.444 -0.744 0 O-C-N 121.656 -0.653 . . . . 10.0 112.398 -177.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.6 t -93.46 7.73 43.38 Favored 'General case' 0 CA--C 1.534 0.339 0 O-C-N 123.52 0.512 . . . . 10.0 110.108 -174.074 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -128.69 -61.04 1.08 Allowed 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 126.678 1.991 . . . . 10.0 112.46 -174.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -135.71 31.03 3.09 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 120.69 1.586 . . . . 10.0 109.462 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 63.99 -97.59 0.23 Allowed Glycine 0 C--N 1.346 1.109 0 CA-C-O 123.79 1.772 . . . . 10.0 108.925 175.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.86 39.41 0.1 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 113.172 -1.514 . . . . 10.0 109.064 167.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.71 -12.95 52.25 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.713 0.805 . . . . 10.0 112.702 -169.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.75 -166.06 52.06 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 175.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -55.35 131.11 44.92 Favored 'General case' 0 N--CA 1.444 -0.771 0 C-N-CA 123.573 0.749 . . . . 10.0 111.935 -168.544 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -65.7 75.79 0.07 Allowed 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.603 0.761 . . . . 10.0 109.676 169.385 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 69.3 mt -45.37 -49.8 12.74 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.602 0.761 . . . . 10.0 110.726 177.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.56 155.86 36.96 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.495 -0.557 . . . . 10.0 109.495 -171.083 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -158.27 166.88 31.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.05 0.54 . . . . 10.0 109.572 -174.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.91 160.17 32.18 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 110.179 -1.169 . . . . 10.0 110.179 -173.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 57.4 t -109.25 138.38 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -171.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.7 mt -75.82 108.96 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 -177.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.5 135.19 12.23 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 109.957 -1.257 . . . . 10.0 109.957 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.3 pt -75.42 127.25 36.89 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.231 0 CA-C-N 118.557 1.178 . . . . 10.0 108.604 174.189 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -75.39 -54.89 6.31 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 107.134 -1.432 . . . . 10.0 107.134 178.506 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.348 -0.834 . . . . 10.0 109.457 172.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 106.85 -1.537 . . . . 10.0 106.85 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 t -167.51 -38.01 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 124.055 0.942 . . . . 10.0 111.881 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 57.1 tttp -133.46 141.39 47.79 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 124.531 1.132 . . . . 10.0 109.843 178.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.66 169.53 21.36 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 126.487 1.915 . . . . 10.0 107.226 176.375 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.9 162.1 35.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 N-CA-C 109.526 -0.546 . . . . 10.0 109.526 -179.248 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.04 97.64 4.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.989 0.916 . . . . 10.0 108.951 175.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -83.73 106.0 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 N-CA-C 108.677 -0.86 . . . . 10.0 108.677 169.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.9 mt -100.14 140.68 34.02 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.63 -0.878 . . . . 10.0 108.63 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.9 ttmt -157.84 163.7 37.72 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.509 -1.293 . . . . 10.0 107.509 169.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.57 -53.14 0.06 OUTLIER Glycine 0 C--O 1.228 -0.255 0 C-N-CA 120.333 -0.937 . . . . 10.0 112.163 169.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -72.64 -45.34 59.49 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.329 -1.36 . . . . 10.0 107.329 -177.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.28 -71.09 0.41 Allowed Glycine 0 CA--C 1.524 0.619 0 CA-C-N 114.355 -1.293 . . . . 10.0 110.342 169.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -57.44 -34.8 98.56 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.462 2.775 . . . . 10.0 111.242 173.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.6 t -65.3 100.81 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.082 0 N-CA-C 107.335 -1.358 . . . . 10.0 107.335 175.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -119.5 116.23 25.67 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.568 1.147 . . . . 10.0 108.381 172.546 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -95.71 145.47 17.79 Favored Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 109.892 -1.283 . . . . 10.0 109.892 169.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.2 mt -151.54 56.94 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.8 mm -80.82 140.23 16.95 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.041 0 O-C-N 121.587 -0.695 . . . . 10.0 110.011 -175.011 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -99.74 115.3 29.19 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.04 1.336 . . . . 10.0 108.298 170.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -92.56 110.38 21.8 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 105.486 -2.042 . . . . 10.0 105.486 170.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -131.17 146.6 52.4 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 119.084 0.856 . . . . 10.0 110.481 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -148.24 16.21 1.05 Allowed 'General case' 0 C--N 1.342 0.274 0 N-CA-C 115.319 1.6 . . . . 10.0 115.319 -178.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? 74.23 -57.38 0.62 Allowed 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 125.595 1.558 . . . . 10.0 113.163 168.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.68 -157.26 0.8 Allowed 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 107.964 -1.124 . . . . 10.0 107.964 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -85.48 -23.08 27.94 Favored 'General case' 0 N--CA 1.45 -0.448 0 O-C-N 120.808 -1.182 . . . . 10.0 110.638 170.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -89.33 -21.27 23.21 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 123.985 0.914 . . . . 10.0 111.503 -173.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.56 151.76 51.68 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.619 -0.545 . . . . 10.0 112.356 -171.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -68.46 137.29 39.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.95 2.433 . . . . 10.0 108.842 169.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -77.74 138.55 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 O-C-N 121.849 -0.532 . . . . 10.0 110.957 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -119.63 124.93 47.52 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.848 -1.538 . . . . 10.0 106.848 168.418 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.3 m -102.76 59.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 124.339 1.055 . . . . 10.0 109.094 -170.104 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.8 p90 -79.03 146.01 33.55 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 119.625 -0.83 . . . . 10.0 111.312 -172.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.39 -169.48 39.2 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.646 -0.981 . . . . 10.0 110.646 169.156 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.4 m -139.6 107.53 5.7 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.065 -0.717 . . . . 10.0 109.065 -170.411 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 pt -78.31 128.01 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 106.873 -1.529 . . . . 10.0 106.873 168.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 tttt -107.21 146.66 31.13 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.115 -1.439 . . . . 10.0 107.115 173.328 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -7.07 31.06 Favored Glycine 0 CA--C 1.522 0.528 0 CA-C-O 119.197 -0.779 . . . . 10.0 112.678 173.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -62.47 177.01 0.55 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.675 1.238 . . . . 10.0 109.284 168.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -113.53 157.06 22.51 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.961 -0.755 . . . . 10.0 108.961 170.039 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -48.9 123.67 7.41 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.062 1.345 . . . . 10.0 111.094 -171.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.66 -169.12 13.13 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 123.794 0.711 . . . . 10.0 112.347 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -77.3 146.77 36.61 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 126.12 1.768 . . . . 10.0 112.391 -170.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -149.48 144.0 26.03 Favored 'General case' 0 C--N 1.342 0.276 0 N-CA-C 114.049 1.129 . . . . 10.0 114.049 -178.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -33.15 126.24 0.34 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 127.145 2.307 . . . . 10.0 112.232 165.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -151.03 108.11 3.58 Favored 'General case' 0 C--O 1.238 0.486 0 CA-C-N 119.504 1.652 . . . . 10.0 109.561 167.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.497 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -151.94 174.44 13.62 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.148 0.975 . . . . 10.0 113.4 179.329 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.9 p -90.61 151.4 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 CA-C-N 112.028 -2.351 . . . . 10.0 108.038 168.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -127.59 142.69 51.29 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 106.931 -1.507 . . . . 10.0 106.931 171.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -37.24 -55.77 0.98 Allowed 'General case' 0 C--O 1.237 0.403 0 C-N-CA 127.535 2.334 . . . . 10.0 113.7 -170.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -106.34 169.31 8.59 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-O 122.367 1.079 . . . . 10.0 112.556 -171.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.42 -23.47 24.05 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 126.664 2.078 . . . . 10.0 109.771 169.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -43.39 120.41 1.9 Allowed 'General case' 0 C--N 1.346 0.417 0 CA-C-O 122.009 0.909 . . . . 10.0 109.863 170.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -134.75 11.9 3.69 Favored 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 125.942 1.697 . . . . 10.0 108.497 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.3 m -59.45 -33.64 71.54 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 119.031 0.832 . . . . 10.0 112.083 -168.216 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.39 -16.14 59.0 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.915 0.886 . . . . 10.0 112.33 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.26 62.92 0.56 Allowed Glycine 0 CA--C 1.521 0.462 0 N-CA-C 108.655 -1.778 . . . . 10.0 108.655 -172.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.6 p 41.31 39.6 1.02 Allowed 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 125.868 1.667 . . . . 10.0 114.122 171.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 16.3 m -108.13 -53.3 2.65 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.759 2.024 . . . . 10.0 105.584 -177.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.4 m -66.66 -15.46 63.5 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.525 1.93 . . . . 10.0 112.665 -175.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -50.06 -6.28 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.936 2.494 . . . . 10.0 115.715 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 105.8 123.41 5.16 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.117 -1.38 . . . . 10.0 110.372 170.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.59 60.16 5.78 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.595 2.863 . . . . 10.0 110.638 173.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.9 m170 65.34 37.61 6.23 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 130.27 3.428 . . . . 10.0 111.897 179.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.1 m-30 -72.89 62.32 0.59 Allowed 'General case' 0 N--CA 1.468 0.462 0 O-C-N 121.196 -0.94 . . . . 10.0 110.628 175.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -74.1 152.66 88.49 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.247 -0.908 . . . . 10.0 111.146 -172.182 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -60.45 -42.67 39.09 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.435 2.756 . . . . 10.0 111.848 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.3 tp -77.91 59.08 2.04 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 123.781 0.832 . . . . 10.0 108.772 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 58.7 p -40.75 104.85 0.04 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.282 2.233 . . . . 10.0 112.128 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -137.62 175.11 9.88 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 126.403 1.881 . . . . 10.0 107.467 -177.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.15 113.93 27.42 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-N 118.952 0.796 . . . . 10.0 109.884 -174.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.0 t60 -30.18 101.55 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 114.593 1.331 . . . . 10.0 114.593 -171.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -114.44 -147.97 9.6 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 176.247 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.33 -148.65 5.64 Favored Glycine 0 C--N 1.332 0.334 0 CA-C-O 118.237 -1.313 . . . . 10.0 109.902 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -62.76 -3.76 4.95 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 CA-C-N 120.225 2.012 . . . . 10.0 111.946 169.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -85.0 -19.61 31.77 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 118.452 -0.785 . . . . 10.0 111.041 171.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -130.55 162.41 29.35 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 123.849 1.785 . . . . 10.0 112.875 -166.309 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -85.43 -24.06 27.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 112.879 -1.964 . . . . 10.0 108.261 166.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -86.34 7.79 24.11 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.532 1.533 . . . . 10.0 110.85 -174.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 33.9 ptt-85 -48.33 126.83 11.93 Favored 'General case' 0 C--N 1.342 0.263 0 N-CA-C 106.507 -1.664 . . . . 10.0 106.507 166.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m80 -50.57 -57.47 8.08 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.11 0.411 . . . . 10.0 112.11 -167.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.7 p -173.9 -45.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 124.711 1.205 . . . . 10.0 108.33 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.14 56.44 0.73 Allowed Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.681 -1.367 . . . . 10.0 109.681 175.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -97.5 97.25 8.92 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 106.001 -1.851 . . . . 10.0 106.001 169.058 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 14.0 mt -76.26 -27.11 56.58 Favored 'General case' 0 C--N 1.34 0.163 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 173.418 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.71 -104.17 3.07 Favored Glycine 0 N--CA 1.439 -1.128 0 N-CA-C 108.638 -1.785 . . . . 10.0 108.638 168.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -122.3 100.28 6.87 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.055 1.342 . . . . 10.0 109.48 -167.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.2 m -95.74 136.92 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 C-N-CA 122.855 0.462 . . . . 10.0 110.187 178.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.8 m -85.19 119.41 25.54 Favored 'General case' 0 N--CA 1.439 -0.985 0 C-N-CA 127.437 2.295 . . . . 10.0 108.819 -177.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.57 134.65 39.52 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 123.568 0.747 . . . . 10.0 109.627 169.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.405 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 16.1 t70 -62.62 169.86 2.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 O-C-N 124.412 1.07 . . . . 10.0 108.751 166.419 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.405 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -61.86 -21.63 64.84 Favored 'General case' 0 N--CA 1.445 -0.705 0 C-N-CA 124.192 0.997 . . . . 10.0 112.892 172.454 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.17 -4.68 45.86 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.036 0.446 . . . . 10.0 110.691 171.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.22 6.3 86.44 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 120.671 -1.268 . . . . 10.0 110.839 178.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.18 106.13 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 127.339 2.256 . . . . 10.0 107.332 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.43 116.47 32.47 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 167.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.28 104.17 10.65 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 126.812 2.045 . . . . 10.0 109.841 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.12 131.86 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 172.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.3 m -157.52 57.63 0.5 Allowed 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.495 1.118 . . . . 10.0 109.476 173.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.84 150.75 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.835 -1.543 . . . . 10.0 106.835 178.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -128.19 150.81 49.85 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 108.626 170.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.13 124.42 6.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 108.873 -0.788 . . . . 10.0 108.873 172.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 11.0 t -79.07 0.48 27.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.291 1.037 . . . . 10.0 112.196 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.41 -24.75 17.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 CA-C-N 119.579 1.081 . . . . 10.0 109.486 177.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.0 159.28 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 124.599 1.16 . . . . 10.0 111.003 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.8 m -152.72 144.93 23.89 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.281 -2.118 . . . . 10.0 105.281 174.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.6 mt -65.04 -8.55 16.7 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 123.95 0.9 . . . . 10.0 111.828 176.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.6 m -150.94 137.96 19.15 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.031 -1.47 . . . . 10.0 107.031 169.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.26 -66.25 0.14 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 109.018 -1.633 . . . . 10.0 109.018 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -167.71 -51.44 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 125.58 1.552 . . . . 10.0 107.981 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.96 -36.19 62.07 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 114.914 -1.039 . . . . 10.0 109.128 -169.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 30.9 t 38.98 70.66 0.2 Allowed 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 126.692 1.997 . . . . 10.0 112.263 167.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -56.67 -10.22 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 114.113 1.153 . . . . 10.0 114.113 177.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 mm -33.87 -52.95 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.327 1.451 . . . . 10.0 112.98 170.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -96.81 9.48 66.11 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-O 118.937 -0.924 . . . . 10.0 114.153 -174.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.94 156.46 21.18 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 118.525 1.162 . . . . 10.0 109.742 176.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 59.1 m -90.4 131.58 36.1 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.768 0.827 . . . . 10.0 109.627 168.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -99.87 145.61 27.58 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 167.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.8 t -137.46 136.34 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 123.516 0.726 . . . . 10.0 109.17 -176.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.35 142.08 17.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 O-C-N 124.579 1.175 . . . . 10.0 108.811 167.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.5 m170 -121.72 162.03 21.53 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.896 1.443 . . . . 10.0 114.896 -175.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.46 ' CD ' ' HZ3' ' A' ' 122' ' ' LYS . 1.7 tm-20 -58.31 -50.87 72.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.266 1.427 . . . . 10.0 110.736 -179.726 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.46 ' HZ3' ' CD ' ' A' ' 121' ' ' GLU . 44.7 mttm -116.39 172.75 7.0 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 121.804 0.812 . . . . 10.0 112.203 -178.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.28 138.96 40.88 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 126.054 1.742 . . . . 10.0 108.981 174.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.497 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -77.36 164.76 25.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 122.232 1.015 . . . . 10.0 111.847 173.596 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -74.82 -8.15 55.57 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 113.608 -1.633 . . . . 10.0 111.298 178.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 14.5 mt 46.8 41.18 10.05 Favored 'General case' 0 C--N 1.339 0.113 0 C-N-CA 124.484 1.114 . . . . 10.0 109.831 -177.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 72.05 19.64 78.53 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 118.313 -1.271 . . . . 10.0 114.765 171.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.251 8.7 mtmp? -77.13 10.65 2.25 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 119.803 1.801 . . . . 10.0 114.991 -176.073 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.72 29.0 61.98 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 109.185 -1.566 . . . . 10.0 109.185 168.196 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -53.19 -30.01 38.17 Favored Glycine 0 N--CA 1.436 -1.351 0 CA-C-O 118.132 -1.371 . . . . 10.0 110.321 167.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 174.61 178.85 0.13 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 106.7 -1.593 . . . . 10.0 106.7 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 37.5 mp0 -49.48 -41.29 40.12 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 112.876 0.695 . . . . 10.0 112.876 179.179 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 -64.33 -24.13 67.54 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 121.244 -0.91 . . . . 10.0 110.684 -178.481 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 55.1 m -45.3 -44.58 11.58 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 122.964 0.506 . . . . 10.0 110.286 175.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 t -84.7 -1.09 55.7 Favored 'General case' 0 CA--C 1.541 0.628 0 O-C-N 124.049 0.843 . . . . 10.0 112.147 -170.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.1 mttt -118.82 -73.65 0.64 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.955 1.302 . . . . 10.0 110.275 -173.386 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.1 p -121.56 26.83 8.56 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 120.164 -1.585 . . . . 10.0 110.242 171.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 72.86 -91.57 0.6 Allowed Glycine 0 C--N 1.342 0.886 0 N-CA-C 109.934 -1.266 . . . . 10.0 109.934 174.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.38 39.12 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.195 1.398 . . . . 10.0 108.886 171.087 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.26 -16.61 62.49 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 121.473 -0.767 . . . . 10.0 112.77 -168.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.37 -162.59 54.66 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.102 -1.199 . . . . 10.0 110.102 175.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -51.9 126.77 19.14 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.036 1.334 . . . . 10.0 113.8 -168.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -64.7 72.89 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.229 1.812 . . . . 10.0 110.996 173.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.2 mt -51.12 -35.67 36.6 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 113.381 0.882 . . . . 10.0 113.381 -178.069 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 154.47 37.09 Favored 'General case' 0 CA--C 1.511 -0.555 0 O-C-N 121.61 -0.681 . . . . 10.0 109.948 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.6 p -153.24 153.7 33.21 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.583 -0.895 . . . . 10.0 108.583 -172.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.81 153.37 24.36 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 112.044 -0.422 . . . . 10.0 112.044 179.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 63.4 t -101.3 125.31 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.012 -2.218 . . . . 10.0 105.012 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.2 mt -68.55 164.93 2.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 CA-C-N 119.009 0.822 . . . . 10.0 110.403 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -160.5 150.66 20.84 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.576 1.56 . . . . 10.0 109.443 -172.136 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.3 mt -70.93 141.7 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.892 1.277 . . . . 10.0 109.023 -173.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.43 -46.51 2.87 Favored 'General case' 0 C--O 1.224 -0.268 0 C-N-CA 123.1 0.56 . . . . 10.0 110.674 170.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.7 tp60 . . . . . 0 C--O 1.25 1.107 0 C-N-CA 126.634 1.974 . . . . 10.0 112.082 -173.04 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.872 0 CA-C-O 117.571 -1.205 . . . . 10.0 108.993 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 t -61.27 -38.16 85.74 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 120.19 1.359 . . . . 10.0 108.852 172.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 36.9 tttt -132.03 156.35 46.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.447 1.499 . . . . 10.0 110.219 168.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.47 175.35 14.14 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 129.01 2.924 . . . . 10.0 106.504 166.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -133.6 179.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 118.677 0.671 . . . . 10.0 110.611 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.43 108.9 2.1 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.093 0.957 . . . . 10.0 109.189 165.039 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -95.17 124.28 47.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 122.959 0.503 . . . . 10.0 110.208 170.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -103.54 146.24 28.84 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 125.441 1.496 . . . . 10.0 110.275 176.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 5.4 tttm -161.73 158.61 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 169.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 179.86 -46.55 0.08 OUTLIER Glycine 0 N--CA 1.46 0.236 0 C-N-CA 118.927 -1.606 . . . . 10.0 113.638 169.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -72.59 -47.71 45.69 Favored 'General case' 0 N--CA 1.451 -0.375 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 -178.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.91 -73.84 0.29 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 114.331 -1.304 . . . . 10.0 109.845 171.115 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -59.07 -34.74 98.98 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.738 2.959 . . . . 10.0 111.18 174.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.5 t -62.2 114.04 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.12 -1.067 . . . . 10.0 108.12 176.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.87 118.6 22.97 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 106.339 -1.726 . . . . 10.0 106.339 168.589 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -102.47 141.12 15.14 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-O 118.598 -1.112 . . . . 10.0 110.48 174.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 9.4 mt -139.78 94.2 0.77 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 C-N-CA 123.874 0.87 . . . . 10.0 109.063 -173.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.7 mm -105.71 139.77 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 C-N-CA 125.658 1.583 . . . . 10.0 112.623 -178.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -106.75 126.6 52.49 Favored 'General case' 0 C--N 1.34 0.179 0 N-CA-C 106.452 -1.685 . . . . 10.0 106.452 167.059 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -104.16 112.42 25.42 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 107.057 -1.46 . . . . 10.0 107.057 168.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -126.82 136.32 52.2 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 118.462 0.573 . . . . 10.0 112.35 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -105.48 112.76 25.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.62 1.568 . . . . 10.0 106.873 169.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.235 0.308 0 N-CA-C 111.93 0.344 . . . . 10.0 111.93 -177.023 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.025 0 CA-C-O 118.59 -1.117 . . . . 10.0 114.496 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -65.26 115.84 3.55 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 CA-C-N 119.834 1.817 . . . . 10.0 107.652 170.375 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t -77.27 84.65 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 105.31 -2.107 . . . . 10.0 105.31 175.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -74.35 117.4 16.12 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.024 -1.473 . . . . 10.0 107.024 179.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.42 58.77 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 C-N-CA 125.085 1.354 . . . . 10.0 108.121 -169.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.4 p90 -81.48 143.21 32.24 Favored 'General case' 0 C--N 1.341 0.209 0 C-N-CA 119.134 -1.026 . . . . 10.0 111.996 -176.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.81 -169.09 41.39 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.636 -1.269 . . . . 10.0 110.106 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 m -153.24 133.11 13.2 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.3 pt -103.63 147.72 9.53 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 N-CA-C 107.995 -1.113 . . . . 10.0 107.995 167.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -124.81 149.98 46.85 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 169.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.48 -6.7 36.24 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 123.428 0.537 . . . . 10.0 112.519 171.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -63.93 174.43 1.49 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.956 0.878 . . . . 10.0 109.965 169.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -101.76 170.81 7.92 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 105.898 -1.89 . . . . 10.0 105.898 165.414 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -59.84 166.67 2.52 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 118.661 0.664 . . . . 10.0 111.829 -171.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.49 -171.56 45.75 Favored Glycine 0 N--CA 1.446 -0.647 0 O-C-N 121.478 -0.764 . . . . 10.0 111.72 169.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -77.5 144.31 37.8 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.259 1.424 . . . . 10.0 111.224 -174.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -147.48 127.88 14.01 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.518 1.127 . . . . 10.0 112.633 -173.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -18.69 128.71 0.01 OUTLIER Glycine 0 C--N 1.342 0.881 0 C-N-CA 127.499 2.476 . . . . 10.0 114.179 165.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.75 104.94 3.23 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 118.605 1.203 . . . . 10.0 109.793 167.73 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.51 176.46 10.93 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 112.766 0.654 . . . . 10.0 112.766 176.385 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 23.4 m -89.82 158.69 2.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 113.601 -1.636 . . . . 10.0 108.626 168.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 74.8 m-70 -136.47 78.11 1.69 Allowed 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 123.586 0.755 . . . . 10.0 111.138 176.021 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.8 tt0 47.65 -94.42 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.792 1.237 . . . . 10.0 113.027 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -78.76 172.03 14.32 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.582 0.628 . . . . 10.0 110.01 -173.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.97 -23.1 23.74 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.553 -1.019 . . . . 10.0 110.553 170.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -37.71 135.07 0.64 Allowed 'General case' 0 C--N 1.343 0.306 0 C-N-CA 124.598 1.159 . . . . 10.0 110.863 170.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -146.05 23.99 1.33 Allowed 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 114.75 -1.114 . . . . 10.0 110.362 173.152 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 2.7 m -52.43 -36.83 55.34 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.065 0.848 . . . . 10.0 110.982 -173.513 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.56 -21.72 28.41 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.29 1.436 . . . . 10.0 113.697 177.178 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.48 101.92 1.45 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.813 1.197 . . . . 10.0 110.183 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.314 2.6 p 17.43 57.65 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 127.752 2.421 . . . . 10.0 114.151 -170.377 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.8 m -130.48 -61.9 0.94 Allowed 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.479 -2.045 . . . . 10.0 105.479 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 39.3 t -69.66 -35.68 75.38 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.009 1.324 . . . . 10.0 111.323 -178.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.88 -47.41 0.13 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 127.122 2.169 . . . . 10.0 114.181 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 138.5 172.54 12.6 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.243 -1.543 . . . . 10.0 109.243 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -78.67 -137.35 0.02 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.222 0 N-CA-C 104.156 -3.055 . . . . 10.0 104.156 166.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.421 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.3 m170 -100.99 50.68 0.86 Allowed 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 121.067 1.758 . . . . 10.0 109.557 170.137 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -71.79 80.05 0.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.169 0.985 . . . . 10.0 110.033 177.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.5 p-10 -80.15 156.31 74.26 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 125.474 1.509 . . . . 10.0 110.222 172.614 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -63.51 -50.1 3.75 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.489 2.126 . . . . 10.0 111.292 177.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.58 57.72 1.64 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.213 0.605 . . . . 10.0 109.887 179.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.9 p -51.35 114.21 1.16 Allowed 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.607 1.163 . . . . 10.0 109.999 -176.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.2 mtt-85 -131.33 -86.49 0.49 Allowed 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 104.996 -2.224 . . . . 10.0 104.996 -176.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 ptpp? -163.26 162.77 25.42 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 167.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 66.9 t60 -58.28 132.67 54.31 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 118.358 -1.337 . . . . 10.0 107.655 168.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.37 -133.23 2.64 Favored Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 169.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 163.51 -161.28 33.99 Favored Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 108.376 -1.89 . . . . 10.0 108.376 178.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.74 4.61 0.8 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.864 1.71 . . . . 10.0 111.928 168.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -114.03 7.94 16.94 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 119.225 0.92 . . . . 10.0 110.481 170.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -125.93 163.09 23.74 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 119.733 1.151 . . . . 10.0 108.977 167.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -81.61 -30.06 33.02 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 169.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -119.65 61.5 0.83 Allowed 'General case' 0 N--CA 1.436 -1.168 0 CA-C-O 122.095 0.95 . . . . 10.0 110.859 -168.489 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . 0.46 HH12 ' CG ' ' B' ' 101' ' ' ASP . 0.3 OUTLIER -56.32 164.39 1.36 Allowed 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 114.393 -1.276 . . . . 10.0 108.697 164.833 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.6 m170 -65.99 -84.57 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 N-CA-C 108.569 -0.9 . . . . 10.0 108.569 169.36 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 49.2 t -149.82 -82.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 104.186 -2.524 . . . . 10.0 104.186 169.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.83 53.89 4.77 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.566 -0.614 . . . . 10.0 111.566 -178.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -93.9 98.78 11.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 104.39 -2.448 . . . . 10.0 104.39 168.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 37.1 mt -81.92 -36.26 28.26 Favored 'General case' 0 C--N 1.334 -0.095 0 N-CA-C 105.744 -1.947 . . . . 10.0 105.744 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.26 -92.06 0.64 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 106.717 -2.553 . . . . 10.0 106.717 169.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -155.82 155.73 33.5 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 122.793 0.437 . . . . 10.0 111.45 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.48 145.68 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 O-C-N 124.762 1.289 . . . . 10.0 108.507 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.0 m -93.43 110.42 21.98 Favored 'General case' 0 N--CA 1.436 -1.135 0 C-N-CA 128.497 2.719 . . . . 10.0 108.88 -172.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.3 135.59 33.49 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 123.771 0.828 . . . . 10.0 110.117 174.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -61.65 168.51 2.91 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 124.091 0.956 . . . . 10.0 109.107 166.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.78 -30.67 45.7 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.492 0.717 . . . . 10.0 111.079 172.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -78.68 1.6 22.36 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-O 121.25 0.548 . . . . 10.0 111.454 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.92 90.7 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 120.843 -1.161 . . . . 10.0 110.947 176.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.1 t -79.77 104.72 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.059 0 C-N-CA 127.09 2.156 . . . . 10.0 107.013 179.242 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -107.55 115.09 29.53 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 168.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.7 123.36 27.59 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 127.381 2.272 . . . . 10.0 108.622 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.0 t -110.79 131.43 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 C-N-CA 125.494 1.517 . . . . 10.0 107.279 178.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 93.0 p -156.98 59.14 0.52 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 123.316 0.646 . . . . 10.0 109.552 177.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.83 154.82 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -176.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -102.33 153.21 20.22 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 126.639 1.976 . . . . 10.0 107.382 170.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . 0.46 ' CG ' HH12 ' B' ' 79' ' ' ARG . 23.8 t0 -149.06 85.17 1.46 Allowed 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.583 0.706 . . . . 10.0 109.292 174.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.8 p -90.25 38.11 0.92 Allowed 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.81 0.844 . . . . 10.0 109.663 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 26.1 t -106.75 -46.19 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 107.444 -1.317 . . . . 10.0 107.444 176.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.261 0.0 OUTLIER -100.88 176.01 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 114.155 1.168 . . . . 10.0 114.155 175.465 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -136.29 142.8 43.95 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.517 -1.66 . . . . 10.0 106.517 169.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -65.58 -25.72 67.54 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.131 0.573 . . . . 10.0 110.117 171.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.451 -0.408 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 170.275 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.9 t . . . . . 0 N--CA 1.443 -0.794 0 CA-C-O 118.356 -0.831 . . . . 10.0 109.301 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 12.5 pt -68.97 65.19 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.324 0 CA-C-O 122.786 1.279 . . . . 10.0 110.388 173.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.6 mm -110.61 151.73 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 129.117 2.967 . . . . 10.0 105.275 167.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 55.31 35.64 61.09 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 124.866 1.222 . . . . 10.0 113.746 171.382 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 83.7 mtt85 -113.96 154.62 27.28 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.305 1.842 . . . . 10.0 107.51 171.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 90.2 m -86.06 133.95 33.86 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.01 0.924 . . . . 10.0 109.7 177.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -98.42 147.46 24.69 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 125.212 1.405 . . . . 10.0 107.297 166.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.57 141.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-N 118.563 0.62 . . . . 10.0 109.369 176.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -103.32 139.45 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 C-N-CA 124.575 1.15 . . . . 10.0 108.981 168.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.6 m-70 -115.91 164.25 14.69 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.814 1.413 . . . . 10.0 114.814 -175.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -59.43 -49.43 77.85 Favored 'General case' 0 C--N 1.343 0.293 0 C-N-CA 123.756 0.823 . . . . 10.0 110.438 178.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.2 mttt -121.24 175.56 6.06 Favored 'General case' 0 N--CA 1.462 0.169 0 N-CA-C 112.229 0.455 . . . . 10.0 112.229 -169.186 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.54 139.03 39.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.201 1.0 . . . . 10.0 109.332 173.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.67 144.1 30.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.059 0.944 . . . . 10.0 108.827 167.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -79.2 28.31 0.23 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 123.395 0.678 . . . . 10.0 111.236 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 6.6 mt 23.86 60.23 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 128.685 2.794 . . . . 10.0 112.157 -168.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 92.63 -35.58 4.0 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 126.192 1.853 . . . . 10.0 112.147 174.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.2 mtmm -84.46 44.15 1.02 Allowed 'General case' 0 CA--C 1.537 0.465 0 O-C-N 121.256 -1.144 . . . . 10.0 111.247 -170.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.44 -18.12 46.8 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 126.518 2.008 . . . . 10.0 110.159 169.371 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.15 35.82 91.41 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 123.965 0.793 . . . . 10.0 112.415 172.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -144.48 169.48 17.87 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 107.916 -1.142 . . . . 10.0 107.916 172.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -52.64 -47.4 67.09 Favored 'General case' 0 N--CA 1.444 -0.736 0 CA-C-O 121.805 0.812 . . . . 10.0 110.351 -177.44 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -65.36 -31.59 72.79 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 121.32 -0.863 . . . . 10.0 111.234 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 12.3 p -55.5 -42.14 74.03 Favored 'General case' 0 N--CA 1.447 -0.604 0 O-C-N 120.818 -1.176 . . . . 10.0 111.353 171.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.6 t -80.91 -24.16 38.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 119.835 -0.746 . . . . 10.0 111.202 -176.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 ttmm -80.81 -50.57 9.65 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 125.886 1.674 . . . . 10.0 111.533 -176.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.421 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 26.1 p -136.2 -15.18 1.72 Allowed 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 114.441 1.274 . . . . 10.0 114.441 176.772 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.53 3.07 55.43 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-O 118.286 -1.286 . . . . 10.0 113.884 -179.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 29.1 m120 73.23 26.97 2.02 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.101 1.45 . . . . 10.0 112.359 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.47 -2.29 13.48 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.272 -0.892 . . . . 10.0 113.298 176.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.0 -170.15 50.92 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 -175.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.51 169.66 2.87 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.167 0.987 . . . . 10.0 112.135 -177.01 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.79 115.96 18.82 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.85 2.06 . . . . 10.0 109.814 168.664 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.423 ' CD2' ' N ' ' B' ' 144' ' ' LEU . 0.4 OUTLIER -92.0 -36.84 13.18 Favored 'General case' 0 C--N 1.34 0.169 0 CA-C-N 119.753 1.16 . . . . 10.0 111.414 -176.263 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.36 149.78 32.4 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 176.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -118.63 142.44 47.64 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.796 1.638 . . . . 10.0 107.672 -168.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -137.06 161.19 25.14 Favored Glycine 0 C--N 1.331 0.265 0 N-CA-C 109.79 -1.324 . . . . 10.0 109.79 171.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -123.52 152.27 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 104.246 -2.501 . . . . 10.0 104.246 171.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.0 mt -67.41 -91.67 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 124.018 0.927 . . . . 10.0 111.625 -167.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.84 136.2 9.22 Favored Glycine 0 CA--C 1.532 1.112 0 N-CA-C 111.68 -0.568 . . . . 10.0 111.68 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 9.5 pt -85.34 146.78 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 C-N-CA 124.534 1.134 . . . . 10.0 110.122 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.87 -24.36 8.19 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.575 0.75 . . . . 10.0 112.8 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.88 0 C-N-CA 124.355 1.062 . . . . 10.0 108.195 -174.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.86 0 CA-C-O 117.89 -1.053 . . . . 10.0 109.158 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -116.81 -50.3 2.61 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 123.947 0.899 . . . . 10.0 112.304 -176.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -111.87 125.73 54.34 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 126.638 1.975 . . . . 10.0 108.825 -176.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 164.22 30.54 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.694 1.198 . . . . 10.0 108.286 170.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.4 m -139.04 164.46 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 C-N-CA 123.7 0.8 . . . . 10.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.66 118.72 15.38 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.644 -0.873 . . . . 10.0 108.644 168.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -92.34 110.23 22.57 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.33 -0.989 . . . . 10.0 108.33 168.248 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -95.0 144.86 25.35 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 108.731 -0.84 . . . . 10.0 108.731 177.032 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.2 mtmt -156.45 161.49 40.06 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 172.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.69 -51.59 0.09 OUTLIER Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.071 -1.061 . . . . 10.0 113.653 169.29 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.4 -44.57 62.3 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.49 -1.3 . . . . 10.0 107.49 -175.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.19 -71.01 0.4 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.684 -1.366 . . . . 10.0 109.684 169.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -58.06 -35.54 98.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 123.089 2.526 . . . . 10.0 111.273 172.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.3 t -64.65 107.33 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 178.264 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.45 104.87 10.0 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 172.489 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.37 137.1 14.15 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 176.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.7 mt -139.08 87.93 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.282 0 N-CA-C 107.381 -1.34 . . . . 10.0 107.381 -175.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -99.75 141.64 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.16 0 C-N-CA 124.819 1.248 . . . . 10.0 110.059 -178.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -126.27 113.45 16.97 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.476 1.91 . . . . 10.0 108.569 175.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -93.51 115.02 27.53 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 126.367 1.867 . . . . 10.0 108.545 177.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -117.5 130.04 56.19 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.85 1.055 . . . . 10.0 113.85 171.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -105.2 111.88 24.8 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 104.545 -2.391 . . . . 10.0 104.545 166.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -65.0 -36.78 85.52 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.952 -0.468 . . . . 10.0 111.131 -172.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -137.6 -165.43 1.77 Allowed 'General case' 0 N--CA 1.436 -1.175 0 N-CA-C 104.521 -2.4 . . . . 10.0 104.521 171.508 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.0 t -78.6 -24.48 45.39 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 118.97 0.805 . . . . 10.0 110.206 173.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.6 m-80 -91.83 -17.88 24.65 Favored 'General case' 0 N--CA 1.448 -0.574 0 C-N-CA 124.648 1.179 . . . . 10.0 110.551 -175.26 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.22 144.82 41.74 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 178.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -63.63 156.87 54.62 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 N-CA-C 108.116 -1.532 . . . . 10.0 108.116 169.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 75.2 t -79.0 102.31 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 N-CA-C 106.036 -1.839 . . . . 10.0 106.036 175.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.2 mtpp -79.0 105.38 10.3 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 105.49 -2.041 . . . . 10.0 105.49 170.022 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -100.58 97.85 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 C-N-CA 125.421 1.488 . . . . 10.0 107.502 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.6 p90 -103.26 174.59 5.8 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.322 0.582 . . . . 10.0 110.205 169.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.07 170.93 37.97 Favored Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 110.79 -0.924 . . . . 10.0 110.79 177.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.6 t -136.82 96.39 3.31 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 177.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 pt -81.24 140.59 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 169.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.512 ' HZ1' ' CG ' ' A' ' 92' ' ' ASP . 5.6 tttm -112.83 158.08 20.59 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 108.522 -0.918 . . . . 10.0 108.522 167.339 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.12 -7.27 58.57 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 123.579 0.609 . . . . 10.0 112.678 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -67.44 170.07 8.04 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 118.235 1.017 . . . . 10.0 109.86 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -103.65 153.33 20.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.688 -1.597 . . . . 10.0 106.688 167.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.6 143.88 4.72 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.25 1.02 . . . . 10.0 112.046 -170.497 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.48 -173.35 24.89 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 123.846 0.736 . . . . 10.0 112.269 171.541 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.26 145.27 54.41 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.594 1.957 . . . . 10.0 111.493 -175.162 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -146.31 141.25 27.1 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.398 1.079 . . . . 10.0 111.77 175.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.402 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -24.69 123.58 0.03 OUTLIER Glycine 0 C--N 1.344 1.008 0 C-N-CA 126.493 1.996 . . . . 10.0 112.219 165.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -144.55 104.54 4.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 119.735 1.767 . . . . 10.0 109.502 171.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.26 170.41 20.1 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 121.835 0.826 . . . . 10.0 111.557 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.4 m -88.54 149.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-N 112.139 -2.301 . . . . 10.0 106.259 167.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -120.6 128.08 52.7 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 103.782 -2.673 . . . . 10.0 103.782 169.049 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -58.54 -51.35 70.25 Favored 'General case' 0 N--CA 1.44 -0.932 0 O-C-N 124.99 1.431 . . . . 10.0 110.016 -168.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -79.55 137.84 37.29 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 -179.542 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.34 25.57 9.72 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.853 -0.899 . . . . 10.0 110.853 173.077 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.7 p30 -75.84 72.48 2.73 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 123.542 1.639 . . . . 10.0 109.317 170.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -75.82 6.24 5.28 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 113.658 -1.61 . . . . 10.0 112.66 -173.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -39.2 -44.26 1.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 128.207 2.603 . . . . 10.0 111.982 175.221 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.37 -19.97 48.89 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.247 1.019 . . . . 10.0 113.258 -177.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.79 87.13 1.47 Allowed Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.404 -1.079 . . . . 10.0 110.404 -177.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 m 52.31 29.14 6.38 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.417 1.487 . . . . 10.0 112.407 172.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.5 m -117.53 -54.83 2.34 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.295 -1.372 . . . . 10.0 107.295 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.1 m -77.01 -16.19 59.39 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 123.961 0.905 . . . . 10.0 112.579 -171.081 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -53.03 -12.88 0.38 Allowed 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.979 1.712 . . . . 10.0 115.234 -170.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.23 125.87 3.06 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 118.647 -1.085 . . . . 10.0 110.436 171.621 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -75.53 64.01 6.47 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.49 2.793 . . . . 10.0 111.732 179.326 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 26.7 m170 67.07 53.91 0.78 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 128.692 2.797 . . . . 10.0 111.108 175.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 -71.85 43.77 0.1 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 114.604 1.335 . . . . 10.0 114.604 -173.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -56.57 147.38 50.75 Favored Pre-proline 0 CA--C 1.54 0.568 0 O-C-N 120.817 -1.177 . . . . 10.0 112.565 -174.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -64.89 -43.03 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.81 2.34 . . . . 10.0 110.853 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 75.9 mt -76.69 54.6 0.98 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.484 0.714 . . . . 10.0 109.381 176.493 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.9 p -35.47 109.75 0.09 Allowed 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 126.019 1.727 . . . . 10.0 110.868 -173.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -131.71 -174.03 3.3 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 104.474 -2.417 . . . . 10.0 104.474 -170.126 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -82.39 159.02 23.1 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 106.262 -1.755 . . . . 10.0 106.262 169.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.7 t60 -59.04 123.5 16.79 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 106.826 -1.546 . . . . 10.0 106.826 162.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.93 -144.0 5.39 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 108.635 -1.786 . . . . 10.0 108.635 174.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.41 -163.39 29.72 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 109.746 -1.342 . . . . 10.0 109.746 169.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -63.99 3.68 0.69 Allowed 'Trans proline' 0 N--CA 1.455 -0.761 0 CA-C-N 119.763 1.782 . . . . 10.0 111.99 169.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 42.3 mmtt -100.19 -16.13 17.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.082 -0.961 . . . . 10.0 110.707 171.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -114.54 165.95 12.23 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 119.051 0.841 . . . . 10.0 109.901 -178.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -77.25 -38.61 50.72 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 105.431 -2.063 . . . . 10.0 105.431 167.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.277 1.5 pt-20 -103.48 49.89 0.82 Allowed 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 115.461 1.652 . . . . 10.0 115.461 -160.843 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -55.65 159.31 3.03 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 125.651 1.581 . . . . 10.0 108.799 167.656 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -66.69 -65.86 0.63 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.637 0.732 . . . . 10.0 109.619 168.372 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.3 p -161.85 -69.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 N-CA-C 107.31 -1.367 . . . . 10.0 107.31 177.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.48 56.23 0.47 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 109.598 -1.401 . . . . 10.0 109.598 177.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -87.98 91.26 8.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 104.058 -2.571 . . . . 10.0 104.058 167.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.9 -32.36 69.28 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.1 -91.7 0.7 Allowed Glycine 0 N--CA 1.434 -1.485 0 N-CA-C 108.273 -1.931 . . . . 10.0 108.273 167.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -145.27 147.35 32.28 Favored 'General case' 0 N--CA 1.447 -0.596 0 O-C-N 123.818 0.364 . . . . 10.0 110.755 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.2 m -124.21 139.08 51.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 171.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 m -89.99 113.92 25.67 Favored 'General case' 0 N--CA 1.441 -0.888 0 C-N-CA 127.887 2.475 . . . . 10.0 107.711 -178.371 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.46 138.01 32.09 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 109.623 -0.51 . . . . 10.0 109.623 169.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -65.72 170.65 4.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.959 1.304 . . . . 10.0 109.658 168.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -50.69 -34.51 26.98 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.467 -0.788 . . . . 10.0 110.894 169.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.512 ' CG ' ' HZ1' ' A' ' 36' ' ' LYS . 25.4 t0 -81.03 5.35 16.74 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.38 0.609 . . . . 10.0 112.039 -178.677 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.09 4.5 83.59 Favored Glycine 0 C--N 1.342 0.908 0 O-C-N 120.877 -1.139 . . . . 10.0 111.341 175.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.8 t -79.68 109.16 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.975 0 C-N-CA 127.76 2.424 . . . . 10.0 106.597 176.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.66 115.88 31.0 Favored 'General case' 0 CA--C 1.513 -0.459 0 N-CA-C 108.087 -1.079 . . . . 10.0 108.087 167.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -81.97 86.21 6.58 Favored 'General case' 0 N--CA 1.436 -1.157 0 C-N-CA 127.458 2.303 . . . . 10.0 109.294 179.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 32.9 t -75.72 131.94 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 N-CA-C 105.097 -2.186 . . . . 10.0 105.097 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -158.3 64.02 0.44 Allowed 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 122.995 0.518 . . . . 10.0 110.198 -175.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -111.47 158.6 11.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 106.948 -1.501 . . . . 10.0 106.948 -175.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -135.19 137.71 42.93 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 123.797 0.839 . . . . 10.0 109.942 168.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.39 147.43 43.4 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.124 0.97 . . . . 10.0 108.809 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 22.9 p -110.45 -2.14 16.7 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.076 1.75 . . . . 10.0 113.882 -172.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.9 p -97.22 -38.78 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 119.821 1.192 . . . . 10.0 109.081 172.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -65.22 136.91 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.953 -1.869 . . . . 10.0 105.953 167.158 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 25.2 m -154.86 132.42 11.28 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 108.943 -0.762 . . . . 10.0 108.943 -175.248 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -78.75 61.02 2.92 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.805 -1.183 . . . . 10.0 107.805 175.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.8 m -84.12 -119.27 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 123.81 0.844 . . . . 10.0 110.165 -174.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.96 -47.32 0.05 OUTLIER Glycine 0 CA--C 1.524 0.628 0 N-CA-C 107.91 -2.076 . . . . 10.0 107.91 -174.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -64.54 -59.32 4.44 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.899 0.88 . . . . 10.0 109.04 169.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.6 -39.05 58.53 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.276 -0.875 . . . . 10.0 108.658 -174.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.6 t 39.01 76.38 0.06 Allowed 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.525 1.53 . . . . 10.0 112.702 171.18 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pp -61.36 -26.94 40.84 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 115.899 -0.592 . . . . 10.0 110.382 168.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 32.2 mm -38.67 132.59 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 C-N-CA 126.003 1.721 . . . . 10.0 111.781 173.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.63 7.96 86.73 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-O 118.487 -1.174 . . . . 10.0 113.613 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 64.1 mtt85 -77.57 158.72 29.7 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 118.742 1.271 . . . . 10.0 109.673 169.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.82 115.5 27.52 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.111 -0.7 . . . . 10.0 109.111 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -83.97 138.27 33.21 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 170.028 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 71.9 t -125.34 137.09 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.99 -1.115 . . . . 10.0 107.99 178.033 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.06 132.95 46.99 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 105.542 -2.021 . . . . 10.0 105.542 166.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.402 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 8.5 m-70 -106.88 154.63 20.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 123.186 1.47 . . . . 10.0 114.623 -174.233 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -41.75 -61.92 1.0 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 128.398 2.679 . . . . 10.0 109.157 177.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mtmt -110.0 169.25 8.85 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 125.463 1.505 . . . . 10.0 111.84 -176.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.74 136.9 56.85 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.131 -1.395 . . . . 10.0 108.035 169.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -84.57 158.94 20.77 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 123.763 0.825 . . . . 10.0 110.169 170.687 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -104.02 17.06 24.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.07 0.948 . . . . 10.0 111.701 179.542 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 64.7 mt 43.56 40.72 2.99 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 119.269 0.941 . . . . 10.0 112.782 178.493 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.63 -4.16 53.7 Favored Glycine 0 C--N 1.336 0.565 0 CA-C-O 118.924 -0.931 . . . . 10.0 114.068 175.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mttt -118.01 30.69 7.1 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 118.136 0.968 . . . . 10.0 111.217 -166.162 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.65 -36.53 58.35 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 127.521 2.486 . . . . 10.0 110.907 171.674 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 72.45 43.68 44.38 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 111.179 -0.768 . . . . 10.0 111.179 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -145.34 168.93 19.3 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 105.983 -1.858 . . . . 10.0 105.983 171.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.407 ' OE1' ' NZ ' ' A' ' 136' ' ' LYS . 15.8 tm-20 -52.57 -42.56 64.6 Favored 'General case' 0 N--CA 1.441 -0.899 0 CA-C-O 121.239 0.542 . . . . 10.0 110.958 177.627 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -63.49 -31.83 73.1 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.263 -0.898 . . . . 10.0 113.23 178.605 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 17.1 t -43.96 -48.4 8.61 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.226 1.01 . . . . 10.0 109.778 176.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 7.8 t -80.4 -3.72 50.82 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-O 118.333 -0.841 . . . . 10.0 112.134 -169.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.407 ' NZ ' ' OE1' ' A' ' 132' ' ' GLU . 41.9 mtmt -111.61 -79.41 0.58 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.317 1.447 . . . . 10.0 110.308 -177.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.9 p -105.94 1.85 27.0 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 120.13 1.332 . . . . 10.0 113.272 177.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.72 27.24 35.64 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-O 118.904 -0.942 . . . . 10.0 113.139 169.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.2 m120 59.36 21.9 10.25 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 118.382 1.091 . . . . 10.0 112.978 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.73 -10.6 48.68 Favored 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 124.897 1.279 . . . . 10.0 112.645 176.635 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.61 -161.83 51.68 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 110.268 -1.133 . . . . 10.0 110.268 177.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.8 m -58.74 139.97 55.47 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 124.129 0.972 . . . . 10.0 112.651 -167.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.13 68.16 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.813 1.245 . . . . 10.0 109.329 167.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . 0.261 0.4 OUTLIER -64.32 -17.04 63.29 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.616 0.969 . . . . 10.0 113.616 -169.144 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 150.92 24.9 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.099 -0.704 . . . . 10.0 109.099 168.094 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.5 p -153.72 165.35 36.25 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.39 0.276 . . . . 10.0 111.034 -177.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.0 -168.04 11.77 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.438 1.018 . . . . 10.0 111.559 -177.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 33.7 t -136.92 130.75 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 104.487 -2.412 . . . . 10.0 104.487 176.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -66.47 139.7 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-N 119.438 1.017 . . . . 10.0 110.815 178.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.6 146.67 18.58 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 124.829 1.204 . . . . 10.0 111.214 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 74.8 mt -68.83 152.26 9.63 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 177.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.36 -36.11 1.14 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 114.515 1.302 . . . . 10.0 114.515 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.121 0 N-CA-C 117.529 2.418 . . . . 10.0 117.529 -177.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . 0.489 ' C ' ' H ' ' B' ' 3' ' ' LYS . . . . . . . . 0 N--CA 1.474 0.74 0 CA-C-O 118.232 -0.89 . . . . 10.0 109.099 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . 0.282 9.2 t 70.62 -29.68 0.19 Allowed 'General case' 0 C--N 1.343 0.312 0 C-N-CA 131.397 3.879 . . . . 10.0 111.835 175.036 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . 0.489 ' H ' ' C ' ' B' ' 1' ' ' ALA . 61.3 tttt -152.15 131.37 12.77 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 126.288 1.835 . . . . 10.0 106.98 -168.843 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.59 165.96 25.85 Favored 'General case' 0 CA--C 1.522 -0.131 0 C-N-CA 124.476 1.11 . . . . 10.0 108.54 171.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 7.7 m -131.38 179.97 3.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.395 0 C-N-CA 122.889 0.476 . . . . 10.0 110.563 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.27 110.66 3.74 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 124.459 1.104 . . . . 10.0 108.561 167.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -96.88 92.23 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 C-N-CA 124.065 0.946 . . . . 10.0 109.419 171.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -80.32 137.82 36.64 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.197 0.999 . . . . 10.0 110.608 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.5 tttt -156.25 160.67 40.0 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.972 -1.122 . . . . 10.0 107.972 170.263 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.41 -50.06 0.05 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 121.333 -0.46 . . . . 10.0 112.215 171.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.26 -46.58 32.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 106.738 -1.578 . . . . 10.0 106.738 -173.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.94 -66.26 0.57 Allowed Glycine 0 CA--C 1.527 0.815 0 CA-C-N 113.891 -1.504 . . . . 10.0 110.382 -179.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -60.57 -35.41 90.14 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.964 2.442 . . . . 10.0 111.323 174.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.0 t -70.35 111.21 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 N-CA-C 107.582 -1.266 . . . . 10.0 107.582 175.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.74 110.04 11.83 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.88 -1.896 . . . . 10.0 105.88 168.626 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -97.79 133.37 11.32 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 110.012 -1.235 . . . . 10.0 110.012 179.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 5.4 mt -137.57 87.77 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 108.252 -1.018 . . . . 10.0 108.252 -169.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -99.23 152.17 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.133 0 C-N-CA 124.672 1.189 . . . . 10.0 110.546 178.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 21.1 m-80 -134.43 121.57 21.29 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 128.457 2.703 . . . . 10.0 107.807 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -106.58 116.66 32.3 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 174.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.91 143.67 44.77 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.091 0.86 . . . . 10.0 112.861 169.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -93.69 94.02 8.35 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.617 1.567 . . . . 10.0 108.808 -176.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.2 tmtt? . . . . . 0 N--CA 1.445 -0.721 0 C-N-CA 126.369 1.868 . . . . 10.0 110.943 179.508 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.603 0 N-CA-C 106.93 -2.468 . . . . 10.0 106.93 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -66.48 148.79 84.34 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 121.841 1.694 . . . . 10.0 109.553 179.05 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.5 t -78.82 124.95 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 104.313 -2.477 . . . . 10.0 104.313 168.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -98.34 122.4 41.47 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 106.313 -1.736 . . . . 10.0 106.313 168.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.2 p -106.18 106.03 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 C-N-CA 127.708 2.403 . . . . 10.0 105.509 177.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -130.45 173.08 11.18 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 120.9 0.381 . . . . 10.0 110.844 179.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.76 -153.29 25.21 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 107.152 -2.379 . . . . 10.0 107.152 169.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 5.4 m -153.15 145.49 23.99 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 119.044 -1.063 . . . . 10.0 110.607 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 pt -111.97 136.75 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 CA-C-N 115.948 -0.569 . . . . 10.0 109.679 168.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.5 tptt -110.77 141.27 44.32 Favored 'General case' 0 N--CA 1.441 -0.922 0 N-CA-C 106.289 -1.745 . . . . 10.0 106.289 171.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.3 -6.37 23.16 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 123.757 0.694 . . . . 10.0 112.991 169.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -65.19 176.21 1.4 Allowed 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 118.147 0.974 . . . . 10.0 111.022 176.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -109.82 156.09 20.8 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 168.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -53.33 132.48 39.29 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.792 1.637 . . . . 10.0 111.443 -170.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 122.13 -173.2 15.81 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 118.724 0.693 . . . . 10.0 112.037 173.275 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.66 152.84 39.13 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.741 1.616 . . . . 10.0 110.756 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -150.31 147.73 27.98 Favored 'General case' 0 C--N 1.344 0.367 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -174.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -28.01 121.0 0.06 OUTLIER Glycine 0 C--N 1.34 0.784 0 C-N-CA 128.822 3.105 . . . . 10.0 113.14 161.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -153.73 101.31 2.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 119.712 1.756 . . . . 10.0 111.6 168.286 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.41 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -154.23 173.1 16.58 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 114.573 1.323 . . . . 10.0 114.573 -178.943 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 33.5 m -82.0 151.2 4.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 112.995 -1.912 . . . . 10.0 109.449 168.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -133.1 82.91 2.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.089 -1.078 . . . . 10.0 108.089 172.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 35.04 -80.8 0.0 OUTLIER 'General case' 0 C--O 1.239 0.506 0 C-N-CA 127.674 2.389 . . . . 10.0 115.135 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -77.84 173.78 11.75 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 122.043 0.925 . . . . 10.0 110.089 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -101.03 -19.53 16.71 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 125.152 1.358 . . . . 10.0 110.599 168.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.31 156.39 0.85 Allowed 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.802 1.241 . . . . 10.0 111.946 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.63 27.86 0.44 Allowed 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.322 -0.854 . . . . 10.0 111.822 169.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -55.06 -39.22 69.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.198 0.999 . . . . 10.0 111.624 -169.728 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.44 -23.71 42.96 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.055 0.942 . . . . 10.0 112.786 177.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.91 114.25 1.53 Allowed Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.829 -0.908 . . . . 10.0 110.829 -170.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 23.5 m 38.06 46.28 0.81 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 127.206 2.203 . . . . 10.0 115.529 169.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -153.31 -54.15 0.11 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 173.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 47.0 t -54.91 -38.61 67.82 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.479 1.112 . . . . 10.0 110.892 -173.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.97 -50.68 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 127.863 2.465 . . . . 10.0 114.487 170.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.01 157.19 9.61 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.299 -1.12 . . . . 10.0 110.299 177.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -74.76 -163.38 0.18 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 N-CA-C 105.395 -2.579 . . . . 10.0 105.395 165.026 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.453 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.9 m170 -81.03 48.66 1.13 Allowed 'General case' 0 CA--C 1.547 0.83 0 O-C-N 119.619 -1.925 . . . . 10.0 110.694 -176.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 m-30 -75.35 67.72 1.96 Allowed 'General case' 0 N--CA 1.466 0.341 0 O-C-N 120.936 -1.102 . . . . 10.0 110.332 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -66.19 154.64 89.66 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.408 -0.808 . . . . 10.0 109.919 170.547 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -76.46 49.68 2.72 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 123.572 2.848 . . . . 10.0 111.204 177.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -178.35 55.78 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 127.482 2.313 . . . . 10.0 105.677 -178.618 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.0 p -37.11 110.23 0.12 Allowed 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.8 1.24 . . . . 10.0 109.992 177.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -173.69 3.1 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 102.447 -3.168 . . . . 10.0 102.447 177.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -78.08 167.56 21.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 116.651 -2.019 . . . . 10.0 106.831 167.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -65.48 123.62 20.12 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 106.845 -1.539 . . . . 10.0 106.845 162.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.16 -142.05 4.42 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.458 -1.857 . . . . 10.0 108.458 173.605 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.448 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -175.15 -165.24 31.08 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.67 -1.628 . . . . 10.0 109.044 173.233 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -69.16 10.47 0.4 Allowed 'Trans proline' 0 CA--C 1.541 0.827 0 CA-C-N 119.923 1.861 . . . . 10.0 110.727 167.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.448 ' H ' ' C ' ' B' ' 73' ' ' GLY . 5.2 mtpm? -108.8 -1.16 19.48 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 124.84 1.256 . . . . 10.0 110.402 170.121 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -132.22 169.36 16.55 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 119.67 1.123 . . . . 10.0 109.007 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -78.71 -39.23 37.05 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 103.795 -2.669 . . . . 10.0 103.795 165.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -82.14 42.87 0.76 Allowed 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 114.117 1.154 . . . . 10.0 114.117 -165.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.32 159.29 18.33 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 124.006 0.922 . . . . 10.0 109.714 167.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -68.97 -79.91 0.05 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 169.111 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . 0.438 ' CG1' ' H ' ' B' ' 82' ' ' GLY 0.25 8.6 p -149.18 -79.28 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 N-CA-C 107.175 -1.417 . . . . 10.0 107.175 167.923 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . 0.438 ' H ' ' CG1' ' B' ' 81' ' ' VAL . . . -86.43 62.52 4.28 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.258 -1.137 . . . . 10.0 110.258 178.415 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -101.55 100.45 10.87 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 105.714 -1.958 . . . . 10.0 105.714 169.065 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -73.73 -9.39 58.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 118.339 0.518 . . . . 10.0 111.452 -174.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.89 -99.7 2.34 Favored Glycine 0 N--CA 1.442 -0.94 0 N-CA-C 107.347 -2.301 . . . . 10.0 107.347 -176.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -148.17 144.97 28.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 -177.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.6 m -112.93 137.57 45.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 108.216 -1.031 . . . . 10.0 108.216 168.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -97.94 116.44 30.17 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.962 0.905 . . . . 10.0 109.582 -176.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.67 130.6 35.94 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.604 1.162 . . . . 10.0 109.15 174.572 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.05 168.11 3.47 Favored 'General case' 0 N--CA 1.448 -0.573 0 O-C-N 124.584 1.177 . . . . 10.0 109.824 168.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.9 tttp -47.76 -36.61 11.82 Favored 'General case' 0 N--CA 1.432 -1.327 0 C-N-CA 126.42 1.888 . . . . 10.0 111.468 168.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -79.84 1.04 28.49 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.992 0.517 . . . . 10.0 112.318 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.18 16.79 80.27 Favored Glycine 0 C--N 1.339 0.721 0 O-C-N 120.101 -1.624 . . . . 10.0 110.791 178.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 37.2 t -92.93 105.84 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 C-N-CA 126.513 1.925 . . . . 10.0 106.033 175.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.18 117.74 35.41 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 107.139 -1.43 . . . . 10.0 107.139 168.582 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -94.23 124.6 38.34 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.315 1.009 . . . . 10.0 108.279 177.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.99 134.53 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 C-N-CA 125.838 1.655 . . . . 10.0 108.421 -174.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -157.46 95.52 1.46 Allowed 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.719 1.207 . . . . 10.0 108.761 170.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 mp -123.59 145.36 30.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 108.105 -1.072 . . . . 10.0 108.105 176.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -106.06 135.28 47.8 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 128.691 2.797 . . . . 10.0 107.745 169.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -140.05 155.38 47.08 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 168.238 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.4 p -126.39 49.19 2.04 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.587 1.155 . . . . 10.0 109.771 174.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 p -133.33 -45.45 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.491 1.117 . . . . 10.0 110.246 172.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.32 131.81 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.298 -1.001 . . . . 10.0 108.298 169.575 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 67.8 m -125.37 112.71 16.64 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 170.078 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 18.1 mt -46.2 -41.52 12.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.193 1.397 . . . . 10.0 110.318 176.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 22.8 p . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 105.844 -1.91 . . . . 10.0 105.844 168.657 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 34.9 t . . . . . 0 N--CA 1.45 -0.473 0 CA-C-O 122.414 1.102 . . . . 10.0 109.922 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 3.6 pt -75.63 58.6 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.849 -0.797 . . . . 10.0 108.849 172.478 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 44.5 mm -108.84 -58.36 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.671 0.788 . . . . 10.0 109.176 -177.638 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -93.46 50.93 2.38 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 109.409 -1.477 . . . . 10.0 109.409 173.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.09 158.24 24.53 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.304 1.842 . . . . 10.0 107.401 177.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 67.1 m -108.68 119.07 38.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 127.042 2.137 . . . . 10.0 106.264 -178.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 62.6 mt -93.49 150.87 20.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 108.224 -1.028 . . . . 10.0 108.224 168.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 79.6 t -132.81 138.36 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 N-CA-C 108.159 -1.052 . . . . 10.0 108.159 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.85 136.76 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 168.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 9.4 m-70 -116.03 161.12 19.34 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -175.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -60.04 -50.11 75.0 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.217 -0.901 . . . . 10.0 109.677 177.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 92.6 mttt -104.53 163.3 12.56 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.927 0.714 . . . . 10.0 112.927 -168.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.93 157.02 34.29 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 114.301 -1.318 . . . . 10.0 108.991 172.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -109.79 134.78 51.64 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 124.153 0.981 . . . . 10.0 109.243 -169.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -73.26 -24.56 60.47 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 124.861 1.264 . . . . 10.0 110.337 -174.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 59.64 42.87 16.5 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.52 -0.918 . . . . 10.0 108.52 -173.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.53 -53.12 1.02 Allowed Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 124.959 1.266 . . . . 10.0 110.971 170.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -79.29 49.88 1.02 Allowed 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.356 1.062 . . . . 10.0 113.072 -170.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -29.77 7.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 127.118 2.294 . . . . 10.0 110.593 169.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 75.81 18.71 79.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 118.978 -0.901 . . . . 10.0 112.395 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -111.65 160.22 17.45 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 105.947 -1.871 . . . . 10.0 105.947 168.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -50.26 -47.48 55.21 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.33 -1.304 . . . . 10.0 108.397 171.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -64.34 -37.43 87.47 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 112.915 0.709 . . . . 10.0 112.915 177.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.6 m -51.63 -45.47 63.3 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.336 1.425 . . . . 10.0 111.035 172.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.9 t -82.45 -22.51 35.2 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 111.922 0.341 . . . . 10.0 111.922 -173.177 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 25.2 ttmt -89.41 -46.89 8.39 Favored 'General case' 0 N--CA 1.439 -0.978 0 C-N-CA 125.225 1.41 . . . . 10.0 112.129 -177.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.453 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 30.7 p -133.44 -11.62 2.78 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 114.172 1.175 . . . . 10.0 114.172 178.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.22 15.72 37.5 Favored Glycine 0 C--O 1.221 -0.678 0 CA-C-O 118.982 -0.899 . . . . 10.0 112.15 -171.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 57.35 35.1 25.62 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.13 1.465 . . . . 10.0 111.233 -178.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.17 -13.59 62.1 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.515 1.926 . . . . 10.0 111.886 -178.435 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.89 -171.06 54.59 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 109.223 -1.551 . . . . 10.0 109.223 -169.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.1 m -52.52 166.12 0.21 Allowed 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 124.48 1.112 . . . . 10.0 113.071 -177.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -83.93 102.02 12.11 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 107.467 -1.308 . . . . 10.0 107.467 168.472 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.409 ' CD2' ' N ' ' B' ' 144' ' ' LEU . 0.4 OUTLIER -71.61 -47.98 51.07 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.05 -1.092 . . . . 10.0 108.05 -177.642 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -143.49 144.54 32.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.094 -0.706 . . . . 10.0 109.094 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 39.0 m -126.71 147.98 49.91 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.669 -1.234 . . . . 10.0 107.669 -176.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.87 141.1 11.57 Favored Glycine 0 C--N 1.332 0.315 0 N-CA-C 108.834 -1.706 . . . . 10.0 108.834 172.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.71 136.8 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 N-CA-C 101.612 -3.477 . . . . 10.0 101.612 169.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 68.5 mt -61.86 -81.41 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 CA-C-O 121.418 0.628 . . . . 10.0 110.285 -168.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.99 134.43 8.33 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.371 -0.691 . . . . 10.0 111.371 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.78 137.25 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.089 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 173.435 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.98 -70.08 0.54 Allowed 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 106.742 -1.577 . . . . 10.0 106.742 171.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . 0.428 ' C ' ' H3 ' ' B' ' 1' ' ' ALA . 20.4 tm0? . . . . . 0 C--O 1.253 1.249 0 N-CA-C 104.827 -2.286 . . . . 10.0 104.827 167.266 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.62 0 N-CA-C 105.511 -2.033 . . . . 10.0 105.511 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.5 t -63.18 -30.62 71.73 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.978 1.263 . . . . 10.0 108.1 167.427 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.5 tmtm? -117.08 146.95 42.8 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 126.088 1.755 . . . . 10.0 108.675 177.562 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.06 177.04 11.78 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 125.829 1.652 . . . . 10.0 109.195 169.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.9 t -136.2 164.04 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 125.277 1.431 . . . . 10.0 108.749 -176.49 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.68 104.36 3.03 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.054 0.941 . . . . 10.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.5 m -93.47 127.99 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 109.322 -0.621 . . . . 10.0 109.322 176.389 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.93 137.28 47.92 Favored 'General case' 0 C--O 1.225 -0.218 0 C-N-CA 124.762 1.225 . . . . 10.0 108.559 -178.736 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 40.1 mtpt -146.22 164.93 30.71 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-N 120.69 1.586 . . . . 10.0 107.968 170.797 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.59 -60.24 0.04 OUTLIER Glycine 0 CA--C 1.511 -0.19 0 C-N-CA 120.377 -0.916 . . . . 10.0 112.291 169.701 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.64 -44.91 61.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 -177.647 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.9 -69.74 0.44 Allowed Glycine 0 CA--C 1.524 0.612 0 CA-C-N 114.296 -1.32 . . . . 10.0 110.887 172.78 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -57.3 -36.3 98.94 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 123.25 2.633 . . . . 10.0 111.263 174.971 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.8 t -65.62 97.56 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.117 -1.438 . . . . 10.0 107.117 175.323 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.56 105.86 11.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.138 0.975 . . . . 10.0 108.424 173.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.03 149.79 29.92 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 109.623 -1.391 . . . . 10.0 109.623 168.38 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -155.22 59.6 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 C-N-CA 125.925 1.69 . . . . 10.0 106.848 -168.939 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 mm -74.94 146.47 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 O-C-N 121.621 -0.675 . . . . 10.0 109.657 -179.27 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -118.9 124.53 47.32 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 126.711 2.004 . . . . 10.0 107.061 177.013 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -106.63 120.6 42.39 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 178.703 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.5 mp0 -125.73 117.8 24.23 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.33 0.652 . . . . 10.0 111.472 176.515 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -124.03 108.99 12.96 Favored 'General case' 0 C--O 1.227 -0.113 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 168.287 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.42 -50.92 68.53 Favored 'General case' 0 C--N 1.333 -0.117 0 O-C-N 121.749 -0.595 . . . . 10.0 110.671 -178.824 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -129.57 170.42 13.78 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 103.557 -2.757 . . . . 10.0 103.557 168.38 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 92.3 p -68.61 -19.75 64.46 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 123.837 0.855 . . . . 10.0 110.39 170.12 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -78.77 -14.83 59.06 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 123.321 0.649 . . . . 10.0 109.278 174.144 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.43 138.67 15.47 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.183 -1.567 . . . . 10.0 109.183 175.828 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -62.4 135.8 55.74 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 CA-C-N 119.414 1.607 . . . . 10.0 108.069 171.328 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.1 p -75.97 120.36 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.425 0 N-CA-C 107.545 -1.28 . . . . 10.0 107.545 -176.779 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.1 mtpt -91.52 109.68 20.98 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.942 -2.244 . . . . 10.0 104.942 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.3 m -104.77 88.82 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 178.768 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -97.33 170.94 8.73 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-O 121.75 0.786 . . . . 10.0 111.664 169.509 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.06 -169.15 38.84 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.51 -1.036 . . . . 10.0 110.51 172.025 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.9 p -147.15 102.35 3.49 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.908 -0.775 . . . . 10.0 108.908 -175.844 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 pt -78.44 130.8 35.69 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 N-CA-C 106.428 -1.694 . . . . 10.0 106.428 168.38 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 ptmt -118.73 136.17 54.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.708 -1.219 . . . . 10.0 107.708 173.864 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.95 -3.95 14.31 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.75 1.167 . . . . 10.0 112.979 179.676 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -66.35 176.97 1.61 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.625 1.212 . . . . 10.0 111.109 177.516 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.5 t -112.35 155.9 23.37 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 105.308 -2.108 . . . . 10.0 105.308 166.04 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -50.23 157.53 0.67 Allowed 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.29 1.036 . . . . 10.0 111.678 -170.365 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.51 -175.37 29.14 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 170.791 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -78.39 149.2 33.39 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.699 1.599 . . . . 10.0 110.695 -175.99 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.1 m-70 -144.39 137.63 27.21 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.516 0.726 . . . . 10.0 112.953 -175.586 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.402 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -40.96 122.07 2.16 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 126.574 2.035 . . . . 10.0 110.217 168.247 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -136.73 113.03 9.88 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.177 1.489 . . . . 10.0 107.925 169.799 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.69 174.69 13.2 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-O 122.247 1.022 . . . . 10.0 112.163 -179.158 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.0 t -96.32 143.9 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 CA-C-N 111.318 -2.674 . . . . 10.0 107.2 169.609 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 76.9 m-70 -123.39 126.4 46.75 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 103.643 -2.725 . . . . 10.0 103.643 172.55 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.5 tp10 -61.17 -42.76 99.14 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.184 -1.371 . . . . 10.0 112.746 -165.508 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -81.91 118.64 23.1 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 119.288 -0.965 . . . . 10.0 109.459 177.696 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.1 -13.89 16.19 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.707 2.575 . . . . 10.0 112.523 169.992 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -42.83 127.28 3.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 122.384 1.088 . . . . 10.0 111.173 168.966 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -137.39 23.12 2.96 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.521 164.854 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -66.71 -44.43 81.69 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 106.542 -1.651 . . . . 10.0 106.542 168.525 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.69 -21.92 44.08 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.335 -0.393 . . . . 10.0 111.55 173.062 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.58 71.49 1.31 Allowed Glycine 0 CA--C 1.528 0.848 0 C-N-CA 124.134 0.873 . . . . 10.0 111.28 173.015 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.291 23.2 p 43.12 48.98 5.5 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.665 1.186 . . . . 10.0 113.783 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 p -127.21 -66.95 0.86 Allowed 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 127.344 2.258 . . . . 10.0 105.354 173.072 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.1 m -79.05 -4.68 51.34 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 123.364 0.665 . . . . 10.0 112.56 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.7 -14.69 1.45 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.41 1.484 . . . . 10.0 112.925 173.377 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.22 131.55 6.89 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 108.847 -1.701 . . . . 10.0 108.847 170.071 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -75.17 59.97 5.44 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.8 3.0 . . . . 10.0 110.38 172.247 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 23.3 m170 71.7 49.74 0.27 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 129.312 3.045 . . . . 10.0 111.275 175.435 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -72.21 38.12 0.07 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 115.258 1.577 . . . . 10.0 115.258 -173.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.27 151.15 0.57 Allowed Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.55 1.54 . . . . 10.0 113.107 169.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -66.02 -46.37 4.75 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.884 2.389 . . . . 10.0 111.953 179.544 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 71.1 mt -79.39 54.01 1.63 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.631 -0.668 . . . . 10.0 110.457 -177.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 40.0 p -55.5 109.2 0.52 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.537 1.135 . . . . 10.0 110.406 -173.826 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.4 mtt180 -121.29 -97.15 0.46 Allowed 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 -179.889 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.4 140.87 23.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 105.261 -2.126 . . . . 10.0 105.261 177.278 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -47.08 116.95 1.52 Allowed 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.654 -0.418 . . . . 10.0 110.991 169.402 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.48 -141.01 4.29 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 106.536 -2.626 . . . . 10.0 106.536 170.531 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.411 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 177.95 -147.51 8.1 Favored Glycine 0 C--O 1.227 -0.312 0 CA-C-O 118.644 -1.086 . . . . 10.0 111.229 175.267 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -68.27 14.93 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 120.041 1.921 . . . . 10.0 111.943 177.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.411 ' H ' ' C ' ' A' ' 73' ' ' GLY . 58.0 mmtt -104.68 -14.96 15.41 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 119.038 0.835 . . . . 10.0 110.042 169.805 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.33 177.34 7.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.337 1.065 . . . . 10.0 113.064 -165.049 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -98.64 -13.31 20.39 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 113.449 -1.705 . . . . 10.0 108.502 168.198 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.11 -16.26 56.97 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 124.735 1.214 . . . . 10.0 112.23 -168.598 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.28 135.88 2.47 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.596 1.158 . . . . 10.0 110.333 -169.78 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -73.66 61.99 0.76 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 123.405 0.682 . . . . 10.0 111.588 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.4 t 31.78 48.66 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 C-N-CA 126.872 2.069 . . . . 10.0 111.418 -174.511 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.22 42.0 0.05 OUTLIER Glycine 0 CA--C 1.531 1.062 0 CA-C-N 116.032 -0.531 . . . . 10.0 113.877 -178.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -97.07 100.42 11.92 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 103.617 -2.735 . . . . 10.0 103.617 166.049 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 27.5 mt -75.62 -24.86 56.53 Favored 'General case' 0 N--CA 1.462 0.174 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 177.865 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.94 -102.25 2.83 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.311 -1.916 . . . . 10.0 108.311 168.527 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -129.24 133.67 47.62 Favored 'General case' 0 CA--C 1.517 -0.311 0 C-N-CA 123.888 0.875 . . . . 10.0 112.176 -168.633 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.8 m -124.88 145.47 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.143 -1.799 . . . . 10.0 106.143 167.202 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -98.44 126.14 43.87 Favored 'General case' 0 C--O 1.225 -0.223 0 C-N-CA 124.851 1.261 . . . . 10.0 108.959 -178.025 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.52 134.46 34.35 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 172.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.437 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 42.5 t0 -67.17 172.45 4.67 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-O 121.592 0.71 . . . . 10.0 109.609 168.45 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.437 ' HZ1' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -47.46 -32.2 4.91 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.39 2.276 . . . . 10.0 111.099 171.528 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -78.68 -11.34 59.97 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.855 0.359 . . . . 10.0 110.607 -175.804 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.06 15.67 69.17 Favored Glycine 0 C--N 1.339 0.75 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 -177.189 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.4 t -94.97 111.15 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 126.796 2.038 . . . . 10.0 105.921 175.162 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.02 120.24 41.28 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 168.734 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -78.53 131.08 36.66 Favored 'General case' 0 N--CA 1.429 -1.524 0 C-N-CA 125.906 1.682 . . . . 10.0 107.892 173.89 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.4 t -117.55 133.89 62.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.303 0 N-CA-C 106.235 -1.765 . . . . 10.0 106.235 179.459 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.5 p -157.45 70.42 0.6 Allowed 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 123.685 0.794 . . . . 10.0 109.554 175.554 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.43 153.22 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 179.406 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -137.35 123.16 20.02 Favored 'General case' 0 N--CA 1.443 -0.812 0 C-N-CA 125.557 1.543 . . . . 10.0 106.897 169.298 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -128.29 153.99 46.4 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.62 0.724 . . . . 10.0 109.051 -178.723 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 33.7 t -117.48 46.18 1.77 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.629 1.572 . . . . 10.0 110.043 -168.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.3 p -155.8 -46.13 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.132 0 N-CA-C 109.181 -0.674 . . . . 10.0 109.181 177.105 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 29.8 mm -56.35 142.22 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 123.49 0.716 . . . . 10.0 109.664 172.333 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.7 m -155.62 133.92 11.61 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 123.9 0.88 . . . . 10.0 108.758 171.671 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 82.7 mt -47.27 -55.21 9.11 Favored 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 126.914 2.086 . . . . 10.0 111.318 176.402 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.0 t -130.75 152.24 50.31 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 105.278 -2.119 . . . . 10.0 105.278 170.025 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.52 -84.77 0.12 Allowed Glycine 0 C--N 1.333 0.369 0 N-CA-C 110.058 -1.217 . . . . 10.0 110.058 -177.351 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -136.23 -53.47 0.74 Allowed 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 126.744 2.017 . . . . 10.0 107.5 -179.588 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -76.49 -31.15 57.57 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.117 -0.947 . . . . 10.0 108.57 -175.239 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 48.96 63.37 2.15 Favored 'General case' 0 N--CA 1.447 -0.594 0 C-N-CA 125.669 1.588 . . . . 10.0 109.372 177.109 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.315 1.1 tp -61.45 -18.77 19.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 C-N-CA 123.411 0.684 . . . . 10.0 112.112 -176.116 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.4 mm -48.75 135.79 5.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 118.812 0.733 . . . . 10.0 110.062 167.278 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.88 14.28 82.18 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.055 -0.858 . . . . 10.0 113.489 172.473 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.4 mmt-85 -84.02 175.43 9.54 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 167.898 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.3 m -108.36 122.27 46.64 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 177.003 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 6.5 mp -99.51 147.33 25.43 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-N 119.606 1.093 . . . . 10.0 108.535 171.058 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.6 t -131.18 135.93 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 N-CA-C 108.734 -0.839 . . . . 10.0 108.734 179.795 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 p -104.78 129.76 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 168.106 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.402 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 10.1 m-70 -111.12 158.86 18.39 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 114.994 1.479 . . . . 10.0 114.994 -169.672 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -46.42 -60.51 2.3 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.493 2.717 . . . . 10.0 110.903 171.369 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.2 mttp -117.27 165.61 13.24 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.104 0.478 . . . . 10.0 110.356 -172.917 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.39 140.8 54.21 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 168.854 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.03 153.75 32.06 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 108.837 -0.801 . . . . 10.0 108.837 168.264 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -78.59 10.73 2.97 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.118 0.967 . . . . 10.0 111.146 177.457 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.3 mt 38.94 51.35 1.85 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 125.151 1.38 . . . . 10.0 110.86 -170.334 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.94 -27.62 17.41 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-N 114.059 -1.428 . . . . 10.0 112.638 173.522 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -78.83 16.05 0.96 Allowed 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 113.66 0.985 . . . . 10.0 113.66 -168.42 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.93 -32.39 82.5 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 170.295 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 69.94 31.13 69.78 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 122.488 -0.419 . . . . 10.0 112.34 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.95 176.21 8.24 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 125.299 1.44 . . . . 10.0 107.545 173.338 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -59.51 -51.27 70.57 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 113.403 -1.726 . . . . 10.0 109.425 177.742 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.407 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 5.4 tp10 -52.97 -43.9 66.74 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.565 1.146 . . . . 10.0 110.692 171.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.5 m -53.55 -46.59 70.28 Favored 'General case' 0 N--CA 1.441 -0.917 0 O-C-N 120.851 -1.156 . . . . 10.0 110.968 -179.118 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.5 t -77.65 -0.57 27.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 119.786 -0.766 . . . . 10.0 111.857 -177.121 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -113.91 -82.1 0.6 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.312 1.845 . . . . 10.0 111.197 -179.657 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.407 ' HG1' ' CD ' ' A' ' 133' ' ' GLU 0.299 2.0 p -105.95 11.84 31.24 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 120.738 1.608 . . . . 10.0 113.054 177.939 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.09 10.75 78.52 Favored Glycine 0 C--O 1.221 -0.699 0 CA-C-O 119.047 -0.863 . . . . 10.0 114.336 166.812 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 m120 65.7 26.35 11.42 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.594 1.197 . . . . 10.0 111.596 -176.863 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.59 -11.82 8.29 Favored 'General case' 0 CA--C 1.533 0.327 0 O-C-N 121.644 -0.66 . . . . 10.0 111.683 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.58 -140.32 21.74 Favored Glycine 0 N--CA 1.443 -0.852 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 168.495 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -70.72 118.23 13.25 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.23 0.538 . . . . 10.0 111.283 -168.359 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.41 76.55 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.734 1.214 . . . . 10.0 111.35 168.624 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 50.3 mt -52.12 -40.89 61.97 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.101 0.778 . . . . 10.0 113.101 -176.051 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 155.09 24.77 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 108.335 -0.987 . . . . 10.0 108.335 -171.579 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -167.15 166.07 15.18 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 116.049 -0.523 . . . . 10.0 109.626 -167.59 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.7 179.3 46.95 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.658 -0.782 . . . . 10.0 112.062 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 71.3 t -109.24 156.22 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 N-CA-C 104.978 -2.23 . . . . 10.0 104.978 -175.677 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.4 mt -75.07 -96.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 C-N-CA 123.656 0.782 . . . . 10.0 110.747 -168.478 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 106.28 130.85 6.68 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-O 121.917 0.732 . . . . 10.0 112.098 179.381 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 92.2 mt -72.18 141.25 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.689 0 C-N-CA 124.968 1.307 . . . . 10.0 108.968 179.083 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.11 -102.11 0.41 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 105.761 -1.94 . . . . 10.0 105.761 165.519 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 . . . . . 0 C--O 1.247 0.962 0 C-N-CA 131.033 3.733 . . . . 10.0 103.075 -171.237 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 106.267 -1.753 . . . . 10.0 106.267 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -160.49 -47.33 0.05 OUTLIER 'General case' 0 C--O 1.232 0.139 0 CA-C-N 118.89 0.768 . . . . 10.0 110.668 172.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -119.64 142.71 48.19 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 126.839 2.056 . . . . 10.0 107.691 173.877 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.44 155.51 45.86 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.118 0.967 . . . . 10.0 108.396 169.36 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -122.65 153.99 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 C-N-CA 123.873 0.869 . . . . 10.0 109.265 -175.181 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.74 93.11 2.16 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 167.367 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 31.6 m -83.19 133.45 29.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 107.803 -1.184 . . . . 10.0 107.803 169.425 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mt -107.34 138.15 44.07 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.836 -1.172 . . . . 10.0 107.836 -177.507 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 36.5 mtpt -146.34 153.72 40.85 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 120.582 1.537 . . . . 10.0 107.545 169.518 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.51 -52.71 0.08 OUTLIER Glycine 0 N--CA 1.462 0.388 0 C-N-CA 119.217 -1.468 . . . . 10.0 114.171 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -72.68 -43.41 63.13 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.649 -1.241 . . . . 10.0 107.649 -172.065 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.74 -70.55 0.4 Allowed Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 114.055 -1.429 . . . . 10.0 110.032 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -54.91 -39.73 88.99 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.783 2.322 . . . . 10.0 110.879 170.817 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.7 t -58.65 107.54 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.246 0 CA-C-N 119.083 0.856 . . . . 10.0 109.157 179.688 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.04 92.2 3.68 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.744 -2.317 . . . . 10.0 104.744 168.676 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.44 152.19 37.35 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 109.401 -1.479 . . . . 10.0 109.401 177.045 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -154.26 87.22 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -171.16 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.8 mm -96.56 142.18 14.35 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 C-N-CA 124.846 1.258 . . . . 10.0 109.464 174.872 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -127.64 119.31 25.61 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 125.38 1.472 . . . . 10.0 108.082 174.142 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -98.0 113.76 25.7 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.058 1.343 . . . . 10.0 107.5 173.409 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -117.89 136.06 53.7 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 119.133 0.878 . . . . 10.0 110.775 170.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 36.1 tt0 -126.54 81.15 1.98 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 124.638 1.175 . . . . 10.0 109.763 -176.102 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt . . . . . 0 N--CA 1.452 -0.359 0 C-N-CA 124.863 1.265 . . . . 10.0 111.963 -175.223 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.15 0 CA-C-O 118.565 -1.131 . . . . 10.0 114.48 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -71.17 108.18 2.28 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 N-CA-C 106.22 -2.261 . . . . 10.0 106.22 169.122 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 26.2 t -77.35 95.74 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.349 0 N-CA-C 105.374 -2.084 . . . . 10.0 105.374 174.612 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -76.33 96.63 4.02 Favored 'General case' 0 N--CA 1.444 -0.76 0 N-CA-C 105.594 -2.002 . . . . 10.0 105.594 174.516 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -92.58 90.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.751 0 N-CA-C 106.87 -1.53 . . . . 10.0 106.87 175.654 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -99.48 176.58 5.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 121.443 0.64 . . . . 10.0 109.4 169.428 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.15 173.58 40.32 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 110.016 -1.234 . . . . 10.0 110.016 176.206 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.6 m -149.52 89.55 1.64 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 -179.626 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.5 pt -77.38 150.46 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 174.313 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.8 pttt -136.96 126.05 24.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 O-C-N 124.288 0.992 . . . . 10.0 108.848 169.425 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.97 6.76 5.31 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-O 118.791 -1.005 . . . . 10.0 114.629 166.064 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.416 ' N ' ' CD1' ' B' ' 38' ' ' LEU . 0.0 OUTLIER -89.82 179.34 6.02 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-N 118.728 1.264 . . . . 10.0 108.62 172.443 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -81.09 175.12 10.94 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.348 -0.845 . . . . 10.0 111.011 172.175 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -63.23 169.72 3.38 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.426 1.49 . . . . 10.0 111.48 -174.616 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.94 -174.74 51.42 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 124.008 0.813 . . . . 10.0 113.256 167.376 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -66.19 143.0 57.53 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.795 1.638 . . . . 10.0 110.608 178.603 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -142.36 139.34 31.72 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 114.214 1.19 . . . . 10.0 114.214 -178.655 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -26.03 111.77 0.02 OUTLIER Glycine 0 C--N 1.342 0.883 0 C-N-CA 128.418 2.913 . . . . 10.0 114.208 165.493 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -138.57 102.95 4.73 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 120.376 2.088 . . . . 10.0 110.516 174.844 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.516 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -148.56 179.23 7.97 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.331 0.586 . . . . 10.0 111.829 -178.358 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 p -100.21 148.26 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 112.704 -2.044 . . . . 10.0 108.127 168.33 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -123.93 129.6 51.23 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.067 -2.568 . . . . 10.0 104.067 169.154 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -59.13 -44.73 92.04 Favored 'General case' 0 N--CA 1.441 -0.898 0 O-C-N 124.528 1.142 . . . . 10.0 112.363 -166.646 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -75.19 112.49 11.52 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 105.239 -2.134 . . . . 10.0 105.239 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -57.65 -33.51 67.45 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 109.503 -1.439 . . . . 10.0 109.503 168.798 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -35.93 146.34 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 125.253 1.421 . . . . 10.0 112.06 169.547 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -144.36 28.44 1.34 Allowed 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 115.261 -0.881 . . . . 10.0 111.406 176.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -49.12 -43.06 41.14 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 112.859 0.688 . . . . 10.0 112.859 -169.028 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -86.82 -23.5 25.32 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 113.378 0.881 . . . . 10.0 113.378 177.052 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.97 101.39 2.69 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.172 -1.571 . . . . 10.0 109.172 -170.273 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.289 26.3 p 11.5 49.62 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 129.633 3.173 . . . . 10.0 116.955 -168.673 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 42.4 m -120.84 -53.68 2.06 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 105.077 -2.194 . . . . 10.0 105.077 174.977 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.5 m -44.89 -40.45 6.29 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 126.158 1.783 . . . . 10.0 109.936 168.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.84 -25.25 0.09 Allowed 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 127.726 2.41 . . . . 10.0 114.999 176.934 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.41 155.79 29.45 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 108.572 -1.811 . . . . 10.0 108.572 169.35 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -68.5 -172.73 0.48 Allowed 'Trans proline' 0 N--CA 1.445 -1.352 0 N-CA-C 106.888 -2.005 . . . . 10.0 106.888 166.719 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.428 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 37.6 m170 -78.81 45.09 0.58 Allowed 'General case' 0 CA--C 1.542 0.649 0 O-C-N 119.743 -1.848 . . . . 10.0 112.047 -171.511 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.1 m-30 -72.55 68.22 0.8 Allowed 'General case' 0 C--O 1.221 -0.413 0 CA-C-N 119.846 1.203 . . . . 10.0 109.676 178.759 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -63.57 155.66 74.83 Favored Pre-proline 0 C--N 1.331 -0.226 0 N-CA-C 107.535 -1.283 . . . . 10.0 107.535 173.768 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -54.92 -27.95 56.47 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.097 1.865 . . . . 10.0 112.281 175.222 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -107.78 25.14 11.89 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.043 0.937 . . . . 10.0 111.815 177.189 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 44.7 p -40.98 117.79 0.9 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.646 1.179 . . . . 10.0 112.273 177.94 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -124.58 -88.89 0.59 Allowed 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 107.676 -1.231 . . . . 10.0 107.676 177.361 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -125.49 152.6 44.76 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 108.316 -0.994 . . . . 10.0 108.316 168.541 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 36.2 t60 -58.14 128.36 36.72 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 117.659 -1.617 . . . . 10.0 106.734 165.812 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -150.09 -141.16 3.35 Favored Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 109.905 -1.278 . . . . 10.0 109.905 -178.771 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.6 -147.52 11.43 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 107.95 -2.06 . . . . 10.0 107.95 169.976 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.05 12.94 0.2 Allowed 'Trans proline' 0 N--CA 1.452 -0.923 0 CA-C-N 120.114 1.957 . . . . 10.0 111.621 169.429 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -127.65 1.51 6.15 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.59 1.156 . . . . 10.0 111.737 176.502 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . 0.42 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 0.2 OUTLIER -123.81 150.58 44.35 Favored 'General case' 0 C--N 1.34 0.168 0 N-CA-C 102.426 -3.175 . . . . 10.0 102.426 166.825 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -82.55 -17.74 43.9 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 121.646 -0.659 . . . . 10.0 109.832 174.705 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.9 pm0 -118.16 36.54 4.31 Favored 'General case' 0 N--CA 1.438 -1.056 0 C-N-CA 125.901 1.68 . . . . 10.0 111.579 -167.515 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -44.25 153.58 0.14 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.58 1.552 . . . . 10.0 109.578 168.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 38.4 m80 -60.9 -48.17 83.06 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 10.0 109.966 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.1 t 173.31 -75.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 C-N-CA 129.284 3.034 . . . . 10.0 105.059 166.082 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.03 59.06 5.02 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 179.305 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -106.08 95.07 5.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.557 -2.016 . . . . 10.0 105.557 169.322 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 43.6 mt -75.23 -33.87 61.39 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 106.741 -1.577 . . . . 10.0 106.741 175.632 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.51 -96.94 1.31 Allowed Glycine 0 N--CA 1.436 -1.337 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 169.442 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -132.42 136.14 46.56 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 122.863 0.465 . . . . 10.0 110.021 -169.518 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.5 m -122.24 140.3 46.54 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.955 -0.758 . . . . 10.0 108.955 169.488 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 9.4 m -81.93 119.25 23.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 127.457 2.303 . . . . 10.0 110.499 -177.159 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.4 130.46 44.53 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.984 1.314 . . . . 10.0 110.642 170.022 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -59.88 166.31 2.73 Favored 'General case' 0 N--CA 1.455 -0.222 0 O-C-N 124.069 0.855 . . . . 10.0 109.603 167.366 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 35.6 pttt -52.47 -30.5 30.18 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.804 1.241 . . . . 10.0 110.93 173.37 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -77.08 -9.52 58.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 117.676 0.216 . . . . 10.0 111.027 -178.148 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.54 10.57 67.54 Favored Glycine 0 C--N 1.34 0.774 0 O-C-N 121.092 -1.005 . . . . 10.0 111.038 -178.191 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.0 t -86.14 111.44 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 127.184 2.194 . . . . 10.0 106.466 175.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -114.61 120.71 41.1 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 118.715 0.689 . . . . 10.0 109.509 172.825 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -78.5 132.43 37.23 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 107.325 -1.361 . . . . 10.0 107.325 169.864 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.8 t -114.94 133.44 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 N-CA-C 104.777 -2.305 . . . . 10.0 104.777 169.063 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -156.73 62.8 0.52 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 118.174 0.443 . . . . 10.0 110.139 -178.731 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.69 152.85 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 N-CA-C 107.735 -1.209 . . . . 10.0 107.735 -173.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -136.6 139.22 41.95 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 123.798 0.839 . . . . 10.0 109.667 168.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -148.47 153.53 38.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.3 p -115.52 44.48 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 126.494 1.917 . . . . 10.0 109.549 177.403 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -111.69 -48.04 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 170.457 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 42.5 mm -65.1 148.49 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 108.007 -1.108 . . . . 10.0 108.007 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.4 m -157.29 120.97 4.16 Favored 'General case' 0 C--O 1.226 -0.134 0 N-CA-C 108.029 -1.1 . . . . 10.0 108.029 173.578 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.9 mp -59.62 -29.94 68.36 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.614 1.166 . . . . 10.0 111.955 -169.603 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.2 m . . . . . 0 N--CA 1.454 -0.227 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 176.096 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 7.1 t . . . . . 0 CA--C 1.531 0.247 0 CA-C-O 120.547 0.213 . . . . 10.0 111.176 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 mt 63.82 16.32 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 124.173 0.989 . . . . 10.0 110.721 174.104 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.8 mm -71.02 -56.1 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 124.478 1.111 . . . . 10.0 110.037 175.824 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.72 48.82 3.55 Favored Glycine 0 CA--C 1.526 0.758 0 O-C-N 120.617 -1.302 . . . . 10.0 112.501 -177.49 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.03 168.06 11.93 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 126.612 1.965 . . . . 10.0 108.692 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -114.21 141.11 47.95 Favored 'General case' 0 CA--C 1.515 -0.396 0 C-N-CA 124.654 1.181 . . . . 10.0 108.306 -172.07 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.8 mp -111.85 145.92 38.62 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.83 1.652 . . . . 10.0 108.474 172.489 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.9 t -131.71 136.06 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 178.278 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 p -97.57 120.17 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 105.838 -1.912 . . . . 10.0 105.838 168.007 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -98.5 158.29 15.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 115.59 1.7 . . . . 10.0 115.59 -176.373 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -38.47 -66.18 0.29 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 129.834 3.254 . . . . 10.0 110.619 170.517 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -113.75 174.86 5.72 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 125.174 1.389 . . . . 10.0 110.319 -174.561 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.84 137.23 35.3 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.879 -1.055 . . . . 10.0 108.465 171.311 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.516 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -77.4 141.73 39.63 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.287 1.035 . . . . 10.0 109.284 169.892 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -78.45 24.51 0.27 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.375 0.67 . . . . 10.0 111.86 179.63 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.5 mt 36.64 51.6 0.91 Allowed 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.792 2.037 . . . . 10.0 111.7 -176.674 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.44 -32.03 6.6 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 125.594 1.569 . . . . 10.0 112.384 175.078 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . 0.42 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 7.2 mttm -80.08 18.67 0.81 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.628 1.171 . . . . 10.0 113.222 -167.819 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.27 -18.73 75.29 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 109.531 -1.428 . . . . 10.0 109.531 167.109 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.78 40.19 92.52 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 124.402 1.001 . . . . 10.0 111.749 175.403 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -145.25 169.6 17.91 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.093 0.946 . . . . 10.0 109.583 173.643 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 13.0 tm-20 -46.83 -49.85 19.4 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.711 1.204 . . . . 10.0 110.139 -179.875 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 17.9 tp10 -71.35 -34.74 70.77 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 121.781 -0.574 . . . . 10.0 111.657 179.217 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.9 p -54.15 -43.63 70.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 120.715 -1.241 . . . . 10.0 110.799 172.149 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.272 5.6 t -77.81 -23.02 49.18 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 119.568 -0.853 . . . . 10.0 111.557 -173.627 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -84.71 -49.01 8.86 Favored 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 127.486 2.314 . . . . 10.0 112.525 -177.738 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.428 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 19.2 p -136.3 -15.04 1.71 Allowed 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 114.495 1.295 . . . . 10.0 114.495 175.556 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.76 3.9 52.18 Favored Glycine 0 C--N 1.339 0.707 0 CA-C-O 118.379 -1.234 . . . . 10.0 114.105 177.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 27.2 m120 72.18 25.26 2.95 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 118.573 1.186 . . . . 10.0 112.01 -177.788 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.34 -8.83 43.34 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.435 0.902 . . . . 10.0 113.435 179.356 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.93 -160.8 48.8 Favored Glycine 0 CA--C 1.524 0.608 0 O-C-N 121.029 -1.045 . . . . 10.0 111.536 172.622 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 m -60.63 134.69 57.33 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.7 1.2 . . . . 10.0 113.657 -167.675 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.9 84.92 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.524 1.529 . . . . 10.0 110.21 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 65.8 mt -58.02 -39.18 77.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.425 0.557 . . . . 10.0 112.094 -179.031 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -154.46 153.34 31.37 Favored 'General case' 0 CA--C 1.516 -0.334 0 O-C-N 121.683 -0.635 . . . . 10.0 110.655 -179.912 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.2 m -121.68 141.14 51.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.014 1.726 . . . . 10.0 108.556 -169.041 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.4 158.43 27.5 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 109.675 -1.37 . . . . 10.0 109.675 168.539 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.8 t -118.8 135.52 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 -179.838 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 59.8 mt -71.88 153.35 7.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 N-CA-C 108.658 -0.867 . . . . 10.0 108.658 176.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -164.77 151.24 20.15 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 109.099 -1.601 . . . . 10.0 109.099 -175.089 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.47 123.75 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 117.514 0.657 . . . . 10.0 109.768 -172.809 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.06 -26.26 39.74 Favored 'General case' 0 N--CA 1.446 -0.628 0 O-C-N 120.894 -1.129 . . . . 10.0 111.809 -173.276 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.428 -1.533 0 N-CA-C 103.918 -2.623 . . . . 10.0 103.918 -173.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.791 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -79.57 -38.91 33.02 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.194 0.598 . . . . 10.0 110.028 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -121.16 130.08 53.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.148 1.379 . . . . 10.0 107.331 -179.328 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.11 151.92 51.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.595 -0.891 . . . . 10.0 108.595 172.874 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -109.24 170.52 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 123.115 0.566 . . . . 10.0 110.45 169.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -156.02 102.38 2.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 106.64 -1.615 . . . . 10.0 106.64 166.045 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.7 m -92.24 128.4 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 108.795 -0.817 . . . . 10.0 108.795 171.078 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.2 mp -103.18 152.83 21.0 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 108.853 -0.795 . . . . 10.0 108.853 178.231 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 ttmt -161.16 162.24 31.31 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 108.044 -1.095 . . . . 10.0 108.044 169.52 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.37 -56.16 0.04 OUTLIER Glycine 0 C--N 1.33 0.21 0 N-CA-C 111.459 -0.657 . . . . 10.0 111.459 172.801 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.97 -45.89 39.12 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -174.769 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.88 -67.72 0.55 Allowed Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 113.739 -1.573 . . . . 10.0 110.338 -179.506 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -56.96 -38.77 95.19 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.914 2.409 . . . . 10.0 111.172 173.876 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -68.05 105.59 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.062 0 N-CA-C 107.033 -1.469 . . . . 10.0 107.033 175.255 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -124.57 120.63 32.49 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 108.601 -0.888 . . . . 10.0 108.601 169.384 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.49 150.96 21.08 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.452 -1.459 . . . . 10.0 109.452 169.36 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -156.37 82.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 105.491 -2.04 . . . . 10.0 105.491 -172.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.6 mm -104.62 145.03 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.39 1.076 . . . . 10.0 108.841 -178.561 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -122.91 122.78 39.43 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 127.161 2.185 . . . . 10.0 108.337 169.011 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -103.24 123.03 45.97 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 106.704 -1.591 . . . . 10.0 106.704 173.327 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -117.91 135.52 54.06 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 123.962 0.788 . . . . 10.0 113.126 169.553 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -123.82 100.02 6.56 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 127.42 2.288 . . . . 10.0 105.264 171.135 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.466 ' HZ3' ' CD ' ' A' ' 24' ' ' GLU . 17.8 tttp -64.65 -62.63 1.46 Allowed 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 124.61 1.164 . . . . 10.0 109.392 -169.719 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.466 ' CD ' ' HZ3' ' A' ' 23' ' ' LYS . 3.7 mp0 -109.59 165.81 11.38 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 102.896 -3.001 . . . . 10.0 102.896 166.873 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.9 t -66.65 -21.54 66.11 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 -178.912 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.6 m-80 -76.76 -19.62 57.41 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.537 -0.756 . . . . 10.0 110.511 -179.595 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.55 140.82 32.57 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 109.862 -1.295 . . . . 10.0 109.862 -178.763 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -61.62 149.15 91.05 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 N-CA-C 107.041 -1.946 . . . . 10.0 107.041 168.877 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 t -79.29 113.68 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.087 0 N-CA-C 105.976 -1.861 . . . . 10.0 105.976 178.584 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -93.9 117.58 30.3 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 171.193 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -110.4 108.67 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 C-N-CA 126.817 2.047 . . . . 10.0 106.857 -175.558 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 20.8 p90 -127.49 163.11 24.84 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 112.103 0.408 . . . . 10.0 112.103 179.616 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.03 -147.37 18.32 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 106.917 -2.473 . . . . 10.0 106.917 170.144 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 52.2 p -157.96 164.78 36.49 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.065 -1.054 . . . . 10.0 112.551 178.617 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.45 121.53 67.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 C-N-CA 126.062 1.745 . . . . 10.0 106.668 166.628 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.61 54.78 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 175.025 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.14 -0.14 9.68 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.174 1.369 . . . . 10.0 113.539 178.537 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.26 178.38 2.87 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 118.394 1.097 . . . . 10.0 111.231 179.183 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -107.71 156.11 19.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.203 -1.777 . . . . 10.0 106.203 165.244 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -51.27 150.74 3.21 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.463 1.105 . . . . 10.0 112.347 -169.504 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.04 -171.36 23.49 Favored Glycine 0 C--N 1.336 0.558 0 N-CA-C 111.201 -0.76 . . . . 10.0 111.201 170.232 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.73 149.16 36.37 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.574 1.149 . . . . 10.0 111.363 -173.319 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -143.15 141.32 31.15 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.71 1.204 . . . . 10.0 112.502 -177.698 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.404 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -35.73 122.15 0.61 Allowed Glycine 0 C--N 1.341 0.86 0 C-N-CA 126.582 2.039 . . . . 10.0 112.878 166.303 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -143.43 115.42 8.32 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 120.085 1.942 . . . . 10.0 110.975 167.442 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.7 174.25 12.79 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 120.994 0.426 . . . . 10.0 111.787 -178.974 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.1 m -113.47 82.24 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 126.036 1.735 . . . . 10.0 109.995 -179.656 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -56.8 141.31 44.91 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 122.292 1.044 . . . . 10.0 110.599 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -71.58 -53.21 14.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 112.045 -2.343 . . . . 10.0 110.456 -168.234 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.3 m-30 -76.49 110.09 10.75 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 175.154 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.42 48.71 1.22 Allowed Glycine 0 CA--C 1.531 1.051 0 N-CA-C 110.04 -1.224 . . . . 10.0 110.04 167.806 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.76 143.41 30.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.885 1.674 . . . . 10.0 106.825 170.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -139.5 2.13 2.0 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 126.344 1.858 . . . . 10.0 109.324 174.103 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.406 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 1.9 m -61.92 -30.36 70.84 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 120.098 1.317 . . . . 10.0 110.525 -170.111 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.18 -15.36 60.07 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.174 0.99 . . . . 10.0 112.047 176.136 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.14 76.55 1.33 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.57 -1.412 . . . . 10.0 109.57 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 74.0 m 47.56 45.66 17.63 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.53 1.132 . . . . 10.0 111.145 175.658 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.5 m -134.59 -52.5 0.81 Allowed 'General case' 0 N--CA 1.439 -0.995 0 N-CA-C 108.948 -0.76 . . . . 10.0 108.948 -168.863 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 t -99.5 21.04 12.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.425 0.528 . . . . 10.0 112.425 -170.28 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.12 3.52 0.85 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.15 0.98 . . . . 10.0 113.401 178.956 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.28 129.98 1.57 Allowed Glycine 0 CA--C 1.529 0.967 0 O-C-N 120.874 -1.141 . . . . 10.0 110.341 175.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.16 61.54 7.78 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 123.197 2.598 . . . . 10.0 110.556 178.605 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 28.9 m170 63.07 59.75 1.28 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 128.46 2.704 . . . . 10.0 110.858 177.581 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.1 m-85 -72.19 55.19 0.31 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.558 1.143 . . . . 10.0 113.892 -176.727 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -71.18 144.53 89.88 Favored Pre-proline 0 C--N 1.326 -0.437 0 C-N-CA 125.56 1.544 . . . . 10.0 113.18 -174.158 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -71.78 -37.87 4.75 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.283 2.655 . . . . 10.0 111.398 176.706 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.79 56.95 0.98 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.653 0.781 . . . . 10.0 110.533 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 67.9 p -42.06 94.85 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 126.676 1.99 . . . . 10.0 112.948 -169.58 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.2 mtt85 -121.14 172.15 8.18 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 126.129 1.772 . . . . 10.0 108.163 174.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 35.1 mtmm -102.0 106.32 17.22 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 -176.667 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -19.22 105.43 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.32 0 C-N-CA 126.71 2.004 . . . . 10.0 114.407 -171.024 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -115.35 -146.45 8.89 Favored Glycine 0 N--CA 1.439 -1.101 0 C-N-CA 125.828 1.68 . . . . 10.0 109.467 176.541 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.98 -166.39 24.93 Favored Glycine 0 N--CA 1.45 -0.41 0 N-CA-C 108.587 -1.805 . . . . 10.0 108.587 171.603 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.4 -3.16 3.86 Favored 'Trans proline' 0 N--CA 1.454 -0.814 0 CA-C-N 119.87 1.835 . . . . 10.0 111.829 173.104 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -99.19 -17.35 18.19 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.592 0.757 . . . . 10.0 111.61 174.667 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -111.71 169.68 8.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.191 -1.041 . . . . 10.0 108.191 -179.138 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -80.8 -36.28 31.93 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.824 -1.547 . . . . 10.0 106.824 169.056 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 12.6 mt-10 -84.98 32.93 0.53 Allowed 'General case' 0 N--CA 1.442 -0.871 0 CA-C-O 122.646 1.213 . . . . 10.0 113.185 -166.02 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 ptm180 -66.68 133.65 50.65 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 170.091 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -66.56 -70.75 0.23 Allowed 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.461 0.648 . . . . 10.0 110.704 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 80.8 t -147.19 -105.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.038 -2.949 . . . . 10.0 103.038 177.729 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.34 62.8 4.52 Favored Glycine 0 CA--C 1.524 0.655 0 O-C-N 121.336 -0.852 . . . . 10.0 111.227 176.441 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -89.94 105.07 17.56 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 101.118 -3.66 . . . . 10.0 101.118 163.955 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -87.43 -37.29 17.14 Favored 'General case' 0 N--CA 1.461 0.109 0 N-CA-C 107.41 -1.33 . . . . 10.0 107.41 173.298 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.17 -95.68 1.26 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 123.448 0.547 . . . . 10.0 111.884 167.75 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -116.09 104.27 11.39 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.903 1.281 . . . . 10.0 111.304 -167.451 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.07 133.81 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 168.851 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 m -100.21 111.96 24.26 Favored 'General case' 0 N--CA 1.441 -0.895 0 C-N-CA 125.692 1.597 . . . . 10.0 109.07 -169.142 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.75 129.71 35.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.243 0.617 . . . . 10.0 110.912 179.123 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -57.33 170.86 0.46 Allowed 'General case' 0 C--O 1.233 0.224 0 O-C-N 124.778 1.299 . . . . 10.0 110.116 167.494 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.8 ptmm? -54.29 -30.56 51.26 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 114.676 -1.147 . . . . 10.0 111.189 172.14 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -78.87 -2.05 37.94 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.988 0.915 . . . . 10.0 111.439 -179.049 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.86 20.38 73.6 Favored Glycine 0 C--N 1.337 0.598 0 N-CA-C 110.625 -0.99 . . . . 10.0 110.625 179.204 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.16 102.43 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.954 0 N-CA-C 105.462 -2.051 . . . . 10.0 105.462 179.393 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -99.53 121.97 41.93 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.83 -1.174 . . . . 10.0 107.83 169.259 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -81.23 143.09 32.56 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.796 1.638 . . . . 10.0 109.347 173.597 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 85.4 t -117.79 129.84 73.59 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 N-CA-C 105.745 -1.946 . . . . 10.0 105.745 168.175 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 17.4 m -158.1 69.77 0.53 Allowed 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 124.515 1.126 . . . . 10.0 108.403 169.257 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -108.61 157.75 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -176.844 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -132.09 133.46 44.36 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 125.415 1.486 . . . . 10.0 108.691 170.892 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -136.26 135.07 38.7 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 108.288 -1.004 . . . . 10.0 108.288 -173.482 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 16.4 m -104.09 16.39 26.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.695 1.198 . . . . 10.0 111.729 -175.357 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.7 p -136.51 11.8 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 123.691 0.796 . . . . 10.0 110.33 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -113.95 136.13 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 103.11 -2.922 . . . . 10.0 103.11 169.905 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 11.5 m -139.53 123.68 17.9 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 123.358 0.663 . . . . 10.0 109.646 -178.223 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.1 mt -69.57 -31.6 69.88 Favored 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.985 0.914 . . . . 10.0 109.8 170.216 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 63.3 m -152.0 135.8 16.33 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.231 1.012 . . . . 10.0 108.339 170.666 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 164.59 -57.74 0.26 Allowed Glycine 0 C--N 1.333 0.391 0 N-CA-C 109.684 -1.367 . . . . 10.0 109.684 179.449 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -164.51 -50.06 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.694 1.998 . . . . 10.0 107.334 -178.129 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -74.37 -38.49 63.15 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.919 -1.037 . . . . 10.0 108.373 -169.597 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 45.5 t 42.03 55.14 3.9 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 126.486 1.914 . . . . 10.0 110.771 172.574 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.14 21.48 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 N-CA-C 113.873 1.064 . . . . 10.0 113.873 -168.626 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.7 mm -58.66 142.66 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 C-N-CA 125.33 1.452 . . . . 10.0 107.614 169.306 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.83 14.65 82.36 Favored Glycine 0 CA--C 1.534 1.245 0 CA-C-O 118.745 -1.031 . . . . 10.0 114.19 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.3 mmt180 -74.11 175.05 7.84 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 107.389 -1.338 . . . . 10.0 107.389 168.198 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -117.79 128.24 54.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.743 -1.206 . . . . 10.0 107.743 169.83 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 27.8 mt -98.42 142.73 29.68 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 107.953 -1.129 . . . . 10.0 107.953 174.317 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -131.09 132.33 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.324 -1.361 . . . . 10.0 107.324 178.191 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.31 123.66 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.254 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.044 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.404 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.2 m170 -101.01 161.55 13.51 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 114.465 1.283 . . . . 10.0 114.465 -173.956 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -56.21 -50.64 70.67 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 126.433 1.893 . . . . 10.0 110.967 178.441 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 48.8 mttm -112.35 163.44 14.4 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.421 0.629 . . . . 10.0 111.508 -171.104 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.37 141.23 42.72 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 114.628 -1.169 . . . . 10.0 108.773 172.172 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -76.45 148.15 37.44 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 108.56 -0.904 . . . . 10.0 108.56 174.768 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.86 -37.03 15.65 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 126.814 2.046 . . . . 10.0 109.757 -178.414 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 20.4 mt 66.48 36.88 4.84 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.788 0.835 . . . . 10.0 113.059 -176.742 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 111.58 -25.77 12.9 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 118.553 0.615 . . . . 10.0 114.435 165.35 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.252 0.0 OUTLIER -94.56 31.12 1.83 Allowed 'General case' 0 CA--C 1.543 0.69 0 N-CA-C 113.386 0.884 . . . . 10.0 113.386 -172.758 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.16 -12.21 62.02 Favored Glycine 0 C--N 1.343 0.938 0 C-N-CA 125.342 1.449 . . . . 10.0 112.06 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.62 44.95 47.62 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.252 0.929 . . . . 10.0 112.778 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -153.28 175.46 13.06 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.479 -0.934 . . . . 10.0 108.479 175.722 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -56.67 -40.16 75.03 Favored 'General case' 0 N--CA 1.437 -1.079 0 O-C-N 121.356 -0.84 . . . . 10.0 111.845 -175.31 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -63.13 -36.57 84.03 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 118.056 -0.973 . . . . 10.0 109.723 175.838 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 59.0 p -51.01 -42.89 60.7 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 119.62 1.1 . . . . 10.0 110.954 -172.955 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.252 12.3 t -81.93 -11.31 58.95 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 112.522 0.564 . . . . 10.0 112.522 -175.448 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -115.88 -58.45 2.11 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.532 1.533 . . . . 10.0 113.648 -170.266 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 16.9 p -128.98 10.84 5.96 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 120.449 1.477 . . . . 10.0 112.182 175.447 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.25 -97.01 2.17 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 125.401 1.477 . . . . 10.0 109.742 176.073 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -168.09 37.88 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 122.944 1.354 . . . . 10.0 107.706 178.864 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.11 -22.73 55.21 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 113.534 -1.667 . . . . 10.0 108.446 -173.803 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.82 -157.37 53.07 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 109.506 -1.438 . . . . 10.0 109.506 169.497 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.26 120.29 3.93 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 124.28 1.032 . . . . 10.0 113.229 -167.663 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -63.06 80.47 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.412 1.085 . . . . 10.0 109.939 171.229 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.8 mt -45.56 -52.68 10.14 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.343 0.592 . . . . 10.0 110.96 178.061 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.93 152.8 31.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.723 -0.672 . . . . 10.0 109.501 -168.623 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -147.13 161.06 41.65 Favored 'General case' 0 N--CA 1.447 -0.592 0 O-C-N 123.83 0.706 . . . . 10.0 111.009 -176.79 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.94 168.59 28.15 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 125.473 1.511 . . . . 10.0 109.413 -177.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.0 t -120.76 137.85 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 106.366 -1.716 . . . . 10.0 106.366 -178.84 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.9 mt -73.12 116.81 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.655 -0.498 . . . . 10.0 109.655 -177.451 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.25 154.25 17.08 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 111.331 -176.029 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.23 145.89 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 C-N-CA 124.763 1.225 . . . . 10.0 108.395 176.008 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.11 -25.99 5.2 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 113.58 0.956 . . . . 10.0 113.58 178.422 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.2 tp60 . . . . . 0 C--O 1.25 1.125 0 CA-C-O 117.074 -1.441 . . . . 10.0 107.153 -177.142 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.564 0 N-CA-C 106.534 -1.654 . . . . 10.0 106.534 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.2 t -156.83 -49.22 0.07 Allowed 'General case' 0 C--O 1.224 -0.242 0 CA-C-N 119.365 0.984 . . . . 10.0 110.957 169.161 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -124.01 122.23 37.35 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 125.13 1.372 . . . . 10.0 108.768 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -130.92 152.09 50.62 Favored 'General case' 0 CA--C 1.52 -0.184 0 C-N-CA 123.785 0.834 . . . . 10.0 109.523 170.019 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -118.38 161.15 17.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 C-N-CA 122.947 0.499 . . . . 10.0 111.091 178.022 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.9 110.4 5.78 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.165 -0.925 . . . . 10.0 108.561 167.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 2.6 m -96.95 108.48 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 124.246 1.019 . . . . 10.0 109.349 172.763 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.9 mt -92.17 131.56 37.31 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.527 -0.916 . . . . 10.0 108.527 -178.396 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -143.65 157.09 44.67 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.612 -1.255 . . . . 10.0 107.612 171.042 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.02 -60.91 0.05 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 121.157 -0.544 . . . . 10.0 113.045 169.35 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.25 -43.78 66.58 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 -177.318 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.58 -71.22 0.42 Allowed Glycine 0 CA--C 1.523 0.578 0 CA-C-N 114.358 -1.292 . . . . 10.0 110.631 168.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -57.1 -31.98 91.93 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 123.282 2.655 . . . . 10.0 111.313 171.757 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 93.5 t -67.97 94.5 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 107.118 -1.438 . . . . 10.0 107.118 177.334 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -115.55 112.4 22.14 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 105.91 -1.885 . . . . 10.0 105.91 178.591 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.07 139.62 14.59 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 172.182 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . 0.406 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 4.5 mt -140.77 95.85 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 108.286 -1.005 . . . . 10.0 108.286 -174.986 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -106.9 149.15 10.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 124.578 1.151 . . . . 10.0 113.011 -178.184 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -122.98 110.04 14.88 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.939 2.096 . . . . 10.0 108.24 168.749 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -86.97 108.2 18.73 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 170.821 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -109.3 113.41 26.22 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-O 121.395 0.616 . . . . 10.0 111.646 179.81 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -78.1 101.77 7.15 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 169.854 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 2.1 mmmp? . . . . . 0 CA--C 1.522 -0.103 0 C-N-CA 127.345 2.258 . . . . 10.0 109.72 177.511 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.961 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -61.88 144.02 96.27 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.491 2.127 . . . . 10.0 109.633 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 t -78.93 87.18 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.999 0 N-CA-C 106.417 -1.698 . . . . 10.0 106.417 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.4 mttm -67.08 108.19 2.55 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 106.854 -1.536 . . . . 10.0 106.854 169.012 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -110.03 108.87 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 125.624 1.569 . . . . 10.0 107.465 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 21.9 p90 -123.38 168.12 12.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.509 0.671 . . . . 10.0 110.123 173.408 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.46 -170.76 43.92 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 179.243 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.3 m -154.98 111.88 3.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -175.939 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 pt -84.22 175.19 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.573 -0.851 . . . . 10.0 110.115 169.703 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -149.98 156.35 41.56 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 166.675 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.52 -25.17 11.36 Favored Glycine 0 C--N 1.338 0.678 0 CA-C-O 119.372 -0.682 . . . . 10.0 114.154 171.039 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.4 mp -75.04 179.59 4.89 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 118.388 1.094 . . . . 10.0 111.513 -170.84 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.6 t -101.84 161.55 13.58 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.637 -0.875 . . . . 10.0 108.637 168.263 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -49.2 153.0 1.05 Allowed 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.192 1.797 . . . . 10.0 113.675 -169.292 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.43 179.55 39.43 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 124.607 1.099 . . . . 10.0 113.033 168.525 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 95.2 mt -49.49 137.71 14.61 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.119 1.768 . . . . 10.0 112.755 171.894 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -138.2 147.12 43.46 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 124.773 1.229 . . . . 10.0 112.048 171.351 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -18.65 118.5 0.01 OUTLIER Glycine 0 C--N 1.337 0.598 0 C-N-CA 127.835 2.636 . . . . 10.0 114.16 165.466 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -151.35 106.02 3.26 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 120.218 2.009 . . . . 10.0 112.909 167.296 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.418 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -151.07 168.39 24.76 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.655 -0.702 . . . . 10.0 111.269 176.504 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 16.7 m -86.7 155.09 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 112.21 -2.268 . . . . 10.0 107.06 166.681 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -126.09 152.91 45.23 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 173.243 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -59.7 -42.98 94.24 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 113.689 0.996 . . . . 10.0 113.689 -168.857 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -96.38 174.96 6.61 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.749 -0.834 . . . . 10.0 108.749 -177.193 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -111.35 10.8 28.64 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 125.418 1.485 . . . . 10.0 109.668 166.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.49 112.62 1.65 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 122.327 1.06 . . . . 10.0 109.067 176.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -120.56 9.97 10.99 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 114.244 -1.344 . . . . 10.0 108.305 168.006 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 15.5 m -67.59 -34.6 77.35 Favored 'General case' 0 C--N 1.344 0.359 0 C-N-CA 125.235 1.414 . . . . 10.0 108.625 171.02 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.41 -22.34 60.26 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.323 -0.399 . . . . 10.0 110.479 174.702 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.5 54.33 1.7 Allowed Glycine 0 C--N 1.34 0.761 0 C-N-CA 123.893 0.759 . . . . 10.0 111.557 172.083 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 37.5 m 59.76 28.96 18.51 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.03 0.932 . . . . 10.0 110.166 -176.136 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 38.7 m -112.09 -49.8 2.95 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 125.439 1.495 . . . . 10.0 107.147 -169.596 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 8.4 t -117.31 26.62 9.62 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 113.563 0.949 . . . . 10.0 113.563 -175.041 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.42 -7.57 6.97 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.701 1.001 . . . . 10.0 113.701 179.548 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.36 123.61 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.763 1.173 . . . . 10.0 111.052 172.856 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -81.34 55.86 5.78 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 123.074 2.516 . . . . 10.0 112.16 -172.154 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.418 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 16.1 m170 66.76 36.84 4.42 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 128.956 2.903 . . . . 10.0 111.78 176.192 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -76.99 71.66 3.5 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 120.692 1.587 . . . . 10.0 109.998 175.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -61.87 158.19 44.78 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 125.201 1.4 . . . . 10.0 110.208 169.31 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -62.91 -46.63 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.024 1.816 . . . . 10.0 111.153 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 69.9 mt -78.84 56.45 1.91 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 123.204 0.601 . . . . 10.0 110.309 -179.383 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -45.25 112.21 0.42 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.639 1.176 . . . . 10.0 110.775 -179.305 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.5 mtp85 -137.33 -97.83 0.2 Allowed 'General case' 0 CA--C 1.506 -0.74 0 N-CA-C 104.492 -2.41 . . . . 10.0 104.492 -175.624 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 50.7 mttp -144.38 164.72 29.98 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.706 -1.22 . . . . 10.0 107.706 166.733 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -66.47 120.65 13.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 106.59 -1.634 . . . . 10.0 106.59 164.641 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.23 -137.79 3.66 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 108.087 -2.005 . . . . 10.0 108.087 175.304 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.6 -160.63 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 109.422 -1.471 . . . . 10.0 109.422 173.493 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -65.41 4.45 0.77 Allowed 'Trans proline' 0 N--CA 1.454 -0.834 0 C-N-CA 122.15 1.9 . . . . 10.0 111.83 169.824 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 57.8 mmtt -94.31 -24.03 17.58 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-O 118.508 -0.758 . . . . 10.0 110.127 170.282 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -108.29 161.42 15.02 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-O 121.051 0.453 . . . . 10.0 111.176 -167.53 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -97.46 -9.72 26.71 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.134 -0.939 . . . . 10.0 109.585 174.15 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -123.05 28.5 7.16 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 119.32 -0.372 . . . . 10.0 110.645 -178.91 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . 0.444 HH12 ' CG ' ' B' ' 101' ' ' ASP . 14.9 ptt180 -50.38 154.53 1.24 Allowed 'General case' 0 C--N 1.344 0.354 0 C-N-CA 123.337 0.655 . . . . 10.0 109.879 169.217 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -65.78 -64.88 0.76 Allowed 'General case' 0 N--CA 1.453 -0.319 0 CA-C-O 121.552 0.691 . . . . 10.0 109.503 -178.534 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . 0.419 ' CG1' ' H ' ' B' ' 82' ' ' GLY . 4.0 p -169.34 -93.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 105.602 -1.999 . . . . 10.0 105.602 176.195 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . 0.419 ' H ' ' CG1' ' B' ' 81' ' ' VAL . . . -78.94 58.98 4.27 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.479 -1.048 . . . . 10.0 110.479 173.905 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.83 98.93 10.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 102.306 -3.22 . . . . 10.0 102.306 165.951 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -78.26 10.77 2.76 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.24 0.473 . . . . 10.0 110.585 -175.571 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 81.12 -109.44 2.99 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 104.128 -3.589 . . . . 10.0 104.128 -175.28 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -159.53 149.78 18.97 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.354 -1.721 . . . . 10.0 106.354 -178.435 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.45 128.18 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 C-N-CA 123.18 0.592 . . . . 10.0 111.202 -171.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.87 97.52 5.3 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 126.676 1.99 . . . . 10.0 111.176 -174.412 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.33 134.36 39.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.071 -0.393 . . . . 10.0 110.482 173.066 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.411 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 17.3 t70 -61.91 169.0 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.874 0.845 . . . . 10.0 109.249 167.358 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.411 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 34.7 mtmt -48.06 -34.4 9.51 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.873 1.669 . . . . 10.0 111.395 169.331 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -78.16 -8.32 58.15 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.999 0.428 . . . . 10.0 112.077 -179.377 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.69 1.94 70.38 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 120.933 -1.104 . . . . 10.0 111.572 -176.102 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -84.81 101.39 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.115 0 C-N-CA 125.77 1.628 . . . . 10.0 108.007 -179.232 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.13 115.72 27.87 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 168.252 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -80.86 119.35 23.3 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 106.737 -1.579 . . . . 10.0 106.737 169.24 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 66.5 t -104.11 131.12 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -177.446 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.3 p -157.24 83.81 0.92 Allowed 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 174.033 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -115.18 159.46 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 105.088 -2.19 . . . . 10.0 105.088 176.325 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -133.52 133.19 41.85 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 109.103 -0.703 . . . . 10.0 109.103 168.082 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . 0.444 ' CG ' HH12 ' B' ' 79' ' ' ARG . 7.1 t0 -113.89 111.93 22.51 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 124.229 0.955 . . . . 10.0 109.377 -173.052 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.6 p -100.77 61.73 1.0 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.446 1.498 . . . . 10.0 107.079 -176.229 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.5 p -155.39 -47.07 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.145 0 N-CA-C 110.204 -0.295 . . . . 10.0 110.204 -173.006 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.355 0.0 OUTLIER -102.15 176.89 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.143 0 N-CA-C 113.622 0.971 . . . . 10.0 113.622 172.231 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 49.9 m -151.62 146.1 25.57 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 105.915 -1.883 . . . . 10.0 105.915 -179.723 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 29.0 mt -68.01 -14.7 63.18 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 117.948 0.34 . . . . 10.0 111.354 -175.615 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.8 m . . . . . 0 N--CA 1.451 -0.421 0 O-C-N 120.949 -1.094 . . . . 10.0 108.62 174.382 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 CA--C 1.534 0.335 0 N-CA-C 114.227 1.195 . . . . 10.0 114.227 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 36.7 pt -72.79 -11.86 15.22 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 C-N-CA 123.717 0.807 . . . . 10.0 112.45 176.854 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm -52.11 133.11 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 O-C-N 121.488 -0.758 . . . . 10.0 110.059 178.774 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.87 1.4 84.39 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 118.81 -0.995 . . . . 10.0 114.016 -178.749 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 57.2 mtt85 -85.92 175.94 8.35 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.719 1.759 . . . . 10.0 108.487 168.459 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.04 140.13 50.19 Favored 'General case' 0 CA--C 1.513 -0.467 0 C-N-CA 125.458 1.503 . . . . 10.0 108.512 179.101 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.5 mp -110.14 155.93 21.27 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 107.641 -1.244 . . . . 10.0 107.641 166.03 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 91.2 t -128.82 134.3 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.149 0 N-CA-C 106.695 -1.595 . . . . 10.0 106.695 -179.183 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.84 121.62 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.363 0 N-CA-C 105.71 -1.959 . . . . 10.0 105.71 166.865 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -102.95 160.5 14.55 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 116.316 1.969 . . . . 10.0 116.316 -168.925 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -43.46 -56.73 3.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 129.085 2.954 . . . . 10.0 111.19 173.73 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 78.1 mttt -113.52 168.84 9.42 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 124.067 0.947 . . . . 10.0 113.352 -168.569 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.44 154.0 41.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 124.68 1.238 . . . . 10.0 108.641 169.822 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -106.07 141.43 37.45 Favored 'General case' 0 N--CA 1.454 -0.243 0 O-C-N 123.902 0.751 . . . . 10.0 111.287 -168.6 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -74.54 -31.03 61.98 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 125.169 1.388 . . . . 10.0 110.195 -177.355 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 13.7 mt 60.62 50.57 5.59 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 122.618 1.199 . . . . 10.0 108.014 -176.005 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.68 -52.08 4.18 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 115.392 -0.822 . . . . 10.0 111.401 172.571 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 48.75 0.98 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.517 1.127 . . . . 10.0 112.249 -172.679 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.16 -26.97 7.14 Favored Glycine 0 CA--C 1.522 0.492 0 C-N-CA 127.936 2.684 . . . . 10.0 111.17 173.426 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.45 18.01 65.17 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-O 118.472 -1.182 . . . . 10.0 112.65 172.908 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -131.95 168.75 17.35 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-N 119.677 1.739 . . . . 10.0 108.277 168.361 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.45 -55.04 6.56 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.571 1.148 . . . . 10.0 108.878 178.042 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -63.62 -34.22 77.35 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 118.169 -0.919 . . . . 10.0 111.791 -175.674 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.3 m -49.16 -46.86 45.9 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 120.202 1.365 . . . . 10.0 110.804 169.301 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -89.3 -15.6 33.09 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.245 -0.883 . . . . 10.0 113.257 -170.549 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -98.07 -40.93 8.19 Favored 'General case' 0 N--CA 1.438 -1.062 0 C-N-CA 125.027 1.331 . . . . 10.0 111.773 179.146 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.405 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 38.4 p -136.28 -7.02 2.02 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 114.567 1.321 . . . . 10.0 114.567 175.086 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.83 17.14 52.96 Favored Glycine 0 C--O 1.221 -0.669 0 CA-C-O 118.463 -1.187 . . . . 10.0 112.306 -173.27 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 55.53 30.29 14.94 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.533 1.667 . . . . 10.0 111.765 178.76 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.59 54.8 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 125.979 1.712 . . . . 10.0 112.057 -175.323 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.33 54.81 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 110.595 -1.002 . . . . 10.0 110.595 174.605 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.2 m -55.6 139.63 43.75 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 123.966 0.906 . . . . 10.0 111.887 -168.354 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 22.6 mtt85 -71.02 70.84 0.53 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.828 1.251 . . . . 10.0 110.06 176.684 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.3 tp -44.6 -36.2 2.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 127.84 2.456 . . . . 10.0 112.536 -176.673 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.28 151.13 17.05 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 172.959 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -146.7 164.82 31.5 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 109.914 -0.402 . . . . 10.0 109.914 177.129 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.64 -176.63 25.44 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.496 -1.042 . . . . 10.0 110.496 178.249 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.4 t -122.56 143.13 36.41 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 107.568 -1.271 . . . . 10.0 107.568 179.817 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 11.4 mt -78.38 112.42 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 124.1 0.96 . . . . 10.0 109.493 -179.066 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.69 146.12 16.52 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 178.2 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -79.96 119.02 28.57 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 177.22 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.56 -43.05 40.56 Favored 'General case' 0 C--O 1.221 -0.439 0 O-C-N 121.078 -1.014 . . . . 10.0 108.554 -176.038 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.946 0 C-N-CA 125.793 1.637 . . . . 10.0 110.815 170.577 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.836 0 CA-C-O 118.628 -0.701 . . . . 10.0 109.661 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.5 t -97.15 -32.71 11.81 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 124.982 1.313 . . . . 10.0 110.369 -178.295 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -148.25 151.62 35.77 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.344 -0.984 . . . . 10.0 108.344 -177.849 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.15 155.41 45.31 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 122.878 0.471 . . . . 10.0 110.548 176.401 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.1 p -126.84 151.4 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 C-N-CA 128.152 2.581 . . . . 10.0 107.028 -178.762 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.62 116.29 11.41 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.174 -2.158 . . . . 10.0 105.174 168.265 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.3 p -81.29 103.72 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 108.822 -0.807 . . . . 10.0 108.822 174.42 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.76 116.45 23.26 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.027 -1.101 . . . . 10.0 108.027 178.333 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -137.84 155.99 48.4 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 174.401 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -163.19 -66.28 0.02 OUTLIER Glycine 0 C--O 1.229 -0.18 0 CA-C-N 114.915 -1.039 . . . . 10.0 111.891 174.67 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.76 -43.91 57.64 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 -172.706 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.52 -67.66 0.53 Allowed Glycine 0 N--CA 1.443 -0.895 0 CA-C-N 113.481 -1.691 . . . . 10.0 110.525 179.779 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -58.23 -37.96 93.1 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.911 2.408 . . . . 10.0 111.142 174.617 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 94.4 t -64.54 96.81 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 176.425 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -120.35 123.1 42.27 Favored 'General case' 0 N--CA 1.446 -0.661 0 C-N-CA 125.104 1.361 . . . . 10.0 107.381 175.666 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -116.25 136.6 13.0 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 123.652 0.644 . . . . 10.0 112.168 175.363 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 58.6 mt -124.56 74.09 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 -179.018 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -64.09 148.85 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.374 -0.83 . . . . 10.0 109.598 171.67 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -139.05 97.85 3.4 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 127.437 2.295 . . . . 10.0 107.548 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -89.79 118.87 29.7 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.781 -1.192 . . . . 10.0 107.781 171.301 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -104.8 130.88 52.83 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.838 0.745 . . . . 10.0 110.971 168.644 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -123.1 92.3 3.67 Favored 'General case' 0 C--N 1.341 0.217 0 C-N-CA 125.076 1.35 . . . . 10.0 109.102 171.759 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 11.0 mmtp -49.94 -60.91 2.48 Favored 'General case' 0 N--CA 1.46 0.072 0 C-N-CA 124.653 1.181 . . . . 10.0 111.054 175.804 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.0 176.65 8.57 Favored 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 105.604 -1.998 . . . . 10.0 105.604 171.2 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 t -74.72 -13.74 60.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 122.341 0.256 . . . . 10.0 110.708 177.229 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -88.25 -12.94 42.21 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 123.729 0.811 . . . . 10.0 109.794 174.434 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.14 119.54 4.98 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 109.357 -1.497 . . . . 10.0 109.357 178.573 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -60.83 127.73 23.37 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 N-CA-C 106.558 -2.132 . . . . 10.0 106.558 169.41 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -77.01 138.06 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 108.702 -0.851 . . . . 10.0 108.702 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.79 106.24 18.22 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 104.759 -2.311 . . . . 10.0 104.759 171.76 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 m -87.03 93.33 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 105.467 -2.049 . . . . 10.0 105.467 174.137 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -109.18 178.79 4.35 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-O 120.83 0.348 . . . . 10.0 111.219 173.721 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.58 -164.09 30.15 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 169.043 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.6 p -152.19 122.43 7.19 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 118.641 -0.695 . . . . 10.0 110.934 -169.383 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.88 136.6 31.73 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 105.891 -1.892 . . . . 10.0 105.891 166.325 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.411 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -130.14 160.05 34.96 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 168.809 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.7 -12.52 62.79 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 118.042 0.383 . . . . 10.0 113.208 -178.815 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 15.4 mt -68.2 -179.49 1.28 Allowed 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.872 0.869 . . . . 10.0 110.489 171.651 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -111.95 166.46 11.2 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 167.554 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -46.64 148.96 0.88 Allowed 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 127.359 2.264 . . . . 10.0 113.419 -169.534 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.65 -179.09 42.98 Favored Glycine 0 C--N 1.336 0.569 0 C-N-CA 124.235 0.922 . . . . 10.0 114.091 167.139 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.6 mt -52.38 137.9 28.23 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.878 1.671 . . . . 10.0 113.02 176.63 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 -135.31 141.57 45.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.439 1.095 . . . . 10.0 111.075 169.525 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -25.46 121.75 0.03 OUTLIER Glycine 0 C--N 1.344 0.992 0 CA-C-O 116.648 -2.195 . . . . 10.0 111.773 165.776 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -144.54 109.5 5.04 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 120.431 2.115 . . . . 10.0 111.053 169.768 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.09 175.02 11.36 Favored 'General case' 0 CA--C 1.512 -0.487 0 C-N-CA 123.572 0.749 . . . . 10.0 109.102 -179.612 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.88 98.29 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 113.595 -1.638 . . . . 10.0 109.653 179.448 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 20.4 m-70 -72.74 148.02 45.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 125.898 1.679 . . . . 10.0 109.681 -172.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -62.03 -55.72 26.34 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 123.958 0.786 . . . . 10.0 112.077 -173.435 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -87.92 150.6 23.38 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 119.258 -0.977 . . . . 10.0 109.583 177.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.98 32.92 5.57 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.098 -1.201 . . . . 10.0 110.098 168.414 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -79.8 70.22 6.28 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 123.251 1.5 . . . . 10.0 108.683 179.153 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -73.98 5.5 4.19 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.557 -1.201 . . . . 10.0 113.519 -174.014 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -32.79 -50.75 0.27 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 129.607 3.163 . . . . 10.0 112.703 175.144 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.97 -20.4 45.6 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 113.517 0.932 . . . . 10.0 113.517 -174.572 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.25 71.24 0.89 Allowed Glycine 0 CA--C 1.524 0.62 0 N-CA-C 106.987 -2.445 . . . . 10.0 106.987 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.8 t 49.33 24.01 0.95 Allowed 'General case' 0 CA--C 1.529 0.145 0 N-CA-C 115.844 1.794 . . . . 10.0 115.844 171.356 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.5 m -94.27 -52.48 4.34 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -178.388 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.2 m -66.86 -25.36 66.38 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 125.359 1.464 . . . . 10.0 112.732 -169.332 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.43 -38.27 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.542 2.737 . . . . 10.0 113.73 173.483 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 152.71 9.61 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 111.299 -0.72 . . . . 10.0 111.299 167.713 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.85 57.28 6.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.414 2.076 . . . . 10.0 110.571 172.784 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 30.2 m170 71.56 -64.8 0.37 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 128.014 2.526 . . . . 10.0 108.875 -179.557 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.285 1.1 p90 26.02 49.32 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 129.845 3.258 . . . . 10.0 115.096 175.16 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -51.66 157.2 1.96 Allowed Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 114.438 -1.256 . . . . 10.0 111.057 169.415 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.14 -40.82 24.61 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 121.943 1.762 . . . . 10.0 111.054 -173.735 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mp -77.03 59.63 1.7 Allowed 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.532 -0.914 . . . . 10.0 108.532 169.134 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.3 p -60.95 106.87 0.63 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 107.942 -1.133 . . . . 10.0 107.942 -177.418 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -129.93 -87.64 0.51 Allowed 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 107.34 -1.356 . . . . 10.0 107.34 -169.857 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.3 mmtp -139.05 153.69 48.11 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 122.313 1.054 . . . . 10.0 109.573 169.076 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -70.42 119.78 15.1 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 105.742 -1.948 . . . . 10.0 105.742 162.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.26 -135.88 2.91 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 107.104 -2.398 . . . . 10.0 107.104 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.26 -147.73 6.21 Favored Glycine 0 C--O 1.226 -0.403 0 CA-C-O 117.965 -1.464 . . . . 10.0 109.677 171.65 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -67.13 7.78 0.43 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 119.818 1.809 . . . . 10.0 111.105 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -113.37 3.4 15.86 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 118.225 -0.893 . . . . 10.0 111.563 170.944 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -122.42 149.67 43.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.604 -1.628 . . . . 10.0 106.604 170.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -83.05 -24.77 32.63 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.65 -0.871 . . . . 10.0 108.65 171.189 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -113.3 26.2 10.65 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 125.242 1.417 . . . . 10.0 111.068 -168.665 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -47.62 161.54 0.09 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 128.589 2.756 . . . . 10.0 110.078 168.371 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -78.69 46.85 0.69 Allowed 'General case' 0 N--CA 1.463 0.216 0 O-C-N 120.575 -1.328 . . . . 10.0 112.318 -178.106 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.2 p 33.16 35.94 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 126.861 2.064 . . . . 10.0 113.595 -174.278 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 165.98 37.69 0.02 OUTLIER Glycine 0 CA--C 1.532 1.113 0 O-C-N 121.538 -0.726 . . . . 10.0 111.961 -169.246 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -113.71 108.15 16.72 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -81.33 -29.48 34.16 Favored 'General case' 0 N--CA 1.461 0.121 0 N-CA-C 107.557 -1.275 . . . . 10.0 107.557 169.033 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.16 -96.64 1.31 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 108.424 -1.871 . . . . 10.0 108.424 168.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -134.92 117.98 16.41 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 125.6 1.56 . . . . 10.0 106.905 -169.497 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 22.4 m -111.61 132.26 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 CA-C-N 118.553 0.615 . . . . 10.0 111.296 179.428 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.8 m -78.46 107.88 11.43 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.771 2.429 . . . . 10.0 112.468 -170.472 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.51 137.26 32.48 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.869 0.467 . . . . 10.0 111.309 174.225 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -62.18 174.6 0.87 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 122.009 0.909 . . . . 10.0 110.328 166.927 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.5 pttt -51.74 -32.48 30.68 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.516 1.927 . . . . 10.0 112.709 169.191 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.411 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 22.8 t70 -79.17 -10.46 59.83 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 122.14 0.971 . . . . 10.0 110.658 178.107 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.89 3.7 65.72 Favored Glycine 0 N--CA 1.431 -1.634 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 -171.898 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 26.4 t -75.55 95.65 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.095 0 N-CA-C 106.327 -1.731 . . . . 10.0 106.327 -172.461 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.21 113.17 25.01 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 169.052 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -81.78 115.14 20.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 C-N-CA 127.199 2.2 . . . . 10.0 108.832 175.191 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.2 133.31 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 176.406 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 72.7 p -158.52 80.88 0.81 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.963 0.905 . . . . 10.0 109.799 170.642 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -112.26 143.1 22.68 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 177.628 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -99.73 127.37 45.86 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.393 1.477 . . . . 10.0 107.564 169.372 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -133.7 156.15 48.45 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.601 0.715 . . . . 10.0 109.083 176.721 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.5 t -128.1 49.58 2.15 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 126.022 1.729 . . . . 10.0 109.015 -173.41 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -157.79 -39.42 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 123.361 0.664 . . . . 10.0 110.63 176.837 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 45.6 mm -59.92 116.53 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 169.887 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 48.5 m -131.34 119.29 21.51 Favored 'General case' 0 CA--C 1.528 0.115 0 C-N-CA 124.251 1.02 . . . . 10.0 108.417 178.396 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 59.1 mt -53.97 -38.39 64.97 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 125.108 1.363 . . . . 10.0 111.166 173.491 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.2 m -152.17 151.89 31.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.475 -0.935 . . . . 10.0 108.475 -176.095 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.3 -97.17 0.19 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.295 -1.922 . . . . 10.0 108.295 -174.825 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -122.31 -51.1 1.99 Allowed 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 127.066 2.146 . . . . 10.0 107.935 177.523 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.8 m-70 -73.56 -35.7 65.52 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 114.959 -1.019 . . . . 10.0 108.258 -169.695 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.4 t 42.47 61.47 2.02 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 125.839 1.656 . . . . 10.0 112.951 167.289 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.7 pp -68.71 -9.14 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 113.697 0.999 . . . . 10.0 113.697 -171.633 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 10.5 mm -47.09 133.37 3.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.957 -0.757 . . . . 10.0 108.957 168.893 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.3 -7.49 75.52 Favored Glycine 0 CA--C 1.533 1.156 0 CA-C-O 118.851 -0.972 . . . . 10.0 114.51 -178.483 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.7 mtp-105 -76.26 175.33 9.15 Favored 'General case' 0 CA--C 1.544 0.74 0 CA-C-N 119.843 1.821 . . . . 10.0 106.858 168.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -127.78 132.23 49.53 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 119.091 0.86 . . . . 10.0 112.006 -170.586 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -85.23 148.29 26.16 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 123.997 0.919 . . . . 10.0 108.533 171.863 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 91.9 t -133.32 128.4 55.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.636 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -95.58 123.99 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 106.164 -1.791 . . . . 10.0 106.164 166.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -98.86 159.72 14.76 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.963 1.468 . . . . 10.0 114.963 -172.805 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -40.47 -58.21 1.62 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 128.415 2.686 . . . . 10.0 110.362 172.385 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -121.44 170.97 9.13 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 113.865 1.061 . . . . 10.0 113.865 -168.209 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.29 136.69 58.13 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 113.938 -1.483 . . . . 10.0 109.072 172.673 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -76.93 148.68 36.22 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.77 0.795 . . . . 10.0 110.634 -179.877 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -81.82 -41.61 20.84 Favored 'General case' 0 N--CA 1.447 -0.625 0 C-N-CA 130.977 3.711 . . . . 10.0 108.955 -176.746 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 16.8 mt 61.29 43.85 10.33 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.451 0.7 . . . . 10.0 112.172 -178.049 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.01 19.55 77.21 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 113.991 0.356 . . . . 10.0 113.991 169.585 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -86.83 -21.8 26.21 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.534 1.133 . . . . 10.0 110.884 172.471 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -56.43 -30.02 58.02 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.777 0.703 . . . . 10.0 111.805 178.578 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.67 30.19 71.75 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.351 -1.1 . . . . 10.0 110.351 -176.124 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.4 166.6 12.46 Favored 'General case' 0 CA--C 1.511 -0.538 0 N-CA-C 108.594 -0.891 . . . . 10.0 108.594 173.006 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -48.67 -54.56 14.3 Favored 'General case' 0 N--CA 1.431 -1.389 0 C-N-CA 124.511 1.125 . . . . 10.0 108.517 176.006 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -51.6 -47.3 63.66 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 124.131 0.973 . . . . 10.0 112.2 173.644 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.9 p -52.67 -37.67 59.15 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 118.991 -0.528 . . . . 10.0 109.94 -179.223 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.251 14.8 t -90.67 0.57 57.35 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 113.807 1.04 . . . . 10.0 113.807 -179.26 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.99 -53.37 2.71 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.77 1.628 . . . . 10.0 112.596 -179.354 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.418 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 35.3 p -129.41 5.4 5.2 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 119.807 1.185 . . . . 10.0 111.862 171.342 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 81.52 -118.54 4.65 Favored Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 103.264 -3.934 . . . . 10.0 103.264 -167.181 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -168.81 39.14 0.03 OUTLIER 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 126.247 1.819 . . . . 10.0 107.789 -178.401 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.67 0.11 13.85 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.585 1.154 . . . . 10.0 111.792 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.15 -163.59 50.73 Favored Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 110.437 -1.065 . . . . 10.0 110.437 171.261 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.34 140.38 45.45 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.835 0.854 . . . . 10.0 111.798 -168.717 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -65.36 72.82 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.567 1.147 . . . . 10.0 110.068 169.709 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 6.0 tp -44.67 -45.53 9.75 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.991 1.716 . . . . 10.0 112.121 -175.685 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 145.93 20.19 Favored 'General case' 0 C--O 1.234 0.281 0 N-CA-C 108.199 -1.038 . . . . 10.0 108.199 -175.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 m -139.6 152.64 46.98 Favored 'General case' 0 CA--C 1.518 -0.259 0 C-N-CA 123.12 0.568 . . . . 10.0 109.974 -169.125 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -149.81 145.42 13.54 Favored Glycine 0 C--N 1.338 0.652 0 N-CA-C 110.536 -1.026 . . . . 10.0 110.536 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 23.8 t -102.07 138.04 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 106.335 -1.728 . . . . 10.0 106.335 -175.319 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 48.5 mt -76.04 107.74 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 N-CA-C 109.917 -0.401 . . . . 10.0 109.917 -173.457 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.8 164.52 12.04 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.574 1.559 . . . . 10.0 111.635 178.465 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.4 mt -64.37 143.67 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 C-N-CA 124.93 1.292 . . . . 10.0 111.495 -177.908 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -136.72 162.27 33.65 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.404 -1.332 . . . . 10.0 107.404 167.542 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 . . . . . 0 C--O 1.251 1.162 0 N-CA-C 104.256 -2.498 . . . . 10.0 104.256 166.884 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.49 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -105.54 -27.77 11.19 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 126.041 1.737 . . . . 10.0 111.743 170.009 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.8 tttt -131.05 137.06 48.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.846 0.859 . . . . 10.0 109.354 179.421 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.93 161.0 30.9 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 123.375 0.67 . . . . 10.0 110.083 170.792 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.6 t -120.45 154.66 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 C-N-CA 126.354 1.861 . . . . 10.0 108.874 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.46 108.57 4.77 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 167.86 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.7 m -98.72 121.74 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 109.303 -0.629 . . . . 10.0 109.303 177.909 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.76 133.58 43.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.611 -0.709 . . . . 10.0 109.89 -175.266 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.3 mtpt -144.41 156.89 44.42 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 119.368 0.985 . . . . 10.0 109.153 167.447 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.47 -59.59 0.06 OUTLIER Glycine 0 N--CA 1.461 0.312 0 C-N-CA 119.696 -1.24 . . . . 10.0 113.861 169.776 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -71.12 -42.85 68.69 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -174.882 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.5 -70.05 0.41 Allowed Glycine 0 CA--C 1.523 0.532 0 CA-C-N 114.157 -1.383 . . . . 10.0 110.35 169.207 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.83 -36.82 99.0 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 123.338 2.692 . . . . 10.0 111.357 172.393 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.7 91.16 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 125.804 1.641 . . . . 10.0 107.802 177.098 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -117.82 112.39 20.33 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.205 1.402 . . . . 10.0 107.934 176.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.48 148.95 16.86 Favored Glycine 0 N--CA 1.432 -1.592 0 CA-C-N 114.137 -1.392 . . . . 10.0 111.328 -178.338 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.2 mt -151.42 84.11 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.332 1.853 . . . . 10.0 107.107 -169.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.0 mm -97.01 149.89 4.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 C-N-CA 124.914 1.286 . . . . 10.0 110.566 179.708 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.18 111.66 11.62 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 128.901 2.88 . . . . 10.0 108.382 -178.031 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -98.29 111.02 23.5 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 117.435 -1.269 . . . . 10.0 107.845 172.948 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -108.77 108.55 19.41 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.365 0.984 . . . . 10.0 112.271 174.073 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -103.87 96.21 6.53 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.588 1.955 . . . . 10.0 107.153 174.442 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 65.6 mttt . . . . . 0 CA--C 1.518 -0.273 0 C-N-CA 123.946 0.898 . . . . 10.0 110.637 -169.052 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.022 0 N-CA-C 110.024 -1.231 . . . . 10.0 110.024 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.8 127.79 18.58 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 N-CA-C 107.045 -1.944 . . . . 10.0 107.045 169.832 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.5 p -76.46 85.81 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-O 122.432 1.11 . . . . 10.0 108.349 -174.36 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 mtpt -58.82 111.31 1.24 Allowed 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 169.607 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 p -102.07 101.87 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.754 0 C-N-CA 126.219 1.807 . . . . 10.0 106.395 -177.64 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -116.18 174.4 6.07 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 116.319 -0.401 . . . . 10.0 111.385 176.531 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.03 -156.01 26.72 Favored Glycine 0 C--N 1.331 0.264 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 169.294 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.2 p -149.71 146.56 27.29 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.451 0.644 . . . . 10.0 112.595 -172.373 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -120.95 115.41 46.75 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.329 0 C-N-CA 125.909 1.684 . . . . 10.0 108.693 169.774 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -102.49 143.1 32.63 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 169.746 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.72 9.35 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 124.562 1.077 . . . . 10.0 112.969 170.332 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 mt -87.77 -175.67 5.24 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.961 0.886 . . . . 10.0 110.571 -171.274 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -102.72 155.78 18.08 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 167.516 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -53.54 159.09 1.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.589 1.156 . . . . 10.0 111.793 -174.878 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.71 -177.15 35.59 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.717 0.675 . . . . 10.0 111.803 170.608 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -66.56 149.82 49.9 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 125.46 1.504 . . . . 10.0 112.373 -177.861 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.6 m-70 -146.8 142.28 27.56 Favored 'General case' 0 C--N 1.344 0.352 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -177.467 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -30.99 125.62 0.17 Allowed Glycine 0 C--N 1.343 0.943 0 C-N-CA 127.74 2.59 . . . . 10.0 113.03 165.679 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.67 105.12 2.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 119.343 1.572 . . . . 10.0 113.002 168.577 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.13 172.74 15.31 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.156 0.503 . . . . 10.0 111.501 179.64 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.0 m -93.99 149.93 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 113.156 -1.838 . . . . 10.0 108.408 169.299 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 24.2 m-70 -130.94 140.31 50.16 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.719 1.608 . . . . 10.0 106.888 174.795 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -52.76 -54.86 27.92 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 125.27 1.428 . . . . 10.0 112.327 -169.721 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -77.62 114.59 16.61 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -61.05 -32.16 79.29 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.261 -1.136 . . . . 10.0 110.261 172.257 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -32.16 125.35 0.29 Allowed 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 125.296 1.439 . . . . 10.0 112.548 172.282 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -129.69 11.36 5.7 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 113.967 -1.47 . . . . 10.0 111.401 176.628 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 8.2 p -37.17 -63.27 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 125.972 1.709 . . . . 10.0 113.309 -175.477 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -74.67 -16.03 60.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.444 -1.253 . . . . 10.0 111.89 -174.458 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 136.11 -75.57 0.4 Allowed Glycine 0 CA--C 1.521 0.464 0 N-CA-C 109.004 -1.638 . . . . 10.0 109.004 177.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 9.3 t -157.0 18.65 0.3 Allowed 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 112.734 0.642 . . . . 10.0 112.734 -172.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.0 p -99.07 -57.43 2.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 105.718 -1.956 . . . . 10.0 105.718 -176.527 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -55.64 -25.77 40.84 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.424 1.89 . . . . 10.0 111.81 -179.409 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.14 -29.64 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 127.953 2.501 . . . . 10.0 114.226 168.349 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.61 154.96 28.28 Favored Glycine 0 C--N 1.34 0.752 0 N-CA-C 109.359 -1.496 . . . . 10.0 109.359 170.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -74.12 -170.84 0.77 Allowed 'Trans proline' 0 N--CA 1.446 -1.315 0 N-CA-C 107.787 -1.659 . . . . 10.0 107.787 168.778 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.1 m170 -80.95 60.67 4.25 Favored 'General case' 0 CA--C 1.537 0.444 0 O-C-N 120.658 -1.276 . . . . 10.0 109.827 -177.079 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -73.67 72.71 1.48 Allowed 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 122.117 0.96 . . . . 10.0 109.698 174.408 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -73.16 135.06 79.99 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.636 -0.665 . . . . 10.0 110.042 173.271 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.18 -44.56 4.82 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 122.57 2.18 . . . . 10.0 110.867 -177.426 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.8 mt -72.63 67.85 0.8 Allowed 'General case' 0 C--O 1.225 -0.234 0 C-N-CA 123.481 0.712 . . . . 10.0 109.312 175.067 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 40.5 p -37.03 108.67 0.08 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 125.853 1.661 . . . . 10.0 111.054 -179.187 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.83 173.03 12.05 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 103.086 -2.931 . . . . 10.0 103.086 -170.568 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.7 mptt -80.06 152.44 29.37 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 117.341 -1.743 . . . . 10.0 107.99 170.338 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.418 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 79.1 t60 -63.27 103.2 0.47 Allowed 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.398 -0.964 . . . . 10.0 108.398 165.596 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.37 -127.34 4.05 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.156 -1.977 . . . . 10.0 108.156 177.718 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.7 -163.83 32.47 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 108.377 -1.889 . . . . 10.0 108.377 173.346 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -63.29 -5.5 8.27 Favored 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 119.832 1.816 . . . . 10.0 110.793 167.499 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -87.53 -26.09 23.33 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 125.407 1.483 . . . . 10.0 110.076 175.131 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -98.94 158.36 15.7 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 106.798 -1.556 . . . . 10.0 106.798 179.299 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -79.0 -32.38 45.14 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 107.421 -1.326 . . . . 10.0 107.421 168.541 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -114.5 51.36 0.89 Allowed 'General case' 0 N--CA 1.447 -0.604 0 C-N-CA 124.26 1.024 . . . . 10.0 111.018 -168.684 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -61.43 164.53 5.58 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.589 1.556 . . . . 10.0 110.689 169.159 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . 0.418 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 9.9 m170 -66.59 -63.09 1.14 Allowed 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.418 0.525 . . . . 10.0 112.418 -170.022 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 8.2 p -171.65 -47.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.19 0.996 . . . . 10.0 109.818 -178.092 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.59 72.28 0.37 Allowed Glycine 0 C--N 1.336 0.572 0 N-CA-C 107.149 -2.38 . . . . 10.0 107.149 176.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.05 98.11 5.83 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.497 -2.038 . . . . 10.0 105.497 -173.358 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 40.5 mt -80.72 5.92 14.35 Favored 'General case' 0 N--CA 1.463 0.177 0 C-N-CA 122.678 0.391 . . . . 10.0 111.774 -169.844 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 82.65 -106.36 2.73 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 107.475 -2.25 . . . . 10.0 107.475 -174.582 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -158.65 152.53 23.54 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.125 0.97 . . . . 10.0 110.248 -177.146 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -122.74 133.99 67.23 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 123.275 0.63 . . . . 10.0 110.174 -176.402 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -78.57 133.23 37.35 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 126.546 1.938 . . . . 10.0 109.266 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.29 132.56 50.41 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.548 1.939 . . . . 10.0 110.155 169.726 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.403 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 24.0 t70 -63.6 171.22 2.72 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.993 1.717 . . . . 10.0 111.145 168.733 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.403 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 17.9 pttp -49.07 -35.03 14.95 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 124.565 1.146 . . . . 10.0 110.647 169.535 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.9 -3.15 40.28 Favored 'General case' 0 C--N 1.342 0.249 0 O-C-N 122.326 -0.234 . . . . 10.0 110.535 -175.919 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.68 22.88 78.75 Favored Glycine 0 N--CA 1.444 -0.797 0 N-CA-C 109.469 -1.452 . . . . 10.0 109.469 -175.289 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.0 t -96.21 106.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.86 0 C-N-CA 127.57 2.348 . . . . 10.0 105.093 173.438 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.44 125.05 48.03 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.287 -1.005 . . . . 10.0 108.287 169.341 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -94.68 121.33 36.15 Favored 'General case' 0 N--CA 1.435 -1.179 0 C-N-CA 127.838 2.455 . . . . 10.0 108.832 179.308 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 43.3 t -101.26 135.81 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 124.767 1.227 . . . . 10.0 108.147 177.326 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.26 72.43 0.62 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.945 1.298 . . . . 10.0 109.408 169.689 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -106.38 162.46 5.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 107.565 -1.272 . . . . 10.0 107.565 -179.036 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -146.13 136.46 23.87 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.584 1.554 . . . . 10.0 109.568 175.69 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -134.02 142.34 47.58 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.091 -1.818 . . . . 10.0 106.091 173.759 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 75.2 p -103.5 51.48 0.79 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.868 1.267 . . . . 10.0 107.811 174.228 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.32 -47.91 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.323 0.649 . . . . 10.0 110.377 -176.97 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.47 118.26 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 171.431 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.1 m -120.62 112.67 19.19 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 108.562 -0.903 . . . . 10.0 108.562 -176.658 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 77.4 mt -56.81 -43.97 81.51 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.457 0.646 . . . . 10.0 110.41 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.452 -0.345 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 -174.358 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t . . . . . 0 N--CA 1.45 -0.43 0 CA-C-O 122.957 1.36 . . . . 10.0 108.112 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 31.0 mm -73.57 -14.06 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 CA-C-N 113.543 -1.662 . . . . 10.0 112.228 -168.973 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.5 mm -51.48 147.32 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 N-CA-C 109.363 -0.606 . . . . 10.0 109.363 169.696 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.81 2.44 90.54 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 121.357 -0.84 . . . . 10.0 114.592 178.815 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 54.4 mmt-85 -77.58 163.31 26.37 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 118.914 1.357 . . . . 10.0 108.716 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.1 118.17 35.24 Favored 'General case' 0 C--N 1.34 0.153 0 N-CA-C 109.287 -0.634 . . . . 10.0 109.287 170.51 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -75.49 142.99 42.79 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.048 -1.464 . . . . 10.0 107.048 167.184 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.64 129.36 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.831 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.04 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.7 p -97.35 135.3 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.715 0 N-CA-C 107.96 -1.126 . . . . 10.0 107.96 169.275 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 3.8 m170 -115.02 159.72 20.46 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 116.465 2.024 . . . . 10.0 116.465 -175.891 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -48.92 -58.38 4.95 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 129.832 3.253 . . . . 10.0 111.932 177.071 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 54.8 mttp -111.93 173.46 6.35 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.966 0.906 . . . . 10.0 112.804 -169.874 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.05 136.04 35.26 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 126.524 1.929 . . . . 10.0 110.304 -179.165 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.69 144.22 32.42 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 113.362 0.875 . . . . 10.0 113.362 -169.558 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -74.9 -38.56 61.82 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.187 1.395 . . . . 10.0 109.206 177.855 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.8 mt 62.12 49.92 4.23 Favored 'General case' 0 C--N 1.337 0.054 0 C-N-CA 125.21 1.404 . . . . 10.0 110.006 -172.259 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' B' ' 129' ' ' GLY . . . 82.82 -45.58 3.45 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.562 1.077 . . . . 10.0 110.988 170.638 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.5 pttp -73.43 21.63 0.08 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.83 1.652 . . . . 10.0 112.72 -175.147 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . 0.402 ' H ' ' C ' ' B' ' 127' ' ' GLY . . . -77.91 -32.71 43.99 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 126.475 1.988 . . . . 10.0 108.298 166.103 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.22 19.08 69.97 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.284 -0.731 . . . . 10.0 111.859 -179.124 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -112.07 162.27 15.59 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 104.839 -2.282 . . . . 10.0 104.839 169.215 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . 0.496 ' CD ' ' HZ2' ' B' ' 136' ' ' LYS . 15.6 tm-20 -60.92 -40.04 91.7 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 119.505 -0.878 . . . . 10.0 110.748 -169.849 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -69.12 -28.28 66.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 118.749 -0.643 . . . . 10.0 112.242 177.529 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -48.76 -47.47 41.64 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 119.68 1.127 . . . . 10.0 110.242 168.852 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.4 t -85.1 -10.15 57.15 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 118.461 -0.781 . . . . 10.0 112.711 -171.366 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.496 ' HZ2' ' CD ' ' B' ' 132' ' ' GLU . 1.1 ttmp? -100.61 -92.34 0.3 Allowed 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.69 1.596 . . . . 10.0 108.15 175.292 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.467 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 44.5 p -86.26 1.35 51.23 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 122.135 2.243 . . . . 10.0 112.744 -176.062 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.58 21.89 73.88 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 120.416 1.462 . . . . 10.0 110.79 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 61.72 19.92 10.93 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 119.577 1.688 . . . . 10.0 112.854 169.649 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -80.29 9.96 5.12 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 113.623 0.972 . . . . 10.0 113.623 -168.021 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.72 -165.07 53.94 Favored Glycine 0 N--CA 1.444 -0.781 0 O-C-N 121.252 -0.905 . . . . 10.0 111.502 170.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.5 m -59.3 135.63 57.71 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 124.1 0.96 . . . . 10.0 112.901 -167.705 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -67.23 86.99 0.16 Allowed 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 125.129 1.372 . . . . 10.0 110.276 174.042 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 58.5 mt -60.85 -35.12 75.76 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.827 0.676 . . . . 10.0 112.827 -177.19 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.39 154.35 26.81 Favored 'General case' 0 C--O 1.234 0.244 0 O-C-N 121.625 -0.672 . . . . 10.0 111.495 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -123.55 152.36 41.9 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 125.857 1.663 . . . . 10.0 109.088 -178.674 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.57 156.04 26.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.413 -1.075 . . . . 10.0 110.413 168.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 66.1 t -109.58 140.07 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 -175.588 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 27.6 mt -75.62 125.15 34.92 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-O 118.594 -0.717 . . . . 10.0 109.764 -178.622 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.81 162.76 24.48 Favored Glycine 0 CA--C 1.53 1.022 0 C-N-CA 124.383 0.992 . . . . 10.0 113.569 -178.573 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.8 mm -73.34 144.91 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.274 1.03 . . . . 10.0 111.226 -169.904 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.96 -47.2 2.18 Favored 'General case' 0 CA--C 1.51 -0.592 0 CA-C-N 118.45 0.568 . . . . 10.0 111.433 166.652 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 116.38 -1.771 . . . . 10.0 107.544 175.78 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.659 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.7 t -151.55 -48.44 0.11 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 119.12 0.873 . . . . 10.0 110.7 178.686 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 40.8 tttt -132.87 153.64 51.14 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.2 -1.778 . . . . 10.0 106.2 172.59 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.22 151.18 43.55 Favored 'General case' 0 CA--C 1.513 -0.46 0 N-CA-C 108.93 -0.767 . . . . 10.0 108.93 169.286 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.38 161.12 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 O-C-N 124.061 0.851 . . . . 10.0 110.223 172.464 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.41 98.96 3.07 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.206 -1.775 . . . . 10.0 106.206 165.703 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.5 m -93.29 98.02 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 122.844 0.458 . . . . 10.0 110.687 -179.204 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.5 mp -79.6 136.26 36.8 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 121.227 -0.921 . . . . 10.0 109.833 -175.756 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -144.73 156.15 43.92 Favored 'General case' 0 C--N 1.341 0.212 0 C-N-CA 124.426 1.09 . . . . 10.0 108.344 168.346 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.6 -69.08 0.02 OUTLIER Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.185 -0.531 . . . . 10.0 112.166 169.252 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -74.24 -41.51 61.2 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 107.179 -1.415 . . . . 10.0 107.179 -175.656 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.91 -67.67 0.48 Allowed Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 114.996 -1.002 . . . . 10.0 111.588 176.969 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -55.15 -42.05 72.58 Favored 'Trans proline' 0 N--CA 1.45 -1.077 0 C-N-CA 121.972 1.782 . . . . 10.0 110.077 175.846 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 47.9 t -58.49 87.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 C-N-CA 126.182 1.793 . . . . 10.0 108.034 175.197 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.47 116.95 31.75 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.709 -1.96 . . . . 10.0 105.709 171.453 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.91 142.89 15.97 Favored Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 108.656 -1.778 . . . . 10.0 108.656 174.258 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.426 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 7.1 mt -138.71 60.81 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 N-CA-C 107.357 -1.349 . . . . 10.0 107.357 -169.684 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.4 mm -77.87 133.56 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 N-CA-C 108.801 -0.814 . . . . 10.0 108.801 -176.072 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m-80 -122.44 105.11 9.87 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.203 2.201 . . . . 10.0 107.22 -176.805 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -89.1 136.44 33.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.499 1.12 . . . . 10.0 108.025 177.749 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -117.49 148.29 41.97 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 123.703 0.627 . . . . 10.0 110.701 168.191 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -122.46 107.14 11.69 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.7 1.6 . . . . 10.0 108.01 168.816 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -65.91 -59.2 4.08 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.974 0.91 . . . . 10.0 110.644 -178.492 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.1 mp0 -128.22 168.02 16.04 Favored 'General case' 0 N--CA 1.425 -1.725 0 N-CA-C 103.608 -2.738 . . . . 10.0 103.608 174.079 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.2 p -65.98 -25.74 67.24 Favored 'General case' 0 N--CA 1.44 -0.937 0 O-C-N 121.748 -0.595 . . . . 10.0 109.429 174.759 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -98.69 -6.33 29.85 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.207 1.403 . . . . 10.0 110.828 -173.361 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.63 144.57 21.4 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 -173.772 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -64.02 139.42 67.29 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 121.721 1.614 . . . . 10.0 108.101 170.525 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 m -93.12 142.51 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -176.861 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.41 ' NZ ' ' OE1' ' A' ' 100' ' ' GLU . 1.9 ttmp? -108.06 123.21 48.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.298 -2.482 . . . . 10.0 104.298 166.606 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 m -108.99 103.45 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 105.916 -1.883 . . . . 10.0 105.916 -179.371 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 8.0 p90 -114.44 171.82 7.39 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 -176.298 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.65 -154.4 25.53 Favored Glycine 0 N--CA 1.447 -0.618 0 N-CA-C 108.537 -1.825 . . . . 10.0 108.537 169.076 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 m -153.54 150.24 28.5 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 117.124 0.462 . . . . 10.0 110.899 177.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -111.17 112.65 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 C-N-CA 127.356 2.263 . . . . 10.0 106.861 168.493 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.5 ptmt -121.73 90.3 3.28 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 112.214 0.45 . . . . 10.0 112.214 -178.276 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.65 32.35 0.02 OUTLIER Glycine 0 CA--C 1.52 0.406 0 CA-C-O 118.981 -0.9 . . . . 10.0 113.996 174.032 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -125.06 175.41 7.37 Favored 'General case' 0 C--O 1.224 -0.246 0 N-CA-C 108.237 -1.023 . . . . 10.0 108.237 177.144 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -75.6 168.54 19.81 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 118.83 0.741 . . . . 10.0 110.844 177.712 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 65.1 tt0 -61.02 173.3 0.81 Allowed 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.21 1.804 . . . . 10.0 111.288 -176.874 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.14 179.73 49.73 Favored Glycine 0 CA--C 1.522 0.52 0 C-N-CA 123.781 0.705 . . . . 10.0 112.017 168.897 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.0 mp -66.02 143.56 57.28 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.376 1.07 . . . . 10.0 110.275 178.449 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -140.39 146.5 38.45 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 113.384 0.883 . . . . 10.0 113.384 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -29.25 122.72 0.09 OUTLIER Glycine 0 C--N 1.341 0.851 0 C-N-CA 127.547 2.499 . . . . 10.0 112.269 165.25 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -150.62 106.01 3.37 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 120.034 1.917 . . . . 10.0 113.12 169.758 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.416 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.43 175.18 12.99 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.509 0.671 . . . . 10.0 112.803 -176.497 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.7 m -91.42 153.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 112.655 -2.066 . . . . 10.0 106.3 166.499 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.32 123.27 35.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 102.884 -3.006 . . . . 10.0 102.884 169.113 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -61.33 -35.03 76.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 114.894 1.442 . . . . 10.0 114.894 -164.571 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-30 -75.91 119.54 20.02 Favored 'General case' 0 C--N 1.342 0.251 0 C-N-CA 117.285 -1.766 . . . . 10.0 106.984 169.576 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.01 37.08 0.92 Allowed Glycine 0 CA--C 1.525 0.676 0 C-N-CA 125.041 1.305 . . . . 10.0 111.241 168.883 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -107.55 171.56 7.32 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 124.899 1.279 . . . . 10.0 107.697 177.459 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.1 25.65 0.14 Allowed 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 114.653 -1.158 . . . . 10.0 112.231 168.747 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.39 -36.96 66.97 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.451 1.1 . . . . 10.0 111.253 -170.481 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.38 -19.6 55.95 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 124.022 0.929 . . . . 10.0 112.468 -179.695 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 87.04 97.87 0.85 Allowed Glycine 0 CA--C 1.528 0.866 0 N-CA-C 109.02 -1.632 . . . . 10.0 109.02 -169.698 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 59.2 m 43.11 55.17 4.67 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.032 1.733 . . . . 10.0 113.962 173.074 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.76 -49.62 0.08 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.078 0.551 . . . . 10.0 110.139 176.034 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 47.4 t -60.8 -28.89 69.12 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 122.44 0.296 . . . . 10.0 111.059 -173.314 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.42 -28.97 0.07 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 127.448 2.299 . . . . 10.0 115.156 179.758 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 134.26 8.41 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-O 118.449 -1.195 . . . . 10.0 110.528 170.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -78.46 62.24 8.14 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 123.211 2.607 . . . . 10.0 112.319 -174.315 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 14.0 m170 61.74 28.02 17.21 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.511 2.324 . . . . 10.0 110.581 177.372 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -53.72 -39.05 64.91 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 113.871 1.064 . . . . 10.0 113.871 -166.67 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 34.27 172.23 0.0 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 128.807 2.843 . . . . 10.0 115.518 -169.662 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -67.81 -65.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.349 0.573 0 O-C-N 118.621 -1.305 . . . . 10.0 110.849 -172.781 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.0 74.52 2.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 169.006 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 p -47.89 113.76 0.78 Allowed 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.048 0.939 . . . . 10.0 108.946 169.487 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 40.6 mtt180 -133.13 -167.06 1.85 Allowed 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 105.783 -1.932 . . . . 10.0 105.783 -178.465 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.81 137.54 33.66 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 118.046 -1.462 . . . . 10.0 110.304 -171.022 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 65.8 t60 -47.15 119.66 2.71 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 120.337 -0.545 . . . . 10.0 110.517 168.218 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.61 -143.76 4.22 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 108.636 -1.786 . . . . 10.0 108.636 177.583 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.445 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -171.61 -149.94 6.86 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-O 118.158 -1.357 . . . . 10.0 109.981 175.431 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 79.7 Cg_endo -69.27 14.68 0.22 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 122.162 1.908 . . . . 10.0 111.415 169.287 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.445 ' H ' ' C ' ' A' ' 73' ' ' GLY . 6.0 mtpm? -110.08 -10.78 14.67 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 124.616 1.166 . . . . 10.0 110.075 169.592 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -111.41 158.55 18.96 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.369 -1.345 . . . . 10.0 107.369 -179.176 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -79.41 -36.86 38.42 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.653 -1.24 . . . . 10.0 107.653 173.033 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -96.8 -49.7 4.96 Favored 'General case' 0 CA--C 1.498 -1.024 0 CA-C-O 121.453 0.644 . . . . 10.0 112.137 -166.3 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 7.1 ptp180 41.52 -141.4 0.09 Allowed 'General case' 0 N--CA 1.434 -1.253 0 CA-C-N 113.709 -1.587 . . . . 10.0 109.108 -169.478 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -112.12 44.56 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 O-C-N 120.611 -1.306 . . . . 10.0 108.073 166.511 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.9 t 37.8 38.96 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 124.081 0.953 . . . . 10.0 111.04 -167.596 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 70.69 0.02 OUTLIER Glycine 0 CA--C 1.533 1.195 0 O-C-N 121.541 -0.724 . . . . 10.0 112.431 -174.002 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -136.94 111.15 8.39 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 104.008 -2.59 . . . . 10.0 104.008 168.181 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 19.3 mt -72.19 -23.18 61.22 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 118.667 0.667 . . . . 10.0 109.225 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.11 -89.8 0.55 Allowed Glycine 0 N--CA 1.441 -1.025 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 167.042 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 m-20 -147.8 126.44 12.53 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -173.794 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.7 m -109.82 124.87 66.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 118.043 0.383 . . . . 10.0 110.097 176.293 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.1 m -79.51 111.39 15.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 127.245 2.218 . . . . 10.0 111.228 -176.825 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.56 129.75 34.75 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 123.176 0.59 . . . . 10.0 109.985 170.813 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.505 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 18.2 t70 -61.29 166.69 3.66 Favored 'General case' 0 N--CA 1.454 -0.272 0 O-C-N 124.574 1.171 . . . . 10.0 109.119 167.756 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.505 ' HZ2' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -56.64 -26.0 54.92 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 123.91 0.884 . . . . 10.0 111.446 175.882 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -75.76 -10.62 59.59 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 120.583 0.23 . . . . 10.0 110.675 179.525 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.04 23.15 42.3 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.403 -1.079 . . . . 10.0 110.403 178.664 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.1 t -106.99 105.57 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.986 0 C-N-CA 128.359 2.664 . . . . 10.0 105.95 -178.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.83 121.46 42.52 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.668 -1.234 . . . . 10.0 107.668 168.635 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -92.32 132.63 36.56 Favored 'General case' 0 N--CA 1.434 -1.261 0 C-N-CA 127.188 2.195 . . . . 10.0 108.899 176.36 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -113.08 133.12 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.979 0 C-N-CA 125.298 1.439 . . . . 10.0 107.676 175.14 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.5 p -158.35 57.82 0.45 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.278 0.631 . . . . 10.0 110.688 169.651 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.79 155.15 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.101 0 N-CA-C 107.999 -1.112 . . . . 10.0 107.999 -173.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.41 ' OE1' ' NZ ' ' A' ' 30' ' ' LYS . 0.8 OUTLIER -122.2 156.41 33.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 124.746 1.218 . . . . 10.0 111.904 173.809 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -148.97 164.19 35.3 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.057 -1.428 . . . . 10.0 108.989 168.721 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.7 p -118.8 44.01 2.4 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 126.227 1.811 . . . . 10.0 110.364 -178.012 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.2 p -145.19 -43.46 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 118.255 0.48 . . . . 10.0 111.251 177.013 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.39 147.31 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.318 -1.364 . . . . 10.0 107.318 169.176 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.1 m -151.57 135.44 16.45 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.128 -1.064 . . . . 10.0 108.128 174.385 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -70.04 -38.16 75.77 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.832 0.853 . . . . 10.0 108.919 -179.593 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 22.6 m -137.75 130.22 29.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.74 -1.578 . . . . 10.0 106.74 170.335 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.91 -65.66 0.1 OUTLIER Glycine 0 C--N 1.333 0.369 0 N-CA-C 109.258 -1.537 . . . . 10.0 109.258 -177.941 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -163.06 -51.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.773 1.629 . . . . 10.0 107.703 -179.835 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -74.1 -41.59 61.4 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 114.38 -1.282 . . . . 10.0 108.091 -169.64 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.9 t 41.11 74.25 0.11 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 126.477 1.911 . . . . 10.0 111.702 174.858 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -68.22 -3.64 2.64 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 N-CA-C 112.932 0.716 . . . . 10.0 112.932 -179.682 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.1 mm -33.02 -44.34 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 126.453 1.901 . . . . 10.0 114.042 173.421 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.89 38.81 3.14 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 124.185 0.898 . . . . 10.0 112.515 -176.748 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -102.78 176.69 5.08 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.475 1.51 . . . . 10.0 111.643 170.046 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 4.7 m -119.1 131.22 55.9 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.952 2.101 . . . . 10.0 106.36 177.85 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 58.7 mt -103.9 148.35 26.26 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 125.28 1.432 . . . . 10.0 109.324 172.285 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.2 t -136.36 134.36 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 O-C-N 123.71 0.631 . . . . 10.0 109.364 -178.593 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.39 135.63 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 168.648 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.3 m170 -112.26 155.64 23.7 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 116.673 2.101 . . . . 10.0 116.673 -178.565 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.43 ' CD ' ' HZ3' ' A' ' 122' ' ' LYS . 34.2 tt0 -42.24 -62.93 0.83 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.779 3.231 . . . . 10.0 111.548 173.314 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.43 ' HZ3' ' CD ' ' A' ' 121' ' ' GLU . 8.1 mtmt -106.89 172.41 6.84 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.993 1.317 . . . . 10.0 111.823 -177.298 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.4 150.96 39.76 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.994 -1.457 . . . . 10.0 109.605 172.459 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.416 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.3 m-20 -79.46 150.23 31.32 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.565 1.146 . . . . 10.0 112.495 177.317 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -74.36 -29.56 61.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.973 -1.467 . . . . 10.0 110.122 169.943 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 27.4 mt 54.97 44.27 28.53 Favored 'General case' 0 C--N 1.339 0.129 0 CA-C-O 121.847 0.832 . . . . 10.0 108.799 -167.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.38 -10.17 67.71 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 125.667 1.603 . . . . 10.0 113.151 173.204 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -78.33 -3.93 45.5 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 118.405 1.102 . . . . 10.0 113.117 -170.795 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.2 -38.62 95.94 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.813 -0.915 . . . . 10.0 110.813 175.152 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.43 33.45 81.88 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.114 -1.194 . . . . 10.0 110.114 -173.387 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -117.59 161.96 18.79 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 106.05 -1.833 . . . . 10.0 106.05 169.69 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -51.36 -48.87 62.36 Favored 'General case' 0 N--CA 1.428 -1.525 0 N-CA-C 108.721 -0.844 . . . . 10.0 108.721 170.773 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -59.04 -40.1 84.04 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.318 -0.401 . . . . 10.0 111.31 176.96 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 16.6 p -55.75 -40.15 72.16 Favored 'General case' 0 N--CA 1.443 -0.794 0 O-C-N 120.926 -1.109 . . . . 10.0 110.708 179.287 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -84.64 4.93 30.11 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 118.491 -0.766 . . . . 10.0 112.122 -178.265 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -112.83 -85.44 0.58 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.037 1.735 . . . . 10.0 110.091 175.022 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.4 p -111.43 30.87 6.56 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 121.088 1.767 . . . . 10.0 112.52 178.179 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.83 27.52 56.18 Favored Glycine 0 C--N 1.341 0.858 0 C-N-CA 123.757 0.694 . . . . 10.0 113.9 168.333 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 46.8 29.62 1.03 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.055 0.942 . . . . 10.0 113.01 -172.108 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.35 -4.57 18.77 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.228 -0.92 . . . . 10.0 112.24 -177.424 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.67 -161.92 50.17 Favored Glycine 0 N--CA 1.444 -0.812 0 O-C-N 121.129 -0.982 . . . . 10.0 111.315 169.212 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.1 m -55.12 128.39 33.57 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 114.644 -0.778 . . . . 10.0 112.842 -167.274 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 22.5 mtt85 -66.43 73.03 0.08 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.738 1.615 . . . . 10.0 109.758 172.078 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 35.1 mt -49.3 -36.82 21.94 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.595 1.158 . . . . 10.0 112.976 -175.722 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 152.1 24.72 Favored 'General case' 0 CA--C 1.513 -0.461 0 O-C-N 121.57 -0.706 . . . . 10.0 110.526 -177.877 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.0 m -130.87 145.66 52.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 124.821 1.326 . . . . 10.0 108.679 -175.661 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -135.48 141.28 12.46 Favored Glycine 0 C--N 1.332 0.314 0 N-CA-C 108.621 -1.792 . . . . 10.0 108.621 171.508 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -99.79 136.61 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 105.869 -1.9 . . . . 10.0 105.869 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.0 mt -72.09 158.93 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 -177.072 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -172.67 168.66 41.75 Favored Glycine 0 CA--C 1.527 0.787 0 O-C-N 121.379 -0.826 . . . . 10.0 111.737 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.7 mt -53.19 142.31 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 125.451 1.5 . . . . 10.0 111.534 -174.209 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.83 163.64 36.79 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.665 0.745 . . . . 10.0 109.489 166.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 . . . . . 0 C--O 1.256 1.405 0 N-CA-C 104.7 -2.333 . . . . 10.0 104.7 166.636 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.848 0 CA-C-O 117.997 -1.002 . . . . 10.0 108.432 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -165.21 -45.32 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.837 0.855 . . . . 10.0 110.208 178.346 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mttt -136.69 154.27 50.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 125.245 1.418 . . . . 10.0 109.248 169.711 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.59 164.43 30.23 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.366 1.466 . . . . 10.0 107.528 168.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -134.3 157.95 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 N-CA-C 109.327 -0.62 . . . . 10.0 109.327 -178.884 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.93 99.96 5.95 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.045 0.938 . . . . 10.0 109.502 172.925 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -81.24 93.03 2.18 Favored 'Isoleucine or valine' 0 C--N 1.341 0.229 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 167.966 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mt -84.71 136.68 33.62 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.474 1.11 . . . . 10.0 108.561 -178.732 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -159.74 161.64 34.79 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.441 -1.318 . . . . 10.0 107.441 173.771 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.38 -44.82 0.11 Allowed Glycine 0 C--O 1.227 -0.331 0 C-N-CA 119.813 -1.184 . . . . 10.0 113.473 168.938 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -74.1 -45.17 50.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.721 -1.215 . . . . 10.0 107.721 -176.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 144.22 -71.36 0.38 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.636 -1.386 . . . . 10.0 109.636 171.487 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -59.1 -37.52 92.12 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.303 2.669 . . . . 10.0 111.14 171.768 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 58.4 t -58.93 111.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 108.538 -0.912 . . . . 10.0 108.538 178.094 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -125.96 127.86 46.6 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 105.598 -2.001 . . . . 10.0 105.598 167.949 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -114.12 135.46 12.5 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 108.765 -1.734 . . . . 10.0 108.765 170.505 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 4.6 mt -134.97 68.07 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 106.706 -1.591 . . . . 10.0 106.706 -173.836 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.4 mm -97.59 139.82 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 115.145 -0.934 . . . . 10.0 110.467 -170.925 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -107.39 130.52 54.79 Favored 'General case' 0 CA--C 1.527 0.095 0 C-N-CA 126.833 2.053 . . . . 10.0 109.168 -176.183 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -116.75 100.38 7.76 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.376 -1.342 . . . . 10.0 107.376 177.91 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.47 156.89 17.37 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.33 0.514 . . . . 10.0 110.973 175.637 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 34.5 tp60 -154.2 65.49 0.7 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.979 1.312 . . . . 10.0 109.851 -177.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? . . . . . 0 N--CA 1.432 -1.347 0 C-N-CA 124.86 1.264 . . . . 10.0 107.71 176.955 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.297 0 N-CA-C 115.419 0.928 . . . . 10.0 115.419 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.71 104.06 1.67 Allowed 'Trans proline' 0 N--CA 1.445 -1.361 0 N-CA-C 105.939 -2.369 . . . . 10.0 105.939 168.339 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 t -77.67 78.95 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.502 -2.036 . . . . 10.0 105.502 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.3 ttmm -69.83 109.57 4.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.385 -1.709 . . . . 10.0 106.385 169.046 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -90.84 102.61 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 105.413 -2.069 . . . . 10.0 105.413 173.852 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -119.56 150.59 40.02 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.92 -160.92 32.93 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 109.502 -1.439 . . . . 10.0 109.502 169.293 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.1 p -147.47 115.15 6.39 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 108.898 -0.779 . . . . 10.0 108.898 -173.542 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.3 pt -80.19 179.15 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 108.748 -0.834 . . . . 10.0 108.748 168.146 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 92' ' ' ASP . 0.2 OUTLIER -155.86 159.86 39.71 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 107.472 -1.307 . . . . 10.0 107.472 164.034 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.06 -12.63 57.46 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-O 119.13 -0.817 . . . . 10.0 113.96 170.106 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.5 mp -70.65 176.65 4.0 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 119.036 1.418 . . . . 10.0 109.237 171.736 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -90.13 167.11 12.98 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.431 -0.951 . . . . 10.0 108.431 167.778 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -62.17 170.38 2.28 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.706 0.802 . . . . 10.0 111.734 -170.683 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.39 -174.23 33.45 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 124.317 0.96 . . . . 10.0 112.285 168.611 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -71.85 141.89 49.6 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.185 0.994 . . . . 10.0 109.409 175.761 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.82 148.92 41.34 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 114.7 1.37 . . . . 10.0 114.7 -179.368 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -36.85 127.05 1.09 Allowed Glycine 0 C--N 1.343 0.932 0 C-N-CA 127.649 2.547 . . . . 10.0 110.738 164.537 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -155.65 105.96 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 118.777 1.289 . . . . 10.0 109.055 168.485 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.497 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -156.05 175.34 14.1 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -178.2 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 29.0 m -90.04 151.58 3.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 113.771 -1.558 . . . . 10.0 110.265 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -142.42 137.75 30.61 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.592 1.557 . . . . 10.0 108.125 178.534 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -50.7 -57.14 9.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 114.944 1.461 . . . . 10.0 114.944 -169.103 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -78.46 123.13 26.7 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.92 -0.77 . . . . 10.0 108.92 -169.476 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.52 -30.53 77.88 Favored Glycine 0 CA--C 1.531 1.08 0 N-CA-C 107.444 -2.262 . . . . 10.0 107.444 165.6 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -45.81 142.58 2.46 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-O 123.303 1.525 . . . . 10.0 111.046 171.51 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -165.11 22.5 0.05 Allowed 'General case' 0 N--CA 1.434 -1.24 0 C-N-CA 126.05 1.74 . . . . 10.0 110.144 -169.573 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.426 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 1.3 p -53.16 -40.86 64.62 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 122.874 0.469 . . . . 10.0 112.11 -178.877 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.62 -18.31 54.7 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.227 0.611 . . . . 10.0 112.095 176.133 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.21 110.56 0.8 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.239 0.923 . . . . 10.0 111.986 -178.517 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.1 m 48.7 33.69 4.49 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.676 1.59 . . . . 10.0 112.336 172.492 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 22.3 m -138.18 -55.12 0.65 Allowed 'General case' 0 N--CA 1.437 -1.092 0 C-N-CA 126.296 1.838 . . . . 10.0 106.318 -173.591 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -67.04 -12.9 61.22 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.753 0.821 . . . . 10.0 111.722 178.041 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.31 -36.43 1.25 Allowed 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 126.961 2.104 . . . . 10.0 112.442 175.689 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.38 163.8 39.39 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 107.425 -2.27 . . . . 10.0 107.425 -178.644 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -74.73 -170.26 0.73 Allowed 'Trans proline' 0 N--CA 1.443 -1.463 0 C-N-CA 121.268 1.312 . . . . 10.0 109.252 172.2 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 38.3 m170 -78.6 58.7 2.29 Favored 'General case' 0 CA--C 1.538 0.515 0 O-C-N 121.269 -0.894 . . . . 10.0 110.572 -173.251 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -71.86 79.46 0.88 Allowed 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 123.096 1.427 . . . . 10.0 110.45 178.524 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -74.1 147.2 85.61 Favored Pre-proline 0 N--CA 1.445 -0.69 0 C-N-CA 125.015 1.326 . . . . 10.0 110.222 169.012 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -65.42 -43.53 10.5 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.319 2.013 . . . . 10.0 110.394 178.127 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 tt -78.14 56.82 1.71 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.024 0.93 . . . . 10.0 108.907 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 38.9 p -35.96 106.16 0.04 OUTLIER 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 126.055 1.742 . . . . 10.0 110.989 -173.098 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . 0.419 HH22 ' CD ' ' B' ' 77' ' ' GLU . 2.8 ttt180 -133.29 -174.75 3.58 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 104.029 -2.582 . . . . 10.0 104.029 -178.919 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 22.3 mmtp -75.33 161.11 29.57 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 117.618 -1.633 . . . . 10.0 108.523 170.543 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -65.01 123.31 19.13 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 161.786 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.33 -138.42 4.03 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 108.209 -1.956 . . . . 10.0 108.209 171.687 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.4 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 177.25 -160.08 26.75 Favored Glycine 0 C--O 1.224 -0.502 0 N-CA-C 108.869 -1.692 . . . . 10.0 108.869 177.192 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -66.6 2.03 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 CA-C-N 119.544 1.672 . . . . 10.0 110.131 166.332 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.4 ' H ' ' C ' ' B' ' 73' ' ' GLY . 25.0 mmtt -107.9 6.16 27.05 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 125.598 1.559 . . . . 10.0 110.192 173.987 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -141.48 155.89 45.8 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 119.565 1.075 . . . . 10.0 110.611 167.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . 0.419 ' CD ' HH22 ' B' ' 69' ' ' ARG . 5.8 tm-20 -79.36 -26.98 41.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.641 -1.614 . . . . 10.0 106.641 168.632 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -85.87 27.55 0.87 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.669 1.188 . . . . 10.0 111.732 -172.77 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 37.5 ptt-85 -63.72 150.41 44.5 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.208 1.003 . . . . 10.0 111.018 179.003 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -64.68 -70.61 0.22 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.781 0.433 . . . . 10.0 110.884 -177.659 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -165.83 -63.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.2 0 C-N-CA 126.01 1.724 . . . . 10.0 107.399 -175.938 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -120.92 55.29 0.64 Allowed Glycine 0 C--N 1.335 0.497 0 N-CA-C 108.804 -1.718 . . . . 10.0 108.804 -176.002 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -93.03 90.45 6.92 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 105.152 -2.166 . . . . 10.0 105.152 169.282 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 9.6 mp -65.8 -25.63 67.32 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 118.632 0.651 . . . . 10.0 110.84 -173.114 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.67 -94.11 0.58 Allowed Glycine 0 N--CA 1.436 -1.315 0 N-CA-C 107.872 -2.091 . . . . 10.0 107.872 172.845 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.2 m-20 -156.7 107.8 2.39 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.432 -0.581 . . . . 10.0 109.432 -169.621 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.2 m -89.12 122.71 40.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 CA-C-N 118.163 0.438 . . . . 10.0 110.401 -177.619 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.1 m -79.79 81.96 5.97 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 127.705 2.402 . . . . 10.0 112.55 -171.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -70.95 130.4 41.51 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 121.573 -0.704 . . . . 10.0 112.692 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -63.18 172.16 2.0 Allowed 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 125.479 1.511 . . . . 10.0 110.049 166.756 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.08 -28.85 59.32 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 124.2 1.0 . . . . 10.0 111.839 171.141 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 36' ' ' LYS . 30.5 t70 -77.4 -2.88 37.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 122.261 1.029 . . . . 10.0 111.113 175.898 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.3 2.03 87.89 Favored Glycine 0 N--CA 1.44 -1.076 0 N-CA-C 109.959 -1.256 . . . . 10.0 109.959 -173.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.24 94.9 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 108.002 -1.11 . . . . 10.0 108.002 -171.572 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.23 118.74 29.14 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 166.76 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -78.16 117.69 19.68 Favored 'General case' 0 N--CA 1.433 -1.28 0 C-N-CA 126.005 1.722 . . . . 10.0 107.744 170.366 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 42.6 t -108.14 131.6 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.16 0 N-CA-C 106.735 -1.58 . . . . 10.0 106.735 -178.555 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.1 p -157.49 51.48 0.46 Allowed 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.394 0.678 . . . . 10.0 109.529 169.455 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -87.91 152.23 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -174.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -137.55 146.63 44.33 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.716 1.206 . . . . 10.0 109.986 -178.346 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -152.07 140.13 20.19 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 107.271 -1.381 . . . . 10.0 107.271 168.855 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 77.6 p -108.71 63.34 0.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 -174.265 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.3 p -151.97 -47.61 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 115.608 -0.724 . . . . 10.0 109.055 -177.751 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 20.9 mm -64.5 155.45 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 124.124 0.97 . . . . 10.0 110.058 172.734 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 28.8 t -150.69 147.28 27.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.717 -1.216 . . . . 10.0 107.717 168.367 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 68.2 mt -55.18 -30.61 60.25 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.995 -1.002 . . . . 10.0 109.82 167.085 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t . . . . . 0 N--CA 1.451 -0.383 0 N-CA-C 106.919 -1.511 . . . . 10.0 106.919 -179.312 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.532 0.267 0 CA-C-O 121.992 0.901 . . . . 10.0 109.576 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.295 0.0 OUTLIER -53.31 -28.26 14.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.23 -0.896 . . . . 10.0 113.218 -168.569 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.9 mm -27.13 -55.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 127.221 2.208 . . . . 10.0 114.045 173.776 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -83.67 4.69 81.39 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-O 118.493 -1.17 . . . . 10.0 115.08 -169.726 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 mmt180 -87.6 160.47 18.17 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.663 1.231 . . . . 10.0 111.95 -177.827 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 19.3 m -92.96 130.48 38.53 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 169.007 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -97.64 138.46 35.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 169.773 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 83.1 t -129.81 135.35 61.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 107.748 -1.204 . . . . 10.0 107.748 -177.336 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -103.05 145.99 11.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 123.897 0.879 . . . . 10.0 108.644 168.419 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 2.7 m170 -123.89 160.38 27.62 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 116.329 1.974 . . . . 10.0 116.329 -173.717 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.6 tt0 -43.07 -56.57 3.3 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.692 3.197 . . . . 10.0 111.918 172.827 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 76.0 mttt -117.3 170.02 9.02 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 123.599 0.76 . . . . 10.0 112.397 -169.29 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.9 149.7 47.54 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 114.003 -1.453 . . . . 10.0 109.458 173.701 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.497 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.2 m-20 -80.58 146.21 31.35 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 123.881 0.872 . . . . 10.0 111.773 173.66 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -76.26 -27.97 56.9 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 124.235 0.959 . . . . 10.0 109.5 168.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 72.4 mt 62.04 53.01 3.1 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 123.058 1.408 . . . . 10.0 108.925 -174.923 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.28 -43.23 2.54 Favored Glycine 0 N--CA 1.445 -0.764 0 CA-C-N 112.561 -2.109 . . . . 10.0 110.637 173.581 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.1 mtmm -81.38 44.74 0.81 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.919 0.888 . . . . 10.0 112.392 -169.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.15 -22.7 14.44 Favored Glycine 0 CA--C 1.523 0.568 0 C-N-CA 125.921 1.724 . . . . 10.0 110.903 169.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.77 34.43 89.92 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 110.996 -0.841 . . . . 10.0 110.996 175.845 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -138.27 168.53 19.55 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.883 -1.525 . . . . 10.0 106.883 169.397 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.11 -48.53 73.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 116.038 -0.528 . . . . 10.0 109.865 -176.199 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -68.02 -26.4 65.87 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.006 -1.059 . . . . 10.0 110.935 178.977 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.0 p -56.92 -44.53 82.54 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 120.996 1.725 . . . . 10.0 110.544 171.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -83.92 -10.78 57.71 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.85 -0.595 . . . . 10.0 112.1 -173.75 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -103.33 -51.72 3.17 Favored 'General case' 0 N--CA 1.441 -0.905 0 C-N-CA 126.038 1.735 . . . . 10.0 112.319 -178.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.2 p -139.29 31.17 2.15 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.557 1.071 . . . . 10.0 112.461 176.045 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 58.23 25.87 57.98 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 118.723 0.692 . . . . 10.0 112.719 175.456 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 52.96 24.89 3.63 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 117.59 0.695 . . . . 10.0 112.585 -176.724 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.13 -4.26 9.67 Favored 'General case' 0 C--N 1.342 0.276 0 O-C-N 121.12 -0.988 . . . . 10.0 113.014 -173.32 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.03 -158.93 41.05 Favored Glycine 0 N--CA 1.446 -0.69 0 O-C-N 121.027 -1.045 . . . . 10.0 111.187 167.249 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 m -58.49 125.73 24.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.463 0.705 . . . . 10.0 111.767 -167.83 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -58.74 68.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.955 2.102 . . . . 10.0 111.864 172.048 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.7 mt -50.59 -36.93 37.26 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.898 -1.127 . . . . 10.0 113.714 -174.469 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -163.11 157.53 20.76 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 -170.823 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 23.6 p -161.76 168.29 23.47 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.96 -0.385 . . . . 10.0 109.96 -174.637 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.5 155.37 26.46 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.312 -1.515 . . . . 10.0 109.312 -176.44 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -107.94 131.25 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 105.776 -1.935 . . . . 10.0 105.776 -177.507 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 16.0 mt -79.48 165.95 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 118.818 0.736 . . . . 10.0 110.615 -179.782 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -169.13 170.92 42.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 127.875 2.655 . . . . 10.0 107.097 -177.065 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 20.3 mt -84.8 140.67 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 124.481 1.112 . . . . 10.0 110.1 -168.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -102.57 -114.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.903 -1.147 . . . . 10.0 107.903 167.44 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.252 1.227 0 C-N-CA 131.077 3.751 . . . . 10.0 106.136 172.297 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.799 0 CA-C-O 118.571 -0.728 . . . . 10.0 109.794 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 60.4 p -96.21 -63.89 1.1 Allowed 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 124.555 1.142 . . . . 10.0 110.001 -169.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -135.63 135.4 40.16 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 126.724 2.01 . . . . 10.0 107.857 -169.547 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -133.59 166.99 21.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.752 1.221 . . . . 10.0 110.119 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.73 162.12 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 125.803 1.641 . . . . 10.0 109.317 -179.015 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -149.89 90.72 1.71 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 106.204 -1.776 . . . . 10.0 106.204 166.631 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.7 m -77.37 118.97 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 170.915 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.6 mt -97.85 147.73 24.13 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 -178.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.06 162.56 17.95 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 168.994 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.43 -58.33 0.05 OUTLIER Glycine 0 C--O 1.227 -0.291 0 C-N-CA 121.09 -0.576 . . . . 10.0 112.057 169.861 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -72.98 -46.46 52.15 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.9 -69.81 0.51 Allowed Glycine 0 CA--C 1.527 0.796 0 CA-C-N 114.313 -1.312 . . . . 10.0 110.089 174.099 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -75.82 37.45 0.52 Allowed 'Trans proline' 0 CA--C 1.536 0.614 1 C-N-CA 125.69 4.26 . . . . 10.0 111.944 -179.884 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.8 t -149.01 100.38 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 C-N-CA 131.454 3.902 . . . . 10.0 100.537 178.603 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.72 116.04 22.39 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 106.032 -1.84 . . . . 10.0 106.032 -174.181 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -95.81 142.71 16.25 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 174.766 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.456 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 6.3 mt -135.14 86.02 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.721 -1.214 . . . . 10.0 107.721 173.795 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -97.46 142.64 13.94 Favored 'Isoleucine or valine' 0 C--N 1.339 0.118 0 C-N-CA 124.028 0.931 . . . . 10.0 110.008 178.002 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -128.88 123.1 31.82 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 127.262 2.225 . . . . 10.0 109.511 174.353 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -105.23 116.87 32.68 Favored 'General case' 0 C--O 1.23 0.074 0 C-N-CA 125.294 1.437 . . . . 10.0 108.684 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.5 ' CD ' ' HZ1' ' A' ' 23' ' ' LYS . 20.4 tt0 -105.58 134.71 48.24 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 118.666 0.666 . . . . 10.0 112.268 171.788 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 tp60 -109.71 99.36 8.54 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.672 1.989 . . . . 10.0 107.037 168.853 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.5 ' HZ1' ' CD ' ' A' ' 21' ' ' GLU . 40.5 mmtt -58.72 -64.79 0.8 Allowed 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.752 -0.462 . . . . 10.0 109.752 175.469 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -124.13 164.62 19.09 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 104.657 -2.349 . . . . 10.0 104.657 169.453 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 t -71.47 -15.74 62.33 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 108.77 -0.826 . . . . 10.0 108.77 173.665 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.82 -24.31 44.55 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.021 0.529 . . . . 10.0 110.273 173.388 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.44 141.77 23.25 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 109.887 -1.285 . . . . 10.0 109.887 -176.825 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -62.56 142.21 89.16 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 CA-C-N 119.525 1.663 . . . . 10.0 107.866 169.252 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.5 t -77.92 125.77 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -174.731 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.1 mtmm -90.87 104.94 17.47 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.658 -1.238 . . . . 10.0 107.658 178.575 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 p -94.08 93.19 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 125.908 1.683 . . . . 10.0 107.555 174.264 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.9 p90 -102.28 175.07 5.64 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 121.207 0.527 . . . . 10.0 109.982 169.153 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.75 174.8 38.34 Favored Glycine 0 N--CA 1.441 -0.983 0 N-CA-C 111.367 -0.693 . . . . 10.0 111.367 176.892 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.0 p -145.69 102.78 3.72 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.239 -1.393 . . . . 10.0 107.239 178.751 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.5 pt -78.05 174.16 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 C-N-CA 118.878 -1.129 . . . . 10.0 108.099 169.225 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -154.83 144.17 21.22 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 168.808 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.6 -37.24 2.47 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-N 118.695 0.679 . . . . 10.0 113.957 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.1 mp -68.8 177.86 2.38 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.968 0.89 . . . . 10.0 112.651 -167.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.8 t -100.41 156.8 17.06 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.866 -0.606 . . . . 10.0 109.384 171.168 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -52.42 147.11 8.56 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.944 1.298 . . . . 10.0 112.191 -169.526 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.0 -172.12 17.68 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.124 0.869 . . . . 10.0 111.448 171.407 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -72.71 148.5 44.64 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.069 1.348 . . . . 10.0 110.855 -177.774 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -147.38 143.66 28.14 Favored 'General case' 0 C--N 1.338 0.067 0 C-N-CA 124.115 0.966 . . . . 10.0 112.314 -179.439 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -23.28 124.49 0.02 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.347 2.403 . . . . 10.0 114.062 165.301 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 20.1 t80 -149.25 106.5 3.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 119.286 1.543 . . . . 10.0 109.848 168.671 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.49 172.37 14.59 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.317 0.579 . . . . 10.0 111.04 174.102 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.4 p -112.82 120.93 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 CA-C-N 112.86 -1.973 . . . . 10.0 107.502 168.676 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -89.41 151.61 21.94 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.873 1.669 . . . . 10.0 108.223 -179.37 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -64.76 -57.01 10.08 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 114.798 -1.092 . . . . 10.0 110.473 -173.098 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -76.62 124.46 27.67 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.227 -1.397 . . . . 10.0 107.227 -173.403 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.07 -2.41 77.99 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.426 -0.652 . . . . 10.0 112.136 178.047 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -43.98 131.0 5.88 Favored 'General case' 0 C--N 1.344 0.343 0 CA-C-O 122.8 1.286 . . . . 10.0 112.525 175.289 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -138.43 3.19 2.32 Favored 'General case' 0 N--CA 1.434 -1.232 0 CA-C-N 112.676 -2.056 . . . . 10.0 109.519 163.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -53.5 -40.09 65.12 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 125.063 1.345 . . . . 10.0 108.605 168.566 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.8 -15.12 59.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 116.041 -0.527 . . . . 10.0 111.976 178.223 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.75 75.5 0.99 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 109.092 -1.603 . . . . 10.0 109.092 -173.384 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t 38.78 48.87 1.41 Allowed 'General case' 0 C--O 1.231 0.105 0 C-N-CA 125.554 1.542 . . . . 10.0 114.448 177.311 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.4 m -127.76 -53.5 1.33 Allowed 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.996 -1.483 . . . . 10.0 106.996 -172.745 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.3 m -90.22 16.95 7.67 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.129 0.422 . . . . 10.0 111.527 173.758 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.56 -19.77 58.38 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.21 1.004 . . . . 10.0 111.032 169.379 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.3 135.85 7.98 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-O 119.017 -0.88 . . . . 10.0 111.232 168.578 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -73.39 66.04 4.5 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 123.244 2.63 . . . . 10.0 110.77 173.474 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.403 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 28.8 m170 71.81 -34.16 0.29 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 128.41 2.684 . . . . 10.0 112.664 175.385 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 43.42 25.9 0.09 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 128.308 2.643 . . . . 10.0 116.374 171.625 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -59.06 134.33 87.59 Favored Pre-proline 0 CA--C 1.534 0.354 0 N-CA-C 114.464 1.283 . . . . 10.0 114.464 -169.945 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -60.95 -37.49 76.47 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.565 2.177 . . . . 10.0 110.042 175.901 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 66.0 mt -63.05 2.8 0.29 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.748 1.219 . . . . 10.0 113.776 175.761 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 12.4 m 26.84 54.22 0.05 OUTLIER 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 128.293 2.637 . . . . 10.0 114.982 175.738 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtt85 -99.29 -179.15 4.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.572 1.149 . . . . 10.0 110.752 -172.983 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt -112.54 92.52 4.05 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.046 -0.724 . . . . 10.0 109.046 -174.643 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -5.88 97.16 0.01 OUTLIER 'General case' 0 C--O 1.223 -0.318 0 C-N-CA 128.255 2.622 . . . . 10.0 113.937 -176.916 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.41 -134.04 7.81 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.897 -1.681 . . . . 10.0 108.897 178.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.49 -170.33 40.43 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 106.915 -2.474 . . . . 10.0 106.915 171.498 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -63.59 -4.64 7.26 Favored 'Trans proline' 0 N--CA 1.455 -0.794 0 CA-C-N 119.867 1.834 . . . . 10.0 110.929 168.276 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -88.65 -24.06 22.88 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.313 1.045 . . . . 10.0 110.536 174.069 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.8 178.41 4.29 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 108.246 -1.02 . . . . 10.0 108.246 -178.262 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -92.81 -26.81 17.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 167.088 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.1 mm-40 -87.06 28.79 0.88 Allowed 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.391 -1.443 . . . . 10.0 112.436 -169.641 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.5 133.62 53.48 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.67 -1.233 . . . . 10.0 107.67 169.345 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.9 m170 -64.58 -57.92 7.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.823 -0.548 . . . . 10.0 112.007 -175.378 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.8 p -170.97 -43.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 C-N-CA 124.461 1.104 . . . . 10.0 109.065 -172.375 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -150.43 56.44 0.46 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 109.759 -1.336 . . . . 10.0 109.759 178.385 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -92.76 92.15 7.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 172.256 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.29 -36.69 63.78 Favored 'General case' 0 N--CA 1.461 0.1 0 N-CA-C 107.648 -1.242 . . . . 10.0 107.648 177.067 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.34 -98.66 1.23 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 110.833 -0.907 . . . . 10.0 110.833 167.859 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.3 m-80 -123.73 132.3 53.79 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.855 0.862 . . . . 10.0 111.274 -168.365 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.0 m -114.68 129.92 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 123.771 0.828 . . . . 10.0 109.14 168.072 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 28.2 m -86.81 104.09 15.85 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 127.651 2.381 . . . . 10.0 110.572 -174.857 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.03 33.49 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 122.825 0.45 . . . . 10.0 110.544 174.776 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -66.76 175.23 2.49 Favored 'General case' 0 CA--C 1.528 0.103 0 O-C-N 123.633 0.583 . . . . 10.0 109.728 167.661 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.13 -29.48 13.56 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.585 1.554 . . . . 10.0 111.746 172.38 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -79.42 -4.5 51.39 Favored 'General case' 0 N--CA 1.453 -0.301 0 O-C-N 123.226 0.329 . . . . 10.0 110.229 -177.779 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.8 9.28 86.94 Favored Glycine 0 C--N 1.337 0.635 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 -178.377 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 50.9 t -90.82 107.65 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.277 0 C-N-CA 126.149 1.78 . . . . 10.0 106.356 179.619 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.85 118.52 37.02 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.579 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -79.24 112.2 16.23 Favored 'General case' 0 N--CA 1.434 -1.239 0 C-N-CA 125.927 1.691 . . . . 10.0 108.541 171.127 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.82 133.23 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.234 -1.765 . . . . 10.0 106.234 176.337 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -157.63 60.69 0.48 Allowed 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.861 -0.422 . . . . 10.0 109.861 -178.398 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 44.0 mt -115.46 154.69 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 107.97 -1.122 . . . . 10.0 107.97 -169.696 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -127.87 145.51 50.92 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.338 -0.615 . . . . 10.0 109.338 167.512 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -145.29 154.73 42.66 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 -178.752 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.4 p -108.32 -9.35 15.49 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 128.145 2.578 . . . . 10.0 112.28 -174.28 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.6 p -79.6 -36.98 18.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.147 0 N-CA-C 107.602 -1.259 . . . . 10.0 107.602 -174.87 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.309 0.0 OUTLIER -79.51 150.24 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 124.714 1.206 . . . . 10.0 113.026 172.676 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.6 m -157.28 133.56 9.7 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.089 0.956 . . . . 10.0 108.47 179.616 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -75.54 52.87 0.66 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.223 2.209 . . . . 10.0 108.394 175.13 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.2 t -88.38 -157.04 0.4 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.472 1.909 . . . . 10.0 110.204 -169.803 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.0 -53.65 0.13 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 128.177 2.799 . . . . 10.0 107.429 -178.302 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -64.99 -60.16 3.36 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.227 -0.657 . . . . 10.0 109.227 171.203 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -77.94 -28.35 49.54 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 115.903 -0.589 . . . . 10.0 110.228 -175.259 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t 13.32 78.63 0.01 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 128.3 2.64 . . . . 10.0 113.672 175.776 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -65.53 -16.19 19.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 112.04 0.385 . . . . 10.0 112.04 176.328 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 49.2 mm -46.39 137.64 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 C-N-CA 123.832 0.853 . . . . 10.0 110.318 169.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.08 -1.97 88.18 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.153 -1.36 . . . . 10.0 115.286 174.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.9 mtp85 -77.05 168.14 20.6 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.019 1.41 . . . . 10.0 107.364 169.122 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -106.6 120.86 43.07 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.48 0.582 . . . . 10.0 111.752 -174.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -77.22 145.72 37.42 Favored 'General case' 0 CA--C 1.517 -0.294 0 N-CA-C 108.337 -0.986 . . . . 10.0 108.337 168.698 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 86.8 t -131.93 132.49 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.899 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.145 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -104.48 134.8 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 N-CA-C 106.268 -1.753 . . . . 10.0 106.268 167.831 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 8.2 m-70 -112.67 156.95 21.88 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 115.794 1.776 . . . . 10.0 115.794 -170.906 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -43.25 -55.3 4.07 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.68 2.792 . . . . 10.0 112.155 171.597 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -115.55 162.8 16.69 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.784 0.834 . . . . 10.0 111.543 -169.675 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.87 153.86 42.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.877 -1.056 . . . . 10.0 109.129 170.103 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -93.51 144.41 25.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 C-N-CA 123.814 0.845 . . . . 10.0 110.75 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -76.7 -16.12 59.6 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-N 114.387 -1.279 . . . . 10.0 110.83 168.379 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.4 mt 53.23 40.57 31.48 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.178 0.991 . . . . 10.0 110.247 -172.953 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.77 -47.97 0.98 Allowed Glycine 0 C--N 1.337 0.59 0 C-N-CA 125.122 1.344 . . . . 10.0 111.023 169.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.42 51.97 1.75 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 122.035 -0.685 . . . . 10.0 112.466 -169.831 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.43 -38.62 5.85 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 124.786 1.184 . . . . 10.0 110.351 169.914 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.43 31.33 78.51 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 -169.451 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -114.21 157.42 22.7 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 106.067 -1.827 . . . . 10.0 106.067 169.236 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.414 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 4.8 tm-20 -51.75 -44.87 63.49 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.875 -1.057 . . . . 10.0 109.062 174.13 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -65.44 -34.08 77.44 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.162 0.985 . . . . 10.0 112.452 173.937 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 54.3 p -57.73 -35.99 71.45 Favored 'General case' 0 N--CA 1.448 -0.571 0 O-C-N 120.244 -1.535 . . . . 10.0 111.781 -175.953 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -84.65 -1.11 55.61 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 118.855 -0.593 . . . . 10.0 112.163 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 94.1 mttt -114.05 -56.13 2.43 Favored 'General case' 0 C--N 1.342 0.261 0 C-N-CA 124.628 1.171 . . . . 10.0 111.315 -176.523 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.403 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 2.8 p -120.17 -5.54 9.96 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.888 0.767 . . . . 10.0 113.061 175.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.03 33.65 Favored Glycine 0 C--N 1.342 0.889 0 CA-C-O 119.252 -0.749 . . . . 10.0 112.175 -177.465 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 62.12 23.79 14.09 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 118.317 1.059 . . . . 10.0 111.597 -177.694 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.27 -11.78 24.28 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 125.656 1.583 . . . . 10.0 112.013 -177.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.88 -157.28 48.61 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 172.926 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.2 m -61.39 133.93 56.35 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.875 0.87 . . . . 10.0 113.121 -167.495 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -66.25 71.39 0.07 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.968 1.307 . . . . 10.0 110.017 169.596 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.6 mt -55.85 -33.56 64.64 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 112.742 0.645 . . . . 10.0 112.742 -177.435 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.19 146.35 15.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.473 -0.566 . . . . 10.0 109.473 -175.749 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 18.1 m -148.51 161.25 42.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -169.855 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.07 -174.96 17.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.504 -0.639 . . . . 10.0 111.504 178.419 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 49.8 t -127.05 133.75 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 104.825 -2.287 . . . . 10.0 104.825 175.755 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 22.1 mt -69.37 117.46 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 108.903 -0.777 . . . . 10.0 108.903 177.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.83 141.86 16.7 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 110.611 -0.996 . . . . 10.0 110.611 -179.72 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.17 132.7 32.97 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 CA-C-N 119.353 1.577 . . . . 10.0 108.942 175.31 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.61 -26.27 50.5 Favored 'General case' 0 C--O 1.223 -0.342 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 167.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.253 1.278 0 C-N-CA 126.187 1.795 . . . . 10.0 109.318 169.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.706 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -150.76 -60.48 0.18 Allowed 'General case' 0 C--O 1.232 0.139 0 N-CA-C 108.958 -0.756 . . . . 10.0 108.958 176.135 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 57.0 tttp -117.18 135.4 53.8 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 126.888 2.075 . . . . 10.0 106.852 174.904 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.85 161.7 34.88 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 125.253 1.421 . . . . 10.0 110.75 178.543 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 m -128.4 178.1 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 124.837 1.255 . . . . 10.0 110.042 -176.218 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -162.27 97.28 1.0 Allowed 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 125.368 1.467 . . . . 10.0 107.634 166.641 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -89.73 104.53 15.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.21 0.604 . . . . 10.0 110.818 173.765 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.7 mp -93.58 146.23 23.96 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.244 1.418 . . . . 10.0 110.176 178.195 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 2.9 tttm -162.12 164.07 28.19 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 171.206 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.68 -47.65 0.14 Allowed Glycine 0 N--CA 1.462 0.398 0 C-N-CA 119.389 -1.386 . . . . 10.0 114.102 168.796 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -72.08 -45.73 59.58 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.141 -1.429 . . . . 10.0 107.141 -177.057 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.65 -75.17 0.28 Allowed Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 114.162 -1.381 . . . . 10.0 109.932 169.125 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -55.92 -39.22 92.49 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 123.511 2.808 . . . . 10.0 110.985 173.008 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 72.6 t -59.66 112.31 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 179.643 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.04 124.33 42.32 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 168.446 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -104.67 136.92 13.35 Favored Glycine 0 C--O 1.224 -0.494 0 N-CA-C 107.794 -2.122 . . . . 10.0 107.794 169.491 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.0 mt -138.59 68.04 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -174.579 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 mm -89.05 151.89 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 N-CA-C 109.668 -0.493 . . . . 10.0 109.668 -173.503 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.24 143.89 48.04 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 126.617 1.967 . . . . 10.0 108.111 175.194 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -129.05 130.91 47.16 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 104.411 -2.44 . . . . 10.0 104.411 168.273 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -128.62 150.48 50.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 119.796 1.18 . . . . 10.0 110.402 172.375 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.58 97.59 5.12 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 178.392 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.515 -0.375 0 C-N-CA 123.978 0.911 . . . . 10.0 110.053 170.482 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.569 0 N-CA-C 109.397 -1.481 . . . . 10.0 109.397 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.27 129.94 24.12 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.808 2.338 . . . . 10.0 109.456 -177.499 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.1 t -79.87 111.52 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 N-CA-C 104.918 -2.253 . . . . 10.0 104.918 172.469 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -82.65 126.54 32.44 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 169.204 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -100.5 109.38 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 C-N-CA 126.37 1.868 . . . . 10.0 106.703 172.826 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.9 p90 -130.38 156.63 44.4 Favored 'General case' 0 C--O 1.226 -0.177 0 N-CA-C 113.504 0.927 . . . . 10.0 113.504 -179.729 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.65 -152.24 24.12 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 106.824 -2.511 . . . . 10.0 106.824 172.924 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 21.2 p -156.38 165.93 34.89 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 119.584 -0.846 . . . . 10.0 110.412 174.335 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 pt -107.01 179.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-N 114.344 -1.298 . . . . 10.0 109.424 165.366 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.19 163.17 40.54 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 124.689 1.196 . . . . 10.0 108.407 162.921 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.21 -17.12 44.69 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-O 119.315 -0.714 . . . . 10.0 113.155 172.626 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.4 mp -71.7 178.61 3.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.005 0.902 . . . . 10.0 110.194 173.708 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -97.4 170.45 9.05 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 166.408 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -60.03 170.69 1.15 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.203 1.001 . . . . 10.0 112.111 -171.341 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.95 -174.61 32.99 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 124.201 0.905 . . . . 10.0 112.08 168.461 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.24 146.78 50.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 123.834 0.854 . . . . 10.0 109.581 176.164 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -147.17 144.94 29.32 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 123.493 0.717 . . . . 10.0 111.703 178.558 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . 0.401 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -34.79 120.5 0.39 Allowed Glycine 0 C--N 1.339 0.74 0 C-N-CA 127.738 2.59 . . . . 10.0 112.626 167.371 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.69 110.47 5.14 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-N 119.456 1.628 . . . . 10.0 109.458 168.306 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.534 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.1 OUTLIER -146.57 170.65 16.46 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-O 121.718 0.771 . . . . 10.0 111.802 176.496 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.16 129.09 46.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 CA-C-N 111.146 -2.752 . . . . 10.0 105.647 168.193 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 41.5 m-70 -105.78 146.59 29.65 Favored 'General case' 0 CA--C 1.509 -0.611 0 N-CA-C 107.675 -1.231 . . . . 10.0 107.675 174.382 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 23.8 tp10 -66.64 -59.04 3.96 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.544 -1.207 . . . . 10.0 108.98 -172.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 22.2 m-30 -77.1 106.88 9.09 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 -175.222 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.68 42.8 1.31 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 124.592 1.091 . . . . 10.0 111.448 174.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.32 131.76 41.07 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 124.975 1.31 . . . . 10.0 108.241 177.057 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -122.8 1.43 9.36 Favored 'General case' 0 N--CA 1.444 -0.755 0 C-N-CA 124.714 1.205 . . . . 10.0 110.28 168.968 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.456 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.18 -36.53 70.93 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.773 1.17 . . . . 10.0 108.792 178.194 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.38 -17.88 55.83 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.53 1.132 . . . . 10.0 112.965 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 77.61 0.77 Allowed Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.272 -0.731 . . . . 10.0 111.272 -178.273 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 34.8 m 50.96 34.36 10.46 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 124.754 1.222 . . . . 10.0 112.614 172.501 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 6.3 m -127.75 -57.43 1.26 Allowed 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -169.958 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 11.8 t -92.14 21.22 5.24 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 111.896 0.332 . . . . 10.0 111.896 179.166 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -68.1 -7.26 28.09 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.615 0.766 . . . . 10.0 111.949 176.285 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.47 127.66 2.19 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 109.704 -1.358 . . . . 10.0 109.704 174.132 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -74.81 65.42 5.88 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.517 2.811 . . . . 10.0 111.523 178.437 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.2 m170 59.98 55.83 3.64 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 128.382 2.673 . . . . 10.0 109.94 177.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -70.51 63.7 0.27 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.553 0.741 . . . . 10.0 112.393 -178.041 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -67.48 147.45 98.78 Favored Pre-proline 0 CA--C 1.532 0.27 0 O-C-N 121.642 -0.661 . . . . 10.0 110.858 -175.559 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -63.11 -49.44 4.88 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.245 1.963 . . . . 10.0 110.2 179.308 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.6 tt -81.41 59.64 4.12 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.358 0.663 . . . . 10.0 109.348 -177.852 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.0 t -14.96 97.31 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 128.411 2.684 . . . . 10.0 112.886 -176.806 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.59 168.58 10.88 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.423 1.089 . . . . 10.0 108.725 -175.807 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -108.24 105.91 15.84 Favored 'General case' 0 C--O 1.224 -0.26 0 N-CA-C 108.457 -0.942 . . . . 10.0 108.457 175.508 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 56.3 t60 -9.99 96.51 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 127.213 2.205 . . . . 10.0 115.482 -177.769 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.78 -141.1 10.37 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 173.658 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.03 -161.09 27.09 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 108.79 -1.724 . . . . 10.0 108.79 171.091 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -66.59 5.97 0.64 Allowed 'Trans proline' 0 N--CA 1.456 -0.704 0 CA-C-N 120.417 2.109 . . . . 10.0 111.889 174.106 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -103.56 -15.21 15.9 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 117.596 -1.193 . . . . 10.0 110.994 172.887 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -131.36 162.25 30.53 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 119.164 0.893 . . . . 10.0 108.925 -167.855 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -78.61 -33.07 47.7 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.231 -1.396 . . . . 10.0 107.231 176.361 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -82.25 26.46 0.54 Allowed 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 125.431 1.493 . . . . 10.0 112.528 -167.108 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 36.2 ptt85 -64.58 134.35 54.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.304 -0.998 . . . . 10.0 108.304 173.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.5 m80 -58.86 -50.74 72.87 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 121.012 0.434 . . . . 10.0 111.088 -178.699 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 p -172.37 -105.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 104.06 -2.571 . . . . 10.0 104.06 177.864 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -77.54 57.36 3.78 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.864 0.756 . . . . 10.0 111.558 172.313 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -84.91 88.35 7.42 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 103.935 -2.616 . . . . 10.0 103.935 166.856 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 16.0 mt -71.72 -31.08 66.34 Favored 'General case' 0 N--CA 1.463 0.189 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -178.52 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.37 -102.54 2.57 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 109.82 -1.312 . . . . 10.0 109.82 167.571 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -121.05 104.11 9.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.603 1.161 . . . . 10.0 109.29 -167.201 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.1 m -94.66 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 118.725 0.693 . . . . 10.0 109.504 172.7 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 80.0 m -89.96 117.57 28.87 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 126.585 1.954 . . . . 10.0 108.908 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.82 134.6 43.55 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 124.536 1.135 . . . . 10.0 111.313 178.442 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.428 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 17.2 t70 -59.53 170.98 0.91 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 124.165 0.986 . . . . 10.0 110.811 166.769 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.428 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 28.3 mttm -52.06 -33.0 37.13 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.806 1.643 . . . . 10.0 112.453 169.183 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.45 -1.23 32.62 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-O 122.158 0.98 . . . . 10.0 111.307 176.601 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.41 0.89 84.24 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.052 -1.619 . . . . 10.0 109.052 -176.175 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.3 t -78.15 95.66 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -170.074 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.38 119.08 29.52 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 166.582 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.21 114.22 17.97 Favored 'General case' 0 N--CA 1.436 -1.163 0 C-N-CA 126.759 2.023 . . . . 10.0 108.971 171.95 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 91.8 t -98.11 131.23 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.705 -1.591 . . . . 10.0 106.705 174.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.6 p -157.76 57.69 0.49 Allowed 'General case' 0 CA--C 1.534 0.355 0 O-C-N 122.0 -0.437 . . . . 10.0 110.305 171.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.94 161.01 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 C-N-CA 124.784 1.234 . . . . 10.0 107.672 -170.892 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -130.54 146.25 52.03 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 124.625 1.17 . . . . 10.0 110.385 175.366 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 58.8 t0 -144.52 154.77 43.24 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.276 -1.009 . . . . 10.0 108.276 175.679 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 33.4 p -134.22 2.87 3.35 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 126.64 1.976 . . . . 10.0 112.544 -179.542 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.8 p -79.3 -31.84 14.62 Favored 'Isoleucine or valine' 0 C--N 1.343 0.324 0 CA-C-N 120.017 1.28 . . . . 10.0 107.891 169.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.273 0.7 OUTLIER -82.56 174.08 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 124.156 0.983 . . . . 10.0 111.556 169.423 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 31.1 m -158.7 143.56 16.07 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 105.423 -2.066 . . . . 10.0 105.423 172.084 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 mt -75.5 -10.37 59.39 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.943 0.497 . . . . 10.0 112.335 -172.272 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 75.7 m . . . . . 0 N--CA 1.451 -0.414 0 C-N-CA 126.257 1.823 . . . . 10.0 106.43 173.242 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.0 t . . . . . 0 N--CA 1.453 -0.304 0 CA-C-O 121.444 0.64 . . . . 10.0 112.636 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.96 -7.61 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 112.802 0.667 . . . . 10.0 112.802 -176.704 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 41.0 mm -45.92 125.0 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 O-C-N 121.55 -0.719 . . . . 10.0 110.1 171.81 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.4 2.03 77.34 Favored Glycine 0 CA--C 1.527 0.81 0 CA-C-O 118.735 -1.036 . . . . 10.0 113.637 178.862 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -76.2 178.92 6.06 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 106.007 -1.849 . . . . 10.0 106.007 166.75 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -124.59 129.72 51.1 Favored 'General case' 0 CA--C 1.514 -0.438 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 -174.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 7.8 mp -96.97 139.72 32.57 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 171.37 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.4 t -123.17 129.8 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 O-C-N 124.605 1.191 . . . . 10.0 108.303 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.6 p -93.03 131.41 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.47 -1.308 . . . . 10.0 107.47 167.618 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . 0.401 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.5 m170 -111.72 158.33 19.45 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.448 1.277 . . . . 10.0 114.448 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . 0.49 ' CD ' ' HZ1' ' B' ' 122' ' ' LYS . 2.3 tm-20 -56.6 -54.81 41.68 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 125.15 1.38 . . . . 10.0 110.98 178.757 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.49 ' HZ1' ' CD ' ' B' ' 121' ' ' GLU . 43.7 mttm -109.44 176.11 5.2 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 118.686 0.676 . . . . 10.0 110.136 177.268 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.17 140.74 29.18 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.058 1.343 . . . . 10.0 108.515 176.781 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.534 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -76.69 152.63 35.66 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 123.297 0.639 . . . . 10.0 111.943 -177.362 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 51.2 m-20 -76.38 6.2 5.99 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 127.115 2.166 . . . . 10.0 111.491 178.899 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.7 mt 42.12 40.11 1.58 Allowed 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.369 1.868 . . . . 10.0 111.194 -173.137 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.24 -33.52 5.94 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-O 119.509 -0.606 . . . . 10.0 112.639 168.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 3.3 mppt? -80.42 40.84 0.51 Allowed 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 117.597 0.699 . . . . 10.0 110.974 -176.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . 0.431 ' HA3' ' CB ' ' B' ' 134' ' ' SER . . . -88.97 -30.22 15.31 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 124.806 1.193 . . . . 10.0 112.616 -173.317 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 94.63 6.95 60.57 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.793 -1.004 . . . . 10.0 114.751 170.391 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -141.39 175.47 9.64 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 119.844 1.822 . . . . 10.0 106.726 169.036 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -51.19 -58.52 5.93 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.742 1.217 . . . . 10.0 109.279 178.208 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -49.94 -52.47 33.11 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 123.109 1.433 . . . . 10.0 110.562 176.505 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 134' ' ' SER . . . . . 0.431 ' CB ' ' HA3' ' B' ' 129' ' ' GLY . 0.2 OUTLIER -62.23 -4.8 1.93 Allowed 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 127.497 2.319 . . . . 10.0 113.27 179.979 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.24 15.01 6.72 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.731 0.813 . . . . 10.0 110.703 172.808 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmmm -122.22 -62.52 1.38 Allowed 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.727 2.011 . . . . 10.0 109.432 -178.56 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -113.71 16.1 18.64 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 119.513 1.052 . . . . 10.0 110.487 167.207 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.96 20.73 70.98 Favored Glycine 0 C--O 1.22 -0.764 0 C-N-CA 124.088 0.851 . . . . 10.0 113.2 168.81 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . 0.4 ' ND2' ' HG ' ' B' ' 134' ' ' SER . 0.3 OUTLIER 60.03 24.74 13.94 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.327 1.064 . . . . 10.0 112.63 -179.76 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.74 -13.8 17.24 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.736 -0.603 . . . . 10.0 110.967 169.843 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.38 -158.87 42.23 Favored Glycine 0 N--CA 1.439 -1.11 0 N-CA-C 109.268 -1.533 . . . . 10.0 109.268 169.553 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -49.43 121.29 4.88 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 124.808 1.243 . . . . 10.0 112.635 -168.881 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 72.68 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.96 1.704 . . . . 10.0 108.983 169.232 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 52.8 mt -47.1 -41.27 16.97 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 124.317 1.047 . . . . 10.0 112.139 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.57 156.48 25.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 108.516 -0.92 . . . . 10.0 108.516 -171.351 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.8 p -162.33 168.78 21.68 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 108.897 -0.779 . . . . 10.0 108.897 -176.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.82 -175.18 17.75 Favored Glycine 0 N--CA 1.461 0.318 0 N-CA-C 111.229 -0.748 . . . . 10.0 111.229 -176.408 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 53.2 t -118.29 139.71 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 101.52 -3.511 . . . . 10.0 101.52 168.275 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 50.5 mt -59.32 -83.93 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 118.436 0.562 . . . . 10.0 110.33 -171.541 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.2 147.18 20.29 Favored Glycine 0 CA--C 1.52 0.363 0 O-C-N 121.724 -0.61 . . . . 10.0 112.65 178.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pt -73.6 154.31 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.393 -1.706 . . . . 10.0 106.393 168.15 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -52.91 6.43 Favored 'General case' 0 CA--C 1.512 -0.487 0 N-CA-C 106.078 -1.823 . . . . 10.0 106.078 169.748 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.252 1.187 0 O-C-N 126.328 2.268 . . . . 10.0 107.966 168.798 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.725 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.0 t -171.41 -43.43 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 124.468 1.107 . . . . 10.0 109.622 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -104.57 147.0 28.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 125.769 1.628 . . . . 10.0 107.639 171.006 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.0 157.96 37.05 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 168.543 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.5 m -130.16 177.61 6.47 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-O 121.642 0.734 . . . . 10.0 110.447 177.619 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.81 121.3 4.03 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 103.462 -2.792 . . . . 10.0 103.462 166.932 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.97 111.55 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 178.119 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.17 142.3 28.51 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 -171.164 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 mtpt -144.57 162.13 37.39 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 169.995 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.43 -65.75 0.02 OUTLIER Glycine 0 C--O 1.229 -0.198 0 CA-C-N 115.403 -0.817 . . . . 10.0 111.501 171.281 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.44 -45.45 46.33 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 106.597 -1.631 . . . . 10.0 106.597 -173.468 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.29 -65.46 0.59 Allowed Glycine 0 N--CA 1.444 -0.79 0 CA-C-N 113.431 -1.713 . . . . 10.0 110.866 -175.719 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -54.36 -38.97 89.17 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.579 2.186 . . . . 10.0 111.367 173.101 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.4 t -66.87 101.31 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.043 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 172.059 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -118.66 101.9 8.46 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.189 1.396 . . . . 10.0 107.709 171.278 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.89 148.36 24.55 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 125.13 1.348 . . . . 10.0 111.888 174.865 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -155.45 93.22 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 126.023 1.729 . . . . 10.0 106.463 -168.876 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.0 mm -86.49 151.18 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 C-N-CA 125.113 1.365 . . . . 10.0 109.767 179.045 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.1 m-80 -143.58 59.79 1.39 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.821 0.282 . . . . 10.0 111.725 179.402 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -47.68 120.91 3.63 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 117.559 -1.21 . . . . 10.0 109.417 -175.519 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -111.69 124.53 52.51 Favored 'General case' 0 C--O 1.233 0.2 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 176.506 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.2 tp60 -125.43 85.44 2.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.777 1.231 . . . . 10.0 109.055 172.058 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.15 -43.74 7.24 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 127.007 2.123 . . . . 10.0 112.309 -179.254 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -153.5 173.67 15.41 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 105.95 -1.87 . . . . 10.0 105.95 169.498 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 49.2 m -66.24 -19.55 65.86 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 122.943 0.497 . . . . 10.0 110.694 175.099 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -79.11 -15.54 58.0 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.423 0.689 . . . . 10.0 110.113 175.963 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.55 156.35 33.28 Favored Glycine 0 CA--C 1.532 1.101 0 O-C-N 122.145 -0.347 . . . . 10.0 112.964 -175.14 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -75.68 144.8 28.48 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 N-CA-C 105.727 -2.451 . . . . 10.0 105.727 165.911 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.2 t -78.94 127.17 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.521 -1.659 . . . . 10.0 106.521 179.467 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 mtmt -95.93 110.9 23.03 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.942 -0.762 . . . . 10.0 108.942 172.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.0 m -85.05 56.52 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 123.888 0.875 . . . . 10.0 110.788 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -40.24 139.28 0.75 Allowed 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 124.32 1.048 . . . . 10.0 112.947 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.73 131.93 4.52 Favored Glycine 0 N--CA 1.437 -1.258 0 N-CA-C 107.382 -2.287 . . . . 10.0 107.382 168.279 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.1 m -123.68 62.03 1.06 Allowed 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 106.654 -1.61 . . . . 10.0 106.654 172.06 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 pt -78.08 116.58 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.29 -1.004 . . . . 10.0 108.29 -176.541 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -99.37 141.07 32.62 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 107.722 -1.214 . . . . 10.0 107.722 172.537 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.53 -5.86 18.87 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 124.272 0.939 . . . . 10.0 112.211 173.907 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.44 173.2 4.22 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 118.494 1.147 . . . . 10.0 110.143 176.251 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.8 t -106.26 150.36 25.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.839 -1.541 . . . . 10.0 106.839 167.957 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -48.14 147.28 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.795 1.238 . . . . 10.0 110.299 -175.747 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.57 179.8 28.14 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.391 -1.083 . . . . 10.0 110.391 176.198 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.25 153.79 35.73 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.532 1.533 . . . . 10.0 111.404 -172.014 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -145.08 141.61 28.98 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 125.001 1.32 . . . . 10.0 110.535 -179.425 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.41 124.58 7.93 Favored Glycine 0 C--N 1.344 1.024 0 N-CA-C 107.308 -2.317 . . . . 10.0 107.308 166.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 57.4 t80 -145.7 118.72 8.79 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 118.851 1.326 . . . . 10.0 109.112 171.989 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -159.22 171.76 19.28 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.287 0.565 . . . . 10.0 110.103 -174.817 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -91.46 148.79 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 CA-C-N 112.757 -2.019 . . . . 10.0 106.972 168.027 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 62.1 m-70 -120.12 139.96 51.79 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.17 -1.789 . . . . 10.0 106.17 173.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -47.08 -57.35 5.16 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 124.609 1.193 . . . . 10.0 111.461 -171.872 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.38 136.76 33.33 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 109.559 -0.534 . . . . 10.0 109.559 -177.611 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.38 -8.6 86.93 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.421 -1.072 . . . . 10.0 110.421 167.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -47.78 144.63 3.25 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.63 1.205 . . . . 10.0 109.748 169.568 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -148.38 29.43 0.86 Allowed 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 114.585 -1.188 . . . . 10.0 110.393 172.75 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.401 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -58.41 -37.05 74.55 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 122.362 0.265 . . . . 10.0 111.609 -169.142 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.17 -23.51 40.98 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.652 0.781 . . . . 10.0 113.079 173.817 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.89 111.37 1.8 Allowed Glycine 0 CA--C 1.534 1.233 0 N-CA-C 110.178 -1.169 . . . . 10.0 110.178 -169.128 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.3 m 39.35 53.63 2.28 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 127.273 2.229 . . . . 10.0 114.07 170.901 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -156.17 -54.85 0.09 Allowed 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.526 -0.916 . . . . 10.0 108.526 178.569 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 m -61.39 -30.91 70.84 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.825 0.85 . . . . 10.0 112.127 -172.835 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.77 -30.31 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 129.188 2.995 . . . . 10.0 115.463 174.739 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.8 129.16 6.01 Favored Glycine 0 CA--C 1.524 0.633 0 CA-C-O 118.227 -1.318 . . . . 10.0 110.068 169.738 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -73.91 65.92 5.0 Favored 'Trans proline' 0 CA--C 1.535 0.549 0 C-N-CA 124.21 3.273 . . . . 10.0 111.76 179.829 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 56.9 58.12 4.24 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.236 2.614 . . . . 10.0 109.395 179.925 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 42.6 m-85 -68.0 74.39 0.2 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 122.112 0.958 . . . . 10.0 111.695 -179.366 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -85.73 126.39 66.26 Favored Pre-proline 0 C--N 1.323 -0.551 0 C-N-CA 126.306 1.842 . . . . 10.0 111.18 -178.494 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -68.04 -37.6 14.55 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.986 2.457 . . . . 10.0 110.668 -177.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 79.6 mt -76.72 52.47 0.83 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.212 0.605 . . . . 10.0 109.405 171.571 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -41.13 90.34 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 127.568 2.347 . . . . 10.0 113.817 -169.675 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -116.19 -164.0 0.94 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.843 1.257 . . . . 10.0 109.151 -174.592 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -116.18 108.49 16.21 Favored 'General case' 0 C--O 1.224 -0.284 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 -174.699 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.2 t60 -16.27 100.49 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.436 0 C-N-CA 126.11 1.764 . . . . 10.0 113.641 -179.218 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.47 -136.22 7.48 Favored Glycine 0 N--CA 1.449 -0.498 0 N-CA-C 108.022 -2.031 . . . . 10.0 108.022 -177.453 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.445 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 176.63 -165.39 35.61 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 108.262 -1.935 . . . . 10.0 108.262 169.195 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -67.64 12.85 0.19 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 121.751 1.634 . . . . 10.0 110.838 168.775 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.445 ' H ' ' C ' ' A' ' 73' ' ' GLY . 12.8 mmtp -104.52 -19.24 14.07 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 123.883 0.873 . . . . 10.0 108.89 172.286 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -119.7 167.19 12.29 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.375 -1.343 . . . . 10.0 107.375 -172.886 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -87.5 -24.57 24.05 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 172.106 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.313 1.8 pt-20 -107.36 40.95 1.58 Allowed 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 115.882 1.808 . . . . 10.0 115.882 -166.237 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.437 ' CD ' ' H ' ' A' ' 79' ' ' ARG . 0.3 OUTLIER -46.61 145.88 1.72 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.182 -1.372 . . . . 10.0 107.973 166.634 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.6 m170 -54.31 -58.81 5.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 109.276 -0.639 . . . . 10.0 109.276 169.202 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.1 p -168.42 -55.75 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 C-N-CA 124.477 1.111 . . . . 10.0 108.379 175.188 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -127.63 55.1 0.76 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.116 -1.194 . . . . 10.0 110.116 -176.564 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -86.45 97.62 10.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.784 -1.932 . . . . 10.0 105.784 169.433 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -72.69 -39.91 66.66 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 105.265 -2.124 . . . . 10.0 105.265 171.817 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 106.59 -106.98 2.62 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 109.127 -1.589 . . . . 10.0 109.127 166.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -106.72 131.41 53.89 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.301 1.04 . . . . 10.0 110.083 -168.004 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -120.63 129.03 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.325 0.511 . . . . 10.0 109.63 168.426 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.9 t -96.93 132.73 42.41 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 124.328 1.051 . . . . 10.0 109.757 -177.218 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.4 140.09 35.14 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 122.913 0.485 . . . . 10.0 110.759 176.277 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.34 170.68 2.22 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.759 0.824 . . . . 10.0 109.487 168.236 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.27 -23.43 48.31 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 123.65 0.78 . . . . 10.0 113.1 169.689 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -77.18 -8.18 57.11 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 122.773 0.429 . . . . 10.0 111.726 173.932 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.68 18.76 67.39 Favored Glycine 0 C--N 1.34 0.781 0 N-CA-C 110.16 -1.176 . . . . 10.0 110.16 -178.895 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 36.2 t -98.89 110.26 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.627 2.371 . . . . 10.0 106.927 -179.364 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 121.82 42.58 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 119.054 0.843 . . . . 10.0 109.202 169.448 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -101.59 78.2 1.82 Allowed 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 128.427 2.691 . . . . 10.0 110.948 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.43 61.34 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 C-N-CA 124.452 1.101 . . . . 10.0 112.311 -169.228 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -90.77 55.63 3.01 Favored 'General case' 0 C--N 1.317 -0.845 0 O-C-N 121.251 -0.905 . . . . 10.0 108.726 -178.447 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.58 145.74 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 108.333 -0.988 . . . . 10.0 108.333 -174.144 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.86 139.54 35.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 126.477 1.911 . . . . 10.0 110.001 178.09 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.73 159.63 41.63 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 108.172 -1.047 . . . . 10.0 108.172 166.334 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 t -124.66 55.81 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 124.444 1.098 . . . . 10.0 109.236 176.976 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -148.66 -41.28 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 123.586 0.754 . . . . 10.0 110.854 175.84 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 49.7 mm -67.13 89.28 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 C-N-CA 124.372 1.069 . . . . 10.0 109.543 170.657 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.8 m -88.44 123.99 33.52 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.615 0.766 . . . . 10.0 109.933 172.509 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.7 mt -48.25 -55.71 9.83 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.108 0.963 . . . . 10.0 111.076 177.237 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.5 p -135.49 175.34 9.68 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 127.271 2.229 . . . . 10.0 107.826 -179.165 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 132.22 -92.55 0.28 Allowed Glycine 0 C--N 1.335 0.493 0 N-CA-C 109.114 -1.595 . . . . 10.0 109.114 176.362 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -125.03 -52.23 1.66 Allowed 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.423 1.889 . . . . 10.0 107.655 179.323 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -74.3 -37.41 63.64 Favored 'General case' 0 N--CA 1.457 -0.116 0 CA-C-N 114.717 -1.129 . . . . 10.0 108.26 -173.518 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t 44.4 65.99 0.95 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.824 1.65 . . . . 10.0 113.024 168.75 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -65.19 -19.18 25.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 113.252 0.834 . . . . 10.0 113.252 -174.161 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.0 mm -48.58 126.02 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 118.336 0.516 . . . . 10.0 109.706 172.653 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.34 1.52 55.68 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.77 -1.016 . . . . 10.0 113.779 -179.094 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.99 176.33 9.25 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 118.757 1.278 . . . . 10.0 109.984 169.179 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -113.13 140.57 47.79 Favored 'General case' 0 C--N 1.34 0.159 0 C-N-CA 124.505 1.122 . . . . 10.0 108.802 169.757 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -98.13 139.49 33.86 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.562 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.6 t -117.76 135.18 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 107.349 -1.352 . . . . 10.0 107.349 170.93 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.39 122.07 55.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 N-CA-C 106.04 -1.837 . . . . 10.0 106.04 167.579 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.2 m-70 -100.44 161.78 13.38 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.92 1.343 . . . . 10.0 114.225 -169.253 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -53.85 -68.8 0.15 Allowed 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.641 2.376 . . . . 10.0 109.107 177.31 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 57.2 mttp -106.92 168.37 9.24 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 123.476 0.71 . . . . 10.0 111.164 -178.125 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.62 142.35 58.46 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.593 1.157 . . . . 10.0 109.528 171.322 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -81.93 144.3 31.04 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.359 0.599 . . . . 10.0 109.902 168.381 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -78.43 7.8 6.07 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.079 0.951 . . . . 10.0 110.972 175.555 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 33.4 mt 49.75 45.62 24.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 124.133 0.973 . . . . 10.0 109.668 -177.835 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.38 -31.46 8.03 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 114.943 -1.026 . . . . 10.0 111.188 174.876 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mtmm -84.23 42.34 0.88 Allowed 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.746 -0.855 . . . . 10.0 110.759 -170.108 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.85 -34.67 6.43 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 126.983 2.23 . . . . 10.0 109.999 176.719 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 58.64 47.9 87.64 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 111.73 -0.548 . . . . 10.0 111.73 -174.402 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -137.49 173.34 11.77 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.1 -1.815 . . . . 10.0 106.1 169.552 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -54.69 -54.05 46.82 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 109.195 -0.669 . . . . 10.0 109.195 173.502 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -58.71 -31.38 68.2 Favored 'General case' 0 C--N 1.344 0.359 0 O-C-N 121.396 -0.815 . . . . 10.0 112.502 179.452 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.3 p -51.18 -34.88 33.54 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 119.646 1.112 . . . . 10.0 110.461 178.276 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.3 t -98.34 11.13 39.02 Favored 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 113.549 0.944 . . . . 10.0 113.549 -179.793 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 73.3 mmtt -120.36 -54.67 2.08 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 125.299 1.44 . . . . 10.0 111.153 179.617 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -131.95 9.59 4.54 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 113.388 0.884 . . . . 10.0 113.388 171.92 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.14 16.18 61.32 Favored Glycine 0 C--O 1.221 -0.707 0 CA-C-O 119.216 -0.769 . . . . 10.0 113.366 173.063 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 69.36 17.75 8.1 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.188 0.994 . . . . 10.0 112.525 -177.121 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.08 -14.42 54.47 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 123.317 0.647 . . . . 10.0 112.005 176.553 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.87 -147.04 30.25 Favored Glycine 0 N--CA 1.442 -0.937 0 N-CA-C 109.816 -1.313 . . . . 10.0 109.816 169.848 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.3 m -61.07 121.31 12.14 Favored 'General case' 0 N--CA 1.444 -0.769 0 O-C-N 122.1 -0.647 . . . . 10.0 110.764 -168.74 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -56.24 71.25 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.866 1.666 . . . . 10.0 110.711 167.335 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 11.0 tp -45.91 -41.38 11.38 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 127.181 2.192 . . . . 10.0 112.925 -171.475 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.93 155.46 31.4 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.177 -1.046 . . . . 10.0 108.177 -175.78 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.1 p -164.12 170.85 15.89 Favored 'General case' 0 N--CA 1.454 -0.253 0 O-C-N 122.01 -0.431 . . . . 10.0 110.095 -176.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -166.95 -176.69 38.14 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.705 -1.358 . . . . 10.0 109.705 -177.629 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.89 143.28 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -169.717 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 61.0 mt -73.55 137.4 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 122.784 0.434 . . . . 10.0 110.536 -176.405 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.72 141.59 12.77 Favored Glycine 0 CA--C 1.529 0.906 0 C-N-CA 125.306 1.432 . . . . 10.0 111.272 -178.537 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 42.5 mt -57.05 139.04 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 125.212 1.405 . . . . 10.0 108.603 170.943 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -136.57 156.67 48.26 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.318 0.58 . . . . 10.0 109.887 172.032 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.287 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 165.667 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.68 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -14.68 60.79 Favored 'General case' 0 CA--C 1.527 0.062 0 CA-C-N 118.857 0.753 . . . . 10.0 110.679 176.439 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 45.4 tttt -151.4 148.26 27.9 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.723 -0.473 . . . . 10.0 109.723 169.528 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.73 165.97 25.85 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.295 1.438 . . . . 10.0 107.501 169.543 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.61 164.06 35.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 123.426 0.69 . . . . 10.0 109.168 176.039 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.15 111.63 10.47 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 169.238 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.1 m -86.88 100.5 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 169.95 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.3 mt -78.83 134.37 36.97 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 123.912 0.885 . . . . 10.0 109.423 176.348 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -158.6 162.19 37.31 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 169.302 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.5 -56.85 0.05 OUTLIER Glycine 0 N--CA 1.454 -0.125 0 N-CA-C 111.485 -0.646 . . . . 10.0 111.485 171.205 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.37 -45.72 45.13 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.486 -1.672 . . . . 10.0 106.486 -170.923 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.4 -65.92 0.57 Allowed Glycine 0 CA--C 1.526 0.753 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.734 -179.141 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -58.33 -36.8 97.26 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.913 2.409 . . . . 10.0 111.236 173.685 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.7 113.57 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.378 -0.971 . . . . 10.0 108.378 175.788 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.31 126.28 31.07 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.202 -1.036 . . . . 10.0 108.202 168.581 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -120.44 140.76 14.65 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-O 119.428 -0.651 . . . . 10.0 111.696 176.582 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . 0.401 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 10.6 mt -135.37 75.24 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 -169.276 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.2 mm -92.25 139.65 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.819 -0.628 . . . . 10.0 110.023 -174.293 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -114.62 120.94 41.87 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 128.419 2.688 . . . . 10.0 108.02 -178.104 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.9 105.56 14.41 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.315 1.446 . . . . 10.0 107.576 178.838 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -100.57 150.54 22.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 118.414 0.552 . . . . 10.0 111.122 178.277 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 63.8 tp60 -142.24 102.31 4.08 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.7 2.0 . . . . 10.0 108.264 -179.057 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp . . . . . 0 N--CA 1.438 -1.069 0 C-N-CA 126.228 1.811 . . . . 10.0 110.879 -172.546 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.184 0 N-CA-C 111.943 -0.463 . . . . 10.0 111.943 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.18 154.34 61.94 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.418 2.079 . . . . 10.0 108.081 168.867 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 t -79.01 92.04 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 104.753 -2.314 . . . . 10.0 104.753 169.172 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.464 ' NZ ' ' OE1' ' B' ' 100' ' ' GLU . 35.3 tttp -77.17 104.03 7.44 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 106.832 -1.544 . . . . 10.0 106.832 169.042 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -96.42 104.41 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 C-N-CA 126.566 1.946 . . . . 10.0 106.539 -179.352 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -122.24 163.03 20.33 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 112.693 0.627 . . . . 10.0 112.693 174.278 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.66 -154.15 25.33 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 106.866 -2.494 . . . . 10.0 106.866 169.666 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -155.14 160.55 41.02 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 120.134 -0.626 . . . . 10.0 110.198 176.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pt -117.43 142.47 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.683 0 CA-C-N 114.262 -1.335 . . . . 10.0 109.557 167.475 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -117.35 149.54 40.32 Favored 'General case' 0 N--CA 1.443 -0.776 0 N-CA-C 106.864 -1.532 . . . . 10.0 106.864 168.385 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.04 -8.36 33.4 Favored Glycine 0 C--N 1.336 0.564 0 CA-C-O 119.34 -0.7 . . . . 10.0 112.731 171.395 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -62.15 175.36 0.73 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.198 0.999 . . . . 10.0 109.246 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.79 166.26 10.58 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 167.351 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -54.48 149.93 9.78 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.25 0.62 . . . . 10.0 111.469 -172.097 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.75 -168.6 31.81 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-O 121.763 0.646 . . . . 10.0 112.838 168.971 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.3 mp -75.26 144.8 42.37 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 126.824 2.05 . . . . 10.0 111.787 -169.652 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -147.85 145.08 28.57 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 113.813 1.042 . . . . 10.0 113.813 -177.322 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -28.22 128.41 0.07 OUTLIER Glycine 0 C--N 1.341 0.835 0 C-N-CA 127.284 2.373 . . . . 10.0 111.288 165.606 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -151.37 102.15 2.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 119.144 1.472 . . . . 10.0 111.675 169.861 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.452 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -150.57 170.07 20.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.764 0.653 . . . . 10.0 112.764 -179.83 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 24.2 m -97.4 -30.27 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 126.244 1.817 . . . . 10.0 113.986 -170.766 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 57.3 m-70 58.03 171.82 0.05 Allowed 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 122.905 1.336 . . . . 10.0 112.989 -177.571 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -83.25 -51.56 7.35 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 114.779 -1.101 . . . . 10.0 110.037 170.327 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -75.95 114.0 14.08 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 118.628 0.649 . . . . 10.0 109.669 -168.019 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.23 -31.71 81.75 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 107.824 -2.111 . . . . 10.0 107.824 165.792 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -58.82 161.46 4.83 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-O 123.251 1.5 . . . . 10.0 114.423 -176.551 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.14 21.68 0.08 Allowed 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 112.941 -1.936 . . . . 10.0 113.962 -168.128 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -58.31 -29.24 65.74 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 123.816 0.847 . . . . 10.0 111.75 -179.562 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.13 -15.95 59.35 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 122.909 0.484 . . . . 10.0 111.796 176.599 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.77 85.43 0.81 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 124.356 0.979 . . . . 10.0 111.049 178.521 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 65.5 m 37.6 47.53 0.8 Allowed 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 126.946 2.098 . . . . 10.0 112.146 -179.952 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -121.85 -54.89 1.92 Allowed 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 -169.659 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.0 t -128.34 54.81 1.72 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.021 0.928 . . . . 10.0 108.763 -177.472 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.02 49.97 0.45 Allowed 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 123.14 0.576 . . . . 10.0 110.399 172.149 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.0 125.92 0.13 Allowed Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.272 0.939 . . . . 10.0 111.448 172.346 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -77.46 47.39 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.86 0 C-N-CA 123.374 2.716 . . . . 10.0 112.605 179.607 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 60.76 47.79 7.64 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.931 2.492 . . . . 10.0 110.996 178.059 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -70.74 70.28 0.47 Allowed 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.886 0.85 . . . . 10.0 110.778 174.602 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -71.62 148.56 92.88 Favored Pre-proline 0 C--N 1.325 -0.467 0 C-N-CA 123.388 0.675 . . . . 10.0 112.709 -174.17 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -64.52 -46.61 6.93 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.975 2.45 . . . . 10.0 111.522 -179.722 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -78.89 48.9 0.87 Allowed 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.538 -0.726 . . . . 10.0 110.002 178.553 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 64.1 p -14.94 102.93 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 129.711 3.204 . . . . 10.0 113.466 -170.209 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 mtt85 -137.07 -179.77 5.91 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 118.612 0.642 . . . . 10.0 112.635 -170.635 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -111.79 102.09 10.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 105.753 -1.943 . . . . 10.0 105.753 -176.836 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.401 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.5 t60 -22.66 107.51 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.455 1.902 . . . . 10.0 114.185 -171.274 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.03 -149.55 8.38 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.964 -1.255 . . . . 10.0 109.964 176.652 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.96 -162.66 22.65 Favored Glycine 0 C--N 1.331 0.301 0 N-CA-C 108.51 -1.836 . . . . 10.0 108.51 -179.316 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -64.94 -6.69 13.26 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 121.367 1.378 . . . . 10.0 109.797 165.551 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 30.2 mmtt -101.89 2.43 38.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.82 1.648 . . . . 10.0 110.099 177.35 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 128' ' ' LYS . 3.7 t70 -129.32 170.98 12.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 N-CA-C 107.498 -1.297 . . . . 10.0 107.498 167.399 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -91.59 -27.17 18.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.426 -0.953 . . . . 10.0 108.426 169.186 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -102.89 39.3 1.57 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 122.831 1.301 . . . . 10.0 110.206 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.7 ptp180 -55.89 142.3 35.86 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 126.057 1.743 . . . . 10.0 108.941 169.664 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . 0.401 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.0 m170 -64.98 -56.74 11.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 O-C-N 121.855 -0.528 . . . . 10.0 110.237 -175.181 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 3.6 p -170.37 -68.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.992 -0.744 . . . . 10.0 108.992 176.908 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -118.2 67.91 0.34 Allowed Glycine 0 C--N 1.333 0.413 0 N-CA-C 107.522 -2.231 . . . . 10.0 107.522 -179.41 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -106.79 97.65 7.41 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.322 -2.473 . . . . 10.0 104.322 172.407 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 23.9 mt -82.09 22.94 0.75 Allowed 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.235 0.541 . . . . 10.0 110.56 -173.612 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.85 -104.85 2.36 Favored Glycine 0 N--CA 1.437 -1.287 0 N-CA-C 106.422 -2.671 . . . . 10.0 106.422 173.596 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -157.64 151.28 23.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.726 -1.213 . . . . 10.0 107.726 169.704 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.0 m -113.9 137.25 47.73 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 O-C-N 123.835 0.709 . . . . 10.0 109.547 -175.032 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 88.7 m -94.89 109.35 21.36 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 128.364 2.666 . . . . 10.0 108.491 -171.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.25 136.49 32.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 122.904 0.482 . . . . 10.0 110.205 174.845 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -57.56 171.51 0.44 Allowed 'General case' 0 C--O 1.235 0.298 0 O-C-N 124.079 0.862 . . . . 10.0 108.841 166.323 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 58.3 pttt -57.45 -29.04 63.87 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 123.541 0.736 . . . . 10.0 110.508 175.524 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -79.13 -0.64 32.54 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.785 0.834 . . . . 10.0 111.051 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.19 4.69 88.05 Favored Glycine 0 C--N 1.339 0.736 0 O-C-N 120.99 -1.069 . . . . 10.0 110.79 179.644 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.66 97.3 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 C-N-CA 126.128 1.771 . . . . 10.0 107.52 -178.008 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.72 118.83 37.75 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 108.367 -0.975 . . . . 10.0 108.367 169.192 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -82.15 129.13 34.74 Favored 'General case' 0 N--CA 1.437 -1.124 0 C-N-CA 126.856 2.062 . . . . 10.0 109.9 174.633 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.17 134.06 58.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 C-N-CA 125.907 1.683 . . . . 10.0 107.769 173.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 13.7 p -158.44 57.44 0.45 Allowed 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 112.804 0.668 . . . . 10.0 112.804 171.791 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.86 155.76 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.921 -0.77 . . . . 10.0 108.921 -172.075 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . 0.464 ' OE1' ' NZ ' ' B' ' 30' ' ' LYS . 1.5 pt-20 -116.47 99.25 7.05 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 126.546 1.938 . . . . 10.0 110.38 174.358 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -81.72 85.42 6.6 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.626 -1.249 . . . . 10.0 107.626 176.417 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 64.7 p -83.15 60.51 5.56 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 106.315 -1.735 . . . . 10.0 106.315 173.168 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.84 -47.77 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 O-C-N 123.356 0.41 . . . . 10.0 110.273 -170.9 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.325 0.0 OUTLIER -103.42 176.87 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 C-N-CA 123.74 0.816 . . . . 10.0 112.033 169.378 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -140.7 123.98 16.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.49 -29.57 50.51 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.358 1.463 . . . . 10.0 111.318 -179.031 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.4 m . . . . . 0 N--CA 1.452 -0.373 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 167.23 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' B' B ' 111' ' ' SER . . . . . 0.42 ' C ' ' H ' ' B' ' 113' ' ' ILE . 7.5 t . . . . . 0 N--CA 1.448 -0.529 0 CA-C-O 121.186 0.517 . . . . 10.0 111.818 . . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.95 20.17 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 124.796 1.238 . . . . 10.0 114.291 -174.477 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . 0.42 ' H ' ' C ' ' B' ' 111' ' ' SER . 17.9 mm -54.92 146.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 C-N-CA 125.538 1.535 . . . . 10.0 108.085 168.745 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.91 21.99 69.98 Favored Glycine 0 CA--C 1.533 1.169 0 CA-C-O 118.599 -1.111 . . . . 10.0 114.335 178.278 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.2 mmt180 -97.53 172.55 7.66 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 166.513 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -124.22 108.54 12.38 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.082 0.855 . . . . 10.0 111.454 -170.529 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -64.89 134.21 53.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 107.344 -1.354 . . . . 10.0 107.344 169.743 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.6 t -125.11 131.37 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 106.83 -1.544 . . . . 10.0 106.83 174.747 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.4 m -105.99 131.52 55.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 O-C-N 124.007 0.817 . . . . 10.0 110.084 169.466 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 5.3 m170 -113.04 163.5 14.62 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 114.813 1.412 . . . . 10.0 114.813 -170.583 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -51.31 -55.51 17.94 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 127.172 2.189 . . . . 10.0 109.468 -179.393 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -121.05 174.27 6.75 Favored 'General case' 0 CA--C 1.521 -0.154 0 C-N-CA 124.366 1.066 . . . . 10.0 112.228 -171.155 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.6 151.65 30.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.857 1.263 . . . . 10.0 110.06 -179.835 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.452 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -78.37 153.68 31.42 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 123.773 0.829 . . . . 10.0 111.799 175.733 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -76.31 -27.98 56.77 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 114.897 -1.047 . . . . 10.0 109.4 168.742 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 68.9 mt 59.52 52.04 6.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 123.669 1.7 . . . . 10.0 108.524 -172.8 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.65 -41.53 2.84 Favored Glycine 0 N--CA 1.443 -0.852 0 CA-C-N 111.655 -2.52 . . . . 10.0 111.489 169.171 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 19.1 mtmm -79.26 41.44 0.46 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.34 1.456 . . . . 10.0 112.47 -170.863 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.46 -15.73 34.07 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 126.653 2.073 . . . . 10.0 110.497 169.332 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.34 46.69 51.93 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 124.393 0.997 . . . . 10.0 111.951 -179.309 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.5 p30 -151.07 172.83 15.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 118.249 1.024 . . . . 10.0 109.883 176.216 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.3 tm-20 -55.18 -41.02 71.37 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.697 1.199 . . . . 10.0 110.915 -176.689 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 19.0 tp10 -71.42 -39.07 71.31 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 121.681 -0.637 . . . . 10.0 110.587 174.121 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.5 p -52.24 -43.92 64.56 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 118.451 0.569 . . . . 10.0 110.57 -176.376 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.3 t -74.92 -10.53 59.58 Favored 'General case' 0 CA--C 1.543 0.703 0 O-C-N 124.332 1.02 . . . . 10.0 113.058 -177.216 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.6 ttmt -115.21 -64.64 1.29 Allowed 'General case' 0 N--CA 1.436 -1.131 0 C-N-CA 126.973 2.109 . . . . 10.0 112.899 -168.878 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.5 p -126.46 17.01 7.63 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 120.048 1.295 . . . . 10.0 110.208 175.939 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.53 -105.7 1.91 Allowed Glycine 0 C--N 1.339 0.744 0 N-CA-C 106.952 -2.459 . . . . 10.0 106.952 -173.877 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -152.52 39.38 0.56 Allowed 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 170.009 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.22 -26.32 64.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.231 -0.895 . . . . 10.0 111.144 -177.03 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.48 -142.61 23.0 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 124.876 1.226 . . . . 10.0 110.379 170.707 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -69.16 134.96 49.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 -175.82 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.07 120.84 12.21 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 106.414 -1.698 . . . . 10.0 106.414 167.758 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 31.9 mt -76.65 -60.43 2.35 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 169.547 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -139.18 163.17 33.14 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 122.974 0.51 . . . . 10.0 110.104 -174.03 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -154.15 163.71 39.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.353 -0.385 . . . . 10.0 110.443 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.33 149.1 18.22 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 109.418 -1.473 . . . . 10.0 109.418 -171.624 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -108.67 139.65 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 C-N-CA 124.916 1.286 . . . . 10.0 108.041 -169.065 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 19.0 mt -77.5 112.32 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 122.916 0.486 . . . . 10.0 109.966 -173.455 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.75 143.54 18.09 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.808 1.194 . . . . 10.0 112.21 -174.451 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.49 136.34 25.81 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.296 0 C-N-CA 126.315 1.846 . . . . 10.0 110.333 -175.758 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.74 -46.78 1.98 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.681 0.673 . . . . 10.0 111.759 177.821 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 . . . . . 0 C--O 1.25 1.103 0 CA-C-O 116.368 -1.777 . . . . 10.0 112.107 -169.443 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 108.411 -0.959 . . . . 10.0 108.411 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -80.06 -21.52 43.33 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.948 -1.13 . . . . 10.0 107.948 168.144 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.496 ' HZ2' ' C ' ' A' ' 153' ' ' GLN . 1.8 ttmp? -127.04 161.5 28.24 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.763 1.625 . . . . 10.0 107.868 179.078 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.24 164.28 38.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.435 -1.691 . . . . 10.0 106.435 168.337 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 m -125.76 -179.9 2.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 118.08 0.4 . . . . 10.0 110.094 -179.429 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.71 108.37 2.9 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.852 -0.795 . . . . 10.0 108.852 165.207 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.3 m -92.91 115.53 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 171.282 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.7 mt -103.85 150.32 24.25 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.751 1.221 . . . . 10.0 109.224 -179.801 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.6 ttmt -163.12 159.83 23.57 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.721 1.146 . . . . 10.0 109.204 169.836 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.42 -56.35 0.02 OUTLIER Glycine 0 C--O 1.229 -0.197 0 N-CA-C 111.349 -0.7 . . . . 10.0 111.349 169.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -75.25 -45.85 37.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 106.575 -1.639 . . . . 10.0 106.575 -172.825 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.5 -64.85 0.6 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 113.859 -1.519 . . . . 10.0 110.902 -178.413 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -58.3 -41.29 67.86 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 122.512 2.142 . . . . 10.0 110.839 172.08 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -70.43 105.38 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.427 -1.694 . . . . 10.0 106.427 176.361 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.81 131.93 46.34 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.766 -0.827 . . . . 10.0 108.766 167.296 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.419 ' HA2' ' CG2' ' A' ' 35' ' ' ILE . . . -99.39 147.52 18.39 Favored Glycine 0 N--CA 1.441 -1.005 0 N-CA-C 109.658 -1.377 . . . . 10.0 109.658 174.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -150.81 81.8 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 105.355 -2.091 . . . . 10.0 105.355 -170.422 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -100.51 146.33 9.41 Favored 'Isoleucine or valine' 0 C--N 1.338 0.1 0 C-N-CA 125.091 1.356 . . . . 10.0 109.738 -178.283 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -126.0 117.15 22.65 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 127.502 2.321 . . . . 10.0 109.005 170.172 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -98.41 116.86 31.53 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 106.817 -1.549 . . . . 10.0 106.817 173.269 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -116.62 138.5 51.39 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 119.476 1.034 . . . . 10.0 112.948 171.18 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -114.35 85.37 2.22 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.728 2.011 . . . . 10.0 107.966 -178.176 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.427 ' NZ ' ' OE2' ' A' ' 100' ' ' GLU . 0.0 OUTLIER -46.07 -44.09 15.14 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.711 1.605 . . . . 10.0 111.366 -172.643 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -142.95 168.46 19.65 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 102.989 -2.967 . . . . 10.0 102.989 165.534 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.0 t -61.71 -29.17 69.93 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 174.525 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -81.09 -17.52 49.73 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 124.397 1.079 . . . . 10.0 110.783 -179.225 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.41 141.97 16.48 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 110.446 -1.062 . . . . 10.0 110.446 -171.174 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -63.55 136.48 54.6 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.078 1.852 . . . . 10.0 109.221 174.872 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.6 m -78.03 124.39 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -176.458 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 37.7 ttmt -88.11 116.48 26.33 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.759 -2.682 . . . . 10.0 103.759 167.591 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -97.51 104.19 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 171.258 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 21.2 p90 -112.88 167.65 10.33 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 116.129 -0.487 . . . . 10.0 110.086 176.473 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.36 176.15 42.51 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.878 -1.153 . . . . 10.0 111.688 178.33 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.6 t -144.84 99.17 3.3 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 107.775 -1.194 . . . . 10.0 107.775 177.252 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.419 ' CG2' ' HA2' ' A' ' 16' ' ' GLY . 3.4 pt -80.57 153.61 4.39 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.584 -1.265 . . . . 10.0 107.584 168.4 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.68 151.06 50.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 124.062 0.851 . . . . 10.0 109.085 167.83 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.65 -8.91 34.73 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.967 0.794 . . . . 10.0 113.541 175.443 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -61.06 176.27 0.44 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 122.301 1.048 . . . . 10.0 111.188 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -107.4 151.38 25.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 106.579 -1.638 . . . . 10.0 106.579 166.999 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -49.44 144.19 5.87 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.244 1.017 . . . . 10.0 111.717 -169.826 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.83 -168.01 21.18 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 123.685 0.659 . . . . 10.0 112.203 172.751 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -75.81 148.75 38.19 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.842 2.057 . . . . 10.0 111.768 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -147.6 134.24 19.9 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.477 1.111 . . . . 10.0 111.472 179.344 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.23 123.61 1.33 Allowed Glycine 0 C--N 1.345 1.076 0 C-N-CA 124.843 1.211 . . . . 10.0 111.02 168.337 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -136.75 108.64 7.1 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 124.133 0.973 . . . . 10.0 109.37 176.397 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -155.57 174.4 15.32 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 121.788 0.804 . . . . 10.0 111.712 -178.101 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.7 m -102.35 144.65 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 CA-C-N 111.798 -2.456 . . . . 10.0 106.369 168.214 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -121.66 148.07 45.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 107.246 -1.39 . . . . 10.0 107.246 176.543 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.401 ' HB3' ' CE1' ' A' ' 64' ' ' PHE . 2.3 tp10 -59.43 -39.32 83.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 122.854 0.462 . . . . 10.0 112.213 -169.963 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -74.76 153.23 38.9 Favored 'General case' 0 CA--C 1.527 0.079 0 C-N-CA 118.358 -1.337 . . . . 10.0 109.561 177.205 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.58 -11.84 46.3 Favored Glycine 0 CA--C 1.54 1.602 0 N-CA-C 109.385 -1.486 . . . . 10.0 109.385 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -48.2 107.13 0.11 Allowed 'General case' 0 C--N 1.344 0.357 0 C-N-CA 126.653 1.981 . . . . 10.0 112.382 172.658 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -112.68 6.44 18.23 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 113.268 -1.787 . . . . 10.0 109.34 168.015 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.8 -39.92 78.7 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.254 1.021 . . . . 10.0 109.456 -178.91 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.5 -15.52 58.51 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.053 0.941 . . . . 10.0 112.699 177.622 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.48 -108.08 3.06 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 108.736 -1.746 . . . . 10.0 108.736 -173.13 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 60.9 m -131.0 43.7 3.06 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 124.307 1.043 . . . . 10.0 109.43 -173.215 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 55.3 m -130.18 -54.24 1.11 Allowed 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 125.796 1.638 . . . . 10.0 107.141 -171.748 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.9 t -80.75 4.61 18.36 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.265 0.555 . . . . 10.0 111.663 178.445 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.54 -25.87 7.52 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.871 1.268 . . . . 10.0 112.415 173.137 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.42 144.99 18.26 Favored Glycine 0 C--N 1.339 0.742 0 N-CA-C 110.576 -1.01 . . . . 10.0 110.576 173.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -80.07 57.74 6.65 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 CA-C-N 120.584 2.192 . . . . 10.0 111.399 179.649 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.9 m170 71.77 -62.27 0.46 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 127.122 2.169 . . . . 10.0 108.211 -175.685 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.401 ' CE1' ' HB3' ' A' ' 49' ' ' GLU 0.343 3.1 p90 34.28 36.72 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 129.998 3.319 . . . . 10.0 116.85 174.635 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -45.29 152.24 0.64 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 129.837 3.255 . . . . 10.0 113.287 167.78 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -74.17 -48.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.493 2.795 . . . . 10.0 111.29 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 81.7 mt -68.82 83.44 0.3 Allowed 'General case' 0 C--N 1.339 0.145 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 172.839 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.7 p -69.54 64.65 0.18 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 126.628 1.971 . . . . 10.0 113.982 -169.358 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -87.73 -178.75 6.14 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.575 1.95 . . . . 10.0 109.779 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -111.43 84.98 2.04 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.188 0.518 . . . . 10.0 112.205 -169.356 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.409 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 64.8 t60 11.14 87.3 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 128.009 2.524 . . . . 10.0 114.627 175.791 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.26 -161.44 18.33 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 108.681 -1.767 . . . . 10.0 108.681 174.923 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.17 -155.88 6.73 Favored Glycine 0 C--O 1.224 -0.495 0 CA-C-O 117.671 -1.627 . . . . 10.0 110.512 170.106 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -64.91 -2.05 5.01 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 CA-C-N 120.756 2.278 . . . . 10.0 111.27 171.139 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 29.3 mtpt -88.41 -17.6 30.14 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.245 -0.884 . . . . 10.0 110.801 172.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -128.98 174.83 9.17 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 118.812 0.733 . . . . 10.0 109.482 -175.831 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -97.51 -15.05 20.73 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.707 0.803 . . . . 10.0 109.505 168.539 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 70.5 mm-40 -79.69 10.74 3.7 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.145 1.378 . . . . 10.0 112.78 178.712 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 16.4 ptt180 -51.65 127.56 20.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 166.995 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.409 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 21.3 m170 -65.7 -51.1 62.03 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 122.11 -0.369 . . . . 10.0 111.512 -169.982 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.6 p -166.94 -30.29 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 123.026 0.531 . . . . 10.0 111.804 -169.626 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.69 70.97 0.08 OUTLIER Glycine 0 C--N 1.334 0.442 0 N-CA-C 106.199 -2.761 . . . . 10.0 106.199 -176.557 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -116.58 91.11 3.49 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 -169.554 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp -72.86 -28.83 62.75 Favored 'General case' 0 CA--C 1.527 0.09 0 N-CA-C 107.314 -1.365 . . . . 10.0 107.314 -178.151 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.53 -87.78 0.77 Allowed Glycine 0 N--CA 1.44 -1.04 0 N-CA-C 106.493 -2.643 . . . . 10.0 106.493 172.12 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -140.98 149.38 41.71 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 122.884 0.473 . . . . 10.0 111.902 -176.414 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -129.32 143.41 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 105.506 -2.035 . . . . 10.0 105.506 168.093 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -95.48 121.58 37.31 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.357 1.863 . . . . 10.0 107.521 -176.285 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.14 137.4 32.37 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.721 -0.474 . . . . 10.0 109.721 171.208 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -67.5 173.25 4.25 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 126.193 1.797 . . . . 10.0 109.786 168.966 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -56.68 -24.36 48.28 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 124.75 1.22 . . . . 10.0 112.274 177.825 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -78.24 -17.61 56.48 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.092 -0.336 . . . . 10.0 110.092 179.527 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.28 7.74 69.39 Favored Glycine 0 C--N 1.338 0.647 0 N-CA-C 110.525 -1.03 . . . . 10.0 110.525 -171.86 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -80.7 119.54 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 N-CA-C 106.714 -1.587 . . . . 10.0 106.714 172.938 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -113.94 118.78 35.14 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 119.11 0.868 . . . . 10.0 108.691 169.482 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -79.2 117.35 20.14 Favored 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 126.366 1.866 . . . . 10.0 108.096 174.345 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 46.5 t -105.93 131.39 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 178.537 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 80.0 p -157.77 71.75 0.63 Allowed 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.735 0.814 . . . . 10.0 109.579 173.069 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.58 155.0 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 106.92 -1.511 . . . . 10.0 106.92 177.456 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.427 ' OE2' ' NZ ' ' A' ' 23' ' ' LYS . 26.3 tt0 -135.95 128.18 30.02 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 124.914 1.286 . . . . 10.0 108.276 174.742 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -136.7 152.8 50.78 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 124.046 0.842 . . . . 10.0 109.814 -177.601 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.4 p -118.68 48.75 1.39 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 127.484 2.314 . . . . 10.0 109.875 -171.068 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 14.6 p -155.34 -49.37 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 122.295 0.238 . . . . 10.0 110.655 173.002 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.99 119.48 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.663 -1.606 . . . . 10.0 106.663 170.617 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.09 85.79 2.3 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -176.038 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.2 pp -51.9 -10.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.603 1.561 . . . . 10.0 114.294 -177.961 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 24.9 t -148.36 137.01 21.55 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 103.953 -2.61 . . . . 10.0 103.953 168.862 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.78 -72.41 0.39 Allowed Glycine 0 C--N 1.334 0.421 0 N-CA-C 109.846 -1.301 . . . . 10.0 109.846 -176.526 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.45 -53.37 0.08 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 179.75 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -83.7 48.25 1.4 Allowed 'General case' 0 C--O 1.233 0.199 0 N-CA-C 109.269 -0.641 . . . . 10.0 109.269 -176.773 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.7 t -73.64 72.22 1.44 Allowed 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.072 1.349 . . . . 10.0 107.615 178.019 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.8 pt -72.2 39.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 126.251 1.821 . . . . 10.0 112.058 -177.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 44.2 mm -66.58 -47.5 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 125.246 1.418 . . . . 10.0 109.456 -178.445 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.77 51.3 3.74 Favored Glycine 0 CA--C 1.525 0.691 0 O-C-N 121.622 -0.674 . . . . 10.0 113.408 -175.053 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.29 145.81 46.72 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 -177.783 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 28.3 m -90.21 119.62 30.68 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 104.902 -2.259 . . . . 10.0 104.902 169.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.21 143.14 31.66 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -179.453 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 55.3 t -129.81 136.29 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 O-C-N 124.321 1.013 . . . . 10.0 109.405 -169.528 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -105.96 119.32 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 N-CA-C 105.067 -2.198 . . . . 10.0 105.067 168.603 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -99.19 161.45 13.62 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 113.823 1.045 . . . . 10.0 113.823 -169.563 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -64.77 -53.06 53.03 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.685 -1.143 . . . . 10.0 108.483 -176.92 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -113.12 176.64 4.93 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.902 0.858 . . . . 10.0 111.987 -178.462 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.89 135.99 50.14 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.067 1.347 . . . . 10.0 111.19 -178.495 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -77.49 110.13 12.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 124.491 1.116 . . . . 10.0 108.507 173.757 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -80.36 58.41 3.11 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 123.196 0.31 . . . . 10.0 111.284 -179.379 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt -11.86 81.49 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 129.346 3.058 . . . . 10.0 115.384 -177.797 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 75.61 -7.48 25.76 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.927 -0.929 . . . . 10.0 113.812 168.779 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.7 pttp -116.03 27.34 9.33 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 118.4 1.1 . . . . 10.0 112.316 -174.458 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.23 -18.26 79.76 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.437 1.018 . . . . 10.0 111.273 170.662 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.83 44.33 98.01 Favored Glycine 0 CA--C 1.53 0.971 0 O-C-N 121.655 -0.909 . . . . 10.0 112.138 173.007 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -164.15 175.81 9.84 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 126.272 1.829 . . . . 10.0 106.821 177.913 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -56.0 -42.09 75.88 Favored 'General case' 0 N--CA 1.439 -1.023 0 CA-C-N 119.014 0.824 . . . . 10.0 111.906 -174.593 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -61.03 -28.79 69.31 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.813 -0.554 . . . . 10.0 110.179 -179.823 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.4 t -47.92 -46.02 31.43 Favored 'General case' 0 CA--C 1.519 -0.243 0 C-N-CA 124.228 1.011 . . . . 10.0 109.219 176.243 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -90.73 8.46 34.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 112.59 0.589 . . . . 10.0 112.59 -175.859 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.97 -81.19 0.63 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.045 1.338 . . . . 10.0 110.565 -178.918 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.1 29.45 7.88 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 121.735 2.061 . . . . 10.0 111.537 174.091 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.95 -87.34 0.13 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 125.35 1.453 . . . . 10.0 110.823 179.012 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -165.64 33.24 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 122.115 -0.638 . . . . 10.0 112.211 170.627 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.13 -13.42 61.94 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.586 0.587 . . . . 10.0 112.586 -174.014 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.61 -147.57 45.49 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.217 -1.953 . . . . 10.0 108.217 174.223 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -58.56 120.44 8.86 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 122.729 0.412 . . . . 10.0 111.765 -169.54 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.65 73.68 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.488 1.515 . . . . 10.0 111.623 168.04 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 11.7 tp -38.45 -49.74 1.49 Allowed 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.139 2.176 . . . . 10.0 113.894 -179.883 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.01 158.09 37.27 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -170.856 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 20.0 p -164.35 171.82 14.3 Favored 'General case' 0 N--CA 1.454 -0.247 0 O-C-N 121.759 -0.588 . . . . 10.0 111.222 -171.866 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -172.65 -161.39 23.0 Favored Glycine 0 N--CA 1.451 -0.334 0 N-CA-C 110.224 -1.15 . . . . 10.0 110.224 -178.894 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -133.0 154.66 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.392 -2.077 . . . . 10.0 105.392 -172.891 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mt -69.17 -85.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 123.613 0.765 . . . . 10.0 110.147 -169.301 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.54 132.92 7.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.151 -0.779 . . . . 10.0 111.151 179.645 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 58.1 mt -68.51 145.31 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 123.435 0.694 . . . . 10.0 110.069 -179.262 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.89 176.27 8.86 Favored 'General case' 0 N--CA 1.442 -0.856 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 164.732 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . 0.496 ' C ' ' HZ2' ' A' ' 3' ' ' LYS . 15.1 tt0 . . . . . 0 N--CA 1.44 -0.967 0 N-CA-C 106.213 -1.773 . . . . 10.0 106.213 167.889 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 N-CA-C 108.424 -0.954 . . . . 10.0 108.424 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.3 t -78.96 -14.58 59.13 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.436 0.695 . . . . 10.0 110.662 -178.149 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.0 ttmt -134.32 149.22 50.86 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 125.023 1.329 . . . . 10.0 107.774 -179.716 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.64 151.63 47.39 Favored 'General case' 0 CA--C 1.512 -0.505 0 C-N-CA 123.32 0.648 . . . . 10.0 109.382 169.48 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -106.62 154.63 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.223 0 O-C-N 124.741 1.276 . . . . 10.0 111.813 -172.576 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.8 93.79 2.46 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 123.217 0.323 . . . . 10.0 111.449 169.28 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.3 m -81.65 103.54 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.365 0 N-CA-C 109.328 -0.619 . . . . 10.0 109.328 169.17 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.9 mt -97.36 127.37 43.26 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.336 1.054 . . . . 10.0 109.029 -177.796 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.3 mtpt -146.86 161.64 40.29 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 120.367 1.439 . . . . 10.0 108.66 173.76 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.31 -55.37 0.06 OUTLIER Glycine 0 N--CA 1.461 0.325 0 CA-C-N 115.798 -0.637 . . . . 10.0 113.318 168.63 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -72.63 -43.78 62.8 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 -176.477 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.12 -70.61 0.42 Allowed Glycine 0 CA--C 1.524 0.613 0 CA-C-N 114.334 -1.303 . . . . 10.0 109.923 170.075 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -58.27 -33.86 98.04 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.427 2.751 . . . . 10.0 111.291 172.044 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.9 t -65.01 100.62 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.637 -1.245 . . . . 10.0 107.637 176.179 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -124.55 108.29 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.606 1.562 . . . . 10.0 108.117 177.978 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.02 143.46 16.49 Favored Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 167.934 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.4 mt -141.62 67.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.651 -1.611 . . . . 10.0 106.651 -179.797 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.06 148.96 4.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.476 0.655 . . . . 10.0 110.852 -174.926 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -123.53 119.31 29.56 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 125.703 1.601 . . . . 10.0 109.263 169.834 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -94.73 124.6 38.86 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 116.712 -1.614 . . . . 10.0 106.653 168.332 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -112.52 136.54 51.91 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 119.592 1.087 . . . . 10.0 111.184 165.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -89.27 112.71 23.84 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.025 -2.213 . . . . 10.0 105.025 168.471 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.9 mmpt? . . . . . 0 CA--C 1.513 -0.45 0 C-N-CA 125.649 1.58 . . . . 10.0 110.075 -171.554 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.046 0 N-CA-C 109.361 -1.496 . . . . 10.0 109.361 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -59.17 145.54 97.41 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.263 1.976 . . . . 10.0 109.132 175.731 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.7 t -87.76 114.55 26.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 105.22 -2.141 . . . . 10.0 105.22 174.811 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 10.9 ttmm -89.21 119.75 29.97 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 169.895 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -89.44 107.91 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 126.387 1.875 . . . . 10.0 106.397 169.593 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.0 p90 -126.3 164.63 20.61 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.886 0.851 . . . . 10.0 112.614 173.08 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.68 -152.93 24.43 Favored Glycine 0 N--CA 1.438 -1.208 0 N-CA-C 107.586 -2.205 . . . . 10.0 107.586 169.905 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 34.3 p -154.01 113.91 3.86 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 118.595 -0.717 . . . . 10.0 109.495 -169.956 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.8 pt -81.75 140.43 16.51 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 166.994 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -119.58 148.88 42.81 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 169.622 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.34 -5.85 41.76 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-O 119.365 -0.686 . . . . 10.0 113.652 174.965 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.34 176.8 2.12 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 118.584 1.192 . . . . 10.0 110.787 176.903 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -109.65 158.26 18.25 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 105.661 -1.977 . . . . 10.0 105.661 165.898 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -49.44 159.59 0.32 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.483 1.513 . . . . 10.0 112.487 -169.055 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.48 -172.94 35.04 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-O 121.786 0.659 . . . . 10.0 111.909 169.254 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -72.03 144.14 48.89 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.976 1.711 . . . . 10.0 110.207 -176.616 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -145.36 147.79 32.67 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.168 0.987 . . . . 10.0 113.036 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -20.37 117.73 0.01 OUTLIER Glycine 0 C--N 1.339 0.726 0 C-N-CA 129.36 3.362 . . . . 10.0 115.473 165.012 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -154.59 103.38 2.47 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.943 1.872 . . . . 10.0 111.541 170.736 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.446 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 2.2 m80 -133.6 -163.53 1.37 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 124.465 1.106 . . . . 10.0 111.188 179.415 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.2 p -116.66 -46.6 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 124.286 1.034 . . . . 10.0 112.045 -177.067 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 62.16 148.12 0.02 OUTLIER 'General case' 0 C--N 1.342 0.27 0 C-N-CA 125.589 1.556 . . . . 10.0 112.223 -171.595 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -75.31 -58.01 3.55 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 177.297 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -77.78 128.05 33.4 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 -172.797 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.91 -1.61 87.57 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.257 -1.537 . . . . 10.0 109.257 165.781 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -41.06 140.21 0.8 Allowed 'General case' 0 C--N 1.346 0.425 0 CA-C-N 117.982 0.891 . . . . 10.0 110.887 173.121 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -150.18 18.83 0.86 Allowed 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.512 -1.222 . . . . 10.0 111.328 167.455 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -54.89 -35.97 64.68 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 118.903 0.774 . . . . 10.0 109.305 177.893 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.74 -21.45 44.48 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.347 1.459 . . . . 10.0 113.407 177.069 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.58 91.18 0.71 Allowed Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.444 -0.662 . . . . 10.0 111.444 -176.818 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 32.0 m 44.61 38.67 2.84 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.156 1.782 . . . . 10.0 112.625 176.414 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.2 m -133.33 -49.7 0.85 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.702 0.801 . . . . 10.0 109.25 -168.964 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -106.04 20.12 19.46 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.553 0.741 . . . . 10.0 110.265 -177.133 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.96 47.79 0.45 Allowed 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 124.438 1.095 . . . . 10.0 111.011 175.974 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.22 101.41 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 126.043 1.782 . . . . 10.0 113.683 168.455 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -68.15 72.7 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 123.635 2.89 . . . . 10.0 112.833 178.629 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.459 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 15.9 m170 58.55 45.69 15.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.237 3.415 . . . . 10.0 110.943 173.298 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -69.33 64.69 0.16 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 126.146 1.778 . . . . 10.0 111.692 177.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -82.9 154.22 67.56 Favored Pre-proline 0 C--N 1.32 -0.69 0 C-N-CA 126.067 1.747 . . . . 10.0 109.796 179.557 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.13 -52.03 0.54 Allowed 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.574 2.182 . . . . 10.0 111.447 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.2 mt -78.68 49.58 0.9 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.94 0.896 . . . . 10.0 110.584 -176.652 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.7 124.94 23.23 Favored 'General case' 0 N--CA 1.451 -0.4 0 O-C-N 122.024 -0.422 . . . . 10.0 111.096 -168.53 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.81 -75.22 0.32 Allowed 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 107.1 -1.444 . . . . 10.0 107.1 -172.503 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.7 mttt -149.26 164.77 33.89 Favored 'General case' 0 N--CA 1.422 -1.853 0 CA-C-N 114.871 -1.059 . . . . 10.0 108.583 169.317 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 76.3 t60 -71.6 126.82 30.68 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 105.165 -2.161 . . . . 10.0 105.165 162.873 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.05 -138.36 3.65 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 108.86 -1.696 . . . . 10.0 108.86 173.634 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.62 -160.87 25.98 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 107.884 -2.086 . . . . 10.0 107.884 173.414 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.51 1.36 2.66 Favored 'Trans proline' 0 CA--C 1.541 0.839 0 CA-C-N 119.819 1.81 . . . . 10.0 110.644 167.372 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -108.35 10.19 27.63 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 125.857 1.663 . . . . 10.0 109.8 173.905 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -135.47 161.44 35.47 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 165.571 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -77.59 -37.86 49.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 105.242 -2.133 . . . . 10.0 105.242 167.328 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -97.15 58.1 1.52 Allowed 'General case' 0 N--CA 1.446 -0.646 0 CA-C-O 121.718 0.77 . . . . 10.0 109.323 -169.614 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -70.37 154.01 42.37 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.521 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -67.66 -65.95 0.62 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.989 0.813 . . . . 10.0 109.39 177.831 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . 0.434 ' CG1' ' H ' ' B' ' 82' ' ' GLY . 7.5 p -161.67 -90.46 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 170.664 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . 0.434 ' H ' ' CG1' ' B' ' 81' ' ' VAL . . . -84.12 69.31 3.36 Favored Glycine 0 CA--C 1.525 0.693 0 O-C-N 120.374 -1.454 . . . . 10.0 109.486 176.071 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -104.39 94.42 5.33 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 104.013 -2.588 . . . . 10.0 104.013 167.32 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -70.73 -34.1 71.55 Favored 'General case' 0 C--O 1.227 -0.114 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 -176.336 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 117.68 -85.96 0.4 Allowed Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 110.175 -1.17 . . . . 10.0 110.175 167.021 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -142.37 141.26 32.28 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.53 -0.915 . . . . 10.0 108.53 -177.627 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.3 m -114.63 135.65 53.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 166.891 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -104.23 117.97 35.5 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.75 0.82 . . . . 10.0 109.465 -171.666 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.26 134.54 34.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.08 -0.388 . . . . 10.0 110.327 -178.166 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -60.9 168.97 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.529 1.132 . . . . 10.0 109.579 167.695 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.9 -29.14 40.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.633 -0.712 . . . . 10.0 111.298 173.485 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -78.41 -9.26 59.22 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.003 0.521 . . . . 10.0 111.291 -178.704 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 10.06 73.74 Favored Glycine 0 C--N 1.341 0.807 0 O-C-N 121.099 -1.001 . . . . 10.0 111.101 -177.148 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.7 t -87.21 106.71 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 C-N-CA 126.273 1.829 . . . . 10.0 106.743 176.049 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.82 119.57 39.32 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.476 -0.935 . . . . 10.0 108.476 169.653 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -79.53 135.4 36.61 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.081 1.752 . . . . 10.0 108.454 175.088 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.52 132.53 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.454 1.502 . . . . 10.0 106.975 177.907 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 23.4 p -158.78 55.4 0.43 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.752 0.821 . . . . 10.0 111.79 168.821 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.0 mp -92.81 145.0 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 108.662 -0.866 . . . . 10.0 108.662 -174.536 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -101.67 126.33 48.5 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 126.814 2.046 . . . . 10.0 108.543 174.359 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -117.45 155.04 30.36 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.541 -0.911 . . . . 10.0 108.541 168.157 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.4 p -130.42 27.42 5.03 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 125.453 1.501 . . . . 10.0 111.989 -177.4 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.71 -40.54 1.32 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.894 0.77 . . . . 10.0 111.021 169.788 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.481 0.0 OUTLIER -69.38 158.07 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 119.895 1.225 . . . . 10.0 112.47 174.592 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 40.5 m -153.95 121.69 5.93 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 120.937 -1.102 . . . . 10.0 109.805 -179.235 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.1 mt -68.2 -30.74 69.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.698 1.199 . . . . 10.0 110.598 -175.536 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 68.6 m . . . . . 0 N--CA 1.45 -0.458 0 N-CA-C 108.187 -1.042 . . . . 10.0 108.187 169.462 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.6 t . . . . . 0 N--CA 1.448 -0.547 0 CA-C-O 120.775 0.321 . . . . 10.0 111.022 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -69.77 37.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 C-N-CA 126.302 1.841 . . . . 10.0 111.844 -177.598 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 1.1 mp -56.07 -45.63 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 O-C-N 119.157 -2.214 . . . . 10.0 112.096 177.481 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.79 50.92 3.03 Favored Glycine 0 CA--C 1.534 1.251 0 CA-C-N 119.932 1.242 . . . . 10.0 114.244 -175.416 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -84.56 176.6 8.51 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 127.327 2.251 . . . . 10.0 109.784 170.123 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -135.85 99.19 4.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.35 -0.982 . . . . 10.0 108.35 169.114 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.74 129.65 42.04 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 105.565 -2.013 . . . . 10.0 105.565 167.625 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.16 129.4 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.24 -2.133 . . . . 10.0 105.24 169.168 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -100.71 106.05 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.942 0 N-CA-C 104.868 -2.271 . . . . 10.0 104.868 170.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -87.72 160.08 18.23 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 122.822 1.296 . . . . 10.0 114.258 -169.818 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 52.0 tt0 -50.79 -56.55 11.58 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.839 2.056 . . . . 10.0 109.034 176.917 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -107.64 168.06 9.52 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.863 0.69 . . . . 10.0 112.863 -169.654 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.26 151.57 43.3 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 113.777 -1.556 . . . . 10.0 107.575 169.125 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 31.2 m-20 -100.94 132.36 46.38 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.235 -1.024 . . . . 10.0 108.235 -179.602 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -76.39 -12.68 60.1 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 124.857 1.263 . . . . 10.0 111.05 -176.796 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 15.4 mt 59.31 49.36 9.04 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 122.211 1.005 . . . . 10.0 109.04 177.39 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.4 -44.1 2.47 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 125.611 1.576 . . . . 10.0 110.445 174.645 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.7 mtmm -79.47 42.16 0.5 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.716 1.607 . . . . 10.0 112.518 -168.842 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.7 -17.77 27.36 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.281 2.372 . . . . 10.0 111.103 169.765 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.24 42.25 88.03 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.961 0.791 . . . . 10.0 111.777 178.861 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -145.94 166.38 26.2 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 169.929 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -52.23 -48.5 65.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 120.978 0.418 . . . . 10.0 110.143 -177.17 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -64.87 -30.45 71.45 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 119.225 -0.417 . . . . 10.0 110.427 -179.591 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 p -56.04 -35.33 66.77 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 120.146 1.339 . . . . 10.0 112.308 171.544 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -101.72 -14.73 17.23 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 118.294 0.497 . . . . 10.0 111.169 -170.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 53.9 mttt -88.0 -47.57 8.43 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 125.923 1.689 . . . . 10.0 111.256 173.715 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.459 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 44.7 p -134.09 -11.71 2.55 Favored 'General case' 0 CA--C 1.533 0.308 0 N-CA-C 115.057 1.502 . . . . 10.0 115.057 177.323 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.38 24.77 11.85 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 119.404 1.002 . . . . 10.0 112.978 -171.722 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 61.89 25.06 15.01 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 119.698 1.749 . . . . 10.0 111.432 179.316 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.73 -14.21 41.74 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 126.54 1.936 . . . . 10.0 112.5 -173.064 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.38 -160.22 52.98 Favored Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 108.776 -1.73 . . . . 10.0 108.776 172.434 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -55.29 130.54 42.74 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 109.24 -0.652 . . . . 10.0 109.24 -171.155 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.77 71.65 0.06 Allowed 'General case' 0 CA--C 1.543 0.708 0 O-C-N 121.667 -0.646 . . . . 10.0 110.274 172.198 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 11.7 tp -45.08 -35.78 3.25 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 128.118 2.567 . . . . 10.0 114.585 -172.858 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -165.77 159.18 15.9 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.049 -1.093 . . . . 10.0 108.049 -179.361 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.4 p -163.61 169.8 18.09 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.663 -0.495 . . . . 10.0 109.663 -178.045 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.12 -178.79 16.76 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 109.63 -1.388 . . . . 10.0 109.63 178.595 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 91.5 t -123.73 126.46 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 104.224 -2.51 . . . . 10.0 104.224 170.609 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.3 mt -81.72 152.08 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 CA-C-N 118.198 0.454 . . . . 10.0 110.787 -171.179 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -151.76 157.58 27.3 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 125.547 1.546 . . . . 10.0 111.059 -169.4 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.9 mt -54.12 140.27 11.33 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 C-N-CA 125.436 1.494 . . . . 10.0 111.806 172.64 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.72 170.17 16.23 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 107.492 -1.299 . . . . 10.0 107.492 165.759 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 . . . . . 0 C--O 1.25 1.096 0 N-CA-C 107.537 -1.283 . . . . 10.0 107.537 167.616 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.81 0 CA-C-O 117.971 -1.014 . . . . 10.0 108.952 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 t -105.47 -21.54 13.19 Favored 'General case' 0 C--O 1.223 -0.342 0 O-C-N 123.807 0.692 . . . . 10.0 110.503 176.897 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.74 172.5 13.2 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-O 121.368 0.604 . . . . 10.0 111.04 169.203 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.99 168.55 24.84 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 172.732 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -132.64 164.07 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.318 1.047 . . . . 10.0 109.284 176.771 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.01 116.87 10.97 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 167.898 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -95.66 102.77 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 124.542 1.137 . . . . 10.0 109.137 170.349 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -92.45 134.98 34.44 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.062 0.945 . . . . 10.0 109.703 -179.884 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt -145.38 162.44 37.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 168.797 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.95 -60.18 0.04 OUTLIER Glycine 0 C--O 1.229 -0.178 0 CA-C-N 115.393 -0.821 . . . . 10.0 112.542 172.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.37 -43.91 59.69 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 106.443 -1.688 . . . . 10.0 106.443 -171.532 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.25 -66.06 0.56 Allowed Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 113.713 -1.585 . . . . 10.0 110.097 177.65 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -58.54 -38.75 88.28 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 122.481 2.12 . . . . 10.0 111.276 172.297 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.1 t -64.44 108.17 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.691 -1.225 . . . . 10.0 107.691 178.363 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -122.6 116.27 23.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 105.452 -2.055 . . . . 10.0 105.452 168.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -100.38 131.29 10.52 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 175.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.415 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 11.5 mt -133.19 89.57 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 107.111 -1.441 . . . . 10.0 107.111 -171.157 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.6 mm -104.17 141.88 18.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 124.396 1.078 . . . . 10.0 109.826 -178.665 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -126.5 119.42 27.11 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.939 2.095 . . . . 10.0 108.636 171.408 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -101.16 120.69 40.59 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 107.321 -1.362 . . . . 10.0 107.321 176.771 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -113.55 143.49 44.46 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 119.379 0.99 . . . . 10.0 112.832 172.214 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -127.42 97.33 4.85 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 128.166 2.586 . . . . 10.0 107.92 169.656 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.0 pttt -58.52 -48.14 81.82 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.287 1.035 . . . . 10.0 111.946 -176.255 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.76 166.61 24.29 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 104.38 -2.452 . . . . 10.0 104.38 168.14 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -65.21 -19.5 66.0 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 122.356 0.262 . . . . 10.0 110.893 179.891 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -80.66 -24.12 39.17 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 123.096 0.558 . . . . 10.0 110.499 176.617 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.41 155.1 53.39 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.645 -0.582 . . . . 10.0 111.645 -175.885 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -71.06 147.77 55.23 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 N-CA-C 106.155 -2.286 . . . . 10.0 106.155 165.56 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 t -79.61 128.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.04 0 N-CA-C 106.626 -1.62 . . . . 10.0 106.626 174.32 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -109.0 125.08 51.68 Favored 'General case' 0 C--O 1.233 0.234 0 N-CA-C 106.504 -1.665 . . . . 10.0 106.504 171.911 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.0 m -111.44 105.95 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.63 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 -176.5 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.5 p90 -117.13 168.54 10.2 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.25 0.548 . . . . 10.0 111.06 176.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.5 175.9 41.57 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.188 -1.006 . . . . 10.0 111.585 176.002 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 2.6 p -147.46 95.8 2.59 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 107.949 -1.13 . . . . 10.0 107.949 -177.098 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.4 pt -77.42 174.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.03 170.917 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -156.01 155.77 33.28 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.8 -17.23 33.0 Favored Glycine 0 CA--C 1.523 0.566 0 CA-C-O 119.411 -0.661 . . . . 10.0 113.824 173.326 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -72.73 179.85 3.43 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 118.395 1.097 . . . . 10.0 110.354 178.362 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -95.81 175.78 6.38 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.586 -0.894 . . . . 10.0 108.586 166.404 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -63.6 176.54 0.85 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 124.633 1.173 . . . . 10.0 111.604 -172.024 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.04 -173.8 43.38 Favored Glycine 0 C--O 1.225 -0.438 0 C-N-CA 124.005 0.812 . . . . 10.0 112.563 167.345 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -77.22 140.7 40.18 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.332 1.453 . . . . 10.0 109.476 177.452 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -133.03 140.66 47.84 Favored 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 124.264 1.026 . . . . 10.0 112.366 -176.742 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -43.72 125.65 5.41 Favored Glycine 0 C--N 1.344 1.026 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 166.177 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -145.52 109.73 4.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 119.042 1.421 . . . . 10.0 109.025 171.122 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.22 173.12 17.32 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 113.74 1.015 . . . . 10.0 113.74 -174.139 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 33.3 m -88.0 154.37 3.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 113.629 -1.623 . . . . 10.0 109.578 171.246 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 -139.35 75.7 1.53 Allowed 'General case' 0 C--O 1.222 -0.37 0 C-N-CA 123.217 0.607 . . . . 10.0 112.122 -174.513 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 64.3 tt0 51.71 -87.22 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 125.301 1.44 . . . . 10.0 113.989 169.501 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -90.62 -172.34 3.37 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.537 -0.912 . . . . 10.0 108.537 -179.935 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -136.76 22.93 3.27 Favored Glycine 0 N--CA 1.452 -0.297 0 O-C-N 121.521 -0.737 . . . . 10.0 111.82 174.425 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -82.34 160.06 22.93 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 107.626 -1.25 . . . . 10.0 107.626 168.583 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.18 28.9 0.58 Allowed 'General case' 0 N--CA 1.448 -0.572 0 O-C-N 121.578 -0.701 . . . . 10.0 112.446 178.454 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -49.7 -40.38 40.04 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.344 1.458 . . . . 10.0 112.373 -175.173 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -81.66 -24.31 36.37 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 123.391 0.676 . . . . 10.0 112.432 177.656 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.1 115.74 1.24 Allowed Glycine 0 CA--C 1.53 0.999 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 -169.512 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 64.2 m 42.27 53.37 4.47 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 125.629 1.572 . . . . 10.0 113.169 175.062 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -158.11 -56.98 0.07 Allowed 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 177.056 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -53.15 -45.34 68.38 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 124.909 1.284 . . . . 10.0 111.002 -169.233 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -53.59 0.18 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 127.039 2.136 . . . . 10.0 113.681 169.993 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.08 160.5 11.61 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.121 -1.192 . . . . 10.0 110.121 -176.838 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -74.02 -162.3 0.14 Allowed 'Trans proline' 0 N--CA 1.448 -1.169 0 N-CA-C 105.651 -2.48 . . . . 10.0 105.651 165.837 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -80.17 48.99 1.05 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 119.613 -1.93 . . . . 10.0 110.827 -175.386 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-30 -77.65 56.55 1.48 Allowed 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.935 1.35 . . . . 10.0 112.11 -176.632 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -59.83 148.52 75.92 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.81 1.244 . . . . 10.0 108.501 167.057 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.67 -48.59 8.75 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.693 2.262 . . . . 10.0 112.022 -174.285 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.19 57.65 1.46 Allowed 'General case' 0 CA--C 1.534 0.335 0 O-C-N 121.595 -0.69 . . . . 10.0 110.717 174.162 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.3 p -55.66 107.66 0.36 Allowed 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.842 1.257 . . . . 10.0 109.844 -179.705 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -119.45 -91.11 0.56 Allowed 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 -178.321 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -143.65 150.89 39.41 Favored 'General case' 0 N--CA 1.437 -1.095 0 CA-C-O 121.927 0.87 . . . . 10.0 109.81 169.012 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.5 t60 -57.79 120.96 9.35 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.643 -1.243 . . . . 10.0 107.643 165.699 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.73 -141.81 3.92 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 108.692 -1.763 . . . . 10.0 108.692 -177.96 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.497 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -174.17 -158.98 19.71 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 109.337 -1.505 . . . . 10.0 109.337 169.697 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -69.36 25.5 0.16 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 119.844 1.822 . . . . 10.0 111.173 168.739 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.497 ' H ' ' C ' ' A' ' 73' ' ' GLY . 71.7 mttt -123.96 -12.89 7.45 Favored 'General case' 0 N--CA 1.438 -1.028 0 C-N-CA 126.379 1.872 . . . . 10.0 109.787 171.942 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -135.96 129.11 31.65 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 104.842 -2.281 . . . . 10.0 104.842 -172.352 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -75.57 -22.19 57.21 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.243 -1.021 . . . . 10.0 108.243 -174.277 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -83.21 4.97 24.53 Favored 'General case' 0 N--CA 1.433 -1.323 0 C-N-CA 125.935 1.694 . . . . 10.0 111.122 -179.756 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.29 158.53 0.03 OUTLIER 'General case' 0 C--N 1.349 0.567 0 C-N-CA 124.53 1.132 . . . . 10.0 112.161 172.844 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.3 m170 -69.65 -103.81 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.689 -0.632 . . . . 10.0 109.359 176.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 88.0 t -126.7 -90.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 104.522 -2.399 . . . . 10.0 104.522 169.385 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -79.08 62.61 3.98 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.689 -0.565 . . . . 10.0 111.689 178.745 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -97.26 94.84 7.33 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 104.368 -2.456 . . . . 10.0 104.368 166.954 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -72.68 -7.46 50.54 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 117.913 0.324 . . . . 10.0 111.033 -174.229 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.27 -103.22 2.96 Favored Glycine 0 N--CA 1.44 -1.046 0 N-CA-C 105.006 -3.237 . . . . 10.0 105.006 -170.084 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -146.47 159.74 43.01 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 107.609 -1.256 . . . . 10.0 107.609 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.33 128.05 74.71 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 123.096 0.558 . . . . 10.0 110.575 170.422 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 m -79.68 114.08 18.33 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.758 2.823 . . . . 10.0 110.563 -178.889 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.16 46.51 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.298 1.039 . . . . 10.0 110.857 177.985 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -61.18 170.03 1.85 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 125.495 1.518 . . . . 10.0 109.096 166.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.95 -30.0 44.91 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.803 0.841 . . . . 10.0 111.408 176.723 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.1 -3.0 43.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 124.298 1.039 . . . . 10.0 110.863 -178.221 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.41 1.28 89.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.518 -1.033 . . . . 10.0 110.518 -175.633 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 62.1 t -79.47 103.53 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.288 0 N-CA-C 106.965 -1.495 . . . . 10.0 106.965 -176.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -100.95 118.67 37.44 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.825 -0.806 . . . . 10.0 108.825 169.213 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.2 110.01 15.21 Favored 'General case' 0 N--CA 1.434 -1.25 0 C-N-CA 126.265 1.826 . . . . 10.0 108.84 170.736 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.9 t -97.79 132.87 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 106.656 -1.609 . . . . 10.0 106.656 177.183 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.0 m -158.69 76.93 0.75 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.98 1.312 . . . . 10.0 109.863 169.799 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.7 161.13 3.83 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 177.505 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -142.51 130.85 22.24 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.65 1.98 . . . . 10.0 107.786 176.994 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -144.95 163.6 33.67 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.295 1.038 . . . . 10.0 108.959 179.126 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.4 p -125.36 51.39 1.7 Allowed 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.897 1.279 . . . . 10.0 109.876 176.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -142.69 -46.02 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.761 0.824 . . . . 10.0 110.762 174.475 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -63.29 139.74 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 169.339 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.3 m -126.74 156.19 41.55 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.941 0.877 . . . . 10.0 110.108 172.173 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -82.47 -29.54 30.53 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.75 0.82 . . . . 10.0 109.492 172.401 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.7 m -156.93 168.82 26.33 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 -174.599 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.32 -92.92 0.58 Allowed Glycine 0 C--N 1.333 0.407 0 N-CA-C 108.471 -1.852 . . . . 10.0 108.471 179.117 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -134.39 -51.64 0.81 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 125.72 1.608 . . . . 10.0 108.403 177.584 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -81.7 38.42 0.51 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.605 0.762 . . . . 10.0 110.145 -175.03 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.4 t -74.32 112.96 11.0 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 126.127 1.771 . . . . 10.0 108.627 -176.109 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 16.6 pt -81.87 11.49 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 173.16 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 30.9 mm -61.09 137.59 23.18 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 120.112 1.324 . . . . 10.0 109.925 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.56 87.01 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.0 -1.444 . . . . 10.0 114.707 172.544 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 29.5 mmt180 -83.93 171.13 13.31 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 168.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -105.4 136.48 44.87 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 124.677 1.191 . . . . 10.0 110.351 171.681 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -96.29 143.08 27.69 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 167.209 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 91.9 t -132.03 137.67 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.875 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 176.864 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.5 p -108.5 142.08 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.592 0 C-N-CA 124.996 1.318 . . . . 10.0 108.698 170.368 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -119.99 171.1 8.68 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.963 0.905 . . . . 10.0 113.143 -171.71 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -74.28 -46.83 38.75 Favored 'General case' 0 C--O 1.223 -0.323 0 C-N-CA 123.932 0.893 . . . . 10.0 111.669 -176.596 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -109.81 170.76 7.86 Favored 'General case' 0 CA--C 1.522 -0.113 0 C-N-CA 123.702 0.801 . . . . 10.0 113.015 -171.763 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.44 145.68 39.12 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.951 1.3 . . . . 10.0 108.777 174.134 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.53 164.47 24.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 122.167 0.984 . . . . 10.0 112.753 -178.208 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 63.9 m-20 -77.5 -22.4 51.28 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 112.625 -2.079 . . . . 10.0 109.631 167.082 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 40.2 mt 50.2 46.5 24.76 Favored 'General case' 0 C--N 1.341 0.232 0 CA-C-O 122.631 1.205 . . . . 10.0 108.354 -167.574 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.17 -32.79 4.76 Favored Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.125 -1.398 . . . . 10.0 112.247 177.765 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 25.4 mtmm -79.57 37.79 0.35 Allowed 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.672 1.189 . . . . 10.0 113.205 -168.535 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.8 -14.41 37.22 Favored Glycine 0 CA--C 1.526 0.778 0 C-N-CA 127.185 2.326 . . . . 10.0 110.036 169.419 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.17 43.07 32.75 Favored Glycine 0 C--N 1.34 0.781 0 C-N-CA 124.516 1.055 . . . . 10.0 112.081 -177.88 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -142.26 167.2 22.68 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 118.926 1.363 . . . . 10.0 109.221 173.088 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -37.5 -54.82 1.12 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 126.392 1.877 . . . . 10.0 111.374 176.531 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -72.2 -39.08 68.84 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.087 0.555 . . . . 10.0 110.739 179.927 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.8 p -53.04 -45.5 68.04 Favored 'General case' 0 N--CA 1.446 -0.635 0 O-C-N 120.893 -1.129 . . . . 10.0 110.589 -178.711 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.1 t -79.69 -2.45 42.92 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 118.744 -0.646 . . . . 10.0 111.799 -173.815 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -112.21 -71.07 0.77 Allowed 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.035 1.734 . . . . 10.0 110.811 -178.296 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.1 p -121.17 14.21 11.32 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 120.729 1.604 . . . . 10.0 112.841 177.462 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.46 21.08 78.7 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-O 119.236 -0.758 . . . . 10.0 113.473 168.752 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 50.75 24.83 1.85 Allowed 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 118.21 1.005 . . . . 10.0 112.202 -174.663 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.21 -7.55 47.59 Favored 'General case' 0 C--O 1.223 -0.323 0 O-C-N 121.41 -0.806 . . . . 10.0 111.554 -176.829 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 129.57 170.12 12.68 Favored Glycine 0 C--N 1.332 0.324 0 N-CA-C 110.199 -1.16 . . . . 10.0 110.199 169.674 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -82.38 54.85 2.71 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 123.029 0.532 . . . . 10.0 112.082 -169.058 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 42.66 72.87 0.16 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.057 1.343 . . . . 10.0 111.709 173.902 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -63.9 -36.4 83.82 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 123.041 0.537 . . . . 10.0 111.39 -169.185 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.06 138.22 14.65 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.904 -0.776 . . . . 10.0 108.904 -170.622 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -133.75 147.36 51.3 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.315 1.046 . . . . 10.0 109.678 -168.373 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.16 168.57 23.32 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.542 -1.023 . . . . 10.0 110.542 177.033 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 65.1 t -118.55 137.82 51.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 106.384 -1.71 . . . . 10.0 106.384 178.42 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 80.7 mt -73.96 126.18 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 118.099 0.409 . . . . 10.0 110.923 -176.297 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.65 145.61 18.63 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.365 -1.094 . . . . 10.0 110.365 176.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 47.9 mt -68.44 152.77 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 CA-C-N 119.358 1.579 . . . . 10.0 110.41 178.044 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.7 162.82 32.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 107.661 -1.237 . . . . 10.0 107.661 166.936 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.5 tt0 . . . . . 0 C--O 1.251 1.147 0 N-CA-C 106.338 -1.727 . . . . 10.0 106.338 169.603 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.507 0 N-CA-C 109.134 -0.691 . . . . 10.0 109.134 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.3 t -94.94 -32.18 13.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.978 1.311 . . . . 10.0 110.913 174.965 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.2 ttmp? -124.61 138.9 54.28 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 124.471 1.108 . . . . 10.0 110.231 -177.862 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.59 159.54 42.04 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.159 1.384 . . . . 10.0 108.101 170.236 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -136.02 164.4 32.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 119.012 0.824 . . . . 10.0 110.307 177.41 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.88 118.91 18.49 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 124.7 1.2 . . . . 10.0 109.118 168.199 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -89.05 89.65 3.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 108.387 -0.968 . . . . 10.0 108.387 168.911 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mp -79.67 120.76 24.43 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 118.544 -0.741 . . . . 10.0 109.688 -179.752 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 22.7 mtpt -140.5 160.41 40.05 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 119.133 0.879 . . . . 10.0 109.207 171.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.52 -60.71 0.05 OUTLIER Glycine 0 N--CA 1.46 0.276 0 CA-C-N 114.87 -1.059 . . . . 10.0 113.071 170.923 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -71.24 -44.0 66.17 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 -176.748 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.14 -69.17 0.43 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-N 114.234 -1.348 . . . . 10.0 110.575 169.771 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -60.14 -32.32 94.43 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 123.714 2.943 . . . . 10.0 111.735 173.019 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.7 t -67.62 92.53 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 107.145 -1.428 . . . . 10.0 107.145 177.902 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -120.11 105.65 11.21 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 125.22 1.408 . . . . 10.0 107.822 -178.24 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.68 139.72 14.65 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 110.364 -1.094 . . . . 10.0 110.364 169.718 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -138.15 58.5 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 N-CA-C 105.552 -2.018 . . . . 10.0 105.552 -173.403 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -81.96 134.8 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 114.879 -1.055 . . . . 10.0 109.39 -169.913 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -112.35 116.48 30.41 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.195 1.798 . . . . 10.0 108.973 -177.517 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -103.19 113.79 27.55 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 125.963 1.705 . . . . 10.0 107.759 -176.107 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -114.36 135.86 53.62 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.053 0.941 . . . . 10.0 111.524 -177.992 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -115.77 104.6 11.82 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 104.985 -2.228 . . . . 10.0 104.985 167.784 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.235 0.306 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -169.683 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.853 0 CA-C-O 117.562 -1.688 . . . . 10.0 115.372 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -66.1 145.45 79.03 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 CA-C-N 119.841 1.82 . . . . 10.0 107.625 170.867 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.37 97.43 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 106.196 -1.779 . . . . 10.0 106.196 173.542 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -79.09 102.42 8.41 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.504 -2.036 . . . . 10.0 105.504 168.895 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.93 101.12 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 C-N-CA 125.928 1.691 . . . . 10.0 107.822 -177.477 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -113.37 168.02 10.08 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.535 0.683 . . . . 10.0 111.867 169.88 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.55 178.37 32.51 Favored Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.642 -0.983 . . . . 10.0 110.642 168.886 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.5 p -124.33 102.06 7.49 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 108.593 -0.891 . . . . 10.0 108.593 -173.182 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 pt -81.78 133.99 28.03 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 108.219 -1.03 . . . . 10.0 108.219 168.852 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.9 tptt -108.09 148.83 29.28 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 170.069 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.67 -6.94 35.96 Favored Glycine 0 C--N 1.337 0.586 0 CA-C-O 119.563 -0.576 . . . . 10.0 113.47 169.348 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -66.43 175.93 2.06 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 118.276 1.038 . . . . 10.0 110.518 176.029 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -108.66 164.6 12.23 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 105.289 -2.115 . . . . 10.0 105.289 165.557 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -53.78 161.23 1.18 Allowed 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 113.11 0.782 . . . . 10.0 113.11 -169.041 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.12 -179.19 51.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 124.318 0.961 . . . . 10.0 112.085 169.049 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 mt -57.04 146.35 27.58 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.076 1.75 . . . . 10.0 112.921 175.501 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.5 m-70 -149.33 144.73 26.63 Favored 'General case' 0 C--N 1.339 0.149 0 C-N-CA 124.423 1.089 . . . . 10.0 113.439 -179.835 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -26.08 122.64 0.04 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 127.621 2.534 . . . . 10.0 113.243 166.515 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -152.37 105.52 3.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 119.059 1.429 . . . . 10.0 111.818 169.425 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.17 171.67 17.01 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 112.801 0.667 . . . . 10.0 112.801 -178.153 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.1 m -99.95 146.29 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 111.924 -2.398 . . . . 10.0 106.275 167.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -120.83 144.95 48.08 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 -179.437 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . 0.403 ' CG ' ' HA3' ' B' ' 61' ' ' GLY . 0.0 OUTLIER -6.73 -86.59 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.992 2.117 . . . . 10.0 116.593 170.978 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -102.14 171.86 7.24 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 119.737 1.153 . . . . 10.0 109.825 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.78 -25.71 52.28 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 117.63 -1.65 . . . . 10.0 111.234 174.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -40.16 113.04 0.32 Allowed 'General case' 0 C--N 1.342 0.278 0 CA-C-N 118.165 0.982 . . . . 10.0 111.448 178.064 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.33 20.85 12.96 Favored 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.748 -1.115 . . . . 10.0 109.972 167.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.415 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 4.2 m -55.44 -35.7 65.72 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 118.922 0.783 . . . . 10.0 110.49 -169.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.55 -21.35 45.27 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.803 1.241 . . . . 10.0 113.524 178.446 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.61 81.96 1.28 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 109.579 -1.408 . . . . 10.0 109.579 -174.056 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.327 25.7 p 18.73 55.51 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.914 2.086 . . . . 10.0 115.451 -167.88 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.6 m -112.87 -57.76 2.24 Favored 'General case' 0 N--CA 1.442 -0.848 0 N-CA-C 105.454 -2.054 . . . . 10.0 105.454 173.953 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.4 t -90.83 -4.0 56.95 Favored 'General case' 0 N--CA 1.443 -0.789 0 C-N-CA 124.724 1.21 . . . . 10.0 110.355 -178.323 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.38 41.51 0.14 Allowed 'General case' 0 C--N 1.341 0.239 0 C-N-CA 124.542 1.137 . . . . 10.0 112.787 -179.279 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . 0.403 ' HA3' ' CG ' ' B' ' 49' ' ' GLU . . . 88.35 125.93 2.47 Favored Glycine 0 N--CA 1.44 -1.077 0 N-CA-C 118.433 2.133 . . . . 10.0 118.433 162.168 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -81.5 55.85 5.73 Favored 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 121.646 1.564 . . . . 10.0 109.9 165.147 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.447 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 17.2 m170 66.17 -72.05 0.08 Allowed 'General case' 0 N--CA 1.461 0.099 0 C-N-CA 127.946 2.499 . . . . 10.0 111.034 -175.956 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 0.72 56.95 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 131.358 3.863 . . . . 10.0 116.076 -172.64 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -63.23 162.07 27.26 Favored Pre-proline 0 CA--C 1.538 0.487 0 CA-C-N 115.846 -0.616 . . . . 10.0 111.463 -172.499 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -53.7 -38.44 84.71 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 123.251 2.634 . . . . 10.0 112.985 179.531 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.45 -1.88 4.01 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 113.054 0.761 . . . . 10.0 113.054 176.596 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.3 p 22.34 89.83 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 129.436 3.094 . . . . 10.0 115.392 169.073 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -130.53 -168.92 2.05 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 179.461 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -103.98 128.91 51.53 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.216 -1.401 . . . . 10.0 107.216 177.047 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -42.88 109.27 0.13 Allowed 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 124.063 0.852 . . . . 10.0 112.061 -178.815 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.25 -155.84 9.5 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.1 -2.4 . . . . 10.0 107.1 169.667 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.24 -153.32 6.06 Favored Glycine 0 C--N 1.332 0.312 0 CA-C-N 118.371 1.085 . . . . 10.0 112.675 173.044 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -61.1 -9.47 12.46 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.241 1.961 . . . . 10.0 111.685 174.753 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -91.84 -18.65 23.51 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.609 1.164 . . . . 10.0 109.006 -179.101 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 20.8 m-20 -113.6 162.85 15.7 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 -169.308 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -92.07 -18.12 24.03 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.623 -1.171 . . . . 10.0 109.674 172.028 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -97.98 2.54 49.07 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 126.258 1.823 . . . . 10.0 112.49 -170.399 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -35.37 125.44 0.63 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.542 1.537 . . . . 10.0 109.447 169.037 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -47.05 -54.67 9.78 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.497 0.589 . . . . 10.0 112.242 -168.694 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -172.01 -40.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 C-N-CA 125.814 1.646 . . . . 10.0 108.404 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -149.27 68.67 0.34 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 109.395 -1.482 . . . . 10.0 109.395 174.413 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -97.05 103.59 15.54 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 105.099 -2.186 . . . . 10.0 105.099 168.65 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 28.1 mt -82.27 25.44 0.6 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 118.891 0.769 . . . . 10.0 111.433 -176.828 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 75.7 -113.13 3.81 Favored Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 174.43 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -158.6 128.78 5.95 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 -174.867 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 16.7 m -106.09 132.46 53.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 123.015 0.526 . . . . 10.0 110.422 -169.681 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 99.1 m -85.39 107.71 17.51 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 127.605 2.362 . . . . 10.0 110.308 -170.956 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.29 137.51 32.92 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 123.153 0.581 . . . . 10.0 110.338 171.981 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -65.9 172.02 3.96 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.818 1.247 . . . . 10.0 109.541 168.518 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.59 -28.41 63.6 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.117 0.484 . . . . 10.0 110.917 177.735 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -80.89 -0.5 39.39 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.899 0.88 . . . . 10.0 111.187 -178.255 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.34 80.35 Favored Glycine 0 C--N 1.339 0.737 0 O-C-N 120.74 -1.225 . . . . 10.0 110.808 176.942 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.7 t -91.62 108.71 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 C-N-CA 126.971 2.108 . . . . 10.0 105.642 174.816 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.76 118.61 37.13 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 119.189 0.904 . . . . 10.0 108.633 169.102 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -81.13 95.97 7.05 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 126.64 1.976 . . . . 10.0 108.285 172.586 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -78.77 131.92 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 105.626 -1.99 . . . . 10.0 105.626 170.916 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 6.7 p -157.8 60.03 0.48 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.814 0.845 . . . . 10.0 109.073 -179.629 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 30.1 mt -114.87 160.2 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.072 -1.455 . . . . 10.0 107.072 -169.743 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -138.77 135.74 34.97 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 109.725 -0.472 . . . . 10.0 109.725 168.846 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 16.6 t0 -117.2 101.62 8.6 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 -178.866 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 40.3 m -85.7 54.53 3.16 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 124.798 1.239 . . . . 10.0 108.471 -173.695 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 92.0 t -136.91 -54.33 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 -171.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.385 0.0 OUTLIER -88.19 175.37 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.384 0.674 . . . . 10.0 111.544 170.408 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 56.0 m -157.83 97.2 1.54 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.418 -0.801 . . . . 10.0 109.882 -168.042 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.9 tp -37.88 -27.37 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 129.211 3.004 . . . . 10.0 116.37 -169.616 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 38.3 t . . . . . 0 N--CA 1.453 -0.296 0 C-N-CA 124.152 0.981 . . . . 10.0 109.743 176.544 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.8 t . . . . . 0 N--CA 1.442 -0.847 0 N-CA-C 110.318 -0.253 . . . . 10.0 110.318 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.2 pt 46.24 35.21 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.962 1.705 . . . . 10.0 113.774 177.87 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 11.5 mm -61.29 -71.19 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.452 0 C-N-CA 123.122 0.569 . . . . 10.0 110.012 -178.66 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.25 58.48 1.12 Allowed Glycine 0 CA--C 1.54 1.645 0 O-C-N 120.814 -1.179 . . . . 10.0 115.042 -177.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 30.7 mmt180 -103.77 161.47 13.9 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 127.161 2.185 . . . . 10.0 105.706 167.494 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.99 128.22 42.69 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 104.269 -2.493 . . . . 10.0 104.269 171.442 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 11.1 mp -108.26 151.27 26.18 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 109.084 -0.71 . . . . 10.0 109.084 172.292 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 93.7 t -137.77 138.41 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.948 0 N-CA-C 108.412 -0.958 . . . . 10.0 108.412 -175.377 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.7 p -104.12 131.49 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 168.154 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.2 m170 -113.7 159.8 19.31 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 116.433 2.012 . . . . 10.0 116.433 -170.692 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -43.79 -57.12 3.41 Favored 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 129.26 3.024 . . . . 10.0 112.133 176.09 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 75.0 mttt -118.67 171.31 8.28 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 124.198 0.999 . . . . 10.0 112.937 -168.581 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -80.24 138.64 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.647 1.579 . . . . 10.0 109.91 177.815 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.08 152.11 33.09 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -172.525 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -76.81 -30.16 56.29 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.624 1.97 . . . . 10.0 109.968 169.579 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 26.9 mt 54.4 49.88 17.43 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 124.115 0.966 . . . . 10.0 109.979 -172.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . 0.408 ' C ' ' H ' ' B' ' 129' ' ' GLY . . . 83.06 -43.36 3.11 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.033 -0.827 . . . . 10.0 111.033 176.062 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 28.2 mtmm -76.64 30.3 0.13 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.617 1.967 . . . . 10.0 112.236 -172.142 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . 0.408 ' H ' ' C ' ' B' ' 127' ' ' GLY . . . -92.54 -33.04 7.74 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 128.32 2.867 . . . . 10.0 109.474 168.647 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.34 21.68 77.42 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.001 -0.889 . . . . 10.0 112.104 -177.224 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -107.48 161.65 14.64 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 168.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 8.0 tm-20 -50.81 -51.67 48.63 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 114.957 -1.019 . . . . 10.0 108.279 172.448 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . 0.414 ' OE1' ' NZ ' ' B' ' 136' ' ' LYS . 7.2 tp10 -57.7 -40.51 79.65 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.812 0.671 . . . . 10.0 112.812 178.043 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -48.92 -50.09 36.97 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 119.9 1.227 . . . . 10.0 110.555 171.488 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -80.18 -19.63 46.63 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 112.983 0.734 . . . . 10.0 112.983 -174.23 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE1' ' B' ' 133' ' ' GLU . 2.5 ttmt -96.74 -42.76 7.84 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 124.957 1.303 . . . . 10.0 112.512 -173.403 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.447 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 60.7 p -135.14 -7.53 2.31 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 176.716 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.03 13.39 71.84 Favored Glycine 0 C--O 1.221 -0.662 0 CA-C-O 118.188 -1.34 . . . . 10.0 111.813 -170.039 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 64.81 19.54 11.87 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 120.18 1.99 . . . . 10.0 112.41 170.092 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.65 7.57 6.67 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.742 0.817 . . . . 10.0 112.525 -169.834 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.52 -166.81 52.69 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.453 -0.78 . . . . 10.0 111.262 173.075 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 50.2 m -60.36 141.79 55.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 113.522 0.934 . . . . 10.0 113.522 -168.505 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -60.38 97.19 0.05 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.85 1.66 . . . . 10.0 109.454 168.734 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 27.1 mt -72.64 -34.66 67.45 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 119.284 0.947 . . . . 10.0 111.989 178.51 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.15 149.05 28.35 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.887 -0.508 . . . . 10.0 110.476 176.257 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.74 142.14 46.41 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 126.991 2.116 . . . . 10.0 107.654 -176.439 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -140.88 160.96 26.74 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 109.176 -1.57 . . . . 10.0 109.176 168.944 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 51.8 t -119.23 131.45 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 104.52 -2.4 . . . . 10.0 104.52 174.181 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 20.3 mt -73.35 146.81 10.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-N 119.332 0.969 . . . . 10.0 109.288 174.77 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.71 150.35 22.5 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 125.858 1.694 . . . . 10.0 109.053 179.603 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.0 pt -72.47 132.21 33.7 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.359 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 -176.11 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.68 -42.6 7.16 Favored 'General case' 0 CA--C 1.512 -0.519 0 C-N-CA 123.9 0.88 . . . . 10.0 109.932 173.281 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.433 -1.299 0 N-CA-C 105.17 -2.159 . . . . 10.0 105.17 176.327 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.881 0 N-CA-C 107.894 -1.15 . . . . 10.0 107.894 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.1 t -86.47 -16.47 36.97 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 166.625 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 47.5 tttt -131.88 164.54 25.86 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 125.603 1.561 . . . . 10.0 108.244 177.239 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -158.03 171.97 19.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 126.018 1.727 . . . . 10.0 106.689 168.537 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -133.05 173.93 14.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 107.702 -1.221 . . . . 10.0 107.702 171.246 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.46 113.24 6.05 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.302 -1.37 . . . . 10.0 107.302 165.46 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 5.8 m -92.62 120.32 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.623 -1.251 . . . . 10.0 107.623 168.141 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -100.13 131.7 45.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.861 -1.533 . . . . 10.0 106.861 179.289 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -141.78 158.73 43.45 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 106.325 -1.731 . . . . 10.0 106.325 167.766 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.25 -64.04 0.04 OUTLIER Glycine 0 N--CA 1.461 0.326 0 C-N-CA 119.393 -1.384 . . . . 10.0 113.685 168.772 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -72.7 -41.44 65.28 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.411 -1.329 . . . . 10.0 107.411 -172.927 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.03 -67.72 0.42 Allowed Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 114.173 -1.376 . . . . 10.0 111.667 169.443 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -57.8 -39.57 86.07 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.581 2.187 . . . . 10.0 111.367 179.002 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.18 118.88 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 107.902 -1.147 . . . . 10.0 107.902 179.645 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.63 104.09 8.49 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 103.548 -2.76 . . . . 10.0 103.548 168.702 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -86.23 142.27 18.82 Favored Glycine 0 N--CA 1.44 -1.086 0 N-CA-C 108.281 -1.928 . . . . 10.0 108.281 177.014 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.514 ' CG2' HG22 ' B' ' 54' ' ' THR . 5.2 mt -140.73 92.52 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 -174.248 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.7 mm -102.1 139.36 23.39 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 C-N-CA 124.487 1.115 . . . . 10.0 110.2 174.04 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -112.37 118.89 36.46 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 127.452 2.301 . . . . 10.0 106.88 168.601 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -99.89 115.42 29.58 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 105.832 -1.914 . . . . 10.0 105.832 175.377 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -116.81 127.25 54.14 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 119.032 0.833 . . . . 10.0 110.444 170.002 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -79.8 88.16 5.25 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 106.236 -1.764 . . . . 10.0 106.236 174.562 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.23 -40.55 16.63 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 126.729 2.012 . . . . 10.0 112.099 -167.612 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -130.4 162.36 29.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 101.576 -3.49 . . . . 10.0 101.576 162.766 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.7 t -55.7 -33.36 64.11 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.738 -0.838 . . . . 10.0 108.738 173.518 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 30.3 m-80 -99.39 -2.15 36.93 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 125.749 1.62 . . . . 10.0 110.948 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.25 164.73 24.78 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.762 -0.935 . . . . 10.0 110.762 -170.804 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -61.95 149.57 89.74 Favored 'Trans proline' 0 N--CA 1.449 -1.125 0 C-N-CA 121.563 1.509 . . . . 10.0 108.29 169.477 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.0 t -86.11 122.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 -179.403 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.3 tttt -90.28 113.99 25.94 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 108.205 -1.035 . . . . 10.0 108.205 177.566 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.7 m -98.34 58.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 125.725 1.61 . . . . 10.0 108.395 -172.486 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.5 p90 -77.27 158.32 30.29 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 119.915 -0.714 . . . . 10.0 110.011 -175.281 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.02 179.9 48.21 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.968 179.145 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 20.4 m -150.41 96.39 2.39 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.503 -1.295 . . . . 10.0 107.503 -178.729 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.9 pt -77.65 154.76 5.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 170.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -138.82 146.97 41.93 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.266 -1.383 . . . . 10.0 107.266 169.317 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.09 -2.29 38.01 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.46 170.642 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.7 mp -72.31 178.83 3.7 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 119.398 1.599 . . . . 10.0 108.802 169.531 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 11.2 t -88.37 176.48 7.18 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 166.717 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 49.4 tt0 -64.02 169.69 4.15 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.04 0.936 . . . . 10.0 112.111 -172.311 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.12 -176.51 48.79 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 124.085 0.85 . . . . 10.0 113.079 167.15 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -62.42 150.85 38.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 123.815 0.846 . . . . 10.0 109.696 174.13 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -142.66 153.4 43.38 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 113.895 1.072 . . . . 10.0 113.895 176.614 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -39.54 125.02 2.1 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 127.542 2.496 . . . . 10.0 110.459 163.049 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -149.73 105.85 3.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 119.823 1.811 . . . . 10.0 108.094 165.724 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.486 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -153.04 -179.99 8.18 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-O 121.844 0.83 . . . . 10.0 113.173 179.558 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.0 m -102.85 151.51 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 CA-C-N 113.219 -1.81 . . . . 10.0 110.345 174.116 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.85 133.4 45.89 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.276 1.83 . . . . 10.0 106.433 178.015 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.8 tp10 -62.41 -55.8 24.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 114.428 1.27 . . . . 10.0 114.428 -165.527 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 59.2 m-85 -77.66 144.94 36.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 117.612 -1.635 . . . . 10.0 108.243 179.652 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.38 20.8 48.35 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 172.684 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -80.67 70.73 7.47 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 125.765 2.698 . . . . 10.0 109.045 179.649 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -69.33 -13.5 62.41 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 111.242 -2.708 . . . . 10.0 111.852 -174.056 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -27.69 -52.99 0.08 Allowed 'General case' 0 C--N 1.341 0.201 1 C-N-CA 131.92 4.088 . . . . 10.0 114.283 -175.799 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.53 -14.77 59.58 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 124.068 0.947 . . . . 10.0 112.657 -172.518 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 107.1 52.96 0.71 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.925 -2.07 . . . . 10.0 107.925 -168.257 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 46.89 50.91 13.21 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.768 1.396 . . . . 10.0 114.768 169.784 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.2 p -111.79 -57.84 2.2 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 106.347 -1.723 . . . . 10.0 106.347 171.561 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.7 m -47.63 -33.19 6.41 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 127.167 2.187 . . . . 10.0 111.459 177.413 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -28.07 -39.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 128.666 2.786 . . . . 10.0 113.796 168.255 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.72 159.86 23.79 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 108.67 -1.772 . . . . 10.0 108.67 169.346 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -70.71 -170.25 0.44 Allowed 'Trans proline' 0 N--CA 1.445 -1.354 0 N-CA-C 107.585 -1.736 . . . . 10.0 107.585 167.5 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 36.9 m170 -78.89 55.93 1.83 Allowed 'General case' 0 CA--C 1.545 0.777 0 O-C-N 120.622 -1.299 . . . . 10.0 111.636 -170.121 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -74.88 64.47 1.29 Allowed 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 119.86 1.209 . . . . 10.0 112.275 -175.512 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.7 p-10 -57.6 155.37 21.1 Favored Pre-proline 0 CA--C 1.538 0.491 0 C-N-CA 123.283 0.633 . . . . 10.0 111.164 169.904 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -59.05 -45.8 26.05 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.534 2.156 . . . . 10.0 111.425 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -75.88 64.91 1.9 Allowed 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.116 -0.698 . . . . 10.0 109.116 174.725 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.9 p -42.04 113.76 0.47 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.685 1.194 . . . . 10.0 109.564 179.397 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.4 mtt-85 -145.97 -177.49 5.62 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 105.16 -2.163 . . . . 10.0 105.16 -169.88 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.427 ' HZ3' ' CD ' ' A' ' 78' ' ' GLU . 19.4 mmtp -75.0 154.34 38.12 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 118.099 -1.44 . . . . 10.0 109.127 176.069 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -69.92 105.39 2.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 162.401 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.64 -140.65 6.85 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 107.909 -2.076 . . . . 10.0 107.909 173.822 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.425 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -179.7 -155.43 15.23 Favored Glycine 0 C--O 1.227 -0.309 0 CA-C-O 117.521 -1.711 . . . . 10.0 109.293 169.614 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -67.32 13.95 0.15 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 CA-C-N 120.378 2.089 . . . . 10.0 111.829 170.335 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.425 ' H ' ' C ' ' A' ' 73' ' ' GLY . 51.1 mttm -121.2 3.15 10.39 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-O 117.948 -1.025 . . . . 10.0 111.634 170.828 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -127.21 159.09 35.36 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 170.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -79.4 -32.52 42.97 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.639 -1.615 . . . . 10.0 106.639 167.017 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.427 ' CD ' ' HZ3' ' A' ' 70' ' ' LYS . 15.4 mt-10 -82.89 28.48 0.49 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 124.58 1.152 . . . . 10.0 112.274 -168.643 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 164.08 11.97 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 119.839 1.199 . . . . 10.0 109.753 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -78.54 -67.58 0.73 Allowed 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.733 -0.604 . . . . 10.0 109.515 178.662 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -158.72 -116.35 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.827 -1.546 . . . . 10.0 106.827 -174.207 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -78.34 54.7 3.99 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-N 119.704 1.138 . . . . 10.0 111.012 178.749 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -79.46 92.3 5.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.735 -1.95 . . . . 10.0 105.735 170.014 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 29.1 mt -71.46 -21.7 61.92 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 118.755 -1.178 . . . . 10.0 108.204 175.325 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 83.13 -73.37 2.69 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.754 -1.338 . . . . 10.0 109.754 168.72 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -139.96 103.09 4.55 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 108.802 -0.814 . . . . 10.0 108.802 -169.412 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 23.9 m -109.09 129.53 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 119.068 0.849 . . . . 10.0 111.435 176.12 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -79.25 110.18 14.28 Favored 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 127.724 2.41 . . . . 10.0 112.371 -170.45 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.81 132.6 39.42 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 122.702 0.401 . . . . 10.0 110.154 169.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -53.5 166.98 0.24 Allowed 'General case' 0 CA--C 1.518 -0.258 0 O-C-N 124.093 0.871 . . . . 10.0 109.198 166.144 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -41.56 -43.19 2.64 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 126.324 1.85 . . . . 10.0 110.419 169.343 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.78 0.48 39.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.351 1.46 . . . . 10.0 110.948 -170.913 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.99 2.91 85.83 Favored Glycine 0 C--N 1.339 0.717 0 N-CA-C 111.408 -0.677 . . . . 10.0 111.408 178.116 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 33.1 t -78.97 106.5 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.376 -1.712 . . . . 10.0 106.376 -178.38 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -115.23 118.41 33.21 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 118.645 0.657 . . . . 10.0 109.638 176.541 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -79.73 126.68 31.26 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.526 1.93 . . . . 10.0 109.068 174.403 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -118.98 134.01 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.955 0 N-CA-C 107.319 -1.363 . . . . 10.0 107.319 175.548 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.8 p -156.62 59.75 0.55 Allowed 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 118.461 0.573 . . . . 10.0 110.872 174.457 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.11 153.48 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 -178.232 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -123.86 131.68 53.62 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 123.936 0.894 . . . . 10.0 108.908 169.398 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -120.57 147.95 44.51 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-O 121.639 0.733 . . . . 10.0 109.042 179.618 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.8 p -105.4 7.24 33.14 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.394 2.678 . . . . 10.0 111.865 -173.31 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.2 p -122.89 9.42 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.35 0.977 . . . . 10.0 110.763 179.525 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -108.45 150.03 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 105.944 -1.873 . . . . 10.0 105.944 176.773 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.7 m -146.29 152.69 39.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 169.939 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 55.4 mt -103.56 0.2 30.58 Favored 'General case' 0 C--O 1.237 0.437 0 C-N-CA 123.751 0.82 . . . . 10.0 111.66 -175.538 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.4 t -162.03 -172.38 3.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 126.472 1.909 . . . . 10.0 107.439 166.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 105.85 -69.87 0.23 Allowed Glycine 0 C--O 1.227 -0.336 0 C-N-CA 125.291 1.424 . . . . 10.0 110.307 167.302 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -162.69 -50.15 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 124.873 1.269 . . . . 10.0 107.611 -179.922 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -80.32 41.96 0.56 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.176 0.99 . . . . 10.0 109.034 179.449 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.5 t -81.4 83.8 6.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 126.076 1.75 . . . . 10.0 106.758 -171.773 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 20.8 pt -55.63 -21.61 10.42 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 113.649 0.981 . . . . 10.0 113.649 -170.172 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.6 mp -14.04 -56.5 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 129.369 3.067 . . . . 10.0 115.139 174.866 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -87.7 6.6 83.19 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.208 -1.329 . . . . 10.0 114.812 -170.468 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.6 mpt_? -77.45 175.78 9.49 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.887 1.344 . . . . 10.0 108.751 174.014 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -113.94 127.65 56.06 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.723 -1.584 . . . . 10.0 106.723 169.91 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.5 mt -102.86 152.73 20.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 118.754 0.707 . . . . 10.0 109.395 174.309 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.2 t -141.46 136.22 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 123.542 0.526 . . . . 10.0 110.178 -171.927 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.4 m -104.52 139.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 O-C-N 124.641 1.213 . . . . 10.0 109.201 164.13 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -117.14 163.21 16.62 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 114.954 1.465 . . . . 10.0 114.954 -169.15 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -55.99 -54.66 42.19 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.693 -1.14 . . . . 10.0 110.103 178.032 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -111.31 173.4 6.36 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-O 121.305 0.574 . . . . 10.0 110.277 -178.231 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -96.19 136.82 36.15 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 125.24 1.416 . . . . 10.0 108.16 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.486 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -77.41 161.18 28.19 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 121.474 0.654 . . . . 10.0 111.943 -174.279 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -73.85 -15.5 61.16 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.763 -1.108 . . . . 10.0 110.809 -177.349 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mt 58.31 44.81 17.99 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.383 1.073 . . . . 10.0 108.292 -172.394 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.74 -15.65 59.45 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.96 1.267 . . . . 10.0 113.786 170.005 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -75.5 -4.46 39.89 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 114.838 1.421 . . . . 10.0 114.838 -166.548 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.51 -23.77 75.21 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-N 119.422 1.01 . . . . 10.0 110.65 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.34 18.74 50.95 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.812 -0.993 . . . . 10.0 114.429 179.267 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -116.92 176.66 5.02 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 119.474 1.637 . . . . 10.0 110.735 179.094 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -32.48 -61.76 0.25 Allowed 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 126.631 1.973 . . . . 10.0 112.186 171.396 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.88 -44.55 92.73 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.43 0.692 . . . . 10.0 111.529 178.536 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.8 m -49.24 -42.15 39.74 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 119.294 -0.384 . . . . 10.0 110.505 -176.06 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -87.18 -3.37 59.05 Favored 'General case' 0 N--CA 1.451 -0.386 0 O-C-N 124.32 1.013 . . . . 10.0 112.605 -172.464 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -114.53 -48.52 2.86 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.462 1.105 . . . . 10.0 111.521 -174.986 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 30.4 p -133.44 0.46 3.34 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 119.108 0.867 . . . . 10.0 112.286 171.658 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.75 -105.53 3.04 Favored Glycine 0 C--N 1.341 0.819 0 N-CA-C 107.289 -2.325 . . . . 10.0 107.289 -172.864 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.2 m-20 -167.52 43.44 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 125.298 1.439 . . . . 10.0 108.541 -179.477 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.43 -15.18 63.23 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.674 -0.641 . . . . 10.0 111.756 -177.636 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.17 -162.66 54.54 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 -176.742 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.1 m -62.25 149.52 41.67 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 113.736 1.013 . . . . 10.0 113.736 -170.043 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.2 74.59 0.69 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.161 2.584 . . . . 10.0 111.267 174.113 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.58 -27.32 67.62 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.187 -0.945 . . . . 10.0 113.361 -178.701 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.36 153.17 30.05 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 118.881 0.764 . . . . 10.0 110.392 171.737 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.0 p -155.52 155.64 33.77 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 123.081 0.552 . . . . 10.0 110.367 -168.482 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.92 162.64 30.56 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 124.054 0.835 . . . . 10.0 112.023 -174.727 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 62.1 t -122.64 66.85 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 105.263 -2.125 . . . . 10.0 105.263 -172.515 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mm 30.44 -114.63 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 C-N-CA 127.1 2.16 . . . . 10.0 113.349 -173.737 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 126.61 102.5 1.25 Allowed Glycine 0 CA--C 1.531 1.045 0 N-CA-C 109.653 -1.379 . . . . 10.0 109.653 -169.536 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 56.3 mt -53.31 137.6 13.56 Favored 'Isoleucine or valine' 0 C--N 1.341 0.197 0 C-N-CA 124.151 0.98 . . . . 10.0 110.415 170.717 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.57 158.58 44.07 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 107.92 -1.141 . . . . 10.0 107.92 169.748 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.7 tt0 . . . . . 0 C--O 1.25 1.081 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 168.133 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.875 0 CA-C-O 118.538 -0.744 . . . . 10.0 109.62 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.7 t -90.57 -36.71 14.29 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.666 0.787 . . . . 10.0 110.705 169.951 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.3 tttp -127.44 124.15 37.77 Favored 'General case' 0 C--O 1.238 0.485 0 C-N-CA 125.798 1.639 . . . . 10.0 109.217 -171.814 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.11 155.92 49.89 Favored 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.741 0.816 . . . . 10.0 109.687 176.673 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.1 m -106.68 178.73 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 O-C-N 123.965 0.791 . . . . 10.0 109.94 176.944 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -160.7 93.75 1.01 Allowed 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.35 1.46 . . . . 10.0 108.056 175.68 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -92.41 95.09 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 C-N-CA 123.753 0.821 . . . . 10.0 110.722 179.453 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.6 mp -80.09 130.41 35.23 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 123.192 0.597 . . . . 10.0 109.41 175.938 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.34 158.99 44.44 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 106.211 -1.774 . . . . 10.0 106.211 168.938 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.48 -64.39 0.05 OUTLIER Glycine 0 CA--C 1.51 -0.231 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.967 169.311 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -70.34 -45.01 67.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 -178.831 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.11 -70.52 0.38 Allowed Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.425 -1.261 . . . . 10.0 110.784 169.571 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -57.12 -35.0 98.78 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 123.228 2.618 . . . . 10.0 111.821 175.81 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 37.4 t -68.63 89.24 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 C-N-CA 124.623 1.169 . . . . 10.0 107.986 179.033 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -113.12 116.22 29.51 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.109 -1.441 . . . . 10.0 107.109 -179.871 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.3 136.79 13.72 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.368 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 7.8 mt -135.49 74.68 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 -175.286 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.7 mm -95.09 149.8 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 114.826 -1.079 . . . . 10.0 109.655 -172.347 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -126.37 114.6 18.43 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 126.775 2.03 . . . . 10.0 106.666 -170.57 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -102.36 115.54 30.78 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 106.229 -1.767 . . . . 10.0 106.229 176.559 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -119.24 137.51 53.61 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.085 0.772 . . . . 10.0 113.085 169.13 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -113.08 111.0 21.39 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 104.638 -2.356 . . . . 10.0 104.638 167.754 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? . . . . . 0 N--CA 1.445 -0.701 0 C-N-CA 125.554 1.542 . . . . 10.0 109.136 -176.117 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.891 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.02 163.16 39.67 Favored 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 123.051 2.501 . . . . 10.0 109.207 178.105 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -79.57 134.64 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 104.831 -2.285 . . . . 10.0 104.831 166.934 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 32.5 mttt -114.67 125.13 53.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 104.812 -2.292 . . . . 10.0 104.812 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -109.48 104.14 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 C-N-CA 126.404 1.882 . . . . 10.0 106.587 -178.072 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -126.16 159.46 32.88 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 112.728 0.64 . . . . 10.0 112.728 -178.029 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.99 -146.09 13.99 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 107.811 -2.116 . . . . 10.0 107.811 169.948 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 31.8 p -155.38 160.68 40.87 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 122.113 0.958 . . . . 10.0 112.044 175.033 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -110.92 145.42 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-N 113.25 -1.795 . . . . 10.0 107.509 166.871 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -125.15 142.97 51.17 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 107.167 -1.42 . . . . 10.0 107.167 168.834 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.22 0.57 20.69 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.082 0.849 . . . . 10.0 113.247 176.634 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.41 176.87 8.95 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 118.594 1.197 . . . . 10.0 110.321 -179.155 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -109.62 153.74 23.78 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.925 -1.88 . . . . 10.0 105.925 166.097 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.09 147.83 2.0 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.594 1.157 . . . . 10.0 112.315 -171.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.75 -173.22 18.25 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.05 0.833 . . . . 10.0 111.795 170.774 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -73.03 146.89 45.59 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.26 1.424 . . . . 10.0 110.594 -179.142 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -147.06 147.97 31.16 Favored 'General case' 0 C--N 1.342 0.25 0 N-CA-C 114.509 1.3 . . . . 10.0 114.509 -177.49 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -26.46 121.99 0.04 OUTLIER Glycine 0 C--N 1.339 0.738 0 C-N-CA 128.653 3.025 . . . . 10.0 114.501 164.587 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -152.72 109.2 3.42 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.665 1.233 . . . . 10.0 110.544 166.267 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.14 179.17 7.82 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.254 0.55 . . . . 10.0 112.193 173.098 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.4 m -116.56 134.24 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.066 -1.879 . . . . 10.0 106.848 166.02 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -110.91 152.99 26.1 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 125.268 1.427 . . . . 10.0 107.912 -178.701 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.23 -54.71 43.67 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.875 -0.602 . . . . 10.0 111.413 -172.863 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.51 111.96 13.79 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -169.189 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.57 -30.47 68.67 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.164 -1.174 . . . . 10.0 110.164 169.44 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -40.29 139.43 0.74 Allowed 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 124.788 1.235 . . . . 10.0 111.214 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -143.88 24.07 1.69 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 124.353 1.061 . . . . 10.0 112.551 169.863 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.514 HG22 ' CG2' ' A' ' 17' ' ' ILE . 3.6 m -61.82 -35.15 77.39 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.371 0.668 . . . . 10.0 110.748 -174.957 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.23 -16.45 59.82 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 122.215 -0.303 . . . . 10.0 111.582 176.103 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.39 -151.59 19.08 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 106.61 -2.596 . . . . 10.0 106.61 -169.656 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 1.8 m -69.26 67.63 0.19 Allowed 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 126.018 1.727 . . . . 10.0 111.298 -179.039 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -163.88 -53.16 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.317 1.847 . . . . 10.0 107.583 -179.299 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -39.16 -40.59 0.74 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 127.648 2.379 . . . . 10.0 111.235 174.132 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.81 -47.55 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.009 2.524 . . . . 10.0 114.062 168.28 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.08 152.24 26.45 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 110.424 -1.071 . . . . 10.0 110.424 173.512 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -79.13 46.94 2.34 Favored 'Trans proline' 0 CA--C 1.537 0.629 0 C-N-CA 124.379 3.386 . . . . 10.0 113.482 -171.065 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 57.14 58.03 4.19 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.1 1.76 . . . . 10.0 108.585 -175.825 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -66.77 75.64 0.11 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.769 0.795 . . . . 10.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -77.65 137.02 63.03 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.2 -0.938 . . . . 10.0 110.508 -177.52 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.06 -52.16 0.99 Allowed 'Trans proline' 0 N--CA 1.455 -0.752 0 C-N-CA 122.578 2.185 . . . . 10.0 111.132 -173.19 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mp -76.17 65.74 2.19 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 108.122 -1.066 . . . . 10.0 108.122 175.054 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 66.6 p -30.02 101.64 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.325 2.25 . . . . 10.0 114.021 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.2 mtp180 -139.85 177.7 7.77 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.072 0.949 . . . . 10.0 110.927 -174.729 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 67.2 mmtt -107.26 89.07 2.89 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 113.233 0.827 . . . . 10.0 113.233 -168.66 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 81.9 t60 5.73 92.85 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.23 0 C-N-CA 128.45 2.7 . . . . 10.0 114.849 179.219 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.24 -139.04 9.64 Favored Glycine 0 N--CA 1.442 -0.921 0 N-CA-C 110.144 -1.182 . . . . 10.0 110.144 178.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.03 -162.24 34.34 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 175.394 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.62 1.31 1.81 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 CA-C-N 120.055 1.927 . . . . 10.0 111.472 168.417 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.31 8.6 18.09 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.913 1.685 . . . . 10.0 110.516 176.4 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -142.03 169.62 17.24 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.442 1.019 . . . . 10.0 108.948 165.125 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -87.99 -22.6 24.17 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.235 -1.394 . . . . 10.0 107.235 167.996 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 -82.27 31.05 0.39 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 120.661 -1.274 . . . . 10.0 112.777 -176.526 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.6 132.7 54.77 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 172.898 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 16.9 m170 -63.17 -61.52 2.32 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 121.176 0.512 . . . . 10.0 110.538 -177.787 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.4 p -168.23 -56.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 -179.141 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.16 63.14 0.63 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 177.45 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.1 m-20 -92.7 95.5 9.6 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 104.101 -2.555 . . . . 10.0 104.101 167.528 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 9.2 mp -66.75 -26.61 67.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 118.828 0.74 . . . . 10.0 109.342 -176.713 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 116.9 -88.17 0.45 Allowed Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 108.106 -1.998 . . . . 10.0 108.106 168.631 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 38.5 m-80 -149.39 142.49 24.96 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.58 134.12 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 107.657 -1.238 . . . . 10.0 107.657 169.001 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -86.9 130.06 34.62 Favored 'General case' 0 C--O 1.226 -0.166 0 C-N-CA 123.978 0.911 . . . . 10.0 108.643 179.663 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.77 127.87 52.71 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.227 1.411 . . . . 10.0 109.43 175.247 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -61.29 167.71 3.04 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.888 1.368 . . . . 10.0 109.933 168.064 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -52.32 -30.8 30.11 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.681 1.192 . . . . 10.0 110.77 172.202 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -77.25 -7.73 56.42 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.035 0.379 . . . . 10.0 110.758 -177.541 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.14 17.01 73.02 Favored Glycine 0 C--N 1.34 0.788 0 N-CA-C 110.611 -0.995 . . . . 10.0 110.611 -178.497 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -94.54 119.29 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 C-N-CA 127.359 2.264 . . . . 10.0 105.434 172.532 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -115.82 126.6 54.21 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 123.706 0.802 . . . . 10.0 109.017 174.431 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -88.57 133.62 34.11 Favored 'General case' 0 N--CA 1.437 -1.096 0 C-N-CA 127.154 2.181 . . . . 10.0 109.567 178.936 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 50.1 t -113.97 130.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 C-N-CA 125.825 1.65 . . . . 10.0 108.228 174.624 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 78.1 p -157.78 73.81 0.71 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.132 0.973 . . . . 10.0 108.923 169.685 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.29 163.06 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 106.984 -1.487 . . . . 10.0 106.984 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -147.72 150.45 34.33 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 125.191 1.396 . . . . 10.0 109.933 174.333 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -155.32 159.28 39.84 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.323 -1.362 . . . . 10.0 107.323 172.881 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.2 p -104.81 -16.85 14.79 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 128.136 2.574 . . . . 10.0 112.281 179.053 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 4.5 p -78.34 -38.28 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 -176.387 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -70.64 154.72 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 C-N-CA 124.522 1.129 . . . . 10.0 107.978 168.771 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 11.1 m -153.77 163.28 40.28 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 172.088 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 79.2 mt -101.96 -11.06 19.24 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.797 0.839 . . . . 10.0 111.539 176.937 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.451 -0.38 0 C-N-CA 125.808 1.643 . . . . 10.0 107.239 169.498 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 13.6 t . . . . . 0 N--CA 1.438 -1.069 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 39.4 pt 162.87 -23.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.336 1 C-N-CA 133.226 4.61 . . . . 10.0 107.34 -171.482 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -43.25 120.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 118.854 0.752 . . . . 10.0 110.397 175.425 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 104.0 -6.55 47.53 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.786 -1.008 . . . . 10.0 113.781 179.025 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -77.1 154.64 33.1 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 118.309 1.055 . . . . 10.0 110.288 175.562 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 32.6 m -94.93 109.03 21.09 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.565 1.146 . . . . 10.0 109.183 178.553 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -79.57 147.92 31.94 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 167.272 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 65.3 t -142.63 132.87 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 C-N-CA 123.953 0.901 . . . . 10.0 109.551 -173.565 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.7 t -109.0 136.67 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.648 0 C-N-CA 126.173 1.789 . . . . 10.0 109.898 172.239 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 6.6 m-70 -117.52 158.68 24.13 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 116.466 2.024 . . . . 10.0 116.466 -171.179 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 57.8 tt0 -48.8 -53.06 20.72 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 129.836 3.254 . . . . 10.0 111.813 175.166 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -112.75 168.79 9.38 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 123.332 0.653 . . . . 10.0 111.876 -169.704 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.62 154.1 40.92 Favored 'General case' 0 N--CA 1.443 -0.82 0 O-C-N 125.016 1.448 . . . . 10.0 108.214 169.013 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -107.25 140.53 39.98 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 124.197 0.999 . . . . 10.0 109.032 -169.014 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -72.99 -28.99 62.71 Favored 'General case' 0 C--O 1.232 0.168 0 O-C-N 123.724 0.64 . . . . 10.0 109.803 -175.331 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.6 mt 59.86 50.95 6.4 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 107.896 -1.15 . . . . 10.0 107.896 -171.413 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 94.05 -39.33 2.94 Favored Glycine 0 CA--C 1.521 0.456 0 C-N-CA 126.189 1.852 . . . . 10.0 110.788 169.531 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 29.8 mtmm -80.91 39.79 0.51 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.004 0.922 . . . . 10.0 112.591 -169.485 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.18 -24.11 13.39 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 126.565 2.031 . . . . 10.0 110.262 169.186 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 59.94 36.11 89.15 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 123.732 0.682 . . . . 10.0 111.547 176.517 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -137.67 166.6 23.55 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 108.467 -0.938 . . . . 10.0 108.467 173.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -48.5 -47.4 38.79 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 124.363 1.065 . . . . 10.0 110.295 -178.586 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . 0.462 ' CD ' ' HZ2' ' B' ' 136' ' ' LYS . 5.1 tp10 -70.48 -33.7 71.55 Favored 'General case' 0 N--CA 1.448 -0.549 0 O-C-N 121.922 -0.486 . . . . 10.0 111.671 179.417 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 26.6 p -55.69 -45.76 77.74 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 119.398 0.999 . . . . 10.0 110.435 177.274 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.5 t -76.3 -14.38 60.11 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.756 -0.656 . . . . 10.0 112.345 -171.728 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.462 ' HZ2' ' CD ' ' B' ' 133' ' ' GLU . 10.5 ttmt -107.16 -49.34 3.29 Favored 'General case' 0 N--CA 1.434 -1.255 0 C-N-CA 125.987 1.715 . . . . 10.0 110.904 -172.141 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.03 23.77 2.58 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.972 0.806 . . . . 10.0 111.673 176.223 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 61.4 26.62 66.56 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 119.516 1.053 . . . . 10.0 111.951 177.983 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 57.16 23.19 8.32 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.286 1.043 . . . . 10.0 112.908 -178.798 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.58 -12.31 9.66 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 125.554 1.542 . . . . 10.0 114.045 -175.889 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.11 -162.92 52.93 Favored Glycine 0 N--CA 1.445 -0.765 0 O-C-N 121.029 -1.044 . . . . 10.0 110.849 172.193 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.4 m -56.19 128.32 35.04 Favored 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 124.097 0.959 . . . . 10.0 111.807 -167.96 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -73.48 98.78 2.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.45 1.1 . . . . 10.0 108.105 178.169 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 36.2 mt -79.24 -28.53 42.46 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.039 0.536 . . . . 10.0 112.024 -171.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.59 138.74 22.41 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.146 -0.687 . . . . 10.0 109.146 179.341 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -137.52 130.23 30.01 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 -178.185 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.24 -174.05 13.63 Favored Glycine 0 C--O 1.228 -0.235 0 N-CA-C 109.5 -1.44 . . . . 10.0 109.5 178.459 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.7 t -131.68 150.97 34.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 103.478 -2.786 . . . . 10.0 103.478 168.245 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.1 mt -60.12 -86.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.574 1.15 . . . . 10.0 111.534 -168.166 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.94 128.88 6.17 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 110.627 -0.989 . . . . 10.0 110.627 -179.01 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.6 pt -76.68 126.91 37.76 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 177.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.99 -45.68 12.86 Favored 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 108.533 -0.914 . . . . 10.0 108.533 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 . . . . . 0 C--O 1.253 1.262 0 CA-C-O 116.016 -1.945 . . . . 10.0 109.665 -176.064 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 106.331 -1.729 . . . . 10.0 106.331 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -88.81 -16.09 32.93 Favored 'General case' 0 C--O 1.228 -0.076 0 CA-C-N 119.917 1.235 . . . . 10.0 111.475 177.118 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -151.88 144.54 24.27 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.245 0.475 . . . . 10.0 112.261 177.792 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.2 160.62 37.28 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.832 1.653 . . . . 10.0 109.497 173.865 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 t -121.58 150.99 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 125.762 1.625 . . . . 10.0 109.93 179.502 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.55 100.59 5.01 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.782 1.233 . . . . 10.0 108.98 169.671 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -83.97 109.12 17.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 109.85 -0.426 . . . . 10.0 109.85 170.555 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -96.19 145.95 25.1 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.069 0.948 . . . . 10.0 109.316 177.419 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -157.89 164.53 36.82 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 107.89 -1.152 . . . . 10.0 107.89 171.227 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.07 -67.3 0.02 OUTLIER Glycine 0 C--O 1.229 -0.174 0 N-CA-C 111.574 -0.611 . . . . 10.0 111.574 171.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -75.99 -42.1 49.22 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 107.358 -1.349 . . . . 10.0 107.358 -176.557 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.98 -67.12 0.53 Allowed Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 114.851 -1.068 . . . . 10.0 111.615 -177.308 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -57.29 -41.69 70.5 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.157 1.904 . . . . 10.0 110.888 179.563 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -69.56 108.84 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 N-CA-C 107.176 -1.416 . . . . 10.0 107.176 176.843 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -120.48 117.51 27.84 Favored 'General case' 0 N--CA 1.437 -1.098 0 C-N-CA 126.049 1.74 . . . . 10.0 106.757 174.395 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -95.31 142.27 15.99 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 108.973 -1.651 . . . . 10.0 108.973 169.177 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 mt -145.49 67.18 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 N-CA-C 106.049 -1.834 . . . . 10.0 106.049 -173.611 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.6 mm -90.91 135.51 26.53 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 CA-C-N 116.39 -0.368 . . . . 10.0 110.061 -172.4 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 m-80 -101.84 132.55 47.55 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 125.019 1.328 . . . . 10.0 108.708 175.589 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -116.18 87.41 2.68 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 126.626 1.97 . . . . 10.0 107.822 178.541 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -83.94 155.83 22.64 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-O 121.46 0.648 . . . . 10.0 111.169 175.68 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -145.23 99.16 3.27 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 126.068 1.747 . . . . 10.0 107.174 174.828 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.4 ptmt -62.31 -57.48 11.22 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 122.172 -0.33 . . . . 10.0 110.128 179.305 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -128.91 163.01 26.21 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 103.814 -2.661 . . . . 10.0 103.814 168.093 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.4 t -76.75 -4.59 44.19 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 119.172 0.897 . . . . 10.0 109.904 173.189 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -80.92 -21.86 40.15 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 124.452 1.101 . . . . 10.0 109.532 168.914 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.71 148.72 30.81 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 110.132 -1.187 . . . . 10.0 110.132 178.316 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -64.72 141.14 71.02 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 N-CA-C 107.803 -1.653 . . . . 10.0 107.803 169.245 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.8 t -78.3 83.12 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 174.241 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.0 tttt -63.33 111.58 2.34 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.915 -1.142 . . . . 10.0 107.915 171.429 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 18.1 m -91.62 121.67 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 N-CA-C 106.884 -1.524 . . . . 10.0 106.884 176.769 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 31.0 p90 -133.04 151.09 52.08 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 122.19 0.995 . . . . 10.0 113.145 170.5 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.08 -177.19 47.17 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 109.629 -1.388 . . . . 10.0 109.629 170.071 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.2 m -128.76 103.27 6.97 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.745 -1.206 . . . . 10.0 107.745 -173.551 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 pt -77.02 150.36 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.39 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 168.281 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.63 141.86 43.23 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.644 -0.502 . . . . 10.0 109.644 169.312 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.05 0.33 28.48 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.323 0.963 . . . . 10.0 112.899 175.76 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -65.12 176.05 1.41 Allowed 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 121.998 0.904 . . . . 10.0 109.669 169.922 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -98.92 167.1 10.95 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.649 -1.612 . . . . 10.0 106.649 164.95 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -58.19 169.08 0.89 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.398 1.079 . . . . 10.0 111.256 -171.251 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.94 -178.34 45.11 Favored Glycine 0 N--CA 1.448 -0.526 0 O-C-N 120.883 -1.136 . . . . 10.0 111.896 166.992 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.9 mp -70.63 153.3 42.99 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.283 1.433 . . . . 10.0 110.395 179.832 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -148.92 143.44 26.2 Favored 'General case' 0 C--N 1.34 0.185 0 N-CA-C 113.627 0.973 . . . . 10.0 113.627 -175.439 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.06 127.91 0.25 Allowed Glycine 0 C--N 1.34 0.777 0 C-N-CA 126.963 2.221 . . . . 10.0 111.644 164.391 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.39 103.48 2.33 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 119.744 1.772 . . . . 10.0 111.394 168.409 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.521 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.01 174.62 13.43 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 114.253 1.205 . . . . 10.0 114.253 -173.382 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.1 p -79.16 140.81 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 112.016 -2.356 . . . . 10.0 107.966 166.567 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.4 ' CD2' ' CG2' ' A' ' 118' ' ' VAL . 86.5 m-70 -126.17 100.5 6.35 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 102.875 -3.009 . . . . 10.0 102.875 163.861 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 6.89 -78.84 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 128.67 2.788 . . . . 10.0 116.017 178.773 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -81.69 162.22 23.08 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 119.166 0.894 . . . . 10.0 110.63 -171.098 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.01 -18.87 58.74 Favored Glycine 0 CA--C 1.524 0.61 0 O-C-N 121.306 -0.871 . . . . 10.0 110.956 170.91 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -65.34 162.82 16.76 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 122.275 1.036 . . . . 10.0 112.716 -170.268 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.58 17.91 0.11 Allowed 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 113.931 1.086 . . . . 10.0 113.931 -169.452 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.81 -37.89 53.52 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.489 1.116 . . . . 10.0 113.464 -169.003 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.22 -21.94 45.56 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 112.306 0.484 . . . . 10.0 112.306 179.485 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.61 100.9 2.65 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 -174.313 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 52.0 30.68 7.66 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 125.379 1.472 . . . . 10.0 114.502 169.147 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.8 m -133.79 -59.35 0.85 Allowed 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 106.816 -1.55 . . . . 10.0 106.816 -173.585 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.3 m -47.5 -46.12 26.96 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 126.5 1.92 . . . . 10.0 111.52 -169.469 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.88 -49.7 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 128.239 2.616 . . . . 10.0 114.975 169.4 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.12 171.37 12.95 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.769 -0.932 . . . . 10.0 110.769 173.094 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -79.45 -136.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 123.384 2.723 . . . . 10.0 106.092 166.022 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 18.1 m170 -106.29 50.35 0.78 Allowed 'General case' 0 CA--C 1.544 0.733 0 CA-C-N 121.67 2.032 . . . . 10.0 110.102 171.371 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -78.69 61.35 2.97 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.618 1.554 . . . . 10.0 110.218 174.591 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -61.94 155.97 59.97 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 127.581 2.353 . . . . 10.0 111.138 171.089 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.19 -58.28 0.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.228 2.618 . . . . 10.0 112.75 178.452 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -78.05 58.64 2.02 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.941 0.791 . . . . 10.0 110.509 -177.983 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.8 t -59.08 110.76 1.11 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 122.913 0.485 . . . . 10.0 109.752 -174.709 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 65.8 mtt180 -127.2 -90.08 0.53 Allowed 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 105.361 -2.089 . . . . 10.0 105.361 178.166 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.1 mttm -144.43 156.35 44.16 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.001 0.905 . . . . 10.0 108.812 169.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -63.29 120.2 11.11 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 118.493 -1.283 . . . . 10.0 107.804 166.656 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.12 -156.64 7.04 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 106.571 -2.612 . . . . 10.0 106.571 177.282 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.43 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -151.14 -159.35 8.79 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 118.442 1.121 . . . . 10.0 112.007 178.781 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -71.1 12.11 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 121.414 1.409 . . . . 10.0 109.466 165.724 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.43 ' H ' ' C ' ' A' ' 73' ' ' GLY . 37.5 mmtm -95.87 -24.78 16.28 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 169.704 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.426 ' OD1' ' NZ ' ' A' ' 128' ' ' LYS . 20.4 m-20 -115.56 171.27 7.83 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 -170.016 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -121.14 10.13 10.63 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.539 1.135 . . . . 10.0 110.279 171.394 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -109.16 6.47 24.85 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.515 1.126 . . . . 10.0 110.497 172.098 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -47.3 148.27 1.33 Allowed 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.531 1.532 . . . . 10.0 110.263 178.058 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -60.78 -64.11 1.07 Allowed 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 117.842 0.292 . . . . 10.0 111.185 -176.168 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.8 p -167.89 -51.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 C-N-CA 123.739 0.815 . . . . 10.0 109.266 174.552 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -136.51 47.96 0.94 Allowed Glycine 0 CA--C 1.526 0.741 0 C-N-CA 123.939 0.78 . . . . 10.0 111.327 -175.198 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -86.23 109.11 18.7 Favored 'General case' 0 CA--C 1.53 0.173 0 N-CA-C 105.068 -2.197 . . . . 10.0 105.068 168.395 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.3 mt -74.85 -14.57 60.69 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 118.607 0.639 . . . . 10.0 111.744 -170.94 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.61 -97.93 1.14 Allowed Glycine 0 N--CA 1.44 -1.048 0 N-CA-C 107.434 -2.267 . . . . 10.0 107.434 178.907 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -153.0 120.68 6.02 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 -172.317 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.1 m -102.53 147.27 9.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 N-CA-C 106.039 -1.838 . . . . 10.0 106.039 168.957 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -120.45 133.12 55.47 Favored 'General case' 0 C--N 1.334 -0.095 0 C-N-CA 123.426 0.69 . . . . 10.0 111.588 -173.358 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.75 132.75 48.69 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.244 1.018 . . . . 10.0 111.361 -175.025 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.04 172.74 0.53 Allowed 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 122.496 1.141 . . . . 10.0 110.319 167.778 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 mtmp? -63.15 -19.49 64.52 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 114.309 -1.314 . . . . 10.0 112.425 178.433 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -77.8 -20.31 53.47 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 122.35 0.26 . . . . 10.0 110.741 173.881 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.85 6.67 60.43 Favored Glycine 0 C--N 1.338 0.684 0 CA-C-O 118.749 -1.028 . . . . 10.0 110.685 -170.19 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 t -79.37 114.61 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 C-N-CA 125.502 1.521 . . . . 10.0 107.154 176.265 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -115.38 123.93 49.93 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.865 -0.791 . . . . 10.0 108.865 174.353 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -78.84 129.03 34.12 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.327 -0.99 . . . . 10.0 108.327 171.745 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.4 t -112.15 129.84 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 104.179 -2.526 . . . . 10.0 104.179 167.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.9 p -157.79 57.27 0.48 Allowed 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 123.025 0.53 . . . . 10.0 110.844 174.596 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.36 148.67 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 124.087 0.955 . . . . 10.0 109.024 -169.883 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -129.27 123.66 32.47 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.535 1.134 . . . . 10.0 110.243 174.253 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -127.61 107.15 9.67 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.823 1.649 . . . . 10.0 108.511 -177.653 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 45.2 p -85.22 58.54 5.09 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.823 2.049 . . . . 10.0 107.195 -171.294 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.3 p -142.07 -48.87 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 123.996 0.919 . . . . 10.0 109.307 -176.273 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.312 0.0 OUTLIER -79.91 174.65 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 N-CA-C 113.023 0.749 . . . . 10.0 113.023 174.933 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -167.88 155.0 8.17 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.994 1.318 . . . . 10.0 107.901 169.39 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 70.3 mt -62.29 -24.53 67.34 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 123.413 0.685 . . . . 10.0 111.214 -176.087 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.9 m -147.87 161.32 41.54 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.856 -1.905 . . . . 10.0 105.856 169.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 154.82 -74.57 0.24 Allowed Glycine 0 C--N 1.334 0.434 0 N-CA-C 109.925 -1.27 . . . . 10.0 109.925 -177.457 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -152.19 -53.69 0.12 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.768 2.027 . . . . 10.0 106.387 178.698 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -75.0 -38.6 61.54 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 114.069 -1.423 . . . . 10.0 108.507 -175.002 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.3 t 46.5 56.17 6.72 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.86 1.264 . . . . 10.0 110.309 169.401 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -66.77 6.92 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 N-CA-C 115.647 1.721 . . . . 10.0 115.647 -166.424 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.7 mm -57.41 142.02 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 167.103 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.95 19.21 79.77 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-O 118.916 -0.935 . . . . 10.0 114.033 175.129 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -79.81 175.87 10.24 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 106.779 -1.563 . . . . 10.0 106.779 166.035 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 16.5 m -111.64 131.92 54.94 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 103.302 -2.851 . . . . 10.0 103.302 169.467 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.3 135.81 37.63 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 105.751 -1.944 . . . . 10.0 105.751 167.455 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.4 ' CG2' ' CD2' ' A' ' 48' ' ' HIS . 86.8 t -118.84 132.95 67.23 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.874 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 169.148 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.07 127.51 58.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.75 -1.945 . . . . 10.0 105.75 168.028 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 7.4 m-70 -103.69 159.13 15.88 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 123.529 1.633 . . . . 10.0 114.946 -169.835 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -43.71 -60.73 1.66 Allowed 'General case' 0 N--CA 1.442 -0.873 0 C-N-CA 129.079 2.951 . . . . 10.0 110.041 172.62 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mtmm -115.93 175.4 5.56 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.912 1.285 . . . . 10.0 111.638 -171.897 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.57 149.54 32.99 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 125.938 1.695 . . . . 10.0 111.161 -176.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.521 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.9 m-20 -79.34 144.06 34.57 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.517 0.727 . . . . 10.0 112.567 175.502 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 m-20 -77.18 -35.55 55.74 Favored 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 124.781 1.301 . . . . 10.0 108.974 167.96 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 57.0 mt 66.55 48.8 1.43 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 125.439 1.496 . . . . 10.0 109.368 -167.689 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.83 50.21 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 125.243 1.402 . . . . 10.0 113.001 172.556 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . 0.426 ' NZ ' ' OD1' ' A' ' 76' ' ' ASP . 18.1 mttm -78.82 -1.71 36.2 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.711 0.805 . . . . 10.0 111.273 -168.598 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.91 -26.58 73.2 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 109.087 -1.605 . . . . 10.0 109.087 166.387 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.32 39.25 82.1 Favored Glycine 0 C--N 1.341 0.856 0 N-CA-C 110.822 -0.911 . . . . 10.0 110.822 -179.544 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.9 m-80 -122.06 161.71 22.53 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 176.132 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -48.72 -45.5 39.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 113.388 -1.733 . . . . 10.0 108.781 171.038 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -64.76 -49.7 69.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.167 -0.47 . . . . 10.0 111.714 172.217 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.7 t -52.97 -44.72 67.36 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 120.552 -1.342 . . . . 10.0 110.65 -175.418 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.1 t -74.95 -5.98 46.8 Favored 'General case' 0 CA--C 1.538 0.492 0 O-C-N 123.186 0.304 . . . . 10.0 111.542 -174.955 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 87.9 mttt -102.83 -83.05 0.48 Allowed 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 126.578 1.951 . . . . 10.0 110.147 172.583 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.21 25.84 10.99 Favored 'General case' 0 C--N 1.345 0.391 0 CA-C-N 121.298 1.863 . . . . 10.0 112.988 -177.02 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 59.72 27.66 64.36 Favored Glycine 0 C--N 1.339 0.721 0 CA-C-N 118.942 0.792 . . . . 10.0 112.397 170.001 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.0 m-80 50.21 27.86 2.83 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 123.988 0.915 . . . . 10.0 112.689 -173.501 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.52 -3.85 9.85 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.527 -0.733 . . . . 10.0 112.243 179.694 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.35 -163.6 51.92 Favored Glycine 0 N--CA 1.443 -0.894 0 N-CA-C 110.866 -0.893 . . . . 10.0 110.866 169.192 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.8 m -56.98 142.22 42.58 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.5 0.667 . . . . 10.0 111.612 -169.248 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.0 mtp85 -68.9 64.79 0.12 Allowed 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 125.627 1.571 . . . . 10.0 109.681 175.357 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 11.9 tp -43.91 -35.11 1.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.669 1.988 . . . . 10.0 113.917 -174.537 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -162.53 159.06 24.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -162.16 168.15 22.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 -174.881 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.47 169.77 42.77 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 112.094 -0.402 . . . . 10.0 112.094 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 4.8 t -107.28 138.78 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 -171.304 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mt -80.11 136.58 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-N 118.0 0.364 . . . . 10.0 110.607 179.568 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.05 146.99 17.5 Favored Glycine 0 CA--C 1.53 0.984 0 C-N-CA 125.068 1.318 . . . . 10.0 110.81 176.977 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 10.8 pt -71.49 142.07 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.138 0 CA-C-N 117.82 0.81 . . . . 10.0 109.28 176.771 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.52 -19.71 8.05 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.282 1.433 . . . . 10.0 113.313 -176.372 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.9 tp60 . . . . . 0 C--O 1.254 1.298 0 C-N-CA 130.278 3.431 . . . . 10.0 117.278 -175.504 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 117.652 -1.166 . . . . 10.0 108.997 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.3 t -76.02 -37.35 58.51 Favored 'General case' 0 CA--C 1.516 -0.327 0 CA-C-N 120.217 1.371 . . . . 10.0 110.41 -178.767 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -124.54 136.44 53.99 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 123.377 0.671 . . . . 10.0 111.201 -171.561 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.36 165.5 28.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.146 1.378 . . . . 10.0 107.502 171.004 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 7.9 m -128.32 -178.28 2.29 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 123.367 0.667 . . . . 10.0 110.114 178.904 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.39 110.97 4.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.774 1.23 . . . . 10.0 108.262 165.453 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -95.83 104.52 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 123.786 0.835 . . . . 10.0 109.615 170.633 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -95.06 135.57 36.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 124.026 0.93 . . . . 10.0 110.035 -177.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 43.2 mtpt -149.22 169.48 20.65 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 107.459 -1.312 . . . . 10.0 107.459 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.38 -72.6 0.04 OUTLIER Glycine 0 C--O 1.229 -0.201 0 CA-C-N 115.944 -0.571 . . . . 10.0 111.68 174.394 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -74.09 -41.29 61.91 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.15 -1.426 . . . . 10.0 107.15 -178.295 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.84 -65.92 0.58 Allowed Glycine 0 CA--C 1.526 0.759 0 C-N-CA 124.836 1.207 . . . . 10.0 110.498 -178.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -79.14 37.48 0.67 Allowed 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 124.874 3.716 . . . . 10.0 111.446 -175.282 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -148.74 108.11 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.534 0 N-CA-C 100.405 -3.924 . . . . 10.0 100.405 173.244 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.47 122.84 28.43 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 177.101 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.56 140.21 15.3 Favored Glycine 0 C--O 1.224 -0.508 0 N-CA-C 110.493 -1.043 . . . . 10.0 110.493 -179.745 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.6 mt -139.98 88.75 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.148 -1.427 . . . . 10.0 107.148 -174.317 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -100.23 146.52 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.13 0 C-N-CA 124.978 1.311 . . . . 10.0 111.288 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -123.99 121.3 34.91 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 127.056 2.142 . . . . 10.0 108.102 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -99.32 108.0 20.42 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.855 1.262 . . . . 10.0 107.999 171.761 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -105.13 139.08 40.34 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 119.039 0.836 . . . . 10.0 109.534 167.421 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -116.91 106.13 13.1 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.668 -1.604 . . . . 10.0 106.668 168.22 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt . . . . . 0 N--CA 1.424 -1.731 0 C-N-CA 125.343 1.457 . . . . 10.0 108.926 -178.317 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.163 0 CA-C-O 117.581 -1.677 . . . . 10.0 115.218 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -73.86 140.76 29.31 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 122.527 2.151 . . . . 10.0 108.77 175.091 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -85.81 99.5 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 107.212 -1.403 . . . . 10.0 107.212 173.754 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 60.4 mttm -79.3 109.06 13.29 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.489 -1.3 . . . . 10.0 107.489 174.093 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.39 97.21 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 126.446 1.899 . . . . 10.0 107.392 -178.153 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.7 p90 -116.18 171.31 7.89 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.245 0.545 . . . . 10.0 110.144 169.715 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.26 -165.41 36.59 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 111.126 -0.789 . . . . 10.0 111.126 170.069 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.3 m -154.68 107.86 2.84 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 108.876 -0.787 . . . . 10.0 108.876 -170.832 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 6.9 pt -79.87 177.71 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 108.869 -0.789 . . . . 10.0 108.869 169.01 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 tptt -153.5 153.88 33.29 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 170.858 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.17 -38.94 2.67 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 118.51 0.595 . . . . 10.0 111.622 169.728 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.0 mp -64.14 177.0 0.87 Allowed 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 122.034 0.921 . . . . 10.0 111.664 -170.031 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -103.58 162.05 13.38 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.617 -0.719 . . . . 10.0 109.186 168.731 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -52.32 153.48 2.87 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 125.584 1.553 . . . . 10.0 112.18 -169.456 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.81 -173.41 20.04 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 123.517 0.58 . . . . 10.0 111.858 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -74.64 151.25 39.34 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.937 1.295 . . . . 10.0 110.364 -177.665 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -150.18 151.86 33.74 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 123.634 0.774 . . . . 10.0 112.605 -178.392 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -44.75 127.18 7.09 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 127.259 2.362 . . . . 10.0 110.96 165.985 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -154.73 111.17 3.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 119.038 1.419 . . . . 10.0 108.862 165.771 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.473 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -155.4 167.64 29.72 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-O 121.312 0.577 . . . . 10.0 111.466 179.285 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.0 m -86.51 149.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 112.504 -2.135 . . . . 10.0 106.563 168.014 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -117.57 164.01 15.58 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 123.014 0.526 . . . . 10.0 110.263 176.292 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -52.57 -54.41 33.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.162 0.985 . . . . 10.0 112.589 -176.025 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -106.54 -178.45 3.65 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 118.829 0.741 . . . . 10.0 109.381 178.219 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -139.47 13.41 3.22 Favored Glycine 0 C--N 1.333 0.382 0 O-C-N 122.109 -0.369 . . . . 10.0 113.461 176.093 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -67.13 153.31 43.98 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 107.276 -1.379 . . . . 10.0 107.276 167.188 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -149.13 22.53 0.96 Allowed 'General case' 0 N--CA 1.451 -0.421 0 O-C-N 121.649 -0.657 . . . . 10.0 112.189 -172.372 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.23 -38.42 26.46 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.758 2.023 . . . . 10.0 112.447 -177.489 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.2 -19.77 56.27 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 122.136 -0.353 . . . . 10.0 111.916 -178.278 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 125.9 -66.97 0.54 Allowed Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.309 -1.117 . . . . 10.0 110.309 -176.857 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 35.0 t -160.05 70.06 0.42 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 122.391 1.091 . . . . 10.0 110.625 -178.73 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -163.17 -50.73 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 125.282 1.433 . . . . 10.0 109.253 -174.235 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -48.8 -38.67 22.75 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 125.667 1.587 . . . . 10.0 111.447 -171.218 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.12 -41.54 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 128.662 2.785 . . . . 10.0 114.351 168.63 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.85 161.88 29.84 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 107.647 -2.181 . . . . 10.0 107.647 177.392 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -68.88 -143.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.547 1.132 0 C-N-CA 121.894 1.729 . . . . 10.0 109.615 169.783 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.6 m170 -104.17 42.91 1.14 Allowed 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.267 -1.52 . . . . 10.0 110.629 -179.665 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -73.31 71.98 1.26 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 120.601 1.546 . . . . 10.0 111.32 -179.707 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -62.56 155.06 70.76 Favored Pre-proline 0 CA--C 1.538 0.499 0 C-N-CA 124.218 1.007 . . . . 10.0 111.614 169.837 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.62 -47.95 2.54 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.282 1.988 . . . . 10.0 111.361 176.838 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.85 68.33 1.29 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.774 -0.579 . . . . 10.0 110.816 175.488 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 14.1 t -40.81 102.88 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.427 1.891 . . . . 10.0 111.782 -178.627 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.8 mtt85 -130.28 175.43 8.94 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 126.275 1.83 . . . . 10.0 108.863 177.07 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 62.0 mmtt -106.19 84.11 1.99 Allowed 'General case' 0 CA--C 1.531 0.227 0 CA-C-O 121.457 0.646 . . . . 10.0 112.473 -170.887 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 54.2 t60 13.79 88.39 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.433 2.293 . . . . 10.0 115.594 174.044 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -121.27 -164.6 12.37 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 126.985 2.231 . . . . 10.0 109.004 178.627 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.59 -154.88 15.24 Favored Glycine 0 C--O 1.227 -0.304 0 N-CA-C 106.973 -2.451 . . . . 10.0 106.973 -172.357 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -64.13 9.56 0.14 Allowed 'Trans proline' 0 CA--C 1.542 0.915 0 CA-C-N 120.119 1.96 . . . . 10.0 112.414 169.095 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.65 -31.33 11.27 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.738 1.215 . . . . 10.0 111.209 170.249 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -141.46 154.9 45.83 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-N 119.277 0.944 . . . . 10.0 110.445 -170.197 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 49.2 tt0 -75.87 -20.54 58.01 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.053 -1.091 . . . . 10.0 108.053 178.906 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -80.38 30.93 0.28 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.741 1.216 . . . . 10.0 112.096 -178.384 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -57.52 138.77 54.79 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.111 -0.993 . . . . 10.0 109.135 171.221 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -74.72 -61.03 2.02 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 179.776 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -156.42 -125.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 105.863 -1.903 . . . . 10.0 105.863 -174.444 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -74.4 69.96 1.66 Allowed Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.357 -1.097 . . . . 10.0 110.357 175.891 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -95.94 93.25 6.91 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 106.947 -1.501 . . . . 10.0 106.947 170.209 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.3 mt -65.19 -29.69 70.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.895 0.855 . . . . 10.0 108.987 178.814 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.87 -79.8 0.29 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 169.284 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -144.17 108.07 4.71 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 118.185 -0.912 . . . . 10.0 108.627 -173.366 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.9 m -105.63 130.76 56.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 119.677 1.126 . . . . 10.0 111.924 -179.029 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -90.48 123.02 33.83 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 128.804 2.841 . . . . 10.0 111.269 -169.973 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.39 137.88 42.48 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 124.118 0.967 . . . . 10.0 111.411 177.198 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -62.08 171.65 1.69 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 124.325 1.05 . . . . 10.0 109.458 166.46 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.68 -28.96 58.38 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.554 0.742 . . . . 10.0 111.781 173.245 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -78.27 -3.94 45.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.336 0.588 . . . . 10.0 110.192 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.85 -0.63 82.61 Favored Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 110.257 -1.137 . . . . 10.0 110.257 -177.491 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.7 t -78.83 101.28 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 -173.154 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.49 117.19 30.39 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.45 -0.944 . . . . 10.0 108.45 168.392 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.37 106.84 12.69 Favored 'General case' 0 N--CA 1.435 -1.199 0 C-N-CA 126.814 2.046 . . . . 10.0 109.364 172.428 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 95.8 t -96.3 134.48 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.876 0 N-CA-C 106.964 -1.495 . . . . 10.0 106.964 178.626 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -158.22 79.09 0.82 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.382 0.673 . . . . 10.0 111.502 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -122.3 164.58 19.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 106.064 -1.828 . . . . 10.0 106.064 -179.419 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -138.1 145.0 41.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 121.469 -0.77 . . . . 10.0 111.498 168.743 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -109.62 104.15 13.12 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 125.769 1.628 . . . . 10.0 107.74 178.703 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 67.8 p -86.25 52.75 2.57 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 172.984 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 p -157.77 -49.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 C-N-CA 123.464 0.706 . . . . 10.0 109.325 -174.431 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 48.7 mm -66.58 155.46 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 108.704 -0.851 . . . . 10.0 108.704 169.845 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 41.3 m -153.13 137.35 16.51 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.232 -1.025 . . . . 10.0 108.232 174.455 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 34.5 mt -73.57 53.05 0.41 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.833 1.653 . . . . 10.0 111.459 177.28 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 CA--C 1.532 0.276 0 C-N-CA 127.942 2.497 . . . . 10.0 109.896 179.277 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.237 0.402 0 CA-C-O 122.085 0.945 . . . . 10.0 113.079 . . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -76.79 55.5 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-O 122.183 0.992 . . . . 10.0 109.518 167.439 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -117.75 -49.08 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 127.969 2.508 . . . . 10.0 108.295 178.659 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.04 10.25 71.47 Favored Glycine 0 CA--C 1.532 1.142 0 CA-C-O 119.193 -0.782 . . . . 10.0 112.794 -176.76 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -88.29 162.24 16.72 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 125.484 1.514 . . . . 10.0 108.892 178.678 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -103.84 140.24 37.92 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.505 0.722 . . . . 10.0 109.898 169.568 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -92.3 140.18 29.87 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 106.169 -1.789 . . . . 10.0 106.169 166.748 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 60.4 t -125.94 135.5 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 N-CA-C 107.563 -1.273 . . . . 10.0 107.563 174.736 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 8.6 p -105.39 129.68 57.88 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 106.216 -1.772 . . . . 10.0 106.216 169.109 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 3.5 m170 -113.31 157.75 21.42 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 115.13 1.53 . . . . 10.0 115.13 -169.362 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 58.3 tt0 -39.36 -63.24 0.57 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 128.518 2.727 . . . . 10.0 110.288 171.082 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 57.6 mttt -118.86 173.24 6.99 Favored 'General case' 0 CA--C 1.513 -0.461 0 C-N-CA 123.492 0.717 . . . . 10.0 109.685 -174.687 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -92.41 148.78 21.84 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 179.309 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.504 ' HB2' ' CD2' ' B' ' 126' ' ' LEU . 0.9 OUTLIER -74.69 160.97 30.1 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.253 0.549 . . . . 10.0 111.675 -174.974 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.39 -28.53 61.14 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 114.624 -1.171 . . . . 10.0 110.152 174.855 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . 0.504 ' CD2' ' HB2' ' B' ' 124' ' ' ASP . 2.8 mm? 62.57 56.95 1.93 Allowed 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 125.585 1.554 . . . . 10.0 109.847 -173.437 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 81.54 -40.57 2.61 Favored Glycine 0 CA--C 1.525 0.687 0 CA-C-N 113.971 -1.468 . . . . 10.0 111.78 168.115 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -77.13 49.29 0.67 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.048 1.339 . . . . 10.0 111.173 177.35 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.72 -32.67 4.69 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 126.226 1.869 . . . . 10.0 110.427 173.614 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.58 42.76 99.31 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.673 -0.971 . . . . 10.0 110.673 -171.761 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -132.76 163.35 29.21 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 106.607 -1.627 . . . . 10.0 106.607 173.338 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.57 -52.31 64.17 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 108.46 -0.941 . . . . 10.0 108.46 171.625 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -53.7 -33.54 55.85 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.216 -0.897 . . . . 10.0 112.416 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 21.0 p -52.15 -41.81 62.86 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-N 119.497 1.044 . . . . 10.0 110.649 179.21 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -85.01 -3.48 58.8 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-O 118.517 -0.754 . . . . 10.0 112.914 -178.97 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.95 -60.74 1.81 Allowed 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 126.291 1.836 . . . . 10.0 112.501 -174.223 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -136.25 23.77 3.24 Favored 'General case' 0 CA--C 1.547 0.827 0 CA-C-N 119.488 1.04 . . . . 10.0 110.483 175.447 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.16 -98.03 0.62 Allowed Glycine 0 C--N 1.342 0.91 0 N-CA-C 108.764 -1.734 . . . . 10.0 108.764 -177.461 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -165.34 43.57 0.08 Allowed 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 107.872 -1.158 . . . . 10.0 107.872 170.481 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.61 -19.69 64.01 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.396 0.678 . . . . 10.0 112.565 -174.13 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.01 -147.42 30.47 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 109.94 -1.264 . . . . 10.0 109.94 172.344 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.8 t -68.61 126.81 30.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.559 0.695 . . . . 10.0 110.64 -170.023 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.06 78.32 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.845 0.858 . . . . 10.0 110.604 169.502 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 56.5 mt -52.49 -40.17 62.05 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.922 -0.486 . . . . 10.0 112.11 179.331 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -149.13 145.65 27.3 Favored 'General case' 0 C--O 1.233 0.236 0 O-C-N 121.628 -0.67 . . . . 10.0 111.676 -179.574 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 m -123.72 147.9 47.06 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 126.686 1.995 . . . . 10.0 108.034 -178.224 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.61 141.95 10.82 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 109.761 -1.336 . . . . 10.0 109.761 171.598 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 95.8 t -89.8 150.57 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 102.894 -3.002 . . . . 10.0 102.894 172.646 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 90.4 mt -72.16 -88.03 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-O 121.474 0.654 . . . . 10.0 110.26 -167.566 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 99.87 132.69 7.82 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 124.329 0.966 . . . . 10.0 111.529 177.69 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 73.6 mt -63.31 147.75 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 125.155 1.382 . . . . 10.0 107.75 174.307 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.73 -32.81 4.43 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 113.466 0.913 . . . . 10.0 113.466 174.121 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . 0.405 HE21 ' C ' ' B' ' 153' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.898 0 N-CA-C 108.042 -1.096 . . . . 10.0 108.042 178.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.444 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.5 t -166.22 -41.08 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 127.159 2.184 . . . . 10.0 112.938 178.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -119.37 137.29 53.83 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.244 -1.761 . . . . 10.0 106.244 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -136.73 145.21 44.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -134.99 150.04 29.59 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.236 0 N-CA-C 107.003 -1.481 . . . . 10.0 107.003 174.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.03 129.19 47.56 Favored 'General case' 0 CA--C 1.512 -0.499 0 C-N-CA 126.938 2.095 . . . . 10.0 105.457 168.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.1 m -98.78 121.89 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 168.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -97.16 149.23 22.23 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 119.095 0.861 . . . . 10.0 109.046 177.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.1 tttt -159.29 160.35 35.08 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 108.432 -0.951 . . . . 10.0 108.432 169.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.35 -53.68 0.06 OUTLIER Glycine 0 C--N 1.332 0.35 0 N-CA-C 111.684 -0.566 . . . . 10.0 111.684 170.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -74.1 -45.86 46.44 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.36 -67.75 0.54 Allowed Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.031 -1.441 . . . . 10.0 110.568 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -57.11 -42.94 58.13 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.451 2.101 . . . . 10.0 110.41 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.2 t -63.94 97.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 106.522 -1.658 . . . . 10.0 106.522 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -116.28 118.6 33.21 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.129 -1.434 . . . . 10.0 107.129 169.415 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -99.17 152.95 19.68 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 109.931 -1.268 . . . . 10.0 109.931 174.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -156.47 83.69 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 -172.166 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 tp -85.35 157.21 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 C-N-CA 125.166 1.387 . . . . 10.0 111.016 176.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.406 ' HB2' ' CD1' ' A' ' 32' ' ' TRP . 5.1 m120 -139.1 99.5 3.78 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 127.567 2.347 . . . . 10.0 106.621 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 m-30 -99.07 102.85 14.68 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 105.194 -2.15 . . . . 10.0 105.194 174.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -117.67 132.48 56.48 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 120.409 -0.516 . . . . 10.0 111.591 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -104.36 107.99 19.18 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.701 -1.222 . . . . 10.0 107.701 172.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.2 pttp -54.53 -40.84 69.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 122.955 0.502 . . . . 10.0 110.65 174.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -146.37 172.92 12.78 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 104.937 -2.246 . . . . 10.0 104.937 168.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 86.8 p -69.12 -20.8 64.05 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 124.13 0.972 . . . . 10.0 109.576 174.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -93.89 -3.06 52.42 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.822 -0.627 . . . . 10.0 111.119 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.18 144.8 18.18 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 173.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -61.36 149.7 88.29 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 N-CA-C 106.902 -1.999 . . . . 10.0 106.902 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.7 t -79.0 120.96 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 N-CA-C 104.754 -2.313 . . . . 10.0 104.754 176.178 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.6 tttt -83.24 113.26 20.56 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 105.558 -2.015 . . . . 10.0 105.558 169.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.7 m -97.31 59.14 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 C-N-CA 125.774 1.63 . . . . 10.0 107.975 -170.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.406 ' CD1' ' HB2' ' A' ' 19' ' ' ASN . 14.8 p90 -84.7 171.85 12.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.167 -0.679 . . . . 10.0 109.167 -171.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.12 175.25 38.3 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 119.823 -1.179 . . . . 10.0 112.489 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.3 p -149.03 85.18 1.46 Allowed 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 121.066 0.46 . . . . 10.0 111.972 -169.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -76.83 147.19 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 107.664 -1.235 . . . . 10.0 107.664 174.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.99 156.14 46.77 Favored 'General case' 0 C--O 1.232 0.157 0 O-C-N 124.102 0.876 . . . . 10.0 110.015 167.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.22 2.86 48.16 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 124.043 0.83 . . . . 10.0 114.52 177.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.3 mp -87.75 176.64 7.3 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.542 1.137 . . . . 10.0 108.778 -177.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -91.06 172.71 8.38 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 165.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -64.33 176.02 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.226 1.01 . . . . 10.0 110.889 -172.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.63 175.46 48.42 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 124.137 0.875 . . . . 10.0 111.581 167.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.7 mt -62.24 147.58 47.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.332 -0.511 . . . . 10.0 110.173 171.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -133.59 147.03 51.48 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.637 0.775 . . . . 10.0 110.678 176.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -36.14 112.89 0.14 Allowed Glycine 0 CA--C 1.526 0.736 0 CA-C-O 116.105 -2.497 . . . . 10.0 113.445 164.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -137.08 107.65 6.53 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 121.522 2.661 . . . . 10.0 111.916 170.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.453 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -148.17 -178.99 6.6 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 113.783 1.031 . . . . 10.0 113.783 -175.442 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.7 p -91.5 -47.59 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 127.554 2.342 . . . . 10.0 114.506 -169.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 57.1 161.96 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 125.498 1.519 . . . . 10.0 112.431 -169.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -78.01 -67.85 0.69 Allowed 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.944 -0.571 . . . . 10.0 109.862 -176.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -78.63 146.27 34.21 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 119.954 -0.699 . . . . 10.0 109.432 -171.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -75.74 -28.42 61.09 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 108.905 -1.678 . . . . 10.0 108.905 169.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.3 145.68 1.62 Allowed 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.746 1.26 . . . . 10.0 113.995 -175.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -135.8 16.06 3.33 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 113.679 -1.6 . . . . 10.0 110.453 -178.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -58.08 -36.45 72.86 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 119.181 0.901 . . . . 10.0 112.477 -169.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.07 -17.71 58.54 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 111.778 0.288 . . . . 10.0 111.778 178.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 97.85 84.18 1.74 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.107 -1.597 . . . . 10.0 109.107 -173.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 94.2 m 48.81 57.13 6.71 Favored 'General case' 0 N--CA 1.464 0.228 0 C-N-CA 124.305 1.042 . . . . 10.0 111.391 175.268 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -157.66 -54.61 0.07 Allowed 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.6 p -54.73 -30.26 55.73 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 124.121 0.968 . . . . 10.0 111.023 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.26 -38.47 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 127.977 2.511 . . . . 10.0 113.995 167.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.75 170.06 20.17 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -79.29 -167.13 0.47 Allowed 'Trans proline' 0 N--CA 1.439 -1.679 0 N-CA-C 106.377 -2.201 . . . . 10.0 106.377 166.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.452 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.4 m170 -83.32 59.07 4.82 Favored 'General case' 0 CA--C 1.537 0.457 0 O-C-N 120.561 -1.337 . . . . 10.0 110.097 -175.763 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -76.61 51.66 0.76 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.6 1.191 . . . . 10.0 112.587 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -56.94 149.72 42.7 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 125.601 1.561 . . . . 10.0 111.008 168.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -67.96 -48.04 1.56 Allowed 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.652 2.235 . . . . 10.0 111.401 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.92 54.09 0.98 Allowed 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.743 -0.598 . . . . 10.0 111.103 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.6 t -58.63 100.85 0.07 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.048 0.939 . . . . 10.0 110.111 -174.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtt-85 -113.78 -90.47 0.52 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 105.857 -1.905 . . . . 10.0 105.857 -177.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -149.42 144.59 26.46 Favored 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 109.334 -0.617 . . . . 10.0 109.334 168.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -51.5 119.78 4.48 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 119.714 -0.794 . . . . 10.0 109.929 168.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.0 -129.48 1.97 Allowed Glycine 0 N--CA 1.451 -0.359 0 N-CA-C 107.513 -2.235 . . . . 10.0 107.513 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.53 -143.29 5.84 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 118.182 0.991 . . . . 10.0 111.03 169.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -68.83 1.26 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 CA-C-N 120.075 1.937 . . . . 10.0 110.228 168.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 31.2 mmtp -93.9 -15.96 24.47 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-O 117.844 -1.074 . . . . 10.0 110.494 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -127.61 161.38 28.98 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 119.255 0.934 . . . . 10.0 109.5 -171.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -84.28 -28.91 26.83 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -78.94 -11.52 60.0 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 124.465 1.106 . . . . 10.0 112.059 -169.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.4 ptp180 -33.45 138.46 0.07 Allowed 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 126.415 1.886 . . . . 10.0 114.596 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.4 m170 -69.5 177.17 3.03 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.562 -0.533 . . . . 10.0 109.562 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 p -72.85 39.32 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 125.525 1.53 . . . . 10.0 114.228 -172.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 48.03 0.04 OUTLIER Glycine 0 CA--C 1.524 0.655 0 O-C-N 120.597 -1.315 . . . . 10.0 111.526 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -85.0 102.81 13.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 104.92 -2.252 . . . . 10.0 104.92 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.7 mt -74.62 -32.19 62.23 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 107.073 -1.454 . . . . 10.0 107.073 169.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.82 -104.35 3.04 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 109.586 -1.406 . . . . 10.0 109.586 168.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 39.9 m-20 -126.4 105.79 9.02 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 126.743 2.017 . . . . 10.0 106.511 -167.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.63 134.67 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 123.411 0.684 . . . . 10.0 109.566 173.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.58 122.43 26.49 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.524 2.73 . . . . 10.0 112.809 -167.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.01 133.99 34.86 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.49 0.716 . . . . 10.0 109.255 169.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -60.76 171.53 1.15 Allowed 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.459 0.703 . . . . 10.0 110.001 168.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 pttt -47.54 -34.22 7.37 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.741 1.617 . . . . 10.0 111.311 171.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.8 -7.25 59.36 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 123.655 0.782 . . . . 10.0 111.166 -176.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.86 1.22 77.09 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.77 -0.932 . . . . 10.0 110.77 -175.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -77.19 103.87 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 -176.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.43 114.37 28.32 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 107.809 -1.182 . . . . 10.0 107.809 169.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -85.44 127.96 34.57 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 107.539 -1.282 . . . . 10.0 107.539 169.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 56.9 t -110.11 132.04 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 106.389 -1.708 . . . . 10.0 106.389 170.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -154.52 71.28 0.82 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.994 0.918 . . . . 10.0 108.955 170.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -114.62 159.01 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 105.603 -1.999 . . . . 10.0 105.603 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -130.95 142.44 50.35 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.854 0.861 . . . . 10.0 110.074 172.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -131.25 133.66 45.65 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.266 1.027 . . . . 10.0 109.683 -172.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 62.3 p -110.96 57.09 0.62 Allowed 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.373 1.869 . . . . 10.0 108.63 174.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 96.0 t -141.77 -61.73 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.14 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 -177.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.279 0.0 OUTLIER -60.68 170.94 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 N-CA-C 113.229 0.826 . . . . 10.0 113.229 174.83 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.6 m -145.5 111.97 5.8 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 121.498 -0.751 . . . . 10.0 109.286 175.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.2 tt -49.05 -44.89 42.11 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 126.09 1.756 . . . . 10.0 109.955 177.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -143.72 160.8 40.08 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 106.465 -1.679 . . . . 10.0 106.465 169.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.32 -95.96 0.2 Allowed Glycine 0 C--N 1.334 0.418 0 N-CA-C 109.349 -1.5 . . . . 10.0 109.349 -177.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -119.54 -51.69 2.28 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.265 1.826 . . . . 10.0 107.886 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -73.51 -37.31 65.72 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.681 -1.229 . . . . 10.0 107.681 -171.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 t 47.47 59.27 4.22 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.773 1.629 . . . . 10.0 108.078 169.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.2 pt -74.86 65.77 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 O-C-N 124.622 1.201 . . . . 10.0 110.121 -172.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.7 mm -110.64 -68.34 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 127.808 2.443 . . . . 10.0 108.33 -176.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.68 51.8 4.06 Favored Glycine 0 CA--C 1.531 1.092 0 O-C-N 121.221 -0.925 . . . . 10.0 112.086 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.4 ptm180 -112.36 162.16 15.85 Favored 'General case' 0 CA--C 1.53 0.173 0 C-N-CA 127.213 2.205 . . . . 10.0 107.168 176.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -109.61 104.72 13.79 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 118.565 0.621 . . . . 10.0 109.513 -179.116 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -64.47 131.02 45.94 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 106.695 -1.594 . . . . 10.0 106.695 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.2 t -122.5 132.59 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.7 p -94.56 122.35 45.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 105.829 -1.915 . . . . 10.0 105.829 166.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 6.9 m-70 -100.92 162.78 12.66 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.711 0.767 . . . . 10.0 112.631 174.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -64.58 -56.16 15.76 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.48 -0.782 . . . . 10.0 109.316 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -98.8 165.49 11.75 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 119.474 -0.89 . . . . 10.0 112.076 -168.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.7 147.15 53.04 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.801 -1.545 . . . . 10.0 107.792 169.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.453 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 6.7 m-20 -78.45 163.49 25.57 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.86 -0.793 . . . . 10.0 108.86 172.499 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.15 -10.38 59.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 113.736 -1.575 . . . . 10.0 110.781 168.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.5 mt 43.02 45.92 4.61 Favored 'General case' 0 C--N 1.343 0.32 0 C-N-CA 124.826 1.25 . . . . 10.0 109.856 -168.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.19 -21.83 44.01 Favored Glycine 0 CA--C 1.529 0.968 0 CA-C-N 113.713 -1.585 . . . . 10.0 113.728 170.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -77.48 0.78 21.45 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 115.543 1.682 . . . . 10.0 115.543 -165.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.89 -36.59 88.23 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.831 -0.907 . . . . 10.0 110.831 177.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.23 39.82 98.34 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 108.31 -1.916 . . . . 10.0 108.31 -169.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -128.39 164.46 22.64 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -54.79 -47.98 73.3 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.131 -0.941 . . . . 10.0 108.62 174.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -55.08 -39.61 69.47 Favored 'General case' 0 C--N 1.344 0.347 0 C-N-CA 123.283 0.633 . . . . 10.0 111.387 171.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.305 1.8 p -58.73 -36.06 73.7 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-O 118.138 -0.934 . . . . 10.0 111.733 -173.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.1 t -83.06 3.31 30.94 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.315 0.962 . . . . 10.0 112.541 178.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -118.6 -81.17 0.62 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.669 1.588 . . . . 10.0 110.511 -174.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.8 p -108.52 9.71 27.38 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 121.067 1.758 . . . . 10.0 111.43 175.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.1 -79.83 1.87 Allowed Glycine 0 C--N 1.342 0.891 0 O-C-N 120.708 -1.245 . . . . 10.0 110.0 176.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 178.71 36.87 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.684 1.993 . . . . 10.0 109.347 178.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.75 -14.29 61.96 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 123.832 0.853 . . . . 10.0 111.978 -169.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.02 -170.05 54.44 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 109.146 -1.582 . . . . 10.0 109.146 -169.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.4 m -55.06 165.0 0.74 Allowed 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 124.295 1.038 . . . . 10.0 112.667 -177.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -80.96 114.32 19.76 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 167.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.413 ' N ' ' CD2' ' A' ' 144' ' ' LEU . 1.1 mm? -84.5 -45.29 12.78 Favored 'General case' 0 C--N 1.333 -0.149 0 N-CA-C 108.396 -0.965 . . . . 10.0 108.396 -176.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -147.29 157.04 43.44 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 p -154.28 164.1 39.11 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 116.44 -0.345 . . . . 10.0 110.762 -176.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.86 150.8 22.43 Favored Glycine 0 C--N 1.336 0.531 0 C-N-CA 124.246 0.927 . . . . 10.0 110.916 -173.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.73 148.4 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 104.34 -2.467 . . . . 10.0 104.34 175.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 83.9 mt -76.66 -86.79 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 122.649 1.214 . . . . 10.0 109.169 -171.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.18 25.4 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.744 1.64 . . . . 10.0 115.257 170.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER 63.8 152.64 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 C-N-CA 124.283 1.033 . . . . 10.0 111.413 -173.335 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -113.36 -49.05 2.92 Favored 'General case' 0 CA--C 1.51 -0.592 0 O-C-N 120.456 -1.403 . . . . 10.0 110.316 169.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.433 -1.316 0 N-CA-C 106.047 -1.834 . . . . 10.0 106.047 -178.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.941 0 CA-C-O 118.01 -0.995 . . . . 10.0 108.886 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.5 t -95.15 -45.27 7.27 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.967 0.907 . . . . 10.0 111.952 -175.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.7 tttp -111.09 133.83 53.16 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.328 1.051 . . . . 10.0 109.011 176.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 166.82 23.73 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.12 1.368 . . . . 10.0 108.408 171.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.49 175.19 10.59 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 123.046 0.538 . . . . 10.0 109.767 175.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -149.45 103.85 3.32 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 106.346 -1.724 . . . . 10.0 106.346 166.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 22.7 m -83.13 111.84 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 108.834 -0.802 . . . . 10.0 108.834 170.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.96 143.45 26.85 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.056 -1.09 . . . . 10.0 108.056 175.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 46.5 tttt -163.73 163.76 24.01 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 108.097 -1.075 . . . . 10.0 108.097 170.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.61 -50.76 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 111.803 -0.519 . . . . 10.0 111.803 169.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.24 -47.16 20.9 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.106 -1.442 . . . . 10.0 107.106 -169.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.18 -61.1 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.919 -1.491 . . . . 10.0 111.785 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -62.74 -39.15 44.65 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 122.642 2.228 . . . . 10.0 110.89 170.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 68.1 t -77.6 115.03 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.553 1.141 . . . . 10.0 108.255 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -147.46 139.05 23.95 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 123.208 0.318 . . . . 10.0 110.605 166.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.66 153.53 16.79 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 110.15 -1.18 . . . . 10.0 110.15 169.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 4.0 mt -138.93 59.41 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 106.179 -1.786 . . . . 10.0 106.179 -176.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.1 mm -78.86 136.72 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-N 115.221 -0.9 . . . . 10.0 109.205 -169.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -108.71 117.13 33.39 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 127.329 2.252 . . . . 10.0 108.076 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -101.15 111.18 23.32 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.256 -1.387 . . . . 10.0 107.256 175.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -118.03 133.26 56.08 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-O 121.358 0.599 . . . . 10.0 112.068 172.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -121.72 113.15 19.31 Favored 'General case' 0 N--CA 1.446 -0.646 0 N-CA-C 105.519 -2.03 . . . . 10.0 105.519 170.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 39.2 pttt -59.97 -29.66 68.58 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.3 1.04 . . . . 10.0 110.725 -175.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 53.6 mt-10 -132.35 179.95 5.81 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 103.853 -2.647 . . . . 10.0 103.853 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 34.3 m -87.43 -1.08 57.67 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 118.698 0.681 . . . . 10.0 109.858 173.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 35.0 m-80 -128.71 4.48 5.5 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 123.981 0.913 . . . . 10.0 112.179 -176.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.37 174.88 55.0 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 109.893 -1.283 . . . . 10.0 109.893 175.107 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -60.88 136.63 67.19 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 CA-C-N 119.735 1.767 . . . . 10.0 109.537 169.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.7 t -79.86 97.41 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 104.038 -2.579 . . . . 10.0 104.038 168.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . 0.266 71.2 tttt -82.84 112.63 19.83 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 172.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -95.48 101.45 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 C-N-CA 126.952 2.101 . . . . 10.0 105.855 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -121.23 160.94 22.82 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 112.325 0.491 . . . . 10.0 112.325 173.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.87 -152.48 24.14 Favored Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 170.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 40.1 t -155.72 151.49 27.41 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 120.211 -0.596 . . . . 10.0 110.321 177.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -100.99 122.98 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 N-CA-C 107.433 -1.321 . . . . 10.0 107.433 165.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 20.9 ptmt -105.38 139.89 39.32 Favored 'General case' 0 N--CA 1.453 -0.296 0 O-C-N 123.891 0.744 . . . . 10.0 108.995 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.18 -5.52 15.48 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.417 1.008 . . . . 10.0 113.269 176.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -68.21 176.76 2.57 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 118.366 1.083 . . . . 10.0 111.09 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -108.54 161.03 15.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.28 -2.118 . . . . 10.0 105.28 165.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -52.03 160.43 0.73 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.636 1.174 . . . . 10.0 111.725 -169.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.84 -179.98 34.38 Favored Glycine 0 N--CA 1.447 -0.602 0 O-C-N 121.549 -0.719 . . . . 10.0 111.486 168.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.9 mp -68.62 149.01 49.64 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.735 1.614 . . . . 10.0 110.446 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -148.75 148.63 30.21 Favored 'General case' 0 C--O 1.233 0.198 0 C-N-CA 123.42 0.688 . . . . 10.0 112.432 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.4 121.29 0.2 Allowed Glycine 0 C--N 1.339 0.748 0 C-N-CA 127.941 2.686 . . . . 10.0 113.038 165.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -151.64 110.92 3.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 119.088 1.444 . . . . 10.0 110.044 167.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.516 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.2 OUTLIER -144.24 174.3 11.01 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-O 121.373 0.606 . . . . 10.0 111.888 178.131 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 3.2 t -114.42 86.75 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 CA-C-N 112.599 -2.091 . . . . 10.0 107.981 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -67.66 149.99 49.31 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 124.876 1.27 . . . . 10.0 109.898 174.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -71.65 -59.6 2.67 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.136 -1.393 . . . . 10.0 110.412 -170.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -79.09 136.59 37.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 120.891 -0.323 . . . . 10.0 110.237 -171.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -54.75 -50.42 57.99 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 108.304 -1.918 . . . . 10.0 108.304 169.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -24.12 124.0 0.04 OUTLIER 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 128.069 2.547 . . . . 10.0 113.737 -173.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.92 11.99 2.65 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.63 -175.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.41 -40.35 59.13 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 126.049 1.74 . . . . 10.0 111.389 -170.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.51 -20.73 46.51 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 124.703 1.201 . . . . 10.0 113.209 178.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.92 82.83 1.67 Allowed Glycine 0 CA--C 1.528 0.864 0 C-N-CA 124.67 1.129 . . . . 10.0 110.624 -178.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.9 m 53.22 21.1 2.09 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.382 1.473 . . . . 10.0 112.733 176.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -111.56 -42.29 3.89 Favored 'General case' 0 N--CA 1.437 -1.089 0 O-C-N 120.613 -1.304 . . . . 10.0 108.092 -168.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 70.3 m -92.14 -11.05 36.67 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 117.831 -1.08 . . . . 10.0 113.541 -168.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.35 2.01 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 128.597 2.759 . . . . 10.0 117.14 -174.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.2 119.24 2.25 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 109.482 -1.447 . . . . 10.0 109.482 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -76.52 64.12 7.31 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.483 2.789 . . . . 10.0 111.02 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 22.5 m170 69.53 53.62 0.41 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 128.752 2.821 . . . . 10.0 110.132 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -73.95 52.08 0.42 Allowed 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.306 1.042 . . . . 10.0 112.997 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -65.49 153.91 89.2 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 126.823 2.049 . . . . 10.0 111.62 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.8 -43.94 2.34 Favored 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 123.079 2.519 . . . . 10.0 111.955 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 67.3 mt -78.85 53.77 1.44 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.718 0.807 . . . . 10.0 110.363 -177.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.6 p -58.39 102.41 0.11 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.823 1.249 . . . . 10.0 110.337 -172.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 mtp85 -132.48 -87.88 0.44 Allowed 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 -171.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -145.13 155.61 43.41 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 121.689 0.757 . . . . 10.0 109.444 168.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -63.05 120.7 11.93 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 105.592 -2.003 . . . . 10.0 105.592 163.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -140.29 -136.44 3.34 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 107.602 -2.199 . . . . 10.0 107.602 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.446 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -175.36 -166.37 32.91 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 177.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.11 10.12 0.42 Allowed 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.607 1.538 . . . . 10.0 109.938 166.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.446 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.0 mmtt -97.28 -25.67 15.18 Favored 'General case' 0 N--CA 1.44 -0.927 0 C-N-CA 124.75 1.22 . . . . 10.0 107.818 173.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . 0.415 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 23.1 m-20 -120.69 158.12 28.15 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.488 -1.671 . . . . 10.0 106.488 -169.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -80.66 -34.11 35.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.776 -1.194 . . . . 10.0 107.776 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -78.31 1.6 21.24 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 125.939 1.696 . . . . 10.0 113.311 -165.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -40.24 144.18 0.24 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.037 1.735 . . . . 10.0 111.694 174.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.4 m170 -61.52 -58.03 9.76 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-O 120.989 0.424 . . . . 10.0 110.425 -175.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.2 p -174.2 -69.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.457 -0.104 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 172.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.7 62.22 0.37 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 109.478 -1.449 . . . . 10.0 109.478 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -100.5 95.52 6.78 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 103.878 -2.638 . . . . 10.0 103.878 168.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.54 -17.87 64.81 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.694 0.679 . . . . 10.0 111.454 -171.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 107.24 -103.08 1.92 Allowed Glycine 0 N--CA 1.438 -1.228 0 N-CA-C 106.08 -2.808 . . . . 10.0 106.08 -176.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -147.65 139.11 23.78 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 -178.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 28.5 m -106.82 134.45 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.243 0 N-CA-C 105.914 -1.884 . . . . 10.0 105.914 169.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.2 t -109.13 126.21 52.99 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.527 -0.546 . . . . 10.0 109.527 -173.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.42 132.09 37.05 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 122.9 0.48 . . . . 10.0 110.773 -176.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -60.69 168.86 2.05 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 166.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -50.3 -29.26 9.35 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 126.387 1.875 . . . . 10.0 111.414 173.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -78.06 -11.88 59.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.967 0.507 . . . . 10.0 110.701 -177.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.29 20.59 48.34 Favored Glycine 0 C--N 1.338 0.694 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -103.66 107.31 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.838 0 C-N-CA 127.13 2.172 . . . . 10.0 106.115 -178.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.95 125.29 50.79 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 108.883 -0.784 . . . . 10.0 108.883 171.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -79.37 135.0 36.59 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.612 1.165 . . . . 10.0 109.807 175.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.26 129.83 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 127.145 2.178 . . . . 10.0 106.436 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.2 p -158.69 57.4 0.44 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.277 0.944 . . . . 10.0 112.726 176.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.4 152.38 12.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.954 0.902 . . . . 10.0 109.554 -169.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -99.27 112.21 24.42 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 10.0 109.708 167.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -79.13 71.41 5.62 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 104.89 -2.263 . . . . 10.0 104.89 169.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.09 54.37 2.75 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 127.011 2.124 . . . . 10.0 105.416 -174.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.5 t -148.0 -51.99 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 125.817 1.647 . . . . 10.0 109.393 -168.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.322 1.2 pp -113.37 -178.8 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 126.203 1.801 . . . . 10.0 112.683 -172.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 61.2 m -146.94 151.84 37.67 Favored 'General case' 0 C--O 1.232 0.172 0 O-C-N 121.052 -1.03 . . . . 10.0 110.78 -178.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 81.9 mt -70.39 -33.85 71.88 Favored 'General case' 0 N--CA 1.458 -0.047 0 C-N-CA 124.271 1.028 . . . . 10.0 110.891 -177.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.4 p -153.84 153.89 32.94 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 108.866 -0.79 . . . . 10.0 108.866 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.88 -100.92 0.5 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 106.497 -2.641 . . . . 10.0 106.497 -169.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -123.86 -44.82 2.05 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 125.444 1.498 . . . . 10.0 109.184 -169.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 12.1 m-70 -75.12 -41.83 57.64 Favored 'General case' 0 N--CA 1.456 -0.127 0 N-CA-C 108.05 -1.093 . . . . 10.0 108.05 -178.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 39.8 t 42.48 57.64 3.36 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 125.67 1.588 . . . . 10.0 113.581 167.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -71.19 -7.1 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 113.789 1.033 . . . . 10.0 113.789 -174.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.7 mm -52.14 127.71 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 109.17 -0.678 . . . . 10.0 109.17 173.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.78 -25.5 11.74 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.383 -0.687 . . . . 10.0 111.383 -175.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 13.3 mtp-105 -72.05 161.8 30.37 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 119.094 1.447 . . . . 10.0 109.526 -169.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -111.03 131.77 54.78 Favored 'General case' 0 CA--C 1.514 -0.412 0 C-N-CA 124.53 1.132 . . . . 10.0 109.652 -167.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 26.4 mt -104.64 140.38 38.11 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.674 -0.861 . . . . 10.0 108.674 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 85.5 t -134.41 125.81 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.884 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 -175.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.3 p -90.35 129.02 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.772 -1.566 . . . . 10.0 106.772 167.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.8 m170 -106.54 157.12 17.91 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.076 1.139 . . . . 10.0 114.076 179.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -50.63 -51.84 45.18 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.667 1.587 . . . . 10.0 110.906 176.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -115.67 167.87 10.53 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-N 118.581 0.628 . . . . 10.0 111.593 -169.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.13 150.17 49.52 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.744 -1.116 . . . . 10.0 110.022 177.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.516 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.6 OUTLIER -79.16 135.16 36.73 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.204 1.002 . . . . 10.0 110.903 171.9 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -79.39 -15.83 57.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 124.621 1.201 . . . . 10.0 110.541 167.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 80.0 mt 58.86 46.11 14.37 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.234 1.014 . . . . 10.0 111.667 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.34 -51.76 1.24 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 110.22 -1.152 . . . . 10.0 110.22 173.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . 0.415 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -82.21 48.77 1.3 Allowed 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 117.583 0.691 . . . . 10.0 112.099 -175.7 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.13 -38.52 5.67 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 108.648 -1.781 . . . . 10.0 108.648 169.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.54 33.26 16.95 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 178.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -130.61 165.08 23.55 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 105.83 -1.915 . . . . 10.0 105.83 168.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -50.38 -43.9 54.64 Favored 'General case' 0 N--CA 1.425 -1.724 0 CA-C-O 121.863 0.84 . . . . 10.0 108.796 171.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -65.7 -35.36 80.54 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-O 117.903 -1.046 . . . . 10.0 112.929 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 44.0 p -54.49 -46.28 73.39 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 120.987 1.721 . . . . 10.0 110.037 171.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -78.47 -13.65 59.74 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 118.11 -0.948 . . . . 10.0 113.162 -174.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.1 ttmm -103.92 -50.85 3.29 Favored 'General case' 0 N--CA 1.443 -0.778 0 C-N-CA 126.518 1.927 . . . . 10.0 112.51 -174.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 19.3 p -137.21 8.41 2.93 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 119.683 1.128 . . . . 10.0 113.658 174.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 88.23 20.56 48.65 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-O 118.577 -1.124 . . . . 10.0 113.215 174.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 6.9 m120 56.09 17.35 2.64 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 119.108 1.454 . . . . 10.0 112.244 -176.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.43 -11.69 58.43 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.007 0.923 . . . . 10.0 112.128 -174.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.97 -160.46 48.41 Favored Glycine 0 N--CA 1.441 -0.973 0 N-CA-C 111.104 -0.798 . . . . 10.0 111.104 168.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.8 m -51.6 125.27 14.26 Favored 'General case' 0 N--CA 1.439 -1.015 0 C-N-CA 124.622 1.169 . . . . 10.0 113.31 -168.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.5 mtm-85 -72.01 75.69 0.92 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 125.412 1.485 . . . . 10.0 109.595 176.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 70.2 mt -43.73 -49.08 8.02 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.997 0.919 . . . . 10.0 112.26 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.99 153.62 32.29 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.796 -0.816 . . . . 10.0 108.796 -168.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.06 166.12 34.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.58 -0.282 . . . . 10.0 110.805 -174.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.63 163.29 30.73 Favored Glycine 0 CA--C 1.523 0.563 0 C-N-CA 125.096 1.331 . . . . 10.0 109.856 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 37.6 t -120.94 136.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 106.088 -1.819 . . . . 10.0 106.088 -173.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 64.2 mt -70.52 130.42 34.71 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-N 118.175 0.443 . . . . 10.0 110.617 -177.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.64 141.98 13.24 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 124.254 0.93 . . . . 10.0 110.794 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -71.26 151.9 8.73 Favored 'Isoleucine or valine' 0 C--N 1.342 0.278 0 CA-C-N 118.44 1.12 . . . . 10.0 111.587 -178.323 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.3 -33.59 2.13 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 124.768 1.227 . . . . 10.0 113.267 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.063 0 CA-C-O 116.856 -1.545 . . . . 10.0 107.424 171.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.601 0 CA-C-O 118.863 -0.589 . . . . 10.0 110.059 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.9 t 125.01 -23.95 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 1 C-N-CA 131.942 4.097 . . . . 10.0 108.523 -174.309 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp -131.0 132.31 44.91 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 126.071 1.748 . . . . 10.0 108.124 169.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.54 168.75 18.66 Favored 'General case' 0 N--CA 1.462 0.149 0 C-N-CA 124.747 1.219 . . . . 10.0 109.443 169.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.2 m -127.65 179.24 3.84 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.357 0 C-N-CA 124.177 0.991 . . . . 10.0 110.766 -174.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.81 114.77 2.64 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 106.879 -1.526 . . . . 10.0 106.879 164.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -98.66 96.26 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 C-N-CA 124.018 0.927 . . . . 10.0 110.21 172.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 mp -84.57 142.67 29.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.416 1.086 . . . . 10.0 110.023 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -153.2 165.06 36.85 Favored 'General case' 0 C--N 1.338 0.074 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 169.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.48 -59.65 0.04 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.391 -0.368 . . . . 10.0 113.268 169.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.19 -42.92 62.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -170.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.25 -66.51 0.53 Allowed Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 113.728 -1.578 . . . . 10.0 109.708 176.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -58.33 -39.95 79.77 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.62 2.213 . . . . 10.0 110.808 171.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.9 t -63.73 110.63 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 N-CA-C 108.134 -1.062 . . . . 10.0 108.134 178.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.18 132.01 51.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 168.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -114.28 134.03 11.49 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 109.47 -1.452 . . . . 10.0 109.47 174.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.41 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 9.9 mt -136.19 97.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 -170.298 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -102.52 152.24 5.74 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 C-N-CA 124.464 1.106 . . . . 10.0 110.979 -176.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -126.53 113.94 17.45 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 126.294 1.838 . . . . 10.0 107.714 169.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -96.94 100.01 11.54 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 172.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -110.65 118.73 36.99 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 120.436 -0.506 . . . . 10.0 111.594 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -90.73 103.61 16.29 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 105.752 -1.944 . . . . 10.0 105.752 172.222 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 27.1 mmmt -48.31 -57.56 5.82 Favored 'General case' 0 C--O 1.228 -0.071 0 C-N-CA 125.433 1.493 . . . . 10.0 110.811 -177.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.14 178.96 6.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 104.258 -2.497 . . . . 10.0 104.258 169.464 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -66.32 -26.98 67.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.594 0.712 . . . . 10.0 109.733 175.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -77.89 -22.68 49.39 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.507 -0.77 . . . . 10.0 109.815 177.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.8 144.75 22.24 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 110.779 -0.928 . . . . 10.0 110.779 -173.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -63.54 153.9 72.06 Favored 'Trans proline' 0 N--CA 1.449 -1.122 0 N-CA-C 107.237 -1.871 . . . . 10.0 107.237 168.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.4 p -77.21 117.24 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 N-CA-C 106.174 -1.787 . . . . 10.0 106.174 173.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 48.4 tttp -85.11 108.8 17.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 106.361 -1.718 . . . . 10.0 106.361 169.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -88.41 93.84 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.112 -1.811 . . . . 10.0 106.112 171.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.3 p90 -106.27 165.77 11.0 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 108.901 -0.777 . . . . 10.0 108.901 168.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.84 163.77 30.54 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -140.23 94.51 2.76 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.209 -1.034 . . . . 10.0 108.209 -175.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.7 pt -77.83 172.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 118.754 -1.179 . . . . 10.0 109.157 171.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -155.58 151.47 27.6 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 167.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.69 -18.97 19.38 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-O 118.83 -0.984 . . . . 10.0 114.036 174.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.8 mp -71.86 179.24 3.26 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 119.34 1.57 . . . . 10.0 111.672 -178.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -95.53 164.89 12.6 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.085 -1.08 . . . . 10.0 108.085 167.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -60.08 171.85 0.91 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.934 1.294 . . . . 10.0 112.892 -169.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.67 -173.08 43.33 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 123.879 0.752 . . . . 10.0 112.462 167.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -70.49 142.62 51.88 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.151 1.381 . . . . 10.0 110.017 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -144.13 147.46 33.75 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 123.64 0.776 . . . . 10.0 112.62 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.05 128.19 0.25 Allowed Glycine 0 C--N 1.341 0.853 0 C-N-CA 127.378 2.418 . . . . 10.0 111.589 165.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -153.79 106.32 2.86 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 118.904 1.352 . . . . 10.0 109.984 167.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.46 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -150.34 174.04 13.31 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 122.303 1.049 . . . . 10.0 113.686 -179.754 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.16 144.57 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 111.694 -2.503 . . . . 10.0 107.873 169.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.7 m-70 -128.14 138.95 52.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.085 -1.45 . . . . 10.0 107.085 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -50.64 -62.79 1.39 Allowed 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.974 1.31 . . . . 10.0 112.143 -169.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -80.22 130.24 35.08 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 119.624 -0.83 . . . . 10.0 109.294 -175.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.57 -13.74 71.63 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.313 -1.115 . . . . 10.0 110.313 167.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -46.37 144.84 1.94 Allowed 'General case' 0 C--N 1.345 0.387 0 CA-C-O 122.45 1.119 . . . . 10.0 109.697 168.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -153.82 15.6 0.49 Allowed 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.309 -1.314 . . . . 10.0 111.724 177.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.42 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -58.77 -34.29 71.26 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.331 0.969 . . . . 10.0 110.671 -174.044 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.67 -20.9 45.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.846 1.258 . . . . 10.0 113.062 175.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.22 97.59 1.36 Allowed Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.392 -1.083 . . . . 10.0 110.392 -170.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.288 20.9 p 15.36 60.27 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 128.597 2.759 . . . . 10.0 116.685 176.055 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 40.9 m -132.18 -61.77 0.86 Allowed 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 128.021 2.528 . . . . 10.0 105.172 174.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.6 m -57.25 -24.75 56.81 Favored 'General case' 0 C--N 1.34 0.156 0 C-N-CA 125.606 1.563 . . . . 10.0 111.667 176.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -41.89 -30.3 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 126.208 1.803 . . . . 10.0 112.502 168.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.93 125.66 5.62 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 109.845 -1.302 . . . . 10.0 109.845 169.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.6 66.95 3.78 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 124.096 3.197 . . . . 10.0 112.28 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 64.16 46.27 3.7 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 129.438 3.095 . . . . 10.0 111.227 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -70.85 69.79 0.47 Allowed 'General case' 0 CA--C 1.531 0.244 0 CA-C-O 121.759 0.79 . . . . 10.0 111.402 178.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.8 p-10 -68.61 152.1 96.86 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.306 -0.871 . . . . 10.0 109.206 169.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.19 -58.68 0.4 Allowed 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 122.26 1.974 . . . . 10.0 111.571 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -76.09 72.27 2.9 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 121.439 -0.788 . . . . 10.0 110.447 174.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.4 m -40.34 112.65 0.29 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.016 0.926 . . . . 10.0 110.699 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.92 -96.27 0.47 Allowed 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 176.348 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -149.39 155.86 41.13 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.988 0.899 . . . . 10.0 109.271 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 63.5 t60 -60.81 115.2 3.49 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 118.364 -1.334 . . . . 10.0 109.096 166.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.69 -137.4 3.49 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 107.935 -2.066 . . . . 10.0 107.935 176.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.26 -162.3 23.36 Favored Glycine 0 N--CA 1.45 -0.368 0 N-CA-C 109.03 -1.628 . . . . 10.0 109.03 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -61.56 -4.8 4.76 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 CA-C-N 119.585 1.692 . . . . 10.0 111.271 168.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -89.29 -26.81 20.94 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.724 1.21 . . . . 10.0 110.401 175.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 34.0 t0 -102.61 157.48 16.91 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 107.227 -1.398 . . . . 10.0 107.227 -178.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -80.6 -30.25 36.86 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.048 -1.093 . . . . 10.0 108.048 167.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -91.05 6.65 44.03 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.07 1.348 . . . . 10.0 113.419 -168.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -42.33 140.35 1.21 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.145 0.978 . . . . 10.0 110.835 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -60.27 -65.09 0.74 Allowed 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.852 0.835 . . . . 10.0 110.453 -171.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.408 ' CG1' ' H ' ' A' ' 82' ' ' GLY . 7.7 p -160.48 -87.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.336 -2.098 . . . . 10.0 105.336 171.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.408 ' H ' ' CG1' ' A' ' 81' ' ' VAL . . . -88.38 59.95 4.06 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.311 -1.116 . . . . 10.0 110.311 178.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -96.15 91.53 5.97 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 104.916 -2.253 . . . . 10.0 104.916 168.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -66.88 -32.8 74.3 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 108.704 -0.85 . . . . 10.0 108.704 -175.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.45 -85.66 0.38 Allowed Glycine 0 N--CA 1.439 -1.13 0 N-CA-C 108.277 -1.929 . . . . 10.0 108.277 168.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 -150.76 135.78 17.56 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.161 -1.422 . . . . 10.0 107.161 -178.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -106.93 133.11 52.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 169.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -87.57 131.76 34.29 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 108.208 -1.034 . . . . 10.0 108.208 176.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -107.11 135.9 47.86 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.029 0.932 . . . . 10.0 109.012 173.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -59.63 172.09 0.75 Allowed 'General case' 0 C--O 1.232 0.135 0 O-C-N 124.243 0.965 . . . . 10.0 109.912 167.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -47.39 -35.87 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 125.732 1.613 . . . . 10.0 110.387 170.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -79.69 -5.95 56.21 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.634 1.173 . . . . 10.0 110.723 -173.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 3.71 89.07 Favored Glycine 0 C--N 1.338 0.684 0 N-CA-C 111.101 -0.799 . . . . 10.0 111.101 -176.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.6 t -79.66 107.83 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 N-CA-C 106.465 -1.68 . . . . 10.0 106.465 179.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.39 120.93 42.83 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 108.829 -0.804 . . . . 10.0 108.829 169.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -79.81 114.8 19.0 Favored 'General case' 0 N--CA 1.434 -1.27 0 C-N-CA 125.849 1.659 . . . . 10.0 109.442 170.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.0 t -101.46 133.76 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 105.417 -2.068 . . . . 10.0 105.417 169.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 7.0 m -158.05 58.85 0.47 Allowed 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 118.969 0.804 . . . . 10.0 110.878 176.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.16 153.61 6.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 C-N-CA 124.001 0.92 . . . . 10.0 108.581 -174.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -123.08 136.27 54.74 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.395 1.478 . . . . 10.0 109.409 172.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -143.75 153.22 42.2 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.7 p -107.95 -26.47 10.69 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 127.148 2.179 . . . . 10.0 111.914 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.2 p -77.91 -45.15 28.08 Favored 'Isoleucine or valine' 0 C--N 1.342 0.27 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -73.72 134.46 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 105.09 -2.189 . . . . 10.0 105.09 165.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -166.28 158.48 14.07 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 125.422 1.489 . . . . 10.0 108.117 -177.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.1 mt -60.59 -50.77 72.18 Favored 'General case' 0 N--CA 1.457 -0.08 0 CA-C-N 116.152 -0.477 . . . . 10.0 110.825 -171.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -120.1 -165.58 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.592 1.157 . . . . 10.0 108.28 172.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 97.77 62.65 0.89 Allowed Glycine 0 CA--C 1.524 0.608 0 C-N-CA 124.394 0.997 . . . . 10.0 111.198 169.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 t70 71.07 -57.54 0.6 Allowed 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 129.469 3.108 . . . . 10.0 109.334 -178.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -74.33 -39.96 62.5 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 -169.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.2 t 39.84 85.05 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 126.111 1.764 . . . . 10.0 113.012 167.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 35.7 pt -58.69 -22.7 21.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -177.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.5 mm -47.26 131.11 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 O-C-N 121.799 -0.563 . . . . 10.0 110.365 174.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.64 1.6 82.92 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 118.408 -1.218 . . . . 10.0 113.987 175.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mmt-85 -81.34 165.76 21.07 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.8 1.3 . . . . 10.0 111.348 171.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -100.7 130.51 46.75 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 105.309 -2.108 . . . . 10.0 105.309 169.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.7 mp -108.66 149.58 28.76 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.416 -0.957 . . . . 10.0 108.416 170.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 96.7 t -135.98 137.09 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.945 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 -173.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.6 p -108.19 138.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 168.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.6 m170 -116.22 161.16 19.4 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 115.641 1.719 . . . . 10.0 115.641 -170.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -43.33 -55.36 4.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 128.621 2.768 . . . . 10.0 110.046 177.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -124.21 174.41 7.7 Favored 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 125.065 1.346 . . . . 10.0 111.34 -169.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.25 148.86 45.06 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.667 1.187 . . . . 10.0 110.401 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.46 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.2 m-20 -78.59 147.33 33.74 Favored 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 124.145 0.978 . . . . 10.0 111.702 174.186 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -75.44 -30.23 59.93 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 114.372 -1.285 . . . . 10.0 109.675 169.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 29.9 mt 57.45 52.67 8.28 Favored 'General case' 0 C--N 1.339 0.13 0 N-CA-C 107.688 -1.227 . . . . 10.0 107.688 -167.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.42 -24.7 12.97 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-N 113.521 -1.672 . . . . 10.0 112.99 173.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -75.11 6.5 4.18 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 114.543 1.312 . . . . 10.0 114.543 -167.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.83 -16.6 79.27 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.057 0.836 . . . . 10.0 112.097 171.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.82 43.77 48.28 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 118.082 0.941 . . . . 10.0 111.801 -176.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -130.88 163.4 27.52 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 106.943 -1.503 . . . . 10.0 106.943 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -54.07 -49.54 68.8 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.16 -0.927 . . . . 10.0 108.502 169.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -56.95 -44.21 82.32 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 122.775 0.43 . . . . 10.0 110.519 173.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.3 p -56.3 -43.74 79.21 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 120.635 -1.29 . . . . 10.0 110.576 -178.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -82.24 2.12 33.37 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 118.848 -0.596 . . . . 10.0 112.071 -178.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.5 -75.84 0.61 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.328 1.851 . . . . 10.0 110.196 176.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 6.6 p -120.96 27.06 8.69 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 120.786 1.63 . . . . 10.0 113.371 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.2 27.99 70.01 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 121.811 -0.556 . . . . 10.0 113.771 167.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 47.65 30.06 1.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.816 0.808 . . . . 10.0 112.177 -173.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.18 -5.33 13.2 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.723 -0.61 . . . . 10.0 110.855 175.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.59 -156.06 36.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 109.806 -1.318 . . . . 10.0 109.806 168.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.3 m -59.86 131.95 52.45 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 109.497 -0.557 . . . . 10.0 109.497 -171.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.46 68.01 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 168.1 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.77 -27.45 67.99 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 -169.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.35 145.83 24.08 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-O 121.475 0.655 . . . . 10.0 109.278 -178.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 15.8 p -162.46 163.65 27.48 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-N 115.849 -0.614 . . . . 10.0 109.641 -167.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 179.6 36.23 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 110.588 -1.005 . . . . 10.0 110.588 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.88 148.12 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.675 0 N-CA-C 103.72 -2.696 . . . . 10.0 103.72 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 3.9 mt -65.81 -87.7 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 C-N-CA 123.222 0.609 . . . . 10.0 111.203 -168.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.57 135.29 7.05 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.426 -0.669 . . . . 10.0 111.426 -178.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 62.3 mt -76.37 150.44 6.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 C-N-CA 125.132 1.373 . . . . 10.0 108.166 -176.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.14 -45.44 3.29 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 120.974 1.716 . . . . 10.0 112.006 169.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.3 tp60 . . . . . 0 C--O 1.252 1.219 0 C-N-CA 124.14 0.976 . . . . 10.0 109.772 -174.526 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.673 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.4 t -166.38 -46.88 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 124.486 1.114 . . . . 10.0 108.788 173.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -123.95 136.53 54.38 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.232 1.413 . . . . 10.0 109.165 -175.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 167.43 22.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 125.942 1.697 . . . . 10.0 107.803 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.49 168.88 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 118.488 0.585 . . . . 10.0 112.314 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.99 104.28 4.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 106.899 -1.519 . . . . 10.0 106.899 167.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 10.9 m -92.09 76.38 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 123.476 0.71 . . . . 10.0 109.212 175.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.5 mp -74.69 145.82 42.81 Favored 'General case' 0 N--CA 1.449 -0.521 0 O-C-N 121.299 -0.876 . . . . 10.0 109.263 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 161.4 19.77 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 107.992 -1.114 . . . . 10.0 107.992 -175.263 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.56 -58.37 0.04 OUTLIER Glycine 0 C--N 1.329 0.175 0 CA-C-N 115.628 -0.714 . . . . 10.0 111.579 169.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.21 -46.49 33.62 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 106.645 -1.613 . . . . 10.0 106.645 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.82 -68.37 0.51 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 113.383 -1.735 . . . . 10.0 110.729 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -59.89 -35.95 92.08 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.957 2.438 . . . . 10.0 111.424 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 96.5 t -68.71 99.74 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.141 0 N-CA-C 107.063 -1.458 . . . . 10.0 107.063 176.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -121.95 111.9 17.63 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.37 138.71 14.16 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 109.133 -1.587 . . . . 10.0 109.133 169.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.42 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 6.5 mt -139.31 78.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 106.681 -1.6 . . . . 10.0 106.681 -177.022 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -102.59 148.88 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.143 -0.935 . . . . 10.0 109.59 -175.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -118.37 114.04 22.32 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.831 1.652 . . . . 10.0 108.223 171.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -86.09 99.28 11.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 175.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.37 153.3 21.85 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 123.964 0.79 . . . . 10.0 109.883 -178.145 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -158.84 86.9 0.85 Allowed 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.254 -0.647 . . . . 10.0 109.254 -173.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 2.0 ttpm? -147.14 83.48 1.57 Allowed 'General case' 0 N--CA 1.424 -1.755 0 CA-C-O 122.257 1.027 . . . . 10.0 109.74 -174.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.62 172.28 18.55 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 102.622 -3.103 . . . . 10.0 102.622 166.136 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 21.1 t -78.31 -11.3 59.93 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.796 -0.362 . . . . 10.0 110.616 175.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 -88.65 -18.79 27.21 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 124.08 0.952 . . . . 10.0 109.214 172.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 43.2 53.75 5.58 Favored Glycine 0 CA--C 1.532 1.126 0 C-N-CA 125.711 1.624 . . . . 10.0 114.723 178.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -67.0 151.44 82.03 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.371 2.048 . . . . 10.0 108.34 169.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.49 92.38 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 105.842 -1.91 . . . . 10.0 105.842 169.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttp -83.76 98.43 9.69 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -97.58 99.69 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.95 0 C-N-CA 125.628 1.571 . . . . 10.0 106.819 -174.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 13.3 p90 -117.16 165.54 13.29 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.528 0.68 . . . . 10.0 112.605 171.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.76 -150.04 21.97 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 106.922 -2.471 . . . . 10.0 106.922 169.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 28.6 p -156.04 166.41 33.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 119.352 -0.939 . . . . 10.0 110.931 173.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.7 pt -106.43 174.75 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.843 -1.071 . . . . 10.0 110.491 167.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt -140.4 152.15 45.51 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.552 2.341 . . . . 10.0 105.893 169.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.12 -25.09 14.66 Favored Glycine 0 C--N 1.338 0.653 0 N-CA-C 116.007 1.163 . . . . 10.0 116.007 167.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -78.47 177.6 8.4 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 119.207 1.504 . . . . 10.0 110.945 -169.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.0 t -93.1 165.1 13.0 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 108.973 -0.751 . . . . 10.0 108.973 168.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.99 160.04 6.45 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.576 1.15 . . . . 10.0 111.45 -172.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.87 -170.24 29.06 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.626 -0.59 . . . . 10.0 111.626 169.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.77 148.6 42.39 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.405 1.082 . . . . 10.0 111.783 -172.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -144.42 141.74 29.84 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.215 1.006 . . . . 10.0 113.42 -177.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.2 126.48 1.6 Allowed Glycine 0 C--N 1.342 0.903 0 C-N-CA 126.803 2.144 . . . . 10.0 110.511 165.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -151.36 111.43 4.1 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.887 1.343 . . . . 10.0 108.295 168.083 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -153.76 168.33 26.66 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.978 0.894 . . . . 10.0 112.459 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 18.7 m -88.78 149.34 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 111.869 -2.423 . . . . 10.0 105.812 166.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -124.83 169.72 11.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.691 0.757 . . . . 10.0 109.309 169.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . 0.646 ' CG ' ' H ' ' B' ' 50' ' ' PHE . 0.8 OUTLIER 4.0 -113.68 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 130.503 3.521 . . . . 10.0 117.624 167.727 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . 0.646 ' H ' ' CG ' ' B' ' 49' ' ' GLU . 51.9 m-85 -95.29 -141.88 0.26 Allowed 'General case' 0 N--CA 1.434 -1.231 0 C-N-CA 127.96 2.504 . . . . 10.0 106.024 172.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.43 31.5 4.82 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 125.171 1.367 . . . . 10.0 110.875 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -70.5 158.55 35.88 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 119.685 1.742 . . . . 10.0 108.273 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -163.45 12.07 0.06 Allowed 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 126.288 1.835 . . . . 10.0 111.899 173.085 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.41 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -60.48 -31.63 70.65 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 119.904 1.229 . . . . 10.0 110.954 -173.048 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.03 -18.37 58.18 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.26 1.024 . . . . 10.0 111.887 176.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.83 -171.58 13.78 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 107.539 -2.225 . . . . 10.0 107.539 -169.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 84.7 m -70.43 70.04 0.41 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.826 -1.176 . . . . 10.0 107.826 169.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.14 -51.05 0.08 Allowed 'General case' 0 N--CA 1.448 -0.544 0 O-C-N 120.706 -1.246 . . . . 10.0 110.911 -169.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 10.7 t -98.96 -0.15 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.711 0.804 . . . . 10.0 110.076 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -70.46 60.02 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.821 1.648 . . . . 10.0 109.461 171.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.24 130.42 0.89 Allowed Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 124.612 1.101 . . . . 10.0 115.227 164.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -87.84 42.49 0.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 123.279 2.653 . . . . 10.0 108.168 165.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 15.1 m170 65.47 54.28 1.16 Allowed 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.993 2.517 . . . . 10.0 110.964 -172.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -69.37 70.27 0.26 Allowed 'General case' 0 N--CA 1.47 0.554 0 O-C-N 121.794 -0.566 . . . . 10.0 110.638 171.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -80.01 152.13 73.91 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.521 -0.737 . . . . 10.0 110.333 175.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.05 -48.57 1.29 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.601 2.201 . . . . 10.0 111.298 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 86.0 mt -77.5 59.49 1.92 Allowed 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -56.24 99.51 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 124.761 1.224 . . . . 10.0 110.172 -176.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.48 -89.89 0.53 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 105.517 -2.031 . . . . 10.0 105.517 -177.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -142.87 153.59 43.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.091 0.948 . . . . 10.0 110.286 168.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -64.85 123.24 18.88 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 165.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.41 -144.2 4.08 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 107.857 -2.097 . . . . 10.0 107.857 179.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.432 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -176.05 -153.37 10.42 Favored Glycine 0 N--CA 1.452 -0.296 0 N-CA-C 108.565 -1.814 . . . . 10.0 108.565 170.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -69.12 15.26 0.19 Allowed 'Trans proline' 0 CA--C 1.54 0.802 0 CA-C-N 119.519 1.66 . . . . 10.0 111.404 169.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.432 ' H ' ' C ' ' B' ' 73' ' ' GLY . 72.3 mttt -119.49 0.46 11.05 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.177 1.391 . . . . 10.0 110.791 169.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.4 t0 -118.03 156.48 28.51 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.264 -1.384 . . . . 10.0 107.264 172.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -79.3 -31.61 43.33 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 171.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -118.59 36.94 4.22 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 123.861 0.864 . . . . 10.0 112.466 -165.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.74 148.96 3.61 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 125.257 1.423 . . . . 10.0 110.66 169.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 26.0 m170 -55.26 -62.35 1.73 Allowed 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.161 0.584 . . . . 10.0 112.192 -171.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -172.35 -60.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.181 0 C-N-CA 124.32 1.048 . . . . 10.0 108.332 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.71 51.98 0.82 Allowed Glycine 0 C--N 1.337 0.613 0 N-CA-C 109.319 -1.513 . . . . 10.0 109.319 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -84.77 92.28 8.19 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.447 -2.797 . . . . 10.0 103.447 167.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.5 mt -63.06 -30.4 71.57 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 -173.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.55 -89.8 0.48 Allowed Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.607 -1.397 . . . . 10.0 109.607 166.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -151.79 100.73 2.7 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.332 -0.988 . . . . 10.0 108.332 -171.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -86.37 141.86 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 172.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -99.47 129.87 45.69 Favored 'General case' 0 C--O 1.224 -0.257 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.56 134.81 40.99 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.916 -0.772 . . . . 10.0 108.916 172.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -59.84 169.59 1.39 Allowed 'General case' 0 N--CA 1.451 -0.382 0 O-C-N 124.526 1.141 . . . . 10.0 110.045 167.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 61.8 pttt -50.41 -33.19 19.94 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 124.229 1.011 . . . . 10.0 110.876 169.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -78.53 -1.25 33.0 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 122.87 0.468 . . . . 10.0 111.409 -178.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.36 17.86 75.2 Favored Glycine 0 C--N 1.34 0.781 0 O-C-N 120.746 -1.221 . . . . 10.0 110.49 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.69 103.61 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 C-N-CA 126.439 1.896 . . . . 10.0 106.789 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.35 121.64 40.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 167.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.46 117.79 20.74 Favored 'General case' 0 N--CA 1.436 -1.161 0 C-N-CA 126.579 1.951 . . . . 10.0 108.665 170.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 56.6 t -101.73 134.57 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 107.185 -1.413 . . . . 10.0 107.185 175.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -158.62 57.11 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.409 0.684 . . . . 10.0 111.263 175.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.71 158.2 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -172.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -130.73 90.72 2.95 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 126.762 2.025 . . . . 10.0 108.925 -176.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -84.46 83.78 7.88 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 63.1 p -78.73 60.31 2.74 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 169.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.3 t -143.22 -51.16 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 125.174 1.39 . . . . 10.0 107.704 -168.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.326 0.0 OUTLIER -118.91 165.12 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 113.656 0.984 . . . . 10.0 113.656 175.91 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.0 p -108.17 132.1 53.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.641 1.176 . . . . 10.0 109.646 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -69.83 -41.16 75.31 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.3 t -134.31 116.64 15.49 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 105.985 -1.857 . . . . 10.0 105.985 174.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.89 -66.33 0.09 OUTLIER Glycine 0 C--O 1.228 -0.242 0 N-CA-C 108.7 -1.76 . . . . 10.0 108.7 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -161.42 -48.66 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 113.581 -1.31 . . . . 10.0 109.263 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.63 -32.96 60.46 Favored 'General case' 0 N--CA 1.456 -0.147 0 CA-C-N 115.777 -0.647 . . . . 10.0 110.086 -168.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.9 t 33.65 75.1 0.05 Allowed 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 127.167 2.187 . . . . 10.0 112.25 168.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.9 pt -75.01 44.38 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 C-N-CA 123.752 0.821 . . . . 10.0 111.841 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 17.7 mm -78.25 -68.52 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 C-N-CA 125.685 1.594 . . . . 10.0 109.981 -174.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.42 52.31 3.05 Favored Glycine 0 CA--C 1.533 1.198 0 O-C-N 120.8 -1.187 . . . . 10.0 112.302 176.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.1 mmt85 -121.09 153.55 37.3 Favored 'General case' 0 C--O 1.233 0.192 0 C-N-CA 126.147 1.779 . . . . 10.0 110.614 -178.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 53.9 m -97.75 121.26 39.44 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.121 0.968 . . . . 10.0 109.587 177.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -98.24 144.33 27.79 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 125.916 1.686 . . . . 10.0 107.743 169.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 53.1 t -128.8 140.67 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 108.409 -0.96 . . . . 10.0 108.409 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 p -113.39 128.75 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 C-N-CA 125.666 1.586 . . . . 10.0 106.932 169.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 3.4 m170 -114.09 163.74 14.78 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 116.082 1.882 . . . . 10.0 116.082 -169.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -45.02 -59.1 2.76 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.602 2.761 . . . . 10.0 112.628 174.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -122.81 176.29 6.06 Favored 'General case' 0 CA--C 1.522 -0.134 0 C-N-CA 124.366 1.067 . . . . 10.0 113.317 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.58 155.59 38.78 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.827 1.651 . . . . 10.0 111.094 176.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.5 146.86 24.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 124.8 1.24 . . . . 10.0 110.795 172.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -74.9 -32.88 61.94 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 114.849 -1.068 . . . . 10.0 109.321 170.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 52.2 mt 62.94 65.34 0.81 Allowed 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 123.265 1.507 . . . . 10.0 108.237 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.77 -51.11 4.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 112.945 -1.934 . . . . 10.0 111.726 170.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 38.3 mtmt -80.32 53.21 1.74 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.371 1.468 . . . . 10.0 111.591 -169.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.94 -3.71 23.11 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.208 1.861 . . . . 10.0 112.462 177.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.54 42.55 27.16 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.244 0.926 . . . . 10.0 112.797 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -135.98 158.32 44.69 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 107.577 -1.268 . . . . 10.0 107.577 176.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -54.15 -42.94 70.14 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 169.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -58.91 -44.39 91.26 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.983 -0.553 . . . . 10.0 112.175 170.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 10.1 p -56.19 -43.25 78.26 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 119.581 1.082 . . . . 10.0 111.22 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -71.24 -7.85 49.65 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-O 118.083 -0.961 . . . . 10.0 113.091 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -119.7 -65.65 1.14 Allowed 'General case' 0 N--CA 1.439 -1.008 0 C-N-CA 127.677 2.391 . . . . 10.0 113.141 -168.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.5 p -130.16 26.2 5.18 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.274 1.397 . . . . 10.0 109.908 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 68.32 -104.45 1.2 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 107.375 -2.29 . . . . 10.0 107.375 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -154.93 39.06 0.42 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 107.551 -1.278 . . . . 10.0 107.551 170.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.62 -12.48 23.38 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 123.527 0.731 . . . . 10.0 112.512 -171.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.96 -167.55 51.19 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 109.734 -1.346 . . . . 10.0 109.734 175.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 53.1 m -56.03 133.41 51.81 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 121.602 0.715 . . . . 10.0 111.729 -169.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 19.7 mtt180 -65.15 75.32 0.05 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.457 -0.792 . . . . 10.0 109.177 168.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.9 mt -47.56 -48.73 27.69 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.96 0.409 . . . . 10.0 109.986 177.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.15 152.54 37.46 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.414 0.626 . . . . 10.0 110.566 -172.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -148.42 167.71 24.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.595 -0.73 . . . . 10.0 109.308 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.0 148.66 19.75 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 109.592 -1.403 . . . . 10.0 109.592 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 75.1 t -101.35 124.26 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 N-CA-C 104.365 -2.457 . . . . 10.0 104.365 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 21.0 mt -67.75 157.74 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 CA-C-N 118.969 0.804 . . . . 10.0 110.454 -178.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -159.97 147.24 14.07 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.594 1.568 . . . . 10.0 110.423 -170.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 62.0 mt -69.15 135.41 28.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 C-N-CA 126.476 1.91 . . . . 10.0 110.452 -169.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -125.8 -48.4 1.64 Allowed 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.624 -0.673 . . . . 10.0 112.199 -178.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.254 1.294 0 C-N-CA 125.437 1.495 . . . . 10.0 110.517 -168.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 116.164 -1.874 . . . . 10.0 106.571 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -96.55 -33.77 11.69 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.773 1.169 . . . . 10.0 112.79 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -137.54 133.32 34.38 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 123.958 0.903 . . . . 10.0 111.615 -177.327 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.92 162.31 28.88 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.185 1.394 . . . . 10.0 109.457 173.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.2 t -124.31 154.89 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 125.784 1.634 . . . . 10.0 108.272 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.46 111.9 6.35 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 168.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.9 m -101.26 113.47 37.51 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.28 0.632 . . . . 10.0 110.945 -178.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -90.05 139.24 30.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 121.743 -0.598 . . . . 10.0 111.945 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -151.84 159.95 43.71 Favored 'General case' 0 N--CA 1.455 -0.197 0 N-CA-C 107.25 -1.389 . . . . 10.0 107.25 167.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.73 -56.68 0.06 OUTLIER Glycine 0 N--CA 1.461 0.351 0 C-N-CA 120.247 -0.978 . . . . 10.0 112.389 169.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -71.42 -44.5 64.76 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -178.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.3 -70.6 0.43 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.328 -1.305 . . . . 10.0 110.37 169.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -58.28 -33.12 97.35 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 123.528 2.819 . . . . 10.0 111.554 173.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.61 94.24 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 173.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -114.09 126.62 55.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.508 -1.293 . . . . 10.0 107.508 175.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -121.17 145.23 17.08 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 124.294 0.949 . . . . 10.0 111.045 -177.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.429 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 4.9 mt -146.42 84.22 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 106.555 -1.646 . . . . 10.0 106.555 -170.397 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.8 mm -95.46 142.74 13.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 C-N-CA 124.439 1.096 . . . . 10.0 108.571 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -124.3 127.63 47.93 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 125.957 1.703 . . . . 10.0 108.559 172.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -106.43 112.92 26.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.424 -1.324 . . . . 10.0 107.424 176.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -105.26 127.42 52.93 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.601 0.637 . . . . 10.0 111.195 168.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -114.93 88.68 2.92 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.526 1.531 . . . . 10.0 107.288 169.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.531 ' HZ1' ' CD ' ' A' ' 24' ' ' GLU . 12.5 pttp -59.58 -44.0 93.47 Favored 'General case' 0 N--CA 1.457 -0.09 0 C-N-CA 124.199 1.0 . . . . 10.0 110.279 -171.15 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.531 ' CD ' ' HZ1' ' A' ' 23' ' ' LYS . 2.9 mt-10 -133.1 161.58 34.01 Favored 'General case' 0 N--CA 1.425 -1.704 0 N-CA-C 104.301 -2.481 . . . . 10.0 104.301 174.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.9 p -66.18 -18.96 65.68 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 121.505 0.669 . . . . 10.0 109.691 169.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 29.9 m120 -79.1 -21.52 46.56 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 124.828 1.251 . . . . 10.0 110.708 177.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.48 127.52 8.03 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 109.802 -1.319 . . . . 10.0 109.802 -174.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.63 131.39 29.36 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 N-CA-C 106.93 -1.988 . . . . 10.0 106.93 169.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.3 t -78.47 101.95 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -169.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -69.7 106.82 3.21 Favored 'General case' 0 N--CA 1.446 -0.667 0 N-CA-C 107.828 -1.175 . . . . 10.0 107.828 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.7 m -82.8 111.73 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 N-CA-C 106.265 -1.754 . . . . 10.0 106.265 169.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.8 p90 -122.38 168.0 12.61 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.245 0.545 . . . . 10.0 112.304 170.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.33 -152.51 24.57 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 107.738 -2.145 . . . . 10.0 107.738 169.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.3 p -156.17 155.54 32.65 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 119.306 -0.958 . . . . 10.0 112.527 -176.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -117.76 129.14 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 125.489 1.516 . . . . 10.0 107.92 168.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 48.1 tttp -110.08 148.32 31.95 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.73 1.612 . . . . 10.0 107.138 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.61 -10.02 25.92 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 123.796 0.712 . . . . 10.0 113.891 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.0 mt -73.04 179.25 3.87 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.335 1.054 . . . . 10.0 110.522 178.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.3 t -104.86 165.31 11.16 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 167.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -55.38 156.16 4.64 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.489 1.116 . . . . 10.0 113.195 -169.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.98 177.38 51.97 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.429 1.014 . . . . 10.0 112.669 169.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 84.9 mt -40.88 137.88 1.14 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.625 1.97 . . . . 10.0 114.74 175.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.21 150.68 44.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.631 1.572 . . . . 10.0 110.661 170.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -35.95 123.44 0.73 Allowed Glycine 0 C--N 1.338 0.651 0 CA-C-O 116.855 -2.08 . . . . 10.0 109.39 163.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -149.88 108.11 3.76 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 120.207 2.003 . . . . 10.0 109.205 167.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.411 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -154.22 175.47 13.45 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.503 0.668 . . . . 10.0 110.763 -176.807 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.97 156.63 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.639 0 CA-C-N 112.425 -2.171 . . . . 10.0 108.297 168.319 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -132.99 130.81 39.99 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 104.259 -2.497 . . . . 10.0 104.259 174.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -58.25 -53.08 62.37 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.162 0.914 . . . . 10.0 111.321 -168.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -77.04 135.93 38.66 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 118.388 -1.325 . . . . 10.0 107.71 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.07 -31.79 72.5 Favored Glycine 0 N--CA 1.441 -0.97 0 N-CA-C 109.59 -1.404 . . . . 10.0 109.59 169.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -36.35 126.86 0.8 Allowed 'General case' 0 C--N 1.341 0.216 0 C-N-CA 126.352 1.861 . . . . 10.0 112.761 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -130.48 9.94 5.17 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 114.445 -1.252 . . . . 10.0 110.894 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.413 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -54.61 -35.68 63.67 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.312 1.045 . . . . 10.0 112.112 -169.618 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.35 -17.17 58.47 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.197 0.599 . . . . 10.0 112.241 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.89 76.31 0.88 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 108.865 -1.694 . . . . 10.0 108.865 -177.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.84 6.52 0.91 Allowed 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.086 1.354 . . . . 10.0 113.312 176.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 45.1 m -98.72 -42.11 7.37 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 107.774 -1.195 . . . . 10.0 107.774 -169.029 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.93 -39.62 71.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 123.771 0.828 . . . . 10.0 111.022 -169.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.78 -25.2 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.754 3.621 . . . . 10.0 116.863 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.92 121.98 3.95 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.437 -1.465 . . . . 10.0 109.437 172.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.4 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 72.9 Cg_endo -69.16 73.25 1.1 Allowed 'Trans proline' 0 CA--C 1.54 0.792 0 C-N-CA 123.596 2.864 . . . . 10.0 111.759 177.279 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 25.4 m170 61.09 46.84 7.79 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.624 3.17 . . . . 10.0 111.305 176.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.4 ' CZ ' ' HD2' ' A' ' 62' ' ' PRO . 19.5 m-85 -74.29 48.66 0.34 Allowed 'General case' 0 N--CA 1.467 0.39 0 O-C-N 121.799 -0.563 . . . . 10.0 111.993 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -63.62 149.45 92.42 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 121.36 -0.837 . . . . 10.0 108.804 178.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -54.23 -60.03 0.73 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 122.977 2.451 . . . . 10.0 111.879 -172.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.01 66.5 2.22 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.743 -0.598 . . . . 10.0 109.665 169.705 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t -59.1 102.5 0.13 Allowed 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.5 mtp85 -105.36 -89.9 0.42 Allowed 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 106.063 -1.828 . . . . 10.0 106.063 -176.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.2 mmtt -143.32 146.62 33.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.244 0.545 . . . . 10.0 109.664 168.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.0 t60 -55.99 121.57 9.64 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 117.976 -1.489 . . . . 10.0 107.6 165.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.71 -149.99 5.48 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.09 -150.97 8.17 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.265 -1.297 . . . . 10.0 110.675 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -70.05 17.37 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.849 1.699 . . . . 10.0 111.285 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.17 -19.33 16.49 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 108.017 -1.105 . . . . 10.0 108.017 168.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.28 -178.59 4.91 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.895 -1.15 . . . . 10.0 107.895 -168.204 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -116.39 -5.4 11.76 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 123.424 0.69 . . . . 10.0 110.734 170.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.407 ' CD ' ' N ' ' A' ' 78' ' ' GLU . 0.8 OUTLIER -98.11 -2.88 39.04 Favored 'General case' 0 CA--C 1.517 -0.323 0 O-C-N 121.02 -1.05 . . . . 10.0 111.536 -174.258 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 9.6 ptt85 -28.76 129.83 0.07 Allowed 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.408 2.283 . . . . 10.0 111.019 167.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -59.52 151.99 22.95 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.968 -0.753 . . . . 10.0 108.968 172.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 94.5 t -59.5 89.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.955 -1.128 . . . . 10.0 107.955 171.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.64 28.58 3.42 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 125.724 1.631 . . . . 10.0 113.496 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -85.92 101.04 12.52 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 105.055 -2.202 . . . . 10.0 105.055 164.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.65 16.48 1.75 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 119.286 0.948 . . . . 10.0 110.83 173.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.03 -107.98 2.49 Favored Glycine 0 N--CA 1.434 -1.499 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 -179.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -155.94 144.59 20.27 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 106.646 -1.613 . . . . 10.0 106.646 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -120.77 135.99 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 C-N-CA 123.062 0.545 . . . . 10.0 109.867 -171.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -82.72 131.85 35.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 125.134 1.374 . . . . 10.0 109.616 -174.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.76 142.24 31.5 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 123.918 0.887 . . . . 10.0 110.897 170.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -60.93 167.43 2.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.473 1.109 . . . . 10.0 109.744 166.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.4 ptmt -54.1 -26.77 28.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.149 1.379 . . . . 10.0 112.184 173.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -75.9 -29.94 58.61 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 109.75 -0.463 . . . . 10.0 109.75 177.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 112.05 4.71 25.7 Favored Glycine 0 N--CA 1.446 -0.68 0 CA-C-O 118.626 -1.097 . . . . 10.0 111.216 -169.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.7 t -78.61 99.1 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 C-N-CA 125.069 1.347 . . . . 10.0 108.279 177.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 117.47 33.38 Favored 'General case' 0 CA--C 1.518 -0.264 0 N-CA-C 106.886 -1.524 . . . . 10.0 106.886 166.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -89.03 119.78 29.86 Favored 'General case' 0 N--CA 1.436 -1.142 0 C-N-CA 127.879 2.472 . . . . 10.0 109.106 177.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.6 t -105.15 135.06 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 C-N-CA 125.127 1.371 . . . . 10.0 107.787 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 88.9 p -159.72 69.74 0.43 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.309 0.855 . . . . 10.0 113.309 172.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -123.96 143.19 38.08 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 124.53 1.132 . . . . 10.0 110.38 -170.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -116.28 149.84 38.57 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.942 2.097 . . . . 10.0 110.128 173.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -149.87 153.39 36.63 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 106.744 -1.576 . . . . 10.0 106.744 167.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 78.1 p -95.47 56.04 1.78 Allowed 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 125.395 1.478 . . . . 10.0 108.528 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 58.4 t -144.12 -53.18 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -176.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.7 mm -54.48 139.08 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 C-N-CA 124.022 0.929 . . . . 10.0 109.488 173.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.9 m -155.15 134.94 12.78 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 169.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.6 mt -55.85 -52.04 65.42 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.645 1.178 . . . . 10.0 110.436 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.0 t -140.52 -179.27 5.93 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.313 0.645 . . . . 10.0 109.514 176.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.85 -100.3 0.56 Allowed Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 106.22 -2.752 . . . . 10.0 106.22 -170.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -128.92 -49.77 1.23 Allowed 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 125.356 1.462 . . . . 10.0 108.356 -169.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.5 -41.07 48.32 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.888 -1.051 . . . . 10.0 108.867 -176.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t 38.71 89.81 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.391 2.276 . . . . 10.0 113.796 172.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pp -73.63 -15.31 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 112.534 0.568 . . . . 10.0 112.534 178.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.3 mm -50.12 122.63 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 O-C-N 121.188 -0.945 . . . . 10.0 110.412 174.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.44 5.43 56.94 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.466 1.032 . . . . 10.0 112.968 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.6 mpt_? -75.66 179.38 5.41 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.017 0.927 . . . . 10.0 109.533 169.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -129.72 141.56 50.87 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 173.284 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 6.1 mp -107.94 157.43 18.22 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.75 -0.833 . . . . 10.0 108.75 168.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -140.04 137.86 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 O-C-N 123.934 0.771 . . . . 10.0 109.206 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.4 m -103.25 134.56 44.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 O-C-N 124.473 1.108 . . . . 10.0 108.912 164.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.7 m170 -110.83 159.21 17.88 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 114.497 1.295 . . . . 10.0 114.497 -174.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.73 -50.05 73.37 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.973 1.309 . . . . 10.0 110.46 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -113.03 172.17 7.1 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.629 0.728 . . . . 10.0 112.366 -177.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.22 151.24 33.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.138 1.375 . . . . 10.0 109.503 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.411 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 3.4 m-20 -79.49 147.04 32.38 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.207 0.447 . . . . 10.0 112.207 176.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -86.49 3.02 45.81 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.506 1.129 . . . . 10.0 111.637 168.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.4 mt 48.06 51.89 13.94 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 125.247 1.419 . . . . 10.0 111.859 170.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.38 -7.87 64.13 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 113.756 -1.565 . . . . 10.0 112.187 173.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -114.23 35.16 4.29 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.25 1.02 . . . . 10.0 110.691 -168.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -82.89 -23.55 55.3 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 126.124 1.821 . . . . 10.0 111.697 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.44 48.1 81.48 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-N 118.184 0.992 . . . . 10.0 111.547 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -158.13 167.4 29.93 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 127.746 2.418 . . . . 10.0 105.734 -175.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.456 ' CD ' ' HZ2' ' A' ' 136' ' ' LYS . 4.1 tm-20 -57.49 -44.51 85.01 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.627 0.727 . . . . 10.0 109.645 175.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -52.89 -31.15 38.16 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.788 0.835 . . . . 10.0 112.327 175.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.0 t -46.77 -47.14 20.86 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 124.054 0.942 . . . . 10.0 109.035 178.24 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.6 t -83.67 0.56 46.45 Favored 'General case' 0 CA--C 1.539 0.556 0 CA-C-O 118.35 -0.833 . . . . 10.0 112.714 -173.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.456 ' HZ2' ' CD ' ' A' ' 132' ' ' GLU . 91.0 mttt -121.55 -83.02 0.66 Allowed 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.464 1.906 . . . . 10.0 111.897 -174.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.36 24.46 13.06 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 121.759 2.072 . . . . 10.0 110.662 174.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.89 -87.3 0.29 Allowed Glycine 0 C--N 1.34 0.793 0 C-N-CA 125.151 1.358 . . . . 10.0 110.027 175.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.22 34.08 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 125.233 1.413 . . . . 10.0 110.477 172.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.98 -9.76 56.28 Favored 'General case' 0 C--N 1.341 0.212 0 O-C-N 121.041 -1.037 . . . . 10.0 112.192 -172.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.77 -163.62 52.66 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 169.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -49.73 123.79 8.53 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.161 1.384 . . . . 10.0 113.428 -168.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -63.54 74.18 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.259 1.824 . . . . 10.0 110.734 173.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 52.7 mt -49.68 -36.81 26.3 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 113.189 0.811 . . . . 10.0 113.189 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.31 144.44 23.0 Favored 'General case' 0 CA--C 1.513 -0.442 0 O-C-N 121.711 -0.618 . . . . 10.0 109.418 178.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.9 p -132.37 152.16 51.56 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 124.206 0.941 . . . . 10.0 109.876 176.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.39 141.98 11.26 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.297 -1.121 . . . . 10.0 110.297 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.5 t -97.11 142.71 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 105.971 -1.863 . . . . 10.0 105.971 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 14.1 mt -79.29 136.7 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 N-CA-C 110.038 -0.356 . . . . 10.0 110.038 -176.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.84 145.49 17.34 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.75 1.167 . . . . 10.0 111.877 -175.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.3 mt -67.83 139.57 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 124.4 1.08 . . . . 10.0 108.362 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.9 -26.92 2.59 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 114.805 1.409 . . . . 10.0 114.805 -176.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.025 0 CA-C-O 117.61 -1.186 . . . . 10.0 111.84 -178.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.789 0 CA-C-O 116.73 -1.605 . . . . 10.0 107.134 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t -68.99 -18.83 64.11 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-N 120.533 1.515 . . . . 10.0 108.615 169.098 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.6 ptpt -144.39 162.27 36.9 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 120.831 0.348 . . . . 10.0 110.88 165.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -152.95 166.87 31.03 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 127.139 2.175 . . . . 10.0 107.645 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.71 162.79 36.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 C-N-CA 123.419 0.688 . . . . 10.0 111.014 -176.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.39 108.51 5.48 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.931 0.892 . . . . 10.0 109.307 168.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.1 m -82.5 81.81 1.53 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.485 0.714 . . . . 10.0 110.294 171.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -73.13 127.18 31.86 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.714 -0.847 . . . . 10.0 108.714 -171.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.6 mtmp? -147.54 160.36 42.71 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.324 -0.991 . . . . 10.0 108.324 -177.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.17 -57.51 0.06 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 120.479 -0.867 . . . . 10.0 112.928 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -72.65 -43.85 62.63 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 -175.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.02 -70.97 0.43 Allowed Glycine 0 CA--C 1.524 0.596 0 CA-C-N 114.273 -1.33 . . . . 10.0 110.078 171.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -56.46 -34.26 94.27 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.056 2.504 . . . . 10.0 111.28 172.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.8 t -66.83 100.63 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 176.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -122.35 109.52 14.52 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 174.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.56 134.86 11.98 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.751 -1.34 . . . . 10.0 109.751 169.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.413 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 17.7 mt -129.55 67.66 0.34 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.153 0 N-CA-C 107.255 -1.387 . . . . 10.0 107.255 -174.273 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -89.25 137.92 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 114.611 -1.177 . . . . 10.0 109.735 -171.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -120.68 116.03 24.49 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.051 2.14 . . . . 10.0 107.97 -173.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -98.72 109.62 22.35 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 116.986 -1.483 . . . . 10.0 107.672 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -104.18 138.87 40.03 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 119.856 1.207 . . . . 10.0 112.592 169.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 40.2 tp60 -124.21 91.89 3.55 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 129.719 3.208 . . . . 10.0 107.288 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 59.0 tttt -155.21 86.47 1.1 Allowed 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 177.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -158.26 170.46 22.21 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 103.649 -2.723 . . . . 10.0 103.649 166.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 26.1 t -91.79 7.94 39.46 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 123.589 0.756 . . . . 10.0 109.84 171.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -112.44 -10.48 13.74 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 124.74 1.216 . . . . 10.0 109.236 168.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 54.76 35.77 58.48 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-O 117.21 -1.883 . . . . 10.0 116.279 173.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -68.26 128.27 17.17 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 CA-C-N 121.362 2.581 . . . . 10.0 106.174 168.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 1.3 p -76.92 112.39 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.547 0 N-CA-C 105.968 -1.864 . . . . 10.0 105.968 169.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.5 tttt -85.77 107.19 17.5 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.994 -2.225 . . . . 10.0 104.994 172.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 p -95.48 96.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 C-N-CA 126.816 2.046 . . . . 10.0 105.733 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.0 p90 -117.65 169.04 9.89 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 121.827 0.822 . . . . 10.0 112.228 173.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.9 -157.26 27.2 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 106.959 -2.456 . . . . 10.0 106.959 169.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 p -149.24 160.3 43.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 176.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pp -111.52 175.61 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 CA-C-N 114.69 -1.141 . . . . 10.0 109.393 167.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ptmt -143.83 141.43 30.35 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 106.185 -1.783 . . . . 10.0 106.185 166.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.02 -5.43 20.14 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.122 0.867 . . . . 10.0 114.734 170.731 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -70.07 178.13 2.89 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 118.712 1.256 . . . . 10.0 111.502 -179.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.6 t -111.76 156.14 22.41 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 167.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -50.26 156.67 0.79 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.362 1.465 . . . . 10.0 113.073 -169.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.57 -169.24 32.61 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 123.422 0.534 . . . . 10.0 111.784 168.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.49 146.33 44.99 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 124.61 1.164 . . . . 10.0 111.135 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -143.2 151.19 40.34 Favored 'General case' 0 C--N 1.34 0.19 0 N-CA-C 113.684 0.994 . . . . 10.0 113.684 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.05 119.68 0.16 Allowed Glycine 0 C--N 1.339 0.714 0 C-N-CA 129.337 3.351 . . . . 10.0 113.662 166.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -152.4 112.48 4.02 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 120.047 1.923 . . . . 10.0 112.785 168.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.557 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 1.0 OUTLIER -142.22 173.1 11.83 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.645 0.736 . . . . 10.0 111.532 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 46.1 t -106.43 117.77 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 CA-C-N 111.927 -2.397 . . . . 10.0 104.691 168.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -92.81 148.61 21.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 172.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -60.1 -57.16 14.03 Favored 'General case' 0 N--CA 1.45 -0.475 0 CA-C-N 115.113 -0.949 . . . . 10.0 109.979 -171.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -77.67 148.49 34.98 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 108.91 -0.774 . . . . 10.0 108.91 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.55 -5.33 69.33 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 125.022 1.296 . . . . 10.0 110.15 166.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -40.7 143.03 0.38 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.805 1.242 . . . . 10.0 111.422 169.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -153.29 23.56 0.55 Allowed 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 113.89 -1.505 . . . . 10.0 111.359 168.309 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.429 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.83 -36.15 71.86 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 118.685 0.675 . . . . 10.0 110.865 -172.361 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.92 -22.98 39.23 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.673 1.189 . . . . 10.0 112.966 175.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.24 107.42 1.46 Allowed Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.251 0.929 . . . . 10.0 111.45 -174.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 28.7 m 33.45 55.55 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 127.557 2.343 . . . . 10.0 113.537 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.3 -54.81 0.08 Allowed 'General case' 0 N--CA 1.448 -0.568 0 O-C-N 121.439 -0.788 . . . . 10.0 108.955 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 59' ' ' SER . . . . . 0.427 ' C ' ' H ' ' B' ' 61' ' ' GLY . 52.5 m -79.77 -5.52 55.47 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.251 0.621 . . . . 10.0 112.43 -174.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.37 8.31 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.365 1.866 . . . . 10.0 114.829 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . 0.427 ' H ' ' C ' ' B' ' 59' ' ' SER . . . 87.26 113.21 0.99 Allowed Glycine 0 CA--C 1.528 0.862 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 175.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.02 69.17 3.12 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.909 2.406 . . . . 10.0 111.299 175.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.44 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 11.8 m170 70.52 43.29 0.79 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.605 2.762 . . . . 10.0 110.231 170.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -73.95 45.89 0.22 Allowed 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.738 1.215 . . . . 10.0 114.183 -175.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -51.76 155.81 2.73 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.19 1.396 . . . . 10.0 111.54 169.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.47 -51.21 0.76 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.538 2.158 . . . . 10.0 111.866 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -74.97 53.63 0.61 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.954 0.902 . . . . 10.0 112.7 -177.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -54.2 108.82 0.41 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 122.793 0.437 . . . . 10.0 110.133 -171.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 mtt180 -120.61 -91.74 0.55 Allowed 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 105.892 -1.892 . . . . 10.0 105.892 -174.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -148.23 157.11 43.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 168.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -62.02 116.78 5.2 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 117.869 -1.533 . . . . 10.0 107.643 164.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.56 -145.99 6.44 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 107.695 -2.162 . . . . 10.0 107.695 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.4 -164.76 18.09 Favored Glycine 0 C--N 1.33 0.225 0 N-CA-C 108.771 -1.732 . . . . 10.0 108.771 173.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.89 -1.19 3.9 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.983 1.788 . . . . 10.0 110.951 167.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -84.29 -29.35 26.48 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 123.803 0.841 . . . . 10.0 109.279 171.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -107.46 161.72 14.58 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 123.161 0.584 . . . . 10.0 109.483 -170.054 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -92.49 -9.11 42.59 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.512 0.725 . . . . 10.0 109.293 167.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -97.04 0.23 48.34 Favored 'General case' 0 N--CA 1.438 -1.05 0 CA-C-O 116.035 -1.936 . . . . 10.0 113.521 -176.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.8 137.32 0.65 Allowed 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 120.101 1.319 . . . . 10.0 110.57 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -59.32 -37.23 77.27 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 120.159 -0.616 . . . . 10.0 111.341 -170.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.1 -61.23 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 106.61 -1.626 . . . . 10.0 106.61 172.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.46 -56.04 0.32 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 173.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 39.29 85.5 0.02 OUTLIER 'General case' 0 C--N 1.346 0.429 0 C-N-CA 126.325 1.85 . . . . 10.0 108.618 -167.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -49.79 -33.14 15.63 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.349 1.06 . . . . 10.0 112.749 -166.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.03 -89.13 0.42 Allowed Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 168.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -155.06 101.14 2.23 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.639 -0.875 . . . . 10.0 108.639 -170.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -83.6 128.83 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.137 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 174.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.3 t -90.83 130.33 36.8 Favored 'General case' 0 C--O 1.225 -0.2 0 N-CA-C 108.733 -0.84 . . . . 10.0 108.733 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.15 131.86 48.4 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.407 -0.961 . . . . 10.0 108.407 171.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -58.88 168.31 1.31 Allowed 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 124.246 0.966 . . . . 10.0 109.832 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -30.2 18.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.083 0.953 . . . . 10.0 111.3 170.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.71 -7.09 56.01 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 120.958 -0.297 . . . . 10.0 111.091 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.56 28.14 55.82 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.566 -1.413 . . . . 10.0 109.566 -178.197 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 34.9 t -107.7 115.48 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.862 0 N-CA-C 104.617 -2.364 . . . . 10.0 104.617 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -113.53 123.27 49.61 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 107.544 -1.28 . . . . 10.0 107.544 174.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -85.15 119.66 25.78 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 127.32 2.248 . . . . 10.0 109.044 174.14 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 93.9 t -105.12 133.76 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 C-N-CA 124.636 1.174 . . . . 10.0 107.848 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 84.5 p -158.91 72.29 0.56 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 123.564 0.746 . . . . 10.0 111.015 169.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -104.6 153.47 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -117.91 81.74 1.72 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 128.43 2.692 . . . . 10.0 108.103 -176.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -75.84 113.74 13.66 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.768 -1.938 . . . . 10.0 105.768 -176.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 15.1 m -108.48 35.58 3.13 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.819 -1.082 . . . . 10.0 109.963 -174.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.5 p -126.02 -43.07 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-O 118.538 -0.744 . . . . 10.0 110.622 171.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.361 0.0 OUTLIER -91.83 176.11 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 N-CA-C 113.707 1.002 . . . . 10.0 113.707 178.422 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 34.0 m -152.69 145.9 24.7 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 121.615 -0.678 . . . . 10.0 109.972 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -66.23 -18.14 65.17 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 124.159 0.984 . . . . 10.0 112.464 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.9 t -154.89 137.88 15.5 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.15 -61.91 0.19 Allowed Glycine 0 C--N 1.334 0.422 0 N-CA-C 110.739 -0.945 . . . . 10.0 110.739 179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -154.72 -51.9 0.09 Allowed 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 126.795 2.038 . . . . 10.0 106.662 -178.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -75.15 -42.33 56.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.311 -1.313 . . . . 10.0 108.568 -174.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 65.42 -59.77 0.27 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 125.926 1.69 . . . . 10.0 109.89 -170.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.32 0.2 OUTLIER 78.68 -40.22 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 125.264 1.426 . . . . 10.0 112.075 168.817 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.9 mm -24.23 127.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 128.086 2.554 . . . . 10.0 111.342 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 90.2 28.6 17.06 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-O 119.054 -0.859 . . . . 10.0 112.588 -170.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -81.03 176.31 9.93 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.705 -1.22 . . . . 10.0 107.705 166.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -128.66 123.3 32.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.554 -2.017 . . . . 10.0 105.554 167.044 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 mp -96.0 149.75 21.23 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.251 -1.389 . . . . 10.0 107.251 169.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 84.3 t -132.01 133.74 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.703 -1.591 . . . . 10.0 106.703 -174.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -104.34 122.95 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 N-CA-C 107.078 -1.453 . . . . 10.0 107.078 171.155 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -105.43 157.44 17.35 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 115.893 1.812 . . . . 10.0 115.893 -171.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.1 tt0 -43.26 -57.5 2.96 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 128.279 2.632 . . . . 10.0 111.009 173.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -111.42 162.49 15.02 Favored 'General case' 0 CA--C 1.515 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.664 -170.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.13 140.41 58.79 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.888 1.275 . . . . 10.0 107.586 174.012 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.557 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 69.2 m-20 -77.34 132.79 38.76 Favored 'General case' 0 N--CA 1.441 -0.919 0 N-CA-C 108.579 -0.897 . . . . 10.0 108.579 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -81.56 -4.22 55.42 Favored 'General case' 0 N--CA 1.448 -0.574 0 O-C-N 123.483 0.489 . . . . 10.0 110.81 174.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 37.6 mt 53.59 41.11 32.15 Favored 'General case' 0 N--CA 1.463 0.188 0 O-C-N 120.455 -1.403 . . . . 10.0 110.629 172.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.99 -29.87 9.35 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-O 119.072 -0.849 . . . . 10.0 113.089 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.59 10.1 3.49 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 120.054 1.927 . . . . 10.0 113.617 -169.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.41 -16.91 69.96 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.009 0.814 . . . . 10.0 112.003 173.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.88 31.55 76.48 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.52 0.581 . . . . 10.0 112.505 174.004 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -142.37 176.01 9.33 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 108.165 -1.05 . . . . 10.0 108.165 171.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -59.01 -45.93 89.46 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 116.219 -0.446 . . . . 10.0 110.637 -175.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -67.05 -26.01 66.54 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 120.937 -1.102 . . . . 10.0 110.324 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -52.09 -48.38 64.76 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 119.546 1.066 . . . . 10.0 110.301 168.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -86.8 -15.26 39.81 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 124.073 0.858 . . . . 10.0 111.851 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.8 ttmm -89.82 -48.56 7.17 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 125.416 1.486 . . . . 10.0 111.666 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.421 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 8.9 p -133.88 -14.49 2.41 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 114.98 1.474 . . . . 10.0 114.98 176.154 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.37 30.93 8.73 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 119.668 1.122 . . . . 10.0 112.797 -171.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 32.8 m120 50.82 34.74 10.73 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 119.21 1.505 . . . . 10.0 111.918 -177.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.94 -11.71 61.08 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.764 1.226 . . . . 10.0 111.982 -173.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.91 -158.43 53.06 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 109.633 -1.387 . . . . 10.0 109.633 174.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 128.11 35.42 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.61 0.719 . . . . 10.0 110.643 -169.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.01 73.02 0.07 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 123.997 0.919 . . . . 10.0 109.663 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 79.2 mt -45.8 -41.83 11.46 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 124.726 1.211 . . . . 10.0 112.78 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.56 154.17 22.31 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 -171.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.01 164.53 38.33 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.834 -0.621 . . . . 10.0 109.907 -175.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.32 -176.09 14.34 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 -179.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.4 t -131.95 141.67 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 173.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 8.2 mt -70.78 115.52 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.441 0.564 . . . . 10.0 110.464 -177.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.71 136.72 13.7 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.696 1.141 . . . . 10.0 111.197 -178.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 83.1 mt -65.87 142.15 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 124.516 1.126 . . . . 10.0 109.993 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.03 -52.63 1.31 Allowed 'General case' 0 C--O 1.225 -0.204 0 C-N-CA 123.277 0.631 . . . . 10.0 110.957 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 13.3 tt0 . . . . . 0 C--O 1.25 1.114 0 CA-C-O 116.356 -1.783 . . . . 10.0 112.937 -172.489 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.757 0 N-CA-C 108.266 -1.013 . . . . 10.0 108.266 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -166.84 -42.97 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.77 1.228 . . . . 10.0 110.039 175.382 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.9 mtpm? -114.13 148.73 36.72 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 171.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.33 163.25 38.8 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.396 1.479 . . . . 10.0 107.725 177.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -139.94 167.13 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 122.88 0.472 . . . . 10.0 110.718 -177.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.39 114.72 7.95 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 124.14 0.976 . . . . 10.0 108.393 167.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -94.1 118.74 40.75 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 123.832 0.853 . . . . 10.0 108.705 171.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt -104.9 140.89 37.47 Favored 'General case' 0 C--O 1.224 -0.237 0 CA-C-O 118.089 -0.957 . . . . 10.0 109.308 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt -148.42 162.13 40.2 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-N 120.312 1.415 . . . . 10.0 107.866 168.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.29 -72.44 0.02 OUTLIER Glycine 0 C--O 1.228 -0.237 0 CA-C-N 115.117 -0.947 . . . . 10.0 112.295 169.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.73 -41.48 62.48 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 106.972 -1.492 . . . . 10.0 106.972 -170.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.64 -61.39 0.56 Allowed Glycine 0 N--CA 1.441 -0.99 0 CA-C-N 113.697 -1.592 . . . . 10.0 112.401 175.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -55.3 -43.18 61.21 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 CA-C-N 119.12 1.46 . . . . 10.0 110.68 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -64.63 117.51 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.985 0 N-CA-C 108.486 -0.931 . . . . 10.0 108.486 177.219 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.16 109.52 12.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.731 -2.322 . . . . 10.0 104.731 168.437 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.39 143.29 17.82 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 109.181 -1.568 . . . . 10.0 109.181 175.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.434 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 2.9 mt -143.11 86.87 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 -178.31 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -97.95 145.46 9.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 C-N-CA 123.874 0.87 . . . . 10.0 109.599 177.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -126.13 143.38 51.15 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 125.321 1.448 . . . . 10.0 109.271 170.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -125.57 106.17 9.56 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 107.457 -1.312 . . . . 10.0 107.457 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -103.54 111.57 24.09 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 114.074 1.139 . . . . 10.0 114.074 176.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -78.75 95.06 5.23 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.297 -2.112 . . . . 10.0 105.297 165.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -56.14 -53.7 53.9 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 126.285 1.834 . . . . 10.0 109.741 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.78 -156.88 0.71 Allowed 'General case' 0 N--CA 1.434 -1.236 0 N-CA-C 104.111 -2.551 . . . . 10.0 104.111 168.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.36 -27.48 25.83 Favored 'General case' 0 N--CA 1.443 -0.789 0 O-C-N 122.131 -0.356 . . . . 10.0 110.06 169.141 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -108.23 -6.33 16.41 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.953 1.301 . . . . 10.0 111.314 -171.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.57 149.29 49.52 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.597 -1.001 . . . . 10.0 110.597 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -62.98 125.31 15.62 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 N-CA-C 107.392 -1.811 . . . . 10.0 107.392 169.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.8 t -79.34 103.15 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 106.647 -1.612 . . . . 10.0 106.647 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -67.97 112.49 5.0 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 105.858 -1.905 . . . . 10.0 105.858 167.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -95.62 104.99 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 105.61 -1.996 . . . . 10.0 105.61 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 19.9 p90 -112.48 164.18 13.59 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.238 0.542 . . . . 10.0 109.671 177.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -177.44 157.51 22.21 Favored Glycine 0 N--CA 1.434 -1.464 0 C-N-CA 119.946 -1.121 . . . . 10.0 110.506 176.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.6 p -128.54 86.37 2.44 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 106.853 -1.536 . . . . 10.0 106.853 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.2 pt -76.99 154.21 5.58 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 C-N-CA 117.736 -1.585 . . . . 10.0 107.271 168.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.1 ptmm? -145.79 119.77 9.38 Favored 'General case' 0 N--CA 1.446 -0.638 0 O-C-N 124.192 0.932 . . . . 10.0 109.242 172.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.28 8.43 4.98 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-O 118.802 -0.999 . . . . 10.0 114.442 166.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.403 ' CD1' ' N ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -83.07 179.0 7.87 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 107.201 -1.407 . . . . 10.0 107.201 168.795 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -77.9 167.06 22.1 Favored 'General case' 0 N--CA 1.453 -0.317 0 O-C-N 121.04 -1.038 . . . . 10.0 109.174 169.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -65.67 179.09 0.88 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.813 0.845 . . . . 10.0 112.051 -175.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.9 -171.01 44.32 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.211 -0.756 . . . . 10.0 111.211 169.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -76.24 140.46 41.61 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.184 1.394 . . . . 10.0 110.736 -177.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -140.92 139.64 34.36 Favored 'General case' 0 C--N 1.341 0.228 0 N-CA-C 113.907 1.076 . . . . 10.0 113.907 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -37.4 117.13 0.46 Allowed Glycine 0 C--N 1.341 0.852 0 C-N-CA 128.646 3.022 . . . . 10.0 111.945 166.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -135.65 109.18 7.93 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 120.005 1.903 . . . . 10.0 110.324 170.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.426 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -151.12 170.07 20.32 Favored 'General case' 0 CA--C 1.513 -0.462 0 C-N-CA 123.413 0.685 . . . . 10.0 110.372 176.679 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 34.2 m -105.39 -27.11 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 C-N-CA 127.048 2.139 . . . . 10.0 113.171 -169.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 24.9 m-70 61.09 165.18 0.08 Allowed 'General case' 0 C--N 1.342 0.244 0 C-N-CA 124.436 1.095 . . . . 10.0 112.92 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -75.99 -56.53 4.58 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 121.726 -0.609 . . . . 10.0 111.121 171.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -75.98 111.26 11.18 Favored 'General case' 0 C--N 1.341 0.216 0 C-N-CA 119.888 -0.725 . . . . 10.0 110.881 -169.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.3 -39.32 95.92 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 108.852 -1.699 . . . . 10.0 108.852 166.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -34.65 122.82 0.53 Allowed 'General case' 0 C--N 1.341 0.223 0 C-N-CA 125.638 1.575 . . . . 10.0 112.219 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -129.06 18.13 6.07 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 124.529 1.132 . . . . 10.0 111.354 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.467 HG22 ' CG2' ' B' ' 17' ' ' ILE . 2.8 m -54.21 -36.75 63.82 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 119.49 1.041 . . . . 10.0 111.036 -175.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.01 -22.04 53.69 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.386 0.674 . . . . 10.0 112.106 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.61 -163.15 18.61 Favored Glycine 0 N--CA 1.443 -0.891 0 N-CA-C 107.328 -2.309 . . . . 10.0 107.328 -169.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 90.5 m -74.69 49.56 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.202 1.401 . . . . 10.0 111.052 176.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -137.58 -45.83 0.55 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 126.493 1.917 . . . . 10.0 109.574 -177.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -47.99 -31.44 5.32 Favored 'General case' 0 C--N 1.341 0.239 0 C-N-CA 123.146 0.578 . . . . 10.0 111.219 171.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.89 -42.01 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 128.132 2.573 . . . . 10.0 114.639 169.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.43 150.33 26.76 Favored Glycine 0 C--N 1.339 0.7 0 N-CA-C 110.64 -0.984 . . . . 10.0 110.64 168.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -80.54 54.43 5.22 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.192 1.928 . . . . 10.0 111.079 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.426 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 19.6 m170 65.6 -65.93 0.16 Allowed 'General case' 0 C--O 1.226 -0.183 0 C-N-CA 128.502 2.721 . . . . 10.0 111.468 -177.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.265 10.7 p90 36.08 23.4 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 130.594 3.558 . . . . 10.0 118.944 174.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -49.72 158.13 0.9 Allowed Pre-proline 0 CA--C 1.541 0.628 0 C-N-CA 125.98 1.712 . . . . 10.0 114.634 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -57.07 -45.01 38.77 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.583 2.855 . . . . 10.0 112.473 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 78.1 mt -75.1 58.21 0.88 Allowed 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.887 -0.782 . . . . 10.0 108.887 172.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -66.3 72.7 0.08 Allowed 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 128.748 2.819 . . . . 10.0 108.798 -176.697 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 mtt180 -92.16 -91.37 0.16 Allowed 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 105.231 -2.137 . . . . 10.0 105.231 -173.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.1 mttp -149.83 144.48 26.01 Favored 'General case' 0 N--CA 1.425 -1.7 0 N-CA-C 104.21 -2.515 . . . . 10.0 104.21 164.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -52.64 117.59 3.01 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 118.871 -1.131 . . . . 10.0 109.672 167.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.4 -154.72 7.9 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 107.037 -2.425 . . . . 10.0 107.037 175.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.43 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -162.92 -160.87 11.6 Favored Glycine 0 C--O 1.225 -0.413 0 N-CA-C 108.755 -1.738 . . . . 10.0 108.755 174.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -65.51 10.08 0.17 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 CA-C-N 120.864 2.332 . . . . 10.0 111.318 169.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.43 ' H ' ' C ' ' A' ' 73' ' ' GLY . 26.1 mmtp -107.36 -13.6 15.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 119.204 0.911 . . . . 10.0 109.065 175.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -140.82 140.5 34.69 Favored 'General case' 0 C--N 1.348 0.526 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 -169.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -76.13 -20.08 57.93 Favored 'General case' 0 C--N 1.332 -0.167 0 O-C-N 121.106 -0.996 . . . . 10.0 108.819 -169.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -77.18 -5.91 50.95 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 124.412 1.085 . . . . 10.0 111.962 -173.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -35.54 133.92 0.35 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.038 1.335 . . . . 10.0 112.862 -179.163 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -61.5 -79.7 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.246 0.545 . . . . 10.0 110.028 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -130.45 -91.42 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -108.93 52.39 0.65 Allowed Glycine 0 CA--C 1.521 0.421 0 N-CA-C 109.899 -1.28 . . . . 10.0 109.899 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.3 m-20 -72.37 93.64 1.54 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 105.759 -1.941 . . . . 10.0 105.759 168.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 26.6 mt -75.32 -29.42 60.01 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.73 -104.29 2.82 Favored Glycine 0 N--CA 1.439 -1.105 0 N-CA-C 110.559 -1.016 . . . . 10.0 110.559 168.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -125.67 101.02 6.69 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 125.713 1.605 . . . . 10.0 110.54 -167.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 5.0 m -110.04 140.19 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.616 0.766 . . . . 10.0 111.334 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.32 129.73 34.74 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 128.079 2.552 . . . . 10.0 112.416 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -110.16 134.48 52.16 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.342 1.457 . . . . 10.0 109.591 169.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -59.46 169.13 1.33 Allowed 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.015 1.326 . . . . 10.0 111.133 169.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 7.0 ptmt -47.52 -33.19 6.06 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.751 2.02 . . . . 10.0 111.348 172.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.69 -14.05 59.04 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 122.64 0.376 . . . . 10.0 111.13 -176.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.03 17.42 51.29 Favored Glycine 0 C--N 1.341 0.839 0 N-CA-C 110.44 -1.064 . . . . 10.0 110.44 -175.215 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.94 109.57 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 C-N-CA 126.645 1.978 . . . . 10.0 106.962 -179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.34 118.28 36.16 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.071 -0.715 . . . . 10.0 109.071 169.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -85.01 84.38 7.74 Favored 'General case' 0 N--CA 1.437 -1.119 0 C-N-CA 127.416 2.286 . . . . 10.0 109.327 174.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -75.86 129.57 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.307 0 N-CA-C 105.136 -2.172 . . . . 10.0 105.136 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -156.93 59.72 0.52 Allowed 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 122.869 0.467 . . . . 10.0 109.948 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.51 164.02 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -176.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -134.31 135.41 42.78 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.558 0.743 . . . . 10.0 111.215 169.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -131.1 131.11 43.94 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.973 1.309 . . . . 10.0 108.554 -175.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.5 p -98.31 24.2 7.52 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.851 0.86 . . . . 10.0 110.107 169.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.3 p -149.27 20.41 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.032 0.933 . . . . 10.0 110.722 -172.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -122.28 134.52 65.27 Favored 'Isoleucine or valine' 0 C--N 1.34 0.158 0 N-CA-C 102.591 -3.115 . . . . 10.0 102.591 169.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.5 m -146.73 125.77 12.85 Favored 'General case' 0 CA--C 1.527 0.074 0 CA-C-N 118.451 0.569 . . . . 10.0 109.699 -176.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.9 mp -54.53 -48.42 71.98 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.699 1.199 . . . . 10.0 110.52 177.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -137.02 176.35 8.79 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.549 1.54 . . . . 10.0 106.925 169.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.66 -97.25 0.4 Allowed Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 108.15 -1.98 . . . . 10.0 108.15 -176.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -121.96 -50.98 2.03 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 125.758 1.623 . . . . 10.0 108.461 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -73.5 -42.76 61.42 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.249 -1.389 . . . . 10.0 107.249 -171.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.4 t 47.19 54.88 8.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 126.004 1.722 . . . . 10.0 111.94 169.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.1 pt -60.01 -3.9 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 127.746 2.418 . . . . 10.0 115.222 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.3 mp -52.13 144.16 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 O-C-N 121.26 -0.9 . . . . 10.0 111.258 169.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.82 7.52 87.9 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.163 -0.798 . . . . 10.0 113.064 173.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -85.62 172.72 10.69 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.817 0.809 . . . . 10.0 109.123 170.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -122.43 104.64 9.53 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.908 0.883 . . . . 10.0 110.56 -175.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -62.42 130.14 43.88 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 108.261 -1.014 . . . . 10.0 108.261 172.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 51.2 t -119.64 132.65 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 169.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -100.99 121.86 52.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.245 -1.761 . . . . 10.0 106.245 169.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -106.32 164.16 12.25 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.364 1.246 . . . . 10.0 114.364 -173.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -45.13 -57.43 3.91 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 129.354 3.061 . . . . 10.0 111.476 174.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 61.2 mttt -126.17 175.32 7.86 Favored 'General case' 0 CA--C 1.522 -0.116 0 C-N-CA 124.552 1.141 . . . . 10.0 112.581 -169.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.89 152.57 41.4 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.051 1.341 . . . . 10.0 110.878 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -82.77 145.47 29.52 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 116.031 -0.531 . . . . 10.0 111.183 169.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -81.41 -16.07 53.24 Favored 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 125.025 1.453 . . . . 10.0 110.257 166.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 84.4 mt 57.37 64.14 1.68 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 122.721 1.248 . . . . 10.0 109.447 176.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.64 -41.41 3.07 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 114.714 -1.13 . . . . 10.0 110.937 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 29.1 mtmm -78.75 36.09 0.26 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.488 1.515 . . . . 10.0 112.341 -174.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.23 -7.27 52.45 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 127.252 2.358 . . . . 10.0 110.892 170.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 42.38 49.53 5.65 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.98 1.752 . . . . 10.0 114.009 177.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -153.29 172.56 16.83 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 169.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.0 mp0 -44.77 -50.64 10.02 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 123.021 0.528 . . . . 10.0 111.104 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.63 -28.36 66.83 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 118.694 -0.67 . . . . 10.0 111.035 -177.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.8 p -54.95 -37.6 66.66 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 119.902 1.228 . . . . 10.0 112.255 175.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -85.98 -0.26 55.03 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 123.348 0.405 . . . . 10.0 111.73 -178.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.1 mttt -111.71 -66.46 1.08 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.834 1.254 . . . . 10.0 111.125 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -128.99 23.07 5.69 Favored 'General case' 0 CA--C 1.543 0.698 0 CA-C-N 119.434 1.015 . . . . 10.0 112.042 -175.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.6 -87.26 0.35 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -172.34 37.93 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 125.164 1.386 . . . . 10.0 109.073 169.055 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.09 -13.92 62.58 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -168.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.23 54.81 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.275 -1.13 . . . . 10.0 110.275 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -56.08 128.75 36.95 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 123.976 0.91 . . . . 10.0 112.038 -168.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.9 mtm105 -66.68 74.79 0.1 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 124.956 1.302 . . . . 10.0 110.44 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 71.0 mt -46.88 -49.78 19.75 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.447 0.699 . . . . 10.0 111.881 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.65 155.63 38.75 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -169.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.17 165.07 37.47 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 122.564 0.346 . . . . 10.0 111.436 -175.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.78 170.16 38.23 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 125.339 1.447 . . . . 10.0 109.931 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 7.7 t -116.96 142.99 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 118.16 0.98 . . . . 10.0 108.693 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 41.2 mt -83.06 119.63 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.717 0 C-N-CA 123.728 0.811 . . . . 10.0 109.303 -176.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.17 159.75 24.13 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.775 -0.53 . . . . 10.0 111.775 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 55.6 mt -74.4 150.9 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 125.086 1.354 . . . . 10.0 110.415 -169.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.95 -106.59 0.38 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 167.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.922 1 C-N-CA 132.302 4.241 . . . . 10.0 102.72 -169.554 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.624 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.9 t -145.4 -51.81 0.26 Allowed 'General case' 0 CA--C 1.514 -0.418 0 C-N-CA 125.194 1.398 . . . . 10.0 108.482 176.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -110.24 145.81 36.71 Favored 'General case' 0 N--CA 1.44 -0.941 0 C-N-CA 126.567 1.947 . . . . 10.0 106.159 -172.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.57 149.6 30.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 172.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.5 m -129.69 161.31 39.51 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 O-C-N 123.718 0.636 . . . . 10.0 110.388 -176.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.16 105.11 4.03 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.418 -0.956 . . . . 10.0 108.418 170.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.02 91.85 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 170.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -77.36 143.59 38.61 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 108.309 -0.997 . . . . 10.0 108.309 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.14 165.14 32.23 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 107.959 -1.126 . . . . 10.0 107.959 173.027 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -168.67 -58.5 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 115.583 -0.735 . . . . 10.0 111.665 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.52 -45.23 47.17 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 -173.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.04 -68.28 0.52 Allowed Glycine 0 N--CA 1.445 -0.754 0 CA-C-N 113.75 -1.568 . . . . 10.0 110.288 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -57.84 -37.49 96.16 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.852 2.368 . . . . 10.0 111.068 174.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.26 102.76 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 N-CA-C 107.083 -1.451 . . . . 10.0 107.083 175.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -118.97 117.99 30.29 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -99.17 132.05 10.78 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 172.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.467 ' CG2' HG22 ' A' ' 54' ' ' THR . 6.5 mt -135.15 88.62 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 N-CA-C 107.01 -1.478 . . . . 10.0 107.01 -174.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -103.05 140.92 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 125.258 1.423 . . . . 10.0 109.659 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -124.87 112.47 16.68 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.047 1.739 . . . . 10.0 108.109 169.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -93.03 119.24 32.07 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.489 -1.301 . . . . 10.0 107.489 171.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -111.26 143.24 42.36 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 118.926 0.785 . . . . 10.0 111.447 168.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -92.6 118.14 30.7 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 103.909 -2.626 . . . . 10.0 103.909 166.359 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 79.3 mttt -55.1 -49.79 70.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.742 0.782 . . . . 10.0 109.412 171.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -130.21 -144.81 0.27 Allowed 'General case' 0 N--CA 1.432 -1.334 0 N-CA-C 105.454 -2.054 . . . . 10.0 105.454 -170.053 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.6 t -110.61 -12.55 14.33 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.275 0.56 . . . . 10.0 110.307 167.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -127.68 2.17 6.12 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.632 1.173 . . . . 10.0 110.999 -175.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.19 163.04 51.81 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 108.932 -1.667 . . . . 10.0 108.932 179.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -65.48 135.73 43.71 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.637 1.558 . . . . 10.0 108.446 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -78.23 107.22 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -77.11 108.91 10.53 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 106.284 -1.747 . . . . 10.0 106.284 170.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -85.85 105.99 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 25.3 p90 -113.99 163.81 14.64 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.444 0.64 . . . . 10.0 110.969 170.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 177.63 170.12 39.51 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.224 -0.75 . . . . 10.0 111.224 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.1 p -140.03 100.55 3.95 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.997 -1.483 . . . . 10.0 106.997 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 6.6 pt -78.12 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 C-N-CA 118.64 -1.224 . . . . 10.0 109.247 170.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -152.91 155.01 36.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 168.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.4 34.1 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 119.033 -0.87 . . . . 10.0 115.011 169.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.5 mp -72.45 177.79 4.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 118.934 1.367 . . . . 10.0 110.649 -177.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.25 161.56 15.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.295 -1.002 . . . . 10.0 108.295 168.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -55.74 163.34 1.42 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.227 1.011 . . . . 10.0 112.249 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.98 -175.37 33.66 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-O 121.863 0.702 . . . . 10.0 112.501 168.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -68.2 143.91 55.15 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.409 1.484 . . . . 10.0 109.999 -178.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -142.05 147.78 37.39 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 113.394 0.887 . . . . 10.0 113.394 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.38 125.5 0.27 Allowed Glycine 0 C--N 1.341 0.823 0 C-N-CA 127.738 2.59 . . . . 10.0 111.878 165.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -151.69 108.64 3.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 119.104 1.452 . . . . 10.0 110.473 166.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.503 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -147.66 172.29 14.29 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 122.407 1.099 . . . . 10.0 113.046 179.043 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.96 134.75 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.671 0 CA-C-N 111.191 -2.731 . . . . 10.0 106.418 169.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 47.1 m-70 -116.77 141.44 48.2 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 106.214 -1.773 . . . . 10.0 106.214 171.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -54.68 -52.23 63.03 Favored 'General case' 0 N--CA 1.451 -0.399 0 O-C-N 124.144 0.903 . . . . 10.0 111.915 -168.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -76.92 137.78 39.3 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 -175.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.62 12.51 51.78 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 124.381 0.991 . . . . 10.0 111.649 167.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -79.69 174.76 11.26 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-O 121.864 0.84 . . . . 10.0 110.123 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -165.3 30.56 0.06 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.552 -1.204 . . . . 10.0 112.641 168.625 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.434 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.41 -35.24 79.75 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 119.696 1.134 . . . . 10.0 112.423 -168.923 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.46 -20.75 50.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 118.06 0.391 . . . . 10.0 111.737 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.73 -160.43 13.2 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 105.852 -2.899 . . . . 10.0 105.852 -167.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 59.9 m -70.21 65.75 0.27 Allowed 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 126.321 1.848 . . . . 10.0 111.547 -175.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -153.38 -52.53 0.1 Allowed 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 124.446 1.098 . . . . 10.0 108.727 177.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 18.4 m -51.38 -34.94 36.52 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.205 1.002 . . . . 10.0 111.809 -177.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -26.8 -38.88 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.848 2.859 . . . . 10.0 114.47 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 110.39 139.69 8.3 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 110.285 -1.126 . . . . 10.0 110.285 169.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.27 55.54 4.65 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.61 3.54 . . . . 10.0 113.266 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 18.2 m170 62.88 48.58 3.94 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.418 2.287 . . . . 10.0 109.197 178.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -66.84 71.78 0.09 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.296 1.038 . . . . 10.0 111.68 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.0 p-10 -84.1 153.33 63.05 Favored Pre-proline 0 C--N 1.326 -0.45 0 O-C-N 121.212 -0.93 . . . . 10.0 111.84 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.66 -43.9 1.7 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.685 2.256 . . . . 10.0 111.447 176.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.0 mt -75.98 62.27 1.61 Allowed 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.711 0.805 . . . . 10.0 109.94 -178.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.2 p -40.28 99.87 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.423 1.889 . . . . 10.0 112.796 -173.087 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 14.2 mtp180 -140.26 177.71 7.8 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 126.058 1.743 . . . . 10.0 107.961 -175.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.5 mttt -110.66 82.47 1.6 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 112.218 0.451 . . . . 10.0 112.218 -168.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.439 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 69.1 t60 18.0 93.4 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 116.275 1.954 . . . . 10.0 116.275 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.07 -157.45 16.41 Favored Glycine 0 N--CA 1.441 -0.983 0 C-N-CA 125.223 1.392 . . . . 10.0 110.766 177.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.46 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -165.86 -159.21 11.56 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 106.351 -2.699 . . . . 10.0 106.351 169.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -63.88 6.45 0.28 Allowed 'Trans proline' 0 CA--C 1.543 0.967 0 CA-C-N 120.665 2.233 . . . . 10.0 111.546 168.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.46 ' H ' ' C ' ' B' ' 73' ' ' GLY . 11.7 mmmt -114.15 5.88 16.1 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 125.59 1.556 . . . . 10.0 110.064 176.108 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -141.32 169.13 18.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 119.729 1.15 . . . . 10.0 109.342 167.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.71 -27.05 29.27 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 166.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.87 33.51 0.33 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 124.621 1.168 . . . . 10.0 113.217 -171.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.02 138.76 11.3 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 167.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . 0.439 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 30.9 m80 -66.48 -62.45 1.46 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 118.16 -1.416 . . . . 10.0 108.611 169.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.4 p -164.45 -58.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 108.679 -0.86 . . . . 10.0 108.679 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.8 66.5 0.35 Allowed Glycine 0 C--N 1.334 0.471 0 N-CA-C 109.067 -1.613 . . . . 10.0 109.067 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -112.07 101.62 9.89 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.822 -1.918 . . . . 10.0 105.822 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 19.4 mt -72.65 -18.37 61.58 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.27 0.486 . . . . 10.0 112.195 -169.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 112.73 -95.44 0.78 Allowed Glycine 0 N--CA 1.443 -0.866 0 N-CA-C 106.781 -2.528 . . . . 10.0 106.781 -173.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -155.12 150.61 27.35 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.099 -1.075 . . . . 10.0 108.099 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.05 131.39 62.41 Favored 'Isoleucine or valine' 0 C--O 1.232 0.143 0 N-CA-C 107.332 -1.359 . . . . 10.0 107.332 168.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -95.22 119.12 33.18 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.006 0.522 . . . . 10.0 109.594 -176.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.96 133.54 38.61 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.707 1.203 . . . . 10.0 110.261 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -61.31 168.99 2.38 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.572 1.149 . . . . 10.0 109.215 166.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.18 -29.41 45.66 Favored 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 123.357 0.663 . . . . 10.0 111.385 172.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -77.63 -5.04 48.98 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 121.204 0.526 . . . . 10.0 111.423 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.0 3.17 88.0 Favored Glycine 0 C--N 1.338 0.694 0 O-C-N 120.785 -1.197 . . . . 10.0 111.067 -176.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.47 106.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.16 -1.422 . . . . 10.0 107.16 179.251 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.46 126.01 50.36 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 109.18 -0.674 . . . . 10.0 109.18 170.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -79.43 126.33 30.7 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 168.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 54.1 t -107.23 131.16 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 168.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.1 p -157.92 56.2 0.48 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 118.316 0.507 . . . . 10.0 111.152 176.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.93 152.05 4.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 C-N-CA 124.301 1.04 . . . . 10.0 109.055 -171.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -102.86 106.8 17.44 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 125.766 1.626 . . . . 10.0 108.865 174.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -80.11 77.58 6.81 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.103 -1.443 . . . . 10.0 107.103 175.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.1 m -80.61 50.03 1.26 Allowed 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -155.38 -48.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 C-N-CA 122.606 0.362 . . . . 10.0 110.994 -168.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.343 1.1 pp -104.22 177.09 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 C-N-CA 123.6 0.76 . . . . 10.0 112.24 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -138.12 138.92 39.15 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.848 -1.167 . . . . 10.0 107.848 171.209 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.88 -24.68 26.56 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.99 117.33 9.04 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 104.149 -2.538 . . . . 10.0 104.149 168.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.27 -67.91 0.09 OUTLIER Glycine 0 C--N 1.332 0.322 0 N-CA-C 108.257 -1.937 . . . . 10.0 108.257 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -156.99 -51.1 0.07 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 113.578 -1.311 . . . . 10.0 108.536 176.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -76.25 -23.14 54.48 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.206 -0.906 . . . . 10.0 110.312 -169.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 32.2 t 28.73 79.14 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 128.65 2.78 . . . . 10.0 111.306 178.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 8.1 pt -69.83 49.69 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 C-N-CA 125.783 1.633 . . . . 10.0 111.848 176.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -97.95 151.4 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 C-N-CA 126.5 1.92 . . . . 10.0 107.052 171.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 59.52 32.27 72.78 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.319 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 mmt-85 -105.34 170.44 7.88 Favored 'General case' 0 CA--C 1.536 0.424 0 N-CA-C 106.612 -1.625 . . . . 10.0 106.612 168.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.6 m -112.95 129.38 56.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 177.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 64.6 mt -102.07 141.57 34.71 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 107.806 -1.183 . . . . 10.0 107.806 173.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 67.8 t -129.39 133.32 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.084 -1.45 . . . . 10.0 107.084 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -106.51 134.09 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 105.963 -1.866 . . . . 10.0 105.963 169.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 6.1 m170 -112.13 157.6 20.64 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 123.589 1.661 . . . . 10.0 114.63 -170.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 52.1 tt0 -45.79 -53.24 9.9 Favored 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 128.102 2.561 . . . . 10.0 110.041 179.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -119.58 175.56 5.79 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 125.084 1.354 . . . . 10.0 111.234 -172.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.91 149.68 37.69 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 124.667 1.187 . . . . 10.0 110.48 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.503 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.3 m-20 -77.13 135.62 38.57 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 123.325 0.65 . . . . 10.0 110.238 170.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.3 m-20 -77.13 -21.29 54.41 Favored 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 124.891 1.369 . . . . 10.0 109.72 168.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 76.9 mt 60.71 58.5 2.39 Favored 'General case' 0 C--N 1.342 0.253 0 CA-C-O 123.279 1.514 . . . . 10.0 109.387 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.36 -43.23 3.11 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 112.737 -2.029 . . . . 10.0 110.158 169.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 17.9 mtmm -78.24 44.28 0.49 Allowed 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.625 1.57 . . . . 10.0 111.821 -175.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.21 -33.82 7.47 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.574 2.035 . . . . 10.0 110.12 172.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.17 33.69 48.74 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 123.473 0.559 . . . . 10.0 112.278 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -145.11 165.5 28.08 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 105.905 -1.887 . . . . 10.0 105.905 174.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -55.08 -48.42 73.56 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-O 121.246 0.546 . . . . 10.0 110.068 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -59.86 -30.35 68.92 Favored 'General case' 0 N--CA 1.453 -0.312 0 O-C-N 121.69 -0.631 . . . . 10.0 111.726 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -51.84 -51.91 53.2 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 121.358 -0.838 . . . . 10.0 110.174 169.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.9 t -82.19 -10.74 59.05 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.841 -0.618 . . . . 10.0 112.105 -173.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.4 ttmm -100.17 -52.73 3.32 Favored 'General case' 0 N--CA 1.436 -1.143 0 C-N-CA 125.417 1.487 . . . . 10.0 111.506 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.0 p -140.05 31.18 1.99 Allowed 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.65 0.78 . . . . 10.0 112.2 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.23 19.65 64.28 Favored Glycine 0 C--N 1.339 0.706 0 CA-C-N 119.246 0.93 . . . . 10.0 112.29 174.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 53.62 26.14 5.52 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 117.915 0.858 . . . . 10.0 112.325 -173.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.37 0.78 3.53 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.698 -0.626 . . . . 10.0 112.455 -178.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.75 -165.18 47.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 109.918 -1.273 . . . . 10.0 109.918 168.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -54.19 134.11 44.5 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.61 0.719 . . . . 10.0 110.084 -172.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.04 67.59 0.07 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 169.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -61.71 -25.18 67.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.815 0.672 . . . . 10.0 112.815 -168.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -154.33 148.68 26.08 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.133 0.492 . . . . 10.0 109.793 177.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 21.2 p -158.13 168.78 26.13 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.947 0.499 . . . . 10.0 109.958 -175.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -165.53 167.51 39.02 Favored Glycine 0 CA--C 1.528 0.844 0 N-CA-C 110.704 -0.959 . . . . 10.0 110.704 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 74.0 t -109.64 142.85 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.38 0 C-N-CA 125.48 1.512 . . . . 10.0 107.139 -169.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 67.7 mt -80.35 112.88 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 C-N-CA 122.492 0.317 . . . . 10.0 110.793 -172.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.05 145.39 17.66 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 124.691 1.138 . . . . 10.0 110.745 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 44.9 mt -62.89 148.52 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 124.473 1.109 . . . . 10.0 109.661 174.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.34 170.13 17.43 Favored 'General case' 0 N--CA 1.439 -0.983 0 CA-C-O 122.619 1.2 . . . . 10.0 110.84 168.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 . . . . . 0 C--O 1.25 1.082 0 C-N-CA 129.585 3.154 . . . . 10.0 103.097 165.132 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.803 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -156.35 -44.29 0.07 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 118.47 0.577 . . . . 10.0 110.955 172.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.5 ttpp -113.78 142.87 45.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 106.918 -1.512 . . . . 10.0 106.918 167.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.74 171.06 14.77 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.477 -1.305 . . . . 10.0 107.477 171.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -140.42 166.59 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 123.897 0.879 . . . . 10.0 110.235 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.68 112.37 5.36 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 168.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.4 m -97.59 114.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 173.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -103.51 137.2 41.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 -174.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -146.33 165.39 29.44 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.924 1.238 . . . . 10.0 107.998 170.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.71 -58.81 0.04 OUTLIER Glycine 0 C--O 1.23 -0.096 0 CA-C-N 115.024 -0.989 . . . . 10.0 112.791 169.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.41 -44.91 49.82 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -171.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.48 -65.7 0.57 Allowed Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 113.601 -1.636 . . . . 10.0 110.659 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -59.0 -37.1 95.24 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.737 2.291 . . . . 10.0 111.315 174.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -67.33 106.58 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.007 0 N-CA-C 107.017 -1.475 . . . . 10.0 107.017 175.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -121.78 106.81 11.63 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.03 -1.841 . . . . 10.0 106.03 170.007 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.43 143.39 17.26 Favored Glycine 0 N--CA 1.434 -1.491 0 N-CA-C 109.66 -1.376 . . . . 10.0 109.66 173.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.1 mt -150.22 84.56 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.207 -1.405 . . . . 10.0 107.207 -169.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -96.19 145.43 8.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 C-N-CA 125.273 1.429 . . . . 10.0 110.963 175.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -128.95 117.49 21.05 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.942 2.097 . . . . 10.0 109.126 169.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -95.52 125.45 40.13 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.72 1.208 . . . . 10.0 108.862 178.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.53 132.99 53.62 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 125.121 1.368 . . . . 10.0 111.456 175.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -132.64 79.71 1.86 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 127.971 2.508 . . . . 10.0 106.045 168.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -56.12 -45.63 79.47 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 127.873 2.469 . . . . 10.0 110.658 -172.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -122.75 161.71 23.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 102.305 -3.22 . . . . 10.0 102.305 167.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -58.51 -30.27 66.92 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.473 -0.785 . . . . 10.0 109.073 174.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 m-80 -90.26 -9.13 49.1 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 124.892 1.277 . . . . 10.0 111.037 -174.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.29 138.8 27.01 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -59.82 135.46 63.68 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 N-CA-C 106.044 -2.329 . . . . 10.0 106.044 168.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 t -78.73 129.06 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.016 -1.476 . . . . 10.0 107.016 -170.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt -101.01 118.15 36.44 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -103.03 96.74 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 172.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -103.4 167.14 10.0 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 121.932 0.872 . . . . 10.0 110.613 168.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.03 -177.74 47.61 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.616 -0.802 . . . . 10.0 111.211 175.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.8 m -154.5 91.77 1.43 Allowed 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 -175.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.5 pt -78.96 151.68 4.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 CA-C-O 118.327 -0.844 . . . . 10.0 108.775 169.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.408 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -135.6 156.4 48.92 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 165.614 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.33 -10.13 39.21 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 123.836 0.731 . . . . 10.0 112.887 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -68.68 176.26 3.08 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 118.172 0.986 . . . . 10.0 109.641 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.1 t -105.32 150.41 25.21 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.451 -1.314 . . . . 10.0 107.451 167.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -50.86 146.11 6.34 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.115 0.966 . . . . 10.0 112.276 -169.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.3 -179.26 29.51 Favored Glycine 0 CA--C 1.528 0.85 0 C-N-CA 124.279 0.942 . . . . 10.0 112.128 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mt -57.85 148.72 24.5 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.133 2.173 . . . . 10.0 112.87 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -150.88 147.92 27.81 Favored 'General case' 0 CA--C 1.518 -0.254 0 C-N-CA 125.78 1.632 . . . . 10.0 112.18 176.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -33.17 125.36 0.33 Allowed Glycine 0 C--N 1.338 0.68 0 C-N-CA 126.462 1.982 . . . . 10.0 112.2 164.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -153.13 107.52 3.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 119.158 1.479 . . . . 10.0 110.279 166.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -154.93 169.52 23.85 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.67 0.748 . . . . 10.0 112.021 -179.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.1 m -84.72 153.18 3.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 112.663 -2.062 . . . . 10.0 107.715 168.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.91 148.43 50.49 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 107.536 -1.283 . . . . 10.0 107.536 171.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -35.91 -60.94 0.51 Allowed 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 126.576 1.95 . . . . 10.0 113.736 -170.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -98.8 161.14 13.8 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-O 121.925 0.869 . . . . 10.0 111.368 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.34 -22.88 28.25 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 126.46 1.981 . . . . 10.0 109.866 168.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -44.41 136.93 3.9 Favored 'General case' 0 C--N 1.342 0.243 0 C-N-CA 123.669 0.788 . . . . 10.0 110.275 169.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -141.51 21.1 2.2 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 10.0 111.439 -178.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.6 p -52.06 -39.01 59.03 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 113.961 1.096 . . . . 10.0 113.961 -174.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.04 -11.29 59.92 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.244 0.618 . . . . 10.0 111.619 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 118.66 -64.02 0.42 Allowed Glycine 0 C--O 1.225 -0.425 0 C-N-CA 126.052 1.787 . . . . 10.0 109.253 179.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.5 t -155.19 55.23 0.64 Allowed 'General case' 0 C--O 1.234 0.277 0 CA-C-O 121.789 0.804 . . . . 10.0 109.732 172.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -134.62 -46.47 0.74 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.7 0.8 . . . . 10.0 109.229 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.1 m -51.75 -29.34 18.34 Favored 'General case' 0 C--N 1.344 0.367 0 C-N-CA 123.886 0.874 . . . . 10.0 111.235 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.89 -42.27 0.08 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.748 2.419 . . . . 10.0 112.878 167.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.28 165.93 39.08 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -79.39 -164.86 0.3 Allowed 'Trans proline' 0 N--CA 1.444 -1.409 0 N-CA-C 107.353 -1.826 . . . . 10.0 107.353 169.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -80.25 46.54 0.83 Allowed 'General case' 0 CA--C 1.542 0.657 0 O-C-N 120.69 -1.256 . . . . 10.0 110.634 -176.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -75.31 70.08 2.19 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 119.352 0.978 . . . . 10.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -71.15 149.19 94.42 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 169.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -58.77 -47.12 19.7 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.407 2.071 . . . . 10.0 111.147 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.32 60.82 2.06 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 108.731 -0.841 . . . . 10.0 108.731 174.155 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.5 t -61.19 112.46 2.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 108.664 -0.865 . . . . 10.0 108.664 -178.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 75.4 mtt180 -105.82 -98.66 0.34 Allowed 'General case' 0 CA--C 1.512 -0.491 0 N-CA-C 106.157 -1.794 . . . . 10.0 106.157 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.9 pttt -158.81 144.97 16.84 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 104.982 -2.229 . . . . 10.0 104.982 169.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -47.33 121.78 4.12 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.366 0.603 . . . . 10.0 111.526 174.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.13 -156.13 6.69 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 106.235 -2.746 . . . . 10.0 106.235 169.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.474 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -148.34 -168.84 14.73 Favored Glycine 0 C--O 1.225 -0.43 0 CA-C-N 118.477 1.139 . . . . 10.0 113.464 -178.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -69.73 16.27 0.22 Allowed 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 123.416 2.744 . . . . 10.0 112.303 175.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.474 ' H ' ' C ' ' A' ' 73' ' ' GLY . 0.5 OUTLIER -105.53 -29.24 10.3 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 126.4 1.88 . . . . 10.0 108.999 168.786 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -107.9 172.19 6.97 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -89.41 -26.76 20.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 122.065 0.936 . . . . 10.0 109.351 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -78.6 -11.18 59.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 125.965 1.706 . . . . 10.0 114.692 -167.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.444 HH21 ' CG ' ' A' ' 101' ' ' ASP . 0.0 OUTLIER -34.69 129.17 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.699 1.2 . . . . 10.0 112.186 176.915 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -65.59 169.76 5.84 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 107.81 -1.182 . . . . 10.0 107.81 175.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.2 p -63.55 15.04 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 N-CA-C 115.864 1.801 . . . . 10.0 115.864 -169.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.51 55.91 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.621 0 N-CA-C 108.997 -1.641 . . . . 10.0 108.997 170.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -97.37 102.5 14.28 Favored 'General case' 0 N--CA 1.457 -0.109 0 N-CA-C 106.746 -1.575 . . . . 10.0 106.746 168.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -83.03 9.7 9.66 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.956 0.344 . . . . 10.0 111.49 -177.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 84.55 -100.18 2.35 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 107.536 -2.226 . . . . 10.0 107.536 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -145.57 157.57 43.96 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 107.287 -1.375 . . . . 10.0 107.287 174.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.3 m -112.48 126.12 69.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 109.02 -0.733 . . . . 10.0 109.02 169.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 70.1 m -94.72 101.53 13.38 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 127.518 2.327 . . . . 10.0 109.254 -170.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.7 141.64 37.75 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 122.373 -0.204 . . . . 10.0 111.113 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -69.5 173.77 5.61 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.343 2.257 . . . . 10.0 109.267 167.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -23.91 67.56 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.028 0.381 . . . . 10.0 112.028 174.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.408 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 32.7 t70 -78.21 -1.47 32.99 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 120.993 0.425 . . . . 10.0 111.226 173.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.23 1.11 89.58 Favored Glycine 0 C--N 1.339 0.732 0 O-C-N 120.679 -1.263 . . . . 10.0 110.51 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -77.41 105.66 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 -176.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.64 113.26 26.49 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.389 -0.967 . . . . 10.0 108.389 169.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.29 117.97 20.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 126.603 1.961 . . . . 10.0 107.91 173.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 26.4 t -105.89 135.86 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 N-CA-C 106.399 -1.704 . . . . 10.0 106.399 177.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -158.64 62.41 0.43 Allowed 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 123.649 0.779 . . . . 10.0 110.22 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -107.46 161.63 6.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -139.64 151.76 46.23 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.263 1.025 . . . . 10.0 109.404 167.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.444 ' CG ' HH21 ' A' ' 79' ' ' ARG . 25.0 t0 -146.97 152.43 38.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.645 -1.243 . . . . 10.0 107.645 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.9 p -105.66 -13.26 15.62 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.862 2.465 . . . . 10.0 112.154 -176.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -102.27 16.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 119.603 1.092 . . . . 10.0 110.315 179.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -118.05 142.79 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 104.714 -2.328 . . . . 10.0 104.714 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 91.8 p -142.44 149.8 39.74 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 172.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.2 mt -62.34 -41.17 98.35 Favored 'General case' 0 C--O 1.231 0.105 0 CA-C-N 119.025 0.83 . . . . 10.0 109.485 170.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.3 p -146.95 164.56 32.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.176 1.39 . . . . 10.0 108.947 -178.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 122.87 -105.0 0.91 Allowed Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 106.431 -2.668 . . . . 10.0 106.431 -169.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -126.68 -43.61 1.71 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.368 1.067 . . . . 10.0 110.362 -168.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 20.8 m-70 -73.7 -48.53 31.44 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 105.116 -2.179 . . . . 10.0 105.116 174.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.3 t 45.12 60.7 2.86 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 124.771 1.228 . . . . 10.0 113.214 167.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.8 pt -63.97 -11.43 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 113.339 0.866 . . . . 10.0 113.339 -175.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.1 mm -48.13 141.08 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 119.976 1.262 . . . . 10.0 110.923 170.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.44 16.98 75.9 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 125.074 1.321 . . . . 10.0 115.609 169.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 24.9 mmt-85 -84.65 165.61 17.79 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.917 1.358 . . . . 10.0 108.003 166.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 74.1 m -90.48 127.9 36.37 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 107.572 -1.27 . . . . 10.0 107.572 166.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.08 136.81 32.8 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 165.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.48 136.56 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.743 0 N-CA-C 107.075 -1.454 . . . . 10.0 107.075 171.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -105.25 134.53 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.166 -2.161 . . . . 10.0 105.166 167.038 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -114.11 158.13 21.68 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -170.32 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.67 -48.91 79.46 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 112.883 -1.962 . . . . 10.0 109.08 -174.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.9 mttm -110.76 175.05 5.57 Favored 'General case' 0 C--N 1.34 0.191 0 CA-C-O 121.492 0.663 . . . . 10.0 111.934 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.37 152.81 24.88 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.615 -1.175 . . . . 10.0 110.092 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -76.75 149.11 36.34 Favored 'General case' 0 N--CA 1.443 -0.775 0 C-N-CA 123.782 0.833 . . . . 10.0 112.175 -179.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -79.06 -28.3 43.16 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 112.534 -2.121 . . . . 10.0 110.425 172.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 50.7 mt 50.57 48.47 22.53 Favored 'General case' 0 C--N 1.341 0.219 0 CA-C-O 122.349 1.071 . . . . 10.0 109.812 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.3 -11.06 70.9 Favored Glycine 0 CA--C 1.53 1.011 0 CA-C-N 113.907 -1.497 . . . . 10.0 114.086 169.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -81.57 -0.63 43.1 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.07 1.435 . . . . 10.0 114.078 -168.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.64 -22.44 79.01 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.75 38.86 65.33 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.345 -0.702 . . . . 10.0 111.345 -177.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -135.39 172.37 13.11 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 107.613 -1.254 . . . . 10.0 107.613 174.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -54.63 -47.89 72.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.424 0.631 . . . . 10.0 109.809 -178.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.27 -39.77 80.1 Favored 'General case' 0 C--O 1.236 0.353 0 O-C-N 121.516 -0.74 . . . . 10.0 111.707 176.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.3 p -53.28 -38.76 63.38 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 118.655 -0.688 . . . . 10.0 110.375 177.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.9 t -87.24 -7.83 57.46 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 123.703 0.627 . . . . 10.0 112.333 -177.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.9 mttt -103.17 -60.88 1.48 Allowed 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.215 -0.928 . . . . 10.0 111.277 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 14.3 p -135.55 17.4 3.35 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 118.677 0.671 . . . . 10.0 111.16 -177.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 75.93 -102.43 1.55 Allowed Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 107.453 -2.259 . . . . 10.0 107.453 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.7 m-20 -165.38 40.21 0.07 Allowed 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 124.933 1.293 . . . . 10.0 107.962 173.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.12 -11.95 61.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.519 0.728 . . . . 10.0 111.639 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.32 -163.33 54.63 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.61 -1.396 . . . . 10.0 109.61 174.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -51.05 133.98 26.87 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 124.258 1.023 . . . . 10.0 112.788 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.5 mtt180 -67.95 64.11 0.09 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.518 1.927 . . . . 10.0 108.592 171.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -60.59 -22.92 64.25 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -168.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.12 148.5 22.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 109.323 -0.621 . . . . 10.0 109.323 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 17.7 p -163.25 168.97 19.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 110.109 -0.33 . . . . 10.0 110.109 -171.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.99 169.75 42.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.325 -0.71 . . . . 10.0 111.325 -176.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 96.6 t -109.87 145.55 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 106.271 -1.752 . . . . 10.0 106.271 -171.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 89.0 mt -74.6 138.22 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 110.403 -0.221 . . . . 10.0 110.403 -175.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.8 146.7 16.66 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.035 1.302 . . . . 10.0 110.308 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 80.4 mt -80.32 154.06 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.607 1.203 . . . . 10.0 109.17 177.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.88 -109.15 0.33 Allowed 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.326 -1.361 . . . . 10.0 107.326 167.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 1 C-N-CA 132.795 4.438 . . . . 10.0 102.843 -174.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 119.085 -0.483 . . . . 10.0 110.783 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.0 t -113.6 -13.19 12.76 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 124.105 0.962 . . . . 10.0 112.796 170.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -141.57 147.85 38.35 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 118.525 0.602 . . . . 10.0 109.718 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.99 156.55 47.11 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 123.984 0.914 . . . . 10.0 109.828 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -116.83 153.58 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 126.239 1.815 . . . . 10.0 109.044 172.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.86 97.99 3.55 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.924 -1.51 . . . . 10.0 106.924 166.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 m -77.86 121.63 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.111 -1.07 . . . . 10.0 108.111 170.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mt -103.16 130.32 50.3 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 117.85 -1.072 . . . . 10.0 108.769 -174.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 45.0 mtpt -145.46 160.01 42.23 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 120.236 1.38 . . . . 10.0 109.467 170.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.81 -71.26 0.01 OUTLIER Glycine 0 C--O 1.229 -0.177 0 CA-C-N 114.845 -1.07 . . . . 10.0 111.808 173.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.61 -43.64 54.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 106.865 -1.531 . . . . 10.0 106.865 -171.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.57 -65.5 0.57 Allowed Glycine 0 N--CA 1.443 -0.871 0 CA-C-N 113.299 -1.773 . . . . 10.0 111.27 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -54.57 -39.78 86.92 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.6 2.2 . . . . 10.0 111.019 173.262 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 64.9 t -66.33 99.49 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 107.729 -1.212 . . . . 10.0 107.729 173.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -124.61 123.0 39.11 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 125.169 1.388 . . . . 10.0 108.593 173.385 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.01 156.7 15.52 Favored Glycine 0 C--N 1.333 0.402 0 N-CA-C 111.872 -0.491 . . . . 10.0 111.872 171.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.2 mt -141.12 63.45 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 C-N-CA 124.466 1.106 . . . . 10.0 108.609 -172.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -78.22 141.09 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.073 0 O-C-N 121.502 -0.748 . . . . 10.0 110.138 -170.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.6 115.79 24.08 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 128.812 2.845 . . . . 10.0 108.156 -175.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -108.97 107.17 17.44 Favored 'General case' 0 C--N 1.333 -0.128 0 C-N-CA 124.411 1.084 . . . . 10.0 108.098 173.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -99.22 130.62 45.54 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 119.211 0.914 . . . . 10.0 112.064 169.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 tp60 -79.79 110.48 15.18 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 105.146 -2.168 . . . . 10.0 105.146 168.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mmmt -48.14 -67.79 0.24 Allowed 'General case' 0 CA--C 1.514 -0.423 0 C-N-CA 126.801 2.04 . . . . 10.0 110.0 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -123.57 -130.6 0.26 Allowed 'General case' 0 N--CA 1.421 -1.886 0 N-CA-C 103.957 -2.609 . . . . 10.0 103.957 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.6 t -93.23 -49.67 5.86 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.538 -1.282 . . . . 10.0 107.538 167.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -107.17 4.62 26.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.152 -1.386 . . . . 10.0 110.776 -170.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.91 152.8 50.71 Favored Glycine 0 CA--C 1.531 1.09 0 N-CA-C 108.699 -1.76 . . . . 10.0 108.699 173.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -60.51 140.04 89.31 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.297 1.998 . . . . 10.0 109.643 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.3 t -79.27 108.22 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.048 0 N-CA-C 105.569 -2.012 . . . . 10.0 105.569 175.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 56.1 mttm -83.52 119.05 24.22 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 105.126 -2.176 . . . . 10.0 105.126 168.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -105.79 111.15 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 177.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -129.15 170.9 12.97 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 120.79 0.329 . . . . 10.0 111.72 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.63 -153.25 25.17 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 107.787 -2.125 . . . . 10.0 107.787 172.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.7 156.52 35.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 117.656 0.728 . . . . 10.0 110.286 177.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.29 113.79 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 127.479 2.312 . . . . 10.0 106.894 167.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 1.3 pttt -96.58 136.43 37.11 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 108.413 -0.958 . . . . 10.0 108.413 168.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.95 0.27 9.03 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 124.892 1.234 . . . . 10.0 113.679 173.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -75.12 177.17 6.63 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 118.74 1.27 . . . . 10.0 110.785 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.0 t -107.76 149.75 27.81 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.706 -1.59 . . . . 10.0 106.706 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -44.87 140.72 2.45 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.811 1.644 . . . . 10.0 112.156 -172.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.75 -175.28 19.28 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 123.583 0.611 . . . . 10.0 112.18 171.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -70.91 147.59 48.61 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.305 1.442 . . . . 10.0 110.803 -174.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 81.9 m-70 -144.29 145.02 31.76 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.162 0.801 . . . . 10.0 113.162 178.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -27.7 125.0 0.06 OUTLIER Glycine 0 C--N 1.344 0.996 0 C-N-CA 127.039 2.257 . . . . 10.0 111.973 164.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -150.1 105.36 3.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 119.317 1.559 . . . . 10.0 112.085 168.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.08 171.25 18.16 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 122.054 0.931 . . . . 10.0 111.966 -178.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 8.0 m -92.31 149.0 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.789 -2.46 . . . . 10.0 106.694 167.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -120.64 131.44 54.61 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.069 -2.567 . . . . 10.0 104.069 169.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -60.47 -46.5 89.87 Favored 'General case' 0 N--CA 1.452 -0.334 0 O-C-N 124.315 1.009 . . . . 10.0 113.128 -165.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 11.5 m-30 -78.67 135.31 37.16 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 118.619 -1.232 . . . . 10.0 107.758 175.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.51 -41.26 98.0 Favored Glycine 0 CA--C 1.533 1.164 0 N-CA-C 107.918 -2.073 . . . . 10.0 107.918 166.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -29.48 101.31 0.02 OUTLIER 'General case' 0 C--N 1.344 0.369 0 C-N-CA 128.098 2.559 . . . . 10.0 113.933 -169.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -107.67 14.54 25.52 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 113.836 -1.529 . . . . 10.0 111.297 173.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -57.7 -33.05 67.98 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 120.453 1.479 . . . . 10.0 110.587 -176.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -20.0 51.19 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.049 1.34 . . . . 10.0 113.076 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.89 95.81 1.87 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.74 1.162 . . . . 10.0 110.439 -176.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 26.6 t 19.55 66.85 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.617 2.367 . . . . 10.0 114.219 -174.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.2 m -151.38 -52.09 0.13 Allowed 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 124.946 1.299 . . . . 10.0 107.741 -174.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 13.8 t -73.89 4.57 5.13 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.718 -0.614 . . . . 10.0 112.131 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.05 -22.36 66.8 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.938 1.295 . . . . 10.0 111.37 177.056 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.2 140.32 11.0 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 169.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -75.89 62.31 6.53 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.576 2.851 . . . . 10.0 111.102 176.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.0 m170 58.58 61.89 2.1 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 126.347 1.859 . . . . 10.0 109.123 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -68.66 71.47 0.21 Allowed 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 122.502 1.144 . . . . 10.0 111.843 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -74.96 152.88 86.7 Favored Pre-proline 0 C--N 1.32 -0.693 0 C-N-CA 127.664 2.385 . . . . 10.0 111.443 -178.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.74 163.49 38.05 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.564 2.176 . . . . 10.0 110.534 177.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . 0.29 0.2 OUTLIER 49.52 -96.5 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.745 1.618 . . . . 10.0 110.747 -169.676 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.3 m 172.59 94.8 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 128.079 2.552 . . . . 10.0 108.138 173.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -103.73 156.92 17.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 107.744 -1.206 . . . . 10.0 107.744 169.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 97.06 7.81 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.362 -0.352 . . . . 10.0 110.091 -172.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.476 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.6 t60 -10.17 96.1 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 C-N-CA 126.975 2.11 . . . . 10.0 114.072 -173.488 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -117.97 -162.14 12.25 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 108.971 -1.652 . . . . 10.0 108.971 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.29 -168.92 13.27 Favored Glycine 0 N--CA 1.449 -0.482 0 N-CA-C 110.521 -1.032 . . . . 10.0 110.521 175.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -67.45 11.39 0.22 Allowed 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.155 1.903 . . . . 10.0 112.302 175.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -101.24 -25.03 14.14 Favored 'General case' 0 N--CA 1.443 -0.814 0 C-N-CA 124.563 1.145 . . . . 10.0 108.896 169.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -107.85 170.88 7.72 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -169.284 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -86.03 -31.17 22.13 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 169.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -86.82 21.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 125.563 1.545 . . . . 10.0 113.062 -167.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.54 128.09 34.5 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.104 -1.443 . . . . 10.0 107.104 167.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . 0.476 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 18.4 m170 -58.17 -68.09 0.28 Allowed 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.054 0.454 . . . . 10.0 111.096 -172.042 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.9 p -162.98 -51.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.456 -0.942 . . . . 10.0 108.456 -171.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -138.48 62.94 0.56 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 109.327 -1.509 . . . . 10.0 109.327 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -99.93 104.0 15.61 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 104.626 -2.361 . . . . 10.0 104.626 168.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -78.76 -2.97 42.02 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 119.235 0.925 . . . . 10.0 111.138 -175.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.77 -98.92 2.36 Favored Glycine 0 N--CA 1.44 -1.039 0 N-CA-C 106.584 -2.606 . . . . 10.0 106.584 -173.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -144.78 160.57 41.03 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 123.587 0.755 . . . . 10.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.55 132.03 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 105.495 -2.039 . . . . 10.0 105.495 166.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -94.83 118.12 31.25 Favored 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 108.656 -0.868 . . . . 10.0 108.656 -178.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.03 127.98 34.44 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 123.468 0.707 . . . . 10.0 109.135 175.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.412 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 18.6 t70 -61.94 167.06 4.04 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 124.453 1.096 . . . . 10.0 109.118 168.298 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.412 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 16.0 mtmt -52.54 -28.88 22.61 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 126.022 1.729 . . . . 10.0 111.53 171.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -77.23 -10.86 59.69 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 118.115 0.416 . . . . 10.0 111.597 178.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.09 15.84 60.26 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 121.037 -1.04 . . . . 10.0 111.034 -177.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.0 t -97.43 106.82 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.889 2.076 . . . . 10.0 106.497 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.92 123.93 42.13 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.84 -1.17 . . . . 10.0 107.84 169.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -91.72 132.0 36.7 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 175.312 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -101.64 126.45 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 105.686 -1.968 . . . . 10.0 105.686 168.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 63.4 m -155.15 66.94 0.65 Allowed 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 125.001 1.32 . . . . 10.0 107.749 172.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -113.3 162.47 11.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 106.322 -1.733 . . . . 10.0 106.322 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -141.62 147.69 38.0 Favored 'General case' 0 N--CA 1.446 -0.672 0 O-C-N 121.36 -0.838 . . . . 10.0 111.06 168.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -132.75 137.11 46.74 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.92 1.288 . . . . 10.0 108.988 -175.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 1.7 p -108.79 56.75 0.62 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 125.615 1.566 . . . . 10.0 108.088 171.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.57 -61.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 N-CA-C 109.018 -0.734 . . . . 10.0 109.018 178.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.333 0.0 OUTLIER -70.41 169.55 1.41 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 112.74 0.644 . . . . 10.0 112.74 176.874 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 12.3 m -158.57 138.76 12.34 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 174.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 pp -81.75 -18.64 43.53 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.859 0.464 . . . . 10.0 110.232 172.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t -148.18 122.06 9.37 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 106.569 -1.641 . . . . 10.0 106.569 168.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.79 -62.04 0.1 Allowed Glycine 0 C--N 1.336 0.544 0 N-CA-C 109.645 -1.382 . . . . 10.0 109.645 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -164.01 -51.73 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 126.238 1.815 . . . . 10.0 107.094 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -74.26 -38.35 63.48 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 114.321 -1.309 . . . . 10.0 108.555 -170.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 14.2 t 49.83 70.85 0.45 Allowed 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.488 1.515 . . . . 10.0 110.943 171.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 44.5 pt -56.45 -14.78 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 N-CA-C 113.526 0.936 . . . . 10.0 113.526 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.5 mm -44.79 128.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 O-C-N 121.366 -0.834 . . . . 10.0 109.619 169.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.26 0.17 80.51 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.038 -0.868 . . . . 10.0 112.889 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -79.31 168.13 19.95 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.896 1.348 . . . . 10.0 109.152 168.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -112.31 124.81 53.28 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.72 0.808 . . . . 10.0 109.581 176.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -82.24 147.25 29.05 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.026 -1.101 . . . . 10.0 108.026 168.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 95.7 t -133.12 134.83 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.901 0 N-CA-C 108.217 -1.031 . . . . 10.0 108.217 168.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -103.47 129.95 54.61 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 105.754 -1.943 . . . . 10.0 105.754 167.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.9 m-70 -106.15 157.13 17.78 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 115.42 1.637 . . . . 10.0 115.42 -170.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -39.98 -56.62 1.79 Allowed 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 129.264 3.026 . . . . 10.0 110.623 173.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -119.79 168.35 11.17 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.176 0.991 . . . . 10.0 112.546 -169.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.81 129.13 38.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 113.98 -1.464 . . . . 10.0 109.129 170.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -77.77 108.26 10.87 Favored 'General case' 0 N--CA 1.442 -0.859 0 N-CA-C 107.347 -1.353 . . . . 10.0 107.347 171.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -78.97 3.38 17.33 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 111.676 0.251 . . . . 10.0 111.676 175.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 22.2 mt 59.79 -146.42 0.49 Allowed 'General case' 0 N--CA 1.419 -2.004 0 N-CA-C 105.97 -1.863 . . . . 10.0 105.97 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 -14.28 77.26 Favored Glycine 0 C--N 1.304 -1.221 0 CA-C-N 114.351 -1.295 . . . . 10.0 112.244 -168.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -75.07 -1.27 22.13 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.413 1.107 . . . . 10.0 111.966 -169.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.36 -32.56 77.6 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 108.595 -1.802 . . . . 10.0 108.595 168.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 62.13 37.63 94.8 Favored Glycine 0 C--N 1.341 0.818 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.66 175.34 9.26 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 105.176 -2.157 . . . . 10.0 105.176 170.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -45.82 -54.17 8.49 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 115.044 -0.98 . . . . 10.0 111.23 172.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -64.5 -34.68 78.78 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 119.777 -0.769 . . . . 10.0 111.162 -172.116 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -47.7 -40.0 18.99 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 124.116 0.967 . . . . 10.0 111.702 169.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 t -93.08 -4.04 53.11 Favored 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 119.658 1.117 . . . . 10.0 110.362 -170.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -110.44 -57.82 2.16 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 125.698 1.599 . . . . 10.0 110.922 -171.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.4 p -137.13 5.84 2.8 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.616 0.644 . . . . 10.0 112.563 175.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.69 32.18 57.6 Favored Glycine 0 C--N 1.341 0.848 0 CA-C-N 118.675 0.67 . . . . 10.0 114.37 172.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 63.2 m-20 57.78 19.61 5.78 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.794 0.838 . . . . 10.0 113.175 179.106 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.38 -4.04 20.42 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.128 -0.982 . . . . 10.0 112.945 -176.325 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.54 -164.14 53.99 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.679 -0.968 . . . . 10.0 110.679 172.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.78 141.73 43.28 Favored 'General case' 0 N--CA 1.445 -0.714 0 C-N-CA 123.696 0.798 . . . . 10.0 111.987 -168.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 25.7 mtm-85 -67.22 71.14 0.1 Allowed 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.62 1.568 . . . . 10.0 109.414 172.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 6.8 tp -43.54 -45.56 6.64 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 126.5 1.92 . . . . 10.0 112.212 -174.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -159.48 147.41 17.37 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 -173.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 9.5 m -141.09 157.27 45.53 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 -168.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.6 164.96 30.42 Favored Glycine 0 C--N 1.332 0.346 0 N-CA-C 110.219 -1.152 . . . . 10.0 110.219 175.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.02 135.94 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 108.045 -1.095 . . . . 10.0 108.045 -174.514 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 9.3 mt -75.33 107.13 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 N-CA-C 109.291 -0.633 . . . . 10.0 109.291 -174.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.12 154.97 16.38 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 125.799 1.666 . . . . 10.0 110.976 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 90.4 mt -73.27 140.3 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 124.301 1.04 . . . . 10.0 109.937 -175.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.98 -45.99 2.65 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.84 0.456 . . . . 10.0 111.567 169.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 mm100 . . . . . 0 N--CA 1.445 -0.683 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 179.381 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.974 0 CA-C-O 118.158 -0.925 . . . . 10.0 109.398 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.2 t -84.29 -13.46 52.42 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 119.661 1.119 . . . . 10.0 111.893 -176.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.5 ptpp? -152.6 157.86 41.62 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.499 0.666 . . . . 10.0 112.351 167.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.91 170.62 15.4 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 125.855 1.662 . . . . 10.0 109.635 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.5 150.12 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 C-N-CA 126.462 1.905 . . . . 10.0 110.302 -177.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.62 100.91 4.77 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.005 -1.48 . . . . 10.0 107.005 166.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -82.12 118.91 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 107.821 -1.177 . . . . 10.0 107.821 169.385 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -97.43 138.89 34.18 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.873 -1.158 . . . . 10.0 107.873 177.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.9 ttmt -156.76 162.85 39.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.34 -50.21 0.07 OUTLIER Glycine 0 C--O 1.228 -0.256 0 C-N-CA 120.303 -0.951 . . . . 10.0 112.963 169.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -73.31 -45.73 53.75 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.35 -71.48 0.4 Allowed Glycine 0 CA--C 1.524 0.599 0 CA-C-N 114.46 -1.245 . . . . 10.0 110.021 171.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -57.95 -33.82 97.61 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.496 2.798 . . . . 10.0 111.192 173.059 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.1 t -64.91 105.58 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 N-CA-C 107.915 -1.143 . . . . 10.0 107.915 174.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -124.01 110.64 15.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 106.167 -1.79 . . . . 10.0 106.167 173.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.59 144.38 17.14 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 169.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.45 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 4.9 mt -140.1 80.46 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 106.26 -1.755 . . . . 10.0 106.26 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.7 mm -101.97 123.4 55.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 N-CA-C 109.557 -0.534 . . . . 10.0 109.557 -175.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 9.4 m-20 -85.63 151.29 24.01 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 109.268 -0.642 . . . . 10.0 109.268 169.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -126.33 91.53 3.39 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.231 -1.766 . . . . 10.0 106.231 169.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -84.27 138.72 32.78 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.175 0.99 . . . . 10.0 109.812 171.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -127.76 112.05 14.35 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 168.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.06 -56.4 11.72 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 122.7 1.238 . . . . 10.0 111.64 -170.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -139.97 170.39 15.95 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 103.657 -2.72 . . . . 10.0 103.657 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 91.8 p -65.0 -22.71 67.04 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.02 -0.536 . . . . 10.0 110.237 170.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -81.73 -11.75 58.9 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.763 0.825 . . . . 10.0 111.03 177.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.27 159.08 30.71 Favored Glycine 0 CA--C 1.532 1.116 0 O-C-N 121.929 -0.482 . . . . 10.0 112.073 -172.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -78.87 149.03 22.72 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 122.79 2.327 . . . . 10.0 107.889 167.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -76.6 94.38 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 171.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 mtpm? -73.95 97.7 2.88 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.538 -1.282 . . . . 10.0 107.538 169.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.6 m -85.45 115.01 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 107.261 -1.385 . . . . 10.0 107.261 173.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 23.8 p90 -129.9 160.26 34.08 Favored 'General case' 0 CA--C 1.516 -0.36 0 CA-C-O 121.756 0.789 . . . . 10.0 111.952 168.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.57 -173.45 45.41 Favored Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 173.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.8 t -142.43 118.75 10.84 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.683 -1.599 . . . . 10.0 106.683 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pp -80.86 175.07 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 109.095 -0.706 . . . . 10.0 109.095 169.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -146.32 136.58 23.75 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 167.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.33 -5.12 15.31 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.937 0.779 . . . . 10.0 114.656 172.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.09 176.46 3.19 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 119.147 1.473 . . . . 10.0 111.198 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -108.24 159.47 16.6 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.703 -1.962 . . . . 10.0 105.703 166.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -53.49 163.14 0.67 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.531 1.132 . . . . 10.0 112.935 -169.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.17 -174.39 50.84 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 123.962 0.791 . . . . 10.0 112.104 168.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 mp -63.26 144.48 56.9 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 125.233 1.413 . . . . 10.0 110.819 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -146.72 144.02 29.13 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 123.82 0.848 . . . . 10.0 111.352 174.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -24.87 121.98 0.03 OUTLIER Glycine 0 C--N 1.343 0.956 0 C-N-CA 128.242 2.829 . . . . 10.0 111.864 166.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.96 106.71 3.95 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 120.046 1.923 . . . . 10.0 109.728 171.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.461 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -156.46 172.39 18.62 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.56 0.695 . . . . 10.0 112.855 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.15 152.54 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-N 112.581 -2.099 . . . . 10.0 108.078 168.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 79.9 m-70 -126.2 152.69 45.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 170.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -49.31 -60.75 2.54 Favored 'General case' 0 N--CA 1.447 -0.576 0 O-C-N 124.202 0.938 . . . . 10.0 111.379 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -82.38 162.09 22.3 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 121.41 0.624 . . . . 10.0 110.141 -174.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.77 -6.59 52.26 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 167.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.41 172.52 9.31 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-O 122.588 1.185 . . . . 10.0 111.461 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.49 18.15 0.04 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 114.057 1.132 . . . . 10.0 114.057 -169.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -50.41 -36.92 35.08 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.983 1.313 . . . . 10.0 113.713 -169.002 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.26 -21.38 49.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.393 0.677 . . . . 10.0 112.492 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.98 102.28 2.44 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 109.396 -1.481 . . . . 10.0 109.396 -172.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 37.27 60.78 1.01 Allowed 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 126.273 1.829 . . . . 10.0 112.161 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -157.76 -48.06 0.06 Allowed 'General case' 0 N--CA 1.443 -0.821 0 O-C-N 122.023 -0.423 . . . . 10.0 111.401 176.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -50.63 -35.76 32.03 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 125.092 1.357 . . . . 10.0 110.918 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.28 -36.31 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 128.347 2.659 . . . . 10.0 113.768 169.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.51 166.27 26.43 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 107.641 -2.183 . . . . 10.0 107.641 173.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -79.91 -162.77 0.19 Allowed 'Trans proline' 0 N--CA 1.441 -1.599 0 N-CA-C 105.476 -2.548 . . . . 10.0 105.476 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 44.4 m170 -81.49 53.88 2.2 Favored 'General case' 0 CA--C 1.541 0.609 0 O-C-N 120.38 -1.45 . . . . 10.0 110.716 -176.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.6 m-30 -73.09 71.59 1.13 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 123.273 1.511 . . . . 10.0 111.265 -178.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -78.44 141.51 61.28 Favored Pre-proline 0 N--CA 1.447 -0.583 0 C-N-CA 126.158 1.783 . . . . 10.0 109.642 169.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -79.21 47.77 2.61 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.874 2.383 . . . . 10.0 111.213 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -163.79 49.66 0.14 Allowed 'General case' 0 C--O 1.236 0.361 0 C-N-CA 124.761 1.224 . . . . 10.0 107.871 178.206 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.0 p -52.98 108.37 0.31 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.204 1.802 . . . . 10.0 111.57 -169.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -133.32 -173.2 3.14 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.107 -2.183 . . . . 10.0 105.107 169.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.401 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 6.9 mtmp? -85.71 136.63 33.28 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 118.549 -1.26 . . . . 10.0 107.804 -172.373 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.9 t60 -36.05 116.29 0.39 Allowed 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.336 173.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.71 -134.2 4.92 Favored Glycine 0 N--CA 1.441 -1.015 0 N-CA-C 108.139 -1.984 . . . . 10.0 108.139 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.8 -165.81 31.74 Favored Glycine 0 N--CA 1.444 -0.804 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 169.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -57.52 -11.99 10.02 Favored 'Trans proline' 0 N--CA 1.451 -0.976 0 CA-C-N 119.345 1.572 . . . . 10.0 110.849 167.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.87 -33.98 18.35 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 125.223 1.409 . . . . 10.0 110.076 -177.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -107.45 168.54 9.17 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 108.677 -0.861 . . . . 10.0 108.677 -169.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -94.67 -18.88 20.91 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 124.346 1.058 . . . . 10.0 109.761 178.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.401 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -92.02 3.9 54.23 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.395 0.887 . . . . 10.0 113.395 -175.511 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 19.9 ptp180 -34.94 139.0 0.1 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 128.118 2.567 . . . . 10.0 112.272 171.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -71.22 -100.63 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.351 0.66 . . . . 10.0 111.96 -176.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.9 p -148.3 30.13 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.032 0.92 . . . . 10.0 110.228 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.5 47.83 0.02 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.479 -1.448 . . . . 10.0 109.479 -179.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -84.05 88.97 7.19 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 103.203 -2.888 . . . . 10.0 103.203 168.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 42.5 mt -71.3 -33.38 69.65 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 106.451 -1.685 . . . . 10.0 106.451 176.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.66 -97.19 1.34 Allowed Glycine 0 N--CA 1.44 -1.057 0 N-CA-C 108.815 -1.714 . . . . 10.0 108.815 167.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -132.67 129.06 38.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.655 1.182 . . . . 10.0 108.571 -172.195 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.8 m -113.52 141.65 28.7 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.573 -1.64 . . . . 10.0 106.573 168.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -93.13 133.65 36.1 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.738 -0.467 . . . . 10.0 109.738 -177.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.82 133.23 43.41 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.084 0.954 . . . . 10.0 108.848 172.053 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.416 ' OD2' ' NZ ' ' A' ' 91' ' ' LYS . 45.4 t0 -62.03 168.81 3.01 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.678 1.191 . . . . 10.0 108.438 167.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.416 ' NZ ' ' OD2' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -63.38 -19.16 64.41 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.047 0.451 . . . . 10.0 111.816 -179.22 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -77.45 -12.15 59.93 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 123.73 0.812 . . . . 10.0 110.589 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.87 26.88 43.58 Favored Glycine 0 C--N 1.344 0.979 0 N-CA-C 109.766 -1.334 . . . . 10.0 109.766 -178.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 37.7 t -109.08 116.31 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.007 2.523 . . . . 10.0 105.045 178.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -113.49 120.84 42.38 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 107.918 -1.141 . . . . 10.0 107.918 174.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -84.31 117.41 23.55 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 127.141 2.176 . . . . 10.0 108.767 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -102.4 131.88 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 p -159.53 75.91 0.66 Allowed 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 123.88 0.872 . . . . 10.0 110.804 171.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -116.37 147.23 19.89 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.037 0.935 . . . . 10.0 109.146 -176.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -107.14 104.71 14.42 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 126.449 1.9 . . . . 10.0 110.13 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -87.9 123.32 32.53 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 108.746 -0.835 . . . . 10.0 108.746 172.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.7 p -113.13 43.41 1.72 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.209 1.003 . . . . 10.0 110.21 177.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -138.62 -44.57 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 C-N-CA 123.289 0.636 . . . . 10.0 111.255 175.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.365 0.7 OUTLIER -87.85 175.19 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-N 119.342 0.973 . . . . 10.0 112.749 174.103 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.2 m -159.34 138.43 11.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 123.955 0.902 . . . . 10.0 109.007 172.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 pp -82.49 -14.75 54.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.552 0.741 . . . . 10.0 111.944 177.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.1 m -143.46 124.0 14.01 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.662 -1.607 . . . . 10.0 106.662 167.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.96 -59.63 0.2 Allowed Glycine 0 C--N 1.334 0.44 0 N-CA-C 109.638 -1.385 . . . . 10.0 109.638 175.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -166.89 -50.9 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 126.084 1.753 . . . . 10.0 107.465 -177.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -74.98 -36.02 62.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.669 -1.151 . . . . 10.0 108.879 -169.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t 42.41 61.93 1.86 Allowed 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 126.056 1.743 . . . . 10.0 110.99 169.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.57 32.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 113.194 0.812 . . . . 10.0 113.194 -175.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.0 mm -64.5 150.45 10.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 C-N-CA 125.969 1.708 . . . . 10.0 107.424 168.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.25 33.26 86.31 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 121.523 -0.736 . . . . 10.0 113.804 178.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -100.65 163.96 12.1 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 166.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -103.55 127.55 50.95 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-N 118.587 0.63 . . . . 10.0 111.106 170.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.14 139.64 30.26 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.498 -1.668 . . . . 10.0 106.498 166.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 93.0 t -122.88 138.67 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 172.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.1 p -105.69 134.72 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 104.96 -2.237 . . . . 10.0 104.96 166.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 6.5 m170 -113.67 161.36 17.57 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 114.506 1.298 . . . . 10.0 114.506 -172.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -57.73 -49.16 77.47 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 113.694 -1.594 . . . . 10.0 109.548 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -116.09 176.48 5.08 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.47 1.108 . . . . 10.0 111.812 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.1 146.55 23.57 Favored 'General case' 0 N--CA 1.451 -0.425 0 C-N-CA 125.375 1.47 . . . . 10.0 110.271 -177.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.461 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 3.9 m-20 -76.77 151.39 36.01 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.108 0.563 . . . . 10.0 110.612 178.114 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -89.54 16.58 7.48 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 114.836 -1.075 . . . . 10.0 109.878 166.227 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 69.9 mt 36.43 47.57 0.51 Allowed 'General case' 0 C--N 1.344 0.338 0 C-N-CA 127.19 2.196 . . . . 10.0 112.383 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.74 -47.37 1.05 Allowed Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 124.582 1.087 . . . . 10.0 111.851 176.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -83.23 44.27 0.93 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 124.999 1.32 . . . . 10.0 111.844 -168.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -81.98 -38.68 12.93 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.515 -1.434 . . . . 10.0 109.515 169.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.45 48.61 56.53 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 109.37 -1.492 . . . . 10.0 109.37 -170.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.7 m-80 -138.36 166.57 23.9 Favored 'General case' 0 CA--C 1.508 -0.652 0 N-CA-C 106.689 -1.597 . . . . 10.0 106.689 175.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 2.7 tm-20 -52.99 -46.52 68.36 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 114.712 -1.131 . . . . 10.0 108.843 171.042 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -57.1 -43.2 82.0 Favored 'General case' 0 C--N 1.343 0.305 0 CA-C-N 116.332 -0.395 . . . . 10.0 110.889 171.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.297 2.1 p -59.21 -32.95 70.41 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -167.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -78.89 -8.05 58.5 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 118.592 -1.243 . . . . 10.0 112.276 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 89.5 mttt -116.68 -59.46 1.97 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.638 1.575 . . . . 10.0 111.834 -171.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.1 p -123.48 -4.66 8.26 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 119.318 0.963 . . . . 10.0 112.675 179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.19 -82.97 0.45 Allowed Glycine 0 CA--C 1.531 1.039 0 CA-C-N 119.386 0.994 . . . . 10.0 112.762 169.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.12 32.88 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 123.186 1.47 . . . . 10.0 108.343 177.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.64 -26.6 57.89 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.963 -1.471 . . . . 10.0 109.771 -167.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.13 -159.69 51.22 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 109.53 -1.428 . . . . 10.0 109.53 -177.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.0 t -58.49 139.26 55.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 113.136 0.791 . . . . 10.0 113.136 -168.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -65.05 65.72 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 126.764 2.025 . . . . 10.0 109.754 168.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.48 -19.2 61.77 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 113.904 1.076 . . . . 10.0 113.904 -172.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.22 150.89 25.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 122.81 0.444 . . . . 10.0 110.409 169.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.6 p -154.17 165.6 35.74 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.057 0.543 . . . . 10.0 110.049 -176.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -141.0 -172.0 12.82 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 123.434 0.54 . . . . 10.0 112.675 -177.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.7 t -136.79 136.52 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 107.648 -1.241 . . . . 10.0 107.648 172.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.0 mt -73.93 114.63 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 122.887 0.475 . . . . 10.0 110.402 -177.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.46 151.35 18.46 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 125.762 1.649 . . . . 10.0 111.461 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.8 mt -73.32 140.34 17.97 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 124.902 1.281 . . . . 10.0 109.855 -173.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.72 -45.47 2.89 Favored 'General case' 0 C--O 1.225 -0.222 0 O-C-N 121.069 -1.02 . . . . 10.0 111.74 173.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.25 1.09 0 C-N-CA 127.81 2.444 . . . . 10.0 109.203 -168.575 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.886 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -70.93 -31.03 67.5 Favored 'General case' 0 C--O 1.226 -0.142 0 CA-C-N 119.27 0.941 . . . . 10.0 109.847 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . 0.448 ' HZ2' ' CD ' ' B' ' 21' ' ' GLU . 34.9 tttt -144.37 134.12 23.67 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.769 0.828 . . . . 10.0 109.395 -174.19 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 165.41 27.65 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.865 1.666 . . . . 10.0 107.768 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -126.13 171.1 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 118.339 0.518 . . . . 10.0 109.84 174.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.78 112.86 9.73 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.413 -1.328 . . . . 10.0 107.413 166.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 30.8 m -92.01 114.89 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 168.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.6 mt -100.56 135.65 41.67 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -158.13 157.43 32.73 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.862 1.21 . . . . 10.0 108.705 170.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.3 -52.17 0.04 OUTLIER Glycine 0 C--O 1.228 -0.269 0 C-N-CA 121.414 -0.422 . . . . 10.0 112.148 172.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.8 -45.95 40.1 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.609 -1.626 . . . . 10.0 106.609 -171.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.29 -67.06 0.55 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 113.711 -1.586 . . . . 10.0 110.461 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -56.97 -41.07 79.2 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.646 2.231 . . . . 10.0 110.68 172.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.8 t -65.94 105.83 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -123.02 117.98 26.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 169.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.83 141.63 15.36 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.358 -1.097 . . . . 10.0 110.358 172.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 mt -143.13 81.13 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 106.476 -1.676 . . . . 10.0 106.476 -175.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.6 mm -102.72 151.37 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.324 1.049 . . . . 10.0 109.715 -173.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -121.48 119.93 33.43 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.939 2.095 . . . . 10.0 108.164 174.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -102.89 108.92 20.3 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.783 -1.562 . . . . 10.0 106.783 176.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.448 ' CD ' ' HZ2' ' B' ' 3' ' ' LYS . 36.8 mt-10 -119.49 141.05 49.52 Favored 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.247 0.832 . . . . 10.0 113.247 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -118.39 119.18 33.82 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.332 -1.729 . . . . 10.0 106.332 166.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -154.95 40.27 0.43 Allowed 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 112.842 0.682 . . . . 10.0 112.842 -172.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.99 170.53 13.85 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 102.219 -3.252 . . . . 10.0 102.219 166.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 20.1 t -71.28 -21.83 62.03 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.108 0.48 . . . . 10.0 109.905 -178.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 15.4 m-80 -79.66 -12.63 59.81 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 123.165 0.586 . . . . 10.0 110.1 177.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 49.07 45.02 33.41 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-O 118.398 -1.223 . . . . 10.0 114.509 -177.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -65.63 136.59 46.72 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 107.191 -1.888 . . . . 10.0 107.191 172.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.49 105.19 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 106.028 -1.842 . . . . 10.0 106.028 174.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -97.49 112.85 24.52 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 173.412 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -111.99 113.59 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 125.126 1.37 . . . . 10.0 108.776 -173.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.5 p90 -132.65 170.82 14.67 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.874 0.368 . . . . 10.0 110.804 173.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.88 -147.92 18.84 Favored Glycine 0 N--CA 1.448 -0.52 0 N-CA-C 106.955 -2.458 . . . . 10.0 106.955 170.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.2 t -155.86 156.61 34.98 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 119.306 -0.958 . . . . 10.0 111.192 177.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.9 pt -117.08 153.68 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 N-CA-C 108.032 -1.099 . . . . 10.0 108.032 166.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -127.62 151.41 48.96 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 106.801 -1.555 . . . . 10.0 106.801 167.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.24 -14.44 15.93 Favored Glycine 0 C--N 1.336 0.542 0 CA-C-O 119.002 -0.888 . . . . 10.0 113.322 169.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.6 mp -76.4 176.84 7.84 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 118.652 1.226 . . . . 10.0 110.388 -177.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.59 152.76 20.13 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.596 -0.729 . . . . 10.0 109.348 169.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -45.34 143.98 1.58 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.109 1.764 . . . . 10.0 111.87 -176.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.72 -177.31 22.66 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 123.927 0.775 . . . . 10.0 112.159 171.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -71.69 153.55 41.97 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 125.347 1.459 . . . . 10.0 110.921 -177.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -149.34 146.93 27.77 Favored 'General case' 0 C--N 1.343 0.319 0 N-CA-C 113.959 1.096 . . . . 10.0 113.959 -177.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -31.48 114.26 0.07 OUTLIER Glycine 0 C--N 1.34 0.803 0 C-N-CA 128.379 2.895 . . . . 10.0 113.215 164.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -141.48 101.43 3.99 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 120.519 2.16 . . . . 10.0 109.353 173.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.516 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -151.17 170.15 20.16 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-O 121.749 0.785 . . . . 10.0 111.938 178.603 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.2 m -93.08 154.86 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.223 -2.262 . . . . 10.0 106.788 168.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 61.2 m-70 -126.58 135.87 51.81 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 170.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -50.92 -50.57 57.29 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 118.445 -0.788 . . . . 10.0 112.186 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -82.6 137.29 34.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 117.714 -1.594 . . . . 10.0 109.501 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.58 3.01 87.41 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 126.29 1.9 . . . . 10.0 112.147 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 p-10 -76.3 81.82 3.07 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-O 123.613 1.673 . . . . 10.0 110.181 -173.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.31 9.75 1.94 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.488 -1.233 . . . . 10.0 113.732 -175.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.45 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -44.96 -45.94 10.79 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 127.734 2.414 . . . . 10.0 112.634 -170.818 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.86 -20.72 41.68 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.7 87.82 2.02 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 107.955 -2.058 . . . . 10.0 107.955 -168.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 16.88 54.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 127.987 2.515 . . . . 10.0 116.108 -169.221 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 17.0 m -125.97 -56.25 1.46 Allowed 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 105.69 -1.967 . . . . 10.0 105.69 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -47.74 -37.4 13.18 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.403 1.481 . . . . 10.0 110.708 169.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.14 -31.5 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 127.864 2.466 . . . . 10.0 115.257 169.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.27 148.64 18.98 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 109.517 -1.433 . . . . 10.0 109.517 169.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.51 -179.27 0.85 Allowed 'Trans proline' 0 N--CA 1.446 -1.305 0 N-CA-C 107.674 -1.702 . . . . 10.0 107.674 166.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.413 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 37.8 m170 -76.24 76.57 3.04 Favored 'General case' 0 CA--C 1.543 0.685 0 O-C-N 120.422 -1.424 . . . . 10.0 110.501 -169.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -71.46 69.44 0.59 Allowed 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 123.182 1.468 . . . . 10.0 112.417 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 1.7 p30 -56.15 145.51 55.46 Favored Pre-proline 0 C--N 1.321 -0.649 0 C-N-CA 127.326 2.251 . . . . 10.0 112.155 168.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -74.79 167.74 26.41 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 122.106 1.871 . . . . 10.0 108.296 167.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 tp 62.46 -101.06 0.1 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 125.09 1.356 . . . . 10.0 108.041 -174.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.2 p 171.59 97.45 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.753 1.621 . . . . 10.0 110.263 -174.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 75.9 mtt180 -130.02 163.64 26.04 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 119.651 1.114 . . . . 10.0 110.346 176.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -113.44 55.32 0.71 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 124.648 1.179 . . . . 10.0 111.422 -168.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 65.3 t60 47.05 88.2 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 125.091 1.356 . . . . 10.0 114.646 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.06 -145.18 11.07 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.262 -1.336 . . . . 10.0 110.067 178.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.78 -173.96 32.1 Favored Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 109.152 -1.579 . . . . 10.0 109.152 176.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -55.22 -13.15 6.49 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 123.025 2.483 . . . . 10.0 112.434 173.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -94.27 -30.25 14.65 Favored 'General case' 0 N--CA 1.444 -0.754 0 C-N-CA 125.189 1.396 . . . . 10.0 110.607 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -103.18 169.0 8.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -169.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -78.77 -33.52 46.33 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -77.14 18.14 0.41 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.309 1.043 . . . . 10.0 113.421 -165.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 20.2 ptp180 -64.55 117.22 7.05 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.106 -1.072 . . . . 10.0 108.106 -177.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 11.1 m170 -57.98 -60.96 2.92 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 120.824 0.345 . . . . 10.0 111.846 -170.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p -165.5 -47.09 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 -169.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -152.99 71.49 0.28 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 108.551 -1.82 . . . . 10.0 108.551 172.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -102.57 106.61 17.33 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 105.73 -1.952 . . . . 10.0 105.73 171.092 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.22 -12.07 60.03 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 111.7 -172.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.78 -98.26 1.56 Allowed Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 107.924 -2.071 . . . . 10.0 107.924 -178.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -156.28 146.96 21.82 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 107.099 -1.445 . . . . 10.0 107.099 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.7 m -122.08 131.95 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 107.208 -1.405 . . . . 10.0 107.208 169.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 63.0 m -90.89 107.26 19.07 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 126.298 1.839 . . . . 10.0 109.228 -172.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -77.82 130.33 36.54 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 110.172 -0.307 . . . . 10.0 110.172 172.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.406 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 17.5 t70 -61.85 170.1 2.22 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 124.274 1.03 . . . . 10.0 109.295 167.324 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.406 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 16.5 mtmt -55.79 -29.08 59.09 Favored 'General case' 0 N--CA 1.433 -1.294 0 C-N-CA 125.884 1.674 . . . . 10.0 111.647 171.352 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -78.38 -1.67 34.55 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-O 121.163 0.506 . . . . 10.0 111.371 175.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.09 1.46 90.33 Favored Glycine 0 C--N 1.339 0.746 0 O-C-N 120.376 -1.452 . . . . 10.0 111.179 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 44.8 t -78.43 105.98 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 C-N-CA 126.929 2.092 . . . . 10.0 107.03 178.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.78 124.62 49.23 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 169.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.56 122.74 26.86 Favored 'General case' 0 N--CA 1.432 -1.338 0 C-N-CA 125.832 1.653 . . . . 10.0 107.816 169.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.4 t -101.92 128.85 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.208 0 N-CA-C 106.851 -1.537 . . . . 10.0 106.851 173.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.9 t -156.85 92.67 1.3 Allowed 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 169.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.3 mp -135.94 164.29 32.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 125.96 1.704 . . . . 10.0 106.542 -177.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -148.64 159.63 43.91 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.74 116.21 7.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.023 -0.732 . . . . 10.0 109.023 171.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 52.0 p -90.41 61.6 5.05 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 106.909 -1.515 . . . . 10.0 106.909 -171.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.16 -50.53 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 123.731 0.644 . . . . 10.0 110.068 -176.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -79.91 142.42 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.592 -1.262 . . . . 10.0 107.592 169.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 22.9 m -128.22 114.22 16.68 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.697 -1.594 . . . . 10.0 106.697 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mt -59.23 -4.34 0.53 Allowed 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 114.411 1.263 . . . . 10.0 114.411 -173.049 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.7 m -147.91 152.72 38.03 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.582 1.953 . . . . 10.0 107.558 177.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 117.91 -91.72 0.53 Allowed Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 106.515 -2.634 . . . . 10.0 106.515 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -135.81 -53.83 0.76 Allowed 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 125.515 1.526 . . . . 10.0 107.777 -169.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 -80.67 36.72 0.39 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.038 0.935 . . . . 10.0 110.49 -175.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.1 t -77.57 110.09 12.07 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 124.624 1.17 . . . . 10.0 107.963 -173.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.6 pt -83.98 23.42 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 122.957 0.503 . . . . 10.0 111.997 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.49 -73.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 CA-C-N 118.8 0.727 . . . . 10.0 111.268 -177.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.66 50.33 3.55 Favored Glycine 0 CA--C 1.532 1.133 0 O-C-N 120.642 -1.286 . . . . 10.0 112.546 -177.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.4 mmt-85 -110.3 152.38 26.24 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 124.832 1.253 . . . . 10.0 109.697 176.386 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.9 m -88.88 125.14 34.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.975 -0.75 . . . . 10.0 108.975 171.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -96.13 138.76 33.29 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 126.42 1.888 . . . . 10.0 107.7 170.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -126.44 135.67 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 N-CA-C 108.517 -0.919 . . . . 10.0 108.517 -177.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -106.16 121.87 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 106.807 -1.553 . . . . 10.0 106.807 171.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.3 m-70 -105.63 158.12 16.93 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 123.75 1.738 . . . . 10.0 115.605 -171.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -43.82 -61.48 1.41 Allowed 'General case' 0 N--CA 1.442 -0.862 0 C-N-CA 129.738 3.215 . . . . 10.0 110.551 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.3 mttp -112.77 172.86 6.67 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.061 0.944 . . . . 10.0 111.395 -175.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.13 154.64 40.96 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.016 1.326 . . . . 10.0 110.571 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.516 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.0 OUTLIER -78.49 144.98 35.22 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 123.98 0.912 . . . . 10.0 111.578 174.083 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -76.27 -32.89 59.07 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 124.781 1.301 . . . . 10.0 109.349 168.057 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt 63.5 56.42 1.62 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 123.491 1.615 . . . . 10.0 109.572 -168.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.92 -47.96 3.44 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 113.582 -1.645 . . . . 10.0 111.341 165.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.19 44.97 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.8 1.64 . . . . 10.0 112.012 -173.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -10.83 50.08 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 126.263 1.887 . . . . 10.0 111.892 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.88 32.43 18.63 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.448 -0.64 . . . . 10.0 112.071 -174.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -113.66 152.34 30.56 Favored 'General case' 0 CA--C 1.506 -0.716 0 N-CA-C 105.65 -1.982 . . . . 10.0 105.65 171.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.8 tm-20 -50.54 -37.57 40.08 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 114.921 -1.036 . . . . 10.0 108.695 169.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 16.8 tp10 -70.81 -38.5 73.29 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 113.889 1.07 . . . . 10.0 113.889 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 76.7 p -57.67 -42.63 83.95 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 120.642 1.565 . . . . 10.0 110.456 -175.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 6.3 t -69.17 -10.3 57.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 113.109 0.781 . . . . 10.0 113.109 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 20.5 ttmt -113.71 -47.97 2.95 Favored 'General case' 0 N--CA 1.435 -1.204 0 C-N-CA 125.43 1.492 . . . . 10.0 112.347 -168.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.413 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 32.0 p -130.78 -2.87 4.14 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.016 0.747 . . . . 10.0 113.016 172.173 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.2 19.7 60.33 Favored Glycine 0 C--N 1.34 0.803 0 N-CA-C 110.809 -0.917 . . . . 10.0 110.809 -175.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 54.45 31.7 15.22 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 117.837 0.819 . . . . 10.0 111.718 176.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.47 7.26 4.62 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 123.906 0.882 . . . . 10.0 111.673 -176.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.85 -168.23 53.48 Favored Glycine 0 N--CA 1.444 -0.798 0 N-CA-C 110.065 -1.214 . . . . 10.0 110.065 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.8 t -67.4 158.32 32.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 122.582 1.182 . . . . 10.0 111.273 -169.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.94 112.37 4.91 Favored 'General case' 0 N--CA 1.442 -0.857 0 C-N-CA 125.075 1.35 . . . . 10.0 107.966 170.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 29.0 mt -72.68 -55.71 6.4 Favored 'General case' 0 N--CA 1.458 -0.054 0 N-CA-C 109.098 -0.704 . . . . 10.0 109.098 170.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.34 156.6 47.47 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.858 -0.61 . . . . 10.0 110.273 -170.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.5 m -129.29 147.63 51.14 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.31 1.444 . . . . 10.0 108.805 -168.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -150.7 156.89 26.93 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.456 -1.458 . . . . 10.0 109.456 169.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 70.1 t -116.1 128.54 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 105.133 -2.173 . . . . 10.0 105.133 177.059 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 16.8 mt -69.03 156.93 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 CA-C-N 119.266 0.939 . . . . 10.0 110.06 176.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.02 160.91 32.47 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 124.995 1.283 . . . . 10.0 110.156 -176.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 96.0 mt -69.75 135.46 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.976 1.31 . . . . 10.0 109.478 -171.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.63 -47.1 2.44 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 123.366 0.666 . . . . 10.0 110.899 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 . . . . . 0 C--O 1.254 1.291 0 CA-C-O 117.809 -1.091 . . . . 10.0 111.031 -169.4 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.463 0 N-CA-C 110.161 -0.311 . . . . 10.0 110.161 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER 169.26 -41.06 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 129.861 3.264 . . . . 10.0 103.891 -167.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.407 ' NZ ' ' OE2' ' A' ' 21' ' ' GLU . 29.3 mtpp -106.39 132.35 52.52 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.243 -2.132 . . . . 10.0 105.243 166.119 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 163.05 33.97 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 107.526 -1.286 . . . . 10.0 107.526 169.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -124.28 176.51 5.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 C-N-CA 123.037 0.535 . . . . 10.0 109.998 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.77 117.13 5.68 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 118.504 0.593 . . . . 10.0 109.887 166.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -97.99 104.27 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 C-N-CA 124.609 1.164 . . . . 10.0 110.519 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mt -98.41 122.74 41.97 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.862 1.665 . . . . 10.0 109.517 -177.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -143.53 157.23 44.59 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 120.034 1.288 . . . . 10.0 108.513 173.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.26 -59.3 0.03 OUTLIER Glycine 0 N--CA 1.464 0.518 0 C-N-CA 120.317 -0.944 . . . . 10.0 113.005 169.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -70.93 -43.91 67.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.86 -71.45 0.38 Allowed Glycine 0 CA--C 1.521 0.451 0 CA-C-N 114.186 -1.37 . . . . 10.0 110.644 168.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -57.39 -33.36 96.13 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.786 2.99 . . . . 10.0 111.369 172.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 57.9 t -64.75 95.89 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.547 -1.279 . . . . 10.0 107.547 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 -120.58 111.27 17.45 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 125.684 1.594 . . . . 10.0 107.775 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -100.81 133.98 11.52 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-O 119.521 -0.6 . . . . 10.0 111.955 171.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.433 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 8.7 mt -136.08 85.93 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 -172.39 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.55 152.8 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 C-N-CA 124.404 1.081 . . . . 10.0 111.136 -171.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -120.68 116.8 26.01 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 126.504 1.922 . . . . 10.0 108.905 170.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -91.5 99.34 12.3 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 174.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.407 ' OE2' ' NZ ' ' A' ' 3' ' ' LYS . 16.4 mm-40 -97.39 117.86 32.58 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.775 0.798 . . . . 10.0 111.025 178.512 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.1 tp60 -117.61 97.31 5.8 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 127.895 2.478 . . . . 10.0 105.788 178.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 4.8 mtmp? -59.08 -52.76 64.33 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 123.004 0.522 . . . . 10.0 110.377 -173.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -131.09 172.31 12.25 Favored 'General case' 0 N--CA 1.424 -1.748 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 173.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.9 t -71.49 -20.28 62.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 108.879 -0.785 . . . . 10.0 108.879 170.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . 0.306 0.0 OUTLIER -89.13 -5.43 57.78 Favored 'General case' 0 C--N 1.344 0.359 0 N-CA-C 113.401 0.889 . . . . 10.0 113.401 173.446 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.72 160.11 35.34 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 109.619 -1.393 . . . . 10.0 109.619 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -71.55 148.2 53.25 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 N-CA-C 107.592 -1.734 . . . . 10.0 107.592 168.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.3 t -78.39 110.92 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 105.39 -2.078 . . . . 10.0 105.39 173.275 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.2 102.86 15.58 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 171.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -98.92 99.7 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.415 -1.328 . . . . 10.0 107.415 179.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.8 p90 -118.15 166.87 12.06 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.566 0.698 . . . . 10.0 112.267 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.79 -150.3 21.81 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.07 -2.412 . . . . 10.0 107.07 171.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.7 t -155.23 152.87 29.84 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 119.773 -0.771 . . . . 10.0 110.914 -178.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pt -110.63 142.85 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 115.215 -0.902 . . . . 10.0 108.616 166.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -118.81 148.85 42.41 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 169.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.71 -5.35 40.18 Favored Glycine 0 CA--C 1.525 0.664 0 CA-C-O 119.235 -0.759 . . . . 10.0 113.499 174.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -69.62 176.78 3.31 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 118.805 1.302 . . . . 10.0 110.122 177.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.1 t -104.75 167.83 9.46 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.319 -2.104 . . . . 10.0 105.319 165.232 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -57.07 166.38 1.07 Allowed 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.373 0.669 . . . . 10.0 111.254 -171.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.98 -177.17 42.94 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.286 -0.884 . . . . 10.0 112.375 168.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.0 mp -74.21 145.42 44.14 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 124.851 1.26 . . . . 10.0 110.093 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -144.91 145.36 31.53 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 124.177 0.991 . . . . 10.0 112.685 -175.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.48 125.97 0.28 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 126.695 2.093 . . . . 10.0 113.398 166.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -150.11 108.55 3.8 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.098 1.449 . . . . 10.0 108.253 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.25 173.0 12.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 122.732 1.253 . . . . 10.0 113.481 177.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 85.8 t -98.19 129.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 CA-C-N 111.03 -2.805 . . . . 10.0 105.487 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -105.8 139.72 39.93 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.194 -1.409 . . . . 10.0 107.194 170.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -58.1 -58.04 10.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 O-C-N 124.094 0.871 . . . . 10.0 110.214 -169.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -76.86 119.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.653 -1.61 . . . . 10.0 106.653 -171.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.74 46.81 2.94 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.523 -1.031 . . . . 10.0 110.523 171.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -108.89 118.72 37.53 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.929 1.291 . . . . 10.0 108.153 176.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -117.94 5.78 12.16 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.218 1.807 . . . . 10.0 109.988 178.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.401 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 1.3 m -57.07 -37.1 71.37 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 120.096 1.316 . . . . 10.0 111.667 -169.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -21.83 45.68 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.079 0.952 . . . . 10.0 112.682 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 143.85 -86.46 0.18 Allowed Glycine 0 CA--C 1.527 0.797 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 -172.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 24.1 p -170.78 43.29 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.152 0.981 . . . . 10.0 110.989 172.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 m -104.92 -49.31 3.52 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 m -50.18 -27.63 6.18 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 126.372 1.869 . . . . 10.0 111.641 174.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -37.16 -32.1 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 128.02 2.528 . . . . 10.0 113.848 168.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.32 126.64 5.2 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.277 -1.291 . . . . 10.0 109.95 170.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -72.4 65.34 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.81 0 C-N-CA 123.729 2.953 . . . . 10.0 112.268 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.7 m170 68.87 42.8 1.29 Allowed 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 129.773 3.229 . . . . 10.0 111.505 172.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -72.51 57.96 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.728 1.01 . . . . 10.0 113.728 -173.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.0 p-10 -68.3 159.57 79.95 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 118.968 0.804 . . . . 10.0 110.931 175.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -61.28 -47.68 11.55 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.216 1.944 . . . . 10.0 111.218 176.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 94.8 mt -78.1 59.05 2.12 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 109.301 -0.629 . . . . 10.0 109.301 177.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.0 t -58.97 95.64 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.417 1.087 . . . . 10.0 108.77 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.59 -96.57 0.41 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.796 -1.557 . . . . 10.0 106.796 -177.172 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.5 mttp -151.67 139.92 20.34 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 106.397 -1.705 . . . . 10.0 106.397 173.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.6 t60 -40.91 124.15 2.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 O-C-N 123.776 0.673 . . . . 10.0 110.903 170.401 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.15 -138.12 3.66 Favored Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 108.367 -1.893 . . . . 10.0 108.367 177.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -177.37 -165.94 33.35 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 107.342 -2.303 . . . . 10.0 107.342 169.297 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -62.54 -0.72 2.06 Favored 'Trans proline' 0 CA--C 1.542 0.878 0 CA-C-N 120.305 2.053 . . . . 10.0 110.948 167.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.403 ' H ' ' C ' ' A' ' 73' ' ' GLY . 61.0 mmtt -91.07 -24.62 19.98 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 124.409 1.084 . . . . 10.0 110.625 173.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.77 174.8 5.72 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -176.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -87.82 -32.15 19.19 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 170.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -82.25 2.0 33.99 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 115.032 1.493 . . . . 10.0 115.032 -165.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -41.54 137.36 1.59 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 125.639 1.575 . . . . 10.0 112.172 -177.12 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -71.88 -77.64 0.09 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.704 -0.798 . . . . 10.0 112.185 -170.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 p -161.41 58.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 121.324 -0.86 . . . . 10.0 109.46 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 106.94 50.55 0.83 Allowed Glycine 0 CA--C 1.523 0.533 0 N-CA-C 109.943 -1.263 . . . . 10.0 109.943 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -87.05 90.97 8.54 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 104.026 -2.583 . . . . 10.0 104.026 167.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.3 mt -70.3 -31.63 69.06 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 107.316 -1.364 . . . . 10.0 107.316 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 101.08 -106.43 3.08 Favored Glycine 0 N--CA 1.434 -1.44 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 168.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -109.23 119.41 39.42 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.506 1.122 . . . . 10.0 110.388 -168.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.1 m -104.89 135.36 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 168.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 50.0 m -99.64 108.8 21.26 Favored 'General case' 0 N--CA 1.442 -0.858 0 C-N-CA 126.316 1.846 . . . . 10.0 109.641 -168.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.44 130.24 35.24 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.229 1.011 . . . . 10.0 110.748 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 45.4 t0 -66.26 170.71 5.52 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 123.956 0.902 . . . . 10.0 109.455 168.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -52.96 -26.99 16.91 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.872 1.669 . . . . 10.0 111.599 177.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -79.03 -15.52 58.11 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.349 1.059 . . . . 10.0 110.065 -175.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.81 74.21 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 110.991 -0.844 . . . . 10.0 110.991 -173.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.0 t -87.64 113.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 C-N-CA 126.338 1.855 . . . . 10.0 106.265 173.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.9 121.38 44.87 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.461 -0.94 . . . . 10.0 108.461 171.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -78.17 130.55 36.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 172.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 75.0 t -104.91 129.39 57.59 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.369 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 169.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -156.93 66.95 0.53 Allowed 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 175.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.35 155.02 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.37 138.36 38.2 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.929 0.492 . . . . 10.0 110.727 169.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.95 131.14 51.15 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.858 1.263 . . . . 10.0 108.789 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.4 p -95.96 42.75 1.09 Allowed 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.626 1.971 . . . . 10.0 108.424 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.3 -49.88 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 123.337 0.655 . . . . 10.0 109.644 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 33.7 mm -57.57 134.55 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 169.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.5 m -164.66 94.22 0.68 Allowed 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.668 0.787 . . . . 10.0 109.441 -176.218 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -68.61 27.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.644 1.177 . . . . 10.0 113.839 175.328 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.9 p -157.8 113.4 2.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 121.275 -0.891 . . . . 10.0 110.32 -176.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 162.26 -54.1 0.31 Allowed Glycine 0 C--N 1.335 0.481 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 169.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.75 -50.14 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 126.337 1.855 . . . . 10.0 107.475 -173.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 -74.42 -38.53 63.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.944 -1.025 . . . . 10.0 108.623 -169.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 40.53 62.2 1.42 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.154 1.782 . . . . 10.0 110.01 172.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 24.3 pt -74.62 46.77 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.745 2.018 . . . . 10.0 111.77 -175.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.3 mm -72.49 -65.17 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 128.971 2.908 . . . . 10.0 108.207 172.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.75 47.52 3.07 Favored Glycine 0 CA--C 1.529 0.953 0 O-C-N 121.343 -0.848 . . . . 10.0 113.808 -169.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -89.65 174.63 7.64 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 125.105 1.362 . . . . 10.0 108.68 172.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 20.2 m -109.87 115.11 29.22 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.787 -2.301 . . . . 10.0 104.787 168.127 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.6 mp -97.94 151.78 19.92 Favored 'General case' 0 CA--C 1.512 -0.511 0 N-CA-C 108.296 -1.001 . . . . 10.0 108.296 175.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.7 t -143.16 136.89 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 O-C-N 123.837 0.711 . . . . 10.0 109.803 -170.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.8 m -105.89 140.35 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.952 1.301 . . . . 10.0 108.887 167.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.0 m170 -120.66 159.13 25.94 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.49 2.033 . . . . 10.0 116.49 -172.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -39.46 -58.61 1.23 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 130.289 3.436 . . . . 10.0 111.886 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -123.17 168.34 12.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 124.679 1.192 . . . . 10.0 110.48 -171.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.76 137.66 55.61 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 108.308 -0.997 . . . . 10.0 108.308 169.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.421 ' C ' ' H ' ' A' ' 126' ' ' LEU . 0.0 OUTLIER -77.84 144.12 37.27 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.191 -1.04 . . . . 10.0 108.191 168.193 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -78.14 25.04 0.23 Allowed 'General case' 0 CA--C 1.539 0.519 0 CA-C-O 121.133 0.492 . . . . 10.0 111.126 177.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.421 ' H ' ' C ' ' A' ' 124' ' ' ASP . 18.8 mt 30.53 45.82 0.03 OUTLIER 'General case' 0 C--N 1.34 0.162 0 C-N-CA 128.23 2.612 . . . . 10.0 112.629 -170.161 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.6 -45.53 1.3 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 124.623 1.106 . . . . 10.0 112.488 177.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -83.34 50.6 1.8 Allowed 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.092 0.957 . . . . 10.0 111.452 -169.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -87.45 -35.89 9.14 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 125.969 1.747 . . . . 10.0 110.022 172.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.27 38.7 71.56 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.865 -0.894 . . . . 10.0 110.865 -178.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 56.1 m-80 -130.8 163.74 26.7 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 169.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -53.31 -39.35 63.96 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.718 0.771 . . . . 10.0 109.592 173.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -67.14 -35.16 79.12 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.448 1.099 . . . . 10.0 112.934 173.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 60.0 p -56.31 -34.01 66.12 Favored 'General case' 0 N--CA 1.443 -0.776 0 O-C-N 120.029 -1.669 . . . . 10.0 112.033 -175.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -81.35 -1.98 47.44 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 118.738 -0.649 . . . . 10.0 112.139 -178.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -112.69 -82.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.263 1.825 . . . . 10.0 110.545 -177.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -109.6 25.45 11.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 120.725 1.602 . . . . 10.0 111.974 174.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.1 18.03 66.42 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.602 167.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 m120 62.24 23.54 13.93 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 118.085 0.943 . . . . 10.0 112.224 -171.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.03 -11.91 33.65 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.24 -0.913 . . . . 10.0 113.097 177.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.62 -161.2 46.1 Favored Glycine 0 CA--C 1.523 0.553 0 O-C-N 121.151 -0.968 . . . . 10.0 111.128 170.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.9 t -57.07 129.68 42.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 124.327 1.051 . . . . 10.0 113.135 -167.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.1 mtt85 -65.94 71.97 0.06 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.454 1.902 . . . . 10.0 111.404 175.152 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 51.7 mt -52.05 -33.4 38.68 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.286 1.034 . . . . 10.0 113.733 -177.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.81 147.18 26.96 Favored 'General case' 0 CA--C 1.512 -0.495 0 O-C-N 121.727 -0.608 . . . . 10.0 110.055 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.8 m -140.9 149.85 42.45 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 107.627 -1.249 . . . . 10.0 107.627 -170.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.58 36.42 Favored Glycine 0 CA--C 1.521 0.416 0 N-CA-C 111.397 -0.681 . . . . 10.0 111.397 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 52.9 t -115.23 154.68 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 103.145 -2.909 . . . . 10.0 103.145 171.082 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 8.3 mt -71.45 -90.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 123.51 0.724 . . . . 10.0 109.306 -169.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 108.06 125.61 5.3 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 81.2 mt -61.18 140.47 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 C-N-CA 125.686 1.594 . . . . 10.0 108.721 175.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.36 -38.84 4.57 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-N 119.525 1.057 . . . . 10.0 111.495 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? . . . . . 0 C--O 1.249 1.038 0 CA-C-O 117.308 -1.33 . . . . 10.0 109.899 178.22 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 106.458 -1.682 . . . . 10.0 106.458 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -88.1 -56.17 3.44 Favored 'General case' 0 N--CA 1.458 -0.027 0 O-C-N 124.293 0.995 . . . . 10.0 110.853 -174.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.07 138.79 49.73 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.415 1.086 . . . . 10.0 110.155 -176.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.48 162.64 33.99 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.63 0.772 . . . . 10.0 110.653 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 m -121.04 160.89 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.557 1.143 . . . . 10.0 109.617 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 95.82 2.9 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.556 -1.275 . . . . 10.0 107.556 166.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 2.7 m -82.15 108.48 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 169.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -93.99 137.8 32.8 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 178.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 tttt -156.58 159.03 38.12 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 119.912 1.233 . . . . 10.0 107.87 171.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.89 -47.91 0.04 OUTLIER Glycine 0 C--O 1.229 -0.2 0 C-N-CA 120.684 -0.769 . . . . 10.0 111.481 169.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.52 -46.43 26.59 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 -171.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.72 -69.0 0.52 Allowed Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 113.905 -1.498 . . . . 10.0 110.145 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -56.28 -44.04 50.23 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.311 2.007 . . . . 10.0 110.539 171.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.96 101.2 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.13 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 -175.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -120.81 110.75 16.72 Favored 'General case' 0 N--CA 1.441 -0.921 0 N-CA-C 106.103 -1.814 . . . . 10.0 106.103 173.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.05 140.38 15.48 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.615 -1.794 . . . . 10.0 108.615 171.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.401 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 4.0 mt -141.53 88.84 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 -173.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -101.3 144.13 13.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 C-N-CA 123.576 0.75 . . . . 10.0 110.362 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -121.19 114.26 21.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 126.499 1.92 . . . . 10.0 108.266 168.639 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -98.19 106.4 18.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 mt-10 -107.54 123.86 49.07 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 112.789 0.662 . . . . 10.0 112.789 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -81.62 115.16 20.76 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 104.112 -2.551 . . . . 10.0 104.112 166.286 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -49.7 -54.15 20.46 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 123.954 0.902 . . . . 10.0 109.92 169.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -129.97 -136.6 0.22 Allowed 'General case' 0 N--CA 1.425 -1.684 0 N-CA-C 106.755 -1.572 . . . . 10.0 106.755 -176.097 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.4 t -108.42 -21.8 12.58 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-O 121.145 0.497 . . . . 10.0 110.689 168.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -127.32 6.7 6.39 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.548 1.139 . . . . 10.0 110.743 -176.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.98 169.06 54.72 Favored Glycine 0 CA--C 1.529 0.929 0 N-CA-C 108.862 -1.695 . . . . 10.0 108.862 174.184 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -65.7 132.18 29.94 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.5 1.467 . . . . 10.0 108.497 171.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.9 t -78.07 108.34 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 104.778 -2.305 . . . . 10.0 104.778 169.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -79.62 109.74 14.29 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 105.275 -2.12 . . . . 10.0 105.275 169.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -96.67 97.07 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 106.328 -1.73 . . . . 10.0 106.328 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 20.5 p90 -108.76 164.37 12.44 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.163 0.506 . . . . 10.0 110.595 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.88 178.86 48.45 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 110.391 -1.084 . . . . 10.0 110.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -150.88 106.07 3.34 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.663 -0.866 . . . . 10.0 108.663 178.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 6.2 pt -79.9 173.15 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 119.55 -0.86 . . . . 10.0 109.738 173.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.0 pttt -150.85 153.36 35.22 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 168.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.82 -15.36 40.86 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-O 118.993 -0.893 . . . . 10.0 115.274 169.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.6 mp -75.33 179.66 5.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.943 1.372 . . . . 10.0 110.362 -177.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -91.56 174.95 7.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 166.018 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -62.25 175.09 0.78 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 124.391 1.076 . . . . 10.0 111.435 -173.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.44 -172.74 47.23 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 123.885 0.755 . . . . 10.0 112.588 166.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -75.89 142.78 42.02 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.425 1.49 . . . . 10.0 110.093 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -137.39 143.25 41.84 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 114.753 1.39 . . . . 10.0 114.753 -175.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.04 124.95 0.24 Allowed Glycine 0 C--N 1.343 0.917 0 C-N-CA 127.262 2.363 . . . . 10.0 111.711 162.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.35 103.42 2.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.343 1.572 . . . . 10.0 109.949 170.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.518 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.79 173.98 15.7 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 113.806 1.039 . . . . 10.0 113.806 -176.91 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 m -85.26 151.99 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 CA-C-N 113.006 -1.906 . . . . 10.0 109.385 169.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -132.89 84.9 2.17 Favored 'General case' 0 C--O 1.221 -0.428 0 C-N-CA 124.756 1.222 . . . . 10.0 108.365 174.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 22.5 -83.96 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 128.046 2.539 . . . . 10.0 116.129 -176.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -76.76 179.06 6.31 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-O 121.555 0.693 . . . . 10.0 109.594 -169.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.69 -26.17 10.98 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.508 -1.037 . . . . 10.0 110.508 169.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -37.47 130.24 0.98 Allowed 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 125.502 1.521 . . . . 10.0 110.317 176.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -138.38 18.61 2.75 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 114.944 -1.026 . . . . 10.0 111.398 175.159 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.433 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -56.92 -35.76 69.41 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 118.362 0.528 . . . . 10.0 110.223 -178.197 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.95 -20.25 42.4 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 125.42 1.488 . . . . 10.0 113.515 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.29 99.12 1.04 Allowed Glycine 0 CA--C 1.531 1.065 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 -169.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.9 p 3.94 61.6 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 128.555 2.742 . . . . 10.0 117.508 -169.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.1 m -135.33 -60.03 0.76 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.013 -1.847 . . . . 10.0 106.013 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 41.6 t -50.93 -34.52 28.92 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.736 0.814 . . . . 10.0 110.002 169.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.07 -47.52 0.28 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 126.29 1.836 . . . . 10.0 112.64 168.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 131.63 140.6 4.59 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.082 -0.844 . . . . 10.0 111.998 171.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -73.13 64.68 4.26 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.824 3.016 . . . . 10.0 110.501 169.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 30.3 m170 75.57 -44.31 0.52 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 129.781 3.232 . . . . 10.0 111.05 175.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 31.13 59.4 0.26 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 127.75 2.42 . . . . 10.0 113.252 -174.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -55.34 146.23 43.32 Favored Pre-proline 0 C--N 1.324 -0.519 0 N-CA-C 113.441 0.904 . . . . 10.0 113.441 175.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.84 -47.54 0.34 Allowed 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.762 2.308 . . . . 10.0 110.832 177.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -81.71 56.57 3.07 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.821 0.848 . . . . 10.0 109.879 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -18.35 77.31 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.278 3.031 . . . . 10.0 116.48 -169.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt85 -116.53 -179.86 3.8 Favored 'General case' 0 CA--C 1.509 -0.598 0 C-N-CA 125.499 1.52 . . . . 10.0 109.84 173.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -114.59 89.4 3.09 Favored 'General case' 0 N--CA 1.439 -1.014 0 O-C-N 124.238 0.962 . . . . 10.0 112.755 -171.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.465 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 75.1 t60 12.83 89.19 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.174 2.19 . . . . 10.0 115.084 176.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -106.42 -141.69 10.45 Favored Glycine 0 C--N 1.318 -0.435 0 N-CA-C 108.721 -1.752 . . . . 10.0 108.721 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.417 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -177.67 -168.23 37.0 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 109.896 -1.281 . . . . 10.0 109.896 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -66.72 12.13 0.16 Allowed 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.224 1.95 . . . . 10.0 111.662 169.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.417 ' H ' ' C ' ' B' ' 73' ' ' GLY . 62.7 mmtt -107.55 -18.84 13.74 Favored 'General case' 0 N--CA 1.438 -1.025 0 C-N-CA 124.731 1.213 . . . . 10.0 109.541 173.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -135.54 162.75 31.8 Favored 'General case' 0 C--N 1.348 0.513 0 CA-C-N 118.766 0.712 . . . . 10.0 109.822 -167.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -82.62 -18.76 40.05 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 107.969 -1.123 . . . . 10.0 107.969 173.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -84.27 21.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.219 0 O-C-N 119.908 -1.745 . . . . 10.0 112.854 -169.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.01 138.04 5.4 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.54 1.136 . . . . 10.0 109.196 170.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . 0.465 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 11.6 m170 -70.41 -65.61 0.71 Allowed 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 173.812 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.8 p -174.42 -69.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.117 1.367 . . . . 10.0 108.248 -178.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.84 63.12 0.31 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 109.602 -1.399 . . . . 10.0 109.602 -175.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.8 95.3 5.51 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 26.1 mt -75.33 2.43 11.24 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 120.295 -0.562 . . . . 10.0 110.906 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 89.16 -95.63 2.12 Favored Glycine 0 N--CA 1.437 -1.25 0 N-CA-C 108.174 -1.97 . . . . 10.0 108.174 171.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.3 m-20 -156.17 113.56 3.23 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 118.622 -0.704 . . . . 10.0 109.258 -172.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.3 m -96.72 131.08 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 118.524 0.602 . . . . 10.0 110.215 177.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 14.4 m -87.21 108.64 19.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 127.85 2.46 . . . . 10.0 110.424 -173.218 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.8 133.17 34.34 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.156 0.583 . . . . 10.0 109.752 171.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -61.86 174.05 0.91 Allowed 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.939 0.876 . . . . 10.0 109.591 167.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -51.57 -29.88 18.83 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 125.244 1.418 . . . . 10.0 110.961 173.134 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.01 -9.55 59.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 123.35 0.66 . . . . 10.0 110.501 -175.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.07 7.14 83.98 Favored Glycine 0 C--N 1.339 0.745 0 N-CA-C 111.33 -0.708 . . . . 10.0 111.33 -177.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 47.5 t -90.02 114.18 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 126.144 1.778 . . . . 10.0 106.366 178.301 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.81 118.57 36.5 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 169.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -80.09 121.69 25.85 Favored 'General case' 0 N--CA 1.451 -0.393 0 O-C-N 124.886 1.366 . . . . 10.0 107.547 169.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 99.1 t -105.81 131.07 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 C-N-CA 125.928 1.691 . . . . 10.0 106.625 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.5 p -155.46 74.58 0.9 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 174.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.69 159.01 7.41 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -142.68 133.66 25.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 O-C-N 121.77 -0.581 . . . . 10.0 110.738 173.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -142.88 135.34 27.57 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.976 0.91 . . . . 10.0 109.543 -172.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 3.8 p -93.92 -10.52 33.52 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.17 1.388 . . . . 10.0 111.188 169.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -85.07 -15.75 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.916 0.886 . . . . 10.0 110.28 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -98.15 149.84 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 106.659 -1.608 . . . . 10.0 106.659 169.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.6 m -153.34 141.16 20.11 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 169.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -56.14 -50.04 72.24 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.886 0.874 . . . . 10.0 109.558 -178.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.3 m -136.21 161.93 34.38 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 124.862 1.265 . . . . 10.0 108.688 -178.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.29 -92.01 0.37 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 107.156 -2.378 . . . . 10.0 107.156 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -128.31 -46.09 1.35 Allowed 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 125.083 1.353 . . . . 10.0 109.21 -168.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -75.14 -36.4 61.58 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 107.609 -1.256 . . . . 10.0 107.609 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t 42.43 58.12 3.17 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 126.373 1.869 . . . . 10.0 114.514 166.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 28.1 pt -70.64 -12.16 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 N-CA-C 113.168 0.803 . . . . 10.0 113.168 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.4 mm -57.66 115.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 119.847 1.203 . . . . 10.0 110.208 171.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 102.69 2.6 49.79 Favored Glycine 0 C--N 1.336 0.546 0 C-N-CA 124.496 1.046 . . . . 10.0 111.804 173.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.77 148.8 31.32 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 117.845 0.822 . . . . 10.0 110.605 173.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 31.3 m -80.66 126.69 31.59 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.838 1.255 . . . . 10.0 108.091 168.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -103.48 145.47 29.95 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.305 1.442 . . . . 10.0 107.825 169.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 68.9 t -135.54 143.5 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 4.4 p -110.89 139.8 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 O-C-N 124.535 1.147 . . . . 10.0 108.679 169.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.6 m-70 -117.2 162.41 17.91 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 114.729 1.381 . . . . 10.0 114.729 -174.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -61.72 -51.11 69.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 114.888 -1.051 . . . . 10.0 109.789 178.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -109.65 170.18 8.23 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.51 0.671 . . . . 10.0 111.613 -168.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.21 148.77 45.23 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 114.278 -1.328 . . . . 10.0 109.078 178.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.518 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.7 OUTLIER -74.93 151.14 38.91 Favored 'General case' 0 N--CA 1.443 -0.775 0 N-CA-C 109.226 -0.657 . . . . 10.0 109.226 172.686 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -76.0 -38.35 57.45 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 112.713 -2.039 . . . . 10.0 108.936 172.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 62.8 mt 62.45 64.54 0.93 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 123.97 1.843 . . . . 10.0 108.061 -176.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 76.21 -38.49 1.38 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 112.136 -2.302 . . . . 10.0 116.14 167.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 11.9 mtmt -75.35 5.09 6.1 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.099 1.148 . . . . 10.0 114.099 -167.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.45 -34.93 90.14 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 108.388 -1.885 . . . . 10.0 108.388 166.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.71 25.61 51.77 Favored Glycine 0 C--N 1.341 0.827 0 N-CA-C 111.191 -0.764 . . . . 10.0 111.191 -176.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -108.2 172.88 6.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 170.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -57.1 -45.6 83.27 Favored 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 123.957 0.903 . . . . 10.0 109.277 -177.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 mp0 -52.96 -42.76 65.79 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.456 1.102 . . . . 10.0 109.992 173.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.12 -9.21 20.92 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 117.341 -1.314 . . . . 10.0 113.362 179.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.2 t -108.73 7.57 26.44 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 121.009 1.731 . . . . 10.0 110.627 173.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -127.05 -59.44 1.25 Allowed 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 124.909 1.284 . . . . 10.0 110.94 -170.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.7 p -140.63 22.42 2.33 Favored 'General case' 0 CA--C 1.544 0.736 0 CA-C-N 119.016 0.826 . . . . 10.0 112.008 176.37 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 78.03 -100.23 1.6 Allowed Glycine 0 C--N 1.341 0.857 0 N-CA-C 107.533 -2.227 . . . . 10.0 107.533 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -163.62 42.19 0.1 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 125.696 1.598 . . . . 10.0 107.6 169.075 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.43 -8.98 45.46 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.296 1.038 . . . . 10.0 113.009 -174.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.01 -171.34 55.13 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.669 -1.372 . . . . 10.0 109.669 -173.228 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -53.32 164.11 0.51 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 124.822 1.249 . . . . 10.0 112.004 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.25 114.25 19.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 168.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.425 ' N ' ' CD2' ' B' ' 144' ' ' LEU . 0.7 OUTLIER -84.63 -48.13 9.81 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 108.315 -0.994 . . . . 10.0 108.315 -177.716 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.64 141.17 39.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 116.208 -0.451 . . . . 10.0 110.121 -175.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 m -118.6 145.37 45.46 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 126.491 1.916 . . . . 10.0 108.297 -169.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.19 155.46 26.49 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.859 -1.296 . . . . 10.0 109.859 168.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 18.1 t -116.24 129.51 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 103.946 -2.613 . . . . 10.0 103.946 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.7 mt -65.93 133.65 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 119.188 0.904 . . . . 10.0 111.255 -177.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.04 143.38 16.15 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.338 -1.505 . . . . 10.0 109.338 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -80.94 128.21 38.89 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.346 0 CA-C-N 118.442 1.121 . . . . 10.0 108.622 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.33 -49.23 17.42 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 -175.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.8 tp60 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 117.218 -1.373 . . . . 10.0 109.527 175.195 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 108.466 -0.938 . . . . 10.0 108.466 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t -133.81 -49.09 0.82 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 124.061 0.944 . . . . 10.0 111.439 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -120.93 139.54 53.08 Favored 'General case' 0 C--O 1.235 0.31 0 C-N-CA 125.462 1.505 . . . . 10.0 109.371 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.87 164.12 36.23 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 173.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 m -123.72 179.57 2.7 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 O-C-N 123.469 0.481 . . . . 10.0 109.9 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.89 118.25 8.45 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 126.683 1.993 . . . . 10.0 107.631 164.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 m -97.23 86.81 1.6 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 124.211 1.005 . . . . 10.0 111.007 173.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -79.47 140.15 37.42 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 121.789 -0.569 . . . . 10.0 109.609 -179.007 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.8 mtmt -152.35 163.65 39.06 Favored 'General case' 0 N--CA 1.456 -0.168 0 N-CA-C 106.622 -1.621 . . . . 10.0 106.622 170.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -166.4 -65.71 0.03 OUTLIER Glycine 0 C--N 1.33 0.249 0 C-N-CA 120.606 -0.806 . . . . 10.0 112.249 169.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -74.11 -42.1 60.59 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.08 -66.45 0.5 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 114.885 -1.052 . . . . 10.0 111.959 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.81 -41.24 71.76 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.89 1.727 . . . . 10.0 110.621 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -68.0 109.47 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.331 -1.359 . . . . 10.0 107.331 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -120.46 122.37 40.54 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.161 -2.163 . . . . 10.0 105.161 171.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.94 133.64 11.78 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 109.649 -1.38 . . . . 10.0 109.649 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mt -138.17 86.38 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -173.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.5 mm -95.57 143.33 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 C-N-CA 123.948 0.899 . . . . 10.0 109.111 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 32.7 m-80 -115.54 121.68 43.4 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 126.13 1.772 . . . . 10.0 108.721 168.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -102.28 98.11 8.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 125.862 1.665 . . . . 10.0 107.025 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -117.89 121.31 40.39 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.072 0.851 . . . . 10.0 113.109 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -94.05 105.49 17.49 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 125.867 1.667 . . . . 10.0 107.831 168.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.47 -42.76 61.83 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.795 0.838 . . . . 10.0 110.174 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -135.98 158.53 44.17 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 102.193 -3.262 . . . . 10.0 102.193 165.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 t -77.32 -3.87 42.19 Favored 'General case' 0 C--O 1.226 -0.135 0 CA-C-N 119.37 0.986 . . . . 10.0 109.817 173.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m120 -85.02 -24.6 28.12 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 125.182 1.393 . . . . 10.0 109.361 168.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.62 156.84 45.06 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 109.43 -1.468 . . . . 10.0 109.43 174.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -64.55 153.16 78.71 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 N-CA-C 108.006 -1.575 . . . . 10.0 108.006 169.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.8 p -79.14 121.14 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 N-CA-C 106.69 -1.596 . . . . 10.0 106.69 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -88.79 113.73 24.66 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.16 -1.793 . . . . 10.0 106.16 168.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 m -92.31 95.97 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.824 0 N-CA-C 105.555 -2.017 . . . . 10.0 105.555 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.7 p90 -106.97 161.8 14.4 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.178 0.513 . . . . 10.0 110.538 171.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.16 169.29 39.48 Favored Glycine 0 N--CA 1.438 -1.187 0 C-N-CA 120.055 -1.069 . . . . 10.0 110.63 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.0 t -139.37 95.75 2.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.992 -1.485 . . . . 10.0 106.992 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.4 pt -77.07 166.33 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.124 -1.065 . . . . 10.0 108.124 169.093 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -149.29 146.53 27.6 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 106.58 -1.637 . . . . 10.0 106.58 166.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.53 -4.93 24.73 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 123.921 0.772 . . . . 10.0 113.567 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -73.23 177.93 4.8 Favored 'General case' 0 N--CA 1.444 -0.752 0 CA-C-N 118.117 0.959 . . . . 10.0 109.245 173.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 7.9 t -90.39 172.29 8.85 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.632 -0.877 . . . . 10.0 108.632 166.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.91 169.88 2.37 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.43 1.092 . . . . 10.0 110.837 -173.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.73 -178.92 41.26 Favored Glycine 0 N--CA 1.448 -0.503 0 O-C-N 121.428 -0.795 . . . . 10.0 112.843 167.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.6 mp -69.4 143.83 53.54 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.612 1.165 . . . . 10.0 109.779 176.04 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -142.61 139.49 31.31 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 123.381 0.672 . . . . 10.0 112.662 -176.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -26.84 117.94 0.04 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.106 2.289 . . . . 10.0 113.036 164.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.03 106.23 4.56 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 120.2 2.0 . . . . 10.0 110.095 170.03 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.48 172.06 15.09 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-O 121.174 0.512 . . . . 10.0 112.075 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.43 -44.57 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 C-N-CA 126.249 1.819 . . . . 10.0 113.429 -168.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 63.64 144.45 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 126.887 2.075 . . . . 10.0 112.074 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -67.0 -47.7 70.68 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.694 -0.854 . . . . 10.0 108.694 177.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -74.88 129.98 38.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 107.788 -1.19 . . . . 10.0 107.788 -169.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -88.75 -28.43 21.47 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 126.572 2.034 . . . . 10.0 110.695 175.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.59 176.43 0.65 Allowed 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 125.144 1.378 . . . . 10.0 112.819 -176.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -146.34 -64.41 0.3 Allowed 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.078 -1.419 . . . . 10.0 110.021 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER 46.54 -57.17 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.652 1 C-N-CA 133.211 4.604 . . . . 10.0 115.134 179.546 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . 0.293 . . -69.66 -37.05 76.57 Favored 'General case' 0 N--CA 1.437 -1.081 0 C-N-CA 127.763 2.425 . . . . 10.0 108.216 169.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.29 -143.76 14.96 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.233 -2.747 . . . . 10.0 106.233 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.3 t -78.8 39.35 0.35 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 122.178 0.99 . . . . 10.0 112.066 -172.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.4 m -111.27 -49.33 3.02 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 127.826 2.451 . . . . 10.0 106.811 -169.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.402 ' C ' ' H ' ' A' ' 61' ' ' GLY . 16.1 m -91.0 16.92 8.64 Favored 'General case' 0 N--CA 1.435 -1.224 0 C-N-CA 126.488 1.915 . . . . 10.0 110.113 -171.292 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.69 61.44 1.37 Allowed 'General case' 0 C--O 1.236 0.379 0 C-N-CA 124.101 0.96 . . . . 10.0 109.365 169.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.402 ' H ' ' C ' ' A' ' 59' ' ' SER . . . 0.26 103.92 0.01 OUTLIER Glycine 0 C--N 1.335 0.488 1 C-N-CA 131.62 4.438 . . . . 10.0 111.087 166.705 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -73.04 73.5 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 122.752 2.301 . . . . 10.0 113.129 -168.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 11.1 m170 71.82 36.2 1.24 Allowed 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 129.592 3.157 . . . . 10.0 110.749 170.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -73.62 60.02 0.66 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.451 1.1 . . . . 10.0 110.709 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -75.03 156.96 85.85 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 123.673 0.789 . . . . 10.0 110.181 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -65.43 -65.36 0.05 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.441 2.094 . . . . 10.0 111.5 -175.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.99 66.81 1.22 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.661 0.743 . . . . 10.0 109.975 172.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 113.74 3.3 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.401 -0.812 . . . . 10.0 109.557 178.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.6 mtt180 -116.8 -87.91 0.6 Allowed 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 103.298 -2.852 . . . . 10.0 103.298 -173.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtm -145.72 160.12 42.18 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 122.627 1.203 . . . . 10.0 108.702 167.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 42.7 t60 -62.2 127.27 30.59 Favored 'General case' 0 N--CA 1.439 -1.022 0 N-CA-C 105.364 -2.088 . . . . 10.0 105.364 163.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.89 -138.26 3.27 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 107.79 -2.124 . . . . 10.0 107.79 177.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.469 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.42 -158.39 22.26 Favored Glycine 0 N--CA 1.449 -0.444 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 169.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -65.98 10.58 0.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 CA-C-N 119.869 1.835 . . . . 10.0 110.945 168.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.469 ' H ' ' C ' ' A' ' 73' ' ' GLY . 1.9 mmmp? -108.68 -15.83 14.32 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.621 1.168 . . . . 10.0 109.257 177.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.419 ' OD2' ' NZ ' ' A' ' 128' ' ' LYS . 2.3 m-20 -141.32 132.13 25.85 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.617 -1.623 . . . . 10.0 106.617 -168.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -73.46 -22.58 60.14 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 -171.372 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -79.57 1.82 24.55 Favored 'General case' 0 N--CA 1.433 -1.313 0 C-N-CA 124.737 1.215 . . . . 10.0 111.579 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -42.15 142.97 0.65 Allowed 'General case' 0 C--N 1.346 0.445 0 C-N-CA 124.956 1.302 . . . . 10.0 112.436 177.305 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -59.49 -62.28 2.0 Allowed 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 121.238 0.542 . . . . 10.0 111.132 -173.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.8 p -167.37 -64.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 179.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -122.04 60.26 0.56 Allowed Glycine 0 CA--C 1.522 0.503 0 N-CA-C 109.637 -1.385 . . . . 10.0 109.637 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -92.37 90.97 7.45 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.672 -2.344 . . . . 10.0 104.672 168.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 40.4 mt -70.07 -31.49 69.11 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 173.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.1 -102.73 2.27 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 108.536 -1.825 . . . . 10.0 108.536 168.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 52.4 m-20 -124.51 124.22 41.81 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.686 1.194 . . . . 10.0 110.631 -168.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 16.2 m -111.1 137.71 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 108.057 -1.09 . . . . 10.0 108.057 168.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 54.1 m -92.22 120.18 32.55 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.897 1.679 . . . . 10.0 108.667 -175.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.62 133.2 44.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 123.901 0.88 . . . . 10.0 110.508 176.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -59.38 170.97 0.87 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 123.589 0.755 . . . . 10.0 109.834 167.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.6 pttp -47.37 -34.89 7.51 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.787 1.635 . . . . 10.0 110.403 171.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -79.48 -0.74 34.43 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 124.683 1.193 . . . . 10.0 111.438 -174.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.45 8.55 87.69 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 110.671 -0.972 . . . . 10.0 110.671 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.5 t -88.0 106.92 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 125.95 1.7 . . . . 10.0 106.614 -178.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.9 117.84 35.28 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 168.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.26 114.37 18.14 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 126.038 1.735 . . . . 10.0 108.654 172.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.2 t -107.24 133.43 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 178.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 94.9 p -156.62 59.21 0.55 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.264 0.625 . . . . 10.0 110.088 172.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.6 mt -96.43 157.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -174.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -133.06 143.0 49.06 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.805 0.729 . . . . 10.0 111.057 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -127.09 124.14 38.52 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.274 1.43 . . . . 10.0 108.861 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 p -89.99 -8.89 50.57 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.352 1.461 . . . . 10.0 111.147 169.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.4 p -95.91 -39.23 9.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 124.331 1.052 . . . . 10.0 109.929 -174.081 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -97.03 155.89 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 125.347 1.459 . . . . 10.0 108.514 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.6 m -157.63 156.39 31.74 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 108.281 -1.007 . . . . 10.0 108.281 -173.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -74.53 -23.04 58.75 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 120.919 0.39 . . . . 10.0 110.478 174.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.8 m -150.47 142.57 24.05 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.051 -1.462 . . . . 10.0 107.051 -177.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.73 -67.2 0.29 Allowed Glycine 0 C--N 1.334 0.427 0 N-CA-C 109.014 -1.634 . . . . 10.0 109.014 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -163.37 -51.36 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 126.398 1.879 . . . . 10.0 107.287 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.19 -28.29 59.97 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 114.755 -1.111 . . . . 10.0 110.241 -169.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.1 t 22.86 81.47 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 129.028 2.931 . . . . 10.0 111.814 172.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.8 pt -75.93 39.23 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 112.213 0.449 . . . . 10.0 112.213 -173.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -83.39 -48.61 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 124.899 1.28 . . . . 10.0 111.268 -171.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.79 46.02 1.32 Allowed Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.816 -0.914 . . . . 10.0 110.816 -175.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -111.13 162.02 15.35 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 125.201 1.4 . . . . 10.0 108.881 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -110.22 102.56 11.23 Favored 'General case' 0 C--N 1.347 0.476 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 179.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.82 134.98 40.24 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.514 -0.921 . . . . 10.0 108.514 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 61.9 t -124.11 131.74 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 O-C-N 123.911 0.757 . . . . 10.0 110.407 -172.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.8 t -98.19 123.37 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 128.416 2.686 . . . . 10.0 107.639 168.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -109.94 157.54 19.15 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 115.868 1.803 . . . . 10.0 115.868 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -41.34 -65.13 0.47 Allowed 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 129.767 3.227 . . . . 10.0 111.73 171.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.1 mttp -112.28 175.41 5.44 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.861 0.865 . . . . 10.0 111.74 -172.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.61 147.91 37.29 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 114.005 -1.452 . . . . 10.0 109.72 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -78.77 142.75 36.73 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 123.62 0.768 . . . . 10.0 110.659 171.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -78.53 -13.59 59.76 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.512 -1.222 . . . . 10.0 110.563 167.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 76.5 mt 61.62 42.86 10.56 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 125.474 1.51 . . . . 10.0 110.949 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.14 -5.94 56.12 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 124.262 0.934 . . . . 10.0 112.611 173.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . 0.419 ' NZ ' ' OD2' ' A' ' 76' ' ' ASP . 11.9 mttt -110.65 35.79 3.35 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.752 0.821 . . . . 10.0 110.628 -167.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -84.09 -31.18 26.51 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.861 2.172 . . . . 10.0 111.901 178.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.61 48.41 84.7 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -176.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -150.29 165.62 32.46 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.781 2.432 . . . . 10.0 106.289 -175.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -58.41 -47.65 83.23 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-O 121.588 0.709 . . . . 10.0 109.139 174.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -54.02 -30.92 49.54 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.979 1.312 . . . . 10.0 112.695 175.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.0 t -47.22 -47.46 24.43 Favored 'General case' 0 C--O 1.223 -0.307 0 C-N-CA 124.395 1.078 . . . . 10.0 108.412 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -88.24 10.19 20.46 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 118.751 -0.642 . . . . 10.0 112.55 -173.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -122.38 -94.39 0.5 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.455 1.902 . . . . 10.0 109.875 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.85 25.04 9.08 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 121.353 1.888 . . . . 10.0 110.158 177.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.07 -91.32 0.44 Allowed Glycine 0 C--N 1.339 0.743 0 N-CA-C 108.886 -1.686 . . . . 10.0 108.886 177.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 m-80 -162.27 35.97 0.12 Allowed 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 126.428 1.891 . . . . 10.0 108.246 172.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.55 -9.92 55.95 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 121.219 -0.926 . . . . 10.0 112.116 -173.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.96 -167.92 53.82 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.862 -0.895 . . . . 10.0 110.862 174.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 58.4 p -59.12 139.34 56.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 122.308 1.051 . . . . 10.0 112.277 -168.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 40.2 mtt85 -66.76 74.84 0.11 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.526 1.131 . . . . 10.0 110.838 173.173 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.3 mt -47.31 -38.7 13.22 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 123.506 0.722 . . . . 10.0 112.09 176.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.8 157.17 40.38 Favored 'General case' 0 CA--C 1.514 -0.43 0 O-C-N 121.827 -0.546 . . . . 10.0 111.121 176.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -159.01 167.32 29.63 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.458 -0.337 . . . . 10.0 110.218 171.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.63 165.42 36.23 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 109.331 -1.508 . . . . 10.0 109.331 -176.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 92.9 t -105.53 146.95 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 103.018 -2.956 . . . . 10.0 103.018 -175.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . 0.3 5.0 mt -68.36 -86.88 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 CA-C-O 121.469 0.652 . . . . 10.0 112.46 -168.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 93.49 135.44 7.5 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.775 1.179 . . . . 10.0 112.699 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.1 mt -70.46 142.15 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 125.057 1.343 . . . . 10.0 109.357 -176.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.77 -45.22 2.29 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.077 0.951 . . . . 10.0 111.383 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.537 1.935 . . . . 10.0 113.266 -178.505 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 107.166 -1.42 . . . . 10.0 107.166 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -78.14 -50.44 11.99 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-O 122.299 1.047 . . . . 10.0 109.743 171.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -156.04 153.97 30.29 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.692 -1.14 . . . . 10.0 109.76 -169.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.4 151.47 48.58 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.074 0.949 . . . . 10.0 108.629 169.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.6 t -109.56 159.31 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 125.044 1.338 . . . . 10.0 110.099 174.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.99 97.17 3.01 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 124.31 1.044 . . . . 10.0 108.562 166.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.1 m -82.29 126.36 39.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -106.11 149.74 26.46 Favored 'General case' 0 CA--C 1.529 0.136 0 CA-C-O 117.914 -1.041 . . . . 10.0 108.351 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 47.0 tttt -165.13 161.73 19.72 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 120.083 1.31 . . . . 10.0 108.679 170.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.42 -50.26 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 116.204 -0.453 . . . . 10.0 112.208 169.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -77.62 -46.34 22.41 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 -170.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 131.79 -61.7 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.928 -1.487 . . . . 10.0 111.303 -175.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -63.02 -39.68 38.6 Favored 'Trans proline' 0 N--CA 1.454 -0.811 0 C-N-CA 122.586 2.191 . . . . 10.0 110.79 169.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.97 115.34 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.114 -1.069 . . . . 10.0 108.114 -178.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.43 140.05 27.33 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-O 121.014 0.435 . . . . 10.0 110.091 165.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.07 157.28 15.43 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 125.256 1.408 . . . . 10.0 112.388 178.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -147.19 85.0 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 N-CA-C 106.29 -1.745 . . . . 10.0 106.29 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.78 145.09 9.38 Favored 'Isoleucine or valine' 0 C--O 1.231 0.093 0 C-N-CA 124.062 0.945 . . . . 10.0 110.778 178.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -123.19 111.74 16.85 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 129.854 3.261 . . . . 10.0 106.928 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -101.09 103.22 14.3 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 79.0 mt-10 -96.38 137.1 35.95 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.139 0.881 . . . . 10.0 110.843 170.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -106.15 100.95 10.47 Favored 'General case' 0 CA--C 1.53 0.186 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 24.0 tttp -57.83 -50.56 72.88 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 125.959 1.704 . . . . 10.0 110.297 -176.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -145.17 169.63 17.81 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 104.167 -2.531 . . . . 10.0 104.167 179.068 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.4 t -75.26 -13.51 60.44 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 109.162 -0.681 . . . . 10.0 109.162 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -124.47 27.03 7.1 Favored 'General case' 0 N--CA 1.443 -0.823 0 C-N-CA 123.573 0.749 . . . . 10.0 109.904 169.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.24 151.69 23.77 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 172.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -62.83 130.15 28.47 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 N-CA-C 107.966 -1.59 . . . . 10.0 107.966 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.4 t -79.99 99.73 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 105.98 -1.859 . . . . 10.0 105.98 174.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -77.04 119.34 20.63 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 104.67 -2.344 . . . . 10.0 104.67 167.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -105.16 114.15 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 106.323 -1.732 . . . . 10.0 106.323 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -135.8 172.6 12.78 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 121.166 0.508 . . . . 10.0 111.831 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.59 -149.15 21.21 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 106.334 -2.706 . . . . 10.0 106.334 169.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.0 m -155.53 159.43 39.71 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 119.079 -1.048 . . . . 10.0 111.25 177.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pt -117.28 147.1 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.772 -1.104 . . . . 10.0 108.565 166.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -126.07 138.72 53.73 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 124.38 1.05 . . . . 10.0 109.226 168.539 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.27 -8.05 10.47 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.972 1.272 . . . . 10.0 113.29 175.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -62.44 178.55 0.4 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.288 1.044 . . . . 10.0 112.237 177.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.2 t -115.0 156.72 24.57 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 106.897 -1.52 . . . . 10.0 106.897 167.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -46.95 143.95 2.71 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.583 1.553 . . . . 10.0 112.902 -169.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.24 -178.42 31.71 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 124.222 0.915 . . . . 10.0 111.887 171.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 10.6 mt -64.0 150.48 45.15 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.657 1.583 . . . . 10.0 112.71 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -146.11 148.57 32.75 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.681 1.192 . . . . 10.0 112.764 177.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -25.7 124.31 0.04 OUTLIER Glycine 0 C--N 1.341 0.852 0 C-N-CA 126.668 2.08 . . . . 10.0 112.616 166.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -148.91 98.9 2.91 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 119.888 1.844 . . . . 10.0 111.46 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.52 172.59 14.74 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 122.807 0.443 . . . . 10.0 111.151 -178.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.3 m -105.43 -24.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 115.826 1.787 . . . . 10.0 115.826 -167.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 62.39 175.22 0.14 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 121.529 0.68 . . . . 10.0 112.568 177.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -81.09 -56.32 4.17 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.985 -0.552 . . . . 10.0 110.195 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -87.25 156.14 19.78 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.161 0.437 . . . . 10.0 110.158 -172.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.01 -19.26 22.23 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.036 -1.226 . . . . 10.0 110.036 169.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -63.38 160.43 16.11 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 122.556 1.17 . . . . 10.0 111.688 -176.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -153.79 16.66 0.51 Allowed 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.242 -0.89 . . . . 10.0 113.001 -171.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -45.53 -40.86 9.08 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 127.141 2.177 . . . . 10.0 112.707 -177.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.1 -18.56 57.88 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 111.915 0.339 . . . . 10.0 111.915 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.88 -66.2 0.56 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 109.474 -1.45 . . . . 10.0 109.474 -179.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 48.2 t -157.84 18.31 0.25 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.645 1.178 . . . . 10.0 110.584 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -98.87 -45.3 6.04 Favored 'General case' 0 N--CA 1.44 -0.931 0 O-C-N 120.184 -1.572 . . . . 10.0 108.695 -177.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -49.11 -39.71 29.44 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.438 1.495 . . . . 10.0 111.792 -169.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.46 -42.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 129.027 2.931 . . . . 10.0 114.205 168.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.33 163.24 28.43 Favored Glycine 0 N--CA 1.439 -1.113 0 N-CA-C 107.87 -2.092 . . . . 10.0 107.87 172.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -74.42 -169.29 0.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.547 0 N-CA-C 106.734 -2.064 . . . . 10.0 106.734 167.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.425 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 31.7 m170 -82.12 58.41 3.96 Favored 'General case' 0 CA--C 1.539 0.52 0 O-C-N 120.109 -1.62 . . . . 10.0 110.314 -174.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -76.51 59.66 1.51 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 123.06 1.41 . . . . 10.0 111.733 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -60.35 153.67 57.74 Favored Pre-proline 0 C--N 1.324 -0.516 0 C-N-CA 126.44 1.896 . . . . 10.0 110.965 169.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.77 -43.95 0.55 Allowed 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.686 2.257 . . . . 10.0 111.377 175.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 tt -79.3 62.77 3.75 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.175 0.99 . . . . 10.0 109.743 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 10.1 t -39.36 107.61 0.07 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.142 1.777 . . . . 10.0 113.368 -169.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.4 mtt180 -136.5 -174.07 3.59 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.422 1.489 . . . . 10.0 109.708 175.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.5 mmpt? -117.64 57.88 0.81 Allowed 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 113.975 1.102 . . . . 10.0 113.975 -167.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.402 ' CD2' ' CA ' ' B' ' 138' ' ' GLY . 63.5 t60 38.03 94.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 116.209 1.929 . . . . 10.0 116.209 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.6 -164.64 12.51 Favored Glycine 0 C--N 1.315 -0.61 0 N-CA-C 108.524 -1.83 . . . . 10.0 108.524 168.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.408 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -139.53 -162.4 9.1 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.143 -0.783 . . . . 10.0 111.143 171.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -69.81 10.32 0.51 Allowed 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.324 2.016 . . . . 10.0 111.569 176.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.408 ' H ' ' C ' ' B' ' 73' ' ' GLY . 84.3 mttt -101.28 -19.74 15.53 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.657 0.783 . . . . 10.0 109.174 170.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -125.67 -178.64 4.33 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 107.945 -1.132 . . . . 10.0 107.945 -167.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . 0.273 0.6 OUTLIER -110.43 -1.6 17.0 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 112.752 0.649 . . . . 10.0 112.752 167.918 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -77.61 -1.82 32.72 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 121.815 -0.553 . . . . 10.0 109.945 175.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 21.0 ptt-85 -42.25 124.43 2.8 Favored 'General case' 0 C--N 1.344 0.335 0 C-N-CA 124.965 1.306 . . . . 10.0 109.148 169.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -74.67 -54.3 7.67 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.574 -0.528 . . . . 10.0 109.574 -172.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 6.6 p -165.02 -66.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.537 0.735 . . . . 10.0 109.157 176.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -118.7 77.01 0.3 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.663 -2.175 . . . . 10.0 107.663 178.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -119.54 97.97 5.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.99 -2.226 . . . . 10.0 104.99 178.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -83.13 23.06 0.9 Allowed 'General case' 0 CA--C 1.526 0.048 0 CA-C-O 120.962 0.41 . . . . 10.0 110.553 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.4 -109.93 2.91 Favored Glycine 0 N--CA 1.432 -1.615 0 N-CA-C 105.653 -2.979 . . . . 10.0 105.653 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -158.93 139.12 12.2 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.857 -1.164 . . . . 10.0 107.857 -178.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.3 m -108.46 130.49 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 123.535 0.734 . . . . 10.0 111.867 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -80.95 101.52 9.54 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.973 2.909 . . . . 10.0 111.488 -170.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.99 134.34 35.36 Favored 'General case' 0 N--CA 1.451 -0.398 0 O-C-N 121.866 -0.521 . . . . 10.0 109.733 170.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.405 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 16.8 t70 -61.9 167.57 3.68 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 122.033 0.921 . . . . 10.0 108.75 167.09 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.405 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 30.6 ttpt -49.87 -31.13 11.34 Favored 'General case' 0 N--CA 1.432 -1.358 0 C-N-CA 125.934 1.694 . . . . 10.0 111.964 169.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -77.03 -10.29 59.27 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.188 0.449 . . . . 10.0 111.258 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.2 12.11 66.03 Favored Glycine 0 C--N 1.34 0.797 0 O-C-N 120.993 -1.067 . . . . 10.0 110.798 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -92.6 111.48 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 C-N-CA 126.66 1.984 . . . . 10.0 106.311 176.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -108.53 121.6 45.31 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -82.64 123.06 28.91 Favored 'General case' 0 N--CA 1.434 -1.253 0 C-N-CA 126.893 2.077 . . . . 10.0 107.989 170.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.94 131.85 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.935 -1.505 . . . . 10.0 106.935 175.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.85 75.8 0.71 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.991 0.916 . . . . 10.0 109.583 169.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.9 164.31 3.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.589 -1.634 . . . . 10.0 106.589 179.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -137.49 138.9 40.19 Favored 'General case' 0 N--CA 1.451 -0.383 0 O-C-N 121.459 -0.776 . . . . 10.0 110.868 171.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.99 145.53 49.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 124.454 1.096 . . . . 10.0 108.558 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.2 p -120.1 16.71 12.44 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.12 1.368 . . . . 10.0 110.7 172.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -107.65 -49.23 7.93 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 124.362 1.065 . . . . 10.0 109.634 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.329 0.7 OUTLIER -67.82 170.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-O 121.206 0.527 . . . . 10.0 112.094 171.544 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 52.1 p -151.91 140.25 20.46 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.151 -1.055 . . . . 10.0 108.151 174.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.4 pp -85.85 -24.68 26.63 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 108.27 -1.011 . . . . 10.0 108.27 167.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m -148.54 120.9 8.44 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 166.292 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.33 -72.1 0.08 OUTLIER Glycine 0 C--O 1.227 -0.292 0 N-CA-C 108.715 -1.754 . . . . 10.0 108.715 -173.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -152.17 -53.0 0.12 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 113.641 -1.279 . . . . 10.0 108.003 176.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -75.71 -34.7 60.39 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-N 114.517 -1.22 . . . . 10.0 109.065 -170.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t 43.09 71.74 0.21 Allowed 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 125.709 1.604 . . . . 10.0 111.981 171.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 41.1 pt -66.4 1.53 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 113.619 0.97 . . . . 10.0 113.619 -178.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.8 mm -41.42 -40.88 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.302 0 C-N-CA 125.113 1.365 . . . . 10.0 113.783 177.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -105.5 25.59 24.1 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.82 1.2 . . . . 10.0 113.198 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.58 175.94 6.03 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.44 1.096 . . . . 10.0 110.439 174.31 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -123.71 107.98 12.04 Favored 'General case' 0 C--N 1.344 0.355 0 C-N-CA 124.554 1.142 . . . . 10.0 111.168 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -61.94 130.76 47.15 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 167.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.03 131.21 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 N-CA-C 107.504 -1.295 . . . . 10.0 107.504 173.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -100.72 126.35 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.4 m170 -104.26 157.0 17.44 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 115.248 1.573 . . . . 10.0 115.248 -174.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -47.48 -57.06 5.82 Favored 'General case' 0 N--CA 1.447 -0.614 0 C-N-CA 127.784 2.434 . . . . 10.0 110.657 177.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -107.53 170.84 7.73 Favored 'General case' 0 N--CA 1.463 0.199 0 C-N-CA 124.493 1.117 . . . . 10.0 112.478 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.28 149.93 38.67 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.558 1.543 . . . . 10.0 109.804 171.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.01 144.85 38.39 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 112.924 0.713 . . . . 10.0 112.924 177.101 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -78.32 -23.87 46.86 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.755 1.622 . . . . 10.0 109.259 167.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 48.9 mt 54.76 58.28 4.97 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 122.611 1.196 . . . . 10.0 109.693 -174.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.96 -47.31 3.82 Favored Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 113.996 -1.456 . . . . 10.0 112.505 167.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.91 42.39 0.38 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 118.026 0.913 . . . . 10.0 112.649 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.2 -22.82 26.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 127.122 2.296 . . . . 10.0 109.442 168.096 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.78 32.95 83.57 Favored Glycine 0 C--N 1.337 0.6 0 N-CA-C 110.975 -0.85 . . . . 10.0 110.975 176.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -135.67 162.94 31.32 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.132 -1.062 . . . . 10.0 108.132 172.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -45.87 -48.77 15.95 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 124.409 1.083 . . . . 10.0 110.02 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -70.46 -33.6 71.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.671 -0.643 . . . . 10.0 112.143 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.9 p -53.3 -44.26 68.2 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 119.374 0.988 . . . . 10.0 110.331 174.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.6 t -80.71 -19.18 45.66 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 112.852 0.686 . . . . 10.0 112.852 -173.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -101.41 -45.37 5.34 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 125.304 1.442 . . . . 10.0 112.666 -172.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.425 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 30.8 p -132.18 -1.97 3.59 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 119.211 0.914 . . . . 10.0 113.128 174.278 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . 0.402 ' CA ' ' CD2' ' B' ' 71' ' ' HIS . . . 88.89 22.97 36.95 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-O 118.601 -1.11 . . . . 10.0 112.241 -176.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 60.48 15.65 5.75 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 119.567 1.683 . . . . 10.0 112.056 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.98 3.13 5.7 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.103 -0.998 . . . . 10.0 112.438 -170.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.94 -168.55 54.76 Favored Glycine 0 N--CA 1.444 -0.813 0 N-CA-C 110.586 -1.006 . . . . 10.0 110.586 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.4 t -58.04 143.86 41.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 115.05 -0.575 . . . . 10.0 111.755 -169.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.9 mtm-85 -64.02 78.86 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.042 0.937 . . . . 10.0 110.02 168.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 5.7 tp -39.87 -55.37 2.0 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.234 1.813 . . . . 10.0 110.847 176.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.81 149.67 29.27 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.153 -0.684 . . . . 10.0 109.153 -173.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 12.6 m -128.48 153.78 46.79 Favored 'General case' 0 CA--C 1.522 -0.132 0 C-N-CA 125.477 1.511 . . . . 10.0 109.101 -173.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -133.57 169.95 22.56 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 108.964 -1.654 . . . . 10.0 108.964 167.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 17.2 t -117.83 132.44 67.64 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 169.363 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 71.4 mt -69.24 157.99 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.382 -0.97 . . . . 10.0 108.382 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.88 156.16 27.26 Favored Glycine 0 CA--C 1.528 0.891 0 O-C-N 121.249 -0.907 . . . . 10.0 111.731 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.7 mp -55.52 133.38 19.3 Favored 'Isoleucine or valine' 0 C--N 1.341 0.22 0 C-N-CA 125.618 1.567 . . . . 10.0 109.765 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -120.21 165.6 14.59 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.38 -1.341 . . . . 10.0 107.38 166.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 . . . . . 0 C--O 1.25 1.084 0 C-N-CA 125.939 1.695 . . . . 10.0 106.834 169.831 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 106.205 -1.776 . . . . 10.0 106.205 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.7 t -69.4 -14.34 62.85 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.496 1.044 . . . . 10.0 109.171 168.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.67 155.12 50.29 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 125.406 1.483 . . . . 10.0 107.481 168.253 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.04 158.24 44.03 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 125.483 1.513 . . . . 10.0 106.952 169.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -122.05 152.61 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 C-N-CA 123.529 0.732 . . . . 10.0 110.106 -178.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.8 97.23 4.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 125.099 1.359 . . . . 10.0 108.502 168.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -79.64 109.25 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.13 -1.433 . . . . 10.0 107.13 167.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.3 mt -90.07 139.85 30.22 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 18.9 tttt -162.18 161.09 27.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 120.01 1.277 . . . . 10.0 108.388 170.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.42 -53.32 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.206 0 N-CA-C 111.66 -0.576 . . . . 10.0 111.66 170.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -75.72 -47.31 26.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 106.713 -1.588 . . . . 10.0 106.713 -171.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.53 -61.26 0.66 Allowed Glycine 0 CA--C 1.53 0.993 0 CA-C-N 113.822 -1.536 . . . . 10.0 111.807 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.14 -34.92 67.27 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 122.63 2.22 . . . . 10.0 111.23 172.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.0 t -75.58 110.1 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.176 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 176.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.21 129.69 38.08 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 123.448 0.699 . . . . 10.0 109.326 166.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -105.75 147.11 16.18 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 125.595 1.569 . . . . 10.0 109.559 171.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.9 mt -140.82 59.68 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 -176.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm -78.95 140.27 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 N-CA-C 109.095 -0.705 . . . . 10.0 109.095 -172.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -116.61 110.52 18.63 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 126.939 2.096 . . . . 10.0 107.271 178.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -94.45 109.73 21.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 176.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.54 158.64 16.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.572 0.624 . . . . 10.0 112.127 170.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -155.61 83.23 1.04 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.818 2.047 . . . . 10.0 106.646 166.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 6.5 mmtp -52.13 -55.72 19.11 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 125.294 1.437 . . . . 10.0 110.503 -173.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -123.62 167.22 14.24 Favored 'General case' 0 N--CA 1.434 -1.264 0 N-CA-C 103.992 -2.595 . . . . 10.0 103.992 169.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -71.73 -14.58 62.06 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.885 -0.598 . . . . 10.0 109.917 173.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -79.8 -17.03 54.34 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 123.304 0.642 . . . . 10.0 109.314 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.67 140.98 23.17 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 178.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -62.06 153.35 69.74 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.118 1.879 . . . . 10.0 107.543 169.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -76.81 89.82 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.167 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 170.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.6 tmtp? -85.45 114.16 22.28 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 106.075 -1.824 . . . . 10.0 106.075 170.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.2 m -110.31 125.21 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 107.173 -1.417 . . . . 10.0 107.173 -174.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.7 p90 -134.46 164.78 26.69 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.118 0.485 . . . . 10.0 111.878 173.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.2 -148.67 19.52 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 107.827 -2.109 . . . . 10.0 107.827 170.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.5 t -155.31 150.77 27.22 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 116.973 0.387 . . . . 10.0 110.143 -176.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.49 111.51 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.268 0 C-N-CA 125.836 1.654 . . . . 10.0 106.611 165.551 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -95.93 137.33 35.15 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 108.073 -1.084 . . . . 10.0 108.073 170.151 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.78 -0.94 9.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 125.137 1.351 . . . . 10.0 112.585 173.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.04 174.96 7.89 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 118.453 1.126 . . . . 10.0 109.285 176.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -100.58 156.89 17.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.077 -1.823 . . . . 10.0 106.077 165.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -55.03 151.59 8.78 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.373 0.669 . . . . 10.0 111.834 -169.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.54 -178.93 26.56 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.115 0.864 . . . . 10.0 112.081 175.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -67.23 151.08 48.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.899 1.28 . . . . 10.0 111.355 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -151.02 153.77 35.77 Favored 'General case' 0 C--N 1.342 0.265 0 N-CA-C 113.577 0.955 . . . . 10.0 113.577 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.23 125.93 1.57 Allowed Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.693 2.568 . . . . 10.0 113.057 165.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -155.2 114.13 3.58 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.525 -1.287 . . . . 10.0 107.525 165.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 170.44 18.46 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.843 0.83 . . . . 10.0 111.582 174.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -115.33 127.28 72.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 104.251 -2.5 . . . . 10.0 104.251 168.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -167.52 175.16 7.31 Favored 'General case' 0 N--CA 1.451 -0.38 0 O-C-N 121.908 -0.495 . . . . 10.0 110.891 -168.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . 0.28 14.0 pt-20 50.3 -157.51 0.09 Allowed 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 126.279 2.237 . . . . 10.0 113.281 167.116 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.8 m-30 -82.64 -167.37 1.59 Allowed 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 109.247 -0.649 . . . . 10.0 109.247 177.086 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.37 -0.35 24.99 Favored Glycine 0 CA--C 1.536 1.347 0 C-N-CA 126.256 1.884 . . . . 10.0 112.975 174.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -75.0 83.0 2.24 Favored 'General case' 0 C--N 1.342 0.258 0 CA-C-N 119.737 1.768 . . . . 10.0 110.637 -176.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -79.51 8.41 6.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-N 115.282 -0.872 . . . . 10.0 113.077 177.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -42.53 -48.07 5.25 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 127.992 2.517 . . . . 10.0 113.376 -171.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.08 -26.74 39.49 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 123.206 0.602 . . . . 10.0 112.348 -179.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 137.99 -150.69 21.03 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 106.727 -2.549 . . . . 10.0 106.727 -169.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.8 m -80.23 33.16 0.28 Allowed 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 124.668 1.187 . . . . 10.0 112.273 -179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.8 m -125.24 -57.72 1.48 Allowed 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 108.646 -0.872 . . . . 10.0 108.646 -168.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 t -58.61 -39.79 81.46 Favored 'General case' 0 C--N 1.341 0.204 0 O-C-N 123.416 0.448 . . . . 10.0 110.935 -168.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.03 -41.69 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 127.387 2.275 . . . . 10.0 113.997 169.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.5 -162.93 19.65 Favored Glycine 0 C--N 1.34 0.779 0 N-CA-C 109.597 -1.401 . . . . 10.0 109.597 169.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -110.44 178.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.935 1 C-N-CA 125.558 4.172 . . . . 10.0 106.354 164.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.6 m170 -66.87 79.86 0.11 Allowed 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 120.088 1.313 . . . . 10.0 110.927 -176.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -105.85 53.93 0.7 Allowed 'General case' 0 N--CA 1.462 0.138 0 C-N-CA 127.262 2.225 . . . . 10.0 108.802 172.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -52.99 145.41 23.21 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 125.502 1.521 . . . . 10.0 110.772 168.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -64.98 -43.46 11.78 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 123.338 2.692 . . . . 10.0 111.243 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.4 68.68 0.55 Allowed 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.528 -0.915 . . . . 10.0 108.528 170.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.5 p -58.74 104.79 0.25 Allowed 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.381 1.073 . . . . 10.0 109.893 -175.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.1 mtt180 -141.55 -176.56 4.79 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 105.722 -1.955 . . . . 10.0 105.722 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.37 129.48 35.89 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 -177.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.1 t60 -44.92 112.13 0.4 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 122.558 0.343 . . . . 10.0 111.749 178.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.49 -147.66 6.52 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.442 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -156.03 -167.93 18.18 Favored Glycine 0 C--O 1.225 -0.451 0 CA-C-N 117.98 0.89 . . . . 10.0 111.567 179.411 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -68.36 16.09 0.16 Allowed 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.518 2.145 . . . . 10.0 112.398 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.442 ' H ' ' C ' ' A' ' 73' ' ' GLY . 6.2 mtpm? -110.39 -20.6 12.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 124.934 1.294 . . . . 10.0 110.25 169.403 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.67 162.65 16.94 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.754 -1.572 . . . . 10.0 106.754 -167.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -88.98 -21.85 23.31 Favored 'General case' 0 C--N 1.329 -0.32 0 O-C-N 121.629 -0.669 . . . . 10.0 109.877 178.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -83.4 -6.37 59.44 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 124.538 1.135 . . . . 10.0 111.474 -169.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -35.65 118.95 0.51 Allowed 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 126.145 1.778 . . . . 10.0 111.108 171.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m170 -50.37 -50.66 50.75 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 115.828 1.788 . . . . 10.0 115.828 -167.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -178.25 -46.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 106.945 -1.502 . . . . 10.0 106.945 -174.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -153.45 62.33 0.38 Allowed Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -85.84 95.96 9.61 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 103.705 -2.702 . . . . 10.0 103.705 166.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -70.47 -10.42 59.1 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.578 0.626 . . . . 10.0 111.833 -171.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.85 -93.96 0.93 Allowed Glycine 0 N--CA 1.445 -0.744 0 N-CA-C 107.69 -2.164 . . . . 10.0 107.69 176.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -150.54 147.11 27.06 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 124.871 1.268 . . . . 10.0 107.79 -174.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.1 m -117.98 128.04 75.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 118.606 0.639 . . . . 10.0 109.755 169.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.7 m -90.19 95.11 10.04 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 127.267 2.227 . . . . 10.0 111.506 -169.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -69.63 128.5 36.68 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.778 -0.576 . . . . 10.0 111.654 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.1 171.8 5.25 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.123 1.369 . . . . 10.0 109.888 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 pttm -54.89 -29.35 55.62 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.218 1.007 . . . . 10.0 111.088 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -78.25 0.21 26.11 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.031 0.444 . . . . 10.0 111.213 178.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.45 17.59 79.81 Favored Glycine 0 C--N 1.339 0.734 0 O-C-N 120.654 -1.279 . . . . 10.0 110.766 178.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 18.3 t -97.68 103.34 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.734 0 C-N-CA 127.812 2.445 . . . . 10.0 106.356 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.33 118.42 33.77 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 168.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -79.42 141.87 36.45 Favored 'General case' 0 N--CA 1.425 -1.679 0 C-N-CA 124.643 1.177 . . . . 10.0 108.718 178.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 86.8 t -111.63 133.22 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 106.509 -1.663 . . . . 10.0 106.509 169.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.6 p -158.88 58.4 0.43 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.501 0.72 . . . . 10.0 111.512 170.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -101.3 152.73 5.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.897 0.879 . . . . 10.0 109.085 -171.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -112.01 127.94 56.03 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 126.568 1.947 . . . . 10.0 108.448 172.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -130.22 145.72 51.77 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-O 121.378 0.609 . . . . 10.0 111.001 169.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.8 t -133.07 64.66 1.61 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.089 2.156 . . . . 10.0 106.652 -178.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.01 -52.73 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.077 0 C-N-CA 123.672 0.789 . . . . 10.0 109.225 175.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.328 0.0 OUTLIER -78.84 174.82 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.145 0.497 . . . . 10.0 112.19 172.048 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 m -153.99 153.72 32.49 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.372 -1.714 . . . . 10.0 106.372 169.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 95.7 mt -68.45 -14.52 63.06 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.109 0.564 . . . . 10.0 111.602 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.4 m -151.75 157.21 41.7 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.056 -1.831 . . . . 10.0 106.056 169.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 151.84 -66.95 0.33 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 178.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -161.02 -51.74 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 126.298 1.839 . . . . 10.0 107.239 -178.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -73.79 -39.44 64.13 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.513 -1.222 . . . . 10.0 108.165 -169.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 17.8 t 35.53 74.86 0.06 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 127.559 2.344 . . . . 10.0 110.31 169.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 pt -76.36 46.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.986 0.914 . . . . 10.0 111.422 -173.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 35.1 mm -92.31 -86.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 124.936 1.295 . . . . 10.0 108.613 -171.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.23 50.57 2.76 Favored Glycine 0 CA--C 1.537 1.468 0 O-C-N 120.291 -1.506 . . . . 10.0 113.669 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 13.4 mmt-85 -101.05 175.63 5.53 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 126.195 1.798 . . . . 10.0 108.006 169.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 17.2 m -102.46 104.34 14.78 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.362 1.465 . . . . 10.0 107.086 172.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.02 144.65 40.74 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 105.428 -2.064 . . . . 10.0 105.428 168.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.7 t -134.69 139.03 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 N-CA-C 108.645 -0.872 . . . . 10.0 108.645 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -107.39 131.72 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 N-CA-C 106.039 -1.837 . . . . 10.0 106.039 167.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.8 m170 -114.8 158.89 21.27 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 115.693 1.738 . . . . 10.0 115.693 -169.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.2 tt0 -43.84 -57.31 3.34 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 129.035 2.934 . . . . 10.0 111.835 174.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -116.84 169.17 9.59 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 113.835 1.05 . . . . 10.0 113.835 -168.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.05 132.24 37.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.557 1.543 . . . . 10.0 109.829 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 125.956 1.702 . . . . 10.0 110.563 -175.058 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.6 -37.42 50.39 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 124.388 1.075 . . . . 10.0 109.859 174.252 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.0 mt 76.07 53.62 0.06 Allowed 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.916 2.086 . . . . 10.0 112.755 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.92 -25.2 22.87 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 115.509 0.964 . . . . 10.0 115.509 167.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mptt -75.82 -4.13 38.98 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 119.313 1.557 . . . . 10.0 112.56 -172.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.84 -29.41 64.66 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 109.076 -1.609 . . . . 10.0 109.076 168.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.29 41.02 99.39 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.273 -1.131 . . . . 10.0 110.273 -176.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -130.78 171.98 12.51 Favored 'General case' 0 CA--C 1.501 -0.94 0 N-CA-C 106.731 -1.581 . . . . 10.0 106.731 170.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.1 mp0 -40.22 -58.78 1.41 Allowed 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 10.0 110.109 168.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -50.1 -54.52 19.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 116.072 -0.513 . . . . 10.0 109.999 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.4 p -55.29 -44.46 75.73 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 120.022 -0.671 . . . . 10.0 110.313 -177.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -78.24 -7.75 57.52 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.622 1.169 . . . . 10.0 111.16 -173.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -109.36 -68.38 0.92 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.911 1.684 . . . . 10.0 111.38 -178.473 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -114.55 -6.95 12.82 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 121.456 1.934 . . . . 10.0 112.326 179.276 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.55 33.64 47.04 Favored Glycine 0 C--O 1.222 -0.606 0 CA-C-O 118.976 -0.902 . . . . 10.0 111.837 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 61.21 24.91 14.97 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 119.74 1.77 . . . . 10.0 112.189 176.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.7 -9.08 58.29 Favored 'General case' 0 CA--C 1.527 0.082 0 C-N-CA 123.544 0.738 . . . . 10.0 112.31 -177.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.21 -166.12 54.76 Favored Glycine 0 N--CA 1.447 -0.607 0 O-C-N 121.269 -0.894 . . . . 10.0 111.409 172.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.1 m -58.13 136.36 57.21 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.064 0.946 . . . . 10.0 113.078 -167.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -64.03 89.11 0.05 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.123 0.969 . . . . 10.0 109.191 168.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 62.0 mt -58.07 -51.46 69.61 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.848 -0.427 . . . . 10.0 109.848 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -147.97 152.05 36.83 Favored 'General case' 0 N--CA 1.454 -0.261 0 O-C-N 122.273 -0.267 . . . . 10.0 110.371 -169.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 88.2 m -130.49 154.13 48.09 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 124.756 1.222 . . . . 10.0 109.539 -173.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.43 154.58 25.2 Favored Glycine 0 CA--C 1.519 0.328 0 N-CA-C 110.156 -1.178 . . . . 10.0 110.156 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 58.4 t -115.09 126.36 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 105.098 -2.186 . . . . 10.0 105.098 178.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 49.2 mt -78.71 147.7 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 108.895 -0.78 . . . . 10.0 108.895 -177.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -153.43 178.5 30.41 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.337 -1.105 . . . . 10.0 110.337 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -64.31 122.68 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 C-N-CA 124.477 1.111 . . . . 10.0 108.941 -177.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -116.89 148.84 40.96 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 168.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.016 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 167.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 119.111 -0.471 . . . . 10.0 110.174 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 t -81.77 -40.85 22.04 Favored 'General case' 0 C--O 1.226 -0.149 0 C-N-CA 124.217 1.007 . . . . 10.0 110.511 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 49.1 mttp -134.24 140.56 46.55 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 125.221 1.408 . . . . 10.0 109.192 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.43 152.89 47.42 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.017 0.927 . . . . 10.0 108.858 171.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -120.77 158.22 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 123.931 0.892 . . . . 10.0 110.153 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.47 101.94 4.49 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.427 -0.953 . . . . 10.0 108.427 168.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -79.64 105.97 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 108.692 -0.855 . . . . 10.0 108.692 169.666 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -91.86 128.13 37.58 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.364 -0.976 . . . . 10.0 108.364 -178.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -143.38 162.32 36.06 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 120.098 1.317 . . . . 10.0 108.494 170.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.67 -56.89 0.07 OUTLIER Glycine 0 N--CA 1.461 0.319 0 CA-C-N 115.077 -0.965 . . . . 10.0 113.146 169.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.47 -44.27 65.08 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 -177.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.4 -70.68 0.41 Allowed Glycine 0 CA--C 1.523 0.569 0 CA-C-N 114.319 -1.309 . . . . 10.0 110.323 169.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -59.13 -33.08 98.28 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 123.643 2.895 . . . . 10.0 111.515 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 65.2 t -67.06 95.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 177.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -117.69 101.15 8.1 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.522 -2.029 . . . . 10.0 105.522 178.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.415 ' HA2' ' CG2' ' B' ' 35' ' ' ILE . . . -85.47 142.04 19.28 Favored Glycine 0 N--CA 1.435 -1.401 0 N-CA-C 109.577 -1.409 . . . . 10.0 109.577 172.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mt -140.37 81.29 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 105.949 -1.871 . . . . 10.0 105.949 -179.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -90.9 140.7 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 C-N-CA 123.892 0.877 . . . . 10.0 109.05 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 13.5 m-80 -126.44 114.7 18.52 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.044 1.338 . . . . 10.0 109.234 171.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -91.42 132.48 36.19 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 124.882 1.273 . . . . 10.0 108.248 174.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.6 156.38 24.8 Favored 'General case' 0 C--N 1.339 0.151 0 O-C-N 123.519 0.512 . . . . 10.0 111.874 169.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.59 135.0 55.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 102.519 -3.141 . . . . 10.0 102.519 162.063 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -76.04 -77.13 0.14 Allowed 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 170.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 62.1 mm-40 -99.98 -125.9 0.17 Allowed 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.923 1.689 . . . . 10.0 106.616 175.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 73.4 m -136.18 13.68 3.3 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 121.868 -0.52 . . . . 10.0 111.971 165.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -123.6 -2.82 8.35 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 124.894 1.278 . . . . 10.0 109.876 168.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.7 156.49 47.99 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 110.136 -1.186 . . . . 10.0 110.136 -178.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -66.29 125.22 13.64 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 123.021 2.48 . . . . 10.0 108.831 175.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 m -79.96 64.51 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 122.774 0.43 . . . . 10.0 110.382 -175.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.8 tttt -54.42 111.95 0.9 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.139 -0.689 . . . . 10.0 109.139 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -103.9 112.28 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 C-N-CA 127.412 2.285 . . . . 10.0 106.556 -176.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -106.14 171.43 7.35 Favored 'General case' 0 CA--C 1.511 -0.532 0 CA-C-O 121.847 0.832 . . . . 10.0 110.507 173.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.59 173.88 45.09 Favored Glycine 0 N--CA 1.436 -1.306 0 N-CA-C 110.124 -1.19 . . . . 10.0 110.124 174.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 19.5 m -145.75 90.19 1.97 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.565 -0.902 . . . . 10.0 108.565 -179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . 0.415 ' CG2' ' HA2' ' B' ' 16' ' ' GLY . 3.4 pt -79.93 146.93 6.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.497 0 N-CA-C 108.661 -0.866 . . . . 10.0 108.661 175.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -126.7 149.74 49.41 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.39 -5.87 49.18 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.665 174.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -63.47 177.69 0.65 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.445 1.123 . . . . 10.0 110.599 173.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.1 t -115.25 168.09 10.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 105.687 -1.968 . . . . 10.0 105.687 165.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -46.57 156.84 0.16 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.785 1.634 . . . . 10.0 113.406 -170.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.14 -162.47 46.29 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-O 122.139 0.855 . . . . 10.0 113.376 166.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -79.7 141.32 36.51 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 125.873 1.669 . . . . 10.0 111.342 -170.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -139.72 145.39 38.26 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 114.504 1.298 . . . . 10.0 114.504 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -34.61 117.94 0.25 Allowed Glycine 0 C--N 1.343 0.95 0 C-N-CA 129.556 3.455 . . . . 10.0 114.569 167.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -141.37 109.23 5.71 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 120.012 1.906 . . . . 10.0 110.931 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.497 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -148.15 170.43 17.86 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 112.708 0.632 . . . . 10.0 112.708 178.66 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 m -116.69 79.1 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 C-N-CA 128.625 2.77 . . . . 10.0 111.247 -168.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 38.4 m-70 -79.23 142.69 36.02 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 124.802 1.241 . . . . 10.0 112.056 -171.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -62.47 -46.31 89.08 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 114.605 1.335 . . . . 10.0 114.605 -169.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -75.7 92.43 2.98 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.798 -2.667 . . . . 10.0 103.798 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.88 -27.13 74.14 Favored Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 128.103 2.764 . . . . 10.0 109.99 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -52.57 175.88 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.777 0 CA-C-O 122.752 1.263 . . . . 10.0 110.78 167.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -149.99 31.82 0.69 Allowed 'General case' 0 N--CA 1.431 -1.378 0 CA-C-N 114.603 -1.18 . . . . 10.0 112.809 168.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -51.78 -38.91 57.52 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.958 0.903 . . . . 10.0 111.084 -177.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.01 -18.08 54.24 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.84 1.256 . . . . 10.0 113.217 -179.425 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.09 85.56 0.62 Allowed Glycine 0 CA--C 1.533 1.161 0 N-CA-C 111.478 -0.649 . . . . 10.0 111.478 -176.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 71.4 m 44.11 39.36 2.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 128.008 2.523 . . . . 10.0 112.634 173.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -134.3 -54.32 0.85 Allowed 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 108.156 -1.053 . . . . 10.0 108.156 -169.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.7 m -90.56 34.31 0.89 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.109 0.563 . . . . 10.0 109.844 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -67.04 -23.18 65.86 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.401 1.08 . . . . 10.0 109.868 177.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.76 141.2 11.61 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 110.911 -0.876 . . . . 10.0 110.911 172.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -76.23 63.01 6.97 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.213 3.275 . . . . 10.0 113.202 -174.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 22.6 m170 63.26 44.04 5.87 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 126.697 1.999 . . . . 10.0 109.939 171.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -67.89 79.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 124.863 2.268 . . . . 10.0 111.351 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -81.89 147.15 57.54 Favored Pre-proline 0 C--N 1.318 -0.772 0 C-N-CA 126.396 1.878 . . . . 10.0 108.316 168.142 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -79.56 40.3 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 122.484 2.123 . . . . 10.0 111.775 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -162.84 37.68 0.1 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.787 0.835 . . . . 10.0 109.996 -176.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -42.31 100.05 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.599 1.56 . . . . 10.0 112.719 -170.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.57 -78.85 0.6 Allowed 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.284 -1.006 . . . . 10.0 108.284 -171.139 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -154.24 144.35 21.97 Favored 'General case' 0 N--CA 1.425 -1.678 0 CA-C-N 115.484 -0.78 . . . . 10.0 109.223 171.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -61.76 118.64 7.41 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 106.711 -1.589 . . . . 10.0 106.711 165.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.06 -146.19 6.25 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 107.743 -2.143 . . . . 10.0 107.743 175.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.423 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -166.53 -165.71 24.37 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 107.813 -2.115 . . . . 10.0 107.813 169.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -64.19 6.36 0.31 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.151 1.9 . . . . 10.0 112.207 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.423 ' H ' ' C ' ' B' ' 73' ' ' GLY . 0.0 OUTLIER -96.86 -29.99 13.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 118.997 0.817 . . . . 10.0 110.35 168.812 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -86.83 166.23 15.37 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 109.347 -0.612 . . . . 10.0 109.347 -174.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -86.18 -24.57 26.08 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.346 -1.297 . . . . 10.0 108.492 167.062 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -76.41 -93.78 0.02 OUTLIER 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 107.667 -1.234 . . . . 10.0 107.667 -173.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 28.5 mtm180 72.43 159.74 0.22 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 127.144 2.178 . . . . 10.0 108.644 -167.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.9 m170 -78.18 -48.63 15.45 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 118.965 -1.094 . . . . 10.0 110.093 169.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.3 p -166.26 -51.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 178.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.29 -76.28 0.9 Allowed Glycine 0 C--N 1.336 0.552 0 N-CA-C 109.019 -1.633 . . . . 10.0 109.019 171.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 41.42 78.58 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.792 1.237 . . . . 10.0 109.654 -169.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -20.97 64.96 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.939 0.348 . . . . 10.0 111.939 -168.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.91 -94.93 0.67 Allowed Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.027 -1.229 . . . . 10.0 110.027 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 33.2 m120 -155.61 106.45 2.51 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -168.647 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -99.24 130.6 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 119.773 1.17 . . . . 10.0 110.708 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -86.93 107.94 18.59 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 128.795 2.838 . . . . 10.0 110.945 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.88 131.51 36.47 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 122.857 0.463 . . . . 10.0 109.908 172.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -59.23 170.98 0.82 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.282 1.033 . . . . 10.0 109.806 168.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 12.4 pttm -51.36 -32.19 24.91 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 125.988 1.715 . . . . 10.0 110.584 175.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.36 -8.36 59.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 124.177 0.991 . . . . 10.0 110.963 -175.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.82 8.19 87.06 Favored Glycine 0 C--N 1.338 0.692 0 O-C-N 121.532 -0.73 . . . . 10.0 111.286 -177.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 50.0 t -80.18 114.92 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 N-CA-C 105.726 -1.953 . . . . 10.0 105.726 170.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.27 121.43 42.0 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 118.87 0.759 . . . . 10.0 109.006 170.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -83.0 121.78 27.45 Favored 'General case' 0 N--CA 1.433 -1.288 0 C-N-CA 126.404 1.881 . . . . 10.0 108.334 173.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 94.0 t -110.49 136.48 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 N-CA-C 106.543 -1.651 . . . . 10.0 106.543 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 18.7 m -157.77 64.97 0.47 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.071 1.349 . . . . 10.0 109.379 169.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 61.9 mt -101.97 156.35 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.859 1.263 . . . . 10.0 108.719 -171.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -144.81 140.48 28.46 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.645 1.578 . . . . 10.0 108.6 175.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -152.4 135.08 15.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 106.667 -1.605 . . . . 10.0 106.667 169.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.4 p -87.53 58.59 5.02 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.745 1.618 . . . . 10.0 107.916 -171.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 p -145.35 -46.53 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.918 -0.583 . . . . 10.0 109.677 -172.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 36.7 mm -66.8 143.04 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 N-CA-C 109.178 -0.675 . . . . 10.0 109.178 171.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 74.3 m -138.38 134.44 34.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 173.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -110.29 17.37 20.97 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.737 0.815 . . . . 10.0 110.59 172.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.17 156.5 34.32 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.131 -1.433 . . . . 10.0 107.131 173.409 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 93.67 55.38 1.54 Allowed Glycine 0 CA--C 1.525 0.689 0 O-C-N 123.743 0.652 . . . . 10.0 111.51 169.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 8.6 t70 71.02 -57.03 0.61 Allowed 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 129.663 3.185 . . . . 10.0 109.328 -178.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -82.64 48.31 1.3 Allowed 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 124.206 1.002 . . . . 10.0 109.53 -173.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -88.59 112.09 22.65 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 125.664 1.586 . . . . 10.0 107.983 -170.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -69.73 13.87 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 114.095 1.146 . . . . 10.0 114.095 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 33.2 mm -55.74 135.12 19.22 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 O-C-N 120.627 -1.296 . . . . 10.0 108.063 172.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.74 11.66 73.62 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-O 118.132 -1.371 . . . . 10.0 113.855 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mmt-85 -79.38 161.84 25.93 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.242 1.521 . . . . 10.0 108.866 167.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.4 121.25 41.94 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 123.529 0.732 . . . . 10.0 109.99 171.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -84.37 132.37 34.6 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 107.218 -1.401 . . . . 10.0 107.218 167.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.1 t -116.51 137.43 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.792 -1.188 . . . . 10.0 107.792 169.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -104.76 123.99 59.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.2 m170 -107.69 159.09 16.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 116.582 2.067 . . . . 10.0 116.582 -172.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -41.45 -65.61 0.42 Allowed 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 129.631 3.173 . . . . 10.0 111.67 170.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.1 mttp -109.89 175.38 5.46 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.658 1.183 . . . . 10.0 111.559 -173.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.03 151.73 35.43 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 125.75 1.62 . . . . 10.0 109.903 175.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.497 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -77.53 154.64 32.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 122.901 0.48 . . . . 10.0 110.889 169.928 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 53.4 m-20 -76.27 -36.65 58.32 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.289 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 63.5 mt 64.26 56.32 1.35 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.99 1.376 . . . . 10.0 109.27 -170.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.15 -44.34 3.29 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-N 113.376 -1.738 . . . . 10.0 110.918 171.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -76.64 41.06 0.25 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.088 1.755 . . . . 10.0 112.919 -173.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -99.85 -17.83 24.46 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 125.838 1.685 . . . . 10.0 110.65 169.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.26 44.89 65.0 Favored Glycine 0 C--N 1.339 0.696 0 C-N-CA 123.861 0.743 . . . . 10.0 111.443 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -146.02 168.02 21.93 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 172.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.1 -42.55 76.97 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 116.144 -0.48 . . . . 10.0 109.88 -176.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -64.78 -40.37 95.15 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.502 -0.748 . . . . 10.0 110.825 175.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -50.8 -44.02 58.88 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 118.704 0.684 . . . . 10.0 110.449 -179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -76.94 -8.26 57.06 Favored 'General case' 0 CA--C 1.542 0.662 0 CA-C-O 117.759 -1.115 . . . . 10.0 113.79 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 ttmm -114.87 -58.0 2.2 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 127.728 2.411 . . . . 10.0 113.072 -170.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 14.6 p -134.86 17.75 3.52 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.774 1.17 . . . . 10.0 110.784 175.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.12 -110.09 2.95 Favored Glycine 0 C--O 1.219 -0.81 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 -171.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -160.61 43.79 0.19 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 171.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.45 -14.76 62.66 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.787 -1.097 . . . . 10.0 112.194 -170.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.2 -163.5 54.53 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 110.48 -1.048 . . . . 10.0 110.48 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.7 m -56.94 130.41 45.85 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 123.929 0.891 . . . . 10.0 112.43 -168.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.58 73.36 0.06 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.809 1.644 . . . . 10.0 109.91 171.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 61.8 mt -50.96 -36.45 38.96 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.52 0.728 . . . . 10.0 112.116 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.31 159.59 28.7 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.971 -0.752 . . . . 10.0 108.971 -176.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -159.8 165.38 32.51 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.637 -0.505 . . . . 10.0 109.637 -177.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.31 167.73 35.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.421 -1.071 . . . . 10.0 110.421 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 15.9 t -115.41 138.67 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 107.233 -1.395 . . . . 10.0 107.233 -169.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.8 mt -73.18 109.82 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 110.212 -0.292 . . . . 10.0 110.212 -174.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.86 154.65 17.32 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 125.737 1.637 . . . . 10.0 110.373 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.1 mt -86.23 139.4 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 124.894 1.278 . . . . 10.0 108.815 -174.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -91.71 -114.71 0.08 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 167.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 . . . . . 0 C--O 1.248 1.006 0 C-N-CA 127.332 2.253 . . . . 10.0 105.014 166.937 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 107.416 -1.327 . . . . 10.0 107.416 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.2 t -158.45 -44.24 0.06 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.926 0.784 . . . . 10.0 111.328 177.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 11.7 tmtt? -131.78 134.04 45.39 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 123.68 0.792 . . . . 10.0 108.863 178.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.33 169.55 18.05 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 125.281 1.432 . . . . 10.0 109.936 -175.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -129.32 172.72 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 123.159 0.584 . . . . 10.0 112.236 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.72 107.47 4.46 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.826 1.25 . . . . 10.0 107.869 166.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -87.0 89.61 3.07 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-O 121.946 0.879 . . . . 10.0 109.111 172.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mt -80.52 116.22 20.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.573 1.549 . . . . 10.0 109.443 -175.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -142.27 159.35 42.41 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.702 1.137 . . . . 10.0 108.35 173.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.62 -65.02 0.02 OUTLIER Glycine 0 N--CA 1.461 0.365 0 CA-C-N 115.249 -0.887 . . . . 10.0 112.216 169.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -72.15 -41.66 66.85 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 106.891 -1.522 . . . . 10.0 106.891 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.44 -64.26 0.55 Allowed Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.695 -1.059 . . . . 10.0 111.368 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -58.14 -37.91 93.61 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.056 1.837 . . . . 10.0 110.492 174.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 80.3 t -62.85 105.55 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 N-CA-C 107.644 -1.243 . . . . 10.0 107.644 174.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -124.02 118.98 28.22 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.089 -1.819 . . . . 10.0 106.089 171.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.87 130.53 10.15 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 109.725 -1.35 . . . . 10.0 109.725 170.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.494 ' CG2' HG22 ' B' ' 54' ' ' THR . 16.4 mt -128.29 72.04 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.15 -1.796 . . . . 10.0 106.15 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.14 147.19 6.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.288 -0.869 . . . . 10.0 110.447 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.03 106.24 8.74 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 126.78 2.032 . . . . 10.0 107.804 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -86.37 125.11 33.43 Favored 'General case' 0 N--CA 1.451 -0.425 0 CA-C-O 117.73 -1.129 . . . . 10.0 108.012 175.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -120.19 145.27 47.14 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 123.922 0.763 . . . . 10.0 110.963 167.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 tp60 -125.89 105.18 8.74 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 126.858 2.063 . . . . 10.0 107.036 169.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.77 -61.24 2.44 Favored 'General case' 0 C--N 1.339 0.15 0 C-N-CA 124.767 1.227 . . . . 10.0 110.24 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -134.01 167.48 20.53 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 104.552 -2.388 . . . . 10.0 104.552 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.7 t -69.41 -14.94 63.17 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 119.71 -0.186 . . . . 10.0 110.573 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -79.89 -18.02 51.68 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 123.386 0.675 . . . . 10.0 110.171 174.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.6 151.68 39.97 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.23 -0.748 . . . . 10.0 111.23 -176.097 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.23 146.66 40.94 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 N-CA-C 105.493 -2.541 . . . . 10.0 105.493 165.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -76.65 119.35 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 N-CA-C 106.166 -1.791 . . . . 10.0 106.166 -179.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.454 ' HZ2' ' CD ' ' A' ' 100' ' ' GLU . 18.0 mttp -90.97 110.57 21.83 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 106.432 -1.692 . . . . 10.0 106.432 176.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.13 106.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -128.85 169.96 13.95 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.744 0.783 . . . . 10.0 112.214 171.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.05 -153.09 24.77 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 106.592 -2.603 . . . . 10.0 106.592 169.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 27.5 t -156.06 155.98 33.58 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.54 -0.864 . . . . 10.0 109.464 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 pt -108.01 175.63 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 CA-C-N 115.153 -0.931 . . . . 10.0 110.082 167.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.2 ptmt -152.37 150.66 29.94 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.86 -15.57 33.99 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-O 118.985 -0.897 . . . . 10.0 114.566 171.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.1 mp -72.95 -179.67 3.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 118.948 1.374 . . . . 10.0 109.609 177.119 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -96.0 175.55 6.44 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.402 -0.962 . . . . 10.0 108.402 166.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -58.65 168.95 1.04 Allowed 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.676 1.19 . . . . 10.0 112.025 -172.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.37 -168.01 49.65 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-O 122.019 0.788 . . . . 10.0 112.909 167.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -71.26 146.13 49.15 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.762 1.625 . . . . 10.0 110.397 -176.363 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.07 152.69 35.21 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 113.125 0.787 . . . . 10.0 113.125 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -37.3 121.43 0.83 Allowed Glycine 0 C--N 1.339 0.727 0 C-N-CA 128.274 2.845 . . . . 10.0 111.069 165.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -155.68 106.21 2.48 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 106.558 -1.645 . . . . 10.0 106.558 169.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.42 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -148.07 170.6 17.42 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.876 0.846 . . . . 10.0 112.904 178.561 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.36 132.54 60.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 104.336 -2.468 . . . . 10.0 104.336 168.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 1.7 p80 -168.4 177.47 5.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 107.737 -1.208 . . . . 10.0 107.737 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 52.71 -167.75 0.05 Allowed 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 125.984 2.052 . . . . 10.0 116.157 162.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.75 159.42 19.77 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-O 121.593 0.711 . . . . 10.0 110.893 -175.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.01 -18.44 77.76 Favored Glycine 0 CA--C 1.523 0.565 0 C-N-CA 125.443 1.497 . . . . 10.0 110.308 168.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -50.61 140.6 14.03 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 122.723 1.249 . . . . 10.0 108.259 166.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -151.79 8.86 0.51 Allowed 'General case' 0 N--CA 1.412 -2.342 0 CA-C-N 113.5 -1.682 . . . . 10.0 109.889 -168.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -41.45 -55.24 2.87 Favored 'General case' 0 C--N 1.343 0.29 0 C-N-CA 125.842 1.657 . . . . 10.0 114.425 -167.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.18 -18.37 57.84 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.836 0.454 . . . . 10.0 111.554 -173.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.72 78.63 1.38 Allowed Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.312 -1.115 . . . . 10.0 110.312 -175.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.2 m 70.24 35.3 2.12 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.989 1.315 . . . . 10.0 111.752 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -131.8 -57.51 0.98 Allowed 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 107.184 -1.413 . . . . 10.0 107.184 175.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.3 m -52.05 -43.14 63.64 Favored 'General case' 0 C--N 1.343 0.289 0 C-N-CA 123.913 0.885 . . . . 10.0 111.331 -170.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.11 -55.31 0.03 OUTLIER 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 128.35 2.66 . . . . 10.0 113.645 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 139.92 -154.18 23.68 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 110.533 -1.027 . . . . 10.0 110.533 175.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -122.21 -155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.54 0.811 1 C-N-CA 126.865 5.043 . . . . 10.0 105.85 165.049 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -77.93 46.85 0.6 Allowed 'General case' 0 CA--C 1.548 0.896 0 O-C-N 118.587 -2.571 . . . . 10.0 112.113 177.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -77.51 60.9 2.18 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.923 1.289 . . . . 10.0 109.566 169.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -71.74 157.13 90.29 Favored Pre-proline 0 C--N 1.325 -0.457 0 C-N-CA 124.002 0.921 . . . . 10.0 108.67 171.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -56.17 -43.42 56.4 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 121.347 1.365 . . . . 10.0 109.478 169.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 68.2 mt -84.23 47.47 1.34 Allowed 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.831 -0.543 . . . . 10.0 111.232 173.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 p -61.29 91.39 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 107.407 -1.331 . . . . 10.0 107.407 166.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -113.36 -69.06 0.89 Allowed 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 104.183 -2.525 . . . . 10.0 104.183 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -154.64 161.33 41.63 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 106.171 -1.788 . . . . 10.0 106.171 167.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.8 t60 -72.48 129.07 37.48 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 105.194 -2.151 . . . . 10.0 105.194 163.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -150.03 -140.81 3.29 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 108.316 -1.913 . . . . 10.0 108.316 176.004 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.422 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.33 -157.99 21.59 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.812 -2.115 . . . . 10.0 107.812 170.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -69.38 18.3 0.17 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 119.627 1.713 . . . . 10.0 111.326 169.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.422 ' H ' ' C ' ' A' ' 73' ' ' GLY . 30.4 mmtm -104.96 -21.03 13.36 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 124.753 1.221 . . . . 10.0 108.643 169.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -120.9 166.51 13.7 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.121 -1.807 . . . . 10.0 106.121 -171.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -79.32 -42.15 26.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 107.667 -1.235 . . . . 10.0 107.667 173.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -96.2 34.88 1.51 Allowed 'General case' 0 N--CA 1.441 -0.921 0 C-N-CA 127.53 2.332 . . . . 10.0 114.974 -161.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ptp180 -57.28 153.79 11.55 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.521 1.129 . . . . 10.0 110.867 174.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -72.97 159.21 34.03 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 118.9 -1.12 . . . . 10.0 108.497 168.064 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -38.91 -40.09 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 125.974 1.71 . . . . 10.0 114.397 -172.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.6 42.88 1.32 Allowed Glycine 0 C--N 1.338 0.664 0 CA-C-N 118.178 0.445 . . . . 10.0 112.641 179.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.0 89.48 5.34 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 106.619 -1.623 . . . . 10.0 106.619 167.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 21.4 mt -67.97 -37.71 81.86 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.15 -86.08 0.41 Allowed Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 114.873 -1.058 . . . . 10.0 110.537 167.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -140.72 131.03 25.07 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 -172.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.0 m -115.24 137.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.944 -0.762 . . . . 10.0 108.944 169.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -85.19 131.92 34.36 Favored 'General case' 0 C--O 1.226 -0.168 0 C-N-CA 124.761 1.224 . . . . 10.0 109.485 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.05 138.47 45.35 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.37 1.468 . . . . 10.0 109.625 171.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -58.92 171.6 0.66 Allowed 'General case' 0 N--CA 1.456 -0.135 0 O-C-N 124.181 0.926 . . . . 10.0 109.191 167.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 27.5 pttt -45.91 -34.96 4.23 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 127.225 2.21 . . . . 10.0 110.852 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -82.53 -3.04 55.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.861 1.264 . . . . 10.0 110.83 -173.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.52 8.48 83.08 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.556 -1.017 . . . . 10.0 110.556 -177.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 73.5 t -87.83 98.82 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 107.289 -1.374 . . . . 10.0 107.289 -177.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.53 121.66 38.59 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 107.523 -1.288 . . . . 10.0 107.523 168.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -84.47 114.41 21.9 Favored 'General case' 0 N--CA 1.439 -1.003 0 C-N-CA 126.955 2.102 . . . . 10.0 108.202 169.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 87.9 t -102.05 131.36 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.672 -1.233 . . . . 10.0 107.672 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.6 p -157.97 88.95 0.98 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.392 1.077 . . . . 10.0 109.067 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -129.17 163.51 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 106.818 -1.549 . . . . 10.0 106.818 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.454 ' CD ' ' HZ2' ' A' ' 30' ' ' LYS . 12.4 pt-20 -136.67 150.39 48.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 121.471 -0.768 . . . . 10.0 110.407 170.176 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -147.0 155.6 42.37 Favored 'General case' 0 N--CA 1.447 -0.608 0 O-C-N 124.551 1.157 . . . . 10.0 108.761 178.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.3 p -113.27 44.57 1.53 Allowed 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 127.583 2.353 . . . . 10.0 110.39 -173.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.8 p -142.59 -46.24 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 C-N-CA 123.624 0.77 . . . . 10.0 109.557 177.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 39.8 mm -54.73 110.33 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 169.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.4 m -120.82 105.16 10.45 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 124.386 1.074 . . . . 10.0 109.217 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 37.2 mt -58.15 -28.8 65.06 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.984 0.514 . . . . 10.0 111.935 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 m -150.29 160.79 43.45 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.869 -1.53 . . . . 10.0 106.869 174.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 66.1 0.4 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.333 -1.107 . . . . 10.0 110.333 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t70 71.53 -59.67 0.54 Allowed 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 129.557 3.143 . . . . 10.0 109.519 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.9 m-70 -76.49 -22.03 55.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.637 -0.71 . . . . 10.0 111.165 -169.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.1 t 26.43 78.26 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 128.358 2.663 . . . . 10.0 112.213 168.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -67.76 -6.36 5.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 112.599 0.592 . . . . 10.0 112.599 -174.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.5 mm -51.46 132.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 O-C-N 120.952 -1.092 . . . . 10.0 108.309 168.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.428 ' HA3' ' CG2' ' B' ' 113' ' ' ILE . . . 93.38 11.81 57.94 Favored Glycine 0 CA--C 1.523 0.577 0 CA-C-O 117.701 -1.611 . . . . 10.0 115.952 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -80.0 176.29 9.87 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 119.594 1.697 . . . . 10.0 108.554 167.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 99.7 m -106.54 121.46 44.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 125.095 1.358 . . . . 10.0 107.637 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -76.88 144.37 39.01 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 106.498 -1.667 . . . . 10.0 106.498 167.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.2 t -131.88 123.76 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 107.696 -1.224 . . . . 10.0 107.696 -176.021 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 11.7 t -104.49 137.83 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.9 m170 -124.89 157.65 35.44 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 114.553 1.316 . . . . 10.0 114.553 -174.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 68.7 tt0 -45.61 -55.92 5.78 Favored 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 128.833 2.853 . . . . 10.0 109.183 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 63.6 mttt -123.6 175.11 7.0 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.586 1.154 . . . . 10.0 110.751 -170.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.33 143.35 28.72 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 108.715 -0.846 . . . . 10.0 108.715 176.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.42 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.1 OUTLIER -73.64 151.66 40.75 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.435 -0.58 . . . . 10.0 109.435 175.572 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -83.28 13.49 4.24 Favored 'General case' 0 N--CA 1.448 -0.529 0 O-C-N 124.355 1.034 . . . . 10.0 111.168 167.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 75.7 mt 45.58 46.6 11.21 Favored 'General case' 0 C--N 1.343 0.307 0 C-N-CA 125.513 1.525 . . . . 10.0 112.779 171.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 107.79 -21.88 29.08 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-N 115.724 -0.671 . . . . 10.0 112.119 173.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.2 mtmm -112.26 43.89 1.53 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.056 1.343 . . . . 10.0 111.598 -168.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.49 -16.42 64.19 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.343 1.925 . . . . 10.0 112.435 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.33 47.9 88.31 Favored Glycine 0 CA--C 1.532 1.104 0 O-C-N 121.473 -1.016 . . . . 10.0 112.554 173.45 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -165.77 173.81 10.3 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 126.682 1.993 . . . . 10.0 106.094 177.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.416 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 23.7 tt0 -56.9 -42.54 80.08 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 119.802 1.183 . . . . 10.0 111.24 -174.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -70.18 -18.32 63.19 Favored 'General case' 0 N--CA 1.454 -0.273 0 O-C-N 121.29 -0.881 . . . . 10.0 111.916 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.3 t -44.54 -43.53 8.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 C-N-CA 124.836 1.254 . . . . 10.0 109.549 170.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -93.79 5.95 49.96 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 112.411 0.523 . . . . 10.0 112.411 -174.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.416 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 87.1 mttt -117.87 -73.77 0.63 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.203 1.401 . . . . 10.0 110.286 179.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.4 p -111.87 7.81 20.2 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 120.213 1.369 . . . . 10.0 110.943 178.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.78 -90.15 1.06 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 108.413 -1.875 . . . . 10.0 108.413 -173.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.76 39.55 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 124.721 1.208 . . . . 10.0 109.872 176.229 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.35 -10.37 32.53 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 124.217 1.007 . . . . 10.0 112.745 -176.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.67 -168.01 53.34 Favored Glycine 0 N--CA 1.445 -0.743 0 O-C-N 121.059 -1.026 . . . . 10.0 110.736 178.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -59.68 138.99 57.58 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 123.781 0.832 . . . . 10.0 112.354 -168.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.8 mtm180 -68.18 69.32 0.14 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.714 1.206 . . . . 10.0 110.464 169.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.62 -9.16 32.77 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 113.654 0.983 . . . . 10.0 113.654 -178.024 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.38 143.4 17.68 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.47 0.708 . . . . 10.0 111.858 168.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 5.4 p -144.28 166.31 25.41 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.148 -0.686 . . . . 10.0 109.148 171.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.1 150.95 21.15 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 109.74 -1.344 . . . . 10.0 109.74 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.8 139.68 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 106.212 -1.773 . . . . 10.0 106.212 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 58.8 mt -76.84 127.34 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-O 119.555 -0.26 . . . . 10.0 110.937 -173.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -125.31 140.78 12.54 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 123.79 0.71 . . . . 10.0 111.882 -177.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 94.1 mt -68.29 140.96 18.2 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 C-N-CA 124.632 1.173 . . . . 10.0 108.699 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.21 -46.33 1.51 Allowed 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 112.348 0.499 . . . . 10.0 112.348 -176.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 . . . . . 0 C--O 1.248 0.986 0 CA-C-O 117.277 -1.344 . . . . 10.0 110.24 -167.896 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.556 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -88.26 -15.74 35.04 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.865 1.266 . . . . 10.0 111.469 -175.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 31.2 tttp -130.18 135.44 48.17 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.142 1.377 . . . . 10.0 108.645 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.74 161.47 35.47 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.769 1.628 . . . . 10.0 108.843 169.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.1 t -117.98 152.86 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 C-N-CA 125.489 1.516 . . . . 10.0 110.163 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.47 94.96 3.28 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.416 1.887 . . . . 10.0 108.739 171.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.1 m -88.29 111.3 22.18 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 N-CA-C 109.368 -0.604 . . . . 10.0 109.368 172.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.4 mt -94.61 145.68 24.66 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 109.179 -0.674 . . . . 10.0 109.179 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.5 mtmt -166.72 159.28 13.76 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.533 1.133 . . . . 10.0 108.397 172.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.28 -48.7 0.11 Allowed Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.351 -0.928 . . . . 10.0 113.112 169.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -72.94 -45.96 55.15 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 107.548 -1.278 . . . . 10.0 107.548 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.04 -71.36 0.4 Allowed Glycine 0 CA--C 1.523 0.537 0 CA-C-N 114.323 -1.308 . . . . 10.0 109.909 170.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -58.18 -35.72 98.47 Favored 'Trans proline' 0 N--CA 1.453 -0.862 0 C-N-CA 123.156 2.57 . . . . 10.0 111.249 173.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.6 t -64.59 107.59 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 107.573 -1.269 . . . . 10.0 107.573 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.47 124.16 39.48 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 108.608 -0.886 . . . . 10.0 108.608 169.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -104.17 149.4 17.11 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 109.879 -1.289 . . . . 10.0 109.879 170.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 mt -146.75 56.89 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 N-CA-C 107.251 -1.388 . . . . 10.0 107.251 -176.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mm -86.35 135.6 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.09 -0.707 . . . . 10.0 109.09 -169.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -103.23 115.76 31.18 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.249 1.82 . . . . 10.0 107.126 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -96.4 115.01 26.74 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.721 -1.585 . . . . 10.0 106.721 175.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -122.79 151.46 41.62 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 119.321 0.964 . . . . 10.0 112.699 172.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.6 tt0 -139.6 95.83 2.98 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.148 1.379 . . . . 10.0 108.733 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 68.6 tttt -143.2 83.42 1.79 Allowed 'General case' 0 N--CA 1.426 -1.626 0 C-N-CA 124.15 0.98 . . . . 10.0 109.3 178.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -157.66 170.14 23.06 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 102.701 -3.074 . . . . 10.0 102.701 165.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 16.0 t -71.91 -21.1 61.68 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 109.785 -0.45 . . . . 10.0 109.785 171.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 18.2 m-80 -88.05 -2.78 58.81 Favored 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 123.189 0.596 . . . . 10.0 111.062 -175.363 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.62 49.17 22.0 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-O 118.91 -0.939 . . . . 10.0 114.621 -176.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -68.57 116.33 4.36 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 107.3 -1.846 . . . . 10.0 107.3 169.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.8 t -79.37 99.94 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 104.272 -2.492 . . . . 10.0 104.272 169.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -92.08 112.03 23.8 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 175.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -101.73 102.73 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.908 0 C-N-CA 126.631 1.972 . . . . 10.0 105.98 -174.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.1 p90 -125.14 160.76 28.37 Favored 'General case' 0 C--N 1.339 0.126 0 N-CA-C 112.683 0.623 . . . . 10.0 112.683 177.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.28 -157.64 27.38 Favored Glycine 0 N--CA 1.449 -0.44 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -143.48 127.96 17.96 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 109.613 -0.514 . . . . 10.0 109.613 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.4 pt -90.14 139.84 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 N-CA-C 106.611 -1.626 . . . . 10.0 106.611 166.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.0 142.34 50.42 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 123.8 0.688 . . . . 10.0 109.437 171.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.98 -4.64 25.65 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.221 -0.766 . . . . 10.0 112.888 178.196 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -60.44 176.8 0.33 Allowed 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 118.676 1.238 . . . . 10.0 110.918 170.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -109.65 164.35 12.62 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 105.406 -2.072 . . . . 10.0 105.406 165.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -52.72 163.09 0.5 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.863 0.865 . . . . 10.0 112.974 -169.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.74 -171.59 47.26 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 123.745 0.688 . . . . 10.0 112.297 169.128 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -71.5 144.39 49.66 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.624 1.969 . . . . 10.0 110.961 -177.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -148.48 138.59 22.44 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 113.638 0.977 . . . . 10.0 113.638 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -20.26 120.87 0.01 OUTLIER Glycine 0 C--N 1.341 0.841 0 C-N-CA 129.134 3.254 . . . . 10.0 115.084 165.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.27 108.09 4.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 119.518 1.659 . . . . 10.0 109.827 168.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.561 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 2.0 m80 -139.5 179.88 6.3 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.607 0.718 . . . . 10.0 112.288 177.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 76.1 t -112.43 128.33 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 C-N-CA 127.173 2.189 . . . . 10.0 106.368 169.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 67.0 m-70 -109.42 138.42 45.8 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 125.589 1.555 . . . . 10.0 107.299 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -53.76 -57.73 9.79 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 124.189 0.996 . . . . 10.0 111.844 -169.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -80.06 135.2 36.29 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 118.109 -1.437 . . . . 10.0 109.59 -177.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.86 -19.76 79.56 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 109.827 -1.309 . . . . 10.0 109.827 168.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t0 -39.57 148.63 0.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.008 1.323 . . . . 10.0 112.48 175.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -153.88 20.06 0.52 Allowed 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.424 -1.262 . . . . 10.0 113.214 174.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.494 HG22 ' CG2' ' A' ' 17' ' ' ILE . 1.8 m -52.74 -38.04 60.27 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 119.389 0.995 . . . . 10.0 111.978 -171.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.41 -22.87 47.12 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.025 0.93 . . . . 10.0 113.007 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.05 111.39 2.65 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.056 -1.218 . . . . 10.0 110.056 -169.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.8 m 34.1 51.73 0.43 Allowed 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 127.816 2.446 . . . . 10.0 115.515 170.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.97 -46.18 0.05 Allowed 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.423 0.689 . . . . 10.0 110.032 173.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.8 t -57.09 -26.69 60.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.546 0.738 . . . . 10.0 111.333 -178.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.02 -32.52 0.09 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.032 2.133 . . . . 10.0 112.958 167.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.59 162.66 15.91 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 108.72 -1.752 . . . . 10.0 108.72 173.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . 0.4 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 44.5 Cg_endo -73.94 -134.05 0.01 OUTLIER 'Trans proline' 0 N--CA 1.437 -1.822 0 N-CA-C 103.986 -3.121 . . . . 10.0 103.986 165.321 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.489 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 16.4 m170 -110.18 40.18 2.0 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 120.322 -1.486 . . . . 10.0 109.42 -177.301 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . 0.4 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 0.0 OUTLIER -78.04 57.36 1.77 Allowed 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.061 0.846 . . . . 10.0 112.494 -179.506 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -54.38 167.04 0.61 Allowed Pre-proline 0 CA--C 1.541 0.597 0 C-N-CA 129.782 3.233 . . . . 10.0 112.175 173.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -93.87 19.53 0.76 Allowed 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.738 2.292 . . . . 10.0 111.744 -173.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -144.48 48.73 1.34 Allowed 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.156 1.383 . . . . 10.0 107.444 -171.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.3 p -40.61 107.17 0.07 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 126.716 2.006 . . . . 10.0 112.03 -169.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 45.3 mtp180 -147.56 177.96 8.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 104.98 -2.23 . . . . 10.0 104.98 -175.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -73.41 143.09 46.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 117.395 -1.722 . . . . 10.0 110.257 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.5 t60 -52.53 116.96 2.54 Favored 'General case' 0 CA--C 1.519 -0.216 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 167.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.07 -178.84 22.69 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 106.659 -2.576 . . . . 10.0 106.659 178.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -151.77 -148.34 4.8 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 -174.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -65.58 -0.13 3.43 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 CA-C-N 119.386 1.593 . . . . 10.0 110.591 167.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -87.86 -27.17 22.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 118.798 0.726 . . . . 10.0 109.784 172.018 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -115.05 164.69 13.81 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.71 0.766 . . . . 10.0 111.315 -169.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -96.12 -9.0 31.78 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 124.855 1.262 . . . . 10.0 109.216 168.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 50.0 mm-40 -78.2 -81.32 0.1 Allowed 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 124.874 1.269 . . . . 10.0 109.953 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? 59.76 175.69 0.08 Allowed 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 114.634 -1.166 . . . . 10.0 110.722 -167.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -102.43 -59.81 1.64 Allowed 'General case' 0 CA--C 1.529 0.142 0 O-C-N 121.468 -0.77 . . . . 10.0 110.443 168.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.1 p -157.41 -55.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.146 0 C-N-CA 122.991 0.516 . . . . 10.0 109.698 -178.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.19 50.47 0.69 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.104 -1.598 . . . . 10.0 109.104 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -76.22 97.25 4.1 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 169.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 18.7 mt -75.26 -31.22 60.71 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 102.46 -95.94 1.35 Allowed Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 108.063 -2.015 . . . . 10.0 108.063 171.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -135.72 137.0 41.28 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 112.115 0.413 . . . . 10.0 112.115 -168.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.0 m -119.46 143.83 29.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 108.423 -0.955 . . . . 10.0 108.423 168.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.06 134.75 34.55 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.828 1.651 . . . . 10.0 109.473 -178.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.43 134.38 49.67 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.721 1.208 . . . . 10.0 111.515 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -63.6 169.8 3.67 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.893 -0.78 . . . . 10.0 108.893 165.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.01 -25.48 30.43 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.592 1.157 . . . . 10.0 111.79 175.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -75.55 -11.06 59.95 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.838 0.351 . . . . 10.0 110.286 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.66 12.07 75.87 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 110.138 -1.185 . . . . 10.0 110.138 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.0 t -85.45 107.87 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 106.37 -1.715 . . . . 10.0 106.37 175.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.65 119.5 39.47 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 168.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -78.41 131.01 36.76 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.727 2.011 . . . . 10.0 108.432 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 38.6 t -117.65 131.46 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 126.671 1.988 . . . . 10.0 106.64 -179.318 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 m -158.47 68.06 0.47 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 125.33 1.452 . . . . 10.0 109.196 170.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.1 mt -107.38 166.13 4.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 124.632 1.173 . . . . 10.0 108.283 -176.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -152.68 125.27 8.28 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.714 1.606 . . . . 10.0 109.415 -169.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -140.29 136.24 33.08 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 170.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 68.5 p -105.4 60.33 0.67 Allowed 'General case' 0 N--CA 1.457 -0.124 0 N-CA-C 107.003 -1.48 . . . . 10.0 107.003 174.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 99.9 t -127.92 -56.71 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -177.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . 0.425 ' CD1' ' H ' ' B' ' 104' ' ' ILE 0.301 0.0 OUTLIER -81.31 173.18 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 124.378 1.071 . . . . 10.0 112.226 170.555 . . . . . . . . 4 4 . 1 . 010 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.9 m -147.65 171.35 15.75 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.229 -0.919 . . . . 10.0 108.744 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 61.1 mt -105.81 -18.65 13.99 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 124.796 1.238 . . . . 10.0 110.343 175.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 73.0 m -156.99 157.78 35.35 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 125.269 1.427 . . . . 10.0 107.243 174.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.47 -71.8 0.49 Allowed Glycine 0 C--N 1.334 0.428 0 N-CA-C 108.818 -1.713 . . . . 10.0 108.818 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -160.48 -49.97 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 125.981 1.712 . . . . 10.0 107.197 176.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -80.46 40.0 0.48 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.122 0.969 . . . . 10.0 110.205 -176.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 43.3 t -75.25 88.26 2.51 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 126.914 2.086 . . . . 10.0 108.862 -172.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 4.6 pt -78.35 45.76 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 O-C-N 121.349 -0.845 . . . . 10.0 112.618 -176.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . 0.428 ' CG2' ' HA3' ' A' ' 114' ' ' GLY . 1.3 mp -72.71 -63.83 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 O-C-N 121.599 -0.688 . . . . 10.0 110.299 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.76 48.71 3.54 Favored Glycine 0 CA--C 1.532 1.105 0 O-C-N 120.744 -1.223 . . . . 10.0 112.458 -178.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.04 166.17 10.81 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 127.064 2.146 . . . . 10.0 106.985 172.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -121.03 136.75 54.91 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.113 -1.069 . . . . 10.0 108.113 174.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mp -103.07 147.3 27.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 173.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -123.69 134.82 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 106.884 -1.525 . . . . 10.0 106.884 174.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -101.29 121.29 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 169.111 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 9.6 m-70 -101.3 154.08 19.09 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 115.677 1.732 . . . . 10.0 115.677 -169.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -38.49 -61.03 0.74 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 128.715 2.806 . . . . 10.0 111.124 171.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 66.0 mttt -117.0 175.3 5.65 Favored 'General case' 0 CA--C 1.517 -0.322 0 C-N-CA 124.973 1.309 . . . . 10.0 109.916 -173.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.3 140.11 35.02 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 108.131 -1.062 . . . . 10.0 108.131 174.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.561 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -77.81 160.85 28.08 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 122.077 0.941 . . . . 10.0 111.592 170.477 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -74.78 -27.68 60.42 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 113.804 -1.544 . . . . 10.0 109.863 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 3.9 mm? 61.05 63.29 1.28 Allowed 'General case' 0 CA--C 1.521 -0.149 0 C-N-CA 125.711 1.605 . . . . 10.0 107.782 -167.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.74 -52.49 3.64 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.299 168.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.8 pttp -78.62 55.71 1.7 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.315 1.046 . . . . 10.0 112.421 -171.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.36 -34.22 4.85 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 125.387 1.47 . . . . 10.0 110.379 169.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 73.71 35.01 55.71 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.345 -1.102 . . . . 10.0 110.345 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -125.75 156.38 39.51 Favored 'General case' 0 CA--C 1.506 -0.717 0 N-CA-C 105.418 -2.068 . . . . 10.0 105.418 169.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.4 tt0 -49.23 -48.86 45.24 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 107.555 -1.276 . . . . 10.0 107.555 169.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -55.95 -41.73 75.14 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 114.648 -1.16 . . . . 10.0 111.959 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 23.2 p -58.61 -42.41 88.09 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 120.368 1.44 . . . . 10.0 111.183 178.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.9 t -78.5 -16.1 57.88 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 113.079 0.77 . . . . 10.0 113.079 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -102.21 -46.01 4.96 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 126.129 1.772 . . . . 10.0 112.889 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.489 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 29.4 p -127.07 -12.33 5.82 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.375 -0.828 . . . . 10.0 112.669 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 1.68 82.64 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.234 -1.314 . . . . 10.0 112.65 -169.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 69.24 29.71 4.51 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 119.95 1.875 . . . . 10.0 111.907 172.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.81 0.9 11.77 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 124.522 1.129 . . . . 10.0 112.552 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.93 -163.09 53.19 Favored Glycine 0 N--CA 1.445 -0.744 0 O-C-N 120.948 -1.095 . . . . 10.0 111.439 173.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -59.3 136.61 58.02 Favored 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.585 1.154 . . . . 10.0 114.005 -166.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -64.43 75.52 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.227 1.411 . . . . 10.0 109.822 168.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 47.8 mt -54.51 -37.88 65.87 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 118.655 0.661 . . . . 10.0 111.548 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.86 158.84 35.88 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -177.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -151.63 167.6 27.63 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.127 0.571 . . . . 10.0 109.543 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.26 147.43 16.92 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-O 118.446 -1.197 . . . . 10.0 110.361 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.2 t -96.64 127.5 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 N-CA-C 104.358 -2.46 . . . . 10.0 104.358 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.9 mt -70.16 158.02 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.055 0.843 . . . . 10.0 109.936 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -155.57 145.63 12.74 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.201 -1.16 . . . . 10.0 110.201 -172.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 98.6 mt -57.41 131.71 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 C-N-CA 126.335 1.854 . . . . 10.0 109.612 176.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -110.05 -44.37 3.79 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 118.85 0.75 . . . . 10.0 111.942 173.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.584 -2.151 . . . . 10.0 110.908 176.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.859 0 CA-C-O 118.698 -0.668 . . . . 10.0 109.276 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.8 t -165.11 -45.85 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.349 1.06 . . . . 10.0 109.919 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 20.0 ttmm -104.27 138.8 40.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.223 -1.769 . . . . 10.0 106.223 168.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.22 163.4 37.12 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 169.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -137.62 166.09 25.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-N 118.286 0.494 . . . . 10.0 110.171 -177.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.89 106.89 4.93 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 167.332 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.4 m -80.94 101.02 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 168.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mt -78.88 138.73 38.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.707 -0.849 . . . . 10.0 108.707 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.93 160.94 34.09 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.61 -0.885 . . . . 10.0 108.61 168.243 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.45 -60.73 0.03 OUTLIER Glycine 0 C--O 1.23 -0.144 0 N-CA-C 110.592 -1.003 . . . . 10.0 110.592 173.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -74.71 -45.14 46.25 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.53 -69.45 0.48 Allowed Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 114.731 -1.122 . . . . 10.0 111.331 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -55.58 -39.28 91.98 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 122.236 1.957 . . . . 10.0 111.062 -179.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.0 t -63.26 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 C-N-CA 129.064 2.946 . . . . 10.0 109.094 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -95.45 47.75 1.13 Allowed 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.92 1.288 . . . . 10.0 110.173 -167.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -58.77 150.73 34.87 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 121.142 -0.551 . . . . 10.0 114.041 -168.146 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.543 ' CG2' HG22 ' B' ' 54' ' ' THR . 9.4 mt -136.63 89.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 106.31 -1.737 . . . . 10.0 106.31 -171.446 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.9 mm -96.24 136.74 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.139 0.576 . . . . 10.0 109.455 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -122.7 111.45 16.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 126.027 1.731 . . . . 10.0 107.522 172.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -92.85 118.74 31.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.2 1.4 . . . . 10.0 107.343 175.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -124.0 117.84 25.66 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 123.62 0.575 . . . . 10.0 111.161 175.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -101.13 102.57 13.53 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 105.876 -1.898 . . . . 10.0 105.876 168.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.3 mmmp? -54.32 -53.6 51.65 Favored 'General case' 0 C--N 1.338 0.108 0 C-N-CA 124.738 1.215 . . . . 10.0 110.821 -169.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.67 178.45 6.99 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 104.798 -2.297 . . . . 10.0 104.798 169.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -70.04 -20.37 63.25 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 110.311 -0.255 . . . . 10.0 110.311 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.8 m-80 -79.5 -21.88 44.72 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 123.742 0.817 . . . . 10.0 109.68 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.47 149.64 33.9 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.096 -0.802 . . . . 10.0 111.096 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -66.82 159.81 49.7 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 122.353 2.035 . . . . 10.0 107.597 168.176 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.29 96.33 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 105.93 -1.878 . . . . 10.0 105.93 174.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.9 mtpm? -71.98 100.6 2.51 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 106.42 -1.696 . . . . 10.0 106.42 172.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.54 97.7 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 125.52 1.528 . . . . 10.0 107.28 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.2 p90 -108.79 169.06 8.9 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 121.017 0.437 . . . . 10.0 110.606 169.299 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.57 -168.43 36.74 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.804 -0.518 . . . . 10.0 111.804 173.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 11.7 m -147.79 122.84 10.11 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.753 -0.223 . . . . 10.0 111.565 -177.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -99.53 95.42 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 C-N-CA 126.64 1.976 . . . . 10.0 107.449 169.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -106.0 102.45 11.88 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.009 0.524 . . . . 10.0 110.243 176.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.61 29.5 0.06 OUTLIER Glycine 0 C--N 1.334 0.463 0 CA-C-O 118.819 -0.989 . . . . 10.0 114.847 171.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -126.23 175.87 7.49 Favored 'General case' 0 C--O 1.223 -0.302 0 CA-C-N 118.329 1.065 . . . . 10.0 109.022 -177.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.3 t -75.52 160.42 30.2 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 109.325 171.437 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -62.24 -176.4 0.1 Allowed 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.029 1.332 . . . . 10.0 112.74 -176.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.9 -177.65 46.48 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.059 -0.816 . . . . 10.0 111.059 171.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.27 150.29 46.54 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.904 0.882 . . . . 10.0 109.216 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 -144.55 149.05 35.2 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.359 0.664 . . . . 10.0 112.484 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -30.09 121.77 0.11 Allowed Glycine 0 C--N 1.34 0.774 0 C-N-CA 128.34 2.876 . . . . 10.0 112.215 165.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -149.56 107.53 3.72 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 120.045 1.923 . . . . 10.0 113.412 168.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.509 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -149.29 168.78 22.38 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 122.18 0.99 . . . . 10.0 112.747 177.777 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 43.5 t -95.36 143.34 12.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 111.186 -2.734 . . . . 10.0 105.964 168.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -125.58 152.24 45.36 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 125.022 1.329 . . . . 10.0 108.889 177.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -62.35 -55.82 24.34 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 123.621 0.768 . . . . 10.0 109.87 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -76.55 104.89 7.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.154 -1.795 . . . . 10.0 106.154 -170.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.57 -36.54 92.59 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 108.844 -1.702 . . . . 10.0 108.844 173.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -54.11 160.99 1.39 Allowed 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 122.735 1.255 . . . . 10.0 113.254 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -156.33 22.39 0.36 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.206 -1.361 . . . . 10.0 114.506 -172.027 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -48.94 -36.95 18.59 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.366 1.066 . . . . 10.0 111.387 174.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.6 -18.14 57.12 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.556 1.142 . . . . 10.0 112.854 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.52 84.15 0.57 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 123.686 0.66 . . . . 10.0 112.03 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.1 m 47.13 35.51 3.61 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.152 1.781 . . . . 10.0 112.378 174.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.5 m -129.44 -52.39 1.17 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 124.176 0.991 . . . . 10.0 108.396 -169.106 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.1 t -104.32 24.38 11.65 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.525 0.73 . . . . 10.0 109.394 178.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.29 46.51 0.62 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 123.607 0.763 . . . . 10.0 110.68 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.15 100.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.1 0 C-N-CA 126.263 1.887 . . . . 10.0 113.919 168.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -68.61 73.79 0.89 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 123.523 2.815 . . . . 10.0 113.086 179.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.436 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 20.0 m170 60.64 44.24 11.67 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.365 3.466 . . . . 10.0 110.6 172.384 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -68.96 68.84 0.17 Allowed 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.917 1.287 . . . . 10.0 111.659 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -84.77 154.97 61.84 Favored Pre-proline 0 C--N 1.322 -0.621 0 C-N-CA 125.512 1.525 . . . . 10.0 109.593 177.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.23 -44.19 5.24 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 122.433 2.089 . . . . 10.0 111.564 178.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.14 53.55 0.99 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.753 0.821 . . . . 10.0 111.021 -178.113 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.6 t -47.34 114.23 0.83 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.086 0.954 . . . . 10.0 111.009 -169.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 54.6 mtt180 -151.69 178.0 9.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 105.458 -2.053 . . . . 10.0 105.458 -169.645 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.5 ' HZ1' ' CD ' ' A' ' 78' ' ' GLU . 0.0 OUTLIER -78.72 141.47 37.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 118.614 -1.235 . . . . 10.0 108.892 -177.766 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -44.98 118.04 1.53 Allowed 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 121.002 -0.279 . . . . 10.0 111.514 168.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.54 -141.64 4.32 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.461 -1.055 . . . . 10.0 110.461 179.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.436 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -162.32 -175.49 33.4 Favored Glycine 0 C--O 1.223 -0.591 0 CA-C-N 118.426 1.113 . . . . 10.0 113.562 -173.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -66.58 7.6 0.39 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.176 1.917 . . . . 10.0 111.09 168.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.436 ' H ' ' C ' ' A' ' 73' ' ' GLY . 71.7 mmtt -96.57 -22.47 17.04 Favored 'General case' 0 N--CA 1.435 -1.183 0 C-N-CA 124.422 1.089 . . . . 10.0 108.407 173.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -126.56 -172.61 2.67 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 112.476 0.547 . . . . 10.0 112.476 -168.301 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -115.1 -6.21 12.48 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.967 1.307 . . . . 10.0 111.071 -174.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.5 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 2.8 mt-10 -100.74 -14.34 18.1 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 124.646 1.178 . . . . 10.0 112.143 -178.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -26.09 114.65 0.06 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 125.929 1.691 . . . . 10.0 111.331 167.707 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -53.62 -53.11 56.53 Favored 'General case' 0 C--O 1.226 -0.14 0 CA-C-O 121.419 0.628 . . . . 10.0 111.718 -167.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.5 p -165.38 -103.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 104.376 -2.453 . . . . 10.0 104.376 170.192 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -76.49 59.39 3.31 Favored Glycine 0 CA--C 1.53 1.018 0 CA-C-N 119.098 0.863 . . . . 10.0 112.476 176.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -91.11 108.18 19.69 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 103.77 -2.678 . . . . 10.0 103.77 166.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -81.59 -19.9 40.96 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 118.446 0.566 . . . . 10.0 111.34 -172.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.03 -92.46 0.59 Allowed Glycine 0 C--O 1.217 -0.937 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -155.19 159.52 40.18 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 -178.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.6 m -126.13 126.6 69.83 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 123.665 0.786 . . . . 10.0 110.283 170.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -80.11 124.47 28.79 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 127.025 2.13 . . . . 10.0 111.773 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.82 129.55 49.53 Favored 'General case' 0 C--O 1.234 0.243 0 C-N-CA 126.051 1.74 . . . . 10.0 109.58 170.031 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -64.98 172.14 3.09 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 123.985 0.803 . . . . 10.0 109.958 169.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -48.59 -34.61 11.86 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 126.586 1.954 . . . . 10.0 109.983 173.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -78.99 -6.53 56.55 Favored 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 123.943 0.897 . . . . 10.0 110.146 -172.452 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.13 21.18 71.23 Favored Glycine 0 C--N 1.339 0.738 0 N-CA-C 110.27 -1.132 . . . . 10.0 110.27 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.5 t -101.79 106.7 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 127.501 2.32 . . . . 10.0 105.266 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.9 120.39 40.32 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.092 -1.077 . . . . 10.0 108.092 169.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -88.77 134.72 33.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 169.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 90.1 t -109.68 131.78 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 104.705 -2.331 . . . . 10.0 104.705 168.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.9 m -154.79 68.5 0.71 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 124.158 0.983 . . . . 10.0 108.795 174.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -117.22 160.82 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 106.736 -1.579 . . . . 10.0 106.736 -174.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -132.01 123.91 28.25 Favored 'General case' 0 N--CA 1.446 -0.626 0 O-C-N 121.842 -0.536 . . . . 10.0 110.139 168.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -104.47 128.0 52.28 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.783 1.233 . . . . 10.0 109.403 -172.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.9 p -113.42 38.25 2.95 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.047 1.339 . . . . 10.0 110.867 177.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.53 -39.73 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 C-N-CA 123.644 0.778 . . . . 10.0 111.47 173.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.369 0.8 OUTLIER -90.27 175.66 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 119.566 1.076 . . . . 10.0 112.106 170.173 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 83.7 p -146.39 158.74 43.92 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.402 -0.811 . . . . 10.0 109.107 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.8 mp -89.82 -26.56 20.49 Favored 'General case' 0 N--CA 1.457 -0.077 0 C-N-CA 122.756 0.422 . . . . 10.0 110.493 170.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -155.9 46.51 0.47 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.188 0.449 . . . . 10.0 110.853 -172.035 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -151.92 70.44 0.3 Allowed Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.549 -1.82 . . . . 10.0 108.549 -178.001 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.8 t70 73.94 -52.32 0.69 Allowed 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 128.711 2.804 . . . . 10.0 111.21 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -75.3 -36.7 61.09 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -167.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.5 t 37.79 75.48 0.07 Allowed 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.694 1.598 . . . . 10.0 113.731 166.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.8 pt -61.98 -9.37 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 N-CA-C 114.133 1.16 . . . . 10.0 114.133 -177.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 39.1 mm -45.28 129.45 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 O-C-N 121.066 -1.022 . . . . 10.0 110.263 170.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.74 -3.41 86.89 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.5 -1.167 . . . . 10.0 114.116 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -78.26 175.67 9.99 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 119.101 1.451 . . . . 10.0 108.04 168.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -123.4 135.2 54.01 Favored 'General case' 0 C--N 1.338 0.105 0 C-N-CA 123.308 0.643 . . . . 10.0 110.151 171.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -89.53 147.22 24.09 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 107.64 -1.245 . . . . 10.0 107.64 168.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.4 t -129.27 131.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.2 -1.407 . . . . 10.0 107.2 169.254 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -102.97 133.18 47.46 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 N-CA-C 105.787 -1.931 . . . . 10.0 105.787 168.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -111.52 157.67 20.07 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.839 1.422 . . . . 10.0 114.839 -170.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 52.0 tt0 -43.52 -52.46 6.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 128.598 2.759 . . . . 10.0 110.332 176.274 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -118.21 165.28 14.0 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 123.584 0.754 . . . . 10.0 110.915 -169.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -58.58 147.16 33.27 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.002 -0.999 . . . . 10.0 109.698 169.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.509 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 26.1 m-20 -79.49 130.56 35.52 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 124.459 1.104 . . . . 10.0 109.829 171.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.51 -16.66 59.59 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 123.876 0.735 . . . . 10.0 111.014 173.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.2 mt 55.6 49.74 15.89 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-O 122.251 1.024 . . . . 10.0 109.386 -173.105 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.52 -29.49 9.61 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.069 -1.423 . . . . 10.0 112.399 169.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt -77.06 9.94 2.68 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.731 1.011 . . . . 10.0 113.731 -168.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.07 -19.98 74.36 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 124.378 0.99 . . . . 10.0 111.86 172.469 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.79 42.51 68.9 Favored Glycine 0 C--N 1.343 0.944 0 N-CA-C 111.031 -0.828 . . . . 10.0 111.031 -176.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -131.51 159.09 39.16 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 106.139 -1.8 . . . . 10.0 106.139 177.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -50.68 -49.0 58.36 Favored 'General case' 0 N--CA 1.442 -0.841 0 CA-C-N 114.522 -1.217 . . . . 10.0 107.82 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -63.28 -33.67 76.02 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 115.376 -0.829 . . . . 10.0 112.41 175.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.9 p -59.43 -43.23 93.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 120.153 -1.592 . . . . 10.0 111.06 174.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -81.47 -21.04 39.02 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 122.973 0.171 . . . . 10.0 111.187 -174.115 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 15.6 mmtp -89.11 -49.3 6.83 Favored 'General case' 0 C--N 1.339 0.129 0 C-N-CA 124.781 1.232 . . . . 10.0 113.099 179.223 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.436 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 34.7 p -128.81 -18.08 3.89 Favored 'General case' 0 C--O 1.227 -0.125 0 N-CA-C 114.734 1.383 . . . . 10.0 114.734 177.709 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 106.55 26.26 5.97 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 119.452 1.024 . . . . 10.0 112.96 -176.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 58.64 21.6 8.93 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 118.349 1.074 . . . . 10.0 111.033 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.4 -5.36 35.93 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 123.965 0.906 . . . . 10.0 111.8 -169.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.84 -165.58 53.66 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.808 -1.317 . . . . 10.0 109.808 168.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 60.2 m -52.01 129.62 27.67 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-O 121.362 0.601 . . . . 10.0 110.037 -171.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.71 72.95 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.004 1.322 . . . . 10.0 110.414 171.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 6.5 tp -47.75 -35.2 9.48 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 128.202 2.601 . . . . 10.0 113.122 -172.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.93 157.09 25.87 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.73 -0.841 . . . . 10.0 108.73 172.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -145.31 163.32 34.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.047 -0.524 . . . . 10.0 109.714 177.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.18 147.32 15.39 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.495 -1.442 . . . . 10.0 109.495 -174.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 69.9 t -105.88 131.88 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 C-N-CA 126.142 1.777 . . . . 10.0 106.771 -169.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 8.2 mt -77.14 117.62 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.735 0 CA-C-N 117.884 0.311 . . . . 10.0 110.398 -174.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.45 158.87 14.1 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.572 1.082 . . . . 10.0 112.036 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.1 mt -64.74 142.56 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 125.309 1.444 . . . . 10.0 109.803 177.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.77 165.11 28.16 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.575 -1.269 . . . . 10.0 107.575 167.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.12 0 N-CA-C 105.023 -2.214 . . . . 10.0 105.023 167.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.551 0 N-CA-C 106.815 -1.55 . . . . 10.0 106.815 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.1 t -94.9 -35.1 12.17 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.558 1.143 . . . . 10.0 109.539 175.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -134.23 160.32 38.22 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 124.486 1.114 . . . . 10.0 110.467 -171.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.99 166.18 34.41 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 169.161 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -128.4 175.78 9.25 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 N-CA-C 107.739 -1.208 . . . . 10.0 107.739 171.175 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.04 122.61 13.24 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 124.064 0.946 . . . . 10.0 109.076 168.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -102.65 100.41 10.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 C-N-CA 124.482 1.113 . . . . 10.0 110.43 174.179 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.65 130.41 35.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.742 0.817 . . . . 10.0 109.188 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -144.62 162.68 36.04 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 119.529 1.059 . . . . 10.0 108.423 170.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -167.22 -61.37 0.03 OUTLIER Glycine 0 C--O 1.229 -0.208 0 CA-C-N 115.331 -0.85 . . . . 10.0 112.057 171.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -73.81 -44.64 55.19 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 106.544 -1.65 . . . . 10.0 106.544 -171.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.07 -65.57 0.59 Allowed Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 113.614 -1.63 . . . . 10.0 110.404 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -55.44 -38.75 93.67 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 122.644 2.23 . . . . 10.0 111.148 171.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 98.6 t -67.91 107.47 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 N-CA-C 108.058 -1.09 . . . . 10.0 108.058 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.04 107.7 10.67 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 125.662 1.585 . . . . 10.0 107.266 172.676 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -95.67 136.57 12.94 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.181 -0.768 . . . . 10.0 111.181 173.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.9 mt -140.75 89.58 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -102.39 149.77 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.087 0 C-N-CA 124.819 1.248 . . . . 10.0 110.753 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -119.57 133.39 55.68 Favored 'General case' 0 C--O 1.232 0.155 0 C-N-CA 127.639 2.376 . . . . 10.0 107.417 174.148 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -119.32 113.62 21.11 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 171.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -110.74 137.46 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 118.714 0.688 . . . . 10.0 111.478 167.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -96.93 113.92 25.5 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.655 -1.98 . . . . 10.0 105.655 167.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.7 tttt -57.64 -51.63 68.72 Favored 'General case' 0 N--CA 1.443 -0.775 0 C-N-CA 125.804 1.642 . . . . 10.0 109.672 -175.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 74.8 mt-10 -126.39 -139.11 0.27 Allowed 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 105.392 -2.077 . . . . 10.0 105.392 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 22.8 t -107.18 -12.05 15.47 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 120.12 1.327 . . . . 10.0 110.838 168.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -130.4 5.8 4.81 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 124.071 0.948 . . . . 10.0 110.901 176.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.01 148.57 43.09 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 108.164 -1.974 . . . . 10.0 108.164 171.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -59.59 149.18 83.92 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 122.63 2.22 . . . . 10.0 110.269 -177.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -88.99 108.1 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 105.913 -1.884 . . . . 10.0 105.913 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 40.4 tttt -88.39 116.86 26.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 105.886 -1.894 . . . . 10.0 105.886 168.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -92.56 103.22 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -123.28 152.41 41.4 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 112.63 0.604 . . . . 10.0 112.63 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.42 -150.86 22.07 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 106.556 -2.618 . . . . 10.0 106.556 172.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.98 154.62 31.38 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 118.86 -1.136 . . . . 10.0 110.733 -176.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 pt -113.89 141.38 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 114.91 -1.041 . . . . 10.0 109.614 167.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 tttm -118.81 141.28 48.78 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.81 -8.76 31.96 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 119.517 -0.602 . . . . 10.0 113.95 174.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.39 176.7 0.59 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 118.303 1.052 . . . . 10.0 111.601 175.121 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -112.7 154.04 26.75 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 105.656 -1.979 . . . . 10.0 105.656 165.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -48.95 154.38 0.74 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.869 1.267 . . . . 10.0 113.3 -168.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -171.11 22.29 Favored Glycine 0 C--N 1.337 0.61 0 C-N-CA 123.84 0.733 . . . . 10.0 112.212 168.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -73.3 144.13 46.71 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.293 1.437 . . . . 10.0 109.782 -178.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -148.03 150.03 33.2 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 113.504 0.928 . . . . 10.0 113.504 -177.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -29.73 119.87 0.08 OUTLIER Glycine 0 C--N 1.339 0.731 0 C-N-CA 128.409 2.909 . . . . 10.0 113.847 165.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -153.77 110.92 3.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 118.72 1.26 . . . . 10.0 111.029 168.493 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -146.86 175.01 10.97 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 121.436 0.636 . . . . 10.0 110.382 177.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.9 m -103.1 155.62 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 104.903 -2.258 . . . . 10.0 104.903 166.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -138.58 154.98 48.73 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.845 1.258 . . . . 10.0 109.835 -173.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.7 tt0 -57.48 -64.62 0.83 Allowed 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.387 2.275 . . . . 10.0 112.387 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -77.06 105.92 8.44 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 -172.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.15 -23.9 66.61 Favored Glycine 0 CA--C 1.532 1.116 0 N-CA-C 108.995 -1.642 . . . . 10.0 108.995 167.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.38 152.43 0.44 Allowed 'General case' 0 N--CA 1.445 -0.699 0 C-N-CA 124.928 1.291 . . . . 10.0 111.682 168.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -152.21 24.46 0.63 Allowed 'General case' 0 N--CA 1.439 -1.007 0 CA-C-N 114.629 -1.169 . . . . 10.0 112.49 168.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.543 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -60.6 -25.41 66.22 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 121.783 -0.573 . . . . 10.0 110.292 176.878 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.57 -17.18 60.13 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.632 0.773 . . . . 10.0 111.149 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.05 73.71 0.9 Allowed Glycine 0 CA--C 1.527 0.795 0 N-CA-C 110.709 -0.956 . . . . 10.0 110.709 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 53.72 32.5 14.83 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.092 0.957 . . . . 10.0 112.534 170.201 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -122.4 -48.63 2.07 Favored 'General case' 0 N--CA 1.441 -0.923 0 C-N-CA 124.943 1.297 . . . . 10.0 108.317 -169.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.8 t -125.37 48.94 1.96 Allowed 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.58 -0.896 . . . . 10.0 108.58 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.81 50.62 0.72 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.603 0.761 . . . . 10.0 110.265 176.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 69.78 120.07 0.04 OUTLIER Glycine 0 CA--C 1.537 1.42 0 C-N-CA 124.947 1.261 . . . . 10.0 113.093 173.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -80.98 50.77 3.69 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 122.729 2.286 . . . . 10.0 112.817 -173.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.412 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 17.5 m170 62.33 100.33 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 127.966 2.507 . . . . 10.0 109.631 -175.718 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -27.38 -47.01 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 128.279 2.632 . . . . 10.0 115.725 -175.19 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 19.39 76.75 0.19 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 128.047 2.539 . . . . 10.0 116.011 -174.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.26 -50.63 2.61 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 121.128 1.218 . . . . 10.0 109.576 172.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 23.3 tp -77.58 75.9 4.12 Favored 'General case' 0 N--CA 1.453 -0.285 0 O-C-N 121.677 -0.64 . . . . 10.0 109.322 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.2 t -17.3 90.25 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 128.051 2.54 . . . . 10.0 114.241 174.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -135.34 164.77 26.99 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 126.721 2.008 . . . . 10.0 107.981 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -105.62 95.33 5.74 Favored 'General case' 0 C--O 1.224 -0.247 0 C-N-CA 122.897 0.479 . . . . 10.0 109.853 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.477 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 84.6 t60 2.16 94.84 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.406 0 C-N-CA 127.56 2.344 . . . . 10.0 115.254 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -100.91 -144.82 16.06 Favored Glycine 0 C--N 1.316 -0.582 0 N-CA-C 109.836 -1.306 . . . . 10.0 109.836 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.455 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 179.14 -165.82 34.95 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 106.749 -2.54 . . . . 10.0 106.749 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -65.28 7.25 0.31 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 CA-C-N 119.887 1.843 . . . . 10.0 111.169 167.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.455 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.8 mmmt -119.94 1.56 10.95 Favored 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 126.509 1.923 . . . . 10.0 110.775 178.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -143.34 159.68 41.92 Favored 'General case' 0 C--N 1.348 0.533 0 CA-C-N 120.709 1.595 . . . . 10.0 108.92 168.183 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.2 mm-40 -78.73 -22.0 47.2 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.588 -0.893 . . . . 10.0 108.588 177.09 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -87.14 34.13 0.68 Allowed 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.433 1.093 . . . . 10.0 111.713 -170.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.0 mtm180 -49.12 142.27 7.13 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.591 1.156 . . . . 10.0 108.254 169.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . 0.477 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 24.4 m170 -75.74 -50.35 15.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.639 0.654 . . . . 10.0 110.367 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER 175.46 -19.88 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 126.949 2.1 . . . . 10.0 111.675 174.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -161.46 68.98 0.23 Allowed Glycine 0 C--N 1.338 0.642 0 N-CA-C 108.469 -1.852 . . . . 10.0 108.469 -169.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -127.58 94.79 4.06 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -168.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.1 mp -64.5 -35.9 82.44 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.468 -0.568 . . . . 10.0 109.468 -172.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.74 -88.14 0.41 Allowed Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 107.19 -2.364 . . . . 10.0 107.19 176.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.6 m120 -149.82 141.46 23.54 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.731 -1.211 . . . . 10.0 107.731 -172.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.5 m -116.52 135.5 56.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 118.443 0.565 . . . . 10.0 110.425 169.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 19.8 m -94.92 100.9 12.68 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 128.173 2.589 . . . . 10.0 110.584 -170.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.92 131.23 35.8 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.066 0.547 . . . . 10.0 110.645 174.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -64.92 168.92 5.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.919 1.688 . . . . 10.0 109.139 167.438 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.15 -32.03 33.93 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.488 1.115 . . . . 10.0 111.039 175.77 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -80.68 -2.0 44.88 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 124.445 1.098 . . . . 10.0 110.794 -176.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.83 82.72 Favored Glycine 0 C--N 1.34 0.762 0 O-C-N 121.158 -0.964 . . . . 10.0 110.86 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 62.8 t -90.37 104.12 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 106.069 -1.826 . . . . 10.0 106.069 176.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.61 122.68 44.88 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 107.61 -1.256 . . . . 10.0 107.61 169.531 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -89.7 124.75 34.88 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.305 1.042 . . . . 10.0 108.25 174.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 51.9 t -110.07 131.53 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.937 1.695 . . . . 10.0 107.529 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 95.2 p -156.53 60.8 0.55 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.174 0.589 . . . . 10.0 109.901 174.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.49 155.02 5.13 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 -173.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -131.56 142.37 49.9 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.575 0.75 . . . . 10.0 111.067 177.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -140.37 161.8 36.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.552 -1.648 . . . . 10.0 106.552 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 11.1 t -136.98 10.33 3.06 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 125.398 1.479 . . . . 10.0 112.893 175.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -89.19 -15.46 8.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 120.077 1.308 . . . . 10.0 109.628 174.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.29 1.0 OUTLIER -111.79 162.57 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 125.333 1.453 . . . . 10.0 112.05 175.578 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.2 m -148.66 147.5 29.0 Favored 'General case' 0 C--N 1.34 0.171 0 C-N-CA 124.087 0.955 . . . . 10.0 109.355 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.45 -21.25 66.2 Favored 'General case' 0 C--O 1.227 -0.113 0 C-N-CA 125.208 1.403 . . . . 10.0 111.35 176.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.7 t -156.73 -172.25 3.98 Favored 'General case' 0 N--CA 1.453 -0.299 0 O-C-N 121.293 -0.879 . . . . 10.0 109.674 171.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 112.45 -89.57 0.53 Allowed Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 107.377 -2.289 . . . . 10.0 107.377 172.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -123.58 -46.94 1.99 Allowed 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 125.232 1.413 . . . . 10.0 109.579 173.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -72.31 -42.91 64.91 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 107.37 -1.344 . . . . 10.0 107.37 -168.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 21.2 t 37.9 75.64 0.07 Allowed 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 127.353 2.261 . . . . 10.0 111.899 168.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 pt -74.29 55.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 123.834 0.854 . . . . 10.0 111.281 176.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 43.5 mm -108.46 -49.3 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 125.848 1.659 . . . . 10.0 109.956 179.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -90.19 18.68 47.22 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.372 -0.682 . . . . 10.0 113.074 -174.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.7 mtt85 -99.64 179.73 4.45 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.115 1.366 . . . . 10.0 110.556 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -133.87 147.62 51.18 Favored 'General case' 0 CA--C 1.507 -0.688 0 C-N-CA 125.789 1.636 . . . . 10.0 106.726 -175.484 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 7.7 mp -113.49 153.81 28.09 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.331 -0.988 . . . . 10.0 108.331 173.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.0 t -131.97 130.46 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -97.82 123.92 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.349 -1.723 . . . . 10.0 106.349 169.125 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -105.06 155.04 19.35 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 115.857 1.799 . . . . 10.0 115.857 -172.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 59.3 tt0 -44.79 -53.35 7.51 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 128.139 2.576 . . . . 10.0 111.726 175.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -113.08 167.19 10.73 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.952 0.723 . . . . 10.0 112.952 -168.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -70.49 147.28 49.57 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 113.967 -1.469 . . . . 10.0 108.424 170.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -94.84 131.34 40.82 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -173.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -76.51 -17.42 59.28 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.36 1.064 . . . . 10.0 110.19 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 22.6 mt 57.74 56.6 4.72 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 122.513 1.149 . . . . 10.0 108.969 -179.363 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.1 -40.83 3.06 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.745 -1.57 . . . . 10.0 110.722 168.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 30.7 mtmt -79.01 48.99 0.89 Allowed 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.637 1.175 . . . . 10.0 110.81 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -112.07 -9.21 20.73 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 127.203 2.335 . . . . 10.0 112.377 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.7 37.73 43.1 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 123.951 0.786 . . . . 10.0 112.973 176.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 -134.0 157.87 44.97 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 106.359 -1.719 . . . . 10.0 106.359 174.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -54.86 -45.94 74.63 Favored 'General case' 0 N--CA 1.439 -0.999 0 CA-C-O 122.305 1.05 . . . . 10.0 108.207 170.207 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 24.0 tp10 -58.48 -33.83 70.23 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 121.185 -0.947 . . . . 10.0 112.978 173.084 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.0 p -56.51 -42.09 77.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 120.606 1.548 . . . . 10.0 111.074 172.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.3 t -82.78 -19.65 37.36 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 118.485 -0.769 . . . . 10.0 112.421 -178.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -90.86 -46.46 8.18 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 124.448 1.099 . . . . 10.0 112.128 -176.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.412 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 26.9 p -133.51 -9.26 2.86 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.098 1.147 . . . . 10.0 114.098 176.504 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.42 23.61 12.31 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 119.289 0.95 . . . . 10.0 112.546 -173.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 61.67 21.83 12.46 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.769 1.284 . . . . 10.0 111.248 -176.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.33 -7.76 20.99 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 125.592 1.557 . . . . 10.0 112.285 -171.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.18 -167.97 54.84 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.069 -1.212 . . . . 10.0 110.069 170.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 12.6 t -53.96 129.1 32.94 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 121.819 0.819 . . . . 10.0 110.862 -169.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.45 73.23 0.08 Allowed 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 124.049 0.94 . . . . 10.0 108.961 169.449 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 66.3 mt -47.14 -45.56 22.6 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.868 0.867 . . . . 10.0 111.676 -177.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.24 152.38 27.69 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -169.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -161.42 165.26 29.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.855 -0.611 . . . . 10.0 109.485 -172.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.44 163.24 30.22 Favored Glycine 0 C--N 1.331 0.255 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -174.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -101.91 156.05 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 N-CA-C 104.05 -2.574 . . . . 10.0 104.05 169.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 77.9 mt -74.75 -94.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 109.765 -0.457 . . . . 10.0 109.765 -169.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 112.92 135.95 6.48 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.626 1.108 . . . . 10.0 112.049 175.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -62.48 138.63 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.106 1.363 . . . . 10.0 110.096 179.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.87 146.59 49.37 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.434 -1.321 . . . . 10.0 107.434 169.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 . . . . . 0 C--O 1.248 0.99 0 N-CA-C 106.195 -1.779 . . . . 10.0 106.195 169.295 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 t -172.37 -36.44 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.703 1.201 . . . . 10.0 112.077 -179.109 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 48.0 tttt -137.98 134.46 34.9 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 123.267 0.627 . . . . 10.0 110.357 -179.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.5 167.85 26.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.012 1.325 . . . . 10.0 108.849 -175.21 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -126.89 164.15 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 118.746 0.703 . . . . 10.0 110.519 170.071 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.74 112.31 11.27 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.285 1.434 . . . . 10.0 107.711 167.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.0 m -95.88 103.14 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 123.666 0.787 . . . . 10.0 110.216 177.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mt -87.77 107.83 18.84 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 118.637 -0.697 . . . . 10.0 110.038 -173.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -133.24 158.69 42.26 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 120.644 1.565 . . . . 10.0 108.453 175.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.71 -68.82 0.02 OUTLIER Glycine 0 N--CA 1.462 0.372 0 CA-C-N 114.818 -1.083 . . . . 10.0 112.342 170.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -72.37 -39.5 68.0 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.064 -1.458 . . . . 10.0 107.064 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.24 -60.48 0.56 Allowed Glycine 0 N--CA 1.443 -0.86 0 CA-C-O 118.476 -1.18 . . . . 10.0 112.608 170.241 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -60.62 -39.62 62.7 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 CA-C-N 119.198 1.499 . . . . 10.0 110.848 -177.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -70.66 115.32 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 177.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.84 103.95 7.78 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.413 -2.44 . . . . 10.0 104.413 170.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.38 145.79 19.19 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 108.445 -1.862 . . . . 10.0 108.445 174.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.3 mt -144.85 74.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -168.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 mm -87.45 128.8 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 N-CA-C 109.741 -0.466 . . . . 10.0 109.741 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -99.6 112.15 24.4 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 126.41 1.884 . . . . 10.0 107.752 173.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -88.06 113.43 23.69 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 107.211 -1.403 . . . . 10.0 107.211 173.081 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -121.28 111.39 17.3 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 118.797 0.726 . . . . 10.0 111.272 168.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -99.53 91.54 4.95 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.129 -1.804 . . . . 10.0 106.129 168.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.48 -36.71 66.91 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.972 0.909 . . . . 10.0 112.939 -168.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.05 171.2 14.76 Favored 'General case' 0 N--CA 1.432 -1.362 0 N-CA-C 104.834 -2.284 . . . . 10.0 104.834 167.398 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.4 p -64.81 -24.65 67.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.235 0.54 . . . . 10.0 110.248 179.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -81.58 -19.29 42.29 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 115.221 -0.9 . . . . 10.0 110.259 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -82.02 154.48 33.71 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.617 -0.593 . . . . 10.0 111.617 -173.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_endo -67.36 146.8 76.37 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.71 2.274 . . . . 10.0 106.876 167.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.9 p -80.29 110.05 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 174.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.474 ' HZ3' ' CD ' ' A' ' 100' ' ' GLU . 20.0 tttt -84.3 115.91 22.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.431 -0.952 . . . . 10.0 108.431 176.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 30.2 m -98.48 57.91 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 124.233 1.013 . . . . 10.0 108.73 -170.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 9.3 p90 -77.78 144.88 36.79 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 118.921 -1.112 . . . . 10.0 110.963 -175.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -175.88 172.04 45.06 Favored Glycine 0 N--CA 1.441 -0.976 0 O-C-N 121.24 -0.913 . . . . 10.0 110.89 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.8 t -128.58 107.91 10.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 178.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.7 pt -81.76 142.18 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 108.396 -0.964 . . . . 10.0 108.396 169.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.7 ptmm? -127.13 137.03 52.9 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.192 -1.04 . . . . 10.0 108.192 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.71 -1.92 27.52 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.075 0.845 . . . . 10.0 113.399 176.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -62.53 174.05 1.09 Allowed 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 122.132 0.968 . . . . 10.0 110.467 169.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -103.61 164.49 11.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.18 -1.785 . . . . 10.0 106.18 164.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -54.61 162.87 1.04 Allowed 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.576 0.751 . . . . 10.0 112.062 -172.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.72 -179.78 43.12 Favored Glycine 0 C--N 1.334 0.469 0 O-C-N 121.248 -0.908 . . . . 10.0 112.29 168.144 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.1 mt -66.55 142.22 57.58 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.059 0.943 . . . . 10.0 110.65 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -138.02 128.82 26.91 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 117.729 -1.129 . . . . 10.0 111.103 176.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -15.2 113.46 0.01 OUTLIER Glycine 0 C--N 1.347 1.148 0 CA-C-O 115.949 -2.584 . . . . 10.0 112.49 167.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -137.73 100.15 4.11 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 120.989 2.394 . . . . 10.0 109.91 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.413 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -156.73 169.84 23.79 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-O 122.04 0.924 . . . . 10.0 112.79 -174.075 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.8 t -96.81 141.14 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 111.566 -2.561 . . . . 10.0 107.729 177.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -116.28 168.58 10.0 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.178 0.991 . . . . 10.0 109.397 178.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -67.23 -72.51 0.16 Allowed 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.697 -0.683 . . . . 10.0 111.246 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.55 136.98 34.71 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 120.161 -0.616 . . . . 10.0 110.132 -169.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -66.87 -31.59 78.63 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 109.278 -1.529 . . . . 10.0 109.278 168.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -45.14 155.34 0.12 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 122.837 1.303 . . . . 10.0 114.353 -175.32 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.17 15.37 0.82 Allowed 'General case' 0 N--CA 1.439 -0.985 0 CA-C-N 113.446 -1.707 . . . . 10.0 111.037 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -53.76 -43.07 68.88 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 120.266 1.394 . . . . 10.0 112.352 -167.676 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.59 -17.94 52.74 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.98 0.912 . . . . 10.0 112.65 -179.331 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.05 60.77 0.37 Allowed Glycine 0 CA--C 1.528 0.862 0 C-N-CA 124.468 1.033 . . . . 10.0 111.139 -177.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 61.24 18.65 9.35 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 114.513 1.301 . . . . 10.0 114.513 171.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 p -93.81 -57.53 2.53 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 176.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.4 m -49.91 -34.44 20.42 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.363 2.265 . . . . 10.0 111.853 -178.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -39.25 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.849 2.46 . . . . 10.0 112.078 168.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.74 154.02 28.63 Favored Glycine 0 N--CA 1.436 -1.339 0 N-CA-C 108.28 -1.928 . . . . 10.0 108.28 168.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -71.44 -164.95 0.17 Allowed 'Trans proline' 0 N--CA 1.442 -1.552 0 N-CA-C 107.269 -1.858 . . . . 10.0 107.269 167.295 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.413 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 50.4 m170 -79.84 62.75 4.17 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 120.596 -1.315 . . . . 10.0 109.951 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -75.28 67.28 1.86 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 123.702 1.715 . . . . 10.0 111.18 178.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -72.65 153.6 91.53 Favored Pre-proline 0 N--CA 1.448 -0.54 0 C-N-CA 128.205 2.602 . . . . 10.0 110.181 169.295 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.85 -40.2 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.767 2.312 . . . . 10.0 111.37 177.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mt -78.09 49.18 0.79 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.284 1.034 . . . . 10.0 110.442 -177.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.4 p -57.14 106.55 0.33 Allowed 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.417 1.087 . . . . 10.0 109.826 -170.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.4 mtt180 -134.7 -88.02 0.37 Allowed 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 106.562 -1.644 . . . . 10.0 106.562 -171.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.5 mmtp -140.71 155.39 46.48 Favored 'General case' 0 N--CA 1.438 -1.074 0 CA-C-O 122.695 1.236 . . . . 10.0 110.273 169.184 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 69.2 t60 -69.03 119.31 13.12 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 164.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.9 -138.24 3.81 Favored Glycine 0 N--CA 1.442 -0.919 0 N-CA-C 109.38 -1.488 . . . . 10.0 109.38 -175.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.475 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -176.94 -157.5 18.14 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 109.558 -1.417 . . . . 10.0 109.558 169.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -67.79 14.72 0.15 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.158 1.905 . . . . 10.0 111.424 168.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.475 ' H ' ' C ' ' A' ' 73' ' ' GLY . 4.5 mtpm? -120.91 -6.93 9.54 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.626 1.571 . . . . 10.0 110.677 174.542 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -110.89 162.39 14.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 177.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.4 pm0 -98.74 -16.16 19.06 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 126.319 1.847 . . . . 10.0 109.866 169.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -105.39 6.9 32.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.852 1.661 . . . . 10.0 112.324 -174.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -35.52 149.81 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.575 1.95 . . . . 10.0 112.924 171.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -70.06 -100.42 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 112.47 0.545 . . . . 10.0 112.47 -178.312 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 p -151.64 25.06 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 O-C-N 120.606 -1.309 . . . . 10.0 110.392 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 157.36 51.33 0.01 OUTLIER Glycine 0 CA--C 1.522 0.483 0 N-CA-C 108.814 -1.715 . . . . 10.0 108.814 -173.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.55 99.74 11.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 105.346 -2.094 . . . . 10.0 105.346 169.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.7 mt -94.49 33.02 1.47 Allowed 'General case' 0 N--CA 1.461 0.122 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 172.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 46.09 -106.38 0.13 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 126.514 2.006 . . . . 10.0 111.025 -178.351 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -151.92 117.66 5.43 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 123.557 0.743 . . . . 10.0 110.439 -168.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -92.86 138.69 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 122.731 0.412 . . . . 10.0 110.83 -171.111 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.31 118.56 24.28 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 125.035 1.334 . . . . 10.0 110.493 -172.391 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.59 134.74 38.12 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 123.225 0.61 . . . . 10.0 109.847 173.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -57.92 167.57 1.16 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.856 0.862 . . . . 10.0 109.025 167.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.11 -23.69 62.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.104 -0.498 . . . . 10.0 112.157 177.644 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -78.4 -13.09 60.0 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.266 0.627 . . . . 10.0 110.958 179.121 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.74 6.27 67.8 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.952 -0.859 . . . . 10.0 110.952 -176.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.9 t -81.49 108.1 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.516 1.927 . . . . 10.0 106.978 174.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -112.99 121.12 43.68 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 108.831 -0.803 . . . . 10.0 108.831 173.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -83.08 131.4 35.16 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.719 -0.845 . . . . 10.0 108.719 173.18 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.7 t -119.23 130.79 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 N-CA-C 104.815 -2.291 . . . . 10.0 104.815 168.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -155.75 57.78 0.61 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 118.655 0.661 . . . . 10.0 111.18 -177.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 71.6 mt -116.55 138.77 46.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.208 1.403 . . . . 10.0 109.824 -170.156 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.474 ' CD ' ' HZ3' ' A' ' 30' ' ' LYS . 2.3 pm0 -91.35 104.12 16.68 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 127.843 2.457 . . . . 10.0 109.121 172.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -81.34 116.48 21.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.009 -0.738 . . . . 10.0 109.009 175.256 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.8 p -111.3 46.46 1.09 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 125.448 1.499 . . . . 10.0 109.68 174.081 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.23 -41.06 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.168 0 CA-C-O 118.157 -0.925 . . . . 10.0 110.543 175.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.407 0.0 OUTLIER -106.27 177.21 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-N 119.553 1.069 . . . . 10.0 113.549 169.501 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.6 t -146.23 153.71 40.92 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 108.112 -1.07 . . . . 10.0 108.112 -176.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 93.1 mt -69.77 -17.53 63.43 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.318 0.647 . . . . 10.0 110.801 173.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.3 t -151.15 150.55 30.79 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.536 0.607 . . . . 10.0 109.533 177.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.6 68.09 0.43 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.017 -1.233 . . . . 10.0 110.017 -179.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.8 t70 71.61 -56.67 0.63 Allowed 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 129.536 3.134 . . . . 10.0 109.847 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -78.15 -2.46 37.61 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 113.011 0.745 . . . . 10.0 113.011 -168.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.9 t -17.76 96.41 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 129.025 2.93 . . . . 10.0 112.523 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 29.2 pt -72.84 -3.58 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 112.776 0.658 . . . . 10.0 112.776 -175.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.8 mm -52.54 130.28 13.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 O-C-N 121.092 -1.005 . . . . 10.0 108.493 169.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.92 8.71 87.67 Favored Glycine 0 CA--C 1.533 1.205 0 CA-C-O 118.67 -1.072 . . . . 10.0 114.22 -176.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -78.36 176.43 9.34 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 166.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -127.96 136.82 51.84 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 106.854 -1.535 . . . . 10.0 106.854 171.179 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.9 mp -107.61 158.07 17.55 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.183 -1.414 . . . . 10.0 107.183 168.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.1 t -132.27 136.79 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 107.487 -1.301 . . . . 10.0 107.487 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.3 125.19 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 103.674 -2.713 . . . . 10.0 103.674 167.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 7.0 m170 -106.37 164.37 12.08 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 120.207 1.367 . . . . 10.0 114.37 -171.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.39 -49.79 73.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 114.036 -1.438 . . . . 10.0 109.438 -175.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -117.97 173.05 6.99 Favored 'General case' 0 N--CA 1.456 -0.131 0 CA-C-O 122.425 1.107 . . . . 10.0 113.355 -174.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -73.57 143.28 46.5 Favored 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 113.475 -1.693 . . . . 10.0 109.646 169.454 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.13 156.3 36.11 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 123.851 0.861 . . . . 10.0 110.637 174.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 -85.35 8.92 16.98 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.414 -0.812 . . . . 10.0 109.968 166.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.4 mt 39.32 52.79 2.24 Favored 'General case' 0 C--N 1.344 0.369 0 C-N-CA 126.148 1.779 . . . . 10.0 110.782 -172.478 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.55 -26.24 24.68 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 113.642 -1.617 . . . . 10.0 112.59 173.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -78.97 24.37 0.31 Allowed 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 114.29 1.219 . . . . 10.0 114.29 -167.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.48 -38.41 38.29 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 108.49 -1.844 . . . . 10.0 108.49 169.034 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.84 47.8 58.7 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 109.431 -1.468 . . . . 10.0 109.431 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -152.17 164.08 38.06 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.544 -2.021 . . . . 10.0 105.544 176.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -44.74 -47.15 10.77 Favored 'General case' 0 N--CA 1.438 -1.055 0 C-N-CA 123.031 0.532 . . . . 10.0 111.344 -175.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.77 -34.56 71.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.453 -0.34 . . . . 10.0 110.176 -177.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -51.45 -44.44 62.36 Favored 'General case' 0 N--CA 1.446 -0.651 0 O-C-N 121.725 -0.61 . . . . 10.0 110.677 172.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -84.38 6.75 22.0 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.382 0.512 . . . . 10.0 112.382 -176.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -118.91 -75.62 0.58 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 125.594 1.557 . . . . 10.0 109.619 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 p -111.16 13.64 21.83 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 120.419 1.463 . . . . 10.0 113.689 175.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.66 -21.2 11.5 Favored Glycine 0 C--N 1.338 0.674 0 O-C-N 120.819 -1.176 . . . . 10.0 115.455 168.265 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 90.74 28.02 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 128.183 2.593 . . . . 10.0 110.097 -168.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.18 -2.2 1.28 Allowed 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.767 0.827 . . . . 10.0 112.686 169.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.11 -171.84 55.16 Favored Glycine 0 N--CA 1.443 -0.867 0 N-CA-C 109.882 -1.287 . . . . 10.0 109.882 174.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -60.88 144.92 51.9 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.881 0.848 . . . . 10.0 112.153 -169.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mtm-85 -63.71 63.29 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 127.305 2.242 . . . . 10.0 110.806 169.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.46 -14.86 59.21 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.941 1.089 . . . . 10.0 113.941 -173.021 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.86 146.3 17.63 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 123.303 0.641 . . . . 10.0 109.738 169.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.0 p -155.07 156.48 35.95 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.79 -0.818 . . . . 10.0 108.79 -171.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.22 145.39 12.38 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.412 -1.075 . . . . 10.0 110.412 -169.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.86 140.85 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 125.903 1.681 . . . . 10.0 106.838 -172.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.8 mt -80.56 120.1 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-O 118.716 -0.659 . . . . 10.0 110.575 -174.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -128.51 154.37 20.01 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 124.263 0.935 . . . . 10.0 113.085 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 mm -64.75 146.21 13.37 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 C-N-CA 124.292 1.037 . . . . 10.0 112.254 -169.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.57 -17.47 1.73 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 116.231 1.937 . . . . 10.0 116.231 178.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.252 1.206 0 CA-C-O 117.693 -1.146 . . . . 10.0 110.683 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 108.383 -0.969 . . . . 10.0 108.383 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -170.13 -47.2 0.02 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 124.099 0.96 . . . . 10.0 109.785 178.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -138.51 125.76 21.59 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 125.256 1.422 . . . . 10.0 107.973 -169.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.02 162.58 35.09 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 124.545 1.138 . . . . 10.0 109.053 -172.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 m -115.74 172.94 3.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-O 121.611 0.719 . . . . 10.0 110.086 171.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.44 102.56 3.85 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 104.425 -2.435 . . . . 10.0 104.425 165.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 m -90.03 120.02 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 170.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.16 136.22 39.44 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 108.326 -0.99 . . . . 10.0 108.326 -177.011 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 39.4 mtpt -145.45 160.26 41.86 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.659 -1.237 . . . . 10.0 107.659 169.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.07 -54.56 0.07 OUTLIER Glycine 0 N--CA 1.461 0.323 0 C-N-CA 120.522 -0.846 . . . . 10.0 113.669 169.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -72.06 -43.58 64.67 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 -174.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.84 -70.95 0.4 Allowed Glycine 0 CA--C 1.521 0.425 0 CA-C-N 114.223 -1.353 . . . . 10.0 109.86 169.656 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -57.62 -36.16 98.62 Favored 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 123.381 2.721 . . . . 10.0 111.389 172.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.95 101.69 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -117.79 106.91 13.52 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 124.633 1.173 . . . . 10.0 107.957 172.001 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -86.83 147.75 21.3 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 109.912 -1.275 . . . . 10.0 109.912 169.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.56 76.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 N-CA-C 104.761 -2.311 . . . . 10.0 104.761 -175.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -97.44 146.15 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 124.744 1.218 . . . . 10.0 108.85 -178.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -126.11 125.17 42.1 Favored 'General case' 0 C--O 1.232 0.133 0 C-N-CA 126.669 1.988 . . . . 10.0 107.864 -175.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -112.69 105.57 13.76 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.406 1.482 . . . . 10.0 107.805 178.137 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -113.13 123.78 51.05 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 123.823 0.702 . . . . 10.0 111.486 175.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -95.18 97.78 10.15 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.332 1.453 . . . . 10.0 108.003 174.274 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? -47.06 -61.88 1.67 Allowed 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 126.275 1.83 . . . . 10.0 110.955 -175.001 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -141.51 171.61 13.82 Favored 'General case' 0 N--CA 1.432 -1.37 0 N-CA-C 102.614 -3.106 . . . . 10.0 102.614 168.068 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.3 p -71.4 -15.62 62.37 Favored 'General case' 0 N--CA 1.445 -0.707 0 O-C-N 121.367 -0.833 . . . . 10.0 109.874 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 34.2 m120 -78.56 -26.6 45.63 Favored 'General case' 0 N--CA 1.441 -0.906 0 C-N-CA 123.59 0.756 . . . . 10.0 110.746 174.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.78 156.11 31.13 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.458 -1.057 . . . . 10.0 110.458 -177.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.57 161.0 45.43 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.122 1.881 . . . . 10.0 109.073 171.487 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 14.1 t -87.44 112.28 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 N-CA-C 105.208 -2.145 . . . . 10.0 105.208 169.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -92.98 121.12 33.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.599 -1.63 . . . . 10.0 106.599 169.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.69 106.38 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.307 1.843 . . . . 10.0 106.495 177.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -127.64 152.87 47.13 Favored 'General case' 0 CA--C 1.522 -0.133 0 N-CA-C 113.461 0.912 . . . . 10.0 113.461 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.26 -150.31 21.54 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 108.2 -1.96 . . . . 10.0 108.2 172.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 22.6 t -155.14 158.31 38.79 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 119.598 -0.841 . . . . 10.0 112.299 -177.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -118.88 114.21 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 127.147 2.179 . . . . 10.0 108.76 169.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -100.27 142.87 31.16 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 168.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.43 -1.17 14.21 Favored Glycine 0 C--N 1.337 0.599 0 C-N-CA 124.597 1.094 . . . . 10.0 112.932 169.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 31.7 mt -80.78 175.98 10.21 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.875 0.845 . . . . 10.0 110.491 -178.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -93.11 150.77 20.28 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 68.9 tt0 -53.77 145.32 16.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.4 1.08 . . . . 10.0 110.824 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.4 -176.64 21.8 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.799 0.714 . . . . 10.0 111.882 176.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.8 mp -70.83 150.33 45.93 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.485 1.514 . . . . 10.0 111.87 -172.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -143.22 144.15 32.04 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 112.969 0.729 . . . . 10.0 112.969 178.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -37.19 115.82 0.34 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.405 2.431 . . . . 10.0 112.211 166.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -135.66 106.6 6.65 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.754 1.777 . . . . 10.0 110.592 172.179 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.506 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -152.75 171.35 18.37 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-N 115.376 -0.829 . . . . 10.0 109.885 178.142 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 12.3 m -99.93 147.16 7.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 112.952 -1.931 . . . . 10.0 107.106 167.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 22.7 m-70 -116.14 131.19 57.01 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 103.949 -2.612 . . . . 10.0 103.949 173.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -59.73 -48.78 80.32 Favored 'General case' 0 N--CA 1.45 -0.443 0 O-C-N 124.206 0.941 . . . . 10.0 111.643 -167.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.7 m-30 -80.01 148.28 31.18 Favored 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 118.386 -1.326 . . . . 10.0 108.324 175.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.72 35.89 4.29 Favored Glycine 0 N--CA 1.441 -1.021 0 N-CA-C 108.083 -2.007 . . . . 10.0 108.083 166.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.7 74.73 6.38 Favored 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 126.895 3.236 . . . . 10.0 107.318 171.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -76.63 -0.37 23.16 Favored 'General case' 0 N--CA 1.416 -2.133 0 CA-C-N 109.63 -3.441 . . . . 10.0 111.029 -173.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -32.08 -52.38 0.26 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 130.194 3.397 . . . . 10.0 112.932 175.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -21.97 47.45 Favored 'General case' 0 CA--C 1.529 0.147 0 N-CA-C 112.871 0.693 . . . . 10.0 112.871 -176.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.24 75.85 1.3 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -174.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 19.9 m 63.75 56.82 1.47 Allowed 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 123.716 0.806 . . . . 10.0 112.208 168.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -155.14 -58.19 0.1 Allowed 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 108.239 -1.023 . . . . 10.0 108.239 175.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.5 m -61.42 -26.63 67.99 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 122.376 0.27 . . . . 10.0 111.578 -173.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.02 -34.56 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.977 2.511 . . . . 10.0 112.734 168.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.97 155.97 9.24 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.144 -0.783 . . . . 10.0 111.144 166.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -75.92 58.83 5.6 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 123.566 2.844 . . . . 10.0 108.494 166.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.293 26.1 m170 75.2 -44.3 0.53 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 127.181 2.192 . . . . 10.0 109.519 -177.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 51.61 47.62 24.45 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 126.461 1.904 . . . . 10.0 111.57 172.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -72.01 142.73 85.57 Favored Pre-proline 0 C--N 1.321 -0.638 0 C-N-CA 125.571 1.548 . . . . 10.0 112.987 178.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.92 -44.43 0.35 Allowed 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 123.623 2.882 . . . . 10.0 110.843 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 14.4 mt -68.96 88.13 0.38 Allowed 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.223 -1.399 . . . . 10.0 107.223 171.544 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -57.7 82.13 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.658 1.983 . . . . 10.0 111.25 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.68 -179.83 4.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 127.19 2.196 . . . . 10.0 108.126 177.588 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -111.1 107.89 17.41 Favored 'General case' 0 C--O 1.224 -0.244 0 N-CA-C 108.263 -1.014 . . . . 10.0 108.263 -177.155 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.46 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 83.1 t60 -12.09 98.23 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.439 0 C-N-CA 126.783 2.033 . . . . 10.0 113.892 -178.336 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.44 -175.54 14.11 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 106.916 -2.474 . . . . 10.0 106.916 176.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.32 -155.89 7.26 Favored Glycine 0 C--O 1.226 -0.376 0 N-CA-C 107.061 -2.416 . . . . 10.0 107.061 -177.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -67.22 1.45 2.95 Favored 'Trans proline' 0 CA--C 1.544 0.99 0 CA-C-N 119.69 1.745 . . . . 10.0 110.287 165.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 56.3 mmtt -89.8 -15.57 32.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.834 1.653 . . . . 10.0 110.416 171.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -133.81 178.53 6.87 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 119.832 1.196 . . . . 10.0 109.826 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -90.3 -32.41 16.53 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 169.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -95.14 43.52 1.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 122.299 1.047 . . . . 10.0 111.909 -169.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.58 144.31 17.72 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 115.849 -0.614 . . . . 10.0 110.48 168.47 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . 0.46 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.2 m170 -68.95 -56.86 6.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 -173.175 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.4 p -173.74 -38.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 123.715 0.806 . . . . 10.0 111.429 -174.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -158.56 69.61 0.26 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 108.072 -2.011 . . . . 10.0 108.072 -169.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -122.92 94.4 4.26 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.401 -2.074 . . . . 10.0 105.401 -171.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 5.0 mt -72.07 -28.3 63.24 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 88.39 -94.58 2.01 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 108.007 -2.037 . . . . 10.0 108.007 176.117 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -128.98 124.18 34.38 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.092 0.557 . . . . 10.0 110.531 -168.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 6.6 m -121.48 145.52 27.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.2 m -94.17 113.72 25.71 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 127.172 2.189 . . . . 10.0 111.97 -167.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.45 130.48 36.12 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 109.457 -0.571 . . . . 10.0 109.457 169.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -59.51 169.71 1.21 Allowed 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 125.098 1.359 . . . . 10.0 110.311 168.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.06 -32.29 34.03 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.035 1.334 . . . . 10.0 112.115 169.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -77.34 -1.4 29.75 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.3 0.64 . . . . 10.0 110.987 178.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.37 20.41 69.42 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 120.584 -1.323 . . . . 10.0 110.178 175.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.37 105.5 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 128.529 2.732 . . . . 10.0 106.604 -177.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.88 125.13 44.21 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 168.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 p-10 -88.52 122.7 32.27 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 127.052 2.141 . . . . 10.0 109.045 175.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 96.6 t -107.72 134.25 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 174.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.6 m -158.13 66.56 0.46 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.607 1.163 . . . . 10.0 109.695 169.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.59 156.07 5.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.277 -1.379 . . . . 10.0 107.277 -177.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -133.42 139.95 47.04 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.893 1.277 . . . . 10.0 109.946 175.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -147.29 159.14 44.01 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.071 -1.455 . . . . 10.0 107.071 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.66 14.49 4.04 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.423 1.889 . . . . 10.0 111.857 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -89.44 1.69 7.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 119.19 0.905 . . . . 10.0 109.523 169.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.264 0.0 OUTLIER -129.08 171.28 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 126.313 1.845 . . . . 10.0 111.612 -179.328 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 6.2 m -163.56 147.13 10.31 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 107.462 -1.31 . . . . 10.0 107.462 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -62.38 -48.22 80.71 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 123.303 0.641 . . . . 10.0 109.706 -176.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.4 t -139.4 174.47 10.48 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 125.347 1.459 . . . . 10.0 107.469 169.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 128.56 -101.37 0.55 Allowed Glycine 0 N--CA 1.45 -0.374 0 N-CA-C 107.919 -2.073 . . . . 10.0 107.919 -171.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -120.22 -51.13 2.22 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 125.765 1.626 . . . . 10.0 108.282 178.085 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -73.75 -31.35 63.29 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 115.033 -0.985 . . . . 10.0 108.713 -171.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 22.3 t 33.43 72.21 0.09 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 127.994 2.517 . . . . 10.0 115.809 167.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 29.7 pt -71.67 -15.11 18.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 114.048 1.129 . . . . 10.0 114.048 -178.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.5 mm -46.51 127.65 2.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 CA-C-N 119.051 0.841 . . . . 10.0 110.173 172.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.27 -0.11 83.22 Favored Glycine 0 CA--C 1.532 1.137 0 CA-C-O 118.969 -0.906 . . . . 10.0 114.583 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -76.22 175.41 9.05 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 119.243 1.521 . . . . 10.0 108.507 169.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -121.7 125.99 47.9 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.362 0.665 . . . . 10.0 111.002 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -80.93 139.98 35.55 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 170.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 98.9 t -124.72 132.49 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 108.025 -1.102 . . . . 10.0 108.025 171.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -98.78 125.81 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.189 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 168.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.0 m170 -102.11 161.0 14.02 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 122.954 1.359 . . . . 10.0 114.022 -176.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.7 tt0 -46.79 -56.73 5.76 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 128.031 2.532 . . . . 10.0 109.288 176.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -124.49 177.03 6.13 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.655 1.582 . . . . 10.0 110.355 -173.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.21 145.38 35.58 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 125.615 1.566 . . . . 10.0 110.401 176.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.506 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.1 OUTLIER -85.38 157.39 20.53 Favored 'General case' 0 N--CA 1.457 -0.098 0 CA-C-O 121.392 0.615 . . . . 10.0 112.156 169.277 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -78.99 -11.31 60.0 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 115.078 -0.964 . . . . 10.0 111.278 174.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 52.93 57.04 6.76 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.887 1.275 . . . . 10.0 108.841 -174.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.93 -42.32 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 113.706 -1.588 . . . . 10.0 111.161 168.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.7 mtmt -80.53 42.57 0.61 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.684 0.794 . . . . 10.0 112.179 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -94.75 -20.04 30.03 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 127.922 2.677 . . . . 10.0 110.101 168.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.56 49.77 38.57 Favored Glycine 0 C--N 1.34 0.778 0 C-N-CA 124.314 0.959 . . . . 10.0 111.802 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -155.28 172.79 17.6 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 117.784 0.792 . . . . 10.0 108.875 176.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . 0.511 ' CD ' ' HZ1' ' B' ' 136' ' ' LYS . 8.6 tm-20 -52.19 -46.24 65.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 C-N-CA 123.351 0.66 . . . . 10.0 111.269 -177.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -70.06 -30.97 68.35 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.825 -0.607 . . . . 10.0 109.756 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.9 p -50.66 -41.36 55.43 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 119.287 0.949 . . . . 10.0 111.258 -177.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.7 t -86.91 -3.28 59.06 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 113.285 0.846 . . . . 10.0 113.285 -177.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.511 ' HZ1' ' CD ' ' B' ' 132' ' ' GLU . 32.1 tttt -114.48 -57.26 2.29 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 127.424 2.29 . . . . 10.0 111.952 -166.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 6.1 p -132.31 7.19 4.21 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 118.453 -0.784 . . . . 10.0 111.041 168.184 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.23 -105.1 2.95 Favored Glycine 0 C--N 1.344 1.009 0 N-CA-C 108.91 -1.676 . . . . 10.0 108.91 -169.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.15 34.17 0.14 Allowed 'General case' 0 C--N 1.321 -0.65 0 O-C-N 121.095 -1.238 . . . . 10.0 108.342 177.453 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.63 -9.21 58.33 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.899 -1.046 . . . . 10.0 111.467 -169.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.31 -158.39 41.78 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 109.261 -1.535 . . . . 10.0 109.261 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.6 m -57.43 128.9 39.36 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-O 121.45 0.643 . . . . 10.0 109.822 -174.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.2 72.78 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 124.711 1.204 . . . . 10.0 111.132 169.463 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 10.0 tp -44.61 -38.0 3.99 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 128.036 2.535 . . . . 10.0 114.517 -174.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -162.32 158.98 24.9 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 178.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.8 165.29 36.63 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 122.471 -0.143 . . . . 10.0 110.906 -178.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.88 146.47 14.16 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 110.374 -1.091 . . . . 10.0 110.374 -172.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 64.4 t -100.46 138.76 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 N-CA-C 105.851 -1.907 . . . . 10.0 105.851 -174.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 38.5 mt -73.33 120.71 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 C-N-CA 122.524 0.33 . . . . 10.0 110.172 -173.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.56 134.35 10.85 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.095 1.331 . . . . 10.0 112.103 -172.482 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.71 137.0 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 125.604 1.562 . . . . 10.0 109.463 179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.21 -48.15 1.1 Allowed 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 113.305 0.854 . . . . 10.0 113.305 -174.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 44.7 tt0 . . . . . 0 C--O 1.253 1.282 0 N-CA-C 108.782 -0.821 . . . . 10.0 108.782 -165.944 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 108.635 -0.876 . . . . 10.0 108.635 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.9 -6.77 55.44 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 118.52 0.6 . . . . 10.0 109.825 -174.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.93 156.66 42.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.028 0.531 . . . . 10.0 109.986 168.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.41 156.26 35.03 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 m -126.82 160.44 35.17 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 109.552 -0.536 . . . . 10.0 109.552 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.27 107.77 7.85 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 107.578 -1.268 . . . . 10.0 107.578 169.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.4 m -84.37 109.06 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 170.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mt -93.23 146.39 23.73 Favored 'General case' 0 C--O 1.224 -0.246 0 CA-C-O 117.97 -1.014 . . . . 10.0 108.434 -174.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.2 mtmt -164.78 158.93 18.04 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 120.081 1.31 . . . . 10.0 108.351 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.74 -51.05 0.1 OUTLIER Glycine 0 N--CA 1.461 0.365 0 C-N-CA 120.013 -1.089 . . . . 10.0 113.768 168.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -73.35 -44.17 59.27 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.975 -1.12 . . . . 10.0 107.975 -173.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.01 -71.44 0.35 Allowed Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 114.086 -1.416 . . . . 10.0 110.536 169.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -55.0 -39.91 88.55 Favored 'Trans proline' 0 N--CA 1.451 -1.028 0 C-N-CA 122.703 2.269 . . . . 10.0 110.72 172.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.7 t -58.52 112.91 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 C-N-CA 123.862 0.865 . . . . 10.0 109.83 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -131.0 109.23 10.37 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 122.752 0.421 . . . . 10.0 110.062 167.295 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.05 154.77 32.26 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.837 -0.905 . . . . 10.0 110.837 168.161 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.22 56.44 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 126.024 1.73 . . . . 10.0 106.858 -179.122 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 tp -67.25 145.46 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 O-C-N 121.473 -0.767 . . . . 10.0 109.494 -179.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -138.04 101.14 4.34 Favored 'General case' 0 CA--C 1.519 -0.22 0 C-N-CA 126.319 1.847 . . . . 10.0 109.429 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 15.7 m-30 -100.48 129.69 46.47 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.561 -1.274 . . . . 10.0 107.561 -177.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.527 ' CD ' ' HZ2' ' A' ' 23' ' ' LYS . 4.8 tt0 -129.38 152.22 49.18 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.574 0.749 . . . . 10.0 110.752 176.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -125.77 114.65 18.89 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.603 -1.629 . . . . 10.0 106.603 166.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.527 ' HZ2' ' CD ' ' A' ' 21' ' ' GLU . 47.0 mmtt -61.34 -60.26 4.01 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 109.07 -0.715 . . . . 10.0 109.07 169.509 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -126.79 165.84 18.54 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.312 -2.107 . . . . 10.0 105.312 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.4 t -73.52 -10.96 60.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-O 121.516 0.674 . . . . 10.0 109.32 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.8 m120 -78.45 -19.65 52.7 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.194 0.998 . . . . 10.0 110.228 173.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.89 150.76 41.61 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.582 -1.007 . . . . 10.0 110.582 178.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -76.16 148.53 31.03 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 N-CA-C 106.078 -2.316 . . . . 10.0 106.078 166.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.6 t -75.22 100.13 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.9 mtpp -68.48 93.87 0.52 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 106.755 -1.572 . . . . 10.0 106.755 170.138 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.3 m -82.06 59.87 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 124.772 1.229 . . . . 10.0 108.853 -172.373 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -82.7 174.25 11.17 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 119.119 -1.032 . . . . 10.0 111.471 -168.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.11 -159.44 28.35 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.427 -1.469 . . . . 10.0 109.427 167.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 15.2 m -155.99 124.72 5.97 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 109.138 -0.69 . . . . 10.0 109.138 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 pt -93.1 143.5 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 106.505 -1.665 . . . . 10.0 106.505 165.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.16 119.1 17.37 Favored 'General case' 0 N--CA 1.45 -0.435 0 O-C-N 123.803 0.689 . . . . 10.0 110.91 171.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.27 14.24 1.81 Allowed Glycine 0 C--N 1.341 0.839 0 CA-C-O 118.849 -0.973 . . . . 10.0 114.967 168.37 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.421 ' N ' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -97.03 179.49 4.92 Favored 'General case' 0 C--O 1.224 -0.269 0 CA-C-N 118.808 1.304 . . . . 10.0 108.397 174.245 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -75.55 174.26 9.93 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 119.6 -0.84 . . . . 10.0 110.885 170.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -63.85 177.29 0.77 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.078 1.751 . . . . 10.0 110.167 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.8 -174.35 40.89 Favored Glycine 0 N--CA 1.448 -0.55 0 O-C-N 121.32 -0.862 . . . . 10.0 112.987 167.323 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.08 147.77 49.59 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.672 1.189 . . . . 10.0 109.273 175.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -144.38 141.9 29.99 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 114.009 1.115 . . . . 10.0 114.009 -176.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -27.48 122.17 0.06 OUTLIER Glycine 0 C--N 1.343 0.925 0 C-N-CA 128.291 2.853 . . . . 10.0 114.0 166.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.75 107.06 3.13 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 119.575 1.687 . . . . 10.0 113.185 169.082 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.457 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -146.28 173.13 12.52 Favored 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 123.368 0.667 . . . . 10.0 110.903 178.505 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.0 t -89.97 -41.99 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 113.624 -1.625 . . . . 10.0 113.107 -168.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 61.29 157.56 0.04 OUTLIER 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 126.145 1.778 . . . . 10.0 114.24 -174.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -72.64 -64.89 0.87 Allowed 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 113.996 -1.456 . . . . 10.0 111.176 -177.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -77.79 149.76 34.4 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.025 0.441 . . . . 10.0 110.214 -173.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.18 -11.47 54.34 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.124 -1.591 . . . . 10.0 109.124 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.92 158.04 0.74 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.58 1.181 . . . . 10.0 111.992 171.601 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -151.17 28.78 0.66 Allowed 'General case' 0 N--CA 1.434 -1.262 0 CA-C-N 113.745 -1.571 . . . . 10.0 112.026 166.158 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -59.12 -29.58 67.5 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 122.527 0.331 . . . . 10.0 110.425 173.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.56 -18.92 59.61 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 122.563 0.345 . . . . 10.0 111.302 176.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.42 82.08 0.27 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 110.923 -0.871 . . . . 10.0 110.923 -177.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m 33.56 58.18 0.53 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 127.499 2.32 . . . . 10.0 111.649 -177.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -136.06 -56.34 0.77 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 -170.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 t -126.3 43.78 3.01 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.015 -1.476 . . . . 10.0 107.015 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.82 65.15 1.34 Allowed 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 174.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.28 92.8 0.01 OUTLIER Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.816 1.198 . . . . 10.0 113.487 169.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -74.62 68.01 5.49 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 123.938 3.092 . . . . 10.0 113.374 -169.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.457 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 34.3 m170 65.34 77.13 0.31 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 128.52 2.728 . . . . 10.0 111.196 173.083 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -18.42 -60.72 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 128.504 2.722 . . . . 10.0 114.578 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.1 t30 4.49 86.55 0.04 OUTLIER Pre-proline 0 CA--C 1.54 0.577 0 C-N-CA 128.664 2.786 . . . . 10.0 114.676 -169.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -66.43 -35.9 28.9 Favored 'Trans proline' 0 N--CA 1.456 -0.701 0 C-N-CA 122.538 2.159 . . . . 10.0 111.551 -175.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.3 tt -74.25 66.74 1.32 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 108.181 -1.044 . . . . 10.0 108.181 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.7 t -31.86 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 127.467 2.307 . . . . 10.0 112.346 -174.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -131.06 170.0 15.11 Favored 'General case' 0 N--CA 1.444 -0.744 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -89.87 123.4 33.79 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 108.419 -0.956 . . . . 10.0 108.419 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 68.2 t60 -29.55 104.04 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 174.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.34 -170.33 12.68 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 108.503 -1.839 . . . . 10.0 108.503 176.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -135.08 -164.84 10.59 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-O 119.406 -0.664 . . . . 10.0 111.638 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -67.2 7.49 0.47 Allowed 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.042 1.828 . . . . 10.0 111.958 170.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -89.94 -29.27 18.61 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.787 -1.19 . . . . 10.0 107.787 169.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.67 177.69 4.57 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.396 1.079 . . . . 10.0 108.334 -168.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -110.99 -12.34 14.23 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.74 -1.118 . . . . 10.0 110.697 169.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -86.86 -0.67 56.87 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.051 0.94 . . . . 10.0 111.245 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -36.81 138.1 0.27 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 127.367 2.267 . . . . 10.0 112.217 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -82.13 60.86 5.11 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.073 -0.392 . . . . 10.0 110.05 -178.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.283 11.7 p 10.46 64.33 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 129.284 3.034 . . . . 10.0 114.507 -176.091 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.36 49.06 0.06 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 126.028 1.775 . . . . 10.0 109.583 -173.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -131.7 105.87 7.78 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 103.889 -2.634 . . . . 10.0 103.889 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -75.88 -13.32 60.26 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -166.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.37 -97.91 1.46 Allowed Glycine 0 C--O 1.219 -0.802 0 N-CA-C 108.006 -2.038 . . . . 10.0 108.006 -175.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -155.09 151.03 27.85 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 124.917 1.287 . . . . 10.0 108.599 -176.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.9 m -120.97 135.62 60.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 108.917 -0.771 . . . . 10.0 108.917 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -88.11 119.19 28.25 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 127.691 2.397 . . . . 10.0 110.594 -177.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.23 133.44 43.52 Favored 'General case' 0 CA--C 1.523 -0.095 0 C-N-CA 124.772 1.229 . . . . 10.0 111.064 176.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -61.02 169.57 1.93 Allowed 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.354 0.662 . . . . 10.0 110.146 168.243 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 -23.25 16.8 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.459 1.104 . . . . 10.0 112.898 170.055 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -17.69 60.8 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 110.29 -0.263 . . . . 10.0 110.29 177.215 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.8 13.89 66.14 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 110.524 -1.03 . . . . 10.0 110.524 -171.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.6 t -91.25 110.38 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.91 0 C-N-CA 126.973 2.109 . . . . 10.0 106.217 175.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.26 116.01 30.72 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 168.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -79.83 123.18 27.5 Favored 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 127.003 2.121 . . . . 10.0 108.09 171.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 29.6 t -108.41 129.06 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 106.86 -1.533 . . . . 10.0 106.86 178.39 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -155.97 64.09 0.58 Allowed 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.142 -1.058 . . . . 10.0 108.142 173.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 49.8 mt -102.13 153.47 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 N-CA-C 106.623 -1.621 . . . . 10.0 106.623 176.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -122.25 110.11 15.3 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.856 0.862 . . . . 10.0 110.75 176.246 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.23 129.18 37.25 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.212 1.005 . . . . 10.0 108.615 -177.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.2 t -119.05 44.83 2.23 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.134 0.974 . . . . 10.0 109.399 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -135.74 -43.09 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 124.05 0.94 . . . . 10.0 111.269 172.208 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.379 0.9 OUTLIER -87.46 161.01 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 CA-C-N 119.477 1.035 . . . . 10.0 111.956 169.948 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.0 m -151.93 106.83 3.25 Favored 'General case' 0 C--N 1.341 0.214 0 C-N-CA 123.997 0.919 . . . . 10.0 109.413 -172.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 36.4 mt -37.79 -38.02 0.27 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.141 2.176 . . . . 10.0 115.326 -174.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 57.3 m -144.83 56.31 1.26 Allowed 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.229 -1.026 . . . . 10.0 108.229 170.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.32 -63.11 1.67 Allowed Glycine 0 C--N 1.335 0.483 0 N-CA-C 109.099 -1.6 . . . . 10.0 109.099 174.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -167.67 -53.38 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.434 1.894 . . . . 10.0 107.141 -178.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.61 -45.6 36.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.266 -1.334 . . . . 10.0 107.896 -173.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.0 t 53.77 173.64 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 125.844 1.658 . . . . 10.0 112.443 -175.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.7 pt -130.54 20.44 2.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 126.008 1.723 . . . . 10.0 108.961 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.9 mm -70.37 140.13 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.268 0.627 . . . . 10.0 109.593 169.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.37 32.42 84.12 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.298 0.952 . . . . 10.0 113.177 173.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -106.25 176.08 5.29 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.968 1.707 . . . . 10.0 107.919 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -124.52 108.52 12.2 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.285 -1.006 . . . . 10.0 108.285 -178.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.7 mp -80.75 138.18 36.29 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 107.36 -1.348 . . . . 10.0 107.36 177.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 64.5 t -117.62 129.59 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.975 0 N-CA-C 105.939 -1.875 . . . . 10.0 105.939 -178.357 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -99.35 110.35 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 102.851 -3.018 . . . . 10.0 102.851 169.455 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 6.4 m170 -91.41 156.66 17.57 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 122.591 1.186 . . . . 10.0 113.492 -170.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.59 -52.92 20.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 126.688 1.995 . . . . 10.0 109.957 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -110.1 170.85 7.81 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 124.183 0.993 . . . . 10.0 112.306 -172.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.22 140.9 57.44 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 114.113 -1.403 . . . . 10.0 109.3 173.089 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.86 125.41 29.25 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 107.483 -1.302 . . . . 10.0 107.483 176.53 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -76.0 -9.74 58.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.761 0.425 . . . . 10.0 111.13 -177.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.6 mt 48.24 38.72 10.65 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.007 0.908 . . . . 10.0 109.924 -176.22 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.28 -15.29 63.6 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.707 1.622 . . . . 10.0 112.554 172.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ptpt -75.7 3.08 10.42 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.239 1.519 . . . . 10.0 112.716 -171.076 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.56 -22.13 76.48 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 169.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.1 35.9 50.49 Favored Glycine 0 CA--C 1.526 0.765 0 C-N-CA 123.89 0.757 . . . . 10.0 112.487 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -136.84 173.72 11.39 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 122.1 0.953 . . . . 10.0 110.058 175.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.6 tm-20 -46.08 -51.98 12.83 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.996 1.719 . . . . 10.0 111.221 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -73.05 -37.14 66.96 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.743 -0.598 . . . . 10.0 110.75 179.463 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -48.84 -43.5 38.67 Favored 'General case' 0 C--N 1.344 0.357 0 O-C-N 121.357 -0.84 . . . . 10.0 110.272 175.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -81.38 -5.3 57.73 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 119.147 -0.454 . . . . 10.0 111.65 -169.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.6 mtmt -114.15 -76.8 0.58 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.593 1.557 . . . . 10.0 110.726 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . 0.26 17.2 p -104.2 12.99 33.13 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 120.157 1.344 . . . . 10.0 113.042 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 28.9 69.12 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 119.351 0.978 . . . . 10.0 113.243 169.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 35.2 m120 49.57 21.25 0.59 Allowed 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 118.203 1.002 . . . . 10.0 113.003 -176.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.75 -6.34 36.82 Favored 'General case' 0 C--O 1.221 -0.43 0 O-C-N 121.491 -0.756 . . . . 10.0 111.542 -171.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.45 162.71 15.05 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 109.919 -1.272 . . . . 10.0 109.919 174.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.6 t -81.41 58.78 3.76 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.688 0.795 . . . . 10.0 111.094 -169.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 45.72 58.81 4.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.311 1.445 . . . . 10.0 112.941 169.571 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -69.15 -10.48 57.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 113.601 0.963 . . . . 10.0 113.601 -169.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -164.98 143.27 6.41 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.226 1.01 . . . . 10.0 108.584 172.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -157.01 166.3 33.72 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 122.83 0.452 . . . . 10.0 110.016 -172.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.53 158.25 29.7 Favored Glycine 0 C--N 1.332 0.34 0 N-CA-C 109.207 -1.557 . . . . 10.0 109.207 -178.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 30.5 t -105.91 137.5 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 106.823 -1.547 . . . . 10.0 106.823 -167.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.3 mt -75.85 125.35 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 118.161 0.437 . . . . 10.0 110.607 -176.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.06 149.52 18.13 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.59 1.09 . . . . 10.0 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.1 mt -56.35 137.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 124.305 1.042 . . . . 10.0 109.594 176.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.81 165.69 19.64 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 107.505 -1.295 . . . . 10.0 107.505 167.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 . . . . . 0 C--O 1.251 1.165 0 C-N-CA 124.997 1.319 . . . . 10.0 107.59 167.731 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 107.162 -1.421 . . . . 10.0 107.162 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.6 t -77.2 -48.52 17.39 Favored 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 119.137 0.88 . . . . 10.0 109.168 174.11 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.66 121.87 40.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 126.109 1.763 . . . . 10.0 107.441 -170.137 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -127.61 159.57 34.27 Favored 'General case' 0 CA--C 1.519 -0.249 0 C-N-CA 124.526 1.13 . . . . 10.0 109.239 177.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.1 t -117.41 156.15 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 123.761 0.824 . . . . 10.0 109.726 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.47 112.14 9.4 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.595 1.558 . . . . 10.0 108.514 169.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -94.11 106.11 17.68 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 C-N-CA 122.857 0.463 . . . . 10.0 110.845 171.443 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mt -86.82 127.67 35.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.396 1.079 . . . . 10.0 110.015 177.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -147.55 162.47 39.02 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.469 -1.308 . . . . 10.0 107.469 169.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.73 -53.71 0.08 OUTLIER Glycine 0 N--CA 1.461 0.303 0 C-N-CA 120.664 -0.779 . . . . 10.0 113.521 169.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -72.26 -44.04 63.43 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.461 -1.311 . . . . 10.0 107.461 -174.328 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.51 -70.88 0.4 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.149 -1.387 . . . . 10.0 110.073 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -57.34 -34.54 98.06 Favored 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 123.436 2.757 . . . . 10.0 111.366 172.078 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 73.8 t -64.58 109.78 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 108.386 -0.968 . . . . 10.0 108.386 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -129.03 118.21 22.17 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.33 1.052 . . . . 10.0 108.376 169.461 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.02 140.05 15.31 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 124.166 0.889 . . . . 10.0 111.373 173.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 9.4 mt -137.03 72.41 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 N-CA-C 106.4 -1.704 . . . . 10.0 106.4 -169.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mm -95.55 138.55 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 115.749 -0.659 . . . . 10.0 109.74 -170.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -114.48 117.89 32.26 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.139 1.775 . . . . 10.0 108.338 -179.289 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -102.51 107.45 18.42 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.872 -1.159 . . . . 10.0 107.872 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -108.12 122.49 47.0 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 114.949 1.463 . . . . 10.0 114.949 173.568 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -82.52 115.61 21.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 101.715 -3.439 . . . . 10.0 101.715 162.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mtpm? -62.26 -40.98 98.0 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.979 -0.378 . . . . 10.0 109.979 -178.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 65.0 mt-10 -137.26 -145.06 0.2 Allowed 'General case' 0 N--CA 1.428 -1.558 0 N-CA-C 105.79 -1.93 . . . . 10.0 105.79 -170.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 25.8 t -103.39 -19.91 14.26 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 110.207 -0.294 . . . . 10.0 110.207 168.182 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -129.1 11.64 6.01 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.07 0.948 . . . . 10.0 110.791 -174.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.12 166.76 51.89 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.93 -1.668 . . . . 10.0 108.93 175.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -68.28 145.05 64.66 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 N-CA-C 108.131 -1.527 . . . . 10.0 108.131 169.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.78 108.67 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 N-CA-C 104.966 -2.235 . . . . 10.0 104.966 169.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.7 mtpp -90.2 113.56 25.37 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 169.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -101.64 111.26 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 106.977 -1.49 . . . . 10.0 106.977 179.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.1 p90 -126.38 167.63 15.28 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.323 0.582 . . . . 10.0 112.069 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.64 -151.37 23.12 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 107.159 -2.377 . . . . 10.0 107.159 169.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 33.5 t -155.18 158.72 39.38 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 120.222 -0.591 . . . . 10.0 110.222 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pt -117.14 136.74 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 114.866 -1.061 . . . . 10.0 108.816 167.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 27.5 tptt -108.83 146.44 33.67 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 105.938 -1.875 . . . . 10.0 105.938 170.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.56 -7.07 39.07 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.421 -0.655 . . . . 10.0 113.71 169.524 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.07 175.04 2.22 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 118.348 1.074 . . . . 10.0 110.079 173.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -104.55 167.08 9.97 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 105.693 -1.965 . . . . 10.0 105.693 165.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 7.9 tm-20 -54.88 163.6 0.96 Allowed 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.904 0.881 . . . . 10.0 112.103 -169.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.36 -168.68 46.62 Favored Glycine 0 N--CA 1.445 -0.731 0 CA-C-O 122.012 0.785 . . . . 10.0 112.831 167.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -74.5 143.4 44.6 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.471 1.908 . . . . 10.0 110.606 -173.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -147.07 143.41 28.31 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 124.319 1.048 . . . . 10.0 112.27 -177.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -33.43 128.32 0.39 Allowed Glycine 0 C--N 1.339 0.73 0 C-N-CA 127.669 2.557 . . . . 10.0 112.351 168.279 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -149.74 110.86 4.38 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.09 -1.078 . . . . 10.0 108.09 166.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.04 170.82 16.93 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.437 0.637 . . . . 10.0 112.589 175.491 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 t -91.89 146.11 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 CA-C-N 112.143 -2.299 . . . . 10.0 106.966 169.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -129.41 147.1 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.29 1.436 . . . . 10.0 107.586 176.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.28 -68.06 0.22 Allowed 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.013 0.925 . . . . 10.0 110.6 -172.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -77.63 132.23 38.15 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.914 -1.143 . . . . 10.0 107.914 -169.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.07 -24.94 76.21 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 172.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.29 162.16 0.36 Allowed 'General case' 0 N--CA 1.447 -0.597 0 CA-C-O 123.031 1.396 . . . . 10.0 113.044 177.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.71 30.08 0.47 Allowed 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 114.185 -1.37 . . . . 10.0 111.759 172.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.4 -37.57 72.92 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.288 1.035 . . . . 10.0 112.535 -168.779 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.14 -21.17 54.53 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.014 0.525 . . . . 10.0 111.687 176.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.59 -155.83 16.06 Favored Glycine 0 N--CA 1.435 -1.372 0 N-CA-C 106.189 -2.765 . . . . 10.0 106.189 -166.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.43 54.33 0.44 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 127.214 2.206 . . . . 10.0 113.461 -168.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -161.24 -39.35 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 O-C-N 120.79 -1.194 . . . . 10.0 111.82 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 9.5 t -50.71 -30.28 13.43 Favored 'General case' 0 C--N 1.343 0.319 0 C-N-CA 124.307 1.043 . . . . 10.0 111.137 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.27 -36.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 127.247 2.219 . . . . 10.0 114.194 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.17 143.31 10.98 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 110.694 -0.962 . . . . 10.0 110.694 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -77.06 58.6 6.22 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 124.425 3.417 . . . . 10.0 112.882 -175.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.455 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 17.5 m170 61.0 48.85 6.16 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.738 2.415 . . . . 10.0 109.854 177.059 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -69.7 74.65 0.42 Allowed 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.931 0.872 . . . . 10.0 111.046 178.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -74.99 150.8 86.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 O-C-N 121.343 -0.848 . . . . 10.0 110.832 171.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -67.12 -45.11 4.21 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.631 2.221 . . . . 10.0 111.159 178.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.96 57.29 1.05 Allowed 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.53 0.732 . . . . 10.0 110.038 178.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 39.5 p -42.48 108.73 0.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.629 1.572 . . . . 10.0 110.935 -172.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 58.7 mtt180 -148.6 -172.08 4.01 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.792 -2.299 . . . . 10.0 104.792 -171.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -83.98 146.38 28.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 118.42 -1.312 . . . . 10.0 107.6 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -50.81 119.74 4.16 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 166.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.87 -134.66 4.34 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 108.103 -1.999 . . . . 10.0 108.103 177.051 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.53 -161.36 32.03 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 107.537 -2.225 . . . . 10.0 107.537 169.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -66.02 5.02 0.72 Allowed 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.519 1.479 . . . . 10.0 111.053 168.062 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.8 mtpm? -114.99 8.23 15.75 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.591 1.156 . . . . 10.0 111.412 172.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -126.04 169.16 13.03 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.018 -1.105 . . . . 10.0 108.018 165.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -89.45 -24.8 21.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.724 -0.843 . . . . 10.0 108.724 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -105.48 13.48 30.08 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 115.363 1.616 . . . . 10.0 115.363 -165.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -28.1 130.73 0.05 Allowed 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 127.547 2.339 . . . . 10.0 111.866 168.687 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -47.08 -68.38 0.2 Allowed 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.115 0.966 . . . . 10.0 110.83 -175.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.0 p -168.18 -50.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.193 0 N-CA-C 107.456 -1.313 . . . . 10.0 107.456 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.32 53.3 0.68 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.907 1.241 . . . . 10.0 110.504 179.279 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -91.84 92.91 8.58 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 105.817 -1.92 . . . . 10.0 105.817 169.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -73.67 -37.26 65.32 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.308 -1.738 . . . . 10.0 106.308 174.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.83 -104.28 2.73 Favored Glycine 0 N--CA 1.436 -1.328 0 N-CA-C 108.433 -1.867 . . . . 10.0 108.433 169.349 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -114.48 131.62 56.56 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.239 0.616 . . . . 10.0 110.191 -169.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -115.2 139.34 42.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 107.756 -1.202 . . . . 10.0 107.756 167.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -100.53 123.05 44.23 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 125.017 1.327 . . . . 10.0 110.244 -173.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.08 135.1 43.09 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 124.17 0.988 . . . . 10.0 110.514 179.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -58.99 168.8 1.18 Allowed 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.593 0.757 . . . . 10.0 110.213 167.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -50.58 -34.02 24.2 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.812 0.845 . . . . 10.0 110.767 169.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.0 t0 -79.37 0.71 28.03 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 120.859 0.361 . . . . 10.0 111.761 -178.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.25 13.83 82.36 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 120.733 -1.229 . . . . 10.0 110.695 177.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 45.2 t -89.73 103.33 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 C-N-CA 127.039 2.136 . . . . 10.0 106.29 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.66 120.92 41.1 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 168.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -81.45 117.64 22.05 Favored 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 126.479 1.911 . . . . 10.0 108.494 172.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 67.8 t -98.9 129.14 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.081 0 N-CA-C 106.553 -1.647 . . . . 10.0 106.553 175.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.8 p -157.91 68.29 0.5 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.678 0.791 . . . . 10.0 109.326 170.539 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.13 160.27 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.274 -1.75 . . . . 10.0 106.274 -177.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -135.7 148.01 48.72 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 121.755 -0.591 . . . . 10.0 111.055 169.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -133.14 160.98 35.65 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 125.408 1.483 . . . . 10.0 108.506 179.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.5 t -134.64 41.61 2.89 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.116 1.366 . . . . 10.0 111.933 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.8 p -132.43 -45.04 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 123.352 0.661 . . . . 10.0 110.315 167.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.06 154.16 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 121.843 0.83 . . . . 10.0 109.762 169.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.8 m -154.01 152.87 31.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.533 1.133 . . . . 10.0 108.458 168.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.87 -25.43 62.8 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.013 0.925 . . . . 10.0 110.137 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 16.2 t -131.6 179.91 5.77 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.456 1.102 . . . . 10.0 108.122 169.218 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.95 -71.47 0.48 Allowed Glycine 0 C--N 1.332 0.349 0 C-N-CA 124.873 1.225 . . . . 10.0 110.227 170.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -158.27 -52.22 0.07 Allowed 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 126.5 1.92 . . . . 10.0 106.72 -176.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -74.3 -32.28 62.81 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 114.277 -1.329 . . . . 10.0 108.995 -174.009 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t 25.2 76.28 0.02 OUTLIER 'General case' 0 C--N 1.344 0.338 0 C-N-CA 128.191 2.596 . . . . 10.0 112.67 169.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 27.1 pt -63.17 -10.59 6.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 N-CA-C 113.984 1.105 . . . . 10.0 113.984 -169.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.7 mm -34.51 -45.71 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.271 0 C-N-CA 126.741 2.016 . . . . 10.0 114.833 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.78 14.43 57.53 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.363 0.982 . . . . 10.0 113.629 -173.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -90.68 175.89 6.86 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.688 1.195 . . . . 10.0 110.497 178.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -122.19 142.28 50.58 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 124.419 1.088 . . . . 10.0 109.747 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -101.5 154.96 18.37 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.248 -1.39 . . . . 10.0 107.248 168.032 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.11 137.54 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -106.2 138.22 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.269 -2.123 . . . . 10.0 105.269 168.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 5.0 m170 -117.83 160.33 21.57 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 114.763 1.394 . . . . 10.0 114.763 -169.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 68.1 tt0 -45.19 -53.72 7.84 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.597 2.759 . . . . 10.0 109.949 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.5 mttt -124.52 175.35 7.21 Favored 'General case' 0 CA--C 1.518 -0.27 0 C-N-CA 125.286 1.434 . . . . 10.0 110.273 -170.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.28 139.03 35.67 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.513 0.725 . . . . 10.0 109.168 175.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -78.12 148.1 34.33 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 123.326 0.65 . . . . 10.0 110.484 169.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -78.1 10.12 3.18 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 124.986 1.314 . . . . 10.0 111.196 174.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 16.5 mt 46.16 41.27 8.4 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.223 1.409 . . . . 10.0 110.829 -179.073 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 104.59 -39.76 2.71 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 125.233 1.397 . . . . 10.0 112.538 177.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.9 37.34 0.36 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.176 1.39 . . . . 10.0 111.769 -167.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -95.57 -12.07 54.35 Favored Glycine 0 CA--C 1.523 0.564 0 C-N-CA 125.568 1.556 . . . . 10.0 111.671 177.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.99 38.18 23.88 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 123.892 0.758 . . . . 10.0 111.779 -175.369 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -124.75 155.58 39.09 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.3 tm-20 -52.58 -44.24 65.79 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 114.123 -1.399 . . . . 10.0 108.353 169.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -65.05 -40.01 94.11 Favored 'General case' 0 CA--C 1.541 0.606 0 O-C-N 121.608 -0.683 . . . . 10.0 112.049 171.056 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 9.1 p -57.2 -40.67 77.91 Favored 'General case' 0 C--N 1.347 0.467 0 CA-C-N 121.141 1.791 . . . . 10.0 111.249 -179.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.1 t -72.97 -18.27 61.38 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 119.953 -0.699 . . . . 10.0 112.515 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -103.74 -50.65 3.36 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.14 1.776 . . . . 10.0 112.799 -168.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.455 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 24.1 p -120.92 -10.92 9.02 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 118.584 -0.722 . . . . 10.0 112.896 171.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 92.94 -1.57 71.0 Favored Glycine 0 C--N 1.337 0.636 0 CA-C-O 118.784 -1.009 . . . . 10.0 112.388 -172.13 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 71.12 31.76 2.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.596 1.198 . . . . 10.0 111.297 177.388 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.11 6.32 2.24 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.43 1.092 . . . . 10.0 112.209 174.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.87 -162.38 53.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.279 -1.128 . . . . 10.0 110.279 172.045 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.3 m -56.83 129.16 40.2 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-O 121.571 0.7 . . . . 10.0 111.388 -168.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.62 73.73 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.881 1.273 . . . . 10.0 109.259 169.751 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -74.09 -12.71 60.68 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 113.79 1.033 . . . . 10.0 113.79 -169.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.98 144.45 13.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.09 0.471 . . . . 10.0 111.795 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -138.28 151.43 47.6 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 126.507 1.923 . . . . 10.0 108.327 -169.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.36 142.28 9.07 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 179.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.3 t -102.87 137.12 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 105.672 -1.973 . . . . 10.0 105.672 -175.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 5.5 mt -72.19 158.06 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 108.939 -0.763 . . . . 10.0 108.939 -179.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -166.97 154.84 25.55 Favored Glycine 0 CA--C 1.528 0.888 0 O-C-N 122.007 -0.433 . . . . 10.0 112.247 -173.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 92.1 mt -68.19 131.41 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 124.882 1.273 . . . . 10.0 109.432 -174.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.81 -12.24 1.13 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 115.993 1.849 . . . . 10.0 115.993 -173.159 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.274 0.0 OUTLIER . . . . . 0 C--O 1.254 1.3 0 C-N-CA 128.774 2.83 . . . . 10.0 116.471 -170.171 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.829 0 N-CA-C 108.03 -1.1 . . . . 10.0 108.03 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -155.99 -43.73 0.08 Allowed 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.525 0.602 . . . . 10.0 111.247 171.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -118.79 130.49 55.81 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 169.076 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.89 163.24 26.78 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.751 1.221 . . . . 10.0 108.422 176.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 m -143.24 163.71 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 118.235 0.471 . . . . 10.0 109.873 -177.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.5 110.43 6.83 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.707 1.254 . . . . 10.0 108.048 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -82.61 119.88 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 N-CA-C 106.445 -1.687 . . . . 10.0 106.445 167.427 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.5 mt -98.52 135.51 39.97 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -157.54 159.72 37.45 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 120.564 1.529 . . . . 10.0 108.217 172.101 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 173.54 -40.32 0.14 Allowed Glycine 0 N--CA 1.461 0.304 0 C-N-CA 119.858 -1.163 . . . . 10.0 113.312 169.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -73.96 -47.3 38.44 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 107.589 -1.264 . . . . 10.0 107.589 -177.392 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.65 -73.08 0.31 Allowed Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.691 -1.364 . . . . 10.0 109.691 170.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -58.6 -39.6 81.35 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 123.126 2.551 . . . . 10.0 111.119 173.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.49 101.8 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 107.808 -1.182 . . . . 10.0 107.808 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -118.4 108.08 14.61 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 108.116 -1.068 . . . . 10.0 108.116 170.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.92 147.04 22.45 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 123.995 0.807 . . . . 10.0 111.556 169.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mt -140.72 82.2 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 N-CA-C 105.946 -1.872 . . . . 10.0 105.946 177.013 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.0 mm -89.92 138.96 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 C-N-CA 124.002 0.921 . . . . 10.0 108.956 177.161 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -130.47 126.65 37.46 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 125.693 1.597 . . . . 10.0 109.552 175.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -109.87 105.21 14.31 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.267 1.427 . . . . 10.0 109.368 177.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -86.26 134.32 33.77 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 120.034 -0.666 . . . . 10.0 110.81 167.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -135.07 82.84 1.98 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.642 2.377 . . . . 10.0 106.136 168.074 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.4 tttp -53.01 -51.03 62.97 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 125.793 1.637 . . . . 10.0 109.454 179.404 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 58.8 mt-10 -135.95 169.17 18.02 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 105.932 -1.877 . . . . 10.0 105.932 169.279 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.2 p -72.41 -10.0 59.24 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.992 -0.374 . . . . 10.0 109.992 170.098 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.5 m-80 -75.41 -24.79 57.17 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.519 -0.549 . . . . 10.0 109.519 170.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.33 129.0 9.3 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.29 -1.124 . . . . 10.0 110.29 -173.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -63.2 131.06 30.8 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 N-CA-C 105.957 -2.363 . . . . 10.0 105.957 168.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.2 t -78.0 107.88 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.154 -1.054 . . . . 10.0 108.154 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.62 96.39 3.55 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 170.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -83.6 106.61 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 N-CA-C 106.494 -1.669 . . . . 10.0 106.494 170.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.1 p90 -113.91 171.12 7.79 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.47 0.653 . . . . 10.0 109.901 172.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.94 170.11 41.09 Favored Glycine 0 N--CA 1.437 -1.256 0 C-N-CA 120.088 -1.053 . . . . 10.0 110.564 174.119 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.3 p -137.98 107.97 6.36 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 pt -90.8 145.22 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 167.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -140.05 147.58 40.54 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.37 -1.344 . . . . 10.0 107.37 175.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.25 -14.13 25.81 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.287 -0.729 . . . . 10.0 114.108 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.6 mp -74.27 179.48 4.49 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 118.692 1.246 . . . . 10.0 110.475 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -95.97 169.02 10.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 165.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -58.21 168.29 1.09 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.981 1.312 . . . . 10.0 111.532 -172.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.93 -176.61 36.31 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-O 122.039 0.8 . . . . 10.0 112.671 167.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.65 142.49 51.6 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 124.539 1.136 . . . . 10.0 109.681 177.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -142.05 150.42 41.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 112.896 0.702 . . . . 10.0 112.896 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -37.78 123.85 1.21 Allowed Glycine 0 C--N 1.34 0.786 0 C-N-CA 127.382 2.42 . . . . 10.0 112.061 166.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -151.88 108.5 3.47 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 118.563 1.181 . . . . 10.0 108.997 168.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 174.59 12.21 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 120.876 0.37 . . . . 10.0 111.354 177.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 11.1 m -104.77 -18.38 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 O-C-N 125.658 1.849 . . . . 10.0 114.676 -168.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 57.29 175.76 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 125.322 1.449 . . . . 10.0 112.861 -177.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -72.62 -69.45 0.41 Allowed 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.561 -0.745 . . . . 10.0 109.855 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -92.02 176.92 6.33 Favored 'General case' 0 N--CA 1.454 -0.256 0 O-C-N 123.534 0.521 . . . . 10.0 111.279 -168.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.12 -22.75 11.36 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 125.477 1.513 . . . . 10.0 111.556 170.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -50.81 117.9 2.79 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-O 122.343 1.068 . . . . 10.0 111.935 -177.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -123.14 17.84 9.96 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.988 -1.006 . . . . 10.0 111.552 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -48.42 -41.77 30.2 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.176 1.79 . . . . 10.0 111.562 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.11 -21.62 46.38 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.225 1.01 . . . . 10.0 112.763 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.0 102.31 0.92 Allowed Glycine 0 CA--C 1.527 0.825 0 N-CA-C 108.392 -1.883 . . . . 10.0 108.392 -169.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.276 1.5 p 15.75 80.42 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 127.031 2.132 . . . . 10.0 113.819 -173.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -161.38 -54.99 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 107.541 -1.281 . . . . 10.0 107.541 179.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -65.59 -31.38 72.38 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 123.8 0.84 . . . . 10.0 110.99 -177.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.97 -6.76 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 129.024 2.93 . . . . 10.0 118.012 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.36 123.26 3.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.212 -1.155 . . . . 10.0 110.212 176.183 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.7 60.49 6.67 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.582 2.855 . . . . 10.0 110.765 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.7 m170 72.12 38.28 0.9 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 129.716 3.206 . . . . 10.0 112.584 172.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -74.53 67.94 1.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.386 0.994 . . . . 10.0 111.671 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.7 p-10 -58.97 154.71 36.92 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 123.947 0.899 . . . . 10.0 111.108 169.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.36 -46.15 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 122.656 2.238 . . . . 10.0 111.602 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 86.8 mt -75.53 59.79 1.15 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.266 0.627 . . . . 10.0 109.696 176.134 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -45.95 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.771 1.628 . . . . 10.0 111.558 -171.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -132.21 -176.54 4.11 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 107.237 -1.394 . . . . 10.0 107.237 -176.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -93.78 123.74 37.33 Favored 'General case' 0 N--CA 1.438 -1.068 0 C-N-CA 118.224 -1.39 . . . . 10.0 108.622 -169.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -35.2 112.53 0.16 Allowed 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 113.316 0.858 . . . . 10.0 113.316 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.03 -136.98 4.33 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 108.058 -2.017 . . . . 10.0 108.058 -178.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.06 -168.77 30.66 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 173.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -63.26 -2.8 4.25 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.025 1.817 . . . . 10.0 111.603 168.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -94.97 -19.92 19.81 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.265 1.026 . . . . 10.0 110.746 173.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -103.11 167.58 9.73 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -86.49 -31.99 21.02 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 107.322 -1.362 . . . . 10.0 107.322 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.257 7.1 pt-20 -100.49 24.55 8.78 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 114.435 1.272 . . . . 10.0 114.435 -165.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.5 ptm180 -42.83 145.3 0.48 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 127.218 2.207 . . . . 10.0 110.346 168.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.9 m170 -67.61 -64.58 0.83 Allowed 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.52 0.676 . . . . 10.0 109.66 178.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.5 p -169.33 -91.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 105.472 -2.048 . . . . 10.0 105.472 173.358 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -80.51 56.32 4.7 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 111.04 -0.824 . . . . 10.0 111.04 174.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -90.9 83.16 5.64 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 103.342 -2.836 . . . . 10.0 103.342 166.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -65.26 -26.45 68.1 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 118.391 0.541 . . . . 10.0 109.821 -173.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 114.41 -89.08 0.5 Allowed Glycine 0 N--CA 1.44 -1.044 0 N-CA-C 108.082 -2.007 . . . . 10.0 108.082 169.428 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -155.52 124.82 6.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 -171.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.39 125.89 66.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 118.193 0.452 . . . . 10.0 110.84 178.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -78.82 112.01 15.54 Favored 'General case' 0 N--CA 1.444 -0.761 0 C-N-CA 127.554 2.341 . . . . 10.0 111.116 -177.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.74 134.79 34.16 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.863 0.465 . . . . 10.0 109.938 171.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -60.1 172.27 0.83 Allowed 'General case' 0 C--O 1.232 0.154 0 O-C-N 123.82 0.7 . . . . 10.0 109.441 168.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.5 pttm -48.67 -33.2 9.59 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.745 1.618 . . . . 10.0 109.793 173.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -79.1 -8.19 58.77 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 124.486 1.115 . . . . 10.0 110.812 -173.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.02 -0.26 86.01 Favored Glycine 0 C--N 1.338 0.678 0 N-CA-C 111.234 -0.746 . . . . 10.0 111.234 -174.247 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.5 t -78.43 105.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 106.776 -1.564 . . . . 10.0 106.776 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.23 117.47 34.12 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 169.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -80.37 118.05 21.67 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 127.123 2.169 . . . . 10.0 108.892 172.481 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.2 t -108.32 131.0 59.98 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.964 0 N-CA-C 106.862 -1.532 . . . . 10.0 106.862 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.2 p -157.36 86.81 0.95 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.455 0.702 . . . . 10.0 109.49 171.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.99 143.09 28.11 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 N-CA-C 107.991 -1.115 . . . . 10.0 107.991 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -111.61 129.5 56.06 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.816 -1.92 . . . . 10.0 105.816 167.069 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -140.54 117.69 11.26 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.5 p -87.15 49.42 1.81 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.891 1.676 . . . . 10.0 108.256 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 p -145.24 -51.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.478 -0.783 . . . . 10.0 109.433 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -51.11 132.36 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 122.926 0.49 . . . . 10.0 110.016 175.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.9 p -131.92 136.12 47.14 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.214 1.406 . . . . 10.0 108.551 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 50.1 mt -56.63 -42.69 79.3 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 169.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.8 t -146.07 128.88 16.3 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 149.54 69.4 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.771 -1.332 . . . . 10.0 109.771 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.7 t70 72.41 -60.25 0.53 Allowed 'General case' 0 CA--C 1.509 -0.633 0 C-N-CA 129.742 3.217 . . . . 10.0 109.482 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.7 m-70 -74.19 -44.71 52.3 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t 54.96 82.05 0.1 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.051 1.34 . . . . 10.0 111.714 173.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.5 pt -71.65 -18.16 19.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 O-C-N 120.999 -1.063 . . . . 10.0 112.699 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 16.2 mm -52.65 129.89 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 118.202 0.456 . . . . 10.0 110.156 172.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.58 22.57 77.06 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.684 -1.064 . . . . 10.0 113.644 175.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.9 mtt85 -89.08 175.75 7.26 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 118.235 1.018 . . . . 10.0 110.602 167.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -118.47 110.63 17.64 Favored 'General case' 0 C--N 1.347 0.486 0 N-CA-C 106.844 -1.539 . . . . 10.0 106.844 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mp -87.18 138.88 31.11 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.548 -0.908 . . . . 10.0 108.548 176.313 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 49.1 t -132.04 132.34 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.615 -1.254 . . . . 10.0 107.615 -173.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -105.67 128.11 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 106.081 -1.822 . . . . 10.0 106.081 174.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.6 m170 -111.78 157.55 20.42 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 114.554 1.316 . . . . 10.0 114.554 -171.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -46.64 -59.52 2.97 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 127.572 2.349 . . . . 10.0 110.488 176.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 51.3 mttp -112.21 169.86 8.57 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.702 0.763 . . . . 10.0 112.042 -170.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.5 151.08 47.95 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 114.034 -1.439 . . . . 10.0 109.291 172.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -77.03 150.04 35.81 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 122.296 1.046 . . . . 10.0 110.944 172.649 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . 0.436 ' HB3' ' CA ' ' A' ' 138' ' ' GLY . 4.4 t70 -79.04 -37.75 38.26 Favored 'General case' 0 N--CA 1.443 -0.824 0 C-N-CA 130.103 3.361 . . . . 10.0 110.596 172.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 48.5 mt 63.53 46.53 4.2 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.924 1.29 . . . . 10.0 111.656 178.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 79.64 10.24 86.0 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-N 115.23 -0.895 . . . . 10.0 114.703 167.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 26.8 mttm -97.06 -11.81 23.98 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 117.999 0.899 . . . . 10.0 112.18 -174.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.98 -21.45 69.68 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 125.124 1.345 . . . . 10.0 112.384 176.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.08 35.75 65.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.247 -0.741 . . . . 10.0 111.247 -177.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -129.89 169.94 14.56 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 173.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.444 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 40.9 tt0 -52.43 -48.0 66.03 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 123.654 0.781 . . . . 10.0 109.628 -178.413 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -58.98 -45.5 90.41 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 118.669 -0.682 . . . . 10.0 111.712 175.731 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.9 p -49.87 -43.59 49.32 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 109.206 -0.665 . . . . 10.0 109.206 177.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.1 t -84.3 -3.56 58.32 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -174.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.444 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 92.5 mttt -110.71 -69.58 0.86 Allowed 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.692 1.597 . . . . 10.0 111.85 -179.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -127.3 28.91 5.64 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 119.437 1.017 . . . . 10.0 109.935 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.436 ' CA ' ' HB3' ' A' ' 125' ' ' ASP . . . 66.84 -105.31 1.29 Allowed Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 107.519 -2.232 . . . . 10.0 107.519 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -157.3 42.6 0.33 Allowed 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 107.059 -1.46 . . . . 10.0 107.059 169.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.84 -12.38 53.87 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.606 0.762 . . . . 10.0 111.616 -175.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.81 -158.7 48.81 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.618 -1.393 . . . . 10.0 109.618 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.0 m -61.76 129.27 40.2 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 123.129 0.572 . . . . 10.0 111.599 -169.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -59.03 92.03 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.991 0.916 . . . . 10.0 109.661 169.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.4 mt -64.44 -41.58 96.49 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.444 -0.785 . . . . 10.0 111.309 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.0 148.89 28.26 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.731 0.301 . . . . 10.0 110.391 -172.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -124.24 146.68 48.58 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.679 1.591 . . . . 10.0 107.801 -169.426 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.85 156.65 27.03 Favored Glycine 0 CA--C 1.52 0.362 0 N-CA-C 108.545 -1.822 . . . . 10.0 108.545 168.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.8 t -119.69 134.91 61.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 -175.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.1 mt -75.66 138.44 20.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 CA-C-N 118.679 0.672 . . . . 10.0 111.014 -177.005 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -150.55 172.7 30.27 Favored Glycine 0 CA--C 1.53 0.984 0 N-CA-C 112.313 -0.315 . . . . 10.0 112.313 170.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 64.7 mt -72.79 142.4 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 125.194 1.397 . . . . 10.0 109.08 -169.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.98 -48.22 2.36 Favored 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 123.4 0.68 . . . . 10.0 111.301 172.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 . . . . . 0 C--O 1.248 1.009 0 CA-C-O 116.685 -1.626 . . . . 10.0 110.026 -167.969 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.694 0 N-CA-C 105.631 -1.989 . . . . 10.0 105.631 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.24 76.88 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 120.055 1.298 . . . . 10.0 108.278 168.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.37 158.0 32.09 Favored 'General case' 0 C--O 1.242 0.667 0 C-N-CA 124.481 1.112 . . . . 10.0 109.576 168.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.14 158.51 41.93 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 127.04 2.136 . . . . 10.0 106.078 169.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 m -111.44 178.67 1.25 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 CA-C-N 118.365 0.53 . . . . 10.0 109.601 174.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.24 101.63 2.4 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 165.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 32.2 m -92.33 130.75 40.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 N-CA-C 107.863 -1.162 . . . . 10.0 107.863 172.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -110.05 155.7 21.51 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.32 1.048 . . . . 10.0 108.641 176.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.0 tttt -164.2 167.99 19.41 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 169.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.2 -48.42 0.1 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.047 -1.549 . . . . 10.0 112.29 168.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -76.08 -46.63 28.04 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 107.893 -1.151 . . . . 10.0 107.893 -177.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.76 -67.2 0.52 Allowed Glycine 0 CA--C 1.526 0.775 0 CA-C-N 114.483 -1.235 . . . . 10.0 110.604 178.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -62.5 -36.2 66.84 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 122.794 2.329 . . . . 10.0 110.68 171.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 89.2 t -72.82 113.91 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.93 134.13 27.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.764 -0.458 . . . . 10.0 109.764 166.199 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.96 154.38 18.71 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 124.635 1.112 . . . . 10.0 111.269 175.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -153.31 81.5 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 -172.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -105.67 151.96 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 C-N-CA 125.216 1.407 . . . . 10.0 109.657 -175.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -126.17 118.4 25.13 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 127.199 2.199 . . . . 10.0 107.295 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -98.41 116.46 30.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 170.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -117.25 125.61 51.41 Favored 'General case' 0 N--CA 1.465 0.308 0 O-C-N 123.716 0.635 . . . . 10.0 112.61 169.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -81.34 106.49 13.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.404 -2.072 . . . . 10.0 105.404 169.079 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.0 tttt -56.81 -43.63 81.19 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 124.869 1.268 . . . . 10.0 109.214 -171.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -130.43 -167.42 1.82 Allowed 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 103.0 -2.963 . . . . 10.0 103.0 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.7 m -79.0 -26.4 43.28 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 119.902 1.228 . . . . 10.0 109.412 172.494 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -111.88 -5.22 14.39 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 124.369 1.068 . . . . 10.0 111.799 -176.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.49 151.3 52.16 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 109.593 -1.403 . . . . 10.0 109.593 177.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -59.61 140.96 96.23 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.451 2.101 . . . . 10.0 108.292 174.085 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 p -79.89 103.56 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.537 0 N-CA-C 106.482 -1.673 . . . . 10.0 106.482 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.1 tttp -80.13 122.16 26.46 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 172.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.13 100.47 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 C-N-CA 127.566 2.346 . . . . 10.0 105.726 -178.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.8 p90 -125.56 155.71 40.24 Favored 'General case' 0 C--N 1.339 0.149 0 N-CA-C 112.986 0.735 . . . . 10.0 112.986 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.34 -145.86 13.68 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 106.383 -2.687 . . . . 10.0 106.383 173.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.5 p -157.35 168.16 28.18 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 118.798 -1.161 . . . . 10.0 111.998 177.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pt -117.72 146.46 22.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 114.379 -1.282 . . . . 10.0 109.44 166.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.7 tptt -115.11 146.51 41.27 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 106.464 -1.68 . . . . 10.0 106.464 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.96 -10.1 37.27 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-O 119.538 -0.59 . . . . 10.0 114.073 168.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -62.0 174.45 0.87 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 118.181 0.99 . . . . 10.0 110.561 175.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -108.72 160.7 15.75 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 106.595 -1.631 . . . . 10.0 106.595 167.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -53.72 150.57 7.12 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.61 0.764 . . . . 10.0 111.962 -169.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.51 -172.64 23.19 Favored Glycine 0 CA--C 1.524 0.629 0 C-N-CA 123.496 0.569 . . . . 10.0 111.922 169.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -74.95 149.93 39.23 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.272 1.429 . . . . 10.0 111.594 -173.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -150.97 143.62 24.4 Favored 'General case' 0 C--N 1.342 0.24 0 N-CA-C 113.912 1.079 . . . . 10.0 113.912 -175.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -31.72 126.21 0.23 Allowed Glycine 0 C--N 1.341 0.808 0 C-N-CA 128.247 2.832 . . . . 10.0 112.38 166.019 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.32 107.62 4.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 119.646 1.723 . . . . 10.0 109.887 167.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 176.54 9.75 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 109.718 -0.475 . . . . 10.0 109.718 174.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.4 m -117.71 -15.48 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 125.134 1.521 . . . . 10.0 113.662 -173.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 58.15 171.7 0.05 Allowed 'General case' 0 C--N 1.345 0.412 0 CA-C-O 122.437 1.113 . . . . 10.0 111.661 175.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -72.37 -59.39 2.75 Favored 'General case' 0 N--CA 1.441 -0.885 0 O-C-N 121.507 -0.746 . . . . 10.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -87.04 156.62 19.68 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 121.831 -0.543 . . . . 10.0 109.546 -171.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.72 14.42 29.53 Favored Glycine 0 CA--C 1.524 0.62 0 C-N-CA 125.179 1.371 . . . . 10.0 110.754 177.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.77 175.23 6.81 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 121.918 0.866 . . . . 10.0 110.03 179.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -151.81 33.02 0.55 Allowed 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.055 -0.975 . . . . 10.0 111.165 169.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.23 -37.2 79.6 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.593 -0.692 . . . . 10.0 112.763 -168.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.57 -20.55 46.73 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 117.766 0.257 . . . . 10.0 111.146 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 123.72 -157.59 18.17 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 105.727 -2.949 . . . . 10.0 105.727 -167.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 2.8 t -65.27 7.72 0.19 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.06 1.744 . . . . 10.0 115.189 -169.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 62.2 m -97.74 -49.09 4.96 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 125.93 1.692 . . . . 10.0 108.544 -171.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.1 m -47.41 -39.96 16.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 126.326 1.85 . . . . 10.0 113.061 -166.482 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.89 -39.92 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 128.067 2.547 . . . . 10.0 113.929 168.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.3 162.84 15.23 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 121.44 -0.787 . . . . 10.0 111.951 167.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -86.7 37.94 0.54 Allowed 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.375 2.717 . . . . 10.0 111.885 -172.418 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 71.31 116.38 0.05 OUTLIER 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.38 2.272 . . . . 10.0 110.834 -170.271 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . 0.462 ' N ' ' CD1' ' B' ' 64' ' ' PHE . 0.0 OUTLIER -33.8 94.06 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 127.089 2.156 . . . . 10.0 113.268 165.922 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -105.69 32.71 0.05 OUTLIER Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 116.948 2.203 . . . . 10.0 116.948 -177.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -62.82 -55.88 0.73 Allowed 'Trans proline' 0 C--N 1.35 0.658 0 CA-C-N 122.951 2.09 . . . . 10.0 112.585 -172.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.03 41.88 0.45 Allowed 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.236 -0.915 . . . . 10.0 112.86 -176.308 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 88.0 p 17.41 69.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 128.48 2.712 . . . . 10.0 114.868 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.72 149.17 43.64 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 105.801 -1.926 . . . . 10.0 105.801 172.634 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 30.6 mttm -101.64 106.23 17.26 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 118.746 -0.645 . . . . 10.0 109.637 -168.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -2.33 87.46 0.0 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 126.596 1.959 . . . . 10.0 115.193 -178.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.49 -135.33 8.72 Favored Glycine 0 C--N 1.318 -0.465 0 N-CA-C 109.045 -1.622 . . . . 10.0 109.045 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.68 -168.82 37.88 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 107.467 -2.253 . . . . 10.0 107.467 173.039 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -65.25 -0.72 3.7 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 CA-C-N 119.561 1.68 . . . . 10.0 110.749 167.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.7 mtpm? -109.24 6.79 24.96 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 125.924 1.689 . . . . 10.0 111.0 175.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.99 174.14 10.95 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 165.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.3 -37.01 38.76 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.1 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -81.71 28.59 0.41 Allowed 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 125.433 1.493 . . . . 10.0 114.626 -165.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.67 134.89 41.61 Favored 'General case' 0 N--CA 1.456 -0.141 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 168.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -56.17 -66.43 0.43 Allowed 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.664 -0.495 . . . . 10.0 109.664 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 3.9 p -169.23 -46.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 O-C-N 124.262 0.976 . . . . 10.0 109.132 -176.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.79 53.67 0.79 Allowed Glycine 0 CA--C 1.536 1.379 0 CA-C-N 118.909 0.777 . . . . 10.0 111.865 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -89.38 99.35 12.36 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.655 -1.239 . . . . 10.0 107.655 172.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -70.49 -40.96 73.29 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.289 -1.375 . . . . 10.0 107.289 174.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.02 -93.42 1.03 Allowed Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 124.409 1.004 . . . . 10.0 112.266 168.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -127.66 123.69 36.14 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 123.779 0.832 . . . . 10.0 109.992 -168.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.3 m -119.95 150.31 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 N-CA-C 108.536 -0.913 . . . . 10.0 108.536 167.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -98.24 125.34 43.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.859 1.663 . . . . 10.0 109.204 -177.285 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.27 134.45 38.03 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 108.804 -0.813 . . . . 10.0 108.804 171.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.42 ' CG ' ' HZ3' ' B' ' 91' ' ' LYS . 31.8 t0 -62.05 170.1 2.35 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 124.188 0.93 . . . . 10.0 109.565 167.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.42 ' HZ3' ' CG ' ' B' ' 90' ' ' ASP . 9.4 pttm -52.19 -31.26 30.9 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 125.213 1.405 . . . . 10.0 111.246 173.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -81.91 -1.76 48.97 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.218 0.607 . . . . 10.0 111.386 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.37 9.32 86.65 Favored Glycine 0 C--N 1.339 0.717 0 O-C-N 120.787 -1.195 . . . . 10.0 111.216 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.3 t -80.62 106.11 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 126.2 1.8 . . . . 10.0 106.32 172.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -107.39 120.15 41.36 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.096 -1.076 . . . . 10.0 108.096 169.119 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -80.96 125.5 30.22 Favored 'General case' 0 N--CA 1.437 -1.112 0 C-N-CA 127.233 2.213 . . . . 10.0 109.762 176.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.2 t -111.03 133.71 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.957 0 C-N-CA 125.645 1.578 . . . . 10.0 108.105 175.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 96.9 p -157.63 57.61 0.49 Allowed 'General case' 0 C--O 1.235 0.303 0 C-N-CA 123.141 0.576 . . . . 10.0 111.207 169.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -93.38 144.52 9.3 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.287 0 N-CA-C 107.395 -1.335 . . . . 10.0 107.395 -172.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -90.98 128.13 36.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 167.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -107.06 100.93 10.38 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.278 -1.749 . . . . 10.0 106.278 166.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.77 24.14 4.33 Favored 'General case' 0 N--CA 1.44 -0.957 0 C-N-CA 126.688 1.995 . . . . 10.0 109.948 176.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 38.9 t -120.74 -55.86 3.31 Favored 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 -178.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.348 0.6 OUTLIER -94.3 178.03 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 C-N-CA 123.839 0.856 . . . . 10.0 113.266 -179.039 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 27.1 m -155.4 161.4 41.02 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 123.785 0.834 . . . . 10.0 110.109 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 92.5 mt -81.25 3.92 22.25 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 125.721 1.608 . . . . 10.0 112.456 -175.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.9 t -157.93 -169.48 2.84 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 107.845 -1.168 . . . . 10.0 107.845 168.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 111.32 -85.09 0.38 Allowed Glycine 0 C--N 1.333 0.374 0 N-CA-C 109.114 -1.594 . . . . 10.0 109.114 168.443 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -136.66 -49.61 0.65 Allowed 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 125.935 1.694 . . . . 10.0 107.899 174.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -72.43 -35.02 68.21 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 107.838 -1.171 . . . . 10.0 107.838 -171.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 42.3 t 31.95 67.13 0.15 Allowed 'General case' 0 N--CA 1.442 -0.868 0 C-N-CA 128.271 2.629 . . . . 10.0 110.503 167.669 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 1.3 pt -79.04 57.53 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 122.372 1.082 . . . . 10.0 110.806 -171.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 19.4 mm -96.21 -37.8 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 C-N-CA 127.725 2.41 . . . . 10.0 110.474 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.75 49.92 0.81 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.563 -1.015 . . . . 10.0 110.563 -175.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.57 169.52 8.65 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.864 2.065 . . . . 10.0 108.746 175.108 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -122.91 103.37 8.57 Favored 'General case' 0 C--N 1.344 0.353 0 C-N-CA 124.837 1.255 . . . . 10.0 109.955 -177.026 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -61.85 134.57 56.86 Favored 'General case' 0 CA--C 1.52 -0.183 0 N-CA-C 108.152 -1.055 . . . . 10.0 108.152 169.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.45 132.78 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 107.924 -1.139 . . . . 10.0 107.924 176.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 m -108.27 134.43 50.15 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 O-C-N 124.282 0.989 . . . . 10.0 110.366 167.415 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 6.3 m170 -110.54 158.0 19.03 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -171.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -40.22 -57.18 1.77 Allowed 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 129.272 3.029 . . . . 10.0 111.192 173.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 mttm -123.85 175.18 7.06 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.902 1.281 . . . . 10.0 109.495 -175.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.17 149.56 33.72 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.766 0.826 . . . . 10.0 109.708 175.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -74.92 152.84 38.81 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.78 -1.193 . . . . 10.0 107.78 168.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -76.15 -5.79 48.28 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 124.591 1.182 . . . . 10.0 110.719 171.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 50.5 mt 51.03 58.15 5.87 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 124.32 1.048 . . . . 10.0 108.798 -177.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.42 -39.44 3.12 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 124.93 1.252 . . . . 10.0 111.261 169.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.8 mtmt -79.13 47.19 0.76 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.211 1.004 . . . . 10.0 111.373 -178.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.57 -22.31 10.48 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 126.891 2.186 . . . . 10.0 111.298 174.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.18 44.41 43.06 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.055 0.836 . . . . 10.0 112.784 176.58 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -151.49 172.84 15.35 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 108.797 -0.816 . . . . 10.0 108.797 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -51.75 -41.53 61.65 Favored 'General case' 0 N--CA 1.445 -0.72 0 C-N-CA 122.96 0.504 . . . . 10.0 111.652 -176.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -71.59 -25.0 62.0 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.33 -0.856 . . . . 10.0 111.891 178.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 36.8 p -59.96 -20.8 59.54 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 113.61 0.967 . . . . 10.0 113.61 -177.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.4 t -94.75 -12.81 26.47 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.622 0.646 . . . . 10.0 110.258 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -109.32 -65.96 1.1 Allowed 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 126.7 2.0 . . . . 10.0 111.514 -171.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.02 31.4 3.87 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 120.266 1.394 . . . . 10.0 110.857 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 65.04 -93.57 0.16 Allowed Glycine 0 C--N 1.343 0.933 0 N-CA-C 108.859 -1.696 . . . . 10.0 108.859 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -164.43 39.73 0.08 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.709 1.204 . . . . 10.0 108.402 167.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.04 -11.84 58.21 Favored 'General case' 0 N--CA 1.456 -0.167 0 N-CA-C 113.637 0.977 . . . . 10.0 113.637 -168.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.44 -165.22 53.64 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.427 -1.069 . . . . 10.0 110.427 177.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.3 t -57.02 130.9 48.1 Favored 'General case' 0 N--CA 1.447 -0.611 0 C-N-CA 123.812 0.845 . . . . 10.0 112.217 -168.082 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -64.21 76.61 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.107 1.363 . . . . 10.0 110.171 170.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.8 mt -53.78 -36.9 62.91 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 112.735 0.643 . . . . 10.0 112.735 -177.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 148.4 28.29 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 109.884 -0.413 . . . . 10.0 109.884 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 p -155.54 132.85 10.93 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.2 1.0 . . . . 10.0 108.911 -169.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.88 -162.02 10.82 Favored Glycine 0 CA--C 1.52 0.382 0 C-N-CA 123.84 0.733 . . . . 10.0 111.973 -173.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 7.1 t -138.9 153.18 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 104.684 -2.339 . . . . 10.0 104.684 168.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.3 mt -67.49 -88.17 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 123.784 0.834 . . . . 10.0 110.409 -169.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.33 134.02 8.07 Favored Glycine 0 CA--C 1.534 1.235 0 O-C-N 121.64 -0.662 . . . . 10.0 112.326 178.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 88.5 mt -72.31 144.97 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 125.143 1.377 . . . . 10.0 109.529 -176.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -124.21 -50.53 1.79 Allowed 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.974 0.909 . . . . 10.0 110.633 176.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 . . . . . 0 C--O 1.25 1.104 0 C-N-CA 125.011 1.324 . . . . 10.0 112.688 -171.931 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.1 t -104.55 -11.11 17.16 Favored 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.921 1.288 . . . . 10.0 110.605 -178.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 15.5 ptmt -155.22 160.77 41.1 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.76 168.44 22.93 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 126.871 2.068 . . . . 10.0 108.778 -177.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 m -126.37 169.23 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 C-N-CA 123.038 0.535 . . . . 10.0 110.825 175.261 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.51 107.68 6.07 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 107.132 -1.433 . . . . 10.0 107.132 165.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -87.26 95.13 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 C-N-CA 123.549 0.74 . . . . 10.0 109.008 173.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -78.76 126.18 30.37 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 107.888 -1.153 . . . . 10.0 107.888 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.4 mptt -146.87 155.15 42.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 168.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.18 -65.91 0.03 OUTLIER Glycine 0 N--CA 1.46 0.272 0 C-N-CA 118.842 -1.646 . . . . 10.0 112.925 169.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -71.66 -43.74 65.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 107.205 -1.406 . . . . 10.0 107.205 -177.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 148.37 -71.1 0.32 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 114.324 -1.307 . . . . 10.0 111.351 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -56.71 -37.69 97.27 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 122.87 2.38 . . . . 10.0 112.078 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 m -72.23 87.19 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 108.529 -0.915 . . . . 10.0 108.529 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -104.19 108.36 19.69 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.097 -1.816 . . . . 10.0 106.097 -178.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.47 141.13 15.43 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.036 -0.826 . . . . 10.0 111.036 172.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.515 ' CG2' HG21 ' B' ' 54' ' ' THR . 9.0 mt -139.37 81.83 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 -177.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -90.87 146.83 5.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 C-N-CA 123.529 0.732 . . . . 10.0 109.509 175.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -129.0 114.42 16.39 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.6 2.36 . . . . 10.0 107.331 177.199 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -93.74 115.65 28.08 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 172.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -117.87 137.8 52.54 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.804 0.729 . . . . 10.0 111.507 168.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -134.19 91.79 2.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.266 2.226 . . . . 10.0 106.235 -178.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -51.26 -38.66 53.86 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 125.581 1.552 . . . . 10.0 112.473 -168.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -152.23 -179.22 7.34 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 105.803 -1.925 . . . . 10.0 105.803 171.426 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.9 p -72.18 -18.96 61.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 118.14 0.427 . . . . 10.0 110.074 -178.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -83.81 -17.31 41.46 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 124.224 1.01 . . . . 10.0 109.438 175.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.63 147.84 30.01 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.647 -0.981 . . . . 10.0 110.647 175.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.26 170.99 15.85 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.443 2.095 . . . . 10.0 108.682 168.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.1 t -87.33 104.92 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 106.197 -1.779 . . . . 10.0 106.197 170.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -84.88 113.99 21.78 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 104.784 -2.302 . . . . 10.0 104.784 168.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.17 98.78 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.023 -1.473 . . . . 10.0 107.023 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.3 p90 -113.16 179.9 3.83 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.893 0.378 . . . . 10.0 110.705 174.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.74 -154.53 22.68 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.701 -2.16 . . . . 10.0 107.701 168.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 61.3 p -155.36 155.41 33.61 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 118.678 -1.209 . . . . 10.0 112.304 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.69 135.8 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 C-N-CA 126.229 1.812 . . . . 10.0 107.031 171.474 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -121.3 150.04 42.01 Favored 'General case' 0 CA--C 1.528 0.105 0 N-CA-C 107.354 -1.35 . . . . 10.0 107.354 170.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.77 -21.54 18.41 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-N 119.146 0.884 . . . . 10.0 114.161 175.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.5 mt -62.94 179.52 0.37 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 125.29 1.436 . . . . 10.0 111.652 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -103.75 175.54 5.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.777 -1.102 . . . . 10.0 108.107 166.092 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -64.28 169.73 4.36 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.054 0.942 . . . . 10.0 111.765 -171.054 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.76 -173.73 28.48 Favored Glycine 0 C--O 1.223 -0.583 0 C-N-CA 124.347 0.975 . . . . 10.0 111.841 167.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.88 148.73 47.48 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.854 0.862 . . . . 10.0 109.107 169.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.1 m-70 -141.53 143.46 33.78 Favored 'General case' 0 C--N 1.34 0.18 0 N-CA-C 113.718 1.007 . . . . 10.0 113.718 -177.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -18.14 116.41 0.01 OUTLIER Glycine 0 C--N 1.339 0.721 0 C-N-CA 129.104 3.24 . . . . 10.0 115.061 163.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -149.41 98.32 2.77 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 120.208 2.004 . . . . 10.0 114.609 174.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.464 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -144.85 170.85 15.34 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.649 0.78 . . . . 10.0 112.16 178.664 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.4 t -105.5 -28.09 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 128.355 2.662 . . . . 10.0 112.827 -168.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.5 m-70 63.03 176.08 0.15 Allowed 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.586 1.154 . . . . 10.0 112.451 178.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -92.47 -64.83 1.06 Allowed 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.582 -0.736 . . . . 10.0 110.855 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -79.21 148.92 32.08 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 119.174 -1.01 . . . . 10.0 109.615 -176.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.0 -25.71 33.56 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 109.797 -1.321 . . . . 10.0 109.797 169.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -62.06 166.57 4.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 123.093 1.425 . . . . 10.0 112.897 -176.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.56 21.55 0.1 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.482 -1.235 . . . . 10.0 113.137 -169.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -52.44 -35.23 51.78 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 124.797 1.239 . . . . 10.0 111.823 -176.556 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.05 -19.79 53.62 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 122.892 0.477 . . . . 10.0 112.138 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.84 107.0 1.22 Allowed Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.741 -1.343 . . . . 10.0 109.741 -172.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.1 m 34.75 59.91 0.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.357 1.863 . . . . 10.0 112.046 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.5 m -153.77 -54.24 0.11 Allowed 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.577 -0.897 . . . . 10.0 108.577 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -51.19 -39.5 56.62 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.857 1.263 . . . . 10.0 110.768 -173.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -29.67 -38.51 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 128.526 2.73 . . . . 10.0 114.786 168.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.49 131.63 6.65 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.125 -1.19 . . . . 10.0 110.125 172.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.94 64.78 3.29 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.531 2.821 . . . . 10.0 112.36 174.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.491 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 11.6 m170 69.86 38.09 1.68 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 128.527 2.731 . . . . 10.0 111.926 168.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -73.19 26.64 0.06 Allowed 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 115.372 1.619 . . . . 10.0 115.372 -170.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -46.22 150.72 1.05 Allowed Pre-proline 0 CA--C 1.54 0.558 0 C-N-CA 125.0 1.32 . . . . 10.0 112.703 -170.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -52.88 -52.86 7.87 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.087 2.524 . . . . 10.0 112.348 -173.28 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -77.06 61.14 1.97 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.9 -0.778 . . . . 10.0 108.9 169.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.4 t -60.02 113.99 2.61 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 106.877 -1.527 . . . . 10.0 106.877 178.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.68 -81.13 0.41 Allowed 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 109.41 -0.589 . . . . 10.0 109.41 -175.227 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -145.53 150.67 36.85 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-O 122.31 1.053 . . . . 10.0 110.91 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 52.8 t60 -64.69 117.88 8.1 Favored 'General case' 0 N--CA 1.447 -0.623 0 C-N-CA 119.146 -1.021 . . . . 10.0 108.642 166.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.97 -132.45 2.58 Favored Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 107.465 -2.254 . . . . 10.0 107.465 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.1 -160.79 24.62 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 109.13 -1.588 . . . . 10.0 109.13 177.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -60.75 -6.91 6.52 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.767 1.645 . . . . 10.0 110.973 167.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -85.21 -27.54 26.03 Favored 'General case' 0 N--CA 1.445 -0.68 0 C-N-CA 124.529 1.132 . . . . 10.0 109.942 175.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -106.63 154.83 20.34 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.938 -1.134 . . . . 10.0 107.938 -173.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -85.37 -24.69 27.47 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 115.073 -0.967 . . . . 10.0 109.052 169.039 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -101.39 14.39 32.12 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.585 0.587 . . . . 10.0 112.585 -173.37 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -43.1 149.72 0.2 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.19 2.196 . . . . 10.0 110.181 171.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -77.46 48.86 0.68 Allowed 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.2 -0.937 . . . . 10.0 112.61 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 26.0 t 33.66 49.38 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 126.099 1.759 . . . . 10.0 110.561 -177.375 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.47 42.55 0.03 OUTLIER Glycine 0 CA--C 1.532 1.156 0 CA-C-N 116.11 -0.495 . . . . 10.0 114.014 -169.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -118.01 111.87 19.51 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 104.466 -2.42 . . . . 10.0 104.466 168.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.8 mt -79.51 -29.92 41.7 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 119.75 1.159 . . . . 10.0 108.783 174.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.49 -83.82 0.36 Allowed Glycine 0 C--O 1.221 -0.683 0 N-CA-C 111.22 -0.752 . . . . 10.0 111.22 167.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -155.64 143.5 19.78 Favored 'General case' 0 CA--C 1.517 -0.318 0 N-CA-C 107.909 -1.145 . . . . 10.0 107.909 -176.125 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -130.93 135.24 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 O-C-N 123.68 0.612 . . . . 10.0 110.299 174.353 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -79.31 108.46 12.84 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 127.232 2.213 . . . . 10.0 111.849 -175.024 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.54 130.17 35.3 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.21 1.404 . . . . 10.0 111.036 173.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -59.6 168.53 1.61 Allowed 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 124.311 1.007 . . . . 10.0 109.984 167.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -53.97 -29.83 44.5 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.754 0.821 . . . . 10.0 112.023 171.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.79 -3.57 42.03 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.033 0.382 . . . . 10.0 112.033 177.366 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.18 3.88 88.59 Favored Glycine 0 C--N 1.337 0.601 0 O-C-N 120.971 -1.08 . . . . 10.0 111.53 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.83 97.73 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 106.673 -1.603 . . . . 10.0 106.673 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.23 121.94 42.77 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 169.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -96.13 127.37 42.08 Favored 'General case' 0 C--N 1.329 -0.292 0 O-C-N 124.118 0.886 . . . . 10.0 109.377 174.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.7 t -108.81 139.53 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 C-N-CA 126.789 2.035 . . . . 10.0 108.934 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 95.4 p -156.39 70.35 0.66 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.694 1.198 . . . . 10.0 110.204 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 8.6 mm -106.53 167.45 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 C-N-CA 125.143 1.377 . . . . 10.0 109.303 -174.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 66.3 tt0 -155.35 123.16 5.71 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 127.224 2.21 . . . . 10.0 108.487 -170.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -155.74 158.23 37.85 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 104.37 -2.456 . . . . 10.0 104.37 173.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 15.1 p -106.14 -19.56 13.68 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 126.301 1.841 . . . . 10.0 111.751 -177.311 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 70.4 t -77.05 -38.68 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 -169.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.292 0.0 OUTLIER -76.19 54.43 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 C-N-CA 124.356 1.063 . . . . 10.0 112.3 178.677 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.93 145.03 52.21 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.229 1.012 . . . . 10.0 111.329 -169.774 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 76.0 mt -47.62 -52.84 16.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.352 0.596 . . . . 10.0 110.478 176.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.3 m -150.44 158.43 44.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 125.28 1.432 . . . . 10.0 107.354 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.9 -67.8 0.25 Allowed Glycine 0 C--N 1.335 0.492 0 N-CA-C 109.609 -1.396 . . . . 10.0 109.609 -176.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -155.82 -53.16 0.09 Allowed 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 126.904 2.082 . . . . 10.0 106.315 178.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.1 -37.62 64.09 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 114.197 -1.365 . . . . 10.0 108.771 -173.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.6 t 47.57 91.6 0.01 OUTLIER 'General case' 0 C--O 1.232 0.182 0 C-N-CA 127.112 2.165 . . . . 10.0 113.872 168.123 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 17.6 pt -68.13 -27.34 36.87 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 119.956 -0.697 . . . . 10.0 111.78 174.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -49.79 126.32 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 119.584 1.084 . . . . 10.0 109.911 175.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.74 14.68 79.35 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-O 118.457 -1.191 . . . . 10.0 114.424 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.8 mmt-85 -84.27 -179.46 7.2 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.092 1.357 . . . . 10.0 109.084 166.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -136.9 104.23 5.41 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -179.451 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.434 ' CD1' HD11 ' A' ' 149' ' ' ILE . 8.9 mp -72.82 146.08 46.53 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 108.3 -1.0 . . . . 10.0 108.3 173.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.2 t -129.04 131.89 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.18 0 N-CA-C 107.17 -1.419 . . . . 10.0 107.17 175.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.7 p -99.69 136.93 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 106.837 -1.542 . . . . 10.0 106.837 168.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 14.4 m-70 -114.74 160.7 19.09 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 114.516 1.302 . . . . 10.0 114.516 -173.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -60.39 -60.12 4.32 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 114.847 -1.07 . . . . 10.0 108.638 173.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -90.38 164.76 14.19 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.735 -0.786 . . . . 10.0 112.007 -170.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.47 147.76 37.66 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 106.951 -1.499 . . . . 10.0 106.951 169.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -98.41 141.22 31.56 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 123.546 0.739 . . . . 10.0 109.441 -169.314 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 -72.32 -20.86 61.42 Favored 'General case' 0 N--CA 1.46 0.061 0 CA-C-O 120.822 0.344 . . . . 10.0 110.705 -173.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.5 mt 55.21 42.54 30.43 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 -167.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.98 -15.46 62.96 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 126.494 1.997 . . . . 10.0 113.194 171.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -76.88 -2.24 32.52 Favored 'General case' 0 CA--C 1.535 0.381 0 N-CA-C 114.443 1.275 . . . . 10.0 114.443 -167.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.17 -16.25 64.28 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 118.562 0.619 . . . . 10.0 111.983 174.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.01 40.89 67.2 Favored Glycine 0 CA--C 1.527 0.824 0 CA-C-N 117.981 0.89 . . . . 10.0 110.983 -178.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -128.3 161.91 28.29 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.477 -1.675 . . . . 10.0 106.477 177.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -53.34 -50.14 65.62 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.269 -1.382 . . . . 10.0 107.269 169.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -52.95 -44.25 66.95 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 115.382 -0.827 . . . . 10.0 112.11 172.494 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 23.1 p -57.4 -39.14 75.5 Favored 'General case' 0 N--CA 1.445 -0.677 0 O-C-N 120.449 -1.407 . . . . 10.0 110.763 -178.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.1 t -85.98 6.26 29.53 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 111.731 0.271 . . . . 10.0 111.731 -179.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 27.7 mmtp -106.75 -84.86 0.51 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.708 1.603 . . . . 10.0 109.241 171.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.491 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 2.9 p -95.47 -12.22 26.23 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 121.242 1.837 . . . . 10.0 112.841 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 80.58 32.97 32.34 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -168.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 53.69 44.69 29.33 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.376 1.088 . . . . 10.0 111.103 -178.06 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.13 -2.49 13.14 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.38 0.672 . . . . 10.0 112.256 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 94.95 -67.01 1.28 Allowed Glycine 0 C--N 1.336 0.556 0 O-C-N 120.921 -1.112 . . . . 10.0 111.215 169.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -166.89 175.21 7.86 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 -178.375 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -105.86 98.93 8.56 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.414 1.886 . . . . 10.0 106.981 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.437 ' N ' ' CD2' ' A' ' 144' ' ' LEU . 0.6 OUTLIER -84.93 -25.22 28.0 Favored 'General case' 0 C--O 1.232 0.178 0 C-N-CA 122.956 0.502 . . . . 10.0 110.963 -167.856 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 139.29 10.96 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.582 -0.896 . . . . 10.0 108.582 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 97.1 m -118.99 144.79 46.3 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.472 1.509 . . . . 10.0 107.657 -177.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.64 134.27 5.39 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.695 -0.962 . . . . 10.0 110.695 173.409 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -95.63 134.0 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 106.958 -1.497 . . . . 10.0 106.958 -170.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.434 HD11 ' CD1' ' A' ' 117' ' ' LEU . 9.4 mt -76.49 115.84 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 N-CA-C 110.517 -0.179 . . . . 10.0 110.517 -168.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.89 136.91 13.83 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.033 0.825 . . . . 10.0 111.515 -175.336 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 68.8 mt -54.7 138.44 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 C-N-CA 125.67 1.588 . . . . 10.0 108.433 173.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.57 -47.75 1.96 Allowed 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 123.265 0.626 . . . . 10.0 111.02 176.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.952 -1.975 . . . . 10.0 113.148 -174.245 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.923 0 CA-C-O 116.423 -1.751 . . . . 10.0 107.306 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . 0.254 1.9 t -141.0 -49.46 0.43 Allowed 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 120.493 1.497 . . . . 10.0 113.072 174.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -103.4 129.56 50.52 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 107.833 -1.173 . . . . 10.0 107.833 169.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.3 158.12 44.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 169.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.8 m -121.02 172.66 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.159 0 CA-C-N 117.89 0.314 . . . . 10.0 110.168 175.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.2 98.56 3.76 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.342 -1.355 . . . . 10.0 107.342 167.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 13.2 m -83.39 104.89 12.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.256 -1.016 . . . . 10.0 108.256 169.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.5 mt -92.71 145.2 24.6 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.011 -0.737 . . . . 10.0 109.011 -177.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 46.0 tttt -160.46 161.07 32.79 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 173.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.27 -51.01 0.05 OUTLIER Glycine 0 C--O 1.228 -0.271 0 CA-C-N 116.347 -0.388 . . . . 10.0 112.272 169.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.7 -45.78 34.87 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 -170.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.08 -67.85 0.54 Allowed Glycine 0 N--CA 1.442 -0.934 0 CA-C-N 113.672 -1.603 . . . . 10.0 110.292 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -56.25 -42.87 61.64 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.547 2.165 . . . . 10.0 110.543 171.117 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -63.66 114.13 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 -179.351 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.0 121.01 28.75 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.665 -1.605 . . . . 10.0 106.665 168.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -97.65 144.08 17.09 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 168.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 mt -144.2 71.29 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.097 -1.446 . . . . 10.0 107.097 -176.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -94.1 141.58 14.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 O-C-N 122.042 -0.411 . . . . 10.0 109.938 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.7 m-80 -110.46 128.05 55.42 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 126.034 1.733 . . . . 10.0 109.48 171.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -109.4 98.01 7.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 174.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -105.24 124.18 49.09 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.599 0.714 . . . . 10.0 112.34 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 tt0 -91.36 99.18 12.19 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.201 1.801 . . . . 10.0 108.241 176.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.42 ' CE ' ' OE2' ' B' ' 24' ' ' GLU . 28.3 tttt -53.95 -54.29 40.99 Favored 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 126.956 2.102 . . . . 10.0 110.17 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . 0.42 ' OE2' ' CE ' ' B' ' 23' ' ' LYS . 35.3 mt-10 -138.08 161.86 35.68 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 102.45 -3.167 . . . . 10.0 102.45 -178.214 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 m -69.58 -19.33 63.67 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 119.304 0.957 . . . . 10.0 110.138 -174.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -114.42 7.49 16.31 Favored 'General case' 0 N--CA 1.437 -1.095 0 O-C-N 124.916 1.385 . . . . 10.0 110.822 177.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.62 152.66 32.27 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 108.78 -1.728 . . . . 10.0 108.78 178.082 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -62.71 141.04 83.9 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 N-CA-C 108.097 -1.54 . . . . 10.0 108.097 170.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.4 t -87.19 109.39 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 105.322 -2.103 . . . . 10.0 105.322 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -76.93 113.18 14.35 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.645 -1.983 . . . . 10.0 105.645 168.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.47 102.19 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 171.088 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -120.73 154.71 35.25 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.202 0.525 . . . . 10.0 112.039 176.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.28 -168.59 36.58 Favored Glycine 0 N--CA 1.444 -0.831 0 N-CA-C 109.616 -1.393 . . . . 10.0 109.616 169.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.8 p -144.78 113.26 6.62 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 109.061 -0.718 . . . . 10.0 109.061 -169.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.4 pt -78.79 170.7 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.063 -1.088 . . . . 10.0 108.063 167.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -154.13 154.35 33.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.343 -0.984 . . . . 10.0 108.343 166.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.35 -15.62 32.6 Favored Glycine 0 CA--C 1.525 0.677 0 CA-C-O 119.139 -0.812 . . . . 10.0 114.08 177.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.7 mp -71.91 -179.21 2.62 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 118.757 1.278 . . . . 10.0 110.918 177.064 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -101.51 175.34 5.6 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.54 -0.911 . . . . 10.0 108.54 166.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -51.07 164.57 0.15 Allowed 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.23 2.212 . . . . 10.0 113.214 -173.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.76 -170.68 55.04 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 124.16 0.886 . . . . 10.0 114.008 165.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.96 141.76 54.86 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.127 1.771 . . . . 10.0 111.798 -175.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.4 m-70 -138.58 123.89 19.31 Favored 'General case' 0 C--N 1.339 0.115 0 C-N-CA 125.013 1.325 . . . . 10.0 109.847 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.42 127.83 1.75 Allowed Glycine 0 C--N 1.346 1.086 0 C-N-CA 126.839 2.161 . . . . 10.0 109.637 171.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.414 ' CZ ' ' HB3' ' B' ' 84' ' ' LEU 0.274 0.3 OUTLIER -145.67 123.82 12.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 119.041 1.42 . . . . 10.0 112.406 168.139 . . . . . . . . 4 4 . 1 . 015 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.429 ' NE2' ' OD2' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -160.33 175.64 12.6 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.573 -0.74 . . . . 10.0 111.719 -174.264 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.2 m -88.72 153.43 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 O-C-N 125.697 1.873 . . . . 10.0 107.807 167.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 64.6 m-70 -134.72 95.04 3.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 108.329 -0.989 . . . . 10.0 108.329 177.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 24.43 -87.54 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 127.228 2.211 . . . . 10.0 114.24 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -78.87 161.76 26.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 122.734 1.254 . . . . 10.0 111.883 -169.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.44 -32.53 57.68 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 108.261 -1.936 . . . . 10.0 108.261 169.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -39.48 150.74 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 125.978 1.711 . . . . 10.0 113.929 176.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -157.17 21.17 0.3 Allowed 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 113.882 -1.508 . . . . 10.0 113.081 178.527 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.515 HG21 ' CG2' ' A' ' 17' ' ' ILE . 6.0 m -41.69 -48.7 4.2 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.512 1.125 . . . . 10.0 113.093 -167.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.09 -25.36 47.53 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.891 0.876 . . . . 10.0 112.859 -176.393 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.17 104.15 2.6 Favored Glycine 0 CA--C 1.528 0.905 0 N-CA-C 109.544 -1.422 . . . . 10.0 109.544 -169.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 17.9 m 49.72 48.51 21.49 Favored 'General case' 0 N--CA 1.462 0.165 0 C-N-CA 125.474 1.51 . . . . 10.0 112.757 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -154.51 -55.86 0.1 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.6 m -50.56 -43.62 56.3 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.496 1.118 . . . . 10.0 111.45 -171.045 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.84 -51.47 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 128.005 2.522 . . . . 10.0 114.033 168.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.08 162.74 11.52 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.603 -1.399 . . . . 10.0 109.603 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -71.71 -164.68 0.17 Allowed 'Trans proline' 0 N--CA 1.447 -1.232 0 N-CA-C 105.019 -2.723 . . . . 10.0 105.019 163.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.43 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 34.1 m170 -81.47 53.55 2.12 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 119.288 -2.132 . . . . 10.0 109.72 -176.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -69.91 88.22 0.56 Allowed 'General case' 0 C--O 1.225 -0.225 0 CA-C-O 122.984 1.373 . . . . 10.0 109.383 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.9 p30 -96.34 151.2 37.95 Favored Pre-proline 0 C--N 1.325 -0.463 0 C-N-CA 127.236 2.214 . . . . 10.0 110.605 -176.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.4 -42.88 4.82 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.803 2.335 . . . . 10.0 111.282 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 77.0 mt -77.89 55.03 1.35 Allowed 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.829 0.852 . . . . 10.0 110.587 -178.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -38.28 101.77 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 126.752 2.021 . . . . 10.0 112.063 -171.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -140.38 -175.79 4.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.361 -1.348 . . . . 10.0 107.361 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -94.26 127.67 40.26 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -178.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -36.87 113.26 0.23 Allowed 'General case' 0 C--O 1.225 -0.207 0 O-C-N 123.639 0.587 . . . . 10.0 112.035 176.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.09 -137.09 5.65 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 177.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 168.44 -153.72 22.98 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.487 -2.245 . . . . 10.0 107.487 169.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -64.27 6.64 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.939 0 CA-C-N 120.635 2.217 . . . . 10.0 112.346 169.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.413 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.0 mmmt -121.4 12.26 10.84 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 126.978 2.111 . . . . 10.0 110.287 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . 0.406 ' CG ' ' HZ1' ' B' ' 128' ' ' LYS . 2.1 m-20 -151.73 158.01 42.8 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 118.945 0.793 . . . . 10.0 108.919 168.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -79.39 -26.69 41.9 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 173.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -79.81 5.79 12.71 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 124.671 1.189 . . . . 10.0 112.82 -169.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt180 -35.23 120.75 0.55 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.796 1.639 . . . . 10.0 110.571 168.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.8 m170 -52.32 -53.55 43.0 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.506 1.122 . . . . 10.0 112.566 -170.057 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -178.03 -47.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 C-N-CA 125.667 1.587 . . . . 10.0 107.74 178.129 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.19 56.0 0.74 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.511 -1.435 . . . . 10.0 109.511 178.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -91.98 86.69 5.93 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 105.0 -2.222 . . . . 10.0 105.0 168.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . 0.414 ' HB3' ' CZ ' ' B' ' 45' ' ' PHE . 5.4 mp -72.98 -30.54 63.9 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 106.908 -1.516 . . . . 10.0 106.908 176.098 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.95 -93.18 0.86 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 124.687 1.137 . . . . 10.0 110.439 165.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 p30 -151.88 141.22 21.49 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.084 0.554 . . . . 10.0 110.021 -173.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.6 138.87 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 C-N-CA 124.451 1.1 . . . . 10.0 111.677 179.219 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.4 m -79.17 115.05 18.6 Favored 'General case' 0 N--CA 1.437 -1.116 0 C-N-CA 128.821 2.849 . . . . 10.0 110.635 -177.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.7 134.17 38.94 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 123.855 0.862 . . . . 10.0 110.154 171.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -57.51 171.2 0.46 Allowed 'General case' 0 C--O 1.233 0.192 0 O-C-N 123.982 0.801 . . . . 10.0 109.634 167.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.63 -29.6 38.78 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 123.874 0.87 . . . . 10.0 110.955 173.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -79.08 -7.6 58.27 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.126 0.489 . . . . 10.0 111.203 -178.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.04 -0.24 72.25 Favored Glycine 0 C--N 1.338 0.684 0 O-C-N 121.195 -0.94 . . . . 10.0 111.001 -175.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 55.7 t -78.95 101.35 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 107.518 -1.289 . . . . 10.0 107.518 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -99.4 118.09 35.25 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.825 -1.176 . . . . 10.0 107.825 168.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.49 125.59 29.58 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 106.829 -1.545 . . . . 10.0 106.829 169.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 59.3 t -107.97 128.95 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 N-CA-C 105.385 -2.079 . . . . 10.0 105.385 169.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 73.0 m -152.72 59.85 0.8 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.798 0.839 . . . . 10.0 108.783 175.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.6 151.24 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 N-CA-C 108.138 -1.06 . . . . 10.0 108.138 -173.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -130.18 141.3 50.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.417 1.087 . . . . 10.0 109.155 170.292 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -149.27 161.03 42.84 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 29.7 p -122.6 4.89 9.55 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 127.237 2.215 . . . . 10.0 111.894 -172.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -84.14 -42.53 17.13 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 N-CA-C 107.699 -1.222 . . . . 10.0 107.699 177.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.283 0.0 OUTLIER -71.31 159.37 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 123.959 0.904 . . . . 10.0 113.228 172.378 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -160.04 155.0 24.59 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.202 -1.407 . . . . 10.0 107.202 170.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -82.14 55.88 2.98 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 108.129 -1.063 . . . . 10.0 108.129 169.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.5 t -73.83 -159.0 0.07 Allowed 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.598 1.959 . . . . 10.0 108.666 177.246 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -120.96 -51.89 0.25 Allowed Glycine 0 CA--C 1.528 0.903 0 C-N-CA 128.466 2.936 . . . . 10.0 107.662 173.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -65.77 -58.25 6.09 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 125.902 1.681 . . . . 10.0 108.908 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -81.8 -38.32 25.74 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.639 -0.71 . . . . 10.0 109.979 -176.147 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.3 t 3.39 109.43 0.0 OUTLIER 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 129.489 3.115 . . . . 10.0 115.575 177.217 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 34.8 pt -73.51 6.2 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 N-CA-C 112.823 0.675 . . . . 10.0 112.823 171.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 9.1 mm -56.95 -67.13 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.311 0 CA-C-N 119.352 0.978 . . . . 10.0 111.458 -176.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -81.63 56.1 4.89 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 120.856 -1.152 . . . . 10.0 111.924 -175.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.1 mmt-85 -122.4 150.57 42.27 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.929 1.291 . . . . 10.0 107.957 176.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -92.24 129.26 38.23 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 104.065 -2.569 . . . . 10.0 104.065 168.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 10.9 mp -112.16 145.42 39.86 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.415 -0.957 . . . . 10.0 108.415 169.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 94.1 t -122.93 145.81 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 -171.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.5 p -117.2 122.74 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 C-N-CA 126.769 2.027 . . . . 10.0 106.473 169.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 10.2 m170 -105.29 167.22 9.87 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 115.722 1.749 . . . . 10.0 115.722 -168.463 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -59.29 -66.06 0.57 Allowed 'General case' 0 C--O 1.223 -0.29 0 C-N-CA 125.887 1.675 . . . . 10.0 110.186 174.155 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -107.06 177.71 4.77 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 118.817 0.735 . . . . 10.0 112.137 -169.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.08 144.13 48.81 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.683 1.193 . . . . 10.0 110.567 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.429 ' OD2' ' NE2' ' B' ' 46' ' ' HIS . 19.5 m-20 -89.59 149.36 22.88 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 109.091 -0.707 . . . . 10.0 109.091 168.039 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -76.76 -11.23 59.81 Favored 'General case' 0 N--CA 1.453 -0.289 0 O-C-N 124.73 1.269 . . . . 10.0 111.01 176.202 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 18.0 mt 57.37 40.05 27.8 Favored 'General case' 0 N--CA 1.457 -0.105 0 CA-C-N 118.26 0.482 . . . . 10.0 109.757 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 106.98 -33.41 6.43 Favored Glycine 0 CA--C 1.525 0.664 0 C-N-CA 125.325 1.44 . . . . 10.0 112.29 173.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . 0.406 ' HZ1' ' CG ' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -83.49 42.63 0.84 Allowed 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 118.471 1.135 . . . . 10.0 110.674 -169.29 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.71 -20.83 12.15 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.142 1.83 . . . . 10.0 111.743 -176.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.34 45.73 44.73 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 123.972 0.796 . . . . 10.0 112.554 178.477 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -152.03 172.43 16.29 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.444 0.622 . . . . 10.0 109.74 175.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 12.8 tm-20 -52.2 -43.78 64.37 Favored 'General case' 0 N--CA 1.443 -0.807 0 C-N-CA 123.699 0.799 . . . . 10.0 111.834 -176.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -72.43 -30.02 64.23 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.397 -0.815 . . . . 10.0 111.097 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 30.0 p -50.44 -40.42 50.4 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 119.419 1.009 . . . . 10.0 111.341 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -85.03 -13.79 49.4 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 123.793 0.683 . . . . 10.0 112.405 -175.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.2 ttmt -107.86 -48.75 3.34 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 126.841 2.056 . . . . 10.0 112.431 -166.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.43 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 8.9 p -131.93 -9.85 3.45 Favored 'General case' 0 C--O 1.224 -0.274 0 CA-C-O 116.794 -1.574 . . . . 10.0 112.258 169.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.0 -105.98 3.08 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 107.089 -2.404 . . . . 10.0 107.089 -166.394 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -171.81 21.53 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 115.187 1.551 . . . . 10.0 115.187 -176.702 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.09 -14.91 62.56 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 120.853 -1.154 . . . . 10.0 111.976 -178.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.53 -117.58 5.0 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.348 -1.901 . . . . 10.0 108.348 169.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 112.11 6.33 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 112.575 0.583 . . . . 10.0 112.575 -167.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.84 73.84 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.405 1.082 . . . . 10.0 109.938 166.172 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.9 mt -51.59 -45.2 63.07 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.783 0.66 . . . . 10.0 112.783 -175.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.27 156.82 41.62 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -168.047 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.0 p -163.4 170.13 17.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.951 -0.388 . . . . 10.0 109.951 -173.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.89 162.33 33.0 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.343 -1.503 . . . . 10.0 109.343 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.91 129.46 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 105.644 -1.984 . . . . 10.0 105.644 -176.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 22.6 mt -69.55 160.98 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 CA-C-N 118.773 0.715 . . . . 10.0 110.03 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.01 166.27 39.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 125.529 1.538 . . . . 10.0 109.919 -173.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 95.5 mt -74.29 134.56 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 C-N-CA 124.858 1.263 . . . . 10.0 109.785 -169.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.57 -35.25 3.59 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 112.795 0.665 . . . . 10.0 112.795 176.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.252 1.186 0 CA-C-O 116.953 -1.498 . . . . 10.0 108.893 174.508 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t -162.34 -43.77 0.04 OUTLIER 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 118.904 0.774 . . . . 10.0 110.795 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -118.41 138.52 52.39 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.34 155.68 49.13 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 124.148 0.905 . . . . 10.0 109.482 175.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -121.8 148.82 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 C-N-CA 125.618 1.567 . . . . 10.0 109.183 -176.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.33 100.85 4.36 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 108.022 -1.103 . . . . 10.0 108.022 167.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.2 m -79.51 100.99 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 109.055 -0.72 . . . . 10.0 109.055 171.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.9 mt -81.17 142.76 32.91 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -158.23 160.27 36.96 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 173.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -165.25 -60.68 0.02 OUTLIER Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.41 -0.424 . . . . 10.0 112.153 171.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -74.72 -45.86 41.39 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 106.644 -1.613 . . . . 10.0 106.644 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.69 -64.46 0.61 Allowed Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 114.021 -1.445 . . . . 10.0 111.203 -176.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -52.45 -42.74 59.33 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.06 1.84 . . . . 10.0 111.058 173.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 m -72.16 113.78 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.269 -1.011 . . . . 10.0 108.269 177.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -119.49 120.99 38.41 Favored 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 104.783 -2.303 . . . . 10.0 104.783 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.22 141.46 15.34 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.275 -1.93 . . . . 10.0 108.275 169.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.7 mt -137.16 67.26 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.069 -1.086 . . . . 10.0 108.069 -173.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.1 mm -77.06 133.86 29.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 109.4 -0.593 . . . . 10.0 109.4 -178.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -121.25 98.58 6.04 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.517 1.927 . . . . 10.0 107.6 -178.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -81.27 128.79 34.19 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 118.155 -0.926 . . . . 10.0 108.616 177.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.77 122.21 43.81 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.619 0.768 . . . . 10.0 110.723 171.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -122.27 103.17 8.58 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.793 2.037 . . . . 10.0 106.483 168.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -61.77 -60.96 2.88 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 122.709 0.403 . . . . 10.0 110.467 -174.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -128.43 177.51 6.93 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 104.31 -2.478 . . . . 10.0 104.31 169.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.5 p -73.87 -17.17 61.08 Favored 'General case' 0 C--N 1.322 -0.594 0 O-C-N 122.114 -0.367 . . . . 10.0 110.578 -175.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.2 m-80 -79.2 -22.37 45.0 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.984 0.914 . . . . 10.0 109.461 172.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.64 124.73 18.83 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 109.91 -1.276 . . . . 10.0 109.91 179.325 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.92 141.95 86.34 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 N-CA-C 107.097 -1.924 . . . . 10.0 107.097 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 71.0 t -79.54 116.93 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 107.786 -1.19 . . . . 10.0 107.786 -169.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -88.91 108.4 19.53 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.122 -1.807 . . . . 10.0 106.122 177.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 18.6 m -101.32 90.59 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 125.328 1.451 . . . . 10.0 108.122 -177.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -101.49 167.5 10.11 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 122.03 0.919 . . . . 10.0 110.777 168.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.19 162.2 28.05 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.578 -1.409 . . . . 10.0 109.578 171.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.3 m -128.28 102.39 6.66 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 176.099 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.8 pt -77.08 176.32 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 N-CA-C 108.133 -1.062 . . . . 10.0 108.133 170.037 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.9 pttt -153.89 149.1 26.97 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 106.942 -1.503 . . . . 10.0 106.942 169.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.35 -24.24 12.7 Favored Glycine 0 C--N 1.338 0.654 0 CA-C-O 119.248 -0.751 . . . . 10.0 114.438 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.8 mp -65.56 175.92 1.66 Allowed 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 118.414 1.107 . . . . 10.0 111.063 -175.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -89.77 148.12 23.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.378 -0.828 . . . . 10.0 110.284 171.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -39.59 125.47 1.78 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.867 2.467 . . . . 10.0 110.938 174.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 121.42 -174.64 15.99 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 123.602 0.62 . . . . 10.0 112.961 171.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.64 151.91 44.45 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.806 1.642 . . . . 10.0 111.234 -178.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -148.27 143.3 26.86 Favored 'General case' 0 C--N 1.343 0.31 0 N-CA-C 113.524 0.935 . . . . 10.0 113.524 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -30.86 122.75 0.14 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.853 2.644 . . . . 10.0 110.917 165.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.92 106.41 4.42 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 119.989 1.894 . . . . 10.0 110.259 172.557 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.447 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -158.06 172.54 18.25 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-O 121.797 0.808 . . . . 10.0 111.764 -177.922 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 9.8 p -100.05 152.62 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-N 112.418 -2.174 . . . . 10.0 109.366 171.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -128.08 135.47 49.87 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 176.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -51.31 -61.77 2.03 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.318 1.447 . . . . 10.0 112.309 -168.323 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -83.9 147.79 27.31 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 119.539 -0.865 . . . . 10.0 109.516 -178.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.06 9.12 58.36 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 124.919 1.247 . . . . 10.0 111.321 170.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -67.56 98.45 0.68 Allowed 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 123.547 1.642 . . . . 10.0 110.907 -178.184 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.34 14.73 30.85 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 111.516 -2.584 . . . . 10.0 110.588 167.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.427 HG21 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -71.45 -40.95 70.0 Favored 'General case' 0 C--N 1.339 0.152 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 168.516 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -20.22 48.79 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.414 0.524 . . . . 10.0 112.414 170.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.02 78.83 1.37 Allowed Glycine 0 CA--C 1.529 0.909 0 N-CA-C 111.322 -0.711 . . . . 10.0 111.322 178.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.4 p 37.39 43.17 0.37 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 126.841 2.057 . . . . 10.0 114.292 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.2 m -133.14 -57.74 0.91 Allowed 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 105.682 -1.97 . . . . 10.0 105.682 -178.301 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -55.99 -29.05 59.7 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 122.823 0.449 . . . . 10.0 109.934 169.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.03 -27.7 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.564 1.545 . . . . 10.0 113.382 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.54 124.26 5.38 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-O 117.751 -1.583 . . . . 10.0 109.57 168.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -72.31 65.46 3.58 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.066 3.177 . . . . 10.0 111.69 176.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.6 m170 67.09 46.58 1.51 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 130.338 3.455 . . . . 10.0 111.868 176.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -70.48 64.68 0.28 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.194 0.597 . . . . 10.0 111.595 178.533 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -73.31 142.19 81.49 Favored Pre-proline 0 CA--C 1.533 0.292 0 O-C-N 120.154 -1.591 . . . . 10.0 109.102 172.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -57.94 -34.28 98.16 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.563 2.175 . . . . 10.0 111.591 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.45 -17.48 63.86 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.201 0.815 . . . . 10.0 113.201 177.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.4 t 20.75 81.93 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 127.495 2.318 . . . . 10.0 114.726 175.276 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.0 mtt180 -111.32 -84.73 0.57 Allowed 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 105.546 -2.02 . . . . 10.0 105.546 -177.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.09 160.56 41.07 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 109.131 -0.692 . . . . 10.0 109.131 167.557 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.0 t60 -56.74 126.68 27.94 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.316 -1.735 . . . . 10.0 106.316 165.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.39 -136.32 3.13 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 107.343 -2.303 . . . . 10.0 107.343 176.09 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 164.68 -150.64 18.98 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 108.982 -1.647 . . . . 10.0 108.982 169.569 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -68.11 19.22 0.13 Allowed 'Trans proline' 0 N--CA 1.453 -0.911 0 CA-C-N 119.77 1.785 . . . . 10.0 112.307 173.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.403 ' H ' ' C ' ' A' ' 73' ' ' GLY . 59.9 mttt -120.87 -11.66 8.92 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 118.161 -0.923 . . . . 10.0 111.243 169.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -143.6 118.44 9.93 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 104.856 -2.276 . . . . 10.0 104.856 -168.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 36.2 tp10 -75.11 -16.5 60.55 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 107.68 -1.23 . . . . 10.0 107.68 -171.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -82.56 11.11 6.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 C-N-CA 125.803 1.641 . . . . 10.0 111.991 175.656 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.8 ptt-85 -43.86 153.13 0.14 Allowed 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.76 1.624 . . . . 10.0 113.674 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -72.09 160.73 31.98 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 107.334 -1.358 . . . . 10.0 107.334 166.082 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.6 p -38.38 -47.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 125.358 1.463 . . . . 10.0 114.259 -172.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.74 55.0 0.76 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 123.396 0.522 . . . . 10.0 111.975 -177.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -82.47 93.5 7.26 Favored 'General case' 0 CA--C 1.528 0.126 0 N-CA-C 105.38 -2.082 . . . . 10.0 105.38 166.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -71.61 -28.94 64.14 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 106.79 -1.559 . . . . 10.0 106.79 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.63 -104.01 2.7 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 106.867 -2.493 . . . . 10.0 106.867 168.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -126.4 131.09 51.82 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.883 -1.155 . . . . 10.0 107.883 -169.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.98 135.58 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 119.076 0.853 . . . . 10.0 110.834 170.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.74 110.83 15.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.429 2.692 . . . . 10.0 110.51 -177.288 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.9 132.31 37.15 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.182 -0.673 . . . . 10.0 109.182 169.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.403 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 19.5 t70 -53.97 168.43 0.21 Allowed 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 125.047 1.339 . . . . 10.0 110.635 168.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.403 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 22.2 tttp -47.7 -35.43 9.64 Favored 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 125.654 1.582 . . . . 10.0 112.231 169.109 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -78.27 -9.84 59.4 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 121.203 0.525 . . . . 10.0 111.896 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.35 11.86 60.51 Favored Glycine 0 C--N 1.337 0.621 0 O-C-N 120.887 -1.133 . . . . 10.0 110.891 -177.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.3 t -92.19 103.92 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 125.749 1.62 . . . . 10.0 107.705 -178.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.88 121.72 41.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 109.052 -0.722 . . . . 10.0 109.052 169.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -84.6 86.16 7.34 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 127.528 2.331 . . . . 10.0 109.884 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.46 129.82 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.251 0 N-CA-C 105.67 -1.974 . . . . 10.0 105.67 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -158.18 72.06 0.61 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 122.986 0.514 . . . . 10.0 110.728 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -116.71 163.71 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.161 -1.792 . . . . 10.0 106.161 -178.016 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.66 144.85 39.83 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.571 0.623 . . . . 10.0 110.475 167.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -129.56 125.9 37.32 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 125.074 1.349 . . . . 10.0 110.205 -169.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 69.3 p -98.4 53.25 1.04 Allowed 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 107.172 -1.418 . . . . 10.0 107.172 169.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -157.24 -45.25 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 C-N-CA 124.085 0.954 . . . . 10.0 109.29 -175.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -74.23 145.09 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 167.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -133.08 157.15 46.0 Favored 'General case' 0 CA--C 1.528 0.124 0 N-CA-C 107.782 -1.192 . . . . 10.0 107.782 168.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.1 mt -95.39 -34.1 12.25 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 108.429 -0.952 . . . . 10.0 108.429 167.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.0 m -156.73 67.25 0.55 Allowed 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 124.486 1.114 . . . . 10.0 108.614 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -165.05 63.24 0.23 Allowed Glycine 0 C--N 1.333 0.365 0 N-CA-C 108.037 -2.025 . . . . 10.0 108.037 -179.313 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 69.75 -57.89 0.54 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 129.712 3.205 . . . . 10.0 109.532 -174.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -82.48 33.23 0.41 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 123.43 0.692 . . . . 10.0 111.416 -168.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.2 t -52.43 104.1 0.08 Allowed 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 126.618 1.967 . . . . 10.0 110.524 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 30.3 pt -86.06 23.55 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 C-N-CA 123.352 0.661 . . . . 10.0 111.787 171.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 20.8 mm -64.45 143.44 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 O-C-N 120.407 -1.433 . . . . 10.0 108.394 173.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.89 19.01 67.17 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-O 119.198 -0.779 . . . . 10.0 114.509 177.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.3 mmt-85 -88.29 176.4 7.24 Favored 'General case' 0 C--O 1.232 0.18 0 N-CA-C 107.76 -1.2 . . . . 10.0 107.76 167.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -121.08 132.66 55.01 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 106.841 -1.541 . . . . 10.0 106.841 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.9 mp -99.41 147.56 25.12 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.343 -1.354 . . . . 10.0 107.343 169.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 90.4 t -127.23 133.63 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.795 -1.557 . . . . 10.0 106.795 170.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.8 p -103.77 125.33 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.581 0 N-CA-C 103.913 -2.625 . . . . 10.0 103.913 167.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 7.2 m170 -105.56 160.6 15.05 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.052 1.406 . . . . 10.0 114.365 -168.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 -41.48 -58.15 1.99 Allowed 'General case' 0 N--CA 1.444 -0.773 0 C-N-CA 128.088 2.555 . . . . 10.0 109.702 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -124.81 176.96 6.26 Favored 'General case' 0 C--N 1.338 0.093 0 C-N-CA 125.791 1.636 . . . . 10.0 110.85 -174.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.69 135.92 33.34 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.143 0.977 . . . . 10.0 109.891 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.447 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.2 OUTLIER -78.55 143.3 36.64 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.433 1.893 . . . . 10.0 111.897 177.787 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.75 19.95 0.26 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.986 1.314 . . . . 10.0 112.132 178.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 40.1 48.08 2.13 Favored 'General case' 0 C--O 1.226 -0.137 0 C-N-CA 126.25 1.82 . . . . 10.0 112.622 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 105.93 -11.31 45.09 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-O 118.781 -1.011 . . . . 10.0 113.437 173.113 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -120.96 40.6 3.52 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.743 0.771 . . . . 10.0 112.185 -166.276 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.28 -15.34 66.86 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 126.035 1.779 . . . . 10.0 112.323 173.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.7 49.19 78.88 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 118.417 1.109 . . . . 10.0 113.023 175.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -161.12 167.63 25.88 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 127.35 2.26 . . . . 10.0 105.095 -177.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -46.31 -47.89 18.33 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.791 0.805 . . . . 10.0 111.026 172.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -56.74 -33.24 66.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.253 -0.885 . . . . 10.0 111.715 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.0 t -45.65 -46.59 14.71 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 125.064 1.346 . . . . 10.0 109.346 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.6 t -91.68 0.92 57.46 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 112.395 0.517 . . . . 10.0 112.395 -173.177 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -113.18 -81.64 0.59 Allowed 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 126.054 1.741 . . . . 10.0 110.537 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.4 p -111.23 22.82 14.78 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 121.176 1.807 . . . . 10.0 111.02 172.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 -88.51 0.41 Allowed Glycine 0 C--N 1.341 0.816 0 N-CA-C 109.932 -1.267 . . . . 10.0 109.932 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -173.77 40.17 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 125.895 1.678 . . . . 10.0 109.069 172.036 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.21 -4.18 9.73 Favored 'General case' 0 C--N 1.34 0.164 0 O-C-N 121.543 -0.723 . . . . 10.0 112.224 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.56 -166.99 53.85 Favored Glycine 0 N--CA 1.441 -0.987 0 N-CA-C 109.259 -1.537 . . . . 10.0 109.259 179.174 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.6 t -62.41 146.15 52.15 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 122.457 1.122 . . . . 10.0 111.324 -168.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.07 64.22 0.06 Allowed 'General case' 0 N--CA 1.444 -0.743 0 C-N-CA 126.837 2.055 . . . . 10.0 109.145 171.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.63 -19.16 64.64 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 113.206 0.817 . . . . 10.0 113.206 -168.721 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.36 145.7 21.91 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.398 0.544 . . . . 10.0 110.129 172.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.9 m -146.85 158.51 43.93 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 123.852 0.861 . . . . 10.0 109.492 -167.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.92 167.09 36.5 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.472 -1.051 . . . . 10.0 110.472 175.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.8 t -116.28 142.01 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 107.398 -1.334 . . . . 10.0 107.398 -169.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 11.0 mt -80.03 113.68 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 123.291 0.636 . . . . 10.0 110.52 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.07 152.32 17.59 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.244 1.402 . . . . 10.0 111.728 -178.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 84.0 mt -73.55 141.32 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 124.562 1.145 . . . . 10.0 109.179 -178.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.69 -48.16 2.59 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 123.35 0.66 . . . . 10.0 110.764 176.28 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.1 tt0 . . . . . 0 C--O 1.25 1.125 0 C-N-CA 127.268 2.227 . . . . 10.0 112.146 -172.114 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 108.684 -0.858 . . . . 10.0 108.684 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -91.46 -30.19 16.61 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 123.169 0.587 . . . . 10.0 111.149 -179.073 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 12.4 mtpt -124.44 127.9 48.21 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 124.882 1.273 . . . . 10.0 111.1 -175.527 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.01 155.47 49.93 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.957 0.503 . . . . 10.0 110.751 171.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.2 m -114.55 165.05 10.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.421 1.088 . . . . 10.0 109.346 171.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -153.69 104.59 2.72 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 106.417 -1.697 . . . . 10.0 106.417 166.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -106.4 125.23 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 109.217 -0.66 . . . . 10.0 109.217 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -104.44 152.07 22.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.919 1.288 . . . . 10.0 109.352 -172.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.8 tttt -160.0 162.64 34.34 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 169.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 175.0 -43.25 0.12 Allowed Glycine 0 C--O 1.228 -0.242 0 C-N-CA 119.768 -1.206 . . . . 10.0 113.682 168.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -74.22 -46.19 43.4 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.9 -72.37 0.33 Allowed Glycine 0 CA--C 1.52 0.348 0 N-CA-C 109.679 -1.368 . . . . 10.0 109.679 171.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -58.9 -39.23 83.17 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 123.211 2.607 . . . . 10.0 110.834 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.4 t -59.72 110.59 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -121.03 113.62 20.33 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 104.495 -2.409 . . . . 10.0 104.495 168.674 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.04 143.53 16.68 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 108.236 -1.946 . . . . 10.0 108.236 172.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.427 ' CG2' HG21 ' A' ' 54' ' ' THR . 3.0 mt -143.04 91.43 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 -176.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -104.31 138.66 28.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 C-N-CA 124.785 1.234 . . . . 10.0 109.29 178.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -122.84 122.35 38.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 126.38 1.872 . . . . 10.0 108.769 169.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -102.75 126.2 49.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 107.363 -1.347 . . . . 10.0 107.363 176.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -116.53 135.95 53.39 Favored 'General case' 0 C--O 1.233 0.203 0 O-C-N 123.759 0.662 . . . . 10.0 110.986 167.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.2 tt0 -119.52 114.15 21.83 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 106.095 -1.817 . . . . 10.0 106.095 168.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.4 mmpt? -65.11 -53.85 38.95 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 123.912 0.885 . . . . 10.0 110.028 -169.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -125.62 -156.98 0.76 Allowed 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 104.775 -2.305 . . . . 10.0 104.775 177.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 29.1 m -95.11 -18.94 20.54 Favored 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 120.43 -0.508 . . . . 10.0 110.653 167.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -81.74 -34.38 30.53 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.876 0.87 . . . . 10.0 110.389 179.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.76 151.57 52.39 Favored Glycine 0 CA--C 1.533 1.21 0 N-CA-C 111.437 -0.665 . . . . 10.0 111.437 -176.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_endo -62.63 159.45 36.8 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.874 2.383 . . . . 10.0 108.737 170.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 41.1 t -86.74 115.99 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.22 0 N-CA-C 105.325 -2.102 . . . . 10.0 105.325 169.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.484 ' HZ2' ' CD ' ' B' ' 100' ' ' GLU . 38.8 tttp -92.07 112.45 24.39 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 168.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -94.44 100.66 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 C-N-CA 127.32 2.248 . . . . 10.0 106.484 176.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 23.3 p90 -112.77 171.32 7.6 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.304 0.573 . . . . 10.0 111.11 169.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.66 170.24 38.28 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.869 -0.892 . . . . 10.0 110.869 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.6 m -148.94 95.14 2.36 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.666 -1.605 . . . . 10.0 106.666 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.9 pt -75.8 176.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 108.725 -0.842 . . . . 10.0 108.725 173.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 17.1 ptmt -156.57 164.8 37.77 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 163.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.69 -13.73 59.3 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 119.341 -0.7 . . . . 10.0 113.168 172.065 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.8 mp -69.71 176.69 3.42 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 118.568 1.184 . . . . 10.0 110.211 172.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.0 t -94.06 166.66 12.03 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 107.427 -1.324 . . . . 10.0 107.427 165.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.27 171.46 1.03 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.475 1.11 . . . . 10.0 112.21 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.18 179.89 39.64 Favored Glycine 0 C--N 1.334 0.428 0 C-N-CA 123.943 0.783 . . . . 10.0 112.074 168.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -66.99 142.6 57.19 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.632 0.773 . . . . 10.0 109.083 176.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.4 m-70 -139.68 151.79 46.19 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 123.087 0.555 . . . . 10.0 112.476 177.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -36.44 121.47 0.68 Allowed Glycine 0 C--N 1.341 0.822 0 C-N-CA 129.323 3.344 . . . . 10.0 110.883 166.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -149.59 115.21 5.58 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 119.335 1.567 . . . . 10.0 110.022 168.727 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.535 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.59 168.34 27.1 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-O 121.601 0.715 . . . . 10.0 111.406 176.401 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 7.7 m -93.28 148.88 4.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 111.957 -2.383 . . . . 10.0 105.389 166.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -121.91 153.55 38.3 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 174.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -40.1 -43.42 1.61 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 127.719 2.408 . . . . 10.0 115.403 -175.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -115.21 159.03 21.45 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 124.793 1.237 . . . . 10.0 109.264 -170.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.01 -7.71 63.96 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 126.009 1.766 . . . . 10.0 110.983 169.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -42.86 151.21 0.13 Allowed 'General case' 0 C--O 1.239 0.515 0 CA-C-O 123.174 1.464 . . . . 10.0 112.494 169.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -162.46 21.68 0.1 Allowed 'General case' 0 N--CA 1.437 -1.096 0 CA-C-N 112.485 -2.143 . . . . 10.0 111.997 167.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.83 -35.54 76.81 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.736 0.698 . . . . 10.0 110.821 -169.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.75 -17.6 55.54 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.602 1.161 . . . . 10.0 112.254 175.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.85 -173.2 17.25 Favored Glycine 0 N--CA 1.442 -0.909 0 N-CA-C 106.844 -2.502 . . . . 10.0 106.844 -167.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 60.1 m -66.53 69.96 0.07 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.311 1.444 . . . . 10.0 108.424 172.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -153.53 -53.04 0.1 Allowed 'General case' 0 N--CA 1.444 -0.774 0 O-C-N 120.693 -1.254 . . . . 10.0 109.617 -168.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.4 t -96.22 -1.26 48.55 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.874 0.87 . . . . 10.0 110.203 -178.069 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.31 47.3 0.37 Allowed 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.811 1.244 . . . . 10.0 112.225 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.05 131.57 2.43 Favored Glycine 0 N--CA 1.44 -1.097 0 N-CA-C 117.479 1.752 . . . . 10.0 117.479 162.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -92.69 23.88 0.51 Allowed 'Trans proline' 0 CA--C 1.545 1.069 0 C-N-CA 123.135 2.557 . . . . 10.0 113.282 168.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 21.1 m170 86.77 35.16 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 129.231 3.012 . . . . 10.0 112.352 176.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.24 70.34 0.16 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.319 1.048 . . . . 10.0 111.588 173.182 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -70.13 155.61 93.18 Favored Pre-proline 0 CA--C 1.536 0.413 0 C-N-CA 123.12 0.568 . . . . 10.0 109.965 170.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.57 -48.24 2.39 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 121.965 1.777 . . . . 10.0 110.815 176.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 tt -75.67 63.8 1.63 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.265 1.426 . . . . 10.0 109.205 -175.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -45.06 102.02 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 128.042 2.537 . . . . 10.0 113.143 -168.381 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.3 mtp85 -129.1 178.06 6.68 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 126.049 1.74 . . . . 10.0 108.027 175.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -111.94 56.98 0.64 Allowed 'General case' 0 C--O 1.226 -0.171 0 N-CA-C 113.12 0.785 . . . . 10.0 113.12 -167.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 67.8 t60 44.98 85.81 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 122.959 1.361 . . . . 10.0 114.069 175.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.65 -161.11 25.9 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 168.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.409 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -171.21 -152.99 8.6 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 107.043 -2.423 . . . . 10.0 107.043 173.662 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.42 8.44 0.12 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 120.15 1.975 . . . . 10.0 112.631 169.179 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.409 ' H ' ' C ' ' B' ' 73' ' ' GLY . 70.4 mttt -123.69 -0.49 8.58 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 117.419 -1.277 . . . . 10.0 113.066 175.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.32 163.55 32.71 Favored 'General case' 0 C--N 1.346 0.439 0 CA-C-N 120.629 1.559 . . . . 10.0 108.602 174.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -77.03 -30.29 55.67 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 177.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -76.58 26.07 0.13 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.651 1.58 . . . . 10.0 113.077 -166.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 18.1 mtm180 -47.58 129.5 13.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 107.392 -1.336 . . . . 10.0 107.392 168.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.1 m170 -67.67 -57.59 6.13 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 121.237 0.541 . . . . 10.0 109.932 176.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.8 p -163.82 -58.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 109.072 -0.714 . . . . 10.0 109.072 -176.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -137.23 62.91 0.58 Allowed Glycine 0 C--N 1.337 0.6 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 178.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -90.78 90.74 8.07 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.371 -1.344 . . . . 10.0 107.371 171.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.39 -25.5 57.68 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 121.352 0.596 . . . . 10.0 109.551 177.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.98 -66.98 3.68 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 115.161 0.825 . . . . 10.0 115.161 167.676 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -137.93 109.29 6.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 118.677 -0.678 . . . . 10.0 109.249 -167.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -115.84 125.77 73.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 118.789 0.722 . . . . 10.0 110.451 169.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 10.9 m -81.35 97.51 7.74 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 128.325 2.65 . . . . 10.0 112.134 -171.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.64 132.77 39.6 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 123.824 0.849 . . . . 10.0 112.236 176.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -63.13 173.44 1.45 Allowed 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 125.308 1.443 . . . . 10.0 110.312 167.1 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.3 pttm -55.03 -30.5 59.68 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 123.766 0.827 . . . . 10.0 111.95 170.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.88 3.25 20.37 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.069 0.938 . . . . 10.0 110.953 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.47 -0.26 89.71 Favored Glycine 0 N--CA 1.441 -1.013 0 O-C-N 120.572 -1.33 . . . . 10.0 110.033 -174.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 67.0 t -78.33 94.79 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 108.414 -0.958 . . . . 10.0 108.414 -169.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -88.15 119.11 28.22 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 167.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -77.34 123.59 26.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.951 -1.5 . . . . 10.0 106.951 169.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 65.8 t -104.65 131.69 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 105.292 -2.114 . . . . 10.0 105.292 169.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -158.01 57.84 0.47 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 118.917 0.78 . . . . 10.0 111.815 177.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.6 151.61 12.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.166 0.986 . . . . 10.0 109.631 -169.279 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . 0.484 ' CD ' ' HZ2' ' B' ' 30' ' ' LYS . 2.4 pm0 -109.1 141.99 40.48 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 126.068 1.747 . . . . 10.0 109.601 170.318 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -137.67 155.35 49.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 O-C-N 124.093 0.871 . . . . 10.0 109.413 173.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.5 p -128.07 58.37 1.52 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 126.86 2.064 . . . . 10.0 108.526 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -155.01 -44.5 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 C-N-CA 124.643 1.177 . . . . 10.0 108.888 174.096 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 33.6 mm -55.91 147.66 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 168.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.0 m -153.85 135.3 14.24 Favored 'General case' 0 C--O 1.233 0.22 0 N-CA-C 109.048 -0.723 . . . . 10.0 109.048 169.511 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -79.18 57.42 2.26 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.367 1.467 . . . . 10.0 108.492 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 15.5 t -83.2 -168.35 2.05 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 126.913 2.085 . . . . 10.0 110.416 -171.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -124.49 -51.93 0.19 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 127.896 2.665 . . . . 10.0 107.469 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -65.24 -58.89 4.83 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 109.776 -0.453 . . . . 10.0 109.776 169.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -76.92 -38.33 53.65 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 108.048 -1.093 . . . . 10.0 108.048 -173.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.4 t 37.18 69.13 0.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 127.009 2.124 . . . . 10.0 113.966 169.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.2 pp -56.0 -30.29 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 166.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.7 mm -31.12 -36.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 C-N-CA 128.306 2.642 . . . . 10.0 115.234 169.495 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -104.56 28.95 12.86 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-O 118.711 -1.049 . . . . 10.0 112.784 -175.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -104.87 169.85 8.21 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 125.106 1.362 . . . . 10.0 110.176 177.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 18.4 m -108.26 127.7 54.08 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.696 1.598 . . . . 10.0 109.104 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -84.9 141.23 30.55 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 106.71 -1.589 . . . . 10.0 106.71 167.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.5 t -125.46 136.7 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 170.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 p -105.65 130.9 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 125.083 1.353 . . . . 10.0 107.583 169.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 3.3 m170 -114.68 157.84 22.59 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 115.75 1.759 . . . . 10.0 115.75 -171.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -37.11 -63.76 0.41 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 129.301 3.04 . . . . 10.0 111.078 169.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.5 mttt -117.93 175.32 5.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 C-N-CA 124.231 1.012 . . . . 10.0 110.131 -173.077 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -91.72 148.19 22.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.894 1.278 . . . . 10.0 109.478 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.535 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -75.04 143.35 43.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 112.053 0.39 . . . . 10.0 112.053 -178.786 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -80.64 -3.62 51.21 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 124.394 1.059 . . . . 10.0 110.791 166.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 71.1 mt 51.24 50.73 18.4 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 125.426 1.49 . . . . 10.0 111.218 170.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.37 -36.08 4.3 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-N 114.525 -1.216 . . . . 10.0 110.935 174.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.31 35.22 0.49 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 121.025 -1.279 . . . . 10.0 110.847 -173.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.92 -36.11 6.51 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 109.51 -1.436 . . . . 10.0 109.51 179.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.62 51.21 59.26 Favored Glycine 0 CA--C 1.529 0.938 0 N-CA-C 111.39 -0.684 . . . . 10.0 111.39 -171.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -142.66 171.7 13.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 104.605 -2.368 . . . . 10.0 104.605 170.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 24.4 mp0 -51.78 -48.11 63.91 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 120.726 -0.39 . . . . 10.0 110.379 174.328 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -53.08 -38.17 62.32 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.451 -0.34 . . . . 10.0 110.282 177.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.8 p -57.72 -30.01 65.19 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 118.013 -0.994 . . . . 10.0 112.513 -176.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -98.2 17.47 18.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.412 1.005 . . . . 10.0 109.834 -177.551 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -142.19 -69.74 0.35 Allowed 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 124.822 1.249 . . . . 10.0 110.38 -169.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.4 p -126.73 21.61 6.99 Favored 'General case' 0 CA--C 1.547 0.859 0 CA-C-N 119.653 1.115 . . . . 10.0 112.29 177.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 79.07 -88.07 1.18 Allowed Glycine 0 C--N 1.343 0.958 0 O-C-N 121.111 -0.993 . . . . 10.0 111.01 170.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.09 38.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 122.989 1.376 . . . . 10.0 107.934 174.34 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.76 -29.05 61.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 125.169 1.388 . . . . 10.0 109.607 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.95 -157.61 53.09 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 109.847 -1.301 . . . . 10.0 109.847 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 56.7 m -56.84 130.57 46.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 113.59 0.959 . . . . 10.0 113.59 -167.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.9 mtt85 -66.68 75.22 0.11 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.934 1.294 . . . . 10.0 110.654 172.695 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 55.1 mt -50.58 -40.19 51.77 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 118.349 0.522 . . . . 10.0 112.226 179.535 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.31 160.41 40.73 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 121.943 -0.473 . . . . 10.0 109.867 -177.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 p -159.42 166.46 30.99 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 109.982 -0.377 . . . . 10.0 109.982 -177.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.56 165.55 36.24 Favored Glycine 0 C--N 1.334 0.433 0 N-CA-C 110.689 -0.965 . . . . 10.0 110.689 -177.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.68 137.53 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 106.002 -1.851 . . . . 10.0 106.002 -171.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 16.7 mt -68.42 157.3 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 108.491 -0.929 . . . . 10.0 108.491 177.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -163.83 155.38 26.72 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 109.732 -1.347 . . . . 10.0 109.732 -176.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -90.32 125.84 43.16 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-N 118.475 1.138 . . . . 10.0 111.368 -173.1 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.75 -25.96 27.92 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.126 -0.984 . . . . 10.0 111.245 177.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.251 1.133 0 C-N-CA 125.837 1.655 . . . . 10.0 107.676 178.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.835 0 CA-C-O 118.253 -0.88 . . . . 10.0 108.636 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.31 -53.61 1.91 Allowed 'General case' 0 N--CA 1.463 0.175 0 C-N-CA 124.274 1.029 . . . . 10.0 110.828 -175.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -105.51 128.36 53.53 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.32 161.74 35.45 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.132 0.573 . . . . 10.0 109.665 172.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -125.94 153.45 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 125.71 1.604 . . . . 10.0 109.782 -179.202 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.73 127.53 21.98 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 108.251 -1.018 . . . . 10.0 108.251 165.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.9 m -115.36 83.7 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 C-N-CA 124.783 1.233 . . . . 10.0 110.772 -174.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.7 mp -76.02 150.01 37.44 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.144 -0.972 . . . . 10.0 109.856 -169.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.96 155.24 11.81 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 -179.206 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.19 -46.2 0.18 Allowed Glycine 0 N--CA 1.463 0.477 0 C-N-CA 119.505 -1.331 . . . . 10.0 114.136 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -73.33 -45.35 55.74 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -175.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.71 -73.13 0.32 Allowed Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 170.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -56.75 -39.55 90.55 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.835 2.357 . . . . 10.0 110.996 172.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 98.4 t -62.97 106.54 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 CA-C-N 119.245 0.93 . . . . 10.0 108.507 -177.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.63 112.44 20.53 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 169.679 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.17 142.57 16.2 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 109.576 -1.41 . . . . 10.0 109.576 174.293 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -147.12 93.32 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 -172.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.4 mm -111.88 139.82 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 C-N-CA 125.582 1.553 . . . . 10.0 110.111 -175.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -118.32 122.45 42.9 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.943 1.697 . . . . 10.0 109.157 168.247 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -101.74 114.11 27.89 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 125.255 1.422 . . . . 10.0 107.259 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -120.6 112.68 19.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 122.154 0.978 . . . . 10.0 113.084 -179.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -82.29 104.8 12.86 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 106.307 -1.738 . . . . 10.0 106.307 168.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.3 -24.44 67.3 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 118.97 -0.538 . . . . 10.0 110.405 177.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -135.75 -161.22 1.13 Allowed 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.419 -0.586 . . . . 10.0 109.419 178.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 23.1 t -99.87 -7.68 25.02 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 119.363 -0.351 . . . . 10.0 110.355 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.9 m-80 -139.63 21.34 2.52 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.819 1.248 . . . . 10.0 108.969 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.98 161.8 42.09 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.278 -1.129 . . . . 10.0 110.278 -172.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -67.69 117.28 4.76 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 104.226 -3.029 . . . . 10.0 104.226 165.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.77 131.56 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 -174.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.1 mttt -101.53 122.74 44.37 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 106.541 -1.651 . . . . 10.0 106.541 174.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.1 m -119.73 111.93 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.82 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 -175.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -128.99 167.96 16.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 121.209 0.528 . . . . 10.0 109.988 -179.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.77 171.17 38.68 Favored Glycine 0 N--CA 1.437 -1.295 0 N-CA-C 110.009 -1.236 . . . . 10.0 110.009 -176.353 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.5 t -142.55 99.04 3.41 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 177.663 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.9 pt -79.51 156.26 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 C-N-CA 118.514 -1.275 . . . . 10.0 107.642 167.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.5 ptmt -141.9 164.6 29.76 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.519 -0.919 . . . . 10.0 108.519 164.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.66 -14.23 46.2 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-O 119.105 -0.831 . . . . 10.0 113.08 177.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.4 mp -70.77 176.9 3.88 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 118.566 1.183 . . . . 10.0 110.482 178.08 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -95.9 149.82 21.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.397 -0.82 . . . . 10.0 109.309 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -43.61 137.53 2.91 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.685 1.994 . . . . 10.0 111.58 -176.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 114.62 -172.87 14.49 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.881 0.753 . . . . 10.0 112.585 170.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.89 145.32 50.28 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 125.024 1.33 . . . . 10.0 110.908 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -147.9 143.58 27.48 Favored 'General case' 0 C--N 1.34 0.189 0 N-CA-C 113.099 0.777 . . . . 10.0 113.099 177.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -28.55 117.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 C-N-CA 127.842 2.639 . . . . 10.0 113.078 165.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -143.1 109.18 5.24 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 120.207 2.004 . . . . 10.0 110.873 169.046 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.484 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -156.78 171.79 19.77 Favored 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 115.438 -0.801 . . . . 10.0 110.765 178.573 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.9 m -89.45 163.39 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.514 -2.13 . . . . 10.0 106.895 166.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -124.47 158.23 33.32 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 124.857 1.263 . . . . 10.0 107.859 172.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -58.04 -41.3 82.95 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 123.994 0.918 . . . . 10.0 112.935 -169.794 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -107.41 174.65 5.79 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.034 0.934 . . . . 10.0 109.82 176.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.39 -9.96 14.14 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.236 1.874 . . . . 10.0 112.449 175.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -65.81 161.34 21.18 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 122.379 1.085 . . . . 10.0 110.949 -178.138 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -158.0 28.98 0.26 Allowed 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.445 -0.798 . . . . 10.0 112.289 -170.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -59.19 -36.43 75.35 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.569 -0.707 . . . . 10.0 112.368 -171.622 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.44 -17.54 56.2 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.178 0.591 . . . . 10.0 111.499 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.37 -156.25 15.73 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 104.664 -3.374 . . . . 10.0 104.664 -167.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 93.6 m -68.23 72.33 0.19 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 125.133 1.373 . . . . 10.0 110.174 177.033 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -158.56 -47.92 0.06 Allowed 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 123.564 0.746 . . . . 10.0 111.128 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -56.0 -35.17 66.5 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.27 1.028 . . . . 10.0 111.476 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.09 -28.86 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.482 3.113 . . . . 10.0 116.395 174.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.04 165.87 29.03 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 107.84 -2.104 . . . . 10.0 107.84 175.46 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -72.81 -141.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.347 0 N-CA-C 106.635 -2.102 . . . . 10.0 106.635 166.249 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -105.04 38.03 2.03 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 120.515 1.507 . . . . 10.0 111.556 179.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -72.18 73.17 0.93 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.848 1.658 . . . . 10.0 112.181 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 7.2 p-10 -61.12 151.43 75.44 Favored Pre-proline 0 CA--C 1.537 0.456 0 O-C-N 121.557 -0.715 . . . . 10.0 110.524 169.146 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -62.02 -43.55 24.22 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 122.571 2.181 . . . . 10.0 111.459 -178.338 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -77.06 60.4 1.84 Allowed 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 175.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 p -42.23 108.95 0.11 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 126.238 1.815 . . . . 10.0 111.762 -169.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -124.67 176.23 6.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 108.393 -0.965 . . . . 10.0 108.393 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -98.42 113.81 25.93 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -174.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.2 t60 -25.52 102.48 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 124.856 1.262 . . . . 10.0 113.894 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.81 -136.94 7.6 Favored Glycine 0 N--CA 1.443 -0.885 0 N-CA-C 107.975 -2.05 . . . . 10.0 107.975 178.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.03 -164.5 24.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 107.554 -2.219 . . . . 10.0 107.554 168.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -52.67 -18.27 8.44 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.14 1.894 . . . . 10.0 112.237 170.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.477 ' HZ3' ' CG ' ' A' ' 76' ' ' ASP . 0.0 OUTLIER -83.45 -33.36 25.66 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.025 0.93 . . . . 10.0 110.828 -177.424 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.477 ' CG ' ' HZ3' ' A' ' 75' ' ' LYS . 1.4 m-20 -98.04 175.14 6.22 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -171.597 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -89.42 -28.39 19.77 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 167.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -86.79 16.8 4.46 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 125.518 1.527 . . . . 10.0 113.156 -168.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.38 136.05 13.07 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.779 0.831 . . . . 10.0 109.729 168.399 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -71.77 -176.7 1.72 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 107.906 -1.146 . . . . 10.0 107.906 168.262 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.49 41.19 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 N-CA-C 113.754 1.02 . . . . 10.0 113.754 -175.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.82 56.71 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.237 -1.545 . . . . 10.0 109.237 172.166 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -98.01 95.89 7.78 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 169.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -80.16 -30.14 38.87 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.99 -102.02 1.89 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 107.954 -2.058 . . . . 10.0 107.954 168.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -132.34 114.0 13.87 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.998 1.319 . . . . 10.0 109.586 -167.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.5 m -103.6 137.2 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 C-N-CA 122.709 0.403 . . . . 10.0 110.192 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 92.1 m -83.27 105.47 14.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 127.13 2.172 . . . . 10.0 109.681 -177.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.75 131.07 35.21 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.253 0.621 . . . . 10.0 109.945 170.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -59.33 170.63 0.93 Allowed 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.13 1.372 . . . . 10.0 110.182 168.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 66.6 tttt -51.49 -35.27 39.42 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 125.925 1.69 . . . . 10.0 111.845 169.084 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -79.81 2.11 24.29 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 121.556 0.693 . . . . 10.0 111.292 177.293 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.34 -2.81 87.95 Favored Glycine 0 N--CA 1.445 -0.74 0 O-C-N 120.322 -1.487 . . . . 10.0 110.435 -178.312 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 69.5 t -75.67 103.99 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -170.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.23 115.25 30.06 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 108.43 -0.952 . . . . 10.0 108.43 173.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -79.16 125.44 29.45 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 114.44 -1.254 . . . . 10.0 108.107 173.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -106.28 128.67 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.397 0 N-CA-C 104.442 -2.429 . . . . 10.0 104.442 168.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.9 m -155.13 73.88 0.89 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 123.474 0.709 . . . . 10.0 110.028 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 15.8 mm -112.24 161.17 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 124.311 1.044 . . . . 10.0 111.29 -174.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -123.73 134.86 53.61 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 129.733 3.213 . . . . 10.0 107.047 169.092 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -145.68 144.17 30.24 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.505 -0.554 . . . . 10.0 109.505 175.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 5.1 p -109.57 18.72 20.02 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.311 1.844 . . . . 10.0 112.701 -174.24 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.8 t -126.38 -54.26 1.84 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.2 0 C-N-CA 125.595 1.558 . . . . 10.0 107.507 -177.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 10.9 mm -48.92 115.47 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 124.575 1.15 . . . . 10.0 109.086 172.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -114.51 116.78 29.37 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.897 0.879 . . . . 10.0 108.952 -176.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.97 -47.72 32.75 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 125.309 1.444 . . . . 10.0 109.647 176.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.4 m -149.13 164.39 34.83 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.137 -1.431 . . . . 10.0 107.137 174.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 134.27 -99.52 0.35 Allowed Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 107.211 -2.356 . . . . 10.0 107.211 -172.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -120.13 -49.2 2.3 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 124.653 1.181 . . . . 10.0 109.216 -168.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.03 -44.49 39.04 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 -177.315 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.1 t 46.97 76.14 0.11 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.994 1.717 . . . . 10.0 112.559 169.452 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 26.3 pt -59.77 -25.72 33.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 112.146 0.424 . . . . 10.0 112.146 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.1 mm -42.8 122.25 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 CA-C-N 119.068 0.849 . . . . 10.0 111.291 175.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.99 8.59 78.82 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 119.013 -0.881 . . . . 10.0 113.029 175.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.13 169.51 11.86 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.421 1.11 . . . . 10.0 108.499 168.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.92 141.37 36.67 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.862 0.865 . . . . 10.0 111.287 174.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -95.64 141.46 29.12 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.427 -1.323 . . . . 10.0 107.427 168.503 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 72.4 t -123.48 138.96 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 108.604 -0.887 . . . . 10.0 108.604 172.395 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -102.7 122.14 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 167.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 6.3 m-70 -104.88 160.29 15.12 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 115.207 1.558 . . . . 10.0 115.207 -173.036 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.34 -56.23 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 113.818 -1.537 . . . . 10.0 110.657 176.355 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 41.0 mttm -113.8 175.65 5.37 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-O 121.789 0.804 . . . . 10.0 111.918 -179.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.12 139.34 35.68 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.936 1.694 . . . . 10.0 109.051 172.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.484 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -78.14 164.63 24.81 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 121.843 0.83 . . . . 10.0 111.601 174.227 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -73.99 -16.56 61.07 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 114.618 -1.174 . . . . 10.0 110.54 -178.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 10.1 mt 52.13 46.68 26.19 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 -168.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.62 -13.29 67.05 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.65 2.072 . . . . 10.0 113.785 171.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.3 mtmp? -79.31 3.94 16.65 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 115.376 1.621 . . . . 10.0 115.376 -167.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.97 -33.15 51.26 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.493 1.042 . . . . 10.0 110.891 178.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.22 41.99 93.14 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 111.846 -0.502 . . . . 10.0 111.846 -173.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -132.96 170.34 15.49 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 124.684 1.194 . . . . 10.0 108.138 173.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -41.46 -55.66 2.76 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 125.497 1.519 . . . . 10.0 110.479 175.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 49.1 mp0 -56.43 -51.85 66.85 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 125.096 1.359 . . . . 10.0 110.311 176.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.6 p -51.46 -38.26 52.92 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 123.138 0.575 . . . . 10.0 111.009 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.91 -11.65 56.6 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 123.999 0.812 . . . . 10.0 111.307 -170.709 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -112.57 -48.84 2.98 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.829 1.251 . . . . 10.0 112.081 -172.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.7 p -137.05 23.65 3.03 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 120.289 1.404 . . . . 10.0 110.634 174.087 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.81 -113.79 6.19 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 106.065 -2.814 . . . . 10.0 106.065 -171.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 19.3 m-80 -157.95 44.05 0.32 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 107.258 -1.386 . . . . 10.0 107.258 174.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.84 -13.34 55.65 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 124.205 1.002 . . . . 10.0 112.313 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.6 -164.96 54.86 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 110.355 -1.098 . . . . 10.0 110.355 176.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.2 t -54.84 134.14 48.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 113.396 0.888 . . . . 10.0 113.396 -168.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -64.55 73.3 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.967 1.707 . . . . 10.0 109.432 168.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 39.8 mt -49.83 -39.3 38.31 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 118.383 0.538 . . . . 10.0 111.927 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.98 157.42 36.17 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.135 -0.691 . . . . 10.0 109.135 -177.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -157.08 162.3 39.47 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.415 -0.357 . . . . 10.0 110.531 -173.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.62 175.6 26.87 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.847 1.213 . . . . 10.0 110.088 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 13.6 t -122.04 140.81 44.82 Favored 'Isoleucine or valine' 0 C--N 1.343 0.298 0 CA-C-N 118.882 1.341 . . . . 10.0 107.422 -177.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.5 mt -75.82 119.56 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 123.76 0.824 . . . . 10.0 109.836 -176.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.97 148.9 17.89 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 125.428 1.49 . . . . 10.0 111.737 -178.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 89.0 mt -69.16 135.16 28.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.58 1.552 . . . . 10.0 110.163 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.02 -7.13 4.41 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 115.45 1.648 . . . . 10.0 115.45 -173.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.253 1.269 0 CA-C-O 117.528 -1.225 . . . . 10.0 110.199 -179.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.669 0 CA-C-O 118.272 -0.871 . . . . 10.0 109.043 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -78.19 -26.83 47.72 Favored 'General case' 0 C--O 1.224 -0.24 0 C-N-CA 123.345 0.658 . . . . 10.0 110.895 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 62.5 tttt -130.05 137.3 50.16 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.093 0.473 . . . . 10.0 111.068 176.257 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.29 161.17 36.17 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 125.129 1.372 . . . . 10.0 107.964 171.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -126.91 156.26 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 C-N-CA 125.184 1.394 . . . . 10.0 109.735 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.85 112.31 8.2 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 168.589 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 11.6 m -100.41 128.65 52.22 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 108.31 -0.996 . . . . 10.0 108.31 171.004 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.18 145.35 31.64 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 123.917 0.887 . . . . 10.0 110.534 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -161.19 160.45 30.12 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.921 -1.141 . . . . 10.0 107.921 168.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.1 -45.58 0.12 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.982 -1.104 . . . . 10.0 113.285 169.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 -45.04 53.12 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.604 -1.258 . . . . 10.0 107.604 -175.588 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.37 -71.19 0.39 Allowed Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.644 -1.382 . . . . 10.0 109.644 170.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -57.86 -38.88 90.87 Favored 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 123.076 2.518 . . . . 10.0 111.095 171.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 92.2 t -61.47 103.05 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.035 0 N-CA-C 107.824 -1.176 . . . . 10.0 107.824 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -118.1 128.86 55.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.339 -1.356 . . . . 10.0 107.339 169.641 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.15 146.29 18.54 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 110.953 -0.859 . . . . 10.0 110.953 175.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 mt -146.57 89.55 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 C-N-CA 125.634 1.573 . . . . 10.0 107.657 -176.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -102.5 139.25 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.744 1.618 . . . . 10.0 110.082 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -115.9 110.73 19.41 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 129.314 3.046 . . . . 10.0 107.366 176.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -95.02 114.64 26.47 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -112.47 122.34 47.42 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 118.64 0.655 . . . . 10.0 112.721 169.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 5.0 tp-100 -82.55 110.11 17.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.145 -2.168 . . . . 10.0 105.145 166.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt -39.18 -69.7 0.12 Allowed 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 130.429 3.492 . . . . 10.0 111.456 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 11.4 mp0 -127.42 -116.06 0.26 Allowed 'General case' 0 N--CA 1.423 -1.824 0 O-C-N 124.3 1.0 . . . . 10.0 109.088 -178.097 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 12.0 m -121.2 -15.57 8.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 112.26 0.467 . . . . 10.0 112.26 170.013 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -134.67 12.47 3.72 Favored 'General case' 0 N--CA 1.456 -0.138 0 C-N-CA 123.991 0.916 . . . . 10.0 109.975 179.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.97 166.58 48.78 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 176.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.04 151.05 86.97 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.458 1.439 . . . . 10.0 108.744 171.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 t -79.76 124.07 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.984 -2.599 . . . . 10.0 103.984 168.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -99.66 112.53 24.75 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.496 -1.668 . . . . 10.0 106.496 169.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -95.99 103.99 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.959 0 C-N-CA 127.08 2.152 . . . . 10.0 106.135 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -124.75 165.17 18.44 Favored 'General case' 0 C--O 1.223 -0.323 0 N-CA-C 112.648 0.61 . . . . 10.0 112.648 173.285 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.8 -156.63 27.1 Favored Glycine 0 N--CA 1.449 -0.494 0 N-CA-C 107.216 -2.354 . . . . 10.0 107.216 172.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 50.8 p -156.25 160.52 39.87 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.565 -1.254 . . . . 10.0 112.52 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.18 136.56 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 C-N-CA 126.197 1.799 . . . . 10.0 107.519 167.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.82 159.38 37.52 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.289 0.368 . . . . 10.0 110.452 167.276 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.14 -0.19 44.31 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.779 0.704 . . . . 10.0 113.22 -178.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.9 mp -85.02 175.62 8.93 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 118.0 0.9 . . . . 10.0 109.703 -178.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.5 t -90.89 154.45 19.47 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.913 -0.773 . . . . 10.0 108.913 168.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -51.22 145.32 8.14 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 126.536 1.935 . . . . 10.0 111.324 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.92 -170.49 21.84 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-O 121.593 0.552 . . . . 10.0 111.95 172.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -73.88 147.56 43.1 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.296 1.438 . . . . 10.0 112.535 -170.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -147.94 127.49 13.24 Favored 'General case' 0 C--N 1.341 0.218 0 N-CA-C 114.395 1.257 . . . . 10.0 114.395 -178.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -17.75 124.41 0.01 OUTLIER Glycine 0 C--N 1.342 0.89 0 C-N-CA 127.473 2.463 . . . . 10.0 114.489 164.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -147.18 106.17 3.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 119.863 1.832 . . . . 10.0 111.339 167.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.45 172.49 15.87 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.417 0.627 . . . . 10.0 111.165 175.206 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 19.5 m -96.91 153.92 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 112.632 -2.076 . . . . 10.0 108.479 168.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -134.49 135.47 42.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.005 2.122 . . . . 10.0 105.349 177.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -56.7 -48.36 77.87 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.896 0.748 . . . . 10.0 112.84 -168.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -78.42 112.66 15.68 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 118.126 -1.43 . . . . 10.0 108.486 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.74 -26.37 62.56 Favored Glycine 0 N--CA 1.44 -1.068 0 N-CA-C 109.534 -1.426 . . . . 10.0 109.534 167.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -34.37 109.12 0.07 Allowed 'General case' 0 CA--C 1.516 -0.364 0 C-N-CA 125.237 1.415 . . . . 10.0 111.343 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.97 13.13 13.9 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 113.417 -1.719 . . . . 10.0 110.672 174.307 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.23 -39.84 67.14 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 119.102 0.864 . . . . 10.0 111.999 -168.314 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.88 -17.98 54.68 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.313 1.045 . . . . 10.0 113.027 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.23 76.07 1.11 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 108.269 -1.932 . . . . 10.0 108.269 -169.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.6 p 30.55 37.5 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 128.338 2.655 . . . . 10.0 116.177 -177.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.4 m -100.33 -50.25 3.99 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 -178.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.1 m -67.04 -14.73 63.18 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 126.378 1.871 . . . . 10.0 112.201 177.698 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.26 -26.74 0.35 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 127.228 2.211 . . . . 10.0 114.334 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 156.26 26.59 Favored Glycine 0 N--CA 1.438 -1.213 0 N-CA-C 109.002 -1.639 . . . . 10.0 109.002 169.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -69.31 -170.92 0.39 Allowed 'Trans proline' 0 N--CA 1.44 -1.65 0 N-CA-C 106.756 -2.055 . . . . 10.0 106.756 167.003 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.417 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 31.2 m170 -81.61 60.33 4.53 Favored 'General case' 0 CA--C 1.542 0.647 0 O-C-N 120.325 -1.485 . . . . 10.0 109.99 -172.398 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -70.85 75.52 0.62 Allowed 'General case' 0 C--O 1.223 -0.328 0 CA-C-N 118.917 0.781 . . . . 10.0 110.584 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -75.26 148.01 83.36 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.336 -0.853 . . . . 10.0 110.933 172.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.14 -42.97 12.32 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.57 2.18 . . . . 10.0 110.661 176.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.2 mt -75.87 54.77 0.84 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 123.806 0.843 . . . . 10.0 109.86 176.253 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.5 p -40.29 112.01 0.24 Allowed 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 125.787 1.635 . . . . 10.0 111.571 -172.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -142.34 178.4 7.6 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.42 -2.437 . . . . 10.0 104.42 -176.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -65.92 156.74 32.61 Favored 'General case' 0 N--CA 1.439 -0.977 0 C-N-CA 116.606 -2.038 . . . . 10.0 108.917 168.386 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -66.43 126.32 28.47 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 104.976 -2.231 . . . . 10.0 104.976 161.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.27 -133.21 3.07 Favored Glycine 0 N--CA 1.451 -0.35 0 N-CA-C 109.226 -1.55 . . . . 10.0 109.226 172.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.84 -155.08 23.19 Favored Glycine 0 C--O 1.226 -0.405 0 CA-C-O 118.028 -1.429 . . . . 10.0 109.53 174.64 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -64.88 2.37 1.37 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 CA-C-N 119.803 1.801 . . . . 10.0 112.155 172.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -95.18 -21.57 18.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 117.65 -1.167 . . . . 10.0 110.862 172.319 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -126.72 156.14 41.6 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 119.318 0.963 . . . . 10.0 109.817 -170.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -78.17 -32.79 50.31 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 106.885 -1.524 . . . . 10.0 106.885 167.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -88.01 57.17 4.18 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 125.553 1.541 . . . . 10.0 108.167 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 14.3 ptm180 -83.78 147.81 27.39 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 106.259 -1.756 . . . . 10.0 106.259 165.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -63.55 -57.95 8.52 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.481 1.037 . . . . 10.0 110.548 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.1 p 179.78 -99.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 104.883 -2.265 . . . . 10.0 104.883 -179.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -74.68 54.15 2.48 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.45 1.023 . . . . 10.0 112.417 172.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 70.0 m-20 -95.76 92.56 6.62 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.223 -2.51 . . . . 10.0 104.223 167.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 80.7 mt -89.44 38.84 0.92 Allowed 'General case' 0 CA--C 1.531 0.214 0 N-CA-C 107.983 -1.117 . . . . 10.0 107.983 177.195 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 32.91 -103.08 0.01 OUTLIER Glycine 0 C--N 1.341 0.84 0 C-N-CA 128.124 2.773 . . . . 10.0 112.206 -175.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -143.85 147.11 33.6 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.11 0.964 . . . . 10.0 109.769 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 32.4 m -113.15 139.04 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 125.095 1.358 . . . . 10.0 108.355 -174.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -83.41 122.47 28.54 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.273 0.629 . . . . 10.0 109.917 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.75 131.31 37.92 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.581 1.153 . . . . 10.0 109.255 171.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -56.15 169.36 0.41 Allowed 'General case' 0 N--CA 1.451 -0.41 0 O-C-N 124.486 1.116 . . . . 10.0 110.007 168.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 11.3 tttp -49.99 -35.46 24.56 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.284 1.434 . . . . 10.0 112.185 169.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -79.47 0.31 30.04 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.275 0.559 . . . . 10.0 112.202 177.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.03 -1.0 86.54 Favored Glycine 0 C--N 1.337 0.623 0 O-C-N 120.394 -1.441 . . . . 10.0 110.698 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 56.0 t -77.15 97.71 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 107.443 -1.317 . . . . 10.0 107.443 -174.639 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.3 116.98 29.44 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 168.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -88.19 130.35 35.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.839 -1.171 . . . . 10.0 107.839 174.014 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.0 t -107.7 129.89 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.257 -2.127 . . . . 10.0 105.257 168.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -157.77 55.88 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 118.696 0.68 . . . . 10.0 110.957 175.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.58 143.68 17.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.466 -0.771 . . . . 10.0 110.222 -169.084 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -97.85 129.21 44.83 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 128.638 2.775 . . . . 10.0 107.049 168.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -143.23 134.0 25.26 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 109.454 -0.573 . . . . 10.0 109.454 -176.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.6 p -115.64 45.78 1.63 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.559 1.544 . . . . 10.0 110.011 -169.337 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.9 p -142.98 -46.79 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 122.634 0.374 . . . . 10.0 111.219 177.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.31 0.0 OUTLIER -65.12 161.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 119.787 -0.765 . . . . 10.0 111.441 169.517 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 20.3 m -146.32 165.47 29.17 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 169.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 83.4 mt -100.55 -18.52 16.59 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 123.138 0.575 . . . . 10.0 110.061 175.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 44.7 m -156.3 164.47 38.28 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.443 1.497 . . . . 10.0 107.189 174.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 119.53 -95.11 0.59 Allowed Glycine 0 C--N 1.333 0.385 0 N-CA-C 108.378 -1.889 . . . . 10.0 108.378 -178.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -131.79 -52.29 0.99 Allowed 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 126.056 1.743 . . . . 10.0 107.966 176.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -81.85 37.13 0.47 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.645 0.778 . . . . 10.0 110.489 -170.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.7 t -74.81 93.12 2.58 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 127.261 2.224 . . . . 10.0 109.481 -169.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 24.5 pt -75.41 34.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.519 -0.738 . . . . 10.0 112.746 -177.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 38.2 mm -85.25 146.54 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 O-C-N 120.281 -1.512 . . . . 10.0 109.395 -175.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.85 24.21 69.78 Favored Glycine 0 CA--C 1.531 1.079 0 O-C-N 121.976 -0.452 . . . . 10.0 112.677 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -93.3 149.49 21.19 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 125.172 1.389 . . . . 10.0 107.347 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -87.47 139.96 30.01 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 168.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -116.61 159.01 22.79 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 108.135 -1.061 . . . . 10.0 108.135 168.704 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 74.5 t -137.94 129.51 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 107.981 -1.118 . . . . 10.0 107.981 -172.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 3.0 p -94.52 122.65 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 105.929 -1.878 . . . . 10.0 105.929 167.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -105.98 160.24 15.43 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 115.303 1.594 . . . . 10.0 115.303 -171.329 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -41.38 -60.94 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.069 2.948 . . . . 10.0 111.968 171.108 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -120.16 172.16 7.97 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.71 1.204 . . . . 10.0 113.166 -168.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.54 154.47 38.61 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 114.186 -1.37 . . . . 10.0 108.187 168.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -92.74 168.73 11.0 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 124.337 1.055 . . . . 10.0 111.034 -176.061 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.58 -20.99 59.72 Favored 'General case' 0 C--O 1.223 -0.336 0 C-N-CA 125.11 1.364 . . . . 10.0 108.278 175.049 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 49.8 mt 49.45 43.31 23.52 Favored 'General case' 0 C--N 1.341 0.237 0 C-N-CA 124.457 1.103 . . . . 10.0 109.998 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.51 33.17 80.48 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.087 -1.415 . . . . 10.0 113.174 178.142 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -75.4 0.08 18.18 Favored 'General case' 0 C--N 1.339 0.142 0 CA-C-N 118.913 1.357 . . . . 10.0 112.337 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.82 17.97 78.63 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.45 -1.46 . . . . 10.0 109.45 178.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.25 -26.08 74.32 Favored Glycine 0 N--CA 1.443 -0.834 0 N-CA-C 110.352 -1.099 . . . . 10.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 34.3 m-80 -156.07 163.14 40.03 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 118.067 0.933 . . . . 10.0 108.925 -168.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -56.23 -42.21 76.92 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 109.546 -0.539 . . . . 10.0 109.546 171.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -61.38 -23.96 66.15 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 112.635 0.606 . . . . 10.0 112.635 175.174 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.3 p -52.42 -39.32 60.83 Favored 'General case' 0 CA--C 1.512 -0.519 0 CA-C-N 118.556 0.617 . . . . 10.0 110.393 -172.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.7 t -90.17 -1.76 57.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 O-C-N 124.671 1.232 . . . . 10.0 111.67 -173.593 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -116.82 -48.93 2.64 Favored 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 126.769 2.028 . . . . 10.0 111.367 -168.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.417 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 1.7 p -135.43 -2.61 2.45 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 118.653 -0.689 . . . . 10.0 111.543 168.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 -106.38 3.19 Favored Glycine 0 N--CA 1.433 -1.52 0 N-CA-C 105.693 -2.963 . . . . 10.0 105.693 -166.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -168.79 30.55 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.22 1.01 . . . . 10.0 110.07 -173.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.19 -20.27 66.37 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.971 0.909 . . . . 10.0 113.277 -167.267 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.45 -160.69 53.25 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 110.394 -1.083 . . . . 10.0 110.394 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.5 m -55.57 130.8 44.38 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.074 0.94 . . . . 10.0 113.151 -167.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 60.6 mtt180 -69.23 68.25 0.19 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.129 1.771 . . . . 10.0 110.415 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 37.8 mt -54.41 -31.9 56.08 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 113.141 0.793 . . . . 10.0 113.141 -173.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.22 153.15 25.19 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 109.129 -0.693 . . . . 10.0 109.129 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.5 m -146.19 161.55 39.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 115.548 -0.751 . . . . 10.0 109.934 -166.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.36 172.78 34.81 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.089 -1.204 . . . . 10.0 110.089 176.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -122.4 135.32 62.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 9.1 mt -69.23 116.66 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 C-N-CA 122.983 0.513 . . . . 10.0 110.034 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.05 144.47 17.72 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 124.812 1.196 . . . . 10.0 110.526 -178.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 59.8 mt -65.77 144.56 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 N-CA-C 108.045 -1.094 . . . . 10.0 108.045 176.114 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.55 -43.05 3.06 Favored 'General case' 0 C--O 1.227 -0.124 0 CA-C-N 119.268 0.94 . . . . 10.0 111.923 170.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 117.088 -1.434 . . . . 10.0 110.854 179.029 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.656 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.6 t -154.77 -49.31 0.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 123.479 0.712 . . . . 10.0 109.501 173.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 ttmt -106.41 155.84 19.14 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.222 -1.77 . . . . 10.0 106.222 169.317 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.77 164.82 38.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 107.093 -1.447 . . . . 10.0 107.093 170.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -136.17 164.4 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 O-C-N 123.325 0.391 . . . . 10.0 110.854 -176.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.37 101.85 4.09 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.123 -1.065 . . . . 10.0 108.123 168.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.5 m -85.84 88.26 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 170.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -81.67 126.38 31.71 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.087 -0.708 . . . . 10.0 109.087 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 46.8 mtpt -140.8 160.41 40.11 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.05 -1.463 . . . . 10.0 107.05 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.07 -60.93 0.04 OUTLIER Glycine 0 C--O 1.229 -0.199 0 C-N-CA 120.808 -0.71 . . . . 10.0 112.745 169.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.99 -43.94 64.3 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 -176.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.82 -70.75 0.41 Allowed Glycine 0 CA--C 1.523 0.581 0 CA-C-N 114.23 -1.35 . . . . 10.0 110.446 169.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -58.16 -32.61 96.08 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 123.511 2.807 . . . . 10.0 111.665 173.483 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.0 t -67.22 93.75 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 N-CA-C 107.094 -1.447 . . . . 10.0 107.094 177.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -117.96 106.94 13.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.65 142.18 15.91 Favored Glycine 0 N--CA 1.441 -1.017 0 N-CA-C 109.171 -1.572 . . . . 10.0 109.171 169.204 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.4 mt -143.77 58.66 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 -169.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.0 mm -79.74 137.28 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 115.688 -0.687 . . . . 10.0 109.328 -173.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -115.33 117.04 29.33 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.433 1.493 . . . . 10.0 108.024 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -102.74 122.88 45.36 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 177.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -118.37 144.61 45.77 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.675 0.671 . . . . 10.0 112.405 173.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -125.31 102.01 7.24 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 127.85 2.46 . . . . 10.0 106.594 167.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -49.74 -56.14 11.34 Favored 'General case' 0 C--N 1.338 0.098 0 C-N-CA 124.415 1.086 . . . . 10.0 109.931 172.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.56 178.54 6.99 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 105.128 -2.175 . . . . 10.0 105.128 171.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.0 t -72.31 -18.79 61.75 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.455 -0.202 . . . . 10.0 110.455 177.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -79.68 -19.38 49.15 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 123.673 0.789 . . . . 10.0 109.765 177.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.61 143.46 45.55 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.531 -1.028 . . . . 10.0 110.531 179.217 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.48 149.03 43.73 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.466 2.11 . . . . 10.0 107.648 168.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 t -79.58 100.34 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -81.91 108.0 15.07 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.927 -1.508 . . . . 10.0 106.927 168.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.3 m -90.11 103.41 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 107.108 -1.441 . . . . 10.0 107.108 173.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.4 p90 -112.73 153.95 26.93 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-O 121.481 0.657 . . . . 10.0 112.61 173.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.47 179.37 41.28 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.637 -0.792 . . . . 10.0 111.274 169.156 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.4 p -131.67 103.94 6.65 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 -175.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.8 pt -79.8 140.99 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 169.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -118.28 149.84 40.46 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 169.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.55 -8.15 37.22 Favored Glycine 0 C--N 1.336 0.569 0 CA-C-O 119.534 -0.592 . . . . 10.0 113.354 170.071 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -60.97 176.68 0.39 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.915 0.864 . . . . 10.0 109.75 170.648 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -110.61 171.65 7.34 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 166.111 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -48.93 156.27 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.858 1.263 . . . . 10.0 112.816 -172.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.01 -169.93 46.84 Favored Glycine 0 N--CA 1.443 -0.858 0 CA-C-O 122.667 1.149 . . . . 10.0 113.848 166.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mp -69.86 141.78 53.16 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 126.246 1.818 . . . . 10.0 110.139 -177.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -142.54 151.98 42.15 Favored 'General case' 0 C--N 1.341 0.203 0 N-CA-C 114.132 1.16 . . . . 10.0 114.132 178.085 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -30.71 122.39 0.13 Allowed Glycine 0 C--N 1.34 0.783 0 C-N-CA 128.533 2.968 . . . . 10.0 112.709 164.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -156.14 107.22 2.46 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.206 1.503 . . . . 10.0 111.72 168.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.463 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -157.55 169.75 23.96 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 113.2 0.815 . . . . 10.0 113.2 -179.764 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.4 m -84.13 157.79 3.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 CA-C-N 112.694 -2.048 . . . . 10.0 109.929 169.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -142.14 140.15 32.35 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 126.58 1.952 . . . . 10.0 107.366 179.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -58.55 -59.72 4.94 Favored 'General case' 0 N--CA 1.446 -0.645 0 O-C-N 124.212 0.945 . . . . 10.0 111.249 -172.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -76.95 123.02 25.7 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 117.932 -1.507 . . . . 10.0 108.984 -169.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.05 -9.25 63.0 Favored Glycine 0 CA--C 1.535 1.317 0 N-CA-C 110.336 -1.106 . . . . 10.0 110.336 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -59.07 99.84 0.06 Allowed 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 122.371 1.081 . . . . 10.0 111.453 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -107.53 14.39 25.84 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 113.506 -1.679 . . . . 10.0 110.432 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.1 m -54.71 -35.51 63.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 120.065 1.302 . . . . 10.0 110.776 -177.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.72 -19.99 57.05 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.769 0.828 . . . . 10.0 112.392 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 133.05 -87.74 0.27 Allowed Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.432 1.492 . . . . 10.0 109.533 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 15.7 t -155.17 62.04 0.64 Allowed 'General case' 0 CA--C 1.529 0.162 0 O-C-N 122.067 -0.666 . . . . 10.0 109.705 -172.233 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -162.5 -49.92 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.557 -0.714 . . . . 10.0 110.175 -175.239 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.7 t -57.47 -19.98 27.77 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 123.941 0.896 . . . . 10.0 111.149 -178.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.82 -27.36 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.822 2.049 . . . . 10.0 113.589 168.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.48 170.69 33.17 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 108.071 -2.012 . . . . 10.0 108.071 168.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -81.5 -166.38 0.4 Allowed 'Trans proline' 0 N--CA 1.441 -1.582 0 N-CA-C 107.077 -1.932 . . . . 10.0 107.077 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.437 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.6 m170 -82.85 58.94 4.57 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 120.893 -1.129 . . . . 10.0 110.629 -174.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -71.99 74.18 0.9 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.949 0.88 . . . . 10.0 111.257 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 -74.92 153.11 86.84 Favored Pre-proline 0 CA--C 1.537 0.444 0 C-N-CA 124.292 1.037 . . . . 10.0 110.302 171.336 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.12 -43.54 11.23 Favored 'Trans proline' 0 N--CA 1.456 -0.712 0 C-N-CA 122.322 2.015 . . . . 10.0 111.019 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.6 51.21 0.73 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.401 0.68 . . . . 10.0 110.579 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 35.0 p -52.48 112.51 0.83 Allowed 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.247 1.019 . . . . 10.0 109.907 -174.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 30.1 mtt85 -136.93 -85.71 0.32 Allowed 'General case' 0 CA--C 1.511 -0.545 0 N-CA-C 106.953 -1.499 . . . . 10.0 106.953 -170.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -144.7 158.2 43.88 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-O 122.402 1.096 . . . . 10.0 109.361 167.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 67.3 t60 -73.13 120.46 18.79 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 162.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.5 -131.75 2.45 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 108.148 -1.981 . . . . 10.0 108.148 175.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.09 -149.2 7.87 Favored Glycine 0 C--O 1.226 -0.351 0 N-CA-C 109.106 -1.598 . . . . 10.0 109.106 169.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -64.92 3.71 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.863 0 CA-C-N 120.344 2.072 . . . . 10.0 111.656 169.112 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -92.35 -22.48 19.67 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 124.901 1.28 . . . . 10.0 110.611 172.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 59.6 t0 -117.18 152.77 34.09 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.118 -1.067 . . . . 10.0 108.118 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -79.2 -33.43 43.87 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.403 -1.271 . . . . 10.0 108.078 169.188 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -91.02 8.1 37.08 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.415 1.486 . . . . 10.0 111.606 -170.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.21 142.1 3.04 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.456 1.103 . . . . 10.0 110.478 176.109 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.7 m170 -59.73 -59.37 5.54 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.447 0.641 . . . . 10.0 110.342 -169.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.3 p -173.5 -98.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 104.586 -2.376 . . . . 10.0 104.586 177.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -79.1 58.38 4.34 Favored Glycine 0 CA--C 1.529 0.954 0 CA-C-N 118.776 0.716 . . . . 10.0 111.457 174.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -90.59 90.59 8.05 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 104.309 -2.478 . . . . 10.0 104.309 167.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 8.6 mt -70.79 -33.28 70.57 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.28 -76.53 0.51 Allowed Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 10.0 111.32 167.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -135.43 118.58 16.52 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 117.938 0.869 . . . . 10.0 109.45 -175.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.2 m -103.98 122.44 56.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 168.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 m -82.67 101.75 11.04 Favored 'General case' 0 N--CA 1.437 -1.107 0 C-N-CA 127.402 2.281 . . . . 10.0 109.507 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.64 130.24 35.33 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.251 0.62 . . . . 10.0 110.561 175.587 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -58.94 169.03 1.1 Allowed 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 124.215 0.947 . . . . 10.0 109.277 167.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 ptmm? -50.78 -32.4 19.76 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.539 1.535 . . . . 10.0 111.565 169.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.8 m-20 -78.28 -5.16 51.2 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.933 0.893 . . . . 10.0 111.321 -178.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.78 6.91 88.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 111.071 -0.811 . . . . 10.0 111.071 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.0 t -79.95 107.2 12.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.926 0 C-N-CA 126.532 1.933 . . . . 10.0 106.043 176.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.12 118.58 36.78 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 169.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -81.68 123.97 29.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 O-C-N 124.408 1.068 . . . . 10.0 108.461 172.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 99.4 t -112.38 130.44 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.238 0 C-N-CA 127.097 2.159 . . . . 10.0 106.365 177.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.3 p -156.11 65.34 0.57 Allowed 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.477 0.711 . . . . 10.0 109.458 174.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -96.63 156.9 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 -177.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -136.02 121.86 19.87 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 125.465 1.506 . . . . 10.0 109.38 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -125.66 117.78 24.24 Favored 'General case' 0 C--O 1.232 0.174 0 C-N-CA 124.623 1.169 . . . . 10.0 108.6 -177.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -89.14 54.64 3.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 171.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.02 -53.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 C-N-CA 122.932 0.493 . . . . 10.0 110.245 -176.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -58.27 147.52 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 172.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.1 p -137.48 136.19 37.5 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.365 -0.379 . . . . 10.0 110.402 170.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -77.79 -35.08 51.91 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 107.862 -1.162 . . . . 10.0 107.862 168.511 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.7 m -151.39 130.58 12.73 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 103.534 -2.765 . . . . 10.0 103.534 168.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.33 -79.7 0.1 Allowed Glycine 0 C--N 1.331 0.302 0 N-CA-C 109.219 -1.552 . . . . 10.0 109.219 -169.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -147.22 -54.29 0.22 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.09 -1.055 . . . . 10.0 108.68 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -75.84 -36.99 59.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.372 -1.286 . . . . 10.0 108.633 -173.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.7 t 45.69 61.12 2.77 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.317 1.047 . . . . 10.0 110.326 169.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 25.5 pt -74.53 31.77 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.89 0.852 . . . . 10.0 112.956 -169.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.7 mm -81.76 123.82 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 C-N-CA 125.627 1.571 . . . . 10.0 107.912 -176.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.14 4.66 64.5 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 123.947 0.785 . . . . 10.0 111.541 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -83.58 171.05 13.71 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 168.189 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 2.4 m -119.12 140.7 49.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 108.245 -1.021 . . . . 10.0 108.245 -177.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.43 164.25 13.85 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.61 0.641 . . . . 10.0 109.631 168.174 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -140.56 134.22 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 O-C-N 123.953 0.783 . . . . 10.0 109.345 -172.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.9 m -96.95 133.0 40.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 106.554 -1.647 . . . . 10.0 106.554 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -114.01 158.3 21.37 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 114.948 1.462 . . . . 10.0 114.948 -175.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -55.78 -47.16 77.55 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.246 1.819 . . . . 10.0 111.35 -179.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 79.3 mttt -112.46 163.39 14.51 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 119.121 0.873 . . . . 10.0 112.903 -175.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.76 152.78 30.32 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 124.697 1.199 . . . . 10.0 108.755 169.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.463 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.5 OUTLIER -78.96 151.4 31.64 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-O 122.746 1.26 . . . . 10.0 112.292 -179.378 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.82 -29.54 44.83 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 112.133 -2.303 . . . . 10.0 109.448 170.633 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.0 mt 58.55 34.68 24.08 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 124.694 1.198 . . . . 10.0 111.893 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.1 -18.48 57.27 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 123.969 0.795 . . . . 10.0 111.768 170.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -74.77 -5.98 46.4 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 124.344 1.058 . . . . 10.0 111.941 -168.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.54 -28.99 70.59 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.362 -1.095 . . . . 10.0 110.362 168.217 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.76 43.46 54.15 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.512 -1.035 . . . . 10.0 110.512 -170.274 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -128.28 168.16 15.89 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.115 -1.069 . . . . 10.0 108.115 175.058 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -48.52 -50.24 32.69 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.076 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 58.8 mp0 -55.85 -54.13 48.26 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 125.805 1.642 . . . . 10.0 111.811 171.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.8 p -49.74 -44.98 48.87 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 109.389 -0.596 . . . . 10.0 109.389 -173.118 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.7 t -81.19 -1.64 45.51 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.503 0.557 . . . . 10.0 112.503 -171.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.7 mttt -112.68 -50.37 2.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 125.653 1.581 . . . . 10.0 112.128 -176.627 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.1 p -139.09 17.17 2.62 Favored 'General case' 0 C--N 1.34 0.174 0 CA-C-N 119.545 1.066 . . . . 10.0 111.817 173.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.07 -116.45 5.56 Favored Glycine 0 N--CA 1.436 -1.311 0 N-CA-C 103.794 -3.722 . . . . 10.0 103.794 -169.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -163.88 40.42 0.09 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.582 -1.636 . . . . 10.0 106.582 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.71 -4.47 37.65 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 124.06 0.944 . . . . 10.0 112.193 -170.539 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.72 -164.3 53.09 Favored Glycine 0 N--CA 1.446 -0.679 0 O-C-N 121.415 -0.803 . . . . 10.0 111.527 169.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.6 m -53.86 131.37 39.76 Favored 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 124.711 1.204 . . . . 10.0 114.019 -168.117 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 34.0 mtt180 -64.95 73.47 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.519 1.928 . . . . 10.0 111.168 174.248 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 43.1 mt -51.03 -35.67 35.5 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 112.642 0.608 . . . . 10.0 112.642 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.49 153.09 32.78 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 121.901 -0.5 . . . . 10.0 109.722 176.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.6 p -149.98 156.51 41.85 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 109.38 -0.6 . . . . 10.0 109.38 178.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.85 153.95 25.17 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.063 -0.815 . . . . 10.0 111.063 -176.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 84.6 t -102.88 139.86 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 105.967 -1.864 . . . . 10.0 105.967 -173.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 18.0 mt -74.91 110.31 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 122.843 0.457 . . . . 10.0 109.894 -175.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.61 141.92 15.38 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 124.237 0.922 . . . . 10.0 110.972 -177.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.8 mt -64.83 146.38 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.401 1.48 . . . . 10.0 110.523 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.59 165.57 29.97 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-O 122.564 1.173 . . . . 10.0 110.506 167.814 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 . . . . . 0 C--O 1.255 1.384 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 166.15 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 105.885 -1.894 . . . . 10.0 105.885 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.7 t -76.81 -46.62 24.21 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 119.996 1.271 . . . . 10.0 110.351 -168.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -127.36 128.3 45.64 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 124.321 1.048 . . . . 10.0 111.317 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.04 160.88 38.73 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 123.348 0.659 . . . . 10.0 109.591 168.742 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.13 162.09 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 124.129 0.972 . . . . 10.0 109.291 -178.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.41 102.75 3.88 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.703 -1.221 . . . . 10.0 107.703 169.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -85.12 111.88 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 N-CA-C 108.851 -0.796 . . . . 10.0 108.851 169.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mt -88.16 141.12 28.82 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.481 -0.933 . . . . 10.0 108.481 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -157.8 161.72 38.41 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.696 1.135 . . . . 10.0 108.14 171.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.59 -55.98 0.04 OUTLIER Glycine 0 C--N 1.329 0.166 0 N-CA-C 111.937 -0.465 . . . . 10.0 111.937 170.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.75 -45.78 41.65 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 -170.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.48 -66.19 0.57 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 113.676 -1.602 . . . . 10.0 110.786 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -57.81 -36.9 98.07 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.763 2.308 . . . . 10.0 111.071 172.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -67.52 109.9 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 108.472 -0.936 . . . . 10.0 108.472 174.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -126.57 112.25 15.3 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 106.381 -1.711 . . . . 10.0 106.381 168.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.39 145.28 17.75 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.718 -1.353 . . . . 10.0 109.718 171.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -145.62 87.63 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -169.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -105.99 145.33 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.204 0 C-N-CA 124.446 1.098 . . . . 10.0 110.253 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -121.06 126.33 49.57 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 127.078 2.151 . . . . 10.0 109.564 168.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -103.68 114.07 28.07 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 170.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -109.27 126.97 53.89 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 123.502 0.501 . . . . 10.0 111.333 169.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 -94.08 99.41 11.71 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 106.811 -1.552 . . . . 10.0 106.811 174.065 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -50.31 -63.19 1.19 Allowed 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 124.83 1.252 . . . . 10.0 109.928 -177.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -143.6 167.26 22.67 Favored 'General case' 0 N--CA 1.435 -1.208 0 N-CA-C 102.244 -3.243 . . . . 10.0 102.244 167.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.3 m -74.49 -10.07 59.2 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 118.545 0.611 . . . . 10.0 110.038 174.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 32.6 m120 -78.58 -24.53 45.44 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 124.055 0.942 . . . . 10.0 110.508 172.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.77 159.14 26.61 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 110.073 -1.211 . . . . 10.0 110.073 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -66.12 150.54 85.06 Favored 'Trans proline' 0 N--CA 1.451 -1.029 0 C-N-CA 121.811 1.674 . . . . 10.0 108.426 169.648 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.11 121.0 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 N-CA-C 105.723 -1.954 . . . . 10.0 105.723 169.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.5 ttmp? -95.81 120.57 36.31 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 107.124 -1.436 . . . . 10.0 107.124 169.142 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -100.17 103.94 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 C-N-CA 126.824 2.049 . . . . 10.0 106.147 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -126.84 166.35 17.63 Favored 'General case' 0 CA--C 1.52 -0.198 0 N-CA-C 112.355 0.502 . . . . 10.0 112.355 177.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.18 -150.57 22.44 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 106.928 -2.469 . . . . 10.0 106.928 169.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.0 p -156.38 165.38 36.5 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.88 175.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pp -113.67 173.19 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-N 115.298 -0.864 . . . . 10.0 108.868 167.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.8 tttt -144.03 142.04 30.44 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 106.492 -1.67 . . . . 10.0 106.492 164.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.03 -8.32 11.57 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 113.05 170.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -67.37 177.73 1.79 Allowed 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.181 0.993 . . . . 10.0 111.037 177.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.1 t -110.77 152.85 26.13 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.724 -1.584 . . . . 10.0 106.724 168.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -53.52 150.78 6.41 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.437 0.695 . . . . 10.0 112.216 -168.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.67 -168.49 20.59 Favored Glycine 0 CA--C 1.523 0.567 0 C-N-CA 123.828 0.728 . . . . 10.0 111.295 173.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mp -78.16 138.87 38.92 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.335 1.454 . . . . 10.0 110.892 -172.192 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -142.02 131.91 24.39 Favored 'General case' 0 CA--C 1.521 -0.165 0 C-N-CA 124.376 1.07 . . . . 10.0 112.254 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -17.75 122.92 0.01 OUTLIER Glycine 0 C--N 1.343 0.918 0 C-N-CA 128.001 2.715 . . . . 10.0 113.161 167.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -148.76 106.3 3.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 119.198 1.499 . . . . 10.0 110.633 171.459 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.84 169.95 21.0 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.596 0.712 . . . . 10.0 111.393 177.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 9.3 p -90.6 145.88 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 CA-C-N 111.946 -2.388 . . . . 10.0 107.274 166.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -125.69 146.16 49.86 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.019 -1.845 . . . . 10.0 106.019 170.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . 0.424 ' CD ' ' HE ' ' B' ' 115' ' ' ARG . 29.7 tp10 -76.42 -31.5 57.94 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.295 -0.866 . . . . 10.0 111.887 -166.639 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -78.95 113.94 17.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.081 -1.081 . . . . 10.0 108.081 174.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.34 -15.6 68.18 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 167.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -42.89 148.47 0.25 Allowed 'General case' 0 C--N 1.343 0.305 0 C-N-CA 124.735 1.214 . . . . 10.0 111.716 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -158.24 16.54 0.22 Allowed 'General case' 0 N--CA 1.441 -0.925 0 C-N-CA 125.519 1.528 . . . . 10.0 111.564 169.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 3.1 m -54.95 -37.4 66.42 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 119.458 1.026 . . . . 10.0 111.469 -169.147 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.8 -22.23 46.57 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.409 1.084 . . . . 10.0 112.528 177.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 126.89 -167.01 19.46 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 106.246 -2.742 . . . . 10.0 106.246 -169.308 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m -72.65 53.28 0.32 Allowed 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 125.005 1.322 . . . . 10.0 107.877 169.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 88.9 m -120.83 -50.22 2.18 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 127.638 2.375 . . . . 10.0 108.245 -165.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 14.4 m -114.11 10.61 17.44 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.935 1.294 . . . . 10.0 112.226 -169.174 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -72.49 32.09 0.06 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.434 1.094 . . . . 10.0 113.721 -175.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.67 122.67 0.31 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.151 0.882 . . . . 10.0 112.667 168.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -77.33 60.79 7.14 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.13 2.553 . . . . 10.0 111.492 174.682 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 62.62 48.27 4.44 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.95 1.7 . . . . 10.0 110.235 173.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -71.03 62.21 0.29 Allowed 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.766 0.712 . . . . 10.0 111.373 179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -65.58 142.36 98.25 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.291 -0.881 . . . . 10.0 111.303 -172.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.35 -41.61 6.52 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.723 2.282 . . . . 10.0 110.249 -177.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.75 55.16 1.04 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.166 0.986 . . . . 10.0 108.771 175.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.9 p -34.15 104.95 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 126.539 1.936 . . . . 10.0 111.859 -169.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.11 176.97 8.18 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 104.319 -2.475 . . . . 10.0 104.319 -173.166 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -69.78 154.28 42.2 Favored 'General case' 0 N--CA 1.435 -1.185 0 C-N-CA 117.148 -1.821 . . . . 10.0 107.994 169.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -65.72 118.29 9.38 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 104.717 -2.327 . . . . 10.0 104.717 159.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.79 -177.3 22.09 Favored Glycine 0 N--CA 1.435 -1.409 0 N-CA-C 106.699 -2.561 . . . . 10.0 106.699 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.65 -156.59 6.93 Favored Glycine 0 C--O 1.227 -0.294 0 N-CA-C 109.35 -1.5 . . . . 10.0 109.35 -177.423 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -65.48 1.66 2.0 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.323 1.349 . . . . 10.0 110.613 166.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -109.16 0.86 19.97 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 117.754 -1.117 . . . . 10.0 112.007 173.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -116.22 162.78 16.95 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 169.235 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -79.1 -39.79 32.8 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 167.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -110.55 63.53 0.61 Allowed 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 124.697 1.199 . . . . 10.0 111.65 -168.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -60.65 161.81 7.33 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.359 1.064 . . . . 10.0 109.728 166.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 15.5 m170 -66.49 -71.54 0.19 Allowed 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 113.062 0.764 . . . . 10.0 113.062 -174.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -166.79 -53.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 O-C-N 121.638 -0.664 . . . . 10.0 109.689 -173.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -131.48 60.47 0.68 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 171.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -112.15 90.5 3.36 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.074 -2.195 . . . . 10.0 105.074 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -82.22 -30.38 30.83 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 106.362 -1.718 . . . . 10.0 106.362 -178.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.92 -83.96 0.36 Allowed Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 168.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -156.88 156.35 32.99 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 122.839 0.456 . . . . 10.0 111.101 -177.628 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.5 m -124.48 142.08 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 C-N-CA 125.289 1.435 . . . . 10.0 109.766 -174.339 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -85.71 103.1 14.19 Favored 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 129.433 3.093 . . . . 10.0 110.927 -172.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.48 136.12 36.25 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.861 -0.524 . . . . 10.0 109.844 169.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.402 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 23.8 t70 -65.93 172.49 3.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.733 1.613 . . . . 10.0 110.23 167.546 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.402 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -62.23 -23.48 66.69 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 122.771 0.428 . . . . 10.0 112.091 173.534 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -75.83 -3.05 33.0 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 120.864 0.364 . . . . 10.0 110.252 174.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.48 24.73 60.23 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 108.719 -1.752 . . . . 10.0 108.719 176.327 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.6 t -110.13 109.51 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 127.081 2.152 . . . . 10.0 106.904 -174.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.17 120.19 40.04 Favored 'General case' 0 CA--C 1.513 -0.467 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 169.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -79.97 119.21 22.5 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 127.415 2.286 . . . . 10.0 108.8 170.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -103.68 130.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 C-N-CA 124.839 1.256 . . . . 10.0 107.754 177.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.9 p -158.42 83.02 0.83 Allowed 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 118.646 -0.693 . . . . 10.0 109.227 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.68 152.59 20.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 N-CA-C 107.553 -1.277 . . . . 10.0 107.553 179.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -126.81 137.01 53.13 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 126.014 1.726 . . . . 10.0 110.31 174.055 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.27 141.08 39.86 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.829 0.852 . . . . 10.0 109.513 177.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 18.6 p -106.3 22.91 14.97 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.363 1.465 . . . . 10.0 109.924 169.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 51.0 t -94.88 -15.21 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 C-N-CA 124.859 1.264 . . . . 10.0 109.479 -177.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -134.53 175.17 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 125.461 1.504 . . . . 10.0 112.42 -169.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -158.85 147.0 18.1 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 107.631 -1.248 . . . . 10.0 107.631 169.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -60.03 -50.61 73.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.727 -0.842 . . . . 10.0 108.727 -178.238 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 49.8 p -131.39 155.26 47.58 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 172.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 144.9 -101.84 0.26 Allowed Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 107.537 -2.225 . . . . 10.0 107.537 -169.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -128.08 -50.89 1.32 Allowed 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 125.466 1.506 . . . . 10.0 108.7 -167.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -75.7 -42.24 51.5 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.184 -1.413 . . . . 10.0 107.184 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.0 t 52.23 66.91 1.07 Allowed 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 126.87 2.068 . . . . 10.0 110.921 168.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 20.6 pt -67.75 -10.05 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 113.606 0.965 . . . . 10.0 113.606 -172.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 21.2 mm -53.41 139.58 11.18 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 O-C-N 120.854 -1.153 . . . . 10.0 110.159 169.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.41 4.5 84.44 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.556 -1.136 . . . . 10.0 113.986 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . 0.424 ' HE ' ' CD ' ' B' ' 49' ' ' GLU . 27.7 mmt-85 -79.55 178.57 8.04 Favored 'General case' 0 C--N 1.342 0.239 0 CA-C-N 119.223 1.512 . . . . 10.0 109.542 168.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -124.69 135.54 53.13 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 106.454 -1.684 . . . . 10.0 106.454 178.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 7.9 mp -105.08 148.57 26.67 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.406 -1.331 . . . . 10.0 107.406 169.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.5 t -126.88 135.22 64.29 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 N-CA-C 107.429 -1.323 . . . . 10.0 107.429 178.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -102.91 121.0 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.883 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 169.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -106.12 162.6 13.48 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -169.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -47.95 -50.05 28.41 Favored 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 128.425 2.69 . . . . 10.0 112.477 174.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -128.49 171.97 11.58 Favored 'General case' 0 C--N 1.334 -0.086 0 C-N-CA 124.141 0.976 . . . . 10.0 112.225 -168.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.02 165.7 24.68 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.304 -0.862 . . . . 10.0 109.798 170.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.76 155.85 17.15 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.97 1.308 . . . . 10.0 111.637 -176.049 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -77.85 -15.3 59.15 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 114.731 -1.122 . . . . 10.0 110.254 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 73.2 mt 51.65 45.42 28.14 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 124.538 1.135 . . . . 10.0 110.335 172.179 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.19 27.85 73.26 Favored Glycine 0 N--CA 1.437 -1.246 0 CA-C-N 113.797 -1.547 . . . . 10.0 113.378 173.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -74.78 -3.84 34.06 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.295 1.548 . . . . 10.0 112.356 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.22 25.27 73.63 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 108.791 -1.724 . . . . 10.0 108.791 175.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -56.03 -30.15 56.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 170.601 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -155.87 167.84 29.12 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.59 -0.892 . . . . 10.0 108.59 -168.365 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.2 tm-20 -56.29 -46.27 79.83 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 108.511 -0.922 . . . . 10.0 108.511 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -59.04 -24.48 62.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 115.96 -0.564 . . . . 10.0 111.997 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 51.9 m -56.13 -32.63 64.41 Favored 'General case' 0 N--CA 1.444 -0.744 0 O-C-N 121.656 -0.653 . . . . 10.0 112.398 -177.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.6 t -93.46 7.73 43.38 Favored 'General case' 0 CA--C 1.534 0.339 0 O-C-N 123.52 0.512 . . . . 10.0 110.108 -174.074 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -128.69 -61.04 1.08 Allowed 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 126.678 1.991 . . . . 10.0 112.46 -174.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -135.71 31.03 3.09 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 120.69 1.586 . . . . 10.0 109.462 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 63.99 -97.59 0.23 Allowed Glycine 0 C--N 1.346 1.109 0 CA-C-O 123.79 1.772 . . . . 10.0 108.925 175.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.86 39.41 0.1 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 113.172 -1.514 . . . . 10.0 109.064 167.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.71 -12.95 52.25 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.713 0.805 . . . . 10.0 112.702 -169.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.75 -166.06 52.06 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 175.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -55.35 131.11 44.92 Favored 'General case' 0 N--CA 1.444 -0.771 0 C-N-CA 123.573 0.749 . . . . 10.0 111.935 -168.544 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -65.7 75.79 0.07 Allowed 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.603 0.761 . . . . 10.0 109.676 169.385 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 69.3 mt -45.37 -49.8 12.74 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.602 0.761 . . . . 10.0 110.726 177.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.56 155.86 36.96 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.495 -0.557 . . . . 10.0 109.495 -171.083 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -158.27 166.88 31.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.05 0.54 . . . . 10.0 109.572 -174.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.91 160.17 32.18 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 110.179 -1.169 . . . . 10.0 110.179 -173.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 57.4 t -109.25 138.38 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -171.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.7 mt -75.82 108.96 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 -177.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.5 135.19 12.23 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 109.957 -1.257 . . . . 10.0 109.957 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.3 pt -75.42 127.25 36.89 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.231 0 CA-C-N 118.557 1.178 . . . . 10.0 108.604 174.189 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -75.39 -54.89 6.31 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 107.134 -1.432 . . . . 10.0 107.134 178.506 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.348 -0.834 . . . . 10.0 109.457 172.1 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 106.85 -1.537 . . . . 10.0 106.85 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 t -167.51 -38.01 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 124.055 0.942 . . . . 10.0 111.881 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 57.1 tttp -133.46 141.39 47.79 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 124.531 1.132 . . . . 10.0 109.843 178.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.66 169.53 21.36 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 126.487 1.915 . . . . 10.0 107.226 176.375 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.9 162.1 35.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 N-CA-C 109.526 -0.546 . . . . 10.0 109.526 -179.248 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.04 97.64 4.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.989 0.916 . . . . 10.0 108.951 175.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -83.73 106.0 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 N-CA-C 108.677 -0.86 . . . . 10.0 108.677 169.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.9 mt -100.14 140.68 34.02 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.63 -0.878 . . . . 10.0 108.63 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.9 ttmt -157.84 163.7 37.72 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.509 -1.293 . . . . 10.0 107.509 169.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.57 -53.14 0.06 OUTLIER Glycine 0 C--O 1.228 -0.255 0 C-N-CA 120.333 -0.937 . . . . 10.0 112.163 169.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -72.64 -45.34 59.49 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.329 -1.36 . . . . 10.0 107.329 -177.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.28 -71.09 0.41 Allowed Glycine 0 CA--C 1.524 0.619 0 CA-C-N 114.355 -1.293 . . . . 10.0 110.342 169.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -57.44 -34.8 98.56 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.462 2.775 . . . . 10.0 111.242 173.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.6 t -65.3 100.81 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.082 0 N-CA-C 107.335 -1.358 . . . . 10.0 107.335 175.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -119.5 116.23 25.67 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.568 1.147 . . . . 10.0 108.381 172.546 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -95.71 145.47 17.79 Favored Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 109.892 -1.283 . . . . 10.0 109.892 169.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.2 mt -151.54 56.94 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.8 mm -80.82 140.23 16.95 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.041 0 O-C-N 121.587 -0.695 . . . . 10.0 110.011 -175.011 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -99.74 115.3 29.19 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.04 1.336 . . . . 10.0 108.298 170.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -92.56 110.38 21.8 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 105.486 -2.042 . . . . 10.0 105.486 170.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -131.17 146.6 52.4 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 119.084 0.856 . . . . 10.0 110.481 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -148.24 16.21 1.05 Allowed 'General case' 0 C--N 1.342 0.274 0 N-CA-C 115.319 1.6 . . . . 10.0 115.319 -178.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? 74.23 -57.38 0.62 Allowed 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 125.595 1.558 . . . . 10.0 113.163 168.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.68 -157.26 0.8 Allowed 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 107.964 -1.124 . . . . 10.0 107.964 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -85.48 -23.08 27.94 Favored 'General case' 0 N--CA 1.45 -0.448 0 O-C-N 120.808 -1.182 . . . . 10.0 110.638 170.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -89.33 -21.27 23.21 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 123.985 0.914 . . . . 10.0 111.503 -173.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.56 151.76 51.68 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.619 -0.545 . . . . 10.0 112.356 -171.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -68.46 137.29 39.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.95 2.433 . . . . 10.0 108.842 169.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -77.74 138.55 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 O-C-N 121.849 -0.532 . . . . 10.0 110.957 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -119.63 124.93 47.52 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.848 -1.538 . . . . 10.0 106.848 168.418 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.3 m -102.76 59.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 124.339 1.055 . . . . 10.0 109.094 -170.104 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.8 p90 -79.03 146.01 33.55 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 119.625 -0.83 . . . . 10.0 111.312 -172.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.39 -169.48 39.2 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.646 -0.981 . . . . 10.0 110.646 169.156 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.4 m -139.6 107.53 5.7 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.065 -0.717 . . . . 10.0 109.065 -170.411 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 pt -78.31 128.01 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 106.873 -1.529 . . . . 10.0 106.873 168.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 tttt -107.21 146.66 31.13 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.115 -1.439 . . . . 10.0 107.115 173.328 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -7.07 31.06 Favored Glycine 0 CA--C 1.522 0.528 0 CA-C-O 119.197 -0.779 . . . . 10.0 112.678 173.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -62.47 177.01 0.55 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.675 1.238 . . . . 10.0 109.284 168.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -113.53 157.06 22.51 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.961 -0.755 . . . . 10.0 108.961 170.039 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -48.9 123.67 7.41 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.062 1.345 . . . . 10.0 111.094 -171.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.66 -169.12 13.13 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 123.794 0.711 . . . . 10.0 112.347 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -77.3 146.77 36.61 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 126.12 1.768 . . . . 10.0 112.391 -170.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -149.48 144.0 26.03 Favored 'General case' 0 C--N 1.342 0.276 0 N-CA-C 114.049 1.129 . . . . 10.0 114.049 -178.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -33.15 126.24 0.34 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 127.145 2.307 . . . . 10.0 112.232 165.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -151.03 108.11 3.58 Favored 'General case' 0 C--O 1.238 0.486 0 CA-C-N 119.504 1.652 . . . . 10.0 109.561 167.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.497 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -151.94 174.44 13.62 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.148 0.975 . . . . 10.0 113.4 179.329 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.9 p -90.61 151.4 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 CA-C-N 112.028 -2.351 . . . . 10.0 108.038 168.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -127.59 142.69 51.29 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 106.931 -1.507 . . . . 10.0 106.931 171.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -37.24 -55.77 0.98 Allowed 'General case' 0 C--O 1.237 0.403 0 C-N-CA 127.535 2.334 . . . . 10.0 113.7 -170.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -106.34 169.31 8.59 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-O 122.367 1.079 . . . . 10.0 112.556 -171.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.42 -23.47 24.05 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 126.664 2.078 . . . . 10.0 109.771 169.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -43.39 120.41 1.9 Allowed 'General case' 0 C--N 1.346 0.417 0 CA-C-O 122.009 0.909 . . . . 10.0 109.863 170.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -134.75 11.9 3.69 Favored 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 125.942 1.697 . . . . 10.0 108.497 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.3 m -59.45 -33.64 71.54 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 119.031 0.832 . . . . 10.0 112.083 -168.216 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.39 -16.14 59.0 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.915 0.886 . . . . 10.0 112.33 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.26 62.92 0.56 Allowed Glycine 0 CA--C 1.521 0.462 0 N-CA-C 108.655 -1.778 . . . . 10.0 108.655 -172.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.6 p 41.31 39.6 1.02 Allowed 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 125.868 1.667 . . . . 10.0 114.122 171.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 16.3 m -108.13 -53.3 2.65 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.759 2.024 . . . . 10.0 105.584 -177.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.4 m -66.66 -15.46 63.5 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.525 1.93 . . . . 10.0 112.665 -175.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -50.06 -6.28 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.936 2.494 . . . . 10.0 115.715 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 105.8 123.41 5.16 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.117 -1.38 . . . . 10.0 110.372 170.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.59 60.16 5.78 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.595 2.863 . . . . 10.0 110.638 173.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.9 m170 65.34 37.61 6.23 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 130.27 3.428 . . . . 10.0 111.897 179.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.1 m-30 -72.89 62.32 0.59 Allowed 'General case' 0 N--CA 1.468 0.462 0 O-C-N 121.196 -0.94 . . . . 10.0 110.628 175.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -74.1 152.66 88.49 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.247 -0.908 . . . . 10.0 111.146 -172.182 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -60.45 -42.67 39.09 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.435 2.756 . . . . 10.0 111.848 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.3 tp -77.91 59.08 2.04 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 123.781 0.832 . . . . 10.0 108.772 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 58.7 p -40.75 104.85 0.04 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.282 2.233 . . . . 10.0 112.128 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -137.62 175.11 9.88 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 126.403 1.881 . . . . 10.0 107.467 -177.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.15 113.93 27.42 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-N 118.952 0.796 . . . . 10.0 109.884 -174.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.0 t60 -30.18 101.55 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 114.593 1.331 . . . . 10.0 114.593 -171.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -114.44 -147.97 9.6 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 176.247 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.33 -148.65 5.64 Favored Glycine 0 C--N 1.332 0.334 0 CA-C-O 118.237 -1.313 . . . . 10.0 109.902 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -62.76 -3.76 4.95 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 CA-C-N 120.225 2.012 . . . . 10.0 111.946 169.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -85.0 -19.61 31.77 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 118.452 -0.785 . . . . 10.0 111.041 171.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -130.55 162.41 29.35 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 123.849 1.785 . . . . 10.0 112.875 -166.309 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -85.43 -24.06 27.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 112.879 -1.964 . . . . 10.0 108.261 166.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -86.34 7.79 24.11 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.532 1.533 . . . . 10.0 110.85 -174.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 33.9 ptt-85 -48.33 126.83 11.93 Favored 'General case' 0 C--N 1.342 0.263 0 N-CA-C 106.507 -1.664 . . . . 10.0 106.507 166.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m80 -50.57 -57.47 8.08 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.11 0.411 . . . . 10.0 112.11 -167.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.7 p -173.9 -45.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 124.711 1.205 . . . . 10.0 108.33 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.14 56.44 0.73 Allowed Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.681 -1.367 . . . . 10.0 109.681 175.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -97.5 97.25 8.92 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 106.001 -1.851 . . . . 10.0 106.001 169.058 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 14.0 mt -76.26 -27.11 56.58 Favored 'General case' 0 C--N 1.34 0.163 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 173.418 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.71 -104.17 3.07 Favored Glycine 0 N--CA 1.439 -1.128 0 N-CA-C 108.638 -1.785 . . . . 10.0 108.638 168.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -122.3 100.28 6.87 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.055 1.342 . . . . 10.0 109.48 -167.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.2 m -95.74 136.92 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 C-N-CA 122.855 0.462 . . . . 10.0 110.187 178.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.8 m -85.19 119.41 25.54 Favored 'General case' 0 N--CA 1.439 -0.985 0 C-N-CA 127.437 2.295 . . . . 10.0 108.819 -177.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.57 134.65 39.52 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 123.568 0.747 . . . . 10.0 109.627 169.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.405 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 16.1 t70 -62.62 169.86 2.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 O-C-N 124.412 1.07 . . . . 10.0 108.751 166.419 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.405 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -61.86 -21.63 64.84 Favored 'General case' 0 N--CA 1.445 -0.705 0 C-N-CA 124.192 0.997 . . . . 10.0 112.892 172.454 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.17 -4.68 45.86 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.036 0.446 . . . . 10.0 110.691 171.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.22 6.3 86.44 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 120.671 -1.268 . . . . 10.0 110.839 178.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.18 106.13 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 127.339 2.256 . . . . 10.0 107.332 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.43 116.47 32.47 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 167.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.28 104.17 10.65 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 126.812 2.045 . . . . 10.0 109.841 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.12 131.86 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 172.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.3 m -157.52 57.63 0.5 Allowed 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.495 1.118 . . . . 10.0 109.476 173.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.84 150.75 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.835 -1.543 . . . . 10.0 106.835 178.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -128.19 150.81 49.85 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 108.626 170.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.13 124.42 6.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 108.873 -0.788 . . . . 10.0 108.873 172.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 11.0 t -79.07 0.48 27.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.291 1.037 . . . . 10.0 112.196 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.41 -24.75 17.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 CA-C-N 119.579 1.081 . . . . 10.0 109.486 177.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.0 159.28 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 124.599 1.16 . . . . 10.0 111.003 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.8 m -152.72 144.93 23.89 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.281 -2.118 . . . . 10.0 105.281 174.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.6 mt -65.04 -8.55 16.7 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 123.95 0.9 . . . . 10.0 111.828 176.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.6 m -150.94 137.96 19.15 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.031 -1.47 . . . . 10.0 107.031 169.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.26 -66.25 0.14 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 109.018 -1.633 . . . . 10.0 109.018 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -167.71 -51.44 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 125.58 1.552 . . . . 10.0 107.981 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.96 -36.19 62.07 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 114.914 -1.039 . . . . 10.0 109.128 -169.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 30.9 t 38.98 70.66 0.2 Allowed 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 126.692 1.997 . . . . 10.0 112.263 167.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -56.67 -10.22 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 114.113 1.153 . . . . 10.0 114.113 177.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 mm -33.87 -52.95 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.327 1.451 . . . . 10.0 112.98 170.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -96.81 9.48 66.11 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-O 118.937 -0.924 . . . . 10.0 114.153 -174.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.94 156.46 21.18 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 118.525 1.162 . . . . 10.0 109.742 176.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 59.1 m -90.4 131.58 36.1 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.768 0.827 . . . . 10.0 109.627 168.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -99.87 145.61 27.58 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 167.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.8 t -137.46 136.34 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 123.516 0.726 . . . . 10.0 109.17 -176.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.35 142.08 17.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 O-C-N 124.579 1.175 . . . . 10.0 108.811 167.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.5 m170 -121.72 162.03 21.53 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.896 1.443 . . . . 10.0 114.896 -175.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.46 ' CD ' ' HZ3' ' A' ' 122' ' ' LYS . 1.7 tm-20 -58.31 -50.87 72.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.266 1.427 . . . . 10.0 110.736 -179.726 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.46 ' HZ3' ' CD ' ' A' ' 121' ' ' GLU . 44.7 mttm -116.39 172.75 7.0 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 121.804 0.812 . . . . 10.0 112.203 -178.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.28 138.96 40.88 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 126.054 1.742 . . . . 10.0 108.981 174.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.497 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -77.36 164.76 25.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 122.232 1.015 . . . . 10.0 111.847 173.596 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -74.82 -8.15 55.57 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 113.608 -1.633 . . . . 10.0 111.298 178.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 14.5 mt 46.8 41.18 10.05 Favored 'General case' 0 C--N 1.339 0.113 0 C-N-CA 124.484 1.114 . . . . 10.0 109.831 -177.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 72.05 19.64 78.53 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 118.313 -1.271 . . . . 10.0 114.765 171.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.251 8.7 mtmp? -77.13 10.65 2.25 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 119.803 1.801 . . . . 10.0 114.991 -176.073 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.72 29.0 61.98 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 109.185 -1.566 . . . . 10.0 109.185 168.196 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -53.19 -30.01 38.17 Favored Glycine 0 N--CA 1.436 -1.351 0 CA-C-O 118.132 -1.371 . . . . 10.0 110.321 167.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 174.61 178.85 0.13 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 106.7 -1.593 . . . . 10.0 106.7 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 37.5 mp0 -49.48 -41.29 40.12 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 112.876 0.695 . . . . 10.0 112.876 179.179 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 -64.33 -24.13 67.54 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 121.244 -0.91 . . . . 10.0 110.684 -178.481 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 55.1 m -45.3 -44.58 11.58 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 122.964 0.506 . . . . 10.0 110.286 175.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 t -84.7 -1.09 55.7 Favored 'General case' 0 CA--C 1.541 0.628 0 O-C-N 124.049 0.843 . . . . 10.0 112.147 -170.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.1 mttt -118.82 -73.65 0.64 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.955 1.302 . . . . 10.0 110.275 -173.386 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.1 p -121.56 26.83 8.56 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 120.164 -1.585 . . . . 10.0 110.242 171.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 72.86 -91.57 0.6 Allowed Glycine 0 C--N 1.342 0.886 0 N-CA-C 109.934 -1.266 . . . . 10.0 109.934 174.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.38 39.12 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.195 1.398 . . . . 10.0 108.886 171.087 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.26 -16.61 62.49 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 121.473 -0.767 . . . . 10.0 112.77 -168.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.37 -162.59 54.66 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.102 -1.199 . . . . 10.0 110.102 175.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -51.9 126.77 19.14 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.036 1.334 . . . . 10.0 113.8 -168.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -64.7 72.89 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.229 1.812 . . . . 10.0 110.996 173.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.2 mt -51.12 -35.67 36.6 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 113.381 0.882 . . . . 10.0 113.381 -178.069 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 154.47 37.09 Favored 'General case' 0 CA--C 1.511 -0.555 0 O-C-N 121.61 -0.681 . . . . 10.0 109.948 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.6 p -153.24 153.7 33.21 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.583 -0.895 . . . . 10.0 108.583 -172.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.81 153.37 24.36 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 112.044 -0.422 . . . . 10.0 112.044 179.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 63.4 t -101.3 125.31 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.012 -2.218 . . . . 10.0 105.012 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.2 mt -68.55 164.93 2.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 CA-C-N 119.009 0.822 . . . . 10.0 110.403 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -160.5 150.66 20.84 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.576 1.56 . . . . 10.0 109.443 -172.136 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.3 mt -70.93 141.7 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.892 1.277 . . . . 10.0 109.023 -173.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.43 -46.51 2.87 Favored 'General case' 0 C--O 1.224 -0.268 0 C-N-CA 123.1 0.56 . . . . 10.0 110.674 170.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.7 tp60 . . . . . 0 C--O 1.25 1.107 0 C-N-CA 126.634 1.974 . . . . 10.0 112.082 -173.04 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.872 0 CA-C-O 117.571 -1.205 . . . . 10.0 108.993 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 t -61.27 -38.16 85.74 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 120.19 1.359 . . . . 10.0 108.852 172.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 36.9 tttt -132.03 156.35 46.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.447 1.499 . . . . 10.0 110.219 168.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.47 175.35 14.14 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 129.01 2.924 . . . . 10.0 106.504 166.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -133.6 179.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 118.677 0.671 . . . . 10.0 110.611 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.43 108.9 2.1 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.093 0.957 . . . . 10.0 109.189 165.039 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -95.17 124.28 47.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 122.959 0.503 . . . . 10.0 110.208 170.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -103.54 146.24 28.84 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 125.441 1.496 . . . . 10.0 110.275 176.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 5.4 tttm -161.73 158.61 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 169.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 179.86 -46.55 0.08 OUTLIER Glycine 0 N--CA 1.46 0.236 0 C-N-CA 118.927 -1.606 . . . . 10.0 113.638 169.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -72.59 -47.71 45.69 Favored 'General case' 0 N--CA 1.451 -0.375 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 -178.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.91 -73.84 0.29 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 114.331 -1.304 . . . . 10.0 109.845 171.115 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -59.07 -34.74 98.98 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.738 2.959 . . . . 10.0 111.18 174.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.5 t -62.2 114.04 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.12 -1.067 . . . . 10.0 108.12 176.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.87 118.6 22.97 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 106.339 -1.726 . . . . 10.0 106.339 168.589 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -102.47 141.12 15.14 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-O 118.598 -1.112 . . . . 10.0 110.48 174.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 9.4 mt -139.78 94.2 0.77 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 C-N-CA 123.874 0.87 . . . . 10.0 109.063 -173.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.7 mm -105.71 139.77 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 C-N-CA 125.658 1.583 . . . . 10.0 112.623 -178.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -106.75 126.6 52.49 Favored 'General case' 0 C--N 1.34 0.179 0 N-CA-C 106.452 -1.685 . . . . 10.0 106.452 167.059 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -104.16 112.42 25.42 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 107.057 -1.46 . . . . 10.0 107.057 168.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -126.82 136.32 52.2 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 118.462 0.573 . . . . 10.0 112.35 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -105.48 112.76 25.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.62 1.568 . . . . 10.0 106.873 169.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.23 34.95 1.34 Allowed 'General case' 0 C--O 1.235 0.308 0 N-CA-C 111.93 0.344 . . . . 10.0 111.93 -177.023 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -142.9 166.35 24.88 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 104.903 -2.258 . . . . 10.0 104.903 169.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 29.4 t -91.28 14.98 12.93 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 109.031 -0.729 . . . . 10.0 109.031 -173.365 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -112.62 7.61 18.84 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 123.832 0.853 . . . . 10.0 108.892 167.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.57 47.13 23.65 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.59 -1.117 . . . . 10.0 114.496 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -65.26 115.84 3.55 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 CA-C-N 119.834 1.817 . . . . 10.0 107.652 170.375 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t -77.27 84.65 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 105.31 -2.107 . . . . 10.0 105.31 175.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -74.35 117.4 16.12 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.024 -1.473 . . . . 10.0 107.024 179.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.42 58.77 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 C-N-CA 125.085 1.354 . . . . 10.0 108.121 -169.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.4 p90 -81.48 143.21 32.24 Favored 'General case' 0 C--N 1.341 0.209 0 C-N-CA 119.134 -1.026 . . . . 10.0 111.996 -176.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.81 -169.09 41.39 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.636 -1.269 . . . . 10.0 110.106 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 m -153.24 133.11 13.2 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.3 pt -103.63 147.72 9.53 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 N-CA-C 107.995 -1.113 . . . . 10.0 107.995 167.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -124.81 149.98 46.85 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 169.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.48 -6.7 36.24 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 123.428 0.537 . . . . 10.0 112.519 171.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -63.93 174.43 1.49 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.956 0.878 . . . . 10.0 109.965 169.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -101.76 170.81 7.92 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 105.898 -1.89 . . . . 10.0 105.898 165.414 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -59.84 166.67 2.52 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 118.661 0.664 . . . . 10.0 111.829 -171.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.49 -171.56 45.75 Favored Glycine 0 N--CA 1.446 -0.647 0 O-C-N 121.478 -0.764 . . . . 10.0 111.72 169.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -77.5 144.31 37.8 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.259 1.424 . . . . 10.0 111.224 -174.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -147.48 127.88 14.01 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.518 1.127 . . . . 10.0 112.633 -173.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -18.69 128.71 0.01 OUTLIER Glycine 0 C--N 1.342 0.881 0 C-N-CA 127.499 2.476 . . . . 10.0 114.179 165.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.75 104.94 3.23 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 118.605 1.203 . . . . 10.0 109.793 167.73 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.51 176.46 10.93 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 112.766 0.654 . . . . 10.0 112.766 176.385 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 23.4 m -89.82 158.69 2.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 113.601 -1.636 . . . . 10.0 108.626 168.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 74.8 m-70 -136.47 78.11 1.69 Allowed 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 123.586 0.755 . . . . 10.0 111.138 176.021 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.8 tt0 47.65 -94.42 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.792 1.237 . . . . 10.0 113.027 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -78.76 172.03 14.32 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.582 0.628 . . . . 10.0 110.01 -173.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.97 -23.1 23.74 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.553 -1.019 . . . . 10.0 110.553 170.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -37.71 135.07 0.64 Allowed 'General case' 0 C--N 1.343 0.306 0 C-N-CA 124.598 1.159 . . . . 10.0 110.863 170.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -146.05 23.99 1.33 Allowed 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 114.75 -1.114 . . . . 10.0 110.362 173.152 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 2.7 m -52.43 -36.83 55.34 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.065 0.848 . . . . 10.0 110.982 -173.513 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.56 -21.72 28.41 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.29 1.436 . . . . 10.0 113.697 177.178 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.48 101.92 1.45 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.813 1.197 . . . . 10.0 110.183 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.314 2.6 p 17.43 57.65 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 127.752 2.421 . . . . 10.0 114.151 -170.377 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.8 m -130.48 -61.9 0.94 Allowed 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.479 -2.045 . . . . 10.0 105.479 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 39.3 t -69.66 -35.68 75.38 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.009 1.324 . . . . 10.0 111.323 -178.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.88 -47.41 0.13 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 127.122 2.169 . . . . 10.0 114.181 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 138.5 172.54 12.6 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.243 -1.543 . . . . 10.0 109.243 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -78.67 -137.35 0.02 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.222 0 N-CA-C 104.156 -3.055 . . . . 10.0 104.156 166.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.421 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.3 m170 -100.99 50.68 0.86 Allowed 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 121.067 1.758 . . . . 10.0 109.557 170.137 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -71.79 80.05 0.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.169 0.985 . . . . 10.0 110.033 177.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.5 p-10 -80.15 156.31 74.26 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 125.474 1.509 . . . . 10.0 110.222 172.614 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -63.51 -50.1 3.75 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.489 2.126 . . . . 10.0 111.292 177.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.58 57.72 1.64 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.213 0.605 . . . . 10.0 109.887 179.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.9 p -51.35 114.21 1.16 Allowed 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.607 1.163 . . . . 10.0 109.999 -176.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.2 mtt-85 -131.33 -86.49 0.49 Allowed 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 104.996 -2.224 . . . . 10.0 104.996 -176.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 ptpp? -163.26 162.77 25.42 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 167.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 66.9 t60 -58.28 132.67 54.31 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 118.358 -1.337 . . . . 10.0 107.655 168.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.37 -133.23 2.64 Favored Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 169.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 163.51 -161.28 33.99 Favored Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 108.376 -1.89 . . . . 10.0 108.376 178.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.74 4.61 0.8 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.864 1.71 . . . . 10.0 111.928 168.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -114.03 7.94 16.94 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 119.225 0.92 . . . . 10.0 110.481 170.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -125.93 163.09 23.74 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 119.733 1.151 . . . . 10.0 108.977 167.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -81.61 -30.06 33.02 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 169.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -119.65 61.5 0.83 Allowed 'General case' 0 N--CA 1.436 -1.168 0 CA-C-O 122.095 0.95 . . . . 10.0 110.859 -168.489 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . 0.46 HH12 ' CG ' ' B' ' 101' ' ' ASP . 0.3 OUTLIER -56.32 164.39 1.36 Allowed 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 114.393 -1.276 . . . . 10.0 108.697 164.833 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.6 m170 -65.99 -84.57 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 N-CA-C 108.569 -0.9 . . . . 10.0 108.569 169.36 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 49.2 t -149.82 -82.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 104.186 -2.524 . . . . 10.0 104.186 169.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.83 53.89 4.77 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.566 -0.614 . . . . 10.0 111.566 -178.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -93.9 98.78 11.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 104.39 -2.448 . . . . 10.0 104.39 168.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 37.1 mt -81.92 -36.26 28.26 Favored 'General case' 0 C--N 1.334 -0.095 0 N-CA-C 105.744 -1.947 . . . . 10.0 105.744 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.26 -92.06 0.64 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 106.717 -2.553 . . . . 10.0 106.717 169.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -155.82 155.73 33.5 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 122.793 0.437 . . . . 10.0 111.45 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.48 145.68 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 O-C-N 124.762 1.289 . . . . 10.0 108.507 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.0 m -93.43 110.42 21.98 Favored 'General case' 0 N--CA 1.436 -1.135 0 C-N-CA 128.497 2.719 . . . . 10.0 108.88 -172.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.3 135.59 33.49 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 123.771 0.828 . . . . 10.0 110.117 174.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -61.65 168.51 2.91 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 124.091 0.956 . . . . 10.0 109.107 166.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.78 -30.67 45.7 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.492 0.717 . . . . 10.0 111.079 172.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -78.68 1.6 22.36 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-O 121.25 0.548 . . . . 10.0 111.454 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.92 90.7 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 120.843 -1.161 . . . . 10.0 110.947 176.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.1 t -79.77 104.72 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.059 0 C-N-CA 127.09 2.156 . . . . 10.0 107.013 179.242 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -107.55 115.09 29.53 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 168.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.7 123.36 27.59 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 127.381 2.272 . . . . 10.0 108.622 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.0 t -110.79 131.43 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 C-N-CA 125.494 1.517 . . . . 10.0 107.279 178.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 93.0 p -156.98 59.14 0.52 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 123.316 0.646 . . . . 10.0 109.552 177.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.83 154.82 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -176.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -102.33 153.21 20.22 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 126.639 1.976 . . . . 10.0 107.382 170.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . 0.46 ' CG ' HH12 ' B' ' 79' ' ' ARG . 23.8 t0 -149.06 85.17 1.46 Allowed 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.583 0.706 . . . . 10.0 109.292 174.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.8 p -90.25 38.11 0.92 Allowed 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.81 0.844 . . . . 10.0 109.663 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 26.1 t -106.75 -46.19 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 107.444 -1.317 . . . . 10.0 107.444 176.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.261 0.0 OUTLIER -100.88 176.01 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 114.155 1.168 . . . . 10.0 114.155 175.465 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -136.29 142.8 43.95 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.517 -1.66 . . . . 10.0 106.517 169.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -65.58 -25.72 67.54 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.131 0.573 . . . . 10.0 110.117 171.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.1 p -140.76 118.94 12.0 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 170.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.04 -63.04 0.05 OUTLIER Glycine 0 C--N 1.333 0.41 0 N-CA-C 109.024 -1.63 . . . . 10.0 109.024 -177.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -163.04 -51.87 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 125.877 1.671 . . . . 10.0 107.489 177.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -74.33 -38.61 63.23 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 114.413 -1.267 . . . . 10.0 108.621 -169.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.9 t 47.76 75.36 0.13 Allowed 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 126.166 1.786 . . . . 10.0 109.301 169.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 12.5 pt -68.97 65.19 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.324 0 CA-C-O 122.786 1.279 . . . . 10.0 110.388 173.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.6 mm -110.61 151.73 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 129.117 2.967 . . . . 10.0 105.275 167.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 55.31 35.64 61.09 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 124.866 1.222 . . . . 10.0 113.746 171.382 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 83.7 mtt85 -113.96 154.62 27.28 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.305 1.842 . . . . 10.0 107.51 171.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 90.2 m -86.06 133.95 33.86 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.01 0.924 . . . . 10.0 109.7 177.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -98.42 147.46 24.69 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 125.212 1.405 . . . . 10.0 107.297 166.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.57 141.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-N 118.563 0.62 . . . . 10.0 109.369 176.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -103.32 139.45 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 C-N-CA 124.575 1.15 . . . . 10.0 108.981 168.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.6 m-70 -115.91 164.25 14.69 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.814 1.413 . . . . 10.0 114.814 -175.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -59.43 -49.43 77.85 Favored 'General case' 0 C--N 1.343 0.293 0 C-N-CA 123.756 0.823 . . . . 10.0 110.438 178.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.2 mttt -121.24 175.56 6.06 Favored 'General case' 0 N--CA 1.462 0.169 0 N-CA-C 112.229 0.455 . . . . 10.0 112.229 -169.186 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.54 139.03 39.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.201 1.0 . . . . 10.0 109.332 173.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.67 144.1 30.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.059 0.944 . . . . 10.0 108.827 167.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -79.2 28.31 0.23 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 123.395 0.678 . . . . 10.0 111.236 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 6.6 mt 23.86 60.23 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 128.685 2.794 . . . . 10.0 112.157 -168.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 92.63 -35.58 4.0 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 126.192 1.853 . . . . 10.0 112.147 174.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.2 mtmm -84.46 44.15 1.02 Allowed 'General case' 0 CA--C 1.537 0.465 0 O-C-N 121.256 -1.144 . . . . 10.0 111.247 -170.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.44 -18.12 46.8 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 126.518 2.008 . . . . 10.0 110.159 169.371 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.15 35.82 91.41 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 123.965 0.793 . . . . 10.0 112.415 172.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -144.48 169.48 17.87 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 107.916 -1.142 . . . . 10.0 107.916 172.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -52.64 -47.4 67.09 Favored 'General case' 0 N--CA 1.444 -0.736 0 CA-C-O 121.805 0.812 . . . . 10.0 110.351 -177.44 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -65.36 -31.59 72.79 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 121.32 -0.863 . . . . 10.0 111.234 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 12.3 p -55.5 -42.14 74.03 Favored 'General case' 0 N--CA 1.447 -0.604 0 O-C-N 120.818 -1.176 . . . . 10.0 111.353 171.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.6 t -80.91 -24.16 38.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 119.835 -0.746 . . . . 10.0 111.202 -176.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 ttmm -80.81 -50.57 9.65 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 125.886 1.674 . . . . 10.0 111.533 -176.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.421 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 26.1 p -136.2 -15.18 1.72 Allowed 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 114.441 1.274 . . . . 10.0 114.441 176.772 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.53 3.07 55.43 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-O 118.286 -1.286 . . . . 10.0 113.884 -179.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 29.1 m120 73.23 26.97 2.02 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.101 1.45 . . . . 10.0 112.359 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.47 -2.29 13.48 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.272 -0.892 . . . . 10.0 113.298 176.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.0 -170.15 50.92 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 -175.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.51 169.66 2.87 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.167 0.987 . . . . 10.0 112.135 -177.01 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.79 115.96 18.82 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.85 2.06 . . . . 10.0 109.814 168.664 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.423 ' CD2' ' N ' ' B' ' 144' ' ' LEU . 0.4 OUTLIER -92.0 -36.84 13.18 Favored 'General case' 0 C--N 1.34 0.169 0 CA-C-N 119.753 1.16 . . . . 10.0 111.414 -176.263 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.36 149.78 32.4 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 176.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -118.63 142.44 47.64 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.796 1.638 . . . . 10.0 107.672 -168.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -137.06 161.19 25.14 Favored Glycine 0 C--N 1.331 0.265 0 N-CA-C 109.79 -1.324 . . . . 10.0 109.79 171.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -123.52 152.27 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 104.246 -2.501 . . . . 10.0 104.246 171.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.0 mt -67.41 -91.67 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 124.018 0.927 . . . . 10.0 111.625 -167.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.84 136.2 9.22 Favored Glycine 0 CA--C 1.532 1.112 0 N-CA-C 111.68 -0.568 . . . . 10.0 111.68 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 9.5 pt -85.34 146.78 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 C-N-CA 124.534 1.134 . . . . 10.0 110.122 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.87 -24.36 8.19 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.575 0.75 . . . . 10.0 112.8 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.88 0 C-N-CA 124.355 1.062 . . . . 10.0 108.195 -174.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.86 0 CA-C-O 117.89 -1.053 . . . . 10.0 109.158 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -116.81 -50.3 2.61 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 123.947 0.899 . . . . 10.0 112.304 -176.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -111.87 125.73 54.34 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 126.638 1.975 . . . . 10.0 108.825 -176.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 164.22 30.54 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.694 1.198 . . . . 10.0 108.286 170.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.4 m -139.04 164.46 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 C-N-CA 123.7 0.8 . . . . 10.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.66 118.72 15.38 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.644 -0.873 . . . . 10.0 108.644 168.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -92.34 110.23 22.57 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.33 -0.989 . . . . 10.0 108.33 168.248 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -95.0 144.86 25.35 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 108.731 -0.84 . . . . 10.0 108.731 177.032 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.2 mtmt -156.45 161.49 40.06 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 172.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.69 -51.59 0.09 OUTLIER Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.071 -1.061 . . . . 10.0 113.653 169.29 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.4 -44.57 62.3 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.49 -1.3 . . . . 10.0 107.49 -175.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.19 -71.01 0.4 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.684 -1.366 . . . . 10.0 109.684 169.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -58.06 -35.54 98.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 123.089 2.526 . . . . 10.0 111.273 172.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.3 t -64.65 107.33 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 178.264 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.45 104.87 10.0 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 172.489 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.37 137.1 14.15 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 176.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.7 mt -139.08 87.93 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.282 0 N-CA-C 107.381 -1.34 . . . . 10.0 107.381 -175.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -99.75 141.64 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.16 0 C-N-CA 124.819 1.248 . . . . 10.0 110.059 -178.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -126.27 113.45 16.97 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.476 1.91 . . . . 10.0 108.569 175.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -93.51 115.02 27.53 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 126.367 1.867 . . . . 10.0 108.545 177.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -117.5 130.04 56.19 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.85 1.055 . . . . 10.0 113.85 171.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -105.2 111.88 24.8 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 104.545 -2.391 . . . . 10.0 104.545 166.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -65.0 -36.78 85.52 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.952 -0.468 . . . . 10.0 111.131 -172.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -137.6 -165.43 1.77 Allowed 'General case' 0 N--CA 1.436 -1.175 0 N-CA-C 104.521 -2.4 . . . . 10.0 104.521 171.508 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.0 t -78.6 -24.48 45.39 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 118.97 0.805 . . . . 10.0 110.206 173.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.6 m-80 -91.83 -17.88 24.65 Favored 'General case' 0 N--CA 1.448 -0.574 0 C-N-CA 124.648 1.179 . . . . 10.0 110.551 -175.26 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.22 144.82 41.74 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 178.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -63.63 156.87 54.62 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 N-CA-C 108.116 -1.532 . . . . 10.0 108.116 169.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 75.2 t -79.0 102.31 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 N-CA-C 106.036 -1.839 . . . . 10.0 106.036 175.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.2 mtpp -79.0 105.38 10.3 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 105.49 -2.041 . . . . 10.0 105.49 170.022 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -100.58 97.85 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 C-N-CA 125.421 1.488 . . . . 10.0 107.502 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.6 p90 -103.26 174.59 5.8 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.322 0.582 . . . . 10.0 110.205 169.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.07 170.93 37.97 Favored Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 110.79 -0.924 . . . . 10.0 110.79 177.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.6 t -136.82 96.39 3.31 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 177.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 pt -81.24 140.59 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 169.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.512 ' HZ1' ' CG ' ' A' ' 92' ' ' ASP . 5.6 tttm -112.83 158.08 20.59 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 108.522 -0.918 . . . . 10.0 108.522 167.339 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.12 -7.27 58.57 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 123.579 0.609 . . . . 10.0 112.678 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -67.44 170.07 8.04 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 118.235 1.017 . . . . 10.0 109.86 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -103.65 153.33 20.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.688 -1.597 . . . . 10.0 106.688 167.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.6 143.88 4.72 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.25 1.02 . . . . 10.0 112.046 -170.497 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.48 -173.35 24.89 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 123.846 0.736 . . . . 10.0 112.269 171.541 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.26 145.27 54.41 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.594 1.957 . . . . 10.0 111.493 -175.162 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -146.31 141.25 27.1 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.398 1.079 . . . . 10.0 111.77 175.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.402 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -24.69 123.58 0.03 OUTLIER Glycine 0 C--N 1.344 1.008 0 C-N-CA 126.493 1.996 . . . . 10.0 112.219 165.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -144.55 104.54 4.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 119.735 1.767 . . . . 10.0 109.502 171.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.26 170.41 20.1 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 121.835 0.826 . . . . 10.0 111.557 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.4 m -88.54 149.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-N 112.139 -2.301 . . . . 10.0 106.259 167.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -120.6 128.08 52.7 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 103.782 -2.673 . . . . 10.0 103.782 169.049 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -58.54 -51.35 70.25 Favored 'General case' 0 N--CA 1.44 -0.932 0 O-C-N 124.99 1.431 . . . . 10.0 110.016 -168.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -79.55 137.84 37.29 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 -179.542 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.34 25.57 9.72 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.853 -0.899 . . . . 10.0 110.853 173.077 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.7 p30 -75.84 72.48 2.73 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 123.542 1.639 . . . . 10.0 109.317 170.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -75.82 6.24 5.28 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 113.658 -1.61 . . . . 10.0 112.66 -173.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -39.2 -44.26 1.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 128.207 2.603 . . . . 10.0 111.982 175.221 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.37 -19.97 48.89 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.247 1.019 . . . . 10.0 113.258 -177.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.79 87.13 1.47 Allowed Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.404 -1.079 . . . . 10.0 110.404 -177.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 m 52.31 29.14 6.38 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.417 1.487 . . . . 10.0 112.407 172.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.5 m -117.53 -54.83 2.34 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.295 -1.372 . . . . 10.0 107.295 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.1 m -77.01 -16.19 59.39 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 123.961 0.905 . . . . 10.0 112.579 -171.081 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -53.03 -12.88 0.38 Allowed 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.979 1.712 . . . . 10.0 115.234 -170.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.23 125.87 3.06 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 118.647 -1.085 . . . . 10.0 110.436 171.621 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -75.53 64.01 6.47 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.49 2.793 . . . . 10.0 111.732 179.326 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 26.7 m170 67.07 53.91 0.78 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 128.692 2.797 . . . . 10.0 111.108 175.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 -71.85 43.77 0.1 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 114.604 1.335 . . . . 10.0 114.604 -173.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -56.57 147.38 50.75 Favored Pre-proline 0 CA--C 1.54 0.568 0 O-C-N 120.817 -1.177 . . . . 10.0 112.565 -174.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -64.89 -43.03 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.81 2.34 . . . . 10.0 110.853 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 75.9 mt -76.69 54.6 0.98 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.484 0.714 . . . . 10.0 109.381 176.493 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.9 p -35.47 109.75 0.09 Allowed 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 126.019 1.727 . . . . 10.0 110.868 -173.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -131.71 -174.03 3.3 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 104.474 -2.417 . . . . 10.0 104.474 -170.126 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -82.39 159.02 23.1 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 106.262 -1.755 . . . . 10.0 106.262 169.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.7 t60 -59.04 123.5 16.79 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 106.826 -1.546 . . . . 10.0 106.826 162.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.93 -144.0 5.39 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 108.635 -1.786 . . . . 10.0 108.635 174.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.41 -163.39 29.72 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 109.746 -1.342 . . . . 10.0 109.746 169.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -63.99 3.68 0.69 Allowed 'Trans proline' 0 N--CA 1.455 -0.761 0 CA-C-N 119.763 1.782 . . . . 10.0 111.99 169.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 42.3 mmtt -100.19 -16.13 17.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.082 -0.961 . . . . 10.0 110.707 171.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -114.54 165.95 12.23 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 119.051 0.841 . . . . 10.0 109.901 -178.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -77.25 -38.61 50.72 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 105.431 -2.063 . . . . 10.0 105.431 167.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.277 1.5 pt-20 -103.48 49.89 0.82 Allowed 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 115.461 1.652 . . . . 10.0 115.461 -160.843 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -55.65 159.31 3.03 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 125.651 1.581 . . . . 10.0 108.799 167.656 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -66.69 -65.86 0.63 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.637 0.732 . . . . 10.0 109.619 168.372 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.3 p -161.85 -69.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 N-CA-C 107.31 -1.367 . . . . 10.0 107.31 177.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.48 56.23 0.47 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 109.598 -1.401 . . . . 10.0 109.598 177.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -87.98 91.26 8.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 104.058 -2.571 . . . . 10.0 104.058 167.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.9 -32.36 69.28 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.1 -91.7 0.7 Allowed Glycine 0 N--CA 1.434 -1.485 0 N-CA-C 108.273 -1.931 . . . . 10.0 108.273 167.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -145.27 147.35 32.28 Favored 'General case' 0 N--CA 1.447 -0.596 0 O-C-N 123.818 0.364 . . . . 10.0 110.755 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.2 m -124.21 139.08 51.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 171.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 m -89.99 113.92 25.67 Favored 'General case' 0 N--CA 1.441 -0.888 0 C-N-CA 127.887 2.475 . . . . 10.0 107.711 -178.371 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.46 138.01 32.09 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 109.623 -0.51 . . . . 10.0 109.623 169.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -65.72 170.65 4.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.959 1.304 . . . . 10.0 109.658 168.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -50.69 -34.51 26.98 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.467 -0.788 . . . . 10.0 110.894 169.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.512 ' CG ' ' HZ1' ' A' ' 36' ' ' LYS . 25.4 t0 -81.03 5.35 16.74 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.38 0.609 . . . . 10.0 112.039 -178.677 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.09 4.5 83.59 Favored Glycine 0 C--N 1.342 0.908 0 O-C-N 120.877 -1.139 . . . . 10.0 111.341 175.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.8 t -79.68 109.16 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.975 0 C-N-CA 127.76 2.424 . . . . 10.0 106.597 176.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.66 115.88 31.0 Favored 'General case' 0 CA--C 1.513 -0.459 0 N-CA-C 108.087 -1.079 . . . . 10.0 108.087 167.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -81.97 86.21 6.58 Favored 'General case' 0 N--CA 1.436 -1.157 0 C-N-CA 127.458 2.303 . . . . 10.0 109.294 179.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 32.9 t -75.72 131.94 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 N-CA-C 105.097 -2.186 . . . . 10.0 105.097 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -158.3 64.02 0.44 Allowed 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 122.995 0.518 . . . . 10.0 110.198 -175.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -111.47 158.6 11.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 106.948 -1.501 . . . . 10.0 106.948 -175.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -135.19 137.71 42.93 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 123.797 0.839 . . . . 10.0 109.942 168.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.39 147.43 43.4 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.124 0.97 . . . . 10.0 108.809 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 22.9 p -110.45 -2.14 16.7 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.076 1.75 . . . . 10.0 113.882 -172.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.9 p -97.22 -38.78 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 119.821 1.192 . . . . 10.0 109.081 172.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -65.22 136.91 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.953 -1.869 . . . . 10.0 105.953 167.158 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 25.2 m -154.86 132.42 11.28 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 108.943 -0.762 . . . . 10.0 108.943 -175.248 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -78.75 61.02 2.92 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.805 -1.183 . . . . 10.0 107.805 175.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.8 m -84.12 -119.27 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 123.81 0.844 . . . . 10.0 110.165 -174.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.96 -47.32 0.05 OUTLIER Glycine 0 CA--C 1.524 0.628 0 N-CA-C 107.91 -2.076 . . . . 10.0 107.91 -174.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -64.54 -59.32 4.44 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.899 0.88 . . . . 10.0 109.04 169.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.6 -39.05 58.53 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.276 -0.875 . . . . 10.0 108.658 -174.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.6 t 39.01 76.38 0.06 Allowed 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.525 1.53 . . . . 10.0 112.702 171.18 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pp -61.36 -26.94 40.84 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 115.899 -0.592 . . . . 10.0 110.382 168.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 32.2 mm -38.67 132.59 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 C-N-CA 126.003 1.721 . . . . 10.0 111.781 173.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.63 7.96 86.73 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-O 118.487 -1.174 . . . . 10.0 113.613 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 64.1 mtt85 -77.57 158.72 29.7 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 118.742 1.271 . . . . 10.0 109.673 169.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.82 115.5 27.52 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.111 -0.7 . . . . 10.0 109.111 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -83.97 138.27 33.21 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 170.028 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 71.9 t -125.34 137.09 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.99 -1.115 . . . . 10.0 107.99 178.033 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.06 132.95 46.99 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 105.542 -2.021 . . . . 10.0 105.542 166.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.402 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 8.5 m-70 -106.88 154.63 20.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 123.186 1.47 . . . . 10.0 114.623 -174.233 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -41.75 -61.92 1.0 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 128.398 2.679 . . . . 10.0 109.157 177.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mtmt -110.0 169.25 8.85 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 125.463 1.505 . . . . 10.0 111.84 -176.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.74 136.9 56.85 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.131 -1.395 . . . . 10.0 108.035 169.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -84.57 158.94 20.77 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 123.763 0.825 . . . . 10.0 110.169 170.687 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -104.02 17.06 24.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.07 0.948 . . . . 10.0 111.701 179.542 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 64.7 mt 43.56 40.72 2.99 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 119.269 0.941 . . . . 10.0 112.782 178.493 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.63 -4.16 53.7 Favored Glycine 0 C--N 1.336 0.565 0 CA-C-O 118.924 -0.931 . . . . 10.0 114.068 175.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mttt -118.01 30.69 7.1 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 118.136 0.968 . . . . 10.0 111.217 -166.162 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.65 -36.53 58.35 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 127.521 2.486 . . . . 10.0 110.907 171.674 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 72.45 43.68 44.38 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 111.179 -0.768 . . . . 10.0 111.179 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -145.34 168.93 19.3 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 105.983 -1.858 . . . . 10.0 105.983 171.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.407 ' OE1' ' NZ ' ' A' ' 136' ' ' LYS . 15.8 tm-20 -52.57 -42.56 64.6 Favored 'General case' 0 N--CA 1.441 -0.899 0 CA-C-O 121.239 0.542 . . . . 10.0 110.958 177.627 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -63.49 -31.83 73.1 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.263 -0.898 . . . . 10.0 113.23 178.605 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 17.1 t -43.96 -48.4 8.61 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.226 1.01 . . . . 10.0 109.778 176.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 7.8 t -80.4 -3.72 50.82 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-O 118.333 -0.841 . . . . 10.0 112.134 -169.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.407 ' NZ ' ' OE1' ' A' ' 132' ' ' GLU . 41.9 mtmt -111.61 -79.41 0.58 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.317 1.447 . . . . 10.0 110.308 -177.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.9 p -105.94 1.85 27.0 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 120.13 1.332 . . . . 10.0 113.272 177.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.72 27.24 35.64 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-O 118.904 -0.942 . . . . 10.0 113.139 169.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.2 m120 59.36 21.9 10.25 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 118.382 1.091 . . . . 10.0 112.978 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.73 -10.6 48.68 Favored 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 124.897 1.279 . . . . 10.0 112.645 176.635 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.61 -161.83 51.68 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 110.268 -1.133 . . . . 10.0 110.268 177.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.8 m -58.74 139.97 55.47 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 124.129 0.972 . . . . 10.0 112.651 -167.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.13 68.16 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.813 1.245 . . . . 10.0 109.329 167.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . 0.261 0.4 OUTLIER -64.32 -17.04 63.29 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.616 0.969 . . . . 10.0 113.616 -169.144 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 150.92 24.9 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.099 -0.704 . . . . 10.0 109.099 168.094 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.5 p -153.72 165.35 36.25 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.39 0.276 . . . . 10.0 111.034 -177.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.0 -168.04 11.77 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.438 1.018 . . . . 10.0 111.559 -177.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 33.7 t -136.92 130.75 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 104.487 -2.412 . . . . 10.0 104.487 176.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -66.47 139.7 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-N 119.438 1.017 . . . . 10.0 110.815 178.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.6 146.67 18.58 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 124.829 1.204 . . . . 10.0 111.214 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 74.8 mt -68.83 152.26 9.63 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 177.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.36 -36.11 1.14 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 114.515 1.302 . . . . 10.0 114.515 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.121 0 N-CA-C 117.529 2.418 . . . . 10.0 117.529 -177.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . 0.489 ' C ' ' H ' ' B' ' 3' ' ' LYS . . . . . . . . 0 N--CA 1.474 0.74 0 CA-C-O 118.232 -0.89 . . . . 10.0 109.099 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . 0.282 9.2 t 70.62 -29.68 0.19 Allowed 'General case' 0 C--N 1.343 0.312 0 C-N-CA 131.397 3.879 . . . . 10.0 111.835 175.036 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . 0.489 ' H ' ' C ' ' B' ' 1' ' ' ALA . 61.3 tttt -152.15 131.37 12.77 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 126.288 1.835 . . . . 10.0 106.98 -168.843 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.59 165.96 25.85 Favored 'General case' 0 CA--C 1.522 -0.131 0 C-N-CA 124.476 1.11 . . . . 10.0 108.54 171.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 7.7 m -131.38 179.97 3.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.395 0 C-N-CA 122.889 0.476 . . . . 10.0 110.563 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.27 110.66 3.74 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 124.459 1.104 . . . . 10.0 108.561 167.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -96.88 92.23 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 C-N-CA 124.065 0.946 . . . . 10.0 109.419 171.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -80.32 137.82 36.64 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.197 0.999 . . . . 10.0 110.608 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.5 tttt -156.25 160.67 40.0 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.972 -1.122 . . . . 10.0 107.972 170.263 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.41 -50.06 0.05 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 121.333 -0.46 . . . . 10.0 112.215 171.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.26 -46.58 32.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 106.738 -1.578 . . . . 10.0 106.738 -173.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.94 -66.26 0.57 Allowed Glycine 0 CA--C 1.527 0.815 0 CA-C-N 113.891 -1.504 . . . . 10.0 110.382 -179.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -60.57 -35.41 90.14 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.964 2.442 . . . . 10.0 111.323 174.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.0 t -70.35 111.21 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 N-CA-C 107.582 -1.266 . . . . 10.0 107.582 175.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.74 110.04 11.83 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.88 -1.896 . . . . 10.0 105.88 168.626 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -97.79 133.37 11.32 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 110.012 -1.235 . . . . 10.0 110.012 179.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 5.4 mt -137.57 87.77 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 108.252 -1.018 . . . . 10.0 108.252 -169.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -99.23 152.17 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.133 0 C-N-CA 124.672 1.189 . . . . 10.0 110.546 178.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 21.1 m-80 -134.43 121.57 21.29 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 128.457 2.703 . . . . 10.0 107.807 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -106.58 116.66 32.3 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 174.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.91 143.67 44.77 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.091 0.86 . . . . 10.0 112.861 169.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -93.69 94.02 8.35 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.617 1.567 . . . . 10.0 108.808 -176.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.2 tmtt? -44.51 -61.33 1.58 Allowed 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 126.369 1.868 . . . . 10.0 110.943 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -145.21 176.35 9.6 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 104.459 -2.423 . . . . 10.0 104.459 170.458 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 23.1 t -86.8 -2.29 58.44 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.976 -0.379 . . . . 10.0 109.976 174.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 29.5 m-80 -130.28 35.4 4.09 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 124.251 1.02 . . . . 10.0 108.4 169.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -126.87 160.16 21.13 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 106.93 -2.468 . . . . 10.0 106.93 170.466 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -66.48 148.79 84.34 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 121.841 1.694 . . . . 10.0 109.553 179.05 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.5 t -78.82 124.95 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 104.313 -2.477 . . . . 10.0 104.313 168.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -98.34 122.4 41.47 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 106.313 -1.736 . . . . 10.0 106.313 168.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.2 p -106.18 106.03 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 C-N-CA 127.708 2.403 . . . . 10.0 105.509 177.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -130.45 173.08 11.18 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 120.9 0.381 . . . . 10.0 110.844 179.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.76 -153.29 25.21 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 107.152 -2.379 . . . . 10.0 107.152 169.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 5.4 m -153.15 145.49 23.99 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 119.044 -1.063 . . . . 10.0 110.607 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 pt -111.97 136.75 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 CA-C-N 115.948 -0.569 . . . . 10.0 109.679 168.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.5 tptt -110.77 141.27 44.32 Favored 'General case' 0 N--CA 1.441 -0.922 0 N-CA-C 106.289 -1.745 . . . . 10.0 106.289 171.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.3 -6.37 23.16 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 123.757 0.694 . . . . 10.0 112.991 169.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -65.19 176.21 1.4 Allowed 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 118.147 0.974 . . . . 10.0 111.022 176.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -109.82 156.09 20.8 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 168.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -53.33 132.48 39.29 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.792 1.637 . . . . 10.0 111.443 -170.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 122.13 -173.2 15.81 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 118.724 0.693 . . . . 10.0 112.037 173.275 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.66 152.84 39.13 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.741 1.616 . . . . 10.0 110.756 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -150.31 147.73 27.98 Favored 'General case' 0 C--N 1.344 0.367 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -174.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -28.01 121.0 0.06 OUTLIER Glycine 0 C--N 1.34 0.784 0 C-N-CA 128.822 3.105 . . . . 10.0 113.14 161.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -153.73 101.31 2.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 119.712 1.756 . . . . 10.0 111.6 168.286 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.41 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -154.23 173.1 16.58 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 114.573 1.323 . . . . 10.0 114.573 -178.943 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 33.5 m -82.0 151.2 4.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 112.995 -1.912 . . . . 10.0 109.449 168.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -133.1 82.91 2.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.089 -1.078 . . . . 10.0 108.089 172.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 35.04 -80.8 0.0 OUTLIER 'General case' 0 C--O 1.239 0.506 0 C-N-CA 127.674 2.389 . . . . 10.0 115.135 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -77.84 173.78 11.75 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 122.043 0.925 . . . . 10.0 110.089 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -101.03 -19.53 16.71 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 125.152 1.358 . . . . 10.0 110.599 168.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.31 156.39 0.85 Allowed 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.802 1.241 . . . . 10.0 111.946 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.63 27.86 0.44 Allowed 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.322 -0.854 . . . . 10.0 111.822 169.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -55.06 -39.22 69.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.198 0.999 . . . . 10.0 111.624 -169.728 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.44 -23.71 42.96 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.055 0.942 . . . . 10.0 112.786 177.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.91 114.25 1.53 Allowed Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.829 -0.908 . . . . 10.0 110.829 -170.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 23.5 m 38.06 46.28 0.81 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 127.206 2.203 . . . . 10.0 115.529 169.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -153.31 -54.15 0.11 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 173.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 47.0 t -54.91 -38.61 67.82 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.479 1.112 . . . . 10.0 110.892 -173.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.97 -50.68 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 127.863 2.465 . . . . 10.0 114.487 170.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.01 157.19 9.61 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.299 -1.12 . . . . 10.0 110.299 177.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -74.76 -163.38 0.18 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 N-CA-C 105.395 -2.579 . . . . 10.0 105.395 165.026 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.453 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.9 m170 -81.03 48.66 1.13 Allowed 'General case' 0 CA--C 1.547 0.83 0 O-C-N 119.619 -1.925 . . . . 10.0 110.694 -176.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 m-30 -75.35 67.72 1.96 Allowed 'General case' 0 N--CA 1.466 0.341 0 O-C-N 120.936 -1.102 . . . . 10.0 110.332 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -66.19 154.64 89.66 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.408 -0.808 . . . . 10.0 109.919 170.547 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -76.46 49.68 2.72 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 123.572 2.848 . . . . 10.0 111.204 177.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -178.35 55.78 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 127.482 2.313 . . . . 10.0 105.677 -178.618 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.0 p -37.11 110.23 0.12 Allowed 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.8 1.24 . . . . 10.0 109.992 177.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -173.69 3.1 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 102.447 -3.168 . . . . 10.0 102.447 177.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -78.08 167.56 21.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 116.651 -2.019 . . . . 10.0 106.831 167.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -65.48 123.62 20.12 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 106.845 -1.539 . . . . 10.0 106.845 162.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.16 -142.05 4.42 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.458 -1.857 . . . . 10.0 108.458 173.605 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.448 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -175.15 -165.24 31.08 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.67 -1.628 . . . . 10.0 109.044 173.233 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -69.16 10.47 0.4 Allowed 'Trans proline' 0 CA--C 1.541 0.827 0 CA-C-N 119.923 1.861 . . . . 10.0 110.727 167.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.448 ' H ' ' C ' ' B' ' 73' ' ' GLY . 5.2 mtpm? -108.8 -1.16 19.48 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 124.84 1.256 . . . . 10.0 110.402 170.121 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -132.22 169.36 16.55 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 119.67 1.123 . . . . 10.0 109.007 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -78.71 -39.23 37.05 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 103.795 -2.669 . . . . 10.0 103.795 165.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -82.14 42.87 0.76 Allowed 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 114.117 1.154 . . . . 10.0 114.117 -165.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.32 159.29 18.33 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 124.006 0.922 . . . . 10.0 109.714 167.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -68.97 -79.91 0.05 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 169.111 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . 0.438 ' CG1' ' H ' ' B' ' 82' ' ' GLY 0.25 8.6 p -149.18 -79.28 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 N-CA-C 107.175 -1.417 . . . . 10.0 107.175 167.923 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . 0.438 ' H ' ' CG1' ' B' ' 81' ' ' VAL . . . -86.43 62.52 4.28 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.258 -1.137 . . . . 10.0 110.258 178.415 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -101.55 100.45 10.87 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 105.714 -1.958 . . . . 10.0 105.714 169.065 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -73.73 -9.39 58.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 118.339 0.518 . . . . 10.0 111.452 -174.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.89 -99.7 2.34 Favored Glycine 0 N--CA 1.442 -0.94 0 N-CA-C 107.347 -2.301 . . . . 10.0 107.347 -176.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -148.17 144.97 28.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 -177.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.6 m -112.93 137.57 45.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 108.216 -1.031 . . . . 10.0 108.216 168.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -97.94 116.44 30.17 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.962 0.905 . . . . 10.0 109.582 -176.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.67 130.6 35.94 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.604 1.162 . . . . 10.0 109.15 174.572 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.05 168.11 3.47 Favored 'General case' 0 N--CA 1.448 -0.573 0 O-C-N 124.584 1.177 . . . . 10.0 109.824 168.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.9 tttp -47.76 -36.61 11.82 Favored 'General case' 0 N--CA 1.432 -1.327 0 C-N-CA 126.42 1.888 . . . . 10.0 111.468 168.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -79.84 1.04 28.49 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.992 0.517 . . . . 10.0 112.318 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.18 16.79 80.27 Favored Glycine 0 C--N 1.339 0.721 0 O-C-N 120.101 -1.624 . . . . 10.0 110.791 178.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 37.2 t -92.93 105.84 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 C-N-CA 126.513 1.925 . . . . 10.0 106.033 175.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.18 117.74 35.41 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 107.139 -1.43 . . . . 10.0 107.139 168.582 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -94.23 124.6 38.34 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.315 1.009 . . . . 10.0 108.279 177.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.99 134.53 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 C-N-CA 125.838 1.655 . . . . 10.0 108.421 -174.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -157.46 95.52 1.46 Allowed 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.719 1.207 . . . . 10.0 108.761 170.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 mp -123.59 145.36 30.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 108.105 -1.072 . . . . 10.0 108.105 176.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -106.06 135.28 47.8 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 128.691 2.797 . . . . 10.0 107.745 169.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -140.05 155.38 47.08 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 168.238 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.4 p -126.39 49.19 2.04 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.587 1.155 . . . . 10.0 109.771 174.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 p -133.33 -45.45 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.491 1.117 . . . . 10.0 110.246 172.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.32 131.81 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.298 -1.001 . . . . 10.0 108.298 169.575 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 67.8 m -125.37 112.71 16.64 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 170.078 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 18.1 mt -46.2 -41.52 12.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.193 1.397 . . . . 10.0 110.318 176.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 22.8 p -132.54 118.48 19.3 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 105.844 -1.91 . . . . 10.0 105.844 168.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.49 -59.74 0.06 OUTLIER Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.344 -1.102 . . . . 10.0 110.344 178.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -165.29 -51.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 125.195 1.398 . . . . 10.0 107.977 -176.166 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -73.88 -40.24 63.35 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 114.3 -1.318 . . . . 10.0 108.098 -169.332 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 34.9 t 42.51 70.07 0.32 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 125.47 1.508 . . . . 10.0 109.922 172.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 3.6 pt -75.63 58.6 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.849 -0.797 . . . . 10.0 108.849 172.478 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 44.5 mm -108.84 -58.36 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.671 0.788 . . . . 10.0 109.176 -177.638 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -93.46 50.93 2.38 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 109.409 -1.477 . . . . 10.0 109.409 173.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.09 158.24 24.53 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.304 1.842 . . . . 10.0 107.401 177.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 67.1 m -108.68 119.07 38.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 127.042 2.137 . . . . 10.0 106.264 -178.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 62.6 mt -93.49 150.87 20.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 108.224 -1.028 . . . . 10.0 108.224 168.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 79.6 t -132.81 138.36 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 N-CA-C 108.159 -1.052 . . . . 10.0 108.159 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.85 136.76 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 168.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 9.4 m-70 -116.03 161.12 19.34 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -175.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -60.04 -50.11 75.0 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.217 -0.901 . . . . 10.0 109.677 177.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 92.6 mttt -104.53 163.3 12.56 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.927 0.714 . . . . 10.0 112.927 -168.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.93 157.02 34.29 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 114.301 -1.318 . . . . 10.0 108.991 172.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -109.79 134.78 51.64 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 124.153 0.981 . . . . 10.0 109.243 -169.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -73.26 -24.56 60.47 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 124.861 1.264 . . . . 10.0 110.337 -174.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 59.64 42.87 16.5 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.52 -0.918 . . . . 10.0 108.52 -173.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.53 -53.12 1.02 Allowed Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 124.959 1.266 . . . . 10.0 110.971 170.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -79.29 49.88 1.02 Allowed 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.356 1.062 . . . . 10.0 113.072 -170.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -29.77 7.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 127.118 2.294 . . . . 10.0 110.593 169.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 75.81 18.71 79.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 118.978 -0.901 . . . . 10.0 112.395 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -111.65 160.22 17.45 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 105.947 -1.871 . . . . 10.0 105.947 168.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -50.26 -47.48 55.21 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.33 -1.304 . . . . 10.0 108.397 171.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -64.34 -37.43 87.47 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 112.915 0.709 . . . . 10.0 112.915 177.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.6 m -51.63 -45.47 63.3 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.336 1.425 . . . . 10.0 111.035 172.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.9 t -82.45 -22.51 35.2 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 111.922 0.341 . . . . 10.0 111.922 -173.177 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 25.2 ttmt -89.41 -46.89 8.39 Favored 'General case' 0 N--CA 1.439 -0.978 0 C-N-CA 125.225 1.41 . . . . 10.0 112.129 -177.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.453 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 30.7 p -133.44 -11.62 2.78 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 114.172 1.175 . . . . 10.0 114.172 178.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.22 15.72 37.5 Favored Glycine 0 C--O 1.221 -0.678 0 CA-C-O 118.982 -0.899 . . . . 10.0 112.15 -171.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 57.35 35.1 25.62 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.13 1.465 . . . . 10.0 111.233 -178.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.17 -13.59 62.1 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.515 1.926 . . . . 10.0 111.886 -178.435 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.89 -171.06 54.59 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 109.223 -1.551 . . . . 10.0 109.223 -169.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.1 m -52.52 166.12 0.21 Allowed 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 124.48 1.112 . . . . 10.0 113.071 -177.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -83.93 102.02 12.11 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 107.467 -1.308 . . . . 10.0 107.467 168.472 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.409 ' CD2' ' N ' ' B' ' 144' ' ' LEU . 0.4 OUTLIER -71.61 -47.98 51.07 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.05 -1.092 . . . . 10.0 108.05 -177.642 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -143.49 144.54 32.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.094 -0.706 . . . . 10.0 109.094 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 39.0 m -126.71 147.98 49.91 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.669 -1.234 . . . . 10.0 107.669 -176.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.87 141.1 11.57 Favored Glycine 0 C--N 1.332 0.315 0 N-CA-C 108.834 -1.706 . . . . 10.0 108.834 172.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.71 136.8 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 N-CA-C 101.612 -3.477 . . . . 10.0 101.612 169.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 68.5 mt -61.86 -81.41 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 CA-C-O 121.418 0.628 . . . . 10.0 110.285 -168.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.99 134.43 8.33 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.371 -0.691 . . . . 10.0 111.371 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.78 137.25 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.089 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 173.435 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.98 -70.08 0.54 Allowed 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 106.742 -1.577 . . . . 10.0 106.742 171.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . 0.428 ' C ' ' H3 ' ' B' ' 1' ' ' ALA . 20.4 tm0? . . . . . 0 C--O 1.253 1.249 0 N-CA-C 104.827 -2.286 . . . . 10.0 104.827 167.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.62 0 N-CA-C 105.511 -2.033 . . . . 10.0 105.511 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.5 t -63.18 -30.62 71.73 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.978 1.263 . . . . 10.0 108.1 167.427 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.5 tmtm? -117.08 146.95 42.8 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 126.088 1.755 . . . . 10.0 108.675 177.562 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.06 177.04 11.78 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 125.829 1.652 . . . . 10.0 109.195 169.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.9 t -136.2 164.04 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 125.277 1.431 . . . . 10.0 108.749 -176.49 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.68 104.36 3.03 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.054 0.941 . . . . 10.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.5 m -93.47 127.99 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 109.322 -0.621 . . . . 10.0 109.322 176.389 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.93 137.28 47.92 Favored 'General case' 0 C--O 1.225 -0.218 0 C-N-CA 124.762 1.225 . . . . 10.0 108.559 -178.736 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 40.1 mtpt -146.22 164.93 30.71 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-N 120.69 1.586 . . . . 10.0 107.968 170.797 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.59 -60.24 0.04 OUTLIER Glycine 0 CA--C 1.511 -0.19 0 C-N-CA 120.377 -0.916 . . . . 10.0 112.291 169.701 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.64 -44.91 61.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 -177.647 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.9 -69.74 0.44 Allowed Glycine 0 CA--C 1.524 0.612 0 CA-C-N 114.296 -1.32 . . . . 10.0 110.887 172.78 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -57.3 -36.3 98.94 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 123.25 2.633 . . . . 10.0 111.263 174.971 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.8 t -65.62 97.56 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.117 -1.438 . . . . 10.0 107.117 175.323 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.56 105.86 11.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.138 0.975 . . . . 10.0 108.424 173.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.03 149.79 29.92 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 109.623 -1.391 . . . . 10.0 109.623 168.38 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -155.22 59.6 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 C-N-CA 125.925 1.69 . . . . 10.0 106.848 -168.939 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 mm -74.94 146.47 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 O-C-N 121.621 -0.675 . . . . 10.0 109.657 -179.27 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -118.9 124.53 47.32 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 126.711 2.004 . . . . 10.0 107.061 177.013 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -106.63 120.6 42.39 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 178.703 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.5 mp0 -125.73 117.8 24.23 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.33 0.652 . . . . 10.0 111.472 176.515 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -124.03 108.99 12.96 Favored 'General case' 0 C--O 1.227 -0.113 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 168.287 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.42 -50.92 68.53 Favored 'General case' 0 C--N 1.333 -0.117 0 O-C-N 121.749 -0.595 . . . . 10.0 110.671 -178.824 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -129.57 170.42 13.78 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 103.557 -2.757 . . . . 10.0 103.557 168.38 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 92.3 p -68.61 -19.75 64.46 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 123.837 0.855 . . . . 10.0 110.39 170.12 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -78.77 -14.83 59.06 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 123.321 0.649 . . . . 10.0 109.278 174.144 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.43 138.67 15.47 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.183 -1.567 . . . . 10.0 109.183 175.828 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -62.4 135.8 55.74 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 CA-C-N 119.414 1.607 . . . . 10.0 108.069 171.328 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.1 p -75.97 120.36 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.425 0 N-CA-C 107.545 -1.28 . . . . 10.0 107.545 -176.779 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.1 mtpt -91.52 109.68 20.98 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.942 -2.244 . . . . 10.0 104.942 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.3 m -104.77 88.82 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 178.768 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -97.33 170.94 8.73 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-O 121.75 0.786 . . . . 10.0 111.664 169.509 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.06 -169.15 38.84 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.51 -1.036 . . . . 10.0 110.51 172.025 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.9 p -147.15 102.35 3.49 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.908 -0.775 . . . . 10.0 108.908 -175.844 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 pt -78.44 130.8 35.69 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 N-CA-C 106.428 -1.694 . . . . 10.0 106.428 168.38 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 ptmt -118.73 136.17 54.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.708 -1.219 . . . . 10.0 107.708 173.864 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.95 -3.95 14.31 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.75 1.167 . . . . 10.0 112.979 179.676 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -66.35 176.97 1.61 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.625 1.212 . . . . 10.0 111.109 177.516 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.5 t -112.35 155.9 23.37 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 105.308 -2.108 . . . . 10.0 105.308 166.04 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -50.23 157.53 0.67 Allowed 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.29 1.036 . . . . 10.0 111.678 -170.365 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.51 -175.37 29.14 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 170.791 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -78.39 149.2 33.39 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.699 1.599 . . . . 10.0 110.695 -175.99 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.1 m-70 -144.39 137.63 27.21 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.516 0.726 . . . . 10.0 112.953 -175.586 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.402 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -40.96 122.07 2.16 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 126.574 2.035 . . . . 10.0 110.217 168.247 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -136.73 113.03 9.88 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.177 1.489 . . . . 10.0 107.925 169.799 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.69 174.69 13.2 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-O 122.247 1.022 . . . . 10.0 112.163 -179.158 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.0 t -96.32 143.9 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 CA-C-N 111.318 -2.674 . . . . 10.0 107.2 169.609 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 76.9 m-70 -123.39 126.4 46.75 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 103.643 -2.725 . . . . 10.0 103.643 172.55 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.5 tp10 -61.17 -42.76 99.14 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.184 -1.371 . . . . 10.0 112.746 -165.508 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -81.91 118.64 23.1 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 119.288 -0.965 . . . . 10.0 109.459 177.696 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.1 -13.89 16.19 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.707 2.575 . . . . 10.0 112.523 169.992 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -42.83 127.28 3.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 122.384 1.088 . . . . 10.0 111.173 168.966 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -137.39 23.12 2.96 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.521 164.854 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -66.71 -44.43 81.69 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 106.542 -1.651 . . . . 10.0 106.542 168.525 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.69 -21.92 44.08 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.335 -0.393 . . . . 10.0 111.55 173.062 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.58 71.49 1.31 Allowed Glycine 0 CA--C 1.528 0.848 0 C-N-CA 124.134 0.873 . . . . 10.0 111.28 173.015 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.291 23.2 p 43.12 48.98 5.5 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.665 1.186 . . . . 10.0 113.783 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 p -127.21 -66.95 0.86 Allowed 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 127.344 2.258 . . . . 10.0 105.354 173.072 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.1 m -79.05 -4.68 51.34 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 123.364 0.665 . . . . 10.0 112.56 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.7 -14.69 1.45 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.41 1.484 . . . . 10.0 112.925 173.377 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.22 131.55 6.89 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 108.847 -1.701 . . . . 10.0 108.847 170.071 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -75.17 59.97 5.44 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.8 3.0 . . . . 10.0 110.38 172.247 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 23.3 m170 71.7 49.74 0.27 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 129.312 3.045 . . . . 10.0 111.275 175.435 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -72.21 38.12 0.07 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 115.258 1.577 . . . . 10.0 115.258 -173.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.27 151.15 0.57 Allowed Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.55 1.54 . . . . 10.0 113.107 169.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -66.02 -46.37 4.75 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.884 2.389 . . . . 10.0 111.953 179.544 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 71.1 mt -79.39 54.01 1.63 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.631 -0.668 . . . . 10.0 110.457 -177.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 40.0 p -55.5 109.2 0.52 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.537 1.135 . . . . 10.0 110.406 -173.826 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.4 mtt180 -121.29 -97.15 0.46 Allowed 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 -179.889 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.4 140.87 23.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 105.261 -2.126 . . . . 10.0 105.261 177.278 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -47.08 116.95 1.52 Allowed 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.654 -0.418 . . . . 10.0 110.991 169.402 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.48 -141.01 4.29 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 106.536 -2.626 . . . . 10.0 106.536 170.531 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.411 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 177.95 -147.51 8.1 Favored Glycine 0 C--O 1.227 -0.312 0 CA-C-O 118.644 -1.086 . . . . 10.0 111.229 175.267 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -68.27 14.93 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 120.041 1.921 . . . . 10.0 111.943 177.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.411 ' H ' ' C ' ' A' ' 73' ' ' GLY . 58.0 mmtt -104.68 -14.96 15.41 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 119.038 0.835 . . . . 10.0 110.042 169.805 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.33 177.34 7.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.337 1.065 . . . . 10.0 113.064 -165.049 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -98.64 -13.31 20.39 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 113.449 -1.705 . . . . 10.0 108.502 168.198 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.11 -16.26 56.97 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 124.735 1.214 . . . . 10.0 112.23 -168.598 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.28 135.88 2.47 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.596 1.158 . . . . 10.0 110.333 -169.78 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -73.66 61.99 0.76 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 123.405 0.682 . . . . 10.0 111.588 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.4 t 31.78 48.66 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 C-N-CA 126.872 2.069 . . . . 10.0 111.418 -174.511 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.22 42.0 0.05 OUTLIER Glycine 0 CA--C 1.531 1.062 0 CA-C-N 116.032 -0.531 . . . . 10.0 113.877 -178.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -97.07 100.42 11.92 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 103.617 -2.735 . . . . 10.0 103.617 166.049 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 27.5 mt -75.62 -24.86 56.53 Favored 'General case' 0 N--CA 1.462 0.174 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 177.865 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.94 -102.25 2.83 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.311 -1.916 . . . . 10.0 108.311 168.527 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -129.24 133.67 47.62 Favored 'General case' 0 CA--C 1.517 -0.311 0 C-N-CA 123.888 0.875 . . . . 10.0 112.176 -168.633 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.8 m -124.88 145.47 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.143 -1.799 . . . . 10.0 106.143 167.202 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -98.44 126.14 43.87 Favored 'General case' 0 C--O 1.225 -0.223 0 C-N-CA 124.851 1.261 . . . . 10.0 108.959 -178.025 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.52 134.46 34.35 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 172.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.437 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 42.5 t0 -67.17 172.45 4.67 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-O 121.592 0.71 . . . . 10.0 109.609 168.45 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.437 ' HZ1' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -47.46 -32.2 4.91 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.39 2.276 . . . . 10.0 111.099 171.528 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -78.68 -11.34 59.97 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.855 0.359 . . . . 10.0 110.607 -175.804 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.06 15.67 69.17 Favored Glycine 0 C--N 1.339 0.75 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 -177.189 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.4 t -94.97 111.15 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 126.796 2.038 . . . . 10.0 105.921 175.162 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.02 120.24 41.28 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 168.734 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -78.53 131.08 36.66 Favored 'General case' 0 N--CA 1.429 -1.524 0 C-N-CA 125.906 1.682 . . . . 10.0 107.892 173.89 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.4 t -117.55 133.89 62.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.303 0 N-CA-C 106.235 -1.765 . . . . 10.0 106.235 179.459 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.5 p -157.45 70.42 0.6 Allowed 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 123.685 0.794 . . . . 10.0 109.554 175.554 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.43 153.22 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 179.406 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -137.35 123.16 20.02 Favored 'General case' 0 N--CA 1.443 -0.812 0 C-N-CA 125.557 1.543 . . . . 10.0 106.897 169.298 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -128.29 153.99 46.4 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.62 0.724 . . . . 10.0 109.051 -178.723 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 33.7 t -117.48 46.18 1.77 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.629 1.572 . . . . 10.0 110.043 -168.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.3 p -155.8 -46.13 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.132 0 N-CA-C 109.181 -0.674 . . . . 10.0 109.181 177.105 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 29.8 mm -56.35 142.22 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 123.49 0.716 . . . . 10.0 109.664 172.333 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.7 m -155.62 133.92 11.61 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 123.9 0.88 . . . . 10.0 108.758 171.671 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 82.7 mt -47.27 -55.21 9.11 Favored 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 126.914 2.086 . . . . 10.0 111.318 176.402 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.0 t -130.75 152.24 50.31 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 105.278 -2.119 . . . . 10.0 105.278 170.025 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.52 -84.77 0.12 Allowed Glycine 0 C--N 1.333 0.369 0 N-CA-C 110.058 -1.217 . . . . 10.0 110.058 -177.351 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -136.23 -53.47 0.74 Allowed 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 126.744 2.017 . . . . 10.0 107.5 -179.588 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -76.49 -31.15 57.57 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.117 -0.947 . . . . 10.0 108.57 -175.239 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 48.96 63.37 2.15 Favored 'General case' 0 N--CA 1.447 -0.594 0 C-N-CA 125.669 1.588 . . . . 10.0 109.372 177.109 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.315 1.1 tp -61.45 -18.77 19.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 C-N-CA 123.411 0.684 . . . . 10.0 112.112 -176.116 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.4 mm -48.75 135.79 5.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 118.812 0.733 . . . . 10.0 110.062 167.278 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.88 14.28 82.18 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.055 -0.858 . . . . 10.0 113.489 172.473 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.4 mmt-85 -84.02 175.43 9.54 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 167.898 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.3 m -108.36 122.27 46.64 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 177.003 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 6.5 mp -99.51 147.33 25.43 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-N 119.606 1.093 . . . . 10.0 108.535 171.058 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.6 t -131.18 135.93 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 N-CA-C 108.734 -0.839 . . . . 10.0 108.734 179.795 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 p -104.78 129.76 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 168.106 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.402 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 10.1 m-70 -111.12 158.86 18.39 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 114.994 1.479 . . . . 10.0 114.994 -169.672 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -46.42 -60.51 2.3 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.493 2.717 . . . . 10.0 110.903 171.369 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.2 mttp -117.27 165.61 13.24 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.104 0.478 . . . . 10.0 110.356 -172.917 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.39 140.8 54.21 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 168.854 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.03 153.75 32.06 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 108.837 -0.801 . . . . 10.0 108.837 168.264 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -78.59 10.73 2.97 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.118 0.967 . . . . 10.0 111.146 177.457 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.3 mt 38.94 51.35 1.85 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 125.151 1.38 . . . . 10.0 110.86 -170.334 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.94 -27.62 17.41 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-N 114.059 -1.428 . . . . 10.0 112.638 173.522 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -78.83 16.05 0.96 Allowed 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 113.66 0.985 . . . . 10.0 113.66 -168.42 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.93 -32.39 82.5 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 170.295 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 69.94 31.13 69.78 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 122.488 -0.419 . . . . 10.0 112.34 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.95 176.21 8.24 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 125.299 1.44 . . . . 10.0 107.545 173.338 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -59.51 -51.27 70.57 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 113.403 -1.726 . . . . 10.0 109.425 177.742 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.407 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 5.4 tp10 -52.97 -43.9 66.74 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.565 1.146 . . . . 10.0 110.692 171.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.5 m -53.55 -46.59 70.28 Favored 'General case' 0 N--CA 1.441 -0.917 0 O-C-N 120.851 -1.156 . . . . 10.0 110.968 -179.118 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.5 t -77.65 -0.57 27.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 119.786 -0.766 . . . . 10.0 111.857 -177.121 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -113.91 -82.1 0.6 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.312 1.845 . . . . 10.0 111.197 -179.657 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.407 ' HG1' ' CD ' ' A' ' 133' ' ' GLU 0.299 2.0 p -105.95 11.84 31.24 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 120.738 1.608 . . . . 10.0 113.054 177.939 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.09 10.75 78.52 Favored Glycine 0 C--O 1.221 -0.699 0 CA-C-O 119.047 -0.863 . . . . 10.0 114.336 166.812 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 m120 65.7 26.35 11.42 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.594 1.197 . . . . 10.0 111.596 -176.863 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.59 -11.82 8.29 Favored 'General case' 0 CA--C 1.533 0.327 0 O-C-N 121.644 -0.66 . . . . 10.0 111.683 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.58 -140.32 21.74 Favored Glycine 0 N--CA 1.443 -0.852 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 168.495 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -70.72 118.23 13.25 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.23 0.538 . . . . 10.0 111.283 -168.359 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.41 76.55 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.734 1.214 . . . . 10.0 111.35 168.624 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 50.3 mt -52.12 -40.89 61.97 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.101 0.778 . . . . 10.0 113.101 -176.051 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 155.09 24.77 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 108.335 -0.987 . . . . 10.0 108.335 -171.579 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -167.15 166.07 15.18 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 116.049 -0.523 . . . . 10.0 109.626 -167.59 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.7 179.3 46.95 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.658 -0.782 . . . . 10.0 112.062 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 71.3 t -109.24 156.22 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 N-CA-C 104.978 -2.23 . . . . 10.0 104.978 -175.677 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.4 mt -75.07 -96.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 C-N-CA 123.656 0.782 . . . . 10.0 110.747 -168.478 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 106.28 130.85 6.68 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-O 121.917 0.732 . . . . 10.0 112.098 179.381 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 92.2 mt -72.18 141.25 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.689 0 C-N-CA 124.968 1.307 . . . . 10.0 108.968 179.083 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.11 -102.11 0.41 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 105.761 -1.94 . . . . 10.0 105.761 165.519 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 . . . . . 0 C--O 1.247 0.962 0 C-N-CA 131.033 3.733 . . . . 10.0 103.075 -171.237 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 106.267 -1.753 . . . . 10.0 106.267 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -160.49 -47.33 0.05 OUTLIER 'General case' 0 C--O 1.232 0.139 0 CA-C-N 118.89 0.768 . . . . 10.0 110.668 172.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -119.64 142.71 48.19 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 126.839 2.056 . . . . 10.0 107.691 173.877 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.44 155.51 45.86 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.118 0.967 . . . . 10.0 108.396 169.36 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -122.65 153.99 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 C-N-CA 123.873 0.869 . . . . 10.0 109.265 -175.181 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.74 93.11 2.16 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 167.367 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 31.6 m -83.19 133.45 29.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 107.803 -1.184 . . . . 10.0 107.803 169.425 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mt -107.34 138.15 44.07 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.836 -1.172 . . . . 10.0 107.836 -177.507 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 36.5 mtpt -146.34 153.72 40.85 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 120.582 1.537 . . . . 10.0 107.545 169.518 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.51 -52.71 0.08 OUTLIER Glycine 0 N--CA 1.462 0.388 0 C-N-CA 119.217 -1.468 . . . . 10.0 114.171 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -72.68 -43.41 63.13 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.649 -1.241 . . . . 10.0 107.649 -172.065 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.74 -70.55 0.4 Allowed Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 114.055 -1.429 . . . . 10.0 110.032 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -54.91 -39.73 88.99 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.783 2.322 . . . . 10.0 110.879 170.817 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.7 t -58.65 107.54 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.246 0 CA-C-N 119.083 0.856 . . . . 10.0 109.157 179.688 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.04 92.2 3.68 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.744 -2.317 . . . . 10.0 104.744 168.676 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.44 152.19 37.35 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 109.401 -1.479 . . . . 10.0 109.401 177.045 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -154.26 87.22 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -171.16 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.8 mm -96.56 142.18 14.35 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 C-N-CA 124.846 1.258 . . . . 10.0 109.464 174.872 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -127.64 119.31 25.61 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 125.38 1.472 . . . . 10.0 108.082 174.142 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -98.0 113.76 25.7 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.058 1.343 . . . . 10.0 107.5 173.409 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -117.89 136.06 53.7 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 119.133 0.878 . . . . 10.0 110.775 170.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 36.1 tt0 -126.54 81.15 1.98 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 124.638 1.175 . . . . 10.0 109.763 -176.102 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -130.92 73.85 1.57 Allowed 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.863 1.265 . . . . 10.0 111.963 -175.223 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -157.05 172.02 19.42 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 104.192 -2.522 . . . . 10.0 104.192 166.172 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.9 t -96.81 16.37 19.41 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 124.014 0.926 . . . . 10.0 108.646 179.522 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -117.19 4.18 12.66 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.122 0.969 . . . . 10.0 109.855 169.658 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 49.96 45.95 41.27 Favored Glycine 0 CA--C 1.532 1.15 0 CA-C-O 118.565 -1.131 . . . . 10.0 114.48 -177.682 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -71.17 108.18 2.28 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 N-CA-C 106.22 -2.261 . . . . 10.0 106.22 169.122 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 26.2 t -77.35 95.74 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.349 0 N-CA-C 105.374 -2.084 . . . . 10.0 105.374 174.612 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -76.33 96.63 4.02 Favored 'General case' 0 N--CA 1.444 -0.76 0 N-CA-C 105.594 -2.002 . . . . 10.0 105.594 174.516 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -92.58 90.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.751 0 N-CA-C 106.87 -1.53 . . . . 10.0 106.87 175.654 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -99.48 176.58 5.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 121.443 0.64 . . . . 10.0 109.4 169.428 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.15 173.58 40.32 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 110.016 -1.234 . . . . 10.0 110.016 176.206 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.6 m -149.52 89.55 1.64 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 -179.626 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.5 pt -77.38 150.46 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 174.313 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.8 pttt -136.96 126.05 24.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 O-C-N 124.288 0.992 . . . . 10.0 108.848 169.425 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.97 6.76 5.31 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-O 118.791 -1.005 . . . . 10.0 114.629 166.064 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.416 ' N ' ' CD1' ' B' ' 38' ' ' LEU . 0.0 OUTLIER -89.82 179.34 6.02 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-N 118.728 1.264 . . . . 10.0 108.62 172.443 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -81.09 175.12 10.94 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.348 -0.845 . . . . 10.0 111.011 172.175 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -63.23 169.72 3.38 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.426 1.49 . . . . 10.0 111.48 -174.616 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.94 -174.74 51.42 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 124.008 0.813 . . . . 10.0 113.256 167.376 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -66.19 143.0 57.53 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.795 1.638 . . . . 10.0 110.608 178.603 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -142.36 139.34 31.72 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 114.214 1.19 . . . . 10.0 114.214 -178.655 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -26.03 111.77 0.02 OUTLIER Glycine 0 C--N 1.342 0.883 0 C-N-CA 128.418 2.913 . . . . 10.0 114.208 165.493 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -138.57 102.95 4.73 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 120.376 2.088 . . . . 10.0 110.516 174.844 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.516 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -148.56 179.23 7.97 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.331 0.586 . . . . 10.0 111.829 -178.358 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 p -100.21 148.26 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 112.704 -2.044 . . . . 10.0 108.127 168.33 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -123.93 129.6 51.23 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.067 -2.568 . . . . 10.0 104.067 169.154 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -59.13 -44.73 92.04 Favored 'General case' 0 N--CA 1.441 -0.898 0 O-C-N 124.528 1.142 . . . . 10.0 112.363 -166.646 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -75.19 112.49 11.52 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 105.239 -2.134 . . . . 10.0 105.239 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -57.65 -33.51 67.45 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 109.503 -1.439 . . . . 10.0 109.503 168.798 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -35.93 146.34 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 125.253 1.421 . . . . 10.0 112.06 169.547 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -144.36 28.44 1.34 Allowed 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 115.261 -0.881 . . . . 10.0 111.406 176.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -49.12 -43.06 41.14 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 112.859 0.688 . . . . 10.0 112.859 -169.028 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -86.82 -23.5 25.32 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 113.378 0.881 . . . . 10.0 113.378 177.052 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.97 101.39 2.69 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.172 -1.571 . . . . 10.0 109.172 -170.273 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.289 26.3 p 11.5 49.62 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 129.633 3.173 . . . . 10.0 116.955 -168.673 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 42.4 m -120.84 -53.68 2.06 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 105.077 -2.194 . . . . 10.0 105.077 174.977 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.5 m -44.89 -40.45 6.29 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 126.158 1.783 . . . . 10.0 109.936 168.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.84 -25.25 0.09 Allowed 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 127.726 2.41 . . . . 10.0 114.999 176.934 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.41 155.79 29.45 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 108.572 -1.811 . . . . 10.0 108.572 169.35 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -68.5 -172.73 0.48 Allowed 'Trans proline' 0 N--CA 1.445 -1.352 0 N-CA-C 106.888 -2.005 . . . . 10.0 106.888 166.719 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.428 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 37.6 m170 -78.81 45.09 0.58 Allowed 'General case' 0 CA--C 1.542 0.649 0 O-C-N 119.743 -1.848 . . . . 10.0 112.047 -171.511 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.1 m-30 -72.55 68.22 0.8 Allowed 'General case' 0 C--O 1.221 -0.413 0 CA-C-N 119.846 1.203 . . . . 10.0 109.676 178.759 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -63.57 155.66 74.83 Favored Pre-proline 0 C--N 1.331 -0.226 0 N-CA-C 107.535 -1.283 . . . . 10.0 107.535 173.768 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -54.92 -27.95 56.47 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.097 1.865 . . . . 10.0 112.281 175.222 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -107.78 25.14 11.89 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.043 0.937 . . . . 10.0 111.815 177.189 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 44.7 p -40.98 117.79 0.9 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.646 1.179 . . . . 10.0 112.273 177.94 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -124.58 -88.89 0.59 Allowed 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 107.676 -1.231 . . . . 10.0 107.676 177.361 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -125.49 152.6 44.76 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 108.316 -0.994 . . . . 10.0 108.316 168.541 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 36.2 t60 -58.14 128.36 36.72 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 117.659 -1.617 . . . . 10.0 106.734 165.812 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -150.09 -141.16 3.35 Favored Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 109.905 -1.278 . . . . 10.0 109.905 -178.771 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.6 -147.52 11.43 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 107.95 -2.06 . . . . 10.0 107.95 169.976 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.05 12.94 0.2 Allowed 'Trans proline' 0 N--CA 1.452 -0.923 0 CA-C-N 120.114 1.957 . . . . 10.0 111.621 169.429 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -127.65 1.51 6.15 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.59 1.156 . . . . 10.0 111.737 176.502 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . 0.42 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 0.2 OUTLIER -123.81 150.58 44.35 Favored 'General case' 0 C--N 1.34 0.168 0 N-CA-C 102.426 -3.175 . . . . 10.0 102.426 166.825 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -82.55 -17.74 43.9 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 121.646 -0.659 . . . . 10.0 109.832 174.705 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.9 pm0 -118.16 36.54 4.31 Favored 'General case' 0 N--CA 1.438 -1.056 0 C-N-CA 125.901 1.68 . . . . 10.0 111.579 -167.515 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -44.25 153.58 0.14 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.58 1.552 . . . . 10.0 109.578 168.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 38.4 m80 -60.9 -48.17 83.06 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 10.0 109.966 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.1 t 173.31 -75.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 C-N-CA 129.284 3.034 . . . . 10.0 105.059 166.082 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.03 59.06 5.02 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 179.305 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -106.08 95.07 5.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.557 -2.016 . . . . 10.0 105.557 169.322 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 43.6 mt -75.23 -33.87 61.39 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 106.741 -1.577 . . . . 10.0 106.741 175.632 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.51 -96.94 1.31 Allowed Glycine 0 N--CA 1.436 -1.337 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 169.442 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -132.42 136.14 46.56 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 122.863 0.465 . . . . 10.0 110.021 -169.518 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.5 m -122.24 140.3 46.54 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.955 -0.758 . . . . 10.0 108.955 169.488 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 9.4 m -81.93 119.25 23.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 127.457 2.303 . . . . 10.0 110.499 -177.159 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.4 130.46 44.53 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.984 1.314 . . . . 10.0 110.642 170.022 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -59.88 166.31 2.73 Favored 'General case' 0 N--CA 1.455 -0.222 0 O-C-N 124.069 0.855 . . . . 10.0 109.603 167.366 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 35.6 pttt -52.47 -30.5 30.18 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.804 1.241 . . . . 10.0 110.93 173.37 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -77.08 -9.52 58.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 117.676 0.216 . . . . 10.0 111.027 -178.148 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.54 10.57 67.54 Favored Glycine 0 C--N 1.34 0.774 0 O-C-N 121.092 -1.005 . . . . 10.0 111.038 -178.191 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.0 t -86.14 111.44 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 127.184 2.194 . . . . 10.0 106.466 175.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -114.61 120.71 41.1 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 118.715 0.689 . . . . 10.0 109.509 172.825 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -78.5 132.43 37.23 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 107.325 -1.361 . . . . 10.0 107.325 169.864 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.8 t -114.94 133.44 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 N-CA-C 104.777 -2.305 . . . . 10.0 104.777 169.063 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -156.73 62.8 0.52 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 118.174 0.443 . . . . 10.0 110.139 -178.731 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.69 152.85 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 N-CA-C 107.735 -1.209 . . . . 10.0 107.735 -173.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -136.6 139.22 41.95 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 123.798 0.839 . . . . 10.0 109.667 168.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -148.47 153.53 38.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.3 p -115.52 44.48 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 126.494 1.917 . . . . 10.0 109.549 177.403 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -111.69 -48.04 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 170.457 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 42.5 mm -65.1 148.49 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 108.007 -1.108 . . . . 10.0 108.007 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.4 m -157.29 120.97 4.16 Favored 'General case' 0 C--O 1.226 -0.134 0 N-CA-C 108.029 -1.1 . . . . 10.0 108.029 173.578 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.9 mp -59.62 -29.94 68.36 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.614 1.166 . . . . 10.0 111.955 -169.603 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.2 m -149.88 66.81 0.98 Allowed 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 176.096 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.03 -72.43 1.17 Allowed Glycine 0 C--N 1.333 0.364 0 N-CA-C 108.628 -1.789 . . . . 10.0 108.628 177.203 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -152.03 -57.84 0.15 Allowed 'General case' 0 N--CA 1.44 -0.926 0 C-N-CA 127.462 2.305 . . . . 10.0 107.435 -167.646 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -85.25 -32.37 22.61 Favored 'General case' 0 N--CA 1.445 -0.7 0 C-N-CA 125.632 1.573 . . . . 10.0 108.826 -179.207 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 7.1 t 70.77 -51.21 0.68 Allowed 'General case' 0 C--N 1.342 0.277 0 C-N-CA 127.504 2.322 . . . . 10.0 111.176 178.221 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 mt 63.82 16.32 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 124.173 0.989 . . . . 10.0 110.721 174.104 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.8 mm -71.02 -56.1 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 124.478 1.111 . . . . 10.0 110.037 175.824 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.72 48.82 3.55 Favored Glycine 0 CA--C 1.526 0.758 0 O-C-N 120.617 -1.302 . . . . 10.0 112.501 -177.49 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.03 168.06 11.93 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 126.612 1.965 . . . . 10.0 108.692 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -114.21 141.11 47.95 Favored 'General case' 0 CA--C 1.515 -0.396 0 C-N-CA 124.654 1.181 . . . . 10.0 108.306 -172.07 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.8 mp -111.85 145.92 38.62 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.83 1.652 . . . . 10.0 108.474 172.489 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.9 t -131.71 136.06 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 178.278 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 p -97.57 120.17 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 105.838 -1.912 . . . . 10.0 105.838 168.007 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -98.5 158.29 15.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 115.59 1.7 . . . . 10.0 115.59 -176.373 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -38.47 -66.18 0.29 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 129.834 3.254 . . . . 10.0 110.619 170.517 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -113.75 174.86 5.72 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 125.174 1.389 . . . . 10.0 110.319 -174.561 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.84 137.23 35.3 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.879 -1.055 . . . . 10.0 108.465 171.311 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.516 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -77.4 141.73 39.63 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.287 1.035 . . . . 10.0 109.284 169.892 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -78.45 24.51 0.27 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.375 0.67 . . . . 10.0 111.86 179.63 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.5 mt 36.64 51.6 0.91 Allowed 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.792 2.037 . . . . 10.0 111.7 -176.674 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.44 -32.03 6.6 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 125.594 1.569 . . . . 10.0 112.384 175.078 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . 0.42 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 7.2 mttm -80.08 18.67 0.81 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.628 1.171 . . . . 10.0 113.222 -167.819 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.27 -18.73 75.29 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 109.531 -1.428 . . . . 10.0 109.531 167.109 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.78 40.19 92.52 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 124.402 1.001 . . . . 10.0 111.749 175.403 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -145.25 169.6 17.91 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.093 0.946 . . . . 10.0 109.583 173.643 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 13.0 tm-20 -46.83 -49.85 19.4 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.711 1.204 . . . . 10.0 110.139 -179.875 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 17.9 tp10 -71.35 -34.74 70.77 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 121.781 -0.574 . . . . 10.0 111.657 179.217 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.9 p -54.15 -43.63 70.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 120.715 -1.241 . . . . 10.0 110.799 172.149 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.272 5.6 t -77.81 -23.02 49.18 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 119.568 -0.853 . . . . 10.0 111.557 -173.627 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -84.71 -49.01 8.86 Favored 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 127.486 2.314 . . . . 10.0 112.525 -177.738 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.428 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 19.2 p -136.3 -15.04 1.71 Allowed 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 114.495 1.295 . . . . 10.0 114.495 175.556 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.76 3.9 52.18 Favored Glycine 0 C--N 1.339 0.707 0 CA-C-O 118.379 -1.234 . . . . 10.0 114.105 177.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 27.2 m120 72.18 25.26 2.95 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 118.573 1.186 . . . . 10.0 112.01 -177.788 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.34 -8.83 43.34 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.435 0.902 . . . . 10.0 113.435 179.356 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.93 -160.8 48.8 Favored Glycine 0 CA--C 1.524 0.608 0 O-C-N 121.029 -1.045 . . . . 10.0 111.536 172.622 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 m -60.63 134.69 57.33 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.7 1.2 . . . . 10.0 113.657 -167.675 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.9 84.92 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.524 1.529 . . . . 10.0 110.21 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 65.8 mt -58.02 -39.18 77.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.425 0.557 . . . . 10.0 112.094 -179.031 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -154.46 153.34 31.37 Favored 'General case' 0 CA--C 1.516 -0.334 0 O-C-N 121.683 -0.635 . . . . 10.0 110.655 -179.912 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.2 m -121.68 141.14 51.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.014 1.726 . . . . 10.0 108.556 -169.041 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.4 158.43 27.5 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 109.675 -1.37 . . . . 10.0 109.675 168.539 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.8 t -118.8 135.52 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 -179.838 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 59.8 mt -71.88 153.35 7.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 N-CA-C 108.658 -0.867 . . . . 10.0 108.658 176.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -164.77 151.24 20.15 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 109.099 -1.601 . . . . 10.0 109.099 -175.089 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.47 123.75 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 117.514 0.657 . . . . 10.0 109.768 -172.809 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.06 -26.26 39.74 Favored 'General case' 0 N--CA 1.446 -0.628 0 O-C-N 120.894 -1.129 . . . . 10.0 111.809 -173.276 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.428 -1.533 0 N-CA-C 103.918 -2.623 . . . . 10.0 103.918 -173.859 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.791 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -79.57 -38.91 33.02 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.194 0.598 . . . . 10.0 110.028 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -121.16 130.08 53.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.148 1.379 . . . . 10.0 107.331 -179.328 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.11 151.92 51.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.595 -0.891 . . . . 10.0 108.595 172.874 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -109.24 170.52 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 123.115 0.566 . . . . 10.0 110.45 169.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -156.02 102.38 2.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 106.64 -1.615 . . . . 10.0 106.64 166.045 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.7 m -92.24 128.4 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 108.795 -0.817 . . . . 10.0 108.795 171.078 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.2 mp -103.18 152.83 21.0 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 108.853 -0.795 . . . . 10.0 108.853 178.231 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 ttmt -161.16 162.24 31.31 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 108.044 -1.095 . . . . 10.0 108.044 169.52 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.37 -56.16 0.04 OUTLIER Glycine 0 C--N 1.33 0.21 0 N-CA-C 111.459 -0.657 . . . . 10.0 111.459 172.801 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.97 -45.89 39.12 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -174.769 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.88 -67.72 0.55 Allowed Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 113.739 -1.573 . . . . 10.0 110.338 -179.506 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -56.96 -38.77 95.19 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.914 2.409 . . . . 10.0 111.172 173.876 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -68.05 105.59 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.062 0 N-CA-C 107.033 -1.469 . . . . 10.0 107.033 175.255 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -124.57 120.63 32.49 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 108.601 -0.888 . . . . 10.0 108.601 169.384 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.49 150.96 21.08 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.452 -1.459 . . . . 10.0 109.452 169.36 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -156.37 82.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 105.491 -2.04 . . . . 10.0 105.491 -172.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.6 mm -104.62 145.03 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.39 1.076 . . . . 10.0 108.841 -178.561 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -122.91 122.78 39.43 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 127.161 2.185 . . . . 10.0 108.337 169.011 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -103.24 123.03 45.97 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 106.704 -1.591 . . . . 10.0 106.704 173.327 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -117.91 135.52 54.06 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 123.962 0.788 . . . . 10.0 113.126 169.553 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -123.82 100.02 6.56 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 127.42 2.288 . . . . 10.0 105.264 171.135 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.466 ' HZ3' ' CD ' ' A' ' 24' ' ' GLU . 17.8 tttp -64.65 -62.63 1.46 Allowed 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 124.61 1.164 . . . . 10.0 109.392 -169.719 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.466 ' CD ' ' HZ3' ' A' ' 23' ' ' LYS . 3.7 mp0 -109.59 165.81 11.38 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 102.896 -3.001 . . . . 10.0 102.896 166.873 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.9 t -66.65 -21.54 66.11 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 -178.912 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.6 m-80 -76.76 -19.62 57.41 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.537 -0.756 . . . . 10.0 110.511 -179.595 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.55 140.82 32.57 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 109.862 -1.295 . . . . 10.0 109.862 -178.763 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -61.62 149.15 91.05 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 N-CA-C 107.041 -1.946 . . . . 10.0 107.041 168.877 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 t -79.29 113.68 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.087 0 N-CA-C 105.976 -1.861 . . . . 10.0 105.976 178.584 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -93.9 117.58 30.3 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 171.193 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -110.4 108.67 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 C-N-CA 126.817 2.047 . . . . 10.0 106.857 -175.558 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 20.8 p90 -127.49 163.11 24.84 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 112.103 0.408 . . . . 10.0 112.103 179.616 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.03 -147.37 18.32 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 106.917 -2.473 . . . . 10.0 106.917 170.144 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 52.2 p -157.96 164.78 36.49 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.065 -1.054 . . . . 10.0 112.551 178.617 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.45 121.53 67.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 C-N-CA 126.062 1.745 . . . . 10.0 106.668 166.628 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.61 54.78 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 175.025 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.14 -0.14 9.68 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.174 1.369 . . . . 10.0 113.539 178.537 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.26 178.38 2.87 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 118.394 1.097 . . . . 10.0 111.231 179.183 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -107.71 156.11 19.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.203 -1.777 . . . . 10.0 106.203 165.244 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -51.27 150.74 3.21 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.463 1.105 . . . . 10.0 112.347 -169.504 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.04 -171.36 23.49 Favored Glycine 0 C--N 1.336 0.558 0 N-CA-C 111.201 -0.76 . . . . 10.0 111.201 170.232 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.73 149.16 36.37 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.574 1.149 . . . . 10.0 111.363 -173.319 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -143.15 141.32 31.15 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.71 1.204 . . . . 10.0 112.502 -177.698 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.404 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -35.73 122.15 0.61 Allowed Glycine 0 C--N 1.341 0.86 0 C-N-CA 126.582 2.039 . . . . 10.0 112.878 166.303 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -143.43 115.42 8.32 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 120.085 1.942 . . . . 10.0 110.975 167.442 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.7 174.25 12.79 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 120.994 0.426 . . . . 10.0 111.787 -178.974 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.1 m -113.47 82.24 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 126.036 1.735 . . . . 10.0 109.995 -179.656 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -56.8 141.31 44.91 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 122.292 1.044 . . . . 10.0 110.599 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -71.58 -53.21 14.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 112.045 -2.343 . . . . 10.0 110.456 -168.234 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.3 m-30 -76.49 110.09 10.75 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 175.154 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.42 48.71 1.22 Allowed Glycine 0 CA--C 1.531 1.051 0 N-CA-C 110.04 -1.224 . . . . 10.0 110.04 167.806 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.76 143.41 30.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.885 1.674 . . . . 10.0 106.825 170.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -139.5 2.13 2.0 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 126.344 1.858 . . . . 10.0 109.324 174.103 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.406 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 1.9 m -61.92 -30.36 70.84 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 120.098 1.317 . . . . 10.0 110.525 -170.111 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.18 -15.36 60.07 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.174 0.99 . . . . 10.0 112.047 176.136 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.14 76.55 1.33 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.57 -1.412 . . . . 10.0 109.57 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 74.0 m 47.56 45.66 17.63 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.53 1.132 . . . . 10.0 111.145 175.658 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.5 m -134.59 -52.5 0.81 Allowed 'General case' 0 N--CA 1.439 -0.995 0 N-CA-C 108.948 -0.76 . . . . 10.0 108.948 -168.863 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 t -99.5 21.04 12.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.425 0.528 . . . . 10.0 112.425 -170.28 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.12 3.52 0.85 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.15 0.98 . . . . 10.0 113.401 178.956 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.28 129.98 1.57 Allowed Glycine 0 CA--C 1.529 0.967 0 O-C-N 120.874 -1.141 . . . . 10.0 110.341 175.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.16 61.54 7.78 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 123.197 2.598 . . . . 10.0 110.556 178.605 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 28.9 m170 63.07 59.75 1.28 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 128.46 2.704 . . . . 10.0 110.858 177.581 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.1 m-85 -72.19 55.19 0.31 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.558 1.143 . . . . 10.0 113.892 -176.727 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -71.18 144.53 89.88 Favored Pre-proline 0 C--N 1.326 -0.437 0 C-N-CA 125.56 1.544 . . . . 10.0 113.18 -174.158 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -71.78 -37.87 4.75 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.283 2.655 . . . . 10.0 111.398 176.706 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.79 56.95 0.98 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.653 0.781 . . . . 10.0 110.533 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 67.9 p -42.06 94.85 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 126.676 1.99 . . . . 10.0 112.948 -169.58 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.2 mtt85 -121.14 172.15 8.18 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 126.129 1.772 . . . . 10.0 108.163 174.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 35.1 mtmm -102.0 106.32 17.22 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 -176.667 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -19.22 105.43 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.32 0 C-N-CA 126.71 2.004 . . . . 10.0 114.407 -171.024 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -115.35 -146.45 8.89 Favored Glycine 0 N--CA 1.439 -1.101 0 C-N-CA 125.828 1.68 . . . . 10.0 109.467 176.541 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.98 -166.39 24.93 Favored Glycine 0 N--CA 1.45 -0.41 0 N-CA-C 108.587 -1.805 . . . . 10.0 108.587 171.603 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.4 -3.16 3.86 Favored 'Trans proline' 0 N--CA 1.454 -0.814 0 CA-C-N 119.87 1.835 . . . . 10.0 111.829 173.104 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -99.19 -17.35 18.19 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.592 0.757 . . . . 10.0 111.61 174.667 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -111.71 169.68 8.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.191 -1.041 . . . . 10.0 108.191 -179.138 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -80.8 -36.28 31.93 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.824 -1.547 . . . . 10.0 106.824 169.056 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 12.6 mt-10 -84.98 32.93 0.53 Allowed 'General case' 0 N--CA 1.442 -0.871 0 CA-C-O 122.646 1.213 . . . . 10.0 113.185 -166.02 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 ptm180 -66.68 133.65 50.65 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 170.091 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -66.56 -70.75 0.23 Allowed 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.461 0.648 . . . . 10.0 110.704 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 80.8 t -147.19 -105.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.038 -2.949 . . . . 10.0 103.038 177.729 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.34 62.8 4.52 Favored Glycine 0 CA--C 1.524 0.655 0 O-C-N 121.336 -0.852 . . . . 10.0 111.227 176.441 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -89.94 105.07 17.56 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 101.118 -3.66 . . . . 10.0 101.118 163.955 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -87.43 -37.29 17.14 Favored 'General case' 0 N--CA 1.461 0.109 0 N-CA-C 107.41 -1.33 . . . . 10.0 107.41 173.298 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.17 -95.68 1.26 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 123.448 0.547 . . . . 10.0 111.884 167.75 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -116.09 104.27 11.39 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.903 1.281 . . . . 10.0 111.304 -167.451 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.07 133.81 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 168.851 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 m -100.21 111.96 24.26 Favored 'General case' 0 N--CA 1.441 -0.895 0 C-N-CA 125.692 1.597 . . . . 10.0 109.07 -169.142 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.75 129.71 35.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.243 0.617 . . . . 10.0 110.912 179.123 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -57.33 170.86 0.46 Allowed 'General case' 0 C--O 1.233 0.224 0 O-C-N 124.778 1.299 . . . . 10.0 110.116 167.494 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.8 ptmm? -54.29 -30.56 51.26 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 114.676 -1.147 . . . . 10.0 111.189 172.14 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -78.87 -2.05 37.94 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.988 0.915 . . . . 10.0 111.439 -179.049 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.86 20.38 73.6 Favored Glycine 0 C--N 1.337 0.598 0 N-CA-C 110.625 -0.99 . . . . 10.0 110.625 179.204 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.16 102.43 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.954 0 N-CA-C 105.462 -2.051 . . . . 10.0 105.462 179.393 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -99.53 121.97 41.93 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.83 -1.174 . . . . 10.0 107.83 169.259 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -81.23 143.09 32.56 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.796 1.638 . . . . 10.0 109.347 173.597 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 85.4 t -117.79 129.84 73.59 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 N-CA-C 105.745 -1.946 . . . . 10.0 105.745 168.175 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 17.4 m -158.1 69.77 0.53 Allowed 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 124.515 1.126 . . . . 10.0 108.403 169.257 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -108.61 157.75 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -176.844 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -132.09 133.46 44.36 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 125.415 1.486 . . . . 10.0 108.691 170.892 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -136.26 135.07 38.7 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 108.288 -1.004 . . . . 10.0 108.288 -173.482 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 16.4 m -104.09 16.39 26.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.695 1.198 . . . . 10.0 111.729 -175.357 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.7 p -136.51 11.8 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 123.691 0.796 . . . . 10.0 110.33 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -113.95 136.13 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 103.11 -2.922 . . . . 10.0 103.11 169.905 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 11.5 m -139.53 123.68 17.9 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 123.358 0.663 . . . . 10.0 109.646 -178.223 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.1 mt -69.57 -31.6 69.88 Favored 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.985 0.914 . . . . 10.0 109.8 170.216 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 63.3 m -152.0 135.8 16.33 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.231 1.012 . . . . 10.0 108.339 170.666 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 164.59 -57.74 0.26 Allowed Glycine 0 C--N 1.333 0.391 0 N-CA-C 109.684 -1.367 . . . . 10.0 109.684 179.449 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -164.51 -50.06 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.694 1.998 . . . . 10.0 107.334 -178.129 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -74.37 -38.49 63.15 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.919 -1.037 . . . . 10.0 108.373 -169.597 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 45.5 t 42.03 55.14 3.9 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 126.486 1.914 . . . . 10.0 110.771 172.574 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.14 21.48 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 N-CA-C 113.873 1.064 . . . . 10.0 113.873 -168.626 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.7 mm -58.66 142.66 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 C-N-CA 125.33 1.452 . . . . 10.0 107.614 169.306 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.83 14.65 82.36 Favored Glycine 0 CA--C 1.534 1.245 0 CA-C-O 118.745 -1.031 . . . . 10.0 114.19 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.3 mmt180 -74.11 175.05 7.84 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 107.389 -1.338 . . . . 10.0 107.389 168.198 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -117.79 128.24 54.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.743 -1.206 . . . . 10.0 107.743 169.83 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 27.8 mt -98.42 142.73 29.68 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 107.953 -1.129 . . . . 10.0 107.953 174.317 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -131.09 132.33 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.324 -1.361 . . . . 10.0 107.324 178.191 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.31 123.66 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.254 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.044 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.404 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.2 m170 -101.01 161.55 13.51 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 114.465 1.283 . . . . 10.0 114.465 -173.956 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -56.21 -50.64 70.67 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 126.433 1.893 . . . . 10.0 110.967 178.441 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 48.8 mttm -112.35 163.44 14.4 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.421 0.629 . . . . 10.0 111.508 -171.104 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.37 141.23 42.72 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 114.628 -1.169 . . . . 10.0 108.773 172.172 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -76.45 148.15 37.44 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 108.56 -0.904 . . . . 10.0 108.56 174.768 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.86 -37.03 15.65 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 126.814 2.046 . . . . 10.0 109.757 -178.414 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 20.4 mt 66.48 36.88 4.84 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.788 0.835 . . . . 10.0 113.059 -176.742 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 111.58 -25.77 12.9 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 118.553 0.615 . . . . 10.0 114.435 165.35 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.252 0.0 OUTLIER -94.56 31.12 1.83 Allowed 'General case' 0 CA--C 1.543 0.69 0 N-CA-C 113.386 0.884 . . . . 10.0 113.386 -172.758 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.16 -12.21 62.02 Favored Glycine 0 C--N 1.343 0.938 0 C-N-CA 125.342 1.449 . . . . 10.0 112.06 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.62 44.95 47.62 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.252 0.929 . . . . 10.0 112.778 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -153.28 175.46 13.06 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.479 -0.934 . . . . 10.0 108.479 175.722 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -56.67 -40.16 75.03 Favored 'General case' 0 N--CA 1.437 -1.079 0 O-C-N 121.356 -0.84 . . . . 10.0 111.845 -175.31 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -63.13 -36.57 84.03 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 118.056 -0.973 . . . . 10.0 109.723 175.838 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 59.0 p -51.01 -42.89 60.7 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 119.62 1.1 . . . . 10.0 110.954 -172.955 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.252 12.3 t -81.93 -11.31 58.95 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 112.522 0.564 . . . . 10.0 112.522 -175.448 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -115.88 -58.45 2.11 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.532 1.533 . . . . 10.0 113.648 -170.266 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 16.9 p -128.98 10.84 5.96 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 120.449 1.477 . . . . 10.0 112.182 175.447 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.25 -97.01 2.17 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 125.401 1.477 . . . . 10.0 109.742 176.073 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -168.09 37.88 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 122.944 1.354 . . . . 10.0 107.706 178.864 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.11 -22.73 55.21 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 113.534 -1.667 . . . . 10.0 108.446 -173.803 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.82 -157.37 53.07 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 109.506 -1.438 . . . . 10.0 109.506 169.497 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.26 120.29 3.93 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 124.28 1.032 . . . . 10.0 113.229 -167.663 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -63.06 80.47 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.412 1.085 . . . . 10.0 109.939 171.229 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.8 mt -45.56 -52.68 10.14 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.343 0.592 . . . . 10.0 110.96 178.061 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.93 152.8 31.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.723 -0.672 . . . . 10.0 109.501 -168.623 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -147.13 161.06 41.65 Favored 'General case' 0 N--CA 1.447 -0.592 0 O-C-N 123.83 0.706 . . . . 10.0 111.009 -176.79 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.94 168.59 28.15 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 125.473 1.511 . . . . 10.0 109.413 -177.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.0 t -120.76 137.85 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 106.366 -1.716 . . . . 10.0 106.366 -178.84 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.9 mt -73.12 116.81 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.655 -0.498 . . . . 10.0 109.655 -177.451 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.25 154.25 17.08 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 111.331 -176.029 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.23 145.89 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 C-N-CA 124.763 1.225 . . . . 10.0 108.395 176.008 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.11 -25.99 5.2 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 113.58 0.956 . . . . 10.0 113.58 178.422 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.2 tp60 . . . . . 0 C--O 1.25 1.125 0 CA-C-O 117.074 -1.441 . . . . 10.0 107.153 -177.142 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.564 0 N-CA-C 106.534 -1.654 . . . . 10.0 106.534 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.2 t -156.83 -49.22 0.07 Allowed 'General case' 0 C--O 1.224 -0.242 0 CA-C-N 119.365 0.984 . . . . 10.0 110.957 169.161 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -124.01 122.23 37.35 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 125.13 1.372 . . . . 10.0 108.768 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -130.92 152.09 50.62 Favored 'General case' 0 CA--C 1.52 -0.184 0 C-N-CA 123.785 0.834 . . . . 10.0 109.523 170.019 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -118.38 161.15 17.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 C-N-CA 122.947 0.499 . . . . 10.0 111.091 178.022 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.9 110.4 5.78 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.165 -0.925 . . . . 10.0 108.561 167.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 2.6 m -96.95 108.48 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 124.246 1.019 . . . . 10.0 109.349 172.763 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.9 mt -92.17 131.56 37.31 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.527 -0.916 . . . . 10.0 108.527 -178.396 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -143.65 157.09 44.67 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.612 -1.255 . . . . 10.0 107.612 171.042 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.02 -60.91 0.05 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 121.157 -0.544 . . . . 10.0 113.045 169.35 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.25 -43.78 66.58 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 -177.318 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.58 -71.22 0.42 Allowed Glycine 0 CA--C 1.523 0.578 0 CA-C-N 114.358 -1.292 . . . . 10.0 110.631 168.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -57.1 -31.98 91.93 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 123.282 2.655 . . . . 10.0 111.313 171.757 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 93.5 t -67.97 94.5 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 107.118 -1.438 . . . . 10.0 107.118 177.334 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -115.55 112.4 22.14 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 105.91 -1.885 . . . . 10.0 105.91 178.591 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.07 139.62 14.59 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 172.182 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.406 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 4.5 mt -140.77 95.85 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 108.286 -1.005 . . . . 10.0 108.286 -174.986 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -106.9 149.15 10.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 124.578 1.151 . . . . 10.0 113.011 -178.184 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -122.98 110.04 14.88 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.939 2.096 . . . . 10.0 108.24 168.749 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -86.97 108.2 18.73 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 170.821 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -109.3 113.41 26.22 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-O 121.395 0.616 . . . . 10.0 111.646 179.81 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -78.1 101.77 7.15 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 169.854 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 2.1 mmmp? -42.32 -66.4 0.36 Allowed 'General case' 0 CA--C 1.522 -0.103 0 C-N-CA 127.345 2.258 . . . . 10.0 109.72 177.511 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 16.5 mp0 -120.8 -169.87 1.9 Allowed 'General case' 0 N--CA 1.423 -1.809 0 N-CA-C 102.211 -3.255 . . . . 10.0 102.211 167.961 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 9.8 t -75.94 -29.79 58.44 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 118.163 -1.415 . . . . 10.0 109.024 173.012 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -97.1 -15.44 20.97 Favored 'General case' 0 N--CA 1.446 -0.631 0 C-N-CA 124.379 1.072 . . . . 10.0 111.777 -175.205 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.39 158.94 52.12 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 -179.734 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -61.88 144.02 96.27 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.491 2.127 . . . . 10.0 109.633 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 t -78.93 87.18 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.999 0 N-CA-C 106.417 -1.698 . . . . 10.0 106.417 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.4 mttm -67.08 108.19 2.55 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 106.854 -1.536 . . . . 10.0 106.854 169.012 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -110.03 108.87 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 125.624 1.569 . . . . 10.0 107.465 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 21.9 p90 -123.38 168.12 12.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.509 0.671 . . . . 10.0 110.123 173.408 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.46 -170.76 43.92 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 179.243 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.3 m -154.98 111.88 3.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -175.939 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 pt -84.22 175.19 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.573 -0.851 . . . . 10.0 110.115 169.703 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -149.98 156.35 41.56 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 166.675 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.52 -25.17 11.36 Favored Glycine 0 C--N 1.338 0.678 0 CA-C-O 119.372 -0.682 . . . . 10.0 114.154 171.039 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.4 mp -75.04 179.59 4.89 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 118.388 1.094 . . . . 10.0 111.513 -170.84 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.6 t -101.84 161.55 13.58 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.637 -0.875 . . . . 10.0 108.637 168.263 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -49.2 153.0 1.05 Allowed 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.192 1.797 . . . . 10.0 113.675 -169.292 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.43 179.55 39.43 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 124.607 1.099 . . . . 10.0 113.033 168.525 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 95.2 mt -49.49 137.71 14.61 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.119 1.768 . . . . 10.0 112.755 171.894 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -138.2 147.12 43.46 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 124.773 1.229 . . . . 10.0 112.048 171.351 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -18.65 118.5 0.01 OUTLIER Glycine 0 C--N 1.337 0.598 0 C-N-CA 127.835 2.636 . . . . 10.0 114.16 165.466 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -151.35 106.02 3.26 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 120.218 2.009 . . . . 10.0 112.909 167.296 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.418 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -151.07 168.39 24.76 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.655 -0.702 . . . . 10.0 111.269 176.504 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 16.7 m -86.7 155.09 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 112.21 -2.268 . . . . 10.0 107.06 166.681 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -126.09 152.91 45.23 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 173.243 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -59.7 -42.98 94.24 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 113.689 0.996 . . . . 10.0 113.689 -168.857 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -96.38 174.96 6.61 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.749 -0.834 . . . . 10.0 108.749 -177.193 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -111.35 10.8 28.64 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 125.418 1.485 . . . . 10.0 109.668 166.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.49 112.62 1.65 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 122.327 1.06 . . . . 10.0 109.067 176.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -120.56 9.97 10.99 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 114.244 -1.344 . . . . 10.0 108.305 168.006 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 15.5 m -67.59 -34.6 77.35 Favored 'General case' 0 C--N 1.344 0.359 0 C-N-CA 125.235 1.414 . . . . 10.0 108.625 171.02 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.41 -22.34 60.26 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.323 -0.399 . . . . 10.0 110.479 174.702 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.5 54.33 1.7 Allowed Glycine 0 C--N 1.34 0.761 0 C-N-CA 123.893 0.759 . . . . 10.0 111.557 172.083 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 37.5 m 59.76 28.96 18.51 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.03 0.932 . . . . 10.0 110.166 -176.136 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 38.7 m -112.09 -49.8 2.95 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 125.439 1.495 . . . . 10.0 107.147 -169.596 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 8.4 t -117.31 26.62 9.62 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 113.563 0.949 . . . . 10.0 113.563 -175.041 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.42 -7.57 6.97 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.701 1.001 . . . . 10.0 113.701 179.548 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.36 123.61 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.763 1.173 . . . . 10.0 111.052 172.856 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -81.34 55.86 5.78 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 123.074 2.516 . . . . 10.0 112.16 -172.154 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.418 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 16.1 m170 66.76 36.84 4.42 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 128.956 2.903 . . . . 10.0 111.78 176.192 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -76.99 71.66 3.5 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 120.692 1.587 . . . . 10.0 109.998 175.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -61.87 158.19 44.78 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 125.201 1.4 . . . . 10.0 110.208 169.31 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -62.91 -46.63 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.024 1.816 . . . . 10.0 111.153 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 69.9 mt -78.84 56.45 1.91 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 123.204 0.601 . . . . 10.0 110.309 -179.383 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -45.25 112.21 0.42 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.639 1.176 . . . . 10.0 110.775 -179.305 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.5 mtp85 -137.33 -97.83 0.2 Allowed 'General case' 0 CA--C 1.506 -0.74 0 N-CA-C 104.492 -2.41 . . . . 10.0 104.492 -175.624 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 50.7 mttp -144.38 164.72 29.98 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.706 -1.22 . . . . 10.0 107.706 166.733 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -66.47 120.65 13.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 106.59 -1.634 . . . . 10.0 106.59 164.641 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.23 -137.79 3.66 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 108.087 -2.005 . . . . 10.0 108.087 175.304 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.6 -160.63 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 109.422 -1.471 . . . . 10.0 109.422 173.493 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -65.41 4.45 0.77 Allowed 'Trans proline' 0 N--CA 1.454 -0.834 0 C-N-CA 122.15 1.9 . . . . 10.0 111.83 169.824 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 57.8 mmtt -94.31 -24.03 17.58 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-O 118.508 -0.758 . . . . 10.0 110.127 170.282 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -108.29 161.42 15.02 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-O 121.051 0.453 . . . . 10.0 111.176 -167.53 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -97.46 -9.72 26.71 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.134 -0.939 . . . . 10.0 109.585 174.15 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -123.05 28.5 7.16 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 119.32 -0.372 . . . . 10.0 110.645 -178.91 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . 0.444 HH12 ' CG ' ' B' ' 101' ' ' ASP . 14.9 ptt180 -50.38 154.53 1.24 Allowed 'General case' 0 C--N 1.344 0.354 0 C-N-CA 123.337 0.655 . . . . 10.0 109.879 169.217 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -65.78 -64.88 0.76 Allowed 'General case' 0 N--CA 1.453 -0.319 0 CA-C-O 121.552 0.691 . . . . 10.0 109.503 -178.534 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . 0.419 ' CG1' ' H ' ' B' ' 82' ' ' GLY . 4.0 p -169.34 -93.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 105.602 -1.999 . . . . 10.0 105.602 176.195 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . 0.419 ' H ' ' CG1' ' B' ' 81' ' ' VAL . . . -78.94 58.98 4.27 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.479 -1.048 . . . . 10.0 110.479 173.905 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.83 98.93 10.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 102.306 -3.22 . . . . 10.0 102.306 165.951 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -78.26 10.77 2.76 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.24 0.473 . . . . 10.0 110.585 -175.571 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 81.12 -109.44 2.99 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 104.128 -3.589 . . . . 10.0 104.128 -175.28 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -159.53 149.78 18.97 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.354 -1.721 . . . . 10.0 106.354 -178.435 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.45 128.18 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 C-N-CA 123.18 0.592 . . . . 10.0 111.202 -171.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.87 97.52 5.3 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 126.676 1.99 . . . . 10.0 111.176 -174.412 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.33 134.36 39.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.071 -0.393 . . . . 10.0 110.482 173.066 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.411 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 17.3 t70 -61.91 169.0 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.874 0.845 . . . . 10.0 109.249 167.358 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.411 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 34.7 mtmt -48.06 -34.4 9.51 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.873 1.669 . . . . 10.0 111.395 169.331 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -78.16 -8.32 58.15 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.999 0.428 . . . . 10.0 112.077 -179.377 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.69 1.94 70.38 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 120.933 -1.104 . . . . 10.0 111.572 -176.102 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -84.81 101.39 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.115 0 C-N-CA 125.77 1.628 . . . . 10.0 108.007 -179.232 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.13 115.72 27.87 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 168.252 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -80.86 119.35 23.3 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 106.737 -1.579 . . . . 10.0 106.737 169.24 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 66.5 t -104.11 131.12 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -177.446 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.3 p -157.24 83.81 0.92 Allowed 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 174.033 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -115.18 159.46 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 105.088 -2.19 . . . . 10.0 105.088 176.325 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -133.52 133.19 41.85 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 109.103 -0.703 . . . . 10.0 109.103 168.082 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . 0.444 ' CG ' HH12 ' B' ' 79' ' ' ARG . 7.1 t0 -113.89 111.93 22.51 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 124.229 0.955 . . . . 10.0 109.377 -173.052 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.6 p -100.77 61.73 1.0 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.446 1.498 . . . . 10.0 107.079 -176.229 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.5 p -155.39 -47.07 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.145 0 N-CA-C 110.204 -0.295 . . . . 10.0 110.204 -173.006 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.355 0.0 OUTLIER -102.15 176.89 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.143 0 N-CA-C 113.622 0.971 . . . . 10.0 113.622 172.231 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 49.9 m -151.62 146.1 25.57 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 105.915 -1.883 . . . . 10.0 105.915 -179.723 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 29.0 mt -68.01 -14.7 63.18 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 117.948 0.34 . . . . 10.0 111.354 -175.615 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.8 m -145.65 158.72 43.82 Favored 'General case' 0 N--CA 1.451 -0.421 0 O-C-N 120.949 -1.094 . . . . 10.0 108.62 174.382 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.21 -101.08 0.56 Allowed Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 106.167 -2.773 . . . . 10.0 106.167 -169.761 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -129.56 -47.37 1.17 Allowed 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 125.455 1.502 . . . . 10.0 109.199 -168.885 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 36.1 m-70 -75.44 -39.56 58.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 115.158 -0.928 . . . . 10.0 109.133 -170.472 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 11.4 t 21.35 92.84 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 128.868 2.867 . . . . 10.0 114.227 172.142 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 36.7 pt -72.79 -11.86 15.22 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 C-N-CA 123.717 0.807 . . . . 10.0 112.45 176.854 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm -52.11 133.11 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 O-C-N 121.488 -0.758 . . . . 10.0 110.059 178.774 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.87 1.4 84.39 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 118.81 -0.995 . . . . 10.0 114.016 -178.749 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 57.2 mtt85 -85.92 175.94 8.35 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.719 1.759 . . . . 10.0 108.487 168.459 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.04 140.13 50.19 Favored 'General case' 0 CA--C 1.513 -0.467 0 C-N-CA 125.458 1.503 . . . . 10.0 108.512 179.101 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.5 mp -110.14 155.93 21.27 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 107.641 -1.244 . . . . 10.0 107.641 166.03 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 91.2 t -128.82 134.3 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.149 0 N-CA-C 106.695 -1.595 . . . . 10.0 106.695 -179.183 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.84 121.62 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.363 0 N-CA-C 105.71 -1.959 . . . . 10.0 105.71 166.865 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -102.95 160.5 14.55 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 116.316 1.969 . . . . 10.0 116.316 -168.925 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -43.46 -56.73 3.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 129.085 2.954 . . . . 10.0 111.19 173.73 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 78.1 mttt -113.52 168.84 9.42 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 124.067 0.947 . . . . 10.0 113.352 -168.569 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.44 154.0 41.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 124.68 1.238 . . . . 10.0 108.641 169.822 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -106.07 141.43 37.45 Favored 'General case' 0 N--CA 1.454 -0.243 0 O-C-N 123.902 0.751 . . . . 10.0 111.287 -168.6 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -74.54 -31.03 61.98 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 125.169 1.388 . . . . 10.0 110.195 -177.355 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 13.7 mt 60.62 50.57 5.59 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 122.618 1.199 . . . . 10.0 108.014 -176.005 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.68 -52.08 4.18 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 115.392 -0.822 . . . . 10.0 111.401 172.571 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 48.75 0.98 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.517 1.127 . . . . 10.0 112.249 -172.679 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.16 -26.97 7.14 Favored Glycine 0 CA--C 1.522 0.492 0 C-N-CA 127.936 2.684 . . . . 10.0 111.17 173.426 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.45 18.01 65.17 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-O 118.472 -1.182 . . . . 10.0 112.65 172.908 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -131.95 168.75 17.35 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-N 119.677 1.739 . . . . 10.0 108.277 168.361 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.45 -55.04 6.56 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.571 1.148 . . . . 10.0 108.878 178.042 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -63.62 -34.22 77.35 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 118.169 -0.919 . . . . 10.0 111.791 -175.674 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.3 m -49.16 -46.86 45.9 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 120.202 1.365 . . . . 10.0 110.804 169.301 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -89.3 -15.6 33.09 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.245 -0.883 . . . . 10.0 113.257 -170.549 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -98.07 -40.93 8.19 Favored 'General case' 0 N--CA 1.438 -1.062 0 C-N-CA 125.027 1.331 . . . . 10.0 111.773 179.146 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.405 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 38.4 p -136.28 -7.02 2.02 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 114.567 1.321 . . . . 10.0 114.567 175.086 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.83 17.14 52.96 Favored Glycine 0 C--O 1.221 -0.669 0 CA-C-O 118.463 -1.187 . . . . 10.0 112.306 -173.27 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 55.53 30.29 14.94 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.533 1.667 . . . . 10.0 111.765 178.76 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.59 54.8 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 125.979 1.712 . . . . 10.0 112.057 -175.323 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.33 54.81 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 110.595 -1.002 . . . . 10.0 110.595 174.605 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.2 m -55.6 139.63 43.75 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 123.966 0.906 . . . . 10.0 111.887 -168.354 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 22.6 mtt85 -71.02 70.84 0.53 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.828 1.251 . . . . 10.0 110.06 176.684 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.3 tp -44.6 -36.2 2.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 127.84 2.456 . . . . 10.0 112.536 -176.673 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.28 151.13 17.05 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 172.959 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -146.7 164.82 31.5 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 109.914 -0.402 . . . . 10.0 109.914 177.129 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.64 -176.63 25.44 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.496 -1.042 . . . . 10.0 110.496 178.249 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.4 t -122.56 143.13 36.41 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 107.568 -1.271 . . . . 10.0 107.568 179.817 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 11.4 mt -78.38 112.42 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 124.1 0.96 . . . . 10.0 109.493 -179.066 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.69 146.12 16.52 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 178.2 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -79.96 119.02 28.57 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 177.22 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.56 -43.05 40.56 Favored 'General case' 0 C--O 1.221 -0.439 0 O-C-N 121.078 -1.014 . . . . 10.0 108.554 -176.038 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.946 0 C-N-CA 125.793 1.637 . . . . 10.0 110.815 170.577 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.836 0 CA-C-O 118.628 -0.701 . . . . 10.0 109.661 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.5 t -97.15 -32.71 11.81 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 124.982 1.313 . . . . 10.0 110.369 -178.295 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -148.25 151.62 35.77 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.344 -0.984 . . . . 10.0 108.344 -177.849 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.15 155.41 45.31 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 122.878 0.471 . . . . 10.0 110.548 176.401 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.1 p -126.84 151.4 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 C-N-CA 128.152 2.581 . . . . 10.0 107.028 -178.762 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.62 116.29 11.41 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.174 -2.158 . . . . 10.0 105.174 168.265 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.3 p -81.29 103.72 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 108.822 -0.807 . . . . 10.0 108.822 174.42 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.76 116.45 23.26 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.027 -1.101 . . . . 10.0 108.027 178.333 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -137.84 155.99 48.4 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 174.401 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -163.19 -66.28 0.02 OUTLIER Glycine 0 C--O 1.229 -0.18 0 CA-C-N 114.915 -1.039 . . . . 10.0 111.891 174.67 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.76 -43.91 57.64 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 -172.706 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.52 -67.66 0.53 Allowed Glycine 0 N--CA 1.443 -0.895 0 CA-C-N 113.481 -1.691 . . . . 10.0 110.525 179.779 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -58.23 -37.96 93.1 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.911 2.408 . . . . 10.0 111.142 174.617 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 94.4 t -64.54 96.81 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 176.425 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -120.35 123.1 42.27 Favored 'General case' 0 N--CA 1.446 -0.661 0 C-N-CA 125.104 1.361 . . . . 10.0 107.381 175.666 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -116.25 136.6 13.0 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 123.652 0.644 . . . . 10.0 112.168 175.363 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 58.6 mt -124.56 74.09 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 -179.018 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -64.09 148.85 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.374 -0.83 . . . . 10.0 109.598 171.67 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -139.05 97.85 3.4 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 127.437 2.295 . . . . 10.0 107.548 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -89.79 118.87 29.7 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.781 -1.192 . . . . 10.0 107.781 171.301 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -104.8 130.88 52.83 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.838 0.745 . . . . 10.0 110.971 168.644 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -123.1 92.3 3.67 Favored 'General case' 0 C--N 1.341 0.217 0 C-N-CA 125.076 1.35 . . . . 10.0 109.102 171.759 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 11.0 mmtp -49.94 -60.91 2.48 Favored 'General case' 0 N--CA 1.46 0.072 0 C-N-CA 124.653 1.181 . . . . 10.0 111.054 175.804 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.0 176.65 8.57 Favored 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 105.604 -1.998 . . . . 10.0 105.604 171.2 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 t -74.72 -13.74 60.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 122.341 0.256 . . . . 10.0 110.708 177.229 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -88.25 -12.94 42.21 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 123.729 0.811 . . . . 10.0 109.794 174.434 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.14 119.54 4.98 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 109.357 -1.497 . . . . 10.0 109.357 178.573 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -60.83 127.73 23.37 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 N-CA-C 106.558 -2.132 . . . . 10.0 106.558 169.41 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -77.01 138.06 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 108.702 -0.851 . . . . 10.0 108.702 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.79 106.24 18.22 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 104.759 -2.311 . . . . 10.0 104.759 171.76 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 m -87.03 93.33 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 105.467 -2.049 . . . . 10.0 105.467 174.137 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -109.18 178.79 4.35 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-O 120.83 0.348 . . . . 10.0 111.219 173.721 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.58 -164.09 30.15 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 169.043 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.6 p -152.19 122.43 7.19 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 118.641 -0.695 . . . . 10.0 110.934 -169.383 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.88 136.6 31.73 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 105.891 -1.892 . . . . 10.0 105.891 166.325 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.411 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -130.14 160.05 34.96 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 168.809 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.7 -12.52 62.79 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 118.042 0.383 . . . . 10.0 113.208 -178.815 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 15.4 mt -68.2 -179.49 1.28 Allowed 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.872 0.869 . . . . 10.0 110.489 171.651 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -111.95 166.46 11.2 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 167.554 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -46.64 148.96 0.88 Allowed 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 127.359 2.264 . . . . 10.0 113.419 -169.534 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.65 -179.09 42.98 Favored Glycine 0 C--N 1.336 0.569 0 C-N-CA 124.235 0.922 . . . . 10.0 114.091 167.139 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.6 mt -52.38 137.9 28.23 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.878 1.671 . . . . 10.0 113.02 176.63 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 -135.31 141.57 45.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.439 1.095 . . . . 10.0 111.075 169.525 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -25.46 121.75 0.03 OUTLIER Glycine 0 C--N 1.344 0.992 0 CA-C-O 116.648 -2.195 . . . . 10.0 111.773 165.776 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -144.54 109.5 5.04 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 120.431 2.115 . . . . 10.0 111.053 169.768 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.09 175.02 11.36 Favored 'General case' 0 CA--C 1.512 -0.487 0 C-N-CA 123.572 0.749 . . . . 10.0 109.102 -179.612 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.88 98.29 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 113.595 -1.638 . . . . 10.0 109.653 179.448 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 20.4 m-70 -72.74 148.02 45.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 125.898 1.679 . . . . 10.0 109.681 -172.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -62.03 -55.72 26.34 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 123.958 0.786 . . . . 10.0 112.077 -173.435 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -87.92 150.6 23.38 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 119.258 -0.977 . . . . 10.0 109.583 177.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.98 32.92 5.57 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.098 -1.201 . . . . 10.0 110.098 168.414 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -79.8 70.22 6.28 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 123.251 1.5 . . . . 10.0 108.683 179.153 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -73.98 5.5 4.19 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.557 -1.201 . . . . 10.0 113.519 -174.014 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -32.79 -50.75 0.27 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 129.607 3.163 . . . . 10.0 112.703 175.144 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.97 -20.4 45.6 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 113.517 0.932 . . . . 10.0 113.517 -174.572 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.25 71.24 0.89 Allowed Glycine 0 CA--C 1.524 0.62 0 N-CA-C 106.987 -2.445 . . . . 10.0 106.987 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.8 t 49.33 24.01 0.95 Allowed 'General case' 0 CA--C 1.529 0.145 0 N-CA-C 115.844 1.794 . . . . 10.0 115.844 171.356 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.5 m -94.27 -52.48 4.34 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -178.388 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.2 m -66.86 -25.36 66.38 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 125.359 1.464 . . . . 10.0 112.732 -169.332 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.43 -38.27 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.542 2.737 . . . . 10.0 113.73 173.483 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 152.71 9.61 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 111.299 -0.72 . . . . 10.0 111.299 167.713 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.85 57.28 6.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.414 2.076 . . . . 10.0 110.571 172.784 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 30.2 m170 71.56 -64.8 0.37 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 128.014 2.526 . . . . 10.0 108.875 -179.557 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.285 1.1 p90 26.02 49.32 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 129.845 3.258 . . . . 10.0 115.096 175.16 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -51.66 157.2 1.96 Allowed Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 114.438 -1.256 . . . . 10.0 111.057 169.415 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.14 -40.82 24.61 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 121.943 1.762 . . . . 10.0 111.054 -173.735 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mp -77.03 59.63 1.7 Allowed 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.532 -0.914 . . . . 10.0 108.532 169.134 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.3 p -60.95 106.87 0.63 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 107.942 -1.133 . . . . 10.0 107.942 -177.418 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -129.93 -87.64 0.51 Allowed 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 107.34 -1.356 . . . . 10.0 107.34 -169.857 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.3 mmtp -139.05 153.69 48.11 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 122.313 1.054 . . . . 10.0 109.573 169.076 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -70.42 119.78 15.1 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 105.742 -1.948 . . . . 10.0 105.742 162.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.26 -135.88 2.91 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 107.104 -2.398 . . . . 10.0 107.104 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.26 -147.73 6.21 Favored Glycine 0 C--O 1.226 -0.403 0 CA-C-O 117.965 -1.464 . . . . 10.0 109.677 171.65 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -67.13 7.78 0.43 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 119.818 1.809 . . . . 10.0 111.105 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -113.37 3.4 15.86 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 118.225 -0.893 . . . . 10.0 111.563 170.944 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -122.42 149.67 43.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.604 -1.628 . . . . 10.0 106.604 170.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -83.05 -24.77 32.63 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.65 -0.871 . . . . 10.0 108.65 171.189 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -113.3 26.2 10.65 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 125.242 1.417 . . . . 10.0 111.068 -168.665 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -47.62 161.54 0.09 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 128.589 2.756 . . . . 10.0 110.078 168.371 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -78.69 46.85 0.69 Allowed 'General case' 0 N--CA 1.463 0.216 0 O-C-N 120.575 -1.328 . . . . 10.0 112.318 -178.106 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.2 p 33.16 35.94 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 126.861 2.064 . . . . 10.0 113.595 -174.278 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 165.98 37.69 0.02 OUTLIER Glycine 0 CA--C 1.532 1.113 0 O-C-N 121.538 -0.726 . . . . 10.0 111.961 -169.246 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -113.71 108.15 16.72 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -81.33 -29.48 34.16 Favored 'General case' 0 N--CA 1.461 0.121 0 N-CA-C 107.557 -1.275 . . . . 10.0 107.557 169.033 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.16 -96.64 1.31 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 108.424 -1.871 . . . . 10.0 108.424 168.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -134.92 117.98 16.41 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 125.6 1.56 . . . . 10.0 106.905 -169.497 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 22.4 m -111.61 132.26 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 CA-C-N 118.553 0.615 . . . . 10.0 111.296 179.428 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.8 m -78.46 107.88 11.43 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.771 2.429 . . . . 10.0 112.468 -170.472 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.51 137.26 32.48 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.869 0.467 . . . . 10.0 111.309 174.225 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -62.18 174.6 0.87 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 122.009 0.909 . . . . 10.0 110.328 166.927 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.5 pttt -51.74 -32.48 30.68 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.516 1.927 . . . . 10.0 112.709 169.191 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.411 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 22.8 t70 -79.17 -10.46 59.83 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 122.14 0.971 . . . . 10.0 110.658 178.107 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.89 3.7 65.72 Favored Glycine 0 N--CA 1.431 -1.634 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 -171.898 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 26.4 t -75.55 95.65 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.095 0 N-CA-C 106.327 -1.731 . . . . 10.0 106.327 -172.461 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.21 113.17 25.01 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 169.052 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -81.78 115.14 20.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 C-N-CA 127.199 2.2 . . . . 10.0 108.832 175.191 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.2 133.31 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 176.406 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 72.7 p -158.52 80.88 0.81 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.963 0.905 . . . . 10.0 109.799 170.642 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -112.26 143.1 22.68 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 177.628 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -99.73 127.37 45.86 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.393 1.477 . . . . 10.0 107.564 169.372 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -133.7 156.15 48.45 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.601 0.715 . . . . 10.0 109.083 176.721 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.5 t -128.1 49.58 2.15 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 126.022 1.729 . . . . 10.0 109.015 -173.41 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -157.79 -39.42 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 123.361 0.664 . . . . 10.0 110.63 176.837 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 45.6 mm -59.92 116.53 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 169.887 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 48.5 m -131.34 119.29 21.51 Favored 'General case' 0 CA--C 1.528 0.115 0 C-N-CA 124.251 1.02 . . . . 10.0 108.417 178.396 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 59.1 mt -53.97 -38.39 64.97 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 125.108 1.363 . . . . 10.0 111.166 173.491 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.2 m -152.17 151.89 31.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.475 -0.935 . . . . 10.0 108.475 -176.095 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.3 -97.17 0.19 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.295 -1.922 . . . . 10.0 108.295 -174.825 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -122.31 -51.1 1.99 Allowed 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 127.066 2.146 . . . . 10.0 107.935 177.523 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.8 m-70 -73.56 -35.7 65.52 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 114.959 -1.019 . . . . 10.0 108.258 -169.695 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.4 t 42.47 61.47 2.02 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 125.839 1.656 . . . . 10.0 112.951 167.289 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.7 pp -68.71 -9.14 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 113.697 0.999 . . . . 10.0 113.697 -171.633 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 10.5 mm -47.09 133.37 3.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.957 -0.757 . . . . 10.0 108.957 168.893 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.3 -7.49 75.52 Favored Glycine 0 CA--C 1.533 1.156 0 CA-C-O 118.851 -0.972 . . . . 10.0 114.51 -178.483 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.7 mtp-105 -76.26 175.33 9.15 Favored 'General case' 0 CA--C 1.544 0.74 0 CA-C-N 119.843 1.821 . . . . 10.0 106.858 168.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -127.78 132.23 49.53 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 119.091 0.86 . . . . 10.0 112.006 -170.586 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -85.23 148.29 26.16 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 123.997 0.919 . . . . 10.0 108.533 171.863 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 91.9 t -133.32 128.4 55.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.636 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -95.58 123.99 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 106.164 -1.791 . . . . 10.0 106.164 166.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -98.86 159.72 14.76 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.963 1.468 . . . . 10.0 114.963 -172.805 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -40.47 -58.21 1.62 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 128.415 2.686 . . . . 10.0 110.362 172.385 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -121.44 170.97 9.13 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 113.865 1.061 . . . . 10.0 113.865 -168.209 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.29 136.69 58.13 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 113.938 -1.483 . . . . 10.0 109.072 172.673 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -76.93 148.68 36.22 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.77 0.795 . . . . 10.0 110.634 -179.877 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -81.82 -41.61 20.84 Favored 'General case' 0 N--CA 1.447 -0.625 0 C-N-CA 130.977 3.711 . . . . 10.0 108.955 -176.746 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 16.8 mt 61.29 43.85 10.33 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.451 0.7 . . . . 10.0 112.172 -178.049 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.01 19.55 77.21 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 113.991 0.356 . . . . 10.0 113.991 169.585 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -86.83 -21.8 26.21 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.534 1.133 . . . . 10.0 110.884 172.471 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -56.43 -30.02 58.02 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.777 0.703 . . . . 10.0 111.805 178.578 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.67 30.19 71.75 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.351 -1.1 . . . . 10.0 110.351 -176.124 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.4 166.6 12.46 Favored 'General case' 0 CA--C 1.511 -0.538 0 N-CA-C 108.594 -0.891 . . . . 10.0 108.594 173.006 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -48.67 -54.56 14.3 Favored 'General case' 0 N--CA 1.431 -1.389 0 C-N-CA 124.511 1.125 . . . . 10.0 108.517 176.006 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -51.6 -47.3 63.66 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 124.131 0.973 . . . . 10.0 112.2 173.644 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.9 p -52.67 -37.67 59.15 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 118.991 -0.528 . . . . 10.0 109.94 -179.223 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.251 14.8 t -90.67 0.57 57.35 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 113.807 1.04 . . . . 10.0 113.807 -179.26 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.99 -53.37 2.71 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.77 1.628 . . . . 10.0 112.596 -179.354 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.418 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 35.3 p -129.41 5.4 5.2 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 119.807 1.185 . . . . 10.0 111.862 171.342 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 81.52 -118.54 4.65 Favored Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 103.264 -3.934 . . . . 10.0 103.264 -167.181 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -168.81 39.14 0.03 OUTLIER 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 126.247 1.819 . . . . 10.0 107.789 -178.401 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.67 0.11 13.85 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.585 1.154 . . . . 10.0 111.792 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.15 -163.59 50.73 Favored Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 110.437 -1.065 . . . . 10.0 110.437 171.261 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.34 140.38 45.45 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.835 0.854 . . . . 10.0 111.798 -168.717 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -65.36 72.82 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.567 1.147 . . . . 10.0 110.068 169.709 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 6.0 tp -44.67 -45.53 9.75 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.991 1.716 . . . . 10.0 112.121 -175.685 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 145.93 20.19 Favored 'General case' 0 C--O 1.234 0.281 0 N-CA-C 108.199 -1.038 . . . . 10.0 108.199 -175.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 m -139.6 152.64 46.98 Favored 'General case' 0 CA--C 1.518 -0.259 0 C-N-CA 123.12 0.568 . . . . 10.0 109.974 -169.125 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -149.81 145.42 13.54 Favored Glycine 0 C--N 1.338 0.652 0 N-CA-C 110.536 -1.026 . . . . 10.0 110.536 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 23.8 t -102.07 138.04 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 106.335 -1.728 . . . . 10.0 106.335 -175.319 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 48.5 mt -76.04 107.74 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 N-CA-C 109.917 -0.401 . . . . 10.0 109.917 -173.457 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.8 164.52 12.04 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.574 1.559 . . . . 10.0 111.635 178.465 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.4 mt -64.37 143.67 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 C-N-CA 124.93 1.292 . . . . 10.0 111.495 -177.908 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -136.72 162.27 33.65 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.404 -1.332 . . . . 10.0 107.404 167.542 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 . . . . . 0 C--O 1.251 1.162 0 N-CA-C 104.256 -2.498 . . . . 10.0 104.256 166.884 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.49 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -105.54 -27.77 11.19 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 126.041 1.737 . . . . 10.0 111.743 170.009 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.8 tttt -131.05 137.06 48.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.846 0.859 . . . . 10.0 109.354 179.421 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.93 161.0 30.9 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 123.375 0.67 . . . . 10.0 110.083 170.792 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.6 t -120.45 154.66 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 C-N-CA 126.354 1.861 . . . . 10.0 108.874 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.46 108.57 4.77 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 167.86 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.7 m -98.72 121.74 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 109.303 -0.629 . . . . 10.0 109.303 177.909 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.76 133.58 43.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.611 -0.709 . . . . 10.0 109.89 -175.266 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.3 mtpt -144.41 156.89 44.42 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 119.368 0.985 . . . . 10.0 109.153 167.447 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.47 -59.59 0.06 OUTLIER Glycine 0 N--CA 1.461 0.312 0 C-N-CA 119.696 -1.24 . . . . 10.0 113.861 169.776 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -71.12 -42.85 68.69 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -174.882 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.5 -70.05 0.41 Allowed Glycine 0 CA--C 1.523 0.532 0 CA-C-N 114.157 -1.383 . . . . 10.0 110.35 169.207 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.83 -36.82 99.0 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 123.338 2.692 . . . . 10.0 111.357 172.393 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.7 91.16 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 125.804 1.641 . . . . 10.0 107.802 177.098 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -117.82 112.39 20.33 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.205 1.402 . . . . 10.0 107.934 176.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.48 148.95 16.86 Favored Glycine 0 N--CA 1.432 -1.592 0 CA-C-N 114.137 -1.392 . . . . 10.0 111.328 -178.338 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.2 mt -151.42 84.11 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.332 1.853 . . . . 10.0 107.107 -169.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.0 mm -97.01 149.89 4.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 C-N-CA 124.914 1.286 . . . . 10.0 110.566 179.708 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.18 111.66 11.62 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 128.901 2.88 . . . . 10.0 108.382 -178.031 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -98.29 111.02 23.5 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 117.435 -1.269 . . . . 10.0 107.845 172.948 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -108.77 108.55 19.41 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.365 0.984 . . . . 10.0 112.271 174.073 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -103.87 96.21 6.53 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.588 1.955 . . . . 10.0 107.153 174.442 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 65.6 mttt -59.19 -50.22 74.85 Favored 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 123.946 0.898 . . . . 10.0 110.637 -169.052 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -135.13 171.56 14.25 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 102.755 -3.054 . . . . 10.0 102.755 -176.524 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.5 p -71.92 -18.25 62.04 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 119.174 0.897 . . . . 10.0 109.467 173.893 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -78.93 -19.35 52.01 Favored 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 123.606 0.763 . . . . 10.0 110.796 172.397 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.21 123.1 9.19 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 110.024 -1.231 . . . . 10.0 110.024 -175.876 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.8 127.79 18.58 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 N-CA-C 107.045 -1.944 . . . . 10.0 107.045 169.832 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.5 p -76.46 85.81 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-O 122.432 1.11 . . . . 10.0 108.349 -174.36 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 mtpt -58.82 111.31 1.24 Allowed 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 169.607 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 p -102.07 101.87 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.754 0 C-N-CA 126.219 1.807 . . . . 10.0 106.395 -177.64 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -116.18 174.4 6.07 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 116.319 -0.401 . . . . 10.0 111.385 176.531 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.03 -156.01 26.72 Favored Glycine 0 C--N 1.331 0.264 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 169.294 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.2 p -149.71 146.56 27.29 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.451 0.644 . . . . 10.0 112.595 -172.373 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -120.95 115.41 46.75 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.329 0 C-N-CA 125.909 1.684 . . . . 10.0 108.693 169.774 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -102.49 143.1 32.63 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 169.746 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.72 9.35 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 124.562 1.077 . . . . 10.0 112.969 170.332 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 mt -87.77 -175.67 5.24 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.961 0.886 . . . . 10.0 110.571 -171.274 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -102.72 155.78 18.08 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 167.516 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -53.54 159.09 1.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.589 1.156 . . . . 10.0 111.793 -174.878 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.71 -177.15 35.59 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.717 0.675 . . . . 10.0 111.803 170.608 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -66.56 149.82 49.9 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 125.46 1.504 . . . . 10.0 112.373 -177.861 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.6 m-70 -146.8 142.28 27.56 Favored 'General case' 0 C--N 1.344 0.352 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -177.467 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -30.99 125.62 0.17 Allowed Glycine 0 C--N 1.343 0.943 0 C-N-CA 127.74 2.59 . . . . 10.0 113.03 165.679 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.67 105.12 2.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 119.343 1.572 . . . . 10.0 113.002 168.577 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.13 172.74 15.31 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.156 0.503 . . . . 10.0 111.501 179.64 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.0 m -93.99 149.93 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 113.156 -1.838 . . . . 10.0 108.408 169.299 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 24.2 m-70 -130.94 140.31 50.16 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.719 1.608 . . . . 10.0 106.888 174.795 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -52.76 -54.86 27.92 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 125.27 1.428 . . . . 10.0 112.327 -169.721 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -77.62 114.59 16.61 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -61.05 -32.16 79.29 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.261 -1.136 . . . . 10.0 110.261 172.257 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -32.16 125.35 0.29 Allowed 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 125.296 1.439 . . . . 10.0 112.548 172.282 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -129.69 11.36 5.7 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 113.967 -1.47 . . . . 10.0 111.401 176.628 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 8.2 p -37.17 -63.27 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 125.972 1.709 . . . . 10.0 113.309 -175.477 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -74.67 -16.03 60.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.444 -1.253 . . . . 10.0 111.89 -174.458 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 136.11 -75.57 0.4 Allowed Glycine 0 CA--C 1.521 0.464 0 N-CA-C 109.004 -1.638 . . . . 10.0 109.004 177.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 9.3 t -157.0 18.65 0.3 Allowed 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 112.734 0.642 . . . . 10.0 112.734 -172.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.0 p -99.07 -57.43 2.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 105.718 -1.956 . . . . 10.0 105.718 -176.527 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -55.64 -25.77 40.84 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.424 1.89 . . . . 10.0 111.81 -179.409 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.14 -29.64 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 127.953 2.501 . . . . 10.0 114.226 168.349 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.61 154.96 28.28 Favored Glycine 0 C--N 1.34 0.752 0 N-CA-C 109.359 -1.496 . . . . 10.0 109.359 170.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -74.12 -170.84 0.77 Allowed 'Trans proline' 0 N--CA 1.446 -1.315 0 N-CA-C 107.787 -1.659 . . . . 10.0 107.787 168.778 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.1 m170 -80.95 60.67 4.25 Favored 'General case' 0 CA--C 1.537 0.444 0 O-C-N 120.658 -1.276 . . . . 10.0 109.827 -177.079 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -73.67 72.71 1.48 Allowed 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 122.117 0.96 . . . . 10.0 109.698 174.408 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -73.16 135.06 79.99 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.636 -0.665 . . . . 10.0 110.042 173.271 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.18 -44.56 4.82 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 122.57 2.18 . . . . 10.0 110.867 -177.426 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.8 mt -72.63 67.85 0.8 Allowed 'General case' 0 C--O 1.225 -0.234 0 C-N-CA 123.481 0.712 . . . . 10.0 109.312 175.067 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 40.5 p -37.03 108.67 0.08 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 125.853 1.661 . . . . 10.0 111.054 -179.187 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.83 173.03 12.05 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 103.086 -2.931 . . . . 10.0 103.086 -170.568 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.7 mptt -80.06 152.44 29.37 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 117.341 -1.743 . . . . 10.0 107.99 170.338 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.418 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 79.1 t60 -63.27 103.2 0.47 Allowed 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.398 -0.964 . . . . 10.0 108.398 165.596 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.37 -127.34 4.05 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.156 -1.977 . . . . 10.0 108.156 177.718 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.7 -163.83 32.47 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 108.377 -1.889 . . . . 10.0 108.377 173.346 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -63.29 -5.5 8.27 Favored 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 119.832 1.816 . . . . 10.0 110.793 167.499 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -87.53 -26.09 23.33 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 125.407 1.483 . . . . 10.0 110.076 175.131 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -98.94 158.36 15.7 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 106.798 -1.556 . . . . 10.0 106.798 179.299 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -79.0 -32.38 45.14 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 107.421 -1.326 . . . . 10.0 107.421 168.541 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -114.5 51.36 0.89 Allowed 'General case' 0 N--CA 1.447 -0.604 0 C-N-CA 124.26 1.024 . . . . 10.0 111.018 -168.684 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -61.43 164.53 5.58 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.589 1.556 . . . . 10.0 110.689 169.159 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . 0.418 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 9.9 m170 -66.59 -63.09 1.14 Allowed 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.418 0.525 . . . . 10.0 112.418 -170.022 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 8.2 p -171.65 -47.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.19 0.996 . . . . 10.0 109.818 -178.092 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.59 72.28 0.37 Allowed Glycine 0 C--N 1.336 0.572 0 N-CA-C 107.149 -2.38 . . . . 10.0 107.149 176.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.05 98.11 5.83 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.497 -2.038 . . . . 10.0 105.497 -173.358 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 40.5 mt -80.72 5.92 14.35 Favored 'General case' 0 N--CA 1.463 0.177 0 C-N-CA 122.678 0.391 . . . . 10.0 111.774 -169.844 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 82.65 -106.36 2.73 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 107.475 -2.25 . . . . 10.0 107.475 -174.582 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -158.65 152.53 23.54 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.125 0.97 . . . . 10.0 110.248 -177.146 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -122.74 133.99 67.23 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 123.275 0.63 . . . . 10.0 110.174 -176.402 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -78.57 133.23 37.35 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 126.546 1.938 . . . . 10.0 109.266 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.29 132.56 50.41 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.548 1.939 . . . . 10.0 110.155 169.726 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.403 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 24.0 t70 -63.6 171.22 2.72 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.993 1.717 . . . . 10.0 111.145 168.733 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.403 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 17.9 pttp -49.07 -35.03 14.95 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 124.565 1.146 . . . . 10.0 110.647 169.535 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.9 -3.15 40.28 Favored 'General case' 0 C--N 1.342 0.249 0 O-C-N 122.326 -0.234 . . . . 10.0 110.535 -175.919 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.68 22.88 78.75 Favored Glycine 0 N--CA 1.444 -0.797 0 N-CA-C 109.469 -1.452 . . . . 10.0 109.469 -175.289 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.0 t -96.21 106.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.86 0 C-N-CA 127.57 2.348 . . . . 10.0 105.093 173.438 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.44 125.05 48.03 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.287 -1.005 . . . . 10.0 108.287 169.341 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -94.68 121.33 36.15 Favored 'General case' 0 N--CA 1.435 -1.179 0 C-N-CA 127.838 2.455 . . . . 10.0 108.832 179.308 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 43.3 t -101.26 135.81 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 124.767 1.227 . . . . 10.0 108.147 177.326 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.26 72.43 0.62 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.945 1.298 . . . . 10.0 109.408 169.689 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -106.38 162.46 5.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 107.565 -1.272 . . . . 10.0 107.565 -179.036 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -146.13 136.46 23.87 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.584 1.554 . . . . 10.0 109.568 175.69 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -134.02 142.34 47.58 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.091 -1.818 . . . . 10.0 106.091 173.759 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 75.2 p -103.5 51.48 0.79 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.868 1.267 . . . . 10.0 107.811 174.228 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.32 -47.91 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.323 0.649 . . . . 10.0 110.377 -176.97 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.47 118.26 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 171.431 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.1 m -120.62 112.67 19.19 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 108.562 -0.903 . . . . 10.0 108.562 -176.658 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 77.4 mt -56.81 -43.97 81.51 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.457 0.646 . . . . 10.0 110.41 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.0 m -156.5 83.5 0.97 Allowed 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 -174.358 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -147.65 -61.53 0.01 OUTLIER Glycine 0 C--N 1.334 0.435 0 N-CA-C 111.062 -0.815 . . . . 10.0 111.062 -170.328 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -153.95 -52.88 0.1 Allowed 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 126.02 1.728 . . . . 10.0 106.827 -175.799 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -77.57 -34.95 53.52 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.868 -1.16 . . . . 10.0 107.868 -175.218 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t 56.14 61.48 2.73 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.135 1.374 . . . . 10.0 108.112 173.084 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 31.0 mm -73.57 -14.06 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 CA-C-N 113.543 -1.662 . . . . 10.0 112.228 -168.973 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.5 mm -51.48 147.32 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 N-CA-C 109.363 -0.606 . . . . 10.0 109.363 169.696 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.81 2.44 90.54 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 121.357 -0.84 . . . . 10.0 114.592 178.815 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 54.4 mmt-85 -77.58 163.31 26.37 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 118.914 1.357 . . . . 10.0 108.716 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.1 118.17 35.24 Favored 'General case' 0 C--N 1.34 0.153 0 N-CA-C 109.287 -0.634 . . . . 10.0 109.287 170.51 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -75.49 142.99 42.79 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.048 -1.464 . . . . 10.0 107.048 167.184 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.64 129.36 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.831 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.04 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.7 p -97.35 135.3 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.715 0 N-CA-C 107.96 -1.126 . . . . 10.0 107.96 169.275 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 3.8 m170 -115.02 159.72 20.46 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 116.465 2.024 . . . . 10.0 116.465 -175.891 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -48.92 -58.38 4.95 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 129.832 3.253 . . . . 10.0 111.932 177.071 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 54.8 mttp -111.93 173.46 6.35 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.966 0.906 . . . . 10.0 112.804 -169.874 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.05 136.04 35.26 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 126.524 1.929 . . . . 10.0 110.304 -179.165 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.69 144.22 32.42 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 113.362 0.875 . . . . 10.0 113.362 -169.558 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -74.9 -38.56 61.82 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.187 1.395 . . . . 10.0 109.206 177.855 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.8 mt 62.12 49.92 4.23 Favored 'General case' 0 C--N 1.337 0.054 0 C-N-CA 125.21 1.404 . . . . 10.0 110.006 -172.259 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' B' ' 129' ' ' GLY . . . 82.82 -45.58 3.45 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.562 1.077 . . . . 10.0 110.988 170.638 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.5 pttp -73.43 21.63 0.08 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.83 1.652 . . . . 10.0 112.72 -175.147 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . 0.402 ' H ' ' C ' ' B' ' 127' ' ' GLY . . . -77.91 -32.71 43.99 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 126.475 1.988 . . . . 10.0 108.298 166.103 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.22 19.08 69.97 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.284 -0.731 . . . . 10.0 111.859 -179.124 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -112.07 162.27 15.59 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 104.839 -2.282 . . . . 10.0 104.839 169.215 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . 0.496 ' CD ' ' HZ2' ' B' ' 136' ' ' LYS . 15.6 tm-20 -60.92 -40.04 91.7 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 119.505 -0.878 . . . . 10.0 110.748 -169.849 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -69.12 -28.28 66.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 118.749 -0.643 . . . . 10.0 112.242 177.529 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -48.76 -47.47 41.64 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 119.68 1.127 . . . . 10.0 110.242 168.852 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.4 t -85.1 -10.15 57.15 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 118.461 -0.781 . . . . 10.0 112.711 -171.366 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.496 ' HZ2' ' CD ' ' B' ' 132' ' ' GLU . 1.1 ttmp? -100.61 -92.34 0.3 Allowed 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.69 1.596 . . . . 10.0 108.15 175.292 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.467 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 44.5 p -86.26 1.35 51.23 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 122.135 2.243 . . . . 10.0 112.744 -176.062 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.58 21.89 73.88 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 120.416 1.462 . . . . 10.0 110.79 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 61.72 19.92 10.93 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 119.577 1.688 . . . . 10.0 112.854 169.649 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -80.29 9.96 5.12 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 113.623 0.972 . . . . 10.0 113.623 -168.021 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.72 -165.07 53.94 Favored Glycine 0 N--CA 1.444 -0.781 0 O-C-N 121.252 -0.905 . . . . 10.0 111.502 170.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.5 m -59.3 135.63 57.71 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 124.1 0.96 . . . . 10.0 112.901 -167.705 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -67.23 86.99 0.16 Allowed 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 125.129 1.372 . . . . 10.0 110.276 174.042 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 58.5 mt -60.85 -35.12 75.76 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.827 0.676 . . . . 10.0 112.827 -177.19 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.39 154.35 26.81 Favored 'General case' 0 C--O 1.234 0.244 0 O-C-N 121.625 -0.672 . . . . 10.0 111.495 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -123.55 152.36 41.9 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 125.857 1.663 . . . . 10.0 109.088 -178.674 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.57 156.04 26.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.413 -1.075 . . . . 10.0 110.413 168.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 66.1 t -109.58 140.07 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 -175.588 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 27.6 mt -75.62 125.15 34.92 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-O 118.594 -0.717 . . . . 10.0 109.764 -178.622 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.81 162.76 24.48 Favored Glycine 0 CA--C 1.53 1.022 0 C-N-CA 124.383 0.992 . . . . 10.0 113.569 -178.573 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.8 mm -73.34 144.91 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.274 1.03 . . . . 10.0 111.226 -169.904 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.96 -47.2 2.18 Favored 'General case' 0 CA--C 1.51 -0.592 0 CA-C-N 118.45 0.568 . . . . 10.0 111.433 166.652 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 116.38 -1.771 . . . . 10.0 107.544 175.78 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.659 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.7 t -151.55 -48.44 0.11 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 119.12 0.873 . . . . 10.0 110.7 178.686 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 40.8 tttt -132.87 153.64 51.14 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.2 -1.778 . . . . 10.0 106.2 172.59 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.22 151.18 43.55 Favored 'General case' 0 CA--C 1.513 -0.46 0 N-CA-C 108.93 -0.767 . . . . 10.0 108.93 169.286 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.38 161.12 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 O-C-N 124.061 0.851 . . . . 10.0 110.223 172.464 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.41 98.96 3.07 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.206 -1.775 . . . . 10.0 106.206 165.703 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.5 m -93.29 98.02 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 122.844 0.458 . . . . 10.0 110.687 -179.204 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.5 mp -79.6 136.26 36.8 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 121.227 -0.921 . . . . 10.0 109.833 -175.756 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -144.73 156.15 43.92 Favored 'General case' 0 C--N 1.341 0.212 0 C-N-CA 124.426 1.09 . . . . 10.0 108.344 168.346 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.6 -69.08 0.02 OUTLIER Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.185 -0.531 . . . . 10.0 112.166 169.252 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -74.24 -41.51 61.2 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 107.179 -1.415 . . . . 10.0 107.179 -175.656 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.91 -67.67 0.48 Allowed Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 114.996 -1.002 . . . . 10.0 111.588 176.969 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -55.15 -42.05 72.58 Favored 'Trans proline' 0 N--CA 1.45 -1.077 0 C-N-CA 121.972 1.782 . . . . 10.0 110.077 175.846 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 47.9 t -58.49 87.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 C-N-CA 126.182 1.793 . . . . 10.0 108.034 175.197 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.47 116.95 31.75 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.709 -1.96 . . . . 10.0 105.709 171.453 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.91 142.89 15.97 Favored Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 108.656 -1.778 . . . . 10.0 108.656 174.258 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.426 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 7.1 mt -138.71 60.81 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 N-CA-C 107.357 -1.349 . . . . 10.0 107.357 -169.684 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.4 mm -77.87 133.56 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 N-CA-C 108.801 -0.814 . . . . 10.0 108.801 -176.072 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m-80 -122.44 105.11 9.87 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.203 2.201 . . . . 10.0 107.22 -176.805 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -89.1 136.44 33.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.499 1.12 . . . . 10.0 108.025 177.749 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -117.49 148.29 41.97 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 123.703 0.627 . . . . 10.0 110.701 168.191 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -122.46 107.14 11.69 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.7 1.6 . . . . 10.0 108.01 168.816 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -65.91 -59.2 4.08 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.974 0.91 . . . . 10.0 110.644 -178.492 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.1 mp0 -128.22 168.02 16.04 Favored 'General case' 0 N--CA 1.425 -1.725 0 N-CA-C 103.608 -2.738 . . . . 10.0 103.608 174.079 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.2 p -65.98 -25.74 67.24 Favored 'General case' 0 N--CA 1.44 -0.937 0 O-C-N 121.748 -0.595 . . . . 10.0 109.429 174.759 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -98.69 -6.33 29.85 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.207 1.403 . . . . 10.0 110.828 -173.361 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.63 144.57 21.4 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 -173.772 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -64.02 139.42 67.29 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 121.721 1.614 . . . . 10.0 108.101 170.525 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 m -93.12 142.51 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -176.861 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.41 ' NZ ' ' OE1' ' A' ' 100' ' ' GLU . 1.9 ttmp? -108.06 123.21 48.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.298 -2.482 . . . . 10.0 104.298 166.606 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 m -108.99 103.45 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 105.916 -1.883 . . . . 10.0 105.916 -179.371 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 8.0 p90 -114.44 171.82 7.39 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 -176.298 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.65 -154.4 25.53 Favored Glycine 0 N--CA 1.447 -0.618 0 N-CA-C 108.537 -1.825 . . . . 10.0 108.537 169.076 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 m -153.54 150.24 28.5 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 117.124 0.462 . . . . 10.0 110.899 177.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -111.17 112.65 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 C-N-CA 127.356 2.263 . . . . 10.0 106.861 168.493 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.5 ptmt -121.73 90.3 3.28 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 112.214 0.45 . . . . 10.0 112.214 -178.276 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.65 32.35 0.02 OUTLIER Glycine 0 CA--C 1.52 0.406 0 CA-C-O 118.981 -0.9 . . . . 10.0 113.996 174.032 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -125.06 175.41 7.37 Favored 'General case' 0 C--O 1.224 -0.246 0 N-CA-C 108.237 -1.023 . . . . 10.0 108.237 177.144 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -75.6 168.54 19.81 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 118.83 0.741 . . . . 10.0 110.844 177.712 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 65.1 tt0 -61.02 173.3 0.81 Allowed 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.21 1.804 . . . . 10.0 111.288 -176.874 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.14 179.73 49.73 Favored Glycine 0 CA--C 1.522 0.52 0 C-N-CA 123.781 0.705 . . . . 10.0 112.017 168.897 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.0 mp -66.02 143.56 57.28 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.376 1.07 . . . . 10.0 110.275 178.449 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -140.39 146.5 38.45 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 113.384 0.883 . . . . 10.0 113.384 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -29.25 122.72 0.09 OUTLIER Glycine 0 C--N 1.341 0.851 0 C-N-CA 127.547 2.499 . . . . 10.0 112.269 165.25 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -150.62 106.01 3.37 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 120.034 1.917 . . . . 10.0 113.12 169.758 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.416 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.43 175.18 12.99 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.509 0.671 . . . . 10.0 112.803 -176.497 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.7 m -91.42 153.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 112.655 -2.066 . . . . 10.0 106.3 166.499 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.32 123.27 35.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 102.884 -3.006 . . . . 10.0 102.884 169.113 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -61.33 -35.03 76.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 114.894 1.442 . . . . 10.0 114.894 -164.571 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-30 -75.91 119.54 20.02 Favored 'General case' 0 C--N 1.342 0.251 0 C-N-CA 117.285 -1.766 . . . . 10.0 106.984 169.576 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.01 37.08 0.92 Allowed Glycine 0 CA--C 1.525 0.676 0 C-N-CA 125.041 1.305 . . . . 10.0 111.241 168.883 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -107.55 171.56 7.32 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 124.899 1.279 . . . . 10.0 107.697 177.459 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.1 25.65 0.14 Allowed 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 114.653 -1.158 . . . . 10.0 112.231 168.747 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.39 -36.96 66.97 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.451 1.1 . . . . 10.0 111.253 -170.481 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.38 -19.6 55.95 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 124.022 0.929 . . . . 10.0 112.468 -179.695 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 87.04 97.87 0.85 Allowed Glycine 0 CA--C 1.528 0.866 0 N-CA-C 109.02 -1.632 . . . . 10.0 109.02 -169.698 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 59.2 m 43.11 55.17 4.67 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.032 1.733 . . . . 10.0 113.962 173.074 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.76 -49.62 0.08 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.078 0.551 . . . . 10.0 110.139 176.034 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 47.4 t -60.8 -28.89 69.12 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 122.44 0.296 . . . . 10.0 111.059 -173.314 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.42 -28.97 0.07 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 127.448 2.299 . . . . 10.0 115.156 179.758 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 134.26 8.41 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-O 118.449 -1.195 . . . . 10.0 110.528 170.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -78.46 62.24 8.14 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 123.211 2.607 . . . . 10.0 112.319 -174.315 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 14.0 m170 61.74 28.02 17.21 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.511 2.324 . . . . 10.0 110.581 177.372 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -53.72 -39.05 64.91 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 113.871 1.064 . . . . 10.0 113.871 -166.67 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 34.27 172.23 0.0 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 128.807 2.843 . . . . 10.0 115.518 -169.662 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -67.81 -65.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.349 0.573 0 O-C-N 118.621 -1.305 . . . . 10.0 110.849 -172.781 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.0 74.52 2.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 169.006 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 p -47.89 113.76 0.78 Allowed 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.048 0.939 . . . . 10.0 108.946 169.487 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 40.6 mtt180 -133.13 -167.06 1.85 Allowed 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 105.783 -1.932 . . . . 10.0 105.783 -178.465 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.81 137.54 33.66 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 118.046 -1.462 . . . . 10.0 110.304 -171.022 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 65.8 t60 -47.15 119.66 2.71 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 120.337 -0.545 . . . . 10.0 110.517 168.218 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.61 -143.76 4.22 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 108.636 -1.786 . . . . 10.0 108.636 177.583 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.445 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -171.61 -149.94 6.86 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-O 118.158 -1.357 . . . . 10.0 109.981 175.431 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 79.7 Cg_endo -69.27 14.68 0.22 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 122.162 1.908 . . . . 10.0 111.415 169.287 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.445 ' H ' ' C ' ' A' ' 73' ' ' GLY . 6.0 mtpm? -110.08 -10.78 14.67 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 124.616 1.166 . . . . 10.0 110.075 169.592 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -111.41 158.55 18.96 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.369 -1.345 . . . . 10.0 107.369 -179.176 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -79.41 -36.86 38.42 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.653 -1.24 . . . . 10.0 107.653 173.033 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -96.8 -49.7 4.96 Favored 'General case' 0 CA--C 1.498 -1.024 0 CA-C-O 121.453 0.644 . . . . 10.0 112.137 -166.3 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 7.1 ptp180 41.52 -141.4 0.09 Allowed 'General case' 0 N--CA 1.434 -1.253 0 CA-C-N 113.709 -1.587 . . . . 10.0 109.108 -169.478 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -112.12 44.56 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 O-C-N 120.611 -1.306 . . . . 10.0 108.073 166.511 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.9 t 37.8 38.96 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 124.081 0.953 . . . . 10.0 111.04 -167.596 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 70.69 0.02 OUTLIER Glycine 0 CA--C 1.533 1.195 0 O-C-N 121.541 -0.724 . . . . 10.0 112.431 -174.002 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -136.94 111.15 8.39 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 104.008 -2.59 . . . . 10.0 104.008 168.181 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 19.3 mt -72.19 -23.18 61.22 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 118.667 0.667 . . . . 10.0 109.225 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.11 -89.8 0.55 Allowed Glycine 0 N--CA 1.441 -1.025 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 167.042 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 m-20 -147.8 126.44 12.53 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -173.794 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.7 m -109.82 124.87 66.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 118.043 0.383 . . . . 10.0 110.097 176.293 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.1 m -79.51 111.39 15.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 127.245 2.218 . . . . 10.0 111.228 -176.825 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.56 129.75 34.75 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 123.176 0.59 . . . . 10.0 109.985 170.813 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.505 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 18.2 t70 -61.29 166.69 3.66 Favored 'General case' 0 N--CA 1.454 -0.272 0 O-C-N 124.574 1.171 . . . . 10.0 109.119 167.756 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.505 ' HZ2' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -56.64 -26.0 54.92 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 123.91 0.884 . . . . 10.0 111.446 175.882 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -75.76 -10.62 59.59 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 120.583 0.23 . . . . 10.0 110.675 179.525 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.04 23.15 42.3 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.403 -1.079 . . . . 10.0 110.403 178.664 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.1 t -106.99 105.57 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.986 0 C-N-CA 128.359 2.664 . . . . 10.0 105.95 -178.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.83 121.46 42.52 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.668 -1.234 . . . . 10.0 107.668 168.635 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -92.32 132.63 36.56 Favored 'General case' 0 N--CA 1.434 -1.261 0 C-N-CA 127.188 2.195 . . . . 10.0 108.899 176.36 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -113.08 133.12 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.979 0 C-N-CA 125.298 1.439 . . . . 10.0 107.676 175.14 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.5 p -158.35 57.82 0.45 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.278 0.631 . . . . 10.0 110.688 169.651 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.79 155.15 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.101 0 N-CA-C 107.999 -1.112 . . . . 10.0 107.999 -173.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.41 ' OE1' ' NZ ' ' A' ' 30' ' ' LYS . 0.8 OUTLIER -122.2 156.41 33.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 124.746 1.218 . . . . 10.0 111.904 173.809 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -148.97 164.19 35.3 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.057 -1.428 . . . . 10.0 108.989 168.721 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.7 p -118.8 44.01 2.4 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 126.227 1.811 . . . . 10.0 110.364 -178.012 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.2 p -145.19 -43.46 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 118.255 0.48 . . . . 10.0 111.251 177.013 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.39 147.31 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.318 -1.364 . . . . 10.0 107.318 169.176 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.1 m -151.57 135.44 16.45 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.128 -1.064 . . . . 10.0 108.128 174.385 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -70.04 -38.16 75.77 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.832 0.853 . . . . 10.0 108.919 -179.593 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 22.6 m -137.75 130.22 29.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.74 -1.578 . . . . 10.0 106.74 170.335 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.91 -65.66 0.1 OUTLIER Glycine 0 C--N 1.333 0.369 0 N-CA-C 109.258 -1.537 . . . . 10.0 109.258 -177.941 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -163.06 -51.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.773 1.629 . . . . 10.0 107.703 -179.835 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -74.1 -41.59 61.4 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 114.38 -1.282 . . . . 10.0 108.091 -169.64 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.9 t 41.11 74.25 0.11 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 126.477 1.911 . . . . 10.0 111.702 174.858 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -68.22 -3.64 2.64 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 N-CA-C 112.932 0.716 . . . . 10.0 112.932 -179.682 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.1 mm -33.02 -44.34 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 126.453 1.901 . . . . 10.0 114.042 173.421 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.89 38.81 3.14 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 124.185 0.898 . . . . 10.0 112.515 -176.748 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -102.78 176.69 5.08 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.475 1.51 . . . . 10.0 111.643 170.046 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 4.7 m -119.1 131.22 55.9 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.952 2.101 . . . . 10.0 106.36 177.85 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 58.7 mt -103.9 148.35 26.26 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 125.28 1.432 . . . . 10.0 109.324 172.285 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.2 t -136.36 134.36 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 O-C-N 123.71 0.631 . . . . 10.0 109.364 -178.593 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.39 135.63 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 168.648 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.3 m170 -112.26 155.64 23.7 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 116.673 2.101 . . . . 10.0 116.673 -178.565 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.43 ' CD ' ' HZ3' ' A' ' 122' ' ' LYS . 34.2 tt0 -42.24 -62.93 0.83 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.779 3.231 . . . . 10.0 111.548 173.314 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.43 ' HZ3' ' CD ' ' A' ' 121' ' ' GLU . 8.1 mtmt -106.89 172.41 6.84 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.993 1.317 . . . . 10.0 111.823 -177.298 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.4 150.96 39.76 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.994 -1.457 . . . . 10.0 109.605 172.459 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.416 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.3 m-20 -79.46 150.23 31.32 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.565 1.146 . . . . 10.0 112.495 177.317 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -74.36 -29.56 61.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.973 -1.467 . . . . 10.0 110.122 169.943 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 27.4 mt 54.97 44.27 28.53 Favored 'General case' 0 C--N 1.339 0.129 0 CA-C-O 121.847 0.832 . . . . 10.0 108.799 -167.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.38 -10.17 67.71 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 125.667 1.603 . . . . 10.0 113.151 173.204 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -78.33 -3.93 45.5 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 118.405 1.102 . . . . 10.0 113.117 -170.795 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.2 -38.62 95.94 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.813 -0.915 . . . . 10.0 110.813 175.152 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.43 33.45 81.88 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.114 -1.194 . . . . 10.0 110.114 -173.387 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -117.59 161.96 18.79 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 106.05 -1.833 . . . . 10.0 106.05 169.69 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -51.36 -48.87 62.36 Favored 'General case' 0 N--CA 1.428 -1.525 0 N-CA-C 108.721 -0.844 . . . . 10.0 108.721 170.773 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -59.04 -40.1 84.04 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.318 -0.401 . . . . 10.0 111.31 176.96 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 16.6 p -55.75 -40.15 72.16 Favored 'General case' 0 N--CA 1.443 -0.794 0 O-C-N 120.926 -1.109 . . . . 10.0 110.708 179.287 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -84.64 4.93 30.11 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 118.491 -0.766 . . . . 10.0 112.122 -178.265 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -112.83 -85.44 0.58 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.037 1.735 . . . . 10.0 110.091 175.022 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.4 p -111.43 30.87 6.56 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 121.088 1.767 . . . . 10.0 112.52 178.179 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.83 27.52 56.18 Favored Glycine 0 C--N 1.341 0.858 0 C-N-CA 123.757 0.694 . . . . 10.0 113.9 168.333 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 46.8 29.62 1.03 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.055 0.942 . . . . 10.0 113.01 -172.108 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.35 -4.57 18.77 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.228 -0.92 . . . . 10.0 112.24 -177.424 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.67 -161.92 50.17 Favored Glycine 0 N--CA 1.444 -0.812 0 O-C-N 121.129 -0.982 . . . . 10.0 111.315 169.212 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.1 m -55.12 128.39 33.57 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 114.644 -0.778 . . . . 10.0 112.842 -167.274 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 22.5 mtt85 -66.43 73.03 0.08 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.738 1.615 . . . . 10.0 109.758 172.078 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 35.1 mt -49.3 -36.82 21.94 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.595 1.158 . . . . 10.0 112.976 -175.722 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 152.1 24.72 Favored 'General case' 0 CA--C 1.513 -0.461 0 O-C-N 121.57 -0.706 . . . . 10.0 110.526 -177.877 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.0 m -130.87 145.66 52.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 124.821 1.326 . . . . 10.0 108.679 -175.661 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -135.48 141.28 12.46 Favored Glycine 0 C--N 1.332 0.314 0 N-CA-C 108.621 -1.792 . . . . 10.0 108.621 171.508 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -99.79 136.61 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 105.869 -1.9 . . . . 10.0 105.869 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.0 mt -72.09 158.93 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 -177.072 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -172.67 168.66 41.75 Favored Glycine 0 CA--C 1.527 0.787 0 O-C-N 121.379 -0.826 . . . . 10.0 111.737 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.7 mt -53.19 142.31 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 125.451 1.5 . . . . 10.0 111.534 -174.209 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.83 163.64 36.79 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.665 0.745 . . . . 10.0 109.489 166.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 . . . . . 0 C--O 1.256 1.405 0 N-CA-C 104.7 -2.333 . . . . 10.0 104.7 166.636 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.848 0 CA-C-O 117.997 -1.002 . . . . 10.0 108.432 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -165.21 -45.32 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.837 0.855 . . . . 10.0 110.208 178.346 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mttt -136.69 154.27 50.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 125.245 1.418 . . . . 10.0 109.248 169.711 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.59 164.43 30.23 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.366 1.466 . . . . 10.0 107.528 168.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -134.3 157.95 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 N-CA-C 109.327 -0.62 . . . . 10.0 109.327 -178.884 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.93 99.96 5.95 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.045 0.938 . . . . 10.0 109.502 172.925 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -81.24 93.03 2.18 Favored 'Isoleucine or valine' 0 C--N 1.341 0.229 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 167.966 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mt -84.71 136.68 33.62 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.474 1.11 . . . . 10.0 108.561 -178.732 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -159.74 161.64 34.79 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.441 -1.318 . . . . 10.0 107.441 173.771 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.38 -44.82 0.11 Allowed Glycine 0 C--O 1.227 -0.331 0 C-N-CA 119.813 -1.184 . . . . 10.0 113.473 168.938 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -74.1 -45.17 50.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.721 -1.215 . . . . 10.0 107.721 -176.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 144.22 -71.36 0.38 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.636 -1.386 . . . . 10.0 109.636 171.487 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -59.1 -37.52 92.12 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.303 2.669 . . . . 10.0 111.14 171.768 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 58.4 t -58.93 111.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 108.538 -0.912 . . . . 10.0 108.538 178.094 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -125.96 127.86 46.6 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 105.598 -2.001 . . . . 10.0 105.598 167.949 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -114.12 135.46 12.5 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 108.765 -1.734 . . . . 10.0 108.765 170.505 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 4.6 mt -134.97 68.07 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 106.706 -1.591 . . . . 10.0 106.706 -173.836 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.4 mm -97.59 139.82 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 115.145 -0.934 . . . . 10.0 110.467 -170.925 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -107.39 130.52 54.79 Favored 'General case' 0 CA--C 1.527 0.095 0 C-N-CA 126.833 2.053 . . . . 10.0 109.168 -176.183 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -116.75 100.38 7.76 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.376 -1.342 . . . . 10.0 107.376 177.91 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.47 156.89 17.37 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.33 0.514 . . . . 10.0 110.973 175.637 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 34.5 tp60 -154.2 65.49 0.7 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.979 1.312 . . . . 10.0 109.851 -177.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -142.04 92.64 2.46 Favored 'General case' 0 N--CA 1.432 -1.347 0 C-N-CA 124.86 1.264 . . . . 10.0 107.71 176.955 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -153.02 -170.12 3.53 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 103.557 -2.757 . . . . 10.0 103.557 166.709 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 29.2 m -89.92 -9.21 49.72 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 118.141 0.428 . . . . 10.0 111.055 174.843 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -128.68 8.94 5.87 Favored 'General case' 0 CA--C 1.529 0.15 0 C-N-CA 123.756 0.822 . . . . 10.0 111.355 -169.703 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 41.93 55.05 4.22 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 124.71 1.148 . . . . 10.0 115.419 179.637 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.71 104.06 1.67 Allowed 'Trans proline' 0 N--CA 1.445 -1.361 0 N-CA-C 105.939 -2.369 . . . . 10.0 105.939 168.339 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 t -77.67 78.95 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.502 -2.036 . . . . 10.0 105.502 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.3 ttmm -69.83 109.57 4.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.385 -1.709 . . . . 10.0 106.385 169.046 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -90.84 102.61 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 105.413 -2.069 . . . . 10.0 105.413 173.852 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -119.56 150.59 40.02 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.92 -160.92 32.93 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 109.502 -1.439 . . . . 10.0 109.502 169.293 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.1 p -147.47 115.15 6.39 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 108.898 -0.779 . . . . 10.0 108.898 -173.542 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.3 pt -80.19 179.15 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 108.748 -0.834 . . . . 10.0 108.748 168.146 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 92' ' ' ASP . 0.2 OUTLIER -155.86 159.86 39.71 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 107.472 -1.307 . . . . 10.0 107.472 164.034 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.06 -12.63 57.46 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-O 119.13 -0.817 . . . . 10.0 113.96 170.106 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.5 mp -70.65 176.65 4.0 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 119.036 1.418 . . . . 10.0 109.237 171.736 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -90.13 167.11 12.98 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.431 -0.951 . . . . 10.0 108.431 167.778 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -62.17 170.38 2.28 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.706 0.802 . . . . 10.0 111.734 -170.683 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.39 -174.23 33.45 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 124.317 0.96 . . . . 10.0 112.285 168.611 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -71.85 141.89 49.6 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.185 0.994 . . . . 10.0 109.409 175.761 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.82 148.92 41.34 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 114.7 1.37 . . . . 10.0 114.7 -179.368 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -36.85 127.05 1.09 Allowed Glycine 0 C--N 1.343 0.932 0 C-N-CA 127.649 2.547 . . . . 10.0 110.738 164.537 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -155.65 105.96 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 118.777 1.289 . . . . 10.0 109.055 168.485 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.497 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -156.05 175.34 14.1 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -178.2 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 29.0 m -90.04 151.58 3.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 113.771 -1.558 . . . . 10.0 110.265 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -142.42 137.75 30.61 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.592 1.557 . . . . 10.0 108.125 178.534 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -50.7 -57.14 9.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 114.944 1.461 . . . . 10.0 114.944 -169.103 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -78.46 123.13 26.7 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.92 -0.77 . . . . 10.0 108.92 -169.476 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.52 -30.53 77.88 Favored Glycine 0 CA--C 1.531 1.08 0 N-CA-C 107.444 -2.262 . . . . 10.0 107.444 165.6 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -45.81 142.58 2.46 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-O 123.303 1.525 . . . . 10.0 111.046 171.51 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -165.11 22.5 0.05 Allowed 'General case' 0 N--CA 1.434 -1.24 0 C-N-CA 126.05 1.74 . . . . 10.0 110.144 -169.573 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.426 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 1.3 p -53.16 -40.86 64.62 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 122.874 0.469 . . . . 10.0 112.11 -178.877 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.62 -18.31 54.7 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.227 0.611 . . . . 10.0 112.095 176.133 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.21 110.56 0.8 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.239 0.923 . . . . 10.0 111.986 -178.517 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.1 m 48.7 33.69 4.49 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.676 1.59 . . . . 10.0 112.336 172.492 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 22.3 m -138.18 -55.12 0.65 Allowed 'General case' 0 N--CA 1.437 -1.092 0 C-N-CA 126.296 1.838 . . . . 10.0 106.318 -173.591 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -67.04 -12.9 61.22 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.753 0.821 . . . . 10.0 111.722 178.041 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.31 -36.43 1.25 Allowed 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 126.961 2.104 . . . . 10.0 112.442 175.689 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.38 163.8 39.39 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 107.425 -2.27 . . . . 10.0 107.425 -178.644 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -74.73 -170.26 0.73 Allowed 'Trans proline' 0 N--CA 1.443 -1.463 0 C-N-CA 121.268 1.312 . . . . 10.0 109.252 172.2 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 38.3 m170 -78.6 58.7 2.29 Favored 'General case' 0 CA--C 1.538 0.515 0 O-C-N 121.269 -0.894 . . . . 10.0 110.572 -173.251 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -71.86 79.46 0.88 Allowed 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 123.096 1.427 . . . . 10.0 110.45 178.524 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -74.1 147.2 85.61 Favored Pre-proline 0 N--CA 1.445 -0.69 0 C-N-CA 125.015 1.326 . . . . 10.0 110.222 169.012 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -65.42 -43.53 10.5 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.319 2.013 . . . . 10.0 110.394 178.127 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 tt -78.14 56.82 1.71 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.024 0.93 . . . . 10.0 108.907 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 38.9 p -35.96 106.16 0.04 OUTLIER 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 126.055 1.742 . . . . 10.0 110.989 -173.098 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . 0.419 HH22 ' CD ' ' B' ' 77' ' ' GLU . 2.8 ttt180 -133.29 -174.75 3.58 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 104.029 -2.582 . . . . 10.0 104.029 -178.919 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 22.3 mmtp -75.33 161.11 29.57 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 117.618 -1.633 . . . . 10.0 108.523 170.543 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -65.01 123.31 19.13 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 161.786 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.33 -138.42 4.03 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 108.209 -1.956 . . . . 10.0 108.209 171.687 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.4 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 177.25 -160.08 26.75 Favored Glycine 0 C--O 1.224 -0.502 0 N-CA-C 108.869 -1.692 . . . . 10.0 108.869 177.192 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -66.6 2.03 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 CA-C-N 119.544 1.672 . . . . 10.0 110.131 166.332 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.4 ' H ' ' C ' ' B' ' 73' ' ' GLY . 25.0 mmtt -107.9 6.16 27.05 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 125.598 1.559 . . . . 10.0 110.192 173.987 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -141.48 155.89 45.8 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 119.565 1.075 . . . . 10.0 110.611 167.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . 0.419 ' CD ' HH22 ' B' ' 69' ' ' ARG . 5.8 tm-20 -79.36 -26.98 41.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.641 -1.614 . . . . 10.0 106.641 168.632 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -85.87 27.55 0.87 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.669 1.188 . . . . 10.0 111.732 -172.77 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 37.5 ptt-85 -63.72 150.41 44.5 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.208 1.003 . . . . 10.0 111.018 179.003 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -64.68 -70.61 0.22 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.781 0.433 . . . . 10.0 110.884 -177.659 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -165.83 -63.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.2 0 C-N-CA 126.01 1.724 . . . . 10.0 107.399 -175.938 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -120.92 55.29 0.64 Allowed Glycine 0 C--N 1.335 0.497 0 N-CA-C 108.804 -1.718 . . . . 10.0 108.804 -176.002 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -93.03 90.45 6.92 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 105.152 -2.166 . . . . 10.0 105.152 169.282 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 9.6 mp -65.8 -25.63 67.32 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 118.632 0.651 . . . . 10.0 110.84 -173.114 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.67 -94.11 0.58 Allowed Glycine 0 N--CA 1.436 -1.315 0 N-CA-C 107.872 -2.091 . . . . 10.0 107.872 172.845 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.2 m-20 -156.7 107.8 2.39 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.432 -0.581 . . . . 10.0 109.432 -169.621 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.2 m -89.12 122.71 40.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 CA-C-N 118.163 0.438 . . . . 10.0 110.401 -177.619 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.1 m -79.79 81.96 5.97 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 127.705 2.402 . . . . 10.0 112.55 -171.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -70.95 130.4 41.51 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 121.573 -0.704 . . . . 10.0 112.692 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -63.18 172.16 2.0 Allowed 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 125.479 1.511 . . . . 10.0 110.049 166.756 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.08 -28.85 59.32 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 124.2 1.0 . . . . 10.0 111.839 171.141 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 36' ' ' LYS . 30.5 t70 -77.4 -2.88 37.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 122.261 1.029 . . . . 10.0 111.113 175.898 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.3 2.03 87.89 Favored Glycine 0 N--CA 1.44 -1.076 0 N-CA-C 109.959 -1.256 . . . . 10.0 109.959 -173.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.24 94.9 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 108.002 -1.11 . . . . 10.0 108.002 -171.572 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.23 118.74 29.14 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 166.76 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -78.16 117.69 19.68 Favored 'General case' 0 N--CA 1.433 -1.28 0 C-N-CA 126.005 1.722 . . . . 10.0 107.744 170.366 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 42.6 t -108.14 131.6 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.16 0 N-CA-C 106.735 -1.58 . . . . 10.0 106.735 -178.555 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.1 p -157.49 51.48 0.46 Allowed 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.394 0.678 . . . . 10.0 109.529 169.455 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -87.91 152.23 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -174.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -137.55 146.63 44.33 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.716 1.206 . . . . 10.0 109.986 -178.346 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -152.07 140.13 20.19 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 107.271 -1.381 . . . . 10.0 107.271 168.855 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 77.6 p -108.71 63.34 0.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 -174.265 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.3 p -151.97 -47.61 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 115.608 -0.724 . . . . 10.0 109.055 -177.751 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 20.9 mm -64.5 155.45 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 124.124 0.97 . . . . 10.0 110.058 172.734 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 28.8 t -150.69 147.28 27.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.717 -1.216 . . . . 10.0 107.717 168.367 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 68.2 mt -55.18 -30.61 60.25 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.995 -1.002 . . . . 10.0 109.82 167.085 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t -153.57 109.11 3.23 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 106.919 -1.511 . . . . 10.0 106.919 -179.312 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.37 -63.53 0.01 OUTLIER Glycine 0 C--N 1.333 0.373 0 N-CA-C 109.746 -1.342 . . . . 10.0 109.746 -177.858 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -156.37 -53.57 0.08 Allowed 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 126.721 2.008 . . . . 10.0 106.185 178.373 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -75.36 -36.84 60.91 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 113.998 -1.455 . . . . 10.0 108.758 -174.322 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.2 t 56.74 63.26 2.0 Allowed 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.083 0.953 . . . . 10.0 109.576 169.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.295 0.0 OUTLIER -53.31 -28.26 14.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.23 -0.896 . . . . 10.0 113.218 -168.569 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.9 mm -27.13 -55.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 127.221 2.208 . . . . 10.0 114.045 173.776 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -83.67 4.69 81.39 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-O 118.493 -1.17 . . . . 10.0 115.08 -169.726 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 mmt180 -87.6 160.47 18.17 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.663 1.231 . . . . 10.0 111.95 -177.827 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 19.3 m -92.96 130.48 38.53 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 169.007 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -97.64 138.46 35.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 169.773 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 83.1 t -129.81 135.35 61.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 107.748 -1.204 . . . . 10.0 107.748 -177.336 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -103.05 145.99 11.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 123.897 0.879 . . . . 10.0 108.644 168.419 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 2.7 m170 -123.89 160.38 27.62 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 116.329 1.974 . . . . 10.0 116.329 -173.717 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.6 tt0 -43.07 -56.57 3.3 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.692 3.197 . . . . 10.0 111.918 172.827 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 76.0 mttt -117.3 170.02 9.02 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 123.599 0.76 . . . . 10.0 112.397 -169.29 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.9 149.7 47.54 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 114.003 -1.453 . . . . 10.0 109.458 173.701 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.497 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.2 m-20 -80.58 146.21 31.35 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 123.881 0.872 . . . . 10.0 111.773 173.66 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -76.26 -27.97 56.9 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 124.235 0.959 . . . . 10.0 109.5 168.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 72.4 mt 62.04 53.01 3.1 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 123.058 1.408 . . . . 10.0 108.925 -174.923 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.28 -43.23 2.54 Favored Glycine 0 N--CA 1.445 -0.764 0 CA-C-N 112.561 -2.109 . . . . 10.0 110.637 173.581 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.1 mtmm -81.38 44.74 0.81 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.919 0.888 . . . . 10.0 112.392 -169.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.15 -22.7 14.44 Favored Glycine 0 CA--C 1.523 0.568 0 C-N-CA 125.921 1.724 . . . . 10.0 110.903 169.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.77 34.43 89.92 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 110.996 -0.841 . . . . 10.0 110.996 175.845 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -138.27 168.53 19.55 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.883 -1.525 . . . . 10.0 106.883 169.397 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.11 -48.53 73.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 116.038 -0.528 . . . . 10.0 109.865 -176.199 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -68.02 -26.4 65.87 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.006 -1.059 . . . . 10.0 110.935 178.977 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.0 p -56.92 -44.53 82.54 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 120.996 1.725 . . . . 10.0 110.544 171.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -83.92 -10.78 57.71 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.85 -0.595 . . . . 10.0 112.1 -173.75 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -103.33 -51.72 3.17 Favored 'General case' 0 N--CA 1.441 -0.905 0 C-N-CA 126.038 1.735 . . . . 10.0 112.319 -178.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.2 p -139.29 31.17 2.15 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.557 1.071 . . . . 10.0 112.461 176.045 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 58.23 25.87 57.98 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 118.723 0.692 . . . . 10.0 112.719 175.456 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 52.96 24.89 3.63 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 117.59 0.695 . . . . 10.0 112.585 -176.724 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.13 -4.26 9.67 Favored 'General case' 0 C--N 1.342 0.276 0 O-C-N 121.12 -0.988 . . . . 10.0 113.014 -173.32 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.03 -158.93 41.05 Favored Glycine 0 N--CA 1.446 -0.69 0 O-C-N 121.027 -1.045 . . . . 10.0 111.187 167.249 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 m -58.49 125.73 24.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.463 0.705 . . . . 10.0 111.767 -167.83 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -58.74 68.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.955 2.102 . . . . 10.0 111.864 172.048 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.7 mt -50.59 -36.93 37.26 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.898 -1.127 . . . . 10.0 113.714 -174.469 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -163.11 157.53 20.76 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 -170.823 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 23.6 p -161.76 168.29 23.47 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.96 -0.385 . . . . 10.0 109.96 -174.637 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.5 155.37 26.46 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.312 -1.515 . . . . 10.0 109.312 -176.44 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -107.94 131.25 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 105.776 -1.935 . . . . 10.0 105.776 -177.507 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 16.0 mt -79.48 165.95 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 118.818 0.736 . . . . 10.0 110.615 -179.782 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -169.13 170.92 42.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 127.875 2.655 . . . . 10.0 107.097 -177.065 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 20.3 mt -84.8 140.67 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 124.481 1.112 . . . . 10.0 110.1 -168.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -102.57 -114.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.903 -1.147 . . . . 10.0 107.903 167.44 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.252 1.227 0 C-N-CA 131.077 3.751 . . . . 10.0 106.136 172.297 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.799 0 CA-C-O 118.571 -0.728 . . . . 10.0 109.794 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 60.4 p -96.21 -63.89 1.1 Allowed 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 124.555 1.142 . . . . 10.0 110.001 -169.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -135.63 135.4 40.16 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 126.724 2.01 . . . . 10.0 107.857 -169.547 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -133.59 166.99 21.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.752 1.221 . . . . 10.0 110.119 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.73 162.12 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 125.803 1.641 . . . . 10.0 109.317 -179.015 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -149.89 90.72 1.71 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 106.204 -1.776 . . . . 10.0 106.204 166.631 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.7 m -77.37 118.97 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 170.915 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.6 mt -97.85 147.73 24.13 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 -178.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.06 162.56 17.95 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 168.994 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.43 -58.33 0.05 OUTLIER Glycine 0 C--O 1.227 -0.291 0 C-N-CA 121.09 -0.576 . . . . 10.0 112.057 169.861 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -72.98 -46.46 52.15 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.9 -69.81 0.51 Allowed Glycine 0 CA--C 1.527 0.796 0 CA-C-N 114.313 -1.312 . . . . 10.0 110.089 174.099 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -75.82 37.45 0.52 Allowed 'Trans proline' 0 CA--C 1.536 0.614 1 C-N-CA 125.69 4.26 . . . . 10.0 111.944 -179.884 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.8 t -149.01 100.38 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 C-N-CA 131.454 3.902 . . . . 10.0 100.537 178.603 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.72 116.04 22.39 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 106.032 -1.84 . . . . 10.0 106.032 -174.181 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -95.81 142.71 16.25 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 174.766 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.456 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 6.3 mt -135.14 86.02 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.721 -1.214 . . . . 10.0 107.721 173.795 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -97.46 142.64 13.94 Favored 'Isoleucine or valine' 0 C--N 1.339 0.118 0 C-N-CA 124.028 0.931 . . . . 10.0 110.008 178.002 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -128.88 123.1 31.82 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 127.262 2.225 . . . . 10.0 109.511 174.353 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -105.23 116.87 32.68 Favored 'General case' 0 C--O 1.23 0.074 0 C-N-CA 125.294 1.437 . . . . 10.0 108.684 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.5 ' CD ' ' HZ1' ' A' ' 23' ' ' LYS . 20.4 tt0 -105.58 134.71 48.24 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 118.666 0.666 . . . . 10.0 112.268 171.788 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 tp60 -109.71 99.36 8.54 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.672 1.989 . . . . 10.0 107.037 168.853 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.5 ' HZ1' ' CD ' ' A' ' 21' ' ' GLU . 40.5 mmtt -58.72 -64.79 0.8 Allowed 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.752 -0.462 . . . . 10.0 109.752 175.469 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -124.13 164.62 19.09 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 104.657 -2.349 . . . . 10.0 104.657 169.453 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 t -71.47 -15.74 62.33 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 108.77 -0.826 . . . . 10.0 108.77 173.665 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.82 -24.31 44.55 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.021 0.529 . . . . 10.0 110.273 173.388 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.44 141.77 23.25 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 109.887 -1.285 . . . . 10.0 109.887 -176.825 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -62.56 142.21 89.16 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 CA-C-N 119.525 1.663 . . . . 10.0 107.866 169.252 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.5 t -77.92 125.77 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -174.731 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.1 mtmm -90.87 104.94 17.47 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.658 -1.238 . . . . 10.0 107.658 178.575 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 p -94.08 93.19 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 125.908 1.683 . . . . 10.0 107.555 174.264 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.9 p90 -102.28 175.07 5.64 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 121.207 0.527 . . . . 10.0 109.982 169.153 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.75 174.8 38.34 Favored Glycine 0 N--CA 1.441 -0.983 0 N-CA-C 111.367 -0.693 . . . . 10.0 111.367 176.892 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.0 p -145.69 102.78 3.72 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.239 -1.393 . . . . 10.0 107.239 178.751 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.5 pt -78.05 174.16 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 C-N-CA 118.878 -1.129 . . . . 10.0 108.099 169.225 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -154.83 144.17 21.22 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 168.808 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.6 -37.24 2.47 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-N 118.695 0.679 . . . . 10.0 113.957 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.1 mp -68.8 177.86 2.38 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.968 0.89 . . . . 10.0 112.651 -167.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.8 t -100.41 156.8 17.06 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.866 -0.606 . . . . 10.0 109.384 171.168 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -52.42 147.11 8.56 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.944 1.298 . . . . 10.0 112.191 -169.526 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.0 -172.12 17.68 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.124 0.869 . . . . 10.0 111.448 171.407 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -72.71 148.5 44.64 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.069 1.348 . . . . 10.0 110.855 -177.774 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -147.38 143.66 28.14 Favored 'General case' 0 C--N 1.338 0.067 0 C-N-CA 124.115 0.966 . . . . 10.0 112.314 -179.439 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -23.28 124.49 0.02 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.347 2.403 . . . . 10.0 114.062 165.301 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 20.1 t80 -149.25 106.5 3.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 119.286 1.543 . . . . 10.0 109.848 168.671 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.49 172.37 14.59 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.317 0.579 . . . . 10.0 111.04 174.102 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.4 p -112.82 120.93 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 CA-C-N 112.86 -1.973 . . . . 10.0 107.502 168.676 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -89.41 151.61 21.94 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.873 1.669 . . . . 10.0 108.223 -179.37 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -64.76 -57.01 10.08 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 114.798 -1.092 . . . . 10.0 110.473 -173.098 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -76.62 124.46 27.67 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.227 -1.397 . . . . 10.0 107.227 -173.403 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.07 -2.41 77.99 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.426 -0.652 . . . . 10.0 112.136 178.047 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -43.98 131.0 5.88 Favored 'General case' 0 C--N 1.344 0.343 0 CA-C-O 122.8 1.286 . . . . 10.0 112.525 175.289 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -138.43 3.19 2.32 Favored 'General case' 0 N--CA 1.434 -1.232 0 CA-C-N 112.676 -2.056 . . . . 10.0 109.519 163.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -53.5 -40.09 65.12 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 125.063 1.345 . . . . 10.0 108.605 168.566 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.8 -15.12 59.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 116.041 -0.527 . . . . 10.0 111.976 178.223 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.75 75.5 0.99 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 109.092 -1.603 . . . . 10.0 109.092 -173.384 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t 38.78 48.87 1.41 Allowed 'General case' 0 C--O 1.231 0.105 0 C-N-CA 125.554 1.542 . . . . 10.0 114.448 177.311 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.4 m -127.76 -53.5 1.33 Allowed 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.996 -1.483 . . . . 10.0 106.996 -172.745 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.3 m -90.22 16.95 7.67 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.129 0.422 . . . . 10.0 111.527 173.758 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.56 -19.77 58.38 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.21 1.004 . . . . 10.0 111.032 169.379 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.3 135.85 7.98 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-O 119.017 -0.88 . . . . 10.0 111.232 168.578 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -73.39 66.04 4.5 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 123.244 2.63 . . . . 10.0 110.77 173.474 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.403 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 28.8 m170 71.81 -34.16 0.29 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 128.41 2.684 . . . . 10.0 112.664 175.385 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 43.42 25.9 0.09 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 128.308 2.643 . . . . 10.0 116.374 171.625 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -59.06 134.33 87.59 Favored Pre-proline 0 CA--C 1.534 0.354 0 N-CA-C 114.464 1.283 . . . . 10.0 114.464 -169.945 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -60.95 -37.49 76.47 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.565 2.177 . . . . 10.0 110.042 175.901 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 66.0 mt -63.05 2.8 0.29 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.748 1.219 . . . . 10.0 113.776 175.761 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 12.4 m 26.84 54.22 0.05 OUTLIER 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 128.293 2.637 . . . . 10.0 114.982 175.738 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtt85 -99.29 -179.15 4.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.572 1.149 . . . . 10.0 110.752 -172.983 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt -112.54 92.52 4.05 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.046 -0.724 . . . . 10.0 109.046 -174.643 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -5.88 97.16 0.01 OUTLIER 'General case' 0 C--O 1.223 -0.318 0 C-N-CA 128.255 2.622 . . . . 10.0 113.937 -176.916 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.41 -134.04 7.81 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.897 -1.681 . . . . 10.0 108.897 178.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.49 -170.33 40.43 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 106.915 -2.474 . . . . 10.0 106.915 171.498 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -63.59 -4.64 7.26 Favored 'Trans proline' 0 N--CA 1.455 -0.794 0 CA-C-N 119.867 1.834 . . . . 10.0 110.929 168.276 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -88.65 -24.06 22.88 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.313 1.045 . . . . 10.0 110.536 174.069 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.8 178.41 4.29 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 108.246 -1.02 . . . . 10.0 108.246 -178.262 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -92.81 -26.81 17.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 167.088 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.1 mm-40 -87.06 28.79 0.88 Allowed 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.391 -1.443 . . . . 10.0 112.436 -169.641 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.5 133.62 53.48 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.67 -1.233 . . . . 10.0 107.67 169.345 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.9 m170 -64.58 -57.92 7.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.823 -0.548 . . . . 10.0 112.007 -175.378 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.8 p -170.97 -43.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 C-N-CA 124.461 1.104 . . . . 10.0 109.065 -172.375 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -150.43 56.44 0.46 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 109.759 -1.336 . . . . 10.0 109.759 178.385 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -92.76 92.15 7.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 172.256 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.29 -36.69 63.78 Favored 'General case' 0 N--CA 1.461 0.1 0 N-CA-C 107.648 -1.242 . . . . 10.0 107.648 177.067 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.34 -98.66 1.23 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 110.833 -0.907 . . . . 10.0 110.833 167.859 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.3 m-80 -123.73 132.3 53.79 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.855 0.862 . . . . 10.0 111.274 -168.365 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.0 m -114.68 129.92 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 123.771 0.828 . . . . 10.0 109.14 168.072 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 28.2 m -86.81 104.09 15.85 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 127.651 2.381 . . . . 10.0 110.572 -174.857 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.03 33.49 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 122.825 0.45 . . . . 10.0 110.544 174.776 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -66.76 175.23 2.49 Favored 'General case' 0 CA--C 1.528 0.103 0 O-C-N 123.633 0.583 . . . . 10.0 109.728 167.661 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.13 -29.48 13.56 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.585 1.554 . . . . 10.0 111.746 172.38 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -79.42 -4.5 51.39 Favored 'General case' 0 N--CA 1.453 -0.301 0 O-C-N 123.226 0.329 . . . . 10.0 110.229 -177.779 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.8 9.28 86.94 Favored Glycine 0 C--N 1.337 0.635 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 -178.377 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 50.9 t -90.82 107.65 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.277 0 C-N-CA 126.149 1.78 . . . . 10.0 106.356 179.619 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.85 118.52 37.02 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.579 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -79.24 112.2 16.23 Favored 'General case' 0 N--CA 1.434 -1.239 0 C-N-CA 125.927 1.691 . . . . 10.0 108.541 171.127 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.82 133.23 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.234 -1.765 . . . . 10.0 106.234 176.337 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -157.63 60.69 0.48 Allowed 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.861 -0.422 . . . . 10.0 109.861 -178.398 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 44.0 mt -115.46 154.69 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 107.97 -1.122 . . . . 10.0 107.97 -169.696 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -127.87 145.51 50.92 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.338 -0.615 . . . . 10.0 109.338 167.512 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -145.29 154.73 42.66 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 -178.752 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.4 p -108.32 -9.35 15.49 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 128.145 2.578 . . . . 10.0 112.28 -174.28 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.6 p -79.6 -36.98 18.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.147 0 N-CA-C 107.602 -1.259 . . . . 10.0 107.602 -174.87 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.309 0.0 OUTLIER -79.51 150.24 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 124.714 1.206 . . . . 10.0 113.026 172.676 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.6 m -157.28 133.56 9.7 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.089 0.956 . . . . 10.0 108.47 179.616 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -75.54 52.87 0.66 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.223 2.209 . . . . 10.0 108.394 175.13 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.2 t -88.38 -157.04 0.4 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.472 1.909 . . . . 10.0 110.204 -169.803 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.0 -53.65 0.13 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 128.177 2.799 . . . . 10.0 107.429 -178.302 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -64.99 -60.16 3.36 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.227 -0.657 . . . . 10.0 109.227 171.203 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -77.94 -28.35 49.54 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 115.903 -0.589 . . . . 10.0 110.228 -175.259 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t 13.32 78.63 0.01 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 128.3 2.64 . . . . 10.0 113.672 175.776 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -65.53 -16.19 19.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 112.04 0.385 . . . . 10.0 112.04 176.328 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 49.2 mm -46.39 137.64 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 C-N-CA 123.832 0.853 . . . . 10.0 110.318 169.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.08 -1.97 88.18 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.153 -1.36 . . . . 10.0 115.286 174.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.9 mtp85 -77.05 168.14 20.6 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.019 1.41 . . . . 10.0 107.364 169.122 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -106.6 120.86 43.07 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.48 0.582 . . . . 10.0 111.752 -174.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -77.22 145.72 37.42 Favored 'General case' 0 CA--C 1.517 -0.294 0 N-CA-C 108.337 -0.986 . . . . 10.0 108.337 168.698 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 86.8 t -131.93 132.49 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.899 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.145 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -104.48 134.8 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 N-CA-C 106.268 -1.753 . . . . 10.0 106.268 167.831 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 8.2 m-70 -112.67 156.95 21.88 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 115.794 1.776 . . . . 10.0 115.794 -170.906 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -43.25 -55.3 4.07 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.68 2.792 . . . . 10.0 112.155 171.597 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -115.55 162.8 16.69 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.784 0.834 . . . . 10.0 111.543 -169.675 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.87 153.86 42.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.877 -1.056 . . . . 10.0 109.129 170.103 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -93.51 144.41 25.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 C-N-CA 123.814 0.845 . . . . 10.0 110.75 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -76.7 -16.12 59.6 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-N 114.387 -1.279 . . . . 10.0 110.83 168.379 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.4 mt 53.23 40.57 31.48 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.178 0.991 . . . . 10.0 110.247 -172.953 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.77 -47.97 0.98 Allowed Glycine 0 C--N 1.337 0.59 0 C-N-CA 125.122 1.344 . . . . 10.0 111.023 169.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.42 51.97 1.75 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 122.035 -0.685 . . . . 10.0 112.466 -169.831 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.43 -38.62 5.85 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 124.786 1.184 . . . . 10.0 110.351 169.914 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.43 31.33 78.51 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 -169.451 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -114.21 157.42 22.7 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 106.067 -1.827 . . . . 10.0 106.067 169.236 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.414 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 4.8 tm-20 -51.75 -44.87 63.49 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.875 -1.057 . . . . 10.0 109.062 174.13 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -65.44 -34.08 77.44 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.162 0.985 . . . . 10.0 112.452 173.937 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 54.3 p -57.73 -35.99 71.45 Favored 'General case' 0 N--CA 1.448 -0.571 0 O-C-N 120.244 -1.535 . . . . 10.0 111.781 -175.953 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -84.65 -1.11 55.61 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 118.855 -0.593 . . . . 10.0 112.163 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 94.1 mttt -114.05 -56.13 2.43 Favored 'General case' 0 C--N 1.342 0.261 0 C-N-CA 124.628 1.171 . . . . 10.0 111.315 -176.523 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.403 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 2.8 p -120.17 -5.54 9.96 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.888 0.767 . . . . 10.0 113.061 175.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.03 33.65 Favored Glycine 0 C--N 1.342 0.889 0 CA-C-O 119.252 -0.749 . . . . 10.0 112.175 -177.465 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 62.12 23.79 14.09 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 118.317 1.059 . . . . 10.0 111.597 -177.694 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.27 -11.78 24.28 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 125.656 1.583 . . . . 10.0 112.013 -177.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.88 -157.28 48.61 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 172.926 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.2 m -61.39 133.93 56.35 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.875 0.87 . . . . 10.0 113.121 -167.495 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -66.25 71.39 0.07 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.968 1.307 . . . . 10.0 110.017 169.596 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.6 mt -55.85 -33.56 64.64 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 112.742 0.645 . . . . 10.0 112.742 -177.435 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.19 146.35 15.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.473 -0.566 . . . . 10.0 109.473 -175.749 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 18.1 m -148.51 161.25 42.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -169.855 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.07 -174.96 17.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.504 -0.639 . . . . 10.0 111.504 178.419 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 49.8 t -127.05 133.75 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 104.825 -2.287 . . . . 10.0 104.825 175.755 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 22.1 mt -69.37 117.46 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 108.903 -0.777 . . . . 10.0 108.903 177.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.83 141.86 16.7 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 110.611 -0.996 . . . . 10.0 110.611 -179.72 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.17 132.7 32.97 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 CA-C-N 119.353 1.577 . . . . 10.0 108.942 175.31 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.61 -26.27 50.5 Favored 'General case' 0 C--O 1.223 -0.342 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 167.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.253 1.278 0 C-N-CA 126.187 1.795 . . . . 10.0 109.318 169.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.706 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -150.76 -60.48 0.18 Allowed 'General case' 0 C--O 1.232 0.139 0 N-CA-C 108.958 -0.756 . . . . 10.0 108.958 176.135 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 57.0 tttp -117.18 135.4 53.8 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 126.888 2.075 . . . . 10.0 106.852 174.904 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.85 161.7 34.88 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 125.253 1.421 . . . . 10.0 110.75 178.543 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 m -128.4 178.1 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 124.837 1.255 . . . . 10.0 110.042 -176.218 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -162.27 97.28 1.0 Allowed 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 125.368 1.467 . . . . 10.0 107.634 166.641 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -89.73 104.53 15.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.21 0.604 . . . . 10.0 110.818 173.765 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.7 mp -93.58 146.23 23.96 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.244 1.418 . . . . 10.0 110.176 178.195 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 2.9 tttm -162.12 164.07 28.19 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 171.206 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.68 -47.65 0.14 Allowed Glycine 0 N--CA 1.462 0.398 0 C-N-CA 119.389 -1.386 . . . . 10.0 114.102 168.796 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -72.08 -45.73 59.58 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.141 -1.429 . . . . 10.0 107.141 -177.057 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.65 -75.17 0.28 Allowed Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 114.162 -1.381 . . . . 10.0 109.932 169.125 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -55.92 -39.22 92.49 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 123.511 2.808 . . . . 10.0 110.985 173.008 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 72.6 t -59.66 112.31 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 179.643 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.04 124.33 42.32 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 168.446 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -104.67 136.92 13.35 Favored Glycine 0 C--O 1.224 -0.494 0 N-CA-C 107.794 -2.122 . . . . 10.0 107.794 169.491 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.0 mt -138.59 68.04 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -174.579 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 mm -89.05 151.89 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 N-CA-C 109.668 -0.493 . . . . 10.0 109.668 -173.503 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.24 143.89 48.04 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 126.617 1.967 . . . . 10.0 108.111 175.194 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -129.05 130.91 47.16 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 104.411 -2.44 . . . . 10.0 104.411 168.273 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -128.62 150.48 50.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 119.796 1.18 . . . . 10.0 110.402 172.375 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.58 97.59 5.12 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 178.392 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -42.8 -57.51 2.75 Favored 'General case' 0 CA--C 1.515 -0.375 0 C-N-CA 123.978 0.911 . . . . 10.0 110.053 170.482 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 15.0 mp0 -134.15 178.71 6.75 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 128.892 2.877 . . . . 10.0 103.461 168.378 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 22.6 t -94.2 13.8 22.15 Favored 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.221 -0.659 . . . . 10.0 109.221 170.366 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -149.18 28.15 0.83 Allowed 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 125.435 1.494 . . . . 10.0 110.199 -173.311 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -141.45 174.94 22.68 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.397 -1.481 . . . . 10.0 109.397 -172.893 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.27 129.94 24.12 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.808 2.338 . . . . 10.0 109.456 -177.499 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.1 t -79.87 111.52 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 N-CA-C 104.918 -2.253 . . . . 10.0 104.918 172.469 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -82.65 126.54 32.44 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 169.204 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -100.5 109.38 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 C-N-CA 126.37 1.868 . . . . 10.0 106.703 172.826 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.9 p90 -130.38 156.63 44.4 Favored 'General case' 0 C--O 1.226 -0.177 0 N-CA-C 113.504 0.927 . . . . 10.0 113.504 -179.729 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.65 -152.24 24.12 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 106.824 -2.511 . . . . 10.0 106.824 172.924 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 21.2 p -156.38 165.93 34.89 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 119.584 -0.846 . . . . 10.0 110.412 174.335 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 pt -107.01 179.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-N 114.344 -1.298 . . . . 10.0 109.424 165.366 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.19 163.17 40.54 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 124.689 1.196 . . . . 10.0 108.407 162.921 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.21 -17.12 44.69 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-O 119.315 -0.714 . . . . 10.0 113.155 172.626 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.4 mp -71.7 178.61 3.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.005 0.902 . . . . 10.0 110.194 173.708 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -97.4 170.45 9.05 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 166.408 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -60.03 170.69 1.15 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.203 1.001 . . . . 10.0 112.111 -171.341 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.95 -174.61 32.99 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 124.201 0.905 . . . . 10.0 112.08 168.461 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.24 146.78 50.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 123.834 0.854 . . . . 10.0 109.581 176.164 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -147.17 144.94 29.32 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 123.493 0.717 . . . . 10.0 111.703 178.558 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . 0.401 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -34.79 120.5 0.39 Allowed Glycine 0 C--N 1.339 0.74 0 C-N-CA 127.738 2.59 . . . . 10.0 112.626 167.371 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.69 110.47 5.14 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-N 119.456 1.628 . . . . 10.0 109.458 168.306 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.534 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.1 OUTLIER -146.57 170.65 16.46 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-O 121.718 0.771 . . . . 10.0 111.802 176.496 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.16 129.09 46.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 CA-C-N 111.146 -2.752 . . . . 10.0 105.647 168.193 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 41.5 m-70 -105.78 146.59 29.65 Favored 'General case' 0 CA--C 1.509 -0.611 0 N-CA-C 107.675 -1.231 . . . . 10.0 107.675 174.382 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 23.8 tp10 -66.64 -59.04 3.96 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.544 -1.207 . . . . 10.0 108.98 -172.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 22.2 m-30 -77.1 106.88 9.09 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 -175.222 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.68 42.8 1.31 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 124.592 1.091 . . . . 10.0 111.448 174.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.32 131.76 41.07 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 124.975 1.31 . . . . 10.0 108.241 177.057 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -122.8 1.43 9.36 Favored 'General case' 0 N--CA 1.444 -0.755 0 C-N-CA 124.714 1.205 . . . . 10.0 110.28 168.968 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.456 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.18 -36.53 70.93 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.773 1.17 . . . . 10.0 108.792 178.194 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.38 -17.88 55.83 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.53 1.132 . . . . 10.0 112.965 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 77.61 0.77 Allowed Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.272 -0.731 . . . . 10.0 111.272 -178.273 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 34.8 m 50.96 34.36 10.46 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 124.754 1.222 . . . . 10.0 112.614 172.501 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 6.3 m -127.75 -57.43 1.26 Allowed 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -169.958 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 11.8 t -92.14 21.22 5.24 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 111.896 0.332 . . . . 10.0 111.896 179.166 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -68.1 -7.26 28.09 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.615 0.766 . . . . 10.0 111.949 176.285 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.47 127.66 2.19 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 109.704 -1.358 . . . . 10.0 109.704 174.132 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -74.81 65.42 5.88 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.517 2.811 . . . . 10.0 111.523 178.437 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.2 m170 59.98 55.83 3.64 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 128.382 2.673 . . . . 10.0 109.94 177.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -70.51 63.7 0.27 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.553 0.741 . . . . 10.0 112.393 -178.041 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -67.48 147.45 98.78 Favored Pre-proline 0 CA--C 1.532 0.27 0 O-C-N 121.642 -0.661 . . . . 10.0 110.858 -175.559 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -63.11 -49.44 4.88 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.245 1.963 . . . . 10.0 110.2 179.308 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.6 tt -81.41 59.64 4.12 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.358 0.663 . . . . 10.0 109.348 -177.852 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.0 t -14.96 97.31 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 128.411 2.684 . . . . 10.0 112.886 -176.806 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.59 168.58 10.88 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.423 1.089 . . . . 10.0 108.725 -175.807 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -108.24 105.91 15.84 Favored 'General case' 0 C--O 1.224 -0.26 0 N-CA-C 108.457 -0.942 . . . . 10.0 108.457 175.508 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 56.3 t60 -9.99 96.51 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 127.213 2.205 . . . . 10.0 115.482 -177.769 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.78 -141.1 10.37 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 173.658 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.03 -161.09 27.09 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 108.79 -1.724 . . . . 10.0 108.79 171.091 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -66.59 5.97 0.64 Allowed 'Trans proline' 0 N--CA 1.456 -0.704 0 CA-C-N 120.417 2.109 . . . . 10.0 111.889 174.106 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -103.56 -15.21 15.9 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 117.596 -1.193 . . . . 10.0 110.994 172.887 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -131.36 162.25 30.53 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 119.164 0.893 . . . . 10.0 108.925 -167.855 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -78.61 -33.07 47.7 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.231 -1.396 . . . . 10.0 107.231 176.361 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -82.25 26.46 0.54 Allowed 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 125.431 1.493 . . . . 10.0 112.528 -167.108 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 36.2 ptt85 -64.58 134.35 54.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.304 -0.998 . . . . 10.0 108.304 173.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.5 m80 -58.86 -50.74 72.87 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 121.012 0.434 . . . . 10.0 111.088 -178.699 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 p -172.37 -105.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 104.06 -2.571 . . . . 10.0 104.06 177.864 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -77.54 57.36 3.78 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.864 0.756 . . . . 10.0 111.558 172.313 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -84.91 88.35 7.42 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 103.935 -2.616 . . . . 10.0 103.935 166.856 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 16.0 mt -71.72 -31.08 66.34 Favored 'General case' 0 N--CA 1.463 0.189 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -178.52 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.37 -102.54 2.57 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 109.82 -1.312 . . . . 10.0 109.82 167.571 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -121.05 104.11 9.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.603 1.161 . . . . 10.0 109.29 -167.201 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.1 m -94.66 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 118.725 0.693 . . . . 10.0 109.504 172.7 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 80.0 m -89.96 117.57 28.87 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 126.585 1.954 . . . . 10.0 108.908 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.82 134.6 43.55 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 124.536 1.135 . . . . 10.0 111.313 178.442 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.428 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 17.2 t70 -59.53 170.98 0.91 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 124.165 0.986 . . . . 10.0 110.811 166.769 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.428 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 28.3 mttm -52.06 -33.0 37.13 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.806 1.643 . . . . 10.0 112.453 169.183 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.45 -1.23 32.62 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-O 122.158 0.98 . . . . 10.0 111.307 176.601 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.41 0.89 84.24 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.052 -1.619 . . . . 10.0 109.052 -176.175 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.3 t -78.15 95.66 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -170.074 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.38 119.08 29.52 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 166.582 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.21 114.22 17.97 Favored 'General case' 0 N--CA 1.436 -1.163 0 C-N-CA 126.759 2.023 . . . . 10.0 108.971 171.95 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 91.8 t -98.11 131.23 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.705 -1.591 . . . . 10.0 106.705 174.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.6 p -157.76 57.69 0.49 Allowed 'General case' 0 CA--C 1.534 0.355 0 O-C-N 122.0 -0.437 . . . . 10.0 110.305 171.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.94 161.01 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 C-N-CA 124.784 1.234 . . . . 10.0 107.672 -170.892 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -130.54 146.25 52.03 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 124.625 1.17 . . . . 10.0 110.385 175.366 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 58.8 t0 -144.52 154.77 43.24 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.276 -1.009 . . . . 10.0 108.276 175.679 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 33.4 p -134.22 2.87 3.35 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 126.64 1.976 . . . . 10.0 112.544 -179.542 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.8 p -79.3 -31.84 14.62 Favored 'Isoleucine or valine' 0 C--N 1.343 0.324 0 CA-C-N 120.017 1.28 . . . . 10.0 107.891 169.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.273 0.7 OUTLIER -82.56 174.08 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 124.156 0.983 . . . . 10.0 111.556 169.423 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 31.1 m -158.7 143.56 16.07 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 105.423 -2.066 . . . . 10.0 105.423 172.084 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 mt -75.5 -10.37 59.39 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.943 0.497 . . . . 10.0 112.335 -172.272 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 75.7 m -155.71 178.51 10.17 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 126.257 1.823 . . . . 10.0 106.43 173.242 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.67 -65.13 0.31 Allowed Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.777 -0.929 . . . . 10.0 110.777 169.373 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -161.21 -48.81 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 125.425 1.49 . . . . 10.0 108.068 -173.509 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -72.59 -39.78 67.09 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 107.073 -1.454 . . . . 10.0 107.073 -173.007 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.0 t 23.86 69.83 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 128.694 2.798 . . . . 10.0 112.636 167.116 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.96 -7.61 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 112.802 0.667 . . . . 10.0 112.802 -176.704 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 41.0 mm -45.92 125.0 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 O-C-N 121.55 -0.719 . . . . 10.0 110.1 171.81 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.4 2.03 77.34 Favored Glycine 0 CA--C 1.527 0.81 0 CA-C-O 118.735 -1.036 . . . . 10.0 113.637 178.862 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -76.2 178.92 6.06 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 106.007 -1.849 . . . . 10.0 106.007 166.75 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -124.59 129.72 51.1 Favored 'General case' 0 CA--C 1.514 -0.438 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 -174.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 7.8 mp -96.97 139.72 32.57 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 171.37 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.4 t -123.17 129.8 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 O-C-N 124.605 1.191 . . . . 10.0 108.303 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.6 p -93.03 131.41 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.47 -1.308 . . . . 10.0 107.47 167.618 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . 0.401 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.5 m170 -111.72 158.33 19.45 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.448 1.277 . . . . 10.0 114.448 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . 0.49 ' CD ' ' HZ1' ' B' ' 122' ' ' LYS . 2.3 tm-20 -56.6 -54.81 41.68 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 125.15 1.38 . . . . 10.0 110.98 178.757 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.49 ' HZ1' ' CD ' ' B' ' 121' ' ' GLU . 43.7 mttm -109.44 176.11 5.2 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 118.686 0.676 . . . . 10.0 110.136 177.268 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.17 140.74 29.18 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.058 1.343 . . . . 10.0 108.515 176.781 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.534 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -76.69 152.63 35.66 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 123.297 0.639 . . . . 10.0 111.943 -177.362 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 51.2 m-20 -76.38 6.2 5.99 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 127.115 2.166 . . . . 10.0 111.491 178.899 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.7 mt 42.12 40.11 1.58 Allowed 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.369 1.868 . . . . 10.0 111.194 -173.137 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.24 -33.52 5.94 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-O 119.509 -0.606 . . . . 10.0 112.639 168.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 3.3 mppt? -80.42 40.84 0.51 Allowed 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 117.597 0.699 . . . . 10.0 110.974 -176.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . 0.431 ' HA3' ' CB ' ' B' ' 134' ' ' SER . . . -88.97 -30.22 15.31 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 124.806 1.193 . . . . 10.0 112.616 -173.317 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 94.63 6.95 60.57 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.793 -1.004 . . . . 10.0 114.751 170.391 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -141.39 175.47 9.64 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 119.844 1.822 . . . . 10.0 106.726 169.036 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -51.19 -58.52 5.93 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.742 1.217 . . . . 10.0 109.279 178.208 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -49.94 -52.47 33.11 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 123.109 1.433 . . . . 10.0 110.562 176.505 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 134' ' ' SER . . . . . 0.431 ' CB ' ' HA3' ' B' ' 129' ' ' GLY . 0.2 OUTLIER -62.23 -4.8 1.93 Allowed 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 127.497 2.319 . . . . 10.0 113.27 179.979 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.24 15.01 6.72 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.731 0.813 . . . . 10.0 110.703 172.808 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmmm -122.22 -62.52 1.38 Allowed 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.727 2.011 . . . . 10.0 109.432 -178.56 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -113.71 16.1 18.64 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 119.513 1.052 . . . . 10.0 110.487 167.207 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.96 20.73 70.98 Favored Glycine 0 C--O 1.22 -0.764 0 C-N-CA 124.088 0.851 . . . . 10.0 113.2 168.81 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . 0.4 ' ND2' ' HG ' ' B' ' 134' ' ' SER . 0.3 OUTLIER 60.03 24.74 13.94 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.327 1.064 . . . . 10.0 112.63 -179.76 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.74 -13.8 17.24 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.736 -0.603 . . . . 10.0 110.967 169.843 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.38 -158.87 42.23 Favored Glycine 0 N--CA 1.439 -1.11 0 N-CA-C 109.268 -1.533 . . . . 10.0 109.268 169.553 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -49.43 121.29 4.88 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 124.808 1.243 . . . . 10.0 112.635 -168.881 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 72.68 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.96 1.704 . . . . 10.0 108.983 169.232 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 52.8 mt -47.1 -41.27 16.97 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 124.317 1.047 . . . . 10.0 112.139 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.57 156.48 25.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 108.516 -0.92 . . . . 10.0 108.516 -171.351 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.8 p -162.33 168.78 21.68 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 108.897 -0.779 . . . . 10.0 108.897 -176.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.82 -175.18 17.75 Favored Glycine 0 N--CA 1.461 0.318 0 N-CA-C 111.229 -0.748 . . . . 10.0 111.229 -176.408 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 53.2 t -118.29 139.71 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 101.52 -3.511 . . . . 10.0 101.52 168.275 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 50.5 mt -59.32 -83.93 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 118.436 0.562 . . . . 10.0 110.33 -171.541 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.2 147.18 20.29 Favored Glycine 0 CA--C 1.52 0.363 0 O-C-N 121.724 -0.61 . . . . 10.0 112.65 178.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pt -73.6 154.31 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.393 -1.706 . . . . 10.0 106.393 168.15 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -52.91 6.43 Favored 'General case' 0 CA--C 1.512 -0.487 0 N-CA-C 106.078 -1.823 . . . . 10.0 106.078 169.748 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.252 1.187 0 O-C-N 126.328 2.268 . . . . 10.0 107.966 168.798 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.725 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.0 t -171.41 -43.43 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 124.468 1.107 . . . . 10.0 109.622 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -104.57 147.0 28.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 125.769 1.628 . . . . 10.0 107.639 171.006 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.0 157.96 37.05 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 168.543 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.5 m -130.16 177.61 6.47 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-O 121.642 0.734 . . . . 10.0 110.447 177.619 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.81 121.3 4.03 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 103.462 -2.792 . . . . 10.0 103.462 166.932 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.97 111.55 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 178.119 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.17 142.3 28.51 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 -171.164 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 mtpt -144.57 162.13 37.39 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 169.995 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.43 -65.75 0.02 OUTLIER Glycine 0 C--O 1.229 -0.198 0 CA-C-N 115.403 -0.817 . . . . 10.0 111.501 171.281 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.44 -45.45 46.33 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 106.597 -1.631 . . . . 10.0 106.597 -173.468 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.29 -65.46 0.59 Allowed Glycine 0 N--CA 1.444 -0.79 0 CA-C-N 113.431 -1.713 . . . . 10.0 110.866 -175.719 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -54.36 -38.97 89.17 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.579 2.186 . . . . 10.0 111.367 173.101 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.4 t -66.87 101.31 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.043 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 172.059 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -118.66 101.9 8.46 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.189 1.396 . . . . 10.0 107.709 171.278 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.89 148.36 24.55 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 125.13 1.348 . . . . 10.0 111.888 174.865 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -155.45 93.22 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 126.023 1.729 . . . . 10.0 106.463 -168.876 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.0 mm -86.49 151.18 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 C-N-CA 125.113 1.365 . . . . 10.0 109.767 179.045 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.1 m-80 -143.58 59.79 1.39 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.821 0.282 . . . . 10.0 111.725 179.402 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -47.68 120.91 3.63 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 117.559 -1.21 . . . . 10.0 109.417 -175.519 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -111.69 124.53 52.51 Favored 'General case' 0 C--O 1.233 0.2 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 176.506 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.2 tp60 -125.43 85.44 2.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.777 1.231 . . . . 10.0 109.055 172.058 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.15 -43.74 7.24 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 127.007 2.123 . . . . 10.0 112.309 -179.254 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -153.5 173.67 15.41 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 105.95 -1.87 . . . . 10.0 105.95 169.498 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 49.2 m -66.24 -19.55 65.86 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 122.943 0.497 . . . . 10.0 110.694 175.099 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -79.11 -15.54 58.0 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.423 0.689 . . . . 10.0 110.113 175.963 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.55 156.35 33.28 Favored Glycine 0 CA--C 1.532 1.101 0 O-C-N 122.145 -0.347 . . . . 10.0 112.964 -175.14 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -75.68 144.8 28.48 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 N-CA-C 105.727 -2.451 . . . . 10.0 105.727 165.911 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.2 t -78.94 127.17 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.521 -1.659 . . . . 10.0 106.521 179.467 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 mtmt -95.93 110.9 23.03 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.942 -0.762 . . . . 10.0 108.942 172.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.0 m -85.05 56.52 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 123.888 0.875 . . . . 10.0 110.788 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -40.24 139.28 0.75 Allowed 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 124.32 1.048 . . . . 10.0 112.947 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.73 131.93 4.52 Favored Glycine 0 N--CA 1.437 -1.258 0 N-CA-C 107.382 -2.287 . . . . 10.0 107.382 168.279 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.1 m -123.68 62.03 1.06 Allowed 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 106.654 -1.61 . . . . 10.0 106.654 172.06 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 pt -78.08 116.58 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.29 -1.004 . . . . 10.0 108.29 -176.541 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -99.37 141.07 32.62 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 107.722 -1.214 . . . . 10.0 107.722 172.537 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.53 -5.86 18.87 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 124.272 0.939 . . . . 10.0 112.211 173.907 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.44 173.2 4.22 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 118.494 1.147 . . . . 10.0 110.143 176.251 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.8 t -106.26 150.36 25.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.839 -1.541 . . . . 10.0 106.839 167.957 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -48.14 147.28 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.795 1.238 . . . . 10.0 110.299 -175.747 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.57 179.8 28.14 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.391 -1.083 . . . . 10.0 110.391 176.198 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.25 153.79 35.73 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.532 1.533 . . . . 10.0 111.404 -172.014 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -145.08 141.61 28.98 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 125.001 1.32 . . . . 10.0 110.535 -179.425 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.41 124.58 7.93 Favored Glycine 0 C--N 1.344 1.024 0 N-CA-C 107.308 -2.317 . . . . 10.0 107.308 166.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 57.4 t80 -145.7 118.72 8.79 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 118.851 1.326 . . . . 10.0 109.112 171.989 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -159.22 171.76 19.28 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.287 0.565 . . . . 10.0 110.103 -174.817 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -91.46 148.79 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 CA-C-N 112.757 -2.019 . . . . 10.0 106.972 168.027 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 62.1 m-70 -120.12 139.96 51.79 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.17 -1.789 . . . . 10.0 106.17 173.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -47.08 -57.35 5.16 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 124.609 1.193 . . . . 10.0 111.461 -171.872 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.38 136.76 33.33 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 109.559 -0.534 . . . . 10.0 109.559 -177.611 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.38 -8.6 86.93 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.421 -1.072 . . . . 10.0 110.421 167.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -47.78 144.63 3.25 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.63 1.205 . . . . 10.0 109.748 169.568 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -148.38 29.43 0.86 Allowed 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 114.585 -1.188 . . . . 10.0 110.393 172.75 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.401 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -58.41 -37.05 74.55 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 122.362 0.265 . . . . 10.0 111.609 -169.142 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.17 -23.51 40.98 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.652 0.781 . . . . 10.0 113.079 173.817 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.89 111.37 1.8 Allowed Glycine 0 CA--C 1.534 1.233 0 N-CA-C 110.178 -1.169 . . . . 10.0 110.178 -169.128 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.3 m 39.35 53.63 2.28 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 127.273 2.229 . . . . 10.0 114.07 170.901 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -156.17 -54.85 0.09 Allowed 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.526 -0.916 . . . . 10.0 108.526 178.569 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 m -61.39 -30.91 70.84 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.825 0.85 . . . . 10.0 112.127 -172.835 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.77 -30.31 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 129.188 2.995 . . . . 10.0 115.463 174.739 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.8 129.16 6.01 Favored Glycine 0 CA--C 1.524 0.633 0 CA-C-O 118.227 -1.318 . . . . 10.0 110.068 169.738 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -73.91 65.92 5.0 Favored 'Trans proline' 0 CA--C 1.535 0.549 0 C-N-CA 124.21 3.273 . . . . 10.0 111.76 179.829 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 56.9 58.12 4.24 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.236 2.614 . . . . 10.0 109.395 179.925 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 42.6 m-85 -68.0 74.39 0.2 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 122.112 0.958 . . . . 10.0 111.695 -179.366 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -85.73 126.39 66.26 Favored Pre-proline 0 C--N 1.323 -0.551 0 C-N-CA 126.306 1.842 . . . . 10.0 111.18 -178.494 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -68.04 -37.6 14.55 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.986 2.457 . . . . 10.0 110.668 -177.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 79.6 mt -76.72 52.47 0.83 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.212 0.605 . . . . 10.0 109.405 171.571 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -41.13 90.34 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 127.568 2.347 . . . . 10.0 113.817 -169.675 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -116.19 -164.0 0.94 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.843 1.257 . . . . 10.0 109.151 -174.592 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -116.18 108.49 16.21 Favored 'General case' 0 C--O 1.224 -0.284 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 -174.699 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.2 t60 -16.27 100.49 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.436 0 C-N-CA 126.11 1.764 . . . . 10.0 113.641 -179.218 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.47 -136.22 7.48 Favored Glycine 0 N--CA 1.449 -0.498 0 N-CA-C 108.022 -2.031 . . . . 10.0 108.022 -177.453 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.445 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 176.63 -165.39 35.61 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 108.262 -1.935 . . . . 10.0 108.262 169.195 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -67.64 12.85 0.19 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 121.751 1.634 . . . . 10.0 110.838 168.775 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.445 ' H ' ' C ' ' A' ' 73' ' ' GLY . 12.8 mmtp -104.52 -19.24 14.07 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 123.883 0.873 . . . . 10.0 108.89 172.286 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -119.7 167.19 12.29 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.375 -1.343 . . . . 10.0 107.375 -172.886 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -87.5 -24.57 24.05 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 172.106 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.313 1.8 pt-20 -107.36 40.95 1.58 Allowed 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 115.882 1.808 . . . . 10.0 115.882 -166.237 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.437 ' CD ' ' H ' ' A' ' 79' ' ' ARG . 0.3 OUTLIER -46.61 145.88 1.72 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.182 -1.372 . . . . 10.0 107.973 166.634 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.6 m170 -54.31 -58.81 5.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 109.276 -0.639 . . . . 10.0 109.276 169.202 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.1 p -168.42 -55.75 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 C-N-CA 124.477 1.111 . . . . 10.0 108.379 175.188 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -127.63 55.1 0.76 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.116 -1.194 . . . . 10.0 110.116 -176.564 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -86.45 97.62 10.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.784 -1.932 . . . . 10.0 105.784 169.433 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -72.69 -39.91 66.66 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 105.265 -2.124 . . . . 10.0 105.265 171.817 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 106.59 -106.98 2.62 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 109.127 -1.589 . . . . 10.0 109.127 166.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -106.72 131.41 53.89 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.301 1.04 . . . . 10.0 110.083 -168.004 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -120.63 129.03 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.325 0.511 . . . . 10.0 109.63 168.426 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.9 t -96.93 132.73 42.41 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 124.328 1.051 . . . . 10.0 109.757 -177.218 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.4 140.09 35.14 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 122.913 0.485 . . . . 10.0 110.759 176.277 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.34 170.68 2.22 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.759 0.824 . . . . 10.0 109.487 168.236 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.27 -23.43 48.31 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 123.65 0.78 . . . . 10.0 113.1 169.689 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -77.18 -8.18 57.11 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 122.773 0.429 . . . . 10.0 111.726 173.932 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.68 18.76 67.39 Favored Glycine 0 C--N 1.34 0.781 0 N-CA-C 110.16 -1.176 . . . . 10.0 110.16 -178.895 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 36.2 t -98.89 110.26 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.627 2.371 . . . . 10.0 106.927 -179.364 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 121.82 42.58 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 119.054 0.843 . . . . 10.0 109.202 169.448 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -101.59 78.2 1.82 Allowed 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 128.427 2.691 . . . . 10.0 110.948 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.43 61.34 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 C-N-CA 124.452 1.101 . . . . 10.0 112.311 -169.228 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -90.77 55.63 3.01 Favored 'General case' 0 C--N 1.317 -0.845 0 O-C-N 121.251 -0.905 . . . . 10.0 108.726 -178.447 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.58 145.74 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 108.333 -0.988 . . . . 10.0 108.333 -174.144 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.86 139.54 35.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 126.477 1.911 . . . . 10.0 110.001 178.09 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.73 159.63 41.63 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 108.172 -1.047 . . . . 10.0 108.172 166.334 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 t -124.66 55.81 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 124.444 1.098 . . . . 10.0 109.236 176.976 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -148.66 -41.28 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 123.586 0.754 . . . . 10.0 110.854 175.84 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 49.7 mm -67.13 89.28 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 C-N-CA 124.372 1.069 . . . . 10.0 109.543 170.657 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.8 m -88.44 123.99 33.52 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.615 0.766 . . . . 10.0 109.933 172.509 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.7 mt -48.25 -55.71 9.83 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.108 0.963 . . . . 10.0 111.076 177.237 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.5 p -135.49 175.34 9.68 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 127.271 2.229 . . . . 10.0 107.826 -179.165 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 132.22 -92.55 0.28 Allowed Glycine 0 C--N 1.335 0.493 0 N-CA-C 109.114 -1.595 . . . . 10.0 109.114 176.362 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -125.03 -52.23 1.66 Allowed 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.423 1.889 . . . . 10.0 107.655 179.323 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -74.3 -37.41 63.64 Favored 'General case' 0 N--CA 1.457 -0.116 0 CA-C-N 114.717 -1.129 . . . . 10.0 108.26 -173.518 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t 44.4 65.99 0.95 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.824 1.65 . . . . 10.0 113.024 168.75 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -65.19 -19.18 25.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 113.252 0.834 . . . . 10.0 113.252 -174.161 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.0 mm -48.58 126.02 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 118.336 0.516 . . . . 10.0 109.706 172.653 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.34 1.52 55.68 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.77 -1.016 . . . . 10.0 113.779 -179.094 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.99 176.33 9.25 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 118.757 1.278 . . . . 10.0 109.984 169.179 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -113.13 140.57 47.79 Favored 'General case' 0 C--N 1.34 0.159 0 C-N-CA 124.505 1.122 . . . . 10.0 108.802 169.757 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -98.13 139.49 33.86 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.562 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.6 t -117.76 135.18 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 107.349 -1.352 . . . . 10.0 107.349 170.93 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.39 122.07 55.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 N-CA-C 106.04 -1.837 . . . . 10.0 106.04 167.579 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.2 m-70 -100.44 161.78 13.38 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.92 1.343 . . . . 10.0 114.225 -169.253 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -53.85 -68.8 0.15 Allowed 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.641 2.376 . . . . 10.0 109.107 177.31 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 57.2 mttp -106.92 168.37 9.24 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 123.476 0.71 . . . . 10.0 111.164 -178.125 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.62 142.35 58.46 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.593 1.157 . . . . 10.0 109.528 171.322 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -81.93 144.3 31.04 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.359 0.599 . . . . 10.0 109.902 168.381 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -78.43 7.8 6.07 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.079 0.951 . . . . 10.0 110.972 175.555 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 33.4 mt 49.75 45.62 24.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 124.133 0.973 . . . . 10.0 109.668 -177.835 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.38 -31.46 8.03 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 114.943 -1.026 . . . . 10.0 111.188 174.876 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mtmm -84.23 42.34 0.88 Allowed 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.746 -0.855 . . . . 10.0 110.759 -170.108 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.85 -34.67 6.43 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 126.983 2.23 . . . . 10.0 109.999 176.719 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 58.64 47.9 87.64 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 111.73 -0.548 . . . . 10.0 111.73 -174.402 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -137.49 173.34 11.77 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.1 -1.815 . . . . 10.0 106.1 169.552 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -54.69 -54.05 46.82 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 109.195 -0.669 . . . . 10.0 109.195 173.502 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -58.71 -31.38 68.2 Favored 'General case' 0 C--N 1.344 0.359 0 O-C-N 121.396 -0.815 . . . . 10.0 112.502 179.452 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.3 p -51.18 -34.88 33.54 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 119.646 1.112 . . . . 10.0 110.461 178.276 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.3 t -98.34 11.13 39.02 Favored 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 113.549 0.944 . . . . 10.0 113.549 -179.793 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 73.3 mmtt -120.36 -54.67 2.08 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 125.299 1.44 . . . . 10.0 111.153 179.617 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -131.95 9.59 4.54 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 113.388 0.884 . . . . 10.0 113.388 171.92 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.14 16.18 61.32 Favored Glycine 0 C--O 1.221 -0.707 0 CA-C-O 119.216 -0.769 . . . . 10.0 113.366 173.063 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 69.36 17.75 8.1 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.188 0.994 . . . . 10.0 112.525 -177.121 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.08 -14.42 54.47 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 123.317 0.647 . . . . 10.0 112.005 176.553 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.87 -147.04 30.25 Favored Glycine 0 N--CA 1.442 -0.937 0 N-CA-C 109.816 -1.313 . . . . 10.0 109.816 169.848 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.3 m -61.07 121.31 12.14 Favored 'General case' 0 N--CA 1.444 -0.769 0 O-C-N 122.1 -0.647 . . . . 10.0 110.764 -168.74 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -56.24 71.25 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.866 1.666 . . . . 10.0 110.711 167.335 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 11.0 tp -45.91 -41.38 11.38 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 127.181 2.192 . . . . 10.0 112.925 -171.475 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.93 155.46 31.4 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.177 -1.046 . . . . 10.0 108.177 -175.78 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.1 p -164.12 170.85 15.89 Favored 'General case' 0 N--CA 1.454 -0.253 0 O-C-N 122.01 -0.431 . . . . 10.0 110.095 -176.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -166.95 -176.69 38.14 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.705 -1.358 . . . . 10.0 109.705 -177.629 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.89 143.28 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -169.717 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 61.0 mt -73.55 137.4 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 122.784 0.434 . . . . 10.0 110.536 -176.405 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.72 141.59 12.77 Favored Glycine 0 CA--C 1.529 0.906 0 C-N-CA 125.306 1.432 . . . . 10.0 111.272 -178.537 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 42.5 mt -57.05 139.04 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 125.212 1.405 . . . . 10.0 108.603 170.943 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -136.57 156.67 48.26 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.318 0.58 . . . . 10.0 109.887 172.032 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.287 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 165.667 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.68 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -14.68 60.79 Favored 'General case' 0 CA--C 1.527 0.062 0 CA-C-N 118.857 0.753 . . . . 10.0 110.679 176.439 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 45.4 tttt -151.4 148.26 27.9 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.723 -0.473 . . . . 10.0 109.723 169.528 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.73 165.97 25.85 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.295 1.438 . . . . 10.0 107.501 169.543 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.61 164.06 35.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 123.426 0.69 . . . . 10.0 109.168 176.039 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.15 111.63 10.47 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 169.238 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.1 m -86.88 100.5 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 169.95 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.3 mt -78.83 134.37 36.97 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 123.912 0.885 . . . . 10.0 109.423 176.348 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -158.6 162.19 37.31 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 169.302 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.5 -56.85 0.05 OUTLIER Glycine 0 N--CA 1.454 -0.125 0 N-CA-C 111.485 -0.646 . . . . 10.0 111.485 171.205 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.37 -45.72 45.13 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.486 -1.672 . . . . 10.0 106.486 -170.923 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.4 -65.92 0.57 Allowed Glycine 0 CA--C 1.526 0.753 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.734 -179.141 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -58.33 -36.8 97.26 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.913 2.409 . . . . 10.0 111.236 173.685 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.7 113.57 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.378 -0.971 . . . . 10.0 108.378 175.788 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.31 126.28 31.07 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.202 -1.036 . . . . 10.0 108.202 168.581 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -120.44 140.76 14.65 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-O 119.428 -0.651 . . . . 10.0 111.696 176.582 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.401 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 10.6 mt -135.37 75.24 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 -169.276 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.2 mm -92.25 139.65 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.819 -0.628 . . . . 10.0 110.023 -174.293 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -114.62 120.94 41.87 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 128.419 2.688 . . . . 10.0 108.02 -178.104 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.9 105.56 14.41 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.315 1.446 . . . . 10.0 107.576 178.838 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -100.57 150.54 22.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 118.414 0.552 . . . . 10.0 111.122 178.277 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 63.8 tp60 -142.24 102.31 4.08 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.7 2.0 . . . . 10.0 108.264 -179.057 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp -65.18 -54.98 21.44 Favored 'General case' 0 N--CA 1.438 -1.069 0 C-N-CA 126.228 1.811 . . . . 10.0 110.879 -172.546 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -140.17 169.75 17.11 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 102.475 -3.157 . . . . 10.0 102.475 178.492 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.2 p -68.02 -18.31 64.67 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 120.71 1.596 . . . . 10.0 109.928 179.577 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 35.0 m120 -77.56 -19.21 56.04 Favored 'General case' 0 N--CA 1.441 -0.9 0 C-N-CA 123.792 0.837 . . . . 10.0 111.415 178.511 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.1 154.85 52.94 Favored Glycine 0 CA--C 1.533 1.184 0 N-CA-C 111.943 -0.463 . . . . 10.0 111.943 -174.54 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.18 154.34 61.94 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.418 2.079 . . . . 10.0 108.081 168.867 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 t -79.01 92.04 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 104.753 -2.314 . . . . 10.0 104.753 169.172 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.464 ' NZ ' ' OE1' ' B' ' 100' ' ' GLU . 35.3 tttp -77.17 104.03 7.44 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 106.832 -1.544 . . . . 10.0 106.832 169.042 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -96.42 104.41 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 C-N-CA 126.566 1.946 . . . . 10.0 106.539 -179.352 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -122.24 163.03 20.33 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 112.693 0.627 . . . . 10.0 112.693 174.278 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.66 -154.15 25.33 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 106.866 -2.494 . . . . 10.0 106.866 169.666 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -155.14 160.55 41.02 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 120.134 -0.626 . . . . 10.0 110.198 176.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pt -117.43 142.47 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.683 0 CA-C-N 114.262 -1.335 . . . . 10.0 109.557 167.475 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -117.35 149.54 40.32 Favored 'General case' 0 N--CA 1.443 -0.776 0 N-CA-C 106.864 -1.532 . . . . 10.0 106.864 168.385 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.04 -8.36 33.4 Favored Glycine 0 C--N 1.336 0.564 0 CA-C-O 119.34 -0.7 . . . . 10.0 112.731 171.395 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -62.15 175.36 0.73 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.198 0.999 . . . . 10.0 109.246 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.79 166.26 10.58 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 167.351 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -54.48 149.93 9.78 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.25 0.62 . . . . 10.0 111.469 -172.097 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.75 -168.6 31.81 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-O 121.763 0.646 . . . . 10.0 112.838 168.971 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.3 mp -75.26 144.8 42.37 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 126.824 2.05 . . . . 10.0 111.787 -169.652 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -147.85 145.08 28.57 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 113.813 1.042 . . . . 10.0 113.813 -177.322 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -28.22 128.41 0.07 OUTLIER Glycine 0 C--N 1.341 0.835 0 C-N-CA 127.284 2.373 . . . . 10.0 111.288 165.606 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -151.37 102.15 2.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 119.144 1.472 . . . . 10.0 111.675 169.861 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.452 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -150.57 170.07 20.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.764 0.653 . . . . 10.0 112.764 -179.83 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 24.2 m -97.4 -30.27 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 126.244 1.817 . . . . 10.0 113.986 -170.766 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 57.3 m-70 58.03 171.82 0.05 Allowed 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 122.905 1.336 . . . . 10.0 112.989 -177.571 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -83.25 -51.56 7.35 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 114.779 -1.101 . . . . 10.0 110.037 170.327 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -75.95 114.0 14.08 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 118.628 0.649 . . . . 10.0 109.669 -168.019 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.23 -31.71 81.75 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 107.824 -2.111 . . . . 10.0 107.824 165.792 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -58.82 161.46 4.83 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-O 123.251 1.5 . . . . 10.0 114.423 -176.551 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.14 21.68 0.08 Allowed 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 112.941 -1.936 . . . . 10.0 113.962 -168.128 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -58.31 -29.24 65.74 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 123.816 0.847 . . . . 10.0 111.75 -179.562 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.13 -15.95 59.35 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 122.909 0.484 . . . . 10.0 111.796 176.599 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.77 85.43 0.81 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 124.356 0.979 . . . . 10.0 111.049 178.521 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 65.5 m 37.6 47.53 0.8 Allowed 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 126.946 2.098 . . . . 10.0 112.146 -179.952 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -121.85 -54.89 1.92 Allowed 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 -169.659 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.0 t -128.34 54.81 1.72 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.021 0.928 . . . . 10.0 108.763 -177.472 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.02 49.97 0.45 Allowed 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 123.14 0.576 . . . . 10.0 110.399 172.149 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.0 125.92 0.13 Allowed Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.272 0.939 . . . . 10.0 111.448 172.346 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -77.46 47.39 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.86 0 C-N-CA 123.374 2.716 . . . . 10.0 112.605 179.607 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 60.76 47.79 7.64 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.931 2.492 . . . . 10.0 110.996 178.059 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -70.74 70.28 0.47 Allowed 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.886 0.85 . . . . 10.0 110.778 174.602 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -71.62 148.56 92.88 Favored Pre-proline 0 C--N 1.325 -0.467 0 C-N-CA 123.388 0.675 . . . . 10.0 112.709 -174.17 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -64.52 -46.61 6.93 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.975 2.45 . . . . 10.0 111.522 -179.722 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -78.89 48.9 0.87 Allowed 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.538 -0.726 . . . . 10.0 110.002 178.553 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 64.1 p -14.94 102.93 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 129.711 3.204 . . . . 10.0 113.466 -170.209 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 mtt85 -137.07 -179.77 5.91 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 118.612 0.642 . . . . 10.0 112.635 -170.635 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -111.79 102.09 10.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 105.753 -1.943 . . . . 10.0 105.753 -176.836 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.401 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.5 t60 -22.66 107.51 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.455 1.902 . . . . 10.0 114.185 -171.274 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.03 -149.55 8.38 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.964 -1.255 . . . . 10.0 109.964 176.652 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.96 -162.66 22.65 Favored Glycine 0 C--N 1.331 0.301 0 N-CA-C 108.51 -1.836 . . . . 10.0 108.51 -179.316 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -64.94 -6.69 13.26 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 121.367 1.378 . . . . 10.0 109.797 165.551 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 30.2 mmtt -101.89 2.43 38.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.82 1.648 . . . . 10.0 110.099 177.35 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 128' ' ' LYS . 3.7 t70 -129.32 170.98 12.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 N-CA-C 107.498 -1.297 . . . . 10.0 107.498 167.399 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -91.59 -27.17 18.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.426 -0.953 . . . . 10.0 108.426 169.186 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -102.89 39.3 1.57 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 122.831 1.301 . . . . 10.0 110.206 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.7 ptp180 -55.89 142.3 35.86 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 126.057 1.743 . . . . 10.0 108.941 169.664 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . 0.401 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.0 m170 -64.98 -56.74 11.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 O-C-N 121.855 -0.528 . . . . 10.0 110.237 -175.181 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 3.6 p -170.37 -68.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.992 -0.744 . . . . 10.0 108.992 176.908 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -118.2 67.91 0.34 Allowed Glycine 0 C--N 1.333 0.413 0 N-CA-C 107.522 -2.231 . . . . 10.0 107.522 -179.41 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -106.79 97.65 7.41 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.322 -2.473 . . . . 10.0 104.322 172.407 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 23.9 mt -82.09 22.94 0.75 Allowed 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.235 0.541 . . . . 10.0 110.56 -173.612 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.85 -104.85 2.36 Favored Glycine 0 N--CA 1.437 -1.287 0 N-CA-C 106.422 -2.671 . . . . 10.0 106.422 173.596 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -157.64 151.28 23.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.726 -1.213 . . . . 10.0 107.726 169.704 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.0 m -113.9 137.25 47.73 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 O-C-N 123.835 0.709 . . . . 10.0 109.547 -175.032 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 88.7 m -94.89 109.35 21.36 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 128.364 2.666 . . . . 10.0 108.491 -171.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.25 136.49 32.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 122.904 0.482 . . . . 10.0 110.205 174.845 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -57.56 171.51 0.44 Allowed 'General case' 0 C--O 1.235 0.298 0 O-C-N 124.079 0.862 . . . . 10.0 108.841 166.323 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 58.3 pttt -57.45 -29.04 63.87 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 123.541 0.736 . . . . 10.0 110.508 175.524 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -79.13 -0.64 32.54 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.785 0.834 . . . . 10.0 111.051 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.19 4.69 88.05 Favored Glycine 0 C--N 1.339 0.736 0 O-C-N 120.99 -1.069 . . . . 10.0 110.79 179.644 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.66 97.3 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 C-N-CA 126.128 1.771 . . . . 10.0 107.52 -178.008 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.72 118.83 37.75 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 108.367 -0.975 . . . . 10.0 108.367 169.192 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -82.15 129.13 34.74 Favored 'General case' 0 N--CA 1.437 -1.124 0 C-N-CA 126.856 2.062 . . . . 10.0 109.9 174.633 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.17 134.06 58.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 C-N-CA 125.907 1.683 . . . . 10.0 107.769 173.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 13.7 p -158.44 57.44 0.45 Allowed 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 112.804 0.668 . . . . 10.0 112.804 171.791 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.86 155.76 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.921 -0.77 . . . . 10.0 108.921 -172.075 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . 0.464 ' OE1' ' NZ ' ' B' ' 30' ' ' LYS . 1.5 pt-20 -116.47 99.25 7.05 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 126.546 1.938 . . . . 10.0 110.38 174.358 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -81.72 85.42 6.6 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.626 -1.249 . . . . 10.0 107.626 176.417 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 64.7 p -83.15 60.51 5.56 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 106.315 -1.735 . . . . 10.0 106.315 173.168 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.84 -47.77 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 O-C-N 123.356 0.41 . . . . 10.0 110.273 -170.9 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.325 0.0 OUTLIER -103.42 176.87 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 C-N-CA 123.74 0.816 . . . . 10.0 112.033 169.378 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -140.7 123.98 16.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.49 -29.57 50.51 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.358 1.463 . . . . 10.0 111.318 -179.031 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.4 m -140.1 135.73 32.84 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 167.23 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.01 -64.2 0.19 Allowed Glycine 0 C--N 1.333 0.393 0 N-CA-C 108.819 -1.713 . . . . 10.0 108.819 -175.096 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -166.4 -50.38 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 125.979 1.712 . . . . 10.0 107.872 -179.787 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 -74.73 -36.65 62.65 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.858 -1.064 . . . . 10.0 109.527 -169.278 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 111' ' ' SER . . . . . 0.42 ' C ' ' H ' ' B' ' 113' ' ' ILE . 7.5 t 31.43 73.61 0.06 Allowed 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.68 2.392 . . . . 10.0 111.818 169.723 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.95 20.17 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 124.796 1.238 . . . . 10.0 114.291 -174.477 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . 0.42 ' H ' ' C ' ' B' ' 111' ' ' SER . 17.9 mm -54.92 146.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 C-N-CA 125.538 1.535 . . . . 10.0 108.085 168.745 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.91 21.99 69.98 Favored Glycine 0 CA--C 1.533 1.169 0 CA-C-O 118.599 -1.111 . . . . 10.0 114.335 178.278 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.2 mmt180 -97.53 172.55 7.66 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 166.513 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -124.22 108.54 12.38 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.082 0.855 . . . . 10.0 111.454 -170.529 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -64.89 134.21 53.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 107.344 -1.354 . . . . 10.0 107.344 169.743 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.6 t -125.11 131.37 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 106.83 -1.544 . . . . 10.0 106.83 174.747 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.4 m -105.99 131.52 55.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 O-C-N 124.007 0.817 . . . . 10.0 110.084 169.466 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 5.3 m170 -113.04 163.5 14.62 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 114.813 1.412 . . . . 10.0 114.813 -170.583 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -51.31 -55.51 17.94 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 127.172 2.189 . . . . 10.0 109.468 -179.393 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -121.05 174.27 6.75 Favored 'General case' 0 CA--C 1.521 -0.154 0 C-N-CA 124.366 1.066 . . . . 10.0 112.228 -171.155 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.6 151.65 30.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.857 1.263 . . . . 10.0 110.06 -179.835 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.452 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -78.37 153.68 31.42 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 123.773 0.829 . . . . 10.0 111.799 175.733 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -76.31 -27.98 56.77 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 114.897 -1.047 . . . . 10.0 109.4 168.742 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 68.9 mt 59.52 52.04 6.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 123.669 1.7 . . . . 10.0 108.524 -172.8 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.65 -41.53 2.84 Favored Glycine 0 N--CA 1.443 -0.852 0 CA-C-N 111.655 -2.52 . . . . 10.0 111.489 169.171 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 19.1 mtmm -79.26 41.44 0.46 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.34 1.456 . . . . 10.0 112.47 -170.863 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.46 -15.73 34.07 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 126.653 2.073 . . . . 10.0 110.497 169.332 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.34 46.69 51.93 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 124.393 0.997 . . . . 10.0 111.951 -179.309 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.5 p30 -151.07 172.83 15.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 118.249 1.024 . . . . 10.0 109.883 176.216 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.3 tm-20 -55.18 -41.02 71.37 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.697 1.199 . . . . 10.0 110.915 -176.689 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 19.0 tp10 -71.42 -39.07 71.31 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 121.681 -0.637 . . . . 10.0 110.587 174.121 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.5 p -52.24 -43.92 64.56 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 118.451 0.569 . . . . 10.0 110.57 -176.376 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.3 t -74.92 -10.53 59.58 Favored 'General case' 0 CA--C 1.543 0.703 0 O-C-N 124.332 1.02 . . . . 10.0 113.058 -177.216 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.6 ttmt -115.21 -64.64 1.29 Allowed 'General case' 0 N--CA 1.436 -1.131 0 C-N-CA 126.973 2.109 . . . . 10.0 112.899 -168.878 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.5 p -126.46 17.01 7.63 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 120.048 1.295 . . . . 10.0 110.208 175.939 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.53 -105.7 1.91 Allowed Glycine 0 C--N 1.339 0.744 0 N-CA-C 106.952 -2.459 . . . . 10.0 106.952 -173.877 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -152.52 39.38 0.56 Allowed 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 170.009 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.22 -26.32 64.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.231 -0.895 . . . . 10.0 111.144 -177.03 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.48 -142.61 23.0 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 124.876 1.226 . . . . 10.0 110.379 170.707 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -69.16 134.96 49.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 -175.82 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.07 120.84 12.21 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 106.414 -1.698 . . . . 10.0 106.414 167.758 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 31.9 mt -76.65 -60.43 2.35 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 169.547 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -139.18 163.17 33.14 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 122.974 0.51 . . . . 10.0 110.104 -174.03 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -154.15 163.71 39.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.353 -0.385 . . . . 10.0 110.443 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.33 149.1 18.22 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 109.418 -1.473 . . . . 10.0 109.418 -171.624 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -108.67 139.65 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 C-N-CA 124.916 1.286 . . . . 10.0 108.041 -169.065 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 19.0 mt -77.5 112.32 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 122.916 0.486 . . . . 10.0 109.966 -173.455 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.75 143.54 18.09 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.808 1.194 . . . . 10.0 112.21 -174.451 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.49 136.34 25.81 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.296 0 C-N-CA 126.315 1.846 . . . . 10.0 110.333 -175.758 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.74 -46.78 1.98 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.681 0.673 . . . . 10.0 111.759 177.821 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 . . . . . 0 C--O 1.25 1.103 0 CA-C-O 116.368 -1.777 . . . . 10.0 112.107 -169.443 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 108.411 -0.959 . . . . 10.0 108.411 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -80.06 -21.52 43.33 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.948 -1.13 . . . . 10.0 107.948 168.144 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.496 ' HZ2' ' C ' ' A' ' 153' ' ' GLN . 1.8 ttmp? -127.04 161.5 28.24 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.763 1.625 . . . . 10.0 107.868 179.078 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.24 164.28 38.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.435 -1.691 . . . . 10.0 106.435 168.337 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 m -125.76 -179.9 2.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 118.08 0.4 . . . . 10.0 110.094 -179.429 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.71 108.37 2.9 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.852 -0.795 . . . . 10.0 108.852 165.207 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.3 m -92.91 115.53 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 171.282 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.7 mt -103.85 150.32 24.25 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.751 1.221 . . . . 10.0 109.224 -179.801 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.6 ttmt -163.12 159.83 23.57 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.721 1.146 . . . . 10.0 109.204 169.836 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.42 -56.35 0.02 OUTLIER Glycine 0 C--O 1.229 -0.197 0 N-CA-C 111.349 -0.7 . . . . 10.0 111.349 169.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -75.25 -45.85 37.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 106.575 -1.639 . . . . 10.0 106.575 -172.825 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.5 -64.85 0.6 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 113.859 -1.519 . . . . 10.0 110.902 -178.413 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -58.3 -41.29 67.86 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 122.512 2.142 . . . . 10.0 110.839 172.08 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -70.43 105.38 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.427 -1.694 . . . . 10.0 106.427 176.361 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.81 131.93 46.34 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.766 -0.827 . . . . 10.0 108.766 167.296 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.419 ' HA2' ' CG2' ' A' ' 35' ' ' ILE . . . -99.39 147.52 18.39 Favored Glycine 0 N--CA 1.441 -1.005 0 N-CA-C 109.658 -1.377 . . . . 10.0 109.658 174.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -150.81 81.8 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 105.355 -2.091 . . . . 10.0 105.355 -170.422 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -100.51 146.33 9.41 Favored 'Isoleucine or valine' 0 C--N 1.338 0.1 0 C-N-CA 125.091 1.356 . . . . 10.0 109.738 -178.283 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -126.0 117.15 22.65 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 127.502 2.321 . . . . 10.0 109.005 170.172 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -98.41 116.86 31.53 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 106.817 -1.549 . . . . 10.0 106.817 173.269 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -116.62 138.5 51.39 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 119.476 1.034 . . . . 10.0 112.948 171.18 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -114.35 85.37 2.22 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.728 2.011 . . . . 10.0 107.966 -178.176 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.427 ' NZ ' ' OE2' ' A' ' 100' ' ' GLU . 0.0 OUTLIER -46.07 -44.09 15.14 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.711 1.605 . . . . 10.0 111.366 -172.643 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -142.95 168.46 19.65 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 102.989 -2.967 . . . . 10.0 102.989 165.534 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.0 t -61.71 -29.17 69.93 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 174.525 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -81.09 -17.52 49.73 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 124.397 1.079 . . . . 10.0 110.783 -179.225 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.41 141.97 16.48 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 110.446 -1.062 . . . . 10.0 110.446 -171.174 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -63.55 136.48 54.6 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.078 1.852 . . . . 10.0 109.221 174.872 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.6 m -78.03 124.39 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -176.458 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 37.7 ttmt -88.11 116.48 26.33 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.759 -2.682 . . . . 10.0 103.759 167.591 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -97.51 104.19 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 171.258 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 21.2 p90 -112.88 167.65 10.33 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 116.129 -0.487 . . . . 10.0 110.086 176.473 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.36 176.15 42.51 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.878 -1.153 . . . . 10.0 111.688 178.33 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.6 t -144.84 99.17 3.3 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 107.775 -1.194 . . . . 10.0 107.775 177.252 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.419 ' CG2' ' HA2' ' A' ' 16' ' ' GLY . 3.4 pt -80.57 153.61 4.39 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.584 -1.265 . . . . 10.0 107.584 168.4 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.68 151.06 50.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 124.062 0.851 . . . . 10.0 109.085 167.83 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.65 -8.91 34.73 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.967 0.794 . . . . 10.0 113.541 175.443 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -61.06 176.27 0.44 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 122.301 1.048 . . . . 10.0 111.188 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -107.4 151.38 25.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 106.579 -1.638 . . . . 10.0 106.579 166.999 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -49.44 144.19 5.87 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.244 1.017 . . . . 10.0 111.717 -169.826 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.83 -168.01 21.18 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 123.685 0.659 . . . . 10.0 112.203 172.751 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -75.81 148.75 38.19 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.842 2.057 . . . . 10.0 111.768 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -147.6 134.24 19.9 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.477 1.111 . . . . 10.0 111.472 179.344 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.23 123.61 1.33 Allowed Glycine 0 C--N 1.345 1.076 0 C-N-CA 124.843 1.211 . . . . 10.0 111.02 168.337 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -136.75 108.64 7.1 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 124.133 0.973 . . . . 10.0 109.37 176.397 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -155.57 174.4 15.32 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 121.788 0.804 . . . . 10.0 111.712 -178.101 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.7 m -102.35 144.65 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 CA-C-N 111.798 -2.456 . . . . 10.0 106.369 168.214 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -121.66 148.07 45.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 107.246 -1.39 . . . . 10.0 107.246 176.543 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.401 ' HB3' ' CE1' ' A' ' 64' ' ' PHE . 2.3 tp10 -59.43 -39.32 83.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 122.854 0.462 . . . . 10.0 112.213 -169.963 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -74.76 153.23 38.9 Favored 'General case' 0 CA--C 1.527 0.079 0 C-N-CA 118.358 -1.337 . . . . 10.0 109.561 177.205 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.58 -11.84 46.3 Favored Glycine 0 CA--C 1.54 1.602 0 N-CA-C 109.385 -1.486 . . . . 10.0 109.385 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -48.2 107.13 0.11 Allowed 'General case' 0 C--N 1.344 0.357 0 C-N-CA 126.653 1.981 . . . . 10.0 112.382 172.658 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -112.68 6.44 18.23 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 113.268 -1.787 . . . . 10.0 109.34 168.015 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.8 -39.92 78.7 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.254 1.021 . . . . 10.0 109.456 -178.91 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.5 -15.52 58.51 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.053 0.941 . . . . 10.0 112.699 177.622 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.48 -108.08 3.06 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 108.736 -1.746 . . . . 10.0 108.736 -173.13 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 60.9 m -131.0 43.7 3.06 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 124.307 1.043 . . . . 10.0 109.43 -173.215 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 55.3 m -130.18 -54.24 1.11 Allowed 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 125.796 1.638 . . . . 10.0 107.141 -171.748 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.9 t -80.75 4.61 18.36 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.265 0.555 . . . . 10.0 111.663 178.445 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.54 -25.87 7.52 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.871 1.268 . . . . 10.0 112.415 173.137 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.42 144.99 18.26 Favored Glycine 0 C--N 1.339 0.742 0 N-CA-C 110.576 -1.01 . . . . 10.0 110.576 173.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -80.07 57.74 6.65 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 CA-C-N 120.584 2.192 . . . . 10.0 111.399 179.649 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.9 m170 71.77 -62.27 0.46 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 127.122 2.169 . . . . 10.0 108.211 -175.685 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.401 ' CE1' ' HB3' ' A' ' 49' ' ' GLU 0.343 3.1 p90 34.28 36.72 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 129.998 3.319 . . . . 10.0 116.85 174.635 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -45.29 152.24 0.64 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 129.837 3.255 . . . . 10.0 113.287 167.78 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -74.17 -48.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.493 2.795 . . . . 10.0 111.29 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 81.7 mt -68.82 83.44 0.3 Allowed 'General case' 0 C--N 1.339 0.145 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 172.839 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.7 p -69.54 64.65 0.18 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 126.628 1.971 . . . . 10.0 113.982 -169.358 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -87.73 -178.75 6.14 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.575 1.95 . . . . 10.0 109.779 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -111.43 84.98 2.04 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.188 0.518 . . . . 10.0 112.205 -169.356 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.409 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 64.8 t60 11.14 87.3 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 128.009 2.524 . . . . 10.0 114.627 175.791 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.26 -161.44 18.33 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 108.681 -1.767 . . . . 10.0 108.681 174.923 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.17 -155.88 6.73 Favored Glycine 0 C--O 1.224 -0.495 0 CA-C-O 117.671 -1.627 . . . . 10.0 110.512 170.106 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -64.91 -2.05 5.01 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 CA-C-N 120.756 2.278 . . . . 10.0 111.27 171.139 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 29.3 mtpt -88.41 -17.6 30.14 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.245 -0.884 . . . . 10.0 110.801 172.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -128.98 174.83 9.17 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 118.812 0.733 . . . . 10.0 109.482 -175.831 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -97.51 -15.05 20.73 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.707 0.803 . . . . 10.0 109.505 168.539 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 70.5 mm-40 -79.69 10.74 3.7 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.145 1.378 . . . . 10.0 112.78 178.712 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 16.4 ptt180 -51.65 127.56 20.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 166.995 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.409 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 21.3 m170 -65.7 -51.1 62.03 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 122.11 -0.369 . . . . 10.0 111.512 -169.982 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.6 p -166.94 -30.29 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 123.026 0.531 . . . . 10.0 111.804 -169.626 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.69 70.97 0.08 OUTLIER Glycine 0 C--N 1.334 0.442 0 N-CA-C 106.199 -2.761 . . . . 10.0 106.199 -176.557 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -116.58 91.11 3.49 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 -169.554 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp -72.86 -28.83 62.75 Favored 'General case' 0 CA--C 1.527 0.09 0 N-CA-C 107.314 -1.365 . . . . 10.0 107.314 -178.151 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.53 -87.78 0.77 Allowed Glycine 0 N--CA 1.44 -1.04 0 N-CA-C 106.493 -2.643 . . . . 10.0 106.493 172.12 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -140.98 149.38 41.71 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 122.884 0.473 . . . . 10.0 111.902 -176.414 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -129.32 143.41 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 105.506 -2.035 . . . . 10.0 105.506 168.093 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -95.48 121.58 37.31 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.357 1.863 . . . . 10.0 107.521 -176.285 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.14 137.4 32.37 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.721 -0.474 . . . . 10.0 109.721 171.208 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -67.5 173.25 4.25 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 126.193 1.797 . . . . 10.0 109.786 168.966 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -56.68 -24.36 48.28 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 124.75 1.22 . . . . 10.0 112.274 177.825 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -78.24 -17.61 56.48 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.092 -0.336 . . . . 10.0 110.092 179.527 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.28 7.74 69.39 Favored Glycine 0 C--N 1.338 0.647 0 N-CA-C 110.525 -1.03 . . . . 10.0 110.525 -171.86 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -80.7 119.54 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 N-CA-C 106.714 -1.587 . . . . 10.0 106.714 172.938 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -113.94 118.78 35.14 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 119.11 0.868 . . . . 10.0 108.691 169.482 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -79.2 117.35 20.14 Favored 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 126.366 1.866 . . . . 10.0 108.096 174.345 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 46.5 t -105.93 131.39 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 178.537 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 80.0 p -157.77 71.75 0.63 Allowed 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.735 0.814 . . . . 10.0 109.579 173.069 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.58 155.0 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 106.92 -1.511 . . . . 10.0 106.92 177.456 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.427 ' OE2' ' NZ ' ' A' ' 23' ' ' LYS . 26.3 tt0 -135.95 128.18 30.02 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 124.914 1.286 . . . . 10.0 108.276 174.742 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -136.7 152.8 50.78 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 124.046 0.842 . . . . 10.0 109.814 -177.601 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.4 p -118.68 48.75 1.39 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 127.484 2.314 . . . . 10.0 109.875 -171.068 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 14.6 p -155.34 -49.37 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 122.295 0.238 . . . . 10.0 110.655 173.002 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.99 119.48 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.663 -1.606 . . . . 10.0 106.663 170.617 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.09 85.79 2.3 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -176.038 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.2 pp -51.9 -10.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.603 1.561 . . . . 10.0 114.294 -177.961 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 24.9 t -148.36 137.01 21.55 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 103.953 -2.61 . . . . 10.0 103.953 168.862 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.78 -72.41 0.39 Allowed Glycine 0 C--N 1.334 0.421 0 N-CA-C 109.846 -1.301 . . . . 10.0 109.846 -176.526 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.45 -53.37 0.08 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 179.75 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -83.7 48.25 1.4 Allowed 'General case' 0 C--O 1.233 0.199 0 N-CA-C 109.269 -0.641 . . . . 10.0 109.269 -176.773 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.7 t -73.64 72.22 1.44 Allowed 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.072 1.349 . . . . 10.0 107.615 178.019 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.8 pt -72.2 39.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 126.251 1.821 . . . . 10.0 112.058 -177.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 44.2 mm -66.58 -47.5 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 125.246 1.418 . . . . 10.0 109.456 -178.445 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.77 51.3 3.74 Favored Glycine 0 CA--C 1.525 0.691 0 O-C-N 121.622 -0.674 . . . . 10.0 113.408 -175.053 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.29 145.81 46.72 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 -177.783 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 28.3 m -90.21 119.62 30.68 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 104.902 -2.259 . . . . 10.0 104.902 169.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.21 143.14 31.66 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -179.453 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 55.3 t -129.81 136.29 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 O-C-N 124.321 1.013 . . . . 10.0 109.405 -169.528 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -105.96 119.32 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 N-CA-C 105.067 -2.198 . . . . 10.0 105.067 168.603 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -99.19 161.45 13.62 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 113.823 1.045 . . . . 10.0 113.823 -169.563 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -64.77 -53.06 53.03 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.685 -1.143 . . . . 10.0 108.483 -176.92 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -113.12 176.64 4.93 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.902 0.858 . . . . 10.0 111.987 -178.462 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.89 135.99 50.14 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.067 1.347 . . . . 10.0 111.19 -178.495 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -77.49 110.13 12.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 124.491 1.116 . . . . 10.0 108.507 173.757 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -80.36 58.41 3.11 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 123.196 0.31 . . . . 10.0 111.284 -179.379 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt -11.86 81.49 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 129.346 3.058 . . . . 10.0 115.384 -177.797 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 75.61 -7.48 25.76 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.927 -0.929 . . . . 10.0 113.812 168.779 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.7 pttp -116.03 27.34 9.33 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 118.4 1.1 . . . . 10.0 112.316 -174.458 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.23 -18.26 79.76 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.437 1.018 . . . . 10.0 111.273 170.662 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.83 44.33 98.01 Favored Glycine 0 CA--C 1.53 0.971 0 O-C-N 121.655 -0.909 . . . . 10.0 112.138 173.007 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -164.15 175.81 9.84 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 126.272 1.829 . . . . 10.0 106.821 177.913 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -56.0 -42.09 75.88 Favored 'General case' 0 N--CA 1.439 -1.023 0 CA-C-N 119.014 0.824 . . . . 10.0 111.906 -174.593 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -61.03 -28.79 69.31 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.813 -0.554 . . . . 10.0 110.179 -179.823 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.4 t -47.92 -46.02 31.43 Favored 'General case' 0 CA--C 1.519 -0.243 0 C-N-CA 124.228 1.011 . . . . 10.0 109.219 176.243 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -90.73 8.46 34.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 112.59 0.589 . . . . 10.0 112.59 -175.859 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.97 -81.19 0.63 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.045 1.338 . . . . 10.0 110.565 -178.918 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.1 29.45 7.88 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 121.735 2.061 . . . . 10.0 111.537 174.091 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.95 -87.34 0.13 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 125.35 1.453 . . . . 10.0 110.823 179.012 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -165.64 33.24 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 122.115 -0.638 . . . . 10.0 112.211 170.627 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.13 -13.42 61.94 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.586 0.587 . . . . 10.0 112.586 -174.014 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.61 -147.57 45.49 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.217 -1.953 . . . . 10.0 108.217 174.223 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -58.56 120.44 8.86 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 122.729 0.412 . . . . 10.0 111.765 -169.54 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.65 73.68 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.488 1.515 . . . . 10.0 111.623 168.04 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 11.7 tp -38.45 -49.74 1.49 Allowed 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.139 2.176 . . . . 10.0 113.894 -179.883 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.01 158.09 37.27 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -170.856 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 20.0 p -164.35 171.82 14.3 Favored 'General case' 0 N--CA 1.454 -0.247 0 O-C-N 121.759 -0.588 . . . . 10.0 111.222 -171.866 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -172.65 -161.39 23.0 Favored Glycine 0 N--CA 1.451 -0.334 0 N-CA-C 110.224 -1.15 . . . . 10.0 110.224 -178.894 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -133.0 154.66 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.392 -2.077 . . . . 10.0 105.392 -172.891 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mt -69.17 -85.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 123.613 0.765 . . . . 10.0 110.147 -169.301 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.54 132.92 7.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.151 -0.779 . . . . 10.0 111.151 179.645 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 58.1 mt -68.51 145.31 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 123.435 0.694 . . . . 10.0 110.069 -179.262 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.89 176.27 8.86 Favored 'General case' 0 N--CA 1.442 -0.856 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 164.732 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . 0.496 ' C ' ' HZ2' ' A' ' 3' ' ' LYS . 15.1 tt0 . . . . . 0 N--CA 1.44 -0.967 0 N-CA-C 106.213 -1.773 . . . . 10.0 106.213 167.889 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 N-CA-C 108.424 -0.954 . . . . 10.0 108.424 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.3 t -78.96 -14.58 59.13 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.436 0.695 . . . . 10.0 110.662 -178.149 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.0 ttmt -134.32 149.22 50.86 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 125.023 1.329 . . . . 10.0 107.774 -179.716 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.64 151.63 47.39 Favored 'General case' 0 CA--C 1.512 -0.505 0 C-N-CA 123.32 0.648 . . . . 10.0 109.382 169.48 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -106.62 154.63 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.223 0 O-C-N 124.741 1.276 . . . . 10.0 111.813 -172.576 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.8 93.79 2.46 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 123.217 0.323 . . . . 10.0 111.449 169.28 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.3 m -81.65 103.54 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.365 0 N-CA-C 109.328 -0.619 . . . . 10.0 109.328 169.17 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.9 mt -97.36 127.37 43.26 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.336 1.054 . . . . 10.0 109.029 -177.796 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.3 mtpt -146.86 161.64 40.29 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 120.367 1.439 . . . . 10.0 108.66 173.76 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.31 -55.37 0.06 OUTLIER Glycine 0 N--CA 1.461 0.325 0 CA-C-N 115.798 -0.637 . . . . 10.0 113.318 168.63 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -72.63 -43.78 62.8 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 -176.477 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.12 -70.61 0.42 Allowed Glycine 0 CA--C 1.524 0.613 0 CA-C-N 114.334 -1.303 . . . . 10.0 109.923 170.075 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -58.27 -33.86 98.04 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.427 2.751 . . . . 10.0 111.291 172.044 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.9 t -65.01 100.62 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.637 -1.245 . . . . 10.0 107.637 176.179 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -124.55 108.29 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.606 1.562 . . . . 10.0 108.117 177.978 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.02 143.46 16.49 Favored Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 167.934 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.4 mt -141.62 67.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.651 -1.611 . . . . 10.0 106.651 -179.797 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.06 148.96 4.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.476 0.655 . . . . 10.0 110.852 -174.926 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -123.53 119.31 29.56 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 125.703 1.601 . . . . 10.0 109.263 169.834 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -94.73 124.6 38.86 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 116.712 -1.614 . . . . 10.0 106.653 168.332 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -112.52 136.54 51.91 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 119.592 1.087 . . . . 10.0 111.184 165.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -89.27 112.71 23.84 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.025 -2.213 . . . . 10.0 105.025 168.471 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.9 mmpt? -55.29 -58.11 9.04 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 125.649 1.58 . . . . 10.0 110.075 -171.554 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 80.4 mt-10 -122.67 -130.42 0.27 Allowed 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 105.146 -2.168 . . . . 10.0 105.146 176.969 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 19.8 t -103.69 -36.82 7.74 Favored 'General case' 0 N--CA 1.446 -0.662 0 O-C-N 123.288 0.368 . . . . 10.0 110.015 167.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -111.83 -1.41 15.57 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.298 1.039 . . . . 10.0 111.282 -175.279 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.42 156.75 53.43 Favored Glycine 0 CA--C 1.531 1.046 0 N-CA-C 109.361 -1.496 . . . . 10.0 109.361 175.622 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -59.17 145.54 97.41 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.263 1.976 . . . . 10.0 109.132 175.731 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.7 t -87.76 114.55 26.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 105.22 -2.141 . . . . 10.0 105.22 174.811 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 10.9 ttmm -89.21 119.75 29.97 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 169.895 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -89.44 107.91 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 126.387 1.875 . . . . 10.0 106.397 169.593 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.0 p90 -126.3 164.63 20.61 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.886 0.851 . . . . 10.0 112.614 173.08 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.68 -152.93 24.43 Favored Glycine 0 N--CA 1.438 -1.208 0 N-CA-C 107.586 -2.205 . . . . 10.0 107.586 169.905 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 34.3 p -154.01 113.91 3.86 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 118.595 -0.717 . . . . 10.0 109.495 -169.956 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.8 pt -81.75 140.43 16.51 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 166.994 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -119.58 148.88 42.81 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 169.622 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.34 -5.85 41.76 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-O 119.365 -0.686 . . . . 10.0 113.652 174.965 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.34 176.8 2.12 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 118.584 1.192 . . . . 10.0 110.787 176.903 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -109.65 158.26 18.25 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 105.661 -1.977 . . . . 10.0 105.661 165.898 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -49.44 159.59 0.32 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.483 1.513 . . . . 10.0 112.487 -169.055 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.48 -172.94 35.04 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-O 121.786 0.659 . . . . 10.0 111.909 169.254 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -72.03 144.14 48.89 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.976 1.711 . . . . 10.0 110.207 -176.616 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -145.36 147.79 32.67 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.168 0.987 . . . . 10.0 113.036 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -20.37 117.73 0.01 OUTLIER Glycine 0 C--N 1.339 0.726 0 C-N-CA 129.36 3.362 . . . . 10.0 115.473 165.012 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -154.59 103.38 2.47 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.943 1.872 . . . . 10.0 111.541 170.736 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.446 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 2.2 m80 -133.6 -163.53 1.37 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 124.465 1.106 . . . . 10.0 111.188 179.415 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.2 p -116.66 -46.6 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 124.286 1.034 . . . . 10.0 112.045 -177.067 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 62.16 148.12 0.02 OUTLIER 'General case' 0 C--N 1.342 0.27 0 C-N-CA 125.589 1.556 . . . . 10.0 112.223 -171.595 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -75.31 -58.01 3.55 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 177.297 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -77.78 128.05 33.4 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 -172.797 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.91 -1.61 87.57 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.257 -1.537 . . . . 10.0 109.257 165.781 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -41.06 140.21 0.8 Allowed 'General case' 0 C--N 1.346 0.425 0 CA-C-N 117.982 0.891 . . . . 10.0 110.887 173.121 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -150.18 18.83 0.86 Allowed 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.512 -1.222 . . . . 10.0 111.328 167.455 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -54.89 -35.97 64.68 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 118.903 0.774 . . . . 10.0 109.305 177.893 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.74 -21.45 44.48 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.347 1.459 . . . . 10.0 113.407 177.069 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.58 91.18 0.71 Allowed Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.444 -0.662 . . . . 10.0 111.444 -176.818 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 32.0 m 44.61 38.67 2.84 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.156 1.782 . . . . 10.0 112.625 176.414 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.2 m -133.33 -49.7 0.85 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.702 0.801 . . . . 10.0 109.25 -168.964 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -106.04 20.12 19.46 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.553 0.741 . . . . 10.0 110.265 -177.133 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.96 47.79 0.45 Allowed 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 124.438 1.095 . . . . 10.0 111.011 175.974 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.22 101.41 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 126.043 1.782 . . . . 10.0 113.683 168.455 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -68.15 72.7 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 123.635 2.89 . . . . 10.0 112.833 178.629 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.459 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 15.9 m170 58.55 45.69 15.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.237 3.415 . . . . 10.0 110.943 173.298 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -69.33 64.69 0.16 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 126.146 1.778 . . . . 10.0 111.692 177.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -82.9 154.22 67.56 Favored Pre-proline 0 C--N 1.32 -0.69 0 C-N-CA 126.067 1.747 . . . . 10.0 109.796 179.557 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.13 -52.03 0.54 Allowed 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.574 2.182 . . . . 10.0 111.447 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.2 mt -78.68 49.58 0.9 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.94 0.896 . . . . 10.0 110.584 -176.652 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.7 124.94 23.23 Favored 'General case' 0 N--CA 1.451 -0.4 0 O-C-N 122.024 -0.422 . . . . 10.0 111.096 -168.53 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.81 -75.22 0.32 Allowed 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 107.1 -1.444 . . . . 10.0 107.1 -172.503 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.7 mttt -149.26 164.77 33.89 Favored 'General case' 0 N--CA 1.422 -1.853 0 CA-C-N 114.871 -1.059 . . . . 10.0 108.583 169.317 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 76.3 t60 -71.6 126.82 30.68 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 105.165 -2.161 . . . . 10.0 105.165 162.873 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.05 -138.36 3.65 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 108.86 -1.696 . . . . 10.0 108.86 173.634 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.62 -160.87 25.98 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 107.884 -2.086 . . . . 10.0 107.884 173.414 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.51 1.36 2.66 Favored 'Trans proline' 0 CA--C 1.541 0.839 0 CA-C-N 119.819 1.81 . . . . 10.0 110.644 167.372 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -108.35 10.19 27.63 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 125.857 1.663 . . . . 10.0 109.8 173.905 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -135.47 161.44 35.47 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 165.571 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -77.59 -37.86 49.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 105.242 -2.133 . . . . 10.0 105.242 167.328 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -97.15 58.1 1.52 Allowed 'General case' 0 N--CA 1.446 -0.646 0 CA-C-O 121.718 0.77 . . . . 10.0 109.323 -169.614 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -70.37 154.01 42.37 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.521 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -67.66 -65.95 0.62 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.989 0.813 . . . . 10.0 109.39 177.831 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . 0.434 ' CG1' ' H ' ' B' ' 82' ' ' GLY . 7.5 p -161.67 -90.46 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 170.664 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . 0.434 ' H ' ' CG1' ' B' ' 81' ' ' VAL . . . -84.12 69.31 3.36 Favored Glycine 0 CA--C 1.525 0.693 0 O-C-N 120.374 -1.454 . . . . 10.0 109.486 176.071 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -104.39 94.42 5.33 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 104.013 -2.588 . . . . 10.0 104.013 167.32 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -70.73 -34.1 71.55 Favored 'General case' 0 C--O 1.227 -0.114 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 -176.336 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 117.68 -85.96 0.4 Allowed Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 110.175 -1.17 . . . . 10.0 110.175 167.021 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -142.37 141.26 32.28 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.53 -0.915 . . . . 10.0 108.53 -177.627 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.3 m -114.63 135.65 53.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 166.891 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -104.23 117.97 35.5 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.75 0.82 . . . . 10.0 109.465 -171.666 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.26 134.54 34.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.08 -0.388 . . . . 10.0 110.327 -178.166 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -60.9 168.97 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.529 1.132 . . . . 10.0 109.579 167.695 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.9 -29.14 40.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.633 -0.712 . . . . 10.0 111.298 173.485 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -78.41 -9.26 59.22 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.003 0.521 . . . . 10.0 111.291 -178.704 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 10.06 73.74 Favored Glycine 0 C--N 1.341 0.807 0 O-C-N 121.099 -1.001 . . . . 10.0 111.101 -177.148 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.7 t -87.21 106.71 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 C-N-CA 126.273 1.829 . . . . 10.0 106.743 176.049 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.82 119.57 39.32 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.476 -0.935 . . . . 10.0 108.476 169.653 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -79.53 135.4 36.61 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.081 1.752 . . . . 10.0 108.454 175.088 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.52 132.53 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.454 1.502 . . . . 10.0 106.975 177.907 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 23.4 p -158.78 55.4 0.43 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.752 0.821 . . . . 10.0 111.79 168.821 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.0 mp -92.81 145.0 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 108.662 -0.866 . . . . 10.0 108.662 -174.536 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -101.67 126.33 48.5 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 126.814 2.046 . . . . 10.0 108.543 174.359 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -117.45 155.04 30.36 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.541 -0.911 . . . . 10.0 108.541 168.157 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.4 p -130.42 27.42 5.03 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 125.453 1.501 . . . . 10.0 111.989 -177.4 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.71 -40.54 1.32 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.894 0.77 . . . . 10.0 111.021 169.788 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.481 0.0 OUTLIER -69.38 158.07 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 119.895 1.225 . . . . 10.0 112.47 174.592 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 40.5 m -153.95 121.69 5.93 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 120.937 -1.102 . . . . 10.0 109.805 -179.235 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.1 mt -68.2 -30.74 69.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.698 1.199 . . . . 10.0 110.598 -175.536 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 68.6 m -149.35 148.82 29.96 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 108.187 -1.042 . . . . 10.0 108.187 169.462 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 165.82 -58.62 0.24 Allowed Glycine 0 C--N 1.334 0.419 0 N-CA-C 108.856 -1.698 . . . . 10.0 108.856 -179.258 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -166.56 -49.82 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 126.218 1.807 . . . . 10.0 107.757 -179.088 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -75.45 -39.87 58.24 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.98 -1.009 . . . . 10.0 109.035 -169.505 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.6 t 40.9 54.44 3.19 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.91 1.684 . . . . 10.0 111.022 175.242 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -69.77 37.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 C-N-CA 126.302 1.841 . . . . 10.0 111.844 -177.598 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 1.1 mp -56.07 -45.63 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 O-C-N 119.157 -2.214 . . . . 10.0 112.096 177.481 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.79 50.92 3.03 Favored Glycine 0 CA--C 1.534 1.251 0 CA-C-N 119.932 1.242 . . . . 10.0 114.244 -175.416 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -84.56 176.6 8.51 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 127.327 2.251 . . . . 10.0 109.784 170.123 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -135.85 99.19 4.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.35 -0.982 . . . . 10.0 108.35 169.114 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.74 129.65 42.04 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 105.565 -2.013 . . . . 10.0 105.565 167.625 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.16 129.4 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.24 -2.133 . . . . 10.0 105.24 169.168 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -100.71 106.05 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.942 0 N-CA-C 104.868 -2.271 . . . . 10.0 104.868 170.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -87.72 160.08 18.23 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 122.822 1.296 . . . . 10.0 114.258 -169.818 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 52.0 tt0 -50.79 -56.55 11.58 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.839 2.056 . . . . 10.0 109.034 176.917 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -107.64 168.06 9.52 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.863 0.69 . . . . 10.0 112.863 -169.654 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.26 151.57 43.3 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 113.777 -1.556 . . . . 10.0 107.575 169.125 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 31.2 m-20 -100.94 132.36 46.38 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.235 -1.024 . . . . 10.0 108.235 -179.602 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -76.39 -12.68 60.1 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 124.857 1.263 . . . . 10.0 111.05 -176.796 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 15.4 mt 59.31 49.36 9.04 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 122.211 1.005 . . . . 10.0 109.04 177.39 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.4 -44.1 2.47 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 125.611 1.576 . . . . 10.0 110.445 174.645 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.7 mtmm -79.47 42.16 0.5 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.716 1.607 . . . . 10.0 112.518 -168.842 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.7 -17.77 27.36 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.281 2.372 . . . . 10.0 111.103 169.765 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.24 42.25 88.03 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.961 0.791 . . . . 10.0 111.777 178.861 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -145.94 166.38 26.2 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 169.929 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -52.23 -48.5 65.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 120.978 0.418 . . . . 10.0 110.143 -177.17 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -64.87 -30.45 71.45 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 119.225 -0.417 . . . . 10.0 110.427 -179.591 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 p -56.04 -35.33 66.77 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 120.146 1.339 . . . . 10.0 112.308 171.544 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -101.72 -14.73 17.23 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 118.294 0.497 . . . . 10.0 111.169 -170.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 53.9 mttt -88.0 -47.57 8.43 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 125.923 1.689 . . . . 10.0 111.256 173.715 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.459 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 44.7 p -134.09 -11.71 2.55 Favored 'General case' 0 CA--C 1.533 0.308 0 N-CA-C 115.057 1.502 . . . . 10.0 115.057 177.323 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.38 24.77 11.85 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 119.404 1.002 . . . . 10.0 112.978 -171.722 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 61.89 25.06 15.01 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 119.698 1.749 . . . . 10.0 111.432 179.316 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.73 -14.21 41.74 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 126.54 1.936 . . . . 10.0 112.5 -173.064 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.38 -160.22 52.98 Favored Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 108.776 -1.73 . . . . 10.0 108.776 172.434 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -55.29 130.54 42.74 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 109.24 -0.652 . . . . 10.0 109.24 -171.155 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.77 71.65 0.06 Allowed 'General case' 0 CA--C 1.543 0.708 0 O-C-N 121.667 -0.646 . . . . 10.0 110.274 172.198 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 11.7 tp -45.08 -35.78 3.25 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 128.118 2.567 . . . . 10.0 114.585 -172.858 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -165.77 159.18 15.9 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.049 -1.093 . . . . 10.0 108.049 -179.361 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.4 p -163.61 169.8 18.09 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.663 -0.495 . . . . 10.0 109.663 -178.045 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.12 -178.79 16.76 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 109.63 -1.388 . . . . 10.0 109.63 178.595 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 91.5 t -123.73 126.46 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 104.224 -2.51 . . . . 10.0 104.224 170.609 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.3 mt -81.72 152.08 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 CA-C-N 118.198 0.454 . . . . 10.0 110.787 -171.179 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -151.76 157.58 27.3 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 125.547 1.546 . . . . 10.0 111.059 -169.4 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.9 mt -54.12 140.27 11.33 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 C-N-CA 125.436 1.494 . . . . 10.0 111.806 172.64 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.72 170.17 16.23 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 107.492 -1.299 . . . . 10.0 107.492 165.759 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 . . . . . 0 C--O 1.25 1.096 0 N-CA-C 107.537 -1.283 . . . . 10.0 107.537 167.616 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.81 0 CA-C-O 117.971 -1.014 . . . . 10.0 108.952 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 t -105.47 -21.54 13.19 Favored 'General case' 0 C--O 1.223 -0.342 0 O-C-N 123.807 0.692 . . . . 10.0 110.503 176.897 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.74 172.5 13.2 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-O 121.368 0.604 . . . . 10.0 111.04 169.203 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.99 168.55 24.84 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 172.732 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -132.64 164.07 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.318 1.047 . . . . 10.0 109.284 176.771 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.01 116.87 10.97 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 167.898 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -95.66 102.77 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 124.542 1.137 . . . . 10.0 109.137 170.349 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -92.45 134.98 34.44 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.062 0.945 . . . . 10.0 109.703 -179.884 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt -145.38 162.44 37.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 168.797 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.95 -60.18 0.04 OUTLIER Glycine 0 C--O 1.229 -0.178 0 CA-C-N 115.393 -0.821 . . . . 10.0 112.542 172.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.37 -43.91 59.69 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 106.443 -1.688 . . . . 10.0 106.443 -171.532 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.25 -66.06 0.56 Allowed Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 113.713 -1.585 . . . . 10.0 110.097 177.65 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -58.54 -38.75 88.28 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 122.481 2.12 . . . . 10.0 111.276 172.297 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.1 t -64.44 108.17 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.691 -1.225 . . . . 10.0 107.691 178.363 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -122.6 116.27 23.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 105.452 -2.055 . . . . 10.0 105.452 168.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -100.38 131.29 10.52 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 175.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.415 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 11.5 mt -133.19 89.57 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 107.111 -1.441 . . . . 10.0 107.111 -171.157 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.6 mm -104.17 141.88 18.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 124.396 1.078 . . . . 10.0 109.826 -178.665 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -126.5 119.42 27.11 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.939 2.095 . . . . 10.0 108.636 171.408 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -101.16 120.69 40.59 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 107.321 -1.362 . . . . 10.0 107.321 176.771 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -113.55 143.49 44.46 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 119.379 0.99 . . . . 10.0 112.832 172.214 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -127.42 97.33 4.85 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 128.166 2.586 . . . . 10.0 107.92 169.656 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.0 pttt -58.52 -48.14 81.82 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.287 1.035 . . . . 10.0 111.946 -176.255 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.76 166.61 24.29 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 104.38 -2.452 . . . . 10.0 104.38 168.14 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -65.21 -19.5 66.0 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 122.356 0.262 . . . . 10.0 110.893 179.891 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -80.66 -24.12 39.17 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 123.096 0.558 . . . . 10.0 110.499 176.617 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.41 155.1 53.39 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.645 -0.582 . . . . 10.0 111.645 -175.885 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -71.06 147.77 55.23 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 N-CA-C 106.155 -2.286 . . . . 10.0 106.155 165.56 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 t -79.61 128.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.04 0 N-CA-C 106.626 -1.62 . . . . 10.0 106.626 174.32 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -109.0 125.08 51.68 Favored 'General case' 0 C--O 1.233 0.234 0 N-CA-C 106.504 -1.665 . . . . 10.0 106.504 171.911 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.0 m -111.44 105.95 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.63 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 -176.5 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.5 p90 -117.13 168.54 10.2 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.25 0.548 . . . . 10.0 111.06 176.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.5 175.9 41.57 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.188 -1.006 . . . . 10.0 111.585 176.002 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 2.6 p -147.46 95.8 2.59 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 107.949 -1.13 . . . . 10.0 107.949 -177.098 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.4 pt -77.42 174.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.03 170.917 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -156.01 155.77 33.28 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.8 -17.23 33.0 Favored Glycine 0 CA--C 1.523 0.566 0 CA-C-O 119.411 -0.661 . . . . 10.0 113.824 173.326 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -72.73 179.85 3.43 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 118.395 1.097 . . . . 10.0 110.354 178.362 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -95.81 175.78 6.38 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.586 -0.894 . . . . 10.0 108.586 166.404 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -63.6 176.54 0.85 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 124.633 1.173 . . . . 10.0 111.604 -172.024 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.04 -173.8 43.38 Favored Glycine 0 C--O 1.225 -0.438 0 C-N-CA 124.005 0.812 . . . . 10.0 112.563 167.345 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -77.22 140.7 40.18 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.332 1.453 . . . . 10.0 109.476 177.452 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -133.03 140.66 47.84 Favored 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 124.264 1.026 . . . . 10.0 112.366 -176.742 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -43.72 125.65 5.41 Favored Glycine 0 C--N 1.344 1.026 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 166.177 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -145.52 109.73 4.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 119.042 1.421 . . . . 10.0 109.025 171.122 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.22 173.12 17.32 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 113.74 1.015 . . . . 10.0 113.74 -174.139 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 33.3 m -88.0 154.37 3.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 113.629 -1.623 . . . . 10.0 109.578 171.246 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 -139.35 75.7 1.53 Allowed 'General case' 0 C--O 1.222 -0.37 0 C-N-CA 123.217 0.607 . . . . 10.0 112.122 -174.513 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 64.3 tt0 51.71 -87.22 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 125.301 1.44 . . . . 10.0 113.989 169.501 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -90.62 -172.34 3.37 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.537 -0.912 . . . . 10.0 108.537 -179.935 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -136.76 22.93 3.27 Favored Glycine 0 N--CA 1.452 -0.297 0 O-C-N 121.521 -0.737 . . . . 10.0 111.82 174.425 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -82.34 160.06 22.93 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 107.626 -1.25 . . . . 10.0 107.626 168.583 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.18 28.9 0.58 Allowed 'General case' 0 N--CA 1.448 -0.572 0 O-C-N 121.578 -0.701 . . . . 10.0 112.446 178.454 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -49.7 -40.38 40.04 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.344 1.458 . . . . 10.0 112.373 -175.173 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -81.66 -24.31 36.37 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 123.391 0.676 . . . . 10.0 112.432 177.656 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.1 115.74 1.24 Allowed Glycine 0 CA--C 1.53 0.999 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 -169.512 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 64.2 m 42.27 53.37 4.47 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 125.629 1.572 . . . . 10.0 113.169 175.062 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -158.11 -56.98 0.07 Allowed 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 177.056 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -53.15 -45.34 68.38 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 124.909 1.284 . . . . 10.0 111.002 -169.233 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -53.59 0.18 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 127.039 2.136 . . . . 10.0 113.681 169.993 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.08 160.5 11.61 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.121 -1.192 . . . . 10.0 110.121 -176.838 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -74.02 -162.3 0.14 Allowed 'Trans proline' 0 N--CA 1.448 -1.169 0 N-CA-C 105.651 -2.48 . . . . 10.0 105.651 165.837 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -80.17 48.99 1.05 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 119.613 -1.93 . . . . 10.0 110.827 -175.386 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-30 -77.65 56.55 1.48 Allowed 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.935 1.35 . . . . 10.0 112.11 -176.632 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -59.83 148.52 75.92 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.81 1.244 . . . . 10.0 108.501 167.057 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.67 -48.59 8.75 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.693 2.262 . . . . 10.0 112.022 -174.285 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.19 57.65 1.46 Allowed 'General case' 0 CA--C 1.534 0.335 0 O-C-N 121.595 -0.69 . . . . 10.0 110.717 174.162 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.3 p -55.66 107.66 0.36 Allowed 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.842 1.257 . . . . 10.0 109.844 -179.705 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -119.45 -91.11 0.56 Allowed 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 -178.321 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -143.65 150.89 39.41 Favored 'General case' 0 N--CA 1.437 -1.095 0 CA-C-O 121.927 0.87 . . . . 10.0 109.81 169.012 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.5 t60 -57.79 120.96 9.35 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.643 -1.243 . . . . 10.0 107.643 165.699 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.73 -141.81 3.92 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 108.692 -1.763 . . . . 10.0 108.692 -177.96 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.497 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -174.17 -158.98 19.71 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 109.337 -1.505 . . . . 10.0 109.337 169.697 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -69.36 25.5 0.16 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 119.844 1.822 . . . . 10.0 111.173 168.739 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.497 ' H ' ' C ' ' A' ' 73' ' ' GLY . 71.7 mttt -123.96 -12.89 7.45 Favored 'General case' 0 N--CA 1.438 -1.028 0 C-N-CA 126.379 1.872 . . . . 10.0 109.787 171.942 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -135.96 129.11 31.65 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 104.842 -2.281 . . . . 10.0 104.842 -172.352 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -75.57 -22.19 57.21 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.243 -1.021 . . . . 10.0 108.243 -174.277 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -83.21 4.97 24.53 Favored 'General case' 0 N--CA 1.433 -1.323 0 C-N-CA 125.935 1.694 . . . . 10.0 111.122 -179.756 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.29 158.53 0.03 OUTLIER 'General case' 0 C--N 1.349 0.567 0 C-N-CA 124.53 1.132 . . . . 10.0 112.161 172.844 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.3 m170 -69.65 -103.81 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.689 -0.632 . . . . 10.0 109.359 176.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 88.0 t -126.7 -90.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 104.522 -2.399 . . . . 10.0 104.522 169.385 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -79.08 62.61 3.98 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.689 -0.565 . . . . 10.0 111.689 178.745 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -97.26 94.84 7.33 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 104.368 -2.456 . . . . 10.0 104.368 166.954 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -72.68 -7.46 50.54 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 117.913 0.324 . . . . 10.0 111.033 -174.229 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.27 -103.22 2.96 Favored Glycine 0 N--CA 1.44 -1.046 0 N-CA-C 105.006 -3.237 . . . . 10.0 105.006 -170.084 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -146.47 159.74 43.01 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 107.609 -1.256 . . . . 10.0 107.609 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.33 128.05 74.71 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 123.096 0.558 . . . . 10.0 110.575 170.422 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 m -79.68 114.08 18.33 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.758 2.823 . . . . 10.0 110.563 -178.889 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.16 46.51 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.298 1.039 . . . . 10.0 110.857 177.985 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -61.18 170.03 1.85 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 125.495 1.518 . . . . 10.0 109.096 166.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.95 -30.0 44.91 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.803 0.841 . . . . 10.0 111.408 176.723 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.1 -3.0 43.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 124.298 1.039 . . . . 10.0 110.863 -178.221 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.41 1.28 89.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.518 -1.033 . . . . 10.0 110.518 -175.633 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 62.1 t -79.47 103.53 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.288 0 N-CA-C 106.965 -1.495 . . . . 10.0 106.965 -176.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -100.95 118.67 37.44 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.825 -0.806 . . . . 10.0 108.825 169.213 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.2 110.01 15.21 Favored 'General case' 0 N--CA 1.434 -1.25 0 C-N-CA 126.265 1.826 . . . . 10.0 108.84 170.736 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.9 t -97.79 132.87 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 106.656 -1.609 . . . . 10.0 106.656 177.183 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.0 m -158.69 76.93 0.75 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.98 1.312 . . . . 10.0 109.863 169.799 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.7 161.13 3.83 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 177.505 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -142.51 130.85 22.24 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.65 1.98 . . . . 10.0 107.786 176.994 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -144.95 163.6 33.67 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.295 1.038 . . . . 10.0 108.959 179.126 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.4 p -125.36 51.39 1.7 Allowed 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.897 1.279 . . . . 10.0 109.876 176.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -142.69 -46.02 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.761 0.824 . . . . 10.0 110.762 174.475 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -63.29 139.74 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 169.339 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.3 m -126.74 156.19 41.55 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.941 0.877 . . . . 10.0 110.108 172.173 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -82.47 -29.54 30.53 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.75 0.82 . . . . 10.0 109.492 172.401 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.7 m -156.93 168.82 26.33 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 -174.599 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.32 -92.92 0.58 Allowed Glycine 0 C--N 1.333 0.407 0 N-CA-C 108.471 -1.852 . . . . 10.0 108.471 179.117 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -134.39 -51.64 0.81 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 125.72 1.608 . . . . 10.0 108.403 177.584 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -81.7 38.42 0.51 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.605 0.762 . . . . 10.0 110.145 -175.03 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.4 t -74.32 112.96 11.0 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 126.127 1.771 . . . . 10.0 108.627 -176.109 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 16.6 pt -81.87 11.49 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 173.16 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 30.9 mm -61.09 137.59 23.18 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 120.112 1.324 . . . . 10.0 109.925 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.56 87.01 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.0 -1.444 . . . . 10.0 114.707 172.544 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 29.5 mmt180 -83.93 171.13 13.31 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 168.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -105.4 136.48 44.87 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 124.677 1.191 . . . . 10.0 110.351 171.681 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -96.29 143.08 27.69 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 167.209 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 91.9 t -132.03 137.67 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.875 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 176.864 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.5 p -108.5 142.08 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.592 0 C-N-CA 124.996 1.318 . . . . 10.0 108.698 170.368 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -119.99 171.1 8.68 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.963 0.905 . . . . 10.0 113.143 -171.71 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -74.28 -46.83 38.75 Favored 'General case' 0 C--O 1.223 -0.323 0 C-N-CA 123.932 0.893 . . . . 10.0 111.669 -176.596 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -109.81 170.76 7.86 Favored 'General case' 0 CA--C 1.522 -0.113 0 C-N-CA 123.702 0.801 . . . . 10.0 113.015 -171.763 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.44 145.68 39.12 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.951 1.3 . . . . 10.0 108.777 174.134 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.53 164.47 24.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 122.167 0.984 . . . . 10.0 112.753 -178.208 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 63.9 m-20 -77.5 -22.4 51.28 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 112.625 -2.079 . . . . 10.0 109.631 167.082 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 40.2 mt 50.2 46.5 24.76 Favored 'General case' 0 C--N 1.341 0.232 0 CA-C-O 122.631 1.205 . . . . 10.0 108.354 -167.574 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.17 -32.79 4.76 Favored Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.125 -1.398 . . . . 10.0 112.247 177.765 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 25.4 mtmm -79.57 37.79 0.35 Allowed 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.672 1.189 . . . . 10.0 113.205 -168.535 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.8 -14.41 37.22 Favored Glycine 0 CA--C 1.526 0.778 0 C-N-CA 127.185 2.326 . . . . 10.0 110.036 169.419 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.17 43.07 32.75 Favored Glycine 0 C--N 1.34 0.781 0 C-N-CA 124.516 1.055 . . . . 10.0 112.081 -177.88 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -142.26 167.2 22.68 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 118.926 1.363 . . . . 10.0 109.221 173.088 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -37.5 -54.82 1.12 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 126.392 1.877 . . . . 10.0 111.374 176.531 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -72.2 -39.08 68.84 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.087 0.555 . . . . 10.0 110.739 179.927 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.8 p -53.04 -45.5 68.04 Favored 'General case' 0 N--CA 1.446 -0.635 0 O-C-N 120.893 -1.129 . . . . 10.0 110.589 -178.711 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.1 t -79.69 -2.45 42.92 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 118.744 -0.646 . . . . 10.0 111.799 -173.815 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -112.21 -71.07 0.77 Allowed 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.035 1.734 . . . . 10.0 110.811 -178.296 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.1 p -121.17 14.21 11.32 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 120.729 1.604 . . . . 10.0 112.841 177.462 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.46 21.08 78.7 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-O 119.236 -0.758 . . . . 10.0 113.473 168.752 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 50.75 24.83 1.85 Allowed 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 118.21 1.005 . . . . 10.0 112.202 -174.663 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.21 -7.55 47.59 Favored 'General case' 0 C--O 1.223 -0.323 0 O-C-N 121.41 -0.806 . . . . 10.0 111.554 -176.829 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 129.57 170.12 12.68 Favored Glycine 0 C--N 1.332 0.324 0 N-CA-C 110.199 -1.16 . . . . 10.0 110.199 169.674 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -82.38 54.85 2.71 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 123.029 0.532 . . . . 10.0 112.082 -169.058 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 42.66 72.87 0.16 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.057 1.343 . . . . 10.0 111.709 173.902 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -63.9 -36.4 83.82 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 123.041 0.537 . . . . 10.0 111.39 -169.185 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.06 138.22 14.65 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.904 -0.776 . . . . 10.0 108.904 -170.622 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -133.75 147.36 51.3 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.315 1.046 . . . . 10.0 109.678 -168.373 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.16 168.57 23.32 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.542 -1.023 . . . . 10.0 110.542 177.033 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 65.1 t -118.55 137.82 51.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 106.384 -1.71 . . . . 10.0 106.384 178.42 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 80.7 mt -73.96 126.18 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 118.099 0.409 . . . . 10.0 110.923 -176.297 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.65 145.61 18.63 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.365 -1.094 . . . . 10.0 110.365 176.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 47.9 mt -68.44 152.77 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 CA-C-N 119.358 1.579 . . . . 10.0 110.41 178.044 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.7 162.82 32.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 107.661 -1.237 . . . . 10.0 107.661 166.936 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.5 tt0 . . . . . 0 C--O 1.251 1.147 0 N-CA-C 106.338 -1.727 . . . . 10.0 106.338 169.603 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.507 0 N-CA-C 109.134 -0.691 . . . . 10.0 109.134 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.3 t -94.94 -32.18 13.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.978 1.311 . . . . 10.0 110.913 174.965 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.2 ttmp? -124.61 138.9 54.28 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 124.471 1.108 . . . . 10.0 110.231 -177.862 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.59 159.54 42.04 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.159 1.384 . . . . 10.0 108.101 170.236 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -136.02 164.4 32.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 119.012 0.824 . . . . 10.0 110.307 177.41 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.88 118.91 18.49 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 124.7 1.2 . . . . 10.0 109.118 168.199 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -89.05 89.65 3.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 108.387 -0.968 . . . . 10.0 108.387 168.911 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mp -79.67 120.76 24.43 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 118.544 -0.741 . . . . 10.0 109.688 -179.752 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 22.7 mtpt -140.5 160.41 40.05 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 119.133 0.879 . . . . 10.0 109.207 171.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.52 -60.71 0.05 OUTLIER Glycine 0 N--CA 1.46 0.276 0 CA-C-N 114.87 -1.059 . . . . 10.0 113.071 170.923 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -71.24 -44.0 66.17 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 -176.748 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.14 -69.17 0.43 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-N 114.234 -1.348 . . . . 10.0 110.575 169.771 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -60.14 -32.32 94.43 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 123.714 2.943 . . . . 10.0 111.735 173.019 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.7 t -67.62 92.53 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 107.145 -1.428 . . . . 10.0 107.145 177.902 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -120.11 105.65 11.21 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 125.22 1.408 . . . . 10.0 107.822 -178.24 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -96.68 139.72 14.65 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 110.364 -1.094 . . . . 10.0 110.364 169.718 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -138.15 58.5 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 N-CA-C 105.552 -2.018 . . . . 10.0 105.552 -173.403 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -81.96 134.8 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 114.879 -1.055 . . . . 10.0 109.39 -169.913 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -112.35 116.48 30.41 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.195 1.798 . . . . 10.0 108.973 -177.517 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -103.19 113.79 27.55 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 125.963 1.705 . . . . 10.0 107.759 -176.107 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -114.36 135.86 53.62 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.053 0.941 . . . . 10.0 111.524 -177.992 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -115.77 104.6 11.82 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 104.985 -2.228 . . . . 10.0 104.985 167.784 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.51 30.74 0.74 Allowed 'General case' 0 C--O 1.235 0.306 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -169.683 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . 0.521 ' CD ' ' H ' ' B' ' 25' ' ' SER . 2.2 tm-20 -131.25 166.55 20.93 Favored 'General case' 0 N--CA 1.432 -1.357 0 N-CA-C 101.779 -3.415 . . . . 10.0 101.779 167.591 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 25' ' ' SER . . . . . 0.521 ' H ' ' CD ' ' B' ' 24' ' ' GLU . 22.7 t -77.01 -14.56 59.82 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 109.471 -0.566 . . . . 10.0 109.471 178.321 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -78.49 -15.08 59.01 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 119.828 -0.749 . . . . 10.0 109.308 169.163 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.08 43.53 17.93 Favored Glycine 0 CA--C 1.528 0.853 0 C-N-CA 126.076 1.798 . . . . 10.0 115.372 -178.436 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -66.1 145.45 79.03 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 CA-C-N 119.841 1.82 . . . . 10.0 107.625 170.867 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.37 97.43 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 106.196 -1.779 . . . . 10.0 106.196 173.542 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -79.09 102.42 8.41 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.504 -2.036 . . . . 10.0 105.504 168.895 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.93 101.12 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 C-N-CA 125.928 1.691 . . . . 10.0 107.822 -177.477 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -113.37 168.02 10.08 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.535 0.683 . . . . 10.0 111.867 169.88 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.55 178.37 32.51 Favored Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.642 -0.983 . . . . 10.0 110.642 168.886 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.5 p -124.33 102.06 7.49 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 108.593 -0.891 . . . . 10.0 108.593 -173.182 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 pt -81.78 133.99 28.03 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 108.219 -1.03 . . . . 10.0 108.219 168.852 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.9 tptt -108.09 148.83 29.28 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 170.069 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.67 -6.94 35.96 Favored Glycine 0 C--N 1.337 0.586 0 CA-C-O 119.563 -0.576 . . . . 10.0 113.47 169.348 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -66.43 175.93 2.06 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 118.276 1.038 . . . . 10.0 110.518 176.029 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -108.66 164.6 12.23 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 105.289 -2.115 . . . . 10.0 105.289 165.557 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -53.78 161.23 1.18 Allowed 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 113.11 0.782 . . . . 10.0 113.11 -169.041 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.12 -179.19 51.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 124.318 0.961 . . . . 10.0 112.085 169.049 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 mt -57.04 146.35 27.58 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.076 1.75 . . . . 10.0 112.921 175.501 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.5 m-70 -149.33 144.73 26.63 Favored 'General case' 0 C--N 1.339 0.149 0 C-N-CA 124.423 1.089 . . . . 10.0 113.439 -179.835 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -26.08 122.64 0.04 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 127.621 2.534 . . . . 10.0 113.243 166.515 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -152.37 105.52 3.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 119.059 1.429 . . . . 10.0 111.818 169.425 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.17 171.67 17.01 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 112.801 0.667 . . . . 10.0 112.801 -178.153 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.1 m -99.95 146.29 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 111.924 -2.398 . . . . 10.0 106.275 167.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -120.83 144.95 48.08 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 -179.437 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . 0.403 ' CG ' ' HA3' ' B' ' 61' ' ' GLY . 0.0 OUTLIER -6.73 -86.59 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.992 2.117 . . . . 10.0 116.593 170.978 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -102.14 171.86 7.24 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 119.737 1.153 . . . . 10.0 109.825 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.78 -25.71 52.28 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 117.63 -1.65 . . . . 10.0 111.234 174.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -40.16 113.04 0.32 Allowed 'General case' 0 C--N 1.342 0.278 0 CA-C-N 118.165 0.982 . . . . 10.0 111.448 178.064 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.33 20.85 12.96 Favored 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.748 -1.115 . . . . 10.0 109.972 167.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.415 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 4.2 m -55.44 -35.7 65.72 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 118.922 0.783 . . . . 10.0 110.49 -169.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.55 -21.35 45.27 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.803 1.241 . . . . 10.0 113.524 178.446 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.61 81.96 1.28 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 109.579 -1.408 . . . . 10.0 109.579 -174.056 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.327 25.7 p 18.73 55.51 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.914 2.086 . . . . 10.0 115.451 -167.88 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.6 m -112.87 -57.76 2.24 Favored 'General case' 0 N--CA 1.442 -0.848 0 N-CA-C 105.454 -2.054 . . . . 10.0 105.454 173.953 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.4 t -90.83 -4.0 56.95 Favored 'General case' 0 N--CA 1.443 -0.789 0 C-N-CA 124.724 1.21 . . . . 10.0 110.355 -178.323 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.38 41.51 0.14 Allowed 'General case' 0 C--N 1.341 0.239 0 C-N-CA 124.542 1.137 . . . . 10.0 112.787 -179.279 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . 0.403 ' HA3' ' CG ' ' B' ' 49' ' ' GLU . . . 88.35 125.93 2.47 Favored Glycine 0 N--CA 1.44 -1.077 0 N-CA-C 118.433 2.133 . . . . 10.0 118.433 162.168 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -81.5 55.85 5.73 Favored 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 121.646 1.564 . . . . 10.0 109.9 165.147 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.447 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 17.2 m170 66.17 -72.05 0.08 Allowed 'General case' 0 N--CA 1.461 0.099 0 C-N-CA 127.946 2.499 . . . . 10.0 111.034 -175.956 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 0.72 56.95 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 131.358 3.863 . . . . 10.0 116.076 -172.64 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -63.23 162.07 27.26 Favored Pre-proline 0 CA--C 1.538 0.487 0 CA-C-N 115.846 -0.616 . . . . 10.0 111.463 -172.499 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -53.7 -38.44 84.71 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 123.251 2.634 . . . . 10.0 112.985 179.531 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.45 -1.88 4.01 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 113.054 0.761 . . . . 10.0 113.054 176.596 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.3 p 22.34 89.83 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 129.436 3.094 . . . . 10.0 115.392 169.073 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -130.53 -168.92 2.05 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 179.461 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -103.98 128.91 51.53 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.216 -1.401 . . . . 10.0 107.216 177.047 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -42.88 109.27 0.13 Allowed 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 124.063 0.852 . . . . 10.0 112.061 -178.815 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.25 -155.84 9.5 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.1 -2.4 . . . . 10.0 107.1 169.667 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.24 -153.32 6.06 Favored Glycine 0 C--N 1.332 0.312 0 CA-C-N 118.371 1.085 . . . . 10.0 112.675 173.044 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -61.1 -9.47 12.46 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.241 1.961 . . . . 10.0 111.685 174.753 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -91.84 -18.65 23.51 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.609 1.164 . . . . 10.0 109.006 -179.101 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 20.8 m-20 -113.6 162.85 15.7 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 -169.308 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -92.07 -18.12 24.03 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.623 -1.171 . . . . 10.0 109.674 172.028 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -97.98 2.54 49.07 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 126.258 1.823 . . . . 10.0 112.49 -170.399 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -35.37 125.44 0.63 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.542 1.537 . . . . 10.0 109.447 169.037 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -47.05 -54.67 9.78 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.497 0.589 . . . . 10.0 112.242 -168.694 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -172.01 -40.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 C-N-CA 125.814 1.646 . . . . 10.0 108.404 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -149.27 68.67 0.34 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 109.395 -1.482 . . . . 10.0 109.395 174.413 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -97.05 103.59 15.54 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 105.099 -2.186 . . . . 10.0 105.099 168.65 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 28.1 mt -82.27 25.44 0.6 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 118.891 0.769 . . . . 10.0 111.433 -176.828 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 75.7 -113.13 3.81 Favored Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 174.43 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -158.6 128.78 5.95 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 -174.867 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 16.7 m -106.09 132.46 53.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 123.015 0.526 . . . . 10.0 110.422 -169.681 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 99.1 m -85.39 107.71 17.51 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 127.605 2.362 . . . . 10.0 110.308 -170.956 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.29 137.51 32.92 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 123.153 0.581 . . . . 10.0 110.338 171.981 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -65.9 172.02 3.96 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.818 1.247 . . . . 10.0 109.541 168.518 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.59 -28.41 63.6 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.117 0.484 . . . . 10.0 110.917 177.735 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -80.89 -0.5 39.39 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.899 0.88 . . . . 10.0 111.187 -178.255 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.34 80.35 Favored Glycine 0 C--N 1.339 0.737 0 O-C-N 120.74 -1.225 . . . . 10.0 110.808 176.942 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.7 t -91.62 108.71 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 C-N-CA 126.971 2.108 . . . . 10.0 105.642 174.816 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.76 118.61 37.13 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 119.189 0.904 . . . . 10.0 108.633 169.102 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -81.13 95.97 7.05 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 126.64 1.976 . . . . 10.0 108.285 172.586 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -78.77 131.92 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 105.626 -1.99 . . . . 10.0 105.626 170.916 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 6.7 p -157.8 60.03 0.48 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.814 0.845 . . . . 10.0 109.073 -179.629 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 30.1 mt -114.87 160.2 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.072 -1.455 . . . . 10.0 107.072 -169.743 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -138.77 135.74 34.97 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 109.725 -0.472 . . . . 10.0 109.725 168.846 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 16.6 t0 -117.2 101.62 8.6 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 -178.866 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 40.3 m -85.7 54.53 3.16 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 124.798 1.239 . . . . 10.0 108.471 -173.695 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 92.0 t -136.91 -54.33 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 -171.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.385 0.0 OUTLIER -88.19 175.37 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.384 0.674 . . . . 10.0 111.544 170.408 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 56.0 m -157.83 97.2 1.54 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.418 -0.801 . . . . 10.0 109.882 -168.042 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.9 tp -37.88 -27.37 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 129.211 3.004 . . . . 10.0 116.37 -169.616 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 38.3 t -153.09 45.43 0.67 Allowed 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.152 0.981 . . . . 10.0 109.743 176.544 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -141.04 62.13 0.54 Allowed Glycine 0 C--N 1.337 0.611 0 N-CA-C 109.422 -1.471 . . . . 10.0 109.422 -178.907 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.6 t70 68.98 -55.32 0.55 Allowed 'General case' 0 CA--C 1.52 -0.193 0 C-N-CA 129.673 3.189 . . . . 10.0 109.303 -171.31 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -81.42 45.83 0.9 Allowed 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 124.551 1.14 . . . . 10.0 110.156 -174.038 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.8 t -67.39 -44.49 78.78 Favored 'General case' 0 N--CA 1.442 -0.847 0 C-N-CA 126.879 2.071 . . . . 10.0 110.318 -172.947 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.2 pt 46.24 35.21 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.962 1.705 . . . . 10.0 113.774 177.87 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 11.5 mm -61.29 -71.19 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.452 0 C-N-CA 123.122 0.569 . . . . 10.0 110.012 -178.66 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.25 58.48 1.12 Allowed Glycine 0 CA--C 1.54 1.645 0 O-C-N 120.814 -1.179 . . . . 10.0 115.042 -177.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 30.7 mmt180 -103.77 161.47 13.9 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 127.161 2.185 . . . . 10.0 105.706 167.494 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.99 128.22 42.69 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 104.269 -2.493 . . . . 10.0 104.269 171.442 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 11.1 mp -108.26 151.27 26.18 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 109.084 -0.71 . . . . 10.0 109.084 172.292 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 93.7 t -137.77 138.41 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.948 0 N-CA-C 108.412 -0.958 . . . . 10.0 108.412 -175.377 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.7 p -104.12 131.49 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 168.154 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 4.2 m170 -113.7 159.8 19.31 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 116.433 2.012 . . . . 10.0 116.433 -170.692 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -43.79 -57.12 3.41 Favored 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 129.26 3.024 . . . . 10.0 112.133 176.09 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 75.0 mttt -118.67 171.31 8.28 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 124.198 0.999 . . . . 10.0 112.937 -168.581 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -80.24 138.64 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.647 1.579 . . . . 10.0 109.91 177.815 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.08 152.11 33.09 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -172.525 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -76.81 -30.16 56.29 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.624 1.97 . . . . 10.0 109.968 169.579 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 26.9 mt 54.4 49.88 17.43 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 124.115 0.966 . . . . 10.0 109.979 -172.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . 0.408 ' C ' ' H ' ' B' ' 129' ' ' GLY . . . 83.06 -43.36 3.11 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.033 -0.827 . . . . 10.0 111.033 176.062 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 28.2 mtmm -76.64 30.3 0.13 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.617 1.967 . . . . 10.0 112.236 -172.142 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . 0.408 ' H ' ' C ' ' B' ' 127' ' ' GLY . . . -92.54 -33.04 7.74 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 128.32 2.867 . . . . 10.0 109.474 168.647 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.34 21.68 77.42 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.001 -0.889 . . . . 10.0 112.104 -177.224 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -107.48 161.65 14.64 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 168.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 8.0 tm-20 -50.81 -51.67 48.63 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 114.957 -1.019 . . . . 10.0 108.279 172.448 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . 0.414 ' OE1' ' NZ ' ' B' ' 136' ' ' LYS . 7.2 tp10 -57.7 -40.51 79.65 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.812 0.671 . . . . 10.0 112.812 178.043 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -48.92 -50.09 36.97 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 119.9 1.227 . . . . 10.0 110.555 171.488 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -80.18 -19.63 46.63 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 112.983 0.734 . . . . 10.0 112.983 -174.23 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE1' ' B' ' 133' ' ' GLU . 2.5 ttmt -96.74 -42.76 7.84 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 124.957 1.303 . . . . 10.0 112.512 -173.403 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.447 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 60.7 p -135.14 -7.53 2.31 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 176.716 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.03 13.39 71.84 Favored Glycine 0 C--O 1.221 -0.662 0 CA-C-O 118.188 -1.34 . . . . 10.0 111.813 -170.039 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 64.81 19.54 11.87 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 120.18 1.99 . . . . 10.0 112.41 170.092 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.65 7.57 6.67 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.742 0.817 . . . . 10.0 112.525 -169.834 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.52 -166.81 52.69 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.453 -0.78 . . . . 10.0 111.262 173.075 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 50.2 m -60.36 141.79 55.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 113.522 0.934 . . . . 10.0 113.522 -168.505 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -60.38 97.19 0.05 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.85 1.66 . . . . 10.0 109.454 168.734 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 27.1 mt -72.64 -34.66 67.45 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 119.284 0.947 . . . . 10.0 111.989 178.51 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.15 149.05 28.35 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.887 -0.508 . . . . 10.0 110.476 176.257 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.74 142.14 46.41 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 126.991 2.116 . . . . 10.0 107.654 -176.439 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -140.88 160.96 26.74 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 109.176 -1.57 . . . . 10.0 109.176 168.944 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 51.8 t -119.23 131.45 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 104.52 -2.4 . . . . 10.0 104.52 174.181 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 20.3 mt -73.35 146.81 10.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-N 119.332 0.969 . . . . 10.0 109.288 174.77 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.71 150.35 22.5 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 125.858 1.694 . . . . 10.0 109.053 179.603 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.0 pt -72.47 132.21 33.7 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.359 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 -176.11 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.68 -42.6 7.16 Favored 'General case' 0 CA--C 1.512 -0.519 0 C-N-CA 123.9 0.88 . . . . 10.0 109.932 173.281 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.433 -1.299 0 N-CA-C 105.17 -2.159 . . . . 10.0 105.17 176.327 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.881 0 N-CA-C 107.894 -1.15 . . . . 10.0 107.894 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.1 t -86.47 -16.47 36.97 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 166.625 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 47.5 tttt -131.88 164.54 25.86 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 125.603 1.561 . . . . 10.0 108.244 177.239 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -158.03 171.97 19.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 126.018 1.727 . . . . 10.0 106.689 168.537 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -133.05 173.93 14.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 107.702 -1.221 . . . . 10.0 107.702 171.246 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.46 113.24 6.05 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.302 -1.37 . . . . 10.0 107.302 165.46 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 5.8 m -92.62 120.32 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.623 -1.251 . . . . 10.0 107.623 168.141 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -100.13 131.7 45.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.861 -1.533 . . . . 10.0 106.861 179.289 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -141.78 158.73 43.45 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 106.325 -1.731 . . . . 10.0 106.325 167.766 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.25 -64.04 0.04 OUTLIER Glycine 0 N--CA 1.461 0.326 0 C-N-CA 119.393 -1.384 . . . . 10.0 113.685 168.772 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -72.7 -41.44 65.28 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.411 -1.329 . . . . 10.0 107.411 -172.927 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.03 -67.72 0.42 Allowed Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 114.173 -1.376 . . . . 10.0 111.667 169.443 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -57.8 -39.57 86.07 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.581 2.187 . . . . 10.0 111.367 179.002 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.18 118.88 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 107.902 -1.147 . . . . 10.0 107.902 179.645 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.63 104.09 8.49 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 103.548 -2.76 . . . . 10.0 103.548 168.702 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -86.23 142.27 18.82 Favored Glycine 0 N--CA 1.44 -1.086 0 N-CA-C 108.281 -1.928 . . . . 10.0 108.281 177.014 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.514 ' CG2' HG22 ' B' ' 54' ' ' THR . 5.2 mt -140.73 92.52 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 -174.248 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.7 mm -102.1 139.36 23.39 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 C-N-CA 124.487 1.115 . . . . 10.0 110.2 174.04 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -112.37 118.89 36.46 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 127.452 2.301 . . . . 10.0 106.88 168.601 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -99.89 115.42 29.58 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 105.832 -1.914 . . . . 10.0 105.832 175.377 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -116.81 127.25 54.14 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 119.032 0.833 . . . . 10.0 110.444 170.002 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -79.8 88.16 5.25 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 106.236 -1.764 . . . . 10.0 106.236 174.562 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.23 -40.55 16.63 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 126.729 2.012 . . . . 10.0 112.099 -167.612 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -130.4 162.36 29.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 101.576 -3.49 . . . . 10.0 101.576 162.766 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.7 t -55.7 -33.36 64.11 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.738 -0.838 . . . . 10.0 108.738 173.518 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 30.3 m-80 -99.39 -2.15 36.93 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 125.749 1.62 . . . . 10.0 110.948 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.25 164.73 24.78 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.762 -0.935 . . . . 10.0 110.762 -170.804 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -61.95 149.57 89.74 Favored 'Trans proline' 0 N--CA 1.449 -1.125 0 C-N-CA 121.563 1.509 . . . . 10.0 108.29 169.477 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.0 t -86.11 122.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 -179.403 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.3 tttt -90.28 113.99 25.94 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 108.205 -1.035 . . . . 10.0 108.205 177.566 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.7 m -98.34 58.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 125.725 1.61 . . . . 10.0 108.395 -172.486 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.5 p90 -77.27 158.32 30.29 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 119.915 -0.714 . . . . 10.0 110.011 -175.281 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.02 179.9 48.21 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.968 179.145 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 20.4 m -150.41 96.39 2.39 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.503 -1.295 . . . . 10.0 107.503 -178.729 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.9 pt -77.65 154.76 5.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 170.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -138.82 146.97 41.93 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.266 -1.383 . . . . 10.0 107.266 169.317 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.09 -2.29 38.01 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.46 170.642 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.7 mp -72.31 178.83 3.7 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 119.398 1.599 . . . . 10.0 108.802 169.531 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 11.2 t -88.37 176.48 7.18 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 166.717 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 49.4 tt0 -64.02 169.69 4.15 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.04 0.936 . . . . 10.0 112.111 -172.311 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.12 -176.51 48.79 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 124.085 0.85 . . . . 10.0 113.079 167.15 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -62.42 150.85 38.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 123.815 0.846 . . . . 10.0 109.696 174.13 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -142.66 153.4 43.38 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 113.895 1.072 . . . . 10.0 113.895 176.614 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -39.54 125.02 2.1 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 127.542 2.496 . . . . 10.0 110.459 163.049 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -149.73 105.85 3.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 119.823 1.811 . . . . 10.0 108.094 165.724 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.486 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -153.04 -179.99 8.18 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-O 121.844 0.83 . . . . 10.0 113.173 179.558 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.0 m -102.85 151.51 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 CA-C-N 113.219 -1.81 . . . . 10.0 110.345 174.116 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.85 133.4 45.89 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.276 1.83 . . . . 10.0 106.433 178.015 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.8 tp10 -62.41 -55.8 24.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 114.428 1.27 . . . . 10.0 114.428 -165.527 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 59.2 m-85 -77.66 144.94 36.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 117.612 -1.635 . . . . 10.0 108.243 179.652 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.38 20.8 48.35 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 172.684 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -80.67 70.73 7.47 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 125.765 2.698 . . . . 10.0 109.045 179.649 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -69.33 -13.5 62.41 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 111.242 -2.708 . . . . 10.0 111.852 -174.056 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -27.69 -52.99 0.08 Allowed 'General case' 0 C--N 1.341 0.201 1 C-N-CA 131.92 4.088 . . . . 10.0 114.283 -175.799 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.53 -14.77 59.58 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 124.068 0.947 . . . . 10.0 112.657 -172.518 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 107.1 52.96 0.71 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.925 -2.07 . . . . 10.0 107.925 -168.257 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 46.89 50.91 13.21 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.768 1.396 . . . . 10.0 114.768 169.784 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.2 p -111.79 -57.84 2.2 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 106.347 -1.723 . . . . 10.0 106.347 171.561 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.7 m -47.63 -33.19 6.41 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 127.167 2.187 . . . . 10.0 111.459 177.413 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -28.07 -39.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 128.666 2.786 . . . . 10.0 113.796 168.255 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.72 159.86 23.79 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 108.67 -1.772 . . . . 10.0 108.67 169.346 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -70.71 -170.25 0.44 Allowed 'Trans proline' 0 N--CA 1.445 -1.354 0 N-CA-C 107.585 -1.736 . . . . 10.0 107.585 167.5 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 36.9 m170 -78.89 55.93 1.83 Allowed 'General case' 0 CA--C 1.545 0.777 0 O-C-N 120.622 -1.299 . . . . 10.0 111.636 -170.121 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -74.88 64.47 1.29 Allowed 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 119.86 1.209 . . . . 10.0 112.275 -175.512 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.7 p-10 -57.6 155.37 21.1 Favored Pre-proline 0 CA--C 1.538 0.491 0 C-N-CA 123.283 0.633 . . . . 10.0 111.164 169.904 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -59.05 -45.8 26.05 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.534 2.156 . . . . 10.0 111.425 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -75.88 64.91 1.9 Allowed 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.116 -0.698 . . . . 10.0 109.116 174.725 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.9 p -42.04 113.76 0.47 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.685 1.194 . . . . 10.0 109.564 179.397 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.4 mtt-85 -145.97 -177.49 5.62 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 105.16 -2.163 . . . . 10.0 105.16 -169.88 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.427 ' HZ3' ' CD ' ' A' ' 78' ' ' GLU . 19.4 mmtp -75.0 154.34 38.12 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 118.099 -1.44 . . . . 10.0 109.127 176.069 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -69.92 105.39 2.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 162.401 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.64 -140.65 6.85 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 107.909 -2.076 . . . . 10.0 107.909 173.822 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.425 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -179.7 -155.43 15.23 Favored Glycine 0 C--O 1.227 -0.309 0 CA-C-O 117.521 -1.711 . . . . 10.0 109.293 169.614 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -67.32 13.95 0.15 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 CA-C-N 120.378 2.089 . . . . 10.0 111.829 170.335 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.425 ' H ' ' C ' ' A' ' 73' ' ' GLY . 51.1 mttm -121.2 3.15 10.39 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-O 117.948 -1.025 . . . . 10.0 111.634 170.828 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -127.21 159.09 35.36 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 170.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -79.4 -32.52 42.97 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.639 -1.615 . . . . 10.0 106.639 167.017 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.427 ' CD ' ' HZ3' ' A' ' 70' ' ' LYS . 15.4 mt-10 -82.89 28.48 0.49 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 124.58 1.152 . . . . 10.0 112.274 -168.643 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 164.08 11.97 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 119.839 1.199 . . . . 10.0 109.753 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -78.54 -67.58 0.73 Allowed 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.733 -0.604 . . . . 10.0 109.515 178.662 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -158.72 -116.35 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.827 -1.546 . . . . 10.0 106.827 -174.207 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -78.34 54.7 3.99 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-N 119.704 1.138 . . . . 10.0 111.012 178.749 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -79.46 92.3 5.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.735 -1.95 . . . . 10.0 105.735 170.014 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 29.1 mt -71.46 -21.7 61.92 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 118.755 -1.178 . . . . 10.0 108.204 175.325 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 83.13 -73.37 2.69 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.754 -1.338 . . . . 10.0 109.754 168.72 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -139.96 103.09 4.55 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 108.802 -0.814 . . . . 10.0 108.802 -169.412 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 23.9 m -109.09 129.53 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 119.068 0.849 . . . . 10.0 111.435 176.12 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -79.25 110.18 14.28 Favored 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 127.724 2.41 . . . . 10.0 112.371 -170.45 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.81 132.6 39.42 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 122.702 0.401 . . . . 10.0 110.154 169.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -53.5 166.98 0.24 Allowed 'General case' 0 CA--C 1.518 -0.258 0 O-C-N 124.093 0.871 . . . . 10.0 109.198 166.144 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -41.56 -43.19 2.64 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 126.324 1.85 . . . . 10.0 110.419 169.343 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.78 0.48 39.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.351 1.46 . . . . 10.0 110.948 -170.913 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.99 2.91 85.83 Favored Glycine 0 C--N 1.339 0.717 0 N-CA-C 111.408 -0.677 . . . . 10.0 111.408 178.116 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 33.1 t -78.97 106.5 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.376 -1.712 . . . . 10.0 106.376 -178.38 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -115.23 118.41 33.21 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 118.645 0.657 . . . . 10.0 109.638 176.541 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -79.73 126.68 31.26 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.526 1.93 . . . . 10.0 109.068 174.403 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -118.98 134.01 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.955 0 N-CA-C 107.319 -1.363 . . . . 10.0 107.319 175.548 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.8 p -156.62 59.75 0.55 Allowed 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 118.461 0.573 . . . . 10.0 110.872 174.457 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.11 153.48 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 -178.232 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -123.86 131.68 53.62 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 123.936 0.894 . . . . 10.0 108.908 169.398 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -120.57 147.95 44.51 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-O 121.639 0.733 . . . . 10.0 109.042 179.618 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.8 p -105.4 7.24 33.14 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.394 2.678 . . . . 10.0 111.865 -173.31 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.2 p -122.89 9.42 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.35 0.977 . . . . 10.0 110.763 179.525 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -108.45 150.03 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 105.944 -1.873 . . . . 10.0 105.944 176.773 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.7 m -146.29 152.69 39.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 169.939 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 55.4 mt -103.56 0.2 30.58 Favored 'General case' 0 C--O 1.237 0.437 0 C-N-CA 123.751 0.82 . . . . 10.0 111.66 -175.538 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.4 t -162.03 -172.38 3.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 126.472 1.909 . . . . 10.0 107.439 166.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 105.85 -69.87 0.23 Allowed Glycine 0 C--O 1.227 -0.336 0 C-N-CA 125.291 1.424 . . . . 10.0 110.307 167.302 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -162.69 -50.15 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 124.873 1.269 . . . . 10.0 107.611 -179.922 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -80.32 41.96 0.56 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.176 0.99 . . . . 10.0 109.034 179.449 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.5 t -81.4 83.8 6.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 126.076 1.75 . . . . 10.0 106.758 -171.773 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 20.8 pt -55.63 -21.61 10.42 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 113.649 0.981 . . . . 10.0 113.649 -170.172 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.6 mp -14.04 -56.5 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 129.369 3.067 . . . . 10.0 115.139 174.866 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -87.7 6.6 83.19 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.208 -1.329 . . . . 10.0 114.812 -170.468 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.6 mpt_? -77.45 175.78 9.49 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.887 1.344 . . . . 10.0 108.751 174.014 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -113.94 127.65 56.06 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.723 -1.584 . . . . 10.0 106.723 169.91 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.5 mt -102.86 152.73 20.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 118.754 0.707 . . . . 10.0 109.395 174.309 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.2 t -141.46 136.22 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 123.542 0.526 . . . . 10.0 110.178 -171.927 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.4 m -104.52 139.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 O-C-N 124.641 1.213 . . . . 10.0 109.201 164.13 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -117.14 163.21 16.62 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 114.954 1.465 . . . . 10.0 114.954 -169.15 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -55.99 -54.66 42.19 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.693 -1.14 . . . . 10.0 110.103 178.032 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -111.31 173.4 6.36 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-O 121.305 0.574 . . . . 10.0 110.277 -178.231 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -96.19 136.82 36.15 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 125.24 1.416 . . . . 10.0 108.16 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.486 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -77.41 161.18 28.19 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 121.474 0.654 . . . . 10.0 111.943 -174.279 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -73.85 -15.5 61.16 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.763 -1.108 . . . . 10.0 110.809 -177.349 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mt 58.31 44.81 17.99 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.383 1.073 . . . . 10.0 108.292 -172.394 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.74 -15.65 59.45 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.96 1.267 . . . . 10.0 113.786 170.005 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -75.5 -4.46 39.89 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 114.838 1.421 . . . . 10.0 114.838 -166.548 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.51 -23.77 75.21 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-N 119.422 1.01 . . . . 10.0 110.65 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.34 18.74 50.95 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.812 -0.993 . . . . 10.0 114.429 179.267 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -116.92 176.66 5.02 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 119.474 1.637 . . . . 10.0 110.735 179.094 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -32.48 -61.76 0.25 Allowed 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 126.631 1.973 . . . . 10.0 112.186 171.396 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.88 -44.55 92.73 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.43 0.692 . . . . 10.0 111.529 178.536 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.8 m -49.24 -42.15 39.74 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 119.294 -0.384 . . . . 10.0 110.505 -176.06 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -87.18 -3.37 59.05 Favored 'General case' 0 N--CA 1.451 -0.386 0 O-C-N 124.32 1.013 . . . . 10.0 112.605 -172.464 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -114.53 -48.52 2.86 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.462 1.105 . . . . 10.0 111.521 -174.986 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 30.4 p -133.44 0.46 3.34 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 119.108 0.867 . . . . 10.0 112.286 171.658 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.75 -105.53 3.04 Favored Glycine 0 C--N 1.341 0.819 0 N-CA-C 107.289 -2.325 . . . . 10.0 107.289 -172.864 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.2 m-20 -167.52 43.44 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 125.298 1.439 . . . . 10.0 108.541 -179.477 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.43 -15.18 63.23 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.674 -0.641 . . . . 10.0 111.756 -177.636 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.17 -162.66 54.54 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 -176.742 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.1 m -62.25 149.52 41.67 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 113.736 1.013 . . . . 10.0 113.736 -170.043 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.2 74.59 0.69 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.161 2.584 . . . . 10.0 111.267 174.113 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.58 -27.32 67.62 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.187 -0.945 . . . . 10.0 113.361 -178.701 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.36 153.17 30.05 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 118.881 0.764 . . . . 10.0 110.392 171.737 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.0 p -155.52 155.64 33.77 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 123.081 0.552 . . . . 10.0 110.367 -168.482 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.92 162.64 30.56 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 124.054 0.835 . . . . 10.0 112.023 -174.727 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 62.1 t -122.64 66.85 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 105.263 -2.125 . . . . 10.0 105.263 -172.515 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mm 30.44 -114.63 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 C-N-CA 127.1 2.16 . . . . 10.0 113.349 -173.737 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 126.61 102.5 1.25 Allowed Glycine 0 CA--C 1.531 1.045 0 N-CA-C 109.653 -1.379 . . . . 10.0 109.653 -169.536 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 56.3 mt -53.31 137.6 13.56 Favored 'Isoleucine or valine' 0 C--N 1.341 0.197 0 C-N-CA 124.151 0.98 . . . . 10.0 110.415 170.717 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.57 158.58 44.07 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 107.92 -1.141 . . . . 10.0 107.92 169.748 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.7 tt0 . . . . . 0 C--O 1.25 1.081 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 168.133 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.875 0 CA-C-O 118.538 -0.744 . . . . 10.0 109.62 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.7 t -90.57 -36.71 14.29 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.666 0.787 . . . . 10.0 110.705 169.951 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.3 tttp -127.44 124.15 37.77 Favored 'General case' 0 C--O 1.238 0.485 0 C-N-CA 125.798 1.639 . . . . 10.0 109.217 -171.814 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.11 155.92 49.89 Favored 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.741 0.816 . . . . 10.0 109.687 176.673 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.1 m -106.68 178.73 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 O-C-N 123.965 0.791 . . . . 10.0 109.94 176.944 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -160.7 93.75 1.01 Allowed 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.35 1.46 . . . . 10.0 108.056 175.68 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -92.41 95.09 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 C-N-CA 123.753 0.821 . . . . 10.0 110.722 179.453 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.6 mp -80.09 130.41 35.23 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 123.192 0.597 . . . . 10.0 109.41 175.938 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.34 158.99 44.44 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 106.211 -1.774 . . . . 10.0 106.211 168.938 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.48 -64.39 0.05 OUTLIER Glycine 0 CA--C 1.51 -0.231 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.967 169.311 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -70.34 -45.01 67.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 -178.831 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.11 -70.52 0.38 Allowed Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.425 -1.261 . . . . 10.0 110.784 169.571 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -57.12 -35.0 98.78 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 123.228 2.618 . . . . 10.0 111.821 175.81 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 37.4 t -68.63 89.24 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 C-N-CA 124.623 1.169 . . . . 10.0 107.986 179.033 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -113.12 116.22 29.51 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.109 -1.441 . . . . 10.0 107.109 -179.871 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.3 136.79 13.72 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.368 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 7.8 mt -135.49 74.68 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 -175.286 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.7 mm -95.09 149.8 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 114.826 -1.079 . . . . 10.0 109.655 -172.347 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -126.37 114.6 18.43 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 126.775 2.03 . . . . 10.0 106.666 -170.57 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -102.36 115.54 30.78 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 106.229 -1.767 . . . . 10.0 106.229 176.559 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -119.24 137.51 53.61 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.085 0.772 . . . . 10.0 113.085 169.13 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -113.08 111.0 21.39 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 104.638 -2.356 . . . . 10.0 104.638 167.754 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? -56.25 -70.81 0.1 Allowed 'General case' 0 N--CA 1.445 -0.701 0 C-N-CA 125.554 1.542 . . . . 10.0 109.136 -176.117 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 23.0 mp0 -107.14 -133.38 0.33 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 107.133 -1.432 . . . . 10.0 107.133 176.487 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.3 m -136.86 15.32 3.09 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.195 0.521 . . . . 10.0 112.049 166.545 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -115.57 -22.97 8.98 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 124.803 1.241 . . . . 10.0 109.536 167.351 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.01 156.44 53.22 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 169.181 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.02 163.16 39.67 Favored 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 123.051 2.501 . . . . 10.0 109.207 178.105 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -79.57 134.64 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 104.831 -2.285 . . . . 10.0 104.831 166.934 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 32.5 mttt -114.67 125.13 53.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 104.812 -2.292 . . . . 10.0 104.812 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -109.48 104.14 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 C-N-CA 126.404 1.882 . . . . 10.0 106.587 -178.072 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -126.16 159.46 32.88 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 112.728 0.64 . . . . 10.0 112.728 -178.029 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.99 -146.09 13.99 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 107.811 -2.116 . . . . 10.0 107.811 169.948 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 31.8 p -155.38 160.68 40.87 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 122.113 0.958 . . . . 10.0 112.044 175.033 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -110.92 145.42 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-N 113.25 -1.795 . . . . 10.0 107.509 166.871 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -125.15 142.97 51.17 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 107.167 -1.42 . . . . 10.0 107.167 168.834 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.22 0.57 20.69 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.082 0.849 . . . . 10.0 113.247 176.634 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.41 176.87 8.95 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 118.594 1.197 . . . . 10.0 110.321 -179.155 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -109.62 153.74 23.78 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.925 -1.88 . . . . 10.0 105.925 166.097 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.09 147.83 2.0 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.594 1.157 . . . . 10.0 112.315 -171.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.75 -173.22 18.25 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.05 0.833 . . . . 10.0 111.795 170.774 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -73.03 146.89 45.59 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.26 1.424 . . . . 10.0 110.594 -179.142 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -147.06 147.97 31.16 Favored 'General case' 0 C--N 1.342 0.25 0 N-CA-C 114.509 1.3 . . . . 10.0 114.509 -177.49 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -26.46 121.99 0.04 OUTLIER Glycine 0 C--N 1.339 0.738 0 C-N-CA 128.653 3.025 . . . . 10.0 114.501 164.587 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -152.72 109.2 3.42 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.665 1.233 . . . . 10.0 110.544 166.267 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.14 179.17 7.82 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.254 0.55 . . . . 10.0 112.193 173.098 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.4 m -116.56 134.24 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.066 -1.879 . . . . 10.0 106.848 166.02 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -110.91 152.99 26.1 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 125.268 1.427 . . . . 10.0 107.912 -178.701 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.23 -54.71 43.67 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.875 -0.602 . . . . 10.0 111.413 -172.863 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.51 111.96 13.79 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -169.189 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.57 -30.47 68.67 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.164 -1.174 . . . . 10.0 110.164 169.44 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -40.29 139.43 0.74 Allowed 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 124.788 1.235 . . . . 10.0 111.214 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -143.88 24.07 1.69 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 124.353 1.061 . . . . 10.0 112.551 169.863 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.514 HG22 ' CG2' ' A' ' 17' ' ' ILE . 3.6 m -61.82 -35.15 77.39 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.371 0.668 . . . . 10.0 110.748 -174.957 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.23 -16.45 59.82 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 122.215 -0.303 . . . . 10.0 111.582 176.103 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.39 -151.59 19.08 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 106.61 -2.596 . . . . 10.0 106.61 -169.656 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 1.8 m -69.26 67.63 0.19 Allowed 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 126.018 1.727 . . . . 10.0 111.298 -179.039 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -163.88 -53.16 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.317 1.847 . . . . 10.0 107.583 -179.299 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -39.16 -40.59 0.74 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 127.648 2.379 . . . . 10.0 111.235 174.132 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.81 -47.55 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.009 2.524 . . . . 10.0 114.062 168.28 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.08 152.24 26.45 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 110.424 -1.071 . . . . 10.0 110.424 173.512 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -79.13 46.94 2.34 Favored 'Trans proline' 0 CA--C 1.537 0.629 0 C-N-CA 124.379 3.386 . . . . 10.0 113.482 -171.065 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 57.14 58.03 4.19 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.1 1.76 . . . . 10.0 108.585 -175.825 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -66.77 75.64 0.11 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.769 0.795 . . . . 10.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -77.65 137.02 63.03 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.2 -0.938 . . . . 10.0 110.508 -177.52 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.06 -52.16 0.99 Allowed 'Trans proline' 0 N--CA 1.455 -0.752 0 C-N-CA 122.578 2.185 . . . . 10.0 111.132 -173.19 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mp -76.17 65.74 2.19 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 108.122 -1.066 . . . . 10.0 108.122 175.054 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 66.6 p -30.02 101.64 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.325 2.25 . . . . 10.0 114.021 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.2 mtp180 -139.85 177.7 7.77 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.072 0.949 . . . . 10.0 110.927 -174.729 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 67.2 mmtt -107.26 89.07 2.89 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 113.233 0.827 . . . . 10.0 113.233 -168.66 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 81.9 t60 5.73 92.85 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.23 0 C-N-CA 128.45 2.7 . . . . 10.0 114.849 179.219 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.24 -139.04 9.64 Favored Glycine 0 N--CA 1.442 -0.921 0 N-CA-C 110.144 -1.182 . . . . 10.0 110.144 178.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.03 -162.24 34.34 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 175.394 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.62 1.31 1.81 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 CA-C-N 120.055 1.927 . . . . 10.0 111.472 168.417 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.31 8.6 18.09 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.913 1.685 . . . . 10.0 110.516 176.4 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -142.03 169.62 17.24 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.442 1.019 . . . . 10.0 108.948 165.125 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -87.99 -22.6 24.17 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.235 -1.394 . . . . 10.0 107.235 167.996 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 -82.27 31.05 0.39 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 120.661 -1.274 . . . . 10.0 112.777 -176.526 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.6 132.7 54.77 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 172.898 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 16.9 m170 -63.17 -61.52 2.32 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 121.176 0.512 . . . . 10.0 110.538 -177.787 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.4 p -168.23 -56.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 -179.141 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.16 63.14 0.63 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 177.45 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.1 m-20 -92.7 95.5 9.6 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 104.101 -2.555 . . . . 10.0 104.101 167.528 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 9.2 mp -66.75 -26.61 67.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 118.828 0.74 . . . . 10.0 109.342 -176.713 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 116.9 -88.17 0.45 Allowed Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 108.106 -1.998 . . . . 10.0 108.106 168.631 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 38.5 m-80 -149.39 142.49 24.96 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.58 134.12 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 107.657 -1.238 . . . . 10.0 107.657 169.001 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -86.9 130.06 34.62 Favored 'General case' 0 C--O 1.226 -0.166 0 C-N-CA 123.978 0.911 . . . . 10.0 108.643 179.663 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.77 127.87 52.71 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.227 1.411 . . . . 10.0 109.43 175.247 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -61.29 167.71 3.04 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.888 1.368 . . . . 10.0 109.933 168.064 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -52.32 -30.8 30.11 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.681 1.192 . . . . 10.0 110.77 172.202 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -77.25 -7.73 56.42 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.035 0.379 . . . . 10.0 110.758 -177.541 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.14 17.01 73.02 Favored Glycine 0 C--N 1.34 0.788 0 N-CA-C 110.611 -0.995 . . . . 10.0 110.611 -178.497 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -94.54 119.29 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 C-N-CA 127.359 2.264 . . . . 10.0 105.434 172.532 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -115.82 126.6 54.21 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 123.706 0.802 . . . . 10.0 109.017 174.431 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -88.57 133.62 34.11 Favored 'General case' 0 N--CA 1.437 -1.096 0 C-N-CA 127.154 2.181 . . . . 10.0 109.567 178.936 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 50.1 t -113.97 130.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 C-N-CA 125.825 1.65 . . . . 10.0 108.228 174.624 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 78.1 p -157.78 73.81 0.71 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.132 0.973 . . . . 10.0 108.923 169.685 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.29 163.06 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 106.984 -1.487 . . . . 10.0 106.984 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -147.72 150.45 34.33 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 125.191 1.396 . . . . 10.0 109.933 174.333 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -155.32 159.28 39.84 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.323 -1.362 . . . . 10.0 107.323 172.881 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.2 p -104.81 -16.85 14.79 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 128.136 2.574 . . . . 10.0 112.281 179.053 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 4.5 p -78.34 -38.28 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 -176.387 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -70.64 154.72 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 C-N-CA 124.522 1.129 . . . . 10.0 107.978 168.771 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 11.1 m -153.77 163.28 40.28 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 172.088 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 79.2 mt -101.96 -11.06 19.24 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.797 0.839 . . . . 10.0 111.539 176.937 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.5 m -148.94 139.48 22.58 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.808 1.643 . . . . 10.0 107.239 169.498 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 178.54 -61.06 0.08 OUTLIER Glycine 0 C--O 1.227 -0.331 0 N-CA-C 107.296 -2.322 . . . . 10.0 107.296 171.017 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -169.71 -52.69 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 127.321 2.249 . . . . 10.0 106.804 174.102 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -78.39 -41.34 33.48 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 114.399 -1.273 . . . . 10.0 108.52 -174.506 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 13.6 t 49.86 -105.75 0.19 Allowed 'General case' 0 N--CA 1.438 -1.069 0 C-N-CA 125.637 1.575 . . . . 10.0 108.182 -169.55 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 39.4 pt 162.87 -23.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.336 1 C-N-CA 133.226 4.61 . . . . 10.0 107.34 -171.482 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -43.25 120.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 118.854 0.752 . . . . 10.0 110.397 175.425 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 104.0 -6.55 47.53 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.786 -1.008 . . . . 10.0 113.781 179.025 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -77.1 154.64 33.1 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 118.309 1.055 . . . . 10.0 110.288 175.562 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 32.6 m -94.93 109.03 21.09 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.565 1.146 . . . . 10.0 109.183 178.553 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -79.57 147.92 31.94 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 167.272 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 65.3 t -142.63 132.87 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 C-N-CA 123.953 0.901 . . . . 10.0 109.551 -173.565 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.7 t -109.0 136.67 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.648 0 C-N-CA 126.173 1.789 . . . . 10.0 109.898 172.239 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 6.6 m-70 -117.52 158.68 24.13 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 116.466 2.024 . . . . 10.0 116.466 -171.179 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 57.8 tt0 -48.8 -53.06 20.72 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 129.836 3.254 . . . . 10.0 111.813 175.166 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -112.75 168.79 9.38 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 123.332 0.653 . . . . 10.0 111.876 -169.704 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.62 154.1 40.92 Favored 'General case' 0 N--CA 1.443 -0.82 0 O-C-N 125.016 1.448 . . . . 10.0 108.214 169.013 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -107.25 140.53 39.98 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 124.197 0.999 . . . . 10.0 109.032 -169.014 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -72.99 -28.99 62.71 Favored 'General case' 0 C--O 1.232 0.168 0 O-C-N 123.724 0.64 . . . . 10.0 109.803 -175.331 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.6 mt 59.86 50.95 6.4 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 107.896 -1.15 . . . . 10.0 107.896 -171.413 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 94.05 -39.33 2.94 Favored Glycine 0 CA--C 1.521 0.456 0 C-N-CA 126.189 1.852 . . . . 10.0 110.788 169.531 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 29.8 mtmm -80.91 39.79 0.51 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.004 0.922 . . . . 10.0 112.591 -169.485 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.18 -24.11 13.39 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 126.565 2.031 . . . . 10.0 110.262 169.186 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 59.94 36.11 89.15 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 123.732 0.682 . . . . 10.0 111.547 176.517 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -137.67 166.6 23.55 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 108.467 -0.938 . . . . 10.0 108.467 173.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -48.5 -47.4 38.79 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 124.363 1.065 . . . . 10.0 110.295 -178.586 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . 0.462 ' CD ' ' HZ2' ' B' ' 136' ' ' LYS . 5.1 tp10 -70.48 -33.7 71.55 Favored 'General case' 0 N--CA 1.448 -0.549 0 O-C-N 121.922 -0.486 . . . . 10.0 111.671 179.417 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 26.6 p -55.69 -45.76 77.74 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 119.398 0.999 . . . . 10.0 110.435 177.274 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.5 t -76.3 -14.38 60.11 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.756 -0.656 . . . . 10.0 112.345 -171.728 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.462 ' HZ2' ' CD ' ' B' ' 133' ' ' GLU . 10.5 ttmt -107.16 -49.34 3.29 Favored 'General case' 0 N--CA 1.434 -1.255 0 C-N-CA 125.987 1.715 . . . . 10.0 110.904 -172.141 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.03 23.77 2.58 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.972 0.806 . . . . 10.0 111.673 176.223 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 61.4 26.62 66.56 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 119.516 1.053 . . . . 10.0 111.951 177.983 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 57.16 23.19 8.32 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.286 1.043 . . . . 10.0 112.908 -178.798 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.58 -12.31 9.66 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 125.554 1.542 . . . . 10.0 114.045 -175.889 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.11 -162.92 52.93 Favored Glycine 0 N--CA 1.445 -0.765 0 O-C-N 121.029 -1.044 . . . . 10.0 110.849 172.193 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.4 m -56.19 128.32 35.04 Favored 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 124.097 0.959 . . . . 10.0 111.807 -167.96 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -73.48 98.78 2.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.45 1.1 . . . . 10.0 108.105 178.169 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 36.2 mt -79.24 -28.53 42.46 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.039 0.536 . . . . 10.0 112.024 -171.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.59 138.74 22.41 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.146 -0.687 . . . . 10.0 109.146 179.341 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -137.52 130.23 30.01 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 -178.185 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.24 -174.05 13.63 Favored Glycine 0 C--O 1.228 -0.235 0 N-CA-C 109.5 -1.44 . . . . 10.0 109.5 178.459 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.7 t -131.68 150.97 34.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 103.478 -2.786 . . . . 10.0 103.478 168.245 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.1 mt -60.12 -86.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.574 1.15 . . . . 10.0 111.534 -168.166 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.94 128.88 6.17 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 110.627 -0.989 . . . . 10.0 110.627 -179.01 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.6 pt -76.68 126.91 37.76 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 177.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.99 -45.68 12.86 Favored 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 108.533 -0.914 . . . . 10.0 108.533 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 . . . . . 0 C--O 1.253 1.262 0 CA-C-O 116.016 -1.945 . . . . 10.0 109.665 -176.064 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 106.331 -1.729 . . . . 10.0 106.331 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -88.81 -16.09 32.93 Favored 'General case' 0 C--O 1.228 -0.076 0 CA-C-N 119.917 1.235 . . . . 10.0 111.475 177.118 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -151.88 144.54 24.27 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.245 0.475 . . . . 10.0 112.261 177.792 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.2 160.62 37.28 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.832 1.653 . . . . 10.0 109.497 173.865 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 t -121.58 150.99 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 125.762 1.625 . . . . 10.0 109.93 179.502 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.55 100.59 5.01 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.782 1.233 . . . . 10.0 108.98 169.671 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -83.97 109.12 17.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 109.85 -0.426 . . . . 10.0 109.85 170.555 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -96.19 145.95 25.1 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.069 0.948 . . . . 10.0 109.316 177.419 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -157.89 164.53 36.82 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 107.89 -1.152 . . . . 10.0 107.89 171.227 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.07 -67.3 0.02 OUTLIER Glycine 0 C--O 1.229 -0.174 0 N-CA-C 111.574 -0.611 . . . . 10.0 111.574 171.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -75.99 -42.1 49.22 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 107.358 -1.349 . . . . 10.0 107.358 -176.557 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.98 -67.12 0.53 Allowed Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 114.851 -1.068 . . . . 10.0 111.615 -177.308 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -57.29 -41.69 70.5 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.157 1.904 . . . . 10.0 110.888 179.563 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -69.56 108.84 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 N-CA-C 107.176 -1.416 . . . . 10.0 107.176 176.843 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -120.48 117.51 27.84 Favored 'General case' 0 N--CA 1.437 -1.098 0 C-N-CA 126.049 1.74 . . . . 10.0 106.757 174.395 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -95.31 142.27 15.99 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 108.973 -1.651 . . . . 10.0 108.973 169.177 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 mt -145.49 67.18 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 N-CA-C 106.049 -1.834 . . . . 10.0 106.049 -173.611 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.6 mm -90.91 135.51 26.53 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 CA-C-N 116.39 -0.368 . . . . 10.0 110.061 -172.4 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 m-80 -101.84 132.55 47.55 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 125.019 1.328 . . . . 10.0 108.708 175.589 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -116.18 87.41 2.68 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 126.626 1.97 . . . . 10.0 107.822 178.541 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -83.94 155.83 22.64 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-O 121.46 0.648 . . . . 10.0 111.169 175.68 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -145.23 99.16 3.27 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 126.068 1.747 . . . . 10.0 107.174 174.828 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.4 ptmt -62.31 -57.48 11.22 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 122.172 -0.33 . . . . 10.0 110.128 179.305 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -128.91 163.01 26.21 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 103.814 -2.661 . . . . 10.0 103.814 168.093 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.4 t -76.75 -4.59 44.19 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 119.172 0.897 . . . . 10.0 109.904 173.189 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -80.92 -21.86 40.15 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 124.452 1.101 . . . . 10.0 109.532 168.914 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.71 148.72 30.81 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 110.132 -1.187 . . . . 10.0 110.132 178.316 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -64.72 141.14 71.02 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 N-CA-C 107.803 -1.653 . . . . 10.0 107.803 169.245 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.8 t -78.3 83.12 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 174.241 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.0 tttt -63.33 111.58 2.34 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.915 -1.142 . . . . 10.0 107.915 171.429 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 18.1 m -91.62 121.67 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 N-CA-C 106.884 -1.524 . . . . 10.0 106.884 176.769 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 31.0 p90 -133.04 151.09 52.08 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 122.19 0.995 . . . . 10.0 113.145 170.5 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.08 -177.19 47.17 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 109.629 -1.388 . . . . 10.0 109.629 170.071 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.2 m -128.76 103.27 6.97 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.745 -1.206 . . . . 10.0 107.745 -173.551 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 pt -77.02 150.36 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.39 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 168.281 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.63 141.86 43.23 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.644 -0.502 . . . . 10.0 109.644 169.312 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.05 0.33 28.48 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.323 0.963 . . . . 10.0 112.899 175.76 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -65.12 176.05 1.41 Allowed 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 121.998 0.904 . . . . 10.0 109.669 169.922 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -98.92 167.1 10.95 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.649 -1.612 . . . . 10.0 106.649 164.95 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -58.19 169.08 0.89 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.398 1.079 . . . . 10.0 111.256 -171.251 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.94 -178.34 45.11 Favored Glycine 0 N--CA 1.448 -0.526 0 O-C-N 120.883 -1.136 . . . . 10.0 111.896 166.992 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.9 mp -70.63 153.3 42.99 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.283 1.433 . . . . 10.0 110.395 179.832 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -148.92 143.44 26.2 Favored 'General case' 0 C--N 1.34 0.185 0 N-CA-C 113.627 0.973 . . . . 10.0 113.627 -175.439 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -32.06 127.91 0.25 Allowed Glycine 0 C--N 1.34 0.777 0 C-N-CA 126.963 2.221 . . . . 10.0 111.644 164.391 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.39 103.48 2.33 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 119.744 1.772 . . . . 10.0 111.394 168.409 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.521 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.01 174.62 13.43 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 114.253 1.205 . . . . 10.0 114.253 -173.382 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.1 p -79.16 140.81 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 112.016 -2.356 . . . . 10.0 107.966 166.567 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.4 ' CD2' ' CG2' ' A' ' 118' ' ' VAL . 86.5 m-70 -126.17 100.5 6.35 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 102.875 -3.009 . . . . 10.0 102.875 163.861 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 6.89 -78.84 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 128.67 2.788 . . . . 10.0 116.017 178.773 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -81.69 162.22 23.08 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 119.166 0.894 . . . . 10.0 110.63 -171.098 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.01 -18.87 58.74 Favored Glycine 0 CA--C 1.524 0.61 0 O-C-N 121.306 -0.871 . . . . 10.0 110.956 170.91 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -65.34 162.82 16.76 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 122.275 1.036 . . . . 10.0 112.716 -170.268 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.58 17.91 0.11 Allowed 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 113.931 1.086 . . . . 10.0 113.931 -169.452 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.81 -37.89 53.52 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.489 1.116 . . . . 10.0 113.464 -169.003 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.22 -21.94 45.56 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 112.306 0.484 . . . . 10.0 112.306 179.485 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.61 100.9 2.65 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 -174.313 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 52.0 30.68 7.66 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 125.379 1.472 . . . . 10.0 114.502 169.147 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.8 m -133.79 -59.35 0.85 Allowed 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 106.816 -1.55 . . . . 10.0 106.816 -173.585 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.3 m -47.5 -46.12 26.96 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 126.5 1.92 . . . . 10.0 111.52 -169.469 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.88 -49.7 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 128.239 2.616 . . . . 10.0 114.975 169.4 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.12 171.37 12.95 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.769 -0.932 . . . . 10.0 110.769 173.094 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -79.45 -136.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 123.384 2.723 . . . . 10.0 106.092 166.022 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 18.1 m170 -106.29 50.35 0.78 Allowed 'General case' 0 CA--C 1.544 0.733 0 CA-C-N 121.67 2.032 . . . . 10.0 110.102 171.371 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -78.69 61.35 2.97 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.618 1.554 . . . . 10.0 110.218 174.591 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -61.94 155.97 59.97 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 127.581 2.353 . . . . 10.0 111.138 171.089 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.19 -58.28 0.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.228 2.618 . . . . 10.0 112.75 178.452 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -78.05 58.64 2.02 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.941 0.791 . . . . 10.0 110.509 -177.983 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.8 t -59.08 110.76 1.11 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 122.913 0.485 . . . . 10.0 109.752 -174.709 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 65.8 mtt180 -127.2 -90.08 0.53 Allowed 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 105.361 -2.089 . . . . 10.0 105.361 178.166 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.1 mttm -144.43 156.35 44.16 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.001 0.905 . . . . 10.0 108.812 169.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -63.29 120.2 11.11 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 118.493 -1.283 . . . . 10.0 107.804 166.656 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.12 -156.64 7.04 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 106.571 -2.612 . . . . 10.0 106.571 177.282 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.43 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -151.14 -159.35 8.79 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 118.442 1.121 . . . . 10.0 112.007 178.781 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -71.1 12.11 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 121.414 1.409 . . . . 10.0 109.466 165.724 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.43 ' H ' ' C ' ' A' ' 73' ' ' GLY . 37.5 mmtm -95.87 -24.78 16.28 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 169.704 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.426 ' OD1' ' NZ ' ' A' ' 128' ' ' LYS . 20.4 m-20 -115.56 171.27 7.83 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 -170.016 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -121.14 10.13 10.63 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.539 1.135 . . . . 10.0 110.279 171.394 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -109.16 6.47 24.85 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.515 1.126 . . . . 10.0 110.497 172.098 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -47.3 148.27 1.33 Allowed 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.531 1.532 . . . . 10.0 110.263 178.058 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -60.78 -64.11 1.07 Allowed 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 117.842 0.292 . . . . 10.0 111.185 -176.168 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.8 p -167.89 -51.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 C-N-CA 123.739 0.815 . . . . 10.0 109.266 174.552 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -136.51 47.96 0.94 Allowed Glycine 0 CA--C 1.526 0.741 0 C-N-CA 123.939 0.78 . . . . 10.0 111.327 -175.198 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -86.23 109.11 18.7 Favored 'General case' 0 CA--C 1.53 0.173 0 N-CA-C 105.068 -2.197 . . . . 10.0 105.068 168.395 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.3 mt -74.85 -14.57 60.69 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 118.607 0.639 . . . . 10.0 111.744 -170.94 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.61 -97.93 1.14 Allowed Glycine 0 N--CA 1.44 -1.048 0 N-CA-C 107.434 -2.267 . . . . 10.0 107.434 178.907 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -153.0 120.68 6.02 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 -172.317 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.1 m -102.53 147.27 9.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 N-CA-C 106.039 -1.838 . . . . 10.0 106.039 168.957 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -120.45 133.12 55.47 Favored 'General case' 0 C--N 1.334 -0.095 0 C-N-CA 123.426 0.69 . . . . 10.0 111.588 -173.358 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.75 132.75 48.69 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.244 1.018 . . . . 10.0 111.361 -175.025 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.04 172.74 0.53 Allowed 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 122.496 1.141 . . . . 10.0 110.319 167.778 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 mtmp? -63.15 -19.49 64.52 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 114.309 -1.314 . . . . 10.0 112.425 178.433 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -77.8 -20.31 53.47 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 122.35 0.26 . . . . 10.0 110.741 173.881 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.85 6.67 60.43 Favored Glycine 0 C--N 1.338 0.684 0 CA-C-O 118.749 -1.028 . . . . 10.0 110.685 -170.19 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 t -79.37 114.61 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 C-N-CA 125.502 1.521 . . . . 10.0 107.154 176.265 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -115.38 123.93 49.93 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.865 -0.791 . . . . 10.0 108.865 174.353 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -78.84 129.03 34.12 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.327 -0.99 . . . . 10.0 108.327 171.745 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.4 t -112.15 129.84 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 104.179 -2.526 . . . . 10.0 104.179 167.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.9 p -157.79 57.27 0.48 Allowed 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 123.025 0.53 . . . . 10.0 110.844 174.596 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.36 148.67 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 124.087 0.955 . . . . 10.0 109.024 -169.883 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -129.27 123.66 32.47 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.535 1.134 . . . . 10.0 110.243 174.253 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -127.61 107.15 9.67 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.823 1.649 . . . . 10.0 108.511 -177.653 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 45.2 p -85.22 58.54 5.09 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.823 2.049 . . . . 10.0 107.195 -171.294 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.3 p -142.07 -48.87 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 123.996 0.919 . . . . 10.0 109.307 -176.273 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.312 0.0 OUTLIER -79.91 174.65 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 N-CA-C 113.023 0.749 . . . . 10.0 113.023 174.933 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -167.88 155.0 8.17 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.994 1.318 . . . . 10.0 107.901 169.39 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 70.3 mt -62.29 -24.53 67.34 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 123.413 0.685 . . . . 10.0 111.214 -176.087 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.9 m -147.87 161.32 41.54 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.856 -1.905 . . . . 10.0 105.856 169.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 154.82 -74.57 0.24 Allowed Glycine 0 C--N 1.334 0.434 0 N-CA-C 109.925 -1.27 . . . . 10.0 109.925 -177.457 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -152.19 -53.69 0.12 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.768 2.027 . . . . 10.0 106.387 178.698 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -75.0 -38.6 61.54 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 114.069 -1.423 . . . . 10.0 108.507 -175.002 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.3 t 46.5 56.17 6.72 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.86 1.264 . . . . 10.0 110.309 169.401 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -66.77 6.92 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 N-CA-C 115.647 1.721 . . . . 10.0 115.647 -166.424 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.7 mm -57.41 142.02 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 167.103 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.95 19.21 79.77 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-O 118.916 -0.935 . . . . 10.0 114.033 175.129 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -79.81 175.87 10.24 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 106.779 -1.563 . . . . 10.0 106.779 166.035 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 16.5 m -111.64 131.92 54.94 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 103.302 -2.851 . . . . 10.0 103.302 169.467 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.3 135.81 37.63 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 105.751 -1.944 . . . . 10.0 105.751 167.455 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.4 ' CG2' ' CD2' ' A' ' 48' ' ' HIS . 86.8 t -118.84 132.95 67.23 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.874 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 169.148 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.07 127.51 58.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.75 -1.945 . . . . 10.0 105.75 168.028 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 7.4 m-70 -103.69 159.13 15.88 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 123.529 1.633 . . . . 10.0 114.946 -169.835 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -43.71 -60.73 1.66 Allowed 'General case' 0 N--CA 1.442 -0.873 0 C-N-CA 129.079 2.951 . . . . 10.0 110.041 172.62 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mtmm -115.93 175.4 5.56 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.912 1.285 . . . . 10.0 111.638 -171.897 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.57 149.54 32.99 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 125.938 1.695 . . . . 10.0 111.161 -176.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.521 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.9 m-20 -79.34 144.06 34.57 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.517 0.727 . . . . 10.0 112.567 175.502 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 m-20 -77.18 -35.55 55.74 Favored 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 124.781 1.301 . . . . 10.0 108.974 167.96 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 57.0 mt 66.55 48.8 1.43 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 125.439 1.496 . . . . 10.0 109.368 -167.689 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.83 50.21 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 125.243 1.402 . . . . 10.0 113.001 172.556 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . 0.426 ' NZ ' ' OD1' ' A' ' 76' ' ' ASP . 18.1 mttm -78.82 -1.71 36.2 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.711 0.805 . . . . 10.0 111.273 -168.598 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.91 -26.58 73.2 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 109.087 -1.605 . . . . 10.0 109.087 166.387 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.32 39.25 82.1 Favored Glycine 0 C--N 1.341 0.856 0 N-CA-C 110.822 -0.911 . . . . 10.0 110.822 -179.544 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.9 m-80 -122.06 161.71 22.53 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 176.132 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -48.72 -45.5 39.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 113.388 -1.733 . . . . 10.0 108.781 171.038 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -64.76 -49.7 69.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.167 -0.47 . . . . 10.0 111.714 172.217 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.7 t -52.97 -44.72 67.36 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 120.552 -1.342 . . . . 10.0 110.65 -175.418 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.1 t -74.95 -5.98 46.8 Favored 'General case' 0 CA--C 1.538 0.492 0 O-C-N 123.186 0.304 . . . . 10.0 111.542 -174.955 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 87.9 mttt -102.83 -83.05 0.48 Allowed 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 126.578 1.951 . . . . 10.0 110.147 172.583 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.21 25.84 10.99 Favored 'General case' 0 C--N 1.345 0.391 0 CA-C-N 121.298 1.863 . . . . 10.0 112.988 -177.02 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 59.72 27.66 64.36 Favored Glycine 0 C--N 1.339 0.721 0 CA-C-N 118.942 0.792 . . . . 10.0 112.397 170.001 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.0 m-80 50.21 27.86 2.83 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 123.988 0.915 . . . . 10.0 112.689 -173.501 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.52 -3.85 9.85 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.527 -0.733 . . . . 10.0 112.243 179.694 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.35 -163.6 51.92 Favored Glycine 0 N--CA 1.443 -0.894 0 N-CA-C 110.866 -0.893 . . . . 10.0 110.866 169.192 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.8 m -56.98 142.22 42.58 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.5 0.667 . . . . 10.0 111.612 -169.248 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.0 mtp85 -68.9 64.79 0.12 Allowed 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 125.627 1.571 . . . . 10.0 109.681 175.357 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 11.9 tp -43.91 -35.11 1.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.669 1.988 . . . . 10.0 113.917 -174.537 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -162.53 159.06 24.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -162.16 168.15 22.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 -174.881 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.47 169.77 42.77 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 112.094 -0.402 . . . . 10.0 112.094 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 4.8 t -107.28 138.78 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 -171.304 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mt -80.11 136.58 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-N 118.0 0.364 . . . . 10.0 110.607 179.568 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.05 146.99 17.5 Favored Glycine 0 CA--C 1.53 0.984 0 C-N-CA 125.068 1.318 . . . . 10.0 110.81 176.977 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 10.8 pt -71.49 142.07 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.138 0 CA-C-N 117.82 0.81 . . . . 10.0 109.28 176.771 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.52 -19.71 8.05 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.282 1.433 . . . . 10.0 113.313 -176.372 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.9 tp60 . . . . . 0 C--O 1.254 1.298 0 C-N-CA 130.278 3.431 . . . . 10.0 117.278 -175.504 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 117.652 -1.166 . . . . 10.0 108.997 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.3 t -76.02 -37.35 58.51 Favored 'General case' 0 CA--C 1.516 -0.327 0 CA-C-N 120.217 1.371 . . . . 10.0 110.41 -178.767 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -124.54 136.44 53.99 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 123.377 0.671 . . . . 10.0 111.201 -171.561 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.36 165.5 28.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.146 1.378 . . . . 10.0 107.502 171.004 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 7.9 m -128.32 -178.28 2.29 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 123.367 0.667 . . . . 10.0 110.114 178.904 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.39 110.97 4.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.774 1.23 . . . . 10.0 108.262 165.453 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -95.83 104.52 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 123.786 0.835 . . . . 10.0 109.615 170.633 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -95.06 135.57 36.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 124.026 0.93 . . . . 10.0 110.035 -177.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 43.2 mtpt -149.22 169.48 20.65 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 107.459 -1.312 . . . . 10.0 107.459 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.38 -72.6 0.04 OUTLIER Glycine 0 C--O 1.229 -0.201 0 CA-C-N 115.944 -0.571 . . . . 10.0 111.68 174.394 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -74.09 -41.29 61.91 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.15 -1.426 . . . . 10.0 107.15 -178.295 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.84 -65.92 0.58 Allowed Glycine 0 CA--C 1.526 0.759 0 C-N-CA 124.836 1.207 . . . . 10.0 110.498 -178.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -79.14 37.48 0.67 Allowed 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 124.874 3.716 . . . . 10.0 111.446 -175.282 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -148.74 108.11 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.534 0 N-CA-C 100.405 -3.924 . . . . 10.0 100.405 173.244 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.47 122.84 28.43 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 177.101 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.56 140.21 15.3 Favored Glycine 0 C--O 1.224 -0.508 0 N-CA-C 110.493 -1.043 . . . . 10.0 110.493 -179.745 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.6 mt -139.98 88.75 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.148 -1.427 . . . . 10.0 107.148 -174.317 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -100.23 146.52 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.13 0 C-N-CA 124.978 1.311 . . . . 10.0 111.288 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -123.99 121.3 34.91 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 127.056 2.142 . . . . 10.0 108.102 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -99.32 108.0 20.42 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.855 1.262 . . . . 10.0 107.999 171.761 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -105.13 139.08 40.34 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 119.039 0.836 . . . . 10.0 109.534 167.421 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -116.91 106.13 13.1 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.668 -1.604 . . . . 10.0 106.668 168.22 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt -152.19 79.13 1.24 Allowed 'General case' 0 N--CA 1.424 -1.731 0 C-N-CA 125.343 1.457 . . . . 10.0 108.926 -178.317 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -158.45 165.05 35.56 Favored 'General case' 0 N--CA 1.434 -1.265 0 N-CA-C 102.647 -3.094 . . . . 10.0 102.647 165.063 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 10.2 t -72.32 -18.3 61.78 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 121.372 0.606 . . . . 10.0 109.446 170.565 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 14.0 m-80 -79.95 -10.42 59.77 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.656 -0.498 . . . . 10.0 109.656 173.582 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.71 44.76 23.91 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-O 117.581 -1.677 . . . . 10.0 115.218 -178.64 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -73.86 140.76 29.31 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 122.527 2.151 . . . . 10.0 108.77 175.091 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -85.81 99.5 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 107.212 -1.403 . . . . 10.0 107.212 173.754 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 60.4 mttm -79.3 109.06 13.29 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.489 -1.3 . . . . 10.0 107.489 174.093 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.39 97.21 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 126.446 1.899 . . . . 10.0 107.392 -178.153 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.7 p90 -116.18 171.31 7.89 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.245 0.545 . . . . 10.0 110.144 169.715 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.26 -165.41 36.59 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 111.126 -0.789 . . . . 10.0 111.126 170.069 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.3 m -154.68 107.86 2.84 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 108.876 -0.787 . . . . 10.0 108.876 -170.832 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 6.9 pt -79.87 177.71 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 108.869 -0.789 . . . . 10.0 108.869 169.01 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 tptt -153.5 153.88 33.29 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 170.858 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.17 -38.94 2.67 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 118.51 0.595 . . . . 10.0 111.622 169.728 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.0 mp -64.14 177.0 0.87 Allowed 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 122.034 0.921 . . . . 10.0 111.664 -170.031 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -103.58 162.05 13.38 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.617 -0.719 . . . . 10.0 109.186 168.731 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -52.32 153.48 2.87 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 125.584 1.553 . . . . 10.0 112.18 -169.456 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.81 -173.41 20.04 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 123.517 0.58 . . . . 10.0 111.858 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -74.64 151.25 39.34 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.937 1.295 . . . . 10.0 110.364 -177.665 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -150.18 151.86 33.74 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 123.634 0.774 . . . . 10.0 112.605 -178.392 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -44.75 127.18 7.09 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 127.259 2.362 . . . . 10.0 110.96 165.985 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -154.73 111.17 3.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 119.038 1.419 . . . . 10.0 108.862 165.771 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.473 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -155.4 167.64 29.72 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-O 121.312 0.577 . . . . 10.0 111.466 179.285 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.0 m -86.51 149.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 112.504 -2.135 . . . . 10.0 106.563 168.014 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -117.57 164.01 15.58 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 123.014 0.526 . . . . 10.0 110.263 176.292 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -52.57 -54.41 33.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.162 0.985 . . . . 10.0 112.589 -176.025 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -106.54 -178.45 3.65 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 118.829 0.741 . . . . 10.0 109.381 178.219 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -139.47 13.41 3.22 Favored Glycine 0 C--N 1.333 0.382 0 O-C-N 122.109 -0.369 . . . . 10.0 113.461 176.093 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -67.13 153.31 43.98 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 107.276 -1.379 . . . . 10.0 107.276 167.188 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -149.13 22.53 0.96 Allowed 'General case' 0 N--CA 1.451 -0.421 0 O-C-N 121.649 -0.657 . . . . 10.0 112.189 -172.372 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.23 -38.42 26.46 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.758 2.023 . . . . 10.0 112.447 -177.489 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.2 -19.77 56.27 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 122.136 -0.353 . . . . 10.0 111.916 -178.278 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 125.9 -66.97 0.54 Allowed Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.309 -1.117 . . . . 10.0 110.309 -176.857 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 35.0 t -160.05 70.06 0.42 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 122.391 1.091 . . . . 10.0 110.625 -178.73 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -163.17 -50.73 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 125.282 1.433 . . . . 10.0 109.253 -174.235 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -48.8 -38.67 22.75 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 125.667 1.587 . . . . 10.0 111.447 -171.218 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.12 -41.54 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 128.662 2.785 . . . . 10.0 114.351 168.63 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.85 161.88 29.84 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 107.647 -2.181 . . . . 10.0 107.647 177.392 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -68.88 -143.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.547 1.132 0 C-N-CA 121.894 1.729 . . . . 10.0 109.615 169.783 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.6 m170 -104.17 42.91 1.14 Allowed 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.267 -1.52 . . . . 10.0 110.629 -179.665 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -73.31 71.98 1.26 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 120.601 1.546 . . . . 10.0 111.32 -179.707 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -62.56 155.06 70.76 Favored Pre-proline 0 CA--C 1.538 0.499 0 C-N-CA 124.218 1.007 . . . . 10.0 111.614 169.837 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.62 -47.95 2.54 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.282 1.988 . . . . 10.0 111.361 176.838 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.85 68.33 1.29 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.774 -0.579 . . . . 10.0 110.816 175.488 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 14.1 t -40.81 102.88 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.427 1.891 . . . . 10.0 111.782 -178.627 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.8 mtt85 -130.28 175.43 8.94 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 126.275 1.83 . . . . 10.0 108.863 177.07 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 62.0 mmtt -106.19 84.11 1.99 Allowed 'General case' 0 CA--C 1.531 0.227 0 CA-C-O 121.457 0.646 . . . . 10.0 112.473 -170.887 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 54.2 t60 13.79 88.39 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.433 2.293 . . . . 10.0 115.594 174.044 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -121.27 -164.6 12.37 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 126.985 2.231 . . . . 10.0 109.004 178.627 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.59 -154.88 15.24 Favored Glycine 0 C--O 1.227 -0.304 0 N-CA-C 106.973 -2.451 . . . . 10.0 106.973 -172.357 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -64.13 9.56 0.14 Allowed 'Trans proline' 0 CA--C 1.542 0.915 0 CA-C-N 120.119 1.96 . . . . 10.0 112.414 169.095 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.65 -31.33 11.27 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.738 1.215 . . . . 10.0 111.209 170.249 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -141.46 154.9 45.83 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-N 119.277 0.944 . . . . 10.0 110.445 -170.197 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 49.2 tt0 -75.87 -20.54 58.01 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.053 -1.091 . . . . 10.0 108.053 178.906 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -80.38 30.93 0.28 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.741 1.216 . . . . 10.0 112.096 -178.384 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -57.52 138.77 54.79 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.111 -0.993 . . . . 10.0 109.135 171.221 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -74.72 -61.03 2.02 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 179.776 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -156.42 -125.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 105.863 -1.903 . . . . 10.0 105.863 -174.444 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -74.4 69.96 1.66 Allowed Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.357 -1.097 . . . . 10.0 110.357 175.891 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -95.94 93.25 6.91 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 106.947 -1.501 . . . . 10.0 106.947 170.209 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.3 mt -65.19 -29.69 70.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.895 0.855 . . . . 10.0 108.987 178.814 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.87 -79.8 0.29 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 169.284 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -144.17 108.07 4.71 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 118.185 -0.912 . . . . 10.0 108.627 -173.366 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.9 m -105.63 130.76 56.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 119.677 1.126 . . . . 10.0 111.924 -179.029 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -90.48 123.02 33.83 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 128.804 2.841 . . . . 10.0 111.269 -169.973 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.39 137.88 42.48 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 124.118 0.967 . . . . 10.0 111.411 177.198 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -62.08 171.65 1.69 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 124.325 1.05 . . . . 10.0 109.458 166.46 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.68 -28.96 58.38 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.554 0.742 . . . . 10.0 111.781 173.245 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -78.27 -3.94 45.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.336 0.588 . . . . 10.0 110.192 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.85 -0.63 82.61 Favored Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 110.257 -1.137 . . . . 10.0 110.257 -177.491 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.7 t -78.83 101.28 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 -173.154 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.49 117.19 30.39 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.45 -0.944 . . . . 10.0 108.45 168.392 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.37 106.84 12.69 Favored 'General case' 0 N--CA 1.435 -1.199 0 C-N-CA 126.814 2.046 . . . . 10.0 109.364 172.428 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 95.8 t -96.3 134.48 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.876 0 N-CA-C 106.964 -1.495 . . . . 10.0 106.964 178.626 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -158.22 79.09 0.82 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.382 0.673 . . . . 10.0 111.502 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -122.3 164.58 19.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 106.064 -1.828 . . . . 10.0 106.064 -179.419 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -138.1 145.0 41.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 121.469 -0.77 . . . . 10.0 111.498 168.743 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -109.62 104.15 13.12 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 125.769 1.628 . . . . 10.0 107.74 178.703 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 67.8 p -86.25 52.75 2.57 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 172.984 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 p -157.77 -49.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 C-N-CA 123.464 0.706 . . . . 10.0 109.325 -174.431 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 48.7 mm -66.58 155.46 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 108.704 -0.851 . . . . 10.0 108.704 169.845 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 41.3 m -153.13 137.35 16.51 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.232 -1.025 . . . . 10.0 108.232 174.455 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 34.5 mt -73.57 53.05 0.41 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.833 1.653 . . . . 10.0 111.459 177.28 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.6 m -87.16 -165.24 1.24 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 127.942 2.497 . . . . 10.0 109.896 179.277 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -106.2 -25.61 6.33 Favored Glycine 0 CA--C 1.527 0.82 0 C-N-CA 125.093 1.33 . . . . 10.0 111.725 176.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -70.15 -56.98 5.48 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 126.029 1.731 . . . . 10.0 108.31 -175.03 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -87.02 -39.32 15.76 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.176 -1.375 . . . . 10.0 109.174 178.126 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 31.81 79.76 0.02 OUTLIER 'General case' 0 C--O 1.237 0.402 0 C-N-CA 126.223 1.809 . . . . 10.0 113.079 178.969 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -76.79 55.5 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-O 122.183 0.992 . . . . 10.0 109.518 167.439 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -117.75 -49.08 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 127.969 2.508 . . . . 10.0 108.295 178.659 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.04 10.25 71.47 Favored Glycine 0 CA--C 1.532 1.142 0 CA-C-O 119.193 -0.782 . . . . 10.0 112.794 -176.76 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -88.29 162.24 16.72 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 125.484 1.514 . . . . 10.0 108.892 178.678 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -103.84 140.24 37.92 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.505 0.722 . . . . 10.0 109.898 169.568 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -92.3 140.18 29.87 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 106.169 -1.789 . . . . 10.0 106.169 166.748 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 60.4 t -125.94 135.5 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 N-CA-C 107.563 -1.273 . . . . 10.0 107.563 174.736 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 8.6 p -105.39 129.68 57.88 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 106.216 -1.772 . . . . 10.0 106.216 169.109 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 3.5 m170 -113.31 157.75 21.42 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 115.13 1.53 . . . . 10.0 115.13 -169.362 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 58.3 tt0 -39.36 -63.24 0.57 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 128.518 2.727 . . . . 10.0 110.288 171.082 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 57.6 mttt -118.86 173.24 6.99 Favored 'General case' 0 CA--C 1.513 -0.461 0 C-N-CA 123.492 0.717 . . . . 10.0 109.685 -174.687 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -92.41 148.78 21.84 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 179.309 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.504 ' HB2' ' CD2' ' B' ' 126' ' ' LEU . 0.9 OUTLIER -74.69 160.97 30.1 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.253 0.549 . . . . 10.0 111.675 -174.974 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.39 -28.53 61.14 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 114.624 -1.171 . . . . 10.0 110.152 174.855 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . 0.504 ' CD2' ' HB2' ' B' ' 124' ' ' ASP . 2.8 mm? 62.57 56.95 1.93 Allowed 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 125.585 1.554 . . . . 10.0 109.847 -173.437 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 81.54 -40.57 2.61 Favored Glycine 0 CA--C 1.525 0.687 0 CA-C-N 113.971 -1.468 . . . . 10.0 111.78 168.115 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -77.13 49.29 0.67 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.048 1.339 . . . . 10.0 111.173 177.35 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.72 -32.67 4.69 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 126.226 1.869 . . . . 10.0 110.427 173.614 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.58 42.76 99.31 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.673 -0.971 . . . . 10.0 110.673 -171.761 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -132.76 163.35 29.21 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 106.607 -1.627 . . . . 10.0 106.607 173.338 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.57 -52.31 64.17 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 108.46 -0.941 . . . . 10.0 108.46 171.625 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -53.7 -33.54 55.85 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.216 -0.897 . . . . 10.0 112.416 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 21.0 p -52.15 -41.81 62.86 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-N 119.497 1.044 . . . . 10.0 110.649 179.21 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -85.01 -3.48 58.8 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-O 118.517 -0.754 . . . . 10.0 112.914 -178.97 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.95 -60.74 1.81 Allowed 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 126.291 1.836 . . . . 10.0 112.501 -174.223 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -136.25 23.77 3.24 Favored 'General case' 0 CA--C 1.547 0.827 0 CA-C-N 119.488 1.04 . . . . 10.0 110.483 175.447 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.16 -98.03 0.62 Allowed Glycine 0 C--N 1.342 0.91 0 N-CA-C 108.764 -1.734 . . . . 10.0 108.764 -177.461 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -165.34 43.57 0.08 Allowed 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 107.872 -1.158 . . . . 10.0 107.872 170.481 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.61 -19.69 64.01 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.396 0.678 . . . . 10.0 112.565 -174.13 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.01 -147.42 30.47 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 109.94 -1.264 . . . . 10.0 109.94 172.344 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.8 t -68.61 126.81 30.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.559 0.695 . . . . 10.0 110.64 -170.023 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.06 78.32 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.845 0.858 . . . . 10.0 110.604 169.502 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 56.5 mt -52.49 -40.17 62.05 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.922 -0.486 . . . . 10.0 112.11 179.331 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -149.13 145.65 27.3 Favored 'General case' 0 C--O 1.233 0.236 0 O-C-N 121.628 -0.67 . . . . 10.0 111.676 -179.574 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 m -123.72 147.9 47.06 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 126.686 1.995 . . . . 10.0 108.034 -178.224 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.61 141.95 10.82 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 109.761 -1.336 . . . . 10.0 109.761 171.598 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 95.8 t -89.8 150.57 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 102.894 -3.002 . . . . 10.0 102.894 172.646 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 90.4 mt -72.16 -88.03 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-O 121.474 0.654 . . . . 10.0 110.26 -167.566 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 99.87 132.69 7.82 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 124.329 0.966 . . . . 10.0 111.529 177.69 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 73.6 mt -63.31 147.75 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 125.155 1.382 . . . . 10.0 107.75 174.307 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.73 -32.81 4.43 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 113.466 0.913 . . . . 10.0 113.466 174.121 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . 0.405 HE21 ' C ' ' B' ' 153' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.898 0 N-CA-C 108.042 -1.096 . . . . 10.0 108.042 178.66 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.444 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.5 t -166.22 -41.08 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 127.159 2.184 . . . . 10.0 112.938 178.572 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -119.37 137.29 53.83 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.244 -1.761 . . . . 10.0 106.244 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -136.73 145.21 44.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.578 HG12 ' HB2' ' A' ' 152' ' ' ALA . 0.2 OUTLIER -134.99 150.04 29.59 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.236 0 N-CA-C 107.003 -1.481 . . . . 10.0 107.003 174.476 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.694 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -127.03 129.19 47.56 Favored 'General case' 0 CA--C 1.512 -0.499 0 C-N-CA 126.938 2.095 . . . . 10.0 105.457 168.068 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.444 HG12 HG23 ' A' ' 17' ' ' ILE . 35.1 m -98.78 121.89 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 168.571 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -97.16 149.23 22.23 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 119.095 0.861 . . . . 10.0 109.046 177.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.47 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 13.1 tttt -159.29 160.35 35.08 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 108.432 -0.951 . . . . 10.0 108.432 169.685 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.35 -53.68 0.06 OUTLIER Glycine 0 C--N 1.332 0.35 0 N-CA-C 111.684 -0.566 . . . . 10.0 111.684 170.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -74.1 -45.86 46.44 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.36 -67.75 0.54 Allowed Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.031 -1.441 . . . . 10.0 110.568 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -57.11 -42.94 58.13 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.451 2.101 . . . . 10.0 110.41 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.2 t -63.94 97.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 106.522 -1.658 . . . . 10.0 106.522 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -116.28 118.6 33.21 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.129 -1.434 . . . . 10.0 107.129 169.415 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.426 ' HA2' ' CG2' ' A' ' 35' ' ' ILE . . . -99.17 152.95 19.68 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 109.931 -1.268 . . . . 10.0 109.931 174.814 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.444 HG23 HG12 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -156.47 83.69 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 -172.166 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.612 HD12 ' HA3' ' A' ' 33' ' ' GLY . 1.1 tp -85.35 157.21 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 C-N-CA 125.166 1.387 . . . . 10.0 111.016 176.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.438 ' HB2' ' CD1' ' A' ' 32' ' ' TRP . 5.1 m120 -139.1 99.5 3.78 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 127.567 2.347 . . . . 10.0 106.621 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 m-30 -99.07 102.85 14.68 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 105.194 -2.15 . . . . 10.0 105.194 174.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -117.67 132.48 56.48 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 120.409 -0.516 . . . . 10.0 111.591 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -104.36 107.99 19.18 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.701 -1.222 . . . . 10.0 107.701 172.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.2 pttp -54.53 -40.84 69.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 122.955 0.502 . . . . 10.0 110.65 174.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -146.37 172.92 12.78 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 104.937 -2.246 . . . . 10.0 104.937 168.399 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 86.8 p -69.12 -20.8 64.05 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 124.13 0.972 . . . . 10.0 109.576 174.3 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -93.89 -3.06 52.42 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.822 -0.627 . . . . 10.0 111.119 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.18 144.8 18.18 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 173.57 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -61.36 149.7 88.29 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 N-CA-C 106.902 -1.999 . . . . 10.0 106.902 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.7 t -79.0 120.96 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 N-CA-C 104.754 -2.313 . . . . 10.0 104.754 176.178 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.6 tttt -83.24 113.26 20.56 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 105.558 -2.015 . . . . 10.0 105.558 169.537 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.7 m -97.31 59.14 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 C-N-CA 125.774 1.63 . . . . 10.0 107.975 -170.257 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.438 ' CD1' ' HB2' ' A' ' 19' ' ' ASN . 14.8 p90 -84.7 171.85 12.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.167 -0.679 . . . . 10.0 109.167 -171.742 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.612 ' HA3' HD12 ' A' ' 18' ' ' ILE . . . 169.12 175.25 38.3 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 119.823 -1.179 . . . . 10.0 112.489 178.247 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.3 p -149.03 85.18 1.46 Allowed 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 121.066 0.46 . . . . 10.0 111.972 -169.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.707 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -76.83 147.19 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 107.664 -1.235 . . . . 10.0 107.664 174.446 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.99 156.14 46.77 Favored 'General case' 0 C--O 1.232 0.157 0 O-C-N 124.102 0.876 . . . . 10.0 110.015 167.586 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.22 2.86 48.16 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 124.043 0.83 . . . . 10.0 114.52 177.717 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.45 ' N ' HD12 ' A' ' 38' ' ' LEU . 5.3 mp -87.75 176.64 7.3 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.542 1.137 . . . . 10.0 108.778 -177.27 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -91.06 172.71 8.38 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 165.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -64.33 176.02 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.226 1.01 . . . . 10.0 110.889 -172.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.63 175.46 48.42 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 124.137 0.875 . . . . 10.0 111.581 167.272 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.443 HD22 ' HB3' ' A' ' 86' ' ' ASN . 4.7 mt -62.24 147.58 47.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.332 -0.511 . . . . 10.0 110.173 171.731 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -133.59 147.03 51.48 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.637 0.775 . . . . 10.0 110.678 176.332 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.621 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -36.14 112.89 0.14 Allowed Glycine 0 CA--C 1.526 0.736 0 CA-C-O 116.105 -2.497 . . . . 10.0 113.445 164.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -137.08 107.65 6.53 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 121.522 2.661 . . . . 10.0 111.916 170.001 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.452 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -148.17 -178.99 6.6 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 113.783 1.031 . . . . 10.0 113.783 -175.442 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.7 p -91.5 -47.59 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 127.554 2.342 . . . . 10.0 114.506 -169.022 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 57.1 161.96 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 125.498 1.519 . . . . 10.0 112.431 -169.064 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -78.01 -67.85 0.69 Allowed 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.944 -0.571 . . . . 10.0 109.862 -176.59 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -78.63 146.27 34.21 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 119.954 -0.699 . . . . 10.0 109.432 -171.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -75.74 -28.42 61.09 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 108.905 -1.678 . . . . 10.0 108.905 169.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.3 145.68 1.62 Allowed 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.746 1.26 . . . . 10.0 113.995 -175.826 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -135.8 16.06 3.33 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 113.679 -1.6 . . . . 10.0 110.453 -178.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.424 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -58.08 -36.45 72.86 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 119.181 0.901 . . . . 10.0 112.477 -169.745 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.07 -17.71 58.54 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 111.778 0.288 . . . . 10.0 111.778 178.764 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 97.85 84.18 1.74 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.107 -1.597 . . . . 10.0 109.107 -173.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 94.2 m 48.81 57.13 6.71 Favored 'General case' 0 N--CA 1.464 0.228 0 C-N-CA 124.305 1.042 . . . . 10.0 111.391 175.268 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -157.66 -54.61 0.07 Allowed 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.6 p -54.73 -30.26 55.73 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 124.121 0.968 . . . . 10.0 111.023 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.26 -38.47 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 127.977 2.511 . . . . 10.0 113.995 167.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.75 170.06 20.17 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -79.29 -167.13 0.47 Allowed 'Trans proline' 0 N--CA 1.439 -1.679 0 N-CA-C 106.377 -2.201 . . . . 10.0 106.377 166.416 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.452 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.4 m170 -83.32 59.07 4.82 Favored 'General case' 0 CA--C 1.537 0.457 0 O-C-N 120.561 -1.337 . . . . 10.0 110.097 -175.763 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -76.61 51.66 0.76 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.6 1.191 . . . . 10.0 112.587 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -56.94 149.72 42.7 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 125.601 1.561 . . . . 10.0 111.008 168.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -67.96 -48.04 1.56 Allowed 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.652 2.235 . . . . 10.0 111.401 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.92 54.09 0.98 Allowed 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.743 -0.598 . . . . 10.0 111.103 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.6 t -58.63 100.85 0.07 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.048 0.939 . . . . 10.0 110.111 -174.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtt-85 -113.78 -90.47 0.52 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 105.857 -1.905 . . . . 10.0 105.857 -177.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -149.42 144.59 26.46 Favored 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 109.334 -0.617 . . . . 10.0 109.334 168.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -51.5 119.78 4.48 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 119.714 -0.794 . . . . 10.0 109.929 168.376 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.0 -129.48 1.97 Allowed Glycine 0 N--CA 1.451 -0.359 0 N-CA-C 107.513 -2.235 . . . . 10.0 107.513 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.53 -143.29 5.84 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 118.182 0.991 . . . . 10.0 111.03 169.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -68.83 1.26 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 CA-C-N 120.075 1.937 . . . . 10.0 110.228 168.041 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 31.2 mmtp -93.9 -15.96 24.47 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-O 117.844 -1.074 . . . . 10.0 110.494 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -127.61 161.38 28.98 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 119.255 0.934 . . . . 10.0 109.5 -171.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -84.28 -28.91 26.83 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.549 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -78.94 -11.52 60.0 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 124.465 1.106 . . . . 10.0 112.059 -169.338 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.4 ptp180 -33.45 138.46 0.07 Allowed 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 126.415 1.886 . . . . 10.0 114.596 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 40.0 m-70 -69.5 177.17 3.03 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.562 -0.533 . . . . 10.0 109.562 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 p -72.85 39.32 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 125.525 1.53 . . . . 10.0 114.228 -172.062 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 48.03 0.04 OUTLIER Glycine 0 CA--C 1.524 0.655 0 O-C-N 120.597 -1.315 . . . . 10.0 111.526 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -85.0 102.81 13.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 104.92 -2.252 . . . . 10.0 104.92 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.7 mt -74.62 -32.19 62.23 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 107.073 -1.454 . . . . 10.0 107.073 169.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.82 -104.35 3.04 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 109.586 -1.406 . . . . 10.0 109.586 168.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.443 ' HB3' HD22 ' A' ' 42' ' ' LEU . 39.9 m-20 -126.4 105.79 9.02 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 126.743 2.017 . . . . 10.0 106.511 -167.312 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.63 134.67 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 123.411 0.684 . . . . 10.0 109.566 173.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.58 122.43 26.49 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.524 2.73 . . . . 10.0 112.809 -167.731 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.01 133.99 34.86 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.49 0.716 . . . . 10.0 109.255 169.15 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -60.76 171.53 1.15 Allowed 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.459 0.703 . . . . 10.0 110.001 168.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 pttt -47.54 -34.22 7.37 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.741 1.617 . . . . 10.0 111.311 171.2 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.8 -7.25 59.36 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 123.655 0.782 . . . . 10.0 111.166 -176.236 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.86 1.22 77.09 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.77 -0.932 . . . . 10.0 110.77 -175.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -77.19 103.87 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 -176.562 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.707 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -101.43 114.37 28.32 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 107.809 -1.182 . . . . 10.0 107.809 169.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -85.44 127.96 34.57 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 107.539 -1.282 . . . . 10.0 107.539 169.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 56.9 t -110.11 132.04 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 106.389 -1.708 . . . . 10.0 106.389 170.237 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -154.52 71.28 0.82 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.994 0.918 . . . . 10.0 108.955 170.385 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -114.62 159.01 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 105.603 -1.999 . . . . 10.0 105.603 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -130.95 142.44 50.35 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.854 0.861 . . . . 10.0 110.074 172.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -131.25 133.66 45.65 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.266 1.027 . . . . 10.0 109.683 -172.019 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 62.3 p -110.96 57.09 0.62 Allowed 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.373 1.869 . . . . 10.0 108.63 174.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 96.0 t -141.77 -61.73 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.14 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 -177.713 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.279 0.0 OUTLIER -60.68 170.94 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 N-CA-C 113.229 0.826 . . . . 10.0 113.229 174.83 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.6 m -145.5 111.97 5.8 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 121.498 -0.751 . . . . 10.0 109.286 175.331 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.2 tt -49.05 -44.89 42.11 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 126.09 1.756 . . . . 10.0 109.955 177.353 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -143.72 160.8 40.08 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 106.465 -1.679 . . . . 10.0 106.465 169.589 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.32 -95.96 0.2 Allowed Glycine 0 C--N 1.334 0.418 0 N-CA-C 109.349 -1.5 . . . . 10.0 109.349 -177.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -119.54 -51.69 2.28 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.265 1.826 . . . . 10.0 107.886 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -73.51 -37.31 65.72 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.681 -1.229 . . . . 10.0 107.681 -171.15 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 t 47.47 59.27 4.22 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.773 1.629 . . . . 10.0 108.078 169.663 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.2 pt -74.86 65.77 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 O-C-N 124.622 1.201 . . . . 10.0 110.121 -172.308 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.7 mm -110.64 -68.34 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 127.808 2.443 . . . . 10.0 108.33 -176.238 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.68 51.8 4.06 Favored Glycine 0 CA--C 1.531 1.092 0 O-C-N 121.221 -0.925 . . . . 10.0 112.086 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.4 ptm180 -112.36 162.16 15.85 Favored 'General case' 0 CA--C 1.53 0.173 0 C-N-CA 127.213 2.205 . . . . 10.0 107.168 176.056 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -109.61 104.72 13.79 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 118.565 0.621 . . . . 10.0 109.513 -179.116 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -64.47 131.02 45.94 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 106.695 -1.594 . . . . 10.0 106.695 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.2 t -122.5 132.59 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.522 ' CG1' ' HB3' ' A' ' 145' ' ' ALA . 1.7 p -94.56 122.35 45.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 105.829 -1.915 . . . . 10.0 105.829 166.154 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.621 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.9 m-70 -100.92 162.78 12.66 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.711 0.767 . . . . 10.0 112.631 174.002 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -64.58 -56.16 15.76 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.48 -0.782 . . . . 10.0 109.316 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -98.8 165.49 11.75 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 119.474 -0.89 . . . . 10.0 112.076 -168.191 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.7 147.15 53.04 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.801 -1.545 . . . . 10.0 107.792 169.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.432 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 6.7 m-20 -78.45 163.49 25.57 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.86 -0.793 . . . . 10.0 108.86 172.499 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.15 -10.38 59.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 113.736 -1.575 . . . . 10.0 110.781 168.545 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.5 mt 43.02 45.92 4.61 Favored 'General case' 0 C--N 1.343 0.32 0 C-N-CA 124.826 1.25 . . . . 10.0 109.856 -168.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.19 -21.83 44.01 Favored Glycine 0 CA--C 1.529 0.968 0 CA-C-N 113.713 -1.585 . . . . 10.0 113.728 170.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -77.48 0.78 21.45 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 115.543 1.682 . . . . 10.0 115.543 -165.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.89 -36.59 88.23 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.831 -0.907 . . . . 10.0 110.831 177.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.23 39.82 98.34 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 108.31 -1.916 . . . . 10.0 108.31 -169.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -128.39 164.46 22.64 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -54.79 -47.98 73.3 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.131 -0.941 . . . . 10.0 108.62 174.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -55.08 -39.61 69.47 Favored 'General case' 0 C--N 1.344 0.347 0 C-N-CA 123.283 0.633 . . . . 10.0 111.387 171.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.305 1.8 p -58.73 -36.06 73.7 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-O 118.138 -0.934 . . . . 10.0 111.733 -173.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.1 t -83.06 3.31 30.94 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.315 0.962 . . . . 10.0 112.541 178.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -118.6 -81.17 0.62 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.669 1.588 . . . . 10.0 110.511 -174.071 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.8 p -108.52 9.71 27.38 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 121.067 1.758 . . . . 10.0 111.43 175.129 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.1 -79.83 1.87 Allowed Glycine 0 C--N 1.342 0.891 0 O-C-N 120.708 -1.245 . . . . 10.0 110.0 176.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 178.71 36.87 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.684 1.993 . . . . 10.0 109.347 178.641 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.75 -14.29 61.96 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 123.832 0.853 . . . . 10.0 111.978 -169.721 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.02 -170.05 54.44 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 109.146 -1.582 . . . . 10.0 109.146 -169.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.4 m -55.06 165.0 0.74 Allowed 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 124.295 1.038 . . . . 10.0 112.667 -177.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -80.96 114.32 19.76 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 167.009 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.413 ' N ' ' CD2' ' A' ' 144' ' ' LEU . 1.1 mm? -84.5 -45.29 12.78 Favored 'General case' 0 C--N 1.333 -0.149 0 N-CA-C 108.396 -0.965 . . . . 10.0 108.396 -176.799 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.522 ' HB3' ' CG1' ' A' ' 119' ' ' VAL . . . -147.29 157.04 43.44 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 p -154.28 164.1 39.11 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 116.44 -0.345 . . . . 10.0 110.762 -176.034 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.86 150.8 22.43 Favored Glycine 0 C--N 1.336 0.531 0 C-N-CA 124.246 0.927 . . . . 10.0 110.916 -173.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.73 148.4 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 104.34 -2.467 . . . . 10.0 104.34 175.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.694 HG12 ' HB2' ' A' ' 6' ' ' ALA . 83.9 mt -76.66 -86.79 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 122.649 1.214 . . . . 10.0 109.169 -171.71 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.18 25.4 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.744 1.64 . . . . 10.0 115.257 170.225 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER 63.8 152.64 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 C-N-CA 124.283 1.033 . . . . 10.0 111.413 -173.335 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.578 ' HB2' HG12 ' A' ' 5' ' ' VAL . . . -113.36 -49.05 2.92 Favored 'General case' 0 CA--C 1.51 -0.592 0 O-C-N 120.456 -1.403 . . . . 10.0 110.316 169.819 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.433 -1.316 0 N-CA-C 106.047 -1.834 . . . . 10.0 106.047 -178.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.941 0 CA-C-O 118.01 -0.995 . . . . 10.0 108.886 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.5 t -95.15 -45.27 7.27 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.967 0.907 . . . . 10.0 111.952 -175.57 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.7 tttp -111.09 133.83 53.16 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.328 1.051 . . . . 10.0 109.011 176.133 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 166.82 23.73 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.12 1.368 . . . . 10.0 108.408 171.419 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.49 175.19 10.59 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 123.046 0.538 . . . . 10.0 109.767 175.408 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 6' ' ' ALA . . . . . 0.474 ' CB ' HD12 ' B' ' 117' ' ' LEU . . . -149.45 103.85 3.32 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 106.346 -1.724 . . . . 10.0 106.346 166.325 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 22.7 m -83.13 111.84 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 108.834 -0.802 . . . . 10.0 108.834 170.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.96 143.45 26.85 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.056 -1.09 . . . . 10.0 108.056 175.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 9' ' ' LYS . . . . . 0.402 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 46.5 tttt -163.73 163.76 24.01 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 108.097 -1.075 . . . . 10.0 108.097 170.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.61 -50.76 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 111.803 -0.519 . . . . 10.0 111.803 169.111 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.24 -47.16 20.9 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.106 -1.442 . . . . 10.0 107.106 -169.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.18 -61.1 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.919 -1.491 . . . . 10.0 111.785 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -62.74 -39.15 44.65 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 122.642 2.228 . . . . 10.0 110.89 170.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 68.1 t -77.6 115.03 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.553 1.141 . . . . 10.0 108.255 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -147.46 139.05 23.95 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 123.208 0.318 . . . . 10.0 110.605 166.5 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -107.66 153.53 16.79 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 110.15 -1.18 . . . . 10.0 110.15 169.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.424 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.0 mt -138.93 59.41 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 106.179 -1.786 . . . . 10.0 106.179 -176.325 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.1 mm -78.86 136.72 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-N 115.221 -0.9 . . . . 10.0 109.205 -169.295 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -108.71 117.13 33.39 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 127.329 2.252 . . . . 10.0 108.076 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.463 ' CE1' HD11 ' B' ' 117' ' ' LEU . 21.9 m-85 -101.15 111.18 23.32 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.256 -1.387 . . . . 10.0 107.256 175.383 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -118.03 133.26 56.08 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-O 121.358 0.599 . . . . 10.0 112.068 172.125 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -121.72 113.15 19.31 Favored 'General case' 0 N--CA 1.446 -0.646 0 N-CA-C 105.519 -2.03 . . . . 10.0 105.519 170.089 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 39.2 pttt . . . . . 0 CA--C 1.531 0.223 0 C-N-CA 124.3 1.04 . . . . 10.0 110.725 -175.114 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.038 0 N-CA-C 109.893 -1.283 . . . . 10.0 109.893 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -60.88 136.63 67.19 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 CA-C-N 119.735 1.767 . . . . 10.0 109.537 169.728 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.7 t -79.86 97.41 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 104.038 -2.579 . . . . 10.0 104.038 168.13 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . 0.266 71.2 tttt -82.84 112.63 19.83 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 172.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -95.48 101.45 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 C-N-CA 126.952 2.101 . . . . 10.0 105.855 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -121.23 160.94 22.82 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 112.325 0.491 . . . . 10.0 112.325 173.347 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.87 -152.48 24.14 Favored Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 170.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 40.1 t -155.72 151.49 27.41 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 120.211 -0.596 . . . . 10.0 110.321 177.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.439 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 0.9 OUTLIER -100.99 122.98 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 N-CA-C 107.433 -1.321 . . . . 10.0 107.433 165.836 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 20.9 ptmt -105.38 139.89 39.32 Favored 'General case' 0 N--CA 1.453 -0.296 0 O-C-N 123.891 0.744 . . . . 10.0 108.995 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.18 -5.52 15.48 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.417 1.008 . . . . 10.0 113.269 176.157 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -68.21 176.76 2.57 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 118.366 1.083 . . . . 10.0 111.09 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -108.54 161.03 15.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.28 -2.118 . . . . 10.0 105.28 165.081 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -52.03 160.43 0.73 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.636 1.174 . . . . 10.0 111.725 -169.707 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.84 -179.98 34.38 Favored Glycine 0 N--CA 1.447 -0.602 0 O-C-N 121.549 -0.719 . . . . 10.0 111.486 168.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.9 mp -68.62 149.01 49.64 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.735 1.614 . . . . 10.0 110.446 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -148.75 148.63 30.21 Favored 'General case' 0 C--O 1.233 0.198 0 C-N-CA 123.42 0.688 . . . . 10.0 112.432 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.684 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.4 121.29 0.2 Allowed Glycine 0 C--N 1.339 0.748 0 C-N-CA 127.941 2.686 . . . . 10.0 113.038 165.52 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -151.64 110.92 3.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 119.088 1.444 . . . . 10.0 110.044 167.602 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.521 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.2 OUTLIER -144.24 174.3 11.01 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-O 121.373 0.606 . . . . 10.0 111.888 178.131 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 47' ' ' VAL . . . . . 0.589 HG12 HH11 ' B' ' 115' ' ' ARG . 3.2 t -114.42 86.75 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 CA-C-N 112.599 -2.091 . . . . 10.0 107.981 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -67.66 149.99 49.31 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 124.876 1.27 . . . . 10.0 109.898 174.276 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -71.65 -59.6 2.67 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.136 -1.393 . . . . 10.0 110.412 -170.127 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -79.09 136.59 37.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 120.891 -0.323 . . . . 10.0 110.237 -171.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -54.75 -50.42 57.99 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 108.304 -1.918 . . . . 10.0 108.304 169.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -24.12 124.0 0.04 OUTLIER 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 128.069 2.547 . . . . 10.0 113.737 -173.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.92 11.99 2.65 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.63 -175.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.43 HG23 HG22 ' A' ' 17' ' ' ILE . 0.2 OUTLIER -51.41 -40.35 59.13 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 126.049 1.74 . . . . 10.0 111.389 -170.867 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.51 -20.73 46.51 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 124.703 1.201 . . . . 10.0 113.209 178.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.92 82.83 1.67 Allowed Glycine 0 CA--C 1.528 0.864 0 C-N-CA 124.67 1.129 . . . . 10.0 110.624 -178.254 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.9 m 53.22 21.1 2.09 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.382 1.473 . . . . 10.0 112.733 176.264 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -111.56 -42.29 3.89 Favored 'General case' 0 N--CA 1.437 -1.089 0 O-C-N 120.613 -1.304 . . . . 10.0 108.092 -168.782 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 70.3 m -92.14 -11.05 36.67 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 117.831 -1.08 . . . . 10.0 113.541 -168.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.35 2.01 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 128.597 2.759 . . . . 10.0 117.14 -174.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.2 119.24 2.25 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 109.482 -1.447 . . . . 10.0 109.482 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -76.52 64.12 7.31 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.483 2.789 . . . . 10.0 111.02 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER 69.53 53.62 0.41 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 128.752 2.821 . . . . 10.0 110.132 175.134 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -73.95 52.08 0.42 Allowed 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.306 1.042 . . . . 10.0 112.997 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -65.49 153.91 89.2 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 126.823 2.049 . . . . 10.0 111.62 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.8 -43.94 2.34 Favored 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 123.079 2.519 . . . . 10.0 111.955 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 67.3 mt -78.85 53.77 1.44 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.718 0.807 . . . . 10.0 110.363 -177.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.6 p -58.39 102.41 0.11 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.823 1.249 . . . . 10.0 110.337 -172.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 mtp85 -132.48 -87.88 0.44 Allowed 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 -171.003 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -145.13 155.61 43.41 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 121.689 0.757 . . . . 10.0 109.444 168.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -63.05 120.7 11.93 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 105.592 -2.003 . . . . 10.0 105.592 163.017 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -140.29 -136.44 3.34 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 107.602 -2.199 . . . . 10.0 107.602 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.36 -166.37 32.91 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.11 10.12 0.42 Allowed 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.607 1.538 . . . . 10.0 109.938 166.394 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 45.0 mmtt -97.28 -25.67 15.18 Favored 'General case' 0 N--CA 1.44 -0.927 0 C-N-CA 124.75 1.22 . . . . 10.0 107.818 173.22 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.415 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 23.1 m-20 -120.69 158.12 28.15 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.488 -1.671 . . . . 10.0 106.488 -169.404 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -80.66 -34.11 35.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.776 -1.194 . . . . 10.0 107.776 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -78.31 1.6 21.24 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 125.939 1.696 . . . . 10.0 113.311 -165.623 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -40.24 144.18 0.24 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.037 1.735 . . . . 10.0 111.694 174.628 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.4 m170 -61.52 -58.03 9.76 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-O 120.989 0.424 . . . . 10.0 110.425 -175.569 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.555 HG13 ' H ' ' B' ' 82' ' ' GLY . 5.2 p -174.2 -69.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.457 -0.104 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 172.197 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.555 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -104.7 62.22 0.37 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 109.478 -1.449 . . . . 10.0 109.478 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -100.5 95.52 6.78 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 103.878 -2.638 . . . . 10.0 103.878 168.047 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.54 -17.87 64.81 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.694 0.679 . . . . 10.0 111.454 -171.477 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 107.24 -103.08 1.92 Allowed Glycine 0 N--CA 1.438 -1.228 0 N-CA-C 106.08 -2.808 . . . . 10.0 106.08 -176.644 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -147.65 139.11 23.78 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 -178.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 28.5 m -106.82 134.45 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.243 0 N-CA-C 105.914 -1.884 . . . . 10.0 105.914 169.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.2 t -109.13 126.21 52.99 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.527 -0.546 . . . . 10.0 109.527 -173.332 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.42 132.09 37.05 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 122.9 0.48 . . . . 10.0 110.773 -176.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -60.69 168.86 2.05 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 166.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -50.3 -29.26 9.35 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 126.387 1.875 . . . . 10.0 111.414 173.796 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -78.06 -11.88 59.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.967 0.507 . . . . 10.0 110.701 -177.273 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.29 20.59 48.34 Favored Glycine 0 C--N 1.338 0.694 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -103.66 107.31 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.838 0 C-N-CA 127.13 2.172 . . . . 10.0 106.115 -178.651 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.401 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -104.95 125.29 50.79 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 108.883 -0.784 . . . . 10.0 108.883 171.616 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -79.37 135.0 36.59 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.612 1.165 . . . . 10.0 109.807 175.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.26 129.83 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 127.145 2.178 . . . . 10.0 106.436 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.2 p -158.69 57.4 0.44 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.277 0.944 . . . . 10.0 112.726 176.435 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.4 152.38 12.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.954 0.902 . . . . 10.0 109.554 -169.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -99.27 112.21 24.42 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 10.0 109.708 167.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -79.13 71.41 5.62 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 104.89 -2.263 . . . . 10.0 104.89 169.66 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.09 54.37 2.75 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 127.011 2.124 . . . . 10.0 105.416 -174.134 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.5 t -148.0 -51.99 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 125.817 1.647 . . . . 10.0 109.393 -168.084 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.435 ' C ' HD12 ' B' ' 104' ' ' ILE 0.322 1.2 pp -113.37 -178.8 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 126.203 1.801 . . . . 10.0 112.683 -172.445 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 61.2 m -146.94 151.84 37.67 Favored 'General case' 0 C--O 1.232 0.172 0 O-C-N 121.052 -1.03 . . . . 10.0 110.78 -178.183 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 81.9 mt -70.39 -33.85 71.88 Favored 'General case' 0 N--CA 1.458 -0.047 0 C-N-CA 124.271 1.028 . . . . 10.0 110.891 -177.65 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 108.866 -0.79 . . . . 10.0 108.866 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 39.8 t . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 113.581 0.956 . . . . 10.0 113.581 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -71.19 -7.1 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 113.789 1.033 . . . . 10.0 113.789 -174.416 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.7 mm -52.14 127.71 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 109.17 -0.678 . . . . 10.0 109.17 173.395 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.78 -25.5 11.74 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.383 -0.687 . . . . 10.0 111.383 -175.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 115' ' ' ARG . . . . . 0.589 HH11 HG12 ' B' ' 47' ' ' VAL . 13.3 mtp-105 -72.05 161.8 30.37 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 119.094 1.447 . . . . 10.0 109.526 -169.699 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -111.03 131.77 54.78 Favored 'General case' 0 CA--C 1.514 -0.412 0 C-N-CA 124.53 1.132 . . . . 10.0 109.652 -167.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.474 HD12 ' CB ' ' B' ' 6' ' ' ALA . 26.4 mt -104.64 140.38 38.11 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.674 -0.861 . . . . 10.0 108.674 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 85.5 t -134.41 125.81 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.884 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 -175.462 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.407 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 2.3 p -90.35 129.02 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.772 -1.566 . . . . 10.0 106.772 167.55 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.684 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.8 m170 -106.54 157.12 17.91 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.076 1.139 . . . . 10.0 114.076 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -50.63 -51.84 45.18 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.667 1.587 . . . . 10.0 110.906 176.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -115.67 167.87 10.53 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-N 118.581 0.628 . . . . 10.0 111.593 -169.506 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.13 150.17 49.52 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.744 -1.116 . . . . 10.0 110.022 177.138 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.521 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.6 OUTLIER -79.16 135.16 36.73 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.204 1.002 . . . . 10.0 110.903 171.9 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -79.39 -15.83 57.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 124.621 1.201 . . . . 10.0 110.541 167.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 80.0 mt 58.86 46.11 14.37 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.234 1.014 . . . . 10.0 111.667 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.34 -51.76 1.24 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 110.22 -1.152 . . . . 10.0 110.22 173.074 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.415 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -82.21 48.77 1.3 Allowed 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 117.583 0.691 . . . . 10.0 112.099 -175.7 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.13 -38.52 5.67 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 108.648 -1.781 . . . . 10.0 108.648 169.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.54 33.26 16.95 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 178.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -130.61 165.08 23.55 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 105.83 -1.915 . . . . 10.0 105.83 168.685 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -50.38 -43.9 54.64 Favored 'General case' 0 N--CA 1.425 -1.724 0 CA-C-O 121.863 0.84 . . . . 10.0 108.796 171.285 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -65.7 -35.36 80.54 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-O 117.903 -1.046 . . . . 10.0 112.929 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 44.0 p -54.49 -46.28 73.39 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 120.987 1.721 . . . . 10.0 110.037 171.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -78.47 -13.65 59.74 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 118.11 -0.948 . . . . 10.0 113.162 -174.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.1 ttmm -103.92 -50.85 3.29 Favored 'General case' 0 N--CA 1.443 -0.778 0 C-N-CA 126.518 1.927 . . . . 10.0 112.51 -174.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 19.3 p -137.21 8.41 2.93 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 119.683 1.128 . . . . 10.0 113.658 174.753 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 88.23 20.56 48.65 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-O 118.577 -1.124 . . . . 10.0 113.215 174.438 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 6.9 m120 56.09 17.35 2.64 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 119.108 1.454 . . . . 10.0 112.244 -176.37 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.43 -11.69 58.43 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.007 0.923 . . . . 10.0 112.128 -174.209 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.97 -160.46 48.41 Favored Glycine 0 N--CA 1.441 -0.973 0 N-CA-C 111.104 -0.798 . . . . 10.0 111.104 168.05 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.8 m -51.6 125.27 14.26 Favored 'General case' 0 N--CA 1.439 -1.015 0 C-N-CA 124.622 1.169 . . . . 10.0 113.31 -168.452 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.5 mtm-85 -72.01 75.69 0.92 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 125.412 1.485 . . . . 10.0 109.595 176.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 70.2 mt -43.73 -49.08 8.02 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.997 0.919 . . . . 10.0 112.26 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.407 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -153.99 153.62 32.29 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.796 -0.816 . . . . 10.0 108.796 -168.797 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.06 166.12 34.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.58 -0.282 . . . . 10.0 110.805 -174.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.63 163.29 30.73 Favored Glycine 0 CA--C 1.523 0.563 0 C-N-CA 125.096 1.331 . . . . 10.0 109.856 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 37.6 t -120.94 136.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 106.088 -1.819 . . . . 10.0 106.088 -173.49 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 64.2 mt -70.52 130.42 34.71 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-N 118.175 0.443 . . . . 10.0 110.617 -177.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.64 141.98 13.24 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 124.254 0.93 . . . . 10.0 110.794 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -71.26 151.9 8.73 Favored 'Isoleucine or valine' 0 C--N 1.342 0.278 0 CA-C-N 118.44 1.12 . . . . 10.0 111.587 -178.323 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.3 -33.59 2.13 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 124.768 1.227 . . . . 10.0 113.267 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.063 0 CA-C-O 116.856 -1.545 . . . . 10.0 107.424 171.145 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.601 0 CA-C-O 118.863 -0.589 . . . . 10.0 110.059 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.9 t 125.01 -23.95 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 1 C-N-CA 131.942 4.097 . . . . 10.0 108.523 -174.309 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp -131.0 132.31 44.91 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 126.071 1.748 . . . . 10.0 108.124 169.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.54 168.75 18.66 Favored 'General case' 0 N--CA 1.462 0.149 0 C-N-CA 124.747 1.219 . . . . 10.0 109.443 169.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.413 ' O ' HG23 ' A' ' 149' ' ' ILE . 2.2 m -127.65 179.24 3.84 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.357 0 C-N-CA 124.177 0.991 . . . . 10.0 110.766 -174.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.81 114.77 2.64 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 106.879 -1.526 . . . . 10.0 106.879 164.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -98.66 96.26 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 C-N-CA 124.018 0.927 . . . . 10.0 110.21 172.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 mp -84.57 142.67 29.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.416 1.086 . . . . 10.0 110.023 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -153.2 165.06 36.85 Favored 'General case' 0 C--N 1.338 0.074 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 169.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.48 -59.65 0.04 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.391 -0.368 . . . . 10.0 113.268 169.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.19 -42.92 62.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -170.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.25 -66.51 0.53 Allowed Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 113.728 -1.578 . . . . 10.0 109.708 176.331 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -58.33 -39.95 79.77 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.62 2.213 . . . . 10.0 110.808 171.04 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.47 HG13 HD11 ' A' ' 38' ' ' LEU . 54.9 t -63.73 110.63 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 N-CA-C 108.134 -1.062 . . . . 10.0 108.134 178.17 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.18 132.01 51.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 168.549 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.687 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -114.28 134.03 11.49 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 109.47 -1.452 . . . . 10.0 109.47 174.226 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.43 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.9 mt -136.19 97.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 -170.298 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -102.52 152.24 5.74 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 C-N-CA 124.464 1.106 . . . . 10.0 110.979 -176.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -126.53 113.94 17.45 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 126.294 1.838 . . . . 10.0 107.714 169.167 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -96.94 100.01 11.54 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 172.316 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -110.65 118.73 36.99 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 120.436 -0.506 . . . . 10.0 111.594 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -90.73 103.61 16.29 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 105.752 -1.944 . . . . 10.0 105.752 172.222 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 27.1 mmmt -48.31 -57.56 5.82 Favored 'General case' 0 C--O 1.228 -0.071 0 C-N-CA 125.433 1.493 . . . . 10.0 110.811 -177.237 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.14 178.96 6.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 104.258 -2.497 . . . . 10.0 104.258 169.464 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -66.32 -26.98 67.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.594 0.712 . . . . 10.0 109.733 175.231 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -77.89 -22.68 49.39 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.507 -0.77 . . . . 10.0 109.815 177.405 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.8 144.75 22.24 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 110.779 -0.928 . . . . 10.0 110.779 -173.269 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -63.54 153.9 72.06 Favored 'Trans proline' 0 N--CA 1.449 -1.122 0 N-CA-C 107.237 -1.871 . . . . 10.0 107.237 168.235 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.4 p -77.21 117.24 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 N-CA-C 106.174 -1.787 . . . . 10.0 106.174 173.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 48.4 tttp -85.11 108.8 17.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 106.361 -1.718 . . . . 10.0 106.361 169.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -88.41 93.84 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.112 -1.811 . . . . 10.0 106.112 171.608 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.3 p90 -106.27 165.77 11.0 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 108.901 -0.777 . . . . 10.0 108.901 168.471 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.84 163.77 30.54 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -140.23 94.51 2.76 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.209 -1.034 . . . . 10.0 108.209 -175.04 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.687 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.7 pt -77.83 172.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 118.754 -1.179 . . . . 10.0 109.157 171.31 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -155.58 151.47 27.6 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 167.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.69 -18.97 19.38 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-O 118.83 -0.984 . . . . 10.0 114.036 174.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.47 HD11 HG13 ' A' ' 14' ' ' VAL . 6.8 mp -71.86 179.24 3.26 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 119.34 1.57 . . . . 10.0 111.672 -178.779 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -95.53 164.89 12.6 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.085 -1.08 . . . . 10.0 108.085 167.121 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -60.08 171.85 0.91 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.934 1.294 . . . . 10.0 112.892 -169.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.67 -173.08 43.33 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 123.879 0.752 . . . . 10.0 112.462 167.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -70.49 142.62 51.88 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.151 1.381 . . . . 10.0 110.017 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -144.13 147.46 33.75 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 123.64 0.776 . . . . 10.0 112.62 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.616 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.05 128.19 0.25 Allowed Glycine 0 C--N 1.341 0.853 0 C-N-CA 127.378 2.418 . . . . 10.0 111.589 165.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -153.79 106.32 2.86 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 118.904 1.352 . . . . 10.0 109.984 167.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.456 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -150.34 174.04 13.31 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 122.303 1.049 . . . . 10.0 113.686 -179.754 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.16 144.57 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 111.694 -2.503 . . . . 10.0 107.873 169.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.7 m-70 -128.14 138.95 52.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.085 -1.45 . . . . 10.0 107.085 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -50.64 -62.79 1.39 Allowed 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.974 1.31 . . . . 10.0 112.143 -169.448 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -80.22 130.24 35.08 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 119.624 -0.83 . . . . 10.0 109.294 -175.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.57 -13.74 71.63 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.313 -1.115 . . . . 10.0 110.313 167.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -46.37 144.84 1.94 Allowed 'General case' 0 C--N 1.345 0.387 0 CA-C-O 122.45 1.119 . . . . 10.0 109.697 168.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.424 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -153.82 15.6 0.49 Allowed 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.309 -1.314 . . . . 10.0 111.724 177.523 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.511 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -58.77 -34.29 71.26 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.331 0.969 . . . . 10.0 110.671 -174.044 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.67 -20.9 45.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.846 1.258 . . . . 10.0 113.062 175.106 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.22 97.59 1.36 Allowed Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.392 -1.083 . . . . 10.0 110.392 -170.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.288 20.9 p 15.36 60.27 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 128.597 2.759 . . . . 10.0 116.685 176.055 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 40.9 m -132.18 -61.77 0.86 Allowed 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 128.021 2.528 . . . . 10.0 105.172 174.153 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.6 m -57.25 -24.75 56.81 Favored 'General case' 0 C--N 1.34 0.156 0 C-N-CA 125.606 1.563 . . . . 10.0 111.667 176.165 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -41.89 -30.3 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 126.208 1.803 . . . . 10.0 112.502 168.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.93 125.66 5.62 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 109.845 -1.302 . . . . 10.0 109.845 169.48 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.6 66.95 3.78 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 124.096 3.197 . . . . 10.0 112.28 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 64.16 46.27 3.7 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 129.438 3.095 . . . . 10.0 111.227 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -70.85 69.79 0.47 Allowed 'General case' 0 CA--C 1.531 0.244 0 CA-C-O 121.759 0.79 . . . . 10.0 111.402 178.861 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.8 p-10 -68.61 152.1 96.86 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.306 -0.871 . . . . 10.0 109.206 169.161 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.19 -58.68 0.4 Allowed 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 122.26 1.974 . . . . 10.0 111.571 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -76.09 72.27 2.9 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 121.439 -0.788 . . . . 10.0 110.447 174.206 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.4 m -40.34 112.65 0.29 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.016 0.926 . . . . 10.0 110.699 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.92 -96.27 0.47 Allowed 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 176.348 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -149.39 155.86 41.13 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.988 0.899 . . . . 10.0 109.271 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 63.5 t60 -60.81 115.2 3.49 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 118.364 -1.334 . . . . 10.0 109.096 166.076 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.69 -137.4 3.49 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 107.935 -2.066 . . . . 10.0 107.935 176.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.26 -162.3 23.36 Favored Glycine 0 N--CA 1.45 -0.368 0 N-CA-C 109.03 -1.628 . . . . 10.0 109.03 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -61.56 -4.8 4.76 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 CA-C-N 119.585 1.692 . . . . 10.0 111.271 168.119 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -89.29 -26.81 20.94 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.724 1.21 . . . . 10.0 110.401 175.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 34.0 t0 -102.61 157.48 16.91 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 107.227 -1.398 . . . . 10.0 107.227 -178.208 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -80.6 -30.25 36.86 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.048 -1.093 . . . . 10.0 108.048 167.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -91.05 6.65 44.03 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.07 1.348 . . . . 10.0 113.419 -168.492 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -42.33 140.35 1.21 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.145 0.978 . . . . 10.0 110.835 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -60.27 -65.09 0.74 Allowed 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.852 0.835 . . . . 10.0 110.453 -171.323 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.714 HG13 ' H ' ' A' ' 82' ' ' GLY . 7.7 p -160.48 -87.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.336 -2.098 . . . . 10.0 105.336 171.633 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.714 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -88.38 59.95 4.06 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.311 -1.116 . . . . 10.0 110.311 178.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -96.15 91.53 5.97 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 104.916 -2.253 . . . . 10.0 104.916 168.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -66.88 -32.8 74.3 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 108.704 -0.85 . . . . 10.0 108.704 -175.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.45 -85.66 0.38 Allowed Glycine 0 N--CA 1.439 -1.13 0 N-CA-C 108.277 -1.929 . . . . 10.0 108.277 168.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 -150.76 135.78 17.56 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.161 -1.422 . . . . 10.0 107.161 -178.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -106.93 133.11 52.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 169.508 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -87.57 131.76 34.29 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 108.208 -1.034 . . . . 10.0 108.208 176.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -107.11 135.9 47.86 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.029 0.932 . . . . 10.0 109.012 173.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -59.63 172.09 0.75 Allowed 'General case' 0 C--O 1.232 0.135 0 O-C-N 124.243 0.965 . . . . 10.0 109.912 167.239 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -47.39 -35.87 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 125.732 1.613 . . . . 10.0 110.387 170.363 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -79.69 -5.95 56.21 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.634 1.173 . . . . 10.0 110.723 -173.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 3.71 89.07 Favored Glycine 0 C--N 1.338 0.684 0 N-CA-C 111.101 -0.799 . . . . 10.0 111.101 -176.704 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.6 t -79.66 107.83 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 N-CA-C 106.465 -1.68 . . . . 10.0 106.465 179.05 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.453 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -105.39 120.93 42.83 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 108.829 -0.804 . . . . 10.0 108.829 169.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -79.81 114.8 19.0 Favored 'General case' 0 N--CA 1.434 -1.27 0 C-N-CA 125.849 1.659 . . . . 10.0 109.442 170.265 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.0 t -101.46 133.76 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 105.417 -2.068 . . . . 10.0 105.417 169.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 7.0 m -158.05 58.85 0.47 Allowed 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 118.969 0.804 . . . . 10.0 110.878 176.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.16 153.61 6.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 C-N-CA 124.001 0.92 . . . . 10.0 108.581 -174.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -123.08 136.27 54.74 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.395 1.478 . . . . 10.0 109.409 172.07 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -143.75 153.22 42.2 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.7 p -107.95 -26.47 10.69 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 127.148 2.179 . . . . 10.0 111.914 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.2 p -77.91 -45.15 28.08 Favored 'Isoleucine or valine' 0 C--N 1.342 0.27 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -73.72 134.46 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 105.09 -2.189 . . . . 10.0 105.09 165.779 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -166.28 158.48 14.07 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 125.422 1.489 . . . . 10.0 108.117 -177.347 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.1 mt -60.59 -50.77 72.18 Favored 'General case' 0 N--CA 1.457 -0.08 0 CA-C-N 116.152 -0.477 . . . . 10.0 110.825 -171.584 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -120.1 -165.58 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.592 1.157 . . . . 10.0 108.28 172.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 97.77 62.65 0.89 Allowed Glycine 0 CA--C 1.524 0.608 0 C-N-CA 124.394 0.997 . . . . 10.0 111.198 169.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 t70 71.07 -57.54 0.6 Allowed 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 129.469 3.108 . . . . 10.0 109.334 -178.365 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -74.33 -39.96 62.5 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 -169.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.2 t 39.84 85.05 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 126.111 1.764 . . . . 10.0 113.012 167.634 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 35.7 pt -58.69 -22.7 21.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -177.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.5 mm -47.26 131.11 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 O-C-N 121.799 -0.563 . . . . 10.0 110.365 174.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.64 1.6 82.92 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 118.408 -1.218 . . . . 10.0 113.987 175.001 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mmt-85 -81.34 165.76 21.07 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.8 1.3 . . . . 10.0 111.348 171.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -100.7 130.51 46.75 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 105.309 -2.108 . . . . 10.0 105.309 169.151 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.7 mp -108.66 149.58 28.76 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.416 -0.957 . . . . 10.0 108.416 170.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 96.7 t -135.98 137.09 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.945 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 -173.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.6 p -108.19 138.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 168.054 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.616 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.6 m170 -116.22 161.16 19.4 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 115.641 1.719 . . . . 10.0 115.641 -170.308 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -43.33 -55.36 4.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 128.621 2.768 . . . . 10.0 110.046 177.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -124.21 174.41 7.7 Favored 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 125.065 1.346 . . . . 10.0 111.34 -169.492 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.25 148.86 45.06 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.667 1.187 . . . . 10.0 110.401 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.456 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.2 m-20 -78.59 147.33 33.74 Favored 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 124.145 0.978 . . . . 10.0 111.702 174.186 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -75.44 -30.23 59.93 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 114.372 -1.285 . . . . 10.0 109.675 169.706 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 29.9 mt 57.45 52.67 8.28 Favored 'General case' 0 C--N 1.339 0.13 0 N-CA-C 107.688 -1.227 . . . . 10.0 107.688 -167.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.42 -24.7 12.97 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-N 113.521 -1.672 . . . . 10.0 112.99 173.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -75.11 6.5 4.18 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 114.543 1.312 . . . . 10.0 114.543 -167.614 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.83 -16.6 79.27 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.057 0.836 . . . . 10.0 112.097 171.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.82 43.77 48.28 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 118.082 0.941 . . . . 10.0 111.801 -176.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -130.88 163.4 27.52 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 106.943 -1.503 . . . . 10.0 106.943 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -54.07 -49.54 68.8 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.16 -0.927 . . . . 10.0 108.502 169.45 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -56.95 -44.21 82.32 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 122.775 0.43 . . . . 10.0 110.519 173.606 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.3 p -56.3 -43.74 79.21 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 120.635 -1.29 . . . . 10.0 110.576 -178.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -82.24 2.12 33.37 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 118.848 -0.596 . . . . 10.0 112.071 -178.123 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.5 -75.84 0.61 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.328 1.851 . . . . 10.0 110.196 176.567 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 6.6 p -120.96 27.06 8.69 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 120.786 1.63 . . . . 10.0 113.371 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.2 27.99 70.01 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 121.811 -0.556 . . . . 10.0 113.771 167.127 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 47.65 30.06 1.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.816 0.808 . . . . 10.0 112.177 -173.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.18 -5.33 13.2 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.723 -0.61 . . . . 10.0 110.855 175.331 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.59 -156.06 36.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 109.806 -1.318 . . . . 10.0 109.806 168.648 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.3 m -59.86 131.95 52.45 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 109.497 -0.557 . . . . 10.0 109.497 -171.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.46 68.01 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 168.1 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.77 -27.45 67.99 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 -169.153 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.35 145.83 24.08 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-O 121.475 0.655 . . . . 10.0 109.278 -178.74 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 15.8 p -162.46 163.65 27.48 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-N 115.849 -0.614 . . . . 10.0 109.641 -167.484 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 179.6 36.23 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 110.588 -1.005 . . . . 10.0 110.588 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.88 148.12 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.675 0 N-CA-C 103.72 -2.696 . . . . 10.0 103.72 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.413 HG23 ' O ' ' A' ' 5' ' ' VAL . 3.9 mt -65.81 -87.7 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 C-N-CA 123.222 0.609 . . . . 10.0 111.203 -168.294 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.57 135.29 7.05 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.426 -0.669 . . . . 10.0 111.426 -178.033 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 62.3 mt -76.37 150.44 6.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 C-N-CA 125.132 1.373 . . . . 10.0 108.166 -176.156 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.14 -45.44 3.29 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 120.974 1.716 . . . . 10.0 112.006 169.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.3 tp60 . . . . . 0 C--O 1.252 1.219 0 C-N-CA 124.14 0.976 . . . . 10.0 109.772 -174.526 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.673 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.4 t -166.38 -46.88 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 124.486 1.114 . . . . 10.0 108.788 173.209 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -123.95 136.53 54.38 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.232 1.413 . . . . 10.0 109.165 -175.06 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 167.43 22.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 125.942 1.697 . . . . 10.0 107.803 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.49 168.88 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 118.488 0.585 . . . . 10.0 112.314 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.99 104.28 4.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 106.899 -1.519 . . . . 10.0 106.899 167.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.424 HG21 ' HB3' ' A' ' 53' ' ' ASN . 10.9 m -92.09 76.38 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 123.476 0.71 . . . . 10.0 109.212 175.284 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.5 mp -74.69 145.82 42.81 Favored 'General case' 0 N--CA 1.449 -0.521 0 O-C-N 121.299 -0.876 . . . . 10.0 109.263 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 161.4 19.77 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 107.992 -1.114 . . . . 10.0 107.992 -175.263 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.56 -58.37 0.04 OUTLIER Glycine 0 C--N 1.329 0.175 0 CA-C-N 115.628 -0.714 . . . . 10.0 111.579 169.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.21 -46.49 33.62 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 106.645 -1.613 . . . . 10.0 106.645 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.82 -68.37 0.51 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 113.383 -1.735 . . . . 10.0 110.729 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -59.89 -35.95 92.08 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.957 2.438 . . . . 10.0 111.424 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.408 HG13 HD11 ' B' ' 38' ' ' LEU . 96.5 t -68.71 99.74 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.141 0 N-CA-C 107.063 -1.458 . . . . 10.0 107.063 176.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -121.95 111.9 17.63 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.483 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -94.37 138.71 14.16 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 109.133 -1.587 . . . . 10.0 109.133 169.05 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.511 ' CG2' HG23 ' A' ' 54' ' ' THR . 6.5 mt -139.31 78.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 106.681 -1.6 . . . . 10.0 106.681 -177.022 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -102.59 148.88 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.143 -0.935 . . . . 10.0 109.59 -175.262 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -118.37 114.04 22.32 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.831 1.652 . . . . 10.0 108.223 171.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -86.09 99.28 11.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 175.083 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.37 153.3 21.85 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 123.964 0.79 . . . . 10.0 109.883 -178.145 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -158.84 86.9 0.85 Allowed 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.254 -0.647 . . . . 10.0 109.254 -173.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 2.0 ttpm? . . . . . 0 N--CA 1.424 -1.755 0 CA-C-O 122.257 1.027 . . . . 10.0 109.74 -174.506 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.126 0 CA-C-O 117.838 -1.534 . . . . 10.0 114.723 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -67.0 151.44 82.03 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.371 2.048 . . . . 10.0 108.34 169.25 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.49 92.38 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 105.842 -1.91 . . . . 10.0 105.842 169.421 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttp -83.76 98.43 9.69 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -97.58 99.69 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.95 0 C-N-CA 125.628 1.571 . . . . 10.0 106.819 -174.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 13.3 p90 -117.16 165.54 13.29 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.528 0.68 . . . . 10.0 112.605 171.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.76 -150.04 21.97 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 106.922 -2.471 . . . . 10.0 106.922 169.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 28.6 p -156.04 166.41 33.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 119.352 -0.939 . . . . 10.0 110.931 173.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.483 HG22 ' HA2' ' B' ' 16' ' ' GLY . 4.7 pt -106.43 174.75 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.843 -1.071 . . . . 10.0 110.491 167.316 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt -140.4 152.15 45.51 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.552 2.341 . . . . 10.0 105.893 169.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.12 -25.09 14.66 Favored Glycine 0 C--N 1.338 0.653 0 N-CA-C 116.007 1.163 . . . . 10.0 116.007 167.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.528 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.3 mp -78.47 177.6 8.4 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 119.207 1.504 . . . . 10.0 110.945 -169.192 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.0 t -93.1 165.1 13.0 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 108.973 -0.751 . . . . 10.0 108.973 168.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.99 160.04 6.45 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.576 1.15 . . . . 10.0 111.45 -172.106 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.87 -170.24 29.06 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.626 -0.59 . . . . 10.0 111.626 169.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.77 148.6 42.39 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.405 1.082 . . . . 10.0 111.783 -172.145 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -144.42 141.74 29.84 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.215 1.006 . . . . 10.0 113.42 -177.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.512 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -38.2 126.48 1.6 Allowed Glycine 0 C--N 1.342 0.903 0 C-N-CA 126.803 2.144 . . . . 10.0 110.511 165.339 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -151.36 111.43 4.1 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.887 1.343 . . . . 10.0 108.295 168.083 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -153.76 168.33 26.66 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.978 0.894 . . . . 10.0 112.459 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 18.7 m -88.78 149.34 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 111.869 -2.423 . . . . 10.0 105.812 166.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -124.83 169.72 11.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.691 0.757 . . . . 10.0 109.309 169.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 49' ' ' GLU . . . . . 0.51 ' CG ' ' H ' ' B' ' 50' ' ' PHE . 0.8 OUTLIER 4.0 -113.68 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 130.503 3.521 . . . . 10.0 117.624 167.727 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 50' ' ' PHE . . . . . 0.51 ' H ' ' CG ' ' B' ' 49' ' ' GLU . 51.9 m-85 -95.29 -141.88 0.26 Allowed 'General case' 0 N--CA 1.434 -1.231 0 C-N-CA 127.96 2.504 . . . . 10.0 106.024 172.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.43 31.5 4.82 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 125.171 1.367 . . . . 10.0 110.875 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -70.5 158.55 35.88 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 119.685 1.742 . . . . 10.0 108.273 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -163.45 12.07 0.06 Allowed 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 126.288 1.835 . . . . 10.0 111.899 173.085 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.43 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -60.48 -31.63 70.65 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 119.904 1.229 . . . . 10.0 110.954 -173.048 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.03 -18.37 58.18 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.26 1.024 . . . . 10.0 111.887 176.142 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.83 -171.58 13.78 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 107.539 -2.225 . . . . 10.0 107.539 -169.34 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 84.7 m -70.43 70.04 0.41 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.826 -1.176 . . . . 10.0 107.826 169.556 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.14 -51.05 0.08 Allowed 'General case' 0 N--CA 1.448 -0.544 0 O-C-N 120.706 -1.246 . . . . 10.0 110.911 -169.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 10.7 t -98.96 -0.15 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.711 0.804 . . . . 10.0 110.076 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -70.46 60.02 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.821 1.648 . . . . 10.0 109.461 171.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 61' ' ' GLY . . . . . 0.463 ' HA3' ' HG2' ' B' ' 49' ' ' GLU . . . 80.24 130.42 0.89 Allowed Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 124.612 1.101 . . . . 10.0 115.227 164.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -87.84 42.49 0.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 123.279 2.653 . . . . 10.0 108.168 165.74 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' HG22 ' B' ' 137' ' ' THR . 15.1 m170 65.47 54.28 1.16 Allowed 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.993 2.517 . . . . 10.0 110.964 -172.237 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -69.37 70.27 0.26 Allowed 'General case' 0 N--CA 1.47 0.554 0 O-C-N 121.794 -0.566 . . . . 10.0 110.638 171.033 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -80.01 152.13 73.91 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.521 -0.737 . . . . 10.0 110.333 175.691 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.05 -48.57 1.29 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.601 2.201 . . . . 10.0 111.298 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 86.0 mt -77.5 59.49 1.92 Allowed 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -56.24 99.51 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 124.761 1.224 . . . . 10.0 110.172 -176.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.48 -89.89 0.53 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 105.517 -2.031 . . . . 10.0 105.517 -177.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -142.87 153.59 43.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.091 0.948 . . . . 10.0 110.286 168.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -64.85 123.24 18.88 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 165.015 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.41 -144.2 4.08 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 107.857 -2.097 . . . . 10.0 107.857 179.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.05 -153.37 10.42 Favored Glycine 0 N--CA 1.452 -0.296 0 N-CA-C 108.565 -1.814 . . . . 10.0 108.565 170.615 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -69.12 15.26 0.19 Allowed 'Trans proline' 0 CA--C 1.54 0.802 0 CA-C-N 119.519 1.66 . . . . 10.0 111.404 169.173 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 72.3 mttt -119.49 0.46 11.05 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.177 1.391 . . . . 10.0 110.791 169.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.4 t0 -118.03 156.48 28.51 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.264 -1.384 . . . . 10.0 107.264 172.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -79.3 -31.61 43.33 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 171.06 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -118.59 36.94 4.22 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 123.861 0.864 . . . . 10.0 112.466 -165.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.74 148.96 3.61 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 125.257 1.423 . . . . 10.0 110.66 169.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 26.0 m170 -55.26 -62.35 1.73 Allowed 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.161 0.584 . . . . 10.0 112.192 -171.274 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -172.35 -60.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.181 0 C-N-CA 124.32 1.048 . . . . 10.0 108.332 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.71 51.98 0.82 Allowed Glycine 0 C--N 1.337 0.613 0 N-CA-C 109.319 -1.513 . . . . 10.0 109.319 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -84.77 92.28 8.19 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.447 -2.797 . . . . 10.0 103.447 167.447 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.5 mt -63.06 -30.4 71.57 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 -173.291 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.55 -89.8 0.48 Allowed Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.607 -1.397 . . . . 10.0 109.607 166.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -151.79 100.73 2.7 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.332 -0.988 . . . . 10.0 108.332 -171.057 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -86.37 141.86 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 172.052 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -99.47 129.87 45.69 Favored 'General case' 0 C--O 1.224 -0.257 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.56 134.81 40.99 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.916 -0.772 . . . . 10.0 108.916 172.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -59.84 169.59 1.39 Allowed 'General case' 0 N--CA 1.451 -0.382 0 O-C-N 124.526 1.141 . . . . 10.0 110.045 167.434 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 61.8 pttt -50.41 -33.19 19.94 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 124.229 1.011 . . . . 10.0 110.876 169.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -78.53 -1.25 33.0 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 122.87 0.468 . . . . 10.0 111.409 -178.163 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.36 17.86 75.2 Favored Glycine 0 C--N 1.34 0.781 0 O-C-N 120.746 -1.221 . . . . 10.0 110.49 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.69 103.61 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 C-N-CA 126.439 1.896 . . . . 10.0 106.789 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.441 ' H ' HG12 ' B' ' 35' ' ' ILE . . . -98.35 121.64 40.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 167.645 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.46 117.79 20.74 Favored 'General case' 0 N--CA 1.436 -1.161 0 C-N-CA 126.579 1.951 . . . . 10.0 108.665 170.555 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 56.6 t -101.73 134.57 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 107.185 -1.413 . . . . 10.0 107.185 175.026 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -158.62 57.11 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.409 0.684 . . . . 10.0 111.263 175.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.71 158.2 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -172.182 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -130.73 90.72 2.95 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 126.762 2.025 . . . . 10.0 108.925 -176.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -84.46 83.78 7.88 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 63.1 p -78.73 60.31 2.74 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 169.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.3 t -143.22 -51.16 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 125.174 1.39 . . . . 10.0 107.704 -168.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.42 HD13 ' H ' ' B' ' 104' ' ' ILE 0.326 0.0 OUTLIER -118.91 165.12 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 113.656 0.984 . . . . 10.0 113.656 175.91 . . . . . . . . 4 4 . 1 . 002 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.0 p -108.17 132.1 53.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.641 1.176 . . . . 10.0 109.646 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -69.83 -41.16 75.31 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.3 t . . . . . 0 N--CA 1.447 -0.623 0 N-CA-C 105.985 -1.857 . . . . 10.0 105.985 174.906 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.9 t . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 121.434 0.635 . . . . 10.0 112.25 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.9 pt -75.01 44.38 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 C-N-CA 123.752 0.821 . . . . 10.0 111.841 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 17.7 mm -78.25 -68.52 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 C-N-CA 125.685 1.594 . . . . 10.0 109.981 -174.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.42 52.31 3.05 Favored Glycine 0 CA--C 1.533 1.198 0 O-C-N 120.8 -1.187 . . . . 10.0 112.302 176.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.1 mmt85 -121.09 153.55 37.3 Favored 'General case' 0 C--O 1.233 0.192 0 C-N-CA 126.147 1.779 . . . . 10.0 110.614 -178.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 53.9 m -97.75 121.26 39.44 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.121 0.968 . . . . 10.0 109.587 177.538 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -98.24 144.33 27.79 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 125.916 1.686 . . . . 10.0 107.743 169.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 53.1 t -128.8 140.67 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 108.409 -0.96 . . . . 10.0 108.409 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 p -113.39 128.75 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 C-N-CA 125.666 1.586 . . . . 10.0 106.932 169.82 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.512 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.4 m170 -114.09 163.74 14.78 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 116.082 1.882 . . . . 10.0 116.082 -169.163 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -45.02 -59.1 2.76 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.602 2.761 . . . . 10.0 112.628 174.263 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -122.81 176.29 6.06 Favored 'General case' 0 CA--C 1.522 -0.134 0 C-N-CA 124.366 1.067 . . . . 10.0 113.317 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.58 155.59 38.78 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.827 1.651 . . . . 10.0 111.094 176.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.5 146.86 24.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 124.8 1.24 . . . . 10.0 110.795 172.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -74.9 -32.88 61.94 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 114.849 -1.068 . . . . 10.0 109.321 170.211 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 52.2 mt 62.94 65.34 0.81 Allowed 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 123.265 1.507 . . . . 10.0 108.237 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.77 -51.11 4.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 112.945 -1.934 . . . . 10.0 111.726 170.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 38.3 mtmt -80.32 53.21 1.74 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.371 1.468 . . . . 10.0 111.591 -169.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.94 -3.71 23.11 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.208 1.861 . . . . 10.0 112.462 177.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.54 42.55 27.16 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.244 0.926 . . . . 10.0 112.797 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -135.98 158.32 44.69 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 107.577 -1.268 . . . . 10.0 107.577 176.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -54.15 -42.94 70.14 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 169.059 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -58.91 -44.39 91.26 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.983 -0.553 . . . . 10.0 112.175 170.597 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 10.1 p -56.19 -43.25 78.26 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 119.581 1.082 . . . . 10.0 111.22 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -71.24 -7.85 49.65 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-O 118.083 -0.961 . . . . 10.0 113.091 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -119.7 -65.65 1.14 Allowed 'General case' 0 N--CA 1.439 -1.008 0 C-N-CA 127.677 2.391 . . . . 10.0 113.141 -168.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.499 HG22 ' CD2' ' B' ' 63' ' ' HIS . 1.5 p -130.16 26.2 5.18 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.274 1.397 . . . . 10.0 109.908 177.198 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 68.32 -104.45 1.2 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 107.375 -2.29 . . . . 10.0 107.375 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -154.93 39.06 0.42 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 107.551 -1.278 . . . . 10.0 107.551 170.216 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.62 -12.48 23.38 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 123.527 0.731 . . . . 10.0 112.512 -171.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.96 -167.55 51.19 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 109.734 -1.346 . . . . 10.0 109.734 175.258 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 53.1 m -56.03 133.41 51.81 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 121.602 0.715 . . . . 10.0 111.729 -169.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 19.7 mtt180 -65.15 75.32 0.05 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.457 -0.792 . . . . 10.0 109.177 168.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.9 mt -47.56 -48.73 27.69 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.96 0.409 . . . . 10.0 109.986 177.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.15 152.54 37.46 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.414 0.626 . . . . 10.0 110.566 -172.133 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -148.42 167.71 24.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.595 -0.73 . . . . 10.0 109.308 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.0 148.66 19.75 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 109.592 -1.403 . . . . 10.0 109.592 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 75.1 t -101.35 124.26 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 N-CA-C 104.365 -2.457 . . . . 10.0 104.365 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 21.0 mt -67.75 157.74 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 CA-C-N 118.969 0.804 . . . . 10.0 110.454 -178.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -159.97 147.24 14.07 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.594 1.568 . . . . 10.0 110.423 -170.119 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 62.0 mt -69.15 135.41 28.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 C-N-CA 126.476 1.91 . . . . 10.0 110.452 -169.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -125.8 -48.4 1.64 Allowed 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.624 -0.673 . . . . 10.0 112.199 -178.22 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.254 1.294 0 C-N-CA 125.437 1.495 . . . . 10.0 110.517 -168.219 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 116.164 -1.874 . . . . 10.0 106.571 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -96.55 -33.77 11.69 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.773 1.169 . . . . 10.0 112.79 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -137.54 133.32 34.38 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 123.958 0.903 . . . . 10.0 111.615 -177.327 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.92 162.31 28.88 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.185 1.394 . . . . 10.0 109.457 173.243 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.2 t -124.31 154.89 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 125.784 1.634 . . . . 10.0 108.272 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.46 111.9 6.35 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 168.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.9 m -101.26 113.47 37.51 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.28 0.632 . . . . 10.0 110.945 -178.75 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -90.05 139.24 30.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 121.743 -0.598 . . . . 10.0 111.945 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -151.84 159.95 43.71 Favored 'General case' 0 N--CA 1.455 -0.197 0 N-CA-C 107.25 -1.389 . . . . 10.0 107.25 167.388 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.73 -56.68 0.06 OUTLIER Glycine 0 N--CA 1.461 0.351 0 C-N-CA 120.247 -0.978 . . . . 10.0 112.389 169.124 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -71.42 -44.5 64.76 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -178.376 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.3 -70.6 0.43 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.328 -1.305 . . . . 10.0 110.37 169.113 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -58.28 -33.12 97.35 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 123.528 2.819 . . . . 10.0 111.554 173.125 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.61 94.24 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 173.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -114.09 126.62 55.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.508 -1.293 . . . . 10.0 107.508 175.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -121.17 145.23 17.08 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 124.294 0.949 . . . . 10.0 111.045 -177.222 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.429 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 4.9 mt -146.42 84.22 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 106.555 -1.646 . . . . 10.0 106.555 -170.397 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.8 mm -95.46 142.74 13.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 C-N-CA 124.439 1.096 . . . . 10.0 108.571 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -124.3 127.63 47.93 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 125.957 1.703 . . . . 10.0 108.559 172.297 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.432 ' CD2' HG12 ' A' ' 31' ' ' VAL . 24.9 m-85 -106.43 112.92 26.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.424 -1.324 . . . . 10.0 107.424 176.6 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -105.26 127.42 52.93 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.601 0.637 . . . . 10.0 111.195 168.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -114.93 88.68 2.92 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.526 1.531 . . . . 10.0 107.288 169.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.5 pttp -59.58 -44.0 93.47 Favored 'General case' 0 N--CA 1.457 -0.09 0 C-N-CA 124.199 1.0 . . . . 10.0 110.279 -171.15 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -133.1 161.58 34.01 Favored 'General case' 0 N--CA 1.425 -1.704 0 N-CA-C 104.301 -2.481 . . . . 10.0 104.301 174.798 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.9 p -66.18 -18.96 65.68 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 121.505 0.669 . . . . 10.0 109.691 169.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 29.9 m120 -79.1 -21.52 46.56 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 124.828 1.251 . . . . 10.0 110.708 177.572 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.48 127.52 8.03 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 109.802 -1.319 . . . . 10.0 109.802 -174.248 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.63 131.39 29.36 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 N-CA-C 106.93 -1.988 . . . . 10.0 106.93 169.48 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.3 t -78.47 101.95 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -169.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -69.7 106.82 3.21 Favored 'General case' 0 N--CA 1.446 -0.667 0 N-CA-C 107.828 -1.175 . . . . 10.0 107.828 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.432 HG12 ' CD2' ' A' ' 20' ' ' PHE . 10.7 m -82.8 111.73 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 N-CA-C 106.265 -1.754 . . . . 10.0 106.265 169.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.8 p90 -122.38 168.0 12.61 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.245 0.545 . . . . 10.0 112.304 170.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.33 -152.51 24.57 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 107.738 -2.145 . . . . 10.0 107.738 169.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.3 p -156.17 155.54 32.65 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 119.306 -0.958 . . . . 10.0 112.527 -176.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.427 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -117.76 129.14 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 125.489 1.516 . . . . 10.0 107.92 168.868 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 48.1 tttp -110.08 148.32 31.95 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.73 1.612 . . . . 10.0 107.138 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.61 -10.02 25.92 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 123.796 0.712 . . . . 10.0 113.891 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.0 mt -73.04 179.25 3.87 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.335 1.054 . . . . 10.0 110.522 178.682 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.3 t -104.86 165.31 11.16 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 167.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -55.38 156.16 4.64 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.489 1.116 . . . . 10.0 113.195 -169.086 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.98 177.38 51.97 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.429 1.014 . . . . 10.0 112.669 169.157 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 84.9 mt -40.88 137.88 1.14 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.625 1.97 . . . . 10.0 114.74 175.186 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.21 150.68 44.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.631 1.572 . . . . 10.0 110.661 170.262 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.549 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -35.95 123.44 0.73 Allowed Glycine 0 C--N 1.338 0.651 0 CA-C-O 116.855 -2.08 . . . . 10.0 109.39 163.549 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -149.88 108.11 3.76 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 120.207 2.003 . . . . 10.0 109.205 167.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -154.22 175.47 13.45 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.503 0.668 . . . . 10.0 110.763 -176.807 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.97 156.63 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.639 0 CA-C-N 112.425 -2.171 . . . . 10.0 108.297 168.319 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -132.99 130.81 39.99 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 104.259 -2.497 . . . . 10.0 104.259 174.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -58.25 -53.08 62.37 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.162 0.914 . . . . 10.0 111.321 -168.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -77.04 135.93 38.66 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 118.388 -1.325 . . . . 10.0 107.71 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.07 -31.79 72.5 Favored Glycine 0 N--CA 1.441 -0.97 0 N-CA-C 109.59 -1.404 . . . . 10.0 109.59 169.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -36.35 126.86 0.8 Allowed 'General case' 0 C--N 1.341 0.216 0 C-N-CA 126.352 1.861 . . . . 10.0 112.761 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -130.48 9.94 5.17 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 114.445 -1.252 . . . . 10.0 110.894 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.442 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -54.61 -35.68 63.67 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.312 1.045 . . . . 10.0 112.112 -169.618 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.35 -17.17 58.47 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.197 0.599 . . . . 10.0 112.241 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.89 76.31 0.88 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 108.865 -1.694 . . . . 10.0 108.865 -177.096 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.84 6.52 0.91 Allowed 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.086 1.354 . . . . 10.0 113.312 176.386 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 45.1 m -98.72 -42.11 7.37 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 107.774 -1.195 . . . . 10.0 107.774 -169.029 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.93 -39.62 71.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 123.771 0.828 . . . . 10.0 111.022 -169.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.78 -25.2 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.754 3.621 . . . . 10.0 116.863 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.92 121.98 3.95 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.437 -1.465 . . . . 10.0 109.437 172.35 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.16 73.25 1.1 Allowed 'Trans proline' 0 CA--C 1.54 0.792 0 C-N-CA 123.596 2.864 . . . . 10.0 111.759 177.279 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 25.4 m170 61.09 46.84 7.79 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.624 3.17 . . . . 10.0 111.305 176.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -74.29 48.66 0.34 Allowed 'General case' 0 N--CA 1.467 0.39 0 O-C-N 121.799 -0.563 . . . . 10.0 111.993 178.709 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -63.62 149.45 92.42 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 121.36 -0.837 . . . . 10.0 108.804 178.037 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -54.23 -60.03 0.73 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 122.977 2.451 . . . . 10.0 111.879 -172.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.01 66.5 2.22 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.743 -0.598 . . . . 10.0 109.665 169.705 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t -59.1 102.5 0.13 Allowed 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.459 ' HE ' ' HA ' ' A' ' 78' ' ' GLU . 43.5 mtp85 -105.36 -89.9 0.42 Allowed 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 106.063 -1.828 . . . . 10.0 106.063 -176.122 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.2 mmtt -143.32 146.62 33.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.244 0.545 . . . . 10.0 109.664 168.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.0 t60 -55.99 121.57 9.64 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 117.976 -1.489 . . . . 10.0 107.6 165.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.71 -149.99 5.48 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.09 -150.97 8.17 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.265 -1.297 . . . . 10.0 110.675 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -70.05 17.37 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.849 1.699 . . . . 10.0 111.285 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.17 -19.33 16.49 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 108.017 -1.105 . . . . 10.0 108.017 168.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.28 -178.59 4.91 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.895 -1.15 . . . . 10.0 107.895 -168.204 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -116.39 -5.4 11.76 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 123.424 0.69 . . . . 10.0 110.734 170.274 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.459 ' HA ' ' HE ' ' A' ' 69' ' ' ARG . 0.8 OUTLIER -98.11 -2.88 39.04 Favored 'General case' 0 CA--C 1.517 -0.323 0 O-C-N 121.02 -1.05 . . . . 10.0 111.536 -174.258 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 9.6 ptt85 -28.76 129.83 0.07 Allowed 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.408 2.283 . . . . 10.0 111.019 167.28 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -59.52 151.99 22.95 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.968 -0.753 . . . . 10.0 108.968 172.227 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 94.5 t -59.5 89.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.955 -1.128 . . . . 10.0 107.955 171.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.64 28.58 3.42 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 125.724 1.631 . . . . 10.0 113.496 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -85.92 101.04 12.52 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 105.055 -2.202 . . . . 10.0 105.055 164.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.65 16.48 1.75 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 119.286 0.948 . . . . 10.0 110.83 173.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.03 -107.98 2.49 Favored Glycine 0 N--CA 1.434 -1.499 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 -179.12 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -155.94 144.59 20.27 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 106.646 -1.613 . . . . 10.0 106.646 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -120.77 135.99 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 C-N-CA 123.062 0.545 . . . . 10.0 109.867 -171.167 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -82.72 131.85 35.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 125.134 1.374 . . . . 10.0 109.616 -174.614 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.76 142.24 31.5 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 123.918 0.887 . . . . 10.0 110.897 170.07 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -60.93 167.43 2.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.473 1.109 . . . . 10.0 109.744 166.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.4 ptmt -54.1 -26.77 28.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.149 1.379 . . . . 10.0 112.184 173.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -75.9 -29.94 58.61 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 109.75 -0.463 . . . . 10.0 109.75 177.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 112.05 4.71 25.7 Favored Glycine 0 N--CA 1.446 -0.68 0 CA-C-O 118.626 -1.097 . . . . 10.0 111.216 -169.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.7 t -78.61 99.1 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 C-N-CA 125.069 1.347 . . . . 10.0 108.279 177.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 117.47 33.38 Favored 'General case' 0 CA--C 1.518 -0.264 0 N-CA-C 106.886 -1.524 . . . . 10.0 106.886 166.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -89.03 119.78 29.86 Favored 'General case' 0 N--CA 1.436 -1.142 0 C-N-CA 127.879 2.472 . . . . 10.0 109.106 177.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.6 t -105.15 135.06 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 C-N-CA 125.127 1.371 . . . . 10.0 107.787 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 88.9 p -159.72 69.74 0.43 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.309 0.855 . . . . 10.0 113.309 172.275 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -123.96 143.19 38.08 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 124.53 1.132 . . . . 10.0 110.38 -170.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -116.28 149.84 38.57 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.942 2.097 . . . . 10.0 110.128 173.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -149.87 153.39 36.63 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 106.744 -1.576 . . . . 10.0 106.744 167.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 78.1 p -95.47 56.04 1.78 Allowed 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 125.395 1.478 . . . . 10.0 108.528 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 58.4 t -144.12 -53.18 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -176.723 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.7 mm -54.48 139.08 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 C-N-CA 124.022 0.929 . . . . 10.0 109.488 173.038 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.9 m -155.15 134.94 12.78 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 169.271 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.6 mt -55.85 -52.04 65.42 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.645 1.178 . . . . 10.0 110.436 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.0 t -140.52 -179.27 5.93 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.313 0.645 . . . . 10.0 109.514 176.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.85 -100.3 0.56 Allowed Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 106.22 -2.752 . . . . 10.0 106.22 -170.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -128.92 -49.77 1.23 Allowed 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 125.356 1.462 . . . . 10.0 108.356 -169.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.5 -41.07 48.32 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.888 -1.051 . . . . 10.0 108.867 -176.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t 38.71 89.81 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.391 2.276 . . . . 10.0 113.796 172.653 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pp -73.63 -15.31 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 112.534 0.568 . . . . 10.0 112.534 178.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.3 mm -50.12 122.63 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 O-C-N 121.188 -0.945 . . . . 10.0 110.412 174.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.44 5.43 56.94 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.466 1.032 . . . . 10.0 112.968 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.6 mpt_? -75.66 179.38 5.41 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.017 0.927 . . . . 10.0 109.533 169.062 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -129.72 141.56 50.87 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 173.284 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.659 HD11 HD11 ' A' ' 149' ' ' ILE . 6.1 mp -107.94 157.43 18.22 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.75 -0.833 . . . . 10.0 108.75 168.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -140.04 137.86 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 O-C-N 123.934 0.771 . . . . 10.0 109.206 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.4 m -103.25 134.56 44.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 O-C-N 124.473 1.108 . . . . 10.0 108.912 164.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.549 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.7 m170 -110.83 159.21 17.88 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 114.497 1.295 . . . . 10.0 114.497 -174.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.73 -50.05 73.37 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.973 1.309 . . . . 10.0 110.46 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -113.03 172.17 7.1 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.629 0.728 . . . . 10.0 112.366 -177.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.22 151.24 33.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.138 1.375 . . . . 10.0 109.503 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -79.49 147.04 32.38 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.207 0.447 . . . . 10.0 112.207 176.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -86.49 3.02 45.81 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.506 1.129 . . . . 10.0 111.637 168.372 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.4 mt 48.06 51.89 13.94 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 125.247 1.419 . . . . 10.0 111.859 170.022 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.38 -7.87 64.13 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 113.756 -1.565 . . . . 10.0 112.187 173.586 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -114.23 35.16 4.29 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.25 1.02 . . . . 10.0 110.691 -168.192 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -82.89 -23.55 55.3 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 126.124 1.821 . . . . 10.0 111.697 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.44 48.1 81.48 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-N 118.184 0.992 . . . . 10.0 111.547 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.517 ' H ' ' HB2' ' A' ' 134' ' ' SER . 37.3 m-80 -158.13 167.4 29.93 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 127.746 2.418 . . . . 10.0 105.734 -175.666 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -57.49 -44.51 85.01 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.627 0.727 . . . . 10.0 109.645 175.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -52.89 -31.15 38.16 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.788 0.835 . . . . 10.0 112.327 175.278 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.517 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 7.0 t -46.77 -47.14 20.86 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 124.054 0.942 . . . . 10.0 109.035 178.24 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.6 t -83.67 0.56 46.45 Favored 'General case' 0 CA--C 1.539 0.556 0 CA-C-O 118.35 -0.833 . . . . 10.0 112.714 -173.766 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -121.55 -83.02 0.66 Allowed 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.464 1.906 . . . . 10.0 111.897 -174.151 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.36 24.46 13.06 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 121.759 2.072 . . . . 10.0 110.662 174.721 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.89 -87.3 0.29 Allowed Glycine 0 C--N 1.34 0.793 0 C-N-CA 125.151 1.358 . . . . 10.0 110.027 175.27 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.22 34.08 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 125.233 1.413 . . . . 10.0 110.477 172.81 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.98 -9.76 56.28 Favored 'General case' 0 C--N 1.341 0.212 0 O-C-N 121.041 -1.037 . . . . 10.0 112.192 -172.102 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.77 -163.62 52.66 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 169.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -49.73 123.79 8.53 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.161 1.384 . . . . 10.0 113.428 -168.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -63.54 74.18 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.259 1.824 . . . . 10.0 110.734 173.329 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 52.7 mt -49.68 -36.81 26.3 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 113.189 0.811 . . . . 10.0 113.189 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.31 144.44 23.0 Favored 'General case' 0 CA--C 1.513 -0.442 0 O-C-N 121.711 -0.618 . . . . 10.0 109.418 178.232 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.9 p -132.37 152.16 51.56 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 124.206 0.941 . . . . 10.0 109.876 176.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.39 141.98 11.26 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.297 -1.121 . . . . 10.0 110.297 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.5 t -97.11 142.71 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 105.971 -1.863 . . . . 10.0 105.971 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.659 HD11 HD11 ' A' ' 117' ' ' LEU . 14.1 mt -79.29 136.7 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 N-CA-C 110.038 -0.356 . . . . 10.0 110.038 -176.58 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.84 145.49 17.34 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.75 1.167 . . . . 10.0 111.877 -175.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.3 mt -67.83 139.57 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 124.4 1.08 . . . . 10.0 108.362 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.9 -26.92 2.59 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 114.805 1.409 . . . . 10.0 114.805 -176.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.025 0 CA-C-O 117.61 -1.186 . . . . 10.0 111.84 -178.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.789 0 CA-C-O 116.73 -1.605 . . . . 10.0 107.134 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t -68.99 -18.83 64.11 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-N 120.533 1.515 . . . . 10.0 108.615 169.098 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.6 ptpt -144.39 162.27 36.9 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 120.831 0.348 . . . . 10.0 110.88 165.458 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -152.95 166.87 31.03 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 127.139 2.175 . . . . 10.0 107.645 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.71 162.79 36.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 C-N-CA 123.419 0.688 . . . . 10.0 111.014 -176.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.39 108.51 5.48 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.931 0.892 . . . . 10.0 109.307 168.251 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.1 m -82.5 81.81 1.53 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.485 0.714 . . . . 10.0 110.294 171.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -73.13 127.18 31.86 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.714 -0.847 . . . . 10.0 108.714 -171.511 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.6 mtmp? -147.54 160.36 42.71 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.324 -0.991 . . . . 10.0 108.324 -177.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.17 -57.51 0.06 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 120.479 -0.867 . . . . 10.0 112.928 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -72.65 -43.85 62.63 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 -175.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.02 -70.97 0.43 Allowed Glycine 0 CA--C 1.524 0.596 0 CA-C-N 114.273 -1.33 . . . . 10.0 110.078 171.142 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -56.46 -34.26 94.27 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.056 2.504 . . . . 10.0 111.28 172.739 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.8 t -66.83 100.63 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 176.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -122.35 109.52 14.52 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 174.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.642 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.56 134.86 11.98 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.751 -1.34 . . . . 10.0 109.751 169.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.442 ' CG2' HG23 ' A' ' 54' ' ' THR . 17.7 mt -129.55 67.66 0.34 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.153 0 N-CA-C 107.255 -1.387 . . . . 10.0 107.255 -174.273 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -89.25 137.92 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 114.611 -1.177 . . . . 10.0 109.735 -171.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -120.68 116.03 24.49 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.051 2.14 . . . . 10.0 107.97 -173.222 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -98.72 109.62 22.35 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 116.986 -1.483 . . . . 10.0 107.672 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -104.18 138.87 40.03 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 119.856 1.207 . . . . 10.0 112.592 169.53 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 40.2 tp60 -124.21 91.89 3.55 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 129.719 3.208 . . . . 10.0 107.288 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 59.0 tttt . . . . . 0 N--CA 1.426 -1.646 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 177.477 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.039 0 CA-C-O 117.21 -1.883 . . . . 10.0 116.279 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -68.26 128.27 17.17 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 CA-C-N 121.362 2.581 . . . . 10.0 106.174 168.821 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' VAL . . . . . 0.455 ' CG1' HD11 ' B' ' 104' ' ' ILE . 1.3 p -76.92 112.39 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.547 0 N-CA-C 105.968 -1.864 . . . . 10.0 105.968 169.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.5 tttt -85.77 107.19 17.5 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.994 -2.225 . . . . 10.0 104.994 172.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 p -95.48 96.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 C-N-CA 126.816 2.046 . . . . 10.0 105.733 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.0 p90 -117.65 169.04 9.89 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 121.827 0.822 . . . . 10.0 112.228 173.454 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.9 -157.26 27.2 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 106.959 -2.456 . . . . 10.0 106.959 169.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 p -149.24 160.3 43.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 176.357 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.642 HG22 ' HA2' ' B' ' 16' ' ' GLY . 1.5 pp -111.52 175.61 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 CA-C-N 114.69 -1.141 . . . . 10.0 109.393 167.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ptmt -143.83 141.43 30.35 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 106.185 -1.783 . . . . 10.0 106.185 166.191 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.02 -5.43 20.14 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.122 0.867 . . . . 10.0 114.734 170.731 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.607 HD23 HD13 ' B' ' 35' ' ' ILE . 0.6 OUTLIER -70.07 178.13 2.89 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 118.712 1.256 . . . . 10.0 111.502 -179.739 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.6 t -111.76 156.14 22.41 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 167.044 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -50.26 156.67 0.79 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.362 1.465 . . . . 10.0 113.073 -169.465 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.57 -169.24 32.61 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 123.422 0.534 . . . . 10.0 111.784 168.359 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.49 146.33 44.99 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 124.61 1.164 . . . . 10.0 111.135 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -143.2 151.19 40.34 Favored 'General case' 0 C--N 1.34 0.19 0 N-CA-C 113.684 0.994 . . . . 10.0 113.684 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.697 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.05 119.68 0.16 Allowed Glycine 0 C--N 1.339 0.714 0 C-N-CA 129.337 3.351 . . . . 10.0 113.662 166.408 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -152.4 112.48 4.02 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 120.047 1.923 . . . . 10.0 112.785 168.547 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -142.22 173.1 11.83 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.645 0.736 . . . . 10.0 111.532 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 46.1 t -106.43 117.77 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 CA-C-N 111.927 -2.397 . . . . 10.0 104.691 168.559 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -92.81 148.61 21.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 172.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -60.1 -57.16 14.03 Favored 'General case' 0 N--CA 1.45 -0.475 0 CA-C-N 115.113 -0.949 . . . . 10.0 109.979 -171.178 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -77.67 148.49 34.98 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 108.91 -0.774 . . . . 10.0 108.91 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.55 -5.33 69.33 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 125.022 1.296 . . . . 10.0 110.15 166.245 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -40.7 143.03 0.38 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.805 1.242 . . . . 10.0 111.422 169.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.508 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -153.29 23.56 0.55 Allowed 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 113.89 -1.505 . . . . 10.0 111.359 168.309 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.429 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.83 -36.15 71.86 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 118.685 0.675 . . . . 10.0 110.865 -172.361 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.92 -22.98 39.23 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.673 1.189 . . . . 10.0 112.966 175.411 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.24 107.42 1.46 Allowed Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.251 0.929 . . . . 10.0 111.45 -174.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 28.7 m 33.45 55.55 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 127.557 2.343 . . . . 10.0 113.537 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.3 -54.81 0.08 Allowed 'General case' 0 N--CA 1.448 -0.568 0 O-C-N 121.439 -0.788 . . . . 10.0 108.955 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 52.5 m -79.77 -5.52 55.47 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.251 0.621 . . . . 10.0 112.43 -174.766 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.37 8.31 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.365 1.866 . . . . 10.0 114.829 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.26 113.21 0.99 Allowed Glycine 0 CA--C 1.528 0.862 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 175.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.02 69.17 3.12 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.909 2.406 . . . . 10.0 111.299 175.059 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER 70.52 43.29 0.79 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.605 2.762 . . . . 10.0 110.231 170.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -73.95 45.89 0.22 Allowed 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.738 1.215 . . . . 10.0 114.183 -175.468 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -51.76 155.81 2.73 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.19 1.396 . . . . 10.0 111.54 169.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.47 -51.21 0.76 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.538 2.158 . . . . 10.0 111.866 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 67' ' ' LEU . . . . . 0.579 HD23 ' H ' ' B' ' 67' ' ' LEU . 1.7 pt? -74.97 53.63 0.61 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.954 0.902 . . . . 10.0 112.7 -177.261 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -54.2 108.82 0.41 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 122.793 0.437 . . . . 10.0 110.133 -171.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 mtt180 -120.61 -91.74 0.55 Allowed 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 105.892 -1.892 . . . . 10.0 105.892 -174.518 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -148.23 157.11 43.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 168.75 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -62.02 116.78 5.2 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 117.869 -1.533 . . . . 10.0 107.643 164.09 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.56 -145.99 6.44 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 107.695 -2.162 . . . . 10.0 107.695 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.4 -164.76 18.09 Favored Glycine 0 C--N 1.33 0.225 0 N-CA-C 108.771 -1.732 . . . . 10.0 108.771 173.034 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.89 -1.19 3.9 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.983 1.788 . . . . 10.0 110.951 167.323 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -84.29 -29.35 26.48 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 123.803 0.841 . . . . 10.0 109.279 171.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -107.46 161.72 14.58 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 123.161 0.584 . . . . 10.0 109.483 -170.054 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -92.49 -9.11 42.59 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.512 0.725 . . . . 10.0 109.293 167.567 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -97.04 0.23 48.34 Favored 'General case' 0 N--CA 1.438 -1.05 0 CA-C-O 116.035 -1.936 . . . . 10.0 113.521 -176.059 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.8 137.32 0.65 Allowed 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 120.101 1.319 . . . . 10.0 110.57 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -59.32 -37.23 77.27 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 120.159 -0.616 . . . . 10.0 111.341 -170.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.42 HG13 ' H ' ' B' ' 82' ' ' GLY . 2.5 p -154.1 -61.23 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 106.61 -1.626 . . . . 10.0 106.61 172.457 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.42 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -116.46 -56.04 0.32 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 173.475 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 39.29 85.5 0.02 OUTLIER 'General case' 0 C--N 1.346 0.429 0 C-N-CA 126.325 1.85 . . . . 10.0 108.618 -167.752 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -49.79 -33.14 15.63 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.349 1.06 . . . . 10.0 112.749 -166.036 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.03 -89.13 0.42 Allowed Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 168.18 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -155.06 101.14 2.23 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.639 -0.875 . . . . 10.0 108.639 -170.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -83.6 128.83 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.137 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 174.863 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.3 t -90.83 130.33 36.8 Favored 'General case' 0 C--O 1.225 -0.2 0 N-CA-C 108.733 -0.84 . . . . 10.0 108.733 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.15 131.86 48.4 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.407 -0.961 . . . . 10.0 108.407 171.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -58.88 168.31 1.31 Allowed 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 124.246 0.966 . . . . 10.0 109.832 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -30.2 18.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.083 0.953 . . . . 10.0 111.3 170.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.71 -7.09 56.01 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 120.958 -0.297 . . . . 10.0 111.091 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.56 28.14 55.82 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.566 -1.413 . . . . 10.0 109.566 -178.197 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 34.9 t -107.7 115.48 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.862 0 N-CA-C 104.617 -2.364 . . . . 10.0 104.617 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.438 ' HB3' HG13 ' B' ' 35' ' ' ILE . . . -113.53 123.27 49.61 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 107.544 -1.28 . . . . 10.0 107.544 174.702 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -85.15 119.66 25.78 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 127.32 2.248 . . . . 10.0 109.044 174.14 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 93.9 t -105.12 133.76 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 C-N-CA 124.636 1.174 . . . . 10.0 107.848 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 84.5 p -158.91 72.29 0.56 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 123.564 0.746 . . . . 10.0 111.015 169.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -104.6 153.47 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -117.91 81.74 1.72 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 128.43 2.692 . . . . 10.0 108.103 -176.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -75.84 113.74 13.66 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.768 -1.938 . . . . 10.0 105.768 -176.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 15.1 m -108.48 35.58 3.13 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.819 -1.082 . . . . 10.0 109.963 -174.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.5 p -126.02 -43.07 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-O 118.538 -0.744 . . . . 10.0 110.622 171.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.619 HD13 ' C ' ' B' ' 104' ' ' ILE 0.361 0.0 OUTLIER -91.83 176.11 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 N-CA-C 113.707 1.002 . . . . 10.0 113.707 178.422 . . . . . . . . 4 4 . 1 . 003 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 34.0 m -152.69 145.9 24.7 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 121.615 -0.678 . . . . 10.0 109.972 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -66.23 -18.14 65.17 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 124.159 0.984 . . . . 10.0 112.464 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.9 t . . . . . 0 N--CA 1.451 -0.421 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.467 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.531 0.23 0 N-CA-C 109.89 -0.411 . . . . 10.0 109.89 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.32 0.2 OUTLIER 78.68 -40.22 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 125.264 1.426 . . . . 10.0 112.075 168.817 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.9 mm -24.23 127.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 128.086 2.554 . . . . 10.0 111.342 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 90.2 28.6 17.06 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-O 119.054 -0.859 . . . . 10.0 112.588 -170.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -81.03 176.31 9.93 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.705 -1.22 . . . . 10.0 107.705 166.728 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -128.66 123.3 32.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.554 -2.017 . . . . 10.0 105.554 167.044 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 mp -96.0 149.75 21.23 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.251 -1.389 . . . . 10.0 107.251 169.442 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 84.3 t -132.01 133.74 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.703 -1.591 . . . . 10.0 106.703 -174.382 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -104.34 122.95 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 N-CA-C 107.078 -1.453 . . . . 10.0 107.078 171.155 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.697 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.4 m-70 -105.43 157.44 17.35 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 115.893 1.812 . . . . 10.0 115.893 -171.063 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.1 tt0 -43.26 -57.5 2.96 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 128.279 2.632 . . . . 10.0 111.009 173.225 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -111.42 162.49 15.02 Favored 'General case' 0 CA--C 1.515 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.664 -170.188 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.13 140.41 58.79 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.888 1.275 . . . . 10.0 107.586 174.012 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.465 ' OD1' ' HB2' ' B' ' 140' ' ' ALA . 69.2 m-20 -77.34 132.79 38.76 Favored 'General case' 0 N--CA 1.441 -0.919 0 N-CA-C 108.579 -0.897 . . . . 10.0 108.579 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 125' ' ' ASP . . . . . 0.409 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 6.7 t0 -81.56 -4.22 55.42 Favored 'General case' 0 N--CA 1.448 -0.574 0 O-C-N 123.483 0.489 . . . . 10.0 110.81 174.47 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 37.6 mt 53.59 41.11 32.15 Favored 'General case' 0 N--CA 1.463 0.188 0 O-C-N 120.455 -1.403 . . . . 10.0 110.629 172.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.99 -29.87 9.35 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-O 119.072 -0.849 . . . . 10.0 113.089 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.409 ' NZ ' ' OD1' ' B' ' 125' ' ' ASP . 0.0 OUTLIER -78.59 10.1 3.49 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 120.054 1.927 . . . . 10.0 113.617 -169.721 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.41 -16.91 69.96 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.009 0.814 . . . . 10.0 112.003 173.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.88 31.55 76.48 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.52 0.581 . . . . 10.0 112.505 174.004 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -142.37 176.01 9.33 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 108.165 -1.05 . . . . 10.0 108.165 171.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -59.01 -45.93 89.46 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 116.219 -0.446 . . . . 10.0 110.637 -175.117 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -67.05 -26.01 66.54 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 120.937 -1.102 . . . . 10.0 110.324 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -52.09 -48.38 64.76 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 119.546 1.066 . . . . 10.0 110.301 168.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -86.8 -15.26 39.81 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 124.073 0.858 . . . . 10.0 111.851 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.8 ttmm -89.82 -48.56 7.17 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 125.416 1.486 . . . . 10.0 111.666 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.9 p -133.88 -14.49 2.41 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 114.98 1.474 . . . . 10.0 114.98 176.154 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.37 30.93 8.73 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 119.668 1.122 . . . . 10.0 112.797 -171.372 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 32.8 m120 50.82 34.74 10.73 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 119.21 1.505 . . . . 10.0 111.918 -177.336 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 140' ' ' ALA . . . . . 0.465 ' HB2' ' OD1' ' B' ' 124' ' ' ASP . . . -69.94 -11.71 61.08 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.764 1.226 . . . . 10.0 111.982 -173.758 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.91 -158.43 53.06 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 109.633 -1.387 . . . . 10.0 109.633 174.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 128.11 35.42 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.61 0.719 . . . . 10.0 110.643 -169.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.01 73.02 0.07 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 123.997 0.919 . . . . 10.0 109.663 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 79.2 mt -45.8 -41.83 11.46 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 124.726 1.211 . . . . 10.0 112.78 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.56 154.17 22.31 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 -171.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.01 164.53 38.33 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.834 -0.621 . . . . 10.0 109.907 -175.382 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.32 -176.09 14.34 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 -179.118 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.4 t -131.95 141.67 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 173.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 8.2 mt -70.78 115.52 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.441 0.564 . . . . 10.0 110.464 -177.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.71 136.72 13.7 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.696 1.141 . . . . 10.0 111.197 -178.486 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 83.1 mt -65.87 142.15 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 124.516 1.126 . . . . 10.0 109.993 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.03 -52.63 1.31 Allowed 'General case' 0 C--O 1.225 -0.204 0 C-N-CA 123.277 0.631 . . . . 10.0 110.957 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 13.3 tt0 . . . . . 0 C--O 1.25 1.114 0 CA-C-O 116.356 -1.783 . . . . 10.0 112.937 -172.489 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.757 0 N-CA-C 108.266 -1.013 . . . . 10.0 108.266 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -166.84 -42.97 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.77 1.228 . . . . 10.0 110.039 175.382 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.9 mtpm? -114.13 148.73 36.72 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 171.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.33 163.25 38.8 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.396 1.479 . . . . 10.0 107.725 177.133 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.43 HG22 ' HA ' ' B' ' 52' ' ' ASP . 0.7 OUTLIER -139.94 167.13 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 122.88 0.472 . . . . 10.0 110.718 -177.94 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.39 114.72 7.95 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 124.14 0.976 . . . . 10.0 108.393 167.311 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -94.1 118.74 40.75 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 123.832 0.853 . . . . 10.0 108.705 171.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt -104.9 140.89 37.47 Favored 'General case' 0 C--O 1.224 -0.237 0 CA-C-O 118.089 -0.957 . . . . 10.0 109.308 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt -148.42 162.13 40.2 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-N 120.312 1.415 . . . . 10.0 107.866 168.756 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.29 -72.44 0.02 OUTLIER Glycine 0 C--O 1.228 -0.237 0 CA-C-N 115.117 -0.947 . . . . 10.0 112.295 169.587 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.73 -41.48 62.48 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 106.972 -1.492 . . . . 10.0 106.972 -170.034 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.64 -61.39 0.56 Allowed Glycine 0 N--CA 1.441 -0.99 0 CA-C-N 113.697 -1.592 . . . . 10.0 112.401 175.28 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -55.3 -43.18 61.21 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 CA-C-N 119.12 1.46 . . . . 10.0 110.68 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.415 HG23 HD12 ' A' ' 38' ' ' LEU . 0.2 OUTLIER -64.63 117.51 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.985 0 N-CA-C 108.486 -0.931 . . . . 10.0 108.486 177.219 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.16 109.52 12.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.731 -2.322 . . . . 10.0 104.731 168.437 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.765 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.39 143.29 17.82 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 109.181 -1.568 . . . . 10.0 109.181 175.477 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.434 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 2.9 mt -143.11 86.87 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 -178.31 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -97.95 145.46 9.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 C-N-CA 123.874 0.87 . . . . 10.0 109.599 177.3 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -126.13 143.38 51.15 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 125.321 1.448 . . . . 10.0 109.271 170.53 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -125.57 106.17 9.56 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 107.457 -1.312 . . . . 10.0 107.457 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -103.54 111.57 24.09 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 114.074 1.139 . . . . 10.0 114.074 176.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -78.75 95.06 5.23 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.297 -2.112 . . . . 10.0 105.297 165.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -56.14 -53.7 53.9 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 126.285 1.834 . . . . 10.0 109.741 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.78 -156.88 0.71 Allowed 'General case' 0 N--CA 1.434 -1.236 0 N-CA-C 104.111 -2.551 . . . . 10.0 104.111 168.795 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.36 -27.48 25.83 Favored 'General case' 0 N--CA 1.443 -0.789 0 O-C-N 122.131 -0.356 . . . . 10.0 110.06 169.141 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -108.23 -6.33 16.41 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.953 1.301 . . . . 10.0 111.314 -171.248 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.57 149.29 49.52 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.597 -1.001 . . . . 10.0 110.597 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -62.98 125.31 15.62 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 N-CA-C 107.392 -1.811 . . . . 10.0 107.392 169.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.8 t -79.34 103.15 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 106.647 -1.612 . . . . 10.0 106.647 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -67.97 112.49 5.0 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 105.858 -1.905 . . . . 10.0 105.858 167.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -95.62 104.99 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 105.61 -1.996 . . . . 10.0 105.61 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 19.9 p90 -112.48 164.18 13.59 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.238 0.542 . . . . 10.0 109.671 177.589 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -177.44 157.51 22.21 Favored Glycine 0 N--CA 1.434 -1.464 0 C-N-CA 119.946 -1.121 . . . . 10.0 110.506 176.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.6 p -128.54 86.37 2.44 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 106.853 -1.536 . . . . 10.0 106.853 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.765 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.2 pt -76.99 154.21 5.58 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 C-N-CA 117.736 -1.585 . . . . 10.0 107.271 168.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.1 ptmm? -145.79 119.77 9.38 Favored 'General case' 0 N--CA 1.446 -0.638 0 O-C-N 124.192 0.932 . . . . 10.0 109.242 172.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.28 8.43 4.98 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-O 118.802 -0.999 . . . . 10.0 114.442 166.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.739 ' H ' HD13 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -83.07 179.0 7.87 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 107.201 -1.407 . . . . 10.0 107.201 168.795 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -77.9 167.06 22.1 Favored 'General case' 0 N--CA 1.453 -0.317 0 O-C-N 121.04 -1.038 . . . . 10.0 109.174 169.186 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -65.67 179.09 0.88 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.813 0.845 . . . . 10.0 112.051 -175.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.9 -171.01 44.32 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.211 -0.756 . . . . 10.0 111.211 169.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -76.24 140.46 41.61 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.184 1.394 . . . . 10.0 110.736 -177.341 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -140.92 139.64 34.36 Favored 'General case' 0 C--N 1.341 0.228 0 N-CA-C 113.907 1.076 . . . . 10.0 113.907 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.507 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.4 117.13 0.46 Allowed Glycine 0 C--N 1.341 0.852 0 C-N-CA 128.646 3.022 . . . . 10.0 111.945 166.111 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -135.65 109.18 7.93 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 120.005 1.903 . . . . 10.0 110.324 170.111 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.12 170.07 20.32 Favored 'General case' 0 CA--C 1.513 -0.462 0 C-N-CA 123.413 0.685 . . . . 10.0 110.372 176.679 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 34.2 m -105.39 -27.11 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 C-N-CA 127.048 2.139 . . . . 10.0 113.171 -169.271 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 24.9 m-70 61.09 165.18 0.08 Allowed 'General case' 0 C--N 1.342 0.244 0 C-N-CA 124.436 1.095 . . . . 10.0 112.92 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -75.99 -56.53 4.58 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 121.726 -0.609 . . . . 10.0 111.121 171.294 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -75.98 111.26 11.18 Favored 'General case' 0 C--N 1.341 0.216 0 C-N-CA 119.888 -0.725 . . . . 10.0 110.881 -169.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.3 -39.32 95.92 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 108.852 -1.699 . . . . 10.0 108.852 166.597 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -34.65 122.82 0.53 Allowed 'General case' 0 C--N 1.341 0.223 0 C-N-CA 125.638 1.575 . . . . 10.0 112.219 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -129.06 18.13 6.07 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 124.529 1.132 . . . . 10.0 111.354 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.633 HG23 ' CG2' ' B' ' 17' ' ' ILE . 2.8 m -54.21 -36.75 63.82 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 119.49 1.041 . . . . 10.0 111.036 -175.746 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.01 -22.04 53.69 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.386 0.674 . . . . 10.0 112.106 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.61 -163.15 18.61 Favored Glycine 0 N--CA 1.443 -0.891 0 N-CA-C 107.328 -2.309 . . . . 10.0 107.328 -169.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 90.5 m -74.69 49.56 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.202 1.401 . . . . 10.0 111.052 176.565 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -137.58 -45.83 0.55 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 126.493 1.917 . . . . 10.0 109.574 -177.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -47.99 -31.44 5.32 Favored 'General case' 0 C--N 1.341 0.239 0 C-N-CA 123.146 0.578 . . . . 10.0 111.219 171.201 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.89 -42.01 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 128.132 2.573 . . . . 10.0 114.639 169.109 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.43 150.33 26.76 Favored Glycine 0 C--N 1.339 0.7 0 N-CA-C 110.64 -0.984 . . . . 10.0 110.64 168.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -80.54 54.43 5.22 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.192 1.928 . . . . 10.0 111.079 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER 65.6 -65.93 0.16 Allowed 'General case' 0 C--O 1.226 -0.183 0 C-N-CA 128.502 2.721 . . . . 10.0 111.468 -177.503 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.265 10.7 p90 36.08 23.4 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 130.594 3.558 . . . . 10.0 118.944 174.335 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -49.72 158.13 0.9 Allowed Pre-proline 0 CA--C 1.541 0.628 0 C-N-CA 125.98 1.712 . . . . 10.0 114.634 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -57.07 -45.01 38.77 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.583 2.855 . . . . 10.0 112.473 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 78.1 mt -75.1 58.21 0.88 Allowed 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.887 -0.782 . . . . 10.0 108.887 172.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -66.3 72.7 0.08 Allowed 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 128.748 2.819 . . . . 10.0 108.798 -176.697 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 mtt180 -92.16 -91.37 0.16 Allowed 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 105.231 -2.137 . . . . 10.0 105.231 -173.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.1 mttp -149.83 144.48 26.01 Favored 'General case' 0 N--CA 1.425 -1.7 0 N-CA-C 104.21 -2.515 . . . . 10.0 104.21 164.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -52.64 117.59 3.01 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 118.871 -1.131 . . . . 10.0 109.672 167.291 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.4 -154.72 7.9 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 107.037 -2.425 . . . . 10.0 107.037 175.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.407 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -162.92 -160.87 11.6 Favored Glycine 0 C--O 1.225 -0.413 0 N-CA-C 108.755 -1.738 . . . . 10.0 108.755 174.281 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -65.51 10.08 0.17 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 CA-C-N 120.864 2.332 . . . . 10.0 111.318 169.185 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.407 ' H ' ' C ' ' A' ' 73' ' ' GLY . 26.1 mmtp -107.36 -13.6 15.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 119.204 0.911 . . . . 10.0 109.065 175.516 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -140.82 140.5 34.69 Favored 'General case' 0 C--N 1.348 0.526 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 -169.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -76.13 -20.08 57.93 Favored 'General case' 0 C--N 1.332 -0.167 0 O-C-N 121.106 -0.996 . . . . 10.0 108.819 -169.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -77.18 -5.91 50.95 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 124.412 1.085 . . . . 10.0 111.962 -173.399 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -35.54 133.92 0.35 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.038 1.335 . . . . 10.0 112.862 -179.163 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -61.5 -79.7 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.246 0.545 . . . . 10.0 110.028 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -130.45 -91.42 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -108.93 52.39 0.65 Allowed Glycine 0 CA--C 1.521 0.421 0 N-CA-C 109.899 -1.28 . . . . 10.0 109.899 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.3 m-20 -72.37 93.64 1.54 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 105.759 -1.941 . . . . 10.0 105.759 168.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 26.6 mt -75.32 -29.42 60.01 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.407 ' HA2' HD21 ' A' ' 126' ' ' LEU . . . 99.73 -104.29 2.82 Favored Glycine 0 N--CA 1.439 -1.105 0 N-CA-C 110.559 -1.016 . . . . 10.0 110.559 168.133 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -125.67 101.02 6.69 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 125.713 1.605 . . . . 10.0 110.54 -167.654 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 5.0 m -110.04 140.19 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.616 0.766 . . . . 10.0 111.334 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.32 129.73 34.74 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 128.079 2.552 . . . . 10.0 112.416 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -110.16 134.48 52.16 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.342 1.457 . . . . 10.0 109.591 169.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -59.46 169.13 1.33 Allowed 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.015 1.326 . . . . 10.0 111.133 169.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 7.0 ptmt -47.52 -33.19 6.06 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.751 2.02 . . . . 10.0 111.348 172.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.69 -14.05 59.04 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 122.64 0.376 . . . . 10.0 111.13 -176.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.03 17.42 51.29 Favored Glycine 0 C--N 1.341 0.839 0 N-CA-C 110.44 -1.064 . . . . 10.0 110.44 -175.215 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.94 109.57 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 C-N-CA 126.645 1.978 . . . . 10.0 106.962 -179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.503 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -105.34 118.28 36.16 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.071 -0.715 . . . . 10.0 109.071 169.361 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -85.01 84.38 7.74 Favored 'General case' 0 N--CA 1.437 -1.119 0 C-N-CA 127.416 2.286 . . . . 10.0 109.327 174.08 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -75.86 129.57 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.307 0 N-CA-C 105.136 -2.172 . . . . 10.0 105.136 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -156.93 59.72 0.52 Allowed 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 122.869 0.467 . . . . 10.0 109.948 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.51 164.02 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -176.612 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -134.31 135.41 42.78 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.558 0.743 . . . . 10.0 111.215 169.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -131.1 131.11 43.94 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.973 1.309 . . . . 10.0 108.554 -175.483 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.5 p -98.31 24.2 7.52 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.851 0.86 . . . . 10.0 110.107 169.751 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.3 p -149.27 20.41 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.032 0.933 . . . . 10.0 110.722 -172.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -122.28 134.52 65.27 Favored 'Isoleucine or valine' 0 C--N 1.34 0.158 0 N-CA-C 102.591 -3.115 . . . . 10.0 102.591 169.159 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.5 m -146.73 125.77 12.85 Favored 'General case' 0 CA--C 1.527 0.074 0 CA-C-N 118.451 0.569 . . . . 10.0 109.699 -176.157 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.9 mp -54.53 -48.42 71.98 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.699 1.199 . . . . 10.0 110.52 177.019 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -137.02 176.35 8.79 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.549 1.54 . . . . 10.0 106.925 169.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.66 -97.25 0.4 Allowed Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 108.15 -1.98 . . . . 10.0 108.15 -176.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -121.96 -50.98 2.03 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 125.758 1.623 . . . . 10.0 108.461 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -73.5 -42.76 61.42 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.249 -1.389 . . . . 10.0 107.249 -171.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.4 t 47.19 54.88 8.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 126.004 1.722 . . . . 10.0 111.94 169.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.1 pt -60.01 -3.9 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 127.746 2.418 . . . . 10.0 115.222 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.3 mp -52.13 144.16 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 O-C-N 121.26 -0.9 . . . . 10.0 111.258 169.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.82 7.52 87.9 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.163 -0.798 . . . . 10.0 113.064 173.228 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -85.62 172.72 10.69 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.817 0.809 . . . . 10.0 109.123 170.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -122.43 104.64 9.53 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.908 0.883 . . . . 10.0 110.56 -175.2 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.467 ' CD2' HD11 ' A' ' 149' ' ' ILE . 3.8 mm? -62.42 130.14 43.88 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 108.261 -1.014 . . . . 10.0 108.261 172.26 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 51.2 t -119.64 132.65 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 169.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.473 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -100.99 121.86 52.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.245 -1.761 . . . . 10.0 106.245 169.913 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.507 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.2 m170 -106.32 164.16 12.25 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.364 1.246 . . . . 10.0 114.364 -173.625 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -45.13 -57.43 3.91 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 129.354 3.061 . . . . 10.0 111.476 174.364 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 61.2 mttt -126.17 175.32 7.86 Favored 'General case' 0 CA--C 1.522 -0.116 0 C-N-CA 124.552 1.141 . . . . 10.0 112.581 -169.124 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.89 152.57 41.4 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.051 1.341 . . . . 10.0 110.878 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -82.77 145.47 29.52 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 116.031 -0.531 . . . . 10.0 111.183 169.25 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -81.41 -16.07 53.24 Favored 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 125.025 1.453 . . . . 10.0 110.257 166.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.407 HD21 ' HA2' ' A' ' 85' ' ' GLY . 84.4 mt 57.37 64.14 1.68 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 122.721 1.248 . . . . 10.0 109.447 176.691 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.64 -41.41 3.07 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 114.714 -1.13 . . . . 10.0 110.937 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 29.1 mtmm -78.75 36.09 0.26 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.488 1.515 . . . . 10.0 112.341 -174.169 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.433 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -100.23 -7.27 52.45 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 127.252 2.358 . . . . 10.0 110.892 170.608 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 42.38 49.53 5.65 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.98 1.752 . . . . 10.0 114.009 177.259 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -153.29 172.56 16.83 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 169.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.0 mp0 -44.77 -50.64 10.02 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 123.021 0.528 . . . . 10.0 111.104 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.63 -28.36 66.83 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 118.694 -0.67 . . . . 10.0 111.035 -177.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.433 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 7.8 p -54.95 -37.6 66.66 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 119.902 1.228 . . . . 10.0 112.255 175.077 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -85.98 -0.26 55.03 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 123.348 0.405 . . . . 10.0 111.73 -178.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.1 mttt -111.71 -66.46 1.08 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.834 1.254 . . . . 10.0 111.125 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -128.99 23.07 5.69 Favored 'General case' 0 CA--C 1.543 0.698 0 CA-C-N 119.434 1.015 . . . . 10.0 112.042 -175.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.6 -87.26 0.35 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -172.34 37.93 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 125.164 1.386 . . . . 10.0 109.073 169.055 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.09 -13.92 62.58 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -168.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.23 54.81 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.275 -1.13 . . . . 10.0 110.275 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -56.08 128.75 36.95 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 123.976 0.91 . . . . 10.0 112.038 -168.187 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.9 mtm105 -66.68 74.79 0.1 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 124.956 1.302 . . . . 10.0 110.44 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 71.0 mt -46.88 -49.78 19.75 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.447 0.699 . . . . 10.0 111.881 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.473 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -151.65 155.63 38.75 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -169.091 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.17 165.07 37.47 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 122.564 0.346 . . . . 10.0 111.436 -175.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.78 170.16 38.23 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 125.339 1.447 . . . . 10.0 109.931 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 7.7 t -116.96 142.99 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 118.16 0.98 . . . . 10.0 108.693 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.467 HD11 ' CD2' ' A' ' 117' ' ' LEU . 41.2 mt -83.06 119.63 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.717 0 C-N-CA 123.728 0.811 . . . . 10.0 109.303 -176.647 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.17 159.75 24.13 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.775 -0.53 . . . . 10.0 111.775 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 55.6 mt -74.4 150.9 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 125.086 1.354 . . . . 10.0 110.415 -169.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.95 -106.59 0.38 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 167.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.922 1 C-N-CA 132.302 4.241 . . . . 10.0 102.72 -169.554 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.624 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.9 t -145.4 -51.81 0.26 Allowed 'General case' 0 CA--C 1.514 -0.418 0 C-N-CA 125.194 1.398 . . . . 10.0 108.482 176.306 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -110.24 145.81 36.71 Favored 'General case' 0 N--CA 1.44 -0.941 0 C-N-CA 126.567 1.947 . . . . 10.0 106.159 -172.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.57 149.6 30.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 172.257 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.5 m -129.69 161.31 39.51 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 O-C-N 123.718 0.636 . . . . 10.0 110.388 -176.365 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.16 105.11 4.03 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.418 -0.956 . . . . 10.0 108.418 170.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.02 91.85 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 170.37 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -77.36 143.59 38.61 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 108.309 -0.997 . . . . 10.0 108.309 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.14 165.14 32.23 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 107.959 -1.126 . . . . 10.0 107.959 173.027 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -168.67 -58.5 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 115.583 -0.735 . . . . 10.0 111.665 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.52 -45.23 47.17 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 -173.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.04 -68.28 0.52 Allowed Glycine 0 N--CA 1.445 -0.754 0 CA-C-N 113.75 -1.568 . . . . 10.0 110.288 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -57.84 -37.49 96.16 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.852 2.368 . . . . 10.0 111.068 174.477 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.26 102.76 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 N-CA-C 107.083 -1.451 . . . . 10.0 107.083 175.416 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -118.97 117.99 30.29 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.73 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -99.17 132.05 10.78 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 172.492 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.633 ' CG2' HG23 ' A' ' 54' ' ' THR . 6.5 mt -135.15 88.62 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 N-CA-C 107.01 -1.478 . . . . 10.0 107.01 -174.101 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -103.05 140.92 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 125.258 1.423 . . . . 10.0 109.659 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -124.87 112.47 16.68 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.047 1.739 . . . . 10.0 108.109 169.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -93.03 119.24 32.07 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.489 -1.301 . . . . 10.0 107.489 171.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -111.26 143.24 42.36 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 118.926 0.785 . . . . 10.0 111.447 168.037 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -92.6 118.14 30.7 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 103.909 -2.626 . . . . 10.0 103.909 166.359 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 79.3 mttt . . . . . 0 C--N 1.33 -0.262 0 CA-C-O 121.742 0.782 . . . . 10.0 109.412 171.955 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.686 0 N-CA-C 108.932 -1.667 . . . . 10.0 108.932 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -65.48 135.73 43.71 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.637 1.558 . . . . 10.0 108.446 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -78.23 107.22 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -77.11 108.91 10.53 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 106.284 -1.747 . . . . 10.0 106.284 170.647 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -85.85 105.99 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 25.3 p90 -113.99 163.81 14.64 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.444 0.64 . . . . 10.0 110.969 170.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 177.63 170.12 39.51 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.224 -0.75 . . . . 10.0 111.224 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.1 p -140.03 100.55 3.95 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.997 -1.483 . . . . 10.0 106.997 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.73 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.6 pt -78.12 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 C-N-CA 118.64 -1.224 . . . . 10.0 109.247 170.435 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -152.91 155.01 36.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 168.1 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.4 34.1 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 119.033 -0.87 . . . . 10.0 115.011 169.297 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.501 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.5 mp -72.45 177.79 4.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 118.934 1.367 . . . . 10.0 110.649 -177.141 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.25 161.56 15.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.295 -1.002 . . . . 10.0 108.295 168.259 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -55.74 163.34 1.42 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.227 1.011 . . . . 10.0 112.249 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.98 -175.37 33.66 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-O 121.863 0.702 . . . . 10.0 112.501 168.111 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -68.2 143.91 55.15 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.409 1.484 . . . . 10.0 109.999 -178.748 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -142.05 147.78 37.39 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 113.394 0.887 . . . . 10.0 113.394 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.63 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.38 125.5 0.27 Allowed Glycine 0 C--N 1.341 0.823 0 C-N-CA 127.738 2.59 . . . . 10.0 111.878 165.269 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -151.69 108.64 3.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 119.104 1.452 . . . . 10.0 110.473 166.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.498 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -147.66 172.29 14.29 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 122.407 1.099 . . . . 10.0 113.046 179.043 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.96 134.75 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.671 0 CA-C-N 111.191 -2.731 . . . . 10.0 106.418 169.576 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 47.1 m-70 -116.77 141.44 48.2 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 106.214 -1.773 . . . . 10.0 106.214 171.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -54.68 -52.23 63.03 Favored 'General case' 0 N--CA 1.451 -0.399 0 O-C-N 124.144 0.903 . . . . 10.0 111.915 -168.545 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -76.92 137.78 39.3 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 -175.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.62 12.51 51.78 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 124.381 0.991 . . . . 10.0 111.649 167.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.43 ' HA ' HG22 ' A' ' 5' ' ' VAL . 0.0 OUTLIER -79.69 174.76 11.26 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-O 121.864 0.84 . . . . 10.0 110.123 -179.503 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -165.3 30.56 0.06 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.552 -1.204 . . . . 10.0 112.641 168.625 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.434 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.41 -35.24 79.75 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 119.696 1.134 . . . . 10.0 112.423 -168.923 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.46 -20.75 50.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 118.06 0.391 . . . . 10.0 111.737 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.73 -160.43 13.2 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 105.852 -2.899 . . . . 10.0 105.852 -167.032 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 59.9 m -70.21 65.75 0.27 Allowed 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 126.321 1.848 . . . . 10.0 111.547 -175.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -153.38 -52.53 0.1 Allowed 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 124.446 1.098 . . . . 10.0 108.727 177.543 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 18.4 m -51.38 -34.94 36.52 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.205 1.002 . . . . 10.0 111.809 -177.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -26.8 -38.88 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.848 2.859 . . . . 10.0 114.47 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 110.39 139.69 8.3 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 110.285 -1.126 . . . . 10.0 110.285 169.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.27 55.54 4.65 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.61 3.54 . . . . 10.0 113.266 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 18.2 m170 62.88 48.58 3.94 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.418 2.287 . . . . 10.0 109.197 178.286 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -66.84 71.78 0.09 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.296 1.038 . . . . 10.0 111.68 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.0 p-10 -84.1 153.33 63.05 Favored Pre-proline 0 C--N 1.326 -0.45 0 O-C-N 121.212 -0.93 . . . . 10.0 111.84 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.66 -43.9 1.7 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.685 2.256 . . . . 10.0 111.447 176.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.0 mt -75.98 62.27 1.61 Allowed 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.711 0.805 . . . . 10.0 109.94 -178.499 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.2 p -40.28 99.87 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.423 1.889 . . . . 10.0 112.796 -173.087 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 14.2 mtp180 -140.26 177.71 7.8 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 126.058 1.743 . . . . 10.0 107.961 -175.27 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.5 mttt -110.66 82.47 1.6 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 112.218 0.451 . . . . 10.0 112.218 -168.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.459 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 69.1 t60 18.0 93.4 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 116.275 1.954 . . . . 10.0 116.275 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.07 -157.45 16.41 Favored Glycine 0 N--CA 1.441 -0.983 0 C-N-CA 125.223 1.392 . . . . 10.0 110.766 177.224 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -165.86 -159.21 11.56 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 106.351 -2.699 . . . . 10.0 106.351 169.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -63.88 6.45 0.28 Allowed 'Trans proline' 0 CA--C 1.543 0.967 0 CA-C-N 120.665 2.233 . . . . 10.0 111.546 168.032 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.415 ' H ' ' C ' ' B' ' 73' ' ' GLY . 11.7 mmmt -114.15 5.88 16.1 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 125.59 1.556 . . . . 10.0 110.064 176.108 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -141.32 169.13 18.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 119.729 1.15 . . . . 10.0 109.342 167.414 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.71 -27.05 29.27 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 166.172 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.87 33.51 0.33 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 124.621 1.168 . . . . 10.0 113.217 -171.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.02 138.76 11.3 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 167.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.459 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 30.9 m80 -66.48 -62.45 1.46 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 118.16 -1.416 . . . . 10.0 108.611 169.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.4 p -164.45 -58.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 108.679 -0.86 . . . . 10.0 108.679 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.8 66.5 0.35 Allowed Glycine 0 C--N 1.334 0.471 0 N-CA-C 109.067 -1.613 . . . . 10.0 109.067 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -112.07 101.62 9.89 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.822 -1.918 . . . . 10.0 105.822 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 19.4 mt -72.65 -18.37 61.58 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.27 0.486 . . . . 10.0 112.195 -169.779 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 112.73 -95.44 0.78 Allowed Glycine 0 N--CA 1.443 -0.866 0 N-CA-C 106.781 -2.528 . . . . 10.0 106.781 -173.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -155.12 150.61 27.35 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.099 -1.075 . . . . 10.0 108.099 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.05 131.39 62.41 Favored 'Isoleucine or valine' 0 C--O 1.232 0.143 0 N-CA-C 107.332 -1.359 . . . . 10.0 107.332 168.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -95.22 119.12 33.18 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.006 0.522 . . . . 10.0 109.594 -176.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.96 133.54 38.61 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.707 1.203 . . . . 10.0 110.261 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -61.31 168.99 2.38 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.572 1.149 . . . . 10.0 109.215 166.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.18 -29.41 45.66 Favored 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 123.357 0.663 . . . . 10.0 111.385 172.63 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -77.63 -5.04 48.98 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 121.204 0.526 . . . . 10.0 111.423 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.0 3.17 88.0 Favored Glycine 0 C--N 1.338 0.694 0 O-C-N 120.785 -1.197 . . . . 10.0 111.067 -176.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.47 106.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.16 -1.422 . . . . 10.0 107.16 179.251 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.452 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -103.46 126.01 50.36 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 109.18 -0.674 . . . . 10.0 109.18 170.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -79.43 126.33 30.7 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 168.39 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 54.1 t -107.23 131.16 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 168.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.1 p -157.92 56.2 0.48 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 118.316 0.507 . . . . 10.0 111.152 176.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.93 152.05 4.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 C-N-CA 124.301 1.04 . . . . 10.0 109.055 -171.195 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -102.86 106.8 17.44 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 125.766 1.626 . . . . 10.0 108.865 174.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -80.11 77.58 6.81 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.103 -1.443 . . . . 10.0 107.103 175.449 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.1 m -80.61 50.03 1.26 Allowed 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -155.38 -48.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 C-N-CA 122.606 0.362 . . . . 10.0 110.994 -168.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.499 ' C ' HD12 ' B' ' 104' ' ' ILE 0.343 1.1 pp -104.22 177.09 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 C-N-CA 123.6 0.76 . . . . 10.0 112.24 178.482 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -138.12 138.92 39.15 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.848 -1.167 . . . . 10.0 107.848 171.209 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.88 -24.68 26.56 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 104.149 -2.538 . . . . 10.0 104.149 168.532 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 32.2 t . . . . . 0 N--CA 1.445 -0.693 0 CA-C-O 120.342 0.115 . . . . 10.0 111.306 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 8.1 pt -69.83 49.69 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 C-N-CA 125.783 1.633 . . . . 10.0 111.848 176.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -97.95 151.4 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 C-N-CA 126.5 1.92 . . . . 10.0 107.052 171.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 59.52 32.27 72.78 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.319 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 mmt-85 -105.34 170.44 7.88 Favored 'General case' 0 CA--C 1.536 0.424 0 N-CA-C 106.612 -1.625 . . . . 10.0 106.612 168.383 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.6 m -112.95 129.38 56.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 177.424 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.494 HD21 HD11 ' B' ' 149' ' ' ILE . 64.6 mt -102.07 141.57 34.71 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 107.806 -1.183 . . . . 10.0 107.806 173.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 67.8 t -129.39 133.32 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.084 -1.45 . . . . 10.0 107.084 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -106.51 134.09 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 105.963 -1.866 . . . . 10.0 105.963 169.489 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.63 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.1 m170 -112.13 157.6 20.64 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 123.589 1.661 . . . . 10.0 114.63 -170.537 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 121' ' ' GLU . . . . . 0.475 ' N ' HD22 ' B' ' 144' ' ' LEU . 52.1 tt0 -45.79 -53.24 9.9 Favored 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 128.102 2.561 . . . . 10.0 110.041 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -119.58 175.56 5.79 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 125.084 1.354 . . . . 10.0 111.234 -172.27 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.91 149.68 37.69 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 124.667 1.187 . . . . 10.0 110.48 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.498 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.3 m-20 -77.13 135.62 38.57 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 123.325 0.65 . . . . 10.0 110.238 170.415 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.3 m-20 -77.13 -21.29 54.41 Favored 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 124.891 1.369 . . . . 10.0 109.72 168.316 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 76.9 mt 60.71 58.5 2.39 Favored 'General case' 0 C--N 1.342 0.253 0 CA-C-O 123.279 1.514 . . . . 10.0 109.387 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.36 -43.23 3.11 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 112.737 -2.029 . . . . 10.0 110.158 169.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 17.9 mtmm -78.24 44.28 0.49 Allowed 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.625 1.57 . . . . 10.0 111.821 -175.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.21 -33.82 7.47 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.574 2.035 . . . . 10.0 110.12 172.052 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.17 33.69 48.74 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 123.473 0.559 . . . . 10.0 112.278 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -145.11 165.5 28.08 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 105.905 -1.887 . . . . 10.0 105.905 174.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -55.08 -48.42 73.56 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-O 121.246 0.546 . . . . 10.0 110.068 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -59.86 -30.35 68.92 Favored 'General case' 0 N--CA 1.453 -0.312 0 O-C-N 121.69 -0.631 . . . . 10.0 111.726 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -51.84 -51.91 53.2 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 121.358 -0.838 . . . . 10.0 110.174 169.565 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.9 t -82.19 -10.74 59.05 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.841 -0.618 . . . . 10.0 112.105 -173.082 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.4 ttmm -100.17 -52.73 3.32 Favored 'General case' 0 N--CA 1.436 -1.143 0 C-N-CA 125.417 1.487 . . . . 10.0 111.506 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.0 p -140.05 31.18 1.99 Allowed 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.65 0.78 . . . . 10.0 112.2 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.23 19.65 64.28 Favored Glycine 0 C--N 1.339 0.706 0 CA-C-N 119.246 0.93 . . . . 10.0 112.29 174.874 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 53.62 26.14 5.52 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 117.915 0.858 . . . . 10.0 112.325 -173.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.37 0.78 3.53 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.698 -0.626 . . . . 10.0 112.455 -178.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.75 -165.18 47.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 109.918 -1.273 . . . . 10.0 109.918 168.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -54.19 134.11 44.5 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.61 0.719 . . . . 10.0 110.084 -172.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.04 67.59 0.07 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 169.266 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.475 HD22 ' N ' ' B' ' 121' ' ' GLU . 1.1 pt? -61.71 -25.18 67.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.815 0.672 . . . . 10.0 112.815 -168.174 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -154.33 148.68 26.08 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.133 0.492 . . . . 10.0 109.793 177.258 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 21.2 p -158.13 168.78 26.13 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.947 0.499 . . . . 10.0 109.958 -175.082 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -165.53 167.51 39.02 Favored Glycine 0 CA--C 1.528 0.844 0 N-CA-C 110.704 -0.959 . . . . 10.0 110.704 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 74.0 t -109.64 142.85 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.38 0 C-N-CA 125.48 1.512 . . . . 10.0 107.139 -169.724 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.494 HD11 HD21 ' B' ' 117' ' ' LEU . 67.7 mt -80.35 112.88 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 C-N-CA 122.492 0.317 . . . . 10.0 110.793 -172.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.05 145.39 17.66 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 124.691 1.138 . . . . 10.0 110.745 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 44.9 mt -62.89 148.52 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 124.473 1.109 . . . . 10.0 109.661 174.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.34 170.13 17.43 Favored 'General case' 0 N--CA 1.439 -0.983 0 CA-C-O 122.619 1.2 . . . . 10.0 110.84 168.541 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 . . . . . 0 C--O 1.25 1.082 0 C-N-CA 129.585 3.154 . . . . 10.0 103.097 165.132 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.803 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -156.35 -44.29 0.07 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 118.47 0.577 . . . . 10.0 110.955 172.227 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.5 ttpp -113.78 142.87 45.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 106.918 -1.512 . . . . 10.0 106.918 167.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.74 171.06 14.77 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.477 -1.305 . . . . 10.0 107.477 171.793 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -140.42 166.59 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 123.897 0.879 . . . . 10.0 110.235 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.68 112.37 5.36 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 168.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.448 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.4 m -97.59 114.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 173.124 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -103.51 137.2 41.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 -174.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -146.33 165.39 29.44 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.924 1.238 . . . . 10.0 107.998 170.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.71 -58.81 0.04 OUTLIER Glycine 0 C--O 1.23 -0.096 0 CA-C-N 115.024 -0.989 . . . . 10.0 112.791 169.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.41 -44.91 49.82 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -171.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.48 -65.7 0.57 Allowed Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 113.601 -1.636 . . . . 10.0 110.659 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -59.0 -37.1 95.24 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.737 2.291 . . . . 10.0 111.315 174.154 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -67.33 106.58 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.007 0 N-CA-C 107.017 -1.475 . . . . 10.0 107.017 175.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -121.78 106.81 11.63 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.03 -1.841 . . . . 10.0 106.03 170.007 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.819 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -89.43 143.39 17.26 Favored Glycine 0 N--CA 1.434 -1.491 0 N-CA-C 109.66 -1.376 . . . . 10.0 109.66 173.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.634 HG22 HG23 ' B' ' 54' ' ' THR . 1.1 mt -150.22 84.56 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.207 -1.405 . . . . 10.0 107.207 -169.286 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.574 HD12 ' HA3' ' A' ' 33' ' ' GLY . 1.0 OUTLIER -96.19 145.43 8.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 C-N-CA 125.273 1.429 . . . . 10.0 110.963 175.815 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -128.95 117.49 21.05 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.942 2.097 . . . . 10.0 109.126 169.134 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -95.52 125.45 40.13 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.72 1.208 . . . . 10.0 108.862 178.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.53 132.99 53.62 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 125.121 1.368 . . . . 10.0 111.456 175.651 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -132.64 79.71 1.86 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 127.971 2.508 . . . . 10.0 106.045 168.227 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -56.12 -45.63 79.47 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 127.873 2.469 . . . . 10.0 110.658 -172.49 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -122.75 161.71 23.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 102.305 -3.22 . . . . 10.0 102.305 167.047 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -58.51 -30.27 66.92 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.473 -0.785 . . . . 10.0 109.073 174.233 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 m-80 -90.26 -9.13 49.1 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 124.892 1.277 . . . . 10.0 111.037 -174.074 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.29 138.8 27.01 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -59.82 135.46 63.68 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 N-CA-C 106.044 -2.329 . . . . 10.0 106.044 168.493 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 t -78.73 129.06 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.016 -1.476 . . . . 10.0 107.016 -170.244 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt -101.01 118.15 36.44 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.495 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -103.03 96.74 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 172.669 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -103.4 167.14 10.0 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 121.932 0.872 . . . . 10.0 110.613 168.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.574 ' HA3' HD12 ' A' ' 18' ' ' ILE . . . 176.03 -177.74 47.61 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.616 -0.802 . . . . 10.0 111.211 175.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.8 m -154.5 91.77 1.43 Allowed 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 -175.171 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.819 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.5 pt -78.96 151.68 4.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 CA-C-O 118.327 -0.844 . . . . 10.0 108.775 169.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.408 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -135.6 156.4 48.92 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 165.614 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.33 -10.13 39.21 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 123.836 0.731 . . . . 10.0 112.887 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -68.68 176.26 3.08 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 118.172 0.986 . . . . 10.0 109.641 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.1 t -105.32 150.41 25.21 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.451 -1.314 . . . . 10.0 107.451 167.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -50.86 146.11 6.34 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.115 0.966 . . . . 10.0 112.276 -169.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.3 -179.26 29.51 Favored Glycine 0 CA--C 1.528 0.85 0 C-N-CA 124.279 0.942 . . . . 10.0 112.128 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mt -57.85 148.72 24.5 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.133 2.173 . . . . 10.0 112.87 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -150.88 147.92 27.81 Favored 'General case' 0 CA--C 1.518 -0.254 0 C-N-CA 125.78 1.632 . . . . 10.0 112.18 176.477 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.621 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -33.17 125.36 0.33 Allowed Glycine 0 C--N 1.338 0.68 0 C-N-CA 126.462 1.982 . . . . 10.0 112.2 164.719 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -153.13 107.52 3.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 119.158 1.479 . . . . 10.0 110.279 166.265 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.4 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -154.93 169.52 23.85 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.67 0.748 . . . . 10.0 112.021 -179.214 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.1 m -84.72 153.18 3.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 112.663 -2.062 . . . . 10.0 107.715 168.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.91 148.43 50.49 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 107.536 -1.283 . . . . 10.0 107.536 171.233 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -35.91 -60.94 0.51 Allowed 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 126.576 1.95 . . . . 10.0 113.736 -170.467 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -98.8 161.14 13.8 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-O 121.925 0.869 . . . . 10.0 111.368 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.34 -22.88 28.25 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 126.46 1.981 . . . . 10.0 109.866 168.182 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -44.41 136.93 3.9 Favored 'General case' 0 C--N 1.342 0.243 0 C-N-CA 123.669 0.788 . . . . 10.0 110.275 169.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -141.51 21.1 2.2 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 10.0 111.439 -178.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.874 HG22 ' CG2' ' B' ' 17' ' ' ILE . 3.6 p -52.06 -39.01 59.03 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 113.961 1.096 . . . . 10.0 113.961 -174.722 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.04 -11.29 59.92 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.244 0.618 . . . . 10.0 111.619 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 118.66 -64.02 0.42 Allowed Glycine 0 C--O 1.225 -0.425 0 C-N-CA 126.052 1.787 . . . . 10.0 109.253 179.182 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.5 t -155.19 55.23 0.64 Allowed 'General case' 0 C--O 1.234 0.277 0 CA-C-O 121.789 0.804 . . . . 10.0 109.732 172.526 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -134.62 -46.47 0.74 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.7 0.8 . . . . 10.0 109.229 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.1 m -51.75 -29.34 18.34 Favored 'General case' 0 C--N 1.344 0.367 0 C-N-CA 123.886 0.874 . . . . 10.0 111.235 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.89 -42.27 0.08 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.748 2.419 . . . . 10.0 112.878 167.741 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.28 165.93 39.08 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -79.39 -164.86 0.3 Allowed 'Trans proline' 0 N--CA 1.444 -1.409 0 N-CA-C 107.353 -1.826 . . . . 10.0 107.353 169.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -80.25 46.54 0.83 Allowed 'General case' 0 CA--C 1.542 0.657 0 O-C-N 120.69 -1.256 . . . . 10.0 110.634 -176.571 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -75.31 70.08 2.19 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 119.352 0.978 . . . . 10.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -71.15 149.19 94.42 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 169.07 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -58.77 -47.12 19.7 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.407 2.071 . . . . 10.0 111.147 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.32 60.82 2.06 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 108.731 -0.841 . . . . 10.0 108.731 174.155 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.5 t -61.19 112.46 2.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 108.664 -0.865 . . . . 10.0 108.664 -178.143 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 75.4 mtt180 -105.82 -98.66 0.34 Allowed 'General case' 0 CA--C 1.512 -0.491 0 N-CA-C 106.157 -1.794 . . . . 10.0 106.157 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.9 pttt -158.81 144.97 16.84 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 104.982 -2.229 . . . . 10.0 104.982 169.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -47.33 121.78 4.12 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.366 0.603 . . . . 10.0 111.526 174.087 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.13 -156.13 6.69 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 106.235 -2.746 . . . . 10.0 106.235 169.456 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -148.34 -168.84 14.73 Favored Glycine 0 C--O 1.225 -0.43 0 CA-C-N 118.477 1.139 . . . . 10.0 113.464 -178.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -69.73 16.27 0.22 Allowed 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 123.416 2.744 . . . . 10.0 112.303 175.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -105.53 -29.24 10.3 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 126.4 1.88 . . . . 10.0 108.999 168.786 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -107.9 172.19 6.97 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -89.41 -26.76 20.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 122.065 0.936 . . . . 10.0 109.351 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -78.6 -11.18 59.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 125.965 1.706 . . . . 10.0 114.692 -167.276 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.432 HH21 ' CG ' ' A' ' 101' ' ' ASP . 0.0 OUTLIER -34.69 129.17 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.699 1.2 . . . . 10.0 112.186 176.915 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -65.59 169.76 5.84 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 107.81 -1.182 . . . . 10.0 107.81 175.351 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.2 p -63.55 15.04 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 N-CA-C 115.864 1.801 . . . . 10.0 115.864 -169.664 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.51 55.91 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.621 0 N-CA-C 108.997 -1.641 . . . . 10.0 108.997 170.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -97.37 102.5 14.28 Favored 'General case' 0 N--CA 1.457 -0.109 0 N-CA-C 106.746 -1.575 . . . . 10.0 106.746 168.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -83.03 9.7 9.66 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.956 0.344 . . . . 10.0 111.49 -177.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 84.55 -100.18 2.35 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 107.536 -2.226 . . . . 10.0 107.536 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -145.57 157.57 43.96 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 107.287 -1.375 . . . . 10.0 107.287 174.157 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.3 m -112.48 126.12 69.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 109.02 -0.733 . . . . 10.0 109.02 169.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 70.1 m -94.72 101.53 13.38 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 127.518 2.327 . . . . 10.0 109.254 -170.118 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.7 141.64 37.75 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 122.373 -0.204 . . . . 10.0 111.113 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -69.5 173.77 5.61 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.343 2.257 . . . . 10.0 109.267 167.161 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -23.91 67.56 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.028 0.381 . . . . 10.0 112.028 174.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.408 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 32.7 t70 -78.21 -1.47 32.99 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 120.993 0.425 . . . . 10.0 111.226 173.203 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.23 1.11 89.58 Favored Glycine 0 C--N 1.339 0.732 0 O-C-N 120.679 -1.263 . . . . 10.0 110.51 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -77.41 105.66 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 -176.288 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.527 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -102.64 113.26 26.49 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.389 -0.967 . . . . 10.0 108.389 169.429 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.29 117.97 20.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 126.603 1.961 . . . . 10.0 107.91 173.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 26.4 t -105.89 135.86 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 N-CA-C 106.399 -1.704 . . . . 10.0 106.399 177.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -158.64 62.41 0.43 Allowed 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 123.649 0.779 . . . . 10.0 110.22 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -107.46 161.63 6.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -139.64 151.76 46.23 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.263 1.025 . . . . 10.0 109.404 167.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.432 ' CG ' HH21 ' A' ' 79' ' ' ARG . 25.0 t0 -146.97 152.43 38.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.645 -1.243 . . . . 10.0 107.645 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.9 p -105.66 -13.26 15.62 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.862 2.465 . . . . 10.0 112.154 -176.766 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -102.27 16.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 119.603 1.092 . . . . 10.0 110.315 179.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -118.05 142.79 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 104.714 -2.328 . . . . 10.0 104.714 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 91.8 p -142.44 149.8 39.74 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 172.046 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.2 mt -62.34 -41.17 98.35 Favored 'General case' 0 C--O 1.231 0.105 0 CA-C-N 119.025 0.83 . . . . 10.0 109.485 170.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.3 p -146.95 164.56 32.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.176 1.39 . . . . 10.0 108.947 -178.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 122.87 -105.0 0.91 Allowed Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 106.431 -2.668 . . . . 10.0 106.431 -169.211 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -126.68 -43.61 1.71 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.368 1.067 . . . . 10.0 110.362 -168.252 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 20.8 m-70 -73.7 -48.53 31.44 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 105.116 -2.179 . . . . 10.0 105.116 174.864 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.3 t 45.12 60.7 2.86 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 124.771 1.228 . . . . 10.0 113.214 167.093 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.8 pt -63.97 -11.43 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 113.339 0.866 . . . . 10.0 113.339 -175.07 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.1 mm -48.13 141.08 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 119.976 1.262 . . . . 10.0 110.923 170.607 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.44 16.98 75.9 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 125.074 1.321 . . . . 10.0 115.609 169.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 24.9 mmt-85 -84.65 165.61 17.79 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.917 1.358 . . . . 10.0 108.003 166.793 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 74.1 m -90.48 127.9 36.37 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 107.572 -1.27 . . . . 10.0 107.572 166.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.08 136.81 32.8 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 165.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.48 136.56 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.743 0 N-CA-C 107.075 -1.454 . . . . 10.0 107.075 171.56 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -105.25 134.53 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.166 -2.161 . . . . 10.0 105.166 167.038 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.621 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m-70 -114.11 158.13 21.68 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -170.32 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.418 ' N ' HD22 ' A' ' 144' ' ' LEU . 0.5 OUTLIER -58.67 -48.91 79.46 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 112.883 -1.962 . . . . 10.0 109.08 -174.735 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.9 mttm -110.76 175.05 5.57 Favored 'General case' 0 C--N 1.34 0.191 0 CA-C-O 121.492 0.663 . . . . 10.0 111.934 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.37 152.81 24.88 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.615 -1.175 . . . . 10.0 110.092 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.4 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.6 OUTLIER -76.75 149.11 36.34 Favored 'General case' 0 N--CA 1.443 -0.775 0 C-N-CA 123.782 0.833 . . . . 10.0 112.175 -179.382 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -79.06 -28.3 43.16 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 112.534 -2.121 . . . . 10.0 110.425 172.03 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 50.7 mt 50.57 48.47 22.53 Favored 'General case' 0 C--N 1.341 0.219 0 CA-C-O 122.349 1.071 . . . . 10.0 109.812 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.3 -11.06 70.9 Favored Glycine 0 CA--C 1.53 1.011 0 CA-C-N 113.907 -1.497 . . . . 10.0 114.086 169.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -81.57 -0.63 43.1 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.07 1.435 . . . . 10.0 114.078 -168.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.64 -22.44 79.01 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.75 38.86 65.33 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.345 -0.702 . . . . 10.0 111.345 -177.453 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -135.39 172.37 13.11 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 107.613 -1.254 . . . . 10.0 107.613 174.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -54.63 -47.89 72.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.424 0.631 . . . . 10.0 109.809 -178.093 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.27 -39.77 80.1 Favored 'General case' 0 C--O 1.236 0.353 0 O-C-N 121.516 -0.74 . . . . 10.0 111.707 176.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.3 p -53.28 -38.76 63.38 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 118.655 -0.688 . . . . 10.0 110.375 177.626 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.9 t -87.24 -7.83 57.46 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 123.703 0.627 . . . . 10.0 112.333 -177.217 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.9 mttt -103.17 -60.88 1.48 Allowed 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.215 -0.928 . . . . 10.0 111.277 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 14.3 p -135.55 17.4 3.35 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 118.677 0.671 . . . . 10.0 111.16 -177.359 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 75.93 -102.43 1.55 Allowed Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 107.453 -2.259 . . . . 10.0 107.453 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.7 m-20 -165.38 40.21 0.07 Allowed 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 124.933 1.293 . . . . 10.0 107.962 173.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.12 -11.95 61.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.519 0.728 . . . . 10.0 111.639 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.32 -163.33 54.63 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.61 -1.396 . . . . 10.0 109.61 174.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -51.05 133.98 26.87 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 124.258 1.023 . . . . 10.0 112.788 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.5 mtt180 -67.95 64.11 0.09 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.518 1.927 . . . . 10.0 108.592 171.738 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.449 HD22 ' C ' ' A' ' 120' ' ' HIS . 1.1 pt? -60.59 -22.92 64.25 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -168.787 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.12 148.5 22.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 109.323 -0.621 . . . . 10.0 109.323 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 17.7 p -163.25 168.97 19.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 110.109 -0.33 . . . . 10.0 110.109 -171.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.99 169.75 42.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.325 -0.71 . . . . 10.0 111.325 -176.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 96.6 t -109.87 145.55 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 106.271 -1.752 . . . . 10.0 106.271 -171.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 89.0 mt -74.6 138.22 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 110.403 -0.221 . . . . 10.0 110.403 -175.394 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.8 146.7 16.66 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.035 1.302 . . . . 10.0 110.308 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 80.4 mt -80.32 154.06 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.607 1.203 . . . . 10.0 109.17 177.54 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.88 -109.15 0.33 Allowed 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.326 -1.361 . . . . 10.0 107.326 167.202 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 1 C-N-CA 132.795 4.438 . . . . 10.0 102.843 -174.289 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 119.085 -0.483 . . . . 10.0 110.783 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.0 t -113.6 -13.19 12.76 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 124.105 0.962 . . . . 10.0 112.796 170.1 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -141.57 147.85 38.35 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 118.525 0.602 . . . . 10.0 109.718 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.99 156.55 47.11 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 123.984 0.914 . . . . 10.0 109.828 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -116.83 153.58 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 126.239 1.815 . . . . 10.0 109.044 172.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.86 97.99 3.55 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.924 -1.51 . . . . 10.0 106.924 166.268 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 m -77.86 121.63 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.111 -1.07 . . . . 10.0 108.111 170.371 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mt -103.16 130.32 50.3 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 117.85 -1.072 . . . . 10.0 108.769 -174.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 45.0 mtpt -145.46 160.01 42.23 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 120.236 1.38 . . . . 10.0 109.467 170.059 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.81 -71.26 0.01 OUTLIER Glycine 0 C--O 1.229 -0.177 0 CA-C-N 114.845 -1.07 . . . . 10.0 111.808 173.246 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.61 -43.64 54.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 106.865 -1.531 . . . . 10.0 106.865 -171.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.57 -65.5 0.57 Allowed Glycine 0 N--CA 1.443 -0.871 0 CA-C-N 113.299 -1.773 . . . . 10.0 111.27 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -54.57 -39.78 86.92 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.6 2.2 . . . . 10.0 111.019 173.262 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 64.9 t -66.33 99.49 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 107.729 -1.212 . . . . 10.0 107.729 173.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -124.61 123.0 39.11 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 125.169 1.388 . . . . 10.0 108.593 173.385 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.01 156.7 15.52 Favored Glycine 0 C--N 1.333 0.402 0 N-CA-C 111.872 -0.491 . . . . 10.0 111.872 171.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.874 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.2 mt -141.12 63.45 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 C-N-CA 124.466 1.106 . . . . 10.0 108.609 -172.489 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -78.22 141.09 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.073 0 O-C-N 121.502 -0.748 . . . . 10.0 110.138 -170.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.6 115.79 24.08 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 128.812 2.845 . . . . 10.0 108.156 -175.539 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -108.97 107.17 17.44 Favored 'General case' 0 C--N 1.333 -0.128 0 C-N-CA 124.411 1.084 . . . . 10.0 108.098 173.61 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -99.22 130.62 45.54 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 119.211 0.914 . . . . 10.0 112.064 169.603 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 tp60 -79.79 110.48 15.18 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 105.146 -2.168 . . . . 10.0 105.146 168.175 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mmmt . . . . . 0 CA--C 1.514 -0.423 0 C-N-CA 126.801 2.04 . . . . 10.0 110.0 -177.53 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.09 0 N-CA-C 108.699 -1.76 . . . . 10.0 108.699 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -60.51 140.04 89.31 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.297 1.998 . . . . 10.0 109.643 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.3 t -79.27 108.22 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.048 0 N-CA-C 105.569 -2.012 . . . . 10.0 105.569 175.118 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 56.1 mttm -83.52 119.05 24.22 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 105.126 -2.176 . . . . 10.0 105.126 168.348 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -105.79 111.15 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 177.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -129.15 170.9 12.97 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 120.79 0.329 . . . . 10.0 111.72 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.63 -153.25 25.17 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 107.787 -2.125 . . . . 10.0 107.787 172.285 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.7 156.52 35.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 117.656 0.728 . . . . 10.0 110.286 177.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.779 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -116.29 113.79 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 127.479 2.312 . . . . 10.0 106.894 167.782 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 1.3 pttt -96.58 136.43 37.11 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 108.413 -0.958 . . . . 10.0 108.413 168.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.95 0.27 9.03 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 124.892 1.234 . . . . 10.0 113.679 173.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -75.12 177.17 6.63 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 118.74 1.27 . . . . 10.0 110.785 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.0 t -107.76 149.75 27.81 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.706 -1.59 . . . . 10.0 106.706 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -44.87 140.72 2.45 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.811 1.644 . . . . 10.0 112.156 -172.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.75 -175.28 19.28 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 123.583 0.611 . . . . 10.0 112.18 171.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -70.91 147.59 48.61 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.305 1.442 . . . . 10.0 110.803 -174.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 81.9 m-70 -144.29 145.02 31.76 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.162 0.801 . . . . 10.0 113.162 178.001 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.667 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -27.7 125.0 0.06 OUTLIER Glycine 0 C--N 1.344 0.996 0 C-N-CA 127.039 2.257 . . . . 10.0 111.973 164.501 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -150.1 105.36 3.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 119.317 1.559 . . . . 10.0 112.085 168.729 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.08 171.25 18.16 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 122.054 0.931 . . . . 10.0 111.966 -178.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 8.0 m -92.31 149.0 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.789 -2.46 . . . . 10.0 106.694 167.385 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -120.64 131.44 54.61 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.069 -2.567 . . . . 10.0 104.069 169.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -60.47 -46.5 89.87 Favored 'General case' 0 N--CA 1.452 -0.334 0 O-C-N 124.315 1.009 . . . . 10.0 113.128 -165.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 11.5 m-30 -78.67 135.31 37.16 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 118.619 -1.232 . . . . 10.0 107.758 175.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.51 -41.26 98.0 Favored Glycine 0 CA--C 1.533 1.164 0 N-CA-C 107.918 -2.073 . . . . 10.0 107.918 166.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -29.48 101.31 0.02 OUTLIER 'General case' 0 C--N 1.344 0.369 0 C-N-CA 128.098 2.559 . . . . 10.0 113.933 -169.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.448 ' HB3' HG21 ' A' ' 7' ' ' VAL . 1.1 m-80 -107.67 14.54 25.52 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 113.836 -1.529 . . . . 10.0 111.297 173.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.634 HG23 HG22 ' A' ' 17' ' ' ILE . 0.8 OUTLIER -57.7 -33.05 67.98 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 120.453 1.479 . . . . 10.0 110.587 -176.594 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -20.0 51.19 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.049 1.34 . . . . 10.0 113.076 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.89 95.81 1.87 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.74 1.162 . . . . 10.0 110.439 -176.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 26.6 t 19.55 66.85 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.617 2.367 . . . . 10.0 114.219 -174.221 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.2 m -151.38 -52.09 0.13 Allowed 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 124.946 1.299 . . . . 10.0 107.741 -174.093 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 13.8 t -73.89 4.57 5.13 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.718 -0.614 . . . . 10.0 112.131 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.05 -22.36 66.8 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.938 1.295 . . . . 10.0 111.37 177.056 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.2 140.32 11.0 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 169.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -75.89 62.31 6.53 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.576 2.851 . . . . 10.0 111.102 176.39 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.0 m170 58.58 61.89 2.1 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 126.347 1.859 . . . . 10.0 109.123 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -68.66 71.47 0.21 Allowed 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 122.502 1.144 . . . . 10.0 111.843 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -74.96 152.88 86.7 Favored Pre-proline 0 C--N 1.32 -0.693 0 C-N-CA 127.664 2.385 . . . . 10.0 111.443 -178.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.74 163.49 38.05 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.564 2.176 . . . . 10.0 110.534 177.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . 0.29 0.2 OUTLIER 49.52 -96.5 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.745 1.618 . . . . 10.0 110.747 -169.676 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.3 m 172.59 94.8 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 128.079 2.552 . . . . 10.0 108.138 173.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -103.73 156.92 17.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 107.744 -1.206 . . . . 10.0 107.744 169.234 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 97.06 7.81 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.362 -0.352 . . . . 10.0 110.091 -172.31 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.552 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.6 t60 -10.17 96.1 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 C-N-CA 126.975 2.11 . . . . 10.0 114.072 -173.488 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -117.97 -162.14 12.25 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 108.971 -1.652 . . . . 10.0 108.971 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.29 -168.92 13.27 Favored Glycine 0 N--CA 1.449 -0.482 0 N-CA-C 110.521 -1.032 . . . . 10.0 110.521 175.076 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -67.45 11.39 0.22 Allowed 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.155 1.903 . . . . 10.0 112.302 175.454 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -101.24 -25.03 14.14 Favored 'General case' 0 N--CA 1.443 -0.814 0 C-N-CA 124.563 1.145 . . . . 10.0 108.896 169.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -107.85 170.88 7.72 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -169.284 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -86.03 -31.17 22.13 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 169.14 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -86.82 21.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 125.563 1.545 . . . . 10.0 113.062 -167.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.54 128.09 34.5 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.104 -1.443 . . . . 10.0 107.104 167.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.552 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 18.4 m170 -58.17 -68.09 0.28 Allowed 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.054 0.454 . . . . 10.0 111.096 -172.042 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.9 p -162.98 -51.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.456 -0.942 . . . . 10.0 108.456 -171.569 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -138.48 62.94 0.56 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 109.327 -1.509 . . . . 10.0 109.327 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -99.93 104.0 15.61 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 104.626 -2.361 . . . . 10.0 104.626 168.476 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -78.76 -2.97 42.02 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 119.235 0.925 . . . . 10.0 111.138 -175.637 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 85' ' ' GLY . . . . . 0.553 ' HA2' HD21 ' B' ' 126' ' ' LEU . . . 94.77 -98.92 2.36 Favored Glycine 0 N--CA 1.44 -1.039 0 N-CA-C 106.584 -2.606 . . . . 10.0 106.584 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -144.78 160.57 41.03 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 123.587 0.755 . . . . 10.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.55 132.03 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 105.495 -2.039 . . . . 10.0 105.495 166.184 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -94.83 118.12 31.25 Favored 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 108.656 -0.868 . . . . 10.0 108.656 -178.373 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.03 127.98 34.44 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 123.468 0.707 . . . . 10.0 109.135 175.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -61.94 167.06 4.04 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 124.453 1.096 . . . . 10.0 109.118 168.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -52.54 -28.88 22.61 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 126.022 1.729 . . . . 10.0 111.53 171.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -77.23 -10.86 59.69 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 118.115 0.416 . . . . 10.0 111.597 178.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.09 15.84 60.26 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 121.037 -1.04 . . . . 10.0 111.034 -177.316 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.0 t -97.43 106.82 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.889 2.076 . . . . 10.0 106.497 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.779 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -97.92 123.93 42.13 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.84 -1.17 . . . . 10.0 107.84 169.369 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -91.72 132.0 36.7 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 175.312 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -101.64 126.45 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 105.686 -1.968 . . . . 10.0 105.686 168.63 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 63.4 m -155.15 66.94 0.65 Allowed 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 125.001 1.32 . . . . 10.0 107.749 172.035 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -113.3 162.47 11.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 106.322 -1.733 . . . . 10.0 106.322 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -141.62 147.69 38.0 Favored 'General case' 0 N--CA 1.446 -0.672 0 O-C-N 121.36 -0.838 . . . . 10.0 111.06 168.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -132.75 137.11 46.74 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.92 1.288 . . . . 10.0 108.988 -175.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 1.7 p -108.79 56.75 0.62 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 125.615 1.566 . . . . 10.0 108.088 171.131 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.57 -61.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 N-CA-C 109.018 -0.734 . . . . 10.0 109.018 178.641 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.333 0.0 OUTLIER -70.41 169.55 1.41 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 112.74 0.644 . . . . 10.0 112.74 176.874 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 12.3 m -158.57 138.76 12.34 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 174.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 pp -81.75 -18.64 43.53 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.859 0.464 . . . . 10.0 110.232 172.477 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t . . . . . 0 N--CA 1.452 -0.351 0 N-CA-C 106.569 -1.641 . . . . 10.0 106.569 168.196 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 14.2 t . . . . . 0 N--CA 1.452 -0.368 0 CA-C-O 120.62 0.248 . . . . 10.0 110.943 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 44.5 pt -56.45 -14.78 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 N-CA-C 113.526 0.936 . . . . 10.0 113.526 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.5 mm -44.79 128.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 O-C-N 121.366 -0.834 . . . . 10.0 109.619 169.497 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.26 0.17 80.51 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.038 -0.868 . . . . 10.0 112.889 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -79.31 168.13 19.95 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.896 1.348 . . . . 10.0 109.152 168.659 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -112.31 124.81 53.28 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.72 0.808 . . . . 10.0 109.581 176.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.402 HD21 HD11 ' B' ' 149' ' ' ILE . 4.4 mm? -82.24 147.25 29.05 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.026 -1.101 . . . . 10.0 108.026 168.591 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 95.7 t -133.12 134.83 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.901 0 N-CA-C 108.217 -1.031 . . . . 10.0 108.217 168.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -103.47 129.95 54.61 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 105.754 -1.943 . . . . 10.0 105.754 167.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.667 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.9 m-70 -106.15 157.13 17.78 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 115.42 1.637 . . . . 10.0 115.42 -170.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -39.98 -56.62 1.79 Allowed 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 129.264 3.026 . . . . 10.0 110.623 173.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -119.79 168.35 11.17 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.176 0.991 . . . . 10.0 112.546 -169.244 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.81 129.13 38.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 113.98 -1.464 . . . . 10.0 109.129 170.163 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.419 ' CG ' HD23 ' B' ' 126' ' ' LEU . 62.4 t0 -77.77 108.26 10.87 Favored 'General case' 0 N--CA 1.442 -0.859 0 N-CA-C 107.347 -1.353 . . . . 10.0 107.347 171.714 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -78.97 3.38 17.33 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 111.676 0.251 . . . . 10.0 111.676 175.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.553 HD21 ' HA2' ' B' ' 85' ' ' GLY . 22.2 mt 59.79 -146.42 0.49 Allowed 'General case' 0 N--CA 1.419 -2.004 0 N-CA-C 105.97 -1.863 . . . . 10.0 105.97 -177.269 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 -14.28 77.26 Favored Glycine 0 C--N 1.304 -1.221 0 CA-C-N 114.351 -1.295 . . . . 10.0 112.244 -168.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -75.07 -1.27 22.13 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.413 1.107 . . . . 10.0 111.966 -169.665 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.36 -32.56 77.6 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 108.595 -1.802 . . . . 10.0 108.595 168.185 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 62.13 37.63 94.8 Favored Glycine 0 C--N 1.341 0.818 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.66 175.34 9.26 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 105.176 -2.157 . . . . 10.0 105.176 170.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -45.82 -54.17 8.49 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 115.044 -0.98 . . . . 10.0 111.23 172.613 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -64.5 -34.68 78.78 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 119.777 -0.769 . . . . 10.0 111.162 -172.116 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -47.7 -40.0 18.99 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 124.116 0.967 . . . . 10.0 111.702 169.777 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 t -93.08 -4.04 53.11 Favored 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 119.658 1.117 . . . . 10.0 110.362 -170.548 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -110.44 -57.82 2.16 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 125.698 1.599 . . . . 10.0 110.922 -171.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.4 p -137.13 5.84 2.8 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.616 0.644 . . . . 10.0 112.563 175.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.69 32.18 57.6 Favored Glycine 0 C--N 1.341 0.848 0 CA-C-N 118.675 0.67 . . . . 10.0 114.37 172.016 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 15.6 m120 57.78 19.61 5.78 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.794 0.838 . . . . 10.0 113.175 179.106 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.38 -4.04 20.42 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.128 -0.982 . . . . 10.0 112.945 -176.325 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.54 -164.14 53.99 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.679 -0.968 . . . . 10.0 110.679 172.553 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.78 141.73 43.28 Favored 'General case' 0 N--CA 1.445 -0.714 0 C-N-CA 123.696 0.798 . . . . 10.0 111.987 -168.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 25.7 mtm-85 -67.22 71.14 0.1 Allowed 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.62 1.568 . . . . 10.0 109.414 172.501 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 6.8 tp -43.54 -45.56 6.64 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 126.5 1.92 . . . . 10.0 112.212 -174.134 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -159.48 147.41 17.37 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 -173.111 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 9.5 m -141.09 157.27 45.53 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 -168.545 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.6 164.96 30.42 Favored Glycine 0 C--N 1.332 0.346 0 N-CA-C 110.219 -1.152 . . . . 10.0 110.219 175.696 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.02 135.94 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 108.045 -1.095 . . . . 10.0 108.045 -174.514 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.402 HD11 HD21 ' B' ' 117' ' ' LEU . 9.3 mt -75.33 107.13 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 N-CA-C 109.291 -0.633 . . . . 10.0 109.291 -174.766 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.12 154.97 16.38 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 125.799 1.666 . . . . 10.0 110.976 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 90.4 mt -73.27 140.3 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 124.301 1.04 . . . . 10.0 109.937 -175.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.98 -45.99 2.65 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.84 0.456 . . . . 10.0 111.567 169.349 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 mm100 . . . . . 0 N--CA 1.445 -0.683 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 179.381 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.974 0 CA-C-O 118.158 -0.925 . . . . 10.0 109.398 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.2 t -84.29 -13.46 52.42 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 119.661 1.119 . . . . 10.0 111.893 -176.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.5 ptpp? -152.6 157.86 41.62 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.499 0.666 . . . . 10.0 112.351 167.438 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.91 170.62 15.4 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 125.855 1.662 . . . . 10.0 109.635 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.5 150.12 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 C-N-CA 126.462 1.905 . . . . 10.0 110.302 -177.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.62 100.91 4.77 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.005 -1.48 . . . . 10.0 107.005 166.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.495 HG21 ' HB3' ' B' ' 53' ' ' ASN . 6.0 m -82.12 118.91 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 107.821 -1.177 . . . . 10.0 107.821 169.385 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -97.43 138.89 34.18 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.873 -1.158 . . . . 10.0 107.873 177.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.9 ttmt -156.76 162.85 39.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.34 -50.21 0.07 OUTLIER Glycine 0 C--O 1.228 -0.256 0 C-N-CA 120.303 -0.951 . . . . 10.0 112.963 169.117 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -73.31 -45.73 53.75 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.35 -71.48 0.4 Allowed Glycine 0 CA--C 1.524 0.599 0 CA-C-N 114.46 -1.245 . . . . 10.0 110.021 171.394 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -57.95 -33.82 97.61 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.496 2.798 . . . . 10.0 111.192 173.059 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.1 t -64.91 105.58 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 N-CA-C 107.915 -1.143 . . . . 10.0 107.915 174.312 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -124.01 110.64 15.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 106.167 -1.79 . . . . 10.0 106.167 173.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.703 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -91.59 144.38 17.14 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 169.479 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.538 ' CG2' HG22 ' B' ' 54' ' ' THR . 4.9 mt -140.1 80.46 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 106.26 -1.755 . . . . 10.0 106.26 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.7 mm -101.97 123.4 55.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 N-CA-C 109.557 -0.534 . . . . 10.0 109.557 -175.149 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 9.4 m-20 -85.63 151.29 24.01 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 109.268 -0.642 . . . . 10.0 109.268 169.545 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -126.33 91.53 3.39 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.231 -1.766 . . . . 10.0 106.231 169.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -84.27 138.72 32.78 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.175 0.99 . . . . 10.0 109.812 171.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -127.76 112.05 14.35 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 168.71 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.06 -56.4 11.72 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 122.7 1.238 . . . . 10.0 111.64 -170.17 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -139.97 170.39 15.95 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 103.657 -2.72 . . . . 10.0 103.657 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 91.8 p -65.0 -22.71 67.04 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.02 -0.536 . . . . 10.0 110.237 170.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -81.73 -11.75 58.9 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.763 0.825 . . . . 10.0 111.03 177.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.27 159.08 30.71 Favored Glycine 0 CA--C 1.532 1.116 0 O-C-N 121.929 -0.482 . . . . 10.0 112.073 -172.069 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -78.87 149.03 22.72 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 122.79 2.327 . . . . 10.0 107.889 167.79 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -76.6 94.38 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 171.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 mtpm? -73.95 97.7 2.88 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.538 -1.282 . . . . 10.0 107.538 169.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.6 m -85.45 115.01 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 107.261 -1.385 . . . . 10.0 107.261 173.015 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 23.8 p90 -129.9 160.26 34.08 Favored 'General case' 0 CA--C 1.516 -0.36 0 CA-C-O 121.756 0.789 . . . . 10.0 111.952 168.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.57 -173.45 45.41 Favored Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 173.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.8 t -142.43 118.75 10.84 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.683 -1.599 . . . . 10.0 106.683 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.703 HG22 ' HA2' ' A' ' 16' ' ' GLY . 1.5 pp -80.86 175.07 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 109.095 -0.706 . . . . 10.0 109.095 169.813 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -146.32 136.58 23.75 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 167.32 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.33 -5.12 15.31 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.937 0.779 . . . . 10.0 114.656 172.365 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.62 HD23 HD13 ' A' ' 35' ' ' ILE . 0.6 OUTLIER -69.09 176.46 3.19 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 119.147 1.473 . . . . 10.0 111.198 179.36 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -108.24 159.47 16.6 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.703 -1.962 . . . . 10.0 105.703 166.253 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -53.49 163.14 0.67 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.531 1.132 . . . . 10.0 112.935 -169.224 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.17 -174.39 50.84 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 123.962 0.791 . . . . 10.0 112.104 168.279 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 mp -63.26 144.48 56.9 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 125.233 1.413 . . . . 10.0 110.819 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -146.72 144.02 29.13 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 123.82 0.848 . . . . 10.0 111.352 174.421 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.644 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -24.87 121.98 0.03 OUTLIER Glycine 0 C--N 1.343 0.956 0 C-N-CA 128.242 2.829 . . . . 10.0 111.864 166.778 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.96 106.71 3.95 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 120.046 1.923 . . . . 10.0 109.728 171.607 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.456 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -156.46 172.39 18.62 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.56 0.695 . . . . 10.0 112.855 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.15 152.54 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-N 112.581 -2.099 . . . . 10.0 108.078 168.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 79.9 m-70 -126.2 152.69 45.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 170.722 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -49.31 -60.75 2.54 Favored 'General case' 0 N--CA 1.447 -0.576 0 O-C-N 124.202 0.938 . . . . 10.0 111.379 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -82.38 162.09 22.3 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 121.41 0.624 . . . . 10.0 110.141 -174.498 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.77 -6.59 52.26 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 167.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.41 172.52 9.31 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-O 122.588 1.185 . . . . 10.0 111.461 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.49 18.15 0.04 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 114.057 1.132 . . . . 10.0 114.057 -169.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.4 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.3 OUTLIER -50.41 -36.92 35.08 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.983 1.313 . . . . 10.0 113.713 -169.002 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.26 -21.38 49.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.393 0.677 . . . . 10.0 112.492 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.98 102.28 2.44 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 109.396 -1.481 . . . . 10.0 109.396 -172.602 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 37.27 60.78 1.01 Allowed 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 126.273 1.829 . . . . 10.0 112.161 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -157.76 -48.06 0.06 Allowed 'General case' 0 N--CA 1.443 -0.821 0 O-C-N 122.023 -0.423 . . . . 10.0 111.401 176.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -50.63 -35.76 32.03 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 125.092 1.357 . . . . 10.0 110.918 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.28 -36.31 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 128.347 2.659 . . . . 10.0 113.768 169.058 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.51 166.27 26.43 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 107.641 -2.183 . . . . 10.0 107.641 173.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -79.91 -162.77 0.19 Allowed 'Trans proline' 0 N--CA 1.441 -1.599 0 N-CA-C 105.476 -2.548 . . . . 10.0 105.476 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -81.49 53.88 2.2 Favored 'General case' 0 CA--C 1.541 0.609 0 O-C-N 120.38 -1.45 . . . . 10.0 110.716 -176.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.6 m-30 -73.09 71.59 1.13 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 123.273 1.511 . . . . 10.0 111.265 -178.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -78.44 141.51 61.28 Favored Pre-proline 0 N--CA 1.447 -0.583 0 C-N-CA 126.158 1.783 . . . . 10.0 109.642 169.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -79.21 47.77 2.61 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.874 2.383 . . . . 10.0 111.213 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -163.79 49.66 0.14 Allowed 'General case' 0 C--O 1.236 0.361 0 C-N-CA 124.761 1.224 . . . . 10.0 107.871 178.206 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.0 p -52.98 108.37 0.31 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.204 1.802 . . . . 10.0 111.57 -169.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -133.32 -173.2 3.14 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.107 -2.183 . . . . 10.0 105.107 169.679 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.401 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 6.9 mtmp? -85.71 136.63 33.28 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 118.549 -1.26 . . . . 10.0 107.804 -172.373 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.9 t60 -36.05 116.29 0.39 Allowed 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.336 173.229 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.71 -134.2 4.92 Favored Glycine 0 N--CA 1.441 -1.015 0 N-CA-C 108.139 -1.984 . . . . 10.0 108.139 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.8 -165.81 31.74 Favored Glycine 0 N--CA 1.444 -0.804 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 169.699 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -57.52 -11.99 10.02 Favored 'Trans proline' 0 N--CA 1.451 -0.976 0 CA-C-N 119.345 1.572 . . . . 10.0 110.849 167.829 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.87 -33.98 18.35 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 125.223 1.409 . . . . 10.0 110.076 -177.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -107.45 168.54 9.17 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 108.677 -0.861 . . . . 10.0 108.677 -169.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -94.67 -18.88 20.91 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 124.346 1.058 . . . . 10.0 109.761 178.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.401 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -92.02 3.9 54.23 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.395 0.887 . . . . 10.0 113.395 -175.511 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 19.9 ptp180 -34.94 139.0 0.1 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 128.118 2.567 . . . . 10.0 112.272 171.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -71.22 -100.63 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.351 0.66 . . . . 10.0 111.96 -176.091 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.9 p -148.3 30.13 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.032 0.92 . . . . 10.0 110.228 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.5 47.83 0.02 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.479 -1.448 . . . . 10.0 109.479 -179.286 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -84.05 88.97 7.19 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 103.203 -2.888 . . . . 10.0 103.203 168.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 42.5 mt -71.3 -33.38 69.65 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 106.451 -1.685 . . . . 10.0 106.451 176.123 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.66 -97.19 1.34 Allowed Glycine 0 N--CA 1.44 -1.057 0 N-CA-C 108.815 -1.714 . . . . 10.0 108.815 167.073 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -132.67 129.06 38.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.655 1.182 . . . . 10.0 108.571 -172.195 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.8 m -113.52 141.65 28.7 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.573 -1.64 . . . . 10.0 106.573 168.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -93.13 133.65 36.1 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.738 -0.467 . . . . 10.0 109.738 -177.646 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.82 133.23 43.41 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.084 0.954 . . . . 10.0 108.848 172.053 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.416 ' OD2' ' NZ ' ' A' ' 91' ' ' LYS . 45.4 t0 -62.03 168.81 3.01 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.678 1.191 . . . . 10.0 108.438 167.78 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.416 ' NZ ' ' OD2' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -63.38 -19.16 64.41 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.047 0.451 . . . . 10.0 111.816 -179.22 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -77.45 -12.15 59.93 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 123.73 0.812 . . . . 10.0 110.589 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.87 26.88 43.58 Favored Glycine 0 C--N 1.344 0.979 0 N-CA-C 109.766 -1.334 . . . . 10.0 109.766 -178.696 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 37.7 t -109.08 116.31 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.007 2.523 . . . . 10.0 105.045 178.105 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -113.49 120.84 42.38 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 107.918 -1.141 . . . . 10.0 107.918 174.456 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -84.31 117.41 23.55 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 127.141 2.176 . . . . 10.0 108.767 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -102.4 131.88 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 p -159.53 75.91 0.66 Allowed 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 123.88 0.872 . . . . 10.0 110.804 171.176 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -116.37 147.23 19.89 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.037 0.935 . . . . 10.0 109.146 -176.396 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -107.14 104.71 14.42 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 126.449 1.9 . . . . 10.0 110.13 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -87.9 123.32 32.53 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 108.746 -0.835 . . . . 10.0 108.746 172.458 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.7 p -113.13 43.41 1.72 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.209 1.003 . . . . 10.0 110.21 177.511 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -138.62 -44.57 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 C-N-CA 123.289 0.636 . . . . 10.0 111.255 175.472 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.413 HD12 ' C ' ' A' ' 104' ' ' ILE 0.365 0.7 OUTLIER -87.85 175.19 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-N 119.342 0.973 . . . . 10.0 112.749 174.103 . . . . . . . . 4 4 . 1 . 006 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.2 m -159.34 138.43 11.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 123.955 0.902 . . . . 10.0 109.007 172.048 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 pp -82.49 -14.75 54.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.552 0.741 . . . . 10.0 111.944 177.116 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.1 m -143.46 124.0 14.01 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.662 -1.607 . . . . 10.0 106.662 167.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.96 -59.63 0.2 Allowed Glycine 0 C--N 1.334 0.44 0 N-CA-C 109.638 -1.385 . . . . 10.0 109.638 175.473 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -166.89 -50.9 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 126.084 1.753 . . . . 10.0 107.465 -177.37 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -74.98 -36.02 62.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.669 -1.151 . . . . 10.0 108.879 -169.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t 42.41 61.93 1.86 Allowed 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 126.056 1.743 . . . . 10.0 110.99 169.606 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.57 32.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 113.194 0.812 . . . . 10.0 113.194 -175.4 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.0 mm -64.5 150.45 10.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 C-N-CA 125.969 1.708 . . . . 10.0 107.424 168.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.25 33.26 86.31 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 121.523 -0.736 . . . . 10.0 113.804 178.666 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -100.65 163.96 12.1 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 166.549 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -103.55 127.55 50.95 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-N 118.587 0.63 . . . . 10.0 111.106 170.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.14 139.64 30.26 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.498 -1.668 . . . . 10.0 106.498 166.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.404 HG12 ' CD2' ' A' ' 120' ' ' HIS . 93.0 t -122.88 138.67 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 172.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.1 p -105.69 134.72 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 104.96 -2.237 . . . . 10.0 104.96 166.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.644 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.5 m170 -113.67 161.36 17.57 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 114.506 1.298 . . . . 10.0 114.506 -172.355 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -57.73 -49.16 77.47 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 113.694 -1.594 . . . . 10.0 109.548 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -116.09 176.48 5.08 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.47 1.108 . . . . 10.0 111.812 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.1 146.55 23.57 Favored 'General case' 0 N--CA 1.451 -0.425 0 C-N-CA 125.375 1.47 . . . . 10.0 110.271 -177.217 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.456 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 3.9 m-20 -76.77 151.39 36.01 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.108 0.563 . . . . 10.0 110.612 178.114 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -89.54 16.58 7.48 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 114.836 -1.075 . . . . 10.0 109.878 166.227 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 69.9 mt 36.43 47.57 0.51 Allowed 'General case' 0 C--N 1.344 0.338 0 C-N-CA 127.19 2.196 . . . . 10.0 112.383 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.74 -47.37 1.05 Allowed Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 124.582 1.087 . . . . 10.0 111.851 176.464 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -83.23 44.27 0.93 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 124.999 1.32 . . . . 10.0 111.844 -168.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -81.98 -38.68 12.93 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.515 -1.434 . . . . 10.0 109.515 169.886 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.45 48.61 56.53 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 109.37 -1.492 . . . . 10.0 109.37 -170.108 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 25.9 m120 -138.36 166.57 23.9 Favored 'General case' 0 CA--C 1.508 -0.652 0 N-CA-C 106.689 -1.597 . . . . 10.0 106.689 175.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 2.7 tm-20 -52.99 -46.52 68.36 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 114.712 -1.131 . . . . 10.0 108.843 171.042 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -57.1 -43.2 82.0 Favored 'General case' 0 C--N 1.343 0.305 0 CA-C-N 116.332 -0.395 . . . . 10.0 110.889 171.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.297 2.1 p -59.21 -32.95 70.41 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -167.755 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -78.89 -8.05 58.5 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 118.592 -1.243 . . . . 10.0 112.276 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 89.5 mttt -116.68 -59.46 1.97 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.638 1.575 . . . . 10.0 111.834 -171.11 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.1 p -123.48 -4.66 8.26 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 119.318 0.963 . . . . 10.0 112.675 179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.19 -82.97 0.45 Allowed Glycine 0 CA--C 1.531 1.039 0 CA-C-N 119.386 0.994 . . . . 10.0 112.762 169.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.12 32.88 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 123.186 1.47 . . . . 10.0 108.343 177.473 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.64 -26.6 57.89 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.963 -1.471 . . . . 10.0 109.771 -167.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.13 -159.69 51.22 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 109.53 -1.428 . . . . 10.0 109.53 -177.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.0 t -58.49 139.26 55.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 113.136 0.791 . . . . 10.0 113.136 -168.456 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -65.05 65.72 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 126.764 2.025 . . . . 10.0 109.754 168.786 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.48 -19.2 61.77 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 113.904 1.076 . . . . 10.0 113.904 -172.466 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.22 150.89 25.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 122.81 0.444 . . . . 10.0 110.409 169.397 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.6 p -154.17 165.6 35.74 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.057 0.543 . . . . 10.0 110.049 -176.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -141.0 -172.0 12.82 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 123.434 0.54 . . . . 10.0 112.675 -177.402 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.7 t -136.79 136.52 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 107.648 -1.241 . . . . 10.0 107.648 172.515 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.0 mt -73.93 114.63 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 122.887 0.475 . . . . 10.0 110.402 -177.18 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.46 151.35 18.46 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 125.762 1.649 . . . . 10.0 111.461 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.8 mt -73.32 140.34 17.97 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 124.902 1.281 . . . . 10.0 109.855 -173.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.72 -45.47 2.89 Favored 'General case' 0 C--O 1.225 -0.222 0 O-C-N 121.069 -1.02 . . . . 10.0 111.74 173.445 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.25 1.09 0 C-N-CA 127.81 2.444 . . . . 10.0 109.203 -168.575 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.886 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -70.93 -31.03 67.5 Favored 'General case' 0 C--O 1.226 -0.142 0 CA-C-N 119.27 0.941 . . . . 10.0 109.847 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.9 tttt -144.37 134.12 23.67 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.769 0.828 . . . . 10.0 109.395 -174.19 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 165.41 27.65 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.865 1.666 . . . . 10.0 107.768 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -126.13 171.1 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 118.339 0.518 . . . . 10.0 109.84 174.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.78 112.86 9.73 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.413 -1.328 . . . . 10.0 107.413 166.527 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 30.8 m -92.01 114.89 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 168.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.6 mt -100.56 135.65 41.67 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -158.13 157.43 32.73 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.862 1.21 . . . . 10.0 108.705 170.199 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.3 -52.17 0.04 OUTLIER Glycine 0 C--O 1.228 -0.269 0 C-N-CA 121.414 -0.422 . . . . 10.0 112.148 172.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.8 -45.95 40.1 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.609 -1.626 . . . . 10.0 106.609 -171.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.29 -67.06 0.55 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 113.711 -1.586 . . . . 10.0 110.461 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -56.97 -41.07 79.2 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.646 2.231 . . . . 10.0 110.68 172.008 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.8 t -65.94 105.83 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -123.02 117.98 26.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 169.122 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.646 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -101.83 141.63 15.36 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.358 -1.097 . . . . 10.0 110.358 172.383 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.4 HG22 ' CG2' ' A' ' 54' ' ' THR . 2.6 mt -143.13 81.13 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 106.476 -1.676 . . . . 10.0 106.476 -175.737 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.6 mm -102.72 151.37 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.324 1.049 . . . . 10.0 109.715 -173.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 9.6 m-20 -121.48 119.93 33.43 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.939 2.095 . . . . 10.0 108.164 174.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -102.89 108.92 20.3 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.783 -1.562 . . . . 10.0 106.783 176.252 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -119.49 141.05 49.52 Favored 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.247 0.832 . . . . 10.0 113.247 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -118.39 119.18 33.82 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.332 -1.729 . . . . 10.0 106.332 166.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 57.6 pttt . . . . . 0 CA--C 1.529 0.166 0 N-CA-C 112.842 0.682 . . . . 10.0 112.842 -172.969 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.182 0 CA-C-O 118.398 -1.223 . . . . 10.0 114.509 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -65.63 136.59 46.72 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 107.191 -1.888 . . . . 10.0 107.191 172.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.49 105.19 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 106.028 -1.842 . . . . 10.0 106.028 174.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -97.49 112.85 24.52 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 173.412 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -111.99 113.59 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 125.126 1.37 . . . . 10.0 108.776 -173.62 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.5 p90 -132.65 170.82 14.67 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.874 0.368 . . . . 10.0 110.804 173.597 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.88 -147.92 18.84 Favored Glycine 0 N--CA 1.448 -0.52 0 N-CA-C 106.955 -2.458 . . . . 10.0 106.955 170.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.2 t -155.86 156.61 34.98 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 119.306 -0.958 . . . . 10.0 111.192 177.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.646 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.9 pt -117.08 153.68 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 N-CA-C 108.032 -1.099 . . . . 10.0 108.032 166.379 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -127.62 151.41 48.96 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 106.801 -1.555 . . . . 10.0 106.801 167.015 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.24 -14.44 15.93 Favored Glycine 0 C--N 1.336 0.542 0 CA-C-O 119.002 -0.888 . . . . 10.0 113.322 169.267 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.517 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.6 mp -76.4 176.84 7.84 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 118.652 1.226 . . . . 10.0 110.388 -177.018 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.59 152.76 20.13 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.596 -0.729 . . . . 10.0 109.348 169.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -45.34 143.98 1.58 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.109 1.764 . . . . 10.0 111.87 -176.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.72 -177.31 22.66 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 123.927 0.775 . . . . 10.0 112.159 171.119 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -71.69 153.55 41.97 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 125.347 1.459 . . . . 10.0 110.921 -177.171 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -149.34 146.93 27.77 Favored 'General case' 0 C--N 1.343 0.319 0 N-CA-C 113.959 1.096 . . . . 10.0 113.959 -177.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.711 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -31.48 114.26 0.07 OUTLIER Glycine 0 C--N 1.34 0.803 0 C-N-CA 128.379 2.895 . . . . 10.0 113.215 164.761 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.418 ' HZ ' HG21 ' B' ' 35' ' ' ILE . 1.5 m-85 -141.48 101.43 3.99 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 120.519 2.16 . . . . 10.0 109.353 173.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.509 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -151.17 170.15 20.16 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-O 121.749 0.785 . . . . 10.0 111.938 178.603 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.2 m -93.08 154.86 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.223 -2.262 . . . . 10.0 106.788 168.121 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 61.2 m-70 -126.58 135.87 51.81 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 170.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -50.92 -50.57 57.29 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 118.445 -0.788 . . . . 10.0 112.186 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -82.6 137.29 34.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 117.714 -1.594 . . . . 10.0 109.501 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.58 3.01 87.41 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 126.29 1.9 . . . . 10.0 112.147 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 p-10 -76.3 81.82 3.07 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-O 123.613 1.673 . . . . 10.0 110.181 -173.384 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.495 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.9 OUTLIER -75.31 9.75 1.94 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.488 -1.233 . . . . 10.0 113.732 -175.17 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.538 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -44.96 -45.94 10.79 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 127.734 2.414 . . . . 10.0 112.634 -170.818 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.86 -20.72 41.68 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.7 87.82 2.02 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 107.955 -2.058 . . . . 10.0 107.955 -168.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 16.88 54.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 127.987 2.515 . . . . 10.0 116.108 -169.221 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 17.0 m -125.97 -56.25 1.46 Allowed 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 105.69 -1.967 . . . . 10.0 105.69 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -47.74 -37.4 13.18 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.403 1.481 . . . . 10.0 110.708 169.57 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.14 -31.5 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 127.864 2.466 . . . . 10.0 115.257 169.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.27 148.64 18.98 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 109.517 -1.433 . . . . 10.0 109.517 169.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.51 -179.27 0.85 Allowed 'Trans proline' 0 N--CA 1.446 -1.305 0 N-CA-C 107.674 -1.702 . . . . 10.0 107.674 166.048 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 37.8 m170 -76.24 76.57 3.04 Favored 'General case' 0 CA--C 1.543 0.685 0 O-C-N 120.422 -1.424 . . . . 10.0 110.501 -169.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -71.46 69.44 0.59 Allowed 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 123.182 1.468 . . . . 10.0 112.417 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 65' ' ' ASN . . . . . 0.405 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 1.7 p30 -56.15 145.51 55.46 Favored Pre-proline 0 C--N 1.321 -0.649 0 C-N-CA 127.326 2.251 . . . . 10.0 112.155 168.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -74.79 167.74 26.41 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 122.106 1.871 . . . . 10.0 108.296 167.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 tp 62.46 -101.06 0.1 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 125.09 1.356 . . . . 10.0 108.041 -174.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.2 p 171.59 97.45 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.753 1.621 . . . . 10.0 110.263 -174.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 75.9 mtt180 -130.02 163.64 26.04 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 119.651 1.114 . . . . 10.0 110.346 176.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -113.44 55.32 0.71 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 124.648 1.179 . . . . 10.0 111.422 -168.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 65.3 t60 47.05 88.2 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 125.091 1.356 . . . . 10.0 114.646 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.06 -145.18 11.07 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.262 -1.336 . . . . 10.0 110.067 178.353 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.78 -173.96 32.1 Favored Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 109.152 -1.579 . . . . 10.0 109.152 176.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -55.22 -13.15 6.49 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 123.025 2.483 . . . . 10.0 112.434 173.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -94.27 -30.25 14.65 Favored 'General case' 0 N--CA 1.444 -0.754 0 C-N-CA 125.189 1.396 . . . . 10.0 110.607 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -103.18 169.0 8.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -169.133 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -78.77 -33.52 46.33 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -77.14 18.14 0.41 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.309 1.043 . . . . 10.0 113.421 -165.652 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 20.2 ptp180 -64.55 117.22 7.05 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.106 -1.072 . . . . 10.0 108.106 -177.393 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.405 ' HB3' ' HB3' ' B' ' 65' ' ' ASN . 11.1 m170 -57.98 -60.96 2.92 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 120.824 0.345 . . . . 10.0 111.846 -170.451 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p -165.5 -47.09 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 -169.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -152.99 71.49 0.28 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 108.551 -1.82 . . . . 10.0 108.551 172.403 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -102.57 106.61 17.33 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 105.73 -1.952 . . . . 10.0 105.73 171.092 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.22 -12.07 60.03 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 111.7 -172.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.78 -98.26 1.56 Allowed Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 107.924 -2.071 . . . . 10.0 107.924 -178.301 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -156.28 146.96 21.82 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 107.099 -1.445 . . . . 10.0 107.099 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.7 m -122.08 131.95 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 107.208 -1.405 . . . . 10.0 107.208 169.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 63.0 m -90.89 107.26 19.07 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 126.298 1.839 . . . . 10.0 109.228 -172.036 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -77.82 130.33 36.54 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 110.172 -0.307 . . . . 10.0 110.172 172.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -61.85 170.1 2.22 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 124.274 1.03 . . . . 10.0 109.295 167.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -55.79 -29.08 59.09 Favored 'General case' 0 N--CA 1.433 -1.294 0 C-N-CA 125.884 1.674 . . . . 10.0 111.647 171.352 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -78.38 -1.67 34.55 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-O 121.163 0.506 . . . . 10.0 111.371 175.53 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.09 1.46 90.33 Favored Glycine 0 C--N 1.339 0.746 0 O-C-N 120.376 -1.452 . . . . 10.0 111.179 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 44.8 t -78.43 105.98 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 C-N-CA 126.929 2.092 . . . . 10.0 107.03 178.236 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.479 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -103.78 124.62 49.23 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 169.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.56 122.74 26.86 Favored 'General case' 0 N--CA 1.432 -1.338 0 C-N-CA 125.832 1.653 . . . . 10.0 107.816 169.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.4 t -101.92 128.85 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.208 0 N-CA-C 106.851 -1.537 . . . . 10.0 106.851 173.135 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.9 t -156.85 92.67 1.3 Allowed 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 169.32 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.3 mp -135.94 164.29 32.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 125.96 1.704 . . . . 10.0 106.542 -177.117 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -148.64 159.63 43.91 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.26 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.74 116.21 7.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.023 -0.732 . . . . 10.0 109.023 171.175 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 52.0 p -90.41 61.6 5.05 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 106.909 -1.515 . . . . 10.0 106.909 -171.307 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.16 -50.53 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 123.731 0.644 . . . . 10.0 110.068 -176.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -79.91 142.42 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.592 -1.262 . . . . 10.0 107.592 169.663 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 22.9 m -128.22 114.22 16.68 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.697 -1.594 . . . . 10.0 106.697 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mt -59.23 -4.34 0.53 Allowed 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 114.411 1.263 . . . . 10.0 114.411 -173.049 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.7 m . . . . . 0 N--CA 1.448 -0.567 0 C-N-CA 126.582 1.953 . . . . 10.0 107.558 177.165 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.1 t . . . . . 0 N--CA 1.441 -0.893 0 N-CA-C 107.963 -1.125 . . . . 10.0 107.963 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.6 pt -83.98 23.42 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 122.957 0.503 . . . . 10.0 111.997 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.49 -73.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 CA-C-N 118.8 0.727 . . . . 10.0 111.268 -177.141 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.66 50.33 3.55 Favored Glycine 0 CA--C 1.532 1.133 0 O-C-N 120.642 -1.286 . . . . 10.0 112.546 -177.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.4 mmt-85 -110.3 152.38 26.24 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 124.832 1.253 . . . . 10.0 109.697 176.386 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.9 m -88.88 125.14 34.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.975 -0.75 . . . . 10.0 108.975 171.071 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -96.13 138.76 33.29 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 126.42 1.888 . . . . 10.0 107.7 170.829 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -126.44 135.67 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 N-CA-C 108.517 -0.919 . . . . 10.0 108.517 -177.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.459 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.2 OUTLIER -106.16 121.87 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 106.807 -1.553 . . . . 10.0 106.807 171.77 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.711 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.3 m-70 -105.63 158.12 16.93 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 123.75 1.738 . . . . 10.0 115.605 -171.421 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -43.82 -61.48 1.41 Allowed 'General case' 0 N--CA 1.442 -0.862 0 C-N-CA 129.738 3.215 . . . . 10.0 110.551 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.3 mttp -112.77 172.86 6.67 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.061 0.944 . . . . 10.0 111.395 -175.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.13 154.64 40.96 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.016 1.326 . . . . 10.0 110.571 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.509 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.0 OUTLIER -78.49 144.98 35.22 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 123.98 0.912 . . . . 10.0 111.578 174.083 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -76.27 -32.89 59.07 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 124.781 1.301 . . . . 10.0 109.349 168.057 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt 63.5 56.42 1.62 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 123.491 1.615 . . . . 10.0 109.572 -168.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.92 -47.96 3.44 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 113.582 -1.645 . . . . 10.0 111.341 165.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.19 44.97 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.8 1.64 . . . . 10.0 112.012 -173.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -10.83 50.08 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 126.263 1.887 . . . . 10.0 111.892 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.88 32.43 18.63 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.448 -0.64 . . . . 10.0 112.071 -174.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -113.66 152.34 30.56 Favored 'General case' 0 CA--C 1.506 -0.716 0 N-CA-C 105.65 -1.982 . . . . 10.0 105.65 171.12 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.8 tm-20 -50.54 -37.57 40.08 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 114.921 -1.036 . . . . 10.0 108.695 169.216 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 16.8 tp10 -70.81 -38.5 73.29 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 113.889 1.07 . . . . 10.0 113.889 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 76.7 p -57.67 -42.63 83.95 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 120.642 1.565 . . . . 10.0 110.456 -175.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 6.3 t -69.17 -10.3 57.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 113.109 0.781 . . . . 10.0 113.109 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 20.5 ttmt -113.71 -47.97 2.95 Favored 'General case' 0 N--CA 1.435 -1.204 0 C-N-CA 125.43 1.492 . . . . 10.0 112.347 -168.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 32.0 p -130.78 -2.87 4.14 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.016 0.747 . . . . 10.0 113.016 172.173 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.2 19.7 60.33 Favored Glycine 0 C--N 1.34 0.803 0 N-CA-C 110.809 -0.917 . . . . 10.0 110.809 -175.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 54.45 31.7 15.22 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 117.837 0.819 . . . . 10.0 111.718 176.603 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.47 7.26 4.62 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 123.906 0.882 . . . . 10.0 111.673 -176.199 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.85 -168.23 53.48 Favored Glycine 0 N--CA 1.444 -0.798 0 N-CA-C 110.065 -1.214 . . . . 10.0 110.065 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.8 t -67.4 158.32 32.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 122.582 1.182 . . . . 10.0 111.273 -169.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 143' ' ' ARG . . . . . 0.44 ' NE ' ' H ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -67.94 112.37 4.91 Favored 'General case' 0 N--CA 1.442 -0.857 0 C-N-CA 125.075 1.35 . . . . 10.0 107.966 170.69 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 29.0 mt -72.68 -55.71 6.4 Favored 'General case' 0 N--CA 1.458 -0.054 0 N-CA-C 109.098 -0.704 . . . . 10.0 109.098 170.026 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.459 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -138.34 156.6 47.47 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.858 -0.61 . . . . 10.0 110.273 -170.623 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.5 m -129.29 147.63 51.14 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.31 1.444 . . . . 10.0 108.805 -168.501 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -150.7 156.89 26.93 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.456 -1.458 . . . . 10.0 109.456 169.124 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 70.1 t -116.1 128.54 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 105.133 -2.173 . . . . 10.0 105.133 177.059 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.438 HD13 HG21 ' B' ' 149' ' ' ILE . 16.8 mt -69.03 156.93 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 CA-C-N 119.266 0.939 . . . . 10.0 110.06 176.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.02 160.91 32.47 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 124.995 1.283 . . . . 10.0 110.156 -176.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 96.0 mt -69.75 135.46 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.976 1.31 . . . . 10.0 109.478 -171.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.63 -47.1 2.44 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 123.366 0.666 . . . . 10.0 110.899 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 . . . . . 0 C--O 1.254 1.291 0 CA-C-O 117.809 -1.091 . . . . 10.0 111.031 -169.4 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.463 0 N-CA-C 110.161 -0.311 . . . . 10.0 110.161 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER 169.26 -41.06 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 129.861 3.264 . . . . 10.0 103.891 -167.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -106.39 132.35 52.52 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.243 -2.132 . . . . 10.0 105.243 166.119 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 163.05 33.97 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 107.526 -1.286 . . . . 10.0 107.526 169.569 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -124.28 176.51 5.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 C-N-CA 123.037 0.535 . . . . 10.0 109.998 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.77 117.13 5.68 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 118.504 0.593 . . . . 10.0 109.887 166.434 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -97.99 104.27 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 C-N-CA 124.609 1.164 . . . . 10.0 110.519 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mt -98.41 122.74 41.97 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.862 1.665 . . . . 10.0 109.517 -177.1 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -143.53 157.23 44.59 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 120.034 1.288 . . . . 10.0 108.513 173.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.26 -59.3 0.03 OUTLIER Glycine 0 N--CA 1.464 0.518 0 C-N-CA 120.317 -0.944 . . . . 10.0 113.005 169.685 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -70.93 -43.91 67.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.86 -71.45 0.38 Allowed Glycine 0 CA--C 1.521 0.451 0 CA-C-N 114.186 -1.37 . . . . 10.0 110.644 168.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -57.39 -33.36 96.13 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.786 2.99 . . . . 10.0 111.369 172.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 57.9 t -64.75 95.89 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.547 -1.279 . . . . 10.0 107.547 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 -120.58 111.27 17.45 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 125.684 1.594 . . . . 10.0 107.775 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.521 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -100.81 133.98 11.52 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-O 119.521 -0.6 . . . . 10.0 111.955 171.768 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.526 ' CG2' HG23 ' B' ' 54' ' ' THR . 8.7 mt -136.08 85.93 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 -172.39 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.55 152.8 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 C-N-CA 124.404 1.081 . . . . 10.0 111.136 -171.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.3 m-20 -120.68 116.8 26.01 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 126.504 1.922 . . . . 10.0 108.905 170.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -91.5 99.34 12.3 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 174.14 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -97.39 117.86 32.58 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.775 0.798 . . . . 10.0 111.025 178.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.1 tp60 -117.61 97.31 5.8 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 127.895 2.478 . . . . 10.0 105.788 178.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.401 ' NZ ' ' OE2' ' A' ' 24' ' ' GLU . 4.8 mtmp? -59.08 -52.76 64.33 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 123.004 0.522 . . . . 10.0 110.377 -173.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.401 ' OE2' ' NZ ' ' A' ' 23' ' ' LYS . 2.0 mp0 -131.09 172.31 12.25 Favored 'General case' 0 N--CA 1.424 -1.748 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 173.703 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.9 t -71.49 -20.28 62.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 108.879 -0.785 . . . . 10.0 108.879 170.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . 0.306 0.4 OUTLIER -89.13 -5.43 57.78 Favored 'General case' 0 C--N 1.344 0.359 0 N-CA-C 113.401 0.889 . . . . 10.0 113.401 173.446 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.72 160.11 35.34 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 109.619 -1.393 . . . . 10.0 109.619 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -71.55 148.2 53.25 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 N-CA-C 107.592 -1.734 . . . . 10.0 107.592 168.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.3 t -78.39 110.92 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 105.39 -2.078 . . . . 10.0 105.39 173.275 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.2 102.86 15.58 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 171.329 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -98.92 99.7 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.415 -1.328 . . . . 10.0 107.415 179.497 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.8 p90 -118.15 166.87 12.06 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.566 0.698 . . . . 10.0 112.267 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.79 -150.3 21.81 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.07 -2.412 . . . . 10.0 107.07 171.189 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.7 t -155.23 152.87 29.84 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 119.773 -0.771 . . . . 10.0 110.914 -178.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.638 ' CG1' ' HB3' ' A' ' 95' ' ' ALA . 1.9 pt -110.63 142.85 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 115.215 -0.902 . . . . 10.0 108.616 166.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -118.81 148.85 42.41 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 169.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.71 -5.35 40.18 Favored Glycine 0 CA--C 1.525 0.664 0 CA-C-O 119.235 -0.759 . . . . 10.0 113.499 174.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -69.62 176.78 3.31 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 118.805 1.302 . . . . 10.0 110.122 177.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.1 t -104.75 167.83 9.46 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.319 -2.104 . . . . 10.0 105.319 165.232 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -57.07 166.38 1.07 Allowed 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.373 0.669 . . . . 10.0 111.254 -171.388 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.98 -177.17 42.94 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.286 -0.884 . . . . 10.0 112.375 168.56 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.0 mp -74.21 145.42 44.14 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 124.851 1.26 . . . . 10.0 110.093 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -144.91 145.36 31.53 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 124.177 0.991 . . . . 10.0 112.685 -175.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.65 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.48 125.97 0.28 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 126.695 2.093 . . . . 10.0 113.398 166.288 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -150.11 108.55 3.8 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.098 1.449 . . . . 10.0 108.253 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.25 173.0 12.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 122.732 1.253 . . . . 10.0 113.481 177.665 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 85.8 t -98.19 129.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 CA-C-N 111.03 -2.805 . . . . 10.0 105.487 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -105.8 139.72 39.93 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.194 -1.409 . . . . 10.0 107.194 170.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -58.1 -58.04 10.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 O-C-N 124.094 0.871 . . . . 10.0 110.214 -169.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -76.86 119.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.653 -1.61 . . . . 10.0 106.653 -171.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.74 46.81 2.94 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.523 -1.031 . . . . 10.0 110.523 171.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -108.89 118.72 37.53 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.929 1.291 . . . . 10.0 108.153 176.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.415 ' HB3' HG21 ' B' ' 7' ' ' VAL . 12.0 m120 -117.94 5.78 12.16 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.218 1.807 . . . . 10.0 109.988 178.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.42 HG23 ' CG2' ' B' ' 17' ' ' ILE . 1.3 m -57.07 -37.1 71.37 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 120.096 1.316 . . . . 10.0 111.667 -169.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -21.83 45.68 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.079 0.952 . . . . 10.0 112.682 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 143.85 -86.46 0.18 Allowed Glycine 0 CA--C 1.527 0.797 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 -172.003 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 24.1 p -170.78 43.29 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.152 0.981 . . . . 10.0 110.989 172.827 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 m -104.92 -49.31 3.52 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 m -50.18 -27.63 6.18 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 126.372 1.869 . . . . 10.0 111.641 174.149 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -37.16 -32.1 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 128.02 2.528 . . . . 10.0 113.848 168.528 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.32 126.64 5.2 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.277 -1.291 . . . . 10.0 109.95 170.103 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -72.4 65.34 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.81 0 C-N-CA 123.729 2.953 . . . . 10.0 112.268 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER 68.87 42.8 1.29 Allowed 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 129.773 3.229 . . . . 10.0 111.505 172.036 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -72.51 57.96 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.728 1.01 . . . . 10.0 113.728 -173.596 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.0 p-10 -68.3 159.57 79.95 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 118.968 0.804 . . . . 10.0 110.931 175.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -61.28 -47.68 11.55 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.216 1.944 . . . . 10.0 111.218 176.174 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 94.8 mt -78.1 59.05 2.12 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 109.301 -0.629 . . . . 10.0 109.301 177.344 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.0 t -58.97 95.64 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.417 1.087 . . . . 10.0 108.77 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.59 -96.57 0.41 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.796 -1.557 . . . . 10.0 106.796 -177.172 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.5 mttp -151.67 139.92 20.34 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 106.397 -1.705 . . . . 10.0 106.397 173.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.6 t60 -40.91 124.15 2.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 O-C-N 123.776 0.673 . . . . 10.0 110.903 170.401 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.15 -138.12 3.66 Favored Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 108.367 -1.893 . . . . 10.0 108.367 177.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.37 -165.94 33.35 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 107.342 -2.303 . . . . 10.0 107.342 169.297 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -62.54 -0.72 2.06 Favored 'Trans proline' 0 CA--C 1.542 0.878 0 CA-C-N 120.305 2.053 . . . . 10.0 110.948 167.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 61.0 mmtt -91.07 -24.62 19.98 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 124.409 1.084 . . . . 10.0 110.625 173.676 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.77 174.8 5.72 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -176.418 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -87.82 -32.15 19.19 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 170.159 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -82.25 2.0 33.99 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 115.032 1.493 . . . . 10.0 115.032 -165.053 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -41.54 137.36 1.59 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 125.639 1.575 . . . . 10.0 112.172 -177.12 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -71.88 -77.64 0.09 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.704 -0.798 . . . . 10.0 112.185 -170.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 p -161.41 58.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 121.324 -0.86 . . . . 10.0 109.46 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 106.94 50.55 0.83 Allowed Glycine 0 CA--C 1.523 0.533 0 N-CA-C 109.943 -1.263 . . . . 10.0 109.943 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -87.05 90.97 8.54 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 104.026 -2.583 . . . . 10.0 104.026 167.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.3 mt -70.3 -31.63 69.06 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 107.316 -1.364 . . . . 10.0 107.316 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 101.08 -106.43 3.08 Favored Glycine 0 N--CA 1.434 -1.44 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 168.236 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -109.23 119.41 39.42 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.506 1.122 . . . . 10.0 110.388 -168.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.1 m -104.89 135.36 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 168.016 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 50.0 m -99.64 108.8 21.26 Favored 'General case' 0 N--CA 1.442 -0.858 0 C-N-CA 126.316 1.846 . . . . 10.0 109.641 -168.514 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.44 130.24 35.24 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.229 1.011 . . . . 10.0 110.748 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 45.4 t0 -66.26 170.71 5.52 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 123.956 0.902 . . . . 10.0 109.455 168.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -52.96 -26.99 16.91 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.872 1.669 . . . . 10.0 111.599 177.47 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -79.03 -15.52 58.11 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.349 1.059 . . . . 10.0 110.065 -175.299 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.81 74.21 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 110.991 -0.844 . . . . 10.0 110.991 -173.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.0 t -87.64 113.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 C-N-CA 126.338 1.855 . . . . 10.0 106.265 173.265 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.638 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -111.9 121.38 44.87 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.461 -0.94 . . . . 10.0 108.461 171.295 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -78.17 130.55 36.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 172.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 75.0 t -104.91 129.39 57.59 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.369 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 169.286 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -156.93 66.95 0.53 Allowed 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 175.471 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.35 155.02 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.261 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.37 138.36 38.2 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.929 0.492 . . . . 10.0 110.727 169.146 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.95 131.14 51.15 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.858 1.263 . . . . 10.0 108.789 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.4 p -95.96 42.75 1.09 Allowed 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.626 1.971 . . . . 10.0 108.424 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.3 -49.88 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 123.337 0.655 . . . . 10.0 109.644 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 33.7 mm -57.57 134.55 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 169.011 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.5 m -164.66 94.22 0.68 Allowed 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.668 0.787 . . . . 10.0 109.441 -176.218 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.631 ' H ' HD13 ' A' ' 106' ' ' LEU . 0.0 OUTLIER -68.61 27.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.644 1.177 . . . . 10.0 113.839 175.328 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.9 p -157.8 113.4 2.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 121.275 -0.891 . . . . 10.0 110.32 -176.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 162.26 -54.1 0.31 Allowed Glycine 0 C--N 1.335 0.481 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 169.648 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.75 -50.14 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 126.337 1.855 . . . . 10.0 107.475 -173.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 -74.42 -38.53 63.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.944 -1.025 . . . . 10.0 108.623 -169.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 40.53 62.2 1.42 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.154 1.782 . . . . 10.0 110.01 172.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 24.3 pt -74.62 46.77 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.745 2.018 . . . . 10.0 111.77 -175.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.3 mm -72.49 -65.17 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 128.971 2.908 . . . . 10.0 108.207 172.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.75 47.52 3.07 Favored Glycine 0 CA--C 1.529 0.953 0 O-C-N 121.343 -0.848 . . . . 10.0 113.808 -169.112 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -89.65 174.63 7.64 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 125.105 1.362 . . . . 10.0 108.68 172.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 20.2 m -109.87 115.11 29.22 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.787 -2.301 . . . . 10.0 104.787 168.127 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.6 mp -97.94 151.78 19.92 Favored 'General case' 0 CA--C 1.512 -0.511 0 N-CA-C 108.296 -1.001 . . . . 10.0 108.296 175.039 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.7 t -143.16 136.89 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 O-C-N 123.837 0.711 . . . . 10.0 109.803 -170.327 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.8 m -105.89 140.35 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.952 1.301 . . . . 10.0 108.887 167.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.65 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m170 -120.66 159.13 25.94 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.49 2.033 . . . . 10.0 116.49 -172.234 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -39.46 -58.61 1.23 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 130.289 3.436 . . . . 10.0 111.886 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -123.17 168.34 12.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 124.679 1.192 . . . . 10.0 110.48 -171.039 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.76 137.66 55.61 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 108.308 -0.997 . . . . 10.0 108.308 169.57 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.84 144.12 37.27 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.191 -1.04 . . . . 10.0 108.191 168.193 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -78.14 25.04 0.23 Allowed 'General case' 0 CA--C 1.539 0.519 0 CA-C-O 121.133 0.492 . . . . 10.0 111.126 177.326 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 18.8 mt 30.53 45.82 0.03 OUTLIER 'General case' 0 C--N 1.34 0.162 0 C-N-CA 128.23 2.612 . . . . 10.0 112.629 -170.161 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.6 -45.53 1.3 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 124.623 1.106 . . . . 10.0 112.488 177.226 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -83.34 50.6 1.8 Allowed 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.092 0.957 . . . . 10.0 111.452 -169.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -87.45 -35.89 9.14 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 125.969 1.747 . . . . 10.0 110.022 172.733 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.27 38.7 71.56 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.865 -0.894 . . . . 10.0 110.865 -178.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 56.1 m-80 -130.8 163.74 26.7 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 169.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -53.31 -39.35 63.96 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.718 0.771 . . . . 10.0 109.592 173.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -67.14 -35.16 79.12 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.448 1.099 . . . . 10.0 112.934 173.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.4 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 60.0 p -56.31 -34.01 66.12 Favored 'General case' 0 N--CA 1.443 -0.776 0 O-C-N 120.029 -1.669 . . . . 10.0 112.033 -175.138 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -81.35 -1.98 47.44 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 118.738 -0.649 . . . . 10.0 112.139 -178.373 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -112.69 -82.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.263 1.825 . . . . 10.0 110.545 -177.025 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -109.6 25.45 11.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 120.725 1.602 . . . . 10.0 111.974 174.784 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.1 18.03 66.42 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.602 167.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 m120 62.24 23.54 13.93 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 118.085 0.943 . . . . 10.0 112.224 -171.608 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.03 -11.91 33.65 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.24 -0.913 . . . . 10.0 113.097 177.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.62 -161.2 46.1 Favored Glycine 0 CA--C 1.523 0.553 0 O-C-N 121.151 -0.968 . . . . 10.0 111.128 170.04 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.9 t -57.07 129.68 42.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 124.327 1.051 . . . . 10.0 113.135 -167.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.1 mtt85 -65.94 71.97 0.06 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.454 1.902 . . . . 10.0 111.404 175.152 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 51.7 mt -52.05 -33.4 38.68 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.286 1.034 . . . . 10.0 113.733 -177.336 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.81 147.18 26.96 Favored 'General case' 0 CA--C 1.512 -0.495 0 O-C-N 121.727 -0.608 . . . . 10.0 110.055 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.8 m -140.9 149.85 42.45 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 107.627 -1.249 . . . . 10.0 107.627 -170.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.58 36.42 Favored Glycine 0 CA--C 1.521 0.416 0 N-CA-C 111.397 -0.681 . . . . 10.0 111.397 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 52.9 t -115.23 154.68 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 103.145 -2.909 . . . . 10.0 103.145 171.082 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 8.3 mt -71.45 -90.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 123.51 0.724 . . . . 10.0 109.306 -169.382 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 108.06 125.61 5.3 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 81.2 mt -61.18 140.47 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 C-N-CA 125.686 1.594 . . . . 10.0 108.721 175.337 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.36 -38.84 4.57 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-N 119.525 1.057 . . . . 10.0 111.495 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? . . . . . 0 C--O 1.249 1.038 0 CA-C-O 117.308 -1.33 . . . . 10.0 109.899 178.22 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 106.458 -1.682 . . . . 10.0 106.458 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -88.1 -56.17 3.44 Favored 'General case' 0 N--CA 1.458 -0.027 0 O-C-N 124.293 0.995 . . . . 10.0 110.853 -174.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.07 138.79 49.73 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.415 1.086 . . . . 10.0 110.155 -176.042 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.48 162.64 33.99 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.63 0.772 . . . . 10.0 110.653 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 m -121.04 160.89 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.557 1.143 . . . . 10.0 109.617 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 95.82 2.9 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.556 -1.275 . . . . 10.0 107.556 166.198 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.415 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.7 m -82.15 108.48 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 169.317 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -93.99 137.8 32.8 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 178.013 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 tttt -156.58 159.03 38.12 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 119.912 1.233 . . . . 10.0 107.87 171.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.89 -47.91 0.04 OUTLIER Glycine 0 C--O 1.229 -0.2 0 C-N-CA 120.684 -0.769 . . . . 10.0 111.481 169.729 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.52 -46.43 26.59 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 -171.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.72 -69.0 0.52 Allowed Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 113.905 -1.498 . . . . 10.0 110.145 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -56.28 -44.04 50.23 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.311 2.007 . . . . 10.0 110.539 171.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.96 101.2 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.13 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 -175.649 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -120.81 110.75 16.72 Favored 'General case' 0 N--CA 1.441 -0.921 0 N-CA-C 106.103 -1.814 . . . . 10.0 106.103 173.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.797 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -90.05 140.38 15.48 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.615 -1.794 . . . . 10.0 108.615 171.051 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.42 ' CG2' HG23 ' A' ' 54' ' ' THR . 4.0 mt -141.53 88.84 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 -173.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -101.3 144.13 13.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 C-N-CA 123.576 0.75 . . . . 10.0 110.362 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -121.19 114.26 21.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 126.499 1.92 . . . . 10.0 108.266 168.639 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -98.19 106.4 18.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 mt-10 -107.54 123.86 49.07 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 112.789 0.662 . . . . 10.0 112.789 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -81.62 115.16 20.76 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 104.112 -2.551 . . . . 10.0 104.112 166.286 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt . . . . . 0 N--CA 1.449 -0.475 0 C-N-CA 123.954 0.902 . . . . 10.0 109.92 169.826 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.929 0 N-CA-C 108.862 -1.695 . . . . 10.0 108.862 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -65.7 132.18 29.94 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.5 1.467 . . . . 10.0 108.497 171.59 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.9 t -78.07 108.34 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 104.778 -2.305 . . . . 10.0 104.778 169.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -79.62 109.74 14.29 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 105.275 -2.12 . . . . 10.0 105.275 169.093 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -96.67 97.07 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 106.328 -1.73 . . . . 10.0 106.328 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 20.5 p90 -108.76 164.37 12.44 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.163 0.506 . . . . 10.0 110.595 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.88 178.86 48.45 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 110.391 -1.084 . . . . 10.0 110.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -150.88 106.07 3.34 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.663 -0.866 . . . . 10.0 108.663 178.376 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.797 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.2 pt -79.9 173.15 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 119.55 -0.86 . . . . 10.0 109.738 173.123 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.0 pttt -150.85 153.36 35.22 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 168.144 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.82 -15.36 40.86 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-O 118.993 -0.893 . . . . 10.0 115.274 169.724 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.485 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.6 mp -75.33 179.66 5.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.943 1.372 . . . . 10.0 110.362 -177.737 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -91.56 174.95 7.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 166.018 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -62.25 175.09 0.78 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 124.391 1.076 . . . . 10.0 111.435 -173.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.44 -172.74 47.23 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 123.885 0.755 . . . . 10.0 112.588 166.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -75.89 142.78 42.02 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.425 1.49 . . . . 10.0 110.093 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -137.39 143.25 41.84 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 114.753 1.39 . . . . 10.0 114.753 -175.425 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.658 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.04 124.95 0.24 Allowed Glycine 0 C--N 1.343 0.917 0 C-N-CA 127.262 2.363 . . . . 10.0 111.711 162.891 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.35 103.42 2.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.343 1.572 . . . . 10.0 109.949 170.548 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.515 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.79 173.98 15.7 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 113.806 1.039 . . . . 10.0 113.806 -176.91 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 m -85.26 151.99 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 CA-C-N 113.006 -1.906 . . . . 10.0 109.385 169.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -132.89 84.9 2.17 Favored 'General case' 0 C--O 1.221 -0.428 0 C-N-CA 124.756 1.222 . . . . 10.0 108.365 174.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 22.5 -83.96 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 128.046 2.539 . . . . 10.0 116.129 -176.025 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -76.76 179.06 6.31 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-O 121.555 0.693 . . . . 10.0 109.594 -169.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.69 -26.17 10.98 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.508 -1.037 . . . . 10.0 110.508 169.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -37.47 130.24 0.98 Allowed 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 125.502 1.521 . . . . 10.0 110.317 176.166 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -138.38 18.61 2.75 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 114.944 -1.026 . . . . 10.0 111.398 175.159 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.526 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -56.92 -35.76 69.41 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 118.362 0.528 . . . . 10.0 110.223 -178.197 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.95 -20.25 42.4 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 125.42 1.488 . . . . 10.0 113.515 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.29 99.12 1.04 Allowed Glycine 0 CA--C 1.531 1.065 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 -169.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.9 p 3.94 61.6 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 128.555 2.742 . . . . 10.0 117.508 -169.059 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.1 m -135.33 -60.03 0.76 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.013 -1.847 . . . . 10.0 106.013 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 41.6 t -50.93 -34.52 28.92 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.736 0.814 . . . . 10.0 110.002 169.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.07 -47.52 0.28 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 126.29 1.836 . . . . 10.0 112.64 168.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 131.63 140.6 4.59 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.082 -0.844 . . . . 10.0 111.998 171.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 62' ' ' PRO . . . . . 0.403 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 89.0 Cg_endo -73.13 64.68 4.26 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.824 3.016 . . . . 10.0 110.501 169.276 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 30.3 m170 75.57 -44.31 0.52 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 129.781 3.232 . . . . 10.0 111.05 175.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 64' ' ' PHE . . . . . 0.403 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 27.8 m-85 31.13 59.4 0.26 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 127.75 2.42 . . . . 10.0 113.252 -174.337 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 65' ' ' ASN . . . . . 0.547 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 0.0 OUTLIER -55.34 146.23 43.32 Favored Pre-proline 0 C--N 1.324 -0.519 0 N-CA-C 113.441 0.904 . . . . 10.0 113.441 175.117 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.84 -47.54 0.34 Allowed 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.762 2.308 . . . . 10.0 110.832 177.172 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -81.71 56.57 3.07 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.821 0.848 . . . . 10.0 109.879 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -18.35 77.31 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.278 3.031 . . . . 10.0 116.48 -169.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt85 -116.53 -179.86 3.8 Favored 'General case' 0 CA--C 1.509 -0.598 0 C-N-CA 125.499 1.52 . . . . 10.0 109.84 173.648 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -114.59 89.4 3.09 Favored 'General case' 0 N--CA 1.439 -1.014 0 O-C-N 124.238 0.962 . . . . 10.0 112.755 -171.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.482 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 75.1 t60 12.83 89.19 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.174 2.19 . . . . 10.0 115.084 176.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -106.42 -141.69 10.45 Favored Glycine 0 C--N 1.318 -0.435 0 N-CA-C 108.721 -1.752 . . . . 10.0 108.721 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.67 -168.23 37.0 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 109.896 -1.281 . . . . 10.0 109.896 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -66.72 12.13 0.16 Allowed 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.224 1.95 . . . . 10.0 111.662 169.174 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 62.7 mmtt -107.55 -18.84 13.74 Favored 'General case' 0 N--CA 1.438 -1.025 0 C-N-CA 124.731 1.213 . . . . 10.0 109.541 173.063 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -135.54 162.75 31.8 Favored 'General case' 0 C--N 1.348 0.513 0 CA-C-N 118.766 0.712 . . . . 10.0 109.822 -167.558 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -82.62 -18.76 40.05 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 107.969 -1.123 . . . . 10.0 107.969 173.259 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -84.27 21.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.219 0 O-C-N 119.908 -1.745 . . . . 10.0 112.854 -169.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.01 138.04 5.4 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.54 1.136 . . . . 10.0 109.196 170.454 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.547 ' HB3' ' HB3' ' B' ' 65' ' ' ASN . 11.6 m170 -70.41 -65.61 0.71 Allowed 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 173.812 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.47 HG13 ' H ' ' B' ' 82' ' ' GLY . 7.8 p -174.42 -69.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.117 1.367 . . . . 10.0 108.248 -178.366 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.47 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -105.84 63.12 0.31 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 109.602 -1.399 . . . . 10.0 109.602 -175.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.8 95.3 5.51 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.287 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 26.1 mt -75.33 2.43 11.24 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 120.295 -0.562 . . . . 10.0 110.906 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 89.16 -95.63 2.12 Favored Glycine 0 N--CA 1.437 -1.25 0 N-CA-C 108.174 -1.97 . . . . 10.0 108.174 171.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.3 m-20 -156.17 113.56 3.23 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 118.622 -0.704 . . . . 10.0 109.258 -172.312 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.3 m -96.72 131.08 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 118.524 0.602 . . . . 10.0 110.215 177.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 14.4 m -87.21 108.64 19.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 127.85 2.46 . . . . 10.0 110.424 -173.218 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.8 133.17 34.34 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.156 0.583 . . . . 10.0 109.752 171.092 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -61.86 174.05 0.91 Allowed 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.939 0.876 . . . . 10.0 109.591 167.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -51.57 -29.88 18.83 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 125.244 1.418 . . . . 10.0 110.961 173.134 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.01 -9.55 59.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 123.35 0.66 . . . . 10.0 110.501 -175.023 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.07 7.14 83.98 Favored Glycine 0 C--N 1.339 0.745 0 N-CA-C 111.33 -0.708 . . . . 10.0 111.33 -177.013 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 47.5 t -90.02 114.18 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 126.144 1.778 . . . . 10.0 106.366 178.301 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.444 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -110.81 118.57 36.5 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 169.273 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -80.09 121.69 25.85 Favored 'General case' 0 N--CA 1.451 -0.393 0 O-C-N 124.886 1.366 . . . . 10.0 107.547 169.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 99.1 t -105.81 131.07 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 C-N-CA 125.928 1.691 . . . . 10.0 106.625 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.5 p -155.46 74.58 0.9 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 174.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.69 159.01 7.41 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -142.68 133.66 25.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 O-C-N 121.77 -0.581 . . . . 10.0 110.738 173.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -142.88 135.34 27.57 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.976 0.91 . . . . 10.0 109.543 -172.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 3.8 p -93.92 -10.52 33.52 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.17 1.388 . . . . 10.0 111.188 169.646 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -85.07 -15.75 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.916 0.886 . . . . 10.0 110.28 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -98.15 149.84 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 106.659 -1.608 . . . . 10.0 106.659 169.515 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.6 m -153.34 141.16 20.11 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 169.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -56.14 -50.04 72.24 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.886 0.874 . . . . 10.0 109.558 -178.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.455 -0.184 0 C-N-CA 124.862 1.265 . . . . 10.0 108.688 -178.771 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t . . . . . 0 N--CA 1.448 -0.571 0 N-CA-C 114.514 1.302 . . . . 10.0 114.514 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 28.1 pt -70.64 -12.16 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 N-CA-C 113.168 0.803 . . . . 10.0 113.168 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.4 mm -57.66 115.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 119.847 1.203 . . . . 10.0 110.208 171.334 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 102.69 2.6 49.79 Favored Glycine 0 C--N 1.336 0.546 0 C-N-CA 124.496 1.046 . . . . 10.0 111.804 173.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.77 148.8 31.32 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 117.845 0.822 . . . . 10.0 110.605 173.349 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 31.3 m -80.66 126.69 31.59 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.838 1.255 . . . . 10.0 108.091 168.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -103.48 145.47 29.95 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.305 1.442 . . . . 10.0 107.825 169.07 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 68.9 t -135.54 143.5 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 4.4 p -110.89 139.8 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 O-C-N 124.535 1.147 . . . . 10.0 108.679 169.518 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.658 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.6 m-70 -117.2 162.41 17.91 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 114.729 1.381 . . . . 10.0 114.729 -174.657 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 121' ' ' GLU . . . . . 0.424 ' HB2' HD21 ' B' ' 144' ' ' LEU . 62.4 tt0 -61.72 -51.11 69.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 114.888 -1.051 . . . . 10.0 109.789 178.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -109.65 170.18 8.23 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.51 0.671 . . . . 10.0 111.613 -168.575 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.21 148.77 45.23 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 114.278 -1.328 . . . . 10.0 109.078 178.632 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.515 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.7 OUTLIER -74.93 151.14 38.91 Favored 'General case' 0 N--CA 1.443 -0.775 0 N-CA-C 109.226 -0.657 . . . . 10.0 109.226 172.686 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -76.0 -38.35 57.45 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 112.713 -2.039 . . . . 10.0 108.936 172.157 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 62.8 mt 62.45 64.54 0.93 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 123.97 1.843 . . . . 10.0 108.061 -176.035 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 76.21 -38.49 1.38 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 112.136 -2.302 . . . . 10.0 116.14 167.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 11.9 mtmt -75.35 5.09 6.1 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.099 1.148 . . . . 10.0 114.099 -167.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.45 -34.93 90.14 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 108.388 -1.885 . . . . 10.0 108.388 166.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.71 25.61 51.77 Favored Glycine 0 C--N 1.341 0.827 0 N-CA-C 111.191 -0.764 . . . . 10.0 111.191 -176.055 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -108.2 172.88 6.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 170.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -57.1 -45.6 83.27 Favored 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 123.957 0.903 . . . . 10.0 109.277 -177.145 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 mp0 -52.96 -42.76 65.79 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.456 1.102 . . . . 10.0 109.992 173.14 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.12 -9.21 20.92 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 117.341 -1.314 . . . . 10.0 113.362 179.458 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.2 t -108.73 7.57 26.44 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 121.009 1.731 . . . . 10.0 110.627 173.559 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -127.05 -59.44 1.25 Allowed 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 124.909 1.284 . . . . 10.0 110.94 -170.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.7 p -140.63 22.42 2.33 Favored 'General case' 0 CA--C 1.544 0.736 0 CA-C-N 119.016 0.826 . . . . 10.0 112.008 176.37 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 78.03 -100.23 1.6 Allowed Glycine 0 C--N 1.341 0.857 0 N-CA-C 107.533 -2.227 . . . . 10.0 107.533 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -163.62 42.19 0.1 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 125.696 1.598 . . . . 10.0 107.6 169.075 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.43 -8.98 45.46 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.296 1.038 . . . . 10.0 113.009 -174.372 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.01 -171.34 55.13 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.669 -1.372 . . . . 10.0 109.669 -173.228 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -53.32 164.11 0.51 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 124.822 1.249 . . . . 10.0 112.004 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.25 114.25 19.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 168.019 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.425 ' N ' ' CD2' ' B' ' 144' ' ' LEU . 0.7 OUTLIER -84.63 -48.13 9.81 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 108.315 -0.994 . . . . 10.0 108.315 -177.716 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.64 141.17 39.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 116.208 -0.451 . . . . 10.0 110.121 -175.464 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 m -118.6 145.37 45.46 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 126.491 1.916 . . . . 10.0 108.297 -169.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.19 155.46 26.49 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.859 -1.296 . . . . 10.0 109.859 168.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 18.1 t -116.24 129.51 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 103.946 -2.613 . . . . 10.0 103.946 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.7 mt -65.93 133.65 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 119.188 0.904 . . . . 10.0 111.255 -177.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.04 143.38 16.15 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.338 -1.505 . . . . 10.0 109.338 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -80.94 128.21 38.89 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.346 0 CA-C-N 118.442 1.121 . . . . 10.0 108.622 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.33 -49.23 17.42 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 -175.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.8 tp60 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 117.218 -1.373 . . . . 10.0 109.527 175.195 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 108.466 -0.938 . . . . 10.0 108.466 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t -133.81 -49.09 0.82 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 124.061 0.944 . . . . 10.0 111.439 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -120.93 139.54 53.08 Favored 'General case' 0 C--O 1.235 0.31 0 C-N-CA 125.462 1.505 . . . . 10.0 109.371 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.87 164.12 36.23 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 173.186 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 m -123.72 179.57 2.7 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 O-C-N 123.469 0.481 . . . . 10.0 109.9 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.89 118.25 8.45 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 126.683 1.993 . . . . 10.0 107.631 164.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 m -97.23 86.81 1.6 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 124.211 1.005 . . . . 10.0 111.007 173.271 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.426 ' N ' HD12 ' A' ' 8' ' ' LEU . 5.7 mp -79.47 140.15 37.42 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 121.789 -0.569 . . . . 10.0 109.609 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.8 mtmt -152.35 163.65 39.06 Favored 'General case' 0 N--CA 1.456 -0.168 0 N-CA-C 106.622 -1.621 . . . . 10.0 106.622 170.023 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -166.4 -65.71 0.03 OUTLIER Glycine 0 C--N 1.33 0.249 0 C-N-CA 120.606 -0.806 . . . . 10.0 112.249 169.177 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -74.11 -42.1 60.59 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.08 -66.45 0.5 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 114.885 -1.052 . . . . 10.0 111.959 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.81 -41.24 71.76 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.89 1.727 . . . . 10.0 110.621 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.466 HG23 HD11 ' A' ' 38' ' ' LEU . 0.4 OUTLIER -68.0 109.47 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.331 -1.359 . . . . 10.0 107.331 177.364 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -120.46 122.37 40.54 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.161 -2.163 . . . . 10.0 105.161 171.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.736 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -108.94 133.64 11.78 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 109.649 -1.38 . . . . 10.0 109.649 175.274 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.597 ' CG2' HG22 ' B' ' 54' ' ' THR . 2.2 mt -138.17 86.38 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -173.567 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.5 mm -95.57 143.33 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 C-N-CA 123.948 0.899 . . . . 10.0 109.111 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 32.7 m-80 -115.54 121.68 43.4 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 126.13 1.772 . . . . 10.0 108.721 168.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -102.28 98.11 8.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 125.862 1.665 . . . . 10.0 107.025 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -117.89 121.31 40.39 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.072 0.851 . . . . 10.0 113.109 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -94.05 105.49 17.49 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 125.867 1.667 . . . . 10.0 107.831 168.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.47 -42.76 61.83 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.795 0.838 . . . . 10.0 110.174 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -135.98 158.53 44.17 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 102.193 -3.262 . . . . 10.0 102.193 165.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 t -77.32 -3.87 42.19 Favored 'General case' 0 C--O 1.226 -0.135 0 CA-C-N 119.37 0.986 . . . . 10.0 109.817 173.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m120 -85.02 -24.6 28.12 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 125.182 1.393 . . . . 10.0 109.361 168.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.62 156.84 45.06 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 109.43 -1.468 . . . . 10.0 109.43 174.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -64.55 153.16 78.71 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 N-CA-C 108.006 -1.575 . . . . 10.0 108.006 169.145 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.8 p -79.14 121.14 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 N-CA-C 106.69 -1.596 . . . . 10.0 106.69 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -88.79 113.73 24.66 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.16 -1.793 . . . . 10.0 106.16 168.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 m -92.31 95.97 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.824 0 N-CA-C 105.555 -2.017 . . . . 10.0 105.555 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.7 p90 -106.97 161.8 14.4 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.178 0.513 . . . . 10.0 110.538 171.179 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.16 169.29 39.48 Favored Glycine 0 N--CA 1.438 -1.187 0 C-N-CA 120.055 -1.069 . . . . 10.0 110.63 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.0 t -139.37 95.75 2.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.992 -1.485 . . . . 10.0 106.992 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.736 HG22 ' HA2' ' A' ' 16' ' ' GLY . 6.4 pt -77.07 166.33 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.124 -1.065 . . . . 10.0 108.124 169.093 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -149.29 146.53 27.6 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 106.58 -1.637 . . . . 10.0 106.58 166.728 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.53 -4.93 24.73 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 123.921 0.772 . . . . 10.0 113.567 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.494 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.3 mp -73.23 177.93 4.8 Favored 'General case' 0 N--CA 1.444 -0.752 0 CA-C-N 118.117 0.959 . . . . 10.0 109.245 173.66 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 7.9 t -90.39 172.29 8.85 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.632 -0.877 . . . . 10.0 108.632 166.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.91 169.88 2.37 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.43 1.092 . . . . 10.0 110.837 -173.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.73 -178.92 41.26 Favored Glycine 0 N--CA 1.448 -0.503 0 O-C-N 121.428 -0.795 . . . . 10.0 112.843 167.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.6 mp -69.4 143.83 53.54 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.612 1.165 . . . . 10.0 109.779 176.04 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -142.61 139.49 31.31 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 123.381 0.672 . . . . 10.0 112.662 -176.358 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.627 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -26.84 117.94 0.04 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.106 2.289 . . . . 10.0 113.036 164.566 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.03 106.23 4.56 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 120.2 2.0 . . . . 10.0 110.095 170.03 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.422 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -148.48 172.06 15.09 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-O 121.174 0.512 . . . . 10.0 112.075 179.872 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.43 -44.57 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 C-N-CA 126.249 1.819 . . . . 10.0 113.429 -168.506 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 63.64 144.45 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 126.887 2.075 . . . . 10.0 112.074 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -67.0 -47.7 70.68 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.694 -0.854 . . . . 10.0 108.694 177.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -74.88 129.98 38.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 107.788 -1.19 . . . . 10.0 107.788 -169.591 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -88.75 -28.43 21.47 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 126.572 2.034 . . . . 10.0 110.695 175.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.59 176.43 0.65 Allowed 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 125.144 1.378 . . . . 10.0 112.819 -176.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -146.34 -64.41 0.3 Allowed 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.078 -1.419 . . . . 10.0 110.021 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.792 HG22 HG22 ' B' ' 17' ' ' ILE . 1.0 OUTLIER 46.54 -57.17 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.652 1 C-N-CA 133.211 4.604 . . . . 10.0 115.134 179.546 . . . . . . . . 4 4 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . 0.293 . . -69.66 -37.05 76.57 Favored 'General case' 0 N--CA 1.437 -1.081 0 C-N-CA 127.763 2.425 . . . . 10.0 108.216 169.618 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.29 -143.76 14.96 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.233 -2.747 . . . . 10.0 106.233 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.3 t -78.8 39.35 0.35 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 122.178 0.99 . . . . 10.0 112.066 -172.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.4 m -111.27 -49.33 3.02 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 127.826 2.451 . . . . 10.0 106.811 -169.518 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 16.1 m -91.0 16.92 8.64 Favored 'General case' 0 N--CA 1.435 -1.224 0 C-N-CA 126.488 1.915 . . . . 10.0 110.113 -171.292 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.69 61.44 1.37 Allowed 'General case' 0 C--O 1.236 0.379 0 C-N-CA 124.101 0.96 . . . . 10.0 109.365 169.453 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 0.26 103.92 0.01 OUTLIER Glycine 0 C--N 1.335 0.488 1 C-N-CA 131.62 4.438 . . . . 10.0 111.087 166.705 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -73.04 73.5 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 122.752 2.301 . . . . 10.0 113.129 -168.345 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.4 m80 71.82 36.2 1.24 Allowed 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 129.592 3.157 . . . . 10.0 110.749 170.008 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -73.62 60.02 0.66 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.451 1.1 . . . . 10.0 110.709 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -75.03 156.96 85.85 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 123.673 0.789 . . . . 10.0 110.181 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -65.43 -65.36 0.05 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.441 2.094 . . . . 10.0 111.5 -175.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.99 66.81 1.22 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.661 0.743 . . . . 10.0 109.975 172.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 113.74 3.3 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.401 -0.812 . . . . 10.0 109.557 178.102 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.6 mtt180 -116.8 -87.91 0.6 Allowed 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 103.298 -2.852 . . . . 10.0 103.298 -173.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtm -145.72 160.12 42.18 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 122.627 1.203 . . . . 10.0 108.702 167.589 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 42.7 t60 -62.2 127.27 30.59 Favored 'General case' 0 N--CA 1.439 -1.022 0 N-CA-C 105.364 -2.088 . . . . 10.0 105.364 163.019 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.89 -138.26 3.27 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 107.79 -2.124 . . . . 10.0 107.79 177.067 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.45 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.42 -158.39 22.26 Favored Glycine 0 N--CA 1.449 -0.444 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 169.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -65.98 10.58 0.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 CA-C-N 119.869 1.835 . . . . 10.0 110.945 168.058 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.45 ' H ' ' C ' ' A' ' 73' ' ' GLY . 1.9 mmmp? -108.68 -15.83 14.32 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.621 1.168 . . . . 10.0 109.257 177.368 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.419 ' OD2' ' NZ ' ' A' ' 128' ' ' LYS . 2.3 m-20 -141.32 132.13 25.85 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.617 -1.623 . . . . 10.0 106.617 -168.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -73.46 -22.58 60.14 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 -171.372 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -79.57 1.82 24.55 Favored 'General case' 0 N--CA 1.433 -1.313 0 C-N-CA 124.737 1.215 . . . . 10.0 111.579 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -42.15 142.97 0.65 Allowed 'General case' 0 C--N 1.346 0.445 0 C-N-CA 124.956 1.302 . . . . 10.0 112.436 177.305 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -59.49 -62.28 2.0 Allowed 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 121.238 0.542 . . . . 10.0 111.132 -173.575 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.438 HG13 ' H ' ' A' ' 82' ' ' GLY . 5.8 p -167.37 -64.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 179.288 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.438 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -122.04 60.26 0.56 Allowed Glycine 0 CA--C 1.522 0.503 0 N-CA-C 109.637 -1.385 . . . . 10.0 109.637 -179.151 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -92.37 90.97 7.45 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.672 -2.344 . . . . 10.0 104.672 168.411 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 40.4 mt -70.07 -31.49 69.11 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 173.568 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.1 -102.73 2.27 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 108.536 -1.825 . . . . 10.0 108.536 168.249 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 52.4 m-20 -124.51 124.22 41.81 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.686 1.194 . . . . 10.0 110.631 -168.698 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 16.2 m -111.1 137.71 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 108.057 -1.09 . . . . 10.0 108.057 168.16 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 54.1 m -92.22 120.18 32.55 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.897 1.679 . . . . 10.0 108.667 -175.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.62 133.2 44.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 123.901 0.88 . . . . 10.0 110.508 176.443 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -59.38 170.97 0.87 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 123.589 0.755 . . . . 10.0 109.834 167.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.42 ' NZ ' ' OD1' ' A' ' 92' ' ' ASP . 12.6 pttp -47.37 -34.89 7.51 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.787 1.635 . . . . 10.0 110.403 171.016 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.42 ' OD1' ' NZ ' ' A' ' 91' ' ' LYS . 0.2 OUTLIER -79.48 -0.74 34.43 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 124.683 1.193 . . . . 10.0 111.438 -174.768 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.45 8.55 87.69 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 110.671 -0.972 . . . . 10.0 110.671 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.5 t -88.0 106.92 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 125.95 1.7 . . . . 10.0 106.614 -178.191 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.496 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -103.9 117.84 35.28 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 168.619 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.26 114.37 18.14 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 126.038 1.735 . . . . 10.0 108.654 172.539 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.2 t -107.24 133.43 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 178.336 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 94.9 p -156.62 59.21 0.55 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.264 0.625 . . . . 10.0 110.088 172.243 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.6 mt -96.43 157.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -174.129 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -133.06 143.0 49.06 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.805 0.729 . . . . 10.0 111.057 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -127.09 124.14 38.52 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.274 1.43 . . . . 10.0 108.861 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 p -89.99 -8.89 50.57 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.352 1.461 . . . . 10.0 111.147 169.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.4 p -95.91 -39.23 9.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 124.331 1.052 . . . . 10.0 109.929 -174.081 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -97.03 155.89 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 125.347 1.459 . . . . 10.0 108.514 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.6 m -157.63 156.39 31.74 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 108.281 -1.007 . . . . 10.0 108.281 -173.121 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -74.53 -23.04 58.75 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 120.919 0.39 . . . . 10.0 110.478 174.044 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.8 m -150.47 142.57 24.05 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.051 -1.462 . . . . 10.0 107.051 -177.44 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.73 -67.2 0.29 Allowed Glycine 0 C--N 1.334 0.427 0 N-CA-C 109.014 -1.634 . . . . 10.0 109.014 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -163.37 -51.36 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 126.398 1.879 . . . . 10.0 107.287 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.19 -28.29 59.97 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 114.755 -1.111 . . . . 10.0 110.241 -169.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.1 t 22.86 81.47 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 129.028 2.931 . . . . 10.0 111.814 172.141 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.8 pt -75.93 39.23 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 112.213 0.449 . . . . 10.0 112.213 -173.469 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -83.39 -48.61 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 124.899 1.28 . . . . 10.0 111.268 -171.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.79 46.02 1.32 Allowed Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.816 -0.914 . . . . 10.0 110.816 -175.51 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -111.13 162.02 15.35 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 125.201 1.4 . . . . 10.0 108.881 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -110.22 102.56 11.23 Favored 'General case' 0 C--N 1.347 0.476 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 179.358 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.82 134.98 40.24 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.514 -0.921 . . . . 10.0 108.514 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.408 HG12 ' CD2' ' A' ' 120' ' ' HIS . 61.9 t -124.11 131.74 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 O-C-N 123.911 0.757 . . . . 10.0 110.407 -172.253 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.445 HG13 HD21 ' A' ' 38' ' ' LEU . 1.8 t -98.19 123.37 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 128.416 2.686 . . . . 10.0 107.639 168.199 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.627 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.5 m-70 -109.94 157.54 19.15 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 115.868 1.803 . . . . 10.0 115.868 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -41.34 -65.13 0.47 Allowed 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 129.767 3.227 . . . . 10.0 111.73 171.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.1 mttp -112.28 175.41 5.44 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.861 0.865 . . . . 10.0 111.74 -172.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.61 147.91 37.29 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 114.005 -1.452 . . . . 10.0 109.72 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.422 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 4.5 m-20 -78.77 142.75 36.73 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 123.62 0.768 . . . . 10.0 110.659 171.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -78.53 -13.59 59.76 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.512 -1.222 . . . . 10.0 110.563 167.283 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 76.5 mt 61.62 42.86 10.56 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 125.474 1.51 . . . . 10.0 110.949 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.14 -5.94 56.12 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 124.262 0.934 . . . . 10.0 112.611 173.39 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.419 ' NZ ' ' OD2' ' A' ' 76' ' ' ASP . 11.9 mttt -110.65 35.79 3.35 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.752 0.821 . . . . 10.0 110.628 -167.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -84.09 -31.18 26.51 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.861 2.172 . . . . 10.0 111.901 178.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.61 48.41 84.7 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -176.034 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.481 ' H ' ' HB2' ' A' ' 134' ' ' SER . 14.8 m-80 -150.29 165.62 32.46 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.781 2.432 . . . . 10.0 106.289 -175.131 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -58.41 -47.65 83.23 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-O 121.588 0.709 . . . . 10.0 109.139 174.243 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -54.02 -30.92 49.54 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.979 1.312 . . . . 10.0 112.695 175.408 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.481 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 7.0 t -47.22 -47.46 24.43 Favored 'General case' 0 C--O 1.223 -0.307 0 C-N-CA 124.395 1.078 . . . . 10.0 108.412 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -88.24 10.19 20.46 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 118.751 -0.642 . . . . 10.0 112.55 -173.044 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -122.38 -94.39 0.5 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.455 1.902 . . . . 10.0 109.875 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.85 25.04 9.08 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 121.353 1.888 . . . . 10.0 110.158 177.294 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.07 -91.32 0.44 Allowed Glycine 0 C--N 1.339 0.743 0 N-CA-C 108.886 -1.686 . . . . 10.0 108.886 177.101 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 m-80 -162.27 35.97 0.12 Allowed 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 126.428 1.891 . . . . 10.0 108.246 172.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.55 -9.92 55.95 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 121.219 -0.926 . . . . 10.0 112.116 -173.155 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.96 -167.92 53.82 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.862 -0.895 . . . . 10.0 110.862 174.686 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 58.4 p -59.12 139.34 56.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 122.308 1.051 . . . . 10.0 112.277 -168.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 40.2 mtt85 -66.76 74.84 0.11 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.526 1.131 . . . . 10.0 110.838 173.173 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.3 mt -47.31 -38.7 13.22 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 123.506 0.722 . . . . 10.0 112.09 176.345 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.8 157.17 40.38 Favored 'General case' 0 CA--C 1.514 -0.43 0 O-C-N 121.827 -0.546 . . . . 10.0 111.121 176.494 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -159.01 167.32 29.63 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.458 -0.337 . . . . 10.0 110.218 171.273 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.63 165.42 36.23 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 109.331 -1.508 . . . . 10.0 109.331 -176.669 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 92.9 t -105.53 146.95 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 103.018 -2.956 . . . . 10.0 103.018 -175.828 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . 0.3 5.0 mt -68.36 -86.88 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 CA-C-O 121.469 0.652 . . . . 10.0 112.46 -168.427 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 93.49 135.44 7.5 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.775 1.179 . . . . 10.0 112.699 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.1 mt -70.46 142.15 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 125.057 1.343 . . . . 10.0 109.357 -176.611 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.77 -45.22 2.29 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.077 0.951 . . . . 10.0 111.383 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.537 1.935 . . . . 10.0 113.266 -178.505 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 107.166 -1.42 . . . . 10.0 107.166 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -78.14 -50.44 11.99 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-O 122.299 1.047 . . . . 10.0 109.743 171.459 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -156.04 153.97 30.29 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.692 -1.14 . . . . 10.0 109.76 -169.058 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.4 151.47 48.58 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.074 0.949 . . . . 10.0 108.629 169.06 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.6 t -109.56 159.31 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 125.044 1.338 . . . . 10.0 110.099 174.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.99 97.17 3.01 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 124.31 1.044 . . . . 10.0 108.562 166.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.458 HG12 HG23 ' B' ' 17' ' ' ILE . 29.1 m -82.29 126.36 39.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.657 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -106.11 149.74 26.46 Favored 'General case' 0 CA--C 1.529 0.136 0 CA-C-O 117.914 -1.041 . . . . 10.0 108.351 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 9' ' ' LYS . . . . . 0.429 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 47.0 tttt -165.13 161.73 19.72 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 120.083 1.31 . . . . 10.0 108.679 170.289 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.42 -50.26 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 116.204 -0.453 . . . . 10.0 112.208 169.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -77.62 -46.34 22.41 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 -170.055 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 131.79 -61.7 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.928 -1.487 . . . . 10.0 111.303 -175.079 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -63.02 -39.68 38.6 Favored 'Trans proline' 0 N--CA 1.454 -0.811 0 C-N-CA 122.586 2.191 . . . . 10.0 110.79 169.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.97 115.34 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.114 -1.069 . . . . 10.0 108.114 -178.351 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.43 140.05 27.33 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-O 121.014 0.435 . . . . 10.0 110.091 165.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.486 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -108.07 157.28 15.43 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 125.256 1.408 . . . . 10.0 112.388 178.038 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.792 HG22 HG22 ' A' ' 54' ' ' THR . 0.3 OUTLIER -147.19 85.0 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 N-CA-C 106.29 -1.745 . . . . 10.0 106.29 -179.525 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.78 145.09 9.38 Favored 'Isoleucine or valine' 0 C--O 1.231 0.093 0 C-N-CA 124.062 0.945 . . . . 10.0 110.778 178.622 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -123.19 111.74 16.85 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 129.854 3.261 . . . . 10.0 106.928 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -101.09 103.22 14.3 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.561 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 79.0 mt-10 -96.38 137.1 35.95 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.139 0.881 . . . . 10.0 110.843 170.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -106.15 100.95 10.47 Favored 'General case' 0 CA--C 1.53 0.186 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 24.0 tttp . . . . . 0 N--CA 1.441 -0.903 0 C-N-CA 125.959 1.704 . . . . 10.0 110.297 -176.735 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.868 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -62.83 130.15 28.47 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 N-CA-C 107.966 -1.59 . . . . 10.0 107.966 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.4 t -79.99 99.73 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 105.98 -1.859 . . . . 10.0 105.98 174.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -77.04 119.34 20.63 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 104.67 -2.344 . . . . 10.0 104.67 167.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -105.16 114.15 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 106.323 -1.732 . . . . 10.0 106.323 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -135.8 172.6 12.78 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 121.166 0.508 . . . . 10.0 111.831 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.59 -149.15 21.21 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 106.334 -2.706 . . . . 10.0 106.334 169.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.0 m -155.53 159.43 39.71 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 119.079 -1.048 . . . . 10.0 111.25 177.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.567 HG12 ' HB3' ' B' ' 95' ' ' ALA . 1.5 pt -117.28 147.1 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.772 -1.104 . . . . 10.0 108.565 166.738 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -126.07 138.72 53.73 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 124.38 1.05 . . . . 10.0 109.226 168.539 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.27 -8.05 10.47 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.972 1.272 . . . . 10.0 113.29 175.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -62.44 178.55 0.4 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.288 1.044 . . . . 10.0 112.237 177.533 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.2 t -115.0 156.72 24.57 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 106.897 -1.52 . . . . 10.0 106.897 167.088 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -46.95 143.95 2.71 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.583 1.553 . . . . 10.0 112.902 -169.235 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.24 -178.42 31.71 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 124.222 0.915 . . . . 10.0 111.887 171.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 10.6 mt -64.0 150.48 45.15 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.657 1.583 . . . . 10.0 112.71 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -146.11 148.57 32.75 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.681 1.192 . . . . 10.0 112.764 177.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.639 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -25.7 124.31 0.04 OUTLIER Glycine 0 C--N 1.341 0.852 0 C-N-CA 126.668 2.08 . . . . 10.0 112.616 166.473 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -148.91 98.9 2.91 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 119.888 1.844 . . . . 10.0 111.46 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.52 172.59 14.74 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 122.807 0.443 . . . . 10.0 111.151 -178.289 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.3 m -105.43 -24.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 115.826 1.787 . . . . 10.0 115.826 -167.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 62.39 175.22 0.14 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 121.529 0.68 . . . . 10.0 112.568 177.8 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -81.09 -56.32 4.17 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.985 -0.552 . . . . 10.0 110.195 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -87.25 156.14 19.78 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.161 0.437 . . . . 10.0 110.158 -172.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.01 -19.26 22.23 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.036 -1.226 . . . . 10.0 110.036 169.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -63.38 160.43 16.11 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 122.556 1.17 . . . . 10.0 111.688 -176.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -153.79 16.66 0.51 Allowed 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.242 -0.89 . . . . 10.0 113.001 -171.095 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.597 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -45.53 -40.86 9.08 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 127.141 2.177 . . . . 10.0 112.707 -177.887 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.1 -18.56 57.88 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 111.915 0.339 . . . . 10.0 111.915 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.88 -66.2 0.56 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 109.474 -1.45 . . . . 10.0 109.474 -179.382 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 48.2 t -157.84 18.31 0.25 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.645 1.178 . . . . 10.0 110.584 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -98.87 -45.3 6.04 Favored 'General case' 0 N--CA 1.44 -0.931 0 O-C-N 120.184 -1.572 . . . . 10.0 108.695 -177.204 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -49.11 -39.71 29.44 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.438 1.495 . . . . 10.0 111.792 -169.044 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.46 -42.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 129.027 2.931 . . . . 10.0 114.205 168.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.33 163.24 28.43 Favored Glycine 0 N--CA 1.439 -1.113 0 N-CA-C 107.87 -2.092 . . . . 10.0 107.87 172.652 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -74.42 -169.29 0.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.547 0 N-CA-C 106.734 -2.064 . . . . 10.0 106.734 167.058 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -82.12 58.41 3.96 Favored 'General case' 0 CA--C 1.539 0.52 0 O-C-N 120.109 -1.62 . . . . 10.0 110.314 -174.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -76.51 59.66 1.51 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 123.06 1.41 . . . . 10.0 111.733 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -60.35 153.67 57.74 Favored Pre-proline 0 C--N 1.324 -0.516 0 C-N-CA 126.44 1.896 . . . . 10.0 110.965 169.132 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.77 -43.95 0.55 Allowed 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.686 2.257 . . . . 10.0 111.377 175.061 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 tt -79.3 62.77 3.75 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.175 0.99 . . . . 10.0 109.743 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 10.1 t -39.36 107.61 0.07 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.142 1.777 . . . . 10.0 113.368 -169.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.4 mtt180 -136.5 -174.07 3.59 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.422 1.489 . . . . 10.0 109.708 175.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.5 mmpt? -117.64 57.88 0.81 Allowed 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 113.975 1.102 . . . . 10.0 113.975 -167.089 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.402 ' CD2' ' CA ' ' B' ' 138' ' ' GLY . 63.5 t60 38.03 94.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 116.209 1.929 . . . . 10.0 116.209 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.6 -164.64 12.51 Favored Glycine 0 C--N 1.315 -0.61 0 N-CA-C 108.524 -1.83 . . . . 10.0 108.524 168.432 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -139.53 -162.4 9.1 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.143 -0.783 . . . . 10.0 111.143 171.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -69.81 10.32 0.51 Allowed 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.324 2.016 . . . . 10.0 111.569 176.655 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 84.3 mttt -101.28 -19.74 15.53 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.657 0.783 . . . . 10.0 109.174 170.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -125.67 -178.64 4.33 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 107.945 -1.132 . . . . 10.0 107.945 -167.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . 0.273 0.6 OUTLIER -110.43 -1.6 17.0 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 112.752 0.649 . . . . 10.0 112.752 167.918 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -77.61 -1.82 32.72 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 121.815 -0.553 . . . . 10.0 109.945 175.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 21.0 ptt-85 -42.25 124.43 2.8 Favored 'General case' 0 C--N 1.344 0.335 0 C-N-CA 124.965 1.306 . . . . 10.0 109.148 169.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -74.67 -54.3 7.67 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.574 -0.528 . . . . 10.0 109.574 -172.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.479 HG13 ' H ' ' B' ' 82' ' ' GLY . 6.6 p -165.02 -66.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.537 0.735 . . . . 10.0 109.157 176.143 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.479 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -118.7 77.01 0.3 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.663 -2.175 . . . . 10.0 107.663 178.8 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -119.54 97.97 5.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.99 -2.226 . . . . 10.0 104.99 178.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -83.13 23.06 0.9 Allowed 'General case' 0 CA--C 1.526 0.048 0 CA-C-O 120.962 0.41 . . . . 10.0 110.553 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.4 -109.93 2.91 Favored Glycine 0 N--CA 1.432 -1.615 0 N-CA-C 105.653 -2.979 . . . . 10.0 105.653 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -158.93 139.12 12.2 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.857 -1.164 . . . . 10.0 107.857 -178.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.3 m -108.46 130.49 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 123.535 0.734 . . . . 10.0 111.867 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -80.95 101.52 9.54 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.973 2.909 . . . . 10.0 111.488 -170.189 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.99 134.34 35.36 Favored 'General case' 0 N--CA 1.451 -0.398 0 O-C-N 121.866 -0.521 . . . . 10.0 109.733 170.586 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -61.9 167.57 3.68 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 122.033 0.921 . . . . 10.0 108.75 167.09 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 30.6 ttpt -49.87 -31.13 11.34 Favored 'General case' 0 N--CA 1.432 -1.358 0 C-N-CA 125.934 1.694 . . . . 10.0 111.964 169.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -77.03 -10.29 59.27 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.188 0.449 . . . . 10.0 111.258 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.2 12.11 66.03 Favored Glycine 0 C--N 1.34 0.797 0 O-C-N 120.993 -1.067 . . . . 10.0 110.798 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -92.6 111.48 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 C-N-CA 126.66 1.984 . . . . 10.0 106.311 176.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.567 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -108.53 121.6 45.31 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.792 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -82.64 123.06 28.91 Favored 'General case' 0 N--CA 1.434 -1.253 0 C-N-CA 126.893 2.077 . . . . 10.0 107.989 170.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.94 131.85 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.935 -1.505 . . . . 10.0 106.935 175.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.85 75.8 0.71 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.991 0.916 . . . . 10.0 109.583 169.607 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.9 164.31 3.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.589 -1.634 . . . . 10.0 106.589 179.274 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -137.49 138.9 40.19 Favored 'General case' 0 N--CA 1.451 -0.383 0 O-C-N 121.459 -0.776 . . . . 10.0 110.868 171.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.99 145.53 49.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 124.454 1.096 . . . . 10.0 108.558 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.2 p -120.1 16.71 12.44 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.12 1.368 . . . . 10.0 110.7 172.398 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -107.65 -49.23 7.93 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 124.362 1.065 . . . . 10.0 109.634 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.329 0.7 OUTLIER -67.82 170.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-O 121.206 0.527 . . . . 10.0 112.094 171.544 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 52.1 p -151.91 140.25 20.46 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.151 -1.055 . . . . 10.0 108.151 174.362 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.4 pp -85.85 -24.68 26.63 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 108.27 -1.011 . . . . 10.0 108.27 167.272 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m . . . . . 0 N--CA 1.451 -0.396 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 166.292 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t . . . . . 0 CA--C 1.531 0.229 0 CA-C-O 122.171 0.986 . . . . 10.0 111.981 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 41.1 pt -66.4 1.53 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 113.619 0.97 . . . . 10.0 113.619 -178.29 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.8 mm -41.42 -40.88 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.302 0 C-N-CA 125.113 1.365 . . . . 10.0 113.783 177.721 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -105.5 25.59 24.1 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.82 1.2 . . . . 10.0 113.198 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.58 175.94 6.03 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.44 1.096 . . . . 10.0 110.439 174.31 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -123.71 107.98 12.04 Favored 'General case' 0 C--N 1.344 0.355 0 C-N-CA 124.554 1.142 . . . . 10.0 111.168 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -61.94 130.76 47.15 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 167.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.03 131.21 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 N-CA-C 107.504 -1.295 . . . . 10.0 107.504 173.167 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.445 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.8 OUTLIER -100.72 126.35 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.537 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.639 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.4 m170 -104.26 157.0 17.44 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 115.248 1.573 . . . . 10.0 115.248 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -47.48 -57.06 5.82 Favored 'General case' 0 N--CA 1.447 -0.614 0 C-N-CA 127.784 2.434 . . . . 10.0 110.657 177.321 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -107.53 170.84 7.73 Favored 'General case' 0 N--CA 1.463 0.199 0 C-N-CA 124.493 1.117 . . . . 10.0 112.478 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.28 149.93 38.67 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.558 1.543 . . . . 10.0 109.804 171.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.01 144.85 38.39 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 112.924 0.713 . . . . 10.0 112.924 177.101 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -78.32 -23.87 46.86 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.755 1.622 . . . . 10.0 109.259 167.109 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 48.9 mt 54.76 58.28 4.97 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 122.611 1.196 . . . . 10.0 109.693 -174.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.96 -47.31 3.82 Favored Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 113.996 -1.456 . . . . 10.0 112.505 167.122 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.91 42.39 0.38 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 118.026 0.913 . . . . 10.0 112.649 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.2 -22.82 26.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 127.122 2.296 . . . . 10.0 109.442 168.096 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.78 32.95 83.57 Favored Glycine 0 C--N 1.337 0.6 0 N-CA-C 110.975 -0.85 . . . . 10.0 110.975 176.23 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -135.67 162.94 31.32 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.132 -1.062 . . . . 10.0 108.132 172.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -45.87 -48.77 15.95 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 124.409 1.083 . . . . 10.0 110.02 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -70.46 -33.6 71.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.671 -0.643 . . . . 10.0 112.143 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.9 p -53.3 -44.26 68.2 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 119.374 0.988 . . . . 10.0 110.331 174.291 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.6 t -80.71 -19.18 45.66 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 112.852 0.686 . . . . 10.0 112.852 -173.572 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -101.41 -45.37 5.34 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 125.304 1.442 . . . . 10.0 112.666 -172.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 30.8 p -132.18 -1.97 3.59 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 119.211 0.914 . . . . 10.0 113.128 174.278 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 138' ' ' GLY . . . . . 0.402 ' CA ' ' CD2' ' B' ' 71' ' ' HIS . . . 88.89 22.97 36.95 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-O 118.601 -1.11 . . . . 10.0 112.241 -176.128 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 60.48 15.65 5.75 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 119.567 1.683 . . . . 10.0 112.056 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.98 3.13 5.7 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.103 -0.998 . . . . 10.0 112.438 -170.334 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.94 -168.55 54.76 Favored Glycine 0 N--CA 1.444 -0.813 0 N-CA-C 110.586 -1.006 . . . . 10.0 110.586 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.4 t -58.04 143.86 41.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 115.05 -0.575 . . . . 10.0 111.755 -169.485 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.9 mtm-85 -64.02 78.86 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.042 0.937 . . . . 10.0 110.02 168.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 5.7 tp -39.87 -55.37 2.0 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.234 1.813 . . . . 10.0 110.847 176.126 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.445 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -151.81 149.67 29.27 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.153 -0.684 . . . . 10.0 109.153 -173.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 12.6 m -128.48 153.78 46.79 Favored 'General case' 0 CA--C 1.522 -0.132 0 C-N-CA 125.477 1.511 . . . . 10.0 109.101 -173.373 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -133.57 169.95 22.56 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 108.964 -1.654 . . . . 10.0 108.964 167.397 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' A' ' 148' ' ' VAL . 17.2 t -117.83 132.44 67.64 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 169.363 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 71.4 mt -69.24 157.99 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.382 -0.97 . . . . 10.0 108.382 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.88 156.16 27.26 Favored Glycine 0 CA--C 1.528 0.891 0 O-C-N 121.249 -0.907 . . . . 10.0 111.731 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.7 mp -55.52 133.38 19.3 Favored 'Isoleucine or valine' 0 C--N 1.341 0.22 0 C-N-CA 125.618 1.567 . . . . 10.0 109.765 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -120.21 165.6 14.59 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.38 -1.341 . . . . 10.0 107.38 166.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 . . . . . 0 C--O 1.25 1.084 0 C-N-CA 125.939 1.695 . . . . 10.0 106.834 169.831 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 106.205 -1.776 . . . . 10.0 106.205 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.7 t -69.4 -14.34 62.85 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.496 1.044 . . . . 10.0 109.171 168.335 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.67 155.12 50.29 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 125.406 1.483 . . . . 10.0 107.481 168.253 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.04 158.24 44.03 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 125.483 1.513 . . . . 10.0 106.952 169.22 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -122.05 152.61 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 C-N-CA 123.529 0.732 . . . . 10.0 110.106 -178.373 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.557 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -127.8 97.23 4.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 125.099 1.359 . . . . 10.0 108.502 168.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.0 OUTLIER -79.64 109.25 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.13 -1.433 . . . . 10.0 107.13 167.427 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.3 mt -90.07 139.85 30.22 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.068 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.413 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 18.9 tttt -162.18 161.09 27.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 120.01 1.277 . . . . 10.0 108.388 170.191 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.42 -53.32 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.206 0 N-CA-C 111.66 -0.576 . . . . 10.0 111.66 170.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -75.72 -47.31 26.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 106.713 -1.588 . . . . 10.0 106.713 -171.347 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.53 -61.26 0.66 Allowed Glycine 0 CA--C 1.53 0.993 0 CA-C-N 113.822 -1.536 . . . . 10.0 111.807 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.14 -34.92 67.27 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 122.63 2.22 . . . . 10.0 111.23 172.687 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.0 t -75.58 110.1 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.176 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 176.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.21 129.69 38.08 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 123.448 0.699 . . . . 10.0 109.326 166.753 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.47 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -105.75 147.11 16.18 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 125.595 1.569 . . . . 10.0 109.559 171.828 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.448 HG22 HG22 ' B' ' 54' ' ' THR . 2.9 mt -140.82 59.68 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 -176.459 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm -78.95 140.27 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 N-CA-C 109.095 -0.705 . . . . 10.0 109.095 -172.446 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -116.61 110.52 18.63 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 126.939 2.096 . . . . 10.0 107.271 178.368 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -94.45 109.73 21.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 176.115 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.54 158.64 16.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.572 0.624 . . . . 10.0 112.127 170.507 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -155.61 83.23 1.04 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.818 2.047 . . . . 10.0 106.646 166.02 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 6.5 mmtp -52.13 -55.72 19.11 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 125.294 1.437 . . . . 10.0 110.503 -173.238 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -123.62 167.22 14.24 Favored 'General case' 0 N--CA 1.434 -1.264 0 N-CA-C 103.992 -2.595 . . . . 10.0 103.992 169.05 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -71.73 -14.58 62.06 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.885 -0.598 . . . . 10.0 109.917 173.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -79.8 -17.03 54.34 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 123.304 0.642 . . . . 10.0 109.314 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.67 140.98 23.17 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 178.275 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -62.06 153.35 69.74 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.118 1.879 . . . . 10.0 107.543 169.003 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -76.81 89.82 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.167 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 170.119 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.6 tmtp? -85.45 114.16 22.28 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 106.075 -1.824 . . . . 10.0 106.075 170.469 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.2 m -110.31 125.21 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 107.173 -1.417 . . . . 10.0 107.173 -174.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.7 p90 -134.46 164.78 26.69 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.118 0.485 . . . . 10.0 111.878 173.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.2 -148.67 19.52 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 107.827 -2.109 . . . . 10.0 107.827 170.054 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.5 t -155.31 150.77 27.22 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 116.973 0.387 . . . . 10.0 110.143 -176.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.47 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -113.49 111.51 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.268 0 C-N-CA 125.836 1.654 . . . . 10.0 106.611 165.551 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -95.93 137.33 35.15 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 108.073 -1.084 . . . . 10.0 108.073 170.151 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.78 -0.94 9.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 125.137 1.351 . . . . 10.0 112.585 173.091 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.04 174.96 7.89 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 118.453 1.126 . . . . 10.0 109.285 176.738 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -100.58 156.89 17.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.077 -1.823 . . . . 10.0 106.077 165.249 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -55.03 151.59 8.78 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.373 0.669 . . . . 10.0 111.834 -169.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.54 -178.93 26.56 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.115 0.864 . . . . 10.0 112.081 175.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -67.23 151.08 48.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.899 1.28 . . . . 10.0 111.355 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -151.02 153.77 35.77 Favored 'General case' 0 C--N 1.342 0.265 0 N-CA-C 113.577 0.955 . . . . 10.0 113.577 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.635 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -38.23 125.93 1.57 Allowed Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.693 2.568 . . . . 10.0 113.057 165.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -155.2 114.13 3.58 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.525 -1.287 . . . . 10.0 107.525 165.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 170.44 18.46 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.843 0.83 . . . . 10.0 111.582 174.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -115.33 127.28 72.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 104.251 -2.5 . . . . 10.0 104.251 168.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -167.52 175.16 7.31 Favored 'General case' 0 N--CA 1.451 -0.38 0 O-C-N 121.908 -0.495 . . . . 10.0 110.891 -168.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . 0.28 14.0 pt-20 50.3 -157.51 0.09 Allowed 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 126.279 2.237 . . . . 10.0 113.281 167.116 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.8 m-30 -82.64 -167.37 1.59 Allowed 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 109.247 -0.649 . . . . 10.0 109.247 177.086 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.37 -0.35 24.99 Favored Glycine 0 CA--C 1.536 1.347 0 C-N-CA 126.256 1.884 . . . . 10.0 112.975 174.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -75.0 83.0 2.24 Favored 'General case' 0 C--N 1.342 0.258 0 CA-C-N 119.737 1.768 . . . . 10.0 110.637 -176.152 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -79.51 8.41 6.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-N 115.282 -0.872 . . . . 10.0 113.077 177.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.518 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -42.53 -48.07 5.25 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 127.992 2.517 . . . . 10.0 113.376 -171.906 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.08 -26.74 39.49 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 123.206 0.602 . . . . 10.0 112.348 -179.305 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 137.99 -150.69 21.03 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 106.727 -2.549 . . . . 10.0 106.727 -169.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.8 m -80.23 33.16 0.28 Allowed 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 124.668 1.187 . . . . 10.0 112.273 -179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.8 m -125.24 -57.72 1.48 Allowed 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 108.646 -0.872 . . . . 10.0 108.646 -168.43 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 t -58.61 -39.79 81.46 Favored 'General case' 0 C--N 1.341 0.204 0 O-C-N 123.416 0.448 . . . . 10.0 110.935 -168.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.03 -41.69 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 127.387 2.275 . . . . 10.0 113.997 169.532 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.5 -162.93 19.65 Favored Glycine 0 C--N 1.34 0.779 0 N-CA-C 109.597 -1.401 . . . . 10.0 109.597 169.536 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -110.44 178.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.935 1 C-N-CA 125.558 4.172 . . . . 10.0 106.354 164.596 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.6 m170 -66.87 79.86 0.11 Allowed 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 120.088 1.313 . . . . 10.0 110.927 -176.553 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -105.85 53.93 0.7 Allowed 'General case' 0 N--CA 1.462 0.138 0 C-N-CA 127.262 2.225 . . . . 10.0 108.802 172.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -52.99 145.41 23.21 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 125.502 1.521 . . . . 10.0 110.772 168.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -64.98 -43.46 11.78 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 123.338 2.692 . . . . 10.0 111.243 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.4 68.68 0.55 Allowed 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.528 -0.915 . . . . 10.0 108.528 170.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.5 p -58.74 104.79 0.25 Allowed 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.381 1.073 . . . . 10.0 109.893 -175.557 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.1 mtt180 -141.55 -176.56 4.79 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 105.722 -1.955 . . . . 10.0 105.722 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.37 129.48 35.89 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 -177.579 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.1 t60 -44.92 112.13 0.4 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 122.558 0.343 . . . . 10.0 111.749 178.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.49 -147.66 6.52 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.03 -167.93 18.18 Favored Glycine 0 C--O 1.225 -0.451 0 CA-C-N 117.98 0.89 . . . . 10.0 111.567 179.411 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -68.36 16.09 0.16 Allowed 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.518 2.145 . . . . 10.0 112.398 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -110.39 -20.6 12.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 124.934 1.294 . . . . 10.0 110.25 169.403 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.67 162.65 16.94 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.754 -1.572 . . . . 10.0 106.754 -167.761 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -88.98 -21.85 23.31 Favored 'General case' 0 C--N 1.329 -0.32 0 O-C-N 121.629 -0.669 . . . . 10.0 109.877 178.167 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -83.4 -6.37 59.44 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 124.538 1.135 . . . . 10.0 111.474 -169.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -35.65 118.95 0.51 Allowed 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 126.145 1.778 . . . . 10.0 111.108 171.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 9.3 m-70 -50.37 -50.66 50.75 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 115.828 1.788 . . . . 10.0 115.828 -167.327 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -178.25 -46.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 106.945 -1.502 . . . . 10.0 106.945 -174.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -153.45 62.33 0.38 Allowed Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -85.84 95.96 9.61 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 103.705 -2.702 . . . . 10.0 103.705 166.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -70.47 -10.42 59.1 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.578 0.626 . . . . 10.0 111.833 -171.18 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.85 -93.96 0.93 Allowed Glycine 0 N--CA 1.445 -0.744 0 N-CA-C 107.69 -2.164 . . . . 10.0 107.69 176.063 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -150.54 147.11 27.06 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 124.871 1.268 . . . . 10.0 107.79 -174.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.1 m -117.98 128.04 75.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 118.606 0.639 . . . . 10.0 109.755 169.14 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.7 m -90.19 95.11 10.04 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 127.267 2.227 . . . . 10.0 111.506 -169.639 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -69.63 128.5 36.68 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.778 -0.576 . . . . 10.0 111.654 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.1 171.8 5.25 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.123 1.369 . . . . 10.0 109.888 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 pttm -54.89 -29.35 55.62 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.218 1.007 . . . . 10.0 111.088 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -78.25 0.21 26.11 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.031 0.444 . . . . 10.0 111.213 178.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.45 17.59 79.81 Favored Glycine 0 C--N 1.339 0.734 0 O-C-N 120.654 -1.279 . . . . 10.0 110.766 178.536 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 18.3 t -97.68 103.34 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.734 0 C-N-CA 127.812 2.445 . . . . 10.0 106.356 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.404 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -97.33 118.42 33.77 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 168.449 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -79.42 141.87 36.45 Favored 'General case' 0 N--CA 1.425 -1.679 0 C-N-CA 124.643 1.177 . . . . 10.0 108.718 178.384 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 86.8 t -111.63 133.22 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 106.509 -1.663 . . . . 10.0 106.509 169.116 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.6 p -158.88 58.4 0.43 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.501 0.72 . . . . 10.0 111.512 170.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -101.3 152.73 5.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.897 0.879 . . . . 10.0 109.085 -171.61 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -112.01 127.94 56.03 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 126.568 1.947 . . . . 10.0 108.448 172.045 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -130.22 145.72 51.77 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-O 121.378 0.609 . . . . 10.0 111.001 169.326 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.8 t -133.07 64.66 1.61 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.089 2.156 . . . . 10.0 106.652 -178.014 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.01 -52.73 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.077 0 C-N-CA 123.672 0.789 . . . . 10.0 109.225 175.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.328 0.0 OUTLIER -78.84 174.82 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.145 0.497 . . . . 10.0 112.19 172.048 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 m -153.99 153.72 32.49 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.372 -1.714 . . . . 10.0 106.372 169.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 95.7 mt -68.45 -14.52 63.06 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.109 0.564 . . . . 10.0 111.602 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.4 m -151.75 157.21 41.7 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.056 -1.831 . . . . 10.0 106.056 169.402 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 151.84 -66.95 0.33 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 178.309 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -161.02 -51.74 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 126.298 1.839 . . . . 10.0 107.239 -178.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -73.79 -39.44 64.13 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.513 -1.222 . . . . 10.0 108.165 -169.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 17.8 t 35.53 74.86 0.06 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 127.559 2.344 . . . . 10.0 110.31 169.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 pt -76.36 46.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.986 0.914 . . . . 10.0 111.422 -173.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 35.1 mm -92.31 -86.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 124.936 1.295 . . . . 10.0 108.613 -171.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.23 50.57 2.76 Favored Glycine 0 CA--C 1.537 1.468 0 O-C-N 120.291 -1.506 . . . . 10.0 113.669 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 13.4 mmt-85 -101.05 175.63 5.53 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 126.195 1.798 . . . . 10.0 108.006 169.239 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 17.2 m -102.46 104.34 14.78 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.362 1.465 . . . . 10.0 107.086 172.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.02 144.65 40.74 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 105.428 -2.064 . . . . 10.0 105.428 168.427 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.7 t -134.69 139.03 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 N-CA-C 108.645 -0.872 . . . . 10.0 108.645 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -107.39 131.72 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 N-CA-C 106.039 -1.837 . . . . 10.0 106.039 167.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.635 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.8 m170 -114.8 158.89 21.27 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 115.693 1.738 . . . . 10.0 115.693 -169.828 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.2 tt0 -43.84 -57.31 3.34 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 129.035 2.934 . . . . 10.0 111.835 174.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -116.84 169.17 9.59 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 113.835 1.05 . . . . 10.0 113.835 -168.584 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.05 132.24 37.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.557 1.543 . . . . 10.0 109.829 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 125.956 1.702 . . . . 10.0 110.563 -175.058 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.6 -37.42 50.39 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 124.388 1.075 . . . . 10.0 109.859 174.252 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.0 mt 76.07 53.62 0.06 Allowed 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.916 2.086 . . . . 10.0 112.755 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.92 -25.2 22.87 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 115.509 0.964 . . . . 10.0 115.509 167.005 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mptt -75.82 -4.13 38.98 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 119.313 1.557 . . . . 10.0 112.56 -172.558 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.84 -29.41 64.66 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 109.076 -1.609 . . . . 10.0 109.076 168.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.29 41.02 99.39 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.273 -1.131 . . . . 10.0 110.273 -176.549 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -130.78 171.98 12.51 Favored 'General case' 0 CA--C 1.501 -0.94 0 N-CA-C 106.731 -1.581 . . . . 10.0 106.731 170.189 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.1 mp0 -40.22 -58.78 1.41 Allowed 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 10.0 110.109 168.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -50.1 -54.52 19.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 116.072 -0.513 . . . . 10.0 109.999 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.4 p -55.29 -44.46 75.73 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 120.022 -0.671 . . . . 10.0 110.313 -177.288 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -78.24 -7.75 57.52 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.622 1.169 . . . . 10.0 111.16 -173.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -109.36 -68.38 0.92 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.911 1.684 . . . . 10.0 111.38 -178.473 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -114.55 -6.95 12.82 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 121.456 1.934 . . . . 10.0 112.326 179.276 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.55 33.64 47.04 Favored Glycine 0 C--O 1.222 -0.606 0 CA-C-O 118.976 -0.902 . . . . 10.0 111.837 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 61.21 24.91 14.97 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 119.74 1.77 . . . . 10.0 112.189 176.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.7 -9.08 58.29 Favored 'General case' 0 CA--C 1.527 0.082 0 C-N-CA 123.544 0.738 . . . . 10.0 112.31 -177.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.21 -166.12 54.76 Favored Glycine 0 N--CA 1.447 -0.607 0 O-C-N 121.269 -0.894 . . . . 10.0 111.409 172.497 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.1 m -58.13 136.36 57.21 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.064 0.946 . . . . 10.0 113.078 -167.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -64.03 89.11 0.05 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.123 0.969 . . . . 10.0 109.191 168.769 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 62.0 mt -58.07 -51.46 69.61 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.848 -0.427 . . . . 10.0 109.848 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.413 ' HB1' ' C ' ' A' ' 9' ' ' LYS . . . -147.97 152.05 36.83 Favored 'General case' 0 N--CA 1.454 -0.261 0 O-C-N 122.273 -0.267 . . . . 10.0 110.371 -169.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 88.2 m -130.49 154.13 48.09 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 124.756 1.222 . . . . 10.0 109.539 -173.156 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.43 154.58 25.2 Favored Glycine 0 CA--C 1.519 0.328 0 N-CA-C 110.156 -1.178 . . . . 10.0 110.156 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 58.4 t -115.09 126.36 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 105.098 -2.186 . . . . 10.0 105.098 178.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.557 HG12 ' HB2' ' A' ' 6' ' ' ALA . 49.2 mt -78.71 147.7 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 108.895 -0.78 . . . . 10.0 108.895 -177.444 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -153.43 178.5 30.41 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.337 -1.105 . . . . 10.0 110.337 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -64.31 122.68 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 C-N-CA 124.477 1.111 . . . . 10.0 108.941 -177.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -116.89 148.84 40.96 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 168.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.016 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 167.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 119.111 -0.471 . . . . 10.0 110.174 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 t -81.77 -40.85 22.04 Favored 'General case' 0 C--O 1.226 -0.149 0 C-N-CA 124.217 1.007 . . . . 10.0 110.511 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 49.1 mttp -134.24 140.56 46.55 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 125.221 1.408 . . . . 10.0 109.192 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.43 152.89 47.42 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.017 0.927 . . . . 10.0 108.858 171.551 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -120.77 158.22 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 123.931 0.892 . . . . 10.0 110.153 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.47 101.94 4.49 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.427 -0.953 . . . . 10.0 108.427 168.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -79.64 105.97 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 108.692 -0.855 . . . . 10.0 108.692 169.666 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -91.86 128.13 37.58 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.364 -0.976 . . . . 10.0 108.364 -178.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -143.38 162.32 36.06 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 120.098 1.317 . . . . 10.0 108.494 170.637 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.67 -56.89 0.07 OUTLIER Glycine 0 N--CA 1.461 0.319 0 CA-C-N 115.077 -0.965 . . . . 10.0 113.146 169.497 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.47 -44.27 65.08 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 -177.159 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.4 -70.68 0.41 Allowed Glycine 0 CA--C 1.523 0.569 0 CA-C-N 114.319 -1.309 . . . . 10.0 110.323 169.232 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -59.13 -33.08 98.28 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 123.643 2.895 . . . . 10.0 111.515 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 65.2 t -67.06 95.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 177.508 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -117.69 101.15 8.1 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.522 -2.029 . . . . 10.0 105.522 178.168 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.938 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -85.47 142.04 19.28 Favored Glycine 0 N--CA 1.435 -1.401 0 N-CA-C 109.577 -1.409 . . . . 10.0 109.577 172.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.518 ' CG2' HG22 ' A' ' 54' ' ' THR . 2.2 mt -140.37 81.29 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 105.949 -1.871 . . . . 10.0 105.949 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -90.9 140.7 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 C-N-CA 123.892 0.877 . . . . 10.0 109.05 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 13.5 m-80 -126.44 114.7 18.52 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.044 1.338 . . . . 10.0 109.234 171.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -91.42 132.48 36.19 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 124.882 1.273 . . . . 10.0 108.248 174.002 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.6 156.38 24.8 Favored 'General case' 0 C--N 1.339 0.151 0 O-C-N 123.519 0.512 . . . . 10.0 111.874 169.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.59 135.0 55.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 102.519 -3.141 . . . . 10.0 102.519 162.063 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 10.6 mptt . . . . . 0 N--CA 1.451 -0.415 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 170.639 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.949 0 N-CA-C 110.136 -1.186 . . . . 10.0 110.136 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -66.29 125.22 13.64 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 123.021 2.48 . . . . 10.0 108.831 175.614 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 m -79.96 64.51 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 122.774 0.43 . . . . 10.0 110.382 -175.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.8 tttt -54.42 111.95 0.9 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.139 -0.689 . . . . 10.0 109.139 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -103.9 112.28 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 C-N-CA 127.412 2.285 . . . . 10.0 106.556 -176.231 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -106.14 171.43 7.35 Favored 'General case' 0 CA--C 1.511 -0.532 0 CA-C-O 121.847 0.832 . . . . 10.0 110.507 173.506 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.59 173.88 45.09 Favored Glycine 0 N--CA 1.436 -1.306 0 N-CA-C 110.124 -1.19 . . . . 10.0 110.124 174.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 19.5 m -145.75 90.19 1.97 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.565 -0.902 . . . . 10.0 108.565 -179.451 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.938 HG22 ' HA2' ' B' ' 16' ' ' GLY . 3.4 pt -79.93 146.93 6.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.497 0 N-CA-C 108.661 -0.866 . . . . 10.0 108.661 175.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -126.7 149.74 49.41 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.39 -5.87 49.18 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.665 174.578 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -63.47 177.69 0.65 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.445 1.123 . . . . 10.0 110.599 173.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.1 t -115.25 168.09 10.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 105.687 -1.968 . . . . 10.0 105.687 165.413 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -46.57 156.84 0.16 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.785 1.634 . . . . 10.0 113.406 -170.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.14 -162.47 46.29 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-O 122.139 0.855 . . . . 10.0 113.376 166.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -79.7 141.32 36.51 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 125.873 1.669 . . . . 10.0 111.342 -170.387 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -139.72 145.39 38.26 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 114.504 1.298 . . . . 10.0 114.504 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.558 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -34.61 117.94 0.25 Allowed Glycine 0 C--N 1.343 0.95 0 C-N-CA 129.556 3.455 . . . . 10.0 114.569 167.345 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.451 ' HZ ' HG21 ' B' ' 35' ' ' ILE . 3.2 m-85 -141.37 109.23 5.71 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 120.012 1.906 . . . . 10.0 110.931 169.378 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.502 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -148.15 170.43 17.86 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 112.708 0.632 . . . . 10.0 112.708 178.66 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 m -116.69 79.1 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 C-N-CA 128.625 2.77 . . . . 10.0 111.247 -168.159 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 38.4 m-70 -79.23 142.69 36.02 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 124.802 1.241 . . . . 10.0 112.056 -171.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -62.47 -46.31 89.08 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 114.605 1.335 . . . . 10.0 114.605 -169.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -75.7 92.43 2.98 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.798 -2.667 . . . . 10.0 103.798 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.88 -27.13 74.14 Favored Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 128.103 2.764 . . . . 10.0 109.99 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -52.57 175.88 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.777 0 CA-C-O 122.752 1.263 . . . . 10.0 110.78 167.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.537 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.4 OUTLIER -149.99 31.82 0.69 Allowed 'General case' 0 N--CA 1.431 -1.378 0 CA-C-N 114.603 -1.18 . . . . 10.0 112.809 168.815 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.448 HG22 HG22 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -51.78 -38.91 57.52 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.958 0.903 . . . . 10.0 111.084 -177.835 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.01 -18.08 54.24 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.84 1.256 . . . . 10.0 113.217 -179.425 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.09 85.56 0.62 Allowed Glycine 0 CA--C 1.533 1.161 0 N-CA-C 111.478 -0.649 . . . . 10.0 111.478 -176.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 71.4 m 44.11 39.36 2.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 128.008 2.523 . . . . 10.0 112.634 173.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -134.3 -54.32 0.85 Allowed 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 108.156 -1.053 . . . . 10.0 108.156 -169.773 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.7 m -90.56 34.31 0.89 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.109 0.563 . . . . 10.0 109.844 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -67.04 -23.18 65.86 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.401 1.08 . . . . 10.0 109.868 177.033 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.76 141.2 11.61 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 110.911 -0.876 . . . . 10.0 110.911 172.488 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -76.23 63.01 6.97 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.213 3.275 . . . . 10.0 113.202 -174.222 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 63.26 44.04 5.87 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 126.697 1.999 . . . . 10.0 109.939 171.354 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -67.89 79.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 124.863 2.268 . . . . 10.0 111.351 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -81.89 147.15 57.54 Favored Pre-proline 0 C--N 1.318 -0.772 0 C-N-CA 126.396 1.878 . . . . 10.0 108.316 168.142 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -79.56 40.3 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 122.484 2.123 . . . . 10.0 111.775 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -162.84 37.68 0.1 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.787 0.835 . . . . 10.0 109.996 -176.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -42.31 100.05 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.599 1.56 . . . . 10.0 112.719 -170.37 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.57 -78.85 0.6 Allowed 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.284 -1.006 . . . . 10.0 108.284 -171.139 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -154.24 144.35 21.97 Favored 'General case' 0 N--CA 1.425 -1.678 0 CA-C-N 115.484 -0.78 . . . . 10.0 109.223 171.491 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -61.76 118.64 7.41 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 106.711 -1.589 . . . . 10.0 106.711 165.377 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.06 -146.19 6.25 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 107.743 -2.143 . . . . 10.0 107.743 175.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.53 -165.71 24.37 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 107.813 -2.115 . . . . 10.0 107.813 169.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -64.19 6.36 0.31 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.151 1.9 . . . . 10.0 112.207 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.407 ' HE2' ' HB2' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -96.86 -29.99 13.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 118.997 0.817 . . . . 10.0 110.35 168.812 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.407 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 1.4 t70 -86.83 166.23 15.37 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 109.347 -0.612 . . . . 10.0 109.347 -174.598 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -86.18 -24.57 26.08 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.346 -1.297 . . . . 10.0 108.492 167.062 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -76.41 -93.78 0.02 OUTLIER 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 107.667 -1.234 . . . . 10.0 107.667 -173.05 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 28.5 mtm180 72.43 159.74 0.22 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 127.144 2.178 . . . . 10.0 108.644 -167.764 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.9 m170 -78.18 -48.63 15.45 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 118.965 -1.094 . . . . 10.0 110.093 169.351 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.3 p -166.26 -51.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 178.57 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.29 -76.28 0.9 Allowed Glycine 0 C--N 1.336 0.552 0 N-CA-C 109.019 -1.633 . . . . 10.0 109.019 171.512 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 41.42 78.58 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.792 1.237 . . . . 10.0 109.654 -169.435 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -20.97 64.96 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.939 0.348 . . . . 10.0 111.939 -168.164 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.91 -94.93 0.67 Allowed Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.027 -1.229 . . . . 10.0 110.027 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 33.2 m120 -155.61 106.45 2.51 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -168.647 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -99.24 130.6 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 119.773 1.17 . . . . 10.0 110.708 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -86.93 107.94 18.59 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 128.795 2.838 . . . . 10.0 110.945 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.88 131.51 36.47 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 122.857 0.463 . . . . 10.0 109.908 172.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 90' ' ' ASP . . . . . 0.407 ' OD2' ' NZ ' ' B' ' 91' ' ' LYS . 43.2 t0 -59.23 170.98 0.82 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.282 1.033 . . . . 10.0 109.806 168.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 91' ' ' LYS . . . . . 0.407 ' NZ ' ' OD2' ' B' ' 90' ' ' ASP . 12.4 pttm -51.36 -32.19 24.91 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 125.988 1.715 . . . . 10.0 110.584 175.309 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.36 -8.36 59.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 124.177 0.991 . . . . 10.0 110.963 -175.619 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.82 8.19 87.06 Favored Glycine 0 C--N 1.338 0.692 0 O-C-N 121.532 -0.73 . . . . 10.0 111.286 -177.118 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 50.0 t -80.18 114.92 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 N-CA-C 105.726 -1.953 . . . . 10.0 105.726 170.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.671 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -116.27 121.43 42.0 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 118.87 0.759 . . . . 10.0 109.006 170.021 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -83.0 121.78 27.45 Favored 'General case' 0 N--CA 1.433 -1.288 0 C-N-CA 126.404 1.881 . . . . 10.0 108.334 173.625 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 94.0 t -110.49 136.48 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 N-CA-C 106.543 -1.651 . . . . 10.0 106.543 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 18.7 m -157.77 64.97 0.47 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.071 1.349 . . . . 10.0 109.379 169.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 61.9 mt -101.97 156.35 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.859 1.263 . . . . 10.0 108.719 -171.623 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -144.81 140.48 28.46 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.645 1.578 . . . . 10.0 108.6 175.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -152.4 135.08 15.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 106.667 -1.605 . . . . 10.0 106.667 169.65 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.4 p -87.53 58.59 5.02 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.745 1.618 . . . . 10.0 107.916 -171.786 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 p -145.35 -46.53 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.918 -0.583 . . . . 10.0 109.677 -172.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 36.7 mm -66.8 143.04 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 N-CA-C 109.178 -0.675 . . . . 10.0 109.178 171.431 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 74.3 m -138.38 134.44 34.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 173.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -110.29 17.37 20.97 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.737 0.815 . . . . 10.0 110.59 172.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 107.131 -1.433 . . . . 10.0 107.131 173.409 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t . . . . . 0 N--CA 1.441 -0.885 0 N-CA-C 107.983 -1.117 . . . . 10.0 107.983 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -69.73 13.87 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 114.095 1.146 . . . . 10.0 114.095 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 33.2 mm -55.74 135.12 19.22 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 O-C-N 120.627 -1.296 . . . . 10.0 108.063 172.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.74 11.66 73.62 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-O 118.132 -1.371 . . . . 10.0 113.855 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mmt-85 -79.38 161.84 25.93 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.242 1.521 . . . . 10.0 108.866 167.402 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.4 121.25 41.94 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 123.529 0.732 . . . . 10.0 109.99 171.41 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -84.37 132.37 34.6 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 107.218 -1.401 . . . . 10.0 107.218 167.591 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.1 t -116.51 137.43 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.792 -1.188 . . . . 10.0 107.792 169.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -104.76 123.99 59.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.558 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.2 m170 -107.69 159.09 16.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 116.582 2.067 . . . . 10.0 116.582 -172.786 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -41.45 -65.61 0.42 Allowed 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 129.631 3.173 . . . . 10.0 111.67 170.796 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.1 mttp -109.89 175.38 5.46 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.658 1.183 . . . . 10.0 111.559 -173.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.03 151.73 35.43 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 125.75 1.62 . . . . 10.0 109.903 175.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.502 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -77.53 154.64 32.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 122.901 0.48 . . . . 10.0 110.889 169.928 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 53.4 m-20 -76.27 -36.65 58.32 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.289 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 63.5 mt 64.26 56.32 1.35 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.99 1.376 . . . . 10.0 109.27 -170.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.15 -44.34 3.29 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-N 113.376 -1.738 . . . . 10.0 110.918 171.133 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -76.64 41.06 0.25 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.088 1.755 . . . . 10.0 112.919 -173.003 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -99.85 -17.83 24.46 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 125.838 1.685 . . . . 10.0 110.65 169.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.26 44.89 65.0 Favored Glycine 0 C--N 1.339 0.696 0 C-N-CA 123.861 0.743 . . . . 10.0 111.443 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -146.02 168.02 21.93 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 172.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.1 -42.55 76.97 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 116.144 -0.48 . . . . 10.0 109.88 -176.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -64.78 -40.37 95.15 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.502 -0.748 . . . . 10.0 110.825 175.218 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -50.8 -44.02 58.88 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 118.704 0.684 . . . . 10.0 110.449 -179.59 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -76.94 -8.26 57.06 Favored 'General case' 0 CA--C 1.542 0.662 0 CA-C-O 117.759 -1.115 . . . . 10.0 113.79 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 ttmm -114.87 -58.0 2.2 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 127.728 2.411 . . . . 10.0 113.072 -170.216 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 14.6 p -134.86 17.75 3.52 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.774 1.17 . . . . 10.0 110.784 175.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.12 -110.09 2.95 Favored Glycine 0 C--O 1.219 -0.81 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 -171.303 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -160.61 43.79 0.19 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 171.46 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.45 -14.76 62.66 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.787 -1.097 . . . . 10.0 112.194 -170.098 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.2 -163.5 54.53 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 110.48 -1.048 . . . . 10.0 110.48 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.7 m -56.94 130.41 45.85 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 123.929 0.891 . . . . 10.0 112.43 -168.266 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.58 73.36 0.06 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.809 1.644 . . . . 10.0 109.91 171.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 61.8 mt -50.96 -36.45 38.96 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.52 0.728 . . . . 10.0 112.116 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.31 159.59 28.7 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.971 -0.752 . . . . 10.0 108.971 -176.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -159.8 165.38 32.51 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.637 -0.505 . . . . 10.0 109.637 -177.384 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.31 167.73 35.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.421 -1.071 . . . . 10.0 110.421 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 15.9 t -115.41 138.67 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 107.233 -1.395 . . . . 10.0 107.233 -169.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.8 mt -73.18 109.82 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 110.212 -0.292 . . . . 10.0 110.212 -174.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.86 154.65 17.32 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 125.737 1.637 . . . . 10.0 110.373 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.1 mt -86.23 139.4 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 124.894 1.278 . . . . 10.0 108.815 -174.164 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -91.71 -114.71 0.08 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 167.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 . . . . . 0 C--O 1.248 1.006 0 C-N-CA 127.332 2.253 . . . . 10.0 105.014 166.937 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 107.416 -1.327 . . . . 10.0 107.416 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.2 t -158.45 -44.24 0.06 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.926 0.784 . . . . 10.0 111.328 177.504 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 11.7 tmtt? -131.78 134.04 45.39 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 123.68 0.792 . . . . 10.0 108.863 178.743 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.33 169.55 18.05 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 125.281 1.432 . . . . 10.0 109.936 -175.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -129.32 172.72 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 123.159 0.584 . . . . 10.0 112.236 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.72 107.47 4.46 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.826 1.25 . . . . 10.0 107.869 166.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -87.0 89.61 3.07 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-O 121.946 0.879 . . . . 10.0 109.111 172.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.65 HD21 ' HB3' ' A' ' 117' ' ' LEU . 9.1 mt -80.52 116.22 20.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.573 1.549 . . . . 10.0 109.443 -175.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -142.27 159.35 42.41 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.702 1.137 . . . . 10.0 108.35 173.709 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.62 -65.02 0.02 OUTLIER Glycine 0 N--CA 1.461 0.365 0 CA-C-N 115.249 -0.887 . . . . 10.0 112.216 169.338 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -72.15 -41.66 66.85 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 106.891 -1.522 . . . . 10.0 106.891 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.44 -64.26 0.55 Allowed Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.695 -1.059 . . . . 10.0 111.368 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -58.14 -37.91 93.61 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.056 1.837 . . . . 10.0 110.492 174.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.46 HG13 HD11 ' A' ' 38' ' ' LEU . 80.3 t -62.85 105.55 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 N-CA-C 107.644 -1.243 . . . . 10.0 107.644 174.144 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -124.02 118.98 28.22 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.089 -1.819 . . . . 10.0 106.089 171.179 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.536 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -107.87 130.53 10.15 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 109.725 -1.35 . . . . 10.0 109.725 170.843 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.595 ' CG2' HG23 ' B' ' 54' ' ' THR . 16.4 mt -128.29 72.04 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.15 -1.796 . . . . 10.0 106.15 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.14 147.19 6.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.288 -0.869 . . . . 10.0 110.447 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.03 106.24 8.74 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 126.78 2.032 . . . . 10.0 107.804 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -86.37 125.11 33.43 Favored 'General case' 0 N--CA 1.451 -0.425 0 CA-C-O 117.73 -1.129 . . . . 10.0 108.012 175.182 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -120.19 145.27 47.14 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 123.922 0.763 . . . . 10.0 110.963 167.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 tp60 -125.89 105.18 8.74 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 126.858 2.063 . . . . 10.0 107.036 169.537 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.77 -61.24 2.44 Favored 'General case' 0 C--N 1.339 0.15 0 C-N-CA 124.767 1.227 . . . . 10.0 110.24 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -134.01 167.48 20.53 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 104.552 -2.388 . . . . 10.0 104.552 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.7 t -69.41 -14.94 63.17 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 119.71 -0.186 . . . . 10.0 110.573 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -79.89 -18.02 51.68 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 123.386 0.675 . . . . 10.0 110.171 174.162 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.6 151.68 39.97 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.23 -0.748 . . . . 10.0 111.23 -176.097 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.23 146.66 40.94 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 N-CA-C 105.493 -2.541 . . . . 10.0 105.493 165.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -76.65 119.35 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 N-CA-C 106.166 -1.791 . . . . 10.0 106.166 -179.002 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 18.0 mttp -90.97 110.57 21.83 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 106.432 -1.692 . . . . 10.0 106.432 176.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.13 106.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -128.85 169.96 13.95 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.744 0.783 . . . . 10.0 112.214 171.076 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.05 -153.09 24.77 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 106.592 -2.603 . . . . 10.0 106.592 169.063 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 27.5 t -156.06 155.98 33.58 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.54 -0.864 . . . . 10.0 109.464 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.536 HG22 ' CA ' ' A' ' 16' ' ' GLY . 3.1 pt -108.01 175.63 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 CA-C-N 115.153 -0.931 . . . . 10.0 110.082 167.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.2 ptmt -152.37 150.66 29.94 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.86 -15.57 33.99 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-O 118.985 -0.897 . . . . 10.0 114.566 171.063 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.533 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.1 mp -72.95 -179.67 3.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 118.948 1.374 . . . . 10.0 109.609 177.119 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -96.0 175.55 6.44 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.402 -0.962 . . . . 10.0 108.402 166.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -58.65 168.95 1.04 Allowed 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.676 1.19 . . . . 10.0 112.025 -172.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.37 -168.01 49.65 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-O 122.019 0.788 . . . . 10.0 112.909 167.185 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -71.26 146.13 49.15 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.762 1.625 . . . . 10.0 110.397 -176.363 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.07 152.69 35.21 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 113.125 0.787 . . . . 10.0 113.125 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.664 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.3 121.43 0.83 Allowed Glycine 0 C--N 1.339 0.727 0 C-N-CA 128.274 2.845 . . . . 10.0 111.069 165.239 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -155.68 106.21 2.48 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 106.558 -1.645 . . . . 10.0 106.558 169.272 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.07 170.6 17.42 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.876 0.846 . . . . 10.0 112.904 178.561 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.36 132.54 60.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 104.336 -2.468 . . . . 10.0 104.336 168.673 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 1.7 p80 -168.4 177.47 5.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 107.737 -1.208 . . . . 10.0 107.737 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 52.71 -167.75 0.05 Allowed 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 125.984 2.052 . . . . 10.0 116.157 162.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.75 159.42 19.77 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-O 121.593 0.711 . . . . 10.0 110.893 -175.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.01 -18.44 77.76 Favored Glycine 0 CA--C 1.523 0.565 0 C-N-CA 125.443 1.497 . . . . 10.0 110.308 168.584 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -50.61 140.6 14.03 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 122.723 1.249 . . . . 10.0 108.259 166.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -151.79 8.86 0.51 Allowed 'General case' 0 N--CA 1.412 -2.342 0 CA-C-N 113.5 -1.682 . . . . 10.0 109.889 -168.267 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.931 HG22 HG22 ' B' ' 17' ' ' ILE . 1.0 OUTLIER -41.45 -55.24 2.87 Favored 'General case' 0 C--N 1.343 0.29 0 C-N-CA 125.842 1.657 . . . . 10.0 114.425 -167.928 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.18 -18.37 57.84 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.836 0.454 . . . . 10.0 111.554 -173.6 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.72 78.63 1.38 Allowed Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.312 -1.115 . . . . 10.0 110.312 -175.305 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.2 m 70.24 35.3 2.12 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.989 1.315 . . . . 10.0 111.752 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -131.8 -57.51 0.98 Allowed 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 107.184 -1.413 . . . . 10.0 107.184 175.319 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.3 m -52.05 -43.14 63.64 Favored 'General case' 0 C--N 1.343 0.289 0 C-N-CA 123.913 0.885 . . . . 10.0 111.331 -170.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.11 -55.31 0.03 OUTLIER 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 128.35 2.66 . . . . 10.0 113.645 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 139.92 -154.18 23.68 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 110.533 -1.027 . . . . 10.0 110.533 175.634 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -122.21 -155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.54 0.811 1 C-N-CA 126.865 5.043 . . . . 10.0 105.85 165.049 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -77.93 46.85 0.6 Allowed 'General case' 0 CA--C 1.548 0.896 0 O-C-N 118.587 -2.571 . . . . 10.0 112.113 177.436 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -77.51 60.9 2.18 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.923 1.289 . . . . 10.0 109.566 169.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -71.74 157.13 90.29 Favored Pre-proline 0 C--N 1.325 -0.457 0 C-N-CA 124.002 0.921 . . . . 10.0 108.67 171.061 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -56.17 -43.42 56.4 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 121.347 1.365 . . . . 10.0 109.478 169.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 68.2 mt -84.23 47.47 1.34 Allowed 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.831 -0.543 . . . . 10.0 111.232 173.51 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 p -61.29 91.39 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 107.407 -1.331 . . . . 10.0 107.407 166.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -113.36 -69.06 0.89 Allowed 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 104.183 -2.525 . . . . 10.0 104.183 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -154.64 161.33 41.63 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 106.171 -1.788 . . . . 10.0 106.171 167.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.8 t60 -72.48 129.07 37.48 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 105.194 -2.151 . . . . 10.0 105.194 163.083 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -150.03 -140.81 3.29 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 108.316 -1.913 . . . . 10.0 108.316 176.004 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.33 -157.99 21.59 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.812 -2.115 . . . . 10.0 107.812 170.094 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -69.38 18.3 0.17 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 119.627 1.713 . . . . 10.0 111.326 169.046 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.402 ' H ' ' C ' ' A' ' 73' ' ' GLY . 30.4 mmtm -104.96 -21.03 13.36 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 124.753 1.221 . . . . 10.0 108.643 169.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.401 ' OD2' ' NZ ' ' A' ' 128' ' ' LYS . 4.8 m-20 -120.9 166.51 13.7 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.121 -1.807 . . . . 10.0 106.121 -171.732 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -79.32 -42.15 26.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 107.667 -1.235 . . . . 10.0 107.667 173.735 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -96.2 34.88 1.51 Allowed 'General case' 0 N--CA 1.441 -0.921 0 C-N-CA 127.53 2.332 . . . . 10.0 114.974 -161.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ptp180 -57.28 153.79 11.55 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.521 1.129 . . . . 10.0 110.867 174.669 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -72.97 159.21 34.03 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 118.9 -1.12 . . . . 10.0 108.497 168.064 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -38.91 -40.09 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 125.974 1.71 . . . . 10.0 114.397 -172.822 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.6 42.88 1.32 Allowed Glycine 0 C--N 1.338 0.664 0 CA-C-N 118.178 0.445 . . . . 10.0 112.641 179.0 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.0 89.48 5.34 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 106.619 -1.623 . . . . 10.0 106.619 167.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 21.4 mt -67.97 -37.71 81.86 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.15 -86.08 0.41 Allowed Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 114.873 -1.058 . . . . 10.0 110.537 167.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -140.72 131.03 25.07 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 -172.359 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.0 m -115.24 137.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.944 -0.762 . . . . 10.0 108.944 169.462 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -85.19 131.92 34.36 Favored 'General case' 0 C--O 1.226 -0.168 0 C-N-CA 124.761 1.224 . . . . 10.0 109.485 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.05 138.47 45.35 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.37 1.468 . . . . 10.0 109.625 171.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -58.92 171.6 0.66 Allowed 'General case' 0 N--CA 1.456 -0.135 0 O-C-N 124.181 0.926 . . . . 10.0 109.191 167.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 27.5 pttt -45.91 -34.96 4.23 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 127.225 2.21 . . . . 10.0 110.852 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -82.53 -3.04 55.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.861 1.264 . . . . 10.0 110.83 -173.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.52 8.48 83.08 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.556 -1.017 . . . . 10.0 110.556 -177.226 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 73.5 t -87.83 98.82 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 107.289 -1.374 . . . . 10.0 107.289 -177.068 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.53 121.66 38.59 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 107.523 -1.288 . . . . 10.0 107.523 168.402 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -84.47 114.41 21.9 Favored 'General case' 0 N--CA 1.439 -1.003 0 C-N-CA 126.955 2.102 . . . . 10.0 108.202 169.146 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 87.9 t -102.05 131.36 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.672 -1.233 . . . . 10.0 107.672 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.6 p -157.97 88.95 0.98 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.392 1.077 . . . . 10.0 109.067 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -129.17 163.51 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 106.818 -1.549 . . . . 10.0 106.818 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -136.67 150.39 48.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 121.471 -0.768 . . . . 10.0 110.407 170.176 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -147.0 155.6 42.37 Favored 'General case' 0 N--CA 1.447 -0.608 0 O-C-N 124.551 1.157 . . . . 10.0 108.761 178.38 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.3 p -113.27 44.57 1.53 Allowed 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 127.583 2.353 . . . . 10.0 110.39 -173.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.8 p -142.59 -46.24 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 C-N-CA 123.624 0.77 . . . . 10.0 109.557 177.335 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 39.8 mm -54.73 110.33 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 169.319 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.4 m -120.82 105.16 10.45 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 124.386 1.074 . . . . 10.0 109.217 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 37.2 mt -58.15 -28.8 65.06 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.984 0.514 . . . . 10.0 111.935 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 m -150.29 160.79 43.45 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.869 -1.53 . . . . 10.0 106.869 174.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 66.1 0.4 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.333 -1.107 . . . . 10.0 110.333 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t70 71.53 -59.67 0.54 Allowed 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 129.557 3.143 . . . . 10.0 109.519 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.9 m-70 -76.49 -22.03 55.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.637 -0.71 . . . . 10.0 111.165 -169.24 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.1 t 26.43 78.26 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 128.358 2.663 . . . . 10.0 112.213 168.739 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -67.76 -6.36 5.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 112.599 0.592 . . . . 10.0 112.599 -174.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.5 mm -51.46 132.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 O-C-N 120.952 -1.092 . . . . 10.0 108.309 168.169 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.487 ' HA3' ' CG2' ' B' ' 113' ' ' ILE . . . 93.38 11.81 57.94 Favored Glycine 0 CA--C 1.523 0.577 0 CA-C-O 117.701 -1.611 . . . . 10.0 115.952 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -80.0 176.29 9.87 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 119.594 1.697 . . . . 10.0 108.554 167.135 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 99.7 m -106.54 121.46 44.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 125.095 1.358 . . . . 10.0 107.637 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.65 ' HB3' HD21 ' A' ' 8' ' ' LEU . 3.9 mm? -76.88 144.37 39.01 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 106.498 -1.667 . . . . 10.0 106.498 167.59 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.2 t -131.88 123.76 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 107.696 -1.224 . . . . 10.0 107.696 -176.021 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 11.7 t -104.49 137.83 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.664 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.9 m170 -124.89 157.65 35.44 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 114.553 1.316 . . . . 10.0 114.553 -174.138 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 68.7 tt0 -45.61 -55.92 5.78 Favored 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 128.833 2.853 . . . . 10.0 109.183 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 63.6 mttt -123.6 175.11 7.0 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.586 1.154 . . . . 10.0 110.751 -170.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.33 143.35 28.72 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 108.715 -0.846 . . . . 10.0 108.715 176.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -73.64 151.66 40.75 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.435 -0.58 . . . . 10.0 109.435 175.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -83.28 13.49 4.24 Favored 'General case' 0 N--CA 1.448 -0.529 0 O-C-N 124.355 1.034 . . . . 10.0 111.168 167.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 75.7 mt 45.58 46.6 11.21 Favored 'General case' 0 C--N 1.343 0.307 0 C-N-CA 125.513 1.525 . . . . 10.0 112.779 171.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 107.79 -21.88 29.08 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-N 115.724 -0.671 . . . . 10.0 112.119 173.5 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.401 ' NZ ' ' OD2' ' A' ' 76' ' ' ASP . 7.2 mtmm -112.26 43.89 1.53 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.056 1.343 . . . . 10.0 111.598 -168.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.49 -16.42 64.19 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.343 1.925 . . . . 10.0 112.435 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.33 47.9 88.31 Favored Glycine 0 CA--C 1.532 1.104 0 O-C-N 121.473 -1.016 . . . . 10.0 112.554 173.45 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.464 ' H ' ' HB2' ' A' ' 134' ' ' SER . 7.3 p30 -165.77 173.81 10.3 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 126.682 1.993 . . . . 10.0 106.094 177.259 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -56.9 -42.54 80.08 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 119.802 1.183 . . . . 10.0 111.24 -174.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -70.18 -18.32 63.19 Favored 'General case' 0 N--CA 1.454 -0.273 0 O-C-N 121.29 -0.881 . . . . 10.0 111.916 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.464 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 11.3 t -44.54 -43.53 8.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 C-N-CA 124.836 1.254 . . . . 10.0 109.549 170.542 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -93.79 5.95 49.96 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 112.411 0.523 . . . . 10.0 112.411 -174.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -117.87 -73.77 0.63 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.203 1.401 . . . . 10.0 110.286 179.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.4 p -111.87 7.81 20.2 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 120.213 1.369 . . . . 10.0 110.943 178.432 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.78 -90.15 1.06 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 108.413 -1.875 . . . . 10.0 108.413 -173.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.76 39.55 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 124.721 1.208 . . . . 10.0 109.872 176.229 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.35 -10.37 32.53 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 124.217 1.007 . . . . 10.0 112.745 -176.104 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.67 -168.01 53.34 Favored Glycine 0 N--CA 1.445 -0.743 0 O-C-N 121.059 -1.026 . . . . 10.0 110.736 178.261 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -59.68 138.99 57.58 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 123.781 0.832 . . . . 10.0 112.354 -168.243 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.8 mtm180 -68.18 69.32 0.14 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.714 1.206 . . . . 10.0 110.464 169.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.62 -9.16 32.77 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 113.654 0.983 . . . . 10.0 113.654 -178.024 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.38 143.4 17.68 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.47 0.708 . . . . 10.0 111.858 168.063 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 5.4 p -144.28 166.31 25.41 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.148 -0.686 . . . . 10.0 109.148 171.125 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.1 150.95 21.15 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 109.74 -1.344 . . . . 10.0 109.74 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.8 139.68 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 106.212 -1.773 . . . . 10.0 106.212 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.472 HD11 ' CD2' ' A' ' 117' ' ' LEU . 58.8 mt -76.84 127.34 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-O 119.555 -0.26 . . . . 10.0 110.937 -173.167 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -125.31 140.78 12.54 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 123.79 0.71 . . . . 10.0 111.882 -177.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 94.1 mt -68.29 140.96 18.2 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 C-N-CA 124.632 1.173 . . . . 10.0 108.699 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.21 -46.33 1.51 Allowed 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 112.348 0.499 . . . . 10.0 112.348 -176.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 . . . . . 0 C--O 1.248 0.986 0 CA-C-O 117.277 -1.344 . . . . 10.0 110.24 -167.896 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.556 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -88.26 -15.74 35.04 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.865 1.266 . . . . 10.0 111.469 -175.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 31.2 tttp -130.18 135.44 48.17 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.142 1.377 . . . . 10.0 108.645 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.74 161.47 35.47 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.769 1.628 . . . . 10.0 108.843 169.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.1 t -117.98 152.86 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 C-N-CA 125.489 1.516 . . . . 10.0 110.163 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.47 94.96 3.28 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.416 1.887 . . . . 10.0 108.739 171.461 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.1 m -88.29 111.3 22.18 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 N-CA-C 109.368 -0.604 . . . . 10.0 109.368 172.029 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.4 mt -94.61 145.68 24.66 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 109.179 -0.674 . . . . 10.0 109.179 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.5 mtmt -166.72 159.28 13.76 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.533 1.133 . . . . 10.0 108.397 172.641 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.28 -48.7 0.11 Allowed Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.351 -0.928 . . . . 10.0 113.112 169.052 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -72.94 -45.96 55.15 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 107.548 -1.278 . . . . 10.0 107.548 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.04 -71.36 0.4 Allowed Glycine 0 CA--C 1.523 0.537 0 CA-C-N 114.323 -1.308 . . . . 10.0 109.909 170.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -58.18 -35.72 98.47 Favored 'Trans proline' 0 N--CA 1.453 -0.862 0 C-N-CA 123.156 2.57 . . . . 10.0 111.249 173.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.6 t -64.59 107.59 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 107.573 -1.269 . . . . 10.0 107.573 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.47 124.16 39.48 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 108.608 -0.886 . . . . 10.0 108.608 169.267 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.644 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -104.17 149.4 17.11 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 109.879 -1.289 . . . . 10.0 109.879 170.002 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.931 HG22 HG22 ' A' ' 54' ' ' THR . 1.5 mt -146.75 56.89 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 N-CA-C 107.251 -1.388 . . . . 10.0 107.251 -176.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mm -86.35 135.6 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.09 -0.707 . . . . 10.0 109.09 -169.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -103.23 115.76 31.18 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.249 1.82 . . . . 10.0 107.126 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -96.4 115.01 26.74 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.721 -1.585 . . . . 10.0 106.721 175.252 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -122.79 151.46 41.62 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 119.321 0.964 . . . . 10.0 112.699 172.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.6 tt0 -139.6 95.83 2.98 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.148 1.379 . . . . 10.0 108.733 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 68.6 tttt . . . . . 0 N--CA 1.426 -1.626 0 C-N-CA 124.15 0.98 . . . . 10.0 109.3 178.847 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.222 0 CA-C-O 118.91 -0.939 . . . . 10.0 114.621 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -68.57 116.33 4.36 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 107.3 -1.846 . . . . 10.0 107.3 169.566 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.8 t -79.37 99.94 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 104.272 -2.492 . . . . 10.0 104.272 169.399 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -92.08 112.03 23.8 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 175.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -101.73 102.73 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.908 0 C-N-CA 126.631 1.972 . . . . 10.0 105.98 -174.296 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.1 p90 -125.14 160.76 28.37 Favored 'General case' 0 C--N 1.339 0.126 0 N-CA-C 112.683 0.623 . . . . 10.0 112.683 177.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.28 -157.64 27.38 Favored Glycine 0 N--CA 1.449 -0.44 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -143.48 127.96 17.96 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 109.613 -0.514 . . . . 10.0 109.613 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.644 HG22 ' CA ' ' B' ' 16' ' ' GLY . 3.4 pt -90.14 139.84 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 N-CA-C 106.611 -1.626 . . . . 10.0 106.611 166.032 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.0 142.34 50.42 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 123.8 0.688 . . . . 10.0 109.437 171.162 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.98 -4.64 25.65 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.221 -0.766 . . . . 10.0 112.888 178.196 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -60.44 176.8 0.33 Allowed 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 118.676 1.238 . . . . 10.0 110.918 170.297 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -109.65 164.35 12.62 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 105.406 -2.072 . . . . 10.0 105.406 165.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -52.72 163.09 0.5 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.863 0.865 . . . . 10.0 112.974 -169.189 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.74 -171.59 47.26 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 123.745 0.688 . . . . 10.0 112.297 169.128 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -71.5 144.39 49.66 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.624 1.969 . . . . 10.0 110.961 -177.288 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -148.48 138.59 22.44 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 113.638 0.977 . . . . 10.0 113.638 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.736 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -20.26 120.87 0.01 OUTLIER Glycine 0 C--N 1.341 0.841 0 C-N-CA 129.134 3.254 . . . . 10.0 115.084 165.697 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.27 108.09 4.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 119.518 1.659 . . . . 10.0 109.827 168.726 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 2.0 m80 -139.5 179.88 6.3 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.607 0.718 . . . . 10.0 112.288 177.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 76.1 t -112.43 128.33 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 C-N-CA 127.173 2.189 . . . . 10.0 106.368 169.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 67.0 m-70 -109.42 138.42 45.8 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 125.589 1.555 . . . . 10.0 107.299 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -53.76 -57.73 9.79 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 124.189 0.996 . . . . 10.0 111.844 -169.452 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -80.06 135.2 36.29 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 118.109 -1.437 . . . . 10.0 109.59 -177.059 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.86 -19.76 79.56 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 109.827 -1.309 . . . . 10.0 109.827 168.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t0 -39.57 148.63 0.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.008 1.323 . . . . 10.0 112.48 175.03 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -153.88 20.06 0.52 Allowed 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.424 -1.262 . . . . 10.0 113.214 174.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.595 HG23 ' CG2' ' A' ' 17' ' ' ILE . 1.8 m -52.74 -38.04 60.27 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 119.389 0.995 . . . . 10.0 111.978 -171.694 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.41 -22.87 47.12 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.025 0.93 . . . . 10.0 113.007 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.05 111.39 2.65 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.056 -1.218 . . . . 10.0 110.056 -169.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.8 m 34.1 51.73 0.43 Allowed 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 127.816 2.446 . . . . 10.0 115.515 170.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.97 -46.18 0.05 Allowed 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.423 0.689 . . . . 10.0 110.032 173.61 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.8 t -57.09 -26.69 60.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.546 0.738 . . . . 10.0 111.333 -178.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.02 -32.52 0.09 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.032 2.133 . . . . 10.0 112.958 167.452 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.59 162.66 15.91 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 108.72 -1.752 . . . . 10.0 108.72 173.491 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 62' ' ' PRO . . . . . 0.443 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 44.5 Cg_endo -73.94 -134.05 0.01 OUTLIER 'Trans proline' 0 N--CA 1.437 -1.822 0 N-CA-C 103.986 -3.121 . . . . 10.0 103.986 165.321 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -110.18 40.18 2.0 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 120.322 -1.486 . . . . 10.0 109.42 -177.301 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 64' ' ' PHE . . . . . 0.443 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 0.0 OUTLIER -78.04 57.36 1.77 Allowed 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.061 0.846 . . . . 10.0 112.494 -179.506 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -54.38 167.04 0.61 Allowed Pre-proline 0 CA--C 1.541 0.597 0 C-N-CA 129.782 3.233 . . . . 10.0 112.175 173.619 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -93.87 19.53 0.76 Allowed 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.738 2.292 . . . . 10.0 111.744 -173.337 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -144.48 48.73 1.34 Allowed 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.156 1.383 . . . . 10.0 107.444 -171.652 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.3 p -40.61 107.17 0.07 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 126.716 2.006 . . . . 10.0 112.03 -169.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 45.3 mtp180 -147.56 177.96 8.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 104.98 -2.23 . . . . 10.0 104.98 -175.46 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -73.41 143.09 46.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 117.395 -1.722 . . . . 10.0 110.257 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.5 t60 -52.53 116.96 2.54 Favored 'General case' 0 CA--C 1.519 -0.216 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 167.214 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.07 -178.84 22.69 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 106.659 -2.576 . . . . 10.0 106.659 178.144 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -151.77 -148.34 4.8 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 -174.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -65.58 -0.13 3.43 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 CA-C-N 119.386 1.593 . . . . 10.0 110.591 167.027 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -87.86 -27.17 22.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 118.798 0.726 . . . . 10.0 109.784 172.018 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -115.05 164.69 13.81 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.71 0.766 . . . . 10.0 111.315 -169.195 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -96.12 -9.0 31.78 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 124.855 1.262 . . . . 10.0 109.216 168.712 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 50.0 mm-40 -78.2 -81.32 0.1 Allowed 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 124.874 1.269 . . . . 10.0 109.953 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? 59.76 175.69 0.08 Allowed 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 114.634 -1.166 . . . . 10.0 110.722 -167.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -102.43 -59.81 1.64 Allowed 'General case' 0 CA--C 1.529 0.142 0 O-C-N 121.468 -0.77 . . . . 10.0 110.443 168.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.1 p -157.41 -55.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.146 0 C-N-CA 122.991 0.516 . . . . 10.0 109.698 -178.417 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.19 50.47 0.69 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.104 -1.598 . . . . 10.0 109.104 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -76.22 97.25 4.1 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 169.411 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 18.7 mt -75.26 -31.22 60.71 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 102.46 -95.94 1.35 Allowed Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 108.063 -2.015 . . . . 10.0 108.063 171.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -135.72 137.0 41.28 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 112.115 0.413 . . . . 10.0 112.115 -168.815 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.0 m -119.46 143.83 29.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 108.423 -0.955 . . . . 10.0 108.423 168.655 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.06 134.75 34.55 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.828 1.651 . . . . 10.0 109.473 -178.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.43 134.38 49.67 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.721 1.208 . . . . 10.0 111.515 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -63.6 169.8 3.67 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.893 -0.78 . . . . 10.0 108.893 165.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.01 -25.48 30.43 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.592 1.157 . . . . 10.0 111.79 175.203 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -75.55 -11.06 59.95 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.838 0.351 . . . . 10.0 110.286 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.66 12.07 75.87 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 110.138 -1.185 . . . . 10.0 110.138 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.0 t -85.45 107.87 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 106.37 -1.715 . . . . 10.0 106.37 175.22 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.65 119.5 39.47 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 168.46 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -78.41 131.01 36.76 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.727 2.011 . . . . 10.0 108.432 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 38.6 t -117.65 131.46 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 126.671 1.988 . . . . 10.0 106.64 -179.318 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 m -158.47 68.06 0.47 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 125.33 1.452 . . . . 10.0 109.196 170.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.1 mt -107.38 166.13 4.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 124.632 1.173 . . . . 10.0 108.283 -176.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -152.68 125.27 8.28 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.714 1.606 . . . . 10.0 109.415 -169.477 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -140.29 136.24 33.08 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 170.222 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 68.5 p -105.4 60.33 0.67 Allowed 'General case' 0 N--CA 1.457 -0.124 0 N-CA-C 107.003 -1.48 . . . . 10.0 107.003 174.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 99.9 t -127.92 -56.71 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -177.105 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.504 ' H ' ' CD1' ' B' ' 104' ' ' ILE 0.301 0.0 OUTLIER -81.31 173.18 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 124.378 1.071 . . . . 10.0 112.226 170.555 . . . . . . . . 4 4 . 1 . 010 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.9 m -147.65 171.35 15.75 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.229 -0.919 . . . . 10.0 108.744 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 61.1 mt -105.81 -18.65 13.99 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 124.796 1.238 . . . . 10.0 110.343 175.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 73.0 m . . . . . 0 N--CA 1.453 -0.314 0 C-N-CA 125.269 1.427 . . . . 10.0 107.243 174.778 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 43.3 t . . . . . 0 N--CA 1.447 -0.599 0 N-CA-C 108.862 -0.792 . . . . 10.0 108.862 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 4.6 pt -78.35 45.76 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 O-C-N 121.349 -0.845 . . . . 10.0 112.618 -176.186 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 113' ' ' ILE . . . . . 0.487 ' CG2' ' HA3' ' A' ' 114' ' ' GLY . 1.3 mp -72.71 -63.83 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 O-C-N 121.599 -0.688 . . . . 10.0 110.299 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.76 48.71 3.54 Favored Glycine 0 CA--C 1.532 1.105 0 O-C-N 120.744 -1.223 . . . . 10.0 112.458 -178.322 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.04 166.17 10.81 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 127.064 2.146 . . . . 10.0 106.985 172.708 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -121.03 136.75 54.91 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.113 -1.069 . . . . 10.0 108.113 174.423 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mp -103.07 147.3 27.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 173.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -123.69 134.82 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 106.884 -1.525 . . . . 10.0 106.884 174.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -101.29 121.29 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 169.111 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.736 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 9.6 m-70 -101.3 154.08 19.09 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 115.677 1.732 . . . . 10.0 115.677 -169.77 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -38.49 -61.03 0.74 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 128.715 2.806 . . . . 10.0 111.124 171.351 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 66.0 mttt -117.0 175.3 5.65 Favored 'General case' 0 CA--C 1.517 -0.322 0 C-N-CA 124.973 1.309 . . . . 10.0 109.916 -173.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.3 140.11 35.02 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 108.131 -1.062 . . . . 10.0 108.131 174.054 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.81 160.85 28.08 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 122.077 0.941 . . . . 10.0 111.592 170.477 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -74.78 -27.68 60.42 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 113.804 -1.544 . . . . 10.0 109.863 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 126' ' ' LEU . 3.9 mm? 61.05 63.29 1.28 Allowed 'General case' 0 CA--C 1.521 -0.149 0 C-N-CA 125.711 1.605 . . . . 10.0 107.782 -167.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.74 -52.49 3.64 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.299 168.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.8 pttp -78.62 55.71 1.7 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.315 1.046 . . . . 10.0 112.421 -171.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.36 -34.22 4.85 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 125.387 1.47 . . . . 10.0 110.379 169.334 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 73.71 35.01 55.71 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.345 -1.102 . . . . 10.0 110.345 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -125.75 156.38 39.51 Favored 'General case' 0 CA--C 1.506 -0.717 0 N-CA-C 105.418 -2.068 . . . . 10.0 105.418 169.038 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.4 tt0 -49.23 -48.86 45.24 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 107.555 -1.276 . . . . 10.0 107.555 169.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -55.95 -41.73 75.14 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 114.648 -1.16 . . . . 10.0 111.959 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 23.2 p -58.61 -42.41 88.09 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 120.368 1.44 . . . . 10.0 111.183 178.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.9 t -78.5 -16.1 57.88 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 113.079 0.77 . . . . 10.0 113.079 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -102.21 -46.01 4.96 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 126.129 1.772 . . . . 10.0 112.889 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 29.4 p -127.07 -12.33 5.82 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.375 -0.828 . . . . 10.0 112.669 172.667 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 1.68 82.64 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.234 -1.314 . . . . 10.0 112.65 -169.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 69.24 29.71 4.51 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 119.95 1.875 . . . . 10.0 111.907 172.121 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.81 0.9 11.77 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 124.522 1.129 . . . . 10.0 112.552 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.93 -163.09 53.19 Favored Glycine 0 N--CA 1.445 -0.744 0 O-C-N 120.948 -1.095 . . . . 10.0 111.439 173.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -59.3 136.61 58.02 Favored 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.585 1.154 . . . . 10.0 114.005 -166.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -64.43 75.52 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.227 1.411 . . . . 10.0 109.822 168.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 47.8 mt -54.51 -37.88 65.87 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 118.655 0.661 . . . . 10.0 111.548 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.86 158.84 35.88 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -177.654 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -151.63 167.6 27.63 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.127 0.571 . . . . 10.0 109.543 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.26 147.43 16.92 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-O 118.446 -1.197 . . . . 10.0 110.361 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.2 t -96.64 127.5 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 N-CA-C 104.358 -2.46 . . . . 10.0 104.358 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.41 HG22 ' HA ' ' B' ' 113' ' ' ILE . 18.9 mt -70.16 158.02 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.055 0.843 . . . . 10.0 109.936 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -155.57 145.63 12.74 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.201 -1.16 . . . . 10.0 110.201 -172.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 98.6 mt -57.41 131.71 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 C-N-CA 126.335 1.854 . . . . 10.0 109.612 176.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -110.05 -44.37 3.79 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 118.85 0.75 . . . . 10.0 111.942 173.165 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.584 -2.151 . . . . 10.0 110.908 176.136 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.859 0 CA-C-O 118.698 -0.668 . . . . 10.0 109.276 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.8 t -165.11 -45.85 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.349 1.06 . . . . 10.0 109.919 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 20.0 ttmm -104.27 138.8 40.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.223 -1.769 . . . . 10.0 106.223 168.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.22 163.4 37.12 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 169.67 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -137.62 166.09 25.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-N 118.286 0.494 . . . . 10.0 110.171 -177.669 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.89 106.89 4.93 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 167.332 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.4 m -80.94 101.02 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 168.662 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mt -78.88 138.73 38.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.707 -0.849 . . . . 10.0 108.707 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.93 160.94 34.09 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.61 -0.885 . . . . 10.0 108.61 168.243 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.45 -60.73 0.03 OUTLIER Glycine 0 C--O 1.23 -0.144 0 N-CA-C 110.592 -1.003 . . . . 10.0 110.592 173.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -74.71 -45.14 46.25 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.53 -69.45 0.48 Allowed Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 114.731 -1.122 . . . . 10.0 111.331 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -55.58 -39.28 91.98 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 122.236 1.957 . . . . 10.0 111.062 -179.22 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.731 HG13 HD12 ' A' ' 38' ' ' LEU . 21.0 t -63.26 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 C-N-CA 129.064 2.946 . . . . 10.0 109.094 178.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -95.45 47.75 1.13 Allowed 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.92 1.288 . . . . 10.0 110.173 -167.891 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.407 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -58.77 150.73 34.87 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 121.142 -0.551 . . . . 10.0 114.041 -168.146 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.727 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.4 mt -136.63 89.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 106.31 -1.737 . . . . 10.0 106.31 -171.446 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.9 mm -96.24 136.74 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.139 0.576 . . . . 10.0 109.455 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 30.5 m-20 -122.7 111.45 16.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 126.027 1.731 . . . . 10.0 107.522 172.67 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -92.85 118.74 31.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.2 1.4 . . . . 10.0 107.343 175.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -124.0 117.84 25.66 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 123.62 0.575 . . . . 10.0 111.161 175.087 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -101.13 102.57 13.53 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 105.876 -1.898 . . . . 10.0 105.876 168.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.3 mmmp? -54.32 -53.6 51.65 Favored 'General case' 0 C--N 1.338 0.108 0 C-N-CA 124.738 1.215 . . . . 10.0 110.821 -169.83 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.67 178.45 6.99 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 104.798 -2.297 . . . . 10.0 104.798 169.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -70.04 -20.37 63.25 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 110.311 -0.255 . . . . 10.0 110.311 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.8 m-80 -79.5 -21.88 44.72 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 123.742 0.817 . . . . 10.0 109.68 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.47 149.64 33.9 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.096 -0.802 . . . . 10.0 111.096 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -66.82 159.81 49.7 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 122.353 2.035 . . . . 10.0 107.597 168.176 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.29 96.33 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 105.93 -1.878 . . . . 10.0 105.93 174.144 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.9 mtpm? -71.98 100.6 2.51 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 106.42 -1.696 . . . . 10.0 106.42 172.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.54 97.7 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 125.52 1.528 . . . . 10.0 107.28 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.2 p90 -108.79 169.06 8.9 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 121.017 0.437 . . . . 10.0 110.606 169.299 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.57 -168.43 36.74 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.804 -0.518 . . . . 10.0 111.804 173.014 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 11.7 m -147.79 122.84 10.11 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.753 -0.223 . . . . 10.0 111.565 -177.468 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.436 ' HB ' HD11 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -99.53 95.42 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 C-N-CA 126.64 1.976 . . . . 10.0 107.449 169.471 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -106.0 102.45 11.88 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.009 0.524 . . . . 10.0 110.243 176.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.61 29.5 0.06 OUTLIER Glycine 0 C--N 1.334 0.463 0 CA-C-O 118.819 -0.989 . . . . 10.0 114.847 171.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.731 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -126.23 175.87 7.49 Favored 'General case' 0 C--O 1.223 -0.302 0 CA-C-N 118.329 1.065 . . . . 10.0 109.022 -177.827 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.3 t -75.52 160.42 30.2 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 109.325 171.437 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -62.24 -176.4 0.1 Allowed 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.029 1.332 . . . . 10.0 112.74 -176.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.9 -177.65 46.48 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.059 -0.816 . . . . 10.0 111.059 171.295 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.27 150.29 46.54 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.904 0.882 . . . . 10.0 109.216 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 -144.55 149.05 35.2 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.359 0.664 . . . . 10.0 112.484 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.653 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.09 121.77 0.11 Allowed Glycine 0 C--N 1.34 0.774 0 C-N-CA 128.34 2.876 . . . . 10.0 112.215 165.557 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -149.56 107.53 3.72 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 120.045 1.923 . . . . 10.0 113.412 168.359 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.29 168.78 22.38 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 122.18 0.99 . . . . 10.0 112.747 177.777 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 43.5 t -95.36 143.34 12.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 111.186 -2.734 . . . . 10.0 105.964 168.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -125.58 152.24 45.36 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 125.022 1.329 . . . . 10.0 108.889 177.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -62.35 -55.82 24.34 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 123.621 0.768 . . . . 10.0 109.87 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -76.55 104.89 7.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.154 -1.795 . . . . 10.0 106.154 -170.699 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.57 -36.54 92.59 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 108.844 -1.702 . . . . 10.0 108.844 173.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -54.11 160.99 1.39 Allowed 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 122.735 1.255 . . . . 10.0 113.254 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.425 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -156.33 22.39 0.36 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.206 -1.361 . . . . 10.0 114.506 -172.027 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.559 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.0 OUTLIER -48.94 -36.95 18.59 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.366 1.066 . . . . 10.0 111.387 174.529 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.6 -18.14 57.12 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.556 1.142 . . . . 10.0 112.854 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.52 84.15 0.57 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 123.686 0.66 . . . . 10.0 112.03 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.1 m 47.13 35.51 3.61 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.152 1.781 . . . . 10.0 112.378 174.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.5 m -129.44 -52.39 1.17 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 124.176 0.991 . . . . 10.0 108.396 -169.106 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.1 t -104.32 24.38 11.65 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.525 0.73 . . . . 10.0 109.394 178.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.29 46.51 0.62 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 123.607 0.763 . . . . 10.0 110.68 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.15 100.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.1 0 C-N-CA 126.263 1.887 . . . . 10.0 113.919 168.694 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -68.61 73.79 0.89 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 123.523 2.815 . . . . 10.0 113.086 179.404 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.0 m170 60.64 44.24 11.67 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.365 3.466 . . . . 10.0 110.6 172.384 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -68.96 68.84 0.17 Allowed 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.917 1.287 . . . . 10.0 111.659 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -84.77 154.97 61.84 Favored Pre-proline 0 C--N 1.322 -0.621 0 C-N-CA 125.512 1.525 . . . . 10.0 109.593 177.712 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.23 -44.19 5.24 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 122.433 2.089 . . . . 10.0 111.564 178.303 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.14 53.55 0.99 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.753 0.821 . . . . 10.0 111.021 -178.113 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.6 t -47.34 114.23 0.83 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.086 0.954 . . . . 10.0 111.009 -169.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 54.6 mtt180 -151.69 178.0 9.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 105.458 -2.053 . . . . 10.0 105.458 -169.645 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.72 141.47 37.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 118.614 -1.235 . . . . 10.0 108.892 -177.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -44.98 118.04 1.53 Allowed 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 121.002 -0.279 . . . . 10.0 111.514 168.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.54 -141.64 4.32 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.461 -1.055 . . . . 10.0 110.461 179.514 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.32 -175.49 33.4 Favored Glycine 0 C--O 1.223 -0.591 0 CA-C-N 118.426 1.113 . . . . 10.0 113.562 -173.539 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -66.58 7.6 0.39 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.176 1.917 . . . . 10.0 111.09 168.341 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.7 mmtt -96.57 -22.47 17.04 Favored 'General case' 0 N--CA 1.435 -1.183 0 C-N-CA 124.422 1.089 . . . . 10.0 108.407 173.403 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -126.56 -172.61 2.67 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 112.476 0.547 . . . . 10.0 112.476 -168.301 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -115.1 -6.21 12.48 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.967 1.307 . . . . 10.0 111.071 -174.595 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -100.74 -14.34 18.1 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 124.646 1.178 . . . . 10.0 112.143 -178.596 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -26.09 114.65 0.06 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 125.929 1.691 . . . . 10.0 111.331 167.707 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -53.62 -53.11 56.53 Favored 'General case' 0 C--O 1.226 -0.14 0 CA-C-O 121.419 0.628 . . . . 10.0 111.718 -167.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.496 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.5 p -165.38 -103.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 104.376 -2.453 . . . . 10.0 104.376 170.192 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.496 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -76.49 59.39 3.31 Favored Glycine 0 CA--C 1.53 1.018 0 CA-C-N 119.098 0.863 . . . . 10.0 112.476 176.664 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -91.11 108.18 19.69 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 103.77 -2.678 . . . . 10.0 103.77 166.279 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -81.59 -19.9 40.96 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 118.446 0.566 . . . . 10.0 111.34 -172.295 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.03 -92.46 0.59 Allowed Glycine 0 C--O 1.217 -0.937 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -155.19 159.52 40.18 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 -178.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.6 m -126.13 126.6 69.83 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 123.665 0.786 . . . . 10.0 110.283 170.203 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -80.11 124.47 28.79 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 127.025 2.13 . . . . 10.0 111.773 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.82 129.55 49.53 Favored 'General case' 0 C--O 1.234 0.243 0 C-N-CA 126.051 1.74 . . . . 10.0 109.58 170.031 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -64.98 172.14 3.09 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 123.985 0.803 . . . . 10.0 109.958 169.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -48.59 -34.61 11.86 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 126.586 1.954 . . . . 10.0 109.983 173.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -78.99 -6.53 56.55 Favored 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 123.943 0.897 . . . . 10.0 110.146 -172.452 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.13 21.18 71.23 Favored Glycine 0 C--N 1.339 0.738 0 N-CA-C 110.27 -1.132 . . . . 10.0 110.27 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.5 t -101.79 106.7 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 127.501 2.32 . . . . 10.0 105.266 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.412 ' HB3' HG13 ' A' ' 35' ' ' ILE . . . -101.9 120.39 40.32 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.092 -1.077 . . . . 10.0 108.092 169.391 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -88.77 134.72 33.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 169.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 90.1 t -109.68 131.78 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 104.705 -2.331 . . . . 10.0 104.705 168.786 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.9 m -154.79 68.5 0.71 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 124.158 0.983 . . . . 10.0 108.795 174.509 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -117.22 160.82 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 106.736 -1.579 . . . . 10.0 106.736 -174.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -132.01 123.91 28.25 Favored 'General case' 0 N--CA 1.446 -0.626 0 O-C-N 121.842 -0.536 . . . . 10.0 110.139 168.324 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -104.47 128.0 52.28 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.783 1.233 . . . . 10.0 109.403 -172.607 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.9 p -113.42 38.25 2.95 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.047 1.339 . . . . 10.0 110.867 177.783 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.53 -39.73 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 C-N-CA 123.644 0.778 . . . . 10.0 111.47 173.575 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.433 HD12 ' C ' ' A' ' 104' ' ' ILE 0.369 0.8 OUTLIER -90.27 175.66 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 119.566 1.076 . . . . 10.0 112.106 170.173 . . . . . . . . 4 4 . 1 . 011 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 83.7 p -146.39 158.74 43.92 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.402 -0.811 . . . . 10.0 109.107 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.8 mp -89.82 -26.56 20.49 Favored 'General case' 0 N--CA 1.457 -0.077 0 C-N-CA 122.756 0.422 . . . . 10.0 110.493 170.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -155.9 46.51 0.47 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.188 0.449 . . . . 10.0 110.853 -172.035 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -151.92 70.44 0.3 Allowed Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.549 -1.82 . . . . 10.0 108.549 -178.001 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.8 t70 73.94 -52.32 0.69 Allowed 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 128.711 2.804 . . . . 10.0 111.21 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -75.3 -36.7 61.09 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -167.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.5 t 37.79 75.48 0.07 Allowed 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.694 1.598 . . . . 10.0 113.731 166.398 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.8 pt -61.98 -9.37 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 N-CA-C 114.133 1.16 . . . . 10.0 114.133 -177.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 39.1 mm -45.28 129.45 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 O-C-N 121.066 -1.022 . . . . 10.0 110.263 170.199 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.74 -3.41 86.89 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.5 -1.167 . . . . 10.0 114.116 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -78.26 175.67 9.99 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 119.101 1.451 . . . . 10.0 108.04 168.709 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -123.4 135.2 54.01 Favored 'General case' 0 C--N 1.338 0.105 0 C-N-CA 123.308 0.643 . . . . 10.0 110.151 171.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.542 HD21 HD11 ' A' ' 149' ' ' ILE . 3.6 mm? -89.53 147.22 24.09 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 107.64 -1.245 . . . . 10.0 107.64 168.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.4 t -129.27 131.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.2 -1.407 . . . . 10.0 107.2 169.254 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -102.97 133.18 47.46 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 N-CA-C 105.787 -1.931 . . . . 10.0 105.787 168.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.653 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.5 m-70 -111.52 157.67 20.07 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.839 1.422 . . . . 10.0 114.839 -170.649 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.574 ' HA ' HD22 ' A' ' 144' ' ' LEU . 52.0 tt0 -43.52 -52.46 6.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 128.598 2.759 . . . . 10.0 110.332 176.274 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -118.21 165.28 14.0 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 123.584 0.754 . . . . 10.0 110.915 -169.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -58.58 147.16 33.27 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.002 -0.999 . . . . 10.0 109.698 169.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.532 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 26.1 m-20 -79.49 130.56 35.52 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 124.459 1.104 . . . . 10.0 109.829 171.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.51 -16.66 59.59 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 123.876 0.735 . . . . 10.0 111.014 173.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.2 mt 55.6 49.74 15.89 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-O 122.251 1.024 . . . . 10.0 109.386 -173.105 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.52 -29.49 9.61 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.069 -1.423 . . . . 10.0 112.399 169.783 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt -77.06 9.94 2.68 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.731 1.011 . . . . 10.0 113.731 -168.584 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.07 -19.98 74.36 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 124.378 0.99 . . . . 10.0 111.86 172.469 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.79 42.51 68.9 Favored Glycine 0 C--N 1.343 0.944 0 N-CA-C 111.031 -0.828 . . . . 10.0 111.031 -176.6 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -131.51 159.09 39.16 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 106.139 -1.8 . . . . 10.0 106.139 177.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -50.68 -49.0 58.36 Favored 'General case' 0 N--CA 1.442 -0.841 0 CA-C-N 114.522 -1.217 . . . . 10.0 107.82 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -63.28 -33.67 76.02 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 115.376 -0.829 . . . . 10.0 112.41 175.345 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.9 p -59.43 -43.23 93.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 120.153 -1.592 . . . . 10.0 111.06 174.642 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -81.47 -21.04 39.02 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 122.973 0.171 . . . . 10.0 111.187 -174.115 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 15.6 mmtp -89.11 -49.3 6.83 Favored 'General case' 0 C--N 1.339 0.129 0 C-N-CA 124.781 1.232 . . . . 10.0 113.099 179.223 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 34.7 p -128.81 -18.08 3.89 Favored 'General case' 0 C--O 1.227 -0.125 0 N-CA-C 114.734 1.383 . . . . 10.0 114.734 177.709 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 106.55 26.26 5.97 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 119.452 1.024 . . . . 10.0 112.96 -176.515 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 58.64 21.6 8.93 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 118.349 1.074 . . . . 10.0 111.033 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.4 -5.36 35.93 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 123.965 0.906 . . . . 10.0 111.8 -169.051 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.84 -165.58 53.66 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.808 -1.317 . . . . 10.0 109.808 168.788 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 60.2 m -52.01 129.62 27.67 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-O 121.362 0.601 . . . . 10.0 110.037 -171.392 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.71 72.95 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.004 1.322 . . . . 10.0 110.414 171.581 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.574 HD22 ' HA ' ' A' ' 121' ' ' GLU . 6.5 tp -47.75 -35.2 9.48 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 128.202 2.601 . . . . 10.0 113.122 -172.364 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.93 157.09 25.87 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.73 -0.841 . . . . 10.0 108.73 172.549 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -145.31 163.32 34.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.047 -0.524 . . . . 10.0 109.714 177.596 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.18 147.32 15.39 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.495 -1.442 . . . . 10.0 109.495 -174.731 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 69.9 t -105.88 131.88 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 C-N-CA 126.142 1.777 . . . . 10.0 106.771 -169.468 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.542 HD11 HD21 ' A' ' 117' ' ' LEU . 8.2 mt -77.14 117.62 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.735 0 CA-C-N 117.884 0.311 . . . . 10.0 110.398 -174.36 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.45 158.87 14.1 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.572 1.082 . . . . 10.0 112.036 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.1 mt -64.74 142.56 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 125.309 1.444 . . . . 10.0 109.803 177.503 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.77 165.11 28.16 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.575 -1.269 . . . . 10.0 107.575 167.552 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.12 0 N-CA-C 105.023 -2.214 . . . . 10.0 105.023 167.538 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.551 0 N-CA-C 106.815 -1.55 . . . . 10.0 106.815 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.1 t -94.9 -35.1 12.17 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.558 1.143 . . . . 10.0 109.539 175.749 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -134.23 160.32 38.22 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 124.486 1.114 . . . . 10.0 110.467 -171.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.99 166.18 34.41 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 169.161 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -128.4 175.78 9.25 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 N-CA-C 107.739 -1.208 . . . . 10.0 107.739 171.175 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.04 122.61 13.24 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 124.064 0.946 . . . . 10.0 109.076 168.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.425 HG21 ' HB3' ' A' ' 53' ' ' ASN . 1.5 m -102.65 100.41 10.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 C-N-CA 124.482 1.113 . . . . 10.0 110.43 174.179 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.442 ' N ' HD12 ' B' ' 8' ' ' LEU . 5.7 mp -89.65 130.41 35.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.742 0.817 . . . . 10.0 109.188 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -144.62 162.68 36.04 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 119.529 1.059 . . . . 10.0 108.423 170.333 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -167.22 -61.37 0.03 OUTLIER Glycine 0 C--O 1.229 -0.208 0 CA-C-N 115.331 -0.85 . . . . 10.0 112.057 171.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -73.81 -44.64 55.19 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 106.544 -1.65 . . . . 10.0 106.544 -171.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.07 -65.57 0.59 Allowed Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 113.614 -1.63 . . . . 10.0 110.404 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -55.44 -38.75 93.67 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 122.644 2.23 . . . . 10.0 111.148 171.62 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 98.6 t -67.91 107.47 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 N-CA-C 108.058 -1.09 . . . . 10.0 108.058 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.04 107.7 10.67 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 125.662 1.585 . . . . 10.0 107.266 172.676 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.693 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -95.67 136.57 12.94 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.181 -0.768 . . . . 10.0 111.181 173.194 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.559 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.9 mt -140.75 89.58 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.674 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -102.39 149.77 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.087 0 C-N-CA 124.819 1.248 . . . . 10.0 110.753 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -119.57 133.39 55.68 Favored 'General case' 0 C--O 1.232 0.155 0 C-N-CA 127.639 2.376 . . . . 10.0 107.417 174.148 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -119.32 113.62 21.11 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 171.566 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -110.74 137.46 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 118.714 0.688 . . . . 10.0 111.478 167.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -96.93 113.92 25.5 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.655 -1.98 . . . . 10.0 105.655 167.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.7 tttt . . . . . 0 N--CA 1.443 -0.775 0 C-N-CA 125.804 1.642 . . . . 10.0 109.672 -175.008 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.949 0 N-CA-C 108.164 -1.974 . . . . 10.0 108.164 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -59.59 149.18 83.92 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 122.63 2.22 . . . . 10.0 110.269 -177.706 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -88.99 108.1 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 105.913 -1.884 . . . . 10.0 105.913 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 40.4 tttt -88.39 116.86 26.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 105.886 -1.894 . . . . 10.0 105.886 168.511 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -92.56 103.22 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -123.28 152.41 41.4 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 112.63 0.604 . . . . 10.0 112.63 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.42 -150.86 22.07 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 106.556 -2.618 . . . . 10.0 106.556 172.057 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.98 154.62 31.38 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 118.86 -1.136 . . . . 10.0 110.733 -176.302 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.693 HG22 ' HA2' ' B' ' 16' ' ' GLY . 1.7 pt -113.89 141.38 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 114.91 -1.041 . . . . 10.0 109.614 167.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 tttm -118.81 141.28 48.78 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.81 -8.76 31.96 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 119.517 -0.602 . . . . 10.0 113.95 174.761 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.39 176.7 0.59 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 118.303 1.052 . . . . 10.0 111.601 175.121 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -112.7 154.04 26.75 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 105.656 -1.979 . . . . 10.0 105.656 165.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -48.95 154.38 0.74 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.869 1.267 . . . . 10.0 113.3 -168.411 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -171.11 22.29 Favored Glycine 0 C--N 1.337 0.61 0 C-N-CA 123.84 0.733 . . . . 10.0 112.212 168.753 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -73.3 144.13 46.71 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.293 1.437 . . . . 10.0 109.782 -178.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -148.03 150.03 33.2 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 113.504 0.928 . . . . 10.0 113.504 -177.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.714 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -29.73 119.87 0.08 OUTLIER Glycine 0 C--N 1.339 0.731 0 C-N-CA 128.409 2.909 . . . . 10.0 113.847 165.088 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -153.77 110.92 3.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 118.72 1.26 . . . . 10.0 111.029 168.493 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -146.86 175.01 10.97 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 121.436 0.636 . . . . 10.0 110.382 177.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.9 m -103.1 155.62 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 104.903 -2.258 . . . . 10.0 104.903 166.014 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -138.58 154.98 48.73 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.845 1.258 . . . . 10.0 109.835 -173.799 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.7 tt0 -57.48 -64.62 0.83 Allowed 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.387 2.275 . . . . 10.0 112.387 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -77.06 105.92 8.44 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 -172.057 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.15 -23.9 66.61 Favored Glycine 0 CA--C 1.532 1.116 0 N-CA-C 108.995 -1.642 . . . . 10.0 108.995 167.73 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.38 152.43 0.44 Allowed 'General case' 0 N--CA 1.445 -0.699 0 C-N-CA 124.928 1.291 . . . . 10.0 111.682 168.69 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -152.21 24.46 0.63 Allowed 'General case' 0 N--CA 1.439 -1.007 0 CA-C-N 114.629 -1.169 . . . . 10.0 112.49 168.588 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.727 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -60.6 -25.41 66.22 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 121.783 -0.573 . . . . 10.0 110.292 176.878 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.57 -17.18 60.13 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.632 0.773 . . . . 10.0 111.149 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.05 73.71 0.9 Allowed Glycine 0 CA--C 1.527 0.795 0 N-CA-C 110.709 -0.956 . . . . 10.0 110.709 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 53.72 32.5 14.83 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.092 0.957 . . . . 10.0 112.534 170.201 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -122.4 -48.63 2.07 Favored 'General case' 0 N--CA 1.441 -0.923 0 C-N-CA 124.943 1.297 . . . . 10.0 108.317 -169.324 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.8 t -125.37 48.94 1.96 Allowed 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.58 -0.896 . . . . 10.0 108.58 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.81 50.62 0.72 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.603 0.761 . . . . 10.0 110.265 176.232 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 69.78 120.07 0.04 OUTLIER Glycine 0 CA--C 1.537 1.42 0 C-N-CA 124.947 1.261 . . . . 10.0 113.093 173.173 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -80.98 50.77 3.69 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 122.729 2.286 . . . . 10.0 112.817 -173.637 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER 62.33 100.33 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 127.966 2.507 . . . . 10.0 109.631 -175.718 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -27.38 -47.01 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 128.279 2.632 . . . . 10.0 115.725 -175.19 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 19.39 76.75 0.19 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 128.047 2.539 . . . . 10.0 116.011 -174.117 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.26 -50.63 2.61 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 121.128 1.218 . . . . 10.0 109.576 172.664 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 23.3 tp -77.58 75.9 4.12 Favored 'General case' 0 N--CA 1.453 -0.285 0 O-C-N 121.677 -0.64 . . . . 10.0 109.322 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.2 t -17.3 90.25 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 128.051 2.54 . . . . 10.0 114.241 174.277 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -135.34 164.77 26.99 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 126.721 2.008 . . . . 10.0 107.981 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -105.62 95.33 5.74 Favored 'General case' 0 C--O 1.224 -0.247 0 C-N-CA 122.897 0.479 . . . . 10.0 109.853 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.523 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 84.6 t60 2.16 94.84 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.406 0 C-N-CA 127.56 2.344 . . . . 10.0 115.254 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -100.91 -144.82 16.06 Favored Glycine 0 C--N 1.316 -0.582 0 N-CA-C 109.836 -1.306 . . . . 10.0 109.836 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.439 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 179.14 -165.82 34.95 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 106.749 -2.54 . . . . 10.0 106.749 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -65.28 7.25 0.31 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 CA-C-N 119.887 1.843 . . . . 10.0 111.169 167.49 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.439 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.8 mmmt -119.94 1.56 10.95 Favored 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 126.509 1.923 . . . . 10.0 110.775 178.534 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -143.34 159.68 41.92 Favored 'General case' 0 C--N 1.348 0.533 0 CA-C-N 120.709 1.595 . . . . 10.0 108.92 168.183 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.2 mm-40 -78.73 -22.0 47.2 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.588 -0.893 . . . . 10.0 108.588 177.09 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -87.14 34.13 0.68 Allowed 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.433 1.093 . . . . 10.0 111.713 -170.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.0 mtm180 -49.12 142.27 7.13 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.591 1.156 . . . . 10.0 108.254 169.263 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.523 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 24.4 m170 -75.74 -50.35 15.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.639 0.654 . . . . 10.0 110.367 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER 175.46 -19.88 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 126.949 2.1 . . . . 10.0 111.675 174.52 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -161.46 68.98 0.23 Allowed Glycine 0 C--N 1.338 0.642 0 N-CA-C 108.469 -1.852 . . . . 10.0 108.469 -169.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -127.58 94.79 4.06 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -168.342 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.1 mp -64.5 -35.9 82.44 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.468 -0.568 . . . . 10.0 109.468 -172.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.74 -88.14 0.41 Allowed Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 107.19 -2.364 . . . . 10.0 107.19 176.395 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 86' ' ' ASN . . . . . 0.41 ' ND2' ' H ' ' B' ' 124' ' ' ASP . 7.6 m120 -149.82 141.46 23.54 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.731 -1.211 . . . . 10.0 107.731 -172.227 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.5 m -116.52 135.5 56.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 118.443 0.565 . . . . 10.0 110.425 169.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 19.8 m -94.92 100.9 12.68 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 128.173 2.589 . . . . 10.0 110.584 -170.402 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.92 131.23 35.8 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.066 0.547 . . . . 10.0 110.645 174.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -64.92 168.92 5.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.919 1.688 . . . . 10.0 109.139 167.438 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.15 -32.03 33.93 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.488 1.115 . . . . 10.0 111.039 175.77 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -80.68 -2.0 44.88 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 124.445 1.098 . . . . 10.0 110.794 -176.372 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.83 82.72 Favored Glycine 0 C--N 1.34 0.762 0 O-C-N 121.158 -0.964 . . . . 10.0 110.86 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 62.8 t -90.37 104.12 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 106.069 -1.826 . . . . 10.0 106.069 176.085 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.628 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -102.61 122.68 44.88 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 107.61 -1.256 . . . . 10.0 107.61 169.531 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -89.7 124.75 34.88 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.305 1.042 . . . . 10.0 108.25 174.526 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 51.9 t -110.07 131.53 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.937 1.695 . . . . 10.0 107.529 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 95.2 p -156.53 60.8 0.55 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.174 0.589 . . . . 10.0 109.901 174.792 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.49 155.02 5.13 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 -173.142 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -131.56 142.37 49.9 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.575 0.75 . . . . 10.0 111.067 177.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -140.37 161.8 36.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.552 -1.648 . . . . 10.0 106.552 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 11.1 t -136.98 10.33 3.06 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 125.398 1.479 . . . . 10.0 112.893 175.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -89.19 -15.46 8.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 120.077 1.308 . . . . 10.0 109.628 174.294 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.29 1.0 OUTLIER -111.79 162.57 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 125.333 1.453 . . . . 10.0 112.05 175.578 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.2 m -148.66 147.5 29.0 Favored 'General case' 0 C--N 1.34 0.171 0 C-N-CA 124.087 0.955 . . . . 10.0 109.355 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.45 -21.25 66.2 Favored 'General case' 0 C--O 1.227 -0.113 0 C-N-CA 125.208 1.403 . . . . 10.0 111.35 176.721 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.7 t . . . . . 0 N--CA 1.453 -0.299 0 O-C-N 121.293 -0.879 . . . . 10.0 109.674 171.957 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.445 -0.717 0 N-CA-C 111.899 0.333 . . . . 10.0 111.899 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 pt -74.29 55.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 123.834 0.854 . . . . 10.0 111.281 176.461 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 43.5 mm -108.46 -49.3 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 125.848 1.659 . . . . 10.0 109.956 179.296 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -90.19 18.68 47.22 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.372 -0.682 . . . . 10.0 113.074 -174.211 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.7 mtt85 -99.64 179.73 4.45 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.115 1.366 . . . . 10.0 110.556 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -133.87 147.62 51.18 Favored 'General case' 0 CA--C 1.507 -0.688 0 C-N-CA 125.789 1.636 . . . . 10.0 106.726 -175.484 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.436 ' N ' HD12 ' B' ' 117' ' ' LEU . 7.7 mp -113.49 153.81 28.09 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.331 -0.988 . . . . 10.0 108.331 173.129 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.0 t -131.97 130.46 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -97.82 123.92 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.349 -1.723 . . . . 10.0 106.349 169.125 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.714 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.3 m-70 -105.06 155.04 19.35 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 115.857 1.799 . . . . 10.0 115.857 -172.492 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 59.3 tt0 -44.79 -53.35 7.51 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 128.139 2.576 . . . . 10.0 111.726 175.026 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -113.08 167.19 10.73 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.952 0.723 . . . . 10.0 112.952 -168.799 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -70.49 147.28 49.57 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 113.967 -1.469 . . . . 10.0 108.424 170.416 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.41 ' H ' ' ND2' ' B' ' 86' ' ' ASN . 14.6 m-20 -94.84 131.34 40.82 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -173.649 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -76.51 -17.42 59.28 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.36 1.064 . . . . 10.0 110.19 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 22.6 mt 57.74 56.6 4.72 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 122.513 1.149 . . . . 10.0 108.969 -179.363 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.1 -40.83 3.06 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.745 -1.57 . . . . 10.0 110.722 168.423 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 30.7 mtmt -79.01 48.99 0.89 Allowed 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.637 1.175 . . . . 10.0 110.81 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -112.07 -9.21 20.73 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 127.203 2.335 . . . . 10.0 112.377 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.7 37.73 43.1 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 123.951 0.786 . . . . 10.0 112.973 176.733 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 -134.0 157.87 44.97 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 106.359 -1.719 . . . . 10.0 106.359 174.84 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -54.86 -45.94 74.63 Favored 'General case' 0 N--CA 1.439 -0.999 0 CA-C-O 122.305 1.05 . . . . 10.0 108.207 170.207 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 24.0 tp10 -58.48 -33.83 70.23 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 121.185 -0.947 . . . . 10.0 112.978 173.084 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.0 p -56.51 -42.09 77.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 120.606 1.548 . . . . 10.0 111.074 172.118 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.3 t -82.78 -19.65 37.36 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 118.485 -0.769 . . . . 10.0 112.421 -178.756 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -90.86 -46.46 8.18 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 124.448 1.099 . . . . 10.0 112.128 -176.265 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 26.9 p -133.51 -9.26 2.86 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.098 1.147 . . . . 10.0 114.098 176.504 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.42 23.61 12.31 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 119.289 0.95 . . . . 10.0 112.546 -173.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 61.67 21.83 12.46 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.769 1.284 . . . . 10.0 111.248 -176.576 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.33 -7.76 20.99 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 125.592 1.557 . . . . 10.0 112.285 -171.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.18 -167.97 54.84 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.069 -1.212 . . . . 10.0 110.069 170.815 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 12.6 t -53.96 129.1 32.94 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 121.819 0.819 . . . . 10.0 110.862 -169.319 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.45 73.23 0.08 Allowed 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 124.049 0.94 . . . . 10.0 108.961 169.449 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 66.3 mt -47.14 -45.56 22.6 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.868 0.867 . . . . 10.0 111.676 -177.638 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.24 152.38 27.69 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -169.071 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -161.42 165.26 29.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.855 -0.611 . . . . 10.0 109.485 -172.319 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.44 163.24 30.22 Favored Glycine 0 C--N 1.331 0.255 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -174.667 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -101.91 156.05 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 N-CA-C 104.05 -2.574 . . . . 10.0 104.05 169.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 77.9 mt -74.75 -94.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 109.765 -0.457 . . . . 10.0 109.765 -169.122 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 112.92 135.95 6.48 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.626 1.108 . . . . 10.0 112.049 175.675 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -62.48 138.63 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.106 1.363 . . . . 10.0 110.096 179.372 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.87 146.59 49.37 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.434 -1.321 . . . . 10.0 107.434 169.514 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 . . . . . 0 C--O 1.248 0.99 0 N-CA-C 106.195 -1.779 . . . . 10.0 106.195 169.295 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 t -172.37 -36.44 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.703 1.201 . . . . 10.0 112.077 -179.109 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 48.0 tttt -137.98 134.46 34.9 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 123.267 0.627 . . . . 10.0 110.357 -179.615 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.5 167.85 26.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.012 1.325 . . . . 10.0 108.849 -175.21 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -126.89 164.15 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 118.746 0.703 . . . . 10.0 110.519 170.071 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.74 112.31 11.27 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.285 1.434 . . . . 10.0 107.711 167.255 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.479 HG21 ' HB3' ' B' ' 53' ' ' ASN . 3.0 m -95.88 103.14 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 123.666 0.787 . . . . 10.0 110.216 177.319 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mt -87.77 107.83 18.84 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 118.637 -0.697 . . . . 10.0 110.038 -173.25 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -133.24 158.69 42.26 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 120.644 1.565 . . . . 10.0 108.453 175.718 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.71 -68.82 0.02 OUTLIER Glycine 0 N--CA 1.462 0.372 0 CA-C-N 114.818 -1.083 . . . . 10.0 112.342 170.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -72.37 -39.5 68.0 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.064 -1.458 . . . . 10.0 107.064 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.24 -60.48 0.56 Allowed Glycine 0 N--CA 1.443 -0.86 0 CA-C-O 118.476 -1.18 . . . . 10.0 112.608 170.241 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -60.62 -39.62 62.7 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 CA-C-N 119.198 1.499 . . . . 10.0 110.848 -177.345 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.437 HG12 ' H ' ' A' ' 14' ' ' VAL . 0.2 OUTLIER -70.66 115.32 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 177.322 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.84 103.95 7.78 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.413 -2.44 . . . . 10.0 104.413 170.631 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.75 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.38 145.79 19.19 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 108.445 -1.862 . . . . 10.0 108.445 174.072 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.657 ' CG2' HG22 ' B' ' 54' ' ' THR . 3.3 mt -144.85 74.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -168.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 mm -87.45 128.8 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 N-CA-C 109.741 -0.466 . . . . 10.0 109.741 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -99.6 112.15 24.4 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 126.41 1.884 . . . . 10.0 107.752 173.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.421 ' CD2' HG12 ' A' ' 31' ' ' VAL . 25.7 m-85 -88.06 113.43 23.69 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 107.211 -1.403 . . . . 10.0 107.211 173.081 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -121.28 111.39 17.3 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 118.797 0.726 . . . . 10.0 111.272 168.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -99.53 91.54 4.95 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.129 -1.804 . . . . 10.0 106.129 168.273 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.48 -36.71 66.91 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.972 0.909 . . . . 10.0 112.939 -168.715 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.05 171.2 14.76 Favored 'General case' 0 N--CA 1.432 -1.362 0 N-CA-C 104.834 -2.284 . . . . 10.0 104.834 167.398 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.4 p -64.81 -24.65 67.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.235 0.54 . . . . 10.0 110.248 179.139 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -81.58 -19.29 42.29 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 115.221 -0.9 . . . . 10.0 110.259 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -82.02 154.48 33.71 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.617 -0.593 . . . . 10.0 111.617 -173.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_endo -67.36 146.8 76.37 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.71 2.274 . . . . 10.0 106.876 167.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.9 p -80.29 110.05 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 174.694 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -84.3 115.91 22.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.431 -0.952 . . . . 10.0 108.431 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.421 HG12 ' CD2' ' A' ' 20' ' ' PHE . 30.2 m -98.48 57.91 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 124.233 1.013 . . . . 10.0 108.73 -170.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 9.3 p90 -77.78 144.88 36.79 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 118.921 -1.112 . . . . 10.0 110.963 -175.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -175.88 172.04 45.06 Favored Glycine 0 N--CA 1.441 -0.976 0 O-C-N 121.24 -0.913 . . . . 10.0 110.89 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.8 t -128.58 107.91 10.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 178.875 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.758 ' CG1' ' HB3' ' A' ' 95' ' ' ALA . 2.7 pt -81.76 142.18 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 108.396 -0.964 . . . . 10.0 108.396 169.884 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.7 ptmm? -127.13 137.03 52.9 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.192 -1.04 . . . . 10.0 108.192 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.71 -1.92 27.52 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.075 0.845 . . . . 10.0 113.399 176.072 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -62.53 174.05 1.09 Allowed 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 122.132 0.968 . . . . 10.0 110.467 169.291 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -103.61 164.49 11.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.18 -1.785 . . . . 10.0 106.18 164.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -54.61 162.87 1.04 Allowed 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.576 0.751 . . . . 10.0 112.062 -172.769 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.72 -179.78 43.12 Favored Glycine 0 C--N 1.334 0.469 0 O-C-N 121.248 -0.908 . . . . 10.0 112.29 168.144 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.1 mt -66.55 142.22 57.58 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.059 0.943 . . . . 10.0 110.65 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -138.02 128.82 26.91 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 117.729 -1.129 . . . . 10.0 111.103 176.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.513 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -15.2 113.46 0.01 OUTLIER Glycine 0 C--N 1.347 1.148 0 CA-C-O 115.949 -2.584 . . . . 10.0 112.49 167.387 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -137.73 100.15 4.11 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 120.989 2.394 . . . . 10.0 109.91 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.413 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -156.73 169.84 23.79 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-O 122.04 0.924 . . . . 10.0 112.79 -174.075 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.8 t -96.81 141.14 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 111.566 -2.561 . . . . 10.0 107.729 177.618 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -116.28 168.58 10.0 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.178 0.991 . . . . 10.0 109.397 178.236 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -67.23 -72.51 0.16 Allowed 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.697 -0.683 . . . . 10.0 111.246 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.55 136.98 34.71 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 120.161 -0.616 . . . . 10.0 110.132 -169.442 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -66.87 -31.59 78.63 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 109.278 -1.529 . . . . 10.0 109.278 168.227 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -45.14 155.34 0.12 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 122.837 1.303 . . . . 10.0 114.353 -175.32 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.17 15.37 0.82 Allowed 'General case' 0 N--CA 1.439 -0.985 0 CA-C-N 113.446 -1.707 . . . . 10.0 111.037 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.522 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -53.76 -43.07 68.88 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 120.266 1.394 . . . . 10.0 112.352 -167.676 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.59 -17.94 52.74 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.98 0.912 . . . . 10.0 112.65 -179.331 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.05 60.77 0.37 Allowed Glycine 0 CA--C 1.528 0.862 0 C-N-CA 124.468 1.033 . . . . 10.0 111.139 -177.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 61.24 18.65 9.35 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 114.513 1.301 . . . . 10.0 114.513 171.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 p -93.81 -57.53 2.53 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 176.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.4 m -49.91 -34.44 20.42 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.363 2.265 . . . . 10.0 111.853 -178.496 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -39.25 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.849 2.46 . . . . 10.0 112.078 168.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.74 154.02 28.63 Favored Glycine 0 N--CA 1.436 -1.339 0 N-CA-C 108.28 -1.928 . . . . 10.0 108.28 168.66 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -71.44 -164.95 0.17 Allowed 'Trans proline' 0 N--CA 1.442 -1.552 0 N-CA-C 107.269 -1.858 . . . . 10.0 107.269 167.295 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.413 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 50.4 m170 -79.84 62.75 4.17 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 120.596 -1.315 . . . . 10.0 109.951 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -75.28 67.28 1.86 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 123.702 1.715 . . . . 10.0 111.18 178.332 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -72.65 153.6 91.53 Favored Pre-proline 0 N--CA 1.448 -0.54 0 C-N-CA 128.205 2.602 . . . . 10.0 110.181 169.295 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.85 -40.2 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.767 2.312 . . . . 10.0 111.37 177.839 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mt -78.09 49.18 0.79 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.284 1.034 . . . . 10.0 110.442 -177.697 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.4 p -57.14 106.55 0.33 Allowed 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.417 1.087 . . . . 10.0 109.826 -170.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.4 mtt180 -134.7 -88.02 0.37 Allowed 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 106.562 -1.644 . . . . 10.0 106.562 -171.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.5 mmtp -140.71 155.39 46.48 Favored 'General case' 0 N--CA 1.438 -1.074 0 CA-C-O 122.695 1.236 . . . . 10.0 110.273 169.184 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 69.2 t60 -69.03 119.31 13.12 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 164.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.9 -138.24 3.81 Favored Glycine 0 N--CA 1.442 -0.919 0 N-CA-C 109.38 -1.488 . . . . 10.0 109.38 -175.645 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -176.94 -157.5 18.14 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 109.558 -1.417 . . . . 10.0 109.558 169.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -67.79 14.72 0.15 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.158 1.905 . . . . 10.0 111.424 168.236 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.438 ' H ' ' C ' ' A' ' 73' ' ' GLY . 4.5 mtpm? -120.91 -6.93 9.54 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.626 1.571 . . . . 10.0 110.677 174.542 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -110.89 162.39 14.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 177.357 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.4 pm0 -98.74 -16.16 19.06 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 126.319 1.847 . . . . 10.0 109.866 169.525 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -105.39 6.9 32.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.852 1.661 . . . . 10.0 112.324 -174.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -35.52 149.81 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.575 1.95 . . . . 10.0 112.924 171.069 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 38.2 m-70 -70.06 -100.42 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 112.47 0.545 . . . . 10.0 112.47 -178.312 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 p -151.64 25.06 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 O-C-N 120.606 -1.309 . . . . 10.0 110.392 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 157.36 51.33 0.01 OUTLIER Glycine 0 CA--C 1.522 0.483 0 N-CA-C 108.814 -1.715 . . . . 10.0 108.814 -173.268 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.55 99.74 11.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 105.346 -2.094 . . . . 10.0 105.346 169.895 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.7 mt -94.49 33.02 1.47 Allowed 'General case' 0 N--CA 1.461 0.122 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 172.143 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 46.09 -106.38 0.13 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 126.514 2.006 . . . . 10.0 111.025 -178.351 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -151.92 117.66 5.43 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 123.557 0.743 . . . . 10.0 110.439 -168.234 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -92.86 138.69 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 122.731 0.412 . . . . 10.0 110.83 -171.111 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.31 118.56 24.28 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 125.035 1.334 . . . . 10.0 110.493 -172.391 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.59 134.74 38.12 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 123.225 0.61 . . . . 10.0 109.847 173.644 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -57.92 167.57 1.16 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.856 0.862 . . . . 10.0 109.025 167.607 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.11 -23.69 62.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.104 -0.498 . . . . 10.0 112.157 177.644 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -78.4 -13.09 60.0 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.266 0.627 . . . . 10.0 110.958 179.121 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.74 6.27 67.8 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.952 -0.859 . . . . 10.0 110.952 -176.517 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.9 t -81.49 108.1 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.516 1.927 . . . . 10.0 106.978 174.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.758 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -112.99 121.12 43.68 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 108.831 -0.803 . . . . 10.0 108.831 173.552 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -83.08 131.4 35.16 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.719 -0.845 . . . . 10.0 108.719 173.18 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.7 t -119.23 130.79 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 N-CA-C 104.815 -2.291 . . . . 10.0 104.815 168.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -155.75 57.78 0.61 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 118.655 0.661 . . . . 10.0 111.18 -177.425 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 71.6 mt -116.55 138.77 46.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.208 1.403 . . . . 10.0 109.824 -170.156 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -91.35 104.12 16.68 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 127.843 2.457 . . . . 10.0 109.121 172.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -81.34 116.48 21.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.009 -0.738 . . . . 10.0 109.009 175.256 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.8 p -111.3 46.46 1.09 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 125.448 1.499 . . . . 10.0 109.68 174.081 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.23 -41.06 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.168 0 CA-C-O 118.157 -0.925 . . . . 10.0 110.543 175.668 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.407 0.0 OUTLIER -106.27 177.21 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-N 119.553 1.069 . . . . 10.0 113.549 169.501 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.6 t -146.23 153.71 40.92 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 108.112 -1.07 . . . . 10.0 108.112 -176.299 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 93.1 mt -69.77 -17.53 63.43 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.318 0.647 . . . . 10.0 110.801 173.297 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.3 t -151.15 150.55 30.79 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.536 0.607 . . . . 10.0 109.533 177.51 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.6 68.09 0.43 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.017 -1.233 . . . . 10.0 110.017 -179.079 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.8 t70 71.61 -56.67 0.63 Allowed 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 129.536 3.134 . . . . 10.0 109.847 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -78.15 -2.46 37.61 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 113.011 0.745 . . . . 10.0 113.011 -168.691 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.9 t -17.76 96.41 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 129.025 2.93 . . . . 10.0 112.523 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 29.2 pt -72.84 -3.58 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 112.776 0.658 . . . . 10.0 112.776 -175.009 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.8 mm -52.54 130.28 13.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 O-C-N 121.092 -1.005 . . . . 10.0 108.493 169.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.92 8.71 87.67 Favored Glycine 0 CA--C 1.533 1.205 0 CA-C-O 118.67 -1.072 . . . . 10.0 114.22 -176.672 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -78.36 176.43 9.34 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 166.222 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -127.96 136.82 51.84 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 106.854 -1.535 . . . . 10.0 106.854 171.179 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.9 mp -107.61 158.07 17.55 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.183 -1.414 . . . . 10.0 107.183 168.819 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.1 t -132.27 136.79 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 107.487 -1.301 . . . . 10.0 107.487 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.3 125.19 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 103.674 -2.713 . . . . 10.0 103.674 167.638 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.513 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.0 m170 -106.37 164.37 12.08 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 120.207 1.367 . . . . 10.0 114.37 -171.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.39 -49.79 73.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 114.036 -1.438 . . . . 10.0 109.438 -175.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -117.97 173.05 6.99 Favored 'General case' 0 N--CA 1.456 -0.131 0 CA-C-O 122.425 1.107 . . . . 10.0 113.355 -174.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -73.57 143.28 46.5 Favored 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 113.475 -1.693 . . . . 10.0 109.646 169.454 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.13 156.3 36.11 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 123.851 0.861 . . . . 10.0 110.637 174.229 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 -85.35 8.92 16.98 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.414 -0.812 . . . . 10.0 109.968 166.483 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.4 mt 39.32 52.79 2.24 Favored 'General case' 0 C--N 1.344 0.369 0 C-N-CA 126.148 1.779 . . . . 10.0 110.782 -172.478 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.55 -26.24 24.68 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 113.642 -1.617 . . . . 10.0 112.59 173.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -78.97 24.37 0.31 Allowed 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 114.29 1.219 . . . . 10.0 114.29 -167.321 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.48 -38.41 38.29 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 108.49 -1.844 . . . . 10.0 108.49 169.034 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.84 47.8 58.7 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 109.431 -1.468 . . . . 10.0 109.431 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -152.17 164.08 38.06 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.544 -2.021 . . . . 10.0 105.544 176.474 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -44.74 -47.15 10.77 Favored 'General case' 0 N--CA 1.438 -1.055 0 C-N-CA 123.031 0.532 . . . . 10.0 111.344 -175.688 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.77 -34.56 71.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.453 -0.34 . . . . 10.0 110.176 -177.36 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -51.45 -44.44 62.36 Favored 'General case' 0 N--CA 1.446 -0.651 0 O-C-N 121.725 -0.61 . . . . 10.0 110.677 172.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -84.38 6.75 22.0 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.382 0.512 . . . . 10.0 112.382 -176.315 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -118.91 -75.62 0.58 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 125.594 1.557 . . . . 10.0 109.619 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 p -111.16 13.64 21.83 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 120.419 1.463 . . . . 10.0 113.689 175.392 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.66 -21.2 11.5 Favored Glycine 0 C--N 1.338 0.674 0 O-C-N 120.819 -1.176 . . . . 10.0 115.455 168.265 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 90.74 28.02 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 128.183 2.593 . . . . 10.0 110.097 -168.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.18 -2.2 1.28 Allowed 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.767 0.827 . . . . 10.0 112.686 169.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.11 -171.84 55.16 Favored Glycine 0 N--CA 1.443 -0.867 0 N-CA-C 109.882 -1.287 . . . . 10.0 109.882 174.622 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -60.88 144.92 51.9 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.881 0.848 . . . . 10.0 112.153 -169.098 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mtm-85 -63.71 63.29 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 127.305 2.242 . . . . 10.0 110.806 169.118 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.46 -14.86 59.21 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.941 1.089 . . . . 10.0 113.941 -173.021 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.86 146.3 17.63 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 123.303 0.641 . . . . 10.0 109.738 169.522 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.0 p -155.07 156.48 35.95 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.79 -0.818 . . . . 10.0 108.79 -171.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.22 145.39 12.38 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.412 -1.075 . . . . 10.0 110.412 -169.152 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.86 140.85 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 125.903 1.681 . . . . 10.0 106.838 -172.679 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.8 mt -80.56 120.1 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-O 118.716 -0.659 . . . . 10.0 110.575 -174.142 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -128.51 154.37 20.01 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 124.263 0.935 . . . . 10.0 113.085 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 mm -64.75 146.21 13.37 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 C-N-CA 124.292 1.037 . . . . 10.0 112.254 -169.468 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.57 -17.47 1.73 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 116.231 1.937 . . . . 10.0 116.231 178.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.252 1.206 0 CA-C-O 117.693 -1.146 . . . . 10.0 110.683 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 108.383 -0.969 . . . . 10.0 108.383 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -170.13 -47.2 0.02 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 124.099 0.96 . . . . 10.0 109.785 178.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -138.51 125.76 21.59 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 125.256 1.422 . . . . 10.0 107.973 -169.648 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.02 162.58 35.09 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 124.545 1.138 . . . . 10.0 109.053 -172.681 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 m -115.74 172.94 3.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-O 121.611 0.719 . . . . 10.0 110.086 171.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.44 102.56 3.85 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 104.425 -2.435 . . . . 10.0 104.425 165.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 m -90.03 120.02 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 170.871 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.417 ' N ' HD12 ' B' ' 8' ' ' LEU . 4.8 mp -99.16 136.22 39.44 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 108.326 -0.99 . . . . 10.0 108.326 -177.011 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 9' ' ' LYS . . . . . 0.409 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 39.4 mtpt -145.45 160.26 41.86 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.659 -1.237 . . . . 10.0 107.659 169.392 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.07 -54.56 0.07 OUTLIER Glycine 0 N--CA 1.461 0.323 0 C-N-CA 120.522 -0.846 . . . . 10.0 113.669 169.582 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -72.06 -43.58 64.67 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 -174.871 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.84 -70.95 0.4 Allowed Glycine 0 CA--C 1.521 0.425 0 CA-C-N 114.223 -1.353 . . . . 10.0 109.86 169.656 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -57.62 -36.16 98.62 Favored 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 123.381 2.721 . . . . 10.0 111.389 172.613 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.95 101.69 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -117.79 106.91 13.52 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 124.633 1.173 . . . . 10.0 107.957 172.001 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.44 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -86.83 147.75 21.3 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 109.912 -1.275 . . . . 10.0 109.912 169.638 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 54' ' ' THR . 0.9 OUTLIER -149.56 76.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 N-CA-C 104.761 -2.311 . . . . 10.0 104.761 -175.851 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -97.44 146.15 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 124.744 1.218 . . . . 10.0 108.85 -178.562 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -126.11 125.17 42.1 Favored 'General case' 0 C--O 1.232 0.133 0 C-N-CA 126.669 1.988 . . . . 10.0 107.864 -175.518 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -112.69 105.57 13.76 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.406 1.482 . . . . 10.0 107.805 178.137 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -113.13 123.78 51.05 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 123.823 0.702 . . . . 10.0 111.486 175.557 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -95.18 97.78 10.15 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.332 1.453 . . . . 10.0 108.003 174.274 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? . . . . . 0 N--CA 1.448 -0.56 0 C-N-CA 126.275 1.83 . . . . 10.0 110.955 -175.001 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.852 0 N-CA-C 110.458 -1.057 . . . . 10.0 110.458 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.57 161.0 45.43 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.122 1.881 . . . . 10.0 109.073 171.487 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 14.1 t -87.44 112.28 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 N-CA-C 105.208 -2.145 . . . . 10.0 105.208 169.324 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -92.98 121.12 33.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.599 -1.63 . . . . 10.0 106.599 169.386 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.69 106.38 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.307 1.843 . . . . 10.0 106.495 177.26 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -127.64 152.87 47.13 Favored 'General case' 0 CA--C 1.522 -0.133 0 N-CA-C 113.461 0.912 . . . . 10.0 113.461 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.26 -150.31 21.54 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 108.2 -1.96 . . . . 10.0 108.2 172.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 22.6 t -155.14 158.31 38.79 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 119.598 -0.841 . . . . 10.0 112.299 -177.033 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.652 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -118.88 114.21 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 127.147 2.179 . . . . 10.0 108.76 169.806 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -100.27 142.87 31.16 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 168.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.43 -1.17 14.21 Favored Glycine 0 C--N 1.337 0.599 0 C-N-CA 124.597 1.094 . . . . 10.0 112.932 169.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 31.7 mt -80.78 175.98 10.21 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.875 0.845 . . . . 10.0 110.491 -178.14 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -93.11 150.77 20.28 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 68.9 tt0 -53.77 145.32 16.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.4 1.08 . . . . 10.0 110.824 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.4 -176.64 21.8 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.799 0.714 . . . . 10.0 111.882 176.469 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.8 mp -70.83 150.33 45.93 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.485 1.514 . . . . 10.0 111.87 -172.782 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -143.22 144.15 32.04 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 112.969 0.729 . . . . 10.0 112.969 178.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.515 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -37.19 115.82 0.34 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.405 2.431 . . . . 10.0 112.211 166.744 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.541 ' CZ ' HD12 ' B' ' 35' ' ' ILE . 2.0 m-85 -135.66 106.6 6.65 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.754 1.777 . . . . 10.0 110.592 172.179 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.75 171.35 18.37 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-N 115.376 -0.829 . . . . 10.0 109.885 178.142 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 12.3 m -99.93 147.16 7.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 112.952 -1.931 . . . . 10.0 107.106 167.542 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 22.7 m-70 -116.14 131.19 57.01 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 103.949 -2.612 . . . . 10.0 103.949 173.099 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -59.73 -48.78 80.32 Favored 'General case' 0 N--CA 1.45 -0.443 0 O-C-N 124.206 0.941 . . . . 10.0 111.643 -167.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.7 m-30 -80.01 148.28 31.18 Favored 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 118.386 -1.326 . . . . 10.0 108.324 175.304 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.72 35.89 4.29 Favored Glycine 0 N--CA 1.441 -1.021 0 N-CA-C 108.083 -2.007 . . . . 10.0 108.083 166.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.7 74.73 6.38 Favored 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 126.895 3.236 . . . . 10.0 107.318 171.255 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.479 ' HB3' HG21 ' A' ' 7' ' ' VAL . 3.2 t-20 -76.63 -0.37 23.16 Favored 'General case' 0 N--CA 1.416 -2.133 0 CA-C-N 109.63 -3.441 . . . . 10.0 111.029 -173.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.657 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -32.08 -52.38 0.26 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 130.194 3.397 . . . . 10.0 112.932 175.526 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -21.97 47.45 Favored 'General case' 0 CA--C 1.529 0.147 0 N-CA-C 112.871 0.693 . . . . 10.0 112.871 -176.12 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.24 75.85 1.3 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -174.589 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 19.9 m 63.75 56.82 1.47 Allowed 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 123.716 0.806 . . . . 10.0 112.208 168.486 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -155.14 -58.19 0.1 Allowed 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 108.239 -1.023 . . . . 10.0 108.239 175.628 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.5 m -61.42 -26.63 67.99 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 122.376 0.27 . . . . 10.0 111.578 -173.748 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.02 -34.56 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.977 2.511 . . . . 10.0 112.734 168.409 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.97 155.97 9.24 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.144 -0.783 . . . . 10.0 111.144 166.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 62' ' ' PRO . . . . . 0.416 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 88.8 Cg_endo -75.92 58.83 5.6 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 123.566 2.844 . . . . 10.0 108.494 166.592 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.293 1.0 OUTLIER 75.2 -44.3 0.53 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 127.181 2.192 . . . . 10.0 109.519 -177.669 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 64' ' ' PHE . . . . . 0.416 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 2.8 m-85 51.61 47.62 24.45 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 126.461 1.904 . . . . 10.0 111.57 172.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -72.01 142.73 85.57 Favored Pre-proline 0 C--N 1.321 -0.638 0 C-N-CA 125.571 1.548 . . . . 10.0 112.987 178.549 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.92 -44.43 0.35 Allowed 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 123.623 2.882 . . . . 10.0 110.843 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 14.4 mt -68.96 88.13 0.38 Allowed 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.223 -1.399 . . . . 10.0 107.223 171.544 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -57.7 82.13 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.658 1.983 . . . . 10.0 111.25 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.68 -179.83 4.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 127.19 2.196 . . . . 10.0 108.126 177.588 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -111.1 107.89 17.41 Favored 'General case' 0 C--O 1.224 -0.244 0 N-CA-C 108.263 -1.014 . . . . 10.0 108.263 -177.155 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.522 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 83.1 t60 -12.09 98.23 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.439 0 C-N-CA 126.783 2.033 . . . . 10.0 113.892 -178.336 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.44 -175.54 14.11 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 106.916 -2.474 . . . . 10.0 106.916 176.401 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.32 -155.89 7.26 Favored Glycine 0 C--O 1.226 -0.376 0 N-CA-C 107.061 -2.416 . . . . 10.0 107.061 -177.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -67.22 1.45 2.95 Favored 'Trans proline' 0 CA--C 1.544 0.99 0 CA-C-N 119.69 1.745 . . . . 10.0 110.287 165.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 56.3 mmtt -89.8 -15.57 32.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.834 1.653 . . . . 10.0 110.416 171.789 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -133.81 178.53 6.87 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 119.832 1.196 . . . . 10.0 109.826 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -90.3 -32.41 16.53 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 169.225 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -95.14 43.52 1.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 122.299 1.047 . . . . 10.0 111.909 -169.721 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.58 144.31 17.72 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 115.849 -0.614 . . . . 10.0 110.48 168.47 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.522 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.2 m170 -68.95 -56.86 6.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 -173.175 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.4 p -173.74 -38.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 123.715 0.806 . . . . 10.0 111.429 -174.62 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -158.56 69.61 0.26 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 108.072 -2.011 . . . . 10.0 108.072 -169.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -122.92 94.4 4.26 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.401 -2.074 . . . . 10.0 105.401 -171.745 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 5.0 mt -72.07 -28.3 63.24 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 85' ' ' GLY . . . . . 0.412 ' CA ' HD11 ' B' ' 126' ' ' LEU . . . 88.39 -94.58 2.01 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 108.007 -2.037 . . . . 10.0 108.007 176.117 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -128.98 124.18 34.38 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.092 0.557 . . . . 10.0 110.531 -168.667 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.476 HG22 ' CD1' ' B' ' 45' ' ' PHE . 6.6 m -121.48 145.52 27.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.866 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.2 m -94.17 113.72 25.71 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 127.172 2.189 . . . . 10.0 111.97 -167.82 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.45 130.48 36.12 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 109.457 -0.571 . . . . 10.0 109.457 169.272 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -59.51 169.71 1.21 Allowed 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 125.098 1.359 . . . . 10.0 110.311 168.451 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.06 -32.29 34.03 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.035 1.334 . . . . 10.0 112.115 169.605 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -77.34 -1.4 29.75 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.3 0.64 . . . . 10.0 110.987 178.305 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.37 20.41 69.42 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 120.584 -1.323 . . . . 10.0 110.178 175.672 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.37 105.5 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 128.529 2.732 . . . . 10.0 106.604 -177.327 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.652 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -98.88 125.13 44.21 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 168.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 p-10 -88.52 122.7 32.27 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 127.052 2.141 . . . . 10.0 109.045 175.283 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 96.6 t -107.72 134.25 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 174.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.6 m -158.13 66.56 0.46 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.607 1.163 . . . . 10.0 109.695 169.424 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.59 156.07 5.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.277 -1.379 . . . . 10.0 107.277 -177.605 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -133.42 139.95 47.04 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.893 1.277 . . . . 10.0 109.946 175.348 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -147.29 159.14 44.01 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.071 -1.455 . . . . 10.0 107.071 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.66 14.49 4.04 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.423 1.889 . . . . 10.0 111.857 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -89.44 1.69 7.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 119.19 0.905 . . . . 10.0 109.523 169.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.465 HD13 ' H ' ' B' ' 104' ' ' ILE 0.264 0.0 OUTLIER -129.08 171.28 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 126.313 1.845 . . . . 10.0 111.612 -179.328 . . . . . . . . 4 4 . 1 . 012 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 6.2 m -163.56 147.13 10.31 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 107.462 -1.31 . . . . 10.0 107.462 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -62.38 -48.22 80.71 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 123.303 0.641 . . . . 10.0 109.706 -176.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.4 t . . . . . 0 N--CA 1.453 -0.296 0 C-N-CA 125.347 1.459 . . . . 10.0 107.469 169.66 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 22.3 t . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 115.809 1.781 . . . . 10.0 115.809 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 29.7 pt -71.67 -15.11 18.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 114.048 1.129 . . . . 10.0 114.048 -178.239 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.5 mm -46.51 127.65 2.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 CA-C-N 119.051 0.841 . . . . 10.0 110.173 172.027 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.27 -0.11 83.22 Favored Glycine 0 CA--C 1.532 1.137 0 CA-C-O 118.969 -0.906 . . . . 10.0 114.583 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -76.22 175.41 9.05 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 119.243 1.521 . . . . 10.0 108.507 169.402 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -121.7 125.99 47.9 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.362 0.665 . . . . 10.0 111.002 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -80.93 139.98 35.55 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 170.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 98.9 t -124.72 132.49 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 108.025 -1.102 . . . . 10.0 108.025 171.873 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.443 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 3.7 p -98.78 125.81 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.189 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 168.005 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.515 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.0 m170 -102.11 161.0 14.02 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 122.954 1.359 . . . . 10.0 114.022 -176.583 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 121' ' ' GLU . . . . . 0.574 ' HA ' HD22 ' B' ' 144' ' ' LEU . 62.7 tt0 -46.79 -56.73 5.76 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 128.031 2.532 . . . . 10.0 109.288 176.319 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -124.49 177.03 6.13 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.655 1.582 . . . . 10.0 110.355 -173.26 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.21 145.38 35.58 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 125.615 1.566 . . . . 10.0 110.401 176.689 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -85.38 157.39 20.53 Favored 'General case' 0 N--CA 1.457 -0.098 0 CA-C-O 121.392 0.615 . . . . 10.0 112.156 169.277 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -78.99 -11.31 60.0 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 115.078 -0.964 . . . . 10.0 111.278 174.118 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.412 HD11 ' CA ' ' B' ' 85' ' ' GLY . 3.8 mm? 52.93 57.04 6.76 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.887 1.275 . . . . 10.0 108.841 -174.202 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.93 -42.32 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 113.706 -1.588 . . . . 10.0 111.161 168.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.7 mtmt -80.53 42.57 0.61 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.684 0.794 . . . . 10.0 112.179 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -94.75 -20.04 30.03 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 127.922 2.677 . . . . 10.0 110.101 168.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.56 49.77 38.57 Favored Glycine 0 C--N 1.34 0.778 0 C-N-CA 124.314 0.959 . . . . 10.0 111.802 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -155.28 172.79 17.6 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 117.784 0.792 . . . . 10.0 108.875 176.787 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 8.6 tm-20 -52.19 -46.24 65.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 C-N-CA 123.351 0.66 . . . . 10.0 111.269 -177.015 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -70.06 -30.97 68.35 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.825 -0.607 . . . . 10.0 109.756 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.9 p -50.66 -41.36 55.43 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 119.287 0.949 . . . . 10.0 111.258 -177.706 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.7 t -86.91 -3.28 59.06 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 113.285 0.846 . . . . 10.0 113.285 -177.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 32.1 tttt -114.48 -57.26 2.29 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 127.424 2.29 . . . . 10.0 111.952 -166.45 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 6.1 p -132.31 7.19 4.21 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 118.453 -0.784 . . . . 10.0 111.041 168.184 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.23 -105.1 2.95 Favored Glycine 0 C--N 1.344 1.009 0 N-CA-C 108.91 -1.676 . . . . 10.0 108.91 -169.727 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.15 34.17 0.14 Allowed 'General case' 0 C--N 1.321 -0.65 0 O-C-N 121.095 -1.238 . . . . 10.0 108.342 177.453 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.63 -9.21 58.33 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.899 -1.046 . . . . 10.0 111.467 -169.827 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.31 -158.39 41.78 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 109.261 -1.535 . . . . 10.0 109.261 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.6 m -57.43 128.9 39.36 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-O 121.45 0.643 . . . . 10.0 109.822 -174.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.2 72.78 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 124.711 1.204 . . . . 10.0 111.132 169.463 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.574 HD22 ' HA ' ' B' ' 121' ' ' GLU . 10.0 tp -44.61 -38.0 3.99 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 128.036 2.535 . . . . 10.0 114.517 -174.303 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.443 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -162.32 158.98 24.9 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 178.515 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.8 165.29 36.63 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 122.471 -0.143 . . . . 10.0 110.906 -178.409 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.88 146.47 14.16 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 110.374 -1.091 . . . . 10.0 110.374 -172.118 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 64.4 t -100.46 138.76 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 N-CA-C 105.851 -1.907 . . . . 10.0 105.851 -174.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 38.5 mt -73.33 120.71 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 C-N-CA 122.524 0.33 . . . . 10.0 110.172 -173.325 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.56 134.35 10.85 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.095 1.331 . . . . 10.0 112.103 -172.482 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.71 137.0 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 125.604 1.562 . . . . 10.0 109.463 179.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.21 -48.15 1.1 Allowed 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 113.305 0.854 . . . . 10.0 113.305 -174.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 44.7 tt0 . . . . . 0 C--O 1.253 1.282 0 N-CA-C 108.782 -0.821 . . . . 10.0 108.782 -165.944 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 108.635 -0.876 . . . . 10.0 108.635 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.9 -6.77 55.44 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 118.52 0.6 . . . . 10.0 109.825 -174.728 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.93 156.66 42.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.028 0.531 . . . . 10.0 109.986 168.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.41 156.26 35.03 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 m -126.82 160.44 35.17 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 109.552 -0.536 . . . . 10.0 109.552 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.27 107.77 7.85 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 107.578 -1.268 . . . . 10.0 107.578 169.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.4 m -84.37 109.06 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 170.851 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mt -93.23 146.39 23.73 Favored 'General case' 0 C--O 1.224 -0.246 0 CA-C-O 117.97 -1.014 . . . . 10.0 108.434 -174.248 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.2 mtmt -164.78 158.93 18.04 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 120.081 1.31 . . . . 10.0 108.351 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.74 -51.05 0.1 OUTLIER Glycine 0 N--CA 1.461 0.365 0 C-N-CA 120.013 -1.089 . . . . 10.0 113.768 168.146 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -73.35 -44.17 59.27 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.975 -1.12 . . . . 10.0 107.975 -173.536 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.01 -71.44 0.35 Allowed Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 114.086 -1.416 . . . . 10.0 110.536 169.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -55.0 -39.91 88.55 Favored 'Trans proline' 0 N--CA 1.451 -1.028 0 C-N-CA 122.703 2.269 . . . . 10.0 110.72 172.471 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.739 HG13 HD12 ' A' ' 38' ' ' LEU . 97.7 t -58.52 112.91 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 C-N-CA 123.862 0.865 . . . . 10.0 109.83 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -131.0 109.23 10.37 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 122.752 0.421 . . . . 10.0 110.062 167.295 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.614 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -83.05 154.77 32.26 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.837 -0.905 . . . . 10.0 110.837 168.161 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.22 56.44 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 126.024 1.73 . . . . 10.0 106.858 -179.122 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.429 HD12 ' HA ' ' A' ' 18' ' ' ILE . 1.2 tp -67.25 145.46 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 O-C-N 121.473 -0.767 . . . . 10.0 109.494 -179.15 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -138.04 101.14 4.34 Favored 'General case' 0 CA--C 1.519 -0.22 0 C-N-CA 126.319 1.847 . . . . 10.0 109.429 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.441 ' CE1' ' HB ' ' A' ' 31' ' ' VAL . 15.7 m-30 -100.48 129.69 46.47 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.561 -1.274 . . . . 10.0 107.561 -177.691 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -129.38 152.22 49.18 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.574 0.749 . . . . 10.0 110.752 176.688 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -125.77 114.65 18.89 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.603 -1.629 . . . . 10.0 106.603 166.082 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 47.0 mmtt -61.34 -60.26 4.01 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 109.07 -0.715 . . . . 10.0 109.07 169.509 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -126.79 165.84 18.54 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.312 -2.107 . . . . 10.0 105.312 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.4 t -73.52 -10.96 60.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-O 121.516 0.674 . . . . 10.0 109.32 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.8 m120 -78.45 -19.65 52.7 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.194 0.998 . . . . 10.0 110.228 173.495 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.89 150.76 41.61 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.582 -1.007 . . . . 10.0 110.582 178.575 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -76.16 148.53 31.03 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 N-CA-C 106.078 -2.316 . . . . 10.0 106.078 166.362 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.6 t -75.22 100.13 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.9 mtpp -68.48 93.87 0.52 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 106.755 -1.572 . . . . 10.0 106.755 170.138 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.441 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 4.3 m -82.06 59.87 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 124.772 1.229 . . . . 10.0 108.853 -172.373 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -82.7 174.25 11.17 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 119.119 -1.032 . . . . 10.0 111.471 -168.506 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.11 -159.44 28.35 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.427 -1.469 . . . . 10.0 109.427 167.716 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 15.2 m -155.99 124.72 5.97 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 109.138 -0.69 . . . . 10.0 109.138 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.614 HG22 ' CA ' ' A' ' 16' ' ' GLY . 2.6 pt -93.1 143.5 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 106.505 -1.665 . . . . 10.0 106.505 165.792 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.16 119.1 17.37 Favored 'General case' 0 N--CA 1.45 -0.435 0 O-C-N 123.803 0.689 . . . . 10.0 110.91 171.314 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.27 14.24 1.81 Allowed Glycine 0 C--N 1.341 0.839 0 CA-C-O 118.849 -0.973 . . . . 10.0 114.967 168.37 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.739 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -97.03 179.49 4.92 Favored 'General case' 0 C--O 1.224 -0.269 0 CA-C-N 118.808 1.304 . . . . 10.0 108.397 174.245 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -75.55 174.26 9.93 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 119.6 -0.84 . . . . 10.0 110.885 170.481 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -63.85 177.29 0.77 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.078 1.751 . . . . 10.0 110.167 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.8 -174.35 40.89 Favored Glycine 0 N--CA 1.448 -0.55 0 O-C-N 121.32 -0.862 . . . . 10.0 112.987 167.323 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.08 147.77 49.59 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.672 1.189 . . . . 10.0 109.273 175.469 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -144.38 141.9 29.99 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 114.009 1.115 . . . . 10.0 114.009 -176.622 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.635 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -27.48 122.17 0.06 OUTLIER Glycine 0 C--N 1.343 0.925 0 C-N-CA 128.291 2.853 . . . . 10.0 114.0 166.427 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.75 107.06 3.13 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 119.575 1.687 . . . . 10.0 113.185 169.082 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.457 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -146.28 173.13 12.52 Favored 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 123.368 0.667 . . . . 10.0 110.903 178.505 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.0 t -89.97 -41.99 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 113.624 -1.625 . . . . 10.0 113.107 -168.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 61.29 157.56 0.04 OUTLIER 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 126.145 1.778 . . . . 10.0 114.24 -174.595 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -72.64 -64.89 0.87 Allowed 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 113.996 -1.456 . . . . 10.0 111.176 -177.536 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -77.79 149.76 34.4 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.025 0.441 . . . . 10.0 110.214 -173.508 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.18 -11.47 54.34 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.124 -1.591 . . . . 10.0 109.124 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.92 158.04 0.74 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.58 1.181 . . . . 10.0 111.992 171.601 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.534 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -151.17 28.78 0.66 Allowed 'General case' 0 N--CA 1.434 -1.262 0 CA-C-N 113.745 -1.571 . . . . 10.0 112.026 166.158 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.453 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.0 OUTLIER -59.12 -29.58 67.5 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 122.527 0.331 . . . . 10.0 110.425 173.643 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.56 -18.92 59.61 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 122.563 0.345 . . . . 10.0 111.302 176.44 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.42 82.08 0.27 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 110.923 -0.871 . . . . 10.0 110.923 -177.849 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m 33.56 58.18 0.53 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 127.499 2.32 . . . . 10.0 111.649 -177.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -136.06 -56.34 0.77 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 -170.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 t -126.3 43.78 3.01 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.015 -1.476 . . . . 10.0 107.015 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.82 65.15 1.34 Allowed 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 174.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.28 92.8 0.01 OUTLIER Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.816 1.198 . . . . 10.0 113.487 169.391 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -74.62 68.01 5.49 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 123.938 3.092 . . . . 10.0 113.374 -169.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.457 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 34.3 m170 65.34 77.13 0.31 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 128.52 2.728 . . . . 10.0 111.196 173.083 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -18.42 -60.72 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 128.504 2.722 . . . . 10.0 114.578 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.1 t30 4.49 86.55 0.04 OUTLIER Pre-proline 0 CA--C 1.54 0.577 0 C-N-CA 128.664 2.786 . . . . 10.0 114.676 -169.209 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -66.43 -35.9 28.9 Favored 'Trans proline' 0 N--CA 1.456 -0.701 0 C-N-CA 122.538 2.159 . . . . 10.0 111.551 -175.36 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.3 tt -74.25 66.74 1.32 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 108.181 -1.044 . . . . 10.0 108.181 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.7 t -31.86 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 127.467 2.307 . . . . 10.0 112.346 -174.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -131.06 170.0 15.11 Favored 'General case' 0 N--CA 1.444 -0.744 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -89.87 123.4 33.79 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 108.419 -0.956 . . . . 10.0 108.419 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 68.2 t60 -29.55 104.04 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 174.808 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.34 -170.33 12.68 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 108.503 -1.839 . . . . 10.0 108.503 176.036 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -135.08 -164.84 10.59 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-O 119.406 -0.664 . . . . 10.0 111.638 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -67.2 7.49 0.47 Allowed 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.042 1.828 . . . . 10.0 111.958 170.227 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -89.94 -29.27 18.61 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.787 -1.19 . . . . 10.0 107.787 169.158 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.67 177.69 4.57 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.396 1.079 . . . . 10.0 108.334 -168.238 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -110.99 -12.34 14.23 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.74 -1.118 . . . . 10.0 110.697 169.333 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -86.86 -0.67 56.87 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.051 0.94 . . . . 10.0 111.245 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -36.81 138.1 0.27 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 127.367 2.267 . . . . 10.0 112.217 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -82.13 60.86 5.11 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.073 -0.392 . . . . 10.0 110.05 -178.592 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.283 11.7 p 10.46 64.33 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 129.284 3.034 . . . . 10.0 114.507 -176.091 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.36 49.06 0.06 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 126.028 1.775 . . . . 10.0 109.583 -173.712 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -131.7 105.87 7.78 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 103.889 -2.634 . . . . 10.0 103.889 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -75.88 -13.32 60.26 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -166.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.37 -97.91 1.46 Allowed Glycine 0 C--O 1.219 -0.802 0 N-CA-C 108.006 -2.038 . . . . 10.0 108.006 -175.005 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -155.09 151.03 27.85 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 124.917 1.287 . . . . 10.0 108.599 -176.014 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.9 m -120.97 135.62 60.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 108.917 -0.771 . . . . 10.0 108.917 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -88.11 119.19 28.25 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 127.691 2.397 . . . . 10.0 110.594 -177.183 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.23 133.44 43.52 Favored 'General case' 0 CA--C 1.523 -0.095 0 C-N-CA 124.772 1.229 . . . . 10.0 111.064 176.008 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -61.02 169.57 1.93 Allowed 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.354 0.662 . . . . 10.0 110.146 168.243 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 -23.25 16.8 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.459 1.104 . . . . 10.0 112.898 170.055 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -17.69 60.8 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 110.29 -0.263 . . . . 10.0 110.29 177.215 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.8 13.89 66.14 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 110.524 -1.03 . . . . 10.0 110.524 -171.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.6 t -91.25 110.38 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.91 0 C-N-CA 126.973 2.109 . . . . 10.0 106.217 175.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.473 ' HB3' HG13 ' A' ' 35' ' ' ILE . . . -110.26 116.01 30.72 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 168.617 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -79.83 123.18 27.5 Favored 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 127.003 2.121 . . . . 10.0 108.09 171.401 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 29.6 t -108.41 129.06 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 106.86 -1.533 . . . . 10.0 106.86 178.39 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -155.97 64.09 0.58 Allowed 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.142 -1.058 . . . . 10.0 108.142 173.387 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 49.8 mt -102.13 153.47 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 N-CA-C 106.623 -1.621 . . . . 10.0 106.623 176.532 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -122.25 110.11 15.3 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.856 0.862 . . . . 10.0 110.75 176.246 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.23 129.18 37.25 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.212 1.005 . . . . 10.0 108.615 -177.722 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.2 t -119.05 44.83 2.23 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.134 0.974 . . . . 10.0 109.399 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -135.74 -43.09 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 124.05 0.94 . . . . 10.0 111.269 172.208 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.431 HD12 ' C ' ' A' ' 104' ' ' ILE 0.379 0.9 OUTLIER -87.46 161.01 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 CA-C-N 119.477 1.035 . . . . 10.0 111.956 169.948 . . . . . . . . 4 4 . 1 . 013 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.0 m -151.93 106.83 3.25 Favored 'General case' 0 C--N 1.341 0.214 0 C-N-CA 123.997 0.919 . . . . 10.0 109.413 -172.592 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 36.4 mt -37.79 -38.02 0.27 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.141 2.176 . . . . 10.0 115.326 -174.055 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 57.3 m -144.83 56.31 1.26 Allowed 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.229 -1.026 . . . . 10.0 108.229 170.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.32 -63.11 1.67 Allowed Glycine 0 C--N 1.335 0.483 0 N-CA-C 109.099 -1.6 . . . . 10.0 109.099 174.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -167.67 -53.38 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.434 1.894 . . . . 10.0 107.141 -178.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.61 -45.6 36.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.266 -1.334 . . . . 10.0 107.896 -173.537 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.0 t 53.77 173.64 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 125.844 1.658 . . . . 10.0 112.443 -175.495 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.7 pt -130.54 20.44 2.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 126.008 1.723 . . . . 10.0 108.961 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.9 mm -70.37 140.13 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.268 0.627 . . . . 10.0 109.593 169.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.37 32.42 84.12 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.298 0.952 . . . . 10.0 113.177 173.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -106.25 176.08 5.29 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.968 1.707 . . . . 10.0 107.919 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -124.52 108.52 12.2 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.285 -1.006 . . . . 10.0 108.285 -178.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.7 mp -80.75 138.18 36.29 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 107.36 -1.348 . . . . 10.0 107.36 177.621 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.406 HG12 ' CD2' ' A' ' 120' ' ' HIS . 64.5 t -117.62 129.59 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.975 0 N-CA-C 105.939 -1.875 . . . . 10.0 105.939 -178.357 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -99.35 110.35 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 102.851 -3.018 . . . . 10.0 102.851 169.455 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.635 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.4 m170 -91.41 156.66 17.57 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 122.591 1.186 . . . . 10.0 113.492 -170.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.59 -52.92 20.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 126.688 1.995 . . . . 10.0 109.957 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -110.1 170.85 7.81 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 124.183 0.993 . . . . 10.0 112.306 -172.634 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.22 140.9 57.44 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 114.113 -1.403 . . . . 10.0 109.3 173.089 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.522 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 0.0 OUTLIER -76.86 125.41 29.25 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 107.483 -1.302 . . . . 10.0 107.483 176.53 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -76.0 -9.74 58.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.761 0.425 . . . . 10.0 111.13 -177.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.6 mt 48.24 38.72 10.65 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.007 0.908 . . . . 10.0 109.924 -176.22 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.28 -15.29 63.6 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.707 1.622 . . . . 10.0 112.554 172.557 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ptpt -75.7 3.08 10.42 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.239 1.519 . . . . 10.0 112.716 -171.076 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.56 -22.13 76.48 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 169.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.1 35.9 50.49 Favored Glycine 0 CA--C 1.526 0.765 0 C-N-CA 123.89 0.757 . . . . 10.0 112.487 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -136.84 173.72 11.39 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 122.1 0.953 . . . . 10.0 110.058 175.313 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.6 tm-20 -46.08 -51.98 12.83 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.996 1.719 . . . . 10.0 111.221 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -73.05 -37.14 66.96 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.743 -0.598 . . . . 10.0 110.75 179.463 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -48.84 -43.5 38.67 Favored 'General case' 0 C--N 1.344 0.357 0 O-C-N 121.357 -0.84 . . . . 10.0 110.272 175.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -81.38 -5.3 57.73 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 119.147 -0.454 . . . . 10.0 111.65 -169.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.6 mtmt -114.15 -76.8 0.58 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.593 1.557 . . . . 10.0 110.726 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . 0.26 17.2 p -104.2 12.99 33.13 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 120.157 1.344 . . . . 10.0 113.042 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 28.9 69.12 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 119.351 0.978 . . . . 10.0 113.243 169.569 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 35.2 m120 49.57 21.25 0.59 Allowed 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 118.203 1.002 . . . . 10.0 113.003 -176.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 120' ' ' HIS . . . -70.75 -6.34 36.82 Favored 'General case' 0 C--O 1.221 -0.43 0 O-C-N 121.491 -0.756 . . . . 10.0 111.542 -171.348 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.45 162.71 15.05 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 109.919 -1.272 . . . . 10.0 109.919 174.431 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.6 t -81.41 58.78 3.76 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.688 0.795 . . . . 10.0 111.094 -169.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 45.72 58.81 4.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.311 1.445 . . . . 10.0 112.941 169.571 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.43 HD13 ' N ' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -69.15 -10.48 57.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 113.601 0.963 . . . . 10.0 113.601 -169.818 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.44 ' HB3' HG11 ' A' ' 14' ' ' VAL . . . -164.98 143.27 6.41 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.226 1.01 . . . . 10.0 108.584 172.609 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -157.01 166.3 33.72 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 122.83 0.452 . . . . 10.0 110.016 -172.82 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.53 158.25 29.7 Favored Glycine 0 C--N 1.332 0.34 0 N-CA-C 109.207 -1.557 . . . . 10.0 109.207 -178.452 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 30.5 t -105.91 137.5 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 106.823 -1.547 . . . . 10.0 106.823 -167.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.3 mt -75.85 125.35 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 118.161 0.437 . . . . 10.0 110.607 -176.652 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.06 149.52 18.13 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.59 1.09 . . . . 10.0 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.1 mt -56.35 137.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 124.305 1.042 . . . . 10.0 109.594 176.072 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.81 165.69 19.64 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 107.505 -1.295 . . . . 10.0 107.505 167.387 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 . . . . . 0 C--O 1.251 1.165 0 C-N-CA 124.997 1.319 . . . . 10.0 107.59 167.731 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 107.162 -1.421 . . . . 10.0 107.162 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.6 t -77.2 -48.52 17.39 Favored 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 119.137 0.88 . . . . 10.0 109.168 174.11 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.66 121.87 40.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 126.109 1.763 . . . . 10.0 107.441 -170.137 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -127.61 159.57 34.27 Favored 'General case' 0 CA--C 1.519 -0.249 0 C-N-CA 124.526 1.13 . . . . 10.0 109.239 177.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.1 t -117.41 156.15 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 123.761 0.824 . . . . 10.0 109.726 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.47 112.14 9.4 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.595 1.558 . . . . 10.0 108.514 169.148 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.534 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.7 OUTLIER -94.11 106.11 17.68 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 C-N-CA 122.857 0.463 . . . . 10.0 110.845 171.443 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.657 HD21 ' HB2' ' B' ' 117' ' ' LEU . 11.2 mt -86.82 127.67 35.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.396 1.079 . . . . 10.0 110.015 177.264 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -147.55 162.47 39.02 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.469 -1.308 . . . . 10.0 107.469 169.326 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.73 -53.71 0.08 OUTLIER Glycine 0 N--CA 1.461 0.303 0 C-N-CA 120.664 -0.779 . . . . 10.0 113.521 169.198 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -72.26 -44.04 63.43 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.461 -1.311 . . . . 10.0 107.461 -174.328 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.51 -70.88 0.4 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.149 -1.387 . . . . 10.0 110.073 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -57.34 -34.54 98.06 Favored 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 123.436 2.757 . . . . 10.0 111.366 172.078 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 73.8 t -64.58 109.78 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 108.386 -0.968 . . . . 10.0 108.386 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -129.03 118.21 22.17 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.33 1.052 . . . . 10.0 108.376 169.461 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.581 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -108.02 140.05 15.31 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 124.166 0.889 . . . . 10.0 111.373 173.113 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.453 ' CG2' HG22 ' A' ' 54' ' ' THR . 9.4 mt -137.03 72.41 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 N-CA-C 106.4 -1.704 . . . . 10.0 106.4 -169.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mm -95.55 138.55 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 115.749 -0.659 . . . . 10.0 109.74 -170.729 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -114.48 117.89 32.26 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.139 1.775 . . . . 10.0 108.338 -179.289 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -102.51 107.45 18.42 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.872 -1.159 . . . . 10.0 107.872 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -108.12 122.49 47.0 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 114.949 1.463 . . . . 10.0 114.949 173.568 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -82.52 115.61 21.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 101.715 -3.439 . . . . 10.0 101.715 162.637 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mtpm? . . . . . 0 N--CA 1.45 -0.455 0 N-CA-C 109.979 -0.378 . . . . 10.0 109.979 -178.644 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.894 0 N-CA-C 108.93 -1.668 . . . . 10.0 108.93 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -68.28 145.05 64.66 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 N-CA-C 108.131 -1.527 . . . . 10.0 108.131 169.347 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.78 108.67 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 N-CA-C 104.966 -2.235 . . . . 10.0 104.966 169.464 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.7 mtpp -90.2 113.56 25.37 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 169.602 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -101.64 111.26 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 106.977 -1.49 . . . . 10.0 106.977 179.101 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.1 p90 -126.38 167.63 15.28 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.323 0.582 . . . . 10.0 112.069 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.64 -151.37 23.12 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 107.159 -2.377 . . . . 10.0 107.159 169.574 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 33.5 t -155.18 158.72 39.38 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 120.222 -0.591 . . . . 10.0 110.222 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.581 HG22 ' CA ' ' B' ' 16' ' ' GLY . 1.5 pt -117.14 136.74 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 114.866 -1.061 . . . . 10.0 108.816 167.701 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 27.5 tptt -108.83 146.44 33.67 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 105.938 -1.875 . . . . 10.0 105.938 170.61 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.56 -7.07 39.07 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.421 -0.655 . . . . 10.0 113.71 169.524 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.07 175.04 2.22 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 118.348 1.074 . . . . 10.0 110.079 173.486 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -104.55 167.08 9.97 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 105.693 -1.965 . . . . 10.0 105.693 165.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 7.9 tm-20 -54.88 163.6 0.96 Allowed 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.904 0.881 . . . . 10.0 112.103 -169.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.36 -168.68 46.62 Favored Glycine 0 N--CA 1.445 -0.731 0 CA-C-O 122.012 0.785 . . . . 10.0 112.831 167.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -74.5 143.4 44.6 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.471 1.908 . . . . 10.0 110.606 -173.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -147.07 143.41 28.31 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 124.319 1.048 . . . . 10.0 112.27 -177.153 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.564 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -33.43 128.32 0.39 Allowed Glycine 0 C--N 1.339 0.73 0 C-N-CA 127.669 2.557 . . . . 10.0 112.351 168.279 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -149.74 110.86 4.38 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.09 -1.078 . . . . 10.0 108.09 166.74 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.04 170.82 16.93 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.437 0.637 . . . . 10.0 112.589 175.491 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 t -91.89 146.11 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 CA-C-N 112.143 -2.299 . . . . 10.0 106.966 169.176 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -129.41 147.1 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.29 1.436 . . . . 10.0 107.586 176.27 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.28 -68.06 0.22 Allowed 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.013 0.925 . . . . 10.0 110.6 -172.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -77.63 132.23 38.15 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.914 -1.143 . . . . 10.0 107.914 -169.758 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.07 -24.94 76.21 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 172.729 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.29 162.16 0.36 Allowed 'General case' 0 N--CA 1.447 -0.597 0 CA-C-O 123.031 1.396 . . . . 10.0 113.044 177.718 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.71 30.08 0.47 Allowed 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 114.185 -1.37 . . . . 10.0 111.759 172.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.4 -37.57 72.92 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.288 1.035 . . . . 10.0 112.535 -168.779 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.14 -21.17 54.53 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.014 0.525 . . . . 10.0 111.687 176.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.59 -155.83 16.06 Favored Glycine 0 N--CA 1.435 -1.372 0 N-CA-C 106.189 -2.765 . . . . 10.0 106.189 -166.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.43 54.33 0.44 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 127.214 2.206 . . . . 10.0 113.461 -168.469 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -161.24 -39.35 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 O-C-N 120.79 -1.194 . . . . 10.0 111.82 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 9.5 t -50.71 -30.28 13.43 Favored 'General case' 0 C--N 1.343 0.319 0 C-N-CA 124.307 1.043 . . . . 10.0 111.137 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.27 -36.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 127.247 2.219 . . . . 10.0 114.194 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.17 143.31 10.98 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 110.694 -0.962 . . . . 10.0 110.694 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -77.06 58.6 6.22 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 124.425 3.417 . . . . 10.0 112.882 -175.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER 61.0 48.85 6.16 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.738 2.415 . . . . 10.0 109.854 177.059 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -69.7 74.65 0.42 Allowed 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.931 0.872 . . . . 10.0 111.046 178.248 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -74.99 150.8 86.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 O-C-N 121.343 -0.848 . . . . 10.0 110.832 171.486 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -67.12 -45.11 4.21 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.631 2.221 . . . . 10.0 111.159 178.542 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.96 57.29 1.05 Allowed 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.53 0.732 . . . . 10.0 110.038 178.446 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 39.5 p -42.48 108.73 0.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.629 1.572 . . . . 10.0 110.935 -172.812 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 58.7 mtt180 -148.6 -172.08 4.01 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.792 -2.299 . . . . 10.0 104.792 -171.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -83.98 146.38 28.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 118.42 -1.312 . . . . 10.0 107.6 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -50.81 119.74 4.16 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 166.715 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.87 -134.66 4.34 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 108.103 -1.999 . . . . 10.0 108.103 177.051 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.53 -161.36 32.03 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 107.537 -2.225 . . . . 10.0 107.537 169.395 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -66.02 5.02 0.72 Allowed 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.519 1.479 . . . . 10.0 111.053 168.062 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.8 mtpm? -114.99 8.23 15.75 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.591 1.156 . . . . 10.0 111.412 172.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -126.04 169.16 13.03 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.018 -1.105 . . . . 10.0 108.018 165.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -89.45 -24.8 21.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.724 -0.843 . . . . 10.0 108.724 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -105.48 13.48 30.08 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 115.363 1.616 . . . . 10.0 115.363 -165.723 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -28.1 130.73 0.05 Allowed 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 127.547 2.339 . . . . 10.0 111.866 168.687 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -47.08 -68.38 0.2 Allowed 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.115 0.966 . . . . 10.0 110.83 -175.087 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.0 p -168.18 -50.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.193 0 N-CA-C 107.456 -1.313 . . . . 10.0 107.456 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.32 53.3 0.68 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.907 1.241 . . . . 10.0 110.504 179.279 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -91.84 92.91 8.58 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 105.817 -1.92 . . . . 10.0 105.817 169.193 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -73.67 -37.26 65.32 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.308 -1.738 . . . . 10.0 106.308 174.643 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.83 -104.28 2.73 Favored Glycine 0 N--CA 1.436 -1.328 0 N-CA-C 108.433 -1.867 . . . . 10.0 108.433 169.349 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -114.48 131.62 56.56 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.239 0.616 . . . . 10.0 110.191 -169.201 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -115.2 139.34 42.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 107.756 -1.202 . . . . 10.0 107.756 167.589 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -100.53 123.05 44.23 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 125.017 1.327 . . . . 10.0 110.244 -173.815 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.08 135.1 43.09 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 124.17 0.988 . . . . 10.0 110.514 179.331 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -58.99 168.8 1.18 Allowed 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.593 0.757 . . . . 10.0 110.213 167.637 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -50.58 -34.02 24.2 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.812 0.845 . . . . 10.0 110.767 169.859 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.0 t0 -79.37 0.71 28.03 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 120.859 0.361 . . . . 10.0 111.761 -178.197 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.25 13.83 82.36 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 120.733 -1.229 . . . . 10.0 110.695 177.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 45.2 t -89.73 103.33 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 C-N-CA 127.039 2.136 . . . . 10.0 106.29 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.548 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.66 120.92 41.1 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 168.23 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -81.45 117.64 22.05 Favored 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 126.479 1.911 . . . . 10.0 108.494 172.372 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 67.8 t -98.9 129.14 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.081 0 N-CA-C 106.553 -1.647 . . . . 10.0 106.553 175.016 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.8 p -157.91 68.29 0.5 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.678 0.791 . . . . 10.0 109.326 170.539 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.13 160.27 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.274 -1.75 . . . . 10.0 106.274 -177.523 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -135.7 148.01 48.72 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 121.755 -0.591 . . . . 10.0 111.055 169.678 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -133.14 160.98 35.65 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 125.408 1.483 . . . . 10.0 108.506 179.015 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.5 t -134.64 41.61 2.89 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.116 1.366 . . . . 10.0 111.933 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.8 p -132.43 -45.04 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 123.352 0.661 . . . . 10.0 110.315 167.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.06 154.16 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 121.843 0.83 . . . . 10.0 109.762 169.403 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.8 m -154.01 152.87 31.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.533 1.133 . . . . 10.0 108.458 168.477 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.87 -25.43 62.8 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.013 0.925 . . . . 10.0 110.137 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 16.2 t . . . . . 0 N--CA 1.453 -0.282 0 C-N-CA 124.456 1.102 . . . . 10.0 108.122 169.218 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t . . . . . 0 C--O 1.232 0.155 0 CA-C-O 121.484 0.659 . . . . 10.0 112.67 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 27.1 pt -63.17 -10.59 6.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 N-CA-C 113.984 1.105 . . . . 10.0 113.984 -169.902 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.7 mm -34.51 -45.71 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.271 0 C-N-CA 126.741 2.016 . . . . 10.0 114.833 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.78 14.43 57.53 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.363 0.982 . . . . 10.0 113.629 -173.447 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -90.68 175.89 6.86 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.688 1.195 . . . . 10.0 110.497 178.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -122.19 142.28 50.58 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 124.419 1.088 . . . . 10.0 109.747 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.657 ' HB2' HD21 ' B' ' 8' ' ' LEU . 1.7 mm? -101.5 154.96 18.37 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.248 -1.39 . . . . 10.0 107.248 168.032 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.11 137.54 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.064 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.465 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.5 OUTLIER -106.2 138.22 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.269 -2.123 . . . . 10.0 105.269 168.586 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.564 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.0 m170 -117.83 160.33 21.57 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 114.763 1.394 . . . . 10.0 114.763 -169.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 68.1 tt0 -45.19 -53.72 7.84 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.597 2.759 . . . . 10.0 109.949 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.5 mttt -124.52 175.35 7.21 Favored 'General case' 0 CA--C 1.518 -0.27 0 C-N-CA 125.286 1.434 . . . . 10.0 110.273 -170.085 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.28 139.03 35.67 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.513 0.725 . . . . 10.0 109.168 175.036 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -78.12 148.1 34.33 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 123.326 0.65 . . . . 10.0 110.484 169.703 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -78.1 10.12 3.18 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 124.986 1.314 . . . . 10.0 111.196 174.493 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 16.5 mt 46.16 41.27 8.4 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.223 1.409 . . . . 10.0 110.829 -179.073 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 104.59 -39.76 2.71 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 125.233 1.397 . . . . 10.0 112.538 177.615 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.5 ' H ' ' HD3' ' B' ' 128' ' ' LYS . 0.1 OUTLIER -79.9 37.34 0.36 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.176 1.39 . . . . 10.0 111.769 -167.64 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -95.57 -12.07 54.35 Favored Glycine 0 CA--C 1.523 0.564 0 C-N-CA 125.568 1.556 . . . . 10.0 111.671 177.469 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.99 38.18 23.88 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 123.892 0.758 . . . . 10.0 111.779 -175.369 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -124.75 155.58 39.09 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.3 tm-20 -52.58 -44.24 65.79 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 114.123 -1.399 . . . . 10.0 108.353 169.203 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -65.05 -40.01 94.11 Favored 'General case' 0 CA--C 1.541 0.606 0 O-C-N 121.608 -0.683 . . . . 10.0 112.049 171.056 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 9.1 p -57.2 -40.67 77.91 Favored 'General case' 0 C--N 1.347 0.467 0 CA-C-N 121.141 1.791 . . . . 10.0 111.249 -179.281 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.1 t -72.97 -18.27 61.38 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 119.953 -0.699 . . . . 10.0 112.515 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -103.74 -50.65 3.36 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.14 1.776 . . . . 10.0 112.799 -168.345 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 24.1 p -120.92 -10.92 9.02 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 118.584 -0.722 . . . . 10.0 112.896 171.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 92.94 -1.57 71.0 Favored Glycine 0 C--N 1.337 0.636 0 CA-C-O 118.784 -1.009 . . . . 10.0 112.388 -172.13 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 71.12 31.76 2.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.596 1.198 . . . . 10.0 111.297 177.388 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.11 6.32 2.24 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.43 1.092 . . . . 10.0 112.209 174.327 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.87 -162.38 53.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.279 -1.128 . . . . 10.0 110.279 172.045 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.3 m -56.83 129.16 40.2 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-O 121.571 0.7 . . . . 10.0 111.388 -168.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.62 73.73 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.881 1.273 . . . . 10.0 109.259 169.751 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -74.09 -12.71 60.68 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 113.79 1.033 . . . . 10.0 113.79 -169.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.465 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -160.98 144.45 13.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.09 0.471 . . . . 10.0 111.795 175.261 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -138.28 151.43 47.6 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 126.507 1.923 . . . . 10.0 108.327 -169.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 147' ' ' GLY . . . . . 0.521 ' N ' HD23 ' B' ' 8' ' ' LEU . . . -153.36 142.28 9.07 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 179.391 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.3 t -102.87 137.12 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 105.672 -1.973 . . . . 10.0 105.672 -175.818 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.524 HD11 HD21 ' B' ' 117' ' ' LEU . 5.5 mt -72.19 158.06 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 108.939 -0.763 . . . . 10.0 108.939 -179.144 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -166.97 154.84 25.55 Favored Glycine 0 CA--C 1.528 0.888 0 O-C-N 122.007 -0.433 . . . . 10.0 112.247 -173.237 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 92.1 mt -68.19 131.41 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 124.882 1.273 . . . . 10.0 109.432 -174.392 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.81 -12.24 1.13 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 115.993 1.849 . . . . 10.0 115.993 -173.159 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.274 0.0 OUTLIER . . . . . 0 C--O 1.254 1.3 0 C-N-CA 128.774 2.83 . . . . 10.0 116.471 -170.171 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.829 0 N-CA-C 108.03 -1.1 . . . . 10.0 108.03 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -155.99 -43.73 0.08 Allowed 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.525 0.602 . . . . 10.0 111.247 171.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -118.79 130.49 55.81 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 169.076 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.89 163.24 26.78 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.751 1.221 . . . . 10.0 108.422 176.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.498 ' CG1' ' HB2' ' B' ' 52' ' ' ASP . 2.0 m -143.24 163.71 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 118.235 0.471 . . . . 10.0 109.873 -177.765 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.5 110.43 6.83 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.707 1.254 . . . . 10.0 108.048 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.445 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.3 OUTLIER -82.61 119.88 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 N-CA-C 106.445 -1.687 . . . . 10.0 106.445 167.427 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.5 mt -98.52 135.51 39.97 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -157.54 159.72 37.45 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 120.564 1.529 . . . . 10.0 108.217 172.101 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 173.54 -40.32 0.14 Allowed Glycine 0 N--CA 1.461 0.304 0 C-N-CA 119.858 -1.163 . . . . 10.0 113.312 169.628 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -73.96 -47.3 38.44 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 107.589 -1.264 . . . . 10.0 107.589 -177.392 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.65 -73.08 0.31 Allowed Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.691 -1.364 . . . . 10.0 109.691 170.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -58.6 -39.6 81.35 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 123.126 2.551 . . . . 10.0 111.119 173.017 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.49 101.8 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 107.808 -1.182 . . . . 10.0 107.808 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -118.4 108.08 14.61 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 108.116 -1.068 . . . . 10.0 108.116 170.79 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.684 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -84.92 147.04 22.45 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 123.995 0.807 . . . . 10.0 111.556 169.008 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mt -140.72 82.2 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 N-CA-C 105.946 -1.872 . . . . 10.0 105.946 177.013 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.0 mm -89.92 138.96 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 C-N-CA 124.002 0.921 . . . . 10.0 108.956 177.161 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -130.47 126.65 37.46 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 125.693 1.597 . . . . 10.0 109.552 175.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -109.87 105.21 14.31 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.267 1.427 . . . . 10.0 109.368 177.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -86.26 134.32 33.77 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 120.034 -0.666 . . . . 10.0 110.81 167.066 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -135.07 82.84 1.98 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.642 2.377 . . . . 10.0 106.136 168.074 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.4 tttp -53.01 -51.03 62.97 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 125.793 1.637 . . . . 10.0 109.454 179.404 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 58.8 mt-10 -135.95 169.17 18.02 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 105.932 -1.877 . . . . 10.0 105.932 169.279 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.2 p -72.41 -10.0 59.24 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.992 -0.374 . . . . 10.0 109.992 170.098 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.5 m-80 -75.41 -24.79 57.17 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.519 -0.549 . . . . 10.0 109.519 170.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.33 129.0 9.3 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.29 -1.124 . . . . 10.0 110.29 -173.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -63.2 131.06 30.8 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 N-CA-C 105.957 -2.363 . . . . 10.0 105.957 168.615 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.2 t -78.0 107.88 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.154 -1.054 . . . . 10.0 108.154 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.62 96.39 3.55 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 170.347 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -83.6 106.61 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 N-CA-C 106.494 -1.669 . . . . 10.0 106.494 170.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.1 p90 -113.91 171.12 7.79 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.47 0.653 . . . . 10.0 109.901 172.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.94 170.11 41.09 Favored Glycine 0 N--CA 1.437 -1.256 0 C-N-CA 120.088 -1.053 . . . . 10.0 110.564 174.119 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.3 p -137.98 107.97 6.36 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.486 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.684 HG22 ' CA ' ' A' ' 16' ' ' GLY . 1.7 pt -90.8 145.22 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 167.383 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -140.05 147.58 40.54 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.37 -1.344 . . . . 10.0 107.37 175.569 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.25 -14.13 25.81 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.287 -0.729 . . . . 10.0 114.108 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.442 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.6 mp -74.27 179.48 4.49 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 118.692 1.246 . . . . 10.0 110.475 -179.763 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -95.97 169.02 10.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 165.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -58.21 168.29 1.09 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.981 1.312 . . . . 10.0 111.532 -172.46 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.93 -176.61 36.31 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-O 122.039 0.8 . . . . 10.0 112.671 167.349 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.65 142.49 51.6 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 124.539 1.136 . . . . 10.0 109.681 177.158 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -142.05 150.42 41.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 112.896 0.702 . . . . 10.0 112.896 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.613 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.78 123.85 1.21 Allowed Glycine 0 C--N 1.34 0.786 0 C-N-CA 127.382 2.42 . . . . 10.0 112.061 166.227 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -151.88 108.5 3.47 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 118.563 1.181 . . . . 10.0 108.997 168.558 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 174.59 12.21 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 120.876 0.37 . . . . 10.0 111.354 177.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 11.1 m -104.77 -18.38 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 O-C-N 125.658 1.849 . . . . 10.0 114.676 -168.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 57.29 175.76 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 125.322 1.449 . . . . 10.0 112.861 -177.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -72.62 -69.45 0.41 Allowed 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.561 -0.745 . . . . 10.0 109.855 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -92.02 176.92 6.33 Favored 'General case' 0 N--CA 1.454 -0.256 0 O-C-N 123.534 0.521 . . . . 10.0 111.279 -168.668 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.12 -22.75 11.36 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 125.477 1.513 . . . . 10.0 111.556 170.048 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -50.81 117.9 2.79 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-O 122.343 1.068 . . . . 10.0 111.935 -177.252 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -123.14 17.84 9.96 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.988 -1.006 . . . . 10.0 111.552 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -48.42 -41.77 30.2 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.176 1.79 . . . . 10.0 111.562 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.11 -21.62 46.38 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.225 1.01 . . . . 10.0 112.763 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.0 102.31 0.92 Allowed Glycine 0 CA--C 1.527 0.825 0 N-CA-C 108.392 -1.883 . . . . 10.0 108.392 -169.331 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.276 1.5 p 15.75 80.42 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 127.031 2.132 . . . . 10.0 113.819 -173.391 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -161.38 -54.99 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 107.541 -1.281 . . . . 10.0 107.541 179.047 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -65.59 -31.38 72.38 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 123.8 0.84 . . . . 10.0 110.99 -177.624 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.97 -6.76 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 129.024 2.93 . . . . 10.0 118.012 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.36 123.26 3.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.212 -1.155 . . . . 10.0 110.212 176.183 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.7 60.49 6.67 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.582 2.855 . . . . 10.0 110.765 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 72.12 38.28 0.9 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 129.716 3.206 . . . . 10.0 112.584 172.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -74.53 67.94 1.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.386 0.994 . . . . 10.0 111.671 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.7 p-10 -58.97 154.71 36.92 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 123.947 0.899 . . . . 10.0 111.108 169.513 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.36 -46.15 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 122.656 2.238 . . . . 10.0 111.602 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 86.8 mt -75.53 59.79 1.15 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.266 0.627 . . . . 10.0 109.696 176.134 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -45.95 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.771 1.628 . . . . 10.0 111.558 -171.2 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -132.21 -176.54 4.11 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 107.237 -1.394 . . . . 10.0 107.237 -176.363 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.412 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 24.2 mttp -93.78 123.74 37.33 Favored 'General case' 0 N--CA 1.438 -1.068 0 C-N-CA 118.224 -1.39 . . . . 10.0 108.622 -169.512 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.432 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 85.9 t60 -35.2 112.53 0.16 Allowed 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 113.316 0.858 . . . . 10.0 113.316 178.659 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.03 -136.98 4.33 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 108.058 -2.017 . . . . 10.0 108.058 -178.519 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.06 -168.77 30.66 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 173.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -63.26 -2.8 4.25 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.025 1.817 . . . . 10.0 111.603 168.78 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -94.97 -19.92 19.81 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.265 1.026 . . . . 10.0 110.746 173.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -103.11 167.58 9.73 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -86.49 -31.99 21.02 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 107.322 -1.362 . . . . 10.0 107.322 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.412 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS 0.257 7.1 pt-20 -100.49 24.55 8.78 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 114.435 1.272 . . . . 10.0 114.435 -165.525 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.5 ptm180 -42.83 145.3 0.48 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 127.218 2.207 . . . . 10.0 110.346 168.261 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.432 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 30.9 m170 -67.61 -64.58 0.83 Allowed 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.52 0.676 . . . . 10.0 109.66 178.778 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.62 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.5 p -169.33 -91.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 105.472 -2.048 . . . . 10.0 105.472 173.358 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.62 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -80.51 56.32 4.7 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 111.04 -0.824 . . . . 10.0 111.04 174.629 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -90.9 83.16 5.64 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 103.342 -2.836 . . . . 10.0 103.342 166.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -65.26 -26.45 68.1 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 118.391 0.541 . . . . 10.0 109.821 -173.001 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 114.41 -89.08 0.5 Allowed Glycine 0 N--CA 1.44 -1.044 0 N-CA-C 108.082 -2.007 . . . . 10.0 108.082 169.428 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -155.52 124.82 6.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 -171.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.39 125.89 66.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 118.193 0.452 . . . . 10.0 110.84 178.506 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -78.82 112.01 15.54 Favored 'General case' 0 N--CA 1.444 -0.761 0 C-N-CA 127.554 2.341 . . . . 10.0 111.116 -177.612 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.74 134.79 34.16 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.863 0.465 . . . . 10.0 109.938 171.611 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -60.1 172.27 0.83 Allowed 'General case' 0 C--O 1.232 0.154 0 O-C-N 123.82 0.7 . . . . 10.0 109.441 168.36 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.5 pttm -48.67 -33.2 9.59 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.745 1.618 . . . . 10.0 109.793 173.176 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -79.1 -8.19 58.77 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 124.486 1.115 . . . . 10.0 110.812 -173.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.02 -0.26 86.01 Favored Glycine 0 C--N 1.338 0.678 0 N-CA-C 111.234 -0.746 . . . . 10.0 111.234 -174.247 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.5 t -78.43 105.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 106.776 -1.564 . . . . 10.0 106.776 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.53 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -106.23 117.47 34.12 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 169.695 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -80.37 118.05 21.67 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 127.123 2.169 . . . . 10.0 108.892 172.481 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.2 t -108.32 131.0 59.98 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.964 0 N-CA-C 106.862 -1.532 . . . . 10.0 106.862 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.2 p -157.36 86.81 0.95 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.455 0.702 . . . . 10.0 109.49 171.446 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.99 143.09 28.11 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 N-CA-C 107.991 -1.115 . . . . 10.0 107.991 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -111.61 129.5 56.06 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.816 -1.92 . . . . 10.0 105.816 167.069 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -140.54 117.69 11.26 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.042 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.5 p -87.15 49.42 1.81 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.891 1.676 . . . . 10.0 108.256 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 p -145.24 -51.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.478 -0.783 . . . . 10.0 109.433 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -51.11 132.36 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 122.926 0.49 . . . . 10.0 110.016 175.246 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.9 p -131.92 136.12 47.14 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.214 1.406 . . . . 10.0 108.551 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 50.1 mt -56.63 -42.69 79.3 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 169.445 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.8 t -146.07 128.88 16.3 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 149.54 69.4 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.771 -1.332 . . . . 10.0 109.771 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.7 t70 72.41 -60.25 0.53 Allowed 'General case' 0 CA--C 1.509 -0.633 0 C-N-CA 129.742 3.217 . . . . 10.0 109.482 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.7 m-70 -74.19 -44.71 52.3 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t 54.96 82.05 0.1 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.051 1.34 . . . . 10.0 111.714 173.259 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.5 pt -71.65 -18.16 19.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 O-C-N 120.999 -1.063 . . . . 10.0 112.699 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 16.2 mm -52.65 129.89 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 118.202 0.456 . . . . 10.0 110.156 172.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.58 22.57 77.06 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.684 -1.064 . . . . 10.0 113.644 175.699 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.9 mtt85 -89.08 175.75 7.26 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 118.235 1.018 . . . . 10.0 110.602 167.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -118.47 110.63 17.64 Favored 'General case' 0 C--N 1.347 0.486 0 N-CA-C 106.844 -1.539 . . . . 10.0 106.844 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mp -87.18 138.88 31.11 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.548 -0.908 . . . . 10.0 108.548 176.313 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 49.1 t -132.04 132.34 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.615 -1.254 . . . . 10.0 107.615 -173.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.487 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.5 OUTLIER -105.67 128.11 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 106.081 -1.822 . . . . 10.0 106.081 174.806 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.613 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.6 m170 -111.78 157.55 20.42 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 114.554 1.316 . . . . 10.0 114.554 -171.434 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -46.64 -59.52 2.97 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 127.572 2.349 . . . . 10.0 110.488 176.395 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 51.3 mttp -112.21 169.86 8.57 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.702 0.763 . . . . 10.0 112.042 -170.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.5 151.08 47.95 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 114.034 -1.439 . . . . 10.0 109.291 172.513 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -77.03 150.04 35.81 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 122.296 1.046 . . . . 10.0 110.944 172.649 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.476 ' HB3' ' CA ' ' A' ' 138' ' ' GLY . 4.4 t70 -79.04 -37.75 38.26 Favored 'General case' 0 N--CA 1.443 -0.824 0 C-N-CA 130.103 3.361 . . . . 10.0 110.596 172.853 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 48.5 mt 63.53 46.53 4.2 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.924 1.29 . . . . 10.0 111.656 178.423 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 79.64 10.24 86.0 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-N 115.23 -0.895 . . . . 10.0 114.703 167.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 26.8 mttm -97.06 -11.81 23.98 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 117.999 0.899 . . . . 10.0 112.18 -174.88 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.98 -21.45 69.68 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 125.124 1.345 . . . . 10.0 112.384 176.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.08 35.75 65.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.247 -0.741 . . . . 10.0 111.247 -177.215 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -129.89 169.94 14.56 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 173.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -52.43 -48.0 66.03 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 123.654 0.781 . . . . 10.0 109.628 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -58.98 -45.5 90.41 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 118.669 -0.682 . . . . 10.0 111.712 175.731 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.9 p -49.87 -43.59 49.32 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 109.206 -0.665 . . . . 10.0 109.206 177.657 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.1 t -84.3 -3.56 58.32 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -174.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 92.5 mttt -110.71 -69.58 0.86 Allowed 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.692 1.597 . . . . 10.0 111.85 -179.201 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -127.3 28.91 5.64 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 119.437 1.017 . . . . 10.0 109.935 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.476 ' CA ' ' HB3' ' A' ' 125' ' ' ASP . . . 66.84 -105.31 1.29 Allowed Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 107.519 -2.232 . . . . 10.0 107.519 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -157.3 42.6 0.33 Allowed 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 107.059 -1.46 . . . . 10.0 107.059 169.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.84 -12.38 53.87 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.606 0.762 . . . . 10.0 111.616 -175.649 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.81 -158.7 48.81 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.618 -1.393 . . . . 10.0 109.618 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.0 m -61.76 129.27 40.2 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 123.129 0.572 . . . . 10.0 111.599 -169.042 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -59.03 92.03 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.991 0.916 . . . . 10.0 109.661 169.286 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.4 mt -64.44 -41.58 96.49 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.444 -0.785 . . . . 10.0 111.309 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.487 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -152.0 148.89 28.26 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.731 0.301 . . . . 10.0 110.391 -172.144 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -124.24 146.68 48.58 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.679 1.591 . . . . 10.0 107.801 -169.426 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.85 156.65 27.03 Favored Glycine 0 CA--C 1.52 0.362 0 N-CA-C 108.545 -1.822 . . . . 10.0 108.545 168.569 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.8 t -119.69 134.91 61.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 -175.551 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.1 mt -75.66 138.44 20.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 CA-C-N 118.679 0.672 . . . . 10.0 111.014 -177.005 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -150.55 172.7 30.27 Favored Glycine 0 CA--C 1.53 0.984 0 N-CA-C 112.313 -0.315 . . . . 10.0 112.313 170.254 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 64.7 mt -72.79 142.4 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 125.194 1.397 . . . . 10.0 109.08 -169.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.421 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . . . -119.98 -48.22 2.36 Favored 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 123.4 0.68 . . . . 10.0 111.301 172.041 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 . . . . . 0 C--O 1.248 1.009 0 CA-C-O 116.685 -1.626 . . . . 10.0 110.026 -167.969 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.694 0 N-CA-C 105.631 -1.989 . . . . 10.0 105.631 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.24 76.88 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 120.055 1.298 . . . . 10.0 108.278 168.558 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.37 158.0 32.09 Favored 'General case' 0 C--O 1.242 0.667 0 C-N-CA 124.481 1.112 . . . . 10.0 109.576 168.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.14 158.51 41.93 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 127.04 2.136 . . . . 10.0 106.078 169.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 m -111.44 178.67 1.25 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 CA-C-N 118.365 0.53 . . . . 10.0 109.601 174.259 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.24 101.63 2.4 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 165.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.417 HG12 HG23 ' B' ' 17' ' ' ILE . 32.2 m -92.33 130.75 40.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 N-CA-C 107.863 -1.162 . . . . 10.0 107.863 172.579 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.448 ' N ' HD12 ' B' ' 8' ' ' LEU . 5.1 mp -110.05 155.7 21.51 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.32 1.048 . . . . 10.0 108.641 176.175 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.0 tttt -164.2 167.99 19.41 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 169.107 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.2 -48.42 0.1 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.047 -1.549 . . . . 10.0 112.29 168.589 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -76.08 -46.63 28.04 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 107.893 -1.151 . . . . 10.0 107.893 -177.537 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.76 -67.2 0.52 Allowed Glycine 0 CA--C 1.526 0.775 0 CA-C-N 114.483 -1.235 . . . . 10.0 110.604 178.055 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -62.5 -36.2 66.84 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 122.794 2.329 . . . . 10.0 110.68 171.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 89.2 t -72.82 113.91 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.93 134.13 27.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.764 -0.458 . . . . 10.0 109.764 166.199 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.52 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -101.96 154.38 18.71 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 124.635 1.112 . . . . 10.0 111.269 175.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.417 HG23 HG12 ' B' ' 7' ' ' VAL . 0.1 OUTLIER -153.31 81.5 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 -172.878 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -105.67 151.96 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 C-N-CA 125.216 1.407 . . . . 10.0 109.657 -175.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -126.17 118.4 25.13 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 127.199 2.199 . . . . 10.0 107.295 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -98.41 116.46 30.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 170.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -117.25 125.61 51.41 Favored 'General case' 0 N--CA 1.465 0.308 0 O-C-N 123.716 0.635 . . . . 10.0 112.61 169.588 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -81.34 106.49 13.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.404 -2.072 . . . . 10.0 105.404 169.079 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.0 tttt . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 124.869 1.268 . . . . 10.0 109.214 -171.497 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.995 0 N-CA-C 109.593 -1.403 . . . . 10.0 109.593 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -59.61 140.96 96.23 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.451 2.101 . . . . 10.0 108.292 174.085 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 p -79.89 103.56 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.537 0 N-CA-C 106.482 -1.673 . . . . 10.0 106.482 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.1 tttp -80.13 122.16 26.46 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 172.42 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.13 100.47 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 C-N-CA 127.566 2.346 . . . . 10.0 105.726 -178.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.8 p90 -125.56 155.71 40.24 Favored 'General case' 0 C--N 1.339 0.149 0 N-CA-C 112.986 0.735 . . . . 10.0 112.986 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.34 -145.86 13.68 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 106.383 -2.687 . . . . 10.0 106.383 173.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.5 p -157.35 168.16 28.18 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 118.798 -1.161 . . . . 10.0 111.998 177.226 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.613 HG12 ' HB3' ' B' ' 95' ' ' ALA . 1.8 pt -117.72 146.46 22.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 114.379 -1.282 . . . . 10.0 109.44 166.678 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.7 tptt -115.11 146.51 41.27 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 106.464 -1.68 . . . . 10.0 106.464 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.96 -10.1 37.27 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-O 119.538 -0.59 . . . . 10.0 114.073 168.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -62.0 174.45 0.87 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 118.181 0.99 . . . . 10.0 110.561 175.624 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -108.72 160.7 15.75 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 106.595 -1.631 . . . . 10.0 106.595 167.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -53.72 150.57 7.12 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.61 0.764 . . . . 10.0 111.962 -169.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.51 -172.64 23.19 Favored Glycine 0 CA--C 1.524 0.629 0 C-N-CA 123.496 0.569 . . . . 10.0 111.922 169.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -74.95 149.93 39.23 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.272 1.429 . . . . 10.0 111.594 -173.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -150.97 143.62 24.4 Favored 'General case' 0 C--N 1.342 0.24 0 N-CA-C 113.912 1.079 . . . . 10.0 113.912 -175.519 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.557 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -31.72 126.21 0.23 Allowed Glycine 0 C--N 1.341 0.808 0 C-N-CA 128.247 2.832 . . . . 10.0 112.38 166.019 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.464 ' CE1' HD12 ' B' ' 117' ' ' LEU . 0.1 OUTLIER -147.32 107.62 4.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 119.646 1.723 . . . . 10.0 109.887 167.303 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 176.54 9.75 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 109.718 -0.475 . . . . 10.0 109.718 174.506 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 47' ' ' VAL . . . . . 0.466 HG12 HD13 ' B' ' 117' ' ' LEU . 2.4 m -117.71 -15.48 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 125.134 1.521 . . . . 10.0 113.662 -173.107 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 58.15 171.7 0.05 Allowed 'General case' 0 C--N 1.345 0.412 0 CA-C-O 122.437 1.113 . . . . 10.0 111.661 175.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -72.37 -59.39 2.75 Favored 'General case' 0 N--CA 1.441 -0.885 0 O-C-N 121.507 -0.746 . . . . 10.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -87.04 156.62 19.68 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 121.831 -0.543 . . . . 10.0 109.546 -171.004 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.72 14.42 29.53 Favored Glycine 0 CA--C 1.524 0.62 0 C-N-CA 125.179 1.371 . . . . 10.0 110.754 177.845 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.498 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . 0.1 OUTLIER -93.77 175.23 6.81 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 121.918 0.866 . . . . 10.0 110.03 179.839 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.445 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -151.81 33.02 0.55 Allowed 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.055 -0.975 . . . . 10.0 111.165 169.241 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.23 -37.2 79.6 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.593 -0.692 . . . . 10.0 112.763 -168.742 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.57 -20.55 46.73 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 117.766 0.257 . . . . 10.0 111.146 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 123.72 -157.59 18.17 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 105.727 -2.949 . . . . 10.0 105.727 -167.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 2.8 t -65.27 7.72 0.19 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.06 1.744 . . . . 10.0 115.189 -169.514 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 62.2 m -97.74 -49.09 4.96 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 125.93 1.692 . . . . 10.0 108.544 -171.657 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.1 m -47.41 -39.96 16.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 126.326 1.85 . . . . 10.0 113.061 -166.482 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.89 -39.92 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 128.067 2.547 . . . . 10.0 113.929 168.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.3 162.84 15.23 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 121.44 -0.787 . . . . 10.0 111.951 167.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -86.7 37.94 0.54 Allowed 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.375 2.717 . . . . 10.0 111.885 -172.418 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 71.31 116.38 0.05 OUTLIER 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.38 2.272 . . . . 10.0 110.834 -170.271 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 64' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' B' ' 64' ' ' PHE . 0.0 OUTLIER -33.8 94.06 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 127.089 2.156 . . . . 10.0 113.268 165.922 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -105.69 32.71 0.05 OUTLIER Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 116.948 2.203 . . . . 10.0 116.948 -177.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -62.82 -55.88 0.73 Allowed 'Trans proline' 0 C--N 1.35 0.658 0 CA-C-N 122.951 2.09 . . . . 10.0 112.585 -172.462 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.03 41.88 0.45 Allowed 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.236 -0.915 . . . . 10.0 112.86 -176.308 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 88.0 p 17.41 69.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 128.48 2.712 . . . . 10.0 114.868 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.72 149.17 43.64 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 105.801 -1.926 . . . . 10.0 105.801 172.634 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 30.6 mttm -101.64 106.23 17.26 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 118.746 -0.645 . . . . 10.0 109.637 -168.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -2.33 87.46 0.0 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 126.596 1.959 . . . . 10.0 115.193 -178.361 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.49 -135.33 8.72 Favored Glycine 0 C--N 1.318 -0.465 0 N-CA-C 109.045 -1.622 . . . . 10.0 109.045 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.68 -168.82 37.88 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 107.467 -2.253 . . . . 10.0 107.467 173.039 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -65.25 -0.72 3.7 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 CA-C-N 119.561 1.68 . . . . 10.0 110.749 167.56 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.7 mtpm? -109.24 6.79 24.96 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 125.924 1.689 . . . . 10.0 111.0 175.476 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.99 174.14 10.95 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 165.61 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.3 -37.01 38.76 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.1 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -81.71 28.59 0.41 Allowed 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 125.433 1.493 . . . . 10.0 114.626 -165.454 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.67 134.89 41.61 Favored 'General case' 0 N--CA 1.456 -0.141 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 168.493 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -56.17 -66.43 0.43 Allowed 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.664 -0.495 . . . . 10.0 109.664 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 3.9 p -169.23 -46.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 O-C-N 124.262 0.976 . . . . 10.0 109.132 -176.548 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.79 53.67 0.79 Allowed Glycine 0 CA--C 1.536 1.379 0 CA-C-N 118.909 0.777 . . . . 10.0 111.865 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -89.38 99.35 12.36 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.655 -1.239 . . . . 10.0 107.655 172.718 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -70.49 -40.96 73.29 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.289 -1.375 . . . . 10.0 107.289 174.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.02 -93.42 1.03 Allowed Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 124.409 1.004 . . . . 10.0 112.266 168.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -127.66 123.69 36.14 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 123.779 0.832 . . . . 10.0 109.992 -168.06 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.3 m -119.95 150.31 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 N-CA-C 108.536 -0.913 . . . . 10.0 108.536 167.222 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -98.24 125.34 43.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.859 1.663 . . . . 10.0 109.204 -177.285 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.27 134.45 38.03 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 108.804 -0.813 . . . . 10.0 108.804 171.626 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.8 t0 -62.05 170.1 2.35 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 124.188 0.93 . . . . 10.0 109.565 167.414 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 9.4 pttm -52.19 -31.26 30.9 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 125.213 1.405 . . . . 10.0 111.246 173.093 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -81.91 -1.76 48.97 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.218 0.607 . . . . 10.0 111.386 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.37 9.32 86.65 Favored Glycine 0 C--N 1.339 0.717 0 O-C-N 120.787 -1.195 . . . . 10.0 111.216 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.3 t -80.62 106.11 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 126.2 1.8 . . . . 10.0 106.32 172.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.613 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -107.39 120.15 41.36 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.096 -1.076 . . . . 10.0 108.096 169.119 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -80.96 125.5 30.22 Favored 'General case' 0 N--CA 1.437 -1.112 0 C-N-CA 127.233 2.213 . . . . 10.0 109.762 176.397 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.2 t -111.03 133.71 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.957 0 C-N-CA 125.645 1.578 . . . . 10.0 108.105 175.455 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 96.9 p -157.63 57.61 0.49 Allowed 'General case' 0 C--O 1.235 0.303 0 C-N-CA 123.141 0.576 . . . . 10.0 111.207 169.863 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -93.38 144.52 9.3 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.287 0 N-CA-C 107.395 -1.335 . . . . 10.0 107.395 -172.174 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -90.98 128.13 36.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 167.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -107.06 100.93 10.38 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.278 -1.749 . . . . 10.0 106.278 166.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.77 24.14 4.33 Favored 'General case' 0 N--CA 1.44 -0.957 0 C-N-CA 126.688 1.995 . . . . 10.0 109.948 176.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 38.9 t -120.74 -55.86 3.31 Favored 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 -178.13 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.348 0.6 OUTLIER -94.3 178.03 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 C-N-CA 123.839 0.856 . . . . 10.0 113.266 -179.039 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 27.1 m -155.4 161.4 41.02 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 123.785 0.834 . . . . 10.0 110.109 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 92.5 mt -81.25 3.92 22.25 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 125.721 1.608 . . . . 10.0 112.456 -175.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 107.845 -1.168 . . . . 10.0 107.845 168.937 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 42.3 t . . . . . 0 N--CA 1.442 -0.868 0 N-CA-C 110.503 -0.184 . . . . 10.0 110.503 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 1.3 pt -79.04 57.53 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 122.372 1.082 . . . . 10.0 110.806 -171.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 19.4 mm -96.21 -37.8 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 C-N-CA 127.725 2.41 . . . . 10.0 110.474 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.75 49.92 0.81 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.563 -1.015 . . . . 10.0 110.563 -175.379 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.57 169.52 8.65 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.864 2.065 . . . . 10.0 108.746 175.108 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -122.91 103.37 8.57 Favored 'General case' 0 C--N 1.344 0.353 0 C-N-CA 124.837 1.255 . . . . 10.0 109.955 -177.026 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.466 HD13 HG12 ' B' ' 47' ' ' VAL . 1.1 mm? -61.85 134.57 56.86 Favored 'General case' 0 CA--C 1.52 -0.183 0 N-CA-C 108.152 -1.055 . . . . 10.0 108.152 169.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.45 132.78 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 107.924 -1.139 . . . . 10.0 107.924 176.086 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 m -108.27 134.43 50.15 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 O-C-N 124.282 0.989 . . . . 10.0 110.366 167.415 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.557 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.3 m170 -110.54 158.0 19.03 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -171.529 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -40.22 -57.18 1.77 Allowed 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 129.272 3.029 . . . . 10.0 111.192 173.537 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 mttm -123.85 175.18 7.06 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.902 1.281 . . . . 10.0 109.495 -175.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.17 149.56 33.72 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.766 0.826 . . . . 10.0 109.708 175.431 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -74.92 152.84 38.81 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.78 -1.193 . . . . 10.0 107.78 168.699 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -76.15 -5.79 48.28 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 124.591 1.182 . . . . 10.0 110.719 171.694 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 50.5 mt 51.03 58.15 5.87 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 124.32 1.048 . . . . 10.0 108.798 -177.785 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.42 -39.44 3.12 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 124.93 1.252 . . . . 10.0 111.261 169.365 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.8 mtmt -79.13 47.19 0.76 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.211 1.004 . . . . 10.0 111.373 -178.343 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.57 -22.31 10.48 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 126.891 2.186 . . . . 10.0 111.298 174.302 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.18 44.41 43.06 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.055 0.836 . . . . 10.0 112.784 176.58 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -151.49 172.84 15.35 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 108.797 -0.816 . . . . 10.0 108.797 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -51.75 -41.53 61.65 Favored 'General case' 0 N--CA 1.445 -0.72 0 C-N-CA 122.96 0.504 . . . . 10.0 111.652 -176.44 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -71.59 -25.0 62.0 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.33 -0.856 . . . . 10.0 111.891 178.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 36.8 p -59.96 -20.8 59.54 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 113.61 0.967 . . . . 10.0 113.61 -177.136 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.4 t -94.75 -12.81 26.47 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.622 0.646 . . . . 10.0 110.258 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -109.32 -65.96 1.1 Allowed 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 126.7 2.0 . . . . 10.0 111.514 -171.723 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.02 31.4 3.87 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 120.266 1.394 . . . . 10.0 110.857 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 65.04 -93.57 0.16 Allowed Glycine 0 C--N 1.343 0.933 0 N-CA-C 108.859 -1.696 . . . . 10.0 108.859 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -164.43 39.73 0.08 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.709 1.204 . . . . 10.0 108.402 167.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.04 -11.84 58.21 Favored 'General case' 0 N--CA 1.456 -0.167 0 N-CA-C 113.637 0.977 . . . . 10.0 113.637 -168.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.44 -165.22 53.64 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.427 -1.069 . . . . 10.0 110.427 177.474 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.3 t -57.02 130.9 48.1 Favored 'General case' 0 N--CA 1.447 -0.611 0 C-N-CA 123.812 0.845 . . . . 10.0 112.217 -168.082 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -64.21 76.61 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.107 1.363 . . . . 10.0 110.171 170.13 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.8 mt -53.78 -36.9 62.91 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 112.735 0.643 . . . . 10.0 112.735 -177.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 148.4 28.29 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 109.884 -0.413 . . . . 10.0 109.884 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 p -155.54 132.85 10.93 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.2 1.0 . . . . 10.0 108.911 -169.233 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.88 -162.02 10.82 Favored Glycine 0 CA--C 1.52 0.382 0 C-N-CA 123.84 0.733 . . . . 10.0 111.973 -173.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 7.1 t -138.9 153.18 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 104.684 -2.339 . . . . 10.0 104.684 168.508 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.3 mt -67.49 -88.17 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 123.784 0.834 . . . . 10.0 110.409 -169.743 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.33 134.02 8.07 Favored Glycine 0 CA--C 1.534 1.235 0 O-C-N 121.64 -0.662 . . . . 10.0 112.326 178.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 88.5 mt -72.31 144.97 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 125.143 1.377 . . . . 10.0 109.529 -176.616 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -124.21 -50.53 1.79 Allowed 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.974 0.909 . . . . 10.0 110.633 176.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 . . . . . 0 C--O 1.25 1.104 0 C-N-CA 125.011 1.324 . . . . 10.0 112.688 -171.931 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.1 t -104.55 -11.11 17.16 Favored 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.921 1.288 . . . . 10.0 110.605 -178.378 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 15.5 ptmt -155.22 160.77 41.1 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.76 168.44 22.93 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 126.871 2.068 . . . . 10.0 108.778 -177.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 m -126.37 169.23 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 C-N-CA 123.038 0.535 . . . . 10.0 110.825 175.261 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.51 107.68 6.07 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 107.132 -1.433 . . . . 10.0 107.132 165.466 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.469 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.6 OUTLIER -87.26 95.13 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 C-N-CA 123.549 0.74 . . . . 10.0 109.008 173.768 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -78.76 126.18 30.37 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 107.888 -1.153 . . . . 10.0 107.888 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.4 mptt -146.87 155.15 42.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 168.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.18 -65.91 0.03 OUTLIER Glycine 0 N--CA 1.46 0.272 0 C-N-CA 118.842 -1.646 . . . . 10.0 112.925 169.3 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -71.66 -43.74 65.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 107.205 -1.406 . . . . 10.0 107.205 -177.67 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 148.37 -71.1 0.32 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 114.324 -1.307 . . . . 10.0 111.351 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -56.71 -37.69 97.27 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 122.87 2.38 . . . . 10.0 112.078 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 m -72.23 87.19 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 108.529 -0.915 . . . . 10.0 108.529 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -104.19 108.36 19.69 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.097 -1.816 . . . . 10.0 106.097 -178.771 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.432 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -96.47 141.13 15.43 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.036 -0.826 . . . . 10.0 111.036 172.679 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.63 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.0 mt -139.37 81.83 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 -177.903 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -90.87 146.83 5.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 C-N-CA 123.529 0.732 . . . . 10.0 109.509 175.544 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -129.0 114.42 16.39 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.6 2.36 . . . . 10.0 107.331 177.199 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -93.74 115.65 28.08 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 172.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -117.87 137.8 52.54 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.804 0.729 . . . . 10.0 111.507 168.86 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -134.19 91.79 2.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.266 2.226 . . . . 10.0 106.235 -178.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -51.26 -38.66 53.86 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 125.581 1.552 . . . . 10.0 112.473 -168.512 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -152.23 -179.22 7.34 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 105.803 -1.925 . . . . 10.0 105.803 171.426 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.9 p -72.18 -18.96 61.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 118.14 0.427 . . . . 10.0 110.074 -178.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -83.81 -17.31 41.46 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 124.224 1.01 . . . . 10.0 109.438 175.286 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.63 147.84 30.01 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.647 -0.981 . . . . 10.0 110.647 175.031 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.26 170.99 15.85 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.443 2.095 . . . . 10.0 108.682 168.691 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.1 t -87.33 104.92 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 106.197 -1.779 . . . . 10.0 106.197 170.392 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -84.88 113.99 21.78 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 104.784 -2.302 . . . . 10.0 104.784 168.378 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.17 98.78 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.023 -1.473 . . . . 10.0 107.023 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.3 p90 -113.16 179.9 3.83 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.893 0.378 . . . . 10.0 110.705 174.343 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.74 -154.53 22.68 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.701 -2.16 . . . . 10.0 107.701 168.517 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 61.3 p -155.36 155.41 33.61 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 118.678 -1.209 . . . . 10.0 112.304 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.741 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -115.69 135.8 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 C-N-CA 126.229 1.812 . . . . 10.0 107.031 171.474 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -121.3 150.04 42.01 Favored 'General case' 0 CA--C 1.528 0.105 0 N-CA-C 107.354 -1.35 . . . . 10.0 107.354 170.669 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.77 -21.54 18.41 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-N 119.146 0.884 . . . . 10.0 114.161 175.259 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.5 mt -62.94 179.52 0.37 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 125.29 1.436 . . . . 10.0 111.652 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -103.75 175.54 5.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.777 -1.102 . . . . 10.0 108.107 166.092 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -64.28 169.73 4.36 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.054 0.942 . . . . 10.0 111.765 -171.054 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.76 -173.73 28.48 Favored Glycine 0 C--O 1.223 -0.583 0 C-N-CA 124.347 0.975 . . . . 10.0 111.841 167.499 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.88 148.73 47.48 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.854 0.862 . . . . 10.0 109.107 169.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.1 m-70 -141.53 143.46 33.78 Favored 'General case' 0 C--N 1.34 0.18 0 N-CA-C 113.718 1.007 . . . . 10.0 113.718 -177.156 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.798 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -18.14 116.41 0.01 OUTLIER Glycine 0 C--N 1.339 0.721 0 C-N-CA 129.104 3.24 . . . . 10.0 115.061 163.759 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -149.41 98.32 2.77 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 120.208 2.004 . . . . 10.0 114.609 174.388 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -144.85 170.85 15.34 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.649 0.78 . . . . 10.0 112.16 178.664 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.4 t -105.5 -28.09 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 128.355 2.662 . . . . 10.0 112.827 -168.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.5 m-70 63.03 176.08 0.15 Allowed 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.586 1.154 . . . . 10.0 112.451 178.362 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -92.47 -64.83 1.06 Allowed 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.582 -0.736 . . . . 10.0 110.855 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -79.21 148.92 32.08 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 119.174 -1.01 . . . . 10.0 109.615 -176.444 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.0 -25.71 33.56 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 109.797 -1.321 . . . . 10.0 109.797 169.58 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -62.06 166.57 4.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 123.093 1.425 . . . . 10.0 112.897 -176.076 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.434 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -162.56 21.55 0.1 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.482 -1.235 . . . . 10.0 113.137 -169.907 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.454 HG22 HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -52.44 -35.23 51.78 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 124.797 1.239 . . . . 10.0 111.823 -176.556 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.05 -19.79 53.62 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 122.892 0.477 . . . . 10.0 112.138 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.84 107.0 1.22 Allowed Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.741 -1.343 . . . . 10.0 109.741 -172.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.1 m 34.75 59.91 0.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.357 1.863 . . . . 10.0 112.046 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.5 m -153.77 -54.24 0.11 Allowed 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.577 -0.897 . . . . 10.0 108.577 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -51.19 -39.5 56.62 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.857 1.263 . . . . 10.0 110.768 -173.149 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -29.67 -38.51 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 128.526 2.73 . . . . 10.0 114.786 168.47 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.49 131.63 6.65 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.125 -1.19 . . . . 10.0 110.125 172.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.94 64.78 3.29 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.531 2.821 . . . . 10.0 112.36 174.611 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 69.86 38.09 1.68 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 128.527 2.731 . . . . 10.0 111.926 168.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -73.19 26.64 0.06 Allowed 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 115.372 1.619 . . . . 10.0 115.372 -170.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -46.22 150.72 1.05 Allowed Pre-proline 0 CA--C 1.54 0.558 0 C-N-CA 125.0 1.32 . . . . 10.0 112.703 -170.152 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -52.88 -52.86 7.87 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.087 2.524 . . . . 10.0 112.348 -173.28 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -77.06 61.14 1.97 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.9 -0.778 . . . . 10.0 108.9 169.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.4 t -60.02 113.99 2.61 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 106.877 -1.527 . . . . 10.0 106.877 178.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.68 -81.13 0.41 Allowed 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 109.41 -0.589 . . . . 10.0 109.41 -175.227 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -145.53 150.67 36.85 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-O 122.31 1.053 . . . . 10.0 110.91 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 52.8 t60 -64.69 117.88 8.1 Favored 'General case' 0 N--CA 1.447 -0.623 0 C-N-CA 119.146 -1.021 . . . . 10.0 108.642 166.194 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.97 -132.45 2.58 Favored Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 107.465 -2.254 . . . . 10.0 107.465 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.1 -160.79 24.62 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 109.13 -1.588 . . . . 10.0 109.13 177.744 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -60.75 -6.91 6.52 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.767 1.645 . . . . 10.0 110.973 167.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -85.21 -27.54 26.03 Favored 'General case' 0 N--CA 1.445 -0.68 0 C-N-CA 124.529 1.132 . . . . 10.0 109.942 175.806 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -106.63 154.83 20.34 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.938 -1.134 . . . . 10.0 107.938 -173.575 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -85.37 -24.69 27.47 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 115.073 -0.967 . . . . 10.0 109.052 169.039 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -101.39 14.39 32.12 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.585 0.587 . . . . 10.0 112.585 -173.37 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -43.1 149.72 0.2 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.19 2.196 . . . . 10.0 110.181 171.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -77.46 48.86 0.68 Allowed 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.2 -0.937 . . . . 10.0 112.61 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 26.0 t 33.66 49.38 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 126.099 1.759 . . . . 10.0 110.561 -177.375 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.47 42.55 0.03 OUTLIER Glycine 0 CA--C 1.532 1.156 0 CA-C-N 116.11 -0.495 . . . . 10.0 114.014 -169.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -118.01 111.87 19.51 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 104.466 -2.42 . . . . 10.0 104.466 168.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.8 mt -79.51 -29.92 41.7 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 119.75 1.159 . . . . 10.0 108.783 174.558 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.49 -83.82 0.36 Allowed Glycine 0 C--O 1.221 -0.683 0 N-CA-C 111.22 -0.752 . . . . 10.0 111.22 167.185 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -155.64 143.5 19.78 Favored 'General case' 0 CA--C 1.517 -0.318 0 N-CA-C 107.909 -1.145 . . . . 10.0 107.909 -176.125 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -130.93 135.24 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 O-C-N 123.68 0.612 . . . . 10.0 110.299 174.353 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -79.31 108.46 12.84 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 127.232 2.213 . . . . 10.0 111.849 -175.024 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.54 130.17 35.3 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.21 1.404 . . . . 10.0 111.036 173.323 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -59.6 168.53 1.61 Allowed 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 124.311 1.007 . . . . 10.0 109.984 167.251 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -53.97 -29.83 44.5 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.754 0.821 . . . . 10.0 112.023 171.017 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.79 -3.57 42.03 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.033 0.382 . . . . 10.0 112.033 177.366 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.18 3.88 88.59 Favored Glycine 0 C--N 1.337 0.601 0 O-C-N 120.971 -1.08 . . . . 10.0 111.53 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.83 97.73 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 106.673 -1.603 . . . . 10.0 106.673 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.741 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -101.23 121.94 42.77 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 169.482 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -96.13 127.37 42.08 Favored 'General case' 0 C--N 1.329 -0.292 0 O-C-N 124.118 0.886 . . . . 10.0 109.377 174.287 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.7 t -108.81 139.53 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 C-N-CA 126.789 2.035 . . . . 10.0 108.934 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 95.4 p -156.39 70.35 0.66 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.694 1.198 . . . . 10.0 110.204 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 8.6 mm -106.53 167.45 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 C-N-CA 125.143 1.377 . . . . 10.0 109.303 -174.809 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 66.3 tt0 -155.35 123.16 5.71 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 127.224 2.21 . . . . 10.0 108.487 -170.212 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -155.74 158.23 37.85 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 104.37 -2.456 . . . . 10.0 104.37 173.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 15.1 p -106.14 -19.56 13.68 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 126.301 1.841 . . . . 10.0 111.751 -177.311 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 70.4 t -77.05 -38.68 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 -169.588 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.292 0.0 OUTLIER -76.19 54.43 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 C-N-CA 124.356 1.063 . . . . 10.0 112.3 178.677 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.93 145.03 52.21 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.229 1.012 . . . . 10.0 111.329 -169.774 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 76.0 mt -47.62 -52.84 16.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.352 0.596 . . . . 10.0 110.478 176.433 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.3 m -150.44 158.43 44.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 125.28 1.432 . . . . 10.0 107.354 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.9 -67.8 0.25 Allowed Glycine 0 C--N 1.335 0.492 0 N-CA-C 109.609 -1.396 . . . . 10.0 109.609 -176.285 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -155.82 -53.16 0.09 Allowed 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 126.904 2.082 . . . . 10.0 106.315 178.645 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.1 -37.62 64.09 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 114.197 -1.365 . . . . 10.0 108.771 -173.003 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.6 t 47.57 91.6 0.01 OUTLIER 'General case' 0 C--O 1.232 0.182 0 C-N-CA 127.112 2.165 . . . . 10.0 113.872 168.123 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 17.6 pt -68.13 -27.34 36.87 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 119.956 -0.697 . . . . 10.0 111.78 174.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -49.79 126.32 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 119.584 1.084 . . . . 10.0 109.911 175.298 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.74 14.68 79.35 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-O 118.457 -1.191 . . . . 10.0 114.424 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.507 ' HB2' HD12 ' A' ' 149' ' ' ILE . 5.8 mmt-85 -84.27 -179.46 7.2 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.092 1.357 . . . . 10.0 109.084 166.698 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -136.9 104.23 5.41 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -179.451 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.65 ' CD1' HD11 ' A' ' 149' ' ' ILE . 8.9 mp -72.82 146.08 46.53 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 108.3 -1.0 . . . . 10.0 108.3 173.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.2 t -129.04 131.89 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.18 0 N-CA-C 107.17 -1.419 . . . . 10.0 107.17 175.616 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.7 p -99.69 136.93 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 106.837 -1.542 . . . . 10.0 106.837 168.449 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.798 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 14.4 m-70 -114.74 160.7 19.09 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 114.516 1.302 . . . . 10.0 114.516 -173.141 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -60.39 -60.12 4.32 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 114.847 -1.07 . . . . 10.0 108.638 173.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -90.38 164.76 14.19 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.735 -0.786 . . . . 10.0 112.007 -170.798 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.47 147.76 37.66 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 106.951 -1.499 . . . . 10.0 106.951 169.552 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.52 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 27.7 m-20 -98.41 141.22 31.56 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 123.546 0.739 . . . . 10.0 109.441 -169.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 -72.32 -20.86 61.42 Favored 'General case' 0 N--CA 1.46 0.061 0 CA-C-O 120.822 0.344 . . . . 10.0 110.705 -173.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.5 mt 55.21 42.54 30.43 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 -167.83 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.98 -15.46 62.96 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 126.494 1.997 . . . . 10.0 113.194 171.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -76.88 -2.24 32.52 Favored 'General case' 0 CA--C 1.535 0.381 0 N-CA-C 114.443 1.275 . . . . 10.0 114.443 -167.446 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.17 -16.25 64.28 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 118.562 0.619 . . . . 10.0 111.983 174.408 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.01 40.89 67.2 Favored Glycine 0 CA--C 1.527 0.824 0 CA-C-N 117.981 0.89 . . . . 10.0 110.983 -178.067 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -128.3 161.91 28.29 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.477 -1.675 . . . . 10.0 106.477 177.086 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.403 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 3.0 tm-20 -53.34 -50.14 65.62 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.269 -1.382 . . . . 10.0 107.269 169.048 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -52.95 -44.25 66.95 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 115.382 -0.827 . . . . 10.0 112.11 172.494 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 23.1 p -57.4 -39.14 75.5 Favored 'General case' 0 N--CA 1.445 -0.677 0 O-C-N 120.449 -1.407 . . . . 10.0 110.763 -178.089 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.1 t -85.98 6.26 29.53 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 111.731 0.271 . . . . 10.0 111.731 -179.323 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.403 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 27.7 mmtp -106.75 -84.86 0.51 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.708 1.603 . . . . 10.0 109.241 171.306 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -95.47 -12.22 26.23 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 121.242 1.837 . . . . 10.0 112.841 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 80.58 32.97 32.34 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -168.58 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 53.69 44.69 29.33 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.376 1.088 . . . . 10.0 111.103 -178.06 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.13 -2.49 13.14 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.38 0.672 . . . . 10.0 112.256 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 94.95 -67.01 1.28 Allowed Glycine 0 C--N 1.336 0.556 0 O-C-N 120.921 -1.112 . . . . 10.0 111.215 169.368 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -166.89 175.21 7.86 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 -178.375 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -105.86 98.93 8.56 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.414 1.886 . . . . 10.0 106.981 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.437 ' CD2' ' N ' ' A' ' 144' ' ' LEU . 0.6 OUTLIER -84.93 -25.22 28.0 Favored 'General case' 0 C--O 1.232 0.178 0 C-N-CA 122.956 0.502 . . . . 10.0 110.963 -167.856 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 139.29 10.96 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.582 -0.896 . . . . 10.0 108.582 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 97.1 m -118.99 144.79 46.3 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.472 1.509 . . . . 10.0 107.657 -177.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.64 134.27 5.39 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.695 -0.962 . . . . 10.0 110.695 173.409 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -95.63 134.0 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 106.958 -1.497 . . . . 10.0 106.958 -170.761 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.65 HD11 ' CD1' ' A' ' 117' ' ' LEU . 9.4 mt -76.49 115.84 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 N-CA-C 110.517 -0.179 . . . . 10.0 110.517 -168.826 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.89 136.91 13.83 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.033 0.825 . . . . 10.0 111.515 -175.336 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 68.8 mt -54.7 138.44 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 C-N-CA 125.67 1.588 . . . . 10.0 108.433 173.559 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.57 -47.75 1.96 Allowed 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 123.265 0.626 . . . . 10.0 111.02 176.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.952 -1.975 . . . . 10.0 113.148 -174.245 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.923 0 CA-C-O 116.423 -1.751 . . . . 10.0 107.306 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . 0.254 1.9 t -141.0 -49.46 0.43 Allowed 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 120.493 1.497 . . . . 10.0 113.072 174.629 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -103.4 129.56 50.52 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 107.833 -1.173 . . . . 10.0 107.833 169.76 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.3 158.12 44.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 169.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.8 m -121.02 172.66 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.159 0 CA-C-N 117.89 0.314 . . . . 10.0 110.168 175.149 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.2 98.56 3.76 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.342 -1.355 . . . . 10.0 107.342 167.172 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.434 HG21 ' HB3' ' A' ' 53' ' ' ASN . 13.2 m -83.39 104.89 12.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.256 -1.016 . . . . 10.0 108.256 169.39 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.5 mt -92.71 145.2 24.6 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.011 -0.737 . . . . 10.0 109.011 -177.667 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 46.0 tttt -160.46 161.07 32.79 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 173.027 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.27 -51.01 0.05 OUTLIER Glycine 0 C--O 1.228 -0.271 0 CA-C-N 116.347 -0.388 . . . . 10.0 112.272 169.323 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.7 -45.78 34.87 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 -170.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.08 -67.85 0.54 Allowed Glycine 0 N--CA 1.442 -0.934 0 CA-C-N 113.672 -1.603 . . . . 10.0 110.292 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -56.25 -42.87 61.64 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.547 2.165 . . . . 10.0 110.543 171.117 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.434 HG13 HD11 ' B' ' 38' ' ' LEU . 53.9 t -63.66 114.13 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 -179.351 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.0 121.01 28.75 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.665 -1.605 . . . . 10.0 106.665 168.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.599 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -97.65 144.08 17.09 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 168.83 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.454 HG22 HG22 ' A' ' 54' ' ' THR . 1.3 mt -144.2 71.29 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.097 -1.446 . . . . 10.0 107.097 -176.704 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -94.1 141.58 14.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 O-C-N 122.042 -0.411 . . . . 10.0 109.938 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.7 m-80 -110.46 128.05 55.42 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 126.034 1.733 . . . . 10.0 109.48 171.741 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -109.4 98.01 7.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 174.543 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -105.24 124.18 49.09 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.599 0.714 . . . . 10.0 112.34 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 tt0 -91.36 99.18 12.19 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.201 1.801 . . . . 10.0 108.241 176.586 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.3 tttt . . . . . 0 N--CA 1.441 -0.887 0 C-N-CA 126.956 2.102 . . . . 10.0 110.17 179.857 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.68 0 N-CA-C 108.78 -1.728 . . . . 10.0 108.78 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -62.71 141.04 83.9 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 N-CA-C 108.097 -1.54 . . . . 10.0 108.097 170.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.4 t -87.19 109.39 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 105.322 -2.103 . . . . 10.0 105.322 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -76.93 113.18 14.35 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.645 -1.983 . . . . 10.0 105.645 168.78 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.47 102.19 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 171.088 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -120.73 154.71 35.25 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.202 0.525 . . . . 10.0 112.039 176.818 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.28 -168.59 36.58 Favored Glycine 0 N--CA 1.444 -0.831 0 N-CA-C 109.616 -1.393 . . . . 10.0 109.616 169.744 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.8 p -144.78 113.26 6.62 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 109.061 -0.718 . . . . 10.0 109.061 -169.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.599 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.4 pt -78.79 170.7 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.063 -1.088 . . . . 10.0 108.063 167.736 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -154.13 154.35 33.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.343 -0.984 . . . . 10.0 108.343 166.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.35 -15.62 32.6 Favored Glycine 0 CA--C 1.525 0.677 0 CA-C-O 119.139 -0.812 . . . . 10.0 114.08 177.245 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.453 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.7 mp -71.91 -179.21 2.62 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 118.757 1.278 . . . . 10.0 110.918 177.064 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -101.51 175.34 5.6 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.54 -0.911 . . . . 10.0 108.54 166.5 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -51.07 164.57 0.15 Allowed 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.23 2.212 . . . . 10.0 113.214 -173.031 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.76 -170.68 55.04 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 124.16 0.886 . . . . 10.0 114.008 165.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.96 141.76 54.86 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.127 1.771 . . . . 10.0 111.798 -175.605 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.4 m-70 -138.58 123.89 19.31 Favored 'General case' 0 C--N 1.339 0.115 0 C-N-CA 125.013 1.325 . . . . 10.0 109.847 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.42 127.83 1.75 Allowed Glycine 0 C--N 1.346 1.086 0 C-N-CA 126.839 2.161 . . . . 10.0 109.637 171.132 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.564 ' CE1' HG13 ' B' ' 87' ' ' VAL 0.274 0.3 OUTLIER -145.67 123.82 12.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 119.041 1.42 . . . . 10.0 112.406 168.139 . . . . . . . . 4 4 . 1 . 015 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.429 ' NE2' ' OD2' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -160.33 175.64 12.6 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.573 -0.74 . . . . 10.0 111.719 -174.264 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.2 m -88.72 153.43 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 O-C-N 125.697 1.873 . . . . 10.0 107.807 167.64 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 64.6 m-70 -134.72 95.04 3.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 108.329 -0.989 . . . . 10.0 108.329 177.438 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 24.43 -87.54 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 127.228 2.211 . . . . 10.0 114.24 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -78.87 161.76 26.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 122.734 1.254 . . . . 10.0 111.883 -169.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.44 -32.53 57.68 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 108.261 -1.936 . . . . 10.0 108.261 169.138 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -39.48 150.74 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 125.978 1.711 . . . . 10.0 113.929 176.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.469 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.6 OUTLIER -157.17 21.17 0.3 Allowed 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 113.882 -1.508 . . . . 10.0 113.081 178.527 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.63 HG23 ' CG2' ' A' ' 17' ' ' ILE . 6.0 m -41.69 -48.7 4.2 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.512 1.125 . . . . 10.0 113.093 -167.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.09 -25.36 47.53 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.891 0.876 . . . . 10.0 112.859 -176.393 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.17 104.15 2.6 Favored Glycine 0 CA--C 1.528 0.905 0 N-CA-C 109.544 -1.422 . . . . 10.0 109.544 -169.269 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 17.9 m 49.72 48.51 21.49 Favored 'General case' 0 N--CA 1.462 0.165 0 C-N-CA 125.474 1.51 . . . . 10.0 112.757 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -154.51 -55.86 0.1 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.6 m -50.56 -43.62 56.3 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.496 1.118 . . . . 10.0 111.45 -171.045 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.84 -51.47 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 128.005 2.522 . . . . 10.0 114.033 168.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.08 162.74 11.52 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.603 -1.399 . . . . 10.0 109.603 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -71.71 -164.68 0.17 Allowed 'Trans proline' 0 N--CA 1.447 -1.232 0 N-CA-C 105.019 -2.723 . . . . 10.0 105.019 163.72 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -81.47 53.55 2.12 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 119.288 -2.132 . . . . 10.0 109.72 -176.505 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -69.91 88.22 0.56 Allowed 'General case' 0 C--O 1.225 -0.225 0 CA-C-O 122.984 1.373 . . . . 10.0 109.383 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 -96.34 151.2 37.95 Favored Pre-proline 0 C--N 1.325 -0.463 0 C-N-CA 127.236 2.214 . . . . 10.0 110.605 -176.56 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.4 -42.88 4.82 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.803 2.335 . . . . 10.0 111.282 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 77.0 mt -77.89 55.03 1.35 Allowed 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.829 0.852 . . . . 10.0 110.587 -178.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -38.28 101.77 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 126.752 2.021 . . . . 10.0 112.063 -171.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -140.38 -175.79 4.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.361 -1.348 . . . . 10.0 107.361 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -94.26 127.67 40.26 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -178.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -36.87 113.26 0.23 Allowed 'General case' 0 C--O 1.225 -0.207 0 O-C-N 123.639 0.587 . . . . 10.0 112.035 176.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.09 -137.09 5.65 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 177.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.409 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 168.44 -153.72 22.98 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.487 -2.245 . . . . 10.0 107.487 169.848 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -64.27 6.64 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.939 0 CA-C-N 120.635 2.217 . . . . 10.0 112.346 169.541 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.409 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.0 mmmt -121.4 12.26 10.84 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 126.978 2.111 . . . . 10.0 110.287 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -151.73 158.01 42.8 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 118.945 0.793 . . . . 10.0 108.919 168.025 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -79.39 -26.69 41.9 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 173.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -79.81 5.79 12.71 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 124.671 1.189 . . . . 10.0 112.82 -169.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt180 -35.23 120.75 0.55 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.796 1.639 . . . . 10.0 110.571 168.429 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.8 m170 -52.32 -53.55 43.0 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.506 1.122 . . . . 10.0 112.566 -170.057 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -178.03 -47.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 C-N-CA 125.667 1.587 . . . . 10.0 107.74 178.129 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.19 56.0 0.74 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.511 -1.435 . . . . 10.0 109.511 178.68 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -91.98 86.69 5.93 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 105.0 -2.222 . . . . 10.0 105.0 168.522 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 84' ' ' LEU . . . . . 0.516 ' HB3' ' CZ ' ' B' ' 45' ' ' PHE . 5.4 mp -72.98 -30.54 63.9 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 106.908 -1.516 . . . . 10.0 106.908 176.098 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.95 -93.18 0.86 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 124.687 1.137 . . . . 10.0 110.439 165.771 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 p30 -151.88 141.22 21.49 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.084 0.554 . . . . 10.0 110.021 -173.801 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.564 HG13 ' CE1' ' B' ' 45' ' ' PHE . 0.2 OUTLIER -128.6 138.87 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 C-N-CA 124.451 1.1 . . . . 10.0 111.677 179.219 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.4 m -79.17 115.05 18.6 Favored 'General case' 0 N--CA 1.437 -1.116 0 C-N-CA 128.821 2.849 . . . . 10.0 110.635 -177.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.7 134.17 38.94 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 123.855 0.862 . . . . 10.0 110.154 171.176 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -57.51 171.2 0.46 Allowed 'General case' 0 C--O 1.233 0.192 0 O-C-N 123.982 0.801 . . . . 10.0 109.634 167.46 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.63 -29.6 38.78 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 123.874 0.87 . . . . 10.0 110.955 173.322 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -79.08 -7.6 58.27 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.126 0.489 . . . . 10.0 111.203 -178.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.04 -0.24 72.25 Favored Glycine 0 C--N 1.338 0.684 0 O-C-N 121.195 -0.94 . . . . 10.0 111.001 -175.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 55.7 t -78.95 101.35 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 107.518 -1.289 . . . . 10.0 107.518 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.421 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -99.4 118.09 35.25 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.825 -1.176 . . . . 10.0 107.825 168.799 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.49 125.59 29.58 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 106.829 -1.545 . . . . 10.0 106.829 169.016 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 59.3 t -107.97 128.95 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 N-CA-C 105.385 -2.079 . . . . 10.0 105.385 169.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 73.0 m -152.72 59.85 0.8 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.798 0.839 . . . . 10.0 108.783 175.3 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.6 151.24 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 N-CA-C 108.138 -1.06 . . . . 10.0 108.138 -173.223 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -130.18 141.3 50.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.417 1.087 . . . . 10.0 109.155 170.292 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -149.27 161.03 42.84 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 29.7 p -122.6 4.89 9.55 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 127.237 2.215 . . . . 10.0 111.894 -172.462 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -84.14 -42.53 17.13 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 N-CA-C 107.699 -1.222 . . . . 10.0 107.699 177.131 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.283 0.0 OUTLIER -71.31 159.37 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 123.959 0.904 . . . . 10.0 113.228 172.378 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -160.04 155.0 24.59 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.202 -1.407 . . . . 10.0 107.202 170.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -82.14 55.88 2.98 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 108.129 -1.063 . . . . 10.0 108.129 169.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.5 t . . . . . 0 CA--C 1.542 0.648 0 C-N-CA 126.598 1.959 . . . . 10.0 108.666 177.246 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.3 t . . . . . 0 N--CA 1.455 -0.222 0 N-CA-C 115.575 1.694 . . . . 10.0 115.575 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 34.8 pt -73.51 6.2 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 N-CA-C 112.823 0.675 . . . . 10.0 112.823 171.344 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 9.1 mm -56.95 -67.13 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.311 0 CA-C-N 119.352 0.978 . . . . 10.0 111.458 -176.403 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -81.63 56.1 4.89 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 120.856 -1.152 . . . . 10.0 111.924 -175.664 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.1 mmt-85 -122.4 150.57 42.27 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.929 1.291 . . . . 10.0 107.957 176.295 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 116' ' ' THR . . . . . 0.456 ' C ' HD12 ' B' ' 117' ' ' LEU . 1.1 m -92.24 129.26 38.23 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 104.065 -2.569 . . . . 10.0 104.065 168.7 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.456 HD12 ' C ' ' B' ' 116' ' ' THR . 10.9 mp -112.16 145.42 39.86 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.415 -0.957 . . . . 10.0 108.415 169.522 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.408 HG12 ' CD2' ' B' ' 120' ' ' HIS . 94.1 t -122.93 145.81 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 -171.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.501 HG13 ' HB3' ' B' ' 145' ' ' ALA . 1.5 p -117.2 122.74 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 C-N-CA 126.769 2.027 . . . . 10.0 106.473 169.5 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.408 ' CD2' HG12 ' B' ' 118' ' ' VAL . 10.2 m170 -105.29 167.22 9.87 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 115.722 1.749 . . . . 10.0 115.722 -168.463 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -59.29 -66.06 0.57 Allowed 'General case' 0 C--O 1.223 -0.29 0 C-N-CA 125.887 1.675 . . . . 10.0 110.186 174.155 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -107.06 177.71 4.77 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 118.817 0.735 . . . . 10.0 112.137 -169.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.08 144.13 48.81 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.683 1.193 . . . . 10.0 110.567 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.429 ' OD2' ' NE2' ' B' ' 46' ' ' HIS . 19.5 m-20 -89.59 149.36 22.88 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 109.091 -0.707 . . . . 10.0 109.091 168.039 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -76.76 -11.23 59.81 Favored 'General case' 0 N--CA 1.453 -0.289 0 O-C-N 124.73 1.269 . . . . 10.0 111.01 176.202 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 18.0 mt 57.37 40.05 27.8 Favored 'General case' 0 N--CA 1.457 -0.105 0 CA-C-N 118.26 0.482 . . . . 10.0 109.757 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 106.98 -33.41 6.43 Favored Glycine 0 CA--C 1.525 0.664 0 C-N-CA 125.325 1.44 . . . . 10.0 112.29 173.633 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.49 42.63 0.84 Allowed 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 118.471 1.135 . . . . 10.0 110.674 -169.29 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.71 -20.83 12.15 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.142 1.83 . . . . 10.0 111.743 -176.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.34 45.73 44.73 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 123.972 0.796 . . . . 10.0 112.554 178.477 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -152.03 172.43 16.29 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.444 0.622 . . . . 10.0 109.74 175.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 12.8 tm-20 -52.2 -43.78 64.37 Favored 'General case' 0 N--CA 1.443 -0.807 0 C-N-CA 123.699 0.799 . . . . 10.0 111.834 -176.272 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -72.43 -30.02 64.23 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.397 -0.815 . . . . 10.0 111.097 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 30.0 p -50.44 -40.42 50.4 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 119.419 1.009 . . . . 10.0 111.341 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -85.03 -13.79 49.4 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 123.793 0.683 . . . . 10.0 112.405 -175.808 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.2 ttmt -107.86 -48.75 3.34 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 126.841 2.056 . . . . 10.0 112.431 -166.611 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.9 p -131.93 -9.85 3.45 Favored 'General case' 0 C--O 1.224 -0.274 0 CA-C-O 116.794 -1.574 . . . . 10.0 112.258 169.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.0 -105.98 3.08 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 107.089 -2.404 . . . . 10.0 107.089 -166.394 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -171.81 21.53 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 115.187 1.551 . . . . 10.0 115.187 -176.702 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.09 -14.91 62.56 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 120.853 -1.154 . . . . 10.0 111.976 -178.215 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.53 -117.58 5.0 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.348 -1.901 . . . . 10.0 108.348 169.256 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 112.11 6.33 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 112.575 0.583 . . . . 10.0 112.575 -167.798 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.84 73.84 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.405 1.082 . . . . 10.0 109.938 166.172 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.9 mt -51.59 -45.2 63.07 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.783 0.66 . . . . 10.0 112.783 -175.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.501 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -151.27 156.82 41.62 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -168.047 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.0 p -163.4 170.13 17.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.951 -0.388 . . . . 10.0 109.951 -173.52 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.89 162.33 33.0 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.343 -1.503 . . . . 10.0 109.343 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.91 129.46 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 105.644 -1.984 . . . . 10.0 105.644 -176.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 22.6 mt -69.55 160.98 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 CA-C-N 118.773 0.715 . . . . 10.0 110.03 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.01 166.27 39.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 125.529 1.538 . . . . 10.0 109.919 -173.724 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 95.5 mt -74.29 134.56 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 C-N-CA 124.858 1.263 . . . . 10.0 109.785 -169.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.57 -35.25 3.59 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 112.795 0.665 . . . . 10.0 112.795 176.328 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.252 1.186 0 CA-C-O 116.953 -1.498 . . . . 10.0 108.893 174.508 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t -162.34 -43.77 0.04 OUTLIER 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 118.904 0.774 . . . . 10.0 110.795 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -118.41 138.52 52.39 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.579 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.34 155.68 49.13 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 124.148 0.905 . . . . 10.0 109.482 175.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -121.8 148.82 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 C-N-CA 125.618 1.567 . . . . 10.0 109.183 -176.239 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.33 100.85 4.36 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 108.022 -1.103 . . . . 10.0 108.022 167.131 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.481 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.2 m -79.51 100.99 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 109.055 -0.72 . . . . 10.0 109.055 171.571 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.9 mt -81.17 142.76 32.91 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -158.23 160.27 36.96 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 173.331 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -165.25 -60.68 0.02 OUTLIER Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.41 -0.424 . . . . 10.0 112.153 171.049 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -74.72 -45.86 41.39 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 106.644 -1.613 . . . . 10.0 106.644 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.69 -64.46 0.61 Allowed Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 114.021 -1.445 . . . . 10.0 111.203 -176.197 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -52.45 -42.74 59.33 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.06 1.84 . . . . 10.0 111.058 173.156 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.405 ' CG2' ' HB2' ' A' ' 145' ' ' ALA . 1.3 m -72.16 113.78 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.269 -1.011 . . . . 10.0 108.269 177.35 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -119.49 120.99 38.41 Favored 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 104.783 -2.303 . . . . 10.0 104.783 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.786 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -101.22 141.46 15.34 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.275 -1.93 . . . . 10.0 108.275 169.345 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.7 mt -137.16 67.26 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.069 -1.086 . . . . 10.0 108.069 -173.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.1 mm -77.06 133.86 29.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 109.4 -0.593 . . . . 10.0 109.4 -178.245 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -121.25 98.58 6.04 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.517 1.927 . . . . 10.0 107.6 -178.378 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.441 ' CD2' HG12 ' A' ' 31' ' ' VAL . 74.6 m-85 -81.27 128.79 34.19 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 118.155 -0.926 . . . . 10.0 108.616 177.612 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.77 122.21 43.81 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.619 0.768 . . . . 10.0 110.723 171.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -122.27 103.17 8.58 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.793 2.037 . . . . 10.0 106.483 168.508 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -61.77 -60.96 2.88 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 122.709 0.403 . . . . 10.0 110.467 -174.851 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -128.43 177.51 6.93 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 104.31 -2.478 . . . . 10.0 104.31 169.504 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.5 p -73.87 -17.17 61.08 Favored 'General case' 0 C--N 1.322 -0.594 0 O-C-N 122.114 -0.367 . . . . 10.0 110.578 -175.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.2 m-80 -79.2 -22.37 45.0 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.984 0.914 . . . . 10.0 109.461 172.45 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.64 124.73 18.83 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 109.91 -1.276 . . . . 10.0 109.91 179.325 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.92 141.95 86.34 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 N-CA-C 107.097 -1.924 . . . . 10.0 107.097 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 71.0 t -79.54 116.93 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 107.786 -1.19 . . . . 10.0 107.786 -169.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -88.91 108.4 19.53 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.122 -1.807 . . . . 10.0 106.122 177.696 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.441 HG12 ' CD2' ' A' ' 20' ' ' PHE . 18.6 m -101.32 90.59 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 125.328 1.451 . . . . 10.0 108.122 -177.756 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -101.49 167.5 10.11 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 122.03 0.919 . . . . 10.0 110.777 168.145 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.19 162.2 28.05 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.578 -1.409 . . . . 10.0 109.578 171.312 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.3 m -128.28 102.39 6.66 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 176.099 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.786 HG22 ' HA2' ' A' ' 16' ' ' GLY . 8.8 pt -77.08 176.32 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 N-CA-C 108.133 -1.062 . . . . 10.0 108.133 170.037 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.9 pttt -153.89 149.1 26.97 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 106.942 -1.503 . . . . 10.0 106.942 169.357 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.35 -24.24 12.7 Favored Glycine 0 C--N 1.338 0.654 0 CA-C-O 119.248 -0.751 . . . . 10.0 114.438 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.46 HD13 HD12 ' A' ' 35' ' ' ILE . 6.8 mp -65.56 175.92 1.66 Allowed 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 118.414 1.107 . . . . 10.0 111.063 -175.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -89.77 148.12 23.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.378 -0.828 . . . . 10.0 110.284 171.576 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -39.59 125.47 1.78 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.867 2.467 . . . . 10.0 110.938 174.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 121.42 -174.64 15.99 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 123.602 0.62 . . . . 10.0 112.961 171.415 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.64 151.91 44.45 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.806 1.642 . . . . 10.0 111.234 -178.02 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -148.27 143.3 26.86 Favored 'General case' 0 C--N 1.343 0.31 0 N-CA-C 113.524 0.935 . . . . 10.0 113.524 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.56 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.86 122.75 0.14 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.853 2.644 . . . . 10.0 110.917 165.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.92 106.41 4.42 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 119.989 1.894 . . . . 10.0 110.259 172.557 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -158.06 172.54 18.25 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-O 121.797 0.808 . . . . 10.0 111.764 -177.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 9.8 p -100.05 152.62 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-N 112.418 -2.174 . . . . 10.0 109.366 171.283 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -128.08 135.47 49.87 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 176.561 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -51.31 -61.77 2.03 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.318 1.447 . . . . 10.0 112.309 -168.323 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -83.9 147.79 27.31 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 119.539 -0.865 . . . . 10.0 109.516 -178.125 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.06 9.12 58.36 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 124.919 1.247 . . . . 10.0 111.321 170.811 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -67.56 98.45 0.68 Allowed 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 123.547 1.642 . . . . 10.0 110.907 -178.184 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.34 14.73 30.85 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 111.516 -2.584 . . . . 10.0 110.588 167.727 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.584 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -71.45 -40.95 70.0 Favored 'General case' 0 C--N 1.339 0.152 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 168.516 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -20.22 48.79 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.414 0.524 . . . . 10.0 112.414 170.682 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.02 78.83 1.37 Allowed Glycine 0 CA--C 1.529 0.909 0 N-CA-C 111.322 -0.711 . . . . 10.0 111.322 178.501 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.4 p 37.39 43.17 0.37 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 126.841 2.057 . . . . 10.0 114.292 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.2 m -133.14 -57.74 0.91 Allowed 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 105.682 -1.97 . . . . 10.0 105.682 -178.301 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -55.99 -29.05 59.7 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 122.823 0.449 . . . . 10.0 109.934 169.109 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.03 -27.7 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.564 1.545 . . . . 10.0 113.382 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.54 124.26 5.38 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-O 117.751 -1.583 . . . . 10.0 109.57 168.801 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -72.31 65.46 3.58 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.066 3.177 . . . . 10.0 111.69 176.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.6 m170 67.09 46.58 1.51 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 130.338 3.455 . . . . 10.0 111.868 176.754 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -70.48 64.68 0.28 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.194 0.597 . . . . 10.0 111.595 178.533 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -73.31 142.19 81.49 Favored Pre-proline 0 CA--C 1.533 0.292 0 O-C-N 120.154 -1.591 . . . . 10.0 109.102 172.582 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -57.94 -34.28 98.16 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.563 2.175 . . . . 10.0 111.591 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.45 -17.48 63.86 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.201 0.815 . . . . 10.0 113.201 177.358 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.4 t 20.75 81.93 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 127.495 2.318 . . . . 10.0 114.726 175.276 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.0 mtt180 -111.32 -84.73 0.57 Allowed 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 105.546 -2.02 . . . . 10.0 105.546 -177.356 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.09 160.56 41.07 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 109.131 -0.692 . . . . 10.0 109.131 167.557 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.0 t60 -56.74 126.68 27.94 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.316 -1.735 . . . . 10.0 106.316 165.032 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.39 -136.32 3.13 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 107.343 -2.303 . . . . 10.0 107.343 176.09 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 164.68 -150.64 18.98 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 108.982 -1.647 . . . . 10.0 108.982 169.569 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -68.11 19.22 0.13 Allowed 'Trans proline' 0 N--CA 1.453 -0.911 0 CA-C-N 119.77 1.785 . . . . 10.0 112.307 173.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 59.9 mttt -120.87 -11.66 8.92 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 118.161 -0.923 . . . . 10.0 111.243 169.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -143.6 118.44 9.93 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 104.856 -2.276 . . . . 10.0 104.856 -168.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 36.2 tp10 -75.11 -16.5 60.55 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 107.68 -1.23 . . . . 10.0 107.68 -171.541 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -82.56 11.11 6.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 C-N-CA 125.803 1.641 . . . . 10.0 111.991 175.656 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.8 ptt-85 -43.86 153.13 0.14 Allowed 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.76 1.624 . . . . 10.0 113.674 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -72.09 160.73 31.98 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 107.334 -1.358 . . . . 10.0 107.334 166.082 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.6 p -38.38 -47.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 125.358 1.463 . . . . 10.0 114.259 -172.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.74 55.0 0.76 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 123.396 0.522 . . . . 10.0 111.975 -177.25 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -82.47 93.5 7.26 Favored 'General case' 0 CA--C 1.528 0.126 0 N-CA-C 105.38 -2.082 . . . . 10.0 105.38 166.142 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -71.61 -28.94 64.14 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 106.79 -1.559 . . . . 10.0 106.79 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.63 -104.01 2.7 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 106.867 -2.493 . . . . 10.0 106.867 168.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -126.4 131.09 51.82 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.883 -1.155 . . . . 10.0 107.883 -169.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.98 135.58 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 119.076 0.853 . . . . 10.0 110.834 170.602 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.74 110.83 15.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.429 2.692 . . . . 10.0 110.51 -177.288 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.9 132.31 37.15 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.182 -0.673 . . . . 10.0 109.182 169.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -53.97 168.43 0.21 Allowed 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 125.047 1.339 . . . . 10.0 110.635 168.648 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 22.2 tttp -47.7 -35.43 9.64 Favored 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 125.654 1.582 . . . . 10.0 112.231 169.109 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -78.27 -9.84 59.4 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 121.203 0.525 . . . . 10.0 111.896 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.35 11.86 60.51 Favored Glycine 0 C--N 1.337 0.621 0 O-C-N 120.887 -1.133 . . . . 10.0 110.891 -177.132 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.3 t -92.19 103.92 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 125.749 1.62 . . . . 10.0 107.705 -178.272 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.43 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -98.88 121.72 41.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 109.052 -0.722 . . . . 10.0 109.052 169.633 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -84.6 86.16 7.34 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 127.528 2.331 . . . . 10.0 109.884 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.46 129.82 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.251 0 N-CA-C 105.67 -1.974 . . . . 10.0 105.67 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -158.18 72.06 0.61 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 122.986 0.514 . . . . 10.0 110.728 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -116.71 163.71 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.161 -1.792 . . . . 10.0 106.161 -178.016 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.66 144.85 39.83 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.571 0.623 . . . . 10.0 110.475 167.659 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -129.56 125.9 37.32 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 125.074 1.349 . . . . 10.0 110.205 -169.549 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 69.3 p -98.4 53.25 1.04 Allowed 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 107.172 -1.418 . . . . 10.0 107.172 169.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -157.24 -45.25 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 C-N-CA 124.085 0.954 . . . . 10.0 109.29 -175.608 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -74.23 145.09 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 167.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -133.08 157.15 46.0 Favored 'General case' 0 CA--C 1.528 0.124 0 N-CA-C 107.782 -1.192 . . . . 10.0 107.782 168.502 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.1 mt -95.39 -34.1 12.25 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 108.429 -0.952 . . . . 10.0 108.429 167.496 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.0 m -156.73 67.25 0.55 Allowed 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 124.486 1.114 . . . . 10.0 108.614 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -165.05 63.24 0.23 Allowed Glycine 0 C--N 1.333 0.365 0 N-CA-C 108.037 -2.025 . . . . 10.0 108.037 -179.313 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 69.75 -57.89 0.54 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 129.712 3.205 . . . . 10.0 109.532 -174.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -82.48 33.23 0.41 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 123.43 0.692 . . . . 10.0 111.416 -168.554 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.2 t -52.43 104.1 0.08 Allowed 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 126.618 1.967 . . . . 10.0 110.524 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 30.3 pt -86.06 23.55 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 C-N-CA 123.352 0.661 . . . . 10.0 111.787 171.432 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 20.8 mm -64.45 143.44 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 O-C-N 120.407 -1.433 . . . . 10.0 108.394 173.02 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.89 19.01 67.17 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-O 119.198 -0.779 . . . . 10.0 114.509 177.763 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.477 ' HD3' HD11 ' B' ' 151' ' ' ILE . 4.3 mmt-85 -88.29 176.4 7.24 Favored 'General case' 0 C--O 1.232 0.18 0 N-CA-C 107.76 -1.2 . . . . 10.0 107.76 167.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -121.08 132.66 55.01 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 106.841 -1.541 . . . . 10.0 106.841 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.9 mp -99.41 147.56 25.12 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.343 -1.354 . . . . 10.0 107.343 169.483 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.424 HG12 ' CD2' ' A' ' 120' ' ' HIS . 90.4 t -127.23 133.63 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.795 -1.557 . . . . 10.0 106.795 170.62 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.8 p -103.77 125.33 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.581 0 N-CA-C 103.913 -2.625 . . . . 10.0 103.913 167.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.56 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.2 m170 -105.56 160.6 15.05 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.052 1.406 . . . . 10.0 114.365 -168.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 -41.48 -58.15 1.99 Allowed 'General case' 0 N--CA 1.444 -0.773 0 C-N-CA 128.088 2.555 . . . . 10.0 109.702 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -124.81 176.96 6.26 Favored 'General case' 0 C--N 1.338 0.093 0 C-N-CA 125.791 1.636 . . . . 10.0 110.85 -174.06 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.69 135.92 33.34 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.143 0.977 . . . . 10.0 109.891 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.55 143.3 36.64 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.433 1.893 . . . . 10.0 111.897 177.787 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.75 19.95 0.26 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.986 1.314 . . . . 10.0 112.132 178.516 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 40.1 48.08 2.13 Favored 'General case' 0 C--O 1.226 -0.137 0 C-N-CA 126.25 1.82 . . . . 10.0 112.622 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 105.93 -11.31 45.09 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-O 118.781 -1.011 . . . . 10.0 113.437 173.113 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -120.96 40.6 3.52 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.743 0.771 . . . . 10.0 112.185 -166.276 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.28 -15.34 66.86 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 126.035 1.779 . . . . 10.0 112.323 173.815 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.7 49.19 78.88 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 118.417 1.109 . . . . 10.0 113.023 175.145 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.499 ' H ' ' HB2' ' A' ' 134' ' ' SER . 39.8 m-80 -161.12 167.63 25.88 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 127.35 2.26 . . . . 10.0 105.095 -177.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -46.31 -47.89 18.33 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.791 0.805 . . . . 10.0 111.026 172.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -56.74 -33.24 66.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.253 -0.885 . . . . 10.0 111.715 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.499 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 11.0 t -45.65 -46.59 14.71 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 125.064 1.346 . . . . 10.0 109.346 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.6 t -91.68 0.92 57.46 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 112.395 0.517 . . . . 10.0 112.395 -173.177 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -113.18 -81.64 0.59 Allowed 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 126.054 1.741 . . . . 10.0 110.537 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.4 p -111.23 22.82 14.78 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 121.176 1.807 . . . . 10.0 111.02 172.397 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 -88.51 0.41 Allowed Glycine 0 C--N 1.341 0.816 0 N-CA-C 109.932 -1.267 . . . . 10.0 109.932 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -173.77 40.17 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 125.895 1.678 . . . . 10.0 109.069 172.036 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.21 -4.18 9.73 Favored 'General case' 0 C--N 1.34 0.164 0 O-C-N 121.543 -0.723 . . . . 10.0 112.224 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.56 -166.99 53.85 Favored Glycine 0 N--CA 1.441 -0.987 0 N-CA-C 109.259 -1.537 . . . . 10.0 109.259 179.174 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.6 t -62.41 146.15 52.15 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 122.457 1.122 . . . . 10.0 111.324 -168.618 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.07 64.22 0.06 Allowed 'General case' 0 N--CA 1.444 -0.743 0 C-N-CA 126.837 2.055 . . . . 10.0 109.145 171.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.63 -19.16 64.64 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 113.206 0.817 . . . . 10.0 113.206 -168.721 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.405 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . . . -155.36 145.7 21.91 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.398 0.544 . . . . 10.0 110.129 172.369 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.9 m -146.85 158.51 43.93 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 123.852 0.861 . . . . 10.0 109.492 -167.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.92 167.09 36.5 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.472 -1.051 . . . . 10.0 110.472 175.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.8 t -116.28 142.01 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 107.398 -1.334 . . . . 10.0 107.398 -169.308 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 11.0 mt -80.03 113.68 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 123.291 0.636 . . . . 10.0 110.52 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.07 152.32 17.59 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.244 1.402 . . . . 10.0 111.728 -178.475 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 84.0 mt -73.55 141.32 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 124.562 1.145 . . . . 10.0 109.179 -178.053 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.69 -48.16 2.59 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 123.35 0.66 . . . . 10.0 110.764 176.28 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.1 tt0 . . . . . 0 C--O 1.25 1.125 0 C-N-CA 127.268 2.227 . . . . 10.0 112.146 -172.114 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 108.684 -0.858 . . . . 10.0 108.684 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 2' ' ' THR . . . . . 0.498 HG23 ' HG3' ' B' ' 3' ' ' LYS . 15.0 t -91.46 -30.19 16.61 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 123.169 0.587 . . . . 10.0 111.149 -179.073 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 3' ' ' LYS . . . . . 0.498 ' HG3' HG23 ' B' ' 2' ' ' THR . 12.4 mtpt -124.44 127.9 48.21 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 124.882 1.273 . . . . 10.0 111.1 -175.527 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.01 155.47 49.93 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.957 0.503 . . . . 10.0 110.751 171.188 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.2 m -114.55 165.05 10.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.421 1.088 . . . . 10.0 109.346 171.712 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 6' ' ' ALA . . . . . 0.433 ' HB2' HG12 ' B' ' 149' ' ' ILE . . . -153.69 104.59 2.72 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 106.417 -1.697 . . . . 10.0 106.417 166.667 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -106.4 125.23 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 109.217 -0.66 . . . . 10.0 109.217 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.436 ' N ' HD12 ' B' ' 8' ' ' LEU . 4.1 mp -104.44 152.07 22.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.919 1.288 . . . . 10.0 109.352 -172.392 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 9' ' ' LYS . . . . . 0.409 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 44.8 tttt -160.0 162.64 34.34 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 169.863 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 175.0 -43.25 0.12 Allowed Glycine 0 C--O 1.228 -0.242 0 C-N-CA 119.768 -1.206 . . . . 10.0 113.682 168.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -74.22 -46.19 43.4 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.9 -72.37 0.33 Allowed Glycine 0 CA--C 1.52 0.348 0 N-CA-C 109.679 -1.368 . . . . 10.0 109.679 171.523 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -58.9 -39.23 83.17 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 123.211 2.607 . . . . 10.0 110.834 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.4 t -59.72 110.59 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -121.03 113.62 20.33 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 104.495 -2.409 . . . . 10.0 104.495 168.674 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.74 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -91.04 143.53 16.68 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 108.236 -1.946 . . . . 10.0 108.236 172.66 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.584 ' CG2' HG23 ' A' ' 54' ' ' THR . 3.0 mt -143.04 91.43 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 -176.419 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -104.31 138.66 28.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 C-N-CA 124.785 1.234 . . . . 10.0 109.29 178.081 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -122.84 122.35 38.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 126.38 1.872 . . . . 10.0 108.769 169.648 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -102.75 126.2 49.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 107.363 -1.347 . . . . 10.0 107.363 176.771 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -116.53 135.95 53.39 Favored 'General case' 0 C--O 1.233 0.203 0 O-C-N 123.759 0.662 . . . . 10.0 110.986 167.74 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.2 tt0 -119.52 114.15 21.83 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 106.095 -1.817 . . . . 10.0 106.095 168.456 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.4 mmpt? . . . . . 0 N--CA 1.453 -0.313 0 C-N-CA 123.912 0.885 . . . . 10.0 110.028 -169.828 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.21 0 N-CA-C 111.437 -0.665 . . . . 10.0 111.437 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_endo -62.63 159.45 36.8 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.874 2.383 . . . . 10.0 108.737 170.65 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 41.1 t -86.74 115.99 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.22 0 N-CA-C 105.325 -2.102 . . . . 10.0 105.325 169.477 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 38.8 tttp -92.07 112.45 24.39 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 168.57 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -94.44 100.66 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 C-N-CA 127.32 2.248 . . . . 10.0 106.484 176.543 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 23.3 p90 -112.77 171.32 7.6 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.304 0.573 . . . . 10.0 111.11 169.712 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.66 170.24 38.28 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.869 -0.892 . . . . 10.0 110.869 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.6 m -148.94 95.14 2.36 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.666 -1.605 . . . . 10.0 106.666 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.74 HG22 ' HA2' ' B' ' 16' ' ' GLY . 7.9 pt -75.8 176.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 108.725 -0.842 . . . . 10.0 108.725 173.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 36' ' ' LYS . . . . . 0.417 ' HE3' ' HB2' ' B' ' 36' ' ' LYS . 17.1 ptmt -156.57 164.8 37.77 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 163.285 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.69 -13.73 59.3 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 119.341 -0.7 . . . . 10.0 113.168 172.065 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.448 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.8 mp -69.71 176.69 3.42 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 118.568 1.184 . . . . 10.0 110.211 172.422 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.0 t -94.06 166.66 12.03 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 107.427 -1.324 . . . . 10.0 107.427 165.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.27 171.46 1.03 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.475 1.11 . . . . 10.0 112.21 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.18 179.89 39.64 Favored Glycine 0 C--N 1.334 0.428 0 C-N-CA 123.943 0.783 . . . . 10.0 112.074 168.488 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -66.99 142.6 57.19 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.632 0.773 . . . . 10.0 109.083 176.609 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.4 m-70 -139.68 151.79 46.19 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 123.087 0.555 . . . . 10.0 112.476 177.154 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.669 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -36.44 121.47 0.68 Allowed Glycine 0 C--N 1.341 0.822 0 C-N-CA 129.323 3.344 . . . . 10.0 110.883 166.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -149.59 115.21 5.58 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 119.335 1.567 . . . . 10.0 110.022 168.727 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.533 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.59 168.34 27.1 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-O 121.601 0.715 . . . . 10.0 111.406 176.401 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 7.7 m -93.28 148.88 4.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 111.957 -2.383 . . . . 10.0 105.389 166.744 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -121.91 153.55 38.3 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 174.622 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 49' ' ' GLU . . . . . 0.483 ' CD ' ' HA3' ' B' ' 61' ' ' GLY . 2.6 pm0 -40.1 -43.42 1.61 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 127.719 2.408 . . . . 10.0 115.403 -175.289 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -115.21 159.03 21.45 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 124.793 1.237 . . . . 10.0 109.264 -170.654 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.01 -7.71 63.96 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 126.009 1.766 . . . . 10.0 110.983 169.665 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -42.86 151.21 0.13 Allowed 'General case' 0 C--O 1.239 0.515 0 CA-C-O 123.174 1.464 . . . . 10.0 112.494 169.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.481 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -162.46 21.68 0.1 Allowed 'General case' 0 N--CA 1.437 -1.096 0 CA-C-N 112.485 -2.143 . . . . 10.0 111.997 167.955 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.83 -35.54 76.81 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.736 0.698 . . . . 10.0 110.821 -169.796 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.75 -17.6 55.54 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.602 1.161 . . . . 10.0 112.254 175.208 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.85 -173.2 17.25 Favored Glycine 0 N--CA 1.442 -0.909 0 N-CA-C 106.844 -2.502 . . . . 10.0 106.844 -167.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 60.1 m -66.53 69.96 0.07 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.311 1.444 . . . . 10.0 108.424 172.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -153.53 -53.04 0.1 Allowed 'General case' 0 N--CA 1.444 -0.774 0 O-C-N 120.693 -1.254 . . . . 10.0 109.617 -168.166 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.4 t -96.22 -1.26 48.55 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.874 0.87 . . . . 10.0 110.203 -178.069 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.31 47.3 0.37 Allowed 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.811 1.244 . . . . 10.0 112.225 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 61' ' ' GLY . . . . . 0.483 ' HA3' ' CD ' ' B' ' 49' ' ' GLU . . . 85.05 131.57 2.43 Favored Glycine 0 N--CA 1.44 -1.097 0 N-CA-C 117.479 1.752 . . . . 10.0 117.479 162.782 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -92.69 23.88 0.51 Allowed 'Trans proline' 0 CA--C 1.545 1.069 0 C-N-CA 123.135 2.557 . . . . 10.0 113.282 168.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.504 ' CD2' HG22 ' B' ' 137' ' ' THR . 21.1 m170 86.77 35.16 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 129.231 3.012 . . . . 10.0 112.352 176.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.24 70.34 0.16 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.319 1.048 . . . . 10.0 111.588 173.182 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -70.13 155.61 93.18 Favored Pre-proline 0 CA--C 1.536 0.413 0 C-N-CA 123.12 0.568 . . . . 10.0 109.965 170.715 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.57 -48.24 2.39 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 121.965 1.777 . . . . 10.0 110.815 176.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 tt -75.67 63.8 1.63 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.265 1.426 . . . . 10.0 109.205 -175.778 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -45.06 102.02 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 128.042 2.537 . . . . 10.0 113.143 -168.381 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.3 mtp85 -129.1 178.06 6.68 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 126.049 1.74 . . . . 10.0 108.027 175.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -111.94 56.98 0.64 Allowed 'General case' 0 C--O 1.226 -0.171 0 N-CA-C 113.12 0.785 . . . . 10.0 113.12 -167.15 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 67.8 t60 44.98 85.81 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 122.959 1.361 . . . . 10.0 114.069 175.448 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.65 -161.11 25.9 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 168.249 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.546 ' HA3' HD22 ' B' ' 126' ' ' LEU . . . -171.21 -152.99 8.6 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 107.043 -2.423 . . . . 10.0 107.043 173.662 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.42 8.44 0.12 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 120.15 1.975 . . . . 10.0 112.631 169.179 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.4 mttt -123.69 -0.49 8.58 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 117.419 -1.277 . . . . 10.0 113.066 175.351 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.32 163.55 32.71 Favored 'General case' 0 C--N 1.346 0.439 0 CA-C-N 120.629 1.559 . . . . 10.0 108.602 174.57 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -77.03 -30.29 55.67 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 177.017 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -76.58 26.07 0.13 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.651 1.58 . . . . 10.0 113.077 -166.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 18.1 mtm180 -47.58 129.5 13.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 107.392 -1.336 . . . . 10.0 107.392 168.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.1 m170 -67.67 -57.59 6.13 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 121.237 0.541 . . . . 10.0 109.932 176.783 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.8 p -163.82 -58.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 109.072 -0.714 . . . . 10.0 109.072 -176.31 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -137.23 62.91 0.58 Allowed Glycine 0 C--N 1.337 0.6 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 178.696 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -90.78 90.74 8.07 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.371 -1.344 . . . . 10.0 107.371 171.003 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.39 -25.5 57.68 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 121.352 0.596 . . . . 10.0 109.551 177.612 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 85' ' ' GLY . . . . . 0.559 ' CA ' HD21 ' B' ' 126' ' ' LEU . . . 80.98 -66.98 3.68 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 115.161 0.825 . . . . 10.0 115.161 167.676 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -137.93 109.29 6.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 118.677 -0.678 . . . . 10.0 109.249 -167.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -115.84 125.77 73.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 118.789 0.722 . . . . 10.0 110.451 169.721 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 10.9 m -81.35 97.51 7.74 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 128.325 2.65 . . . . 10.0 112.134 -171.705 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.64 132.77 39.6 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 123.824 0.849 . . . . 10.0 112.236 176.117 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -63.13 173.44 1.45 Allowed 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 125.308 1.443 . . . . 10.0 110.312 167.1 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.3 pttm -55.03 -30.5 59.68 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 123.766 0.827 . . . . 10.0 111.95 170.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.88 3.25 20.37 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.069 0.938 . . . . 10.0 110.953 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.47 -0.26 89.71 Favored Glycine 0 N--CA 1.441 -1.013 0 O-C-N 120.572 -1.33 . . . . 10.0 110.033 -174.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 67.0 t -78.33 94.79 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 108.414 -0.958 . . . . 10.0 108.414 -169.36 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -88.15 119.11 28.22 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 167.563 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -77.34 123.59 26.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.951 -1.5 . . . . 10.0 106.951 169.17 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 65.8 t -104.65 131.69 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 105.292 -2.114 . . . . 10.0 105.292 169.369 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -158.01 57.84 0.47 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 118.917 0.78 . . . . 10.0 111.815 177.413 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.6 151.61 12.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.166 0.986 . . . . 10.0 109.631 -169.279 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -109.1 141.99 40.48 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 126.068 1.747 . . . . 10.0 109.601 170.318 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -137.67 155.35 49.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 O-C-N 124.093 0.871 . . . . 10.0 109.413 173.291 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.5 p -128.07 58.37 1.52 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 126.86 2.064 . . . . 10.0 108.526 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -155.01 -44.5 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 C-N-CA 124.643 1.177 . . . . 10.0 108.888 174.096 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 33.6 mm -55.91 147.66 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 168.766 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.0 m -153.85 135.3 14.24 Favored 'General case' 0 C--O 1.233 0.22 0 N-CA-C 109.048 -0.723 . . . . 10.0 109.048 169.511 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -79.18 57.42 2.26 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.367 1.467 . . . . 10.0 108.492 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 15.5 t . . . . . 0 CA--C 1.536 0.432 0 C-N-CA 126.913 2.085 . . . . 10.0 110.416 -171.783 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.4 t . . . . . 0 C--O 1.238 0.492 0 N-CA-C 113.966 1.099 . . . . 10.0 113.966 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.2 pp -56.0 -30.29 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 166.791 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.7 mm -31.12 -36.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 C-N-CA 128.306 2.642 . . . . 10.0 115.234 169.495 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -104.56 28.95 12.86 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-O 118.711 -1.049 . . . . 10.0 112.784 -175.56 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -104.87 169.85 8.21 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 125.106 1.362 . . . . 10.0 110.176 177.57 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 18.4 m -108.26 127.7 54.08 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.696 1.598 . . . . 10.0 109.104 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.407 HD21 HD11 ' B' ' 149' ' ' ILE . 4.5 mm? -84.9 141.23 30.55 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 106.71 -1.589 . . . . 10.0 106.71 167.059 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.5 t -125.46 136.7 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 170.799 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.425 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 6.0 p -105.65 130.9 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 125.083 1.353 . . . . 10.0 107.583 169.733 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.669 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.3 m170 -114.68 157.84 22.59 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 115.75 1.759 . . . . 10.0 115.75 -171.298 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -37.11 -63.76 0.41 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 129.301 3.04 . . . . 10.0 111.078 169.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.5 mttt -117.93 175.32 5.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 C-N-CA 124.231 1.012 . . . . 10.0 110.131 -173.077 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -91.72 148.19 22.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.894 1.278 . . . . 10.0 109.478 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.533 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -75.04 143.35 43.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 112.053 0.39 . . . . 10.0 112.053 -178.786 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -80.64 -3.62 51.21 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 124.394 1.059 . . . . 10.0 110.791 166.564 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.559 HD21 ' CA ' ' B' ' 85' ' ' GLY . 71.1 mt 51.24 50.73 18.4 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 125.426 1.49 . . . . 10.0 111.218 170.6 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.37 -36.08 4.3 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-N 114.525 -1.216 . . . . 10.0 110.935 174.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.434 ' H ' ' HD3' ' B' ' 128' ' ' LYS . 0.2 OUTLIER -83.31 35.22 0.49 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 121.025 -1.279 . . . . 10.0 110.847 -173.844 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.92 -36.11 6.51 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 109.51 -1.436 . . . . 10.0 109.51 179.06 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.62 51.21 59.26 Favored Glycine 0 CA--C 1.529 0.938 0 N-CA-C 111.39 -0.684 . . . . 10.0 111.39 -171.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -142.66 171.7 13.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 104.605 -2.368 . . . . 10.0 104.605 170.756 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 24.4 mp0 -51.78 -48.11 63.91 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 120.726 -0.39 . . . . 10.0 110.379 174.328 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -53.08 -38.17 62.32 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.451 -0.34 . . . . 10.0 110.282 177.387 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.8 p -57.72 -30.01 65.19 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 118.013 -0.994 . . . . 10.0 112.513 -176.398 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -98.2 17.47 18.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.412 1.005 . . . . 10.0 109.834 -177.551 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -142.19 -69.74 0.35 Allowed 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 124.822 1.249 . . . . 10.0 110.38 -169.282 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.504 HG22 ' CD2' ' B' ' 63' ' ' HIS . 11.4 p -126.73 21.61 6.99 Favored 'General case' 0 CA--C 1.547 0.859 0 CA-C-N 119.653 1.115 . . . . 10.0 112.29 177.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 79.07 -88.07 1.18 Allowed Glycine 0 C--N 1.343 0.958 0 O-C-N 121.111 -0.993 . . . . 10.0 111.01 170.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.09 38.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 122.989 1.376 . . . . 10.0 107.934 174.34 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.76 -29.05 61.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 125.169 1.388 . . . . 10.0 109.607 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.95 -157.61 53.09 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 109.847 -1.301 . . . . 10.0 109.847 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 56.7 m -56.84 130.57 46.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 113.59 0.959 . . . . 10.0 113.59 -167.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.9 mtt85 -66.68 75.22 0.11 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.934 1.294 . . . . 10.0 110.654 172.695 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 55.1 mt -50.58 -40.19 51.77 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 118.349 0.522 . . . . 10.0 112.226 179.535 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.425 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -155.31 160.41 40.73 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 121.943 -0.473 . . . . 10.0 109.867 -177.692 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 p -159.42 166.46 30.99 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 109.982 -0.377 . . . . 10.0 109.982 -177.04 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.56 165.55 36.24 Favored Glycine 0 C--N 1.334 0.433 0 N-CA-C 110.689 -0.965 . . . . 10.0 110.689 -177.195 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.68 137.53 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 106.002 -1.851 . . . . 10.0 106.002 -171.219 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.433 HG12 ' HB2' ' B' ' 6' ' ' ALA . 16.7 mt -68.42 157.3 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 108.491 -0.929 . . . . 10.0 108.491 177.811 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -163.83 155.38 26.72 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 109.732 -1.347 . . . . 10.0 109.732 -176.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 151' ' ' ILE . . . . . 0.477 HD11 ' HD3' ' A' ' 115' ' ' ARG . 1.9 pp -90.32 125.84 43.16 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-N 118.475 1.138 . . . . 10.0 111.368 -173.1 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.75 -25.96 27.92 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.126 -0.984 . . . . 10.0 111.245 177.774 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.251 1.133 0 C-N-CA 125.837 1.655 . . . . 10.0 107.676 178.476 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.835 0 CA-C-O 118.253 -0.88 . . . . 10.0 108.636 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.31 -53.61 1.91 Allowed 'General case' 0 N--CA 1.463 0.175 0 C-N-CA 124.274 1.029 . . . . 10.0 110.828 -175.659 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -105.51 128.36 53.53 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.32 161.74 35.45 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.132 0.573 . . . . 10.0 109.665 172.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -125.94 153.45 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 125.71 1.604 . . . . 10.0 109.782 -179.202 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.73 127.53 21.98 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 108.251 -1.018 . . . . 10.0 108.251 165.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.648 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.9 m -115.36 83.7 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 C-N-CA 124.783 1.233 . . . . 10.0 110.772 -174.537 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.426 ' N ' HD12 ' A' ' 8' ' ' LEU . 2.7 mp -76.02 150.01 37.44 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.144 -0.972 . . . . 10.0 109.856 -169.069 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.429 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -165.96 155.24 11.81 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 -179.206 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.19 -46.2 0.18 Allowed Glycine 0 N--CA 1.463 0.477 0 C-N-CA 119.505 -1.331 . . . . 10.0 114.136 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -73.33 -45.35 55.74 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -175.387 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.71 -73.13 0.32 Allowed Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 170.073 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -56.75 -39.55 90.55 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.835 2.357 . . . . 10.0 110.996 172.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 98.4 t -62.97 106.54 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 CA-C-N 119.245 0.93 . . . . 10.0 108.507 -177.189 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.63 112.44 20.53 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 169.679 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.775 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -96.17 142.57 16.2 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 109.576 -1.41 . . . . 10.0 109.576 174.293 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -147.12 93.32 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 -172.071 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.4 mm -111.88 139.82 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 C-N-CA 125.582 1.553 . . . . 10.0 110.111 -175.581 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -118.32 122.45 42.9 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.943 1.697 . . . . 10.0 109.157 168.247 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -101.74 114.11 27.89 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 125.255 1.422 . . . . 10.0 107.259 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -120.6 112.68 19.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 122.154 0.978 . . . . 10.0 113.084 -179.459 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -82.29 104.8 12.86 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 106.307 -1.738 . . . . 10.0 106.307 168.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.3 -24.44 67.3 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 118.97 -0.538 . . . . 10.0 110.405 177.117 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -135.75 -161.22 1.13 Allowed 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.419 -0.586 . . . . 10.0 109.419 178.535 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 23.1 t -99.87 -7.68 25.02 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 119.363 -0.351 . . . . 10.0 110.355 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.9 m-80 -139.63 21.34 2.52 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.819 1.248 . . . . 10.0 108.969 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.98 161.8 42.09 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.278 -1.129 . . . . 10.0 110.278 -172.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -67.69 117.28 4.76 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 104.226 -3.029 . . . . 10.0 104.226 165.812 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.77 131.56 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 -174.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.1 mttt -101.53 122.74 44.37 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 106.541 -1.651 . . . . 10.0 106.541 174.683 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.1 m -119.73 111.93 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.82 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 -175.218 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -128.99 167.96 16.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 121.209 0.528 . . . . 10.0 109.988 -179.291 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.77 171.17 38.68 Favored Glycine 0 N--CA 1.437 -1.295 0 N-CA-C 110.009 -1.236 . . . . 10.0 110.009 -176.353 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.5 t -142.55 99.04 3.41 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 177.663 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.775 HG22 ' HA2' ' A' ' 16' ' ' GLY . 4.9 pt -79.51 156.26 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 C-N-CA 118.514 -1.275 . . . . 10.0 107.642 167.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.5 ptmt -141.9 164.6 29.76 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.519 -0.919 . . . . 10.0 108.519 164.311 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.66 -14.23 46.2 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-O 119.105 -0.831 . . . . 10.0 113.08 177.67 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.496 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.4 mp -70.77 176.9 3.88 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 118.566 1.183 . . . . 10.0 110.482 178.08 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -95.9 149.82 21.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.397 -0.82 . . . . 10.0 109.309 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -43.61 137.53 2.91 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.685 1.994 . . . . 10.0 111.58 -176.28 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 114.62 -172.87 14.49 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.881 0.753 . . . . 10.0 112.585 170.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.89 145.32 50.28 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 125.024 1.33 . . . . 10.0 110.908 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -147.9 143.58 27.48 Favored 'General case' 0 C--N 1.34 0.189 0 N-CA-C 113.099 0.777 . . . . 10.0 113.099 177.509 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.633 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -28.55 117.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 C-N-CA 127.842 2.639 . . . . 10.0 113.078 165.397 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -143.1 109.18 5.24 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 120.207 2.004 . . . . 10.0 110.873 169.046 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.78 171.79 19.77 Favored 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 115.438 -0.801 . . . . 10.0 110.765 178.573 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.9 m -89.45 163.39 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.514 -2.13 . . . . 10.0 106.895 166.449 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -124.47 158.23 33.32 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 124.857 1.263 . . . . 10.0 107.859 172.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -58.04 -41.3 82.95 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 123.994 0.918 . . . . 10.0 112.935 -169.794 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -107.41 174.65 5.79 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.034 0.934 . . . . 10.0 109.82 176.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.39 -9.96 14.14 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.236 1.874 . . . . 10.0 112.449 175.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -65.81 161.34 21.18 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 122.379 1.085 . . . . 10.0 110.949 -178.138 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -158.0 28.98 0.26 Allowed 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.445 -0.798 . . . . 10.0 112.289 -170.735 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.639 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -59.19 -36.43 75.35 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.569 -0.707 . . . . 10.0 112.368 -171.622 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.44 -17.54 56.2 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.178 0.591 . . . . 10.0 111.499 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.37 -156.25 15.73 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 104.664 -3.374 . . . . 10.0 104.664 -167.435 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 93.6 m -68.23 72.33 0.19 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 125.133 1.373 . . . . 10.0 110.174 177.033 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -158.56 -47.92 0.06 Allowed 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 123.564 0.746 . . . . 10.0 111.128 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -56.0 -35.17 66.5 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.27 1.028 . . . . 10.0 111.476 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.09 -28.86 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.482 3.113 . . . . 10.0 116.395 174.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.04 165.87 29.03 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 107.84 -2.104 . . . . 10.0 107.84 175.46 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -72.81 -141.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.347 0 N-CA-C 106.635 -2.102 . . . . 10.0 106.635 166.249 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -105.04 38.03 2.03 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 120.515 1.507 . . . . 10.0 111.556 179.423 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -72.18 73.17 0.93 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.848 1.658 . . . . 10.0 112.181 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 7.2 p-10 -61.12 151.43 75.44 Favored Pre-proline 0 CA--C 1.537 0.456 0 O-C-N 121.557 -0.715 . . . . 10.0 110.524 169.146 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -62.02 -43.55 24.22 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 122.571 2.181 . . . . 10.0 111.459 -178.338 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -77.06 60.4 1.84 Allowed 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 175.461 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 p -42.23 108.95 0.11 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 126.238 1.815 . . . . 10.0 111.762 -169.524 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -124.67 176.23 6.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 108.393 -0.965 . . . . 10.0 108.393 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -98.42 113.81 25.93 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -174.394 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.2 t60 -25.52 102.48 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 124.856 1.262 . . . . 10.0 113.894 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.81 -136.94 7.6 Favored Glycine 0 N--CA 1.443 -0.885 0 N-CA-C 107.975 -2.05 . . . . 10.0 107.975 178.387 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.03 -164.5 24.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 107.554 -2.219 . . . . 10.0 107.554 168.586 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -52.67 -18.27 8.44 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.14 1.894 . . . . 10.0 112.237 170.533 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.45 ' HZ1' ' CG ' ' A' ' 76' ' ' ASP . 0.0 OUTLIER -83.45 -33.36 25.66 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.025 0.93 . . . . 10.0 110.828 -177.424 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.45 ' CG ' ' HZ1' ' A' ' 75' ' ' LYS . 1.4 m-20 -98.04 175.14 6.22 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -171.597 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -89.42 -28.39 19.77 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 167.54 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -86.79 16.8 4.46 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 125.518 1.527 . . . . 10.0 113.156 -168.134 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.38 136.05 13.07 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.779 0.831 . . . . 10.0 109.729 168.399 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -71.77 -176.7 1.72 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 107.906 -1.146 . . . . 10.0 107.906 168.262 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.49 41.19 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 N-CA-C 113.754 1.02 . . . . 10.0 113.754 -175.093 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.82 56.71 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.237 -1.545 . . . . 10.0 109.237 172.166 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -98.01 95.89 7.78 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 169.433 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -80.16 -30.14 38.87 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.99 -102.02 1.89 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 107.954 -2.058 . . . . 10.0 107.954 168.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -132.34 114.0 13.87 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.998 1.319 . . . . 10.0 109.586 -167.869 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.5 m -103.6 137.2 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 C-N-CA 122.709 0.403 . . . . 10.0 110.192 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 92.1 m -83.27 105.47 14.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 127.13 2.172 . . . . 10.0 109.681 -177.078 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.75 131.07 35.21 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.253 0.621 . . . . 10.0 109.945 170.431 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -59.33 170.63 0.93 Allowed 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.13 1.372 . . . . 10.0 110.182 168.376 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 66.6 tttt -51.49 -35.27 39.42 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 125.925 1.69 . . . . 10.0 111.845 169.084 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -79.81 2.11 24.29 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 121.556 0.693 . . . . 10.0 111.292 177.293 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.34 -2.81 87.95 Favored Glycine 0 N--CA 1.445 -0.74 0 O-C-N 120.322 -1.487 . . . . 10.0 110.435 -178.312 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 69.5 t -75.67 103.99 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -170.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.595 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -104.23 115.25 30.06 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 108.43 -0.952 . . . . 10.0 108.43 173.812 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -79.16 125.44 29.45 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 114.44 -1.254 . . . . 10.0 108.107 173.741 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -106.28 128.67 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.397 0 N-CA-C 104.442 -2.429 . . . . 10.0 104.442 168.76 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.9 m -155.13 73.88 0.89 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 123.474 0.709 . . . . 10.0 110.028 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 15.8 mm -112.24 161.17 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 124.311 1.044 . . . . 10.0 111.29 -174.442 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -123.73 134.86 53.61 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 129.733 3.213 . . . . 10.0 107.047 169.092 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -145.68 144.17 30.24 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.505 -0.554 . . . . 10.0 109.505 175.141 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 5.1 p -109.57 18.72 20.02 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.311 1.844 . . . . 10.0 112.701 -174.24 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.8 t -126.38 -54.26 1.84 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.2 0 C-N-CA 125.595 1.558 . . . . 10.0 107.507 -177.555 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 10.9 mm -48.92 115.47 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 124.575 1.15 . . . . 10.0 109.086 172.865 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -114.51 116.78 29.37 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.897 0.879 . . . . 10.0 108.952 -176.054 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.97 -47.72 32.75 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 125.309 1.444 . . . . 10.0 109.647 176.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.4 m -149.13 164.39 34.83 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.137 -1.431 . . . . 10.0 107.137 174.755 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 134.27 -99.52 0.35 Allowed Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 107.211 -2.356 . . . . 10.0 107.211 -172.759 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -120.13 -49.2 2.3 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 124.653 1.181 . . . . 10.0 109.216 -168.573 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.03 -44.49 39.04 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 -177.315 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.1 t 46.97 76.14 0.11 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.994 1.717 . . . . 10.0 112.559 169.452 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 26.3 pt -59.77 -25.72 33.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 112.146 0.424 . . . . 10.0 112.146 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.1 mm -42.8 122.25 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 CA-C-N 119.068 0.849 . . . . 10.0 111.291 175.317 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.99 8.59 78.82 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 119.013 -0.881 . . . . 10.0 113.029 175.03 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.13 169.51 11.86 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.421 1.11 . . . . 10.0 108.499 168.113 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.92 141.37 36.67 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.862 0.865 . . . . 10.0 111.287 174.648 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.429 HD21 HD11 ' A' ' 149' ' ' ILE . 4.5 mm? -95.64 141.46 29.12 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.427 -1.323 . . . . 10.0 107.427 168.503 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.439 HG12 ' CD2' ' A' ' 120' ' ' HIS . 72.4 t -123.48 138.96 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 108.604 -0.887 . . . . 10.0 108.604 172.395 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.445 HG13 ' HB3' ' A' ' 145' ' ' ALA . 1.3 p -102.7 122.14 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 167.291 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.633 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.3 m-70 -104.88 160.29 15.12 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 115.207 1.558 . . . . 10.0 115.207 -173.036 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.34 -56.23 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 113.818 -1.537 . . . . 10.0 110.657 176.355 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 41.0 mttm -113.8 175.65 5.37 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-O 121.789 0.804 . . . . 10.0 111.918 -179.22 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.12 139.34 35.68 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.936 1.694 . . . . 10.0 109.051 172.683 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.14 164.63 24.81 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 121.843 0.83 . . . . 10.0 111.601 174.227 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -73.99 -16.56 61.07 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 114.618 -1.174 . . . . 10.0 110.54 -178.184 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 10.1 mt 52.13 46.68 26.19 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 -168.326 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.62 -13.29 67.05 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.65 2.072 . . . . 10.0 113.785 171.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.3 mtmp? -79.31 3.94 16.65 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 115.376 1.621 . . . . 10.0 115.376 -167.586 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.97 -33.15 51.26 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.493 1.042 . . . . 10.0 110.891 178.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.22 41.99 93.14 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 111.846 -0.502 . . . . 10.0 111.846 -173.392 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -132.96 170.34 15.49 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 124.684 1.194 . . . . 10.0 108.138 173.21 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -41.46 -55.66 2.76 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 125.497 1.519 . . . . 10.0 110.479 175.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 49.1 mp0 -56.43 -51.85 66.85 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 125.096 1.359 . . . . 10.0 110.311 176.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.6 p -51.46 -38.26 52.92 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 123.138 0.575 . . . . 10.0 111.009 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.91 -11.65 56.6 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 123.999 0.812 . . . . 10.0 111.307 -170.709 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -112.57 -48.84 2.98 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.829 1.251 . . . . 10.0 112.081 -172.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.7 p -137.05 23.65 3.03 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 120.289 1.404 . . . . 10.0 110.634 174.087 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.81 -113.79 6.19 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 106.065 -2.814 . . . . 10.0 106.065 -171.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 19.3 m-80 -157.95 44.05 0.32 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 107.258 -1.386 . . . . 10.0 107.258 174.795 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.84 -13.34 55.65 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 124.205 1.002 . . . . 10.0 112.313 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.6 -164.96 54.86 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 110.355 -1.098 . . . . 10.0 110.355 176.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.2 t -54.84 134.14 48.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 113.396 0.888 . . . . 10.0 113.396 -168.049 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -64.55 73.3 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.967 1.707 . . . . 10.0 109.432 168.308 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 39.8 mt -49.83 -39.3 38.31 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 118.383 0.538 . . . . 10.0 111.927 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.445 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -155.98 157.42 36.17 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.135 -0.691 . . . . 10.0 109.135 -177.783 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -157.08 162.3 39.47 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.415 -0.357 . . . . 10.0 110.531 -173.795 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.62 175.6 26.87 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.847 1.213 . . . . 10.0 110.088 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 13.6 t -122.04 140.81 44.82 Favored 'Isoleucine or valine' 0 C--N 1.343 0.298 0 CA-C-N 118.882 1.341 . . . . 10.0 107.422 -177.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.429 HD11 HD21 ' A' ' 117' ' ' LEU . 17.5 mt -75.82 119.56 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 123.76 0.824 . . . . 10.0 109.836 -176.805 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.97 148.9 17.89 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 125.428 1.49 . . . . 10.0 111.737 -178.485 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 89.0 mt -69.16 135.16 28.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.58 1.552 . . . . 10.0 110.163 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.02 -7.13 4.41 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 115.45 1.648 . . . . 10.0 115.45 -173.265 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.253 1.269 0 CA-C-O 117.528 -1.225 . . . . 10.0 110.199 -179.369 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.669 0 CA-C-O 118.272 -0.871 . . . . 10.0 109.043 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -78.19 -26.83 47.72 Favored 'General case' 0 C--O 1.224 -0.24 0 C-N-CA 123.345 0.658 . . . . 10.0 110.895 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 62.5 tttt -130.05 137.3 50.16 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.093 0.473 . . . . 10.0 111.068 176.257 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.29 161.17 36.17 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 125.129 1.372 . . . . 10.0 107.964 171.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -126.91 156.26 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 C-N-CA 125.184 1.394 . . . . 10.0 109.735 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 6' ' ' ALA . . . . . 0.423 ' HB1' HD11 ' B' ' 117' ' ' LEU . . . -138.85 112.31 8.2 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 168.589 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 11.6 m -100.41 128.65 52.22 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 108.31 -0.996 . . . . 10.0 108.31 171.004 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.18 145.35 31.64 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 123.917 0.887 . . . . 10.0 110.534 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -161.19 160.45 30.12 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.921 -1.141 . . . . 10.0 107.921 168.635 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.1 -45.58 0.12 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.982 -1.104 . . . . 10.0 113.285 169.107 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 -45.04 53.12 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.604 -1.258 . . . . 10.0 107.604 -175.588 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.37 -71.19 0.39 Allowed Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.644 -1.382 . . . . 10.0 109.644 170.853 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -57.86 -38.88 90.87 Favored 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 123.076 2.518 . . . . 10.0 111.095 171.326 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 92.2 t -61.47 103.05 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.035 0 N-CA-C 107.824 -1.176 . . . . 10.0 107.824 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -118.1 128.86 55.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.339 -1.356 . . . . 10.0 107.339 169.641 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.429 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -118.15 146.29 18.54 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 110.953 -0.859 . . . . 10.0 110.953 175.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.639 HG22 HG22 ' A' ' 54' ' ' THR . 1.5 mt -146.57 89.55 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 C-N-CA 125.634 1.573 . . . . 10.0 107.657 -176.821 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -102.5 139.25 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.744 1.618 . . . . 10.0 110.082 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -115.9 110.73 19.41 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 129.314 3.046 . . . . 10.0 107.366 176.621 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -95.02 114.64 26.47 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.865 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -112.47 122.34 47.42 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 118.64 0.655 . . . . 10.0 112.721 169.506 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 5.0 tp-100 -82.55 110.11 17.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.145 -2.168 . . . . 10.0 105.145 166.241 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt . . . . . 0 N--CA 1.442 -0.836 0 C-N-CA 130.429 3.492 . . . . 10.0 111.456 -179.963 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.04 151.05 86.97 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.458 1.439 . . . . 10.0 108.744 171.35 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 t -79.76 124.07 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.984 -2.599 . . . . 10.0 103.984 168.368 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -99.66 112.53 24.75 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.496 -1.668 . . . . 10.0 106.496 169.092 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -95.99 103.99 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.959 0 C-N-CA 127.08 2.152 . . . . 10.0 106.135 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -124.75 165.17 18.44 Favored 'General case' 0 C--O 1.223 -0.323 0 N-CA-C 112.648 0.61 . . . . 10.0 112.648 173.285 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.8 -156.63 27.1 Favored Glycine 0 N--CA 1.449 -0.494 0 N-CA-C 107.216 -2.354 . . . . 10.0 107.216 172.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 50.8 p -156.25 160.52 39.87 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.565 -1.254 . . . . 10.0 112.52 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.752 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -116.18 136.56 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 C-N-CA 126.197 1.799 . . . . 10.0 107.519 167.887 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 36' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 92' ' ' ASP . 0.1 OUTLIER -130.82 159.38 37.52 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.289 0.368 . . . . 10.0 110.452 167.276 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.14 -0.19 44.31 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.779 0.704 . . . . 10.0 113.22 -178.218 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.433 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.9 mp -85.02 175.62 8.93 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 118.0 0.9 . . . . 10.0 109.703 -178.308 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.5 t -90.89 154.45 19.47 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.913 -0.773 . . . . 10.0 108.913 168.131 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -51.22 145.32 8.14 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 126.536 1.935 . . . . 10.0 111.324 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.92 -170.49 21.84 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-O 121.593 0.552 . . . . 10.0 111.95 172.554 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -73.88 147.56 43.1 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.296 1.438 . . . . 10.0 112.535 -170.26 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -147.94 127.49 13.24 Favored 'General case' 0 C--N 1.341 0.218 0 N-CA-C 114.395 1.257 . . . . 10.0 114.395 -178.709 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.675 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -17.75 124.41 0.01 OUTLIER Glycine 0 C--N 1.342 0.89 0 C-N-CA 127.473 2.463 . . . . 10.0 114.489 164.784 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -147.18 106.17 3.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 119.863 1.832 . . . . 10.0 111.339 167.783 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.45 172.49 15.87 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.417 0.627 . . . . 10.0 111.165 175.206 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 19.5 m -96.91 153.92 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 112.632 -2.076 . . . . 10.0 108.479 168.875 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -134.49 135.47 42.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.005 2.122 . . . . 10.0 105.349 177.674 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -56.7 -48.36 77.87 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.896 0.748 . . . . 10.0 112.84 -168.694 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -78.42 112.66 15.68 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 118.126 -1.43 . . . . 10.0 108.486 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.74 -26.37 62.56 Favored Glycine 0 N--CA 1.44 -1.068 0 N-CA-C 109.534 -1.426 . . . . 10.0 109.534 167.224 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -34.37 109.12 0.07 Allowed 'General case' 0 CA--C 1.516 -0.364 0 C-N-CA 125.237 1.415 . . . . 10.0 111.343 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.648 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.7 OUTLIER -117.97 13.13 13.9 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 113.417 -1.719 . . . . 10.0 110.672 174.307 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.23 -39.84 67.14 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 119.102 0.864 . . . . 10.0 111.999 -168.314 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.88 -17.98 54.68 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.313 1.045 . . . . 10.0 113.027 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.23 76.07 1.11 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 108.269 -1.932 . . . . 10.0 108.269 -169.565 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.6 p 30.55 37.5 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 128.338 2.655 . . . . 10.0 116.177 -177.201 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.4 m -100.33 -50.25 3.99 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 -178.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.1 m -67.04 -14.73 63.18 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 126.378 1.871 . . . . 10.0 112.201 177.698 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.26 -26.74 0.35 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 127.228 2.211 . . . . 10.0 114.334 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 156.26 26.59 Favored Glycine 0 N--CA 1.438 -1.213 0 N-CA-C 109.002 -1.639 . . . . 10.0 109.002 169.646 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -69.31 -170.92 0.39 Allowed 'Trans proline' 0 N--CA 1.44 -1.65 0 N-CA-C 106.756 -2.055 . . . . 10.0 106.756 167.003 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 31.2 m170 -81.61 60.33 4.53 Favored 'General case' 0 CA--C 1.542 0.647 0 O-C-N 120.325 -1.485 . . . . 10.0 109.99 -172.398 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -70.85 75.52 0.62 Allowed 'General case' 0 C--O 1.223 -0.328 0 CA-C-N 118.917 0.781 . . . . 10.0 110.584 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -75.26 148.01 83.36 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.336 -0.853 . . . . 10.0 110.933 172.783 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.14 -42.97 12.32 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.57 2.18 . . . . 10.0 110.661 176.027 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.2 mt -75.87 54.77 0.84 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 123.806 0.843 . . . . 10.0 109.86 176.253 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.5 p -40.29 112.01 0.24 Allowed 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 125.787 1.635 . . . . 10.0 111.571 -172.869 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -142.34 178.4 7.6 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.42 -2.437 . . . . 10.0 104.42 -176.487 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -65.92 156.74 32.61 Favored 'General case' 0 N--CA 1.439 -0.977 0 C-N-CA 116.606 -2.038 . . . . 10.0 108.917 168.386 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -66.43 126.32 28.47 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 104.976 -2.231 . . . . 10.0 104.976 161.539 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.27 -133.21 3.07 Favored Glycine 0 N--CA 1.451 -0.35 0 N-CA-C 109.226 -1.55 . . . . 10.0 109.226 172.03 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.84 -155.08 23.19 Favored Glycine 0 C--O 1.226 -0.405 0 CA-C-O 118.028 -1.429 . . . . 10.0 109.53 174.64 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -64.88 2.37 1.37 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 CA-C-N 119.803 1.801 . . . . 10.0 112.155 172.531 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -95.18 -21.57 18.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 117.65 -1.167 . . . . 10.0 110.862 172.319 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -126.72 156.14 41.6 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 119.318 0.963 . . . . 10.0 109.817 -170.779 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -78.17 -32.79 50.31 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 106.885 -1.524 . . . . 10.0 106.885 167.62 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -88.01 57.17 4.18 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 125.553 1.541 . . . . 10.0 108.167 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 14.3 ptm180 -83.78 147.81 27.39 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 106.259 -1.756 . . . . 10.0 106.259 165.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -63.55 -57.95 8.52 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.481 1.037 . . . . 10.0 110.548 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.458 HG22 HG22 ' B' ' 104' ' ' ILE . 2.1 p 179.78 -99.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 104.883 -2.265 . . . . 10.0 104.883 -179.388 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.438 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -74.68 54.15 2.48 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.45 1.023 . . . . 10.0 112.417 172.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 70.0 m-20 -95.76 92.56 6.62 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.223 -2.51 . . . . 10.0 104.223 167.313 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 80.7 mt -89.44 38.84 0.92 Allowed 'General case' 0 CA--C 1.531 0.214 0 N-CA-C 107.983 -1.117 . . . . 10.0 107.983 177.195 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 32.91 -103.08 0.01 OUTLIER Glycine 0 C--N 1.341 0.84 0 C-N-CA 128.124 2.773 . . . . 10.0 112.206 -175.296 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -143.85 147.11 33.6 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.11 0.964 . . . . 10.0 109.769 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 32.4 m -113.15 139.04 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 125.095 1.358 . . . . 10.0 108.355 -174.748 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -83.41 122.47 28.54 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.273 0.629 . . . . 10.0 109.917 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.75 131.31 37.92 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.581 1.153 . . . . 10.0 109.255 171.053 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -56.15 169.36 0.41 Allowed 'General case' 0 N--CA 1.451 -0.41 0 O-C-N 124.486 1.116 . . . . 10.0 110.007 168.066 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 11.3 tttp -49.99 -35.46 24.56 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.284 1.434 . . . . 10.0 112.185 169.431 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 92' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 36' ' ' LYS . 36.1 t70 -79.47 0.31 30.04 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.275 0.559 . . . . 10.0 112.202 177.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.03 -1.0 86.54 Favored Glycine 0 C--N 1.337 0.623 0 O-C-N 120.394 -1.441 . . . . 10.0 110.698 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 56.0 t -77.15 97.71 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 107.443 -1.317 . . . . 10.0 107.443 -174.639 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.752 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -94.3 116.98 29.44 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 168.573 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -88.19 130.35 35.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.839 -1.171 . . . . 10.0 107.839 174.014 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.0 t -107.7 129.89 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.257 -2.127 . . . . 10.0 105.257 168.73 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -157.77 55.88 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 118.696 0.68 . . . . 10.0 110.957 175.449 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.58 143.68 17.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.466 -0.771 . . . . 10.0 110.222 -169.084 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -97.85 129.21 44.83 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 128.638 2.775 . . . . 10.0 107.049 168.846 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -143.23 134.0 25.26 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 109.454 -0.573 . . . . 10.0 109.454 -176.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.6 p -115.64 45.78 1.63 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.559 1.544 . . . . 10.0 110.011 -169.337 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.9 p -142.98 -46.79 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 122.634 0.374 . . . . 10.0 111.219 177.261 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.458 HG22 HG22 ' B' ' 81' ' ' VAL 0.31 0.0 OUTLIER -65.12 161.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 119.787 -0.765 . . . . 10.0 111.441 169.517 . . . . . . . . 4 4 . 1 . 017 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 20.3 m -146.32 165.47 29.17 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 169.552 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 83.4 mt -100.55 -18.52 16.59 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 123.138 0.575 . . . . 10.0 110.061 175.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 44.7 m . . . . . 0 N--CA 1.452 -0.344 0 C-N-CA 125.443 1.497 . . . . 10.0 107.189 174.358 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.7 t . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.481 -0.563 . . . . 10.0 109.481 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 24.5 pt -75.41 34.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.519 -0.738 . . . . 10.0 112.746 -177.732 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 38.2 mm -85.25 146.54 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 O-C-N 120.281 -1.512 . . . . 10.0 109.395 -175.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.85 24.21 69.78 Favored Glycine 0 CA--C 1.531 1.079 0 O-C-N 121.976 -0.452 . . . . 10.0 112.677 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -93.3 149.49 21.19 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 125.172 1.389 . . . . 10.0 107.347 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -87.47 139.96 30.01 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 168.768 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.423 HD11 ' HB1' ' B' ' 6' ' ' ALA . 0.0 OUTLIER -116.61 159.01 22.79 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 108.135 -1.061 . . . . 10.0 108.135 168.704 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 74.5 t -137.94 129.51 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 107.981 -1.118 . . . . 10.0 107.981 -172.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.409 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 3.0 p -94.52 122.65 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 105.929 -1.878 . . . . 10.0 105.929 167.035 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.675 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.7 m-70 -105.98 160.24 15.43 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 115.303 1.594 . . . . 10.0 115.303 -171.329 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -41.38 -60.94 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.069 2.948 . . . . 10.0 111.968 171.108 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -120.16 172.16 7.97 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.71 1.204 . . . . 10.0 113.166 -168.355 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.54 154.47 38.61 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 114.186 -1.37 . . . . 10.0 108.187 168.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -92.74 168.73 11.0 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 124.337 1.055 . . . . 10.0 111.034 -176.061 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.58 -20.99 59.72 Favored 'General case' 0 C--O 1.223 -0.336 0 C-N-CA 125.11 1.364 . . . . 10.0 108.278 175.049 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 49.8 mt 49.45 43.31 23.52 Favored 'General case' 0 C--N 1.341 0.237 0 C-N-CA 124.457 1.103 . . . . 10.0 109.998 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.51 33.17 80.48 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.087 -1.415 . . . . 10.0 113.174 178.142 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -75.4 0.08 18.18 Favored 'General case' 0 C--N 1.339 0.142 0 CA-C-N 118.913 1.357 . . . . 10.0 112.337 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.82 17.97 78.63 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.45 -1.46 . . . . 10.0 109.45 178.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.25 -26.08 74.32 Favored Glycine 0 N--CA 1.443 -0.834 0 N-CA-C 110.352 -1.099 . . . . 10.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -156.07 163.14 40.03 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 118.067 0.933 . . . . 10.0 108.925 -168.362 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -56.23 -42.21 76.92 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 109.546 -0.539 . . . . 10.0 109.546 171.545 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -61.38 -23.96 66.15 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 112.635 0.606 . . . . 10.0 112.635 175.174 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.3 p -52.42 -39.32 60.83 Favored 'General case' 0 CA--C 1.512 -0.519 0 CA-C-N 118.556 0.617 . . . . 10.0 110.393 -172.696 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.7 t -90.17 -1.76 57.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 O-C-N 124.671 1.232 . . . . 10.0 111.67 -173.593 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -116.82 -48.93 2.64 Favored 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 126.769 2.028 . . . . 10.0 111.367 -168.871 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.7 p -135.43 -2.61 2.45 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 118.653 -0.689 . . . . 10.0 111.543 168.812 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 -106.38 3.19 Favored Glycine 0 N--CA 1.433 -1.52 0 N-CA-C 105.693 -2.963 . . . . 10.0 105.693 -166.078 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -168.79 30.55 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.22 1.01 . . . . 10.0 110.07 -173.866 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.19 -20.27 66.37 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.971 0.909 . . . . 10.0 113.277 -167.267 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.45 -160.69 53.25 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 110.394 -1.083 . . . . 10.0 110.394 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.5 m -55.57 130.8 44.38 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.074 0.94 . . . . 10.0 113.151 -167.476 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 60.6 mtt180 -69.23 68.25 0.19 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.129 1.771 . . . . 10.0 110.415 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 37.8 mt -54.41 -31.9 56.08 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 113.141 0.793 . . . . 10.0 113.141 -173.764 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.409 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -158.22 153.15 25.19 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 109.129 -0.693 . . . . 10.0 109.129 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.5 m -146.19 161.55 39.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 115.548 -0.751 . . . . 10.0 109.934 -166.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.36 172.78 34.81 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.089 -1.204 . . . . 10.0 110.089 176.455 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -122.4 135.32 62.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 9.1 mt -69.23 116.66 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 C-N-CA 122.983 0.513 . . . . 10.0 110.034 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.05 144.47 17.72 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 124.812 1.196 . . . . 10.0 110.526 -178.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 59.8 mt -65.77 144.56 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 N-CA-C 108.045 -1.094 . . . . 10.0 108.045 176.114 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.55 -43.05 3.06 Favored 'General case' 0 C--O 1.227 -0.124 0 CA-C-N 119.268 0.94 . . . . 10.0 111.923 170.187 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 117.088 -1.434 . . . . 10.0 110.854 179.029 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.656 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.6 t -154.77 -49.31 0.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 123.479 0.712 . . . . 10.0 109.501 173.694 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 ttmt -106.41 155.84 19.14 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.222 -1.77 . . . . 10.0 106.222 169.317 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.77 164.82 38.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 107.093 -1.447 . . . . 10.0 107.093 170.027 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -136.17 164.4 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 O-C-N 123.325 0.391 . . . . 10.0 110.854 -176.25 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.37 101.85 4.09 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.123 -1.065 . . . . 10.0 108.123 168.562 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.43 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.5 m -85.84 88.26 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 170.11 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -81.67 126.38 31.71 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.087 -0.708 . . . . 10.0 109.087 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 46.8 mtpt -140.8 160.41 40.11 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.05 -1.463 . . . . 10.0 107.05 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.07 -60.93 0.04 OUTLIER Glycine 0 C--O 1.229 -0.199 0 C-N-CA 120.808 -0.71 . . . . 10.0 112.745 169.26 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.99 -43.94 64.3 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 -176.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.82 -70.75 0.41 Allowed Glycine 0 CA--C 1.523 0.581 0 CA-C-N 114.23 -1.35 . . . . 10.0 110.446 169.542 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -58.16 -32.61 96.08 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 123.511 2.807 . . . . 10.0 111.665 173.483 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.0 t -67.22 93.75 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 N-CA-C 107.094 -1.447 . . . . 10.0 107.094 177.079 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -117.96 106.94 13.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.777 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -94.65 142.18 15.91 Favored Glycine 0 N--CA 1.441 -1.017 0 N-CA-C 109.171 -1.572 . . . . 10.0 109.171 169.204 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.611 HG22 HG23 ' B' ' 54' ' ' THR . 2.4 mt -143.77 58.66 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 -169.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.0 mm -79.74 137.28 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 115.688 -0.687 . . . . 10.0 109.328 -173.359 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -115.33 117.04 29.33 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.433 1.493 . . . . 10.0 108.024 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -102.74 122.88 45.36 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 177.566 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -118.37 144.61 45.77 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.675 0.671 . . . . 10.0 112.405 173.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -125.31 102.01 7.24 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 127.85 2.46 . . . . 10.0 106.594 167.009 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -49.74 -56.14 11.34 Favored 'General case' 0 C--N 1.338 0.098 0 C-N-CA 124.415 1.086 . . . . 10.0 109.931 172.62 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.56 178.54 6.99 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 105.128 -2.175 . . . . 10.0 105.128 171.85 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.0 t -72.31 -18.79 61.75 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.455 -0.202 . . . . 10.0 110.455 177.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -79.68 -19.38 49.15 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 123.673 0.789 . . . . 10.0 109.765 177.716 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.61 143.46 45.55 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.531 -1.028 . . . . 10.0 110.531 179.217 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.48 149.03 43.73 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.466 2.11 . . . . 10.0 107.648 168.149 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 t -79.58 100.34 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.404 ' NZ ' ' OE2' ' A' ' 100' ' ' GLU . 1.8 ttmp? -81.91 108.0 15.07 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.927 -1.508 . . . . 10.0 106.927 168.719 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.3 m -90.11 103.41 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 107.108 -1.441 . . . . 10.0 107.108 173.674 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.4 p90 -112.73 153.95 26.93 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-O 121.481 0.657 . . . . 10.0 112.61 173.529 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.47 179.37 41.28 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.637 -0.792 . . . . 10.0 111.274 169.156 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.4 p -131.67 103.94 6.65 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 -175.403 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.777 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.8 pt -79.8 140.99 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 169.178 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -118.28 149.84 40.46 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 169.446 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.55 -8.15 37.22 Favored Glycine 0 C--N 1.336 0.569 0 CA-C-O 119.534 -0.592 . . . . 10.0 113.354 170.071 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -60.97 176.68 0.39 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.915 0.864 . . . . 10.0 109.75 170.648 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -110.61 171.65 7.34 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 166.111 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -48.93 156.27 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.858 1.263 . . . . 10.0 112.816 -172.151 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.01 -169.93 46.84 Favored Glycine 0 N--CA 1.443 -0.858 0 CA-C-O 122.667 1.149 . . . . 10.0 113.848 166.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mp -69.86 141.78 53.16 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 126.246 1.818 . . . . 10.0 110.139 -177.321 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -142.54 151.98 42.15 Favored 'General case' 0 C--N 1.341 0.203 0 N-CA-C 114.132 1.16 . . . . 10.0 114.132 178.085 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.694 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.71 122.39 0.13 Allowed Glycine 0 C--N 1.34 0.783 0 C-N-CA 128.533 2.968 . . . . 10.0 112.709 164.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -156.14 107.22 2.46 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.206 1.503 . . . . 10.0 111.72 168.509 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.464 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -157.55 169.75 23.96 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 113.2 0.815 . . . . 10.0 113.2 -179.764 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.4 m -84.13 157.79 3.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 CA-C-N 112.694 -2.048 . . . . 10.0 109.929 169.701 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -142.14 140.15 32.35 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 126.58 1.952 . . . . 10.0 107.366 179.079 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -58.55 -59.72 4.94 Favored 'General case' 0 N--CA 1.446 -0.645 0 O-C-N 124.212 0.945 . . . . 10.0 111.249 -172.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -76.95 123.02 25.7 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 117.932 -1.507 . . . . 10.0 108.984 -169.056 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.05 -9.25 63.0 Favored Glycine 0 CA--C 1.535 1.317 0 N-CA-C 110.336 -1.106 . . . . 10.0 110.336 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -59.07 99.84 0.06 Allowed 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 122.371 1.081 . . . . 10.0 111.453 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -107.53 14.39 25.84 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 113.506 -1.679 . . . . 10.0 110.432 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.675 HG23 HG22 ' B' ' 17' ' ' ILE . 3.1 m -54.71 -35.51 63.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 120.065 1.302 . . . . 10.0 110.776 -177.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.72 -19.99 57.05 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.769 0.828 . . . . 10.0 112.392 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 133.05 -87.74 0.27 Allowed Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.432 1.492 . . . . 10.0 109.533 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 15.7 t -155.17 62.04 0.64 Allowed 'General case' 0 CA--C 1.529 0.162 0 O-C-N 122.067 -0.666 . . . . 10.0 109.705 -172.233 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -162.5 -49.92 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.557 -0.714 . . . . 10.0 110.175 -175.239 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.7 t -57.47 -19.98 27.77 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 123.941 0.896 . . . . 10.0 111.149 -178.578 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.82 -27.36 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.822 2.049 . . . . 10.0 113.589 168.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.48 170.69 33.17 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 108.071 -2.012 . . . . 10.0 108.071 168.114 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -81.5 -166.38 0.4 Allowed 'Trans proline' 0 N--CA 1.441 -1.582 0 N-CA-C 107.077 -1.932 . . . . 10.0 107.077 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -82.85 58.94 4.57 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 120.893 -1.129 . . . . 10.0 110.629 -174.835 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -71.99 74.18 0.9 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.949 0.88 . . . . 10.0 111.257 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 -74.92 153.11 86.84 Favored Pre-proline 0 CA--C 1.537 0.444 0 C-N-CA 124.292 1.037 . . . . 10.0 110.302 171.336 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.12 -43.54 11.23 Favored 'Trans proline' 0 N--CA 1.456 -0.712 0 C-N-CA 122.322 2.015 . . . . 10.0 111.019 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.6 51.21 0.73 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.401 0.68 . . . . 10.0 110.579 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 35.0 p -52.48 112.51 0.83 Allowed 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.247 1.019 . . . . 10.0 109.907 -174.835 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 30.1 mtt85 -136.93 -85.71 0.32 Allowed 'General case' 0 CA--C 1.511 -0.545 0 N-CA-C 106.953 -1.499 . . . . 10.0 106.953 -170.683 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -144.7 158.2 43.88 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-O 122.402 1.096 . . . . 10.0 109.361 167.455 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 67.3 t60 -73.13 120.46 18.79 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 162.879 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.5 -131.75 2.45 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 108.148 -1.981 . . . . 10.0 108.148 175.602 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.09 -149.2 7.87 Favored Glycine 0 C--O 1.226 -0.351 0 N-CA-C 109.106 -1.598 . . . . 10.0 109.106 169.324 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -64.92 3.71 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.863 0 CA-C-N 120.344 2.072 . . . . 10.0 111.656 169.112 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -92.35 -22.48 19.67 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 124.901 1.28 . . . . 10.0 110.611 172.09 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 59.6 t0 -117.18 152.77 34.09 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.118 -1.067 . . . . 10.0 108.118 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -79.2 -33.43 43.87 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.403 -1.271 . . . . 10.0 108.078 169.188 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -91.02 8.1 37.08 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.415 1.486 . . . . 10.0 111.606 -170.246 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.21 142.1 3.04 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.456 1.103 . . . . 10.0 110.478 176.109 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.7 m170 -59.73 -59.37 5.54 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.447 0.641 . . . . 10.0 110.342 -169.781 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.52 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.3 p -173.5 -98.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 104.586 -2.376 . . . . 10.0 104.586 177.469 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.52 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -79.1 58.38 4.34 Favored Glycine 0 CA--C 1.529 0.954 0 CA-C-N 118.776 0.716 . . . . 10.0 111.457 174.391 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -90.59 90.59 8.05 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 104.309 -2.478 . . . . 10.0 104.309 167.284 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 8.6 mt -70.79 -33.28 70.57 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.28 -76.53 0.51 Allowed Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 10.0 111.32 167.289 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 72.8 m-20 -135.43 118.58 16.52 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 117.938 0.869 . . . . 10.0 109.45 -175.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.2 m -103.98 122.44 56.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 168.388 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 m -82.67 101.75 11.04 Favored 'General case' 0 N--CA 1.437 -1.107 0 C-N-CA 127.402 2.281 . . . . 10.0 109.507 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.64 130.24 35.33 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.251 0.62 . . . . 10.0 110.561 175.587 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -58.94 169.03 1.1 Allowed 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 124.215 0.947 . . . . 10.0 109.277 167.835 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 ptmm? -50.78 -32.4 19.76 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.539 1.535 . . . . 10.0 111.565 169.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.8 m-20 -78.28 -5.16 51.2 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.933 0.893 . . . . 10.0 111.321 -178.451 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.78 6.91 88.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 111.071 -0.811 . . . . 10.0 111.071 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.0 t -79.95 107.2 12.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.926 0 C-N-CA 126.532 1.933 . . . . 10.0 106.043 176.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.686 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -110.12 118.58 36.78 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 169.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -81.68 123.97 29.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 O-C-N 124.408 1.068 . . . . 10.0 108.461 172.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 99.4 t -112.38 130.44 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.238 0 C-N-CA 127.097 2.159 . . . . 10.0 106.365 177.043 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.3 p -156.11 65.34 0.57 Allowed 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.477 0.711 . . . . 10.0 109.458 174.028 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -96.63 156.9 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 -177.381 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.404 ' OE2' ' NZ ' ' A' ' 30' ' ' LYS . 8.5 tt0 -136.02 121.86 19.87 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 125.465 1.506 . . . . 10.0 109.38 -178.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -125.66 117.78 24.24 Favored 'General case' 0 C--O 1.232 0.174 0 C-N-CA 124.623 1.169 . . . . 10.0 108.6 -177.398 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -89.14 54.64 3.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 171.798 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.02 -53.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 C-N-CA 122.932 0.493 . . . . 10.0 110.245 -176.448 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -58.27 147.52 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 172.484 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.1 p -137.48 136.19 37.5 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.365 -0.379 . . . . 10.0 110.402 170.706 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -77.79 -35.08 51.91 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 107.862 -1.162 . . . . 10.0 107.862 168.511 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.7 m -151.39 130.58 12.73 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 103.534 -2.765 . . . . 10.0 103.534 168.604 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.33 -79.7 0.1 Allowed Glycine 0 C--N 1.331 0.302 0 N-CA-C 109.219 -1.552 . . . . 10.0 109.219 -169.894 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -147.22 -54.29 0.22 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.09 -1.055 . . . . 10.0 108.68 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -75.84 -36.99 59.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.372 -1.286 . . . . 10.0 108.633 -173.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.7 t 45.69 61.12 2.77 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.317 1.047 . . . . 10.0 110.326 169.722 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 25.5 pt -74.53 31.77 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.89 0.852 . . . . 10.0 112.956 -169.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.7 mm -81.76 123.82 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 C-N-CA 125.627 1.571 . . . . 10.0 107.912 -176.615 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.14 4.66 64.5 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 123.947 0.785 . . . . 10.0 111.541 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -83.58 171.05 13.71 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 168.189 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 2.4 m -119.12 140.7 49.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 108.245 -1.021 . . . . 10.0 108.245 -177.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.517 HD11 ' CG1' ' A' ' 149' ' ' ILE . 0.2 OUTLIER -113.43 164.25 13.85 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.61 0.641 . . . . 10.0 109.631 168.174 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -140.56 134.22 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 O-C-N 123.953 0.783 . . . . 10.0 109.345 -172.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.9 m -96.95 133.0 40.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 106.554 -1.647 . . . . 10.0 106.554 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.694 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m-70 -114.01 158.3 21.37 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 114.948 1.462 . . . . 10.0 114.948 -175.551 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -55.78 -47.16 77.55 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.246 1.819 . . . . 10.0 111.35 -179.424 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 79.3 mttt -112.46 163.39 14.51 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 119.121 0.873 . . . . 10.0 112.903 -175.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.76 152.78 30.32 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 124.697 1.199 . . . . 10.0 108.755 169.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.464 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.5 OUTLIER -78.96 151.4 31.64 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-O 122.746 1.26 . . . . 10.0 112.292 -179.378 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.82 -29.54 44.83 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 112.133 -2.303 . . . . 10.0 109.448 170.633 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.0 mt 58.55 34.68 24.08 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 124.694 1.198 . . . . 10.0 111.893 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.1 -18.48 57.27 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 123.969 0.795 . . . . 10.0 111.768 170.388 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -74.77 -5.98 46.4 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 124.344 1.058 . . . . 10.0 111.941 -168.787 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.54 -28.99 70.59 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.362 -1.095 . . . . 10.0 110.362 168.217 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.76 43.46 54.15 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.512 -1.035 . . . . 10.0 110.512 -170.274 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -128.28 168.16 15.89 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.115 -1.069 . . . . 10.0 108.115 175.058 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -48.52 -50.24 32.69 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.076 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 58.8 mp0 -55.85 -54.13 48.26 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 125.805 1.642 . . . . 10.0 111.811 171.815 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.8 p -49.74 -44.98 48.87 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 109.389 -0.596 . . . . 10.0 109.389 -173.118 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.7 t -81.19 -1.64 45.51 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.503 0.557 . . . . 10.0 112.503 -171.325 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.7 mttt -112.68 -50.37 2.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 125.653 1.581 . . . . 10.0 112.128 -176.627 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.1 p -139.09 17.17 2.62 Favored 'General case' 0 C--N 1.34 0.174 0 CA-C-N 119.545 1.066 . . . . 10.0 111.817 173.786 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.07 -116.45 5.56 Favored Glycine 0 N--CA 1.436 -1.311 0 N-CA-C 103.794 -3.722 . . . . 10.0 103.794 -169.132 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -163.88 40.42 0.09 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.582 -1.636 . . . . 10.0 106.582 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.71 -4.47 37.65 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 124.06 0.944 . . . . 10.0 112.193 -170.539 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.72 -164.3 53.09 Favored Glycine 0 N--CA 1.446 -0.679 0 O-C-N 121.415 -0.803 . . . . 10.0 111.527 169.138 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.6 m -53.86 131.37 39.76 Favored 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 124.711 1.204 . . . . 10.0 114.019 -168.117 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 34.0 mtt180 -64.95 73.47 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.519 1.928 . . . . 10.0 111.168 174.248 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 43.1 mt -51.03 -35.67 35.5 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 112.642 0.608 . . . . 10.0 112.642 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.49 153.09 32.78 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 121.901 -0.5 . . . . 10.0 109.722 176.199 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.6 p -149.98 156.51 41.85 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 109.38 -0.6 . . . . 10.0 109.38 178.565 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.85 153.95 25.17 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.063 -0.815 . . . . 10.0 111.063 -176.434 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 84.6 t -102.88 139.86 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 105.967 -1.864 . . . . 10.0 105.967 -173.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.517 ' CG1' HD11 ' A' ' 117' ' ' LEU . 18.0 mt -74.91 110.31 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 122.843 0.457 . . . . 10.0 109.894 -175.07 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.61 141.92 15.38 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 124.237 0.922 . . . . 10.0 110.972 -177.679 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.8 mt -64.83 146.38 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.401 1.48 . . . . 10.0 110.523 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.59 165.57 29.97 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-O 122.564 1.173 . . . . 10.0 110.506 167.814 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 . . . . . 0 C--O 1.255 1.384 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 166.15 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 105.885 -1.894 . . . . 10.0 105.885 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.7 t -76.81 -46.62 24.21 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 119.996 1.271 . . . . 10.0 110.351 -168.448 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -127.36 128.3 45.64 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 124.321 1.048 . . . . 10.0 111.317 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.04 160.88 38.73 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 123.348 0.659 . . . . 10.0 109.591 168.742 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.13 162.09 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 124.129 0.972 . . . . 10.0 109.291 -178.609 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.41 102.75 3.88 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.703 -1.221 . . . . 10.0 107.703 169.699 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.414 HG12 HG23 ' B' ' 17' ' ' ILE . 1.5 m -85.12 111.88 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 N-CA-C 108.851 -0.796 . . . . 10.0 108.851 169.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mt -88.16 141.12 28.82 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.481 -0.933 . . . . 10.0 108.481 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -157.8 161.72 38.41 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.696 1.135 . . . . 10.0 108.14 171.49 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.59 -55.98 0.04 OUTLIER Glycine 0 C--N 1.329 0.166 0 N-CA-C 111.937 -0.465 . . . . 10.0 111.937 170.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.75 -45.78 41.65 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 -170.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.48 -66.19 0.57 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 113.676 -1.602 . . . . 10.0 110.786 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -57.81 -36.9 98.07 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.763 2.308 . . . . 10.0 111.071 172.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -67.52 109.9 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 108.472 -0.936 . . . . 10.0 108.472 174.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -126.57 112.25 15.3 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 106.381 -1.711 . . . . 10.0 106.381 168.703 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.636 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -96.39 145.28 17.75 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.718 -1.353 . . . . 10.0 109.718 171.091 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.675 HG22 HG23 ' A' ' 54' ' ' THR . 1.7 mt -145.62 87.63 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -169.801 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -105.99 145.33 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.204 0 C-N-CA 124.446 1.098 . . . . 10.0 110.253 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.1 m-20 -121.06 126.33 49.57 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 127.078 2.151 . . . . 10.0 109.564 168.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -103.68 114.07 28.07 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 170.392 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -109.27 126.97 53.89 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 123.502 0.501 . . . . 10.0 111.333 169.859 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 -94.08 99.41 11.71 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 106.811 -1.552 . . . . 10.0 106.811 174.065 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.454 -0.243 0 C-N-CA 124.83 1.252 . . . . 10.0 109.928 -177.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.822 0 N-CA-C 110.073 -1.211 . . . . 10.0 110.073 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -66.12 150.54 85.06 Favored 'Trans proline' 0 N--CA 1.451 -1.029 0 C-N-CA 121.811 1.674 . . . . 10.0 108.426 169.648 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.11 121.0 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 N-CA-C 105.723 -1.954 . . . . 10.0 105.723 169.725 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.5 ttmp? -95.81 120.57 36.31 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 107.124 -1.436 . . . . 10.0 107.124 169.142 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -100.17 103.94 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 C-N-CA 126.824 2.049 . . . . 10.0 106.147 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -126.84 166.35 17.63 Favored 'General case' 0 CA--C 1.52 -0.198 0 N-CA-C 112.355 0.502 . . . . 10.0 112.355 177.417 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.18 -150.57 22.44 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 106.928 -2.469 . . . . 10.0 106.928 169.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.0 p -156.38 165.38 36.5 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.88 175.239 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.636 HG22 ' CA ' ' B' ' 16' ' ' GLY . 1.8 pp -113.67 173.19 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-N 115.298 -0.864 . . . . 10.0 108.868 167.261 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.8 tttt -144.03 142.04 30.44 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 106.492 -1.67 . . . . 10.0 106.492 164.722 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.03 -8.32 11.57 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 113.05 170.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.485 HD23 HD13 ' B' ' 35' ' ' ILE . 0.3 OUTLIER -67.37 177.73 1.79 Allowed 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.181 0.993 . . . . 10.0 111.037 177.464 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.1 t -110.77 152.85 26.13 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.724 -1.584 . . . . 10.0 106.724 168.037 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -53.52 150.78 6.41 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.437 0.695 . . . . 10.0 112.216 -168.626 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.67 -168.49 20.59 Favored Glycine 0 CA--C 1.523 0.567 0 C-N-CA 123.828 0.728 . . . . 10.0 111.295 173.726 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mp -78.16 138.87 38.92 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.335 1.454 . . . . 10.0 110.892 -172.192 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -142.02 131.91 24.39 Favored 'General case' 0 CA--C 1.521 -0.165 0 C-N-CA 124.376 1.07 . . . . 10.0 112.254 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.624 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -17.75 122.92 0.01 OUTLIER Glycine 0 C--N 1.343 0.918 0 C-N-CA 128.001 2.715 . . . . 10.0 113.161 167.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -148.76 106.3 3.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 119.198 1.499 . . . . 10.0 110.633 171.459 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.84 169.95 21.0 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.596 0.712 . . . . 10.0 111.393 177.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 9.3 p -90.6 145.88 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 CA-C-N 111.946 -2.388 . . . . 10.0 107.274 166.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -125.69 146.16 49.86 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.019 -1.845 . . . . 10.0 106.019 170.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 49' ' ' GLU . . . . . 0.51 ' CD ' ' HE ' ' B' ' 115' ' ' ARG . 29.7 tp10 -76.42 -31.5 57.94 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.295 -0.866 . . . . 10.0 111.887 -166.639 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -78.95 113.94 17.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.081 -1.081 . . . . 10.0 108.081 174.687 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.34 -15.6 68.18 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 167.363 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -42.89 148.47 0.25 Allowed 'General case' 0 C--N 1.343 0.305 0 C-N-CA 124.735 1.214 . . . . 10.0 111.716 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.43 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -158.24 16.54 0.22 Allowed 'General case' 0 N--CA 1.441 -0.925 0 C-N-CA 125.519 1.528 . . . . 10.0 111.564 169.917 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.611 HG23 HG22 ' A' ' 17' ' ' ILE . 3.1 m -54.95 -37.4 66.42 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 119.458 1.026 . . . . 10.0 111.469 -169.147 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.8 -22.23 46.57 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.409 1.084 . . . . 10.0 112.528 177.352 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 126.89 -167.01 19.46 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 106.246 -2.742 . . . . 10.0 106.246 -169.308 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m -72.65 53.28 0.32 Allowed 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 125.005 1.322 . . . . 10.0 107.877 169.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 88.9 m -120.83 -50.22 2.18 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 127.638 2.375 . . . . 10.0 108.245 -165.265 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 14.4 m -114.11 10.61 17.44 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.935 1.294 . . . . 10.0 112.226 -169.174 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -72.49 32.09 0.06 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.434 1.094 . . . . 10.0 113.721 -175.86 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.67 122.67 0.31 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.151 0.882 . . . . 10.0 112.667 168.74 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 62' ' ' PRO . . . . . 0.401 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 67.6 Cg_endo -77.33 60.79 7.14 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.13 2.553 . . . . 10.0 111.492 174.682 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 1.2 m80 62.62 48.27 4.44 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.95 1.7 . . . . 10.0 110.235 173.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 64' ' ' PHE . . . . . 0.401 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 28.8 m-85 -71.03 62.21 0.29 Allowed 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.766 0.712 . . . . 10.0 111.373 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -65.58 142.36 98.25 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.291 -0.881 . . . . 10.0 111.303 -172.775 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.35 -41.61 6.52 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.723 2.282 . . . . 10.0 110.249 -177.301 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.75 55.16 1.04 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.166 0.986 . . . . 10.0 108.771 175.563 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.9 p -34.15 104.95 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 126.539 1.936 . . . . 10.0 111.859 -169.829 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.11 176.97 8.18 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 104.319 -2.475 . . . . 10.0 104.319 -173.166 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -69.78 154.28 42.2 Favored 'General case' 0 N--CA 1.435 -1.185 0 C-N-CA 117.148 -1.821 . . . . 10.0 107.994 169.11 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -65.72 118.29 9.38 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 104.717 -2.327 . . . . 10.0 104.717 159.535 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.79 -177.3 22.09 Favored Glycine 0 N--CA 1.435 -1.409 0 N-CA-C 106.699 -2.561 . . . . 10.0 106.699 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.65 -156.59 6.93 Favored Glycine 0 C--O 1.227 -0.294 0 N-CA-C 109.35 -1.5 . . . . 10.0 109.35 -177.423 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -65.48 1.66 2.0 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.323 1.349 . . . . 10.0 110.613 166.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -109.16 0.86 19.97 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 117.754 -1.117 . . . . 10.0 112.007 173.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -116.22 162.78 16.95 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 169.235 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -79.1 -39.79 32.8 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 167.651 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -110.55 63.53 0.61 Allowed 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 124.697 1.199 . . . . 10.0 111.65 -168.132 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -60.65 161.81 7.33 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.359 1.064 . . . . 10.0 109.728 166.602 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 15.5 m170 -66.49 -71.54 0.19 Allowed 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 113.062 0.764 . . . . 10.0 113.062 -174.095 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -166.79 -53.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 O-C-N 121.638 -0.664 . . . . 10.0 109.689 -173.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -131.48 60.47 0.68 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 171.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -112.15 90.5 3.36 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.074 -2.195 . . . . 10.0 105.074 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 84' ' ' LEU . . . . . 0.553 ' C ' HD12 ' B' ' 84' ' ' LEU . 0.3 OUTLIER -82.22 -30.38 30.83 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 106.362 -1.718 . . . . 10.0 106.362 -178.076 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.92 -83.96 0.36 Allowed Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 168.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -156.88 156.35 32.99 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 122.839 0.456 . . . . 10.0 111.101 -177.628 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.5 m -124.48 142.08 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 C-N-CA 125.289 1.435 . . . . 10.0 109.766 -174.339 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -85.71 103.1 14.19 Favored 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 129.433 3.093 . . . . 10.0 110.927 -172.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.48 136.12 36.25 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.861 -0.524 . . . . 10.0 109.844 169.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -65.93 172.49 3.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.733 1.613 . . . . 10.0 110.23 167.546 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.23 -23.48 66.69 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 122.771 0.428 . . . . 10.0 112.091 173.534 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -75.83 -3.05 33.0 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 120.864 0.364 . . . . 10.0 110.252 174.452 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.48 24.73 60.23 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 108.719 -1.752 . . . . 10.0 108.719 176.327 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.6 t -110.13 109.51 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 127.081 2.152 . . . . 10.0 106.904 -174.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.477 ' H ' ' CD1' ' B' ' 35' ' ' ILE . . . -102.17 120.19 40.04 Favored 'General case' 0 CA--C 1.513 -0.467 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 169.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -79.97 119.21 22.5 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 127.415 2.286 . . . . 10.0 108.8 170.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -103.68 130.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 C-N-CA 124.839 1.256 . . . . 10.0 107.754 177.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.9 p -158.42 83.02 0.83 Allowed 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 118.646 -0.693 . . . . 10.0 109.227 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.68 152.59 20.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 N-CA-C 107.553 -1.277 . . . . 10.0 107.553 179.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -126.81 137.01 53.13 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 126.014 1.726 . . . . 10.0 110.31 174.055 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.27 141.08 39.86 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.829 0.852 . . . . 10.0 109.513 177.478 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 18.6 p -106.3 22.91 14.97 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.363 1.465 . . . . 10.0 109.924 169.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 51.0 t -94.88 -15.21 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 C-N-CA 124.859 1.264 . . . . 10.0 109.479 -177.606 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.447 HD13 ' H ' ' B' ' 104' ' ' ILE . 0.0 OUTLIER -134.53 175.17 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 125.461 1.504 . . . . 10.0 112.42 -169.949 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -158.85 147.0 18.1 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 107.631 -1.248 . . . . 10.0 107.631 169.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -60.03 -50.61 73.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.727 -0.842 . . . . 10.0 108.727 -178.238 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 49.8 p . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 172.866 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.44 -0.956 0 CA-C-O 118.995 -0.526 . . . . 10.0 110.921 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 20.6 pt -67.75 -10.05 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 113.606 0.965 . . . . 10.0 113.606 -172.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 113' ' ' ILE . . . . . 0.418 HD12 HG23 ' B' ' 151' ' ' ILE . 21.2 mm -53.41 139.58 11.18 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 O-C-N 120.854 -1.153 . . . . 10.0 110.159 169.692 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.41 4.5 84.44 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.556 -1.136 . . . . 10.0 113.986 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 115' ' ' ARG . . . . . 0.51 ' HE ' ' CD ' ' B' ' 49' ' ' GLU . 27.7 mmt-85 -79.55 178.57 8.04 Favored 'General case' 0 C--N 1.342 0.239 0 CA-C-N 119.223 1.512 . . . . 10.0 109.542 168.871 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -124.69 135.54 53.13 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 106.454 -1.684 . . . . 10.0 106.454 178.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 7.9 mp -105.08 148.57 26.67 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.406 -1.331 . . . . 10.0 107.406 169.122 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.5 t -126.88 135.22 64.29 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 N-CA-C 107.429 -1.323 . . . . 10.0 107.429 178.307 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -102.91 121.0 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.883 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 169.604 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.624 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.0 m170 -106.12 162.6 13.48 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -169.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -47.95 -50.05 28.41 Favored 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 128.425 2.69 . . . . 10.0 112.477 174.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -128.49 171.97 11.58 Favored 'General case' 0 C--N 1.334 -0.086 0 C-N-CA 124.141 0.976 . . . . 10.0 112.225 -168.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.02 165.7 24.68 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.304 -0.862 . . . . 10.0 109.798 170.009 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.76 155.85 17.15 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.97 1.308 . . . . 10.0 111.637 -176.049 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -77.85 -15.3 59.15 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 114.731 -1.122 . . . . 10.0 110.254 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 73.2 mt 51.65 45.42 28.14 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 124.538 1.135 . . . . 10.0 110.335 172.179 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.19 27.85 73.26 Favored Glycine 0 N--CA 1.437 -1.246 0 CA-C-N 113.797 -1.547 . . . . 10.0 113.378 173.891 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -74.78 -3.84 34.06 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.295 1.548 . . . . 10.0 112.356 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.22 25.27 73.63 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 108.791 -1.724 . . . . 10.0 108.791 175.522 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -56.03 -30.15 56.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 170.601 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -155.87 167.84 29.12 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.59 -0.892 . . . . 10.0 108.59 -168.365 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.2 tm-20 -56.29 -46.27 79.83 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 108.511 -0.922 . . . . 10.0 108.511 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -59.04 -24.48 62.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 115.96 -0.564 . . . . 10.0 111.997 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 51.9 m -56.13 -32.63 64.41 Favored 'General case' 0 N--CA 1.444 -0.744 0 O-C-N 121.656 -0.653 . . . . 10.0 112.398 -177.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.6 t -93.46 7.73 43.38 Favored 'General case' 0 CA--C 1.534 0.339 0 O-C-N 123.52 0.512 . . . . 10.0 110.108 -174.074 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -128.69 -61.04 1.08 Allowed 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 126.678 1.991 . . . . 10.0 112.46 -174.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -135.71 31.03 3.09 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 120.69 1.586 . . . . 10.0 109.462 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 63.99 -97.59 0.23 Allowed Glycine 0 C--N 1.346 1.109 0 CA-C-O 123.79 1.772 . . . . 10.0 108.925 175.119 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.86 39.41 0.1 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 113.172 -1.514 . . . . 10.0 109.064 167.803 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.71 -12.95 52.25 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.713 0.805 . . . . 10.0 112.702 -169.224 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.75 -166.06 52.06 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 175.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -55.35 131.11 44.92 Favored 'General case' 0 N--CA 1.444 -0.771 0 C-N-CA 123.573 0.749 . . . . 10.0 111.935 -168.544 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -65.7 75.79 0.07 Allowed 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.603 0.761 . . . . 10.0 109.676 169.385 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 69.3 mt -45.37 -49.8 12.74 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.602 0.761 . . . . 10.0 110.726 177.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.56 155.86 36.96 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.495 -0.557 . . . . 10.0 109.495 -171.083 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -158.27 166.88 31.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.05 0.54 . . . . 10.0 109.572 -174.309 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.91 160.17 32.18 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 110.179 -1.169 . . . . 10.0 110.179 -173.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 57.4 t -109.25 138.38 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -171.747 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.7 mt -75.82 108.96 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 -177.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.5 135.19 12.23 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 109.957 -1.257 . . . . 10.0 109.957 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 151' ' ' ILE . . . . . 0.418 HG23 HD12 ' B' ' 113' ' ' ILE . 2.3 pt -75.42 127.25 36.89 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.231 0 CA-C-N 118.557 1.178 . . . . 10.0 108.604 174.189 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -75.39 -54.89 6.31 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 107.134 -1.432 . . . . 10.0 107.134 178.506 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.348 -0.834 . . . . 10.0 109.457 172.1 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 106.85 -1.537 . . . . 10.0 106.85 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 t -167.51 -38.01 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 124.055 0.942 . . . . 10.0 111.881 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 57.1 tttp -133.46 141.39 47.79 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 124.531 1.132 . . . . 10.0 109.843 178.709 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.66 169.53 21.36 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 126.487 1.915 . . . . 10.0 107.226 176.375 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.9 162.1 35.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 N-CA-C 109.526 -0.546 . . . . 10.0 109.526 -179.248 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.404 ' HB1' HD21 ' A' ' 8' ' ' LEU . . . -132.04 97.64 4.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.989 0.916 . . . . 10.0 108.951 175.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -83.73 106.0 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 N-CA-C 108.677 -0.86 . . . . 10.0 108.677 169.704 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.404 HD21 ' HB1' ' A' ' 6' ' ' ALA . 8.9 mt -100.14 140.68 34.02 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.63 -0.878 . . . . 10.0 108.63 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.9 ttmt -157.84 163.7 37.72 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.509 -1.293 . . . . 10.0 107.509 169.129 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.57 -53.14 0.06 OUTLIER Glycine 0 C--O 1.228 -0.255 0 C-N-CA 120.333 -0.937 . . . . 10.0 112.163 169.33 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -72.64 -45.34 59.49 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.329 -1.36 . . . . 10.0 107.329 -177.665 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.28 -71.09 0.41 Allowed Glycine 0 CA--C 1.524 0.619 0 CA-C-N 114.355 -1.293 . . . . 10.0 110.342 169.782 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -57.44 -34.8 98.56 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.462 2.775 . . . . 10.0 111.242 173.311 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.6 t -65.3 100.81 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.082 0 N-CA-C 107.335 -1.358 . . . . 10.0 107.335 175.055 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -119.5 116.23 25.67 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.568 1.147 . . . . 10.0 108.381 172.546 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.751 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.71 145.47 17.79 Favored Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 109.892 -1.283 . . . . 10.0 109.892 169.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.633 HG22 HG23 ' B' ' 54' ' ' THR . 1.2 mt -151.54 56.94 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.866 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.8 mm -80.82 140.23 16.95 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.041 0 O-C-N 121.587 -0.695 . . . . 10.0 110.011 -175.011 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -99.74 115.3 29.19 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.04 1.336 . . . . 10.0 108.298 170.377 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -92.56 110.38 21.8 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 105.486 -2.042 . . . . 10.0 105.486 170.486 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -131.17 146.6 52.4 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 119.084 0.856 . . . . 10.0 110.481 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.405 ' HB3' ' HA ' ' A' ' 29' ' ' VAL . 13.8 pt20 -148.24 16.21 1.05 Allowed 'General case' 0 C--N 1.342 0.274 0 N-CA-C 115.319 1.6 . . . . 10.0 115.319 -178.682 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? 74.23 -57.38 0.62 Allowed 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 125.595 1.558 . . . . 10.0 113.163 168.739 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.68 -157.26 0.8 Allowed 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 107.964 -1.124 . . . . 10.0 107.964 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -85.48 -23.08 27.94 Favored 'General case' 0 N--CA 1.45 -0.448 0 O-C-N 120.808 -1.182 . . . . 10.0 110.638 170.891 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -89.33 -21.27 23.21 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 123.985 0.914 . . . . 10.0 111.503 -173.456 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.56 151.76 51.68 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.619 -0.545 . . . . 10.0 112.356 -171.234 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -68.46 137.29 39.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.95 2.433 . . . . 10.0 108.842 169.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.405 ' HA ' ' HB3' ' A' ' 22' ' ' GLN . 0.3 OUTLIER -77.74 138.55 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 O-C-N 121.849 -0.532 . . . . 10.0 110.957 179.627 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -119.63 124.93 47.52 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.848 -1.538 . . . . 10.0 106.848 168.418 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.3 m -102.76 59.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 124.339 1.055 . . . . 10.0 109.094 -170.104 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.8 p90 -79.03 146.01 33.55 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 119.625 -0.83 . . . . 10.0 111.312 -172.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.39 -169.48 39.2 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.646 -0.981 . . . . 10.0 110.646 169.156 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.4 m -139.6 107.53 5.7 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.065 -0.717 . . . . 10.0 109.065 -170.411 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.751 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.2 pt -78.31 128.01 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 106.873 -1.529 . . . . 10.0 106.873 168.508 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 tttt -107.21 146.66 31.13 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.115 -1.439 . . . . 10.0 107.115 173.328 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -7.07 31.06 Favored Glycine 0 CA--C 1.522 0.528 0 CA-C-O 119.197 -0.779 . . . . 10.0 112.678 173.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.415 HD21 HD12 ' A' ' 35' ' ' ILE . 3.4 mm? -62.47 177.01 0.55 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.675 1.238 . . . . 10.0 109.284 168.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -113.53 157.06 22.51 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.961 -0.755 . . . . 10.0 108.961 170.039 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -48.9 123.67 7.41 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.062 1.345 . . . . 10.0 111.094 -171.073 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.66 -169.12 13.13 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 123.794 0.711 . . . . 10.0 112.347 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -77.3 146.77 36.61 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 126.12 1.768 . . . . 10.0 112.391 -170.448 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -149.48 144.0 26.03 Favored 'General case' 0 C--N 1.342 0.276 0 N-CA-C 114.049 1.129 . . . . 10.0 114.049 -178.443 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.595 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -33.15 126.24 0.34 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 127.145 2.307 . . . . 10.0 112.232 165.56 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.403 ' CD1' HD12 ' A' ' 84' ' ' LEU . 6.6 t80 -151.03 108.11 3.58 Favored 'General case' 0 C--O 1.238 0.486 0 CA-C-N 119.504 1.652 . . . . 10.0 109.561 167.738 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.94 174.44 13.62 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.148 0.975 . . . . 10.0 113.4 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.9 p -90.61 151.4 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 CA-C-N 112.028 -2.351 . . . . 10.0 108.038 168.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -127.59 142.69 51.29 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 106.931 -1.507 . . . . 10.0 106.931 171.25 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -37.24 -55.77 0.98 Allowed 'General case' 0 C--O 1.237 0.403 0 C-N-CA 127.535 2.334 . . . . 10.0 113.7 -170.006 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -106.34 169.31 8.59 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-O 122.367 1.079 . . . . 10.0 112.556 -171.417 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.42 -23.47 24.05 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 126.664 2.078 . . . . 10.0 109.771 169.506 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -43.39 120.41 1.9 Allowed 'General case' 0 C--N 1.346 0.417 0 CA-C-O 122.009 0.909 . . . . 10.0 109.863 170.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -134.75 11.9 3.69 Favored 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 125.942 1.697 . . . . 10.0 108.497 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.436 HG23 HG22 ' B' ' 17' ' ' ILE . 1.3 m -59.45 -33.64 71.54 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 119.031 0.832 . . . . 10.0 112.083 -168.216 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.39 -16.14 59.0 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.915 0.886 . . . . 10.0 112.33 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.26 62.92 0.56 Allowed Glycine 0 CA--C 1.521 0.462 0 N-CA-C 108.655 -1.778 . . . . 10.0 108.655 -172.355 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.6 p 41.31 39.6 1.02 Allowed 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 125.868 1.667 . . . . 10.0 114.122 171.825 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 16.3 m -108.13 -53.3 2.65 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.759 2.024 . . . . 10.0 105.584 -177.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.4 m -66.66 -15.46 63.5 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.525 1.93 . . . . 10.0 112.665 -175.623 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -50.06 -6.28 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.936 2.494 . . . . 10.0 115.715 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 105.8 123.41 5.16 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.117 -1.38 . . . . 10.0 110.372 170.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.59 60.16 5.78 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.595 2.863 . . . . 10.0 110.638 173.172 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 65.34 37.61 6.23 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 130.27 3.428 . . . . 10.0 111.897 179.347 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.1 m-30 -72.89 62.32 0.59 Allowed 'General case' 0 N--CA 1.468 0.462 0 O-C-N 121.196 -0.94 . . . . 10.0 110.628 175.066 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -74.1 152.66 88.49 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.247 -0.908 . . . . 10.0 111.146 -172.182 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -60.45 -42.67 39.09 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.435 2.756 . . . . 10.0 111.848 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.3 tp -77.91 59.08 2.04 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 123.781 0.832 . . . . 10.0 108.772 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 58.7 p -40.75 104.85 0.04 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.282 2.233 . . . . 10.0 112.128 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -137.62 175.11 9.88 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 126.403 1.881 . . . . 10.0 107.467 -177.735 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.15 113.93 27.42 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-N 118.952 0.796 . . . . 10.0 109.884 -174.698 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.0 t60 -30.18 101.55 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 114.593 1.331 . . . . 10.0 114.593 -171.612 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -114.44 -147.97 9.6 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 176.247 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.33 -148.65 5.64 Favored Glycine 0 C--N 1.332 0.334 0 CA-C-O 118.237 -1.313 . . . . 10.0 109.902 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -62.76 -3.76 4.95 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 CA-C-N 120.225 2.012 . . . . 10.0 111.946 169.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -85.0 -19.61 31.77 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 118.452 -0.785 . . . . 10.0 111.041 171.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -130.55 162.41 29.35 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 123.849 1.785 . . . . 10.0 112.875 -166.309 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -85.43 -24.06 27.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 112.879 -1.964 . . . . 10.0 108.261 166.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -86.34 7.79 24.11 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.532 1.533 . . . . 10.0 110.85 -174.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 33.9 ptt-85 -48.33 126.83 11.93 Favored 'General case' 0 C--N 1.342 0.263 0 N-CA-C 106.507 -1.664 . . . . 10.0 106.507 166.624 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m80 -50.57 -57.47 8.08 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.11 0.411 . . . . 10.0 112.11 -167.651 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.7 p -173.9 -45.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 124.711 1.205 . . . . 10.0 108.33 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.14 56.44 0.73 Allowed Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.681 -1.367 . . . . 10.0 109.681 175.617 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -97.5 97.25 8.92 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 106.001 -1.851 . . . . 10.0 106.001 169.058 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.403 HD12 ' CD1' ' A' ' 45' ' ' PHE . 14.0 mt -76.26 -27.11 56.58 Favored 'General case' 0 C--N 1.34 0.163 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 173.418 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.71 -104.17 3.07 Favored Glycine 0 N--CA 1.439 -1.128 0 N-CA-C 108.638 -1.785 . . . . 10.0 108.638 168.443 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -122.3 100.28 6.87 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.055 1.342 . . . . 10.0 109.48 -167.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.2 m -95.74 136.92 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 C-N-CA 122.855 0.462 . . . . 10.0 110.187 178.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.8 m -85.19 119.41 25.54 Favored 'General case' 0 N--CA 1.439 -0.985 0 C-N-CA 127.437 2.295 . . . . 10.0 108.819 -177.041 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.57 134.65 39.52 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 123.568 0.747 . . . . 10.0 109.627 169.584 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -62.62 169.86 2.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 O-C-N 124.412 1.07 . . . . 10.0 108.751 166.419 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.86 -21.63 64.84 Favored 'General case' 0 N--CA 1.445 -0.705 0 C-N-CA 124.192 0.997 . . . . 10.0 112.892 172.454 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.17 -4.68 45.86 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.036 0.446 . . . . 10.0 110.691 171.523 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.22 6.3 86.44 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 120.671 -1.268 . . . . 10.0 110.839 178.353 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.18 106.13 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 127.339 2.256 . . . . 10.0 107.332 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.432 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -103.43 116.47 32.47 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 167.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.28 104.17 10.65 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 126.812 2.045 . . . . 10.0 109.841 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.12 131.86 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 172.517 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.3 m -157.52 57.63 0.5 Allowed 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.495 1.118 . . . . 10.0 109.476 173.399 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.84 150.75 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.835 -1.543 . . . . 10.0 106.835 178.455 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -128.19 150.81 49.85 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 108.626 170.11 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.13 124.42 6.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 108.873 -0.788 . . . . 10.0 108.873 172.376 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 11.0 t -79.07 0.48 27.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.291 1.037 . . . . 10.0 112.196 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.41 -24.75 17.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 CA-C-N 119.579 1.081 . . . . 10.0 109.486 177.714 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.0 159.28 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 124.599 1.16 . . . . 10.0 111.003 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.8 m -152.72 144.93 23.89 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.281 -2.118 . . . . 10.0 105.281 174.632 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.6 mt -65.04 -8.55 16.7 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 123.95 0.9 . . . . 10.0 111.828 176.279 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.6 m -150.94 137.96 19.15 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.031 -1.47 . . . . 10.0 107.031 169.198 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.26 -66.25 0.14 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 109.018 -1.633 . . . . 10.0 109.018 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -167.71 -51.44 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 125.58 1.552 . . . . 10.0 107.981 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.96 -36.19 62.07 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 114.914 -1.039 . . . . 10.0 109.128 -169.194 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 30.9 t 38.98 70.66 0.2 Allowed 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 126.692 1.997 . . . . 10.0 112.263 167.704 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -56.67 -10.22 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 114.113 1.153 . . . . 10.0 114.113 177.77 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 mm -33.87 -52.95 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.327 1.451 . . . . 10.0 112.98 170.116 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -96.81 9.48 66.11 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-O 118.937 -0.924 . . . . 10.0 114.153 -174.336 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.94 156.46 21.18 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 118.525 1.162 . . . . 10.0 109.742 176.67 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 59.1 m -90.4 131.58 36.1 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.768 0.827 . . . . 10.0 109.627 168.63 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -99.87 145.61 27.58 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 167.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.8 t -137.46 136.34 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 123.516 0.726 . . . . 10.0 109.17 -176.244 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.35 142.08 17.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 O-C-N 124.579 1.175 . . . . 10.0 108.811 167.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.595 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.5 m170 -121.72 162.03 21.53 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.896 1.443 . . . . 10.0 114.896 -175.637 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -58.31 -50.87 72.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.266 1.427 . . . . 10.0 110.736 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -116.39 172.75 7.0 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 121.804 0.812 . . . . 10.0 112.203 -178.853 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.28 138.96 40.88 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 126.054 1.742 . . . . 10.0 108.981 174.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.36 164.76 25.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 122.232 1.015 . . . . 10.0 111.847 173.596 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.413 ' OD1' ' NZ ' ' A' ' 128' ' ' LYS . 25.6 t0 -74.82 -8.15 55.57 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 113.608 -1.633 . . . . 10.0 111.298 178.629 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 14.5 mt 46.8 41.18 10.05 Favored 'General case' 0 C--N 1.339 0.113 0 C-N-CA 124.484 1.114 . . . . 10.0 109.831 -177.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 72.05 19.64 78.53 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 118.313 -1.271 . . . . 10.0 114.765 171.862 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.413 ' NZ ' ' OD1' ' A' ' 125' ' ' ASP 0.251 8.7 mtmp? -77.13 10.65 2.25 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 119.803 1.801 . . . . 10.0 114.991 -176.073 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.72 29.0 61.98 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 109.185 -1.566 . . . . 10.0 109.185 168.196 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -53.19 -30.01 38.17 Favored Glycine 0 N--CA 1.436 -1.351 0 CA-C-O 118.132 -1.371 . . . . 10.0 110.321 167.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 174.61 178.85 0.13 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 106.7 -1.593 . . . . 10.0 106.7 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 37.5 mp0 -49.48 -41.29 40.12 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 112.876 0.695 . . . . 10.0 112.876 179.179 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 -64.33 -24.13 67.54 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 121.244 -0.91 . . . . 10.0 110.684 -178.481 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.413 ' HA ' ' HA2' ' A' ' 138' ' ' GLY . 55.1 m -45.3 -44.58 11.58 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 122.964 0.506 . . . . 10.0 110.286 175.792 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 t -84.7 -1.09 55.7 Favored 'General case' 0 CA--C 1.541 0.628 0 O-C-N 124.049 0.843 . . . . 10.0 112.147 -170.233 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.1 mttt -118.82 -73.65 0.64 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.955 1.302 . . . . 10.0 110.275 -173.386 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.1 p -121.56 26.83 8.56 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 120.164 -1.585 . . . . 10.0 110.242 171.544 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' A' ' 134' ' ' SER . . . 72.86 -91.57 0.6 Allowed Glycine 0 C--N 1.342 0.886 0 N-CA-C 109.934 -1.266 . . . . 10.0 109.934 174.501 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -173.38 39.12 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.195 1.398 . . . . 10.0 108.886 171.087 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.26 -16.61 62.49 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 121.473 -0.767 . . . . 10.0 112.77 -168.311 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.37 -162.59 54.66 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.102 -1.199 . . . . 10.0 110.102 175.631 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -51.9 126.77 19.14 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.036 1.334 . . . . 10.0 113.8 -168.326 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -64.7 72.89 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.229 1.812 . . . . 10.0 110.996 173.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.2 mt -51.12 -35.67 36.6 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 113.381 0.882 . . . . 10.0 113.381 -178.069 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 154.47 37.09 Favored 'General case' 0 CA--C 1.511 -0.555 0 O-C-N 121.61 -0.681 . . . . 10.0 109.948 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.6 p -153.24 153.7 33.21 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.583 -0.895 . . . . 10.0 108.583 -172.512 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.81 153.37 24.36 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 112.044 -0.422 . . . . 10.0 112.044 179.487 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 63.4 t -101.3 125.31 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.012 -2.218 . . . . 10.0 105.012 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.2 mt -68.55 164.93 2.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 CA-C-N 119.009 0.822 . . . . 10.0 110.403 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -160.5 150.66 20.84 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.576 1.56 . . . . 10.0 109.443 -172.136 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.3 mt -70.93 141.7 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.892 1.277 . . . . 10.0 109.023 -173.802 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.43 -46.51 2.87 Favored 'General case' 0 C--O 1.224 -0.268 0 C-N-CA 123.1 0.56 . . . . 10.0 110.674 170.25 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.7 tp60 . . . . . 0 C--O 1.25 1.107 0 C-N-CA 126.634 1.974 . . . . 10.0 112.082 -173.04 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.872 0 CA-C-O 117.571 -1.205 . . . . 10.0 108.993 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 t -61.27 -38.16 85.74 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 120.19 1.359 . . . . 10.0 108.852 172.288 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 36.9 tttt -132.03 156.35 46.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.447 1.499 . . . . 10.0 110.219 168.728 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.47 175.35 14.14 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 129.01 2.924 . . . . 10.0 106.504 166.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -133.6 179.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 118.677 0.671 . . . . 10.0 110.611 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.43 108.9 2.1 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.093 0.957 . . . . 10.0 109.189 165.039 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -95.17 124.28 47.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 122.959 0.503 . . . . 10.0 110.208 170.752 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -103.54 146.24 28.84 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 125.441 1.496 . . . . 10.0 110.275 176.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 5.4 tttm -161.73 158.61 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 169.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 179.86 -46.55 0.08 OUTLIER Glycine 0 N--CA 1.46 0.236 0 C-N-CA 118.927 -1.606 . . . . 10.0 113.638 169.353 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -72.59 -47.71 45.69 Favored 'General case' 0 N--CA 1.451 -0.375 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 -178.399 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.91 -73.84 0.29 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 114.331 -1.304 . . . . 10.0 109.845 171.115 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -59.07 -34.74 98.98 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.738 2.959 . . . . 10.0 111.18 174.728 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.5 t -62.2 114.04 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.12 -1.067 . . . . 10.0 108.12 176.006 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.87 118.6 22.97 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 106.339 -1.726 . . . . 10.0 106.339 168.589 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.679 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -102.47 141.12 15.14 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-O 118.598 -1.112 . . . . 10.0 110.48 174.42 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.436 HG22 HG23 ' A' ' 54' ' ' THR . 9.4 mt -139.78 94.2 0.77 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 C-N-CA 123.874 0.87 . . . . 10.0 109.063 -173.062 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.7 mm -105.71 139.77 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 C-N-CA 125.658 1.583 . . . . 10.0 112.623 -178.893 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -106.75 126.6 52.49 Favored 'General case' 0 C--N 1.34 0.179 0 N-CA-C 106.452 -1.685 . . . . 10.0 106.452 167.059 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -104.16 112.42 25.42 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 107.057 -1.46 . . . . 10.0 107.057 168.54 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -126.82 136.32 52.2 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 118.462 0.573 . . . . 10.0 112.35 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -105.48 112.76 25.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.62 1.568 . . . . 10.0 106.873 169.017 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.235 0.308 0 N-CA-C 111.93 0.344 . . . . 10.0 111.93 -177.023 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.025 0 CA-C-O 118.59 -1.117 . . . . 10.0 114.496 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -65.26 115.84 3.55 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 CA-C-N 119.834 1.817 . . . . 10.0 107.652 170.375 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t -77.27 84.65 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 105.31 -2.107 . . . . 10.0 105.31 175.825 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -74.35 117.4 16.12 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.024 -1.473 . . . . 10.0 107.024 179.38 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.42 58.77 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 C-N-CA 125.085 1.354 . . . . 10.0 108.121 -169.372 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.4 p90 -81.48 143.21 32.24 Favored 'General case' 0 C--N 1.341 0.209 0 C-N-CA 119.134 -1.026 . . . . 10.0 111.996 -176.837 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.81 -169.09 41.39 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.636 -1.269 . . . . 10.0 110.106 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 m -153.24 133.11 13.2 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.679 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.3 pt -103.63 147.72 9.53 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 N-CA-C 107.995 -1.113 . . . . 10.0 107.995 167.212 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -124.81 149.98 46.85 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 169.047 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.48 -6.7 36.24 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 123.428 0.537 . . . . 10.0 112.519 171.665 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.41 HD12 ' CG ' ' B' ' 43' ' ' HIS . 2.0 mm? -63.93 174.43 1.49 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.956 0.878 . . . . 10.0 109.965 169.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -101.76 170.81 7.92 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 105.898 -1.89 . . . . 10.0 105.898 165.414 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -59.84 166.67 2.52 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 118.661 0.664 . . . . 10.0 111.829 -171.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.49 -171.56 45.75 Favored Glycine 0 N--CA 1.446 -0.647 0 O-C-N 121.478 -0.764 . . . . 10.0 111.72 169.487 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -77.5 144.31 37.8 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.259 1.424 . . . . 10.0 111.224 -174.022 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 43' ' ' HIS . . . . . 0.41 ' CG ' HD12 ' B' ' 38' ' ' LEU . 89.7 m-70 -147.48 127.88 14.01 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.518 1.127 . . . . 10.0 112.633 -173.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.69 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -18.69 128.71 0.01 OUTLIER Glycine 0 C--N 1.342 0.881 0 C-N-CA 127.499 2.476 . . . . 10.0 114.179 165.739 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.75 104.94 3.23 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 118.605 1.203 . . . . 10.0 109.793 167.73 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.51 176.46 10.93 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 112.766 0.654 . . . . 10.0 112.766 176.385 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 23.4 m -89.82 158.69 2.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 113.601 -1.636 . . . . 10.0 108.626 168.469 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 74.8 m-70 -136.47 78.11 1.69 Allowed 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 123.586 0.755 . . . . 10.0 111.138 176.021 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.8 tt0 47.65 -94.42 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.792 1.237 . . . . 10.0 113.027 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -78.76 172.03 14.32 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.582 0.628 . . . . 10.0 110.01 -173.128 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.97 -23.1 23.74 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.553 -1.019 . . . . 10.0 110.553 170.141 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -37.71 135.07 0.64 Allowed 'General case' 0 C--N 1.343 0.306 0 C-N-CA 124.598 1.159 . . . . 10.0 110.863 170.46 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.427 HD21 HG21 ' B' ' 116' ' ' THR . 0.3 OUTLIER -146.05 23.99 1.33 Allowed 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 114.75 -1.114 . . . . 10.0 110.362 173.152 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.633 HG23 HG22 ' A' ' 17' ' ' ILE . 2.7 m -52.43 -36.83 55.34 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.065 0.848 . . . . 10.0 110.982 -173.513 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.56 -21.72 28.41 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.29 1.436 . . . . 10.0 113.697 177.178 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.48 101.92 1.45 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.813 1.197 . . . . 10.0 110.183 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.314 2.6 p 17.43 57.65 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 127.752 2.421 . . . . 10.0 114.151 -170.377 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.8 m -130.48 -61.9 0.94 Allowed 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.479 -2.045 . . . . 10.0 105.479 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 39.3 t -69.66 -35.68 75.38 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.009 1.324 . . . . 10.0 111.323 -178.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.88 -47.41 0.13 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 127.122 2.169 . . . . 10.0 114.181 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 138.5 172.54 12.6 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.243 -1.543 . . . . 10.0 109.243 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -78.67 -137.35 0.02 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.222 0 N-CA-C 104.156 -3.055 . . . . 10.0 104.156 166.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -100.99 50.68 0.86 Allowed 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 121.067 1.758 . . . . 10.0 109.557 170.137 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -71.79 80.05 0.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.169 0.985 . . . . 10.0 110.033 177.909 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.5 p-10 -80.15 156.31 74.26 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 125.474 1.509 . . . . 10.0 110.222 172.614 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -63.51 -50.1 3.75 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.489 2.126 . . . . 10.0 111.292 177.791 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.58 57.72 1.64 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.213 0.605 . . . . 10.0 109.887 179.623 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.9 p -51.35 114.21 1.16 Allowed 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.607 1.163 . . . . 10.0 109.999 -176.308 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.2 mtt-85 -131.33 -86.49 0.49 Allowed 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 104.996 -2.224 . . . . 10.0 104.996 -176.566 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 ptpp? -163.26 162.77 25.42 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 167.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 66.9 t60 -58.28 132.67 54.31 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 118.358 -1.337 . . . . 10.0 107.655 168.317 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.37 -133.23 2.64 Favored Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 169.55 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.507 ' HA3' HD13 ' B' ' 126' ' ' LEU . . . 163.51 -161.28 33.99 Favored Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 108.376 -1.89 . . . . 10.0 108.376 178.046 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.74 4.61 0.8 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.864 1.71 . . . . 10.0 111.928 168.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.567 ' HG3' HD12 ' B' ' 126' ' ' LEU . 9.9 mmmt -114.03 7.94 16.94 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 119.225 0.92 . . . . 10.0 110.481 170.876 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -125.93 163.09 23.74 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 119.733 1.151 . . . . 10.0 108.977 167.703 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -81.61 -30.06 33.02 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 169.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -119.65 61.5 0.83 Allowed 'General case' 0 N--CA 1.436 -1.168 0 CA-C-O 122.095 0.95 . . . . 10.0 110.859 -168.489 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 79' ' ' ARG . . . . . 0.442 HH12 ' CG ' ' B' ' 101' ' ' ASP . 0.3 OUTLIER -56.32 164.39 1.36 Allowed 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 114.393 -1.276 . . . . 10.0 108.697 164.833 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.6 m170 -65.99 -84.57 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 N-CA-C 108.569 -0.9 . . . . 10.0 108.569 169.36 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 49.2 t -149.82 -82.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 104.186 -2.524 . . . . 10.0 104.186 169.055 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.83 53.89 4.77 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.566 -0.614 . . . . 10.0 111.566 -178.705 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -93.9 98.78 11.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 104.39 -2.448 . . . . 10.0 104.39 168.224 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 37.1 mt -81.92 -36.26 28.26 Favored 'General case' 0 C--N 1.334 -0.095 0 N-CA-C 105.744 -1.947 . . . . 10.0 105.744 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.26 -92.06 0.64 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 106.717 -2.553 . . . . 10.0 106.717 169.503 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -155.82 155.73 33.5 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 122.793 0.437 . . . . 10.0 111.45 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.48 145.68 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 O-C-N 124.762 1.289 . . . . 10.0 108.507 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.0 m -93.43 110.42 21.98 Favored 'General case' 0 N--CA 1.436 -1.135 0 C-N-CA 128.497 2.719 . . . . 10.0 108.88 -172.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.3 135.59 33.49 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 123.771 0.828 . . . . 10.0 110.117 174.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -61.65 168.51 2.91 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 124.091 0.956 . . . . 10.0 109.107 166.477 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.78 -30.67 45.7 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.492 0.717 . . . . 10.0 111.079 172.63 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -78.68 1.6 22.36 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-O 121.25 0.548 . . . . 10.0 111.454 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.92 90.7 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 120.843 -1.161 . . . . 10.0 110.947 176.769 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.1 t -79.77 104.72 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.059 0 C-N-CA 127.09 2.156 . . . . 10.0 107.013 179.242 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.54 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -107.55 115.09 29.53 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 168.448 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.7 123.36 27.59 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 127.381 2.272 . . . . 10.0 108.622 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.0 t -110.79 131.43 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 C-N-CA 125.494 1.517 . . . . 10.0 107.279 178.804 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 93.0 p -156.98 59.14 0.52 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 123.316 0.646 . . . . 10.0 109.552 177.288 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.83 154.82 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -176.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -102.33 153.21 20.22 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 126.639 1.976 . . . . 10.0 107.382 170.169 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 101' ' ' ASP . . . . . 0.442 ' CG ' HH12 ' B' ' 79' ' ' ARG . 23.8 t0 -149.06 85.17 1.46 Allowed 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.583 0.706 . . . . 10.0 109.292 174.703 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.8 p -90.25 38.11 0.92 Allowed 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.81 0.844 . . . . 10.0 109.663 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 26.1 t -106.75 -46.19 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 107.444 -1.317 . . . . 10.0 107.444 176.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.406 ' CD1' ' H ' ' B' ' 104' ' ' ILE 0.261 0.0 OUTLIER -100.88 176.01 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 114.155 1.168 . . . . 10.0 114.155 175.465 . . . . . . . . 4 4 . 1 . 019 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -136.29 142.8 43.95 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.517 -1.66 . . . . 10.0 106.517 169.167 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -65.58 -25.72 67.54 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.131 0.573 . . . . 10.0 110.117 171.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.451 -0.408 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 170.275 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.9 t . . . . . 0 N--CA 1.443 -0.794 0 CA-C-O 118.356 -0.831 . . . . 10.0 109.301 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 12.5 pt -68.97 65.19 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.324 0 CA-C-O 122.786 1.279 . . . . 10.0 110.388 173.825 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.6 mm -110.61 151.73 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 129.117 2.967 . . . . 10.0 105.275 167.831 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 55.31 35.64 61.09 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 124.866 1.222 . . . . 10.0 113.746 171.382 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 83.7 mtt85 -113.96 154.62 27.28 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.305 1.842 . . . . 10.0 107.51 171.728 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 116' ' ' THR . . . . . 0.427 HG21 HD21 ' B' ' 53' ' ' ASN . 90.2 m -86.06 133.95 33.86 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.01 0.924 . . . . 10.0 109.7 177.257 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -98.42 147.46 24.69 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 125.212 1.405 . . . . 10.0 107.297 166.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.57 141.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-N 118.563 0.62 . . . . 10.0 109.369 176.886 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.418 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 7.6 p -103.32 139.45 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 C-N-CA 124.575 1.15 . . . . 10.0 108.981 168.064 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.69 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.6 m-70 -115.91 164.25 14.69 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.814 1.413 . . . . 10.0 114.814 -175.268 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 121' ' ' GLU . . . . . 0.402 ' HB2' HD21 ' B' ' 144' ' ' LEU . 73.8 tt0 -59.43 -49.43 77.85 Favored 'General case' 0 C--N 1.343 0.293 0 C-N-CA 123.756 0.823 . . . . 10.0 110.438 178.607 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.2 mttt -121.24 175.56 6.06 Favored 'General case' 0 N--CA 1.462 0.169 0 N-CA-C 112.229 0.455 . . . . 10.0 112.229 -169.186 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.54 139.03 39.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.201 1.0 . . . . 10.0 109.332 173.763 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.67 144.1 30.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.059 0.944 . . . . 10.0 108.827 167.67 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -79.2 28.31 0.23 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 123.395 0.678 . . . . 10.0 111.236 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.567 HD12 ' HG3' ' B' ' 75' ' ' LYS . 6.6 mt 23.86 60.23 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 128.685 2.794 . . . . 10.0 112.157 -168.85 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 92.63 -35.58 4.0 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 126.192 1.853 . . . . 10.0 112.147 174.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.2 mtmm -84.46 44.15 1.02 Allowed 'General case' 0 CA--C 1.537 0.465 0 O-C-N 121.256 -1.144 . . . . 10.0 111.247 -170.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.44 -18.12 46.8 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 126.518 2.008 . . . . 10.0 110.159 169.371 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.15 35.82 91.41 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 123.965 0.793 . . . . 10.0 112.415 172.762 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -144.48 169.48 17.87 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 107.916 -1.142 . . . . 10.0 107.916 172.163 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -52.64 -47.4 67.09 Favored 'General case' 0 N--CA 1.444 -0.736 0 CA-C-O 121.805 0.812 . . . . 10.0 110.351 -177.44 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -65.36 -31.59 72.79 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 121.32 -0.863 . . . . 10.0 111.234 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 12.3 p -55.5 -42.14 74.03 Favored 'General case' 0 N--CA 1.447 -0.604 0 O-C-N 120.818 -1.176 . . . . 10.0 111.353 171.601 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.6 t -80.91 -24.16 38.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 119.835 -0.746 . . . . 10.0 111.202 -176.924 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 ttmm -80.81 -50.57 9.65 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 125.886 1.674 . . . . 10.0 111.533 -176.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 26.1 p -136.2 -15.18 1.72 Allowed 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 114.441 1.274 . . . . 10.0 114.441 176.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.53 3.07 55.43 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-O 118.286 -1.286 . . . . 10.0 113.884 -179.464 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 29.1 m120 73.23 26.97 2.02 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.101 1.45 . . . . 10.0 112.359 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.47 -2.29 13.48 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.272 -0.892 . . . . 10.0 113.298 176.586 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.0 -170.15 50.92 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 -175.681 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.51 169.66 2.87 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.167 0.987 . . . . 10.0 112.135 -177.01 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.79 115.96 18.82 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.85 2.06 . . . . 10.0 109.814 168.664 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.423 ' N ' ' CD2' ' B' ' 144' ' ' LEU . 0.4 OUTLIER -92.0 -36.84 13.18 Favored 'General case' 0 C--N 1.34 0.169 0 CA-C-N 119.753 1.16 . . . . 10.0 111.414 -176.263 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.418 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -148.36 149.78 32.4 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 176.838 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -118.63 142.44 47.64 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.796 1.638 . . . . 10.0 107.672 -168.907 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -137.06 161.19 25.14 Favored Glycine 0 C--N 1.331 0.265 0 N-CA-C 109.79 -1.324 . . . . 10.0 109.79 171.566 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -123.52 152.27 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 104.246 -2.501 . . . . 10.0 104.246 171.522 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.0 mt -67.41 -91.67 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 124.018 0.927 . . . . 10.0 111.625 -167.155 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.84 136.2 9.22 Favored Glycine 0 CA--C 1.532 1.112 0 N-CA-C 111.68 -0.568 . . . . 10.0 111.68 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 9.5 pt -85.34 146.78 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 C-N-CA 124.534 1.134 . . . . 10.0 110.122 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.87 -24.36 8.19 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.575 0.75 . . . . 10.0 112.8 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.88 0 C-N-CA 124.355 1.062 . . . . 10.0 108.195 -174.658 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.86 0 CA-C-O 117.89 -1.053 . . . . 10.0 109.158 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -116.81 -50.3 2.61 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 123.947 0.899 . . . . 10.0 112.304 -176.136 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -111.87 125.73 54.34 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 126.638 1.975 . . . . 10.0 108.825 -176.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 164.22 30.54 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.694 1.198 . . . . 10.0 108.286 170.188 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.4 m -139.04 164.46 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 C-N-CA 123.7 0.8 . . . . 10.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.66 118.72 15.38 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.644 -0.873 . . . . 10.0 108.644 168.303 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -92.34 110.23 22.57 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.33 -0.989 . . . . 10.0 108.33 168.248 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.424 ' N ' HD12 ' A' ' 8' ' ' LEU . 5.1 mp -95.0 144.86 25.35 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 108.731 -0.84 . . . . 10.0 108.731 177.032 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.2 mtmt -156.45 161.49 40.06 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 172.699 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.69 -51.59 0.09 OUTLIER Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.071 -1.061 . . . . 10.0 113.653 169.29 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.4 -44.57 62.3 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.49 -1.3 . . . . 10.0 107.49 -175.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.19 -71.01 0.4 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.684 -1.366 . . . . 10.0 109.684 169.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -58.06 -35.54 98.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 123.089 2.526 . . . . 10.0 111.273 172.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.3 t -64.65 107.33 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 178.264 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.45 104.87 10.0 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 172.489 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.807 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.37 137.1 14.15 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 176.003 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.424 ' CG2' HG22 ' B' ' 54' ' ' THR . 3.7 mt -139.08 87.93 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.282 0 N-CA-C 107.381 -1.34 . . . . 10.0 107.381 -175.558 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -99.75 141.64 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.16 0 C-N-CA 124.819 1.248 . . . . 10.0 110.059 -178.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -126.27 113.45 16.97 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.476 1.91 . . . . 10.0 108.569 175.379 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -93.51 115.02 27.53 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 126.367 1.867 . . . . 10.0 108.545 177.888 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -117.5 130.04 56.19 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.85 1.055 . . . . 10.0 113.85 171.606 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -105.2 111.88 24.8 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 104.545 -2.391 . . . . 10.0 104.545 166.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -65.0 -36.78 85.52 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.952 -0.468 . . . . 10.0 111.131 -172.436 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -137.6 -165.43 1.77 Allowed 'General case' 0 N--CA 1.436 -1.175 0 N-CA-C 104.521 -2.4 . . . . 10.0 104.521 171.508 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.0 t -78.6 -24.48 45.39 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 118.97 0.805 . . . . 10.0 110.206 173.048 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.6 m-80 -91.83 -17.88 24.65 Favored 'General case' 0 N--CA 1.448 -0.574 0 C-N-CA 124.648 1.179 . . . . 10.0 110.551 -175.26 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.22 144.82 41.74 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 178.421 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -63.63 156.87 54.62 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 N-CA-C 108.116 -1.532 . . . . 10.0 108.116 169.576 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 75.2 t -79.0 102.31 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 N-CA-C 106.036 -1.839 . . . . 10.0 106.036 175.78 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.2 mtpp -79.0 105.38 10.3 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 105.49 -2.041 . . . . 10.0 105.49 170.022 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -100.58 97.85 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 C-N-CA 125.421 1.488 . . . . 10.0 107.502 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.6 p90 -103.26 174.59 5.8 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.322 0.582 . . . . 10.0 110.205 169.747 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.07 170.93 37.97 Favored Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 110.79 -0.924 . . . . 10.0 110.79 177.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.6 t -136.82 96.39 3.31 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 177.323 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.807 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.6 pt -81.24 140.59 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 169.456 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.6 tttm -112.83 158.08 20.59 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 108.522 -0.918 . . . . 10.0 108.522 167.339 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.12 -7.27 58.57 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 123.579 0.609 . . . . 10.0 112.678 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -67.44 170.07 8.04 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 118.235 1.017 . . . . 10.0 109.86 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -103.65 153.33 20.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.688 -1.597 . . . . 10.0 106.688 167.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.6 143.88 4.72 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.25 1.02 . . . . 10.0 112.046 -170.497 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.48 -173.35 24.89 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 123.846 0.736 . . . . 10.0 112.269 171.541 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.26 145.27 54.41 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.594 1.957 . . . . 10.0 111.493 -175.162 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -146.31 141.25 27.1 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.398 1.079 . . . . 10.0 111.77 175.42 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.67 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -24.69 123.58 0.03 OUTLIER Glycine 0 C--N 1.344 1.008 0 C-N-CA 126.493 1.996 . . . . 10.0 112.219 165.703 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -144.55 104.54 4.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 119.735 1.767 . . . . 10.0 109.502 171.01 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.26 170.41 20.1 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 121.835 0.826 . . . . 10.0 111.557 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.4 m -88.54 149.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-N 112.139 -2.301 . . . . 10.0 106.259 167.313 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -120.6 128.08 52.7 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 103.782 -2.673 . . . . 10.0 103.782 169.049 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -58.54 -51.35 70.25 Favored 'General case' 0 N--CA 1.44 -0.932 0 O-C-N 124.99 1.431 . . . . 10.0 110.016 -168.653 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -79.55 137.84 37.29 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 -179.542 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.34 25.57 9.72 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.853 -0.899 . . . . 10.0 110.853 173.077 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.7 p30 -75.84 72.48 2.73 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 123.542 1.639 . . . . 10.0 109.317 170.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.471 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.6 OUTLIER -75.82 6.24 5.28 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 113.658 -1.61 . . . . 10.0 112.66 -173.853 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.543 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.1 OUTLIER -39.2 -44.26 1.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 128.207 2.603 . . . . 10.0 111.982 175.221 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.37 -19.97 48.89 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.247 1.019 . . . . 10.0 113.258 -177.472 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.79 87.13 1.47 Allowed Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.404 -1.079 . . . . 10.0 110.404 -177.129 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 m 52.31 29.14 6.38 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.417 1.487 . . . . 10.0 112.407 172.212 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.5 m -117.53 -54.83 2.34 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.295 -1.372 . . . . 10.0 107.295 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.1 m -77.01 -16.19 59.39 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 123.961 0.905 . . . . 10.0 112.579 -171.081 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -53.03 -12.88 0.38 Allowed 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.979 1.712 . . . . 10.0 115.234 -170.186 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.23 125.87 3.06 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 118.647 -1.085 . . . . 10.0 110.436 171.621 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -75.53 64.01 6.47 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.49 2.793 . . . . 10.0 111.732 179.326 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 26.7 m170 67.07 53.91 0.78 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 128.692 2.797 . . . . 10.0 111.108 175.636 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 -71.85 43.77 0.1 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 114.604 1.335 . . . . 10.0 114.604 -173.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -56.57 147.38 50.75 Favored Pre-proline 0 CA--C 1.54 0.568 0 O-C-N 120.817 -1.177 . . . . 10.0 112.565 -174.069 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -64.89 -43.03 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.81 2.34 . . . . 10.0 110.853 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 75.9 mt -76.69 54.6 0.98 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.484 0.714 . . . . 10.0 109.381 176.493 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.9 p -35.47 109.75 0.09 Allowed 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 126.019 1.727 . . . . 10.0 110.868 -173.074 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -131.71 -174.03 3.3 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 104.474 -2.417 . . . . 10.0 104.474 -170.126 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -82.39 159.02 23.1 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 106.262 -1.755 . . . . 10.0 106.262 169.408 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.7 t60 -59.04 123.5 16.79 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 106.826 -1.546 . . . . 10.0 106.826 162.713 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.93 -144.0 5.39 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 108.635 -1.786 . . . . 10.0 108.635 174.083 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.41 -163.39 29.72 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 109.746 -1.342 . . . . 10.0 109.746 169.746 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -63.99 3.68 0.69 Allowed 'Trans proline' 0 N--CA 1.455 -0.761 0 CA-C-N 119.763 1.782 . . . . 10.0 111.99 169.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 42.3 mmtt -100.19 -16.13 17.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.082 -0.961 . . . . 10.0 110.707 171.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -114.54 165.95 12.23 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 119.051 0.841 . . . . 10.0 109.901 -178.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -77.25 -38.61 50.72 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 105.431 -2.063 . . . . 10.0 105.431 167.766 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.277 1.5 pt-20 -103.48 49.89 0.82 Allowed 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 115.461 1.652 . . . . 10.0 115.461 -160.843 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -55.65 159.31 3.03 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 125.651 1.581 . . . . 10.0 108.799 167.656 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -66.69 -65.86 0.63 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.637 0.732 . . . . 10.0 109.619 168.372 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.534 HG13 ' H ' ' A' ' 82' ' ' GLY . 6.3 p -161.85 -69.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 N-CA-C 107.31 -1.367 . . . . 10.0 107.31 177.352 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.534 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -109.48 56.23 0.47 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 109.598 -1.401 . . . . 10.0 109.598 177.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -87.98 91.26 8.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 104.058 -2.571 . . . . 10.0 104.058 167.716 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.9 -32.36 69.28 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.1 -91.7 0.7 Allowed Glycine 0 N--CA 1.434 -1.485 0 N-CA-C 108.273 -1.931 . . . . 10.0 108.273 167.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -145.27 147.35 32.28 Favored 'General case' 0 N--CA 1.447 -0.596 0 O-C-N 123.818 0.364 . . . . 10.0 110.755 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.2 m -124.21 139.08 51.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 171.126 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 m -89.99 113.92 25.67 Favored 'General case' 0 N--CA 1.441 -0.888 0 C-N-CA 127.887 2.475 . . . . 10.0 107.711 -178.371 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.46 138.01 32.09 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 109.623 -0.51 . . . . 10.0 109.623 169.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -65.72 170.65 4.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.959 1.304 . . . . 10.0 109.658 168.13 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -50.69 -34.51 26.98 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.467 -0.788 . . . . 10.0 110.894 169.338 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -81.03 5.35 16.74 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.38 0.609 . . . . 10.0 112.039 -178.677 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.09 4.5 83.59 Favored Glycine 0 C--N 1.342 0.908 0 O-C-N 120.877 -1.139 . . . . 10.0 111.341 175.292 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.8 t -79.68 109.16 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.975 0 C-N-CA 127.76 2.424 . . . . 10.0 106.597 176.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.569 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -105.66 115.88 31.0 Favored 'General case' 0 CA--C 1.513 -0.459 0 N-CA-C 108.087 -1.079 . . . . 10.0 108.087 167.658 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -81.97 86.21 6.58 Favored 'General case' 0 N--CA 1.436 -1.157 0 C-N-CA 127.458 2.303 . . . . 10.0 109.294 179.143 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 32.9 t -75.72 131.94 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 N-CA-C 105.097 -2.186 . . . . 10.0 105.097 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -158.3 64.02 0.44 Allowed 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 122.995 0.518 . . . . 10.0 110.198 -175.473 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -111.47 158.6 11.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 106.948 -1.501 . . . . 10.0 106.948 -175.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -135.19 137.71 42.93 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 123.797 0.839 . . . . 10.0 109.942 168.629 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.39 147.43 43.4 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.124 0.97 . . . . 10.0 108.809 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 22.9 p -110.45 -2.14 16.7 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.076 1.75 . . . . 10.0 113.882 -172.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.9 p -97.22 -38.78 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 119.821 1.192 . . . . 10.0 109.081 172.345 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -65.22 136.91 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.953 -1.869 . . . . 10.0 105.953 167.158 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 25.2 m -154.86 132.42 11.28 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 108.943 -0.762 . . . . 10.0 108.943 -175.248 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -78.75 61.02 2.92 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.805 -1.183 . . . . 10.0 107.805 175.463 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.8 m -84.12 -119.27 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 123.81 0.844 . . . . 10.0 110.165 -174.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.96 -47.32 0.05 OUTLIER Glycine 0 CA--C 1.524 0.628 0 N-CA-C 107.91 -2.076 . . . . 10.0 107.91 -174.479 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -64.54 -59.32 4.44 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.899 0.88 . . . . 10.0 109.04 169.625 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.6 -39.05 58.53 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.276 -0.875 . . . . 10.0 108.658 -174.863 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.6 t 39.01 76.38 0.06 Allowed 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.525 1.53 . . . . 10.0 112.702 171.18 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pp -61.36 -26.94 40.84 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 115.899 -0.592 . . . . 10.0 110.382 168.835 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 32.2 mm -38.67 132.59 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 C-N-CA 126.003 1.721 . . . . 10.0 111.781 173.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.63 7.96 86.73 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-O 118.487 -1.174 . . . . 10.0 113.613 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 64.1 mtt85 -77.57 158.72 29.7 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 118.742 1.271 . . . . 10.0 109.673 169.831 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.82 115.5 27.52 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.111 -0.7 . . . . 10.0 109.111 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -83.97 138.27 33.21 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 170.028 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 71.9 t -125.34 137.09 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.99 -1.115 . . . . 10.0 107.99 178.033 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.06 132.95 46.99 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 105.542 -2.021 . . . . 10.0 105.542 166.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.67 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 8.5 m-70 -106.88 154.63 20.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 123.186 1.47 . . . . 10.0 114.623 -174.233 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -41.75 -61.92 1.0 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 128.398 2.679 . . . . 10.0 109.157 177.245 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mtmt -110.0 169.25 8.85 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 125.463 1.505 . . . . 10.0 111.84 -176.576 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.74 136.9 56.85 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.131 -1.395 . . . . 10.0 108.035 169.628 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 140' ' ' ALA . 0.0 OUTLIER -84.57 158.94 20.77 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 123.763 0.825 . . . . 10.0 110.169 170.687 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -104.02 17.06 24.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.07 0.948 . . . . 10.0 111.701 179.542 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 64.7 mt 43.56 40.72 2.99 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 119.269 0.941 . . . . 10.0 112.782 178.493 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.63 -4.16 53.7 Favored Glycine 0 C--N 1.336 0.565 0 CA-C-O 118.924 -0.931 . . . . 10.0 114.068 175.04 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mttt -118.01 30.69 7.1 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 118.136 0.968 . . . . 10.0 111.217 -166.162 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.65 -36.53 58.35 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 127.521 2.486 . . . . 10.0 110.907 171.674 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 72.45 43.68 44.38 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 111.179 -0.768 . . . . 10.0 111.179 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.461 ' H ' ' HB2' ' A' ' 134' ' ' SER . 12.2 m-80 -145.34 168.93 19.3 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 105.983 -1.858 . . . . 10.0 105.983 171.376 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.407 ' OE1' ' NZ ' ' A' ' 136' ' ' LYS . 15.8 tm-20 -52.57 -42.56 64.6 Favored 'General case' 0 N--CA 1.441 -0.899 0 CA-C-O 121.239 0.542 . . . . 10.0 110.958 177.627 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -63.49 -31.83 73.1 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.263 -0.898 . . . . 10.0 113.23 178.605 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.461 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 17.1 t -43.96 -48.4 8.61 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.226 1.01 . . . . 10.0 109.778 176.181 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 7.8 t -80.4 -3.72 50.82 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-O 118.333 -0.841 . . . . 10.0 112.134 -169.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.407 ' NZ ' ' OE1' ' A' ' 132' ' ' GLU . 41.9 mtmt -111.61 -79.41 0.58 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.317 1.447 . . . . 10.0 110.308 -177.763 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.9 p -105.94 1.85 27.0 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 120.13 1.332 . . . . 10.0 113.272 177.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.72 27.24 35.64 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-O 118.904 -0.942 . . . . 10.0 113.139 169.701 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.2 m120 59.36 21.9 10.25 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 118.382 1.091 . . . . 10.0 112.978 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.549 ' HB2' ' HB3' ' A' ' 124' ' ' ASP . . . -66.73 -10.6 48.68 Favored 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 124.897 1.279 . . . . 10.0 112.645 176.635 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.61 -161.83 51.68 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 110.268 -1.133 . . . . 10.0 110.268 177.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.8 m -58.74 139.97 55.47 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 124.129 0.972 . . . . 10.0 112.651 -167.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.13 68.16 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.813 1.245 . . . . 10.0 109.329 167.649 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . 0.261 0.4 OUTLIER -64.32 -17.04 63.29 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.616 0.969 . . . . 10.0 113.616 -169.144 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 150.92 24.9 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.099 -0.704 . . . . 10.0 109.099 168.094 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.5 p -153.72 165.35 36.25 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.39 0.276 . . . . 10.0 111.034 -177.355 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.0 -168.04 11.77 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.438 1.018 . . . . 10.0 111.559 -177.329 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 33.7 t -136.92 130.75 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 104.487 -2.412 . . . . 10.0 104.487 176.736 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -66.47 139.7 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-N 119.438 1.017 . . . . 10.0 110.815 178.424 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.6 146.67 18.58 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 124.829 1.204 . . . . 10.0 111.214 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 74.8 mt -68.83 152.26 9.63 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 177.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.36 -36.11 1.14 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 114.515 1.302 . . . . 10.0 114.515 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.121 0 N-CA-C 117.529 2.418 . . . . 10.0 117.529 -177.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 1' ' ' ALA . . . . . 0.451 ' C ' ' H ' ' B' ' 3' ' ' LYS . . . . . . . . 0 N--CA 1.474 0.74 0 CA-C-O 118.232 -0.89 . . . . 10.0 109.099 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 2' ' ' THR . . . . . 0.421 HG22 ' O ' ' B' ' 1' ' ' ALA 0.282 9.2 t 70.62 -29.68 0.19 Allowed 'General case' 0 C--N 1.343 0.312 0 C-N-CA 131.397 3.879 . . . . 10.0 111.835 175.036 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 3' ' ' LYS . . . . . 0.451 ' H ' ' C ' ' B' ' 1' ' ' ALA . 61.3 tttt -152.15 131.37 12.77 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 126.288 1.835 . . . . 10.0 106.98 -168.843 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.59 165.96 25.85 Favored 'General case' 0 CA--C 1.522 -0.131 0 C-N-CA 124.476 1.11 . . . . 10.0 108.54 171.668 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.525 ' O ' HG23 ' B' ' 149' ' ' ILE . 7.7 m -131.38 179.97 3.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.395 0 C-N-CA 122.889 0.476 . . . . 10.0 110.563 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.27 110.66 3.74 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 124.459 1.104 . . . . 10.0 108.561 167.214 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.471 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.5 OUTLIER -96.88 92.23 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 C-N-CA 124.065 0.946 . . . . 10.0 109.419 171.748 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -80.32 137.82 36.64 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.197 0.999 . . . . 10.0 110.608 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.5 tttt -156.25 160.67 40.0 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.972 -1.122 . . . . 10.0 107.972 170.263 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.41 -50.06 0.05 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 121.333 -0.46 . . . . 10.0 112.215 171.233 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.26 -46.58 32.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 106.738 -1.578 . . . . 10.0 106.738 -173.61 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.94 -66.26 0.57 Allowed Glycine 0 CA--C 1.527 0.815 0 CA-C-N 113.891 -1.504 . . . . 10.0 110.382 -179.086 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -60.57 -35.41 90.14 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.964 2.442 . . . . 10.0 111.323 174.025 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.0 t -70.35 111.21 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 N-CA-C 107.582 -1.266 . . . . 10.0 107.582 175.666 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.74 110.04 11.83 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.88 -1.896 . . . . 10.0 105.88 168.626 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.738 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -97.79 133.37 11.32 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 110.012 -1.235 . . . . 10.0 110.012 179.02 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.543 ' CG2' HG22 ' A' ' 54' ' ' THR . 5.4 mt -137.57 87.77 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 108.252 -1.018 . . . . 10.0 108.252 -169.683 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -99.23 152.17 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.133 0 C-N-CA 124.672 1.189 . . . . 10.0 110.546 178.681 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 21.1 m-80 -134.43 121.57 21.29 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 128.457 2.703 . . . . 10.0 107.807 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -106.58 116.66 32.3 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 174.386 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.91 143.67 44.77 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.091 0.86 . . . . 10.0 112.861 169.472 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -93.69 94.02 8.35 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.617 1.567 . . . . 10.0 108.808 -176.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.2 tmtt? . . . . . 0 N--CA 1.445 -0.721 0 C-N-CA 126.369 1.868 . . . . 10.0 110.943 179.508 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.603 0 N-CA-C 106.93 -2.468 . . . . 10.0 106.93 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -66.48 148.79 84.34 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 121.841 1.694 . . . . 10.0 109.553 179.05 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.5 t -78.82 124.95 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 104.313 -2.477 . . . . 10.0 104.313 168.214 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -98.34 122.4 41.47 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 106.313 -1.736 . . . . 10.0 106.313 168.846 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.2 p -106.18 106.03 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 C-N-CA 127.708 2.403 . . . . 10.0 105.509 177.31 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -130.45 173.08 11.18 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 120.9 0.381 . . . . 10.0 110.844 179.042 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.76 -153.29 25.21 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 107.152 -2.379 . . . . 10.0 107.152 169.335 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 5.4 m -153.15 145.49 23.99 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 119.044 -1.063 . . . . 10.0 110.607 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.738 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.0 pt -111.97 136.75 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 CA-C-N 115.948 -0.569 . . . . 10.0 109.679 168.501 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.5 tptt -110.77 141.27 44.32 Favored 'General case' 0 N--CA 1.441 -0.922 0 N-CA-C 106.289 -1.745 . . . . 10.0 106.289 171.712 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.3 -6.37 23.16 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 123.757 0.694 . . . . 10.0 112.991 169.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -65.19 176.21 1.4 Allowed 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 118.147 0.974 . . . . 10.0 111.022 176.095 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -109.82 156.09 20.8 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 168.352 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -53.33 132.48 39.29 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.792 1.637 . . . . 10.0 111.443 -170.509 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 122.13 -173.2 15.81 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 118.724 0.693 . . . . 10.0 112.037 173.275 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.66 152.84 39.13 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.741 1.616 . . . . 10.0 110.756 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -150.31 147.73 27.98 Favored 'General case' 0 C--N 1.344 0.367 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -174.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.68 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -28.01 121.0 0.06 OUTLIER Glycine 0 C--N 1.34 0.784 0 C-N-CA 128.822 3.105 . . . . 10.0 113.14 161.664 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -153.73 101.31 2.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 119.712 1.756 . . . . 10.0 111.6 168.286 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -154.23 173.1 16.58 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 114.573 1.323 . . . . 10.0 114.573 -178.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 33.5 m -82.0 151.2 4.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 112.995 -1.912 . . . . 10.0 109.449 168.533 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -133.1 82.91 2.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.089 -1.078 . . . . 10.0 108.089 172.561 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 35.04 -80.8 0.0 OUTLIER 'General case' 0 C--O 1.239 0.506 0 C-N-CA 127.674 2.389 . . . . 10.0 115.135 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -77.84 173.78 11.75 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 122.043 0.925 . . . . 10.0 110.089 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -101.03 -19.53 16.71 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 125.152 1.358 . . . . 10.0 110.599 168.34 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.31 156.39 0.85 Allowed 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.802 1.241 . . . . 10.0 111.946 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.63 27.86 0.44 Allowed 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.322 -0.854 . . . . 10.0 111.822 169.006 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.424 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -55.06 -39.22 69.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.198 0.999 . . . . 10.0 111.624 -169.728 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.44 -23.71 42.96 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.055 0.942 . . . . 10.0 112.786 177.25 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.91 114.25 1.53 Allowed Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.829 -0.908 . . . . 10.0 110.829 -170.666 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 23.5 m 38.06 46.28 0.81 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 127.206 2.203 . . . . 10.0 115.529 169.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -153.31 -54.15 0.11 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 173.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 47.0 t -54.91 -38.61 67.82 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.479 1.112 . . . . 10.0 110.892 -173.796 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.97 -50.68 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 127.863 2.465 . . . . 10.0 114.487 170.64 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.01 157.19 9.61 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.299 -1.12 . . . . 10.0 110.299 177.658 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -74.76 -163.38 0.18 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 N-CA-C 105.395 -2.579 . . . . 10.0 105.395 165.026 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -81.03 48.66 1.13 Allowed 'General case' 0 CA--C 1.547 0.83 0 O-C-N 119.619 -1.925 . . . . 10.0 110.694 -176.411 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 m-30 -75.35 67.72 1.96 Allowed 'General case' 0 N--CA 1.466 0.341 0 O-C-N 120.936 -1.102 . . . . 10.0 110.332 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -66.19 154.64 89.66 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.408 -0.808 . . . . 10.0 109.919 170.547 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -76.46 49.68 2.72 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 123.572 2.848 . . . . 10.0 111.204 177.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -178.35 55.78 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 127.482 2.313 . . . . 10.0 105.677 -178.618 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.0 p -37.11 110.23 0.12 Allowed 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.8 1.24 . . . . 10.0 109.992 177.441 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -173.69 3.1 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 102.447 -3.168 . . . . 10.0 102.447 177.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -78.08 167.56 21.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 116.651 -2.019 . . . . 10.0 106.831 167.755 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -65.48 123.62 20.12 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 106.845 -1.539 . . . . 10.0 106.845 162.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.16 -142.05 4.42 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.458 -1.857 . . . . 10.0 108.458 173.605 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.15 -165.24 31.08 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.67 -1.628 . . . . 10.0 109.044 173.233 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -69.16 10.47 0.4 Allowed 'Trans proline' 0 CA--C 1.541 0.827 0 CA-C-N 119.923 1.861 . . . . 10.0 110.727 167.888 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -108.8 -1.16 19.48 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 124.84 1.256 . . . . 10.0 110.402 170.121 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -132.22 169.36 16.55 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 119.67 1.123 . . . . 10.0 109.007 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -78.71 -39.23 37.05 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 103.795 -2.669 . . . . 10.0 103.795 165.266 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -82.14 42.87 0.76 Allowed 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 114.117 1.154 . . . . 10.0 114.117 -165.352 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.32 159.29 18.33 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 124.006 0.922 . . . . 10.0 109.714 167.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -68.97 -79.91 0.05 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 169.111 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.509 HG13 ' H ' ' B' ' 82' ' ' GLY 0.25 8.6 p -149.18 -79.28 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 N-CA-C 107.175 -1.417 . . . . 10.0 107.175 167.923 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.509 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -86.43 62.52 4.28 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.258 -1.137 . . . . 10.0 110.258 178.415 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -101.55 100.45 10.87 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 105.714 -1.958 . . . . 10.0 105.714 169.065 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -73.73 -9.39 58.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 118.339 0.518 . . . . 10.0 111.452 -174.023 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.89 -99.7 2.34 Favored Glycine 0 N--CA 1.442 -0.94 0 N-CA-C 107.347 -2.301 . . . . 10.0 107.347 -176.685 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -148.17 144.97 28.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 -177.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.6 m -112.93 137.57 45.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 108.216 -1.031 . . . . 10.0 108.216 168.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -97.94 116.44 30.17 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.962 0.905 . . . . 10.0 109.582 -176.833 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.67 130.6 35.94 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.604 1.162 . . . . 10.0 109.15 174.572 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.05 168.11 3.47 Favored 'General case' 0 N--CA 1.448 -0.573 0 O-C-N 124.584 1.177 . . . . 10.0 109.824 168.378 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.9 tttp -47.76 -36.61 11.82 Favored 'General case' 0 N--CA 1.432 -1.327 0 C-N-CA 126.42 1.888 . . . . 10.0 111.468 168.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -79.84 1.04 28.49 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.992 0.517 . . . . 10.0 112.318 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.18 16.79 80.27 Favored Glycine 0 C--N 1.339 0.721 0 O-C-N 120.101 -1.624 . . . . 10.0 110.791 178.822 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 37.2 t -92.93 105.84 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 C-N-CA 126.513 1.925 . . . . 10.0 106.033 175.68 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.655 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -102.18 117.74 35.41 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 107.139 -1.43 . . . . 10.0 107.139 168.582 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -94.23 124.6 38.34 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.315 1.009 . . . . 10.0 108.279 177.118 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.99 134.53 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 C-N-CA 125.838 1.655 . . . . 10.0 108.421 -174.694 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -157.46 95.52 1.46 Allowed 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.719 1.207 . . . . 10.0 108.761 170.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 mp -123.59 145.36 30.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 108.105 -1.072 . . . . 10.0 108.105 176.071 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -106.06 135.28 47.8 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 128.691 2.797 . . . . 10.0 107.745 169.075 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -140.05 155.38 47.08 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 168.238 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.4 p -126.39 49.19 2.04 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.587 1.155 . . . . 10.0 109.771 174.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 p -133.33 -45.45 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.491 1.117 . . . . 10.0 110.246 172.537 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.32 131.81 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.298 -1.001 . . . . 10.0 108.298 169.575 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 67.8 m -125.37 112.71 16.64 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 170.078 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 18.1 mt -46.2 -41.52 12.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.193 1.397 . . . . 10.0 110.318 176.214 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 22.8 p . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 105.844 -1.91 . . . . 10.0 105.844 168.657 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 34.9 t . . . . . 0 N--CA 1.45 -0.473 0 CA-C-O 122.414 1.102 . . . . 10.0 109.922 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 3.6 pt -75.63 58.6 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.849 -0.797 . . . . 10.0 108.849 172.478 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 44.5 mm -108.84 -58.36 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.671 0.788 . . . . 10.0 109.176 -177.638 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -93.46 50.93 2.38 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 109.409 -1.477 . . . . 10.0 109.409 173.277 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.09 158.24 24.53 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.304 1.842 . . . . 10.0 107.401 177.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 67.1 m -108.68 119.07 38.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 127.042 2.137 . . . . 10.0 106.264 -178.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 62.6 mt -93.49 150.87 20.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 108.224 -1.028 . . . . 10.0 108.224 168.748 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 79.6 t -132.81 138.36 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 N-CA-C 108.159 -1.052 . . . . 10.0 108.159 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.85 136.76 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 168.15 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.68 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 9.4 m-70 -116.03 161.12 19.34 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -175.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 121' ' ' GLU . . . . . 0.418 ' HB2' HD21 ' B' ' 144' ' ' LEU . 53.6 tt0 -60.04 -50.11 75.0 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.217 -0.901 . . . . 10.0 109.677 177.445 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 92.6 mttt -104.53 163.3 12.56 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.927 0.714 . . . . 10.0 112.927 -168.564 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.93 157.02 34.29 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 114.301 -1.318 . . . . 10.0 108.991 172.191 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.483 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 47.2 m-20 -109.79 134.78 51.64 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 124.153 0.981 . . . . 10.0 109.243 -169.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -73.26 -24.56 60.47 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 124.861 1.264 . . . . 10.0 110.337 -174.777 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 59.64 42.87 16.5 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.52 -0.918 . . . . 10.0 108.52 -173.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.53 -53.12 1.02 Allowed Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 124.959 1.266 . . . . 10.0 110.971 170.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -79.29 49.88 1.02 Allowed 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.356 1.062 . . . . 10.0 113.072 -170.57 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -29.77 7.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 127.118 2.294 . . . . 10.0 110.593 169.604 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 75.81 18.71 79.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 118.978 -0.901 . . . . 10.0 112.395 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -111.65 160.22 17.45 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 105.947 -1.871 . . . . 10.0 105.947 168.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -50.26 -47.48 55.21 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.33 -1.304 . . . . 10.0 108.397 171.609 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -64.34 -37.43 87.47 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 112.915 0.709 . . . . 10.0 112.915 177.651 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.6 m -51.63 -45.47 63.3 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.336 1.425 . . . . 10.0 111.035 172.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.9 t -82.45 -22.51 35.2 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 111.922 0.341 . . . . 10.0 111.922 -173.177 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 25.2 ttmt -89.41 -46.89 8.39 Favored 'General case' 0 N--CA 1.439 -0.978 0 C-N-CA 125.225 1.41 . . . . 10.0 112.129 -177.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 30.7 p -133.44 -11.62 2.78 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 114.172 1.175 . . . . 10.0 114.172 178.818 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.22 15.72 37.5 Favored Glycine 0 C--O 1.221 -0.678 0 CA-C-O 118.982 -0.899 . . . . 10.0 112.15 -171.31 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 57.35 35.1 25.62 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.13 1.465 . . . . 10.0 111.233 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.17 -13.59 62.1 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.515 1.926 . . . . 10.0 111.886 -178.435 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.89 -171.06 54.59 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 109.223 -1.551 . . . . 10.0 109.223 -169.836 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.1 m -52.52 166.12 0.21 Allowed 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 124.48 1.112 . . . . 10.0 113.071 -177.107 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -83.93 102.02 12.11 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 107.467 -1.308 . . . . 10.0 107.467 168.472 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.418 HD21 ' HB2' ' B' ' 121' ' ' GLU . 0.4 OUTLIER -71.61 -47.98 51.07 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.05 -1.092 . . . . 10.0 108.05 -177.642 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -143.49 144.54 32.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.094 -0.706 . . . . 10.0 109.094 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 39.0 m -126.71 147.98 49.91 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.669 -1.234 . . . . 10.0 107.669 -176.42 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.87 141.1 11.57 Favored Glycine 0 C--N 1.332 0.315 0 N-CA-C 108.834 -1.706 . . . . 10.0 108.834 172.152 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.71 136.8 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 N-CA-C 101.612 -3.477 . . . . 10.0 101.612 169.299 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.525 HG23 ' O ' ' B' ' 5' ' ' VAL . 68.5 mt -61.86 -81.41 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 CA-C-O 121.418 0.628 . . . . 10.0 110.285 -168.73 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.99 134.43 8.33 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.371 -0.691 . . . . 10.0 111.371 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.78 137.25 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.089 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 173.435 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.98 -70.08 0.54 Allowed 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 106.742 -1.577 . . . . 10.0 106.742 171.798 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 20.4 tm0? . . . . . 0 C--O 1.253 1.249 0 N-CA-C 104.827 -2.286 . . . . 10.0 104.827 167.266 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.62 0 N-CA-C 105.511 -2.033 . . . . 10.0 105.511 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.5 t -63.18 -30.62 71.73 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.978 1.263 . . . . 10.0 108.1 167.427 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.5 tmtm? -117.08 146.95 42.8 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 126.088 1.755 . . . . 10.0 108.675 177.562 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.06 177.04 11.78 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 125.829 1.652 . . . . 10.0 109.195 169.945 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.9 t -136.2 164.04 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 125.277 1.431 . . . . 10.0 108.749 -176.49 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.68 104.36 3.03 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.054 0.941 . . . . 10.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.5 m -93.47 127.99 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 109.322 -0.621 . . . . 10.0 109.322 176.389 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.93 137.28 47.92 Favored 'General case' 0 C--O 1.225 -0.218 0 C-N-CA 124.762 1.225 . . . . 10.0 108.559 -178.736 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 40.1 mtpt -146.22 164.93 30.71 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-N 120.69 1.586 . . . . 10.0 107.968 170.797 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.59 -60.24 0.04 OUTLIER Glycine 0 CA--C 1.511 -0.19 0 C-N-CA 120.377 -0.916 . . . . 10.0 112.291 169.701 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.64 -44.91 61.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 -177.647 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.9 -69.74 0.44 Allowed Glycine 0 CA--C 1.524 0.612 0 CA-C-N 114.296 -1.32 . . . . 10.0 110.887 172.78 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -57.3 -36.3 98.94 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 123.25 2.633 . . . . 10.0 111.263 174.971 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.8 t -65.62 97.56 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.117 -1.438 . . . . 10.0 107.117 175.323 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.56 105.86 11.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.138 0.975 . . . . 10.0 108.424 173.94 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.781 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -81.03 149.79 29.92 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 109.623 -1.391 . . . . 10.0 109.623 168.38 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -155.22 59.6 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 C-N-CA 125.925 1.69 . . . . 10.0 106.848 -168.939 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 mm -74.94 146.47 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 O-C-N 121.621 -0.675 . . . . 10.0 109.657 -179.27 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -118.9 124.53 47.32 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 126.711 2.004 . . . . 10.0 107.061 177.013 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -106.63 120.6 42.39 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 178.703 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.5 mp0 -125.73 117.8 24.23 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.33 0.652 . . . . 10.0 111.472 176.515 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -124.03 108.99 12.96 Favored 'General case' 0 C--O 1.227 -0.113 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 168.287 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.42 -50.92 68.53 Favored 'General case' 0 C--N 1.333 -0.117 0 O-C-N 121.749 -0.595 . . . . 10.0 110.671 -178.824 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -129.57 170.42 13.78 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 103.557 -2.757 . . . . 10.0 103.557 168.38 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 92.3 p -68.61 -19.75 64.46 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 123.837 0.855 . . . . 10.0 110.39 170.12 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -78.77 -14.83 59.06 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 123.321 0.649 . . . . 10.0 109.278 174.144 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.43 138.67 15.47 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.183 -1.567 . . . . 10.0 109.183 175.828 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -62.4 135.8 55.74 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 CA-C-N 119.414 1.607 . . . . 10.0 108.069 171.328 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.1 p -75.97 120.36 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.425 0 N-CA-C 107.545 -1.28 . . . . 10.0 107.545 -176.779 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.1 mtpt -91.52 109.68 20.98 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.942 -2.244 . . . . 10.0 104.942 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.3 m -104.77 88.82 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 178.768 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -97.33 170.94 8.73 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-O 121.75 0.786 . . . . 10.0 111.664 169.509 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.06 -169.15 38.84 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.51 -1.036 . . . . 10.0 110.51 172.025 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.9 p -147.15 102.35 3.49 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.908 -0.775 . . . . 10.0 108.908 -175.844 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.781 HG22 ' HA2' ' A' ' 16' ' ' GLY . 4.3 pt -78.44 130.8 35.69 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 N-CA-C 106.428 -1.694 . . . . 10.0 106.428 168.38 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 ptmt -118.73 136.17 54.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.708 -1.219 . . . . 10.0 107.708 173.864 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.95 -3.95 14.31 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.75 1.167 . . . . 10.0 112.979 179.676 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -66.35 176.97 1.61 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.625 1.212 . . . . 10.0 111.109 177.516 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.5 t -112.35 155.9 23.37 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 105.308 -2.108 . . . . 10.0 105.308 166.04 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -50.23 157.53 0.67 Allowed 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.29 1.036 . . . . 10.0 111.678 -170.365 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.51 -175.37 29.14 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 170.791 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -78.39 149.2 33.39 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.699 1.599 . . . . 10.0 110.695 -175.99 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.1 m-70 -144.39 137.63 27.21 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.516 0.726 . . . . 10.0 112.953 -175.586 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -40.96 122.07 2.16 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 126.574 2.035 . . . . 10.0 110.217 168.247 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -136.73 113.03 9.88 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.177 1.489 . . . . 10.0 107.925 169.799 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.69 174.69 13.2 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-O 122.247 1.022 . . . . 10.0 112.163 -179.158 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.0 t -96.32 143.9 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 CA-C-N 111.318 -2.674 . . . . 10.0 107.2 169.609 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 76.9 m-70 -123.39 126.4 46.75 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 103.643 -2.725 . . . . 10.0 103.643 172.55 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.5 tp10 -61.17 -42.76 99.14 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.184 -1.371 . . . . 10.0 112.746 -165.508 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -81.91 118.64 23.1 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 119.288 -0.965 . . . . 10.0 109.459 177.696 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.1 -13.89 16.19 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.707 2.575 . . . . 10.0 112.523 169.992 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -42.83 127.28 3.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 122.384 1.088 . . . . 10.0 111.173 168.966 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -137.39 23.12 2.96 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.521 164.854 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -66.71 -44.43 81.69 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 106.542 -1.651 . . . . 10.0 106.542 168.525 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.69 -21.92 44.08 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.335 -0.393 . . . . 10.0 111.55 173.062 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.58 71.49 1.31 Allowed Glycine 0 CA--C 1.528 0.848 0 C-N-CA 124.134 0.873 . . . . 10.0 111.28 173.015 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.291 23.2 p 43.12 48.98 5.5 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.665 1.186 . . . . 10.0 113.783 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 p -127.21 -66.95 0.86 Allowed 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 127.344 2.258 . . . . 10.0 105.354 173.072 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.1 m -79.05 -4.68 51.34 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 123.364 0.665 . . . . 10.0 112.56 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.7 -14.69 1.45 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.41 1.484 . . . . 10.0 112.925 173.377 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.22 131.55 6.89 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 108.847 -1.701 . . . . 10.0 108.847 170.071 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.403 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 70.3 Cg_endo -75.17 59.97 5.44 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.8 3.0 . . . . 10.0 110.38 172.247 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 71.7 49.74 0.27 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 129.312 3.045 . . . . 10.0 111.275 175.435 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.403 ' CZ ' ' HD2' ' A' ' 62' ' ' PRO . 35.1 m-85 -72.21 38.12 0.07 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 115.258 1.577 . . . . 10.0 115.258 -173.344 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.27 151.15 0.57 Allowed Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.55 1.54 . . . . 10.0 113.107 169.98 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -66.02 -46.37 4.75 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.884 2.389 . . . . 10.0 111.953 179.544 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 71.1 mt -79.39 54.01 1.63 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.631 -0.668 . . . . 10.0 110.457 -177.943 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 40.0 p -55.5 109.2 0.52 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.537 1.135 . . . . 10.0 110.406 -173.826 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.4 mtt180 -121.29 -97.15 0.46 Allowed 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 -179.889 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.4 140.87 23.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 105.261 -2.126 . . . . 10.0 105.261 177.278 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -47.08 116.95 1.52 Allowed 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.654 -0.418 . . . . 10.0 110.991 169.402 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.48 -141.01 4.29 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 106.536 -2.626 . . . . 10.0 106.536 170.531 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.95 -147.51 8.1 Favored Glycine 0 C--O 1.227 -0.312 0 CA-C-O 118.644 -1.086 . . . . 10.0 111.229 175.267 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -68.27 14.93 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 120.041 1.921 . . . . 10.0 111.943 177.344 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.0 mmtt -104.68 -14.96 15.41 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 119.038 0.835 . . . . 10.0 110.042 169.805 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.33 177.34 7.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.337 1.065 . . . . 10.0 113.064 -165.049 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -98.64 -13.31 20.39 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 113.449 -1.705 . . . . 10.0 108.502 168.198 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.11 -16.26 56.97 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 124.735 1.214 . . . . 10.0 112.23 -168.598 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.28 135.88 2.47 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.596 1.158 . . . . 10.0 110.333 -169.78 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -73.66 61.99 0.76 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 123.405 0.682 . . . . 10.0 111.588 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.4 t 31.78 48.66 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 C-N-CA 126.872 2.069 . . . . 10.0 111.418 -174.511 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.22 42.0 0.05 OUTLIER Glycine 0 CA--C 1.531 1.062 0 CA-C-N 116.032 -0.531 . . . . 10.0 113.877 -178.918 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -97.07 100.42 11.92 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 103.617 -2.735 . . . . 10.0 103.617 166.049 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 27.5 mt -75.62 -24.86 56.53 Favored 'General case' 0 N--CA 1.462 0.174 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 177.865 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.94 -102.25 2.83 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.311 -1.916 . . . . 10.0 108.311 168.527 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -129.24 133.67 47.62 Favored 'General case' 0 CA--C 1.517 -0.311 0 C-N-CA 123.888 0.875 . . . . 10.0 112.176 -168.633 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.8 m -124.88 145.47 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.143 -1.799 . . . . 10.0 106.143 167.202 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -98.44 126.14 43.87 Favored 'General case' 0 C--O 1.225 -0.223 0 C-N-CA 124.851 1.261 . . . . 10.0 108.959 -178.025 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.52 134.46 34.35 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 172.231 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -67.17 172.45 4.67 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-O 121.592 0.71 . . . . 10.0 109.609 168.45 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.46 -32.2 4.91 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.39 2.276 . . . . 10.0 111.099 171.528 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -78.68 -11.34 59.97 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.855 0.359 . . . . 10.0 110.607 -175.804 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.06 15.67 69.17 Favored Glycine 0 C--N 1.339 0.75 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 -177.189 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.4 t -94.97 111.15 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 126.796 2.038 . . . . 10.0 105.921 175.162 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.536 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -106.02 120.24 41.28 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 168.734 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -78.53 131.08 36.66 Favored 'General case' 0 N--CA 1.429 -1.524 0 C-N-CA 125.906 1.682 . . . . 10.0 107.892 173.89 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.4 t -117.55 133.89 62.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.303 0 N-CA-C 106.235 -1.765 . . . . 10.0 106.235 179.459 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.5 p -157.45 70.42 0.6 Allowed 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 123.685 0.794 . . . . 10.0 109.554 175.554 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.43 153.22 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 179.406 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -137.35 123.16 20.02 Favored 'General case' 0 N--CA 1.443 -0.812 0 C-N-CA 125.557 1.543 . . . . 10.0 106.897 169.298 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -128.29 153.99 46.4 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.62 0.724 . . . . 10.0 109.051 -178.723 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 33.7 t -117.48 46.18 1.77 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.629 1.572 . . . . 10.0 110.043 -168.717 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.3 p -155.8 -46.13 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.132 0 N-CA-C 109.181 -0.674 . . . . 10.0 109.181 177.105 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 29.8 mm -56.35 142.22 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 123.49 0.716 . . . . 10.0 109.664 172.333 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.7 m -155.62 133.92 11.61 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 123.9 0.88 . . . . 10.0 108.758 171.671 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 82.7 mt -47.27 -55.21 9.11 Favored 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 126.914 2.086 . . . . 10.0 111.318 176.402 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.0 t -130.75 152.24 50.31 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 105.278 -2.119 . . . . 10.0 105.278 170.025 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.52 -84.77 0.12 Allowed Glycine 0 C--N 1.333 0.369 0 N-CA-C 110.058 -1.217 . . . . 10.0 110.058 -177.351 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -136.23 -53.47 0.74 Allowed 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 126.744 2.017 . . . . 10.0 107.5 -179.588 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -76.49 -31.15 57.57 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.117 -0.947 . . . . 10.0 108.57 -175.239 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 48.96 63.37 2.15 Favored 'General case' 0 N--CA 1.447 -0.594 0 C-N-CA 125.669 1.588 . . . . 10.0 109.372 177.109 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.315 1.1 tp -61.45 -18.77 19.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 C-N-CA 123.411 0.684 . . . . 10.0 112.112 -176.116 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.4 mm -48.75 135.79 5.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 118.812 0.733 . . . . 10.0 110.062 167.278 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.88 14.28 82.18 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.055 -0.858 . . . . 10.0 113.489 172.473 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.4 mmt-85 -84.02 175.43 9.54 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 167.898 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.3 m -108.36 122.27 46.64 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 177.003 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 6.5 mp -99.51 147.33 25.43 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-N 119.606 1.093 . . . . 10.0 108.535 171.058 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.6 t -131.18 135.93 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 N-CA-C 108.734 -0.839 . . . . 10.0 108.734 179.795 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 p -104.78 129.76 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 168.106 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 10.1 m-70 -111.12 158.86 18.39 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 114.994 1.479 . . . . 10.0 114.994 -169.672 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -46.42 -60.51 2.3 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.493 2.717 . . . . 10.0 110.903 171.369 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.2 mttp -117.27 165.61 13.24 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.104 0.478 . . . . 10.0 110.356 -172.917 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.39 140.8 54.21 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 168.854 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.03 153.75 32.06 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 108.837 -0.801 . . . . 10.0 108.837 168.264 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -78.59 10.73 2.97 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.118 0.967 . . . . 10.0 111.146 177.457 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.3 mt 38.94 51.35 1.85 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 125.151 1.38 . . . . 10.0 110.86 -170.334 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.94 -27.62 17.41 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-N 114.059 -1.428 . . . . 10.0 112.638 173.522 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -78.83 16.05 0.96 Allowed 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 113.66 0.985 . . . . 10.0 113.66 -168.42 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.93 -32.39 82.5 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 170.295 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 69.94 31.13 69.78 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 122.488 -0.419 . . . . 10.0 112.34 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.95 176.21 8.24 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 125.299 1.44 . . . . 10.0 107.545 173.338 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.406 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 2.6 tm-20 -59.51 -51.27 70.57 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 113.403 -1.726 . . . . 10.0 109.425 177.742 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -52.97 -43.9 66.74 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.565 1.146 . . . . 10.0 110.692 171.931 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.5 m -53.55 -46.59 70.28 Favored 'General case' 0 N--CA 1.441 -0.917 0 O-C-N 120.851 -1.156 . . . . 10.0 110.968 -179.118 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.5 t -77.65 -0.57 27.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 119.786 -0.766 . . . . 10.0 111.857 -177.121 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.406 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 90.6 mttt -113.91 -82.1 0.6 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.312 1.845 . . . . 10.0 111.197 -179.657 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . 0.299 2.0 p -105.95 11.84 31.24 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 120.738 1.608 . . . . 10.0 113.054 177.939 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.09 10.75 78.52 Favored Glycine 0 C--O 1.221 -0.699 0 CA-C-O 119.047 -0.863 . . . . 10.0 114.336 166.812 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 m120 65.7 26.35 11.42 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.594 1.197 . . . . 10.0 111.596 -176.863 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.59 -11.82 8.29 Favored 'General case' 0 CA--C 1.533 0.327 0 O-C-N 121.644 -0.66 . . . . 10.0 111.683 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.58 -140.32 21.74 Favored Glycine 0 N--CA 1.443 -0.852 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 168.495 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -70.72 118.23 13.25 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.23 0.538 . . . . 10.0 111.283 -168.359 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.41 76.55 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.734 1.214 . . . . 10.0 111.35 168.624 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 50.3 mt -52.12 -40.89 61.97 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.101 0.778 . . . . 10.0 113.101 -176.051 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 155.09 24.77 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 108.335 -0.987 . . . . 10.0 108.335 -171.579 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -167.15 166.07 15.18 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 116.049 -0.523 . . . . 10.0 109.626 -167.59 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.7 179.3 46.95 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.658 -0.782 . . . . 10.0 112.062 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 71.3 t -109.24 156.22 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 N-CA-C 104.978 -2.23 . . . . 10.0 104.978 -175.677 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.4 mt -75.07 -96.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 C-N-CA 123.656 0.782 . . . . 10.0 110.747 -168.478 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 106.28 130.85 6.68 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-O 121.917 0.732 . . . . 10.0 112.098 179.381 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 92.2 mt -72.18 141.25 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.689 0 C-N-CA 124.968 1.307 . . . . 10.0 108.968 179.083 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.11 -102.11 0.41 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 105.761 -1.94 . . . . 10.0 105.761 165.519 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 . . . . . 0 C--O 1.247 0.962 0 C-N-CA 131.033 3.733 . . . . 10.0 103.075 -171.237 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 106.267 -1.753 . . . . 10.0 106.267 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -160.49 -47.33 0.05 OUTLIER 'General case' 0 C--O 1.232 0.139 0 CA-C-N 118.89 0.768 . . . . 10.0 110.668 172.916 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -119.64 142.71 48.19 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 126.839 2.056 . . . . 10.0 107.691 173.877 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.44 155.51 45.86 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.118 0.967 . . . . 10.0 108.396 169.36 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -122.65 153.99 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 C-N-CA 123.873 0.869 . . . . 10.0 109.265 -175.181 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 6' ' ' ALA . . . . . 0.458 ' HB2' HG12 ' B' ' 149' ' ' ILE . . . -147.74 93.11 2.16 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 167.367 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.674 HG12 HG23 ' B' ' 17' ' ' ILE . 31.6 m -83.19 133.45 29.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 107.803 -1.184 . . . . 10.0 107.803 169.425 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mt -107.34 138.15 44.07 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.836 -1.172 . . . . 10.0 107.836 -177.507 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 36.5 mtpt -146.34 153.72 40.85 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 120.582 1.537 . . . . 10.0 107.545 169.518 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.51 -52.71 0.08 OUTLIER Glycine 0 N--CA 1.462 0.388 0 C-N-CA 119.217 -1.468 . . . . 10.0 114.171 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -72.68 -43.41 63.13 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.649 -1.241 . . . . 10.0 107.649 -172.065 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.74 -70.55 0.4 Allowed Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 114.055 -1.429 . . . . 10.0 110.032 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -54.91 -39.73 88.99 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.783 2.322 . . . . 10.0 110.879 170.817 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.477 HG13 HD12 ' B' ' 38' ' ' LEU . 94.7 t -58.65 107.54 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.246 0 CA-C-N 119.083 0.856 . . . . 10.0 109.157 179.688 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.04 92.2 3.68 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.744 -2.317 . . . . 10.0 104.744 168.676 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.704 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -78.44 152.19 37.35 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 109.401 -1.479 . . . . 10.0 109.401 177.045 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.674 HG23 HG12 ' B' ' 7' ' ' VAL . 0.0 OUTLIER -154.26 87.22 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -171.16 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.8 mm -96.56 142.18 14.35 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 C-N-CA 124.846 1.258 . . . . 10.0 109.464 174.872 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -127.64 119.31 25.61 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 125.38 1.472 . . . . 10.0 108.082 174.142 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -98.0 113.76 25.7 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.058 1.343 . . . . 10.0 107.5 173.409 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -117.89 136.06 53.7 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 119.133 0.878 . . . . 10.0 110.775 170.914 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 36.1 tt0 -126.54 81.15 1.98 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 124.638 1.175 . . . . 10.0 109.763 -176.102 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt . . . . . 0 N--CA 1.452 -0.359 0 C-N-CA 124.863 1.265 . . . . 10.0 111.963 -175.223 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.15 0 CA-C-O 118.565 -1.131 . . . . 10.0 114.48 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -71.17 108.18 2.28 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 N-CA-C 106.22 -2.261 . . . . 10.0 106.22 169.122 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 26.2 t -77.35 95.74 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.349 0 N-CA-C 105.374 -2.084 . . . . 10.0 105.374 174.612 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -76.33 96.63 4.02 Favored 'General case' 0 N--CA 1.444 -0.76 0 N-CA-C 105.594 -2.002 . . . . 10.0 105.594 174.516 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -92.58 90.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.751 0 N-CA-C 106.87 -1.53 . . . . 10.0 106.87 175.654 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -99.48 176.58 5.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 121.443 0.64 . . . . 10.0 109.4 169.428 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.15 173.58 40.32 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 110.016 -1.234 . . . . 10.0 110.016 176.206 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.6 m -149.52 89.55 1.64 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 -179.626 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.704 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.5 pt -77.38 150.46 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 174.313 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.8 pttt -136.96 126.05 24.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 O-C-N 124.288 0.992 . . . . 10.0 108.848 169.425 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.97 6.76 5.31 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-O 118.791 -1.005 . . . . 10.0 114.629 166.064 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.661 HD13 ' H ' ' B' ' 38' ' ' LEU . 0.0 OUTLIER -89.82 179.34 6.02 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-N 118.728 1.264 . . . . 10.0 108.62 172.443 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -81.09 175.12 10.94 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.348 -0.845 . . . . 10.0 111.011 172.175 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -63.23 169.72 3.38 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.426 1.49 . . . . 10.0 111.48 -174.616 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.94 -174.74 51.42 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 124.008 0.813 . . . . 10.0 113.256 167.376 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -66.19 143.0 57.53 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.795 1.638 . . . . 10.0 110.608 178.603 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -142.36 139.34 31.72 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 114.214 1.19 . . . . 10.0 114.214 -178.655 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.629 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.03 111.77 0.02 OUTLIER Glycine 0 C--N 1.342 0.883 0 C-N-CA 128.418 2.913 . . . . 10.0 114.208 165.493 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -138.57 102.95 4.73 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 120.376 2.088 . . . . 10.0 110.516 174.844 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.56 179.23 7.97 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.331 0.586 . . . . 10.0 111.829 -178.358 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 p -100.21 148.26 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 112.704 -2.044 . . . . 10.0 108.127 168.33 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -123.93 129.6 51.23 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.067 -2.568 . . . . 10.0 104.067 169.154 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -59.13 -44.73 92.04 Favored 'General case' 0 N--CA 1.441 -0.898 0 O-C-N 124.528 1.142 . . . . 10.0 112.363 -166.646 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -75.19 112.49 11.52 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 105.239 -2.134 . . . . 10.0 105.239 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -57.65 -33.51 67.45 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 109.503 -1.439 . . . . 10.0 109.503 168.798 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -35.93 146.34 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 125.253 1.421 . . . . 10.0 112.06 169.547 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -144.36 28.44 1.34 Allowed 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 115.261 -0.881 . . . . 10.0 111.406 176.981 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -49.12 -43.06 41.14 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 112.859 0.688 . . . . 10.0 112.859 -169.028 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -86.82 -23.5 25.32 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 113.378 0.881 . . . . 10.0 113.378 177.052 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.97 101.39 2.69 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.172 -1.571 . . . . 10.0 109.172 -170.273 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.289 26.3 p 11.5 49.62 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 129.633 3.173 . . . . 10.0 116.955 -168.673 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 42.4 m -120.84 -53.68 2.06 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 105.077 -2.194 . . . . 10.0 105.077 174.977 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.5 m -44.89 -40.45 6.29 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 126.158 1.783 . . . . 10.0 109.936 168.972 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.84 -25.25 0.09 Allowed 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 127.726 2.41 . . . . 10.0 114.999 176.934 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.41 155.79 29.45 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 108.572 -1.811 . . . . 10.0 108.572 169.35 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -68.5 -172.73 0.48 Allowed 'Trans proline' 0 N--CA 1.445 -1.352 0 N-CA-C 106.888 -2.005 . . . . 10.0 106.888 166.719 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -78.81 45.09 0.58 Allowed 'General case' 0 CA--C 1.542 0.649 0 O-C-N 119.743 -1.848 . . . . 10.0 112.047 -171.511 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.1 m-30 -72.55 68.22 0.8 Allowed 'General case' 0 C--O 1.221 -0.413 0 CA-C-N 119.846 1.203 . . . . 10.0 109.676 178.759 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -63.57 155.66 74.83 Favored Pre-proline 0 C--N 1.331 -0.226 0 N-CA-C 107.535 -1.283 . . . . 10.0 107.535 173.768 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -54.92 -27.95 56.47 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.097 1.865 . . . . 10.0 112.281 175.222 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -107.78 25.14 11.89 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.043 0.937 . . . . 10.0 111.815 177.189 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 44.7 p -40.98 117.79 0.9 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.646 1.179 . . . . 10.0 112.273 177.94 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -124.58 -88.89 0.59 Allowed 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 107.676 -1.231 . . . . 10.0 107.676 177.361 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.418 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 8.5 mtmp? -125.49 152.6 44.76 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 108.316 -0.994 . . . . 10.0 108.316 168.541 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 36.2 t60 -58.14 128.36 36.72 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 117.659 -1.617 . . . . 10.0 106.734 165.812 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.408 ' CA ' ' HB2' ' B' ' 76' ' ' ASP . . . -150.09 -141.16 3.35 Favored Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 109.905 -1.278 . . . . 10.0 109.905 -178.771 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.6 -147.52 11.43 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 107.95 -2.06 . . . . 10.0 107.95 169.976 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.05 12.94 0.2 Allowed 'Trans proline' 0 N--CA 1.452 -0.923 0 CA-C-N 120.114 1.957 . . . . 10.0 111.621 169.429 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -127.65 1.51 6.15 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.59 1.156 . . . . 10.0 111.737 176.502 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.42 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 0.2 OUTLIER -123.81 150.58 44.35 Favored 'General case' 0 C--N 1.34 0.168 0 N-CA-C 102.426 -3.175 . . . . 10.0 102.426 166.825 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -82.55 -17.74 43.9 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 121.646 -0.659 . . . . 10.0 109.832 174.705 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.9 pm0 -118.16 36.54 4.31 Favored 'General case' 0 N--CA 1.438 -1.056 0 C-N-CA 125.901 1.68 . . . . 10.0 111.579 -167.515 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -44.25 153.58 0.14 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.58 1.552 . . . . 10.0 109.578 168.937 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 38.4 m80 -60.9 -48.17 83.06 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 10.0 109.966 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.1 t 173.31 -75.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 C-N-CA 129.284 3.034 . . . . 10.0 105.059 166.082 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.03 59.06 5.02 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 179.305 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -106.08 95.07 5.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.557 -2.016 . . . . 10.0 105.557 169.322 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 43.6 mt -75.23 -33.87 61.39 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 106.741 -1.577 . . . . 10.0 106.741 175.632 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.51 -96.94 1.31 Allowed Glycine 0 N--CA 1.436 -1.337 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 169.442 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -132.42 136.14 46.56 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 122.863 0.465 . . . . 10.0 110.021 -169.518 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.5 m -122.24 140.3 46.54 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.955 -0.758 . . . . 10.0 108.955 169.488 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 9.4 m -81.93 119.25 23.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 127.457 2.303 . . . . 10.0 110.499 -177.159 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.4 130.46 44.53 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.984 1.314 . . . . 10.0 110.642 170.022 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -59.88 166.31 2.73 Favored 'General case' 0 N--CA 1.455 -0.222 0 O-C-N 124.069 0.855 . . . . 10.0 109.603 167.366 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 35.6 pttt -52.47 -30.5 30.18 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.804 1.241 . . . . 10.0 110.93 173.37 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -77.08 -9.52 58.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 117.676 0.216 . . . . 10.0 111.027 -178.148 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.54 10.57 67.54 Favored Glycine 0 C--N 1.34 0.774 0 O-C-N 121.092 -1.005 . . . . 10.0 111.038 -178.191 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.0 t -86.14 111.44 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 127.184 2.194 . . . . 10.0 106.466 175.914 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.577 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -114.61 120.71 41.1 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 118.715 0.689 . . . . 10.0 109.509 172.825 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -78.5 132.43 37.23 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 107.325 -1.361 . . . . 10.0 107.325 169.864 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.8 t -114.94 133.44 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 N-CA-C 104.777 -2.305 . . . . 10.0 104.777 169.063 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -156.73 62.8 0.52 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 118.174 0.443 . . . . 10.0 110.139 -178.731 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.69 152.85 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 N-CA-C 107.735 -1.209 . . . . 10.0 107.735 -173.961 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -136.6 139.22 41.95 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 123.798 0.839 . . . . 10.0 109.667 168.957 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -148.47 153.53 38.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.918 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.3 p -115.52 44.48 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 126.494 1.917 . . . . 10.0 109.549 177.403 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -111.69 -48.04 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 170.457 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 42.5 mm -65.1 148.49 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 108.007 -1.108 . . . . 10.0 108.007 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.4 m -157.29 120.97 4.16 Favored 'General case' 0 C--O 1.226 -0.134 0 N-CA-C 108.029 -1.1 . . . . 10.0 108.029 173.578 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.9 mp -59.62 -29.94 68.36 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.614 1.166 . . . . 10.0 111.955 -169.603 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.2 m . . . . . 0 N--CA 1.454 -0.227 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 176.096 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 7.1 t . . . . . 0 CA--C 1.531 0.247 0 CA-C-O 120.547 0.213 . . . . 10.0 111.176 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 mt 63.82 16.32 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 124.173 0.989 . . . . 10.0 110.721 174.104 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.8 mm -71.02 -56.1 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 124.478 1.111 . . . . 10.0 110.037 175.824 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.72 48.82 3.55 Favored Glycine 0 CA--C 1.526 0.758 0 O-C-N 120.617 -1.302 . . . . 10.0 112.501 -177.49 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.03 168.06 11.93 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 126.612 1.965 . . . . 10.0 108.692 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -114.21 141.11 47.95 Favored 'General case' 0 CA--C 1.515 -0.396 0 C-N-CA 124.654 1.181 . . . . 10.0 108.306 -172.07 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.8 mp -111.85 145.92 38.62 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.83 1.652 . . . . 10.0 108.474 172.489 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.9 t -131.71 136.06 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 178.278 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.405 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.4 p -97.57 120.17 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 105.838 -1.912 . . . . 10.0 105.838 168.007 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.629 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.2 m-70 -98.5 158.29 15.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 115.59 1.7 . . . . 10.0 115.59 -176.373 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -38.47 -66.18 0.29 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 129.834 3.254 . . . . 10.0 110.619 170.517 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -113.75 174.86 5.72 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 125.174 1.389 . . . . 10.0 110.319 -174.561 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.84 137.23 35.3 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.879 -1.055 . . . . 10.0 108.465 171.311 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.4 141.73 39.63 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.287 1.035 . . . . 10.0 109.284 169.892 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -78.45 24.51 0.27 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.375 0.67 . . . . 10.0 111.86 179.63 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.5 mt 36.64 51.6 0.91 Allowed 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.792 2.037 . . . . 10.0 111.7 -176.674 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.44 -32.03 6.6 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 125.594 1.569 . . . . 10.0 112.384 175.078 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.42 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 7.2 mttm -80.08 18.67 0.81 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.628 1.171 . . . . 10.0 113.222 -167.819 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.27 -18.73 75.29 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 109.531 -1.428 . . . . 10.0 109.531 167.109 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.78 40.19 92.52 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 124.402 1.001 . . . . 10.0 111.749 175.403 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -145.25 169.6 17.91 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.093 0.946 . . . . 10.0 109.583 173.643 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 13.0 tm-20 -46.83 -49.85 19.4 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.711 1.204 . . . . 10.0 110.139 -179.875 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 17.9 tp10 -71.35 -34.74 70.77 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 121.781 -0.574 . . . . 10.0 111.657 179.217 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.9 p -54.15 -43.63 70.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 120.715 -1.241 . . . . 10.0 110.799 172.149 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.272 5.6 t -77.81 -23.02 49.18 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 119.568 -0.853 . . . . 10.0 111.557 -173.627 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -84.71 -49.01 8.86 Favored 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 127.486 2.314 . . . . 10.0 112.525 -177.738 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 19.2 p -136.3 -15.04 1.71 Allowed 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 114.495 1.295 . . . . 10.0 114.495 175.556 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.76 3.9 52.18 Favored Glycine 0 C--N 1.339 0.707 0 CA-C-O 118.379 -1.234 . . . . 10.0 114.105 177.914 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 27.2 m120 72.18 25.26 2.95 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 118.573 1.186 . . . . 10.0 112.01 -177.788 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.34 -8.83 43.34 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.435 0.902 . . . . 10.0 113.435 179.356 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.93 -160.8 48.8 Favored Glycine 0 CA--C 1.524 0.608 0 O-C-N 121.029 -1.045 . . . . 10.0 111.536 172.622 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 m -60.63 134.69 57.33 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.7 1.2 . . . . 10.0 113.657 -167.675 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.9 84.92 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.524 1.529 . . . . 10.0 110.21 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 65.8 mt -58.02 -39.18 77.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.425 0.557 . . . . 10.0 112.094 -179.031 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.405 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -154.46 153.34 31.37 Favored 'General case' 0 CA--C 1.516 -0.334 0 O-C-N 121.683 -0.635 . . . . 10.0 110.655 -179.912 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.2 m -121.68 141.14 51.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.014 1.726 . . . . 10.0 108.556 -169.041 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.4 158.43 27.5 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 109.675 -1.37 . . . . 10.0 109.675 168.539 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.8 t -118.8 135.52 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 -179.838 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.458 HG12 ' HB2' ' B' ' 6' ' ' ALA . 59.8 mt -71.88 153.35 7.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 N-CA-C 108.658 -0.867 . . . . 10.0 108.658 176.808 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -164.77 151.24 20.15 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 109.099 -1.601 . . . . 10.0 109.099 -175.089 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.47 123.75 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 117.514 0.657 . . . . 10.0 109.768 -172.809 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.06 -26.26 39.74 Favored 'General case' 0 N--CA 1.446 -0.628 0 O-C-N 120.894 -1.129 . . . . 10.0 111.809 -173.276 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.428 -1.533 0 N-CA-C 103.918 -2.623 . . . . 10.0 103.918 -173.859 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.791 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -79.57 -38.91 33.02 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.194 0.598 . . . . 10.0 110.028 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -121.16 130.08 53.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.148 1.379 . . . . 10.0 107.331 -179.328 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.11 151.92 51.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.595 -0.891 . . . . 10.0 108.595 172.874 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.444 HG13 ' HB2' ' A' ' 152' ' ' ALA . 1.0 OUTLIER -109.24 170.52 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 123.115 0.566 . . . . 10.0 110.45 169.993 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -156.02 102.38 2.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 106.64 -1.615 . . . . 10.0 106.64 166.045 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.598 HG12 HG23 ' A' ' 17' ' ' ILE . 35.7 m -92.24 128.4 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 108.795 -0.817 . . . . 10.0 108.795 171.078 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.436 ' N ' HD12 ' A' ' 8' ' ' LEU . 4.2 mp -103.18 152.83 21.0 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 108.853 -0.795 . . . . 10.0 108.853 178.231 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 ttmt -161.16 162.24 31.31 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 108.044 -1.095 . . . . 10.0 108.044 169.52 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.37 -56.16 0.04 OUTLIER Glycine 0 C--N 1.33 0.21 0 N-CA-C 111.459 -0.657 . . . . 10.0 111.459 172.801 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.97 -45.89 39.12 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -174.769 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.88 -67.72 0.55 Allowed Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 113.739 -1.573 . . . . 10.0 110.338 -179.506 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -56.96 -38.77 95.19 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.914 2.409 . . . . 10.0 111.172 173.876 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -68.05 105.59 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.062 0 N-CA-C 107.033 -1.469 . . . . 10.0 107.033 175.255 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -124.57 120.63 32.49 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 108.601 -0.888 . . . . 10.0 108.601 169.384 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.457 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -90.49 150.96 21.08 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.452 -1.459 . . . . 10.0 109.452 169.36 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.852 HG22 HG23 ' B' ' 54' ' ' THR . 0.0 OUTLIER -156.37 82.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 105.491 -2.04 . . . . 10.0 105.491 -172.994 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.6 mm -104.62 145.03 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.39 1.076 . . . . 10.0 108.841 -178.561 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -122.91 122.78 39.43 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 127.161 2.185 . . . . 10.0 108.337 169.011 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -103.24 123.03 45.97 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 106.704 -1.591 . . . . 10.0 106.704 173.327 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -117.91 135.52 54.06 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 123.962 0.788 . . . . 10.0 113.126 169.553 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -123.82 100.02 6.56 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 127.42 2.288 . . . . 10.0 105.264 171.135 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 17.8 tttp -64.65 -62.63 1.46 Allowed 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 124.61 1.164 . . . . 10.0 109.392 -169.719 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -109.59 165.81 11.38 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 102.896 -3.001 . . . . 10.0 102.896 166.873 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.9 t -66.65 -21.54 66.11 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 -178.912 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.6 m-80 -76.76 -19.62 57.41 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.537 -0.756 . . . . 10.0 110.511 -179.595 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.55 140.82 32.57 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 109.862 -1.295 . . . . 10.0 109.862 -178.763 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -61.62 149.15 91.05 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 N-CA-C 107.041 -1.946 . . . . 10.0 107.041 168.877 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 t -79.29 113.68 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.087 0 N-CA-C 105.976 -1.861 . . . . 10.0 105.976 178.584 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -93.9 117.58 30.3 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 171.193 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -110.4 108.67 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 C-N-CA 126.817 2.047 . . . . 10.0 106.857 -175.558 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 20.8 p90 -127.49 163.11 24.84 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 112.103 0.408 . . . . 10.0 112.103 179.616 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.03 -147.37 18.32 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 106.917 -2.473 . . . . 10.0 106.917 170.144 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 52.2 p -157.96 164.78 36.49 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.065 -1.054 . . . . 10.0 112.551 178.617 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.632 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -116.45 121.53 67.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 C-N-CA 126.062 1.745 . . . . 10.0 106.668 166.628 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.61 54.78 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 175.025 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.14 -0.14 9.68 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.174 1.369 . . . . 10.0 113.539 178.537 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.26 178.38 2.87 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 118.394 1.097 . . . . 10.0 111.231 179.183 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -107.71 156.11 19.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.203 -1.777 . . . . 10.0 106.203 165.244 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -51.27 150.74 3.21 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.463 1.105 . . . . 10.0 112.347 -169.504 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.04 -171.36 23.49 Favored Glycine 0 C--N 1.336 0.558 0 N-CA-C 111.201 -0.76 . . . . 10.0 111.201 170.232 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.73 149.16 36.37 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.574 1.149 . . . . 10.0 111.363 -173.319 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -143.15 141.32 31.15 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.71 1.204 . . . . 10.0 112.502 -177.698 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.534 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -35.73 122.15 0.61 Allowed Glycine 0 C--N 1.341 0.86 0 C-N-CA 126.582 2.039 . . . . 10.0 112.878 166.303 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -143.43 115.42 8.32 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 120.085 1.942 . . . . 10.0 110.975 167.442 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.7 174.25 12.79 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 120.994 0.426 . . . . 10.0 111.787 -178.974 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 117' ' ' LEU . 1.1 m -113.47 82.24 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 126.036 1.735 . . . . 10.0 109.995 -179.656 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -56.8 141.31 44.91 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 122.292 1.044 . . . . 10.0 110.599 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -71.58 -53.21 14.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 112.045 -2.343 . . . . 10.0 110.456 -168.234 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.3 m-30 -76.49 110.09 10.75 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 175.154 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.42 48.71 1.22 Allowed Glycine 0 CA--C 1.531 1.051 0 N-CA-C 110.04 -1.224 . . . . 10.0 110.04 167.806 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.76 143.41 30.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.885 1.674 . . . . 10.0 106.825 170.915 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.468 ' HB3' HG21 ' B' ' 7' ' ' VAL . 10.7 m-20 -139.5 2.13 2.0 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 126.344 1.858 . . . . 10.0 109.324 174.103 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.565 HG23 ' CG2' ' B' ' 17' ' ' ILE . 1.9 m -61.92 -30.36 70.84 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 120.098 1.317 . . . . 10.0 110.525 -170.111 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.18 -15.36 60.07 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.174 0.99 . . . . 10.0 112.047 176.136 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.14 76.55 1.33 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.57 -1.412 . . . . 10.0 109.57 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 74.0 m 47.56 45.66 17.63 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.53 1.132 . . . . 10.0 111.145 175.658 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.5 m -134.59 -52.5 0.81 Allowed 'General case' 0 N--CA 1.439 -0.995 0 N-CA-C 108.948 -0.76 . . . . 10.0 108.948 -168.863 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 t -99.5 21.04 12.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.425 0.528 . . . . 10.0 112.425 -170.28 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.12 3.52 0.85 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.15 0.98 . . . . 10.0 113.401 178.956 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.28 129.98 1.57 Allowed Glycine 0 CA--C 1.529 0.967 0 O-C-N 120.874 -1.141 . . . . 10.0 110.341 175.973 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.16 61.54 7.78 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 123.197 2.598 . . . . 10.0 110.556 178.605 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 28.9 m170 63.07 59.75 1.28 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 128.46 2.704 . . . . 10.0 110.858 177.581 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.1 m-85 -72.19 55.19 0.31 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.558 1.143 . . . . 10.0 113.892 -176.727 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -71.18 144.53 89.88 Favored Pre-proline 0 C--N 1.326 -0.437 0 C-N-CA 125.56 1.544 . . . . 10.0 113.18 -174.158 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -71.78 -37.87 4.75 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.283 2.655 . . . . 10.0 111.398 176.706 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.79 56.95 0.98 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.653 0.781 . . . . 10.0 110.533 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 67.9 p -42.06 94.85 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 126.676 1.99 . . . . 10.0 112.948 -169.58 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.2 mtt85 -121.14 172.15 8.18 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 126.129 1.772 . . . . 10.0 108.163 174.983 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 35.1 mtmm -102.0 106.32 17.22 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 -176.667 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -19.22 105.43 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.32 0 C-N-CA 126.71 2.004 . . . . 10.0 114.407 -171.024 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.424 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . -115.35 -146.45 8.89 Favored Glycine 0 N--CA 1.439 -1.101 0 C-N-CA 125.828 1.68 . . . . 10.0 109.467 176.541 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.98 -166.39 24.93 Favored Glycine 0 N--CA 1.45 -0.41 0 N-CA-C 108.587 -1.805 . . . . 10.0 108.587 171.603 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.4 -3.16 3.86 Favored 'Trans proline' 0 N--CA 1.454 -0.814 0 CA-C-N 119.87 1.835 . . . . 10.0 111.829 173.104 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -99.19 -17.35 18.19 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.592 0.757 . . . . 10.0 111.61 174.667 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.424 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 4.5 t70 -111.71 169.68 8.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.191 -1.041 . . . . 10.0 108.191 -179.138 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -80.8 -36.28 31.93 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.824 -1.547 . . . . 10.0 106.824 169.056 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 12.6 mt-10 -84.98 32.93 0.53 Allowed 'General case' 0 N--CA 1.442 -0.871 0 CA-C-O 122.646 1.213 . . . . 10.0 113.185 -166.02 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 ptm180 -66.68 133.65 50.65 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 170.091 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 69.3 m-70 -66.56 -70.75 0.23 Allowed 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.461 0.648 . . . . 10.0 110.704 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 80.8 t -147.19 -105.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.038 -2.949 . . . . 10.0 103.038 177.729 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.34 62.8 4.52 Favored Glycine 0 CA--C 1.524 0.655 0 O-C-N 121.336 -0.852 . . . . 10.0 111.227 176.441 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -89.94 105.07 17.56 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 101.118 -3.66 . . . . 10.0 101.118 163.955 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -87.43 -37.29 17.14 Favored 'General case' 0 N--CA 1.461 0.109 0 N-CA-C 107.41 -1.33 . . . . 10.0 107.41 173.298 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.17 -95.68 1.26 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 123.448 0.547 . . . . 10.0 111.884 167.75 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -116.09 104.27 11.39 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.903 1.281 . . . . 10.0 111.304 -167.451 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.07 133.81 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 168.851 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 m -100.21 111.96 24.26 Favored 'General case' 0 N--CA 1.441 -0.895 0 C-N-CA 125.692 1.597 . . . . 10.0 109.07 -169.142 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.75 129.71 35.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.243 0.617 . . . . 10.0 110.912 179.123 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -57.33 170.86 0.46 Allowed 'General case' 0 C--O 1.233 0.224 0 O-C-N 124.778 1.299 . . . . 10.0 110.116 167.494 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.8 ptmm? -54.29 -30.56 51.26 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 114.676 -1.147 . . . . 10.0 111.189 172.14 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -78.87 -2.05 37.94 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.988 0.915 . . . . 10.0 111.439 -179.049 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.86 20.38 73.6 Favored Glycine 0 C--N 1.337 0.598 0 N-CA-C 110.625 -0.99 . . . . 10.0 110.625 179.204 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.16 102.43 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.954 0 N-CA-C 105.462 -2.051 . . . . 10.0 105.462 179.393 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.632 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -99.53 121.97 41.93 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.83 -1.174 . . . . 10.0 107.83 169.259 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -81.23 143.09 32.56 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.796 1.638 . . . . 10.0 109.347 173.597 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 85.4 t -117.79 129.84 73.59 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 N-CA-C 105.745 -1.946 . . . . 10.0 105.745 168.175 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 17.4 m -158.1 69.77 0.53 Allowed 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 124.515 1.126 . . . . 10.0 108.403 169.257 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -108.61 157.75 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -176.844 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -132.09 133.46 44.36 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 125.415 1.486 . . . . 10.0 108.691 170.892 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -136.26 135.07 38.7 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 108.288 -1.004 . . . . 10.0 108.288 -173.482 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 16.4 m -104.09 16.39 26.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.695 1.198 . . . . 10.0 111.729 -175.357 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.7 p -136.51 11.8 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 123.691 0.796 . . . . 10.0 110.33 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -113.95 136.13 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 103.11 -2.922 . . . . 10.0 103.11 169.905 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 11.5 m -139.53 123.68 17.9 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 123.358 0.663 . . . . 10.0 109.646 -178.223 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.1 mt -69.57 -31.6 69.88 Favored 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.985 0.914 . . . . 10.0 109.8 170.216 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 63.3 m -152.0 135.8 16.33 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.231 1.012 . . . . 10.0 108.339 170.666 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 164.59 -57.74 0.26 Allowed Glycine 0 C--N 1.333 0.391 0 N-CA-C 109.684 -1.367 . . . . 10.0 109.684 179.449 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -164.51 -50.06 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.694 1.998 . . . . 10.0 107.334 -178.129 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -74.37 -38.49 63.15 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.919 -1.037 . . . . 10.0 108.373 -169.597 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 45.5 t 42.03 55.14 3.9 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 126.486 1.914 . . . . 10.0 110.771 172.574 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.14 21.48 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 N-CA-C 113.873 1.064 . . . . 10.0 113.873 -168.626 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.7 mm -58.66 142.66 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 C-N-CA 125.33 1.452 . . . . 10.0 107.614 169.306 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.83 14.65 82.36 Favored Glycine 0 CA--C 1.534 1.245 0 CA-C-O 118.745 -1.031 . . . . 10.0 114.19 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.3 mmt180 -74.11 175.05 7.84 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 107.389 -1.338 . . . . 10.0 107.389 168.198 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -117.79 128.24 54.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.743 -1.206 . . . . 10.0 107.743 169.83 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.565 HD21 HD11 ' A' ' 149' ' ' ILE . 27.8 mt -98.42 142.73 29.68 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 107.953 -1.129 . . . . 10.0 107.953 174.317 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -131.09 132.33 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.324 -1.361 . . . . 10.0 107.324 178.191 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.31 123.66 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.254 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.044 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.534 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.2 m170 -101.01 161.55 13.51 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 114.465 1.283 . . . . 10.0 114.465 -173.956 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -56.21 -50.64 70.67 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 126.433 1.893 . . . . 10.0 110.967 178.441 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 48.8 mttm -112.35 163.44 14.4 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.421 0.629 . . . . 10.0 111.508 -171.104 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.37 141.23 42.72 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 114.628 -1.169 . . . . 10.0 108.773 172.172 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -76.45 148.15 37.44 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 108.56 -0.904 . . . . 10.0 108.56 174.768 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.86 -37.03 15.65 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 126.814 2.046 . . . . 10.0 109.757 -178.414 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 20.4 mt 66.48 36.88 4.84 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.788 0.835 . . . . 10.0 113.059 -176.742 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 111.58 -25.77 12.9 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 118.553 0.615 . . . . 10.0 114.435 165.35 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.252 0.0 OUTLIER -94.56 31.12 1.83 Allowed 'General case' 0 CA--C 1.543 0.69 0 N-CA-C 113.386 0.884 . . . . 10.0 113.386 -172.758 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.427 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -90.16 -12.21 62.02 Favored Glycine 0 C--N 1.343 0.938 0 C-N-CA 125.342 1.449 . . . . 10.0 112.06 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.62 44.95 47.62 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.252 0.929 . . . . 10.0 112.778 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -153.28 175.46 13.06 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.479 -0.934 . . . . 10.0 108.479 175.722 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -56.67 -40.16 75.03 Favored 'General case' 0 N--CA 1.437 -1.079 0 O-C-N 121.356 -0.84 . . . . 10.0 111.845 -175.31 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -63.13 -36.57 84.03 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 118.056 -0.973 . . . . 10.0 109.723 175.838 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.427 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 59.0 p -51.01 -42.89 60.7 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 119.62 1.1 . . . . 10.0 110.954 -172.955 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.252 12.3 t -81.93 -11.31 58.95 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 112.522 0.564 . . . . 10.0 112.522 -175.448 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -115.88 -58.45 2.11 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.532 1.533 . . . . 10.0 113.648 -170.266 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 16.9 p -128.98 10.84 5.96 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 120.449 1.477 . . . . 10.0 112.182 175.447 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.25 -97.01 2.17 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 125.401 1.477 . . . . 10.0 109.742 176.073 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -168.09 37.88 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 122.944 1.354 . . . . 10.0 107.706 178.864 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.11 -22.73 55.21 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 113.534 -1.667 . . . . 10.0 108.446 -173.803 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.82 -157.37 53.07 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 109.506 -1.438 . . . . 10.0 109.506 169.497 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.26 120.29 3.93 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 124.28 1.032 . . . . 10.0 113.229 -167.663 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -63.06 80.47 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.412 1.085 . . . . 10.0 109.939 171.229 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.8 mt -45.56 -52.68 10.14 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.343 0.592 . . . . 10.0 110.96 178.061 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.93 152.8 31.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.723 -0.672 . . . . 10.0 109.501 -168.623 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -147.13 161.06 41.65 Favored 'General case' 0 N--CA 1.447 -0.592 0 O-C-N 123.83 0.706 . . . . 10.0 111.009 -176.79 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.94 168.59 28.15 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 125.473 1.511 . . . . 10.0 109.413 -177.839 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.0 t -120.76 137.85 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 106.366 -1.716 . . . . 10.0 106.366 -178.84 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.565 HD11 HD21 ' A' ' 117' ' ' LEU . 6.9 mt -73.12 116.81 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.655 -0.498 . . . . 10.0 109.655 -177.451 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.25 154.25 17.08 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 111.331 -176.029 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.23 145.89 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 C-N-CA 124.763 1.225 . . . . 10.0 108.395 176.008 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.444 ' HB2' HG13 ' A' ' 5' ' ' VAL . . . -121.11 -25.99 5.2 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 113.58 0.956 . . . . 10.0 113.58 178.422 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.2 tp60 . . . . . 0 C--O 1.25 1.125 0 CA-C-O 117.074 -1.441 . . . . 10.0 107.153 -177.142 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.564 0 N-CA-C 106.534 -1.654 . . . . 10.0 106.534 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.2 t -156.83 -49.22 0.07 Allowed 'General case' 0 C--O 1.224 -0.242 0 CA-C-N 119.365 0.984 . . . . 10.0 110.957 169.161 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -124.01 122.23 37.35 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 125.13 1.372 . . . . 10.0 108.768 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -130.92 152.09 50.62 Favored 'General case' 0 CA--C 1.52 -0.184 0 C-N-CA 123.785 0.834 . . . . 10.0 109.523 170.019 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -118.38 161.15 17.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 C-N-CA 122.947 0.499 . . . . 10.0 111.091 178.022 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.9 110.4 5.78 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.165 -0.925 . . . . 10.0 108.561 167.859 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.468 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.6 m -96.95 108.48 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 124.246 1.019 . . . . 10.0 109.349 172.763 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.9 mt -92.17 131.56 37.31 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.527 -0.916 . . . . 10.0 108.527 -178.396 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -143.65 157.09 44.67 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.612 -1.255 . . . . 10.0 107.612 171.042 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.02 -60.91 0.05 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 121.157 -0.544 . . . . 10.0 113.045 169.35 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.25 -43.78 66.58 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 -177.318 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.58 -71.22 0.42 Allowed Glycine 0 CA--C 1.523 0.578 0 CA-C-N 114.358 -1.292 . . . . 10.0 110.631 168.994 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -57.1 -31.98 91.93 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 123.282 2.655 . . . . 10.0 111.313 171.757 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.417 HG13 HD11 ' B' ' 38' ' ' LEU . 93.5 t -67.97 94.5 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 107.118 -1.438 . . . . 10.0 107.118 177.334 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -115.55 112.4 22.14 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 105.91 -1.885 . . . . 10.0 105.91 178.591 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.677 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.07 139.62 14.59 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 172.182 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.565 ' CG2' HG23 ' A' ' 54' ' ' THR . 4.5 mt -140.77 95.85 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 108.286 -1.005 . . . . 10.0 108.286 -174.986 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -106.9 149.15 10.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 124.578 1.151 . . . . 10.0 113.011 -178.184 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 31.5 m-20 -122.98 110.04 14.88 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.939 2.096 . . . . 10.0 108.24 168.749 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -86.97 108.2 18.73 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 170.821 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -109.3 113.41 26.22 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-O 121.395 0.616 . . . . 10.0 111.646 179.81 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -78.1 101.77 7.15 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 169.854 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 2.1 mmmp? . . . . . 0 CA--C 1.522 -0.103 0 C-N-CA 127.345 2.258 . . . . 10.0 109.72 177.511 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.961 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -61.88 144.02 96.27 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.491 2.127 . . . . 10.0 109.633 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 t -78.93 87.18 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.999 0 N-CA-C 106.417 -1.698 . . . . 10.0 106.417 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.4 mttm -67.08 108.19 2.55 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 106.854 -1.536 . . . . 10.0 106.854 169.012 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -110.03 108.87 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 125.624 1.569 . . . . 10.0 107.465 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 21.9 p90 -123.38 168.12 12.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.509 0.671 . . . . 10.0 110.123 173.408 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.46 -170.76 43.92 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 179.243 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.3 m -154.98 111.88 3.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -175.939 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.677 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.5 pt -84.22 175.19 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.573 -0.851 . . . . 10.0 110.115 169.703 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -149.98 156.35 41.56 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 166.675 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.52 -25.17 11.36 Favored Glycine 0 C--N 1.338 0.678 0 CA-C-O 119.372 -0.682 . . . . 10.0 114.154 171.039 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.502 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.4 mp -75.04 179.59 4.89 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 118.388 1.094 . . . . 10.0 111.513 -170.84 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.6 t -101.84 161.55 13.58 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.637 -0.875 . . . . 10.0 108.637 168.263 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -49.2 153.0 1.05 Allowed 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.192 1.797 . . . . 10.0 113.675 -169.292 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.43 179.55 39.43 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 124.607 1.099 . . . . 10.0 113.033 168.525 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 95.2 mt -49.49 137.71 14.61 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.119 1.768 . . . . 10.0 112.755 171.894 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -138.2 147.12 43.46 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 124.773 1.229 . . . . 10.0 112.048 171.351 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.694 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -18.65 118.5 0.01 OUTLIER Glycine 0 C--N 1.337 0.598 0 C-N-CA 127.835 2.636 . . . . 10.0 114.16 165.466 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -151.35 106.02 3.26 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 120.218 2.009 . . . . 10.0 112.909 167.296 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.07 168.39 24.76 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.655 -0.702 . . . . 10.0 111.269 176.504 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 16.7 m -86.7 155.09 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 112.21 -2.268 . . . . 10.0 107.06 166.681 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -126.09 152.91 45.23 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 173.243 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -59.7 -42.98 94.24 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 113.689 0.996 . . . . 10.0 113.689 -168.857 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -96.38 174.96 6.61 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.749 -0.834 . . . . 10.0 108.749 -177.193 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -111.35 10.8 28.64 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 125.418 1.485 . . . . 10.0 109.668 166.999 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.49 112.62 1.65 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 122.327 1.06 . . . . 10.0 109.067 176.772 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 39.1 m-20 -120.56 9.97 10.99 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 114.244 -1.344 . . . . 10.0 108.305 168.006 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.852 HG23 HG22 ' A' ' 17' ' ' ILE . 15.5 m -67.59 -34.6 77.35 Favored 'General case' 0 C--N 1.344 0.359 0 C-N-CA 125.235 1.414 . . . . 10.0 108.625 171.02 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.41 -22.34 60.26 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.323 -0.399 . . . . 10.0 110.479 174.702 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.5 54.33 1.7 Allowed Glycine 0 C--N 1.34 0.761 0 C-N-CA 123.893 0.759 . . . . 10.0 111.557 172.083 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 37.5 m 59.76 28.96 18.51 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.03 0.932 . . . . 10.0 110.166 -176.136 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 38.7 m -112.09 -49.8 2.95 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 125.439 1.495 . . . . 10.0 107.147 -169.596 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 8.4 t -117.31 26.62 9.62 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 113.563 0.949 . . . . 10.0 113.563 -175.041 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.42 -7.57 6.97 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.701 1.001 . . . . 10.0 113.701 179.548 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.36 123.61 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.763 1.173 . . . . 10.0 111.052 172.856 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -81.34 55.86 5.78 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 123.074 2.516 . . . . 10.0 112.16 -172.154 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER 66.76 36.84 4.42 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 128.956 2.903 . . . . 10.0 111.78 176.192 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -76.99 71.66 3.5 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 120.692 1.587 . . . . 10.0 109.998 175.911 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -61.87 158.19 44.78 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 125.201 1.4 . . . . 10.0 110.208 169.31 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -62.91 -46.63 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.024 1.816 . . . . 10.0 111.153 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 69.9 mt -78.84 56.45 1.91 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 123.204 0.601 . . . . 10.0 110.309 -179.383 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -45.25 112.21 0.42 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.639 1.176 . . . . 10.0 110.775 -179.305 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.5 mtp85 -137.33 -97.83 0.2 Allowed 'General case' 0 CA--C 1.506 -0.74 0 N-CA-C 104.492 -2.41 . . . . 10.0 104.492 -175.624 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 50.7 mttp -144.38 164.72 29.98 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.706 -1.22 . . . . 10.0 107.706 166.733 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -66.47 120.65 13.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 106.59 -1.634 . . . . 10.0 106.59 164.641 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.23 -137.79 3.66 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 108.087 -2.005 . . . . 10.0 108.087 175.304 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.6 -160.63 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 109.422 -1.471 . . . . 10.0 109.422 173.493 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -65.41 4.45 0.77 Allowed 'Trans proline' 0 N--CA 1.454 -0.834 0 C-N-CA 122.15 1.9 . . . . 10.0 111.83 169.824 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 57.8 mmtt -94.31 -24.03 17.58 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-O 118.508 -0.758 . . . . 10.0 110.127 170.282 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -108.29 161.42 15.02 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-O 121.051 0.453 . . . . 10.0 111.176 -167.53 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -97.46 -9.72 26.71 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.134 -0.939 . . . . 10.0 109.585 174.15 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -123.05 28.5 7.16 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 119.32 -0.372 . . . . 10.0 110.645 -178.91 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 79' ' ' ARG . . . . . 0.437 HH12 ' CG ' ' B' ' 101' ' ' ASP . 14.9 ptt180 -50.38 154.53 1.24 Allowed 'General case' 0 C--N 1.344 0.354 0 C-N-CA 123.337 0.655 . . . . 10.0 109.879 169.217 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -65.78 -64.88 0.76 Allowed 'General case' 0 N--CA 1.453 -0.319 0 CA-C-O 121.552 0.691 . . . . 10.0 109.503 -178.534 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.713 HG13 ' H ' ' B' ' 82' ' ' GLY . 4.0 p -169.34 -93.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 105.602 -1.999 . . . . 10.0 105.602 176.195 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.713 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -78.94 58.98 4.27 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.479 -1.048 . . . . 10.0 110.479 173.905 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.83 98.93 10.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 102.306 -3.22 . . . . 10.0 102.306 165.951 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -78.26 10.77 2.76 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.24 0.473 . . . . 10.0 110.585 -175.571 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 81.12 -109.44 2.99 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 104.128 -3.589 . . . . 10.0 104.128 -175.28 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -159.53 149.78 18.97 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.354 -1.721 . . . . 10.0 106.354 -178.435 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.45 128.18 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 C-N-CA 123.18 0.592 . . . . 10.0 111.202 -171.986 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.87 97.52 5.3 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 126.676 1.99 . . . . 10.0 111.176 -174.412 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.33 134.36 39.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.071 -0.393 . . . . 10.0 110.482 173.066 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -61.91 169.0 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.874 0.845 . . . . 10.0 109.249 167.358 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 34.7 mtmt -48.06 -34.4 9.51 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.873 1.669 . . . . 10.0 111.395 169.331 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -78.16 -8.32 58.15 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.999 0.428 . . . . 10.0 112.077 -179.377 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.69 1.94 70.38 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 120.933 -1.104 . . . . 10.0 111.572 -176.102 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -84.81 101.39 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.115 0 C-N-CA 125.77 1.628 . . . . 10.0 108.007 -179.232 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.438 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -96.13 115.72 27.87 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 168.252 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -80.86 119.35 23.3 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 106.737 -1.579 . . . . 10.0 106.737 169.24 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 66.5 t -104.11 131.12 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -177.446 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.3 p -157.24 83.81 0.92 Allowed 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 174.033 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -115.18 159.46 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 105.088 -2.19 . . . . 10.0 105.088 176.325 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -133.52 133.19 41.85 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 109.103 -0.703 . . . . 10.0 109.103 168.082 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 101' ' ' ASP . . . . . 0.437 ' CG ' HH12 ' B' ' 79' ' ' ARG . 7.1 t0 -113.89 111.93 22.51 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 124.229 0.955 . . . . 10.0 109.377 -173.052 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.6 p -100.77 61.73 1.0 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.446 1.498 . . . . 10.0 107.079 -176.229 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.5 p -155.39 -47.07 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.145 0 N-CA-C 110.204 -0.295 . . . . 10.0 110.204 -173.006 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.355 0.0 OUTLIER -102.15 176.89 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.143 0 N-CA-C 113.622 0.971 . . . . 10.0 113.622 172.231 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 49.9 m -151.62 146.1 25.57 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 105.915 -1.883 . . . . 10.0 105.915 -179.723 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 29.0 mt -68.01 -14.7 63.18 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 117.948 0.34 . . . . 10.0 111.354 -175.615 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.8 m . . . . . 0 N--CA 1.451 -0.421 0 O-C-N 120.949 -1.094 . . . . 10.0 108.62 174.382 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 CA--C 1.534 0.335 0 N-CA-C 114.227 1.195 . . . . 10.0 114.227 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 36.7 pt -72.79 -11.86 15.22 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 C-N-CA 123.717 0.807 . . . . 10.0 112.45 176.854 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm -52.11 133.11 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 O-C-N 121.488 -0.758 . . . . 10.0 110.059 178.774 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.87 1.4 84.39 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 118.81 -0.995 . . . . 10.0 114.016 -178.749 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 57.2 mtt85 -85.92 175.94 8.35 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.719 1.759 . . . . 10.0 108.487 168.459 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.04 140.13 50.19 Favored 'General case' 0 CA--C 1.513 -0.467 0 C-N-CA 125.458 1.503 . . . . 10.0 108.512 179.101 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.502 HD11 ' CG1' ' B' ' 149' ' ' ILE . 1.5 mp -110.14 155.93 21.27 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 107.641 -1.244 . . . . 10.0 107.641 166.03 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.4 HG21 ' HD3' ' B' ' 143' ' ' ARG . 91.2 t -128.82 134.3 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.149 0 N-CA-C 106.695 -1.595 . . . . 10.0 106.695 -179.183 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.84 121.62 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.363 0 N-CA-C 105.71 -1.959 . . . . 10.0 105.71 166.865 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.694 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.5 m-70 -102.95 160.5 14.55 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 116.316 1.969 . . . . 10.0 116.316 -168.925 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -43.46 -56.73 3.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 129.085 2.954 . . . . 10.0 111.19 173.73 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 78.1 mttt -113.52 168.84 9.42 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 124.067 0.947 . . . . 10.0 113.352 -168.569 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.44 154.0 41.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 124.68 1.238 . . . . 10.0 108.641 169.822 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.45 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 13.0 m-20 -106.07 141.43 37.45 Favored 'General case' 0 N--CA 1.454 -0.243 0 O-C-N 123.902 0.751 . . . . 10.0 111.287 -168.6 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -74.54 -31.03 61.98 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 125.169 1.388 . . . . 10.0 110.195 -177.355 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 13.7 mt 60.62 50.57 5.59 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 122.618 1.199 . . . . 10.0 108.014 -176.005 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.68 -52.08 4.18 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 115.392 -0.822 . . . . 10.0 111.401 172.571 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 48.75 0.98 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.517 1.127 . . . . 10.0 112.249 -172.679 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.16 -26.97 7.14 Favored Glycine 0 CA--C 1.522 0.492 0 C-N-CA 127.936 2.684 . . . . 10.0 111.17 173.426 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.45 18.01 65.17 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-O 118.472 -1.182 . . . . 10.0 112.65 172.908 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -131.95 168.75 17.35 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-N 119.677 1.739 . . . . 10.0 108.277 168.361 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.45 -55.04 6.56 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.571 1.148 . . . . 10.0 108.878 178.042 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -63.62 -34.22 77.35 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 118.169 -0.919 . . . . 10.0 111.791 -175.674 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.3 m -49.16 -46.86 45.9 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 120.202 1.365 . . . . 10.0 110.804 169.301 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -89.3 -15.6 33.09 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.245 -0.883 . . . . 10.0 113.257 -170.549 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -98.07 -40.93 8.19 Favored 'General case' 0 N--CA 1.438 -1.062 0 C-N-CA 125.027 1.331 . . . . 10.0 111.773 179.146 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.4 p -136.28 -7.02 2.02 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 114.567 1.321 . . . . 10.0 114.567 175.086 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.83 17.14 52.96 Favored Glycine 0 C--O 1.221 -0.669 0 CA-C-O 118.463 -1.187 . . . . 10.0 112.306 -173.27 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 55.53 30.29 14.94 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.533 1.667 . . . . 10.0 111.765 178.76 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.59 54.8 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 125.979 1.712 . . . . 10.0 112.057 -175.323 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.33 54.81 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 110.595 -1.002 . . . . 10.0 110.595 174.605 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.2 m -55.6 139.63 43.75 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 123.966 0.906 . . . . 10.0 111.887 -168.354 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 143' ' ' ARG . . . . . 0.4 ' HD3' HG21 ' B' ' 118' ' ' VAL . 22.6 mtt85 -71.02 70.84 0.53 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.828 1.251 . . . . 10.0 110.06 176.684 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.3 tp -44.6 -36.2 2.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 127.84 2.456 . . . . 10.0 112.536 -176.673 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.28 151.13 17.05 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 172.959 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -146.7 164.82 31.5 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 109.914 -0.402 . . . . 10.0 109.914 177.129 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.64 -176.63 25.44 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.496 -1.042 . . . . 10.0 110.496 178.249 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.4 t -122.56 143.13 36.41 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 107.568 -1.271 . . . . 10.0 107.568 179.817 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.502 ' CG1' HD11 ' B' ' 117' ' ' LEU . 11.4 mt -78.38 112.42 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 124.1 0.96 . . . . 10.0 109.493 -179.066 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.69 146.12 16.52 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 178.2 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -79.96 119.02 28.57 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 177.22 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.56 -43.05 40.56 Favored 'General case' 0 C--O 1.221 -0.439 0 O-C-N 121.078 -1.014 . . . . 10.0 108.554 -176.038 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.946 0 C-N-CA 125.793 1.637 . . . . 10.0 110.815 170.577 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.836 0 CA-C-O 118.628 -0.701 . . . . 10.0 109.661 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.5 t -97.15 -32.71 11.81 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 124.982 1.313 . . . . 10.0 110.369 -178.295 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -148.25 151.62 35.77 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.344 -0.984 . . . . 10.0 108.344 -177.849 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.15 155.41 45.31 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 122.878 0.471 . . . . 10.0 110.548 176.401 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.636 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.1 p -126.84 151.4 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 C-N-CA 128.152 2.581 . . . . 10.0 107.028 -178.762 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.62 116.29 11.41 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.174 -2.158 . . . . 10.0 105.174 168.265 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.3 p -81.29 103.72 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 108.822 -0.807 . . . . 10.0 108.822 174.42 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.76 116.45 23.26 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.027 -1.101 . . . . 10.0 108.027 178.333 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -137.84 155.99 48.4 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 174.401 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -163.19 -66.28 0.02 OUTLIER Glycine 0 C--O 1.229 -0.18 0 CA-C-N 114.915 -1.039 . . . . 10.0 111.891 174.67 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.76 -43.91 57.64 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 -172.706 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.52 -67.66 0.53 Allowed Glycine 0 N--CA 1.443 -0.895 0 CA-C-N 113.481 -1.691 . . . . 10.0 110.525 179.779 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -58.23 -37.96 93.1 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.911 2.408 . . . . 10.0 111.142 174.617 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 94.4 t -64.54 96.81 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 176.425 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -120.35 123.1 42.27 Favored 'General case' 0 N--CA 1.446 -0.661 0 C-N-CA 125.104 1.361 . . . . 10.0 107.381 175.666 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.549 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -116.25 136.6 13.0 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 123.652 0.644 . . . . 10.0 112.168 175.363 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.428 ' CG2' HG22 ' B' ' 54' ' ' THR . 58.6 mt -124.56 74.09 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 -179.018 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -64.09 148.85 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.374 -0.83 . . . . 10.0 109.598 171.67 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -139.05 97.85 3.4 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 127.437 2.295 . . . . 10.0 107.548 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -89.79 118.87 29.7 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.781 -1.192 . . . . 10.0 107.781 171.301 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -104.8 130.88 52.83 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.838 0.745 . . . . 10.0 110.971 168.644 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -123.1 92.3 3.67 Favored 'General case' 0 C--N 1.341 0.217 0 C-N-CA 125.076 1.35 . . . . 10.0 109.102 171.759 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 11.0 mmtp -49.94 -60.91 2.48 Favored 'General case' 0 N--CA 1.46 0.072 0 C-N-CA 124.653 1.181 . . . . 10.0 111.054 175.804 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.0 176.65 8.57 Favored 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 105.604 -1.998 . . . . 10.0 105.604 171.2 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 t -74.72 -13.74 60.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 122.341 0.256 . . . . 10.0 110.708 177.229 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -88.25 -12.94 42.21 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 123.729 0.811 . . . . 10.0 109.794 174.434 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.14 119.54 4.98 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 109.357 -1.497 . . . . 10.0 109.357 178.573 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -60.83 127.73 23.37 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 N-CA-C 106.558 -2.132 . . . . 10.0 106.558 169.41 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -77.01 138.06 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 108.702 -0.851 . . . . 10.0 108.702 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.79 106.24 18.22 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 104.759 -2.311 . . . . 10.0 104.759 171.76 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 m -87.03 93.33 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 105.467 -2.049 . . . . 10.0 105.467 174.137 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -109.18 178.79 4.35 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-O 120.83 0.348 . . . . 10.0 111.219 173.721 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.58 -164.09 30.15 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 169.043 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.6 p -152.19 122.43 7.19 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 118.641 -0.695 . . . . 10.0 110.934 -169.383 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.629 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -100.88 136.6 31.73 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 105.891 -1.892 . . . . 10.0 105.891 166.325 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.44 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -130.14 160.05 34.96 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 168.809 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.7 -12.52 62.79 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 118.042 0.383 . . . . 10.0 113.208 -178.815 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 15.4 mt -68.2 -179.49 1.28 Allowed 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.872 0.869 . . . . 10.0 110.489 171.651 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -111.95 166.46 11.2 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 167.554 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -46.64 148.96 0.88 Allowed 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 127.359 2.264 . . . . 10.0 113.419 -169.534 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.65 -179.09 42.98 Favored Glycine 0 C--N 1.336 0.569 0 C-N-CA 124.235 0.922 . . . . 10.0 114.091 167.139 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.6 mt -52.38 137.9 28.23 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.878 1.671 . . . . 10.0 113.02 176.63 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 -135.31 141.57 45.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.439 1.095 . . . . 10.0 111.075 169.525 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.628 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -25.46 121.75 0.03 OUTLIER Glycine 0 C--N 1.344 0.992 0 CA-C-O 116.648 -2.195 . . . . 10.0 111.773 165.776 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -144.54 109.5 5.04 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 120.431 2.115 . . . . 10.0 111.053 169.768 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.09 175.02 11.36 Favored 'General case' 0 CA--C 1.512 -0.487 0 C-N-CA 123.572 0.749 . . . . 10.0 109.102 -179.612 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.88 98.29 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 113.595 -1.638 . . . . 10.0 109.653 179.448 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 20.4 m-70 -72.74 148.02 45.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 125.898 1.679 . . . . 10.0 109.681 -172.99 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -62.03 -55.72 26.34 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 123.958 0.786 . . . . 10.0 112.077 -173.435 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -87.92 150.6 23.38 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 119.258 -0.977 . . . . 10.0 109.583 177.959 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.98 32.92 5.57 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.098 -1.201 . . . . 10.0 110.098 168.414 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -79.8 70.22 6.28 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 123.251 1.5 . . . . 10.0 108.683 179.153 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.456 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.5 OUTLIER -73.98 5.5 4.19 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.557 -1.201 . . . . 10.0 113.519 -174.014 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.516 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -32.79 -50.75 0.27 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 129.607 3.163 . . . . 10.0 112.703 175.144 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.97 -20.4 45.6 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 113.517 0.932 . . . . 10.0 113.517 -174.572 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.25 71.24 0.89 Allowed Glycine 0 CA--C 1.524 0.62 0 N-CA-C 106.987 -2.445 . . . . 10.0 106.987 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.8 t 49.33 24.01 0.95 Allowed 'General case' 0 CA--C 1.529 0.145 0 N-CA-C 115.844 1.794 . . . . 10.0 115.844 171.356 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.5 m -94.27 -52.48 4.34 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -178.388 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.2 m -66.86 -25.36 66.38 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 125.359 1.464 . . . . 10.0 112.732 -169.332 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.43 -38.27 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.542 2.737 . . . . 10.0 113.73 173.483 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 152.71 9.61 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 111.299 -0.72 . . . . 10.0 111.299 167.713 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.85 57.28 6.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.414 2.076 . . . . 10.0 110.571 172.784 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER 71.56 -64.8 0.37 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 128.014 2.526 . . . . 10.0 108.875 -179.557 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.285 1.1 p90 26.02 49.32 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 129.845 3.258 . . . . 10.0 115.096 175.16 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -51.66 157.2 1.96 Allowed Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 114.438 -1.256 . . . . 10.0 111.057 169.415 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.14 -40.82 24.61 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 121.943 1.762 . . . . 10.0 111.054 -173.735 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mp -77.03 59.63 1.7 Allowed 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.532 -0.914 . . . . 10.0 108.532 169.134 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.3 p -60.95 106.87 0.63 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 107.942 -1.133 . . . . 10.0 107.942 -177.418 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -129.93 -87.64 0.51 Allowed 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 107.34 -1.356 . . . . 10.0 107.34 -169.857 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.3 mmtp -139.05 153.69 48.11 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 122.313 1.054 . . . . 10.0 109.573 169.076 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -70.42 119.78 15.1 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 105.742 -1.948 . . . . 10.0 105.742 162.916 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.26 -135.88 2.91 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 107.104 -2.398 . . . . 10.0 107.104 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.26 -147.73 6.21 Favored Glycine 0 C--O 1.226 -0.403 0 CA-C-O 117.965 -1.464 . . . . 10.0 109.677 171.65 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -67.13 7.78 0.43 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 119.818 1.809 . . . . 10.0 111.105 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -113.37 3.4 15.86 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 118.225 -0.893 . . . . 10.0 111.563 170.944 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -122.42 149.67 43.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.604 -1.628 . . . . 10.0 106.604 170.94 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -83.05 -24.77 32.63 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.65 -0.871 . . . . 10.0 108.65 171.189 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -113.3 26.2 10.65 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 125.242 1.417 . . . . 10.0 111.068 -168.665 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -47.62 161.54 0.09 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 128.589 2.756 . . . . 10.0 110.078 168.371 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -78.69 46.85 0.69 Allowed 'General case' 0 N--CA 1.463 0.216 0 O-C-N 120.575 -1.328 . . . . 10.0 112.318 -178.106 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.2 p 33.16 35.94 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 126.861 2.064 . . . . 10.0 113.595 -174.278 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 165.98 37.69 0.02 OUTLIER Glycine 0 CA--C 1.532 1.113 0 O-C-N 121.538 -0.726 . . . . 10.0 111.961 -169.246 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -113.71 108.15 16.72 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -81.33 -29.48 34.16 Favored 'General case' 0 N--CA 1.461 0.121 0 N-CA-C 107.557 -1.275 . . . . 10.0 107.557 169.033 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.16 -96.64 1.31 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 108.424 -1.871 . . . . 10.0 108.424 168.928 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -134.92 117.98 16.41 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 125.6 1.56 . . . . 10.0 106.905 -169.497 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 22.4 m -111.61 132.26 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 CA-C-N 118.553 0.615 . . . . 10.0 111.296 179.428 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.8 m -78.46 107.88 11.43 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.771 2.429 . . . . 10.0 112.468 -170.472 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.51 137.26 32.48 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.869 0.467 . . . . 10.0 111.309 174.225 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -62.18 174.6 0.87 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 122.009 0.909 . . . . 10.0 110.328 166.927 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.5 pttt -51.74 -32.48 30.68 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.516 1.927 . . . . 10.0 112.709 169.191 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.44 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 22.8 t70 -79.17 -10.46 59.83 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 122.14 0.971 . . . . 10.0 110.658 178.107 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.89 3.7 65.72 Favored Glycine 0 N--CA 1.431 -1.634 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 -171.898 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 26.4 t -75.55 95.65 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.095 0 N-CA-C 106.327 -1.731 . . . . 10.0 106.327 -172.461 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.629 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -98.21 113.17 25.01 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 169.052 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -81.78 115.14 20.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 C-N-CA 127.199 2.2 . . . . 10.0 108.832 175.191 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.2 133.31 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 176.406 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 72.7 p -158.52 80.88 0.81 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.963 0.905 . . . . 10.0 109.799 170.642 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -112.26 143.1 22.68 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 177.628 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -99.73 127.37 45.86 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.393 1.477 . . . . 10.0 107.564 169.372 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -133.7 156.15 48.45 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.601 0.715 . . . . 10.0 109.083 176.721 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.5 t -128.1 49.58 2.15 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 126.022 1.729 . . . . 10.0 109.015 -173.41 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -157.79 -39.42 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 123.361 0.664 . . . . 10.0 110.63 176.837 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 45.6 mm -59.92 116.53 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 169.887 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 48.5 m -131.34 119.29 21.51 Favored 'General case' 0 CA--C 1.528 0.115 0 C-N-CA 124.251 1.02 . . . . 10.0 108.417 178.396 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 59.1 mt -53.97 -38.39 64.97 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 125.108 1.363 . . . . 10.0 111.166 173.491 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.2 m -152.17 151.89 31.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.475 -0.935 . . . . 10.0 108.475 -176.095 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.3 -97.17 0.19 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.295 -1.922 . . . . 10.0 108.295 -174.825 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -122.31 -51.1 1.99 Allowed 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 127.066 2.146 . . . . 10.0 107.935 177.523 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.8 m-70 -73.56 -35.7 65.52 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 114.959 -1.019 . . . . 10.0 108.258 -169.695 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.4 t 42.47 61.47 2.02 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 125.839 1.656 . . . . 10.0 112.951 167.289 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.7 pp -68.71 -9.14 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 113.697 0.999 . . . . 10.0 113.697 -171.633 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 10.5 mm -47.09 133.37 3.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.957 -0.757 . . . . 10.0 108.957 168.893 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.3 -7.49 75.52 Favored Glycine 0 CA--C 1.533 1.156 0 CA-C-O 118.851 -0.972 . . . . 10.0 114.51 -178.483 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.7 mtp-105 -76.26 175.33 9.15 Favored 'General case' 0 CA--C 1.544 0.74 0 CA-C-N 119.843 1.821 . . . . 10.0 106.858 168.992 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -127.78 132.23 49.53 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 119.091 0.86 . . . . 10.0 112.006 -170.586 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.407 HD22 ' N ' ' A' ' 117' ' ' LEU . 3.6 mm? -85.23 148.29 26.16 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 123.997 0.919 . . . . 10.0 108.533 171.863 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 91.9 t -133.32 128.4 55.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.636 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -95.58 123.99 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 106.164 -1.791 . . . . 10.0 106.164 166.943 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.628 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.5 m-70 -98.86 159.72 14.76 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.963 1.468 . . . . 10.0 114.963 -172.805 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -40.47 -58.21 1.62 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 128.415 2.686 . . . . 10.0 110.362 172.385 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -121.44 170.97 9.13 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 113.865 1.061 . . . . 10.0 113.865 -168.209 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.29 136.69 58.13 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 113.938 -1.483 . . . . 10.0 109.072 172.673 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -76.93 148.68 36.22 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.77 0.795 . . . . 10.0 110.634 -179.877 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -81.82 -41.61 20.84 Favored 'General case' 0 N--CA 1.447 -0.625 0 C-N-CA 130.977 3.711 . . . . 10.0 108.955 -176.746 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 16.8 mt 61.29 43.85 10.33 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.451 0.7 . . . . 10.0 112.172 -178.049 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.01 19.55 77.21 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 113.991 0.356 . . . . 10.0 113.991 169.585 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -86.83 -21.8 26.21 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.534 1.133 . . . . 10.0 110.884 172.471 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -56.43 -30.02 58.02 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.777 0.703 . . . . 10.0 111.805 178.578 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.67 30.19 71.75 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.351 -1.1 . . . . 10.0 110.351 -176.124 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.4 166.6 12.46 Favored 'General case' 0 CA--C 1.511 -0.538 0 N-CA-C 108.594 -0.891 . . . . 10.0 108.594 173.006 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -48.67 -54.56 14.3 Favored 'General case' 0 N--CA 1.431 -1.389 0 C-N-CA 124.511 1.125 . . . . 10.0 108.517 176.006 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -51.6 -47.3 63.66 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 124.131 0.973 . . . . 10.0 112.2 173.644 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.9 p -52.67 -37.67 59.15 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 118.991 -0.528 . . . . 10.0 109.94 -179.223 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.251 14.8 t -90.67 0.57 57.35 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 113.807 1.04 . . . . 10.0 113.807 -179.26 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.99 -53.37 2.71 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.77 1.628 . . . . 10.0 112.596 -179.354 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.3 p -129.41 5.4 5.2 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 119.807 1.185 . . . . 10.0 111.862 171.342 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 81.52 -118.54 4.65 Favored Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 103.264 -3.934 . . . . 10.0 103.264 -167.181 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -168.81 39.14 0.03 OUTLIER 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 126.247 1.819 . . . . 10.0 107.789 -178.401 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.67 0.11 13.85 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.585 1.154 . . . . 10.0 111.792 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.15 -163.59 50.73 Favored Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 110.437 -1.065 . . . . 10.0 110.437 171.261 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.34 140.38 45.45 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.835 0.854 . . . . 10.0 111.798 -168.717 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -65.36 72.82 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.567 1.147 . . . . 10.0 110.068 169.709 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 6.0 tp -44.67 -45.53 9.75 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.991 1.716 . . . . 10.0 112.121 -175.685 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 145.93 20.19 Favored 'General case' 0 C--O 1.234 0.281 0 N-CA-C 108.199 -1.038 . . . . 10.0 108.199 -175.938 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 m -139.6 152.64 46.98 Favored 'General case' 0 CA--C 1.518 -0.259 0 C-N-CA 123.12 0.568 . . . . 10.0 109.974 -169.125 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -149.81 145.42 13.54 Favored Glycine 0 C--N 1.338 0.652 0 N-CA-C 110.536 -1.026 . . . . 10.0 110.536 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 23.8 t -102.07 138.04 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 106.335 -1.728 . . . . 10.0 106.335 -175.319 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 48.5 mt -76.04 107.74 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 N-CA-C 109.917 -0.401 . . . . 10.0 109.917 -173.457 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.8 164.52 12.04 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.574 1.559 . . . . 10.0 111.635 178.465 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.4 mt -64.37 143.67 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 C-N-CA 124.93 1.292 . . . . 10.0 111.495 -177.908 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -136.72 162.27 33.65 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.404 -1.332 . . . . 10.0 107.404 167.542 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 . . . . . 0 C--O 1.251 1.162 0 N-CA-C 104.256 -2.498 . . . . 10.0 104.256 166.884 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.49 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -105.54 -27.77 11.19 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 126.041 1.737 . . . . 10.0 111.743 170.009 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.8 tttt -131.05 137.06 48.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.846 0.859 . . . . 10.0 109.354 179.421 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.93 161.0 30.9 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 123.375 0.67 . . . . 10.0 110.083 170.792 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.6 t -120.45 154.66 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 C-N-CA 126.354 1.861 . . . . 10.0 108.874 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.46 108.57 4.77 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 167.86 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 53' ' ' ASN . 3.7 m -98.72 121.74 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 109.303 -0.629 . . . . 10.0 109.303 177.909 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.76 133.58 43.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.611 -0.709 . . . . 10.0 109.89 -175.266 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.3 mtpt -144.41 156.89 44.42 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 119.368 0.985 . . . . 10.0 109.153 167.447 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.47 -59.59 0.06 OUTLIER Glycine 0 N--CA 1.461 0.312 0 C-N-CA 119.696 -1.24 . . . . 10.0 113.861 169.776 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -71.12 -42.85 68.69 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -174.882 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.5 -70.05 0.41 Allowed Glycine 0 CA--C 1.523 0.532 0 CA-C-N 114.157 -1.383 . . . . 10.0 110.35 169.207 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.83 -36.82 99.0 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 123.338 2.692 . . . . 10.0 111.357 172.393 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.7 91.16 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 125.804 1.641 . . . . 10.0 107.802 177.098 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -117.82 112.39 20.33 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.205 1.402 . . . . 10.0 107.934 176.933 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.434 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -108.48 148.95 16.86 Favored Glycine 0 N--CA 1.432 -1.592 0 CA-C-N 114.137 -1.392 . . . . 10.0 111.328 -178.338 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.516 HG22 HG22 ' A' ' 54' ' ' THR . 1.2 mt -151.42 84.11 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.332 1.853 . . . . 10.0 107.107 -169.907 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.0 mm -97.01 149.89 4.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 C-N-CA 124.914 1.286 . . . . 10.0 110.566 179.708 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.18 111.66 11.62 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 128.901 2.88 . . . . 10.0 108.382 -178.031 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -98.29 111.02 23.5 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 117.435 -1.269 . . . . 10.0 107.845 172.948 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -108.77 108.55 19.41 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.365 0.984 . . . . 10.0 112.271 174.073 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -103.87 96.21 6.53 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.588 1.955 . . . . 10.0 107.153 174.442 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 65.6 mttt . . . . . 0 CA--C 1.518 -0.273 0 C-N-CA 123.946 0.898 . . . . 10.0 110.637 -169.052 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.022 0 N-CA-C 110.024 -1.231 . . . . 10.0 110.024 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.8 127.79 18.58 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 N-CA-C 107.045 -1.944 . . . . 10.0 107.045 169.832 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.5 p -76.46 85.81 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-O 122.432 1.11 . . . . 10.0 108.349 -174.36 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 mtpt -58.82 111.31 1.24 Allowed 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 169.607 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 p -102.07 101.87 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.754 0 C-N-CA 126.219 1.807 . . . . 10.0 106.395 -177.64 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -116.18 174.4 6.07 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 116.319 -0.401 . . . . 10.0 111.385 176.531 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.03 -156.01 26.72 Favored Glycine 0 C--N 1.331 0.264 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 169.294 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.2 p -149.71 146.56 27.29 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.451 0.644 . . . . 10.0 112.595 -172.373 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.616 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -120.95 115.41 46.75 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.329 0 C-N-CA 125.909 1.684 . . . . 10.0 108.693 169.774 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -102.49 143.1 32.63 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 169.746 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.72 9.35 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 124.562 1.077 . . . . 10.0 112.969 170.332 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 mt -87.77 -175.67 5.24 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.961 0.886 . . . . 10.0 110.571 -171.274 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -102.72 155.78 18.08 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 167.516 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -53.54 159.09 1.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.589 1.156 . . . . 10.0 111.793 -174.878 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.71 -177.15 35.59 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.717 0.675 . . . . 10.0 111.803 170.608 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -66.56 149.82 49.9 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 125.46 1.504 . . . . 10.0 112.373 -177.861 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.6 m-70 -146.8 142.28 27.56 Favored 'General case' 0 C--N 1.344 0.352 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -177.467 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.683 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -30.99 125.62 0.17 Allowed Glycine 0 C--N 1.343 0.943 0 C-N-CA 127.74 2.59 . . . . 10.0 113.03 165.679 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.67 105.12 2.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 119.343 1.572 . . . . 10.0 113.002 168.577 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.13 172.74 15.31 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.156 0.503 . . . . 10.0 111.501 179.64 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.0 m -93.99 149.93 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 113.156 -1.838 . . . . 10.0 108.408 169.299 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 24.2 m-70 -130.94 140.31 50.16 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.719 1.608 . . . . 10.0 106.888 174.795 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -52.76 -54.86 27.92 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 125.27 1.428 . . . . 10.0 112.327 -169.721 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -77.62 114.59 16.61 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -61.05 -32.16 79.29 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.261 -1.136 . . . . 10.0 110.261 172.257 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.636 ' HA ' HG11 ' A' ' 5' ' ' VAL . 25.3 t0 -32.16 125.35 0.29 Allowed 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 125.296 1.439 . . . . 10.0 112.548 172.282 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -129.69 11.36 5.7 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 113.967 -1.47 . . . . 10.0 111.401 176.628 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.428 HG22 ' CG2' ' A' ' 17' ' ' ILE . 8.2 p -37.17 -63.27 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 125.972 1.709 . . . . 10.0 113.309 -175.477 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -74.67 -16.03 60.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.444 -1.253 . . . . 10.0 111.89 -174.458 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 136.11 -75.57 0.4 Allowed Glycine 0 CA--C 1.521 0.464 0 N-CA-C 109.004 -1.638 . . . . 10.0 109.004 177.941 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 9.3 t -157.0 18.65 0.3 Allowed 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 112.734 0.642 . . . . 10.0 112.734 -172.921 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.0 p -99.07 -57.43 2.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 105.718 -1.956 . . . . 10.0 105.718 -176.527 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -55.64 -25.77 40.84 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.424 1.89 . . . . 10.0 111.81 -179.409 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.14 -29.64 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 127.953 2.501 . . . . 10.0 114.226 168.349 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.61 154.96 28.28 Favored Glycine 0 C--N 1.34 0.752 0 N-CA-C 109.359 -1.496 . . . . 10.0 109.359 170.031 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -74.12 -170.84 0.77 Allowed 'Trans proline' 0 N--CA 1.446 -1.315 0 N-CA-C 107.787 -1.659 . . . . 10.0 107.787 168.778 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -80.95 60.67 4.25 Favored 'General case' 0 CA--C 1.537 0.444 0 O-C-N 120.658 -1.276 . . . . 10.0 109.827 -177.079 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -73.67 72.71 1.48 Allowed 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 122.117 0.96 . . . . 10.0 109.698 174.408 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -73.16 135.06 79.99 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.636 -0.665 . . . . 10.0 110.042 173.271 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.18 -44.56 4.82 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 122.57 2.18 . . . . 10.0 110.867 -177.426 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.8 mt -72.63 67.85 0.8 Allowed 'General case' 0 C--O 1.225 -0.234 0 C-N-CA 123.481 0.712 . . . . 10.0 109.312 175.067 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 40.5 p -37.03 108.67 0.08 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 125.853 1.661 . . . . 10.0 111.054 -179.187 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.83 173.03 12.05 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 103.086 -2.931 . . . . 10.0 103.086 -170.568 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.418 ' NZ ' ' OE2' ' B' ' 78' ' ' GLU . 6.7 mptt -80.06 152.44 29.37 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 117.341 -1.743 . . . . 10.0 107.99 170.338 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.432 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 79.1 t60 -63.27 103.2 0.47 Allowed 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.398 -0.964 . . . . 10.0 108.398 165.596 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.37 -127.34 4.05 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.156 -1.977 . . . . 10.0 108.156 177.718 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.7 -163.83 32.47 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 108.377 -1.889 . . . . 10.0 108.377 173.346 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -63.29 -5.5 8.27 Favored 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 119.832 1.816 . . . . 10.0 110.793 167.499 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -87.53 -26.09 23.33 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 125.407 1.483 . . . . 10.0 110.076 175.131 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -98.94 158.36 15.7 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 106.798 -1.556 . . . . 10.0 106.798 179.299 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -79.0 -32.38 45.14 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 107.421 -1.326 . . . . 10.0 107.421 168.541 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 78' ' ' GLU . . . . . 0.418 ' OE2' ' NZ ' ' B' ' 70' ' ' LYS . 1.4 pt-20 -114.5 51.36 0.89 Allowed 'General case' 0 N--CA 1.447 -0.604 0 C-N-CA 124.26 1.024 . . . . 10.0 111.018 -168.684 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -61.43 164.53 5.58 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.589 1.556 . . . . 10.0 110.689 169.159 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.432 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 9.9 m170 -66.59 -63.09 1.14 Allowed 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.418 0.525 . . . . 10.0 112.418 -170.022 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 8.2 p -171.65 -47.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.19 0.996 . . . . 10.0 109.818 -178.092 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.59 72.28 0.37 Allowed Glycine 0 C--N 1.336 0.572 0 N-CA-C 107.149 -2.38 . . . . 10.0 107.149 176.967 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.05 98.11 5.83 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.497 -2.038 . . . . 10.0 105.497 -173.358 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 40.5 mt -80.72 5.92 14.35 Favored 'General case' 0 N--CA 1.463 0.177 0 C-N-CA 122.678 0.391 . . . . 10.0 111.774 -169.844 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 82.65 -106.36 2.73 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 107.475 -2.25 . . . . 10.0 107.475 -174.582 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -158.65 152.53 23.54 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.125 0.97 . . . . 10.0 110.248 -177.146 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -122.74 133.99 67.23 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 123.275 0.63 . . . . 10.0 110.174 -176.402 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -78.57 133.23 37.35 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 126.546 1.938 . . . . 10.0 109.266 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.29 132.56 50.41 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.548 1.939 . . . . 10.0 110.155 169.726 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -63.6 171.22 2.72 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.993 1.717 . . . . 10.0 111.145 168.733 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 91' ' ' LYS . . . . . 0.417 ' NZ ' ' OD1' ' B' ' 92' ' ' ASP . 17.9 pttp -49.07 -35.03 14.95 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 124.565 1.146 . . . . 10.0 110.647 169.535 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 92' ' ' ASP . . . . . 0.417 ' OD1' ' NZ ' ' B' ' 91' ' ' LYS . 0.1 OUTLIER -77.9 -3.15 40.28 Favored 'General case' 0 C--N 1.342 0.249 0 O-C-N 122.326 -0.234 . . . . 10.0 110.535 -175.919 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.68 22.88 78.75 Favored Glycine 0 N--CA 1.444 -0.797 0 N-CA-C 109.469 -1.452 . . . . 10.0 109.469 -175.289 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.0 t -96.21 106.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.86 0 C-N-CA 127.57 2.348 . . . . 10.0 105.093 173.438 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.616 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.44 125.05 48.03 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.287 -1.005 . . . . 10.0 108.287 169.341 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -94.68 121.33 36.15 Favored 'General case' 0 N--CA 1.435 -1.179 0 C-N-CA 127.838 2.455 . . . . 10.0 108.832 179.308 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 43.3 t -101.26 135.81 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 124.767 1.227 . . . . 10.0 108.147 177.326 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.26 72.43 0.62 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.945 1.298 . . . . 10.0 109.408 169.689 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -106.38 162.46 5.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 107.565 -1.272 . . . . 10.0 107.565 -179.036 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -146.13 136.46 23.87 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.584 1.554 . . . . 10.0 109.568 175.69 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -134.02 142.34 47.58 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.091 -1.818 . . . . 10.0 106.091 173.759 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 75.2 p -103.5 51.48 0.79 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.868 1.267 . . . . 10.0 107.811 174.228 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.32 -47.91 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.323 0.649 . . . . 10.0 110.377 -176.97 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.47 118.26 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 171.431 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.1 m -120.62 112.67 19.19 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 108.562 -0.903 . . . . 10.0 108.562 -176.658 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 77.4 mt -56.81 -43.97 81.51 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.457 0.646 . . . . 10.0 110.41 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.452 -0.345 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 -174.358 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t . . . . . 0 N--CA 1.45 -0.43 0 CA-C-O 122.957 1.36 . . . . 10.0 108.112 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 31.0 mm -73.57 -14.06 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 CA-C-N 113.543 -1.662 . . . . 10.0 112.228 -168.973 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.5 mm -51.48 147.32 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 N-CA-C 109.363 -0.606 . . . . 10.0 109.363 169.696 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.81 2.44 90.54 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 121.357 -0.84 . . . . 10.0 114.592 178.815 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 54.4 mmt-85 -77.58 163.31 26.37 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 118.914 1.357 . . . . 10.0 108.716 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.1 118.17 35.24 Favored 'General case' 0 C--N 1.34 0.153 0 N-CA-C 109.287 -0.634 . . . . 10.0 109.287 170.51 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.426 HD21 HD11 ' B' ' 149' ' ' ILE . 4.5 mm? -75.49 142.99 42.79 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.048 -1.464 . . . . 10.0 107.048 167.184 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.64 129.36 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.831 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.04 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.42 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.7 p -97.35 135.3 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.715 0 N-CA-C 107.96 -1.126 . . . . 10.0 107.96 169.275 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.683 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.8 m170 -115.02 159.72 20.46 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 116.465 2.024 . . . . 10.0 116.465 -175.891 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -48.92 -58.38 4.95 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 129.832 3.253 . . . . 10.0 111.932 177.071 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 54.8 mttp -111.93 173.46 6.35 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.966 0.906 . . . . 10.0 112.804 -169.874 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.05 136.04 35.26 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 126.524 1.929 . . . . 10.0 110.304 -179.165 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.69 144.22 32.42 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 113.362 0.875 . . . . 10.0 113.362 -169.558 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -74.9 -38.56 61.82 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.187 1.395 . . . . 10.0 109.206 177.855 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.8 mt 62.12 49.92 4.23 Favored 'General case' 0 C--N 1.337 0.054 0 C-N-CA 125.21 1.404 . . . . 10.0 110.006 -172.259 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 82.82 -45.58 3.45 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.562 1.077 . . . . 10.0 110.988 170.638 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.5 pttp -73.43 21.63 0.08 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.83 1.652 . . . . 10.0 112.72 -175.147 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -77.91 -32.71 43.99 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 126.475 1.988 . . . . 10.0 108.298 166.103 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.22 19.08 69.97 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.284 -0.731 . . . . 10.0 111.859 -179.124 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -112.07 162.27 15.59 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 104.839 -2.282 . . . . 10.0 104.839 169.215 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 132' ' ' GLU . . . . . 0.454 ' CD ' ' HZ1' ' B' ' 136' ' ' LYS . 15.6 tm-20 -60.92 -40.04 91.7 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 119.505 -0.878 . . . . 10.0 110.748 -169.849 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -69.12 -28.28 66.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 118.749 -0.643 . . . . 10.0 112.242 177.529 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -48.76 -47.47 41.64 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 119.68 1.127 . . . . 10.0 110.242 168.852 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.4 t -85.1 -10.15 57.15 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 118.461 -0.781 . . . . 10.0 112.711 -171.366 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.454 ' HZ1' ' CD ' ' B' ' 132' ' ' GLU . 1.1 ttmp? -100.61 -92.34 0.3 Allowed 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.69 1.596 . . . . 10.0 108.15 175.292 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 44.5 p -86.26 1.35 51.23 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 122.135 2.243 . . . . 10.0 112.744 -176.062 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.58 21.89 73.88 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 120.416 1.462 . . . . 10.0 110.79 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 61.72 19.92 10.93 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 119.577 1.688 . . . . 10.0 112.854 169.649 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -80.29 9.96 5.12 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 113.623 0.972 . . . . 10.0 113.623 -168.021 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.72 -165.07 53.94 Favored Glycine 0 N--CA 1.444 -0.781 0 O-C-N 121.252 -0.905 . . . . 10.0 111.502 170.954 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.5 m -59.3 135.63 57.71 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 124.1 0.96 . . . . 10.0 112.901 -167.705 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -67.23 86.99 0.16 Allowed 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 125.129 1.372 . . . . 10.0 110.276 174.042 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 58.5 mt -60.85 -35.12 75.76 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.827 0.676 . . . . 10.0 112.827 -177.19 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.42 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -158.39 154.35 26.81 Favored 'General case' 0 C--O 1.234 0.244 0 O-C-N 121.625 -0.672 . . . . 10.0 111.495 179.932 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -123.55 152.36 41.9 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 125.857 1.663 . . . . 10.0 109.088 -178.674 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.57 156.04 26.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.413 -1.075 . . . . 10.0 110.413 168.806 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 66.1 t -109.58 140.07 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 -175.588 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.426 HD11 HD21 ' B' ' 117' ' ' LEU . 27.6 mt -75.62 125.15 34.92 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-O 118.594 -0.717 . . . . 10.0 109.764 -178.622 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.81 162.76 24.48 Favored Glycine 0 CA--C 1.53 1.022 0 C-N-CA 124.383 0.992 . . . . 10.0 113.569 -178.573 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.8 mm -73.34 144.91 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.274 1.03 . . . . 10.0 111.226 -169.904 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.96 -47.2 2.18 Favored 'General case' 0 CA--C 1.51 -0.592 0 CA-C-N 118.45 0.568 . . . . 10.0 111.433 166.652 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 116.38 -1.771 . . . . 10.0 107.544 175.78 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.659 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.7 t -151.55 -48.44 0.11 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 119.12 0.873 . . . . 10.0 110.7 178.686 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 40.8 tttt -132.87 153.64 51.14 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.2 -1.778 . . . . 10.0 106.2 172.59 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.22 151.18 43.55 Favored 'General case' 0 CA--C 1.513 -0.46 0 N-CA-C 108.93 -0.767 . . . . 10.0 108.93 169.286 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.38 161.12 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 O-C-N 124.061 0.851 . . . . 10.0 110.223 172.464 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.432 ' CB ' HD12 ' A' ' 117' ' ' LEU . . . -147.41 98.96 3.07 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.206 -1.775 . . . . 10.0 106.206 165.703 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.481 HG21 ' HB3' ' B' ' 53' ' ' ASN . 7.5 m -93.29 98.02 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 122.844 0.458 . . . . 10.0 110.687 -179.204 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.415 HD12 ' N ' ' A' ' 8' ' ' LEU . 5.5 mp -79.6 136.26 36.8 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 121.227 -0.921 . . . . 10.0 109.833 -175.756 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -144.73 156.15 43.92 Favored 'General case' 0 C--N 1.341 0.212 0 C-N-CA 124.426 1.09 . . . . 10.0 108.344 168.346 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.6 -69.08 0.02 OUTLIER Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.185 -0.531 . . . . 10.0 112.166 169.252 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -74.24 -41.51 61.2 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 107.179 -1.415 . . . . 10.0 107.179 -175.656 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.91 -67.67 0.48 Allowed Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 114.996 -1.002 . . . . 10.0 111.588 176.969 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -55.15 -42.05 72.58 Favored 'Trans proline' 0 N--CA 1.45 -1.077 0 C-N-CA 121.972 1.782 . . . . 10.0 110.077 175.846 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.668 HG13 HD12 ' A' ' 38' ' ' LEU . 47.9 t -58.49 87.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 C-N-CA 126.182 1.793 . . . . 10.0 108.034 175.197 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.47 116.95 31.75 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.709 -1.96 . . . . 10.0 105.709 171.453 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.91 142.89 15.97 Favored Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 108.656 -1.778 . . . . 10.0 108.656 174.258 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.972 ' CG2' HG22 ' B' ' 54' ' ' THR . 7.1 mt -138.71 60.81 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 N-CA-C 107.357 -1.349 . . . . 10.0 107.357 -169.684 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.4 mm -77.87 133.56 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 N-CA-C 108.801 -0.814 . . . . 10.0 108.801 -176.072 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m-80 -122.44 105.11 9.87 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.203 2.201 . . . . 10.0 107.22 -176.805 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -89.1 136.44 33.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.499 1.12 . . . . 10.0 108.025 177.749 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -117.49 148.29 41.97 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 123.703 0.627 . . . . 10.0 110.701 168.191 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -122.46 107.14 11.69 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.7 1.6 . . . . 10.0 108.01 168.816 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -65.91 -59.2 4.08 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.974 0.91 . . . . 10.0 110.644 -178.492 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.1 mp0 -128.22 168.02 16.04 Favored 'General case' 0 N--CA 1.425 -1.725 0 N-CA-C 103.608 -2.738 . . . . 10.0 103.608 174.079 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.2 p -65.98 -25.74 67.24 Favored 'General case' 0 N--CA 1.44 -0.937 0 O-C-N 121.748 -0.595 . . . . 10.0 109.429 174.759 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -98.69 -6.33 29.85 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.207 1.403 . . . . 10.0 110.828 -173.361 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.63 144.57 21.4 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 -173.772 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -64.02 139.42 67.29 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 121.721 1.614 . . . . 10.0 108.101 170.525 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 m -93.12 142.51 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -176.861 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -108.06 123.21 48.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.298 -2.482 . . . . 10.0 104.298 166.606 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 m -108.99 103.45 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 105.916 -1.883 . . . . 10.0 105.916 -179.371 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 8.0 p90 -114.44 171.82 7.39 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 -176.298 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.65 -154.4 25.53 Favored Glycine 0 N--CA 1.447 -0.618 0 N-CA-C 108.537 -1.825 . . . . 10.0 108.537 169.076 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 m -153.54 150.24 28.5 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 117.124 0.462 . . . . 10.0 110.899 177.896 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.61 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -111.17 112.65 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 C-N-CA 127.356 2.263 . . . . 10.0 106.861 168.493 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.5 ptmt -121.73 90.3 3.28 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 112.214 0.45 . . . . 10.0 112.214 -178.276 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.65 32.35 0.02 OUTLIER Glycine 0 CA--C 1.52 0.406 0 CA-C-O 118.981 -0.9 . . . . 10.0 113.996 174.032 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.668 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -125.06 175.41 7.37 Favored 'General case' 0 C--O 1.224 -0.246 0 N-CA-C 108.237 -1.023 . . . . 10.0 108.237 177.144 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -75.6 168.54 19.81 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 118.83 0.741 . . . . 10.0 110.844 177.712 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 65.1 tt0 -61.02 173.3 0.81 Allowed 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.21 1.804 . . . . 10.0 111.288 -176.874 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.14 179.73 49.73 Favored Glycine 0 CA--C 1.522 0.52 0 C-N-CA 123.781 0.705 . . . . 10.0 112.017 168.897 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.0 mp -66.02 143.56 57.28 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.376 1.07 . . . . 10.0 110.275 178.449 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -140.39 146.5 38.45 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 113.384 0.883 . . . . 10.0 113.384 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.661 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -29.25 122.72 0.09 OUTLIER Glycine 0 C--N 1.341 0.851 0 C-N-CA 127.547 2.499 . . . . 10.0 112.269 165.25 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -150.62 106.01 3.37 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 120.034 1.917 . . . . 10.0 113.12 169.758 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.419 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.43 175.18 12.99 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.509 0.671 . . . . 10.0 112.803 -176.497 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.402 HG12 ' CD2' ' A' ' 117' ' ' LEU . 1.7 m -91.42 153.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 112.655 -2.066 . . . . 10.0 106.3 166.499 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.32 123.27 35.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 102.884 -3.006 . . . . 10.0 102.884 169.113 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -61.33 -35.03 76.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 114.894 1.442 . . . . 10.0 114.894 -164.571 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-30 -75.91 119.54 20.02 Favored 'General case' 0 C--N 1.342 0.251 0 C-N-CA 117.285 -1.766 . . . . 10.0 106.984 169.576 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.01 37.08 0.92 Allowed Glycine 0 CA--C 1.525 0.676 0 C-N-CA 125.041 1.305 . . . . 10.0 111.241 168.883 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -107.55 171.56 7.32 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 124.899 1.279 . . . . 10.0 107.697 177.459 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.439 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -161.1 25.65 0.14 Allowed 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 114.653 -1.158 . . . . 10.0 112.231 168.747 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.442 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.2 OUTLIER -55.39 -36.96 66.97 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.451 1.1 . . . . 10.0 111.253 -170.481 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.38 -19.6 55.95 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 124.022 0.929 . . . . 10.0 112.468 -179.695 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 87.04 97.87 0.85 Allowed Glycine 0 CA--C 1.528 0.866 0 N-CA-C 109.02 -1.632 . . . . 10.0 109.02 -169.698 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 59.2 m 43.11 55.17 4.67 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.032 1.733 . . . . 10.0 113.962 173.074 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.76 -49.62 0.08 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.078 0.551 . . . . 10.0 110.139 176.034 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 47.4 t -60.8 -28.89 69.12 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 122.44 0.296 . . . . 10.0 111.059 -173.314 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.42 -28.97 0.07 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 127.448 2.299 . . . . 10.0 115.156 179.758 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 134.26 8.41 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-O 118.449 -1.195 . . . . 10.0 110.528 170.994 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -78.46 62.24 8.14 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 123.211 2.607 . . . . 10.0 112.319 -174.315 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 61.74 28.02 17.21 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.511 2.324 . . . . 10.0 110.581 177.372 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -53.72 -39.05 64.91 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 113.871 1.064 . . . . 10.0 113.871 -166.67 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 34.27 172.23 0.0 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 128.807 2.843 . . . . 10.0 115.518 -169.662 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -67.81 -65.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.349 0.573 0 O-C-N 118.621 -1.305 . . . . 10.0 110.849 -172.781 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.0 74.52 2.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 169.006 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 p -47.89 113.76 0.78 Allowed 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.048 0.939 . . . . 10.0 108.946 169.487 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 40.6 mtt180 -133.13 -167.06 1.85 Allowed 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 105.783 -1.932 . . . . 10.0 105.783 -178.465 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.81 137.54 33.66 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 118.046 -1.462 . . . . 10.0 110.304 -171.022 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 65.8 t60 -47.15 119.66 2.71 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 120.337 -0.545 . . . . 10.0 110.517 168.218 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.61 -143.76 4.22 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 108.636 -1.786 . . . . 10.0 108.636 177.583 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.61 -149.94 6.86 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-O 118.158 -1.357 . . . . 10.0 109.981 175.431 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 79.7 Cg_endo -69.27 14.68 0.22 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 122.162 1.908 . . . . 10.0 111.415 169.287 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.0 mtpm? -110.08 -10.78 14.67 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 124.616 1.166 . . . . 10.0 110.075 169.592 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -111.41 158.55 18.96 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.369 -1.345 . . . . 10.0 107.369 -179.176 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -79.41 -36.86 38.42 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.653 -1.24 . . . . 10.0 107.653 173.033 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -96.8 -49.7 4.96 Favored 'General case' 0 CA--C 1.498 -1.024 0 CA-C-O 121.453 0.644 . . . . 10.0 112.137 -166.3 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 7.1 ptp180 41.52 -141.4 0.09 Allowed 'General case' 0 N--CA 1.434 -1.253 0 CA-C-N 113.709 -1.587 . . . . 10.0 109.108 -169.478 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -112.12 44.56 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 O-C-N 120.611 -1.306 . . . . 10.0 108.073 166.511 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.9 t 37.8 38.96 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 124.081 0.953 . . . . 10.0 111.04 -167.596 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 70.69 0.02 OUTLIER Glycine 0 CA--C 1.533 1.195 0 O-C-N 121.541 -0.724 . . . . 10.0 112.431 -174.002 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -136.94 111.15 8.39 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 104.008 -2.59 . . . . 10.0 104.008 168.181 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 19.3 mt -72.19 -23.18 61.22 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 118.667 0.667 . . . . 10.0 109.225 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.11 -89.8 0.55 Allowed Glycine 0 N--CA 1.441 -1.025 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 167.042 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 m-20 -147.8 126.44 12.53 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -173.794 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.7 m -109.82 124.87 66.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 118.043 0.383 . . . . 10.0 110.097 176.293 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.1 m -79.51 111.39 15.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 127.245 2.218 . . . . 10.0 111.228 -176.825 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.56 129.75 34.75 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 123.176 0.59 . . . . 10.0 109.985 170.813 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -61.29 166.69 3.66 Favored 'General case' 0 N--CA 1.454 -0.272 0 O-C-N 124.574 1.171 . . . . 10.0 109.119 167.756 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.64 -26.0 54.92 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 123.91 0.884 . . . . 10.0 111.446 175.882 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -75.76 -10.62 59.59 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 120.583 0.23 . . . . 10.0 110.675 179.525 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.04 23.15 42.3 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.403 -1.079 . . . . 10.0 110.403 178.664 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.1 t -106.99 105.57 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.986 0 C-N-CA 128.359 2.664 . . . . 10.0 105.95 -178.931 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.61 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -102.83 121.46 42.52 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.668 -1.234 . . . . 10.0 107.668 168.635 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -92.32 132.63 36.56 Favored 'General case' 0 N--CA 1.434 -1.261 0 C-N-CA 127.188 2.195 . . . . 10.0 108.899 176.36 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -113.08 133.12 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.979 0 C-N-CA 125.298 1.439 . . . . 10.0 107.676 175.14 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.5 p -158.35 57.82 0.45 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.278 0.631 . . . . 10.0 110.688 169.651 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.79 155.15 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.101 0 N-CA-C 107.999 -1.112 . . . . 10.0 107.999 -173.986 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -122.2 156.41 33.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 124.746 1.218 . . . . 10.0 111.904 173.809 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -148.97 164.19 35.3 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.057 -1.428 . . . . 10.0 108.989 168.721 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.7 p -118.8 44.01 2.4 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 126.227 1.811 . . . . 10.0 110.364 -178.012 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.2 p -145.19 -43.46 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 118.255 0.48 . . . . 10.0 111.251 177.013 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.39 147.31 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.318 -1.364 . . . . 10.0 107.318 169.176 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.1 m -151.57 135.44 16.45 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.128 -1.064 . . . . 10.0 108.128 174.385 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -70.04 -38.16 75.77 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.832 0.853 . . . . 10.0 108.919 -179.593 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 22.6 m -137.75 130.22 29.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.74 -1.578 . . . . 10.0 106.74 170.335 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.91 -65.66 0.1 OUTLIER Glycine 0 C--N 1.333 0.369 0 N-CA-C 109.258 -1.537 . . . . 10.0 109.258 -177.941 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -163.06 -51.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.773 1.629 . . . . 10.0 107.703 -179.835 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -74.1 -41.59 61.4 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 114.38 -1.282 . . . . 10.0 108.091 -169.64 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.9 t 41.11 74.25 0.11 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 126.477 1.911 . . . . 10.0 111.702 174.858 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -68.22 -3.64 2.64 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 N-CA-C 112.932 0.716 . . . . 10.0 112.932 -179.682 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.1 mm -33.02 -44.34 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 126.453 1.901 . . . . 10.0 114.042 173.421 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.89 38.81 3.14 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 124.185 0.898 . . . . 10.0 112.515 -176.748 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -102.78 176.69 5.08 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.475 1.51 . . . . 10.0 111.643 170.046 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 4.7 m -119.1 131.22 55.9 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.952 2.101 . . . . 10.0 106.36 177.85 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.432 HD12 ' CB ' ' A' ' 6' ' ' ALA . 58.7 mt -103.9 148.35 26.26 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 125.28 1.432 . . . . 10.0 109.324 172.285 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.2 t -136.36 134.36 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 O-C-N 123.71 0.631 . . . . 10.0 109.364 -178.593 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.39 135.63 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 168.648 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.661 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.3 m170 -112.26 155.64 23.7 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 116.673 2.101 . . . . 10.0 116.673 -178.565 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -42.24 -62.93 0.83 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.779 3.231 . . . . 10.0 111.548 173.314 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 8.1 mtmt -106.89 172.41 6.84 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.993 1.317 . . . . 10.0 111.823 -177.298 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.4 150.96 39.76 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.994 -1.457 . . . . 10.0 109.605 172.459 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.419 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.3 m-20 -79.46 150.23 31.32 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.565 1.146 . . . . 10.0 112.495 177.317 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -74.36 -29.56 61.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.973 -1.467 . . . . 10.0 110.122 169.943 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 27.4 mt 54.97 44.27 28.53 Favored 'General case' 0 C--N 1.339 0.129 0 CA-C-O 121.847 0.832 . . . . 10.0 108.799 -167.963 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.38 -10.17 67.71 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 125.667 1.603 . . . . 10.0 113.151 173.204 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -78.33 -3.93 45.5 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 118.405 1.102 . . . . 10.0 113.117 -170.795 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.2 -38.62 95.94 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.813 -0.915 . . . . 10.0 110.813 175.152 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.43 33.45 81.88 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.114 -1.194 . . . . 10.0 110.114 -173.387 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -117.59 161.96 18.79 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 106.05 -1.833 . . . . 10.0 106.05 169.69 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -51.36 -48.87 62.36 Favored 'General case' 0 N--CA 1.428 -1.525 0 N-CA-C 108.721 -0.844 . . . . 10.0 108.721 170.773 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -59.04 -40.1 84.04 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.318 -0.401 . . . . 10.0 111.31 176.96 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 16.6 p -55.75 -40.15 72.16 Favored 'General case' 0 N--CA 1.443 -0.794 0 O-C-N 120.926 -1.109 . . . . 10.0 110.708 179.287 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -84.64 4.93 30.11 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 118.491 -0.766 . . . . 10.0 112.122 -178.265 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -112.83 -85.44 0.58 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.037 1.735 . . . . 10.0 110.091 175.022 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.4 p -111.43 30.87 6.56 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 121.088 1.767 . . . . 10.0 112.52 178.179 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.83 27.52 56.18 Favored Glycine 0 C--N 1.341 0.858 0 C-N-CA 123.757 0.694 . . . . 10.0 113.9 168.333 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 46.8 29.62 1.03 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.055 0.942 . . . . 10.0 113.01 -172.108 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.35 -4.57 18.77 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.228 -0.92 . . . . 10.0 112.24 -177.424 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.67 -161.92 50.17 Favored Glycine 0 N--CA 1.444 -0.812 0 O-C-N 121.129 -0.982 . . . . 10.0 111.315 169.212 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.1 m -55.12 128.39 33.57 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 114.644 -0.778 . . . . 10.0 112.842 -167.274 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 22.5 mtt85 -66.43 73.03 0.08 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.738 1.615 . . . . 10.0 109.758 172.078 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 35.1 mt -49.3 -36.82 21.94 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.595 1.158 . . . . 10.0 112.976 -175.722 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 152.1 24.72 Favored 'General case' 0 CA--C 1.513 -0.461 0 O-C-N 121.57 -0.706 . . . . 10.0 110.526 -177.877 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.0 m -130.87 145.66 52.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 124.821 1.326 . . . . 10.0 108.679 -175.661 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -135.48 141.28 12.46 Favored Glycine 0 C--N 1.332 0.314 0 N-CA-C 108.621 -1.792 . . . . 10.0 108.621 171.508 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -99.79 136.61 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 105.869 -1.9 . . . . 10.0 105.869 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.0 mt -72.09 158.93 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 -177.072 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -172.67 168.66 41.75 Favored Glycine 0 CA--C 1.527 0.787 0 O-C-N 121.379 -0.826 . . . . 10.0 111.737 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.7 mt -53.19 142.31 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 125.451 1.5 . . . . 10.0 111.534 -174.209 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.83 163.64 36.79 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.665 0.745 . . . . 10.0 109.489 166.99 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 . . . . . 0 C--O 1.256 1.405 0 N-CA-C 104.7 -2.333 . . . . 10.0 104.7 166.636 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.848 0 CA-C-O 117.997 -1.002 . . . . 10.0 108.432 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -165.21 -45.32 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.837 0.855 . . . . 10.0 110.208 178.346 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mttt -136.69 154.27 50.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 125.245 1.418 . . . . 10.0 109.248 169.711 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.59 164.43 30.23 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.366 1.466 . . . . 10.0 107.528 168.968 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -134.3 157.95 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 N-CA-C 109.327 -0.62 . . . . 10.0 109.327 -178.884 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.93 99.96 5.95 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.045 0.938 . . . . 10.0 109.502 172.925 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.439 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.2 OUTLIER -81.24 93.03 2.18 Favored 'Isoleucine or valine' 0 C--N 1.341 0.229 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 167.966 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mt -84.71 136.68 33.62 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.474 1.11 . . . . 10.0 108.561 -178.732 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -159.74 161.64 34.79 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.441 -1.318 . . . . 10.0 107.441 173.771 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.38 -44.82 0.11 Allowed Glycine 0 C--O 1.227 -0.331 0 C-N-CA 119.813 -1.184 . . . . 10.0 113.473 168.938 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -74.1 -45.17 50.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.721 -1.215 . . . . 10.0 107.721 -176.0 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 144.22 -71.36 0.38 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.636 -1.386 . . . . 10.0 109.636 171.487 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -59.1 -37.52 92.12 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.303 2.669 . . . . 10.0 111.14 171.768 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.419 HG13 HD11 ' B' ' 38' ' ' LEU . 58.4 t -58.93 111.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 108.538 -0.912 . . . . 10.0 108.538 178.094 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -125.96 127.86 46.6 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 105.598 -2.001 . . . . 10.0 105.598 167.949 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.528 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -114.12 135.46 12.5 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 108.765 -1.734 . . . . 10.0 108.765 170.505 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.442 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.6 mt -134.97 68.07 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 106.706 -1.591 . . . . 10.0 106.706 -173.836 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.4 mm -97.59 139.82 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 115.145 -0.934 . . . . 10.0 110.467 -170.925 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -107.39 130.52 54.79 Favored 'General case' 0 CA--C 1.527 0.095 0 C-N-CA 126.833 2.053 . . . . 10.0 109.168 -176.183 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -116.75 100.38 7.76 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.376 -1.342 . . . . 10.0 107.376 177.91 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.47 156.89 17.37 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.33 0.514 . . . . 10.0 110.973 175.637 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 34.5 tp60 -154.2 65.49 0.7 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.979 1.312 . . . . 10.0 109.851 -177.989 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? . . . . . 0 N--CA 1.432 -1.347 0 C-N-CA 124.86 1.264 . . . . 10.0 107.71 176.955 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.297 0 N-CA-C 115.419 0.928 . . . . 10.0 115.419 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.71 104.06 1.67 Allowed 'Trans proline' 0 N--CA 1.445 -1.361 0 N-CA-C 105.939 -2.369 . . . . 10.0 105.939 168.339 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 t -77.67 78.95 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.502 -2.036 . . . . 10.0 105.502 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.3 ttmm -69.83 109.57 4.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.385 -1.709 . . . . 10.0 106.385 169.046 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -90.84 102.61 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 105.413 -2.069 . . . . 10.0 105.413 173.852 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -119.56 150.59 40.02 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.92 -160.92 32.93 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 109.502 -1.439 . . . . 10.0 109.502 169.293 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.1 p -147.47 115.15 6.39 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 108.898 -0.779 . . . . 10.0 108.898 -173.542 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.528 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.3 pt -80.19 179.15 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 108.748 -0.834 . . . . 10.0 108.748 168.146 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 36' ' ' LYS . . . . . 0.445 ' NZ ' ' OD2' ' B' ' 92' ' ' ASP . 0.2 OUTLIER -155.86 159.86 39.71 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 107.472 -1.307 . . . . 10.0 107.472 164.034 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.06 -12.63 57.46 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-O 119.13 -0.817 . . . . 10.0 113.96 170.106 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.485 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.5 mp -70.65 176.65 4.0 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 119.036 1.418 . . . . 10.0 109.237 171.736 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -90.13 167.11 12.98 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.431 -0.951 . . . . 10.0 108.431 167.778 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -62.17 170.38 2.28 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.706 0.802 . . . . 10.0 111.734 -170.683 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.39 -174.23 33.45 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 124.317 0.96 . . . . 10.0 112.285 168.611 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -71.85 141.89 49.6 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.185 0.994 . . . . 10.0 109.409 175.761 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.82 148.92 41.34 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 114.7 1.37 . . . . 10.0 114.7 -179.368 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.553 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -36.85 127.05 1.09 Allowed Glycine 0 C--N 1.343 0.932 0 C-N-CA 127.649 2.547 . . . . 10.0 110.738 164.537 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.481 ' CD1' HD22 ' B' ' 84' ' ' LEU . 3.9 t80 -155.65 105.96 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 118.777 1.289 . . . . 10.0 109.055 168.485 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.49 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -156.05 175.34 14.1 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -178.2 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 29.0 m -90.04 151.58 3.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 113.771 -1.558 . . . . 10.0 110.265 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -142.42 137.75 30.61 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.592 1.557 . . . . 10.0 108.125 178.534 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -50.7 -57.14 9.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 114.944 1.461 . . . . 10.0 114.944 -169.103 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -78.46 123.13 26.7 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.92 -0.77 . . . . 10.0 108.92 -169.476 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.52 -30.53 77.88 Favored Glycine 0 CA--C 1.531 1.08 0 N-CA-C 107.444 -2.262 . . . . 10.0 107.444 165.6 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -45.81 142.58 2.46 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-O 123.303 1.525 . . . . 10.0 111.046 171.51 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.481 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -165.11 22.5 0.05 Allowed 'General case' 0 N--CA 1.434 -1.24 0 C-N-CA 126.05 1.74 . . . . 10.0 110.144 -169.573 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.972 HG22 ' CG2' ' A' ' 17' ' ' ILE . 1.3 p -53.16 -40.86 64.62 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 122.874 0.469 . . . . 10.0 112.11 -178.877 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.62 -18.31 54.7 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.227 0.611 . . . . 10.0 112.095 176.133 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.21 110.56 0.8 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.239 0.923 . . . . 10.0 111.986 -178.517 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.1 m 48.7 33.69 4.49 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.676 1.59 . . . . 10.0 112.336 172.492 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 22.3 m -138.18 -55.12 0.65 Allowed 'General case' 0 N--CA 1.437 -1.092 0 C-N-CA 126.296 1.838 . . . . 10.0 106.318 -173.591 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -67.04 -12.9 61.22 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.753 0.821 . . . . 10.0 111.722 178.041 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.31 -36.43 1.25 Allowed 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 126.961 2.104 . . . . 10.0 112.442 175.689 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.38 163.8 39.39 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 107.425 -2.27 . . . . 10.0 107.425 -178.644 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -74.73 -170.26 0.73 Allowed 'Trans proline' 0 N--CA 1.443 -1.463 0 C-N-CA 121.268 1.312 . . . . 10.0 109.252 172.2 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 1.7 m-70 -78.6 58.7 2.29 Favored 'General case' 0 CA--C 1.538 0.515 0 O-C-N 121.269 -0.894 . . . . 10.0 110.572 -173.251 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -71.86 79.46 0.88 Allowed 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 123.096 1.427 . . . . 10.0 110.45 178.524 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 65' ' ' ASN . . . . . 0.44 ' HB3' HG22 ' B' ' 81' ' ' VAL . 15.3 p-10 -74.1 147.2 85.61 Favored Pre-proline 0 N--CA 1.445 -0.69 0 C-N-CA 125.015 1.326 . . . . 10.0 110.222 169.012 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -65.42 -43.53 10.5 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.319 2.013 . . . . 10.0 110.394 178.127 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 tt -78.14 56.82 1.71 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.024 0.93 . . . . 10.0 108.907 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 38.9 p -35.96 106.16 0.04 OUTLIER 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 126.055 1.742 . . . . 10.0 110.989 -173.098 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 2.8 ttt180 -133.29 -174.75 3.58 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 104.029 -2.582 . . . . 10.0 104.029 -178.919 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 22.3 mmtp -75.33 161.11 29.57 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 117.618 -1.633 . . . . 10.0 108.523 170.543 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -65.01 123.31 19.13 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 161.786 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.33 -138.42 4.03 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 108.209 -1.956 . . . . 10.0 108.209 171.687 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.25 -160.08 26.75 Favored Glycine 0 C--O 1.224 -0.502 0 N-CA-C 108.869 -1.692 . . . . 10.0 108.869 177.192 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -66.6 2.03 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 CA-C-N 119.544 1.672 . . . . 10.0 110.131 166.332 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 25.0 mmtt -107.9 6.16 27.05 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 125.598 1.559 . . . . 10.0 110.192 173.987 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.405 ' OD2' ' NZ ' ' B' ' 128' ' ' LYS . 1.9 t0 -141.48 155.89 45.8 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 119.565 1.075 . . . . 10.0 110.611 167.822 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tm-20 -79.36 -26.98 41.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.641 -1.614 . . . . 10.0 106.641 168.632 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -85.87 27.55 0.87 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.669 1.188 . . . . 10.0 111.732 -172.77 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 37.5 ptt-85 -63.72 150.41 44.5 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.208 1.003 . . . . 10.0 111.018 179.003 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -64.68 -70.61 0.22 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.781 0.433 . . . . 10.0 110.884 -177.659 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.471 HG23 ' H ' ' B' ' 82' ' ' GLY . 0.1 OUTLIER -165.83 -63.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.2 0 C-N-CA 126.01 1.724 . . . . 10.0 107.399 -175.938 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.471 ' H ' HG23 ' B' ' 81' ' ' VAL . . . -120.92 55.29 0.64 Allowed Glycine 0 C--N 1.335 0.497 0 N-CA-C 108.804 -1.718 . . . . 10.0 108.804 -176.002 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -93.03 90.45 6.92 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 105.152 -2.166 . . . . 10.0 105.152 169.282 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 84' ' ' LEU . . . . . 0.481 HD22 ' CD1' ' B' ' 45' ' ' PHE . 9.6 mp -65.8 -25.63 67.32 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 118.632 0.651 . . . . 10.0 110.84 -173.114 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.67 -94.11 0.58 Allowed Glycine 0 N--CA 1.436 -1.315 0 N-CA-C 107.872 -2.091 . . . . 10.0 107.872 172.845 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.2 m-20 -156.7 107.8 2.39 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.432 -0.581 . . . . 10.0 109.432 -169.621 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.2 m -89.12 122.71 40.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 CA-C-N 118.163 0.438 . . . . 10.0 110.401 -177.619 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.1 m -79.79 81.96 5.97 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 127.705 2.402 . . . . 10.0 112.55 -171.959 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -70.95 130.4 41.51 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 121.573 -0.704 . . . . 10.0 112.692 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -63.18 172.16 2.0 Allowed 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 125.479 1.511 . . . . 10.0 110.049 166.756 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.08 -28.85 59.32 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 124.2 1.0 . . . . 10.0 111.839 171.141 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 92' ' ' ASP . . . . . 0.445 ' OD2' ' NZ ' ' B' ' 36' ' ' LYS . 30.5 t70 -77.4 -2.88 37.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 122.261 1.029 . . . . 10.0 111.113 175.898 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.3 2.03 87.89 Favored Glycine 0 N--CA 1.44 -1.076 0 N-CA-C 109.959 -1.256 . . . . 10.0 109.959 -173.932 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.24 94.9 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 108.002 -1.11 . . . . 10.0 108.002 -171.572 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.23 118.74 29.14 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 166.76 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -78.16 117.69 19.68 Favored 'General case' 0 N--CA 1.433 -1.28 0 C-N-CA 126.005 1.722 . . . . 10.0 107.744 170.366 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 42.6 t -108.14 131.6 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.16 0 N-CA-C 106.735 -1.58 . . . . 10.0 106.735 -178.555 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.1 p -157.49 51.48 0.46 Allowed 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.394 0.678 . . . . 10.0 109.529 169.455 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -87.91 152.23 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -174.326 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -137.55 146.63 44.33 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.716 1.206 . . . . 10.0 109.986 -178.346 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -152.07 140.13 20.19 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 107.271 -1.381 . . . . 10.0 107.271 168.855 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 77.6 p -108.71 63.34 0.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 -174.265 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.3 p -151.97 -47.61 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 115.608 -0.724 . . . . 10.0 109.055 -177.751 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 20.9 mm -64.5 155.45 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 124.124 0.97 . . . . 10.0 110.058 172.734 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 28.8 t -150.69 147.28 27.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.717 -1.216 . . . . 10.0 107.717 168.367 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 68.2 mt -55.18 -30.61 60.25 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.995 -1.002 . . . . 10.0 109.82 167.085 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t . . . . . 0 N--CA 1.451 -0.383 0 N-CA-C 106.919 -1.511 . . . . 10.0 106.919 -179.312 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.532 0.267 0 CA-C-O 121.992 0.901 . . . . 10.0 109.576 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.295 0.0 OUTLIER -53.31 -28.26 14.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.23 -0.896 . . . . 10.0 113.218 -168.569 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.9 mm -27.13 -55.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 127.221 2.208 . . . . 10.0 114.045 173.776 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -83.67 4.69 81.39 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-O 118.493 -1.17 . . . . 10.0 115.08 -169.726 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 mmt180 -87.6 160.47 18.17 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.663 1.231 . . . . 10.0 111.95 -177.827 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 19.3 m -92.96 130.48 38.53 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 169.007 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -97.64 138.46 35.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 169.773 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 83.1 t -129.81 135.35 61.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 107.748 -1.204 . . . . 10.0 107.748 -177.336 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -103.05 145.99 11.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 123.897 0.879 . . . . 10.0 108.644 168.419 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.553 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 2.7 m170 -123.89 160.38 27.62 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 116.329 1.974 . . . . 10.0 116.329 -173.717 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.6 tt0 -43.07 -56.57 3.3 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.692 3.197 . . . . 10.0 111.918 172.827 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 76.0 mttt -117.3 170.02 9.02 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 123.599 0.76 . . . . 10.0 112.397 -169.29 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.9 149.7 47.54 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 114.003 -1.453 . . . . 10.0 109.458 173.701 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.49 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.2 m-20 -80.58 146.21 31.35 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 123.881 0.872 . . . . 10.0 111.773 173.66 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -76.26 -27.97 56.9 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 124.235 0.959 . . . . 10.0 109.5 168.326 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 72.4 mt 62.04 53.01 3.1 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 123.058 1.408 . . . . 10.0 108.925 -174.923 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.28 -43.23 2.54 Favored Glycine 0 N--CA 1.445 -0.764 0 CA-C-N 112.561 -2.109 . . . . 10.0 110.637 173.581 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.405 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 13.1 mtmm -81.38 44.74 0.81 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.919 0.888 . . . . 10.0 112.392 -169.971 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.15 -22.7 14.44 Favored Glycine 0 CA--C 1.523 0.568 0 C-N-CA 125.921 1.724 . . . . 10.0 110.903 169.895 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.77 34.43 89.92 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 110.996 -0.841 . . . . 10.0 110.996 175.845 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -138.27 168.53 19.55 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.883 -1.525 . . . . 10.0 106.883 169.397 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.11 -48.53 73.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 116.038 -0.528 . . . . 10.0 109.865 -176.199 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -68.02 -26.4 65.87 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.006 -1.059 . . . . 10.0 110.935 178.977 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.0 p -56.92 -44.53 82.54 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 120.996 1.725 . . . . 10.0 110.544 171.93 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -83.92 -10.78 57.71 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.85 -0.595 . . . . 10.0 112.1 -173.75 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -103.33 -51.72 3.17 Favored 'General case' 0 N--CA 1.441 -0.905 0 C-N-CA 126.038 1.735 . . . . 10.0 112.319 -178.822 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.2 p -139.29 31.17 2.15 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.557 1.071 . . . . 10.0 112.461 176.045 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 58.23 25.87 57.98 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 118.723 0.692 . . . . 10.0 112.719 175.456 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 52.96 24.89 3.63 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 117.59 0.695 . . . . 10.0 112.585 -176.724 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.13 -4.26 9.67 Favored 'General case' 0 C--N 1.342 0.276 0 O-C-N 121.12 -0.988 . . . . 10.0 113.014 -173.32 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.03 -158.93 41.05 Favored Glycine 0 N--CA 1.446 -0.69 0 O-C-N 121.027 -1.045 . . . . 10.0 111.187 167.249 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 m -58.49 125.73 24.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.463 0.705 . . . . 10.0 111.767 -167.83 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -58.74 68.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.955 2.102 . . . . 10.0 111.864 172.048 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.7 mt -50.59 -36.93 37.26 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.898 -1.127 . . . . 10.0 113.714 -174.469 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -163.11 157.53 20.76 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 -170.823 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 23.6 p -161.76 168.29 23.47 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.96 -0.385 . . . . 10.0 109.96 -174.637 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.5 155.37 26.46 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.312 -1.515 . . . . 10.0 109.312 -176.44 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -107.94 131.25 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 105.776 -1.935 . . . . 10.0 105.776 -177.507 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 16.0 mt -79.48 165.95 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 118.818 0.736 . . . . 10.0 110.615 -179.782 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -169.13 170.92 42.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 127.875 2.655 . . . . 10.0 107.097 -177.065 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 20.3 mt -84.8 140.67 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 124.481 1.112 . . . . 10.0 110.1 -168.93 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -102.57 -114.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.903 -1.147 . . . . 10.0 107.903 167.44 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.252 1.227 0 C-N-CA 131.077 3.751 . . . . 10.0 106.136 172.297 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.799 0 CA-C-O 118.571 -0.728 . . . . 10.0 109.794 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 60.4 p -96.21 -63.89 1.1 Allowed 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 124.555 1.142 . . . . 10.0 110.001 -169.908 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -135.63 135.4 40.16 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 126.724 2.01 . . . . 10.0 107.857 -169.547 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -133.59 166.99 21.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.752 1.221 . . . . 10.0 110.119 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.73 162.12 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 125.803 1.641 . . . . 10.0 109.317 -179.015 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -149.89 90.72 1.71 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 106.204 -1.776 . . . . 10.0 106.204 166.631 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.704 HG21 ' HB3' ' B' ' 53' ' ' ASN . 3.7 m -77.37 118.97 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 170.915 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.6 mt -97.85 147.73 24.13 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 -178.947 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.06 162.56 17.95 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 168.994 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.43 -58.33 0.05 OUTLIER Glycine 0 C--O 1.227 -0.291 0 C-N-CA 121.09 -0.576 . . . . 10.0 112.057 169.861 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -72.98 -46.46 52.15 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.9 -69.81 0.51 Allowed Glycine 0 CA--C 1.527 0.796 0 CA-C-N 114.313 -1.312 . . . . 10.0 110.089 174.099 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -75.82 37.45 0.52 Allowed 'Trans proline' 0 CA--C 1.536 0.614 1 C-N-CA 125.69 4.26 . . . . 10.0 111.944 -179.884 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.8 t -149.01 100.38 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 C-N-CA 131.454 3.902 . . . . 10.0 100.537 178.603 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.72 116.04 22.39 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 106.032 -1.84 . . . . 10.0 106.032 -174.181 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.617 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.81 142.71 16.25 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 174.766 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.562 ' CG2' HG23 ' B' ' 54' ' ' THR . 6.3 mt -135.14 86.02 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.721 -1.214 . . . . 10.0 107.721 173.795 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -97.46 142.64 13.94 Favored 'Isoleucine or valine' 0 C--N 1.339 0.118 0 C-N-CA 124.028 0.931 . . . . 10.0 110.008 178.002 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -128.88 123.1 31.82 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 127.262 2.225 . . . . 10.0 109.511 174.353 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -105.23 116.87 32.68 Favored 'General case' 0 C--O 1.23 0.074 0 C-N-CA 125.294 1.437 . . . . 10.0 108.684 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 20.4 tt0 -105.58 134.71 48.24 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 118.666 0.666 . . . . 10.0 112.268 171.788 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 tp60 -109.71 99.36 8.54 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.672 1.989 . . . . 10.0 107.037 168.853 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 40.5 mmtt -58.72 -64.79 0.8 Allowed 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.752 -0.462 . . . . 10.0 109.752 175.469 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -124.13 164.62 19.09 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 104.657 -2.349 . . . . 10.0 104.657 169.453 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 t -71.47 -15.74 62.33 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 108.77 -0.826 . . . . 10.0 108.77 173.665 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.82 -24.31 44.55 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.021 0.529 . . . . 10.0 110.273 173.388 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.44 141.77 23.25 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 109.887 -1.285 . . . . 10.0 109.887 -176.825 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -62.56 142.21 89.16 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 CA-C-N 119.525 1.663 . . . . 10.0 107.866 169.252 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.5 t -77.92 125.77 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -174.731 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.1 mtmm -90.87 104.94 17.47 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.658 -1.238 . . . . 10.0 107.658 178.575 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 p -94.08 93.19 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 125.908 1.683 . . . . 10.0 107.555 174.264 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.9 p90 -102.28 175.07 5.64 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 121.207 0.527 . . . . 10.0 109.982 169.153 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.75 174.8 38.34 Favored Glycine 0 N--CA 1.441 -0.983 0 N-CA-C 111.367 -0.693 . . . . 10.0 111.367 176.892 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.0 p -145.69 102.78 3.72 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.239 -1.393 . . . . 10.0 107.239 178.751 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.617 HG22 ' HA2' ' A' ' 16' ' ' GLY . 7.5 pt -78.05 174.16 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 C-N-CA 118.878 -1.129 . . . . 10.0 108.099 169.225 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -154.83 144.17 21.22 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 168.808 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.6 -37.24 2.47 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-N 118.695 0.679 . . . . 10.0 113.957 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.518 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.1 mp -68.8 177.86 2.38 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.968 0.89 . . . . 10.0 112.651 -167.987 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.8 t -100.41 156.8 17.06 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.866 -0.606 . . . . 10.0 109.384 171.168 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -52.42 147.11 8.56 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.944 1.298 . . . . 10.0 112.191 -169.526 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.0 -172.12 17.68 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.124 0.869 . . . . 10.0 111.448 171.407 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -72.71 148.5 44.64 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.069 1.348 . . . . 10.0 110.855 -177.774 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -147.38 143.66 28.14 Favored 'General case' 0 C--N 1.338 0.067 0 C-N-CA 124.115 0.966 . . . . 10.0 112.314 -179.439 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.728 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -23.28 124.49 0.02 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.347 2.403 . . . . 10.0 114.062 165.301 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 20.1 t80 -149.25 106.5 3.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 119.286 1.543 . . . . 10.0 109.848 168.671 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.49 172.37 14.59 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.317 0.579 . . . . 10.0 111.04 174.102 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.4 p -112.82 120.93 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 CA-C-N 112.86 -1.973 . . . . 10.0 107.502 168.676 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -89.41 151.61 21.94 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.873 1.669 . . . . 10.0 108.223 -179.37 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -64.76 -57.01 10.08 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 114.798 -1.092 . . . . 10.0 110.473 -173.098 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -76.62 124.46 27.67 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.227 -1.397 . . . . 10.0 107.227 -173.403 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.07 -2.41 77.99 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.426 -0.652 . . . . 10.0 112.136 178.047 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -43.98 131.0 5.88 Favored 'General case' 0 C--N 1.344 0.343 0 CA-C-O 122.8 1.286 . . . . 10.0 112.525 175.289 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.621 ' HB3' HG21 ' B' ' 7' ' ' VAL . 2.9 m-80 -138.43 3.19 2.32 Favored 'General case' 0 N--CA 1.434 -1.232 0 CA-C-N 112.676 -2.056 . . . . 10.0 109.519 163.939 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.666 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -53.5 -40.09 65.12 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 125.063 1.345 . . . . 10.0 108.605 168.566 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.8 -15.12 59.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 116.041 -0.527 . . . . 10.0 111.976 178.223 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.75 75.5 0.99 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 109.092 -1.603 . . . . 10.0 109.092 -173.384 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t 38.78 48.87 1.41 Allowed 'General case' 0 C--O 1.231 0.105 0 C-N-CA 125.554 1.542 . . . . 10.0 114.448 177.311 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.4 m -127.76 -53.5 1.33 Allowed 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.996 -1.483 . . . . 10.0 106.996 -172.745 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.3 m -90.22 16.95 7.67 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.129 0.422 . . . . 10.0 111.527 173.758 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.56 -19.77 58.38 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.21 1.004 . . . . 10.0 111.032 169.379 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.3 135.85 7.98 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-O 119.017 -0.88 . . . . 10.0 111.232 168.578 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -73.39 66.04 4.5 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 123.244 2.63 . . . . 10.0 110.77 173.474 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 28.8 m170 71.81 -34.16 0.29 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 128.41 2.684 . . . . 10.0 112.664 175.385 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 43.42 25.9 0.09 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 128.308 2.643 . . . . 10.0 116.374 171.625 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -59.06 134.33 87.59 Favored Pre-proline 0 CA--C 1.534 0.354 0 N-CA-C 114.464 1.283 . . . . 10.0 114.464 -169.945 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -60.95 -37.49 76.47 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.565 2.177 . . . . 10.0 110.042 175.901 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 66.0 mt -63.05 2.8 0.29 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.748 1.219 . . . . 10.0 113.776 175.761 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 12.4 m 26.84 54.22 0.05 OUTLIER 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 128.293 2.637 . . . . 10.0 114.982 175.738 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtt85 -99.29 -179.15 4.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.572 1.149 . . . . 10.0 110.752 -172.983 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt -112.54 92.52 4.05 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.046 -0.724 . . . . 10.0 109.046 -174.643 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -5.88 97.16 0.01 OUTLIER 'General case' 0 C--O 1.223 -0.318 0 C-N-CA 128.255 2.622 . . . . 10.0 113.937 -176.916 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.41 -134.04 7.81 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.897 -1.681 . . . . 10.0 108.897 178.998 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.49 -170.33 40.43 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 106.915 -2.474 . . . . 10.0 106.915 171.498 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -63.59 -4.64 7.26 Favored 'Trans proline' 0 N--CA 1.455 -0.794 0 CA-C-N 119.867 1.834 . . . . 10.0 110.929 168.276 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -88.65 -24.06 22.88 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.313 1.045 . . . . 10.0 110.536 174.069 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.8 178.41 4.29 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 108.246 -1.02 . . . . 10.0 108.246 -178.262 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -92.81 -26.81 17.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 167.088 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.1 mm-40 -87.06 28.79 0.88 Allowed 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.391 -1.443 . . . . 10.0 112.436 -169.641 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.5 133.62 53.48 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.67 -1.233 . . . . 10.0 107.67 169.345 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.9 m170 -64.58 -57.92 7.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.823 -0.548 . . . . 10.0 112.007 -175.378 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.8 p -170.97 -43.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 C-N-CA 124.461 1.104 . . . . 10.0 109.065 -172.375 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -150.43 56.44 0.46 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 109.759 -1.336 . . . . 10.0 109.759 178.385 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -92.76 92.15 7.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 172.256 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.29 -36.69 63.78 Favored 'General case' 0 N--CA 1.461 0.1 0 N-CA-C 107.648 -1.242 . . . . 10.0 107.648 177.067 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.34 -98.66 1.23 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 110.833 -0.907 . . . . 10.0 110.833 167.859 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.3 m-80 -123.73 132.3 53.79 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.855 0.862 . . . . 10.0 111.274 -168.365 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.0 m -114.68 129.92 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 123.771 0.828 . . . . 10.0 109.14 168.072 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 28.2 m -86.81 104.09 15.85 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 127.651 2.381 . . . . 10.0 110.572 -174.857 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.03 33.49 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 122.825 0.45 . . . . 10.0 110.544 174.776 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -66.76 175.23 2.49 Favored 'General case' 0 CA--C 1.528 0.103 0 O-C-N 123.633 0.583 . . . . 10.0 109.728 167.661 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.13 -29.48 13.56 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.585 1.554 . . . . 10.0 111.746 172.38 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -79.42 -4.5 51.39 Favored 'General case' 0 N--CA 1.453 -0.301 0 O-C-N 123.226 0.329 . . . . 10.0 110.229 -177.779 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.8 9.28 86.94 Favored Glycine 0 C--N 1.337 0.635 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 -178.377 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 50.9 t -90.82 107.65 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.277 0 C-N-CA 126.149 1.78 . . . . 10.0 106.356 179.619 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.445 ' H ' HG12 ' A' ' 35' ' ' ILE . . . -102.85 118.52 37.02 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.579 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -79.24 112.2 16.23 Favored 'General case' 0 N--CA 1.434 -1.239 0 C-N-CA 125.927 1.691 . . . . 10.0 108.541 171.127 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.82 133.23 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.234 -1.765 . . . . 10.0 106.234 176.337 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -157.63 60.69 0.48 Allowed 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.861 -0.422 . . . . 10.0 109.861 -178.398 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 44.0 mt -115.46 154.69 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 107.97 -1.122 . . . . 10.0 107.97 -169.696 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -127.87 145.51 50.92 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.338 -0.615 . . . . 10.0 109.338 167.512 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 102' ' ' SER . 42.2 t0 -145.29 154.73 42.66 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 -178.752 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.406 ' N ' ' OD1' ' A' ' 101' ' ' ASP . 8.4 p -108.32 -9.35 15.49 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 128.145 2.578 . . . . 10.0 112.28 -174.28 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.6 p -79.6 -36.98 18.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.147 0 N-CA-C 107.602 -1.259 . . . . 10.0 107.602 -174.87 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.455 ' H ' ' CD1' ' A' ' 104' ' ' ILE 0.309 0.0 OUTLIER -79.51 150.24 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 124.714 1.206 . . . . 10.0 113.026 172.676 . . . . . . . . 4 4 . 1 . 025 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.6 m -157.28 133.56 9.7 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.089 0.956 . . . . 10.0 108.47 179.616 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.46 ' CD1' HD11 ' A' ' 113' ' ' ILE . 1.1 mm? -75.54 52.87 0.66 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.223 2.209 . . . . 10.0 108.394 175.13 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.2 t -88.38 -157.04 0.4 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.472 1.909 . . . . 10.0 110.204 -169.803 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.0 -53.65 0.13 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 128.177 2.799 . . . . 10.0 107.429 -178.302 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -64.99 -60.16 3.36 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.227 -0.657 . . . . 10.0 109.227 171.203 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -77.94 -28.35 49.54 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 115.903 -0.589 . . . . 10.0 110.228 -175.259 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t 13.32 78.63 0.01 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 128.3 2.64 . . . . 10.0 113.672 175.776 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -65.53 -16.19 19.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 112.04 0.385 . . . . 10.0 112.04 176.328 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.46 HD11 ' CD1' ' A' ' 106' ' ' LEU . 49.2 mm -46.39 137.64 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 C-N-CA 123.832 0.853 . . . . 10.0 110.318 169.981 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.08 -1.97 88.18 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.153 -1.36 . . . . 10.0 115.286 174.986 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.9 mtp85 -77.05 168.14 20.6 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.019 1.41 . . . . 10.0 107.364 169.122 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -106.6 120.86 43.07 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.48 0.582 . . . . 10.0 111.752 -174.902 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -77.22 145.72 37.42 Favored 'General case' 0 CA--C 1.517 -0.294 0 N-CA-C 108.337 -0.986 . . . . 10.0 108.337 168.698 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 86.8 t -131.93 132.49 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.899 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.145 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -104.48 134.8 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 N-CA-C 106.268 -1.753 . . . . 10.0 106.268 167.831 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.728 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 8.2 m-70 -112.67 156.95 21.88 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 115.794 1.776 . . . . 10.0 115.794 -170.906 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -43.25 -55.3 4.07 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.68 2.792 . . . . 10.0 112.155 171.597 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -115.55 162.8 16.69 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.784 0.834 . . . . 10.0 111.543 -169.675 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.87 153.86 42.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.877 -1.056 . . . . 10.0 109.129 170.103 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -93.51 144.41 25.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 C-N-CA 123.814 0.845 . . . . 10.0 110.75 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -76.7 -16.12 59.6 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-N 114.387 -1.279 . . . . 10.0 110.83 168.379 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.4 mt 53.23 40.57 31.48 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.178 0.991 . . . . 10.0 110.247 -172.953 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.77 -47.97 0.98 Allowed Glycine 0 C--N 1.337 0.59 0 C-N-CA 125.122 1.344 . . . . 10.0 111.023 169.988 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.42 51.97 1.75 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 122.035 -0.685 . . . . 10.0 112.466 -169.831 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.43 -38.62 5.85 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 124.786 1.184 . . . . 10.0 110.351 169.914 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.43 31.33 78.51 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 -169.451 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -114.21 157.42 22.7 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 106.067 -1.827 . . . . 10.0 106.067 169.236 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.414 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 4.8 tm-20 -51.75 -44.87 63.49 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.875 -1.057 . . . . 10.0 109.062 174.13 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -65.44 -34.08 77.44 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.162 0.985 . . . . 10.0 112.452 173.937 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 54.3 p -57.73 -35.99 71.45 Favored 'General case' 0 N--CA 1.448 -0.571 0 O-C-N 120.244 -1.535 . . . . 10.0 111.781 -175.953 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -84.65 -1.11 55.61 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 118.855 -0.593 . . . . 10.0 112.163 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 94.1 mttt -114.05 -56.13 2.43 Favored 'General case' 0 C--N 1.342 0.261 0 C-N-CA 124.628 1.171 . . . . 10.0 111.315 -176.523 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.8 p -120.17 -5.54 9.96 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.888 0.767 . . . . 10.0 113.061 175.929 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.03 33.65 Favored Glycine 0 C--N 1.342 0.889 0 CA-C-O 119.252 -0.749 . . . . 10.0 112.175 -177.465 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 62.12 23.79 14.09 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 118.317 1.059 . . . . 10.0 111.597 -177.694 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.27 -11.78 24.28 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 125.656 1.583 . . . . 10.0 112.013 -177.986 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.88 -157.28 48.61 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 172.926 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.2 m -61.39 133.93 56.35 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.875 0.87 . . . . 10.0 113.121 -167.495 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -66.25 71.39 0.07 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.968 1.307 . . . . 10.0 110.017 169.596 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.6 mt -55.85 -33.56 64.64 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 112.742 0.645 . . . . 10.0 112.742 -177.435 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.19 146.35 15.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.473 -0.566 . . . . 10.0 109.473 -175.749 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 18.1 m -148.51 161.25 42.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -169.855 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.07 -174.96 17.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.504 -0.639 . . . . 10.0 111.504 178.419 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 49.8 t -127.05 133.75 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 104.825 -2.287 . . . . 10.0 104.825 175.755 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 22.1 mt -69.37 117.46 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 108.903 -0.777 . . . . 10.0 108.903 177.987 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.83 141.86 16.7 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 110.611 -0.996 . . . . 10.0 110.611 -179.72 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.17 132.7 32.97 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 CA-C-N 119.353 1.577 . . . . 10.0 108.942 175.31 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.61 -26.27 50.5 Favored 'General case' 0 C--O 1.223 -0.342 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 167.94 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.253 1.278 0 C-N-CA 126.187 1.795 . . . . 10.0 109.318 169.363 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.706 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' B' B ' 2' ' ' THR . . . . . 0.4 HG23 ' H ' ' B' ' 3' ' ' LYS . 8.8 t -150.76 -60.48 0.18 Allowed 'General case' 0 C--O 1.232 0.139 0 N-CA-C 108.958 -0.756 . . . . 10.0 108.958 176.135 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 3' ' ' LYS . . . . . 0.4 ' H ' HG23 ' B' ' 2' ' ' THR . 57.0 tttp -117.18 135.4 53.8 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 126.888 2.075 . . . . 10.0 106.852 174.904 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.85 161.7 34.88 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 125.253 1.421 . . . . 10.0 110.75 178.543 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 m -128.4 178.1 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 124.837 1.255 . . . . 10.0 110.042 -176.218 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -162.27 97.28 1.0 Allowed 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 125.368 1.467 . . . . 10.0 107.634 166.641 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.621 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.8 m -89.73 104.53 15.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.21 0.604 . . . . 10.0 110.818 173.765 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.7 mp -93.58 146.23 23.96 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.244 1.418 . . . . 10.0 110.176 178.195 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 9' ' ' LYS . . . . . 0.439 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 2.9 tttm -162.12 164.07 28.19 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 171.206 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.68 -47.65 0.14 Allowed Glycine 0 N--CA 1.462 0.398 0 C-N-CA 119.389 -1.386 . . . . 10.0 114.102 168.796 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -72.08 -45.73 59.58 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.141 -1.429 . . . . 10.0 107.141 -177.057 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.65 -75.17 0.28 Allowed Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 114.162 -1.381 . . . . 10.0 109.932 169.125 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -55.92 -39.22 92.49 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 123.511 2.808 . . . . 10.0 110.985 173.008 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.436 HG13 HD11 ' B' ' 38' ' ' LEU . 72.6 t -59.66 112.31 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 179.643 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.04 124.33 42.32 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 168.446 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.573 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -104.67 136.92 13.35 Favored Glycine 0 C--O 1.224 -0.494 0 N-CA-C 107.794 -2.122 . . . . 10.0 107.794 169.491 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.666 HG22 HG22 ' A' ' 54' ' ' THR . 3.0 mt -138.59 68.04 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -174.579 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 mm -89.05 151.89 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 N-CA-C 109.668 -0.493 . . . . 10.0 109.668 -173.503 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.24 143.89 48.04 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 126.617 1.967 . . . . 10.0 108.111 175.194 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -129.05 130.91 47.16 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 104.411 -2.44 . . . . 10.0 104.411 168.273 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -128.62 150.48 50.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 119.796 1.18 . . . . 10.0 110.402 172.375 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.58 97.59 5.12 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 178.392 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.515 -0.375 0 C-N-CA 123.978 0.911 . . . . 10.0 110.053 170.482 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.569 0 N-CA-C 109.397 -1.481 . . . . 10.0 109.397 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.27 129.94 24.12 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.808 2.338 . . . . 10.0 109.456 -177.499 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.1 t -79.87 111.52 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 N-CA-C 104.918 -2.253 . . . . 10.0 104.918 172.469 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -82.65 126.54 32.44 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 169.204 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -100.5 109.38 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 C-N-CA 126.37 1.868 . . . . 10.0 106.703 172.826 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.9 p90 -130.38 156.63 44.4 Favored 'General case' 0 C--O 1.226 -0.177 0 N-CA-C 113.504 0.927 . . . . 10.0 113.504 -179.729 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.65 -152.24 24.12 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 106.824 -2.511 . . . . 10.0 106.824 172.924 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 21.2 p -156.38 165.93 34.89 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 119.584 -0.846 . . . . 10.0 110.412 174.335 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.573 HG22 ' HA2' ' B' ' 16' ' ' GLY . 4.0 pt -107.01 179.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-N 114.344 -1.298 . . . . 10.0 109.424 165.366 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.19 163.17 40.54 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 124.689 1.196 . . . . 10.0 108.407 162.921 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.21 -17.12 44.69 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-O 119.315 -0.714 . . . . 10.0 113.155 172.626 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.482 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.4 mp -71.7 178.61 3.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.005 0.902 . . . . 10.0 110.194 173.708 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -97.4 170.45 9.05 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 166.408 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -60.03 170.69 1.15 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.203 1.001 . . . . 10.0 112.111 -171.341 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.95 -174.61 32.99 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 124.201 0.905 . . . . 10.0 112.08 168.461 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.24 146.78 50.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 123.834 0.854 . . . . 10.0 109.581 176.164 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -147.17 144.94 29.32 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 123.493 0.717 . . . . 10.0 111.703 178.558 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.66 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -34.79 120.5 0.39 Allowed Glycine 0 C--N 1.339 0.74 0 C-N-CA 127.738 2.59 . . . . 10.0 112.626 167.371 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.69 110.47 5.14 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-N 119.456 1.628 . . . . 10.0 109.458 168.306 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -146.57 170.65 16.46 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-O 121.718 0.771 . . . . 10.0 111.802 176.496 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.16 129.09 46.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 CA-C-N 111.146 -2.752 . . . . 10.0 105.647 168.193 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 41.5 m-70 -105.78 146.59 29.65 Favored 'General case' 0 CA--C 1.509 -0.611 0 N-CA-C 107.675 -1.231 . . . . 10.0 107.675 174.382 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 23.8 tp10 -66.64 -59.04 3.96 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.544 -1.207 . . . . 10.0 108.98 -172.987 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 22.2 m-30 -77.1 106.88 9.09 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 -175.222 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.68 42.8 1.31 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 124.592 1.091 . . . . 10.0 111.448 174.517 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.32 131.76 41.07 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 124.975 1.31 . . . . 10.0 108.241 177.057 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.704 ' HB3' HG21 ' A' ' 7' ' ' VAL . 1.2 m-80 -122.8 1.43 9.36 Favored 'General case' 0 N--CA 1.444 -0.755 0 C-N-CA 124.714 1.205 . . . . 10.0 110.28 168.968 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.562 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.18 -36.53 70.93 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.773 1.17 . . . . 10.0 108.792 178.194 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.38 -17.88 55.83 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.53 1.132 . . . . 10.0 112.965 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 77.61 0.77 Allowed Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.272 -0.731 . . . . 10.0 111.272 -178.273 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 34.8 m 50.96 34.36 10.46 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 124.754 1.222 . . . . 10.0 112.614 172.501 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 6.3 m -127.75 -57.43 1.26 Allowed 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -169.958 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 11.8 t -92.14 21.22 5.24 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 111.896 0.332 . . . . 10.0 111.896 179.166 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -68.1 -7.26 28.09 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.615 0.766 . . . . 10.0 111.949 176.285 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.47 127.66 2.19 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 109.704 -1.358 . . . . 10.0 109.704 174.132 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -74.81 65.42 5.88 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.517 2.811 . . . . 10.0 111.523 178.437 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 59.98 55.83 3.64 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 128.382 2.673 . . . . 10.0 109.94 177.947 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -70.51 63.7 0.27 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.553 0.741 . . . . 10.0 112.393 -178.041 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -67.48 147.45 98.78 Favored Pre-proline 0 CA--C 1.532 0.27 0 O-C-N 121.642 -0.661 . . . . 10.0 110.858 -175.559 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -63.11 -49.44 4.88 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.245 1.963 . . . . 10.0 110.2 179.308 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.6 tt -81.41 59.64 4.12 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.358 0.663 . . . . 10.0 109.348 -177.852 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.0 t -14.96 97.31 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 128.411 2.684 . . . . 10.0 112.886 -176.806 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.59 168.58 10.88 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.423 1.089 . . . . 10.0 108.725 -175.807 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -108.24 105.91 15.84 Favored 'General case' 0 C--O 1.224 -0.26 0 N-CA-C 108.457 -0.942 . . . . 10.0 108.457 175.508 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 56.3 t60 -9.99 96.51 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 127.213 2.205 . . . . 10.0 115.482 -177.769 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.78 -141.1 10.37 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 173.658 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.03 -161.09 27.09 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 108.79 -1.724 . . . . 10.0 108.79 171.091 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -66.59 5.97 0.64 Allowed 'Trans proline' 0 N--CA 1.456 -0.704 0 CA-C-N 120.417 2.109 . . . . 10.0 111.889 174.106 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -103.56 -15.21 15.9 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 117.596 -1.193 . . . . 10.0 110.994 172.887 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.415 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 5.4 m-20 -131.36 162.25 30.53 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 119.164 0.893 . . . . 10.0 108.925 -167.855 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -78.61 -33.07 47.7 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.231 -1.396 . . . . 10.0 107.231 176.361 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -82.25 26.46 0.54 Allowed 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 125.431 1.493 . . . . 10.0 112.528 -167.108 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 36.2 ptt85 -64.58 134.35 54.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.304 -0.998 . . . . 10.0 108.304 173.962 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.5 m80 -58.86 -50.74 72.87 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 121.012 0.434 . . . . 10.0 111.088 -178.699 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 p -172.37 -105.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 104.06 -2.571 . . . . 10.0 104.06 177.864 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -77.54 57.36 3.78 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.864 0.756 . . . . 10.0 111.558 172.313 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -84.91 88.35 7.42 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 103.935 -2.616 . . . . 10.0 103.935 166.856 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 16.0 mt -71.72 -31.08 66.34 Favored 'General case' 0 N--CA 1.463 0.189 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -178.52 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.37 -102.54 2.57 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 109.82 -1.312 . . . . 10.0 109.82 167.571 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -121.05 104.11 9.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.603 1.161 . . . . 10.0 109.29 -167.201 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.1 m -94.66 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 118.725 0.693 . . . . 10.0 109.504 172.7 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 80.0 m -89.96 117.57 28.87 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 126.585 1.954 . . . . 10.0 108.908 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.82 134.6 43.55 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 124.536 1.135 . . . . 10.0 111.313 178.442 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -59.53 170.98 0.91 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 124.165 0.986 . . . . 10.0 110.811 166.769 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 28.3 mttm -52.06 -33.0 37.13 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.806 1.643 . . . . 10.0 112.453 169.183 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.45 -1.23 32.62 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-O 122.158 0.98 . . . . 10.0 111.307 176.601 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.41 0.89 84.24 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.052 -1.619 . . . . 10.0 109.052 -176.175 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.3 t -78.15 95.66 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -170.074 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.38 119.08 29.52 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 166.582 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.21 114.22 17.97 Favored 'General case' 0 N--CA 1.436 -1.163 0 C-N-CA 126.759 2.023 . . . . 10.0 108.971 171.95 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 91.8 t -98.11 131.23 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.705 -1.591 . . . . 10.0 106.705 174.363 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.6 p -157.76 57.69 0.49 Allowed 'General case' 0 CA--C 1.534 0.355 0 O-C-N 122.0 -0.437 . . . . 10.0 110.305 171.88 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.94 161.01 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 C-N-CA 124.784 1.234 . . . . 10.0 107.672 -170.892 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -130.54 146.25 52.03 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 124.625 1.17 . . . . 10.0 110.385 175.366 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 58.8 t0 -144.52 154.77 43.24 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.276 -1.009 . . . . 10.0 108.276 175.679 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 33.4 p -134.22 2.87 3.35 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 126.64 1.976 . . . . 10.0 112.544 -179.542 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.8 p -79.3 -31.84 14.62 Favored 'Isoleucine or valine' 0 C--N 1.343 0.324 0 CA-C-N 120.017 1.28 . . . . 10.0 107.891 169.948 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.402 ' C ' HD12 ' B' ' 104' ' ' ILE 0.273 0.7 OUTLIER -82.56 174.08 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 124.156 0.983 . . . . 10.0 111.556 169.423 . . . . . . . . 4 4 . 1 . 025 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 31.1 m -158.7 143.56 16.07 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 105.423 -2.066 . . . . 10.0 105.423 172.084 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 mt -75.5 -10.37 59.39 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.943 0.497 . . . . 10.0 112.335 -172.272 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 75.7 m . . . . . 0 N--CA 1.451 -0.414 0 C-N-CA 126.257 1.823 . . . . 10.0 106.43 173.242 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.0 t . . . . . 0 N--CA 1.453 -0.304 0 CA-C-O 121.444 0.64 . . . . 10.0 112.636 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.96 -7.61 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 112.802 0.667 . . . . 10.0 112.802 -176.704 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 41.0 mm -45.92 125.0 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 O-C-N 121.55 -0.719 . . . . 10.0 110.1 171.81 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.4 2.03 77.34 Favored Glycine 0 CA--C 1.527 0.81 0 CA-C-O 118.735 -1.036 . . . . 10.0 113.637 178.862 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -76.2 178.92 6.06 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 106.007 -1.849 . . . . 10.0 106.007 166.75 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -124.59 129.72 51.1 Favored 'General case' 0 CA--C 1.514 -0.438 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 -174.962 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.415 ' CD1' HD11 ' B' ' 149' ' ' ILE . 7.8 mp -96.97 139.72 32.57 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 171.37 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.4 t -123.17 129.8 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 O-C-N 124.605 1.191 . . . . 10.0 108.303 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.445 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.6 p -93.03 131.41 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.47 -1.308 . . . . 10.0 107.47 167.618 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.66 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.5 m170 -111.72 158.33 19.45 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.448 1.277 . . . . 10.0 114.448 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -56.6 -54.81 41.68 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 125.15 1.38 . . . . 10.0 110.98 178.757 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 43.7 mttm -109.44 176.11 5.2 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 118.686 0.676 . . . . 10.0 110.136 177.268 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.17 140.74 29.18 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.058 1.343 . . . . 10.0 108.515 176.781 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.69 152.63 35.66 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 123.297 0.639 . . . . 10.0 111.943 -177.362 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 51.2 m-20 -76.38 6.2 5.99 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 127.115 2.166 . . . . 10.0 111.491 178.899 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.7 mt 42.12 40.11 1.58 Allowed 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.369 1.868 . . . . 10.0 111.194 -173.137 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.24 -33.52 5.94 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-O 119.509 -0.606 . . . . 10.0 112.639 168.959 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.415 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 3.3 mppt? -80.42 40.84 0.51 Allowed 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 117.597 0.699 . . . . 10.0 110.974 -176.961 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 129' ' ' GLY . . . . . 0.519 ' HA3' ' CB ' ' B' ' 134' ' ' SER . . . -88.97 -30.22 15.31 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 124.806 1.193 . . . . 10.0 112.616 -173.317 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 94.63 6.95 60.57 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.793 -1.004 . . . . 10.0 114.751 170.391 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 131' ' ' ASN . . . . . 0.416 ' H ' ' HB2' ' B' ' 134' ' ' SER . 0.8 OUTLIER -141.39 175.47 9.64 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 119.844 1.822 . . . . 10.0 106.726 169.036 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -51.19 -58.52 5.93 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.742 1.217 . . . . 10.0 109.279 178.208 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -49.94 -52.47 33.11 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 123.109 1.433 . . . . 10.0 110.562 176.505 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 134' ' ' SER . . . . . 0.519 ' CB ' ' HA3' ' B' ' 129' ' ' GLY . 0.2 OUTLIER -62.23 -4.8 1.93 Allowed 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 127.497 2.319 . . . . 10.0 113.27 179.979 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.24 15.01 6.72 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.731 0.813 . . . . 10.0 110.703 172.808 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmmm -122.22 -62.52 1.38 Allowed 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.727 2.011 . . . . 10.0 109.432 -178.56 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -113.71 16.1 18.64 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 119.513 1.052 . . . . 10.0 110.487 167.207 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.96 20.73 70.98 Favored Glycine 0 C--O 1.22 -0.764 0 C-N-CA 124.088 0.851 . . . . 10.0 113.2 168.81 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 60.03 24.74 13.94 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.327 1.064 . . . . 10.0 112.63 -179.76 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.74 -13.8 17.24 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.736 -0.603 . . . . 10.0 110.967 169.843 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.38 -158.87 42.23 Favored Glycine 0 N--CA 1.439 -1.11 0 N-CA-C 109.268 -1.533 . . . . 10.0 109.268 169.553 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -49.43 121.29 4.88 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 124.808 1.243 . . . . 10.0 112.635 -168.881 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 72.68 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.96 1.704 . . . . 10.0 108.983 169.232 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 52.8 mt -47.1 -41.27 16.97 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 124.317 1.047 . . . . 10.0 112.139 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.445 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -160.57 156.48 25.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 108.516 -0.92 . . . . 10.0 108.516 -171.351 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.8 p -162.33 168.78 21.68 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 108.897 -0.779 . . . . 10.0 108.897 -176.94 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.82 -175.18 17.75 Favored Glycine 0 N--CA 1.461 0.318 0 N-CA-C 111.229 -0.748 . . . . 10.0 111.229 -176.408 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 53.2 t -118.29 139.71 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 101.52 -3.511 . . . . 10.0 101.52 168.275 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.415 HD11 ' CD1' ' B' ' 117' ' ' LEU . 50.5 mt -59.32 -83.93 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 118.436 0.562 . . . . 10.0 110.33 -171.541 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.2 147.18 20.29 Favored Glycine 0 CA--C 1.52 0.363 0 O-C-N 121.724 -0.61 . . . . 10.0 112.65 178.976 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pt -73.6 154.31 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.393 -1.706 . . . . 10.0 106.393 168.15 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -52.91 6.43 Favored 'General case' 0 CA--C 1.512 -0.487 0 N-CA-C 106.078 -1.823 . . . . 10.0 106.078 169.748 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.252 1.187 0 O-C-N 126.328 2.268 . . . . 10.0 107.966 168.798 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.725 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.0 t -171.41 -43.43 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 124.468 1.107 . . . . 10.0 109.622 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -104.57 147.0 28.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 125.769 1.628 . . . . 10.0 107.639 171.006 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.0 157.96 37.05 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 168.543 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.403 ' CG2' ' HA ' ' B' ' 52' ' ' ASP . 3.5 m -130.16 177.61 6.47 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-O 121.642 0.734 . . . . 10.0 110.447 177.619 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.81 121.3 4.03 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 103.462 -2.792 . . . . 10.0 103.462 166.932 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.97 111.55 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 178.119 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.17 142.3 28.51 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 -171.164 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 mtpt -144.57 162.13 37.39 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 169.995 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.43 -65.75 0.02 OUTLIER Glycine 0 C--O 1.229 -0.198 0 CA-C-N 115.403 -0.817 . . . . 10.0 111.501 171.281 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.44 -45.45 46.33 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 106.597 -1.631 . . . . 10.0 106.597 -173.468 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.29 -65.46 0.59 Allowed Glycine 0 N--CA 1.444 -0.79 0 CA-C-N 113.431 -1.713 . . . . 10.0 110.866 -175.719 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -54.36 -38.97 89.17 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.579 2.186 . . . . 10.0 111.367 173.101 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.4 t -66.87 101.31 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.043 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 172.059 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -118.66 101.9 8.46 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.189 1.396 . . . . 10.0 107.709 171.278 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.875 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -83.89 148.36 24.55 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 125.13 1.348 . . . . 10.0 111.888 174.865 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.433 ' CG2' HG22 ' B' ' 54' ' ' THR . 0.8 OUTLIER -155.45 93.22 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 126.023 1.729 . . . . 10.0 106.463 -168.876 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.0 mm -86.49 151.18 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 C-N-CA 125.113 1.365 . . . . 10.0 109.767 179.045 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.1 m-80 -143.58 59.79 1.39 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.821 0.282 . . . . 10.0 111.725 179.402 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -47.68 120.91 3.63 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 117.559 -1.21 . . . . 10.0 109.417 -175.519 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -111.69 124.53 52.51 Favored 'General case' 0 C--O 1.233 0.2 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 176.506 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.2 tp60 -125.43 85.44 2.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.777 1.231 . . . . 10.0 109.055 172.058 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.15 -43.74 7.24 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 127.007 2.123 . . . . 10.0 112.309 -179.254 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -153.5 173.67 15.41 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 105.95 -1.87 . . . . 10.0 105.95 169.498 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 49.2 m -66.24 -19.55 65.86 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 122.943 0.497 . . . . 10.0 110.694 175.099 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -79.11 -15.54 58.0 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.423 0.689 . . . . 10.0 110.113 175.963 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.55 156.35 33.28 Favored Glycine 0 CA--C 1.532 1.101 0 O-C-N 122.145 -0.347 . . . . 10.0 112.964 -175.14 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -75.68 144.8 28.48 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 N-CA-C 105.727 -2.451 . . . . 10.0 105.727 165.911 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.2 t -78.94 127.17 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.521 -1.659 . . . . 10.0 106.521 179.467 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 mtmt -95.93 110.9 23.03 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.942 -0.762 . . . . 10.0 108.942 172.986 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.0 m -85.05 56.52 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 123.888 0.875 . . . . 10.0 110.788 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -40.24 139.28 0.75 Allowed 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 124.32 1.048 . . . . 10.0 112.947 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.73 131.93 4.52 Favored Glycine 0 N--CA 1.437 -1.258 0 N-CA-C 107.382 -2.287 . . . . 10.0 107.382 168.279 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.1 m -123.68 62.03 1.06 Allowed 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 106.654 -1.61 . . . . 10.0 106.654 172.06 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.875 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.2 pt -78.08 116.58 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.29 -1.004 . . . . 10.0 108.29 -176.541 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -99.37 141.07 32.62 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 107.722 -1.214 . . . . 10.0 107.722 172.537 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.53 -5.86 18.87 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 124.272 0.939 . . . . 10.0 112.211 173.907 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.44 173.2 4.22 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 118.494 1.147 . . . . 10.0 110.143 176.251 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.8 t -106.26 150.36 25.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.839 -1.541 . . . . 10.0 106.839 167.957 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -48.14 147.28 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.795 1.238 . . . . 10.0 110.299 -175.747 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.57 179.8 28.14 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.391 -1.083 . . . . 10.0 110.391 176.198 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.25 153.79 35.73 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.532 1.533 . . . . 10.0 111.404 -172.014 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -145.08 141.61 28.98 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 125.001 1.32 . . . . 10.0 110.535 -179.425 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.41 124.58 7.93 Favored Glycine 0 C--N 1.344 1.024 0 N-CA-C 107.308 -2.317 . . . . 10.0 107.308 166.993 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 57.4 t80 -145.7 118.72 8.79 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 118.851 1.326 . . . . 10.0 109.112 171.989 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -159.22 171.76 19.28 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.287 0.565 . . . . 10.0 110.103 -174.817 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -91.46 148.79 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 CA-C-N 112.757 -2.019 . . . . 10.0 106.972 168.027 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 62.1 m-70 -120.12 139.96 51.79 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.17 -1.789 . . . . 10.0 106.17 173.982 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -47.08 -57.35 5.16 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 124.609 1.193 . . . . 10.0 111.461 -171.872 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.38 136.76 33.33 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 109.559 -0.534 . . . . 10.0 109.559 -177.611 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.38 -8.6 86.93 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.421 -1.072 . . . . 10.0 110.421 167.993 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -47.78 144.63 3.25 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.63 1.205 . . . . 10.0 109.748 169.568 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -148.38 29.43 0.86 Allowed 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 114.585 -1.188 . . . . 10.0 110.393 172.75 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.401 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -58.41 -37.05 74.55 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 122.362 0.265 . . . . 10.0 111.609 -169.142 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.17 -23.51 40.98 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.652 0.781 . . . . 10.0 113.079 173.817 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.89 111.37 1.8 Allowed Glycine 0 CA--C 1.534 1.233 0 N-CA-C 110.178 -1.169 . . . . 10.0 110.178 -169.128 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.3 m 39.35 53.63 2.28 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 127.273 2.229 . . . . 10.0 114.07 170.901 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -156.17 -54.85 0.09 Allowed 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.526 -0.916 . . . . 10.0 108.526 178.569 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 m -61.39 -30.91 70.84 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.825 0.85 . . . . 10.0 112.127 -172.835 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.77 -30.31 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 129.188 2.995 . . . . 10.0 115.463 174.739 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.8 129.16 6.01 Favored Glycine 0 CA--C 1.524 0.633 0 CA-C-O 118.227 -1.318 . . . . 10.0 110.068 169.738 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.407 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 88.2 Cg_endo -73.91 65.92 5.0 Favored 'Trans proline' 0 CA--C 1.535 0.549 0 C-N-CA 124.21 3.273 . . . . 10.0 111.76 179.829 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER 56.9 58.12 4.24 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.236 2.614 . . . . 10.0 109.395 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.407 ' CZ ' ' HD2' ' A' ' 62' ' ' PRO . 42.6 m-85 -68.0 74.39 0.2 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 122.112 0.958 . . . . 10.0 111.695 -179.366 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.463 HD22 ' H ' ' A' ' 65' ' ' ASN . 0.8 OUTLIER -85.73 126.39 66.26 Favored Pre-proline 0 C--N 1.323 -0.551 0 C-N-CA 126.306 1.842 . . . . 10.0 111.18 -178.494 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -68.04 -37.6 14.55 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.986 2.457 . . . . 10.0 110.668 -177.915 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 79.6 mt -76.72 52.47 0.83 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.212 0.605 . . . . 10.0 109.405 171.571 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -41.13 90.34 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 127.568 2.347 . . . . 10.0 113.817 -169.675 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -116.19 -164.0 0.94 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.843 1.257 . . . . 10.0 109.151 -174.592 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -116.18 108.49 16.21 Favored 'General case' 0 C--O 1.224 -0.284 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 -174.699 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.444 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 74.2 t60 -16.27 100.49 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.436 0 C-N-CA 126.11 1.764 . . . . 10.0 113.641 -179.218 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.47 -136.22 7.48 Favored Glycine 0 N--CA 1.449 -0.498 0 N-CA-C 108.022 -2.031 . . . . 10.0 108.022 -177.453 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 176.63 -165.39 35.61 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 108.262 -1.935 . . . . 10.0 108.262 169.195 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -67.64 12.85 0.19 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 121.751 1.634 . . . . 10.0 110.838 168.775 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.8 mmtp -104.52 -19.24 14.07 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 123.883 0.873 . . . . 10.0 108.89 172.286 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -119.7 167.19 12.29 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.375 -1.343 . . . . 10.0 107.375 -172.886 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -87.5 -24.57 24.05 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 172.106 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.313 1.8 pt-20 -107.36 40.95 1.58 Allowed 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 115.882 1.808 . . . . 10.0 115.882 -166.237 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.539 ' H ' ' CD ' ' A' ' 79' ' ' ARG . 0.3 OUTLIER -46.61 145.88 1.72 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.182 -1.372 . . . . 10.0 107.973 166.634 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.444 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 21.6 m170 -54.31 -58.81 5.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 109.276 -0.639 . . . . 10.0 109.276 169.202 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.1 p -168.42 -55.75 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 C-N-CA 124.477 1.111 . . . . 10.0 108.379 175.188 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -127.63 55.1 0.76 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.116 -1.194 . . . . 10.0 110.116 -176.564 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -86.45 97.62 10.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.784 -1.932 . . . . 10.0 105.784 169.433 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.559 ' C ' HD13 ' A' ' 84' ' ' LEU . 1.9 tm? -72.69 -39.91 66.66 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 105.265 -2.124 . . . . 10.0 105.265 171.817 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 106.59 -106.98 2.62 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 109.127 -1.589 . . . . 10.0 109.127 166.99 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -106.72 131.41 53.89 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.301 1.04 . . . . 10.0 110.083 -168.004 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -120.63 129.03 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.325 0.511 . . . . 10.0 109.63 168.426 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.9 t -96.93 132.73 42.41 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 124.328 1.051 . . . . 10.0 109.757 -177.218 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.4 140.09 35.14 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 122.913 0.485 . . . . 10.0 110.759 176.277 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.34 170.68 2.22 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.759 0.824 . . . . 10.0 109.487 168.236 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.27 -23.43 48.31 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 123.65 0.78 . . . . 10.0 113.1 169.689 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -77.18 -8.18 57.11 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 122.773 0.429 . . . . 10.0 111.726 173.932 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.68 18.76 67.39 Favored Glycine 0 C--N 1.34 0.781 0 N-CA-C 110.16 -1.176 . . . . 10.0 110.16 -178.895 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 36.2 t -98.89 110.26 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.627 2.371 . . . . 10.0 106.927 -179.364 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.453 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -101.31 121.82 42.58 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 119.054 0.843 . . . . 10.0 109.202 169.448 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -101.59 78.2 1.82 Allowed 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 128.427 2.691 . . . . 10.0 110.948 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.43 61.34 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 C-N-CA 124.452 1.101 . . . . 10.0 112.311 -169.228 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -90.77 55.63 3.01 Favored 'General case' 0 C--N 1.317 -0.845 0 O-C-N 121.251 -0.905 . . . . 10.0 108.726 -178.447 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.58 145.74 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 108.333 -0.988 . . . . 10.0 108.333 -174.144 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.86 139.54 35.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 126.477 1.911 . . . . 10.0 110.001 178.09 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.73 159.63 41.63 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 108.172 -1.047 . . . . 10.0 108.172 166.334 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 t -124.66 55.81 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 124.444 1.098 . . . . 10.0 109.236 176.976 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -148.66 -41.28 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 123.586 0.754 . . . . 10.0 110.854 175.84 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 49.7 mm -67.13 89.28 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 C-N-CA 124.372 1.069 . . . . 10.0 109.543 170.657 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.8 m -88.44 123.99 33.52 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.615 0.766 . . . . 10.0 109.933 172.509 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.7 mt -48.25 -55.71 9.83 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.108 0.963 . . . . 10.0 111.076 177.237 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.5 p -135.49 175.34 9.68 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 127.271 2.229 . . . . 10.0 107.826 -179.165 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 132.22 -92.55 0.28 Allowed Glycine 0 C--N 1.335 0.493 0 N-CA-C 109.114 -1.595 . . . . 10.0 109.114 176.362 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -125.03 -52.23 1.66 Allowed 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.423 1.889 . . . . 10.0 107.655 179.323 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -74.3 -37.41 63.64 Favored 'General case' 0 N--CA 1.457 -0.116 0 CA-C-N 114.717 -1.129 . . . . 10.0 108.26 -173.518 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t 44.4 65.99 0.95 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.824 1.65 . . . . 10.0 113.024 168.75 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -65.19 -19.18 25.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 113.252 0.834 . . . . 10.0 113.252 -174.161 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.0 mm -48.58 126.02 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 118.336 0.516 . . . . 10.0 109.706 172.653 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.34 1.52 55.68 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.77 -1.016 . . . . 10.0 113.779 -179.094 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.99 176.33 9.25 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 118.757 1.278 . . . . 10.0 109.984 169.179 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -113.13 140.57 47.79 Favored 'General case' 0 C--N 1.34 0.159 0 C-N-CA 124.505 1.122 . . . . 10.0 108.802 169.757 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -98.13 139.49 33.86 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.562 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.6 t -117.76 135.18 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 107.349 -1.352 . . . . 10.0 107.349 170.93 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.39 122.07 55.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 N-CA-C 106.04 -1.837 . . . . 10.0 106.04 167.579 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.2 m-70 -100.44 161.78 13.38 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.92 1.343 . . . . 10.0 114.225 -169.253 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.624 ' HA ' HD22 ' A' ' 144' ' ' LEU . 29.2 tt0 -53.85 -68.8 0.15 Allowed 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.641 2.376 . . . . 10.0 109.107 177.31 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 57.2 mttp -106.92 168.37 9.24 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 123.476 0.71 . . . . 10.0 111.164 -178.125 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.62 142.35 58.46 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.593 1.157 . . . . 10.0 109.528 171.322 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -81.93 144.3 31.04 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.359 0.599 . . . . 10.0 109.902 168.381 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -78.43 7.8 6.07 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.079 0.951 . . . . 10.0 110.972 175.555 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 33.4 mt 49.75 45.62 24.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 124.133 0.973 . . . . 10.0 109.668 -177.835 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.38 -31.46 8.03 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 114.943 -1.026 . . . . 10.0 111.188 174.876 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mtmm -84.23 42.34 0.88 Allowed 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.746 -0.855 . . . . 10.0 110.759 -170.108 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.85 -34.67 6.43 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 126.983 2.23 . . . . 10.0 109.999 176.719 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 58.64 47.9 87.64 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 111.73 -0.548 . . . . 10.0 111.73 -174.402 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -137.49 173.34 11.77 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.1 -1.815 . . . . 10.0 106.1 169.552 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -54.69 -54.05 46.82 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 109.195 -0.669 . . . . 10.0 109.195 173.502 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -58.71 -31.38 68.2 Favored 'General case' 0 C--N 1.344 0.359 0 O-C-N 121.396 -0.815 . . . . 10.0 112.502 179.452 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.3 p -51.18 -34.88 33.54 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 119.646 1.112 . . . . 10.0 110.461 178.276 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.3 t -98.34 11.13 39.02 Favored 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 113.549 0.944 . . . . 10.0 113.549 -179.793 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 73.3 mmtt -120.36 -54.67 2.08 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 125.299 1.44 . . . . 10.0 111.153 179.617 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -131.95 9.59 4.54 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 113.388 0.884 . . . . 10.0 113.388 171.92 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.14 16.18 61.32 Favored Glycine 0 C--O 1.221 -0.707 0 CA-C-O 119.216 -0.769 . . . . 10.0 113.366 173.063 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 69.36 17.75 8.1 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.188 0.994 . . . . 10.0 112.525 -177.121 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.08 -14.42 54.47 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 123.317 0.647 . . . . 10.0 112.005 176.553 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.87 -147.04 30.25 Favored Glycine 0 N--CA 1.442 -0.937 0 N-CA-C 109.816 -1.313 . . . . 10.0 109.816 169.848 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.3 m -61.07 121.31 12.14 Favored 'General case' 0 N--CA 1.444 -0.769 0 O-C-N 122.1 -0.647 . . . . 10.0 110.764 -168.74 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -56.24 71.25 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.866 1.666 . . . . 10.0 110.711 167.335 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.624 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.0 tp -45.91 -41.38 11.38 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 127.181 2.192 . . . . 10.0 112.925 -171.475 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.93 155.46 31.4 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.177 -1.046 . . . . 10.0 108.177 -175.78 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.1 p -164.12 170.85 15.89 Favored 'General case' 0 N--CA 1.454 -0.253 0 O-C-N 122.01 -0.431 . . . . 10.0 110.095 -176.705 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -166.95 -176.69 38.14 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.705 -1.358 . . . . 10.0 109.705 -177.629 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.89 143.28 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -169.717 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 61.0 mt -73.55 137.4 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 122.784 0.434 . . . . 10.0 110.536 -176.405 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.72 141.59 12.77 Favored Glycine 0 CA--C 1.529 0.906 0 C-N-CA 125.306 1.432 . . . . 10.0 111.272 -178.537 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 42.5 mt -57.05 139.04 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 125.212 1.405 . . . . 10.0 108.603 170.943 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.504 ' HB2' ' HB3' ' B' ' 52' ' ' ASP . . . -136.57 156.67 48.26 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.318 0.58 . . . . 10.0 109.887 172.032 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.287 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 165.667 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.68 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -14.68 60.79 Favored 'General case' 0 CA--C 1.527 0.062 0 CA-C-N 118.857 0.753 . . . . 10.0 110.679 176.439 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 45.4 tttt -151.4 148.26 27.9 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.723 -0.473 . . . . 10.0 109.723 169.528 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.73 165.97 25.85 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.295 1.438 . . . . 10.0 107.501 169.543 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.61 164.06 35.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 123.426 0.69 . . . . 10.0 109.168 176.039 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.15 111.63 10.47 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 169.238 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.1 m -86.88 100.5 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 169.95 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.403 HD22 HG13 ' B' ' 119' ' ' VAL . 10.3 mt -78.83 134.37 36.97 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 123.912 0.885 . . . . 10.0 109.423 176.348 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -158.6 162.19 37.31 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 169.302 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.5 -56.85 0.05 OUTLIER Glycine 0 N--CA 1.454 -0.125 0 N-CA-C 111.485 -0.646 . . . . 10.0 111.485 171.205 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.37 -45.72 45.13 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.486 -1.672 . . . . 10.0 106.486 -170.923 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.4 -65.92 0.57 Allowed Glycine 0 CA--C 1.526 0.753 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.734 -179.141 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -58.33 -36.8 97.26 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.913 2.409 . . . . 10.0 111.236 173.685 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.7 113.57 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.378 -0.971 . . . . 10.0 108.378 175.788 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.31 126.28 31.07 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.202 -1.036 . . . . 10.0 108.202 168.581 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.672 ' HA3' HG22 ' B' ' 35' ' ' ILE . . . -120.44 140.76 14.65 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-O 119.428 -0.651 . . . . 10.0 111.696 176.582 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.401 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 10.6 mt -135.37 75.24 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 -169.276 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.2 mm -92.25 139.65 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.819 -0.628 . . . . 10.0 110.023 -174.293 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -114.62 120.94 41.87 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 128.419 2.688 . . . . 10.0 108.02 -178.104 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.9 105.56 14.41 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.315 1.446 . . . . 10.0 107.576 178.838 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -100.57 150.54 22.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 118.414 0.552 . . . . 10.0 111.122 178.277 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 63.8 tp60 -142.24 102.31 4.08 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.7 2.0 . . . . 10.0 108.264 -179.057 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp . . . . . 0 N--CA 1.438 -1.069 0 C-N-CA 126.228 1.811 . . . . 10.0 110.879 -172.546 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.184 0 N-CA-C 111.943 -0.463 . . . . 10.0 111.943 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.18 154.34 61.94 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.418 2.079 . . . . 10.0 108.081 168.867 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 t -79.01 92.04 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 104.753 -2.314 . . . . 10.0 104.753 169.172 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 35.3 tttp -77.17 104.03 7.44 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 106.832 -1.544 . . . . 10.0 106.832 169.042 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -96.42 104.41 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 C-N-CA 126.566 1.946 . . . . 10.0 106.539 -179.352 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -122.24 163.03 20.33 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 112.693 0.627 . . . . 10.0 112.693 174.278 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.66 -154.15 25.33 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 106.866 -2.494 . . . . 10.0 106.866 169.666 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -155.14 160.55 41.02 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 120.134 -0.626 . . . . 10.0 110.198 176.705 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.672 HG22 ' HA3' ' B' ' 16' ' ' GLY . 1.8 pt -117.43 142.47 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.683 0 CA-C-N 114.262 -1.335 . . . . 10.0 109.557 167.475 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -117.35 149.54 40.32 Favored 'General case' 0 N--CA 1.443 -0.776 0 N-CA-C 106.864 -1.532 . . . . 10.0 106.864 168.385 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.04 -8.36 33.4 Favored Glycine 0 C--N 1.336 0.564 0 CA-C-O 119.34 -0.7 . . . . 10.0 112.731 171.395 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -62.15 175.36 0.73 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.198 0.999 . . . . 10.0 109.246 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.79 166.26 10.58 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 167.351 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -54.48 149.93 9.78 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.25 0.62 . . . . 10.0 111.469 -172.097 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.75 -168.6 31.81 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-O 121.763 0.646 . . . . 10.0 112.838 168.971 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.3 mp -75.26 144.8 42.37 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 126.824 2.05 . . . . 10.0 111.787 -169.652 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -147.85 145.08 28.57 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 113.813 1.042 . . . . 10.0 113.813 -177.322 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.637 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -28.22 128.41 0.07 OUTLIER Glycine 0 C--N 1.341 0.835 0 C-N-CA 127.284 2.373 . . . . 10.0 111.288 165.606 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -151.37 102.15 2.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 119.144 1.472 . . . . 10.0 111.675 169.861 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.446 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -150.57 170.07 20.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.764 0.653 . . . . 10.0 112.764 -179.83 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 24.2 m -97.4 -30.27 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 126.244 1.817 . . . . 10.0 113.986 -170.766 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 57.3 m-70 58.03 171.82 0.05 Allowed 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 122.905 1.336 . . . . 10.0 112.989 -177.571 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -83.25 -51.56 7.35 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 114.779 -1.101 . . . . 10.0 110.037 170.327 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -75.95 114.0 14.08 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 118.628 0.649 . . . . 10.0 109.669 -168.019 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.23 -31.71 81.75 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 107.824 -2.111 . . . . 10.0 107.824 165.792 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.504 ' HB3' ' HB2' ' A' ' 152' ' ' ALA . 1.7 p30 -58.82 161.46 4.83 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-O 123.251 1.5 . . . . 10.0 114.423 -176.551 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.14 21.68 0.08 Allowed 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 112.941 -1.936 . . . . 10.0 113.962 -168.128 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.433 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -58.31 -29.24 65.74 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 123.816 0.847 . . . . 10.0 111.75 -179.562 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.13 -15.95 59.35 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 122.909 0.484 . . . . 10.0 111.796 176.599 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.77 85.43 0.81 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 124.356 0.979 . . . . 10.0 111.049 178.521 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 65.5 m 37.6 47.53 0.8 Allowed 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 126.946 2.098 . . . . 10.0 112.146 -179.952 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -121.85 -54.89 1.92 Allowed 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 -169.659 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.0 t -128.34 54.81 1.72 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.021 0.928 . . . . 10.0 108.763 -177.472 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.02 49.97 0.45 Allowed 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 123.14 0.576 . . . . 10.0 110.399 172.149 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.0 125.92 0.13 Allowed Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.272 0.939 . . . . 10.0 111.448 172.346 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -77.46 47.39 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.86 0 C-N-CA 123.374 2.716 . . . . 10.0 112.605 179.607 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 60.76 47.79 7.64 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.931 2.492 . . . . 10.0 110.996 178.059 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -70.74 70.28 0.47 Allowed 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.886 0.85 . . . . 10.0 110.778 174.602 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 65' ' ' ASN . . . . . 0.414 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 4.9 p-10 -71.62 148.56 92.88 Favored Pre-proline 0 C--N 1.325 -0.467 0 C-N-CA 123.388 0.675 . . . . 10.0 112.709 -174.17 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -64.52 -46.61 6.93 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.975 2.45 . . . . 10.0 111.522 -179.722 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -78.89 48.9 0.87 Allowed 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.538 -0.726 . . . . 10.0 110.002 178.553 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 64.1 p -14.94 102.93 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 129.711 3.204 . . . . 10.0 113.466 -170.209 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 mtt85 -137.07 -179.77 5.91 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 118.612 0.642 . . . . 10.0 112.635 -170.635 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -111.79 102.09 10.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 105.753 -1.943 . . . . 10.0 105.753 -176.836 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.462 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.5 t60 -22.66 107.51 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.455 1.902 . . . . 10.0 114.185 -171.274 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.03 -149.55 8.38 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.964 -1.255 . . . . 10.0 109.964 176.652 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.96 -162.66 22.65 Favored Glycine 0 C--N 1.331 0.301 0 N-CA-C 108.51 -1.836 . . . . 10.0 108.51 -179.316 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -64.94 -6.69 13.26 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 121.367 1.378 . . . . 10.0 109.797 165.551 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 30.2 mmtt -101.89 2.43 38.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.82 1.648 . . . . 10.0 110.099 177.35 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 128' ' ' LYS . 3.7 t70 -129.32 170.98 12.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 N-CA-C 107.498 -1.297 . . . . 10.0 107.498 167.399 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -91.59 -27.17 18.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.426 -0.953 . . . . 10.0 108.426 169.186 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -102.89 39.3 1.57 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 122.831 1.301 . . . . 10.0 110.206 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.7 ptp180 -55.89 142.3 35.86 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 126.057 1.743 . . . . 10.0 108.941 169.664 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.462 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.0 m170 -64.98 -56.74 11.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 O-C-N 121.855 -0.528 . . . . 10.0 110.237 -175.181 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.515 HG13 ' H ' ' B' ' 82' ' ' GLY . 3.6 p -170.37 -68.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.992 -0.744 . . . . 10.0 108.992 176.908 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.515 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -118.2 67.91 0.34 Allowed Glycine 0 C--N 1.333 0.413 0 N-CA-C 107.522 -2.231 . . . . 10.0 107.522 -179.41 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -106.79 97.65 7.41 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.322 -2.473 . . . . 10.0 104.322 172.407 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 23.9 mt -82.09 22.94 0.75 Allowed 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.235 0.541 . . . . 10.0 110.56 -173.612 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.85 -104.85 2.36 Favored Glycine 0 N--CA 1.437 -1.287 0 N-CA-C 106.422 -2.671 . . . . 10.0 106.422 173.596 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -157.64 151.28 23.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.726 -1.213 . . . . 10.0 107.726 169.704 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.0 m -113.9 137.25 47.73 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 O-C-N 123.835 0.709 . . . . 10.0 109.547 -175.032 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 88.7 m -94.89 109.35 21.36 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 128.364 2.666 . . . . 10.0 108.491 -171.975 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.25 136.49 32.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 122.904 0.482 . . . . 10.0 110.205 174.845 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -57.56 171.51 0.44 Allowed 'General case' 0 C--O 1.235 0.298 0 O-C-N 124.079 0.862 . . . . 10.0 108.841 166.323 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 58.3 pttt -57.45 -29.04 63.87 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 123.541 0.736 . . . . 10.0 110.508 175.524 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -79.13 -0.64 32.54 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.785 0.834 . . . . 10.0 111.051 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.19 4.69 88.05 Favored Glycine 0 C--N 1.339 0.736 0 O-C-N 120.99 -1.069 . . . . 10.0 110.79 179.644 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.66 97.3 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 C-N-CA 126.128 1.771 . . . . 10.0 107.52 -178.008 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.461 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.72 118.83 37.75 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 108.367 -0.975 . . . . 10.0 108.367 169.192 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -82.15 129.13 34.74 Favored 'General case' 0 N--CA 1.437 -1.124 0 C-N-CA 126.856 2.062 . . . . 10.0 109.9 174.633 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.17 134.06 58.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 C-N-CA 125.907 1.683 . . . . 10.0 107.769 173.962 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 13.7 p -158.44 57.44 0.45 Allowed 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 112.804 0.668 . . . . 10.0 112.804 171.791 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.86 155.76 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.921 -0.77 . . . . 10.0 108.921 -172.075 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -116.47 99.25 7.05 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 126.546 1.938 . . . . 10.0 110.38 174.358 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -81.72 85.42 6.6 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.626 -1.249 . . . . 10.0 107.626 176.417 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 64.7 p -83.15 60.51 5.56 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 106.315 -1.735 . . . . 10.0 106.315 173.168 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.84 -47.77 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 O-C-N 123.356 0.41 . . . . 10.0 110.273 -170.9 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.325 0.0 OUTLIER -103.42 176.87 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 C-N-CA 123.74 0.816 . . . . 10.0 112.033 169.378 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -140.7 123.98 16.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.49 -29.57 50.51 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.358 1.463 . . . . 10.0 111.318 -179.031 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.4 m . . . . . 0 N--CA 1.452 -0.373 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 167.23 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.448 -0.529 0 CA-C-O 121.186 0.517 . . . . 10.0 111.818 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.95 20.17 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 124.796 1.238 . . . . 10.0 114.291 -174.477 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 17.9 mm -54.92 146.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 C-N-CA 125.538 1.535 . . . . 10.0 108.085 168.745 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.91 21.99 69.98 Favored Glycine 0 CA--C 1.533 1.169 0 CA-C-O 118.599 -1.111 . . . . 10.0 114.335 178.278 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.2 mmt180 -97.53 172.55 7.66 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 166.513 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -124.22 108.54 12.38 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.082 0.855 . . . . 10.0 111.454 -170.529 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.418 HD21 HD11 ' B' ' 149' ' ' ILE . 3.7 mm? -64.89 134.21 53.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 107.344 -1.354 . . . . 10.0 107.344 169.743 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.6 t -125.11 131.37 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 106.83 -1.544 . . . . 10.0 106.83 174.747 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.403 HG13 HD22 ' B' ' 8' ' ' LEU . 2.4 m -105.99 131.52 55.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 O-C-N 124.007 0.817 . . . . 10.0 110.084 169.466 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.637 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.3 m170 -113.04 163.5 14.62 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 114.813 1.412 . . . . 10.0 114.813 -170.583 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -51.31 -55.51 17.94 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 127.172 2.189 . . . . 10.0 109.468 -179.393 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -121.05 174.27 6.75 Favored 'General case' 0 CA--C 1.521 -0.154 0 C-N-CA 124.366 1.066 . . . . 10.0 112.228 -171.155 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.6 151.65 30.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.857 1.263 . . . . 10.0 110.06 -179.835 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.446 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -78.37 153.68 31.42 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 123.773 0.829 . . . . 10.0 111.799 175.733 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -76.31 -27.98 56.77 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 114.897 -1.047 . . . . 10.0 109.4 168.742 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 68.9 mt 59.52 52.04 6.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 123.669 1.7 . . . . 10.0 108.524 -172.8 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.65 -41.53 2.84 Favored Glycine 0 N--CA 1.443 -0.852 0 CA-C-N 111.655 -2.52 . . . . 10.0 111.489 169.171 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 19.1 mtmm -79.26 41.44 0.46 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.34 1.456 . . . . 10.0 112.47 -170.863 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.46 -15.73 34.07 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 126.653 2.073 . . . . 10.0 110.497 169.332 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.34 46.69 51.93 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 124.393 0.997 . . . . 10.0 111.951 -179.309 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.5 p30 -151.07 172.83 15.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 118.249 1.024 . . . . 10.0 109.883 176.216 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.3 tm-20 -55.18 -41.02 71.37 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.697 1.199 . . . . 10.0 110.915 -176.689 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 19.0 tp10 -71.42 -39.07 71.31 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 121.681 -0.637 . . . . 10.0 110.587 174.121 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.5 p -52.24 -43.92 64.56 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 118.451 0.569 . . . . 10.0 110.57 -176.376 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.3 t -74.92 -10.53 59.58 Favored 'General case' 0 CA--C 1.543 0.703 0 O-C-N 124.332 1.02 . . . . 10.0 113.058 -177.216 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.6 ttmt -115.21 -64.64 1.29 Allowed 'General case' 0 N--CA 1.436 -1.131 0 C-N-CA 126.973 2.109 . . . . 10.0 112.899 -168.878 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.5 p -126.46 17.01 7.63 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 120.048 1.295 . . . . 10.0 110.208 175.939 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.53 -105.7 1.91 Allowed Glycine 0 C--N 1.339 0.744 0 N-CA-C 106.952 -2.459 . . . . 10.0 106.952 -173.877 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -152.52 39.38 0.56 Allowed 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 170.009 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.22 -26.32 64.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.231 -0.895 . . . . 10.0 111.144 -177.03 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.48 -142.61 23.0 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 124.876 1.226 . . . . 10.0 110.379 170.707 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -69.16 134.96 49.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 -175.82 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 143' ' ' ARG . . . . . 0.401 ' NE ' ' H ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -63.07 120.84 12.21 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 106.414 -1.698 . . . . 10.0 106.414 167.758 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 31.9 mt -76.65 -60.43 2.35 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 169.547 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -139.18 163.17 33.14 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 122.974 0.51 . . . . 10.0 110.104 -174.03 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -154.15 163.71 39.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.353 -0.385 . . . . 10.0 110.443 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.33 149.1 18.22 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 109.418 -1.473 . . . . 10.0 109.418 -171.624 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -108.67 139.65 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 C-N-CA 124.916 1.286 . . . . 10.0 108.041 -169.065 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.418 HD11 HD21 ' B' ' 117' ' ' LEU . 19.0 mt -77.5 112.32 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 122.916 0.486 . . . . 10.0 109.966 -173.455 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.75 143.54 18.09 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.808 1.194 . . . . 10.0 112.21 -174.451 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.49 136.34 25.81 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.296 0 C-N-CA 126.315 1.846 . . . . 10.0 110.333 -175.758 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.74 -46.78 1.98 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.681 0.673 . . . . 10.0 111.759 177.821 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 . . . . . 0 C--O 1.25 1.103 0 CA-C-O 116.368 -1.777 . . . . 10.0 112.107 -169.443 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 108.411 -0.959 . . . . 10.0 108.411 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -80.06 -21.52 43.33 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.948 -1.13 . . . . 10.0 107.948 168.144 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.494 ' HZ3' ' C ' ' A' ' 153' ' ' GLN . 1.8 ttmp? -127.04 161.5 28.24 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.763 1.625 . . . . 10.0 107.868 179.078 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.24 164.28 38.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.435 -1.691 . . . . 10.0 106.435 168.337 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.41 ' O ' HG23 ' A' ' 149' ' ' ILE . 2.5 m -125.76 -179.9 2.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 118.08 0.4 . . . . 10.0 110.094 -179.429 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.71 108.37 2.9 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.852 -0.795 . . . . 10.0 108.852 165.207 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.47 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.3 m -92.91 115.53 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 171.282 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.7 mt -103.85 150.32 24.25 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.751 1.221 . . . . 10.0 109.224 -179.801 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.6 ttmt -163.12 159.83 23.57 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.721 1.146 . . . . 10.0 109.204 169.836 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.42 -56.35 0.02 OUTLIER Glycine 0 C--O 1.229 -0.197 0 N-CA-C 111.349 -0.7 . . . . 10.0 111.349 169.977 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -75.25 -45.85 37.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 106.575 -1.639 . . . . 10.0 106.575 -172.825 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.5 -64.85 0.6 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 113.859 -1.519 . . . . 10.0 110.902 -178.413 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -58.3 -41.29 67.86 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 122.512 2.142 . . . . 10.0 110.839 172.08 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -70.43 105.38 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.427 -1.694 . . . . 10.0 106.427 176.361 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.81 131.93 46.34 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.766 -0.827 . . . . 10.0 108.766 167.296 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.938 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -99.39 147.52 18.39 Favored Glycine 0 N--CA 1.441 -1.005 0 N-CA-C 109.658 -1.377 . . . . 10.0 109.658 174.988 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.624 HG22 HG23 ' B' ' 54' ' ' THR . 1.0 OUTLIER -150.81 81.8 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 105.355 -2.091 . . . . 10.0 105.355 -170.422 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -100.51 146.33 9.41 Favored 'Isoleucine or valine' 0 C--N 1.338 0.1 0 C-N-CA 125.091 1.356 . . . . 10.0 109.738 -178.283 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -126.0 117.15 22.65 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 127.502 2.321 . . . . 10.0 109.005 170.172 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -98.41 116.86 31.53 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 106.817 -1.549 . . . . 10.0 106.817 173.269 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -116.62 138.5 51.39 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 119.476 1.034 . . . . 10.0 112.948 171.18 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -114.35 85.37 2.22 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.728 2.011 . . . . 10.0 107.966 -178.176 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.42 ' NZ ' ' OE2' ' A' ' 100' ' ' GLU . 0.0 OUTLIER -46.07 -44.09 15.14 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.711 1.605 . . . . 10.0 111.366 -172.643 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -142.95 168.46 19.65 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 102.989 -2.967 . . . . 10.0 102.989 165.534 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.0 t -61.71 -29.17 69.93 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 174.525 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -81.09 -17.52 49.73 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 124.397 1.079 . . . . 10.0 110.783 -179.225 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.41 141.97 16.48 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 110.446 -1.062 . . . . 10.0 110.446 -171.174 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -63.55 136.48 54.6 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.078 1.852 . . . . 10.0 109.221 174.872 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.6 m -78.03 124.39 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -176.458 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 37.7 ttmt -88.11 116.48 26.33 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.759 -2.682 . . . . 10.0 103.759 167.591 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -97.51 104.19 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 171.258 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 21.2 p90 -112.88 167.65 10.33 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 116.129 -0.487 . . . . 10.0 110.086 176.473 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.36 176.15 42.51 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.878 -1.153 . . . . 10.0 111.688 178.33 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.6 t -144.84 99.17 3.3 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 107.775 -1.194 . . . . 10.0 107.775 177.252 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.938 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.4 pt -80.57 153.61 4.39 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.584 -1.265 . . . . 10.0 107.584 168.4 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.68 151.06 50.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 124.062 0.851 . . . . 10.0 109.085 167.83 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.65 -8.91 34.73 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.967 0.794 . . . . 10.0 113.541 175.443 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -61.06 176.27 0.44 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 122.301 1.048 . . . . 10.0 111.188 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -107.4 151.38 25.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 106.579 -1.638 . . . . 10.0 106.579 166.999 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -49.44 144.19 5.87 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.244 1.017 . . . . 10.0 111.717 -169.826 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.83 -168.01 21.18 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 123.685 0.659 . . . . 10.0 112.203 172.751 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -75.81 148.75 38.19 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.842 2.057 . . . . 10.0 111.768 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -147.6 134.24 19.9 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.477 1.111 . . . . 10.0 111.472 179.344 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.402 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -38.23 123.61 1.33 Allowed Glycine 0 C--N 1.345 1.076 0 C-N-CA 124.843 1.211 . . . . 10.0 111.02 168.337 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.516 ' HZ ' HG21 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -136.75 108.64 7.1 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 124.133 0.973 . . . . 10.0 109.37 176.397 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -155.57 174.4 15.32 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 121.788 0.804 . . . . 10.0 111.712 -178.101 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.7 m -102.35 144.65 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 CA-C-N 111.798 -2.456 . . . . 10.0 106.369 168.214 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -121.66 148.07 45.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 107.246 -1.39 . . . . 10.0 107.246 176.543 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.409 ' HB3' ' CE1' ' A' ' 64' ' ' PHE . 2.3 tp10 -59.43 -39.32 83.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 122.854 0.462 . . . . 10.0 112.213 -169.963 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -74.76 153.23 38.9 Favored 'General case' 0 CA--C 1.527 0.079 0 C-N-CA 118.358 -1.337 . . . . 10.0 109.561 177.205 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.58 -11.84 46.3 Favored Glycine 0 CA--C 1.54 1.602 0 N-CA-C 109.385 -1.486 . . . . 10.0 109.385 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -48.2 107.13 0.11 Allowed 'General case' 0 C--N 1.344 0.357 0 C-N-CA 126.653 1.981 . . . . 10.0 112.382 172.658 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -112.68 6.44 18.23 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 113.268 -1.787 . . . . 10.0 109.34 168.015 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.408 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -57.8 -39.92 78.7 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.254 1.021 . . . . 10.0 109.456 -178.91 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.5 -15.52 58.51 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.053 0.941 . . . . 10.0 112.699 177.622 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.48 -108.08 3.06 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 108.736 -1.746 . . . . 10.0 108.736 -173.13 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 60.9 m -131.0 43.7 3.06 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 124.307 1.043 . . . . 10.0 109.43 -173.215 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 55.3 m -130.18 -54.24 1.11 Allowed 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 125.796 1.638 . . . . 10.0 107.141 -171.748 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.9 t -80.75 4.61 18.36 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.265 0.555 . . . . 10.0 111.663 178.445 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.54 -25.87 7.52 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.871 1.268 . . . . 10.0 112.415 173.137 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.42 144.99 18.26 Favored Glycine 0 C--N 1.339 0.742 0 N-CA-C 110.576 -1.01 . . . . 10.0 110.576 173.984 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -80.07 57.74 6.65 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 CA-C-N 120.584 2.192 . . . . 10.0 111.399 179.649 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 71.77 -62.27 0.46 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 127.122 2.169 . . . . 10.0 108.211 -175.685 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.409 ' CE1' ' HB3' ' A' ' 49' ' ' GLU 0.343 3.1 p90 34.28 36.72 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 129.998 3.319 . . . . 10.0 116.85 174.635 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -45.29 152.24 0.64 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 129.837 3.255 . . . . 10.0 113.287 167.78 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -74.17 -48.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.493 2.795 . . . . 10.0 111.29 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 81.7 mt -68.82 83.44 0.3 Allowed 'General case' 0 C--N 1.339 0.145 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 172.839 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.7 p -69.54 64.65 0.18 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 126.628 1.971 . . . . 10.0 113.982 -169.358 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -87.73 -178.75 6.14 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.575 1.95 . . . . 10.0 109.779 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -111.43 84.98 2.04 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.188 0.518 . . . . 10.0 112.205 -169.356 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.451 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 64.8 t60 11.14 87.3 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 128.009 2.524 . . . . 10.0 114.627 175.791 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.26 -161.44 18.33 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 108.681 -1.767 . . . . 10.0 108.681 174.923 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.17 -155.88 6.73 Favored Glycine 0 C--O 1.224 -0.495 0 CA-C-O 117.671 -1.627 . . . . 10.0 110.512 170.106 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -64.91 -2.05 5.01 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 CA-C-N 120.756 2.278 . . . . 10.0 111.27 171.139 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 29.3 mtpt -88.41 -17.6 30.14 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.245 -0.884 . . . . 10.0 110.801 172.977 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -128.98 174.83 9.17 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 118.812 0.733 . . . . 10.0 109.482 -175.831 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -97.51 -15.05 20.73 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.707 0.803 . . . . 10.0 109.505 168.539 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 70.5 mm-40 -79.69 10.74 3.7 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.145 1.378 . . . . 10.0 112.78 178.712 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 16.4 ptt180 -51.65 127.56 20.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 166.995 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.451 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 21.3 m170 -65.7 -51.1 62.03 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 122.11 -0.369 . . . . 10.0 111.512 -169.982 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.6 p -166.94 -30.29 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 123.026 0.531 . . . . 10.0 111.804 -169.626 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.69 70.97 0.08 OUTLIER Glycine 0 C--N 1.334 0.442 0 N-CA-C 106.199 -2.761 . . . . 10.0 106.199 -176.557 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -116.58 91.11 3.49 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 -169.554 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp -72.86 -28.83 62.75 Favored 'General case' 0 CA--C 1.527 0.09 0 N-CA-C 107.314 -1.365 . . . . 10.0 107.314 -178.151 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.53 -87.78 0.77 Allowed Glycine 0 N--CA 1.44 -1.04 0 N-CA-C 106.493 -2.643 . . . . 10.0 106.493 172.12 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -140.98 149.38 41.71 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 122.884 0.473 . . . . 10.0 111.902 -176.414 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -129.32 143.41 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 105.506 -2.035 . . . . 10.0 105.506 168.093 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -95.48 121.58 37.31 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.357 1.863 . . . . 10.0 107.521 -176.285 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.14 137.4 32.37 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.721 -0.474 . . . . 10.0 109.721 171.208 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -67.5 173.25 4.25 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 126.193 1.797 . . . . 10.0 109.786 168.966 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -56.68 -24.36 48.28 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 124.75 1.22 . . . . 10.0 112.274 177.825 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -78.24 -17.61 56.48 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.092 -0.336 . . . . 10.0 110.092 179.527 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.28 7.74 69.39 Favored Glycine 0 C--N 1.338 0.647 0 N-CA-C 110.525 -1.03 . . . . 10.0 110.525 -171.86 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -80.7 119.54 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 N-CA-C 106.714 -1.587 . . . . 10.0 106.714 172.938 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.568 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -113.94 118.78 35.14 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 119.11 0.868 . . . . 10.0 108.691 169.482 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -79.2 117.35 20.14 Favored 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 126.366 1.866 . . . . 10.0 108.096 174.345 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 46.5 t -105.93 131.39 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 178.537 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 80.0 p -157.77 71.75 0.63 Allowed 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.735 0.814 . . . . 10.0 109.579 173.069 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.58 155.0 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 106.92 -1.511 . . . . 10.0 106.92 177.456 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.42 ' OE2' ' NZ ' ' A' ' 23' ' ' LYS . 26.3 tt0 -135.95 128.18 30.02 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 124.914 1.286 . . . . 10.0 108.276 174.742 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -136.7 152.8 50.78 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 124.046 0.842 . . . . 10.0 109.814 -177.601 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.4 p -118.68 48.75 1.39 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 127.484 2.314 . . . . 10.0 109.875 -171.068 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 14.6 p -155.34 -49.37 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 122.295 0.238 . . . . 10.0 110.655 173.002 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.99 119.48 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.663 -1.606 . . . . 10.0 106.663 170.617 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.09 85.79 2.3 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -176.038 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.2 pp -51.9 -10.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.603 1.561 . . . . 10.0 114.294 -177.961 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 24.9 t -148.36 137.01 21.55 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 103.953 -2.61 . . . . 10.0 103.953 168.862 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.78 -72.41 0.39 Allowed Glycine 0 C--N 1.334 0.421 0 N-CA-C 109.846 -1.301 . . . . 10.0 109.846 -176.526 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.45 -53.37 0.08 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 179.75 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -83.7 48.25 1.4 Allowed 'General case' 0 C--O 1.233 0.199 0 N-CA-C 109.269 -0.641 . . . . 10.0 109.269 -176.773 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.7 t -73.64 72.22 1.44 Allowed 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.072 1.349 . . . . 10.0 107.615 178.019 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.8 pt -72.2 39.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 126.251 1.821 . . . . 10.0 112.058 -177.996 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 44.2 mm -66.58 -47.5 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 125.246 1.418 . . . . 10.0 109.456 -178.445 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.77 51.3 3.74 Favored Glycine 0 CA--C 1.525 0.691 0 O-C-N 121.622 -0.674 . . . . 10.0 113.408 -175.053 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.29 145.81 46.72 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 -177.783 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 28.3 m -90.21 119.62 30.68 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 104.902 -2.259 . . . . 10.0 104.902 169.924 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.21 143.14 31.66 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -179.453 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 55.3 t -129.81 136.29 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 O-C-N 124.321 1.013 . . . . 10.0 109.405 -169.528 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.563 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.4 OUTLIER -105.96 119.32 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 N-CA-C 105.067 -2.198 . . . . 10.0 105.067 168.603 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.402 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 13.1 m-70 -99.19 161.45 13.62 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 113.823 1.045 . . . . 10.0 113.823 -169.563 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.609 ' HA ' HD22 ' A' ' 144' ' ' LEU . 0.5 OUTLIER -64.77 -53.06 53.03 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.685 -1.143 . . . . 10.0 108.483 -176.92 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -113.12 176.64 4.93 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.902 0.858 . . . . 10.0 111.987 -178.462 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.89 135.99 50.14 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.067 1.347 . . . . 10.0 111.19 -178.495 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -77.49 110.13 12.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 124.491 1.116 . . . . 10.0 108.507 173.757 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -80.36 58.41 3.11 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 123.196 0.31 . . . . 10.0 111.284 -179.379 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt -11.86 81.49 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 129.346 3.058 . . . . 10.0 115.384 -177.797 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 75.61 -7.48 25.76 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.927 -0.929 . . . . 10.0 113.812 168.779 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.7 pttp -116.03 27.34 9.33 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 118.4 1.1 . . . . 10.0 112.316 -174.458 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.23 -18.26 79.76 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.437 1.018 . . . . 10.0 111.273 170.662 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.83 44.33 98.01 Favored Glycine 0 CA--C 1.53 0.971 0 O-C-N 121.655 -0.909 . . . . 10.0 112.138 173.007 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.45 ' H ' ' HB2' ' A' ' 134' ' ' SER . 7.3 p30 -164.15 175.81 9.84 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 126.272 1.829 . . . . 10.0 106.821 177.913 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -56.0 -42.09 75.88 Favored 'General case' 0 N--CA 1.439 -1.023 0 CA-C-N 119.014 0.824 . . . . 10.0 111.906 -174.593 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -61.03 -28.79 69.31 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.813 -0.554 . . . . 10.0 110.179 -179.823 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.45 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 3.4 t -47.92 -46.02 31.43 Favored 'General case' 0 CA--C 1.519 -0.243 0 C-N-CA 124.228 1.011 . . . . 10.0 109.219 176.243 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -90.73 8.46 34.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 112.59 0.589 . . . . 10.0 112.59 -175.859 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.97 -81.19 0.63 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.045 1.338 . . . . 10.0 110.565 -178.918 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.1 29.45 7.88 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 121.735 2.061 . . . . 10.0 111.537 174.091 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.95 -87.34 0.13 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 125.35 1.453 . . . . 10.0 110.823 179.012 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -165.64 33.24 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 122.115 -0.638 . . . . 10.0 112.211 170.627 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.13 -13.42 61.94 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.586 0.587 . . . . 10.0 112.586 -174.014 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.61 -147.57 45.49 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.217 -1.953 . . . . 10.0 108.217 174.223 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -58.56 120.44 8.86 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 122.729 0.412 . . . . 10.0 111.765 -169.54 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.65 73.68 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.488 1.515 . . . . 10.0 111.623 168.04 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.609 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.7 tp -38.45 -49.74 1.49 Allowed 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.139 2.176 . . . . 10.0 113.894 -179.883 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.563 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -156.01 158.09 37.27 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -170.856 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 20.0 p -164.35 171.82 14.3 Favored 'General case' 0 N--CA 1.454 -0.247 0 O-C-N 121.759 -0.588 . . . . 10.0 111.222 -171.866 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -172.65 -161.39 23.0 Favored Glycine 0 N--CA 1.451 -0.334 0 N-CA-C 110.224 -1.15 . . . . 10.0 110.224 -178.894 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -133.0 154.66 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.392 -2.077 . . . . 10.0 105.392 -172.891 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.41 HG23 ' O ' ' A' ' 5' ' ' VAL . 2.8 mt -69.17 -85.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 123.613 0.765 . . . . 10.0 110.147 -169.301 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.54 132.92 7.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.151 -0.779 . . . . 10.0 111.151 179.645 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 58.1 mt -68.51 145.31 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 123.435 0.694 . . . . 10.0 110.069 -179.262 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.89 176.27 8.86 Favored 'General case' 0 N--CA 1.442 -0.856 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 164.732 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 153' ' ' GLN . . . . . 0.494 ' C ' ' HZ3' ' A' ' 3' ' ' LYS . 15.1 tt0 . . . . . 0 N--CA 1.44 -0.967 0 N-CA-C 106.213 -1.773 . . . . 10.0 106.213 167.889 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 N-CA-C 108.424 -0.954 . . . . 10.0 108.424 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.3 t -78.96 -14.58 59.13 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.436 0.695 . . . . 10.0 110.662 -178.149 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.0 ttmt -134.32 149.22 50.86 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 125.023 1.329 . . . . 10.0 107.774 -179.716 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.64 151.63 47.39 Favored 'General case' 0 CA--C 1.512 -0.505 0 C-N-CA 123.32 0.648 . . . . 10.0 109.382 169.48 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -106.62 154.63 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.223 0 O-C-N 124.741 1.276 . . . . 10.0 111.813 -172.576 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 6' ' ' ALA . . . . . 0.455 ' HB1' HD21 ' B' ' 8' ' ' LEU . . . -144.8 93.79 2.46 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 123.217 0.323 . . . . 10.0 111.449 169.28 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.3 m -81.65 103.54 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.365 0 N-CA-C 109.328 -0.619 . . . . 10.0 109.328 169.17 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.455 HD21 ' HB1' ' B' ' 6' ' ' ALA . 10.9 mt -97.36 127.37 43.26 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.336 1.054 . . . . 10.0 109.029 -177.796 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.3 mtpt -146.86 161.64 40.29 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 120.367 1.439 . . . . 10.0 108.66 173.76 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.31 -55.37 0.06 OUTLIER Glycine 0 N--CA 1.461 0.325 0 CA-C-N 115.798 -0.637 . . . . 10.0 113.318 168.63 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -72.63 -43.78 62.8 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 -176.477 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.12 -70.61 0.42 Allowed Glycine 0 CA--C 1.524 0.613 0 CA-C-N 114.334 -1.303 . . . . 10.0 109.923 170.075 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -58.27 -33.86 98.04 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.427 2.751 . . . . 10.0 111.291 172.044 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.9 t -65.01 100.62 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.637 -1.245 . . . . 10.0 107.637 176.179 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -124.55 108.29 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.606 1.562 . . . . 10.0 108.117 177.978 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.02 143.46 16.49 Favored Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 167.934 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.408 ' CG2' HG22 ' A' ' 54' ' ' THR . 2.4 mt -141.62 67.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.651 -1.611 . . . . 10.0 106.651 -179.797 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.06 148.96 4.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.476 0.655 . . . . 10.0 110.852 -174.926 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -123.53 119.31 29.56 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 125.703 1.601 . . . . 10.0 109.263 169.834 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -94.73 124.6 38.86 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 116.712 -1.614 . . . . 10.0 106.653 168.332 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -112.52 136.54 51.91 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 119.592 1.087 . . . . 10.0 111.184 165.983 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -89.27 112.71 23.84 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.025 -2.213 . . . . 10.0 105.025 168.471 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.9 mmpt? . . . . . 0 CA--C 1.513 -0.45 0 C-N-CA 125.649 1.58 . . . . 10.0 110.075 -171.554 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.046 0 N-CA-C 109.361 -1.496 . . . . 10.0 109.361 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -59.17 145.54 97.41 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.263 1.976 . . . . 10.0 109.132 175.731 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.7 t -87.76 114.55 26.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 105.22 -2.141 . . . . 10.0 105.22 174.811 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 10.9 ttmm -89.21 119.75 29.97 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 169.895 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -89.44 107.91 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 126.387 1.875 . . . . 10.0 106.397 169.593 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.0 p90 -126.3 164.63 20.61 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.886 0.851 . . . . 10.0 112.614 173.08 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.68 -152.93 24.43 Favored Glycine 0 N--CA 1.438 -1.208 0 N-CA-C 107.586 -2.205 . . . . 10.0 107.586 169.905 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 34.3 p -154.01 113.91 3.86 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 118.595 -0.717 . . . . 10.0 109.495 -169.956 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.615 ' CG1' ' HB3' ' B' ' 95' ' ' ALA . 2.8 pt -81.75 140.43 16.51 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 166.994 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -119.58 148.88 42.81 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 169.622 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.34 -5.85 41.76 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-O 119.365 -0.686 . . . . 10.0 113.652 174.965 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.34 176.8 2.12 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 118.584 1.192 . . . . 10.0 110.787 176.903 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -109.65 158.26 18.25 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 105.661 -1.977 . . . . 10.0 105.661 165.898 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -49.44 159.59 0.32 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.483 1.513 . . . . 10.0 112.487 -169.055 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.48 -172.94 35.04 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-O 121.786 0.659 . . . . 10.0 111.909 169.254 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -72.03 144.14 48.89 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.976 1.711 . . . . 10.0 110.207 -176.616 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -145.36 147.79 32.67 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.168 0.987 . . . . 10.0 113.036 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.639 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -20.37 117.73 0.01 OUTLIER Glycine 0 C--N 1.339 0.726 0 C-N-CA 129.36 3.362 . . . . 10.0 115.473 165.012 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -154.59 103.38 2.47 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.943 1.872 . . . . 10.0 111.541 170.736 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.405 ' NE2' ' OD2' ' B' ' 124' ' ' ASP . 2.2 m80 -133.6 -163.53 1.37 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 124.465 1.106 . . . . 10.0 111.188 179.415 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.2 p -116.66 -46.6 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 124.286 1.034 . . . . 10.0 112.045 -177.067 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 62.16 148.12 0.02 OUTLIER 'General case' 0 C--N 1.342 0.27 0 C-N-CA 125.589 1.556 . . . . 10.0 112.223 -171.595 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -75.31 -58.01 3.55 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 177.297 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -77.78 128.05 33.4 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 -172.797 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.91 -1.61 87.57 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.257 -1.537 . . . . 10.0 109.257 165.781 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -41.06 140.21 0.8 Allowed 'General case' 0 C--N 1.346 0.425 0 CA-C-N 117.982 0.891 . . . . 10.0 110.887 173.121 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.47 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -150.18 18.83 0.86 Allowed 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.512 -1.222 . . . . 10.0 111.328 167.455 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.624 HG23 HG22 ' A' ' 17' ' ' ILE . 0.7 OUTLIER -54.89 -35.97 64.68 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 118.903 0.774 . . . . 10.0 109.305 177.893 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.74 -21.45 44.48 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.347 1.459 . . . . 10.0 113.407 177.069 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.58 91.18 0.71 Allowed Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.444 -0.662 . . . . 10.0 111.444 -176.818 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 32.0 m 44.61 38.67 2.84 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.156 1.782 . . . . 10.0 112.625 176.414 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.2 m -133.33 -49.7 0.85 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.702 0.801 . . . . 10.0 109.25 -168.964 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -106.04 20.12 19.46 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.553 0.741 . . . . 10.0 110.265 -177.133 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.96 47.79 0.45 Allowed 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 124.438 1.095 . . . . 10.0 111.011 175.974 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.22 101.41 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 126.043 1.782 . . . . 10.0 113.683 168.455 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -68.15 72.7 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 123.635 2.89 . . . . 10.0 112.833 178.629 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER 58.55 45.69 15.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.237 3.415 . . . . 10.0 110.943 173.298 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -69.33 64.69 0.16 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 126.146 1.778 . . . . 10.0 111.692 177.919 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -82.9 154.22 67.56 Favored Pre-proline 0 C--N 1.32 -0.69 0 C-N-CA 126.067 1.747 . . . . 10.0 109.796 179.557 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.13 -52.03 0.54 Allowed 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.574 2.182 . . . . 10.0 111.447 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.2 mt -78.68 49.58 0.9 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.94 0.896 . . . . 10.0 110.584 -176.652 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.7 124.94 23.23 Favored 'General case' 0 N--CA 1.451 -0.4 0 O-C-N 122.024 -0.422 . . . . 10.0 111.096 -168.53 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.81 -75.22 0.32 Allowed 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 107.1 -1.444 . . . . 10.0 107.1 -172.503 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.7 mttt -149.26 164.77 33.89 Favored 'General case' 0 N--CA 1.422 -1.853 0 CA-C-N 114.871 -1.059 . . . . 10.0 108.583 169.317 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 76.3 t60 -71.6 126.82 30.68 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 105.165 -2.161 . . . . 10.0 105.165 162.873 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.05 -138.36 3.65 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 108.86 -1.696 . . . . 10.0 108.86 173.634 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.62 -160.87 25.98 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 107.884 -2.086 . . . . 10.0 107.884 173.414 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.51 1.36 2.66 Favored 'Trans proline' 0 CA--C 1.541 0.839 0 CA-C-N 119.819 1.81 . . . . 10.0 110.644 167.372 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -108.35 10.19 27.63 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 125.857 1.663 . . . . 10.0 109.8 173.905 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -135.47 161.44 35.47 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 165.571 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -77.59 -37.86 49.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 105.242 -2.133 . . . . 10.0 105.242 167.328 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -97.15 58.1 1.52 Allowed 'General case' 0 N--CA 1.446 -0.646 0 CA-C-O 121.718 0.77 . . . . 10.0 109.323 -169.614 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -70.37 154.01 42.37 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.521 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -67.66 -65.95 0.62 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.989 0.813 . . . . 10.0 109.39 177.831 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.751 HG13 ' H ' ' B' ' 82' ' ' GLY . 7.5 p -161.67 -90.46 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 170.664 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.751 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -84.12 69.31 3.36 Favored Glycine 0 CA--C 1.525 0.693 0 O-C-N 120.374 -1.454 . . . . 10.0 109.486 176.071 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -104.39 94.42 5.33 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 104.013 -2.588 . . . . 10.0 104.013 167.32 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -70.73 -34.1 71.55 Favored 'General case' 0 C--O 1.227 -0.114 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 -176.336 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 117.68 -85.96 0.4 Allowed Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 110.175 -1.17 . . . . 10.0 110.175 167.021 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -142.37 141.26 32.28 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.53 -0.915 . . . . 10.0 108.53 -177.627 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.3 m -114.63 135.65 53.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 166.891 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -104.23 117.97 35.5 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.75 0.82 . . . . 10.0 109.465 -171.666 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.26 134.54 34.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.08 -0.388 . . . . 10.0 110.327 -178.166 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -60.9 168.97 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.529 1.132 . . . . 10.0 109.579 167.695 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.9 -29.14 40.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.633 -0.712 . . . . 10.0 111.298 173.485 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -78.41 -9.26 59.22 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.003 0.521 . . . . 10.0 111.291 -178.704 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 10.06 73.74 Favored Glycine 0 C--N 1.341 0.807 0 O-C-N 121.099 -1.001 . . . . 10.0 111.101 -177.148 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.7 t -87.21 106.71 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 C-N-CA 126.273 1.829 . . . . 10.0 106.743 176.049 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.615 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -104.82 119.57 39.32 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.476 -0.935 . . . . 10.0 108.476 169.653 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -79.53 135.4 36.61 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.081 1.752 . . . . 10.0 108.454 175.088 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.52 132.53 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.454 1.502 . . . . 10.0 106.975 177.907 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 23.4 p -158.78 55.4 0.43 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.752 0.821 . . . . 10.0 111.79 168.821 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.0 mp -92.81 145.0 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 108.662 -0.866 . . . . 10.0 108.662 -174.536 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -101.67 126.33 48.5 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 126.814 2.046 . . . . 10.0 108.543 174.359 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -117.45 155.04 30.36 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.541 -0.911 . . . . 10.0 108.541 168.157 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.4 p -130.42 27.42 5.03 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 125.453 1.501 . . . . 10.0 111.989 -177.4 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.71 -40.54 1.32 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.894 0.77 . . . . 10.0 111.021 169.788 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.449 HD13 ' C ' ' B' ' 104' ' ' ILE 0.481 0.0 OUTLIER -69.38 158.07 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 119.895 1.225 . . . . 10.0 112.47 174.592 . . . . . . . . 4 4 . 1 . 027 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 40.5 m -153.95 121.69 5.93 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 120.937 -1.102 . . . . 10.0 109.805 -179.235 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.1 mt -68.2 -30.74 69.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.698 1.199 . . . . 10.0 110.598 -175.536 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 68.6 m . . . . . 0 N--CA 1.45 -0.458 0 N-CA-C 108.187 -1.042 . . . . 10.0 108.187 169.462 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.6 t . . . . . 0 N--CA 1.448 -0.547 0 CA-C-O 120.775 0.321 . . . . 10.0 111.022 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -69.77 37.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 C-N-CA 126.302 1.841 . . . . 10.0 111.844 -177.598 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 1.1 mp -56.07 -45.63 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 O-C-N 119.157 -2.214 . . . . 10.0 112.096 177.481 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.79 50.92 3.03 Favored Glycine 0 CA--C 1.534 1.251 0 CA-C-N 119.932 1.242 . . . . 10.0 114.244 -175.416 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -84.56 176.6 8.51 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 127.327 2.251 . . . . 10.0 109.784 170.123 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -135.85 99.19 4.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.35 -0.982 . . . . 10.0 108.35 169.114 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.74 129.65 42.04 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 105.565 -2.013 . . . . 10.0 105.565 167.625 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.16 129.4 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.24 -2.133 . . . . 10.0 105.24 169.168 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.507 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.3 OUTLIER -100.71 106.05 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.942 0 N-CA-C 104.868 -2.271 . . . . 10.0 104.868 170.997 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.639 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 12.0 m-70 -87.72 160.08 18.23 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 122.822 1.296 . . . . 10.0 114.258 -169.818 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 121' ' ' GLU . . . . . 0.664 ' HA ' HD22 ' B' ' 144' ' ' LEU . 52.0 tt0 -50.79 -56.55 11.58 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.839 2.056 . . . . 10.0 109.034 176.917 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -107.64 168.06 9.52 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.863 0.69 . . . . 10.0 112.863 -169.654 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.26 151.57 43.3 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 113.777 -1.556 . . . . 10.0 107.575 169.125 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.484 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 31.2 m-20 -100.94 132.36 46.38 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.235 -1.024 . . . . 10.0 108.235 -179.602 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -76.39 -12.68 60.1 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 124.857 1.263 . . . . 10.0 111.05 -176.796 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 15.4 mt 59.31 49.36 9.04 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 122.211 1.005 . . . . 10.0 109.04 177.39 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.4 -44.1 2.47 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 125.611 1.576 . . . . 10.0 110.445 174.645 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.7 mtmm -79.47 42.16 0.5 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.716 1.607 . . . . 10.0 112.518 -168.842 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.7 -17.77 27.36 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.281 2.372 . . . . 10.0 111.103 169.765 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.24 42.25 88.03 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.961 0.791 . . . . 10.0 111.777 178.861 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -145.94 166.38 26.2 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 169.929 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -52.23 -48.5 65.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 120.978 0.418 . . . . 10.0 110.143 -177.17 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -64.87 -30.45 71.45 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 119.225 -0.417 . . . . 10.0 110.427 -179.591 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 p -56.04 -35.33 66.77 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 120.146 1.339 . . . . 10.0 112.308 171.544 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -101.72 -14.73 17.23 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 118.294 0.497 . . . . 10.0 111.169 -170.515 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 53.9 mttt -88.0 -47.57 8.43 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 125.923 1.689 . . . . 10.0 111.256 173.715 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 44.7 p -134.09 -11.71 2.55 Favored 'General case' 0 CA--C 1.533 0.308 0 N-CA-C 115.057 1.502 . . . . 10.0 115.057 177.323 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.38 24.77 11.85 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 119.404 1.002 . . . . 10.0 112.978 -171.722 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 61.89 25.06 15.01 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 119.698 1.749 . . . . 10.0 111.432 179.316 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.73 -14.21 41.74 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 126.54 1.936 . . . . 10.0 112.5 -173.064 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.38 -160.22 52.98 Favored Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 108.776 -1.73 . . . . 10.0 108.776 172.434 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -55.29 130.54 42.74 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 109.24 -0.652 . . . . 10.0 109.24 -171.155 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.77 71.65 0.06 Allowed 'General case' 0 CA--C 1.543 0.708 0 O-C-N 121.667 -0.646 . . . . 10.0 110.274 172.198 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.664 HD22 ' HA ' ' B' ' 121' ' ' GLU . 11.7 tp -45.08 -35.78 3.25 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 128.118 2.567 . . . . 10.0 114.585 -172.858 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.507 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -165.77 159.18 15.9 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.049 -1.093 . . . . 10.0 108.049 -179.361 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.4 p -163.61 169.8 18.09 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.663 -0.495 . . . . 10.0 109.663 -178.045 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.12 -178.79 16.76 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 109.63 -1.388 . . . . 10.0 109.63 178.595 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 91.5 t -123.73 126.46 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 104.224 -2.51 . . . . 10.0 104.224 170.609 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.3 mt -81.72 152.08 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 CA-C-N 118.198 0.454 . . . . 10.0 110.787 -171.179 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -151.76 157.58 27.3 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 125.547 1.546 . . . . 10.0 111.059 -169.4 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.9 mt -54.12 140.27 11.33 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 C-N-CA 125.436 1.494 . . . . 10.0 111.806 172.64 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.72 170.17 16.23 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 107.492 -1.299 . . . . 10.0 107.492 165.759 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 . . . . . 0 C--O 1.25 1.096 0 N-CA-C 107.537 -1.283 . . . . 10.0 107.537 167.616 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.81 0 CA-C-O 117.971 -1.014 . . . . 10.0 108.952 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 t -105.47 -21.54 13.19 Favored 'General case' 0 C--O 1.223 -0.342 0 O-C-N 123.807 0.692 . . . . 10.0 110.503 176.897 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.74 172.5 13.2 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-O 121.368 0.604 . . . . 10.0 111.04 169.203 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.99 168.55 24.84 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 172.732 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -132.64 164.07 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.318 1.047 . . . . 10.0 109.284 176.771 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.01 116.87 10.97 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 167.898 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -95.66 102.77 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 124.542 1.137 . . . . 10.0 109.137 170.349 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -92.45 134.98 34.44 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.062 0.945 . . . . 10.0 109.703 -179.884 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt -145.38 162.44 37.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 168.797 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.95 -60.18 0.04 OUTLIER Glycine 0 C--O 1.229 -0.178 0 CA-C-N 115.393 -0.821 . . . . 10.0 112.542 172.976 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.37 -43.91 59.69 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 106.443 -1.688 . . . . 10.0 106.443 -171.532 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.25 -66.06 0.56 Allowed Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 113.713 -1.585 . . . . 10.0 110.097 177.65 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -58.54 -38.75 88.28 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 122.481 2.12 . . . . 10.0 111.276 172.297 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.1 t -64.44 108.17 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.691 -1.225 . . . . 10.0 107.691 178.363 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -122.6 116.27 23.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 105.452 -2.055 . . . . 10.0 105.452 168.973 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.765 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -100.38 131.29 10.52 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 175.858 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.492 ' CG2' HG23 ' B' ' 54' ' ' THR . 11.5 mt -133.19 89.57 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 107.111 -1.441 . . . . 10.0 107.111 -171.157 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.6 mm -104.17 141.88 18.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 124.396 1.078 . . . . 10.0 109.826 -178.665 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -126.5 119.42 27.11 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.939 2.095 . . . . 10.0 108.636 171.408 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -101.16 120.69 40.59 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 107.321 -1.362 . . . . 10.0 107.321 176.771 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -113.55 143.49 44.46 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 119.379 0.99 . . . . 10.0 112.832 172.214 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -127.42 97.33 4.85 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 128.166 2.586 . . . . 10.0 107.92 169.656 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.0 pttt -58.52 -48.14 81.82 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.287 1.035 . . . . 10.0 111.946 -176.255 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.76 166.61 24.29 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 104.38 -2.452 . . . . 10.0 104.38 168.14 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -65.21 -19.5 66.0 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 122.356 0.262 . . . . 10.0 110.893 179.891 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -80.66 -24.12 39.17 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 123.096 0.558 . . . . 10.0 110.499 176.617 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.41 155.1 53.39 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.645 -0.582 . . . . 10.0 111.645 -175.885 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -71.06 147.77 55.23 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 N-CA-C 106.155 -2.286 . . . . 10.0 106.155 165.56 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 t -79.61 128.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.04 0 N-CA-C 106.626 -1.62 . . . . 10.0 106.626 174.32 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -109.0 125.08 51.68 Favored 'General case' 0 C--O 1.233 0.234 0 N-CA-C 106.504 -1.665 . . . . 10.0 106.504 171.911 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.0 m -111.44 105.95 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.63 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 -176.5 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.5 p90 -117.13 168.54 10.2 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.25 0.548 . . . . 10.0 111.06 176.975 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.5 175.9 41.57 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.188 -1.006 . . . . 10.0 111.585 176.002 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 2.6 p -147.46 95.8 2.59 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 107.949 -1.13 . . . . 10.0 107.949 -177.098 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.765 HG22 ' HA2' ' A' ' 16' ' ' GLY . 8.4 pt -77.42 174.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.03 170.917 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -156.01 155.77 33.28 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.8 -17.23 33.0 Favored Glycine 0 CA--C 1.523 0.566 0 CA-C-O 119.411 -0.661 . . . . 10.0 113.824 173.326 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.505 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.3 mp -72.73 179.85 3.43 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 118.395 1.097 . . . . 10.0 110.354 178.362 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -95.81 175.78 6.38 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.586 -0.894 . . . . 10.0 108.586 166.404 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -63.6 176.54 0.85 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 124.633 1.173 . . . . 10.0 111.604 -172.024 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.04 -173.8 43.38 Favored Glycine 0 C--O 1.225 -0.438 0 C-N-CA 124.005 0.812 . . . . 10.0 112.563 167.345 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -77.22 140.7 40.18 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.332 1.453 . . . . 10.0 109.476 177.452 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -133.03 140.66 47.84 Favored 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 124.264 1.026 . . . . 10.0 112.366 -176.742 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -43.72 125.65 5.41 Favored Glycine 0 C--N 1.344 1.026 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 166.177 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -145.52 109.73 4.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 119.042 1.421 . . . . 10.0 109.025 171.122 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.22 173.12 17.32 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 113.74 1.015 . . . . 10.0 113.74 -174.139 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 33.3 m -88.0 154.37 3.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 113.629 -1.623 . . . . 10.0 109.578 171.246 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 -139.35 75.7 1.53 Allowed 'General case' 0 C--O 1.222 -0.37 0 C-N-CA 123.217 0.607 . . . . 10.0 112.122 -174.513 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 64.3 tt0 51.71 -87.22 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 125.301 1.44 . . . . 10.0 113.989 169.501 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -90.62 -172.34 3.37 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.537 -0.912 . . . . 10.0 108.537 -179.935 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -136.76 22.93 3.27 Favored Glycine 0 N--CA 1.452 -0.297 0 O-C-N 121.521 -0.737 . . . . 10.0 111.82 174.425 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -82.34 160.06 22.93 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 107.626 -1.25 . . . . 10.0 107.626 168.583 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.18 28.9 0.58 Allowed 'General case' 0 N--CA 1.448 -0.572 0 O-C-N 121.578 -0.701 . . . . 10.0 112.446 178.454 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.467 HG22 HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -49.7 -40.38 40.04 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.344 1.458 . . . . 10.0 112.373 -175.173 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -81.66 -24.31 36.37 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 123.391 0.676 . . . . 10.0 112.432 177.656 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.1 115.74 1.24 Allowed Glycine 0 CA--C 1.53 0.999 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 -169.512 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 64.2 m 42.27 53.37 4.47 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 125.629 1.572 . . . . 10.0 113.169 175.062 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -158.11 -56.98 0.07 Allowed 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 177.056 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -53.15 -45.34 68.38 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 124.909 1.284 . . . . 10.0 111.002 -169.233 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -53.59 0.18 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 127.039 2.136 . . . . 10.0 113.681 169.993 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.08 160.5 11.61 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.121 -1.192 . . . . 10.0 110.121 -176.838 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -74.02 -162.3 0.14 Allowed 'Trans proline' 0 N--CA 1.448 -1.169 0 N-CA-C 105.651 -2.48 . . . . 10.0 105.651 165.837 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -80.17 48.99 1.05 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 119.613 -1.93 . . . . 10.0 110.827 -175.386 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-30 -77.65 56.55 1.48 Allowed 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.935 1.35 . . . . 10.0 112.11 -176.632 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -59.83 148.52 75.92 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.81 1.244 . . . . 10.0 108.501 167.057 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.67 -48.59 8.75 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.693 2.262 . . . . 10.0 112.022 -174.285 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.19 57.65 1.46 Allowed 'General case' 0 CA--C 1.534 0.335 0 O-C-N 121.595 -0.69 . . . . 10.0 110.717 174.162 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.3 p -55.66 107.66 0.36 Allowed 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.842 1.257 . . . . 10.0 109.844 -179.705 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -119.45 -91.11 0.56 Allowed 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 -178.321 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -143.65 150.89 39.41 Favored 'General case' 0 N--CA 1.437 -1.095 0 CA-C-O 121.927 0.87 . . . . 10.0 109.81 169.012 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.426 ' HA ' ' CD2' ' A' ' 80' ' ' HIS . 56.5 t60 -57.79 120.96 9.35 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.643 -1.243 . . . . 10.0 107.643 165.699 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.73 -141.81 3.92 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 108.692 -1.763 . . . . 10.0 108.692 -177.96 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.492 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -174.17 -158.98 19.71 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 109.337 -1.505 . . . . 10.0 109.337 169.697 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -69.36 25.5 0.16 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 119.844 1.822 . . . . 10.0 111.173 168.739 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.492 ' H ' ' C ' ' A' ' 73' ' ' GLY . 71.7 mttt -123.96 -12.89 7.45 Favored 'General case' 0 N--CA 1.438 -1.028 0 C-N-CA 126.379 1.872 . . . . 10.0 109.787 171.942 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -135.96 129.11 31.65 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 104.842 -2.281 . . . . 10.0 104.842 -172.352 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -75.57 -22.19 57.21 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.243 -1.021 . . . . 10.0 108.243 -174.277 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -83.21 4.97 24.53 Favored 'General case' 0 N--CA 1.433 -1.323 0 C-N-CA 125.935 1.694 . . . . 10.0 111.122 -179.756 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.29 158.53 0.03 OUTLIER 'General case' 0 C--N 1.349 0.567 0 C-N-CA 124.53 1.132 . . . . 10.0 112.161 172.844 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.426 ' CD2' ' HA ' ' A' ' 71' ' ' HIS . 47.0 m-70 -69.65 -103.81 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.689 -0.632 . . . . 10.0 109.359 176.997 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 88.0 t -126.7 -90.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 104.522 -2.399 . . . . 10.0 104.522 169.385 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -79.08 62.61 3.98 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.689 -0.565 . . . . 10.0 111.689 178.745 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -97.26 94.84 7.33 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 104.368 -2.456 . . . . 10.0 104.368 166.954 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -72.68 -7.46 50.54 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 117.913 0.324 . . . . 10.0 111.033 -174.229 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.27 -103.22 2.96 Favored Glycine 0 N--CA 1.44 -1.046 0 N-CA-C 105.006 -3.237 . . . . 10.0 105.006 -170.084 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -146.47 159.74 43.01 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 107.609 -1.256 . . . . 10.0 107.609 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.33 128.05 74.71 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 123.096 0.558 . . . . 10.0 110.575 170.422 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 m -79.68 114.08 18.33 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.758 2.823 . . . . 10.0 110.563 -178.889 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.16 46.51 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.298 1.039 . . . . 10.0 110.857 177.985 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -61.18 170.03 1.85 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 125.495 1.518 . . . . 10.0 109.096 166.914 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.95 -30.0 44.91 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.803 0.841 . . . . 10.0 111.408 176.723 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.1 -3.0 43.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 124.298 1.039 . . . . 10.0 110.863 -178.221 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.41 1.28 89.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.518 -1.033 . . . . 10.0 110.518 -175.633 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 62.1 t -79.47 103.53 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.288 0 N-CA-C 106.965 -1.495 . . . . 10.0 106.965 -176.958 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.405 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -100.95 118.67 37.44 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.825 -0.806 . . . . 10.0 108.825 169.213 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.2 110.01 15.21 Favored 'General case' 0 N--CA 1.434 -1.25 0 C-N-CA 126.265 1.826 . . . . 10.0 108.84 170.736 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.9 t -97.79 132.87 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 106.656 -1.609 . . . . 10.0 106.656 177.183 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.0 m -158.69 76.93 0.75 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.98 1.312 . . . . 10.0 109.863 169.799 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.7 161.13 3.83 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 177.505 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -142.51 130.85 22.24 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.65 1.98 . . . . 10.0 107.786 176.994 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -144.95 163.6 33.67 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.295 1.038 . . . . 10.0 108.959 179.126 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.4 p -125.36 51.39 1.7 Allowed 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.897 1.279 . . . . 10.0 109.876 176.974 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -142.69 -46.02 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.761 0.824 . . . . 10.0 110.762 174.475 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -63.29 139.74 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 169.339 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.3 m -126.74 156.19 41.55 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.941 0.877 . . . . 10.0 110.108 172.173 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -82.47 -29.54 30.53 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.75 0.82 . . . . 10.0 109.492 172.401 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.7 m -156.93 168.82 26.33 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 -174.599 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.32 -92.92 0.58 Allowed Glycine 0 C--N 1.333 0.407 0 N-CA-C 108.471 -1.852 . . . . 10.0 108.471 179.117 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -134.39 -51.64 0.81 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 125.72 1.608 . . . . 10.0 108.403 177.584 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -81.7 38.42 0.51 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.605 0.762 . . . . 10.0 110.145 -175.03 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.4 t -74.32 112.96 11.0 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 126.127 1.771 . . . . 10.0 108.627 -176.109 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 16.6 pt -81.87 11.49 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 173.16 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 30.9 mm -61.09 137.59 23.18 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 120.112 1.324 . . . . 10.0 109.925 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.56 87.01 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.0 -1.444 . . . . 10.0 114.707 172.544 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 29.5 mmt180 -83.93 171.13 13.31 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 168.914 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -105.4 136.48 44.87 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 124.677 1.191 . . . . 10.0 110.351 171.681 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.408 ' CD2' HD11 ' A' ' 149' ' ' ILE . 3.9 mm? -96.29 143.08 27.69 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 167.209 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.408 HG22 ' SG ' ' A' ' 146' ' ' CYS . 91.9 t -132.03 137.67 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.875 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 176.864 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.5 p -108.5 142.08 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.592 0 C-N-CA 124.996 1.318 . . . . 10.0 108.698 170.368 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -119.99 171.1 8.68 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.963 0.905 . . . . 10.0 113.143 -171.71 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -74.28 -46.83 38.75 Favored 'General case' 0 C--O 1.223 -0.323 0 C-N-CA 123.932 0.893 . . . . 10.0 111.669 -176.596 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -109.81 170.76 7.86 Favored 'General case' 0 CA--C 1.522 -0.113 0 C-N-CA 123.702 0.801 . . . . 10.0 113.015 -171.763 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.44 145.68 39.12 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.951 1.3 . . . . 10.0 108.777 174.134 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.53 164.47 24.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 122.167 0.984 . . . . 10.0 112.753 -178.208 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 63.9 m-20 -77.5 -22.4 51.28 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 112.625 -2.079 . . . . 10.0 109.631 167.082 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 40.2 mt 50.2 46.5 24.76 Favored 'General case' 0 C--N 1.341 0.232 0 CA-C-O 122.631 1.205 . . . . 10.0 108.354 -167.574 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.17 -32.79 4.76 Favored Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.125 -1.398 . . . . 10.0 112.247 177.765 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 25.4 mtmm -79.57 37.79 0.35 Allowed 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.672 1.189 . . . . 10.0 113.205 -168.535 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.8 -14.41 37.22 Favored Glycine 0 CA--C 1.526 0.778 0 C-N-CA 127.185 2.326 . . . . 10.0 110.036 169.419 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.17 43.07 32.75 Favored Glycine 0 C--N 1.34 0.781 0 C-N-CA 124.516 1.055 . . . . 10.0 112.081 -177.88 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -142.26 167.2 22.68 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 118.926 1.363 . . . . 10.0 109.221 173.088 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.403 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 1.7 tm-20 -37.5 -54.82 1.12 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 126.392 1.877 . . . . 10.0 111.374 176.531 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -72.2 -39.08 68.84 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.087 0.555 . . . . 10.0 110.739 179.927 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.8 p -53.04 -45.5 68.04 Favored 'General case' 0 N--CA 1.446 -0.635 0 O-C-N 120.893 -1.129 . . . . 10.0 110.589 -178.711 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.1 t -79.69 -2.45 42.92 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 118.744 -0.646 . . . . 10.0 111.799 -173.815 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.403 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 94.7 mttt -112.21 -71.07 0.77 Allowed 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.035 1.734 . . . . 10.0 110.811 -178.296 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.1 p -121.17 14.21 11.32 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 120.729 1.604 . . . . 10.0 112.841 177.462 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.46 21.08 78.7 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-O 119.236 -0.758 . . . . 10.0 113.473 168.752 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 50.75 24.83 1.85 Allowed 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 118.21 1.005 . . . . 10.0 112.202 -174.663 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.21 -7.55 47.59 Favored 'General case' 0 C--O 1.223 -0.323 0 O-C-N 121.41 -0.806 . . . . 10.0 111.554 -176.829 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 129.57 170.12 12.68 Favored Glycine 0 C--N 1.332 0.324 0 N-CA-C 110.199 -1.16 . . . . 10.0 110.199 169.674 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -82.38 54.85 2.71 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 123.029 0.532 . . . . 10.0 112.082 -169.058 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 42.66 72.87 0.16 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.057 1.343 . . . . 10.0 111.709 173.902 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -63.9 -36.4 83.82 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 123.041 0.537 . . . . 10.0 111.39 -169.185 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.06 138.22 14.65 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.904 -0.776 . . . . 10.0 108.904 -170.622 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.408 ' SG ' HG22 ' A' ' 118' ' ' VAL . 58.9 m -133.75 147.36 51.3 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.315 1.046 . . . . 10.0 109.678 -168.373 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.16 168.57 23.32 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.542 -1.023 . . . . 10.0 110.542 177.033 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 65.1 t -118.55 137.82 51.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 106.384 -1.71 . . . . 10.0 106.384 178.42 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.408 HD11 ' CD2' ' A' ' 117' ' ' LEU . 80.7 mt -73.96 126.18 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 118.099 0.409 . . . . 10.0 110.923 -176.297 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.65 145.61 18.63 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.365 -1.094 . . . . 10.0 110.365 176.833 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 47.9 mt -68.44 152.77 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 CA-C-N 119.358 1.579 . . . . 10.0 110.41 178.044 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.7 162.82 32.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 107.661 -1.237 . . . . 10.0 107.661 166.936 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.5 tt0 . . . . . 0 C--O 1.251 1.147 0 N-CA-C 106.338 -1.727 . . . . 10.0 106.338 169.603 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' B' B ' 1' ' ' ALA . . . . . 0.418 ' N ' ' O ' ' B' ' 153' ' ' GLN . . . . . . . . 0 N--CA 1.469 0.507 0 N-CA-C 109.134 -0.691 . . . . 10.0 109.134 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.3 t -94.94 -32.18 13.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.978 1.311 . . . . 10.0 110.913 174.965 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.2 ttmp? -124.61 138.9 54.28 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 124.471 1.108 . . . . 10.0 110.231 -177.862 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.59 159.54 42.04 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.159 1.384 . . . . 10.0 108.101 170.236 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -136.02 164.4 32.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 119.012 0.824 . . . . 10.0 110.307 177.41 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.88 118.91 18.49 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 124.7 1.2 . . . . 10.0 109.118 168.199 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -89.05 89.65 3.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 108.387 -0.968 . . . . 10.0 108.387 168.911 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mp -79.67 120.76 24.43 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 118.544 -0.741 . . . . 10.0 109.688 -179.752 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 22.7 mtpt -140.5 160.41 40.05 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 119.133 0.879 . . . . 10.0 109.207 171.802 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.52 -60.71 0.05 OUTLIER Glycine 0 N--CA 1.46 0.276 0 CA-C-N 114.87 -1.059 . . . . 10.0 113.071 170.923 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -71.24 -44.0 66.17 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 -176.748 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.14 -69.17 0.43 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-N 114.234 -1.348 . . . . 10.0 110.575 169.771 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -60.14 -32.32 94.43 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 123.714 2.943 . . . . 10.0 111.735 173.019 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.7 t -67.62 92.53 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 107.145 -1.428 . . . . 10.0 107.145 177.902 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -120.11 105.65 11.21 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 125.22 1.408 . . . . 10.0 107.822 -178.24 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.677 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.68 139.72 14.65 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 110.364 -1.094 . . . . 10.0 110.364 169.718 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.467 HG22 HG22 ' A' ' 54' ' ' THR . 6.5 mt -138.15 58.5 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 N-CA-C 105.552 -2.018 . . . . 10.0 105.552 -173.403 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.422 HD11 HG23 ' B' ' 35' ' ' ILE . 30.2 mm -81.96 134.8 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 114.879 -1.055 . . . . 10.0 109.39 -169.913 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -112.35 116.48 30.41 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.195 1.798 . . . . 10.0 108.973 -177.517 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -103.19 113.79 27.55 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 125.963 1.705 . . . . 10.0 107.759 -176.107 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -114.36 135.86 53.62 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.053 0.941 . . . . 10.0 111.524 -177.992 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -115.77 104.6 11.82 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 104.985 -2.228 . . . . 10.0 104.985 167.784 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.235 0.306 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -169.683 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.853 0 CA-C-O 117.562 -1.688 . . . . 10.0 115.372 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -66.1 145.45 79.03 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 CA-C-N 119.841 1.82 . . . . 10.0 107.625 170.867 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.37 97.43 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 106.196 -1.779 . . . . 10.0 106.196 173.542 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -79.09 102.42 8.41 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.504 -2.036 . . . . 10.0 105.504 168.895 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.93 101.12 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 C-N-CA 125.928 1.691 . . . . 10.0 107.822 -177.477 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -113.37 168.02 10.08 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.535 0.683 . . . . 10.0 111.867 169.88 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.55 178.37 32.51 Favored Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.642 -0.983 . . . . 10.0 110.642 168.886 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.5 p -124.33 102.06 7.49 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 108.593 -0.891 . . . . 10.0 108.593 -173.182 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.677 HG22 ' HA2' ' B' ' 16' ' ' GLY . 3.6 pt -81.78 133.99 28.03 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 108.219 -1.03 . . . . 10.0 108.219 168.852 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.9 tptt -108.09 148.83 29.28 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 170.069 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.67 -6.94 35.96 Favored Glycine 0 C--N 1.337 0.586 0 CA-C-O 119.563 -0.576 . . . . 10.0 113.47 169.348 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -66.43 175.93 2.06 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 118.276 1.038 . . . . 10.0 110.518 176.029 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -108.66 164.6 12.23 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 105.289 -2.115 . . . . 10.0 105.289 165.557 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -53.78 161.23 1.18 Allowed 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 113.11 0.782 . . . . 10.0 113.11 -169.041 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.12 -179.19 51.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 124.318 0.961 . . . . 10.0 112.085 169.049 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 mt -57.04 146.35 27.58 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.076 1.75 . . . . 10.0 112.921 175.501 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.5 m-70 -149.33 144.73 26.63 Favored 'General case' 0 C--N 1.339 0.149 0 C-N-CA 124.423 1.089 . . . . 10.0 113.439 -179.835 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.661 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.08 122.64 0.04 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 127.621 2.534 . . . . 10.0 113.243 166.515 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -152.37 105.52 3.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 119.059 1.429 . . . . 10.0 111.818 169.425 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.17 171.67 17.01 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 112.801 0.667 . . . . 10.0 112.801 -178.153 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.1 m -99.95 146.29 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 111.924 -2.398 . . . . 10.0 106.275 167.0 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -120.83 144.95 48.08 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 -179.437 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 49' ' ' GLU . . . . . 0.532 ' CG ' ' HA3' ' B' ' 61' ' ' GLY . 0.0 OUTLIER -6.73 -86.59 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.992 2.117 . . . . 10.0 116.593 170.978 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -102.14 171.86 7.24 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 119.737 1.153 . . . . 10.0 109.825 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.78 -25.71 52.28 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 117.63 -1.65 . . . . 10.0 111.234 174.976 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -40.16 113.04 0.32 Allowed 'General case' 0 C--N 1.342 0.278 0 CA-C-N 118.165 0.982 . . . . 10.0 111.448 178.064 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.33 20.85 12.96 Favored 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.748 -1.115 . . . . 10.0 109.972 167.973 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.492 HG23 ' CG2' ' A' ' 17' ' ' ILE . 4.2 m -55.44 -35.7 65.72 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 118.922 0.783 . . . . 10.0 110.49 -169.996 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.55 -21.35 45.27 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.803 1.241 . . . . 10.0 113.524 178.446 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.61 81.96 1.28 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 109.579 -1.408 . . . . 10.0 109.579 -174.056 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.327 25.7 p 18.73 55.51 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.914 2.086 . . . . 10.0 115.451 -167.88 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.6 m -112.87 -57.76 2.24 Favored 'General case' 0 N--CA 1.442 -0.848 0 N-CA-C 105.454 -2.054 . . . . 10.0 105.454 173.953 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.4 t -90.83 -4.0 56.95 Favored 'General case' 0 N--CA 1.443 -0.789 0 C-N-CA 124.724 1.21 . . . . 10.0 110.355 -178.323 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.38 41.51 0.14 Allowed 'General case' 0 C--N 1.341 0.239 0 C-N-CA 124.542 1.137 . . . . 10.0 112.787 -179.279 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 61' ' ' GLY . . . . . 0.532 ' HA3' ' CG ' ' B' ' 49' ' ' GLU . . . 88.35 125.93 2.47 Favored Glycine 0 N--CA 1.44 -1.077 0 N-CA-C 118.433 2.133 . . . . 10.0 118.433 162.168 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -81.5 55.85 5.73 Favored 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 121.646 1.564 . . . . 10.0 109.9 165.147 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 1.3 m80 66.17 -72.05 0.08 Allowed 'General case' 0 N--CA 1.461 0.099 0 C-N-CA 127.946 2.499 . . . . 10.0 111.034 -175.956 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 0.72 56.95 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 131.358 3.863 . . . . 10.0 116.076 -172.64 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -63.23 162.07 27.26 Favored Pre-proline 0 CA--C 1.538 0.487 0 CA-C-N 115.846 -0.616 . . . . 10.0 111.463 -172.499 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -53.7 -38.44 84.71 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 123.251 2.634 . . . . 10.0 112.985 179.531 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.45 -1.88 4.01 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 113.054 0.761 . . . . 10.0 113.054 176.596 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.3 p 22.34 89.83 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 129.436 3.094 . . . . 10.0 115.392 169.073 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -130.53 -168.92 2.05 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 179.461 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -103.98 128.91 51.53 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.216 -1.401 . . . . 10.0 107.216 177.047 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.411 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 78.3 t60 -42.88 109.27 0.13 Allowed 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 124.063 0.852 . . . . 10.0 112.061 -178.815 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.25 -155.84 9.5 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.1 -2.4 . . . . 10.0 107.1 169.667 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.24 -153.32 6.06 Favored Glycine 0 C--N 1.332 0.312 0 CA-C-N 118.371 1.085 . . . . 10.0 112.675 173.044 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -61.1 -9.47 12.46 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.241 1.961 . . . . 10.0 111.685 174.753 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -91.84 -18.65 23.51 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.609 1.164 . . . . 10.0 109.006 -179.101 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 20.8 m-20 -113.6 162.85 15.7 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 -169.308 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -92.07 -18.12 24.03 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.623 -1.171 . . . . 10.0 109.674 172.028 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -97.98 2.54 49.07 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 126.258 1.823 . . . . 10.0 112.49 -170.399 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -35.37 125.44 0.63 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.542 1.537 . . . . 10.0 109.447 169.037 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.411 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 18.5 m170 -47.05 -54.67 9.78 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.497 0.589 . . . . 10.0 112.242 -168.694 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -172.01 -40.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 C-N-CA 125.814 1.646 . . . . 10.0 108.404 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -149.27 68.67 0.34 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 109.395 -1.482 . . . . 10.0 109.395 174.413 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -97.05 103.59 15.54 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 105.099 -2.186 . . . . 10.0 105.099 168.65 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 28.1 mt -82.27 25.44 0.6 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 118.891 0.769 . . . . 10.0 111.433 -176.828 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 75.7 -113.13 3.81 Favored Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 174.43 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -158.6 128.78 5.95 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 -174.867 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 16.7 m -106.09 132.46 53.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 123.015 0.526 . . . . 10.0 110.422 -169.681 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 99.1 m -85.39 107.71 17.51 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 127.605 2.362 . . . . 10.0 110.308 -170.956 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.29 137.51 32.92 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 123.153 0.581 . . . . 10.0 110.338 171.981 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -65.9 172.02 3.96 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.818 1.247 . . . . 10.0 109.541 168.518 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.59 -28.41 63.6 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.117 0.484 . . . . 10.0 110.917 177.735 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -80.89 -0.5 39.39 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.899 0.88 . . . . 10.0 111.187 -178.255 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.34 80.35 Favored Glycine 0 C--N 1.339 0.737 0 O-C-N 120.74 -1.225 . . . . 10.0 110.808 176.942 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.7 t -91.62 108.71 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 C-N-CA 126.971 2.108 . . . . 10.0 105.642 174.816 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.567 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -106.76 118.61 37.13 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 119.189 0.904 . . . . 10.0 108.633 169.102 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -81.13 95.97 7.05 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 126.64 1.976 . . . . 10.0 108.285 172.586 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -78.77 131.92 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 105.626 -1.99 . . . . 10.0 105.626 170.916 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 6.7 p -157.8 60.03 0.48 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.814 0.845 . . . . 10.0 109.073 -179.629 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 30.1 mt -114.87 160.2 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.072 -1.455 . . . . 10.0 107.072 -169.743 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -138.77 135.74 34.97 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 109.725 -0.472 . . . . 10.0 109.725 168.846 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 16.6 t0 -117.2 101.62 8.6 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 -178.866 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 40.3 m -85.7 54.53 3.16 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 124.798 1.239 . . . . 10.0 108.471 -173.695 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 92.0 t -136.91 -54.33 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 -171.761 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.445 ' H ' ' CD1' ' B' ' 104' ' ' ILE 0.385 0.0 OUTLIER -88.19 175.37 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.384 0.674 . . . . 10.0 111.544 170.408 . . . . . . . . 4 4 . 1 . 028 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 56.0 m -157.83 97.2 1.54 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.418 -0.801 . . . . 10.0 109.882 -168.042 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.9 tp -37.88 -27.37 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 129.211 3.004 . . . . 10.0 116.37 -169.616 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 38.3 t . . . . . 0 N--CA 1.453 -0.296 0 C-N-CA 124.152 0.981 . . . . 10.0 109.743 176.544 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.8 t . . . . . 0 N--CA 1.442 -0.847 0 N-CA-C 110.318 -0.253 . . . . 10.0 110.318 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.2 pt 46.24 35.21 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.962 1.705 . . . . 10.0 113.774 177.87 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 113' ' ' ILE . . . . . 0.415 ' O ' ' HB ' ' B' ' 149' ' ' ILE . 11.5 mm -61.29 -71.19 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.452 0 C-N-CA 123.122 0.569 . . . . 10.0 110.012 -178.66 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.25 58.48 1.12 Allowed Glycine 0 CA--C 1.54 1.645 0 O-C-N 120.814 -1.179 . . . . 10.0 115.042 -177.975 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 30.7 mmt180 -103.77 161.47 13.9 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 127.161 2.185 . . . . 10.0 105.706 167.494 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.99 128.22 42.69 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 104.269 -2.493 . . . . 10.0 104.269 171.442 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 11.1 mp -108.26 151.27 26.18 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 109.084 -0.71 . . . . 10.0 109.084 172.292 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.427 HG11 ' CG ' ' B' ' 143' ' ' ARG . 93.7 t -137.77 138.41 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.948 0 N-CA-C 108.412 -0.958 . . . . 10.0 108.412 -175.377 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.406 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.7 p -104.12 131.49 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 168.154 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.661 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.2 m170 -113.7 159.8 19.31 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 116.433 2.012 . . . . 10.0 116.433 -170.692 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -43.79 -57.12 3.41 Favored 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 129.26 3.024 . . . . 10.0 112.133 176.09 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 75.0 mttt -118.67 171.31 8.28 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 124.198 0.999 . . . . 10.0 112.937 -168.581 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -80.24 138.64 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.647 1.579 . . . . 10.0 109.91 177.815 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.08 152.11 33.09 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -172.525 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -76.81 -30.16 56.29 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.624 1.97 . . . . 10.0 109.968 169.579 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 26.9 mt 54.4 49.88 17.43 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 124.115 0.966 . . . . 10.0 109.979 -172.975 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.06 -43.36 3.11 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.033 -0.827 . . . . 10.0 111.033 176.062 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 28.2 mtmm -76.64 30.3 0.13 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.617 1.967 . . . . 10.0 112.236 -172.142 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.54 -33.04 7.74 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 128.32 2.867 . . . . 10.0 109.474 168.647 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.34 21.68 77.42 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.001 -0.889 . . . . 10.0 112.104 -177.224 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -107.48 161.65 14.64 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 168.966 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 8.0 tm-20 -50.81 -51.67 48.63 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 114.957 -1.019 . . . . 10.0 108.279 172.448 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 133' ' ' GLU . . . . . 0.414 ' OE1' ' NZ ' ' B' ' 136' ' ' LYS . 7.2 tp10 -57.7 -40.51 79.65 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.812 0.671 . . . . 10.0 112.812 178.043 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -48.92 -50.09 36.97 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 119.9 1.227 . . . . 10.0 110.555 171.488 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -80.18 -19.63 46.63 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 112.983 0.734 . . . . 10.0 112.983 -174.23 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE1' ' B' ' 133' ' ' GLU . 2.5 ttmt -96.74 -42.76 7.84 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 124.957 1.303 . . . . 10.0 112.512 -173.403 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 60.7 p -135.14 -7.53 2.31 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 176.716 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.03 13.39 71.84 Favored Glycine 0 C--O 1.221 -0.662 0 CA-C-O 118.188 -1.34 . . . . 10.0 111.813 -170.039 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 64.81 19.54 11.87 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 120.18 1.99 . . . . 10.0 112.41 170.092 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.65 7.57 6.67 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.742 0.817 . . . . 10.0 112.525 -169.834 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.52 -166.81 52.69 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.453 -0.78 . . . . 10.0 111.262 173.075 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 50.2 m -60.36 141.79 55.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 113.522 0.934 . . . . 10.0 113.522 -168.505 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 143' ' ' ARG . . . . . 0.427 ' CG ' HG11 ' B' ' 118' ' ' VAL . 0.1 OUTLIER -60.38 97.19 0.05 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.85 1.66 . . . . 10.0 109.454 168.734 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 27.1 mt -72.64 -34.66 67.45 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 119.284 0.947 . . . . 10.0 111.989 178.51 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.406 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -152.15 149.05 28.35 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.887 -0.508 . . . . 10.0 110.476 176.257 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.74 142.14 46.41 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 126.991 2.116 . . . . 10.0 107.654 -176.439 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -140.88 160.96 26.74 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 109.176 -1.57 . . . . 10.0 109.176 168.944 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 51.8 t -119.23 131.45 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 104.52 -2.4 . . . . 10.0 104.52 174.181 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.415 ' HB ' ' O ' ' B' ' 113' ' ' ILE . 20.3 mt -73.35 146.81 10.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-N 119.332 0.969 . . . . 10.0 109.288 174.77 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.71 150.35 22.5 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 125.858 1.694 . . . . 10.0 109.053 179.603 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.0 pt -72.47 132.21 33.7 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.359 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 -176.11 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.68 -42.6 7.16 Favored 'General case' 0 CA--C 1.512 -0.519 0 C-N-CA 123.9 0.88 . . . . 10.0 109.932 173.281 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 153' ' ' GLN . . . . . 0.418 ' O ' ' N ' ' B' ' 1' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.433 -1.299 0 N-CA-C 105.17 -2.159 . . . . 10.0 105.17 176.327 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.881 0 N-CA-C 107.894 -1.15 . . . . 10.0 107.894 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.1 t -86.47 -16.47 36.97 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 166.625 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 47.5 tttt -131.88 164.54 25.86 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 125.603 1.561 . . . . 10.0 108.244 177.239 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -158.03 171.97 19.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 126.018 1.727 . . . . 10.0 106.689 168.537 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -133.05 173.93 14.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 107.702 -1.221 . . . . 10.0 107.702 171.246 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.46 113.24 6.05 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.302 -1.37 . . . . 10.0 107.302 165.46 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 5.8 m -92.62 120.32 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.623 -1.251 . . . . 10.0 107.623 168.141 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -100.13 131.7 45.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.861 -1.533 . . . . 10.0 106.861 179.289 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -141.78 158.73 43.45 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 106.325 -1.731 . . . . 10.0 106.325 167.766 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.25 -64.04 0.04 OUTLIER Glycine 0 N--CA 1.461 0.326 0 C-N-CA 119.393 -1.384 . . . . 10.0 113.685 168.772 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -72.7 -41.44 65.28 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.411 -1.329 . . . . 10.0 107.411 -172.927 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.03 -67.72 0.42 Allowed Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 114.173 -1.376 . . . . 10.0 111.667 169.443 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -57.8 -39.57 86.07 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.581 2.187 . . . . 10.0 111.367 179.002 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.18 118.88 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 107.902 -1.147 . . . . 10.0 107.902 179.645 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.63 104.09 8.49 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 103.548 -2.76 . . . . 10.0 103.548 168.702 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.72 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -86.23 142.27 18.82 Favored Glycine 0 N--CA 1.44 -1.086 0 N-CA-C 108.281 -1.928 . . . . 10.0 108.281 177.014 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.719 ' CG2' HG23 ' B' ' 54' ' ' THR . 5.2 mt -140.73 92.52 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 -174.248 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.7 mm -102.1 139.36 23.39 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 C-N-CA 124.487 1.115 . . . . 10.0 110.2 174.04 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -112.37 118.89 36.46 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 127.452 2.301 . . . . 10.0 106.88 168.601 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.535 ' CD2' HG12 ' A' ' 31' ' ' VAL . 4.6 m-85 -99.89 115.42 29.58 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 105.832 -1.914 . . . . 10.0 105.832 175.377 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -116.81 127.25 54.14 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 119.032 0.833 . . . . 10.0 110.444 170.002 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -79.8 88.16 5.25 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 106.236 -1.764 . . . . 10.0 106.236 174.562 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.23 -40.55 16.63 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 126.729 2.012 . . . . 10.0 112.099 -167.612 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -130.4 162.36 29.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 101.576 -3.49 . . . . 10.0 101.576 162.766 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.7 t -55.7 -33.36 64.11 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.738 -0.838 . . . . 10.0 108.738 173.518 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 30.3 m-80 -99.39 -2.15 36.93 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 125.749 1.62 . . . . 10.0 110.948 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.25 164.73 24.78 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.762 -0.935 . . . . 10.0 110.762 -170.804 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -61.95 149.57 89.74 Favored 'Trans proline' 0 N--CA 1.449 -1.125 0 C-N-CA 121.563 1.509 . . . . 10.0 108.29 169.477 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.0 t -86.11 122.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 -179.403 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.3 tttt -90.28 113.99 25.94 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 108.205 -1.035 . . . . 10.0 108.205 177.566 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.535 HG12 ' CD2' ' A' ' 20' ' ' PHE . 35.7 m -98.34 58.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 125.725 1.61 . . . . 10.0 108.395 -172.486 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.5 p90 -77.27 158.32 30.29 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 119.915 -0.714 . . . . 10.0 110.011 -175.281 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.02 179.9 48.21 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.968 179.145 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 20.4 m -150.41 96.39 2.39 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.503 -1.295 . . . . 10.0 107.503 -178.729 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.72 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.9 pt -77.65 154.76 5.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 170.908 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -138.82 146.97 41.93 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.266 -1.383 . . . . 10.0 107.266 169.317 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.09 -2.29 38.01 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.46 170.642 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.475 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.7 mp -72.31 178.83 3.7 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 119.398 1.599 . . . . 10.0 108.802 169.531 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 11.2 t -88.37 176.48 7.18 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 166.717 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 49.4 tt0 -64.02 169.69 4.15 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.04 0.936 . . . . 10.0 112.111 -172.311 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.12 -176.51 48.79 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 124.085 0.85 . . . . 10.0 113.079 167.15 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -62.42 150.85 38.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 123.815 0.846 . . . . 10.0 109.696 174.13 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -142.66 153.4 43.38 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 113.895 1.072 . . . . 10.0 113.895 176.614 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.6 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -39.54 125.02 2.1 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 127.542 2.496 . . . . 10.0 110.459 163.049 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.444 ' CD2' HG12 ' A' ' 119' ' ' VAL . 0.8 OUTLIER -149.73 105.85 3.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 119.823 1.811 . . . . 10.0 108.094 165.724 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.469 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -153.04 -179.99 8.18 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-O 121.844 0.83 . . . . 10.0 113.173 179.558 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.597 HG12 HD22 ' A' ' 117' ' ' LEU . 4.0 m -102.85 151.51 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 CA-C-N 113.219 -1.81 . . . . 10.0 110.345 174.116 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.85 133.4 45.89 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.276 1.83 . . . . 10.0 106.433 178.015 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.8 tp10 -62.41 -55.8 24.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 114.428 1.27 . . . . 10.0 114.428 -165.527 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 59.2 m-85 -77.66 144.94 36.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 117.612 -1.635 . . . . 10.0 108.243 179.652 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.38 20.8 48.35 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 172.684 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -80.67 70.73 7.47 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 125.765 2.698 . . . . 10.0 109.045 179.649 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.599 ' HB3' HG21 ' B' ' 7' ' ' VAL . 1.6 t-20 -69.33 -13.5 62.41 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 111.242 -2.708 . . . . 10.0 111.852 -174.056 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.54 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -27.69 -52.99 0.08 Allowed 'General case' 0 C--N 1.341 0.201 1 C-N-CA 131.92 4.088 . . . . 10.0 114.283 -175.799 . . . . . . . . 4 4 . 1 . 029 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.53 -14.77 59.58 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 124.068 0.947 . . . . 10.0 112.657 -172.518 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 107.1 52.96 0.71 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.925 -2.07 . . . . 10.0 107.925 -168.257 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 46.89 50.91 13.21 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.768 1.396 . . . . 10.0 114.768 169.784 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.2 p -111.79 -57.84 2.2 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 106.347 -1.723 . . . . 10.0 106.347 171.561 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.7 m -47.63 -33.19 6.41 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 127.167 2.187 . . . . 10.0 111.459 177.413 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -28.07 -39.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 128.666 2.786 . . . . 10.0 113.796 168.255 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.72 159.86 23.79 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 108.67 -1.772 . . . . 10.0 108.67 169.346 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -70.71 -170.25 0.44 Allowed 'Trans proline' 0 N--CA 1.445 -1.354 0 N-CA-C 107.585 -1.736 . . . . 10.0 107.585 167.5 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -78.89 55.93 1.83 Allowed 'General case' 0 CA--C 1.545 0.777 0 O-C-N 120.622 -1.299 . . . . 10.0 111.636 -170.121 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -74.88 64.47 1.29 Allowed 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 119.86 1.209 . . . . 10.0 112.275 -175.512 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.7 p-10 -57.6 155.37 21.1 Favored Pre-proline 0 CA--C 1.538 0.491 0 C-N-CA 123.283 0.633 . . . . 10.0 111.164 169.904 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -59.05 -45.8 26.05 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.534 2.156 . . . . 10.0 111.425 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -75.88 64.91 1.9 Allowed 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.116 -0.698 . . . . 10.0 109.116 174.725 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.9 p -42.04 113.76 0.47 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.685 1.194 . . . . 10.0 109.564 179.397 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.4 mtt-85 -145.97 -177.49 5.62 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 105.16 -2.163 . . . . 10.0 105.16 -169.88 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.4 mmtp -75.0 154.34 38.12 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 118.099 -1.44 . . . . 10.0 109.127 176.069 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -69.92 105.39 2.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 162.401 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.64 -140.65 6.85 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 107.909 -2.076 . . . . 10.0 107.909 173.822 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.7 -155.43 15.23 Favored Glycine 0 C--O 1.227 -0.309 0 CA-C-O 117.521 -1.711 . . . . 10.0 109.293 169.614 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -67.32 13.95 0.15 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 CA-C-N 120.378 2.089 . . . . 10.0 111.829 170.335 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 51.1 mttm -121.2 3.15 10.39 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-O 117.948 -1.025 . . . . 10.0 111.634 170.828 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -127.21 159.09 35.36 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 170.908 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -79.4 -32.52 42.97 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.639 -1.615 . . . . 10.0 106.639 167.017 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -82.89 28.48 0.49 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 124.58 1.152 . . . . 10.0 112.274 -168.643 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 164.08 11.97 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 119.839 1.199 . . . . 10.0 109.753 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -78.54 -67.58 0.73 Allowed 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.733 -0.604 . . . . 10.0 109.515 178.662 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -158.72 -116.35 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.827 -1.546 . . . . 10.0 106.827 -174.207 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -78.34 54.7 3.99 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-N 119.704 1.138 . . . . 10.0 111.012 178.749 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -79.46 92.3 5.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.735 -1.95 . . . . 10.0 105.735 170.014 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 29.1 mt -71.46 -21.7 61.92 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 118.755 -1.178 . . . . 10.0 108.204 175.325 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 83.13 -73.37 2.69 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.754 -1.338 . . . . 10.0 109.754 168.72 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -139.96 103.09 4.55 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 108.802 -0.814 . . . . 10.0 108.802 -169.412 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 23.9 m -109.09 129.53 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 119.068 0.849 . . . . 10.0 111.435 176.12 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -79.25 110.18 14.28 Favored 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 127.724 2.41 . . . . 10.0 112.371 -170.45 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.81 132.6 39.42 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 122.702 0.401 . . . . 10.0 110.154 169.946 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -53.5 166.98 0.24 Allowed 'General case' 0 CA--C 1.518 -0.258 0 O-C-N 124.093 0.871 . . . . 10.0 109.198 166.144 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -41.56 -43.19 2.64 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 126.324 1.85 . . . . 10.0 110.419 169.343 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.78 0.48 39.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.351 1.46 . . . . 10.0 110.948 -170.913 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.99 2.91 85.83 Favored Glycine 0 C--N 1.339 0.717 0 N-CA-C 111.408 -0.677 . . . . 10.0 111.408 178.116 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 33.1 t -78.97 106.5 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.376 -1.712 . . . . 10.0 106.376 -178.38 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.593 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -115.23 118.41 33.21 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 118.645 0.657 . . . . 10.0 109.638 176.541 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -79.73 126.68 31.26 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.526 1.93 . . . . 10.0 109.068 174.403 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -118.98 134.01 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.955 0 N-CA-C 107.319 -1.363 . . . . 10.0 107.319 175.548 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.8 p -156.62 59.75 0.55 Allowed 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 118.461 0.573 . . . . 10.0 110.872 174.457 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.11 153.48 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 -178.232 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -123.86 131.68 53.62 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 123.936 0.894 . . . . 10.0 108.908 169.398 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -120.57 147.95 44.51 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-O 121.639 0.733 . . . . 10.0 109.042 179.618 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.8 p -105.4 7.24 33.14 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.394 2.678 . . . . 10.0 111.865 -173.31 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.2 p -122.89 9.42 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.35 0.977 . . . . 10.0 110.763 179.525 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -108.45 150.03 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 105.944 -1.873 . . . . 10.0 105.944 176.773 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.7 m -146.29 152.69 39.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 169.939 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 55.4 mt -103.56 0.2 30.58 Favored 'General case' 0 C--O 1.237 0.437 0 C-N-CA 123.751 0.82 . . . . 10.0 111.66 -175.538 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.4 t -162.03 -172.38 3.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 126.472 1.909 . . . . 10.0 107.439 166.926 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 105.85 -69.87 0.23 Allowed Glycine 0 C--O 1.227 -0.336 0 C-N-CA 125.291 1.424 . . . . 10.0 110.307 167.302 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -162.69 -50.15 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 124.873 1.269 . . . . 10.0 107.611 -179.922 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -80.32 41.96 0.56 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.176 0.99 . . . . 10.0 109.034 179.449 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.5 t -81.4 83.8 6.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 126.076 1.75 . . . . 10.0 106.758 -171.773 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 20.8 pt -55.63 -21.61 10.42 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 113.649 0.981 . . . . 10.0 113.649 -170.172 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.417 ' H ' ' CD1' ' A' ' 113' ' ' ILE . 1.6 mp -14.04 -56.5 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 129.369 3.067 . . . . 10.0 115.139 174.866 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -87.7 6.6 83.19 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.208 -1.329 . . . . 10.0 114.812 -170.468 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.6 mpt_? -77.45 175.78 9.49 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.887 1.344 . . . . 10.0 108.751 174.014 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.41 ' C ' HD23 ' A' ' 117' ' ' LEU . 1.3 m -113.94 127.65 56.06 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.723 -1.584 . . . . 10.0 106.723 169.91 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.597 HD22 HG12 ' A' ' 47' ' ' VAL . 2.5 mt -102.86 152.73 20.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 118.754 0.707 . . . . 10.0 109.395 174.309 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.2 t -141.46 136.22 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 123.542 0.526 . . . . 10.0 110.178 -171.927 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.444 HG12 ' CD2' ' A' ' 45' ' ' PHE . 10.4 m -104.52 139.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 O-C-N 124.641 1.213 . . . . 10.0 109.201 164.13 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.6 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.5 m-70 -117.14 163.21 16.62 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 114.954 1.465 . . . . 10.0 114.954 -169.15 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -55.99 -54.66 42.19 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.693 -1.14 . . . . 10.0 110.103 178.032 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -111.31 173.4 6.36 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-O 121.305 0.574 . . . . 10.0 110.277 -178.231 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -96.19 136.82 36.15 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 125.24 1.416 . . . . 10.0 108.16 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.469 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -77.41 161.18 28.19 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 121.474 0.654 . . . . 10.0 111.943 -174.279 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -73.85 -15.5 61.16 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.763 -1.108 . . . . 10.0 110.809 -177.349 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mt 58.31 44.81 17.99 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.383 1.073 . . . . 10.0 108.292 -172.394 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.74 -15.65 59.45 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.96 1.267 . . . . 10.0 113.786 170.005 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -75.5 -4.46 39.89 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 114.838 1.421 . . . . 10.0 114.838 -166.548 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.51 -23.77 75.21 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-N 119.422 1.01 . . . . 10.0 110.65 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.34 18.74 50.95 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.812 -0.993 . . . . 10.0 114.429 179.267 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -116.92 176.66 5.02 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 119.474 1.637 . . . . 10.0 110.735 179.094 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -32.48 -61.76 0.25 Allowed 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 126.631 1.973 . . . . 10.0 112.186 171.396 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.88 -44.55 92.73 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.43 0.692 . . . . 10.0 111.529 178.536 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.8 m -49.24 -42.15 39.74 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 119.294 -0.384 . . . . 10.0 110.505 -176.06 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -87.18 -3.37 59.05 Favored 'General case' 0 N--CA 1.451 -0.386 0 O-C-N 124.32 1.013 . . . . 10.0 112.605 -172.464 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -114.53 -48.52 2.86 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.462 1.105 . . . . 10.0 111.521 -174.986 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 30.4 p -133.44 0.46 3.34 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 119.108 0.867 . . . . 10.0 112.286 171.658 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.75 -105.53 3.04 Favored Glycine 0 C--N 1.341 0.819 0 N-CA-C 107.289 -2.325 . . . . 10.0 107.289 -172.864 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.2 m-20 -167.52 43.44 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 125.298 1.439 . . . . 10.0 108.541 -179.477 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.43 -15.18 63.23 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.674 -0.641 . . . . 10.0 111.756 -177.636 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.17 -162.66 54.54 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 -176.742 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.1 m -62.25 149.52 41.67 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 113.736 1.013 . . . . 10.0 113.736 -170.043 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.2 74.59 0.69 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.161 2.584 . . . . 10.0 111.267 174.113 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.58 -27.32 67.62 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.187 -0.945 . . . . 10.0 113.361 -178.701 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.36 153.17 30.05 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 118.881 0.764 . . . . 10.0 110.392 171.737 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.0 p -155.52 155.64 33.77 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 123.081 0.552 . . . . 10.0 110.367 -168.482 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.92 162.64 30.56 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 124.054 0.835 . . . . 10.0 112.023 -174.727 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 62.1 t -122.64 66.85 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 105.263 -2.125 . . . . 10.0 105.263 -172.515 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.529 HD11 HD21 ' A' ' 117' ' ' LEU . 7.3 mm 30.44 -114.63 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 C-N-CA 127.1 2.16 . . . . 10.0 113.349 -173.737 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 126.61 102.5 1.25 Allowed Glycine 0 CA--C 1.531 1.045 0 N-CA-C 109.653 -1.379 . . . . 10.0 109.653 -169.536 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 56.3 mt -53.31 137.6 13.56 Favored 'Isoleucine or valine' 0 C--N 1.341 0.197 0 C-N-CA 124.151 0.98 . . . . 10.0 110.415 170.717 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.57 158.58 44.07 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 107.92 -1.141 . . . . 10.0 107.92 169.748 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.7 tt0 . . . . . 0 C--O 1.25 1.081 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 168.133 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.875 0 CA-C-O 118.538 -0.744 . . . . 10.0 109.62 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.7 t -90.57 -36.71 14.29 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.666 0.787 . . . . 10.0 110.705 169.951 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.3 tttp -127.44 124.15 37.77 Favored 'General case' 0 C--O 1.238 0.485 0 C-N-CA 125.798 1.639 . . . . 10.0 109.217 -171.814 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.11 155.92 49.89 Favored 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.741 0.816 . . . . 10.0 109.687 176.673 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.1 m -106.68 178.73 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 O-C-N 123.965 0.791 . . . . 10.0 109.94 176.944 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 6' ' ' ALA . . . . . 0.454 ' HB3' ' HB ' ' B' ' 18' ' ' ILE . . . -160.7 93.75 1.01 Allowed 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.35 1.46 . . . . 10.0 108.056 175.68 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.599 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.9 OUTLIER -92.41 95.09 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 C-N-CA 123.753 0.821 . . . . 10.0 110.722 179.453 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.401 HD22 HG23 ' B' ' 119' ' ' VAL . 1.6 mp -80.09 130.41 35.23 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 123.192 0.597 . . . . 10.0 109.41 175.938 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.34 158.99 44.44 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 106.211 -1.774 . . . . 10.0 106.211 168.938 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.48 -64.39 0.05 OUTLIER Glycine 0 CA--C 1.51 -0.231 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.967 169.311 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -70.34 -45.01 67.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 -178.831 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.11 -70.52 0.38 Allowed Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.425 -1.261 . . . . 10.0 110.784 169.571 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -57.12 -35.0 98.78 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 123.228 2.618 . . . . 10.0 111.821 175.81 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 37.4 t -68.63 89.24 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 C-N-CA 124.623 1.169 . . . . 10.0 107.986 179.033 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -113.12 116.22 29.51 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.109 -1.441 . . . . 10.0 107.109 -179.871 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.472 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -108.3 136.79 13.72 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.368 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.54 ' CG2' HG22 ' A' ' 54' ' ' THR . 7.8 mt -135.49 74.68 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 -175.286 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.454 ' HB ' ' HB3' ' B' ' 6' ' ' ALA . 28.7 mm -95.09 149.8 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 114.826 -1.079 . . . . 10.0 109.655 -172.347 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -126.37 114.6 18.43 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 126.775 2.03 . . . . 10.0 106.666 -170.57 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -102.36 115.54 30.78 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 106.229 -1.767 . . . . 10.0 106.229 176.559 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -119.24 137.51 53.61 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.085 0.772 . . . . 10.0 113.085 169.13 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -113.08 111.0 21.39 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 104.638 -2.356 . . . . 10.0 104.638 167.754 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? . . . . . 0 N--CA 1.445 -0.701 0 C-N-CA 125.554 1.542 . . . . 10.0 109.136 -176.117 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.891 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.02 163.16 39.67 Favored 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 123.051 2.501 . . . . 10.0 109.207 178.105 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -79.57 134.64 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 104.831 -2.285 . . . . 10.0 104.831 166.934 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 32.5 mttt -114.67 125.13 53.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 104.812 -2.292 . . . . 10.0 104.812 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -109.48 104.14 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 C-N-CA 126.404 1.882 . . . . 10.0 106.587 -178.072 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -126.16 159.46 32.88 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 112.728 0.64 . . . . 10.0 112.728 -178.029 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.99 -146.09 13.99 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 107.811 -2.116 . . . . 10.0 107.811 169.948 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 31.8 p -155.38 160.68 40.87 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 122.113 0.958 . . . . 10.0 112.044 175.033 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.75 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -110.92 145.42 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-N 113.25 -1.795 . . . . 10.0 107.509 166.871 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -125.15 142.97 51.17 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 107.167 -1.42 . . . . 10.0 107.167 168.834 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.22 0.57 20.69 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.082 0.849 . . . . 10.0 113.247 176.634 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.41 176.87 8.95 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 118.594 1.197 . . . . 10.0 110.321 -179.155 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -109.62 153.74 23.78 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.925 -1.88 . . . . 10.0 105.925 166.097 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.09 147.83 2.0 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.594 1.157 . . . . 10.0 112.315 -171.952 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.75 -173.22 18.25 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.05 0.833 . . . . 10.0 111.795 170.774 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -73.03 146.89 45.59 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.26 1.424 . . . . 10.0 110.594 -179.142 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -147.06 147.97 31.16 Favored 'General case' 0 C--N 1.342 0.25 0 N-CA-C 114.509 1.3 . . . . 10.0 114.509 -177.49 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.686 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.46 121.99 0.04 OUTLIER Glycine 0 C--N 1.339 0.738 0 C-N-CA 128.653 3.025 . . . . 10.0 114.501 164.587 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -152.72 109.2 3.42 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.665 1.233 . . . . 10.0 110.544 166.267 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.14 179.17 7.82 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.254 0.55 . . . . 10.0 112.193 173.098 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.4 m -116.56 134.24 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.066 -1.879 . . . . 10.0 106.848 166.02 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -110.91 152.99 26.1 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 125.268 1.427 . . . . 10.0 107.912 -178.701 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.23 -54.71 43.67 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.875 -0.602 . . . . 10.0 111.413 -172.863 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.51 111.96 13.79 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -169.189 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.57 -30.47 68.67 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.164 -1.174 . . . . 10.0 110.164 169.44 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -40.29 139.43 0.74 Allowed 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 124.788 1.235 . . . . 10.0 111.214 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -143.88 24.07 1.69 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 124.353 1.061 . . . . 10.0 112.551 169.863 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.719 HG23 ' CG2' ' A' ' 17' ' ' ILE . 3.6 m -61.82 -35.15 77.39 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.371 0.668 . . . . 10.0 110.748 -174.957 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.23 -16.45 59.82 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 122.215 -0.303 . . . . 10.0 111.582 176.103 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.39 -151.59 19.08 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 106.61 -2.596 . . . . 10.0 106.61 -169.656 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 1.8 m -69.26 67.63 0.19 Allowed 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 126.018 1.727 . . . . 10.0 111.298 -179.039 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -163.88 -53.16 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.317 1.847 . . . . 10.0 107.583 -179.299 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -39.16 -40.59 0.74 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 127.648 2.379 . . . . 10.0 111.235 174.132 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.81 -47.55 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.009 2.524 . . . . 10.0 114.062 168.28 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.08 152.24 26.45 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 110.424 -1.071 . . . . 10.0 110.424 173.512 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -79.13 46.94 2.34 Favored 'Trans proline' 0 CA--C 1.537 0.629 0 C-N-CA 124.379 3.386 . . . . 10.0 113.482 -171.065 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 57.14 58.03 4.19 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.1 1.76 . . . . 10.0 108.585 -175.825 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -66.77 75.64 0.11 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.769 0.795 . . . . 10.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -77.65 137.02 63.03 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.2 -0.938 . . . . 10.0 110.508 -177.52 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.06 -52.16 0.99 Allowed 'Trans proline' 0 N--CA 1.455 -0.752 0 C-N-CA 122.578 2.185 . . . . 10.0 111.132 -173.19 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mp -76.17 65.74 2.19 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 108.122 -1.066 . . . . 10.0 108.122 175.054 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 66.6 p -30.02 101.64 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.325 2.25 . . . . 10.0 114.021 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.2 mtp180 -139.85 177.7 7.77 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.072 0.949 . . . . 10.0 110.927 -174.729 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 67.2 mmtt -107.26 89.07 2.89 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 113.233 0.827 . . . . 10.0 113.233 -168.66 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.401 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 81.9 t60 5.73 92.85 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.23 0 C-N-CA 128.45 2.7 . . . . 10.0 114.849 179.219 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.24 -139.04 9.64 Favored Glycine 0 N--CA 1.442 -0.921 0 N-CA-C 110.144 -1.182 . . . . 10.0 110.144 178.0 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.03 -162.24 34.34 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 175.394 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.62 1.31 1.81 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 CA-C-N 120.055 1.927 . . . . 10.0 111.472 168.417 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.31 8.6 18.09 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.913 1.685 . . . . 10.0 110.516 176.4 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -142.03 169.62 17.24 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.442 1.019 . . . . 10.0 108.948 165.125 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -87.99 -22.6 24.17 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.235 -1.394 . . . . 10.0 107.235 167.996 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 -82.27 31.05 0.39 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 120.661 -1.274 . . . . 10.0 112.777 -176.526 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.6 132.7 54.77 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 172.898 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.401 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 16.9 m170 -63.17 -61.52 2.32 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 121.176 0.512 . . . . 10.0 110.538 -177.787 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.4 p -168.23 -56.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 -179.141 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.16 63.14 0.63 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 177.45 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.1 m-20 -92.7 95.5 9.6 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 104.101 -2.555 . . . . 10.0 104.101 167.528 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 9.2 mp -66.75 -26.61 67.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 118.828 0.74 . . . . 10.0 109.342 -176.713 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 116.9 -88.17 0.45 Allowed Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 108.106 -1.998 . . . . 10.0 108.106 168.631 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 38.5 m-80 -149.39 142.49 24.96 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.58 134.12 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 107.657 -1.238 . . . . 10.0 107.657 169.001 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -86.9 130.06 34.62 Favored 'General case' 0 C--O 1.226 -0.166 0 C-N-CA 123.978 0.911 . . . . 10.0 108.643 179.663 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.77 127.87 52.71 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.227 1.411 . . . . 10.0 109.43 175.247 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -61.29 167.71 3.04 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.888 1.368 . . . . 10.0 109.933 168.064 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -52.32 -30.8 30.11 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.681 1.192 . . . . 10.0 110.77 172.202 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -77.25 -7.73 56.42 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.035 0.379 . . . . 10.0 110.758 -177.541 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.14 17.01 73.02 Favored Glycine 0 C--N 1.34 0.788 0 N-CA-C 110.611 -0.995 . . . . 10.0 110.611 -178.497 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -94.54 119.29 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 C-N-CA 127.359 2.264 . . . . 10.0 105.434 172.532 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.75 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -115.82 126.6 54.21 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 123.706 0.802 . . . . 10.0 109.017 174.431 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -88.57 133.62 34.11 Favored 'General case' 0 N--CA 1.437 -1.096 0 C-N-CA 127.154 2.181 . . . . 10.0 109.567 178.936 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 50.1 t -113.97 130.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 C-N-CA 125.825 1.65 . . . . 10.0 108.228 174.624 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 78.1 p -157.78 73.81 0.71 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.132 0.973 . . . . 10.0 108.923 169.685 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.29 163.06 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 106.984 -1.487 . . . . 10.0 106.984 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -147.72 150.45 34.33 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 125.191 1.396 . . . . 10.0 109.933 174.333 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -155.32 159.28 39.84 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.323 -1.362 . . . . 10.0 107.323 172.881 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.2 p -104.81 -16.85 14.79 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 128.136 2.574 . . . . 10.0 112.281 179.053 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 4.5 p -78.34 -38.28 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 -176.387 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -70.64 154.72 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 C-N-CA 124.522 1.129 . . . . 10.0 107.978 168.771 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 11.1 m -153.77 163.28 40.28 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 172.088 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 79.2 mt -101.96 -11.06 19.24 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.797 0.839 . . . . 10.0 111.539 176.937 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.451 -0.38 0 C-N-CA 125.808 1.643 . . . . 10.0 107.239 169.498 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' B' B ' 111' ' ' SER . . . . . 0.681 ' O ' HG23 ' B' ' 112' ' ' ILE . 13.6 t . . . . . 0 N--CA 1.438 -1.069 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.681 HG23 ' O ' ' B' ' 111' ' ' SER . 39.4 pt 162.87 -23.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.336 1 C-N-CA 133.226 4.61 . . . . 10.0 107.34 -171.482 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -43.25 120.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 118.854 0.752 . . . . 10.0 110.397 175.425 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 104.0 -6.55 47.53 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.786 -1.008 . . . . 10.0 113.781 179.025 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -77.1 154.64 33.1 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 118.309 1.055 . . . . 10.0 110.288 175.562 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 32.6 m -94.93 109.03 21.09 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.565 1.146 . . . . 10.0 109.183 178.553 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -79.57 147.92 31.94 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 167.272 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 65.3 t -142.63 132.87 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 C-N-CA 123.953 0.901 . . . . 10.0 109.551 -173.565 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.401 HG23 HD22 ' B' ' 8' ' ' LEU . 2.7 t -109.0 136.67 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.648 0 C-N-CA 126.173 1.789 . . . . 10.0 109.898 172.239 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.686 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.6 m-70 -117.52 158.68 24.13 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 116.466 2.024 . . . . 10.0 116.466 -171.179 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 57.8 tt0 -48.8 -53.06 20.72 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 129.836 3.254 . . . . 10.0 111.813 175.166 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -112.75 168.79 9.38 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 123.332 0.653 . . . . 10.0 111.876 -169.704 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.62 154.1 40.92 Favored 'General case' 0 N--CA 1.443 -0.82 0 O-C-N 125.016 1.448 . . . . 10.0 108.214 169.013 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -107.25 140.53 39.98 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 124.197 0.999 . . . . 10.0 109.032 -169.014 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -72.99 -28.99 62.71 Favored 'General case' 0 C--O 1.232 0.168 0 O-C-N 123.724 0.64 . . . . 10.0 109.803 -175.331 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.6 mt 59.86 50.95 6.4 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 107.896 -1.15 . . . . 10.0 107.896 -171.413 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 94.05 -39.33 2.94 Favored Glycine 0 CA--C 1.521 0.456 0 C-N-CA 126.189 1.852 . . . . 10.0 110.788 169.531 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 29.8 mtmm -80.91 39.79 0.51 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.004 0.922 . . . . 10.0 112.591 -169.485 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.18 -24.11 13.39 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 126.565 2.031 . . . . 10.0 110.262 169.186 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 59.94 36.11 89.15 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 123.732 0.682 . . . . 10.0 111.547 176.517 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -137.67 166.6 23.55 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 108.467 -0.938 . . . . 10.0 108.467 173.0 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -48.5 -47.4 38.79 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 124.363 1.065 . . . . 10.0 110.295 -178.586 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -70.48 -33.7 71.55 Favored 'General case' 0 N--CA 1.448 -0.549 0 O-C-N 121.922 -0.486 . . . . 10.0 111.671 179.417 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 26.6 p -55.69 -45.76 77.74 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 119.398 0.999 . . . . 10.0 110.435 177.274 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.5 t -76.3 -14.38 60.11 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.756 -0.656 . . . . 10.0 112.345 -171.728 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 10.5 ttmt -107.16 -49.34 3.29 Favored 'General case' 0 N--CA 1.434 -1.255 0 C-N-CA 125.987 1.715 . . . . 10.0 110.904 -172.141 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.03 23.77 2.58 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.972 0.806 . . . . 10.0 111.673 176.223 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 61.4 26.62 66.56 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 119.516 1.053 . . . . 10.0 111.951 177.983 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 57.16 23.19 8.32 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.286 1.043 . . . . 10.0 112.908 -178.798 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.58 -12.31 9.66 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 125.554 1.542 . . . . 10.0 114.045 -175.889 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.11 -162.92 52.93 Favored Glycine 0 N--CA 1.445 -0.765 0 O-C-N 121.029 -1.044 . . . . 10.0 110.849 172.193 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.4 m -56.19 128.32 35.04 Favored 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 124.097 0.959 . . . . 10.0 111.807 -167.96 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -73.48 98.78 2.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.45 1.1 . . . . 10.0 108.105 178.169 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 36.2 mt -79.24 -28.53 42.46 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.039 0.536 . . . . 10.0 112.024 -171.978 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.59 138.74 22.41 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.146 -0.687 . . . . 10.0 109.146 179.341 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -137.52 130.23 30.01 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 -178.185 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.24 -174.05 13.63 Favored Glycine 0 C--O 1.228 -0.235 0 N-CA-C 109.5 -1.44 . . . . 10.0 109.5 178.459 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.7 t -131.68 150.97 34.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 103.478 -2.786 . . . . 10.0 103.478 168.245 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.1 mt -60.12 -86.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.574 1.15 . . . . 10.0 111.534 -168.166 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.94 128.88 6.17 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 110.627 -0.989 . . . . 10.0 110.627 -179.01 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.6 pt -76.68 126.91 37.76 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 177.987 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.99 -45.68 12.86 Favored 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 108.533 -0.914 . . . . 10.0 108.533 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 . . . . . 0 C--O 1.253 1.262 0 CA-C-O 116.016 -1.945 . . . . 10.0 109.665 -176.064 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 106.331 -1.729 . . . . 10.0 106.331 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -88.81 -16.09 32.93 Favored 'General case' 0 C--O 1.228 -0.076 0 CA-C-N 119.917 1.235 . . . . 10.0 111.475 177.118 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -151.88 144.54 24.27 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.245 0.475 . . . . 10.0 112.261 177.792 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.2 160.62 37.28 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.832 1.653 . . . . 10.0 109.497 173.865 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 t -121.58 150.99 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 125.762 1.625 . . . . 10.0 109.93 179.502 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.55 100.59 5.01 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.782 1.233 . . . . 10.0 108.98 169.671 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -83.97 109.12 17.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 109.85 -0.426 . . . . 10.0 109.85 170.555 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -96.19 145.95 25.1 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.069 0.948 . . . . 10.0 109.316 177.419 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -157.89 164.53 36.82 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 107.89 -1.152 . . . . 10.0 107.89 171.227 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.07 -67.3 0.02 OUTLIER Glycine 0 C--O 1.229 -0.174 0 N-CA-C 111.574 -0.611 . . . . 10.0 111.574 171.804 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -75.99 -42.1 49.22 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 107.358 -1.349 . . . . 10.0 107.358 -176.557 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.98 -67.12 0.53 Allowed Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 114.851 -1.068 . . . . 10.0 111.615 -177.308 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -57.29 -41.69 70.5 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.157 1.904 . . . . 10.0 110.888 179.563 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -69.56 108.84 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 N-CA-C 107.176 -1.416 . . . . 10.0 107.176 176.843 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -120.48 117.51 27.84 Favored 'General case' 0 N--CA 1.437 -1.098 0 C-N-CA 126.049 1.74 . . . . 10.0 106.757 174.395 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.866 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.31 142.27 15.99 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 108.973 -1.651 . . . . 10.0 108.973 169.177 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.496 ' CG2' HG22 ' B' ' 54' ' ' THR . 2.3 mt -145.49 67.18 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 N-CA-C 106.049 -1.834 . . . . 10.0 106.049 -173.611 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.6 mm -90.91 135.51 26.53 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 CA-C-N 116.39 -0.368 . . . . 10.0 110.061 -172.4 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 m-80 -101.84 132.55 47.55 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 125.019 1.328 . . . . 10.0 108.708 175.589 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -116.18 87.41 2.68 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 126.626 1.97 . . . . 10.0 107.822 178.541 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -83.94 155.83 22.64 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-O 121.46 0.648 . . . . 10.0 111.169 175.68 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -145.23 99.16 3.27 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 126.068 1.747 . . . . 10.0 107.174 174.828 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.4 ptmt -62.31 -57.48 11.22 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 122.172 -0.33 . . . . 10.0 110.128 179.305 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -128.91 163.01 26.21 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 103.814 -2.661 . . . . 10.0 103.814 168.093 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.4 t -76.75 -4.59 44.19 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 119.172 0.897 . . . . 10.0 109.904 173.189 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -80.92 -21.86 40.15 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 124.452 1.101 . . . . 10.0 109.532 168.914 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.71 148.72 30.81 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 110.132 -1.187 . . . . 10.0 110.132 178.316 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -64.72 141.14 71.02 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 N-CA-C 107.803 -1.653 . . . . 10.0 107.803 169.245 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.8 t -78.3 83.12 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 174.241 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.0 tttt -63.33 111.58 2.34 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.915 -1.142 . . . . 10.0 107.915 171.429 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 18.1 m -91.62 121.67 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 N-CA-C 106.884 -1.524 . . . . 10.0 106.884 176.769 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 31.0 p90 -133.04 151.09 52.08 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 122.19 0.995 . . . . 10.0 113.145 170.5 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.08 -177.19 47.17 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 109.629 -1.388 . . . . 10.0 109.629 170.071 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.2 m -128.76 103.27 6.97 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.745 -1.206 . . . . 10.0 107.745 -173.551 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.866 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.7 pt -77.02 150.36 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.39 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 168.281 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.63 141.86 43.23 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.644 -0.502 . . . . 10.0 109.644 169.312 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.05 0.33 28.48 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.323 0.963 . . . . 10.0 112.899 175.76 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -65.12 176.05 1.41 Allowed 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 121.998 0.904 . . . . 10.0 109.669 169.922 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -98.92 167.1 10.95 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.649 -1.612 . . . . 10.0 106.649 164.95 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -58.19 169.08 0.89 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.398 1.079 . . . . 10.0 111.256 -171.251 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.94 -178.34 45.11 Favored Glycine 0 N--CA 1.448 -0.526 0 O-C-N 120.883 -1.136 . . . . 10.0 111.896 166.992 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.9 mp -70.63 153.3 42.99 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.283 1.433 . . . . 10.0 110.395 179.832 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -148.92 143.44 26.2 Favored 'General case' 0 C--N 1.34 0.185 0 N-CA-C 113.627 0.973 . . . . 10.0 113.627 -175.439 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.599 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.06 127.91 0.25 Allowed Glycine 0 C--N 1.34 0.777 0 C-N-CA 126.963 2.221 . . . . 10.0 111.644 164.391 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.39 103.48 2.33 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 119.744 1.772 . . . . 10.0 111.394 168.409 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.527 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.01 174.62 13.43 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 114.253 1.205 . . . . 10.0 114.253 -173.382 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.1 p -79.16 140.81 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 112.016 -2.356 . . . . 10.0 107.966 166.567 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.4 ' CD2' ' CG2' ' A' ' 118' ' ' VAL . 86.5 m-70 -126.17 100.5 6.35 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 102.875 -3.009 . . . . 10.0 102.875 163.861 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 6.89 -78.84 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 128.67 2.788 . . . . 10.0 116.017 178.773 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -81.69 162.22 23.08 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 119.166 0.894 . . . . 10.0 110.63 -171.098 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.01 -18.87 58.74 Favored Glycine 0 CA--C 1.524 0.61 0 O-C-N 121.306 -0.871 . . . . 10.0 110.956 170.91 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -65.34 162.82 16.76 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 122.275 1.036 . . . . 10.0 112.716 -170.268 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.424 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -161.58 17.91 0.11 Allowed 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 113.931 1.086 . . . . 10.0 113.931 -169.452 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.406 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -51.81 -37.89 53.52 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.489 1.116 . . . . 10.0 113.464 -169.003 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.22 -21.94 45.56 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 112.306 0.484 . . . . 10.0 112.306 179.485 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.61 100.9 2.65 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 -174.313 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 52.0 30.68 7.66 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 125.379 1.472 . . . . 10.0 114.502 169.147 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.8 m -133.79 -59.35 0.85 Allowed 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 106.816 -1.55 . . . . 10.0 106.816 -173.585 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.3 m -47.5 -46.12 26.96 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 126.5 1.92 . . . . 10.0 111.52 -169.469 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.88 -49.7 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 128.239 2.616 . . . . 10.0 114.975 169.4 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.12 171.37 12.95 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.769 -0.932 . . . . 10.0 110.769 173.094 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -79.45 -136.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 123.384 2.723 . . . . 10.0 106.092 166.022 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 18.1 m170 -106.29 50.35 0.78 Allowed 'General case' 0 CA--C 1.544 0.733 0 CA-C-N 121.67 2.032 . . . . 10.0 110.102 171.371 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -78.69 61.35 2.97 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.618 1.554 . . . . 10.0 110.218 174.591 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -61.94 155.97 59.97 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 127.581 2.353 . . . . 10.0 111.138 171.089 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.19 -58.28 0.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.228 2.618 . . . . 10.0 112.75 178.452 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -78.05 58.64 2.02 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.941 0.791 . . . . 10.0 110.509 -177.983 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.8 t -59.08 110.76 1.11 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 122.913 0.485 . . . . 10.0 109.752 -174.709 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 65.8 mtt180 -127.2 -90.08 0.53 Allowed 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 105.361 -2.089 . . . . 10.0 105.361 178.166 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.1 mttm -144.43 156.35 44.16 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.001 0.905 . . . . 10.0 108.812 169.999 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -63.29 120.2 11.11 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 118.493 -1.283 . . . . 10.0 107.804 166.656 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.12 -156.64 7.04 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 106.571 -2.612 . . . . 10.0 106.571 177.282 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -151.14 -159.35 8.79 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 118.442 1.121 . . . . 10.0 112.007 178.781 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -71.1 12.11 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 121.414 1.409 . . . . 10.0 109.466 165.724 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 37.5 mmtm -95.87 -24.78 16.28 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 169.704 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.426 ' OD1' ' NZ ' ' A' ' 128' ' ' LYS . 20.4 m-20 -115.56 171.27 7.83 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 -170.016 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -121.14 10.13 10.63 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.539 1.135 . . . . 10.0 110.279 171.394 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -109.16 6.47 24.85 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.515 1.126 . . . . 10.0 110.497 172.098 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -47.3 148.27 1.33 Allowed 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.531 1.532 . . . . 10.0 110.263 178.058 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.2 m-70 -60.78 -64.11 1.07 Allowed 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 117.842 0.292 . . . . 10.0 111.185 -176.168 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.8 p -167.89 -51.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 C-N-CA 123.739 0.815 . . . . 10.0 109.266 174.552 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -136.51 47.96 0.94 Allowed Glycine 0 CA--C 1.526 0.741 0 C-N-CA 123.939 0.78 . . . . 10.0 111.327 -175.198 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -86.23 109.11 18.7 Favored 'General case' 0 CA--C 1.53 0.173 0 N-CA-C 105.068 -2.197 . . . . 10.0 105.068 168.395 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.3 mt -74.85 -14.57 60.69 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 118.607 0.639 . . . . 10.0 111.744 -170.94 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.61 -97.93 1.14 Allowed Glycine 0 N--CA 1.44 -1.048 0 N-CA-C 107.434 -2.267 . . . . 10.0 107.434 178.907 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -153.0 120.68 6.02 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 -172.317 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.1 m -102.53 147.27 9.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 N-CA-C 106.039 -1.838 . . . . 10.0 106.039 168.957 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -120.45 133.12 55.47 Favored 'General case' 0 C--N 1.334 -0.095 0 C-N-CA 123.426 0.69 . . . . 10.0 111.588 -173.358 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.75 132.75 48.69 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.244 1.018 . . . . 10.0 111.361 -175.025 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.04 172.74 0.53 Allowed 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 122.496 1.141 . . . . 10.0 110.319 167.778 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 mtmp? -63.15 -19.49 64.52 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 114.309 -1.314 . . . . 10.0 112.425 178.433 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -77.8 -20.31 53.47 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 122.35 0.26 . . . . 10.0 110.741 173.881 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.85 6.67 60.43 Favored Glycine 0 C--N 1.338 0.684 0 CA-C-O 118.749 -1.028 . . . . 10.0 110.685 -170.19 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 t -79.37 114.61 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 C-N-CA 125.502 1.521 . . . . 10.0 107.154 176.265 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.683 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -115.38 123.93 49.93 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.865 -0.791 . . . . 10.0 108.865 174.353 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -78.84 129.03 34.12 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.327 -0.99 . . . . 10.0 108.327 171.745 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.4 t -112.15 129.84 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 104.179 -2.526 . . . . 10.0 104.179 167.723 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.9 p -157.79 57.27 0.48 Allowed 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 123.025 0.53 . . . . 10.0 110.844 174.596 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.36 148.67 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 124.087 0.955 . . . . 10.0 109.024 -169.883 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -129.27 123.66 32.47 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.535 1.134 . . . . 10.0 110.243 174.253 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -127.61 107.15 9.67 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.823 1.649 . . . . 10.0 108.511 -177.653 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 45.2 p -85.22 58.54 5.09 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.823 2.049 . . . . 10.0 107.195 -171.294 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.3 p -142.07 -48.87 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 123.996 0.919 . . . . 10.0 109.307 -176.273 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.312 0.0 OUTLIER -79.91 174.65 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 N-CA-C 113.023 0.749 . . . . 10.0 113.023 174.933 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -167.88 155.0 8.17 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.994 1.318 . . . . 10.0 107.901 169.39 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 70.3 mt -62.29 -24.53 67.34 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 123.413 0.685 . . . . 10.0 111.214 -176.087 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.9 m -147.87 161.32 41.54 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.856 -1.905 . . . . 10.0 105.856 169.723 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 154.82 -74.57 0.24 Allowed Glycine 0 C--N 1.334 0.434 0 N-CA-C 109.925 -1.27 . . . . 10.0 109.925 -177.457 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -152.19 -53.69 0.12 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.768 2.027 . . . . 10.0 106.387 178.698 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -75.0 -38.6 61.54 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 114.069 -1.423 . . . . 10.0 108.507 -175.002 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.3 t 46.5 56.17 6.72 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.86 1.264 . . . . 10.0 110.309 169.401 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -66.77 6.92 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 N-CA-C 115.647 1.721 . . . . 10.0 115.647 -166.424 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.7 mm -57.41 142.02 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 167.103 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.95 19.21 79.77 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-O 118.916 -0.935 . . . . 10.0 114.033 175.129 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -79.81 175.87 10.24 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 106.779 -1.563 . . . . 10.0 106.779 166.035 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 16.5 m -111.64 131.92 54.94 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 103.302 -2.851 . . . . 10.0 103.302 169.467 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.422 HD12 ' HA ' ' A' ' 117' ' ' LEU . 0.5 OUTLIER -96.3 135.81 37.63 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 105.751 -1.944 . . . . 10.0 105.751 167.455 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.4 ' CG2' ' CD2' ' A' ' 48' ' ' HIS . 86.8 t -118.84 132.95 67.23 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.874 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 169.148 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.07 127.51 58.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.75 -1.945 . . . . 10.0 105.75 168.028 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.599 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.4 m-70 -103.69 159.13 15.88 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 123.529 1.633 . . . . 10.0 114.946 -169.835 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.687 ' HA ' HD22 ' A' ' 144' ' ' LEU . 10.6 tt0 -43.71 -60.73 1.66 Allowed 'General case' 0 N--CA 1.442 -0.873 0 C-N-CA 129.079 2.951 . . . . 10.0 110.041 172.62 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mtmm -115.93 175.4 5.56 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.912 1.285 . . . . 10.0 111.638 -171.897 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.57 149.54 32.99 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 125.938 1.695 . . . . 10.0 111.161 -176.963 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.527 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.9 m-20 -79.34 144.06 34.57 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.517 0.727 . . . . 10.0 112.567 175.502 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 m-20 -77.18 -35.55 55.74 Favored 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 124.781 1.301 . . . . 10.0 108.974 167.96 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 57.0 mt 66.55 48.8 1.43 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 125.439 1.496 . . . . 10.0 109.368 -167.689 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.83 50.21 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 125.243 1.402 . . . . 10.0 113.001 172.556 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.426 ' NZ ' ' OD1' ' A' ' 76' ' ' ASP . 18.1 mttm -78.82 -1.71 36.2 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.711 0.805 . . . . 10.0 111.273 -168.598 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.91 -26.58 73.2 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 109.087 -1.605 . . . . 10.0 109.087 166.387 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.32 39.25 82.1 Favored Glycine 0 C--N 1.341 0.856 0 N-CA-C 110.822 -0.911 . . . . 10.0 110.822 -179.544 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.9 m-80 -122.06 161.71 22.53 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 176.132 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.407 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 3.8 tm-20 -48.72 -45.5 39.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 113.388 -1.733 . . . . 10.0 108.781 171.038 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -64.76 -49.7 69.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.167 -0.47 . . . . 10.0 111.714 172.217 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.7 t -52.97 -44.72 67.36 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 120.552 -1.342 . . . . 10.0 110.65 -175.418 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.1 t -74.95 -5.98 46.8 Favored 'General case' 0 CA--C 1.538 0.492 0 O-C-N 123.186 0.304 . . . . 10.0 111.542 -174.955 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.407 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 87.9 mttt -102.83 -83.05 0.48 Allowed 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 126.578 1.951 . . . . 10.0 110.147 172.583 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.21 25.84 10.99 Favored 'General case' 0 C--N 1.345 0.391 0 CA-C-N 121.298 1.863 . . . . 10.0 112.988 -177.02 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 59.72 27.66 64.36 Favored Glycine 0 C--N 1.339 0.721 0 CA-C-N 118.942 0.792 . . . . 10.0 112.397 170.001 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.0 m-80 50.21 27.86 2.83 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 123.988 0.915 . . . . 10.0 112.689 -173.501 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.52 -3.85 9.85 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.527 -0.733 . . . . 10.0 112.243 179.694 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.35 -163.6 51.92 Favored Glycine 0 N--CA 1.443 -0.894 0 N-CA-C 110.866 -0.893 . . . . 10.0 110.866 169.192 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.8 m -56.98 142.22 42.58 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.5 0.667 . . . . 10.0 111.612 -169.248 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.0 mtp85 -68.9 64.79 0.12 Allowed 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 125.627 1.571 . . . . 10.0 109.681 175.357 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.687 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.9 tp -43.91 -35.11 1.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.669 1.988 . . . . 10.0 113.917 -174.537 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -162.53 159.06 24.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -162.16 168.15 22.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 -174.881 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.47 169.77 42.77 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 112.094 -0.402 . . . . 10.0 112.094 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.409 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 4.8 t -107.28 138.78 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 -171.304 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mt -80.11 136.58 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-N 118.0 0.364 . . . . 10.0 110.607 179.568 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.05 146.99 17.5 Favored Glycine 0 CA--C 1.53 0.984 0 C-N-CA 125.068 1.318 . . . . 10.0 110.81 176.977 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 10.8 pt -71.49 142.07 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.138 0 CA-C-N 117.82 0.81 . . . . 10.0 109.28 176.771 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.52 -19.71 8.05 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.282 1.433 . . . . 10.0 113.313 -176.372 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.9 tp60 . . . . . 0 C--O 1.254 1.298 0 C-N-CA 130.278 3.431 . . . . 10.0 117.278 -175.504 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 117.652 -1.166 . . . . 10.0 108.997 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.3 t -76.02 -37.35 58.51 Favored 'General case' 0 CA--C 1.516 -0.327 0 CA-C-N 120.217 1.371 . . . . 10.0 110.41 -178.767 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -124.54 136.44 53.99 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 123.377 0.671 . . . . 10.0 111.201 -171.561 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.36 165.5 28.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.146 1.378 . . . . 10.0 107.502 171.004 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.441 ' O ' HG23 ' B' ' 149' ' ' ILE . 7.9 m -128.32 -178.28 2.29 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 123.367 0.667 . . . . 10.0 110.114 178.904 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.39 110.97 4.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.774 1.23 . . . . 10.0 108.262 165.453 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.424 HG21 ' HB3' ' A' ' 53' ' ' ASN . 3.2 m -95.83 104.52 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 123.786 0.835 . . . . 10.0 109.615 170.633 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.413 ' N ' HD12 ' B' ' 8' ' ' LEU . 5.7 mp -95.06 135.57 36.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 124.026 0.93 . . . . 10.0 110.035 -177.947 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 43.2 mtpt -149.22 169.48 20.65 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 107.459 -1.312 . . . . 10.0 107.459 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.38 -72.6 0.04 OUTLIER Glycine 0 C--O 1.229 -0.201 0 CA-C-N 115.944 -0.571 . . . . 10.0 111.68 174.394 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -74.09 -41.29 61.91 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.15 -1.426 . . . . 10.0 107.15 -178.295 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.84 -65.92 0.58 Allowed Glycine 0 CA--C 1.526 0.759 0 C-N-CA 124.836 1.207 . . . . 10.0 110.498 -178.978 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -79.14 37.48 0.67 Allowed 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 124.874 3.716 . . . . 10.0 111.446 -175.282 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -148.74 108.11 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.534 0 N-CA-C 100.405 -3.924 . . . . 10.0 100.405 173.244 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.47 122.84 28.43 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 177.101 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.571 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -107.56 140.21 15.3 Favored Glycine 0 C--O 1.224 -0.508 0 N-CA-C 110.493 -1.043 . . . . 10.0 110.493 -179.745 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.406 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.6 mt -139.98 88.75 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.148 -1.427 . . . . 10.0 107.148 -174.317 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -100.23 146.52 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.13 0 C-N-CA 124.978 1.311 . . . . 10.0 111.288 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -123.99 121.3 34.91 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 127.056 2.142 . . . . 10.0 108.102 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -99.32 108.0 20.42 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.855 1.262 . . . . 10.0 107.999 171.761 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -105.13 139.08 40.34 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 119.039 0.836 . . . . 10.0 109.534 167.421 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -116.91 106.13 13.1 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.668 -1.604 . . . . 10.0 106.668 168.22 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt . . . . . 0 N--CA 1.424 -1.731 0 C-N-CA 125.343 1.457 . . . . 10.0 108.926 -178.317 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.163 0 CA-C-O 117.581 -1.677 . . . . 10.0 115.218 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -73.86 140.76 29.31 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 122.527 2.151 . . . . 10.0 108.77 175.091 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -85.81 99.5 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 107.212 -1.403 . . . . 10.0 107.212 173.754 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 60.4 mttm -79.3 109.06 13.29 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.489 -1.3 . . . . 10.0 107.489 174.093 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.39 97.21 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 126.446 1.899 . . . . 10.0 107.392 -178.153 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.7 p90 -116.18 171.31 7.89 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.245 0.545 . . . . 10.0 110.144 169.715 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.26 -165.41 36.59 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 111.126 -0.789 . . . . 10.0 111.126 170.069 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.3 m -154.68 107.86 2.84 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 108.876 -0.787 . . . . 10.0 108.876 -170.832 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.571 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.9 pt -79.87 177.71 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 108.869 -0.789 . . . . 10.0 108.869 169.01 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 tptt -153.5 153.88 33.29 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 170.858 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.17 -38.94 2.67 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 118.51 0.595 . . . . 10.0 111.622 169.728 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.519 ' H ' HD12 ' B' ' 38' ' ' LEU . 6.0 mp -64.14 177.0 0.87 Allowed 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 122.034 0.921 . . . . 10.0 111.664 -170.031 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -103.58 162.05 13.38 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.617 -0.719 . . . . 10.0 109.186 168.731 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -52.32 153.48 2.87 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 125.584 1.553 . . . . 10.0 112.18 -169.456 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.81 -173.41 20.04 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 123.517 0.58 . . . . 10.0 111.858 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -74.64 151.25 39.34 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.937 1.295 . . . . 10.0 110.364 -177.665 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -150.18 151.86 33.74 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 123.634 0.774 . . . . 10.0 112.605 -178.392 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.583 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -44.75 127.18 7.09 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 127.259 2.362 . . . . 10.0 110.96 165.985 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -154.73 111.17 3.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 119.038 1.419 . . . . 10.0 108.862 165.771 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.404 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -155.4 167.64 29.72 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-O 121.312 0.577 . . . . 10.0 111.466 179.285 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.0 m -86.51 149.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 112.504 -2.135 . . . . 10.0 106.563 168.014 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -117.57 164.01 15.58 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 123.014 0.526 . . . . 10.0 110.263 176.292 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -52.57 -54.41 33.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.162 0.985 . . . . 10.0 112.589 -176.025 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -106.54 -178.45 3.65 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 118.829 0.741 . . . . 10.0 109.381 178.219 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -139.47 13.41 3.22 Favored Glycine 0 C--N 1.333 0.382 0 O-C-N 122.109 -0.369 . . . . 10.0 113.461 176.093 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -67.13 153.31 43.98 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 107.276 -1.379 . . . . 10.0 107.276 167.188 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -149.13 22.53 0.96 Allowed 'General case' 0 N--CA 1.451 -0.421 0 O-C-N 121.649 -0.657 . . . . 10.0 112.189 -172.372 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.496 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -49.23 -38.42 26.46 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.758 2.023 . . . . 10.0 112.447 -177.489 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.2 -19.77 56.27 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 122.136 -0.353 . . . . 10.0 111.916 -178.278 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 125.9 -66.97 0.54 Allowed Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.309 -1.117 . . . . 10.0 110.309 -176.857 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 35.0 t -160.05 70.06 0.42 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 122.391 1.091 . . . . 10.0 110.625 -178.73 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -163.17 -50.73 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 125.282 1.433 . . . . 10.0 109.253 -174.235 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -48.8 -38.67 22.75 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 125.667 1.587 . . . . 10.0 111.447 -171.218 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.12 -41.54 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 128.662 2.785 . . . . 10.0 114.351 168.63 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.85 161.88 29.84 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 107.647 -2.181 . . . . 10.0 107.647 177.392 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -68.88 -143.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.547 1.132 0 C-N-CA 121.894 1.729 . . . . 10.0 109.615 169.783 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.6 m170 -104.17 42.91 1.14 Allowed 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.267 -1.52 . . . . 10.0 110.629 -179.665 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -73.31 71.98 1.26 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 120.601 1.546 . . . . 10.0 111.32 -179.707 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -62.56 155.06 70.76 Favored Pre-proline 0 CA--C 1.538 0.499 0 C-N-CA 124.218 1.007 . . . . 10.0 111.614 169.837 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.62 -47.95 2.54 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.282 1.988 . . . . 10.0 111.361 176.838 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.85 68.33 1.29 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.774 -0.579 . . . . 10.0 110.816 175.488 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 14.1 t -40.81 102.88 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.427 1.891 . . . . 10.0 111.782 -178.627 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.8 mtt85 -130.28 175.43 8.94 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 126.275 1.83 . . . . 10.0 108.863 177.07 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 62.0 mmtt -106.19 84.11 1.99 Allowed 'General case' 0 CA--C 1.531 0.227 0 CA-C-O 121.457 0.646 . . . . 10.0 112.473 -170.887 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 54.2 t60 13.79 88.39 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.433 2.293 . . . . 10.0 115.594 174.044 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -121.27 -164.6 12.37 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 126.985 2.231 . . . . 10.0 109.004 178.627 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.59 -154.88 15.24 Favored Glycine 0 C--O 1.227 -0.304 0 N-CA-C 106.973 -2.451 . . . . 10.0 106.973 -172.357 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -64.13 9.56 0.14 Allowed 'Trans proline' 0 CA--C 1.542 0.915 0 CA-C-N 120.119 1.96 . . . . 10.0 112.414 169.095 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.65 -31.33 11.27 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.738 1.215 . . . . 10.0 111.209 170.249 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -141.46 154.9 45.83 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-N 119.277 0.944 . . . . 10.0 110.445 -170.197 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 49.2 tt0 -75.87 -20.54 58.01 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.053 -1.091 . . . . 10.0 108.053 178.906 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -80.38 30.93 0.28 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.741 1.216 . . . . 10.0 112.096 -178.384 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -57.52 138.77 54.79 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.111 -0.993 . . . . 10.0 109.135 171.221 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -74.72 -61.03 2.02 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 179.776 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -156.42 -125.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 105.863 -1.903 . . . . 10.0 105.863 -174.444 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -74.4 69.96 1.66 Allowed Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.357 -1.097 . . . . 10.0 110.357 175.891 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -95.94 93.25 6.91 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 106.947 -1.501 . . . . 10.0 106.947 170.209 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.3 mt -65.19 -29.69 70.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.895 0.855 . . . . 10.0 108.987 178.814 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.87 -79.8 0.29 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 169.284 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 86' ' ' ASN . . . . . 0.484 HD22 ' HB1' ' B' ' 123' ' ' ALA . 23.6 m120 -144.17 108.07 4.71 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 118.185 -0.912 . . . . 10.0 108.627 -173.366 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.9 m -105.63 130.76 56.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 119.677 1.126 . . . . 10.0 111.924 -179.029 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -90.48 123.02 33.83 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 128.804 2.841 . . . . 10.0 111.269 -169.973 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.39 137.88 42.48 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 124.118 0.967 . . . . 10.0 111.411 177.198 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -62.08 171.65 1.69 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 124.325 1.05 . . . . 10.0 109.458 166.46 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.68 -28.96 58.38 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.554 0.742 . . . . 10.0 111.781 173.245 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -78.27 -3.94 45.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.336 0.588 . . . . 10.0 110.192 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.85 -0.63 82.61 Favored Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 110.257 -1.137 . . . . 10.0 110.257 -177.491 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.7 t -78.83 101.28 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 -173.154 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.49 117.19 30.39 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.45 -0.944 . . . . 10.0 108.45 168.392 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.37 106.84 12.69 Favored 'General case' 0 N--CA 1.435 -1.199 0 C-N-CA 126.814 2.046 . . . . 10.0 109.364 172.428 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 95.8 t -96.3 134.48 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.876 0 N-CA-C 106.964 -1.495 . . . . 10.0 106.964 178.626 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -158.22 79.09 0.82 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.382 0.673 . . . . 10.0 111.502 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -122.3 164.58 19.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 106.064 -1.828 . . . . 10.0 106.064 -179.419 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -138.1 145.0 41.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 121.469 -0.77 . . . . 10.0 111.498 168.743 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -109.62 104.15 13.12 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 125.769 1.628 . . . . 10.0 107.74 178.703 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 67.8 p -86.25 52.75 2.57 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 172.984 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 p -157.77 -49.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 C-N-CA 123.464 0.706 . . . . 10.0 109.325 -174.431 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 48.7 mm -66.58 155.46 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 108.704 -0.851 . . . . 10.0 108.704 169.845 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 41.3 m -153.13 137.35 16.51 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.232 -1.025 . . . . 10.0 108.232 174.455 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 34.5 mt -73.57 53.05 0.41 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.833 1.653 . . . . 10.0 111.459 177.28 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 CA--C 1.532 0.276 0 C-N-CA 127.942 2.497 . . . . 10.0 109.896 179.277 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.237 0.402 0 CA-C-O 122.085 0.945 . . . . 10.0 113.079 . . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.458 HD13 ' H ' ' B' ' 112' ' ' ILE . 0.1 OUTLIER -76.79 55.5 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-O 122.183 0.992 . . . . 10.0 109.518 167.439 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -117.75 -49.08 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 127.969 2.508 . . . . 10.0 108.295 178.659 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.04 10.25 71.47 Favored Glycine 0 CA--C 1.532 1.142 0 CA-C-O 119.193 -0.782 . . . . 10.0 112.794 -176.76 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -88.29 162.24 16.72 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 125.484 1.514 . . . . 10.0 108.892 178.678 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -103.84 140.24 37.92 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.505 0.722 . . . . 10.0 109.898 169.568 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.465 HD23 HG12 ' B' ' 149' ' ' ILE . 4.5 mm? -92.3 140.18 29.87 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 106.169 -1.789 . . . . 10.0 106.169 166.748 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 60.4 t -125.94 135.5 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 N-CA-C 107.563 -1.273 . . . . 10.0 107.563 174.736 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 8.6 p -105.39 129.68 57.88 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 106.216 -1.772 . . . . 10.0 106.216 169.109 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.583 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.5 m170 -113.31 157.75 21.42 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 115.13 1.53 . . . . 10.0 115.13 -169.362 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 58.3 tt0 -39.36 -63.24 0.57 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 128.518 2.727 . . . . 10.0 110.288 171.082 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 57.6 mttt -118.86 173.24 6.99 Favored 'General case' 0 CA--C 1.513 -0.461 0 C-N-CA 123.492 0.717 . . . . 10.0 109.685 -174.687 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 123' ' ' ALA . . . . . 0.484 ' HB1' HD22 ' B' ' 86' ' ' ASN . . . -92.41 148.78 21.84 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 179.309 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.643 ' HB2' ' CD2' ' B' ' 126' ' ' LEU . 0.9 OUTLIER -74.69 160.97 30.1 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.253 0.549 . . . . 10.0 111.675 -174.974 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.39 -28.53 61.14 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 114.624 -1.171 . . . . 10.0 110.152 174.855 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.643 ' CD2' ' HB2' ' B' ' 124' ' ' ASP . 2.8 mm? 62.57 56.95 1.93 Allowed 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 125.585 1.554 . . . . 10.0 109.847 -173.437 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 81.54 -40.57 2.61 Favored Glycine 0 CA--C 1.525 0.687 0 CA-C-N 113.971 -1.468 . . . . 10.0 111.78 168.115 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -77.13 49.29 0.67 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.048 1.339 . . . . 10.0 111.173 177.35 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.72 -32.67 4.69 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 126.226 1.869 . . . . 10.0 110.427 173.614 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.58 42.76 99.31 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.673 -0.971 . . . . 10.0 110.673 -171.761 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -132.76 163.35 29.21 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 106.607 -1.627 . . . . 10.0 106.607 173.338 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.57 -52.31 64.17 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 108.46 -0.941 . . . . 10.0 108.46 171.625 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -53.7 -33.54 55.85 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.216 -0.897 . . . . 10.0 112.416 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 21.0 p -52.15 -41.81 62.86 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-N 119.497 1.044 . . . . 10.0 110.649 179.21 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -85.01 -3.48 58.8 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-O 118.517 -0.754 . . . . 10.0 112.914 -178.97 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.95 -60.74 1.81 Allowed 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 126.291 1.836 . . . . 10.0 112.501 -174.223 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -136.25 23.77 3.24 Favored 'General case' 0 CA--C 1.547 0.827 0 CA-C-N 119.488 1.04 . . . . 10.0 110.483 175.447 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.16 -98.03 0.62 Allowed Glycine 0 C--N 1.342 0.91 0 N-CA-C 108.764 -1.734 . . . . 10.0 108.764 -177.461 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -165.34 43.57 0.08 Allowed 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 107.872 -1.158 . . . . 10.0 107.872 170.481 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.61 -19.69 64.01 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.396 0.678 . . . . 10.0 112.565 -174.13 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.01 -147.42 30.47 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 109.94 -1.264 . . . . 10.0 109.94 172.344 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.8 t -68.61 126.81 30.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.559 0.695 . . . . 10.0 110.64 -170.023 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.06 78.32 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.845 0.858 . . . . 10.0 110.604 169.502 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 56.5 mt -52.49 -40.17 62.05 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.922 -0.486 . . . . 10.0 112.11 179.331 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -149.13 145.65 27.3 Favored 'General case' 0 C--O 1.233 0.236 0 O-C-N 121.628 -0.67 . . . . 10.0 111.676 -179.574 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 m -123.72 147.9 47.06 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 126.686 1.995 . . . . 10.0 108.034 -178.224 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.61 141.95 10.82 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 109.761 -1.336 . . . . 10.0 109.761 171.598 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.409 ' HB ' ' HB ' ' A' ' 148' ' ' VAL . 95.8 t -89.8 150.57 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 102.894 -3.002 . . . . 10.0 102.894 172.646 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.465 HG12 HD23 ' B' ' 117' ' ' LEU . 90.4 mt -72.16 -88.03 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-O 121.474 0.654 . . . . 10.0 110.26 -167.566 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 99.87 132.69 7.82 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 124.329 0.966 . . . . 10.0 111.529 177.69 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 73.6 mt -63.31 147.75 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 125.155 1.382 . . . . 10.0 107.75 174.307 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.73 -32.81 4.43 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 113.466 0.913 . . . . 10.0 113.466 174.121 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? . . . . . 0 C--O 1.246 0.898 0 N-CA-C 108.042 -1.096 . . . . 10.0 108.042 178.66 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.444 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.5 t -166.22 -41.08 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 127.159 2.184 . . . . 10.0 112.938 178.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -119.37 137.29 53.83 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.244 -1.761 . . . . 10.0 106.244 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -136.73 145.21 44.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.578 HG12 ' HB2' ' A' ' 152' ' ' ALA . 0.2 OUTLIER -134.99 150.04 29.59 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.236 0 N-CA-C 107.003 -1.481 . . . . 10.0 107.003 174.476 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.694 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -127.03 129.19 47.56 Favored 'General case' 0 CA--C 1.512 -0.499 0 C-N-CA 126.938 2.095 . . . . 10.0 105.457 168.068 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.444 HG12 HG23 ' A' ' 17' ' ' ILE . 35.1 m -98.78 121.89 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 168.571 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -97.16 149.23 22.23 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 119.095 0.861 . . . . 10.0 109.046 177.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.47 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 13.1 tttt -159.29 160.35 35.08 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 108.432 -0.951 . . . . 10.0 108.432 169.685 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.35 -53.68 0.06 OUTLIER Glycine 0 C--N 1.332 0.35 0 N-CA-C 111.684 -0.566 . . . . 10.0 111.684 170.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -74.1 -45.86 46.44 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.36 -67.75 0.54 Allowed Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.031 -1.441 . . . . 10.0 110.568 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -57.11 -42.94 58.13 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.451 2.101 . . . . 10.0 110.41 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.2 t -63.94 97.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 106.522 -1.658 . . . . 10.0 106.522 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -116.28 118.6 33.21 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.129 -1.434 . . . . 10.0 107.129 169.415 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.426 ' HA2' ' CG2' ' A' ' 35' ' ' ILE . . . -99.17 152.95 19.68 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 109.931 -1.268 . . . . 10.0 109.931 174.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.444 HG23 HG12 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -156.47 83.69 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 -172.166 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.612 HD12 ' HA3' ' A' ' 33' ' ' GLY . 1.1 tp -85.35 157.21 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 C-N-CA 125.166 1.387 . . . . 10.0 111.016 176.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.438 ' HB2' ' CD1' ' A' ' 32' ' ' TRP . 5.1 m120 -139.1 99.5 3.78 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 127.567 2.347 . . . . 10.0 106.621 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 m-30 -99.07 102.85 14.68 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 105.194 -2.15 . . . . 10.0 105.194 174.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -117.67 132.48 56.48 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 120.409 -0.516 . . . . 10.0 111.591 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -104.36 107.99 19.18 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.701 -1.222 . . . . 10.0 107.701 172.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.2 pttp -54.53 -40.84 69.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 122.955 0.502 . . . . 10.0 110.65 174.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -146.37 172.92 12.78 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 104.937 -2.246 . . . . 10.0 104.937 168.399 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 86.8 p -69.12 -20.8 64.05 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 124.13 0.972 . . . . 10.0 109.576 174.3 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -93.89 -3.06 52.42 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.822 -0.627 . . . . 10.0 111.119 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.18 144.8 18.18 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 173.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -61.36 149.7 88.29 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 N-CA-C 106.902 -1.999 . . . . 10.0 106.902 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.7 t -79.0 120.96 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 N-CA-C 104.754 -2.313 . . . . 10.0 104.754 176.178 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.6 tttt -83.24 113.26 20.56 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 105.558 -2.015 . . . . 10.0 105.558 169.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.7 m -97.31 59.14 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 C-N-CA 125.774 1.63 . . . . 10.0 107.975 -170.257 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.438 ' CD1' ' HB2' ' A' ' 19' ' ' ASN . 14.8 p90 -84.7 171.85 12.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.167 -0.679 . . . . 10.0 109.167 -171.742 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.612 ' HA3' HD12 ' A' ' 18' ' ' ILE . . . 169.12 175.25 38.3 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 119.823 -1.179 . . . . 10.0 112.489 178.247 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.3 p -149.03 85.18 1.46 Allowed 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 121.066 0.46 . . . . 10.0 111.972 -169.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.707 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -76.83 147.19 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 107.664 -1.235 . . . . 10.0 107.664 174.446 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.99 156.14 46.77 Favored 'General case' 0 C--O 1.232 0.157 0 O-C-N 124.102 0.876 . . . . 10.0 110.015 167.586 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.22 2.86 48.16 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 124.043 0.83 . . . . 10.0 114.52 177.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.45 ' N ' HD12 ' A' ' 38' ' ' LEU . 5.3 mp -87.75 176.64 7.3 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.542 1.137 . . . . 10.0 108.778 -177.27 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -91.06 172.71 8.38 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 165.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -64.33 176.02 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.226 1.01 . . . . 10.0 110.889 -172.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.63 175.46 48.42 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 124.137 0.875 . . . . 10.0 111.581 167.272 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.443 HD22 ' HB3' ' A' ' 86' ' ' ASN . 4.7 mt -62.24 147.58 47.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.332 -0.511 . . . . 10.0 110.173 171.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -133.59 147.03 51.48 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.637 0.775 . . . . 10.0 110.678 176.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.621 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -36.14 112.89 0.14 Allowed Glycine 0 CA--C 1.526 0.736 0 CA-C-O 116.105 -2.497 . . . . 10.0 113.445 164.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -137.08 107.65 6.53 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 121.522 2.661 . . . . 10.0 111.916 170.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.452 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -148.17 -178.99 6.6 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 113.783 1.031 . . . . 10.0 113.783 -175.442 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.7 p -91.5 -47.59 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 127.554 2.342 . . . . 10.0 114.506 -169.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 57.1 161.96 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 125.498 1.519 . . . . 10.0 112.431 -169.064 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -78.01 -67.85 0.69 Allowed 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.944 -0.571 . . . . 10.0 109.862 -176.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -78.63 146.27 34.21 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 119.954 -0.699 . . . . 10.0 109.432 -171.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -75.74 -28.42 61.09 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 108.905 -1.678 . . . . 10.0 108.905 169.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.3 145.68 1.62 Allowed 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.746 1.26 . . . . 10.0 113.995 -175.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -135.8 16.06 3.33 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 113.679 -1.6 . . . . 10.0 110.453 -178.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.424 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -58.08 -36.45 72.86 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 119.181 0.901 . . . . 10.0 112.477 -169.745 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.07 -17.71 58.54 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 111.778 0.288 . . . . 10.0 111.778 178.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 97.85 84.18 1.74 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.107 -1.597 . . . . 10.0 109.107 -173.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 94.2 m 48.81 57.13 6.71 Favored 'General case' 0 N--CA 1.464 0.228 0 C-N-CA 124.305 1.042 . . . . 10.0 111.391 175.268 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -157.66 -54.61 0.07 Allowed 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.6 p -54.73 -30.26 55.73 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 124.121 0.968 . . . . 10.0 111.023 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.26 -38.47 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 127.977 2.511 . . . . 10.0 113.995 167.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.75 170.06 20.17 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -79.29 -167.13 0.47 Allowed 'Trans proline' 0 N--CA 1.439 -1.679 0 N-CA-C 106.377 -2.201 . . . . 10.0 106.377 166.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.452 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.4 m170 -83.32 59.07 4.82 Favored 'General case' 0 CA--C 1.537 0.457 0 O-C-N 120.561 -1.337 . . . . 10.0 110.097 -175.763 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -76.61 51.66 0.76 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.6 1.191 . . . . 10.0 112.587 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -56.94 149.72 42.7 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 125.601 1.561 . . . . 10.0 111.008 168.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -67.96 -48.04 1.56 Allowed 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.652 2.235 . . . . 10.0 111.401 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.92 54.09 0.98 Allowed 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.743 -0.598 . . . . 10.0 111.103 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.6 t -58.63 100.85 0.07 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.048 0.939 . . . . 10.0 110.111 -174.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtt-85 -113.78 -90.47 0.52 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 105.857 -1.905 . . . . 10.0 105.857 -177.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -149.42 144.59 26.46 Favored 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 109.334 -0.617 . . . . 10.0 109.334 168.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -51.5 119.78 4.48 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 119.714 -0.794 . . . . 10.0 109.929 168.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.0 -129.48 1.97 Allowed Glycine 0 N--CA 1.451 -0.359 0 N-CA-C 107.513 -2.235 . . . . 10.0 107.513 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.53 -143.29 5.84 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 118.182 0.991 . . . . 10.0 111.03 169.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -68.83 1.26 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 CA-C-N 120.075 1.937 . . . . 10.0 110.228 168.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 31.2 mmtp -93.9 -15.96 24.47 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-O 117.844 -1.074 . . . . 10.0 110.494 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -127.61 161.38 28.98 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 119.255 0.934 . . . . 10.0 109.5 -171.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -84.28 -28.91 26.83 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -78.94 -11.52 60.0 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 124.465 1.106 . . . . 10.0 112.059 -169.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.4 ptp180 -33.45 138.46 0.07 Allowed 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 126.415 1.886 . . . . 10.0 114.596 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.4 m170 -69.5 177.17 3.03 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.562 -0.533 . . . . 10.0 109.562 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 p -72.85 39.32 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 125.525 1.53 . . . . 10.0 114.228 -172.062 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 48.03 0.04 OUTLIER Glycine 0 CA--C 1.524 0.655 0 O-C-N 120.597 -1.315 . . . . 10.0 111.526 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -85.0 102.81 13.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 104.92 -2.252 . . . . 10.0 104.92 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.7 mt -74.62 -32.19 62.23 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 107.073 -1.454 . . . . 10.0 107.073 169.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.82 -104.35 3.04 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 109.586 -1.406 . . . . 10.0 109.586 168.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.443 ' HB3' HD22 ' A' ' 42' ' ' LEU . 39.9 m-20 -126.4 105.79 9.02 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 126.743 2.017 . . . . 10.0 106.511 -167.312 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.63 134.67 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 123.411 0.684 . . . . 10.0 109.566 173.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.58 122.43 26.49 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.524 2.73 . . . . 10.0 112.809 -167.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.01 133.99 34.86 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.49 0.716 . . . . 10.0 109.255 169.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -60.76 171.53 1.15 Allowed 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.459 0.703 . . . . 10.0 110.001 168.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 pttt -47.54 -34.22 7.37 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.741 1.617 . . . . 10.0 111.311 171.2 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.8 -7.25 59.36 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 123.655 0.782 . . . . 10.0 111.166 -176.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.86 1.22 77.09 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.77 -0.932 . . . . 10.0 110.77 -175.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -77.19 103.87 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 -176.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.707 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -101.43 114.37 28.32 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 107.809 -1.182 . . . . 10.0 107.809 169.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -85.44 127.96 34.57 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 107.539 -1.282 . . . . 10.0 107.539 169.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 56.9 t -110.11 132.04 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 106.389 -1.708 . . . . 10.0 106.389 170.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -154.52 71.28 0.82 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.994 0.918 . . . . 10.0 108.955 170.385 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -114.62 159.01 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 105.603 -1.999 . . . . 10.0 105.603 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -130.95 142.44 50.35 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.854 0.861 . . . . 10.0 110.074 172.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -131.25 133.66 45.65 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.266 1.027 . . . . 10.0 109.683 -172.019 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 62.3 p -110.96 57.09 0.62 Allowed 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.373 1.869 . . . . 10.0 108.63 174.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 96.0 t -141.77 -61.73 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.14 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 -177.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.279 0.0 OUTLIER -60.68 170.94 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 N-CA-C 113.229 0.826 . . . . 10.0 113.229 174.83 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.6 m -145.5 111.97 5.8 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 121.498 -0.751 . . . . 10.0 109.286 175.331 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.2 tt -49.05 -44.89 42.11 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 126.09 1.756 . . . . 10.0 109.955 177.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -143.72 160.8 40.08 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 106.465 -1.679 . . . . 10.0 106.465 169.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.32 -95.96 0.2 Allowed Glycine 0 C--N 1.334 0.418 0 N-CA-C 109.349 -1.5 . . . . 10.0 109.349 -177.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -119.54 -51.69 2.28 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.265 1.826 . . . . 10.0 107.886 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -73.51 -37.31 65.72 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.681 -1.229 . . . . 10.0 107.681 -171.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 t 47.47 59.27 4.22 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.773 1.629 . . . . 10.0 108.078 169.663 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.2 pt -74.86 65.77 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 O-C-N 124.622 1.201 . . . . 10.0 110.121 -172.308 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.7 mm -110.64 -68.34 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 127.808 2.443 . . . . 10.0 108.33 -176.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.68 51.8 4.06 Favored Glycine 0 CA--C 1.531 1.092 0 O-C-N 121.221 -0.925 . . . . 10.0 112.086 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.4 ptm180 -112.36 162.16 15.85 Favored 'General case' 0 CA--C 1.53 0.173 0 C-N-CA 127.213 2.205 . . . . 10.0 107.168 176.056 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -109.61 104.72 13.79 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 118.565 0.621 . . . . 10.0 109.513 -179.116 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -64.47 131.02 45.94 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 106.695 -1.594 . . . . 10.0 106.695 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.2 t -122.5 132.59 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.522 ' CG1' ' HB3' ' A' ' 145' ' ' ALA . 1.7 p -94.56 122.35 45.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 105.829 -1.915 . . . . 10.0 105.829 166.154 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.621 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.9 m-70 -100.92 162.78 12.66 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.711 0.767 . . . . 10.0 112.631 174.002 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -64.58 -56.16 15.76 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.48 -0.782 . . . . 10.0 109.316 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -98.8 165.49 11.75 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 119.474 -0.89 . . . . 10.0 112.076 -168.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.7 147.15 53.04 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.801 -1.545 . . . . 10.0 107.792 169.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.432 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 6.7 m-20 -78.45 163.49 25.57 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.86 -0.793 . . . . 10.0 108.86 172.499 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.15 -10.38 59.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 113.736 -1.575 . . . . 10.0 110.781 168.545 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.5 mt 43.02 45.92 4.61 Favored 'General case' 0 C--N 1.343 0.32 0 C-N-CA 124.826 1.25 . . . . 10.0 109.856 -168.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.19 -21.83 44.01 Favored Glycine 0 CA--C 1.529 0.968 0 CA-C-N 113.713 -1.585 . . . . 10.0 113.728 170.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -77.48 0.78 21.45 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 115.543 1.682 . . . . 10.0 115.543 -165.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.89 -36.59 88.23 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.831 -0.907 . . . . 10.0 110.831 177.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.23 39.82 98.34 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 108.31 -1.916 . . . . 10.0 108.31 -169.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -128.39 164.46 22.64 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -54.79 -47.98 73.3 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.131 -0.941 . . . . 10.0 108.62 174.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -55.08 -39.61 69.47 Favored 'General case' 0 C--N 1.344 0.347 0 C-N-CA 123.283 0.633 . . . . 10.0 111.387 171.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.305 1.8 p -58.73 -36.06 73.7 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-O 118.138 -0.934 . . . . 10.0 111.733 -173.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.1 t -83.06 3.31 30.94 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.315 0.962 . . . . 10.0 112.541 178.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -118.6 -81.17 0.62 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.669 1.588 . . . . 10.0 110.511 -174.071 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.8 p -108.52 9.71 27.38 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 121.067 1.758 . . . . 10.0 111.43 175.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.1 -79.83 1.87 Allowed Glycine 0 C--N 1.342 0.891 0 O-C-N 120.708 -1.245 . . . . 10.0 110.0 176.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 178.71 36.87 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.684 1.993 . . . . 10.0 109.347 178.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.75 -14.29 61.96 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 123.832 0.853 . . . . 10.0 111.978 -169.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.02 -170.05 54.44 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 109.146 -1.582 . . . . 10.0 109.146 -169.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.4 m -55.06 165.0 0.74 Allowed 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 124.295 1.038 . . . . 10.0 112.667 -177.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -80.96 114.32 19.76 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 167.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.413 ' N ' ' CD2' ' A' ' 144' ' ' LEU . 1.1 mm? -84.5 -45.29 12.78 Favored 'General case' 0 C--N 1.333 -0.149 0 N-CA-C 108.396 -0.965 . . . . 10.0 108.396 -176.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.522 ' HB3' ' CG1' ' A' ' 119' ' ' VAL . . . -147.29 157.04 43.44 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 p -154.28 164.1 39.11 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 116.44 -0.345 . . . . 10.0 110.762 -176.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.86 150.8 22.43 Favored Glycine 0 C--N 1.336 0.531 0 C-N-CA 124.246 0.927 . . . . 10.0 110.916 -173.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.73 148.4 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 104.34 -2.467 . . . . 10.0 104.34 175.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.694 HG12 ' HB2' ' A' ' 6' ' ' ALA . 83.9 mt -76.66 -86.79 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 122.649 1.214 . . . . 10.0 109.169 -171.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.18 25.4 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.744 1.64 . . . . 10.0 115.257 170.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER 63.8 152.64 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 C-N-CA 124.283 1.033 . . . . 10.0 111.413 -173.335 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.578 ' HB2' HG12 ' A' ' 5' ' ' VAL . . . -113.36 -49.05 2.92 Favored 'General case' 0 CA--C 1.51 -0.592 0 O-C-N 120.456 -1.403 . . . . 10.0 110.316 169.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.433 -1.316 0 N-CA-C 106.047 -1.834 . . . . 10.0 106.047 -178.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.941 0 CA-C-O 118.01 -0.995 . . . . 10.0 108.886 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.5 t -95.15 -45.27 7.27 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.967 0.907 . . . . 10.0 111.952 -175.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.7 tttp -111.09 133.83 53.16 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.328 1.051 . . . . 10.0 109.011 176.133 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 166.82 23.73 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.12 1.368 . . . . 10.0 108.408 171.419 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.49 175.19 10.59 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 123.046 0.538 . . . . 10.0 109.767 175.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 6' ' ' ALA . . . . . 0.474 ' CB ' HD12 ' B' ' 117' ' ' LEU . . . -149.45 103.85 3.32 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 106.346 -1.724 . . . . 10.0 106.346 166.325 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 22.7 m -83.13 111.84 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 108.834 -0.802 . . . . 10.0 108.834 170.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.96 143.45 26.85 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.056 -1.09 . . . . 10.0 108.056 175.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 9' ' ' LYS . . . . . 0.402 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 46.5 tttt -163.73 163.76 24.01 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 108.097 -1.075 . . . . 10.0 108.097 170.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.61 -50.76 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 111.803 -0.519 . . . . 10.0 111.803 169.111 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.24 -47.16 20.9 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.106 -1.442 . . . . 10.0 107.106 -169.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.18 -61.1 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.919 -1.491 . . . . 10.0 111.785 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -62.74 -39.15 44.65 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 122.642 2.228 . . . . 10.0 110.89 170.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 68.1 t -77.6 115.03 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.553 1.141 . . . . 10.0 108.255 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -147.46 139.05 23.95 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 123.208 0.318 . . . . 10.0 110.605 166.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -107.66 153.53 16.79 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 110.15 -1.18 . . . . 10.0 110.15 169.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.424 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.0 mt -138.93 59.41 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 106.179 -1.786 . . . . 10.0 106.179 -176.325 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.1 mm -78.86 136.72 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-N 115.221 -0.9 . . . . 10.0 109.205 -169.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -108.71 117.13 33.39 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 127.329 2.252 . . . . 10.0 108.076 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.463 ' CE1' HD11 ' B' ' 117' ' ' LEU . 21.9 m-85 -101.15 111.18 23.32 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.256 -1.387 . . . . 10.0 107.256 175.383 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -118.03 133.26 56.08 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-O 121.358 0.599 . . . . 10.0 112.068 172.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -121.72 113.15 19.31 Favored 'General case' 0 N--CA 1.446 -0.646 0 N-CA-C 105.519 -2.03 . . . . 10.0 105.519 170.089 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 39.2 pttt -59.97 -29.66 68.58 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.3 1.04 . . . . 10.0 110.725 -175.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 53.6 mt-10 -132.35 179.95 5.81 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 103.853 -2.647 . . . . 10.0 103.853 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 34.3 m -87.43 -1.08 57.67 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 118.698 0.681 . . . . 10.0 109.858 173.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 35.0 m-80 -128.71 4.48 5.5 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 123.981 0.913 . . . . 10.0 112.179 -176.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.37 174.88 55.0 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 109.893 -1.283 . . . . 10.0 109.893 175.107 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -60.88 136.63 67.19 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 CA-C-N 119.735 1.767 . . . . 10.0 109.537 169.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.7 t -79.86 97.41 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 104.038 -2.579 . . . . 10.0 104.038 168.13 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . 0.266 71.2 tttt -82.84 112.63 19.83 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 172.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -95.48 101.45 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 C-N-CA 126.952 2.101 . . . . 10.0 105.855 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -121.23 160.94 22.82 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 112.325 0.491 . . . . 10.0 112.325 173.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.87 -152.48 24.14 Favored Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 170.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 40.1 t -155.72 151.49 27.41 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 120.211 -0.596 . . . . 10.0 110.321 177.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.439 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 0.9 OUTLIER -100.99 122.98 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 N-CA-C 107.433 -1.321 . . . . 10.0 107.433 165.836 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 20.9 ptmt -105.38 139.89 39.32 Favored 'General case' 0 N--CA 1.453 -0.296 0 O-C-N 123.891 0.744 . . . . 10.0 108.995 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.18 -5.52 15.48 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.417 1.008 . . . . 10.0 113.269 176.157 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -68.21 176.76 2.57 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 118.366 1.083 . . . . 10.0 111.09 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -108.54 161.03 15.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.28 -2.118 . . . . 10.0 105.28 165.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -52.03 160.43 0.73 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.636 1.174 . . . . 10.0 111.725 -169.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.84 -179.98 34.38 Favored Glycine 0 N--CA 1.447 -0.602 0 O-C-N 121.549 -0.719 . . . . 10.0 111.486 168.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.9 mp -68.62 149.01 49.64 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.735 1.614 . . . . 10.0 110.446 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -148.75 148.63 30.21 Favored 'General case' 0 C--O 1.233 0.198 0 C-N-CA 123.42 0.688 . . . . 10.0 112.432 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.684 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.4 121.29 0.2 Allowed Glycine 0 C--N 1.339 0.748 0 C-N-CA 127.941 2.686 . . . . 10.0 113.038 165.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -151.64 110.92 3.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 119.088 1.444 . . . . 10.0 110.044 167.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.521 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.2 OUTLIER -144.24 174.3 11.01 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-O 121.373 0.606 . . . . 10.0 111.888 178.131 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 47' ' ' VAL . . . . . 0.589 HG12 HH11 ' B' ' 115' ' ' ARG . 3.2 t -114.42 86.75 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 CA-C-N 112.599 -2.091 . . . . 10.0 107.981 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -67.66 149.99 49.31 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 124.876 1.27 . . . . 10.0 109.898 174.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -71.65 -59.6 2.67 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.136 -1.393 . . . . 10.0 110.412 -170.127 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -79.09 136.59 37.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 120.891 -0.323 . . . . 10.0 110.237 -171.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -54.75 -50.42 57.99 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 108.304 -1.918 . . . . 10.0 108.304 169.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -24.12 124.0 0.04 OUTLIER 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 128.069 2.547 . . . . 10.0 113.737 -173.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.92 11.99 2.65 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.63 -175.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.43 HG23 HG22 ' A' ' 17' ' ' ILE . 0.2 OUTLIER -51.41 -40.35 59.13 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 126.049 1.74 . . . . 10.0 111.389 -170.867 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.51 -20.73 46.51 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 124.703 1.201 . . . . 10.0 113.209 178.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.92 82.83 1.67 Allowed Glycine 0 CA--C 1.528 0.864 0 C-N-CA 124.67 1.129 . . . . 10.0 110.624 -178.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.9 m 53.22 21.1 2.09 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.382 1.473 . . . . 10.0 112.733 176.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -111.56 -42.29 3.89 Favored 'General case' 0 N--CA 1.437 -1.089 0 O-C-N 120.613 -1.304 . . . . 10.0 108.092 -168.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 70.3 m -92.14 -11.05 36.67 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 117.831 -1.08 . . . . 10.0 113.541 -168.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.35 2.01 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 128.597 2.759 . . . . 10.0 117.14 -174.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.2 119.24 2.25 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 109.482 -1.447 . . . . 10.0 109.482 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -76.52 64.12 7.31 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.483 2.789 . . . . 10.0 111.02 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 22.5 m170 69.53 53.62 0.41 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 128.752 2.821 . . . . 10.0 110.132 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -73.95 52.08 0.42 Allowed 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.306 1.042 . . . . 10.0 112.997 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -65.49 153.91 89.2 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 126.823 2.049 . . . . 10.0 111.62 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.8 -43.94 2.34 Favored 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 123.079 2.519 . . . . 10.0 111.955 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 67.3 mt -78.85 53.77 1.44 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.718 0.807 . . . . 10.0 110.363 -177.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.6 p -58.39 102.41 0.11 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.823 1.249 . . . . 10.0 110.337 -172.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 mtp85 -132.48 -87.88 0.44 Allowed 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 -171.003 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -145.13 155.61 43.41 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 121.689 0.757 . . . . 10.0 109.444 168.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -63.05 120.7 11.93 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 105.592 -2.003 . . . . 10.0 105.592 163.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -140.29 -136.44 3.34 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 107.602 -2.199 . . . . 10.0 107.602 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.36 -166.37 32.91 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.11 10.12 0.42 Allowed 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.607 1.538 . . . . 10.0 109.938 166.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 45.0 mmtt -97.28 -25.67 15.18 Favored 'General case' 0 N--CA 1.44 -0.927 0 C-N-CA 124.75 1.22 . . . . 10.0 107.818 173.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.415 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 23.1 m-20 -120.69 158.12 28.15 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.488 -1.671 . . . . 10.0 106.488 -169.404 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -80.66 -34.11 35.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.776 -1.194 . . . . 10.0 107.776 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -78.31 1.6 21.24 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 125.939 1.696 . . . . 10.0 113.311 -165.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -40.24 144.18 0.24 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.037 1.735 . . . . 10.0 111.694 174.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.4 m170 -61.52 -58.03 9.76 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-O 120.989 0.424 . . . . 10.0 110.425 -175.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.555 HG13 ' H ' ' B' ' 82' ' ' GLY . 5.2 p -174.2 -69.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.457 -0.104 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 172.197 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.555 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -104.7 62.22 0.37 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 109.478 -1.449 . . . . 10.0 109.478 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -100.5 95.52 6.78 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 103.878 -2.638 . . . . 10.0 103.878 168.047 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.54 -17.87 64.81 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.694 0.679 . . . . 10.0 111.454 -171.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 107.24 -103.08 1.92 Allowed Glycine 0 N--CA 1.438 -1.228 0 N-CA-C 106.08 -2.808 . . . . 10.0 106.08 -176.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -147.65 139.11 23.78 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 -178.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 28.5 m -106.82 134.45 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.243 0 N-CA-C 105.914 -1.884 . . . . 10.0 105.914 169.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.2 t -109.13 126.21 52.99 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.527 -0.546 . . . . 10.0 109.527 -173.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.42 132.09 37.05 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 122.9 0.48 . . . . 10.0 110.773 -176.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -60.69 168.86 2.05 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 166.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -50.3 -29.26 9.35 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 126.387 1.875 . . . . 10.0 111.414 173.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -78.06 -11.88 59.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.967 0.507 . . . . 10.0 110.701 -177.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.29 20.59 48.34 Favored Glycine 0 C--N 1.338 0.694 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -103.66 107.31 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.838 0 C-N-CA 127.13 2.172 . . . . 10.0 106.115 -178.651 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.401 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -104.95 125.29 50.79 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 108.883 -0.784 . . . . 10.0 108.883 171.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -79.37 135.0 36.59 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.612 1.165 . . . . 10.0 109.807 175.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.26 129.83 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 127.145 2.178 . . . . 10.0 106.436 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.2 p -158.69 57.4 0.44 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.277 0.944 . . . . 10.0 112.726 176.435 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.4 152.38 12.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.954 0.902 . . . . 10.0 109.554 -169.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -99.27 112.21 24.42 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 10.0 109.708 167.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -79.13 71.41 5.62 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 104.89 -2.263 . . . . 10.0 104.89 169.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.09 54.37 2.75 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 127.011 2.124 . . . . 10.0 105.416 -174.134 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.5 t -148.0 -51.99 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 125.817 1.647 . . . . 10.0 109.393 -168.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.435 ' C ' HD12 ' B' ' 104' ' ' ILE 0.322 1.2 pp -113.37 -178.8 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 126.203 1.801 . . . . 10.0 112.683 -172.445 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 61.2 m -146.94 151.84 37.67 Favored 'General case' 0 C--O 1.232 0.172 0 O-C-N 121.052 -1.03 . . . . 10.0 110.78 -178.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 81.9 mt -70.39 -33.85 71.88 Favored 'General case' 0 N--CA 1.458 -0.047 0 C-N-CA 124.271 1.028 . . . . 10.0 110.891 -177.65 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.4 p -153.84 153.89 32.94 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 108.866 -0.79 . . . . 10.0 108.866 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.88 -100.92 0.5 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 106.497 -2.641 . . . . 10.0 106.497 -169.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -123.86 -44.82 2.05 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 125.444 1.498 . . . . 10.0 109.184 -169.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 12.1 m-70 -75.12 -41.83 57.64 Favored 'General case' 0 N--CA 1.456 -0.127 0 N-CA-C 108.05 -1.093 . . . . 10.0 108.05 -178.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 39.8 t 42.48 57.64 3.36 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 125.67 1.588 . . . . 10.0 113.581 167.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -71.19 -7.1 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 113.789 1.033 . . . . 10.0 113.789 -174.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.7 mm -52.14 127.71 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 109.17 -0.678 . . . . 10.0 109.17 173.395 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.78 -25.5 11.74 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.383 -0.687 . . . . 10.0 111.383 -175.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 115' ' ' ARG . . . . . 0.589 HH11 HG12 ' B' ' 47' ' ' VAL . 13.3 mtp-105 -72.05 161.8 30.37 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 119.094 1.447 . . . . 10.0 109.526 -169.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -111.03 131.77 54.78 Favored 'General case' 0 CA--C 1.514 -0.412 0 C-N-CA 124.53 1.132 . . . . 10.0 109.652 -167.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.474 HD12 ' CB ' ' B' ' 6' ' ' ALA . 26.4 mt -104.64 140.38 38.11 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.674 -0.861 . . . . 10.0 108.674 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 85.5 t -134.41 125.81 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.884 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 -175.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.407 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 2.3 p -90.35 129.02 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.772 -1.566 . . . . 10.0 106.772 167.55 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.684 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.8 m170 -106.54 157.12 17.91 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.076 1.139 . . . . 10.0 114.076 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -50.63 -51.84 45.18 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.667 1.587 . . . . 10.0 110.906 176.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -115.67 167.87 10.53 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-N 118.581 0.628 . . . . 10.0 111.593 -169.506 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.13 150.17 49.52 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.744 -1.116 . . . . 10.0 110.022 177.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.521 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.6 OUTLIER -79.16 135.16 36.73 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.204 1.002 . . . . 10.0 110.903 171.9 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -79.39 -15.83 57.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 124.621 1.201 . . . . 10.0 110.541 167.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 80.0 mt 58.86 46.11 14.37 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.234 1.014 . . . . 10.0 111.667 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.34 -51.76 1.24 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 110.22 -1.152 . . . . 10.0 110.22 173.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.415 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -82.21 48.77 1.3 Allowed 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 117.583 0.691 . . . . 10.0 112.099 -175.7 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.13 -38.52 5.67 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 108.648 -1.781 . . . . 10.0 108.648 169.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.54 33.26 16.95 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 178.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -130.61 165.08 23.55 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 105.83 -1.915 . . . . 10.0 105.83 168.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -50.38 -43.9 54.64 Favored 'General case' 0 N--CA 1.425 -1.724 0 CA-C-O 121.863 0.84 . . . . 10.0 108.796 171.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -65.7 -35.36 80.54 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-O 117.903 -1.046 . . . . 10.0 112.929 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 44.0 p -54.49 -46.28 73.39 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 120.987 1.721 . . . . 10.0 110.037 171.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -78.47 -13.65 59.74 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 118.11 -0.948 . . . . 10.0 113.162 -174.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.1 ttmm -103.92 -50.85 3.29 Favored 'General case' 0 N--CA 1.443 -0.778 0 C-N-CA 126.518 1.927 . . . . 10.0 112.51 -174.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 19.3 p -137.21 8.41 2.93 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 119.683 1.128 . . . . 10.0 113.658 174.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 88.23 20.56 48.65 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-O 118.577 -1.124 . . . . 10.0 113.215 174.438 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 6.9 m120 56.09 17.35 2.64 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 119.108 1.454 . . . . 10.0 112.244 -176.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.43 -11.69 58.43 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.007 0.923 . . . . 10.0 112.128 -174.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.97 -160.46 48.41 Favored Glycine 0 N--CA 1.441 -0.973 0 N-CA-C 111.104 -0.798 . . . . 10.0 111.104 168.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.8 m -51.6 125.27 14.26 Favored 'General case' 0 N--CA 1.439 -1.015 0 C-N-CA 124.622 1.169 . . . . 10.0 113.31 -168.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.5 mtm-85 -72.01 75.69 0.92 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 125.412 1.485 . . . . 10.0 109.595 176.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 70.2 mt -43.73 -49.08 8.02 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.997 0.919 . . . . 10.0 112.26 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.407 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -153.99 153.62 32.29 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.796 -0.816 . . . . 10.0 108.796 -168.797 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.06 166.12 34.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.58 -0.282 . . . . 10.0 110.805 -174.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.63 163.29 30.73 Favored Glycine 0 CA--C 1.523 0.563 0 C-N-CA 125.096 1.331 . . . . 10.0 109.856 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 37.6 t -120.94 136.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 106.088 -1.819 . . . . 10.0 106.088 -173.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 64.2 mt -70.52 130.42 34.71 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-N 118.175 0.443 . . . . 10.0 110.617 -177.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.64 141.98 13.24 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 124.254 0.93 . . . . 10.0 110.794 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -71.26 151.9 8.73 Favored 'Isoleucine or valine' 0 C--N 1.342 0.278 0 CA-C-N 118.44 1.12 . . . . 10.0 111.587 -178.323 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.3 -33.59 2.13 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 124.768 1.227 . . . . 10.0 113.267 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.063 0 CA-C-O 116.856 -1.545 . . . . 10.0 107.424 171.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.601 0 CA-C-O 118.863 -0.589 . . . . 10.0 110.059 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.9 t 125.01 -23.95 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 1 C-N-CA 131.942 4.097 . . . . 10.0 108.523 -174.309 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp -131.0 132.31 44.91 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 126.071 1.748 . . . . 10.0 108.124 169.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.54 168.75 18.66 Favored 'General case' 0 N--CA 1.462 0.149 0 C-N-CA 124.747 1.219 . . . . 10.0 109.443 169.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.413 ' O ' HG23 ' A' ' 149' ' ' ILE . 2.2 m -127.65 179.24 3.84 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.357 0 C-N-CA 124.177 0.991 . . . . 10.0 110.766 -174.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.81 114.77 2.64 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 106.879 -1.526 . . . . 10.0 106.879 164.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -98.66 96.26 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 C-N-CA 124.018 0.927 . . . . 10.0 110.21 172.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 mp -84.57 142.67 29.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.416 1.086 . . . . 10.0 110.023 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -153.2 165.06 36.85 Favored 'General case' 0 C--N 1.338 0.074 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 169.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.48 -59.65 0.04 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.391 -0.368 . . . . 10.0 113.268 169.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.19 -42.92 62.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -170.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.25 -66.51 0.53 Allowed Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 113.728 -1.578 . . . . 10.0 109.708 176.331 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -58.33 -39.95 79.77 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.62 2.213 . . . . 10.0 110.808 171.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.47 HG13 HD11 ' A' ' 38' ' ' LEU . 54.9 t -63.73 110.63 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 N-CA-C 108.134 -1.062 . . . . 10.0 108.134 178.17 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.18 132.01 51.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 168.549 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.687 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -114.28 134.03 11.49 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 109.47 -1.452 . . . . 10.0 109.47 174.226 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.43 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.9 mt -136.19 97.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 -170.298 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -102.52 152.24 5.74 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 C-N-CA 124.464 1.106 . . . . 10.0 110.979 -176.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -126.53 113.94 17.45 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 126.294 1.838 . . . . 10.0 107.714 169.167 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -96.94 100.01 11.54 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 172.316 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -110.65 118.73 36.99 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 120.436 -0.506 . . . . 10.0 111.594 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -90.73 103.61 16.29 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 105.752 -1.944 . . . . 10.0 105.752 172.222 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 27.1 mmmt -48.31 -57.56 5.82 Favored 'General case' 0 C--O 1.228 -0.071 0 C-N-CA 125.433 1.493 . . . . 10.0 110.811 -177.237 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.14 178.96 6.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 104.258 -2.497 . . . . 10.0 104.258 169.464 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -66.32 -26.98 67.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.594 0.712 . . . . 10.0 109.733 175.231 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -77.89 -22.68 49.39 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.507 -0.77 . . . . 10.0 109.815 177.405 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.8 144.75 22.24 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 110.779 -0.928 . . . . 10.0 110.779 -173.269 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -63.54 153.9 72.06 Favored 'Trans proline' 0 N--CA 1.449 -1.122 0 N-CA-C 107.237 -1.871 . . . . 10.0 107.237 168.235 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.4 p -77.21 117.24 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 N-CA-C 106.174 -1.787 . . . . 10.0 106.174 173.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 48.4 tttp -85.11 108.8 17.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 106.361 -1.718 . . . . 10.0 106.361 169.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -88.41 93.84 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.112 -1.811 . . . . 10.0 106.112 171.608 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.3 p90 -106.27 165.77 11.0 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 108.901 -0.777 . . . . 10.0 108.901 168.471 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.84 163.77 30.54 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -140.23 94.51 2.76 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.209 -1.034 . . . . 10.0 108.209 -175.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.687 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.7 pt -77.83 172.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 118.754 -1.179 . . . . 10.0 109.157 171.31 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -155.58 151.47 27.6 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 167.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.69 -18.97 19.38 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-O 118.83 -0.984 . . . . 10.0 114.036 174.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.47 HD11 HG13 ' A' ' 14' ' ' VAL . 6.8 mp -71.86 179.24 3.26 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 119.34 1.57 . . . . 10.0 111.672 -178.779 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -95.53 164.89 12.6 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.085 -1.08 . . . . 10.0 108.085 167.121 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -60.08 171.85 0.91 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.934 1.294 . . . . 10.0 112.892 -169.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.67 -173.08 43.33 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 123.879 0.752 . . . . 10.0 112.462 167.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -70.49 142.62 51.88 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.151 1.381 . . . . 10.0 110.017 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -144.13 147.46 33.75 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 123.64 0.776 . . . . 10.0 112.62 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.616 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.05 128.19 0.25 Allowed Glycine 0 C--N 1.341 0.853 0 C-N-CA 127.378 2.418 . . . . 10.0 111.589 165.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -153.79 106.32 2.86 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 118.904 1.352 . . . . 10.0 109.984 167.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.456 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -150.34 174.04 13.31 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 122.303 1.049 . . . . 10.0 113.686 -179.754 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.16 144.57 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 111.694 -2.503 . . . . 10.0 107.873 169.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.7 m-70 -128.14 138.95 52.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.085 -1.45 . . . . 10.0 107.085 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -50.64 -62.79 1.39 Allowed 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.974 1.31 . . . . 10.0 112.143 -169.448 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -80.22 130.24 35.08 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 119.624 -0.83 . . . . 10.0 109.294 -175.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.57 -13.74 71.63 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.313 -1.115 . . . . 10.0 110.313 167.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -46.37 144.84 1.94 Allowed 'General case' 0 C--N 1.345 0.387 0 CA-C-O 122.45 1.119 . . . . 10.0 109.697 168.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.424 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -153.82 15.6 0.49 Allowed 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.309 -1.314 . . . . 10.0 111.724 177.523 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.511 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -58.77 -34.29 71.26 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.331 0.969 . . . . 10.0 110.671 -174.044 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.67 -20.9 45.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.846 1.258 . . . . 10.0 113.062 175.106 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.22 97.59 1.36 Allowed Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.392 -1.083 . . . . 10.0 110.392 -170.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.288 20.9 p 15.36 60.27 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 128.597 2.759 . . . . 10.0 116.685 176.055 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 40.9 m -132.18 -61.77 0.86 Allowed 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 128.021 2.528 . . . . 10.0 105.172 174.153 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.6 m -57.25 -24.75 56.81 Favored 'General case' 0 C--N 1.34 0.156 0 C-N-CA 125.606 1.563 . . . . 10.0 111.667 176.165 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -41.89 -30.3 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 126.208 1.803 . . . . 10.0 112.502 168.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.93 125.66 5.62 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 109.845 -1.302 . . . . 10.0 109.845 169.48 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.6 66.95 3.78 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 124.096 3.197 . . . . 10.0 112.28 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 64.16 46.27 3.7 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 129.438 3.095 . . . . 10.0 111.227 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -70.85 69.79 0.47 Allowed 'General case' 0 CA--C 1.531 0.244 0 CA-C-O 121.759 0.79 . . . . 10.0 111.402 178.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.8 p-10 -68.61 152.1 96.86 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.306 -0.871 . . . . 10.0 109.206 169.161 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.19 -58.68 0.4 Allowed 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 122.26 1.974 . . . . 10.0 111.571 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -76.09 72.27 2.9 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 121.439 -0.788 . . . . 10.0 110.447 174.206 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.4 m -40.34 112.65 0.29 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.016 0.926 . . . . 10.0 110.699 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.92 -96.27 0.47 Allowed 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 176.348 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -149.39 155.86 41.13 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.988 0.899 . . . . 10.0 109.271 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 63.5 t60 -60.81 115.2 3.49 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 118.364 -1.334 . . . . 10.0 109.096 166.076 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.69 -137.4 3.49 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 107.935 -2.066 . . . . 10.0 107.935 176.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.26 -162.3 23.36 Favored Glycine 0 N--CA 1.45 -0.368 0 N-CA-C 109.03 -1.628 . . . . 10.0 109.03 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -61.56 -4.8 4.76 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 CA-C-N 119.585 1.692 . . . . 10.0 111.271 168.119 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -89.29 -26.81 20.94 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.724 1.21 . . . . 10.0 110.401 175.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 34.0 t0 -102.61 157.48 16.91 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 107.227 -1.398 . . . . 10.0 107.227 -178.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -80.6 -30.25 36.86 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.048 -1.093 . . . . 10.0 108.048 167.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -91.05 6.65 44.03 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.07 1.348 . . . . 10.0 113.419 -168.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -42.33 140.35 1.21 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.145 0.978 . . . . 10.0 110.835 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -60.27 -65.09 0.74 Allowed 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.852 0.835 . . . . 10.0 110.453 -171.323 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.714 HG13 ' H ' ' A' ' 82' ' ' GLY . 7.7 p -160.48 -87.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.336 -2.098 . . . . 10.0 105.336 171.633 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.714 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -88.38 59.95 4.06 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.311 -1.116 . . . . 10.0 110.311 178.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -96.15 91.53 5.97 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 104.916 -2.253 . . . . 10.0 104.916 168.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -66.88 -32.8 74.3 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 108.704 -0.85 . . . . 10.0 108.704 -175.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.45 -85.66 0.38 Allowed Glycine 0 N--CA 1.439 -1.13 0 N-CA-C 108.277 -1.929 . . . . 10.0 108.277 168.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 -150.76 135.78 17.56 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.161 -1.422 . . . . 10.0 107.161 -178.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -106.93 133.11 52.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 169.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -87.57 131.76 34.29 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 108.208 -1.034 . . . . 10.0 108.208 176.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -107.11 135.9 47.86 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.029 0.932 . . . . 10.0 109.012 173.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -59.63 172.09 0.75 Allowed 'General case' 0 C--O 1.232 0.135 0 O-C-N 124.243 0.965 . . . . 10.0 109.912 167.239 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -47.39 -35.87 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 125.732 1.613 . . . . 10.0 110.387 170.363 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -79.69 -5.95 56.21 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.634 1.173 . . . . 10.0 110.723 -173.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 3.71 89.07 Favored Glycine 0 C--N 1.338 0.684 0 N-CA-C 111.101 -0.799 . . . . 10.0 111.101 -176.704 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.6 t -79.66 107.83 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 N-CA-C 106.465 -1.68 . . . . 10.0 106.465 179.05 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.453 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -105.39 120.93 42.83 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 108.829 -0.804 . . . . 10.0 108.829 169.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -79.81 114.8 19.0 Favored 'General case' 0 N--CA 1.434 -1.27 0 C-N-CA 125.849 1.659 . . . . 10.0 109.442 170.265 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.0 t -101.46 133.76 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 105.417 -2.068 . . . . 10.0 105.417 169.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 7.0 m -158.05 58.85 0.47 Allowed 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 118.969 0.804 . . . . 10.0 110.878 176.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.16 153.61 6.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 C-N-CA 124.001 0.92 . . . . 10.0 108.581 -174.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -123.08 136.27 54.74 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.395 1.478 . . . . 10.0 109.409 172.07 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -143.75 153.22 42.2 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.7 p -107.95 -26.47 10.69 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 127.148 2.179 . . . . 10.0 111.914 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.2 p -77.91 -45.15 28.08 Favored 'Isoleucine or valine' 0 C--N 1.342 0.27 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -73.72 134.46 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 105.09 -2.189 . . . . 10.0 105.09 165.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -166.28 158.48 14.07 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 125.422 1.489 . . . . 10.0 108.117 -177.347 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.1 mt -60.59 -50.77 72.18 Favored 'General case' 0 N--CA 1.457 -0.08 0 CA-C-N 116.152 -0.477 . . . . 10.0 110.825 -171.584 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -120.1 -165.58 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.592 1.157 . . . . 10.0 108.28 172.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 97.77 62.65 0.89 Allowed Glycine 0 CA--C 1.524 0.608 0 C-N-CA 124.394 0.997 . . . . 10.0 111.198 169.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 t70 71.07 -57.54 0.6 Allowed 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 129.469 3.108 . . . . 10.0 109.334 -178.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -74.33 -39.96 62.5 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 -169.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.2 t 39.84 85.05 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 126.111 1.764 . . . . 10.0 113.012 167.634 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 35.7 pt -58.69 -22.7 21.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -177.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.5 mm -47.26 131.11 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 O-C-N 121.799 -0.563 . . . . 10.0 110.365 174.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.64 1.6 82.92 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 118.408 -1.218 . . . . 10.0 113.987 175.001 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mmt-85 -81.34 165.76 21.07 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.8 1.3 . . . . 10.0 111.348 171.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -100.7 130.51 46.75 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 105.309 -2.108 . . . . 10.0 105.309 169.151 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.7 mp -108.66 149.58 28.76 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.416 -0.957 . . . . 10.0 108.416 170.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 96.7 t -135.98 137.09 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.945 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 -173.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.6 p -108.19 138.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 168.054 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.616 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.6 m170 -116.22 161.16 19.4 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 115.641 1.719 . . . . 10.0 115.641 -170.308 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -43.33 -55.36 4.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 128.621 2.768 . . . . 10.0 110.046 177.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -124.21 174.41 7.7 Favored 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 125.065 1.346 . . . . 10.0 111.34 -169.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.25 148.86 45.06 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.667 1.187 . . . . 10.0 110.401 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.456 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.2 m-20 -78.59 147.33 33.74 Favored 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 124.145 0.978 . . . . 10.0 111.702 174.186 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -75.44 -30.23 59.93 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 114.372 -1.285 . . . . 10.0 109.675 169.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 29.9 mt 57.45 52.67 8.28 Favored 'General case' 0 C--N 1.339 0.13 0 N-CA-C 107.688 -1.227 . . . . 10.0 107.688 -167.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.42 -24.7 12.97 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-N 113.521 -1.672 . . . . 10.0 112.99 173.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -75.11 6.5 4.18 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 114.543 1.312 . . . . 10.0 114.543 -167.614 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.83 -16.6 79.27 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.057 0.836 . . . . 10.0 112.097 171.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.82 43.77 48.28 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 118.082 0.941 . . . . 10.0 111.801 -176.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -130.88 163.4 27.52 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 106.943 -1.503 . . . . 10.0 106.943 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -54.07 -49.54 68.8 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.16 -0.927 . . . . 10.0 108.502 169.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -56.95 -44.21 82.32 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 122.775 0.43 . . . . 10.0 110.519 173.606 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.3 p -56.3 -43.74 79.21 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 120.635 -1.29 . . . . 10.0 110.576 -178.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -82.24 2.12 33.37 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 118.848 -0.596 . . . . 10.0 112.071 -178.123 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.5 -75.84 0.61 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.328 1.851 . . . . 10.0 110.196 176.567 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 6.6 p -120.96 27.06 8.69 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 120.786 1.63 . . . . 10.0 113.371 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.2 27.99 70.01 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 121.811 -0.556 . . . . 10.0 113.771 167.127 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 47.65 30.06 1.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.816 0.808 . . . . 10.0 112.177 -173.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.18 -5.33 13.2 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.723 -0.61 . . . . 10.0 110.855 175.331 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.59 -156.06 36.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 109.806 -1.318 . . . . 10.0 109.806 168.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.3 m -59.86 131.95 52.45 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 109.497 -0.557 . . . . 10.0 109.497 -171.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.46 68.01 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 168.1 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.77 -27.45 67.99 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 -169.153 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.35 145.83 24.08 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-O 121.475 0.655 . . . . 10.0 109.278 -178.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 15.8 p -162.46 163.65 27.48 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-N 115.849 -0.614 . . . . 10.0 109.641 -167.484 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 179.6 36.23 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 110.588 -1.005 . . . . 10.0 110.588 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.88 148.12 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.675 0 N-CA-C 103.72 -2.696 . . . . 10.0 103.72 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.413 HG23 ' O ' ' A' ' 5' ' ' VAL . 3.9 mt -65.81 -87.7 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 C-N-CA 123.222 0.609 . . . . 10.0 111.203 -168.294 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.57 135.29 7.05 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.426 -0.669 . . . . 10.0 111.426 -178.033 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 62.3 mt -76.37 150.44 6.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 C-N-CA 125.132 1.373 . . . . 10.0 108.166 -176.156 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.14 -45.44 3.29 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 120.974 1.716 . . . . 10.0 112.006 169.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.3 tp60 . . . . . 0 C--O 1.252 1.219 0 C-N-CA 124.14 0.976 . . . . 10.0 109.772 -174.526 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.673 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.4 t -166.38 -46.88 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 124.486 1.114 . . . . 10.0 108.788 173.209 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -123.95 136.53 54.38 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.232 1.413 . . . . 10.0 109.165 -175.06 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 167.43 22.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 125.942 1.697 . . . . 10.0 107.803 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.49 168.88 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 118.488 0.585 . . . . 10.0 112.314 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.99 104.28 4.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 106.899 -1.519 . . . . 10.0 106.899 167.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.424 HG21 ' HB3' ' A' ' 53' ' ' ASN . 10.9 m -92.09 76.38 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 123.476 0.71 . . . . 10.0 109.212 175.284 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.5 mp -74.69 145.82 42.81 Favored 'General case' 0 N--CA 1.449 -0.521 0 O-C-N 121.299 -0.876 . . . . 10.0 109.263 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 161.4 19.77 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 107.992 -1.114 . . . . 10.0 107.992 -175.263 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.56 -58.37 0.04 OUTLIER Glycine 0 C--N 1.329 0.175 0 CA-C-N 115.628 -0.714 . . . . 10.0 111.579 169.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.21 -46.49 33.62 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 106.645 -1.613 . . . . 10.0 106.645 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.82 -68.37 0.51 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 113.383 -1.735 . . . . 10.0 110.729 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -59.89 -35.95 92.08 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.957 2.438 . . . . 10.0 111.424 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.408 HG13 HD11 ' B' ' 38' ' ' LEU . 96.5 t -68.71 99.74 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.141 0 N-CA-C 107.063 -1.458 . . . . 10.0 107.063 176.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -121.95 111.9 17.63 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.483 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -94.37 138.71 14.16 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 109.133 -1.587 . . . . 10.0 109.133 169.05 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.511 ' CG2' HG23 ' A' ' 54' ' ' THR . 6.5 mt -139.31 78.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 106.681 -1.6 . . . . 10.0 106.681 -177.022 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -102.59 148.88 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.143 -0.935 . . . . 10.0 109.59 -175.262 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -118.37 114.04 22.32 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.831 1.652 . . . . 10.0 108.223 171.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -86.09 99.28 11.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 175.083 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.37 153.3 21.85 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 123.964 0.79 . . . . 10.0 109.883 -178.145 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -158.84 86.9 0.85 Allowed 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.254 -0.647 . . . . 10.0 109.254 -173.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 2.0 ttpm? -147.14 83.48 1.57 Allowed 'General case' 0 N--CA 1.424 -1.755 0 CA-C-O 122.257 1.027 . . . . 10.0 109.74 -174.506 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.62 172.28 18.55 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 102.622 -3.103 . . . . 10.0 102.622 166.136 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 21.1 t -78.31 -11.3 59.93 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.796 -0.362 . . . . 10.0 110.616 175.683 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 -88.65 -18.79 27.21 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 124.08 0.952 . . . . 10.0 109.214 172.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 43.2 53.75 5.58 Favored Glycine 0 CA--C 1.532 1.126 0 C-N-CA 125.711 1.624 . . . . 10.0 114.723 178.095 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -67.0 151.44 82.03 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.371 2.048 . . . . 10.0 108.34 169.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.49 92.38 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 105.842 -1.91 . . . . 10.0 105.842 169.421 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttp -83.76 98.43 9.69 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -97.58 99.69 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.95 0 C-N-CA 125.628 1.571 . . . . 10.0 106.819 -174.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 13.3 p90 -117.16 165.54 13.29 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.528 0.68 . . . . 10.0 112.605 171.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.76 -150.04 21.97 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 106.922 -2.471 . . . . 10.0 106.922 169.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 28.6 p -156.04 166.41 33.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 119.352 -0.939 . . . . 10.0 110.931 173.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.483 HG22 ' HA2' ' B' ' 16' ' ' GLY . 4.7 pt -106.43 174.75 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.843 -1.071 . . . . 10.0 110.491 167.316 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt -140.4 152.15 45.51 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.552 2.341 . . . . 10.0 105.893 169.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.12 -25.09 14.66 Favored Glycine 0 C--N 1.338 0.653 0 N-CA-C 116.007 1.163 . . . . 10.0 116.007 167.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.528 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.3 mp -78.47 177.6 8.4 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 119.207 1.504 . . . . 10.0 110.945 -169.192 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.0 t -93.1 165.1 13.0 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 108.973 -0.751 . . . . 10.0 108.973 168.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.99 160.04 6.45 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.576 1.15 . . . . 10.0 111.45 -172.106 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.87 -170.24 29.06 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.626 -0.59 . . . . 10.0 111.626 169.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.77 148.6 42.39 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.405 1.082 . . . . 10.0 111.783 -172.145 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -144.42 141.74 29.84 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.215 1.006 . . . . 10.0 113.42 -177.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.512 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -38.2 126.48 1.6 Allowed Glycine 0 C--N 1.342 0.903 0 C-N-CA 126.803 2.144 . . . . 10.0 110.511 165.339 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -151.36 111.43 4.1 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.887 1.343 . . . . 10.0 108.295 168.083 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -153.76 168.33 26.66 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.978 0.894 . . . . 10.0 112.459 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 18.7 m -88.78 149.34 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 111.869 -2.423 . . . . 10.0 105.812 166.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -124.83 169.72 11.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.691 0.757 . . . . 10.0 109.309 169.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 49' ' ' GLU . . . . . 0.51 ' CG ' ' H ' ' B' ' 50' ' ' PHE . 0.8 OUTLIER 4.0 -113.68 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 130.503 3.521 . . . . 10.0 117.624 167.727 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 50' ' ' PHE . . . . . 0.51 ' H ' ' CG ' ' B' ' 49' ' ' GLU . 51.9 m-85 -95.29 -141.88 0.26 Allowed 'General case' 0 N--CA 1.434 -1.231 0 C-N-CA 127.96 2.504 . . . . 10.0 106.024 172.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.43 31.5 4.82 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 125.171 1.367 . . . . 10.0 110.875 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -70.5 158.55 35.88 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 119.685 1.742 . . . . 10.0 108.273 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -163.45 12.07 0.06 Allowed 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 126.288 1.835 . . . . 10.0 111.899 173.085 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.43 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -60.48 -31.63 70.65 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 119.904 1.229 . . . . 10.0 110.954 -173.048 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.03 -18.37 58.18 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.26 1.024 . . . . 10.0 111.887 176.142 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.83 -171.58 13.78 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 107.539 -2.225 . . . . 10.0 107.539 -169.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 84.7 m -70.43 70.04 0.41 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.826 -1.176 . . . . 10.0 107.826 169.556 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.14 -51.05 0.08 Allowed 'General case' 0 N--CA 1.448 -0.544 0 O-C-N 120.706 -1.246 . . . . 10.0 110.911 -169.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 10.7 t -98.96 -0.15 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.711 0.804 . . . . 10.0 110.076 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -70.46 60.02 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.821 1.648 . . . . 10.0 109.461 171.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 61' ' ' GLY . . . . . 0.463 ' HA3' ' HG2' ' B' ' 49' ' ' GLU . . . 80.24 130.42 0.89 Allowed Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 124.612 1.101 . . . . 10.0 115.227 164.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -87.84 42.49 0.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 123.279 2.653 . . . . 10.0 108.168 165.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' HG22 ' B' ' 137' ' ' THR . 15.1 m170 65.47 54.28 1.16 Allowed 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.993 2.517 . . . . 10.0 110.964 -172.237 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -69.37 70.27 0.26 Allowed 'General case' 0 N--CA 1.47 0.554 0 O-C-N 121.794 -0.566 . . . . 10.0 110.638 171.033 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -80.01 152.13 73.91 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.521 -0.737 . . . . 10.0 110.333 175.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.05 -48.57 1.29 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.601 2.201 . . . . 10.0 111.298 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 86.0 mt -77.5 59.49 1.92 Allowed 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -56.24 99.51 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 124.761 1.224 . . . . 10.0 110.172 -176.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.48 -89.89 0.53 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 105.517 -2.031 . . . . 10.0 105.517 -177.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -142.87 153.59 43.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.091 0.948 . . . . 10.0 110.286 168.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -64.85 123.24 18.88 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 165.015 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.41 -144.2 4.08 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 107.857 -2.097 . . . . 10.0 107.857 179.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.05 -153.37 10.42 Favored Glycine 0 N--CA 1.452 -0.296 0 N-CA-C 108.565 -1.814 . . . . 10.0 108.565 170.615 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -69.12 15.26 0.19 Allowed 'Trans proline' 0 CA--C 1.54 0.802 0 CA-C-N 119.519 1.66 . . . . 10.0 111.404 169.173 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 72.3 mttt -119.49 0.46 11.05 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.177 1.391 . . . . 10.0 110.791 169.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.4 t0 -118.03 156.48 28.51 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.264 -1.384 . . . . 10.0 107.264 172.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -79.3 -31.61 43.33 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 171.06 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -118.59 36.94 4.22 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 123.861 0.864 . . . . 10.0 112.466 -165.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.74 148.96 3.61 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 125.257 1.423 . . . . 10.0 110.66 169.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 26.0 m170 -55.26 -62.35 1.73 Allowed 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.161 0.584 . . . . 10.0 112.192 -171.274 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -172.35 -60.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.181 0 C-N-CA 124.32 1.048 . . . . 10.0 108.332 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.71 51.98 0.82 Allowed Glycine 0 C--N 1.337 0.613 0 N-CA-C 109.319 -1.513 . . . . 10.0 109.319 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -84.77 92.28 8.19 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.447 -2.797 . . . . 10.0 103.447 167.447 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.5 mt -63.06 -30.4 71.57 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 -173.291 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.55 -89.8 0.48 Allowed Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.607 -1.397 . . . . 10.0 109.607 166.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -151.79 100.73 2.7 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.332 -0.988 . . . . 10.0 108.332 -171.057 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -86.37 141.86 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 172.052 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -99.47 129.87 45.69 Favored 'General case' 0 C--O 1.224 -0.257 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.56 134.81 40.99 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.916 -0.772 . . . . 10.0 108.916 172.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -59.84 169.59 1.39 Allowed 'General case' 0 N--CA 1.451 -0.382 0 O-C-N 124.526 1.141 . . . . 10.0 110.045 167.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 61.8 pttt -50.41 -33.19 19.94 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 124.229 1.011 . . . . 10.0 110.876 169.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -78.53 -1.25 33.0 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 122.87 0.468 . . . . 10.0 111.409 -178.163 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.36 17.86 75.2 Favored Glycine 0 C--N 1.34 0.781 0 O-C-N 120.746 -1.221 . . . . 10.0 110.49 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.69 103.61 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 C-N-CA 126.439 1.896 . . . . 10.0 106.789 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.441 ' H ' HG12 ' B' ' 35' ' ' ILE . . . -98.35 121.64 40.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 167.645 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.46 117.79 20.74 Favored 'General case' 0 N--CA 1.436 -1.161 0 C-N-CA 126.579 1.951 . . . . 10.0 108.665 170.555 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 56.6 t -101.73 134.57 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 107.185 -1.413 . . . . 10.0 107.185 175.026 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -158.62 57.11 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.409 0.684 . . . . 10.0 111.263 175.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.71 158.2 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -172.182 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -130.73 90.72 2.95 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 126.762 2.025 . . . . 10.0 108.925 -176.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -84.46 83.78 7.88 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 63.1 p -78.73 60.31 2.74 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 169.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.3 t -143.22 -51.16 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 125.174 1.39 . . . . 10.0 107.704 -168.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.42 HD13 ' H ' ' B' ' 104' ' ' ILE 0.326 0.0 OUTLIER -118.91 165.12 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 113.656 0.984 . . . . 10.0 113.656 175.91 . . . . . . . . 4 4 . 1 . 002 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.0 p -108.17 132.1 53.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.641 1.176 . . . . 10.0 109.646 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -69.83 -41.16 75.31 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.3 t -134.31 116.64 15.49 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 105.985 -1.857 . . . . 10.0 105.985 174.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.89 -66.33 0.09 OUTLIER Glycine 0 C--O 1.228 -0.242 0 N-CA-C 108.7 -1.76 . . . . 10.0 108.7 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -161.42 -48.66 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 113.581 -1.31 . . . . 10.0 109.263 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.63 -32.96 60.46 Favored 'General case' 0 N--CA 1.456 -0.147 0 CA-C-N 115.777 -0.647 . . . . 10.0 110.086 -168.115 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.9 t 33.65 75.1 0.05 Allowed 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 127.167 2.187 . . . . 10.0 112.25 168.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.9 pt -75.01 44.38 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 C-N-CA 123.752 0.821 . . . . 10.0 111.841 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 17.7 mm -78.25 -68.52 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 C-N-CA 125.685 1.594 . . . . 10.0 109.981 -174.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.42 52.31 3.05 Favored Glycine 0 CA--C 1.533 1.198 0 O-C-N 120.8 -1.187 . . . . 10.0 112.302 176.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.1 mmt85 -121.09 153.55 37.3 Favored 'General case' 0 C--O 1.233 0.192 0 C-N-CA 126.147 1.779 . . . . 10.0 110.614 -178.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 53.9 m -97.75 121.26 39.44 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.121 0.968 . . . . 10.0 109.587 177.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -98.24 144.33 27.79 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 125.916 1.686 . . . . 10.0 107.743 169.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 53.1 t -128.8 140.67 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 108.409 -0.96 . . . . 10.0 108.409 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 p -113.39 128.75 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 C-N-CA 125.666 1.586 . . . . 10.0 106.932 169.82 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.512 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.4 m170 -114.09 163.74 14.78 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 116.082 1.882 . . . . 10.0 116.082 -169.163 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -45.02 -59.1 2.76 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.602 2.761 . . . . 10.0 112.628 174.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -122.81 176.29 6.06 Favored 'General case' 0 CA--C 1.522 -0.134 0 C-N-CA 124.366 1.067 . . . . 10.0 113.317 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.58 155.59 38.78 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.827 1.651 . . . . 10.0 111.094 176.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.5 146.86 24.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 124.8 1.24 . . . . 10.0 110.795 172.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -74.9 -32.88 61.94 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 114.849 -1.068 . . . . 10.0 109.321 170.211 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 52.2 mt 62.94 65.34 0.81 Allowed 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 123.265 1.507 . . . . 10.0 108.237 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.77 -51.11 4.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 112.945 -1.934 . . . . 10.0 111.726 170.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 38.3 mtmt -80.32 53.21 1.74 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.371 1.468 . . . . 10.0 111.591 -169.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.94 -3.71 23.11 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.208 1.861 . . . . 10.0 112.462 177.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.54 42.55 27.16 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.244 0.926 . . . . 10.0 112.797 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -135.98 158.32 44.69 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 107.577 -1.268 . . . . 10.0 107.577 176.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -54.15 -42.94 70.14 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 169.059 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -58.91 -44.39 91.26 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.983 -0.553 . . . . 10.0 112.175 170.597 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 10.1 p -56.19 -43.25 78.26 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 119.581 1.082 . . . . 10.0 111.22 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -71.24 -7.85 49.65 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-O 118.083 -0.961 . . . . 10.0 113.091 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -119.7 -65.65 1.14 Allowed 'General case' 0 N--CA 1.439 -1.008 0 C-N-CA 127.677 2.391 . . . . 10.0 113.141 -168.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.499 HG22 ' CD2' ' B' ' 63' ' ' HIS . 1.5 p -130.16 26.2 5.18 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.274 1.397 . . . . 10.0 109.908 177.198 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 68.32 -104.45 1.2 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 107.375 -2.29 . . . . 10.0 107.375 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -154.93 39.06 0.42 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 107.551 -1.278 . . . . 10.0 107.551 170.216 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.62 -12.48 23.38 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 123.527 0.731 . . . . 10.0 112.512 -171.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.96 -167.55 51.19 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 109.734 -1.346 . . . . 10.0 109.734 175.258 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 53.1 m -56.03 133.41 51.81 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 121.602 0.715 . . . . 10.0 111.729 -169.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 19.7 mtt180 -65.15 75.32 0.05 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.457 -0.792 . . . . 10.0 109.177 168.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.9 mt -47.56 -48.73 27.69 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.96 0.409 . . . . 10.0 109.986 177.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.15 152.54 37.46 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.414 0.626 . . . . 10.0 110.566 -172.133 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -148.42 167.71 24.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.595 -0.73 . . . . 10.0 109.308 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.0 148.66 19.75 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 109.592 -1.403 . . . . 10.0 109.592 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 75.1 t -101.35 124.26 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 N-CA-C 104.365 -2.457 . . . . 10.0 104.365 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 21.0 mt -67.75 157.74 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 CA-C-N 118.969 0.804 . . . . 10.0 110.454 -178.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -159.97 147.24 14.07 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.594 1.568 . . . . 10.0 110.423 -170.119 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 62.0 mt -69.15 135.41 28.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 C-N-CA 126.476 1.91 . . . . 10.0 110.452 -169.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -125.8 -48.4 1.64 Allowed 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.624 -0.673 . . . . 10.0 112.199 -178.22 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.254 1.294 0 C-N-CA 125.437 1.495 . . . . 10.0 110.517 -168.219 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 116.164 -1.874 . . . . 10.0 106.571 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -96.55 -33.77 11.69 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.773 1.169 . . . . 10.0 112.79 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -137.54 133.32 34.38 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 123.958 0.903 . . . . 10.0 111.615 -177.327 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.92 162.31 28.88 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.185 1.394 . . . . 10.0 109.457 173.243 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.2 t -124.31 154.89 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 125.784 1.634 . . . . 10.0 108.272 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.46 111.9 6.35 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 168.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.9 m -101.26 113.47 37.51 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.28 0.632 . . . . 10.0 110.945 -178.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -90.05 139.24 30.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 121.743 -0.598 . . . . 10.0 111.945 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -151.84 159.95 43.71 Favored 'General case' 0 N--CA 1.455 -0.197 0 N-CA-C 107.25 -1.389 . . . . 10.0 107.25 167.388 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.73 -56.68 0.06 OUTLIER Glycine 0 N--CA 1.461 0.351 0 C-N-CA 120.247 -0.978 . . . . 10.0 112.389 169.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -71.42 -44.5 64.76 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -178.376 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.3 -70.6 0.43 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.328 -1.305 . . . . 10.0 110.37 169.113 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -58.28 -33.12 97.35 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 123.528 2.819 . . . . 10.0 111.554 173.125 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.61 94.24 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 173.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -114.09 126.62 55.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.508 -1.293 . . . . 10.0 107.508 175.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -121.17 145.23 17.08 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 124.294 0.949 . . . . 10.0 111.045 -177.222 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.429 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 4.9 mt -146.42 84.22 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 106.555 -1.646 . . . . 10.0 106.555 -170.397 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.8 mm -95.46 142.74 13.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 C-N-CA 124.439 1.096 . . . . 10.0 108.571 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -124.3 127.63 47.93 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 125.957 1.703 . . . . 10.0 108.559 172.297 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.432 ' CD2' HG12 ' A' ' 31' ' ' VAL . 24.9 m-85 -106.43 112.92 26.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.424 -1.324 . . . . 10.0 107.424 176.6 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -105.26 127.42 52.93 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.601 0.637 . . . . 10.0 111.195 168.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -114.93 88.68 2.92 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.526 1.531 . . . . 10.0 107.288 169.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.5 pttp -59.58 -44.0 93.47 Favored 'General case' 0 N--CA 1.457 -0.09 0 C-N-CA 124.199 1.0 . . . . 10.0 110.279 -171.15 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -133.1 161.58 34.01 Favored 'General case' 0 N--CA 1.425 -1.704 0 N-CA-C 104.301 -2.481 . . . . 10.0 104.301 174.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.9 p -66.18 -18.96 65.68 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 121.505 0.669 . . . . 10.0 109.691 169.575 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 29.9 m120 -79.1 -21.52 46.56 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 124.828 1.251 . . . . 10.0 110.708 177.572 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.48 127.52 8.03 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 109.802 -1.319 . . . . 10.0 109.802 -174.248 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.63 131.39 29.36 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 N-CA-C 106.93 -1.988 . . . . 10.0 106.93 169.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.3 t -78.47 101.95 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -169.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -69.7 106.82 3.21 Favored 'General case' 0 N--CA 1.446 -0.667 0 N-CA-C 107.828 -1.175 . . . . 10.0 107.828 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.432 HG12 ' CD2' ' A' ' 20' ' ' PHE . 10.7 m -82.8 111.73 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 N-CA-C 106.265 -1.754 . . . . 10.0 106.265 169.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.8 p90 -122.38 168.0 12.61 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.245 0.545 . . . . 10.0 112.304 170.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.33 -152.51 24.57 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 107.738 -2.145 . . . . 10.0 107.738 169.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.3 p -156.17 155.54 32.65 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 119.306 -0.958 . . . . 10.0 112.527 -176.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.427 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -117.76 129.14 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 125.489 1.516 . . . . 10.0 107.92 168.868 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 48.1 tttp -110.08 148.32 31.95 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.73 1.612 . . . . 10.0 107.138 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.61 -10.02 25.92 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 123.796 0.712 . . . . 10.0 113.891 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.0 mt -73.04 179.25 3.87 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.335 1.054 . . . . 10.0 110.522 178.682 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.3 t -104.86 165.31 11.16 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 167.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -55.38 156.16 4.64 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.489 1.116 . . . . 10.0 113.195 -169.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.98 177.38 51.97 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.429 1.014 . . . . 10.0 112.669 169.157 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 84.9 mt -40.88 137.88 1.14 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.625 1.97 . . . . 10.0 114.74 175.186 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.21 150.68 44.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.631 1.572 . . . . 10.0 110.661 170.262 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.549 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -35.95 123.44 0.73 Allowed Glycine 0 C--N 1.338 0.651 0 CA-C-O 116.855 -2.08 . . . . 10.0 109.39 163.549 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -149.88 108.11 3.76 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 120.207 2.003 . . . . 10.0 109.205 167.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -154.22 175.47 13.45 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.503 0.668 . . . . 10.0 110.763 -176.807 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.97 156.63 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.639 0 CA-C-N 112.425 -2.171 . . . . 10.0 108.297 168.319 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -132.99 130.81 39.99 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 104.259 -2.497 . . . . 10.0 104.259 174.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -58.25 -53.08 62.37 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.162 0.914 . . . . 10.0 111.321 -168.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -77.04 135.93 38.66 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 118.388 -1.325 . . . . 10.0 107.71 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.07 -31.79 72.5 Favored Glycine 0 N--CA 1.441 -0.97 0 N-CA-C 109.59 -1.404 . . . . 10.0 109.59 169.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -36.35 126.86 0.8 Allowed 'General case' 0 C--N 1.341 0.216 0 C-N-CA 126.352 1.861 . . . . 10.0 112.761 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -130.48 9.94 5.17 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 114.445 -1.252 . . . . 10.0 110.894 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.442 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -54.61 -35.68 63.67 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.312 1.045 . . . . 10.0 112.112 -169.618 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.35 -17.17 58.47 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.197 0.599 . . . . 10.0 112.241 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.89 76.31 0.88 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 108.865 -1.694 . . . . 10.0 108.865 -177.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.84 6.52 0.91 Allowed 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.086 1.354 . . . . 10.0 113.312 176.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 45.1 m -98.72 -42.11 7.37 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 107.774 -1.195 . . . . 10.0 107.774 -169.029 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.93 -39.62 71.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 123.771 0.828 . . . . 10.0 111.022 -169.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.78 -25.2 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.754 3.621 . . . . 10.0 116.863 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.92 121.98 3.95 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.437 -1.465 . . . . 10.0 109.437 172.35 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.16 73.25 1.1 Allowed 'Trans proline' 0 CA--C 1.54 0.792 0 C-N-CA 123.596 2.864 . . . . 10.0 111.759 177.279 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 25.4 m170 61.09 46.84 7.79 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.624 3.17 . . . . 10.0 111.305 176.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -74.29 48.66 0.34 Allowed 'General case' 0 N--CA 1.467 0.39 0 O-C-N 121.799 -0.563 . . . . 10.0 111.993 178.709 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -63.62 149.45 92.42 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 121.36 -0.837 . . . . 10.0 108.804 178.037 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -54.23 -60.03 0.73 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 122.977 2.451 . . . . 10.0 111.879 -172.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.01 66.5 2.22 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.743 -0.598 . . . . 10.0 109.665 169.705 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t -59.1 102.5 0.13 Allowed 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.459 ' HE ' ' HA ' ' A' ' 78' ' ' GLU . 43.5 mtp85 -105.36 -89.9 0.42 Allowed 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 106.063 -1.828 . . . . 10.0 106.063 -176.122 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.2 mmtt -143.32 146.62 33.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.244 0.545 . . . . 10.0 109.664 168.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.0 t60 -55.99 121.57 9.64 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 117.976 -1.489 . . . . 10.0 107.6 165.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.71 -149.99 5.48 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.09 -150.97 8.17 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.265 -1.297 . . . . 10.0 110.675 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -70.05 17.37 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.849 1.699 . . . . 10.0 111.285 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.17 -19.33 16.49 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 108.017 -1.105 . . . . 10.0 108.017 168.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.28 -178.59 4.91 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.895 -1.15 . . . . 10.0 107.895 -168.204 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -116.39 -5.4 11.76 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 123.424 0.69 . . . . 10.0 110.734 170.274 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.459 ' HA ' ' HE ' ' A' ' 69' ' ' ARG . 0.8 OUTLIER -98.11 -2.88 39.04 Favored 'General case' 0 CA--C 1.517 -0.323 0 O-C-N 121.02 -1.05 . . . . 10.0 111.536 -174.258 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 9.6 ptt85 -28.76 129.83 0.07 Allowed 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.408 2.283 . . . . 10.0 111.019 167.28 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -59.52 151.99 22.95 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.968 -0.753 . . . . 10.0 108.968 172.227 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 94.5 t -59.5 89.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.955 -1.128 . . . . 10.0 107.955 171.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.64 28.58 3.42 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 125.724 1.631 . . . . 10.0 113.496 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -85.92 101.04 12.52 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 105.055 -2.202 . . . . 10.0 105.055 164.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.65 16.48 1.75 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 119.286 0.948 . . . . 10.0 110.83 173.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.03 -107.98 2.49 Favored Glycine 0 N--CA 1.434 -1.499 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 -179.12 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -155.94 144.59 20.27 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 106.646 -1.613 . . . . 10.0 106.646 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -120.77 135.99 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 C-N-CA 123.062 0.545 . . . . 10.0 109.867 -171.167 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -82.72 131.85 35.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 125.134 1.374 . . . . 10.0 109.616 -174.614 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.76 142.24 31.5 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 123.918 0.887 . . . . 10.0 110.897 170.07 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -60.93 167.43 2.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.473 1.109 . . . . 10.0 109.744 166.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.4 ptmt -54.1 -26.77 28.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.149 1.379 . . . . 10.0 112.184 173.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -75.9 -29.94 58.61 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 109.75 -0.463 . . . . 10.0 109.75 177.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 112.05 4.71 25.7 Favored Glycine 0 N--CA 1.446 -0.68 0 CA-C-O 118.626 -1.097 . . . . 10.0 111.216 -169.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.7 t -78.61 99.1 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 C-N-CA 125.069 1.347 . . . . 10.0 108.279 177.664 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 117.47 33.38 Favored 'General case' 0 CA--C 1.518 -0.264 0 N-CA-C 106.886 -1.524 . . . . 10.0 106.886 166.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -89.03 119.78 29.86 Favored 'General case' 0 N--CA 1.436 -1.142 0 C-N-CA 127.879 2.472 . . . . 10.0 109.106 177.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.6 t -105.15 135.06 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 C-N-CA 125.127 1.371 . . . . 10.0 107.787 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 88.9 p -159.72 69.74 0.43 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.309 0.855 . . . . 10.0 113.309 172.275 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -123.96 143.19 38.08 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 124.53 1.132 . . . . 10.0 110.38 -170.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -116.28 149.84 38.57 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.942 2.097 . . . . 10.0 110.128 173.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -149.87 153.39 36.63 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 106.744 -1.576 . . . . 10.0 106.744 167.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 78.1 p -95.47 56.04 1.78 Allowed 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 125.395 1.478 . . . . 10.0 108.528 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 58.4 t -144.12 -53.18 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -176.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.7 mm -54.48 139.08 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 C-N-CA 124.022 0.929 . . . . 10.0 109.488 173.038 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.9 m -155.15 134.94 12.78 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 169.271 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.6 mt -55.85 -52.04 65.42 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.645 1.178 . . . . 10.0 110.436 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.0 t -140.52 -179.27 5.93 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.313 0.645 . . . . 10.0 109.514 176.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.85 -100.3 0.56 Allowed Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 106.22 -2.752 . . . . 10.0 106.22 -170.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -128.92 -49.77 1.23 Allowed 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 125.356 1.462 . . . . 10.0 108.356 -169.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.5 -41.07 48.32 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.888 -1.051 . . . . 10.0 108.867 -176.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t 38.71 89.81 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.391 2.276 . . . . 10.0 113.796 172.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pp -73.63 -15.31 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 112.534 0.568 . . . . 10.0 112.534 178.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.3 mm -50.12 122.63 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 O-C-N 121.188 -0.945 . . . . 10.0 110.412 174.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.44 5.43 56.94 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.466 1.032 . . . . 10.0 112.968 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.6 mpt_? -75.66 179.38 5.41 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.017 0.927 . . . . 10.0 109.533 169.062 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -129.72 141.56 50.87 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 173.284 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.659 HD11 HD11 ' A' ' 149' ' ' ILE . 6.1 mp -107.94 157.43 18.22 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.75 -0.833 . . . . 10.0 108.75 168.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -140.04 137.86 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 O-C-N 123.934 0.771 . . . . 10.0 109.206 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.4 m -103.25 134.56 44.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 O-C-N 124.473 1.108 . . . . 10.0 108.912 164.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.549 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.7 m170 -110.83 159.21 17.88 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 114.497 1.295 . . . . 10.0 114.497 -174.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.73 -50.05 73.37 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.973 1.309 . . . . 10.0 110.46 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -113.03 172.17 7.1 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.629 0.728 . . . . 10.0 112.366 -177.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.22 151.24 33.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.138 1.375 . . . . 10.0 109.503 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -79.49 147.04 32.38 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.207 0.447 . . . . 10.0 112.207 176.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -86.49 3.02 45.81 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.506 1.129 . . . . 10.0 111.637 168.372 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.4 mt 48.06 51.89 13.94 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 125.247 1.419 . . . . 10.0 111.859 170.022 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.38 -7.87 64.13 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 113.756 -1.565 . . . . 10.0 112.187 173.586 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -114.23 35.16 4.29 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.25 1.02 . . . . 10.0 110.691 -168.192 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -82.89 -23.55 55.3 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 126.124 1.821 . . . . 10.0 111.697 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.44 48.1 81.48 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-N 118.184 0.992 . . . . 10.0 111.547 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.517 ' H ' ' HB2' ' A' ' 134' ' ' SER . 37.3 m-80 -158.13 167.4 29.93 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 127.746 2.418 . . . . 10.0 105.734 -175.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -57.49 -44.51 85.01 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.627 0.727 . . . . 10.0 109.645 175.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -52.89 -31.15 38.16 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.788 0.835 . . . . 10.0 112.327 175.278 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.517 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 7.0 t -46.77 -47.14 20.86 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 124.054 0.942 . . . . 10.0 109.035 178.24 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.6 t -83.67 0.56 46.45 Favored 'General case' 0 CA--C 1.539 0.556 0 CA-C-O 118.35 -0.833 . . . . 10.0 112.714 -173.766 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -121.55 -83.02 0.66 Allowed 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.464 1.906 . . . . 10.0 111.897 -174.151 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.36 24.46 13.06 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 121.759 2.072 . . . . 10.0 110.662 174.721 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.89 -87.3 0.29 Allowed Glycine 0 C--N 1.34 0.793 0 C-N-CA 125.151 1.358 . . . . 10.0 110.027 175.27 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.22 34.08 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 125.233 1.413 . . . . 10.0 110.477 172.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.98 -9.76 56.28 Favored 'General case' 0 C--N 1.341 0.212 0 O-C-N 121.041 -1.037 . . . . 10.0 112.192 -172.102 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.77 -163.62 52.66 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 169.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -49.73 123.79 8.53 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.161 1.384 . . . . 10.0 113.428 -168.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -63.54 74.18 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.259 1.824 . . . . 10.0 110.734 173.329 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 52.7 mt -49.68 -36.81 26.3 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 113.189 0.811 . . . . 10.0 113.189 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.31 144.44 23.0 Favored 'General case' 0 CA--C 1.513 -0.442 0 O-C-N 121.711 -0.618 . . . . 10.0 109.418 178.232 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.9 p -132.37 152.16 51.56 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 124.206 0.941 . . . . 10.0 109.876 176.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.39 141.98 11.26 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.297 -1.121 . . . . 10.0 110.297 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.5 t -97.11 142.71 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 105.971 -1.863 . . . . 10.0 105.971 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.659 HD11 HD11 ' A' ' 117' ' ' LEU . 14.1 mt -79.29 136.7 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 N-CA-C 110.038 -0.356 . . . . 10.0 110.038 -176.58 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.84 145.49 17.34 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.75 1.167 . . . . 10.0 111.877 -175.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.3 mt -67.83 139.57 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 124.4 1.08 . . . . 10.0 108.362 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.9 -26.92 2.59 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 114.805 1.409 . . . . 10.0 114.805 -176.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.025 0 CA-C-O 117.61 -1.186 . . . . 10.0 111.84 -178.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.789 0 CA-C-O 116.73 -1.605 . . . . 10.0 107.134 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t -68.99 -18.83 64.11 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-N 120.533 1.515 . . . . 10.0 108.615 169.098 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.6 ptpt -144.39 162.27 36.9 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 120.831 0.348 . . . . 10.0 110.88 165.458 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -152.95 166.87 31.03 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 127.139 2.175 . . . . 10.0 107.645 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.71 162.79 36.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 C-N-CA 123.419 0.688 . . . . 10.0 111.014 -176.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.39 108.51 5.48 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.931 0.892 . . . . 10.0 109.307 168.251 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.1 m -82.5 81.81 1.53 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.485 0.714 . . . . 10.0 110.294 171.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -73.13 127.18 31.86 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.714 -0.847 . . . . 10.0 108.714 -171.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.6 mtmp? -147.54 160.36 42.71 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.324 -0.991 . . . . 10.0 108.324 -177.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.17 -57.51 0.06 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 120.479 -0.867 . . . . 10.0 112.928 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -72.65 -43.85 62.63 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 -175.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.02 -70.97 0.43 Allowed Glycine 0 CA--C 1.524 0.596 0 CA-C-N 114.273 -1.33 . . . . 10.0 110.078 171.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -56.46 -34.26 94.27 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.056 2.504 . . . . 10.0 111.28 172.739 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.8 t -66.83 100.63 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 176.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -122.35 109.52 14.52 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 174.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.642 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.56 134.86 11.98 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.751 -1.34 . . . . 10.0 109.751 169.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.442 ' CG2' HG23 ' A' ' 54' ' ' THR . 17.7 mt -129.55 67.66 0.34 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.153 0 N-CA-C 107.255 -1.387 . . . . 10.0 107.255 -174.273 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -89.25 137.92 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 114.611 -1.177 . . . . 10.0 109.735 -171.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -120.68 116.03 24.49 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.051 2.14 . . . . 10.0 107.97 -173.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -98.72 109.62 22.35 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 116.986 -1.483 . . . . 10.0 107.672 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -104.18 138.87 40.03 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 119.856 1.207 . . . . 10.0 112.592 169.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 40.2 tp60 -124.21 91.89 3.55 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 129.719 3.208 . . . . 10.0 107.288 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 59.0 tttt -155.21 86.47 1.1 Allowed 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 177.477 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -158.26 170.46 22.21 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 103.649 -2.723 . . . . 10.0 103.649 166.281 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 26.1 t -91.79 7.94 39.46 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 123.589 0.756 . . . . 10.0 109.84 171.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 56.4 m-20 -112.44 -10.48 13.74 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 124.74 1.216 . . . . 10.0 109.236 168.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 54.76 35.77 58.48 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-O 117.21 -1.883 . . . . 10.0 116.279 173.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -68.26 128.27 17.17 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 CA-C-N 121.362 2.581 . . . . 10.0 106.174 168.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' VAL . . . . . 0.455 ' CG1' HD11 ' B' ' 104' ' ' ILE . 1.3 p -76.92 112.39 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.547 0 N-CA-C 105.968 -1.864 . . . . 10.0 105.968 169.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.5 tttt -85.77 107.19 17.5 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.994 -2.225 . . . . 10.0 104.994 172.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 p -95.48 96.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 C-N-CA 126.816 2.046 . . . . 10.0 105.733 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.0 p90 -117.65 169.04 9.89 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 121.827 0.822 . . . . 10.0 112.228 173.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.9 -157.26 27.2 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 106.959 -2.456 . . . . 10.0 106.959 169.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 p -149.24 160.3 43.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 176.357 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.642 HG22 ' HA2' ' B' ' 16' ' ' GLY . 1.5 pp -111.52 175.61 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 CA-C-N 114.69 -1.141 . . . . 10.0 109.393 167.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ptmt -143.83 141.43 30.35 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 106.185 -1.783 . . . . 10.0 106.185 166.191 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.02 -5.43 20.14 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.122 0.867 . . . . 10.0 114.734 170.731 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.607 HD23 HD13 ' B' ' 35' ' ' ILE . 0.6 OUTLIER -70.07 178.13 2.89 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 118.712 1.256 . . . . 10.0 111.502 -179.739 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.6 t -111.76 156.14 22.41 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 167.044 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -50.26 156.67 0.79 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.362 1.465 . . . . 10.0 113.073 -169.465 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.57 -169.24 32.61 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 123.422 0.534 . . . . 10.0 111.784 168.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.49 146.33 44.99 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 124.61 1.164 . . . . 10.0 111.135 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -143.2 151.19 40.34 Favored 'General case' 0 C--N 1.34 0.19 0 N-CA-C 113.684 0.994 . . . . 10.0 113.684 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.697 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.05 119.68 0.16 Allowed Glycine 0 C--N 1.339 0.714 0 C-N-CA 129.337 3.351 . . . . 10.0 113.662 166.408 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -152.4 112.48 4.02 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 120.047 1.923 . . . . 10.0 112.785 168.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.521 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 1.0 OUTLIER -142.22 173.1 11.83 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.645 0.736 . . . . 10.0 111.532 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 46.1 t -106.43 117.77 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 CA-C-N 111.927 -2.397 . . . . 10.0 104.691 168.559 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -92.81 148.61 21.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 172.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -60.1 -57.16 14.03 Favored 'General case' 0 N--CA 1.45 -0.475 0 CA-C-N 115.113 -0.949 . . . . 10.0 109.979 -171.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -77.67 148.49 34.98 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 108.91 -0.774 . . . . 10.0 108.91 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.55 -5.33 69.33 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 125.022 1.296 . . . . 10.0 110.15 166.245 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -40.7 143.03 0.38 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.805 1.242 . . . . 10.0 111.422 169.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.508 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -153.29 23.56 0.55 Allowed 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 113.89 -1.505 . . . . 10.0 111.359 168.309 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.429 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.83 -36.15 71.86 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 118.685 0.675 . . . . 10.0 110.865 -172.361 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.92 -22.98 39.23 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.673 1.189 . . . . 10.0 112.966 175.411 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.24 107.42 1.46 Allowed Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.251 0.929 . . . . 10.0 111.45 -174.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 28.7 m 33.45 55.55 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 127.557 2.343 . . . . 10.0 113.537 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.3 -54.81 0.08 Allowed 'General case' 0 N--CA 1.448 -0.568 0 O-C-N 121.439 -0.788 . . . . 10.0 108.955 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 52.5 m -79.77 -5.52 55.47 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.251 0.621 . . . . 10.0 112.43 -174.766 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.37 8.31 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.365 1.866 . . . . 10.0 114.829 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.26 113.21 0.99 Allowed Glycine 0 CA--C 1.528 0.862 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 175.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.02 69.17 3.12 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.909 2.406 . . . . 10.0 111.299 175.059 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.44 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 11.8 m170 70.52 43.29 0.79 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.605 2.762 . . . . 10.0 110.231 170.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -73.95 45.89 0.22 Allowed 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.738 1.215 . . . . 10.0 114.183 -175.468 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -51.76 155.81 2.73 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.19 1.396 . . . . 10.0 111.54 169.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.47 -51.21 0.76 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.538 2.158 . . . . 10.0 111.866 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 67' ' ' LEU . . . . . 0.579 HD23 ' H ' ' B' ' 67' ' ' LEU . 1.7 pt? -74.97 53.63 0.61 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.954 0.902 . . . . 10.0 112.7 -177.261 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -54.2 108.82 0.41 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 122.793 0.437 . . . . 10.0 110.133 -171.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 mtt180 -120.61 -91.74 0.55 Allowed 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 105.892 -1.892 . . . . 10.0 105.892 -174.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -148.23 157.11 43.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 168.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -62.02 116.78 5.2 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 117.869 -1.533 . . . . 10.0 107.643 164.09 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.56 -145.99 6.44 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 107.695 -2.162 . . . . 10.0 107.695 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.4 -164.76 18.09 Favored Glycine 0 C--N 1.33 0.225 0 N-CA-C 108.771 -1.732 . . . . 10.0 108.771 173.034 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.89 -1.19 3.9 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.983 1.788 . . . . 10.0 110.951 167.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -84.29 -29.35 26.48 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 123.803 0.841 . . . . 10.0 109.279 171.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -107.46 161.72 14.58 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 123.161 0.584 . . . . 10.0 109.483 -170.054 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -92.49 -9.11 42.59 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.512 0.725 . . . . 10.0 109.293 167.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -97.04 0.23 48.34 Favored 'General case' 0 N--CA 1.438 -1.05 0 CA-C-O 116.035 -1.936 . . . . 10.0 113.521 -176.059 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.8 137.32 0.65 Allowed 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 120.101 1.319 . . . . 10.0 110.57 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -59.32 -37.23 77.27 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 120.159 -0.616 . . . . 10.0 111.341 -170.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.42 HG13 ' H ' ' B' ' 82' ' ' GLY . 2.5 p -154.1 -61.23 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 106.61 -1.626 . . . . 10.0 106.61 172.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.42 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -116.46 -56.04 0.32 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 173.475 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 39.29 85.5 0.02 OUTLIER 'General case' 0 C--N 1.346 0.429 0 C-N-CA 126.325 1.85 . . . . 10.0 108.618 -167.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -49.79 -33.14 15.63 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.349 1.06 . . . . 10.0 112.749 -166.036 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.03 -89.13 0.42 Allowed Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 168.18 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -155.06 101.14 2.23 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.639 -0.875 . . . . 10.0 108.639 -170.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -83.6 128.83 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.137 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 174.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.3 t -90.83 130.33 36.8 Favored 'General case' 0 C--O 1.225 -0.2 0 N-CA-C 108.733 -0.84 . . . . 10.0 108.733 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.15 131.86 48.4 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.407 -0.961 . . . . 10.0 108.407 171.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -58.88 168.31 1.31 Allowed 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 124.246 0.966 . . . . 10.0 109.832 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -30.2 18.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.083 0.953 . . . . 10.0 111.3 170.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.71 -7.09 56.01 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 120.958 -0.297 . . . . 10.0 111.091 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.56 28.14 55.82 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.566 -1.413 . . . . 10.0 109.566 -178.197 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 34.9 t -107.7 115.48 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.862 0 N-CA-C 104.617 -2.364 . . . . 10.0 104.617 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.438 ' HB3' HG13 ' B' ' 35' ' ' ILE . . . -113.53 123.27 49.61 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 107.544 -1.28 . . . . 10.0 107.544 174.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -85.15 119.66 25.78 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 127.32 2.248 . . . . 10.0 109.044 174.14 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 93.9 t -105.12 133.76 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 C-N-CA 124.636 1.174 . . . . 10.0 107.848 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 84.5 p -158.91 72.29 0.56 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 123.564 0.746 . . . . 10.0 111.015 169.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -104.6 153.47 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -117.91 81.74 1.72 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 128.43 2.692 . . . . 10.0 108.103 -176.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -75.84 113.74 13.66 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.768 -1.938 . . . . 10.0 105.768 -176.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 15.1 m -108.48 35.58 3.13 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.819 -1.082 . . . . 10.0 109.963 -174.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.5 p -126.02 -43.07 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-O 118.538 -0.744 . . . . 10.0 110.622 171.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.619 HD13 ' C ' ' B' ' 104' ' ' ILE 0.361 0.0 OUTLIER -91.83 176.11 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 N-CA-C 113.707 1.002 . . . . 10.0 113.707 178.422 . . . . . . . . 4 4 . 1 . 003 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 34.0 m -152.69 145.9 24.7 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 121.615 -0.678 . . . . 10.0 109.972 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -66.23 -18.14 65.17 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 124.159 0.984 . . . . 10.0 112.464 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.9 t -154.89 137.88 15.5 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.15 -61.91 0.19 Allowed Glycine 0 C--N 1.334 0.422 0 N-CA-C 110.739 -0.945 . . . . 10.0 110.739 179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -154.72 -51.9 0.09 Allowed 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 126.795 2.038 . . . . 10.0 106.662 -178.204 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -75.15 -42.33 56.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.311 -1.313 . . . . 10.0 108.568 -174.092 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 65.42 -59.77 0.27 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 125.926 1.69 . . . . 10.0 109.89 -170.525 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.32 0.2 OUTLIER 78.68 -40.22 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 125.264 1.426 . . . . 10.0 112.075 168.817 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.9 mm -24.23 127.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 128.086 2.554 . . . . 10.0 111.342 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 90.2 28.6 17.06 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-O 119.054 -0.859 . . . . 10.0 112.588 -170.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -81.03 176.31 9.93 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.705 -1.22 . . . . 10.0 107.705 166.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -128.66 123.3 32.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.554 -2.017 . . . . 10.0 105.554 167.044 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 mp -96.0 149.75 21.23 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.251 -1.389 . . . . 10.0 107.251 169.442 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 84.3 t -132.01 133.74 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.703 -1.591 . . . . 10.0 106.703 -174.382 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -104.34 122.95 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 N-CA-C 107.078 -1.453 . . . . 10.0 107.078 171.155 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.697 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.4 m-70 -105.43 157.44 17.35 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 115.893 1.812 . . . . 10.0 115.893 -171.063 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.1 tt0 -43.26 -57.5 2.96 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 128.279 2.632 . . . . 10.0 111.009 173.225 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -111.42 162.49 15.02 Favored 'General case' 0 CA--C 1.515 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.664 -170.188 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.13 140.41 58.79 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.888 1.275 . . . . 10.0 107.586 174.012 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.521 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 69.2 m-20 -77.34 132.79 38.76 Favored 'General case' 0 N--CA 1.441 -0.919 0 N-CA-C 108.579 -0.897 . . . . 10.0 108.579 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 125' ' ' ASP . . . . . 0.409 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 6.7 t0 -81.56 -4.22 55.42 Favored 'General case' 0 N--CA 1.448 -0.574 0 O-C-N 123.483 0.489 . . . . 10.0 110.81 174.47 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 37.6 mt 53.59 41.11 32.15 Favored 'General case' 0 N--CA 1.463 0.188 0 O-C-N 120.455 -1.403 . . . . 10.0 110.629 172.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.99 -29.87 9.35 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-O 119.072 -0.849 . . . . 10.0 113.089 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.409 ' NZ ' ' OD1' ' B' ' 125' ' ' ASP . 0.0 OUTLIER -78.59 10.1 3.49 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 120.054 1.927 . . . . 10.0 113.617 -169.721 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.41 -16.91 69.96 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.009 0.814 . . . . 10.0 112.003 173.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.88 31.55 76.48 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.52 0.581 . . . . 10.0 112.505 174.004 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -142.37 176.01 9.33 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 108.165 -1.05 . . . . 10.0 108.165 171.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -59.01 -45.93 89.46 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 116.219 -0.446 . . . . 10.0 110.637 -175.117 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -67.05 -26.01 66.54 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 120.937 -1.102 . . . . 10.0 110.324 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -52.09 -48.38 64.76 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 119.546 1.066 . . . . 10.0 110.301 168.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -86.8 -15.26 39.81 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 124.073 0.858 . . . . 10.0 111.851 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.8 ttmm -89.82 -48.56 7.17 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 125.416 1.486 . . . . 10.0 111.666 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.9 p -133.88 -14.49 2.41 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 114.98 1.474 . . . . 10.0 114.98 176.154 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.37 30.93 8.73 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 119.668 1.122 . . . . 10.0 112.797 -171.372 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 32.8 m120 50.82 34.74 10.73 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 119.21 1.505 . . . . 10.0 111.918 -177.336 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 140' ' ' ALA . . . . . 0.465 ' HB2' ' OD1' ' B' ' 124' ' ' ASP . . . -69.94 -11.71 61.08 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.764 1.226 . . . . 10.0 111.982 -173.758 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.91 -158.43 53.06 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 109.633 -1.387 . . . . 10.0 109.633 174.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 128.11 35.42 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.61 0.719 . . . . 10.0 110.643 -169.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.01 73.02 0.07 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 123.997 0.919 . . . . 10.0 109.663 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 79.2 mt -45.8 -41.83 11.46 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 124.726 1.211 . . . . 10.0 112.78 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.56 154.17 22.31 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 -171.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.01 164.53 38.33 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.834 -0.621 . . . . 10.0 109.907 -175.382 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.32 -176.09 14.34 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 -179.118 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.4 t -131.95 141.67 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 173.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 8.2 mt -70.78 115.52 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.441 0.564 . . . . 10.0 110.464 -177.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.71 136.72 13.7 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.696 1.141 . . . . 10.0 111.197 -178.486 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 83.1 mt -65.87 142.15 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 124.516 1.126 . . . . 10.0 109.993 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.03 -52.63 1.31 Allowed 'General case' 0 C--O 1.225 -0.204 0 C-N-CA 123.277 0.631 . . . . 10.0 110.957 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 13.3 tt0 . . . . . 0 C--O 1.25 1.114 0 CA-C-O 116.356 -1.783 . . . . 10.0 112.937 -172.489 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.757 0 N-CA-C 108.266 -1.013 . . . . 10.0 108.266 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -166.84 -42.97 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.77 1.228 . . . . 10.0 110.039 175.382 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.9 mtpm? -114.13 148.73 36.72 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 171.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.33 163.25 38.8 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.396 1.479 . . . . 10.0 107.725 177.133 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.43 HG22 ' HA ' ' B' ' 52' ' ' ASP . 0.7 OUTLIER -139.94 167.13 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 122.88 0.472 . . . . 10.0 110.718 -177.94 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.39 114.72 7.95 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 124.14 0.976 . . . . 10.0 108.393 167.311 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -94.1 118.74 40.75 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 123.832 0.853 . . . . 10.0 108.705 171.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt -104.9 140.89 37.47 Favored 'General case' 0 C--O 1.224 -0.237 0 CA-C-O 118.089 -0.957 . . . . 10.0 109.308 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt -148.42 162.13 40.2 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-N 120.312 1.415 . . . . 10.0 107.866 168.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.29 -72.44 0.02 OUTLIER Glycine 0 C--O 1.228 -0.237 0 CA-C-N 115.117 -0.947 . . . . 10.0 112.295 169.587 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.73 -41.48 62.48 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 106.972 -1.492 . . . . 10.0 106.972 -170.034 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.64 -61.39 0.56 Allowed Glycine 0 N--CA 1.441 -0.99 0 CA-C-N 113.697 -1.592 . . . . 10.0 112.401 175.28 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -55.3 -43.18 61.21 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 CA-C-N 119.12 1.46 . . . . 10.0 110.68 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.415 HG23 HD12 ' A' ' 38' ' ' LEU . 0.2 OUTLIER -64.63 117.51 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.985 0 N-CA-C 108.486 -0.931 . . . . 10.0 108.486 177.219 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.16 109.52 12.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.731 -2.322 . . . . 10.0 104.731 168.437 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.765 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.39 143.29 17.82 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 109.181 -1.568 . . . . 10.0 109.181 175.477 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.434 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 2.9 mt -143.11 86.87 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 -178.31 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -97.95 145.46 9.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 C-N-CA 123.874 0.87 . . . . 10.0 109.599 177.3 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -126.13 143.38 51.15 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 125.321 1.448 . . . . 10.0 109.271 170.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -125.57 106.17 9.56 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 107.457 -1.312 . . . . 10.0 107.457 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -103.54 111.57 24.09 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 114.074 1.139 . . . . 10.0 114.074 176.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -78.75 95.06 5.23 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.297 -2.112 . . . . 10.0 105.297 165.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -56.14 -53.7 53.9 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 126.285 1.834 . . . . 10.0 109.741 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.78 -156.88 0.71 Allowed 'General case' 0 N--CA 1.434 -1.236 0 N-CA-C 104.111 -2.551 . . . . 10.0 104.111 168.795 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.36 -27.48 25.83 Favored 'General case' 0 N--CA 1.443 -0.789 0 O-C-N 122.131 -0.356 . . . . 10.0 110.06 169.141 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -108.23 -6.33 16.41 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.953 1.301 . . . . 10.0 111.314 -171.248 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.57 149.29 49.52 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.597 -1.001 . . . . 10.0 110.597 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -62.98 125.31 15.62 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 N-CA-C 107.392 -1.811 . . . . 10.0 107.392 169.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.8 t -79.34 103.15 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 106.647 -1.612 . . . . 10.0 106.647 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -67.97 112.49 5.0 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 105.858 -1.905 . . . . 10.0 105.858 167.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -95.62 104.99 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 105.61 -1.996 . . . . 10.0 105.61 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 19.9 p90 -112.48 164.18 13.59 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.238 0.542 . . . . 10.0 109.671 177.589 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -177.44 157.51 22.21 Favored Glycine 0 N--CA 1.434 -1.464 0 C-N-CA 119.946 -1.121 . . . . 10.0 110.506 176.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.6 p -128.54 86.37 2.44 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 106.853 -1.536 . . . . 10.0 106.853 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.765 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.2 pt -76.99 154.21 5.58 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 C-N-CA 117.736 -1.585 . . . . 10.0 107.271 168.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.1 ptmm? -145.79 119.77 9.38 Favored 'General case' 0 N--CA 1.446 -0.638 0 O-C-N 124.192 0.932 . . . . 10.0 109.242 172.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.28 8.43 4.98 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-O 118.802 -0.999 . . . . 10.0 114.442 166.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.739 ' H ' HD13 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -83.07 179.0 7.87 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 107.201 -1.407 . . . . 10.0 107.201 168.795 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -77.9 167.06 22.1 Favored 'General case' 0 N--CA 1.453 -0.317 0 O-C-N 121.04 -1.038 . . . . 10.0 109.174 169.186 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -65.67 179.09 0.88 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.813 0.845 . . . . 10.0 112.051 -175.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.9 -171.01 44.32 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.211 -0.756 . . . . 10.0 111.211 169.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -76.24 140.46 41.61 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.184 1.394 . . . . 10.0 110.736 -177.341 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -140.92 139.64 34.36 Favored 'General case' 0 C--N 1.341 0.228 0 N-CA-C 113.907 1.076 . . . . 10.0 113.907 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.507 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.4 117.13 0.46 Allowed Glycine 0 C--N 1.341 0.852 0 C-N-CA 128.646 3.022 . . . . 10.0 111.945 166.111 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -135.65 109.18 7.93 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 120.005 1.903 . . . . 10.0 110.324 170.111 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.426 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -151.12 170.07 20.32 Favored 'General case' 0 CA--C 1.513 -0.462 0 C-N-CA 123.413 0.685 . . . . 10.0 110.372 176.679 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 34.2 m -105.39 -27.11 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 C-N-CA 127.048 2.139 . . . . 10.0 113.171 -169.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 24.9 m-70 61.09 165.18 0.08 Allowed 'General case' 0 C--N 1.342 0.244 0 C-N-CA 124.436 1.095 . . . . 10.0 112.92 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -75.99 -56.53 4.58 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 121.726 -0.609 . . . . 10.0 111.121 171.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -75.98 111.26 11.18 Favored 'General case' 0 C--N 1.341 0.216 0 C-N-CA 119.888 -0.725 . . . . 10.0 110.881 -169.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.3 -39.32 95.92 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 108.852 -1.699 . . . . 10.0 108.852 166.597 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -34.65 122.82 0.53 Allowed 'General case' 0 C--N 1.341 0.223 0 C-N-CA 125.638 1.575 . . . . 10.0 112.219 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -129.06 18.13 6.07 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 124.529 1.132 . . . . 10.0 111.354 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.633 HG23 ' CG2' ' B' ' 17' ' ' ILE . 2.8 m -54.21 -36.75 63.82 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 119.49 1.041 . . . . 10.0 111.036 -175.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.01 -22.04 53.69 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.386 0.674 . . . . 10.0 112.106 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.61 -163.15 18.61 Favored Glycine 0 N--CA 1.443 -0.891 0 N-CA-C 107.328 -2.309 . . . . 10.0 107.328 -169.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 90.5 m -74.69 49.56 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.202 1.401 . . . . 10.0 111.052 176.565 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -137.58 -45.83 0.55 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 126.493 1.917 . . . . 10.0 109.574 -177.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -47.99 -31.44 5.32 Favored 'General case' 0 C--N 1.341 0.239 0 C-N-CA 123.146 0.578 . . . . 10.0 111.219 171.201 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.89 -42.01 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 128.132 2.573 . . . . 10.0 114.639 169.109 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.43 150.33 26.76 Favored Glycine 0 C--N 1.339 0.7 0 N-CA-C 110.64 -0.984 . . . . 10.0 110.64 168.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -80.54 54.43 5.22 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.192 1.928 . . . . 10.0 111.079 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.474 ' CD2' HG22 ' A' ' 137' ' ' THR . 19.6 m170 65.6 -65.93 0.16 Allowed 'General case' 0 C--O 1.226 -0.183 0 C-N-CA 128.502 2.721 . . . . 10.0 111.468 -177.503 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.265 10.7 p90 36.08 23.4 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 130.594 3.558 . . . . 10.0 118.944 174.335 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -49.72 158.13 0.9 Allowed Pre-proline 0 CA--C 1.541 0.628 0 C-N-CA 125.98 1.712 . . . . 10.0 114.634 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -57.07 -45.01 38.77 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.583 2.855 . . . . 10.0 112.473 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 78.1 mt -75.1 58.21 0.88 Allowed 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.887 -0.782 . . . . 10.0 108.887 172.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -66.3 72.7 0.08 Allowed 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 128.748 2.819 . . . . 10.0 108.798 -176.697 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 mtt180 -92.16 -91.37 0.16 Allowed 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 105.231 -2.137 . . . . 10.0 105.231 -173.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.1 mttp -149.83 144.48 26.01 Favored 'General case' 0 N--CA 1.425 -1.7 0 N-CA-C 104.21 -2.515 . . . . 10.0 104.21 164.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -52.64 117.59 3.01 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 118.871 -1.131 . . . . 10.0 109.672 167.291 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.4 -154.72 7.9 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 107.037 -2.425 . . . . 10.0 107.037 175.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.407 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -162.92 -160.87 11.6 Favored Glycine 0 C--O 1.225 -0.413 0 N-CA-C 108.755 -1.738 . . . . 10.0 108.755 174.281 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -65.51 10.08 0.17 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 CA-C-N 120.864 2.332 . . . . 10.0 111.318 169.185 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.407 ' H ' ' C ' ' A' ' 73' ' ' GLY . 26.1 mmtp -107.36 -13.6 15.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 119.204 0.911 . . . . 10.0 109.065 175.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -140.82 140.5 34.69 Favored 'General case' 0 C--N 1.348 0.526 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 -169.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -76.13 -20.08 57.93 Favored 'General case' 0 C--N 1.332 -0.167 0 O-C-N 121.106 -0.996 . . . . 10.0 108.819 -169.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -77.18 -5.91 50.95 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 124.412 1.085 . . . . 10.0 111.962 -173.399 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -35.54 133.92 0.35 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.038 1.335 . . . . 10.0 112.862 -179.163 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -61.5 -79.7 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.246 0.545 . . . . 10.0 110.028 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -130.45 -91.42 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -108.93 52.39 0.65 Allowed Glycine 0 CA--C 1.521 0.421 0 N-CA-C 109.899 -1.28 . . . . 10.0 109.899 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.3 m-20 -72.37 93.64 1.54 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 105.759 -1.941 . . . . 10.0 105.759 168.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 26.6 mt -75.32 -29.42 60.01 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.407 ' HA2' HD21 ' A' ' 126' ' ' LEU . . . 99.73 -104.29 2.82 Favored Glycine 0 N--CA 1.439 -1.105 0 N-CA-C 110.559 -1.016 . . . . 10.0 110.559 168.133 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -125.67 101.02 6.69 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 125.713 1.605 . . . . 10.0 110.54 -167.654 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 5.0 m -110.04 140.19 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.616 0.766 . . . . 10.0 111.334 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.32 129.73 34.74 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 128.079 2.552 . . . . 10.0 112.416 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -110.16 134.48 52.16 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.342 1.457 . . . . 10.0 109.591 169.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -59.46 169.13 1.33 Allowed 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.015 1.326 . . . . 10.0 111.133 169.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 7.0 ptmt -47.52 -33.19 6.06 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.751 2.02 . . . . 10.0 111.348 172.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.69 -14.05 59.04 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 122.64 0.376 . . . . 10.0 111.13 -176.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.03 17.42 51.29 Favored Glycine 0 C--N 1.341 0.839 0 N-CA-C 110.44 -1.064 . . . . 10.0 110.44 -175.215 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.94 109.57 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 C-N-CA 126.645 1.978 . . . . 10.0 106.962 -179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.503 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -105.34 118.28 36.16 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.071 -0.715 . . . . 10.0 109.071 169.361 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -85.01 84.38 7.74 Favored 'General case' 0 N--CA 1.437 -1.119 0 C-N-CA 127.416 2.286 . . . . 10.0 109.327 174.08 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -75.86 129.57 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.307 0 N-CA-C 105.136 -2.172 . . . . 10.0 105.136 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -156.93 59.72 0.52 Allowed 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 122.869 0.467 . . . . 10.0 109.948 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.51 164.02 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -176.612 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -134.31 135.41 42.78 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.558 0.743 . . . . 10.0 111.215 169.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -131.1 131.11 43.94 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.973 1.309 . . . . 10.0 108.554 -175.483 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.5 p -98.31 24.2 7.52 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.851 0.86 . . . . 10.0 110.107 169.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.3 p -149.27 20.41 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.032 0.933 . . . . 10.0 110.722 -172.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -122.28 134.52 65.27 Favored 'Isoleucine or valine' 0 C--N 1.34 0.158 0 N-CA-C 102.591 -3.115 . . . . 10.0 102.591 169.159 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.5 m -146.73 125.77 12.85 Favored 'General case' 0 CA--C 1.527 0.074 0 CA-C-N 118.451 0.569 . . . . 10.0 109.699 -176.157 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.9 mp -54.53 -48.42 71.98 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.699 1.199 . . . . 10.0 110.52 177.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -137.02 176.35 8.79 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.549 1.54 . . . . 10.0 106.925 169.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.66 -97.25 0.4 Allowed Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 108.15 -1.98 . . . . 10.0 108.15 -176.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -121.96 -50.98 2.03 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 125.758 1.623 . . . . 10.0 108.461 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -73.5 -42.76 61.42 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.249 -1.389 . . . . 10.0 107.249 -171.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.4 t 47.19 54.88 8.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 126.004 1.722 . . . . 10.0 111.94 169.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.1 pt -60.01 -3.9 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 127.746 2.418 . . . . 10.0 115.222 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.3 mp -52.13 144.16 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 O-C-N 121.26 -0.9 . . . . 10.0 111.258 169.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.82 7.52 87.9 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.163 -0.798 . . . . 10.0 113.064 173.228 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -85.62 172.72 10.69 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.817 0.809 . . . . 10.0 109.123 170.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -122.43 104.64 9.53 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.908 0.883 . . . . 10.0 110.56 -175.2 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.467 ' CD2' HD11 ' A' ' 149' ' ' ILE . 3.8 mm? -62.42 130.14 43.88 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 108.261 -1.014 . . . . 10.0 108.261 172.26 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 51.2 t -119.64 132.65 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 169.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.473 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -100.99 121.86 52.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.245 -1.761 . . . . 10.0 106.245 169.913 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.507 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.2 m170 -106.32 164.16 12.25 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.364 1.246 . . . . 10.0 114.364 -173.625 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -45.13 -57.43 3.91 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 129.354 3.061 . . . . 10.0 111.476 174.364 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 61.2 mttt -126.17 175.32 7.86 Favored 'General case' 0 CA--C 1.522 -0.116 0 C-N-CA 124.552 1.141 . . . . 10.0 112.581 -169.124 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.89 152.57 41.4 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.051 1.341 . . . . 10.0 110.878 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -82.77 145.47 29.52 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 116.031 -0.531 . . . . 10.0 111.183 169.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -81.41 -16.07 53.24 Favored 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 125.025 1.453 . . . . 10.0 110.257 166.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.407 HD21 ' HA2' ' A' ' 85' ' ' GLY . 84.4 mt 57.37 64.14 1.68 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 122.721 1.248 . . . . 10.0 109.447 176.691 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.64 -41.41 3.07 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 114.714 -1.13 . . . . 10.0 110.937 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 29.1 mtmm -78.75 36.09 0.26 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.488 1.515 . . . . 10.0 112.341 -174.169 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.433 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -100.23 -7.27 52.45 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 127.252 2.358 . . . . 10.0 110.892 170.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 42.38 49.53 5.65 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.98 1.752 . . . . 10.0 114.009 177.259 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -153.29 172.56 16.83 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 169.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.0 mp0 -44.77 -50.64 10.02 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 123.021 0.528 . . . . 10.0 111.104 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.63 -28.36 66.83 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 118.694 -0.67 . . . . 10.0 111.035 -177.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.433 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 7.8 p -54.95 -37.6 66.66 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 119.902 1.228 . . . . 10.0 112.255 175.077 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -85.98 -0.26 55.03 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 123.348 0.405 . . . . 10.0 111.73 -178.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.1 mttt -111.71 -66.46 1.08 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.834 1.254 . . . . 10.0 111.125 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.474 HG22 ' CD2' ' A' ' 63' ' ' HIS . 0.8 OUTLIER -128.99 23.07 5.69 Favored 'General case' 0 CA--C 1.543 0.698 0 CA-C-N 119.434 1.015 . . . . 10.0 112.042 -175.569 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.6 -87.26 0.35 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -172.34 37.93 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 125.164 1.386 . . . . 10.0 109.073 169.055 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.09 -13.92 62.58 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -168.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.23 54.81 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.275 -1.13 . . . . 10.0 110.275 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -56.08 128.75 36.95 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 123.976 0.91 . . . . 10.0 112.038 -168.187 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.9 mtm105 -66.68 74.79 0.1 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 124.956 1.302 . . . . 10.0 110.44 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 71.0 mt -46.88 -49.78 19.75 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.447 0.699 . . . . 10.0 111.881 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.473 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -151.65 155.63 38.75 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -169.091 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.17 165.07 37.47 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 122.564 0.346 . . . . 10.0 111.436 -175.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.78 170.16 38.23 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 125.339 1.447 . . . . 10.0 109.931 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 7.7 t -116.96 142.99 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 118.16 0.98 . . . . 10.0 108.693 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.467 HD11 ' CD2' ' A' ' 117' ' ' LEU . 41.2 mt -83.06 119.63 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.717 0 C-N-CA 123.728 0.811 . . . . 10.0 109.303 -176.647 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.17 159.75 24.13 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.775 -0.53 . . . . 10.0 111.775 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 55.6 mt -74.4 150.9 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 125.086 1.354 . . . . 10.0 110.415 -169.292 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.95 -106.59 0.38 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 167.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.922 1 C-N-CA 132.302 4.241 . . . . 10.0 102.72 -169.554 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.624 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.9 t -145.4 -51.81 0.26 Allowed 'General case' 0 CA--C 1.514 -0.418 0 C-N-CA 125.194 1.398 . . . . 10.0 108.482 176.306 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -110.24 145.81 36.71 Favored 'General case' 0 N--CA 1.44 -0.941 0 C-N-CA 126.567 1.947 . . . . 10.0 106.159 -172.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.57 149.6 30.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 172.257 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.5 m -129.69 161.31 39.51 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 O-C-N 123.718 0.636 . . . . 10.0 110.388 -176.365 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.16 105.11 4.03 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.418 -0.956 . . . . 10.0 108.418 170.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.02 91.85 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 170.37 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -77.36 143.59 38.61 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 108.309 -0.997 . . . . 10.0 108.309 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.14 165.14 32.23 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 107.959 -1.126 . . . . 10.0 107.959 173.027 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -168.67 -58.5 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 115.583 -0.735 . . . . 10.0 111.665 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.52 -45.23 47.17 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 -173.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.04 -68.28 0.52 Allowed Glycine 0 N--CA 1.445 -0.754 0 CA-C-N 113.75 -1.568 . . . . 10.0 110.288 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -57.84 -37.49 96.16 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.852 2.368 . . . . 10.0 111.068 174.477 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.26 102.76 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 N-CA-C 107.083 -1.451 . . . . 10.0 107.083 175.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -118.97 117.99 30.29 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.73 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -99.17 132.05 10.78 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 172.492 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.633 ' CG2' HG23 ' A' ' 54' ' ' THR . 6.5 mt -135.15 88.62 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 N-CA-C 107.01 -1.478 . . . . 10.0 107.01 -174.101 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -103.05 140.92 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 125.258 1.423 . . . . 10.0 109.659 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -124.87 112.47 16.68 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.047 1.739 . . . . 10.0 108.109 169.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -93.03 119.24 32.07 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.489 -1.301 . . . . 10.0 107.489 171.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -111.26 143.24 42.36 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 118.926 0.785 . . . . 10.0 111.447 168.037 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -92.6 118.14 30.7 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 103.909 -2.626 . . . . 10.0 103.909 166.359 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 79.3 mttt -55.1 -49.79 70.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.742 0.782 . . . . 10.0 109.412 171.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -130.21 -144.81 0.27 Allowed 'General case' 0 N--CA 1.432 -1.334 0 N-CA-C 105.454 -2.054 . . . . 10.0 105.454 -170.053 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.6 t -110.61 -12.55 14.33 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.275 0.56 . . . . 10.0 110.307 167.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 72.4 m-20 -127.68 2.17 6.12 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.632 1.173 . . . . 10.0 110.999 -175.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.19 163.04 51.81 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 108.932 -1.667 . . . . 10.0 108.932 179.008 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -65.48 135.73 43.71 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.637 1.558 . . . . 10.0 108.446 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -78.23 107.22 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -77.11 108.91 10.53 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 106.284 -1.747 . . . . 10.0 106.284 170.647 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -85.85 105.99 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 25.3 p90 -113.99 163.81 14.64 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.444 0.64 . . . . 10.0 110.969 170.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 177.63 170.12 39.51 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.224 -0.75 . . . . 10.0 111.224 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.1 p -140.03 100.55 3.95 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.997 -1.483 . . . . 10.0 106.997 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.73 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.6 pt -78.12 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 C-N-CA 118.64 -1.224 . . . . 10.0 109.247 170.435 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -152.91 155.01 36.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 168.1 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.4 34.1 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 119.033 -0.87 . . . . 10.0 115.011 169.297 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.501 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.5 mp -72.45 177.79 4.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 118.934 1.367 . . . . 10.0 110.649 -177.141 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.25 161.56 15.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.295 -1.002 . . . . 10.0 108.295 168.259 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -55.74 163.34 1.42 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.227 1.011 . . . . 10.0 112.249 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.98 -175.37 33.66 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-O 121.863 0.702 . . . . 10.0 112.501 168.111 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -68.2 143.91 55.15 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.409 1.484 . . . . 10.0 109.999 -178.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -142.05 147.78 37.39 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 113.394 0.887 . . . . 10.0 113.394 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.63 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.38 125.5 0.27 Allowed Glycine 0 C--N 1.341 0.823 0 C-N-CA 127.738 2.59 . . . . 10.0 111.878 165.269 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -151.69 108.64 3.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 119.104 1.452 . . . . 10.0 110.473 166.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.498 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -147.66 172.29 14.29 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 122.407 1.099 . . . . 10.0 113.046 179.043 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.96 134.75 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.671 0 CA-C-N 111.191 -2.731 . . . . 10.0 106.418 169.576 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 47.1 m-70 -116.77 141.44 48.2 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 106.214 -1.773 . . . . 10.0 106.214 171.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -54.68 -52.23 63.03 Favored 'General case' 0 N--CA 1.451 -0.399 0 O-C-N 124.144 0.903 . . . . 10.0 111.915 -168.545 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -76.92 137.78 39.3 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 -175.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.62 12.51 51.78 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 124.381 0.991 . . . . 10.0 111.649 167.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.43 ' HA ' HG22 ' A' ' 5' ' ' VAL . 0.0 OUTLIER -79.69 174.76 11.26 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-O 121.864 0.84 . . . . 10.0 110.123 -179.503 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -165.3 30.56 0.06 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.552 -1.204 . . . . 10.0 112.641 168.625 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.434 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.41 -35.24 79.75 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 119.696 1.134 . . . . 10.0 112.423 -168.923 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.46 -20.75 50.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 118.06 0.391 . . . . 10.0 111.737 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.73 -160.43 13.2 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 105.852 -2.899 . . . . 10.0 105.852 -167.032 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 59.9 m -70.21 65.75 0.27 Allowed 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 126.321 1.848 . . . . 10.0 111.547 -175.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -153.38 -52.53 0.1 Allowed 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 124.446 1.098 . . . . 10.0 108.727 177.543 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 18.4 m -51.38 -34.94 36.52 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.205 1.002 . . . . 10.0 111.809 -177.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -26.8 -38.88 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.848 2.859 . . . . 10.0 114.47 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 110.39 139.69 8.3 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 110.285 -1.126 . . . . 10.0 110.285 169.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.27 55.54 4.65 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.61 3.54 . . . . 10.0 113.266 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 18.2 m170 62.88 48.58 3.94 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.418 2.287 . . . . 10.0 109.197 178.286 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -66.84 71.78 0.09 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.296 1.038 . . . . 10.0 111.68 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.0 p-10 -84.1 153.33 63.05 Favored Pre-proline 0 C--N 1.326 -0.45 0 O-C-N 121.212 -0.93 . . . . 10.0 111.84 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.66 -43.9 1.7 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.685 2.256 . . . . 10.0 111.447 176.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.0 mt -75.98 62.27 1.61 Allowed 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.711 0.805 . . . . 10.0 109.94 -178.499 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.2 p -40.28 99.87 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.423 1.889 . . . . 10.0 112.796 -173.087 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 14.2 mtp180 -140.26 177.71 7.8 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 126.058 1.743 . . . . 10.0 107.961 -175.27 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.5 mttt -110.66 82.47 1.6 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 112.218 0.451 . . . . 10.0 112.218 -168.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.459 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 69.1 t60 18.0 93.4 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 116.275 1.954 . . . . 10.0 116.275 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.07 -157.45 16.41 Favored Glycine 0 N--CA 1.441 -0.983 0 C-N-CA 125.223 1.392 . . . . 10.0 110.766 177.224 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -165.86 -159.21 11.56 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 106.351 -2.699 . . . . 10.0 106.351 169.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -63.88 6.45 0.28 Allowed 'Trans proline' 0 CA--C 1.543 0.967 0 CA-C-N 120.665 2.233 . . . . 10.0 111.546 168.032 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.415 ' H ' ' C ' ' B' ' 73' ' ' GLY . 11.7 mmmt -114.15 5.88 16.1 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 125.59 1.556 . . . . 10.0 110.064 176.108 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -141.32 169.13 18.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 119.729 1.15 . . . . 10.0 109.342 167.414 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.71 -27.05 29.27 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 166.172 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.87 33.51 0.33 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 124.621 1.168 . . . . 10.0 113.217 -171.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.02 138.76 11.3 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 167.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.459 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 30.9 m80 -66.48 -62.45 1.46 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 118.16 -1.416 . . . . 10.0 108.611 169.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.4 p -164.45 -58.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 108.679 -0.86 . . . . 10.0 108.679 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.8 66.5 0.35 Allowed Glycine 0 C--N 1.334 0.471 0 N-CA-C 109.067 -1.613 . . . . 10.0 109.067 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -112.07 101.62 9.89 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.822 -1.918 . . . . 10.0 105.822 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 19.4 mt -72.65 -18.37 61.58 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.27 0.486 . . . . 10.0 112.195 -169.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 112.73 -95.44 0.78 Allowed Glycine 0 N--CA 1.443 -0.866 0 N-CA-C 106.781 -2.528 . . . . 10.0 106.781 -173.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -155.12 150.61 27.35 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.099 -1.075 . . . . 10.0 108.099 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.05 131.39 62.41 Favored 'Isoleucine or valine' 0 C--O 1.232 0.143 0 N-CA-C 107.332 -1.359 . . . . 10.0 107.332 168.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -95.22 119.12 33.18 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.006 0.522 . . . . 10.0 109.594 -176.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.96 133.54 38.61 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.707 1.203 . . . . 10.0 110.261 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -61.31 168.99 2.38 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.572 1.149 . . . . 10.0 109.215 166.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.18 -29.41 45.66 Favored 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 123.357 0.663 . . . . 10.0 111.385 172.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -77.63 -5.04 48.98 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 121.204 0.526 . . . . 10.0 111.423 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.0 3.17 88.0 Favored Glycine 0 C--N 1.338 0.694 0 O-C-N 120.785 -1.197 . . . . 10.0 111.067 -176.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.47 106.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.16 -1.422 . . . . 10.0 107.16 179.251 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.452 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -103.46 126.01 50.36 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 109.18 -0.674 . . . . 10.0 109.18 170.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -79.43 126.33 30.7 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 168.39 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 54.1 t -107.23 131.16 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 168.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.1 p -157.92 56.2 0.48 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 118.316 0.507 . . . . 10.0 111.152 176.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.93 152.05 4.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 C-N-CA 124.301 1.04 . . . . 10.0 109.055 -171.195 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -102.86 106.8 17.44 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 125.766 1.626 . . . . 10.0 108.865 174.544 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -80.11 77.58 6.81 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.103 -1.443 . . . . 10.0 107.103 175.449 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.1 m -80.61 50.03 1.26 Allowed 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -155.38 -48.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 C-N-CA 122.606 0.362 . . . . 10.0 110.994 -168.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.499 ' C ' HD12 ' B' ' 104' ' ' ILE 0.343 1.1 pp -104.22 177.09 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 C-N-CA 123.6 0.76 . . . . 10.0 112.24 178.482 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -138.12 138.92 39.15 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.848 -1.167 . . . . 10.0 107.848 171.209 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.88 -24.68 26.56 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.99 117.33 9.04 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 104.149 -2.538 . . . . 10.0 104.149 168.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.27 -67.91 0.09 OUTLIER Glycine 0 C--N 1.332 0.322 0 N-CA-C 108.257 -1.937 . . . . 10.0 108.257 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -156.99 -51.1 0.07 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 113.578 -1.311 . . . . 10.0 108.536 176.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -76.25 -23.14 54.48 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.206 -0.906 . . . . 10.0 110.312 -169.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 32.2 t 28.73 79.14 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 128.65 2.78 . . . . 10.0 111.306 178.192 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 8.1 pt -69.83 49.69 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 C-N-CA 125.783 1.633 . . . . 10.0 111.848 176.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -97.95 151.4 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 C-N-CA 126.5 1.92 . . . . 10.0 107.052 171.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 59.52 32.27 72.78 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.319 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 mmt-85 -105.34 170.44 7.88 Favored 'General case' 0 CA--C 1.536 0.424 0 N-CA-C 106.612 -1.625 . . . . 10.0 106.612 168.383 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.6 m -112.95 129.38 56.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 177.424 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.494 HD21 HD11 ' B' ' 149' ' ' ILE . 64.6 mt -102.07 141.57 34.71 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 107.806 -1.183 . . . . 10.0 107.806 173.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 67.8 t -129.39 133.32 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.084 -1.45 . . . . 10.0 107.084 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -106.51 134.09 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 105.963 -1.866 . . . . 10.0 105.963 169.489 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.63 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.1 m170 -112.13 157.6 20.64 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 123.589 1.661 . . . . 10.0 114.63 -170.537 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 121' ' ' GLU . . . . . 0.475 ' N ' HD22 ' B' ' 144' ' ' LEU . 52.1 tt0 -45.79 -53.24 9.9 Favored 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 128.102 2.561 . . . . 10.0 110.041 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -119.58 175.56 5.79 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 125.084 1.354 . . . . 10.0 111.234 -172.27 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.91 149.68 37.69 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 124.667 1.187 . . . . 10.0 110.48 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.498 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.3 m-20 -77.13 135.62 38.57 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 123.325 0.65 . . . . 10.0 110.238 170.415 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.3 m-20 -77.13 -21.29 54.41 Favored 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 124.891 1.369 . . . . 10.0 109.72 168.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 76.9 mt 60.71 58.5 2.39 Favored 'General case' 0 C--N 1.342 0.253 0 CA-C-O 123.279 1.514 . . . . 10.0 109.387 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.36 -43.23 3.11 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 112.737 -2.029 . . . . 10.0 110.158 169.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 17.9 mtmm -78.24 44.28 0.49 Allowed 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.625 1.57 . . . . 10.0 111.821 -175.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.21 -33.82 7.47 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.574 2.035 . . . . 10.0 110.12 172.052 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.17 33.69 48.74 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 123.473 0.559 . . . . 10.0 112.278 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -145.11 165.5 28.08 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 105.905 -1.887 . . . . 10.0 105.905 174.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -55.08 -48.42 73.56 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-O 121.246 0.546 . . . . 10.0 110.068 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -59.86 -30.35 68.92 Favored 'General case' 0 N--CA 1.453 -0.312 0 O-C-N 121.69 -0.631 . . . . 10.0 111.726 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -51.84 -51.91 53.2 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 121.358 -0.838 . . . . 10.0 110.174 169.565 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.9 t -82.19 -10.74 59.05 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.841 -0.618 . . . . 10.0 112.105 -173.082 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.4 ttmm -100.17 -52.73 3.32 Favored 'General case' 0 N--CA 1.436 -1.143 0 C-N-CA 125.417 1.487 . . . . 10.0 111.506 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.0 p -140.05 31.18 1.99 Allowed 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.65 0.78 . . . . 10.0 112.2 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.23 19.65 64.28 Favored Glycine 0 C--N 1.339 0.706 0 CA-C-N 119.246 0.93 . . . . 10.0 112.29 174.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 53.62 26.14 5.52 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 117.915 0.858 . . . . 10.0 112.325 -173.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.37 0.78 3.53 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.698 -0.626 . . . . 10.0 112.455 -178.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.75 -165.18 47.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 109.918 -1.273 . . . . 10.0 109.918 168.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -54.19 134.11 44.5 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.61 0.719 . . . . 10.0 110.084 -172.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.04 67.59 0.07 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 169.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.475 HD22 ' N ' ' B' ' 121' ' ' GLU . 1.1 pt? -61.71 -25.18 67.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.815 0.672 . . . . 10.0 112.815 -168.174 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -154.33 148.68 26.08 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.133 0.492 . . . . 10.0 109.793 177.258 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 21.2 p -158.13 168.78 26.13 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.947 0.499 . . . . 10.0 109.958 -175.082 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -165.53 167.51 39.02 Favored Glycine 0 CA--C 1.528 0.844 0 N-CA-C 110.704 -0.959 . . . . 10.0 110.704 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 74.0 t -109.64 142.85 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.38 0 C-N-CA 125.48 1.512 . . . . 10.0 107.139 -169.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.494 HD11 HD21 ' B' ' 117' ' ' LEU . 67.7 mt -80.35 112.88 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 C-N-CA 122.492 0.317 . . . . 10.0 110.793 -172.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.05 145.39 17.66 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 124.691 1.138 . . . . 10.0 110.745 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 44.9 mt -62.89 148.52 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 124.473 1.109 . . . . 10.0 109.661 174.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.34 170.13 17.43 Favored 'General case' 0 N--CA 1.439 -0.983 0 CA-C-O 122.619 1.2 . . . . 10.0 110.84 168.541 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 . . . . . 0 C--O 1.25 1.082 0 C-N-CA 129.585 3.154 . . . . 10.0 103.097 165.132 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.803 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -156.35 -44.29 0.07 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 118.47 0.577 . . . . 10.0 110.955 172.227 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.5 ttpp -113.78 142.87 45.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 106.918 -1.512 . . . . 10.0 106.918 167.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.74 171.06 14.77 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.477 -1.305 . . . . 10.0 107.477 171.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -140.42 166.59 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 123.897 0.879 . . . . 10.0 110.235 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.68 112.37 5.36 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 168.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.448 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.4 m -97.59 114.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 173.124 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -103.51 137.2 41.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 -174.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -146.33 165.39 29.44 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.924 1.238 . . . . 10.0 107.998 170.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.71 -58.81 0.04 OUTLIER Glycine 0 C--O 1.23 -0.096 0 CA-C-N 115.024 -0.989 . . . . 10.0 112.791 169.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.41 -44.91 49.82 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -171.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.48 -65.7 0.57 Allowed Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 113.601 -1.636 . . . . 10.0 110.659 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -59.0 -37.1 95.24 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.737 2.291 . . . . 10.0 111.315 174.154 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -67.33 106.58 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.007 0 N-CA-C 107.017 -1.475 . . . . 10.0 107.017 175.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -121.78 106.81 11.63 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.03 -1.841 . . . . 10.0 106.03 170.007 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.819 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -89.43 143.39 17.26 Favored Glycine 0 N--CA 1.434 -1.491 0 N-CA-C 109.66 -1.376 . . . . 10.0 109.66 173.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.634 HG22 HG23 ' B' ' 54' ' ' THR . 1.1 mt -150.22 84.56 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.207 -1.405 . . . . 10.0 107.207 -169.286 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.574 HD12 ' HA3' ' A' ' 33' ' ' GLY . 1.0 OUTLIER -96.19 145.43 8.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 C-N-CA 125.273 1.429 . . . . 10.0 110.963 175.815 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -128.95 117.49 21.05 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.942 2.097 . . . . 10.0 109.126 169.134 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -95.52 125.45 40.13 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.72 1.208 . . . . 10.0 108.862 178.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.53 132.99 53.62 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 125.121 1.368 . . . . 10.0 111.456 175.651 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -132.64 79.71 1.86 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 127.971 2.508 . . . . 10.0 106.045 168.227 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -56.12 -45.63 79.47 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 127.873 2.469 . . . . 10.0 110.658 -172.49 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -122.75 161.71 23.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 102.305 -3.22 . . . . 10.0 102.305 167.047 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -58.51 -30.27 66.92 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.473 -0.785 . . . . 10.0 109.073 174.233 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 m-80 -90.26 -9.13 49.1 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 124.892 1.277 . . . . 10.0 111.037 -174.074 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.29 138.8 27.01 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -59.82 135.46 63.68 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 N-CA-C 106.044 -2.329 . . . . 10.0 106.044 168.493 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 t -78.73 129.06 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.016 -1.476 . . . . 10.0 107.016 -170.244 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt -101.01 118.15 36.44 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.495 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -103.03 96.74 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 172.669 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -103.4 167.14 10.0 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 121.932 0.872 . . . . 10.0 110.613 168.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.574 ' HA3' HD12 ' A' ' 18' ' ' ILE . . . 176.03 -177.74 47.61 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.616 -0.802 . . . . 10.0 111.211 175.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.8 m -154.5 91.77 1.43 Allowed 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 -175.171 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.819 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.5 pt -78.96 151.68 4.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 CA-C-O 118.327 -0.844 . . . . 10.0 108.775 169.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.408 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -135.6 156.4 48.92 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 165.614 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.33 -10.13 39.21 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 123.836 0.731 . . . . 10.0 112.887 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -68.68 176.26 3.08 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 118.172 0.986 . . . . 10.0 109.641 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.1 t -105.32 150.41 25.21 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.451 -1.314 . . . . 10.0 107.451 167.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -50.86 146.11 6.34 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.115 0.966 . . . . 10.0 112.276 -169.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.3 -179.26 29.51 Favored Glycine 0 CA--C 1.528 0.85 0 C-N-CA 124.279 0.942 . . . . 10.0 112.128 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mt -57.85 148.72 24.5 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.133 2.173 . . . . 10.0 112.87 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -150.88 147.92 27.81 Favored 'General case' 0 CA--C 1.518 -0.254 0 C-N-CA 125.78 1.632 . . . . 10.0 112.18 176.477 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.621 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -33.17 125.36 0.33 Allowed Glycine 0 C--N 1.338 0.68 0 C-N-CA 126.462 1.982 . . . . 10.0 112.2 164.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -153.13 107.52 3.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 119.158 1.479 . . . . 10.0 110.279 166.265 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.4 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -154.93 169.52 23.85 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.67 0.748 . . . . 10.0 112.021 -179.214 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.1 m -84.72 153.18 3.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 112.663 -2.062 . . . . 10.0 107.715 168.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.91 148.43 50.49 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 107.536 -1.283 . . . . 10.0 107.536 171.233 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -35.91 -60.94 0.51 Allowed 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 126.576 1.95 . . . . 10.0 113.736 -170.467 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -98.8 161.14 13.8 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-O 121.925 0.869 . . . . 10.0 111.368 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.34 -22.88 28.25 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 126.46 1.981 . . . . 10.0 109.866 168.182 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -44.41 136.93 3.9 Favored 'General case' 0 C--N 1.342 0.243 0 C-N-CA 123.669 0.788 . . . . 10.0 110.275 169.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -141.51 21.1 2.2 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 10.0 111.439 -178.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.874 HG22 ' CG2' ' B' ' 17' ' ' ILE . 3.6 p -52.06 -39.01 59.03 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 113.961 1.096 . . . . 10.0 113.961 -174.722 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.04 -11.29 59.92 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.244 0.618 . . . . 10.0 111.619 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 118.66 -64.02 0.42 Allowed Glycine 0 C--O 1.225 -0.425 0 C-N-CA 126.052 1.787 . . . . 10.0 109.253 179.182 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.5 t -155.19 55.23 0.64 Allowed 'General case' 0 C--O 1.234 0.277 0 CA-C-O 121.789 0.804 . . . . 10.0 109.732 172.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -134.62 -46.47 0.74 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.7 0.8 . . . . 10.0 109.229 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.1 m -51.75 -29.34 18.34 Favored 'General case' 0 C--N 1.344 0.367 0 C-N-CA 123.886 0.874 . . . . 10.0 111.235 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.89 -42.27 0.08 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.748 2.419 . . . . 10.0 112.878 167.741 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.28 165.93 39.08 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -79.39 -164.86 0.3 Allowed 'Trans proline' 0 N--CA 1.444 -1.409 0 N-CA-C 107.353 -1.826 . . . . 10.0 107.353 169.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -80.25 46.54 0.83 Allowed 'General case' 0 CA--C 1.542 0.657 0 O-C-N 120.69 -1.256 . . . . 10.0 110.634 -176.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -75.31 70.08 2.19 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 119.352 0.978 . . . . 10.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -71.15 149.19 94.42 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 169.07 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -58.77 -47.12 19.7 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.407 2.071 . . . . 10.0 111.147 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.32 60.82 2.06 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 108.731 -0.841 . . . . 10.0 108.731 174.155 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.5 t -61.19 112.46 2.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 108.664 -0.865 . . . . 10.0 108.664 -178.143 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 75.4 mtt180 -105.82 -98.66 0.34 Allowed 'General case' 0 CA--C 1.512 -0.491 0 N-CA-C 106.157 -1.794 . . . . 10.0 106.157 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.9 pttt -158.81 144.97 16.84 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 104.982 -2.229 . . . . 10.0 104.982 169.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -47.33 121.78 4.12 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.366 0.603 . . . . 10.0 111.526 174.087 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.13 -156.13 6.69 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 106.235 -2.746 . . . . 10.0 106.235 169.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -148.34 -168.84 14.73 Favored Glycine 0 C--O 1.225 -0.43 0 CA-C-N 118.477 1.139 . . . . 10.0 113.464 -178.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -69.73 16.27 0.22 Allowed 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 123.416 2.744 . . . . 10.0 112.303 175.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -105.53 -29.24 10.3 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 126.4 1.88 . . . . 10.0 108.999 168.786 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -107.9 172.19 6.97 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -89.41 -26.76 20.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 122.065 0.936 . . . . 10.0 109.351 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -78.6 -11.18 59.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 125.965 1.706 . . . . 10.0 114.692 -167.276 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.432 HH21 ' CG ' ' A' ' 101' ' ' ASP . 0.0 OUTLIER -34.69 129.17 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.699 1.2 . . . . 10.0 112.186 176.915 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -65.59 169.76 5.84 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 107.81 -1.182 . . . . 10.0 107.81 175.351 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.2 p -63.55 15.04 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 N-CA-C 115.864 1.801 . . . . 10.0 115.864 -169.664 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.51 55.91 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.621 0 N-CA-C 108.997 -1.641 . . . . 10.0 108.997 170.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -97.37 102.5 14.28 Favored 'General case' 0 N--CA 1.457 -0.109 0 N-CA-C 106.746 -1.575 . . . . 10.0 106.746 168.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -83.03 9.7 9.66 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.956 0.344 . . . . 10.0 111.49 -177.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 84.55 -100.18 2.35 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 107.536 -2.226 . . . . 10.0 107.536 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -145.57 157.57 43.96 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 107.287 -1.375 . . . . 10.0 107.287 174.157 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.3 m -112.48 126.12 69.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 109.02 -0.733 . . . . 10.0 109.02 169.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 70.1 m -94.72 101.53 13.38 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 127.518 2.327 . . . . 10.0 109.254 -170.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.7 141.64 37.75 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 122.373 -0.204 . . . . 10.0 111.113 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -69.5 173.77 5.61 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.343 2.257 . . . . 10.0 109.267 167.161 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -23.91 67.56 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.028 0.381 . . . . 10.0 112.028 174.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.408 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 32.7 t70 -78.21 -1.47 32.99 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 120.993 0.425 . . . . 10.0 111.226 173.203 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.23 1.11 89.58 Favored Glycine 0 C--N 1.339 0.732 0 O-C-N 120.679 -1.263 . . . . 10.0 110.51 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -77.41 105.66 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 -176.288 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.527 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -102.64 113.26 26.49 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.389 -0.967 . . . . 10.0 108.389 169.429 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.29 117.97 20.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 126.603 1.961 . . . . 10.0 107.91 173.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 26.4 t -105.89 135.86 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 N-CA-C 106.399 -1.704 . . . . 10.0 106.399 177.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -158.64 62.41 0.43 Allowed 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 123.649 0.779 . . . . 10.0 110.22 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -107.46 161.63 6.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -139.64 151.76 46.23 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.263 1.025 . . . . 10.0 109.404 167.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.432 ' CG ' HH21 ' A' ' 79' ' ' ARG . 25.0 t0 -146.97 152.43 38.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.645 -1.243 . . . . 10.0 107.645 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.9 p -105.66 -13.26 15.62 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.862 2.465 . . . . 10.0 112.154 -176.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -102.27 16.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 119.603 1.092 . . . . 10.0 110.315 179.032 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -118.05 142.79 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 104.714 -2.328 . . . . 10.0 104.714 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 91.8 p -142.44 149.8 39.74 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 172.046 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.2 mt -62.34 -41.17 98.35 Favored 'General case' 0 C--O 1.231 0.105 0 CA-C-N 119.025 0.83 . . . . 10.0 109.485 170.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.3 p -146.95 164.56 32.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.176 1.39 . . . . 10.0 108.947 -178.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 122.87 -105.0 0.91 Allowed Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 106.431 -2.668 . . . . 10.0 106.431 -169.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -126.68 -43.61 1.71 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.368 1.067 . . . . 10.0 110.362 -168.252 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 20.8 m-70 -73.7 -48.53 31.44 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 105.116 -2.179 . . . . 10.0 105.116 174.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.3 t 45.12 60.7 2.86 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 124.771 1.228 . . . . 10.0 113.214 167.093 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.8 pt -63.97 -11.43 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 113.339 0.866 . . . . 10.0 113.339 -175.07 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.1 mm -48.13 141.08 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 119.976 1.262 . . . . 10.0 110.923 170.607 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.44 16.98 75.9 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 125.074 1.321 . . . . 10.0 115.609 169.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 24.9 mmt-85 -84.65 165.61 17.79 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.917 1.358 . . . . 10.0 108.003 166.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 74.1 m -90.48 127.9 36.37 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 107.572 -1.27 . . . . 10.0 107.572 166.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.08 136.81 32.8 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 165.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.48 136.56 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.743 0 N-CA-C 107.075 -1.454 . . . . 10.0 107.075 171.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -105.25 134.53 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.166 -2.161 . . . . 10.0 105.166 167.038 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.621 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m-70 -114.11 158.13 21.68 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -170.32 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.418 ' N ' HD22 ' A' ' 144' ' ' LEU . 0.5 OUTLIER -58.67 -48.91 79.46 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 112.883 -1.962 . . . . 10.0 109.08 -174.735 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.9 mttm -110.76 175.05 5.57 Favored 'General case' 0 C--N 1.34 0.191 0 CA-C-O 121.492 0.663 . . . . 10.0 111.934 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.37 152.81 24.88 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.615 -1.175 . . . . 10.0 110.092 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.4 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.6 OUTLIER -76.75 149.11 36.34 Favored 'General case' 0 N--CA 1.443 -0.775 0 C-N-CA 123.782 0.833 . . . . 10.0 112.175 -179.382 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -79.06 -28.3 43.16 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 112.534 -2.121 . . . . 10.0 110.425 172.03 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 50.7 mt 50.57 48.47 22.53 Favored 'General case' 0 C--N 1.341 0.219 0 CA-C-O 122.349 1.071 . . . . 10.0 109.812 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.3 -11.06 70.9 Favored Glycine 0 CA--C 1.53 1.011 0 CA-C-N 113.907 -1.497 . . . . 10.0 114.086 169.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -81.57 -0.63 43.1 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.07 1.435 . . . . 10.0 114.078 -168.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.64 -22.44 79.01 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.75 38.86 65.33 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.345 -0.702 . . . . 10.0 111.345 -177.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -135.39 172.37 13.11 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 107.613 -1.254 . . . . 10.0 107.613 174.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -54.63 -47.89 72.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.424 0.631 . . . . 10.0 109.809 -178.093 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.27 -39.77 80.1 Favored 'General case' 0 C--O 1.236 0.353 0 O-C-N 121.516 -0.74 . . . . 10.0 111.707 176.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.3 p -53.28 -38.76 63.38 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 118.655 -0.688 . . . . 10.0 110.375 177.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.9 t -87.24 -7.83 57.46 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 123.703 0.627 . . . . 10.0 112.333 -177.217 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.9 mttt -103.17 -60.88 1.48 Allowed 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.215 -0.928 . . . . 10.0 111.277 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 14.3 p -135.55 17.4 3.35 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 118.677 0.671 . . . . 10.0 111.16 -177.359 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 75.93 -102.43 1.55 Allowed Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 107.453 -2.259 . . . . 10.0 107.453 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.7 m-20 -165.38 40.21 0.07 Allowed 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 124.933 1.293 . . . . 10.0 107.962 173.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.12 -11.95 61.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.519 0.728 . . . . 10.0 111.639 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.32 -163.33 54.63 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.61 -1.396 . . . . 10.0 109.61 174.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -51.05 133.98 26.87 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 124.258 1.023 . . . . 10.0 112.788 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.5 mtt180 -67.95 64.11 0.09 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.518 1.927 . . . . 10.0 108.592 171.738 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.449 HD22 ' C ' ' A' ' 120' ' ' HIS . 1.1 pt? -60.59 -22.92 64.25 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -168.787 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.12 148.5 22.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 109.323 -0.621 . . . . 10.0 109.323 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 17.7 p -163.25 168.97 19.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 110.109 -0.33 . . . . 10.0 110.109 -171.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.99 169.75 42.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.325 -0.71 . . . . 10.0 111.325 -176.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 96.6 t -109.87 145.55 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 106.271 -1.752 . . . . 10.0 106.271 -171.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 89.0 mt -74.6 138.22 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 110.403 -0.221 . . . . 10.0 110.403 -175.394 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.8 146.7 16.66 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.035 1.302 . . . . 10.0 110.308 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 80.4 mt -80.32 154.06 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.607 1.203 . . . . 10.0 109.17 177.54 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.88 -109.15 0.33 Allowed 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.326 -1.361 . . . . 10.0 107.326 167.202 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 1 C-N-CA 132.795 4.438 . . . . 10.0 102.843 -174.289 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 119.085 -0.483 . . . . 10.0 110.783 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.0 t -113.6 -13.19 12.76 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 124.105 0.962 . . . . 10.0 112.796 170.1 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -141.57 147.85 38.35 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 118.525 0.602 . . . . 10.0 109.718 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.99 156.55 47.11 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 123.984 0.914 . . . . 10.0 109.828 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -116.83 153.58 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 126.239 1.815 . . . . 10.0 109.044 172.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.86 97.99 3.55 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.924 -1.51 . . . . 10.0 106.924 166.268 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 m -77.86 121.63 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.111 -1.07 . . . . 10.0 108.111 170.371 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mt -103.16 130.32 50.3 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 117.85 -1.072 . . . . 10.0 108.769 -174.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 45.0 mtpt -145.46 160.01 42.23 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 120.236 1.38 . . . . 10.0 109.467 170.059 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.81 -71.26 0.01 OUTLIER Glycine 0 C--O 1.229 -0.177 0 CA-C-N 114.845 -1.07 . . . . 10.0 111.808 173.246 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.61 -43.64 54.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 106.865 -1.531 . . . . 10.0 106.865 -171.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.57 -65.5 0.57 Allowed Glycine 0 N--CA 1.443 -0.871 0 CA-C-N 113.299 -1.773 . . . . 10.0 111.27 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -54.57 -39.78 86.92 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.6 2.2 . . . . 10.0 111.019 173.262 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 64.9 t -66.33 99.49 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 107.729 -1.212 . . . . 10.0 107.729 173.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -124.61 123.0 39.11 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 125.169 1.388 . . . . 10.0 108.593 173.385 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.01 156.7 15.52 Favored Glycine 0 C--N 1.333 0.402 0 N-CA-C 111.872 -0.491 . . . . 10.0 111.872 171.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.874 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.2 mt -141.12 63.45 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 C-N-CA 124.466 1.106 . . . . 10.0 108.609 -172.489 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -78.22 141.09 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.073 0 O-C-N 121.502 -0.748 . . . . 10.0 110.138 -170.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.6 115.79 24.08 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 128.812 2.845 . . . . 10.0 108.156 -175.539 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -108.97 107.17 17.44 Favored 'General case' 0 C--N 1.333 -0.128 0 C-N-CA 124.411 1.084 . . . . 10.0 108.098 173.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -99.22 130.62 45.54 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 119.211 0.914 . . . . 10.0 112.064 169.603 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 tp60 -79.79 110.48 15.18 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 105.146 -2.168 . . . . 10.0 105.146 168.175 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mmmt -48.14 -67.79 0.24 Allowed 'General case' 0 CA--C 1.514 -0.423 0 C-N-CA 126.801 2.04 . . . . 10.0 110.0 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -123.57 -130.6 0.26 Allowed 'General case' 0 N--CA 1.421 -1.886 0 N-CA-C 103.957 -2.609 . . . . 10.0 103.957 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.6 t -93.23 -49.67 5.86 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.538 -1.282 . . . . 10.0 107.538 167.308 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -107.17 4.62 26.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.152 -1.386 . . . . 10.0 110.776 -170.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.91 152.8 50.71 Favored Glycine 0 CA--C 1.531 1.09 0 N-CA-C 108.699 -1.76 . . . . 10.0 108.699 173.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -60.51 140.04 89.31 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.297 1.998 . . . . 10.0 109.643 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.3 t -79.27 108.22 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.048 0 N-CA-C 105.569 -2.012 . . . . 10.0 105.569 175.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 56.1 mttm -83.52 119.05 24.22 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 105.126 -2.176 . . . . 10.0 105.126 168.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -105.79 111.15 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 177.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -129.15 170.9 12.97 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 120.79 0.329 . . . . 10.0 111.72 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.63 -153.25 25.17 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 107.787 -2.125 . . . . 10.0 107.787 172.285 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.7 156.52 35.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 117.656 0.728 . . . . 10.0 110.286 177.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.779 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -116.29 113.79 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 127.479 2.312 . . . . 10.0 106.894 167.782 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 1.3 pttt -96.58 136.43 37.11 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 108.413 -0.958 . . . . 10.0 108.413 168.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.95 0.27 9.03 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 124.892 1.234 . . . . 10.0 113.679 173.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -75.12 177.17 6.63 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 118.74 1.27 . . . . 10.0 110.785 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.0 t -107.76 149.75 27.81 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.706 -1.59 . . . . 10.0 106.706 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -44.87 140.72 2.45 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.811 1.644 . . . . 10.0 112.156 -172.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.75 -175.28 19.28 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 123.583 0.611 . . . . 10.0 112.18 171.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -70.91 147.59 48.61 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.305 1.442 . . . . 10.0 110.803 -174.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 81.9 m-70 -144.29 145.02 31.76 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.162 0.801 . . . . 10.0 113.162 178.001 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.667 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -27.7 125.0 0.06 OUTLIER Glycine 0 C--N 1.344 0.996 0 C-N-CA 127.039 2.257 . . . . 10.0 111.973 164.501 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -150.1 105.36 3.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 119.317 1.559 . . . . 10.0 112.085 168.729 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.08 171.25 18.16 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 122.054 0.931 . . . . 10.0 111.966 -178.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 8.0 m -92.31 149.0 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.789 -2.46 . . . . 10.0 106.694 167.385 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -120.64 131.44 54.61 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.069 -2.567 . . . . 10.0 104.069 169.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -60.47 -46.5 89.87 Favored 'General case' 0 N--CA 1.452 -0.334 0 O-C-N 124.315 1.009 . . . . 10.0 113.128 -165.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 11.5 m-30 -78.67 135.31 37.16 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 118.619 -1.232 . . . . 10.0 107.758 175.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.51 -41.26 98.0 Favored Glycine 0 CA--C 1.533 1.164 0 N-CA-C 107.918 -2.073 . . . . 10.0 107.918 166.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -29.48 101.31 0.02 OUTLIER 'General case' 0 C--N 1.344 0.369 0 C-N-CA 128.098 2.559 . . . . 10.0 113.933 -169.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.448 ' HB3' HG21 ' A' ' 7' ' ' VAL . 1.1 m-80 -107.67 14.54 25.52 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 113.836 -1.529 . . . . 10.0 111.297 173.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.634 HG23 HG22 ' A' ' 17' ' ' ILE . 0.8 OUTLIER -57.7 -33.05 67.98 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 120.453 1.479 . . . . 10.0 110.587 -176.594 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -20.0 51.19 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.049 1.34 . . . . 10.0 113.076 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.89 95.81 1.87 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.74 1.162 . . . . 10.0 110.439 -176.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 26.6 t 19.55 66.85 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.617 2.367 . . . . 10.0 114.219 -174.221 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.2 m -151.38 -52.09 0.13 Allowed 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 124.946 1.299 . . . . 10.0 107.741 -174.093 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 13.8 t -73.89 4.57 5.13 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.718 -0.614 . . . . 10.0 112.131 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.05 -22.36 66.8 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.938 1.295 . . . . 10.0 111.37 177.056 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.2 140.32 11.0 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 169.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -75.89 62.31 6.53 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.576 2.851 . . . . 10.0 111.102 176.39 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.0 m170 58.58 61.89 2.1 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 126.347 1.859 . . . . 10.0 109.123 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -68.66 71.47 0.21 Allowed 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 122.502 1.144 . . . . 10.0 111.843 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -74.96 152.88 86.7 Favored Pre-proline 0 C--N 1.32 -0.693 0 C-N-CA 127.664 2.385 . . . . 10.0 111.443 -178.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.74 163.49 38.05 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.564 2.176 . . . . 10.0 110.534 177.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . 0.29 0.2 OUTLIER 49.52 -96.5 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.745 1.618 . . . . 10.0 110.747 -169.676 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.3 m 172.59 94.8 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 128.079 2.552 . . . . 10.0 108.138 173.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -103.73 156.92 17.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 107.744 -1.206 . . . . 10.0 107.744 169.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 97.06 7.81 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.362 -0.352 . . . . 10.0 110.091 -172.31 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.552 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.6 t60 -10.17 96.1 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 C-N-CA 126.975 2.11 . . . . 10.0 114.072 -173.488 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -117.97 -162.14 12.25 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 108.971 -1.652 . . . . 10.0 108.971 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.29 -168.92 13.27 Favored Glycine 0 N--CA 1.449 -0.482 0 N-CA-C 110.521 -1.032 . . . . 10.0 110.521 175.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -67.45 11.39 0.22 Allowed 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.155 1.903 . . . . 10.0 112.302 175.454 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -101.24 -25.03 14.14 Favored 'General case' 0 N--CA 1.443 -0.814 0 C-N-CA 124.563 1.145 . . . . 10.0 108.896 169.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -107.85 170.88 7.72 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -169.284 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -86.03 -31.17 22.13 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 169.14 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -86.82 21.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 125.563 1.545 . . . . 10.0 113.062 -167.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.54 128.09 34.5 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.104 -1.443 . . . . 10.0 107.104 167.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.552 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 18.4 m170 -58.17 -68.09 0.28 Allowed 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.054 0.454 . . . . 10.0 111.096 -172.042 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.9 p -162.98 -51.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.456 -0.942 . . . . 10.0 108.456 -171.569 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -138.48 62.94 0.56 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 109.327 -1.509 . . . . 10.0 109.327 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -99.93 104.0 15.61 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 104.626 -2.361 . . . . 10.0 104.626 168.476 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -78.76 -2.97 42.02 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 119.235 0.925 . . . . 10.0 111.138 -175.637 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 85' ' ' GLY . . . . . 0.553 ' HA2' HD21 ' B' ' 126' ' ' LEU . . . 94.77 -98.92 2.36 Favored Glycine 0 N--CA 1.44 -1.039 0 N-CA-C 106.584 -2.606 . . . . 10.0 106.584 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -144.78 160.57 41.03 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 123.587 0.755 . . . . 10.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.55 132.03 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 105.495 -2.039 . . . . 10.0 105.495 166.184 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -94.83 118.12 31.25 Favored 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 108.656 -0.868 . . . . 10.0 108.656 -178.373 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.03 127.98 34.44 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 123.468 0.707 . . . . 10.0 109.135 175.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -61.94 167.06 4.04 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 124.453 1.096 . . . . 10.0 109.118 168.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -52.54 -28.88 22.61 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 126.022 1.729 . . . . 10.0 111.53 171.668 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -77.23 -10.86 59.69 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 118.115 0.416 . . . . 10.0 111.597 178.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.09 15.84 60.26 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 121.037 -1.04 . . . . 10.0 111.034 -177.316 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.0 t -97.43 106.82 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.889 2.076 . . . . 10.0 106.497 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.779 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -97.92 123.93 42.13 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.84 -1.17 . . . . 10.0 107.84 169.369 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -91.72 132.0 36.7 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 175.312 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -101.64 126.45 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 105.686 -1.968 . . . . 10.0 105.686 168.63 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 63.4 m -155.15 66.94 0.65 Allowed 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 125.001 1.32 . . . . 10.0 107.749 172.035 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -113.3 162.47 11.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 106.322 -1.733 . . . . 10.0 106.322 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -141.62 147.69 38.0 Favored 'General case' 0 N--CA 1.446 -0.672 0 O-C-N 121.36 -0.838 . . . . 10.0 111.06 168.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -132.75 137.11 46.74 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.92 1.288 . . . . 10.0 108.988 -175.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 1.7 p -108.79 56.75 0.62 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 125.615 1.566 . . . . 10.0 108.088 171.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.57 -61.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 N-CA-C 109.018 -0.734 . . . . 10.0 109.018 178.641 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.333 0.0 OUTLIER -70.41 169.55 1.41 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 112.74 0.644 . . . . 10.0 112.74 176.874 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 12.3 m -158.57 138.76 12.34 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 174.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 pp -81.75 -18.64 43.53 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.859 0.464 . . . . 10.0 110.232 172.477 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t -148.18 122.06 9.37 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 106.569 -1.641 . . . . 10.0 106.569 168.196 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.79 -62.04 0.1 Allowed Glycine 0 C--N 1.336 0.544 0 N-CA-C 109.645 -1.382 . . . . 10.0 109.645 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -164.01 -51.73 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 126.238 1.815 . . . . 10.0 107.094 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -74.26 -38.35 63.48 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 114.321 -1.309 . . . . 10.0 108.555 -170.045 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 14.2 t 49.83 70.85 0.45 Allowed 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.488 1.515 . . . . 10.0 110.943 171.295 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 44.5 pt -56.45 -14.78 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 N-CA-C 113.526 0.936 . . . . 10.0 113.526 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.5 mm -44.79 128.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 O-C-N 121.366 -0.834 . . . . 10.0 109.619 169.497 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.26 0.17 80.51 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.038 -0.868 . . . . 10.0 112.889 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -79.31 168.13 19.95 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.896 1.348 . . . . 10.0 109.152 168.659 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -112.31 124.81 53.28 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.72 0.808 . . . . 10.0 109.581 176.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.402 HD21 HD11 ' B' ' 149' ' ' ILE . 4.4 mm? -82.24 147.25 29.05 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.026 -1.101 . . . . 10.0 108.026 168.591 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 95.7 t -133.12 134.83 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.901 0 N-CA-C 108.217 -1.031 . . . . 10.0 108.217 168.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -103.47 129.95 54.61 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 105.754 -1.943 . . . . 10.0 105.754 167.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.667 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.9 m-70 -106.15 157.13 17.78 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 115.42 1.637 . . . . 10.0 115.42 -170.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -39.98 -56.62 1.79 Allowed 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 129.264 3.026 . . . . 10.0 110.623 173.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -119.79 168.35 11.17 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.176 0.991 . . . . 10.0 112.546 -169.244 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.81 129.13 38.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 113.98 -1.464 . . . . 10.0 109.129 170.163 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.419 ' CG ' HD23 ' B' ' 126' ' ' LEU . 62.4 t0 -77.77 108.26 10.87 Favored 'General case' 0 N--CA 1.442 -0.859 0 N-CA-C 107.347 -1.353 . . . . 10.0 107.347 171.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -78.97 3.38 17.33 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 111.676 0.251 . . . . 10.0 111.676 175.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.553 HD21 ' HA2' ' B' ' 85' ' ' GLY . 22.2 mt 59.79 -146.42 0.49 Allowed 'General case' 0 N--CA 1.419 -2.004 0 N-CA-C 105.97 -1.863 . . . . 10.0 105.97 -177.269 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 -14.28 77.26 Favored Glycine 0 C--N 1.304 -1.221 0 CA-C-N 114.351 -1.295 . . . . 10.0 112.244 -168.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -75.07 -1.27 22.13 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.413 1.107 . . . . 10.0 111.966 -169.665 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.36 -32.56 77.6 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 108.595 -1.802 . . . . 10.0 108.595 168.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 62.13 37.63 94.8 Favored Glycine 0 C--N 1.341 0.818 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.66 175.34 9.26 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 105.176 -2.157 . . . . 10.0 105.176 170.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -45.82 -54.17 8.49 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 115.044 -0.98 . . . . 10.0 111.23 172.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -64.5 -34.68 78.78 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 119.777 -0.769 . . . . 10.0 111.162 -172.116 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -47.7 -40.0 18.99 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 124.116 0.967 . . . . 10.0 111.702 169.777 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 t -93.08 -4.04 53.11 Favored 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 119.658 1.117 . . . . 10.0 110.362 -170.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -110.44 -57.82 2.16 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 125.698 1.599 . . . . 10.0 110.922 -171.668 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.4 p -137.13 5.84 2.8 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.616 0.644 . . . . 10.0 112.563 175.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.69 32.18 57.6 Favored Glycine 0 C--N 1.341 0.848 0 CA-C-N 118.675 0.67 . . . . 10.0 114.37 172.016 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 15.6 m120 57.78 19.61 5.78 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.794 0.838 . . . . 10.0 113.175 179.106 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.38 -4.04 20.42 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.128 -0.982 . . . . 10.0 112.945 -176.325 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.54 -164.14 53.99 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.679 -0.968 . . . . 10.0 110.679 172.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.78 141.73 43.28 Favored 'General case' 0 N--CA 1.445 -0.714 0 C-N-CA 123.696 0.798 . . . . 10.0 111.987 -168.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 25.7 mtm-85 -67.22 71.14 0.1 Allowed 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.62 1.568 . . . . 10.0 109.414 172.501 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 6.8 tp -43.54 -45.56 6.64 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 126.5 1.92 . . . . 10.0 112.212 -174.134 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -159.48 147.41 17.37 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 -173.111 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 9.5 m -141.09 157.27 45.53 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 -168.545 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.6 164.96 30.42 Favored Glycine 0 C--N 1.332 0.346 0 N-CA-C 110.219 -1.152 . . . . 10.0 110.219 175.696 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.02 135.94 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 108.045 -1.095 . . . . 10.0 108.045 -174.514 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.402 HD11 HD21 ' B' ' 117' ' ' LEU . 9.3 mt -75.33 107.13 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 N-CA-C 109.291 -0.633 . . . . 10.0 109.291 -174.766 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.12 154.97 16.38 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 125.799 1.666 . . . . 10.0 110.976 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 90.4 mt -73.27 140.3 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 124.301 1.04 . . . . 10.0 109.937 -175.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.98 -45.99 2.65 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.84 0.456 . . . . 10.0 111.567 169.349 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 mm100 . . . . . 0 N--CA 1.445 -0.683 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 179.381 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.974 0 CA-C-O 118.158 -0.925 . . . . 10.0 109.398 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.2 t -84.29 -13.46 52.42 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 119.661 1.119 . . . . 10.0 111.893 -176.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.5 ptpp? -152.6 157.86 41.62 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.499 0.666 . . . . 10.0 112.351 167.438 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.91 170.62 15.4 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 125.855 1.662 . . . . 10.0 109.635 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.5 150.12 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 C-N-CA 126.462 1.905 . . . . 10.0 110.302 -177.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.62 100.91 4.77 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.005 -1.48 . . . . 10.0 107.005 166.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.495 HG21 ' HB3' ' B' ' 53' ' ' ASN . 6.0 m -82.12 118.91 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 107.821 -1.177 . . . . 10.0 107.821 169.385 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -97.43 138.89 34.18 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.873 -1.158 . . . . 10.0 107.873 177.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.9 ttmt -156.76 162.85 39.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.34 -50.21 0.07 OUTLIER Glycine 0 C--O 1.228 -0.256 0 C-N-CA 120.303 -0.951 . . . . 10.0 112.963 169.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -73.31 -45.73 53.75 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.35 -71.48 0.4 Allowed Glycine 0 CA--C 1.524 0.599 0 CA-C-N 114.46 -1.245 . . . . 10.0 110.021 171.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -57.95 -33.82 97.61 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.496 2.798 . . . . 10.0 111.192 173.059 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.1 t -64.91 105.58 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 N-CA-C 107.915 -1.143 . . . . 10.0 107.915 174.312 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -124.01 110.64 15.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 106.167 -1.79 . . . . 10.0 106.167 173.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.703 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -91.59 144.38 17.14 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 169.479 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.538 ' CG2' HG22 ' B' ' 54' ' ' THR . 4.9 mt -140.1 80.46 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 106.26 -1.755 . . . . 10.0 106.26 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.7 mm -101.97 123.4 55.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 N-CA-C 109.557 -0.534 . . . . 10.0 109.557 -175.149 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 9.4 m-20 -85.63 151.29 24.01 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 109.268 -0.642 . . . . 10.0 109.268 169.545 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -126.33 91.53 3.39 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.231 -1.766 . . . . 10.0 106.231 169.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -84.27 138.72 32.78 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.175 0.99 . . . . 10.0 109.812 171.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -127.76 112.05 14.35 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 168.71 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.06 -56.4 11.72 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 122.7 1.238 . . . . 10.0 111.64 -170.17 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -139.97 170.39 15.95 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 103.657 -2.72 . . . . 10.0 103.657 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 91.8 p -65.0 -22.71 67.04 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.02 -0.536 . . . . 10.0 110.237 170.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -81.73 -11.75 58.9 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.763 0.825 . . . . 10.0 111.03 177.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.27 159.08 30.71 Favored Glycine 0 CA--C 1.532 1.116 0 O-C-N 121.929 -0.482 . . . . 10.0 112.073 -172.069 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -78.87 149.03 22.72 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 122.79 2.327 . . . . 10.0 107.889 167.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -76.6 94.38 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 171.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 mtpm? -73.95 97.7 2.88 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.538 -1.282 . . . . 10.0 107.538 169.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.6 m -85.45 115.01 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 107.261 -1.385 . . . . 10.0 107.261 173.015 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 23.8 p90 -129.9 160.26 34.08 Favored 'General case' 0 CA--C 1.516 -0.36 0 CA-C-O 121.756 0.789 . . . . 10.0 111.952 168.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.57 -173.45 45.41 Favored Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 173.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.8 t -142.43 118.75 10.84 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.683 -1.599 . . . . 10.0 106.683 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.703 HG22 ' HA2' ' A' ' 16' ' ' GLY . 1.5 pp -80.86 175.07 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 109.095 -0.706 . . . . 10.0 109.095 169.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -146.32 136.58 23.75 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 167.32 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.33 -5.12 15.31 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.937 0.779 . . . . 10.0 114.656 172.365 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.62 HD23 HD13 ' A' ' 35' ' ' ILE . 0.6 OUTLIER -69.09 176.46 3.19 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 119.147 1.473 . . . . 10.0 111.198 179.36 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -108.24 159.47 16.6 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.703 -1.962 . . . . 10.0 105.703 166.253 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -53.49 163.14 0.67 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.531 1.132 . . . . 10.0 112.935 -169.224 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.17 -174.39 50.84 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 123.962 0.791 . . . . 10.0 112.104 168.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 mp -63.26 144.48 56.9 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 125.233 1.413 . . . . 10.0 110.819 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -146.72 144.02 29.13 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 123.82 0.848 . . . . 10.0 111.352 174.421 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.644 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -24.87 121.98 0.03 OUTLIER Glycine 0 C--N 1.343 0.956 0 C-N-CA 128.242 2.829 . . . . 10.0 111.864 166.778 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.96 106.71 3.95 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 120.046 1.923 . . . . 10.0 109.728 171.607 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.456 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -156.46 172.39 18.62 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.56 0.695 . . . . 10.0 112.855 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.15 152.54 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-N 112.581 -2.099 . . . . 10.0 108.078 168.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 79.9 m-70 -126.2 152.69 45.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 170.722 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -49.31 -60.75 2.54 Favored 'General case' 0 N--CA 1.447 -0.576 0 O-C-N 124.202 0.938 . . . . 10.0 111.379 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -82.38 162.09 22.3 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 121.41 0.624 . . . . 10.0 110.141 -174.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.77 -6.59 52.26 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 167.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.41 172.52 9.31 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-O 122.588 1.185 . . . . 10.0 111.461 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.49 18.15 0.04 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 114.057 1.132 . . . . 10.0 114.057 -169.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.4 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.3 OUTLIER -50.41 -36.92 35.08 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.983 1.313 . . . . 10.0 113.713 -169.002 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.26 -21.38 49.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.393 0.677 . . . . 10.0 112.492 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.98 102.28 2.44 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 109.396 -1.481 . . . . 10.0 109.396 -172.602 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 37.27 60.78 1.01 Allowed 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 126.273 1.829 . . . . 10.0 112.161 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -157.76 -48.06 0.06 Allowed 'General case' 0 N--CA 1.443 -0.821 0 O-C-N 122.023 -0.423 . . . . 10.0 111.401 176.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -50.63 -35.76 32.03 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 125.092 1.357 . . . . 10.0 110.918 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.28 -36.31 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 128.347 2.659 . . . . 10.0 113.768 169.058 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.51 166.27 26.43 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 107.641 -2.183 . . . . 10.0 107.641 173.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -79.91 -162.77 0.19 Allowed 'Trans proline' 0 N--CA 1.441 -1.599 0 N-CA-C 105.476 -2.548 . . . . 10.0 105.476 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 44.4 m170 -81.49 53.88 2.2 Favored 'General case' 0 CA--C 1.541 0.609 0 O-C-N 120.38 -1.45 . . . . 10.0 110.716 -176.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.6 m-30 -73.09 71.59 1.13 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 123.273 1.511 . . . . 10.0 111.265 -178.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -78.44 141.51 61.28 Favored Pre-proline 0 N--CA 1.447 -0.583 0 C-N-CA 126.158 1.783 . . . . 10.0 109.642 169.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -79.21 47.77 2.61 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.874 2.383 . . . . 10.0 111.213 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -163.79 49.66 0.14 Allowed 'General case' 0 C--O 1.236 0.361 0 C-N-CA 124.761 1.224 . . . . 10.0 107.871 178.206 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.0 p -52.98 108.37 0.31 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.204 1.802 . . . . 10.0 111.57 -169.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -133.32 -173.2 3.14 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.107 -2.183 . . . . 10.0 105.107 169.679 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.401 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 6.9 mtmp? -85.71 136.63 33.28 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 118.549 -1.26 . . . . 10.0 107.804 -172.373 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.9 t60 -36.05 116.29 0.39 Allowed 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.336 173.229 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.71 -134.2 4.92 Favored Glycine 0 N--CA 1.441 -1.015 0 N-CA-C 108.139 -1.984 . . . . 10.0 108.139 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.8 -165.81 31.74 Favored Glycine 0 N--CA 1.444 -0.804 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 169.699 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -57.52 -11.99 10.02 Favored 'Trans proline' 0 N--CA 1.451 -0.976 0 CA-C-N 119.345 1.572 . . . . 10.0 110.849 167.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.87 -33.98 18.35 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 125.223 1.409 . . . . 10.0 110.076 -177.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -107.45 168.54 9.17 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 108.677 -0.861 . . . . 10.0 108.677 -169.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -94.67 -18.88 20.91 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 124.346 1.058 . . . . 10.0 109.761 178.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.401 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -92.02 3.9 54.23 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.395 0.887 . . . . 10.0 113.395 -175.511 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 19.9 ptp180 -34.94 139.0 0.1 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 128.118 2.567 . . . . 10.0 112.272 171.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -71.22 -100.63 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.351 0.66 . . . . 10.0 111.96 -176.091 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.9 p -148.3 30.13 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.032 0.92 . . . . 10.0 110.228 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.5 47.83 0.02 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.479 -1.448 . . . . 10.0 109.479 -179.286 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -84.05 88.97 7.19 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 103.203 -2.888 . . . . 10.0 103.203 168.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 42.5 mt -71.3 -33.38 69.65 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 106.451 -1.685 . . . . 10.0 106.451 176.123 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.66 -97.19 1.34 Allowed Glycine 0 N--CA 1.44 -1.057 0 N-CA-C 108.815 -1.714 . . . . 10.0 108.815 167.073 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -132.67 129.06 38.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.655 1.182 . . . . 10.0 108.571 -172.195 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.8 m -113.52 141.65 28.7 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.573 -1.64 . . . . 10.0 106.573 168.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -93.13 133.65 36.1 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.738 -0.467 . . . . 10.0 109.738 -177.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.82 133.23 43.41 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.084 0.954 . . . . 10.0 108.848 172.053 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.416 ' OD2' ' NZ ' ' A' ' 91' ' ' LYS . 45.4 t0 -62.03 168.81 3.01 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.678 1.191 . . . . 10.0 108.438 167.78 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.416 ' NZ ' ' OD2' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -63.38 -19.16 64.41 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.047 0.451 . . . . 10.0 111.816 -179.22 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -77.45 -12.15 59.93 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 123.73 0.812 . . . . 10.0 110.589 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.87 26.88 43.58 Favored Glycine 0 C--N 1.344 0.979 0 N-CA-C 109.766 -1.334 . . . . 10.0 109.766 -178.696 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 37.7 t -109.08 116.31 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.007 2.523 . . . . 10.0 105.045 178.105 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -113.49 120.84 42.38 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 107.918 -1.141 . . . . 10.0 107.918 174.456 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -84.31 117.41 23.55 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 127.141 2.176 . . . . 10.0 108.767 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -102.4 131.88 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 p -159.53 75.91 0.66 Allowed 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 123.88 0.872 . . . . 10.0 110.804 171.176 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -116.37 147.23 19.89 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.037 0.935 . . . . 10.0 109.146 -176.396 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -107.14 104.71 14.42 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 126.449 1.9 . . . . 10.0 110.13 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -87.9 123.32 32.53 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 108.746 -0.835 . . . . 10.0 108.746 172.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.7 p -113.13 43.41 1.72 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.209 1.003 . . . . 10.0 110.21 177.511 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -138.62 -44.57 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 C-N-CA 123.289 0.636 . . . . 10.0 111.255 175.472 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.413 HD12 ' C ' ' A' ' 104' ' ' ILE 0.365 0.7 OUTLIER -87.85 175.19 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-N 119.342 0.973 . . . . 10.0 112.749 174.103 . . . . . . . . 4 4 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.2 m -159.34 138.43 11.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 123.955 0.902 . . . . 10.0 109.007 172.048 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 pp -82.49 -14.75 54.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.552 0.741 . . . . 10.0 111.944 177.116 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.1 m -143.46 124.0 14.01 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.662 -1.607 . . . . 10.0 106.662 167.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.96 -59.63 0.2 Allowed Glycine 0 C--N 1.334 0.44 0 N-CA-C 109.638 -1.385 . . . . 10.0 109.638 175.473 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -166.89 -50.9 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 126.084 1.753 . . . . 10.0 107.465 -177.37 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -74.98 -36.02 62.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.669 -1.151 . . . . 10.0 108.879 -169.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t 42.41 61.93 1.86 Allowed 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 126.056 1.743 . . . . 10.0 110.99 169.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.57 32.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 113.194 0.812 . . . . 10.0 113.194 -175.4 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.0 mm -64.5 150.45 10.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 C-N-CA 125.969 1.708 . . . . 10.0 107.424 168.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.25 33.26 86.31 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 121.523 -0.736 . . . . 10.0 113.804 178.666 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -100.65 163.96 12.1 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 166.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -103.55 127.55 50.95 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-N 118.587 0.63 . . . . 10.0 111.106 170.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.14 139.64 30.26 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.498 -1.668 . . . . 10.0 106.498 166.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.404 HG12 ' CD2' ' A' ' 120' ' ' HIS . 93.0 t -122.88 138.67 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 172.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.1 p -105.69 134.72 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 104.96 -2.237 . . . . 10.0 104.96 166.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.644 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.5 m170 -113.67 161.36 17.57 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 114.506 1.298 . . . . 10.0 114.506 -172.355 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -57.73 -49.16 77.47 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 113.694 -1.594 . . . . 10.0 109.548 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -116.09 176.48 5.08 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.47 1.108 . . . . 10.0 111.812 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.1 146.55 23.57 Favored 'General case' 0 N--CA 1.451 -0.425 0 C-N-CA 125.375 1.47 . . . . 10.0 110.271 -177.217 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.456 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 3.9 m-20 -76.77 151.39 36.01 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.108 0.563 . . . . 10.0 110.612 178.114 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -89.54 16.58 7.48 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 114.836 -1.075 . . . . 10.0 109.878 166.227 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 69.9 mt 36.43 47.57 0.51 Allowed 'General case' 0 C--N 1.344 0.338 0 C-N-CA 127.19 2.196 . . . . 10.0 112.383 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.74 -47.37 1.05 Allowed Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 124.582 1.087 . . . . 10.0 111.851 176.464 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -83.23 44.27 0.93 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 124.999 1.32 . . . . 10.0 111.844 -168.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -81.98 -38.68 12.93 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.515 -1.434 . . . . 10.0 109.515 169.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.45 48.61 56.53 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 109.37 -1.492 . . . . 10.0 109.37 -170.108 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 25.9 m120 -138.36 166.57 23.9 Favored 'General case' 0 CA--C 1.508 -0.652 0 N-CA-C 106.689 -1.597 . . . . 10.0 106.689 175.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 2.7 tm-20 -52.99 -46.52 68.36 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 114.712 -1.131 . . . . 10.0 108.843 171.042 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -57.1 -43.2 82.0 Favored 'General case' 0 C--N 1.343 0.305 0 CA-C-N 116.332 -0.395 . . . . 10.0 110.889 171.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.297 2.1 p -59.21 -32.95 70.41 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -167.755 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -78.89 -8.05 58.5 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 118.592 -1.243 . . . . 10.0 112.276 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 89.5 mttt -116.68 -59.46 1.97 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.638 1.575 . . . . 10.0 111.834 -171.11 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.1 p -123.48 -4.66 8.26 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 119.318 0.963 . . . . 10.0 112.675 179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.19 -82.97 0.45 Allowed Glycine 0 CA--C 1.531 1.039 0 CA-C-N 119.386 0.994 . . . . 10.0 112.762 169.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.12 32.88 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 123.186 1.47 . . . . 10.0 108.343 177.473 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.64 -26.6 57.89 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.963 -1.471 . . . . 10.0 109.771 -167.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.13 -159.69 51.22 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 109.53 -1.428 . . . . 10.0 109.53 -177.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.0 t -58.49 139.26 55.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 113.136 0.791 . . . . 10.0 113.136 -168.456 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -65.05 65.72 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 126.764 2.025 . . . . 10.0 109.754 168.786 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.48 -19.2 61.77 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 113.904 1.076 . . . . 10.0 113.904 -172.466 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.22 150.89 25.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 122.81 0.444 . . . . 10.0 110.409 169.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.6 p -154.17 165.6 35.74 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.057 0.543 . . . . 10.0 110.049 -176.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -141.0 -172.0 12.82 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 123.434 0.54 . . . . 10.0 112.675 -177.402 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.7 t -136.79 136.52 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 107.648 -1.241 . . . . 10.0 107.648 172.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.0 mt -73.93 114.63 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 122.887 0.475 . . . . 10.0 110.402 -177.18 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.46 151.35 18.46 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 125.762 1.649 . . . . 10.0 111.461 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.8 mt -73.32 140.34 17.97 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 124.902 1.281 . . . . 10.0 109.855 -173.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.72 -45.47 2.89 Favored 'General case' 0 C--O 1.225 -0.222 0 O-C-N 121.069 -1.02 . . . . 10.0 111.74 173.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.25 1.09 0 C-N-CA 127.81 2.444 . . . . 10.0 109.203 -168.575 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.886 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -70.93 -31.03 67.5 Favored 'General case' 0 C--O 1.226 -0.142 0 CA-C-N 119.27 0.941 . . . . 10.0 109.847 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.9 tttt -144.37 134.12 23.67 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.769 0.828 . . . . 10.0 109.395 -174.19 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 165.41 27.65 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.865 1.666 . . . . 10.0 107.768 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -126.13 171.1 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 118.339 0.518 . . . . 10.0 109.84 174.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.78 112.86 9.73 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.413 -1.328 . . . . 10.0 107.413 166.527 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 30.8 m -92.01 114.89 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 168.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.6 mt -100.56 135.65 41.67 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -158.13 157.43 32.73 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.862 1.21 . . . . 10.0 108.705 170.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.3 -52.17 0.04 OUTLIER Glycine 0 C--O 1.228 -0.269 0 C-N-CA 121.414 -0.422 . . . . 10.0 112.148 172.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.8 -45.95 40.1 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.609 -1.626 . . . . 10.0 106.609 -171.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.29 -67.06 0.55 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 113.711 -1.586 . . . . 10.0 110.461 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -56.97 -41.07 79.2 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.646 2.231 . . . . 10.0 110.68 172.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.8 t -65.94 105.83 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -123.02 117.98 26.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 169.122 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.646 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -101.83 141.63 15.36 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.358 -1.097 . . . . 10.0 110.358 172.383 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.4 HG22 ' CG2' ' A' ' 54' ' ' THR . 2.6 mt -143.13 81.13 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 106.476 -1.676 . . . . 10.0 106.476 -175.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.6 mm -102.72 151.37 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.324 1.049 . . . . 10.0 109.715 -173.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 9.6 m-20 -121.48 119.93 33.43 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.939 2.095 . . . . 10.0 108.164 174.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -102.89 108.92 20.3 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.783 -1.562 . . . . 10.0 106.783 176.252 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -119.49 141.05 49.52 Favored 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.247 0.832 . . . . 10.0 113.247 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -118.39 119.18 33.82 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.332 -1.729 . . . . 10.0 106.332 166.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -154.95 40.27 0.43 Allowed 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 112.842 0.682 . . . . 10.0 112.842 -172.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.99 170.53 13.85 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 102.219 -3.252 . . . . 10.0 102.219 166.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 20.1 t -71.28 -21.83 62.03 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.108 0.48 . . . . 10.0 109.905 -178.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 15.4 m-80 -79.66 -12.63 59.81 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 123.165 0.586 . . . . 10.0 110.1 177.184 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 49.07 45.02 33.41 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-O 118.398 -1.223 . . . . 10.0 114.509 -177.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -65.63 136.59 46.72 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 107.191 -1.888 . . . . 10.0 107.191 172.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.49 105.19 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 106.028 -1.842 . . . . 10.0 106.028 174.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -97.49 112.85 24.52 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 173.412 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -111.99 113.59 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 125.126 1.37 . . . . 10.0 108.776 -173.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.5 p90 -132.65 170.82 14.67 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.874 0.368 . . . . 10.0 110.804 173.597 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.88 -147.92 18.84 Favored Glycine 0 N--CA 1.448 -0.52 0 N-CA-C 106.955 -2.458 . . . . 10.0 106.955 170.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.2 t -155.86 156.61 34.98 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 119.306 -0.958 . . . . 10.0 111.192 177.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.646 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.9 pt -117.08 153.68 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 N-CA-C 108.032 -1.099 . . . . 10.0 108.032 166.379 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -127.62 151.41 48.96 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 106.801 -1.555 . . . . 10.0 106.801 167.015 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.24 -14.44 15.93 Favored Glycine 0 C--N 1.336 0.542 0 CA-C-O 119.002 -0.888 . . . . 10.0 113.322 169.267 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.517 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.6 mp -76.4 176.84 7.84 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 118.652 1.226 . . . . 10.0 110.388 -177.018 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.59 152.76 20.13 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.596 -0.729 . . . . 10.0 109.348 169.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -45.34 143.98 1.58 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.109 1.764 . . . . 10.0 111.87 -176.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.72 -177.31 22.66 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 123.927 0.775 . . . . 10.0 112.159 171.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -71.69 153.55 41.97 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 125.347 1.459 . . . . 10.0 110.921 -177.171 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -149.34 146.93 27.77 Favored 'General case' 0 C--N 1.343 0.319 0 N-CA-C 113.959 1.096 . . . . 10.0 113.959 -177.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.711 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -31.48 114.26 0.07 OUTLIER Glycine 0 C--N 1.34 0.803 0 C-N-CA 128.379 2.895 . . . . 10.0 113.215 164.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.418 ' HZ ' HG21 ' B' ' 35' ' ' ILE . 1.5 m-85 -141.48 101.43 3.99 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 120.519 2.16 . . . . 10.0 109.353 173.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.509 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -151.17 170.15 20.16 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-O 121.749 0.785 . . . . 10.0 111.938 178.603 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.2 m -93.08 154.86 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.223 -2.262 . . . . 10.0 106.788 168.121 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 61.2 m-70 -126.58 135.87 51.81 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 170.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -50.92 -50.57 57.29 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 118.445 -0.788 . . . . 10.0 112.186 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -82.6 137.29 34.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 117.714 -1.594 . . . . 10.0 109.501 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.58 3.01 87.41 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 126.29 1.9 . . . . 10.0 112.147 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 p-10 -76.3 81.82 3.07 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-O 123.613 1.673 . . . . 10.0 110.181 -173.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.495 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.9 OUTLIER -75.31 9.75 1.94 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.488 -1.233 . . . . 10.0 113.732 -175.17 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.538 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -44.96 -45.94 10.79 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 127.734 2.414 . . . . 10.0 112.634 -170.818 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.86 -20.72 41.68 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.7 87.82 2.02 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 107.955 -2.058 . . . . 10.0 107.955 -168.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 16.88 54.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 127.987 2.515 . . . . 10.0 116.108 -169.221 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 17.0 m -125.97 -56.25 1.46 Allowed 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 105.69 -1.967 . . . . 10.0 105.69 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -47.74 -37.4 13.18 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.403 1.481 . . . . 10.0 110.708 169.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.14 -31.5 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 127.864 2.466 . . . . 10.0 115.257 169.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.27 148.64 18.98 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 109.517 -1.433 . . . . 10.0 109.517 169.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.51 -179.27 0.85 Allowed 'Trans proline' 0 N--CA 1.446 -1.305 0 N-CA-C 107.674 -1.702 . . . . 10.0 107.674 166.048 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 37.8 m170 -76.24 76.57 3.04 Favored 'General case' 0 CA--C 1.543 0.685 0 O-C-N 120.422 -1.424 . . . . 10.0 110.501 -169.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -71.46 69.44 0.59 Allowed 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 123.182 1.468 . . . . 10.0 112.417 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 65' ' ' ASN . . . . . 0.405 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 1.7 p30 -56.15 145.51 55.46 Favored Pre-proline 0 C--N 1.321 -0.649 0 C-N-CA 127.326 2.251 . . . . 10.0 112.155 168.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -74.79 167.74 26.41 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 122.106 1.871 . . . . 10.0 108.296 167.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 tp 62.46 -101.06 0.1 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 125.09 1.356 . . . . 10.0 108.041 -174.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.2 p 171.59 97.45 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.753 1.621 . . . . 10.0 110.263 -174.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 75.9 mtt180 -130.02 163.64 26.04 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 119.651 1.114 . . . . 10.0 110.346 176.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -113.44 55.32 0.71 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 124.648 1.179 . . . . 10.0 111.422 -168.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 65.3 t60 47.05 88.2 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 125.091 1.356 . . . . 10.0 114.646 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.06 -145.18 11.07 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.262 -1.336 . . . . 10.0 110.067 178.353 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.78 -173.96 32.1 Favored Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 109.152 -1.579 . . . . 10.0 109.152 176.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -55.22 -13.15 6.49 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 123.025 2.483 . . . . 10.0 112.434 173.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -94.27 -30.25 14.65 Favored 'General case' 0 N--CA 1.444 -0.754 0 C-N-CA 125.189 1.396 . . . . 10.0 110.607 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -103.18 169.0 8.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -169.133 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -78.77 -33.52 46.33 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -77.14 18.14 0.41 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.309 1.043 . . . . 10.0 113.421 -165.652 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 20.2 ptp180 -64.55 117.22 7.05 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.106 -1.072 . . . . 10.0 108.106 -177.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.405 ' HB3' ' HB3' ' B' ' 65' ' ' ASN . 11.1 m170 -57.98 -60.96 2.92 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 120.824 0.345 . . . . 10.0 111.846 -170.451 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p -165.5 -47.09 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 -169.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -152.99 71.49 0.28 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 108.551 -1.82 . . . . 10.0 108.551 172.403 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -102.57 106.61 17.33 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 105.73 -1.952 . . . . 10.0 105.73 171.092 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.22 -12.07 60.03 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 111.7 -172.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.78 -98.26 1.56 Allowed Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 107.924 -2.071 . . . . 10.0 107.924 -178.301 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -156.28 146.96 21.82 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 107.099 -1.445 . . . . 10.0 107.099 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.7 m -122.08 131.95 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 107.208 -1.405 . . . . 10.0 107.208 169.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 63.0 m -90.89 107.26 19.07 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 126.298 1.839 . . . . 10.0 109.228 -172.036 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -77.82 130.33 36.54 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 110.172 -0.307 . . . . 10.0 110.172 172.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -61.85 170.1 2.22 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 124.274 1.03 . . . . 10.0 109.295 167.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -55.79 -29.08 59.09 Favored 'General case' 0 N--CA 1.433 -1.294 0 C-N-CA 125.884 1.674 . . . . 10.0 111.647 171.352 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -78.38 -1.67 34.55 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-O 121.163 0.506 . . . . 10.0 111.371 175.53 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.09 1.46 90.33 Favored Glycine 0 C--N 1.339 0.746 0 O-C-N 120.376 -1.452 . . . . 10.0 111.179 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 44.8 t -78.43 105.98 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 C-N-CA 126.929 2.092 . . . . 10.0 107.03 178.236 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.479 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -103.78 124.62 49.23 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 169.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.56 122.74 26.86 Favored 'General case' 0 N--CA 1.432 -1.338 0 C-N-CA 125.832 1.653 . . . . 10.0 107.816 169.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.4 t -101.92 128.85 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.208 0 N-CA-C 106.851 -1.537 . . . . 10.0 106.851 173.135 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.9 t -156.85 92.67 1.3 Allowed 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 169.32 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.3 mp -135.94 164.29 32.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 125.96 1.704 . . . . 10.0 106.542 -177.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -148.64 159.63 43.91 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.26 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.74 116.21 7.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.023 -0.732 . . . . 10.0 109.023 171.175 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 52.0 p -90.41 61.6 5.05 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 106.909 -1.515 . . . . 10.0 106.909 -171.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.16 -50.53 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 123.731 0.644 . . . . 10.0 110.068 -176.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -79.91 142.42 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.592 -1.262 . . . . 10.0 107.592 169.663 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 22.9 m -128.22 114.22 16.68 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.697 -1.594 . . . . 10.0 106.697 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mt -59.23 -4.34 0.53 Allowed 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 114.411 1.263 . . . . 10.0 114.411 -173.049 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.7 m -147.91 152.72 38.03 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.582 1.953 . . . . 10.0 107.558 177.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 117.91 -91.72 0.53 Allowed Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 106.515 -2.634 . . . . 10.0 106.515 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -135.81 -53.83 0.76 Allowed 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 125.515 1.526 . . . . 10.0 107.777 -169.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 -80.67 36.72 0.39 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.038 0.935 . . . . 10.0 110.49 -175.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.1 t -77.57 110.09 12.07 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 124.624 1.17 . . . . 10.0 107.963 -173.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.6 pt -83.98 23.42 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 122.957 0.503 . . . . 10.0 111.997 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.49 -73.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 CA-C-N 118.8 0.727 . . . . 10.0 111.268 -177.141 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.66 50.33 3.55 Favored Glycine 0 CA--C 1.532 1.133 0 O-C-N 120.642 -1.286 . . . . 10.0 112.546 -177.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.4 mmt-85 -110.3 152.38 26.24 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 124.832 1.253 . . . . 10.0 109.697 176.386 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.9 m -88.88 125.14 34.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.975 -0.75 . . . . 10.0 108.975 171.071 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -96.13 138.76 33.29 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 126.42 1.888 . . . . 10.0 107.7 170.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -126.44 135.67 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 N-CA-C 108.517 -0.919 . . . . 10.0 108.517 -177.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.459 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.2 OUTLIER -106.16 121.87 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 106.807 -1.553 . . . . 10.0 106.807 171.77 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.711 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.3 m-70 -105.63 158.12 16.93 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 123.75 1.738 . . . . 10.0 115.605 -171.421 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -43.82 -61.48 1.41 Allowed 'General case' 0 N--CA 1.442 -0.862 0 C-N-CA 129.738 3.215 . . . . 10.0 110.551 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.3 mttp -112.77 172.86 6.67 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.061 0.944 . . . . 10.0 111.395 -175.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.13 154.64 40.96 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.016 1.326 . . . . 10.0 110.571 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.509 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.0 OUTLIER -78.49 144.98 35.22 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 123.98 0.912 . . . . 10.0 111.578 174.083 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -76.27 -32.89 59.07 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 124.781 1.301 . . . . 10.0 109.349 168.057 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt 63.5 56.42 1.62 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 123.491 1.615 . . . . 10.0 109.572 -168.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.92 -47.96 3.44 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 113.582 -1.645 . . . . 10.0 111.341 165.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.19 44.97 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.8 1.64 . . . . 10.0 112.012 -173.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -10.83 50.08 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 126.263 1.887 . . . . 10.0 111.892 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.88 32.43 18.63 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.448 -0.64 . . . . 10.0 112.071 -174.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -113.66 152.34 30.56 Favored 'General case' 0 CA--C 1.506 -0.716 0 N-CA-C 105.65 -1.982 . . . . 10.0 105.65 171.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.8 tm-20 -50.54 -37.57 40.08 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 114.921 -1.036 . . . . 10.0 108.695 169.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 16.8 tp10 -70.81 -38.5 73.29 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 113.889 1.07 . . . . 10.0 113.889 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 76.7 p -57.67 -42.63 83.95 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 120.642 1.565 . . . . 10.0 110.456 -175.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 6.3 t -69.17 -10.3 57.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 113.109 0.781 . . . . 10.0 113.109 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 20.5 ttmt -113.71 -47.97 2.95 Favored 'General case' 0 N--CA 1.435 -1.204 0 C-N-CA 125.43 1.492 . . . . 10.0 112.347 -168.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 32.0 p -130.78 -2.87 4.14 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.016 0.747 . . . . 10.0 113.016 172.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.2 19.7 60.33 Favored Glycine 0 C--N 1.34 0.803 0 N-CA-C 110.809 -0.917 . . . . 10.0 110.809 -175.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 54.45 31.7 15.22 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 117.837 0.819 . . . . 10.0 111.718 176.603 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.47 7.26 4.62 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 123.906 0.882 . . . . 10.0 111.673 -176.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.85 -168.23 53.48 Favored Glycine 0 N--CA 1.444 -0.798 0 N-CA-C 110.065 -1.214 . . . . 10.0 110.065 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.8 t -67.4 158.32 32.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 122.582 1.182 . . . . 10.0 111.273 -169.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 143' ' ' ARG . . . . . 0.44 ' NE ' ' H ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -67.94 112.37 4.91 Favored 'General case' 0 N--CA 1.442 -0.857 0 C-N-CA 125.075 1.35 . . . . 10.0 107.966 170.69 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 29.0 mt -72.68 -55.71 6.4 Favored 'General case' 0 N--CA 1.458 -0.054 0 N-CA-C 109.098 -0.704 . . . . 10.0 109.098 170.026 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.459 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -138.34 156.6 47.47 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.858 -0.61 . . . . 10.0 110.273 -170.623 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.5 m -129.29 147.63 51.14 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.31 1.444 . . . . 10.0 108.805 -168.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -150.7 156.89 26.93 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.456 -1.458 . . . . 10.0 109.456 169.124 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 70.1 t -116.1 128.54 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 105.133 -2.173 . . . . 10.0 105.133 177.059 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.438 HD13 HG21 ' B' ' 149' ' ' ILE . 16.8 mt -69.03 156.93 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 CA-C-N 119.266 0.939 . . . . 10.0 110.06 176.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.02 160.91 32.47 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 124.995 1.283 . . . . 10.0 110.156 -176.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 96.0 mt -69.75 135.46 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.976 1.31 . . . . 10.0 109.478 -171.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.63 -47.1 2.44 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 123.366 0.666 . . . . 10.0 110.899 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 . . . . . 0 C--O 1.254 1.291 0 CA-C-O 117.809 -1.091 . . . . 10.0 111.031 -169.4 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.463 0 N-CA-C 110.161 -0.311 . . . . 10.0 110.161 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER 169.26 -41.06 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 129.861 3.264 . . . . 10.0 103.891 -167.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -106.39 132.35 52.52 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.243 -2.132 . . . . 10.0 105.243 166.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 163.05 33.97 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 107.526 -1.286 . . . . 10.0 107.526 169.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -124.28 176.51 5.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 C-N-CA 123.037 0.535 . . . . 10.0 109.998 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.77 117.13 5.68 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 118.504 0.593 . . . . 10.0 109.887 166.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -97.99 104.27 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 C-N-CA 124.609 1.164 . . . . 10.0 110.519 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mt -98.41 122.74 41.97 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.862 1.665 . . . . 10.0 109.517 -177.1 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -143.53 157.23 44.59 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 120.034 1.288 . . . . 10.0 108.513 173.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.26 -59.3 0.03 OUTLIER Glycine 0 N--CA 1.464 0.518 0 C-N-CA 120.317 -0.944 . . . . 10.0 113.005 169.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -70.93 -43.91 67.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.86 -71.45 0.38 Allowed Glycine 0 CA--C 1.521 0.451 0 CA-C-N 114.186 -1.37 . . . . 10.0 110.644 168.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -57.39 -33.36 96.13 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.786 2.99 . . . . 10.0 111.369 172.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 57.9 t -64.75 95.89 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.547 -1.279 . . . . 10.0 107.547 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 -120.58 111.27 17.45 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 125.684 1.594 . . . . 10.0 107.775 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.521 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -100.81 133.98 11.52 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-O 119.521 -0.6 . . . . 10.0 111.955 171.768 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.526 ' CG2' HG23 ' B' ' 54' ' ' THR . 8.7 mt -136.08 85.93 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 -172.39 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.55 152.8 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 C-N-CA 124.404 1.081 . . . . 10.0 111.136 -171.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.3 m-20 -120.68 116.8 26.01 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 126.504 1.922 . . . . 10.0 108.905 170.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -91.5 99.34 12.3 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 174.14 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -97.39 117.86 32.58 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.775 0.798 . . . . 10.0 111.025 178.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.1 tp60 -117.61 97.31 5.8 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 127.895 2.478 . . . . 10.0 105.788 178.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.401 ' NZ ' ' OE2' ' A' ' 24' ' ' GLU . 4.8 mtmp? -59.08 -52.76 64.33 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 123.004 0.522 . . . . 10.0 110.377 -173.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.401 ' OE2' ' NZ ' ' A' ' 23' ' ' LYS . 2.0 mp0 -131.09 172.31 12.25 Favored 'General case' 0 N--CA 1.424 -1.748 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 173.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.9 t -71.49 -20.28 62.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 108.879 -0.785 . . . . 10.0 108.879 170.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . 0.306 0.4 OUTLIER -89.13 -5.43 57.78 Favored 'General case' 0 C--N 1.344 0.359 0 N-CA-C 113.401 0.889 . . . . 10.0 113.401 173.446 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.72 160.11 35.34 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 109.619 -1.393 . . . . 10.0 109.619 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -71.55 148.2 53.25 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 N-CA-C 107.592 -1.734 . . . . 10.0 107.592 168.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.3 t -78.39 110.92 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 105.39 -2.078 . . . . 10.0 105.39 173.275 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.2 102.86 15.58 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 171.329 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -98.92 99.7 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.415 -1.328 . . . . 10.0 107.415 179.497 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.8 p90 -118.15 166.87 12.06 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.566 0.698 . . . . 10.0 112.267 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.79 -150.3 21.81 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.07 -2.412 . . . . 10.0 107.07 171.189 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.7 t -155.23 152.87 29.84 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 119.773 -0.771 . . . . 10.0 110.914 -178.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.638 ' CG1' ' HB3' ' A' ' 95' ' ' ALA . 1.9 pt -110.63 142.85 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 115.215 -0.902 . . . . 10.0 108.616 166.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -118.81 148.85 42.41 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 169.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.71 -5.35 40.18 Favored Glycine 0 CA--C 1.525 0.664 0 CA-C-O 119.235 -0.759 . . . . 10.0 113.499 174.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -69.62 176.78 3.31 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 118.805 1.302 . . . . 10.0 110.122 177.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.1 t -104.75 167.83 9.46 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.319 -2.104 . . . . 10.0 105.319 165.232 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -57.07 166.38 1.07 Allowed 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.373 0.669 . . . . 10.0 111.254 -171.388 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.98 -177.17 42.94 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.286 -0.884 . . . . 10.0 112.375 168.56 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.0 mp -74.21 145.42 44.14 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 124.851 1.26 . . . . 10.0 110.093 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -144.91 145.36 31.53 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 124.177 0.991 . . . . 10.0 112.685 -175.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.65 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.48 125.97 0.28 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 126.695 2.093 . . . . 10.0 113.398 166.288 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -150.11 108.55 3.8 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.098 1.449 . . . . 10.0 108.253 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.25 173.0 12.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 122.732 1.253 . . . . 10.0 113.481 177.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 85.8 t -98.19 129.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 CA-C-N 111.03 -2.805 . . . . 10.0 105.487 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -105.8 139.72 39.93 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.194 -1.409 . . . . 10.0 107.194 170.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -58.1 -58.04 10.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 O-C-N 124.094 0.871 . . . . 10.0 110.214 -169.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -76.86 119.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.653 -1.61 . . . . 10.0 106.653 -171.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.74 46.81 2.94 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.523 -1.031 . . . . 10.0 110.523 171.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -108.89 118.72 37.53 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.929 1.291 . . . . 10.0 108.153 176.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.415 ' HB3' HG21 ' B' ' 7' ' ' VAL . 12.0 m120 -117.94 5.78 12.16 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.218 1.807 . . . . 10.0 109.988 178.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.42 HG23 ' CG2' ' B' ' 17' ' ' ILE . 1.3 m -57.07 -37.1 71.37 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 120.096 1.316 . . . . 10.0 111.667 -169.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -21.83 45.68 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.079 0.952 . . . . 10.0 112.682 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 143.85 -86.46 0.18 Allowed Glycine 0 CA--C 1.527 0.797 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 -172.003 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 24.1 p -170.78 43.29 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.152 0.981 . . . . 10.0 110.989 172.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 m -104.92 -49.31 3.52 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 m -50.18 -27.63 6.18 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 126.372 1.869 . . . . 10.0 111.641 174.149 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -37.16 -32.1 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 128.02 2.528 . . . . 10.0 113.848 168.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.32 126.64 5.2 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.277 -1.291 . . . . 10.0 109.95 170.103 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -72.4 65.34 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.81 0 C-N-CA 123.729 2.953 . . . . 10.0 112.268 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.7 m170 68.87 42.8 1.29 Allowed 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 129.773 3.229 . . . . 10.0 111.505 172.036 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -72.51 57.96 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.728 1.01 . . . . 10.0 113.728 -173.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.0 p-10 -68.3 159.57 79.95 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 118.968 0.804 . . . . 10.0 110.931 175.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -61.28 -47.68 11.55 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.216 1.944 . . . . 10.0 111.218 176.174 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 94.8 mt -78.1 59.05 2.12 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 109.301 -0.629 . . . . 10.0 109.301 177.344 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.0 t -58.97 95.64 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.417 1.087 . . . . 10.0 108.77 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.59 -96.57 0.41 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.796 -1.557 . . . . 10.0 106.796 -177.172 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.5 mttp -151.67 139.92 20.34 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 106.397 -1.705 . . . . 10.0 106.397 173.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.6 t60 -40.91 124.15 2.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 O-C-N 123.776 0.673 . . . . 10.0 110.903 170.401 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.15 -138.12 3.66 Favored Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 108.367 -1.893 . . . . 10.0 108.367 177.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.37 -165.94 33.35 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 107.342 -2.303 . . . . 10.0 107.342 169.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -62.54 -0.72 2.06 Favored 'Trans proline' 0 CA--C 1.542 0.878 0 CA-C-N 120.305 2.053 . . . . 10.0 110.948 167.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 61.0 mmtt -91.07 -24.62 19.98 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 124.409 1.084 . . . . 10.0 110.625 173.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.77 174.8 5.72 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -176.418 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -87.82 -32.15 19.19 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 170.159 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -82.25 2.0 33.99 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 115.032 1.493 . . . . 10.0 115.032 -165.053 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -41.54 137.36 1.59 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 125.639 1.575 . . . . 10.0 112.172 -177.12 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -71.88 -77.64 0.09 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.704 -0.798 . . . . 10.0 112.185 -170.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 p -161.41 58.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 121.324 -0.86 . . . . 10.0 109.46 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 106.94 50.55 0.83 Allowed Glycine 0 CA--C 1.523 0.533 0 N-CA-C 109.943 -1.263 . . . . 10.0 109.943 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -87.05 90.97 8.54 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 104.026 -2.583 . . . . 10.0 104.026 167.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.3 mt -70.3 -31.63 69.06 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 107.316 -1.364 . . . . 10.0 107.316 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 101.08 -106.43 3.08 Favored Glycine 0 N--CA 1.434 -1.44 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 168.236 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -109.23 119.41 39.42 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.506 1.122 . . . . 10.0 110.388 -168.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.1 m -104.89 135.36 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 168.016 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 50.0 m -99.64 108.8 21.26 Favored 'General case' 0 N--CA 1.442 -0.858 0 C-N-CA 126.316 1.846 . . . . 10.0 109.641 -168.514 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.44 130.24 35.24 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.229 1.011 . . . . 10.0 110.748 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 45.4 t0 -66.26 170.71 5.52 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 123.956 0.902 . . . . 10.0 109.455 168.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -52.96 -26.99 16.91 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.872 1.669 . . . . 10.0 111.599 177.47 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -79.03 -15.52 58.11 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.349 1.059 . . . . 10.0 110.065 -175.299 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.81 74.21 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 110.991 -0.844 . . . . 10.0 110.991 -173.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.0 t -87.64 113.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 C-N-CA 126.338 1.855 . . . . 10.0 106.265 173.265 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.638 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -111.9 121.38 44.87 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.461 -0.94 . . . . 10.0 108.461 171.295 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -78.17 130.55 36.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 172.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 75.0 t -104.91 129.39 57.59 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.369 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 169.286 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -156.93 66.95 0.53 Allowed 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 175.471 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.35 155.02 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.261 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.37 138.36 38.2 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.929 0.492 . . . . 10.0 110.727 169.146 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.95 131.14 51.15 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.858 1.263 . . . . 10.0 108.789 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.4 p -95.96 42.75 1.09 Allowed 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.626 1.971 . . . . 10.0 108.424 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.3 -49.88 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 123.337 0.655 . . . . 10.0 109.644 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 33.7 mm -57.57 134.55 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 169.011 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.5 m -164.66 94.22 0.68 Allowed 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.668 0.787 . . . . 10.0 109.441 -176.218 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.631 ' H ' HD13 ' A' ' 106' ' ' LEU . 0.0 OUTLIER -68.61 27.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.644 1.177 . . . . 10.0 113.839 175.328 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.9 p -157.8 113.4 2.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 121.275 -0.891 . . . . 10.0 110.32 -176.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 162.26 -54.1 0.31 Allowed Glycine 0 C--N 1.335 0.481 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 169.648 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.75 -50.14 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 126.337 1.855 . . . . 10.0 107.475 -173.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 -74.42 -38.53 63.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.944 -1.025 . . . . 10.0 108.623 -169.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 40.53 62.2 1.42 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.154 1.782 . . . . 10.0 110.01 172.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 24.3 pt -74.62 46.77 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.745 2.018 . . . . 10.0 111.77 -175.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.3 mm -72.49 -65.17 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 128.971 2.908 . . . . 10.0 108.207 172.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.75 47.52 3.07 Favored Glycine 0 CA--C 1.529 0.953 0 O-C-N 121.343 -0.848 . . . . 10.0 113.808 -169.112 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -89.65 174.63 7.64 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 125.105 1.362 . . . . 10.0 108.68 172.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 20.2 m -109.87 115.11 29.22 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.787 -2.301 . . . . 10.0 104.787 168.127 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.6 mp -97.94 151.78 19.92 Favored 'General case' 0 CA--C 1.512 -0.511 0 N-CA-C 108.296 -1.001 . . . . 10.0 108.296 175.039 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.7 t -143.16 136.89 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 O-C-N 123.837 0.711 . . . . 10.0 109.803 -170.327 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.8 m -105.89 140.35 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.952 1.301 . . . . 10.0 108.887 167.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.65 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m170 -120.66 159.13 25.94 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.49 2.033 . . . . 10.0 116.49 -172.234 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -39.46 -58.61 1.23 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 130.289 3.436 . . . . 10.0 111.886 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -123.17 168.34 12.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 124.679 1.192 . . . . 10.0 110.48 -171.039 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.76 137.66 55.61 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 108.308 -0.997 . . . . 10.0 108.308 169.57 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.84 144.12 37.27 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.191 -1.04 . . . . 10.0 108.191 168.193 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -78.14 25.04 0.23 Allowed 'General case' 0 CA--C 1.539 0.519 0 CA-C-O 121.133 0.492 . . . . 10.0 111.126 177.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 18.8 mt 30.53 45.82 0.03 OUTLIER 'General case' 0 C--N 1.34 0.162 0 C-N-CA 128.23 2.612 . . . . 10.0 112.629 -170.161 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.6 -45.53 1.3 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 124.623 1.106 . . . . 10.0 112.488 177.226 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -83.34 50.6 1.8 Allowed 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.092 0.957 . . . . 10.0 111.452 -169.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -87.45 -35.89 9.14 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 125.969 1.747 . . . . 10.0 110.022 172.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.27 38.7 71.56 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.865 -0.894 . . . . 10.0 110.865 -178.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 56.1 m-80 -130.8 163.74 26.7 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 169.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -53.31 -39.35 63.96 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.718 0.771 . . . . 10.0 109.592 173.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -67.14 -35.16 79.12 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.448 1.099 . . . . 10.0 112.934 173.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.4 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 60.0 p -56.31 -34.01 66.12 Favored 'General case' 0 N--CA 1.443 -0.776 0 O-C-N 120.029 -1.669 . . . . 10.0 112.033 -175.138 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -81.35 -1.98 47.44 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 118.738 -0.649 . . . . 10.0 112.139 -178.373 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -112.69 -82.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.263 1.825 . . . . 10.0 110.545 -177.025 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -109.6 25.45 11.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 120.725 1.602 . . . . 10.0 111.974 174.784 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.1 18.03 66.42 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.602 167.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 m120 62.24 23.54 13.93 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 118.085 0.943 . . . . 10.0 112.224 -171.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.03 -11.91 33.65 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.24 -0.913 . . . . 10.0 113.097 177.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.62 -161.2 46.1 Favored Glycine 0 CA--C 1.523 0.553 0 O-C-N 121.151 -0.968 . . . . 10.0 111.128 170.04 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.9 t -57.07 129.68 42.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 124.327 1.051 . . . . 10.0 113.135 -167.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.1 mtt85 -65.94 71.97 0.06 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.454 1.902 . . . . 10.0 111.404 175.152 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 51.7 mt -52.05 -33.4 38.68 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.286 1.034 . . . . 10.0 113.733 -177.336 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.81 147.18 26.96 Favored 'General case' 0 CA--C 1.512 -0.495 0 O-C-N 121.727 -0.608 . . . . 10.0 110.055 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.8 m -140.9 149.85 42.45 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 107.627 -1.249 . . . . 10.0 107.627 -170.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.58 36.42 Favored Glycine 0 CA--C 1.521 0.416 0 N-CA-C 111.397 -0.681 . . . . 10.0 111.397 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 52.9 t -115.23 154.68 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 103.145 -2.909 . . . . 10.0 103.145 171.082 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 8.3 mt -71.45 -90.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 123.51 0.724 . . . . 10.0 109.306 -169.382 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 108.06 125.61 5.3 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 81.2 mt -61.18 140.47 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 C-N-CA 125.686 1.594 . . . . 10.0 108.721 175.337 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.36 -38.84 4.57 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-N 119.525 1.057 . . . . 10.0 111.495 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? . . . . . 0 C--O 1.249 1.038 0 CA-C-O 117.308 -1.33 . . . . 10.0 109.899 178.22 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 106.458 -1.682 . . . . 10.0 106.458 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -88.1 -56.17 3.44 Favored 'General case' 0 N--CA 1.458 -0.027 0 O-C-N 124.293 0.995 . . . . 10.0 110.853 -174.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.07 138.79 49.73 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.415 1.086 . . . . 10.0 110.155 -176.042 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.48 162.64 33.99 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.63 0.772 . . . . 10.0 110.653 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 m -121.04 160.89 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.557 1.143 . . . . 10.0 109.617 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 95.82 2.9 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.556 -1.275 . . . . 10.0 107.556 166.198 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.415 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.7 m -82.15 108.48 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 169.317 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -93.99 137.8 32.8 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 178.013 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 tttt -156.58 159.03 38.12 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 119.912 1.233 . . . . 10.0 107.87 171.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.89 -47.91 0.04 OUTLIER Glycine 0 C--O 1.229 -0.2 0 C-N-CA 120.684 -0.769 . . . . 10.0 111.481 169.729 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.52 -46.43 26.59 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 -171.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.72 -69.0 0.52 Allowed Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 113.905 -1.498 . . . . 10.0 110.145 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -56.28 -44.04 50.23 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.311 2.007 . . . . 10.0 110.539 171.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.96 101.2 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.13 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 -175.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -120.81 110.75 16.72 Favored 'General case' 0 N--CA 1.441 -0.921 0 N-CA-C 106.103 -1.814 . . . . 10.0 106.103 173.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.797 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -90.05 140.38 15.48 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.615 -1.794 . . . . 10.0 108.615 171.051 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.42 ' CG2' HG23 ' A' ' 54' ' ' THR . 4.0 mt -141.53 88.84 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 -173.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -101.3 144.13 13.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 C-N-CA 123.576 0.75 . . . . 10.0 110.362 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -121.19 114.26 21.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 126.499 1.92 . . . . 10.0 108.266 168.639 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -98.19 106.4 18.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 mt-10 -107.54 123.86 49.07 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 112.789 0.662 . . . . 10.0 112.789 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -81.62 115.16 20.76 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 104.112 -2.551 . . . . 10.0 104.112 166.286 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -49.7 -54.15 20.46 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 123.954 0.902 . . . . 10.0 109.92 169.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -129.97 -136.6 0.22 Allowed 'General case' 0 N--CA 1.425 -1.684 0 N-CA-C 106.755 -1.572 . . . . 10.0 106.755 -176.097 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.4 t -108.42 -21.8 12.58 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-O 121.145 0.497 . . . . 10.0 110.689 168.325 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -127.32 6.7 6.39 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.548 1.139 . . . . 10.0 110.743 -176.246 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.98 169.06 54.72 Favored Glycine 0 CA--C 1.529 0.929 0 N-CA-C 108.862 -1.695 . . . . 10.0 108.862 174.184 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -65.7 132.18 29.94 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.5 1.467 . . . . 10.0 108.497 171.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.9 t -78.07 108.34 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 104.778 -2.305 . . . . 10.0 104.778 169.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -79.62 109.74 14.29 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 105.275 -2.12 . . . . 10.0 105.275 169.093 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -96.67 97.07 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 106.328 -1.73 . . . . 10.0 106.328 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 20.5 p90 -108.76 164.37 12.44 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.163 0.506 . . . . 10.0 110.595 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.88 178.86 48.45 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 110.391 -1.084 . . . . 10.0 110.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -150.88 106.07 3.34 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.663 -0.866 . . . . 10.0 108.663 178.376 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.797 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.2 pt -79.9 173.15 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 119.55 -0.86 . . . . 10.0 109.738 173.123 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.0 pttt -150.85 153.36 35.22 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 168.144 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.82 -15.36 40.86 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-O 118.993 -0.893 . . . . 10.0 115.274 169.724 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.485 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.6 mp -75.33 179.66 5.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.943 1.372 . . . . 10.0 110.362 -177.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -91.56 174.95 7.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 166.018 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -62.25 175.09 0.78 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 124.391 1.076 . . . . 10.0 111.435 -173.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.44 -172.74 47.23 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 123.885 0.755 . . . . 10.0 112.588 166.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -75.89 142.78 42.02 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.425 1.49 . . . . 10.0 110.093 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -137.39 143.25 41.84 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 114.753 1.39 . . . . 10.0 114.753 -175.425 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.658 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.04 124.95 0.24 Allowed Glycine 0 C--N 1.343 0.917 0 C-N-CA 127.262 2.363 . . . . 10.0 111.711 162.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.35 103.42 2.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.343 1.572 . . . . 10.0 109.949 170.548 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.515 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.79 173.98 15.7 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 113.806 1.039 . . . . 10.0 113.806 -176.91 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 m -85.26 151.99 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 CA-C-N 113.006 -1.906 . . . . 10.0 109.385 169.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -132.89 84.9 2.17 Favored 'General case' 0 C--O 1.221 -0.428 0 C-N-CA 124.756 1.222 . . . . 10.0 108.365 174.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 22.5 -83.96 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 128.046 2.539 . . . . 10.0 116.129 -176.025 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -76.76 179.06 6.31 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-O 121.555 0.693 . . . . 10.0 109.594 -169.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.69 -26.17 10.98 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.508 -1.037 . . . . 10.0 110.508 169.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -37.47 130.24 0.98 Allowed 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 125.502 1.521 . . . . 10.0 110.317 176.166 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -138.38 18.61 2.75 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 114.944 -1.026 . . . . 10.0 111.398 175.159 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.526 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -56.92 -35.76 69.41 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 118.362 0.528 . . . . 10.0 110.223 -178.197 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.95 -20.25 42.4 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 125.42 1.488 . . . . 10.0 113.515 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.29 99.12 1.04 Allowed Glycine 0 CA--C 1.531 1.065 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 -169.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.9 p 3.94 61.6 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 128.555 2.742 . . . . 10.0 117.508 -169.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.1 m -135.33 -60.03 0.76 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.013 -1.847 . . . . 10.0 106.013 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 41.6 t -50.93 -34.52 28.92 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.736 0.814 . . . . 10.0 110.002 169.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.07 -47.52 0.28 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 126.29 1.836 . . . . 10.0 112.64 168.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 131.63 140.6 4.59 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.082 -0.844 . . . . 10.0 111.998 171.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 62' ' ' PRO . . . . . 0.403 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 89.0 Cg_endo -73.13 64.68 4.26 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.824 3.016 . . . . 10.0 110.501 169.276 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 30.3 m170 75.57 -44.31 0.52 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 129.781 3.232 . . . . 10.0 111.05 175.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 64' ' ' PHE . . . . . 0.403 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 27.8 m-85 31.13 59.4 0.26 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 127.75 2.42 . . . . 10.0 113.252 -174.337 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 65' ' ' ASN . . . . . 0.547 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 0.0 OUTLIER -55.34 146.23 43.32 Favored Pre-proline 0 C--N 1.324 -0.519 0 N-CA-C 113.441 0.904 . . . . 10.0 113.441 175.117 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.84 -47.54 0.34 Allowed 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.762 2.308 . . . . 10.0 110.832 177.172 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -81.71 56.57 3.07 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.821 0.848 . . . . 10.0 109.879 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -18.35 77.31 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.278 3.031 . . . . 10.0 116.48 -169.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt85 -116.53 -179.86 3.8 Favored 'General case' 0 CA--C 1.509 -0.598 0 C-N-CA 125.499 1.52 . . . . 10.0 109.84 173.648 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -114.59 89.4 3.09 Favored 'General case' 0 N--CA 1.439 -1.014 0 O-C-N 124.238 0.962 . . . . 10.0 112.755 -171.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.482 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 75.1 t60 12.83 89.19 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.174 2.19 . . . . 10.0 115.084 176.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -106.42 -141.69 10.45 Favored Glycine 0 C--N 1.318 -0.435 0 N-CA-C 108.721 -1.752 . . . . 10.0 108.721 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.67 -168.23 37.0 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 109.896 -1.281 . . . . 10.0 109.896 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -66.72 12.13 0.16 Allowed 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.224 1.95 . . . . 10.0 111.662 169.174 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 62.7 mmtt -107.55 -18.84 13.74 Favored 'General case' 0 N--CA 1.438 -1.025 0 C-N-CA 124.731 1.213 . . . . 10.0 109.541 173.063 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -135.54 162.75 31.8 Favored 'General case' 0 C--N 1.348 0.513 0 CA-C-N 118.766 0.712 . . . . 10.0 109.822 -167.558 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -82.62 -18.76 40.05 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 107.969 -1.123 . . . . 10.0 107.969 173.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -84.27 21.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.219 0 O-C-N 119.908 -1.745 . . . . 10.0 112.854 -169.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.01 138.04 5.4 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.54 1.136 . . . . 10.0 109.196 170.454 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.547 ' HB3' ' HB3' ' B' ' 65' ' ' ASN . 11.6 m170 -70.41 -65.61 0.71 Allowed 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 173.812 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.47 HG13 ' H ' ' B' ' 82' ' ' GLY . 7.8 p -174.42 -69.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.117 1.367 . . . . 10.0 108.248 -178.366 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.47 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -105.84 63.12 0.31 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 109.602 -1.399 . . . . 10.0 109.602 -175.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.8 95.3 5.51 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.287 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 26.1 mt -75.33 2.43 11.24 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 120.295 -0.562 . . . . 10.0 110.906 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 89.16 -95.63 2.12 Favored Glycine 0 N--CA 1.437 -1.25 0 N-CA-C 108.174 -1.97 . . . . 10.0 108.174 171.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.3 m-20 -156.17 113.56 3.23 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 118.622 -0.704 . . . . 10.0 109.258 -172.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.3 m -96.72 131.08 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 118.524 0.602 . . . . 10.0 110.215 177.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 14.4 m -87.21 108.64 19.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 127.85 2.46 . . . . 10.0 110.424 -173.218 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.8 133.17 34.34 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.156 0.583 . . . . 10.0 109.752 171.092 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -61.86 174.05 0.91 Allowed 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.939 0.876 . . . . 10.0 109.591 167.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -51.57 -29.88 18.83 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 125.244 1.418 . . . . 10.0 110.961 173.134 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.01 -9.55 59.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 123.35 0.66 . . . . 10.0 110.501 -175.023 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.07 7.14 83.98 Favored Glycine 0 C--N 1.339 0.745 0 N-CA-C 111.33 -0.708 . . . . 10.0 111.33 -177.013 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 47.5 t -90.02 114.18 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 126.144 1.778 . . . . 10.0 106.366 178.301 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.444 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -110.81 118.57 36.5 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 169.273 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -80.09 121.69 25.85 Favored 'General case' 0 N--CA 1.451 -0.393 0 O-C-N 124.886 1.366 . . . . 10.0 107.547 169.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 99.1 t -105.81 131.07 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 C-N-CA 125.928 1.691 . . . . 10.0 106.625 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.5 p -155.46 74.58 0.9 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 174.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.69 159.01 7.41 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -142.68 133.66 25.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 O-C-N 121.77 -0.581 . . . . 10.0 110.738 173.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -142.88 135.34 27.57 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.976 0.91 . . . . 10.0 109.543 -172.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 3.8 p -93.92 -10.52 33.52 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.17 1.388 . . . . 10.0 111.188 169.646 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -85.07 -15.75 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.916 0.886 . . . . 10.0 110.28 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -98.15 149.84 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 106.659 -1.608 . . . . 10.0 106.659 169.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.6 m -153.34 141.16 20.11 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 169.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -56.14 -50.04 72.24 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.886 0.874 . . . . 10.0 109.558 -178.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.3 m -136.21 161.93 34.38 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 124.862 1.265 . . . . 10.0 108.688 -178.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.29 -92.01 0.37 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 107.156 -2.378 . . . . 10.0 107.156 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -128.31 -46.09 1.35 Allowed 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 125.083 1.353 . . . . 10.0 109.21 -168.463 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -75.14 -36.4 61.58 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 107.609 -1.256 . . . . 10.0 107.609 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t 42.43 58.12 3.17 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 126.373 1.869 . . . . 10.0 114.514 166.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 28.1 pt -70.64 -12.16 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 N-CA-C 113.168 0.803 . . . . 10.0 113.168 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.4 mm -57.66 115.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 119.847 1.203 . . . . 10.0 110.208 171.334 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 102.69 2.6 49.79 Favored Glycine 0 C--N 1.336 0.546 0 C-N-CA 124.496 1.046 . . . . 10.0 111.804 173.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.77 148.8 31.32 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 117.845 0.822 . . . . 10.0 110.605 173.349 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 31.3 m -80.66 126.69 31.59 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.838 1.255 . . . . 10.0 108.091 168.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -103.48 145.47 29.95 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.305 1.442 . . . . 10.0 107.825 169.07 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 68.9 t -135.54 143.5 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 4.4 p -110.89 139.8 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 O-C-N 124.535 1.147 . . . . 10.0 108.679 169.518 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.658 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.6 m-70 -117.2 162.41 17.91 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 114.729 1.381 . . . . 10.0 114.729 -174.657 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 121' ' ' GLU . . . . . 0.424 ' HB2' HD21 ' B' ' 144' ' ' LEU . 62.4 tt0 -61.72 -51.11 69.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 114.888 -1.051 . . . . 10.0 109.789 178.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -109.65 170.18 8.23 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.51 0.671 . . . . 10.0 111.613 -168.575 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.21 148.77 45.23 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 114.278 -1.328 . . . . 10.0 109.078 178.632 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.515 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.7 OUTLIER -74.93 151.14 38.91 Favored 'General case' 0 N--CA 1.443 -0.775 0 N-CA-C 109.226 -0.657 . . . . 10.0 109.226 172.686 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -76.0 -38.35 57.45 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 112.713 -2.039 . . . . 10.0 108.936 172.157 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 62.8 mt 62.45 64.54 0.93 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 123.97 1.843 . . . . 10.0 108.061 -176.035 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 76.21 -38.49 1.38 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 112.136 -2.302 . . . . 10.0 116.14 167.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 11.9 mtmt -75.35 5.09 6.1 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.099 1.148 . . . . 10.0 114.099 -167.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.45 -34.93 90.14 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 108.388 -1.885 . . . . 10.0 108.388 166.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.71 25.61 51.77 Favored Glycine 0 C--N 1.341 0.827 0 N-CA-C 111.191 -0.764 . . . . 10.0 111.191 -176.055 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -108.2 172.88 6.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 170.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -57.1 -45.6 83.27 Favored 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 123.957 0.903 . . . . 10.0 109.277 -177.145 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 mp0 -52.96 -42.76 65.79 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.456 1.102 . . . . 10.0 109.992 173.14 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.12 -9.21 20.92 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 117.341 -1.314 . . . . 10.0 113.362 179.458 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.2 t -108.73 7.57 26.44 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 121.009 1.731 . . . . 10.0 110.627 173.559 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -127.05 -59.44 1.25 Allowed 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 124.909 1.284 . . . . 10.0 110.94 -170.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.7 p -140.63 22.42 2.33 Favored 'General case' 0 CA--C 1.544 0.736 0 CA-C-N 119.016 0.826 . . . . 10.0 112.008 176.37 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 78.03 -100.23 1.6 Allowed Glycine 0 C--N 1.341 0.857 0 N-CA-C 107.533 -2.227 . . . . 10.0 107.533 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -163.62 42.19 0.1 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 125.696 1.598 . . . . 10.0 107.6 169.075 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.43 -8.98 45.46 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.296 1.038 . . . . 10.0 113.009 -174.372 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.01 -171.34 55.13 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.669 -1.372 . . . . 10.0 109.669 -173.228 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -53.32 164.11 0.51 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 124.822 1.249 . . . . 10.0 112.004 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.25 114.25 19.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 168.019 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.425 ' N ' ' CD2' ' B' ' 144' ' ' LEU . 0.7 OUTLIER -84.63 -48.13 9.81 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 108.315 -0.994 . . . . 10.0 108.315 -177.716 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.64 141.17 39.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 116.208 -0.451 . . . . 10.0 110.121 -175.464 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 m -118.6 145.37 45.46 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 126.491 1.916 . . . . 10.0 108.297 -169.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.19 155.46 26.49 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.859 -1.296 . . . . 10.0 109.859 168.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 18.1 t -116.24 129.51 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 103.946 -2.613 . . . . 10.0 103.946 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.7 mt -65.93 133.65 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 119.188 0.904 . . . . 10.0 111.255 -177.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.04 143.38 16.15 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.338 -1.505 . . . . 10.0 109.338 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -80.94 128.21 38.89 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.346 0 CA-C-N 118.442 1.121 . . . . 10.0 108.622 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.33 -49.23 17.42 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 -175.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.8 tp60 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 117.218 -1.373 . . . . 10.0 109.527 175.195 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 108.466 -0.938 . . . . 10.0 108.466 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t -133.81 -49.09 0.82 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 124.061 0.944 . . . . 10.0 111.439 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -120.93 139.54 53.08 Favored 'General case' 0 C--O 1.235 0.31 0 C-N-CA 125.462 1.505 . . . . 10.0 109.371 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.87 164.12 36.23 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 173.186 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 m -123.72 179.57 2.7 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 O-C-N 123.469 0.481 . . . . 10.0 109.9 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.89 118.25 8.45 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 126.683 1.993 . . . . 10.0 107.631 164.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 m -97.23 86.81 1.6 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 124.211 1.005 . . . . 10.0 111.007 173.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.426 ' N ' HD12 ' A' ' 8' ' ' LEU . 5.7 mp -79.47 140.15 37.42 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 121.789 -0.569 . . . . 10.0 109.609 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.8 mtmt -152.35 163.65 39.06 Favored 'General case' 0 N--CA 1.456 -0.168 0 N-CA-C 106.622 -1.621 . . . . 10.0 106.622 170.023 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -166.4 -65.71 0.03 OUTLIER Glycine 0 C--N 1.33 0.249 0 C-N-CA 120.606 -0.806 . . . . 10.0 112.249 169.177 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -74.11 -42.1 60.59 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.08 -66.45 0.5 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 114.885 -1.052 . . . . 10.0 111.959 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.81 -41.24 71.76 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.89 1.727 . . . . 10.0 110.621 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.466 HG23 HD11 ' A' ' 38' ' ' LEU . 0.4 OUTLIER -68.0 109.47 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.331 -1.359 . . . . 10.0 107.331 177.364 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -120.46 122.37 40.54 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.161 -2.163 . . . . 10.0 105.161 171.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.736 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -108.94 133.64 11.78 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 109.649 -1.38 . . . . 10.0 109.649 175.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.597 ' CG2' HG22 ' B' ' 54' ' ' THR . 2.2 mt -138.17 86.38 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -173.567 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.5 mm -95.57 143.33 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 C-N-CA 123.948 0.899 . . . . 10.0 109.111 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 32.7 m-80 -115.54 121.68 43.4 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 126.13 1.772 . . . . 10.0 108.721 168.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -102.28 98.11 8.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 125.862 1.665 . . . . 10.0 107.025 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -117.89 121.31 40.39 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.072 0.851 . . . . 10.0 113.109 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -94.05 105.49 17.49 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 125.867 1.667 . . . . 10.0 107.831 168.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.47 -42.76 61.83 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.795 0.838 . . . . 10.0 110.174 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -135.98 158.53 44.17 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 102.193 -3.262 . . . . 10.0 102.193 165.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 t -77.32 -3.87 42.19 Favored 'General case' 0 C--O 1.226 -0.135 0 CA-C-N 119.37 0.986 . . . . 10.0 109.817 173.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m120 -85.02 -24.6 28.12 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 125.182 1.393 . . . . 10.0 109.361 168.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.62 156.84 45.06 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 109.43 -1.468 . . . . 10.0 109.43 174.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -64.55 153.16 78.71 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 N-CA-C 108.006 -1.575 . . . . 10.0 108.006 169.145 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.8 p -79.14 121.14 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 N-CA-C 106.69 -1.596 . . . . 10.0 106.69 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -88.79 113.73 24.66 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.16 -1.793 . . . . 10.0 106.16 168.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 m -92.31 95.97 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.824 0 N-CA-C 105.555 -2.017 . . . . 10.0 105.555 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.7 p90 -106.97 161.8 14.4 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.178 0.513 . . . . 10.0 110.538 171.179 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.16 169.29 39.48 Favored Glycine 0 N--CA 1.438 -1.187 0 C-N-CA 120.055 -1.069 . . . . 10.0 110.63 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.0 t -139.37 95.75 2.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.992 -1.485 . . . . 10.0 106.992 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.736 HG22 ' HA2' ' A' ' 16' ' ' GLY . 6.4 pt -77.07 166.33 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.124 -1.065 . . . . 10.0 108.124 169.093 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -149.29 146.53 27.6 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 106.58 -1.637 . . . . 10.0 106.58 166.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.53 -4.93 24.73 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 123.921 0.772 . . . . 10.0 113.567 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.494 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.3 mp -73.23 177.93 4.8 Favored 'General case' 0 N--CA 1.444 -0.752 0 CA-C-N 118.117 0.959 . . . . 10.0 109.245 173.66 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 7.9 t -90.39 172.29 8.85 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.632 -0.877 . . . . 10.0 108.632 166.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.91 169.88 2.37 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.43 1.092 . . . . 10.0 110.837 -173.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.73 -178.92 41.26 Favored Glycine 0 N--CA 1.448 -0.503 0 O-C-N 121.428 -0.795 . . . . 10.0 112.843 167.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.6 mp -69.4 143.83 53.54 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.612 1.165 . . . . 10.0 109.779 176.04 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -142.61 139.49 31.31 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 123.381 0.672 . . . . 10.0 112.662 -176.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.627 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -26.84 117.94 0.04 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.106 2.289 . . . . 10.0 113.036 164.566 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.03 106.23 4.56 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 120.2 2.0 . . . . 10.0 110.095 170.03 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.422 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -148.48 172.06 15.09 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-O 121.174 0.512 . . . . 10.0 112.075 179.872 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.43 -44.57 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 C-N-CA 126.249 1.819 . . . . 10.0 113.429 -168.506 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 63.64 144.45 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 126.887 2.075 . . . . 10.0 112.074 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -67.0 -47.7 70.68 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.694 -0.854 . . . . 10.0 108.694 177.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -74.88 129.98 38.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 107.788 -1.19 . . . . 10.0 107.788 -169.591 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -88.75 -28.43 21.47 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 126.572 2.034 . . . . 10.0 110.695 175.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.59 176.43 0.65 Allowed 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 125.144 1.378 . . . . 10.0 112.819 -176.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -146.34 -64.41 0.3 Allowed 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.078 -1.419 . . . . 10.0 110.021 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.792 HG22 HG22 ' B' ' 17' ' ' ILE . 1.0 OUTLIER 46.54 -57.17 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.652 1 C-N-CA 133.211 4.604 . . . . 10.0 115.134 179.546 . . . . . . . . 4 4 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . 0.293 . . -69.66 -37.05 76.57 Favored 'General case' 0 N--CA 1.437 -1.081 0 C-N-CA 127.763 2.425 . . . . 10.0 108.216 169.618 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.29 -143.76 14.96 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.233 -2.747 . . . . 10.0 106.233 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.3 t -78.8 39.35 0.35 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 122.178 0.99 . . . . 10.0 112.066 -172.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.4 m -111.27 -49.33 3.02 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 127.826 2.451 . . . . 10.0 106.811 -169.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 16.1 m -91.0 16.92 8.64 Favored 'General case' 0 N--CA 1.435 -1.224 0 C-N-CA 126.488 1.915 . . . . 10.0 110.113 -171.292 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.69 61.44 1.37 Allowed 'General case' 0 C--O 1.236 0.379 0 C-N-CA 124.101 0.96 . . . . 10.0 109.365 169.453 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 0.26 103.92 0.01 OUTLIER Glycine 0 C--N 1.335 0.488 1 C-N-CA 131.62 4.438 . . . . 10.0 111.087 166.705 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -73.04 73.5 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 122.752 2.301 . . . . 10.0 113.129 -168.345 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.461 ' CD2' HG22 ' A' ' 137' ' ' THR . 11.1 m170 71.82 36.2 1.24 Allowed 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 129.592 3.157 . . . . 10.0 110.749 170.008 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -73.62 60.02 0.66 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.451 1.1 . . . . 10.0 110.709 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -75.03 156.96 85.85 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 123.673 0.789 . . . . 10.0 110.181 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -65.43 -65.36 0.05 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.441 2.094 . . . . 10.0 111.5 -175.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.99 66.81 1.22 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.661 0.743 . . . . 10.0 109.975 172.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 113.74 3.3 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.401 -0.812 . . . . 10.0 109.557 178.102 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.6 mtt180 -116.8 -87.91 0.6 Allowed 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 103.298 -2.852 . . . . 10.0 103.298 -173.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtm -145.72 160.12 42.18 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 122.627 1.203 . . . . 10.0 108.702 167.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 42.7 t60 -62.2 127.27 30.59 Favored 'General case' 0 N--CA 1.439 -1.022 0 N-CA-C 105.364 -2.088 . . . . 10.0 105.364 163.019 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.89 -138.26 3.27 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 107.79 -2.124 . . . . 10.0 107.79 177.067 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.45 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.42 -158.39 22.26 Favored Glycine 0 N--CA 1.449 -0.444 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 169.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -65.98 10.58 0.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 CA-C-N 119.869 1.835 . . . . 10.0 110.945 168.058 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.45 ' H ' ' C ' ' A' ' 73' ' ' GLY . 1.9 mmmp? -108.68 -15.83 14.32 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.621 1.168 . . . . 10.0 109.257 177.368 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.419 ' OD2' ' NZ ' ' A' ' 128' ' ' LYS . 2.3 m-20 -141.32 132.13 25.85 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.617 -1.623 . . . . 10.0 106.617 -168.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -73.46 -22.58 60.14 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 -171.372 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -79.57 1.82 24.55 Favored 'General case' 0 N--CA 1.433 -1.313 0 C-N-CA 124.737 1.215 . . . . 10.0 111.579 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -42.15 142.97 0.65 Allowed 'General case' 0 C--N 1.346 0.445 0 C-N-CA 124.956 1.302 . . . . 10.0 112.436 177.305 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -59.49 -62.28 2.0 Allowed 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 121.238 0.542 . . . . 10.0 111.132 -173.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.438 HG13 ' H ' ' A' ' 82' ' ' GLY . 5.8 p -167.37 -64.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 179.288 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.438 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -122.04 60.26 0.56 Allowed Glycine 0 CA--C 1.522 0.503 0 N-CA-C 109.637 -1.385 . . . . 10.0 109.637 -179.151 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -92.37 90.97 7.45 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.672 -2.344 . . . . 10.0 104.672 168.411 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 40.4 mt -70.07 -31.49 69.11 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 173.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.1 -102.73 2.27 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 108.536 -1.825 . . . . 10.0 108.536 168.249 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 52.4 m-20 -124.51 124.22 41.81 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.686 1.194 . . . . 10.0 110.631 -168.698 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 16.2 m -111.1 137.71 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 108.057 -1.09 . . . . 10.0 108.057 168.16 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 54.1 m -92.22 120.18 32.55 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.897 1.679 . . . . 10.0 108.667 -175.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.62 133.2 44.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 123.901 0.88 . . . . 10.0 110.508 176.443 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -59.38 170.97 0.87 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 123.589 0.755 . . . . 10.0 109.834 167.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.42 ' NZ ' ' OD1' ' A' ' 92' ' ' ASP . 12.6 pttp -47.37 -34.89 7.51 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.787 1.635 . . . . 10.0 110.403 171.016 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.42 ' OD1' ' NZ ' ' A' ' 91' ' ' LYS . 0.2 OUTLIER -79.48 -0.74 34.43 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 124.683 1.193 . . . . 10.0 111.438 -174.768 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.45 8.55 87.69 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 110.671 -0.972 . . . . 10.0 110.671 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.5 t -88.0 106.92 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 125.95 1.7 . . . . 10.0 106.614 -178.191 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.496 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -103.9 117.84 35.28 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 168.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.26 114.37 18.14 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 126.038 1.735 . . . . 10.0 108.654 172.539 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.2 t -107.24 133.43 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 178.336 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 94.9 p -156.62 59.21 0.55 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.264 0.625 . . . . 10.0 110.088 172.243 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.6 mt -96.43 157.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -174.129 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -133.06 143.0 49.06 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.805 0.729 . . . . 10.0 111.057 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -127.09 124.14 38.52 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.274 1.43 . . . . 10.0 108.861 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 p -89.99 -8.89 50.57 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.352 1.461 . . . . 10.0 111.147 169.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.4 p -95.91 -39.23 9.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 124.331 1.052 . . . . 10.0 109.929 -174.081 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -97.03 155.89 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 125.347 1.459 . . . . 10.0 108.514 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.6 m -157.63 156.39 31.74 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 108.281 -1.007 . . . . 10.0 108.281 -173.121 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -74.53 -23.04 58.75 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 120.919 0.39 . . . . 10.0 110.478 174.044 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.8 m -150.47 142.57 24.05 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.051 -1.462 . . . . 10.0 107.051 -177.44 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.73 -67.2 0.29 Allowed Glycine 0 C--N 1.334 0.427 0 N-CA-C 109.014 -1.634 . . . . 10.0 109.014 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -163.37 -51.36 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 126.398 1.879 . . . . 10.0 107.287 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.19 -28.29 59.97 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 114.755 -1.111 . . . . 10.0 110.241 -169.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.1 t 22.86 81.47 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 129.028 2.931 . . . . 10.0 111.814 172.141 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.8 pt -75.93 39.23 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 112.213 0.449 . . . . 10.0 112.213 -173.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -83.39 -48.61 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 124.899 1.28 . . . . 10.0 111.268 -171.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.79 46.02 1.32 Allowed Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.816 -0.914 . . . . 10.0 110.816 -175.51 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -111.13 162.02 15.35 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 125.201 1.4 . . . . 10.0 108.881 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -110.22 102.56 11.23 Favored 'General case' 0 C--N 1.347 0.476 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 179.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.82 134.98 40.24 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.514 -0.921 . . . . 10.0 108.514 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.408 HG12 ' CD2' ' A' ' 120' ' ' HIS . 61.9 t -124.11 131.74 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 O-C-N 123.911 0.757 . . . . 10.0 110.407 -172.253 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.445 HG13 HD21 ' A' ' 38' ' ' LEU . 1.8 t -98.19 123.37 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 128.416 2.686 . . . . 10.0 107.639 168.199 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.627 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.5 m-70 -109.94 157.54 19.15 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 115.868 1.803 . . . . 10.0 115.868 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -41.34 -65.13 0.47 Allowed 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 129.767 3.227 . . . . 10.0 111.73 171.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.1 mttp -112.28 175.41 5.44 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.861 0.865 . . . . 10.0 111.74 -172.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.61 147.91 37.29 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 114.005 -1.452 . . . . 10.0 109.72 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.422 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 4.5 m-20 -78.77 142.75 36.73 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 123.62 0.768 . . . . 10.0 110.659 171.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -78.53 -13.59 59.76 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.512 -1.222 . . . . 10.0 110.563 167.283 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 76.5 mt 61.62 42.86 10.56 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 125.474 1.51 . . . . 10.0 110.949 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.14 -5.94 56.12 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 124.262 0.934 . . . . 10.0 112.611 173.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.419 ' NZ ' ' OD2' ' A' ' 76' ' ' ASP . 11.9 mttt -110.65 35.79 3.35 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.752 0.821 . . . . 10.0 110.628 -167.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -84.09 -31.18 26.51 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.861 2.172 . . . . 10.0 111.901 178.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.61 48.41 84.7 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -176.034 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.481 ' H ' ' HB2' ' A' ' 134' ' ' SER . 14.8 m-80 -150.29 165.62 32.46 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.781 2.432 . . . . 10.0 106.289 -175.131 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -58.41 -47.65 83.23 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-O 121.588 0.709 . . . . 10.0 109.139 174.243 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -54.02 -30.92 49.54 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.979 1.312 . . . . 10.0 112.695 175.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.481 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 7.0 t -47.22 -47.46 24.43 Favored 'General case' 0 C--O 1.223 -0.307 0 C-N-CA 124.395 1.078 . . . . 10.0 108.412 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -88.24 10.19 20.46 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 118.751 -0.642 . . . . 10.0 112.55 -173.044 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -122.38 -94.39 0.5 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.455 1.902 . . . . 10.0 109.875 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.461 HG22 ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -101.85 25.04 9.08 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 121.353 1.888 . . . . 10.0 110.158 177.294 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.07 -91.32 0.44 Allowed Glycine 0 C--N 1.339 0.743 0 N-CA-C 108.886 -1.686 . . . . 10.0 108.886 177.101 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 m-80 -162.27 35.97 0.12 Allowed 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 126.428 1.891 . . . . 10.0 108.246 172.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.55 -9.92 55.95 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 121.219 -0.926 . . . . 10.0 112.116 -173.155 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.96 -167.92 53.82 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.862 -0.895 . . . . 10.0 110.862 174.686 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 58.4 p -59.12 139.34 56.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 122.308 1.051 . . . . 10.0 112.277 -168.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 40.2 mtt85 -66.76 74.84 0.11 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.526 1.131 . . . . 10.0 110.838 173.173 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.3 mt -47.31 -38.7 13.22 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 123.506 0.722 . . . . 10.0 112.09 176.345 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.8 157.17 40.38 Favored 'General case' 0 CA--C 1.514 -0.43 0 O-C-N 121.827 -0.546 . . . . 10.0 111.121 176.494 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -159.01 167.32 29.63 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.458 -0.337 . . . . 10.0 110.218 171.273 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.63 165.42 36.23 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 109.331 -1.508 . . . . 10.0 109.331 -176.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 92.9 t -105.53 146.95 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 103.018 -2.956 . . . . 10.0 103.018 -175.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . 0.3 5.0 mt -68.36 -86.88 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 CA-C-O 121.469 0.652 . . . . 10.0 112.46 -168.427 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 93.49 135.44 7.5 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.775 1.179 . . . . 10.0 112.699 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.1 mt -70.46 142.15 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 125.057 1.343 . . . . 10.0 109.357 -176.611 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.77 -45.22 2.29 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.077 0.951 . . . . 10.0 111.383 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.537 1.935 . . . . 10.0 113.266 -178.505 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 107.166 -1.42 . . . . 10.0 107.166 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -78.14 -50.44 11.99 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-O 122.299 1.047 . . . . 10.0 109.743 171.459 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -156.04 153.97 30.29 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.692 -1.14 . . . . 10.0 109.76 -169.058 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.4 151.47 48.58 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.074 0.949 . . . . 10.0 108.629 169.06 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.6 t -109.56 159.31 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 125.044 1.338 . . . . 10.0 110.099 174.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.99 97.17 3.01 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 124.31 1.044 . . . . 10.0 108.562 166.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.458 HG12 HG23 ' B' ' 17' ' ' ILE . 29.1 m -82.29 126.36 39.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.657 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -106.11 149.74 26.46 Favored 'General case' 0 CA--C 1.529 0.136 0 CA-C-O 117.914 -1.041 . . . . 10.0 108.351 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 9' ' ' LYS . . . . . 0.429 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 47.0 tttt -165.13 161.73 19.72 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 120.083 1.31 . . . . 10.0 108.679 170.289 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.42 -50.26 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 116.204 -0.453 . . . . 10.0 112.208 169.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -77.62 -46.34 22.41 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 -170.055 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 131.79 -61.7 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.928 -1.487 . . . . 10.0 111.303 -175.079 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -63.02 -39.68 38.6 Favored 'Trans proline' 0 N--CA 1.454 -0.811 0 C-N-CA 122.586 2.191 . . . . 10.0 110.79 169.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.97 115.34 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.114 -1.069 . . . . 10.0 108.114 -178.351 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.43 140.05 27.33 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-O 121.014 0.435 . . . . 10.0 110.091 165.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.486 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -108.07 157.28 15.43 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 125.256 1.408 . . . . 10.0 112.388 178.038 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.792 HG22 HG22 ' A' ' 54' ' ' THR . 0.3 OUTLIER -147.19 85.0 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 N-CA-C 106.29 -1.745 . . . . 10.0 106.29 -179.525 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.78 145.09 9.38 Favored 'Isoleucine or valine' 0 C--O 1.231 0.093 0 C-N-CA 124.062 0.945 . . . . 10.0 110.778 178.622 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -123.19 111.74 16.85 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 129.854 3.261 . . . . 10.0 106.928 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -101.09 103.22 14.3 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 79.0 mt-10 -96.38 137.1 35.95 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.139 0.881 . . . . 10.0 110.843 170.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -106.15 100.95 10.47 Favored 'General case' 0 CA--C 1.53 0.186 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 24.0 tttp -57.83 -50.56 72.88 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 125.959 1.704 . . . . 10.0 110.297 -176.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -145.17 169.63 17.81 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 104.167 -2.531 . . . . 10.0 104.167 179.068 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.4 t -75.26 -13.51 60.44 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 109.162 -0.681 . . . . 10.0 109.162 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -124.47 27.03 7.1 Favored 'General case' 0 N--CA 1.443 -0.823 0 C-N-CA 123.573 0.749 . . . . 10.0 109.904 169.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.24 151.69 23.77 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 172.485 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -62.83 130.15 28.47 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 N-CA-C 107.966 -1.59 . . . . 10.0 107.966 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.4 t -79.99 99.73 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 105.98 -1.859 . . . . 10.0 105.98 174.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -77.04 119.34 20.63 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 104.67 -2.344 . . . . 10.0 104.67 167.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -105.16 114.15 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 106.323 -1.732 . . . . 10.0 106.323 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -135.8 172.6 12.78 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 121.166 0.508 . . . . 10.0 111.831 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.59 -149.15 21.21 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 106.334 -2.706 . . . . 10.0 106.334 169.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.0 m -155.53 159.43 39.71 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 119.079 -1.048 . . . . 10.0 111.25 177.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.567 HG12 ' HB3' ' B' ' 95' ' ' ALA . 1.5 pt -117.28 147.1 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.772 -1.104 . . . . 10.0 108.565 166.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -126.07 138.72 53.73 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 124.38 1.05 . . . . 10.0 109.226 168.539 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.27 -8.05 10.47 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.972 1.272 . . . . 10.0 113.29 175.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -62.44 178.55 0.4 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.288 1.044 . . . . 10.0 112.237 177.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.2 t -115.0 156.72 24.57 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 106.897 -1.52 . . . . 10.0 106.897 167.088 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -46.95 143.95 2.71 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.583 1.553 . . . . 10.0 112.902 -169.235 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.24 -178.42 31.71 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 124.222 0.915 . . . . 10.0 111.887 171.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 10.6 mt -64.0 150.48 45.15 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.657 1.583 . . . . 10.0 112.71 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -146.11 148.57 32.75 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.681 1.192 . . . . 10.0 112.764 177.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.639 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -25.7 124.31 0.04 OUTLIER Glycine 0 C--N 1.341 0.852 0 C-N-CA 126.668 2.08 . . . . 10.0 112.616 166.473 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -148.91 98.9 2.91 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 119.888 1.844 . . . . 10.0 111.46 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.52 172.59 14.74 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 122.807 0.443 . . . . 10.0 111.151 -178.289 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.3 m -105.43 -24.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 115.826 1.787 . . . . 10.0 115.826 -167.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 62.39 175.22 0.14 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 121.529 0.68 . . . . 10.0 112.568 177.8 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -81.09 -56.32 4.17 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.985 -0.552 . . . . 10.0 110.195 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -87.25 156.14 19.78 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.161 0.437 . . . . 10.0 110.158 -172.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.01 -19.26 22.23 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.036 -1.226 . . . . 10.0 110.036 169.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -63.38 160.43 16.11 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 122.556 1.17 . . . . 10.0 111.688 -176.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -153.79 16.66 0.51 Allowed 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.242 -0.89 . . . . 10.0 113.001 -171.095 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.597 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -45.53 -40.86 9.08 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 127.141 2.177 . . . . 10.0 112.707 -177.887 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.1 -18.56 57.88 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 111.915 0.339 . . . . 10.0 111.915 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.88 -66.2 0.56 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 109.474 -1.45 . . . . 10.0 109.474 -179.382 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 48.2 t -157.84 18.31 0.25 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.645 1.178 . . . . 10.0 110.584 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -98.87 -45.3 6.04 Favored 'General case' 0 N--CA 1.44 -0.931 0 O-C-N 120.184 -1.572 . . . . 10.0 108.695 -177.204 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -49.11 -39.71 29.44 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.438 1.495 . . . . 10.0 111.792 -169.044 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.46 -42.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 129.027 2.931 . . . . 10.0 114.205 168.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.33 163.24 28.43 Favored Glycine 0 N--CA 1.439 -1.113 0 N-CA-C 107.87 -2.092 . . . . 10.0 107.87 172.652 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -74.42 -169.29 0.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.547 0 N-CA-C 106.734 -2.064 . . . . 10.0 106.734 167.058 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 31.7 m170 -82.12 58.41 3.96 Favored 'General case' 0 CA--C 1.539 0.52 0 O-C-N 120.109 -1.62 . . . . 10.0 110.314 -174.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -76.51 59.66 1.51 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 123.06 1.41 . . . . 10.0 111.733 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -60.35 153.67 57.74 Favored Pre-proline 0 C--N 1.324 -0.516 0 C-N-CA 126.44 1.896 . . . . 10.0 110.965 169.132 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.77 -43.95 0.55 Allowed 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.686 2.257 . . . . 10.0 111.377 175.061 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 tt -79.3 62.77 3.75 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.175 0.99 . . . . 10.0 109.743 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 10.1 t -39.36 107.61 0.07 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.142 1.777 . . . . 10.0 113.368 -169.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.4 mtt180 -136.5 -174.07 3.59 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.422 1.489 . . . . 10.0 109.708 175.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.5 mmpt? -117.64 57.88 0.81 Allowed 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 113.975 1.102 . . . . 10.0 113.975 -167.089 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.402 ' CD2' ' CA ' ' B' ' 138' ' ' GLY . 63.5 t60 38.03 94.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 116.209 1.929 . . . . 10.0 116.209 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.6 -164.64 12.51 Favored Glycine 0 C--N 1.315 -0.61 0 N-CA-C 108.524 -1.83 . . . . 10.0 108.524 168.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -139.53 -162.4 9.1 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.143 -0.783 . . . . 10.0 111.143 171.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -69.81 10.32 0.51 Allowed 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.324 2.016 . . . . 10.0 111.569 176.655 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 84.3 mttt -101.28 -19.74 15.53 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.657 0.783 . . . . 10.0 109.174 170.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -125.67 -178.64 4.33 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 107.945 -1.132 . . . . 10.0 107.945 -167.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . 0.273 0.6 OUTLIER -110.43 -1.6 17.0 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 112.752 0.649 . . . . 10.0 112.752 167.918 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -77.61 -1.82 32.72 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 121.815 -0.553 . . . . 10.0 109.945 175.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 21.0 ptt-85 -42.25 124.43 2.8 Favored 'General case' 0 C--N 1.344 0.335 0 C-N-CA 124.965 1.306 . . . . 10.0 109.148 169.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -74.67 -54.3 7.67 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.574 -0.528 . . . . 10.0 109.574 -172.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.479 HG13 ' H ' ' B' ' 82' ' ' GLY . 6.6 p -165.02 -66.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.537 0.735 . . . . 10.0 109.157 176.143 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.479 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -118.7 77.01 0.3 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.663 -2.175 . . . . 10.0 107.663 178.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -119.54 97.97 5.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.99 -2.226 . . . . 10.0 104.99 178.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -83.13 23.06 0.9 Allowed 'General case' 0 CA--C 1.526 0.048 0 CA-C-O 120.962 0.41 . . . . 10.0 110.553 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.4 -109.93 2.91 Favored Glycine 0 N--CA 1.432 -1.615 0 N-CA-C 105.653 -2.979 . . . . 10.0 105.653 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -158.93 139.12 12.2 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.857 -1.164 . . . . 10.0 107.857 -178.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.3 m -108.46 130.49 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 123.535 0.734 . . . . 10.0 111.867 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -80.95 101.52 9.54 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.973 2.909 . . . . 10.0 111.488 -170.189 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.99 134.34 35.36 Favored 'General case' 0 N--CA 1.451 -0.398 0 O-C-N 121.866 -0.521 . . . . 10.0 109.733 170.586 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -61.9 167.57 3.68 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 122.033 0.921 . . . . 10.0 108.75 167.09 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 30.6 ttpt -49.87 -31.13 11.34 Favored 'General case' 0 N--CA 1.432 -1.358 0 C-N-CA 125.934 1.694 . . . . 10.0 111.964 169.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -77.03 -10.29 59.27 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.188 0.449 . . . . 10.0 111.258 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.2 12.11 66.03 Favored Glycine 0 C--N 1.34 0.797 0 O-C-N 120.993 -1.067 . . . . 10.0 110.798 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -92.6 111.48 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 C-N-CA 126.66 1.984 . . . . 10.0 106.311 176.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.567 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -108.53 121.6 45.31 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -82.64 123.06 28.91 Favored 'General case' 0 N--CA 1.434 -1.253 0 C-N-CA 126.893 2.077 . . . . 10.0 107.989 170.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.94 131.85 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.935 -1.505 . . . . 10.0 106.935 175.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.85 75.8 0.71 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.991 0.916 . . . . 10.0 109.583 169.607 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.9 164.31 3.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.589 -1.634 . . . . 10.0 106.589 179.274 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -137.49 138.9 40.19 Favored 'General case' 0 N--CA 1.451 -0.383 0 O-C-N 121.459 -0.776 . . . . 10.0 110.868 171.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.99 145.53 49.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 124.454 1.096 . . . . 10.0 108.558 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.2 p -120.1 16.71 12.44 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.12 1.368 . . . . 10.0 110.7 172.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -107.65 -49.23 7.93 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 124.362 1.065 . . . . 10.0 109.634 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.329 0.7 OUTLIER -67.82 170.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-O 121.206 0.527 . . . . 10.0 112.094 171.544 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 52.1 p -151.91 140.25 20.46 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.151 -1.055 . . . . 10.0 108.151 174.362 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.4 pp -85.85 -24.68 26.63 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 108.27 -1.011 . . . . 10.0 108.27 167.272 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m -148.54 120.9 8.44 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 166.292 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.33 -72.1 0.08 OUTLIER Glycine 0 C--O 1.227 -0.292 0 N-CA-C 108.715 -1.754 . . . . 10.0 108.715 -173.331 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -152.17 -53.0 0.12 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 113.641 -1.279 . . . . 10.0 108.003 176.31 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -75.71 -34.7 60.39 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-N 114.517 -1.22 . . . . 10.0 109.065 -170.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t 43.09 71.74 0.21 Allowed 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 125.709 1.604 . . . . 10.0 111.981 171.282 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 41.1 pt -66.4 1.53 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 113.619 0.97 . . . . 10.0 113.619 -178.29 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.8 mm -41.42 -40.88 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.302 0 C-N-CA 125.113 1.365 . . . . 10.0 113.783 177.721 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -105.5 25.59 24.1 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.82 1.2 . . . . 10.0 113.198 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.58 175.94 6.03 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.44 1.096 . . . . 10.0 110.439 174.31 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -123.71 107.98 12.04 Favored 'General case' 0 C--N 1.344 0.355 0 C-N-CA 124.554 1.142 . . . . 10.0 111.168 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -61.94 130.76 47.15 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 167.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.03 131.21 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 N-CA-C 107.504 -1.295 . . . . 10.0 107.504 173.167 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.445 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.8 OUTLIER -100.72 126.35 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.537 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.639 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.4 m170 -104.26 157.0 17.44 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 115.248 1.573 . . . . 10.0 115.248 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -47.48 -57.06 5.82 Favored 'General case' 0 N--CA 1.447 -0.614 0 C-N-CA 127.784 2.434 . . . . 10.0 110.657 177.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -107.53 170.84 7.73 Favored 'General case' 0 N--CA 1.463 0.199 0 C-N-CA 124.493 1.117 . . . . 10.0 112.478 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.28 149.93 38.67 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.558 1.543 . . . . 10.0 109.804 171.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.01 144.85 38.39 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 112.924 0.713 . . . . 10.0 112.924 177.101 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -78.32 -23.87 46.86 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.755 1.622 . . . . 10.0 109.259 167.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 48.9 mt 54.76 58.28 4.97 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 122.611 1.196 . . . . 10.0 109.693 -174.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.96 -47.31 3.82 Favored Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 113.996 -1.456 . . . . 10.0 112.505 167.122 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.91 42.39 0.38 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 118.026 0.913 . . . . 10.0 112.649 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.2 -22.82 26.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 127.122 2.296 . . . . 10.0 109.442 168.096 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.78 32.95 83.57 Favored Glycine 0 C--N 1.337 0.6 0 N-CA-C 110.975 -0.85 . . . . 10.0 110.975 176.23 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -135.67 162.94 31.32 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.132 -1.062 . . . . 10.0 108.132 172.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -45.87 -48.77 15.95 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 124.409 1.083 . . . . 10.0 110.02 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -70.46 -33.6 71.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.671 -0.643 . . . . 10.0 112.143 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.9 p -53.3 -44.26 68.2 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 119.374 0.988 . . . . 10.0 110.331 174.291 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.6 t -80.71 -19.18 45.66 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 112.852 0.686 . . . . 10.0 112.852 -173.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -101.41 -45.37 5.34 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 125.304 1.442 . . . . 10.0 112.666 -172.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 30.8 p -132.18 -1.97 3.59 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 119.211 0.914 . . . . 10.0 113.128 174.278 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 138' ' ' GLY . . . . . 0.402 ' CA ' ' CD2' ' B' ' 71' ' ' HIS . . . 88.89 22.97 36.95 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-O 118.601 -1.11 . . . . 10.0 112.241 -176.128 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 60.48 15.65 5.75 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 119.567 1.683 . . . . 10.0 112.056 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.98 3.13 5.7 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.103 -0.998 . . . . 10.0 112.438 -170.334 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.94 -168.55 54.76 Favored Glycine 0 N--CA 1.444 -0.813 0 N-CA-C 110.586 -1.006 . . . . 10.0 110.586 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.4 t -58.04 143.86 41.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 115.05 -0.575 . . . . 10.0 111.755 -169.485 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.9 mtm-85 -64.02 78.86 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.042 0.937 . . . . 10.0 110.02 168.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 5.7 tp -39.87 -55.37 2.0 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.234 1.813 . . . . 10.0 110.847 176.126 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.445 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -151.81 149.67 29.27 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.153 -0.684 . . . . 10.0 109.153 -173.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 12.6 m -128.48 153.78 46.79 Favored 'General case' 0 CA--C 1.522 -0.132 0 C-N-CA 125.477 1.511 . . . . 10.0 109.101 -173.373 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -133.57 169.95 22.56 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 108.964 -1.654 . . . . 10.0 108.964 167.397 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' A' ' 148' ' ' VAL . 17.2 t -117.83 132.44 67.64 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 169.363 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 71.4 mt -69.24 157.99 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.382 -0.97 . . . . 10.0 108.382 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.88 156.16 27.26 Favored Glycine 0 CA--C 1.528 0.891 0 O-C-N 121.249 -0.907 . . . . 10.0 111.731 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.7 mp -55.52 133.38 19.3 Favored 'Isoleucine or valine' 0 C--N 1.341 0.22 0 C-N-CA 125.618 1.567 . . . . 10.0 109.765 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -120.21 165.6 14.59 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.38 -1.341 . . . . 10.0 107.38 166.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 . . . . . 0 C--O 1.25 1.084 0 C-N-CA 125.939 1.695 . . . . 10.0 106.834 169.831 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 106.205 -1.776 . . . . 10.0 106.205 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.7 t -69.4 -14.34 62.85 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.496 1.044 . . . . 10.0 109.171 168.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.67 155.12 50.29 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 125.406 1.483 . . . . 10.0 107.481 168.253 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.04 158.24 44.03 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 125.483 1.513 . . . . 10.0 106.952 169.22 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -122.05 152.61 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 C-N-CA 123.529 0.732 . . . . 10.0 110.106 -178.373 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.557 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -127.8 97.23 4.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 125.099 1.359 . . . . 10.0 108.502 168.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.0 OUTLIER -79.64 109.25 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.13 -1.433 . . . . 10.0 107.13 167.427 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.3 mt -90.07 139.85 30.22 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.068 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.413 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 18.9 tttt -162.18 161.09 27.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 120.01 1.277 . . . . 10.0 108.388 170.191 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.42 -53.32 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.206 0 N-CA-C 111.66 -0.576 . . . . 10.0 111.66 170.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -75.72 -47.31 26.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 106.713 -1.588 . . . . 10.0 106.713 -171.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.53 -61.26 0.66 Allowed Glycine 0 CA--C 1.53 0.993 0 CA-C-N 113.822 -1.536 . . . . 10.0 111.807 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.14 -34.92 67.27 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 122.63 2.22 . . . . 10.0 111.23 172.687 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.0 t -75.58 110.1 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.176 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 176.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.21 129.69 38.08 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 123.448 0.699 . . . . 10.0 109.326 166.753 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.47 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -105.75 147.11 16.18 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 125.595 1.569 . . . . 10.0 109.559 171.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.448 HG22 HG22 ' B' ' 54' ' ' THR . 2.9 mt -140.82 59.68 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 -176.459 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm -78.95 140.27 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 N-CA-C 109.095 -0.705 . . . . 10.0 109.095 -172.446 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -116.61 110.52 18.63 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 126.939 2.096 . . . . 10.0 107.271 178.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -94.45 109.73 21.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 176.115 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.54 158.64 16.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.572 0.624 . . . . 10.0 112.127 170.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -155.61 83.23 1.04 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.818 2.047 . . . . 10.0 106.646 166.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 6.5 mmtp -52.13 -55.72 19.11 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 125.294 1.437 . . . . 10.0 110.503 -173.238 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -123.62 167.22 14.24 Favored 'General case' 0 N--CA 1.434 -1.264 0 N-CA-C 103.992 -2.595 . . . . 10.0 103.992 169.05 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -71.73 -14.58 62.06 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.885 -0.598 . . . . 10.0 109.917 173.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -79.8 -17.03 54.34 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 123.304 0.642 . . . . 10.0 109.314 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.67 140.98 23.17 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 178.275 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -62.06 153.35 69.74 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.118 1.879 . . . . 10.0 107.543 169.003 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -76.81 89.82 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.167 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 170.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.6 tmtp? -85.45 114.16 22.28 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 106.075 -1.824 . . . . 10.0 106.075 170.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.2 m -110.31 125.21 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 107.173 -1.417 . . . . 10.0 107.173 -174.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.7 p90 -134.46 164.78 26.69 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.118 0.485 . . . . 10.0 111.878 173.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.2 -148.67 19.52 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 107.827 -2.109 . . . . 10.0 107.827 170.054 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.5 t -155.31 150.77 27.22 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 116.973 0.387 . . . . 10.0 110.143 -176.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.47 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -113.49 111.51 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.268 0 C-N-CA 125.836 1.654 . . . . 10.0 106.611 165.551 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -95.93 137.33 35.15 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 108.073 -1.084 . . . . 10.0 108.073 170.151 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.78 -0.94 9.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 125.137 1.351 . . . . 10.0 112.585 173.091 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.04 174.96 7.89 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 118.453 1.126 . . . . 10.0 109.285 176.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -100.58 156.89 17.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.077 -1.823 . . . . 10.0 106.077 165.249 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -55.03 151.59 8.78 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.373 0.669 . . . . 10.0 111.834 -169.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.54 -178.93 26.56 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.115 0.864 . . . . 10.0 112.081 175.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -67.23 151.08 48.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.899 1.28 . . . . 10.0 111.355 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -151.02 153.77 35.77 Favored 'General case' 0 C--N 1.342 0.265 0 N-CA-C 113.577 0.955 . . . . 10.0 113.577 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.635 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -38.23 125.93 1.57 Allowed Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.693 2.568 . . . . 10.0 113.057 165.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -155.2 114.13 3.58 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.525 -1.287 . . . . 10.0 107.525 165.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 170.44 18.46 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.843 0.83 . . . . 10.0 111.582 174.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -115.33 127.28 72.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 104.251 -2.5 . . . . 10.0 104.251 168.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -167.52 175.16 7.31 Favored 'General case' 0 N--CA 1.451 -0.38 0 O-C-N 121.908 -0.495 . . . . 10.0 110.891 -168.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . 0.28 14.0 pt-20 50.3 -157.51 0.09 Allowed 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 126.279 2.237 . . . . 10.0 113.281 167.116 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.8 m-30 -82.64 -167.37 1.59 Allowed 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 109.247 -0.649 . . . . 10.0 109.247 177.086 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.37 -0.35 24.99 Favored Glycine 0 CA--C 1.536 1.347 0 C-N-CA 126.256 1.884 . . . . 10.0 112.975 174.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -75.0 83.0 2.24 Favored 'General case' 0 C--N 1.342 0.258 0 CA-C-N 119.737 1.768 . . . . 10.0 110.637 -176.152 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -79.51 8.41 6.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-N 115.282 -0.872 . . . . 10.0 113.077 177.262 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.518 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -42.53 -48.07 5.25 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 127.992 2.517 . . . . 10.0 113.376 -171.906 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.08 -26.74 39.49 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 123.206 0.602 . . . . 10.0 112.348 -179.305 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 137.99 -150.69 21.03 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 106.727 -2.549 . . . . 10.0 106.727 -169.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.8 m -80.23 33.16 0.28 Allowed 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 124.668 1.187 . . . . 10.0 112.273 -179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.8 m -125.24 -57.72 1.48 Allowed 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 108.646 -0.872 . . . . 10.0 108.646 -168.43 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 t -58.61 -39.79 81.46 Favored 'General case' 0 C--N 1.341 0.204 0 O-C-N 123.416 0.448 . . . . 10.0 110.935 -168.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.03 -41.69 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 127.387 2.275 . . . . 10.0 113.997 169.532 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.5 -162.93 19.65 Favored Glycine 0 C--N 1.34 0.779 0 N-CA-C 109.597 -1.401 . . . . 10.0 109.597 169.536 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -110.44 178.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.935 1 C-N-CA 125.558 4.172 . . . . 10.0 106.354 164.596 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.6 m170 -66.87 79.86 0.11 Allowed 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 120.088 1.313 . . . . 10.0 110.927 -176.553 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -105.85 53.93 0.7 Allowed 'General case' 0 N--CA 1.462 0.138 0 C-N-CA 127.262 2.225 . . . . 10.0 108.802 172.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -52.99 145.41 23.21 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 125.502 1.521 . . . . 10.0 110.772 168.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -64.98 -43.46 11.78 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 123.338 2.692 . . . . 10.0 111.243 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.4 68.68 0.55 Allowed 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.528 -0.915 . . . . 10.0 108.528 170.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.5 p -58.74 104.79 0.25 Allowed 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.381 1.073 . . . . 10.0 109.893 -175.557 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.1 mtt180 -141.55 -176.56 4.79 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 105.722 -1.955 . . . . 10.0 105.722 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.37 129.48 35.89 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 -177.579 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.446 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 76.1 t60 -44.92 112.13 0.4 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 122.558 0.343 . . . . 10.0 111.749 178.262 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.49 -147.66 6.52 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.03 -167.93 18.18 Favored Glycine 0 C--O 1.225 -0.451 0 CA-C-N 117.98 0.89 . . . . 10.0 111.567 179.411 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -68.36 16.09 0.16 Allowed 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.518 2.145 . . . . 10.0 112.398 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -110.39 -20.6 12.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 124.934 1.294 . . . . 10.0 110.25 169.403 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.67 162.65 16.94 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.754 -1.572 . . . . 10.0 106.754 -167.761 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -88.98 -21.85 23.31 Favored 'General case' 0 C--N 1.329 -0.32 0 O-C-N 121.629 -0.669 . . . . 10.0 109.877 178.167 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -83.4 -6.37 59.44 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 124.538 1.135 . . . . 10.0 111.474 -169.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -35.65 118.95 0.51 Allowed 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 126.145 1.778 . . . . 10.0 111.108 171.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.446 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 31.1 m170 -50.37 -50.66 50.75 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 115.828 1.788 . . . . 10.0 115.828 -167.327 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -178.25 -46.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 106.945 -1.502 . . . . 10.0 106.945 -174.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -153.45 62.33 0.38 Allowed Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -85.84 95.96 9.61 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 103.705 -2.702 . . . . 10.0 103.705 166.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -70.47 -10.42 59.1 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.578 0.626 . . . . 10.0 111.833 -171.18 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.85 -93.96 0.93 Allowed Glycine 0 N--CA 1.445 -0.744 0 N-CA-C 107.69 -2.164 . . . . 10.0 107.69 176.063 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -150.54 147.11 27.06 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 124.871 1.268 . . . . 10.0 107.79 -174.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.1 m -117.98 128.04 75.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 118.606 0.639 . . . . 10.0 109.755 169.14 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.7 m -90.19 95.11 10.04 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 127.267 2.227 . . . . 10.0 111.506 -169.639 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -69.63 128.5 36.68 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.778 -0.576 . . . . 10.0 111.654 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.1 171.8 5.25 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.123 1.369 . . . . 10.0 109.888 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 pttm -54.89 -29.35 55.62 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.218 1.007 . . . . 10.0 111.088 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -78.25 0.21 26.11 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.031 0.444 . . . . 10.0 111.213 178.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.45 17.59 79.81 Favored Glycine 0 C--N 1.339 0.734 0 O-C-N 120.654 -1.279 . . . . 10.0 110.766 178.536 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 18.3 t -97.68 103.34 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.734 0 C-N-CA 127.812 2.445 . . . . 10.0 106.356 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.404 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -97.33 118.42 33.77 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 168.449 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -79.42 141.87 36.45 Favored 'General case' 0 N--CA 1.425 -1.679 0 C-N-CA 124.643 1.177 . . . . 10.0 108.718 178.384 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 86.8 t -111.63 133.22 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 106.509 -1.663 . . . . 10.0 106.509 169.116 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.6 p -158.88 58.4 0.43 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.501 0.72 . . . . 10.0 111.512 170.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -101.3 152.73 5.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.897 0.879 . . . . 10.0 109.085 -171.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -112.01 127.94 56.03 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 126.568 1.947 . . . . 10.0 108.448 172.045 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -130.22 145.72 51.77 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-O 121.378 0.609 . . . . 10.0 111.001 169.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.8 t -133.07 64.66 1.61 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.089 2.156 . . . . 10.0 106.652 -178.014 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.01 -52.73 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.077 0 C-N-CA 123.672 0.789 . . . . 10.0 109.225 175.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.328 0.0 OUTLIER -78.84 174.82 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.145 0.497 . . . . 10.0 112.19 172.048 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 m -153.99 153.72 32.49 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.372 -1.714 . . . . 10.0 106.372 169.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 95.7 mt -68.45 -14.52 63.06 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.109 0.564 . . . . 10.0 111.602 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.4 m -151.75 157.21 41.7 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.056 -1.831 . . . . 10.0 106.056 169.402 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 151.84 -66.95 0.33 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 178.309 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -161.02 -51.74 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 126.298 1.839 . . . . 10.0 107.239 -178.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -73.79 -39.44 64.13 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.513 -1.222 . . . . 10.0 108.165 -169.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 17.8 t 35.53 74.86 0.06 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 127.559 2.344 . . . . 10.0 110.31 169.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 pt -76.36 46.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.986 0.914 . . . . 10.0 111.422 -173.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 35.1 mm -92.31 -86.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 124.936 1.295 . . . . 10.0 108.613 -171.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.23 50.57 2.76 Favored Glycine 0 CA--C 1.537 1.468 0 O-C-N 120.291 -1.506 . . . . 10.0 113.669 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 13.4 mmt-85 -101.05 175.63 5.53 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 126.195 1.798 . . . . 10.0 108.006 169.239 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 17.2 m -102.46 104.34 14.78 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.362 1.465 . . . . 10.0 107.086 172.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.02 144.65 40.74 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 105.428 -2.064 . . . . 10.0 105.428 168.427 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.7 t -134.69 139.03 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 N-CA-C 108.645 -0.872 . . . . 10.0 108.645 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -107.39 131.72 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 N-CA-C 106.039 -1.837 . . . . 10.0 106.039 167.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.635 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.8 m170 -114.8 158.89 21.27 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 115.693 1.738 . . . . 10.0 115.693 -169.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.2 tt0 -43.84 -57.31 3.34 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 129.035 2.934 . . . . 10.0 111.835 174.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -116.84 169.17 9.59 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 113.835 1.05 . . . . 10.0 113.835 -168.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.05 132.24 37.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.557 1.543 . . . . 10.0 109.829 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 125.956 1.702 . . . . 10.0 110.563 -175.058 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.6 -37.42 50.39 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 124.388 1.075 . . . . 10.0 109.859 174.252 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.0 mt 76.07 53.62 0.06 Allowed 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.916 2.086 . . . . 10.0 112.755 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.92 -25.2 22.87 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 115.509 0.964 . . . . 10.0 115.509 167.005 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mptt -75.82 -4.13 38.98 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 119.313 1.557 . . . . 10.0 112.56 -172.558 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.84 -29.41 64.66 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 109.076 -1.609 . . . . 10.0 109.076 168.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.29 41.02 99.39 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.273 -1.131 . . . . 10.0 110.273 -176.549 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -130.78 171.98 12.51 Favored 'General case' 0 CA--C 1.501 -0.94 0 N-CA-C 106.731 -1.581 . . . . 10.0 106.731 170.189 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.1 mp0 -40.22 -58.78 1.41 Allowed 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 10.0 110.109 168.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -50.1 -54.52 19.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 116.072 -0.513 . . . . 10.0 109.999 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.4 p -55.29 -44.46 75.73 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 120.022 -0.671 . . . . 10.0 110.313 -177.288 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -78.24 -7.75 57.52 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.622 1.169 . . . . 10.0 111.16 -173.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -109.36 -68.38 0.92 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.911 1.684 . . . . 10.0 111.38 -178.473 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -114.55 -6.95 12.82 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 121.456 1.934 . . . . 10.0 112.326 179.276 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.55 33.64 47.04 Favored Glycine 0 C--O 1.222 -0.606 0 CA-C-O 118.976 -0.902 . . . . 10.0 111.837 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 61.21 24.91 14.97 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 119.74 1.77 . . . . 10.0 112.189 176.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.7 -9.08 58.29 Favored 'General case' 0 CA--C 1.527 0.082 0 C-N-CA 123.544 0.738 . . . . 10.0 112.31 -177.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.21 -166.12 54.76 Favored Glycine 0 N--CA 1.447 -0.607 0 O-C-N 121.269 -0.894 . . . . 10.0 111.409 172.497 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.1 m -58.13 136.36 57.21 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.064 0.946 . . . . 10.0 113.078 -167.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -64.03 89.11 0.05 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.123 0.969 . . . . 10.0 109.191 168.769 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 62.0 mt -58.07 -51.46 69.61 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.848 -0.427 . . . . 10.0 109.848 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.413 ' HB1' ' C ' ' A' ' 9' ' ' LYS . . . -147.97 152.05 36.83 Favored 'General case' 0 N--CA 1.454 -0.261 0 O-C-N 122.273 -0.267 . . . . 10.0 110.371 -169.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 88.2 m -130.49 154.13 48.09 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 124.756 1.222 . . . . 10.0 109.539 -173.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.43 154.58 25.2 Favored Glycine 0 CA--C 1.519 0.328 0 N-CA-C 110.156 -1.178 . . . . 10.0 110.156 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 58.4 t -115.09 126.36 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 105.098 -2.186 . . . . 10.0 105.098 178.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.557 HG12 ' HB2' ' A' ' 6' ' ' ALA . 49.2 mt -78.71 147.7 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 108.895 -0.78 . . . . 10.0 108.895 -177.444 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -153.43 178.5 30.41 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.337 -1.105 . . . . 10.0 110.337 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -64.31 122.68 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 C-N-CA 124.477 1.111 . . . . 10.0 108.941 -177.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -116.89 148.84 40.96 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 168.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.016 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 167.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 119.111 -0.471 . . . . 10.0 110.174 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 t -81.77 -40.85 22.04 Favored 'General case' 0 C--O 1.226 -0.149 0 C-N-CA 124.217 1.007 . . . . 10.0 110.511 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 49.1 mttp -134.24 140.56 46.55 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 125.221 1.408 . . . . 10.0 109.192 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.43 152.89 47.42 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.017 0.927 . . . . 10.0 108.858 171.551 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -120.77 158.22 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 123.931 0.892 . . . . 10.0 110.153 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.47 101.94 4.49 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.427 -0.953 . . . . 10.0 108.427 168.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -79.64 105.97 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 108.692 -0.855 . . . . 10.0 108.692 169.666 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -91.86 128.13 37.58 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.364 -0.976 . . . . 10.0 108.364 -178.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -143.38 162.32 36.06 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 120.098 1.317 . . . . 10.0 108.494 170.637 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.67 -56.89 0.07 OUTLIER Glycine 0 N--CA 1.461 0.319 0 CA-C-N 115.077 -0.965 . . . . 10.0 113.146 169.497 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.47 -44.27 65.08 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 -177.159 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.4 -70.68 0.41 Allowed Glycine 0 CA--C 1.523 0.569 0 CA-C-N 114.319 -1.309 . . . . 10.0 110.323 169.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -59.13 -33.08 98.28 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 123.643 2.895 . . . . 10.0 111.515 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 65.2 t -67.06 95.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 177.508 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -117.69 101.15 8.1 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.522 -2.029 . . . . 10.0 105.522 178.168 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.938 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -85.47 142.04 19.28 Favored Glycine 0 N--CA 1.435 -1.401 0 N-CA-C 109.577 -1.409 . . . . 10.0 109.577 172.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.518 ' CG2' HG22 ' A' ' 54' ' ' THR . 2.2 mt -140.37 81.29 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 105.949 -1.871 . . . . 10.0 105.949 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -90.9 140.7 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 C-N-CA 123.892 0.877 . . . . 10.0 109.05 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 13.5 m-80 -126.44 114.7 18.52 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.044 1.338 . . . . 10.0 109.234 171.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -91.42 132.48 36.19 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 124.882 1.273 . . . . 10.0 108.248 174.002 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.6 156.38 24.8 Favored 'General case' 0 C--N 1.339 0.151 0 O-C-N 123.519 0.512 . . . . 10.0 111.874 169.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.59 135.0 55.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 102.519 -3.141 . . . . 10.0 102.519 162.063 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -76.04 -77.13 0.14 Allowed 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 170.639 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 62.1 mm-40 -99.98 -125.9 0.17 Allowed 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.923 1.689 . . . . 10.0 106.616 175.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 73.4 m -136.18 13.68 3.3 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 121.868 -0.52 . . . . 10.0 111.971 165.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -123.6 -2.82 8.35 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 124.894 1.278 . . . . 10.0 109.876 168.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.7 156.49 47.99 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 110.136 -1.186 . . . . 10.0 110.136 -178.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -66.29 125.22 13.64 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 123.021 2.48 . . . . 10.0 108.831 175.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 m -79.96 64.51 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 122.774 0.43 . . . . 10.0 110.382 -175.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.8 tttt -54.42 111.95 0.9 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.139 -0.689 . . . . 10.0 109.139 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -103.9 112.28 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 C-N-CA 127.412 2.285 . . . . 10.0 106.556 -176.231 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -106.14 171.43 7.35 Favored 'General case' 0 CA--C 1.511 -0.532 0 CA-C-O 121.847 0.832 . . . . 10.0 110.507 173.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.59 173.88 45.09 Favored Glycine 0 N--CA 1.436 -1.306 0 N-CA-C 110.124 -1.19 . . . . 10.0 110.124 174.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 19.5 m -145.75 90.19 1.97 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.565 -0.902 . . . . 10.0 108.565 -179.451 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.938 HG22 ' HA2' ' B' ' 16' ' ' GLY . 3.4 pt -79.93 146.93 6.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.497 0 N-CA-C 108.661 -0.866 . . . . 10.0 108.661 175.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -126.7 149.74 49.41 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.39 -5.87 49.18 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.665 174.578 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -63.47 177.69 0.65 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.445 1.123 . . . . 10.0 110.599 173.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.1 t -115.25 168.09 10.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 105.687 -1.968 . . . . 10.0 105.687 165.413 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -46.57 156.84 0.16 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.785 1.634 . . . . 10.0 113.406 -170.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.14 -162.47 46.29 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-O 122.139 0.855 . . . . 10.0 113.376 166.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -79.7 141.32 36.51 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 125.873 1.669 . . . . 10.0 111.342 -170.387 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -139.72 145.39 38.26 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 114.504 1.298 . . . . 10.0 114.504 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.558 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -34.61 117.94 0.25 Allowed Glycine 0 C--N 1.343 0.95 0 C-N-CA 129.556 3.455 . . . . 10.0 114.569 167.345 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.451 ' HZ ' HG21 ' B' ' 35' ' ' ILE . 3.2 m-85 -141.37 109.23 5.71 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 120.012 1.906 . . . . 10.0 110.931 169.378 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.502 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -148.15 170.43 17.86 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 112.708 0.632 . . . . 10.0 112.708 178.66 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 m -116.69 79.1 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 C-N-CA 128.625 2.77 . . . . 10.0 111.247 -168.159 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 38.4 m-70 -79.23 142.69 36.02 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 124.802 1.241 . . . . 10.0 112.056 -171.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -62.47 -46.31 89.08 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 114.605 1.335 . . . . 10.0 114.605 -169.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -75.7 92.43 2.98 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.798 -2.667 . . . . 10.0 103.798 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.88 -27.13 74.14 Favored Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 128.103 2.764 . . . . 10.0 109.99 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -52.57 175.88 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.777 0 CA-C-O 122.752 1.263 . . . . 10.0 110.78 167.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.537 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.4 OUTLIER -149.99 31.82 0.69 Allowed 'General case' 0 N--CA 1.431 -1.378 0 CA-C-N 114.603 -1.18 . . . . 10.0 112.809 168.815 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.448 HG22 HG22 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -51.78 -38.91 57.52 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.958 0.903 . . . . 10.0 111.084 -177.835 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.01 -18.08 54.24 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.84 1.256 . . . . 10.0 113.217 -179.425 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.09 85.56 0.62 Allowed Glycine 0 CA--C 1.533 1.161 0 N-CA-C 111.478 -0.649 . . . . 10.0 111.478 -176.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 71.4 m 44.11 39.36 2.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 128.008 2.523 . . . . 10.0 112.634 173.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -134.3 -54.32 0.85 Allowed 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 108.156 -1.053 . . . . 10.0 108.156 -169.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.7 m -90.56 34.31 0.89 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.109 0.563 . . . . 10.0 109.844 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -67.04 -23.18 65.86 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.401 1.08 . . . . 10.0 109.868 177.033 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.76 141.2 11.61 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 110.911 -0.876 . . . . 10.0 110.911 172.488 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -76.23 63.01 6.97 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.213 3.275 . . . . 10.0 113.202 -174.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 22.6 m170 63.26 44.04 5.87 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 126.697 1.999 . . . . 10.0 109.939 171.354 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -67.89 79.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 124.863 2.268 . . . . 10.0 111.351 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -81.89 147.15 57.54 Favored Pre-proline 0 C--N 1.318 -0.772 0 C-N-CA 126.396 1.878 . . . . 10.0 108.316 168.142 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -79.56 40.3 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 122.484 2.123 . . . . 10.0 111.775 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -162.84 37.68 0.1 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.787 0.835 . . . . 10.0 109.996 -176.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -42.31 100.05 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.599 1.56 . . . . 10.0 112.719 -170.37 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.57 -78.85 0.6 Allowed 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.284 -1.006 . . . . 10.0 108.284 -171.139 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -154.24 144.35 21.97 Favored 'General case' 0 N--CA 1.425 -1.678 0 CA-C-N 115.484 -0.78 . . . . 10.0 109.223 171.491 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -61.76 118.64 7.41 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 106.711 -1.589 . . . . 10.0 106.711 165.377 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.06 -146.19 6.25 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 107.743 -2.143 . . . . 10.0 107.743 175.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.53 -165.71 24.37 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 107.813 -2.115 . . . . 10.0 107.813 169.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -64.19 6.36 0.31 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.151 1.9 . . . . 10.0 112.207 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.407 ' HE2' ' HB2' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -96.86 -29.99 13.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 118.997 0.817 . . . . 10.0 110.35 168.812 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.407 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 1.4 t70 -86.83 166.23 15.37 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 109.347 -0.612 . . . . 10.0 109.347 -174.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -86.18 -24.57 26.08 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.346 -1.297 . . . . 10.0 108.492 167.062 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -76.41 -93.78 0.02 OUTLIER 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 107.667 -1.234 . . . . 10.0 107.667 -173.05 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 28.5 mtm180 72.43 159.74 0.22 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 127.144 2.178 . . . . 10.0 108.644 -167.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.9 m170 -78.18 -48.63 15.45 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 118.965 -1.094 . . . . 10.0 110.093 169.351 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.3 p -166.26 -51.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 178.57 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.29 -76.28 0.9 Allowed Glycine 0 C--N 1.336 0.552 0 N-CA-C 109.019 -1.633 . . . . 10.0 109.019 171.512 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 41.42 78.58 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.792 1.237 . . . . 10.0 109.654 -169.435 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -20.97 64.96 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.939 0.348 . . . . 10.0 111.939 -168.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.91 -94.93 0.67 Allowed Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.027 -1.229 . . . . 10.0 110.027 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 33.2 m120 -155.61 106.45 2.51 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -168.647 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -99.24 130.6 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 119.773 1.17 . . . . 10.0 110.708 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -86.93 107.94 18.59 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 128.795 2.838 . . . . 10.0 110.945 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.88 131.51 36.47 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 122.857 0.463 . . . . 10.0 109.908 172.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 90' ' ' ASP . . . . . 0.407 ' OD2' ' NZ ' ' B' ' 91' ' ' LYS . 43.2 t0 -59.23 170.98 0.82 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.282 1.033 . . . . 10.0 109.806 168.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 91' ' ' LYS . . . . . 0.407 ' NZ ' ' OD2' ' B' ' 90' ' ' ASP . 12.4 pttm -51.36 -32.19 24.91 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 125.988 1.715 . . . . 10.0 110.584 175.309 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.36 -8.36 59.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 124.177 0.991 . . . . 10.0 110.963 -175.619 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.82 8.19 87.06 Favored Glycine 0 C--N 1.338 0.692 0 O-C-N 121.532 -0.73 . . . . 10.0 111.286 -177.118 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 50.0 t -80.18 114.92 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 N-CA-C 105.726 -1.953 . . . . 10.0 105.726 170.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.671 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -116.27 121.43 42.0 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 118.87 0.759 . . . . 10.0 109.006 170.021 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -83.0 121.78 27.45 Favored 'General case' 0 N--CA 1.433 -1.288 0 C-N-CA 126.404 1.881 . . . . 10.0 108.334 173.625 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 94.0 t -110.49 136.48 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 N-CA-C 106.543 -1.651 . . . . 10.0 106.543 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 18.7 m -157.77 64.97 0.47 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.071 1.349 . . . . 10.0 109.379 169.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 61.9 mt -101.97 156.35 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.859 1.263 . . . . 10.0 108.719 -171.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -144.81 140.48 28.46 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.645 1.578 . . . . 10.0 108.6 175.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -152.4 135.08 15.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 106.667 -1.605 . . . . 10.0 106.667 169.65 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.4 p -87.53 58.59 5.02 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.745 1.618 . . . . 10.0 107.916 -171.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 p -145.35 -46.53 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.918 -0.583 . . . . 10.0 109.677 -172.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 36.7 mm -66.8 143.04 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 N-CA-C 109.178 -0.675 . . . . 10.0 109.178 171.431 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 74.3 m -138.38 134.44 34.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 173.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -110.29 17.37 20.97 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.737 0.815 . . . . 10.0 110.59 172.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.17 156.5 34.32 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.131 -1.433 . . . . 10.0 107.131 173.409 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 93.67 55.38 1.54 Allowed Glycine 0 CA--C 1.525 0.689 0 O-C-N 123.743 0.652 . . . . 10.0 111.51 169.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 8.6 t70 71.02 -57.03 0.61 Allowed 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 129.663 3.185 . . . . 10.0 109.328 -178.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -82.64 48.31 1.3 Allowed 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 124.206 1.002 . . . . 10.0 109.53 -173.098 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -88.59 112.09 22.65 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 125.664 1.586 . . . . 10.0 107.983 -170.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -69.73 13.87 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 114.095 1.146 . . . . 10.0 114.095 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 33.2 mm -55.74 135.12 19.22 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 O-C-N 120.627 -1.296 . . . . 10.0 108.063 172.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.74 11.66 73.62 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-O 118.132 -1.371 . . . . 10.0 113.855 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mmt-85 -79.38 161.84 25.93 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.242 1.521 . . . . 10.0 108.866 167.402 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.4 121.25 41.94 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 123.529 0.732 . . . . 10.0 109.99 171.41 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -84.37 132.37 34.6 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 107.218 -1.401 . . . . 10.0 107.218 167.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.1 t -116.51 137.43 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.792 -1.188 . . . . 10.0 107.792 169.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -104.76 123.99 59.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.558 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.2 m170 -107.69 159.09 16.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 116.582 2.067 . . . . 10.0 116.582 -172.786 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -41.45 -65.61 0.42 Allowed 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 129.631 3.173 . . . . 10.0 111.67 170.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.1 mttp -109.89 175.38 5.46 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.658 1.183 . . . . 10.0 111.559 -173.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.03 151.73 35.43 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 125.75 1.62 . . . . 10.0 109.903 175.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.502 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -77.53 154.64 32.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 122.901 0.48 . . . . 10.0 110.889 169.928 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 53.4 m-20 -76.27 -36.65 58.32 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.289 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 63.5 mt 64.26 56.32 1.35 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.99 1.376 . . . . 10.0 109.27 -170.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.15 -44.34 3.29 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-N 113.376 -1.738 . . . . 10.0 110.918 171.133 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -76.64 41.06 0.25 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.088 1.755 . . . . 10.0 112.919 -173.003 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -99.85 -17.83 24.46 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 125.838 1.685 . . . . 10.0 110.65 169.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.26 44.89 65.0 Favored Glycine 0 C--N 1.339 0.696 0 C-N-CA 123.861 0.743 . . . . 10.0 111.443 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -146.02 168.02 21.93 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 172.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.1 -42.55 76.97 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 116.144 -0.48 . . . . 10.0 109.88 -176.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -64.78 -40.37 95.15 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.502 -0.748 . . . . 10.0 110.825 175.218 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -50.8 -44.02 58.88 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 118.704 0.684 . . . . 10.0 110.449 -179.59 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -76.94 -8.26 57.06 Favored 'General case' 0 CA--C 1.542 0.662 0 CA-C-O 117.759 -1.115 . . . . 10.0 113.79 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 ttmm -114.87 -58.0 2.2 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 127.728 2.411 . . . . 10.0 113.072 -170.216 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 14.6 p -134.86 17.75 3.52 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.774 1.17 . . . . 10.0 110.784 175.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.12 -110.09 2.95 Favored Glycine 0 C--O 1.219 -0.81 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 -171.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -160.61 43.79 0.19 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 171.46 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.45 -14.76 62.66 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.787 -1.097 . . . . 10.0 112.194 -170.098 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.2 -163.5 54.53 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 110.48 -1.048 . . . . 10.0 110.48 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.7 m -56.94 130.41 45.85 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 123.929 0.891 . . . . 10.0 112.43 -168.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.58 73.36 0.06 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.809 1.644 . . . . 10.0 109.91 171.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 61.8 mt -50.96 -36.45 38.96 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.52 0.728 . . . . 10.0 112.116 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.31 159.59 28.7 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.971 -0.752 . . . . 10.0 108.971 -176.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -159.8 165.38 32.51 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.637 -0.505 . . . . 10.0 109.637 -177.384 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.31 167.73 35.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.421 -1.071 . . . . 10.0 110.421 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 15.9 t -115.41 138.67 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 107.233 -1.395 . . . . 10.0 107.233 -169.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.8 mt -73.18 109.82 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 110.212 -0.292 . . . . 10.0 110.212 -174.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.86 154.65 17.32 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 125.737 1.637 . . . . 10.0 110.373 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.1 mt -86.23 139.4 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 124.894 1.278 . . . . 10.0 108.815 -174.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -91.71 -114.71 0.08 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 167.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 . . . . . 0 C--O 1.248 1.006 0 C-N-CA 127.332 2.253 . . . . 10.0 105.014 166.937 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 107.416 -1.327 . . . . 10.0 107.416 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.2 t -158.45 -44.24 0.06 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.926 0.784 . . . . 10.0 111.328 177.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 11.7 tmtt? -131.78 134.04 45.39 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 123.68 0.792 . . . . 10.0 108.863 178.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.33 169.55 18.05 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 125.281 1.432 . . . . 10.0 109.936 -175.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -129.32 172.72 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 123.159 0.584 . . . . 10.0 112.236 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.72 107.47 4.46 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.826 1.25 . . . . 10.0 107.869 166.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -87.0 89.61 3.07 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-O 121.946 0.879 . . . . 10.0 109.111 172.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.65 HD21 ' HB3' ' A' ' 117' ' ' LEU . 9.1 mt -80.52 116.22 20.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.573 1.549 . . . . 10.0 109.443 -175.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -142.27 159.35 42.41 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.702 1.137 . . . . 10.0 108.35 173.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.62 -65.02 0.02 OUTLIER Glycine 0 N--CA 1.461 0.365 0 CA-C-N 115.249 -0.887 . . . . 10.0 112.216 169.338 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -72.15 -41.66 66.85 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 106.891 -1.522 . . . . 10.0 106.891 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.44 -64.26 0.55 Allowed Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.695 -1.059 . . . . 10.0 111.368 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -58.14 -37.91 93.61 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.056 1.837 . . . . 10.0 110.492 174.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.46 HG13 HD11 ' A' ' 38' ' ' LEU . 80.3 t -62.85 105.55 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 N-CA-C 107.644 -1.243 . . . . 10.0 107.644 174.144 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -124.02 118.98 28.22 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.089 -1.819 . . . . 10.0 106.089 171.179 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.536 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -107.87 130.53 10.15 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 109.725 -1.35 . . . . 10.0 109.725 170.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.595 ' CG2' HG23 ' B' ' 54' ' ' THR . 16.4 mt -128.29 72.04 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.15 -1.796 . . . . 10.0 106.15 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.14 147.19 6.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.288 -0.869 . . . . 10.0 110.447 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.03 106.24 8.74 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 126.78 2.032 . . . . 10.0 107.804 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -86.37 125.11 33.43 Favored 'General case' 0 N--CA 1.451 -0.425 0 CA-C-O 117.73 -1.129 . . . . 10.0 108.012 175.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -120.19 145.27 47.14 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 123.922 0.763 . . . . 10.0 110.963 167.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 tp60 -125.89 105.18 8.74 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 126.858 2.063 . . . . 10.0 107.036 169.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.77 -61.24 2.44 Favored 'General case' 0 C--N 1.339 0.15 0 C-N-CA 124.767 1.227 . . . . 10.0 110.24 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -134.01 167.48 20.53 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 104.552 -2.388 . . . . 10.0 104.552 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.7 t -69.41 -14.94 63.17 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 119.71 -0.186 . . . . 10.0 110.573 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -79.89 -18.02 51.68 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 123.386 0.675 . . . . 10.0 110.171 174.162 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.6 151.68 39.97 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.23 -0.748 . . . . 10.0 111.23 -176.097 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.23 146.66 40.94 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 N-CA-C 105.493 -2.541 . . . . 10.0 105.493 165.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -76.65 119.35 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 N-CA-C 106.166 -1.791 . . . . 10.0 106.166 -179.002 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 18.0 mttp -90.97 110.57 21.83 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 106.432 -1.692 . . . . 10.0 106.432 176.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.13 106.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -128.85 169.96 13.95 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.744 0.783 . . . . 10.0 112.214 171.076 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.05 -153.09 24.77 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 106.592 -2.603 . . . . 10.0 106.592 169.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 27.5 t -156.06 155.98 33.58 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.54 -0.864 . . . . 10.0 109.464 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.536 HG22 ' CA ' ' A' ' 16' ' ' GLY . 3.1 pt -108.01 175.63 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 CA-C-N 115.153 -0.931 . . . . 10.0 110.082 167.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.2 ptmt -152.37 150.66 29.94 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.86 -15.57 33.99 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-O 118.985 -0.897 . . . . 10.0 114.566 171.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.533 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.1 mp -72.95 -179.67 3.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 118.948 1.374 . . . . 10.0 109.609 177.119 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -96.0 175.55 6.44 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.402 -0.962 . . . . 10.0 108.402 166.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -58.65 168.95 1.04 Allowed 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.676 1.19 . . . . 10.0 112.025 -172.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.37 -168.01 49.65 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-O 122.019 0.788 . . . . 10.0 112.909 167.185 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -71.26 146.13 49.15 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.762 1.625 . . . . 10.0 110.397 -176.363 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.07 152.69 35.21 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 113.125 0.787 . . . . 10.0 113.125 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.664 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.3 121.43 0.83 Allowed Glycine 0 C--N 1.339 0.727 0 C-N-CA 128.274 2.845 . . . . 10.0 111.069 165.239 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -155.68 106.21 2.48 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 106.558 -1.645 . . . . 10.0 106.558 169.272 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.07 170.6 17.42 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.876 0.846 . . . . 10.0 112.904 178.561 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.36 132.54 60.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 104.336 -2.468 . . . . 10.0 104.336 168.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 1.7 p80 -168.4 177.47 5.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 107.737 -1.208 . . . . 10.0 107.737 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 52.71 -167.75 0.05 Allowed 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 125.984 2.052 . . . . 10.0 116.157 162.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.75 159.42 19.77 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-O 121.593 0.711 . . . . 10.0 110.893 -175.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.01 -18.44 77.76 Favored Glycine 0 CA--C 1.523 0.565 0 C-N-CA 125.443 1.497 . . . . 10.0 110.308 168.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -50.61 140.6 14.03 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 122.723 1.249 . . . . 10.0 108.259 166.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -151.79 8.86 0.51 Allowed 'General case' 0 N--CA 1.412 -2.342 0 CA-C-N 113.5 -1.682 . . . . 10.0 109.889 -168.267 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.931 HG22 HG22 ' B' ' 17' ' ' ILE . 1.0 OUTLIER -41.45 -55.24 2.87 Favored 'General case' 0 C--N 1.343 0.29 0 C-N-CA 125.842 1.657 . . . . 10.0 114.425 -167.928 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.18 -18.37 57.84 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.836 0.454 . . . . 10.0 111.554 -173.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.72 78.63 1.38 Allowed Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.312 -1.115 . . . . 10.0 110.312 -175.305 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.2 m 70.24 35.3 2.12 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.989 1.315 . . . . 10.0 111.752 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -131.8 -57.51 0.98 Allowed 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 107.184 -1.413 . . . . 10.0 107.184 175.319 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.3 m -52.05 -43.14 63.64 Favored 'General case' 0 C--N 1.343 0.289 0 C-N-CA 123.913 0.885 . . . . 10.0 111.331 -170.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.11 -55.31 0.03 OUTLIER 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 128.35 2.66 . . . . 10.0 113.645 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 139.92 -154.18 23.68 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 110.533 -1.027 . . . . 10.0 110.533 175.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -122.21 -155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.54 0.811 1 C-N-CA 126.865 5.043 . . . . 10.0 105.85 165.049 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.573 ' CD2' HG22 ' A' ' 137' ' ' THR . 21.3 m170 -77.93 46.85 0.6 Allowed 'General case' 0 CA--C 1.548 0.896 0 O-C-N 118.587 -2.571 . . . . 10.0 112.113 177.436 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -77.51 60.9 2.18 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.923 1.289 . . . . 10.0 109.566 169.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -71.74 157.13 90.29 Favored Pre-proline 0 C--N 1.325 -0.457 0 C-N-CA 124.002 0.921 . . . . 10.0 108.67 171.061 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -56.17 -43.42 56.4 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 121.347 1.365 . . . . 10.0 109.478 169.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 68.2 mt -84.23 47.47 1.34 Allowed 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.831 -0.543 . . . . 10.0 111.232 173.51 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 p -61.29 91.39 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 107.407 -1.331 . . . . 10.0 107.407 166.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -113.36 -69.06 0.89 Allowed 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 104.183 -2.525 . . . . 10.0 104.183 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -154.64 161.33 41.63 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 106.171 -1.788 . . . . 10.0 106.171 167.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.8 t60 -72.48 129.07 37.48 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 105.194 -2.151 . . . . 10.0 105.194 163.083 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -150.03 -140.81 3.29 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 108.316 -1.913 . . . . 10.0 108.316 176.004 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.33 -157.99 21.59 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.812 -2.115 . . . . 10.0 107.812 170.094 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -69.38 18.3 0.17 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 119.627 1.713 . . . . 10.0 111.326 169.046 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.402 ' H ' ' C ' ' A' ' 73' ' ' GLY . 30.4 mmtm -104.96 -21.03 13.36 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 124.753 1.221 . . . . 10.0 108.643 169.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.401 ' OD2' ' NZ ' ' A' ' 128' ' ' LYS . 4.8 m-20 -120.9 166.51 13.7 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.121 -1.807 . . . . 10.0 106.121 -171.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -79.32 -42.15 26.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 107.667 -1.235 . . . . 10.0 107.667 173.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -96.2 34.88 1.51 Allowed 'General case' 0 N--CA 1.441 -0.921 0 C-N-CA 127.53 2.332 . . . . 10.0 114.974 -161.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ptp180 -57.28 153.79 11.55 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.521 1.129 . . . . 10.0 110.867 174.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -72.97 159.21 34.03 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 118.9 -1.12 . . . . 10.0 108.497 168.064 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -38.91 -40.09 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 125.974 1.71 . . . . 10.0 114.397 -172.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.6 42.88 1.32 Allowed Glycine 0 C--N 1.338 0.664 0 CA-C-N 118.178 0.445 . . . . 10.0 112.641 179.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.0 89.48 5.34 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 106.619 -1.623 . . . . 10.0 106.619 167.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 21.4 mt -67.97 -37.71 81.86 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.15 -86.08 0.41 Allowed Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 114.873 -1.058 . . . . 10.0 110.537 167.663 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -140.72 131.03 25.07 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 -172.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.0 m -115.24 137.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.944 -0.762 . . . . 10.0 108.944 169.462 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -85.19 131.92 34.36 Favored 'General case' 0 C--O 1.226 -0.168 0 C-N-CA 124.761 1.224 . . . . 10.0 109.485 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.05 138.47 45.35 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.37 1.468 . . . . 10.0 109.625 171.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -58.92 171.6 0.66 Allowed 'General case' 0 N--CA 1.456 -0.135 0 O-C-N 124.181 0.926 . . . . 10.0 109.191 167.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 27.5 pttt -45.91 -34.96 4.23 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 127.225 2.21 . . . . 10.0 110.852 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -82.53 -3.04 55.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.861 1.264 . . . . 10.0 110.83 -173.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.52 8.48 83.08 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.556 -1.017 . . . . 10.0 110.556 -177.226 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 73.5 t -87.83 98.82 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 107.289 -1.374 . . . . 10.0 107.289 -177.068 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.53 121.66 38.59 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 107.523 -1.288 . . . . 10.0 107.523 168.402 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -84.47 114.41 21.9 Favored 'General case' 0 N--CA 1.439 -1.003 0 C-N-CA 126.955 2.102 . . . . 10.0 108.202 169.146 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 87.9 t -102.05 131.36 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.672 -1.233 . . . . 10.0 107.672 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.6 p -157.97 88.95 0.98 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.392 1.077 . . . . 10.0 109.067 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -129.17 163.51 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 106.818 -1.549 . . . . 10.0 106.818 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -136.67 150.39 48.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 121.471 -0.768 . . . . 10.0 110.407 170.176 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -147.0 155.6 42.37 Favored 'General case' 0 N--CA 1.447 -0.608 0 O-C-N 124.551 1.157 . . . . 10.0 108.761 178.38 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.3 p -113.27 44.57 1.53 Allowed 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 127.583 2.353 . . . . 10.0 110.39 -173.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.8 p -142.59 -46.24 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 C-N-CA 123.624 0.77 . . . . 10.0 109.557 177.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 39.8 mm -54.73 110.33 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 169.319 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.4 m -120.82 105.16 10.45 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 124.386 1.074 . . . . 10.0 109.217 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 37.2 mt -58.15 -28.8 65.06 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.984 0.514 . . . . 10.0 111.935 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 m -150.29 160.79 43.45 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.869 -1.53 . . . . 10.0 106.869 174.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 66.1 0.4 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.333 -1.107 . . . . 10.0 110.333 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t70 71.53 -59.67 0.54 Allowed 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 129.557 3.143 . . . . 10.0 109.519 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.9 m-70 -76.49 -22.03 55.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.637 -0.71 . . . . 10.0 111.165 -169.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.1 t 26.43 78.26 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 128.358 2.663 . . . . 10.0 112.213 168.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -67.76 -6.36 5.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 112.599 0.592 . . . . 10.0 112.599 -174.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.5 mm -51.46 132.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 O-C-N 120.952 -1.092 . . . . 10.0 108.309 168.169 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.487 ' HA3' ' CG2' ' B' ' 113' ' ' ILE . . . 93.38 11.81 57.94 Favored Glycine 0 CA--C 1.523 0.577 0 CA-C-O 117.701 -1.611 . . . . 10.0 115.952 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -80.0 176.29 9.87 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 119.594 1.697 . . . . 10.0 108.554 167.135 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 99.7 m -106.54 121.46 44.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 125.095 1.358 . . . . 10.0 107.637 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.65 ' HB3' HD21 ' A' ' 8' ' ' LEU . 3.9 mm? -76.88 144.37 39.01 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 106.498 -1.667 . . . . 10.0 106.498 167.59 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.2 t -131.88 123.76 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 107.696 -1.224 . . . . 10.0 107.696 -176.021 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 11.7 t -104.49 137.83 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.664 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.9 m170 -124.89 157.65 35.44 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 114.553 1.316 . . . . 10.0 114.553 -174.138 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 68.7 tt0 -45.61 -55.92 5.78 Favored 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 128.833 2.853 . . . . 10.0 109.183 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 63.6 mttt -123.6 175.11 7.0 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.586 1.154 . . . . 10.0 110.751 -170.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.33 143.35 28.72 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 108.715 -0.846 . . . . 10.0 108.715 176.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -73.64 151.66 40.75 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.435 -0.58 . . . . 10.0 109.435 175.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -83.28 13.49 4.24 Favored 'General case' 0 N--CA 1.448 -0.529 0 O-C-N 124.355 1.034 . . . . 10.0 111.168 167.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 75.7 mt 45.58 46.6 11.21 Favored 'General case' 0 C--N 1.343 0.307 0 C-N-CA 125.513 1.525 . . . . 10.0 112.779 171.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 107.79 -21.88 29.08 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-N 115.724 -0.671 . . . . 10.0 112.119 173.5 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.401 ' NZ ' ' OD2' ' A' ' 76' ' ' ASP . 7.2 mtmm -112.26 43.89 1.53 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.056 1.343 . . . . 10.0 111.598 -168.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.49 -16.42 64.19 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.343 1.925 . . . . 10.0 112.435 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.33 47.9 88.31 Favored Glycine 0 CA--C 1.532 1.104 0 O-C-N 121.473 -1.016 . . . . 10.0 112.554 173.45 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.464 ' H ' ' HB2' ' A' ' 134' ' ' SER . 7.3 p30 -165.77 173.81 10.3 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 126.682 1.993 . . . . 10.0 106.094 177.259 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -56.9 -42.54 80.08 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 119.802 1.183 . . . . 10.0 111.24 -174.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -70.18 -18.32 63.19 Favored 'General case' 0 N--CA 1.454 -0.273 0 O-C-N 121.29 -0.881 . . . . 10.0 111.916 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.464 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 11.3 t -44.54 -43.53 8.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 C-N-CA 124.836 1.254 . . . . 10.0 109.549 170.542 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -93.79 5.95 49.96 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 112.411 0.523 . . . . 10.0 112.411 -174.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -117.87 -73.77 0.63 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.203 1.401 . . . . 10.0 110.286 179.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.573 HG22 ' CD2' ' A' ' 63' ' ' HIS . 1.4 p -111.87 7.81 20.2 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 120.213 1.369 . . . . 10.0 110.943 178.432 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.78 -90.15 1.06 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 108.413 -1.875 . . . . 10.0 108.413 -173.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.76 39.55 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 124.721 1.208 . . . . 10.0 109.872 176.229 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.35 -10.37 32.53 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 124.217 1.007 . . . . 10.0 112.745 -176.104 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.67 -168.01 53.34 Favored Glycine 0 N--CA 1.445 -0.743 0 O-C-N 121.059 -1.026 . . . . 10.0 110.736 178.261 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -59.68 138.99 57.58 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 123.781 0.832 . . . . 10.0 112.354 -168.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.8 mtm180 -68.18 69.32 0.14 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.714 1.206 . . . . 10.0 110.464 169.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.62 -9.16 32.77 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 113.654 0.983 . . . . 10.0 113.654 -178.024 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.38 143.4 17.68 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.47 0.708 . . . . 10.0 111.858 168.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 5.4 p -144.28 166.31 25.41 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.148 -0.686 . . . . 10.0 109.148 171.125 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.1 150.95 21.15 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 109.74 -1.344 . . . . 10.0 109.74 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.8 139.68 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 106.212 -1.773 . . . . 10.0 106.212 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.472 HD11 ' CD2' ' A' ' 117' ' ' LEU . 58.8 mt -76.84 127.34 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-O 119.555 -0.26 . . . . 10.0 110.937 -173.167 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -125.31 140.78 12.54 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 123.79 0.71 . . . . 10.0 111.882 -177.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 94.1 mt -68.29 140.96 18.2 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 C-N-CA 124.632 1.173 . . . . 10.0 108.699 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.21 -46.33 1.51 Allowed 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 112.348 0.499 . . . . 10.0 112.348 -176.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 . . . . . 0 C--O 1.248 0.986 0 CA-C-O 117.277 -1.344 . . . . 10.0 110.24 -167.896 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.556 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -88.26 -15.74 35.04 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.865 1.266 . . . . 10.0 111.469 -175.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 31.2 tttp -130.18 135.44 48.17 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.142 1.377 . . . . 10.0 108.645 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.74 161.47 35.47 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.769 1.628 . . . . 10.0 108.843 169.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.1 t -117.98 152.86 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 C-N-CA 125.489 1.516 . . . . 10.0 110.163 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.47 94.96 3.28 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.416 1.887 . . . . 10.0 108.739 171.461 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.1 m -88.29 111.3 22.18 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 N-CA-C 109.368 -0.604 . . . . 10.0 109.368 172.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.4 mt -94.61 145.68 24.66 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 109.179 -0.674 . . . . 10.0 109.179 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.5 mtmt -166.72 159.28 13.76 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.533 1.133 . . . . 10.0 108.397 172.641 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.28 -48.7 0.11 Allowed Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.351 -0.928 . . . . 10.0 113.112 169.052 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -72.94 -45.96 55.15 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 107.548 -1.278 . . . . 10.0 107.548 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.04 -71.36 0.4 Allowed Glycine 0 CA--C 1.523 0.537 0 CA-C-N 114.323 -1.308 . . . . 10.0 109.909 170.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -58.18 -35.72 98.47 Favored 'Trans proline' 0 N--CA 1.453 -0.862 0 C-N-CA 123.156 2.57 . . . . 10.0 111.249 173.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.6 t -64.59 107.59 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 107.573 -1.269 . . . . 10.0 107.573 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.47 124.16 39.48 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 108.608 -0.886 . . . . 10.0 108.608 169.267 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.644 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -104.17 149.4 17.11 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 109.879 -1.289 . . . . 10.0 109.879 170.002 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.931 HG22 HG22 ' A' ' 54' ' ' THR . 1.5 mt -146.75 56.89 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 N-CA-C 107.251 -1.388 . . . . 10.0 107.251 -176.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mm -86.35 135.6 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.09 -0.707 . . . . 10.0 109.09 -169.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -103.23 115.76 31.18 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.249 1.82 . . . . 10.0 107.126 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -96.4 115.01 26.74 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.721 -1.585 . . . . 10.0 106.721 175.252 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -122.79 151.46 41.62 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 119.321 0.964 . . . . 10.0 112.699 172.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.6 tt0 -139.6 95.83 2.98 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.148 1.379 . . . . 10.0 108.733 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 68.6 tttt -143.2 83.42 1.79 Allowed 'General case' 0 N--CA 1.426 -1.626 0 C-N-CA 124.15 0.98 . . . . 10.0 109.3 178.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -157.66 170.14 23.06 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 102.701 -3.074 . . . . 10.0 102.701 165.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 16.0 t -71.91 -21.1 61.68 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 109.785 -0.45 . . . . 10.0 109.785 171.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 18.2 m-80 -88.05 -2.78 58.81 Favored 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 123.189 0.596 . . . . 10.0 111.062 -175.363 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.62 49.17 22.0 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-O 118.91 -0.939 . . . . 10.0 114.621 -176.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -68.57 116.33 4.36 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 107.3 -1.846 . . . . 10.0 107.3 169.566 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.8 t -79.37 99.94 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 104.272 -2.492 . . . . 10.0 104.272 169.399 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -92.08 112.03 23.8 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 175.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -101.73 102.73 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.908 0 C-N-CA 126.631 1.972 . . . . 10.0 105.98 -174.296 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.1 p90 -125.14 160.76 28.37 Favored 'General case' 0 C--N 1.339 0.126 0 N-CA-C 112.683 0.623 . . . . 10.0 112.683 177.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.28 -157.64 27.38 Favored Glycine 0 N--CA 1.449 -0.44 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -143.48 127.96 17.96 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 109.613 -0.514 . . . . 10.0 109.613 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.644 HG22 ' CA ' ' B' ' 16' ' ' GLY . 3.4 pt -90.14 139.84 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 N-CA-C 106.611 -1.626 . . . . 10.0 106.611 166.032 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.0 142.34 50.42 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 123.8 0.688 . . . . 10.0 109.437 171.162 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.98 -4.64 25.65 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.221 -0.766 . . . . 10.0 112.888 178.196 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -60.44 176.8 0.33 Allowed 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 118.676 1.238 . . . . 10.0 110.918 170.297 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -109.65 164.35 12.62 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 105.406 -2.072 . . . . 10.0 105.406 165.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -52.72 163.09 0.5 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.863 0.865 . . . . 10.0 112.974 -169.189 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.74 -171.59 47.26 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 123.745 0.688 . . . . 10.0 112.297 169.128 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -71.5 144.39 49.66 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.624 1.969 . . . . 10.0 110.961 -177.288 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -148.48 138.59 22.44 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 113.638 0.977 . . . . 10.0 113.638 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.736 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -20.26 120.87 0.01 OUTLIER Glycine 0 C--N 1.341 0.841 0 C-N-CA 129.134 3.254 . . . . 10.0 115.084 165.697 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.27 108.09 4.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 119.518 1.659 . . . . 10.0 109.827 168.726 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.559 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 2.0 m80 -139.5 179.88 6.3 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.607 0.718 . . . . 10.0 112.288 177.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 76.1 t -112.43 128.33 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 C-N-CA 127.173 2.189 . . . . 10.0 106.368 169.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 67.0 m-70 -109.42 138.42 45.8 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 125.589 1.555 . . . . 10.0 107.299 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -53.76 -57.73 9.79 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 124.189 0.996 . . . . 10.0 111.844 -169.452 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -80.06 135.2 36.29 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 118.109 -1.437 . . . . 10.0 109.59 -177.059 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.86 -19.76 79.56 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 109.827 -1.309 . . . . 10.0 109.827 168.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t0 -39.57 148.63 0.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.008 1.323 . . . . 10.0 112.48 175.03 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -153.88 20.06 0.52 Allowed 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.424 -1.262 . . . . 10.0 113.214 174.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.595 HG23 ' CG2' ' A' ' 17' ' ' ILE . 1.8 m -52.74 -38.04 60.27 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 119.389 0.995 . . . . 10.0 111.978 -171.694 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.41 -22.87 47.12 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.025 0.93 . . . . 10.0 113.007 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.05 111.39 2.65 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.056 -1.218 . . . . 10.0 110.056 -169.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.8 m 34.1 51.73 0.43 Allowed 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 127.816 2.446 . . . . 10.0 115.515 170.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.97 -46.18 0.05 Allowed 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.423 0.689 . . . . 10.0 110.032 173.61 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.8 t -57.09 -26.69 60.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.546 0.738 . . . . 10.0 111.333 -178.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.02 -32.52 0.09 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.032 2.133 . . . . 10.0 112.958 167.452 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.59 162.66 15.91 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 108.72 -1.752 . . . . 10.0 108.72 173.491 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 62' ' ' PRO . . . . . 0.443 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 44.5 Cg_endo -73.94 -134.05 0.01 OUTLIER 'Trans proline' 0 N--CA 1.437 -1.822 0 N-CA-C 103.986 -3.121 . . . . 10.0 103.986 165.321 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.412 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 16.4 m170 -110.18 40.18 2.0 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 120.322 -1.486 . . . . 10.0 109.42 -177.301 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 64' ' ' PHE . . . . . 0.443 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 0.0 OUTLIER -78.04 57.36 1.77 Allowed 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.061 0.846 . . . . 10.0 112.494 -179.506 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -54.38 167.04 0.61 Allowed Pre-proline 0 CA--C 1.541 0.597 0 C-N-CA 129.782 3.233 . . . . 10.0 112.175 173.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -93.87 19.53 0.76 Allowed 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.738 2.292 . . . . 10.0 111.744 -173.337 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -144.48 48.73 1.34 Allowed 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.156 1.383 . . . . 10.0 107.444 -171.652 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.3 p -40.61 107.17 0.07 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 126.716 2.006 . . . . 10.0 112.03 -169.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 45.3 mtp180 -147.56 177.96 8.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 104.98 -2.23 . . . . 10.0 104.98 -175.46 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -73.41 143.09 46.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 117.395 -1.722 . . . . 10.0 110.257 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.5 t60 -52.53 116.96 2.54 Favored 'General case' 0 CA--C 1.519 -0.216 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 167.214 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.07 -178.84 22.69 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 106.659 -2.576 . . . . 10.0 106.659 178.144 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -151.77 -148.34 4.8 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 -174.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -65.58 -0.13 3.43 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 CA-C-N 119.386 1.593 . . . . 10.0 110.591 167.027 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -87.86 -27.17 22.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 118.798 0.726 . . . . 10.0 109.784 172.018 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -115.05 164.69 13.81 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.71 0.766 . . . . 10.0 111.315 -169.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -96.12 -9.0 31.78 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 124.855 1.262 . . . . 10.0 109.216 168.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 50.0 mm-40 -78.2 -81.32 0.1 Allowed 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 124.874 1.269 . . . . 10.0 109.953 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? 59.76 175.69 0.08 Allowed 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 114.634 -1.166 . . . . 10.0 110.722 -167.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -102.43 -59.81 1.64 Allowed 'General case' 0 CA--C 1.529 0.142 0 O-C-N 121.468 -0.77 . . . . 10.0 110.443 168.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.1 p -157.41 -55.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.146 0 C-N-CA 122.991 0.516 . . . . 10.0 109.698 -178.417 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.19 50.47 0.69 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.104 -1.598 . . . . 10.0 109.104 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -76.22 97.25 4.1 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 169.411 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 18.7 mt -75.26 -31.22 60.71 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 102.46 -95.94 1.35 Allowed Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 108.063 -2.015 . . . . 10.0 108.063 171.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -135.72 137.0 41.28 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 112.115 0.413 . . . . 10.0 112.115 -168.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.0 m -119.46 143.83 29.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 108.423 -0.955 . . . . 10.0 108.423 168.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.06 134.75 34.55 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.828 1.651 . . . . 10.0 109.473 -178.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.43 134.38 49.67 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.721 1.208 . . . . 10.0 111.515 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -63.6 169.8 3.67 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.893 -0.78 . . . . 10.0 108.893 165.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.01 -25.48 30.43 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.592 1.157 . . . . 10.0 111.79 175.203 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -75.55 -11.06 59.95 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.838 0.351 . . . . 10.0 110.286 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.66 12.07 75.87 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 110.138 -1.185 . . . . 10.0 110.138 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.0 t -85.45 107.87 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 106.37 -1.715 . . . . 10.0 106.37 175.22 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.65 119.5 39.47 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 168.46 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -78.41 131.01 36.76 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.727 2.011 . . . . 10.0 108.432 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 38.6 t -117.65 131.46 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 126.671 1.988 . . . . 10.0 106.64 -179.318 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 m -158.47 68.06 0.47 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 125.33 1.452 . . . . 10.0 109.196 170.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.1 mt -107.38 166.13 4.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 124.632 1.173 . . . . 10.0 108.283 -176.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -152.68 125.27 8.28 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.714 1.606 . . . . 10.0 109.415 -169.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -140.29 136.24 33.08 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 170.222 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 68.5 p -105.4 60.33 0.67 Allowed 'General case' 0 N--CA 1.457 -0.124 0 N-CA-C 107.003 -1.48 . . . . 10.0 107.003 174.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 99.9 t -127.92 -56.71 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -177.105 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.504 ' H ' ' CD1' ' B' ' 104' ' ' ILE 0.301 0.0 OUTLIER -81.31 173.18 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 124.378 1.071 . . . . 10.0 112.226 170.555 . . . . . . . . 4 4 . 1 . 010 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.9 m -147.65 171.35 15.75 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.229 -0.919 . . . . 10.0 108.744 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 61.1 mt -105.81 -18.65 13.99 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 124.796 1.238 . . . . 10.0 110.343 175.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 73.0 m -156.99 157.78 35.35 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 125.269 1.427 . . . . 10.0 107.243 174.778 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.47 -71.8 0.49 Allowed Glycine 0 C--N 1.334 0.428 0 N-CA-C 108.818 -1.713 . . . . 10.0 108.818 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -160.48 -49.97 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 125.981 1.712 . . . . 10.0 107.197 176.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -80.46 40.0 0.48 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.122 0.969 . . . . 10.0 110.205 -176.424 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 43.3 t -75.25 88.26 2.51 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 126.914 2.086 . . . . 10.0 108.862 -172.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 4.6 pt -78.35 45.76 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 O-C-N 121.349 -0.845 . . . . 10.0 112.618 -176.186 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 113' ' ' ILE . . . . . 0.487 ' CG2' ' HA3' ' A' ' 114' ' ' GLY . 1.3 mp -72.71 -63.83 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 O-C-N 121.599 -0.688 . . . . 10.0 110.299 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.76 48.71 3.54 Favored Glycine 0 CA--C 1.532 1.105 0 O-C-N 120.744 -1.223 . . . . 10.0 112.458 -178.322 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.04 166.17 10.81 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 127.064 2.146 . . . . 10.0 106.985 172.708 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -121.03 136.75 54.91 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.113 -1.069 . . . . 10.0 108.113 174.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mp -103.07 147.3 27.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 173.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -123.69 134.82 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 106.884 -1.525 . . . . 10.0 106.884 174.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -101.29 121.29 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 169.111 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.736 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 9.6 m-70 -101.3 154.08 19.09 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 115.677 1.732 . . . . 10.0 115.677 -169.77 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -38.49 -61.03 0.74 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 128.715 2.806 . . . . 10.0 111.124 171.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 66.0 mttt -117.0 175.3 5.65 Favored 'General case' 0 CA--C 1.517 -0.322 0 C-N-CA 124.973 1.309 . . . . 10.0 109.916 -173.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.3 140.11 35.02 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 108.131 -1.062 . . . . 10.0 108.131 174.054 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.559 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -77.81 160.85 28.08 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 122.077 0.941 . . . . 10.0 111.592 170.477 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -74.78 -27.68 60.42 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 113.804 -1.544 . . . . 10.0 109.863 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 126' ' ' LEU . 3.9 mm? 61.05 63.29 1.28 Allowed 'General case' 0 CA--C 1.521 -0.149 0 C-N-CA 125.711 1.605 . . . . 10.0 107.782 -167.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.74 -52.49 3.64 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.299 168.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.8 pttp -78.62 55.71 1.7 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.315 1.046 . . . . 10.0 112.421 -171.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.36 -34.22 4.85 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 125.387 1.47 . . . . 10.0 110.379 169.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 73.71 35.01 55.71 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.345 -1.102 . . . . 10.0 110.345 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -125.75 156.38 39.51 Favored 'General case' 0 CA--C 1.506 -0.717 0 N-CA-C 105.418 -2.068 . . . . 10.0 105.418 169.038 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.4 tt0 -49.23 -48.86 45.24 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 107.555 -1.276 . . . . 10.0 107.555 169.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -55.95 -41.73 75.14 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 114.648 -1.16 . . . . 10.0 111.959 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 23.2 p -58.61 -42.41 88.09 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 120.368 1.44 . . . . 10.0 111.183 178.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.9 t -78.5 -16.1 57.88 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 113.079 0.77 . . . . 10.0 113.079 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -102.21 -46.01 4.96 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 126.129 1.772 . . . . 10.0 112.889 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.412 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 29.4 p -127.07 -12.33 5.82 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.375 -0.828 . . . . 10.0 112.669 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 1.68 82.64 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.234 -1.314 . . . . 10.0 112.65 -169.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 69.24 29.71 4.51 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 119.95 1.875 . . . . 10.0 111.907 172.121 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.81 0.9 11.77 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 124.522 1.129 . . . . 10.0 112.552 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.93 -163.09 53.19 Favored Glycine 0 N--CA 1.445 -0.744 0 O-C-N 120.948 -1.095 . . . . 10.0 111.439 173.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -59.3 136.61 58.02 Favored 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.585 1.154 . . . . 10.0 114.005 -166.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -64.43 75.52 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.227 1.411 . . . . 10.0 109.822 168.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 47.8 mt -54.51 -37.88 65.87 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 118.655 0.661 . . . . 10.0 111.548 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.86 158.84 35.88 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -177.654 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -151.63 167.6 27.63 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.127 0.571 . . . . 10.0 109.543 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.26 147.43 16.92 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-O 118.446 -1.197 . . . . 10.0 110.361 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.2 t -96.64 127.5 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 N-CA-C 104.358 -2.46 . . . . 10.0 104.358 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.41 HG22 ' HA ' ' B' ' 113' ' ' ILE . 18.9 mt -70.16 158.02 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.055 0.843 . . . . 10.0 109.936 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -155.57 145.63 12.74 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.201 -1.16 . . . . 10.0 110.201 -172.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 98.6 mt -57.41 131.71 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 C-N-CA 126.335 1.854 . . . . 10.0 109.612 176.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -110.05 -44.37 3.79 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 118.85 0.75 . . . . 10.0 111.942 173.165 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.584 -2.151 . . . . 10.0 110.908 176.136 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.859 0 CA-C-O 118.698 -0.668 . . . . 10.0 109.276 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.8 t -165.11 -45.85 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.349 1.06 . . . . 10.0 109.919 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 20.0 ttmm -104.27 138.8 40.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.223 -1.769 . . . . 10.0 106.223 168.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.22 163.4 37.12 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 169.67 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -137.62 166.09 25.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-N 118.286 0.494 . . . . 10.0 110.171 -177.669 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.89 106.89 4.93 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 167.332 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.4 m -80.94 101.02 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 168.662 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mt -78.88 138.73 38.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.707 -0.849 . . . . 10.0 108.707 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.93 160.94 34.09 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.61 -0.885 . . . . 10.0 108.61 168.243 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.45 -60.73 0.03 OUTLIER Glycine 0 C--O 1.23 -0.144 0 N-CA-C 110.592 -1.003 . . . . 10.0 110.592 173.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -74.71 -45.14 46.25 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.53 -69.45 0.48 Allowed Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 114.731 -1.122 . . . . 10.0 111.331 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -55.58 -39.28 91.98 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 122.236 1.957 . . . . 10.0 111.062 -179.22 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.731 HG13 HD12 ' A' ' 38' ' ' LEU . 21.0 t -63.26 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 C-N-CA 129.064 2.946 . . . . 10.0 109.094 178.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -95.45 47.75 1.13 Allowed 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.92 1.288 . . . . 10.0 110.173 -167.891 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.407 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -58.77 150.73 34.87 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 121.142 -0.551 . . . . 10.0 114.041 -168.146 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.727 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.4 mt -136.63 89.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 106.31 -1.737 . . . . 10.0 106.31 -171.446 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.9 mm -96.24 136.74 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.139 0.576 . . . . 10.0 109.455 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 30.5 m-20 -122.7 111.45 16.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 126.027 1.731 . . . . 10.0 107.522 172.67 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -92.85 118.74 31.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.2 1.4 . . . . 10.0 107.343 175.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -124.0 117.84 25.66 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 123.62 0.575 . . . . 10.0 111.161 175.087 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -101.13 102.57 13.53 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 105.876 -1.898 . . . . 10.0 105.876 168.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.3 mmmp? -54.32 -53.6 51.65 Favored 'General case' 0 C--N 1.338 0.108 0 C-N-CA 124.738 1.215 . . . . 10.0 110.821 -169.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.67 178.45 6.99 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 104.798 -2.297 . . . . 10.0 104.798 169.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -70.04 -20.37 63.25 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 110.311 -0.255 . . . . 10.0 110.311 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.8 m-80 -79.5 -21.88 44.72 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 123.742 0.817 . . . . 10.0 109.68 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.47 149.64 33.9 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.096 -0.802 . . . . 10.0 111.096 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -66.82 159.81 49.7 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 122.353 2.035 . . . . 10.0 107.597 168.176 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.29 96.33 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 105.93 -1.878 . . . . 10.0 105.93 174.144 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.9 mtpm? -71.98 100.6 2.51 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 106.42 -1.696 . . . . 10.0 106.42 172.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.54 97.7 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 125.52 1.528 . . . . 10.0 107.28 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.2 p90 -108.79 169.06 8.9 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 121.017 0.437 . . . . 10.0 110.606 169.299 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.57 -168.43 36.74 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.804 -0.518 . . . . 10.0 111.804 173.014 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 11.7 m -147.79 122.84 10.11 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.753 -0.223 . . . . 10.0 111.565 -177.468 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.436 ' HB ' HD11 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -99.53 95.42 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 C-N-CA 126.64 1.976 . . . . 10.0 107.449 169.471 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -106.0 102.45 11.88 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.009 0.524 . . . . 10.0 110.243 176.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.61 29.5 0.06 OUTLIER Glycine 0 C--N 1.334 0.463 0 CA-C-O 118.819 -0.989 . . . . 10.0 114.847 171.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.731 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -126.23 175.87 7.49 Favored 'General case' 0 C--O 1.223 -0.302 0 CA-C-N 118.329 1.065 . . . . 10.0 109.022 -177.827 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.3 t -75.52 160.42 30.2 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 109.325 171.437 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -62.24 -176.4 0.1 Allowed 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.029 1.332 . . . . 10.0 112.74 -176.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.9 -177.65 46.48 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.059 -0.816 . . . . 10.0 111.059 171.295 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.27 150.29 46.54 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.904 0.882 . . . . 10.0 109.216 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 -144.55 149.05 35.2 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.359 0.664 . . . . 10.0 112.484 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.653 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.09 121.77 0.11 Allowed Glycine 0 C--N 1.34 0.774 0 C-N-CA 128.34 2.876 . . . . 10.0 112.215 165.557 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -149.56 107.53 3.72 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 120.045 1.923 . . . . 10.0 113.412 168.359 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.477 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -149.29 168.78 22.38 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 122.18 0.99 . . . . 10.0 112.747 177.777 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 43.5 t -95.36 143.34 12.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 111.186 -2.734 . . . . 10.0 105.964 168.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -125.58 152.24 45.36 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 125.022 1.329 . . . . 10.0 108.889 177.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -62.35 -55.82 24.34 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 123.621 0.768 . . . . 10.0 109.87 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -76.55 104.89 7.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.154 -1.795 . . . . 10.0 106.154 -170.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.57 -36.54 92.59 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 108.844 -1.702 . . . . 10.0 108.844 173.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -54.11 160.99 1.39 Allowed 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 122.735 1.255 . . . . 10.0 113.254 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.425 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -156.33 22.39 0.36 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.206 -1.361 . . . . 10.0 114.506 -172.027 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.559 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.0 OUTLIER -48.94 -36.95 18.59 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.366 1.066 . . . . 10.0 111.387 174.529 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.6 -18.14 57.12 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.556 1.142 . . . . 10.0 112.854 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.52 84.15 0.57 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 123.686 0.66 . . . . 10.0 112.03 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.1 m 47.13 35.51 3.61 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.152 1.781 . . . . 10.0 112.378 174.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.5 m -129.44 -52.39 1.17 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 124.176 0.991 . . . . 10.0 108.396 -169.106 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.1 t -104.32 24.38 11.65 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.525 0.73 . . . . 10.0 109.394 178.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.29 46.51 0.62 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 123.607 0.763 . . . . 10.0 110.68 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.15 100.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.1 0 C-N-CA 126.263 1.887 . . . . 10.0 113.919 168.694 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -68.61 73.79 0.89 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 123.523 2.815 . . . . 10.0 113.086 179.404 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.0 m170 60.64 44.24 11.67 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.365 3.466 . . . . 10.0 110.6 172.384 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -68.96 68.84 0.17 Allowed 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.917 1.287 . . . . 10.0 111.659 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -84.77 154.97 61.84 Favored Pre-proline 0 C--N 1.322 -0.621 0 C-N-CA 125.512 1.525 . . . . 10.0 109.593 177.712 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.23 -44.19 5.24 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 122.433 2.089 . . . . 10.0 111.564 178.303 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.14 53.55 0.99 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.753 0.821 . . . . 10.0 111.021 -178.113 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.6 t -47.34 114.23 0.83 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.086 0.954 . . . . 10.0 111.009 -169.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 54.6 mtt180 -151.69 178.0 9.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 105.458 -2.053 . . . . 10.0 105.458 -169.645 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.72 141.47 37.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 118.614 -1.235 . . . . 10.0 108.892 -177.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -44.98 118.04 1.53 Allowed 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 121.002 -0.279 . . . . 10.0 111.514 168.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.54 -141.64 4.32 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.461 -1.055 . . . . 10.0 110.461 179.514 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.32 -175.49 33.4 Favored Glycine 0 C--O 1.223 -0.591 0 CA-C-N 118.426 1.113 . . . . 10.0 113.562 -173.539 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -66.58 7.6 0.39 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.176 1.917 . . . . 10.0 111.09 168.341 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.7 mmtt -96.57 -22.47 17.04 Favored 'General case' 0 N--CA 1.435 -1.183 0 C-N-CA 124.422 1.089 . . . . 10.0 108.407 173.403 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -126.56 -172.61 2.67 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 112.476 0.547 . . . . 10.0 112.476 -168.301 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -115.1 -6.21 12.48 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.967 1.307 . . . . 10.0 111.071 -174.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -100.74 -14.34 18.1 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 124.646 1.178 . . . . 10.0 112.143 -178.596 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -26.09 114.65 0.06 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 125.929 1.691 . . . . 10.0 111.331 167.707 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -53.62 -53.11 56.53 Favored 'General case' 0 C--O 1.226 -0.14 0 CA-C-O 121.419 0.628 . . . . 10.0 111.718 -167.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.496 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.5 p -165.38 -103.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 104.376 -2.453 . . . . 10.0 104.376 170.192 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.496 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -76.49 59.39 3.31 Favored Glycine 0 CA--C 1.53 1.018 0 CA-C-N 119.098 0.863 . . . . 10.0 112.476 176.664 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -91.11 108.18 19.69 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 103.77 -2.678 . . . . 10.0 103.77 166.279 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -81.59 -19.9 40.96 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 118.446 0.566 . . . . 10.0 111.34 -172.295 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.03 -92.46 0.59 Allowed Glycine 0 C--O 1.217 -0.937 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -155.19 159.52 40.18 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 -178.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.6 m -126.13 126.6 69.83 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 123.665 0.786 . . . . 10.0 110.283 170.203 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -80.11 124.47 28.79 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 127.025 2.13 . . . . 10.0 111.773 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.82 129.55 49.53 Favored 'General case' 0 C--O 1.234 0.243 0 C-N-CA 126.051 1.74 . . . . 10.0 109.58 170.031 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -64.98 172.14 3.09 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 123.985 0.803 . . . . 10.0 109.958 169.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -48.59 -34.61 11.86 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 126.586 1.954 . . . . 10.0 109.983 173.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -78.99 -6.53 56.55 Favored 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 123.943 0.897 . . . . 10.0 110.146 -172.452 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.13 21.18 71.23 Favored Glycine 0 C--N 1.339 0.738 0 N-CA-C 110.27 -1.132 . . . . 10.0 110.27 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.5 t -101.79 106.7 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 127.501 2.32 . . . . 10.0 105.266 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.412 ' HB3' HG13 ' A' ' 35' ' ' ILE . . . -101.9 120.39 40.32 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.092 -1.077 . . . . 10.0 108.092 169.391 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -88.77 134.72 33.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 169.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 90.1 t -109.68 131.78 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 104.705 -2.331 . . . . 10.0 104.705 168.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.9 m -154.79 68.5 0.71 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 124.158 0.983 . . . . 10.0 108.795 174.509 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -117.22 160.82 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 106.736 -1.579 . . . . 10.0 106.736 -174.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -132.01 123.91 28.25 Favored 'General case' 0 N--CA 1.446 -0.626 0 O-C-N 121.842 -0.536 . . . . 10.0 110.139 168.324 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -104.47 128.0 52.28 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.783 1.233 . . . . 10.0 109.403 -172.607 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.9 p -113.42 38.25 2.95 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.047 1.339 . . . . 10.0 110.867 177.783 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.53 -39.73 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 C-N-CA 123.644 0.778 . . . . 10.0 111.47 173.575 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.433 HD12 ' C ' ' A' ' 104' ' ' ILE 0.369 0.8 OUTLIER -90.27 175.66 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 119.566 1.076 . . . . 10.0 112.106 170.173 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 83.7 p -146.39 158.74 43.92 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.402 -0.811 . . . . 10.0 109.107 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.8 mp -89.82 -26.56 20.49 Favored 'General case' 0 N--CA 1.457 -0.077 0 C-N-CA 122.756 0.422 . . . . 10.0 110.493 170.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -155.9 46.51 0.47 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.188 0.449 . . . . 10.0 110.853 -172.035 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -151.92 70.44 0.3 Allowed Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.549 -1.82 . . . . 10.0 108.549 -178.001 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.8 t70 73.94 -52.32 0.69 Allowed 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 128.711 2.804 . . . . 10.0 111.21 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -75.3 -36.7 61.09 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -167.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.5 t 37.79 75.48 0.07 Allowed 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.694 1.598 . . . . 10.0 113.731 166.398 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.8 pt -61.98 -9.37 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 N-CA-C 114.133 1.16 . . . . 10.0 114.133 -177.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 39.1 mm -45.28 129.45 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 O-C-N 121.066 -1.022 . . . . 10.0 110.263 170.199 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.74 -3.41 86.89 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.5 -1.167 . . . . 10.0 114.116 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -78.26 175.67 9.99 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 119.101 1.451 . . . . 10.0 108.04 168.709 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -123.4 135.2 54.01 Favored 'General case' 0 C--N 1.338 0.105 0 C-N-CA 123.308 0.643 . . . . 10.0 110.151 171.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.542 HD21 HD11 ' A' ' 149' ' ' ILE . 3.6 mm? -89.53 147.22 24.09 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 107.64 -1.245 . . . . 10.0 107.64 168.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.4 t -129.27 131.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.2 -1.407 . . . . 10.0 107.2 169.254 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -102.97 133.18 47.46 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 N-CA-C 105.787 -1.931 . . . . 10.0 105.787 168.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.653 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.5 m-70 -111.52 157.67 20.07 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.839 1.422 . . . . 10.0 114.839 -170.649 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.574 ' HA ' HD22 ' A' ' 144' ' ' LEU . 52.0 tt0 -43.52 -52.46 6.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 128.598 2.759 . . . . 10.0 110.332 176.274 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -118.21 165.28 14.0 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 123.584 0.754 . . . . 10.0 110.915 -169.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -58.58 147.16 33.27 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.002 -0.999 . . . . 10.0 109.698 169.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.532 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 26.1 m-20 -79.49 130.56 35.52 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 124.459 1.104 . . . . 10.0 109.829 171.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.51 -16.66 59.59 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 123.876 0.735 . . . . 10.0 111.014 173.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.2 mt 55.6 49.74 15.89 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-O 122.251 1.024 . . . . 10.0 109.386 -173.105 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.52 -29.49 9.61 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.069 -1.423 . . . . 10.0 112.399 169.783 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt -77.06 9.94 2.68 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.731 1.011 . . . . 10.0 113.731 -168.584 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.07 -19.98 74.36 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 124.378 0.99 . . . . 10.0 111.86 172.469 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.79 42.51 68.9 Favored Glycine 0 C--N 1.343 0.944 0 N-CA-C 111.031 -0.828 . . . . 10.0 111.031 -176.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -131.51 159.09 39.16 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 106.139 -1.8 . . . . 10.0 106.139 177.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -50.68 -49.0 58.36 Favored 'General case' 0 N--CA 1.442 -0.841 0 CA-C-N 114.522 -1.217 . . . . 10.0 107.82 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -63.28 -33.67 76.02 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 115.376 -0.829 . . . . 10.0 112.41 175.345 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.9 p -59.43 -43.23 93.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 120.153 -1.592 . . . . 10.0 111.06 174.642 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -81.47 -21.04 39.02 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 122.973 0.171 . . . . 10.0 111.187 -174.115 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 15.6 mmtp -89.11 -49.3 6.83 Favored 'General case' 0 C--N 1.339 0.129 0 C-N-CA 124.781 1.232 . . . . 10.0 113.099 179.223 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 34.7 p -128.81 -18.08 3.89 Favored 'General case' 0 C--O 1.227 -0.125 0 N-CA-C 114.734 1.383 . . . . 10.0 114.734 177.709 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 106.55 26.26 5.97 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 119.452 1.024 . . . . 10.0 112.96 -176.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 58.64 21.6 8.93 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 118.349 1.074 . . . . 10.0 111.033 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.4 -5.36 35.93 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 123.965 0.906 . . . . 10.0 111.8 -169.051 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.84 -165.58 53.66 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.808 -1.317 . . . . 10.0 109.808 168.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 60.2 m -52.01 129.62 27.67 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-O 121.362 0.601 . . . . 10.0 110.037 -171.392 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.71 72.95 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.004 1.322 . . . . 10.0 110.414 171.581 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.574 HD22 ' HA ' ' A' ' 121' ' ' GLU . 6.5 tp -47.75 -35.2 9.48 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 128.202 2.601 . . . . 10.0 113.122 -172.364 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.93 157.09 25.87 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.73 -0.841 . . . . 10.0 108.73 172.549 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -145.31 163.32 34.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.047 -0.524 . . . . 10.0 109.714 177.596 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.18 147.32 15.39 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.495 -1.442 . . . . 10.0 109.495 -174.731 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 69.9 t -105.88 131.88 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 C-N-CA 126.142 1.777 . . . . 10.0 106.771 -169.468 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.542 HD11 HD21 ' A' ' 117' ' ' LEU . 8.2 mt -77.14 117.62 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.735 0 CA-C-N 117.884 0.311 . . . . 10.0 110.398 -174.36 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.45 158.87 14.1 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.572 1.082 . . . . 10.0 112.036 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.1 mt -64.74 142.56 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 125.309 1.444 . . . . 10.0 109.803 177.503 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.77 165.11 28.16 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.575 -1.269 . . . . 10.0 107.575 167.552 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.12 0 N-CA-C 105.023 -2.214 . . . . 10.0 105.023 167.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.551 0 N-CA-C 106.815 -1.55 . . . . 10.0 106.815 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.1 t -94.9 -35.1 12.17 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.558 1.143 . . . . 10.0 109.539 175.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -134.23 160.32 38.22 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 124.486 1.114 . . . . 10.0 110.467 -171.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.99 166.18 34.41 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 169.161 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -128.4 175.78 9.25 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 N-CA-C 107.739 -1.208 . . . . 10.0 107.739 171.175 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.04 122.61 13.24 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 124.064 0.946 . . . . 10.0 109.076 168.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.425 HG21 ' HB3' ' A' ' 53' ' ' ASN . 1.5 m -102.65 100.41 10.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 C-N-CA 124.482 1.113 . . . . 10.0 110.43 174.179 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.442 ' N ' HD12 ' B' ' 8' ' ' LEU . 5.7 mp -89.65 130.41 35.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.742 0.817 . . . . 10.0 109.188 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -144.62 162.68 36.04 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 119.529 1.059 . . . . 10.0 108.423 170.333 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -167.22 -61.37 0.03 OUTLIER Glycine 0 C--O 1.229 -0.208 0 CA-C-N 115.331 -0.85 . . . . 10.0 112.057 171.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -73.81 -44.64 55.19 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 106.544 -1.65 . . . . 10.0 106.544 -171.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.07 -65.57 0.59 Allowed Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 113.614 -1.63 . . . . 10.0 110.404 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -55.44 -38.75 93.67 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 122.644 2.23 . . . . 10.0 111.148 171.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 98.6 t -67.91 107.47 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 N-CA-C 108.058 -1.09 . . . . 10.0 108.058 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.04 107.7 10.67 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 125.662 1.585 . . . . 10.0 107.266 172.676 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.693 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -95.67 136.57 12.94 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.181 -0.768 . . . . 10.0 111.181 173.194 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.559 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.9 mt -140.75 89.58 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.674 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -102.39 149.77 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.087 0 C-N-CA 124.819 1.248 . . . . 10.0 110.753 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -119.57 133.39 55.68 Favored 'General case' 0 C--O 1.232 0.155 0 C-N-CA 127.639 2.376 . . . . 10.0 107.417 174.148 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -119.32 113.62 21.11 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 171.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -110.74 137.46 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 118.714 0.688 . . . . 10.0 111.478 167.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -96.93 113.92 25.5 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.655 -1.98 . . . . 10.0 105.655 167.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.7 tttt -57.64 -51.63 68.72 Favored 'General case' 0 N--CA 1.443 -0.775 0 C-N-CA 125.804 1.642 . . . . 10.0 109.672 -175.008 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 74.8 mt-10 -126.39 -139.11 0.27 Allowed 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 105.392 -2.077 . . . . 10.0 105.392 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 22.8 t -107.18 -12.05 15.47 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 120.12 1.327 . . . . 10.0 110.838 168.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -130.4 5.8 4.81 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 124.071 0.948 . . . . 10.0 110.901 176.048 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.01 148.57 43.09 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 108.164 -1.974 . . . . 10.0 108.164 171.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -59.59 149.18 83.92 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 122.63 2.22 . . . . 10.0 110.269 -177.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -88.99 108.1 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 105.913 -1.884 . . . . 10.0 105.913 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 40.4 tttt -88.39 116.86 26.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 105.886 -1.894 . . . . 10.0 105.886 168.511 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -92.56 103.22 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -123.28 152.41 41.4 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 112.63 0.604 . . . . 10.0 112.63 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.42 -150.86 22.07 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 106.556 -2.618 . . . . 10.0 106.556 172.057 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.98 154.62 31.38 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 118.86 -1.136 . . . . 10.0 110.733 -176.302 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.693 HG22 ' HA2' ' B' ' 16' ' ' GLY . 1.7 pt -113.89 141.38 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 114.91 -1.041 . . . . 10.0 109.614 167.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 tttm -118.81 141.28 48.78 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.81 -8.76 31.96 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 119.517 -0.602 . . . . 10.0 113.95 174.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.39 176.7 0.59 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 118.303 1.052 . . . . 10.0 111.601 175.121 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -112.7 154.04 26.75 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 105.656 -1.979 . . . . 10.0 105.656 165.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -48.95 154.38 0.74 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.869 1.267 . . . . 10.0 113.3 -168.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -171.11 22.29 Favored Glycine 0 C--N 1.337 0.61 0 C-N-CA 123.84 0.733 . . . . 10.0 112.212 168.753 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -73.3 144.13 46.71 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.293 1.437 . . . . 10.0 109.782 -178.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -148.03 150.03 33.2 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 113.504 0.928 . . . . 10.0 113.504 -177.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.714 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -29.73 119.87 0.08 OUTLIER Glycine 0 C--N 1.339 0.731 0 C-N-CA 128.409 2.909 . . . . 10.0 113.847 165.088 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -153.77 110.92 3.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 118.72 1.26 . . . . 10.0 111.029 168.493 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -146.86 175.01 10.97 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 121.436 0.636 . . . . 10.0 110.382 177.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.9 m -103.1 155.62 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 104.903 -2.258 . . . . 10.0 104.903 166.014 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -138.58 154.98 48.73 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.845 1.258 . . . . 10.0 109.835 -173.799 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.7 tt0 -57.48 -64.62 0.83 Allowed 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.387 2.275 . . . . 10.0 112.387 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -77.06 105.92 8.44 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 -172.057 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.15 -23.9 66.61 Favored Glycine 0 CA--C 1.532 1.116 0 N-CA-C 108.995 -1.642 . . . . 10.0 108.995 167.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.38 152.43 0.44 Allowed 'General case' 0 N--CA 1.445 -0.699 0 C-N-CA 124.928 1.291 . . . . 10.0 111.682 168.69 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -152.21 24.46 0.63 Allowed 'General case' 0 N--CA 1.439 -1.007 0 CA-C-N 114.629 -1.169 . . . . 10.0 112.49 168.588 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.727 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -60.6 -25.41 66.22 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 121.783 -0.573 . . . . 10.0 110.292 176.878 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.57 -17.18 60.13 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.632 0.773 . . . . 10.0 111.149 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.05 73.71 0.9 Allowed Glycine 0 CA--C 1.527 0.795 0 N-CA-C 110.709 -0.956 . . . . 10.0 110.709 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 53.72 32.5 14.83 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.092 0.957 . . . . 10.0 112.534 170.201 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -122.4 -48.63 2.07 Favored 'General case' 0 N--CA 1.441 -0.923 0 C-N-CA 124.943 1.297 . . . . 10.0 108.317 -169.324 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.8 t -125.37 48.94 1.96 Allowed 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.58 -0.896 . . . . 10.0 108.58 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.81 50.62 0.72 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.603 0.761 . . . . 10.0 110.265 176.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 69.78 120.07 0.04 OUTLIER Glycine 0 CA--C 1.537 1.42 0 C-N-CA 124.947 1.261 . . . . 10.0 113.093 173.173 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -80.98 50.77 3.69 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 122.729 2.286 . . . . 10.0 112.817 -173.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.5 m170 62.33 100.33 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 127.966 2.507 . . . . 10.0 109.631 -175.718 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -27.38 -47.01 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 128.279 2.632 . . . . 10.0 115.725 -175.19 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 19.39 76.75 0.19 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 128.047 2.539 . . . . 10.0 116.011 -174.117 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.26 -50.63 2.61 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 121.128 1.218 . . . . 10.0 109.576 172.664 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 23.3 tp -77.58 75.9 4.12 Favored 'General case' 0 N--CA 1.453 -0.285 0 O-C-N 121.677 -0.64 . . . . 10.0 109.322 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.2 t -17.3 90.25 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 128.051 2.54 . . . . 10.0 114.241 174.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -135.34 164.77 26.99 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 126.721 2.008 . . . . 10.0 107.981 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -105.62 95.33 5.74 Favored 'General case' 0 C--O 1.224 -0.247 0 C-N-CA 122.897 0.479 . . . . 10.0 109.853 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.523 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 84.6 t60 2.16 94.84 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.406 0 C-N-CA 127.56 2.344 . . . . 10.0 115.254 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -100.91 -144.82 16.06 Favored Glycine 0 C--N 1.316 -0.582 0 N-CA-C 109.836 -1.306 . . . . 10.0 109.836 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.439 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 179.14 -165.82 34.95 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 106.749 -2.54 . . . . 10.0 106.749 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -65.28 7.25 0.31 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 CA-C-N 119.887 1.843 . . . . 10.0 111.169 167.49 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.439 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.8 mmmt -119.94 1.56 10.95 Favored 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 126.509 1.923 . . . . 10.0 110.775 178.534 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -143.34 159.68 41.92 Favored 'General case' 0 C--N 1.348 0.533 0 CA-C-N 120.709 1.595 . . . . 10.0 108.92 168.183 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.2 mm-40 -78.73 -22.0 47.2 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.588 -0.893 . . . . 10.0 108.588 177.09 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -87.14 34.13 0.68 Allowed 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.433 1.093 . . . . 10.0 111.713 -170.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.0 mtm180 -49.12 142.27 7.13 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.591 1.156 . . . . 10.0 108.254 169.263 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.523 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 24.4 m170 -75.74 -50.35 15.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.639 0.654 . . . . 10.0 110.367 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER 175.46 -19.88 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 126.949 2.1 . . . . 10.0 111.675 174.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -161.46 68.98 0.23 Allowed Glycine 0 C--N 1.338 0.642 0 N-CA-C 108.469 -1.852 . . . . 10.0 108.469 -169.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -127.58 94.79 4.06 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -168.342 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.1 mp -64.5 -35.9 82.44 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.468 -0.568 . . . . 10.0 109.468 -172.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.74 -88.14 0.41 Allowed Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 107.19 -2.364 . . . . 10.0 107.19 176.395 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 86' ' ' ASN . . . . . 0.41 ' ND2' ' H ' ' B' ' 124' ' ' ASP . 7.6 m120 -149.82 141.46 23.54 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.731 -1.211 . . . . 10.0 107.731 -172.227 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.5 m -116.52 135.5 56.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 118.443 0.565 . . . . 10.0 110.425 169.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 19.8 m -94.92 100.9 12.68 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 128.173 2.589 . . . . 10.0 110.584 -170.402 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.92 131.23 35.8 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.066 0.547 . . . . 10.0 110.645 174.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -64.92 168.92 5.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.919 1.688 . . . . 10.0 109.139 167.438 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.15 -32.03 33.93 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.488 1.115 . . . . 10.0 111.039 175.77 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -80.68 -2.0 44.88 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 124.445 1.098 . . . . 10.0 110.794 -176.372 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.83 82.72 Favored Glycine 0 C--N 1.34 0.762 0 O-C-N 121.158 -0.964 . . . . 10.0 110.86 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 62.8 t -90.37 104.12 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 106.069 -1.826 . . . . 10.0 106.069 176.085 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.628 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -102.61 122.68 44.88 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 107.61 -1.256 . . . . 10.0 107.61 169.531 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -89.7 124.75 34.88 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.305 1.042 . . . . 10.0 108.25 174.526 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 51.9 t -110.07 131.53 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.937 1.695 . . . . 10.0 107.529 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 95.2 p -156.53 60.8 0.55 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.174 0.589 . . . . 10.0 109.901 174.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.49 155.02 5.13 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 -173.142 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -131.56 142.37 49.9 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.575 0.75 . . . . 10.0 111.067 177.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -140.37 161.8 36.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.552 -1.648 . . . . 10.0 106.552 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 11.1 t -136.98 10.33 3.06 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 125.398 1.479 . . . . 10.0 112.893 175.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -89.19 -15.46 8.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 120.077 1.308 . . . . 10.0 109.628 174.294 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.29 1.0 OUTLIER -111.79 162.57 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 125.333 1.453 . . . . 10.0 112.05 175.578 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.2 m -148.66 147.5 29.0 Favored 'General case' 0 C--N 1.34 0.171 0 C-N-CA 124.087 0.955 . . . . 10.0 109.355 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.45 -21.25 66.2 Favored 'General case' 0 C--O 1.227 -0.113 0 C-N-CA 125.208 1.403 . . . . 10.0 111.35 176.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.7 t -156.73 -172.25 3.98 Favored 'General case' 0 N--CA 1.453 -0.299 0 O-C-N 121.293 -0.879 . . . . 10.0 109.674 171.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 112.45 -89.57 0.53 Allowed Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 107.377 -2.289 . . . . 10.0 107.377 172.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -123.58 -46.94 1.99 Allowed 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 125.232 1.413 . . . . 10.0 109.579 173.496 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -72.31 -42.91 64.91 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 107.37 -1.344 . . . . 10.0 107.37 -168.3 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 21.2 t 37.9 75.64 0.07 Allowed 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 127.353 2.261 . . . . 10.0 111.899 168.669 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 pt -74.29 55.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 123.834 0.854 . . . . 10.0 111.281 176.461 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 43.5 mm -108.46 -49.3 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 125.848 1.659 . . . . 10.0 109.956 179.296 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -90.19 18.68 47.22 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.372 -0.682 . . . . 10.0 113.074 -174.211 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.7 mtt85 -99.64 179.73 4.45 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.115 1.366 . . . . 10.0 110.556 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -133.87 147.62 51.18 Favored 'General case' 0 CA--C 1.507 -0.688 0 C-N-CA 125.789 1.636 . . . . 10.0 106.726 -175.484 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.436 ' N ' HD12 ' B' ' 117' ' ' LEU . 7.7 mp -113.49 153.81 28.09 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.331 -0.988 . . . . 10.0 108.331 173.129 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.0 t -131.97 130.46 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -97.82 123.92 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.349 -1.723 . . . . 10.0 106.349 169.125 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.714 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.3 m-70 -105.06 155.04 19.35 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 115.857 1.799 . . . . 10.0 115.857 -172.492 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 59.3 tt0 -44.79 -53.35 7.51 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 128.139 2.576 . . . . 10.0 111.726 175.026 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -113.08 167.19 10.73 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.952 0.723 . . . . 10.0 112.952 -168.799 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -70.49 147.28 49.57 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 113.967 -1.469 . . . . 10.0 108.424 170.416 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.41 ' H ' ' ND2' ' B' ' 86' ' ' ASN . 14.6 m-20 -94.84 131.34 40.82 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -173.649 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -76.51 -17.42 59.28 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.36 1.064 . . . . 10.0 110.19 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 22.6 mt 57.74 56.6 4.72 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 122.513 1.149 . . . . 10.0 108.969 -179.363 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.1 -40.83 3.06 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.745 -1.57 . . . . 10.0 110.722 168.423 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 30.7 mtmt -79.01 48.99 0.89 Allowed 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.637 1.175 . . . . 10.0 110.81 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -112.07 -9.21 20.73 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 127.203 2.335 . . . . 10.0 112.377 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.7 37.73 43.1 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 123.951 0.786 . . . . 10.0 112.973 176.733 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 -134.0 157.87 44.97 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 106.359 -1.719 . . . . 10.0 106.359 174.84 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -54.86 -45.94 74.63 Favored 'General case' 0 N--CA 1.439 -0.999 0 CA-C-O 122.305 1.05 . . . . 10.0 108.207 170.207 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 24.0 tp10 -58.48 -33.83 70.23 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 121.185 -0.947 . . . . 10.0 112.978 173.084 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.0 p -56.51 -42.09 77.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 120.606 1.548 . . . . 10.0 111.074 172.118 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.3 t -82.78 -19.65 37.36 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 118.485 -0.769 . . . . 10.0 112.421 -178.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -90.86 -46.46 8.18 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 124.448 1.099 . . . . 10.0 112.128 -176.265 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 26.9 p -133.51 -9.26 2.86 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.098 1.147 . . . . 10.0 114.098 176.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.42 23.61 12.31 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 119.289 0.95 . . . . 10.0 112.546 -173.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 61.67 21.83 12.46 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.769 1.284 . . . . 10.0 111.248 -176.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.33 -7.76 20.99 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 125.592 1.557 . . . . 10.0 112.285 -171.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.18 -167.97 54.84 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.069 -1.212 . . . . 10.0 110.069 170.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 12.6 t -53.96 129.1 32.94 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 121.819 0.819 . . . . 10.0 110.862 -169.319 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.45 73.23 0.08 Allowed 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 124.049 0.94 . . . . 10.0 108.961 169.449 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 66.3 mt -47.14 -45.56 22.6 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.868 0.867 . . . . 10.0 111.676 -177.638 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.24 152.38 27.69 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -169.071 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -161.42 165.26 29.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.855 -0.611 . . . . 10.0 109.485 -172.319 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.44 163.24 30.22 Favored Glycine 0 C--N 1.331 0.255 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -174.667 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -101.91 156.05 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 N-CA-C 104.05 -2.574 . . . . 10.0 104.05 169.506 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 77.9 mt -74.75 -94.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 109.765 -0.457 . . . . 10.0 109.765 -169.122 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 112.92 135.95 6.48 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.626 1.108 . . . . 10.0 112.049 175.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -62.48 138.63 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.106 1.363 . . . . 10.0 110.096 179.372 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.87 146.59 49.37 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.434 -1.321 . . . . 10.0 107.434 169.514 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 . . . . . 0 C--O 1.248 0.99 0 N-CA-C 106.195 -1.779 . . . . 10.0 106.195 169.295 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 t -172.37 -36.44 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.703 1.201 . . . . 10.0 112.077 -179.109 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 48.0 tttt -137.98 134.46 34.9 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 123.267 0.627 . . . . 10.0 110.357 -179.615 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.5 167.85 26.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.012 1.325 . . . . 10.0 108.849 -175.21 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -126.89 164.15 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 118.746 0.703 . . . . 10.0 110.519 170.071 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.74 112.31 11.27 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.285 1.434 . . . . 10.0 107.711 167.255 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.479 HG21 ' HB3' ' B' ' 53' ' ' ASN . 3.0 m -95.88 103.14 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 123.666 0.787 . . . . 10.0 110.216 177.319 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mt -87.77 107.83 18.84 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 118.637 -0.697 . . . . 10.0 110.038 -173.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -133.24 158.69 42.26 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 120.644 1.565 . . . . 10.0 108.453 175.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.71 -68.82 0.02 OUTLIER Glycine 0 N--CA 1.462 0.372 0 CA-C-N 114.818 -1.083 . . . . 10.0 112.342 170.527 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -72.37 -39.5 68.0 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.064 -1.458 . . . . 10.0 107.064 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.24 -60.48 0.56 Allowed Glycine 0 N--CA 1.443 -0.86 0 CA-C-O 118.476 -1.18 . . . . 10.0 112.608 170.241 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -60.62 -39.62 62.7 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 CA-C-N 119.198 1.499 . . . . 10.0 110.848 -177.345 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.437 HG12 ' H ' ' A' ' 14' ' ' VAL . 0.2 OUTLIER -70.66 115.32 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 177.322 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.84 103.95 7.78 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.413 -2.44 . . . . 10.0 104.413 170.631 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.75 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.38 145.79 19.19 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 108.445 -1.862 . . . . 10.0 108.445 174.072 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.657 ' CG2' HG22 ' B' ' 54' ' ' THR . 3.3 mt -144.85 74.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -168.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 mm -87.45 128.8 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 N-CA-C 109.741 -0.466 . . . . 10.0 109.741 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -99.6 112.15 24.4 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 126.41 1.884 . . . . 10.0 107.752 173.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.421 ' CD2' HG12 ' A' ' 31' ' ' VAL . 25.7 m-85 -88.06 113.43 23.69 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 107.211 -1.403 . . . . 10.0 107.211 173.081 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -121.28 111.39 17.3 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 118.797 0.726 . . . . 10.0 111.272 168.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -99.53 91.54 4.95 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.129 -1.804 . . . . 10.0 106.129 168.273 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.48 -36.71 66.91 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.972 0.909 . . . . 10.0 112.939 -168.715 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.05 171.2 14.76 Favored 'General case' 0 N--CA 1.432 -1.362 0 N-CA-C 104.834 -2.284 . . . . 10.0 104.834 167.398 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.4 p -64.81 -24.65 67.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.235 0.54 . . . . 10.0 110.248 179.139 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -81.58 -19.29 42.29 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 115.221 -0.9 . . . . 10.0 110.259 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -82.02 154.48 33.71 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.617 -0.593 . . . . 10.0 111.617 -173.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_endo -67.36 146.8 76.37 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.71 2.274 . . . . 10.0 106.876 167.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.9 p -80.29 110.05 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 174.694 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -84.3 115.91 22.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.431 -0.952 . . . . 10.0 108.431 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.421 HG12 ' CD2' ' A' ' 20' ' ' PHE . 30.2 m -98.48 57.91 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 124.233 1.013 . . . . 10.0 108.73 -170.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 9.3 p90 -77.78 144.88 36.79 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 118.921 -1.112 . . . . 10.0 110.963 -175.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -175.88 172.04 45.06 Favored Glycine 0 N--CA 1.441 -0.976 0 O-C-N 121.24 -0.913 . . . . 10.0 110.89 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.8 t -128.58 107.91 10.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 178.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.758 ' CG1' ' HB3' ' A' ' 95' ' ' ALA . 2.7 pt -81.76 142.18 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 108.396 -0.964 . . . . 10.0 108.396 169.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.7 ptmm? -127.13 137.03 52.9 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.192 -1.04 . . . . 10.0 108.192 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.71 -1.92 27.52 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.075 0.845 . . . . 10.0 113.399 176.072 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -62.53 174.05 1.09 Allowed 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 122.132 0.968 . . . . 10.0 110.467 169.291 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -103.61 164.49 11.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.18 -1.785 . . . . 10.0 106.18 164.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -54.61 162.87 1.04 Allowed 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.576 0.751 . . . . 10.0 112.062 -172.769 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.72 -179.78 43.12 Favored Glycine 0 C--N 1.334 0.469 0 O-C-N 121.248 -0.908 . . . . 10.0 112.29 168.144 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.1 mt -66.55 142.22 57.58 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.059 0.943 . . . . 10.0 110.65 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -138.02 128.82 26.91 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 117.729 -1.129 . . . . 10.0 111.103 176.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.513 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -15.2 113.46 0.01 OUTLIER Glycine 0 C--N 1.347 1.148 0 CA-C-O 115.949 -2.584 . . . . 10.0 112.49 167.387 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -137.73 100.15 4.11 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 120.989 2.394 . . . . 10.0 109.91 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.413 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -156.73 169.84 23.79 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-O 122.04 0.924 . . . . 10.0 112.79 -174.075 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.8 t -96.81 141.14 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 111.566 -2.561 . . . . 10.0 107.729 177.618 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -116.28 168.58 10.0 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.178 0.991 . . . . 10.0 109.397 178.236 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -67.23 -72.51 0.16 Allowed 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.697 -0.683 . . . . 10.0 111.246 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.55 136.98 34.71 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 120.161 -0.616 . . . . 10.0 110.132 -169.442 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -66.87 -31.59 78.63 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 109.278 -1.529 . . . . 10.0 109.278 168.227 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -45.14 155.34 0.12 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 122.837 1.303 . . . . 10.0 114.353 -175.32 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.17 15.37 0.82 Allowed 'General case' 0 N--CA 1.439 -0.985 0 CA-C-N 113.446 -1.707 . . . . 10.0 111.037 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.522 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -53.76 -43.07 68.88 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 120.266 1.394 . . . . 10.0 112.352 -167.676 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.59 -17.94 52.74 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.98 0.912 . . . . 10.0 112.65 -179.331 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.05 60.77 0.37 Allowed Glycine 0 CA--C 1.528 0.862 0 C-N-CA 124.468 1.033 . . . . 10.0 111.139 -177.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 61.24 18.65 9.35 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 114.513 1.301 . . . . 10.0 114.513 171.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 p -93.81 -57.53 2.53 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 176.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.4 m -49.91 -34.44 20.42 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.363 2.265 . . . . 10.0 111.853 -178.496 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -39.25 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.849 2.46 . . . . 10.0 112.078 168.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.74 154.02 28.63 Favored Glycine 0 N--CA 1.436 -1.339 0 N-CA-C 108.28 -1.928 . . . . 10.0 108.28 168.66 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -71.44 -164.95 0.17 Allowed 'Trans proline' 0 N--CA 1.442 -1.552 0 N-CA-C 107.269 -1.858 . . . . 10.0 107.269 167.295 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.413 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 50.4 m170 -79.84 62.75 4.17 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 120.596 -1.315 . . . . 10.0 109.951 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -75.28 67.28 1.86 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 123.702 1.715 . . . . 10.0 111.18 178.332 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -72.65 153.6 91.53 Favored Pre-proline 0 N--CA 1.448 -0.54 0 C-N-CA 128.205 2.602 . . . . 10.0 110.181 169.295 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.85 -40.2 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.767 2.312 . . . . 10.0 111.37 177.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mt -78.09 49.18 0.79 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.284 1.034 . . . . 10.0 110.442 -177.697 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.4 p -57.14 106.55 0.33 Allowed 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.417 1.087 . . . . 10.0 109.826 -170.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.4 mtt180 -134.7 -88.02 0.37 Allowed 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 106.562 -1.644 . . . . 10.0 106.562 -171.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.5 mmtp -140.71 155.39 46.48 Favored 'General case' 0 N--CA 1.438 -1.074 0 CA-C-O 122.695 1.236 . . . . 10.0 110.273 169.184 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 69.2 t60 -69.03 119.31 13.12 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 164.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.9 -138.24 3.81 Favored Glycine 0 N--CA 1.442 -0.919 0 N-CA-C 109.38 -1.488 . . . . 10.0 109.38 -175.645 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -176.94 -157.5 18.14 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 109.558 -1.417 . . . . 10.0 109.558 169.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -67.79 14.72 0.15 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.158 1.905 . . . . 10.0 111.424 168.236 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.438 ' H ' ' C ' ' A' ' 73' ' ' GLY . 4.5 mtpm? -120.91 -6.93 9.54 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.626 1.571 . . . . 10.0 110.677 174.542 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -110.89 162.39 14.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 177.357 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.4 pm0 -98.74 -16.16 19.06 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 126.319 1.847 . . . . 10.0 109.866 169.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -105.39 6.9 32.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.852 1.661 . . . . 10.0 112.324 -174.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -35.52 149.81 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.575 1.95 . . . . 10.0 112.924 171.069 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -70.06 -100.42 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 112.47 0.545 . . . . 10.0 112.47 -178.312 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 p -151.64 25.06 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 O-C-N 120.606 -1.309 . . . . 10.0 110.392 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 157.36 51.33 0.01 OUTLIER Glycine 0 CA--C 1.522 0.483 0 N-CA-C 108.814 -1.715 . . . . 10.0 108.814 -173.268 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.55 99.74 11.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 105.346 -2.094 . . . . 10.0 105.346 169.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.7 mt -94.49 33.02 1.47 Allowed 'General case' 0 N--CA 1.461 0.122 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 172.143 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 46.09 -106.38 0.13 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 126.514 2.006 . . . . 10.0 111.025 -178.351 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -151.92 117.66 5.43 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 123.557 0.743 . . . . 10.0 110.439 -168.234 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -92.86 138.69 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 122.731 0.412 . . . . 10.0 110.83 -171.111 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.31 118.56 24.28 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 125.035 1.334 . . . . 10.0 110.493 -172.391 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.59 134.74 38.12 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 123.225 0.61 . . . . 10.0 109.847 173.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -57.92 167.57 1.16 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.856 0.862 . . . . 10.0 109.025 167.607 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.11 -23.69 62.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.104 -0.498 . . . . 10.0 112.157 177.644 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -78.4 -13.09 60.0 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.266 0.627 . . . . 10.0 110.958 179.121 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.74 6.27 67.8 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.952 -0.859 . . . . 10.0 110.952 -176.517 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.9 t -81.49 108.1 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.516 1.927 . . . . 10.0 106.978 174.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.758 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -112.99 121.12 43.68 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 108.831 -0.803 . . . . 10.0 108.831 173.552 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -83.08 131.4 35.16 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.719 -0.845 . . . . 10.0 108.719 173.18 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.7 t -119.23 130.79 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 N-CA-C 104.815 -2.291 . . . . 10.0 104.815 168.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -155.75 57.78 0.61 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 118.655 0.661 . . . . 10.0 111.18 -177.425 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 71.6 mt -116.55 138.77 46.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.208 1.403 . . . . 10.0 109.824 -170.156 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -91.35 104.12 16.68 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 127.843 2.457 . . . . 10.0 109.121 172.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -81.34 116.48 21.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.009 -0.738 . . . . 10.0 109.009 175.256 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.8 p -111.3 46.46 1.09 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 125.448 1.499 . . . . 10.0 109.68 174.081 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.23 -41.06 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.168 0 CA-C-O 118.157 -0.925 . . . . 10.0 110.543 175.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.407 0.0 OUTLIER -106.27 177.21 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-N 119.553 1.069 . . . . 10.0 113.549 169.501 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.6 t -146.23 153.71 40.92 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 108.112 -1.07 . . . . 10.0 108.112 -176.299 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 93.1 mt -69.77 -17.53 63.43 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.318 0.647 . . . . 10.0 110.801 173.297 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.3 t -151.15 150.55 30.79 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.536 0.607 . . . . 10.0 109.533 177.51 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.6 68.09 0.43 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.017 -1.233 . . . . 10.0 110.017 -179.079 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.8 t70 71.61 -56.67 0.63 Allowed 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 129.536 3.134 . . . . 10.0 109.847 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -78.15 -2.46 37.61 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 113.011 0.745 . . . . 10.0 113.011 -168.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.9 t -17.76 96.41 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 129.025 2.93 . . . . 10.0 112.523 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 29.2 pt -72.84 -3.58 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 112.776 0.658 . . . . 10.0 112.776 -175.009 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.8 mm -52.54 130.28 13.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 O-C-N 121.092 -1.005 . . . . 10.0 108.493 169.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.92 8.71 87.67 Favored Glycine 0 CA--C 1.533 1.205 0 CA-C-O 118.67 -1.072 . . . . 10.0 114.22 -176.672 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -78.36 176.43 9.34 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 166.222 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -127.96 136.82 51.84 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 106.854 -1.535 . . . . 10.0 106.854 171.179 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.9 mp -107.61 158.07 17.55 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.183 -1.414 . . . . 10.0 107.183 168.819 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.1 t -132.27 136.79 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 107.487 -1.301 . . . . 10.0 107.487 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.3 125.19 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 103.674 -2.713 . . . . 10.0 103.674 167.638 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.513 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.0 m170 -106.37 164.37 12.08 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 120.207 1.367 . . . . 10.0 114.37 -171.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.39 -49.79 73.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 114.036 -1.438 . . . . 10.0 109.438 -175.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -117.97 173.05 6.99 Favored 'General case' 0 N--CA 1.456 -0.131 0 CA-C-O 122.425 1.107 . . . . 10.0 113.355 -174.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -73.57 143.28 46.5 Favored 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 113.475 -1.693 . . . . 10.0 109.646 169.454 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.13 156.3 36.11 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 123.851 0.861 . . . . 10.0 110.637 174.229 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 -85.35 8.92 16.98 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.414 -0.812 . . . . 10.0 109.968 166.483 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.4 mt 39.32 52.79 2.24 Favored 'General case' 0 C--N 1.344 0.369 0 C-N-CA 126.148 1.779 . . . . 10.0 110.782 -172.478 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.55 -26.24 24.68 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 113.642 -1.617 . . . . 10.0 112.59 173.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -78.97 24.37 0.31 Allowed 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 114.29 1.219 . . . . 10.0 114.29 -167.321 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.48 -38.41 38.29 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 108.49 -1.844 . . . . 10.0 108.49 169.034 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.84 47.8 58.7 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 109.431 -1.468 . . . . 10.0 109.431 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -152.17 164.08 38.06 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.544 -2.021 . . . . 10.0 105.544 176.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -44.74 -47.15 10.77 Favored 'General case' 0 N--CA 1.438 -1.055 0 C-N-CA 123.031 0.532 . . . . 10.0 111.344 -175.688 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.77 -34.56 71.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.453 -0.34 . . . . 10.0 110.176 -177.36 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -51.45 -44.44 62.36 Favored 'General case' 0 N--CA 1.446 -0.651 0 O-C-N 121.725 -0.61 . . . . 10.0 110.677 172.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -84.38 6.75 22.0 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.382 0.512 . . . . 10.0 112.382 -176.315 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -118.91 -75.62 0.58 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 125.594 1.557 . . . . 10.0 109.619 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 p -111.16 13.64 21.83 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 120.419 1.463 . . . . 10.0 113.689 175.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.66 -21.2 11.5 Favored Glycine 0 C--N 1.338 0.674 0 O-C-N 120.819 -1.176 . . . . 10.0 115.455 168.265 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 90.74 28.02 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 128.183 2.593 . . . . 10.0 110.097 -168.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.18 -2.2 1.28 Allowed 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.767 0.827 . . . . 10.0 112.686 169.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.11 -171.84 55.16 Favored Glycine 0 N--CA 1.443 -0.867 0 N-CA-C 109.882 -1.287 . . . . 10.0 109.882 174.622 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -60.88 144.92 51.9 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.881 0.848 . . . . 10.0 112.153 -169.098 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mtm-85 -63.71 63.29 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 127.305 2.242 . . . . 10.0 110.806 169.118 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.46 -14.86 59.21 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.941 1.089 . . . . 10.0 113.941 -173.021 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.86 146.3 17.63 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 123.303 0.641 . . . . 10.0 109.738 169.522 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.0 p -155.07 156.48 35.95 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.79 -0.818 . . . . 10.0 108.79 -171.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.22 145.39 12.38 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.412 -1.075 . . . . 10.0 110.412 -169.152 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.86 140.85 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 125.903 1.681 . . . . 10.0 106.838 -172.679 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.8 mt -80.56 120.1 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-O 118.716 -0.659 . . . . 10.0 110.575 -174.142 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -128.51 154.37 20.01 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 124.263 0.935 . . . . 10.0 113.085 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 mm -64.75 146.21 13.37 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 C-N-CA 124.292 1.037 . . . . 10.0 112.254 -169.468 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.57 -17.47 1.73 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 116.231 1.937 . . . . 10.0 116.231 178.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.252 1.206 0 CA-C-O 117.693 -1.146 . . . . 10.0 110.683 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 108.383 -0.969 . . . . 10.0 108.383 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -170.13 -47.2 0.02 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 124.099 0.96 . . . . 10.0 109.785 178.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -138.51 125.76 21.59 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 125.256 1.422 . . . . 10.0 107.973 -169.648 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.02 162.58 35.09 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 124.545 1.138 . . . . 10.0 109.053 -172.681 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 m -115.74 172.94 3.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-O 121.611 0.719 . . . . 10.0 110.086 171.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.44 102.56 3.85 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 104.425 -2.435 . . . . 10.0 104.425 165.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 m -90.03 120.02 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 170.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.417 ' N ' HD12 ' B' ' 8' ' ' LEU . 4.8 mp -99.16 136.22 39.44 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 108.326 -0.99 . . . . 10.0 108.326 -177.011 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 9' ' ' LYS . . . . . 0.409 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 39.4 mtpt -145.45 160.26 41.86 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.659 -1.237 . . . . 10.0 107.659 169.392 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.07 -54.56 0.07 OUTLIER Glycine 0 N--CA 1.461 0.323 0 C-N-CA 120.522 -0.846 . . . . 10.0 113.669 169.582 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -72.06 -43.58 64.67 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 -174.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.84 -70.95 0.4 Allowed Glycine 0 CA--C 1.521 0.425 0 CA-C-N 114.223 -1.353 . . . . 10.0 109.86 169.656 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -57.62 -36.16 98.62 Favored 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 123.381 2.721 . . . . 10.0 111.389 172.613 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.95 101.69 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -117.79 106.91 13.52 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 124.633 1.173 . . . . 10.0 107.957 172.001 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.44 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -86.83 147.75 21.3 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 109.912 -1.275 . . . . 10.0 109.912 169.638 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 54' ' ' THR . 0.9 OUTLIER -149.56 76.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 N-CA-C 104.761 -2.311 . . . . 10.0 104.761 -175.851 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -97.44 146.15 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 124.744 1.218 . . . . 10.0 108.85 -178.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -126.11 125.17 42.1 Favored 'General case' 0 C--O 1.232 0.133 0 C-N-CA 126.669 1.988 . . . . 10.0 107.864 -175.518 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -112.69 105.57 13.76 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.406 1.482 . . . . 10.0 107.805 178.137 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -113.13 123.78 51.05 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 123.823 0.702 . . . . 10.0 111.486 175.557 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -95.18 97.78 10.15 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.332 1.453 . . . . 10.0 108.003 174.274 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? -47.06 -61.88 1.67 Allowed 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 126.275 1.83 . . . . 10.0 110.955 -175.001 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -141.51 171.61 13.82 Favored 'General case' 0 N--CA 1.432 -1.37 0 N-CA-C 102.614 -3.106 . . . . 10.0 102.614 168.068 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.3 p -71.4 -15.62 62.37 Favored 'General case' 0 N--CA 1.445 -0.707 0 O-C-N 121.367 -0.833 . . . . 10.0 109.874 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 34.2 m120 -78.56 -26.6 45.63 Favored 'General case' 0 N--CA 1.441 -0.906 0 C-N-CA 123.59 0.756 . . . . 10.0 110.746 174.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.78 156.11 31.13 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.458 -1.057 . . . . 10.0 110.458 -177.744 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.57 161.0 45.43 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.122 1.881 . . . . 10.0 109.073 171.487 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 14.1 t -87.44 112.28 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 N-CA-C 105.208 -2.145 . . . . 10.0 105.208 169.324 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -92.98 121.12 33.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.599 -1.63 . . . . 10.0 106.599 169.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.69 106.38 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.307 1.843 . . . . 10.0 106.495 177.26 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -127.64 152.87 47.13 Favored 'General case' 0 CA--C 1.522 -0.133 0 N-CA-C 113.461 0.912 . . . . 10.0 113.461 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.26 -150.31 21.54 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 108.2 -1.96 . . . . 10.0 108.2 172.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 22.6 t -155.14 158.31 38.79 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 119.598 -0.841 . . . . 10.0 112.299 -177.033 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.652 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -118.88 114.21 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 127.147 2.179 . . . . 10.0 108.76 169.806 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -100.27 142.87 31.16 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 168.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.43 -1.17 14.21 Favored Glycine 0 C--N 1.337 0.599 0 C-N-CA 124.597 1.094 . . . . 10.0 112.932 169.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 31.7 mt -80.78 175.98 10.21 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.875 0.845 . . . . 10.0 110.491 -178.14 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -93.11 150.77 20.28 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 68.9 tt0 -53.77 145.32 16.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.4 1.08 . . . . 10.0 110.824 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.4 -176.64 21.8 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.799 0.714 . . . . 10.0 111.882 176.469 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.8 mp -70.83 150.33 45.93 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.485 1.514 . . . . 10.0 111.87 -172.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -143.22 144.15 32.04 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 112.969 0.729 . . . . 10.0 112.969 178.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.515 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -37.19 115.82 0.34 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.405 2.431 . . . . 10.0 112.211 166.744 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.541 ' CZ ' HD12 ' B' ' 35' ' ' ILE . 2.0 m-85 -135.66 106.6 6.65 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.754 1.777 . . . . 10.0 110.592 172.179 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.507 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -152.75 171.35 18.37 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-N 115.376 -0.829 . . . . 10.0 109.885 178.142 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 12.3 m -99.93 147.16 7.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 112.952 -1.931 . . . . 10.0 107.106 167.542 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 22.7 m-70 -116.14 131.19 57.01 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 103.949 -2.612 . . . . 10.0 103.949 173.099 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -59.73 -48.78 80.32 Favored 'General case' 0 N--CA 1.45 -0.443 0 O-C-N 124.206 0.941 . . . . 10.0 111.643 -167.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.7 m-30 -80.01 148.28 31.18 Favored 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 118.386 -1.326 . . . . 10.0 108.324 175.304 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.72 35.89 4.29 Favored Glycine 0 N--CA 1.441 -1.021 0 N-CA-C 108.083 -2.007 . . . . 10.0 108.083 166.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.7 74.73 6.38 Favored 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 126.895 3.236 . . . . 10.0 107.318 171.255 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.479 ' HB3' HG21 ' A' ' 7' ' ' VAL . 3.2 t-20 -76.63 -0.37 23.16 Favored 'General case' 0 N--CA 1.416 -2.133 0 CA-C-N 109.63 -3.441 . . . . 10.0 111.029 -173.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.657 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -32.08 -52.38 0.26 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 130.194 3.397 . . . . 10.0 112.932 175.526 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -21.97 47.45 Favored 'General case' 0 CA--C 1.529 0.147 0 N-CA-C 112.871 0.693 . . . . 10.0 112.871 -176.12 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.24 75.85 1.3 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -174.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 19.9 m 63.75 56.82 1.47 Allowed 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 123.716 0.806 . . . . 10.0 112.208 168.486 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -155.14 -58.19 0.1 Allowed 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 108.239 -1.023 . . . . 10.0 108.239 175.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.5 m -61.42 -26.63 67.99 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 122.376 0.27 . . . . 10.0 111.578 -173.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.02 -34.56 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.977 2.511 . . . . 10.0 112.734 168.409 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.97 155.97 9.24 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.144 -0.783 . . . . 10.0 111.144 166.458 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 62' ' ' PRO . . . . . 0.416 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 88.8 Cg_endo -75.92 58.83 5.6 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 123.566 2.844 . . . . 10.0 108.494 166.592 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.293 26.1 m170 75.2 -44.3 0.53 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 127.181 2.192 . . . . 10.0 109.519 -177.669 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 64' ' ' PHE . . . . . 0.416 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 2.8 m-85 51.61 47.62 24.45 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 126.461 1.904 . . . . 10.0 111.57 172.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -72.01 142.73 85.57 Favored Pre-proline 0 C--N 1.321 -0.638 0 C-N-CA 125.571 1.548 . . . . 10.0 112.987 178.549 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.92 -44.43 0.35 Allowed 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 123.623 2.882 . . . . 10.0 110.843 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 14.4 mt -68.96 88.13 0.38 Allowed 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.223 -1.399 . . . . 10.0 107.223 171.544 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -57.7 82.13 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.658 1.983 . . . . 10.0 111.25 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.68 -179.83 4.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 127.19 2.196 . . . . 10.0 108.126 177.588 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -111.1 107.89 17.41 Favored 'General case' 0 C--O 1.224 -0.244 0 N-CA-C 108.263 -1.014 . . . . 10.0 108.263 -177.155 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.522 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 83.1 t60 -12.09 98.23 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.439 0 C-N-CA 126.783 2.033 . . . . 10.0 113.892 -178.336 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.44 -175.54 14.11 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 106.916 -2.474 . . . . 10.0 106.916 176.401 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.32 -155.89 7.26 Favored Glycine 0 C--O 1.226 -0.376 0 N-CA-C 107.061 -2.416 . . . . 10.0 107.061 -177.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -67.22 1.45 2.95 Favored 'Trans proline' 0 CA--C 1.544 0.99 0 CA-C-N 119.69 1.745 . . . . 10.0 110.287 165.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 56.3 mmtt -89.8 -15.57 32.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.834 1.653 . . . . 10.0 110.416 171.789 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -133.81 178.53 6.87 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 119.832 1.196 . . . . 10.0 109.826 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -90.3 -32.41 16.53 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 169.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -95.14 43.52 1.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 122.299 1.047 . . . . 10.0 111.909 -169.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.58 144.31 17.72 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 115.849 -0.614 . . . . 10.0 110.48 168.47 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.522 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.2 m170 -68.95 -56.86 6.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 -173.175 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.4 p -173.74 -38.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 123.715 0.806 . . . . 10.0 111.429 -174.62 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -158.56 69.61 0.26 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 108.072 -2.011 . . . . 10.0 108.072 -169.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -122.92 94.4 4.26 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.401 -2.074 . . . . 10.0 105.401 -171.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 5.0 mt -72.07 -28.3 63.24 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 85' ' ' GLY . . . . . 0.412 ' CA ' HD11 ' B' ' 126' ' ' LEU . . . 88.39 -94.58 2.01 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 108.007 -2.037 . . . . 10.0 108.007 176.117 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -128.98 124.18 34.38 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.092 0.557 . . . . 10.0 110.531 -168.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.476 HG22 ' CD1' ' B' ' 45' ' ' PHE . 6.6 m -121.48 145.52 27.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.2 m -94.17 113.72 25.71 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 127.172 2.189 . . . . 10.0 111.97 -167.82 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.45 130.48 36.12 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 109.457 -0.571 . . . . 10.0 109.457 169.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -59.51 169.71 1.21 Allowed 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 125.098 1.359 . . . . 10.0 110.311 168.451 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.06 -32.29 34.03 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.035 1.334 . . . . 10.0 112.115 169.605 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -77.34 -1.4 29.75 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.3 0.64 . . . . 10.0 110.987 178.305 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.37 20.41 69.42 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 120.584 -1.323 . . . . 10.0 110.178 175.672 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.37 105.5 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 128.529 2.732 . . . . 10.0 106.604 -177.327 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.652 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -98.88 125.13 44.21 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 168.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 p-10 -88.52 122.7 32.27 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 127.052 2.141 . . . . 10.0 109.045 175.283 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 96.6 t -107.72 134.25 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 174.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.6 m -158.13 66.56 0.46 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.607 1.163 . . . . 10.0 109.695 169.424 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.59 156.07 5.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.277 -1.379 . . . . 10.0 107.277 -177.605 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -133.42 139.95 47.04 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.893 1.277 . . . . 10.0 109.946 175.348 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -147.29 159.14 44.01 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.071 -1.455 . . . . 10.0 107.071 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.66 14.49 4.04 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.423 1.889 . . . . 10.0 111.857 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -89.44 1.69 7.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 119.19 0.905 . . . . 10.0 109.523 169.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.465 HD13 ' H ' ' B' ' 104' ' ' ILE 0.264 0.0 OUTLIER -129.08 171.28 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 126.313 1.845 . . . . 10.0 111.612 -179.328 . . . . . . . . 4 4 . 1 . 012 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 6.2 m -163.56 147.13 10.31 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 107.462 -1.31 . . . . 10.0 107.462 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -62.38 -48.22 80.71 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 123.303 0.641 . . . . 10.0 109.706 -176.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.4 t -139.4 174.47 10.48 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 125.347 1.459 . . . . 10.0 107.469 169.66 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 128.56 -101.37 0.55 Allowed Glycine 0 N--CA 1.45 -0.374 0 N-CA-C 107.919 -2.073 . . . . 10.0 107.919 -171.749 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -120.22 -51.13 2.22 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 125.765 1.626 . . . . 10.0 108.282 178.085 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -73.75 -31.35 63.29 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 115.033 -0.985 . . . . 10.0 108.713 -171.135 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 22.3 t 33.43 72.21 0.09 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 127.994 2.517 . . . . 10.0 115.809 167.391 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 29.7 pt -71.67 -15.11 18.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 114.048 1.129 . . . . 10.0 114.048 -178.239 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.5 mm -46.51 127.65 2.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 CA-C-N 119.051 0.841 . . . . 10.0 110.173 172.027 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.27 -0.11 83.22 Favored Glycine 0 CA--C 1.532 1.137 0 CA-C-O 118.969 -0.906 . . . . 10.0 114.583 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -76.22 175.41 9.05 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 119.243 1.521 . . . . 10.0 108.507 169.402 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -121.7 125.99 47.9 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.362 0.665 . . . . 10.0 111.002 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -80.93 139.98 35.55 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 170.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 98.9 t -124.72 132.49 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 108.025 -1.102 . . . . 10.0 108.025 171.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.443 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 3.7 p -98.78 125.81 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.189 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 168.005 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.515 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.0 m170 -102.11 161.0 14.02 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 122.954 1.359 . . . . 10.0 114.022 -176.583 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 121' ' ' GLU . . . . . 0.574 ' HA ' HD22 ' B' ' 144' ' ' LEU . 62.7 tt0 -46.79 -56.73 5.76 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 128.031 2.532 . . . . 10.0 109.288 176.319 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -124.49 177.03 6.13 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.655 1.582 . . . . 10.0 110.355 -173.26 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.21 145.38 35.58 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 125.615 1.566 . . . . 10.0 110.401 176.689 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.507 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.1 OUTLIER -85.38 157.39 20.53 Favored 'General case' 0 N--CA 1.457 -0.098 0 CA-C-O 121.392 0.615 . . . . 10.0 112.156 169.277 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -78.99 -11.31 60.0 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 115.078 -0.964 . . . . 10.0 111.278 174.118 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.412 HD11 ' CA ' ' B' ' 85' ' ' GLY . 3.8 mm? 52.93 57.04 6.76 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.887 1.275 . . . . 10.0 108.841 -174.202 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.93 -42.32 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 113.706 -1.588 . . . . 10.0 111.161 168.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.7 mtmt -80.53 42.57 0.61 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.684 0.794 . . . . 10.0 112.179 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -94.75 -20.04 30.03 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 127.922 2.677 . . . . 10.0 110.101 168.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.56 49.77 38.57 Favored Glycine 0 C--N 1.34 0.778 0 C-N-CA 124.314 0.959 . . . . 10.0 111.802 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -155.28 172.79 17.6 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 117.784 0.792 . . . . 10.0 108.875 176.787 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 8.6 tm-20 -52.19 -46.24 65.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 C-N-CA 123.351 0.66 . . . . 10.0 111.269 -177.015 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -70.06 -30.97 68.35 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.825 -0.607 . . . . 10.0 109.756 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.9 p -50.66 -41.36 55.43 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 119.287 0.949 . . . . 10.0 111.258 -177.706 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.7 t -86.91 -3.28 59.06 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 113.285 0.846 . . . . 10.0 113.285 -177.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 32.1 tttt -114.48 -57.26 2.29 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 127.424 2.29 . . . . 10.0 111.952 -166.45 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 6.1 p -132.31 7.19 4.21 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 118.453 -0.784 . . . . 10.0 111.041 168.184 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.23 -105.1 2.95 Favored Glycine 0 C--N 1.344 1.009 0 N-CA-C 108.91 -1.676 . . . . 10.0 108.91 -169.727 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.15 34.17 0.14 Allowed 'General case' 0 C--N 1.321 -0.65 0 O-C-N 121.095 -1.238 . . . . 10.0 108.342 177.453 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.63 -9.21 58.33 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.899 -1.046 . . . . 10.0 111.467 -169.827 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.31 -158.39 41.78 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 109.261 -1.535 . . . . 10.0 109.261 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.6 m -57.43 128.9 39.36 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-O 121.45 0.643 . . . . 10.0 109.822 -174.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.2 72.78 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 124.711 1.204 . . . . 10.0 111.132 169.463 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.574 HD22 ' HA ' ' B' ' 121' ' ' GLU . 10.0 tp -44.61 -38.0 3.99 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 128.036 2.535 . . . . 10.0 114.517 -174.303 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.443 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -162.32 158.98 24.9 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 178.515 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.8 165.29 36.63 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 122.471 -0.143 . . . . 10.0 110.906 -178.409 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.88 146.47 14.16 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 110.374 -1.091 . . . . 10.0 110.374 -172.118 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 64.4 t -100.46 138.76 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 N-CA-C 105.851 -1.907 . . . . 10.0 105.851 -174.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 38.5 mt -73.33 120.71 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 C-N-CA 122.524 0.33 . . . . 10.0 110.172 -173.325 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.56 134.35 10.85 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.095 1.331 . . . . 10.0 112.103 -172.482 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.71 137.0 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 125.604 1.562 . . . . 10.0 109.463 179.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.21 -48.15 1.1 Allowed 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 113.305 0.854 . . . . 10.0 113.305 -174.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 44.7 tt0 . . . . . 0 C--O 1.253 1.282 0 N-CA-C 108.782 -0.821 . . . . 10.0 108.782 -165.944 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 108.635 -0.876 . . . . 10.0 108.635 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.9 -6.77 55.44 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 118.52 0.6 . . . . 10.0 109.825 -174.728 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.93 156.66 42.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.028 0.531 . . . . 10.0 109.986 168.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.41 156.26 35.03 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 m -126.82 160.44 35.17 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 109.552 -0.536 . . . . 10.0 109.552 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.27 107.77 7.85 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 107.578 -1.268 . . . . 10.0 107.578 169.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.4 m -84.37 109.06 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 170.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mt -93.23 146.39 23.73 Favored 'General case' 0 C--O 1.224 -0.246 0 CA-C-O 117.97 -1.014 . . . . 10.0 108.434 -174.248 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.2 mtmt -164.78 158.93 18.04 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 120.081 1.31 . . . . 10.0 108.351 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.74 -51.05 0.1 OUTLIER Glycine 0 N--CA 1.461 0.365 0 C-N-CA 120.013 -1.089 . . . . 10.0 113.768 168.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -73.35 -44.17 59.27 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.975 -1.12 . . . . 10.0 107.975 -173.536 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.01 -71.44 0.35 Allowed Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 114.086 -1.416 . . . . 10.0 110.536 169.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -55.0 -39.91 88.55 Favored 'Trans proline' 0 N--CA 1.451 -1.028 0 C-N-CA 122.703 2.269 . . . . 10.0 110.72 172.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.739 HG13 HD12 ' A' ' 38' ' ' LEU . 97.7 t -58.52 112.91 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 C-N-CA 123.862 0.865 . . . . 10.0 109.83 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -131.0 109.23 10.37 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 122.752 0.421 . . . . 10.0 110.062 167.295 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.614 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -83.05 154.77 32.26 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.837 -0.905 . . . . 10.0 110.837 168.161 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.22 56.44 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 126.024 1.73 . . . . 10.0 106.858 -179.122 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.429 HD12 ' HA ' ' A' ' 18' ' ' ILE . 1.2 tp -67.25 145.46 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 O-C-N 121.473 -0.767 . . . . 10.0 109.494 -179.15 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -138.04 101.14 4.34 Favored 'General case' 0 CA--C 1.519 -0.22 0 C-N-CA 126.319 1.847 . . . . 10.0 109.429 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.441 ' CE1' ' HB ' ' A' ' 31' ' ' VAL . 15.7 m-30 -100.48 129.69 46.47 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.561 -1.274 . . . . 10.0 107.561 -177.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -129.38 152.22 49.18 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.574 0.749 . . . . 10.0 110.752 176.688 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -125.77 114.65 18.89 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.603 -1.629 . . . . 10.0 106.603 166.082 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 47.0 mmtt -61.34 -60.26 4.01 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 109.07 -0.715 . . . . 10.0 109.07 169.509 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -126.79 165.84 18.54 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.312 -2.107 . . . . 10.0 105.312 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.4 t -73.52 -10.96 60.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-O 121.516 0.674 . . . . 10.0 109.32 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.8 m120 -78.45 -19.65 52.7 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.194 0.998 . . . . 10.0 110.228 173.495 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.89 150.76 41.61 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.582 -1.007 . . . . 10.0 110.582 178.575 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -76.16 148.53 31.03 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 N-CA-C 106.078 -2.316 . . . . 10.0 106.078 166.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.6 t -75.22 100.13 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.9 mtpp -68.48 93.87 0.52 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 106.755 -1.572 . . . . 10.0 106.755 170.138 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.441 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 4.3 m -82.06 59.87 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 124.772 1.229 . . . . 10.0 108.853 -172.373 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -82.7 174.25 11.17 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 119.119 -1.032 . . . . 10.0 111.471 -168.506 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.11 -159.44 28.35 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.427 -1.469 . . . . 10.0 109.427 167.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 15.2 m -155.99 124.72 5.97 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 109.138 -0.69 . . . . 10.0 109.138 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.614 HG22 ' CA ' ' A' ' 16' ' ' GLY . 2.6 pt -93.1 143.5 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 106.505 -1.665 . . . . 10.0 106.505 165.792 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.16 119.1 17.37 Favored 'General case' 0 N--CA 1.45 -0.435 0 O-C-N 123.803 0.689 . . . . 10.0 110.91 171.314 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.27 14.24 1.81 Allowed Glycine 0 C--N 1.341 0.839 0 CA-C-O 118.849 -0.973 . . . . 10.0 114.967 168.37 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.739 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -97.03 179.49 4.92 Favored 'General case' 0 C--O 1.224 -0.269 0 CA-C-N 118.808 1.304 . . . . 10.0 108.397 174.245 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -75.55 174.26 9.93 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 119.6 -0.84 . . . . 10.0 110.885 170.481 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -63.85 177.29 0.77 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.078 1.751 . . . . 10.0 110.167 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.8 -174.35 40.89 Favored Glycine 0 N--CA 1.448 -0.55 0 O-C-N 121.32 -0.862 . . . . 10.0 112.987 167.323 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.08 147.77 49.59 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.672 1.189 . . . . 10.0 109.273 175.469 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -144.38 141.9 29.99 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 114.009 1.115 . . . . 10.0 114.009 -176.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.635 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -27.48 122.17 0.06 OUTLIER Glycine 0 C--N 1.343 0.925 0 C-N-CA 128.291 2.853 . . . . 10.0 114.0 166.427 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.75 107.06 3.13 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 119.575 1.687 . . . . 10.0 113.185 169.082 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.457 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -146.28 173.13 12.52 Favored 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 123.368 0.667 . . . . 10.0 110.903 178.505 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.0 t -89.97 -41.99 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 113.624 -1.625 . . . . 10.0 113.107 -168.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 61.29 157.56 0.04 OUTLIER 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 126.145 1.778 . . . . 10.0 114.24 -174.595 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -72.64 -64.89 0.87 Allowed 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 113.996 -1.456 . . . . 10.0 111.176 -177.536 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -77.79 149.76 34.4 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.025 0.441 . . . . 10.0 110.214 -173.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.18 -11.47 54.34 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.124 -1.591 . . . . 10.0 109.124 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.92 158.04 0.74 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.58 1.181 . . . . 10.0 111.992 171.601 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.534 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -151.17 28.78 0.66 Allowed 'General case' 0 N--CA 1.434 -1.262 0 CA-C-N 113.745 -1.571 . . . . 10.0 112.026 166.158 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.453 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.0 OUTLIER -59.12 -29.58 67.5 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 122.527 0.331 . . . . 10.0 110.425 173.643 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.56 -18.92 59.61 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 122.563 0.345 . . . . 10.0 111.302 176.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.42 82.08 0.27 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 110.923 -0.871 . . . . 10.0 110.923 -177.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m 33.56 58.18 0.53 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 127.499 2.32 . . . . 10.0 111.649 -177.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -136.06 -56.34 0.77 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 -170.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 t -126.3 43.78 3.01 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.015 -1.476 . . . . 10.0 107.015 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.82 65.15 1.34 Allowed 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 174.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.28 92.8 0.01 OUTLIER Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.816 1.198 . . . . 10.0 113.487 169.391 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -74.62 68.01 5.49 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 123.938 3.092 . . . . 10.0 113.374 -169.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.457 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 34.3 m170 65.34 77.13 0.31 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 128.52 2.728 . . . . 10.0 111.196 173.083 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -18.42 -60.72 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 128.504 2.722 . . . . 10.0 114.578 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.1 t30 4.49 86.55 0.04 OUTLIER Pre-proline 0 CA--C 1.54 0.577 0 C-N-CA 128.664 2.786 . . . . 10.0 114.676 -169.209 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -66.43 -35.9 28.9 Favored 'Trans proline' 0 N--CA 1.456 -0.701 0 C-N-CA 122.538 2.159 . . . . 10.0 111.551 -175.36 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.3 tt -74.25 66.74 1.32 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 108.181 -1.044 . . . . 10.0 108.181 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.7 t -31.86 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 127.467 2.307 . . . . 10.0 112.346 -174.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -131.06 170.0 15.11 Favored 'General case' 0 N--CA 1.444 -0.744 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -89.87 123.4 33.79 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 108.419 -0.956 . . . . 10.0 108.419 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 68.2 t60 -29.55 104.04 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 174.808 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.34 -170.33 12.68 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 108.503 -1.839 . . . . 10.0 108.503 176.036 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -135.08 -164.84 10.59 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-O 119.406 -0.664 . . . . 10.0 111.638 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -67.2 7.49 0.47 Allowed 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.042 1.828 . . . . 10.0 111.958 170.227 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -89.94 -29.27 18.61 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.787 -1.19 . . . . 10.0 107.787 169.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.67 177.69 4.57 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.396 1.079 . . . . 10.0 108.334 -168.238 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -110.99 -12.34 14.23 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.74 -1.118 . . . . 10.0 110.697 169.333 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -86.86 -0.67 56.87 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.051 0.94 . . . . 10.0 111.245 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -36.81 138.1 0.27 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 127.367 2.267 . . . . 10.0 112.217 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -82.13 60.86 5.11 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.073 -0.392 . . . . 10.0 110.05 -178.592 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.283 11.7 p 10.46 64.33 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 129.284 3.034 . . . . 10.0 114.507 -176.091 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.36 49.06 0.06 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 126.028 1.775 . . . . 10.0 109.583 -173.712 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -131.7 105.87 7.78 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 103.889 -2.634 . . . . 10.0 103.889 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -75.88 -13.32 60.26 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -166.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.37 -97.91 1.46 Allowed Glycine 0 C--O 1.219 -0.802 0 N-CA-C 108.006 -2.038 . . . . 10.0 108.006 -175.005 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -155.09 151.03 27.85 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 124.917 1.287 . . . . 10.0 108.599 -176.014 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.9 m -120.97 135.62 60.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 108.917 -0.771 . . . . 10.0 108.917 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -88.11 119.19 28.25 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 127.691 2.397 . . . . 10.0 110.594 -177.183 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.23 133.44 43.52 Favored 'General case' 0 CA--C 1.523 -0.095 0 C-N-CA 124.772 1.229 . . . . 10.0 111.064 176.008 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -61.02 169.57 1.93 Allowed 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.354 0.662 . . . . 10.0 110.146 168.243 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 -23.25 16.8 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.459 1.104 . . . . 10.0 112.898 170.055 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -17.69 60.8 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 110.29 -0.263 . . . . 10.0 110.29 177.215 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.8 13.89 66.14 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 110.524 -1.03 . . . . 10.0 110.524 -171.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.6 t -91.25 110.38 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.91 0 C-N-CA 126.973 2.109 . . . . 10.0 106.217 175.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.473 ' HB3' HG13 ' A' ' 35' ' ' ILE . . . -110.26 116.01 30.72 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 168.617 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -79.83 123.18 27.5 Favored 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 127.003 2.121 . . . . 10.0 108.09 171.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 29.6 t -108.41 129.06 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 106.86 -1.533 . . . . 10.0 106.86 178.39 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -155.97 64.09 0.58 Allowed 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.142 -1.058 . . . . 10.0 108.142 173.387 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 49.8 mt -102.13 153.47 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 N-CA-C 106.623 -1.621 . . . . 10.0 106.623 176.532 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -122.25 110.11 15.3 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.856 0.862 . . . . 10.0 110.75 176.246 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.23 129.18 37.25 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.212 1.005 . . . . 10.0 108.615 -177.722 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.2 t -119.05 44.83 2.23 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.134 0.974 . . . . 10.0 109.399 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -135.74 -43.09 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 124.05 0.94 . . . . 10.0 111.269 172.208 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.431 HD12 ' C ' ' A' ' 104' ' ' ILE 0.379 0.9 OUTLIER -87.46 161.01 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 CA-C-N 119.477 1.035 . . . . 10.0 111.956 169.948 . . . . . . . . 4 4 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.0 m -151.93 106.83 3.25 Favored 'General case' 0 C--N 1.341 0.214 0 C-N-CA 123.997 0.919 . . . . 10.0 109.413 -172.592 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 36.4 mt -37.79 -38.02 0.27 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.141 2.176 . . . . 10.0 115.326 -174.055 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 57.3 m -144.83 56.31 1.26 Allowed 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.229 -1.026 . . . . 10.0 108.229 170.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.32 -63.11 1.67 Allowed Glycine 0 C--N 1.335 0.483 0 N-CA-C 109.099 -1.6 . . . . 10.0 109.099 174.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -167.67 -53.38 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.434 1.894 . . . . 10.0 107.141 -178.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.61 -45.6 36.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.266 -1.334 . . . . 10.0 107.896 -173.537 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.0 t 53.77 173.64 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 125.844 1.658 . . . . 10.0 112.443 -175.495 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.7 pt -130.54 20.44 2.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 126.008 1.723 . . . . 10.0 108.961 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.9 mm -70.37 140.13 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.268 0.627 . . . . 10.0 109.593 169.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.37 32.42 84.12 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.298 0.952 . . . . 10.0 113.177 173.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -106.25 176.08 5.29 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.968 1.707 . . . . 10.0 107.919 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -124.52 108.52 12.2 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.285 -1.006 . . . . 10.0 108.285 -178.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.7 mp -80.75 138.18 36.29 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 107.36 -1.348 . . . . 10.0 107.36 177.621 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.406 HG12 ' CD2' ' A' ' 120' ' ' HIS . 64.5 t -117.62 129.59 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.975 0 N-CA-C 105.939 -1.875 . . . . 10.0 105.939 -178.357 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -99.35 110.35 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 102.851 -3.018 . . . . 10.0 102.851 169.455 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.635 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.4 m170 -91.41 156.66 17.57 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 122.591 1.186 . . . . 10.0 113.492 -170.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.59 -52.92 20.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 126.688 1.995 . . . . 10.0 109.957 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -110.1 170.85 7.81 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 124.183 0.993 . . . . 10.0 112.306 -172.634 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.22 140.9 57.44 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 114.113 -1.403 . . . . 10.0 109.3 173.089 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.522 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 0.0 OUTLIER -76.86 125.41 29.25 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 107.483 -1.302 . . . . 10.0 107.483 176.53 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -76.0 -9.74 58.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.761 0.425 . . . . 10.0 111.13 -177.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.6 mt 48.24 38.72 10.65 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.007 0.908 . . . . 10.0 109.924 -176.22 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.28 -15.29 63.6 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.707 1.622 . . . . 10.0 112.554 172.557 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ptpt -75.7 3.08 10.42 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.239 1.519 . . . . 10.0 112.716 -171.076 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.56 -22.13 76.48 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 169.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.1 35.9 50.49 Favored Glycine 0 CA--C 1.526 0.765 0 C-N-CA 123.89 0.757 . . . . 10.0 112.487 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -136.84 173.72 11.39 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 122.1 0.953 . . . . 10.0 110.058 175.313 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.6 tm-20 -46.08 -51.98 12.83 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.996 1.719 . . . . 10.0 111.221 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -73.05 -37.14 66.96 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.743 -0.598 . . . . 10.0 110.75 179.463 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -48.84 -43.5 38.67 Favored 'General case' 0 C--N 1.344 0.357 0 O-C-N 121.357 -0.84 . . . . 10.0 110.272 175.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -81.38 -5.3 57.73 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 119.147 -0.454 . . . . 10.0 111.65 -169.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.6 mtmt -114.15 -76.8 0.58 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.593 1.557 . . . . 10.0 110.726 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . 0.26 17.2 p -104.2 12.99 33.13 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 120.157 1.344 . . . . 10.0 113.042 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 28.9 69.12 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 119.351 0.978 . . . . 10.0 113.243 169.569 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 35.2 m120 49.57 21.25 0.59 Allowed 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 118.203 1.002 . . . . 10.0 113.003 -176.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 120' ' ' HIS . . . -70.75 -6.34 36.82 Favored 'General case' 0 C--O 1.221 -0.43 0 O-C-N 121.491 -0.756 . . . . 10.0 111.542 -171.348 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.45 162.71 15.05 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 109.919 -1.272 . . . . 10.0 109.919 174.431 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.6 t -81.41 58.78 3.76 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.688 0.795 . . . . 10.0 111.094 -169.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 45.72 58.81 4.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.311 1.445 . . . . 10.0 112.941 169.571 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.43 HD13 ' N ' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -69.15 -10.48 57.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 113.601 0.963 . . . . 10.0 113.601 -169.818 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.44 ' HB3' HG11 ' A' ' 14' ' ' VAL . . . -164.98 143.27 6.41 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.226 1.01 . . . . 10.0 108.584 172.609 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -157.01 166.3 33.72 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 122.83 0.452 . . . . 10.0 110.016 -172.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.53 158.25 29.7 Favored Glycine 0 C--N 1.332 0.34 0 N-CA-C 109.207 -1.557 . . . . 10.0 109.207 -178.452 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 30.5 t -105.91 137.5 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 106.823 -1.547 . . . . 10.0 106.823 -167.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.3 mt -75.85 125.35 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 118.161 0.437 . . . . 10.0 110.607 -176.652 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.06 149.52 18.13 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.59 1.09 . . . . 10.0 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.1 mt -56.35 137.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 124.305 1.042 . . . . 10.0 109.594 176.072 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.81 165.69 19.64 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 107.505 -1.295 . . . . 10.0 107.505 167.387 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 . . . . . 0 C--O 1.251 1.165 0 C-N-CA 124.997 1.319 . . . . 10.0 107.59 167.731 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 107.162 -1.421 . . . . 10.0 107.162 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.6 t -77.2 -48.52 17.39 Favored 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 119.137 0.88 . . . . 10.0 109.168 174.11 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.66 121.87 40.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 126.109 1.763 . . . . 10.0 107.441 -170.137 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -127.61 159.57 34.27 Favored 'General case' 0 CA--C 1.519 -0.249 0 C-N-CA 124.526 1.13 . . . . 10.0 109.239 177.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.1 t -117.41 156.15 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 123.761 0.824 . . . . 10.0 109.726 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.47 112.14 9.4 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.595 1.558 . . . . 10.0 108.514 169.148 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.534 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.7 OUTLIER -94.11 106.11 17.68 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 C-N-CA 122.857 0.463 . . . . 10.0 110.845 171.443 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.657 HD21 ' HB2' ' B' ' 117' ' ' LEU . 11.2 mt -86.82 127.67 35.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.396 1.079 . . . . 10.0 110.015 177.264 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -147.55 162.47 39.02 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.469 -1.308 . . . . 10.0 107.469 169.326 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.73 -53.71 0.08 OUTLIER Glycine 0 N--CA 1.461 0.303 0 C-N-CA 120.664 -0.779 . . . . 10.0 113.521 169.198 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -72.26 -44.04 63.43 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.461 -1.311 . . . . 10.0 107.461 -174.328 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.51 -70.88 0.4 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.149 -1.387 . . . . 10.0 110.073 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -57.34 -34.54 98.06 Favored 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 123.436 2.757 . . . . 10.0 111.366 172.078 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 73.8 t -64.58 109.78 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 108.386 -0.968 . . . . 10.0 108.386 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -129.03 118.21 22.17 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.33 1.052 . . . . 10.0 108.376 169.461 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.581 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -108.02 140.05 15.31 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 124.166 0.889 . . . . 10.0 111.373 173.113 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.453 ' CG2' HG22 ' A' ' 54' ' ' THR . 9.4 mt -137.03 72.41 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 N-CA-C 106.4 -1.704 . . . . 10.0 106.4 -169.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mm -95.55 138.55 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 115.749 -0.659 . . . . 10.0 109.74 -170.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -114.48 117.89 32.26 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.139 1.775 . . . . 10.0 108.338 -179.289 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -102.51 107.45 18.42 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.872 -1.159 . . . . 10.0 107.872 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -108.12 122.49 47.0 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 114.949 1.463 . . . . 10.0 114.949 173.568 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -82.52 115.61 21.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 101.715 -3.439 . . . . 10.0 101.715 162.637 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mtpm? -62.26 -40.98 98.0 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.979 -0.378 . . . . 10.0 109.979 -178.644 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 65.0 mt-10 -137.26 -145.06 0.2 Allowed 'General case' 0 N--CA 1.428 -1.558 0 N-CA-C 105.79 -1.93 . . . . 10.0 105.79 -170.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 25.8 t -103.39 -19.91 14.26 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 110.207 -0.294 . . . . 10.0 110.207 168.182 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 67.7 m-20 -129.1 11.64 6.01 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.07 0.948 . . . . 10.0 110.791 -174.648 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.12 166.76 51.89 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.93 -1.668 . . . . 10.0 108.93 175.368 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -68.28 145.05 64.66 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 N-CA-C 108.131 -1.527 . . . . 10.0 108.131 169.347 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.78 108.67 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 N-CA-C 104.966 -2.235 . . . . 10.0 104.966 169.464 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.7 mtpp -90.2 113.56 25.37 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 169.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -101.64 111.26 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 106.977 -1.49 . . . . 10.0 106.977 179.101 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.1 p90 -126.38 167.63 15.28 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.323 0.582 . . . . 10.0 112.069 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.64 -151.37 23.12 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 107.159 -2.377 . . . . 10.0 107.159 169.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 33.5 t -155.18 158.72 39.38 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 120.222 -0.591 . . . . 10.0 110.222 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.581 HG22 ' CA ' ' B' ' 16' ' ' GLY . 1.5 pt -117.14 136.74 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 114.866 -1.061 . . . . 10.0 108.816 167.701 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 27.5 tptt -108.83 146.44 33.67 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 105.938 -1.875 . . . . 10.0 105.938 170.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.56 -7.07 39.07 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.421 -0.655 . . . . 10.0 113.71 169.524 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.07 175.04 2.22 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 118.348 1.074 . . . . 10.0 110.079 173.486 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -104.55 167.08 9.97 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 105.693 -1.965 . . . . 10.0 105.693 165.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 7.9 tm-20 -54.88 163.6 0.96 Allowed 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.904 0.881 . . . . 10.0 112.103 -169.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.36 -168.68 46.62 Favored Glycine 0 N--CA 1.445 -0.731 0 CA-C-O 122.012 0.785 . . . . 10.0 112.831 167.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -74.5 143.4 44.6 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.471 1.908 . . . . 10.0 110.606 -173.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -147.07 143.41 28.31 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 124.319 1.048 . . . . 10.0 112.27 -177.153 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.564 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -33.43 128.32 0.39 Allowed Glycine 0 C--N 1.339 0.73 0 C-N-CA 127.669 2.557 . . . . 10.0 112.351 168.279 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -149.74 110.86 4.38 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.09 -1.078 . . . . 10.0 108.09 166.74 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.04 170.82 16.93 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.437 0.637 . . . . 10.0 112.589 175.491 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 t -91.89 146.11 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 CA-C-N 112.143 -2.299 . . . . 10.0 106.966 169.176 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -129.41 147.1 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.29 1.436 . . . . 10.0 107.586 176.27 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.28 -68.06 0.22 Allowed 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.013 0.925 . . . . 10.0 110.6 -172.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -77.63 132.23 38.15 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.914 -1.143 . . . . 10.0 107.914 -169.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.07 -24.94 76.21 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 172.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.29 162.16 0.36 Allowed 'General case' 0 N--CA 1.447 -0.597 0 CA-C-O 123.031 1.396 . . . . 10.0 113.044 177.718 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.71 30.08 0.47 Allowed 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 114.185 -1.37 . . . . 10.0 111.759 172.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.4 -37.57 72.92 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.288 1.035 . . . . 10.0 112.535 -168.779 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.14 -21.17 54.53 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.014 0.525 . . . . 10.0 111.687 176.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.59 -155.83 16.06 Favored Glycine 0 N--CA 1.435 -1.372 0 N-CA-C 106.189 -2.765 . . . . 10.0 106.189 -166.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.43 54.33 0.44 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 127.214 2.206 . . . . 10.0 113.461 -168.469 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -161.24 -39.35 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 O-C-N 120.79 -1.194 . . . . 10.0 111.82 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 9.5 t -50.71 -30.28 13.43 Favored 'General case' 0 C--N 1.343 0.319 0 C-N-CA 124.307 1.043 . . . . 10.0 111.137 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.27 -36.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 127.247 2.219 . . . . 10.0 114.194 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.17 143.31 10.98 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 110.694 -0.962 . . . . 10.0 110.694 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -77.06 58.6 6.22 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 124.425 3.417 . . . . 10.0 112.882 -175.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.421 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 17.5 m170 61.0 48.85 6.16 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.738 2.415 . . . . 10.0 109.854 177.059 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -69.7 74.65 0.42 Allowed 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.931 0.872 . . . . 10.0 111.046 178.248 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -74.99 150.8 86.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 O-C-N 121.343 -0.848 . . . . 10.0 110.832 171.486 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -67.12 -45.11 4.21 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.631 2.221 . . . . 10.0 111.159 178.542 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.96 57.29 1.05 Allowed 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.53 0.732 . . . . 10.0 110.038 178.446 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 39.5 p -42.48 108.73 0.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.629 1.572 . . . . 10.0 110.935 -172.812 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 58.7 mtt180 -148.6 -172.08 4.01 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.792 -2.299 . . . . 10.0 104.792 -171.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -83.98 146.38 28.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 118.42 -1.312 . . . . 10.0 107.6 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -50.81 119.74 4.16 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 166.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.87 -134.66 4.34 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 108.103 -1.999 . . . . 10.0 108.103 177.051 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.53 -161.36 32.03 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 107.537 -2.225 . . . . 10.0 107.537 169.395 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -66.02 5.02 0.72 Allowed 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.519 1.479 . . . . 10.0 111.053 168.062 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.8 mtpm? -114.99 8.23 15.75 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.591 1.156 . . . . 10.0 111.412 172.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -126.04 169.16 13.03 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.018 -1.105 . . . . 10.0 108.018 165.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -89.45 -24.8 21.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.724 -0.843 . . . . 10.0 108.724 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -105.48 13.48 30.08 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 115.363 1.616 . . . . 10.0 115.363 -165.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -28.1 130.73 0.05 Allowed 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 127.547 2.339 . . . . 10.0 111.866 168.687 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -47.08 -68.38 0.2 Allowed 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.115 0.966 . . . . 10.0 110.83 -175.087 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.0 p -168.18 -50.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.193 0 N-CA-C 107.456 -1.313 . . . . 10.0 107.456 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.32 53.3 0.68 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.907 1.241 . . . . 10.0 110.504 179.279 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -91.84 92.91 8.58 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 105.817 -1.92 . . . . 10.0 105.817 169.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -73.67 -37.26 65.32 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.308 -1.738 . . . . 10.0 106.308 174.643 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.83 -104.28 2.73 Favored Glycine 0 N--CA 1.436 -1.328 0 N-CA-C 108.433 -1.867 . . . . 10.0 108.433 169.349 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -114.48 131.62 56.56 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.239 0.616 . . . . 10.0 110.191 -169.201 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -115.2 139.34 42.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 107.756 -1.202 . . . . 10.0 107.756 167.589 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -100.53 123.05 44.23 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 125.017 1.327 . . . . 10.0 110.244 -173.815 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.08 135.1 43.09 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 124.17 0.988 . . . . 10.0 110.514 179.331 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -58.99 168.8 1.18 Allowed 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.593 0.757 . . . . 10.0 110.213 167.637 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -50.58 -34.02 24.2 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.812 0.845 . . . . 10.0 110.767 169.859 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.0 t0 -79.37 0.71 28.03 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 120.859 0.361 . . . . 10.0 111.761 -178.197 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.25 13.83 82.36 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 120.733 -1.229 . . . . 10.0 110.695 177.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 45.2 t -89.73 103.33 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 C-N-CA 127.039 2.136 . . . . 10.0 106.29 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.548 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.66 120.92 41.1 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 168.23 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -81.45 117.64 22.05 Favored 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 126.479 1.911 . . . . 10.0 108.494 172.372 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 67.8 t -98.9 129.14 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.081 0 N-CA-C 106.553 -1.647 . . . . 10.0 106.553 175.016 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.8 p -157.91 68.29 0.5 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.678 0.791 . . . . 10.0 109.326 170.539 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.13 160.27 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.274 -1.75 . . . . 10.0 106.274 -177.523 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -135.7 148.01 48.72 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 121.755 -0.591 . . . . 10.0 111.055 169.678 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -133.14 160.98 35.65 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 125.408 1.483 . . . . 10.0 108.506 179.015 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.5 t -134.64 41.61 2.89 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.116 1.366 . . . . 10.0 111.933 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.8 p -132.43 -45.04 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 123.352 0.661 . . . . 10.0 110.315 167.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.06 154.16 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 121.843 0.83 . . . . 10.0 109.762 169.403 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.8 m -154.01 152.87 31.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.533 1.133 . . . . 10.0 108.458 168.477 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.87 -25.43 62.8 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.013 0.925 . . . . 10.0 110.137 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 16.2 t -131.6 179.91 5.77 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.456 1.102 . . . . 10.0 108.122 169.218 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.95 -71.47 0.48 Allowed Glycine 0 C--N 1.332 0.349 0 C-N-CA 124.873 1.225 . . . . 10.0 110.227 170.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -158.27 -52.22 0.07 Allowed 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 126.5 1.92 . . . . 10.0 106.72 -176.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -74.3 -32.28 62.81 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 114.277 -1.329 . . . . 10.0 108.995 -174.009 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t 25.2 76.28 0.02 OUTLIER 'General case' 0 C--N 1.344 0.338 0 C-N-CA 128.191 2.596 . . . . 10.0 112.67 169.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 27.1 pt -63.17 -10.59 6.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 N-CA-C 113.984 1.105 . . . . 10.0 113.984 -169.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.7 mm -34.51 -45.71 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.271 0 C-N-CA 126.741 2.016 . . . . 10.0 114.833 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.78 14.43 57.53 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.363 0.982 . . . . 10.0 113.629 -173.447 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -90.68 175.89 6.86 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.688 1.195 . . . . 10.0 110.497 178.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -122.19 142.28 50.58 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 124.419 1.088 . . . . 10.0 109.747 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.657 ' HB2' HD21 ' B' ' 8' ' ' LEU . 1.7 mm? -101.5 154.96 18.37 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.248 -1.39 . . . . 10.0 107.248 168.032 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.11 137.54 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.064 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.465 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.5 OUTLIER -106.2 138.22 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.269 -2.123 . . . . 10.0 105.269 168.586 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.564 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.0 m170 -117.83 160.33 21.57 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 114.763 1.394 . . . . 10.0 114.763 -169.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 68.1 tt0 -45.19 -53.72 7.84 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.597 2.759 . . . . 10.0 109.949 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.5 mttt -124.52 175.35 7.21 Favored 'General case' 0 CA--C 1.518 -0.27 0 C-N-CA 125.286 1.434 . . . . 10.0 110.273 -170.085 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.28 139.03 35.67 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.513 0.725 . . . . 10.0 109.168 175.036 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -78.12 148.1 34.33 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 123.326 0.65 . . . . 10.0 110.484 169.703 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -78.1 10.12 3.18 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 124.986 1.314 . . . . 10.0 111.196 174.493 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 16.5 mt 46.16 41.27 8.4 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.223 1.409 . . . . 10.0 110.829 -179.073 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 104.59 -39.76 2.71 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 125.233 1.397 . . . . 10.0 112.538 177.615 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.5 ' H ' ' HD3' ' B' ' 128' ' ' LYS . 0.1 OUTLIER -79.9 37.34 0.36 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.176 1.39 . . . . 10.0 111.769 -167.64 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -95.57 -12.07 54.35 Favored Glycine 0 CA--C 1.523 0.564 0 C-N-CA 125.568 1.556 . . . . 10.0 111.671 177.469 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.99 38.18 23.88 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 123.892 0.758 . . . . 10.0 111.779 -175.369 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -124.75 155.58 39.09 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.3 tm-20 -52.58 -44.24 65.79 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 114.123 -1.399 . . . . 10.0 108.353 169.203 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -65.05 -40.01 94.11 Favored 'General case' 0 CA--C 1.541 0.606 0 O-C-N 121.608 -0.683 . . . . 10.0 112.049 171.056 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 9.1 p -57.2 -40.67 77.91 Favored 'General case' 0 C--N 1.347 0.467 0 CA-C-N 121.141 1.791 . . . . 10.0 111.249 -179.281 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.1 t -72.97 -18.27 61.38 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 119.953 -0.699 . . . . 10.0 112.515 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -103.74 -50.65 3.36 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.14 1.776 . . . . 10.0 112.799 -168.345 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.421 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 24.1 p -120.92 -10.92 9.02 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 118.584 -0.722 . . . . 10.0 112.896 171.888 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 92.94 -1.57 71.0 Favored Glycine 0 C--N 1.337 0.636 0 CA-C-O 118.784 -1.009 . . . . 10.0 112.388 -172.13 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 71.12 31.76 2.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.596 1.198 . . . . 10.0 111.297 177.388 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.11 6.32 2.24 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.43 1.092 . . . . 10.0 112.209 174.327 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.87 -162.38 53.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.279 -1.128 . . . . 10.0 110.279 172.045 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.3 m -56.83 129.16 40.2 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-O 121.571 0.7 . . . . 10.0 111.388 -168.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.62 73.73 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.881 1.273 . . . . 10.0 109.259 169.751 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -74.09 -12.71 60.68 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 113.79 1.033 . . . . 10.0 113.79 -169.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.465 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -160.98 144.45 13.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.09 0.471 . . . . 10.0 111.795 175.261 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -138.28 151.43 47.6 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 126.507 1.923 . . . . 10.0 108.327 -169.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 147' ' ' GLY . . . . . 0.521 ' N ' HD23 ' B' ' 8' ' ' LEU . . . -153.36 142.28 9.07 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 179.391 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.3 t -102.87 137.12 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 105.672 -1.973 . . . . 10.0 105.672 -175.818 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.524 HD11 HD21 ' B' ' 117' ' ' LEU . 5.5 mt -72.19 158.06 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 108.939 -0.763 . . . . 10.0 108.939 -179.144 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -166.97 154.84 25.55 Favored Glycine 0 CA--C 1.528 0.888 0 O-C-N 122.007 -0.433 . . . . 10.0 112.247 -173.237 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 92.1 mt -68.19 131.41 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 124.882 1.273 . . . . 10.0 109.432 -174.392 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.81 -12.24 1.13 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 115.993 1.849 . . . . 10.0 115.993 -173.159 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.274 0.0 OUTLIER . . . . . 0 C--O 1.254 1.3 0 C-N-CA 128.774 2.83 . . . . 10.0 116.471 -170.171 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.829 0 N-CA-C 108.03 -1.1 . . . . 10.0 108.03 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -155.99 -43.73 0.08 Allowed 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.525 0.602 . . . . 10.0 111.247 171.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -118.79 130.49 55.81 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 169.076 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.89 163.24 26.78 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.751 1.221 . . . . 10.0 108.422 176.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.498 ' CG1' ' HB2' ' B' ' 52' ' ' ASP . 2.0 m -143.24 163.71 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 118.235 0.471 . . . . 10.0 109.873 -177.765 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.5 110.43 6.83 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.707 1.254 . . . . 10.0 108.048 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.445 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.3 OUTLIER -82.61 119.88 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 N-CA-C 106.445 -1.687 . . . . 10.0 106.445 167.427 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.5 mt -98.52 135.51 39.97 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -157.54 159.72 37.45 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 120.564 1.529 . . . . 10.0 108.217 172.101 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 173.54 -40.32 0.14 Allowed Glycine 0 N--CA 1.461 0.304 0 C-N-CA 119.858 -1.163 . . . . 10.0 113.312 169.628 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -73.96 -47.3 38.44 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 107.589 -1.264 . . . . 10.0 107.589 -177.392 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.65 -73.08 0.31 Allowed Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.691 -1.364 . . . . 10.0 109.691 170.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -58.6 -39.6 81.35 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 123.126 2.551 . . . . 10.0 111.119 173.017 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.49 101.8 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 107.808 -1.182 . . . . 10.0 107.808 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -118.4 108.08 14.61 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 108.116 -1.068 . . . . 10.0 108.116 170.79 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.684 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -84.92 147.04 22.45 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 123.995 0.807 . . . . 10.0 111.556 169.008 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mt -140.72 82.2 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 N-CA-C 105.946 -1.872 . . . . 10.0 105.946 177.013 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.0 mm -89.92 138.96 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 C-N-CA 124.002 0.921 . . . . 10.0 108.956 177.161 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -130.47 126.65 37.46 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 125.693 1.597 . . . . 10.0 109.552 175.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -109.87 105.21 14.31 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.267 1.427 . . . . 10.0 109.368 177.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -86.26 134.32 33.77 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 120.034 -0.666 . . . . 10.0 110.81 167.066 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -135.07 82.84 1.98 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.642 2.377 . . . . 10.0 106.136 168.074 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.4 tttp -53.01 -51.03 62.97 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 125.793 1.637 . . . . 10.0 109.454 179.404 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 58.8 mt-10 -135.95 169.17 18.02 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 105.932 -1.877 . . . . 10.0 105.932 169.279 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.2 p -72.41 -10.0 59.24 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.992 -0.374 . . . . 10.0 109.992 170.098 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.5 m-80 -75.41 -24.79 57.17 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.519 -0.549 . . . . 10.0 109.519 170.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.33 129.0 9.3 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.29 -1.124 . . . . 10.0 110.29 -173.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -63.2 131.06 30.8 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 N-CA-C 105.957 -2.363 . . . . 10.0 105.957 168.615 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.2 t -78.0 107.88 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.154 -1.054 . . . . 10.0 108.154 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.62 96.39 3.55 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 170.347 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -83.6 106.61 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 N-CA-C 106.494 -1.669 . . . . 10.0 106.494 170.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.1 p90 -113.91 171.12 7.79 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.47 0.653 . . . . 10.0 109.901 172.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.94 170.11 41.09 Favored Glycine 0 N--CA 1.437 -1.256 0 C-N-CA 120.088 -1.053 . . . . 10.0 110.564 174.119 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.3 p -137.98 107.97 6.36 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.486 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.684 HG22 ' CA ' ' A' ' 16' ' ' GLY . 1.7 pt -90.8 145.22 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 167.383 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -140.05 147.58 40.54 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.37 -1.344 . . . . 10.0 107.37 175.569 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.25 -14.13 25.81 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.287 -0.729 . . . . 10.0 114.108 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.442 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.6 mp -74.27 179.48 4.49 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 118.692 1.246 . . . . 10.0 110.475 -179.763 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -95.97 169.02 10.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 165.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -58.21 168.29 1.09 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.981 1.312 . . . . 10.0 111.532 -172.46 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.93 -176.61 36.31 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-O 122.039 0.8 . . . . 10.0 112.671 167.349 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.65 142.49 51.6 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 124.539 1.136 . . . . 10.0 109.681 177.158 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -142.05 150.42 41.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 112.896 0.702 . . . . 10.0 112.896 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.613 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.78 123.85 1.21 Allowed Glycine 0 C--N 1.34 0.786 0 C-N-CA 127.382 2.42 . . . . 10.0 112.061 166.227 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -151.88 108.5 3.47 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 118.563 1.181 . . . . 10.0 108.997 168.558 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 174.59 12.21 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 120.876 0.37 . . . . 10.0 111.354 177.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 11.1 m -104.77 -18.38 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 O-C-N 125.658 1.849 . . . . 10.0 114.676 -168.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 57.29 175.76 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 125.322 1.449 . . . . 10.0 112.861 -177.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -72.62 -69.45 0.41 Allowed 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.561 -0.745 . . . . 10.0 109.855 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -92.02 176.92 6.33 Favored 'General case' 0 N--CA 1.454 -0.256 0 O-C-N 123.534 0.521 . . . . 10.0 111.279 -168.668 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.12 -22.75 11.36 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 125.477 1.513 . . . . 10.0 111.556 170.048 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -50.81 117.9 2.79 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-O 122.343 1.068 . . . . 10.0 111.935 -177.252 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -123.14 17.84 9.96 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.988 -1.006 . . . . 10.0 111.552 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -48.42 -41.77 30.2 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.176 1.79 . . . . 10.0 111.562 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.11 -21.62 46.38 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.225 1.01 . . . . 10.0 112.763 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.0 102.31 0.92 Allowed Glycine 0 CA--C 1.527 0.825 0 N-CA-C 108.392 -1.883 . . . . 10.0 108.392 -169.331 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.276 1.5 p 15.75 80.42 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 127.031 2.132 . . . . 10.0 113.819 -173.391 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -161.38 -54.99 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 107.541 -1.281 . . . . 10.0 107.541 179.047 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -65.59 -31.38 72.38 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 123.8 0.84 . . . . 10.0 110.99 -177.624 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.97 -6.76 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 129.024 2.93 . . . . 10.0 118.012 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.36 123.26 3.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.212 -1.155 . . . . 10.0 110.212 176.183 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.7 60.49 6.67 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.582 2.855 . . . . 10.0 110.765 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.7 m170 72.12 38.28 0.9 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 129.716 3.206 . . . . 10.0 112.584 172.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -74.53 67.94 1.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.386 0.994 . . . . 10.0 111.671 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.7 p-10 -58.97 154.71 36.92 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 123.947 0.899 . . . . 10.0 111.108 169.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.36 -46.15 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 122.656 2.238 . . . . 10.0 111.602 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 86.8 mt -75.53 59.79 1.15 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.266 0.627 . . . . 10.0 109.696 176.134 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -45.95 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.771 1.628 . . . . 10.0 111.558 -171.2 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -132.21 -176.54 4.11 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 107.237 -1.394 . . . . 10.0 107.237 -176.363 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.412 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 24.2 mttp -93.78 123.74 37.33 Favored 'General case' 0 N--CA 1.438 -1.068 0 C-N-CA 118.224 -1.39 . . . . 10.0 108.622 -169.512 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.432 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 85.9 t60 -35.2 112.53 0.16 Allowed 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 113.316 0.858 . . . . 10.0 113.316 178.659 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.03 -136.98 4.33 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 108.058 -2.017 . . . . 10.0 108.058 -178.519 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.06 -168.77 30.66 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 173.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -63.26 -2.8 4.25 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.025 1.817 . . . . 10.0 111.603 168.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -94.97 -19.92 19.81 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.265 1.026 . . . . 10.0 110.746 173.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -103.11 167.58 9.73 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -86.49 -31.99 21.02 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 107.322 -1.362 . . . . 10.0 107.322 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.412 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS 0.257 7.1 pt-20 -100.49 24.55 8.78 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 114.435 1.272 . . . . 10.0 114.435 -165.525 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.5 ptm180 -42.83 145.3 0.48 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 127.218 2.207 . . . . 10.0 110.346 168.261 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.432 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 30.9 m170 -67.61 -64.58 0.83 Allowed 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.52 0.676 . . . . 10.0 109.66 178.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.62 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.5 p -169.33 -91.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 105.472 -2.048 . . . . 10.0 105.472 173.358 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.62 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -80.51 56.32 4.7 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 111.04 -0.824 . . . . 10.0 111.04 174.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -90.9 83.16 5.64 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 103.342 -2.836 . . . . 10.0 103.342 166.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -65.26 -26.45 68.1 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 118.391 0.541 . . . . 10.0 109.821 -173.001 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 114.41 -89.08 0.5 Allowed Glycine 0 N--CA 1.44 -1.044 0 N-CA-C 108.082 -2.007 . . . . 10.0 108.082 169.428 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -155.52 124.82 6.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 -171.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.39 125.89 66.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 118.193 0.452 . . . . 10.0 110.84 178.506 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -78.82 112.01 15.54 Favored 'General case' 0 N--CA 1.444 -0.761 0 C-N-CA 127.554 2.341 . . . . 10.0 111.116 -177.612 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.74 134.79 34.16 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.863 0.465 . . . . 10.0 109.938 171.611 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -60.1 172.27 0.83 Allowed 'General case' 0 C--O 1.232 0.154 0 O-C-N 123.82 0.7 . . . . 10.0 109.441 168.36 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.5 pttm -48.67 -33.2 9.59 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.745 1.618 . . . . 10.0 109.793 173.176 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -79.1 -8.19 58.77 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 124.486 1.115 . . . . 10.0 110.812 -173.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.02 -0.26 86.01 Favored Glycine 0 C--N 1.338 0.678 0 N-CA-C 111.234 -0.746 . . . . 10.0 111.234 -174.247 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.5 t -78.43 105.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 106.776 -1.564 . . . . 10.0 106.776 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.53 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -106.23 117.47 34.12 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 169.695 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -80.37 118.05 21.67 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 127.123 2.169 . . . . 10.0 108.892 172.481 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.2 t -108.32 131.0 59.98 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.964 0 N-CA-C 106.862 -1.532 . . . . 10.0 106.862 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.2 p -157.36 86.81 0.95 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.455 0.702 . . . . 10.0 109.49 171.446 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.99 143.09 28.11 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 N-CA-C 107.991 -1.115 . . . . 10.0 107.991 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -111.61 129.5 56.06 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.816 -1.92 . . . . 10.0 105.816 167.069 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -140.54 117.69 11.26 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.042 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.5 p -87.15 49.42 1.81 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.891 1.676 . . . . 10.0 108.256 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 p -145.24 -51.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.478 -0.783 . . . . 10.0 109.433 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -51.11 132.36 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 122.926 0.49 . . . . 10.0 110.016 175.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.9 p -131.92 136.12 47.14 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.214 1.406 . . . . 10.0 108.551 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 50.1 mt -56.63 -42.69 79.3 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 169.445 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.8 t -146.07 128.88 16.3 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 149.54 69.4 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.771 -1.332 . . . . 10.0 109.771 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.7 t70 72.41 -60.25 0.53 Allowed 'General case' 0 CA--C 1.509 -0.633 0 C-N-CA 129.742 3.217 . . . . 10.0 109.482 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.7 m-70 -74.19 -44.71 52.3 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t 54.96 82.05 0.1 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.051 1.34 . . . . 10.0 111.714 173.259 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.5 pt -71.65 -18.16 19.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 O-C-N 120.999 -1.063 . . . . 10.0 112.699 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 16.2 mm -52.65 129.89 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 118.202 0.456 . . . . 10.0 110.156 172.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.58 22.57 77.06 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.684 -1.064 . . . . 10.0 113.644 175.699 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.9 mtt85 -89.08 175.75 7.26 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 118.235 1.018 . . . . 10.0 110.602 167.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -118.47 110.63 17.64 Favored 'General case' 0 C--N 1.347 0.486 0 N-CA-C 106.844 -1.539 . . . . 10.0 106.844 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mp -87.18 138.88 31.11 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.548 -0.908 . . . . 10.0 108.548 176.313 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 49.1 t -132.04 132.34 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.615 -1.254 . . . . 10.0 107.615 -173.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.487 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.5 OUTLIER -105.67 128.11 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 106.081 -1.822 . . . . 10.0 106.081 174.806 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.613 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.6 m170 -111.78 157.55 20.42 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 114.554 1.316 . . . . 10.0 114.554 -171.434 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -46.64 -59.52 2.97 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 127.572 2.349 . . . . 10.0 110.488 176.395 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 51.3 mttp -112.21 169.86 8.57 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.702 0.763 . . . . 10.0 112.042 -170.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.5 151.08 47.95 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 114.034 -1.439 . . . . 10.0 109.291 172.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -77.03 150.04 35.81 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 122.296 1.046 . . . . 10.0 110.944 172.649 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.476 ' HB3' ' CA ' ' A' ' 138' ' ' GLY . 4.4 t70 -79.04 -37.75 38.26 Favored 'General case' 0 N--CA 1.443 -0.824 0 C-N-CA 130.103 3.361 . . . . 10.0 110.596 172.853 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 48.5 mt 63.53 46.53 4.2 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.924 1.29 . . . . 10.0 111.656 178.423 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 79.64 10.24 86.0 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-N 115.23 -0.895 . . . . 10.0 114.703 167.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 26.8 mttm -97.06 -11.81 23.98 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 117.999 0.899 . . . . 10.0 112.18 -174.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.98 -21.45 69.68 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 125.124 1.345 . . . . 10.0 112.384 176.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.08 35.75 65.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.247 -0.741 . . . . 10.0 111.247 -177.215 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -129.89 169.94 14.56 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 173.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -52.43 -48.0 66.03 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 123.654 0.781 . . . . 10.0 109.628 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -58.98 -45.5 90.41 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 118.669 -0.682 . . . . 10.0 111.712 175.731 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.9 p -49.87 -43.59 49.32 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 109.206 -0.665 . . . . 10.0 109.206 177.657 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.1 t -84.3 -3.56 58.32 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -174.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 92.5 mttt -110.71 -69.58 0.86 Allowed 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.692 1.597 . . . . 10.0 111.85 -179.201 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -127.3 28.91 5.64 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 119.437 1.017 . . . . 10.0 109.935 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.476 ' CA ' ' HB3' ' A' ' 125' ' ' ASP . . . 66.84 -105.31 1.29 Allowed Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 107.519 -2.232 . . . . 10.0 107.519 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -157.3 42.6 0.33 Allowed 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 107.059 -1.46 . . . . 10.0 107.059 169.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.84 -12.38 53.87 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.606 0.762 . . . . 10.0 111.616 -175.649 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.81 -158.7 48.81 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.618 -1.393 . . . . 10.0 109.618 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.0 m -61.76 129.27 40.2 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 123.129 0.572 . . . . 10.0 111.599 -169.042 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -59.03 92.03 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.991 0.916 . . . . 10.0 109.661 169.286 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.4 mt -64.44 -41.58 96.49 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.444 -0.785 . . . . 10.0 111.309 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.487 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -152.0 148.89 28.26 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.731 0.301 . . . . 10.0 110.391 -172.144 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -124.24 146.68 48.58 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.679 1.591 . . . . 10.0 107.801 -169.426 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.85 156.65 27.03 Favored Glycine 0 CA--C 1.52 0.362 0 N-CA-C 108.545 -1.822 . . . . 10.0 108.545 168.569 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.8 t -119.69 134.91 61.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 -175.551 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.1 mt -75.66 138.44 20.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 CA-C-N 118.679 0.672 . . . . 10.0 111.014 -177.005 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -150.55 172.7 30.27 Favored Glycine 0 CA--C 1.53 0.984 0 N-CA-C 112.313 -0.315 . . . . 10.0 112.313 170.254 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 64.7 mt -72.79 142.4 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 125.194 1.397 . . . . 10.0 109.08 -169.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.421 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . . . -119.98 -48.22 2.36 Favored 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 123.4 0.68 . . . . 10.0 111.301 172.041 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 . . . . . 0 C--O 1.248 1.009 0 CA-C-O 116.685 -1.626 . . . . 10.0 110.026 -167.969 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.694 0 N-CA-C 105.631 -1.989 . . . . 10.0 105.631 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.24 76.88 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 120.055 1.298 . . . . 10.0 108.278 168.558 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.37 158.0 32.09 Favored 'General case' 0 C--O 1.242 0.667 0 C-N-CA 124.481 1.112 . . . . 10.0 109.576 168.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.14 158.51 41.93 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 127.04 2.136 . . . . 10.0 106.078 169.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 m -111.44 178.67 1.25 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 CA-C-N 118.365 0.53 . . . . 10.0 109.601 174.259 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.24 101.63 2.4 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 165.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.417 HG12 HG23 ' B' ' 17' ' ' ILE . 32.2 m -92.33 130.75 40.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 N-CA-C 107.863 -1.162 . . . . 10.0 107.863 172.579 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.448 ' N ' HD12 ' B' ' 8' ' ' LEU . 5.1 mp -110.05 155.7 21.51 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.32 1.048 . . . . 10.0 108.641 176.175 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.0 tttt -164.2 167.99 19.41 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 169.107 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.2 -48.42 0.1 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.047 -1.549 . . . . 10.0 112.29 168.589 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -76.08 -46.63 28.04 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 107.893 -1.151 . . . . 10.0 107.893 -177.537 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.76 -67.2 0.52 Allowed Glycine 0 CA--C 1.526 0.775 0 CA-C-N 114.483 -1.235 . . . . 10.0 110.604 178.055 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -62.5 -36.2 66.84 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 122.794 2.329 . . . . 10.0 110.68 171.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 89.2 t -72.82 113.91 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.93 134.13 27.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.764 -0.458 . . . . 10.0 109.764 166.199 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.52 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -101.96 154.38 18.71 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 124.635 1.112 . . . . 10.0 111.269 175.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.417 HG23 HG12 ' B' ' 7' ' ' VAL . 0.1 OUTLIER -153.31 81.5 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 -172.878 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -105.67 151.96 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 C-N-CA 125.216 1.407 . . . . 10.0 109.657 -175.735 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -126.17 118.4 25.13 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 127.199 2.199 . . . . 10.0 107.295 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -98.41 116.46 30.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 170.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -117.25 125.61 51.41 Favored 'General case' 0 N--CA 1.465 0.308 0 O-C-N 123.716 0.635 . . . . 10.0 112.61 169.588 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -81.34 106.49 13.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.404 -2.072 . . . . 10.0 105.404 169.079 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.0 tttt -56.81 -43.63 81.19 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 124.869 1.268 . . . . 10.0 109.214 -171.497 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -130.43 -167.42 1.82 Allowed 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 103.0 -2.963 . . . . 10.0 103.0 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.7 m -79.0 -26.4 43.28 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 119.902 1.228 . . . . 10.0 109.412 172.494 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -111.88 -5.22 14.39 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 124.369 1.068 . . . . 10.0 111.799 -176.3 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.49 151.3 52.16 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 109.593 -1.403 . . . . 10.0 109.593 177.12 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -59.61 140.96 96.23 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.451 2.101 . . . . 10.0 108.292 174.085 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 p -79.89 103.56 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.537 0 N-CA-C 106.482 -1.673 . . . . 10.0 106.482 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.1 tttp -80.13 122.16 26.46 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 172.42 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.13 100.47 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 C-N-CA 127.566 2.346 . . . . 10.0 105.726 -178.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.8 p90 -125.56 155.71 40.24 Favored 'General case' 0 C--N 1.339 0.149 0 N-CA-C 112.986 0.735 . . . . 10.0 112.986 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.34 -145.86 13.68 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 106.383 -2.687 . . . . 10.0 106.383 173.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.5 p -157.35 168.16 28.18 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 118.798 -1.161 . . . . 10.0 111.998 177.226 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.613 HG12 ' HB3' ' B' ' 95' ' ' ALA . 1.8 pt -117.72 146.46 22.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 114.379 -1.282 . . . . 10.0 109.44 166.678 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.7 tptt -115.11 146.51 41.27 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 106.464 -1.68 . . . . 10.0 106.464 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.96 -10.1 37.27 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-O 119.538 -0.59 . . . . 10.0 114.073 168.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -62.0 174.45 0.87 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 118.181 0.99 . . . . 10.0 110.561 175.624 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -108.72 160.7 15.75 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 106.595 -1.631 . . . . 10.0 106.595 167.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -53.72 150.57 7.12 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.61 0.764 . . . . 10.0 111.962 -169.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.51 -172.64 23.19 Favored Glycine 0 CA--C 1.524 0.629 0 C-N-CA 123.496 0.569 . . . . 10.0 111.922 169.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -74.95 149.93 39.23 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.272 1.429 . . . . 10.0 111.594 -173.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -150.97 143.62 24.4 Favored 'General case' 0 C--N 1.342 0.24 0 N-CA-C 113.912 1.079 . . . . 10.0 113.912 -175.519 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.557 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -31.72 126.21 0.23 Allowed Glycine 0 C--N 1.341 0.808 0 C-N-CA 128.247 2.832 . . . . 10.0 112.38 166.019 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.464 ' CE1' HD12 ' B' ' 117' ' ' LEU . 0.1 OUTLIER -147.32 107.62 4.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 119.646 1.723 . . . . 10.0 109.887 167.303 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 176.54 9.75 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 109.718 -0.475 . . . . 10.0 109.718 174.506 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 47' ' ' VAL . . . . . 0.466 HG12 HD13 ' B' ' 117' ' ' LEU . 2.4 m -117.71 -15.48 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 125.134 1.521 . . . . 10.0 113.662 -173.107 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 58.15 171.7 0.05 Allowed 'General case' 0 C--N 1.345 0.412 0 CA-C-O 122.437 1.113 . . . . 10.0 111.661 175.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -72.37 -59.39 2.75 Favored 'General case' 0 N--CA 1.441 -0.885 0 O-C-N 121.507 -0.746 . . . . 10.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -87.04 156.62 19.68 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 121.831 -0.543 . . . . 10.0 109.546 -171.004 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.72 14.42 29.53 Favored Glycine 0 CA--C 1.524 0.62 0 C-N-CA 125.179 1.371 . . . . 10.0 110.754 177.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.498 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . 0.1 OUTLIER -93.77 175.23 6.81 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 121.918 0.866 . . . . 10.0 110.03 179.839 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.445 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -151.81 33.02 0.55 Allowed 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.055 -0.975 . . . . 10.0 111.165 169.241 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.23 -37.2 79.6 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.593 -0.692 . . . . 10.0 112.763 -168.742 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.57 -20.55 46.73 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 117.766 0.257 . . . . 10.0 111.146 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 123.72 -157.59 18.17 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 105.727 -2.949 . . . . 10.0 105.727 -167.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 2.8 t -65.27 7.72 0.19 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.06 1.744 . . . . 10.0 115.189 -169.514 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 62.2 m -97.74 -49.09 4.96 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 125.93 1.692 . . . . 10.0 108.544 -171.657 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.1 m -47.41 -39.96 16.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 126.326 1.85 . . . . 10.0 113.061 -166.482 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.89 -39.92 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 128.067 2.547 . . . . 10.0 113.929 168.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.3 162.84 15.23 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 121.44 -0.787 . . . . 10.0 111.951 167.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -86.7 37.94 0.54 Allowed 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.375 2.717 . . . . 10.0 111.885 -172.418 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 71.31 116.38 0.05 OUTLIER 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.38 2.272 . . . . 10.0 110.834 -170.271 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 64' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' B' ' 64' ' ' PHE . 0.0 OUTLIER -33.8 94.06 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 127.089 2.156 . . . . 10.0 113.268 165.922 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -105.69 32.71 0.05 OUTLIER Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 116.948 2.203 . . . . 10.0 116.948 -177.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -62.82 -55.88 0.73 Allowed 'Trans proline' 0 C--N 1.35 0.658 0 CA-C-N 122.951 2.09 . . . . 10.0 112.585 -172.462 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.03 41.88 0.45 Allowed 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.236 -0.915 . . . . 10.0 112.86 -176.308 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 88.0 p 17.41 69.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 128.48 2.712 . . . . 10.0 114.868 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.72 149.17 43.64 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 105.801 -1.926 . . . . 10.0 105.801 172.634 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 30.6 mttm -101.64 106.23 17.26 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 118.746 -0.645 . . . . 10.0 109.637 -168.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -2.33 87.46 0.0 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 126.596 1.959 . . . . 10.0 115.193 -178.361 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.49 -135.33 8.72 Favored Glycine 0 C--N 1.318 -0.465 0 N-CA-C 109.045 -1.622 . . . . 10.0 109.045 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.68 -168.82 37.88 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 107.467 -2.253 . . . . 10.0 107.467 173.039 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -65.25 -0.72 3.7 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 CA-C-N 119.561 1.68 . . . . 10.0 110.749 167.56 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.7 mtpm? -109.24 6.79 24.96 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 125.924 1.689 . . . . 10.0 111.0 175.476 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.99 174.14 10.95 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 165.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.3 -37.01 38.76 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.1 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -81.71 28.59 0.41 Allowed 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 125.433 1.493 . . . . 10.0 114.626 -165.454 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.67 134.89 41.61 Favored 'General case' 0 N--CA 1.456 -0.141 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 168.493 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -56.17 -66.43 0.43 Allowed 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.664 -0.495 . . . . 10.0 109.664 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 3.9 p -169.23 -46.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 O-C-N 124.262 0.976 . . . . 10.0 109.132 -176.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.79 53.67 0.79 Allowed Glycine 0 CA--C 1.536 1.379 0 CA-C-N 118.909 0.777 . . . . 10.0 111.865 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -89.38 99.35 12.36 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.655 -1.239 . . . . 10.0 107.655 172.718 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -70.49 -40.96 73.29 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.289 -1.375 . . . . 10.0 107.289 174.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.02 -93.42 1.03 Allowed Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 124.409 1.004 . . . . 10.0 112.266 168.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -127.66 123.69 36.14 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 123.779 0.832 . . . . 10.0 109.992 -168.06 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.3 m -119.95 150.31 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 N-CA-C 108.536 -0.913 . . . . 10.0 108.536 167.222 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -98.24 125.34 43.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.859 1.663 . . . . 10.0 109.204 -177.285 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.27 134.45 38.03 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 108.804 -0.813 . . . . 10.0 108.804 171.626 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.8 t0 -62.05 170.1 2.35 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 124.188 0.93 . . . . 10.0 109.565 167.414 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 9.4 pttm -52.19 -31.26 30.9 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 125.213 1.405 . . . . 10.0 111.246 173.093 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -81.91 -1.76 48.97 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.218 0.607 . . . . 10.0 111.386 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.37 9.32 86.65 Favored Glycine 0 C--N 1.339 0.717 0 O-C-N 120.787 -1.195 . . . . 10.0 111.216 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.3 t -80.62 106.11 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 126.2 1.8 . . . . 10.0 106.32 172.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.613 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -107.39 120.15 41.36 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.096 -1.076 . . . . 10.0 108.096 169.119 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -80.96 125.5 30.22 Favored 'General case' 0 N--CA 1.437 -1.112 0 C-N-CA 127.233 2.213 . . . . 10.0 109.762 176.397 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.2 t -111.03 133.71 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.957 0 C-N-CA 125.645 1.578 . . . . 10.0 108.105 175.455 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 96.9 p -157.63 57.61 0.49 Allowed 'General case' 0 C--O 1.235 0.303 0 C-N-CA 123.141 0.576 . . . . 10.0 111.207 169.863 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -93.38 144.52 9.3 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.287 0 N-CA-C 107.395 -1.335 . . . . 10.0 107.395 -172.174 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -90.98 128.13 36.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 167.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -107.06 100.93 10.38 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.278 -1.749 . . . . 10.0 106.278 166.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.77 24.14 4.33 Favored 'General case' 0 N--CA 1.44 -0.957 0 C-N-CA 126.688 1.995 . . . . 10.0 109.948 176.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 38.9 t -120.74 -55.86 3.31 Favored 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 -178.13 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.348 0.6 OUTLIER -94.3 178.03 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 C-N-CA 123.839 0.856 . . . . 10.0 113.266 -179.039 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 27.1 m -155.4 161.4 41.02 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 123.785 0.834 . . . . 10.0 110.109 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 92.5 mt -81.25 3.92 22.25 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 125.721 1.608 . . . . 10.0 112.456 -175.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.9 t -157.93 -169.48 2.84 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 107.845 -1.168 . . . . 10.0 107.845 168.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 111.32 -85.09 0.38 Allowed Glycine 0 C--N 1.333 0.374 0 N-CA-C 109.114 -1.594 . . . . 10.0 109.114 168.443 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -136.66 -49.61 0.65 Allowed 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 125.935 1.694 . . . . 10.0 107.899 174.725 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -72.43 -35.02 68.21 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 107.838 -1.171 . . . . 10.0 107.838 -171.684 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 42.3 t 31.95 67.13 0.15 Allowed 'General case' 0 N--CA 1.442 -0.868 0 C-N-CA 128.271 2.629 . . . . 10.0 110.503 167.669 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 1.3 pt -79.04 57.53 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 122.372 1.082 . . . . 10.0 110.806 -171.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 19.4 mm -96.21 -37.8 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 C-N-CA 127.725 2.41 . . . . 10.0 110.474 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.75 49.92 0.81 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.563 -1.015 . . . . 10.0 110.563 -175.379 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.57 169.52 8.65 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.864 2.065 . . . . 10.0 108.746 175.108 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -122.91 103.37 8.57 Favored 'General case' 0 C--N 1.344 0.353 0 C-N-CA 124.837 1.255 . . . . 10.0 109.955 -177.026 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.466 HD13 HG12 ' B' ' 47' ' ' VAL . 1.1 mm? -61.85 134.57 56.86 Favored 'General case' 0 CA--C 1.52 -0.183 0 N-CA-C 108.152 -1.055 . . . . 10.0 108.152 169.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.45 132.78 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 107.924 -1.139 . . . . 10.0 107.924 176.086 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 m -108.27 134.43 50.15 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 O-C-N 124.282 0.989 . . . . 10.0 110.366 167.415 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.557 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.3 m170 -110.54 158.0 19.03 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -171.529 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -40.22 -57.18 1.77 Allowed 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 129.272 3.029 . . . . 10.0 111.192 173.537 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 mttm -123.85 175.18 7.06 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.902 1.281 . . . . 10.0 109.495 -175.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.17 149.56 33.72 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.766 0.826 . . . . 10.0 109.708 175.431 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -74.92 152.84 38.81 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.78 -1.193 . . . . 10.0 107.78 168.699 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -76.15 -5.79 48.28 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 124.591 1.182 . . . . 10.0 110.719 171.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 50.5 mt 51.03 58.15 5.87 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 124.32 1.048 . . . . 10.0 108.798 -177.785 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.42 -39.44 3.12 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 124.93 1.252 . . . . 10.0 111.261 169.365 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.8 mtmt -79.13 47.19 0.76 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.211 1.004 . . . . 10.0 111.373 -178.343 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.57 -22.31 10.48 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 126.891 2.186 . . . . 10.0 111.298 174.302 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.18 44.41 43.06 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.055 0.836 . . . . 10.0 112.784 176.58 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -151.49 172.84 15.35 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 108.797 -0.816 . . . . 10.0 108.797 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -51.75 -41.53 61.65 Favored 'General case' 0 N--CA 1.445 -0.72 0 C-N-CA 122.96 0.504 . . . . 10.0 111.652 -176.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -71.59 -25.0 62.0 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.33 -0.856 . . . . 10.0 111.891 178.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 36.8 p -59.96 -20.8 59.54 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 113.61 0.967 . . . . 10.0 113.61 -177.136 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.4 t -94.75 -12.81 26.47 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.622 0.646 . . . . 10.0 110.258 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -109.32 -65.96 1.1 Allowed 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 126.7 2.0 . . . . 10.0 111.514 -171.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.02 31.4 3.87 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 120.266 1.394 . . . . 10.0 110.857 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 65.04 -93.57 0.16 Allowed Glycine 0 C--N 1.343 0.933 0 N-CA-C 108.859 -1.696 . . . . 10.0 108.859 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -164.43 39.73 0.08 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.709 1.204 . . . . 10.0 108.402 167.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.04 -11.84 58.21 Favored 'General case' 0 N--CA 1.456 -0.167 0 N-CA-C 113.637 0.977 . . . . 10.0 113.637 -168.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.44 -165.22 53.64 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.427 -1.069 . . . . 10.0 110.427 177.474 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.3 t -57.02 130.9 48.1 Favored 'General case' 0 N--CA 1.447 -0.611 0 C-N-CA 123.812 0.845 . . . . 10.0 112.217 -168.082 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -64.21 76.61 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.107 1.363 . . . . 10.0 110.171 170.13 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.8 mt -53.78 -36.9 62.91 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 112.735 0.643 . . . . 10.0 112.735 -177.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 148.4 28.29 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 109.884 -0.413 . . . . 10.0 109.884 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 p -155.54 132.85 10.93 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.2 1.0 . . . . 10.0 108.911 -169.233 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.88 -162.02 10.82 Favored Glycine 0 CA--C 1.52 0.382 0 C-N-CA 123.84 0.733 . . . . 10.0 111.973 -173.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 7.1 t -138.9 153.18 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 104.684 -2.339 . . . . 10.0 104.684 168.508 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.3 mt -67.49 -88.17 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 123.784 0.834 . . . . 10.0 110.409 -169.743 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.33 134.02 8.07 Favored Glycine 0 CA--C 1.534 1.235 0 O-C-N 121.64 -0.662 . . . . 10.0 112.326 178.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 88.5 mt -72.31 144.97 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 125.143 1.377 . . . . 10.0 109.529 -176.616 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -124.21 -50.53 1.79 Allowed 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.974 0.909 . . . . 10.0 110.633 176.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 . . . . . 0 C--O 1.25 1.104 0 C-N-CA 125.011 1.324 . . . . 10.0 112.688 -171.931 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.1 t -104.55 -11.11 17.16 Favored 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.921 1.288 . . . . 10.0 110.605 -178.378 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 15.5 ptmt -155.22 160.77 41.1 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.76 168.44 22.93 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 126.871 2.068 . . . . 10.0 108.778 -177.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 m -126.37 169.23 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 C-N-CA 123.038 0.535 . . . . 10.0 110.825 175.261 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.51 107.68 6.07 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 107.132 -1.433 . . . . 10.0 107.132 165.466 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.469 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.6 OUTLIER -87.26 95.13 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 C-N-CA 123.549 0.74 . . . . 10.0 109.008 173.768 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -78.76 126.18 30.37 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 107.888 -1.153 . . . . 10.0 107.888 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.4 mptt -146.87 155.15 42.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 168.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.18 -65.91 0.03 OUTLIER Glycine 0 N--CA 1.46 0.272 0 C-N-CA 118.842 -1.646 . . . . 10.0 112.925 169.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -71.66 -43.74 65.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 107.205 -1.406 . . . . 10.0 107.205 -177.67 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 148.37 -71.1 0.32 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 114.324 -1.307 . . . . 10.0 111.351 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -56.71 -37.69 97.27 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 122.87 2.38 . . . . 10.0 112.078 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 m -72.23 87.19 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 108.529 -0.915 . . . . 10.0 108.529 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -104.19 108.36 19.69 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.097 -1.816 . . . . 10.0 106.097 -178.771 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.432 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -96.47 141.13 15.43 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.036 -0.826 . . . . 10.0 111.036 172.679 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.63 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.0 mt -139.37 81.83 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 -177.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -90.87 146.83 5.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 C-N-CA 123.529 0.732 . . . . 10.0 109.509 175.544 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -129.0 114.42 16.39 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.6 2.36 . . . . 10.0 107.331 177.199 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -93.74 115.65 28.08 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 172.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -117.87 137.8 52.54 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.804 0.729 . . . . 10.0 111.507 168.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -134.19 91.79 2.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.266 2.226 . . . . 10.0 106.235 -178.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -51.26 -38.66 53.86 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 125.581 1.552 . . . . 10.0 112.473 -168.512 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -152.23 -179.22 7.34 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 105.803 -1.925 . . . . 10.0 105.803 171.426 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.9 p -72.18 -18.96 61.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 118.14 0.427 . . . . 10.0 110.074 -178.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -83.81 -17.31 41.46 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 124.224 1.01 . . . . 10.0 109.438 175.286 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.63 147.84 30.01 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.647 -0.981 . . . . 10.0 110.647 175.031 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.26 170.99 15.85 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.443 2.095 . . . . 10.0 108.682 168.691 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.1 t -87.33 104.92 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 106.197 -1.779 . . . . 10.0 106.197 170.392 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -84.88 113.99 21.78 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 104.784 -2.302 . . . . 10.0 104.784 168.378 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.17 98.78 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.023 -1.473 . . . . 10.0 107.023 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.3 p90 -113.16 179.9 3.83 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.893 0.378 . . . . 10.0 110.705 174.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.74 -154.53 22.68 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.701 -2.16 . . . . 10.0 107.701 168.517 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 61.3 p -155.36 155.41 33.61 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 118.678 -1.209 . . . . 10.0 112.304 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.741 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -115.69 135.8 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 C-N-CA 126.229 1.812 . . . . 10.0 107.031 171.474 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -121.3 150.04 42.01 Favored 'General case' 0 CA--C 1.528 0.105 0 N-CA-C 107.354 -1.35 . . . . 10.0 107.354 170.669 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.77 -21.54 18.41 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-N 119.146 0.884 . . . . 10.0 114.161 175.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.5 mt -62.94 179.52 0.37 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 125.29 1.436 . . . . 10.0 111.652 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -103.75 175.54 5.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.777 -1.102 . . . . 10.0 108.107 166.092 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -64.28 169.73 4.36 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.054 0.942 . . . . 10.0 111.765 -171.054 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.76 -173.73 28.48 Favored Glycine 0 C--O 1.223 -0.583 0 C-N-CA 124.347 0.975 . . . . 10.0 111.841 167.499 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.88 148.73 47.48 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.854 0.862 . . . . 10.0 109.107 169.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.1 m-70 -141.53 143.46 33.78 Favored 'General case' 0 C--N 1.34 0.18 0 N-CA-C 113.718 1.007 . . . . 10.0 113.718 -177.156 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.798 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -18.14 116.41 0.01 OUTLIER Glycine 0 C--N 1.339 0.721 0 C-N-CA 129.104 3.24 . . . . 10.0 115.061 163.759 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -149.41 98.32 2.77 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 120.208 2.004 . . . . 10.0 114.609 174.388 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.464 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -144.85 170.85 15.34 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.649 0.78 . . . . 10.0 112.16 178.664 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.4 t -105.5 -28.09 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 128.355 2.662 . . . . 10.0 112.827 -168.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.5 m-70 63.03 176.08 0.15 Allowed 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.586 1.154 . . . . 10.0 112.451 178.362 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -92.47 -64.83 1.06 Allowed 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.582 -0.736 . . . . 10.0 110.855 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -79.21 148.92 32.08 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 119.174 -1.01 . . . . 10.0 109.615 -176.444 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.0 -25.71 33.56 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 109.797 -1.321 . . . . 10.0 109.797 169.58 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -62.06 166.57 4.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 123.093 1.425 . . . . 10.0 112.897 -176.076 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.434 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -162.56 21.55 0.1 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.482 -1.235 . . . . 10.0 113.137 -169.907 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.454 HG22 HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -52.44 -35.23 51.78 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 124.797 1.239 . . . . 10.0 111.823 -176.556 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.05 -19.79 53.62 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 122.892 0.477 . . . . 10.0 112.138 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.84 107.0 1.22 Allowed Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.741 -1.343 . . . . 10.0 109.741 -172.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.1 m 34.75 59.91 0.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.357 1.863 . . . . 10.0 112.046 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.5 m -153.77 -54.24 0.11 Allowed 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.577 -0.897 . . . . 10.0 108.577 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -51.19 -39.5 56.62 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.857 1.263 . . . . 10.0 110.768 -173.149 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -29.67 -38.51 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 128.526 2.73 . . . . 10.0 114.786 168.47 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.49 131.63 6.65 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.125 -1.19 . . . . 10.0 110.125 172.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.94 64.78 3.29 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.531 2.821 . . . . 10.0 112.36 174.611 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.472 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 11.6 m170 69.86 38.09 1.68 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 128.527 2.731 . . . . 10.0 111.926 168.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -73.19 26.64 0.06 Allowed 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 115.372 1.619 . . . . 10.0 115.372 -170.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -46.22 150.72 1.05 Allowed Pre-proline 0 CA--C 1.54 0.558 0 C-N-CA 125.0 1.32 . . . . 10.0 112.703 -170.152 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -52.88 -52.86 7.87 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.087 2.524 . . . . 10.0 112.348 -173.28 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -77.06 61.14 1.97 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.9 -0.778 . . . . 10.0 108.9 169.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.4 t -60.02 113.99 2.61 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 106.877 -1.527 . . . . 10.0 106.877 178.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.68 -81.13 0.41 Allowed 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 109.41 -0.589 . . . . 10.0 109.41 -175.227 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -145.53 150.67 36.85 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-O 122.31 1.053 . . . . 10.0 110.91 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 52.8 t60 -64.69 117.88 8.1 Favored 'General case' 0 N--CA 1.447 -0.623 0 C-N-CA 119.146 -1.021 . . . . 10.0 108.642 166.194 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.97 -132.45 2.58 Favored Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 107.465 -2.254 . . . . 10.0 107.465 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.1 -160.79 24.62 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 109.13 -1.588 . . . . 10.0 109.13 177.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -60.75 -6.91 6.52 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.767 1.645 . . . . 10.0 110.973 167.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -85.21 -27.54 26.03 Favored 'General case' 0 N--CA 1.445 -0.68 0 C-N-CA 124.529 1.132 . . . . 10.0 109.942 175.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -106.63 154.83 20.34 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.938 -1.134 . . . . 10.0 107.938 -173.575 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -85.37 -24.69 27.47 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 115.073 -0.967 . . . . 10.0 109.052 169.039 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -101.39 14.39 32.12 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.585 0.587 . . . . 10.0 112.585 -173.37 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -43.1 149.72 0.2 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.19 2.196 . . . . 10.0 110.181 171.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -77.46 48.86 0.68 Allowed 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.2 -0.937 . . . . 10.0 112.61 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 26.0 t 33.66 49.38 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 126.099 1.759 . . . . 10.0 110.561 -177.375 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.47 42.55 0.03 OUTLIER Glycine 0 CA--C 1.532 1.156 0 CA-C-N 116.11 -0.495 . . . . 10.0 114.014 -169.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -118.01 111.87 19.51 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 104.466 -2.42 . . . . 10.0 104.466 168.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.8 mt -79.51 -29.92 41.7 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 119.75 1.159 . . . . 10.0 108.783 174.558 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.49 -83.82 0.36 Allowed Glycine 0 C--O 1.221 -0.683 0 N-CA-C 111.22 -0.752 . . . . 10.0 111.22 167.185 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -155.64 143.5 19.78 Favored 'General case' 0 CA--C 1.517 -0.318 0 N-CA-C 107.909 -1.145 . . . . 10.0 107.909 -176.125 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -130.93 135.24 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 O-C-N 123.68 0.612 . . . . 10.0 110.299 174.353 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -79.31 108.46 12.84 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 127.232 2.213 . . . . 10.0 111.849 -175.024 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.54 130.17 35.3 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.21 1.404 . . . . 10.0 111.036 173.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -59.6 168.53 1.61 Allowed 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 124.311 1.007 . . . . 10.0 109.984 167.251 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -53.97 -29.83 44.5 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.754 0.821 . . . . 10.0 112.023 171.017 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.79 -3.57 42.03 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.033 0.382 . . . . 10.0 112.033 177.366 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.18 3.88 88.59 Favored Glycine 0 C--N 1.337 0.601 0 O-C-N 120.971 -1.08 . . . . 10.0 111.53 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.83 97.73 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 106.673 -1.603 . . . . 10.0 106.673 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.741 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -101.23 121.94 42.77 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 169.482 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -96.13 127.37 42.08 Favored 'General case' 0 C--N 1.329 -0.292 0 O-C-N 124.118 0.886 . . . . 10.0 109.377 174.287 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.7 t -108.81 139.53 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 C-N-CA 126.789 2.035 . . . . 10.0 108.934 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 95.4 p -156.39 70.35 0.66 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.694 1.198 . . . . 10.0 110.204 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 8.6 mm -106.53 167.45 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 C-N-CA 125.143 1.377 . . . . 10.0 109.303 -174.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 66.3 tt0 -155.35 123.16 5.71 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 127.224 2.21 . . . . 10.0 108.487 -170.212 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -155.74 158.23 37.85 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 104.37 -2.456 . . . . 10.0 104.37 173.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 15.1 p -106.14 -19.56 13.68 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 126.301 1.841 . . . . 10.0 111.751 -177.311 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 70.4 t -77.05 -38.68 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 -169.588 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.292 0.0 OUTLIER -76.19 54.43 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 C-N-CA 124.356 1.063 . . . . 10.0 112.3 178.677 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.93 145.03 52.21 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.229 1.012 . . . . 10.0 111.329 -169.774 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 76.0 mt -47.62 -52.84 16.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.352 0.596 . . . . 10.0 110.478 176.433 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.3 m -150.44 158.43 44.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 125.28 1.432 . . . . 10.0 107.354 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.9 -67.8 0.25 Allowed Glycine 0 C--N 1.335 0.492 0 N-CA-C 109.609 -1.396 . . . . 10.0 109.609 -176.285 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -155.82 -53.16 0.09 Allowed 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 126.904 2.082 . . . . 10.0 106.315 178.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.1 -37.62 64.09 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 114.197 -1.365 . . . . 10.0 108.771 -173.003 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.6 t 47.57 91.6 0.01 OUTLIER 'General case' 0 C--O 1.232 0.182 0 C-N-CA 127.112 2.165 . . . . 10.0 113.872 168.123 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 17.6 pt -68.13 -27.34 36.87 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 119.956 -0.697 . . . . 10.0 111.78 174.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -49.79 126.32 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 119.584 1.084 . . . . 10.0 109.911 175.298 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.74 14.68 79.35 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-O 118.457 -1.191 . . . . 10.0 114.424 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.507 ' HB2' HD12 ' A' ' 149' ' ' ILE . 5.8 mmt-85 -84.27 -179.46 7.2 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.092 1.357 . . . . 10.0 109.084 166.698 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -136.9 104.23 5.41 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -179.451 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.65 ' CD1' HD11 ' A' ' 149' ' ' ILE . 8.9 mp -72.82 146.08 46.53 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 108.3 -1.0 . . . . 10.0 108.3 173.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.2 t -129.04 131.89 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.18 0 N-CA-C 107.17 -1.419 . . . . 10.0 107.17 175.616 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.7 p -99.69 136.93 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 106.837 -1.542 . . . . 10.0 106.837 168.449 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.798 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 14.4 m-70 -114.74 160.7 19.09 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 114.516 1.302 . . . . 10.0 114.516 -173.141 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -60.39 -60.12 4.32 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 114.847 -1.07 . . . . 10.0 108.638 173.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -90.38 164.76 14.19 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.735 -0.786 . . . . 10.0 112.007 -170.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.47 147.76 37.66 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 106.951 -1.499 . . . . 10.0 106.951 169.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.52 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 27.7 m-20 -98.41 141.22 31.56 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 123.546 0.739 . . . . 10.0 109.441 -169.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 -72.32 -20.86 61.42 Favored 'General case' 0 N--CA 1.46 0.061 0 CA-C-O 120.822 0.344 . . . . 10.0 110.705 -173.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.5 mt 55.21 42.54 30.43 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 -167.83 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.98 -15.46 62.96 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 126.494 1.997 . . . . 10.0 113.194 171.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -76.88 -2.24 32.52 Favored 'General case' 0 CA--C 1.535 0.381 0 N-CA-C 114.443 1.275 . . . . 10.0 114.443 -167.446 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.17 -16.25 64.28 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 118.562 0.619 . . . . 10.0 111.983 174.408 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.01 40.89 67.2 Favored Glycine 0 CA--C 1.527 0.824 0 CA-C-N 117.981 0.89 . . . . 10.0 110.983 -178.067 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -128.3 161.91 28.29 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.477 -1.675 . . . . 10.0 106.477 177.086 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.403 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 3.0 tm-20 -53.34 -50.14 65.62 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.269 -1.382 . . . . 10.0 107.269 169.048 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -52.95 -44.25 66.95 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 115.382 -0.827 . . . . 10.0 112.11 172.494 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 23.1 p -57.4 -39.14 75.5 Favored 'General case' 0 N--CA 1.445 -0.677 0 O-C-N 120.449 -1.407 . . . . 10.0 110.763 -178.089 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.1 t -85.98 6.26 29.53 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 111.731 0.271 . . . . 10.0 111.731 -179.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.403 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 27.7 mmtp -106.75 -84.86 0.51 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.708 1.603 . . . . 10.0 109.241 171.306 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.472 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 2.9 p -95.47 -12.22 26.23 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 121.242 1.837 . . . . 10.0 112.841 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 80.58 32.97 32.34 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -168.58 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 53.69 44.69 29.33 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.376 1.088 . . . . 10.0 111.103 -178.06 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.13 -2.49 13.14 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.38 0.672 . . . . 10.0 112.256 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 94.95 -67.01 1.28 Allowed Glycine 0 C--N 1.336 0.556 0 O-C-N 120.921 -1.112 . . . . 10.0 111.215 169.368 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -166.89 175.21 7.86 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 -178.375 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -105.86 98.93 8.56 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.414 1.886 . . . . 10.0 106.981 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.437 ' CD2' ' N ' ' A' ' 144' ' ' LEU . 0.6 OUTLIER -84.93 -25.22 28.0 Favored 'General case' 0 C--O 1.232 0.178 0 C-N-CA 122.956 0.502 . . . . 10.0 110.963 -167.856 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 139.29 10.96 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.582 -0.896 . . . . 10.0 108.582 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 97.1 m -118.99 144.79 46.3 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.472 1.509 . . . . 10.0 107.657 -177.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.64 134.27 5.39 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.695 -0.962 . . . . 10.0 110.695 173.409 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -95.63 134.0 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 106.958 -1.497 . . . . 10.0 106.958 -170.761 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.65 HD11 ' CD1' ' A' ' 117' ' ' LEU . 9.4 mt -76.49 115.84 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 N-CA-C 110.517 -0.179 . . . . 10.0 110.517 -168.826 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.89 136.91 13.83 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.033 0.825 . . . . 10.0 111.515 -175.336 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 68.8 mt -54.7 138.44 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 C-N-CA 125.67 1.588 . . . . 10.0 108.433 173.559 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.57 -47.75 1.96 Allowed 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 123.265 0.626 . . . . 10.0 111.02 176.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.952 -1.975 . . . . 10.0 113.148 -174.245 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.923 0 CA-C-O 116.423 -1.751 . . . . 10.0 107.306 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . 0.254 1.9 t -141.0 -49.46 0.43 Allowed 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 120.493 1.497 . . . . 10.0 113.072 174.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -103.4 129.56 50.52 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 107.833 -1.173 . . . . 10.0 107.833 169.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.3 158.12 44.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 169.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.8 m -121.02 172.66 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.159 0 CA-C-N 117.89 0.314 . . . . 10.0 110.168 175.149 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.2 98.56 3.76 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.342 -1.355 . . . . 10.0 107.342 167.172 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.434 HG21 ' HB3' ' A' ' 53' ' ' ASN . 13.2 m -83.39 104.89 12.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.256 -1.016 . . . . 10.0 108.256 169.39 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.5 mt -92.71 145.2 24.6 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.011 -0.737 . . . . 10.0 109.011 -177.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 46.0 tttt -160.46 161.07 32.79 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 173.027 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.27 -51.01 0.05 OUTLIER Glycine 0 C--O 1.228 -0.271 0 CA-C-N 116.347 -0.388 . . . . 10.0 112.272 169.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.7 -45.78 34.87 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 -170.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.08 -67.85 0.54 Allowed Glycine 0 N--CA 1.442 -0.934 0 CA-C-N 113.672 -1.603 . . . . 10.0 110.292 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -56.25 -42.87 61.64 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.547 2.165 . . . . 10.0 110.543 171.117 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.434 HG13 HD11 ' B' ' 38' ' ' LEU . 53.9 t -63.66 114.13 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 -179.351 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.0 121.01 28.75 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.665 -1.605 . . . . 10.0 106.665 168.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.599 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -97.65 144.08 17.09 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 168.83 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.454 HG22 HG22 ' A' ' 54' ' ' THR . 1.3 mt -144.2 71.29 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.097 -1.446 . . . . 10.0 107.097 -176.704 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -94.1 141.58 14.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 O-C-N 122.042 -0.411 . . . . 10.0 109.938 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.7 m-80 -110.46 128.05 55.42 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 126.034 1.733 . . . . 10.0 109.48 171.741 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -109.4 98.01 7.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 174.543 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -105.24 124.18 49.09 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.599 0.714 . . . . 10.0 112.34 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 tt0 -91.36 99.18 12.19 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.201 1.801 . . . . 10.0 108.241 176.586 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.42 ' CE ' ' OE2' ' B' ' 24' ' ' GLU . 28.3 tttt -53.95 -54.29 40.99 Favored 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 126.956 2.102 . . . . 10.0 110.17 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 24' ' ' GLU . . . . . 0.42 ' OE2' ' CE ' ' B' ' 23' ' ' LYS . 35.3 mt-10 -138.08 161.86 35.68 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 102.45 -3.167 . . . . 10.0 102.45 -178.214 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 m -69.58 -19.33 63.67 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 119.304 0.957 . . . . 10.0 110.138 -174.347 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -114.42 7.49 16.31 Favored 'General case' 0 N--CA 1.437 -1.095 0 O-C-N 124.916 1.385 . . . . 10.0 110.822 177.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.62 152.66 32.27 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 108.78 -1.728 . . . . 10.0 108.78 178.082 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -62.71 141.04 83.9 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 N-CA-C 108.097 -1.54 . . . . 10.0 108.097 170.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.4 t -87.19 109.39 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 105.322 -2.103 . . . . 10.0 105.322 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -76.93 113.18 14.35 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.645 -1.983 . . . . 10.0 105.645 168.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.47 102.19 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 171.088 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -120.73 154.71 35.25 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.202 0.525 . . . . 10.0 112.039 176.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.28 -168.59 36.58 Favored Glycine 0 N--CA 1.444 -0.831 0 N-CA-C 109.616 -1.393 . . . . 10.0 109.616 169.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.8 p -144.78 113.26 6.62 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 109.061 -0.718 . . . . 10.0 109.061 -169.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.599 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.4 pt -78.79 170.7 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.063 -1.088 . . . . 10.0 108.063 167.736 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -154.13 154.35 33.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.343 -0.984 . . . . 10.0 108.343 166.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.35 -15.62 32.6 Favored Glycine 0 CA--C 1.525 0.677 0 CA-C-O 119.139 -0.812 . . . . 10.0 114.08 177.245 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.453 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.7 mp -71.91 -179.21 2.62 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 118.757 1.278 . . . . 10.0 110.918 177.064 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -101.51 175.34 5.6 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.54 -0.911 . . . . 10.0 108.54 166.5 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -51.07 164.57 0.15 Allowed 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.23 2.212 . . . . 10.0 113.214 -173.031 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.76 -170.68 55.04 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 124.16 0.886 . . . . 10.0 114.008 165.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.96 141.76 54.86 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.127 1.771 . . . . 10.0 111.798 -175.605 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.4 m-70 -138.58 123.89 19.31 Favored 'General case' 0 C--N 1.339 0.115 0 C-N-CA 125.013 1.325 . . . . 10.0 109.847 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.42 127.83 1.75 Allowed Glycine 0 C--N 1.346 1.086 0 C-N-CA 126.839 2.161 . . . . 10.0 109.637 171.132 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.564 ' CE1' HG13 ' B' ' 87' ' ' VAL 0.274 0.3 OUTLIER -145.67 123.82 12.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 119.041 1.42 . . . . 10.0 112.406 168.139 . . . . . . . . 4 4 . 1 . 015 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.429 ' NE2' ' OD2' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -160.33 175.64 12.6 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.573 -0.74 . . . . 10.0 111.719 -174.264 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.2 m -88.72 153.43 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 O-C-N 125.697 1.873 . . . . 10.0 107.807 167.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 64.6 m-70 -134.72 95.04 3.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 108.329 -0.989 . . . . 10.0 108.329 177.438 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 24.43 -87.54 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 127.228 2.211 . . . . 10.0 114.24 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -78.87 161.76 26.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 122.734 1.254 . . . . 10.0 111.883 -169.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.44 -32.53 57.68 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 108.261 -1.936 . . . . 10.0 108.261 169.138 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -39.48 150.74 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 125.978 1.711 . . . . 10.0 113.929 176.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.469 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.6 OUTLIER -157.17 21.17 0.3 Allowed 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 113.882 -1.508 . . . . 10.0 113.081 178.527 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.63 HG23 ' CG2' ' A' ' 17' ' ' ILE . 6.0 m -41.69 -48.7 4.2 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.512 1.125 . . . . 10.0 113.093 -167.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.09 -25.36 47.53 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.891 0.876 . . . . 10.0 112.859 -176.393 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.17 104.15 2.6 Favored Glycine 0 CA--C 1.528 0.905 0 N-CA-C 109.544 -1.422 . . . . 10.0 109.544 -169.269 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 17.9 m 49.72 48.51 21.49 Favored 'General case' 0 N--CA 1.462 0.165 0 C-N-CA 125.474 1.51 . . . . 10.0 112.757 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -154.51 -55.86 0.1 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.6 m -50.56 -43.62 56.3 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.496 1.118 . . . . 10.0 111.45 -171.045 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.84 -51.47 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 128.005 2.522 . . . . 10.0 114.033 168.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.08 162.74 11.52 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.603 -1.399 . . . . 10.0 109.603 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -71.71 -164.68 0.17 Allowed 'Trans proline' 0 N--CA 1.447 -1.232 0 N-CA-C 105.019 -2.723 . . . . 10.0 105.019 163.72 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 34.1 m170 -81.47 53.55 2.12 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 119.288 -2.132 . . . . 10.0 109.72 -176.505 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -69.91 88.22 0.56 Allowed 'General case' 0 C--O 1.225 -0.225 0 CA-C-O 122.984 1.373 . . . . 10.0 109.383 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 65' ' ' ASN . . . . . 0.407 ' ND2' ' H ' ' B' ' 65' ' ' ASN . 4.9 p30 -96.34 151.2 37.95 Favored Pre-proline 0 C--N 1.325 -0.463 0 C-N-CA 127.236 2.214 . . . . 10.0 110.605 -176.56 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.4 -42.88 4.82 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.803 2.335 . . . . 10.0 111.282 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 77.0 mt -77.89 55.03 1.35 Allowed 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.829 0.852 . . . . 10.0 110.587 -178.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -38.28 101.77 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 126.752 2.021 . . . . 10.0 112.063 -171.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -140.38 -175.79 4.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.361 -1.348 . . . . 10.0 107.361 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -94.26 127.67 40.26 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -178.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -36.87 113.26 0.23 Allowed 'General case' 0 C--O 1.225 -0.207 0 O-C-N 123.639 0.587 . . . . 10.0 112.035 176.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.09 -137.09 5.65 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 177.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.409 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 168.44 -153.72 22.98 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.487 -2.245 . . . . 10.0 107.487 169.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -64.27 6.64 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.939 0 CA-C-N 120.635 2.217 . . . . 10.0 112.346 169.541 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.409 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.0 mmmt -121.4 12.26 10.84 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 126.978 2.111 . . . . 10.0 110.287 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -151.73 158.01 42.8 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 118.945 0.793 . . . . 10.0 108.919 168.025 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -79.39 -26.69 41.9 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 173.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -79.81 5.79 12.71 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 124.671 1.189 . . . . 10.0 112.82 -169.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt180 -35.23 120.75 0.55 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.796 1.639 . . . . 10.0 110.571 168.429 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.8 m170 -52.32 -53.55 43.0 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.506 1.122 . . . . 10.0 112.566 -170.057 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -178.03 -47.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 C-N-CA 125.667 1.587 . . . . 10.0 107.74 178.129 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.19 56.0 0.74 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.511 -1.435 . . . . 10.0 109.511 178.68 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -91.98 86.69 5.93 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 105.0 -2.222 . . . . 10.0 105.0 168.522 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 84' ' ' LEU . . . . . 0.516 ' HB3' ' CZ ' ' B' ' 45' ' ' PHE . 5.4 mp -72.98 -30.54 63.9 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 106.908 -1.516 . . . . 10.0 106.908 176.098 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.95 -93.18 0.86 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 124.687 1.137 . . . . 10.0 110.439 165.771 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 p30 -151.88 141.22 21.49 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.084 0.554 . . . . 10.0 110.021 -173.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.564 HG13 ' CE1' ' B' ' 45' ' ' PHE . 0.2 OUTLIER -128.6 138.87 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 C-N-CA 124.451 1.1 . . . . 10.0 111.677 179.219 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.4 m -79.17 115.05 18.6 Favored 'General case' 0 N--CA 1.437 -1.116 0 C-N-CA 128.821 2.849 . . . . 10.0 110.635 -177.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.7 134.17 38.94 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 123.855 0.862 . . . . 10.0 110.154 171.176 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -57.51 171.2 0.46 Allowed 'General case' 0 C--O 1.233 0.192 0 O-C-N 123.982 0.801 . . . . 10.0 109.634 167.46 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.63 -29.6 38.78 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 123.874 0.87 . . . . 10.0 110.955 173.322 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -79.08 -7.6 58.27 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.126 0.489 . . . . 10.0 111.203 -178.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.04 -0.24 72.25 Favored Glycine 0 C--N 1.338 0.684 0 O-C-N 121.195 -0.94 . . . . 10.0 111.001 -175.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 55.7 t -78.95 101.35 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 107.518 -1.289 . . . . 10.0 107.518 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.421 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -99.4 118.09 35.25 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.825 -1.176 . . . . 10.0 107.825 168.799 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.49 125.59 29.58 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 106.829 -1.545 . . . . 10.0 106.829 169.016 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 59.3 t -107.97 128.95 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 N-CA-C 105.385 -2.079 . . . . 10.0 105.385 169.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 73.0 m -152.72 59.85 0.8 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.798 0.839 . . . . 10.0 108.783 175.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.6 151.24 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 N-CA-C 108.138 -1.06 . . . . 10.0 108.138 -173.223 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -130.18 141.3 50.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.417 1.087 . . . . 10.0 109.155 170.292 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -149.27 161.03 42.84 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 29.7 p -122.6 4.89 9.55 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 127.237 2.215 . . . . 10.0 111.894 -172.462 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -84.14 -42.53 17.13 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 N-CA-C 107.699 -1.222 . . . . 10.0 107.699 177.131 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.283 0.0 OUTLIER -71.31 159.37 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 123.959 0.904 . . . . 10.0 113.228 172.378 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -160.04 155.0 24.59 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.202 -1.407 . . . . 10.0 107.202 170.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -82.14 55.88 2.98 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 108.129 -1.063 . . . . 10.0 108.129 169.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.5 t -73.83 -159.0 0.07 Allowed 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.598 1.959 . . . . 10.0 108.666 177.246 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -120.96 -51.89 0.25 Allowed Glycine 0 CA--C 1.528 0.903 0 C-N-CA 128.466 2.936 . . . . 10.0 107.662 173.535 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -65.77 -58.25 6.09 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 125.902 1.681 . . . . 10.0 108.908 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -81.8 -38.32 25.74 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.639 -0.71 . . . . 10.0 109.979 -176.147 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.3 t 3.39 109.43 0.0 OUTLIER 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 129.489 3.115 . . . . 10.0 115.575 177.217 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 34.8 pt -73.51 6.2 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 N-CA-C 112.823 0.675 . . . . 10.0 112.823 171.344 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 9.1 mm -56.95 -67.13 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.311 0 CA-C-N 119.352 0.978 . . . . 10.0 111.458 -176.403 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -81.63 56.1 4.89 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 120.856 -1.152 . . . . 10.0 111.924 -175.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.1 mmt-85 -122.4 150.57 42.27 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.929 1.291 . . . . 10.0 107.957 176.295 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 116' ' ' THR . . . . . 0.456 ' C ' HD12 ' B' ' 117' ' ' LEU . 1.1 m -92.24 129.26 38.23 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 104.065 -2.569 . . . . 10.0 104.065 168.7 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.456 HD12 ' C ' ' B' ' 116' ' ' THR . 10.9 mp -112.16 145.42 39.86 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.415 -0.957 . . . . 10.0 108.415 169.522 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.408 HG12 ' CD2' ' B' ' 120' ' ' HIS . 94.1 t -122.93 145.81 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 -171.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.501 HG13 ' HB3' ' B' ' 145' ' ' ALA . 1.5 p -117.2 122.74 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 C-N-CA 126.769 2.027 . . . . 10.0 106.473 169.5 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.408 ' CD2' HG12 ' B' ' 118' ' ' VAL . 10.2 m170 -105.29 167.22 9.87 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 115.722 1.749 . . . . 10.0 115.722 -168.463 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -59.29 -66.06 0.57 Allowed 'General case' 0 C--O 1.223 -0.29 0 C-N-CA 125.887 1.675 . . . . 10.0 110.186 174.155 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -107.06 177.71 4.77 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 118.817 0.735 . . . . 10.0 112.137 -169.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.08 144.13 48.81 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.683 1.193 . . . . 10.0 110.567 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.429 ' OD2' ' NE2' ' B' ' 46' ' ' HIS . 19.5 m-20 -89.59 149.36 22.88 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 109.091 -0.707 . . . . 10.0 109.091 168.039 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -76.76 -11.23 59.81 Favored 'General case' 0 N--CA 1.453 -0.289 0 O-C-N 124.73 1.269 . . . . 10.0 111.01 176.202 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 18.0 mt 57.37 40.05 27.8 Favored 'General case' 0 N--CA 1.457 -0.105 0 CA-C-N 118.26 0.482 . . . . 10.0 109.757 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 106.98 -33.41 6.43 Favored Glycine 0 CA--C 1.525 0.664 0 C-N-CA 125.325 1.44 . . . . 10.0 112.29 173.633 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.49 42.63 0.84 Allowed 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 118.471 1.135 . . . . 10.0 110.674 -169.29 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.71 -20.83 12.15 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.142 1.83 . . . . 10.0 111.743 -176.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.34 45.73 44.73 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 123.972 0.796 . . . . 10.0 112.554 178.477 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -152.03 172.43 16.29 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.444 0.622 . . . . 10.0 109.74 175.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 12.8 tm-20 -52.2 -43.78 64.37 Favored 'General case' 0 N--CA 1.443 -0.807 0 C-N-CA 123.699 0.799 . . . . 10.0 111.834 -176.272 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -72.43 -30.02 64.23 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.397 -0.815 . . . . 10.0 111.097 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 30.0 p -50.44 -40.42 50.4 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 119.419 1.009 . . . . 10.0 111.341 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -85.03 -13.79 49.4 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 123.793 0.683 . . . . 10.0 112.405 -175.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.2 ttmt -107.86 -48.75 3.34 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 126.841 2.056 . . . . 10.0 112.431 -166.611 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.9 p -131.93 -9.85 3.45 Favored 'General case' 0 C--O 1.224 -0.274 0 CA-C-O 116.794 -1.574 . . . . 10.0 112.258 169.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.0 -105.98 3.08 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 107.089 -2.404 . . . . 10.0 107.089 -166.394 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -171.81 21.53 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 115.187 1.551 . . . . 10.0 115.187 -176.702 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.09 -14.91 62.56 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 120.853 -1.154 . . . . 10.0 111.976 -178.215 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.53 -117.58 5.0 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.348 -1.901 . . . . 10.0 108.348 169.256 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 112.11 6.33 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 112.575 0.583 . . . . 10.0 112.575 -167.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.84 73.84 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.405 1.082 . . . . 10.0 109.938 166.172 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.9 mt -51.59 -45.2 63.07 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.783 0.66 . . . . 10.0 112.783 -175.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.501 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -151.27 156.82 41.62 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -168.047 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.0 p -163.4 170.13 17.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.951 -0.388 . . . . 10.0 109.951 -173.52 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.89 162.33 33.0 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.343 -1.503 . . . . 10.0 109.343 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.91 129.46 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 105.644 -1.984 . . . . 10.0 105.644 -176.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 22.6 mt -69.55 160.98 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 CA-C-N 118.773 0.715 . . . . 10.0 110.03 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.01 166.27 39.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 125.529 1.538 . . . . 10.0 109.919 -173.724 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 95.5 mt -74.29 134.56 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 C-N-CA 124.858 1.263 . . . . 10.0 109.785 -169.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.57 -35.25 3.59 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 112.795 0.665 . . . . 10.0 112.795 176.328 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.252 1.186 0 CA-C-O 116.953 -1.498 . . . . 10.0 108.893 174.508 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t -162.34 -43.77 0.04 OUTLIER 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 118.904 0.774 . . . . 10.0 110.795 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -118.41 138.52 52.39 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.579 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.34 155.68 49.13 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 124.148 0.905 . . . . 10.0 109.482 175.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -121.8 148.82 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 C-N-CA 125.618 1.567 . . . . 10.0 109.183 -176.239 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.33 100.85 4.36 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 108.022 -1.103 . . . . 10.0 108.022 167.131 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.481 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.2 m -79.51 100.99 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 109.055 -0.72 . . . . 10.0 109.055 171.571 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.9 mt -81.17 142.76 32.91 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -158.23 160.27 36.96 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 173.331 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -165.25 -60.68 0.02 OUTLIER Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.41 -0.424 . . . . 10.0 112.153 171.049 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -74.72 -45.86 41.39 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 106.644 -1.613 . . . . 10.0 106.644 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.69 -64.46 0.61 Allowed Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 114.021 -1.445 . . . . 10.0 111.203 -176.197 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -52.45 -42.74 59.33 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.06 1.84 . . . . 10.0 111.058 173.156 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.405 ' CG2' ' HB2' ' A' ' 145' ' ' ALA . 1.3 m -72.16 113.78 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.269 -1.011 . . . . 10.0 108.269 177.35 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -119.49 120.99 38.41 Favored 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 104.783 -2.303 . . . . 10.0 104.783 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.786 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -101.22 141.46 15.34 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.275 -1.93 . . . . 10.0 108.275 169.345 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.7 mt -137.16 67.26 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.069 -1.086 . . . . 10.0 108.069 -173.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.1 mm -77.06 133.86 29.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 109.4 -0.593 . . . . 10.0 109.4 -178.245 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -121.25 98.58 6.04 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.517 1.927 . . . . 10.0 107.6 -178.378 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.441 ' CD2' HG12 ' A' ' 31' ' ' VAL . 74.6 m-85 -81.27 128.79 34.19 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 118.155 -0.926 . . . . 10.0 108.616 177.612 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.77 122.21 43.81 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.619 0.768 . . . . 10.0 110.723 171.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -122.27 103.17 8.58 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.793 2.037 . . . . 10.0 106.483 168.508 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -61.77 -60.96 2.88 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 122.709 0.403 . . . . 10.0 110.467 -174.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -128.43 177.51 6.93 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 104.31 -2.478 . . . . 10.0 104.31 169.504 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.5 p -73.87 -17.17 61.08 Favored 'General case' 0 C--N 1.322 -0.594 0 O-C-N 122.114 -0.367 . . . . 10.0 110.578 -175.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.2 m-80 -79.2 -22.37 45.0 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.984 0.914 . . . . 10.0 109.461 172.45 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.64 124.73 18.83 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 109.91 -1.276 . . . . 10.0 109.91 179.325 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.92 141.95 86.34 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 N-CA-C 107.097 -1.924 . . . . 10.0 107.097 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 71.0 t -79.54 116.93 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 107.786 -1.19 . . . . 10.0 107.786 -169.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -88.91 108.4 19.53 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.122 -1.807 . . . . 10.0 106.122 177.696 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.441 HG12 ' CD2' ' A' ' 20' ' ' PHE . 18.6 m -101.32 90.59 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 125.328 1.451 . . . . 10.0 108.122 -177.756 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -101.49 167.5 10.11 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 122.03 0.919 . . . . 10.0 110.777 168.145 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.19 162.2 28.05 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.578 -1.409 . . . . 10.0 109.578 171.312 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.3 m -128.28 102.39 6.66 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 176.099 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.786 HG22 ' HA2' ' A' ' 16' ' ' GLY . 8.8 pt -77.08 176.32 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 N-CA-C 108.133 -1.062 . . . . 10.0 108.133 170.037 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.9 pttt -153.89 149.1 26.97 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 106.942 -1.503 . . . . 10.0 106.942 169.357 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.35 -24.24 12.7 Favored Glycine 0 C--N 1.338 0.654 0 CA-C-O 119.248 -0.751 . . . . 10.0 114.438 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.46 HD13 HD12 ' A' ' 35' ' ' ILE . 6.8 mp -65.56 175.92 1.66 Allowed 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 118.414 1.107 . . . . 10.0 111.063 -175.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -89.77 148.12 23.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.378 -0.828 . . . . 10.0 110.284 171.576 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -39.59 125.47 1.78 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.867 2.467 . . . . 10.0 110.938 174.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 121.42 -174.64 15.99 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 123.602 0.62 . . . . 10.0 112.961 171.415 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.64 151.91 44.45 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.806 1.642 . . . . 10.0 111.234 -178.02 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -148.27 143.3 26.86 Favored 'General case' 0 C--N 1.343 0.31 0 N-CA-C 113.524 0.935 . . . . 10.0 113.524 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.56 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.86 122.75 0.14 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.853 2.644 . . . . 10.0 110.917 165.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.92 106.41 4.42 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 119.989 1.894 . . . . 10.0 110.259 172.557 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.443 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -158.06 172.54 18.25 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-O 121.797 0.808 . . . . 10.0 111.764 -177.922 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 9.8 p -100.05 152.62 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-N 112.418 -2.174 . . . . 10.0 109.366 171.283 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -128.08 135.47 49.87 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 176.561 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -51.31 -61.77 2.03 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.318 1.447 . . . . 10.0 112.309 -168.323 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -83.9 147.79 27.31 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 119.539 -0.865 . . . . 10.0 109.516 -178.125 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.06 9.12 58.36 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 124.919 1.247 . . . . 10.0 111.321 170.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -67.56 98.45 0.68 Allowed 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 123.547 1.642 . . . . 10.0 110.907 -178.184 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.34 14.73 30.85 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 111.516 -2.584 . . . . 10.0 110.588 167.727 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.584 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -71.45 -40.95 70.0 Favored 'General case' 0 C--N 1.339 0.152 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 168.516 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -20.22 48.79 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.414 0.524 . . . . 10.0 112.414 170.682 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.02 78.83 1.37 Allowed Glycine 0 CA--C 1.529 0.909 0 N-CA-C 111.322 -0.711 . . . . 10.0 111.322 178.501 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.4 p 37.39 43.17 0.37 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 126.841 2.057 . . . . 10.0 114.292 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.2 m -133.14 -57.74 0.91 Allowed 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 105.682 -1.97 . . . . 10.0 105.682 -178.301 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -55.99 -29.05 59.7 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 122.823 0.449 . . . . 10.0 109.934 169.109 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.03 -27.7 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.564 1.545 . . . . 10.0 113.382 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.54 124.26 5.38 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-O 117.751 -1.583 . . . . 10.0 109.57 168.801 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -72.31 65.46 3.58 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.066 3.177 . . . . 10.0 111.69 176.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.6 m170 67.09 46.58 1.51 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 130.338 3.455 . . . . 10.0 111.868 176.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -70.48 64.68 0.28 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.194 0.597 . . . . 10.0 111.595 178.533 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -73.31 142.19 81.49 Favored Pre-proline 0 CA--C 1.533 0.292 0 O-C-N 120.154 -1.591 . . . . 10.0 109.102 172.582 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -57.94 -34.28 98.16 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.563 2.175 . . . . 10.0 111.591 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.45 -17.48 63.86 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.201 0.815 . . . . 10.0 113.201 177.358 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.4 t 20.75 81.93 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 127.495 2.318 . . . . 10.0 114.726 175.276 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.0 mtt180 -111.32 -84.73 0.57 Allowed 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 105.546 -2.02 . . . . 10.0 105.546 -177.356 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.09 160.56 41.07 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 109.131 -0.692 . . . . 10.0 109.131 167.557 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.0 t60 -56.74 126.68 27.94 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.316 -1.735 . . . . 10.0 106.316 165.032 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.39 -136.32 3.13 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 107.343 -2.303 . . . . 10.0 107.343 176.09 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 164.68 -150.64 18.98 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 108.982 -1.647 . . . . 10.0 108.982 169.569 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -68.11 19.22 0.13 Allowed 'Trans proline' 0 N--CA 1.453 -0.911 0 CA-C-N 119.77 1.785 . . . . 10.0 112.307 173.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 59.9 mttt -120.87 -11.66 8.92 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 118.161 -0.923 . . . . 10.0 111.243 169.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -143.6 118.44 9.93 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 104.856 -2.276 . . . . 10.0 104.856 -168.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 36.2 tp10 -75.11 -16.5 60.55 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 107.68 -1.23 . . . . 10.0 107.68 -171.541 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -82.56 11.11 6.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 C-N-CA 125.803 1.641 . . . . 10.0 111.991 175.656 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.8 ptt-85 -43.86 153.13 0.14 Allowed 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.76 1.624 . . . . 10.0 113.674 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -72.09 160.73 31.98 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 107.334 -1.358 . . . . 10.0 107.334 166.082 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.6 p -38.38 -47.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 125.358 1.463 . . . . 10.0 114.259 -172.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.74 55.0 0.76 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 123.396 0.522 . . . . 10.0 111.975 -177.25 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -82.47 93.5 7.26 Favored 'General case' 0 CA--C 1.528 0.126 0 N-CA-C 105.38 -2.082 . . . . 10.0 105.38 166.142 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -71.61 -28.94 64.14 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 106.79 -1.559 . . . . 10.0 106.79 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.63 -104.01 2.7 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 106.867 -2.493 . . . . 10.0 106.867 168.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -126.4 131.09 51.82 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.883 -1.155 . . . . 10.0 107.883 -169.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.98 135.58 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 119.076 0.853 . . . . 10.0 110.834 170.602 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.74 110.83 15.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.429 2.692 . . . . 10.0 110.51 -177.288 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.9 132.31 37.15 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.182 -0.673 . . . . 10.0 109.182 169.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -53.97 168.43 0.21 Allowed 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 125.047 1.339 . . . . 10.0 110.635 168.648 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 22.2 tttp -47.7 -35.43 9.64 Favored 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 125.654 1.582 . . . . 10.0 112.231 169.109 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -78.27 -9.84 59.4 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 121.203 0.525 . . . . 10.0 111.896 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.35 11.86 60.51 Favored Glycine 0 C--N 1.337 0.621 0 O-C-N 120.887 -1.133 . . . . 10.0 110.891 -177.132 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.3 t -92.19 103.92 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 125.749 1.62 . . . . 10.0 107.705 -178.272 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.43 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -98.88 121.72 41.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 109.052 -0.722 . . . . 10.0 109.052 169.633 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -84.6 86.16 7.34 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 127.528 2.331 . . . . 10.0 109.884 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.46 129.82 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.251 0 N-CA-C 105.67 -1.974 . . . . 10.0 105.67 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -158.18 72.06 0.61 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 122.986 0.514 . . . . 10.0 110.728 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -116.71 163.71 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.161 -1.792 . . . . 10.0 106.161 -178.016 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.66 144.85 39.83 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.571 0.623 . . . . 10.0 110.475 167.659 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -129.56 125.9 37.32 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 125.074 1.349 . . . . 10.0 110.205 -169.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 69.3 p -98.4 53.25 1.04 Allowed 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 107.172 -1.418 . . . . 10.0 107.172 169.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -157.24 -45.25 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 C-N-CA 124.085 0.954 . . . . 10.0 109.29 -175.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -74.23 145.09 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 167.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -133.08 157.15 46.0 Favored 'General case' 0 CA--C 1.528 0.124 0 N-CA-C 107.782 -1.192 . . . . 10.0 107.782 168.502 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.1 mt -95.39 -34.1 12.25 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 108.429 -0.952 . . . . 10.0 108.429 167.496 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.0 m -156.73 67.25 0.55 Allowed 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 124.486 1.114 . . . . 10.0 108.614 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -165.05 63.24 0.23 Allowed Glycine 0 C--N 1.333 0.365 0 N-CA-C 108.037 -2.025 . . . . 10.0 108.037 -179.313 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 69.75 -57.89 0.54 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 129.712 3.205 . . . . 10.0 109.532 -174.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -82.48 33.23 0.41 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 123.43 0.692 . . . . 10.0 111.416 -168.554 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.2 t -52.43 104.1 0.08 Allowed 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 126.618 1.967 . . . . 10.0 110.524 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 30.3 pt -86.06 23.55 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 C-N-CA 123.352 0.661 . . . . 10.0 111.787 171.432 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 20.8 mm -64.45 143.44 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 O-C-N 120.407 -1.433 . . . . 10.0 108.394 173.02 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.89 19.01 67.17 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-O 119.198 -0.779 . . . . 10.0 114.509 177.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.477 ' HD3' HD11 ' B' ' 151' ' ' ILE . 4.3 mmt-85 -88.29 176.4 7.24 Favored 'General case' 0 C--O 1.232 0.18 0 N-CA-C 107.76 -1.2 . . . . 10.0 107.76 167.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -121.08 132.66 55.01 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 106.841 -1.541 . . . . 10.0 106.841 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.9 mp -99.41 147.56 25.12 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.343 -1.354 . . . . 10.0 107.343 169.483 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.424 HG12 ' CD2' ' A' ' 120' ' ' HIS . 90.4 t -127.23 133.63 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.795 -1.557 . . . . 10.0 106.795 170.62 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.8 p -103.77 125.33 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.581 0 N-CA-C 103.913 -2.625 . . . . 10.0 103.913 167.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.56 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.2 m170 -105.56 160.6 15.05 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.052 1.406 . . . . 10.0 114.365 -168.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 -41.48 -58.15 1.99 Allowed 'General case' 0 N--CA 1.444 -0.773 0 C-N-CA 128.088 2.555 . . . . 10.0 109.702 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -124.81 176.96 6.26 Favored 'General case' 0 C--N 1.338 0.093 0 C-N-CA 125.791 1.636 . . . . 10.0 110.85 -174.06 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.69 135.92 33.34 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.143 0.977 . . . . 10.0 109.891 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.443 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.2 OUTLIER -78.55 143.3 36.64 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.433 1.893 . . . . 10.0 111.897 177.787 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.75 19.95 0.26 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.986 1.314 . . . . 10.0 112.132 178.516 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 40.1 48.08 2.13 Favored 'General case' 0 C--O 1.226 -0.137 0 C-N-CA 126.25 1.82 . . . . 10.0 112.622 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 105.93 -11.31 45.09 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-O 118.781 -1.011 . . . . 10.0 113.437 173.113 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -120.96 40.6 3.52 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.743 0.771 . . . . 10.0 112.185 -166.276 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.28 -15.34 66.86 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 126.035 1.779 . . . . 10.0 112.323 173.815 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.7 49.19 78.88 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 118.417 1.109 . . . . 10.0 113.023 175.145 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.499 ' H ' ' HB2' ' A' ' 134' ' ' SER . 39.8 m-80 -161.12 167.63 25.88 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 127.35 2.26 . . . . 10.0 105.095 -177.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -46.31 -47.89 18.33 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.791 0.805 . . . . 10.0 111.026 172.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -56.74 -33.24 66.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.253 -0.885 . . . . 10.0 111.715 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.499 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 11.0 t -45.65 -46.59 14.71 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 125.064 1.346 . . . . 10.0 109.346 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.6 t -91.68 0.92 57.46 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 112.395 0.517 . . . . 10.0 112.395 -173.177 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -113.18 -81.64 0.59 Allowed 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 126.054 1.741 . . . . 10.0 110.537 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.4 p -111.23 22.82 14.78 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 121.176 1.807 . . . . 10.0 111.02 172.397 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 -88.51 0.41 Allowed Glycine 0 C--N 1.341 0.816 0 N-CA-C 109.932 -1.267 . . . . 10.0 109.932 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -173.77 40.17 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 125.895 1.678 . . . . 10.0 109.069 172.036 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.21 -4.18 9.73 Favored 'General case' 0 C--N 1.34 0.164 0 O-C-N 121.543 -0.723 . . . . 10.0 112.224 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.56 -166.99 53.85 Favored Glycine 0 N--CA 1.441 -0.987 0 N-CA-C 109.259 -1.537 . . . . 10.0 109.259 179.174 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.6 t -62.41 146.15 52.15 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 122.457 1.122 . . . . 10.0 111.324 -168.618 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.07 64.22 0.06 Allowed 'General case' 0 N--CA 1.444 -0.743 0 C-N-CA 126.837 2.055 . . . . 10.0 109.145 171.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.63 -19.16 64.64 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 113.206 0.817 . . . . 10.0 113.206 -168.721 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.405 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . . . -155.36 145.7 21.91 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.398 0.544 . . . . 10.0 110.129 172.369 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.9 m -146.85 158.51 43.93 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 123.852 0.861 . . . . 10.0 109.492 -167.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.92 167.09 36.5 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.472 -1.051 . . . . 10.0 110.472 175.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.8 t -116.28 142.01 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 107.398 -1.334 . . . . 10.0 107.398 -169.308 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 11.0 mt -80.03 113.68 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 123.291 0.636 . . . . 10.0 110.52 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.07 152.32 17.59 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.244 1.402 . . . . 10.0 111.728 -178.475 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 84.0 mt -73.55 141.32 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 124.562 1.145 . . . . 10.0 109.179 -178.053 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.69 -48.16 2.59 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 123.35 0.66 . . . . 10.0 110.764 176.28 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.1 tt0 . . . . . 0 C--O 1.25 1.125 0 C-N-CA 127.268 2.227 . . . . 10.0 112.146 -172.114 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 108.684 -0.858 . . . . 10.0 108.684 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 2' ' ' THR . . . . . 0.498 HG23 ' HG3' ' B' ' 3' ' ' LYS . 15.0 t -91.46 -30.19 16.61 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 123.169 0.587 . . . . 10.0 111.149 -179.073 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 3' ' ' LYS . . . . . 0.498 ' HG3' HG23 ' B' ' 2' ' ' THR . 12.4 mtpt -124.44 127.9 48.21 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 124.882 1.273 . . . . 10.0 111.1 -175.527 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.01 155.47 49.93 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.957 0.503 . . . . 10.0 110.751 171.188 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.2 m -114.55 165.05 10.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.421 1.088 . . . . 10.0 109.346 171.712 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 6' ' ' ALA . . . . . 0.433 ' HB2' HG12 ' B' ' 149' ' ' ILE . . . -153.69 104.59 2.72 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 106.417 -1.697 . . . . 10.0 106.417 166.667 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -106.4 125.23 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 109.217 -0.66 . . . . 10.0 109.217 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.436 ' N ' HD12 ' B' ' 8' ' ' LEU . 4.1 mp -104.44 152.07 22.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.919 1.288 . . . . 10.0 109.352 -172.392 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 9' ' ' LYS . . . . . 0.409 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 44.8 tttt -160.0 162.64 34.34 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 169.863 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 175.0 -43.25 0.12 Allowed Glycine 0 C--O 1.228 -0.242 0 C-N-CA 119.768 -1.206 . . . . 10.0 113.682 168.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -74.22 -46.19 43.4 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.9 -72.37 0.33 Allowed Glycine 0 CA--C 1.52 0.348 0 N-CA-C 109.679 -1.368 . . . . 10.0 109.679 171.523 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -58.9 -39.23 83.17 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 123.211 2.607 . . . . 10.0 110.834 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.4 t -59.72 110.59 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -121.03 113.62 20.33 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 104.495 -2.409 . . . . 10.0 104.495 168.674 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.74 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -91.04 143.53 16.68 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 108.236 -1.946 . . . . 10.0 108.236 172.66 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.584 ' CG2' HG23 ' A' ' 54' ' ' THR . 3.0 mt -143.04 91.43 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 -176.419 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -104.31 138.66 28.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 C-N-CA 124.785 1.234 . . . . 10.0 109.29 178.081 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -122.84 122.35 38.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 126.38 1.872 . . . . 10.0 108.769 169.648 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -102.75 126.2 49.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 107.363 -1.347 . . . . 10.0 107.363 176.771 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -116.53 135.95 53.39 Favored 'General case' 0 C--O 1.233 0.203 0 O-C-N 123.759 0.662 . . . . 10.0 110.986 167.74 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.2 tt0 -119.52 114.15 21.83 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 106.095 -1.817 . . . . 10.0 106.095 168.456 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.4 mmpt? -65.11 -53.85 38.95 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 123.912 0.885 . . . . 10.0 110.028 -169.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -125.62 -156.98 0.76 Allowed 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 104.775 -2.305 . . . . 10.0 104.775 177.71 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 29.1 m -95.11 -18.94 20.54 Favored 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 120.43 -0.508 . . . . 10.0 110.653 167.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -81.74 -34.38 30.53 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.876 0.87 . . . . 10.0 110.389 179.523 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.76 151.57 52.39 Favored Glycine 0 CA--C 1.533 1.21 0 N-CA-C 111.437 -0.665 . . . . 10.0 111.437 -176.654 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_endo -62.63 159.45 36.8 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.874 2.383 . . . . 10.0 108.737 170.65 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 41.1 t -86.74 115.99 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.22 0 N-CA-C 105.325 -2.102 . . . . 10.0 105.325 169.477 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 38.8 tttp -92.07 112.45 24.39 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 168.57 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -94.44 100.66 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 C-N-CA 127.32 2.248 . . . . 10.0 106.484 176.543 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 23.3 p90 -112.77 171.32 7.6 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.304 0.573 . . . . 10.0 111.11 169.712 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.66 170.24 38.28 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.869 -0.892 . . . . 10.0 110.869 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.6 m -148.94 95.14 2.36 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.666 -1.605 . . . . 10.0 106.666 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.74 HG22 ' HA2' ' B' ' 16' ' ' GLY . 7.9 pt -75.8 176.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 108.725 -0.842 . . . . 10.0 108.725 173.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 36' ' ' LYS . . . . . 0.417 ' HE3' ' HB2' ' B' ' 36' ' ' LYS . 17.1 ptmt -156.57 164.8 37.77 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 163.285 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.69 -13.73 59.3 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 119.341 -0.7 . . . . 10.0 113.168 172.065 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.448 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.8 mp -69.71 176.69 3.42 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 118.568 1.184 . . . . 10.0 110.211 172.422 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.0 t -94.06 166.66 12.03 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 107.427 -1.324 . . . . 10.0 107.427 165.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.27 171.46 1.03 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.475 1.11 . . . . 10.0 112.21 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.18 179.89 39.64 Favored Glycine 0 C--N 1.334 0.428 0 C-N-CA 123.943 0.783 . . . . 10.0 112.074 168.488 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -66.99 142.6 57.19 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.632 0.773 . . . . 10.0 109.083 176.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.4 m-70 -139.68 151.79 46.19 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 123.087 0.555 . . . . 10.0 112.476 177.154 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.669 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -36.44 121.47 0.68 Allowed Glycine 0 C--N 1.341 0.822 0 C-N-CA 129.323 3.344 . . . . 10.0 110.883 166.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -149.59 115.21 5.58 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 119.335 1.567 . . . . 10.0 110.022 168.727 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.533 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.59 168.34 27.1 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-O 121.601 0.715 . . . . 10.0 111.406 176.401 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 7.7 m -93.28 148.88 4.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 111.957 -2.383 . . . . 10.0 105.389 166.744 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -121.91 153.55 38.3 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 174.622 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 49' ' ' GLU . . . . . 0.483 ' CD ' ' HA3' ' B' ' 61' ' ' GLY . 2.6 pm0 -40.1 -43.42 1.61 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 127.719 2.408 . . . . 10.0 115.403 -175.289 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -115.21 159.03 21.45 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 124.793 1.237 . . . . 10.0 109.264 -170.654 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.01 -7.71 63.96 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 126.009 1.766 . . . . 10.0 110.983 169.665 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -42.86 151.21 0.13 Allowed 'General case' 0 C--O 1.239 0.515 0 CA-C-O 123.174 1.464 . . . . 10.0 112.494 169.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.481 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -162.46 21.68 0.1 Allowed 'General case' 0 N--CA 1.437 -1.096 0 CA-C-N 112.485 -2.143 . . . . 10.0 111.997 167.955 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.83 -35.54 76.81 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.736 0.698 . . . . 10.0 110.821 -169.796 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.75 -17.6 55.54 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.602 1.161 . . . . 10.0 112.254 175.208 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.85 -173.2 17.25 Favored Glycine 0 N--CA 1.442 -0.909 0 N-CA-C 106.844 -2.502 . . . . 10.0 106.844 -167.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 60.1 m -66.53 69.96 0.07 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.311 1.444 . . . . 10.0 108.424 172.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -153.53 -53.04 0.1 Allowed 'General case' 0 N--CA 1.444 -0.774 0 O-C-N 120.693 -1.254 . . . . 10.0 109.617 -168.166 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.4 t -96.22 -1.26 48.55 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.874 0.87 . . . . 10.0 110.203 -178.069 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.31 47.3 0.37 Allowed 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.811 1.244 . . . . 10.0 112.225 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 61' ' ' GLY . . . . . 0.483 ' HA3' ' CD ' ' B' ' 49' ' ' GLU . . . 85.05 131.57 2.43 Favored Glycine 0 N--CA 1.44 -1.097 0 N-CA-C 117.479 1.752 . . . . 10.0 117.479 162.782 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -92.69 23.88 0.51 Allowed 'Trans proline' 0 CA--C 1.545 1.069 0 C-N-CA 123.135 2.557 . . . . 10.0 113.282 168.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.504 ' CD2' HG22 ' B' ' 137' ' ' THR . 21.1 m170 86.77 35.16 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 129.231 3.012 . . . . 10.0 112.352 176.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.24 70.34 0.16 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.319 1.048 . . . . 10.0 111.588 173.182 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -70.13 155.61 93.18 Favored Pre-proline 0 CA--C 1.536 0.413 0 C-N-CA 123.12 0.568 . . . . 10.0 109.965 170.715 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.57 -48.24 2.39 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 121.965 1.777 . . . . 10.0 110.815 176.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 tt -75.67 63.8 1.63 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.265 1.426 . . . . 10.0 109.205 -175.778 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -45.06 102.02 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 128.042 2.537 . . . . 10.0 113.143 -168.381 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.3 mtp85 -129.1 178.06 6.68 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 126.049 1.74 . . . . 10.0 108.027 175.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -111.94 56.98 0.64 Allowed 'General case' 0 C--O 1.226 -0.171 0 N-CA-C 113.12 0.785 . . . . 10.0 113.12 -167.15 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 67.8 t60 44.98 85.81 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 122.959 1.361 . . . . 10.0 114.069 175.448 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.65 -161.11 25.9 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 168.249 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.546 ' HA3' HD22 ' B' ' 126' ' ' LEU . . . -171.21 -152.99 8.6 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 107.043 -2.423 . . . . 10.0 107.043 173.662 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.42 8.44 0.12 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 120.15 1.975 . . . . 10.0 112.631 169.179 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.4 mttt -123.69 -0.49 8.58 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 117.419 -1.277 . . . . 10.0 113.066 175.351 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.32 163.55 32.71 Favored 'General case' 0 C--N 1.346 0.439 0 CA-C-N 120.629 1.559 . . . . 10.0 108.602 174.57 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -77.03 -30.29 55.67 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 177.017 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -76.58 26.07 0.13 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.651 1.58 . . . . 10.0 113.077 -166.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 18.1 mtm180 -47.58 129.5 13.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 107.392 -1.336 . . . . 10.0 107.392 168.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.1 m170 -67.67 -57.59 6.13 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 121.237 0.541 . . . . 10.0 109.932 176.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.8 p -163.82 -58.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 109.072 -0.714 . . . . 10.0 109.072 -176.31 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -137.23 62.91 0.58 Allowed Glycine 0 C--N 1.337 0.6 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 178.696 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -90.78 90.74 8.07 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.371 -1.344 . . . . 10.0 107.371 171.003 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.39 -25.5 57.68 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 121.352 0.596 . . . . 10.0 109.551 177.612 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 85' ' ' GLY . . . . . 0.559 ' CA ' HD21 ' B' ' 126' ' ' LEU . . . 80.98 -66.98 3.68 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 115.161 0.825 . . . . 10.0 115.161 167.676 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -137.93 109.29 6.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 118.677 -0.678 . . . . 10.0 109.249 -167.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -115.84 125.77 73.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 118.789 0.722 . . . . 10.0 110.451 169.721 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 10.9 m -81.35 97.51 7.74 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 128.325 2.65 . . . . 10.0 112.134 -171.705 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.64 132.77 39.6 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 123.824 0.849 . . . . 10.0 112.236 176.117 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -63.13 173.44 1.45 Allowed 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 125.308 1.443 . . . . 10.0 110.312 167.1 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.3 pttm -55.03 -30.5 59.68 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 123.766 0.827 . . . . 10.0 111.95 170.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.88 3.25 20.37 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.069 0.938 . . . . 10.0 110.953 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.47 -0.26 89.71 Favored Glycine 0 N--CA 1.441 -1.013 0 O-C-N 120.572 -1.33 . . . . 10.0 110.033 -174.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 67.0 t -78.33 94.79 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 108.414 -0.958 . . . . 10.0 108.414 -169.36 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -88.15 119.11 28.22 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 167.563 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -77.34 123.59 26.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.951 -1.5 . . . . 10.0 106.951 169.17 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 65.8 t -104.65 131.69 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 105.292 -2.114 . . . . 10.0 105.292 169.369 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -158.01 57.84 0.47 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 118.917 0.78 . . . . 10.0 111.815 177.413 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.6 151.61 12.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.166 0.986 . . . . 10.0 109.631 -169.279 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -109.1 141.99 40.48 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 126.068 1.747 . . . . 10.0 109.601 170.318 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -137.67 155.35 49.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 O-C-N 124.093 0.871 . . . . 10.0 109.413 173.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.5 p -128.07 58.37 1.52 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 126.86 2.064 . . . . 10.0 108.526 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -155.01 -44.5 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 C-N-CA 124.643 1.177 . . . . 10.0 108.888 174.096 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 33.6 mm -55.91 147.66 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 168.766 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.0 m -153.85 135.3 14.24 Favored 'General case' 0 C--O 1.233 0.22 0 N-CA-C 109.048 -0.723 . . . . 10.0 109.048 169.511 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -79.18 57.42 2.26 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.367 1.467 . . . . 10.0 108.492 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 15.5 t -83.2 -168.35 2.05 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 126.913 2.085 . . . . 10.0 110.416 -171.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -124.49 -51.93 0.19 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 127.896 2.665 . . . . 10.0 107.469 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -65.24 -58.89 4.83 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 109.776 -0.453 . . . . 10.0 109.776 169.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -76.92 -38.33 53.65 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 108.048 -1.093 . . . . 10.0 108.048 -173.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.4 t 37.18 69.13 0.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 127.009 2.124 . . . . 10.0 113.966 169.574 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.2 pp -56.0 -30.29 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 166.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.7 mm -31.12 -36.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 C-N-CA 128.306 2.642 . . . . 10.0 115.234 169.495 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -104.56 28.95 12.86 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-O 118.711 -1.049 . . . . 10.0 112.784 -175.56 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -104.87 169.85 8.21 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 125.106 1.362 . . . . 10.0 110.176 177.57 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 18.4 m -108.26 127.7 54.08 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.696 1.598 . . . . 10.0 109.104 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.407 HD21 HD11 ' B' ' 149' ' ' ILE . 4.5 mm? -84.9 141.23 30.55 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 106.71 -1.589 . . . . 10.0 106.71 167.059 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.5 t -125.46 136.7 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 170.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.425 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 6.0 p -105.65 130.9 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 125.083 1.353 . . . . 10.0 107.583 169.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.669 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.3 m170 -114.68 157.84 22.59 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 115.75 1.759 . . . . 10.0 115.75 -171.298 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -37.11 -63.76 0.41 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 129.301 3.04 . . . . 10.0 111.078 169.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.5 mttt -117.93 175.32 5.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 C-N-CA 124.231 1.012 . . . . 10.0 110.131 -173.077 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -91.72 148.19 22.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.894 1.278 . . . . 10.0 109.478 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.533 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -75.04 143.35 43.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 112.053 0.39 . . . . 10.0 112.053 -178.786 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -80.64 -3.62 51.21 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 124.394 1.059 . . . . 10.0 110.791 166.564 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.559 HD21 ' CA ' ' B' ' 85' ' ' GLY . 71.1 mt 51.24 50.73 18.4 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 125.426 1.49 . . . . 10.0 111.218 170.6 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.37 -36.08 4.3 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-N 114.525 -1.216 . . . . 10.0 110.935 174.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.434 ' H ' ' HD3' ' B' ' 128' ' ' LYS . 0.2 OUTLIER -83.31 35.22 0.49 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 121.025 -1.279 . . . . 10.0 110.847 -173.844 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.92 -36.11 6.51 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 109.51 -1.436 . . . . 10.0 109.51 179.06 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.62 51.21 59.26 Favored Glycine 0 CA--C 1.529 0.938 0 N-CA-C 111.39 -0.684 . . . . 10.0 111.39 -171.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -142.66 171.7 13.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 104.605 -2.368 . . . . 10.0 104.605 170.756 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 24.4 mp0 -51.78 -48.11 63.91 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 120.726 -0.39 . . . . 10.0 110.379 174.328 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -53.08 -38.17 62.32 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.451 -0.34 . . . . 10.0 110.282 177.387 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.8 p -57.72 -30.01 65.19 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 118.013 -0.994 . . . . 10.0 112.513 -176.398 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -98.2 17.47 18.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.412 1.005 . . . . 10.0 109.834 -177.551 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -142.19 -69.74 0.35 Allowed 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 124.822 1.249 . . . . 10.0 110.38 -169.282 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.504 HG22 ' CD2' ' B' ' 63' ' ' HIS . 11.4 p -126.73 21.61 6.99 Favored 'General case' 0 CA--C 1.547 0.859 0 CA-C-N 119.653 1.115 . . . . 10.0 112.29 177.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 79.07 -88.07 1.18 Allowed Glycine 0 C--N 1.343 0.958 0 O-C-N 121.111 -0.993 . . . . 10.0 111.01 170.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.09 38.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 122.989 1.376 . . . . 10.0 107.934 174.34 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.76 -29.05 61.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 125.169 1.388 . . . . 10.0 109.607 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.95 -157.61 53.09 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 109.847 -1.301 . . . . 10.0 109.847 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 56.7 m -56.84 130.57 46.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 113.59 0.959 . . . . 10.0 113.59 -167.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.9 mtt85 -66.68 75.22 0.11 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.934 1.294 . . . . 10.0 110.654 172.695 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 55.1 mt -50.58 -40.19 51.77 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 118.349 0.522 . . . . 10.0 112.226 179.535 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.425 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -155.31 160.41 40.73 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 121.943 -0.473 . . . . 10.0 109.867 -177.692 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 p -159.42 166.46 30.99 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 109.982 -0.377 . . . . 10.0 109.982 -177.04 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.56 165.55 36.24 Favored Glycine 0 C--N 1.334 0.433 0 N-CA-C 110.689 -0.965 . . . . 10.0 110.689 -177.195 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.68 137.53 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 106.002 -1.851 . . . . 10.0 106.002 -171.219 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.433 HG12 ' HB2' ' B' ' 6' ' ' ALA . 16.7 mt -68.42 157.3 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 108.491 -0.929 . . . . 10.0 108.491 177.811 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -163.83 155.38 26.72 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 109.732 -1.347 . . . . 10.0 109.732 -176.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 151' ' ' ILE . . . . . 0.477 HD11 ' HD3' ' A' ' 115' ' ' ARG . 1.9 pp -90.32 125.84 43.16 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-N 118.475 1.138 . . . . 10.0 111.368 -173.1 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.75 -25.96 27.92 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.126 -0.984 . . . . 10.0 111.245 177.774 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.251 1.133 0 C-N-CA 125.837 1.655 . . . . 10.0 107.676 178.476 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.835 0 CA-C-O 118.253 -0.88 . . . . 10.0 108.636 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.31 -53.61 1.91 Allowed 'General case' 0 N--CA 1.463 0.175 0 C-N-CA 124.274 1.029 . . . . 10.0 110.828 -175.659 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -105.51 128.36 53.53 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.32 161.74 35.45 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.132 0.573 . . . . 10.0 109.665 172.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -125.94 153.45 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 125.71 1.604 . . . . 10.0 109.782 -179.202 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.73 127.53 21.98 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 108.251 -1.018 . . . . 10.0 108.251 165.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.648 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.9 m -115.36 83.7 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 C-N-CA 124.783 1.233 . . . . 10.0 110.772 -174.537 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.426 ' N ' HD12 ' A' ' 8' ' ' LEU . 2.7 mp -76.02 150.01 37.44 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.144 -0.972 . . . . 10.0 109.856 -169.069 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.429 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -165.96 155.24 11.81 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 -179.206 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.19 -46.2 0.18 Allowed Glycine 0 N--CA 1.463 0.477 0 C-N-CA 119.505 -1.331 . . . . 10.0 114.136 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -73.33 -45.35 55.74 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -175.387 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.71 -73.13 0.32 Allowed Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 170.073 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -56.75 -39.55 90.55 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.835 2.357 . . . . 10.0 110.996 172.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 98.4 t -62.97 106.54 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 CA-C-N 119.245 0.93 . . . . 10.0 108.507 -177.189 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.63 112.44 20.53 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 169.679 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.775 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -96.17 142.57 16.2 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 109.576 -1.41 . . . . 10.0 109.576 174.293 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -147.12 93.32 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 -172.071 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.4 mm -111.88 139.82 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 C-N-CA 125.582 1.553 . . . . 10.0 110.111 -175.581 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -118.32 122.45 42.9 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.943 1.697 . . . . 10.0 109.157 168.247 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -101.74 114.11 27.89 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 125.255 1.422 . . . . 10.0 107.259 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -120.6 112.68 19.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 122.154 0.978 . . . . 10.0 113.084 -179.459 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -82.29 104.8 12.86 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 106.307 -1.738 . . . . 10.0 106.307 168.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.3 -24.44 67.3 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 118.97 -0.538 . . . . 10.0 110.405 177.117 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -135.75 -161.22 1.13 Allowed 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.419 -0.586 . . . . 10.0 109.419 178.535 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 23.1 t -99.87 -7.68 25.02 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 119.363 -0.351 . . . . 10.0 110.355 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.9 m-80 -139.63 21.34 2.52 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.819 1.248 . . . . 10.0 108.969 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.98 161.8 42.09 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.278 -1.129 . . . . 10.0 110.278 -172.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -67.69 117.28 4.76 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 104.226 -3.029 . . . . 10.0 104.226 165.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.77 131.56 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 -174.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.1 mttt -101.53 122.74 44.37 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 106.541 -1.651 . . . . 10.0 106.541 174.683 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.1 m -119.73 111.93 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.82 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 -175.218 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -128.99 167.96 16.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 121.209 0.528 . . . . 10.0 109.988 -179.291 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.77 171.17 38.68 Favored Glycine 0 N--CA 1.437 -1.295 0 N-CA-C 110.009 -1.236 . . . . 10.0 110.009 -176.353 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.5 t -142.55 99.04 3.41 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 177.663 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.775 HG22 ' HA2' ' A' ' 16' ' ' GLY . 4.9 pt -79.51 156.26 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 C-N-CA 118.514 -1.275 . . . . 10.0 107.642 167.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.5 ptmt -141.9 164.6 29.76 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.519 -0.919 . . . . 10.0 108.519 164.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.66 -14.23 46.2 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-O 119.105 -0.831 . . . . 10.0 113.08 177.67 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.496 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.4 mp -70.77 176.9 3.88 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 118.566 1.183 . . . . 10.0 110.482 178.08 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -95.9 149.82 21.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.397 -0.82 . . . . 10.0 109.309 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -43.61 137.53 2.91 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.685 1.994 . . . . 10.0 111.58 -176.28 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 114.62 -172.87 14.49 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.881 0.753 . . . . 10.0 112.585 170.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.89 145.32 50.28 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 125.024 1.33 . . . . 10.0 110.908 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -147.9 143.58 27.48 Favored 'General case' 0 C--N 1.34 0.189 0 N-CA-C 113.099 0.777 . . . . 10.0 113.099 177.509 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.633 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -28.55 117.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 C-N-CA 127.842 2.639 . . . . 10.0 113.078 165.397 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -143.1 109.18 5.24 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 120.207 2.004 . . . . 10.0 110.873 169.046 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.492 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -156.78 171.79 19.77 Favored 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 115.438 -0.801 . . . . 10.0 110.765 178.573 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.9 m -89.45 163.39 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.514 -2.13 . . . . 10.0 106.895 166.449 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -124.47 158.23 33.32 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 124.857 1.263 . . . . 10.0 107.859 172.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -58.04 -41.3 82.95 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 123.994 0.918 . . . . 10.0 112.935 -169.794 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -107.41 174.65 5.79 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.034 0.934 . . . . 10.0 109.82 176.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.39 -9.96 14.14 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.236 1.874 . . . . 10.0 112.449 175.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -65.81 161.34 21.18 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 122.379 1.085 . . . . 10.0 110.949 -178.138 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -158.0 28.98 0.26 Allowed 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.445 -0.798 . . . . 10.0 112.289 -170.735 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.639 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -59.19 -36.43 75.35 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.569 -0.707 . . . . 10.0 112.368 -171.622 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.44 -17.54 56.2 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.178 0.591 . . . . 10.0 111.499 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.37 -156.25 15.73 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 104.664 -3.374 . . . . 10.0 104.664 -167.435 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 93.6 m -68.23 72.33 0.19 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 125.133 1.373 . . . . 10.0 110.174 177.033 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -158.56 -47.92 0.06 Allowed 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 123.564 0.746 . . . . 10.0 111.128 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -56.0 -35.17 66.5 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.27 1.028 . . . . 10.0 111.476 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.09 -28.86 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.482 3.113 . . . . 10.0 116.395 174.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.04 165.87 29.03 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 107.84 -2.104 . . . . 10.0 107.84 175.46 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -72.81 -141.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.347 0 N-CA-C 106.635 -2.102 . . . . 10.0 106.635 166.249 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -105.04 38.03 2.03 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 120.515 1.507 . . . . 10.0 111.556 179.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -72.18 73.17 0.93 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.848 1.658 . . . . 10.0 112.181 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 7.2 p-10 -61.12 151.43 75.44 Favored Pre-proline 0 CA--C 1.537 0.456 0 O-C-N 121.557 -0.715 . . . . 10.0 110.524 169.146 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -62.02 -43.55 24.22 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 122.571 2.181 . . . . 10.0 111.459 -178.338 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -77.06 60.4 1.84 Allowed 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 175.461 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 p -42.23 108.95 0.11 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 126.238 1.815 . . . . 10.0 111.762 -169.524 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -124.67 176.23 6.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 108.393 -0.965 . . . . 10.0 108.393 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -98.42 113.81 25.93 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -174.394 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.2 t60 -25.52 102.48 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 124.856 1.262 . . . . 10.0 113.894 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.81 -136.94 7.6 Favored Glycine 0 N--CA 1.443 -0.885 0 N-CA-C 107.975 -2.05 . . . . 10.0 107.975 178.387 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.03 -164.5 24.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 107.554 -2.219 . . . . 10.0 107.554 168.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -52.67 -18.27 8.44 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.14 1.894 . . . . 10.0 112.237 170.533 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.45 ' HZ1' ' CG ' ' A' ' 76' ' ' ASP . 0.0 OUTLIER -83.45 -33.36 25.66 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.025 0.93 . . . . 10.0 110.828 -177.424 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.45 ' CG ' ' HZ1' ' A' ' 75' ' ' LYS . 1.4 m-20 -98.04 175.14 6.22 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -171.597 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -89.42 -28.39 19.77 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 167.54 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -86.79 16.8 4.46 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 125.518 1.527 . . . . 10.0 113.156 -168.134 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.38 136.05 13.07 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.779 0.831 . . . . 10.0 109.729 168.399 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -71.77 -176.7 1.72 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 107.906 -1.146 . . . . 10.0 107.906 168.262 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.49 41.19 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 N-CA-C 113.754 1.02 . . . . 10.0 113.754 -175.093 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.82 56.71 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.237 -1.545 . . . . 10.0 109.237 172.166 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -98.01 95.89 7.78 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 169.433 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -80.16 -30.14 38.87 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.99 -102.02 1.89 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 107.954 -2.058 . . . . 10.0 107.954 168.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -132.34 114.0 13.87 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.998 1.319 . . . . 10.0 109.586 -167.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.5 m -103.6 137.2 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 C-N-CA 122.709 0.403 . . . . 10.0 110.192 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 92.1 m -83.27 105.47 14.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 127.13 2.172 . . . . 10.0 109.681 -177.078 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.75 131.07 35.21 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.253 0.621 . . . . 10.0 109.945 170.431 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -59.33 170.63 0.93 Allowed 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.13 1.372 . . . . 10.0 110.182 168.376 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 66.6 tttt -51.49 -35.27 39.42 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 125.925 1.69 . . . . 10.0 111.845 169.084 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -79.81 2.11 24.29 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 121.556 0.693 . . . . 10.0 111.292 177.293 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.34 -2.81 87.95 Favored Glycine 0 N--CA 1.445 -0.74 0 O-C-N 120.322 -1.487 . . . . 10.0 110.435 -178.312 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 69.5 t -75.67 103.99 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -170.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.595 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -104.23 115.25 30.06 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 108.43 -0.952 . . . . 10.0 108.43 173.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -79.16 125.44 29.45 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 114.44 -1.254 . . . . 10.0 108.107 173.741 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -106.28 128.67 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.397 0 N-CA-C 104.442 -2.429 . . . . 10.0 104.442 168.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.9 m -155.13 73.88 0.89 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 123.474 0.709 . . . . 10.0 110.028 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 15.8 mm -112.24 161.17 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 124.311 1.044 . . . . 10.0 111.29 -174.442 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -123.73 134.86 53.61 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 129.733 3.213 . . . . 10.0 107.047 169.092 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -145.68 144.17 30.24 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.505 -0.554 . . . . 10.0 109.505 175.141 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 5.1 p -109.57 18.72 20.02 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.311 1.844 . . . . 10.0 112.701 -174.24 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.8 t -126.38 -54.26 1.84 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.2 0 C-N-CA 125.595 1.558 . . . . 10.0 107.507 -177.555 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 10.9 mm -48.92 115.47 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 124.575 1.15 . . . . 10.0 109.086 172.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -114.51 116.78 29.37 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.897 0.879 . . . . 10.0 108.952 -176.054 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.97 -47.72 32.75 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 125.309 1.444 . . . . 10.0 109.647 176.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.4 m -149.13 164.39 34.83 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.137 -1.431 . . . . 10.0 107.137 174.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 134.27 -99.52 0.35 Allowed Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 107.211 -2.356 . . . . 10.0 107.211 -172.759 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -120.13 -49.2 2.3 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 124.653 1.181 . . . . 10.0 109.216 -168.573 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.03 -44.49 39.04 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 -177.315 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.1 t 46.97 76.14 0.11 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.994 1.717 . . . . 10.0 112.559 169.452 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 26.3 pt -59.77 -25.72 33.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 112.146 0.424 . . . . 10.0 112.146 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.1 mm -42.8 122.25 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 CA-C-N 119.068 0.849 . . . . 10.0 111.291 175.317 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.99 8.59 78.82 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 119.013 -0.881 . . . . 10.0 113.029 175.03 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.13 169.51 11.86 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.421 1.11 . . . . 10.0 108.499 168.113 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.92 141.37 36.67 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.862 0.865 . . . . 10.0 111.287 174.648 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.429 HD21 HD11 ' A' ' 149' ' ' ILE . 4.5 mm? -95.64 141.46 29.12 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.427 -1.323 . . . . 10.0 107.427 168.503 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.439 HG12 ' CD2' ' A' ' 120' ' ' HIS . 72.4 t -123.48 138.96 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 108.604 -0.887 . . . . 10.0 108.604 172.395 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.445 HG13 ' HB3' ' A' ' 145' ' ' ALA . 1.3 p -102.7 122.14 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 167.291 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.633 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.3 m-70 -104.88 160.29 15.12 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 115.207 1.558 . . . . 10.0 115.207 -173.036 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.34 -56.23 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 113.818 -1.537 . . . . 10.0 110.657 176.355 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 41.0 mttm -113.8 175.65 5.37 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-O 121.789 0.804 . . . . 10.0 111.918 -179.22 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.12 139.34 35.68 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.936 1.694 . . . . 10.0 109.051 172.683 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.492 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -78.14 164.63 24.81 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 121.843 0.83 . . . . 10.0 111.601 174.227 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -73.99 -16.56 61.07 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 114.618 -1.174 . . . . 10.0 110.54 -178.184 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 10.1 mt 52.13 46.68 26.19 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 -168.326 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.62 -13.29 67.05 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.65 2.072 . . . . 10.0 113.785 171.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.3 mtmp? -79.31 3.94 16.65 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 115.376 1.621 . . . . 10.0 115.376 -167.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.97 -33.15 51.26 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.493 1.042 . . . . 10.0 110.891 178.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.22 41.99 93.14 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 111.846 -0.502 . . . . 10.0 111.846 -173.392 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -132.96 170.34 15.49 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 124.684 1.194 . . . . 10.0 108.138 173.21 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -41.46 -55.66 2.76 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 125.497 1.519 . . . . 10.0 110.479 175.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 49.1 mp0 -56.43 -51.85 66.85 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 125.096 1.359 . . . . 10.0 110.311 176.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.6 p -51.46 -38.26 52.92 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 123.138 0.575 . . . . 10.0 111.009 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.91 -11.65 56.6 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 123.999 0.812 . . . . 10.0 111.307 -170.709 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -112.57 -48.84 2.98 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.829 1.251 . . . . 10.0 112.081 -172.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.7 p -137.05 23.65 3.03 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 120.289 1.404 . . . . 10.0 110.634 174.087 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.81 -113.79 6.19 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 106.065 -2.814 . . . . 10.0 106.065 -171.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 19.3 m-80 -157.95 44.05 0.32 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 107.258 -1.386 . . . . 10.0 107.258 174.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.84 -13.34 55.65 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 124.205 1.002 . . . . 10.0 112.313 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.6 -164.96 54.86 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 110.355 -1.098 . . . . 10.0 110.355 176.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.2 t -54.84 134.14 48.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 113.396 0.888 . . . . 10.0 113.396 -168.049 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -64.55 73.3 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.967 1.707 . . . . 10.0 109.432 168.308 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 39.8 mt -49.83 -39.3 38.31 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 118.383 0.538 . . . . 10.0 111.927 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.445 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -155.98 157.42 36.17 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.135 -0.691 . . . . 10.0 109.135 -177.783 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -157.08 162.3 39.47 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.415 -0.357 . . . . 10.0 110.531 -173.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.62 175.6 26.87 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.847 1.213 . . . . 10.0 110.088 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 13.6 t -122.04 140.81 44.82 Favored 'Isoleucine or valine' 0 C--N 1.343 0.298 0 CA-C-N 118.882 1.341 . . . . 10.0 107.422 -177.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.429 HD11 HD21 ' A' ' 117' ' ' LEU . 17.5 mt -75.82 119.56 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 123.76 0.824 . . . . 10.0 109.836 -176.805 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.97 148.9 17.89 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 125.428 1.49 . . . . 10.0 111.737 -178.485 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 89.0 mt -69.16 135.16 28.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.58 1.552 . . . . 10.0 110.163 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.02 -7.13 4.41 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 115.45 1.648 . . . . 10.0 115.45 -173.265 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.253 1.269 0 CA-C-O 117.528 -1.225 . . . . 10.0 110.199 -179.369 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.669 0 CA-C-O 118.272 -0.871 . . . . 10.0 109.043 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -78.19 -26.83 47.72 Favored 'General case' 0 C--O 1.224 -0.24 0 C-N-CA 123.345 0.658 . . . . 10.0 110.895 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 62.5 tttt -130.05 137.3 50.16 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.093 0.473 . . . . 10.0 111.068 176.257 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.29 161.17 36.17 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 125.129 1.372 . . . . 10.0 107.964 171.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -126.91 156.26 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 C-N-CA 125.184 1.394 . . . . 10.0 109.735 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 6' ' ' ALA . . . . . 0.423 ' HB1' HD11 ' B' ' 117' ' ' LEU . . . -138.85 112.31 8.2 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 168.589 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 11.6 m -100.41 128.65 52.22 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 108.31 -0.996 . . . . 10.0 108.31 171.004 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.18 145.35 31.64 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 123.917 0.887 . . . . 10.0 110.534 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -161.19 160.45 30.12 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.921 -1.141 . . . . 10.0 107.921 168.635 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.1 -45.58 0.12 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.982 -1.104 . . . . 10.0 113.285 169.107 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 -45.04 53.12 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.604 -1.258 . . . . 10.0 107.604 -175.588 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.37 -71.19 0.39 Allowed Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.644 -1.382 . . . . 10.0 109.644 170.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -57.86 -38.88 90.87 Favored 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 123.076 2.518 . . . . 10.0 111.095 171.326 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 92.2 t -61.47 103.05 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.035 0 N-CA-C 107.824 -1.176 . . . . 10.0 107.824 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -118.1 128.86 55.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.339 -1.356 . . . . 10.0 107.339 169.641 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.429 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -118.15 146.29 18.54 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 110.953 -0.859 . . . . 10.0 110.953 175.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.639 HG22 HG22 ' A' ' 54' ' ' THR . 1.5 mt -146.57 89.55 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 C-N-CA 125.634 1.573 . . . . 10.0 107.657 -176.821 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -102.5 139.25 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.744 1.618 . . . . 10.0 110.082 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -115.9 110.73 19.41 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 129.314 3.046 . . . . 10.0 107.366 176.621 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -95.02 114.64 26.47 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -112.47 122.34 47.42 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 118.64 0.655 . . . . 10.0 112.721 169.506 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 5.0 tp-100 -82.55 110.11 17.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.145 -2.168 . . . . 10.0 105.145 166.241 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt -39.18 -69.7 0.12 Allowed 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 130.429 3.492 . . . . 10.0 111.456 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 11.4 mp0 -127.42 -116.06 0.26 Allowed 'General case' 0 N--CA 1.423 -1.824 0 O-C-N 124.3 1.0 . . . . 10.0 109.088 -178.097 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 12.0 m -121.2 -15.57 8.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 112.26 0.467 . . . . 10.0 112.26 170.013 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -134.67 12.47 3.72 Favored 'General case' 0 N--CA 1.456 -0.138 0 C-N-CA 123.991 0.916 . . . . 10.0 109.975 179.335 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.97 166.58 48.78 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 176.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.04 151.05 86.97 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.458 1.439 . . . . 10.0 108.744 171.35 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 t -79.76 124.07 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.984 -2.599 . . . . 10.0 103.984 168.368 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -99.66 112.53 24.75 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.496 -1.668 . . . . 10.0 106.496 169.092 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -95.99 103.99 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.959 0 C-N-CA 127.08 2.152 . . . . 10.0 106.135 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -124.75 165.17 18.44 Favored 'General case' 0 C--O 1.223 -0.323 0 N-CA-C 112.648 0.61 . . . . 10.0 112.648 173.285 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.8 -156.63 27.1 Favored Glycine 0 N--CA 1.449 -0.494 0 N-CA-C 107.216 -2.354 . . . . 10.0 107.216 172.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 50.8 p -156.25 160.52 39.87 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.565 -1.254 . . . . 10.0 112.52 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.752 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -116.18 136.56 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 C-N-CA 126.197 1.799 . . . . 10.0 107.519 167.887 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 36' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 92' ' ' ASP . 0.1 OUTLIER -130.82 159.38 37.52 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.289 0.368 . . . . 10.0 110.452 167.276 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.14 -0.19 44.31 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.779 0.704 . . . . 10.0 113.22 -178.218 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.433 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.9 mp -85.02 175.62 8.93 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 118.0 0.9 . . . . 10.0 109.703 -178.308 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.5 t -90.89 154.45 19.47 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.913 -0.773 . . . . 10.0 108.913 168.131 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -51.22 145.32 8.14 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 126.536 1.935 . . . . 10.0 111.324 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.92 -170.49 21.84 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-O 121.593 0.552 . . . . 10.0 111.95 172.554 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -73.88 147.56 43.1 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.296 1.438 . . . . 10.0 112.535 -170.26 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -147.94 127.49 13.24 Favored 'General case' 0 C--N 1.341 0.218 0 N-CA-C 114.395 1.257 . . . . 10.0 114.395 -178.709 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.675 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -17.75 124.41 0.01 OUTLIER Glycine 0 C--N 1.342 0.89 0 C-N-CA 127.473 2.463 . . . . 10.0 114.489 164.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -147.18 106.17 3.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 119.863 1.832 . . . . 10.0 111.339 167.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.45 172.49 15.87 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.417 0.627 . . . . 10.0 111.165 175.206 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 19.5 m -96.91 153.92 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 112.632 -2.076 . . . . 10.0 108.479 168.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -134.49 135.47 42.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.005 2.122 . . . . 10.0 105.349 177.674 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -56.7 -48.36 77.87 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.896 0.748 . . . . 10.0 112.84 -168.694 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -78.42 112.66 15.68 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 118.126 -1.43 . . . . 10.0 108.486 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.74 -26.37 62.56 Favored Glycine 0 N--CA 1.44 -1.068 0 N-CA-C 109.534 -1.426 . . . . 10.0 109.534 167.224 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -34.37 109.12 0.07 Allowed 'General case' 0 CA--C 1.516 -0.364 0 C-N-CA 125.237 1.415 . . . . 10.0 111.343 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.648 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.7 OUTLIER -117.97 13.13 13.9 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 113.417 -1.719 . . . . 10.0 110.672 174.307 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.23 -39.84 67.14 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 119.102 0.864 . . . . 10.0 111.999 -168.314 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.88 -17.98 54.68 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.313 1.045 . . . . 10.0 113.027 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.23 76.07 1.11 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 108.269 -1.932 . . . . 10.0 108.269 -169.565 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.6 p 30.55 37.5 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 128.338 2.655 . . . . 10.0 116.177 -177.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.4 m -100.33 -50.25 3.99 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 -178.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.1 m -67.04 -14.73 63.18 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 126.378 1.871 . . . . 10.0 112.201 177.698 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.26 -26.74 0.35 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 127.228 2.211 . . . . 10.0 114.334 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 156.26 26.59 Favored Glycine 0 N--CA 1.438 -1.213 0 N-CA-C 109.002 -1.639 . . . . 10.0 109.002 169.646 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -69.31 -170.92 0.39 Allowed 'Trans proline' 0 N--CA 1.44 -1.65 0 N-CA-C 106.756 -2.055 . . . . 10.0 106.756 167.003 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 31.2 m170 -81.61 60.33 4.53 Favored 'General case' 0 CA--C 1.542 0.647 0 O-C-N 120.325 -1.485 . . . . 10.0 109.99 -172.398 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -70.85 75.52 0.62 Allowed 'General case' 0 C--O 1.223 -0.328 0 CA-C-N 118.917 0.781 . . . . 10.0 110.584 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -75.26 148.01 83.36 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.336 -0.853 . . . . 10.0 110.933 172.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.14 -42.97 12.32 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.57 2.18 . . . . 10.0 110.661 176.027 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.2 mt -75.87 54.77 0.84 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 123.806 0.843 . . . . 10.0 109.86 176.253 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.5 p -40.29 112.01 0.24 Allowed 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 125.787 1.635 . . . . 10.0 111.571 -172.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -142.34 178.4 7.6 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.42 -2.437 . . . . 10.0 104.42 -176.487 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -65.92 156.74 32.61 Favored 'General case' 0 N--CA 1.439 -0.977 0 C-N-CA 116.606 -2.038 . . . . 10.0 108.917 168.386 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -66.43 126.32 28.47 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 104.976 -2.231 . . . . 10.0 104.976 161.539 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.27 -133.21 3.07 Favored Glycine 0 N--CA 1.451 -0.35 0 N-CA-C 109.226 -1.55 . . . . 10.0 109.226 172.03 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.84 -155.08 23.19 Favored Glycine 0 C--O 1.226 -0.405 0 CA-C-O 118.028 -1.429 . . . . 10.0 109.53 174.64 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -64.88 2.37 1.37 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 CA-C-N 119.803 1.801 . . . . 10.0 112.155 172.531 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -95.18 -21.57 18.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 117.65 -1.167 . . . . 10.0 110.862 172.319 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -126.72 156.14 41.6 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 119.318 0.963 . . . . 10.0 109.817 -170.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -78.17 -32.79 50.31 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 106.885 -1.524 . . . . 10.0 106.885 167.62 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -88.01 57.17 4.18 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 125.553 1.541 . . . . 10.0 108.167 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 14.3 ptm180 -83.78 147.81 27.39 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 106.259 -1.756 . . . . 10.0 106.259 165.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -63.55 -57.95 8.52 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.481 1.037 . . . . 10.0 110.548 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.458 HG22 HG22 ' B' ' 104' ' ' ILE . 2.1 p 179.78 -99.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 104.883 -2.265 . . . . 10.0 104.883 -179.388 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.438 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -74.68 54.15 2.48 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.45 1.023 . . . . 10.0 112.417 172.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 70.0 m-20 -95.76 92.56 6.62 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.223 -2.51 . . . . 10.0 104.223 167.313 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 80.7 mt -89.44 38.84 0.92 Allowed 'General case' 0 CA--C 1.531 0.214 0 N-CA-C 107.983 -1.117 . . . . 10.0 107.983 177.195 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 32.91 -103.08 0.01 OUTLIER Glycine 0 C--N 1.341 0.84 0 C-N-CA 128.124 2.773 . . . . 10.0 112.206 -175.296 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -143.85 147.11 33.6 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.11 0.964 . . . . 10.0 109.769 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 32.4 m -113.15 139.04 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 125.095 1.358 . . . . 10.0 108.355 -174.748 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -83.41 122.47 28.54 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.273 0.629 . . . . 10.0 109.917 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.75 131.31 37.92 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.581 1.153 . . . . 10.0 109.255 171.053 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -56.15 169.36 0.41 Allowed 'General case' 0 N--CA 1.451 -0.41 0 O-C-N 124.486 1.116 . . . . 10.0 110.007 168.066 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 11.3 tttp -49.99 -35.46 24.56 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.284 1.434 . . . . 10.0 112.185 169.431 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 36' ' ' LYS . 36.1 t70 -79.47 0.31 30.04 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.275 0.559 . . . . 10.0 112.202 177.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.03 -1.0 86.54 Favored Glycine 0 C--N 1.337 0.623 0 O-C-N 120.394 -1.441 . . . . 10.0 110.698 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 56.0 t -77.15 97.71 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 107.443 -1.317 . . . . 10.0 107.443 -174.639 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.752 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -94.3 116.98 29.44 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 168.573 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -88.19 130.35 35.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.839 -1.171 . . . . 10.0 107.839 174.014 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.0 t -107.7 129.89 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.257 -2.127 . . . . 10.0 105.257 168.73 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -157.77 55.88 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 118.696 0.68 . . . . 10.0 110.957 175.449 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.58 143.68 17.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.466 -0.771 . . . . 10.0 110.222 -169.084 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -97.85 129.21 44.83 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 128.638 2.775 . . . . 10.0 107.049 168.846 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -143.23 134.0 25.26 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 109.454 -0.573 . . . . 10.0 109.454 -176.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.6 p -115.64 45.78 1.63 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.559 1.544 . . . . 10.0 110.011 -169.337 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.9 p -142.98 -46.79 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 122.634 0.374 . . . . 10.0 111.219 177.261 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.458 HG22 HG22 ' B' ' 81' ' ' VAL 0.31 0.0 OUTLIER -65.12 161.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 119.787 -0.765 . . . . 10.0 111.441 169.517 . . . . . . . . 4 4 . 1 . 017 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 20.3 m -146.32 165.47 29.17 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 169.552 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 83.4 mt -100.55 -18.52 16.59 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 123.138 0.575 . . . . 10.0 110.061 175.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 44.7 m -156.3 164.47 38.28 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.443 1.497 . . . . 10.0 107.189 174.358 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 119.53 -95.11 0.59 Allowed Glycine 0 C--N 1.333 0.385 0 N-CA-C 108.378 -1.889 . . . . 10.0 108.378 -178.071 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -131.79 -52.29 0.99 Allowed 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 126.056 1.743 . . . . 10.0 107.966 176.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -81.85 37.13 0.47 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.645 0.778 . . . . 10.0 110.489 -170.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.7 t -74.81 93.12 2.58 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 127.261 2.224 . . . . 10.0 109.481 -169.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 24.5 pt -75.41 34.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.519 -0.738 . . . . 10.0 112.746 -177.732 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 38.2 mm -85.25 146.54 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 O-C-N 120.281 -1.512 . . . . 10.0 109.395 -175.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.85 24.21 69.78 Favored Glycine 0 CA--C 1.531 1.079 0 O-C-N 121.976 -0.452 . . . . 10.0 112.677 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -93.3 149.49 21.19 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 125.172 1.389 . . . . 10.0 107.347 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -87.47 139.96 30.01 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 168.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.423 HD11 ' HB1' ' B' ' 6' ' ' ALA . 0.0 OUTLIER -116.61 159.01 22.79 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 108.135 -1.061 . . . . 10.0 108.135 168.704 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 74.5 t -137.94 129.51 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 107.981 -1.118 . . . . 10.0 107.981 -172.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.409 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 3.0 p -94.52 122.65 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 105.929 -1.878 . . . . 10.0 105.929 167.035 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.675 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.7 m-70 -105.98 160.24 15.43 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 115.303 1.594 . . . . 10.0 115.303 -171.329 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -41.38 -60.94 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.069 2.948 . . . . 10.0 111.968 171.108 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -120.16 172.16 7.97 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.71 1.204 . . . . 10.0 113.166 -168.355 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.54 154.47 38.61 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 114.186 -1.37 . . . . 10.0 108.187 168.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -92.74 168.73 11.0 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 124.337 1.055 . . . . 10.0 111.034 -176.061 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.58 -20.99 59.72 Favored 'General case' 0 C--O 1.223 -0.336 0 C-N-CA 125.11 1.364 . . . . 10.0 108.278 175.049 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 49.8 mt 49.45 43.31 23.52 Favored 'General case' 0 C--N 1.341 0.237 0 C-N-CA 124.457 1.103 . . . . 10.0 109.998 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.51 33.17 80.48 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.087 -1.415 . . . . 10.0 113.174 178.142 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -75.4 0.08 18.18 Favored 'General case' 0 C--N 1.339 0.142 0 CA-C-N 118.913 1.357 . . . . 10.0 112.337 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.82 17.97 78.63 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.45 -1.46 . . . . 10.0 109.45 178.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.25 -26.08 74.32 Favored Glycine 0 N--CA 1.443 -0.834 0 N-CA-C 110.352 -1.099 . . . . 10.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -156.07 163.14 40.03 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 118.067 0.933 . . . . 10.0 108.925 -168.362 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -56.23 -42.21 76.92 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 109.546 -0.539 . . . . 10.0 109.546 171.545 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -61.38 -23.96 66.15 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 112.635 0.606 . . . . 10.0 112.635 175.174 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.3 p -52.42 -39.32 60.83 Favored 'General case' 0 CA--C 1.512 -0.519 0 CA-C-N 118.556 0.617 . . . . 10.0 110.393 -172.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.7 t -90.17 -1.76 57.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 O-C-N 124.671 1.232 . . . . 10.0 111.67 -173.593 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -116.82 -48.93 2.64 Favored 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 126.769 2.028 . . . . 10.0 111.367 -168.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.7 p -135.43 -2.61 2.45 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 118.653 -0.689 . . . . 10.0 111.543 168.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 -106.38 3.19 Favored Glycine 0 N--CA 1.433 -1.52 0 N-CA-C 105.693 -2.963 . . . . 10.0 105.693 -166.078 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -168.79 30.55 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.22 1.01 . . . . 10.0 110.07 -173.866 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.19 -20.27 66.37 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.971 0.909 . . . . 10.0 113.277 -167.267 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.45 -160.69 53.25 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 110.394 -1.083 . . . . 10.0 110.394 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.5 m -55.57 130.8 44.38 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.074 0.94 . . . . 10.0 113.151 -167.476 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 60.6 mtt180 -69.23 68.25 0.19 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.129 1.771 . . . . 10.0 110.415 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 37.8 mt -54.41 -31.9 56.08 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 113.141 0.793 . . . . 10.0 113.141 -173.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.409 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -158.22 153.15 25.19 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 109.129 -0.693 . . . . 10.0 109.129 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.5 m -146.19 161.55 39.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 115.548 -0.751 . . . . 10.0 109.934 -166.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.36 172.78 34.81 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.089 -1.204 . . . . 10.0 110.089 176.455 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -122.4 135.32 62.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 9.1 mt -69.23 116.66 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 C-N-CA 122.983 0.513 . . . . 10.0 110.034 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.05 144.47 17.72 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 124.812 1.196 . . . . 10.0 110.526 -178.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 59.8 mt -65.77 144.56 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 N-CA-C 108.045 -1.094 . . . . 10.0 108.045 176.114 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.55 -43.05 3.06 Favored 'General case' 0 C--O 1.227 -0.124 0 CA-C-N 119.268 0.94 . . . . 10.0 111.923 170.187 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 117.088 -1.434 . . . . 10.0 110.854 179.029 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.656 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.6 t -154.77 -49.31 0.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 123.479 0.712 . . . . 10.0 109.501 173.694 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 ttmt -106.41 155.84 19.14 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.222 -1.77 . . . . 10.0 106.222 169.317 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.77 164.82 38.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 107.093 -1.447 . . . . 10.0 107.093 170.027 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -136.17 164.4 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 O-C-N 123.325 0.391 . . . . 10.0 110.854 -176.25 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.37 101.85 4.09 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.123 -1.065 . . . . 10.0 108.123 168.562 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.43 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.5 m -85.84 88.26 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 170.11 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -81.67 126.38 31.71 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.087 -0.708 . . . . 10.0 109.087 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 46.8 mtpt -140.8 160.41 40.11 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.05 -1.463 . . . . 10.0 107.05 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.07 -60.93 0.04 OUTLIER Glycine 0 C--O 1.229 -0.199 0 C-N-CA 120.808 -0.71 . . . . 10.0 112.745 169.26 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.99 -43.94 64.3 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 -176.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.82 -70.75 0.41 Allowed Glycine 0 CA--C 1.523 0.581 0 CA-C-N 114.23 -1.35 . . . . 10.0 110.446 169.542 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -58.16 -32.61 96.08 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 123.511 2.807 . . . . 10.0 111.665 173.483 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.0 t -67.22 93.75 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 N-CA-C 107.094 -1.447 . . . . 10.0 107.094 177.079 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -117.96 106.94 13.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.777 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -94.65 142.18 15.91 Favored Glycine 0 N--CA 1.441 -1.017 0 N-CA-C 109.171 -1.572 . . . . 10.0 109.171 169.204 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.611 HG22 HG23 ' B' ' 54' ' ' THR . 2.4 mt -143.77 58.66 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 -169.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.0 mm -79.74 137.28 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 115.688 -0.687 . . . . 10.0 109.328 -173.359 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -115.33 117.04 29.33 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.433 1.493 . . . . 10.0 108.024 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -102.74 122.88 45.36 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 177.566 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -118.37 144.61 45.77 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.675 0.671 . . . . 10.0 112.405 173.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -125.31 102.01 7.24 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 127.85 2.46 . . . . 10.0 106.594 167.009 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -49.74 -56.14 11.34 Favored 'General case' 0 C--N 1.338 0.098 0 C-N-CA 124.415 1.086 . . . . 10.0 109.931 172.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.56 178.54 6.99 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 105.128 -2.175 . . . . 10.0 105.128 171.85 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.0 t -72.31 -18.79 61.75 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.455 -0.202 . . . . 10.0 110.455 177.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -79.68 -19.38 49.15 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 123.673 0.789 . . . . 10.0 109.765 177.716 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.61 143.46 45.55 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.531 -1.028 . . . . 10.0 110.531 179.217 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.48 149.03 43.73 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.466 2.11 . . . . 10.0 107.648 168.149 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 t -79.58 100.34 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.404 ' NZ ' ' OE2' ' A' ' 100' ' ' GLU . 1.8 ttmp? -81.91 108.0 15.07 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.927 -1.508 . . . . 10.0 106.927 168.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.3 m -90.11 103.41 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 107.108 -1.441 . . . . 10.0 107.108 173.674 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.4 p90 -112.73 153.95 26.93 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-O 121.481 0.657 . . . . 10.0 112.61 173.529 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.47 179.37 41.28 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.637 -0.792 . . . . 10.0 111.274 169.156 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.4 p -131.67 103.94 6.65 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 -175.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.777 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.8 pt -79.8 140.99 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 169.178 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -118.28 149.84 40.46 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 169.446 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.55 -8.15 37.22 Favored Glycine 0 C--N 1.336 0.569 0 CA-C-O 119.534 -0.592 . . . . 10.0 113.354 170.071 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -60.97 176.68 0.39 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.915 0.864 . . . . 10.0 109.75 170.648 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -110.61 171.65 7.34 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 166.111 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -48.93 156.27 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.858 1.263 . . . . 10.0 112.816 -172.151 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.01 -169.93 46.84 Favored Glycine 0 N--CA 1.443 -0.858 0 CA-C-O 122.667 1.149 . . . . 10.0 113.848 166.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mp -69.86 141.78 53.16 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 126.246 1.818 . . . . 10.0 110.139 -177.321 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -142.54 151.98 42.15 Favored 'General case' 0 C--N 1.341 0.203 0 N-CA-C 114.132 1.16 . . . . 10.0 114.132 178.085 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.694 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.71 122.39 0.13 Allowed Glycine 0 C--N 1.34 0.783 0 C-N-CA 128.533 2.968 . . . . 10.0 112.709 164.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -156.14 107.22 2.46 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.206 1.503 . . . . 10.0 111.72 168.509 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.464 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -157.55 169.75 23.96 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 113.2 0.815 . . . . 10.0 113.2 -179.764 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.4 m -84.13 157.79 3.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 CA-C-N 112.694 -2.048 . . . . 10.0 109.929 169.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -142.14 140.15 32.35 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 126.58 1.952 . . . . 10.0 107.366 179.079 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -58.55 -59.72 4.94 Favored 'General case' 0 N--CA 1.446 -0.645 0 O-C-N 124.212 0.945 . . . . 10.0 111.249 -172.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -76.95 123.02 25.7 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 117.932 -1.507 . . . . 10.0 108.984 -169.056 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.05 -9.25 63.0 Favored Glycine 0 CA--C 1.535 1.317 0 N-CA-C 110.336 -1.106 . . . . 10.0 110.336 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -59.07 99.84 0.06 Allowed 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 122.371 1.081 . . . . 10.0 111.453 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -107.53 14.39 25.84 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 113.506 -1.679 . . . . 10.0 110.432 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.675 HG23 HG22 ' B' ' 17' ' ' ILE . 3.1 m -54.71 -35.51 63.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 120.065 1.302 . . . . 10.0 110.776 -177.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.72 -19.99 57.05 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.769 0.828 . . . . 10.0 112.392 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 133.05 -87.74 0.27 Allowed Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.432 1.492 . . . . 10.0 109.533 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 15.7 t -155.17 62.04 0.64 Allowed 'General case' 0 CA--C 1.529 0.162 0 O-C-N 122.067 -0.666 . . . . 10.0 109.705 -172.233 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -162.5 -49.92 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.557 -0.714 . . . . 10.0 110.175 -175.239 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.7 t -57.47 -19.98 27.77 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 123.941 0.896 . . . . 10.0 111.149 -178.578 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.82 -27.36 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.822 2.049 . . . . 10.0 113.589 168.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.48 170.69 33.17 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 108.071 -2.012 . . . . 10.0 108.071 168.114 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -81.5 -166.38 0.4 Allowed 'Trans proline' 0 N--CA 1.441 -1.582 0 N-CA-C 107.077 -1.932 . . . . 10.0 107.077 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.437 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.6 m170 -82.85 58.94 4.57 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 120.893 -1.129 . . . . 10.0 110.629 -174.835 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -71.99 74.18 0.9 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.949 0.88 . . . . 10.0 111.257 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 -74.92 153.11 86.84 Favored Pre-proline 0 CA--C 1.537 0.444 0 C-N-CA 124.292 1.037 . . . . 10.0 110.302 171.336 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.12 -43.54 11.23 Favored 'Trans proline' 0 N--CA 1.456 -0.712 0 C-N-CA 122.322 2.015 . . . . 10.0 111.019 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.6 51.21 0.73 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.401 0.68 . . . . 10.0 110.579 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 35.0 p -52.48 112.51 0.83 Allowed 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.247 1.019 . . . . 10.0 109.907 -174.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 30.1 mtt85 -136.93 -85.71 0.32 Allowed 'General case' 0 CA--C 1.511 -0.545 0 N-CA-C 106.953 -1.499 . . . . 10.0 106.953 -170.683 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -144.7 158.2 43.88 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-O 122.402 1.096 . . . . 10.0 109.361 167.455 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 67.3 t60 -73.13 120.46 18.79 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 162.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.5 -131.75 2.45 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 108.148 -1.981 . . . . 10.0 108.148 175.602 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.09 -149.2 7.87 Favored Glycine 0 C--O 1.226 -0.351 0 N-CA-C 109.106 -1.598 . . . . 10.0 109.106 169.324 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -64.92 3.71 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.863 0 CA-C-N 120.344 2.072 . . . . 10.0 111.656 169.112 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -92.35 -22.48 19.67 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 124.901 1.28 . . . . 10.0 110.611 172.09 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 59.6 t0 -117.18 152.77 34.09 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.118 -1.067 . . . . 10.0 108.118 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -79.2 -33.43 43.87 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.403 -1.271 . . . . 10.0 108.078 169.188 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -91.02 8.1 37.08 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.415 1.486 . . . . 10.0 111.606 -170.246 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.21 142.1 3.04 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.456 1.103 . . . . 10.0 110.478 176.109 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.7 m170 -59.73 -59.37 5.54 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.447 0.641 . . . . 10.0 110.342 -169.781 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.52 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.3 p -173.5 -98.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 104.586 -2.376 . . . . 10.0 104.586 177.469 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.52 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -79.1 58.38 4.34 Favored Glycine 0 CA--C 1.529 0.954 0 CA-C-N 118.776 0.716 . . . . 10.0 111.457 174.391 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -90.59 90.59 8.05 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 104.309 -2.478 . . . . 10.0 104.309 167.284 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 8.6 mt -70.79 -33.28 70.57 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.28 -76.53 0.51 Allowed Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 10.0 111.32 167.289 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 72.8 m-20 -135.43 118.58 16.52 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 117.938 0.869 . . . . 10.0 109.45 -175.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.2 m -103.98 122.44 56.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 168.388 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 m -82.67 101.75 11.04 Favored 'General case' 0 N--CA 1.437 -1.107 0 C-N-CA 127.402 2.281 . . . . 10.0 109.507 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.64 130.24 35.33 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.251 0.62 . . . . 10.0 110.561 175.587 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -58.94 169.03 1.1 Allowed 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 124.215 0.947 . . . . 10.0 109.277 167.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 ptmm? -50.78 -32.4 19.76 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.539 1.535 . . . . 10.0 111.565 169.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.8 m-20 -78.28 -5.16 51.2 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.933 0.893 . . . . 10.0 111.321 -178.451 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.78 6.91 88.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 111.071 -0.811 . . . . 10.0 111.071 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.0 t -79.95 107.2 12.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.926 0 C-N-CA 126.532 1.933 . . . . 10.0 106.043 176.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.686 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -110.12 118.58 36.78 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 169.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -81.68 123.97 29.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 O-C-N 124.408 1.068 . . . . 10.0 108.461 172.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 99.4 t -112.38 130.44 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.238 0 C-N-CA 127.097 2.159 . . . . 10.0 106.365 177.043 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.3 p -156.11 65.34 0.57 Allowed 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.477 0.711 . . . . 10.0 109.458 174.028 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -96.63 156.9 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 -177.381 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.404 ' OE2' ' NZ ' ' A' ' 30' ' ' LYS . 8.5 tt0 -136.02 121.86 19.87 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 125.465 1.506 . . . . 10.0 109.38 -178.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -125.66 117.78 24.24 Favored 'General case' 0 C--O 1.232 0.174 0 C-N-CA 124.623 1.169 . . . . 10.0 108.6 -177.398 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -89.14 54.64 3.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 171.798 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.02 -53.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 C-N-CA 122.932 0.493 . . . . 10.0 110.245 -176.448 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -58.27 147.52 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 172.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.1 p -137.48 136.19 37.5 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.365 -0.379 . . . . 10.0 110.402 170.706 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -77.79 -35.08 51.91 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 107.862 -1.162 . . . . 10.0 107.862 168.511 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.7 m -151.39 130.58 12.73 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 103.534 -2.765 . . . . 10.0 103.534 168.604 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.33 -79.7 0.1 Allowed Glycine 0 C--N 1.331 0.302 0 N-CA-C 109.219 -1.552 . . . . 10.0 109.219 -169.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -147.22 -54.29 0.22 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.09 -1.055 . . . . 10.0 108.68 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -75.84 -36.99 59.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.372 -1.286 . . . . 10.0 108.633 -173.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.7 t 45.69 61.12 2.77 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.317 1.047 . . . . 10.0 110.326 169.722 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 25.5 pt -74.53 31.77 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.89 0.852 . . . . 10.0 112.956 -169.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.7 mm -81.76 123.82 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 C-N-CA 125.627 1.571 . . . . 10.0 107.912 -176.615 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.14 4.66 64.5 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 123.947 0.785 . . . . 10.0 111.541 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -83.58 171.05 13.71 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 168.189 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 2.4 m -119.12 140.7 49.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 108.245 -1.021 . . . . 10.0 108.245 -177.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.517 HD11 ' CG1' ' A' ' 149' ' ' ILE . 0.2 OUTLIER -113.43 164.25 13.85 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.61 0.641 . . . . 10.0 109.631 168.174 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -140.56 134.22 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 O-C-N 123.953 0.783 . . . . 10.0 109.345 -172.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.9 m -96.95 133.0 40.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 106.554 -1.647 . . . . 10.0 106.554 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.694 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m-70 -114.01 158.3 21.37 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 114.948 1.462 . . . . 10.0 114.948 -175.551 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -55.78 -47.16 77.55 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.246 1.819 . . . . 10.0 111.35 -179.424 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 79.3 mttt -112.46 163.39 14.51 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 119.121 0.873 . . . . 10.0 112.903 -175.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.76 152.78 30.32 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 124.697 1.199 . . . . 10.0 108.755 169.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.464 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.5 OUTLIER -78.96 151.4 31.64 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-O 122.746 1.26 . . . . 10.0 112.292 -179.378 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.82 -29.54 44.83 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 112.133 -2.303 . . . . 10.0 109.448 170.633 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.0 mt 58.55 34.68 24.08 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 124.694 1.198 . . . . 10.0 111.893 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.1 -18.48 57.27 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 123.969 0.795 . . . . 10.0 111.768 170.388 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -74.77 -5.98 46.4 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 124.344 1.058 . . . . 10.0 111.941 -168.787 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.54 -28.99 70.59 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.362 -1.095 . . . . 10.0 110.362 168.217 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.76 43.46 54.15 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.512 -1.035 . . . . 10.0 110.512 -170.274 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -128.28 168.16 15.89 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.115 -1.069 . . . . 10.0 108.115 175.058 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -48.52 -50.24 32.69 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.076 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 58.8 mp0 -55.85 -54.13 48.26 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 125.805 1.642 . . . . 10.0 111.811 171.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.8 p -49.74 -44.98 48.87 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 109.389 -0.596 . . . . 10.0 109.389 -173.118 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.7 t -81.19 -1.64 45.51 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.503 0.557 . . . . 10.0 112.503 -171.325 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.7 mttt -112.68 -50.37 2.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 125.653 1.581 . . . . 10.0 112.128 -176.627 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.1 p -139.09 17.17 2.62 Favored 'General case' 0 C--N 1.34 0.174 0 CA-C-N 119.545 1.066 . . . . 10.0 111.817 173.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.07 -116.45 5.56 Favored Glycine 0 N--CA 1.436 -1.311 0 N-CA-C 103.794 -3.722 . . . . 10.0 103.794 -169.132 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -163.88 40.42 0.09 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.582 -1.636 . . . . 10.0 106.582 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.71 -4.47 37.65 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 124.06 0.944 . . . . 10.0 112.193 -170.539 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.72 -164.3 53.09 Favored Glycine 0 N--CA 1.446 -0.679 0 O-C-N 121.415 -0.803 . . . . 10.0 111.527 169.138 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.6 m -53.86 131.37 39.76 Favored 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 124.711 1.204 . . . . 10.0 114.019 -168.117 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 34.0 mtt180 -64.95 73.47 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.519 1.928 . . . . 10.0 111.168 174.248 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 43.1 mt -51.03 -35.67 35.5 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 112.642 0.608 . . . . 10.0 112.642 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.49 153.09 32.78 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 121.901 -0.5 . . . . 10.0 109.722 176.199 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.6 p -149.98 156.51 41.85 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 109.38 -0.6 . . . . 10.0 109.38 178.565 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.85 153.95 25.17 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.063 -0.815 . . . . 10.0 111.063 -176.434 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 84.6 t -102.88 139.86 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 105.967 -1.864 . . . . 10.0 105.967 -173.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.517 ' CG1' HD11 ' A' ' 117' ' ' LEU . 18.0 mt -74.91 110.31 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 122.843 0.457 . . . . 10.0 109.894 -175.07 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.61 141.92 15.38 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 124.237 0.922 . . . . 10.0 110.972 -177.679 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.8 mt -64.83 146.38 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.401 1.48 . . . . 10.0 110.523 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.59 165.57 29.97 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-O 122.564 1.173 . . . . 10.0 110.506 167.814 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 . . . . . 0 C--O 1.255 1.384 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 166.15 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 105.885 -1.894 . . . . 10.0 105.885 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.7 t -76.81 -46.62 24.21 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 119.996 1.271 . . . . 10.0 110.351 -168.448 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -127.36 128.3 45.64 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 124.321 1.048 . . . . 10.0 111.317 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.04 160.88 38.73 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 123.348 0.659 . . . . 10.0 109.591 168.742 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.13 162.09 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 124.129 0.972 . . . . 10.0 109.291 -178.609 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.41 102.75 3.88 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.703 -1.221 . . . . 10.0 107.703 169.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.414 HG12 HG23 ' B' ' 17' ' ' ILE . 1.5 m -85.12 111.88 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 N-CA-C 108.851 -0.796 . . . . 10.0 108.851 169.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mt -88.16 141.12 28.82 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.481 -0.933 . . . . 10.0 108.481 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -157.8 161.72 38.41 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.696 1.135 . . . . 10.0 108.14 171.49 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.59 -55.98 0.04 OUTLIER Glycine 0 C--N 1.329 0.166 0 N-CA-C 111.937 -0.465 . . . . 10.0 111.937 170.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.75 -45.78 41.65 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 -170.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.48 -66.19 0.57 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 113.676 -1.602 . . . . 10.0 110.786 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -57.81 -36.9 98.07 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.763 2.308 . . . . 10.0 111.071 172.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -67.52 109.9 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 108.472 -0.936 . . . . 10.0 108.472 174.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -126.57 112.25 15.3 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 106.381 -1.711 . . . . 10.0 106.381 168.703 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.636 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -96.39 145.28 17.75 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.718 -1.353 . . . . 10.0 109.718 171.091 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.675 HG22 HG23 ' A' ' 54' ' ' THR . 1.7 mt -145.62 87.63 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -169.801 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -105.99 145.33 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.204 0 C-N-CA 124.446 1.098 . . . . 10.0 110.253 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.1 m-20 -121.06 126.33 49.57 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 127.078 2.151 . . . . 10.0 109.564 168.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -103.68 114.07 28.07 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 170.392 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -109.27 126.97 53.89 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 123.502 0.501 . . . . 10.0 111.333 169.859 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 -94.08 99.41 11.71 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 106.811 -1.552 . . . . 10.0 106.811 174.065 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -50.31 -63.19 1.19 Allowed 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 124.83 1.252 . . . . 10.0 109.928 -177.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -143.6 167.26 22.67 Favored 'General case' 0 N--CA 1.435 -1.208 0 N-CA-C 102.244 -3.243 . . . . 10.0 102.244 167.328 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.3 m -74.49 -10.07 59.2 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 118.545 0.611 . . . . 10.0 110.038 174.473 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 32.6 m120 -78.58 -24.53 45.44 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 124.055 0.942 . . . . 10.0 110.508 172.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.77 159.14 26.61 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 110.073 -1.211 . . . . 10.0 110.073 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -66.12 150.54 85.06 Favored 'Trans proline' 0 N--CA 1.451 -1.029 0 C-N-CA 121.811 1.674 . . . . 10.0 108.426 169.648 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.11 121.0 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 N-CA-C 105.723 -1.954 . . . . 10.0 105.723 169.725 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.5 ttmp? -95.81 120.57 36.31 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 107.124 -1.436 . . . . 10.0 107.124 169.142 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -100.17 103.94 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 C-N-CA 126.824 2.049 . . . . 10.0 106.147 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -126.84 166.35 17.63 Favored 'General case' 0 CA--C 1.52 -0.198 0 N-CA-C 112.355 0.502 . . . . 10.0 112.355 177.417 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.18 -150.57 22.44 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 106.928 -2.469 . . . . 10.0 106.928 169.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.0 p -156.38 165.38 36.5 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.88 175.239 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.636 HG22 ' CA ' ' B' ' 16' ' ' GLY . 1.8 pp -113.67 173.19 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-N 115.298 -0.864 . . . . 10.0 108.868 167.261 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.8 tttt -144.03 142.04 30.44 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 106.492 -1.67 . . . . 10.0 106.492 164.722 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.03 -8.32 11.57 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 113.05 170.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.485 HD23 HD13 ' B' ' 35' ' ' ILE . 0.3 OUTLIER -67.37 177.73 1.79 Allowed 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.181 0.993 . . . . 10.0 111.037 177.464 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.1 t -110.77 152.85 26.13 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.724 -1.584 . . . . 10.0 106.724 168.037 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -53.52 150.78 6.41 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.437 0.695 . . . . 10.0 112.216 -168.626 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.67 -168.49 20.59 Favored Glycine 0 CA--C 1.523 0.567 0 C-N-CA 123.828 0.728 . . . . 10.0 111.295 173.726 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mp -78.16 138.87 38.92 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.335 1.454 . . . . 10.0 110.892 -172.192 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -142.02 131.91 24.39 Favored 'General case' 0 CA--C 1.521 -0.165 0 C-N-CA 124.376 1.07 . . . . 10.0 112.254 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.624 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -17.75 122.92 0.01 OUTLIER Glycine 0 C--N 1.343 0.918 0 C-N-CA 128.001 2.715 . . . . 10.0 113.161 167.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -148.76 106.3 3.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 119.198 1.499 . . . . 10.0 110.633 171.459 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.84 169.95 21.0 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.596 0.712 . . . . 10.0 111.393 177.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 9.3 p -90.6 145.88 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 CA-C-N 111.946 -2.388 . . . . 10.0 107.274 166.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -125.69 146.16 49.86 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.019 -1.845 . . . . 10.0 106.019 170.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 49' ' ' GLU . . . . . 0.51 ' CD ' ' HE ' ' B' ' 115' ' ' ARG . 29.7 tp10 -76.42 -31.5 57.94 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.295 -0.866 . . . . 10.0 111.887 -166.639 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -78.95 113.94 17.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.081 -1.081 . . . . 10.0 108.081 174.687 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.34 -15.6 68.18 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 167.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -42.89 148.47 0.25 Allowed 'General case' 0 C--N 1.343 0.305 0 C-N-CA 124.735 1.214 . . . . 10.0 111.716 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.43 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -158.24 16.54 0.22 Allowed 'General case' 0 N--CA 1.441 -0.925 0 C-N-CA 125.519 1.528 . . . . 10.0 111.564 169.917 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.611 HG23 HG22 ' A' ' 17' ' ' ILE . 3.1 m -54.95 -37.4 66.42 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 119.458 1.026 . . . . 10.0 111.469 -169.147 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.8 -22.23 46.57 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.409 1.084 . . . . 10.0 112.528 177.352 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 126.89 -167.01 19.46 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 106.246 -2.742 . . . . 10.0 106.246 -169.308 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m -72.65 53.28 0.32 Allowed 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 125.005 1.322 . . . . 10.0 107.877 169.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 88.9 m -120.83 -50.22 2.18 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 127.638 2.375 . . . . 10.0 108.245 -165.265 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 14.4 m -114.11 10.61 17.44 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.935 1.294 . . . . 10.0 112.226 -169.174 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -72.49 32.09 0.06 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.434 1.094 . . . . 10.0 113.721 -175.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.67 122.67 0.31 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.151 0.882 . . . . 10.0 112.667 168.74 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 62' ' ' PRO . . . . . 0.401 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 67.6 Cg_endo -77.33 60.79 7.14 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.13 2.553 . . . . 10.0 111.492 174.682 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 62.62 48.27 4.44 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.95 1.7 . . . . 10.0 110.235 173.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 64' ' ' PHE . . . . . 0.401 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 28.8 m-85 -71.03 62.21 0.29 Allowed 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.766 0.712 . . . . 10.0 111.373 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -65.58 142.36 98.25 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.291 -0.881 . . . . 10.0 111.303 -172.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.35 -41.61 6.52 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.723 2.282 . . . . 10.0 110.249 -177.301 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.75 55.16 1.04 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.166 0.986 . . . . 10.0 108.771 175.563 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.9 p -34.15 104.95 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 126.539 1.936 . . . . 10.0 111.859 -169.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.11 176.97 8.18 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 104.319 -2.475 . . . . 10.0 104.319 -173.166 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -69.78 154.28 42.2 Favored 'General case' 0 N--CA 1.435 -1.185 0 C-N-CA 117.148 -1.821 . . . . 10.0 107.994 169.11 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -65.72 118.29 9.38 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 104.717 -2.327 . . . . 10.0 104.717 159.535 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.79 -177.3 22.09 Favored Glycine 0 N--CA 1.435 -1.409 0 N-CA-C 106.699 -2.561 . . . . 10.0 106.699 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.65 -156.59 6.93 Favored Glycine 0 C--O 1.227 -0.294 0 N-CA-C 109.35 -1.5 . . . . 10.0 109.35 -177.423 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -65.48 1.66 2.0 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.323 1.349 . . . . 10.0 110.613 166.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -109.16 0.86 19.97 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 117.754 -1.117 . . . . 10.0 112.007 173.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -116.22 162.78 16.95 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 169.235 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -79.1 -39.79 32.8 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 167.651 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -110.55 63.53 0.61 Allowed 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 124.697 1.199 . . . . 10.0 111.65 -168.132 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -60.65 161.81 7.33 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.359 1.064 . . . . 10.0 109.728 166.602 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 15.5 m170 -66.49 -71.54 0.19 Allowed 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 113.062 0.764 . . . . 10.0 113.062 -174.095 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -166.79 -53.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 O-C-N 121.638 -0.664 . . . . 10.0 109.689 -173.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -131.48 60.47 0.68 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 171.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -112.15 90.5 3.36 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.074 -2.195 . . . . 10.0 105.074 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 84' ' ' LEU . . . . . 0.553 ' C ' HD12 ' B' ' 84' ' ' LEU . 0.3 OUTLIER -82.22 -30.38 30.83 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 106.362 -1.718 . . . . 10.0 106.362 -178.076 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.92 -83.96 0.36 Allowed Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 168.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -156.88 156.35 32.99 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 122.839 0.456 . . . . 10.0 111.101 -177.628 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.5 m -124.48 142.08 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 C-N-CA 125.289 1.435 . . . . 10.0 109.766 -174.339 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -85.71 103.1 14.19 Favored 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 129.433 3.093 . . . . 10.0 110.927 -172.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.48 136.12 36.25 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.861 -0.524 . . . . 10.0 109.844 169.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -65.93 172.49 3.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.733 1.613 . . . . 10.0 110.23 167.546 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.23 -23.48 66.69 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 122.771 0.428 . . . . 10.0 112.091 173.534 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -75.83 -3.05 33.0 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 120.864 0.364 . . . . 10.0 110.252 174.452 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.48 24.73 60.23 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 108.719 -1.752 . . . . 10.0 108.719 176.327 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.6 t -110.13 109.51 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 127.081 2.152 . . . . 10.0 106.904 -174.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.477 ' H ' ' CD1' ' B' ' 35' ' ' ILE . . . -102.17 120.19 40.04 Favored 'General case' 0 CA--C 1.513 -0.467 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 169.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -79.97 119.21 22.5 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 127.415 2.286 . . . . 10.0 108.8 170.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -103.68 130.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 C-N-CA 124.839 1.256 . . . . 10.0 107.754 177.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.9 p -158.42 83.02 0.83 Allowed 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 118.646 -0.693 . . . . 10.0 109.227 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.68 152.59 20.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 N-CA-C 107.553 -1.277 . . . . 10.0 107.553 179.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -126.81 137.01 53.13 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 126.014 1.726 . . . . 10.0 110.31 174.055 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.27 141.08 39.86 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.829 0.852 . . . . 10.0 109.513 177.478 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 18.6 p -106.3 22.91 14.97 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.363 1.465 . . . . 10.0 109.924 169.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 51.0 t -94.88 -15.21 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 C-N-CA 124.859 1.264 . . . . 10.0 109.479 -177.606 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.447 HD13 ' H ' ' B' ' 104' ' ' ILE . 0.0 OUTLIER -134.53 175.17 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 125.461 1.504 . . . . 10.0 112.42 -169.949 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -158.85 147.0 18.1 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 107.631 -1.248 . . . . 10.0 107.631 169.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -60.03 -50.61 73.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.727 -0.842 . . . . 10.0 108.727 -178.238 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 49.8 p -131.39 155.26 47.58 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 172.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 144.9 -101.84 0.26 Allowed Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 107.537 -2.225 . . . . 10.0 107.537 -169.721 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -128.08 -50.89 1.32 Allowed 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 125.466 1.506 . . . . 10.0 108.7 -167.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -75.7 -42.24 51.5 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.184 -1.413 . . . . 10.0 107.184 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.0 t 52.23 66.91 1.07 Allowed 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 126.87 2.068 . . . . 10.0 110.921 168.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 20.6 pt -67.75 -10.05 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 113.606 0.965 . . . . 10.0 113.606 -172.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 113' ' ' ILE . . . . . 0.418 HD12 HG23 ' B' ' 151' ' ' ILE . 21.2 mm -53.41 139.58 11.18 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 O-C-N 120.854 -1.153 . . . . 10.0 110.159 169.692 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.41 4.5 84.44 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.556 -1.136 . . . . 10.0 113.986 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 115' ' ' ARG . . . . . 0.51 ' HE ' ' CD ' ' B' ' 49' ' ' GLU . 27.7 mmt-85 -79.55 178.57 8.04 Favored 'General case' 0 C--N 1.342 0.239 0 CA-C-N 119.223 1.512 . . . . 10.0 109.542 168.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -124.69 135.54 53.13 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 106.454 -1.684 . . . . 10.0 106.454 178.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 7.9 mp -105.08 148.57 26.67 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.406 -1.331 . . . . 10.0 107.406 169.122 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.5 t -126.88 135.22 64.29 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 N-CA-C 107.429 -1.323 . . . . 10.0 107.429 178.307 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -102.91 121.0 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.883 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 169.604 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.624 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.0 m170 -106.12 162.6 13.48 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -169.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -47.95 -50.05 28.41 Favored 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 128.425 2.69 . . . . 10.0 112.477 174.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -128.49 171.97 11.58 Favored 'General case' 0 C--N 1.334 -0.086 0 C-N-CA 124.141 0.976 . . . . 10.0 112.225 -168.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.02 165.7 24.68 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.304 -0.862 . . . . 10.0 109.798 170.009 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.76 155.85 17.15 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.97 1.308 . . . . 10.0 111.637 -176.049 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -77.85 -15.3 59.15 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 114.731 -1.122 . . . . 10.0 110.254 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 73.2 mt 51.65 45.42 28.14 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 124.538 1.135 . . . . 10.0 110.335 172.179 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.19 27.85 73.26 Favored Glycine 0 N--CA 1.437 -1.246 0 CA-C-N 113.797 -1.547 . . . . 10.0 113.378 173.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -74.78 -3.84 34.06 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.295 1.548 . . . . 10.0 112.356 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.22 25.27 73.63 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 108.791 -1.724 . . . . 10.0 108.791 175.522 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -56.03 -30.15 56.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 170.601 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -155.87 167.84 29.12 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.59 -0.892 . . . . 10.0 108.59 -168.365 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.2 tm-20 -56.29 -46.27 79.83 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 108.511 -0.922 . . . . 10.0 108.511 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -59.04 -24.48 62.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 115.96 -0.564 . . . . 10.0 111.997 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 51.9 m -56.13 -32.63 64.41 Favored 'General case' 0 N--CA 1.444 -0.744 0 O-C-N 121.656 -0.653 . . . . 10.0 112.398 -177.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.6 t -93.46 7.73 43.38 Favored 'General case' 0 CA--C 1.534 0.339 0 O-C-N 123.52 0.512 . . . . 10.0 110.108 -174.074 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -128.69 -61.04 1.08 Allowed 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 126.678 1.991 . . . . 10.0 112.46 -174.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -135.71 31.03 3.09 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 120.69 1.586 . . . . 10.0 109.462 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 63.99 -97.59 0.23 Allowed Glycine 0 C--N 1.346 1.109 0 CA-C-O 123.79 1.772 . . . . 10.0 108.925 175.119 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.86 39.41 0.1 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 113.172 -1.514 . . . . 10.0 109.064 167.803 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.71 -12.95 52.25 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.713 0.805 . . . . 10.0 112.702 -169.224 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.75 -166.06 52.06 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 175.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -55.35 131.11 44.92 Favored 'General case' 0 N--CA 1.444 -0.771 0 C-N-CA 123.573 0.749 . . . . 10.0 111.935 -168.544 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -65.7 75.79 0.07 Allowed 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.603 0.761 . . . . 10.0 109.676 169.385 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 69.3 mt -45.37 -49.8 12.74 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.602 0.761 . . . . 10.0 110.726 177.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.56 155.86 36.96 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.495 -0.557 . . . . 10.0 109.495 -171.083 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -158.27 166.88 31.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.05 0.54 . . . . 10.0 109.572 -174.309 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.91 160.17 32.18 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 110.179 -1.169 . . . . 10.0 110.179 -173.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 57.4 t -109.25 138.38 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -171.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.7 mt -75.82 108.96 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 -177.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.5 135.19 12.23 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 109.957 -1.257 . . . . 10.0 109.957 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 151' ' ' ILE . . . . . 0.418 HG23 HD12 ' B' ' 113' ' ' ILE . 2.3 pt -75.42 127.25 36.89 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.231 0 CA-C-N 118.557 1.178 . . . . 10.0 108.604 174.189 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -75.39 -54.89 6.31 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 107.134 -1.432 . . . . 10.0 107.134 178.506 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.348 -0.834 . . . . 10.0 109.457 172.1 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 106.85 -1.537 . . . . 10.0 106.85 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 t -167.51 -38.01 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 124.055 0.942 . . . . 10.0 111.881 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 57.1 tttp -133.46 141.39 47.79 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 124.531 1.132 . . . . 10.0 109.843 178.709 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.66 169.53 21.36 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 126.487 1.915 . . . . 10.0 107.226 176.375 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.9 162.1 35.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 N-CA-C 109.526 -0.546 . . . . 10.0 109.526 -179.248 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.404 ' HB1' HD21 ' A' ' 8' ' ' LEU . . . -132.04 97.64 4.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.989 0.916 . . . . 10.0 108.951 175.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -83.73 106.0 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 N-CA-C 108.677 -0.86 . . . . 10.0 108.677 169.704 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.404 HD21 ' HB1' ' A' ' 6' ' ' ALA . 8.9 mt -100.14 140.68 34.02 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.63 -0.878 . . . . 10.0 108.63 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.9 ttmt -157.84 163.7 37.72 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.509 -1.293 . . . . 10.0 107.509 169.129 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.57 -53.14 0.06 OUTLIER Glycine 0 C--O 1.228 -0.255 0 C-N-CA 120.333 -0.937 . . . . 10.0 112.163 169.33 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -72.64 -45.34 59.49 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.329 -1.36 . . . . 10.0 107.329 -177.665 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.28 -71.09 0.41 Allowed Glycine 0 CA--C 1.524 0.619 0 CA-C-N 114.355 -1.293 . . . . 10.0 110.342 169.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -57.44 -34.8 98.56 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.462 2.775 . . . . 10.0 111.242 173.311 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.6 t -65.3 100.81 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.082 0 N-CA-C 107.335 -1.358 . . . . 10.0 107.335 175.055 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -119.5 116.23 25.67 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.568 1.147 . . . . 10.0 108.381 172.546 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.751 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.71 145.47 17.79 Favored Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 109.892 -1.283 . . . . 10.0 109.892 169.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.633 HG22 HG23 ' B' ' 54' ' ' THR . 1.2 mt -151.54 56.94 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.8 mm -80.82 140.23 16.95 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.041 0 O-C-N 121.587 -0.695 . . . . 10.0 110.011 -175.011 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -99.74 115.3 29.19 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.04 1.336 . . . . 10.0 108.298 170.377 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -92.56 110.38 21.8 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 105.486 -2.042 . . . . 10.0 105.486 170.486 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -131.17 146.6 52.4 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 119.084 0.856 . . . . 10.0 110.481 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.405 ' HB3' ' HA ' ' A' ' 29' ' ' VAL . 13.8 pt20 -148.24 16.21 1.05 Allowed 'General case' 0 C--N 1.342 0.274 0 N-CA-C 115.319 1.6 . . . . 10.0 115.319 -178.682 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? 74.23 -57.38 0.62 Allowed 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 125.595 1.558 . . . . 10.0 113.163 168.739 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.68 -157.26 0.8 Allowed 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 107.964 -1.124 . . . . 10.0 107.964 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -85.48 -23.08 27.94 Favored 'General case' 0 N--CA 1.45 -0.448 0 O-C-N 120.808 -1.182 . . . . 10.0 110.638 170.891 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -89.33 -21.27 23.21 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 123.985 0.914 . . . . 10.0 111.503 -173.456 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.56 151.76 51.68 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.619 -0.545 . . . . 10.0 112.356 -171.234 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -68.46 137.29 39.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.95 2.433 . . . . 10.0 108.842 169.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.405 ' HA ' ' HB3' ' A' ' 22' ' ' GLN . 0.3 OUTLIER -77.74 138.55 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 O-C-N 121.849 -0.532 . . . . 10.0 110.957 179.627 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -119.63 124.93 47.52 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.848 -1.538 . . . . 10.0 106.848 168.418 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.3 m -102.76 59.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 124.339 1.055 . . . . 10.0 109.094 -170.104 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.8 p90 -79.03 146.01 33.55 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 119.625 -0.83 . . . . 10.0 111.312 -172.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.39 -169.48 39.2 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.646 -0.981 . . . . 10.0 110.646 169.156 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.4 m -139.6 107.53 5.7 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.065 -0.717 . . . . 10.0 109.065 -170.411 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.751 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.2 pt -78.31 128.01 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 106.873 -1.529 . . . . 10.0 106.873 168.508 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 tttt -107.21 146.66 31.13 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.115 -1.439 . . . . 10.0 107.115 173.328 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -7.07 31.06 Favored Glycine 0 CA--C 1.522 0.528 0 CA-C-O 119.197 -0.779 . . . . 10.0 112.678 173.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.415 HD21 HD12 ' A' ' 35' ' ' ILE . 3.4 mm? -62.47 177.01 0.55 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.675 1.238 . . . . 10.0 109.284 168.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -113.53 157.06 22.51 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.961 -0.755 . . . . 10.0 108.961 170.039 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -48.9 123.67 7.41 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.062 1.345 . . . . 10.0 111.094 -171.073 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.66 -169.12 13.13 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 123.794 0.711 . . . . 10.0 112.347 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -77.3 146.77 36.61 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 126.12 1.768 . . . . 10.0 112.391 -170.448 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -149.48 144.0 26.03 Favored 'General case' 0 C--N 1.342 0.276 0 N-CA-C 114.049 1.129 . . . . 10.0 114.049 -178.443 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.595 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -33.15 126.24 0.34 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 127.145 2.307 . . . . 10.0 112.232 165.56 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.403 ' CD1' HD12 ' A' ' 84' ' ' LEU . 6.6 t80 -151.03 108.11 3.58 Favored 'General case' 0 C--O 1.238 0.486 0 CA-C-N 119.504 1.652 . . . . 10.0 109.561 167.738 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.5 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -151.94 174.44 13.62 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.148 0.975 . . . . 10.0 113.4 179.329 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.9 p -90.61 151.4 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 CA-C-N 112.028 -2.351 . . . . 10.0 108.038 168.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -127.59 142.69 51.29 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 106.931 -1.507 . . . . 10.0 106.931 171.25 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -37.24 -55.77 0.98 Allowed 'General case' 0 C--O 1.237 0.403 0 C-N-CA 127.535 2.334 . . . . 10.0 113.7 -170.006 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -106.34 169.31 8.59 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-O 122.367 1.079 . . . . 10.0 112.556 -171.417 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.42 -23.47 24.05 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 126.664 2.078 . . . . 10.0 109.771 169.506 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -43.39 120.41 1.9 Allowed 'General case' 0 C--N 1.346 0.417 0 CA-C-O 122.009 0.909 . . . . 10.0 109.863 170.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -134.75 11.9 3.69 Favored 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 125.942 1.697 . . . . 10.0 108.497 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.436 HG23 HG22 ' B' ' 17' ' ' ILE . 1.3 m -59.45 -33.64 71.54 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 119.031 0.832 . . . . 10.0 112.083 -168.216 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.39 -16.14 59.0 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.915 0.886 . . . . 10.0 112.33 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.26 62.92 0.56 Allowed Glycine 0 CA--C 1.521 0.462 0 N-CA-C 108.655 -1.778 . . . . 10.0 108.655 -172.355 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.6 p 41.31 39.6 1.02 Allowed 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 125.868 1.667 . . . . 10.0 114.122 171.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 16.3 m -108.13 -53.3 2.65 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.759 2.024 . . . . 10.0 105.584 -177.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.4 m -66.66 -15.46 63.5 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.525 1.93 . . . . 10.0 112.665 -175.623 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -50.06 -6.28 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.936 2.494 . . . . 10.0 115.715 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 105.8 123.41 5.16 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.117 -1.38 . . . . 10.0 110.372 170.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.59 60.16 5.78 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.595 2.863 . . . . 10.0 110.638 173.172 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.518 ' CD2' HG22 ' A' ' 137' ' ' THR . 20.9 m170 65.34 37.61 6.23 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 130.27 3.428 . . . . 10.0 111.897 179.347 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.1 m-30 -72.89 62.32 0.59 Allowed 'General case' 0 N--CA 1.468 0.462 0 O-C-N 121.196 -0.94 . . . . 10.0 110.628 175.066 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -74.1 152.66 88.49 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.247 -0.908 . . . . 10.0 111.146 -172.182 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -60.45 -42.67 39.09 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.435 2.756 . . . . 10.0 111.848 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.3 tp -77.91 59.08 2.04 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 123.781 0.832 . . . . 10.0 108.772 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 58.7 p -40.75 104.85 0.04 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.282 2.233 . . . . 10.0 112.128 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -137.62 175.11 9.88 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 126.403 1.881 . . . . 10.0 107.467 -177.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.15 113.93 27.42 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-N 118.952 0.796 . . . . 10.0 109.884 -174.698 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.0 t60 -30.18 101.55 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 114.593 1.331 . . . . 10.0 114.593 -171.612 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -114.44 -147.97 9.6 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 176.247 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.33 -148.65 5.64 Favored Glycine 0 C--N 1.332 0.334 0 CA-C-O 118.237 -1.313 . . . . 10.0 109.902 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -62.76 -3.76 4.95 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 CA-C-N 120.225 2.012 . . . . 10.0 111.946 169.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -85.0 -19.61 31.77 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 118.452 -0.785 . . . . 10.0 111.041 171.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -130.55 162.41 29.35 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 123.849 1.785 . . . . 10.0 112.875 -166.309 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -85.43 -24.06 27.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 112.879 -1.964 . . . . 10.0 108.261 166.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -86.34 7.79 24.11 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.532 1.533 . . . . 10.0 110.85 -174.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 33.9 ptt-85 -48.33 126.83 11.93 Favored 'General case' 0 C--N 1.342 0.263 0 N-CA-C 106.507 -1.664 . . . . 10.0 106.507 166.624 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m80 -50.57 -57.47 8.08 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.11 0.411 . . . . 10.0 112.11 -167.651 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.7 p -173.9 -45.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 124.711 1.205 . . . . 10.0 108.33 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.14 56.44 0.73 Allowed Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.681 -1.367 . . . . 10.0 109.681 175.617 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -97.5 97.25 8.92 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 106.001 -1.851 . . . . 10.0 106.001 169.058 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.403 HD12 ' CD1' ' A' ' 45' ' ' PHE . 14.0 mt -76.26 -27.11 56.58 Favored 'General case' 0 C--N 1.34 0.163 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 173.418 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.71 -104.17 3.07 Favored Glycine 0 N--CA 1.439 -1.128 0 N-CA-C 108.638 -1.785 . . . . 10.0 108.638 168.443 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -122.3 100.28 6.87 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.055 1.342 . . . . 10.0 109.48 -167.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.2 m -95.74 136.92 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 C-N-CA 122.855 0.462 . . . . 10.0 110.187 178.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.8 m -85.19 119.41 25.54 Favored 'General case' 0 N--CA 1.439 -0.985 0 C-N-CA 127.437 2.295 . . . . 10.0 108.819 -177.041 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.57 134.65 39.52 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 123.568 0.747 . . . . 10.0 109.627 169.584 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -62.62 169.86 2.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 O-C-N 124.412 1.07 . . . . 10.0 108.751 166.419 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.86 -21.63 64.84 Favored 'General case' 0 N--CA 1.445 -0.705 0 C-N-CA 124.192 0.997 . . . . 10.0 112.892 172.454 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.17 -4.68 45.86 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.036 0.446 . . . . 10.0 110.691 171.523 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.22 6.3 86.44 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 120.671 -1.268 . . . . 10.0 110.839 178.353 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.18 106.13 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 127.339 2.256 . . . . 10.0 107.332 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.432 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -103.43 116.47 32.47 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 167.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.28 104.17 10.65 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 126.812 2.045 . . . . 10.0 109.841 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.12 131.86 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 172.517 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.3 m -157.52 57.63 0.5 Allowed 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.495 1.118 . . . . 10.0 109.476 173.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.84 150.75 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.835 -1.543 . . . . 10.0 106.835 178.455 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -128.19 150.81 49.85 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 108.626 170.11 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.13 124.42 6.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 108.873 -0.788 . . . . 10.0 108.873 172.376 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 11.0 t -79.07 0.48 27.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.291 1.037 . . . . 10.0 112.196 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.41 -24.75 17.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 CA-C-N 119.579 1.081 . . . . 10.0 109.486 177.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.0 159.28 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 124.599 1.16 . . . . 10.0 111.003 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.8 m -152.72 144.93 23.89 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.281 -2.118 . . . . 10.0 105.281 174.632 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.6 mt -65.04 -8.55 16.7 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 123.95 0.9 . . . . 10.0 111.828 176.279 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.6 m -150.94 137.96 19.15 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.031 -1.47 . . . . 10.0 107.031 169.198 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.26 -66.25 0.14 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 109.018 -1.633 . . . . 10.0 109.018 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -167.71 -51.44 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 125.58 1.552 . . . . 10.0 107.981 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.96 -36.19 62.07 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 114.914 -1.039 . . . . 10.0 109.128 -169.194 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 30.9 t 38.98 70.66 0.2 Allowed 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 126.692 1.997 . . . . 10.0 112.263 167.704 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -56.67 -10.22 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 114.113 1.153 . . . . 10.0 114.113 177.77 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 mm -33.87 -52.95 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.327 1.451 . . . . 10.0 112.98 170.116 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -96.81 9.48 66.11 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-O 118.937 -0.924 . . . . 10.0 114.153 -174.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.94 156.46 21.18 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 118.525 1.162 . . . . 10.0 109.742 176.67 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 59.1 m -90.4 131.58 36.1 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.768 0.827 . . . . 10.0 109.627 168.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -99.87 145.61 27.58 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 167.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.8 t -137.46 136.34 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 123.516 0.726 . . . . 10.0 109.17 -176.244 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.35 142.08 17.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 O-C-N 124.579 1.175 . . . . 10.0 108.811 167.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.595 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.5 m170 -121.72 162.03 21.53 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.896 1.443 . . . . 10.0 114.896 -175.637 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -58.31 -50.87 72.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.266 1.427 . . . . 10.0 110.736 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -116.39 172.75 7.0 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 121.804 0.812 . . . . 10.0 112.203 -178.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.28 138.96 40.88 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 126.054 1.742 . . . . 10.0 108.981 174.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.5 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -77.36 164.76 25.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 122.232 1.015 . . . . 10.0 111.847 173.596 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.413 ' OD1' ' NZ ' ' A' ' 128' ' ' LYS . 25.6 t0 -74.82 -8.15 55.57 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 113.608 -1.633 . . . . 10.0 111.298 178.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 14.5 mt 46.8 41.18 10.05 Favored 'General case' 0 C--N 1.339 0.113 0 C-N-CA 124.484 1.114 . . . . 10.0 109.831 -177.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 72.05 19.64 78.53 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 118.313 -1.271 . . . . 10.0 114.765 171.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.413 ' NZ ' ' OD1' ' A' ' 125' ' ' ASP 0.251 8.7 mtmp? -77.13 10.65 2.25 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 119.803 1.801 . . . . 10.0 114.991 -176.073 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.72 29.0 61.98 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 109.185 -1.566 . . . . 10.0 109.185 168.196 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -53.19 -30.01 38.17 Favored Glycine 0 N--CA 1.436 -1.351 0 CA-C-O 118.132 -1.371 . . . . 10.0 110.321 167.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 174.61 178.85 0.13 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 106.7 -1.593 . . . . 10.0 106.7 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 37.5 mp0 -49.48 -41.29 40.12 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 112.876 0.695 . . . . 10.0 112.876 179.179 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 -64.33 -24.13 67.54 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 121.244 -0.91 . . . . 10.0 110.684 -178.481 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.413 ' HA ' ' HA2' ' A' ' 138' ' ' GLY . 55.1 m -45.3 -44.58 11.58 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 122.964 0.506 . . . . 10.0 110.286 175.792 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 t -84.7 -1.09 55.7 Favored 'General case' 0 CA--C 1.541 0.628 0 O-C-N 124.049 0.843 . . . . 10.0 112.147 -170.233 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.1 mttt -118.82 -73.65 0.64 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.955 1.302 . . . . 10.0 110.275 -173.386 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.518 HG22 ' CD2' ' A' ' 63' ' ' HIS . 7.1 p -121.56 26.83 8.56 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 120.164 -1.585 . . . . 10.0 110.242 171.544 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' A' ' 134' ' ' SER . . . 72.86 -91.57 0.6 Allowed Glycine 0 C--N 1.342 0.886 0 N-CA-C 109.934 -1.266 . . . . 10.0 109.934 174.501 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -173.38 39.12 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.195 1.398 . . . . 10.0 108.886 171.087 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.26 -16.61 62.49 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 121.473 -0.767 . . . . 10.0 112.77 -168.311 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.37 -162.59 54.66 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.102 -1.199 . . . . 10.0 110.102 175.631 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -51.9 126.77 19.14 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.036 1.334 . . . . 10.0 113.8 -168.326 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -64.7 72.89 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.229 1.812 . . . . 10.0 110.996 173.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.2 mt -51.12 -35.67 36.6 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 113.381 0.882 . . . . 10.0 113.381 -178.069 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 154.47 37.09 Favored 'General case' 0 CA--C 1.511 -0.555 0 O-C-N 121.61 -0.681 . . . . 10.0 109.948 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.6 p -153.24 153.7 33.21 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.583 -0.895 . . . . 10.0 108.583 -172.512 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.81 153.37 24.36 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 112.044 -0.422 . . . . 10.0 112.044 179.487 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 63.4 t -101.3 125.31 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.012 -2.218 . . . . 10.0 105.012 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.2 mt -68.55 164.93 2.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 CA-C-N 119.009 0.822 . . . . 10.0 110.403 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -160.5 150.66 20.84 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.576 1.56 . . . . 10.0 109.443 -172.136 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.3 mt -70.93 141.7 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.892 1.277 . . . . 10.0 109.023 -173.802 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.43 -46.51 2.87 Favored 'General case' 0 C--O 1.224 -0.268 0 C-N-CA 123.1 0.56 . . . . 10.0 110.674 170.25 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.7 tp60 . . . . . 0 C--O 1.25 1.107 0 C-N-CA 126.634 1.974 . . . . 10.0 112.082 -173.04 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.872 0 CA-C-O 117.571 -1.205 . . . . 10.0 108.993 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 t -61.27 -38.16 85.74 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 120.19 1.359 . . . . 10.0 108.852 172.288 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 36.9 tttt -132.03 156.35 46.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.447 1.499 . . . . 10.0 110.219 168.728 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.47 175.35 14.14 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 129.01 2.924 . . . . 10.0 106.504 166.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -133.6 179.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 118.677 0.671 . . . . 10.0 110.611 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.43 108.9 2.1 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.093 0.957 . . . . 10.0 109.189 165.039 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -95.17 124.28 47.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 122.959 0.503 . . . . 10.0 110.208 170.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -103.54 146.24 28.84 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 125.441 1.496 . . . . 10.0 110.275 176.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 5.4 tttm -161.73 158.61 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 169.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 179.86 -46.55 0.08 OUTLIER Glycine 0 N--CA 1.46 0.236 0 C-N-CA 118.927 -1.606 . . . . 10.0 113.638 169.353 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -72.59 -47.71 45.69 Favored 'General case' 0 N--CA 1.451 -0.375 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 -178.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.91 -73.84 0.29 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 114.331 -1.304 . . . . 10.0 109.845 171.115 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -59.07 -34.74 98.98 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.738 2.959 . . . . 10.0 111.18 174.728 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.5 t -62.2 114.04 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.12 -1.067 . . . . 10.0 108.12 176.006 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.87 118.6 22.97 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 106.339 -1.726 . . . . 10.0 106.339 168.589 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.679 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -102.47 141.12 15.14 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-O 118.598 -1.112 . . . . 10.0 110.48 174.42 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.436 HG22 HG23 ' A' ' 54' ' ' THR . 9.4 mt -139.78 94.2 0.77 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 C-N-CA 123.874 0.87 . . . . 10.0 109.063 -173.062 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.7 mm -105.71 139.77 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 C-N-CA 125.658 1.583 . . . . 10.0 112.623 -178.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -106.75 126.6 52.49 Favored 'General case' 0 C--N 1.34 0.179 0 N-CA-C 106.452 -1.685 . . . . 10.0 106.452 167.059 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -104.16 112.42 25.42 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 107.057 -1.46 . . . . 10.0 107.057 168.54 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -126.82 136.32 52.2 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 118.462 0.573 . . . . 10.0 112.35 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -105.48 112.76 25.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.62 1.568 . . . . 10.0 106.873 169.017 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.23 34.95 1.34 Allowed 'General case' 0 C--O 1.235 0.308 0 N-CA-C 111.93 0.344 . . . . 10.0 111.93 -177.023 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -142.9 166.35 24.88 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 104.903 -2.258 . . . . 10.0 104.903 169.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 29.4 t -91.28 14.98 12.93 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 109.031 -0.729 . . . . 10.0 109.031 -173.365 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 -112.62 7.61 18.84 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 123.832 0.853 . . . . 10.0 108.892 167.199 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.57 47.13 23.65 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.59 -1.117 . . . . 10.0 114.496 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -65.26 115.84 3.55 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 CA-C-N 119.834 1.817 . . . . 10.0 107.652 170.375 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t -77.27 84.65 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 105.31 -2.107 . . . . 10.0 105.31 175.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -74.35 117.4 16.12 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.024 -1.473 . . . . 10.0 107.024 179.38 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.42 58.77 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 C-N-CA 125.085 1.354 . . . . 10.0 108.121 -169.372 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.4 p90 -81.48 143.21 32.24 Favored 'General case' 0 C--N 1.341 0.209 0 C-N-CA 119.134 -1.026 . . . . 10.0 111.996 -176.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.81 -169.09 41.39 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.636 -1.269 . . . . 10.0 110.106 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 m -153.24 133.11 13.2 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.679 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.3 pt -103.63 147.72 9.53 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 N-CA-C 107.995 -1.113 . . . . 10.0 107.995 167.212 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -124.81 149.98 46.85 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 169.047 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.48 -6.7 36.24 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 123.428 0.537 . . . . 10.0 112.519 171.665 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.41 HD12 ' CG ' ' B' ' 43' ' ' HIS . 2.0 mm? -63.93 174.43 1.49 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.956 0.878 . . . . 10.0 109.965 169.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -101.76 170.81 7.92 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 105.898 -1.89 . . . . 10.0 105.898 165.414 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -59.84 166.67 2.52 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 118.661 0.664 . . . . 10.0 111.829 -171.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.49 -171.56 45.75 Favored Glycine 0 N--CA 1.446 -0.647 0 O-C-N 121.478 -0.764 . . . . 10.0 111.72 169.487 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -77.5 144.31 37.8 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.259 1.424 . . . . 10.0 111.224 -174.022 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 43' ' ' HIS . . . . . 0.41 ' CG ' HD12 ' B' ' 38' ' ' LEU . 89.7 m-70 -147.48 127.88 14.01 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.518 1.127 . . . . 10.0 112.633 -173.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.69 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -18.69 128.71 0.01 OUTLIER Glycine 0 C--N 1.342 0.881 0 C-N-CA 127.499 2.476 . . . . 10.0 114.179 165.739 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.75 104.94 3.23 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 118.605 1.203 . . . . 10.0 109.793 167.73 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.51 176.46 10.93 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 112.766 0.654 . . . . 10.0 112.766 176.385 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 23.4 m -89.82 158.69 2.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 113.601 -1.636 . . . . 10.0 108.626 168.469 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 74.8 m-70 -136.47 78.11 1.69 Allowed 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 123.586 0.755 . . . . 10.0 111.138 176.021 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.8 tt0 47.65 -94.42 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.792 1.237 . . . . 10.0 113.027 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -78.76 172.03 14.32 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.582 0.628 . . . . 10.0 110.01 -173.128 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.97 -23.1 23.74 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.553 -1.019 . . . . 10.0 110.553 170.141 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -37.71 135.07 0.64 Allowed 'General case' 0 C--N 1.343 0.306 0 C-N-CA 124.598 1.159 . . . . 10.0 110.863 170.46 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.427 HD21 HG21 ' B' ' 116' ' ' THR . 0.3 OUTLIER -146.05 23.99 1.33 Allowed 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 114.75 -1.114 . . . . 10.0 110.362 173.152 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.633 HG23 HG22 ' A' ' 17' ' ' ILE . 2.7 m -52.43 -36.83 55.34 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.065 0.848 . . . . 10.0 110.982 -173.513 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.56 -21.72 28.41 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.29 1.436 . . . . 10.0 113.697 177.178 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.48 101.92 1.45 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.813 1.197 . . . . 10.0 110.183 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.314 2.6 p 17.43 57.65 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 127.752 2.421 . . . . 10.0 114.151 -170.377 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.8 m -130.48 -61.9 0.94 Allowed 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.479 -2.045 . . . . 10.0 105.479 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 39.3 t -69.66 -35.68 75.38 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.009 1.324 . . . . 10.0 111.323 -178.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.88 -47.41 0.13 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 127.122 2.169 . . . . 10.0 114.181 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 138.5 172.54 12.6 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.243 -1.543 . . . . 10.0 109.243 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -78.67 -137.35 0.02 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.222 0 N-CA-C 104.156 -3.055 . . . . 10.0 104.156 166.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 27.3 m170 -100.99 50.68 0.86 Allowed 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 121.067 1.758 . . . . 10.0 109.557 170.137 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -71.79 80.05 0.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.169 0.985 . . . . 10.0 110.033 177.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.5 p-10 -80.15 156.31 74.26 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 125.474 1.509 . . . . 10.0 110.222 172.614 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -63.51 -50.1 3.75 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.489 2.126 . . . . 10.0 111.292 177.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.58 57.72 1.64 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.213 0.605 . . . . 10.0 109.887 179.623 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.9 p -51.35 114.21 1.16 Allowed 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.607 1.163 . . . . 10.0 109.999 -176.308 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.2 mtt-85 -131.33 -86.49 0.49 Allowed 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 104.996 -2.224 . . . . 10.0 104.996 -176.566 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 ptpp? -163.26 162.77 25.42 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 167.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 66.9 t60 -58.28 132.67 54.31 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 118.358 -1.337 . . . . 10.0 107.655 168.317 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.37 -133.23 2.64 Favored Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 169.55 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.507 ' HA3' HD13 ' B' ' 126' ' ' LEU . . . 163.51 -161.28 33.99 Favored Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 108.376 -1.89 . . . . 10.0 108.376 178.046 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.74 4.61 0.8 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.864 1.71 . . . . 10.0 111.928 168.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.567 ' HG3' HD12 ' B' ' 126' ' ' LEU . 9.9 mmmt -114.03 7.94 16.94 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 119.225 0.92 . . . . 10.0 110.481 170.876 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -125.93 163.09 23.74 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 119.733 1.151 . . . . 10.0 108.977 167.703 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -81.61 -30.06 33.02 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 169.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -119.65 61.5 0.83 Allowed 'General case' 0 N--CA 1.436 -1.168 0 CA-C-O 122.095 0.95 . . . . 10.0 110.859 -168.489 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 79' ' ' ARG . . . . . 0.442 HH12 ' CG ' ' B' ' 101' ' ' ASP . 0.3 OUTLIER -56.32 164.39 1.36 Allowed 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 114.393 -1.276 . . . . 10.0 108.697 164.833 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.6 m170 -65.99 -84.57 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 N-CA-C 108.569 -0.9 . . . . 10.0 108.569 169.36 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 49.2 t -149.82 -82.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 104.186 -2.524 . . . . 10.0 104.186 169.055 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.83 53.89 4.77 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.566 -0.614 . . . . 10.0 111.566 -178.705 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -93.9 98.78 11.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 104.39 -2.448 . . . . 10.0 104.39 168.224 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 37.1 mt -81.92 -36.26 28.26 Favored 'General case' 0 C--N 1.334 -0.095 0 N-CA-C 105.744 -1.947 . . . . 10.0 105.744 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.26 -92.06 0.64 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 106.717 -2.553 . . . . 10.0 106.717 169.503 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -155.82 155.73 33.5 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 122.793 0.437 . . . . 10.0 111.45 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.48 145.68 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 O-C-N 124.762 1.289 . . . . 10.0 108.507 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.0 m -93.43 110.42 21.98 Favored 'General case' 0 N--CA 1.436 -1.135 0 C-N-CA 128.497 2.719 . . . . 10.0 108.88 -172.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.3 135.59 33.49 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 123.771 0.828 . . . . 10.0 110.117 174.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -61.65 168.51 2.91 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 124.091 0.956 . . . . 10.0 109.107 166.477 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.78 -30.67 45.7 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.492 0.717 . . . . 10.0 111.079 172.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -78.68 1.6 22.36 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-O 121.25 0.548 . . . . 10.0 111.454 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.92 90.7 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 120.843 -1.161 . . . . 10.0 110.947 176.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.1 t -79.77 104.72 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.059 0 C-N-CA 127.09 2.156 . . . . 10.0 107.013 179.242 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.54 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -107.55 115.09 29.53 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 168.448 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.7 123.36 27.59 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 127.381 2.272 . . . . 10.0 108.622 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.0 t -110.79 131.43 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 C-N-CA 125.494 1.517 . . . . 10.0 107.279 178.804 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 93.0 p -156.98 59.14 0.52 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 123.316 0.646 . . . . 10.0 109.552 177.288 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.83 154.82 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -176.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -102.33 153.21 20.22 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 126.639 1.976 . . . . 10.0 107.382 170.169 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 101' ' ' ASP . . . . . 0.442 ' CG ' HH12 ' B' ' 79' ' ' ARG . 23.8 t0 -149.06 85.17 1.46 Allowed 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.583 0.706 . . . . 10.0 109.292 174.703 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.8 p -90.25 38.11 0.92 Allowed 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.81 0.844 . . . . 10.0 109.663 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 26.1 t -106.75 -46.19 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 107.444 -1.317 . . . . 10.0 107.444 176.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.406 ' CD1' ' H ' ' B' ' 104' ' ' ILE 0.261 0.0 OUTLIER -100.88 176.01 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 114.155 1.168 . . . . 10.0 114.155 175.465 . . . . . . . . 4 4 . 1 . 019 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -136.29 142.8 43.95 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.517 -1.66 . . . . 10.0 106.517 169.167 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -65.58 -25.72 67.54 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.131 0.573 . . . . 10.0 110.117 171.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.1 p -140.76 118.94 12.0 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 170.275 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.04 -63.04 0.05 OUTLIER Glycine 0 C--N 1.333 0.41 0 N-CA-C 109.024 -1.63 . . . . 10.0 109.024 -177.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -163.04 -51.87 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 125.877 1.671 . . . . 10.0 107.489 177.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -74.33 -38.61 63.23 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 114.413 -1.267 . . . . 10.0 108.621 -169.605 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.9 t 47.76 75.36 0.13 Allowed 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 126.166 1.786 . . . . 10.0 109.301 169.306 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 12.5 pt -68.97 65.19 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.324 0 CA-C-O 122.786 1.279 . . . . 10.0 110.388 173.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.6 mm -110.61 151.73 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 129.117 2.967 . . . . 10.0 105.275 167.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 55.31 35.64 61.09 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 124.866 1.222 . . . . 10.0 113.746 171.382 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 83.7 mtt85 -113.96 154.62 27.28 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.305 1.842 . . . . 10.0 107.51 171.728 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 116' ' ' THR . . . . . 0.427 HG21 HD21 ' B' ' 53' ' ' ASN . 90.2 m -86.06 133.95 33.86 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.01 0.924 . . . . 10.0 109.7 177.257 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -98.42 147.46 24.69 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 125.212 1.405 . . . . 10.0 107.297 166.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.57 141.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-N 118.563 0.62 . . . . 10.0 109.369 176.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.418 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 7.6 p -103.32 139.45 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 C-N-CA 124.575 1.15 . . . . 10.0 108.981 168.064 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.69 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.6 m-70 -115.91 164.25 14.69 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.814 1.413 . . . . 10.0 114.814 -175.268 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 121' ' ' GLU . . . . . 0.402 ' HB2' HD21 ' B' ' 144' ' ' LEU . 73.8 tt0 -59.43 -49.43 77.85 Favored 'General case' 0 C--N 1.343 0.293 0 C-N-CA 123.756 0.823 . . . . 10.0 110.438 178.607 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.2 mttt -121.24 175.56 6.06 Favored 'General case' 0 N--CA 1.462 0.169 0 N-CA-C 112.229 0.455 . . . . 10.0 112.229 -169.186 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.54 139.03 39.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.201 1.0 . . . . 10.0 109.332 173.763 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.67 144.1 30.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.059 0.944 . . . . 10.0 108.827 167.67 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -79.2 28.31 0.23 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 123.395 0.678 . . . . 10.0 111.236 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.567 HD12 ' HG3' ' B' ' 75' ' ' LYS . 6.6 mt 23.86 60.23 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 128.685 2.794 . . . . 10.0 112.157 -168.85 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 92.63 -35.58 4.0 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 126.192 1.853 . . . . 10.0 112.147 174.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.2 mtmm -84.46 44.15 1.02 Allowed 'General case' 0 CA--C 1.537 0.465 0 O-C-N 121.256 -1.144 . . . . 10.0 111.247 -170.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.44 -18.12 46.8 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 126.518 2.008 . . . . 10.0 110.159 169.371 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.15 35.82 91.41 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 123.965 0.793 . . . . 10.0 112.415 172.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -144.48 169.48 17.87 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 107.916 -1.142 . . . . 10.0 107.916 172.163 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -52.64 -47.4 67.09 Favored 'General case' 0 N--CA 1.444 -0.736 0 CA-C-O 121.805 0.812 . . . . 10.0 110.351 -177.44 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -65.36 -31.59 72.79 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 121.32 -0.863 . . . . 10.0 111.234 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 12.3 p -55.5 -42.14 74.03 Favored 'General case' 0 N--CA 1.447 -0.604 0 O-C-N 120.818 -1.176 . . . . 10.0 111.353 171.601 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.6 t -80.91 -24.16 38.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 119.835 -0.746 . . . . 10.0 111.202 -176.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 ttmm -80.81 -50.57 9.65 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 125.886 1.674 . . . . 10.0 111.533 -176.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 26.1 p -136.2 -15.18 1.72 Allowed 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 114.441 1.274 . . . . 10.0 114.441 176.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.53 3.07 55.43 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-O 118.286 -1.286 . . . . 10.0 113.884 -179.464 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 29.1 m120 73.23 26.97 2.02 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.101 1.45 . . . . 10.0 112.359 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.47 -2.29 13.48 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.272 -0.892 . . . . 10.0 113.298 176.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.0 -170.15 50.92 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 -175.681 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.51 169.66 2.87 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.167 0.987 . . . . 10.0 112.135 -177.01 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.79 115.96 18.82 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.85 2.06 . . . . 10.0 109.814 168.664 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.423 ' N ' ' CD2' ' B' ' 144' ' ' LEU . 0.4 OUTLIER -92.0 -36.84 13.18 Favored 'General case' 0 C--N 1.34 0.169 0 CA-C-N 119.753 1.16 . . . . 10.0 111.414 -176.263 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.418 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -148.36 149.78 32.4 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 176.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -118.63 142.44 47.64 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.796 1.638 . . . . 10.0 107.672 -168.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -137.06 161.19 25.14 Favored Glycine 0 C--N 1.331 0.265 0 N-CA-C 109.79 -1.324 . . . . 10.0 109.79 171.566 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -123.52 152.27 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 104.246 -2.501 . . . . 10.0 104.246 171.522 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.0 mt -67.41 -91.67 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 124.018 0.927 . . . . 10.0 111.625 -167.155 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.84 136.2 9.22 Favored Glycine 0 CA--C 1.532 1.112 0 N-CA-C 111.68 -0.568 . . . . 10.0 111.68 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 9.5 pt -85.34 146.78 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 C-N-CA 124.534 1.134 . . . . 10.0 110.122 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.87 -24.36 8.19 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.575 0.75 . . . . 10.0 112.8 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.88 0 C-N-CA 124.355 1.062 . . . . 10.0 108.195 -174.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.86 0 CA-C-O 117.89 -1.053 . . . . 10.0 109.158 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -116.81 -50.3 2.61 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 123.947 0.899 . . . . 10.0 112.304 -176.136 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -111.87 125.73 54.34 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 126.638 1.975 . . . . 10.0 108.825 -176.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 164.22 30.54 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.694 1.198 . . . . 10.0 108.286 170.188 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.4 m -139.04 164.46 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 C-N-CA 123.7 0.8 . . . . 10.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.66 118.72 15.38 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.644 -0.873 . . . . 10.0 108.644 168.303 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -92.34 110.23 22.57 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.33 -0.989 . . . . 10.0 108.33 168.248 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.424 ' N ' HD12 ' A' ' 8' ' ' LEU . 5.1 mp -95.0 144.86 25.35 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 108.731 -0.84 . . . . 10.0 108.731 177.032 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.2 mtmt -156.45 161.49 40.06 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 172.699 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.69 -51.59 0.09 OUTLIER Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.071 -1.061 . . . . 10.0 113.653 169.29 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.4 -44.57 62.3 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.49 -1.3 . . . . 10.0 107.49 -175.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.19 -71.01 0.4 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.684 -1.366 . . . . 10.0 109.684 169.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -58.06 -35.54 98.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 123.089 2.526 . . . . 10.0 111.273 172.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.3 t -64.65 107.33 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 178.264 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.45 104.87 10.0 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 172.489 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.807 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.37 137.1 14.15 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 176.003 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.424 ' CG2' HG22 ' B' ' 54' ' ' THR . 3.7 mt -139.08 87.93 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.282 0 N-CA-C 107.381 -1.34 . . . . 10.0 107.381 -175.558 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -99.75 141.64 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.16 0 C-N-CA 124.819 1.248 . . . . 10.0 110.059 -178.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -126.27 113.45 16.97 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.476 1.91 . . . . 10.0 108.569 175.379 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -93.51 115.02 27.53 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 126.367 1.867 . . . . 10.0 108.545 177.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -117.5 130.04 56.19 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.85 1.055 . . . . 10.0 113.85 171.606 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -105.2 111.88 24.8 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 104.545 -2.391 . . . . 10.0 104.545 166.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -65.0 -36.78 85.52 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.952 -0.468 . . . . 10.0 111.131 -172.436 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -137.6 -165.43 1.77 Allowed 'General case' 0 N--CA 1.436 -1.175 0 N-CA-C 104.521 -2.4 . . . . 10.0 104.521 171.508 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.0 t -78.6 -24.48 45.39 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 118.97 0.805 . . . . 10.0 110.206 173.048 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.6 m-80 -91.83 -17.88 24.65 Favored 'General case' 0 N--CA 1.448 -0.574 0 C-N-CA 124.648 1.179 . . . . 10.0 110.551 -175.26 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.22 144.82 41.74 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 178.421 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -63.63 156.87 54.62 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 N-CA-C 108.116 -1.532 . . . . 10.0 108.116 169.576 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 75.2 t -79.0 102.31 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 N-CA-C 106.036 -1.839 . . . . 10.0 106.036 175.78 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.2 mtpp -79.0 105.38 10.3 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 105.49 -2.041 . . . . 10.0 105.49 170.022 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -100.58 97.85 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 C-N-CA 125.421 1.488 . . . . 10.0 107.502 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.6 p90 -103.26 174.59 5.8 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.322 0.582 . . . . 10.0 110.205 169.747 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.07 170.93 37.97 Favored Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 110.79 -0.924 . . . . 10.0 110.79 177.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.6 t -136.82 96.39 3.31 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 177.323 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.807 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.6 pt -81.24 140.59 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 169.456 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.6 tttm -112.83 158.08 20.59 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 108.522 -0.918 . . . . 10.0 108.522 167.339 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.12 -7.27 58.57 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 123.579 0.609 . . . . 10.0 112.678 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -67.44 170.07 8.04 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 118.235 1.017 . . . . 10.0 109.86 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -103.65 153.33 20.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.688 -1.597 . . . . 10.0 106.688 167.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.6 143.88 4.72 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.25 1.02 . . . . 10.0 112.046 -170.497 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.48 -173.35 24.89 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 123.846 0.736 . . . . 10.0 112.269 171.541 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.26 145.27 54.41 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.594 1.957 . . . . 10.0 111.493 -175.162 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -146.31 141.25 27.1 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.398 1.079 . . . . 10.0 111.77 175.42 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.67 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -24.69 123.58 0.03 OUTLIER Glycine 0 C--N 1.344 1.008 0 C-N-CA 126.493 1.996 . . . . 10.0 112.219 165.703 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -144.55 104.54 4.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 119.735 1.767 . . . . 10.0 109.502 171.01 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.26 170.41 20.1 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 121.835 0.826 . . . . 10.0 111.557 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.4 m -88.54 149.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-N 112.139 -2.301 . . . . 10.0 106.259 167.313 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -120.6 128.08 52.7 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 103.782 -2.673 . . . . 10.0 103.782 169.049 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -58.54 -51.35 70.25 Favored 'General case' 0 N--CA 1.44 -0.932 0 O-C-N 124.99 1.431 . . . . 10.0 110.016 -168.653 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -79.55 137.84 37.29 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 -179.542 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.34 25.57 9.72 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.853 -0.899 . . . . 10.0 110.853 173.077 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.7 p30 -75.84 72.48 2.73 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 123.542 1.639 . . . . 10.0 109.317 170.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.471 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.6 OUTLIER -75.82 6.24 5.28 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 113.658 -1.61 . . . . 10.0 112.66 -173.853 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.543 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.1 OUTLIER -39.2 -44.26 1.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 128.207 2.603 . . . . 10.0 111.982 175.221 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.37 -19.97 48.89 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.247 1.019 . . . . 10.0 113.258 -177.472 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.79 87.13 1.47 Allowed Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.404 -1.079 . . . . 10.0 110.404 -177.129 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 m 52.31 29.14 6.38 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.417 1.487 . . . . 10.0 112.407 172.212 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.5 m -117.53 -54.83 2.34 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.295 -1.372 . . . . 10.0 107.295 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.1 m -77.01 -16.19 59.39 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 123.961 0.905 . . . . 10.0 112.579 -171.081 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -53.03 -12.88 0.38 Allowed 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.979 1.712 . . . . 10.0 115.234 -170.186 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.23 125.87 3.06 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 118.647 -1.085 . . . . 10.0 110.436 171.621 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -75.53 64.01 6.47 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.49 2.793 . . . . 10.0 111.732 179.326 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 26.7 m170 67.07 53.91 0.78 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 128.692 2.797 . . . . 10.0 111.108 175.636 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 -71.85 43.77 0.1 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 114.604 1.335 . . . . 10.0 114.604 -173.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -56.57 147.38 50.75 Favored Pre-proline 0 CA--C 1.54 0.568 0 O-C-N 120.817 -1.177 . . . . 10.0 112.565 -174.069 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -64.89 -43.03 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.81 2.34 . . . . 10.0 110.853 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 75.9 mt -76.69 54.6 0.98 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.484 0.714 . . . . 10.0 109.381 176.493 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.9 p -35.47 109.75 0.09 Allowed 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 126.019 1.727 . . . . 10.0 110.868 -173.074 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -131.71 -174.03 3.3 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 104.474 -2.417 . . . . 10.0 104.474 -170.126 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -82.39 159.02 23.1 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 106.262 -1.755 . . . . 10.0 106.262 169.408 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.7 t60 -59.04 123.5 16.79 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 106.826 -1.546 . . . . 10.0 106.826 162.713 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.93 -144.0 5.39 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 108.635 -1.786 . . . . 10.0 108.635 174.083 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.41 -163.39 29.72 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 109.746 -1.342 . . . . 10.0 109.746 169.746 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -63.99 3.68 0.69 Allowed 'Trans proline' 0 N--CA 1.455 -0.761 0 CA-C-N 119.763 1.782 . . . . 10.0 111.99 169.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 42.3 mmtt -100.19 -16.13 17.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.082 -0.961 . . . . 10.0 110.707 171.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -114.54 165.95 12.23 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 119.051 0.841 . . . . 10.0 109.901 -178.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -77.25 -38.61 50.72 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 105.431 -2.063 . . . . 10.0 105.431 167.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.277 1.5 pt-20 -103.48 49.89 0.82 Allowed 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 115.461 1.652 . . . . 10.0 115.461 -160.843 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -55.65 159.31 3.03 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 125.651 1.581 . . . . 10.0 108.799 167.656 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -66.69 -65.86 0.63 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.637 0.732 . . . . 10.0 109.619 168.372 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.534 HG13 ' H ' ' A' ' 82' ' ' GLY . 6.3 p -161.85 -69.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 N-CA-C 107.31 -1.367 . . . . 10.0 107.31 177.352 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.534 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -109.48 56.23 0.47 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 109.598 -1.401 . . . . 10.0 109.598 177.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -87.98 91.26 8.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 104.058 -2.571 . . . . 10.0 104.058 167.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.9 -32.36 69.28 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.1 -91.7 0.7 Allowed Glycine 0 N--CA 1.434 -1.485 0 N-CA-C 108.273 -1.931 . . . . 10.0 108.273 167.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -145.27 147.35 32.28 Favored 'General case' 0 N--CA 1.447 -0.596 0 O-C-N 123.818 0.364 . . . . 10.0 110.755 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.2 m -124.21 139.08 51.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 171.126 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 m -89.99 113.92 25.67 Favored 'General case' 0 N--CA 1.441 -0.888 0 C-N-CA 127.887 2.475 . . . . 10.0 107.711 -178.371 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.46 138.01 32.09 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 109.623 -0.51 . . . . 10.0 109.623 169.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -65.72 170.65 4.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.959 1.304 . . . . 10.0 109.658 168.13 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -50.69 -34.51 26.98 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.467 -0.788 . . . . 10.0 110.894 169.338 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -81.03 5.35 16.74 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.38 0.609 . . . . 10.0 112.039 -178.677 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.09 4.5 83.59 Favored Glycine 0 C--N 1.342 0.908 0 O-C-N 120.877 -1.139 . . . . 10.0 111.341 175.292 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.8 t -79.68 109.16 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.975 0 C-N-CA 127.76 2.424 . . . . 10.0 106.597 176.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.569 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -105.66 115.88 31.0 Favored 'General case' 0 CA--C 1.513 -0.459 0 N-CA-C 108.087 -1.079 . . . . 10.0 108.087 167.658 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -81.97 86.21 6.58 Favored 'General case' 0 N--CA 1.436 -1.157 0 C-N-CA 127.458 2.303 . . . . 10.0 109.294 179.143 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 32.9 t -75.72 131.94 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 N-CA-C 105.097 -2.186 . . . . 10.0 105.097 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -158.3 64.02 0.44 Allowed 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 122.995 0.518 . . . . 10.0 110.198 -175.473 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -111.47 158.6 11.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 106.948 -1.501 . . . . 10.0 106.948 -175.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -135.19 137.71 42.93 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 123.797 0.839 . . . . 10.0 109.942 168.629 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.39 147.43 43.4 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.124 0.97 . . . . 10.0 108.809 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 22.9 p -110.45 -2.14 16.7 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.076 1.75 . . . . 10.0 113.882 -172.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.9 p -97.22 -38.78 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 119.821 1.192 . . . . 10.0 109.081 172.345 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -65.22 136.91 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.953 -1.869 . . . . 10.0 105.953 167.158 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 25.2 m -154.86 132.42 11.28 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 108.943 -0.762 . . . . 10.0 108.943 -175.248 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -78.75 61.02 2.92 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.805 -1.183 . . . . 10.0 107.805 175.463 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.8 m -84.12 -119.27 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 123.81 0.844 . . . . 10.0 110.165 -174.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.96 -47.32 0.05 OUTLIER Glycine 0 CA--C 1.524 0.628 0 N-CA-C 107.91 -2.076 . . . . 10.0 107.91 -174.479 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -64.54 -59.32 4.44 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.899 0.88 . . . . 10.0 109.04 169.625 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.6 -39.05 58.53 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.276 -0.875 . . . . 10.0 108.658 -174.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.6 t 39.01 76.38 0.06 Allowed 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.525 1.53 . . . . 10.0 112.702 171.18 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pp -61.36 -26.94 40.84 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 115.899 -0.592 . . . . 10.0 110.382 168.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 32.2 mm -38.67 132.59 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 C-N-CA 126.003 1.721 . . . . 10.0 111.781 173.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.63 7.96 86.73 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-O 118.487 -1.174 . . . . 10.0 113.613 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 64.1 mtt85 -77.57 158.72 29.7 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 118.742 1.271 . . . . 10.0 109.673 169.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.82 115.5 27.52 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.111 -0.7 . . . . 10.0 109.111 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -83.97 138.27 33.21 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 170.028 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 71.9 t -125.34 137.09 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.99 -1.115 . . . . 10.0 107.99 178.033 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.06 132.95 46.99 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 105.542 -2.021 . . . . 10.0 105.542 166.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.67 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 8.5 m-70 -106.88 154.63 20.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 123.186 1.47 . . . . 10.0 114.623 -174.233 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -41.75 -61.92 1.0 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 128.398 2.679 . . . . 10.0 109.157 177.245 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mtmt -110.0 169.25 8.85 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 125.463 1.505 . . . . 10.0 111.84 -176.576 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.74 136.9 56.85 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.131 -1.395 . . . . 10.0 108.035 169.628 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 140' ' ' ALA . 0.0 OUTLIER -84.57 158.94 20.77 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 123.763 0.825 . . . . 10.0 110.169 170.687 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -104.02 17.06 24.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.07 0.948 . . . . 10.0 111.701 179.542 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 64.7 mt 43.56 40.72 2.99 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 119.269 0.941 . . . . 10.0 112.782 178.493 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.63 -4.16 53.7 Favored Glycine 0 C--N 1.336 0.565 0 CA-C-O 118.924 -0.931 . . . . 10.0 114.068 175.04 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mttt -118.01 30.69 7.1 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 118.136 0.968 . . . . 10.0 111.217 -166.162 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.65 -36.53 58.35 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 127.521 2.486 . . . . 10.0 110.907 171.674 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 72.45 43.68 44.38 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 111.179 -0.768 . . . . 10.0 111.179 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.461 ' H ' ' HB2' ' A' ' 134' ' ' SER . 12.2 m-80 -145.34 168.93 19.3 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 105.983 -1.858 . . . . 10.0 105.983 171.376 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.407 ' OE1' ' NZ ' ' A' ' 136' ' ' LYS . 15.8 tm-20 -52.57 -42.56 64.6 Favored 'General case' 0 N--CA 1.441 -0.899 0 CA-C-O 121.239 0.542 . . . . 10.0 110.958 177.627 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -63.49 -31.83 73.1 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.263 -0.898 . . . . 10.0 113.23 178.605 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.461 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 17.1 t -43.96 -48.4 8.61 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.226 1.01 . . . . 10.0 109.778 176.181 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 7.8 t -80.4 -3.72 50.82 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-O 118.333 -0.841 . . . . 10.0 112.134 -169.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.407 ' NZ ' ' OE1' ' A' ' 132' ' ' GLU . 41.9 mtmt -111.61 -79.41 0.58 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.317 1.447 . . . . 10.0 110.308 -177.763 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.9 p -105.94 1.85 27.0 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 120.13 1.332 . . . . 10.0 113.272 177.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.72 27.24 35.64 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-O 118.904 -0.942 . . . . 10.0 113.139 169.701 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.2 m120 59.36 21.9 10.25 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 118.382 1.091 . . . . 10.0 112.978 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.549 ' HB2' ' HB3' ' A' ' 124' ' ' ASP . . . -66.73 -10.6 48.68 Favored 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 124.897 1.279 . . . . 10.0 112.645 176.635 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.61 -161.83 51.68 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 110.268 -1.133 . . . . 10.0 110.268 177.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.8 m -58.74 139.97 55.47 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 124.129 0.972 . . . . 10.0 112.651 -167.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.13 68.16 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.813 1.245 . . . . 10.0 109.329 167.649 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . 0.261 0.4 OUTLIER -64.32 -17.04 63.29 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.616 0.969 . . . . 10.0 113.616 -169.144 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 150.92 24.9 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.099 -0.704 . . . . 10.0 109.099 168.094 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.5 p -153.72 165.35 36.25 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.39 0.276 . . . . 10.0 111.034 -177.355 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.0 -168.04 11.77 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.438 1.018 . . . . 10.0 111.559 -177.329 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 33.7 t -136.92 130.75 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 104.487 -2.412 . . . . 10.0 104.487 176.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -66.47 139.7 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-N 119.438 1.017 . . . . 10.0 110.815 178.424 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.6 146.67 18.58 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 124.829 1.204 . . . . 10.0 111.214 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 74.8 mt -68.83 152.26 9.63 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 177.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.36 -36.11 1.14 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 114.515 1.302 . . . . 10.0 114.515 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.121 0 N-CA-C 117.529 2.418 . . . . 10.0 117.529 -177.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 1' ' ' ALA . . . . . 0.451 ' C ' ' H ' ' B' ' 3' ' ' LYS . . . . . . . . 0 N--CA 1.474 0.74 0 CA-C-O 118.232 -0.89 . . . . 10.0 109.099 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 2' ' ' THR . . . . . 0.421 HG22 ' O ' ' B' ' 1' ' ' ALA 0.282 9.2 t 70.62 -29.68 0.19 Allowed 'General case' 0 C--N 1.343 0.312 0 C-N-CA 131.397 3.879 . . . . 10.0 111.835 175.036 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 3' ' ' LYS . . . . . 0.451 ' H ' ' C ' ' B' ' 1' ' ' ALA . 61.3 tttt -152.15 131.37 12.77 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 126.288 1.835 . . . . 10.0 106.98 -168.843 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.59 165.96 25.85 Favored 'General case' 0 CA--C 1.522 -0.131 0 C-N-CA 124.476 1.11 . . . . 10.0 108.54 171.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.525 ' O ' HG23 ' B' ' 149' ' ' ILE . 7.7 m -131.38 179.97 3.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.395 0 C-N-CA 122.889 0.476 . . . . 10.0 110.563 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.27 110.66 3.74 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 124.459 1.104 . . . . 10.0 108.561 167.214 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.471 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.5 OUTLIER -96.88 92.23 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 C-N-CA 124.065 0.946 . . . . 10.0 109.419 171.748 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -80.32 137.82 36.64 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.197 0.999 . . . . 10.0 110.608 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.5 tttt -156.25 160.67 40.0 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.972 -1.122 . . . . 10.0 107.972 170.263 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.41 -50.06 0.05 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 121.333 -0.46 . . . . 10.0 112.215 171.233 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.26 -46.58 32.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 106.738 -1.578 . . . . 10.0 106.738 -173.61 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.94 -66.26 0.57 Allowed Glycine 0 CA--C 1.527 0.815 0 CA-C-N 113.891 -1.504 . . . . 10.0 110.382 -179.086 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -60.57 -35.41 90.14 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.964 2.442 . . . . 10.0 111.323 174.025 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.0 t -70.35 111.21 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 N-CA-C 107.582 -1.266 . . . . 10.0 107.582 175.666 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.74 110.04 11.83 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.88 -1.896 . . . . 10.0 105.88 168.626 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.738 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -97.79 133.37 11.32 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 110.012 -1.235 . . . . 10.0 110.012 179.02 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.543 ' CG2' HG22 ' A' ' 54' ' ' THR . 5.4 mt -137.57 87.77 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 108.252 -1.018 . . . . 10.0 108.252 -169.683 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -99.23 152.17 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.133 0 C-N-CA 124.672 1.189 . . . . 10.0 110.546 178.681 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 21.1 m-80 -134.43 121.57 21.29 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 128.457 2.703 . . . . 10.0 107.807 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -106.58 116.66 32.3 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 174.386 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.91 143.67 44.77 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.091 0.86 . . . . 10.0 112.861 169.472 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -93.69 94.02 8.35 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.617 1.567 . . . . 10.0 108.808 -176.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.2 tmtt? -44.51 -61.33 1.58 Allowed 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 126.369 1.868 . . . . 10.0 110.943 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -145.21 176.35 9.6 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 104.459 -2.423 . . . . 10.0 104.459 170.458 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 23.1 t -86.8 -2.29 58.44 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.976 -0.379 . . . . 10.0 109.976 174.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 29.5 m-80 -130.28 35.4 4.09 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 124.251 1.02 . . . . 10.0 108.4 169.164 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -126.87 160.16 21.13 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 106.93 -2.468 . . . . 10.0 106.93 170.466 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -66.48 148.79 84.34 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 121.841 1.694 . . . . 10.0 109.553 179.05 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.5 t -78.82 124.95 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 104.313 -2.477 . . . . 10.0 104.313 168.214 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -98.34 122.4 41.47 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 106.313 -1.736 . . . . 10.0 106.313 168.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.2 p -106.18 106.03 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 C-N-CA 127.708 2.403 . . . . 10.0 105.509 177.31 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -130.45 173.08 11.18 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 120.9 0.381 . . . . 10.0 110.844 179.042 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.76 -153.29 25.21 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 107.152 -2.379 . . . . 10.0 107.152 169.335 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 5.4 m -153.15 145.49 23.99 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 119.044 -1.063 . . . . 10.0 110.607 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.738 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.0 pt -111.97 136.75 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 CA-C-N 115.948 -0.569 . . . . 10.0 109.679 168.501 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.5 tptt -110.77 141.27 44.32 Favored 'General case' 0 N--CA 1.441 -0.922 0 N-CA-C 106.289 -1.745 . . . . 10.0 106.289 171.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.3 -6.37 23.16 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 123.757 0.694 . . . . 10.0 112.991 169.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -65.19 176.21 1.4 Allowed 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 118.147 0.974 . . . . 10.0 111.022 176.095 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -109.82 156.09 20.8 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 168.352 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -53.33 132.48 39.29 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.792 1.637 . . . . 10.0 111.443 -170.509 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 122.13 -173.2 15.81 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 118.724 0.693 . . . . 10.0 112.037 173.275 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.66 152.84 39.13 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.741 1.616 . . . . 10.0 110.756 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -150.31 147.73 27.98 Favored 'General case' 0 C--N 1.344 0.367 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -174.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.68 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -28.01 121.0 0.06 OUTLIER Glycine 0 C--N 1.34 0.784 0 C-N-CA 128.822 3.105 . . . . 10.0 113.14 161.664 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -153.73 101.31 2.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 119.712 1.756 . . . . 10.0 111.6 168.286 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.41 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -154.23 173.1 16.58 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 114.573 1.323 . . . . 10.0 114.573 -178.943 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 33.5 m -82.0 151.2 4.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 112.995 -1.912 . . . . 10.0 109.449 168.533 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -133.1 82.91 2.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.089 -1.078 . . . . 10.0 108.089 172.561 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 35.04 -80.8 0.0 OUTLIER 'General case' 0 C--O 1.239 0.506 0 C-N-CA 127.674 2.389 . . . . 10.0 115.135 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -77.84 173.78 11.75 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 122.043 0.925 . . . . 10.0 110.089 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -101.03 -19.53 16.71 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 125.152 1.358 . . . . 10.0 110.599 168.34 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.31 156.39 0.85 Allowed 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.802 1.241 . . . . 10.0 111.946 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.63 27.86 0.44 Allowed 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.322 -0.854 . . . . 10.0 111.822 169.006 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.424 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -55.06 -39.22 69.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.198 0.999 . . . . 10.0 111.624 -169.728 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.44 -23.71 42.96 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.055 0.942 . . . . 10.0 112.786 177.25 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.91 114.25 1.53 Allowed Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.829 -0.908 . . . . 10.0 110.829 -170.666 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 23.5 m 38.06 46.28 0.81 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 127.206 2.203 . . . . 10.0 115.529 169.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -153.31 -54.15 0.11 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 173.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 47.0 t -54.91 -38.61 67.82 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.479 1.112 . . . . 10.0 110.892 -173.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.97 -50.68 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 127.863 2.465 . . . . 10.0 114.487 170.64 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.01 157.19 9.61 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.299 -1.12 . . . . 10.0 110.299 177.658 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -74.76 -163.38 0.18 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 N-CA-C 105.395 -2.579 . . . . 10.0 105.395 165.026 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.412 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.9 m170 -81.03 48.66 1.13 Allowed 'General case' 0 CA--C 1.547 0.83 0 O-C-N 119.619 -1.925 . . . . 10.0 110.694 -176.411 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 m-30 -75.35 67.72 1.96 Allowed 'General case' 0 N--CA 1.466 0.341 0 O-C-N 120.936 -1.102 . . . . 10.0 110.332 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -66.19 154.64 89.66 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.408 -0.808 . . . . 10.0 109.919 170.547 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -76.46 49.68 2.72 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 123.572 2.848 . . . . 10.0 111.204 177.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -178.35 55.78 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 127.482 2.313 . . . . 10.0 105.677 -178.618 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.0 p -37.11 110.23 0.12 Allowed 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.8 1.24 . . . . 10.0 109.992 177.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -173.69 3.1 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 102.447 -3.168 . . . . 10.0 102.447 177.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -78.08 167.56 21.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 116.651 -2.019 . . . . 10.0 106.831 167.755 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -65.48 123.62 20.12 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 106.845 -1.539 . . . . 10.0 106.845 162.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.16 -142.05 4.42 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.458 -1.857 . . . . 10.0 108.458 173.605 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.15 -165.24 31.08 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.67 -1.628 . . . . 10.0 109.044 173.233 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -69.16 10.47 0.4 Allowed 'Trans proline' 0 CA--C 1.541 0.827 0 CA-C-N 119.923 1.861 . . . . 10.0 110.727 167.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -108.8 -1.16 19.48 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 124.84 1.256 . . . . 10.0 110.402 170.121 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -132.22 169.36 16.55 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 119.67 1.123 . . . . 10.0 109.007 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -78.71 -39.23 37.05 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 103.795 -2.669 . . . . 10.0 103.795 165.266 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -82.14 42.87 0.76 Allowed 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 114.117 1.154 . . . . 10.0 114.117 -165.352 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.32 159.29 18.33 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 124.006 0.922 . . . . 10.0 109.714 167.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -68.97 -79.91 0.05 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 169.111 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.509 HG13 ' H ' ' B' ' 82' ' ' GLY 0.25 8.6 p -149.18 -79.28 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 N-CA-C 107.175 -1.417 . . . . 10.0 107.175 167.923 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.509 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -86.43 62.52 4.28 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.258 -1.137 . . . . 10.0 110.258 178.415 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -101.55 100.45 10.87 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 105.714 -1.958 . . . . 10.0 105.714 169.065 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -73.73 -9.39 58.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 118.339 0.518 . . . . 10.0 111.452 -174.023 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.89 -99.7 2.34 Favored Glycine 0 N--CA 1.442 -0.94 0 N-CA-C 107.347 -2.301 . . . . 10.0 107.347 -176.685 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -148.17 144.97 28.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 -177.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.6 m -112.93 137.57 45.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 108.216 -1.031 . . . . 10.0 108.216 168.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -97.94 116.44 30.17 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.962 0.905 . . . . 10.0 109.582 -176.833 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.67 130.6 35.94 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.604 1.162 . . . . 10.0 109.15 174.572 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.05 168.11 3.47 Favored 'General case' 0 N--CA 1.448 -0.573 0 O-C-N 124.584 1.177 . . . . 10.0 109.824 168.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.9 tttp -47.76 -36.61 11.82 Favored 'General case' 0 N--CA 1.432 -1.327 0 C-N-CA 126.42 1.888 . . . . 10.0 111.468 168.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -79.84 1.04 28.49 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.992 0.517 . . . . 10.0 112.318 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.18 16.79 80.27 Favored Glycine 0 C--N 1.339 0.721 0 O-C-N 120.101 -1.624 . . . . 10.0 110.791 178.822 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 37.2 t -92.93 105.84 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 C-N-CA 126.513 1.925 . . . . 10.0 106.033 175.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.655 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -102.18 117.74 35.41 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 107.139 -1.43 . . . . 10.0 107.139 168.582 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -94.23 124.6 38.34 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.315 1.009 . . . . 10.0 108.279 177.118 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.99 134.53 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 C-N-CA 125.838 1.655 . . . . 10.0 108.421 -174.694 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -157.46 95.52 1.46 Allowed 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.719 1.207 . . . . 10.0 108.761 170.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 mp -123.59 145.36 30.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 108.105 -1.072 . . . . 10.0 108.105 176.071 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -106.06 135.28 47.8 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 128.691 2.797 . . . . 10.0 107.745 169.075 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -140.05 155.38 47.08 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 168.238 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.4 p -126.39 49.19 2.04 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.587 1.155 . . . . 10.0 109.771 174.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 p -133.33 -45.45 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.491 1.117 . . . . 10.0 110.246 172.537 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.32 131.81 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.298 -1.001 . . . . 10.0 108.298 169.575 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 67.8 m -125.37 112.71 16.64 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 170.078 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 18.1 mt -46.2 -41.52 12.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.193 1.397 . . . . 10.0 110.318 176.214 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 22.8 p -132.54 118.48 19.3 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 105.844 -1.91 . . . . 10.0 105.844 168.657 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.49 -59.74 0.06 OUTLIER Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.344 -1.102 . . . . 10.0 110.344 178.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -165.29 -51.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 125.195 1.398 . . . . 10.0 107.977 -176.166 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -73.88 -40.24 63.35 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 114.3 -1.318 . . . . 10.0 108.098 -169.332 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 34.9 t 42.51 70.07 0.32 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 125.47 1.508 . . . . 10.0 109.922 172.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 3.6 pt -75.63 58.6 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.849 -0.797 . . . . 10.0 108.849 172.478 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 44.5 mm -108.84 -58.36 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.671 0.788 . . . . 10.0 109.176 -177.638 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -93.46 50.93 2.38 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 109.409 -1.477 . . . . 10.0 109.409 173.277 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.09 158.24 24.53 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.304 1.842 . . . . 10.0 107.401 177.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 67.1 m -108.68 119.07 38.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 127.042 2.137 . . . . 10.0 106.264 -178.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 62.6 mt -93.49 150.87 20.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 108.224 -1.028 . . . . 10.0 108.224 168.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 79.6 t -132.81 138.36 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 N-CA-C 108.159 -1.052 . . . . 10.0 108.159 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.85 136.76 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 168.15 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.68 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 9.4 m-70 -116.03 161.12 19.34 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -175.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 121' ' ' GLU . . . . . 0.418 ' HB2' HD21 ' B' ' 144' ' ' LEU . 53.6 tt0 -60.04 -50.11 75.0 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.217 -0.901 . . . . 10.0 109.677 177.445 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 92.6 mttt -104.53 163.3 12.56 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.927 0.714 . . . . 10.0 112.927 -168.564 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.93 157.02 34.29 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 114.301 -1.318 . . . . 10.0 108.991 172.191 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.483 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 47.2 m-20 -109.79 134.78 51.64 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 124.153 0.981 . . . . 10.0 109.243 -169.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -73.26 -24.56 60.47 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 124.861 1.264 . . . . 10.0 110.337 -174.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 59.64 42.87 16.5 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.52 -0.918 . . . . 10.0 108.52 -173.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.53 -53.12 1.02 Allowed Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 124.959 1.266 . . . . 10.0 110.971 170.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -79.29 49.88 1.02 Allowed 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.356 1.062 . . . . 10.0 113.072 -170.57 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -29.77 7.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 127.118 2.294 . . . . 10.0 110.593 169.604 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 75.81 18.71 79.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 118.978 -0.901 . . . . 10.0 112.395 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -111.65 160.22 17.45 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 105.947 -1.871 . . . . 10.0 105.947 168.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -50.26 -47.48 55.21 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.33 -1.304 . . . . 10.0 108.397 171.609 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -64.34 -37.43 87.47 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 112.915 0.709 . . . . 10.0 112.915 177.651 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.6 m -51.63 -45.47 63.3 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.336 1.425 . . . . 10.0 111.035 172.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.9 t -82.45 -22.51 35.2 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 111.922 0.341 . . . . 10.0 111.922 -173.177 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 25.2 ttmt -89.41 -46.89 8.39 Favored 'General case' 0 N--CA 1.439 -0.978 0 C-N-CA 125.225 1.41 . . . . 10.0 112.129 -177.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.412 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 30.7 p -133.44 -11.62 2.78 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 114.172 1.175 . . . . 10.0 114.172 178.818 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.22 15.72 37.5 Favored Glycine 0 C--O 1.221 -0.678 0 CA-C-O 118.982 -0.899 . . . . 10.0 112.15 -171.31 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 57.35 35.1 25.62 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.13 1.465 . . . . 10.0 111.233 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.17 -13.59 62.1 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.515 1.926 . . . . 10.0 111.886 -178.435 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.89 -171.06 54.59 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 109.223 -1.551 . . . . 10.0 109.223 -169.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.1 m -52.52 166.12 0.21 Allowed 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 124.48 1.112 . . . . 10.0 113.071 -177.107 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -83.93 102.02 12.11 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 107.467 -1.308 . . . . 10.0 107.467 168.472 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.418 HD21 ' HB2' ' B' ' 121' ' ' GLU . 0.4 OUTLIER -71.61 -47.98 51.07 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.05 -1.092 . . . . 10.0 108.05 -177.642 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -143.49 144.54 32.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.094 -0.706 . . . . 10.0 109.094 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 39.0 m -126.71 147.98 49.91 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.669 -1.234 . . . . 10.0 107.669 -176.42 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.87 141.1 11.57 Favored Glycine 0 C--N 1.332 0.315 0 N-CA-C 108.834 -1.706 . . . . 10.0 108.834 172.152 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.71 136.8 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 N-CA-C 101.612 -3.477 . . . . 10.0 101.612 169.299 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.525 HG23 ' O ' ' B' ' 5' ' ' VAL . 68.5 mt -61.86 -81.41 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 CA-C-O 121.418 0.628 . . . . 10.0 110.285 -168.73 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.99 134.43 8.33 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.371 -0.691 . . . . 10.0 111.371 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.78 137.25 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.089 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 173.435 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.98 -70.08 0.54 Allowed 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 106.742 -1.577 . . . . 10.0 106.742 171.798 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 20.4 tm0? . . . . . 0 C--O 1.253 1.249 0 N-CA-C 104.827 -2.286 . . . . 10.0 104.827 167.266 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.62 0 N-CA-C 105.511 -2.033 . . . . 10.0 105.511 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.5 t -63.18 -30.62 71.73 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.978 1.263 . . . . 10.0 108.1 167.427 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.5 tmtm? -117.08 146.95 42.8 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 126.088 1.755 . . . . 10.0 108.675 177.562 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.06 177.04 11.78 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 125.829 1.652 . . . . 10.0 109.195 169.945 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.9 t -136.2 164.04 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 125.277 1.431 . . . . 10.0 108.749 -176.49 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.68 104.36 3.03 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.054 0.941 . . . . 10.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.5 m -93.47 127.99 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 109.322 -0.621 . . . . 10.0 109.322 176.389 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.93 137.28 47.92 Favored 'General case' 0 C--O 1.225 -0.218 0 C-N-CA 124.762 1.225 . . . . 10.0 108.559 -178.736 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 40.1 mtpt -146.22 164.93 30.71 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-N 120.69 1.586 . . . . 10.0 107.968 170.797 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.59 -60.24 0.04 OUTLIER Glycine 0 CA--C 1.511 -0.19 0 C-N-CA 120.377 -0.916 . . . . 10.0 112.291 169.701 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.64 -44.91 61.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 -177.647 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.9 -69.74 0.44 Allowed Glycine 0 CA--C 1.524 0.612 0 CA-C-N 114.296 -1.32 . . . . 10.0 110.887 172.78 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -57.3 -36.3 98.94 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 123.25 2.633 . . . . 10.0 111.263 174.971 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.8 t -65.62 97.56 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.117 -1.438 . . . . 10.0 107.117 175.323 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.56 105.86 11.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.138 0.975 . . . . 10.0 108.424 173.94 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.781 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -81.03 149.79 29.92 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 109.623 -1.391 . . . . 10.0 109.623 168.38 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -155.22 59.6 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 C-N-CA 125.925 1.69 . . . . 10.0 106.848 -168.939 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 mm -74.94 146.47 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 O-C-N 121.621 -0.675 . . . . 10.0 109.657 -179.27 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -118.9 124.53 47.32 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 126.711 2.004 . . . . 10.0 107.061 177.013 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -106.63 120.6 42.39 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 178.703 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.5 mp0 -125.73 117.8 24.23 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.33 0.652 . . . . 10.0 111.472 176.515 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -124.03 108.99 12.96 Favored 'General case' 0 C--O 1.227 -0.113 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 168.287 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.42 -50.92 68.53 Favored 'General case' 0 C--N 1.333 -0.117 0 O-C-N 121.749 -0.595 . . . . 10.0 110.671 -178.824 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -129.57 170.42 13.78 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 103.557 -2.757 . . . . 10.0 103.557 168.38 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 92.3 p -68.61 -19.75 64.46 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 123.837 0.855 . . . . 10.0 110.39 170.12 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -78.77 -14.83 59.06 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 123.321 0.649 . . . . 10.0 109.278 174.144 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.43 138.67 15.47 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.183 -1.567 . . . . 10.0 109.183 175.828 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -62.4 135.8 55.74 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 CA-C-N 119.414 1.607 . . . . 10.0 108.069 171.328 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.1 p -75.97 120.36 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.425 0 N-CA-C 107.545 -1.28 . . . . 10.0 107.545 -176.779 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.1 mtpt -91.52 109.68 20.98 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.942 -2.244 . . . . 10.0 104.942 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.3 m -104.77 88.82 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 178.768 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -97.33 170.94 8.73 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-O 121.75 0.786 . . . . 10.0 111.664 169.509 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.06 -169.15 38.84 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.51 -1.036 . . . . 10.0 110.51 172.025 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.9 p -147.15 102.35 3.49 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.908 -0.775 . . . . 10.0 108.908 -175.844 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.781 HG22 ' HA2' ' A' ' 16' ' ' GLY . 4.3 pt -78.44 130.8 35.69 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 N-CA-C 106.428 -1.694 . . . . 10.0 106.428 168.38 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 ptmt -118.73 136.17 54.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.708 -1.219 . . . . 10.0 107.708 173.864 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.95 -3.95 14.31 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.75 1.167 . . . . 10.0 112.979 179.676 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -66.35 176.97 1.61 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.625 1.212 . . . . 10.0 111.109 177.516 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.5 t -112.35 155.9 23.37 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 105.308 -2.108 . . . . 10.0 105.308 166.04 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -50.23 157.53 0.67 Allowed 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.29 1.036 . . . . 10.0 111.678 -170.365 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.51 -175.37 29.14 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 170.791 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -78.39 149.2 33.39 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.699 1.599 . . . . 10.0 110.695 -175.99 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.1 m-70 -144.39 137.63 27.21 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.516 0.726 . . . . 10.0 112.953 -175.586 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -40.96 122.07 2.16 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 126.574 2.035 . . . . 10.0 110.217 168.247 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -136.73 113.03 9.88 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.177 1.489 . . . . 10.0 107.925 169.799 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.69 174.69 13.2 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-O 122.247 1.022 . . . . 10.0 112.163 -179.158 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.0 t -96.32 143.9 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 CA-C-N 111.318 -2.674 . . . . 10.0 107.2 169.609 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 76.9 m-70 -123.39 126.4 46.75 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 103.643 -2.725 . . . . 10.0 103.643 172.55 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.5 tp10 -61.17 -42.76 99.14 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.184 -1.371 . . . . 10.0 112.746 -165.508 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -81.91 118.64 23.1 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 119.288 -0.965 . . . . 10.0 109.459 177.696 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.1 -13.89 16.19 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.707 2.575 . . . . 10.0 112.523 169.992 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -42.83 127.28 3.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 122.384 1.088 . . . . 10.0 111.173 168.966 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -137.39 23.12 2.96 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.521 164.854 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -66.71 -44.43 81.69 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 106.542 -1.651 . . . . 10.0 106.542 168.525 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.69 -21.92 44.08 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.335 -0.393 . . . . 10.0 111.55 173.062 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.58 71.49 1.31 Allowed Glycine 0 CA--C 1.528 0.848 0 C-N-CA 124.134 0.873 . . . . 10.0 111.28 173.015 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.291 23.2 p 43.12 48.98 5.5 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.665 1.186 . . . . 10.0 113.783 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 p -127.21 -66.95 0.86 Allowed 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 127.344 2.258 . . . . 10.0 105.354 173.072 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.1 m -79.05 -4.68 51.34 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 123.364 0.665 . . . . 10.0 112.56 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.7 -14.69 1.45 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.41 1.484 . . . . 10.0 112.925 173.377 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.22 131.55 6.89 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 108.847 -1.701 . . . . 10.0 108.847 170.071 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.403 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 70.3 Cg_endo -75.17 59.97 5.44 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.8 3.0 . . . . 10.0 110.38 172.247 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 23.3 m170 71.7 49.74 0.27 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 129.312 3.045 . . . . 10.0 111.275 175.435 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.403 ' CZ ' ' HD2' ' A' ' 62' ' ' PRO . 35.1 m-85 -72.21 38.12 0.07 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 115.258 1.577 . . . . 10.0 115.258 -173.344 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.27 151.15 0.57 Allowed Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.55 1.54 . . . . 10.0 113.107 169.98 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -66.02 -46.37 4.75 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.884 2.389 . . . . 10.0 111.953 179.544 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 71.1 mt -79.39 54.01 1.63 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.631 -0.668 . . . . 10.0 110.457 -177.943 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 40.0 p -55.5 109.2 0.52 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.537 1.135 . . . . 10.0 110.406 -173.826 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.4 mtt180 -121.29 -97.15 0.46 Allowed 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 -179.889 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.4 140.87 23.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 105.261 -2.126 . . . . 10.0 105.261 177.278 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -47.08 116.95 1.52 Allowed 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.654 -0.418 . . . . 10.0 110.991 169.402 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.48 -141.01 4.29 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 106.536 -2.626 . . . . 10.0 106.536 170.531 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.95 -147.51 8.1 Favored Glycine 0 C--O 1.227 -0.312 0 CA-C-O 118.644 -1.086 . . . . 10.0 111.229 175.267 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -68.27 14.93 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 120.041 1.921 . . . . 10.0 111.943 177.344 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.0 mmtt -104.68 -14.96 15.41 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 119.038 0.835 . . . . 10.0 110.042 169.805 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.33 177.34 7.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.337 1.065 . . . . 10.0 113.064 -165.049 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -98.64 -13.31 20.39 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 113.449 -1.705 . . . . 10.0 108.502 168.198 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.11 -16.26 56.97 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 124.735 1.214 . . . . 10.0 112.23 -168.598 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.28 135.88 2.47 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.596 1.158 . . . . 10.0 110.333 -169.78 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -73.66 61.99 0.76 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 123.405 0.682 . . . . 10.0 111.588 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.4 t 31.78 48.66 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 C-N-CA 126.872 2.069 . . . . 10.0 111.418 -174.511 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.22 42.0 0.05 OUTLIER Glycine 0 CA--C 1.531 1.062 0 CA-C-N 116.032 -0.531 . . . . 10.0 113.877 -178.918 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -97.07 100.42 11.92 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 103.617 -2.735 . . . . 10.0 103.617 166.049 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 27.5 mt -75.62 -24.86 56.53 Favored 'General case' 0 N--CA 1.462 0.174 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 177.865 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.94 -102.25 2.83 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.311 -1.916 . . . . 10.0 108.311 168.527 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -129.24 133.67 47.62 Favored 'General case' 0 CA--C 1.517 -0.311 0 C-N-CA 123.888 0.875 . . . . 10.0 112.176 -168.633 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.8 m -124.88 145.47 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.143 -1.799 . . . . 10.0 106.143 167.202 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -98.44 126.14 43.87 Favored 'General case' 0 C--O 1.225 -0.223 0 C-N-CA 124.851 1.261 . . . . 10.0 108.959 -178.025 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.52 134.46 34.35 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 172.231 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -67.17 172.45 4.67 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-O 121.592 0.71 . . . . 10.0 109.609 168.45 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.46 -32.2 4.91 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.39 2.276 . . . . 10.0 111.099 171.528 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -78.68 -11.34 59.97 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.855 0.359 . . . . 10.0 110.607 -175.804 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.06 15.67 69.17 Favored Glycine 0 C--N 1.339 0.75 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 -177.189 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.4 t -94.97 111.15 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 126.796 2.038 . . . . 10.0 105.921 175.162 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.536 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -106.02 120.24 41.28 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 168.734 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -78.53 131.08 36.66 Favored 'General case' 0 N--CA 1.429 -1.524 0 C-N-CA 125.906 1.682 . . . . 10.0 107.892 173.89 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.4 t -117.55 133.89 62.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.303 0 N-CA-C 106.235 -1.765 . . . . 10.0 106.235 179.459 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.5 p -157.45 70.42 0.6 Allowed 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 123.685 0.794 . . . . 10.0 109.554 175.554 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.43 153.22 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 179.406 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -137.35 123.16 20.02 Favored 'General case' 0 N--CA 1.443 -0.812 0 C-N-CA 125.557 1.543 . . . . 10.0 106.897 169.298 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -128.29 153.99 46.4 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.62 0.724 . . . . 10.0 109.051 -178.723 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 33.7 t -117.48 46.18 1.77 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.629 1.572 . . . . 10.0 110.043 -168.717 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.3 p -155.8 -46.13 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.132 0 N-CA-C 109.181 -0.674 . . . . 10.0 109.181 177.105 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 29.8 mm -56.35 142.22 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 123.49 0.716 . . . . 10.0 109.664 172.333 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.7 m -155.62 133.92 11.61 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 123.9 0.88 . . . . 10.0 108.758 171.671 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 82.7 mt -47.27 -55.21 9.11 Favored 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 126.914 2.086 . . . . 10.0 111.318 176.402 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.0 t -130.75 152.24 50.31 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 105.278 -2.119 . . . . 10.0 105.278 170.025 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.52 -84.77 0.12 Allowed Glycine 0 C--N 1.333 0.369 0 N-CA-C 110.058 -1.217 . . . . 10.0 110.058 -177.351 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -136.23 -53.47 0.74 Allowed 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 126.744 2.017 . . . . 10.0 107.5 -179.588 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -76.49 -31.15 57.57 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.117 -0.947 . . . . 10.0 108.57 -175.239 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 48.96 63.37 2.15 Favored 'General case' 0 N--CA 1.447 -0.594 0 C-N-CA 125.669 1.588 . . . . 10.0 109.372 177.109 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.315 1.1 tp -61.45 -18.77 19.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 C-N-CA 123.411 0.684 . . . . 10.0 112.112 -176.116 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.4 mm -48.75 135.79 5.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 118.812 0.733 . . . . 10.0 110.062 167.278 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.88 14.28 82.18 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.055 -0.858 . . . . 10.0 113.489 172.473 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.4 mmt-85 -84.02 175.43 9.54 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 167.898 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.3 m -108.36 122.27 46.64 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 177.003 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 6.5 mp -99.51 147.33 25.43 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-N 119.606 1.093 . . . . 10.0 108.535 171.058 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.6 t -131.18 135.93 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 N-CA-C 108.734 -0.839 . . . . 10.0 108.734 179.795 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 p -104.78 129.76 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 168.106 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 10.1 m-70 -111.12 158.86 18.39 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 114.994 1.479 . . . . 10.0 114.994 -169.672 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -46.42 -60.51 2.3 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.493 2.717 . . . . 10.0 110.903 171.369 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.2 mttp -117.27 165.61 13.24 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.104 0.478 . . . . 10.0 110.356 -172.917 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.39 140.8 54.21 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 168.854 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.03 153.75 32.06 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 108.837 -0.801 . . . . 10.0 108.837 168.264 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -78.59 10.73 2.97 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.118 0.967 . . . . 10.0 111.146 177.457 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.3 mt 38.94 51.35 1.85 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 125.151 1.38 . . . . 10.0 110.86 -170.334 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.94 -27.62 17.41 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-N 114.059 -1.428 . . . . 10.0 112.638 173.522 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -78.83 16.05 0.96 Allowed 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 113.66 0.985 . . . . 10.0 113.66 -168.42 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.93 -32.39 82.5 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 170.295 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 69.94 31.13 69.78 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 122.488 -0.419 . . . . 10.0 112.34 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.95 176.21 8.24 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 125.299 1.44 . . . . 10.0 107.545 173.338 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.406 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 2.6 tm-20 -59.51 -51.27 70.57 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 113.403 -1.726 . . . . 10.0 109.425 177.742 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -52.97 -43.9 66.74 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.565 1.146 . . . . 10.0 110.692 171.931 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.5 m -53.55 -46.59 70.28 Favored 'General case' 0 N--CA 1.441 -0.917 0 O-C-N 120.851 -1.156 . . . . 10.0 110.968 -179.118 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.5 t -77.65 -0.57 27.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 119.786 -0.766 . . . . 10.0 111.857 -177.121 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.406 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 90.6 mttt -113.91 -82.1 0.6 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.312 1.845 . . . . 10.0 111.197 -179.657 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . 0.299 2.0 p -105.95 11.84 31.24 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 120.738 1.608 . . . . 10.0 113.054 177.939 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.09 10.75 78.52 Favored Glycine 0 C--O 1.221 -0.699 0 CA-C-O 119.047 -0.863 . . . . 10.0 114.336 166.812 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 m120 65.7 26.35 11.42 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.594 1.197 . . . . 10.0 111.596 -176.863 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.59 -11.82 8.29 Favored 'General case' 0 CA--C 1.533 0.327 0 O-C-N 121.644 -0.66 . . . . 10.0 111.683 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.58 -140.32 21.74 Favored Glycine 0 N--CA 1.443 -0.852 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 168.495 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -70.72 118.23 13.25 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.23 0.538 . . . . 10.0 111.283 -168.359 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.41 76.55 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.734 1.214 . . . . 10.0 111.35 168.624 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 50.3 mt -52.12 -40.89 61.97 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.101 0.778 . . . . 10.0 113.101 -176.051 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 155.09 24.77 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 108.335 -0.987 . . . . 10.0 108.335 -171.579 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -167.15 166.07 15.18 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 116.049 -0.523 . . . . 10.0 109.626 -167.59 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.7 179.3 46.95 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.658 -0.782 . . . . 10.0 112.062 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 71.3 t -109.24 156.22 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 N-CA-C 104.978 -2.23 . . . . 10.0 104.978 -175.677 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.4 mt -75.07 -96.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 C-N-CA 123.656 0.782 . . . . 10.0 110.747 -168.478 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 106.28 130.85 6.68 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-O 121.917 0.732 . . . . 10.0 112.098 179.381 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 92.2 mt -72.18 141.25 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.689 0 C-N-CA 124.968 1.307 . . . . 10.0 108.968 179.083 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.11 -102.11 0.41 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 105.761 -1.94 . . . . 10.0 105.761 165.519 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 . . . . . 0 C--O 1.247 0.962 0 C-N-CA 131.033 3.733 . . . . 10.0 103.075 -171.237 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 106.267 -1.753 . . . . 10.0 106.267 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -160.49 -47.33 0.05 OUTLIER 'General case' 0 C--O 1.232 0.139 0 CA-C-N 118.89 0.768 . . . . 10.0 110.668 172.916 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -119.64 142.71 48.19 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 126.839 2.056 . . . . 10.0 107.691 173.877 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.44 155.51 45.86 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.118 0.967 . . . . 10.0 108.396 169.36 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -122.65 153.99 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 C-N-CA 123.873 0.869 . . . . 10.0 109.265 -175.181 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 6' ' ' ALA . . . . . 0.458 ' HB2' HG12 ' B' ' 149' ' ' ILE . . . -147.74 93.11 2.16 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 167.367 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.674 HG12 HG23 ' B' ' 17' ' ' ILE . 31.6 m -83.19 133.45 29.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 107.803 -1.184 . . . . 10.0 107.803 169.425 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mt -107.34 138.15 44.07 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.836 -1.172 . . . . 10.0 107.836 -177.507 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 36.5 mtpt -146.34 153.72 40.85 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 120.582 1.537 . . . . 10.0 107.545 169.518 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.51 -52.71 0.08 OUTLIER Glycine 0 N--CA 1.462 0.388 0 C-N-CA 119.217 -1.468 . . . . 10.0 114.171 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -72.68 -43.41 63.13 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.649 -1.241 . . . . 10.0 107.649 -172.065 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.74 -70.55 0.4 Allowed Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 114.055 -1.429 . . . . 10.0 110.032 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -54.91 -39.73 88.99 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.783 2.322 . . . . 10.0 110.879 170.817 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.477 HG13 HD12 ' B' ' 38' ' ' LEU . 94.7 t -58.65 107.54 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.246 0 CA-C-N 119.083 0.856 . . . . 10.0 109.157 179.688 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.04 92.2 3.68 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.744 -2.317 . . . . 10.0 104.744 168.676 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.704 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -78.44 152.19 37.35 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 109.401 -1.479 . . . . 10.0 109.401 177.045 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.674 HG23 HG12 ' B' ' 7' ' ' VAL . 0.0 OUTLIER -154.26 87.22 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -171.16 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.8 mm -96.56 142.18 14.35 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 C-N-CA 124.846 1.258 . . . . 10.0 109.464 174.872 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -127.64 119.31 25.61 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 125.38 1.472 . . . . 10.0 108.082 174.142 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -98.0 113.76 25.7 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.058 1.343 . . . . 10.0 107.5 173.409 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -117.89 136.06 53.7 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 119.133 0.878 . . . . 10.0 110.775 170.914 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 36.1 tt0 -126.54 81.15 1.98 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 124.638 1.175 . . . . 10.0 109.763 -176.102 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -130.92 73.85 1.57 Allowed 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.863 1.265 . . . . 10.0 111.963 -175.223 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -157.05 172.02 19.42 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 104.192 -2.522 . . . . 10.0 104.192 166.172 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.9 t -96.81 16.37 19.41 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 124.014 0.926 . . . . 10.0 108.646 179.522 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 67.1 m-20 -117.19 4.18 12.66 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.122 0.969 . . . . 10.0 109.855 169.658 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 49.96 45.95 41.27 Favored Glycine 0 CA--C 1.532 1.15 0 CA-C-O 118.565 -1.131 . . . . 10.0 114.48 -177.682 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -71.17 108.18 2.28 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 N-CA-C 106.22 -2.261 . . . . 10.0 106.22 169.122 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 26.2 t -77.35 95.74 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.349 0 N-CA-C 105.374 -2.084 . . . . 10.0 105.374 174.612 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -76.33 96.63 4.02 Favored 'General case' 0 N--CA 1.444 -0.76 0 N-CA-C 105.594 -2.002 . . . . 10.0 105.594 174.516 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -92.58 90.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.751 0 N-CA-C 106.87 -1.53 . . . . 10.0 106.87 175.654 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -99.48 176.58 5.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 121.443 0.64 . . . . 10.0 109.4 169.428 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.15 173.58 40.32 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 110.016 -1.234 . . . . 10.0 110.016 176.206 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.6 m -149.52 89.55 1.64 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 -179.626 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.704 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.5 pt -77.38 150.46 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 174.313 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.8 pttt -136.96 126.05 24.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 O-C-N 124.288 0.992 . . . . 10.0 108.848 169.425 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.97 6.76 5.31 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-O 118.791 -1.005 . . . . 10.0 114.629 166.064 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.661 HD13 ' H ' ' B' ' 38' ' ' LEU . 0.0 OUTLIER -89.82 179.34 6.02 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-N 118.728 1.264 . . . . 10.0 108.62 172.443 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -81.09 175.12 10.94 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.348 -0.845 . . . . 10.0 111.011 172.175 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -63.23 169.72 3.38 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.426 1.49 . . . . 10.0 111.48 -174.616 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.94 -174.74 51.42 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 124.008 0.813 . . . . 10.0 113.256 167.376 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -66.19 143.0 57.53 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.795 1.638 . . . . 10.0 110.608 178.603 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -142.36 139.34 31.72 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 114.214 1.19 . . . . 10.0 114.214 -178.655 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.629 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.03 111.77 0.02 OUTLIER Glycine 0 C--N 1.342 0.883 0 C-N-CA 128.418 2.913 . . . . 10.0 114.208 165.493 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -138.57 102.95 4.73 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 120.376 2.088 . . . . 10.0 110.516 174.844 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.525 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -148.56 179.23 7.97 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.331 0.586 . . . . 10.0 111.829 -178.358 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 p -100.21 148.26 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 112.704 -2.044 . . . . 10.0 108.127 168.33 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -123.93 129.6 51.23 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.067 -2.568 . . . . 10.0 104.067 169.154 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -59.13 -44.73 92.04 Favored 'General case' 0 N--CA 1.441 -0.898 0 O-C-N 124.528 1.142 . . . . 10.0 112.363 -166.646 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -75.19 112.49 11.52 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 105.239 -2.134 . . . . 10.0 105.239 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -57.65 -33.51 67.45 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 109.503 -1.439 . . . . 10.0 109.503 168.798 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -35.93 146.34 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 125.253 1.421 . . . . 10.0 112.06 169.547 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -144.36 28.44 1.34 Allowed 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 115.261 -0.881 . . . . 10.0 111.406 176.981 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -49.12 -43.06 41.14 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 112.859 0.688 . . . . 10.0 112.859 -169.028 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -86.82 -23.5 25.32 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 113.378 0.881 . . . . 10.0 113.378 177.052 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.97 101.39 2.69 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.172 -1.571 . . . . 10.0 109.172 -170.273 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.289 26.3 p 11.5 49.62 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 129.633 3.173 . . . . 10.0 116.955 -168.673 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 42.4 m -120.84 -53.68 2.06 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 105.077 -2.194 . . . . 10.0 105.077 174.977 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.5 m -44.89 -40.45 6.29 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 126.158 1.783 . . . . 10.0 109.936 168.972 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.84 -25.25 0.09 Allowed 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 127.726 2.41 . . . . 10.0 114.999 176.934 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.41 155.79 29.45 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 108.572 -1.811 . . . . 10.0 108.572 169.35 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -68.5 -172.73 0.48 Allowed 'Trans proline' 0 N--CA 1.445 -1.352 0 N-CA-C 106.888 -2.005 . . . . 10.0 106.888 166.719 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -78.81 45.09 0.58 Allowed 'General case' 0 CA--C 1.542 0.649 0 O-C-N 119.743 -1.848 . . . . 10.0 112.047 -171.511 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.1 m-30 -72.55 68.22 0.8 Allowed 'General case' 0 C--O 1.221 -0.413 0 CA-C-N 119.846 1.203 . . . . 10.0 109.676 178.759 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -63.57 155.66 74.83 Favored Pre-proline 0 C--N 1.331 -0.226 0 N-CA-C 107.535 -1.283 . . . . 10.0 107.535 173.768 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -54.92 -27.95 56.47 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.097 1.865 . . . . 10.0 112.281 175.222 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -107.78 25.14 11.89 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.043 0.937 . . . . 10.0 111.815 177.189 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 44.7 p -40.98 117.79 0.9 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.646 1.179 . . . . 10.0 112.273 177.94 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -124.58 -88.89 0.59 Allowed 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 107.676 -1.231 . . . . 10.0 107.676 177.361 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.418 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 8.5 mtmp? -125.49 152.6 44.76 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 108.316 -0.994 . . . . 10.0 108.316 168.541 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 36.2 t60 -58.14 128.36 36.72 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 117.659 -1.617 . . . . 10.0 106.734 165.812 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.408 ' CA ' ' HB2' ' B' ' 76' ' ' ASP . . . -150.09 -141.16 3.35 Favored Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 109.905 -1.278 . . . . 10.0 109.905 -178.771 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.6 -147.52 11.43 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 107.95 -2.06 . . . . 10.0 107.95 169.976 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.05 12.94 0.2 Allowed 'Trans proline' 0 N--CA 1.452 -0.923 0 CA-C-N 120.114 1.957 . . . . 10.0 111.621 169.429 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -127.65 1.51 6.15 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.59 1.156 . . . . 10.0 111.737 176.502 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.42 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 0.2 OUTLIER -123.81 150.58 44.35 Favored 'General case' 0 C--N 1.34 0.168 0 N-CA-C 102.426 -3.175 . . . . 10.0 102.426 166.825 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -82.55 -17.74 43.9 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 121.646 -0.659 . . . . 10.0 109.832 174.705 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.9 pm0 -118.16 36.54 4.31 Favored 'General case' 0 N--CA 1.438 -1.056 0 C-N-CA 125.901 1.68 . . . . 10.0 111.579 -167.515 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -44.25 153.58 0.14 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.58 1.552 . . . . 10.0 109.578 168.937 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 38.4 m80 -60.9 -48.17 83.06 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 10.0 109.966 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.1 t 173.31 -75.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 C-N-CA 129.284 3.034 . . . . 10.0 105.059 166.082 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.03 59.06 5.02 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 179.305 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -106.08 95.07 5.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.557 -2.016 . . . . 10.0 105.557 169.322 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 43.6 mt -75.23 -33.87 61.39 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 106.741 -1.577 . . . . 10.0 106.741 175.632 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.51 -96.94 1.31 Allowed Glycine 0 N--CA 1.436 -1.337 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 169.442 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -132.42 136.14 46.56 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 122.863 0.465 . . . . 10.0 110.021 -169.518 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.5 m -122.24 140.3 46.54 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.955 -0.758 . . . . 10.0 108.955 169.488 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 9.4 m -81.93 119.25 23.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 127.457 2.303 . . . . 10.0 110.499 -177.159 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.4 130.46 44.53 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.984 1.314 . . . . 10.0 110.642 170.022 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -59.88 166.31 2.73 Favored 'General case' 0 N--CA 1.455 -0.222 0 O-C-N 124.069 0.855 . . . . 10.0 109.603 167.366 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 35.6 pttt -52.47 -30.5 30.18 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.804 1.241 . . . . 10.0 110.93 173.37 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -77.08 -9.52 58.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 117.676 0.216 . . . . 10.0 111.027 -178.148 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.54 10.57 67.54 Favored Glycine 0 C--N 1.34 0.774 0 O-C-N 121.092 -1.005 . . . . 10.0 111.038 -178.191 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.0 t -86.14 111.44 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 127.184 2.194 . . . . 10.0 106.466 175.914 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.577 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -114.61 120.71 41.1 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 118.715 0.689 . . . . 10.0 109.509 172.825 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -78.5 132.43 37.23 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 107.325 -1.361 . . . . 10.0 107.325 169.864 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.8 t -114.94 133.44 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 N-CA-C 104.777 -2.305 . . . . 10.0 104.777 169.063 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -156.73 62.8 0.52 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 118.174 0.443 . . . . 10.0 110.139 -178.731 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.69 152.85 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 N-CA-C 107.735 -1.209 . . . . 10.0 107.735 -173.961 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -136.6 139.22 41.95 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 123.798 0.839 . . . . 10.0 109.667 168.957 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -148.47 153.53 38.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.918 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.3 p -115.52 44.48 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 126.494 1.917 . . . . 10.0 109.549 177.403 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -111.69 -48.04 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 170.457 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 42.5 mm -65.1 148.49 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 108.007 -1.108 . . . . 10.0 108.007 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.4 m -157.29 120.97 4.16 Favored 'General case' 0 C--O 1.226 -0.134 0 N-CA-C 108.029 -1.1 . . . . 10.0 108.029 173.578 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.9 mp -59.62 -29.94 68.36 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.614 1.166 . . . . 10.0 111.955 -169.603 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.2 m -149.88 66.81 0.98 Allowed 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 176.096 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.03 -72.43 1.17 Allowed Glycine 0 C--N 1.333 0.364 0 N-CA-C 108.628 -1.789 . . . . 10.0 108.628 177.203 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -152.03 -57.84 0.15 Allowed 'General case' 0 N--CA 1.44 -0.926 0 C-N-CA 127.462 2.305 . . . . 10.0 107.435 -167.646 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -85.25 -32.37 22.61 Favored 'General case' 0 N--CA 1.445 -0.7 0 C-N-CA 125.632 1.573 . . . . 10.0 108.826 -179.207 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 7.1 t 70.77 -51.21 0.68 Allowed 'General case' 0 C--N 1.342 0.277 0 C-N-CA 127.504 2.322 . . . . 10.0 111.176 178.221 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 mt 63.82 16.32 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 124.173 0.989 . . . . 10.0 110.721 174.104 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.8 mm -71.02 -56.1 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 124.478 1.111 . . . . 10.0 110.037 175.824 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.72 48.82 3.55 Favored Glycine 0 CA--C 1.526 0.758 0 O-C-N 120.617 -1.302 . . . . 10.0 112.501 -177.49 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.03 168.06 11.93 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 126.612 1.965 . . . . 10.0 108.692 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -114.21 141.11 47.95 Favored 'General case' 0 CA--C 1.515 -0.396 0 C-N-CA 124.654 1.181 . . . . 10.0 108.306 -172.07 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.8 mp -111.85 145.92 38.62 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.83 1.652 . . . . 10.0 108.474 172.489 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.9 t -131.71 136.06 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 178.278 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.405 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.4 p -97.57 120.17 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 105.838 -1.912 . . . . 10.0 105.838 168.007 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.629 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.2 m-70 -98.5 158.29 15.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 115.59 1.7 . . . . 10.0 115.59 -176.373 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -38.47 -66.18 0.29 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 129.834 3.254 . . . . 10.0 110.619 170.517 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -113.75 174.86 5.72 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 125.174 1.389 . . . . 10.0 110.319 -174.561 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.84 137.23 35.3 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.879 -1.055 . . . . 10.0 108.465 171.311 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.525 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -77.4 141.73 39.63 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.287 1.035 . . . . 10.0 109.284 169.892 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -78.45 24.51 0.27 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.375 0.67 . . . . 10.0 111.86 179.63 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.5 mt 36.64 51.6 0.91 Allowed 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.792 2.037 . . . . 10.0 111.7 -176.674 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.44 -32.03 6.6 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 125.594 1.569 . . . . 10.0 112.384 175.078 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.42 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 7.2 mttm -80.08 18.67 0.81 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.628 1.171 . . . . 10.0 113.222 -167.819 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.27 -18.73 75.29 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 109.531 -1.428 . . . . 10.0 109.531 167.109 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.78 40.19 92.52 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 124.402 1.001 . . . . 10.0 111.749 175.403 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -145.25 169.6 17.91 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.093 0.946 . . . . 10.0 109.583 173.643 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 13.0 tm-20 -46.83 -49.85 19.4 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.711 1.204 . . . . 10.0 110.139 -179.875 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 17.9 tp10 -71.35 -34.74 70.77 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 121.781 -0.574 . . . . 10.0 111.657 179.217 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.9 p -54.15 -43.63 70.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 120.715 -1.241 . . . . 10.0 110.799 172.149 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.272 5.6 t -77.81 -23.02 49.18 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 119.568 -0.853 . . . . 10.0 111.557 -173.627 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -84.71 -49.01 8.86 Favored 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 127.486 2.314 . . . . 10.0 112.525 -177.738 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 19.2 p -136.3 -15.04 1.71 Allowed 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 114.495 1.295 . . . . 10.0 114.495 175.556 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.76 3.9 52.18 Favored Glycine 0 C--N 1.339 0.707 0 CA-C-O 118.379 -1.234 . . . . 10.0 114.105 177.914 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 27.2 m120 72.18 25.26 2.95 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 118.573 1.186 . . . . 10.0 112.01 -177.788 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.34 -8.83 43.34 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.435 0.902 . . . . 10.0 113.435 179.356 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.93 -160.8 48.8 Favored Glycine 0 CA--C 1.524 0.608 0 O-C-N 121.029 -1.045 . . . . 10.0 111.536 172.622 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 m -60.63 134.69 57.33 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.7 1.2 . . . . 10.0 113.657 -167.675 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.9 84.92 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.524 1.529 . . . . 10.0 110.21 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 65.8 mt -58.02 -39.18 77.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.425 0.557 . . . . 10.0 112.094 -179.031 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.405 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -154.46 153.34 31.37 Favored 'General case' 0 CA--C 1.516 -0.334 0 O-C-N 121.683 -0.635 . . . . 10.0 110.655 -179.912 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.2 m -121.68 141.14 51.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.014 1.726 . . . . 10.0 108.556 -169.041 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.4 158.43 27.5 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 109.675 -1.37 . . . . 10.0 109.675 168.539 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.8 t -118.8 135.52 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 -179.838 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.458 HG12 ' HB2' ' B' ' 6' ' ' ALA . 59.8 mt -71.88 153.35 7.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 N-CA-C 108.658 -0.867 . . . . 10.0 108.658 176.808 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -164.77 151.24 20.15 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 109.099 -1.601 . . . . 10.0 109.099 -175.089 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.47 123.75 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 117.514 0.657 . . . . 10.0 109.768 -172.809 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.06 -26.26 39.74 Favored 'General case' 0 N--CA 1.446 -0.628 0 O-C-N 120.894 -1.129 . . . . 10.0 111.809 -173.276 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.428 -1.533 0 N-CA-C 103.918 -2.623 . . . . 10.0 103.918 -173.859 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.791 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -79.57 -38.91 33.02 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.194 0.598 . . . . 10.0 110.028 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -121.16 130.08 53.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.148 1.379 . . . . 10.0 107.331 -179.328 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.11 151.92 51.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.595 -0.891 . . . . 10.0 108.595 172.874 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.444 HG13 ' HB2' ' A' ' 152' ' ' ALA . 1.0 OUTLIER -109.24 170.52 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 123.115 0.566 . . . . 10.0 110.45 169.993 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -156.02 102.38 2.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 106.64 -1.615 . . . . 10.0 106.64 166.045 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.598 HG12 HG23 ' A' ' 17' ' ' ILE . 35.7 m -92.24 128.4 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 108.795 -0.817 . . . . 10.0 108.795 171.078 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.436 ' N ' HD12 ' A' ' 8' ' ' LEU . 4.2 mp -103.18 152.83 21.0 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 108.853 -0.795 . . . . 10.0 108.853 178.231 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 ttmt -161.16 162.24 31.31 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 108.044 -1.095 . . . . 10.0 108.044 169.52 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.37 -56.16 0.04 OUTLIER Glycine 0 C--N 1.33 0.21 0 N-CA-C 111.459 -0.657 . . . . 10.0 111.459 172.801 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.97 -45.89 39.12 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -174.769 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.88 -67.72 0.55 Allowed Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 113.739 -1.573 . . . . 10.0 110.338 -179.506 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -56.96 -38.77 95.19 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.914 2.409 . . . . 10.0 111.172 173.876 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -68.05 105.59 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.062 0 N-CA-C 107.033 -1.469 . . . . 10.0 107.033 175.255 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -124.57 120.63 32.49 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 108.601 -0.888 . . . . 10.0 108.601 169.384 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.457 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -90.49 150.96 21.08 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.452 -1.459 . . . . 10.0 109.452 169.36 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.852 HG22 HG23 ' B' ' 54' ' ' THR . 0.0 OUTLIER -156.37 82.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 105.491 -2.04 . . . . 10.0 105.491 -172.994 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.6 mm -104.62 145.03 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.39 1.076 . . . . 10.0 108.841 -178.561 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -122.91 122.78 39.43 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 127.161 2.185 . . . . 10.0 108.337 169.011 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -103.24 123.03 45.97 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 106.704 -1.591 . . . . 10.0 106.704 173.327 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -117.91 135.52 54.06 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 123.962 0.788 . . . . 10.0 113.126 169.553 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -123.82 100.02 6.56 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 127.42 2.288 . . . . 10.0 105.264 171.135 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 17.8 tttp -64.65 -62.63 1.46 Allowed 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 124.61 1.164 . . . . 10.0 109.392 -169.719 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -109.59 165.81 11.38 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 102.896 -3.001 . . . . 10.0 102.896 166.873 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.9 t -66.65 -21.54 66.11 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 -178.912 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.6 m-80 -76.76 -19.62 57.41 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.537 -0.756 . . . . 10.0 110.511 -179.595 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.55 140.82 32.57 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 109.862 -1.295 . . . . 10.0 109.862 -178.763 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -61.62 149.15 91.05 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 N-CA-C 107.041 -1.946 . . . . 10.0 107.041 168.877 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 t -79.29 113.68 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.087 0 N-CA-C 105.976 -1.861 . . . . 10.0 105.976 178.584 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -93.9 117.58 30.3 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 171.193 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -110.4 108.67 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 C-N-CA 126.817 2.047 . . . . 10.0 106.857 -175.558 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 20.8 p90 -127.49 163.11 24.84 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 112.103 0.408 . . . . 10.0 112.103 179.616 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.03 -147.37 18.32 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 106.917 -2.473 . . . . 10.0 106.917 170.144 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 52.2 p -157.96 164.78 36.49 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.065 -1.054 . . . . 10.0 112.551 178.617 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.632 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -116.45 121.53 67.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 C-N-CA 126.062 1.745 . . . . 10.0 106.668 166.628 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.61 54.78 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 175.025 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.14 -0.14 9.68 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.174 1.369 . . . . 10.0 113.539 178.537 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.26 178.38 2.87 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 118.394 1.097 . . . . 10.0 111.231 179.183 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -107.71 156.11 19.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.203 -1.777 . . . . 10.0 106.203 165.244 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -51.27 150.74 3.21 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.463 1.105 . . . . 10.0 112.347 -169.504 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.04 -171.36 23.49 Favored Glycine 0 C--N 1.336 0.558 0 N-CA-C 111.201 -0.76 . . . . 10.0 111.201 170.232 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.73 149.16 36.37 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.574 1.149 . . . . 10.0 111.363 -173.319 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -143.15 141.32 31.15 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.71 1.204 . . . . 10.0 112.502 -177.698 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.534 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -35.73 122.15 0.61 Allowed Glycine 0 C--N 1.341 0.86 0 C-N-CA 126.582 2.039 . . . . 10.0 112.878 166.303 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -143.43 115.42 8.32 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 120.085 1.942 . . . . 10.0 110.975 167.442 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.7 174.25 12.79 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 120.994 0.426 . . . . 10.0 111.787 -178.974 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 117' ' ' LEU . 1.1 m -113.47 82.24 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 126.036 1.735 . . . . 10.0 109.995 -179.656 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -56.8 141.31 44.91 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 122.292 1.044 . . . . 10.0 110.599 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -71.58 -53.21 14.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 112.045 -2.343 . . . . 10.0 110.456 -168.234 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.3 m-30 -76.49 110.09 10.75 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 175.154 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.42 48.71 1.22 Allowed Glycine 0 CA--C 1.531 1.051 0 N-CA-C 110.04 -1.224 . . . . 10.0 110.04 167.806 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.76 143.41 30.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.885 1.674 . . . . 10.0 106.825 170.915 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.468 ' HB3' HG21 ' B' ' 7' ' ' VAL . 10.7 m-20 -139.5 2.13 2.0 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 126.344 1.858 . . . . 10.0 109.324 174.103 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.565 HG23 ' CG2' ' B' ' 17' ' ' ILE . 1.9 m -61.92 -30.36 70.84 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 120.098 1.317 . . . . 10.0 110.525 -170.111 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.18 -15.36 60.07 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.174 0.99 . . . . 10.0 112.047 176.136 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.14 76.55 1.33 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.57 -1.412 . . . . 10.0 109.57 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 74.0 m 47.56 45.66 17.63 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.53 1.132 . . . . 10.0 111.145 175.658 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.5 m -134.59 -52.5 0.81 Allowed 'General case' 0 N--CA 1.439 -0.995 0 N-CA-C 108.948 -0.76 . . . . 10.0 108.948 -168.863 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 t -99.5 21.04 12.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.425 0.528 . . . . 10.0 112.425 -170.28 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.12 3.52 0.85 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.15 0.98 . . . . 10.0 113.401 178.956 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.28 129.98 1.57 Allowed Glycine 0 CA--C 1.529 0.967 0 O-C-N 120.874 -1.141 . . . . 10.0 110.341 175.973 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.16 61.54 7.78 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 123.197 2.598 . . . . 10.0 110.556 178.605 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 28.9 m170 63.07 59.75 1.28 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 128.46 2.704 . . . . 10.0 110.858 177.581 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.1 m-85 -72.19 55.19 0.31 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.558 1.143 . . . . 10.0 113.892 -176.727 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -71.18 144.53 89.88 Favored Pre-proline 0 C--N 1.326 -0.437 0 C-N-CA 125.56 1.544 . . . . 10.0 113.18 -174.158 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -71.78 -37.87 4.75 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.283 2.655 . . . . 10.0 111.398 176.706 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.79 56.95 0.98 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.653 0.781 . . . . 10.0 110.533 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 67.9 p -42.06 94.85 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 126.676 1.99 . . . . 10.0 112.948 -169.58 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.2 mtt85 -121.14 172.15 8.18 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 126.129 1.772 . . . . 10.0 108.163 174.983 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 35.1 mtmm -102.0 106.32 17.22 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 -176.667 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -19.22 105.43 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.32 0 C-N-CA 126.71 2.004 . . . . 10.0 114.407 -171.024 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.424 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . -115.35 -146.45 8.89 Favored Glycine 0 N--CA 1.439 -1.101 0 C-N-CA 125.828 1.68 . . . . 10.0 109.467 176.541 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.98 -166.39 24.93 Favored Glycine 0 N--CA 1.45 -0.41 0 N-CA-C 108.587 -1.805 . . . . 10.0 108.587 171.603 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.4 -3.16 3.86 Favored 'Trans proline' 0 N--CA 1.454 -0.814 0 CA-C-N 119.87 1.835 . . . . 10.0 111.829 173.104 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -99.19 -17.35 18.19 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.592 0.757 . . . . 10.0 111.61 174.667 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.424 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 4.5 t70 -111.71 169.68 8.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.191 -1.041 . . . . 10.0 108.191 -179.138 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -80.8 -36.28 31.93 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.824 -1.547 . . . . 10.0 106.824 169.056 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 12.6 mt-10 -84.98 32.93 0.53 Allowed 'General case' 0 N--CA 1.442 -0.871 0 CA-C-O 122.646 1.213 . . . . 10.0 113.185 -166.02 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 ptm180 -66.68 133.65 50.65 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 170.091 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -66.56 -70.75 0.23 Allowed 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.461 0.648 . . . . 10.0 110.704 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 80.8 t -147.19 -105.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.038 -2.949 . . . . 10.0 103.038 177.729 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.34 62.8 4.52 Favored Glycine 0 CA--C 1.524 0.655 0 O-C-N 121.336 -0.852 . . . . 10.0 111.227 176.441 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -89.94 105.07 17.56 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 101.118 -3.66 . . . . 10.0 101.118 163.955 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -87.43 -37.29 17.14 Favored 'General case' 0 N--CA 1.461 0.109 0 N-CA-C 107.41 -1.33 . . . . 10.0 107.41 173.298 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.17 -95.68 1.26 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 123.448 0.547 . . . . 10.0 111.884 167.75 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -116.09 104.27 11.39 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.903 1.281 . . . . 10.0 111.304 -167.451 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.07 133.81 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 168.851 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 m -100.21 111.96 24.26 Favored 'General case' 0 N--CA 1.441 -0.895 0 C-N-CA 125.692 1.597 . . . . 10.0 109.07 -169.142 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.75 129.71 35.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.243 0.617 . . . . 10.0 110.912 179.123 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -57.33 170.86 0.46 Allowed 'General case' 0 C--O 1.233 0.224 0 O-C-N 124.778 1.299 . . . . 10.0 110.116 167.494 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.8 ptmm? -54.29 -30.56 51.26 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 114.676 -1.147 . . . . 10.0 111.189 172.14 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -78.87 -2.05 37.94 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.988 0.915 . . . . 10.0 111.439 -179.049 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.86 20.38 73.6 Favored Glycine 0 C--N 1.337 0.598 0 N-CA-C 110.625 -0.99 . . . . 10.0 110.625 179.204 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.16 102.43 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.954 0 N-CA-C 105.462 -2.051 . . . . 10.0 105.462 179.393 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.632 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -99.53 121.97 41.93 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.83 -1.174 . . . . 10.0 107.83 169.259 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -81.23 143.09 32.56 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.796 1.638 . . . . 10.0 109.347 173.597 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 85.4 t -117.79 129.84 73.59 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 N-CA-C 105.745 -1.946 . . . . 10.0 105.745 168.175 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 17.4 m -158.1 69.77 0.53 Allowed 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 124.515 1.126 . . . . 10.0 108.403 169.257 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -108.61 157.75 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -176.844 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -132.09 133.46 44.36 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 125.415 1.486 . . . . 10.0 108.691 170.892 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -136.26 135.07 38.7 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 108.288 -1.004 . . . . 10.0 108.288 -173.482 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 16.4 m -104.09 16.39 26.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.695 1.198 . . . . 10.0 111.729 -175.357 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.7 p -136.51 11.8 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 123.691 0.796 . . . . 10.0 110.33 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -113.95 136.13 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 103.11 -2.922 . . . . 10.0 103.11 169.905 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 11.5 m -139.53 123.68 17.9 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 123.358 0.663 . . . . 10.0 109.646 -178.223 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.1 mt -69.57 -31.6 69.88 Favored 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.985 0.914 . . . . 10.0 109.8 170.216 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 63.3 m -152.0 135.8 16.33 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.231 1.012 . . . . 10.0 108.339 170.666 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 164.59 -57.74 0.26 Allowed Glycine 0 C--N 1.333 0.391 0 N-CA-C 109.684 -1.367 . . . . 10.0 109.684 179.449 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -164.51 -50.06 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.694 1.998 . . . . 10.0 107.334 -178.129 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -74.37 -38.49 63.15 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.919 -1.037 . . . . 10.0 108.373 -169.597 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 45.5 t 42.03 55.14 3.9 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 126.486 1.914 . . . . 10.0 110.771 172.574 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.14 21.48 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 N-CA-C 113.873 1.064 . . . . 10.0 113.873 -168.626 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.7 mm -58.66 142.66 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 C-N-CA 125.33 1.452 . . . . 10.0 107.614 169.306 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.83 14.65 82.36 Favored Glycine 0 CA--C 1.534 1.245 0 CA-C-O 118.745 -1.031 . . . . 10.0 114.19 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.3 mmt180 -74.11 175.05 7.84 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 107.389 -1.338 . . . . 10.0 107.389 168.198 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -117.79 128.24 54.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.743 -1.206 . . . . 10.0 107.743 169.83 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.565 HD21 HD11 ' A' ' 149' ' ' ILE . 27.8 mt -98.42 142.73 29.68 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 107.953 -1.129 . . . . 10.0 107.953 174.317 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -131.09 132.33 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.324 -1.361 . . . . 10.0 107.324 178.191 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.31 123.66 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.254 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.044 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.534 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.2 m170 -101.01 161.55 13.51 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 114.465 1.283 . . . . 10.0 114.465 -173.956 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -56.21 -50.64 70.67 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 126.433 1.893 . . . . 10.0 110.967 178.441 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 48.8 mttm -112.35 163.44 14.4 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.421 0.629 . . . . 10.0 111.508 -171.104 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.37 141.23 42.72 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 114.628 -1.169 . . . . 10.0 108.773 172.172 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -76.45 148.15 37.44 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 108.56 -0.904 . . . . 10.0 108.56 174.768 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.86 -37.03 15.65 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 126.814 2.046 . . . . 10.0 109.757 -178.414 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 20.4 mt 66.48 36.88 4.84 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.788 0.835 . . . . 10.0 113.059 -176.742 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 111.58 -25.77 12.9 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 118.553 0.615 . . . . 10.0 114.435 165.35 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.252 0.0 OUTLIER -94.56 31.12 1.83 Allowed 'General case' 0 CA--C 1.543 0.69 0 N-CA-C 113.386 0.884 . . . . 10.0 113.386 -172.758 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.427 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -90.16 -12.21 62.02 Favored Glycine 0 C--N 1.343 0.938 0 C-N-CA 125.342 1.449 . . . . 10.0 112.06 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.62 44.95 47.62 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.252 0.929 . . . . 10.0 112.778 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -153.28 175.46 13.06 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.479 -0.934 . . . . 10.0 108.479 175.722 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -56.67 -40.16 75.03 Favored 'General case' 0 N--CA 1.437 -1.079 0 O-C-N 121.356 -0.84 . . . . 10.0 111.845 -175.31 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -63.13 -36.57 84.03 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 118.056 -0.973 . . . . 10.0 109.723 175.838 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.427 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 59.0 p -51.01 -42.89 60.7 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 119.62 1.1 . . . . 10.0 110.954 -172.955 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.252 12.3 t -81.93 -11.31 58.95 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 112.522 0.564 . . . . 10.0 112.522 -175.448 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -115.88 -58.45 2.11 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.532 1.533 . . . . 10.0 113.648 -170.266 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 16.9 p -128.98 10.84 5.96 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 120.449 1.477 . . . . 10.0 112.182 175.447 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.25 -97.01 2.17 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 125.401 1.477 . . . . 10.0 109.742 176.073 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -168.09 37.88 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 122.944 1.354 . . . . 10.0 107.706 178.864 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.11 -22.73 55.21 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 113.534 -1.667 . . . . 10.0 108.446 -173.803 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.82 -157.37 53.07 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 109.506 -1.438 . . . . 10.0 109.506 169.497 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.26 120.29 3.93 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 124.28 1.032 . . . . 10.0 113.229 -167.663 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -63.06 80.47 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.412 1.085 . . . . 10.0 109.939 171.229 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.8 mt -45.56 -52.68 10.14 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.343 0.592 . . . . 10.0 110.96 178.061 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.93 152.8 31.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.723 -0.672 . . . . 10.0 109.501 -168.623 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -147.13 161.06 41.65 Favored 'General case' 0 N--CA 1.447 -0.592 0 O-C-N 123.83 0.706 . . . . 10.0 111.009 -176.79 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.94 168.59 28.15 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 125.473 1.511 . . . . 10.0 109.413 -177.839 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.0 t -120.76 137.85 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 106.366 -1.716 . . . . 10.0 106.366 -178.84 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.565 HD11 HD21 ' A' ' 117' ' ' LEU . 6.9 mt -73.12 116.81 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.655 -0.498 . . . . 10.0 109.655 -177.451 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.25 154.25 17.08 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 111.331 -176.029 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.23 145.89 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 C-N-CA 124.763 1.225 . . . . 10.0 108.395 176.008 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.444 ' HB2' HG13 ' A' ' 5' ' ' VAL . . . -121.11 -25.99 5.2 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 113.58 0.956 . . . . 10.0 113.58 178.422 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.2 tp60 . . . . . 0 C--O 1.25 1.125 0 CA-C-O 117.074 -1.441 . . . . 10.0 107.153 -177.142 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.564 0 N-CA-C 106.534 -1.654 . . . . 10.0 106.534 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.2 t -156.83 -49.22 0.07 Allowed 'General case' 0 C--O 1.224 -0.242 0 CA-C-N 119.365 0.984 . . . . 10.0 110.957 169.161 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -124.01 122.23 37.35 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 125.13 1.372 . . . . 10.0 108.768 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -130.92 152.09 50.62 Favored 'General case' 0 CA--C 1.52 -0.184 0 C-N-CA 123.785 0.834 . . . . 10.0 109.523 170.019 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -118.38 161.15 17.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 C-N-CA 122.947 0.499 . . . . 10.0 111.091 178.022 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.9 110.4 5.78 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.165 -0.925 . . . . 10.0 108.561 167.859 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.468 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.6 m -96.95 108.48 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 124.246 1.019 . . . . 10.0 109.349 172.763 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.9 mt -92.17 131.56 37.31 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.527 -0.916 . . . . 10.0 108.527 -178.396 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -143.65 157.09 44.67 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.612 -1.255 . . . . 10.0 107.612 171.042 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.02 -60.91 0.05 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 121.157 -0.544 . . . . 10.0 113.045 169.35 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.25 -43.78 66.58 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 -177.318 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.58 -71.22 0.42 Allowed Glycine 0 CA--C 1.523 0.578 0 CA-C-N 114.358 -1.292 . . . . 10.0 110.631 168.994 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -57.1 -31.98 91.93 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 123.282 2.655 . . . . 10.0 111.313 171.757 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.417 HG13 HD11 ' B' ' 38' ' ' LEU . 93.5 t -67.97 94.5 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 107.118 -1.438 . . . . 10.0 107.118 177.334 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -115.55 112.4 22.14 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 105.91 -1.885 . . . . 10.0 105.91 178.591 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.677 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.07 139.62 14.59 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 172.182 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.565 ' CG2' HG23 ' A' ' 54' ' ' THR . 4.5 mt -140.77 95.85 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 108.286 -1.005 . . . . 10.0 108.286 -174.986 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -106.9 149.15 10.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 124.578 1.151 . . . . 10.0 113.011 -178.184 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 31.5 m-20 -122.98 110.04 14.88 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.939 2.096 . . . . 10.0 108.24 168.749 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -86.97 108.2 18.73 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 170.821 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -109.3 113.41 26.22 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-O 121.395 0.616 . . . . 10.0 111.646 179.81 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -78.1 101.77 7.15 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 169.854 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.409 ' NZ ' ' OE2' ' B' ' 24' ' ' GLU . 2.1 mmmp? -42.32 -66.4 0.36 Allowed 'General case' 0 CA--C 1.522 -0.103 0 C-N-CA 127.345 2.258 . . . . 10.0 109.72 177.511 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 24' ' ' GLU . . . . . 0.409 ' OE2' ' NZ ' ' B' ' 23' ' ' LYS . 16.5 mp0 -120.8 -169.87 1.9 Allowed 'General case' 0 N--CA 1.423 -1.809 0 N-CA-C 102.211 -3.255 . . . . 10.0 102.211 167.961 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 9.8 t -75.94 -29.79 58.44 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 118.163 -1.415 . . . . 10.0 109.024 173.012 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -97.1 -15.44 20.97 Favored 'General case' 0 N--CA 1.446 -0.631 0 C-N-CA 124.379 1.072 . . . . 10.0 111.777 -175.205 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.39 158.94 52.12 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 -179.734 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -61.88 144.02 96.27 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.491 2.127 . . . . 10.0 109.633 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 t -78.93 87.18 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.999 0 N-CA-C 106.417 -1.698 . . . . 10.0 106.417 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.4 mttm -67.08 108.19 2.55 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 106.854 -1.536 . . . . 10.0 106.854 169.012 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -110.03 108.87 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 125.624 1.569 . . . . 10.0 107.465 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 21.9 p90 -123.38 168.12 12.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.509 0.671 . . . . 10.0 110.123 173.408 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.46 -170.76 43.92 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 179.243 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.3 m -154.98 111.88 3.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -175.939 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.677 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.5 pt -84.22 175.19 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.573 -0.851 . . . . 10.0 110.115 169.703 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -149.98 156.35 41.56 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 166.675 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.52 -25.17 11.36 Favored Glycine 0 C--N 1.338 0.678 0 CA-C-O 119.372 -0.682 . . . . 10.0 114.154 171.039 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.502 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.4 mp -75.04 179.59 4.89 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 118.388 1.094 . . . . 10.0 111.513 -170.84 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.6 t -101.84 161.55 13.58 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.637 -0.875 . . . . 10.0 108.637 168.263 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -49.2 153.0 1.05 Allowed 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.192 1.797 . . . . 10.0 113.675 -169.292 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.43 179.55 39.43 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 124.607 1.099 . . . . 10.0 113.033 168.525 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 95.2 mt -49.49 137.71 14.61 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.119 1.768 . . . . 10.0 112.755 171.894 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -138.2 147.12 43.46 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 124.773 1.229 . . . . 10.0 112.048 171.351 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.694 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -18.65 118.5 0.01 OUTLIER Glycine 0 C--N 1.337 0.598 0 C-N-CA 127.835 2.636 . . . . 10.0 114.16 165.466 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -151.35 106.02 3.26 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 120.218 2.009 . . . . 10.0 112.909 167.296 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.418 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -151.07 168.39 24.76 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.655 -0.702 . . . . 10.0 111.269 176.504 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 16.7 m -86.7 155.09 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 112.21 -2.268 . . . . 10.0 107.06 166.681 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -126.09 152.91 45.23 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 173.243 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -59.7 -42.98 94.24 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 113.689 0.996 . . . . 10.0 113.689 -168.857 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -96.38 174.96 6.61 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.749 -0.834 . . . . 10.0 108.749 -177.193 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -111.35 10.8 28.64 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 125.418 1.485 . . . . 10.0 109.668 166.999 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.49 112.62 1.65 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 122.327 1.06 . . . . 10.0 109.067 176.772 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 39.1 m-20 -120.56 9.97 10.99 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 114.244 -1.344 . . . . 10.0 108.305 168.006 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.852 HG23 HG22 ' A' ' 17' ' ' ILE . 15.5 m -67.59 -34.6 77.35 Favored 'General case' 0 C--N 1.344 0.359 0 C-N-CA 125.235 1.414 . . . . 10.0 108.625 171.02 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.41 -22.34 60.26 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.323 -0.399 . . . . 10.0 110.479 174.702 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.5 54.33 1.7 Allowed Glycine 0 C--N 1.34 0.761 0 C-N-CA 123.893 0.759 . . . . 10.0 111.557 172.083 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 37.5 m 59.76 28.96 18.51 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.03 0.932 . . . . 10.0 110.166 -176.136 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 38.7 m -112.09 -49.8 2.95 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 125.439 1.495 . . . . 10.0 107.147 -169.596 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 8.4 t -117.31 26.62 9.62 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 113.563 0.949 . . . . 10.0 113.563 -175.041 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.42 -7.57 6.97 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.701 1.001 . . . . 10.0 113.701 179.548 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.36 123.61 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.763 1.173 . . . . 10.0 111.052 172.856 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -81.34 55.86 5.78 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 123.074 2.516 . . . . 10.0 112.16 -172.154 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.418 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 16.1 m170 66.76 36.84 4.42 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 128.956 2.903 . . . . 10.0 111.78 176.192 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -76.99 71.66 3.5 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 120.692 1.587 . . . . 10.0 109.998 175.911 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -61.87 158.19 44.78 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 125.201 1.4 . . . . 10.0 110.208 169.31 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -62.91 -46.63 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.024 1.816 . . . . 10.0 111.153 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 69.9 mt -78.84 56.45 1.91 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 123.204 0.601 . . . . 10.0 110.309 -179.383 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -45.25 112.21 0.42 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.639 1.176 . . . . 10.0 110.775 -179.305 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.5 mtp85 -137.33 -97.83 0.2 Allowed 'General case' 0 CA--C 1.506 -0.74 0 N-CA-C 104.492 -2.41 . . . . 10.0 104.492 -175.624 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 50.7 mttp -144.38 164.72 29.98 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.706 -1.22 . . . . 10.0 107.706 166.733 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -66.47 120.65 13.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 106.59 -1.634 . . . . 10.0 106.59 164.641 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.23 -137.79 3.66 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 108.087 -2.005 . . . . 10.0 108.087 175.304 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.6 -160.63 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 109.422 -1.471 . . . . 10.0 109.422 173.493 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -65.41 4.45 0.77 Allowed 'Trans proline' 0 N--CA 1.454 -0.834 0 C-N-CA 122.15 1.9 . . . . 10.0 111.83 169.824 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 57.8 mmtt -94.31 -24.03 17.58 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-O 118.508 -0.758 . . . . 10.0 110.127 170.282 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -108.29 161.42 15.02 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-O 121.051 0.453 . . . . 10.0 111.176 -167.53 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -97.46 -9.72 26.71 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.134 -0.939 . . . . 10.0 109.585 174.15 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -123.05 28.5 7.16 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 119.32 -0.372 . . . . 10.0 110.645 -178.91 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 79' ' ' ARG . . . . . 0.437 HH12 ' CG ' ' B' ' 101' ' ' ASP . 14.9 ptt180 -50.38 154.53 1.24 Allowed 'General case' 0 C--N 1.344 0.354 0 C-N-CA 123.337 0.655 . . . . 10.0 109.879 169.217 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -65.78 -64.88 0.76 Allowed 'General case' 0 N--CA 1.453 -0.319 0 CA-C-O 121.552 0.691 . . . . 10.0 109.503 -178.534 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.713 HG13 ' H ' ' B' ' 82' ' ' GLY . 4.0 p -169.34 -93.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 105.602 -1.999 . . . . 10.0 105.602 176.195 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.713 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -78.94 58.98 4.27 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.479 -1.048 . . . . 10.0 110.479 173.905 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.83 98.93 10.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 102.306 -3.22 . . . . 10.0 102.306 165.951 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -78.26 10.77 2.76 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.24 0.473 . . . . 10.0 110.585 -175.571 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 81.12 -109.44 2.99 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 104.128 -3.589 . . . . 10.0 104.128 -175.28 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -159.53 149.78 18.97 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.354 -1.721 . . . . 10.0 106.354 -178.435 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.45 128.18 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 C-N-CA 123.18 0.592 . . . . 10.0 111.202 -171.986 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.87 97.52 5.3 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 126.676 1.99 . . . . 10.0 111.176 -174.412 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.33 134.36 39.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.071 -0.393 . . . . 10.0 110.482 173.066 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -61.91 169.0 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.874 0.845 . . . . 10.0 109.249 167.358 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 34.7 mtmt -48.06 -34.4 9.51 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.873 1.669 . . . . 10.0 111.395 169.331 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -78.16 -8.32 58.15 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.999 0.428 . . . . 10.0 112.077 -179.377 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.69 1.94 70.38 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 120.933 -1.104 . . . . 10.0 111.572 -176.102 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -84.81 101.39 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.115 0 C-N-CA 125.77 1.628 . . . . 10.0 108.007 -179.232 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.438 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -96.13 115.72 27.87 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 168.252 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -80.86 119.35 23.3 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 106.737 -1.579 . . . . 10.0 106.737 169.24 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 66.5 t -104.11 131.12 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -177.446 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.3 p -157.24 83.81 0.92 Allowed 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 174.033 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -115.18 159.46 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 105.088 -2.19 . . . . 10.0 105.088 176.325 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -133.52 133.19 41.85 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 109.103 -0.703 . . . . 10.0 109.103 168.082 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 101' ' ' ASP . . . . . 0.437 ' CG ' HH12 ' B' ' 79' ' ' ARG . 7.1 t0 -113.89 111.93 22.51 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 124.229 0.955 . . . . 10.0 109.377 -173.052 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.6 p -100.77 61.73 1.0 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.446 1.498 . . . . 10.0 107.079 -176.229 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.5 p -155.39 -47.07 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.145 0 N-CA-C 110.204 -0.295 . . . . 10.0 110.204 -173.006 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.355 0.0 OUTLIER -102.15 176.89 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.143 0 N-CA-C 113.622 0.971 . . . . 10.0 113.622 172.231 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 49.9 m -151.62 146.1 25.57 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 105.915 -1.883 . . . . 10.0 105.915 -179.723 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 29.0 mt -68.01 -14.7 63.18 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 117.948 0.34 . . . . 10.0 111.354 -175.615 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.8 m -145.65 158.72 43.82 Favored 'General case' 0 N--CA 1.451 -0.421 0 O-C-N 120.949 -1.094 . . . . 10.0 108.62 174.382 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.21 -101.08 0.56 Allowed Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 106.167 -2.773 . . . . 10.0 106.167 -169.761 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -129.56 -47.37 1.17 Allowed 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 125.455 1.502 . . . . 10.0 109.199 -168.885 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 36.1 m-70 -75.44 -39.56 58.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 115.158 -0.928 . . . . 10.0 109.133 -170.472 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 11.4 t 21.35 92.84 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 128.868 2.867 . . . . 10.0 114.227 172.142 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 36.7 pt -72.79 -11.86 15.22 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 C-N-CA 123.717 0.807 . . . . 10.0 112.45 176.854 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm -52.11 133.11 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 O-C-N 121.488 -0.758 . . . . 10.0 110.059 178.774 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.87 1.4 84.39 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 118.81 -0.995 . . . . 10.0 114.016 -178.749 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 57.2 mtt85 -85.92 175.94 8.35 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.719 1.759 . . . . 10.0 108.487 168.459 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.04 140.13 50.19 Favored 'General case' 0 CA--C 1.513 -0.467 0 C-N-CA 125.458 1.503 . . . . 10.0 108.512 179.101 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.502 HD11 ' CG1' ' B' ' 149' ' ' ILE . 1.5 mp -110.14 155.93 21.27 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 107.641 -1.244 . . . . 10.0 107.641 166.03 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.4 HG21 ' HD3' ' B' ' 143' ' ' ARG . 91.2 t -128.82 134.3 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.149 0 N-CA-C 106.695 -1.595 . . . . 10.0 106.695 -179.183 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.84 121.62 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.363 0 N-CA-C 105.71 -1.959 . . . . 10.0 105.71 166.865 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.694 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.5 m-70 -102.95 160.5 14.55 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 116.316 1.969 . . . . 10.0 116.316 -168.925 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -43.46 -56.73 3.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 129.085 2.954 . . . . 10.0 111.19 173.73 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 78.1 mttt -113.52 168.84 9.42 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 124.067 0.947 . . . . 10.0 113.352 -168.569 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.44 154.0 41.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 124.68 1.238 . . . . 10.0 108.641 169.822 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.45 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 13.0 m-20 -106.07 141.43 37.45 Favored 'General case' 0 N--CA 1.454 -0.243 0 O-C-N 123.902 0.751 . . . . 10.0 111.287 -168.6 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -74.54 -31.03 61.98 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 125.169 1.388 . . . . 10.0 110.195 -177.355 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 13.7 mt 60.62 50.57 5.59 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 122.618 1.199 . . . . 10.0 108.014 -176.005 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.68 -52.08 4.18 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 115.392 -0.822 . . . . 10.0 111.401 172.571 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 48.75 0.98 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.517 1.127 . . . . 10.0 112.249 -172.679 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.16 -26.97 7.14 Favored Glycine 0 CA--C 1.522 0.492 0 C-N-CA 127.936 2.684 . . . . 10.0 111.17 173.426 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.45 18.01 65.17 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-O 118.472 -1.182 . . . . 10.0 112.65 172.908 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -131.95 168.75 17.35 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-N 119.677 1.739 . . . . 10.0 108.277 168.361 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.45 -55.04 6.56 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.571 1.148 . . . . 10.0 108.878 178.042 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -63.62 -34.22 77.35 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 118.169 -0.919 . . . . 10.0 111.791 -175.674 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.3 m -49.16 -46.86 45.9 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 120.202 1.365 . . . . 10.0 110.804 169.301 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -89.3 -15.6 33.09 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.245 -0.883 . . . . 10.0 113.257 -170.549 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -98.07 -40.93 8.19 Favored 'General case' 0 N--CA 1.438 -1.062 0 C-N-CA 125.027 1.331 . . . . 10.0 111.773 179.146 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.4 p -136.28 -7.02 2.02 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 114.567 1.321 . . . . 10.0 114.567 175.086 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.83 17.14 52.96 Favored Glycine 0 C--O 1.221 -0.669 0 CA-C-O 118.463 -1.187 . . . . 10.0 112.306 -173.27 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 55.53 30.29 14.94 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.533 1.667 . . . . 10.0 111.765 178.76 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.59 54.8 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 125.979 1.712 . . . . 10.0 112.057 -175.323 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.33 54.81 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 110.595 -1.002 . . . . 10.0 110.595 174.605 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.2 m -55.6 139.63 43.75 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 123.966 0.906 . . . . 10.0 111.887 -168.354 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 143' ' ' ARG . . . . . 0.4 ' HD3' HG21 ' B' ' 118' ' ' VAL . 22.6 mtt85 -71.02 70.84 0.53 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.828 1.251 . . . . 10.0 110.06 176.684 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.3 tp -44.6 -36.2 2.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 127.84 2.456 . . . . 10.0 112.536 -176.673 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.28 151.13 17.05 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 172.959 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -146.7 164.82 31.5 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 109.914 -0.402 . . . . 10.0 109.914 177.129 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.64 -176.63 25.44 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.496 -1.042 . . . . 10.0 110.496 178.249 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.4 t -122.56 143.13 36.41 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 107.568 -1.271 . . . . 10.0 107.568 179.817 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.502 ' CG1' HD11 ' B' ' 117' ' ' LEU . 11.4 mt -78.38 112.42 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 124.1 0.96 . . . . 10.0 109.493 -179.066 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.69 146.12 16.52 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 178.2 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -79.96 119.02 28.57 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 177.22 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.56 -43.05 40.56 Favored 'General case' 0 C--O 1.221 -0.439 0 O-C-N 121.078 -1.014 . . . . 10.0 108.554 -176.038 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.946 0 C-N-CA 125.793 1.637 . . . . 10.0 110.815 170.577 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.836 0 CA-C-O 118.628 -0.701 . . . . 10.0 109.661 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.5 t -97.15 -32.71 11.81 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 124.982 1.313 . . . . 10.0 110.369 -178.295 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -148.25 151.62 35.77 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.344 -0.984 . . . . 10.0 108.344 -177.849 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.15 155.41 45.31 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 122.878 0.471 . . . . 10.0 110.548 176.401 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.636 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.1 p -126.84 151.4 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 C-N-CA 128.152 2.581 . . . . 10.0 107.028 -178.762 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.62 116.29 11.41 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.174 -2.158 . . . . 10.0 105.174 168.265 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.3 p -81.29 103.72 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 108.822 -0.807 . . . . 10.0 108.822 174.42 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.76 116.45 23.26 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.027 -1.101 . . . . 10.0 108.027 178.333 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -137.84 155.99 48.4 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 174.401 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -163.19 -66.28 0.02 OUTLIER Glycine 0 C--O 1.229 -0.18 0 CA-C-N 114.915 -1.039 . . . . 10.0 111.891 174.67 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.76 -43.91 57.64 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 -172.706 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.52 -67.66 0.53 Allowed Glycine 0 N--CA 1.443 -0.895 0 CA-C-N 113.481 -1.691 . . . . 10.0 110.525 179.779 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -58.23 -37.96 93.1 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.911 2.408 . . . . 10.0 111.142 174.617 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 94.4 t -64.54 96.81 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 176.425 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -120.35 123.1 42.27 Favored 'General case' 0 N--CA 1.446 -0.661 0 C-N-CA 125.104 1.361 . . . . 10.0 107.381 175.666 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.549 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -116.25 136.6 13.0 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 123.652 0.644 . . . . 10.0 112.168 175.363 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.428 ' CG2' HG22 ' B' ' 54' ' ' THR . 58.6 mt -124.56 74.09 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 -179.018 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -64.09 148.85 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.374 -0.83 . . . . 10.0 109.598 171.67 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -139.05 97.85 3.4 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 127.437 2.295 . . . . 10.0 107.548 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -89.79 118.87 29.7 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.781 -1.192 . . . . 10.0 107.781 171.301 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -104.8 130.88 52.83 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.838 0.745 . . . . 10.0 110.971 168.644 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -123.1 92.3 3.67 Favored 'General case' 0 C--N 1.341 0.217 0 C-N-CA 125.076 1.35 . . . . 10.0 109.102 171.759 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 11.0 mmtp -49.94 -60.91 2.48 Favored 'General case' 0 N--CA 1.46 0.072 0 C-N-CA 124.653 1.181 . . . . 10.0 111.054 175.804 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.0 176.65 8.57 Favored 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 105.604 -1.998 . . . . 10.0 105.604 171.2 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 t -74.72 -13.74 60.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 122.341 0.256 . . . . 10.0 110.708 177.229 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -88.25 -12.94 42.21 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 123.729 0.811 . . . . 10.0 109.794 174.434 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.14 119.54 4.98 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 109.357 -1.497 . . . . 10.0 109.357 178.573 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -60.83 127.73 23.37 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 N-CA-C 106.558 -2.132 . . . . 10.0 106.558 169.41 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -77.01 138.06 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 108.702 -0.851 . . . . 10.0 108.702 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.79 106.24 18.22 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 104.759 -2.311 . . . . 10.0 104.759 171.76 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 m -87.03 93.33 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 105.467 -2.049 . . . . 10.0 105.467 174.137 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -109.18 178.79 4.35 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-O 120.83 0.348 . . . . 10.0 111.219 173.721 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.58 -164.09 30.15 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 169.043 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.6 p -152.19 122.43 7.19 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 118.641 -0.695 . . . . 10.0 110.934 -169.383 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.629 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -100.88 136.6 31.73 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 105.891 -1.892 . . . . 10.0 105.891 166.325 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.44 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -130.14 160.05 34.96 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 168.809 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.7 -12.52 62.79 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 118.042 0.383 . . . . 10.0 113.208 -178.815 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 15.4 mt -68.2 -179.49 1.28 Allowed 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.872 0.869 . . . . 10.0 110.489 171.651 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -111.95 166.46 11.2 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 167.554 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -46.64 148.96 0.88 Allowed 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 127.359 2.264 . . . . 10.0 113.419 -169.534 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.65 -179.09 42.98 Favored Glycine 0 C--N 1.336 0.569 0 C-N-CA 124.235 0.922 . . . . 10.0 114.091 167.139 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.6 mt -52.38 137.9 28.23 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.878 1.671 . . . . 10.0 113.02 176.63 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 -135.31 141.57 45.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.439 1.095 . . . . 10.0 111.075 169.525 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.628 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -25.46 121.75 0.03 OUTLIER Glycine 0 C--N 1.344 0.992 0 CA-C-O 116.648 -2.195 . . . . 10.0 111.773 165.776 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -144.54 109.5 5.04 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 120.431 2.115 . . . . 10.0 111.053 169.768 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.09 175.02 11.36 Favored 'General case' 0 CA--C 1.512 -0.487 0 C-N-CA 123.572 0.749 . . . . 10.0 109.102 -179.612 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.88 98.29 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 113.595 -1.638 . . . . 10.0 109.653 179.448 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 20.4 m-70 -72.74 148.02 45.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 125.898 1.679 . . . . 10.0 109.681 -172.99 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -62.03 -55.72 26.34 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 123.958 0.786 . . . . 10.0 112.077 -173.435 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -87.92 150.6 23.38 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 119.258 -0.977 . . . . 10.0 109.583 177.959 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.98 32.92 5.57 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.098 -1.201 . . . . 10.0 110.098 168.414 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -79.8 70.22 6.28 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 123.251 1.5 . . . . 10.0 108.683 179.153 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.456 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.5 OUTLIER -73.98 5.5 4.19 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.557 -1.201 . . . . 10.0 113.519 -174.014 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.516 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -32.79 -50.75 0.27 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 129.607 3.163 . . . . 10.0 112.703 175.144 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.97 -20.4 45.6 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 113.517 0.932 . . . . 10.0 113.517 -174.572 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.25 71.24 0.89 Allowed Glycine 0 CA--C 1.524 0.62 0 N-CA-C 106.987 -2.445 . . . . 10.0 106.987 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.8 t 49.33 24.01 0.95 Allowed 'General case' 0 CA--C 1.529 0.145 0 N-CA-C 115.844 1.794 . . . . 10.0 115.844 171.356 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.5 m -94.27 -52.48 4.34 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -178.388 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.2 m -66.86 -25.36 66.38 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 125.359 1.464 . . . . 10.0 112.732 -169.332 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.43 -38.27 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.542 2.737 . . . . 10.0 113.73 173.483 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 152.71 9.61 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 111.299 -0.72 . . . . 10.0 111.299 167.713 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.85 57.28 6.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.414 2.076 . . . . 10.0 110.571 172.784 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 30.2 m170 71.56 -64.8 0.37 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 128.014 2.526 . . . . 10.0 108.875 -179.557 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.285 1.1 p90 26.02 49.32 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 129.845 3.258 . . . . 10.0 115.096 175.16 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -51.66 157.2 1.96 Allowed Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 114.438 -1.256 . . . . 10.0 111.057 169.415 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.14 -40.82 24.61 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 121.943 1.762 . . . . 10.0 111.054 -173.735 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mp -77.03 59.63 1.7 Allowed 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.532 -0.914 . . . . 10.0 108.532 169.134 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.3 p -60.95 106.87 0.63 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 107.942 -1.133 . . . . 10.0 107.942 -177.418 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -129.93 -87.64 0.51 Allowed 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 107.34 -1.356 . . . . 10.0 107.34 -169.857 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.3 mmtp -139.05 153.69 48.11 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 122.313 1.054 . . . . 10.0 109.573 169.076 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -70.42 119.78 15.1 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 105.742 -1.948 . . . . 10.0 105.742 162.916 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.26 -135.88 2.91 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 107.104 -2.398 . . . . 10.0 107.104 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.26 -147.73 6.21 Favored Glycine 0 C--O 1.226 -0.403 0 CA-C-O 117.965 -1.464 . . . . 10.0 109.677 171.65 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -67.13 7.78 0.43 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 119.818 1.809 . . . . 10.0 111.105 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -113.37 3.4 15.86 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 118.225 -0.893 . . . . 10.0 111.563 170.944 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -122.42 149.67 43.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.604 -1.628 . . . . 10.0 106.604 170.94 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -83.05 -24.77 32.63 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.65 -0.871 . . . . 10.0 108.65 171.189 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -113.3 26.2 10.65 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 125.242 1.417 . . . . 10.0 111.068 -168.665 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -47.62 161.54 0.09 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 128.589 2.756 . . . . 10.0 110.078 168.371 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -78.69 46.85 0.69 Allowed 'General case' 0 N--CA 1.463 0.216 0 O-C-N 120.575 -1.328 . . . . 10.0 112.318 -178.106 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.2 p 33.16 35.94 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 126.861 2.064 . . . . 10.0 113.595 -174.278 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 165.98 37.69 0.02 OUTLIER Glycine 0 CA--C 1.532 1.113 0 O-C-N 121.538 -0.726 . . . . 10.0 111.961 -169.246 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -113.71 108.15 16.72 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -81.33 -29.48 34.16 Favored 'General case' 0 N--CA 1.461 0.121 0 N-CA-C 107.557 -1.275 . . . . 10.0 107.557 169.033 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.16 -96.64 1.31 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 108.424 -1.871 . . . . 10.0 108.424 168.928 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -134.92 117.98 16.41 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 125.6 1.56 . . . . 10.0 106.905 -169.497 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 22.4 m -111.61 132.26 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 CA-C-N 118.553 0.615 . . . . 10.0 111.296 179.428 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.8 m -78.46 107.88 11.43 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.771 2.429 . . . . 10.0 112.468 -170.472 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.51 137.26 32.48 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.869 0.467 . . . . 10.0 111.309 174.225 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -62.18 174.6 0.87 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 122.009 0.909 . . . . 10.0 110.328 166.927 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.5 pttt -51.74 -32.48 30.68 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.516 1.927 . . . . 10.0 112.709 169.191 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.44 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 22.8 t70 -79.17 -10.46 59.83 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 122.14 0.971 . . . . 10.0 110.658 178.107 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.89 3.7 65.72 Favored Glycine 0 N--CA 1.431 -1.634 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 -171.898 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 26.4 t -75.55 95.65 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.095 0 N-CA-C 106.327 -1.731 . . . . 10.0 106.327 -172.461 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.629 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -98.21 113.17 25.01 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 169.052 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -81.78 115.14 20.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 C-N-CA 127.199 2.2 . . . . 10.0 108.832 175.191 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.2 133.31 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 176.406 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 72.7 p -158.52 80.88 0.81 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.963 0.905 . . . . 10.0 109.799 170.642 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -112.26 143.1 22.68 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 177.628 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -99.73 127.37 45.86 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.393 1.477 . . . . 10.0 107.564 169.372 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -133.7 156.15 48.45 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.601 0.715 . . . . 10.0 109.083 176.721 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.5 t -128.1 49.58 2.15 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 126.022 1.729 . . . . 10.0 109.015 -173.41 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -157.79 -39.42 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 123.361 0.664 . . . . 10.0 110.63 176.837 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 45.6 mm -59.92 116.53 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 169.887 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 48.5 m -131.34 119.29 21.51 Favored 'General case' 0 CA--C 1.528 0.115 0 C-N-CA 124.251 1.02 . . . . 10.0 108.417 178.396 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 59.1 mt -53.97 -38.39 64.97 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 125.108 1.363 . . . . 10.0 111.166 173.491 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.2 m -152.17 151.89 31.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.475 -0.935 . . . . 10.0 108.475 -176.095 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.3 -97.17 0.19 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.295 -1.922 . . . . 10.0 108.295 -174.825 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -122.31 -51.1 1.99 Allowed 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 127.066 2.146 . . . . 10.0 107.935 177.523 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.8 m-70 -73.56 -35.7 65.52 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 114.959 -1.019 . . . . 10.0 108.258 -169.695 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.4 t 42.47 61.47 2.02 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 125.839 1.656 . . . . 10.0 112.951 167.289 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.7 pp -68.71 -9.14 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 113.697 0.999 . . . . 10.0 113.697 -171.633 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 10.5 mm -47.09 133.37 3.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.957 -0.757 . . . . 10.0 108.957 168.893 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.3 -7.49 75.52 Favored Glycine 0 CA--C 1.533 1.156 0 CA-C-O 118.851 -0.972 . . . . 10.0 114.51 -178.483 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.7 mtp-105 -76.26 175.33 9.15 Favored 'General case' 0 CA--C 1.544 0.74 0 CA-C-N 119.843 1.821 . . . . 10.0 106.858 168.992 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -127.78 132.23 49.53 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 119.091 0.86 . . . . 10.0 112.006 -170.586 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.407 HD22 ' N ' ' A' ' 117' ' ' LEU . 3.6 mm? -85.23 148.29 26.16 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 123.997 0.919 . . . . 10.0 108.533 171.863 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 91.9 t -133.32 128.4 55.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.636 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -95.58 123.99 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 106.164 -1.791 . . . . 10.0 106.164 166.943 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.628 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.5 m-70 -98.86 159.72 14.76 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.963 1.468 . . . . 10.0 114.963 -172.805 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -40.47 -58.21 1.62 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 128.415 2.686 . . . . 10.0 110.362 172.385 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -121.44 170.97 9.13 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 113.865 1.061 . . . . 10.0 113.865 -168.209 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.29 136.69 58.13 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 113.938 -1.483 . . . . 10.0 109.072 172.673 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -76.93 148.68 36.22 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.77 0.795 . . . . 10.0 110.634 -179.877 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -81.82 -41.61 20.84 Favored 'General case' 0 N--CA 1.447 -0.625 0 C-N-CA 130.977 3.711 . . . . 10.0 108.955 -176.746 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 16.8 mt 61.29 43.85 10.33 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.451 0.7 . . . . 10.0 112.172 -178.049 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.01 19.55 77.21 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 113.991 0.356 . . . . 10.0 113.991 169.585 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -86.83 -21.8 26.21 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.534 1.133 . . . . 10.0 110.884 172.471 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -56.43 -30.02 58.02 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.777 0.703 . . . . 10.0 111.805 178.578 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.67 30.19 71.75 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.351 -1.1 . . . . 10.0 110.351 -176.124 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.4 166.6 12.46 Favored 'General case' 0 CA--C 1.511 -0.538 0 N-CA-C 108.594 -0.891 . . . . 10.0 108.594 173.006 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -48.67 -54.56 14.3 Favored 'General case' 0 N--CA 1.431 -1.389 0 C-N-CA 124.511 1.125 . . . . 10.0 108.517 176.006 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -51.6 -47.3 63.66 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 124.131 0.973 . . . . 10.0 112.2 173.644 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.9 p -52.67 -37.67 59.15 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 118.991 -0.528 . . . . 10.0 109.94 -179.223 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.251 14.8 t -90.67 0.57 57.35 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 113.807 1.04 . . . . 10.0 113.807 -179.26 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.99 -53.37 2.71 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.77 1.628 . . . . 10.0 112.596 -179.354 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.3 p -129.41 5.4 5.2 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 119.807 1.185 . . . . 10.0 111.862 171.342 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 81.52 -118.54 4.65 Favored Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 103.264 -3.934 . . . . 10.0 103.264 -167.181 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -168.81 39.14 0.03 OUTLIER 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 126.247 1.819 . . . . 10.0 107.789 -178.401 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.67 0.11 13.85 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.585 1.154 . . . . 10.0 111.792 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.15 -163.59 50.73 Favored Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 110.437 -1.065 . . . . 10.0 110.437 171.261 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.34 140.38 45.45 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.835 0.854 . . . . 10.0 111.798 -168.717 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -65.36 72.82 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.567 1.147 . . . . 10.0 110.068 169.709 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 6.0 tp -44.67 -45.53 9.75 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.991 1.716 . . . . 10.0 112.121 -175.685 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 145.93 20.19 Favored 'General case' 0 C--O 1.234 0.281 0 N-CA-C 108.199 -1.038 . . . . 10.0 108.199 -175.938 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 m -139.6 152.64 46.98 Favored 'General case' 0 CA--C 1.518 -0.259 0 C-N-CA 123.12 0.568 . . . . 10.0 109.974 -169.125 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -149.81 145.42 13.54 Favored Glycine 0 C--N 1.338 0.652 0 N-CA-C 110.536 -1.026 . . . . 10.0 110.536 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 23.8 t -102.07 138.04 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 106.335 -1.728 . . . . 10.0 106.335 -175.319 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 48.5 mt -76.04 107.74 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 N-CA-C 109.917 -0.401 . . . . 10.0 109.917 -173.457 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.8 164.52 12.04 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.574 1.559 . . . . 10.0 111.635 178.465 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.4 mt -64.37 143.67 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 C-N-CA 124.93 1.292 . . . . 10.0 111.495 -177.908 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -136.72 162.27 33.65 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.404 -1.332 . . . . 10.0 107.404 167.542 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 . . . . . 0 C--O 1.251 1.162 0 N-CA-C 104.256 -2.498 . . . . 10.0 104.256 166.884 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.49 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -105.54 -27.77 11.19 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 126.041 1.737 . . . . 10.0 111.743 170.009 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.8 tttt -131.05 137.06 48.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.846 0.859 . . . . 10.0 109.354 179.421 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.93 161.0 30.9 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 123.375 0.67 . . . . 10.0 110.083 170.792 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.6 t -120.45 154.66 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 C-N-CA 126.354 1.861 . . . . 10.0 108.874 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.46 108.57 4.77 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 167.86 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 53' ' ' ASN . 3.7 m -98.72 121.74 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 109.303 -0.629 . . . . 10.0 109.303 177.909 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.76 133.58 43.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.611 -0.709 . . . . 10.0 109.89 -175.266 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.3 mtpt -144.41 156.89 44.42 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 119.368 0.985 . . . . 10.0 109.153 167.447 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.47 -59.59 0.06 OUTLIER Glycine 0 N--CA 1.461 0.312 0 C-N-CA 119.696 -1.24 . . . . 10.0 113.861 169.776 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -71.12 -42.85 68.69 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -174.882 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.5 -70.05 0.41 Allowed Glycine 0 CA--C 1.523 0.532 0 CA-C-N 114.157 -1.383 . . . . 10.0 110.35 169.207 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.83 -36.82 99.0 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 123.338 2.692 . . . . 10.0 111.357 172.393 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.7 91.16 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 125.804 1.641 . . . . 10.0 107.802 177.098 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -117.82 112.39 20.33 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.205 1.402 . . . . 10.0 107.934 176.933 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.434 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -108.48 148.95 16.86 Favored Glycine 0 N--CA 1.432 -1.592 0 CA-C-N 114.137 -1.392 . . . . 10.0 111.328 -178.338 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.516 HG22 HG22 ' A' ' 54' ' ' THR . 1.2 mt -151.42 84.11 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.332 1.853 . . . . 10.0 107.107 -169.907 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.0 mm -97.01 149.89 4.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 C-N-CA 124.914 1.286 . . . . 10.0 110.566 179.708 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.18 111.66 11.62 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 128.901 2.88 . . . . 10.0 108.382 -178.031 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -98.29 111.02 23.5 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 117.435 -1.269 . . . . 10.0 107.845 172.948 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -108.77 108.55 19.41 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.365 0.984 . . . . 10.0 112.271 174.073 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -103.87 96.21 6.53 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.588 1.955 . . . . 10.0 107.153 174.442 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 65.6 mttt -59.19 -50.22 74.85 Favored 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 123.946 0.898 . . . . 10.0 110.637 -169.052 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -135.13 171.56 14.25 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 102.755 -3.054 . . . . 10.0 102.755 -176.524 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.5 p -71.92 -18.25 62.04 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 119.174 0.897 . . . . 10.0 109.467 173.893 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -78.93 -19.35 52.01 Favored 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 123.606 0.763 . . . . 10.0 110.796 172.397 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.21 123.1 9.19 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 110.024 -1.231 . . . . 10.0 110.024 -175.876 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.8 127.79 18.58 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 N-CA-C 107.045 -1.944 . . . . 10.0 107.045 169.832 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.5 p -76.46 85.81 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-O 122.432 1.11 . . . . 10.0 108.349 -174.36 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 mtpt -58.82 111.31 1.24 Allowed 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 169.607 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 p -102.07 101.87 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.754 0 C-N-CA 126.219 1.807 . . . . 10.0 106.395 -177.64 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -116.18 174.4 6.07 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 116.319 -0.401 . . . . 10.0 111.385 176.531 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.03 -156.01 26.72 Favored Glycine 0 C--N 1.331 0.264 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 169.294 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.2 p -149.71 146.56 27.29 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.451 0.644 . . . . 10.0 112.595 -172.373 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.616 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -120.95 115.41 46.75 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.329 0 C-N-CA 125.909 1.684 . . . . 10.0 108.693 169.774 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -102.49 143.1 32.63 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 169.746 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.72 9.35 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 124.562 1.077 . . . . 10.0 112.969 170.332 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 mt -87.77 -175.67 5.24 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.961 0.886 . . . . 10.0 110.571 -171.274 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -102.72 155.78 18.08 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 167.516 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -53.54 159.09 1.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.589 1.156 . . . . 10.0 111.793 -174.878 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.71 -177.15 35.59 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.717 0.675 . . . . 10.0 111.803 170.608 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -66.56 149.82 49.9 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 125.46 1.504 . . . . 10.0 112.373 -177.861 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.6 m-70 -146.8 142.28 27.56 Favored 'General case' 0 C--N 1.344 0.352 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -177.467 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.683 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -30.99 125.62 0.17 Allowed Glycine 0 C--N 1.343 0.943 0 C-N-CA 127.74 2.59 . . . . 10.0 113.03 165.679 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.67 105.12 2.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 119.343 1.572 . . . . 10.0 113.002 168.577 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.13 172.74 15.31 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.156 0.503 . . . . 10.0 111.501 179.64 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.0 m -93.99 149.93 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 113.156 -1.838 . . . . 10.0 108.408 169.299 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 24.2 m-70 -130.94 140.31 50.16 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.719 1.608 . . . . 10.0 106.888 174.795 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -52.76 -54.86 27.92 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 125.27 1.428 . . . . 10.0 112.327 -169.721 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -77.62 114.59 16.61 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -61.05 -32.16 79.29 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.261 -1.136 . . . . 10.0 110.261 172.257 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.636 ' HA ' HG11 ' A' ' 5' ' ' VAL . 25.3 t0 -32.16 125.35 0.29 Allowed 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 125.296 1.439 . . . . 10.0 112.548 172.282 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -129.69 11.36 5.7 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 113.967 -1.47 . . . . 10.0 111.401 176.628 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.428 HG22 ' CG2' ' A' ' 17' ' ' ILE . 8.2 p -37.17 -63.27 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 125.972 1.709 . . . . 10.0 113.309 -175.477 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -74.67 -16.03 60.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.444 -1.253 . . . . 10.0 111.89 -174.458 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 136.11 -75.57 0.4 Allowed Glycine 0 CA--C 1.521 0.464 0 N-CA-C 109.004 -1.638 . . . . 10.0 109.004 177.941 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 9.3 t -157.0 18.65 0.3 Allowed 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 112.734 0.642 . . . . 10.0 112.734 -172.921 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.0 p -99.07 -57.43 2.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 105.718 -1.956 . . . . 10.0 105.718 -176.527 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -55.64 -25.77 40.84 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.424 1.89 . . . . 10.0 111.81 -179.409 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.14 -29.64 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 127.953 2.501 . . . . 10.0 114.226 168.349 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.61 154.96 28.28 Favored Glycine 0 C--N 1.34 0.752 0 N-CA-C 109.359 -1.496 . . . . 10.0 109.359 170.031 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -74.12 -170.84 0.77 Allowed 'Trans proline' 0 N--CA 1.446 -1.315 0 N-CA-C 107.787 -1.659 . . . . 10.0 107.787 168.778 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.428 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.1 m170 -80.95 60.67 4.25 Favored 'General case' 0 CA--C 1.537 0.444 0 O-C-N 120.658 -1.276 . . . . 10.0 109.827 -177.079 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -73.67 72.71 1.48 Allowed 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 122.117 0.96 . . . . 10.0 109.698 174.408 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -73.16 135.06 79.99 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.636 -0.665 . . . . 10.0 110.042 173.271 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.18 -44.56 4.82 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 122.57 2.18 . . . . 10.0 110.867 -177.426 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.8 mt -72.63 67.85 0.8 Allowed 'General case' 0 C--O 1.225 -0.234 0 C-N-CA 123.481 0.712 . . . . 10.0 109.312 175.067 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 40.5 p -37.03 108.67 0.08 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 125.853 1.661 . . . . 10.0 111.054 -179.187 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.83 173.03 12.05 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 103.086 -2.931 . . . . 10.0 103.086 -170.568 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.418 ' NZ ' ' OE2' ' B' ' 78' ' ' GLU . 6.7 mptt -80.06 152.44 29.37 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 117.341 -1.743 . . . . 10.0 107.99 170.338 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.432 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 79.1 t60 -63.27 103.2 0.47 Allowed 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.398 -0.964 . . . . 10.0 108.398 165.596 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.37 -127.34 4.05 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.156 -1.977 . . . . 10.0 108.156 177.718 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.7 -163.83 32.47 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 108.377 -1.889 . . . . 10.0 108.377 173.346 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -63.29 -5.5 8.27 Favored 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 119.832 1.816 . . . . 10.0 110.793 167.499 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -87.53 -26.09 23.33 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 125.407 1.483 . . . . 10.0 110.076 175.131 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -98.94 158.36 15.7 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 106.798 -1.556 . . . . 10.0 106.798 179.299 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -79.0 -32.38 45.14 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 107.421 -1.326 . . . . 10.0 107.421 168.541 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 78' ' ' GLU . . . . . 0.418 ' OE2' ' NZ ' ' B' ' 70' ' ' LYS . 1.4 pt-20 -114.5 51.36 0.89 Allowed 'General case' 0 N--CA 1.447 -0.604 0 C-N-CA 124.26 1.024 . . . . 10.0 111.018 -168.684 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -61.43 164.53 5.58 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.589 1.556 . . . . 10.0 110.689 169.159 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.432 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 9.9 m170 -66.59 -63.09 1.14 Allowed 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.418 0.525 . . . . 10.0 112.418 -170.022 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 8.2 p -171.65 -47.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.19 0.996 . . . . 10.0 109.818 -178.092 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.59 72.28 0.37 Allowed Glycine 0 C--N 1.336 0.572 0 N-CA-C 107.149 -2.38 . . . . 10.0 107.149 176.967 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.05 98.11 5.83 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.497 -2.038 . . . . 10.0 105.497 -173.358 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 40.5 mt -80.72 5.92 14.35 Favored 'General case' 0 N--CA 1.463 0.177 0 C-N-CA 122.678 0.391 . . . . 10.0 111.774 -169.844 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 82.65 -106.36 2.73 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 107.475 -2.25 . . . . 10.0 107.475 -174.582 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -158.65 152.53 23.54 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.125 0.97 . . . . 10.0 110.248 -177.146 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -122.74 133.99 67.23 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 123.275 0.63 . . . . 10.0 110.174 -176.402 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -78.57 133.23 37.35 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 126.546 1.938 . . . . 10.0 109.266 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.29 132.56 50.41 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.548 1.939 . . . . 10.0 110.155 169.726 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -63.6 171.22 2.72 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.993 1.717 . . . . 10.0 111.145 168.733 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 91' ' ' LYS . . . . . 0.417 ' NZ ' ' OD1' ' B' ' 92' ' ' ASP . 17.9 pttp -49.07 -35.03 14.95 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 124.565 1.146 . . . . 10.0 110.647 169.535 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.417 ' OD1' ' NZ ' ' B' ' 91' ' ' LYS . 0.1 OUTLIER -77.9 -3.15 40.28 Favored 'General case' 0 C--N 1.342 0.249 0 O-C-N 122.326 -0.234 . . . . 10.0 110.535 -175.919 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.68 22.88 78.75 Favored Glycine 0 N--CA 1.444 -0.797 0 N-CA-C 109.469 -1.452 . . . . 10.0 109.469 -175.289 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.0 t -96.21 106.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.86 0 C-N-CA 127.57 2.348 . . . . 10.0 105.093 173.438 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.616 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.44 125.05 48.03 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.287 -1.005 . . . . 10.0 108.287 169.341 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -94.68 121.33 36.15 Favored 'General case' 0 N--CA 1.435 -1.179 0 C-N-CA 127.838 2.455 . . . . 10.0 108.832 179.308 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 43.3 t -101.26 135.81 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 124.767 1.227 . . . . 10.0 108.147 177.326 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.26 72.43 0.62 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.945 1.298 . . . . 10.0 109.408 169.689 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -106.38 162.46 5.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 107.565 -1.272 . . . . 10.0 107.565 -179.036 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -146.13 136.46 23.87 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.584 1.554 . . . . 10.0 109.568 175.69 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -134.02 142.34 47.58 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.091 -1.818 . . . . 10.0 106.091 173.759 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 75.2 p -103.5 51.48 0.79 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.868 1.267 . . . . 10.0 107.811 174.228 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.32 -47.91 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.323 0.649 . . . . 10.0 110.377 -176.97 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.47 118.26 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 171.431 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.1 m -120.62 112.67 19.19 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 108.562 -0.903 . . . . 10.0 108.562 -176.658 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 77.4 mt -56.81 -43.97 81.51 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.457 0.646 . . . . 10.0 110.41 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.0 m -156.5 83.5 0.97 Allowed 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 -174.358 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -147.65 -61.53 0.01 OUTLIER Glycine 0 C--N 1.334 0.435 0 N-CA-C 111.062 -0.815 . . . . 10.0 111.062 -170.328 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -153.95 -52.88 0.1 Allowed 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 126.02 1.728 . . . . 10.0 106.827 -175.799 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -77.57 -34.95 53.52 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.868 -1.16 . . . . 10.0 107.868 -175.218 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t 56.14 61.48 2.73 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.135 1.374 . . . . 10.0 108.112 173.084 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 31.0 mm -73.57 -14.06 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 CA-C-N 113.543 -1.662 . . . . 10.0 112.228 -168.973 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.5 mm -51.48 147.32 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 N-CA-C 109.363 -0.606 . . . . 10.0 109.363 169.696 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.81 2.44 90.54 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 121.357 -0.84 . . . . 10.0 114.592 178.815 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 54.4 mmt-85 -77.58 163.31 26.37 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 118.914 1.357 . . . . 10.0 108.716 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.1 118.17 35.24 Favored 'General case' 0 C--N 1.34 0.153 0 N-CA-C 109.287 -0.634 . . . . 10.0 109.287 170.51 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.426 HD21 HD11 ' B' ' 149' ' ' ILE . 4.5 mm? -75.49 142.99 42.79 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.048 -1.464 . . . . 10.0 107.048 167.184 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.64 129.36 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.831 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.04 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.42 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.7 p -97.35 135.3 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.715 0 N-CA-C 107.96 -1.126 . . . . 10.0 107.96 169.275 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.683 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.8 m170 -115.02 159.72 20.46 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 116.465 2.024 . . . . 10.0 116.465 -175.891 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -48.92 -58.38 4.95 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 129.832 3.253 . . . . 10.0 111.932 177.071 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 54.8 mttp -111.93 173.46 6.35 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.966 0.906 . . . . 10.0 112.804 -169.874 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.05 136.04 35.26 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 126.524 1.929 . . . . 10.0 110.304 -179.165 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.69 144.22 32.42 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 113.362 0.875 . . . . 10.0 113.362 -169.558 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -74.9 -38.56 61.82 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.187 1.395 . . . . 10.0 109.206 177.855 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.8 mt 62.12 49.92 4.23 Favored 'General case' 0 C--N 1.337 0.054 0 C-N-CA 125.21 1.404 . . . . 10.0 110.006 -172.259 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 82.82 -45.58 3.45 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.562 1.077 . . . . 10.0 110.988 170.638 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.5 pttp -73.43 21.63 0.08 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.83 1.652 . . . . 10.0 112.72 -175.147 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -77.91 -32.71 43.99 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 126.475 1.988 . . . . 10.0 108.298 166.103 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.22 19.08 69.97 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.284 -0.731 . . . . 10.0 111.859 -179.124 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -112.07 162.27 15.59 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 104.839 -2.282 . . . . 10.0 104.839 169.215 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 132' ' ' GLU . . . . . 0.454 ' CD ' ' HZ1' ' B' ' 136' ' ' LYS . 15.6 tm-20 -60.92 -40.04 91.7 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 119.505 -0.878 . . . . 10.0 110.748 -169.849 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -69.12 -28.28 66.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 118.749 -0.643 . . . . 10.0 112.242 177.529 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -48.76 -47.47 41.64 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 119.68 1.127 . . . . 10.0 110.242 168.852 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.4 t -85.1 -10.15 57.15 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 118.461 -0.781 . . . . 10.0 112.711 -171.366 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.454 ' HZ1' ' CD ' ' B' ' 132' ' ' GLU . 1.1 ttmp? -100.61 -92.34 0.3 Allowed 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.69 1.596 . . . . 10.0 108.15 175.292 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.428 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 44.5 p -86.26 1.35 51.23 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 122.135 2.243 . . . . 10.0 112.744 -176.062 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.58 21.89 73.88 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 120.416 1.462 . . . . 10.0 110.79 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 61.72 19.92 10.93 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 119.577 1.688 . . . . 10.0 112.854 169.649 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -80.29 9.96 5.12 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 113.623 0.972 . . . . 10.0 113.623 -168.021 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.72 -165.07 53.94 Favored Glycine 0 N--CA 1.444 -0.781 0 O-C-N 121.252 -0.905 . . . . 10.0 111.502 170.954 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.5 m -59.3 135.63 57.71 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 124.1 0.96 . . . . 10.0 112.901 -167.705 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -67.23 86.99 0.16 Allowed 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 125.129 1.372 . . . . 10.0 110.276 174.042 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 58.5 mt -60.85 -35.12 75.76 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.827 0.676 . . . . 10.0 112.827 -177.19 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.42 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -158.39 154.35 26.81 Favored 'General case' 0 C--O 1.234 0.244 0 O-C-N 121.625 -0.672 . . . . 10.0 111.495 179.932 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -123.55 152.36 41.9 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 125.857 1.663 . . . . 10.0 109.088 -178.674 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.57 156.04 26.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.413 -1.075 . . . . 10.0 110.413 168.806 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 66.1 t -109.58 140.07 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 -175.588 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.426 HD11 HD21 ' B' ' 117' ' ' LEU . 27.6 mt -75.62 125.15 34.92 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-O 118.594 -0.717 . . . . 10.0 109.764 -178.622 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.81 162.76 24.48 Favored Glycine 0 CA--C 1.53 1.022 0 C-N-CA 124.383 0.992 . . . . 10.0 113.569 -178.573 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.8 mm -73.34 144.91 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.274 1.03 . . . . 10.0 111.226 -169.904 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.96 -47.2 2.18 Favored 'General case' 0 CA--C 1.51 -0.592 0 CA-C-N 118.45 0.568 . . . . 10.0 111.433 166.652 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 116.38 -1.771 . . . . 10.0 107.544 175.78 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.659 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.7 t -151.55 -48.44 0.11 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 119.12 0.873 . . . . 10.0 110.7 178.686 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 40.8 tttt -132.87 153.64 51.14 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.2 -1.778 . . . . 10.0 106.2 172.59 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.22 151.18 43.55 Favored 'General case' 0 CA--C 1.513 -0.46 0 N-CA-C 108.93 -0.767 . . . . 10.0 108.93 169.286 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.38 161.12 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 O-C-N 124.061 0.851 . . . . 10.0 110.223 172.464 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.432 ' CB ' HD12 ' A' ' 117' ' ' LEU . . . -147.41 98.96 3.07 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.206 -1.775 . . . . 10.0 106.206 165.703 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.481 HG21 ' HB3' ' B' ' 53' ' ' ASN . 7.5 m -93.29 98.02 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 122.844 0.458 . . . . 10.0 110.687 -179.204 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.415 HD12 ' N ' ' A' ' 8' ' ' LEU . 5.5 mp -79.6 136.26 36.8 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 121.227 -0.921 . . . . 10.0 109.833 -175.756 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -144.73 156.15 43.92 Favored 'General case' 0 C--N 1.341 0.212 0 C-N-CA 124.426 1.09 . . . . 10.0 108.344 168.346 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.6 -69.08 0.02 OUTLIER Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.185 -0.531 . . . . 10.0 112.166 169.252 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -74.24 -41.51 61.2 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 107.179 -1.415 . . . . 10.0 107.179 -175.656 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.91 -67.67 0.48 Allowed Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 114.996 -1.002 . . . . 10.0 111.588 176.969 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -55.15 -42.05 72.58 Favored 'Trans proline' 0 N--CA 1.45 -1.077 0 C-N-CA 121.972 1.782 . . . . 10.0 110.077 175.846 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.668 HG13 HD12 ' A' ' 38' ' ' LEU . 47.9 t -58.49 87.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 C-N-CA 126.182 1.793 . . . . 10.0 108.034 175.197 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.47 116.95 31.75 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.709 -1.96 . . . . 10.0 105.709 171.453 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.91 142.89 15.97 Favored Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 108.656 -1.778 . . . . 10.0 108.656 174.258 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.972 ' CG2' HG22 ' B' ' 54' ' ' THR . 7.1 mt -138.71 60.81 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 N-CA-C 107.357 -1.349 . . . . 10.0 107.357 -169.684 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.4 mm -77.87 133.56 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 N-CA-C 108.801 -0.814 . . . . 10.0 108.801 -176.072 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m-80 -122.44 105.11 9.87 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.203 2.201 . . . . 10.0 107.22 -176.805 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -89.1 136.44 33.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.499 1.12 . . . . 10.0 108.025 177.749 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -117.49 148.29 41.97 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 123.703 0.627 . . . . 10.0 110.701 168.191 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -122.46 107.14 11.69 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.7 1.6 . . . . 10.0 108.01 168.816 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -65.91 -59.2 4.08 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.974 0.91 . . . . 10.0 110.644 -178.492 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.1 mp0 -128.22 168.02 16.04 Favored 'General case' 0 N--CA 1.425 -1.725 0 N-CA-C 103.608 -2.738 . . . . 10.0 103.608 174.079 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.2 p -65.98 -25.74 67.24 Favored 'General case' 0 N--CA 1.44 -0.937 0 O-C-N 121.748 -0.595 . . . . 10.0 109.429 174.759 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -98.69 -6.33 29.85 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.207 1.403 . . . . 10.0 110.828 -173.361 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.63 144.57 21.4 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 -173.772 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -64.02 139.42 67.29 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 121.721 1.614 . . . . 10.0 108.101 170.525 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 m -93.12 142.51 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -176.861 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -108.06 123.21 48.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.298 -2.482 . . . . 10.0 104.298 166.606 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 m -108.99 103.45 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 105.916 -1.883 . . . . 10.0 105.916 -179.371 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 8.0 p90 -114.44 171.82 7.39 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 -176.298 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.65 -154.4 25.53 Favored Glycine 0 N--CA 1.447 -0.618 0 N-CA-C 108.537 -1.825 . . . . 10.0 108.537 169.076 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 m -153.54 150.24 28.5 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 117.124 0.462 . . . . 10.0 110.899 177.896 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.61 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -111.17 112.65 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 C-N-CA 127.356 2.263 . . . . 10.0 106.861 168.493 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.5 ptmt -121.73 90.3 3.28 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 112.214 0.45 . . . . 10.0 112.214 -178.276 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.65 32.35 0.02 OUTLIER Glycine 0 CA--C 1.52 0.406 0 CA-C-O 118.981 -0.9 . . . . 10.0 113.996 174.032 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.668 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -125.06 175.41 7.37 Favored 'General case' 0 C--O 1.224 -0.246 0 N-CA-C 108.237 -1.023 . . . . 10.0 108.237 177.144 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -75.6 168.54 19.81 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 118.83 0.741 . . . . 10.0 110.844 177.712 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 65.1 tt0 -61.02 173.3 0.81 Allowed 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.21 1.804 . . . . 10.0 111.288 -176.874 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.14 179.73 49.73 Favored Glycine 0 CA--C 1.522 0.52 0 C-N-CA 123.781 0.705 . . . . 10.0 112.017 168.897 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.0 mp -66.02 143.56 57.28 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.376 1.07 . . . . 10.0 110.275 178.449 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -140.39 146.5 38.45 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 113.384 0.883 . . . . 10.0 113.384 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.661 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -29.25 122.72 0.09 OUTLIER Glycine 0 C--N 1.341 0.851 0 C-N-CA 127.547 2.499 . . . . 10.0 112.269 165.25 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -150.62 106.01 3.37 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 120.034 1.917 . . . . 10.0 113.12 169.758 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.419 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.43 175.18 12.99 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.509 0.671 . . . . 10.0 112.803 -176.497 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.402 HG12 ' CD2' ' A' ' 117' ' ' LEU . 1.7 m -91.42 153.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 112.655 -2.066 . . . . 10.0 106.3 166.499 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.32 123.27 35.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 102.884 -3.006 . . . . 10.0 102.884 169.113 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -61.33 -35.03 76.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 114.894 1.442 . . . . 10.0 114.894 -164.571 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-30 -75.91 119.54 20.02 Favored 'General case' 0 C--N 1.342 0.251 0 C-N-CA 117.285 -1.766 . . . . 10.0 106.984 169.576 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.01 37.08 0.92 Allowed Glycine 0 CA--C 1.525 0.676 0 C-N-CA 125.041 1.305 . . . . 10.0 111.241 168.883 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -107.55 171.56 7.32 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 124.899 1.279 . . . . 10.0 107.697 177.459 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.439 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -161.1 25.65 0.14 Allowed 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 114.653 -1.158 . . . . 10.0 112.231 168.747 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.442 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.2 OUTLIER -55.39 -36.96 66.97 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.451 1.1 . . . . 10.0 111.253 -170.481 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.38 -19.6 55.95 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 124.022 0.929 . . . . 10.0 112.468 -179.695 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 87.04 97.87 0.85 Allowed Glycine 0 CA--C 1.528 0.866 0 N-CA-C 109.02 -1.632 . . . . 10.0 109.02 -169.698 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 59.2 m 43.11 55.17 4.67 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.032 1.733 . . . . 10.0 113.962 173.074 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.76 -49.62 0.08 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.078 0.551 . . . . 10.0 110.139 176.034 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 47.4 t -60.8 -28.89 69.12 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 122.44 0.296 . . . . 10.0 111.059 -173.314 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.42 -28.97 0.07 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 127.448 2.299 . . . . 10.0 115.156 179.758 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 134.26 8.41 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-O 118.449 -1.195 . . . . 10.0 110.528 170.994 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -78.46 62.24 8.14 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 123.211 2.607 . . . . 10.0 112.319 -174.315 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 14.0 m170 61.74 28.02 17.21 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.511 2.324 . . . . 10.0 110.581 177.372 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -53.72 -39.05 64.91 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 113.871 1.064 . . . . 10.0 113.871 -166.67 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 34.27 172.23 0.0 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 128.807 2.843 . . . . 10.0 115.518 -169.662 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -67.81 -65.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.349 0.573 0 O-C-N 118.621 -1.305 . . . . 10.0 110.849 -172.781 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.0 74.52 2.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 169.006 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 p -47.89 113.76 0.78 Allowed 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.048 0.939 . . . . 10.0 108.946 169.487 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 40.6 mtt180 -133.13 -167.06 1.85 Allowed 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 105.783 -1.932 . . . . 10.0 105.783 -178.465 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.81 137.54 33.66 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 118.046 -1.462 . . . . 10.0 110.304 -171.022 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 65.8 t60 -47.15 119.66 2.71 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 120.337 -0.545 . . . . 10.0 110.517 168.218 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.61 -143.76 4.22 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 108.636 -1.786 . . . . 10.0 108.636 177.583 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.61 -149.94 6.86 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-O 118.158 -1.357 . . . . 10.0 109.981 175.431 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 79.7 Cg_endo -69.27 14.68 0.22 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 122.162 1.908 . . . . 10.0 111.415 169.287 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.0 mtpm? -110.08 -10.78 14.67 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 124.616 1.166 . . . . 10.0 110.075 169.592 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -111.41 158.55 18.96 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.369 -1.345 . . . . 10.0 107.369 -179.176 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -79.41 -36.86 38.42 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.653 -1.24 . . . . 10.0 107.653 173.033 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -96.8 -49.7 4.96 Favored 'General case' 0 CA--C 1.498 -1.024 0 CA-C-O 121.453 0.644 . . . . 10.0 112.137 -166.3 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 7.1 ptp180 41.52 -141.4 0.09 Allowed 'General case' 0 N--CA 1.434 -1.253 0 CA-C-N 113.709 -1.587 . . . . 10.0 109.108 -169.478 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -112.12 44.56 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 O-C-N 120.611 -1.306 . . . . 10.0 108.073 166.511 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.9 t 37.8 38.96 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 124.081 0.953 . . . . 10.0 111.04 -167.596 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 70.69 0.02 OUTLIER Glycine 0 CA--C 1.533 1.195 0 O-C-N 121.541 -0.724 . . . . 10.0 112.431 -174.002 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -136.94 111.15 8.39 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 104.008 -2.59 . . . . 10.0 104.008 168.181 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 19.3 mt -72.19 -23.18 61.22 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 118.667 0.667 . . . . 10.0 109.225 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.11 -89.8 0.55 Allowed Glycine 0 N--CA 1.441 -1.025 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 167.042 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 m-20 -147.8 126.44 12.53 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -173.794 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.7 m -109.82 124.87 66.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 118.043 0.383 . . . . 10.0 110.097 176.293 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.1 m -79.51 111.39 15.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 127.245 2.218 . . . . 10.0 111.228 -176.825 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.56 129.75 34.75 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 123.176 0.59 . . . . 10.0 109.985 170.813 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -61.29 166.69 3.66 Favored 'General case' 0 N--CA 1.454 -0.272 0 O-C-N 124.574 1.171 . . . . 10.0 109.119 167.756 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.64 -26.0 54.92 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 123.91 0.884 . . . . 10.0 111.446 175.882 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -75.76 -10.62 59.59 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 120.583 0.23 . . . . 10.0 110.675 179.525 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.04 23.15 42.3 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.403 -1.079 . . . . 10.0 110.403 178.664 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.1 t -106.99 105.57 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.986 0 C-N-CA 128.359 2.664 . . . . 10.0 105.95 -178.931 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.61 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -102.83 121.46 42.52 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.668 -1.234 . . . . 10.0 107.668 168.635 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -92.32 132.63 36.56 Favored 'General case' 0 N--CA 1.434 -1.261 0 C-N-CA 127.188 2.195 . . . . 10.0 108.899 176.36 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -113.08 133.12 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.979 0 C-N-CA 125.298 1.439 . . . . 10.0 107.676 175.14 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.5 p -158.35 57.82 0.45 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.278 0.631 . . . . 10.0 110.688 169.651 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.79 155.15 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.101 0 N-CA-C 107.999 -1.112 . . . . 10.0 107.999 -173.986 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -122.2 156.41 33.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 124.746 1.218 . . . . 10.0 111.904 173.809 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -148.97 164.19 35.3 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.057 -1.428 . . . . 10.0 108.989 168.721 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.7 p -118.8 44.01 2.4 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 126.227 1.811 . . . . 10.0 110.364 -178.012 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.2 p -145.19 -43.46 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 118.255 0.48 . . . . 10.0 111.251 177.013 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.39 147.31 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.318 -1.364 . . . . 10.0 107.318 169.176 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.1 m -151.57 135.44 16.45 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.128 -1.064 . . . . 10.0 108.128 174.385 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -70.04 -38.16 75.77 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.832 0.853 . . . . 10.0 108.919 -179.593 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 22.6 m -137.75 130.22 29.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.74 -1.578 . . . . 10.0 106.74 170.335 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.91 -65.66 0.1 OUTLIER Glycine 0 C--N 1.333 0.369 0 N-CA-C 109.258 -1.537 . . . . 10.0 109.258 -177.941 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -163.06 -51.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.773 1.629 . . . . 10.0 107.703 -179.835 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -74.1 -41.59 61.4 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 114.38 -1.282 . . . . 10.0 108.091 -169.64 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.9 t 41.11 74.25 0.11 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 126.477 1.911 . . . . 10.0 111.702 174.858 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -68.22 -3.64 2.64 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 N-CA-C 112.932 0.716 . . . . 10.0 112.932 -179.682 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.1 mm -33.02 -44.34 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 126.453 1.901 . . . . 10.0 114.042 173.421 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.89 38.81 3.14 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 124.185 0.898 . . . . 10.0 112.515 -176.748 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -102.78 176.69 5.08 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.475 1.51 . . . . 10.0 111.643 170.046 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 4.7 m -119.1 131.22 55.9 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.952 2.101 . . . . 10.0 106.36 177.85 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.432 HD12 ' CB ' ' A' ' 6' ' ' ALA . 58.7 mt -103.9 148.35 26.26 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 125.28 1.432 . . . . 10.0 109.324 172.285 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.2 t -136.36 134.36 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 O-C-N 123.71 0.631 . . . . 10.0 109.364 -178.593 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.39 135.63 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 168.648 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.661 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.3 m170 -112.26 155.64 23.7 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 116.673 2.101 . . . . 10.0 116.673 -178.565 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -42.24 -62.93 0.83 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.779 3.231 . . . . 10.0 111.548 173.314 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 8.1 mtmt -106.89 172.41 6.84 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.993 1.317 . . . . 10.0 111.823 -177.298 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.4 150.96 39.76 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.994 -1.457 . . . . 10.0 109.605 172.459 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.419 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.3 m-20 -79.46 150.23 31.32 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.565 1.146 . . . . 10.0 112.495 177.317 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -74.36 -29.56 61.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.973 -1.467 . . . . 10.0 110.122 169.943 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 27.4 mt 54.97 44.27 28.53 Favored 'General case' 0 C--N 1.339 0.129 0 CA-C-O 121.847 0.832 . . . . 10.0 108.799 -167.963 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.38 -10.17 67.71 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 125.667 1.603 . . . . 10.0 113.151 173.204 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -78.33 -3.93 45.5 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 118.405 1.102 . . . . 10.0 113.117 -170.795 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.2 -38.62 95.94 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.813 -0.915 . . . . 10.0 110.813 175.152 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.43 33.45 81.88 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.114 -1.194 . . . . 10.0 110.114 -173.387 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -117.59 161.96 18.79 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 106.05 -1.833 . . . . 10.0 106.05 169.69 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -51.36 -48.87 62.36 Favored 'General case' 0 N--CA 1.428 -1.525 0 N-CA-C 108.721 -0.844 . . . . 10.0 108.721 170.773 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -59.04 -40.1 84.04 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.318 -0.401 . . . . 10.0 111.31 176.96 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 16.6 p -55.75 -40.15 72.16 Favored 'General case' 0 N--CA 1.443 -0.794 0 O-C-N 120.926 -1.109 . . . . 10.0 110.708 179.287 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -84.64 4.93 30.11 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 118.491 -0.766 . . . . 10.0 112.122 -178.265 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -112.83 -85.44 0.58 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.037 1.735 . . . . 10.0 110.091 175.022 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.4 p -111.43 30.87 6.56 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 121.088 1.767 . . . . 10.0 112.52 178.179 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.83 27.52 56.18 Favored Glycine 0 C--N 1.341 0.858 0 C-N-CA 123.757 0.694 . . . . 10.0 113.9 168.333 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 46.8 29.62 1.03 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.055 0.942 . . . . 10.0 113.01 -172.108 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.35 -4.57 18.77 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.228 -0.92 . . . . 10.0 112.24 -177.424 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.67 -161.92 50.17 Favored Glycine 0 N--CA 1.444 -0.812 0 O-C-N 121.129 -0.982 . . . . 10.0 111.315 169.212 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.1 m -55.12 128.39 33.57 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 114.644 -0.778 . . . . 10.0 112.842 -167.274 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 22.5 mtt85 -66.43 73.03 0.08 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.738 1.615 . . . . 10.0 109.758 172.078 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 35.1 mt -49.3 -36.82 21.94 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.595 1.158 . . . . 10.0 112.976 -175.722 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 152.1 24.72 Favored 'General case' 0 CA--C 1.513 -0.461 0 O-C-N 121.57 -0.706 . . . . 10.0 110.526 -177.877 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.0 m -130.87 145.66 52.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 124.821 1.326 . . . . 10.0 108.679 -175.661 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -135.48 141.28 12.46 Favored Glycine 0 C--N 1.332 0.314 0 N-CA-C 108.621 -1.792 . . . . 10.0 108.621 171.508 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -99.79 136.61 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 105.869 -1.9 . . . . 10.0 105.869 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.0 mt -72.09 158.93 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 -177.072 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -172.67 168.66 41.75 Favored Glycine 0 CA--C 1.527 0.787 0 O-C-N 121.379 -0.826 . . . . 10.0 111.737 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.7 mt -53.19 142.31 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 125.451 1.5 . . . . 10.0 111.534 -174.209 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.83 163.64 36.79 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.665 0.745 . . . . 10.0 109.489 166.99 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 . . . . . 0 C--O 1.256 1.405 0 N-CA-C 104.7 -2.333 . . . . 10.0 104.7 166.636 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.848 0 CA-C-O 117.997 -1.002 . . . . 10.0 108.432 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -165.21 -45.32 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.837 0.855 . . . . 10.0 110.208 178.346 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mttt -136.69 154.27 50.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 125.245 1.418 . . . . 10.0 109.248 169.711 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.59 164.43 30.23 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.366 1.466 . . . . 10.0 107.528 168.968 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -134.3 157.95 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 N-CA-C 109.327 -0.62 . . . . 10.0 109.327 -178.884 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.93 99.96 5.95 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.045 0.938 . . . . 10.0 109.502 172.925 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.439 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.2 OUTLIER -81.24 93.03 2.18 Favored 'Isoleucine or valine' 0 C--N 1.341 0.229 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 167.966 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mt -84.71 136.68 33.62 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.474 1.11 . . . . 10.0 108.561 -178.732 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -159.74 161.64 34.79 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.441 -1.318 . . . . 10.0 107.441 173.771 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.38 -44.82 0.11 Allowed Glycine 0 C--O 1.227 -0.331 0 C-N-CA 119.813 -1.184 . . . . 10.0 113.473 168.938 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -74.1 -45.17 50.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.721 -1.215 . . . . 10.0 107.721 -176.0 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 144.22 -71.36 0.38 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.636 -1.386 . . . . 10.0 109.636 171.487 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -59.1 -37.52 92.12 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.303 2.669 . . . . 10.0 111.14 171.768 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.419 HG13 HD11 ' B' ' 38' ' ' LEU . 58.4 t -58.93 111.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 108.538 -0.912 . . . . 10.0 108.538 178.094 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -125.96 127.86 46.6 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 105.598 -2.001 . . . . 10.0 105.598 167.949 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.528 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -114.12 135.46 12.5 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 108.765 -1.734 . . . . 10.0 108.765 170.505 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.442 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.6 mt -134.97 68.07 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 106.706 -1.591 . . . . 10.0 106.706 -173.836 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.4 mm -97.59 139.82 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 115.145 -0.934 . . . . 10.0 110.467 -170.925 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -107.39 130.52 54.79 Favored 'General case' 0 CA--C 1.527 0.095 0 C-N-CA 126.833 2.053 . . . . 10.0 109.168 -176.183 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -116.75 100.38 7.76 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.376 -1.342 . . . . 10.0 107.376 177.91 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.47 156.89 17.37 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.33 0.514 . . . . 10.0 110.973 175.637 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 34.5 tp60 -154.2 65.49 0.7 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.979 1.312 . . . . 10.0 109.851 -177.989 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -142.04 92.64 2.46 Favored 'General case' 0 N--CA 1.432 -1.347 0 C-N-CA 124.86 1.264 . . . . 10.0 107.71 176.955 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -153.02 -170.12 3.53 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 103.557 -2.757 . . . . 10.0 103.557 166.709 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 29.2 m -89.92 -9.21 49.72 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 118.141 0.428 . . . . 10.0 111.055 174.843 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 78.0 m-20 -128.68 8.94 5.87 Favored 'General case' 0 CA--C 1.529 0.15 0 C-N-CA 123.756 0.822 . . . . 10.0 111.355 -169.703 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 41.93 55.05 4.22 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 124.71 1.148 . . . . 10.0 115.419 179.637 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.71 104.06 1.67 Allowed 'Trans proline' 0 N--CA 1.445 -1.361 0 N-CA-C 105.939 -2.369 . . . . 10.0 105.939 168.339 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 t -77.67 78.95 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.502 -2.036 . . . . 10.0 105.502 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.3 ttmm -69.83 109.57 4.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.385 -1.709 . . . . 10.0 106.385 169.046 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -90.84 102.61 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 105.413 -2.069 . . . . 10.0 105.413 173.852 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -119.56 150.59 40.02 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.92 -160.92 32.93 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 109.502 -1.439 . . . . 10.0 109.502 169.293 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.1 p -147.47 115.15 6.39 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 108.898 -0.779 . . . . 10.0 108.898 -173.542 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.528 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.3 pt -80.19 179.15 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 108.748 -0.834 . . . . 10.0 108.748 168.146 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 36' ' ' LYS . . . . . 0.445 ' NZ ' ' OD2' ' B' ' 92' ' ' ASP . 0.2 OUTLIER -155.86 159.86 39.71 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 107.472 -1.307 . . . . 10.0 107.472 164.034 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.06 -12.63 57.46 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-O 119.13 -0.817 . . . . 10.0 113.96 170.106 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.485 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.5 mp -70.65 176.65 4.0 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 119.036 1.418 . . . . 10.0 109.237 171.736 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -90.13 167.11 12.98 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.431 -0.951 . . . . 10.0 108.431 167.778 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -62.17 170.38 2.28 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.706 0.802 . . . . 10.0 111.734 -170.683 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.39 -174.23 33.45 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 124.317 0.96 . . . . 10.0 112.285 168.611 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -71.85 141.89 49.6 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.185 0.994 . . . . 10.0 109.409 175.761 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.82 148.92 41.34 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 114.7 1.37 . . . . 10.0 114.7 -179.368 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.553 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -36.85 127.05 1.09 Allowed Glycine 0 C--N 1.343 0.932 0 C-N-CA 127.649 2.547 . . . . 10.0 110.738 164.537 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.481 ' CD1' HD22 ' B' ' 84' ' ' LEU . 3.9 t80 -155.65 105.96 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 118.777 1.289 . . . . 10.0 109.055 168.485 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.49 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -156.05 175.34 14.1 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -178.2 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 29.0 m -90.04 151.58 3.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 113.771 -1.558 . . . . 10.0 110.265 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -142.42 137.75 30.61 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.592 1.557 . . . . 10.0 108.125 178.534 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -50.7 -57.14 9.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 114.944 1.461 . . . . 10.0 114.944 -169.103 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -78.46 123.13 26.7 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.92 -0.77 . . . . 10.0 108.92 -169.476 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.52 -30.53 77.88 Favored Glycine 0 CA--C 1.531 1.08 0 N-CA-C 107.444 -2.262 . . . . 10.0 107.444 165.6 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -45.81 142.58 2.46 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-O 123.303 1.525 . . . . 10.0 111.046 171.51 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.481 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -165.11 22.5 0.05 Allowed 'General case' 0 N--CA 1.434 -1.24 0 C-N-CA 126.05 1.74 . . . . 10.0 110.144 -169.573 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.972 HG22 ' CG2' ' A' ' 17' ' ' ILE . 1.3 p -53.16 -40.86 64.62 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 122.874 0.469 . . . . 10.0 112.11 -178.877 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.62 -18.31 54.7 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.227 0.611 . . . . 10.0 112.095 176.133 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.21 110.56 0.8 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.239 0.923 . . . . 10.0 111.986 -178.517 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.1 m 48.7 33.69 4.49 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.676 1.59 . . . . 10.0 112.336 172.492 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 22.3 m -138.18 -55.12 0.65 Allowed 'General case' 0 N--CA 1.437 -1.092 0 C-N-CA 126.296 1.838 . . . . 10.0 106.318 -173.591 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -67.04 -12.9 61.22 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.753 0.821 . . . . 10.0 111.722 178.041 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.31 -36.43 1.25 Allowed 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 126.961 2.104 . . . . 10.0 112.442 175.689 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.38 163.8 39.39 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 107.425 -2.27 . . . . 10.0 107.425 -178.644 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -74.73 -170.26 0.73 Allowed 'Trans proline' 0 N--CA 1.443 -1.463 0 C-N-CA 121.268 1.312 . . . . 10.0 109.252 172.2 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 38.3 m170 -78.6 58.7 2.29 Favored 'General case' 0 CA--C 1.538 0.515 0 O-C-N 121.269 -0.894 . . . . 10.0 110.572 -173.251 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -71.86 79.46 0.88 Allowed 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 123.096 1.427 . . . . 10.0 110.45 178.524 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 65' ' ' ASN . . . . . 0.44 ' HB3' HG22 ' B' ' 81' ' ' VAL . 15.3 p-10 -74.1 147.2 85.61 Favored Pre-proline 0 N--CA 1.445 -0.69 0 C-N-CA 125.015 1.326 . . . . 10.0 110.222 169.012 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -65.42 -43.53 10.5 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.319 2.013 . . . . 10.0 110.394 178.127 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 tt -78.14 56.82 1.71 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.024 0.93 . . . . 10.0 108.907 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 38.9 p -35.96 106.16 0.04 OUTLIER 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 126.055 1.742 . . . . 10.0 110.989 -173.098 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 2.8 ttt180 -133.29 -174.75 3.58 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 104.029 -2.582 . . . . 10.0 104.029 -178.919 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 22.3 mmtp -75.33 161.11 29.57 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 117.618 -1.633 . . . . 10.0 108.523 170.543 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -65.01 123.31 19.13 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 161.786 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.33 -138.42 4.03 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 108.209 -1.956 . . . . 10.0 108.209 171.687 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.25 -160.08 26.75 Favored Glycine 0 C--O 1.224 -0.502 0 N-CA-C 108.869 -1.692 . . . . 10.0 108.869 177.192 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -66.6 2.03 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 CA-C-N 119.544 1.672 . . . . 10.0 110.131 166.332 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 25.0 mmtt -107.9 6.16 27.05 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 125.598 1.559 . . . . 10.0 110.192 173.987 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.405 ' OD2' ' NZ ' ' B' ' 128' ' ' LYS . 1.9 t0 -141.48 155.89 45.8 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 119.565 1.075 . . . . 10.0 110.611 167.822 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tm-20 -79.36 -26.98 41.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.641 -1.614 . . . . 10.0 106.641 168.632 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -85.87 27.55 0.87 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.669 1.188 . . . . 10.0 111.732 -172.77 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 37.5 ptt-85 -63.72 150.41 44.5 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.208 1.003 . . . . 10.0 111.018 179.003 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -64.68 -70.61 0.22 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.781 0.433 . . . . 10.0 110.884 -177.659 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.471 HG23 ' H ' ' B' ' 82' ' ' GLY . 0.1 OUTLIER -165.83 -63.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.2 0 C-N-CA 126.01 1.724 . . . . 10.0 107.399 -175.938 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.471 ' H ' HG23 ' B' ' 81' ' ' VAL . . . -120.92 55.29 0.64 Allowed Glycine 0 C--N 1.335 0.497 0 N-CA-C 108.804 -1.718 . . . . 10.0 108.804 -176.002 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -93.03 90.45 6.92 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 105.152 -2.166 . . . . 10.0 105.152 169.282 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 84' ' ' LEU . . . . . 0.481 HD22 ' CD1' ' B' ' 45' ' ' PHE . 9.6 mp -65.8 -25.63 67.32 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 118.632 0.651 . . . . 10.0 110.84 -173.114 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.67 -94.11 0.58 Allowed Glycine 0 N--CA 1.436 -1.315 0 N-CA-C 107.872 -2.091 . . . . 10.0 107.872 172.845 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.2 m-20 -156.7 107.8 2.39 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.432 -0.581 . . . . 10.0 109.432 -169.621 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.2 m -89.12 122.71 40.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 CA-C-N 118.163 0.438 . . . . 10.0 110.401 -177.619 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.1 m -79.79 81.96 5.97 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 127.705 2.402 . . . . 10.0 112.55 -171.959 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -70.95 130.4 41.51 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 121.573 -0.704 . . . . 10.0 112.692 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -63.18 172.16 2.0 Allowed 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 125.479 1.511 . . . . 10.0 110.049 166.756 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.08 -28.85 59.32 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 124.2 1.0 . . . . 10.0 111.839 171.141 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.445 ' OD2' ' NZ ' ' B' ' 36' ' ' LYS . 30.5 t70 -77.4 -2.88 37.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 122.261 1.029 . . . . 10.0 111.113 175.898 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.3 2.03 87.89 Favored Glycine 0 N--CA 1.44 -1.076 0 N-CA-C 109.959 -1.256 . . . . 10.0 109.959 -173.932 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.24 94.9 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 108.002 -1.11 . . . . 10.0 108.002 -171.572 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.23 118.74 29.14 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 166.76 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -78.16 117.69 19.68 Favored 'General case' 0 N--CA 1.433 -1.28 0 C-N-CA 126.005 1.722 . . . . 10.0 107.744 170.366 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 42.6 t -108.14 131.6 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.16 0 N-CA-C 106.735 -1.58 . . . . 10.0 106.735 -178.555 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.1 p -157.49 51.48 0.46 Allowed 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.394 0.678 . . . . 10.0 109.529 169.455 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -87.91 152.23 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -174.326 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -137.55 146.63 44.33 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.716 1.206 . . . . 10.0 109.986 -178.346 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -152.07 140.13 20.19 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 107.271 -1.381 . . . . 10.0 107.271 168.855 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 77.6 p -108.71 63.34 0.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 -174.265 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.3 p -151.97 -47.61 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 115.608 -0.724 . . . . 10.0 109.055 -177.751 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 20.9 mm -64.5 155.45 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 124.124 0.97 . . . . 10.0 110.058 172.734 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 28.8 t -150.69 147.28 27.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.717 -1.216 . . . . 10.0 107.717 168.367 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 68.2 mt -55.18 -30.61 60.25 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.995 -1.002 . . . . 10.0 109.82 167.085 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t -153.57 109.11 3.23 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 106.919 -1.511 . . . . 10.0 106.919 -179.312 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.37 -63.53 0.01 OUTLIER Glycine 0 C--N 1.333 0.373 0 N-CA-C 109.746 -1.342 . . . . 10.0 109.746 -177.858 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -156.37 -53.57 0.08 Allowed 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 126.721 2.008 . . . . 10.0 106.185 178.373 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -75.36 -36.84 60.91 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 113.998 -1.455 . . . . 10.0 108.758 -174.322 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.2 t 56.74 63.26 2.0 Allowed 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.083 0.953 . . . . 10.0 109.576 169.936 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.295 0.0 OUTLIER -53.31 -28.26 14.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.23 -0.896 . . . . 10.0 113.218 -168.569 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.9 mm -27.13 -55.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 127.221 2.208 . . . . 10.0 114.045 173.776 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -83.67 4.69 81.39 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-O 118.493 -1.17 . . . . 10.0 115.08 -169.726 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 mmt180 -87.6 160.47 18.17 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.663 1.231 . . . . 10.0 111.95 -177.827 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 19.3 m -92.96 130.48 38.53 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 169.007 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -97.64 138.46 35.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 169.773 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 83.1 t -129.81 135.35 61.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 107.748 -1.204 . . . . 10.0 107.748 -177.336 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -103.05 145.99 11.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 123.897 0.879 . . . . 10.0 108.644 168.419 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.553 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 2.7 m170 -123.89 160.38 27.62 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 116.329 1.974 . . . . 10.0 116.329 -173.717 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.6 tt0 -43.07 -56.57 3.3 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.692 3.197 . . . . 10.0 111.918 172.827 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 76.0 mttt -117.3 170.02 9.02 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 123.599 0.76 . . . . 10.0 112.397 -169.29 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.9 149.7 47.54 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 114.003 -1.453 . . . . 10.0 109.458 173.701 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.49 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.2 m-20 -80.58 146.21 31.35 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 123.881 0.872 . . . . 10.0 111.773 173.66 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -76.26 -27.97 56.9 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 124.235 0.959 . . . . 10.0 109.5 168.326 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 72.4 mt 62.04 53.01 3.1 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 123.058 1.408 . . . . 10.0 108.925 -174.923 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.28 -43.23 2.54 Favored Glycine 0 N--CA 1.445 -0.764 0 CA-C-N 112.561 -2.109 . . . . 10.0 110.637 173.581 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.405 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 13.1 mtmm -81.38 44.74 0.81 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.919 0.888 . . . . 10.0 112.392 -169.971 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.15 -22.7 14.44 Favored Glycine 0 CA--C 1.523 0.568 0 C-N-CA 125.921 1.724 . . . . 10.0 110.903 169.895 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.77 34.43 89.92 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 110.996 -0.841 . . . . 10.0 110.996 175.845 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -138.27 168.53 19.55 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.883 -1.525 . . . . 10.0 106.883 169.397 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.11 -48.53 73.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 116.038 -0.528 . . . . 10.0 109.865 -176.199 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -68.02 -26.4 65.87 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.006 -1.059 . . . . 10.0 110.935 178.977 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.0 p -56.92 -44.53 82.54 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 120.996 1.725 . . . . 10.0 110.544 171.93 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -83.92 -10.78 57.71 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.85 -0.595 . . . . 10.0 112.1 -173.75 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -103.33 -51.72 3.17 Favored 'General case' 0 N--CA 1.441 -0.905 0 C-N-CA 126.038 1.735 . . . . 10.0 112.319 -178.822 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.2 p -139.29 31.17 2.15 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.557 1.071 . . . . 10.0 112.461 176.045 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 58.23 25.87 57.98 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 118.723 0.692 . . . . 10.0 112.719 175.456 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 52.96 24.89 3.63 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 117.59 0.695 . . . . 10.0 112.585 -176.724 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.13 -4.26 9.67 Favored 'General case' 0 C--N 1.342 0.276 0 O-C-N 121.12 -0.988 . . . . 10.0 113.014 -173.32 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.03 -158.93 41.05 Favored Glycine 0 N--CA 1.446 -0.69 0 O-C-N 121.027 -1.045 . . . . 10.0 111.187 167.249 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 m -58.49 125.73 24.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.463 0.705 . . . . 10.0 111.767 -167.83 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -58.74 68.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.955 2.102 . . . . 10.0 111.864 172.048 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.7 mt -50.59 -36.93 37.26 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.898 -1.127 . . . . 10.0 113.714 -174.469 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -163.11 157.53 20.76 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 -170.823 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 23.6 p -161.76 168.29 23.47 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.96 -0.385 . . . . 10.0 109.96 -174.637 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.5 155.37 26.46 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.312 -1.515 . . . . 10.0 109.312 -176.44 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -107.94 131.25 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 105.776 -1.935 . . . . 10.0 105.776 -177.507 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 16.0 mt -79.48 165.95 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 118.818 0.736 . . . . 10.0 110.615 -179.782 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -169.13 170.92 42.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 127.875 2.655 . . . . 10.0 107.097 -177.065 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 20.3 mt -84.8 140.67 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 124.481 1.112 . . . . 10.0 110.1 -168.93 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -102.57 -114.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.903 -1.147 . . . . 10.0 107.903 167.44 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.252 1.227 0 C-N-CA 131.077 3.751 . . . . 10.0 106.136 172.297 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.799 0 CA-C-O 118.571 -0.728 . . . . 10.0 109.794 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 60.4 p -96.21 -63.89 1.1 Allowed 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 124.555 1.142 . . . . 10.0 110.001 -169.908 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -135.63 135.4 40.16 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 126.724 2.01 . . . . 10.0 107.857 -169.547 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -133.59 166.99 21.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.752 1.221 . . . . 10.0 110.119 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.73 162.12 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 125.803 1.641 . . . . 10.0 109.317 -179.015 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -149.89 90.72 1.71 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 106.204 -1.776 . . . . 10.0 106.204 166.631 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.704 HG21 ' HB3' ' B' ' 53' ' ' ASN . 3.7 m -77.37 118.97 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 170.915 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.6 mt -97.85 147.73 24.13 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 -178.947 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.06 162.56 17.95 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 168.994 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.43 -58.33 0.05 OUTLIER Glycine 0 C--O 1.227 -0.291 0 C-N-CA 121.09 -0.576 . . . . 10.0 112.057 169.861 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -72.98 -46.46 52.15 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.9 -69.81 0.51 Allowed Glycine 0 CA--C 1.527 0.796 0 CA-C-N 114.313 -1.312 . . . . 10.0 110.089 174.099 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -75.82 37.45 0.52 Allowed 'Trans proline' 0 CA--C 1.536 0.614 1 C-N-CA 125.69 4.26 . . . . 10.0 111.944 -179.884 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.8 t -149.01 100.38 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 C-N-CA 131.454 3.902 . . . . 10.0 100.537 178.603 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.72 116.04 22.39 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 106.032 -1.84 . . . . 10.0 106.032 -174.181 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.617 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.81 142.71 16.25 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 174.766 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.562 ' CG2' HG23 ' B' ' 54' ' ' THR . 6.3 mt -135.14 86.02 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.721 -1.214 . . . . 10.0 107.721 173.795 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -97.46 142.64 13.94 Favored 'Isoleucine or valine' 0 C--N 1.339 0.118 0 C-N-CA 124.028 0.931 . . . . 10.0 110.008 178.002 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -128.88 123.1 31.82 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 127.262 2.225 . . . . 10.0 109.511 174.353 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -105.23 116.87 32.68 Favored 'General case' 0 C--O 1.23 0.074 0 C-N-CA 125.294 1.437 . . . . 10.0 108.684 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 20.4 tt0 -105.58 134.71 48.24 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 118.666 0.666 . . . . 10.0 112.268 171.788 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 tp60 -109.71 99.36 8.54 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.672 1.989 . . . . 10.0 107.037 168.853 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 40.5 mmtt -58.72 -64.79 0.8 Allowed 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.752 -0.462 . . . . 10.0 109.752 175.469 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -124.13 164.62 19.09 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 104.657 -2.349 . . . . 10.0 104.657 169.453 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 t -71.47 -15.74 62.33 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 108.77 -0.826 . . . . 10.0 108.77 173.665 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.82 -24.31 44.55 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.021 0.529 . . . . 10.0 110.273 173.388 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.44 141.77 23.25 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 109.887 -1.285 . . . . 10.0 109.887 -176.825 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -62.56 142.21 89.16 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 CA-C-N 119.525 1.663 . . . . 10.0 107.866 169.252 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.5 t -77.92 125.77 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -174.731 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.1 mtmm -90.87 104.94 17.47 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.658 -1.238 . . . . 10.0 107.658 178.575 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 p -94.08 93.19 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 125.908 1.683 . . . . 10.0 107.555 174.264 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.9 p90 -102.28 175.07 5.64 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 121.207 0.527 . . . . 10.0 109.982 169.153 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.75 174.8 38.34 Favored Glycine 0 N--CA 1.441 -0.983 0 N-CA-C 111.367 -0.693 . . . . 10.0 111.367 176.892 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.0 p -145.69 102.78 3.72 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.239 -1.393 . . . . 10.0 107.239 178.751 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.617 HG22 ' HA2' ' A' ' 16' ' ' GLY . 7.5 pt -78.05 174.16 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 C-N-CA 118.878 -1.129 . . . . 10.0 108.099 169.225 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -154.83 144.17 21.22 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 168.808 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.6 -37.24 2.47 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-N 118.695 0.679 . . . . 10.0 113.957 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.518 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.1 mp -68.8 177.86 2.38 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.968 0.89 . . . . 10.0 112.651 -167.987 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.8 t -100.41 156.8 17.06 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.866 -0.606 . . . . 10.0 109.384 171.168 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -52.42 147.11 8.56 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.944 1.298 . . . . 10.0 112.191 -169.526 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.0 -172.12 17.68 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.124 0.869 . . . . 10.0 111.448 171.407 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -72.71 148.5 44.64 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.069 1.348 . . . . 10.0 110.855 -177.774 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -147.38 143.66 28.14 Favored 'General case' 0 C--N 1.338 0.067 0 C-N-CA 124.115 0.966 . . . . 10.0 112.314 -179.439 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.728 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -23.28 124.49 0.02 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.347 2.403 . . . . 10.0 114.062 165.301 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 20.1 t80 -149.25 106.5 3.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 119.286 1.543 . . . . 10.0 109.848 168.671 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.49 172.37 14.59 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.317 0.579 . . . . 10.0 111.04 174.102 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.4 p -112.82 120.93 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 CA-C-N 112.86 -1.973 . . . . 10.0 107.502 168.676 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -89.41 151.61 21.94 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.873 1.669 . . . . 10.0 108.223 -179.37 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -64.76 -57.01 10.08 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 114.798 -1.092 . . . . 10.0 110.473 -173.098 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -76.62 124.46 27.67 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.227 -1.397 . . . . 10.0 107.227 -173.403 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.07 -2.41 77.99 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.426 -0.652 . . . . 10.0 112.136 178.047 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -43.98 131.0 5.88 Favored 'General case' 0 C--N 1.344 0.343 0 CA-C-O 122.8 1.286 . . . . 10.0 112.525 175.289 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.621 ' HB3' HG21 ' B' ' 7' ' ' VAL . 2.9 m-80 -138.43 3.19 2.32 Favored 'General case' 0 N--CA 1.434 -1.232 0 CA-C-N 112.676 -2.056 . . . . 10.0 109.519 163.939 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.666 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -53.5 -40.09 65.12 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 125.063 1.345 . . . . 10.0 108.605 168.566 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.8 -15.12 59.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 116.041 -0.527 . . . . 10.0 111.976 178.223 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.75 75.5 0.99 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 109.092 -1.603 . . . . 10.0 109.092 -173.384 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t 38.78 48.87 1.41 Allowed 'General case' 0 C--O 1.231 0.105 0 C-N-CA 125.554 1.542 . . . . 10.0 114.448 177.311 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.4 m -127.76 -53.5 1.33 Allowed 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.996 -1.483 . . . . 10.0 106.996 -172.745 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.3 m -90.22 16.95 7.67 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.129 0.422 . . . . 10.0 111.527 173.758 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.56 -19.77 58.38 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.21 1.004 . . . . 10.0 111.032 169.379 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.3 135.85 7.98 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-O 119.017 -0.88 . . . . 10.0 111.232 168.578 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -73.39 66.04 4.5 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 123.244 2.63 . . . . 10.0 110.77 173.474 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 28.8 m170 71.81 -34.16 0.29 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 128.41 2.684 . . . . 10.0 112.664 175.385 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 43.42 25.9 0.09 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 128.308 2.643 . . . . 10.0 116.374 171.625 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -59.06 134.33 87.59 Favored Pre-proline 0 CA--C 1.534 0.354 0 N-CA-C 114.464 1.283 . . . . 10.0 114.464 -169.945 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -60.95 -37.49 76.47 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.565 2.177 . . . . 10.0 110.042 175.901 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 66.0 mt -63.05 2.8 0.29 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.748 1.219 . . . . 10.0 113.776 175.761 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 12.4 m 26.84 54.22 0.05 OUTLIER 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 128.293 2.637 . . . . 10.0 114.982 175.738 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtt85 -99.29 -179.15 4.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.572 1.149 . . . . 10.0 110.752 -172.983 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt -112.54 92.52 4.05 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.046 -0.724 . . . . 10.0 109.046 -174.643 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -5.88 97.16 0.01 OUTLIER 'General case' 0 C--O 1.223 -0.318 0 C-N-CA 128.255 2.622 . . . . 10.0 113.937 -176.916 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.41 -134.04 7.81 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.897 -1.681 . . . . 10.0 108.897 178.998 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.49 -170.33 40.43 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 106.915 -2.474 . . . . 10.0 106.915 171.498 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -63.59 -4.64 7.26 Favored 'Trans proline' 0 N--CA 1.455 -0.794 0 CA-C-N 119.867 1.834 . . . . 10.0 110.929 168.276 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -88.65 -24.06 22.88 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.313 1.045 . . . . 10.0 110.536 174.069 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.8 178.41 4.29 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 108.246 -1.02 . . . . 10.0 108.246 -178.262 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -92.81 -26.81 17.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 167.088 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.1 mm-40 -87.06 28.79 0.88 Allowed 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.391 -1.443 . . . . 10.0 112.436 -169.641 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.5 133.62 53.48 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.67 -1.233 . . . . 10.0 107.67 169.345 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.9 m170 -64.58 -57.92 7.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.823 -0.548 . . . . 10.0 112.007 -175.378 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.8 p -170.97 -43.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 C-N-CA 124.461 1.104 . . . . 10.0 109.065 -172.375 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -150.43 56.44 0.46 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 109.759 -1.336 . . . . 10.0 109.759 178.385 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -92.76 92.15 7.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 172.256 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.29 -36.69 63.78 Favored 'General case' 0 N--CA 1.461 0.1 0 N-CA-C 107.648 -1.242 . . . . 10.0 107.648 177.067 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.34 -98.66 1.23 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 110.833 -0.907 . . . . 10.0 110.833 167.859 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.3 m-80 -123.73 132.3 53.79 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.855 0.862 . . . . 10.0 111.274 -168.365 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.0 m -114.68 129.92 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 123.771 0.828 . . . . 10.0 109.14 168.072 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 28.2 m -86.81 104.09 15.85 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 127.651 2.381 . . . . 10.0 110.572 -174.857 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.03 33.49 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 122.825 0.45 . . . . 10.0 110.544 174.776 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -66.76 175.23 2.49 Favored 'General case' 0 CA--C 1.528 0.103 0 O-C-N 123.633 0.583 . . . . 10.0 109.728 167.661 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.13 -29.48 13.56 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.585 1.554 . . . . 10.0 111.746 172.38 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -79.42 -4.5 51.39 Favored 'General case' 0 N--CA 1.453 -0.301 0 O-C-N 123.226 0.329 . . . . 10.0 110.229 -177.779 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.8 9.28 86.94 Favored Glycine 0 C--N 1.337 0.635 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 -178.377 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 50.9 t -90.82 107.65 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.277 0 C-N-CA 126.149 1.78 . . . . 10.0 106.356 179.619 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.445 ' H ' HG12 ' A' ' 35' ' ' ILE . . . -102.85 118.52 37.02 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.579 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -79.24 112.2 16.23 Favored 'General case' 0 N--CA 1.434 -1.239 0 C-N-CA 125.927 1.691 . . . . 10.0 108.541 171.127 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.82 133.23 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.234 -1.765 . . . . 10.0 106.234 176.337 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -157.63 60.69 0.48 Allowed 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.861 -0.422 . . . . 10.0 109.861 -178.398 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 44.0 mt -115.46 154.69 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 107.97 -1.122 . . . . 10.0 107.97 -169.696 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -127.87 145.51 50.92 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.338 -0.615 . . . . 10.0 109.338 167.512 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 102' ' ' SER . 42.2 t0 -145.29 154.73 42.66 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 -178.752 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.406 ' N ' ' OD1' ' A' ' 101' ' ' ASP . 8.4 p -108.32 -9.35 15.49 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 128.145 2.578 . . . . 10.0 112.28 -174.28 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.6 p -79.6 -36.98 18.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.147 0 N-CA-C 107.602 -1.259 . . . . 10.0 107.602 -174.87 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.455 ' H ' ' CD1' ' A' ' 104' ' ' ILE 0.309 0.0 OUTLIER -79.51 150.24 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 124.714 1.206 . . . . 10.0 113.026 172.676 . . . . . . . . 4 4 . 1 . 025 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.6 m -157.28 133.56 9.7 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.089 0.956 . . . . 10.0 108.47 179.616 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.46 ' CD1' HD11 ' A' ' 113' ' ' ILE . 1.1 mm? -75.54 52.87 0.66 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.223 2.209 . . . . 10.0 108.394 175.13 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.2 t -88.38 -157.04 0.4 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.472 1.909 . . . . 10.0 110.204 -169.803 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.0 -53.65 0.13 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 128.177 2.799 . . . . 10.0 107.429 -178.302 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -64.99 -60.16 3.36 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.227 -0.657 . . . . 10.0 109.227 171.203 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -77.94 -28.35 49.54 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 115.903 -0.589 . . . . 10.0 110.228 -175.259 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t 13.32 78.63 0.01 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 128.3 2.64 . . . . 10.0 113.672 175.776 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -65.53 -16.19 19.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 112.04 0.385 . . . . 10.0 112.04 176.328 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.46 HD11 ' CD1' ' A' ' 106' ' ' LEU . 49.2 mm -46.39 137.64 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 C-N-CA 123.832 0.853 . . . . 10.0 110.318 169.981 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.08 -1.97 88.18 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.153 -1.36 . . . . 10.0 115.286 174.986 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.9 mtp85 -77.05 168.14 20.6 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.019 1.41 . . . . 10.0 107.364 169.122 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -106.6 120.86 43.07 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.48 0.582 . . . . 10.0 111.752 -174.902 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -77.22 145.72 37.42 Favored 'General case' 0 CA--C 1.517 -0.294 0 N-CA-C 108.337 -0.986 . . . . 10.0 108.337 168.698 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 86.8 t -131.93 132.49 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.899 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.145 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -104.48 134.8 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 N-CA-C 106.268 -1.753 . . . . 10.0 106.268 167.831 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.728 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 8.2 m-70 -112.67 156.95 21.88 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 115.794 1.776 . . . . 10.0 115.794 -170.906 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -43.25 -55.3 4.07 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.68 2.792 . . . . 10.0 112.155 171.597 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -115.55 162.8 16.69 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.784 0.834 . . . . 10.0 111.543 -169.675 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.87 153.86 42.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.877 -1.056 . . . . 10.0 109.129 170.103 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -93.51 144.41 25.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 C-N-CA 123.814 0.845 . . . . 10.0 110.75 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -76.7 -16.12 59.6 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-N 114.387 -1.279 . . . . 10.0 110.83 168.379 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.4 mt 53.23 40.57 31.48 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.178 0.991 . . . . 10.0 110.247 -172.953 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.77 -47.97 0.98 Allowed Glycine 0 C--N 1.337 0.59 0 C-N-CA 125.122 1.344 . . . . 10.0 111.023 169.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.42 51.97 1.75 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 122.035 -0.685 . . . . 10.0 112.466 -169.831 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.43 -38.62 5.85 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 124.786 1.184 . . . . 10.0 110.351 169.914 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.43 31.33 78.51 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 -169.451 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -114.21 157.42 22.7 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 106.067 -1.827 . . . . 10.0 106.067 169.236 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.414 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 4.8 tm-20 -51.75 -44.87 63.49 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.875 -1.057 . . . . 10.0 109.062 174.13 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -65.44 -34.08 77.44 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.162 0.985 . . . . 10.0 112.452 173.937 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 54.3 p -57.73 -35.99 71.45 Favored 'General case' 0 N--CA 1.448 -0.571 0 O-C-N 120.244 -1.535 . . . . 10.0 111.781 -175.953 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -84.65 -1.11 55.61 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 118.855 -0.593 . . . . 10.0 112.163 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 94.1 mttt -114.05 -56.13 2.43 Favored 'General case' 0 C--N 1.342 0.261 0 C-N-CA 124.628 1.171 . . . . 10.0 111.315 -176.523 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.8 p -120.17 -5.54 9.96 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.888 0.767 . . . . 10.0 113.061 175.929 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.03 33.65 Favored Glycine 0 C--N 1.342 0.889 0 CA-C-O 119.252 -0.749 . . . . 10.0 112.175 -177.465 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 62.12 23.79 14.09 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 118.317 1.059 . . . . 10.0 111.597 -177.694 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.27 -11.78 24.28 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 125.656 1.583 . . . . 10.0 112.013 -177.986 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.88 -157.28 48.61 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 172.926 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.2 m -61.39 133.93 56.35 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.875 0.87 . . . . 10.0 113.121 -167.495 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -66.25 71.39 0.07 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.968 1.307 . . . . 10.0 110.017 169.596 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.6 mt -55.85 -33.56 64.64 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 112.742 0.645 . . . . 10.0 112.742 -177.435 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.19 146.35 15.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.473 -0.566 . . . . 10.0 109.473 -175.749 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 18.1 m -148.51 161.25 42.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -169.855 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.07 -174.96 17.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.504 -0.639 . . . . 10.0 111.504 178.419 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 49.8 t -127.05 133.75 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 104.825 -2.287 . . . . 10.0 104.825 175.755 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 22.1 mt -69.37 117.46 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 108.903 -0.777 . . . . 10.0 108.903 177.987 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.83 141.86 16.7 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 110.611 -0.996 . . . . 10.0 110.611 -179.72 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.17 132.7 32.97 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 CA-C-N 119.353 1.577 . . . . 10.0 108.942 175.31 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.61 -26.27 50.5 Favored 'General case' 0 C--O 1.223 -0.342 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 167.94 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.253 1.278 0 C-N-CA 126.187 1.795 . . . . 10.0 109.318 169.363 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.706 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' B' B ' 2' ' ' THR . . . . . 0.4 HG23 ' H ' ' B' ' 3' ' ' LYS . 8.8 t -150.76 -60.48 0.18 Allowed 'General case' 0 C--O 1.232 0.139 0 N-CA-C 108.958 -0.756 . . . . 10.0 108.958 176.135 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 3' ' ' LYS . . . . . 0.4 ' H ' HG23 ' B' ' 2' ' ' THR . 57.0 tttp -117.18 135.4 53.8 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 126.888 2.075 . . . . 10.0 106.852 174.904 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.85 161.7 34.88 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 125.253 1.421 . . . . 10.0 110.75 178.543 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 m -128.4 178.1 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 124.837 1.255 . . . . 10.0 110.042 -176.218 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -162.27 97.28 1.0 Allowed 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 125.368 1.467 . . . . 10.0 107.634 166.641 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.621 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.8 m -89.73 104.53 15.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.21 0.604 . . . . 10.0 110.818 173.765 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.7 mp -93.58 146.23 23.96 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.244 1.418 . . . . 10.0 110.176 178.195 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 9' ' ' LYS . . . . . 0.439 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 2.9 tttm -162.12 164.07 28.19 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 171.206 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.68 -47.65 0.14 Allowed Glycine 0 N--CA 1.462 0.398 0 C-N-CA 119.389 -1.386 . . . . 10.0 114.102 168.796 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -72.08 -45.73 59.58 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.141 -1.429 . . . . 10.0 107.141 -177.057 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.65 -75.17 0.28 Allowed Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 114.162 -1.381 . . . . 10.0 109.932 169.125 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -55.92 -39.22 92.49 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 123.511 2.808 . . . . 10.0 110.985 173.008 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.436 HG13 HD11 ' B' ' 38' ' ' LEU . 72.6 t -59.66 112.31 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 179.643 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.04 124.33 42.32 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 168.446 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.573 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -104.67 136.92 13.35 Favored Glycine 0 C--O 1.224 -0.494 0 N-CA-C 107.794 -2.122 . . . . 10.0 107.794 169.491 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.666 HG22 HG22 ' A' ' 54' ' ' THR . 3.0 mt -138.59 68.04 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -174.579 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 mm -89.05 151.89 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 N-CA-C 109.668 -0.493 . . . . 10.0 109.668 -173.503 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.24 143.89 48.04 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 126.617 1.967 . . . . 10.0 108.111 175.194 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -129.05 130.91 47.16 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 104.411 -2.44 . . . . 10.0 104.411 168.273 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -128.62 150.48 50.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 119.796 1.18 . . . . 10.0 110.402 172.375 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.58 97.59 5.12 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 178.392 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -42.8 -57.51 2.75 Favored 'General case' 0 CA--C 1.515 -0.375 0 C-N-CA 123.978 0.911 . . . . 10.0 110.053 170.482 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 15.0 mp0 -134.15 178.71 6.75 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 128.892 2.877 . . . . 10.0 103.461 168.378 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 22.6 t -94.2 13.8 22.15 Favored 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.221 -0.659 . . . . 10.0 109.221 170.366 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -149.18 28.15 0.83 Allowed 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 125.435 1.494 . . . . 10.0 110.199 -173.311 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -141.45 174.94 22.68 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.397 -1.481 . . . . 10.0 109.397 -172.893 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.27 129.94 24.12 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.808 2.338 . . . . 10.0 109.456 -177.499 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.1 t -79.87 111.52 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 N-CA-C 104.918 -2.253 . . . . 10.0 104.918 172.469 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -82.65 126.54 32.44 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 169.204 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -100.5 109.38 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 C-N-CA 126.37 1.868 . . . . 10.0 106.703 172.826 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.9 p90 -130.38 156.63 44.4 Favored 'General case' 0 C--O 1.226 -0.177 0 N-CA-C 113.504 0.927 . . . . 10.0 113.504 -179.729 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.65 -152.24 24.12 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 106.824 -2.511 . . . . 10.0 106.824 172.924 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 21.2 p -156.38 165.93 34.89 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 119.584 -0.846 . . . . 10.0 110.412 174.335 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.573 HG22 ' HA2' ' B' ' 16' ' ' GLY . 4.0 pt -107.01 179.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-N 114.344 -1.298 . . . . 10.0 109.424 165.366 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.19 163.17 40.54 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 124.689 1.196 . . . . 10.0 108.407 162.921 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.21 -17.12 44.69 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-O 119.315 -0.714 . . . . 10.0 113.155 172.626 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.482 ' N ' HD12 ' B' ' 38' ' ' LEU . 6.4 mp -71.7 178.61 3.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.005 0.902 . . . . 10.0 110.194 173.708 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -97.4 170.45 9.05 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 166.408 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -60.03 170.69 1.15 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.203 1.001 . . . . 10.0 112.111 -171.341 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.95 -174.61 32.99 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 124.201 0.905 . . . . 10.0 112.08 168.461 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.24 146.78 50.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 123.834 0.854 . . . . 10.0 109.581 176.164 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -147.17 144.94 29.32 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 123.493 0.717 . . . . 10.0 111.703 178.558 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.66 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -34.79 120.5 0.39 Allowed Glycine 0 C--N 1.339 0.74 0 C-N-CA 127.738 2.59 . . . . 10.0 112.626 167.371 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.69 110.47 5.14 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-N 119.456 1.628 . . . . 10.0 109.458 168.306 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.55 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.1 OUTLIER -146.57 170.65 16.46 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-O 121.718 0.771 . . . . 10.0 111.802 176.496 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.16 129.09 46.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 CA-C-N 111.146 -2.752 . . . . 10.0 105.647 168.193 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 41.5 m-70 -105.78 146.59 29.65 Favored 'General case' 0 CA--C 1.509 -0.611 0 N-CA-C 107.675 -1.231 . . . . 10.0 107.675 174.382 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 23.8 tp10 -66.64 -59.04 3.96 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.544 -1.207 . . . . 10.0 108.98 -172.987 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 22.2 m-30 -77.1 106.88 9.09 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 -175.222 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.68 42.8 1.31 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 124.592 1.091 . . . . 10.0 111.448 174.517 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.32 131.76 41.07 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 124.975 1.31 . . . . 10.0 108.241 177.057 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.704 ' HB3' HG21 ' A' ' 7' ' ' VAL . 1.2 m-80 -122.8 1.43 9.36 Favored 'General case' 0 N--CA 1.444 -0.755 0 C-N-CA 124.714 1.205 . . . . 10.0 110.28 168.968 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.562 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.18 -36.53 70.93 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.773 1.17 . . . . 10.0 108.792 178.194 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.38 -17.88 55.83 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.53 1.132 . . . . 10.0 112.965 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 77.61 0.77 Allowed Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.272 -0.731 . . . . 10.0 111.272 -178.273 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 34.8 m 50.96 34.36 10.46 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 124.754 1.222 . . . . 10.0 112.614 172.501 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 6.3 m -127.75 -57.43 1.26 Allowed 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -169.958 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 11.8 t -92.14 21.22 5.24 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 111.896 0.332 . . . . 10.0 111.896 179.166 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -68.1 -7.26 28.09 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.615 0.766 . . . . 10.0 111.949 176.285 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.47 127.66 2.19 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 109.704 -1.358 . . . . 10.0 109.704 174.132 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -74.81 65.42 5.88 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.517 2.811 . . . . 10.0 111.523 178.437 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.2 m170 59.98 55.83 3.64 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 128.382 2.673 . . . . 10.0 109.94 177.947 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -70.51 63.7 0.27 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.553 0.741 . . . . 10.0 112.393 -178.041 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -67.48 147.45 98.78 Favored Pre-proline 0 CA--C 1.532 0.27 0 O-C-N 121.642 -0.661 . . . . 10.0 110.858 -175.559 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -63.11 -49.44 4.88 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.245 1.963 . . . . 10.0 110.2 179.308 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.6 tt -81.41 59.64 4.12 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.358 0.663 . . . . 10.0 109.348 -177.852 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.0 t -14.96 97.31 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 128.411 2.684 . . . . 10.0 112.886 -176.806 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.59 168.58 10.88 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.423 1.089 . . . . 10.0 108.725 -175.807 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -108.24 105.91 15.84 Favored 'General case' 0 C--O 1.224 -0.26 0 N-CA-C 108.457 -0.942 . . . . 10.0 108.457 175.508 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 56.3 t60 -9.99 96.51 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 127.213 2.205 . . . . 10.0 115.482 -177.769 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.78 -141.1 10.37 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 173.658 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.03 -161.09 27.09 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 108.79 -1.724 . . . . 10.0 108.79 171.091 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -66.59 5.97 0.64 Allowed 'Trans proline' 0 N--CA 1.456 -0.704 0 CA-C-N 120.417 2.109 . . . . 10.0 111.889 174.106 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -103.56 -15.21 15.9 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 117.596 -1.193 . . . . 10.0 110.994 172.887 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.415 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 5.4 m-20 -131.36 162.25 30.53 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 119.164 0.893 . . . . 10.0 108.925 -167.855 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -78.61 -33.07 47.7 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.231 -1.396 . . . . 10.0 107.231 176.361 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -82.25 26.46 0.54 Allowed 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 125.431 1.493 . . . . 10.0 112.528 -167.108 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 36.2 ptt85 -64.58 134.35 54.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.304 -0.998 . . . . 10.0 108.304 173.962 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.5 m80 -58.86 -50.74 72.87 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 121.012 0.434 . . . . 10.0 111.088 -178.699 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 p -172.37 -105.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 104.06 -2.571 . . . . 10.0 104.06 177.864 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -77.54 57.36 3.78 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.864 0.756 . . . . 10.0 111.558 172.313 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -84.91 88.35 7.42 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 103.935 -2.616 . . . . 10.0 103.935 166.856 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 16.0 mt -71.72 -31.08 66.34 Favored 'General case' 0 N--CA 1.463 0.189 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -178.52 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.37 -102.54 2.57 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 109.82 -1.312 . . . . 10.0 109.82 167.571 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -121.05 104.11 9.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.603 1.161 . . . . 10.0 109.29 -167.201 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.1 m -94.66 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 118.725 0.693 . . . . 10.0 109.504 172.7 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 80.0 m -89.96 117.57 28.87 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 126.585 1.954 . . . . 10.0 108.908 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.82 134.6 43.55 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 124.536 1.135 . . . . 10.0 111.313 178.442 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -59.53 170.98 0.91 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 124.165 0.986 . . . . 10.0 110.811 166.769 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 28.3 mttm -52.06 -33.0 37.13 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.806 1.643 . . . . 10.0 112.453 169.183 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.45 -1.23 32.62 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-O 122.158 0.98 . . . . 10.0 111.307 176.601 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.41 0.89 84.24 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.052 -1.619 . . . . 10.0 109.052 -176.175 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.3 t -78.15 95.66 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -170.074 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.38 119.08 29.52 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 166.582 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.21 114.22 17.97 Favored 'General case' 0 N--CA 1.436 -1.163 0 C-N-CA 126.759 2.023 . . . . 10.0 108.971 171.95 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 91.8 t -98.11 131.23 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.705 -1.591 . . . . 10.0 106.705 174.363 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.6 p -157.76 57.69 0.49 Allowed 'General case' 0 CA--C 1.534 0.355 0 O-C-N 122.0 -0.437 . . . . 10.0 110.305 171.88 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.94 161.01 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 C-N-CA 124.784 1.234 . . . . 10.0 107.672 -170.892 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -130.54 146.25 52.03 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 124.625 1.17 . . . . 10.0 110.385 175.366 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 58.8 t0 -144.52 154.77 43.24 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.276 -1.009 . . . . 10.0 108.276 175.679 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 33.4 p -134.22 2.87 3.35 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 126.64 1.976 . . . . 10.0 112.544 -179.542 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.8 p -79.3 -31.84 14.62 Favored 'Isoleucine or valine' 0 C--N 1.343 0.324 0 CA-C-N 120.017 1.28 . . . . 10.0 107.891 169.948 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.402 ' C ' HD12 ' B' ' 104' ' ' ILE 0.273 0.7 OUTLIER -82.56 174.08 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 124.156 0.983 . . . . 10.0 111.556 169.423 . . . . . . . . 4 4 . 1 . 025 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 31.1 m -158.7 143.56 16.07 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 105.423 -2.066 . . . . 10.0 105.423 172.084 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 mt -75.5 -10.37 59.39 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.943 0.497 . . . . 10.0 112.335 -172.272 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 75.7 m -155.71 178.51 10.17 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 126.257 1.823 . . . . 10.0 106.43 173.242 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.67 -65.13 0.31 Allowed Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.777 -0.929 . . . . 10.0 110.777 169.373 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -161.21 -48.81 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 125.425 1.49 . . . . 10.0 108.068 -173.509 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -72.59 -39.78 67.09 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 107.073 -1.454 . . . . 10.0 107.073 -173.007 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.0 t 23.86 69.83 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 128.694 2.798 . . . . 10.0 112.636 167.116 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.96 -7.61 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 112.802 0.667 . . . . 10.0 112.802 -176.704 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 41.0 mm -45.92 125.0 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 O-C-N 121.55 -0.719 . . . . 10.0 110.1 171.81 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.4 2.03 77.34 Favored Glycine 0 CA--C 1.527 0.81 0 CA-C-O 118.735 -1.036 . . . . 10.0 113.637 178.862 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -76.2 178.92 6.06 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 106.007 -1.849 . . . . 10.0 106.007 166.75 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -124.59 129.72 51.1 Favored 'General case' 0 CA--C 1.514 -0.438 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 -174.962 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.415 ' CD1' HD11 ' B' ' 149' ' ' ILE . 7.8 mp -96.97 139.72 32.57 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 171.37 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.4 t -123.17 129.8 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 O-C-N 124.605 1.191 . . . . 10.0 108.303 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.445 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.6 p -93.03 131.41 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.47 -1.308 . . . . 10.0 107.47 167.618 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.66 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.5 m170 -111.72 158.33 19.45 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.448 1.277 . . . . 10.0 114.448 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -56.6 -54.81 41.68 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 125.15 1.38 . . . . 10.0 110.98 178.757 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 43.7 mttm -109.44 176.11 5.2 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 118.686 0.676 . . . . 10.0 110.136 177.268 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.17 140.74 29.18 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.058 1.343 . . . . 10.0 108.515 176.781 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.55 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -76.69 152.63 35.66 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 123.297 0.639 . . . . 10.0 111.943 -177.362 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 51.2 m-20 -76.38 6.2 5.99 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 127.115 2.166 . . . . 10.0 111.491 178.899 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.7 mt 42.12 40.11 1.58 Allowed 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.369 1.868 . . . . 10.0 111.194 -173.137 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.24 -33.52 5.94 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-O 119.509 -0.606 . . . . 10.0 112.639 168.959 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.415 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 3.3 mppt? -80.42 40.84 0.51 Allowed 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 117.597 0.699 . . . . 10.0 110.974 -176.961 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 129' ' ' GLY . . . . . 0.519 ' HA3' ' CB ' ' B' ' 134' ' ' SER . . . -88.97 -30.22 15.31 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 124.806 1.193 . . . . 10.0 112.616 -173.317 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 94.63 6.95 60.57 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.793 -1.004 . . . . 10.0 114.751 170.391 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 131' ' ' ASN . . . . . 0.416 ' H ' ' HB2' ' B' ' 134' ' ' SER . 0.8 OUTLIER -141.39 175.47 9.64 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 119.844 1.822 . . . . 10.0 106.726 169.036 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -51.19 -58.52 5.93 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.742 1.217 . . . . 10.0 109.279 178.208 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -49.94 -52.47 33.11 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 123.109 1.433 . . . . 10.0 110.562 176.505 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 134' ' ' SER . . . . . 0.519 ' CB ' ' HA3' ' B' ' 129' ' ' GLY . 0.2 OUTLIER -62.23 -4.8 1.93 Allowed 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 127.497 2.319 . . . . 10.0 113.27 179.979 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.24 15.01 6.72 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.731 0.813 . . . . 10.0 110.703 172.808 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmmm -122.22 -62.52 1.38 Allowed 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.727 2.011 . . . . 10.0 109.432 -178.56 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -113.71 16.1 18.64 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 119.513 1.052 . . . . 10.0 110.487 167.207 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.96 20.73 70.98 Favored Glycine 0 C--O 1.22 -0.764 0 C-N-CA 124.088 0.851 . . . . 10.0 113.2 168.81 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 60.03 24.74 13.94 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.327 1.064 . . . . 10.0 112.63 -179.76 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.74 -13.8 17.24 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.736 -0.603 . . . . 10.0 110.967 169.843 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.38 -158.87 42.23 Favored Glycine 0 N--CA 1.439 -1.11 0 N-CA-C 109.268 -1.533 . . . . 10.0 109.268 169.553 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -49.43 121.29 4.88 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 124.808 1.243 . . . . 10.0 112.635 -168.881 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 72.68 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.96 1.704 . . . . 10.0 108.983 169.232 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 52.8 mt -47.1 -41.27 16.97 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 124.317 1.047 . . . . 10.0 112.139 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.445 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -160.57 156.48 25.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 108.516 -0.92 . . . . 10.0 108.516 -171.351 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.8 p -162.33 168.78 21.68 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 108.897 -0.779 . . . . 10.0 108.897 -176.94 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.82 -175.18 17.75 Favored Glycine 0 N--CA 1.461 0.318 0 N-CA-C 111.229 -0.748 . . . . 10.0 111.229 -176.408 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 53.2 t -118.29 139.71 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 101.52 -3.511 . . . . 10.0 101.52 168.275 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.415 HD11 ' CD1' ' B' ' 117' ' ' LEU . 50.5 mt -59.32 -83.93 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 118.436 0.562 . . . . 10.0 110.33 -171.541 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.2 147.18 20.29 Favored Glycine 0 CA--C 1.52 0.363 0 O-C-N 121.724 -0.61 . . . . 10.0 112.65 178.976 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pt -73.6 154.31 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.393 -1.706 . . . . 10.0 106.393 168.15 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -52.91 6.43 Favored 'General case' 0 CA--C 1.512 -0.487 0 N-CA-C 106.078 -1.823 . . . . 10.0 106.078 169.748 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.252 1.187 0 O-C-N 126.328 2.268 . . . . 10.0 107.966 168.798 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.725 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.0 t -171.41 -43.43 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 124.468 1.107 . . . . 10.0 109.622 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -104.57 147.0 28.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 125.769 1.628 . . . . 10.0 107.639 171.006 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.0 157.96 37.05 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 168.543 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.403 ' CG2' ' HA ' ' B' ' 52' ' ' ASP . 3.5 m -130.16 177.61 6.47 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-O 121.642 0.734 . . . . 10.0 110.447 177.619 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.81 121.3 4.03 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 103.462 -2.792 . . . . 10.0 103.462 166.932 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.97 111.55 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 178.119 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.17 142.3 28.51 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 -171.164 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 mtpt -144.57 162.13 37.39 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 169.995 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.43 -65.75 0.02 OUTLIER Glycine 0 C--O 1.229 -0.198 0 CA-C-N 115.403 -0.817 . . . . 10.0 111.501 171.281 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.44 -45.45 46.33 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 106.597 -1.631 . . . . 10.0 106.597 -173.468 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.29 -65.46 0.59 Allowed Glycine 0 N--CA 1.444 -0.79 0 CA-C-N 113.431 -1.713 . . . . 10.0 110.866 -175.719 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -54.36 -38.97 89.17 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.579 2.186 . . . . 10.0 111.367 173.101 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.4 t -66.87 101.31 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.043 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 172.059 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -118.66 101.9 8.46 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.189 1.396 . . . . 10.0 107.709 171.278 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.875 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -83.89 148.36 24.55 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 125.13 1.348 . . . . 10.0 111.888 174.865 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.433 ' CG2' HG22 ' B' ' 54' ' ' THR . 0.8 OUTLIER -155.45 93.22 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 126.023 1.729 . . . . 10.0 106.463 -168.876 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.0 mm -86.49 151.18 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 C-N-CA 125.113 1.365 . . . . 10.0 109.767 179.045 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.1 m-80 -143.58 59.79 1.39 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.821 0.282 . . . . 10.0 111.725 179.402 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -47.68 120.91 3.63 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 117.559 -1.21 . . . . 10.0 109.417 -175.519 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -111.69 124.53 52.51 Favored 'General case' 0 C--O 1.233 0.2 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 176.506 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.2 tp60 -125.43 85.44 2.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.777 1.231 . . . . 10.0 109.055 172.058 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.15 -43.74 7.24 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 127.007 2.123 . . . . 10.0 112.309 -179.254 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -153.5 173.67 15.41 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 105.95 -1.87 . . . . 10.0 105.95 169.498 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 49.2 m -66.24 -19.55 65.86 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 122.943 0.497 . . . . 10.0 110.694 175.099 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -79.11 -15.54 58.0 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.423 0.689 . . . . 10.0 110.113 175.963 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.55 156.35 33.28 Favored Glycine 0 CA--C 1.532 1.101 0 O-C-N 122.145 -0.347 . . . . 10.0 112.964 -175.14 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -75.68 144.8 28.48 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 N-CA-C 105.727 -2.451 . . . . 10.0 105.727 165.911 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.2 t -78.94 127.17 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.521 -1.659 . . . . 10.0 106.521 179.467 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 mtmt -95.93 110.9 23.03 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.942 -0.762 . . . . 10.0 108.942 172.986 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.0 m -85.05 56.52 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 123.888 0.875 . . . . 10.0 110.788 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -40.24 139.28 0.75 Allowed 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 124.32 1.048 . . . . 10.0 112.947 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.73 131.93 4.52 Favored Glycine 0 N--CA 1.437 -1.258 0 N-CA-C 107.382 -2.287 . . . . 10.0 107.382 168.279 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.1 m -123.68 62.03 1.06 Allowed 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 106.654 -1.61 . . . . 10.0 106.654 172.06 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.875 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.2 pt -78.08 116.58 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.29 -1.004 . . . . 10.0 108.29 -176.541 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -99.37 141.07 32.62 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 107.722 -1.214 . . . . 10.0 107.722 172.537 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.53 -5.86 18.87 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 124.272 0.939 . . . . 10.0 112.211 173.907 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.44 173.2 4.22 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 118.494 1.147 . . . . 10.0 110.143 176.251 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.8 t -106.26 150.36 25.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.839 -1.541 . . . . 10.0 106.839 167.957 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -48.14 147.28 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.795 1.238 . . . . 10.0 110.299 -175.747 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.57 179.8 28.14 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.391 -1.083 . . . . 10.0 110.391 176.198 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.25 153.79 35.73 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.532 1.533 . . . . 10.0 111.404 -172.014 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -145.08 141.61 28.98 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 125.001 1.32 . . . . 10.0 110.535 -179.425 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.41 124.58 7.93 Favored Glycine 0 C--N 1.344 1.024 0 N-CA-C 107.308 -2.317 . . . . 10.0 107.308 166.993 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 57.4 t80 -145.7 118.72 8.79 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 118.851 1.326 . . . . 10.0 109.112 171.989 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -159.22 171.76 19.28 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.287 0.565 . . . . 10.0 110.103 -174.817 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -91.46 148.79 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 CA-C-N 112.757 -2.019 . . . . 10.0 106.972 168.027 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 62.1 m-70 -120.12 139.96 51.79 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.17 -1.789 . . . . 10.0 106.17 173.982 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -47.08 -57.35 5.16 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 124.609 1.193 . . . . 10.0 111.461 -171.872 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.38 136.76 33.33 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 109.559 -0.534 . . . . 10.0 109.559 -177.611 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.38 -8.6 86.93 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.421 -1.072 . . . . 10.0 110.421 167.993 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -47.78 144.63 3.25 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.63 1.205 . . . . 10.0 109.748 169.568 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -148.38 29.43 0.86 Allowed 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 114.585 -1.188 . . . . 10.0 110.393 172.75 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.401 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -58.41 -37.05 74.55 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 122.362 0.265 . . . . 10.0 111.609 -169.142 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.17 -23.51 40.98 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.652 0.781 . . . . 10.0 113.079 173.817 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.89 111.37 1.8 Allowed Glycine 0 CA--C 1.534 1.233 0 N-CA-C 110.178 -1.169 . . . . 10.0 110.178 -169.128 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.3 m 39.35 53.63 2.28 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 127.273 2.229 . . . . 10.0 114.07 170.901 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -156.17 -54.85 0.09 Allowed 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.526 -0.916 . . . . 10.0 108.526 178.569 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 m -61.39 -30.91 70.84 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.825 0.85 . . . . 10.0 112.127 -172.835 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.77 -30.31 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 129.188 2.995 . . . . 10.0 115.463 174.739 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.8 129.16 6.01 Favored Glycine 0 CA--C 1.524 0.633 0 CA-C-O 118.227 -1.318 . . . . 10.0 110.068 169.738 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.407 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 88.2 Cg_endo -73.91 65.92 5.0 Favored 'Trans proline' 0 CA--C 1.535 0.549 0 C-N-CA 124.21 3.273 . . . . 10.0 111.76 179.829 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 56.9 58.12 4.24 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.236 2.614 . . . . 10.0 109.395 179.925 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.407 ' CZ ' ' HD2' ' A' ' 62' ' ' PRO . 42.6 m-85 -68.0 74.39 0.2 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 122.112 0.958 . . . . 10.0 111.695 -179.366 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.463 HD22 ' H ' ' A' ' 65' ' ' ASN . 0.8 OUTLIER -85.73 126.39 66.26 Favored Pre-proline 0 C--N 1.323 -0.551 0 C-N-CA 126.306 1.842 . . . . 10.0 111.18 -178.494 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -68.04 -37.6 14.55 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.986 2.457 . . . . 10.0 110.668 -177.915 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 79.6 mt -76.72 52.47 0.83 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.212 0.605 . . . . 10.0 109.405 171.571 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -41.13 90.34 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 127.568 2.347 . . . . 10.0 113.817 -169.675 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -116.19 -164.0 0.94 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.843 1.257 . . . . 10.0 109.151 -174.592 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -116.18 108.49 16.21 Favored 'General case' 0 C--O 1.224 -0.284 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 -174.699 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.444 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 74.2 t60 -16.27 100.49 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.436 0 C-N-CA 126.11 1.764 . . . . 10.0 113.641 -179.218 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.47 -136.22 7.48 Favored Glycine 0 N--CA 1.449 -0.498 0 N-CA-C 108.022 -2.031 . . . . 10.0 108.022 -177.453 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 176.63 -165.39 35.61 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 108.262 -1.935 . . . . 10.0 108.262 169.195 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -67.64 12.85 0.19 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 121.751 1.634 . . . . 10.0 110.838 168.775 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.8 mmtp -104.52 -19.24 14.07 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 123.883 0.873 . . . . 10.0 108.89 172.286 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -119.7 167.19 12.29 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.375 -1.343 . . . . 10.0 107.375 -172.886 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -87.5 -24.57 24.05 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 172.106 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.313 1.8 pt-20 -107.36 40.95 1.58 Allowed 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 115.882 1.808 . . . . 10.0 115.882 -166.237 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.539 ' H ' ' CD ' ' A' ' 79' ' ' ARG . 0.3 OUTLIER -46.61 145.88 1.72 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.182 -1.372 . . . . 10.0 107.973 166.634 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.444 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 21.6 m170 -54.31 -58.81 5.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 109.276 -0.639 . . . . 10.0 109.276 169.202 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.1 p -168.42 -55.75 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 C-N-CA 124.477 1.111 . . . . 10.0 108.379 175.188 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -127.63 55.1 0.76 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.116 -1.194 . . . . 10.0 110.116 -176.564 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -86.45 97.62 10.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.784 -1.932 . . . . 10.0 105.784 169.433 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.559 ' C ' HD13 ' A' ' 84' ' ' LEU . 1.9 tm? -72.69 -39.91 66.66 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 105.265 -2.124 . . . . 10.0 105.265 171.817 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 106.59 -106.98 2.62 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 109.127 -1.589 . . . . 10.0 109.127 166.99 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -106.72 131.41 53.89 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.301 1.04 . . . . 10.0 110.083 -168.004 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -120.63 129.03 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.325 0.511 . . . . 10.0 109.63 168.426 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.9 t -96.93 132.73 42.41 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 124.328 1.051 . . . . 10.0 109.757 -177.218 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.4 140.09 35.14 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 122.913 0.485 . . . . 10.0 110.759 176.277 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.34 170.68 2.22 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.759 0.824 . . . . 10.0 109.487 168.236 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.27 -23.43 48.31 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 123.65 0.78 . . . . 10.0 113.1 169.689 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -77.18 -8.18 57.11 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 122.773 0.429 . . . . 10.0 111.726 173.932 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.68 18.76 67.39 Favored Glycine 0 C--N 1.34 0.781 0 N-CA-C 110.16 -1.176 . . . . 10.0 110.16 -178.895 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 36.2 t -98.89 110.26 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.627 2.371 . . . . 10.0 106.927 -179.364 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.453 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -101.31 121.82 42.58 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 119.054 0.843 . . . . 10.0 109.202 169.448 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -101.59 78.2 1.82 Allowed 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 128.427 2.691 . . . . 10.0 110.948 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.43 61.34 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 C-N-CA 124.452 1.101 . . . . 10.0 112.311 -169.228 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -90.77 55.63 3.01 Favored 'General case' 0 C--N 1.317 -0.845 0 O-C-N 121.251 -0.905 . . . . 10.0 108.726 -178.447 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.58 145.74 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 108.333 -0.988 . . . . 10.0 108.333 -174.144 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.86 139.54 35.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 126.477 1.911 . . . . 10.0 110.001 178.09 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.73 159.63 41.63 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 108.172 -1.047 . . . . 10.0 108.172 166.334 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 t -124.66 55.81 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 124.444 1.098 . . . . 10.0 109.236 176.976 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -148.66 -41.28 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 123.586 0.754 . . . . 10.0 110.854 175.84 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 49.7 mm -67.13 89.28 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 C-N-CA 124.372 1.069 . . . . 10.0 109.543 170.657 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.8 m -88.44 123.99 33.52 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.615 0.766 . . . . 10.0 109.933 172.509 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.7 mt -48.25 -55.71 9.83 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.108 0.963 . . . . 10.0 111.076 177.237 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.5 p -135.49 175.34 9.68 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 127.271 2.229 . . . . 10.0 107.826 -179.165 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 132.22 -92.55 0.28 Allowed Glycine 0 C--N 1.335 0.493 0 N-CA-C 109.114 -1.595 . . . . 10.0 109.114 176.362 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -125.03 -52.23 1.66 Allowed 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.423 1.889 . . . . 10.0 107.655 179.323 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -74.3 -37.41 63.64 Favored 'General case' 0 N--CA 1.457 -0.116 0 CA-C-N 114.717 -1.129 . . . . 10.0 108.26 -173.518 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t 44.4 65.99 0.95 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.824 1.65 . . . . 10.0 113.024 168.75 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -65.19 -19.18 25.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 113.252 0.834 . . . . 10.0 113.252 -174.161 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.0 mm -48.58 126.02 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 118.336 0.516 . . . . 10.0 109.706 172.653 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.34 1.52 55.68 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.77 -1.016 . . . . 10.0 113.779 -179.094 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.99 176.33 9.25 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 118.757 1.278 . . . . 10.0 109.984 169.179 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -113.13 140.57 47.79 Favored 'General case' 0 C--N 1.34 0.159 0 C-N-CA 124.505 1.122 . . . . 10.0 108.802 169.757 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -98.13 139.49 33.86 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.562 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.6 t -117.76 135.18 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 107.349 -1.352 . . . . 10.0 107.349 170.93 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.39 122.07 55.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 N-CA-C 106.04 -1.837 . . . . 10.0 106.04 167.579 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.2 m-70 -100.44 161.78 13.38 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.92 1.343 . . . . 10.0 114.225 -169.253 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.624 ' HA ' HD22 ' A' ' 144' ' ' LEU . 29.2 tt0 -53.85 -68.8 0.15 Allowed 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.641 2.376 . . . . 10.0 109.107 177.31 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 57.2 mttp -106.92 168.37 9.24 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 123.476 0.71 . . . . 10.0 111.164 -178.125 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.62 142.35 58.46 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.593 1.157 . . . . 10.0 109.528 171.322 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -81.93 144.3 31.04 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.359 0.599 . . . . 10.0 109.902 168.381 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -78.43 7.8 6.07 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.079 0.951 . . . . 10.0 110.972 175.555 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 33.4 mt 49.75 45.62 24.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 124.133 0.973 . . . . 10.0 109.668 -177.835 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.38 -31.46 8.03 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 114.943 -1.026 . . . . 10.0 111.188 174.876 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mtmm -84.23 42.34 0.88 Allowed 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.746 -0.855 . . . . 10.0 110.759 -170.108 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.85 -34.67 6.43 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 126.983 2.23 . . . . 10.0 109.999 176.719 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 58.64 47.9 87.64 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 111.73 -0.548 . . . . 10.0 111.73 -174.402 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -137.49 173.34 11.77 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.1 -1.815 . . . . 10.0 106.1 169.552 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -54.69 -54.05 46.82 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 109.195 -0.669 . . . . 10.0 109.195 173.502 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -58.71 -31.38 68.2 Favored 'General case' 0 C--N 1.344 0.359 0 O-C-N 121.396 -0.815 . . . . 10.0 112.502 179.452 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.3 p -51.18 -34.88 33.54 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 119.646 1.112 . . . . 10.0 110.461 178.276 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.3 t -98.34 11.13 39.02 Favored 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 113.549 0.944 . . . . 10.0 113.549 -179.793 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 73.3 mmtt -120.36 -54.67 2.08 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 125.299 1.44 . . . . 10.0 111.153 179.617 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -131.95 9.59 4.54 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 113.388 0.884 . . . . 10.0 113.388 171.92 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.14 16.18 61.32 Favored Glycine 0 C--O 1.221 -0.707 0 CA-C-O 119.216 -0.769 . . . . 10.0 113.366 173.063 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 69.36 17.75 8.1 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.188 0.994 . . . . 10.0 112.525 -177.121 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.08 -14.42 54.47 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 123.317 0.647 . . . . 10.0 112.005 176.553 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.87 -147.04 30.25 Favored Glycine 0 N--CA 1.442 -0.937 0 N-CA-C 109.816 -1.313 . . . . 10.0 109.816 169.848 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.3 m -61.07 121.31 12.14 Favored 'General case' 0 N--CA 1.444 -0.769 0 O-C-N 122.1 -0.647 . . . . 10.0 110.764 -168.74 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -56.24 71.25 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.866 1.666 . . . . 10.0 110.711 167.335 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.624 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.0 tp -45.91 -41.38 11.38 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 127.181 2.192 . . . . 10.0 112.925 -171.475 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.93 155.46 31.4 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.177 -1.046 . . . . 10.0 108.177 -175.78 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.1 p -164.12 170.85 15.89 Favored 'General case' 0 N--CA 1.454 -0.253 0 O-C-N 122.01 -0.431 . . . . 10.0 110.095 -176.705 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -166.95 -176.69 38.14 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.705 -1.358 . . . . 10.0 109.705 -177.629 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.89 143.28 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -169.717 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 61.0 mt -73.55 137.4 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 122.784 0.434 . . . . 10.0 110.536 -176.405 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.72 141.59 12.77 Favored Glycine 0 CA--C 1.529 0.906 0 C-N-CA 125.306 1.432 . . . . 10.0 111.272 -178.537 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 42.5 mt -57.05 139.04 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 125.212 1.405 . . . . 10.0 108.603 170.943 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.504 ' HB2' ' HB3' ' B' ' 52' ' ' ASP . . . -136.57 156.67 48.26 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.318 0.58 . . . . 10.0 109.887 172.032 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.287 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 165.667 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.68 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -14.68 60.79 Favored 'General case' 0 CA--C 1.527 0.062 0 CA-C-N 118.857 0.753 . . . . 10.0 110.679 176.439 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 45.4 tttt -151.4 148.26 27.9 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.723 -0.473 . . . . 10.0 109.723 169.528 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.73 165.97 25.85 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.295 1.438 . . . . 10.0 107.501 169.543 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.61 164.06 35.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 123.426 0.69 . . . . 10.0 109.168 176.039 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.15 111.63 10.47 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 169.238 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.1 m -86.88 100.5 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 169.95 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.403 HD22 HG13 ' B' ' 119' ' ' VAL . 10.3 mt -78.83 134.37 36.97 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 123.912 0.885 . . . . 10.0 109.423 176.348 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -158.6 162.19 37.31 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 169.302 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.5 -56.85 0.05 OUTLIER Glycine 0 N--CA 1.454 -0.125 0 N-CA-C 111.485 -0.646 . . . . 10.0 111.485 171.205 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.37 -45.72 45.13 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.486 -1.672 . . . . 10.0 106.486 -170.923 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.4 -65.92 0.57 Allowed Glycine 0 CA--C 1.526 0.753 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.734 -179.141 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -58.33 -36.8 97.26 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.913 2.409 . . . . 10.0 111.236 173.685 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.7 113.57 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.378 -0.971 . . . . 10.0 108.378 175.788 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.31 126.28 31.07 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.202 -1.036 . . . . 10.0 108.202 168.581 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.672 ' HA3' HG22 ' B' ' 35' ' ' ILE . . . -120.44 140.76 14.65 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-O 119.428 -0.651 . . . . 10.0 111.696 176.582 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.401 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 10.6 mt -135.37 75.24 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 -169.276 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.2 mm -92.25 139.65 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.819 -0.628 . . . . 10.0 110.023 -174.293 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -114.62 120.94 41.87 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 128.419 2.688 . . . . 10.0 108.02 -178.104 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.9 105.56 14.41 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.315 1.446 . . . . 10.0 107.576 178.838 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -100.57 150.54 22.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 118.414 0.552 . . . . 10.0 111.122 178.277 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 63.8 tp60 -142.24 102.31 4.08 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.7 2.0 . . . . 10.0 108.264 -179.057 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp -65.18 -54.98 21.44 Favored 'General case' 0 N--CA 1.438 -1.069 0 C-N-CA 126.228 1.811 . . . . 10.0 110.879 -172.546 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -140.17 169.75 17.11 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 102.475 -3.157 . . . . 10.0 102.475 178.492 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.2 p -68.02 -18.31 64.67 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 120.71 1.596 . . . . 10.0 109.928 179.577 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 35.0 m120 -77.56 -19.21 56.04 Favored 'General case' 0 N--CA 1.441 -0.9 0 C-N-CA 123.792 0.837 . . . . 10.0 111.415 178.511 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.1 154.85 52.94 Favored Glycine 0 CA--C 1.533 1.184 0 N-CA-C 111.943 -0.463 . . . . 10.0 111.943 -174.54 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.18 154.34 61.94 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.418 2.079 . . . . 10.0 108.081 168.867 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 t -79.01 92.04 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 104.753 -2.314 . . . . 10.0 104.753 169.172 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 35.3 tttp -77.17 104.03 7.44 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 106.832 -1.544 . . . . 10.0 106.832 169.042 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -96.42 104.41 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 C-N-CA 126.566 1.946 . . . . 10.0 106.539 -179.352 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -122.24 163.03 20.33 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 112.693 0.627 . . . . 10.0 112.693 174.278 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.66 -154.15 25.33 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 106.866 -2.494 . . . . 10.0 106.866 169.666 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -155.14 160.55 41.02 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 120.134 -0.626 . . . . 10.0 110.198 176.705 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.672 HG22 ' HA3' ' B' ' 16' ' ' GLY . 1.8 pt -117.43 142.47 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.683 0 CA-C-N 114.262 -1.335 . . . . 10.0 109.557 167.475 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -117.35 149.54 40.32 Favored 'General case' 0 N--CA 1.443 -0.776 0 N-CA-C 106.864 -1.532 . . . . 10.0 106.864 168.385 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.04 -8.36 33.4 Favored Glycine 0 C--N 1.336 0.564 0 CA-C-O 119.34 -0.7 . . . . 10.0 112.731 171.395 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -62.15 175.36 0.73 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.198 0.999 . . . . 10.0 109.246 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.79 166.26 10.58 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 167.351 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -54.48 149.93 9.78 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.25 0.62 . . . . 10.0 111.469 -172.097 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.75 -168.6 31.81 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-O 121.763 0.646 . . . . 10.0 112.838 168.971 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.3 mp -75.26 144.8 42.37 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 126.824 2.05 . . . . 10.0 111.787 -169.652 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -147.85 145.08 28.57 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 113.813 1.042 . . . . 10.0 113.813 -177.322 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.637 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -28.22 128.41 0.07 OUTLIER Glycine 0 C--N 1.341 0.835 0 C-N-CA 127.284 2.373 . . . . 10.0 111.288 165.606 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -151.37 102.15 2.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 119.144 1.472 . . . . 10.0 111.675 169.861 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.446 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -150.57 170.07 20.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.764 0.653 . . . . 10.0 112.764 -179.83 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 24.2 m -97.4 -30.27 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 126.244 1.817 . . . . 10.0 113.986 -170.766 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 57.3 m-70 58.03 171.82 0.05 Allowed 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 122.905 1.336 . . . . 10.0 112.989 -177.571 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -83.25 -51.56 7.35 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 114.779 -1.101 . . . . 10.0 110.037 170.327 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -75.95 114.0 14.08 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 118.628 0.649 . . . . 10.0 109.669 -168.019 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.23 -31.71 81.75 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 107.824 -2.111 . . . . 10.0 107.824 165.792 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.504 ' HB3' ' HB2' ' A' ' 152' ' ' ALA . 1.7 p30 -58.82 161.46 4.83 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-O 123.251 1.5 . . . . 10.0 114.423 -176.551 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.14 21.68 0.08 Allowed 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 112.941 -1.936 . . . . 10.0 113.962 -168.128 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.433 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -58.31 -29.24 65.74 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 123.816 0.847 . . . . 10.0 111.75 -179.562 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.13 -15.95 59.35 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 122.909 0.484 . . . . 10.0 111.796 176.599 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.77 85.43 0.81 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 124.356 0.979 . . . . 10.0 111.049 178.521 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 65.5 m 37.6 47.53 0.8 Allowed 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 126.946 2.098 . . . . 10.0 112.146 -179.952 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -121.85 -54.89 1.92 Allowed 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 -169.659 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.0 t -128.34 54.81 1.72 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.021 0.928 . . . . 10.0 108.763 -177.472 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.02 49.97 0.45 Allowed 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 123.14 0.576 . . . . 10.0 110.399 172.149 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.0 125.92 0.13 Allowed Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.272 0.939 . . . . 10.0 111.448 172.346 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -77.46 47.39 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.86 0 C-N-CA 123.374 2.716 . . . . 10.0 112.605 179.607 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 60.76 47.79 7.64 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.931 2.492 . . . . 10.0 110.996 178.059 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -70.74 70.28 0.47 Allowed 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.886 0.85 . . . . 10.0 110.778 174.602 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 65' ' ' ASN . . . . . 0.414 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 4.9 p-10 -71.62 148.56 92.88 Favored Pre-proline 0 C--N 1.325 -0.467 0 C-N-CA 123.388 0.675 . . . . 10.0 112.709 -174.17 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -64.52 -46.61 6.93 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.975 2.45 . . . . 10.0 111.522 -179.722 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -78.89 48.9 0.87 Allowed 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.538 -0.726 . . . . 10.0 110.002 178.553 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 64.1 p -14.94 102.93 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 129.711 3.204 . . . . 10.0 113.466 -170.209 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 mtt85 -137.07 -179.77 5.91 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 118.612 0.642 . . . . 10.0 112.635 -170.635 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -111.79 102.09 10.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 105.753 -1.943 . . . . 10.0 105.753 -176.836 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.462 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.5 t60 -22.66 107.51 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.455 1.902 . . . . 10.0 114.185 -171.274 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.03 -149.55 8.38 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.964 -1.255 . . . . 10.0 109.964 176.652 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.96 -162.66 22.65 Favored Glycine 0 C--N 1.331 0.301 0 N-CA-C 108.51 -1.836 . . . . 10.0 108.51 -179.316 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -64.94 -6.69 13.26 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 121.367 1.378 . . . . 10.0 109.797 165.551 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 30.2 mmtt -101.89 2.43 38.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.82 1.648 . . . . 10.0 110.099 177.35 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 128' ' ' LYS . 3.7 t70 -129.32 170.98 12.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 N-CA-C 107.498 -1.297 . . . . 10.0 107.498 167.399 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -91.59 -27.17 18.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.426 -0.953 . . . . 10.0 108.426 169.186 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -102.89 39.3 1.57 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 122.831 1.301 . . . . 10.0 110.206 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.7 ptp180 -55.89 142.3 35.86 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 126.057 1.743 . . . . 10.0 108.941 169.664 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.462 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.0 m170 -64.98 -56.74 11.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 O-C-N 121.855 -0.528 . . . . 10.0 110.237 -175.181 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.515 HG13 ' H ' ' B' ' 82' ' ' GLY . 3.6 p -170.37 -68.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.992 -0.744 . . . . 10.0 108.992 176.908 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.515 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -118.2 67.91 0.34 Allowed Glycine 0 C--N 1.333 0.413 0 N-CA-C 107.522 -2.231 . . . . 10.0 107.522 -179.41 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -106.79 97.65 7.41 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.322 -2.473 . . . . 10.0 104.322 172.407 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 23.9 mt -82.09 22.94 0.75 Allowed 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.235 0.541 . . . . 10.0 110.56 -173.612 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.85 -104.85 2.36 Favored Glycine 0 N--CA 1.437 -1.287 0 N-CA-C 106.422 -2.671 . . . . 10.0 106.422 173.596 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -157.64 151.28 23.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.726 -1.213 . . . . 10.0 107.726 169.704 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.0 m -113.9 137.25 47.73 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 O-C-N 123.835 0.709 . . . . 10.0 109.547 -175.032 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 88.7 m -94.89 109.35 21.36 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 128.364 2.666 . . . . 10.0 108.491 -171.975 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.25 136.49 32.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 122.904 0.482 . . . . 10.0 110.205 174.845 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -57.56 171.51 0.44 Allowed 'General case' 0 C--O 1.235 0.298 0 O-C-N 124.079 0.862 . . . . 10.0 108.841 166.323 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 58.3 pttt -57.45 -29.04 63.87 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 123.541 0.736 . . . . 10.0 110.508 175.524 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -79.13 -0.64 32.54 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.785 0.834 . . . . 10.0 111.051 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.19 4.69 88.05 Favored Glycine 0 C--N 1.339 0.736 0 O-C-N 120.99 -1.069 . . . . 10.0 110.79 179.644 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.66 97.3 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 C-N-CA 126.128 1.771 . . . . 10.0 107.52 -178.008 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.461 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.72 118.83 37.75 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 108.367 -0.975 . . . . 10.0 108.367 169.192 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -82.15 129.13 34.74 Favored 'General case' 0 N--CA 1.437 -1.124 0 C-N-CA 126.856 2.062 . . . . 10.0 109.9 174.633 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.17 134.06 58.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 C-N-CA 125.907 1.683 . . . . 10.0 107.769 173.962 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 13.7 p -158.44 57.44 0.45 Allowed 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 112.804 0.668 . . . . 10.0 112.804 171.791 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.86 155.76 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.921 -0.77 . . . . 10.0 108.921 -172.075 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -116.47 99.25 7.05 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 126.546 1.938 . . . . 10.0 110.38 174.358 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -81.72 85.42 6.6 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.626 -1.249 . . . . 10.0 107.626 176.417 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 64.7 p -83.15 60.51 5.56 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 106.315 -1.735 . . . . 10.0 106.315 173.168 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.84 -47.77 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 O-C-N 123.356 0.41 . . . . 10.0 110.273 -170.9 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.325 0.0 OUTLIER -103.42 176.87 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 C-N-CA 123.74 0.816 . . . . 10.0 112.033 169.378 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -140.7 123.98 16.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.49 -29.57 50.51 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.358 1.463 . . . . 10.0 111.318 -179.031 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.4 m -140.1 135.73 32.84 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 167.23 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.01 -64.2 0.19 Allowed Glycine 0 C--N 1.333 0.393 0 N-CA-C 108.819 -1.713 . . . . 10.0 108.819 -175.096 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -166.4 -50.38 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 125.979 1.712 . . . . 10.0 107.872 -179.787 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 -74.73 -36.65 62.65 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.858 -1.064 . . . . 10.0 109.527 -169.278 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 7.5 t 31.43 73.61 0.06 Allowed 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.68 2.392 . . . . 10.0 111.818 169.723 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.95 20.17 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 124.796 1.238 . . . . 10.0 114.291 -174.477 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 17.9 mm -54.92 146.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 C-N-CA 125.538 1.535 . . . . 10.0 108.085 168.745 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.91 21.99 69.98 Favored Glycine 0 CA--C 1.533 1.169 0 CA-C-O 118.599 -1.111 . . . . 10.0 114.335 178.278 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.2 mmt180 -97.53 172.55 7.66 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 166.513 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -124.22 108.54 12.38 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.082 0.855 . . . . 10.0 111.454 -170.529 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.418 HD21 HD11 ' B' ' 149' ' ' ILE . 3.7 mm? -64.89 134.21 53.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 107.344 -1.354 . . . . 10.0 107.344 169.743 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.6 t -125.11 131.37 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 106.83 -1.544 . . . . 10.0 106.83 174.747 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.403 HG13 HD22 ' B' ' 8' ' ' LEU . 2.4 m -105.99 131.52 55.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 O-C-N 124.007 0.817 . . . . 10.0 110.084 169.466 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.637 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.3 m170 -113.04 163.5 14.62 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 114.813 1.412 . . . . 10.0 114.813 -170.583 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -51.31 -55.51 17.94 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 127.172 2.189 . . . . 10.0 109.468 -179.393 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -121.05 174.27 6.75 Favored 'General case' 0 CA--C 1.521 -0.154 0 C-N-CA 124.366 1.066 . . . . 10.0 112.228 -171.155 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.6 151.65 30.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.857 1.263 . . . . 10.0 110.06 -179.835 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.446 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -78.37 153.68 31.42 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 123.773 0.829 . . . . 10.0 111.799 175.733 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -76.31 -27.98 56.77 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 114.897 -1.047 . . . . 10.0 109.4 168.742 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 68.9 mt 59.52 52.04 6.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 123.669 1.7 . . . . 10.0 108.524 -172.8 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.65 -41.53 2.84 Favored Glycine 0 N--CA 1.443 -0.852 0 CA-C-N 111.655 -2.52 . . . . 10.0 111.489 169.171 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 19.1 mtmm -79.26 41.44 0.46 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.34 1.456 . . . . 10.0 112.47 -170.863 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.46 -15.73 34.07 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 126.653 2.073 . . . . 10.0 110.497 169.332 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.34 46.69 51.93 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 124.393 0.997 . . . . 10.0 111.951 -179.309 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.5 p30 -151.07 172.83 15.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 118.249 1.024 . . . . 10.0 109.883 176.216 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.3 tm-20 -55.18 -41.02 71.37 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.697 1.199 . . . . 10.0 110.915 -176.689 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 19.0 tp10 -71.42 -39.07 71.31 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 121.681 -0.637 . . . . 10.0 110.587 174.121 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.5 p -52.24 -43.92 64.56 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 118.451 0.569 . . . . 10.0 110.57 -176.376 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.3 t -74.92 -10.53 59.58 Favored 'General case' 0 CA--C 1.543 0.703 0 O-C-N 124.332 1.02 . . . . 10.0 113.058 -177.216 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.6 ttmt -115.21 -64.64 1.29 Allowed 'General case' 0 N--CA 1.436 -1.131 0 C-N-CA 126.973 2.109 . . . . 10.0 112.899 -168.878 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.5 p -126.46 17.01 7.63 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 120.048 1.295 . . . . 10.0 110.208 175.939 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.53 -105.7 1.91 Allowed Glycine 0 C--N 1.339 0.744 0 N-CA-C 106.952 -2.459 . . . . 10.0 106.952 -173.877 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -152.52 39.38 0.56 Allowed 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 170.009 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.22 -26.32 64.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.231 -0.895 . . . . 10.0 111.144 -177.03 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.48 -142.61 23.0 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 124.876 1.226 . . . . 10.0 110.379 170.707 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -69.16 134.96 49.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 -175.82 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 143' ' ' ARG . . . . . 0.401 ' NE ' ' H ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -63.07 120.84 12.21 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 106.414 -1.698 . . . . 10.0 106.414 167.758 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 31.9 mt -76.65 -60.43 2.35 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 169.547 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -139.18 163.17 33.14 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 122.974 0.51 . . . . 10.0 110.104 -174.03 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -154.15 163.71 39.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.353 -0.385 . . . . 10.0 110.443 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.33 149.1 18.22 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 109.418 -1.473 . . . . 10.0 109.418 -171.624 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -108.67 139.65 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 C-N-CA 124.916 1.286 . . . . 10.0 108.041 -169.065 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.418 HD11 HD21 ' B' ' 117' ' ' LEU . 19.0 mt -77.5 112.32 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 122.916 0.486 . . . . 10.0 109.966 -173.455 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.75 143.54 18.09 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.808 1.194 . . . . 10.0 112.21 -174.451 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.49 136.34 25.81 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.296 0 C-N-CA 126.315 1.846 . . . . 10.0 110.333 -175.758 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.74 -46.78 1.98 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.681 0.673 . . . . 10.0 111.759 177.821 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 . . . . . 0 C--O 1.25 1.103 0 CA-C-O 116.368 -1.777 . . . . 10.0 112.107 -169.443 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 108.411 -0.959 . . . . 10.0 108.411 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -80.06 -21.52 43.33 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.948 -1.13 . . . . 10.0 107.948 168.144 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.494 ' HZ3' ' C ' ' A' ' 153' ' ' GLN . 1.8 ttmp? -127.04 161.5 28.24 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.763 1.625 . . . . 10.0 107.868 179.078 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.24 164.28 38.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.435 -1.691 . . . . 10.0 106.435 168.337 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.41 ' O ' HG23 ' A' ' 149' ' ' ILE . 2.5 m -125.76 -179.9 2.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 118.08 0.4 . . . . 10.0 110.094 -179.429 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.71 108.37 2.9 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.852 -0.795 . . . . 10.0 108.852 165.207 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.47 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.3 m -92.91 115.53 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 171.282 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.7 mt -103.85 150.32 24.25 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.751 1.221 . . . . 10.0 109.224 -179.801 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.6 ttmt -163.12 159.83 23.57 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.721 1.146 . . . . 10.0 109.204 169.836 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.42 -56.35 0.02 OUTLIER Glycine 0 C--O 1.229 -0.197 0 N-CA-C 111.349 -0.7 . . . . 10.0 111.349 169.977 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -75.25 -45.85 37.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 106.575 -1.639 . . . . 10.0 106.575 -172.825 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.5 -64.85 0.6 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 113.859 -1.519 . . . . 10.0 110.902 -178.413 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -58.3 -41.29 67.86 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 122.512 2.142 . . . . 10.0 110.839 172.08 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -70.43 105.38 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.427 -1.694 . . . . 10.0 106.427 176.361 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.81 131.93 46.34 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.766 -0.827 . . . . 10.0 108.766 167.296 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.938 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -99.39 147.52 18.39 Favored Glycine 0 N--CA 1.441 -1.005 0 N-CA-C 109.658 -1.377 . . . . 10.0 109.658 174.988 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.624 HG22 HG23 ' B' ' 54' ' ' THR . 1.0 OUTLIER -150.81 81.8 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 105.355 -2.091 . . . . 10.0 105.355 -170.422 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -100.51 146.33 9.41 Favored 'Isoleucine or valine' 0 C--N 1.338 0.1 0 C-N-CA 125.091 1.356 . . . . 10.0 109.738 -178.283 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -126.0 117.15 22.65 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 127.502 2.321 . . . . 10.0 109.005 170.172 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -98.41 116.86 31.53 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 106.817 -1.549 . . . . 10.0 106.817 173.269 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -116.62 138.5 51.39 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 119.476 1.034 . . . . 10.0 112.948 171.18 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -114.35 85.37 2.22 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.728 2.011 . . . . 10.0 107.966 -178.176 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.42 ' NZ ' ' OE2' ' A' ' 100' ' ' GLU . 0.0 OUTLIER -46.07 -44.09 15.14 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.711 1.605 . . . . 10.0 111.366 -172.643 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -142.95 168.46 19.65 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 102.989 -2.967 . . . . 10.0 102.989 165.534 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.0 t -61.71 -29.17 69.93 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 174.525 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -81.09 -17.52 49.73 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 124.397 1.079 . . . . 10.0 110.783 -179.225 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.41 141.97 16.48 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 110.446 -1.062 . . . . 10.0 110.446 -171.174 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -63.55 136.48 54.6 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.078 1.852 . . . . 10.0 109.221 174.872 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.6 m -78.03 124.39 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -176.458 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 37.7 ttmt -88.11 116.48 26.33 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.759 -2.682 . . . . 10.0 103.759 167.591 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -97.51 104.19 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 171.258 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 21.2 p90 -112.88 167.65 10.33 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 116.129 -0.487 . . . . 10.0 110.086 176.473 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.36 176.15 42.51 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.878 -1.153 . . . . 10.0 111.688 178.33 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.6 t -144.84 99.17 3.3 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 107.775 -1.194 . . . . 10.0 107.775 177.252 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.938 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.4 pt -80.57 153.61 4.39 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.584 -1.265 . . . . 10.0 107.584 168.4 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.68 151.06 50.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 124.062 0.851 . . . . 10.0 109.085 167.83 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.65 -8.91 34.73 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.967 0.794 . . . . 10.0 113.541 175.443 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -61.06 176.27 0.44 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 122.301 1.048 . . . . 10.0 111.188 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -107.4 151.38 25.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 106.579 -1.638 . . . . 10.0 106.579 166.999 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -49.44 144.19 5.87 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.244 1.017 . . . . 10.0 111.717 -169.826 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.83 -168.01 21.18 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 123.685 0.659 . . . . 10.0 112.203 172.751 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -75.81 148.75 38.19 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.842 2.057 . . . . 10.0 111.768 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -147.6 134.24 19.9 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.477 1.111 . . . . 10.0 111.472 179.344 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.402 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -38.23 123.61 1.33 Allowed Glycine 0 C--N 1.345 1.076 0 C-N-CA 124.843 1.211 . . . . 10.0 111.02 168.337 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.516 ' HZ ' HG21 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -136.75 108.64 7.1 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 124.133 0.973 . . . . 10.0 109.37 176.397 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -155.57 174.4 15.32 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 121.788 0.804 . . . . 10.0 111.712 -178.101 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.7 m -102.35 144.65 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 CA-C-N 111.798 -2.456 . . . . 10.0 106.369 168.214 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -121.66 148.07 45.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 107.246 -1.39 . . . . 10.0 107.246 176.543 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.409 ' HB3' ' CE1' ' A' ' 64' ' ' PHE . 2.3 tp10 -59.43 -39.32 83.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 122.854 0.462 . . . . 10.0 112.213 -169.963 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -74.76 153.23 38.9 Favored 'General case' 0 CA--C 1.527 0.079 0 C-N-CA 118.358 -1.337 . . . . 10.0 109.561 177.205 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.58 -11.84 46.3 Favored Glycine 0 CA--C 1.54 1.602 0 N-CA-C 109.385 -1.486 . . . . 10.0 109.385 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -48.2 107.13 0.11 Allowed 'General case' 0 C--N 1.344 0.357 0 C-N-CA 126.653 1.981 . . . . 10.0 112.382 172.658 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -112.68 6.44 18.23 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 113.268 -1.787 . . . . 10.0 109.34 168.015 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.408 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -57.8 -39.92 78.7 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.254 1.021 . . . . 10.0 109.456 -178.91 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.5 -15.52 58.51 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.053 0.941 . . . . 10.0 112.699 177.622 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.48 -108.08 3.06 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 108.736 -1.746 . . . . 10.0 108.736 -173.13 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 60.9 m -131.0 43.7 3.06 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 124.307 1.043 . . . . 10.0 109.43 -173.215 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 55.3 m -130.18 -54.24 1.11 Allowed 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 125.796 1.638 . . . . 10.0 107.141 -171.748 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.9 t -80.75 4.61 18.36 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.265 0.555 . . . . 10.0 111.663 178.445 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.54 -25.87 7.52 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.871 1.268 . . . . 10.0 112.415 173.137 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.42 144.99 18.26 Favored Glycine 0 C--N 1.339 0.742 0 N-CA-C 110.576 -1.01 . . . . 10.0 110.576 173.984 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -80.07 57.74 6.65 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 CA-C-N 120.584 2.192 . . . . 10.0 111.399 179.649 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.477 ' CD2' HG22 ' A' ' 137' ' ' THR . 21.9 m170 71.77 -62.27 0.46 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 127.122 2.169 . . . . 10.0 108.211 -175.685 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.409 ' CE1' ' HB3' ' A' ' 49' ' ' GLU 0.343 3.1 p90 34.28 36.72 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 129.998 3.319 . . . . 10.0 116.85 174.635 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -45.29 152.24 0.64 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 129.837 3.255 . . . . 10.0 113.287 167.78 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -74.17 -48.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.493 2.795 . . . . 10.0 111.29 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 81.7 mt -68.82 83.44 0.3 Allowed 'General case' 0 C--N 1.339 0.145 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 172.839 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.7 p -69.54 64.65 0.18 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 126.628 1.971 . . . . 10.0 113.982 -169.358 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -87.73 -178.75 6.14 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.575 1.95 . . . . 10.0 109.779 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -111.43 84.98 2.04 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.188 0.518 . . . . 10.0 112.205 -169.356 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.451 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 64.8 t60 11.14 87.3 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 128.009 2.524 . . . . 10.0 114.627 175.791 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.26 -161.44 18.33 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 108.681 -1.767 . . . . 10.0 108.681 174.923 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.17 -155.88 6.73 Favored Glycine 0 C--O 1.224 -0.495 0 CA-C-O 117.671 -1.627 . . . . 10.0 110.512 170.106 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -64.91 -2.05 5.01 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 CA-C-N 120.756 2.278 . . . . 10.0 111.27 171.139 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 29.3 mtpt -88.41 -17.6 30.14 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.245 -0.884 . . . . 10.0 110.801 172.977 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -128.98 174.83 9.17 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 118.812 0.733 . . . . 10.0 109.482 -175.831 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -97.51 -15.05 20.73 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.707 0.803 . . . . 10.0 109.505 168.539 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 70.5 mm-40 -79.69 10.74 3.7 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.145 1.378 . . . . 10.0 112.78 178.712 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 16.4 ptt180 -51.65 127.56 20.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 166.995 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.451 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 21.3 m170 -65.7 -51.1 62.03 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 122.11 -0.369 . . . . 10.0 111.512 -169.982 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.6 p -166.94 -30.29 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 123.026 0.531 . . . . 10.0 111.804 -169.626 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.69 70.97 0.08 OUTLIER Glycine 0 C--N 1.334 0.442 0 N-CA-C 106.199 -2.761 . . . . 10.0 106.199 -176.557 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -116.58 91.11 3.49 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 -169.554 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp -72.86 -28.83 62.75 Favored 'General case' 0 CA--C 1.527 0.09 0 N-CA-C 107.314 -1.365 . . . . 10.0 107.314 -178.151 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.53 -87.78 0.77 Allowed Glycine 0 N--CA 1.44 -1.04 0 N-CA-C 106.493 -2.643 . . . . 10.0 106.493 172.12 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -140.98 149.38 41.71 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 122.884 0.473 . . . . 10.0 111.902 -176.414 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -129.32 143.41 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 105.506 -2.035 . . . . 10.0 105.506 168.093 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -95.48 121.58 37.31 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.357 1.863 . . . . 10.0 107.521 -176.285 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.14 137.4 32.37 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.721 -0.474 . . . . 10.0 109.721 171.208 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -67.5 173.25 4.25 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 126.193 1.797 . . . . 10.0 109.786 168.966 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -56.68 -24.36 48.28 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 124.75 1.22 . . . . 10.0 112.274 177.825 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -78.24 -17.61 56.48 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.092 -0.336 . . . . 10.0 110.092 179.527 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.28 7.74 69.39 Favored Glycine 0 C--N 1.338 0.647 0 N-CA-C 110.525 -1.03 . . . . 10.0 110.525 -171.86 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -80.7 119.54 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 N-CA-C 106.714 -1.587 . . . . 10.0 106.714 172.938 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.568 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -113.94 118.78 35.14 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 119.11 0.868 . . . . 10.0 108.691 169.482 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -79.2 117.35 20.14 Favored 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 126.366 1.866 . . . . 10.0 108.096 174.345 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 46.5 t -105.93 131.39 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 178.537 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 80.0 p -157.77 71.75 0.63 Allowed 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.735 0.814 . . . . 10.0 109.579 173.069 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.58 155.0 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 106.92 -1.511 . . . . 10.0 106.92 177.456 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.42 ' OE2' ' NZ ' ' A' ' 23' ' ' LYS . 26.3 tt0 -135.95 128.18 30.02 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 124.914 1.286 . . . . 10.0 108.276 174.742 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -136.7 152.8 50.78 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 124.046 0.842 . . . . 10.0 109.814 -177.601 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.4 p -118.68 48.75 1.39 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 127.484 2.314 . . . . 10.0 109.875 -171.068 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 14.6 p -155.34 -49.37 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 122.295 0.238 . . . . 10.0 110.655 173.002 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.99 119.48 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.663 -1.606 . . . . 10.0 106.663 170.617 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.09 85.79 2.3 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -176.038 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.2 pp -51.9 -10.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.603 1.561 . . . . 10.0 114.294 -177.961 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 24.9 t -148.36 137.01 21.55 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 103.953 -2.61 . . . . 10.0 103.953 168.862 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.78 -72.41 0.39 Allowed Glycine 0 C--N 1.334 0.421 0 N-CA-C 109.846 -1.301 . . . . 10.0 109.846 -176.526 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.45 -53.37 0.08 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 179.75 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -83.7 48.25 1.4 Allowed 'General case' 0 C--O 1.233 0.199 0 N-CA-C 109.269 -0.641 . . . . 10.0 109.269 -176.773 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.7 t -73.64 72.22 1.44 Allowed 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.072 1.349 . . . . 10.0 107.615 178.019 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.8 pt -72.2 39.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 126.251 1.821 . . . . 10.0 112.058 -177.996 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 44.2 mm -66.58 -47.5 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 125.246 1.418 . . . . 10.0 109.456 -178.445 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.77 51.3 3.74 Favored Glycine 0 CA--C 1.525 0.691 0 O-C-N 121.622 -0.674 . . . . 10.0 113.408 -175.053 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.29 145.81 46.72 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 -177.783 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 28.3 m -90.21 119.62 30.68 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 104.902 -2.259 . . . . 10.0 104.902 169.924 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.21 143.14 31.66 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -179.453 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 55.3 t -129.81 136.29 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 O-C-N 124.321 1.013 . . . . 10.0 109.405 -169.528 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.563 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.4 OUTLIER -105.96 119.32 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 N-CA-C 105.067 -2.198 . . . . 10.0 105.067 168.603 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.402 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 13.1 m-70 -99.19 161.45 13.62 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 113.823 1.045 . . . . 10.0 113.823 -169.563 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.609 ' HA ' HD22 ' A' ' 144' ' ' LEU . 0.5 OUTLIER -64.77 -53.06 53.03 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.685 -1.143 . . . . 10.0 108.483 -176.92 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -113.12 176.64 4.93 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.902 0.858 . . . . 10.0 111.987 -178.462 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.89 135.99 50.14 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.067 1.347 . . . . 10.0 111.19 -178.495 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -77.49 110.13 12.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 124.491 1.116 . . . . 10.0 108.507 173.757 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -80.36 58.41 3.11 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 123.196 0.31 . . . . 10.0 111.284 -179.379 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt -11.86 81.49 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 129.346 3.058 . . . . 10.0 115.384 -177.797 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 75.61 -7.48 25.76 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.927 -0.929 . . . . 10.0 113.812 168.779 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.7 pttp -116.03 27.34 9.33 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 118.4 1.1 . . . . 10.0 112.316 -174.458 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.23 -18.26 79.76 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.437 1.018 . . . . 10.0 111.273 170.662 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.83 44.33 98.01 Favored Glycine 0 CA--C 1.53 0.971 0 O-C-N 121.655 -0.909 . . . . 10.0 112.138 173.007 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.45 ' H ' ' HB2' ' A' ' 134' ' ' SER . 7.3 p30 -164.15 175.81 9.84 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 126.272 1.829 . . . . 10.0 106.821 177.913 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -56.0 -42.09 75.88 Favored 'General case' 0 N--CA 1.439 -1.023 0 CA-C-N 119.014 0.824 . . . . 10.0 111.906 -174.593 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -61.03 -28.79 69.31 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.813 -0.554 . . . . 10.0 110.179 -179.823 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.45 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 3.4 t -47.92 -46.02 31.43 Favored 'General case' 0 CA--C 1.519 -0.243 0 C-N-CA 124.228 1.011 . . . . 10.0 109.219 176.243 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -90.73 8.46 34.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 112.59 0.589 . . . . 10.0 112.59 -175.859 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.97 -81.19 0.63 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.045 1.338 . . . . 10.0 110.565 -178.918 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.477 HG22 ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -112.1 29.45 7.88 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 121.735 2.061 . . . . 10.0 111.537 174.091 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.95 -87.34 0.13 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 125.35 1.453 . . . . 10.0 110.823 179.012 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -165.64 33.24 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 122.115 -0.638 . . . . 10.0 112.211 170.627 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.13 -13.42 61.94 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.586 0.587 . . . . 10.0 112.586 -174.014 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.61 -147.57 45.49 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.217 -1.953 . . . . 10.0 108.217 174.223 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -58.56 120.44 8.86 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 122.729 0.412 . . . . 10.0 111.765 -169.54 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.65 73.68 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.488 1.515 . . . . 10.0 111.623 168.04 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.609 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.7 tp -38.45 -49.74 1.49 Allowed 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.139 2.176 . . . . 10.0 113.894 -179.883 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.563 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -156.01 158.09 37.27 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -170.856 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 20.0 p -164.35 171.82 14.3 Favored 'General case' 0 N--CA 1.454 -0.247 0 O-C-N 121.759 -0.588 . . . . 10.0 111.222 -171.866 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -172.65 -161.39 23.0 Favored Glycine 0 N--CA 1.451 -0.334 0 N-CA-C 110.224 -1.15 . . . . 10.0 110.224 -178.894 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -133.0 154.66 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.392 -2.077 . . . . 10.0 105.392 -172.891 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.41 HG23 ' O ' ' A' ' 5' ' ' VAL . 2.8 mt -69.17 -85.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 123.613 0.765 . . . . 10.0 110.147 -169.301 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.54 132.92 7.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.151 -0.779 . . . . 10.0 111.151 179.645 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 58.1 mt -68.51 145.31 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 123.435 0.694 . . . . 10.0 110.069 -179.262 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.89 176.27 8.86 Favored 'General case' 0 N--CA 1.442 -0.856 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 164.732 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 153' ' ' GLN . . . . . 0.494 ' C ' ' HZ3' ' A' ' 3' ' ' LYS . 15.1 tt0 . . . . . 0 N--CA 1.44 -0.967 0 N-CA-C 106.213 -1.773 . . . . 10.0 106.213 167.889 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 N-CA-C 108.424 -0.954 . . . . 10.0 108.424 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.3 t -78.96 -14.58 59.13 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.436 0.695 . . . . 10.0 110.662 -178.149 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.0 ttmt -134.32 149.22 50.86 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 125.023 1.329 . . . . 10.0 107.774 -179.716 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.64 151.63 47.39 Favored 'General case' 0 CA--C 1.512 -0.505 0 C-N-CA 123.32 0.648 . . . . 10.0 109.382 169.48 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -106.62 154.63 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.223 0 O-C-N 124.741 1.276 . . . . 10.0 111.813 -172.576 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 6' ' ' ALA . . . . . 0.455 ' HB1' HD21 ' B' ' 8' ' ' LEU . . . -144.8 93.79 2.46 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 123.217 0.323 . . . . 10.0 111.449 169.28 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.3 m -81.65 103.54 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.365 0 N-CA-C 109.328 -0.619 . . . . 10.0 109.328 169.17 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.455 HD21 ' HB1' ' B' ' 6' ' ' ALA . 10.9 mt -97.36 127.37 43.26 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.336 1.054 . . . . 10.0 109.029 -177.796 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.3 mtpt -146.86 161.64 40.29 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 120.367 1.439 . . . . 10.0 108.66 173.76 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.31 -55.37 0.06 OUTLIER Glycine 0 N--CA 1.461 0.325 0 CA-C-N 115.798 -0.637 . . . . 10.0 113.318 168.63 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -72.63 -43.78 62.8 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 -176.477 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.12 -70.61 0.42 Allowed Glycine 0 CA--C 1.524 0.613 0 CA-C-N 114.334 -1.303 . . . . 10.0 109.923 170.075 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -58.27 -33.86 98.04 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.427 2.751 . . . . 10.0 111.291 172.044 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.9 t -65.01 100.62 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.637 -1.245 . . . . 10.0 107.637 176.179 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -124.55 108.29 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.606 1.562 . . . . 10.0 108.117 177.978 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.02 143.46 16.49 Favored Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 167.934 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.408 ' CG2' HG22 ' A' ' 54' ' ' THR . 2.4 mt -141.62 67.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.651 -1.611 . . . . 10.0 106.651 -179.797 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.06 148.96 4.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.476 0.655 . . . . 10.0 110.852 -174.926 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -123.53 119.31 29.56 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 125.703 1.601 . . . . 10.0 109.263 169.834 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -94.73 124.6 38.86 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 116.712 -1.614 . . . . 10.0 106.653 168.332 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -112.52 136.54 51.91 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 119.592 1.087 . . . . 10.0 111.184 165.983 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -89.27 112.71 23.84 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.025 -2.213 . . . . 10.0 105.025 168.471 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.9 mmpt? -55.29 -58.11 9.04 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 125.649 1.58 . . . . 10.0 110.075 -171.554 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 80.4 mt-10 -122.67 -130.42 0.27 Allowed 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 105.146 -2.168 . . . . 10.0 105.146 176.969 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 19.8 t -103.69 -36.82 7.74 Favored 'General case' 0 N--CA 1.446 -0.662 0 O-C-N 123.288 0.368 . . . . 10.0 110.015 167.989 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -111.83 -1.41 15.57 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.298 1.039 . . . . 10.0 111.282 -175.279 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.42 156.75 53.43 Favored Glycine 0 CA--C 1.531 1.046 0 N-CA-C 109.361 -1.496 . . . . 10.0 109.361 175.622 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -59.17 145.54 97.41 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.263 1.976 . . . . 10.0 109.132 175.731 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.7 t -87.76 114.55 26.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 105.22 -2.141 . . . . 10.0 105.22 174.811 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 10.9 ttmm -89.21 119.75 29.97 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 169.895 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -89.44 107.91 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 126.387 1.875 . . . . 10.0 106.397 169.593 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.0 p90 -126.3 164.63 20.61 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.886 0.851 . . . . 10.0 112.614 173.08 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.68 -152.93 24.43 Favored Glycine 0 N--CA 1.438 -1.208 0 N-CA-C 107.586 -2.205 . . . . 10.0 107.586 169.905 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 34.3 p -154.01 113.91 3.86 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 118.595 -0.717 . . . . 10.0 109.495 -169.956 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.615 ' CG1' ' HB3' ' B' ' 95' ' ' ALA . 2.8 pt -81.75 140.43 16.51 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 166.994 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -119.58 148.88 42.81 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 169.622 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.34 -5.85 41.76 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-O 119.365 -0.686 . . . . 10.0 113.652 174.965 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.34 176.8 2.12 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 118.584 1.192 . . . . 10.0 110.787 176.903 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -109.65 158.26 18.25 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 105.661 -1.977 . . . . 10.0 105.661 165.898 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -49.44 159.59 0.32 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.483 1.513 . . . . 10.0 112.487 -169.055 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.48 -172.94 35.04 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-O 121.786 0.659 . . . . 10.0 111.909 169.254 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -72.03 144.14 48.89 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.976 1.711 . . . . 10.0 110.207 -176.616 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -145.36 147.79 32.67 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.168 0.987 . . . . 10.0 113.036 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.639 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -20.37 117.73 0.01 OUTLIER Glycine 0 C--N 1.339 0.726 0 C-N-CA 129.36 3.362 . . . . 10.0 115.473 165.012 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -154.59 103.38 2.47 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.943 1.872 . . . . 10.0 111.541 170.736 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.446 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 2.2 m80 -133.6 -163.53 1.37 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 124.465 1.106 . . . . 10.0 111.188 179.415 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.2 p -116.66 -46.6 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 124.286 1.034 . . . . 10.0 112.045 -177.067 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 62.16 148.12 0.02 OUTLIER 'General case' 0 C--N 1.342 0.27 0 C-N-CA 125.589 1.556 . . . . 10.0 112.223 -171.595 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -75.31 -58.01 3.55 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 177.297 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -77.78 128.05 33.4 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 -172.797 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.91 -1.61 87.57 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.257 -1.537 . . . . 10.0 109.257 165.781 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -41.06 140.21 0.8 Allowed 'General case' 0 C--N 1.346 0.425 0 CA-C-N 117.982 0.891 . . . . 10.0 110.887 173.121 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.47 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -150.18 18.83 0.86 Allowed 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.512 -1.222 . . . . 10.0 111.328 167.455 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.624 HG23 HG22 ' A' ' 17' ' ' ILE . 0.7 OUTLIER -54.89 -35.97 64.68 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 118.903 0.774 . . . . 10.0 109.305 177.893 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.74 -21.45 44.48 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.347 1.459 . . . . 10.0 113.407 177.069 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.58 91.18 0.71 Allowed Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.444 -0.662 . . . . 10.0 111.444 -176.818 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 32.0 m 44.61 38.67 2.84 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.156 1.782 . . . . 10.0 112.625 176.414 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.2 m -133.33 -49.7 0.85 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.702 0.801 . . . . 10.0 109.25 -168.964 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -106.04 20.12 19.46 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.553 0.741 . . . . 10.0 110.265 -177.133 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.96 47.79 0.45 Allowed 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 124.438 1.095 . . . . 10.0 111.011 175.974 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.22 101.41 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 126.043 1.782 . . . . 10.0 113.683 168.455 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -68.15 72.7 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 123.635 2.89 . . . . 10.0 112.833 178.629 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.446 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 15.9 m170 58.55 45.69 15.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.237 3.415 . . . . 10.0 110.943 173.298 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -69.33 64.69 0.16 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 126.146 1.778 . . . . 10.0 111.692 177.919 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -82.9 154.22 67.56 Favored Pre-proline 0 C--N 1.32 -0.69 0 C-N-CA 126.067 1.747 . . . . 10.0 109.796 179.557 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.13 -52.03 0.54 Allowed 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.574 2.182 . . . . 10.0 111.447 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.2 mt -78.68 49.58 0.9 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.94 0.896 . . . . 10.0 110.584 -176.652 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.7 124.94 23.23 Favored 'General case' 0 N--CA 1.451 -0.4 0 O-C-N 122.024 -0.422 . . . . 10.0 111.096 -168.53 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.81 -75.22 0.32 Allowed 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 107.1 -1.444 . . . . 10.0 107.1 -172.503 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.7 mttt -149.26 164.77 33.89 Favored 'General case' 0 N--CA 1.422 -1.853 0 CA-C-N 114.871 -1.059 . . . . 10.0 108.583 169.317 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 76.3 t60 -71.6 126.82 30.68 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 105.165 -2.161 . . . . 10.0 105.165 162.873 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.05 -138.36 3.65 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 108.86 -1.696 . . . . 10.0 108.86 173.634 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.62 -160.87 25.98 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 107.884 -2.086 . . . . 10.0 107.884 173.414 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.51 1.36 2.66 Favored 'Trans proline' 0 CA--C 1.541 0.839 0 CA-C-N 119.819 1.81 . . . . 10.0 110.644 167.372 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -108.35 10.19 27.63 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 125.857 1.663 . . . . 10.0 109.8 173.905 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -135.47 161.44 35.47 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 165.571 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -77.59 -37.86 49.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 105.242 -2.133 . . . . 10.0 105.242 167.328 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -97.15 58.1 1.52 Allowed 'General case' 0 N--CA 1.446 -0.646 0 CA-C-O 121.718 0.77 . . . . 10.0 109.323 -169.614 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -70.37 154.01 42.37 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.521 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -67.66 -65.95 0.62 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.989 0.813 . . . . 10.0 109.39 177.831 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.751 HG13 ' H ' ' B' ' 82' ' ' GLY . 7.5 p -161.67 -90.46 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 170.664 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.751 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -84.12 69.31 3.36 Favored Glycine 0 CA--C 1.525 0.693 0 O-C-N 120.374 -1.454 . . . . 10.0 109.486 176.071 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -104.39 94.42 5.33 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 104.013 -2.588 . . . . 10.0 104.013 167.32 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -70.73 -34.1 71.55 Favored 'General case' 0 C--O 1.227 -0.114 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 -176.336 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 117.68 -85.96 0.4 Allowed Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 110.175 -1.17 . . . . 10.0 110.175 167.021 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -142.37 141.26 32.28 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.53 -0.915 . . . . 10.0 108.53 -177.627 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.3 m -114.63 135.65 53.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 166.891 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -104.23 117.97 35.5 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.75 0.82 . . . . 10.0 109.465 -171.666 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.26 134.54 34.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.08 -0.388 . . . . 10.0 110.327 -178.166 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -60.9 168.97 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.529 1.132 . . . . 10.0 109.579 167.695 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.9 -29.14 40.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.633 -0.712 . . . . 10.0 111.298 173.485 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -78.41 -9.26 59.22 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.003 0.521 . . . . 10.0 111.291 -178.704 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 10.06 73.74 Favored Glycine 0 C--N 1.341 0.807 0 O-C-N 121.099 -1.001 . . . . 10.0 111.101 -177.148 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.7 t -87.21 106.71 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 C-N-CA 126.273 1.829 . . . . 10.0 106.743 176.049 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.615 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -104.82 119.57 39.32 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.476 -0.935 . . . . 10.0 108.476 169.653 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -79.53 135.4 36.61 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.081 1.752 . . . . 10.0 108.454 175.088 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.52 132.53 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.454 1.502 . . . . 10.0 106.975 177.907 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 23.4 p -158.78 55.4 0.43 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.752 0.821 . . . . 10.0 111.79 168.821 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.0 mp -92.81 145.0 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 108.662 -0.866 . . . . 10.0 108.662 -174.536 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -101.67 126.33 48.5 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 126.814 2.046 . . . . 10.0 108.543 174.359 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -117.45 155.04 30.36 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.541 -0.911 . . . . 10.0 108.541 168.157 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.4 p -130.42 27.42 5.03 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 125.453 1.501 . . . . 10.0 111.989 -177.4 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.71 -40.54 1.32 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.894 0.77 . . . . 10.0 111.021 169.788 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.449 HD13 ' C ' ' B' ' 104' ' ' ILE 0.481 0.0 OUTLIER -69.38 158.07 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 119.895 1.225 . . . . 10.0 112.47 174.592 . . . . . . . . 4 4 . 1 . 027 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 40.5 m -153.95 121.69 5.93 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 120.937 -1.102 . . . . 10.0 109.805 -179.235 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.1 mt -68.2 -30.74 69.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.698 1.199 . . . . 10.0 110.598 -175.536 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 68.6 m -149.35 148.82 29.96 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 108.187 -1.042 . . . . 10.0 108.187 169.462 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 165.82 -58.62 0.24 Allowed Glycine 0 C--N 1.334 0.419 0 N-CA-C 108.856 -1.698 . . . . 10.0 108.856 -179.258 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -166.56 -49.82 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 126.218 1.807 . . . . 10.0 107.757 -179.088 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -75.45 -39.87 58.24 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.98 -1.009 . . . . 10.0 109.035 -169.505 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.6 t 40.9 54.44 3.19 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.91 1.684 . . . . 10.0 111.022 175.242 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -69.77 37.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 C-N-CA 126.302 1.841 . . . . 10.0 111.844 -177.598 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 1.1 mp -56.07 -45.63 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 O-C-N 119.157 -2.214 . . . . 10.0 112.096 177.481 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.79 50.92 3.03 Favored Glycine 0 CA--C 1.534 1.251 0 CA-C-N 119.932 1.242 . . . . 10.0 114.244 -175.416 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -84.56 176.6 8.51 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 127.327 2.251 . . . . 10.0 109.784 170.123 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -135.85 99.19 4.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.35 -0.982 . . . . 10.0 108.35 169.114 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.74 129.65 42.04 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 105.565 -2.013 . . . . 10.0 105.565 167.625 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.16 129.4 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.24 -2.133 . . . . 10.0 105.24 169.168 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.507 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.3 OUTLIER -100.71 106.05 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.942 0 N-CA-C 104.868 -2.271 . . . . 10.0 104.868 170.997 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.639 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 12.0 m-70 -87.72 160.08 18.23 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 122.822 1.296 . . . . 10.0 114.258 -169.818 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 121' ' ' GLU . . . . . 0.664 ' HA ' HD22 ' B' ' 144' ' ' LEU . 52.0 tt0 -50.79 -56.55 11.58 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.839 2.056 . . . . 10.0 109.034 176.917 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -107.64 168.06 9.52 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.863 0.69 . . . . 10.0 112.863 -169.654 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.26 151.57 43.3 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 113.777 -1.556 . . . . 10.0 107.575 169.125 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.484 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 31.2 m-20 -100.94 132.36 46.38 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.235 -1.024 . . . . 10.0 108.235 -179.602 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -76.39 -12.68 60.1 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 124.857 1.263 . . . . 10.0 111.05 -176.796 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 15.4 mt 59.31 49.36 9.04 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 122.211 1.005 . . . . 10.0 109.04 177.39 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.4 -44.1 2.47 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 125.611 1.576 . . . . 10.0 110.445 174.645 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.7 mtmm -79.47 42.16 0.5 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.716 1.607 . . . . 10.0 112.518 -168.842 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.7 -17.77 27.36 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.281 2.372 . . . . 10.0 111.103 169.765 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.24 42.25 88.03 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.961 0.791 . . . . 10.0 111.777 178.861 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -145.94 166.38 26.2 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 169.929 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -52.23 -48.5 65.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 120.978 0.418 . . . . 10.0 110.143 -177.17 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -64.87 -30.45 71.45 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 119.225 -0.417 . . . . 10.0 110.427 -179.591 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 p -56.04 -35.33 66.77 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 120.146 1.339 . . . . 10.0 112.308 171.544 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -101.72 -14.73 17.23 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 118.294 0.497 . . . . 10.0 111.169 -170.515 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 53.9 mttt -88.0 -47.57 8.43 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 125.923 1.689 . . . . 10.0 111.256 173.715 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.404 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 44.7 p -134.09 -11.71 2.55 Favored 'General case' 0 CA--C 1.533 0.308 0 N-CA-C 115.057 1.502 . . . . 10.0 115.057 177.323 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.38 24.77 11.85 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 119.404 1.002 . . . . 10.0 112.978 -171.722 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 61.89 25.06 15.01 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 119.698 1.749 . . . . 10.0 111.432 179.316 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.73 -14.21 41.74 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 126.54 1.936 . . . . 10.0 112.5 -173.064 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.38 -160.22 52.98 Favored Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 108.776 -1.73 . . . . 10.0 108.776 172.434 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -55.29 130.54 42.74 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 109.24 -0.652 . . . . 10.0 109.24 -171.155 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.77 71.65 0.06 Allowed 'General case' 0 CA--C 1.543 0.708 0 O-C-N 121.667 -0.646 . . . . 10.0 110.274 172.198 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.664 HD22 ' HA ' ' B' ' 121' ' ' GLU . 11.7 tp -45.08 -35.78 3.25 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 128.118 2.567 . . . . 10.0 114.585 -172.858 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.507 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -165.77 159.18 15.9 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.049 -1.093 . . . . 10.0 108.049 -179.361 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.4 p -163.61 169.8 18.09 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.663 -0.495 . . . . 10.0 109.663 -178.045 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.12 -178.79 16.76 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 109.63 -1.388 . . . . 10.0 109.63 178.595 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 91.5 t -123.73 126.46 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 104.224 -2.51 . . . . 10.0 104.224 170.609 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.3 mt -81.72 152.08 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 CA-C-N 118.198 0.454 . . . . 10.0 110.787 -171.179 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -151.76 157.58 27.3 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 125.547 1.546 . . . . 10.0 111.059 -169.4 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.9 mt -54.12 140.27 11.33 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 C-N-CA 125.436 1.494 . . . . 10.0 111.806 172.64 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.72 170.17 16.23 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 107.492 -1.299 . . . . 10.0 107.492 165.759 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 . . . . . 0 C--O 1.25 1.096 0 N-CA-C 107.537 -1.283 . . . . 10.0 107.537 167.616 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.81 0 CA-C-O 117.971 -1.014 . . . . 10.0 108.952 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 t -105.47 -21.54 13.19 Favored 'General case' 0 C--O 1.223 -0.342 0 O-C-N 123.807 0.692 . . . . 10.0 110.503 176.897 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.74 172.5 13.2 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-O 121.368 0.604 . . . . 10.0 111.04 169.203 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.99 168.55 24.84 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 172.732 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -132.64 164.07 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.318 1.047 . . . . 10.0 109.284 176.771 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.01 116.87 10.97 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 167.898 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -95.66 102.77 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 124.542 1.137 . . . . 10.0 109.137 170.349 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -92.45 134.98 34.44 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.062 0.945 . . . . 10.0 109.703 -179.884 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt -145.38 162.44 37.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 168.797 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.95 -60.18 0.04 OUTLIER Glycine 0 C--O 1.229 -0.178 0 CA-C-N 115.393 -0.821 . . . . 10.0 112.542 172.976 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.37 -43.91 59.69 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 106.443 -1.688 . . . . 10.0 106.443 -171.532 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.25 -66.06 0.56 Allowed Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 113.713 -1.585 . . . . 10.0 110.097 177.65 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -58.54 -38.75 88.28 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 122.481 2.12 . . . . 10.0 111.276 172.297 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.1 t -64.44 108.17 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.691 -1.225 . . . . 10.0 107.691 178.363 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -122.6 116.27 23.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 105.452 -2.055 . . . . 10.0 105.452 168.973 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.765 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -100.38 131.29 10.52 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 175.858 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.492 ' CG2' HG23 ' B' ' 54' ' ' THR . 11.5 mt -133.19 89.57 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 107.111 -1.441 . . . . 10.0 107.111 -171.157 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.6 mm -104.17 141.88 18.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 124.396 1.078 . . . . 10.0 109.826 -178.665 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -126.5 119.42 27.11 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.939 2.095 . . . . 10.0 108.636 171.408 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -101.16 120.69 40.59 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 107.321 -1.362 . . . . 10.0 107.321 176.771 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -113.55 143.49 44.46 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 119.379 0.99 . . . . 10.0 112.832 172.214 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -127.42 97.33 4.85 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 128.166 2.586 . . . . 10.0 107.92 169.656 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.0 pttt -58.52 -48.14 81.82 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.287 1.035 . . . . 10.0 111.946 -176.255 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.76 166.61 24.29 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 104.38 -2.452 . . . . 10.0 104.38 168.14 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -65.21 -19.5 66.0 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 122.356 0.262 . . . . 10.0 110.893 179.891 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -80.66 -24.12 39.17 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 123.096 0.558 . . . . 10.0 110.499 176.617 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.41 155.1 53.39 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.645 -0.582 . . . . 10.0 111.645 -175.885 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -71.06 147.77 55.23 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 N-CA-C 106.155 -2.286 . . . . 10.0 106.155 165.56 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 t -79.61 128.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.04 0 N-CA-C 106.626 -1.62 . . . . 10.0 106.626 174.32 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -109.0 125.08 51.68 Favored 'General case' 0 C--O 1.233 0.234 0 N-CA-C 106.504 -1.665 . . . . 10.0 106.504 171.911 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.0 m -111.44 105.95 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.63 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 -176.5 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.5 p90 -117.13 168.54 10.2 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.25 0.548 . . . . 10.0 111.06 176.975 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.5 175.9 41.57 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.188 -1.006 . . . . 10.0 111.585 176.002 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 2.6 p -147.46 95.8 2.59 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 107.949 -1.13 . . . . 10.0 107.949 -177.098 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.765 HG22 ' HA2' ' A' ' 16' ' ' GLY . 8.4 pt -77.42 174.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.03 170.917 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -156.01 155.77 33.28 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.8 -17.23 33.0 Favored Glycine 0 CA--C 1.523 0.566 0 CA-C-O 119.411 -0.661 . . . . 10.0 113.824 173.326 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.505 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.3 mp -72.73 179.85 3.43 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 118.395 1.097 . . . . 10.0 110.354 178.362 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -95.81 175.78 6.38 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.586 -0.894 . . . . 10.0 108.586 166.404 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -63.6 176.54 0.85 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 124.633 1.173 . . . . 10.0 111.604 -172.024 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.04 -173.8 43.38 Favored Glycine 0 C--O 1.225 -0.438 0 C-N-CA 124.005 0.812 . . . . 10.0 112.563 167.345 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -77.22 140.7 40.18 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.332 1.453 . . . . 10.0 109.476 177.452 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -133.03 140.66 47.84 Favored 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 124.264 1.026 . . . . 10.0 112.366 -176.742 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -43.72 125.65 5.41 Favored Glycine 0 C--N 1.344 1.026 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 166.177 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -145.52 109.73 4.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 119.042 1.421 . . . . 10.0 109.025 171.122 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.22 173.12 17.32 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 113.74 1.015 . . . . 10.0 113.74 -174.139 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 33.3 m -88.0 154.37 3.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 113.629 -1.623 . . . . 10.0 109.578 171.246 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 -139.35 75.7 1.53 Allowed 'General case' 0 C--O 1.222 -0.37 0 C-N-CA 123.217 0.607 . . . . 10.0 112.122 -174.513 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 64.3 tt0 51.71 -87.22 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 125.301 1.44 . . . . 10.0 113.989 169.501 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -90.62 -172.34 3.37 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.537 -0.912 . . . . 10.0 108.537 -179.935 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -136.76 22.93 3.27 Favored Glycine 0 N--CA 1.452 -0.297 0 O-C-N 121.521 -0.737 . . . . 10.0 111.82 174.425 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -82.34 160.06 22.93 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 107.626 -1.25 . . . . 10.0 107.626 168.583 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.18 28.9 0.58 Allowed 'General case' 0 N--CA 1.448 -0.572 0 O-C-N 121.578 -0.701 . . . . 10.0 112.446 178.454 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.467 HG22 HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -49.7 -40.38 40.04 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.344 1.458 . . . . 10.0 112.373 -175.173 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -81.66 -24.31 36.37 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 123.391 0.676 . . . . 10.0 112.432 177.656 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.1 115.74 1.24 Allowed Glycine 0 CA--C 1.53 0.999 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 -169.512 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 64.2 m 42.27 53.37 4.47 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 125.629 1.572 . . . . 10.0 113.169 175.062 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -158.11 -56.98 0.07 Allowed 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 177.056 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -53.15 -45.34 68.38 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 124.909 1.284 . . . . 10.0 111.002 -169.233 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -53.59 0.18 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 127.039 2.136 . . . . 10.0 113.681 169.993 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.08 160.5 11.61 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.121 -1.192 . . . . 10.0 110.121 -176.838 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -74.02 -162.3 0.14 Allowed 'Trans proline' 0 N--CA 1.448 -1.169 0 N-CA-C 105.651 -2.48 . . . . 10.0 105.651 165.837 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -80.17 48.99 1.05 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 119.613 -1.93 . . . . 10.0 110.827 -175.386 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-30 -77.65 56.55 1.48 Allowed 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.935 1.35 . . . . 10.0 112.11 -176.632 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.4 HD21 ' CD2' ' A' ' 80' ' ' HIS . 1.8 p30 -59.83 148.52 75.92 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.81 1.244 . . . . 10.0 108.501 167.057 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.67 -48.59 8.75 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.693 2.262 . . . . 10.0 112.022 -174.285 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.19 57.65 1.46 Allowed 'General case' 0 CA--C 1.534 0.335 0 O-C-N 121.595 -0.69 . . . . 10.0 110.717 174.162 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.3 p -55.66 107.66 0.36 Allowed 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.842 1.257 . . . . 10.0 109.844 -179.705 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -119.45 -91.11 0.56 Allowed 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 -178.321 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -143.65 150.89 39.41 Favored 'General case' 0 N--CA 1.437 -1.095 0 CA-C-O 121.927 0.87 . . . . 10.0 109.81 169.012 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.5 t60 -57.79 120.96 9.35 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.643 -1.243 . . . . 10.0 107.643 165.699 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.73 -141.81 3.92 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 108.692 -1.763 . . . . 10.0 108.692 -177.96 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.492 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -174.17 -158.98 19.71 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 109.337 -1.505 . . . . 10.0 109.337 169.697 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -69.36 25.5 0.16 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 119.844 1.822 . . . . 10.0 111.173 168.739 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.492 ' H ' ' C ' ' A' ' 73' ' ' GLY . 71.7 mttt -123.96 -12.89 7.45 Favored 'General case' 0 N--CA 1.438 -1.028 0 C-N-CA 126.379 1.872 . . . . 10.0 109.787 171.942 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -135.96 129.11 31.65 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 104.842 -2.281 . . . . 10.0 104.842 -172.352 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -75.57 -22.19 57.21 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.243 -1.021 . . . . 10.0 108.243 -174.277 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -83.21 4.97 24.53 Favored 'General case' 0 N--CA 1.433 -1.323 0 C-N-CA 125.935 1.694 . . . . 10.0 111.122 -179.756 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.29 158.53 0.03 OUTLIER 'General case' 0 C--N 1.349 0.567 0 C-N-CA 124.53 1.132 . . . . 10.0 112.161 172.844 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.4 ' CD2' HD21 ' A' ' 65' ' ' ASN . 32.3 m170 -69.65 -103.81 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.689 -0.632 . . . . 10.0 109.359 176.997 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 88.0 t -126.7 -90.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 104.522 -2.399 . . . . 10.0 104.522 169.385 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -79.08 62.61 3.98 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.689 -0.565 . . . . 10.0 111.689 178.745 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -97.26 94.84 7.33 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 104.368 -2.456 . . . . 10.0 104.368 166.954 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -72.68 -7.46 50.54 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 117.913 0.324 . . . . 10.0 111.033 -174.229 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.27 -103.22 2.96 Favored Glycine 0 N--CA 1.44 -1.046 0 N-CA-C 105.006 -3.237 . . . . 10.0 105.006 -170.084 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -146.47 159.74 43.01 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 107.609 -1.256 . . . . 10.0 107.609 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.33 128.05 74.71 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 123.096 0.558 . . . . 10.0 110.575 170.422 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 m -79.68 114.08 18.33 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.758 2.823 . . . . 10.0 110.563 -178.889 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.16 46.51 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.298 1.039 . . . . 10.0 110.857 177.985 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -61.18 170.03 1.85 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 125.495 1.518 . . . . 10.0 109.096 166.914 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.95 -30.0 44.91 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.803 0.841 . . . . 10.0 111.408 176.723 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.1 -3.0 43.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 124.298 1.039 . . . . 10.0 110.863 -178.221 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.41 1.28 89.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.518 -1.033 . . . . 10.0 110.518 -175.633 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 62.1 t -79.47 103.53 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.288 0 N-CA-C 106.965 -1.495 . . . . 10.0 106.965 -176.958 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.405 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -100.95 118.67 37.44 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.825 -0.806 . . . . 10.0 108.825 169.213 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.2 110.01 15.21 Favored 'General case' 0 N--CA 1.434 -1.25 0 C-N-CA 126.265 1.826 . . . . 10.0 108.84 170.736 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.9 t -97.79 132.87 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 106.656 -1.609 . . . . 10.0 106.656 177.183 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.0 m -158.69 76.93 0.75 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.98 1.312 . . . . 10.0 109.863 169.799 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.7 161.13 3.83 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 177.505 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -142.51 130.85 22.24 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.65 1.98 . . . . 10.0 107.786 176.994 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -144.95 163.6 33.67 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.295 1.038 . . . . 10.0 108.959 179.126 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.4 p -125.36 51.39 1.7 Allowed 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.897 1.279 . . . . 10.0 109.876 176.974 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -142.69 -46.02 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.761 0.824 . . . . 10.0 110.762 174.475 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -63.29 139.74 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 169.339 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.3 m -126.74 156.19 41.55 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.941 0.877 . . . . 10.0 110.108 172.173 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -82.47 -29.54 30.53 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.75 0.82 . . . . 10.0 109.492 172.401 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.7 m -156.93 168.82 26.33 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 -174.599 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.32 -92.92 0.58 Allowed Glycine 0 C--N 1.333 0.407 0 N-CA-C 108.471 -1.852 . . . . 10.0 108.471 179.117 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -134.39 -51.64 0.81 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 125.72 1.608 . . . . 10.0 108.403 177.584 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -81.7 38.42 0.51 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.605 0.762 . . . . 10.0 110.145 -175.03 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.4 t -74.32 112.96 11.0 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 126.127 1.771 . . . . 10.0 108.627 -176.109 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 16.6 pt -81.87 11.49 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 173.16 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 30.9 mm -61.09 137.59 23.18 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 120.112 1.324 . . . . 10.0 109.925 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.56 87.01 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.0 -1.444 . . . . 10.0 114.707 172.544 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 29.5 mmt180 -83.93 171.13 13.31 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 168.914 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -105.4 136.48 44.87 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 124.677 1.191 . . . . 10.0 110.351 171.681 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.408 ' CD2' HD11 ' A' ' 149' ' ' ILE . 3.9 mm? -96.29 143.08 27.69 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 167.209 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.408 HG22 ' SG ' ' A' ' 146' ' ' CYS . 91.9 t -132.03 137.67 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.875 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 176.864 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.5 p -108.5 142.08 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.592 0 C-N-CA 124.996 1.318 . . . . 10.0 108.698 170.368 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -119.99 171.1 8.68 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.963 0.905 . . . . 10.0 113.143 -171.71 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -74.28 -46.83 38.75 Favored 'General case' 0 C--O 1.223 -0.323 0 C-N-CA 123.932 0.893 . . . . 10.0 111.669 -176.596 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -109.81 170.76 7.86 Favored 'General case' 0 CA--C 1.522 -0.113 0 C-N-CA 123.702 0.801 . . . . 10.0 113.015 -171.763 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.44 145.68 39.12 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.951 1.3 . . . . 10.0 108.777 174.134 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.53 164.47 24.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 122.167 0.984 . . . . 10.0 112.753 -178.208 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 63.9 m-20 -77.5 -22.4 51.28 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 112.625 -2.079 . . . . 10.0 109.631 167.082 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 40.2 mt 50.2 46.5 24.76 Favored 'General case' 0 C--N 1.341 0.232 0 CA-C-O 122.631 1.205 . . . . 10.0 108.354 -167.574 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.17 -32.79 4.76 Favored Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.125 -1.398 . . . . 10.0 112.247 177.765 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 25.4 mtmm -79.57 37.79 0.35 Allowed 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.672 1.189 . . . . 10.0 113.205 -168.535 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.8 -14.41 37.22 Favored Glycine 0 CA--C 1.526 0.778 0 C-N-CA 127.185 2.326 . . . . 10.0 110.036 169.419 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.17 43.07 32.75 Favored Glycine 0 C--N 1.34 0.781 0 C-N-CA 124.516 1.055 . . . . 10.0 112.081 -177.88 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -142.26 167.2 22.68 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 118.926 1.363 . . . . 10.0 109.221 173.088 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.403 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 1.7 tm-20 -37.5 -54.82 1.12 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 126.392 1.877 . . . . 10.0 111.374 176.531 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -72.2 -39.08 68.84 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.087 0.555 . . . . 10.0 110.739 179.927 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.8 p -53.04 -45.5 68.04 Favored 'General case' 0 N--CA 1.446 -0.635 0 O-C-N 120.893 -1.129 . . . . 10.0 110.589 -178.711 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.1 t -79.69 -2.45 42.92 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 118.744 -0.646 . . . . 10.0 111.799 -173.815 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.403 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 94.7 mttt -112.21 -71.07 0.77 Allowed 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.035 1.734 . . . . 10.0 110.811 -178.296 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.1 p -121.17 14.21 11.32 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 120.729 1.604 . . . . 10.0 112.841 177.462 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.46 21.08 78.7 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-O 119.236 -0.758 . . . . 10.0 113.473 168.752 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 50.75 24.83 1.85 Allowed 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 118.21 1.005 . . . . 10.0 112.202 -174.663 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.21 -7.55 47.59 Favored 'General case' 0 C--O 1.223 -0.323 0 O-C-N 121.41 -0.806 . . . . 10.0 111.554 -176.829 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 129.57 170.12 12.68 Favored Glycine 0 C--N 1.332 0.324 0 N-CA-C 110.199 -1.16 . . . . 10.0 110.199 169.674 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -82.38 54.85 2.71 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 123.029 0.532 . . . . 10.0 112.082 -169.058 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 42.66 72.87 0.16 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.057 1.343 . . . . 10.0 111.709 173.902 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -63.9 -36.4 83.82 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 123.041 0.537 . . . . 10.0 111.39 -169.185 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.06 138.22 14.65 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.904 -0.776 . . . . 10.0 108.904 -170.622 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.408 ' SG ' HG22 ' A' ' 118' ' ' VAL . 58.9 m -133.75 147.36 51.3 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.315 1.046 . . . . 10.0 109.678 -168.373 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.16 168.57 23.32 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.542 -1.023 . . . . 10.0 110.542 177.033 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 65.1 t -118.55 137.82 51.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 106.384 -1.71 . . . . 10.0 106.384 178.42 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.408 HD11 ' CD2' ' A' ' 117' ' ' LEU . 80.7 mt -73.96 126.18 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 118.099 0.409 . . . . 10.0 110.923 -176.297 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.65 145.61 18.63 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.365 -1.094 . . . . 10.0 110.365 176.833 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 47.9 mt -68.44 152.77 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 CA-C-N 119.358 1.579 . . . . 10.0 110.41 178.044 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.7 162.82 32.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 107.661 -1.237 . . . . 10.0 107.661 166.936 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.5 tt0 . . . . . 0 C--O 1.251 1.147 0 N-CA-C 106.338 -1.727 . . . . 10.0 106.338 169.603 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' B' B ' 1' ' ' ALA . . . . . 0.418 ' N ' ' O ' ' B' ' 153' ' ' GLN . . . . . . . . 0 N--CA 1.469 0.507 0 N-CA-C 109.134 -0.691 . . . . 10.0 109.134 . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.3 t -94.94 -32.18 13.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.978 1.311 . . . . 10.0 110.913 174.965 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.2 ttmp? -124.61 138.9 54.28 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 124.471 1.108 . . . . 10.0 110.231 -177.862 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.59 159.54 42.04 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.159 1.384 . . . . 10.0 108.101 170.236 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -136.02 164.4 32.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 119.012 0.824 . . . . 10.0 110.307 177.41 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.88 118.91 18.49 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 124.7 1.2 . . . . 10.0 109.118 168.199 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -89.05 89.65 3.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 108.387 -0.968 . . . . 10.0 108.387 168.911 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mp -79.67 120.76 24.43 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 118.544 -0.741 . . . . 10.0 109.688 -179.752 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 22.7 mtpt -140.5 160.41 40.05 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 119.133 0.879 . . . . 10.0 109.207 171.802 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.52 -60.71 0.05 OUTLIER Glycine 0 N--CA 1.46 0.276 0 CA-C-N 114.87 -1.059 . . . . 10.0 113.071 170.923 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -71.24 -44.0 66.17 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 -176.748 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.14 -69.17 0.43 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-N 114.234 -1.348 . . . . 10.0 110.575 169.771 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -60.14 -32.32 94.43 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 123.714 2.943 . . . . 10.0 111.735 173.019 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.7 t -67.62 92.53 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 107.145 -1.428 . . . . 10.0 107.145 177.902 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -120.11 105.65 11.21 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 125.22 1.408 . . . . 10.0 107.822 -178.24 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.677 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.68 139.72 14.65 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 110.364 -1.094 . . . . 10.0 110.364 169.718 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.467 HG22 HG22 ' A' ' 54' ' ' THR . 6.5 mt -138.15 58.5 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 N-CA-C 105.552 -2.018 . . . . 10.0 105.552 -173.403 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.422 HD11 HG23 ' B' ' 35' ' ' ILE . 30.2 mm -81.96 134.8 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 114.879 -1.055 . . . . 10.0 109.39 -169.913 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -112.35 116.48 30.41 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.195 1.798 . . . . 10.0 108.973 -177.517 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -103.19 113.79 27.55 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 125.963 1.705 . . . . 10.0 107.759 -176.107 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -114.36 135.86 53.62 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.053 0.941 . . . . 10.0 111.524 -177.992 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -115.77 104.6 11.82 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 104.985 -2.228 . . . . 10.0 104.985 167.784 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.51 30.74 0.74 Allowed 'General case' 0 C--O 1.235 0.306 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -169.683 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -131.25 166.55 20.93 Favored 'General case' 0 N--CA 1.432 -1.357 0 N-CA-C 101.779 -3.415 . . . . 10.0 101.779 167.591 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 22.7 t -77.01 -14.56 59.82 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 109.471 -0.566 . . . . 10.0 109.471 178.321 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -78.49 -15.08 59.01 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 119.828 -0.749 . . . . 10.0 109.308 169.163 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.08 43.53 17.93 Favored Glycine 0 CA--C 1.528 0.853 0 C-N-CA 126.076 1.798 . . . . 10.0 115.372 -178.436 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -66.1 145.45 79.03 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 CA-C-N 119.841 1.82 . . . . 10.0 107.625 170.867 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.37 97.43 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 106.196 -1.779 . . . . 10.0 106.196 173.542 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -79.09 102.42 8.41 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.504 -2.036 . . . . 10.0 105.504 168.895 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.93 101.12 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 C-N-CA 125.928 1.691 . . . . 10.0 107.822 -177.477 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -113.37 168.02 10.08 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.535 0.683 . . . . 10.0 111.867 169.88 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.55 178.37 32.51 Favored Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.642 -0.983 . . . . 10.0 110.642 168.886 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.5 p -124.33 102.06 7.49 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 108.593 -0.891 . . . . 10.0 108.593 -173.182 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.677 HG22 ' HA2' ' B' ' 16' ' ' GLY . 3.6 pt -81.78 133.99 28.03 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 108.219 -1.03 . . . . 10.0 108.219 168.852 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.9 tptt -108.09 148.83 29.28 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 170.069 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.67 -6.94 35.96 Favored Glycine 0 C--N 1.337 0.586 0 CA-C-O 119.563 -0.576 . . . . 10.0 113.47 169.348 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -66.43 175.93 2.06 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 118.276 1.038 . . . . 10.0 110.518 176.029 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -108.66 164.6 12.23 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 105.289 -2.115 . . . . 10.0 105.289 165.557 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -53.78 161.23 1.18 Allowed 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 113.11 0.782 . . . . 10.0 113.11 -169.041 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.12 -179.19 51.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 124.318 0.961 . . . . 10.0 112.085 169.049 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 mt -57.04 146.35 27.58 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.076 1.75 . . . . 10.0 112.921 175.501 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.5 m-70 -149.33 144.73 26.63 Favored 'General case' 0 C--N 1.339 0.149 0 C-N-CA 124.423 1.089 . . . . 10.0 113.439 -179.835 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.661 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.08 122.64 0.04 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 127.621 2.534 . . . . 10.0 113.243 166.515 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -152.37 105.52 3.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 119.059 1.429 . . . . 10.0 111.818 169.425 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.17 171.67 17.01 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 112.801 0.667 . . . . 10.0 112.801 -178.153 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.1 m -99.95 146.29 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 111.924 -2.398 . . . . 10.0 106.275 167.0 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -120.83 144.95 48.08 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 -179.437 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 49' ' ' GLU . . . . . 0.532 ' CG ' ' HA3' ' B' ' 61' ' ' GLY . 0.0 OUTLIER -6.73 -86.59 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.992 2.117 . . . . 10.0 116.593 170.978 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -102.14 171.86 7.24 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 119.737 1.153 . . . . 10.0 109.825 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.78 -25.71 52.28 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 117.63 -1.65 . . . . 10.0 111.234 174.976 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -40.16 113.04 0.32 Allowed 'General case' 0 C--N 1.342 0.278 0 CA-C-N 118.165 0.982 . . . . 10.0 111.448 178.064 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.33 20.85 12.96 Favored 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.748 -1.115 . . . . 10.0 109.972 167.973 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.492 HG23 ' CG2' ' A' ' 17' ' ' ILE . 4.2 m -55.44 -35.7 65.72 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 118.922 0.783 . . . . 10.0 110.49 -169.996 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.55 -21.35 45.27 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.803 1.241 . . . . 10.0 113.524 178.446 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.61 81.96 1.28 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 109.579 -1.408 . . . . 10.0 109.579 -174.056 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.327 25.7 p 18.73 55.51 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.914 2.086 . . . . 10.0 115.451 -167.88 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.6 m -112.87 -57.76 2.24 Favored 'General case' 0 N--CA 1.442 -0.848 0 N-CA-C 105.454 -2.054 . . . . 10.0 105.454 173.953 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.4 t -90.83 -4.0 56.95 Favored 'General case' 0 N--CA 1.443 -0.789 0 C-N-CA 124.724 1.21 . . . . 10.0 110.355 -178.323 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.38 41.51 0.14 Allowed 'General case' 0 C--N 1.341 0.239 0 C-N-CA 124.542 1.137 . . . . 10.0 112.787 -179.279 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 61' ' ' GLY . . . . . 0.532 ' HA3' ' CG ' ' B' ' 49' ' ' GLU . . . 88.35 125.93 2.47 Favored Glycine 0 N--CA 1.44 -1.077 0 N-CA-C 118.433 2.133 . . . . 10.0 118.433 162.168 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -81.5 55.85 5.73 Favored 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 121.646 1.564 . . . . 10.0 109.9 165.147 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.2 m170 66.17 -72.05 0.08 Allowed 'General case' 0 N--CA 1.461 0.099 0 C-N-CA 127.946 2.499 . . . . 10.0 111.034 -175.956 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 0.72 56.95 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 131.358 3.863 . . . . 10.0 116.076 -172.64 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -63.23 162.07 27.26 Favored Pre-proline 0 CA--C 1.538 0.487 0 CA-C-N 115.846 -0.616 . . . . 10.0 111.463 -172.499 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -53.7 -38.44 84.71 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 123.251 2.634 . . . . 10.0 112.985 179.531 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.45 -1.88 4.01 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 113.054 0.761 . . . . 10.0 113.054 176.596 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.3 p 22.34 89.83 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 129.436 3.094 . . . . 10.0 115.392 169.073 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -130.53 -168.92 2.05 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 179.461 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -103.98 128.91 51.53 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.216 -1.401 . . . . 10.0 107.216 177.047 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.411 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 78.3 t60 -42.88 109.27 0.13 Allowed 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 124.063 0.852 . . . . 10.0 112.061 -178.815 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.25 -155.84 9.5 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.1 -2.4 . . . . 10.0 107.1 169.667 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.24 -153.32 6.06 Favored Glycine 0 C--N 1.332 0.312 0 CA-C-N 118.371 1.085 . . . . 10.0 112.675 173.044 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -61.1 -9.47 12.46 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.241 1.961 . . . . 10.0 111.685 174.753 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -91.84 -18.65 23.51 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.609 1.164 . . . . 10.0 109.006 -179.101 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 20.8 m-20 -113.6 162.85 15.7 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 -169.308 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -92.07 -18.12 24.03 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.623 -1.171 . . . . 10.0 109.674 172.028 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -97.98 2.54 49.07 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 126.258 1.823 . . . . 10.0 112.49 -170.399 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -35.37 125.44 0.63 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.542 1.537 . . . . 10.0 109.447 169.037 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.411 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 18.5 m170 -47.05 -54.67 9.78 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.497 0.589 . . . . 10.0 112.242 -168.694 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -172.01 -40.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 C-N-CA 125.814 1.646 . . . . 10.0 108.404 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -149.27 68.67 0.34 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 109.395 -1.482 . . . . 10.0 109.395 174.413 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -97.05 103.59 15.54 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 105.099 -2.186 . . . . 10.0 105.099 168.65 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 28.1 mt -82.27 25.44 0.6 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 118.891 0.769 . . . . 10.0 111.433 -176.828 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 75.7 -113.13 3.81 Favored Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 174.43 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -158.6 128.78 5.95 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 -174.867 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 16.7 m -106.09 132.46 53.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 123.015 0.526 . . . . 10.0 110.422 -169.681 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 99.1 m -85.39 107.71 17.51 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 127.605 2.362 . . . . 10.0 110.308 -170.956 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.29 137.51 32.92 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 123.153 0.581 . . . . 10.0 110.338 171.981 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -65.9 172.02 3.96 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.818 1.247 . . . . 10.0 109.541 168.518 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.59 -28.41 63.6 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.117 0.484 . . . . 10.0 110.917 177.735 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -80.89 -0.5 39.39 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.899 0.88 . . . . 10.0 111.187 -178.255 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.34 80.35 Favored Glycine 0 C--N 1.339 0.737 0 O-C-N 120.74 -1.225 . . . . 10.0 110.808 176.942 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.7 t -91.62 108.71 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 C-N-CA 126.971 2.108 . . . . 10.0 105.642 174.816 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.567 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -106.76 118.61 37.13 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 119.189 0.904 . . . . 10.0 108.633 169.102 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -81.13 95.97 7.05 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 126.64 1.976 . . . . 10.0 108.285 172.586 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -78.77 131.92 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 105.626 -1.99 . . . . 10.0 105.626 170.916 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 6.7 p -157.8 60.03 0.48 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.814 0.845 . . . . 10.0 109.073 -179.629 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 30.1 mt -114.87 160.2 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.072 -1.455 . . . . 10.0 107.072 -169.743 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -138.77 135.74 34.97 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 109.725 -0.472 . . . . 10.0 109.725 168.846 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 16.6 t0 -117.2 101.62 8.6 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 -178.866 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 40.3 m -85.7 54.53 3.16 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 124.798 1.239 . . . . 10.0 108.471 -173.695 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 92.0 t -136.91 -54.33 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 -171.761 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.445 ' H ' ' CD1' ' B' ' 104' ' ' ILE 0.385 0.0 OUTLIER -88.19 175.37 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.384 0.674 . . . . 10.0 111.544 170.408 . . . . . . . . 4 4 . 1 . 028 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 56.0 m -157.83 97.2 1.54 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.418 -0.801 . . . . 10.0 109.882 -168.042 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.9 tp -37.88 -27.37 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 129.211 3.004 . . . . 10.0 116.37 -169.616 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 38.3 t -153.09 45.43 0.67 Allowed 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.152 0.981 . . . . 10.0 109.743 176.544 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -141.04 62.13 0.54 Allowed Glycine 0 C--N 1.337 0.611 0 N-CA-C 109.422 -1.471 . . . . 10.0 109.422 -178.907 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.6 t70 68.98 -55.32 0.55 Allowed 'General case' 0 CA--C 1.52 -0.193 0 C-N-CA 129.673 3.189 . . . . 10.0 109.303 -171.31 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -81.42 45.83 0.9 Allowed 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 124.551 1.14 . . . . 10.0 110.156 -174.038 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.8 t -67.39 -44.49 78.78 Favored 'General case' 0 N--CA 1.442 -0.847 0 C-N-CA 126.879 2.071 . . . . 10.0 110.318 -172.947 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.2 pt 46.24 35.21 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.962 1.705 . . . . 10.0 113.774 177.87 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 113' ' ' ILE . . . . . 0.415 ' O ' ' HB ' ' B' ' 149' ' ' ILE . 11.5 mm -61.29 -71.19 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.452 0 C-N-CA 123.122 0.569 . . . . 10.0 110.012 -178.66 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.25 58.48 1.12 Allowed Glycine 0 CA--C 1.54 1.645 0 O-C-N 120.814 -1.179 . . . . 10.0 115.042 -177.975 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 30.7 mmt180 -103.77 161.47 13.9 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 127.161 2.185 . . . . 10.0 105.706 167.494 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.99 128.22 42.69 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 104.269 -2.493 . . . . 10.0 104.269 171.442 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 11.1 mp -108.26 151.27 26.18 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 109.084 -0.71 . . . . 10.0 109.084 172.292 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.427 HG11 ' CG ' ' B' ' 143' ' ' ARG . 93.7 t -137.77 138.41 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.948 0 N-CA-C 108.412 -0.958 . . . . 10.0 108.412 -175.377 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.406 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.7 p -104.12 131.49 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 168.154 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.661 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.2 m170 -113.7 159.8 19.31 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 116.433 2.012 . . . . 10.0 116.433 -170.692 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -43.79 -57.12 3.41 Favored 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 129.26 3.024 . . . . 10.0 112.133 176.09 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 75.0 mttt -118.67 171.31 8.28 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 124.198 0.999 . . . . 10.0 112.937 -168.581 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -80.24 138.64 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.647 1.579 . . . . 10.0 109.91 177.815 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.08 152.11 33.09 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -172.525 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -76.81 -30.16 56.29 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.624 1.97 . . . . 10.0 109.968 169.579 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 26.9 mt 54.4 49.88 17.43 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 124.115 0.966 . . . . 10.0 109.979 -172.975 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.06 -43.36 3.11 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.033 -0.827 . . . . 10.0 111.033 176.062 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 28.2 mtmm -76.64 30.3 0.13 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.617 1.967 . . . . 10.0 112.236 -172.142 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.54 -33.04 7.74 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 128.32 2.867 . . . . 10.0 109.474 168.647 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.34 21.68 77.42 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.001 -0.889 . . . . 10.0 112.104 -177.224 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -107.48 161.65 14.64 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 168.966 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 8.0 tm-20 -50.81 -51.67 48.63 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 114.957 -1.019 . . . . 10.0 108.279 172.448 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 133' ' ' GLU . . . . . 0.414 ' OE1' ' NZ ' ' B' ' 136' ' ' LYS . 7.2 tp10 -57.7 -40.51 79.65 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.812 0.671 . . . . 10.0 112.812 178.043 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -48.92 -50.09 36.97 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 119.9 1.227 . . . . 10.0 110.555 171.488 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -80.18 -19.63 46.63 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 112.983 0.734 . . . . 10.0 112.983 -174.23 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE1' ' B' ' 133' ' ' GLU . 2.5 ttmt -96.74 -42.76 7.84 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 124.957 1.303 . . . . 10.0 112.512 -173.403 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 60.7 p -135.14 -7.53 2.31 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 176.716 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.03 13.39 71.84 Favored Glycine 0 C--O 1.221 -0.662 0 CA-C-O 118.188 -1.34 . . . . 10.0 111.813 -170.039 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 64.81 19.54 11.87 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 120.18 1.99 . . . . 10.0 112.41 170.092 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.65 7.57 6.67 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.742 0.817 . . . . 10.0 112.525 -169.834 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.52 -166.81 52.69 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.453 -0.78 . . . . 10.0 111.262 173.075 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 50.2 m -60.36 141.79 55.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 113.522 0.934 . . . . 10.0 113.522 -168.505 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 143' ' ' ARG . . . . . 0.427 ' CG ' HG11 ' B' ' 118' ' ' VAL . 0.1 OUTLIER -60.38 97.19 0.05 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.85 1.66 . . . . 10.0 109.454 168.734 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 27.1 mt -72.64 -34.66 67.45 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 119.284 0.947 . . . . 10.0 111.989 178.51 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.406 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -152.15 149.05 28.35 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.887 -0.508 . . . . 10.0 110.476 176.257 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.74 142.14 46.41 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 126.991 2.116 . . . . 10.0 107.654 -176.439 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -140.88 160.96 26.74 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 109.176 -1.57 . . . . 10.0 109.176 168.944 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 51.8 t -119.23 131.45 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 104.52 -2.4 . . . . 10.0 104.52 174.181 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.415 ' HB ' ' O ' ' B' ' 113' ' ' ILE . 20.3 mt -73.35 146.81 10.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-N 119.332 0.969 . . . . 10.0 109.288 174.77 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.71 150.35 22.5 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 125.858 1.694 . . . . 10.0 109.053 179.603 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.0 pt -72.47 132.21 33.7 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.359 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 -176.11 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.68 -42.6 7.16 Favored 'General case' 0 CA--C 1.512 -0.519 0 C-N-CA 123.9 0.88 . . . . 10.0 109.932 173.281 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 153' ' ' GLN . . . . . 0.418 ' O ' ' N ' ' B' ' 1' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.433 -1.299 0 N-CA-C 105.17 -2.159 . . . . 10.0 105.17 176.327 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.881 0 N-CA-C 107.894 -1.15 . . . . 10.0 107.894 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.1 t -86.47 -16.47 36.97 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 166.625 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 47.5 tttt -131.88 164.54 25.86 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 125.603 1.561 . . . . 10.0 108.244 177.239 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -158.03 171.97 19.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 126.018 1.727 . . . . 10.0 106.689 168.537 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -133.05 173.93 14.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 107.702 -1.221 . . . . 10.0 107.702 171.246 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.46 113.24 6.05 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.302 -1.37 . . . . 10.0 107.302 165.46 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 5.8 m -92.62 120.32 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.623 -1.251 . . . . 10.0 107.623 168.141 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -100.13 131.7 45.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.861 -1.533 . . . . 10.0 106.861 179.289 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -141.78 158.73 43.45 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 106.325 -1.731 . . . . 10.0 106.325 167.766 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.25 -64.04 0.04 OUTLIER Glycine 0 N--CA 1.461 0.326 0 C-N-CA 119.393 -1.384 . . . . 10.0 113.685 168.772 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -72.7 -41.44 65.28 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.411 -1.329 . . . . 10.0 107.411 -172.927 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.03 -67.72 0.42 Allowed Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 114.173 -1.376 . . . . 10.0 111.667 169.443 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -57.8 -39.57 86.07 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.581 2.187 . . . . 10.0 111.367 179.002 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.18 118.88 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 107.902 -1.147 . . . . 10.0 107.902 179.645 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.63 104.09 8.49 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 103.548 -2.76 . . . . 10.0 103.548 168.702 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.72 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -86.23 142.27 18.82 Favored Glycine 0 N--CA 1.44 -1.086 0 N-CA-C 108.281 -1.928 . . . . 10.0 108.281 177.014 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.719 ' CG2' HG23 ' B' ' 54' ' ' THR . 5.2 mt -140.73 92.52 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 -174.248 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.7 mm -102.1 139.36 23.39 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 C-N-CA 124.487 1.115 . . . . 10.0 110.2 174.04 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -112.37 118.89 36.46 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 127.452 2.301 . . . . 10.0 106.88 168.601 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.535 ' CD2' HG12 ' A' ' 31' ' ' VAL . 4.6 m-85 -99.89 115.42 29.58 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 105.832 -1.914 . . . . 10.0 105.832 175.377 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -116.81 127.25 54.14 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 119.032 0.833 . . . . 10.0 110.444 170.002 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -79.8 88.16 5.25 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 106.236 -1.764 . . . . 10.0 106.236 174.562 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.23 -40.55 16.63 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 126.729 2.012 . . . . 10.0 112.099 -167.612 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -130.4 162.36 29.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 101.576 -3.49 . . . . 10.0 101.576 162.766 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.7 t -55.7 -33.36 64.11 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.738 -0.838 . . . . 10.0 108.738 173.518 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 30.3 m-80 -99.39 -2.15 36.93 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 125.749 1.62 . . . . 10.0 110.948 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.25 164.73 24.78 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.762 -0.935 . . . . 10.0 110.762 -170.804 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -61.95 149.57 89.74 Favored 'Trans proline' 0 N--CA 1.449 -1.125 0 C-N-CA 121.563 1.509 . . . . 10.0 108.29 169.477 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.0 t -86.11 122.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 -179.403 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.3 tttt -90.28 113.99 25.94 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 108.205 -1.035 . . . . 10.0 108.205 177.566 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.535 HG12 ' CD2' ' A' ' 20' ' ' PHE . 35.7 m -98.34 58.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 125.725 1.61 . . . . 10.0 108.395 -172.486 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.5 p90 -77.27 158.32 30.29 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 119.915 -0.714 . . . . 10.0 110.011 -175.281 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.02 179.9 48.21 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.968 179.145 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 20.4 m -150.41 96.39 2.39 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.503 -1.295 . . . . 10.0 107.503 -178.729 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.72 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.9 pt -77.65 154.76 5.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 170.908 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -138.82 146.97 41.93 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.266 -1.383 . . . . 10.0 107.266 169.317 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.09 -2.29 38.01 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.46 170.642 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.475 ' N ' HD12 ' A' ' 38' ' ' LEU . 6.7 mp -72.31 178.83 3.7 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 119.398 1.599 . . . . 10.0 108.802 169.531 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 11.2 t -88.37 176.48 7.18 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 166.717 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 49.4 tt0 -64.02 169.69 4.15 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.04 0.936 . . . . 10.0 112.111 -172.311 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.12 -176.51 48.79 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 124.085 0.85 . . . . 10.0 113.079 167.15 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -62.42 150.85 38.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 123.815 0.846 . . . . 10.0 109.696 174.13 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -142.66 153.4 43.38 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 113.895 1.072 . . . . 10.0 113.895 176.614 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.6 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -39.54 125.02 2.1 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 127.542 2.496 . . . . 10.0 110.459 163.049 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.444 ' CD2' HG12 ' A' ' 119' ' ' VAL . 0.8 OUTLIER -149.73 105.85 3.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 119.823 1.811 . . . . 10.0 108.094 165.724 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.469 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -153.04 -179.99 8.18 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-O 121.844 0.83 . . . . 10.0 113.173 179.558 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.597 HG12 HD22 ' A' ' 117' ' ' LEU . 4.0 m -102.85 151.51 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 CA-C-N 113.219 -1.81 . . . . 10.0 110.345 174.116 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.85 133.4 45.89 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.276 1.83 . . . . 10.0 106.433 178.015 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.8 tp10 -62.41 -55.8 24.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 114.428 1.27 . . . . 10.0 114.428 -165.527 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 59.2 m-85 -77.66 144.94 36.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 117.612 -1.635 . . . . 10.0 108.243 179.652 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.38 20.8 48.35 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 172.684 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -80.67 70.73 7.47 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 125.765 2.698 . . . . 10.0 109.045 179.649 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.599 ' HB3' HG21 ' B' ' 7' ' ' VAL . 1.6 t-20 -69.33 -13.5 62.41 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 111.242 -2.708 . . . . 10.0 111.852 -174.056 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.54 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -27.69 -52.99 0.08 Allowed 'General case' 0 C--N 1.341 0.201 1 C-N-CA 131.92 4.088 . . . . 10.0 114.283 -175.799 . . . . . . . . 4 4 . 1 . 029 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.53 -14.77 59.58 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 124.068 0.947 . . . . 10.0 112.657 -172.518 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 107.1 52.96 0.71 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.925 -2.07 . . . . 10.0 107.925 -168.257 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 46.89 50.91 13.21 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.768 1.396 . . . . 10.0 114.768 169.784 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.2 p -111.79 -57.84 2.2 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 106.347 -1.723 . . . . 10.0 106.347 171.561 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.7 m -47.63 -33.19 6.41 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 127.167 2.187 . . . . 10.0 111.459 177.413 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -28.07 -39.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 128.666 2.786 . . . . 10.0 113.796 168.255 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.72 159.86 23.79 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 108.67 -1.772 . . . . 10.0 108.67 169.346 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -70.71 -170.25 0.44 Allowed 'Trans proline' 0 N--CA 1.445 -1.354 0 N-CA-C 107.585 -1.736 . . . . 10.0 107.585 167.5 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 36.9 m170 -78.89 55.93 1.83 Allowed 'General case' 0 CA--C 1.545 0.777 0 O-C-N 120.622 -1.299 . . . . 10.0 111.636 -170.121 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -74.88 64.47 1.29 Allowed 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 119.86 1.209 . . . . 10.0 112.275 -175.512 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.7 p-10 -57.6 155.37 21.1 Favored Pre-proline 0 CA--C 1.538 0.491 0 C-N-CA 123.283 0.633 . . . . 10.0 111.164 169.904 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -59.05 -45.8 26.05 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.534 2.156 . . . . 10.0 111.425 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -75.88 64.91 1.9 Allowed 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.116 -0.698 . . . . 10.0 109.116 174.725 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.9 p -42.04 113.76 0.47 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.685 1.194 . . . . 10.0 109.564 179.397 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.4 mtt-85 -145.97 -177.49 5.62 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 105.16 -2.163 . . . . 10.0 105.16 -169.88 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.4 mmtp -75.0 154.34 38.12 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 118.099 -1.44 . . . . 10.0 109.127 176.069 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -69.92 105.39 2.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 162.401 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.64 -140.65 6.85 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 107.909 -2.076 . . . . 10.0 107.909 173.822 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.7 -155.43 15.23 Favored Glycine 0 C--O 1.227 -0.309 0 CA-C-O 117.521 -1.711 . . . . 10.0 109.293 169.614 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -67.32 13.95 0.15 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 CA-C-N 120.378 2.089 . . . . 10.0 111.829 170.335 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 51.1 mttm -121.2 3.15 10.39 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-O 117.948 -1.025 . . . . 10.0 111.634 170.828 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -127.21 159.09 35.36 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 170.908 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -79.4 -32.52 42.97 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.639 -1.615 . . . . 10.0 106.639 167.017 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -82.89 28.48 0.49 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 124.58 1.152 . . . . 10.0 112.274 -168.643 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 164.08 11.97 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 119.839 1.199 . . . . 10.0 109.753 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -78.54 -67.58 0.73 Allowed 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.733 -0.604 . . . . 10.0 109.515 178.662 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -158.72 -116.35 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.827 -1.546 . . . . 10.0 106.827 -174.207 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -78.34 54.7 3.99 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-N 119.704 1.138 . . . . 10.0 111.012 178.749 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -79.46 92.3 5.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.735 -1.95 . . . . 10.0 105.735 170.014 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 29.1 mt -71.46 -21.7 61.92 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 118.755 -1.178 . . . . 10.0 108.204 175.325 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 83.13 -73.37 2.69 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.754 -1.338 . . . . 10.0 109.754 168.72 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -139.96 103.09 4.55 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 108.802 -0.814 . . . . 10.0 108.802 -169.412 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 23.9 m -109.09 129.53 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 119.068 0.849 . . . . 10.0 111.435 176.12 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -79.25 110.18 14.28 Favored 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 127.724 2.41 . . . . 10.0 112.371 -170.45 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.81 132.6 39.42 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 122.702 0.401 . . . . 10.0 110.154 169.946 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -53.5 166.98 0.24 Allowed 'General case' 0 CA--C 1.518 -0.258 0 O-C-N 124.093 0.871 . . . . 10.0 109.198 166.144 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -41.56 -43.19 2.64 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 126.324 1.85 . . . . 10.0 110.419 169.343 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.78 0.48 39.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.351 1.46 . . . . 10.0 110.948 -170.913 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.99 2.91 85.83 Favored Glycine 0 C--N 1.339 0.717 0 N-CA-C 111.408 -0.677 . . . . 10.0 111.408 178.116 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 33.1 t -78.97 106.5 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.376 -1.712 . . . . 10.0 106.376 -178.38 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.593 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -115.23 118.41 33.21 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 118.645 0.657 . . . . 10.0 109.638 176.541 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -79.73 126.68 31.26 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.526 1.93 . . . . 10.0 109.068 174.403 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -118.98 134.01 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.955 0 N-CA-C 107.319 -1.363 . . . . 10.0 107.319 175.548 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.8 p -156.62 59.75 0.55 Allowed 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 118.461 0.573 . . . . 10.0 110.872 174.457 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.11 153.48 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 -178.232 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -123.86 131.68 53.62 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 123.936 0.894 . . . . 10.0 108.908 169.398 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -120.57 147.95 44.51 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-O 121.639 0.733 . . . . 10.0 109.042 179.618 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.8 p -105.4 7.24 33.14 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.394 2.678 . . . . 10.0 111.865 -173.31 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.2 p -122.89 9.42 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.35 0.977 . . . . 10.0 110.763 179.525 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -108.45 150.03 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 105.944 -1.873 . . . . 10.0 105.944 176.773 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.7 m -146.29 152.69 39.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 169.939 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 55.4 mt -103.56 0.2 30.58 Favored 'General case' 0 C--O 1.237 0.437 0 C-N-CA 123.751 0.82 . . . . 10.0 111.66 -175.538 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.4 t -162.03 -172.38 3.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 126.472 1.909 . . . . 10.0 107.439 166.926 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 105.85 -69.87 0.23 Allowed Glycine 0 C--O 1.227 -0.336 0 C-N-CA 125.291 1.424 . . . . 10.0 110.307 167.302 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -162.69 -50.15 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 124.873 1.269 . . . . 10.0 107.611 -179.922 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -80.32 41.96 0.56 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.176 0.99 . . . . 10.0 109.034 179.449 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.5 t -81.4 83.8 6.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 126.076 1.75 . . . . 10.0 106.758 -171.773 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 20.8 pt -55.63 -21.61 10.42 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 113.649 0.981 . . . . 10.0 113.649 -170.172 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.417 ' H ' ' CD1' ' A' ' 113' ' ' ILE . 1.6 mp -14.04 -56.5 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 129.369 3.067 . . . . 10.0 115.139 174.866 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -87.7 6.6 83.19 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.208 -1.329 . . . . 10.0 114.812 -170.468 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.6 mpt_? -77.45 175.78 9.49 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.887 1.344 . . . . 10.0 108.751 174.014 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.41 ' C ' HD23 ' A' ' 117' ' ' LEU . 1.3 m -113.94 127.65 56.06 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.723 -1.584 . . . . 10.0 106.723 169.91 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.597 HD22 HG12 ' A' ' 47' ' ' VAL . 2.5 mt -102.86 152.73 20.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 118.754 0.707 . . . . 10.0 109.395 174.309 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.2 t -141.46 136.22 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 123.542 0.526 . . . . 10.0 110.178 -171.927 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.444 HG12 ' CD2' ' A' ' 45' ' ' PHE . 10.4 m -104.52 139.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 O-C-N 124.641 1.213 . . . . 10.0 109.201 164.13 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.6 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.5 m-70 -117.14 163.21 16.62 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 114.954 1.465 . . . . 10.0 114.954 -169.15 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -55.99 -54.66 42.19 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.693 -1.14 . . . . 10.0 110.103 178.032 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -111.31 173.4 6.36 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-O 121.305 0.574 . . . . 10.0 110.277 -178.231 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -96.19 136.82 36.15 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 125.24 1.416 . . . . 10.0 108.16 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.469 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -77.41 161.18 28.19 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 121.474 0.654 . . . . 10.0 111.943 -174.279 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -73.85 -15.5 61.16 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.763 -1.108 . . . . 10.0 110.809 -177.349 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mt 58.31 44.81 17.99 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.383 1.073 . . . . 10.0 108.292 -172.394 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.74 -15.65 59.45 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.96 1.267 . . . . 10.0 113.786 170.005 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -75.5 -4.46 39.89 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 114.838 1.421 . . . . 10.0 114.838 -166.548 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.51 -23.77 75.21 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-N 119.422 1.01 . . . . 10.0 110.65 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.34 18.74 50.95 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.812 -0.993 . . . . 10.0 114.429 179.267 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -116.92 176.66 5.02 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 119.474 1.637 . . . . 10.0 110.735 179.094 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -32.48 -61.76 0.25 Allowed 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 126.631 1.973 . . . . 10.0 112.186 171.396 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.88 -44.55 92.73 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.43 0.692 . . . . 10.0 111.529 178.536 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.8 m -49.24 -42.15 39.74 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 119.294 -0.384 . . . . 10.0 110.505 -176.06 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -87.18 -3.37 59.05 Favored 'General case' 0 N--CA 1.451 -0.386 0 O-C-N 124.32 1.013 . . . . 10.0 112.605 -172.464 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -114.53 -48.52 2.86 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.462 1.105 . . . . 10.0 111.521 -174.986 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 30.4 p -133.44 0.46 3.34 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 119.108 0.867 . . . . 10.0 112.286 171.658 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.75 -105.53 3.04 Favored Glycine 0 C--N 1.341 0.819 0 N-CA-C 107.289 -2.325 . . . . 10.0 107.289 -172.864 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.2 m-20 -167.52 43.44 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 125.298 1.439 . . . . 10.0 108.541 -179.477 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.43 -15.18 63.23 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.674 -0.641 . . . . 10.0 111.756 -177.636 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.17 -162.66 54.54 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 -176.742 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.1 m -62.25 149.52 41.67 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 113.736 1.013 . . . . 10.0 113.736 -170.043 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.2 74.59 0.69 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.161 2.584 . . . . 10.0 111.267 174.113 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.58 -27.32 67.62 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.187 -0.945 . . . . 10.0 113.361 -178.701 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.36 153.17 30.05 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 118.881 0.764 . . . . 10.0 110.392 171.737 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.0 p -155.52 155.64 33.77 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 123.081 0.552 . . . . 10.0 110.367 -168.482 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.92 162.64 30.56 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 124.054 0.835 . . . . 10.0 112.023 -174.727 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 62.1 t -122.64 66.85 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 105.263 -2.125 . . . . 10.0 105.263 -172.515 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.529 HD11 HD21 ' A' ' 117' ' ' LEU . 7.3 mm 30.44 -114.63 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 C-N-CA 127.1 2.16 . . . . 10.0 113.349 -173.737 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 126.61 102.5 1.25 Allowed Glycine 0 CA--C 1.531 1.045 0 N-CA-C 109.653 -1.379 . . . . 10.0 109.653 -169.536 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 56.3 mt -53.31 137.6 13.56 Favored 'Isoleucine or valine' 0 C--N 1.341 0.197 0 C-N-CA 124.151 0.98 . . . . 10.0 110.415 170.717 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.57 158.58 44.07 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 107.92 -1.141 . . . . 10.0 107.92 169.748 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.7 tt0 . . . . . 0 C--O 1.25 1.081 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 168.133 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.875 0 CA-C-O 118.538 -0.744 . . . . 10.0 109.62 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.7 t -90.57 -36.71 14.29 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.666 0.787 . . . . 10.0 110.705 169.951 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.3 tttp -127.44 124.15 37.77 Favored 'General case' 0 C--O 1.238 0.485 0 C-N-CA 125.798 1.639 . . . . 10.0 109.217 -171.814 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.11 155.92 49.89 Favored 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.741 0.816 . . . . 10.0 109.687 176.673 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.1 m -106.68 178.73 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 O-C-N 123.965 0.791 . . . . 10.0 109.94 176.944 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 6' ' ' ALA . . . . . 0.454 ' HB3' ' HB ' ' B' ' 18' ' ' ILE . . . -160.7 93.75 1.01 Allowed 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.35 1.46 . . . . 10.0 108.056 175.68 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.599 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.9 OUTLIER -92.41 95.09 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 C-N-CA 123.753 0.821 . . . . 10.0 110.722 179.453 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.401 HD22 HG23 ' B' ' 119' ' ' VAL . 1.6 mp -80.09 130.41 35.23 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 123.192 0.597 . . . . 10.0 109.41 175.938 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.34 158.99 44.44 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 106.211 -1.774 . . . . 10.0 106.211 168.938 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.48 -64.39 0.05 OUTLIER Glycine 0 CA--C 1.51 -0.231 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.967 169.311 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -70.34 -45.01 67.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 -178.831 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.11 -70.52 0.38 Allowed Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.425 -1.261 . . . . 10.0 110.784 169.571 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -57.12 -35.0 98.78 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 123.228 2.618 . . . . 10.0 111.821 175.81 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 37.4 t -68.63 89.24 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 C-N-CA 124.623 1.169 . . . . 10.0 107.986 179.033 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -113.12 116.22 29.51 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.109 -1.441 . . . . 10.0 107.109 -179.871 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.472 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -108.3 136.79 13.72 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.368 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.54 ' CG2' HG22 ' A' ' 54' ' ' THR . 7.8 mt -135.49 74.68 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 -175.286 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.454 ' HB ' ' HB3' ' B' ' 6' ' ' ALA . 28.7 mm -95.09 149.8 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 114.826 -1.079 . . . . 10.0 109.655 -172.347 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -126.37 114.6 18.43 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 126.775 2.03 . . . . 10.0 106.666 -170.57 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -102.36 115.54 30.78 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 106.229 -1.767 . . . . 10.0 106.229 176.559 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -119.24 137.51 53.61 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.085 0.772 . . . . 10.0 113.085 169.13 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -113.08 111.0 21.39 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 104.638 -2.356 . . . . 10.0 104.638 167.754 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? -56.25 -70.81 0.1 Allowed 'General case' 0 N--CA 1.445 -0.701 0 C-N-CA 125.554 1.542 . . . . 10.0 109.136 -176.117 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 23.0 mp0 -107.14 -133.38 0.33 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 107.133 -1.432 . . . . 10.0 107.133 176.487 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.3 m -136.86 15.32 3.09 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.195 0.521 . . . . 10.0 112.049 166.545 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 71.2 m-20 -115.57 -22.97 8.98 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 124.803 1.241 . . . . 10.0 109.536 167.351 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.01 156.44 53.22 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 169.181 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.02 163.16 39.67 Favored 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 123.051 2.501 . . . . 10.0 109.207 178.105 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -79.57 134.64 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 104.831 -2.285 . . . . 10.0 104.831 166.934 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 32.5 mttt -114.67 125.13 53.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 104.812 -2.292 . . . . 10.0 104.812 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -109.48 104.14 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 C-N-CA 126.404 1.882 . . . . 10.0 106.587 -178.072 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -126.16 159.46 32.88 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 112.728 0.64 . . . . 10.0 112.728 -178.029 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.99 -146.09 13.99 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 107.811 -2.116 . . . . 10.0 107.811 169.948 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 31.8 p -155.38 160.68 40.87 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 122.113 0.958 . . . . 10.0 112.044 175.033 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.75 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -110.92 145.42 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-N 113.25 -1.795 . . . . 10.0 107.509 166.871 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -125.15 142.97 51.17 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 107.167 -1.42 . . . . 10.0 107.167 168.834 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.22 0.57 20.69 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.082 0.849 . . . . 10.0 113.247 176.634 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.41 176.87 8.95 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 118.594 1.197 . . . . 10.0 110.321 -179.155 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -109.62 153.74 23.78 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.925 -1.88 . . . . 10.0 105.925 166.097 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.09 147.83 2.0 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.594 1.157 . . . . 10.0 112.315 -171.952 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.75 -173.22 18.25 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.05 0.833 . . . . 10.0 111.795 170.774 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -73.03 146.89 45.59 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.26 1.424 . . . . 10.0 110.594 -179.142 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -147.06 147.97 31.16 Favored 'General case' 0 C--N 1.342 0.25 0 N-CA-C 114.509 1.3 . . . . 10.0 114.509 -177.49 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.686 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.46 121.99 0.04 OUTLIER Glycine 0 C--N 1.339 0.738 0 C-N-CA 128.653 3.025 . . . . 10.0 114.501 164.587 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -152.72 109.2 3.42 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.665 1.233 . . . . 10.0 110.544 166.267 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.14 179.17 7.82 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.254 0.55 . . . . 10.0 112.193 173.098 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.4 m -116.56 134.24 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.066 -1.879 . . . . 10.0 106.848 166.02 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -110.91 152.99 26.1 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 125.268 1.427 . . . . 10.0 107.912 -178.701 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.23 -54.71 43.67 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.875 -0.602 . . . . 10.0 111.413 -172.863 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.51 111.96 13.79 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -169.189 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.57 -30.47 68.67 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.164 -1.174 . . . . 10.0 110.164 169.44 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -40.29 139.43 0.74 Allowed 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 124.788 1.235 . . . . 10.0 111.214 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -143.88 24.07 1.69 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 124.353 1.061 . . . . 10.0 112.551 169.863 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.719 HG23 ' CG2' ' A' ' 17' ' ' ILE . 3.6 m -61.82 -35.15 77.39 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.371 0.668 . . . . 10.0 110.748 -174.957 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.23 -16.45 59.82 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 122.215 -0.303 . . . . 10.0 111.582 176.103 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.39 -151.59 19.08 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 106.61 -2.596 . . . . 10.0 106.61 -169.656 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 1.8 m -69.26 67.63 0.19 Allowed 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 126.018 1.727 . . . . 10.0 111.298 -179.039 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -163.88 -53.16 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.317 1.847 . . . . 10.0 107.583 -179.299 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -39.16 -40.59 0.74 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 127.648 2.379 . . . . 10.0 111.235 174.132 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.81 -47.55 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.009 2.524 . . . . 10.0 114.062 168.28 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.08 152.24 26.45 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 110.424 -1.071 . . . . 10.0 110.424 173.512 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -79.13 46.94 2.34 Favored 'Trans proline' 0 CA--C 1.537 0.629 0 C-N-CA 124.379 3.386 . . . . 10.0 113.482 -171.065 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 57.14 58.03 4.19 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.1 1.76 . . . . 10.0 108.585 -175.825 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -66.77 75.64 0.11 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.769 0.795 . . . . 10.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -77.65 137.02 63.03 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.2 -0.938 . . . . 10.0 110.508 -177.52 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.06 -52.16 0.99 Allowed 'Trans proline' 0 N--CA 1.455 -0.752 0 C-N-CA 122.578 2.185 . . . . 10.0 111.132 -173.19 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mp -76.17 65.74 2.19 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 108.122 -1.066 . . . . 10.0 108.122 175.054 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 66.6 p -30.02 101.64 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.325 2.25 . . . . 10.0 114.021 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.2 mtp180 -139.85 177.7 7.77 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.072 0.949 . . . . 10.0 110.927 -174.729 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 67.2 mmtt -107.26 89.07 2.89 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 113.233 0.827 . . . . 10.0 113.233 -168.66 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.401 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 81.9 t60 5.73 92.85 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.23 0 C-N-CA 128.45 2.7 . . . . 10.0 114.849 179.219 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.24 -139.04 9.64 Favored Glycine 0 N--CA 1.442 -0.921 0 N-CA-C 110.144 -1.182 . . . . 10.0 110.144 178.0 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.03 -162.24 34.34 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 175.394 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.62 1.31 1.81 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 CA-C-N 120.055 1.927 . . . . 10.0 111.472 168.417 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.31 8.6 18.09 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.913 1.685 . . . . 10.0 110.516 176.4 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -142.03 169.62 17.24 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.442 1.019 . . . . 10.0 108.948 165.125 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -87.99 -22.6 24.17 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.235 -1.394 . . . . 10.0 107.235 167.996 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 -82.27 31.05 0.39 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 120.661 -1.274 . . . . 10.0 112.777 -176.526 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.6 132.7 54.77 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 172.898 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.401 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 16.9 m170 -63.17 -61.52 2.32 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 121.176 0.512 . . . . 10.0 110.538 -177.787 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.4 p -168.23 -56.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 -179.141 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.16 63.14 0.63 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 177.45 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.1 m-20 -92.7 95.5 9.6 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 104.101 -2.555 . . . . 10.0 104.101 167.528 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 9.2 mp -66.75 -26.61 67.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 118.828 0.74 . . . . 10.0 109.342 -176.713 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 116.9 -88.17 0.45 Allowed Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 108.106 -1.998 . . . . 10.0 108.106 168.631 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 38.5 m-80 -149.39 142.49 24.96 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.58 134.12 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 107.657 -1.238 . . . . 10.0 107.657 169.001 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -86.9 130.06 34.62 Favored 'General case' 0 C--O 1.226 -0.166 0 C-N-CA 123.978 0.911 . . . . 10.0 108.643 179.663 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.77 127.87 52.71 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.227 1.411 . . . . 10.0 109.43 175.247 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -61.29 167.71 3.04 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.888 1.368 . . . . 10.0 109.933 168.064 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -52.32 -30.8 30.11 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.681 1.192 . . . . 10.0 110.77 172.202 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -77.25 -7.73 56.42 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.035 0.379 . . . . 10.0 110.758 -177.541 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.14 17.01 73.02 Favored Glycine 0 C--N 1.34 0.788 0 N-CA-C 110.611 -0.995 . . . . 10.0 110.611 -178.497 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -94.54 119.29 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 C-N-CA 127.359 2.264 . . . . 10.0 105.434 172.532 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.75 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -115.82 126.6 54.21 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 123.706 0.802 . . . . 10.0 109.017 174.431 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -88.57 133.62 34.11 Favored 'General case' 0 N--CA 1.437 -1.096 0 C-N-CA 127.154 2.181 . . . . 10.0 109.567 178.936 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 50.1 t -113.97 130.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 C-N-CA 125.825 1.65 . . . . 10.0 108.228 174.624 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 78.1 p -157.78 73.81 0.71 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.132 0.973 . . . . 10.0 108.923 169.685 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.29 163.06 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 106.984 -1.487 . . . . 10.0 106.984 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -147.72 150.45 34.33 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 125.191 1.396 . . . . 10.0 109.933 174.333 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -155.32 159.28 39.84 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.323 -1.362 . . . . 10.0 107.323 172.881 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.2 p -104.81 -16.85 14.79 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 128.136 2.574 . . . . 10.0 112.281 179.053 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 4.5 p -78.34 -38.28 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 -176.387 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -70.64 154.72 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 C-N-CA 124.522 1.129 . . . . 10.0 107.978 168.771 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 11.1 m -153.77 163.28 40.28 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 172.088 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 79.2 mt -101.96 -11.06 19.24 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.797 0.839 . . . . 10.0 111.539 176.937 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.5 m -148.94 139.48 22.58 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.808 1.643 . . . . 10.0 107.239 169.498 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 178.54 -61.06 0.08 OUTLIER Glycine 0 C--O 1.227 -0.331 0 N-CA-C 107.296 -2.322 . . . . 10.0 107.296 171.017 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -169.71 -52.69 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 127.321 2.249 . . . . 10.0 106.804 174.102 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -78.39 -41.34 33.48 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 114.399 -1.273 . . . . 10.0 108.52 -174.506 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 111' ' ' SER . . . . . 0.681 ' O ' HG23 ' B' ' 112' ' ' ILE . 13.6 t 49.86 -105.75 0.19 Allowed 'General case' 0 N--CA 1.438 -1.069 0 C-N-CA 125.637 1.575 . . . . 10.0 108.182 -169.55 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.681 HG23 ' O ' ' B' ' 111' ' ' SER . 39.4 pt 162.87 -23.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.336 1 C-N-CA 133.226 4.61 . . . . 10.0 107.34 -171.482 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -43.25 120.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 118.854 0.752 . . . . 10.0 110.397 175.425 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 104.0 -6.55 47.53 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.786 -1.008 . . . . 10.0 113.781 179.025 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -77.1 154.64 33.1 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 118.309 1.055 . . . . 10.0 110.288 175.562 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 32.6 m -94.93 109.03 21.09 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.565 1.146 . . . . 10.0 109.183 178.553 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -79.57 147.92 31.94 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 167.272 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 65.3 t -142.63 132.87 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 C-N-CA 123.953 0.901 . . . . 10.0 109.551 -173.565 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.401 HG23 HD22 ' B' ' 8' ' ' LEU . 2.7 t -109.0 136.67 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.648 0 C-N-CA 126.173 1.789 . . . . 10.0 109.898 172.239 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.686 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.6 m-70 -117.52 158.68 24.13 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 116.466 2.024 . . . . 10.0 116.466 -171.179 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 57.8 tt0 -48.8 -53.06 20.72 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 129.836 3.254 . . . . 10.0 111.813 175.166 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -112.75 168.79 9.38 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 123.332 0.653 . . . . 10.0 111.876 -169.704 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.62 154.1 40.92 Favored 'General case' 0 N--CA 1.443 -0.82 0 O-C-N 125.016 1.448 . . . . 10.0 108.214 169.013 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -107.25 140.53 39.98 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 124.197 0.999 . . . . 10.0 109.032 -169.014 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -72.99 -28.99 62.71 Favored 'General case' 0 C--O 1.232 0.168 0 O-C-N 123.724 0.64 . . . . 10.0 109.803 -175.331 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.6 mt 59.86 50.95 6.4 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 107.896 -1.15 . . . . 10.0 107.896 -171.413 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 94.05 -39.33 2.94 Favored Glycine 0 CA--C 1.521 0.456 0 C-N-CA 126.189 1.852 . . . . 10.0 110.788 169.531 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 29.8 mtmm -80.91 39.79 0.51 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.004 0.922 . . . . 10.0 112.591 -169.485 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.18 -24.11 13.39 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 126.565 2.031 . . . . 10.0 110.262 169.186 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 59.94 36.11 89.15 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 123.732 0.682 . . . . 10.0 111.547 176.517 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -137.67 166.6 23.55 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 108.467 -0.938 . . . . 10.0 108.467 173.0 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -48.5 -47.4 38.79 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 124.363 1.065 . . . . 10.0 110.295 -178.586 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -70.48 -33.7 71.55 Favored 'General case' 0 N--CA 1.448 -0.549 0 O-C-N 121.922 -0.486 . . . . 10.0 111.671 179.417 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 26.6 p -55.69 -45.76 77.74 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 119.398 0.999 . . . . 10.0 110.435 177.274 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.5 t -76.3 -14.38 60.11 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.756 -0.656 . . . . 10.0 112.345 -171.728 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 10.5 ttmt -107.16 -49.34 3.29 Favored 'General case' 0 N--CA 1.434 -1.255 0 C-N-CA 125.987 1.715 . . . . 10.0 110.904 -172.141 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.03 23.77 2.58 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.972 0.806 . . . . 10.0 111.673 176.223 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 61.4 26.62 66.56 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 119.516 1.053 . . . . 10.0 111.951 177.983 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 57.16 23.19 8.32 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.286 1.043 . . . . 10.0 112.908 -178.798 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.58 -12.31 9.66 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 125.554 1.542 . . . . 10.0 114.045 -175.889 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.11 -162.92 52.93 Favored Glycine 0 N--CA 1.445 -0.765 0 O-C-N 121.029 -1.044 . . . . 10.0 110.849 172.193 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.4 m -56.19 128.32 35.04 Favored 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 124.097 0.959 . . . . 10.0 111.807 -167.96 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -73.48 98.78 2.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.45 1.1 . . . . 10.0 108.105 178.169 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 36.2 mt -79.24 -28.53 42.46 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.039 0.536 . . . . 10.0 112.024 -171.978 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.59 138.74 22.41 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.146 -0.687 . . . . 10.0 109.146 179.341 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -137.52 130.23 30.01 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 -178.185 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.24 -174.05 13.63 Favored Glycine 0 C--O 1.228 -0.235 0 N-CA-C 109.5 -1.44 . . . . 10.0 109.5 178.459 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.7 t -131.68 150.97 34.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 103.478 -2.786 . . . . 10.0 103.478 168.245 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.1 mt -60.12 -86.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.574 1.15 . . . . 10.0 111.534 -168.166 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.94 128.88 6.17 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 110.627 -0.989 . . . . 10.0 110.627 -179.01 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.6 pt -76.68 126.91 37.76 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 177.987 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.99 -45.68 12.86 Favored 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 108.533 -0.914 . . . . 10.0 108.533 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 . . . . . 0 C--O 1.253 1.262 0 CA-C-O 116.016 -1.945 . . . . 10.0 109.665 -176.064 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 106.331 -1.729 . . . . 10.0 106.331 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -88.81 -16.09 32.93 Favored 'General case' 0 C--O 1.228 -0.076 0 CA-C-N 119.917 1.235 . . . . 10.0 111.475 177.118 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -151.88 144.54 24.27 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.245 0.475 . . . . 10.0 112.261 177.792 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.2 160.62 37.28 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.832 1.653 . . . . 10.0 109.497 173.865 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 t -121.58 150.99 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 125.762 1.625 . . . . 10.0 109.93 179.502 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.55 100.59 5.01 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.782 1.233 . . . . 10.0 108.98 169.671 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -83.97 109.12 17.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 109.85 -0.426 . . . . 10.0 109.85 170.555 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -96.19 145.95 25.1 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.069 0.948 . . . . 10.0 109.316 177.419 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -157.89 164.53 36.82 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 107.89 -1.152 . . . . 10.0 107.89 171.227 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.07 -67.3 0.02 OUTLIER Glycine 0 C--O 1.229 -0.174 0 N-CA-C 111.574 -0.611 . . . . 10.0 111.574 171.804 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -75.99 -42.1 49.22 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 107.358 -1.349 . . . . 10.0 107.358 -176.557 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.98 -67.12 0.53 Allowed Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 114.851 -1.068 . . . . 10.0 111.615 -177.308 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -57.29 -41.69 70.5 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.157 1.904 . . . . 10.0 110.888 179.563 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -69.56 108.84 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 N-CA-C 107.176 -1.416 . . . . 10.0 107.176 176.843 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -120.48 117.51 27.84 Favored 'General case' 0 N--CA 1.437 -1.098 0 C-N-CA 126.049 1.74 . . . . 10.0 106.757 174.395 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.866 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.31 142.27 15.99 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 108.973 -1.651 . . . . 10.0 108.973 169.177 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.496 ' CG2' HG22 ' B' ' 54' ' ' THR . 2.3 mt -145.49 67.18 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 N-CA-C 106.049 -1.834 . . . . 10.0 106.049 -173.611 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.6 mm -90.91 135.51 26.53 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 CA-C-N 116.39 -0.368 . . . . 10.0 110.061 -172.4 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 m-80 -101.84 132.55 47.55 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 125.019 1.328 . . . . 10.0 108.708 175.589 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -116.18 87.41 2.68 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 126.626 1.97 . . . . 10.0 107.822 178.541 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -83.94 155.83 22.64 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-O 121.46 0.648 . . . . 10.0 111.169 175.68 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -145.23 99.16 3.27 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 126.068 1.747 . . . . 10.0 107.174 174.828 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.4 ptmt -62.31 -57.48 11.22 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 122.172 -0.33 . . . . 10.0 110.128 179.305 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -128.91 163.01 26.21 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 103.814 -2.661 . . . . 10.0 103.814 168.093 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.4 t -76.75 -4.59 44.19 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 119.172 0.897 . . . . 10.0 109.904 173.189 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -80.92 -21.86 40.15 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 124.452 1.101 . . . . 10.0 109.532 168.914 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.71 148.72 30.81 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 110.132 -1.187 . . . . 10.0 110.132 178.316 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -64.72 141.14 71.02 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 N-CA-C 107.803 -1.653 . . . . 10.0 107.803 169.245 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.8 t -78.3 83.12 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 174.241 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.0 tttt -63.33 111.58 2.34 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.915 -1.142 . . . . 10.0 107.915 171.429 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 18.1 m -91.62 121.67 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 N-CA-C 106.884 -1.524 . . . . 10.0 106.884 176.769 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 31.0 p90 -133.04 151.09 52.08 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 122.19 0.995 . . . . 10.0 113.145 170.5 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.08 -177.19 47.17 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 109.629 -1.388 . . . . 10.0 109.629 170.071 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.2 m -128.76 103.27 6.97 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.745 -1.206 . . . . 10.0 107.745 -173.551 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.866 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.7 pt -77.02 150.36 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.39 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 168.281 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.63 141.86 43.23 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.644 -0.502 . . . . 10.0 109.644 169.312 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.05 0.33 28.48 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.323 0.963 . . . . 10.0 112.899 175.76 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -65.12 176.05 1.41 Allowed 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 121.998 0.904 . . . . 10.0 109.669 169.922 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -98.92 167.1 10.95 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.649 -1.612 . . . . 10.0 106.649 164.95 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -58.19 169.08 0.89 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.398 1.079 . . . . 10.0 111.256 -171.251 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.94 -178.34 45.11 Favored Glycine 0 N--CA 1.448 -0.526 0 O-C-N 120.883 -1.136 . . . . 10.0 111.896 166.992 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.9 mp -70.63 153.3 42.99 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.283 1.433 . . . . 10.0 110.395 179.832 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -148.92 143.44 26.2 Favored 'General case' 0 C--N 1.34 0.185 0 N-CA-C 113.627 0.973 . . . . 10.0 113.627 -175.439 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.599 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.06 127.91 0.25 Allowed Glycine 0 C--N 1.34 0.777 0 C-N-CA 126.963 2.221 . . . . 10.0 111.644 164.391 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.39 103.48 2.33 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 119.744 1.772 . . . . 10.0 111.394 168.409 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.527 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.01 174.62 13.43 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 114.253 1.205 . . . . 10.0 114.253 -173.382 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.1 p -79.16 140.81 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 112.016 -2.356 . . . . 10.0 107.966 166.567 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.4 ' CD2' ' CG2' ' A' ' 118' ' ' VAL . 86.5 m-70 -126.17 100.5 6.35 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 102.875 -3.009 . . . . 10.0 102.875 163.861 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 6.89 -78.84 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 128.67 2.788 . . . . 10.0 116.017 178.773 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -81.69 162.22 23.08 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 119.166 0.894 . . . . 10.0 110.63 -171.098 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.01 -18.87 58.74 Favored Glycine 0 CA--C 1.524 0.61 0 O-C-N 121.306 -0.871 . . . . 10.0 110.956 170.91 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -65.34 162.82 16.76 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 122.275 1.036 . . . . 10.0 112.716 -170.268 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.424 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -161.58 17.91 0.11 Allowed 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 113.931 1.086 . . . . 10.0 113.931 -169.452 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.406 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -51.81 -37.89 53.52 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.489 1.116 . . . . 10.0 113.464 -169.003 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.22 -21.94 45.56 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 112.306 0.484 . . . . 10.0 112.306 179.485 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.61 100.9 2.65 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 -174.313 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 52.0 30.68 7.66 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 125.379 1.472 . . . . 10.0 114.502 169.147 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.8 m -133.79 -59.35 0.85 Allowed 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 106.816 -1.55 . . . . 10.0 106.816 -173.585 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.3 m -47.5 -46.12 26.96 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 126.5 1.92 . . . . 10.0 111.52 -169.469 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.88 -49.7 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 128.239 2.616 . . . . 10.0 114.975 169.4 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.12 171.37 12.95 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.769 -0.932 . . . . 10.0 110.769 173.094 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -79.45 -136.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 123.384 2.723 . . . . 10.0 106.092 166.022 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 18.1 m170 -106.29 50.35 0.78 Allowed 'General case' 0 CA--C 1.544 0.733 0 CA-C-N 121.67 2.032 . . . . 10.0 110.102 171.371 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -78.69 61.35 2.97 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.618 1.554 . . . . 10.0 110.218 174.591 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -61.94 155.97 59.97 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 127.581 2.353 . . . . 10.0 111.138 171.089 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.19 -58.28 0.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.228 2.618 . . . . 10.0 112.75 178.452 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -78.05 58.64 2.02 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.941 0.791 . . . . 10.0 110.509 -177.983 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.8 t -59.08 110.76 1.11 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 122.913 0.485 . . . . 10.0 109.752 -174.709 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 65.8 mtt180 -127.2 -90.08 0.53 Allowed 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 105.361 -2.089 . . . . 10.0 105.361 178.166 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.1 mttm -144.43 156.35 44.16 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.001 0.905 . . . . 10.0 108.812 169.999 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -63.29 120.2 11.11 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 118.493 -1.283 . . . . 10.0 107.804 166.656 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.12 -156.64 7.04 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 106.571 -2.612 . . . . 10.0 106.571 177.282 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -151.14 -159.35 8.79 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 118.442 1.121 . . . . 10.0 112.007 178.781 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -71.1 12.11 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 121.414 1.409 . . . . 10.0 109.466 165.724 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 37.5 mmtm -95.87 -24.78 16.28 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 169.704 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.426 ' OD1' ' NZ ' ' A' ' 128' ' ' LYS . 20.4 m-20 -115.56 171.27 7.83 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 -170.016 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -121.14 10.13 10.63 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.539 1.135 . . . . 10.0 110.279 171.394 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -109.16 6.47 24.85 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.515 1.126 . . . . 10.0 110.497 172.098 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -47.3 148.27 1.33 Allowed 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.531 1.532 . . . . 10.0 110.263 178.058 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -60.78 -64.11 1.07 Allowed 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 117.842 0.292 . . . . 10.0 111.185 -176.168 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.8 p -167.89 -51.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 C-N-CA 123.739 0.815 . . . . 10.0 109.266 174.552 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -136.51 47.96 0.94 Allowed Glycine 0 CA--C 1.526 0.741 0 C-N-CA 123.939 0.78 . . . . 10.0 111.327 -175.198 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -86.23 109.11 18.7 Favored 'General case' 0 CA--C 1.53 0.173 0 N-CA-C 105.068 -2.197 . . . . 10.0 105.068 168.395 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.3 mt -74.85 -14.57 60.69 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 118.607 0.639 . . . . 10.0 111.744 -170.94 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.61 -97.93 1.14 Allowed Glycine 0 N--CA 1.44 -1.048 0 N-CA-C 107.434 -2.267 . . . . 10.0 107.434 178.907 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -153.0 120.68 6.02 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 -172.317 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.1 m -102.53 147.27 9.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 N-CA-C 106.039 -1.838 . . . . 10.0 106.039 168.957 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -120.45 133.12 55.47 Favored 'General case' 0 C--N 1.334 -0.095 0 C-N-CA 123.426 0.69 . . . . 10.0 111.588 -173.358 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.75 132.75 48.69 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.244 1.018 . . . . 10.0 111.361 -175.025 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.04 172.74 0.53 Allowed 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 122.496 1.141 . . . . 10.0 110.319 167.778 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 mtmp? -63.15 -19.49 64.52 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 114.309 -1.314 . . . . 10.0 112.425 178.433 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -77.8 -20.31 53.47 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 122.35 0.26 . . . . 10.0 110.741 173.881 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.85 6.67 60.43 Favored Glycine 0 C--N 1.338 0.684 0 CA-C-O 118.749 -1.028 . . . . 10.0 110.685 -170.19 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 t -79.37 114.61 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 C-N-CA 125.502 1.521 . . . . 10.0 107.154 176.265 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.683 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -115.38 123.93 49.93 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.865 -0.791 . . . . 10.0 108.865 174.353 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -78.84 129.03 34.12 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.327 -0.99 . . . . 10.0 108.327 171.745 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.4 t -112.15 129.84 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 104.179 -2.526 . . . . 10.0 104.179 167.723 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.9 p -157.79 57.27 0.48 Allowed 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 123.025 0.53 . . . . 10.0 110.844 174.596 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.36 148.67 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 124.087 0.955 . . . . 10.0 109.024 -169.883 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -129.27 123.66 32.47 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.535 1.134 . . . . 10.0 110.243 174.253 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -127.61 107.15 9.67 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.823 1.649 . . . . 10.0 108.511 -177.653 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 45.2 p -85.22 58.54 5.09 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.823 2.049 . . . . 10.0 107.195 -171.294 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.3 p -142.07 -48.87 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 123.996 0.919 . . . . 10.0 109.307 -176.273 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.312 0.0 OUTLIER -79.91 174.65 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 N-CA-C 113.023 0.749 . . . . 10.0 113.023 174.933 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -167.88 155.0 8.17 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.994 1.318 . . . . 10.0 107.901 169.39 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 70.3 mt -62.29 -24.53 67.34 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 123.413 0.685 . . . . 10.0 111.214 -176.087 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.9 m -147.87 161.32 41.54 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.856 -1.905 . . . . 10.0 105.856 169.723 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 154.82 -74.57 0.24 Allowed Glycine 0 C--N 1.334 0.434 0 N-CA-C 109.925 -1.27 . . . . 10.0 109.925 -177.457 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -152.19 -53.69 0.12 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.768 2.027 . . . . 10.0 106.387 178.698 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -75.0 -38.6 61.54 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 114.069 -1.423 . . . . 10.0 108.507 -175.002 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.3 t 46.5 56.17 6.72 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.86 1.264 . . . . 10.0 110.309 169.401 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -66.77 6.92 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 N-CA-C 115.647 1.721 . . . . 10.0 115.647 -166.424 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.7 mm -57.41 142.02 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 167.103 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.95 19.21 79.77 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-O 118.916 -0.935 . . . . 10.0 114.033 175.129 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -79.81 175.87 10.24 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 106.779 -1.563 . . . . 10.0 106.779 166.035 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 16.5 m -111.64 131.92 54.94 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 103.302 -2.851 . . . . 10.0 103.302 169.467 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.422 HD12 ' HA ' ' A' ' 117' ' ' LEU . 0.5 OUTLIER -96.3 135.81 37.63 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 105.751 -1.944 . . . . 10.0 105.751 167.455 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.4 ' CG2' ' CD2' ' A' ' 48' ' ' HIS . 86.8 t -118.84 132.95 67.23 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.874 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 169.148 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.07 127.51 58.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.75 -1.945 . . . . 10.0 105.75 168.028 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.599 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.4 m-70 -103.69 159.13 15.88 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 123.529 1.633 . . . . 10.0 114.946 -169.835 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.687 ' HA ' HD22 ' A' ' 144' ' ' LEU . 10.6 tt0 -43.71 -60.73 1.66 Allowed 'General case' 0 N--CA 1.442 -0.873 0 C-N-CA 129.079 2.951 . . . . 10.0 110.041 172.62 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mtmm -115.93 175.4 5.56 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.912 1.285 . . . . 10.0 111.638 -171.897 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.57 149.54 32.99 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 125.938 1.695 . . . . 10.0 111.161 -176.963 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.527 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.9 m-20 -79.34 144.06 34.57 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.517 0.727 . . . . 10.0 112.567 175.502 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 m-20 -77.18 -35.55 55.74 Favored 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 124.781 1.301 . . . . 10.0 108.974 167.96 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 57.0 mt 66.55 48.8 1.43 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 125.439 1.496 . . . . 10.0 109.368 -167.689 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.83 50.21 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 125.243 1.402 . . . . 10.0 113.001 172.556 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.426 ' NZ ' ' OD1' ' A' ' 76' ' ' ASP . 18.1 mttm -78.82 -1.71 36.2 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.711 0.805 . . . . 10.0 111.273 -168.598 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.91 -26.58 73.2 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 109.087 -1.605 . . . . 10.0 109.087 166.387 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.32 39.25 82.1 Favored Glycine 0 C--N 1.341 0.856 0 N-CA-C 110.822 -0.911 . . . . 10.0 110.822 -179.544 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.9 m-80 -122.06 161.71 22.53 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 176.132 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.407 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 3.8 tm-20 -48.72 -45.5 39.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 113.388 -1.733 . . . . 10.0 108.781 171.038 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -64.76 -49.7 69.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.167 -0.47 . . . . 10.0 111.714 172.217 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.7 t -52.97 -44.72 67.36 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 120.552 -1.342 . . . . 10.0 110.65 -175.418 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.1 t -74.95 -5.98 46.8 Favored 'General case' 0 CA--C 1.538 0.492 0 O-C-N 123.186 0.304 . . . . 10.0 111.542 -174.955 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.407 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 87.9 mttt -102.83 -83.05 0.48 Allowed 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 126.578 1.951 . . . . 10.0 110.147 172.583 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.21 25.84 10.99 Favored 'General case' 0 C--N 1.345 0.391 0 CA-C-N 121.298 1.863 . . . . 10.0 112.988 -177.02 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 59.72 27.66 64.36 Favored Glycine 0 C--N 1.339 0.721 0 CA-C-N 118.942 0.792 . . . . 10.0 112.397 170.001 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.0 m-80 50.21 27.86 2.83 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 123.988 0.915 . . . . 10.0 112.689 -173.501 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.52 -3.85 9.85 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.527 -0.733 . . . . 10.0 112.243 179.694 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.35 -163.6 51.92 Favored Glycine 0 N--CA 1.443 -0.894 0 N-CA-C 110.866 -0.893 . . . . 10.0 110.866 169.192 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.8 m -56.98 142.22 42.58 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.5 0.667 . . . . 10.0 111.612 -169.248 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.0 mtp85 -68.9 64.79 0.12 Allowed 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 125.627 1.571 . . . . 10.0 109.681 175.357 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.687 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.9 tp -43.91 -35.11 1.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.669 1.988 . . . . 10.0 113.917 -174.537 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -162.53 159.06 24.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -162.16 168.15 22.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 -174.881 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.47 169.77 42.77 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 112.094 -0.402 . . . . 10.0 112.094 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.409 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 4.8 t -107.28 138.78 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 -171.304 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mt -80.11 136.58 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-N 118.0 0.364 . . . . 10.0 110.607 179.568 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.05 146.99 17.5 Favored Glycine 0 CA--C 1.53 0.984 0 C-N-CA 125.068 1.318 . . . . 10.0 110.81 176.977 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 10.8 pt -71.49 142.07 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.138 0 CA-C-N 117.82 0.81 . . . . 10.0 109.28 176.771 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.52 -19.71 8.05 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.282 1.433 . . . . 10.0 113.313 -176.372 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.9 tp60 . . . . . 0 C--O 1.254 1.298 0 C-N-CA 130.278 3.431 . . . . 10.0 117.278 -175.504 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 117.652 -1.166 . . . . 10.0 108.997 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.3 t -76.02 -37.35 58.51 Favored 'General case' 0 CA--C 1.516 -0.327 0 CA-C-N 120.217 1.371 . . . . 10.0 110.41 -178.767 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -124.54 136.44 53.99 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 123.377 0.671 . . . . 10.0 111.201 -171.561 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.36 165.5 28.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.146 1.378 . . . . 10.0 107.502 171.004 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.441 ' O ' HG23 ' B' ' 149' ' ' ILE . 7.9 m -128.32 -178.28 2.29 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 123.367 0.667 . . . . 10.0 110.114 178.904 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.39 110.97 4.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.774 1.23 . . . . 10.0 108.262 165.453 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.424 HG21 ' HB3' ' A' ' 53' ' ' ASN . 3.2 m -95.83 104.52 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 123.786 0.835 . . . . 10.0 109.615 170.633 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.413 ' N ' HD12 ' B' ' 8' ' ' LEU . 5.7 mp -95.06 135.57 36.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 124.026 0.93 . . . . 10.0 110.035 -177.947 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 43.2 mtpt -149.22 169.48 20.65 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 107.459 -1.312 . . . . 10.0 107.459 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.38 -72.6 0.04 OUTLIER Glycine 0 C--O 1.229 -0.201 0 CA-C-N 115.944 -0.571 . . . . 10.0 111.68 174.394 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -74.09 -41.29 61.91 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.15 -1.426 . . . . 10.0 107.15 -178.295 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.84 -65.92 0.58 Allowed Glycine 0 CA--C 1.526 0.759 0 C-N-CA 124.836 1.207 . . . . 10.0 110.498 -178.978 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -79.14 37.48 0.67 Allowed 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 124.874 3.716 . . . . 10.0 111.446 -175.282 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -148.74 108.11 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.534 0 N-CA-C 100.405 -3.924 . . . . 10.0 100.405 173.244 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.47 122.84 28.43 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 177.101 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.571 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -107.56 140.21 15.3 Favored Glycine 0 C--O 1.224 -0.508 0 N-CA-C 110.493 -1.043 . . . . 10.0 110.493 -179.745 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.406 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.6 mt -139.98 88.75 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.148 -1.427 . . . . 10.0 107.148 -174.317 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -100.23 146.52 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.13 0 C-N-CA 124.978 1.311 . . . . 10.0 111.288 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -123.99 121.3 34.91 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 127.056 2.142 . . . . 10.0 108.102 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -99.32 108.0 20.42 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.855 1.262 . . . . 10.0 107.999 171.761 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -105.13 139.08 40.34 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 119.039 0.836 . . . . 10.0 109.534 167.421 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -116.91 106.13 13.1 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.668 -1.604 . . . . 10.0 106.668 168.22 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt -152.19 79.13 1.24 Allowed 'General case' 0 N--CA 1.424 -1.731 0 C-N-CA 125.343 1.457 . . . . 10.0 108.926 -178.317 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -158.45 165.05 35.56 Favored 'General case' 0 N--CA 1.434 -1.265 0 N-CA-C 102.647 -3.094 . . . . 10.0 102.647 165.063 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 10.2 t -72.32 -18.3 61.78 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 121.372 0.606 . . . . 10.0 109.446 170.565 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 14.0 m-80 -79.95 -10.42 59.77 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.656 -0.498 . . . . 10.0 109.656 173.582 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.71 44.76 23.91 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-O 117.581 -1.677 . . . . 10.0 115.218 -178.64 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -73.86 140.76 29.31 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 122.527 2.151 . . . . 10.0 108.77 175.091 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -85.81 99.5 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 107.212 -1.403 . . . . 10.0 107.212 173.754 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 60.4 mttm -79.3 109.06 13.29 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.489 -1.3 . . . . 10.0 107.489 174.093 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.39 97.21 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 126.446 1.899 . . . . 10.0 107.392 -178.153 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.7 p90 -116.18 171.31 7.89 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.245 0.545 . . . . 10.0 110.144 169.715 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.26 -165.41 36.59 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 111.126 -0.789 . . . . 10.0 111.126 170.069 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.3 m -154.68 107.86 2.84 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 108.876 -0.787 . . . . 10.0 108.876 -170.832 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.571 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.9 pt -79.87 177.71 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 108.869 -0.789 . . . . 10.0 108.869 169.01 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 tptt -153.5 153.88 33.29 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 170.858 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.17 -38.94 2.67 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 118.51 0.595 . . . . 10.0 111.622 169.728 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.519 ' H ' HD12 ' B' ' 38' ' ' LEU . 6.0 mp -64.14 177.0 0.87 Allowed 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 122.034 0.921 . . . . 10.0 111.664 -170.031 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -103.58 162.05 13.38 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.617 -0.719 . . . . 10.0 109.186 168.731 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -52.32 153.48 2.87 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 125.584 1.553 . . . . 10.0 112.18 -169.456 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.81 -173.41 20.04 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 123.517 0.58 . . . . 10.0 111.858 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -74.64 151.25 39.34 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.937 1.295 . . . . 10.0 110.364 -177.665 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -150.18 151.86 33.74 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 123.634 0.774 . . . . 10.0 112.605 -178.392 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.583 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -44.75 127.18 7.09 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 127.259 2.362 . . . . 10.0 110.96 165.985 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -154.73 111.17 3.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 119.038 1.419 . . . . 10.0 108.862 165.771 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.404 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -155.4 167.64 29.72 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-O 121.312 0.577 . . . . 10.0 111.466 179.285 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.0 m -86.51 149.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 112.504 -2.135 . . . . 10.0 106.563 168.014 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -117.57 164.01 15.58 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 123.014 0.526 . . . . 10.0 110.263 176.292 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -52.57 -54.41 33.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.162 0.985 . . . . 10.0 112.589 -176.025 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -106.54 -178.45 3.65 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 118.829 0.741 . . . . 10.0 109.381 178.219 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -139.47 13.41 3.22 Favored Glycine 0 C--N 1.333 0.382 0 O-C-N 122.109 -0.369 . . . . 10.0 113.461 176.093 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -67.13 153.31 43.98 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 107.276 -1.379 . . . . 10.0 107.276 167.188 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -149.13 22.53 0.96 Allowed 'General case' 0 N--CA 1.451 -0.421 0 O-C-N 121.649 -0.657 . . . . 10.0 112.189 -172.372 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.496 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -49.23 -38.42 26.46 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.758 2.023 . . . . 10.0 112.447 -177.489 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.2 -19.77 56.27 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 122.136 -0.353 . . . . 10.0 111.916 -178.278 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 125.9 -66.97 0.54 Allowed Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.309 -1.117 . . . . 10.0 110.309 -176.857 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 35.0 t -160.05 70.06 0.42 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 122.391 1.091 . . . . 10.0 110.625 -178.73 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -163.17 -50.73 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 125.282 1.433 . . . . 10.0 109.253 -174.235 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -48.8 -38.67 22.75 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 125.667 1.587 . . . . 10.0 111.447 -171.218 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.12 -41.54 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 128.662 2.785 . . . . 10.0 114.351 168.63 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.85 161.88 29.84 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 107.647 -2.181 . . . . 10.0 107.647 177.392 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -68.88 -143.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.547 1.132 0 C-N-CA 121.894 1.729 . . . . 10.0 109.615 169.783 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.6 m170 -104.17 42.91 1.14 Allowed 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.267 -1.52 . . . . 10.0 110.629 -179.665 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -73.31 71.98 1.26 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 120.601 1.546 . . . . 10.0 111.32 -179.707 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -62.56 155.06 70.76 Favored Pre-proline 0 CA--C 1.538 0.499 0 C-N-CA 124.218 1.007 . . . . 10.0 111.614 169.837 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.62 -47.95 2.54 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.282 1.988 . . . . 10.0 111.361 176.838 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.85 68.33 1.29 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.774 -0.579 . . . . 10.0 110.816 175.488 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 14.1 t -40.81 102.88 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.427 1.891 . . . . 10.0 111.782 -178.627 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.8 mtt85 -130.28 175.43 8.94 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 126.275 1.83 . . . . 10.0 108.863 177.07 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 62.0 mmtt -106.19 84.11 1.99 Allowed 'General case' 0 CA--C 1.531 0.227 0 CA-C-O 121.457 0.646 . . . . 10.0 112.473 -170.887 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 54.2 t60 13.79 88.39 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.433 2.293 . . . . 10.0 115.594 174.044 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -121.27 -164.6 12.37 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 126.985 2.231 . . . . 10.0 109.004 178.627 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.59 -154.88 15.24 Favored Glycine 0 C--O 1.227 -0.304 0 N-CA-C 106.973 -2.451 . . . . 10.0 106.973 -172.357 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -64.13 9.56 0.14 Allowed 'Trans proline' 0 CA--C 1.542 0.915 0 CA-C-N 120.119 1.96 . . . . 10.0 112.414 169.095 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.65 -31.33 11.27 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.738 1.215 . . . . 10.0 111.209 170.249 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -141.46 154.9 45.83 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-N 119.277 0.944 . . . . 10.0 110.445 -170.197 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 49.2 tt0 -75.87 -20.54 58.01 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.053 -1.091 . . . . 10.0 108.053 178.906 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -80.38 30.93 0.28 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.741 1.216 . . . . 10.0 112.096 -178.384 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -57.52 138.77 54.79 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.111 -0.993 . . . . 10.0 109.135 171.221 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -74.72 -61.03 2.02 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 179.776 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -156.42 -125.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 105.863 -1.903 . . . . 10.0 105.863 -174.444 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -74.4 69.96 1.66 Allowed Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.357 -1.097 . . . . 10.0 110.357 175.891 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -95.94 93.25 6.91 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 106.947 -1.501 . . . . 10.0 106.947 170.209 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.3 mt -65.19 -29.69 70.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.895 0.855 . . . . 10.0 108.987 178.814 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.87 -79.8 0.29 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 169.284 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 86' ' ' ASN . . . . . 0.484 HD22 ' HB1' ' B' ' 123' ' ' ALA . 23.6 m120 -144.17 108.07 4.71 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 118.185 -0.912 . . . . 10.0 108.627 -173.366 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.9 m -105.63 130.76 56.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 119.677 1.126 . . . . 10.0 111.924 -179.029 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -90.48 123.02 33.83 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 128.804 2.841 . . . . 10.0 111.269 -169.973 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.39 137.88 42.48 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 124.118 0.967 . . . . 10.0 111.411 177.198 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -62.08 171.65 1.69 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 124.325 1.05 . . . . 10.0 109.458 166.46 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.68 -28.96 58.38 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.554 0.742 . . . . 10.0 111.781 173.245 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -78.27 -3.94 45.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.336 0.588 . . . . 10.0 110.192 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.85 -0.63 82.61 Favored Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 110.257 -1.137 . . . . 10.0 110.257 -177.491 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.7 t -78.83 101.28 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 -173.154 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.49 117.19 30.39 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.45 -0.944 . . . . 10.0 108.45 168.392 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.37 106.84 12.69 Favored 'General case' 0 N--CA 1.435 -1.199 0 C-N-CA 126.814 2.046 . . . . 10.0 109.364 172.428 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 95.8 t -96.3 134.48 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.876 0 N-CA-C 106.964 -1.495 . . . . 10.0 106.964 178.626 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -158.22 79.09 0.82 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.382 0.673 . . . . 10.0 111.502 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -122.3 164.58 19.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 106.064 -1.828 . . . . 10.0 106.064 -179.419 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -138.1 145.0 41.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 121.469 -0.77 . . . . 10.0 111.498 168.743 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -109.62 104.15 13.12 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 125.769 1.628 . . . . 10.0 107.74 178.703 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 67.8 p -86.25 52.75 2.57 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 172.984 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 p -157.77 -49.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 C-N-CA 123.464 0.706 . . . . 10.0 109.325 -174.431 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 48.7 mm -66.58 155.46 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 108.704 -0.851 . . . . 10.0 108.704 169.845 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 41.3 m -153.13 137.35 16.51 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.232 -1.025 . . . . 10.0 108.232 174.455 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 34.5 mt -73.57 53.05 0.41 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.833 1.653 . . . . 10.0 111.459 177.28 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.6 m -87.16 -165.24 1.24 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 127.942 2.497 . . . . 10.0 109.896 179.277 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -106.2 -25.61 6.33 Favored Glycine 0 CA--C 1.527 0.82 0 C-N-CA 125.093 1.33 . . . . 10.0 111.725 176.804 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -70.15 -56.98 5.48 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 126.029 1.731 . . . . 10.0 108.31 -175.03 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -87.02 -39.32 15.76 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.176 -1.375 . . . . 10.0 109.174 178.126 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 31.81 79.76 0.02 OUTLIER 'General case' 0 C--O 1.237 0.402 0 C-N-CA 126.223 1.809 . . . . 10.0 113.079 178.969 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.458 HD13 ' H ' ' B' ' 112' ' ' ILE . 0.1 OUTLIER -76.79 55.5 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-O 122.183 0.992 . . . . 10.0 109.518 167.439 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -117.75 -49.08 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 127.969 2.508 . . . . 10.0 108.295 178.659 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.04 10.25 71.47 Favored Glycine 0 CA--C 1.532 1.142 0 CA-C-O 119.193 -0.782 . . . . 10.0 112.794 -176.76 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -88.29 162.24 16.72 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 125.484 1.514 . . . . 10.0 108.892 178.678 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -103.84 140.24 37.92 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.505 0.722 . . . . 10.0 109.898 169.568 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.465 HD23 HG12 ' B' ' 149' ' ' ILE . 4.5 mm? -92.3 140.18 29.87 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 106.169 -1.789 . . . . 10.0 106.169 166.748 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 60.4 t -125.94 135.5 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 N-CA-C 107.563 -1.273 . . . . 10.0 107.563 174.736 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 8.6 p -105.39 129.68 57.88 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 106.216 -1.772 . . . . 10.0 106.216 169.109 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.583 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.5 m170 -113.31 157.75 21.42 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 115.13 1.53 . . . . 10.0 115.13 -169.362 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 58.3 tt0 -39.36 -63.24 0.57 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 128.518 2.727 . . . . 10.0 110.288 171.082 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 57.6 mttt -118.86 173.24 6.99 Favored 'General case' 0 CA--C 1.513 -0.461 0 C-N-CA 123.492 0.717 . . . . 10.0 109.685 -174.687 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 123' ' ' ALA . . . . . 0.484 ' HB1' HD22 ' B' ' 86' ' ' ASN . . . -92.41 148.78 21.84 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 179.309 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.643 ' HB2' ' CD2' ' B' ' 126' ' ' LEU . 0.9 OUTLIER -74.69 160.97 30.1 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.253 0.549 . . . . 10.0 111.675 -174.974 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.39 -28.53 61.14 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 114.624 -1.171 . . . . 10.0 110.152 174.855 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.643 ' CD2' ' HB2' ' B' ' 124' ' ' ASP . 2.8 mm? 62.57 56.95 1.93 Allowed 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 125.585 1.554 . . . . 10.0 109.847 -173.437 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 81.54 -40.57 2.61 Favored Glycine 0 CA--C 1.525 0.687 0 CA-C-N 113.971 -1.468 . . . . 10.0 111.78 168.115 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -77.13 49.29 0.67 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.048 1.339 . . . . 10.0 111.173 177.35 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.72 -32.67 4.69 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 126.226 1.869 . . . . 10.0 110.427 173.614 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.58 42.76 99.31 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.673 -0.971 . . . . 10.0 110.673 -171.761 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -132.76 163.35 29.21 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 106.607 -1.627 . . . . 10.0 106.607 173.338 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.57 -52.31 64.17 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 108.46 -0.941 . . . . 10.0 108.46 171.625 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -53.7 -33.54 55.85 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.216 -0.897 . . . . 10.0 112.416 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 21.0 p -52.15 -41.81 62.86 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-N 119.497 1.044 . . . . 10.0 110.649 179.21 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -85.01 -3.48 58.8 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-O 118.517 -0.754 . . . . 10.0 112.914 -178.97 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.95 -60.74 1.81 Allowed 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 126.291 1.836 . . . . 10.0 112.501 -174.223 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -136.25 23.77 3.24 Favored 'General case' 0 CA--C 1.547 0.827 0 CA-C-N 119.488 1.04 . . . . 10.0 110.483 175.447 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.16 -98.03 0.62 Allowed Glycine 0 C--N 1.342 0.91 0 N-CA-C 108.764 -1.734 . . . . 10.0 108.764 -177.461 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -165.34 43.57 0.08 Allowed 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 107.872 -1.158 . . . . 10.0 107.872 170.481 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.61 -19.69 64.01 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.396 0.678 . . . . 10.0 112.565 -174.13 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.01 -147.42 30.47 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 109.94 -1.264 . . . . 10.0 109.94 172.344 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.8 t -68.61 126.81 30.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.559 0.695 . . . . 10.0 110.64 -170.023 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.06 78.32 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.845 0.858 . . . . 10.0 110.604 169.502 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 56.5 mt -52.49 -40.17 62.05 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.922 -0.486 . . . . 10.0 112.11 179.331 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -149.13 145.65 27.3 Favored 'General case' 0 C--O 1.233 0.236 0 O-C-N 121.628 -0.67 . . . . 10.0 111.676 -179.574 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 m -123.72 147.9 47.06 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 126.686 1.995 . . . . 10.0 108.034 -178.224 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.61 141.95 10.82 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 109.761 -1.336 . . . . 10.0 109.761 171.598 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.409 ' HB ' ' HB ' ' A' ' 148' ' ' VAL . 95.8 t -89.8 150.57 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 102.894 -3.002 . . . . 10.0 102.894 172.646 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.465 HG12 HD23 ' B' ' 117' ' ' LEU . 90.4 mt -72.16 -88.03 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-O 121.474 0.654 . . . . 10.0 110.26 -167.566 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 99.87 132.69 7.82 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 124.329 0.966 . . . . 10.0 111.529 177.69 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 73.6 mt -63.31 147.75 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 125.155 1.382 . . . . 10.0 107.75 174.307 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.73 -32.81 4.43 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 113.466 0.913 . . . . 10.0 113.466 174.121 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? . . . . . 0 C--O 1.246 0.898 0 N-CA-C 108.042 -1.096 . . . . 10.0 108.042 178.66 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.444 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.5 t -166.22 -41.08 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 127.159 2.184 . . . . 10.0 112.938 178.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -119.37 137.29 53.83 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.244 -1.761 . . . . 10.0 106.244 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -136.73 145.21 44.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.578 HG12 ' HB2' ' A' ' 152' ' ' ALA . 0.2 OUTLIER -134.99 150.04 29.59 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.236 0 N-CA-C 107.003 -1.481 . . . . 10.0 107.003 174.476 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.694 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -127.03 129.19 47.56 Favored 'General case' 0 CA--C 1.512 -0.499 0 C-N-CA 126.938 2.095 . . . . 10.0 105.457 168.068 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.444 HG12 HG23 ' A' ' 17' ' ' ILE . 35.1 m -98.78 121.89 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 168.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -97.16 149.23 22.23 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 119.095 0.861 . . . . 10.0 109.046 177.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.47 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 13.1 tttt -159.29 160.35 35.08 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 108.432 -0.951 . . . . 10.0 108.432 169.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.35 -53.68 0.06 OUTLIER Glycine 0 C--N 1.332 0.35 0 N-CA-C 111.684 -0.566 . . . . 10.0 111.684 170.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -74.1 -45.86 46.44 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.36 -67.75 0.54 Allowed Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.031 -1.441 . . . . 10.0 110.568 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -57.11 -42.94 58.13 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.451 2.101 . . . . 10.0 110.41 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.2 t -63.94 97.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 106.522 -1.658 . . . . 10.0 106.522 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -116.28 118.6 33.21 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.129 -1.434 . . . . 10.0 107.129 169.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.426 ' HA2' ' CG2' ' A' ' 35' ' ' ILE . . . -99.17 152.95 19.68 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 109.931 -1.268 . . . . 10.0 109.931 174.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.444 HG23 HG12 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -156.47 83.69 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 -172.166 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.612 HD12 ' HA3' ' A' ' 33' ' ' GLY . 1.1 tp -85.35 157.21 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 C-N-CA 125.166 1.387 . . . . 10.0 111.016 176.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.438 ' HB2' ' CD1' ' A' ' 32' ' ' TRP . 5.1 m120 -139.1 99.5 3.78 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 127.567 2.347 . . . . 10.0 106.621 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 m-30 -99.07 102.85 14.68 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 105.194 -2.15 . . . . 10.0 105.194 174.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -117.67 132.48 56.48 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 120.409 -0.516 . . . . 10.0 111.591 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -104.36 107.99 19.18 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.701 -1.222 . . . . 10.0 107.701 172.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.2 pttp -54.53 -40.84 69.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 122.955 0.502 . . . . 10.0 110.65 174.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -146.37 172.92 12.78 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 104.937 -2.246 . . . . 10.0 104.937 168.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 86.8 p -69.12 -20.8 64.05 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 124.13 0.972 . . . . 10.0 109.576 174.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -93.89 -3.06 52.42 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.822 -0.627 . . . . 10.0 111.119 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.18 144.8 18.18 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 173.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -61.36 149.7 88.29 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 N-CA-C 106.902 -1.999 . . . . 10.0 106.902 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.7 t -79.0 120.96 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 N-CA-C 104.754 -2.313 . . . . 10.0 104.754 176.178 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.6 tttt -83.24 113.26 20.56 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 105.558 -2.015 . . . . 10.0 105.558 169.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.7 m -97.31 59.14 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 C-N-CA 125.774 1.63 . . . . 10.0 107.975 -170.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.438 ' CD1' ' HB2' ' A' ' 19' ' ' ASN . 14.8 p90 -84.7 171.85 12.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.167 -0.679 . . . . 10.0 109.167 -171.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.612 ' HA3' HD12 ' A' ' 18' ' ' ILE . . . 169.12 175.25 38.3 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 119.823 -1.179 . . . . 10.0 112.489 178.247 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.3 p -149.03 85.18 1.46 Allowed 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 121.066 0.46 . . . . 10.0 111.972 -169.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.707 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -76.83 147.19 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 107.664 -1.235 . . . . 10.0 107.664 174.446 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.99 156.14 46.77 Favored 'General case' 0 C--O 1.232 0.157 0 O-C-N 124.102 0.876 . . . . 10.0 110.015 167.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.22 2.86 48.16 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 124.043 0.83 . . . . 10.0 114.52 177.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.45 HD12 ' N ' ' A' ' 38' ' ' LEU . 5.3 mp -87.75 176.64 7.3 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.542 1.137 . . . . 10.0 108.778 -177.27 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -91.06 172.71 8.38 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 165.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -64.33 176.02 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.226 1.01 . . . . 10.0 110.889 -172.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.63 175.46 48.42 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 124.137 0.875 . . . . 10.0 111.581 167.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.443 HD22 ' HB3' ' A' ' 86' ' ' ASN . 4.7 mt -62.24 147.58 47.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.332 -0.511 . . . . 10.0 110.173 171.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -133.59 147.03 51.48 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.637 0.775 . . . . 10.0 110.678 176.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.621 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -36.14 112.89 0.14 Allowed Glycine 0 CA--C 1.526 0.736 0 CA-C-O 116.105 -2.497 . . . . 10.0 113.445 164.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -137.08 107.65 6.53 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 121.522 2.661 . . . . 10.0 111.916 170.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.452 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -148.17 -178.99 6.6 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 113.783 1.031 . . . . 10.0 113.783 -175.442 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.7 p -91.5 -47.59 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 127.554 2.342 . . . . 10.0 114.506 -169.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 57.1 161.96 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 125.498 1.519 . . . . 10.0 112.431 -169.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -78.01 -67.85 0.69 Allowed 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.944 -0.571 . . . . 10.0 109.862 -176.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -78.63 146.27 34.21 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 119.954 -0.699 . . . . 10.0 109.432 -171.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -75.74 -28.42 61.09 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 108.905 -1.678 . . . . 10.0 108.905 169.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.3 145.68 1.62 Allowed 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.746 1.26 . . . . 10.0 113.995 -175.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -135.8 16.06 3.33 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 113.679 -1.6 . . . . 10.0 110.453 -178.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.424 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -58.08 -36.45 72.86 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 119.181 0.901 . . . . 10.0 112.477 -169.745 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.07 -17.71 58.54 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 111.778 0.288 . . . . 10.0 111.778 178.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 97.85 84.18 1.74 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.107 -1.597 . . . . 10.0 109.107 -173.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 94.2 m 48.81 57.13 6.71 Favored 'General case' 0 N--CA 1.464 0.228 0 C-N-CA 124.305 1.042 . . . . 10.0 111.391 175.268 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -157.66 -54.61 0.07 Allowed 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.6 p -54.73 -30.26 55.73 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 124.121 0.968 . . . . 10.0 111.023 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.26 -38.47 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 127.977 2.511 . . . . 10.0 113.995 167.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.75 170.06 20.17 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -79.29 -167.13 0.47 Allowed 'Trans proline' 0 N--CA 1.439 -1.679 0 N-CA-C 106.377 -2.201 . . . . 10.0 106.377 166.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.452 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.4 m170 -83.32 59.07 4.82 Favored 'General case' 0 CA--C 1.537 0.457 0 O-C-N 120.561 -1.337 . . . . 10.0 110.097 -175.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -76.61 51.66 0.76 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.6 1.191 . . . . 10.0 112.587 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -56.94 149.72 42.7 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 125.601 1.561 . . . . 10.0 111.008 168.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -67.96 -48.04 1.56 Allowed 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.652 2.235 . . . . 10.0 111.401 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.92 54.09 0.98 Allowed 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.743 -0.598 . . . . 10.0 111.103 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.6 t -58.63 100.85 0.07 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.048 0.939 . . . . 10.0 110.111 -174.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtt-85 -113.78 -90.47 0.52 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 105.857 -1.905 . . . . 10.0 105.857 -177.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -149.42 144.59 26.46 Favored 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 109.334 -0.617 . . . . 10.0 109.334 168.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -51.5 119.78 4.48 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 119.714 -0.794 . . . . 10.0 109.929 168.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.0 -129.48 1.97 Allowed Glycine 0 N--CA 1.451 -0.359 0 N-CA-C 107.513 -2.235 . . . . 10.0 107.513 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.53 -143.29 5.84 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 118.182 0.991 . . . . 10.0 111.03 169.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -68.83 1.26 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 CA-C-N 120.075 1.937 . . . . 10.0 110.228 168.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 31.2 mmtp -93.9 -15.96 24.47 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-O 117.844 -1.074 . . . . 10.0 110.494 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -127.61 161.38 28.98 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 119.255 0.934 . . . . 10.0 109.5 -171.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -84.28 -28.91 26.83 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -78.94 -11.52 60.0 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 124.465 1.106 . . . . 10.0 112.059 -169.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.4 ptp180 -33.45 138.46 0.07 Allowed 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 126.415 1.886 . . . . 10.0 114.596 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.4 m170 -69.5 177.17 3.03 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.562 -0.533 . . . . 10.0 109.562 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 p -72.85 39.32 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 125.525 1.53 . . . . 10.0 114.228 -172.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 48.03 0.04 OUTLIER Glycine 0 CA--C 1.524 0.655 0 O-C-N 120.597 -1.315 . . . . 10.0 111.526 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -85.0 102.81 13.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 104.92 -2.252 . . . . 10.0 104.92 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.7 mt -74.62 -32.19 62.23 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 107.073 -1.454 . . . . 10.0 107.073 169.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.82 -104.35 3.04 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 109.586 -1.406 . . . . 10.0 109.586 168.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.443 ' HB3' HD22 ' A' ' 42' ' ' LEU . 39.9 m-20 -126.4 105.79 9.02 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 126.743 2.017 . . . . 10.0 106.511 -167.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.63 134.67 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 123.411 0.684 . . . . 10.0 109.566 173.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.58 122.43 26.49 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.524 2.73 . . . . 10.0 112.809 -167.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.01 133.99 34.86 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.49 0.716 . . . . 10.0 109.255 169.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -60.76 171.53 1.15 Allowed 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.459 0.703 . . . . 10.0 110.001 168.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 pttt -47.54 -34.22 7.37 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.741 1.617 . . . . 10.0 111.311 171.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.8 -7.25 59.36 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 123.655 0.782 . . . . 10.0 111.166 -176.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.86 1.22 77.09 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.77 -0.932 . . . . 10.0 110.77 -175.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -77.19 103.87 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 -176.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.707 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -101.43 114.37 28.32 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 107.809 -1.182 . . . . 10.0 107.809 169.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -85.44 127.96 34.57 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 107.539 -1.282 . . . . 10.0 107.539 169.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 56.9 t -110.11 132.04 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 106.389 -1.708 . . . . 10.0 106.389 170.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -154.52 71.28 0.82 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.994 0.918 . . . . 10.0 108.955 170.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -114.62 159.01 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 105.603 -1.999 . . . . 10.0 105.603 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -130.95 142.44 50.35 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.854 0.861 . . . . 10.0 110.074 172.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -131.25 133.66 45.65 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.266 1.027 . . . . 10.0 109.683 -172.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 62.3 p -110.96 57.09 0.62 Allowed 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.373 1.869 . . . . 10.0 108.63 174.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 96.0 t -141.77 -61.73 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.14 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 -177.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.279 0.0 OUTLIER -60.68 170.94 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 N-CA-C 113.229 0.826 . . . . 10.0 113.229 174.83 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.6 m -145.5 111.97 5.8 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 121.498 -0.751 . . . . 10.0 109.286 175.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.2 tt -49.05 -44.89 42.11 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 126.09 1.756 . . . . 10.0 109.955 177.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -143.72 160.8 40.08 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 106.465 -1.679 . . . . 10.0 106.465 169.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.32 -95.96 0.2 Allowed Glycine 0 C--N 1.334 0.418 0 N-CA-C 109.349 -1.5 . . . . 10.0 109.349 -177.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -119.54 -51.69 2.28 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.265 1.826 . . . . 10.0 107.886 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -73.51 -37.31 65.72 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.681 -1.229 . . . . 10.0 107.681 -171.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 t 47.47 59.27 4.22 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.773 1.629 . . . . 10.0 108.078 169.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.2 pt -74.86 65.77 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 O-C-N 124.622 1.201 . . . . 10.0 110.121 -172.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.7 mm -110.64 -68.34 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 127.808 2.443 . . . . 10.0 108.33 -176.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.68 51.8 4.06 Favored Glycine 0 CA--C 1.531 1.092 0 O-C-N 121.221 -0.925 . . . . 10.0 112.086 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.4 ptm180 -112.36 162.16 15.85 Favored 'General case' 0 CA--C 1.53 0.173 0 C-N-CA 127.213 2.205 . . . . 10.0 107.168 176.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -109.61 104.72 13.79 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 118.565 0.621 . . . . 10.0 109.513 -179.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -64.47 131.02 45.94 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 106.695 -1.594 . . . . 10.0 106.695 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.2 t -122.5 132.59 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.522 ' CG1' ' HB3' ' A' ' 145' ' ' ALA . 1.7 p -94.56 122.35 45.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 105.829 -1.915 . . . . 10.0 105.829 166.154 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.621 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.9 m-70 -100.92 162.78 12.66 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.711 0.767 . . . . 10.0 112.631 174.002 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -64.58 -56.16 15.76 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.48 -0.782 . . . . 10.0 109.316 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -98.8 165.49 11.75 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 119.474 -0.89 . . . . 10.0 112.076 -168.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.7 147.15 53.04 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.801 -1.545 . . . . 10.0 107.792 169.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.432 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 6.7 m-20 -78.45 163.49 25.57 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.86 -0.793 . . . . 10.0 108.86 172.499 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.15 -10.38 59.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 113.736 -1.575 . . . . 10.0 110.781 168.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.5 mt 43.02 45.92 4.61 Favored 'General case' 0 C--N 1.343 0.32 0 C-N-CA 124.826 1.25 . . . . 10.0 109.856 -168.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.19 -21.83 44.01 Favored Glycine 0 CA--C 1.529 0.968 0 CA-C-N 113.713 -1.585 . . . . 10.0 113.728 170.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -77.48 0.78 21.45 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 115.543 1.682 . . . . 10.0 115.543 -165.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.89 -36.59 88.23 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.831 -0.907 . . . . 10.0 110.831 177.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.23 39.82 98.34 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 108.31 -1.916 . . . . 10.0 108.31 -169.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -128.39 164.46 22.64 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -54.79 -47.98 73.3 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.131 -0.941 . . . . 10.0 108.62 174.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -55.08 -39.61 69.47 Favored 'General case' 0 C--N 1.344 0.347 0 C-N-CA 123.283 0.633 . . . . 10.0 111.387 171.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.305 1.8 p -58.73 -36.06 73.7 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-O 118.138 -0.934 . . . . 10.0 111.733 -173.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.1 t -83.06 3.31 30.94 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.315 0.962 . . . . 10.0 112.541 178.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -118.6 -81.17 0.62 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.669 1.588 . . . . 10.0 110.511 -174.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.8 p -108.52 9.71 27.38 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 121.067 1.758 . . . . 10.0 111.43 175.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.1 -79.83 1.87 Allowed Glycine 0 C--N 1.342 0.891 0 O-C-N 120.708 -1.245 . . . . 10.0 110.0 176.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 178.71 36.87 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.684 1.993 . . . . 10.0 109.347 178.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.75 -14.29 61.96 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 123.832 0.853 . . . . 10.0 111.978 -169.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.02 -170.05 54.44 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 109.146 -1.582 . . . . 10.0 109.146 -169.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.4 m -55.06 165.0 0.74 Allowed 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 124.295 1.038 . . . . 10.0 112.667 -177.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -80.96 114.32 19.76 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 167.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.413 ' N ' ' CD2' ' A' ' 144' ' ' LEU . 1.1 mm? -84.5 -45.29 12.78 Favored 'General case' 0 C--N 1.333 -0.149 0 N-CA-C 108.396 -0.965 . . . . 10.0 108.396 -176.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.522 ' HB3' ' CG1' ' A' ' 119' ' ' VAL . . . -147.29 157.04 43.44 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 p -154.28 164.1 39.11 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 116.44 -0.345 . . . . 10.0 110.762 -176.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.86 150.8 22.43 Favored Glycine 0 C--N 1.336 0.531 0 C-N-CA 124.246 0.927 . . . . 10.0 110.916 -173.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.73 148.4 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 104.34 -2.467 . . . . 10.0 104.34 175.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.694 HG12 ' HB2' ' A' ' 6' ' ' ALA . 83.9 mt -76.66 -86.79 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 122.649 1.214 . . . . 10.0 109.169 -171.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.18 25.4 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.744 1.64 . . . . 10.0 115.257 170.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER 63.8 152.64 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 C-N-CA 124.283 1.033 . . . . 10.0 111.413 -173.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.578 ' HB2' HG12 ' A' ' 5' ' ' VAL . . . -113.36 -49.05 2.92 Favored 'General case' 0 CA--C 1.51 -0.592 0 O-C-N 120.456 -1.403 . . . . 10.0 110.316 169.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.433 -1.316 0 N-CA-C 106.047 -1.834 . . . . 10.0 106.047 -178.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.941 0 CA-C-O 118.01 -0.995 . . . . 10.0 108.886 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.5 t -95.15 -45.27 7.27 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.967 0.907 . . . . 10.0 111.952 -175.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.7 tttp -111.09 133.83 53.16 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.328 1.051 . . . . 10.0 109.011 176.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 166.82 23.73 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.12 1.368 . . . . 10.0 108.408 171.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.49 175.19 10.59 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 123.046 0.538 . . . . 10.0 109.767 175.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . 0.474 ' CB ' HD12 ' B' ' 117' ' ' LEU . . . -149.45 103.85 3.32 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 106.346 -1.724 . . . . 10.0 106.346 166.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 22.7 m -83.13 111.84 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 108.834 -0.802 . . . . 10.0 108.834 170.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.96 143.45 26.85 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.056 -1.09 . . . . 10.0 108.056 175.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . 0.402 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 46.5 tttt -163.73 163.76 24.01 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 108.097 -1.075 . . . . 10.0 108.097 170.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.61 -50.76 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 111.803 -0.519 . . . . 10.0 111.803 169.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.24 -47.16 20.9 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.106 -1.442 . . . . 10.0 107.106 -169.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.18 -61.1 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.919 -1.491 . . . . 10.0 111.785 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -62.74 -39.15 44.65 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 122.642 2.228 . . . . 10.0 110.89 170.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 68.1 t -77.6 115.03 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.553 1.141 . . . . 10.0 108.255 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -147.46 139.05 23.95 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 123.208 0.318 . . . . 10.0 110.605 166.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -107.66 153.53 16.79 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 110.15 -1.18 . . . . 10.0 110.15 169.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.424 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.0 mt -138.93 59.41 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 106.179 -1.786 . . . . 10.0 106.179 -176.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.1 mm -78.86 136.72 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-N 115.221 -0.9 . . . . 10.0 109.205 -169.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -108.71 117.13 33.39 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 127.329 2.252 . . . . 10.0 108.076 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.463 ' CE1' HD11 ' B' ' 117' ' ' LEU . 21.9 m-85 -101.15 111.18 23.32 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.256 -1.387 . . . . 10.0 107.256 175.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -118.03 133.26 56.08 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-O 121.358 0.599 . . . . 10.0 112.068 172.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -121.72 113.15 19.31 Favored 'General case' 0 N--CA 1.446 -0.646 0 N-CA-C 105.519 -2.03 . . . . 10.0 105.519 170.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 39.2 pttt . . . . . 0 CA--C 1.531 0.223 0 C-N-CA 124.3 1.04 . . . . 10.0 110.725 -175.114 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.038 0 N-CA-C 109.893 -1.283 . . . . 10.0 109.893 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -60.88 136.63 67.19 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 CA-C-N 119.735 1.767 . . . . 10.0 109.537 169.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.7 t -79.86 97.41 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 104.038 -2.579 . . . . 10.0 104.038 168.13 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . 0.266 71.2 tttt -82.84 112.63 19.83 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 172.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -95.48 101.45 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 C-N-CA 126.952 2.101 . . . . 10.0 105.855 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -121.23 160.94 22.82 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 112.325 0.491 . . . . 10.0 112.325 173.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.87 -152.48 24.14 Favored Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 170.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 40.1 t -155.72 151.49 27.41 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 120.211 -0.596 . . . . 10.0 110.321 177.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.439 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 0.9 OUTLIER -100.99 122.98 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 N-CA-C 107.433 -1.321 . . . . 10.0 107.433 165.836 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 20.9 ptmt -105.38 139.89 39.32 Favored 'General case' 0 N--CA 1.453 -0.296 0 O-C-N 123.891 0.744 . . . . 10.0 108.995 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.18 -5.52 15.48 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.417 1.008 . . . . 10.0 113.269 176.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -68.21 176.76 2.57 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 118.366 1.083 . . . . 10.0 111.09 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -108.54 161.03 15.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.28 -2.118 . . . . 10.0 105.28 165.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -52.03 160.43 0.73 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.636 1.174 . . . . 10.0 111.725 -169.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.84 -179.98 34.38 Favored Glycine 0 N--CA 1.447 -0.602 0 O-C-N 121.549 -0.719 . . . . 10.0 111.486 168.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.9 mp -68.62 149.01 49.64 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.735 1.614 . . . . 10.0 110.446 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -148.75 148.63 30.21 Favored 'General case' 0 C--O 1.233 0.198 0 C-N-CA 123.42 0.688 . . . . 10.0 112.432 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.684 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.4 121.29 0.2 Allowed Glycine 0 C--N 1.339 0.748 0 C-N-CA 127.941 2.686 . . . . 10.0 113.038 165.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -151.64 110.92 3.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 119.088 1.444 . . . . 10.0 110.044 167.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.24 174.3 11.01 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-O 121.373 0.606 . . . . 10.0 111.888 178.131 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . 0.589 HG12 HH11 ' B' ' 115' ' ' ARG . 3.2 t -114.42 86.75 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 CA-C-N 112.599 -2.091 . . . . 10.0 107.981 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -67.66 149.99 49.31 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 124.876 1.27 . . . . 10.0 109.898 174.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -71.65 -59.6 2.67 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.136 -1.393 . . . . 10.0 110.412 -170.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -79.09 136.59 37.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 120.891 -0.323 . . . . 10.0 110.237 -171.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -54.75 -50.42 57.99 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 108.304 -1.918 . . . . 10.0 108.304 169.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -24.12 124.0 0.04 OUTLIER 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 128.069 2.547 . . . . 10.0 113.737 -173.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.92 11.99 2.65 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.63 -175.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.43 HG23 HG22 ' A' ' 17' ' ' ILE . 0.2 OUTLIER -51.41 -40.35 59.13 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 126.049 1.74 . . . . 10.0 111.389 -170.867 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.51 -20.73 46.51 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 124.703 1.201 . . . . 10.0 113.209 178.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.92 82.83 1.67 Allowed Glycine 0 CA--C 1.528 0.864 0 C-N-CA 124.67 1.129 . . . . 10.0 110.624 -178.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.9 m 53.22 21.1 2.09 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.382 1.473 . . . . 10.0 112.733 176.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -111.56 -42.29 3.89 Favored 'General case' 0 N--CA 1.437 -1.089 0 O-C-N 120.613 -1.304 . . . . 10.0 108.092 -168.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 70.3 m -92.14 -11.05 36.67 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 117.831 -1.08 . . . . 10.0 113.541 -168.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.35 2.01 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 128.597 2.759 . . . . 10.0 117.14 -174.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.2 119.24 2.25 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 109.482 -1.447 . . . . 10.0 109.482 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -76.52 64.12 7.31 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.483 2.789 . . . . 10.0 111.02 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 22.5 m170 69.53 53.62 0.41 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 128.752 2.821 . . . . 10.0 110.132 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -73.95 52.08 0.42 Allowed 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.306 1.042 . . . . 10.0 112.997 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -65.49 153.91 89.2 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 126.823 2.049 . . . . 10.0 111.62 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.8 -43.94 2.34 Favored 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 123.079 2.519 . . . . 10.0 111.955 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 67.3 mt -78.85 53.77 1.44 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.718 0.807 . . . . 10.0 110.363 -177.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.6 p -58.39 102.41 0.11 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.823 1.249 . . . . 10.0 110.337 -172.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 mtp85 -132.48 -87.88 0.44 Allowed 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 -171.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -145.13 155.61 43.41 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 121.689 0.757 . . . . 10.0 109.444 168.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -63.05 120.7 11.93 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 105.592 -2.003 . . . . 10.0 105.592 163.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -140.29 -136.44 3.34 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 107.602 -2.199 . . . . 10.0 107.602 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.36 -166.37 32.91 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.11 10.12 0.42 Allowed 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.607 1.538 . . . . 10.0 109.938 166.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 45.0 mmtt -97.28 -25.67 15.18 Favored 'General case' 0 N--CA 1.44 -0.927 0 C-N-CA 124.75 1.22 . . . . 10.0 107.818 173.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.415 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 23.1 m-20 -120.69 158.12 28.15 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.488 -1.671 . . . . 10.0 106.488 -169.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -80.66 -34.11 35.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.776 -1.194 . . . . 10.0 107.776 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -78.31 1.6 21.24 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 125.939 1.696 . . . . 10.0 113.311 -165.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -40.24 144.18 0.24 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.037 1.735 . . . . 10.0 111.694 174.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.4 m170 -61.52 -58.03 9.76 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-O 120.989 0.424 . . . . 10.0 110.425 -175.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.555 HG13 ' H ' ' B' ' 82' ' ' GLY . 5.2 p -174.2 -69.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.457 -0.104 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 172.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.555 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -104.7 62.22 0.37 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 109.478 -1.449 . . . . 10.0 109.478 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -100.5 95.52 6.78 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 103.878 -2.638 . . . . 10.0 103.878 168.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.54 -17.87 64.81 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.694 0.679 . . . . 10.0 111.454 -171.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 107.24 -103.08 1.92 Allowed Glycine 0 N--CA 1.438 -1.228 0 N-CA-C 106.08 -2.808 . . . . 10.0 106.08 -176.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -147.65 139.11 23.78 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 -178.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 28.5 m -106.82 134.45 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.243 0 N-CA-C 105.914 -1.884 . . . . 10.0 105.914 169.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.2 t -109.13 126.21 52.99 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.527 -0.546 . . . . 10.0 109.527 -173.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.42 132.09 37.05 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 122.9 0.48 . . . . 10.0 110.773 -176.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -60.69 168.86 2.05 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 166.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -50.3 -29.26 9.35 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 126.387 1.875 . . . . 10.0 111.414 173.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -78.06 -11.88 59.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.967 0.507 . . . . 10.0 110.701 -177.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.29 20.59 48.34 Favored Glycine 0 C--N 1.338 0.694 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -103.66 107.31 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.838 0 C-N-CA 127.13 2.172 . . . . 10.0 106.115 -178.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.401 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -104.95 125.29 50.79 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 108.883 -0.784 . . . . 10.0 108.883 171.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -79.37 135.0 36.59 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.612 1.165 . . . . 10.0 109.807 175.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.26 129.83 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 127.145 2.178 . . . . 10.0 106.436 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.2 p -158.69 57.4 0.44 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.277 0.944 . . . . 10.0 112.726 176.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.4 152.38 12.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.954 0.902 . . . . 10.0 109.554 -169.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -99.27 112.21 24.42 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 10.0 109.708 167.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -79.13 71.41 5.62 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 104.89 -2.263 . . . . 10.0 104.89 169.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.09 54.37 2.75 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 127.011 2.124 . . . . 10.0 105.416 -174.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.5 t -148.0 -51.99 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 125.817 1.647 . . . . 10.0 109.393 -168.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.435 ' C ' HD12 ' B' ' 104' ' ' ILE 0.322 1.2 pp -113.37 -178.8 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 126.203 1.801 . . . . 10.0 112.683 -172.445 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 61.2 m -146.94 151.84 37.67 Favored 'General case' 0 C--O 1.232 0.172 0 O-C-N 121.052 -1.03 . . . . 10.0 110.78 -178.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 81.9 mt -70.39 -33.85 71.88 Favored 'General case' 0 N--CA 1.458 -0.047 0 C-N-CA 124.271 1.028 . . . . 10.0 110.891 -177.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 108.866 -0.79 . . . . 10.0 108.866 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 39.8 t . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 113.581 0.956 . . . . 10.0 113.581 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -71.19 -7.1 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 113.789 1.033 . . . . 10.0 113.789 -174.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.7 mm -52.14 127.71 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 109.17 -0.678 . . . . 10.0 109.17 173.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.78 -25.5 11.74 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.383 -0.687 . . . . 10.0 111.383 -175.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . 0.589 HH11 HG12 ' B' ' 47' ' ' VAL . 13.3 mtp-105 -72.05 161.8 30.37 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 119.094 1.447 . . . . 10.0 109.526 -169.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -111.03 131.77 54.78 Favored 'General case' 0 CA--C 1.514 -0.412 0 C-N-CA 124.53 1.132 . . . . 10.0 109.652 -167.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.474 HD12 ' CB ' ' B' ' 6' ' ' ALA . 26.4 mt -104.64 140.38 38.11 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.674 -0.861 . . . . 10.0 108.674 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 85.5 t -134.41 125.81 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.884 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 -175.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.407 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 2.3 p -90.35 129.02 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.772 -1.566 . . . . 10.0 106.772 167.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.684 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.8 m170 -106.54 157.12 17.91 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.076 1.139 . . . . 10.0 114.076 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -50.63 -51.84 45.18 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.667 1.587 . . . . 10.0 110.906 176.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -115.67 167.87 10.53 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-N 118.581 0.628 . . . . 10.0 111.593 -169.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.13 150.17 49.52 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.744 -1.116 . . . . 10.0 110.022 177.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.16 135.16 36.73 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.204 1.002 . . . . 10.0 110.903 171.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -79.39 -15.83 57.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 124.621 1.201 . . . . 10.0 110.541 167.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 80.0 mt 58.86 46.11 14.37 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.234 1.014 . . . . 10.0 111.667 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.34 -51.76 1.24 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 110.22 -1.152 . . . . 10.0 110.22 173.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.415 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -82.21 48.77 1.3 Allowed 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 117.583 0.691 . . . . 10.0 112.099 -175.7 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.13 -38.52 5.67 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 108.648 -1.781 . . . . 10.0 108.648 169.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.54 33.26 16.95 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 178.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -130.61 165.08 23.55 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 105.83 -1.915 . . . . 10.0 105.83 168.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -50.38 -43.9 54.64 Favored 'General case' 0 N--CA 1.425 -1.724 0 CA-C-O 121.863 0.84 . . . . 10.0 108.796 171.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -65.7 -35.36 80.54 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-O 117.903 -1.046 . . . . 10.0 112.929 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 44.0 p -54.49 -46.28 73.39 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 120.987 1.721 . . . . 10.0 110.037 171.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -78.47 -13.65 59.74 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 118.11 -0.948 . . . . 10.0 113.162 -174.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.1 ttmm -103.92 -50.85 3.29 Favored 'General case' 0 N--CA 1.443 -0.778 0 C-N-CA 126.518 1.927 . . . . 10.0 112.51 -174.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 19.3 p -137.21 8.41 2.93 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 119.683 1.128 . . . . 10.0 113.658 174.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 88.23 20.56 48.65 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-O 118.577 -1.124 . . . . 10.0 113.215 174.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 6.9 m120 56.09 17.35 2.64 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 119.108 1.454 . . . . 10.0 112.244 -176.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.43 -11.69 58.43 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.007 0.923 . . . . 10.0 112.128 -174.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.97 -160.46 48.41 Favored Glycine 0 N--CA 1.441 -0.973 0 N-CA-C 111.104 -0.798 . . . . 10.0 111.104 168.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.8 m -51.6 125.27 14.26 Favored 'General case' 0 N--CA 1.439 -1.015 0 C-N-CA 124.622 1.169 . . . . 10.0 113.31 -168.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.5 mtm-85 -72.01 75.69 0.92 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 125.412 1.485 . . . . 10.0 109.595 176.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 70.2 mt -43.73 -49.08 8.02 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.997 0.919 . . . . 10.0 112.26 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.407 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -153.99 153.62 32.29 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.796 -0.816 . . . . 10.0 108.796 -168.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.06 166.12 34.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.58 -0.282 . . . . 10.0 110.805 -174.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.63 163.29 30.73 Favored Glycine 0 CA--C 1.523 0.563 0 C-N-CA 125.096 1.331 . . . . 10.0 109.856 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 37.6 t -120.94 136.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 106.088 -1.819 . . . . 10.0 106.088 -173.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 64.2 mt -70.52 130.42 34.71 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-N 118.175 0.443 . . . . 10.0 110.617 -177.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.64 141.98 13.24 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 124.254 0.93 . . . . 10.0 110.794 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -71.26 151.9 8.73 Favored 'Isoleucine or valine' 0 C--N 1.342 0.278 0 CA-C-N 118.44 1.12 . . . . 10.0 111.587 -178.323 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.3 -33.59 2.13 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 124.768 1.227 . . . . 10.0 113.267 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.063 0 CA-C-O 116.856 -1.545 . . . . 10.0 107.424 171.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.601 0 CA-C-O 118.863 -0.589 . . . . 10.0 110.059 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.9 t 125.01 -23.95 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 1 C-N-CA 131.942 4.097 . . . . 10.0 108.523 -174.309 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp -131.0 132.31 44.91 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 126.071 1.748 . . . . 10.0 108.124 169.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.54 168.75 18.66 Favored 'General case' 0 N--CA 1.462 0.149 0 C-N-CA 124.747 1.219 . . . . 10.0 109.443 169.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.413 ' O ' HG23 ' A' ' 149' ' ' ILE . 2.2 m -127.65 179.24 3.84 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.357 0 C-N-CA 124.177 0.991 . . . . 10.0 110.766 -174.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.81 114.77 2.64 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 106.879 -1.526 . . . . 10.0 106.879 164.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -98.66 96.26 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 C-N-CA 124.018 0.927 . . . . 10.0 110.21 172.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 mp -84.57 142.67 29.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.416 1.086 . . . . 10.0 110.023 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -153.2 165.06 36.85 Favored 'General case' 0 C--N 1.338 0.074 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 169.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.48 -59.65 0.04 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.391 -0.368 . . . . 10.0 113.268 169.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.19 -42.92 62.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -170.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.25 -66.51 0.53 Allowed Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 113.728 -1.578 . . . . 10.0 109.708 176.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -58.33 -39.95 79.77 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.62 2.213 . . . . 10.0 110.808 171.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.47 HG13 HD11 ' A' ' 38' ' ' LEU . 54.9 t -63.73 110.63 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 N-CA-C 108.134 -1.062 . . . . 10.0 108.134 178.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.18 132.01 51.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 168.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.687 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -114.28 134.03 11.49 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 109.47 -1.452 . . . . 10.0 109.47 174.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.43 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.9 mt -136.19 97.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 -170.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -102.52 152.24 5.74 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 C-N-CA 124.464 1.106 . . . . 10.0 110.979 -176.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -126.53 113.94 17.45 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 126.294 1.838 . . . . 10.0 107.714 169.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -96.94 100.01 11.54 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 172.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -110.65 118.73 36.99 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 120.436 -0.506 . . . . 10.0 111.594 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -90.73 103.61 16.29 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 105.752 -1.944 . . . . 10.0 105.752 172.222 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 27.1 mmmt -48.31 -57.56 5.82 Favored 'General case' 0 C--O 1.228 -0.071 0 C-N-CA 125.433 1.493 . . . . 10.0 110.811 -177.237 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.14 178.96 6.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 104.258 -2.497 . . . . 10.0 104.258 169.464 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -66.32 -26.98 67.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.594 0.712 . . . . 10.0 109.733 175.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -77.89 -22.68 49.39 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.507 -0.77 . . . . 10.0 109.815 177.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.8 144.75 22.24 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 110.779 -0.928 . . . . 10.0 110.779 -173.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -63.54 153.9 72.06 Favored 'Trans proline' 0 N--CA 1.449 -1.122 0 N-CA-C 107.237 -1.871 . . . . 10.0 107.237 168.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.4 p -77.21 117.24 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 N-CA-C 106.174 -1.787 . . . . 10.0 106.174 173.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 48.4 tttp -85.11 108.8 17.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 106.361 -1.718 . . . . 10.0 106.361 169.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -88.41 93.84 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.112 -1.811 . . . . 10.0 106.112 171.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.3 p90 -106.27 165.77 11.0 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 108.901 -0.777 . . . . 10.0 108.901 168.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.84 163.77 30.54 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -140.23 94.51 2.76 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.209 -1.034 . . . . 10.0 108.209 -175.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.687 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.7 pt -77.83 172.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 118.754 -1.179 . . . . 10.0 109.157 171.31 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -155.58 151.47 27.6 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 167.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.69 -18.97 19.38 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-O 118.83 -0.984 . . . . 10.0 114.036 174.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.47 HD11 HG13 ' A' ' 14' ' ' VAL . 6.8 mp -71.86 179.24 3.26 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 119.34 1.57 . . . . 10.0 111.672 -178.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -95.53 164.89 12.6 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.085 -1.08 . . . . 10.0 108.085 167.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -60.08 171.85 0.91 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.934 1.294 . . . . 10.0 112.892 -169.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.67 -173.08 43.33 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 123.879 0.752 . . . . 10.0 112.462 167.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -70.49 142.62 51.88 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.151 1.381 . . . . 10.0 110.017 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -144.13 147.46 33.75 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 123.64 0.776 . . . . 10.0 112.62 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.616 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.05 128.19 0.25 Allowed Glycine 0 C--N 1.341 0.853 0 C-N-CA 127.378 2.418 . . . . 10.0 111.589 165.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -153.79 106.32 2.86 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 118.904 1.352 . . . . 10.0 109.984 167.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.34 174.04 13.31 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 122.303 1.049 . . . . 10.0 113.686 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.16 144.57 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 111.694 -2.503 . . . . 10.0 107.873 169.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.7 m-70 -128.14 138.95 52.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.085 -1.45 . . . . 10.0 107.085 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -50.64 -62.79 1.39 Allowed 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.974 1.31 . . . . 10.0 112.143 -169.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -80.22 130.24 35.08 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 119.624 -0.83 . . . . 10.0 109.294 -175.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.57 -13.74 71.63 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.313 -1.115 . . . . 10.0 110.313 167.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -46.37 144.84 1.94 Allowed 'General case' 0 C--N 1.345 0.387 0 CA-C-O 122.45 1.119 . . . . 10.0 109.697 168.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.424 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -153.82 15.6 0.49 Allowed 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.309 -1.314 . . . . 10.0 111.724 177.523 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.511 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -58.77 -34.29 71.26 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.331 0.969 . . . . 10.0 110.671 -174.044 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.67 -20.9 45.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.846 1.258 . . . . 10.0 113.062 175.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.22 97.59 1.36 Allowed Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.392 -1.083 . . . . 10.0 110.392 -170.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.288 20.9 p 15.36 60.27 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 128.597 2.759 . . . . 10.0 116.685 176.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 40.9 m -132.18 -61.77 0.86 Allowed 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 128.021 2.528 . . . . 10.0 105.172 174.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.6 m -57.25 -24.75 56.81 Favored 'General case' 0 C--N 1.34 0.156 0 C-N-CA 125.606 1.563 . . . . 10.0 111.667 176.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -41.89 -30.3 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 126.208 1.803 . . . . 10.0 112.502 168.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.93 125.66 5.62 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 109.845 -1.302 . . . . 10.0 109.845 169.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.6 66.95 3.78 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 124.096 3.197 . . . . 10.0 112.28 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 64.16 46.27 3.7 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 129.438 3.095 . . . . 10.0 111.227 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -70.85 69.79 0.47 Allowed 'General case' 0 CA--C 1.531 0.244 0 CA-C-O 121.759 0.79 . . . . 10.0 111.402 178.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.8 p-10 -68.61 152.1 96.86 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.306 -0.871 . . . . 10.0 109.206 169.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.19 -58.68 0.4 Allowed 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 122.26 1.974 . . . . 10.0 111.571 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -76.09 72.27 2.9 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 121.439 -0.788 . . . . 10.0 110.447 174.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.4 m -40.34 112.65 0.29 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.016 0.926 . . . . 10.0 110.699 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.92 -96.27 0.47 Allowed 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 176.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -149.39 155.86 41.13 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.988 0.899 . . . . 10.0 109.271 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 63.5 t60 -60.81 115.2 3.49 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 118.364 -1.334 . . . . 10.0 109.096 166.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.69 -137.4 3.49 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 107.935 -2.066 . . . . 10.0 107.935 176.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.26 -162.3 23.36 Favored Glycine 0 N--CA 1.45 -0.368 0 N-CA-C 109.03 -1.628 . . . . 10.0 109.03 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -61.56 -4.8 4.76 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 CA-C-N 119.585 1.692 . . . . 10.0 111.271 168.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -89.29 -26.81 20.94 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.724 1.21 . . . . 10.0 110.401 175.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 34.0 t0 -102.61 157.48 16.91 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 107.227 -1.398 . . . . 10.0 107.227 -178.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -80.6 -30.25 36.86 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.048 -1.093 . . . . 10.0 108.048 167.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -91.05 6.65 44.03 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.07 1.348 . . . . 10.0 113.419 -168.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -42.33 140.35 1.21 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.145 0.978 . . . . 10.0 110.835 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -60.27 -65.09 0.74 Allowed 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.852 0.835 . . . . 10.0 110.453 -171.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.714 HG13 ' H ' ' A' ' 82' ' ' GLY . 7.7 p -160.48 -87.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.336 -2.098 . . . . 10.0 105.336 171.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.714 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -88.38 59.95 4.06 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.311 -1.116 . . . . 10.0 110.311 178.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -96.15 91.53 5.97 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 104.916 -2.253 . . . . 10.0 104.916 168.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -66.88 -32.8 74.3 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 108.704 -0.85 . . . . 10.0 108.704 -175.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.45 -85.66 0.38 Allowed Glycine 0 N--CA 1.439 -1.13 0 N-CA-C 108.277 -1.929 . . . . 10.0 108.277 168.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 -150.76 135.78 17.56 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.161 -1.422 . . . . 10.0 107.161 -178.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -106.93 133.11 52.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 169.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -87.57 131.76 34.29 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 108.208 -1.034 . . . . 10.0 108.208 176.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -107.11 135.9 47.86 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.029 0.932 . . . . 10.0 109.012 173.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -59.63 172.09 0.75 Allowed 'General case' 0 C--O 1.232 0.135 0 O-C-N 124.243 0.965 . . . . 10.0 109.912 167.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -47.39 -35.87 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 125.732 1.613 . . . . 10.0 110.387 170.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -79.69 -5.95 56.21 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.634 1.173 . . . . 10.0 110.723 -173.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 3.71 89.07 Favored Glycine 0 C--N 1.338 0.684 0 N-CA-C 111.101 -0.799 . . . . 10.0 111.101 -176.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.6 t -79.66 107.83 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 N-CA-C 106.465 -1.68 . . . . 10.0 106.465 179.05 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.453 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -105.39 120.93 42.83 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 108.829 -0.804 . . . . 10.0 108.829 169.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -79.81 114.8 19.0 Favored 'General case' 0 N--CA 1.434 -1.27 0 C-N-CA 125.849 1.659 . . . . 10.0 109.442 170.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.0 t -101.46 133.76 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 105.417 -2.068 . . . . 10.0 105.417 169.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 7.0 m -158.05 58.85 0.47 Allowed 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 118.969 0.804 . . . . 10.0 110.878 176.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.16 153.61 6.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 C-N-CA 124.001 0.92 . . . . 10.0 108.581 -174.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -123.08 136.27 54.74 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.395 1.478 . . . . 10.0 109.409 172.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -143.75 153.22 42.2 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.7 p -107.95 -26.47 10.69 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 127.148 2.179 . . . . 10.0 111.914 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.2 p -77.91 -45.15 28.08 Favored 'Isoleucine or valine' 0 C--N 1.342 0.27 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -73.72 134.46 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 105.09 -2.189 . . . . 10.0 105.09 165.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -166.28 158.48 14.07 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 125.422 1.489 . . . . 10.0 108.117 -177.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.1 mt -60.59 -50.77 72.18 Favored 'General case' 0 N--CA 1.457 -0.08 0 CA-C-N 116.152 -0.477 . . . . 10.0 110.825 -171.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -120.1 -165.58 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.592 1.157 . . . . 10.0 108.28 172.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 97.77 62.65 0.89 Allowed Glycine 0 CA--C 1.524 0.608 0 C-N-CA 124.394 0.997 . . . . 10.0 111.198 169.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 t70 71.07 -57.54 0.6 Allowed 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 129.469 3.108 . . . . 10.0 109.334 -178.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -74.33 -39.96 62.5 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 -169.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.2 t 39.84 85.05 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 126.111 1.764 . . . . 10.0 113.012 167.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 35.7 pt -58.69 -22.7 21.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -177.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.5 mm -47.26 131.11 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 O-C-N 121.799 -0.563 . . . . 10.0 110.365 174.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.64 1.6 82.92 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 118.408 -1.218 . . . . 10.0 113.987 175.001 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mmt-85 -81.34 165.76 21.07 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.8 1.3 . . . . 10.0 111.348 171.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -100.7 130.51 46.75 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 105.309 -2.108 . . . . 10.0 105.309 169.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.7 mp -108.66 149.58 28.76 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.416 -0.957 . . . . 10.0 108.416 170.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 96.7 t -135.98 137.09 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.945 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 -173.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.6 p -108.19 138.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 168.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.616 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.6 m170 -116.22 161.16 19.4 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 115.641 1.719 . . . . 10.0 115.641 -170.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -43.33 -55.36 4.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 128.621 2.768 . . . . 10.0 110.046 177.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -124.21 174.41 7.7 Favored 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 125.065 1.346 . . . . 10.0 111.34 -169.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.25 148.86 45.06 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.667 1.187 . . . . 10.0 110.401 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -78.59 147.33 33.74 Favored 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 124.145 0.978 . . . . 10.0 111.702 174.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -75.44 -30.23 59.93 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 114.372 -1.285 . . . . 10.0 109.675 169.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 29.9 mt 57.45 52.67 8.28 Favored 'General case' 0 C--N 1.339 0.13 0 N-CA-C 107.688 -1.227 . . . . 10.0 107.688 -167.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.42 -24.7 12.97 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-N 113.521 -1.672 . . . . 10.0 112.99 173.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -75.11 6.5 4.18 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 114.543 1.312 . . . . 10.0 114.543 -167.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.83 -16.6 79.27 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.057 0.836 . . . . 10.0 112.097 171.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.82 43.77 48.28 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 118.082 0.941 . . . . 10.0 111.801 -176.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -130.88 163.4 27.52 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 106.943 -1.503 . . . . 10.0 106.943 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -54.07 -49.54 68.8 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.16 -0.927 . . . . 10.0 108.502 169.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -56.95 -44.21 82.32 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 122.775 0.43 . . . . 10.0 110.519 173.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.3 p -56.3 -43.74 79.21 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 120.635 -1.29 . . . . 10.0 110.576 -178.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -82.24 2.12 33.37 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 118.848 -0.596 . . . . 10.0 112.071 -178.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.5 -75.84 0.61 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.328 1.851 . . . . 10.0 110.196 176.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 6.6 p -120.96 27.06 8.69 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 120.786 1.63 . . . . 10.0 113.371 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.2 27.99 70.01 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 121.811 -0.556 . . . . 10.0 113.771 167.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 47.65 30.06 1.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.816 0.808 . . . . 10.0 112.177 -173.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.18 -5.33 13.2 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.723 -0.61 . . . . 10.0 110.855 175.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.59 -156.06 36.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 109.806 -1.318 . . . . 10.0 109.806 168.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.3 m -59.86 131.95 52.45 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 109.497 -0.557 . . . . 10.0 109.497 -171.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.46 68.01 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 168.1 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.77 -27.45 67.99 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 -169.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.35 145.83 24.08 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-O 121.475 0.655 . . . . 10.0 109.278 -178.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 15.8 p -162.46 163.65 27.48 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-N 115.849 -0.614 . . . . 10.0 109.641 -167.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 179.6 36.23 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 110.588 -1.005 . . . . 10.0 110.588 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.88 148.12 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.675 0 N-CA-C 103.72 -2.696 . . . . 10.0 103.72 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.413 HG23 ' O ' ' A' ' 5' ' ' VAL . 3.9 mt -65.81 -87.7 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 C-N-CA 123.222 0.609 . . . . 10.0 111.203 -168.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.57 135.29 7.05 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.426 -0.669 . . . . 10.0 111.426 -178.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 62.3 mt -76.37 150.44 6.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 C-N-CA 125.132 1.373 . . . . 10.0 108.166 -176.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.14 -45.44 3.29 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 120.974 1.716 . . . . 10.0 112.006 169.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.3 tp60 . . . . . 0 C--O 1.252 1.219 0 C-N-CA 124.14 0.976 . . . . 10.0 109.772 -174.526 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.673 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.4 t -166.38 -46.88 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 124.486 1.114 . . . . 10.0 108.788 173.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -123.95 136.53 54.38 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.232 1.413 . . . . 10.0 109.165 -175.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 167.43 22.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 125.942 1.697 . . . . 10.0 107.803 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.49 168.88 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 118.488 0.585 . . . . 10.0 112.314 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.99 104.28 4.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 106.899 -1.519 . . . . 10.0 106.899 167.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.424 HG21 ' HB3' ' A' ' 53' ' ' ASN . 10.9 m -92.09 76.38 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 123.476 0.71 . . . . 10.0 109.212 175.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.5 mp -74.69 145.82 42.81 Favored 'General case' 0 N--CA 1.449 -0.521 0 O-C-N 121.299 -0.876 . . . . 10.0 109.263 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 161.4 19.77 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 107.992 -1.114 . . . . 10.0 107.992 -175.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.56 -58.37 0.04 OUTLIER Glycine 0 C--N 1.329 0.175 0 CA-C-N 115.628 -0.714 . . . . 10.0 111.579 169.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.21 -46.49 33.62 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 106.645 -1.613 . . . . 10.0 106.645 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.82 -68.37 0.51 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 113.383 -1.735 . . . . 10.0 110.729 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -59.89 -35.95 92.08 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.957 2.438 . . . . 10.0 111.424 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.408 HG13 HD11 ' B' ' 38' ' ' LEU . 96.5 t -68.71 99.74 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.141 0 N-CA-C 107.063 -1.458 . . . . 10.0 107.063 176.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -121.95 111.9 17.63 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.483 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -94.37 138.71 14.16 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 109.133 -1.587 . . . . 10.0 109.133 169.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.511 ' CG2' HG23 ' A' ' 54' ' ' THR . 6.5 mt -139.31 78.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 106.681 -1.6 . . . . 10.0 106.681 -177.022 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -102.59 148.88 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.143 -0.935 . . . . 10.0 109.59 -175.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -118.37 114.04 22.32 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.831 1.652 . . . . 10.0 108.223 171.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -86.09 99.28 11.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 175.083 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.37 153.3 21.85 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 123.964 0.79 . . . . 10.0 109.883 -178.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -158.84 86.9 0.85 Allowed 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.254 -0.647 . . . . 10.0 109.254 -173.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 2.0 ttpm? . . . . . 0 N--CA 1.424 -1.755 0 CA-C-O 122.257 1.027 . . . . 10.0 109.74 -174.506 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.126 0 CA-C-O 117.838 -1.534 . . . . 10.0 114.723 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -67.0 151.44 82.03 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.371 2.048 . . . . 10.0 108.34 169.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.49 92.38 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 105.842 -1.91 . . . . 10.0 105.842 169.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttp -83.76 98.43 9.69 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -97.58 99.69 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.95 0 C-N-CA 125.628 1.571 . . . . 10.0 106.819 -174.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 13.3 p90 -117.16 165.54 13.29 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.528 0.68 . . . . 10.0 112.605 171.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.76 -150.04 21.97 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 106.922 -2.471 . . . . 10.0 106.922 169.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 28.6 p -156.04 166.41 33.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 119.352 -0.939 . . . . 10.0 110.931 173.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.483 HG22 ' HA2' ' B' ' 16' ' ' GLY . 4.7 pt -106.43 174.75 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.843 -1.071 . . . . 10.0 110.491 167.316 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt -140.4 152.15 45.51 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.552 2.341 . . . . 10.0 105.893 169.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.12 -25.09 14.66 Favored Glycine 0 C--N 1.338 0.653 0 N-CA-C 116.007 1.163 . . . . 10.0 116.007 167.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.528 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.3 mp -78.47 177.6 8.4 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 119.207 1.504 . . . . 10.0 110.945 -169.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.0 t -93.1 165.1 13.0 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 108.973 -0.751 . . . . 10.0 108.973 168.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.99 160.04 6.45 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.576 1.15 . . . . 10.0 111.45 -172.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.87 -170.24 29.06 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.626 -0.59 . . . . 10.0 111.626 169.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.77 148.6 42.39 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.405 1.082 . . . . 10.0 111.783 -172.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -144.42 141.74 29.84 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.215 1.006 . . . . 10.0 113.42 -177.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.512 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -38.2 126.48 1.6 Allowed Glycine 0 C--N 1.342 0.903 0 C-N-CA 126.803 2.144 . . . . 10.0 110.511 165.339 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -151.36 111.43 4.1 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.887 1.343 . . . . 10.0 108.295 168.083 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -153.76 168.33 26.66 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.978 0.894 . . . . 10.0 112.459 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 18.7 m -88.78 149.34 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 111.869 -2.423 . . . . 10.0 105.812 166.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -124.83 169.72 11.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.691 0.757 . . . . 10.0 109.309 169.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . 0.51 ' CG ' ' H ' ' B' ' 50' ' ' PHE . 0.8 OUTLIER 4.0 -113.68 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 130.503 3.521 . . . . 10.0 117.624 167.727 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . 0.51 ' H ' ' CG ' ' B' ' 49' ' ' GLU . 51.9 m-85 -95.29 -141.88 0.26 Allowed 'General case' 0 N--CA 1.434 -1.231 0 C-N-CA 127.96 2.504 . . . . 10.0 106.024 172.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.43 31.5 4.82 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 125.171 1.367 . . . . 10.0 110.875 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -70.5 158.55 35.88 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 119.685 1.742 . . . . 10.0 108.273 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -163.45 12.07 0.06 Allowed 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 126.288 1.835 . . . . 10.0 111.899 173.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.43 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -60.48 -31.63 70.65 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 119.904 1.229 . . . . 10.0 110.954 -173.048 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.03 -18.37 58.18 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.26 1.024 . . . . 10.0 111.887 176.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.83 -171.58 13.78 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 107.539 -2.225 . . . . 10.0 107.539 -169.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 84.7 m -70.43 70.04 0.41 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.826 -1.176 . . . . 10.0 107.826 169.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.14 -51.05 0.08 Allowed 'General case' 0 N--CA 1.448 -0.544 0 O-C-N 120.706 -1.246 . . . . 10.0 110.911 -169.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 10.7 t -98.96 -0.15 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.711 0.804 . . . . 10.0 110.076 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -70.46 60.02 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.821 1.648 . . . . 10.0 109.461 171.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . 0.463 ' HA3' ' HG2' ' B' ' 49' ' ' GLU . . . 80.24 130.42 0.89 Allowed Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 124.612 1.101 . . . . 10.0 115.227 164.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -87.84 42.49 0.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 123.279 2.653 . . . . 10.0 108.168 165.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' HG22 ' B' ' 137' ' ' THR . 15.1 m170 65.47 54.28 1.16 Allowed 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.993 2.517 . . . . 10.0 110.964 -172.237 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -69.37 70.27 0.26 Allowed 'General case' 0 N--CA 1.47 0.554 0 O-C-N 121.794 -0.566 . . . . 10.0 110.638 171.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -80.01 152.13 73.91 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.521 -0.737 . . . . 10.0 110.333 175.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.05 -48.57 1.29 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.601 2.201 . . . . 10.0 111.298 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 86.0 mt -77.5 59.49 1.92 Allowed 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -56.24 99.51 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 124.761 1.224 . . . . 10.0 110.172 -176.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.48 -89.89 0.53 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 105.517 -2.031 . . . . 10.0 105.517 -177.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -142.87 153.59 43.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.091 0.948 . . . . 10.0 110.286 168.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -64.85 123.24 18.88 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 165.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.41 -144.2 4.08 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 107.857 -2.097 . . . . 10.0 107.857 179.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.05 -153.37 10.42 Favored Glycine 0 N--CA 1.452 -0.296 0 N-CA-C 108.565 -1.814 . . . . 10.0 108.565 170.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -69.12 15.26 0.19 Allowed 'Trans proline' 0 CA--C 1.54 0.802 0 CA-C-N 119.519 1.66 . . . . 10.0 111.404 169.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 72.3 mttt -119.49 0.46 11.05 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.177 1.391 . . . . 10.0 110.791 169.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.4 t0 -118.03 156.48 28.51 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.264 -1.384 . . . . 10.0 107.264 172.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -79.3 -31.61 43.33 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 171.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -118.59 36.94 4.22 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 123.861 0.864 . . . . 10.0 112.466 -165.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.74 148.96 3.61 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 125.257 1.423 . . . . 10.0 110.66 169.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 26.0 m170 -55.26 -62.35 1.73 Allowed 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.161 0.584 . . . . 10.0 112.192 -171.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -172.35 -60.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.181 0 C-N-CA 124.32 1.048 . . . . 10.0 108.332 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.71 51.98 0.82 Allowed Glycine 0 C--N 1.337 0.613 0 N-CA-C 109.319 -1.513 . . . . 10.0 109.319 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -84.77 92.28 8.19 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.447 -2.797 . . . . 10.0 103.447 167.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.5 mt -63.06 -30.4 71.57 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 -173.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.55 -89.8 0.48 Allowed Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.607 -1.397 . . . . 10.0 109.607 166.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -151.79 100.73 2.7 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.332 -0.988 . . . . 10.0 108.332 -171.057 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -86.37 141.86 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 172.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -99.47 129.87 45.69 Favored 'General case' 0 C--O 1.224 -0.257 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.56 134.81 40.99 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.916 -0.772 . . . . 10.0 108.916 172.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -59.84 169.59 1.39 Allowed 'General case' 0 N--CA 1.451 -0.382 0 O-C-N 124.526 1.141 . . . . 10.0 110.045 167.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 61.8 pttt -50.41 -33.19 19.94 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 124.229 1.011 . . . . 10.0 110.876 169.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -78.53 -1.25 33.0 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 122.87 0.468 . . . . 10.0 111.409 -178.163 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.36 17.86 75.2 Favored Glycine 0 C--N 1.34 0.781 0 O-C-N 120.746 -1.221 . . . . 10.0 110.49 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.69 103.61 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 C-N-CA 126.439 1.896 . . . . 10.0 106.789 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.441 ' H ' HG12 ' B' ' 35' ' ' ILE . . . -98.35 121.64 40.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 167.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.46 117.79 20.74 Favored 'General case' 0 N--CA 1.436 -1.161 0 C-N-CA 126.579 1.951 . . . . 10.0 108.665 170.555 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 56.6 t -101.73 134.57 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 107.185 -1.413 . . . . 10.0 107.185 175.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -158.62 57.11 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.409 0.684 . . . . 10.0 111.263 175.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.71 158.2 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -172.182 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -130.73 90.72 2.95 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 126.762 2.025 . . . . 10.0 108.925 -176.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -84.46 83.78 7.88 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 63.1 p -78.73 60.31 2.74 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 169.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.3 t -143.22 -51.16 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 125.174 1.39 . . . . 10.0 107.704 -168.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.42 HD13 ' H ' ' B' ' 104' ' ' ILE 0.326 0.0 OUTLIER -118.91 165.12 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 113.656 0.984 . . . . 10.0 113.656 175.91 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.0 p -108.17 132.1 53.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.641 1.176 . . . . 10.0 109.646 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -69.83 -41.16 75.31 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.3 t . . . . . 0 N--CA 1.447 -0.623 0 N-CA-C 105.985 -1.857 . . . . 10.0 105.985 174.906 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.9 t . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 121.434 0.635 . . . . 10.0 112.25 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.9 pt -75.01 44.38 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 C-N-CA 123.752 0.821 . . . . 10.0 111.841 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 17.7 mm -78.25 -68.52 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 C-N-CA 125.685 1.594 . . . . 10.0 109.981 -174.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.42 52.31 3.05 Favored Glycine 0 CA--C 1.533 1.198 0 O-C-N 120.8 -1.187 . . . . 10.0 112.302 176.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.1 mmt85 -121.09 153.55 37.3 Favored 'General case' 0 C--O 1.233 0.192 0 C-N-CA 126.147 1.779 . . . . 10.0 110.614 -178.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 53.9 m -97.75 121.26 39.44 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.121 0.968 . . . . 10.0 109.587 177.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -98.24 144.33 27.79 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 125.916 1.686 . . . . 10.0 107.743 169.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 53.1 t -128.8 140.67 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 108.409 -0.96 . . . . 10.0 108.409 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 p -113.39 128.75 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 C-N-CA 125.666 1.586 . . . . 10.0 106.932 169.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.512 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.4 m170 -114.09 163.74 14.78 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 116.082 1.882 . . . . 10.0 116.082 -169.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -45.02 -59.1 2.76 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.602 2.761 . . . . 10.0 112.628 174.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -122.81 176.29 6.06 Favored 'General case' 0 CA--C 1.522 -0.134 0 C-N-CA 124.366 1.067 . . . . 10.0 113.317 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.58 155.59 38.78 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.827 1.651 . . . . 10.0 111.094 176.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.5 146.86 24.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 124.8 1.24 . . . . 10.0 110.795 172.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -74.9 -32.88 61.94 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 114.849 -1.068 . . . . 10.0 109.321 170.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 52.2 mt 62.94 65.34 0.81 Allowed 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 123.265 1.507 . . . . 10.0 108.237 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.77 -51.11 4.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 112.945 -1.934 . . . . 10.0 111.726 170.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 38.3 mtmt -80.32 53.21 1.74 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.371 1.468 . . . . 10.0 111.591 -169.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.94 -3.71 23.11 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.208 1.861 . . . . 10.0 112.462 177.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.54 42.55 27.16 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.244 0.926 . . . . 10.0 112.797 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -135.98 158.32 44.69 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 107.577 -1.268 . . . . 10.0 107.577 176.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -54.15 -42.94 70.14 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 169.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -58.91 -44.39 91.26 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.983 -0.553 . . . . 10.0 112.175 170.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 10.1 p -56.19 -43.25 78.26 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 119.581 1.082 . . . . 10.0 111.22 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -71.24 -7.85 49.65 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-O 118.083 -0.961 . . . . 10.0 113.091 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -119.7 -65.65 1.14 Allowed 'General case' 0 N--CA 1.439 -1.008 0 C-N-CA 127.677 2.391 . . . . 10.0 113.141 -168.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.499 HG22 ' CD2' ' B' ' 63' ' ' HIS . 1.5 p -130.16 26.2 5.18 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.274 1.397 . . . . 10.0 109.908 177.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 68.32 -104.45 1.2 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 107.375 -2.29 . . . . 10.0 107.375 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -154.93 39.06 0.42 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 107.551 -1.278 . . . . 10.0 107.551 170.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.62 -12.48 23.38 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 123.527 0.731 . . . . 10.0 112.512 -171.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.96 -167.55 51.19 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 109.734 -1.346 . . . . 10.0 109.734 175.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 53.1 m -56.03 133.41 51.81 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 121.602 0.715 . . . . 10.0 111.729 -169.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 19.7 mtt180 -65.15 75.32 0.05 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.457 -0.792 . . . . 10.0 109.177 168.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.9 mt -47.56 -48.73 27.69 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.96 0.409 . . . . 10.0 109.986 177.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.15 152.54 37.46 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.414 0.626 . . . . 10.0 110.566 -172.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -148.42 167.71 24.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.595 -0.73 . . . . 10.0 109.308 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.0 148.66 19.75 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 109.592 -1.403 . . . . 10.0 109.592 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 75.1 t -101.35 124.26 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 N-CA-C 104.365 -2.457 . . . . 10.0 104.365 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 21.0 mt -67.75 157.74 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 CA-C-N 118.969 0.804 . . . . 10.0 110.454 -178.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -159.97 147.24 14.07 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.594 1.568 . . . . 10.0 110.423 -170.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 62.0 mt -69.15 135.41 28.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 C-N-CA 126.476 1.91 . . . . 10.0 110.452 -169.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -125.8 -48.4 1.64 Allowed 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.624 -0.673 . . . . 10.0 112.199 -178.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.254 1.294 0 C-N-CA 125.437 1.495 . . . . 10.0 110.517 -168.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 116.164 -1.874 . . . . 10.0 106.571 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -96.55 -33.77 11.69 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.773 1.169 . . . . 10.0 112.79 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -137.54 133.32 34.38 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 123.958 0.903 . . . . 10.0 111.615 -177.327 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.92 162.31 28.88 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.185 1.394 . . . . 10.0 109.457 173.243 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.2 t -124.31 154.89 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 125.784 1.634 . . . . 10.0 108.272 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.46 111.9 6.35 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 168.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.9 m -101.26 113.47 37.51 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.28 0.632 . . . . 10.0 110.945 -178.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -90.05 139.24 30.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 121.743 -0.598 . . . . 10.0 111.945 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -151.84 159.95 43.71 Favored 'General case' 0 N--CA 1.455 -0.197 0 N-CA-C 107.25 -1.389 . . . . 10.0 107.25 167.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.73 -56.68 0.06 OUTLIER Glycine 0 N--CA 1.461 0.351 0 C-N-CA 120.247 -0.978 . . . . 10.0 112.389 169.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -71.42 -44.5 64.76 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -178.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.3 -70.6 0.43 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.328 -1.305 . . . . 10.0 110.37 169.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -58.28 -33.12 97.35 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 123.528 2.819 . . . . 10.0 111.554 173.125 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.61 94.24 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 173.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -114.09 126.62 55.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.508 -1.293 . . . . 10.0 107.508 175.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -121.17 145.23 17.08 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 124.294 0.949 . . . . 10.0 111.045 -177.222 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.429 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 4.9 mt -146.42 84.22 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 106.555 -1.646 . . . . 10.0 106.555 -170.397 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.8 mm -95.46 142.74 13.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 C-N-CA 124.439 1.096 . . . . 10.0 108.571 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -124.3 127.63 47.93 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 125.957 1.703 . . . . 10.0 108.559 172.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.432 ' CD2' HG12 ' A' ' 31' ' ' VAL . 24.9 m-85 -106.43 112.92 26.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.424 -1.324 . . . . 10.0 107.424 176.6 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -105.26 127.42 52.93 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.601 0.637 . . . . 10.0 111.195 168.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -114.93 88.68 2.92 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.526 1.531 . . . . 10.0 107.288 169.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.5 pttp -59.58 -44.0 93.47 Favored 'General case' 0 N--CA 1.457 -0.09 0 C-N-CA 124.199 1.0 . . . . 10.0 110.279 -171.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -133.1 161.58 34.01 Favored 'General case' 0 N--CA 1.425 -1.704 0 N-CA-C 104.301 -2.481 . . . . 10.0 104.301 174.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.9 p -66.18 -18.96 65.68 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 121.505 0.669 . . . . 10.0 109.691 169.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 29.9 m120 -79.1 -21.52 46.56 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 124.828 1.251 . . . . 10.0 110.708 177.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.48 127.52 8.03 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 109.802 -1.319 . . . . 10.0 109.802 -174.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.63 131.39 29.36 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 N-CA-C 106.93 -1.988 . . . . 10.0 106.93 169.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.3 t -78.47 101.95 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -169.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -69.7 106.82 3.21 Favored 'General case' 0 N--CA 1.446 -0.667 0 N-CA-C 107.828 -1.175 . . . . 10.0 107.828 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.432 HG12 ' CD2' ' A' ' 20' ' ' PHE . 10.7 m -82.8 111.73 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 N-CA-C 106.265 -1.754 . . . . 10.0 106.265 169.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.8 p90 -122.38 168.0 12.61 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.245 0.545 . . . . 10.0 112.304 170.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.33 -152.51 24.57 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 107.738 -2.145 . . . . 10.0 107.738 169.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.3 p -156.17 155.54 32.65 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 119.306 -0.958 . . . . 10.0 112.527 -176.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.427 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -117.76 129.14 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 125.489 1.516 . . . . 10.0 107.92 168.868 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 48.1 tttp -110.08 148.32 31.95 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.73 1.612 . . . . 10.0 107.138 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.61 -10.02 25.92 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 123.796 0.712 . . . . 10.0 113.891 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.0 mt -73.04 179.25 3.87 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.335 1.054 . . . . 10.0 110.522 178.682 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.3 t -104.86 165.31 11.16 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 167.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -55.38 156.16 4.64 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.489 1.116 . . . . 10.0 113.195 -169.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.98 177.38 51.97 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.429 1.014 . . . . 10.0 112.669 169.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 84.9 mt -40.88 137.88 1.14 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.625 1.97 . . . . 10.0 114.74 175.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.21 150.68 44.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.631 1.572 . . . . 10.0 110.661 170.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.549 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -35.95 123.44 0.73 Allowed Glycine 0 C--N 1.338 0.651 0 CA-C-O 116.855 -2.08 . . . . 10.0 109.39 163.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -149.88 108.11 3.76 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 120.207 2.003 . . . . 10.0 109.205 167.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -154.22 175.47 13.45 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.503 0.668 . . . . 10.0 110.763 -176.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.97 156.63 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.639 0 CA-C-N 112.425 -2.171 . . . . 10.0 108.297 168.319 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -132.99 130.81 39.99 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 104.259 -2.497 . . . . 10.0 104.259 174.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -58.25 -53.08 62.37 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.162 0.914 . . . . 10.0 111.321 -168.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -77.04 135.93 38.66 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 118.388 -1.325 . . . . 10.0 107.71 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.07 -31.79 72.5 Favored Glycine 0 N--CA 1.441 -0.97 0 N-CA-C 109.59 -1.404 . . . . 10.0 109.59 169.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -36.35 126.86 0.8 Allowed 'General case' 0 C--N 1.341 0.216 0 C-N-CA 126.352 1.861 . . . . 10.0 112.761 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -130.48 9.94 5.17 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 114.445 -1.252 . . . . 10.0 110.894 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.442 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -54.61 -35.68 63.67 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.312 1.045 . . . . 10.0 112.112 -169.618 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.35 -17.17 58.47 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.197 0.599 . . . . 10.0 112.241 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.89 76.31 0.88 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 108.865 -1.694 . . . . 10.0 108.865 -177.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.84 6.52 0.91 Allowed 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.086 1.354 . . . . 10.0 113.312 176.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 45.1 m -98.72 -42.11 7.37 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 107.774 -1.195 . . . . 10.0 107.774 -169.029 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.93 -39.62 71.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 123.771 0.828 . . . . 10.0 111.022 -169.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.78 -25.2 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.754 3.621 . . . . 10.0 116.863 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.92 121.98 3.95 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.437 -1.465 . . . . 10.0 109.437 172.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.16 73.25 1.1 Allowed 'Trans proline' 0 CA--C 1.54 0.792 0 C-N-CA 123.596 2.864 . . . . 10.0 111.759 177.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 25.4 m170 61.09 46.84 7.79 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.624 3.17 . . . . 10.0 111.305 176.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -74.29 48.66 0.34 Allowed 'General case' 0 N--CA 1.467 0.39 0 O-C-N 121.799 -0.563 . . . . 10.0 111.993 178.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -63.62 149.45 92.42 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 121.36 -0.837 . . . . 10.0 108.804 178.037 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -54.23 -60.03 0.73 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 122.977 2.451 . . . . 10.0 111.879 -172.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.01 66.5 2.22 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.743 -0.598 . . . . 10.0 109.665 169.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t -59.1 102.5 0.13 Allowed 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.459 ' HE ' ' HA ' ' A' ' 78' ' ' GLU . 43.5 mtp85 -105.36 -89.9 0.42 Allowed 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 106.063 -1.828 . . . . 10.0 106.063 -176.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.2 mmtt -143.32 146.62 33.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.244 0.545 . . . . 10.0 109.664 168.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.0 t60 -55.99 121.57 9.64 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 117.976 -1.489 . . . . 10.0 107.6 165.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.71 -149.99 5.48 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.09 -150.97 8.17 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.265 -1.297 . . . . 10.0 110.675 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -70.05 17.37 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.849 1.699 . . . . 10.0 111.285 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.17 -19.33 16.49 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 108.017 -1.105 . . . . 10.0 108.017 168.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.28 -178.59 4.91 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.895 -1.15 . . . . 10.0 107.895 -168.204 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -116.39 -5.4 11.76 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 123.424 0.69 . . . . 10.0 110.734 170.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.459 ' HA ' ' HE ' ' A' ' 69' ' ' ARG . 0.8 OUTLIER -98.11 -2.88 39.04 Favored 'General case' 0 CA--C 1.517 -0.323 0 O-C-N 121.02 -1.05 . . . . 10.0 111.536 -174.258 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 9.6 ptt85 -28.76 129.83 0.07 Allowed 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.408 2.283 . . . . 10.0 111.019 167.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -59.52 151.99 22.95 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.968 -0.753 . . . . 10.0 108.968 172.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 94.5 t -59.5 89.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.955 -1.128 . . . . 10.0 107.955 171.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.64 28.58 3.42 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 125.724 1.631 . . . . 10.0 113.496 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -85.92 101.04 12.52 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 105.055 -2.202 . . . . 10.0 105.055 164.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.65 16.48 1.75 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 119.286 0.948 . . . . 10.0 110.83 173.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.03 -107.98 2.49 Favored Glycine 0 N--CA 1.434 -1.499 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 -179.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -155.94 144.59 20.27 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 106.646 -1.613 . . . . 10.0 106.646 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -120.77 135.99 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 C-N-CA 123.062 0.545 . . . . 10.0 109.867 -171.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -82.72 131.85 35.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 125.134 1.374 . . . . 10.0 109.616 -174.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.76 142.24 31.5 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 123.918 0.887 . . . . 10.0 110.897 170.07 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -60.93 167.43 2.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.473 1.109 . . . . 10.0 109.744 166.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.4 ptmt -54.1 -26.77 28.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.149 1.379 . . . . 10.0 112.184 173.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -75.9 -29.94 58.61 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 109.75 -0.463 . . . . 10.0 109.75 177.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 112.05 4.71 25.7 Favored Glycine 0 N--CA 1.446 -0.68 0 CA-C-O 118.626 -1.097 . . . . 10.0 111.216 -169.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.7 t -78.61 99.1 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 C-N-CA 125.069 1.347 . . . . 10.0 108.279 177.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 117.47 33.38 Favored 'General case' 0 CA--C 1.518 -0.264 0 N-CA-C 106.886 -1.524 . . . . 10.0 106.886 166.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -89.03 119.78 29.86 Favored 'General case' 0 N--CA 1.436 -1.142 0 C-N-CA 127.879 2.472 . . . . 10.0 109.106 177.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.6 t -105.15 135.06 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 C-N-CA 125.127 1.371 . . . . 10.0 107.787 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 88.9 p -159.72 69.74 0.43 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.309 0.855 . . . . 10.0 113.309 172.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -123.96 143.19 38.08 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 124.53 1.132 . . . . 10.0 110.38 -170.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -116.28 149.84 38.57 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.942 2.097 . . . . 10.0 110.128 173.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -149.87 153.39 36.63 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 106.744 -1.576 . . . . 10.0 106.744 167.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 78.1 p -95.47 56.04 1.78 Allowed 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 125.395 1.478 . . . . 10.0 108.528 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 58.4 t -144.12 -53.18 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -176.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.7 mm -54.48 139.08 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 C-N-CA 124.022 0.929 . . . . 10.0 109.488 173.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.9 m -155.15 134.94 12.78 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 169.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.6 mt -55.85 -52.04 65.42 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.645 1.178 . . . . 10.0 110.436 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.0 t -140.52 -179.27 5.93 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.313 0.645 . . . . 10.0 109.514 176.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.85 -100.3 0.56 Allowed Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 106.22 -2.752 . . . . 10.0 106.22 -170.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -128.92 -49.77 1.23 Allowed 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 125.356 1.462 . . . . 10.0 108.356 -169.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.5 -41.07 48.32 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.888 -1.051 . . . . 10.0 108.867 -176.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t 38.71 89.81 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.391 2.276 . . . . 10.0 113.796 172.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pp -73.63 -15.31 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 112.534 0.568 . . . . 10.0 112.534 178.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.3 mm -50.12 122.63 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 O-C-N 121.188 -0.945 . . . . 10.0 110.412 174.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.44 5.43 56.94 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.466 1.032 . . . . 10.0 112.968 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.6 mpt_? -75.66 179.38 5.41 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.017 0.927 . . . . 10.0 109.533 169.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -129.72 141.56 50.87 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 173.284 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.659 HD11 HD11 ' A' ' 149' ' ' ILE . 6.1 mp -107.94 157.43 18.22 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.75 -0.833 . . . . 10.0 108.75 168.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -140.04 137.86 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 O-C-N 123.934 0.771 . . . . 10.0 109.206 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.4 m -103.25 134.56 44.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 O-C-N 124.473 1.108 . . . . 10.0 108.912 164.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.549 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.7 m170 -110.83 159.21 17.88 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 114.497 1.295 . . . . 10.0 114.497 -174.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.73 -50.05 73.37 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.973 1.309 . . . . 10.0 110.46 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -113.03 172.17 7.1 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.629 0.728 . . . . 10.0 112.366 -177.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.22 151.24 33.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.138 1.375 . . . . 10.0 109.503 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -79.49 147.04 32.38 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.207 0.447 . . . . 10.0 112.207 176.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -86.49 3.02 45.81 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.506 1.129 . . . . 10.0 111.637 168.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.4 mt 48.06 51.89 13.94 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 125.247 1.419 . . . . 10.0 111.859 170.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.38 -7.87 64.13 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 113.756 -1.565 . . . . 10.0 112.187 173.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -114.23 35.16 4.29 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.25 1.02 . . . . 10.0 110.691 -168.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -82.89 -23.55 55.3 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 126.124 1.821 . . . . 10.0 111.697 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.44 48.1 81.48 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-N 118.184 0.992 . . . . 10.0 111.547 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.517 ' H ' ' HB2' ' A' ' 134' ' ' SER . 37.3 m-80 -158.13 167.4 29.93 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 127.746 2.418 . . . . 10.0 105.734 -175.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -57.49 -44.51 85.01 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.627 0.727 . . . . 10.0 109.645 175.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -52.89 -31.15 38.16 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.788 0.835 . . . . 10.0 112.327 175.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.517 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 7.0 t -46.77 -47.14 20.86 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 124.054 0.942 . . . . 10.0 109.035 178.24 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.6 t -83.67 0.56 46.45 Favored 'General case' 0 CA--C 1.539 0.556 0 CA-C-O 118.35 -0.833 . . . . 10.0 112.714 -173.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -121.55 -83.02 0.66 Allowed 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.464 1.906 . . . . 10.0 111.897 -174.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.36 24.46 13.06 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 121.759 2.072 . . . . 10.0 110.662 174.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.89 -87.3 0.29 Allowed Glycine 0 C--N 1.34 0.793 0 C-N-CA 125.151 1.358 . . . . 10.0 110.027 175.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.22 34.08 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 125.233 1.413 . . . . 10.0 110.477 172.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.98 -9.76 56.28 Favored 'General case' 0 C--N 1.341 0.212 0 O-C-N 121.041 -1.037 . . . . 10.0 112.192 -172.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.77 -163.62 52.66 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 169.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -49.73 123.79 8.53 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.161 1.384 . . . . 10.0 113.428 -168.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -63.54 74.18 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.259 1.824 . . . . 10.0 110.734 173.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 52.7 mt -49.68 -36.81 26.3 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 113.189 0.811 . . . . 10.0 113.189 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.31 144.44 23.0 Favored 'General case' 0 CA--C 1.513 -0.442 0 O-C-N 121.711 -0.618 . . . . 10.0 109.418 178.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.9 p -132.37 152.16 51.56 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 124.206 0.941 . . . . 10.0 109.876 176.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.39 141.98 11.26 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.297 -1.121 . . . . 10.0 110.297 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.5 t -97.11 142.71 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 105.971 -1.863 . . . . 10.0 105.971 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.659 HD11 HD11 ' A' ' 117' ' ' LEU . 14.1 mt -79.29 136.7 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 N-CA-C 110.038 -0.356 . . . . 10.0 110.038 -176.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.84 145.49 17.34 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.75 1.167 . . . . 10.0 111.877 -175.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.3 mt -67.83 139.57 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 124.4 1.08 . . . . 10.0 108.362 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.9 -26.92 2.59 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 114.805 1.409 . . . . 10.0 114.805 -176.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.025 0 CA-C-O 117.61 -1.186 . . . . 10.0 111.84 -178.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.789 0 CA-C-O 116.73 -1.605 . . . . 10.0 107.134 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t -68.99 -18.83 64.11 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-N 120.533 1.515 . . . . 10.0 108.615 169.098 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.6 ptpt -144.39 162.27 36.9 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 120.831 0.348 . . . . 10.0 110.88 165.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -152.95 166.87 31.03 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 127.139 2.175 . . . . 10.0 107.645 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.71 162.79 36.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 C-N-CA 123.419 0.688 . . . . 10.0 111.014 -176.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.39 108.51 5.48 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.931 0.892 . . . . 10.0 109.307 168.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.1 m -82.5 81.81 1.53 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.485 0.714 . . . . 10.0 110.294 171.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -73.13 127.18 31.86 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.714 -0.847 . . . . 10.0 108.714 -171.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.6 mtmp? -147.54 160.36 42.71 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.324 -0.991 . . . . 10.0 108.324 -177.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.17 -57.51 0.06 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 120.479 -0.867 . . . . 10.0 112.928 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -72.65 -43.85 62.63 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 -175.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.02 -70.97 0.43 Allowed Glycine 0 CA--C 1.524 0.596 0 CA-C-N 114.273 -1.33 . . . . 10.0 110.078 171.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -56.46 -34.26 94.27 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.056 2.504 . . . . 10.0 111.28 172.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.8 t -66.83 100.63 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 176.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -122.35 109.52 14.52 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 174.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.642 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.56 134.86 11.98 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.751 -1.34 . . . . 10.0 109.751 169.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.442 ' CG2' HG23 ' A' ' 54' ' ' THR . 17.7 mt -129.55 67.66 0.34 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.153 0 N-CA-C 107.255 -1.387 . . . . 10.0 107.255 -174.273 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -89.25 137.92 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 114.611 -1.177 . . . . 10.0 109.735 -171.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -120.68 116.03 24.49 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.051 2.14 . . . . 10.0 107.97 -173.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -98.72 109.62 22.35 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 116.986 -1.483 . . . . 10.0 107.672 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -104.18 138.87 40.03 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 119.856 1.207 . . . . 10.0 112.592 169.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 40.2 tp60 -124.21 91.89 3.55 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 129.719 3.208 . . . . 10.0 107.288 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 59.0 tttt . . . . . 0 N--CA 1.426 -1.646 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 177.477 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.039 0 CA-C-O 117.21 -1.883 . . . . 10.0 116.279 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -68.26 128.27 17.17 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 CA-C-N 121.362 2.581 . . . . 10.0 106.174 168.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . 0.455 ' CG1' HD11 ' B' ' 104' ' ' ILE . 1.3 p -76.92 112.39 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.547 0 N-CA-C 105.968 -1.864 . . . . 10.0 105.968 169.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.5 tttt -85.77 107.19 17.5 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.994 -2.225 . . . . 10.0 104.994 172.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 p -95.48 96.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 C-N-CA 126.816 2.046 . . . . 10.0 105.733 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.0 p90 -117.65 169.04 9.89 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 121.827 0.822 . . . . 10.0 112.228 173.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.9 -157.26 27.2 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 106.959 -2.456 . . . . 10.0 106.959 169.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 p -149.24 160.3 43.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 176.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.642 HG22 ' HA2' ' B' ' 16' ' ' GLY . 1.5 pp -111.52 175.61 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 CA-C-N 114.69 -1.141 . . . . 10.0 109.393 167.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ptmt -143.83 141.43 30.35 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 106.185 -1.783 . . . . 10.0 106.185 166.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.02 -5.43 20.14 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.122 0.867 . . . . 10.0 114.734 170.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.607 HD23 HD13 ' B' ' 35' ' ' ILE . 0.6 OUTLIER -70.07 178.13 2.89 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 118.712 1.256 . . . . 10.0 111.502 -179.739 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.6 t -111.76 156.14 22.41 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 167.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -50.26 156.67 0.79 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.362 1.465 . . . . 10.0 113.073 -169.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.57 -169.24 32.61 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 123.422 0.534 . . . . 10.0 111.784 168.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.49 146.33 44.99 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 124.61 1.164 . . . . 10.0 111.135 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -143.2 151.19 40.34 Favored 'General case' 0 C--N 1.34 0.19 0 N-CA-C 113.684 0.994 . . . . 10.0 113.684 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.697 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.05 119.68 0.16 Allowed Glycine 0 C--N 1.339 0.714 0 C-N-CA 129.337 3.351 . . . . 10.0 113.662 166.408 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -152.4 112.48 4.02 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 120.047 1.923 . . . . 10.0 112.785 168.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.44 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 1.0 OUTLIER -142.22 173.1 11.83 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.645 0.736 . . . . 10.0 111.532 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 46.1 t -106.43 117.77 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 CA-C-N 111.927 -2.397 . . . . 10.0 104.691 168.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -92.81 148.61 21.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 172.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -60.1 -57.16 14.03 Favored 'General case' 0 N--CA 1.45 -0.475 0 CA-C-N 115.113 -0.949 . . . . 10.0 109.979 -171.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -77.67 148.49 34.98 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 108.91 -0.774 . . . . 10.0 108.91 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.55 -5.33 69.33 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 125.022 1.296 . . . . 10.0 110.15 166.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -40.7 143.03 0.38 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.805 1.242 . . . . 10.0 111.422 169.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.508 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -153.29 23.56 0.55 Allowed 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 113.89 -1.505 . . . . 10.0 111.359 168.309 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.429 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.83 -36.15 71.86 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 118.685 0.675 . . . . 10.0 110.865 -172.361 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.92 -22.98 39.23 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.673 1.189 . . . . 10.0 112.966 175.411 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.24 107.42 1.46 Allowed Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.251 0.929 . . . . 10.0 111.45 -174.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 28.7 m 33.45 55.55 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 127.557 2.343 . . . . 10.0 113.537 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.3 -54.81 0.08 Allowed 'General case' 0 N--CA 1.448 -0.568 0 O-C-N 121.439 -0.788 . . . . 10.0 108.955 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 52.5 m -79.77 -5.52 55.47 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.251 0.621 . . . . 10.0 112.43 -174.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.37 8.31 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.365 1.866 . . . . 10.0 114.829 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.26 113.21 0.99 Allowed Glycine 0 CA--C 1.528 0.862 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 175.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.02 69.17 3.12 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.909 2.406 . . . . 10.0 111.299 175.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.44 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 11.8 m170 70.52 43.29 0.79 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.605 2.762 . . . . 10.0 110.231 170.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -73.95 45.89 0.22 Allowed 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.738 1.215 . . . . 10.0 114.183 -175.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -51.76 155.81 2.73 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.19 1.396 . . . . 10.0 111.54 169.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.47 -51.21 0.76 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.538 2.158 . . . . 10.0 111.866 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . 0.579 HD23 ' H ' ' B' ' 67' ' ' LEU . 1.7 pt? -74.97 53.63 0.61 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.954 0.902 . . . . 10.0 112.7 -177.261 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -54.2 108.82 0.41 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 122.793 0.437 . . . . 10.0 110.133 -171.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 mtt180 -120.61 -91.74 0.55 Allowed 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 105.892 -1.892 . . . . 10.0 105.892 -174.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -148.23 157.11 43.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 168.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -62.02 116.78 5.2 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 117.869 -1.533 . . . . 10.0 107.643 164.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.56 -145.99 6.44 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 107.695 -2.162 . . . . 10.0 107.695 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.4 -164.76 18.09 Favored Glycine 0 C--N 1.33 0.225 0 N-CA-C 108.771 -1.732 . . . . 10.0 108.771 173.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.89 -1.19 3.9 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.983 1.788 . . . . 10.0 110.951 167.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -84.29 -29.35 26.48 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 123.803 0.841 . . . . 10.0 109.279 171.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -107.46 161.72 14.58 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 123.161 0.584 . . . . 10.0 109.483 -170.054 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -92.49 -9.11 42.59 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.512 0.725 . . . . 10.0 109.293 167.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -97.04 0.23 48.34 Favored 'General case' 0 N--CA 1.438 -1.05 0 CA-C-O 116.035 -1.936 . . . . 10.0 113.521 -176.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.8 137.32 0.65 Allowed 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 120.101 1.319 . . . . 10.0 110.57 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -59.32 -37.23 77.27 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 120.159 -0.616 . . . . 10.0 111.341 -170.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.42 HG13 ' H ' ' B' ' 82' ' ' GLY . 2.5 p -154.1 -61.23 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 106.61 -1.626 . . . . 10.0 106.61 172.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.42 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -116.46 -56.04 0.32 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 173.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 39.29 85.5 0.02 OUTLIER 'General case' 0 C--N 1.346 0.429 0 C-N-CA 126.325 1.85 . . . . 10.0 108.618 -167.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -49.79 -33.14 15.63 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.349 1.06 . . . . 10.0 112.749 -166.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.03 -89.13 0.42 Allowed Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 168.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -155.06 101.14 2.23 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.639 -0.875 . . . . 10.0 108.639 -170.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -83.6 128.83 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.137 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 174.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.3 t -90.83 130.33 36.8 Favored 'General case' 0 C--O 1.225 -0.2 0 N-CA-C 108.733 -0.84 . . . . 10.0 108.733 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.15 131.86 48.4 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.407 -0.961 . . . . 10.0 108.407 171.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -58.88 168.31 1.31 Allowed 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 124.246 0.966 . . . . 10.0 109.832 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -30.2 18.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.083 0.953 . . . . 10.0 111.3 170.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.71 -7.09 56.01 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 120.958 -0.297 . . . . 10.0 111.091 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.56 28.14 55.82 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.566 -1.413 . . . . 10.0 109.566 -178.197 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 34.9 t -107.7 115.48 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.862 0 N-CA-C 104.617 -2.364 . . . . 10.0 104.617 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.438 ' HB3' HG13 ' B' ' 35' ' ' ILE . . . -113.53 123.27 49.61 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 107.544 -1.28 . . . . 10.0 107.544 174.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -85.15 119.66 25.78 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 127.32 2.248 . . . . 10.0 109.044 174.14 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 93.9 t -105.12 133.76 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 C-N-CA 124.636 1.174 . . . . 10.0 107.848 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 84.5 p -158.91 72.29 0.56 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 123.564 0.746 . . . . 10.0 111.015 169.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -104.6 153.47 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -117.91 81.74 1.72 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 128.43 2.692 . . . . 10.0 108.103 -176.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -75.84 113.74 13.66 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.768 -1.938 . . . . 10.0 105.768 -176.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 15.1 m -108.48 35.58 3.13 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.819 -1.082 . . . . 10.0 109.963 -174.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.5 p -126.02 -43.07 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-O 118.538 -0.744 . . . . 10.0 110.622 171.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.619 HD13 ' C ' ' B' ' 104' ' ' ILE 0.361 0.0 OUTLIER -91.83 176.11 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 N-CA-C 113.707 1.002 . . . . 10.0 113.707 178.422 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 34.0 m -152.69 145.9 24.7 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 121.615 -0.678 . . . . 10.0 109.972 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -66.23 -18.14 65.17 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 124.159 0.984 . . . . 10.0 112.464 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.9 t . . . . . 0 N--CA 1.451 -0.421 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.467 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.531 0.23 0 N-CA-C 109.89 -0.411 . . . . 10.0 109.89 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.32 0.2 OUTLIER 78.68 -40.22 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 125.264 1.426 . . . . 10.0 112.075 168.817 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.9 mm -24.23 127.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 128.086 2.554 . . . . 10.0 111.342 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 90.2 28.6 17.06 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-O 119.054 -0.859 . . . . 10.0 112.588 -170.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -81.03 176.31 9.93 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.705 -1.22 . . . . 10.0 107.705 166.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -128.66 123.3 32.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.554 -2.017 . . . . 10.0 105.554 167.044 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 mp -96.0 149.75 21.23 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.251 -1.389 . . . . 10.0 107.251 169.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 84.3 t -132.01 133.74 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.703 -1.591 . . . . 10.0 106.703 -174.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -104.34 122.95 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 N-CA-C 107.078 -1.453 . . . . 10.0 107.078 171.155 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.697 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.4 m-70 -105.43 157.44 17.35 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 115.893 1.812 . . . . 10.0 115.893 -171.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.1 tt0 -43.26 -57.5 2.96 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 128.279 2.632 . . . . 10.0 111.009 173.225 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -111.42 162.49 15.02 Favored 'General case' 0 CA--C 1.515 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.664 -170.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.13 140.41 58.79 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.888 1.275 . . . . 10.0 107.586 174.012 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.465 ' OD1' ' HB2' ' B' ' 140' ' ' ALA . 69.2 m-20 -77.34 132.79 38.76 Favored 'General case' 0 N--CA 1.441 -0.919 0 N-CA-C 108.579 -0.897 . . . . 10.0 108.579 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . 0.409 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 6.7 t0 -81.56 -4.22 55.42 Favored 'General case' 0 N--CA 1.448 -0.574 0 O-C-N 123.483 0.489 . . . . 10.0 110.81 174.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 37.6 mt 53.59 41.11 32.15 Favored 'General case' 0 N--CA 1.463 0.188 0 O-C-N 120.455 -1.403 . . . . 10.0 110.629 172.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.99 -29.87 9.35 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-O 119.072 -0.849 . . . . 10.0 113.089 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.409 ' NZ ' ' OD1' ' B' ' 125' ' ' ASP . 0.0 OUTLIER -78.59 10.1 3.49 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 120.054 1.927 . . . . 10.0 113.617 -169.721 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.41 -16.91 69.96 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.009 0.814 . . . . 10.0 112.003 173.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.88 31.55 76.48 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.52 0.581 . . . . 10.0 112.505 174.004 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -142.37 176.01 9.33 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 108.165 -1.05 . . . . 10.0 108.165 171.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -59.01 -45.93 89.46 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 116.219 -0.446 . . . . 10.0 110.637 -175.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -67.05 -26.01 66.54 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 120.937 -1.102 . . . . 10.0 110.324 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -52.09 -48.38 64.76 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 119.546 1.066 . . . . 10.0 110.301 168.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -86.8 -15.26 39.81 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 124.073 0.858 . . . . 10.0 111.851 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.8 ttmm -89.82 -48.56 7.17 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 125.416 1.486 . . . . 10.0 111.666 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.9 p -133.88 -14.49 2.41 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 114.98 1.474 . . . . 10.0 114.98 176.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.37 30.93 8.73 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 119.668 1.122 . . . . 10.0 112.797 -171.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 32.8 m120 50.82 34.74 10.73 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 119.21 1.505 . . . . 10.0 111.918 -177.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . 0.465 ' HB2' ' OD1' ' B' ' 124' ' ' ASP . . . -69.94 -11.71 61.08 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.764 1.226 . . . . 10.0 111.982 -173.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.91 -158.43 53.06 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 109.633 -1.387 . . . . 10.0 109.633 174.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 128.11 35.42 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.61 0.719 . . . . 10.0 110.643 -169.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.01 73.02 0.07 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 123.997 0.919 . . . . 10.0 109.663 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 79.2 mt -45.8 -41.83 11.46 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 124.726 1.211 . . . . 10.0 112.78 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.56 154.17 22.31 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 -171.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.01 164.53 38.33 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.834 -0.621 . . . . 10.0 109.907 -175.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.32 -176.09 14.34 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 -179.118 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.4 t -131.95 141.67 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 173.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 8.2 mt -70.78 115.52 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.441 0.564 . . . . 10.0 110.464 -177.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.71 136.72 13.7 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.696 1.141 . . . . 10.0 111.197 -178.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 83.1 mt -65.87 142.15 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 124.516 1.126 . . . . 10.0 109.993 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.03 -52.63 1.31 Allowed 'General case' 0 C--O 1.225 -0.204 0 C-N-CA 123.277 0.631 . . . . 10.0 110.957 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 13.3 tt0 . . . . . 0 C--O 1.25 1.114 0 CA-C-O 116.356 -1.783 . . . . 10.0 112.937 -172.489 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.757 0 N-CA-C 108.266 -1.013 . . . . 10.0 108.266 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -166.84 -42.97 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.77 1.228 . . . . 10.0 110.039 175.382 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.9 mtpm? -114.13 148.73 36.72 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 171.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.33 163.25 38.8 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.396 1.479 . . . . 10.0 107.725 177.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.43 HG22 ' HA ' ' B' ' 52' ' ' ASP . 0.7 OUTLIER -139.94 167.13 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 122.88 0.472 . . . . 10.0 110.718 -177.94 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.39 114.72 7.95 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 124.14 0.976 . . . . 10.0 108.393 167.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -94.1 118.74 40.75 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 123.832 0.853 . . . . 10.0 108.705 171.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt -104.9 140.89 37.47 Favored 'General case' 0 C--O 1.224 -0.237 0 CA-C-O 118.089 -0.957 . . . . 10.0 109.308 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt -148.42 162.13 40.2 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-N 120.312 1.415 . . . . 10.0 107.866 168.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.29 -72.44 0.02 OUTLIER Glycine 0 C--O 1.228 -0.237 0 CA-C-N 115.117 -0.947 . . . . 10.0 112.295 169.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.73 -41.48 62.48 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 106.972 -1.492 . . . . 10.0 106.972 -170.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.64 -61.39 0.56 Allowed Glycine 0 N--CA 1.441 -0.99 0 CA-C-N 113.697 -1.592 . . . . 10.0 112.401 175.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -55.3 -43.18 61.21 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 CA-C-N 119.12 1.46 . . . . 10.0 110.68 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.415 HG23 HD12 ' A' ' 38' ' ' LEU . 0.2 OUTLIER -64.63 117.51 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.985 0 N-CA-C 108.486 -0.931 . . . . 10.0 108.486 177.219 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.16 109.52 12.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.731 -2.322 . . . . 10.0 104.731 168.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.765 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.39 143.29 17.82 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 109.181 -1.568 . . . . 10.0 109.181 175.477 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.434 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 2.9 mt -143.11 86.87 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 -178.31 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -97.95 145.46 9.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 C-N-CA 123.874 0.87 . . . . 10.0 109.599 177.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -126.13 143.38 51.15 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 125.321 1.448 . . . . 10.0 109.271 170.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -125.57 106.17 9.56 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 107.457 -1.312 . . . . 10.0 107.457 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -103.54 111.57 24.09 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 114.074 1.139 . . . . 10.0 114.074 176.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -78.75 95.06 5.23 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.297 -2.112 . . . . 10.0 105.297 165.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -56.14 -53.7 53.9 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 126.285 1.834 . . . . 10.0 109.741 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.78 -156.88 0.71 Allowed 'General case' 0 N--CA 1.434 -1.236 0 N-CA-C 104.111 -2.551 . . . . 10.0 104.111 168.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.36 -27.48 25.83 Favored 'General case' 0 N--CA 1.443 -0.789 0 O-C-N 122.131 -0.356 . . . . 10.0 110.06 169.141 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -108.23 -6.33 16.41 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.953 1.301 . . . . 10.0 111.314 -171.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.57 149.29 49.52 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.597 -1.001 . . . . 10.0 110.597 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -62.98 125.31 15.62 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 N-CA-C 107.392 -1.811 . . . . 10.0 107.392 169.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.8 t -79.34 103.15 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 106.647 -1.612 . . . . 10.0 106.647 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -67.97 112.49 5.0 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 105.858 -1.905 . . . . 10.0 105.858 167.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -95.62 104.99 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 105.61 -1.996 . . . . 10.0 105.61 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 19.9 p90 -112.48 164.18 13.59 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.238 0.542 . . . . 10.0 109.671 177.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -177.44 157.51 22.21 Favored Glycine 0 N--CA 1.434 -1.464 0 C-N-CA 119.946 -1.121 . . . . 10.0 110.506 176.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.6 p -128.54 86.37 2.44 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 106.853 -1.536 . . . . 10.0 106.853 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.765 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.2 pt -76.99 154.21 5.58 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 C-N-CA 117.736 -1.585 . . . . 10.0 107.271 168.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.1 ptmm? -145.79 119.77 9.38 Favored 'General case' 0 N--CA 1.446 -0.638 0 O-C-N 124.192 0.932 . . . . 10.0 109.242 172.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.28 8.43 4.98 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-O 118.802 -0.999 . . . . 10.0 114.442 166.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.739 HD13 ' H ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -83.07 179.0 7.87 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 107.201 -1.407 . . . . 10.0 107.201 168.795 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -77.9 167.06 22.1 Favored 'General case' 0 N--CA 1.453 -0.317 0 O-C-N 121.04 -1.038 . . . . 10.0 109.174 169.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -65.67 179.09 0.88 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.813 0.845 . . . . 10.0 112.051 -175.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.9 -171.01 44.32 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.211 -0.756 . . . . 10.0 111.211 169.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -76.24 140.46 41.61 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.184 1.394 . . . . 10.0 110.736 -177.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -140.92 139.64 34.36 Favored 'General case' 0 C--N 1.341 0.228 0 N-CA-C 113.907 1.076 . . . . 10.0 113.907 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.507 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.4 117.13 0.46 Allowed Glycine 0 C--N 1.341 0.852 0 C-N-CA 128.646 3.022 . . . . 10.0 111.945 166.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -135.65 109.18 7.93 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 120.005 1.903 . . . . 10.0 110.324 170.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.426 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -151.12 170.07 20.32 Favored 'General case' 0 CA--C 1.513 -0.462 0 C-N-CA 123.413 0.685 . . . . 10.0 110.372 176.679 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 34.2 m -105.39 -27.11 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 C-N-CA 127.048 2.139 . . . . 10.0 113.171 -169.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 24.9 m-70 61.09 165.18 0.08 Allowed 'General case' 0 C--N 1.342 0.244 0 C-N-CA 124.436 1.095 . . . . 10.0 112.92 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -75.99 -56.53 4.58 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 121.726 -0.609 . . . . 10.0 111.121 171.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -75.98 111.26 11.18 Favored 'General case' 0 C--N 1.341 0.216 0 C-N-CA 119.888 -0.725 . . . . 10.0 110.881 -169.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.3 -39.32 95.92 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 108.852 -1.699 . . . . 10.0 108.852 166.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -34.65 122.82 0.53 Allowed 'General case' 0 C--N 1.341 0.223 0 C-N-CA 125.638 1.575 . . . . 10.0 112.219 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -129.06 18.13 6.07 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 124.529 1.132 . . . . 10.0 111.354 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.633 HG23 ' CG2' ' B' ' 17' ' ' ILE . 2.8 m -54.21 -36.75 63.82 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 119.49 1.041 . . . . 10.0 111.036 -175.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.01 -22.04 53.69 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.386 0.674 . . . . 10.0 112.106 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.61 -163.15 18.61 Favored Glycine 0 N--CA 1.443 -0.891 0 N-CA-C 107.328 -2.309 . . . . 10.0 107.328 -169.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 90.5 m -74.69 49.56 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.202 1.401 . . . . 10.0 111.052 176.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -137.58 -45.83 0.55 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 126.493 1.917 . . . . 10.0 109.574 -177.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -47.99 -31.44 5.32 Favored 'General case' 0 C--N 1.341 0.239 0 C-N-CA 123.146 0.578 . . . . 10.0 111.219 171.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.89 -42.01 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 128.132 2.573 . . . . 10.0 114.639 169.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.43 150.33 26.76 Favored Glycine 0 C--N 1.339 0.7 0 N-CA-C 110.64 -0.984 . . . . 10.0 110.64 168.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -80.54 54.43 5.22 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.192 1.928 . . . . 10.0 111.079 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.474 ' CD2' HG22 ' A' ' 137' ' ' THR . 19.6 m170 65.6 -65.93 0.16 Allowed 'General case' 0 C--O 1.226 -0.183 0 C-N-CA 128.502 2.721 . . . . 10.0 111.468 -177.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.265 10.7 p90 36.08 23.4 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 130.594 3.558 . . . . 10.0 118.944 174.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -49.72 158.13 0.9 Allowed Pre-proline 0 CA--C 1.541 0.628 0 C-N-CA 125.98 1.712 . . . . 10.0 114.634 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -57.07 -45.01 38.77 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.583 2.855 . . . . 10.0 112.473 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 78.1 mt -75.1 58.21 0.88 Allowed 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.887 -0.782 . . . . 10.0 108.887 172.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -66.3 72.7 0.08 Allowed 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 128.748 2.819 . . . . 10.0 108.798 -176.697 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 mtt180 -92.16 -91.37 0.16 Allowed 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 105.231 -2.137 . . . . 10.0 105.231 -173.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.1 mttp -149.83 144.48 26.01 Favored 'General case' 0 N--CA 1.425 -1.7 0 N-CA-C 104.21 -2.515 . . . . 10.0 104.21 164.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -52.64 117.59 3.01 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 118.871 -1.131 . . . . 10.0 109.672 167.291 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.4 -154.72 7.9 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 107.037 -2.425 . . . . 10.0 107.037 175.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.407 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -162.92 -160.87 11.6 Favored Glycine 0 C--O 1.225 -0.413 0 N-CA-C 108.755 -1.738 . . . . 10.0 108.755 174.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -65.51 10.08 0.17 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 CA-C-N 120.864 2.332 . . . . 10.0 111.318 169.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.407 ' H ' ' C ' ' A' ' 73' ' ' GLY . 26.1 mmtp -107.36 -13.6 15.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 119.204 0.911 . . . . 10.0 109.065 175.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -140.82 140.5 34.69 Favored 'General case' 0 C--N 1.348 0.526 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 -169.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -76.13 -20.08 57.93 Favored 'General case' 0 C--N 1.332 -0.167 0 O-C-N 121.106 -0.996 . . . . 10.0 108.819 -169.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -77.18 -5.91 50.95 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 124.412 1.085 . . . . 10.0 111.962 -173.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -35.54 133.92 0.35 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.038 1.335 . . . . 10.0 112.862 -179.163 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -61.5 -79.7 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.246 0.545 . . . . 10.0 110.028 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -130.45 -91.42 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -108.93 52.39 0.65 Allowed Glycine 0 CA--C 1.521 0.421 0 N-CA-C 109.899 -1.28 . . . . 10.0 109.899 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.3 m-20 -72.37 93.64 1.54 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 105.759 -1.941 . . . . 10.0 105.759 168.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 26.6 mt -75.32 -29.42 60.01 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.407 ' HA2' HD21 ' A' ' 126' ' ' LEU . . . 99.73 -104.29 2.82 Favored Glycine 0 N--CA 1.439 -1.105 0 N-CA-C 110.559 -1.016 . . . . 10.0 110.559 168.133 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -125.67 101.02 6.69 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 125.713 1.605 . . . . 10.0 110.54 -167.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 5.0 m -110.04 140.19 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.616 0.766 . . . . 10.0 111.334 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.32 129.73 34.74 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 128.079 2.552 . . . . 10.0 112.416 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -110.16 134.48 52.16 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.342 1.457 . . . . 10.0 109.591 169.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -59.46 169.13 1.33 Allowed 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.015 1.326 . . . . 10.0 111.133 169.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 7.0 ptmt -47.52 -33.19 6.06 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.751 2.02 . . . . 10.0 111.348 172.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.69 -14.05 59.04 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 122.64 0.376 . . . . 10.0 111.13 -176.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.03 17.42 51.29 Favored Glycine 0 C--N 1.341 0.839 0 N-CA-C 110.44 -1.064 . . . . 10.0 110.44 -175.215 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.94 109.57 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 C-N-CA 126.645 1.978 . . . . 10.0 106.962 -179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.503 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -105.34 118.28 36.16 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.071 -0.715 . . . . 10.0 109.071 169.361 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -85.01 84.38 7.74 Favored 'General case' 0 N--CA 1.437 -1.119 0 C-N-CA 127.416 2.286 . . . . 10.0 109.327 174.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -75.86 129.57 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.307 0 N-CA-C 105.136 -2.172 . . . . 10.0 105.136 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -156.93 59.72 0.52 Allowed 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 122.869 0.467 . . . . 10.0 109.948 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.51 164.02 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -176.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -134.31 135.41 42.78 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.558 0.743 . . . . 10.0 111.215 169.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -131.1 131.11 43.94 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.973 1.309 . . . . 10.0 108.554 -175.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.5 p -98.31 24.2 7.52 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.851 0.86 . . . . 10.0 110.107 169.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.3 p -149.27 20.41 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.032 0.933 . . . . 10.0 110.722 -172.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -122.28 134.52 65.27 Favored 'Isoleucine or valine' 0 C--N 1.34 0.158 0 N-CA-C 102.591 -3.115 . . . . 10.0 102.591 169.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.5 m -146.73 125.77 12.85 Favored 'General case' 0 CA--C 1.527 0.074 0 CA-C-N 118.451 0.569 . . . . 10.0 109.699 -176.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.9 mp -54.53 -48.42 71.98 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.699 1.199 . . . . 10.0 110.52 177.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -137.02 176.35 8.79 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.549 1.54 . . . . 10.0 106.925 169.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.66 -97.25 0.4 Allowed Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 108.15 -1.98 . . . . 10.0 108.15 -176.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -121.96 -50.98 2.03 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 125.758 1.623 . . . . 10.0 108.461 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -73.5 -42.76 61.42 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.249 -1.389 . . . . 10.0 107.249 -171.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.4 t 47.19 54.88 8.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 126.004 1.722 . . . . 10.0 111.94 169.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.1 pt -60.01 -3.9 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 127.746 2.418 . . . . 10.0 115.222 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.3 mp -52.13 144.16 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 O-C-N 121.26 -0.9 . . . . 10.0 111.258 169.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.82 7.52 87.9 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.163 -0.798 . . . . 10.0 113.064 173.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -85.62 172.72 10.69 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.817 0.809 . . . . 10.0 109.123 170.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -122.43 104.64 9.53 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.908 0.883 . . . . 10.0 110.56 -175.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.467 ' CD2' HD11 ' A' ' 149' ' ' ILE . 3.8 mm? -62.42 130.14 43.88 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 108.261 -1.014 . . . . 10.0 108.261 172.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 51.2 t -119.64 132.65 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 169.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.473 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -100.99 121.86 52.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.245 -1.761 . . . . 10.0 106.245 169.913 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.507 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.2 m170 -106.32 164.16 12.25 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.364 1.246 . . . . 10.0 114.364 -173.625 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -45.13 -57.43 3.91 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 129.354 3.061 . . . . 10.0 111.476 174.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 61.2 mttt -126.17 175.32 7.86 Favored 'General case' 0 CA--C 1.522 -0.116 0 C-N-CA 124.552 1.141 . . . . 10.0 112.581 -169.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.89 152.57 41.4 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.051 1.341 . . . . 10.0 110.878 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -82.77 145.47 29.52 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 116.031 -0.531 . . . . 10.0 111.183 169.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -81.41 -16.07 53.24 Favored 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 125.025 1.453 . . . . 10.0 110.257 166.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.407 HD21 ' HA2' ' A' ' 85' ' ' GLY . 84.4 mt 57.37 64.14 1.68 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 122.721 1.248 . . . . 10.0 109.447 176.691 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.64 -41.41 3.07 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 114.714 -1.13 . . . . 10.0 110.937 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 29.1 mtmm -78.75 36.09 0.26 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.488 1.515 . . . . 10.0 112.341 -174.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.433 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -100.23 -7.27 52.45 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 127.252 2.358 . . . . 10.0 110.892 170.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 42.38 49.53 5.65 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.98 1.752 . . . . 10.0 114.009 177.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -153.29 172.56 16.83 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 169.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.0 mp0 -44.77 -50.64 10.02 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 123.021 0.528 . . . . 10.0 111.104 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.63 -28.36 66.83 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 118.694 -0.67 . . . . 10.0 111.035 -177.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.433 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 7.8 p -54.95 -37.6 66.66 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 119.902 1.228 . . . . 10.0 112.255 175.077 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -85.98 -0.26 55.03 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 123.348 0.405 . . . . 10.0 111.73 -178.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.1 mttt -111.71 -66.46 1.08 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.834 1.254 . . . . 10.0 111.125 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.474 HG22 ' CD2' ' A' ' 63' ' ' HIS . 0.8 OUTLIER -128.99 23.07 5.69 Favored 'General case' 0 CA--C 1.543 0.698 0 CA-C-N 119.434 1.015 . . . . 10.0 112.042 -175.569 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.6 -87.26 0.35 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -172.34 37.93 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 125.164 1.386 . . . . 10.0 109.073 169.055 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.09 -13.92 62.58 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -168.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.23 54.81 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.275 -1.13 . . . . 10.0 110.275 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -56.08 128.75 36.95 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 123.976 0.91 . . . . 10.0 112.038 -168.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.9 mtm105 -66.68 74.79 0.1 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 124.956 1.302 . . . . 10.0 110.44 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 71.0 mt -46.88 -49.78 19.75 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.447 0.699 . . . . 10.0 111.881 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.473 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -151.65 155.63 38.75 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -169.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.17 165.07 37.47 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 122.564 0.346 . . . . 10.0 111.436 -175.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.78 170.16 38.23 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 125.339 1.447 . . . . 10.0 109.931 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 7.7 t -116.96 142.99 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 118.16 0.98 . . . . 10.0 108.693 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.467 HD11 ' CD2' ' A' ' 117' ' ' LEU . 41.2 mt -83.06 119.63 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.717 0 C-N-CA 123.728 0.811 . . . . 10.0 109.303 -176.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.17 159.75 24.13 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.775 -0.53 . . . . 10.0 111.775 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 55.6 mt -74.4 150.9 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 125.086 1.354 . . . . 10.0 110.415 -169.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.95 -106.59 0.38 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 167.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.922 1 C-N-CA 132.302 4.241 . . . . 10.0 102.72 -169.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.624 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.9 t -145.4 -51.81 0.26 Allowed 'General case' 0 CA--C 1.514 -0.418 0 C-N-CA 125.194 1.398 . . . . 10.0 108.482 176.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -110.24 145.81 36.71 Favored 'General case' 0 N--CA 1.44 -0.941 0 C-N-CA 126.567 1.947 . . . . 10.0 106.159 -172.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.57 149.6 30.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 172.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.5 m -129.69 161.31 39.51 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 O-C-N 123.718 0.636 . . . . 10.0 110.388 -176.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.16 105.11 4.03 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.418 -0.956 . . . . 10.0 108.418 170.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.02 91.85 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 170.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -77.36 143.59 38.61 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 108.309 -0.997 . . . . 10.0 108.309 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.14 165.14 32.23 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 107.959 -1.126 . . . . 10.0 107.959 173.027 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -168.67 -58.5 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 115.583 -0.735 . . . . 10.0 111.665 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.52 -45.23 47.17 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 -173.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.04 -68.28 0.52 Allowed Glycine 0 N--CA 1.445 -0.754 0 CA-C-N 113.75 -1.568 . . . . 10.0 110.288 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -57.84 -37.49 96.16 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.852 2.368 . . . . 10.0 111.068 174.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.26 102.76 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 N-CA-C 107.083 -1.451 . . . . 10.0 107.083 175.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -118.97 117.99 30.29 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.73 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -99.17 132.05 10.78 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 172.492 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.633 ' CG2' HG23 ' A' ' 54' ' ' THR . 6.5 mt -135.15 88.62 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 N-CA-C 107.01 -1.478 . . . . 10.0 107.01 -174.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -103.05 140.92 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 125.258 1.423 . . . . 10.0 109.659 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -124.87 112.47 16.68 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.047 1.739 . . . . 10.0 108.109 169.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -93.03 119.24 32.07 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.489 -1.301 . . . . 10.0 107.489 171.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -111.26 143.24 42.36 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 118.926 0.785 . . . . 10.0 111.447 168.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -92.6 118.14 30.7 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 103.909 -2.626 . . . . 10.0 103.909 166.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 79.3 mttt . . . . . 0 C--N 1.33 -0.262 0 CA-C-O 121.742 0.782 . . . . 10.0 109.412 171.955 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.686 0 N-CA-C 108.932 -1.667 . . . . 10.0 108.932 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -65.48 135.73 43.71 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.637 1.558 . . . . 10.0 108.446 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -78.23 107.22 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -77.11 108.91 10.53 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 106.284 -1.747 . . . . 10.0 106.284 170.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -85.85 105.99 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 25.3 p90 -113.99 163.81 14.64 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.444 0.64 . . . . 10.0 110.969 170.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 177.63 170.12 39.51 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.224 -0.75 . . . . 10.0 111.224 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.1 p -140.03 100.55 3.95 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.997 -1.483 . . . . 10.0 106.997 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.73 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.6 pt -78.12 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 C-N-CA 118.64 -1.224 . . . . 10.0 109.247 170.435 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -152.91 155.01 36.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 168.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.4 34.1 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 119.033 -0.87 . . . . 10.0 115.011 169.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.501 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.5 mp -72.45 177.79 4.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 118.934 1.367 . . . . 10.0 110.649 -177.141 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.25 161.56 15.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.295 -1.002 . . . . 10.0 108.295 168.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -55.74 163.34 1.42 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.227 1.011 . . . . 10.0 112.249 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.98 -175.37 33.66 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-O 121.863 0.702 . . . . 10.0 112.501 168.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -68.2 143.91 55.15 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.409 1.484 . . . . 10.0 109.999 -178.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -142.05 147.78 37.39 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 113.394 0.887 . . . . 10.0 113.394 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.63 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.38 125.5 0.27 Allowed Glycine 0 C--N 1.341 0.823 0 C-N-CA 127.738 2.59 . . . . 10.0 111.878 165.269 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -151.69 108.64 3.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 119.104 1.452 . . . . 10.0 110.473 166.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -147.66 172.29 14.29 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 122.407 1.099 . . . . 10.0 113.046 179.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.96 134.75 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.671 0 CA-C-N 111.191 -2.731 . . . . 10.0 106.418 169.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 47.1 m-70 -116.77 141.44 48.2 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 106.214 -1.773 . . . . 10.0 106.214 171.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -54.68 -52.23 63.03 Favored 'General case' 0 N--CA 1.451 -0.399 0 O-C-N 124.144 0.903 . . . . 10.0 111.915 -168.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -76.92 137.78 39.3 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 -175.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.62 12.51 51.78 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 124.381 0.991 . . . . 10.0 111.649 167.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.43 ' HA ' HG22 ' A' ' 5' ' ' VAL . 0.0 OUTLIER -79.69 174.76 11.26 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-O 121.864 0.84 . . . . 10.0 110.123 -179.503 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -165.3 30.56 0.06 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.552 -1.204 . . . . 10.0 112.641 168.625 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.434 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.41 -35.24 79.75 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 119.696 1.134 . . . . 10.0 112.423 -168.923 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.46 -20.75 50.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 118.06 0.391 . . . . 10.0 111.737 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.73 -160.43 13.2 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 105.852 -2.899 . . . . 10.0 105.852 -167.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 59.9 m -70.21 65.75 0.27 Allowed 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 126.321 1.848 . . . . 10.0 111.547 -175.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -153.38 -52.53 0.1 Allowed 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 124.446 1.098 . . . . 10.0 108.727 177.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 18.4 m -51.38 -34.94 36.52 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.205 1.002 . . . . 10.0 111.809 -177.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -26.8 -38.88 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.848 2.859 . . . . 10.0 114.47 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 110.39 139.69 8.3 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 110.285 -1.126 . . . . 10.0 110.285 169.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.27 55.54 4.65 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.61 3.54 . . . . 10.0 113.266 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 18.2 m170 62.88 48.58 3.94 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.418 2.287 . . . . 10.0 109.197 178.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -66.84 71.78 0.09 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.296 1.038 . . . . 10.0 111.68 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.0 p-10 -84.1 153.33 63.05 Favored Pre-proline 0 C--N 1.326 -0.45 0 O-C-N 121.212 -0.93 . . . . 10.0 111.84 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.66 -43.9 1.7 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.685 2.256 . . . . 10.0 111.447 176.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.0 mt -75.98 62.27 1.61 Allowed 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.711 0.805 . . . . 10.0 109.94 -178.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.2 p -40.28 99.87 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.423 1.889 . . . . 10.0 112.796 -173.087 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 14.2 mtp180 -140.26 177.71 7.8 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 126.058 1.743 . . . . 10.0 107.961 -175.27 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.5 mttt -110.66 82.47 1.6 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 112.218 0.451 . . . . 10.0 112.218 -168.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.459 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 69.1 t60 18.0 93.4 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 116.275 1.954 . . . . 10.0 116.275 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.07 -157.45 16.41 Favored Glycine 0 N--CA 1.441 -0.983 0 C-N-CA 125.223 1.392 . . . . 10.0 110.766 177.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -165.86 -159.21 11.56 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 106.351 -2.699 . . . . 10.0 106.351 169.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -63.88 6.45 0.28 Allowed 'Trans proline' 0 CA--C 1.543 0.967 0 CA-C-N 120.665 2.233 . . . . 10.0 111.546 168.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.415 ' H ' ' C ' ' B' ' 73' ' ' GLY . 11.7 mmmt -114.15 5.88 16.1 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 125.59 1.556 . . . . 10.0 110.064 176.108 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -141.32 169.13 18.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 119.729 1.15 . . . . 10.0 109.342 167.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.71 -27.05 29.27 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 166.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.87 33.51 0.33 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 124.621 1.168 . . . . 10.0 113.217 -171.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.02 138.76 11.3 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 167.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.459 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 30.9 m80 -66.48 -62.45 1.46 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 118.16 -1.416 . . . . 10.0 108.611 169.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.4 p -164.45 -58.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 108.679 -0.86 . . . . 10.0 108.679 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.8 66.5 0.35 Allowed Glycine 0 C--N 1.334 0.471 0 N-CA-C 109.067 -1.613 . . . . 10.0 109.067 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -112.07 101.62 9.89 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.822 -1.918 . . . . 10.0 105.822 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 19.4 mt -72.65 -18.37 61.58 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.27 0.486 . . . . 10.0 112.195 -169.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 112.73 -95.44 0.78 Allowed Glycine 0 N--CA 1.443 -0.866 0 N-CA-C 106.781 -2.528 . . . . 10.0 106.781 -173.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -155.12 150.61 27.35 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.099 -1.075 . . . . 10.0 108.099 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.05 131.39 62.41 Favored 'Isoleucine or valine' 0 C--O 1.232 0.143 0 N-CA-C 107.332 -1.359 . . . . 10.0 107.332 168.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -95.22 119.12 33.18 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.006 0.522 . . . . 10.0 109.594 -176.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.96 133.54 38.61 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.707 1.203 . . . . 10.0 110.261 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -61.31 168.99 2.38 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.572 1.149 . . . . 10.0 109.215 166.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.18 -29.41 45.66 Favored 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 123.357 0.663 . . . . 10.0 111.385 172.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -77.63 -5.04 48.98 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 121.204 0.526 . . . . 10.0 111.423 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.0 3.17 88.0 Favored Glycine 0 C--N 1.338 0.694 0 O-C-N 120.785 -1.197 . . . . 10.0 111.067 -176.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.47 106.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.16 -1.422 . . . . 10.0 107.16 179.251 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.452 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -103.46 126.01 50.36 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 109.18 -0.674 . . . . 10.0 109.18 170.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -79.43 126.33 30.7 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 168.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 54.1 t -107.23 131.16 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 168.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.1 p -157.92 56.2 0.48 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 118.316 0.507 . . . . 10.0 111.152 176.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.93 152.05 4.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 C-N-CA 124.301 1.04 . . . . 10.0 109.055 -171.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -102.86 106.8 17.44 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 125.766 1.626 . . . . 10.0 108.865 174.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -80.11 77.58 6.81 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.103 -1.443 . . . . 10.0 107.103 175.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.1 m -80.61 50.03 1.26 Allowed 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -155.38 -48.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 C-N-CA 122.606 0.362 . . . . 10.0 110.994 -168.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.499 ' C ' HD12 ' B' ' 104' ' ' ILE 0.343 1.1 pp -104.22 177.09 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 C-N-CA 123.6 0.76 . . . . 10.0 112.24 178.482 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -138.12 138.92 39.15 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.848 -1.167 . . . . 10.0 107.848 171.209 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.88 -24.68 26.56 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 104.149 -2.538 . . . . 10.0 104.149 168.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 32.2 t . . . . . 0 N--CA 1.445 -0.693 0 CA-C-O 120.342 0.115 . . . . 10.0 111.306 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 8.1 pt -69.83 49.69 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 C-N-CA 125.783 1.633 . . . . 10.0 111.848 176.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -97.95 151.4 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 C-N-CA 126.5 1.92 . . . . 10.0 107.052 171.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 59.52 32.27 72.78 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.319 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 mmt-85 -105.34 170.44 7.88 Favored 'General case' 0 CA--C 1.536 0.424 0 N-CA-C 106.612 -1.625 . . . . 10.0 106.612 168.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.6 m -112.95 129.38 56.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 177.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.494 HD21 HD11 ' B' ' 149' ' ' ILE . 64.6 mt -102.07 141.57 34.71 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 107.806 -1.183 . . . . 10.0 107.806 173.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 67.8 t -129.39 133.32 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.084 -1.45 . . . . 10.0 107.084 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -106.51 134.09 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 105.963 -1.866 . . . . 10.0 105.963 169.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.63 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.1 m170 -112.13 157.6 20.64 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 123.589 1.661 . . . . 10.0 114.63 -170.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . 0.475 ' N ' HD22 ' B' ' 144' ' ' LEU . 52.1 tt0 -45.79 -53.24 9.9 Favored 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 128.102 2.561 . . . . 10.0 110.041 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -119.58 175.56 5.79 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 125.084 1.354 . . . . 10.0 111.234 -172.27 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.91 149.68 37.69 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 124.667 1.187 . . . . 10.0 110.48 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.453 ' OD1' ' HA2' ' B' ' 44' ' ' GLY . 1.3 m-20 -77.13 135.62 38.57 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 123.325 0.65 . . . . 10.0 110.238 170.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.3 m-20 -77.13 -21.29 54.41 Favored 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 124.891 1.369 . . . . 10.0 109.72 168.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 76.9 mt 60.71 58.5 2.39 Favored 'General case' 0 C--N 1.342 0.253 0 CA-C-O 123.279 1.514 . . . . 10.0 109.387 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.36 -43.23 3.11 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 112.737 -2.029 . . . . 10.0 110.158 169.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 17.9 mtmm -78.24 44.28 0.49 Allowed 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.625 1.57 . . . . 10.0 111.821 -175.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.21 -33.82 7.47 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.574 2.035 . . . . 10.0 110.12 172.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.17 33.69 48.74 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 123.473 0.559 . . . . 10.0 112.278 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -145.11 165.5 28.08 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 105.905 -1.887 . . . . 10.0 105.905 174.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -55.08 -48.42 73.56 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-O 121.246 0.546 . . . . 10.0 110.068 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -59.86 -30.35 68.92 Favored 'General case' 0 N--CA 1.453 -0.312 0 O-C-N 121.69 -0.631 . . . . 10.0 111.726 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -51.84 -51.91 53.2 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 121.358 -0.838 . . . . 10.0 110.174 169.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.9 t -82.19 -10.74 59.05 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.841 -0.618 . . . . 10.0 112.105 -173.082 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.4 ttmm -100.17 -52.73 3.32 Favored 'General case' 0 N--CA 1.436 -1.143 0 C-N-CA 125.417 1.487 . . . . 10.0 111.506 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.0 p -140.05 31.18 1.99 Allowed 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.65 0.78 . . . . 10.0 112.2 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.23 19.65 64.28 Favored Glycine 0 C--N 1.339 0.706 0 CA-C-N 119.246 0.93 . . . . 10.0 112.29 174.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 53.62 26.14 5.52 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 117.915 0.858 . . . . 10.0 112.325 -173.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.37 0.78 3.53 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.698 -0.626 . . . . 10.0 112.455 -178.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.75 -165.18 47.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 109.918 -1.273 . . . . 10.0 109.918 168.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -54.19 134.11 44.5 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.61 0.719 . . . . 10.0 110.084 -172.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.04 67.59 0.07 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 169.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.475 HD22 ' N ' ' B' ' 121' ' ' GLU . 1.1 pt? -61.71 -25.18 67.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.815 0.672 . . . . 10.0 112.815 -168.174 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -154.33 148.68 26.08 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.133 0.492 . . . . 10.0 109.793 177.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 21.2 p -158.13 168.78 26.13 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.947 0.499 . . . . 10.0 109.958 -175.082 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -165.53 167.51 39.02 Favored Glycine 0 CA--C 1.528 0.844 0 N-CA-C 110.704 -0.959 . . . . 10.0 110.704 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 74.0 t -109.64 142.85 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.38 0 C-N-CA 125.48 1.512 . . . . 10.0 107.139 -169.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.494 HD11 HD21 ' B' ' 117' ' ' LEU . 67.7 mt -80.35 112.88 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 C-N-CA 122.492 0.317 . . . . 10.0 110.793 -172.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.05 145.39 17.66 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 124.691 1.138 . . . . 10.0 110.745 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 44.9 mt -62.89 148.52 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 124.473 1.109 . . . . 10.0 109.661 174.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.34 170.13 17.43 Favored 'General case' 0 N--CA 1.439 -0.983 0 CA-C-O 122.619 1.2 . . . . 10.0 110.84 168.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 . . . . . 0 C--O 1.25 1.082 0 C-N-CA 129.585 3.154 . . . . 10.0 103.097 165.132 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.803 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -156.35 -44.29 0.07 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 118.47 0.577 . . . . 10.0 110.955 172.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.5 ttpp -113.78 142.87 45.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 106.918 -1.512 . . . . 10.0 106.918 167.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.74 171.06 14.77 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.477 -1.305 . . . . 10.0 107.477 171.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -140.42 166.59 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 123.897 0.879 . . . . 10.0 110.235 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.68 112.37 5.36 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 168.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.448 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.4 m -97.59 114.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 173.124 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -103.51 137.2 41.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 -174.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -146.33 165.39 29.44 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.924 1.238 . . . . 10.0 107.998 170.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.71 -58.81 0.04 OUTLIER Glycine 0 C--O 1.23 -0.096 0 CA-C-N 115.024 -0.989 . . . . 10.0 112.791 169.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.41 -44.91 49.82 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -171.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.48 -65.7 0.57 Allowed Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 113.601 -1.636 . . . . 10.0 110.659 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -59.0 -37.1 95.24 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.737 2.291 . . . . 10.0 111.315 174.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -67.33 106.58 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.007 0 N-CA-C 107.017 -1.475 . . . . 10.0 107.017 175.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -121.78 106.81 11.63 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.03 -1.841 . . . . 10.0 106.03 170.007 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.819 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -89.43 143.39 17.26 Favored Glycine 0 N--CA 1.434 -1.491 0 N-CA-C 109.66 -1.376 . . . . 10.0 109.66 173.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.634 HG22 HG23 ' B' ' 54' ' ' THR . 1.1 mt -150.22 84.56 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.207 -1.405 . . . . 10.0 107.207 -169.286 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.574 HD12 ' HA3' ' A' ' 33' ' ' GLY . 1.0 OUTLIER -96.19 145.43 8.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 C-N-CA 125.273 1.429 . . . . 10.0 110.963 175.815 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -128.95 117.49 21.05 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.942 2.097 . . . . 10.0 109.126 169.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -95.52 125.45 40.13 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.72 1.208 . . . . 10.0 108.862 178.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.53 132.99 53.62 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 125.121 1.368 . . . . 10.0 111.456 175.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -132.64 79.71 1.86 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 127.971 2.508 . . . . 10.0 106.045 168.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -56.12 -45.63 79.47 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 127.873 2.469 . . . . 10.0 110.658 -172.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -122.75 161.71 23.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 102.305 -3.22 . . . . 10.0 102.305 167.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -58.51 -30.27 66.92 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.473 -0.785 . . . . 10.0 109.073 174.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 m-80 -90.26 -9.13 49.1 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 124.892 1.277 . . . . 10.0 111.037 -174.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.29 138.8 27.01 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -59.82 135.46 63.68 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 N-CA-C 106.044 -2.329 . . . . 10.0 106.044 168.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 t -78.73 129.06 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.016 -1.476 . . . . 10.0 107.016 -170.244 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt -101.01 118.15 36.44 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -103.03 96.74 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 172.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -103.4 167.14 10.0 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 121.932 0.872 . . . . 10.0 110.613 168.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.574 ' HA3' HD12 ' A' ' 18' ' ' ILE . . . 176.03 -177.74 47.61 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.616 -0.802 . . . . 10.0 111.211 175.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.8 m -154.5 91.77 1.43 Allowed 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 -175.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.819 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.5 pt -78.96 151.68 4.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 CA-C-O 118.327 -0.844 . . . . 10.0 108.775 169.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.408 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -135.6 156.4 48.92 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 165.614 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.33 -10.13 39.21 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 123.836 0.731 . . . . 10.0 112.887 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -68.68 176.26 3.08 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 118.172 0.986 . . . . 10.0 109.641 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.1 t -105.32 150.41 25.21 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.451 -1.314 . . . . 10.0 107.451 167.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -50.86 146.11 6.34 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.115 0.966 . . . . 10.0 112.276 -169.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.3 -179.26 29.51 Favored Glycine 0 CA--C 1.528 0.85 0 C-N-CA 124.279 0.942 . . . . 10.0 112.128 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mt -57.85 148.72 24.5 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.133 2.173 . . . . 10.0 112.87 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -150.88 147.92 27.81 Favored 'General case' 0 CA--C 1.518 -0.254 0 C-N-CA 125.78 1.632 . . . . 10.0 112.18 176.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.621 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -33.17 125.36 0.33 Allowed Glycine 0 C--N 1.338 0.68 0 C-N-CA 126.462 1.982 . . . . 10.0 112.2 164.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -153.13 107.52 3.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 119.158 1.479 . . . . 10.0 110.279 166.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.4 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -154.93 169.52 23.85 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.67 0.748 . . . . 10.0 112.021 -179.214 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.1 m -84.72 153.18 3.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 112.663 -2.062 . . . . 10.0 107.715 168.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.91 148.43 50.49 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 107.536 -1.283 . . . . 10.0 107.536 171.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -35.91 -60.94 0.51 Allowed 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 126.576 1.95 . . . . 10.0 113.736 -170.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -98.8 161.14 13.8 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-O 121.925 0.869 . . . . 10.0 111.368 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.34 -22.88 28.25 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 126.46 1.981 . . . . 10.0 109.866 168.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -44.41 136.93 3.9 Favored 'General case' 0 C--N 1.342 0.243 0 C-N-CA 123.669 0.788 . . . . 10.0 110.275 169.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -141.51 21.1 2.2 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 10.0 111.439 -178.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.874 HG22 ' CG2' ' B' ' 17' ' ' ILE . 3.6 p -52.06 -39.01 59.03 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 113.961 1.096 . . . . 10.0 113.961 -174.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.04 -11.29 59.92 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.244 0.618 . . . . 10.0 111.619 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 118.66 -64.02 0.42 Allowed Glycine 0 C--O 1.225 -0.425 0 C-N-CA 126.052 1.787 . . . . 10.0 109.253 179.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.5 t -155.19 55.23 0.64 Allowed 'General case' 0 C--O 1.234 0.277 0 CA-C-O 121.789 0.804 . . . . 10.0 109.732 172.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -134.62 -46.47 0.74 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.7 0.8 . . . . 10.0 109.229 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.1 m -51.75 -29.34 18.34 Favored 'General case' 0 C--N 1.344 0.367 0 C-N-CA 123.886 0.874 . . . . 10.0 111.235 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.89 -42.27 0.08 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.748 2.419 . . . . 10.0 112.878 167.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.28 165.93 39.08 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -79.39 -164.86 0.3 Allowed 'Trans proline' 0 N--CA 1.444 -1.409 0 N-CA-C 107.353 -1.826 . . . . 10.0 107.353 169.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -80.25 46.54 0.83 Allowed 'General case' 0 CA--C 1.542 0.657 0 O-C-N 120.69 -1.256 . . . . 10.0 110.634 -176.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -75.31 70.08 2.19 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 119.352 0.978 . . . . 10.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -71.15 149.19 94.42 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 169.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -58.77 -47.12 19.7 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.407 2.071 . . . . 10.0 111.147 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.32 60.82 2.06 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 108.731 -0.841 . . . . 10.0 108.731 174.155 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.5 t -61.19 112.46 2.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 108.664 -0.865 . . . . 10.0 108.664 -178.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 75.4 mtt180 -105.82 -98.66 0.34 Allowed 'General case' 0 CA--C 1.512 -0.491 0 N-CA-C 106.157 -1.794 . . . . 10.0 106.157 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.9 pttt -158.81 144.97 16.84 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 104.982 -2.229 . . . . 10.0 104.982 169.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -47.33 121.78 4.12 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.366 0.603 . . . . 10.0 111.526 174.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.13 -156.13 6.69 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 106.235 -2.746 . . . . 10.0 106.235 169.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -148.34 -168.84 14.73 Favored Glycine 0 C--O 1.225 -0.43 0 CA-C-N 118.477 1.139 . . . . 10.0 113.464 -178.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -69.73 16.27 0.22 Allowed 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 123.416 2.744 . . . . 10.0 112.303 175.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -105.53 -29.24 10.3 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 126.4 1.88 . . . . 10.0 108.999 168.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -107.9 172.19 6.97 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -89.41 -26.76 20.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 122.065 0.936 . . . . 10.0 109.351 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -78.6 -11.18 59.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 125.965 1.706 . . . . 10.0 114.692 -167.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.432 HH21 ' CG ' ' A' ' 101' ' ' ASP . 0.0 OUTLIER -34.69 129.17 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.699 1.2 . . . . 10.0 112.186 176.915 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -65.59 169.76 5.84 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 107.81 -1.182 . . . . 10.0 107.81 175.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.2 p -63.55 15.04 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 N-CA-C 115.864 1.801 . . . . 10.0 115.864 -169.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.51 55.91 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.621 0 N-CA-C 108.997 -1.641 . . . . 10.0 108.997 170.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -97.37 102.5 14.28 Favored 'General case' 0 N--CA 1.457 -0.109 0 N-CA-C 106.746 -1.575 . . . . 10.0 106.746 168.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -83.03 9.7 9.66 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.956 0.344 . . . . 10.0 111.49 -177.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 84.55 -100.18 2.35 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 107.536 -2.226 . . . . 10.0 107.536 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -145.57 157.57 43.96 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 107.287 -1.375 . . . . 10.0 107.287 174.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.3 m -112.48 126.12 69.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 109.02 -0.733 . . . . 10.0 109.02 169.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 70.1 m -94.72 101.53 13.38 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 127.518 2.327 . . . . 10.0 109.254 -170.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.7 141.64 37.75 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 122.373 -0.204 . . . . 10.0 111.113 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -69.5 173.77 5.61 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.343 2.257 . . . . 10.0 109.267 167.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -23.91 67.56 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.028 0.381 . . . . 10.0 112.028 174.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.408 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 32.7 t70 -78.21 -1.47 32.99 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 120.993 0.425 . . . . 10.0 111.226 173.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.23 1.11 89.58 Favored Glycine 0 C--N 1.339 0.732 0 O-C-N 120.679 -1.263 . . . . 10.0 110.51 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -77.41 105.66 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 -176.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.527 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -102.64 113.26 26.49 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.389 -0.967 . . . . 10.0 108.389 169.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.29 117.97 20.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 126.603 1.961 . . . . 10.0 107.91 173.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 26.4 t -105.89 135.86 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 N-CA-C 106.399 -1.704 . . . . 10.0 106.399 177.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -158.64 62.41 0.43 Allowed 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 123.649 0.779 . . . . 10.0 110.22 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -107.46 161.63 6.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -139.64 151.76 46.23 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.263 1.025 . . . . 10.0 109.404 167.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.432 ' CG ' HH21 ' A' ' 79' ' ' ARG . 25.0 t0 -146.97 152.43 38.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.645 -1.243 . . . . 10.0 107.645 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.9 p -105.66 -13.26 15.62 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.862 2.465 . . . . 10.0 112.154 -176.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -102.27 16.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 119.603 1.092 . . . . 10.0 110.315 179.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -118.05 142.79 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 104.714 -2.328 . . . . 10.0 104.714 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 91.8 p -142.44 149.8 39.74 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 172.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.2 mt -62.34 -41.17 98.35 Favored 'General case' 0 C--O 1.231 0.105 0 CA-C-N 119.025 0.83 . . . . 10.0 109.485 170.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.3 p -146.95 164.56 32.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.176 1.39 . . . . 10.0 108.947 -178.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 122.87 -105.0 0.91 Allowed Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 106.431 -2.668 . . . . 10.0 106.431 -169.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -126.68 -43.61 1.71 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.368 1.067 . . . . 10.0 110.362 -168.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 20.8 m-70 -73.7 -48.53 31.44 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 105.116 -2.179 . . . . 10.0 105.116 174.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.3 t 45.12 60.7 2.86 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 124.771 1.228 . . . . 10.0 113.214 167.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.8 pt -63.97 -11.43 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 113.339 0.866 . . . . 10.0 113.339 -175.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.1 mm -48.13 141.08 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 119.976 1.262 . . . . 10.0 110.923 170.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.44 16.98 75.9 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 125.074 1.321 . . . . 10.0 115.609 169.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 24.9 mmt-85 -84.65 165.61 17.79 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.917 1.358 . . . . 10.0 108.003 166.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 74.1 m -90.48 127.9 36.37 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 107.572 -1.27 . . . . 10.0 107.572 166.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.08 136.81 32.8 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 165.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.48 136.56 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.743 0 N-CA-C 107.075 -1.454 . . . . 10.0 107.075 171.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -105.25 134.53 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.166 -2.161 . . . . 10.0 105.166 167.038 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.621 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m-70 -114.11 158.13 21.68 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -170.32 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.418 ' N ' HD22 ' A' ' 144' ' ' LEU . 0.5 OUTLIER -58.67 -48.91 79.46 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 112.883 -1.962 . . . . 10.0 109.08 -174.735 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.9 mttm -110.76 175.05 5.57 Favored 'General case' 0 C--N 1.34 0.191 0 CA-C-O 121.492 0.663 . . . . 10.0 111.934 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.37 152.81 24.88 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.615 -1.175 . . . . 10.0 110.092 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.4 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.6 OUTLIER -76.75 149.11 36.34 Favored 'General case' 0 N--CA 1.443 -0.775 0 C-N-CA 123.782 0.833 . . . . 10.0 112.175 -179.382 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -79.06 -28.3 43.16 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 112.534 -2.121 . . . . 10.0 110.425 172.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 50.7 mt 50.57 48.47 22.53 Favored 'General case' 0 C--N 1.341 0.219 0 CA-C-O 122.349 1.071 . . . . 10.0 109.812 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.3 -11.06 70.9 Favored Glycine 0 CA--C 1.53 1.011 0 CA-C-N 113.907 -1.497 . . . . 10.0 114.086 169.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -81.57 -0.63 43.1 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.07 1.435 . . . . 10.0 114.078 -168.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.64 -22.44 79.01 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.75 38.86 65.33 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.345 -0.702 . . . . 10.0 111.345 -177.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -135.39 172.37 13.11 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 107.613 -1.254 . . . . 10.0 107.613 174.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -54.63 -47.89 72.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.424 0.631 . . . . 10.0 109.809 -178.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.27 -39.77 80.1 Favored 'General case' 0 C--O 1.236 0.353 0 O-C-N 121.516 -0.74 . . . . 10.0 111.707 176.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.3 p -53.28 -38.76 63.38 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 118.655 -0.688 . . . . 10.0 110.375 177.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.9 t -87.24 -7.83 57.46 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 123.703 0.627 . . . . 10.0 112.333 -177.217 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.9 mttt -103.17 -60.88 1.48 Allowed 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.215 -0.928 . . . . 10.0 111.277 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 14.3 p -135.55 17.4 3.35 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 118.677 0.671 . . . . 10.0 111.16 -177.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 75.93 -102.43 1.55 Allowed Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 107.453 -2.259 . . . . 10.0 107.453 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.7 m-20 -165.38 40.21 0.07 Allowed 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 124.933 1.293 . . . . 10.0 107.962 173.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.12 -11.95 61.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.519 0.728 . . . . 10.0 111.639 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.32 -163.33 54.63 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.61 -1.396 . . . . 10.0 109.61 174.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -51.05 133.98 26.87 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 124.258 1.023 . . . . 10.0 112.788 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.5 mtt180 -67.95 64.11 0.09 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.518 1.927 . . . . 10.0 108.592 171.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.449 HD22 ' C ' ' A' ' 120' ' ' HIS . 1.1 pt? -60.59 -22.92 64.25 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -168.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.12 148.5 22.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 109.323 -0.621 . . . . 10.0 109.323 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 17.7 p -163.25 168.97 19.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 110.109 -0.33 . . . . 10.0 110.109 -171.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.99 169.75 42.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.325 -0.71 . . . . 10.0 111.325 -176.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 96.6 t -109.87 145.55 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 106.271 -1.752 . . . . 10.0 106.271 -171.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 89.0 mt -74.6 138.22 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 110.403 -0.221 . . . . 10.0 110.403 -175.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.8 146.7 16.66 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.035 1.302 . . . . 10.0 110.308 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 80.4 mt -80.32 154.06 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.607 1.203 . . . . 10.0 109.17 177.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.88 -109.15 0.33 Allowed 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.326 -1.361 . . . . 10.0 107.326 167.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 1 C-N-CA 132.795 4.438 . . . . 10.0 102.843 -174.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 119.085 -0.483 . . . . 10.0 110.783 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.0 t -113.6 -13.19 12.76 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 124.105 0.962 . . . . 10.0 112.796 170.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -141.57 147.85 38.35 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 118.525 0.602 . . . . 10.0 109.718 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.99 156.55 47.11 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 123.984 0.914 . . . . 10.0 109.828 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -116.83 153.58 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 126.239 1.815 . . . . 10.0 109.044 172.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.86 97.99 3.55 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.924 -1.51 . . . . 10.0 106.924 166.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 m -77.86 121.63 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.111 -1.07 . . . . 10.0 108.111 170.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mt -103.16 130.32 50.3 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 117.85 -1.072 . . . . 10.0 108.769 -174.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 45.0 mtpt -145.46 160.01 42.23 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 120.236 1.38 . . . . 10.0 109.467 170.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.81 -71.26 0.01 OUTLIER Glycine 0 C--O 1.229 -0.177 0 CA-C-N 114.845 -1.07 . . . . 10.0 111.808 173.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.61 -43.64 54.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 106.865 -1.531 . . . . 10.0 106.865 -171.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.57 -65.5 0.57 Allowed Glycine 0 N--CA 1.443 -0.871 0 CA-C-N 113.299 -1.773 . . . . 10.0 111.27 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -54.57 -39.78 86.92 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.6 2.2 . . . . 10.0 111.019 173.262 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 64.9 t -66.33 99.49 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 107.729 -1.212 . . . . 10.0 107.729 173.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -124.61 123.0 39.11 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 125.169 1.388 . . . . 10.0 108.593 173.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.01 156.7 15.52 Favored Glycine 0 C--N 1.333 0.402 0 N-CA-C 111.872 -0.491 . . . . 10.0 111.872 171.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.874 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.2 mt -141.12 63.45 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 C-N-CA 124.466 1.106 . . . . 10.0 108.609 -172.489 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -78.22 141.09 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.073 0 O-C-N 121.502 -0.748 . . . . 10.0 110.138 -170.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.6 115.79 24.08 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 128.812 2.845 . . . . 10.0 108.156 -175.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -108.97 107.17 17.44 Favored 'General case' 0 C--N 1.333 -0.128 0 C-N-CA 124.411 1.084 . . . . 10.0 108.098 173.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -99.22 130.62 45.54 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 119.211 0.914 . . . . 10.0 112.064 169.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 tp60 -79.79 110.48 15.18 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 105.146 -2.168 . . . . 10.0 105.146 168.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mmmt . . . . . 0 CA--C 1.514 -0.423 0 C-N-CA 126.801 2.04 . . . . 10.0 110.0 -177.53 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.09 0 N-CA-C 108.699 -1.76 . . . . 10.0 108.699 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -60.51 140.04 89.31 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.297 1.998 . . . . 10.0 109.643 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.3 t -79.27 108.22 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.048 0 N-CA-C 105.569 -2.012 . . . . 10.0 105.569 175.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 56.1 mttm -83.52 119.05 24.22 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 105.126 -2.176 . . . . 10.0 105.126 168.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -105.79 111.15 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 177.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -129.15 170.9 12.97 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 120.79 0.329 . . . . 10.0 111.72 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.63 -153.25 25.17 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 107.787 -2.125 . . . . 10.0 107.787 172.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.7 156.52 35.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 117.656 0.728 . . . . 10.0 110.286 177.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.779 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -116.29 113.79 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 127.479 2.312 . . . . 10.0 106.894 167.782 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 1.3 pttt -96.58 136.43 37.11 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 108.413 -0.958 . . . . 10.0 108.413 168.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.95 0.27 9.03 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 124.892 1.234 . . . . 10.0 113.679 173.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -75.12 177.17 6.63 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 118.74 1.27 . . . . 10.0 110.785 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.0 t -107.76 149.75 27.81 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.706 -1.59 . . . . 10.0 106.706 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -44.87 140.72 2.45 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.811 1.644 . . . . 10.0 112.156 -172.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.75 -175.28 19.28 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 123.583 0.611 . . . . 10.0 112.18 171.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -70.91 147.59 48.61 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.305 1.442 . . . . 10.0 110.803 -174.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 81.9 m-70 -144.29 145.02 31.76 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.162 0.801 . . . . 10.0 113.162 178.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.667 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -27.7 125.0 0.06 OUTLIER Glycine 0 C--N 1.344 0.996 0 C-N-CA 127.039 2.257 . . . . 10.0 111.973 164.501 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -150.1 105.36 3.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 119.317 1.559 . . . . 10.0 112.085 168.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.08 171.25 18.16 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 122.054 0.931 . . . . 10.0 111.966 -178.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 8.0 m -92.31 149.0 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.789 -2.46 . . . . 10.0 106.694 167.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -120.64 131.44 54.61 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.069 -2.567 . . . . 10.0 104.069 169.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -60.47 -46.5 89.87 Favored 'General case' 0 N--CA 1.452 -0.334 0 O-C-N 124.315 1.009 . . . . 10.0 113.128 -165.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 11.5 m-30 -78.67 135.31 37.16 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 118.619 -1.232 . . . . 10.0 107.758 175.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.51 -41.26 98.0 Favored Glycine 0 CA--C 1.533 1.164 0 N-CA-C 107.918 -2.073 . . . . 10.0 107.918 166.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -29.48 101.31 0.02 OUTLIER 'General case' 0 C--N 1.344 0.369 0 C-N-CA 128.098 2.559 . . . . 10.0 113.933 -169.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.448 ' HB3' HG21 ' A' ' 7' ' ' VAL . 1.1 m-80 -107.67 14.54 25.52 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 113.836 -1.529 . . . . 10.0 111.297 173.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.634 HG23 HG22 ' A' ' 17' ' ' ILE . 0.8 OUTLIER -57.7 -33.05 67.98 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 120.453 1.479 . . . . 10.0 110.587 -176.594 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -20.0 51.19 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.049 1.34 . . . . 10.0 113.076 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.89 95.81 1.87 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.74 1.162 . . . . 10.0 110.439 -176.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 26.6 t 19.55 66.85 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.617 2.367 . . . . 10.0 114.219 -174.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.2 m -151.38 -52.09 0.13 Allowed 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 124.946 1.299 . . . . 10.0 107.741 -174.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 13.8 t -73.89 4.57 5.13 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.718 -0.614 . . . . 10.0 112.131 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.05 -22.36 66.8 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.938 1.295 . . . . 10.0 111.37 177.056 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.2 140.32 11.0 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 169.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -75.89 62.31 6.53 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.576 2.851 . . . . 10.0 111.102 176.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.0 m170 58.58 61.89 2.1 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 126.347 1.859 . . . . 10.0 109.123 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -68.66 71.47 0.21 Allowed 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 122.502 1.144 . . . . 10.0 111.843 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -74.96 152.88 86.7 Favored Pre-proline 0 C--N 1.32 -0.693 0 C-N-CA 127.664 2.385 . . . . 10.0 111.443 -178.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.74 163.49 38.05 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.564 2.176 . . . . 10.0 110.534 177.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . 0.29 0.2 OUTLIER 49.52 -96.5 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.745 1.618 . . . . 10.0 110.747 -169.676 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.3 m 172.59 94.8 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 128.079 2.552 . . . . 10.0 108.138 173.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -103.73 156.92 17.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 107.744 -1.206 . . . . 10.0 107.744 169.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 97.06 7.81 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.362 -0.352 . . . . 10.0 110.091 -172.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.552 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.6 t60 -10.17 96.1 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 C-N-CA 126.975 2.11 . . . . 10.0 114.072 -173.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -117.97 -162.14 12.25 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 108.971 -1.652 . . . . 10.0 108.971 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.29 -168.92 13.27 Favored Glycine 0 N--CA 1.449 -0.482 0 N-CA-C 110.521 -1.032 . . . . 10.0 110.521 175.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -67.45 11.39 0.22 Allowed 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.155 1.903 . . . . 10.0 112.302 175.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -101.24 -25.03 14.14 Favored 'General case' 0 N--CA 1.443 -0.814 0 C-N-CA 124.563 1.145 . . . . 10.0 108.896 169.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -107.85 170.88 7.72 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -169.284 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -86.03 -31.17 22.13 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 169.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -86.82 21.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 125.563 1.545 . . . . 10.0 113.062 -167.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.54 128.09 34.5 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.104 -1.443 . . . . 10.0 107.104 167.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.552 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 18.4 m170 -58.17 -68.09 0.28 Allowed 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.054 0.454 . . . . 10.0 111.096 -172.042 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.9 p -162.98 -51.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.456 -0.942 . . . . 10.0 108.456 -171.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -138.48 62.94 0.56 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 109.327 -1.509 . . . . 10.0 109.327 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -99.93 104.0 15.61 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 104.626 -2.361 . . . . 10.0 104.626 168.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -78.76 -2.97 42.02 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 119.235 0.925 . . . . 10.0 111.138 -175.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . 0.553 ' HA2' HD21 ' B' ' 126' ' ' LEU . . . 94.77 -98.92 2.36 Favored Glycine 0 N--CA 1.44 -1.039 0 N-CA-C 106.584 -2.606 . . . . 10.0 106.584 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -144.78 160.57 41.03 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 123.587 0.755 . . . . 10.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.55 132.03 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 105.495 -2.039 . . . . 10.0 105.495 166.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -94.83 118.12 31.25 Favored 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 108.656 -0.868 . . . . 10.0 108.656 -178.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.03 127.98 34.44 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 123.468 0.707 . . . . 10.0 109.135 175.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -61.94 167.06 4.04 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 124.453 1.096 . . . . 10.0 109.118 168.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -52.54 -28.88 22.61 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 126.022 1.729 . . . . 10.0 111.53 171.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -77.23 -10.86 59.69 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 118.115 0.416 . . . . 10.0 111.597 178.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.09 15.84 60.26 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 121.037 -1.04 . . . . 10.0 111.034 -177.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.0 t -97.43 106.82 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.889 2.076 . . . . 10.0 106.497 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.779 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -97.92 123.93 42.13 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.84 -1.17 . . . . 10.0 107.84 169.369 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -91.72 132.0 36.7 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 175.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -101.64 126.45 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 105.686 -1.968 . . . . 10.0 105.686 168.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 63.4 m -155.15 66.94 0.65 Allowed 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 125.001 1.32 . . . . 10.0 107.749 172.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -113.3 162.47 11.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 106.322 -1.733 . . . . 10.0 106.322 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -141.62 147.69 38.0 Favored 'General case' 0 N--CA 1.446 -0.672 0 O-C-N 121.36 -0.838 . . . . 10.0 111.06 168.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -132.75 137.11 46.74 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.92 1.288 . . . . 10.0 108.988 -175.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 1.7 p -108.79 56.75 0.62 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 125.615 1.566 . . . . 10.0 108.088 171.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.57 -61.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 N-CA-C 109.018 -0.734 . . . . 10.0 109.018 178.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.333 0.0 OUTLIER -70.41 169.55 1.41 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 112.74 0.644 . . . . 10.0 112.74 176.874 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 12.3 m -158.57 138.76 12.34 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 174.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 pp -81.75 -18.64 43.53 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.859 0.464 . . . . 10.0 110.232 172.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t . . . . . 0 N--CA 1.452 -0.351 0 N-CA-C 106.569 -1.641 . . . . 10.0 106.569 168.196 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 14.2 t . . . . . 0 N--CA 1.452 -0.368 0 CA-C-O 120.62 0.248 . . . . 10.0 110.943 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 44.5 pt -56.45 -14.78 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 N-CA-C 113.526 0.936 . . . . 10.0 113.526 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.5 mm -44.79 128.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 O-C-N 121.366 -0.834 . . . . 10.0 109.619 169.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.26 0.17 80.51 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.038 -0.868 . . . . 10.0 112.889 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -79.31 168.13 19.95 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.896 1.348 . . . . 10.0 109.152 168.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -112.31 124.81 53.28 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.72 0.808 . . . . 10.0 109.581 176.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.402 HD21 HD11 ' B' ' 149' ' ' ILE . 4.4 mm? -82.24 147.25 29.05 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.026 -1.101 . . . . 10.0 108.026 168.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 95.7 t -133.12 134.83 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.901 0 N-CA-C 108.217 -1.031 . . . . 10.0 108.217 168.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -103.47 129.95 54.61 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 105.754 -1.943 . . . . 10.0 105.754 167.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.667 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.9 m-70 -106.15 157.13 17.78 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 115.42 1.637 . . . . 10.0 115.42 -170.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -39.98 -56.62 1.79 Allowed 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 129.264 3.026 . . . . 10.0 110.623 173.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -119.79 168.35 11.17 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.176 0.991 . . . . 10.0 112.546 -169.244 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.81 129.13 38.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 113.98 -1.464 . . . . 10.0 109.129 170.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.419 ' CG ' HD23 ' B' ' 126' ' ' LEU . 62.4 t0 -77.77 108.26 10.87 Favored 'General case' 0 N--CA 1.442 -0.859 0 N-CA-C 107.347 -1.353 . . . . 10.0 107.347 171.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -78.97 3.38 17.33 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 111.676 0.251 . . . . 10.0 111.676 175.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.553 HD21 ' HA2' ' B' ' 85' ' ' GLY . 22.2 mt 59.79 -146.42 0.49 Allowed 'General case' 0 N--CA 1.419 -2.004 0 N-CA-C 105.97 -1.863 . . . . 10.0 105.97 -177.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 -14.28 77.26 Favored Glycine 0 C--N 1.304 -1.221 0 CA-C-N 114.351 -1.295 . . . . 10.0 112.244 -168.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -75.07 -1.27 22.13 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.413 1.107 . . . . 10.0 111.966 -169.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.36 -32.56 77.6 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 108.595 -1.802 . . . . 10.0 108.595 168.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 62.13 37.63 94.8 Favored Glycine 0 C--N 1.341 0.818 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.66 175.34 9.26 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 105.176 -2.157 . . . . 10.0 105.176 170.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -45.82 -54.17 8.49 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 115.044 -0.98 . . . . 10.0 111.23 172.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -64.5 -34.68 78.78 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 119.777 -0.769 . . . . 10.0 111.162 -172.116 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -47.7 -40.0 18.99 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 124.116 0.967 . . . . 10.0 111.702 169.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 t -93.08 -4.04 53.11 Favored 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 119.658 1.117 . . . . 10.0 110.362 -170.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -110.44 -57.82 2.16 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 125.698 1.599 . . . . 10.0 110.922 -171.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.4 p -137.13 5.84 2.8 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.616 0.644 . . . . 10.0 112.563 175.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.69 32.18 57.6 Favored Glycine 0 C--N 1.341 0.848 0 CA-C-N 118.675 0.67 . . . . 10.0 114.37 172.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 63.2 m-20 57.78 19.61 5.78 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.794 0.838 . . . . 10.0 113.175 179.106 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.38 -4.04 20.42 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.128 -0.982 . . . . 10.0 112.945 -176.325 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.54 -164.14 53.99 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.679 -0.968 . . . . 10.0 110.679 172.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.78 141.73 43.28 Favored 'General case' 0 N--CA 1.445 -0.714 0 C-N-CA 123.696 0.798 . . . . 10.0 111.987 -168.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 25.7 mtm-85 -67.22 71.14 0.1 Allowed 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.62 1.568 . . . . 10.0 109.414 172.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 6.8 tp -43.54 -45.56 6.64 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 126.5 1.92 . . . . 10.0 112.212 -174.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -159.48 147.41 17.37 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 -173.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 9.5 m -141.09 157.27 45.53 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 -168.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.6 164.96 30.42 Favored Glycine 0 C--N 1.332 0.346 0 N-CA-C 110.219 -1.152 . . . . 10.0 110.219 175.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.02 135.94 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 108.045 -1.095 . . . . 10.0 108.045 -174.514 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.402 HD11 HD21 ' B' ' 117' ' ' LEU . 9.3 mt -75.33 107.13 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 N-CA-C 109.291 -0.633 . . . . 10.0 109.291 -174.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.12 154.97 16.38 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 125.799 1.666 . . . . 10.0 110.976 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 90.4 mt -73.27 140.3 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 124.301 1.04 . . . . 10.0 109.937 -175.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.98 -45.99 2.65 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.84 0.456 . . . . 10.0 111.567 169.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 mm100 . . . . . 0 N--CA 1.445 -0.683 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 179.381 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.974 0 CA-C-O 118.158 -0.925 . . . . 10.0 109.398 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.2 t -84.29 -13.46 52.42 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 119.661 1.119 . . . . 10.0 111.893 -176.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.5 ptpp? -152.6 157.86 41.62 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.499 0.666 . . . . 10.0 112.351 167.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.91 170.62 15.4 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 125.855 1.662 . . . . 10.0 109.635 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.5 150.12 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 C-N-CA 126.462 1.905 . . . . 10.0 110.302 -177.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.62 100.91 4.77 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.005 -1.48 . . . . 10.0 107.005 166.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.495 HG21 ' HB3' ' B' ' 53' ' ' ASN . 6.0 m -82.12 118.91 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 107.821 -1.177 . . . . 10.0 107.821 169.385 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -97.43 138.89 34.18 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.873 -1.158 . . . . 10.0 107.873 177.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.9 ttmt -156.76 162.85 39.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.34 -50.21 0.07 OUTLIER Glycine 0 C--O 1.228 -0.256 0 C-N-CA 120.303 -0.951 . . . . 10.0 112.963 169.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -73.31 -45.73 53.75 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.35 -71.48 0.4 Allowed Glycine 0 CA--C 1.524 0.599 0 CA-C-N 114.46 -1.245 . . . . 10.0 110.021 171.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -57.95 -33.82 97.61 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.496 2.798 . . . . 10.0 111.192 173.059 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.1 t -64.91 105.58 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 N-CA-C 107.915 -1.143 . . . . 10.0 107.915 174.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -124.01 110.64 15.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 106.167 -1.79 . . . . 10.0 106.167 173.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.703 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -91.59 144.38 17.14 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 169.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.538 ' CG2' HG22 ' B' ' 54' ' ' THR . 4.9 mt -140.1 80.46 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 106.26 -1.755 . . . . 10.0 106.26 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.7 mm -101.97 123.4 55.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 N-CA-C 109.557 -0.534 . . . . 10.0 109.557 -175.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 9.4 m-20 -85.63 151.29 24.01 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 109.268 -0.642 . . . . 10.0 109.268 169.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -126.33 91.53 3.39 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.231 -1.766 . . . . 10.0 106.231 169.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -84.27 138.72 32.78 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.175 0.99 . . . . 10.0 109.812 171.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -127.76 112.05 14.35 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 168.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.06 -56.4 11.72 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 122.7 1.238 . . . . 10.0 111.64 -170.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -139.97 170.39 15.95 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 103.657 -2.72 . . . . 10.0 103.657 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 91.8 p -65.0 -22.71 67.04 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.02 -0.536 . . . . 10.0 110.237 170.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -81.73 -11.75 58.9 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.763 0.825 . . . . 10.0 111.03 177.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.27 159.08 30.71 Favored Glycine 0 CA--C 1.532 1.116 0 O-C-N 121.929 -0.482 . . . . 10.0 112.073 -172.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -78.87 149.03 22.72 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 122.79 2.327 . . . . 10.0 107.889 167.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -76.6 94.38 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 171.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 mtpm? -73.95 97.7 2.88 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.538 -1.282 . . . . 10.0 107.538 169.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.6 m -85.45 115.01 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 107.261 -1.385 . . . . 10.0 107.261 173.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 23.8 p90 -129.9 160.26 34.08 Favored 'General case' 0 CA--C 1.516 -0.36 0 CA-C-O 121.756 0.789 . . . . 10.0 111.952 168.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.57 -173.45 45.41 Favored Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 173.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.8 t -142.43 118.75 10.84 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.683 -1.599 . . . . 10.0 106.683 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.703 HG22 ' HA2' ' A' ' 16' ' ' GLY . 1.5 pp -80.86 175.07 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 109.095 -0.706 . . . . 10.0 109.095 169.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -146.32 136.58 23.75 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 167.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.33 -5.12 15.31 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.937 0.779 . . . . 10.0 114.656 172.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.62 HD23 HD13 ' A' ' 35' ' ' ILE . 0.6 OUTLIER -69.09 176.46 3.19 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 119.147 1.473 . . . . 10.0 111.198 179.36 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -108.24 159.47 16.6 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.703 -1.962 . . . . 10.0 105.703 166.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -53.49 163.14 0.67 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.531 1.132 . . . . 10.0 112.935 -169.224 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.17 -174.39 50.84 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 123.962 0.791 . . . . 10.0 112.104 168.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 mp -63.26 144.48 56.9 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 125.233 1.413 . . . . 10.0 110.819 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -146.72 144.02 29.13 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 123.82 0.848 . . . . 10.0 111.352 174.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.644 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -24.87 121.98 0.03 OUTLIER Glycine 0 C--N 1.343 0.956 0 C-N-CA 128.242 2.829 . . . . 10.0 111.864 166.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.96 106.71 3.95 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 120.046 1.923 . . . . 10.0 109.728 171.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.46 172.39 18.62 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.56 0.695 . . . . 10.0 112.855 179.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.15 152.54 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-N 112.581 -2.099 . . . . 10.0 108.078 168.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 79.9 m-70 -126.2 152.69 45.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 170.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -49.31 -60.75 2.54 Favored 'General case' 0 N--CA 1.447 -0.576 0 O-C-N 124.202 0.938 . . . . 10.0 111.379 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -82.38 162.09 22.3 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 121.41 0.624 . . . . 10.0 110.141 -174.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.77 -6.59 52.26 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 167.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.41 172.52 9.31 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-O 122.588 1.185 . . . . 10.0 111.461 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.49 18.15 0.04 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 114.057 1.132 . . . . 10.0 114.057 -169.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.4 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.3 OUTLIER -50.41 -36.92 35.08 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.983 1.313 . . . . 10.0 113.713 -169.002 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.26 -21.38 49.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.393 0.677 . . . . 10.0 112.492 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.98 102.28 2.44 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 109.396 -1.481 . . . . 10.0 109.396 -172.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 37.27 60.78 1.01 Allowed 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 126.273 1.829 . . . . 10.0 112.161 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -157.76 -48.06 0.06 Allowed 'General case' 0 N--CA 1.443 -0.821 0 O-C-N 122.023 -0.423 . . . . 10.0 111.401 176.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -50.63 -35.76 32.03 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 125.092 1.357 . . . . 10.0 110.918 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.28 -36.31 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 128.347 2.659 . . . . 10.0 113.768 169.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.51 166.27 26.43 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 107.641 -2.183 . . . . 10.0 107.641 173.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -79.91 -162.77 0.19 Allowed 'Trans proline' 0 N--CA 1.441 -1.599 0 N-CA-C 105.476 -2.548 . . . . 10.0 105.476 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 44.4 m170 -81.49 53.88 2.2 Favored 'General case' 0 CA--C 1.541 0.609 0 O-C-N 120.38 -1.45 . . . . 10.0 110.716 -176.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.6 m-30 -73.09 71.59 1.13 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 123.273 1.511 . . . . 10.0 111.265 -178.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -78.44 141.51 61.28 Favored Pre-proline 0 N--CA 1.447 -0.583 0 C-N-CA 126.158 1.783 . . . . 10.0 109.642 169.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -79.21 47.77 2.61 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.874 2.383 . . . . 10.0 111.213 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -163.79 49.66 0.14 Allowed 'General case' 0 C--O 1.236 0.361 0 C-N-CA 124.761 1.224 . . . . 10.0 107.871 178.206 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.0 p -52.98 108.37 0.31 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.204 1.802 . . . . 10.0 111.57 -169.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -133.32 -173.2 3.14 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.107 -2.183 . . . . 10.0 105.107 169.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.401 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 6.9 mtmp? -85.71 136.63 33.28 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 118.549 -1.26 . . . . 10.0 107.804 -172.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.9 t60 -36.05 116.29 0.39 Allowed 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.336 173.229 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.71 -134.2 4.92 Favored Glycine 0 N--CA 1.441 -1.015 0 N-CA-C 108.139 -1.984 . . . . 10.0 108.139 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.8 -165.81 31.74 Favored Glycine 0 N--CA 1.444 -0.804 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 169.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -57.52 -11.99 10.02 Favored 'Trans proline' 0 N--CA 1.451 -0.976 0 CA-C-N 119.345 1.572 . . . . 10.0 110.849 167.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.87 -33.98 18.35 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 125.223 1.409 . . . . 10.0 110.076 -177.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -107.45 168.54 9.17 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 108.677 -0.861 . . . . 10.0 108.677 -169.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -94.67 -18.88 20.91 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 124.346 1.058 . . . . 10.0 109.761 178.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.401 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -92.02 3.9 54.23 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.395 0.887 . . . . 10.0 113.395 -175.511 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 19.9 ptp180 -34.94 139.0 0.1 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 128.118 2.567 . . . . 10.0 112.272 171.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -71.22 -100.63 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.351 0.66 . . . . 10.0 111.96 -176.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.9 p -148.3 30.13 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.032 0.92 . . . . 10.0 110.228 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.5 47.83 0.02 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.479 -1.448 . . . . 10.0 109.479 -179.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -84.05 88.97 7.19 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 103.203 -2.888 . . . . 10.0 103.203 168.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 42.5 mt -71.3 -33.38 69.65 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 106.451 -1.685 . . . . 10.0 106.451 176.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.66 -97.19 1.34 Allowed Glycine 0 N--CA 1.44 -1.057 0 N-CA-C 108.815 -1.714 . . . . 10.0 108.815 167.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -132.67 129.06 38.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.655 1.182 . . . . 10.0 108.571 -172.195 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.8 m -113.52 141.65 28.7 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.573 -1.64 . . . . 10.0 106.573 168.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -93.13 133.65 36.1 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.738 -0.467 . . . . 10.0 109.738 -177.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.82 133.23 43.41 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.084 0.954 . . . . 10.0 108.848 172.053 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.416 ' OD2' ' NZ ' ' A' ' 91' ' ' LYS . 45.4 t0 -62.03 168.81 3.01 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.678 1.191 . . . . 10.0 108.438 167.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.416 ' NZ ' ' OD2' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -63.38 -19.16 64.41 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.047 0.451 . . . . 10.0 111.816 -179.22 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -77.45 -12.15 59.93 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 123.73 0.812 . . . . 10.0 110.589 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.87 26.88 43.58 Favored Glycine 0 C--N 1.344 0.979 0 N-CA-C 109.766 -1.334 . . . . 10.0 109.766 -178.696 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 37.7 t -109.08 116.31 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.007 2.523 . . . . 10.0 105.045 178.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -113.49 120.84 42.38 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 107.918 -1.141 . . . . 10.0 107.918 174.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -84.31 117.41 23.55 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 127.141 2.176 . . . . 10.0 108.767 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -102.4 131.88 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 p -159.53 75.91 0.66 Allowed 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 123.88 0.872 . . . . 10.0 110.804 171.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -116.37 147.23 19.89 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.037 0.935 . . . . 10.0 109.146 -176.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -107.14 104.71 14.42 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 126.449 1.9 . . . . 10.0 110.13 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -87.9 123.32 32.53 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 108.746 -0.835 . . . . 10.0 108.746 172.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.7 p -113.13 43.41 1.72 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.209 1.003 . . . . 10.0 110.21 177.511 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -138.62 -44.57 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 C-N-CA 123.289 0.636 . . . . 10.0 111.255 175.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.413 ' C ' HD12 ' A' ' 104' ' ' ILE 0.365 0.7 OUTLIER -87.85 175.19 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-N 119.342 0.973 . . . . 10.0 112.749 174.103 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.2 m -159.34 138.43 11.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 123.955 0.902 . . . . 10.0 109.007 172.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 pp -82.49 -14.75 54.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.552 0.741 . . . . 10.0 111.944 177.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.1 m -143.46 124.0 14.01 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.662 -1.607 . . . . 10.0 106.662 167.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.96 -59.63 0.2 Allowed Glycine 0 C--N 1.334 0.44 0 N-CA-C 109.638 -1.385 . . . . 10.0 109.638 175.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -166.89 -50.9 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 126.084 1.753 . . . . 10.0 107.465 -177.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -74.98 -36.02 62.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.669 -1.151 . . . . 10.0 108.879 -169.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t 42.41 61.93 1.86 Allowed 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 126.056 1.743 . . . . 10.0 110.99 169.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.57 32.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 113.194 0.812 . . . . 10.0 113.194 -175.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.0 mm -64.5 150.45 10.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 C-N-CA 125.969 1.708 . . . . 10.0 107.424 168.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.25 33.26 86.31 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 121.523 -0.736 . . . . 10.0 113.804 178.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -100.65 163.96 12.1 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 166.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -103.55 127.55 50.95 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-N 118.587 0.63 . . . . 10.0 111.106 170.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.14 139.64 30.26 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.498 -1.668 . . . . 10.0 106.498 166.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.404 HG12 ' CD2' ' A' ' 120' ' ' HIS . 93.0 t -122.88 138.67 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 172.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.1 p -105.69 134.72 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 104.96 -2.237 . . . . 10.0 104.96 166.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.644 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.5 m170 -113.67 161.36 17.57 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 114.506 1.298 . . . . 10.0 114.506 -172.355 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -57.73 -49.16 77.47 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 113.694 -1.594 . . . . 10.0 109.548 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -116.09 176.48 5.08 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.47 1.108 . . . . 10.0 111.812 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.1 146.55 23.57 Favored 'General case' 0 N--CA 1.451 -0.425 0 C-N-CA 125.375 1.47 . . . . 10.0 110.271 -177.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -76.77 151.39 36.01 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.108 0.563 . . . . 10.0 110.612 178.114 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -89.54 16.58 7.48 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 114.836 -1.075 . . . . 10.0 109.878 166.227 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 69.9 mt 36.43 47.57 0.51 Allowed 'General case' 0 C--N 1.344 0.338 0 C-N-CA 127.19 2.196 . . . . 10.0 112.383 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.74 -47.37 1.05 Allowed Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 124.582 1.087 . . . . 10.0 111.851 176.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -83.23 44.27 0.93 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 124.999 1.32 . . . . 10.0 111.844 -168.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -81.98 -38.68 12.93 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.515 -1.434 . . . . 10.0 109.515 169.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.45 48.61 56.53 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 109.37 -1.492 . . . . 10.0 109.37 -170.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.7 m-80 -138.36 166.57 23.9 Favored 'General case' 0 CA--C 1.508 -0.652 0 N-CA-C 106.689 -1.597 . . . . 10.0 106.689 175.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 2.7 tm-20 -52.99 -46.52 68.36 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 114.712 -1.131 . . . . 10.0 108.843 171.042 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -57.1 -43.2 82.0 Favored 'General case' 0 C--N 1.343 0.305 0 CA-C-N 116.332 -0.395 . . . . 10.0 110.889 171.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.297 2.1 p -59.21 -32.95 70.41 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -167.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -78.89 -8.05 58.5 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 118.592 -1.243 . . . . 10.0 112.276 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 89.5 mttt -116.68 -59.46 1.97 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.638 1.575 . . . . 10.0 111.834 -171.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.1 p -123.48 -4.66 8.26 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 119.318 0.963 . . . . 10.0 112.675 179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.19 -82.97 0.45 Allowed Glycine 0 CA--C 1.531 1.039 0 CA-C-N 119.386 0.994 . . . . 10.0 112.762 169.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.12 32.88 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 123.186 1.47 . . . . 10.0 108.343 177.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.64 -26.6 57.89 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.963 -1.471 . . . . 10.0 109.771 -167.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.13 -159.69 51.22 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 109.53 -1.428 . . . . 10.0 109.53 -177.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.0 t -58.49 139.26 55.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 113.136 0.791 . . . . 10.0 113.136 -168.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -65.05 65.72 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 126.764 2.025 . . . . 10.0 109.754 168.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.48 -19.2 61.77 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 113.904 1.076 . . . . 10.0 113.904 -172.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.22 150.89 25.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 122.81 0.444 . . . . 10.0 110.409 169.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.6 p -154.17 165.6 35.74 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.057 0.543 . . . . 10.0 110.049 -176.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -141.0 -172.0 12.82 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 123.434 0.54 . . . . 10.0 112.675 -177.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.7 t -136.79 136.52 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 107.648 -1.241 . . . . 10.0 107.648 172.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.0 mt -73.93 114.63 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 122.887 0.475 . . . . 10.0 110.402 -177.18 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.46 151.35 18.46 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 125.762 1.649 . . . . 10.0 111.461 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.8 mt -73.32 140.34 17.97 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 124.902 1.281 . . . . 10.0 109.855 -173.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.72 -45.47 2.89 Favored 'General case' 0 C--O 1.225 -0.222 0 O-C-N 121.069 -1.02 . . . . 10.0 111.74 173.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.25 1.09 0 C-N-CA 127.81 2.444 . . . . 10.0 109.203 -168.575 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.886 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -70.93 -31.03 67.5 Favored 'General case' 0 C--O 1.226 -0.142 0 CA-C-N 119.27 0.941 . . . . 10.0 109.847 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.9 tttt -144.37 134.12 23.67 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.769 0.828 . . . . 10.0 109.395 -174.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 165.41 27.65 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.865 1.666 . . . . 10.0 107.768 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -126.13 171.1 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 118.339 0.518 . . . . 10.0 109.84 174.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.78 112.86 9.73 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.413 -1.328 . . . . 10.0 107.413 166.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 30.8 m -92.01 114.89 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 168.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.6 mt -100.56 135.65 41.67 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -158.13 157.43 32.73 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.862 1.21 . . . . 10.0 108.705 170.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.3 -52.17 0.04 OUTLIER Glycine 0 C--O 1.228 -0.269 0 C-N-CA 121.414 -0.422 . . . . 10.0 112.148 172.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.8 -45.95 40.1 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.609 -1.626 . . . . 10.0 106.609 -171.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.29 -67.06 0.55 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 113.711 -1.586 . . . . 10.0 110.461 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -56.97 -41.07 79.2 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.646 2.231 . . . . 10.0 110.68 172.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.8 t -65.94 105.83 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -123.02 117.98 26.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 169.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.646 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -101.83 141.63 15.36 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.358 -1.097 . . . . 10.0 110.358 172.383 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.4 HG22 ' CG2' ' A' ' 54' ' ' THR . 2.6 mt -143.13 81.13 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 106.476 -1.676 . . . . 10.0 106.476 -175.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.6 mm -102.72 151.37 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.324 1.049 . . . . 10.0 109.715 -173.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -121.48 119.93 33.43 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.939 2.095 . . . . 10.0 108.164 174.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -102.89 108.92 20.3 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.783 -1.562 . . . . 10.0 106.783 176.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -119.49 141.05 49.52 Favored 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.247 0.832 . . . . 10.0 113.247 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -118.39 119.18 33.82 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.332 -1.729 . . . . 10.0 106.332 166.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 57.6 pttt . . . . . 0 CA--C 1.529 0.166 0 N-CA-C 112.842 0.682 . . . . 10.0 112.842 -172.969 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.182 0 CA-C-O 118.398 -1.223 . . . . 10.0 114.509 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -65.63 136.59 46.72 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 107.191 -1.888 . . . . 10.0 107.191 172.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.49 105.19 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 106.028 -1.842 . . . . 10.0 106.028 174.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -97.49 112.85 24.52 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 173.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -111.99 113.59 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 125.126 1.37 . . . . 10.0 108.776 -173.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.5 p90 -132.65 170.82 14.67 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.874 0.368 . . . . 10.0 110.804 173.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.88 -147.92 18.84 Favored Glycine 0 N--CA 1.448 -0.52 0 N-CA-C 106.955 -2.458 . . . . 10.0 106.955 170.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.2 t -155.86 156.61 34.98 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 119.306 -0.958 . . . . 10.0 111.192 177.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.646 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.9 pt -117.08 153.68 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 N-CA-C 108.032 -1.099 . . . . 10.0 108.032 166.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -127.62 151.41 48.96 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 106.801 -1.555 . . . . 10.0 106.801 167.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.24 -14.44 15.93 Favored Glycine 0 C--N 1.336 0.542 0 CA-C-O 119.002 -0.888 . . . . 10.0 113.322 169.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.517 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.6 mp -76.4 176.84 7.84 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 118.652 1.226 . . . . 10.0 110.388 -177.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.59 152.76 20.13 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.596 -0.729 . . . . 10.0 109.348 169.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -45.34 143.98 1.58 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.109 1.764 . . . . 10.0 111.87 -176.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.72 -177.31 22.66 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 123.927 0.775 . . . . 10.0 112.159 171.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -71.69 153.55 41.97 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 125.347 1.459 . . . . 10.0 110.921 -177.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -149.34 146.93 27.77 Favored 'General case' 0 C--N 1.343 0.319 0 N-CA-C 113.959 1.096 . . . . 10.0 113.959 -177.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.711 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -31.48 114.26 0.07 OUTLIER Glycine 0 C--N 1.34 0.803 0 C-N-CA 128.379 2.895 . . . . 10.0 113.215 164.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.418 ' HZ ' HG21 ' B' ' 35' ' ' ILE . 1.5 m-85 -141.48 101.43 3.99 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 120.519 2.16 . . . . 10.0 109.353 173.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.509 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -151.17 170.15 20.16 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-O 121.749 0.785 . . . . 10.0 111.938 178.603 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.2 m -93.08 154.86 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.223 -2.262 . . . . 10.0 106.788 168.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 61.2 m-70 -126.58 135.87 51.81 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 170.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -50.92 -50.57 57.29 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 118.445 -0.788 . . . . 10.0 112.186 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -82.6 137.29 34.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 117.714 -1.594 . . . . 10.0 109.501 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.58 3.01 87.41 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 126.29 1.9 . . . . 10.0 112.147 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 p-10 -76.3 81.82 3.07 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-O 123.613 1.673 . . . . 10.0 110.181 -173.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.495 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.9 OUTLIER -75.31 9.75 1.94 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.488 -1.233 . . . . 10.0 113.732 -175.17 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.538 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -44.96 -45.94 10.79 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 127.734 2.414 . . . . 10.0 112.634 -170.818 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.86 -20.72 41.68 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.7 87.82 2.02 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 107.955 -2.058 . . . . 10.0 107.955 -168.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 16.88 54.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 127.987 2.515 . . . . 10.0 116.108 -169.221 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 17.0 m -125.97 -56.25 1.46 Allowed 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 105.69 -1.967 . . . . 10.0 105.69 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -47.74 -37.4 13.18 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.403 1.481 . . . . 10.0 110.708 169.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.14 -31.5 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 127.864 2.466 . . . . 10.0 115.257 169.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.27 148.64 18.98 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 109.517 -1.433 . . . . 10.0 109.517 169.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.51 -179.27 0.85 Allowed 'Trans proline' 0 N--CA 1.446 -1.305 0 N-CA-C 107.674 -1.702 . . . . 10.0 107.674 166.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 37.8 m170 -76.24 76.57 3.04 Favored 'General case' 0 CA--C 1.543 0.685 0 O-C-N 120.422 -1.424 . . . . 10.0 110.501 -169.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -71.46 69.44 0.59 Allowed 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 123.182 1.468 . . . . 10.0 112.417 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . 0.405 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 1.7 p30 -56.15 145.51 55.46 Favored Pre-proline 0 C--N 1.321 -0.649 0 C-N-CA 127.326 2.251 . . . . 10.0 112.155 168.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -74.79 167.74 26.41 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 122.106 1.871 . . . . 10.0 108.296 167.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 tp 62.46 -101.06 0.1 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 125.09 1.356 . . . . 10.0 108.041 -174.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.2 p 171.59 97.45 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.753 1.621 . . . . 10.0 110.263 -174.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 75.9 mtt180 -130.02 163.64 26.04 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 119.651 1.114 . . . . 10.0 110.346 176.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -113.44 55.32 0.71 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 124.648 1.179 . . . . 10.0 111.422 -168.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 65.3 t60 47.05 88.2 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 125.091 1.356 . . . . 10.0 114.646 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.06 -145.18 11.07 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.262 -1.336 . . . . 10.0 110.067 178.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.78 -173.96 32.1 Favored Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 109.152 -1.579 . . . . 10.0 109.152 176.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -55.22 -13.15 6.49 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 123.025 2.483 . . . . 10.0 112.434 173.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -94.27 -30.25 14.65 Favored 'General case' 0 N--CA 1.444 -0.754 0 C-N-CA 125.189 1.396 . . . . 10.0 110.607 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -103.18 169.0 8.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -169.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -78.77 -33.52 46.33 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -77.14 18.14 0.41 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.309 1.043 . . . . 10.0 113.421 -165.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 20.2 ptp180 -64.55 117.22 7.05 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.106 -1.072 . . . . 10.0 108.106 -177.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.405 ' HB3' ' HB3' ' B' ' 65' ' ' ASN . 11.1 m170 -57.98 -60.96 2.92 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 120.824 0.345 . . . . 10.0 111.846 -170.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p -165.5 -47.09 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 -169.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -152.99 71.49 0.28 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 108.551 -1.82 . . . . 10.0 108.551 172.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -102.57 106.61 17.33 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 105.73 -1.952 . . . . 10.0 105.73 171.092 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.22 -12.07 60.03 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 111.7 -172.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.78 -98.26 1.56 Allowed Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 107.924 -2.071 . . . . 10.0 107.924 -178.301 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -156.28 146.96 21.82 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 107.099 -1.445 . . . . 10.0 107.099 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.7 m -122.08 131.95 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 107.208 -1.405 . . . . 10.0 107.208 169.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 63.0 m -90.89 107.26 19.07 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 126.298 1.839 . . . . 10.0 109.228 -172.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -77.82 130.33 36.54 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 110.172 -0.307 . . . . 10.0 110.172 172.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -61.85 170.1 2.22 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 124.274 1.03 . . . . 10.0 109.295 167.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -55.79 -29.08 59.09 Favored 'General case' 0 N--CA 1.433 -1.294 0 C-N-CA 125.884 1.674 . . . . 10.0 111.647 171.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -78.38 -1.67 34.55 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-O 121.163 0.506 . . . . 10.0 111.371 175.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.09 1.46 90.33 Favored Glycine 0 C--N 1.339 0.746 0 O-C-N 120.376 -1.452 . . . . 10.0 111.179 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 44.8 t -78.43 105.98 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 C-N-CA 126.929 2.092 . . . . 10.0 107.03 178.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.479 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -103.78 124.62 49.23 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 169.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.56 122.74 26.86 Favored 'General case' 0 N--CA 1.432 -1.338 0 C-N-CA 125.832 1.653 . . . . 10.0 107.816 169.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.4 t -101.92 128.85 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.208 0 N-CA-C 106.851 -1.537 . . . . 10.0 106.851 173.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.9 t -156.85 92.67 1.3 Allowed 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 169.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.3 mp -135.94 164.29 32.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 125.96 1.704 . . . . 10.0 106.542 -177.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -148.64 159.63 43.91 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.74 116.21 7.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.023 -0.732 . . . . 10.0 109.023 171.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 52.0 p -90.41 61.6 5.05 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 106.909 -1.515 . . . . 10.0 106.909 -171.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.16 -50.53 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 123.731 0.644 . . . . 10.0 110.068 -176.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -79.91 142.42 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.592 -1.262 . . . . 10.0 107.592 169.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 22.9 m -128.22 114.22 16.68 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.697 -1.594 . . . . 10.0 106.697 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mt -59.23 -4.34 0.53 Allowed 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 114.411 1.263 . . . . 10.0 114.411 -173.049 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.7 m . . . . . 0 N--CA 1.448 -0.567 0 C-N-CA 126.582 1.953 . . . . 10.0 107.558 177.165 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.1 t . . . . . 0 N--CA 1.441 -0.893 0 N-CA-C 107.963 -1.125 . . . . 10.0 107.963 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.6 pt -83.98 23.42 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 122.957 0.503 . . . . 10.0 111.997 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.49 -73.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 CA-C-N 118.8 0.727 . . . . 10.0 111.268 -177.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.66 50.33 3.55 Favored Glycine 0 CA--C 1.532 1.133 0 O-C-N 120.642 -1.286 . . . . 10.0 112.546 -177.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.4 mmt-85 -110.3 152.38 26.24 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 124.832 1.253 . . . . 10.0 109.697 176.386 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.9 m -88.88 125.14 34.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.975 -0.75 . . . . 10.0 108.975 171.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -96.13 138.76 33.29 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 126.42 1.888 . . . . 10.0 107.7 170.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -126.44 135.67 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 N-CA-C 108.517 -0.919 . . . . 10.0 108.517 -177.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.459 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.2 OUTLIER -106.16 121.87 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 106.807 -1.553 . . . . 10.0 106.807 171.77 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.711 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.3 m-70 -105.63 158.12 16.93 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 123.75 1.738 . . . . 10.0 115.605 -171.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -43.82 -61.48 1.41 Allowed 'General case' 0 N--CA 1.442 -0.862 0 C-N-CA 129.738 3.215 . . . . 10.0 110.551 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.3 mttp -112.77 172.86 6.67 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.061 0.944 . . . . 10.0 111.395 -175.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.13 154.64 40.96 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.016 1.326 . . . . 10.0 110.571 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.509 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.0 OUTLIER -78.49 144.98 35.22 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 123.98 0.912 . . . . 10.0 111.578 174.083 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -76.27 -32.89 59.07 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 124.781 1.301 . . . . 10.0 109.349 168.057 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt 63.5 56.42 1.62 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 123.491 1.615 . . . . 10.0 109.572 -168.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.92 -47.96 3.44 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 113.582 -1.645 . . . . 10.0 111.341 165.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.19 44.97 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.8 1.64 . . . . 10.0 112.012 -173.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -10.83 50.08 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 126.263 1.887 . . . . 10.0 111.892 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.88 32.43 18.63 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.448 -0.64 . . . . 10.0 112.071 -174.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -113.66 152.34 30.56 Favored 'General case' 0 CA--C 1.506 -0.716 0 N-CA-C 105.65 -1.982 . . . . 10.0 105.65 171.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.8 tm-20 -50.54 -37.57 40.08 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 114.921 -1.036 . . . . 10.0 108.695 169.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 16.8 tp10 -70.81 -38.5 73.29 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 113.889 1.07 . . . . 10.0 113.889 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 76.7 p -57.67 -42.63 83.95 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 120.642 1.565 . . . . 10.0 110.456 -175.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 6.3 t -69.17 -10.3 57.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 113.109 0.781 . . . . 10.0 113.109 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 20.5 ttmt -113.71 -47.97 2.95 Favored 'General case' 0 N--CA 1.435 -1.204 0 C-N-CA 125.43 1.492 . . . . 10.0 112.347 -168.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 32.0 p -130.78 -2.87 4.14 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.016 0.747 . . . . 10.0 113.016 172.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.2 19.7 60.33 Favored Glycine 0 C--N 1.34 0.803 0 N-CA-C 110.809 -0.917 . . . . 10.0 110.809 -175.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 54.45 31.7 15.22 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 117.837 0.819 . . . . 10.0 111.718 176.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.47 7.26 4.62 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 123.906 0.882 . . . . 10.0 111.673 -176.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.85 -168.23 53.48 Favored Glycine 0 N--CA 1.444 -0.798 0 N-CA-C 110.065 -1.214 . . . . 10.0 110.065 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.8 t -67.4 158.32 32.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 122.582 1.182 . . . . 10.0 111.273 -169.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . 0.44 ' H ' ' NE ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -67.94 112.37 4.91 Favored 'General case' 0 N--CA 1.442 -0.857 0 C-N-CA 125.075 1.35 . . . . 10.0 107.966 170.69 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 29.0 mt -72.68 -55.71 6.4 Favored 'General case' 0 N--CA 1.458 -0.054 0 N-CA-C 109.098 -0.704 . . . . 10.0 109.098 170.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.459 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -138.34 156.6 47.47 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.858 -0.61 . . . . 10.0 110.273 -170.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.5 m -129.29 147.63 51.14 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.31 1.444 . . . . 10.0 108.805 -168.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -150.7 156.89 26.93 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.456 -1.458 . . . . 10.0 109.456 169.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 70.1 t -116.1 128.54 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 105.133 -2.173 . . . . 10.0 105.133 177.059 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.438 HD13 HG21 ' B' ' 149' ' ' ILE . 16.8 mt -69.03 156.93 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 CA-C-N 119.266 0.939 . . . . 10.0 110.06 176.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.02 160.91 32.47 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 124.995 1.283 . . . . 10.0 110.156 -176.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 96.0 mt -69.75 135.46 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.976 1.31 . . . . 10.0 109.478 -171.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.63 -47.1 2.44 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 123.366 0.666 . . . . 10.0 110.899 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 . . . . . 0 C--O 1.254 1.291 0 CA-C-O 117.809 -1.091 . . . . 10.0 111.031 -169.4 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.463 0 N-CA-C 110.161 -0.311 . . . . 10.0 110.161 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER 169.26 -41.06 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 129.861 3.264 . . . . 10.0 103.891 -167.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -106.39 132.35 52.52 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.243 -2.132 . . . . 10.0 105.243 166.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 163.05 33.97 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 107.526 -1.286 . . . . 10.0 107.526 169.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -124.28 176.51 5.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 C-N-CA 123.037 0.535 . . . . 10.0 109.998 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.77 117.13 5.68 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 118.504 0.593 . . . . 10.0 109.887 166.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -97.99 104.27 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 C-N-CA 124.609 1.164 . . . . 10.0 110.519 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mt -98.41 122.74 41.97 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.862 1.665 . . . . 10.0 109.517 -177.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -143.53 157.23 44.59 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 120.034 1.288 . . . . 10.0 108.513 173.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.26 -59.3 0.03 OUTLIER Glycine 0 N--CA 1.464 0.518 0 C-N-CA 120.317 -0.944 . . . . 10.0 113.005 169.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -70.93 -43.91 67.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.86 -71.45 0.38 Allowed Glycine 0 CA--C 1.521 0.451 0 CA-C-N 114.186 -1.37 . . . . 10.0 110.644 168.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -57.39 -33.36 96.13 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.786 2.99 . . . . 10.0 111.369 172.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 57.9 t -64.75 95.89 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.547 -1.279 . . . . 10.0 107.547 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 -120.58 111.27 17.45 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 125.684 1.594 . . . . 10.0 107.775 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.521 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -100.81 133.98 11.52 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-O 119.521 -0.6 . . . . 10.0 111.955 171.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.526 ' CG2' HG23 ' B' ' 54' ' ' THR . 8.7 mt -136.08 85.93 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 -172.39 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.55 152.8 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 C-N-CA 124.404 1.081 . . . . 10.0 111.136 -171.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -120.68 116.8 26.01 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 126.504 1.922 . . . . 10.0 108.905 170.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -91.5 99.34 12.3 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 174.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -97.39 117.86 32.58 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.775 0.798 . . . . 10.0 111.025 178.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.1 tp60 -117.61 97.31 5.8 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 127.895 2.478 . . . . 10.0 105.788 178.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.401 ' NZ ' ' OE2' ' A' ' 24' ' ' GLU . 4.8 mtmp? -59.08 -52.76 64.33 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 123.004 0.522 . . . . 10.0 110.377 -173.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.401 ' OE2' ' NZ ' ' A' ' 23' ' ' LYS . 2.0 mp0 -131.09 172.31 12.25 Favored 'General case' 0 N--CA 1.424 -1.748 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 173.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.9 t -71.49 -20.28 62.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 108.879 -0.785 . . . . 10.0 108.879 170.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . 0.306 0.0 OUTLIER -89.13 -5.43 57.78 Favored 'General case' 0 C--N 1.344 0.359 0 N-CA-C 113.401 0.889 . . . . 10.0 113.401 173.446 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.72 160.11 35.34 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 109.619 -1.393 . . . . 10.0 109.619 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -71.55 148.2 53.25 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 N-CA-C 107.592 -1.734 . . . . 10.0 107.592 168.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.3 t -78.39 110.92 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 105.39 -2.078 . . . . 10.0 105.39 173.275 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.2 102.86 15.58 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 171.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -98.92 99.7 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.415 -1.328 . . . . 10.0 107.415 179.497 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.8 p90 -118.15 166.87 12.06 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.566 0.698 . . . . 10.0 112.267 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.79 -150.3 21.81 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.07 -2.412 . . . . 10.0 107.07 171.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.7 t -155.23 152.87 29.84 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 119.773 -0.771 . . . . 10.0 110.914 -178.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.638 ' CG1' ' HB3' ' A' ' 95' ' ' ALA . 1.9 pt -110.63 142.85 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 115.215 -0.902 . . . . 10.0 108.616 166.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -118.81 148.85 42.41 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 169.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.71 -5.35 40.18 Favored Glycine 0 CA--C 1.525 0.664 0 CA-C-O 119.235 -0.759 . . . . 10.0 113.499 174.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -69.62 176.78 3.31 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 118.805 1.302 . . . . 10.0 110.122 177.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.1 t -104.75 167.83 9.46 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.319 -2.104 . . . . 10.0 105.319 165.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -57.07 166.38 1.07 Allowed 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.373 0.669 . . . . 10.0 111.254 -171.388 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.98 -177.17 42.94 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.286 -0.884 . . . . 10.0 112.375 168.56 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.0 mp -74.21 145.42 44.14 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 124.851 1.26 . . . . 10.0 110.093 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -144.91 145.36 31.53 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 124.177 0.991 . . . . 10.0 112.685 -175.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.65 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.48 125.97 0.28 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 126.695 2.093 . . . . 10.0 113.398 166.288 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -150.11 108.55 3.8 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.098 1.449 . . . . 10.0 108.253 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.25 173.0 12.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 122.732 1.253 . . . . 10.0 113.481 177.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 85.8 t -98.19 129.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 CA-C-N 111.03 -2.805 . . . . 10.0 105.487 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -105.8 139.72 39.93 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.194 -1.409 . . . . 10.0 107.194 170.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -58.1 -58.04 10.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 O-C-N 124.094 0.871 . . . . 10.0 110.214 -169.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -76.86 119.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.653 -1.61 . . . . 10.0 106.653 -171.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.74 46.81 2.94 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.523 -1.031 . . . . 10.0 110.523 171.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -108.89 118.72 37.53 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.929 1.291 . . . . 10.0 108.153 176.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.415 ' HB3' HG21 ' B' ' 7' ' ' VAL . 12.0 m120 -117.94 5.78 12.16 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.218 1.807 . . . . 10.0 109.988 178.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.42 HG23 ' CG2' ' B' ' 17' ' ' ILE . 1.3 m -57.07 -37.1 71.37 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 120.096 1.316 . . . . 10.0 111.667 -169.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -21.83 45.68 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.079 0.952 . . . . 10.0 112.682 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 143.85 -86.46 0.18 Allowed Glycine 0 CA--C 1.527 0.797 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 -172.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 24.1 p -170.78 43.29 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.152 0.981 . . . . 10.0 110.989 172.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 m -104.92 -49.31 3.52 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 m -50.18 -27.63 6.18 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 126.372 1.869 . . . . 10.0 111.641 174.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -37.16 -32.1 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 128.02 2.528 . . . . 10.0 113.848 168.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.32 126.64 5.2 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.277 -1.291 . . . . 10.0 109.95 170.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -72.4 65.34 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.81 0 C-N-CA 123.729 2.953 . . . . 10.0 112.268 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.7 m170 68.87 42.8 1.29 Allowed 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 129.773 3.229 . . . . 10.0 111.505 172.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -72.51 57.96 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.728 1.01 . . . . 10.0 113.728 -173.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.0 p-10 -68.3 159.57 79.95 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 118.968 0.804 . . . . 10.0 110.931 175.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -61.28 -47.68 11.55 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.216 1.944 . . . . 10.0 111.218 176.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 94.8 mt -78.1 59.05 2.12 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 109.301 -0.629 . . . . 10.0 109.301 177.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.0 t -58.97 95.64 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.417 1.087 . . . . 10.0 108.77 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.59 -96.57 0.41 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.796 -1.557 . . . . 10.0 106.796 -177.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.5 mttp -151.67 139.92 20.34 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 106.397 -1.705 . . . . 10.0 106.397 173.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.6 t60 -40.91 124.15 2.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 O-C-N 123.776 0.673 . . . . 10.0 110.903 170.401 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.15 -138.12 3.66 Favored Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 108.367 -1.893 . . . . 10.0 108.367 177.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.37 -165.94 33.35 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 107.342 -2.303 . . . . 10.0 107.342 169.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -62.54 -0.72 2.06 Favored 'Trans proline' 0 CA--C 1.542 0.878 0 CA-C-N 120.305 2.053 . . . . 10.0 110.948 167.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 61.0 mmtt -91.07 -24.62 19.98 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 124.409 1.084 . . . . 10.0 110.625 173.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.77 174.8 5.72 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -176.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -87.82 -32.15 19.19 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 170.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -82.25 2.0 33.99 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 115.032 1.493 . . . . 10.0 115.032 -165.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -41.54 137.36 1.59 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 125.639 1.575 . . . . 10.0 112.172 -177.12 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -71.88 -77.64 0.09 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.704 -0.798 . . . . 10.0 112.185 -170.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 p -161.41 58.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 121.324 -0.86 . . . . 10.0 109.46 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 106.94 50.55 0.83 Allowed Glycine 0 CA--C 1.523 0.533 0 N-CA-C 109.943 -1.263 . . . . 10.0 109.943 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -87.05 90.97 8.54 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 104.026 -2.583 . . . . 10.0 104.026 167.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.3 mt -70.3 -31.63 69.06 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 107.316 -1.364 . . . . 10.0 107.316 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 101.08 -106.43 3.08 Favored Glycine 0 N--CA 1.434 -1.44 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 168.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -109.23 119.41 39.42 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.506 1.122 . . . . 10.0 110.388 -168.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.1 m -104.89 135.36 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 168.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 50.0 m -99.64 108.8 21.26 Favored 'General case' 0 N--CA 1.442 -0.858 0 C-N-CA 126.316 1.846 . . . . 10.0 109.641 -168.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.44 130.24 35.24 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.229 1.011 . . . . 10.0 110.748 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 45.4 t0 -66.26 170.71 5.52 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 123.956 0.902 . . . . 10.0 109.455 168.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -52.96 -26.99 16.91 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.872 1.669 . . . . 10.0 111.599 177.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -79.03 -15.52 58.11 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.349 1.059 . . . . 10.0 110.065 -175.299 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.81 74.21 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 110.991 -0.844 . . . . 10.0 110.991 -173.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.0 t -87.64 113.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 C-N-CA 126.338 1.855 . . . . 10.0 106.265 173.265 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.638 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -111.9 121.38 44.87 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.461 -0.94 . . . . 10.0 108.461 171.295 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -78.17 130.55 36.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 172.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 75.0 t -104.91 129.39 57.59 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.369 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 169.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -156.93 66.95 0.53 Allowed 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 175.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.35 155.02 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.37 138.36 38.2 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.929 0.492 . . . . 10.0 110.727 169.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.95 131.14 51.15 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.858 1.263 . . . . 10.0 108.789 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.4 p -95.96 42.75 1.09 Allowed 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.626 1.971 . . . . 10.0 108.424 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.3 -49.88 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 123.337 0.655 . . . . 10.0 109.644 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 33.7 mm -57.57 134.55 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 169.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.5 m -164.66 94.22 0.68 Allowed 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.668 0.787 . . . . 10.0 109.441 -176.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.631 HD13 ' H ' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -68.61 27.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.644 1.177 . . . . 10.0 113.839 175.328 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.9 p -157.8 113.4 2.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 121.275 -0.891 . . . . 10.0 110.32 -176.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 162.26 -54.1 0.31 Allowed Glycine 0 C--N 1.335 0.481 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 169.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.75 -50.14 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 126.337 1.855 . . . . 10.0 107.475 -173.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 -74.42 -38.53 63.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.944 -1.025 . . . . 10.0 108.623 -169.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 40.53 62.2 1.42 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.154 1.782 . . . . 10.0 110.01 172.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 24.3 pt -74.62 46.77 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.745 2.018 . . . . 10.0 111.77 -175.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.3 mm -72.49 -65.17 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 128.971 2.908 . . . . 10.0 108.207 172.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.75 47.52 3.07 Favored Glycine 0 CA--C 1.529 0.953 0 O-C-N 121.343 -0.848 . . . . 10.0 113.808 -169.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -89.65 174.63 7.64 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 125.105 1.362 . . . . 10.0 108.68 172.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 20.2 m -109.87 115.11 29.22 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.787 -2.301 . . . . 10.0 104.787 168.127 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.6 mp -97.94 151.78 19.92 Favored 'General case' 0 CA--C 1.512 -0.511 0 N-CA-C 108.296 -1.001 . . . . 10.0 108.296 175.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.7 t -143.16 136.89 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 O-C-N 123.837 0.711 . . . . 10.0 109.803 -170.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.8 m -105.89 140.35 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.952 1.301 . . . . 10.0 108.887 167.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.65 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m170 -120.66 159.13 25.94 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.49 2.033 . . . . 10.0 116.49 -172.234 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -39.46 -58.61 1.23 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 130.289 3.436 . . . . 10.0 111.886 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -123.17 168.34 12.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 124.679 1.192 . . . . 10.0 110.48 -171.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.76 137.66 55.61 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 108.308 -0.997 . . . . 10.0 108.308 169.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.84 144.12 37.27 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.191 -1.04 . . . . 10.0 108.191 168.193 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -78.14 25.04 0.23 Allowed 'General case' 0 CA--C 1.539 0.519 0 CA-C-O 121.133 0.492 . . . . 10.0 111.126 177.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 18.8 mt 30.53 45.82 0.03 OUTLIER 'General case' 0 C--N 1.34 0.162 0 C-N-CA 128.23 2.612 . . . . 10.0 112.629 -170.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.6 -45.53 1.3 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 124.623 1.106 . . . . 10.0 112.488 177.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -83.34 50.6 1.8 Allowed 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.092 0.957 . . . . 10.0 111.452 -169.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -87.45 -35.89 9.14 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 125.969 1.747 . . . . 10.0 110.022 172.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.27 38.7 71.56 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.865 -0.894 . . . . 10.0 110.865 -178.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 56.1 m-80 -130.8 163.74 26.7 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 169.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -53.31 -39.35 63.96 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.718 0.771 . . . . 10.0 109.592 173.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -67.14 -35.16 79.12 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.448 1.099 . . . . 10.0 112.934 173.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.4 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 60.0 p -56.31 -34.01 66.12 Favored 'General case' 0 N--CA 1.443 -0.776 0 O-C-N 120.029 -1.669 . . . . 10.0 112.033 -175.138 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -81.35 -1.98 47.44 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 118.738 -0.649 . . . . 10.0 112.139 -178.373 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -112.69 -82.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.263 1.825 . . . . 10.0 110.545 -177.025 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -109.6 25.45 11.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 120.725 1.602 . . . . 10.0 111.974 174.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.1 18.03 66.42 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.602 167.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 m120 62.24 23.54 13.93 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 118.085 0.943 . . . . 10.0 112.224 -171.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.03 -11.91 33.65 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.24 -0.913 . . . . 10.0 113.097 177.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.62 -161.2 46.1 Favored Glycine 0 CA--C 1.523 0.553 0 O-C-N 121.151 -0.968 . . . . 10.0 111.128 170.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.9 t -57.07 129.68 42.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 124.327 1.051 . . . . 10.0 113.135 -167.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.1 mtt85 -65.94 71.97 0.06 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.454 1.902 . . . . 10.0 111.404 175.152 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 51.7 mt -52.05 -33.4 38.68 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.286 1.034 . . . . 10.0 113.733 -177.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.81 147.18 26.96 Favored 'General case' 0 CA--C 1.512 -0.495 0 O-C-N 121.727 -0.608 . . . . 10.0 110.055 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.8 m -140.9 149.85 42.45 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 107.627 -1.249 . . . . 10.0 107.627 -170.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.58 36.42 Favored Glycine 0 CA--C 1.521 0.416 0 N-CA-C 111.397 -0.681 . . . . 10.0 111.397 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 52.9 t -115.23 154.68 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 103.145 -2.909 . . . . 10.0 103.145 171.082 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 8.3 mt -71.45 -90.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 123.51 0.724 . . . . 10.0 109.306 -169.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 108.06 125.61 5.3 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 81.2 mt -61.18 140.47 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 C-N-CA 125.686 1.594 . . . . 10.0 108.721 175.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.36 -38.84 4.57 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-N 119.525 1.057 . . . . 10.0 111.495 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? . . . . . 0 C--O 1.249 1.038 0 CA-C-O 117.308 -1.33 . . . . 10.0 109.899 178.22 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 106.458 -1.682 . . . . 10.0 106.458 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -88.1 -56.17 3.44 Favored 'General case' 0 N--CA 1.458 -0.027 0 O-C-N 124.293 0.995 . . . . 10.0 110.853 -174.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.07 138.79 49.73 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.415 1.086 . . . . 10.0 110.155 -176.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.48 162.64 33.99 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.63 0.772 . . . . 10.0 110.653 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 m -121.04 160.89 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.557 1.143 . . . . 10.0 109.617 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 95.82 2.9 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.556 -1.275 . . . . 10.0 107.556 166.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.415 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.7 m -82.15 108.48 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 169.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -93.99 137.8 32.8 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 178.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 tttt -156.58 159.03 38.12 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 119.912 1.233 . . . . 10.0 107.87 171.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.89 -47.91 0.04 OUTLIER Glycine 0 C--O 1.229 -0.2 0 C-N-CA 120.684 -0.769 . . . . 10.0 111.481 169.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.52 -46.43 26.59 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 -171.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.72 -69.0 0.52 Allowed Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 113.905 -1.498 . . . . 10.0 110.145 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -56.28 -44.04 50.23 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.311 2.007 . . . . 10.0 110.539 171.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.96 101.2 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.13 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 -175.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -120.81 110.75 16.72 Favored 'General case' 0 N--CA 1.441 -0.921 0 N-CA-C 106.103 -1.814 . . . . 10.0 106.103 173.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.797 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -90.05 140.38 15.48 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.615 -1.794 . . . . 10.0 108.615 171.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.42 ' CG2' HG23 ' A' ' 54' ' ' THR . 4.0 mt -141.53 88.84 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 -173.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -101.3 144.13 13.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 C-N-CA 123.576 0.75 . . . . 10.0 110.362 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -121.19 114.26 21.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 126.499 1.92 . . . . 10.0 108.266 168.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -98.19 106.4 18.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 mt-10 -107.54 123.86 49.07 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 112.789 0.662 . . . . 10.0 112.789 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -81.62 115.16 20.76 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 104.112 -2.551 . . . . 10.0 104.112 166.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt . . . . . 0 N--CA 1.449 -0.475 0 C-N-CA 123.954 0.902 . . . . 10.0 109.92 169.826 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.929 0 N-CA-C 108.862 -1.695 . . . . 10.0 108.862 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -65.7 132.18 29.94 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.5 1.467 . . . . 10.0 108.497 171.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.9 t -78.07 108.34 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 104.778 -2.305 . . . . 10.0 104.778 169.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -79.62 109.74 14.29 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 105.275 -2.12 . . . . 10.0 105.275 169.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -96.67 97.07 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 106.328 -1.73 . . . . 10.0 106.328 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 20.5 p90 -108.76 164.37 12.44 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.163 0.506 . . . . 10.0 110.595 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.88 178.86 48.45 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 110.391 -1.084 . . . . 10.0 110.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -150.88 106.07 3.34 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.663 -0.866 . . . . 10.0 108.663 178.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.797 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.2 pt -79.9 173.15 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 119.55 -0.86 . . . . 10.0 109.738 173.123 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.0 pttt -150.85 153.36 35.22 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 168.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.82 -15.36 40.86 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-O 118.993 -0.893 . . . . 10.0 115.274 169.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.485 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.6 mp -75.33 179.66 5.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.943 1.372 . . . . 10.0 110.362 -177.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -91.56 174.95 7.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 166.018 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -62.25 175.09 0.78 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 124.391 1.076 . . . . 10.0 111.435 -173.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.44 -172.74 47.23 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 123.885 0.755 . . . . 10.0 112.588 166.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -75.89 142.78 42.02 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.425 1.49 . . . . 10.0 110.093 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -137.39 143.25 41.84 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 114.753 1.39 . . . . 10.0 114.753 -175.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.658 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.04 124.95 0.24 Allowed Glycine 0 C--N 1.343 0.917 0 C-N-CA 127.262 2.363 . . . . 10.0 111.711 162.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.35 103.42 2.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.343 1.572 . . . . 10.0 109.949 170.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.515 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.79 173.98 15.7 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 113.806 1.039 . . . . 10.0 113.806 -176.91 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 m -85.26 151.99 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 CA-C-N 113.006 -1.906 . . . . 10.0 109.385 169.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -132.89 84.9 2.17 Favored 'General case' 0 C--O 1.221 -0.428 0 C-N-CA 124.756 1.222 . . . . 10.0 108.365 174.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 22.5 -83.96 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 128.046 2.539 . . . . 10.0 116.129 -176.025 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -76.76 179.06 6.31 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-O 121.555 0.693 . . . . 10.0 109.594 -169.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.69 -26.17 10.98 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.508 -1.037 . . . . 10.0 110.508 169.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -37.47 130.24 0.98 Allowed 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 125.502 1.521 . . . . 10.0 110.317 176.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -138.38 18.61 2.75 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 114.944 -1.026 . . . . 10.0 111.398 175.159 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.526 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -56.92 -35.76 69.41 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 118.362 0.528 . . . . 10.0 110.223 -178.197 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.95 -20.25 42.4 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 125.42 1.488 . . . . 10.0 113.515 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.29 99.12 1.04 Allowed Glycine 0 CA--C 1.531 1.065 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 -169.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.9 p 3.94 61.6 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 128.555 2.742 . . . . 10.0 117.508 -169.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.1 m -135.33 -60.03 0.76 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.013 -1.847 . . . . 10.0 106.013 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 41.6 t -50.93 -34.52 28.92 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.736 0.814 . . . . 10.0 110.002 169.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.07 -47.52 0.28 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 126.29 1.836 . . . . 10.0 112.64 168.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 131.63 140.6 4.59 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.082 -0.844 . . . . 10.0 111.998 171.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . 0.403 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 89.0 Cg_endo -73.13 64.68 4.26 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.824 3.016 . . . . 10.0 110.501 169.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 30.3 m170 75.57 -44.31 0.52 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 129.781 3.232 . . . . 10.0 111.05 175.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . 0.403 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 27.8 m-85 31.13 59.4 0.26 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 127.75 2.42 . . . . 10.0 113.252 -174.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . 0.547 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 0.0 OUTLIER -55.34 146.23 43.32 Favored Pre-proline 0 C--N 1.324 -0.519 0 N-CA-C 113.441 0.904 . . . . 10.0 113.441 175.117 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.84 -47.54 0.34 Allowed 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.762 2.308 . . . . 10.0 110.832 177.172 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -81.71 56.57 3.07 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.821 0.848 . . . . 10.0 109.879 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -18.35 77.31 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.278 3.031 . . . . 10.0 116.48 -169.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt85 -116.53 -179.86 3.8 Favored 'General case' 0 CA--C 1.509 -0.598 0 C-N-CA 125.499 1.52 . . . . 10.0 109.84 173.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -114.59 89.4 3.09 Favored 'General case' 0 N--CA 1.439 -1.014 0 O-C-N 124.238 0.962 . . . . 10.0 112.755 -171.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.482 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 75.1 t60 12.83 89.19 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.174 2.19 . . . . 10.0 115.084 176.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -106.42 -141.69 10.45 Favored Glycine 0 C--N 1.318 -0.435 0 N-CA-C 108.721 -1.752 . . . . 10.0 108.721 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.67 -168.23 37.0 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 109.896 -1.281 . . . . 10.0 109.896 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -66.72 12.13 0.16 Allowed 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.224 1.95 . . . . 10.0 111.662 169.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 62.7 mmtt -107.55 -18.84 13.74 Favored 'General case' 0 N--CA 1.438 -1.025 0 C-N-CA 124.731 1.213 . . . . 10.0 109.541 173.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -135.54 162.75 31.8 Favored 'General case' 0 C--N 1.348 0.513 0 CA-C-N 118.766 0.712 . . . . 10.0 109.822 -167.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -82.62 -18.76 40.05 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 107.969 -1.123 . . . . 10.0 107.969 173.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -84.27 21.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.219 0 O-C-N 119.908 -1.745 . . . . 10.0 112.854 -169.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.01 138.04 5.4 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.54 1.136 . . . . 10.0 109.196 170.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.547 ' HB3' ' HB3' ' B' ' 65' ' ' ASN . 11.6 m170 -70.41 -65.61 0.71 Allowed 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 173.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.47 HG13 ' H ' ' B' ' 82' ' ' GLY . 7.8 p -174.42 -69.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.117 1.367 . . . . 10.0 108.248 -178.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.47 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -105.84 63.12 0.31 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 109.602 -1.399 . . . . 10.0 109.602 -175.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.8 95.3 5.51 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 26.1 mt -75.33 2.43 11.24 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 120.295 -0.562 . . . . 10.0 110.906 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 89.16 -95.63 2.12 Favored Glycine 0 N--CA 1.437 -1.25 0 N-CA-C 108.174 -1.97 . . . . 10.0 108.174 171.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.3 m-20 -156.17 113.56 3.23 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 118.622 -0.704 . . . . 10.0 109.258 -172.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.3 m -96.72 131.08 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 118.524 0.602 . . . . 10.0 110.215 177.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 14.4 m -87.21 108.64 19.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 127.85 2.46 . . . . 10.0 110.424 -173.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.8 133.17 34.34 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.156 0.583 . . . . 10.0 109.752 171.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -61.86 174.05 0.91 Allowed 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.939 0.876 . . . . 10.0 109.591 167.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -51.57 -29.88 18.83 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 125.244 1.418 . . . . 10.0 110.961 173.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.01 -9.55 59.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 123.35 0.66 . . . . 10.0 110.501 -175.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.07 7.14 83.98 Favored Glycine 0 C--N 1.339 0.745 0 N-CA-C 111.33 -0.708 . . . . 10.0 111.33 -177.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 47.5 t -90.02 114.18 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 126.144 1.778 . . . . 10.0 106.366 178.301 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.444 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -110.81 118.57 36.5 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 169.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -80.09 121.69 25.85 Favored 'General case' 0 N--CA 1.451 -0.393 0 O-C-N 124.886 1.366 . . . . 10.0 107.547 169.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 99.1 t -105.81 131.07 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 C-N-CA 125.928 1.691 . . . . 10.0 106.625 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.5 p -155.46 74.58 0.9 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 174.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.69 159.01 7.41 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -142.68 133.66 25.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 O-C-N 121.77 -0.581 . . . . 10.0 110.738 173.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -142.88 135.34 27.57 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.976 0.91 . . . . 10.0 109.543 -172.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 3.8 p -93.92 -10.52 33.52 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.17 1.388 . . . . 10.0 111.188 169.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -85.07 -15.75 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.916 0.886 . . . . 10.0 110.28 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -98.15 149.84 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 106.659 -1.608 . . . . 10.0 106.659 169.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.6 m -153.34 141.16 20.11 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 169.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -56.14 -50.04 72.24 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.886 0.874 . . . . 10.0 109.558 -178.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.455 -0.184 0 C-N-CA 124.862 1.265 . . . . 10.0 108.688 -178.771 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t . . . . . 0 N--CA 1.448 -0.571 0 N-CA-C 114.514 1.302 . . . . 10.0 114.514 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 28.1 pt -70.64 -12.16 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 N-CA-C 113.168 0.803 . . . . 10.0 113.168 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.4 mm -57.66 115.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 119.847 1.203 . . . . 10.0 110.208 171.334 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 102.69 2.6 49.79 Favored Glycine 0 C--N 1.336 0.546 0 C-N-CA 124.496 1.046 . . . . 10.0 111.804 173.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.77 148.8 31.32 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 117.845 0.822 . . . . 10.0 110.605 173.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 31.3 m -80.66 126.69 31.59 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.838 1.255 . . . . 10.0 108.091 168.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -103.48 145.47 29.95 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.305 1.442 . . . . 10.0 107.825 169.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 68.9 t -135.54 143.5 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 4.4 p -110.89 139.8 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 O-C-N 124.535 1.147 . . . . 10.0 108.679 169.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.658 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.6 m-70 -117.2 162.41 17.91 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 114.729 1.381 . . . . 10.0 114.729 -174.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . 0.424 ' HB2' HD21 ' B' ' 144' ' ' LEU . 62.4 tt0 -61.72 -51.11 69.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 114.888 -1.051 . . . . 10.0 109.789 178.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -109.65 170.18 8.23 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.51 0.671 . . . . 10.0 111.613 -168.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.21 148.77 45.23 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 114.278 -1.328 . . . . 10.0 109.078 178.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.515 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.7 OUTLIER -74.93 151.14 38.91 Favored 'General case' 0 N--CA 1.443 -0.775 0 N-CA-C 109.226 -0.657 . . . . 10.0 109.226 172.686 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -76.0 -38.35 57.45 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 112.713 -2.039 . . . . 10.0 108.936 172.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 62.8 mt 62.45 64.54 0.93 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 123.97 1.843 . . . . 10.0 108.061 -176.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 76.21 -38.49 1.38 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 112.136 -2.302 . . . . 10.0 116.14 167.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 11.9 mtmt -75.35 5.09 6.1 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.099 1.148 . . . . 10.0 114.099 -167.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.45 -34.93 90.14 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 108.388 -1.885 . . . . 10.0 108.388 166.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.71 25.61 51.77 Favored Glycine 0 C--N 1.341 0.827 0 N-CA-C 111.191 -0.764 . . . . 10.0 111.191 -176.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -108.2 172.88 6.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 170.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -57.1 -45.6 83.27 Favored 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 123.957 0.903 . . . . 10.0 109.277 -177.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 mp0 -52.96 -42.76 65.79 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.456 1.102 . . . . 10.0 109.992 173.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.12 -9.21 20.92 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 117.341 -1.314 . . . . 10.0 113.362 179.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.2 t -108.73 7.57 26.44 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 121.009 1.731 . . . . 10.0 110.627 173.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -127.05 -59.44 1.25 Allowed 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 124.909 1.284 . . . . 10.0 110.94 -170.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.7 p -140.63 22.42 2.33 Favored 'General case' 0 CA--C 1.544 0.736 0 CA-C-N 119.016 0.826 . . . . 10.0 112.008 176.37 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 78.03 -100.23 1.6 Allowed Glycine 0 C--N 1.341 0.857 0 N-CA-C 107.533 -2.227 . . . . 10.0 107.533 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -163.62 42.19 0.1 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 125.696 1.598 . . . . 10.0 107.6 169.075 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.43 -8.98 45.46 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.296 1.038 . . . . 10.0 113.009 -174.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.01 -171.34 55.13 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.669 -1.372 . . . . 10.0 109.669 -173.228 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -53.32 164.11 0.51 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 124.822 1.249 . . . . 10.0 112.004 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.25 114.25 19.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 168.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.425 ' N ' ' CD2' ' B' ' 144' ' ' LEU . 0.7 OUTLIER -84.63 -48.13 9.81 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 108.315 -0.994 . . . . 10.0 108.315 -177.716 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.64 141.17 39.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 116.208 -0.451 . . . . 10.0 110.121 -175.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 m -118.6 145.37 45.46 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 126.491 1.916 . . . . 10.0 108.297 -169.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.19 155.46 26.49 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.859 -1.296 . . . . 10.0 109.859 168.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 18.1 t -116.24 129.51 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 103.946 -2.613 . . . . 10.0 103.946 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.7 mt -65.93 133.65 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 119.188 0.904 . . . . 10.0 111.255 -177.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.04 143.38 16.15 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.338 -1.505 . . . . 10.0 109.338 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -80.94 128.21 38.89 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.346 0 CA-C-N 118.442 1.121 . . . . 10.0 108.622 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.33 -49.23 17.42 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 -175.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.8 tp60 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 117.218 -1.373 . . . . 10.0 109.527 175.195 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 108.466 -0.938 . . . . 10.0 108.466 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t -133.81 -49.09 0.82 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 124.061 0.944 . . . . 10.0 111.439 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -120.93 139.54 53.08 Favored 'General case' 0 C--O 1.235 0.31 0 C-N-CA 125.462 1.505 . . . . 10.0 109.371 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.87 164.12 36.23 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 173.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 m -123.72 179.57 2.7 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 O-C-N 123.469 0.481 . . . . 10.0 109.9 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.89 118.25 8.45 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 126.683 1.993 . . . . 10.0 107.631 164.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 m -97.23 86.81 1.6 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 124.211 1.005 . . . . 10.0 111.007 173.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.426 HD12 ' N ' ' A' ' 8' ' ' LEU . 5.7 mp -79.47 140.15 37.42 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 121.789 -0.569 . . . . 10.0 109.609 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.8 mtmt -152.35 163.65 39.06 Favored 'General case' 0 N--CA 1.456 -0.168 0 N-CA-C 106.622 -1.621 . . . . 10.0 106.622 170.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -166.4 -65.71 0.03 OUTLIER Glycine 0 C--N 1.33 0.249 0 C-N-CA 120.606 -0.806 . . . . 10.0 112.249 169.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -74.11 -42.1 60.59 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.08 -66.45 0.5 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 114.885 -1.052 . . . . 10.0 111.959 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.81 -41.24 71.76 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.89 1.727 . . . . 10.0 110.621 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.466 HG23 HD11 ' A' ' 38' ' ' LEU . 0.4 OUTLIER -68.0 109.47 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.331 -1.359 . . . . 10.0 107.331 177.364 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -120.46 122.37 40.54 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.161 -2.163 . . . . 10.0 105.161 171.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.736 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -108.94 133.64 11.78 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 109.649 -1.38 . . . . 10.0 109.649 175.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.597 ' CG2' HG22 ' B' ' 54' ' ' THR . 2.2 mt -138.17 86.38 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -173.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.5 mm -95.57 143.33 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 C-N-CA 123.948 0.899 . . . . 10.0 109.111 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 32.7 m-80 -115.54 121.68 43.4 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 126.13 1.772 . . . . 10.0 108.721 168.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -102.28 98.11 8.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 125.862 1.665 . . . . 10.0 107.025 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -117.89 121.31 40.39 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.072 0.851 . . . . 10.0 113.109 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -94.05 105.49 17.49 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 125.867 1.667 . . . . 10.0 107.831 168.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.47 -42.76 61.83 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.795 0.838 . . . . 10.0 110.174 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -135.98 158.53 44.17 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 102.193 -3.262 . . . . 10.0 102.193 165.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 t -77.32 -3.87 42.19 Favored 'General case' 0 C--O 1.226 -0.135 0 CA-C-N 119.37 0.986 . . . . 10.0 109.817 173.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m120 -85.02 -24.6 28.12 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 125.182 1.393 . . . . 10.0 109.361 168.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.62 156.84 45.06 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 109.43 -1.468 . . . . 10.0 109.43 174.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -64.55 153.16 78.71 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 N-CA-C 108.006 -1.575 . . . . 10.0 108.006 169.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.8 p -79.14 121.14 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 N-CA-C 106.69 -1.596 . . . . 10.0 106.69 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -88.79 113.73 24.66 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.16 -1.793 . . . . 10.0 106.16 168.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 m -92.31 95.97 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.824 0 N-CA-C 105.555 -2.017 . . . . 10.0 105.555 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.7 p90 -106.97 161.8 14.4 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.178 0.513 . . . . 10.0 110.538 171.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.16 169.29 39.48 Favored Glycine 0 N--CA 1.438 -1.187 0 C-N-CA 120.055 -1.069 . . . . 10.0 110.63 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.0 t -139.37 95.75 2.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.992 -1.485 . . . . 10.0 106.992 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.736 HG22 ' HA2' ' A' ' 16' ' ' GLY . 6.4 pt -77.07 166.33 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.124 -1.065 . . . . 10.0 108.124 169.093 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -149.29 146.53 27.6 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 106.58 -1.637 . . . . 10.0 106.58 166.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.53 -4.93 24.73 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 123.921 0.772 . . . . 10.0 113.567 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.494 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.3 mp -73.23 177.93 4.8 Favored 'General case' 0 N--CA 1.444 -0.752 0 CA-C-N 118.117 0.959 . . . . 10.0 109.245 173.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 7.9 t -90.39 172.29 8.85 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.632 -0.877 . . . . 10.0 108.632 166.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.91 169.88 2.37 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.43 1.092 . . . . 10.0 110.837 -173.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.73 -178.92 41.26 Favored Glycine 0 N--CA 1.448 -0.503 0 O-C-N 121.428 -0.795 . . . . 10.0 112.843 167.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.6 mp -69.4 143.83 53.54 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.612 1.165 . . . . 10.0 109.779 176.04 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -142.61 139.49 31.31 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 123.381 0.672 . . . . 10.0 112.662 -176.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.627 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -26.84 117.94 0.04 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.106 2.289 . . . . 10.0 113.036 164.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.03 106.23 4.56 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 120.2 2.0 . . . . 10.0 110.095 170.03 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.48 172.06 15.09 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-O 121.174 0.512 . . . . 10.0 112.075 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.43 -44.57 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 C-N-CA 126.249 1.819 . . . . 10.0 113.429 -168.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 63.64 144.45 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 126.887 2.075 . . . . 10.0 112.074 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -67.0 -47.7 70.68 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.694 -0.854 . . . . 10.0 108.694 177.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -74.88 129.98 38.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 107.788 -1.19 . . . . 10.0 107.788 -169.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -88.75 -28.43 21.47 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 126.572 2.034 . . . . 10.0 110.695 175.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.59 176.43 0.65 Allowed 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 125.144 1.378 . . . . 10.0 112.819 -176.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -146.34 -64.41 0.3 Allowed 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.078 -1.419 . . . . 10.0 110.021 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.792 HG22 HG22 ' B' ' 17' ' ' ILE . 1.0 OUTLIER 46.54 -57.17 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.652 1 C-N-CA 133.211 4.604 . . . . 10.0 115.134 179.546 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . 0.293 . . -69.66 -37.05 76.57 Favored 'General case' 0 N--CA 1.437 -1.081 0 C-N-CA 127.763 2.425 . . . . 10.0 108.216 169.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.29 -143.76 14.96 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.233 -2.747 . . . . 10.0 106.233 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.3 t -78.8 39.35 0.35 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 122.178 0.99 . . . . 10.0 112.066 -172.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.4 m -111.27 -49.33 3.02 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 127.826 2.451 . . . . 10.0 106.811 -169.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 16.1 m -91.0 16.92 8.64 Favored 'General case' 0 N--CA 1.435 -1.224 0 C-N-CA 126.488 1.915 . . . . 10.0 110.113 -171.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.69 61.44 1.37 Allowed 'General case' 0 C--O 1.236 0.379 0 C-N-CA 124.101 0.96 . . . . 10.0 109.365 169.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 0.26 103.92 0.01 OUTLIER Glycine 0 C--N 1.335 0.488 1 C-N-CA 131.62 4.438 . . . . 10.0 111.087 166.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -73.04 73.5 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 122.752 2.301 . . . . 10.0 113.129 -168.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.461 ' CD2' HG22 ' A' ' 137' ' ' THR . 11.1 m170 71.82 36.2 1.24 Allowed 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 129.592 3.157 . . . . 10.0 110.749 170.008 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -73.62 60.02 0.66 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.451 1.1 . . . . 10.0 110.709 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -75.03 156.96 85.85 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 123.673 0.789 . . . . 10.0 110.181 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -65.43 -65.36 0.05 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.441 2.094 . . . . 10.0 111.5 -175.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.99 66.81 1.22 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.661 0.743 . . . . 10.0 109.975 172.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 113.74 3.3 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.401 -0.812 . . . . 10.0 109.557 178.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.6 mtt180 -116.8 -87.91 0.6 Allowed 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 103.298 -2.852 . . . . 10.0 103.298 -173.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtm -145.72 160.12 42.18 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 122.627 1.203 . . . . 10.0 108.702 167.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 42.7 t60 -62.2 127.27 30.59 Favored 'General case' 0 N--CA 1.439 -1.022 0 N-CA-C 105.364 -2.088 . . . . 10.0 105.364 163.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.89 -138.26 3.27 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 107.79 -2.124 . . . . 10.0 107.79 177.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.45 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.42 -158.39 22.26 Favored Glycine 0 N--CA 1.449 -0.444 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 169.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -65.98 10.58 0.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 CA-C-N 119.869 1.835 . . . . 10.0 110.945 168.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.45 ' H ' ' C ' ' A' ' 73' ' ' GLY . 1.9 mmmp? -108.68 -15.83 14.32 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.621 1.168 . . . . 10.0 109.257 177.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.419 ' OD2' ' NZ ' ' A' ' 128' ' ' LYS . 2.3 m-20 -141.32 132.13 25.85 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.617 -1.623 . . . . 10.0 106.617 -168.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -73.46 -22.58 60.14 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 -171.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -79.57 1.82 24.55 Favored 'General case' 0 N--CA 1.433 -1.313 0 C-N-CA 124.737 1.215 . . . . 10.0 111.579 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -42.15 142.97 0.65 Allowed 'General case' 0 C--N 1.346 0.445 0 C-N-CA 124.956 1.302 . . . . 10.0 112.436 177.305 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -59.49 -62.28 2.0 Allowed 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 121.238 0.542 . . . . 10.0 111.132 -173.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.438 HG13 ' H ' ' A' ' 82' ' ' GLY . 5.8 p -167.37 -64.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 179.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.438 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -122.04 60.26 0.56 Allowed Glycine 0 CA--C 1.522 0.503 0 N-CA-C 109.637 -1.385 . . . . 10.0 109.637 -179.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -92.37 90.97 7.45 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.672 -2.344 . . . . 10.0 104.672 168.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 40.4 mt -70.07 -31.49 69.11 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 173.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.1 -102.73 2.27 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 108.536 -1.825 . . . . 10.0 108.536 168.249 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 52.4 m-20 -124.51 124.22 41.81 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.686 1.194 . . . . 10.0 110.631 -168.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 16.2 m -111.1 137.71 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 108.057 -1.09 . . . . 10.0 108.057 168.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 54.1 m -92.22 120.18 32.55 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.897 1.679 . . . . 10.0 108.667 -175.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.62 133.2 44.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 123.901 0.88 . . . . 10.0 110.508 176.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -59.38 170.97 0.87 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 123.589 0.755 . . . . 10.0 109.834 167.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.42 ' NZ ' ' OD1' ' A' ' 92' ' ' ASP . 12.6 pttp -47.37 -34.89 7.51 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.787 1.635 . . . . 10.0 110.403 171.016 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.42 ' OD1' ' NZ ' ' A' ' 91' ' ' LYS . 0.2 OUTLIER -79.48 -0.74 34.43 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 124.683 1.193 . . . . 10.0 111.438 -174.768 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.45 8.55 87.69 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 110.671 -0.972 . . . . 10.0 110.671 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.5 t -88.0 106.92 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 125.95 1.7 . . . . 10.0 106.614 -178.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.496 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -103.9 117.84 35.28 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 168.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.26 114.37 18.14 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 126.038 1.735 . . . . 10.0 108.654 172.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.2 t -107.24 133.43 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 178.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 94.9 p -156.62 59.21 0.55 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.264 0.625 . . . . 10.0 110.088 172.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.6 mt -96.43 157.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -174.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -133.06 143.0 49.06 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.805 0.729 . . . . 10.0 111.057 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -127.09 124.14 38.52 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.274 1.43 . . . . 10.0 108.861 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 p -89.99 -8.89 50.57 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.352 1.461 . . . . 10.0 111.147 169.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.4 p -95.91 -39.23 9.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 124.331 1.052 . . . . 10.0 109.929 -174.081 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -97.03 155.89 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 125.347 1.459 . . . . 10.0 108.514 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.6 m -157.63 156.39 31.74 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 108.281 -1.007 . . . . 10.0 108.281 -173.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -74.53 -23.04 58.75 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 120.919 0.39 . . . . 10.0 110.478 174.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.8 m -150.47 142.57 24.05 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.051 -1.462 . . . . 10.0 107.051 -177.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.73 -67.2 0.29 Allowed Glycine 0 C--N 1.334 0.427 0 N-CA-C 109.014 -1.634 . . . . 10.0 109.014 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -163.37 -51.36 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 126.398 1.879 . . . . 10.0 107.287 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.19 -28.29 59.97 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 114.755 -1.111 . . . . 10.0 110.241 -169.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.1 t 22.86 81.47 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 129.028 2.931 . . . . 10.0 111.814 172.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.8 pt -75.93 39.23 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 112.213 0.449 . . . . 10.0 112.213 -173.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -83.39 -48.61 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 124.899 1.28 . . . . 10.0 111.268 -171.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.79 46.02 1.32 Allowed Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.816 -0.914 . . . . 10.0 110.816 -175.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -111.13 162.02 15.35 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 125.201 1.4 . . . . 10.0 108.881 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -110.22 102.56 11.23 Favored 'General case' 0 C--N 1.347 0.476 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 179.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.82 134.98 40.24 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.514 -0.921 . . . . 10.0 108.514 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.408 HG12 ' CD2' ' A' ' 120' ' ' HIS . 61.9 t -124.11 131.74 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 O-C-N 123.911 0.757 . . . . 10.0 110.407 -172.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.445 HG13 HD21 ' A' ' 38' ' ' LEU . 1.8 t -98.19 123.37 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 128.416 2.686 . . . . 10.0 107.639 168.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.627 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.5 m-70 -109.94 157.54 19.15 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 115.868 1.803 . . . . 10.0 115.868 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -41.34 -65.13 0.47 Allowed 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 129.767 3.227 . . . . 10.0 111.73 171.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.1 mttp -112.28 175.41 5.44 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.861 0.865 . . . . 10.0 111.74 -172.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.61 147.91 37.29 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 114.005 -1.452 . . . . 10.0 109.72 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -78.77 142.75 36.73 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 123.62 0.768 . . . . 10.0 110.659 171.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -78.53 -13.59 59.76 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.512 -1.222 . . . . 10.0 110.563 167.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 76.5 mt 61.62 42.86 10.56 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 125.474 1.51 . . . . 10.0 110.949 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.14 -5.94 56.12 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 124.262 0.934 . . . . 10.0 112.611 173.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.419 ' NZ ' ' OD2' ' A' ' 76' ' ' ASP . 11.9 mttt -110.65 35.79 3.35 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.752 0.821 . . . . 10.0 110.628 -167.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -84.09 -31.18 26.51 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.861 2.172 . . . . 10.0 111.901 178.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.61 48.41 84.7 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -176.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.481 ' H ' ' HB2' ' A' ' 134' ' ' SER . 14.8 m-80 -150.29 165.62 32.46 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.781 2.432 . . . . 10.0 106.289 -175.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -58.41 -47.65 83.23 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-O 121.588 0.709 . . . . 10.0 109.139 174.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -54.02 -30.92 49.54 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.979 1.312 . . . . 10.0 112.695 175.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.481 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 7.0 t -47.22 -47.46 24.43 Favored 'General case' 0 C--O 1.223 -0.307 0 C-N-CA 124.395 1.078 . . . . 10.0 108.412 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -88.24 10.19 20.46 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 118.751 -0.642 . . . . 10.0 112.55 -173.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -122.38 -94.39 0.5 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.455 1.902 . . . . 10.0 109.875 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.461 HG22 ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -101.85 25.04 9.08 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 121.353 1.888 . . . . 10.0 110.158 177.294 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.07 -91.32 0.44 Allowed Glycine 0 C--N 1.339 0.743 0 N-CA-C 108.886 -1.686 . . . . 10.0 108.886 177.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 m-80 -162.27 35.97 0.12 Allowed 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 126.428 1.891 . . . . 10.0 108.246 172.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.55 -9.92 55.95 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 121.219 -0.926 . . . . 10.0 112.116 -173.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.96 -167.92 53.82 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.862 -0.895 . . . . 10.0 110.862 174.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 58.4 p -59.12 139.34 56.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 122.308 1.051 . . . . 10.0 112.277 -168.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 40.2 mtt85 -66.76 74.84 0.11 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.526 1.131 . . . . 10.0 110.838 173.173 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.3 mt -47.31 -38.7 13.22 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 123.506 0.722 . . . . 10.0 112.09 176.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.8 157.17 40.38 Favored 'General case' 0 CA--C 1.514 -0.43 0 O-C-N 121.827 -0.546 . . . . 10.0 111.121 176.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -159.01 167.32 29.63 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.458 -0.337 . . . . 10.0 110.218 171.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.63 165.42 36.23 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 109.331 -1.508 . . . . 10.0 109.331 -176.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 92.9 t -105.53 146.95 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 103.018 -2.956 . . . . 10.0 103.018 -175.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . 0.3 5.0 mt -68.36 -86.88 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 CA-C-O 121.469 0.652 . . . . 10.0 112.46 -168.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 93.49 135.44 7.5 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.775 1.179 . . . . 10.0 112.699 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.1 mt -70.46 142.15 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 125.057 1.343 . . . . 10.0 109.357 -176.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.77 -45.22 2.29 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.077 0.951 . . . . 10.0 111.383 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.537 1.935 . . . . 10.0 113.266 -178.505 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 107.166 -1.42 . . . . 10.0 107.166 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -78.14 -50.44 11.99 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-O 122.299 1.047 . . . . 10.0 109.743 171.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -156.04 153.97 30.29 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.692 -1.14 . . . . 10.0 109.76 -169.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.4 151.47 48.58 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.074 0.949 . . . . 10.0 108.629 169.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.6 t -109.56 159.31 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 125.044 1.338 . . . . 10.0 110.099 174.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.99 97.17 3.01 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 124.31 1.044 . . . . 10.0 108.562 166.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.458 HG12 HG23 ' B' ' 17' ' ' ILE . 29.1 m -82.29 126.36 39.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -106.11 149.74 26.46 Favored 'General case' 0 CA--C 1.529 0.136 0 CA-C-O 117.914 -1.041 . . . . 10.0 108.351 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . 0.429 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 47.0 tttt -165.13 161.73 19.72 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 120.083 1.31 . . . . 10.0 108.679 170.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.42 -50.26 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 116.204 -0.453 . . . . 10.0 112.208 169.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -77.62 -46.34 22.41 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 -170.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 131.79 -61.7 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.928 -1.487 . . . . 10.0 111.303 -175.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -63.02 -39.68 38.6 Favored 'Trans proline' 0 N--CA 1.454 -0.811 0 C-N-CA 122.586 2.191 . . . . 10.0 110.79 169.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.97 115.34 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.114 -1.069 . . . . 10.0 108.114 -178.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.43 140.05 27.33 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-O 121.014 0.435 . . . . 10.0 110.091 165.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.486 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -108.07 157.28 15.43 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 125.256 1.408 . . . . 10.0 112.388 178.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.792 HG22 HG22 ' A' ' 54' ' ' THR . 0.3 OUTLIER -147.19 85.0 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 N-CA-C 106.29 -1.745 . . . . 10.0 106.29 -179.525 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.78 145.09 9.38 Favored 'Isoleucine or valine' 0 C--O 1.231 0.093 0 C-N-CA 124.062 0.945 . . . . 10.0 110.778 178.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -123.19 111.74 16.85 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 129.854 3.261 . . . . 10.0 106.928 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -101.09 103.22 14.3 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 79.0 mt-10 -96.38 137.1 35.95 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.139 0.881 . . . . 10.0 110.843 170.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -106.15 100.95 10.47 Favored 'General case' 0 CA--C 1.53 0.186 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 24.0 tttp . . . . . 0 N--CA 1.441 -0.903 0 C-N-CA 125.959 1.704 . . . . 10.0 110.297 -176.735 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.868 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -62.83 130.15 28.47 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 N-CA-C 107.966 -1.59 . . . . 10.0 107.966 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.4 t -79.99 99.73 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 105.98 -1.859 . . . . 10.0 105.98 174.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -77.04 119.34 20.63 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 104.67 -2.344 . . . . 10.0 104.67 167.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -105.16 114.15 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 106.323 -1.732 . . . . 10.0 106.323 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -135.8 172.6 12.78 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 121.166 0.508 . . . . 10.0 111.831 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.59 -149.15 21.21 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 106.334 -2.706 . . . . 10.0 106.334 169.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.0 m -155.53 159.43 39.71 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 119.079 -1.048 . . . . 10.0 111.25 177.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.567 HG12 ' HB3' ' B' ' 95' ' ' ALA . 1.5 pt -117.28 147.1 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.772 -1.104 . . . . 10.0 108.565 166.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -126.07 138.72 53.73 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 124.38 1.05 . . . . 10.0 109.226 168.539 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.27 -8.05 10.47 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.972 1.272 . . . . 10.0 113.29 175.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -62.44 178.55 0.4 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.288 1.044 . . . . 10.0 112.237 177.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.2 t -115.0 156.72 24.57 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 106.897 -1.52 . . . . 10.0 106.897 167.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -46.95 143.95 2.71 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.583 1.553 . . . . 10.0 112.902 -169.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.24 -178.42 31.71 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 124.222 0.915 . . . . 10.0 111.887 171.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 10.6 mt -64.0 150.48 45.15 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.657 1.583 . . . . 10.0 112.71 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -146.11 148.57 32.75 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.681 1.192 . . . . 10.0 112.764 177.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.639 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -25.7 124.31 0.04 OUTLIER Glycine 0 C--N 1.341 0.852 0 C-N-CA 126.668 2.08 . . . . 10.0 112.616 166.473 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -148.91 98.9 2.91 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 119.888 1.844 . . . . 10.0 111.46 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.52 172.59 14.74 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 122.807 0.443 . . . . 10.0 111.151 -178.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.3 m -105.43 -24.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 115.826 1.787 . . . . 10.0 115.826 -167.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 62.39 175.22 0.14 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 121.529 0.68 . . . . 10.0 112.568 177.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -81.09 -56.32 4.17 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.985 -0.552 . . . . 10.0 110.195 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -87.25 156.14 19.78 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.161 0.437 . . . . 10.0 110.158 -172.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.01 -19.26 22.23 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.036 -1.226 . . . . 10.0 110.036 169.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -63.38 160.43 16.11 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 122.556 1.17 . . . . 10.0 111.688 -176.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -153.79 16.66 0.51 Allowed 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.242 -0.89 . . . . 10.0 113.001 -171.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.597 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -45.53 -40.86 9.08 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 127.141 2.177 . . . . 10.0 112.707 -177.887 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.1 -18.56 57.88 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 111.915 0.339 . . . . 10.0 111.915 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.88 -66.2 0.56 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 109.474 -1.45 . . . . 10.0 109.474 -179.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 48.2 t -157.84 18.31 0.25 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.645 1.178 . . . . 10.0 110.584 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -98.87 -45.3 6.04 Favored 'General case' 0 N--CA 1.44 -0.931 0 O-C-N 120.184 -1.572 . . . . 10.0 108.695 -177.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -49.11 -39.71 29.44 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.438 1.495 . . . . 10.0 111.792 -169.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.46 -42.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 129.027 2.931 . . . . 10.0 114.205 168.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.33 163.24 28.43 Favored Glycine 0 N--CA 1.439 -1.113 0 N-CA-C 107.87 -2.092 . . . . 10.0 107.87 172.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -74.42 -169.29 0.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.547 0 N-CA-C 106.734 -2.064 . . . . 10.0 106.734 167.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 31.7 m170 -82.12 58.41 3.96 Favored 'General case' 0 CA--C 1.539 0.52 0 O-C-N 120.109 -1.62 . . . . 10.0 110.314 -174.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -76.51 59.66 1.51 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 123.06 1.41 . . . . 10.0 111.733 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -60.35 153.67 57.74 Favored Pre-proline 0 C--N 1.324 -0.516 0 C-N-CA 126.44 1.896 . . . . 10.0 110.965 169.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.77 -43.95 0.55 Allowed 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.686 2.257 . . . . 10.0 111.377 175.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 tt -79.3 62.77 3.75 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.175 0.99 . . . . 10.0 109.743 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 10.1 t -39.36 107.61 0.07 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.142 1.777 . . . . 10.0 113.368 -169.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.4 mtt180 -136.5 -174.07 3.59 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.422 1.489 . . . . 10.0 109.708 175.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.5 mmpt? -117.64 57.88 0.81 Allowed 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 113.975 1.102 . . . . 10.0 113.975 -167.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.402 ' CD2' ' CA ' ' B' ' 138' ' ' GLY . 63.5 t60 38.03 94.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 116.209 1.929 . . . . 10.0 116.209 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.6 -164.64 12.51 Favored Glycine 0 C--N 1.315 -0.61 0 N-CA-C 108.524 -1.83 . . . . 10.0 108.524 168.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -139.53 -162.4 9.1 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.143 -0.783 . . . . 10.0 111.143 171.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -69.81 10.32 0.51 Allowed 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.324 2.016 . . . . 10.0 111.569 176.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 84.3 mttt -101.28 -19.74 15.53 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.657 0.783 . . . . 10.0 109.174 170.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -125.67 -178.64 4.33 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 107.945 -1.132 . . . . 10.0 107.945 -167.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . 0.273 0.6 OUTLIER -110.43 -1.6 17.0 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 112.752 0.649 . . . . 10.0 112.752 167.918 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -77.61 -1.82 32.72 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 121.815 -0.553 . . . . 10.0 109.945 175.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 21.0 ptt-85 -42.25 124.43 2.8 Favored 'General case' 0 C--N 1.344 0.335 0 C-N-CA 124.965 1.306 . . . . 10.0 109.148 169.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -74.67 -54.3 7.67 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.574 -0.528 . . . . 10.0 109.574 -172.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.479 HG13 ' H ' ' B' ' 82' ' ' GLY . 6.6 p -165.02 -66.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.537 0.735 . . . . 10.0 109.157 176.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.479 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -118.7 77.01 0.3 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.663 -2.175 . . . . 10.0 107.663 178.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -119.54 97.97 5.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.99 -2.226 . . . . 10.0 104.99 178.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -83.13 23.06 0.9 Allowed 'General case' 0 CA--C 1.526 0.048 0 CA-C-O 120.962 0.41 . . . . 10.0 110.553 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.4 -109.93 2.91 Favored Glycine 0 N--CA 1.432 -1.615 0 N-CA-C 105.653 -2.979 . . . . 10.0 105.653 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -158.93 139.12 12.2 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.857 -1.164 . . . . 10.0 107.857 -178.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.3 m -108.46 130.49 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 123.535 0.734 . . . . 10.0 111.867 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -80.95 101.52 9.54 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.973 2.909 . . . . 10.0 111.488 -170.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.99 134.34 35.36 Favored 'General case' 0 N--CA 1.451 -0.398 0 O-C-N 121.866 -0.521 . . . . 10.0 109.733 170.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -61.9 167.57 3.68 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 122.033 0.921 . . . . 10.0 108.75 167.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 30.6 ttpt -49.87 -31.13 11.34 Favored 'General case' 0 N--CA 1.432 -1.358 0 C-N-CA 125.934 1.694 . . . . 10.0 111.964 169.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -77.03 -10.29 59.27 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.188 0.449 . . . . 10.0 111.258 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.2 12.11 66.03 Favored Glycine 0 C--N 1.34 0.797 0 O-C-N 120.993 -1.067 . . . . 10.0 110.798 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -92.6 111.48 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 C-N-CA 126.66 1.984 . . . . 10.0 106.311 176.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.567 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -108.53 121.6 45.31 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -82.64 123.06 28.91 Favored 'General case' 0 N--CA 1.434 -1.253 0 C-N-CA 126.893 2.077 . . . . 10.0 107.989 170.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.94 131.85 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.935 -1.505 . . . . 10.0 106.935 175.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.85 75.8 0.71 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.991 0.916 . . . . 10.0 109.583 169.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.9 164.31 3.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.589 -1.634 . . . . 10.0 106.589 179.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -137.49 138.9 40.19 Favored 'General case' 0 N--CA 1.451 -0.383 0 O-C-N 121.459 -0.776 . . . . 10.0 110.868 171.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.99 145.53 49.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 124.454 1.096 . . . . 10.0 108.558 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.2 p -120.1 16.71 12.44 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.12 1.368 . . . . 10.0 110.7 172.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -107.65 -49.23 7.93 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 124.362 1.065 . . . . 10.0 109.634 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.329 0.7 OUTLIER -67.82 170.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-O 121.206 0.527 . . . . 10.0 112.094 171.544 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 52.1 p -151.91 140.25 20.46 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.151 -1.055 . . . . 10.0 108.151 174.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.4 pp -85.85 -24.68 26.63 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 108.27 -1.011 . . . . 10.0 108.27 167.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m . . . . . 0 N--CA 1.451 -0.396 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 166.292 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t . . . . . 0 CA--C 1.531 0.229 0 CA-C-O 122.171 0.986 . . . . 10.0 111.981 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 41.1 pt -66.4 1.53 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 113.619 0.97 . . . . 10.0 113.619 -178.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.8 mm -41.42 -40.88 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.302 0 C-N-CA 125.113 1.365 . . . . 10.0 113.783 177.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -105.5 25.59 24.1 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.82 1.2 . . . . 10.0 113.198 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.58 175.94 6.03 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.44 1.096 . . . . 10.0 110.439 174.31 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -123.71 107.98 12.04 Favored 'General case' 0 C--N 1.344 0.355 0 C-N-CA 124.554 1.142 . . . . 10.0 111.168 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -61.94 130.76 47.15 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 167.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.03 131.21 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 N-CA-C 107.504 -1.295 . . . . 10.0 107.504 173.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.445 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.8 OUTLIER -100.72 126.35 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.537 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.639 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.4 m170 -104.26 157.0 17.44 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 115.248 1.573 . . . . 10.0 115.248 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -47.48 -57.06 5.82 Favored 'General case' 0 N--CA 1.447 -0.614 0 C-N-CA 127.784 2.434 . . . . 10.0 110.657 177.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -107.53 170.84 7.73 Favored 'General case' 0 N--CA 1.463 0.199 0 C-N-CA 124.493 1.117 . . . . 10.0 112.478 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.28 149.93 38.67 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.558 1.543 . . . . 10.0 109.804 171.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.01 144.85 38.39 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 112.924 0.713 . . . . 10.0 112.924 177.101 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -78.32 -23.87 46.86 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.755 1.622 . . . . 10.0 109.259 167.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 48.9 mt 54.76 58.28 4.97 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 122.611 1.196 . . . . 10.0 109.693 -174.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.96 -47.31 3.82 Favored Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 113.996 -1.456 . . . . 10.0 112.505 167.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.91 42.39 0.38 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 118.026 0.913 . . . . 10.0 112.649 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.2 -22.82 26.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 127.122 2.296 . . . . 10.0 109.442 168.096 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.78 32.95 83.57 Favored Glycine 0 C--N 1.337 0.6 0 N-CA-C 110.975 -0.85 . . . . 10.0 110.975 176.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -135.67 162.94 31.32 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.132 -1.062 . . . . 10.0 108.132 172.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -45.87 -48.77 15.95 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 124.409 1.083 . . . . 10.0 110.02 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -70.46 -33.6 71.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.671 -0.643 . . . . 10.0 112.143 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.9 p -53.3 -44.26 68.2 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 119.374 0.988 . . . . 10.0 110.331 174.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.6 t -80.71 -19.18 45.66 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 112.852 0.686 . . . . 10.0 112.852 -173.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -101.41 -45.37 5.34 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 125.304 1.442 . . . . 10.0 112.666 -172.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 30.8 p -132.18 -1.97 3.59 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 119.211 0.914 . . . . 10.0 113.128 174.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . 0.402 ' CA ' ' CD2' ' B' ' 71' ' ' HIS . . . 88.89 22.97 36.95 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-O 118.601 -1.11 . . . . 10.0 112.241 -176.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 60.48 15.65 5.75 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 119.567 1.683 . . . . 10.0 112.056 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.98 3.13 5.7 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.103 -0.998 . . . . 10.0 112.438 -170.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.94 -168.55 54.76 Favored Glycine 0 N--CA 1.444 -0.813 0 N-CA-C 110.586 -1.006 . . . . 10.0 110.586 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.4 t -58.04 143.86 41.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 115.05 -0.575 . . . . 10.0 111.755 -169.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.9 mtm-85 -64.02 78.86 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.042 0.937 . . . . 10.0 110.02 168.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 5.7 tp -39.87 -55.37 2.0 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.234 1.813 . . . . 10.0 110.847 176.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.445 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -151.81 149.67 29.27 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.153 -0.684 . . . . 10.0 109.153 -173.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 12.6 m -128.48 153.78 46.79 Favored 'General case' 0 CA--C 1.522 -0.132 0 C-N-CA 125.477 1.511 . . . . 10.0 109.101 -173.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -133.57 169.95 22.56 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 108.964 -1.654 . . . . 10.0 108.964 167.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' A' ' 148' ' ' VAL . 17.2 t -117.83 132.44 67.64 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 169.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 71.4 mt -69.24 157.99 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.382 -0.97 . . . . 10.0 108.382 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.88 156.16 27.26 Favored Glycine 0 CA--C 1.528 0.891 0 O-C-N 121.249 -0.907 . . . . 10.0 111.731 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.7 mp -55.52 133.38 19.3 Favored 'Isoleucine or valine' 0 C--N 1.341 0.22 0 C-N-CA 125.618 1.567 . . . . 10.0 109.765 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -120.21 165.6 14.59 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.38 -1.341 . . . . 10.0 107.38 166.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 . . . . . 0 C--O 1.25 1.084 0 C-N-CA 125.939 1.695 . . . . 10.0 106.834 169.831 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 106.205 -1.776 . . . . 10.0 106.205 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.7 t -69.4 -14.34 62.85 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.496 1.044 . . . . 10.0 109.171 168.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.67 155.12 50.29 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 125.406 1.483 . . . . 10.0 107.481 168.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.04 158.24 44.03 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 125.483 1.513 . . . . 10.0 106.952 169.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -122.05 152.61 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 C-N-CA 123.529 0.732 . . . . 10.0 110.106 -178.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.557 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -127.8 97.23 4.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 125.099 1.359 . . . . 10.0 108.502 168.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.0 OUTLIER -79.64 109.25 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.13 -1.433 . . . . 10.0 107.13 167.427 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.3 mt -90.07 139.85 30.22 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.413 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 18.9 tttt -162.18 161.09 27.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 120.01 1.277 . . . . 10.0 108.388 170.191 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.42 -53.32 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.206 0 N-CA-C 111.66 -0.576 . . . . 10.0 111.66 170.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -75.72 -47.31 26.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 106.713 -1.588 . . . . 10.0 106.713 -171.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.53 -61.26 0.66 Allowed Glycine 0 CA--C 1.53 0.993 0 CA-C-N 113.822 -1.536 . . . . 10.0 111.807 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.14 -34.92 67.27 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 122.63 2.22 . . . . 10.0 111.23 172.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.0 t -75.58 110.1 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.176 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 176.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.21 129.69 38.08 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 123.448 0.699 . . . . 10.0 109.326 166.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.47 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -105.75 147.11 16.18 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 125.595 1.569 . . . . 10.0 109.559 171.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.448 HG22 HG22 ' B' ' 54' ' ' THR . 2.9 mt -140.82 59.68 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 -176.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm -78.95 140.27 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 N-CA-C 109.095 -0.705 . . . . 10.0 109.095 -172.446 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -116.61 110.52 18.63 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 126.939 2.096 . . . . 10.0 107.271 178.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -94.45 109.73 21.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 176.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.54 158.64 16.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.572 0.624 . . . . 10.0 112.127 170.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -155.61 83.23 1.04 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.818 2.047 . . . . 10.0 106.646 166.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 6.5 mmtp -52.13 -55.72 19.11 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 125.294 1.437 . . . . 10.0 110.503 -173.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -123.62 167.22 14.24 Favored 'General case' 0 N--CA 1.434 -1.264 0 N-CA-C 103.992 -2.595 . . . . 10.0 103.992 169.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -71.73 -14.58 62.06 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.885 -0.598 . . . . 10.0 109.917 173.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -79.8 -17.03 54.34 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 123.304 0.642 . . . . 10.0 109.314 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.67 140.98 23.17 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 178.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -62.06 153.35 69.74 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.118 1.879 . . . . 10.0 107.543 169.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -76.81 89.82 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.167 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 170.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.6 tmtp? -85.45 114.16 22.28 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 106.075 -1.824 . . . . 10.0 106.075 170.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.2 m -110.31 125.21 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 107.173 -1.417 . . . . 10.0 107.173 -174.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.7 p90 -134.46 164.78 26.69 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.118 0.485 . . . . 10.0 111.878 173.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.2 -148.67 19.52 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 107.827 -2.109 . . . . 10.0 107.827 170.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.5 t -155.31 150.77 27.22 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 116.973 0.387 . . . . 10.0 110.143 -176.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.47 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -113.49 111.51 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.268 0 C-N-CA 125.836 1.654 . . . . 10.0 106.611 165.551 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -95.93 137.33 35.15 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 108.073 -1.084 . . . . 10.0 108.073 170.151 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.78 -0.94 9.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 125.137 1.351 . . . . 10.0 112.585 173.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.04 174.96 7.89 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 118.453 1.126 . . . . 10.0 109.285 176.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -100.58 156.89 17.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.077 -1.823 . . . . 10.0 106.077 165.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -55.03 151.59 8.78 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.373 0.669 . . . . 10.0 111.834 -169.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.54 -178.93 26.56 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.115 0.864 . . . . 10.0 112.081 175.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -67.23 151.08 48.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.899 1.28 . . . . 10.0 111.355 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -151.02 153.77 35.77 Favored 'General case' 0 C--N 1.342 0.265 0 N-CA-C 113.577 0.955 . . . . 10.0 113.577 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.635 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -38.23 125.93 1.57 Allowed Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.693 2.568 . . . . 10.0 113.057 165.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -155.2 114.13 3.58 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.525 -1.287 . . . . 10.0 107.525 165.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 170.44 18.46 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.843 0.83 . . . . 10.0 111.582 174.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -115.33 127.28 72.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 104.251 -2.5 . . . . 10.0 104.251 168.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -167.52 175.16 7.31 Favored 'General case' 0 N--CA 1.451 -0.38 0 O-C-N 121.908 -0.495 . . . . 10.0 110.891 -168.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . 0.28 14.0 pt-20 50.3 -157.51 0.09 Allowed 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 126.279 2.237 . . . . 10.0 113.281 167.116 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.8 m-30 -82.64 -167.37 1.59 Allowed 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 109.247 -0.649 . . . . 10.0 109.247 177.086 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.37 -0.35 24.99 Favored Glycine 0 CA--C 1.536 1.347 0 C-N-CA 126.256 1.884 . . . . 10.0 112.975 174.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -75.0 83.0 2.24 Favored 'General case' 0 C--N 1.342 0.258 0 CA-C-N 119.737 1.768 . . . . 10.0 110.637 -176.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -79.51 8.41 6.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-N 115.282 -0.872 . . . . 10.0 113.077 177.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.518 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -42.53 -48.07 5.25 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 127.992 2.517 . . . . 10.0 113.376 -171.906 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.08 -26.74 39.49 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 123.206 0.602 . . . . 10.0 112.348 -179.305 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 137.99 -150.69 21.03 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 106.727 -2.549 . . . . 10.0 106.727 -169.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.8 m -80.23 33.16 0.28 Allowed 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 124.668 1.187 . . . . 10.0 112.273 -179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.8 m -125.24 -57.72 1.48 Allowed 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 108.646 -0.872 . . . . 10.0 108.646 -168.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 t -58.61 -39.79 81.46 Favored 'General case' 0 C--N 1.341 0.204 0 O-C-N 123.416 0.448 . . . . 10.0 110.935 -168.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.03 -41.69 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 127.387 2.275 . . . . 10.0 113.997 169.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.5 -162.93 19.65 Favored Glycine 0 C--N 1.34 0.779 0 N-CA-C 109.597 -1.401 . . . . 10.0 109.597 169.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -110.44 178.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.935 1 C-N-CA 125.558 4.172 . . . . 10.0 106.354 164.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.6 m170 -66.87 79.86 0.11 Allowed 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 120.088 1.313 . . . . 10.0 110.927 -176.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -105.85 53.93 0.7 Allowed 'General case' 0 N--CA 1.462 0.138 0 C-N-CA 127.262 2.225 . . . . 10.0 108.802 172.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -52.99 145.41 23.21 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 125.502 1.521 . . . . 10.0 110.772 168.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -64.98 -43.46 11.78 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 123.338 2.692 . . . . 10.0 111.243 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.4 68.68 0.55 Allowed 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.528 -0.915 . . . . 10.0 108.528 170.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.5 p -58.74 104.79 0.25 Allowed 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.381 1.073 . . . . 10.0 109.893 -175.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.1 mtt180 -141.55 -176.56 4.79 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 105.722 -1.955 . . . . 10.0 105.722 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.37 129.48 35.89 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 -177.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.446 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 76.1 t60 -44.92 112.13 0.4 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 122.558 0.343 . . . . 10.0 111.749 178.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.49 -147.66 6.52 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.03 -167.93 18.18 Favored Glycine 0 C--O 1.225 -0.451 0 CA-C-N 117.98 0.89 . . . . 10.0 111.567 179.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -68.36 16.09 0.16 Allowed 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.518 2.145 . . . . 10.0 112.398 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -110.39 -20.6 12.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 124.934 1.294 . . . . 10.0 110.25 169.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.67 162.65 16.94 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.754 -1.572 . . . . 10.0 106.754 -167.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -88.98 -21.85 23.31 Favored 'General case' 0 C--N 1.329 -0.32 0 O-C-N 121.629 -0.669 . . . . 10.0 109.877 178.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -83.4 -6.37 59.44 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 124.538 1.135 . . . . 10.0 111.474 -169.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -35.65 118.95 0.51 Allowed 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 126.145 1.778 . . . . 10.0 111.108 171.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.446 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 31.1 m170 -50.37 -50.66 50.75 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 115.828 1.788 . . . . 10.0 115.828 -167.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -178.25 -46.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 106.945 -1.502 . . . . 10.0 106.945 -174.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -153.45 62.33 0.38 Allowed Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -85.84 95.96 9.61 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 103.705 -2.702 . . . . 10.0 103.705 166.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -70.47 -10.42 59.1 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.578 0.626 . . . . 10.0 111.833 -171.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.85 -93.96 0.93 Allowed Glycine 0 N--CA 1.445 -0.744 0 N-CA-C 107.69 -2.164 . . . . 10.0 107.69 176.063 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -150.54 147.11 27.06 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 124.871 1.268 . . . . 10.0 107.79 -174.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.1 m -117.98 128.04 75.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 118.606 0.639 . . . . 10.0 109.755 169.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.7 m -90.19 95.11 10.04 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 127.267 2.227 . . . . 10.0 111.506 -169.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -69.63 128.5 36.68 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.778 -0.576 . . . . 10.0 111.654 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.1 171.8 5.25 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.123 1.369 . . . . 10.0 109.888 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 pttm -54.89 -29.35 55.62 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.218 1.007 . . . . 10.0 111.088 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -78.25 0.21 26.11 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.031 0.444 . . . . 10.0 111.213 178.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.45 17.59 79.81 Favored Glycine 0 C--N 1.339 0.734 0 O-C-N 120.654 -1.279 . . . . 10.0 110.766 178.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 18.3 t -97.68 103.34 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.734 0 C-N-CA 127.812 2.445 . . . . 10.0 106.356 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.404 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -97.33 118.42 33.77 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 168.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -79.42 141.87 36.45 Favored 'General case' 0 N--CA 1.425 -1.679 0 C-N-CA 124.643 1.177 . . . . 10.0 108.718 178.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 86.8 t -111.63 133.22 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 106.509 -1.663 . . . . 10.0 106.509 169.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.6 p -158.88 58.4 0.43 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.501 0.72 . . . . 10.0 111.512 170.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -101.3 152.73 5.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.897 0.879 . . . . 10.0 109.085 -171.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -112.01 127.94 56.03 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 126.568 1.947 . . . . 10.0 108.448 172.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -130.22 145.72 51.77 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-O 121.378 0.609 . . . . 10.0 111.001 169.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.8 t -133.07 64.66 1.61 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.089 2.156 . . . . 10.0 106.652 -178.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.01 -52.73 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.077 0 C-N-CA 123.672 0.789 . . . . 10.0 109.225 175.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.328 0.0 OUTLIER -78.84 174.82 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.145 0.497 . . . . 10.0 112.19 172.048 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 m -153.99 153.72 32.49 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.372 -1.714 . . . . 10.0 106.372 169.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 95.7 mt -68.45 -14.52 63.06 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.109 0.564 . . . . 10.0 111.602 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.4 m -151.75 157.21 41.7 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.056 -1.831 . . . . 10.0 106.056 169.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 151.84 -66.95 0.33 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 178.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -161.02 -51.74 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 126.298 1.839 . . . . 10.0 107.239 -178.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -73.79 -39.44 64.13 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.513 -1.222 . . . . 10.0 108.165 -169.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 17.8 t 35.53 74.86 0.06 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 127.559 2.344 . . . . 10.0 110.31 169.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 pt -76.36 46.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.986 0.914 . . . . 10.0 111.422 -173.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 35.1 mm -92.31 -86.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 124.936 1.295 . . . . 10.0 108.613 -171.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.23 50.57 2.76 Favored Glycine 0 CA--C 1.537 1.468 0 O-C-N 120.291 -1.506 . . . . 10.0 113.669 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 13.4 mmt-85 -101.05 175.63 5.53 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 126.195 1.798 . . . . 10.0 108.006 169.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 17.2 m -102.46 104.34 14.78 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.362 1.465 . . . . 10.0 107.086 172.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.02 144.65 40.74 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 105.428 -2.064 . . . . 10.0 105.428 168.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.7 t -134.69 139.03 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 N-CA-C 108.645 -0.872 . . . . 10.0 108.645 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -107.39 131.72 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 N-CA-C 106.039 -1.837 . . . . 10.0 106.039 167.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.635 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.8 m170 -114.8 158.89 21.27 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 115.693 1.738 . . . . 10.0 115.693 -169.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.2 tt0 -43.84 -57.31 3.34 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 129.035 2.934 . . . . 10.0 111.835 174.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -116.84 169.17 9.59 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 113.835 1.05 . . . . 10.0 113.835 -168.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.05 132.24 37.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.557 1.543 . . . . 10.0 109.829 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 125.956 1.702 . . . . 10.0 110.563 -175.058 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.6 -37.42 50.39 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 124.388 1.075 . . . . 10.0 109.859 174.252 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.0 mt 76.07 53.62 0.06 Allowed 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.916 2.086 . . . . 10.0 112.755 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.92 -25.2 22.87 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 115.509 0.964 . . . . 10.0 115.509 167.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mptt -75.82 -4.13 38.98 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 119.313 1.557 . . . . 10.0 112.56 -172.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.84 -29.41 64.66 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 109.076 -1.609 . . . . 10.0 109.076 168.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.29 41.02 99.39 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.273 -1.131 . . . . 10.0 110.273 -176.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -130.78 171.98 12.51 Favored 'General case' 0 CA--C 1.501 -0.94 0 N-CA-C 106.731 -1.581 . . . . 10.0 106.731 170.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.1 mp0 -40.22 -58.78 1.41 Allowed 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 10.0 110.109 168.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -50.1 -54.52 19.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 116.072 -0.513 . . . . 10.0 109.999 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.4 p -55.29 -44.46 75.73 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 120.022 -0.671 . . . . 10.0 110.313 -177.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -78.24 -7.75 57.52 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.622 1.169 . . . . 10.0 111.16 -173.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -109.36 -68.38 0.92 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.911 1.684 . . . . 10.0 111.38 -178.473 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -114.55 -6.95 12.82 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 121.456 1.934 . . . . 10.0 112.326 179.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.55 33.64 47.04 Favored Glycine 0 C--O 1.222 -0.606 0 CA-C-O 118.976 -0.902 . . . . 10.0 111.837 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 61.21 24.91 14.97 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 119.74 1.77 . . . . 10.0 112.189 176.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.7 -9.08 58.29 Favored 'General case' 0 CA--C 1.527 0.082 0 C-N-CA 123.544 0.738 . . . . 10.0 112.31 -177.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.21 -166.12 54.76 Favored Glycine 0 N--CA 1.447 -0.607 0 O-C-N 121.269 -0.894 . . . . 10.0 111.409 172.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.1 m -58.13 136.36 57.21 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.064 0.946 . . . . 10.0 113.078 -167.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -64.03 89.11 0.05 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.123 0.969 . . . . 10.0 109.191 168.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 62.0 mt -58.07 -51.46 69.61 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.848 -0.427 . . . . 10.0 109.848 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.413 ' HB1' ' C ' ' A' ' 9' ' ' LYS . . . -147.97 152.05 36.83 Favored 'General case' 0 N--CA 1.454 -0.261 0 O-C-N 122.273 -0.267 . . . . 10.0 110.371 -169.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 88.2 m -130.49 154.13 48.09 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 124.756 1.222 . . . . 10.0 109.539 -173.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.43 154.58 25.2 Favored Glycine 0 CA--C 1.519 0.328 0 N-CA-C 110.156 -1.178 . . . . 10.0 110.156 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 58.4 t -115.09 126.36 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 105.098 -2.186 . . . . 10.0 105.098 178.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.557 HG12 ' HB2' ' A' ' 6' ' ' ALA . 49.2 mt -78.71 147.7 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 108.895 -0.78 . . . . 10.0 108.895 -177.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -153.43 178.5 30.41 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.337 -1.105 . . . . 10.0 110.337 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -64.31 122.68 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 C-N-CA 124.477 1.111 . . . . 10.0 108.941 -177.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -116.89 148.84 40.96 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 168.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.016 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 167.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 119.111 -0.471 . . . . 10.0 110.174 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 t -81.77 -40.85 22.04 Favored 'General case' 0 C--O 1.226 -0.149 0 C-N-CA 124.217 1.007 . . . . 10.0 110.511 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 49.1 mttp -134.24 140.56 46.55 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 125.221 1.408 . . . . 10.0 109.192 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.43 152.89 47.42 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.017 0.927 . . . . 10.0 108.858 171.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -120.77 158.22 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 123.931 0.892 . . . . 10.0 110.153 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.47 101.94 4.49 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.427 -0.953 . . . . 10.0 108.427 168.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -79.64 105.97 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 108.692 -0.855 . . . . 10.0 108.692 169.666 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -91.86 128.13 37.58 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.364 -0.976 . . . . 10.0 108.364 -178.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -143.38 162.32 36.06 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 120.098 1.317 . . . . 10.0 108.494 170.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.67 -56.89 0.07 OUTLIER Glycine 0 N--CA 1.461 0.319 0 CA-C-N 115.077 -0.965 . . . . 10.0 113.146 169.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.47 -44.27 65.08 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 -177.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.4 -70.68 0.41 Allowed Glycine 0 CA--C 1.523 0.569 0 CA-C-N 114.319 -1.309 . . . . 10.0 110.323 169.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -59.13 -33.08 98.28 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 123.643 2.895 . . . . 10.0 111.515 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 65.2 t -67.06 95.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 177.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -117.69 101.15 8.1 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.522 -2.029 . . . . 10.0 105.522 178.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.938 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -85.47 142.04 19.28 Favored Glycine 0 N--CA 1.435 -1.401 0 N-CA-C 109.577 -1.409 . . . . 10.0 109.577 172.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.518 ' CG2' HG22 ' A' ' 54' ' ' THR . 2.2 mt -140.37 81.29 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 105.949 -1.871 . . . . 10.0 105.949 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -90.9 140.7 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 C-N-CA 123.892 0.877 . . . . 10.0 109.05 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 13.5 m-80 -126.44 114.7 18.52 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.044 1.338 . . . . 10.0 109.234 171.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -91.42 132.48 36.19 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 124.882 1.273 . . . . 10.0 108.248 174.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.6 156.38 24.8 Favored 'General case' 0 C--N 1.339 0.151 0 O-C-N 123.519 0.512 . . . . 10.0 111.874 169.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.59 135.0 55.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 102.519 -3.141 . . . . 10.0 102.519 162.063 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 10.6 mptt . . . . . 0 N--CA 1.451 -0.415 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 170.639 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.949 0 N-CA-C 110.136 -1.186 . . . . 10.0 110.136 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -66.29 125.22 13.64 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 123.021 2.48 . . . . 10.0 108.831 175.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 m -79.96 64.51 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 122.774 0.43 . . . . 10.0 110.382 -175.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.8 tttt -54.42 111.95 0.9 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.139 -0.689 . . . . 10.0 109.139 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -103.9 112.28 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 C-N-CA 127.412 2.285 . . . . 10.0 106.556 -176.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -106.14 171.43 7.35 Favored 'General case' 0 CA--C 1.511 -0.532 0 CA-C-O 121.847 0.832 . . . . 10.0 110.507 173.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.59 173.88 45.09 Favored Glycine 0 N--CA 1.436 -1.306 0 N-CA-C 110.124 -1.19 . . . . 10.0 110.124 174.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 19.5 m -145.75 90.19 1.97 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.565 -0.902 . . . . 10.0 108.565 -179.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.938 HG22 ' HA2' ' B' ' 16' ' ' GLY . 3.4 pt -79.93 146.93 6.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.497 0 N-CA-C 108.661 -0.866 . . . . 10.0 108.661 175.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -126.7 149.74 49.41 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.39 -5.87 49.18 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.665 174.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -63.47 177.69 0.65 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.445 1.123 . . . . 10.0 110.599 173.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.1 t -115.25 168.09 10.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 105.687 -1.968 . . . . 10.0 105.687 165.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -46.57 156.84 0.16 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.785 1.634 . . . . 10.0 113.406 -170.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.14 -162.47 46.29 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-O 122.139 0.855 . . . . 10.0 113.376 166.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -79.7 141.32 36.51 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 125.873 1.669 . . . . 10.0 111.342 -170.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -139.72 145.39 38.26 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 114.504 1.298 . . . . 10.0 114.504 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.558 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -34.61 117.94 0.25 Allowed Glycine 0 C--N 1.343 0.95 0 C-N-CA 129.556 3.455 . . . . 10.0 114.569 167.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.451 ' HZ ' HG21 ' B' ' 35' ' ' ILE . 3.2 m-85 -141.37 109.23 5.71 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 120.012 1.906 . . . . 10.0 110.931 169.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.15 170.43 17.86 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 112.708 0.632 . . . . 10.0 112.708 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 m -116.69 79.1 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 C-N-CA 128.625 2.77 . . . . 10.0 111.247 -168.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 38.4 m-70 -79.23 142.69 36.02 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 124.802 1.241 . . . . 10.0 112.056 -171.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -62.47 -46.31 89.08 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 114.605 1.335 . . . . 10.0 114.605 -169.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -75.7 92.43 2.98 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.798 -2.667 . . . . 10.0 103.798 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.88 -27.13 74.14 Favored Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 128.103 2.764 . . . . 10.0 109.99 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -52.57 175.88 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.777 0 CA-C-O 122.752 1.263 . . . . 10.0 110.78 167.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.537 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.4 OUTLIER -149.99 31.82 0.69 Allowed 'General case' 0 N--CA 1.431 -1.378 0 CA-C-N 114.603 -1.18 . . . . 10.0 112.809 168.815 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.448 HG22 HG22 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -51.78 -38.91 57.52 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.958 0.903 . . . . 10.0 111.084 -177.835 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.01 -18.08 54.24 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.84 1.256 . . . . 10.0 113.217 -179.425 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.09 85.56 0.62 Allowed Glycine 0 CA--C 1.533 1.161 0 N-CA-C 111.478 -0.649 . . . . 10.0 111.478 -176.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 71.4 m 44.11 39.36 2.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 128.008 2.523 . . . . 10.0 112.634 173.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -134.3 -54.32 0.85 Allowed 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 108.156 -1.053 . . . . 10.0 108.156 -169.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.7 m -90.56 34.31 0.89 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.109 0.563 . . . . 10.0 109.844 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -67.04 -23.18 65.86 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.401 1.08 . . . . 10.0 109.868 177.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.76 141.2 11.61 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 110.911 -0.876 . . . . 10.0 110.911 172.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -76.23 63.01 6.97 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.213 3.275 . . . . 10.0 113.202 -174.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 22.6 m170 63.26 44.04 5.87 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 126.697 1.999 . . . . 10.0 109.939 171.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -67.89 79.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 124.863 2.268 . . . . 10.0 111.351 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -81.89 147.15 57.54 Favored Pre-proline 0 C--N 1.318 -0.772 0 C-N-CA 126.396 1.878 . . . . 10.0 108.316 168.142 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -79.56 40.3 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 122.484 2.123 . . . . 10.0 111.775 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -162.84 37.68 0.1 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.787 0.835 . . . . 10.0 109.996 -176.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -42.31 100.05 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.599 1.56 . . . . 10.0 112.719 -170.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.57 -78.85 0.6 Allowed 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.284 -1.006 . . . . 10.0 108.284 -171.139 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -154.24 144.35 21.97 Favored 'General case' 0 N--CA 1.425 -1.678 0 CA-C-N 115.484 -0.78 . . . . 10.0 109.223 171.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -61.76 118.64 7.41 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 106.711 -1.589 . . . . 10.0 106.711 165.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.06 -146.19 6.25 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 107.743 -2.143 . . . . 10.0 107.743 175.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.53 -165.71 24.37 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 107.813 -2.115 . . . . 10.0 107.813 169.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -64.19 6.36 0.31 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.151 1.9 . . . . 10.0 112.207 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.407 ' HE2' ' HB2' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -96.86 -29.99 13.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 118.997 0.817 . . . . 10.0 110.35 168.812 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.407 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 1.4 t70 -86.83 166.23 15.37 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 109.347 -0.612 . . . . 10.0 109.347 -174.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -86.18 -24.57 26.08 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.346 -1.297 . . . . 10.0 108.492 167.062 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -76.41 -93.78 0.02 OUTLIER 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 107.667 -1.234 . . . . 10.0 107.667 -173.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 28.5 mtm180 72.43 159.74 0.22 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 127.144 2.178 . . . . 10.0 108.644 -167.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.9 m170 -78.18 -48.63 15.45 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 118.965 -1.094 . . . . 10.0 110.093 169.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.3 p -166.26 -51.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 178.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.29 -76.28 0.9 Allowed Glycine 0 C--N 1.336 0.552 0 N-CA-C 109.019 -1.633 . . . . 10.0 109.019 171.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 41.42 78.58 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.792 1.237 . . . . 10.0 109.654 -169.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -20.97 64.96 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.939 0.348 . . . . 10.0 111.939 -168.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.91 -94.93 0.67 Allowed Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.027 -1.229 . . . . 10.0 110.027 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 33.2 m120 -155.61 106.45 2.51 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -168.647 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -99.24 130.6 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 119.773 1.17 . . . . 10.0 110.708 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -86.93 107.94 18.59 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 128.795 2.838 . . . . 10.0 110.945 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.88 131.51 36.47 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 122.857 0.463 . . . . 10.0 109.908 172.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . 0.407 ' OD2' ' NZ ' ' B' ' 91' ' ' LYS . 43.2 t0 -59.23 170.98 0.82 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.282 1.033 . . . . 10.0 109.806 168.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . 0.407 ' NZ ' ' OD2' ' B' ' 90' ' ' ASP . 12.4 pttm -51.36 -32.19 24.91 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 125.988 1.715 . . . . 10.0 110.584 175.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.36 -8.36 59.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 124.177 0.991 . . . . 10.0 110.963 -175.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.82 8.19 87.06 Favored Glycine 0 C--N 1.338 0.692 0 O-C-N 121.532 -0.73 . . . . 10.0 111.286 -177.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 50.0 t -80.18 114.92 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 N-CA-C 105.726 -1.953 . . . . 10.0 105.726 170.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.671 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -116.27 121.43 42.0 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 118.87 0.759 . . . . 10.0 109.006 170.021 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -83.0 121.78 27.45 Favored 'General case' 0 N--CA 1.433 -1.288 0 C-N-CA 126.404 1.881 . . . . 10.0 108.334 173.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 94.0 t -110.49 136.48 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 N-CA-C 106.543 -1.651 . . . . 10.0 106.543 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 18.7 m -157.77 64.97 0.47 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.071 1.349 . . . . 10.0 109.379 169.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 61.9 mt -101.97 156.35 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.859 1.263 . . . . 10.0 108.719 -171.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -144.81 140.48 28.46 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.645 1.578 . . . . 10.0 108.6 175.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -152.4 135.08 15.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 106.667 -1.605 . . . . 10.0 106.667 169.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.4 p -87.53 58.59 5.02 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.745 1.618 . . . . 10.0 107.916 -171.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 p -145.35 -46.53 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.918 -0.583 . . . . 10.0 109.677 -172.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 36.7 mm -66.8 143.04 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 N-CA-C 109.178 -0.675 . . . . 10.0 109.178 171.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 74.3 m -138.38 134.44 34.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 173.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -110.29 17.37 20.97 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.737 0.815 . . . . 10.0 110.59 172.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 107.131 -1.433 . . . . 10.0 107.131 173.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t . . . . . 0 N--CA 1.441 -0.885 0 N-CA-C 107.983 -1.117 . . . . 10.0 107.983 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -69.73 13.87 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 114.095 1.146 . . . . 10.0 114.095 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 33.2 mm -55.74 135.12 19.22 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 O-C-N 120.627 -1.296 . . . . 10.0 108.063 172.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.74 11.66 73.62 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-O 118.132 -1.371 . . . . 10.0 113.855 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mmt-85 -79.38 161.84 25.93 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.242 1.521 . . . . 10.0 108.866 167.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.4 121.25 41.94 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 123.529 0.732 . . . . 10.0 109.99 171.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -84.37 132.37 34.6 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 107.218 -1.401 . . . . 10.0 107.218 167.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.1 t -116.51 137.43 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.792 -1.188 . . . . 10.0 107.792 169.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -104.76 123.99 59.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.558 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.2 m170 -107.69 159.09 16.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 116.582 2.067 . . . . 10.0 116.582 -172.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -41.45 -65.61 0.42 Allowed 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 129.631 3.173 . . . . 10.0 111.67 170.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.1 mttp -109.89 175.38 5.46 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.658 1.183 . . . . 10.0 111.559 -173.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.03 151.73 35.43 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 125.75 1.62 . . . . 10.0 109.903 175.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.53 154.64 32.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 122.901 0.48 . . . . 10.0 110.889 169.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 53.4 m-20 -76.27 -36.65 58.32 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.289 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 63.5 mt 64.26 56.32 1.35 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.99 1.376 . . . . 10.0 109.27 -170.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.15 -44.34 3.29 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-N 113.376 -1.738 . . . . 10.0 110.918 171.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -76.64 41.06 0.25 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.088 1.755 . . . . 10.0 112.919 -173.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -99.85 -17.83 24.46 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 125.838 1.685 . . . . 10.0 110.65 169.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.26 44.89 65.0 Favored Glycine 0 C--N 1.339 0.696 0 C-N-CA 123.861 0.743 . . . . 10.0 111.443 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -146.02 168.02 21.93 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 172.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.1 -42.55 76.97 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 116.144 -0.48 . . . . 10.0 109.88 -176.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -64.78 -40.37 95.15 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.502 -0.748 . . . . 10.0 110.825 175.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -50.8 -44.02 58.88 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 118.704 0.684 . . . . 10.0 110.449 -179.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -76.94 -8.26 57.06 Favored 'General case' 0 CA--C 1.542 0.662 0 CA-C-O 117.759 -1.115 . . . . 10.0 113.79 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 ttmm -114.87 -58.0 2.2 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 127.728 2.411 . . . . 10.0 113.072 -170.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 14.6 p -134.86 17.75 3.52 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.774 1.17 . . . . 10.0 110.784 175.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.12 -110.09 2.95 Favored Glycine 0 C--O 1.219 -0.81 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 -171.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -160.61 43.79 0.19 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 171.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.45 -14.76 62.66 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.787 -1.097 . . . . 10.0 112.194 -170.098 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.2 -163.5 54.53 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 110.48 -1.048 . . . . 10.0 110.48 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.7 m -56.94 130.41 45.85 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 123.929 0.891 . . . . 10.0 112.43 -168.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.58 73.36 0.06 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.809 1.644 . . . . 10.0 109.91 171.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 61.8 mt -50.96 -36.45 38.96 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.52 0.728 . . . . 10.0 112.116 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.31 159.59 28.7 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.971 -0.752 . . . . 10.0 108.971 -176.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -159.8 165.38 32.51 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.637 -0.505 . . . . 10.0 109.637 -177.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.31 167.73 35.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.421 -1.071 . . . . 10.0 110.421 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 15.9 t -115.41 138.67 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 107.233 -1.395 . . . . 10.0 107.233 -169.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.8 mt -73.18 109.82 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 110.212 -0.292 . . . . 10.0 110.212 -174.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.86 154.65 17.32 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 125.737 1.637 . . . . 10.0 110.373 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.1 mt -86.23 139.4 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 124.894 1.278 . . . . 10.0 108.815 -174.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -91.71 -114.71 0.08 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 167.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 . . . . . 0 C--O 1.248 1.006 0 C-N-CA 127.332 2.253 . . . . 10.0 105.014 166.937 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 107.416 -1.327 . . . . 10.0 107.416 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.2 t -158.45 -44.24 0.06 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.926 0.784 . . . . 10.0 111.328 177.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 11.7 tmtt? -131.78 134.04 45.39 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 123.68 0.792 . . . . 10.0 108.863 178.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.33 169.55 18.05 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 125.281 1.432 . . . . 10.0 109.936 -175.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -129.32 172.72 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 123.159 0.584 . . . . 10.0 112.236 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.72 107.47 4.46 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.826 1.25 . . . . 10.0 107.869 166.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -87.0 89.61 3.07 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-O 121.946 0.879 . . . . 10.0 109.111 172.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.65 HD21 ' HB3' ' A' ' 117' ' ' LEU . 9.1 mt -80.52 116.22 20.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.573 1.549 . . . . 10.0 109.443 -175.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -142.27 159.35 42.41 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.702 1.137 . . . . 10.0 108.35 173.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.62 -65.02 0.02 OUTLIER Glycine 0 N--CA 1.461 0.365 0 CA-C-N 115.249 -0.887 . . . . 10.0 112.216 169.338 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -72.15 -41.66 66.85 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 106.891 -1.522 . . . . 10.0 106.891 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.44 -64.26 0.55 Allowed Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.695 -1.059 . . . . 10.0 111.368 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -58.14 -37.91 93.61 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.056 1.837 . . . . 10.0 110.492 174.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.46 HG13 HD11 ' A' ' 38' ' ' LEU . 80.3 t -62.85 105.55 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 N-CA-C 107.644 -1.243 . . . . 10.0 107.644 174.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -124.02 118.98 28.22 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.089 -1.819 . . . . 10.0 106.089 171.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.536 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -107.87 130.53 10.15 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 109.725 -1.35 . . . . 10.0 109.725 170.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.595 ' CG2' HG23 ' B' ' 54' ' ' THR . 16.4 mt -128.29 72.04 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.15 -1.796 . . . . 10.0 106.15 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.14 147.19 6.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.288 -0.869 . . . . 10.0 110.447 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.03 106.24 8.74 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 126.78 2.032 . . . . 10.0 107.804 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -86.37 125.11 33.43 Favored 'General case' 0 N--CA 1.451 -0.425 0 CA-C-O 117.73 -1.129 . . . . 10.0 108.012 175.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -120.19 145.27 47.14 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 123.922 0.763 . . . . 10.0 110.963 167.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 tp60 -125.89 105.18 8.74 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 126.858 2.063 . . . . 10.0 107.036 169.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.77 -61.24 2.44 Favored 'General case' 0 C--N 1.339 0.15 0 C-N-CA 124.767 1.227 . . . . 10.0 110.24 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -134.01 167.48 20.53 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 104.552 -2.388 . . . . 10.0 104.552 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.7 t -69.41 -14.94 63.17 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 119.71 -0.186 . . . . 10.0 110.573 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -79.89 -18.02 51.68 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 123.386 0.675 . . . . 10.0 110.171 174.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.6 151.68 39.97 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.23 -0.748 . . . . 10.0 111.23 -176.097 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.23 146.66 40.94 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 N-CA-C 105.493 -2.541 . . . . 10.0 105.493 165.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -76.65 119.35 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 N-CA-C 106.166 -1.791 . . . . 10.0 106.166 -179.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 18.0 mttp -90.97 110.57 21.83 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 106.432 -1.692 . . . . 10.0 106.432 176.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.13 106.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -128.85 169.96 13.95 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.744 0.783 . . . . 10.0 112.214 171.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.05 -153.09 24.77 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 106.592 -2.603 . . . . 10.0 106.592 169.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 27.5 t -156.06 155.98 33.58 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.54 -0.864 . . . . 10.0 109.464 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.536 HG22 ' CA ' ' A' ' 16' ' ' GLY . 3.1 pt -108.01 175.63 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 CA-C-N 115.153 -0.931 . . . . 10.0 110.082 167.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.2 ptmt -152.37 150.66 29.94 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.86 -15.57 33.99 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-O 118.985 -0.897 . . . . 10.0 114.566 171.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.533 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.1 mp -72.95 -179.67 3.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 118.948 1.374 . . . . 10.0 109.609 177.119 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -96.0 175.55 6.44 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.402 -0.962 . . . . 10.0 108.402 166.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -58.65 168.95 1.04 Allowed 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.676 1.19 . . . . 10.0 112.025 -172.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.37 -168.01 49.65 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-O 122.019 0.788 . . . . 10.0 112.909 167.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -71.26 146.13 49.15 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.762 1.625 . . . . 10.0 110.397 -176.363 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.07 152.69 35.21 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 113.125 0.787 . . . . 10.0 113.125 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.664 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.3 121.43 0.83 Allowed Glycine 0 C--N 1.339 0.727 0 C-N-CA 128.274 2.845 . . . . 10.0 111.069 165.239 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -155.68 106.21 2.48 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 106.558 -1.645 . . . . 10.0 106.558 169.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.07 170.6 17.42 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.876 0.846 . . . . 10.0 112.904 178.561 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.36 132.54 60.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 104.336 -2.468 . . . . 10.0 104.336 168.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 1.7 p80 -168.4 177.47 5.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 107.737 -1.208 . . . . 10.0 107.737 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 52.71 -167.75 0.05 Allowed 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 125.984 2.052 . . . . 10.0 116.157 162.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.75 159.42 19.77 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-O 121.593 0.711 . . . . 10.0 110.893 -175.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.01 -18.44 77.76 Favored Glycine 0 CA--C 1.523 0.565 0 C-N-CA 125.443 1.497 . . . . 10.0 110.308 168.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -50.61 140.6 14.03 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 122.723 1.249 . . . . 10.0 108.259 166.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -151.79 8.86 0.51 Allowed 'General case' 0 N--CA 1.412 -2.342 0 CA-C-N 113.5 -1.682 . . . . 10.0 109.889 -168.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.931 HG22 HG22 ' B' ' 17' ' ' ILE . 1.0 OUTLIER -41.45 -55.24 2.87 Favored 'General case' 0 C--N 1.343 0.29 0 C-N-CA 125.842 1.657 . . . . 10.0 114.425 -167.928 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.18 -18.37 57.84 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.836 0.454 . . . . 10.0 111.554 -173.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.72 78.63 1.38 Allowed Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.312 -1.115 . . . . 10.0 110.312 -175.305 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.2 m 70.24 35.3 2.12 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.989 1.315 . . . . 10.0 111.752 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -131.8 -57.51 0.98 Allowed 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 107.184 -1.413 . . . . 10.0 107.184 175.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.3 m -52.05 -43.14 63.64 Favored 'General case' 0 C--N 1.343 0.289 0 C-N-CA 123.913 0.885 . . . . 10.0 111.331 -170.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.11 -55.31 0.03 OUTLIER 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 128.35 2.66 . . . . 10.0 113.645 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 139.92 -154.18 23.68 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 110.533 -1.027 . . . . 10.0 110.533 175.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -122.21 -155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.54 0.811 1 C-N-CA 126.865 5.043 . . . . 10.0 105.85 165.049 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.573 ' CD2' HG22 ' A' ' 137' ' ' THR . 21.3 m170 -77.93 46.85 0.6 Allowed 'General case' 0 CA--C 1.548 0.896 0 O-C-N 118.587 -2.571 . . . . 10.0 112.113 177.436 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -77.51 60.9 2.18 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.923 1.289 . . . . 10.0 109.566 169.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -71.74 157.13 90.29 Favored Pre-proline 0 C--N 1.325 -0.457 0 C-N-CA 124.002 0.921 . . . . 10.0 108.67 171.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -56.17 -43.42 56.4 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 121.347 1.365 . . . . 10.0 109.478 169.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 68.2 mt -84.23 47.47 1.34 Allowed 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.831 -0.543 . . . . 10.0 111.232 173.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 p -61.29 91.39 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 107.407 -1.331 . . . . 10.0 107.407 166.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -113.36 -69.06 0.89 Allowed 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 104.183 -2.525 . . . . 10.0 104.183 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -154.64 161.33 41.63 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 106.171 -1.788 . . . . 10.0 106.171 167.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.8 t60 -72.48 129.07 37.48 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 105.194 -2.151 . . . . 10.0 105.194 163.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -150.03 -140.81 3.29 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 108.316 -1.913 . . . . 10.0 108.316 176.004 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.33 -157.99 21.59 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.812 -2.115 . . . . 10.0 107.812 170.094 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -69.38 18.3 0.17 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 119.627 1.713 . . . . 10.0 111.326 169.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.402 ' H ' ' C ' ' A' ' 73' ' ' GLY . 30.4 mmtm -104.96 -21.03 13.36 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 124.753 1.221 . . . . 10.0 108.643 169.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.401 ' OD2' ' NZ ' ' A' ' 128' ' ' LYS . 4.8 m-20 -120.9 166.51 13.7 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.121 -1.807 . . . . 10.0 106.121 -171.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -79.32 -42.15 26.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 107.667 -1.235 . . . . 10.0 107.667 173.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -96.2 34.88 1.51 Allowed 'General case' 0 N--CA 1.441 -0.921 0 C-N-CA 127.53 2.332 . . . . 10.0 114.974 -161.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ptp180 -57.28 153.79 11.55 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.521 1.129 . . . . 10.0 110.867 174.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -72.97 159.21 34.03 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 118.9 -1.12 . . . . 10.0 108.497 168.064 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -38.91 -40.09 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 125.974 1.71 . . . . 10.0 114.397 -172.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.6 42.88 1.32 Allowed Glycine 0 C--N 1.338 0.664 0 CA-C-N 118.178 0.445 . . . . 10.0 112.641 179.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.0 89.48 5.34 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 106.619 -1.623 . . . . 10.0 106.619 167.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 21.4 mt -67.97 -37.71 81.86 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.15 -86.08 0.41 Allowed Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 114.873 -1.058 . . . . 10.0 110.537 167.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -140.72 131.03 25.07 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 -172.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.0 m -115.24 137.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.944 -0.762 . . . . 10.0 108.944 169.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -85.19 131.92 34.36 Favored 'General case' 0 C--O 1.226 -0.168 0 C-N-CA 124.761 1.224 . . . . 10.0 109.485 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.05 138.47 45.35 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.37 1.468 . . . . 10.0 109.625 171.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -58.92 171.6 0.66 Allowed 'General case' 0 N--CA 1.456 -0.135 0 O-C-N 124.181 0.926 . . . . 10.0 109.191 167.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 27.5 pttt -45.91 -34.96 4.23 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 127.225 2.21 . . . . 10.0 110.852 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -82.53 -3.04 55.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.861 1.264 . . . . 10.0 110.83 -173.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.52 8.48 83.08 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.556 -1.017 . . . . 10.0 110.556 -177.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 73.5 t -87.83 98.82 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 107.289 -1.374 . . . . 10.0 107.289 -177.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.53 121.66 38.59 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 107.523 -1.288 . . . . 10.0 107.523 168.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -84.47 114.41 21.9 Favored 'General case' 0 N--CA 1.439 -1.003 0 C-N-CA 126.955 2.102 . . . . 10.0 108.202 169.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 87.9 t -102.05 131.36 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.672 -1.233 . . . . 10.0 107.672 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.6 p -157.97 88.95 0.98 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.392 1.077 . . . . 10.0 109.067 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -129.17 163.51 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 106.818 -1.549 . . . . 10.0 106.818 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -136.67 150.39 48.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 121.471 -0.768 . . . . 10.0 110.407 170.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -147.0 155.6 42.37 Favored 'General case' 0 N--CA 1.447 -0.608 0 O-C-N 124.551 1.157 . . . . 10.0 108.761 178.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.3 p -113.27 44.57 1.53 Allowed 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 127.583 2.353 . . . . 10.0 110.39 -173.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.8 p -142.59 -46.24 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 C-N-CA 123.624 0.77 . . . . 10.0 109.557 177.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 39.8 mm -54.73 110.33 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 169.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.4 m -120.82 105.16 10.45 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 124.386 1.074 . . . . 10.0 109.217 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 37.2 mt -58.15 -28.8 65.06 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.984 0.514 . . . . 10.0 111.935 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 m -150.29 160.79 43.45 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.869 -1.53 . . . . 10.0 106.869 174.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 66.1 0.4 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.333 -1.107 . . . . 10.0 110.333 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t70 71.53 -59.67 0.54 Allowed 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 129.557 3.143 . . . . 10.0 109.519 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.9 m-70 -76.49 -22.03 55.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.637 -0.71 . . . . 10.0 111.165 -169.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.1 t 26.43 78.26 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 128.358 2.663 . . . . 10.0 112.213 168.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -67.76 -6.36 5.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 112.599 0.592 . . . . 10.0 112.599 -174.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.5 mm -51.46 132.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 O-C-N 120.952 -1.092 . . . . 10.0 108.309 168.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.487 ' HA3' ' CG2' ' B' ' 113' ' ' ILE . . . 93.38 11.81 57.94 Favored Glycine 0 CA--C 1.523 0.577 0 CA-C-O 117.701 -1.611 . . . . 10.0 115.952 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -80.0 176.29 9.87 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 119.594 1.697 . . . . 10.0 108.554 167.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 99.7 m -106.54 121.46 44.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 125.095 1.358 . . . . 10.0 107.637 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.65 ' HB3' HD21 ' A' ' 8' ' ' LEU . 3.9 mm? -76.88 144.37 39.01 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 106.498 -1.667 . . . . 10.0 106.498 167.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.2 t -131.88 123.76 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 107.696 -1.224 . . . . 10.0 107.696 -176.021 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 11.7 t -104.49 137.83 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.664 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.9 m170 -124.89 157.65 35.44 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 114.553 1.316 . . . . 10.0 114.553 -174.138 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 68.7 tt0 -45.61 -55.92 5.78 Favored 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 128.833 2.853 . . . . 10.0 109.183 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 63.6 mttt -123.6 175.11 7.0 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.586 1.154 . . . . 10.0 110.751 -170.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.33 143.35 28.72 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 108.715 -0.846 . . . . 10.0 108.715 176.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -73.64 151.66 40.75 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.435 -0.58 . . . . 10.0 109.435 175.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -83.28 13.49 4.24 Favored 'General case' 0 N--CA 1.448 -0.529 0 O-C-N 124.355 1.034 . . . . 10.0 111.168 167.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 75.7 mt 45.58 46.6 11.21 Favored 'General case' 0 C--N 1.343 0.307 0 C-N-CA 125.513 1.525 . . . . 10.0 112.779 171.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 107.79 -21.88 29.08 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-N 115.724 -0.671 . . . . 10.0 112.119 173.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.401 ' NZ ' ' OD2' ' A' ' 76' ' ' ASP . 7.2 mtmm -112.26 43.89 1.53 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.056 1.343 . . . . 10.0 111.598 -168.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.49 -16.42 64.19 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.343 1.925 . . . . 10.0 112.435 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.33 47.9 88.31 Favored Glycine 0 CA--C 1.532 1.104 0 O-C-N 121.473 -1.016 . . . . 10.0 112.554 173.45 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.464 ' H ' ' HB2' ' A' ' 134' ' ' SER . 7.3 p30 -165.77 173.81 10.3 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 126.682 1.993 . . . . 10.0 106.094 177.259 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -56.9 -42.54 80.08 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 119.802 1.183 . . . . 10.0 111.24 -174.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -70.18 -18.32 63.19 Favored 'General case' 0 N--CA 1.454 -0.273 0 O-C-N 121.29 -0.881 . . . . 10.0 111.916 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.464 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 11.3 t -44.54 -43.53 8.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 C-N-CA 124.836 1.254 . . . . 10.0 109.549 170.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -93.79 5.95 49.96 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 112.411 0.523 . . . . 10.0 112.411 -174.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -117.87 -73.77 0.63 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.203 1.401 . . . . 10.0 110.286 179.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.573 HG22 ' CD2' ' A' ' 63' ' ' HIS . 1.4 p -111.87 7.81 20.2 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 120.213 1.369 . . . . 10.0 110.943 178.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.78 -90.15 1.06 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 108.413 -1.875 . . . . 10.0 108.413 -173.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.76 39.55 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 124.721 1.208 . . . . 10.0 109.872 176.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.35 -10.37 32.53 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 124.217 1.007 . . . . 10.0 112.745 -176.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.67 -168.01 53.34 Favored Glycine 0 N--CA 1.445 -0.743 0 O-C-N 121.059 -1.026 . . . . 10.0 110.736 178.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -59.68 138.99 57.58 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 123.781 0.832 . . . . 10.0 112.354 -168.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.8 mtm180 -68.18 69.32 0.14 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.714 1.206 . . . . 10.0 110.464 169.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.62 -9.16 32.77 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 113.654 0.983 . . . . 10.0 113.654 -178.024 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.38 143.4 17.68 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.47 0.708 . . . . 10.0 111.858 168.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 5.4 p -144.28 166.31 25.41 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.148 -0.686 . . . . 10.0 109.148 171.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.1 150.95 21.15 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 109.74 -1.344 . . . . 10.0 109.74 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.8 139.68 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 106.212 -1.773 . . . . 10.0 106.212 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.472 HD11 ' CD2' ' A' ' 117' ' ' LEU . 58.8 mt -76.84 127.34 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-O 119.555 -0.26 . . . . 10.0 110.937 -173.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -125.31 140.78 12.54 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 123.79 0.71 . . . . 10.0 111.882 -177.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 94.1 mt -68.29 140.96 18.2 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 C-N-CA 124.632 1.173 . . . . 10.0 108.699 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.21 -46.33 1.51 Allowed 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 112.348 0.499 . . . . 10.0 112.348 -176.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 . . . . . 0 C--O 1.248 0.986 0 CA-C-O 117.277 -1.344 . . . . 10.0 110.24 -167.896 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.556 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -88.26 -15.74 35.04 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.865 1.266 . . . . 10.0 111.469 -175.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 31.2 tttp -130.18 135.44 48.17 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.142 1.377 . . . . 10.0 108.645 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.74 161.47 35.47 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.769 1.628 . . . . 10.0 108.843 169.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.1 t -117.98 152.86 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 C-N-CA 125.489 1.516 . . . . 10.0 110.163 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.47 94.96 3.28 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.416 1.887 . . . . 10.0 108.739 171.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.1 m -88.29 111.3 22.18 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 N-CA-C 109.368 -0.604 . . . . 10.0 109.368 172.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.4 mt -94.61 145.68 24.66 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 109.179 -0.674 . . . . 10.0 109.179 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.5 mtmt -166.72 159.28 13.76 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.533 1.133 . . . . 10.0 108.397 172.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.28 -48.7 0.11 Allowed Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.351 -0.928 . . . . 10.0 113.112 169.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -72.94 -45.96 55.15 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 107.548 -1.278 . . . . 10.0 107.548 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.04 -71.36 0.4 Allowed Glycine 0 CA--C 1.523 0.537 0 CA-C-N 114.323 -1.308 . . . . 10.0 109.909 170.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -58.18 -35.72 98.47 Favored 'Trans proline' 0 N--CA 1.453 -0.862 0 C-N-CA 123.156 2.57 . . . . 10.0 111.249 173.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.6 t -64.59 107.59 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 107.573 -1.269 . . . . 10.0 107.573 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.47 124.16 39.48 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 108.608 -0.886 . . . . 10.0 108.608 169.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.644 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -104.17 149.4 17.11 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 109.879 -1.289 . . . . 10.0 109.879 170.002 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.931 HG22 HG22 ' A' ' 54' ' ' THR . 1.5 mt -146.75 56.89 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 N-CA-C 107.251 -1.388 . . . . 10.0 107.251 -176.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mm -86.35 135.6 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.09 -0.707 . . . . 10.0 109.09 -169.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -103.23 115.76 31.18 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.249 1.82 . . . . 10.0 107.126 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -96.4 115.01 26.74 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.721 -1.585 . . . . 10.0 106.721 175.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -122.79 151.46 41.62 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 119.321 0.964 . . . . 10.0 112.699 172.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.6 tt0 -139.6 95.83 2.98 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.148 1.379 . . . . 10.0 108.733 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 68.6 tttt . . . . . 0 N--CA 1.426 -1.626 0 C-N-CA 124.15 0.98 . . . . 10.0 109.3 178.847 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.222 0 CA-C-O 118.91 -0.939 . . . . 10.0 114.621 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -68.57 116.33 4.36 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 107.3 -1.846 . . . . 10.0 107.3 169.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.8 t -79.37 99.94 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 104.272 -2.492 . . . . 10.0 104.272 169.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -92.08 112.03 23.8 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 175.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -101.73 102.73 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.908 0 C-N-CA 126.631 1.972 . . . . 10.0 105.98 -174.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.1 p90 -125.14 160.76 28.37 Favored 'General case' 0 C--N 1.339 0.126 0 N-CA-C 112.683 0.623 . . . . 10.0 112.683 177.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.28 -157.64 27.38 Favored Glycine 0 N--CA 1.449 -0.44 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -143.48 127.96 17.96 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 109.613 -0.514 . . . . 10.0 109.613 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.644 HG22 ' CA ' ' B' ' 16' ' ' GLY . 3.4 pt -90.14 139.84 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 N-CA-C 106.611 -1.626 . . . . 10.0 106.611 166.032 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.0 142.34 50.42 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 123.8 0.688 . . . . 10.0 109.437 171.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.98 -4.64 25.65 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.221 -0.766 . . . . 10.0 112.888 178.196 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -60.44 176.8 0.33 Allowed 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 118.676 1.238 . . . . 10.0 110.918 170.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -109.65 164.35 12.62 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 105.406 -2.072 . . . . 10.0 105.406 165.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -52.72 163.09 0.5 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.863 0.865 . . . . 10.0 112.974 -169.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.74 -171.59 47.26 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 123.745 0.688 . . . . 10.0 112.297 169.128 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -71.5 144.39 49.66 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.624 1.969 . . . . 10.0 110.961 -177.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -148.48 138.59 22.44 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 113.638 0.977 . . . . 10.0 113.638 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.736 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -20.26 120.87 0.01 OUTLIER Glycine 0 C--N 1.341 0.841 0 C-N-CA 129.134 3.254 . . . . 10.0 115.084 165.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.27 108.09 4.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 119.518 1.659 . . . . 10.0 109.827 168.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 2.0 m80 -139.5 179.88 6.3 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.607 0.718 . . . . 10.0 112.288 177.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 76.1 t -112.43 128.33 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 C-N-CA 127.173 2.189 . . . . 10.0 106.368 169.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 67.0 m-70 -109.42 138.42 45.8 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 125.589 1.555 . . . . 10.0 107.299 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -53.76 -57.73 9.79 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 124.189 0.996 . . . . 10.0 111.844 -169.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -80.06 135.2 36.29 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 118.109 -1.437 . . . . 10.0 109.59 -177.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.86 -19.76 79.56 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 109.827 -1.309 . . . . 10.0 109.827 168.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t0 -39.57 148.63 0.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.008 1.323 . . . . 10.0 112.48 175.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -153.88 20.06 0.52 Allowed 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.424 -1.262 . . . . 10.0 113.214 174.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.595 HG23 ' CG2' ' A' ' 17' ' ' ILE . 1.8 m -52.74 -38.04 60.27 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 119.389 0.995 . . . . 10.0 111.978 -171.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.41 -22.87 47.12 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.025 0.93 . . . . 10.0 113.007 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.05 111.39 2.65 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.056 -1.218 . . . . 10.0 110.056 -169.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.8 m 34.1 51.73 0.43 Allowed 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 127.816 2.446 . . . . 10.0 115.515 170.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.97 -46.18 0.05 Allowed 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.423 0.689 . . . . 10.0 110.032 173.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.8 t -57.09 -26.69 60.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.546 0.738 . . . . 10.0 111.333 -178.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.02 -32.52 0.09 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.032 2.133 . . . . 10.0 112.958 167.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.59 162.66 15.91 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 108.72 -1.752 . . . . 10.0 108.72 173.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . 0.443 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 44.5 Cg_endo -73.94 -134.05 0.01 OUTLIER 'Trans proline' 0 N--CA 1.437 -1.822 0 N-CA-C 103.986 -3.121 . . . . 10.0 103.986 165.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.412 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 16.4 m170 -110.18 40.18 2.0 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 120.322 -1.486 . . . . 10.0 109.42 -177.301 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . 0.443 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 0.0 OUTLIER -78.04 57.36 1.77 Allowed 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.061 0.846 . . . . 10.0 112.494 -179.506 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -54.38 167.04 0.61 Allowed Pre-proline 0 CA--C 1.541 0.597 0 C-N-CA 129.782 3.233 . . . . 10.0 112.175 173.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -93.87 19.53 0.76 Allowed 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.738 2.292 . . . . 10.0 111.744 -173.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -144.48 48.73 1.34 Allowed 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.156 1.383 . . . . 10.0 107.444 -171.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.3 p -40.61 107.17 0.07 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 126.716 2.006 . . . . 10.0 112.03 -169.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 45.3 mtp180 -147.56 177.96 8.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 104.98 -2.23 . . . . 10.0 104.98 -175.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -73.41 143.09 46.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 117.395 -1.722 . . . . 10.0 110.257 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.5 t60 -52.53 116.96 2.54 Favored 'General case' 0 CA--C 1.519 -0.216 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 167.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.07 -178.84 22.69 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 106.659 -2.576 . . . . 10.0 106.659 178.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -151.77 -148.34 4.8 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 -174.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -65.58 -0.13 3.43 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 CA-C-N 119.386 1.593 . . . . 10.0 110.591 167.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -87.86 -27.17 22.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 118.798 0.726 . . . . 10.0 109.784 172.018 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -115.05 164.69 13.81 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.71 0.766 . . . . 10.0 111.315 -169.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -96.12 -9.0 31.78 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 124.855 1.262 . . . . 10.0 109.216 168.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 50.0 mm-40 -78.2 -81.32 0.1 Allowed 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 124.874 1.269 . . . . 10.0 109.953 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? 59.76 175.69 0.08 Allowed 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 114.634 -1.166 . . . . 10.0 110.722 -167.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -102.43 -59.81 1.64 Allowed 'General case' 0 CA--C 1.529 0.142 0 O-C-N 121.468 -0.77 . . . . 10.0 110.443 168.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.1 p -157.41 -55.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.146 0 C-N-CA 122.991 0.516 . . . . 10.0 109.698 -178.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.19 50.47 0.69 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.104 -1.598 . . . . 10.0 109.104 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -76.22 97.25 4.1 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 169.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 18.7 mt -75.26 -31.22 60.71 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 102.46 -95.94 1.35 Allowed Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 108.063 -2.015 . . . . 10.0 108.063 171.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -135.72 137.0 41.28 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 112.115 0.413 . . . . 10.0 112.115 -168.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.0 m -119.46 143.83 29.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 108.423 -0.955 . . . . 10.0 108.423 168.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.06 134.75 34.55 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.828 1.651 . . . . 10.0 109.473 -178.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.43 134.38 49.67 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.721 1.208 . . . . 10.0 111.515 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -63.6 169.8 3.67 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.893 -0.78 . . . . 10.0 108.893 165.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.01 -25.48 30.43 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.592 1.157 . . . . 10.0 111.79 175.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -75.55 -11.06 59.95 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.838 0.351 . . . . 10.0 110.286 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.66 12.07 75.87 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 110.138 -1.185 . . . . 10.0 110.138 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.0 t -85.45 107.87 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 106.37 -1.715 . . . . 10.0 106.37 175.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.65 119.5 39.47 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 168.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -78.41 131.01 36.76 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.727 2.011 . . . . 10.0 108.432 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 38.6 t -117.65 131.46 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 126.671 1.988 . . . . 10.0 106.64 -179.318 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 m -158.47 68.06 0.47 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 125.33 1.452 . . . . 10.0 109.196 170.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.1 mt -107.38 166.13 4.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 124.632 1.173 . . . . 10.0 108.283 -176.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -152.68 125.27 8.28 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.714 1.606 . . . . 10.0 109.415 -169.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -140.29 136.24 33.08 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 170.222 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 68.5 p -105.4 60.33 0.67 Allowed 'General case' 0 N--CA 1.457 -0.124 0 N-CA-C 107.003 -1.48 . . . . 10.0 107.003 174.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 99.9 t -127.92 -56.71 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -177.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.504 ' CD1' ' H ' ' B' ' 104' ' ' ILE 0.301 0.0 OUTLIER -81.31 173.18 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 124.378 1.071 . . . . 10.0 112.226 170.555 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.9 m -147.65 171.35 15.75 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.229 -0.919 . . . . 10.0 108.744 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 61.1 mt -105.81 -18.65 13.99 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 124.796 1.238 . . . . 10.0 110.343 175.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 73.0 m . . . . . 0 N--CA 1.453 -0.314 0 C-N-CA 125.269 1.427 . . . . 10.0 107.243 174.778 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 43.3 t . . . . . 0 N--CA 1.447 -0.599 0 N-CA-C 108.862 -0.792 . . . . 10.0 108.862 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 4.6 pt -78.35 45.76 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 O-C-N 121.349 -0.845 . . . . 10.0 112.618 -176.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . 0.487 ' CG2' ' HA3' ' A' ' 114' ' ' GLY . 1.3 mp -72.71 -63.83 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 O-C-N 121.599 -0.688 . . . . 10.0 110.299 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.76 48.71 3.54 Favored Glycine 0 CA--C 1.532 1.105 0 O-C-N 120.744 -1.223 . . . . 10.0 112.458 -178.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.04 166.17 10.81 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 127.064 2.146 . . . . 10.0 106.985 172.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -121.03 136.75 54.91 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.113 -1.069 . . . . 10.0 108.113 174.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mp -103.07 147.3 27.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 173.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -123.69 134.82 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 106.884 -1.525 . . . . 10.0 106.884 174.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -101.29 121.29 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 169.111 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.736 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 9.6 m-70 -101.3 154.08 19.09 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 115.677 1.732 . . . . 10.0 115.677 -169.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -38.49 -61.03 0.74 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 128.715 2.806 . . . . 10.0 111.124 171.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 66.0 mttt -117.0 175.3 5.65 Favored 'General case' 0 CA--C 1.517 -0.322 0 C-N-CA 124.973 1.309 . . . . 10.0 109.916 -173.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.3 140.11 35.02 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 108.131 -1.062 . . . . 10.0 108.131 174.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.81 160.85 28.08 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 122.077 0.941 . . . . 10.0 111.592 170.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -74.78 -27.68 60.42 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 113.804 -1.544 . . . . 10.0 109.863 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 126' ' ' LEU . 3.9 mm? 61.05 63.29 1.28 Allowed 'General case' 0 CA--C 1.521 -0.149 0 C-N-CA 125.711 1.605 . . . . 10.0 107.782 -167.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.74 -52.49 3.64 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.299 168.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.8 pttp -78.62 55.71 1.7 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.315 1.046 . . . . 10.0 112.421 -171.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.36 -34.22 4.85 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 125.387 1.47 . . . . 10.0 110.379 169.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 73.71 35.01 55.71 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.345 -1.102 . . . . 10.0 110.345 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -125.75 156.38 39.51 Favored 'General case' 0 CA--C 1.506 -0.717 0 N-CA-C 105.418 -2.068 . . . . 10.0 105.418 169.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.4 tt0 -49.23 -48.86 45.24 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 107.555 -1.276 . . . . 10.0 107.555 169.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -55.95 -41.73 75.14 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 114.648 -1.16 . . . . 10.0 111.959 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 23.2 p -58.61 -42.41 88.09 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 120.368 1.44 . . . . 10.0 111.183 178.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.9 t -78.5 -16.1 57.88 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 113.079 0.77 . . . . 10.0 113.079 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -102.21 -46.01 4.96 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 126.129 1.772 . . . . 10.0 112.889 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.412 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 29.4 p -127.07 -12.33 5.82 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.375 -0.828 . . . . 10.0 112.669 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 1.68 82.64 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.234 -1.314 . . . . 10.0 112.65 -169.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 69.24 29.71 4.51 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 119.95 1.875 . . . . 10.0 111.907 172.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.81 0.9 11.77 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 124.522 1.129 . . . . 10.0 112.552 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.93 -163.09 53.19 Favored Glycine 0 N--CA 1.445 -0.744 0 O-C-N 120.948 -1.095 . . . . 10.0 111.439 173.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -59.3 136.61 58.02 Favored 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.585 1.154 . . . . 10.0 114.005 -166.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -64.43 75.52 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.227 1.411 . . . . 10.0 109.822 168.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 47.8 mt -54.51 -37.88 65.87 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 118.655 0.661 . . . . 10.0 111.548 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.86 158.84 35.88 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -177.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -151.63 167.6 27.63 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.127 0.571 . . . . 10.0 109.543 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.26 147.43 16.92 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-O 118.446 -1.197 . . . . 10.0 110.361 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.2 t -96.64 127.5 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 N-CA-C 104.358 -2.46 . . . . 10.0 104.358 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.41 HG22 ' HA ' ' B' ' 113' ' ' ILE . 18.9 mt -70.16 158.02 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.055 0.843 . . . . 10.0 109.936 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -155.57 145.63 12.74 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.201 -1.16 . . . . 10.0 110.201 -172.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 98.6 mt -57.41 131.71 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 C-N-CA 126.335 1.854 . . . . 10.0 109.612 176.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -110.05 -44.37 3.79 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 118.85 0.75 . . . . 10.0 111.942 173.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.584 -2.151 . . . . 10.0 110.908 176.136 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.859 0 CA-C-O 118.698 -0.668 . . . . 10.0 109.276 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.8 t -165.11 -45.85 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.349 1.06 . . . . 10.0 109.919 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 20.0 ttmm -104.27 138.8 40.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.223 -1.769 . . . . 10.0 106.223 168.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.22 163.4 37.12 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 169.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -137.62 166.09 25.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-N 118.286 0.494 . . . . 10.0 110.171 -177.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.89 106.89 4.93 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 167.332 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.4 m -80.94 101.02 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 168.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mt -78.88 138.73 38.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.707 -0.849 . . . . 10.0 108.707 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.93 160.94 34.09 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.61 -0.885 . . . . 10.0 108.61 168.243 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.45 -60.73 0.03 OUTLIER Glycine 0 C--O 1.23 -0.144 0 N-CA-C 110.592 -1.003 . . . . 10.0 110.592 173.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -74.71 -45.14 46.25 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.53 -69.45 0.48 Allowed Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 114.731 -1.122 . . . . 10.0 111.331 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -55.58 -39.28 91.98 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 122.236 1.957 . . . . 10.0 111.062 -179.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.731 HG13 HD12 ' A' ' 38' ' ' LEU . 21.0 t -63.26 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 C-N-CA 129.064 2.946 . . . . 10.0 109.094 178.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -95.45 47.75 1.13 Allowed 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.92 1.288 . . . . 10.0 110.173 -167.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.407 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -58.77 150.73 34.87 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 121.142 -0.551 . . . . 10.0 114.041 -168.146 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.727 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.4 mt -136.63 89.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 106.31 -1.737 . . . . 10.0 106.31 -171.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.9 mm -96.24 136.74 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.139 0.576 . . . . 10.0 109.455 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -122.7 111.45 16.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 126.027 1.731 . . . . 10.0 107.522 172.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -92.85 118.74 31.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.2 1.4 . . . . 10.0 107.343 175.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -124.0 117.84 25.66 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 123.62 0.575 . . . . 10.0 111.161 175.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -101.13 102.57 13.53 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 105.876 -1.898 . . . . 10.0 105.876 168.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.3 mmmp? -54.32 -53.6 51.65 Favored 'General case' 0 C--N 1.338 0.108 0 C-N-CA 124.738 1.215 . . . . 10.0 110.821 -169.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.67 178.45 6.99 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 104.798 -2.297 . . . . 10.0 104.798 169.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -70.04 -20.37 63.25 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 110.311 -0.255 . . . . 10.0 110.311 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.8 m-80 -79.5 -21.88 44.72 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 123.742 0.817 . . . . 10.0 109.68 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.47 149.64 33.9 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.096 -0.802 . . . . 10.0 111.096 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -66.82 159.81 49.7 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 122.353 2.035 . . . . 10.0 107.597 168.176 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.29 96.33 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 105.93 -1.878 . . . . 10.0 105.93 174.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.9 mtpm? -71.98 100.6 2.51 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 106.42 -1.696 . . . . 10.0 106.42 172.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.54 97.7 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 125.52 1.528 . . . . 10.0 107.28 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.2 p90 -108.79 169.06 8.9 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 121.017 0.437 . . . . 10.0 110.606 169.299 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.57 -168.43 36.74 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.804 -0.518 . . . . 10.0 111.804 173.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 11.7 m -147.79 122.84 10.11 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.753 -0.223 . . . . 10.0 111.565 -177.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.436 ' HB ' HD11 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -99.53 95.42 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 C-N-CA 126.64 1.976 . . . . 10.0 107.449 169.471 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -106.0 102.45 11.88 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.009 0.524 . . . . 10.0 110.243 176.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.61 29.5 0.06 OUTLIER Glycine 0 C--N 1.334 0.463 0 CA-C-O 118.819 -0.989 . . . . 10.0 114.847 171.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.731 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -126.23 175.87 7.49 Favored 'General case' 0 C--O 1.223 -0.302 0 CA-C-N 118.329 1.065 . . . . 10.0 109.022 -177.827 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.3 t -75.52 160.42 30.2 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 109.325 171.437 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -62.24 -176.4 0.1 Allowed 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.029 1.332 . . . . 10.0 112.74 -176.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.9 -177.65 46.48 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.059 -0.816 . . . . 10.0 111.059 171.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.27 150.29 46.54 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.904 0.882 . . . . 10.0 109.216 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 -144.55 149.05 35.2 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.359 0.664 . . . . 10.0 112.484 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.653 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.09 121.77 0.11 Allowed Glycine 0 C--N 1.34 0.774 0 C-N-CA 128.34 2.876 . . . . 10.0 112.215 165.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -149.56 107.53 3.72 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 120.045 1.923 . . . . 10.0 113.412 168.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.29 168.78 22.38 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 122.18 0.99 . . . . 10.0 112.747 177.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 43.5 t -95.36 143.34 12.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 111.186 -2.734 . . . . 10.0 105.964 168.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -125.58 152.24 45.36 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 125.022 1.329 . . . . 10.0 108.889 177.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -62.35 -55.82 24.34 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 123.621 0.768 . . . . 10.0 109.87 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -76.55 104.89 7.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.154 -1.795 . . . . 10.0 106.154 -170.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.57 -36.54 92.59 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 108.844 -1.702 . . . . 10.0 108.844 173.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -54.11 160.99 1.39 Allowed 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 122.735 1.255 . . . . 10.0 113.254 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.425 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -156.33 22.39 0.36 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.206 -1.361 . . . . 10.0 114.506 -172.027 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.559 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.0 OUTLIER -48.94 -36.95 18.59 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.366 1.066 . . . . 10.0 111.387 174.529 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.6 -18.14 57.12 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.556 1.142 . . . . 10.0 112.854 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.52 84.15 0.57 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 123.686 0.66 . . . . 10.0 112.03 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.1 m 47.13 35.51 3.61 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.152 1.781 . . . . 10.0 112.378 174.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.5 m -129.44 -52.39 1.17 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 124.176 0.991 . . . . 10.0 108.396 -169.106 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.1 t -104.32 24.38 11.65 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.525 0.73 . . . . 10.0 109.394 178.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.29 46.51 0.62 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 123.607 0.763 . . . . 10.0 110.68 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.15 100.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.1 0 C-N-CA 126.263 1.887 . . . . 10.0 113.919 168.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -68.61 73.79 0.89 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 123.523 2.815 . . . . 10.0 113.086 179.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.0 m170 60.64 44.24 11.67 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.365 3.466 . . . . 10.0 110.6 172.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -68.96 68.84 0.17 Allowed 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.917 1.287 . . . . 10.0 111.659 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -84.77 154.97 61.84 Favored Pre-proline 0 C--N 1.322 -0.621 0 C-N-CA 125.512 1.525 . . . . 10.0 109.593 177.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.23 -44.19 5.24 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 122.433 2.089 . . . . 10.0 111.564 178.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.14 53.55 0.99 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.753 0.821 . . . . 10.0 111.021 -178.113 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.6 t -47.34 114.23 0.83 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.086 0.954 . . . . 10.0 111.009 -169.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 54.6 mtt180 -151.69 178.0 9.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 105.458 -2.053 . . . . 10.0 105.458 -169.645 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.72 141.47 37.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 118.614 -1.235 . . . . 10.0 108.892 -177.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -44.98 118.04 1.53 Allowed 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 121.002 -0.279 . . . . 10.0 111.514 168.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.54 -141.64 4.32 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.461 -1.055 . . . . 10.0 110.461 179.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.32 -175.49 33.4 Favored Glycine 0 C--O 1.223 -0.591 0 CA-C-N 118.426 1.113 . . . . 10.0 113.562 -173.539 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -66.58 7.6 0.39 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.176 1.917 . . . . 10.0 111.09 168.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.7 mmtt -96.57 -22.47 17.04 Favored 'General case' 0 N--CA 1.435 -1.183 0 C-N-CA 124.422 1.089 . . . . 10.0 108.407 173.403 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -126.56 -172.61 2.67 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 112.476 0.547 . . . . 10.0 112.476 -168.301 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -115.1 -6.21 12.48 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.967 1.307 . . . . 10.0 111.071 -174.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -100.74 -14.34 18.1 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 124.646 1.178 . . . . 10.0 112.143 -178.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -26.09 114.65 0.06 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 125.929 1.691 . . . . 10.0 111.331 167.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -53.62 -53.11 56.53 Favored 'General case' 0 C--O 1.226 -0.14 0 CA-C-O 121.419 0.628 . . . . 10.0 111.718 -167.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.496 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.5 p -165.38 -103.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 104.376 -2.453 . . . . 10.0 104.376 170.192 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.496 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -76.49 59.39 3.31 Favored Glycine 0 CA--C 1.53 1.018 0 CA-C-N 119.098 0.863 . . . . 10.0 112.476 176.664 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -91.11 108.18 19.69 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 103.77 -2.678 . . . . 10.0 103.77 166.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -81.59 -19.9 40.96 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 118.446 0.566 . . . . 10.0 111.34 -172.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.03 -92.46 0.59 Allowed Glycine 0 C--O 1.217 -0.937 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -155.19 159.52 40.18 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 -178.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.6 m -126.13 126.6 69.83 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 123.665 0.786 . . . . 10.0 110.283 170.203 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -80.11 124.47 28.79 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 127.025 2.13 . . . . 10.0 111.773 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.82 129.55 49.53 Favored 'General case' 0 C--O 1.234 0.243 0 C-N-CA 126.051 1.74 . . . . 10.0 109.58 170.031 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -64.98 172.14 3.09 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 123.985 0.803 . . . . 10.0 109.958 169.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -48.59 -34.61 11.86 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 126.586 1.954 . . . . 10.0 109.983 173.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -78.99 -6.53 56.55 Favored 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 123.943 0.897 . . . . 10.0 110.146 -172.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.13 21.18 71.23 Favored Glycine 0 C--N 1.339 0.738 0 N-CA-C 110.27 -1.132 . . . . 10.0 110.27 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.5 t -101.79 106.7 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 127.501 2.32 . . . . 10.0 105.266 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.412 ' HB3' HG13 ' A' ' 35' ' ' ILE . . . -101.9 120.39 40.32 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.092 -1.077 . . . . 10.0 108.092 169.391 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -88.77 134.72 33.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 169.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 90.1 t -109.68 131.78 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 104.705 -2.331 . . . . 10.0 104.705 168.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.9 m -154.79 68.5 0.71 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 124.158 0.983 . . . . 10.0 108.795 174.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -117.22 160.82 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 106.736 -1.579 . . . . 10.0 106.736 -174.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -132.01 123.91 28.25 Favored 'General case' 0 N--CA 1.446 -0.626 0 O-C-N 121.842 -0.536 . . . . 10.0 110.139 168.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -104.47 128.0 52.28 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.783 1.233 . . . . 10.0 109.403 -172.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.9 p -113.42 38.25 2.95 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.047 1.339 . . . . 10.0 110.867 177.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.53 -39.73 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 C-N-CA 123.644 0.778 . . . . 10.0 111.47 173.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.433 ' C ' HD12 ' A' ' 104' ' ' ILE 0.369 0.8 OUTLIER -90.27 175.66 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 119.566 1.076 . . . . 10.0 112.106 170.173 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 83.7 p -146.39 158.74 43.92 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.402 -0.811 . . . . 10.0 109.107 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.8 mp -89.82 -26.56 20.49 Favored 'General case' 0 N--CA 1.457 -0.077 0 C-N-CA 122.756 0.422 . . . . 10.0 110.493 170.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -155.9 46.51 0.47 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.188 0.449 . . . . 10.0 110.853 -172.035 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -151.92 70.44 0.3 Allowed Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.549 -1.82 . . . . 10.0 108.549 -178.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.8 t70 73.94 -52.32 0.69 Allowed 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 128.711 2.804 . . . . 10.0 111.21 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -75.3 -36.7 61.09 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -167.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.5 t 37.79 75.48 0.07 Allowed 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.694 1.598 . . . . 10.0 113.731 166.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.8 pt -61.98 -9.37 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 N-CA-C 114.133 1.16 . . . . 10.0 114.133 -177.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 39.1 mm -45.28 129.45 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 O-C-N 121.066 -1.022 . . . . 10.0 110.263 170.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.74 -3.41 86.89 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.5 -1.167 . . . . 10.0 114.116 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -78.26 175.67 9.99 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 119.101 1.451 . . . . 10.0 108.04 168.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -123.4 135.2 54.01 Favored 'General case' 0 C--N 1.338 0.105 0 C-N-CA 123.308 0.643 . . . . 10.0 110.151 171.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.542 HD21 HD11 ' A' ' 149' ' ' ILE . 3.6 mm? -89.53 147.22 24.09 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 107.64 -1.245 . . . . 10.0 107.64 168.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.4 t -129.27 131.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.2 -1.407 . . . . 10.0 107.2 169.254 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -102.97 133.18 47.46 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 N-CA-C 105.787 -1.931 . . . . 10.0 105.787 168.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.653 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.5 m-70 -111.52 157.67 20.07 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.839 1.422 . . . . 10.0 114.839 -170.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.574 ' HA ' HD22 ' A' ' 144' ' ' LEU . 52.0 tt0 -43.52 -52.46 6.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 128.598 2.759 . . . . 10.0 110.332 176.274 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -118.21 165.28 14.0 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 123.584 0.754 . . . . 10.0 110.915 -169.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -58.58 147.16 33.27 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.002 -0.999 . . . . 10.0 109.698 169.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.532 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 26.1 m-20 -79.49 130.56 35.52 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 124.459 1.104 . . . . 10.0 109.829 171.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.51 -16.66 59.59 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 123.876 0.735 . . . . 10.0 111.014 173.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.2 mt 55.6 49.74 15.89 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-O 122.251 1.024 . . . . 10.0 109.386 -173.105 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.52 -29.49 9.61 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.069 -1.423 . . . . 10.0 112.399 169.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt -77.06 9.94 2.68 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.731 1.011 . . . . 10.0 113.731 -168.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.07 -19.98 74.36 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 124.378 0.99 . . . . 10.0 111.86 172.469 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.79 42.51 68.9 Favored Glycine 0 C--N 1.343 0.944 0 N-CA-C 111.031 -0.828 . . . . 10.0 111.031 -176.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -131.51 159.09 39.16 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 106.139 -1.8 . . . . 10.0 106.139 177.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -50.68 -49.0 58.36 Favored 'General case' 0 N--CA 1.442 -0.841 0 CA-C-N 114.522 -1.217 . . . . 10.0 107.82 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -63.28 -33.67 76.02 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 115.376 -0.829 . . . . 10.0 112.41 175.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.9 p -59.43 -43.23 93.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 120.153 -1.592 . . . . 10.0 111.06 174.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -81.47 -21.04 39.02 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 122.973 0.171 . . . . 10.0 111.187 -174.115 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 15.6 mmtp -89.11 -49.3 6.83 Favored 'General case' 0 C--N 1.339 0.129 0 C-N-CA 124.781 1.232 . . . . 10.0 113.099 179.223 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 34.7 p -128.81 -18.08 3.89 Favored 'General case' 0 C--O 1.227 -0.125 0 N-CA-C 114.734 1.383 . . . . 10.0 114.734 177.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 106.55 26.26 5.97 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 119.452 1.024 . . . . 10.0 112.96 -176.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 58.64 21.6 8.93 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 118.349 1.074 . . . . 10.0 111.033 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.4 -5.36 35.93 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 123.965 0.906 . . . . 10.0 111.8 -169.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.84 -165.58 53.66 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.808 -1.317 . . . . 10.0 109.808 168.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 60.2 m -52.01 129.62 27.67 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-O 121.362 0.601 . . . . 10.0 110.037 -171.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.71 72.95 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.004 1.322 . . . . 10.0 110.414 171.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.574 HD22 ' HA ' ' A' ' 121' ' ' GLU . 6.5 tp -47.75 -35.2 9.48 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 128.202 2.601 . . . . 10.0 113.122 -172.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.93 157.09 25.87 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.73 -0.841 . . . . 10.0 108.73 172.549 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -145.31 163.32 34.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.047 -0.524 . . . . 10.0 109.714 177.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.18 147.32 15.39 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.495 -1.442 . . . . 10.0 109.495 -174.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 69.9 t -105.88 131.88 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 C-N-CA 126.142 1.777 . . . . 10.0 106.771 -169.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.542 HD11 HD21 ' A' ' 117' ' ' LEU . 8.2 mt -77.14 117.62 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.735 0 CA-C-N 117.884 0.311 . . . . 10.0 110.398 -174.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.45 158.87 14.1 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.572 1.082 . . . . 10.0 112.036 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.1 mt -64.74 142.56 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 125.309 1.444 . . . . 10.0 109.803 177.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.77 165.11 28.16 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.575 -1.269 . . . . 10.0 107.575 167.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.12 0 N-CA-C 105.023 -2.214 . . . . 10.0 105.023 167.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.551 0 N-CA-C 106.815 -1.55 . . . . 10.0 106.815 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.1 t -94.9 -35.1 12.17 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.558 1.143 . . . . 10.0 109.539 175.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -134.23 160.32 38.22 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 124.486 1.114 . . . . 10.0 110.467 -171.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.99 166.18 34.41 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 169.161 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -128.4 175.78 9.25 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 N-CA-C 107.739 -1.208 . . . . 10.0 107.739 171.175 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.04 122.61 13.24 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 124.064 0.946 . . . . 10.0 109.076 168.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.425 HG21 ' HB3' ' A' ' 53' ' ' ASN . 1.5 m -102.65 100.41 10.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 C-N-CA 124.482 1.113 . . . . 10.0 110.43 174.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.442 HD12 ' N ' ' B' ' 8' ' ' LEU . 5.7 mp -89.65 130.41 35.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.742 0.817 . . . . 10.0 109.188 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -144.62 162.68 36.04 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 119.529 1.059 . . . . 10.0 108.423 170.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -167.22 -61.37 0.03 OUTLIER Glycine 0 C--O 1.229 -0.208 0 CA-C-N 115.331 -0.85 . . . . 10.0 112.057 171.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -73.81 -44.64 55.19 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 106.544 -1.65 . . . . 10.0 106.544 -171.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.07 -65.57 0.59 Allowed Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 113.614 -1.63 . . . . 10.0 110.404 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -55.44 -38.75 93.67 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 122.644 2.23 . . . . 10.0 111.148 171.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 98.6 t -67.91 107.47 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 N-CA-C 108.058 -1.09 . . . . 10.0 108.058 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.04 107.7 10.67 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 125.662 1.585 . . . . 10.0 107.266 172.676 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.693 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -95.67 136.57 12.94 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.181 -0.768 . . . . 10.0 111.181 173.194 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.559 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.9 mt -140.75 89.58 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -102.39 149.77 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.087 0 C-N-CA 124.819 1.248 . . . . 10.0 110.753 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -119.57 133.39 55.68 Favored 'General case' 0 C--O 1.232 0.155 0 C-N-CA 127.639 2.376 . . . . 10.0 107.417 174.148 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -119.32 113.62 21.11 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 171.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -110.74 137.46 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 118.714 0.688 . . . . 10.0 111.478 167.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -96.93 113.92 25.5 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.655 -1.98 . . . . 10.0 105.655 167.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.7 tttt . . . . . 0 N--CA 1.443 -0.775 0 C-N-CA 125.804 1.642 . . . . 10.0 109.672 -175.008 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.949 0 N-CA-C 108.164 -1.974 . . . . 10.0 108.164 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -59.59 149.18 83.92 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 122.63 2.22 . . . . 10.0 110.269 -177.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -88.99 108.1 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 105.913 -1.884 . . . . 10.0 105.913 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 40.4 tttt -88.39 116.86 26.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 105.886 -1.894 . . . . 10.0 105.886 168.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -92.56 103.22 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -123.28 152.41 41.4 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 112.63 0.604 . . . . 10.0 112.63 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.42 -150.86 22.07 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 106.556 -2.618 . . . . 10.0 106.556 172.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.98 154.62 31.38 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 118.86 -1.136 . . . . 10.0 110.733 -176.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.693 HG22 ' HA2' ' B' ' 16' ' ' GLY . 1.7 pt -113.89 141.38 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 114.91 -1.041 . . . . 10.0 109.614 167.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 tttm -118.81 141.28 48.78 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.81 -8.76 31.96 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 119.517 -0.602 . . . . 10.0 113.95 174.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.39 176.7 0.59 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 118.303 1.052 . . . . 10.0 111.601 175.121 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -112.7 154.04 26.75 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 105.656 -1.979 . . . . 10.0 105.656 165.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -48.95 154.38 0.74 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.869 1.267 . . . . 10.0 113.3 -168.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -171.11 22.29 Favored Glycine 0 C--N 1.337 0.61 0 C-N-CA 123.84 0.733 . . . . 10.0 112.212 168.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -73.3 144.13 46.71 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.293 1.437 . . . . 10.0 109.782 -178.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -148.03 150.03 33.2 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 113.504 0.928 . . . . 10.0 113.504 -177.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.714 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -29.73 119.87 0.08 OUTLIER Glycine 0 C--N 1.339 0.731 0 C-N-CA 128.409 2.909 . . . . 10.0 113.847 165.088 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -153.77 110.92 3.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 118.72 1.26 . . . . 10.0 111.029 168.493 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -146.86 175.01 10.97 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 121.436 0.636 . . . . 10.0 110.382 177.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.9 m -103.1 155.62 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 104.903 -2.258 . . . . 10.0 104.903 166.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -138.58 154.98 48.73 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.845 1.258 . . . . 10.0 109.835 -173.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.7 tt0 -57.48 -64.62 0.83 Allowed 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.387 2.275 . . . . 10.0 112.387 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -77.06 105.92 8.44 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 -172.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.15 -23.9 66.61 Favored Glycine 0 CA--C 1.532 1.116 0 N-CA-C 108.995 -1.642 . . . . 10.0 108.995 167.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.38 152.43 0.44 Allowed 'General case' 0 N--CA 1.445 -0.699 0 C-N-CA 124.928 1.291 . . . . 10.0 111.682 168.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -152.21 24.46 0.63 Allowed 'General case' 0 N--CA 1.439 -1.007 0 CA-C-N 114.629 -1.169 . . . . 10.0 112.49 168.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.727 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -60.6 -25.41 66.22 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 121.783 -0.573 . . . . 10.0 110.292 176.878 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.57 -17.18 60.13 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.632 0.773 . . . . 10.0 111.149 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.05 73.71 0.9 Allowed Glycine 0 CA--C 1.527 0.795 0 N-CA-C 110.709 -0.956 . . . . 10.0 110.709 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 53.72 32.5 14.83 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.092 0.957 . . . . 10.0 112.534 170.201 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -122.4 -48.63 2.07 Favored 'General case' 0 N--CA 1.441 -0.923 0 C-N-CA 124.943 1.297 . . . . 10.0 108.317 -169.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.8 t -125.37 48.94 1.96 Allowed 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.58 -0.896 . . . . 10.0 108.58 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.81 50.62 0.72 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.603 0.761 . . . . 10.0 110.265 176.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 69.78 120.07 0.04 OUTLIER Glycine 0 CA--C 1.537 1.42 0 C-N-CA 124.947 1.261 . . . . 10.0 113.093 173.173 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -80.98 50.77 3.69 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 122.729 2.286 . . . . 10.0 112.817 -173.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.5 m170 62.33 100.33 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 127.966 2.507 . . . . 10.0 109.631 -175.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -27.38 -47.01 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 128.279 2.632 . . . . 10.0 115.725 -175.19 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 19.39 76.75 0.19 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 128.047 2.539 . . . . 10.0 116.011 -174.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.26 -50.63 2.61 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 121.128 1.218 . . . . 10.0 109.576 172.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 23.3 tp -77.58 75.9 4.12 Favored 'General case' 0 N--CA 1.453 -0.285 0 O-C-N 121.677 -0.64 . . . . 10.0 109.322 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.2 t -17.3 90.25 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 128.051 2.54 . . . . 10.0 114.241 174.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -135.34 164.77 26.99 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 126.721 2.008 . . . . 10.0 107.981 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -105.62 95.33 5.74 Favored 'General case' 0 C--O 1.224 -0.247 0 C-N-CA 122.897 0.479 . . . . 10.0 109.853 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.523 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 84.6 t60 2.16 94.84 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.406 0 C-N-CA 127.56 2.344 . . . . 10.0 115.254 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -100.91 -144.82 16.06 Favored Glycine 0 C--N 1.316 -0.582 0 N-CA-C 109.836 -1.306 . . . . 10.0 109.836 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.439 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 179.14 -165.82 34.95 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 106.749 -2.54 . . . . 10.0 106.749 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -65.28 7.25 0.31 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 CA-C-N 119.887 1.843 . . . . 10.0 111.169 167.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.439 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.8 mmmt -119.94 1.56 10.95 Favored 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 126.509 1.923 . . . . 10.0 110.775 178.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -143.34 159.68 41.92 Favored 'General case' 0 C--N 1.348 0.533 0 CA-C-N 120.709 1.595 . . . . 10.0 108.92 168.183 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.2 mm-40 -78.73 -22.0 47.2 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.588 -0.893 . . . . 10.0 108.588 177.09 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -87.14 34.13 0.68 Allowed 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.433 1.093 . . . . 10.0 111.713 -170.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.0 mtm180 -49.12 142.27 7.13 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.591 1.156 . . . . 10.0 108.254 169.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.523 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 24.4 m170 -75.74 -50.35 15.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.639 0.654 . . . . 10.0 110.367 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER 175.46 -19.88 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 126.949 2.1 . . . . 10.0 111.675 174.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -161.46 68.98 0.23 Allowed Glycine 0 C--N 1.338 0.642 0 N-CA-C 108.469 -1.852 . . . . 10.0 108.469 -169.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -127.58 94.79 4.06 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -168.342 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.1 mp -64.5 -35.9 82.44 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.468 -0.568 . . . . 10.0 109.468 -172.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.74 -88.14 0.41 Allowed Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 107.19 -2.364 . . . . 10.0 107.19 176.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . 0.41 ' ND2' ' H ' ' B' ' 124' ' ' ASP . 7.6 m120 -149.82 141.46 23.54 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.731 -1.211 . . . . 10.0 107.731 -172.227 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.5 m -116.52 135.5 56.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 118.443 0.565 . . . . 10.0 110.425 169.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 19.8 m -94.92 100.9 12.68 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 128.173 2.589 . . . . 10.0 110.584 -170.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.92 131.23 35.8 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.066 0.547 . . . . 10.0 110.645 174.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -64.92 168.92 5.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.919 1.688 . . . . 10.0 109.139 167.438 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.15 -32.03 33.93 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.488 1.115 . . . . 10.0 111.039 175.77 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -80.68 -2.0 44.88 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 124.445 1.098 . . . . 10.0 110.794 -176.372 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.83 82.72 Favored Glycine 0 C--N 1.34 0.762 0 O-C-N 121.158 -0.964 . . . . 10.0 110.86 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 62.8 t -90.37 104.12 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 106.069 -1.826 . . . . 10.0 106.069 176.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.628 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -102.61 122.68 44.88 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 107.61 -1.256 . . . . 10.0 107.61 169.531 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -89.7 124.75 34.88 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.305 1.042 . . . . 10.0 108.25 174.526 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 51.9 t -110.07 131.53 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.937 1.695 . . . . 10.0 107.529 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 95.2 p -156.53 60.8 0.55 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.174 0.589 . . . . 10.0 109.901 174.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.49 155.02 5.13 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 -173.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -131.56 142.37 49.9 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.575 0.75 . . . . 10.0 111.067 177.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -140.37 161.8 36.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.552 -1.648 . . . . 10.0 106.552 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 11.1 t -136.98 10.33 3.06 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 125.398 1.479 . . . . 10.0 112.893 175.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -89.19 -15.46 8.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 120.077 1.308 . . . . 10.0 109.628 174.294 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.29 1.0 OUTLIER -111.79 162.57 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 125.333 1.453 . . . . 10.0 112.05 175.578 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.2 m -148.66 147.5 29.0 Favored 'General case' 0 C--N 1.34 0.171 0 C-N-CA 124.087 0.955 . . . . 10.0 109.355 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.45 -21.25 66.2 Favored 'General case' 0 C--O 1.227 -0.113 0 C-N-CA 125.208 1.403 . . . . 10.0 111.35 176.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.7 t . . . . . 0 N--CA 1.453 -0.299 0 O-C-N 121.293 -0.879 . . . . 10.0 109.674 171.957 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.445 -0.717 0 N-CA-C 111.899 0.333 . . . . 10.0 111.899 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 pt -74.29 55.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 123.834 0.854 . . . . 10.0 111.281 176.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 43.5 mm -108.46 -49.3 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 125.848 1.659 . . . . 10.0 109.956 179.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -90.19 18.68 47.22 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.372 -0.682 . . . . 10.0 113.074 -174.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.7 mtt85 -99.64 179.73 4.45 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.115 1.366 . . . . 10.0 110.556 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -133.87 147.62 51.18 Favored 'General case' 0 CA--C 1.507 -0.688 0 C-N-CA 125.789 1.636 . . . . 10.0 106.726 -175.484 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.436 HD12 ' N ' ' B' ' 117' ' ' LEU . 7.7 mp -113.49 153.81 28.09 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.331 -0.988 . . . . 10.0 108.331 173.129 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.0 t -131.97 130.46 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -97.82 123.92 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.349 -1.723 . . . . 10.0 106.349 169.125 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.714 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.3 m-70 -105.06 155.04 19.35 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 115.857 1.799 . . . . 10.0 115.857 -172.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 59.3 tt0 -44.79 -53.35 7.51 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 128.139 2.576 . . . . 10.0 111.726 175.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -113.08 167.19 10.73 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.952 0.723 . . . . 10.0 112.952 -168.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -70.49 147.28 49.57 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 113.967 -1.469 . . . . 10.0 108.424 170.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.41 ' H ' ' ND2' ' B' ' 86' ' ' ASN . 14.6 m-20 -94.84 131.34 40.82 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -173.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -76.51 -17.42 59.28 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.36 1.064 . . . . 10.0 110.19 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 22.6 mt 57.74 56.6 4.72 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 122.513 1.149 . . . . 10.0 108.969 -179.363 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.1 -40.83 3.06 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.745 -1.57 . . . . 10.0 110.722 168.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 30.7 mtmt -79.01 48.99 0.89 Allowed 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.637 1.175 . . . . 10.0 110.81 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -112.07 -9.21 20.73 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 127.203 2.335 . . . . 10.0 112.377 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.7 37.73 43.1 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 123.951 0.786 . . . . 10.0 112.973 176.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 -134.0 157.87 44.97 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 106.359 -1.719 . . . . 10.0 106.359 174.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -54.86 -45.94 74.63 Favored 'General case' 0 N--CA 1.439 -0.999 0 CA-C-O 122.305 1.05 . . . . 10.0 108.207 170.207 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 24.0 tp10 -58.48 -33.83 70.23 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 121.185 -0.947 . . . . 10.0 112.978 173.084 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.0 p -56.51 -42.09 77.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 120.606 1.548 . . . . 10.0 111.074 172.118 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.3 t -82.78 -19.65 37.36 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 118.485 -0.769 . . . . 10.0 112.421 -178.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -90.86 -46.46 8.18 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 124.448 1.099 . . . . 10.0 112.128 -176.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 26.9 p -133.51 -9.26 2.86 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.098 1.147 . . . . 10.0 114.098 176.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.42 23.61 12.31 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 119.289 0.95 . . . . 10.0 112.546 -173.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 61.67 21.83 12.46 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.769 1.284 . . . . 10.0 111.248 -176.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.33 -7.76 20.99 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 125.592 1.557 . . . . 10.0 112.285 -171.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.18 -167.97 54.84 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.069 -1.212 . . . . 10.0 110.069 170.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 12.6 t -53.96 129.1 32.94 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 121.819 0.819 . . . . 10.0 110.862 -169.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.45 73.23 0.08 Allowed 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 124.049 0.94 . . . . 10.0 108.961 169.449 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 66.3 mt -47.14 -45.56 22.6 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.868 0.867 . . . . 10.0 111.676 -177.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.24 152.38 27.69 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -169.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -161.42 165.26 29.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.855 -0.611 . . . . 10.0 109.485 -172.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.44 163.24 30.22 Favored Glycine 0 C--N 1.331 0.255 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -174.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -101.91 156.05 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 N-CA-C 104.05 -2.574 . . . . 10.0 104.05 169.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 77.9 mt -74.75 -94.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 109.765 -0.457 . . . . 10.0 109.765 -169.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 112.92 135.95 6.48 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.626 1.108 . . . . 10.0 112.049 175.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -62.48 138.63 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.106 1.363 . . . . 10.0 110.096 179.372 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.87 146.59 49.37 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.434 -1.321 . . . . 10.0 107.434 169.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 . . . . . 0 C--O 1.248 0.99 0 N-CA-C 106.195 -1.779 . . . . 10.0 106.195 169.295 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 t -172.37 -36.44 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.703 1.201 . . . . 10.0 112.077 -179.109 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 48.0 tttt -137.98 134.46 34.9 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 123.267 0.627 . . . . 10.0 110.357 -179.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.5 167.85 26.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.012 1.325 . . . . 10.0 108.849 -175.21 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -126.89 164.15 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 118.746 0.703 . . . . 10.0 110.519 170.071 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.74 112.31 11.27 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.285 1.434 . . . . 10.0 107.711 167.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.479 HG21 ' HB3' ' B' ' 53' ' ' ASN . 3.0 m -95.88 103.14 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 123.666 0.787 . . . . 10.0 110.216 177.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mt -87.77 107.83 18.84 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 118.637 -0.697 . . . . 10.0 110.038 -173.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -133.24 158.69 42.26 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 120.644 1.565 . . . . 10.0 108.453 175.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.71 -68.82 0.02 OUTLIER Glycine 0 N--CA 1.462 0.372 0 CA-C-N 114.818 -1.083 . . . . 10.0 112.342 170.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -72.37 -39.5 68.0 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.064 -1.458 . . . . 10.0 107.064 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.24 -60.48 0.56 Allowed Glycine 0 N--CA 1.443 -0.86 0 CA-C-O 118.476 -1.18 . . . . 10.0 112.608 170.241 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -60.62 -39.62 62.7 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 CA-C-N 119.198 1.499 . . . . 10.0 110.848 -177.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.437 HG12 ' H ' ' A' ' 14' ' ' VAL . 0.2 OUTLIER -70.66 115.32 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 177.322 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.84 103.95 7.78 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.413 -2.44 . . . . 10.0 104.413 170.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.75 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.38 145.79 19.19 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 108.445 -1.862 . . . . 10.0 108.445 174.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.657 ' CG2' HG22 ' B' ' 54' ' ' THR . 3.3 mt -144.85 74.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -168.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 mm -87.45 128.8 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 N-CA-C 109.741 -0.466 . . . . 10.0 109.741 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -99.6 112.15 24.4 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 126.41 1.884 . . . . 10.0 107.752 173.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.421 ' CD2' HG12 ' A' ' 31' ' ' VAL . 25.7 m-85 -88.06 113.43 23.69 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 107.211 -1.403 . . . . 10.0 107.211 173.081 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -121.28 111.39 17.3 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 118.797 0.726 . . . . 10.0 111.272 168.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -99.53 91.54 4.95 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.129 -1.804 . . . . 10.0 106.129 168.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.48 -36.71 66.91 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.972 0.909 . . . . 10.0 112.939 -168.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.05 171.2 14.76 Favored 'General case' 0 N--CA 1.432 -1.362 0 N-CA-C 104.834 -2.284 . . . . 10.0 104.834 167.398 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.4 p -64.81 -24.65 67.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.235 0.54 . . . . 10.0 110.248 179.139 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -81.58 -19.29 42.29 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 115.221 -0.9 . . . . 10.0 110.259 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -82.02 154.48 33.71 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.617 -0.593 . . . . 10.0 111.617 -173.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_endo -67.36 146.8 76.37 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.71 2.274 . . . . 10.0 106.876 167.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.9 p -80.29 110.05 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 174.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -84.3 115.91 22.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.431 -0.952 . . . . 10.0 108.431 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.421 HG12 ' CD2' ' A' ' 20' ' ' PHE . 30.2 m -98.48 57.91 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 124.233 1.013 . . . . 10.0 108.73 -170.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 9.3 p90 -77.78 144.88 36.79 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 118.921 -1.112 . . . . 10.0 110.963 -175.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -175.88 172.04 45.06 Favored Glycine 0 N--CA 1.441 -0.976 0 O-C-N 121.24 -0.913 . . . . 10.0 110.89 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.8 t -128.58 107.91 10.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 178.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.758 ' CG1' ' HB3' ' A' ' 95' ' ' ALA . 2.7 pt -81.76 142.18 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 108.396 -0.964 . . . . 10.0 108.396 169.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.7 ptmm? -127.13 137.03 52.9 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.192 -1.04 . . . . 10.0 108.192 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.71 -1.92 27.52 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.075 0.845 . . . . 10.0 113.399 176.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -62.53 174.05 1.09 Allowed 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 122.132 0.968 . . . . 10.0 110.467 169.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -103.61 164.49 11.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.18 -1.785 . . . . 10.0 106.18 164.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -54.61 162.87 1.04 Allowed 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.576 0.751 . . . . 10.0 112.062 -172.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.72 -179.78 43.12 Favored Glycine 0 C--N 1.334 0.469 0 O-C-N 121.248 -0.908 . . . . 10.0 112.29 168.144 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.1 mt -66.55 142.22 57.58 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.059 0.943 . . . . 10.0 110.65 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -138.02 128.82 26.91 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 117.729 -1.129 . . . . 10.0 111.103 176.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.513 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -15.2 113.46 0.01 OUTLIER Glycine 0 C--N 1.347 1.148 0 CA-C-O 115.949 -2.584 . . . . 10.0 112.49 167.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -137.73 100.15 4.11 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 120.989 2.394 . . . . 10.0 109.91 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.413 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -156.73 169.84 23.79 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-O 122.04 0.924 . . . . 10.0 112.79 -174.075 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.8 t -96.81 141.14 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 111.566 -2.561 . . . . 10.0 107.729 177.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -116.28 168.58 10.0 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.178 0.991 . . . . 10.0 109.397 178.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -67.23 -72.51 0.16 Allowed 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.697 -0.683 . . . . 10.0 111.246 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.55 136.98 34.71 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 120.161 -0.616 . . . . 10.0 110.132 -169.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -66.87 -31.59 78.63 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 109.278 -1.529 . . . . 10.0 109.278 168.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -45.14 155.34 0.12 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 122.837 1.303 . . . . 10.0 114.353 -175.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.17 15.37 0.82 Allowed 'General case' 0 N--CA 1.439 -0.985 0 CA-C-N 113.446 -1.707 . . . . 10.0 111.037 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.522 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -53.76 -43.07 68.88 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 120.266 1.394 . . . . 10.0 112.352 -167.676 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.59 -17.94 52.74 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.98 0.912 . . . . 10.0 112.65 -179.331 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.05 60.77 0.37 Allowed Glycine 0 CA--C 1.528 0.862 0 C-N-CA 124.468 1.033 . . . . 10.0 111.139 -177.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 61.24 18.65 9.35 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 114.513 1.301 . . . . 10.0 114.513 171.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 p -93.81 -57.53 2.53 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 176.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.4 m -49.91 -34.44 20.42 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.363 2.265 . . . . 10.0 111.853 -178.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -39.25 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.849 2.46 . . . . 10.0 112.078 168.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.74 154.02 28.63 Favored Glycine 0 N--CA 1.436 -1.339 0 N-CA-C 108.28 -1.928 . . . . 10.0 108.28 168.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -71.44 -164.95 0.17 Allowed 'Trans proline' 0 N--CA 1.442 -1.552 0 N-CA-C 107.269 -1.858 . . . . 10.0 107.269 167.295 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.413 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 50.4 m170 -79.84 62.75 4.17 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 120.596 -1.315 . . . . 10.0 109.951 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -75.28 67.28 1.86 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 123.702 1.715 . . . . 10.0 111.18 178.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -72.65 153.6 91.53 Favored Pre-proline 0 N--CA 1.448 -0.54 0 C-N-CA 128.205 2.602 . . . . 10.0 110.181 169.295 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.85 -40.2 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.767 2.312 . . . . 10.0 111.37 177.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mt -78.09 49.18 0.79 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.284 1.034 . . . . 10.0 110.442 -177.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.4 p -57.14 106.55 0.33 Allowed 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.417 1.087 . . . . 10.0 109.826 -170.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.4 mtt180 -134.7 -88.02 0.37 Allowed 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 106.562 -1.644 . . . . 10.0 106.562 -171.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.5 mmtp -140.71 155.39 46.48 Favored 'General case' 0 N--CA 1.438 -1.074 0 CA-C-O 122.695 1.236 . . . . 10.0 110.273 169.184 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 69.2 t60 -69.03 119.31 13.12 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 164.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.9 -138.24 3.81 Favored Glycine 0 N--CA 1.442 -0.919 0 N-CA-C 109.38 -1.488 . . . . 10.0 109.38 -175.645 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -176.94 -157.5 18.14 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 109.558 -1.417 . . . . 10.0 109.558 169.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -67.79 14.72 0.15 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.158 1.905 . . . . 10.0 111.424 168.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.438 ' H ' ' C ' ' A' ' 73' ' ' GLY . 4.5 mtpm? -120.91 -6.93 9.54 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.626 1.571 . . . . 10.0 110.677 174.542 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -110.89 162.39 14.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 177.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.4 pm0 -98.74 -16.16 19.06 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 126.319 1.847 . . . . 10.0 109.866 169.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -105.39 6.9 32.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.852 1.661 . . . . 10.0 112.324 -174.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -35.52 149.81 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.575 1.95 . . . . 10.0 112.924 171.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -70.06 -100.42 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 112.47 0.545 . . . . 10.0 112.47 -178.312 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 p -151.64 25.06 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 O-C-N 120.606 -1.309 . . . . 10.0 110.392 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 157.36 51.33 0.01 OUTLIER Glycine 0 CA--C 1.522 0.483 0 N-CA-C 108.814 -1.715 . . . . 10.0 108.814 -173.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.55 99.74 11.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 105.346 -2.094 . . . . 10.0 105.346 169.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.7 mt -94.49 33.02 1.47 Allowed 'General case' 0 N--CA 1.461 0.122 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 172.143 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 46.09 -106.38 0.13 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 126.514 2.006 . . . . 10.0 111.025 -178.351 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -151.92 117.66 5.43 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 123.557 0.743 . . . . 10.0 110.439 -168.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -92.86 138.69 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 122.731 0.412 . . . . 10.0 110.83 -171.111 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.31 118.56 24.28 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 125.035 1.334 . . . . 10.0 110.493 -172.391 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.59 134.74 38.12 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 123.225 0.61 . . . . 10.0 109.847 173.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -57.92 167.57 1.16 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.856 0.862 . . . . 10.0 109.025 167.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.11 -23.69 62.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.104 -0.498 . . . . 10.0 112.157 177.644 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -78.4 -13.09 60.0 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.266 0.627 . . . . 10.0 110.958 179.121 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.74 6.27 67.8 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.952 -0.859 . . . . 10.0 110.952 -176.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.9 t -81.49 108.1 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.516 1.927 . . . . 10.0 106.978 174.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.758 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -112.99 121.12 43.68 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 108.831 -0.803 . . . . 10.0 108.831 173.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -83.08 131.4 35.16 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.719 -0.845 . . . . 10.0 108.719 173.18 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.7 t -119.23 130.79 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 N-CA-C 104.815 -2.291 . . . . 10.0 104.815 168.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -155.75 57.78 0.61 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 118.655 0.661 . . . . 10.0 111.18 -177.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 71.6 mt -116.55 138.77 46.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.208 1.403 . . . . 10.0 109.824 -170.156 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -91.35 104.12 16.68 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 127.843 2.457 . . . . 10.0 109.121 172.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -81.34 116.48 21.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.009 -0.738 . . . . 10.0 109.009 175.256 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.8 p -111.3 46.46 1.09 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 125.448 1.499 . . . . 10.0 109.68 174.081 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.23 -41.06 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.168 0 CA-C-O 118.157 -0.925 . . . . 10.0 110.543 175.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.407 0.0 OUTLIER -106.27 177.21 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-N 119.553 1.069 . . . . 10.0 113.549 169.501 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.6 t -146.23 153.71 40.92 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 108.112 -1.07 . . . . 10.0 108.112 -176.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 93.1 mt -69.77 -17.53 63.43 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.318 0.647 . . . . 10.0 110.801 173.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.3 t -151.15 150.55 30.79 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.536 0.607 . . . . 10.0 109.533 177.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.6 68.09 0.43 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.017 -1.233 . . . . 10.0 110.017 -179.079 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.8 t70 71.61 -56.67 0.63 Allowed 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 129.536 3.134 . . . . 10.0 109.847 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -78.15 -2.46 37.61 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 113.011 0.745 . . . . 10.0 113.011 -168.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.9 t -17.76 96.41 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 129.025 2.93 . . . . 10.0 112.523 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 29.2 pt -72.84 -3.58 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 112.776 0.658 . . . . 10.0 112.776 -175.009 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.8 mm -52.54 130.28 13.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 O-C-N 121.092 -1.005 . . . . 10.0 108.493 169.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.92 8.71 87.67 Favored Glycine 0 CA--C 1.533 1.205 0 CA-C-O 118.67 -1.072 . . . . 10.0 114.22 -176.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -78.36 176.43 9.34 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 166.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -127.96 136.82 51.84 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 106.854 -1.535 . . . . 10.0 106.854 171.179 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.9 mp -107.61 158.07 17.55 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.183 -1.414 . . . . 10.0 107.183 168.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.1 t -132.27 136.79 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 107.487 -1.301 . . . . 10.0 107.487 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.3 125.19 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 103.674 -2.713 . . . . 10.0 103.674 167.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.513 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.0 m170 -106.37 164.37 12.08 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 120.207 1.367 . . . . 10.0 114.37 -171.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.39 -49.79 73.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 114.036 -1.438 . . . . 10.0 109.438 -175.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -117.97 173.05 6.99 Favored 'General case' 0 N--CA 1.456 -0.131 0 CA-C-O 122.425 1.107 . . . . 10.0 113.355 -174.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -73.57 143.28 46.5 Favored 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 113.475 -1.693 . . . . 10.0 109.646 169.454 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.13 156.3 36.11 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 123.851 0.861 . . . . 10.0 110.637 174.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 -85.35 8.92 16.98 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.414 -0.812 . . . . 10.0 109.968 166.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.4 mt 39.32 52.79 2.24 Favored 'General case' 0 C--N 1.344 0.369 0 C-N-CA 126.148 1.779 . . . . 10.0 110.782 -172.478 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.55 -26.24 24.68 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 113.642 -1.617 . . . . 10.0 112.59 173.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -78.97 24.37 0.31 Allowed 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 114.29 1.219 . . . . 10.0 114.29 -167.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.48 -38.41 38.29 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 108.49 -1.844 . . . . 10.0 108.49 169.034 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.84 47.8 58.7 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 109.431 -1.468 . . . . 10.0 109.431 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -152.17 164.08 38.06 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.544 -2.021 . . . . 10.0 105.544 176.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -44.74 -47.15 10.77 Favored 'General case' 0 N--CA 1.438 -1.055 0 C-N-CA 123.031 0.532 . . . . 10.0 111.344 -175.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.77 -34.56 71.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.453 -0.34 . . . . 10.0 110.176 -177.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -51.45 -44.44 62.36 Favored 'General case' 0 N--CA 1.446 -0.651 0 O-C-N 121.725 -0.61 . . . . 10.0 110.677 172.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -84.38 6.75 22.0 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.382 0.512 . . . . 10.0 112.382 -176.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -118.91 -75.62 0.58 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 125.594 1.557 . . . . 10.0 109.619 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 p -111.16 13.64 21.83 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 120.419 1.463 . . . . 10.0 113.689 175.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.66 -21.2 11.5 Favored Glycine 0 C--N 1.338 0.674 0 O-C-N 120.819 -1.176 . . . . 10.0 115.455 168.265 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 90.74 28.02 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 128.183 2.593 . . . . 10.0 110.097 -168.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.18 -2.2 1.28 Allowed 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.767 0.827 . . . . 10.0 112.686 169.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.11 -171.84 55.16 Favored Glycine 0 N--CA 1.443 -0.867 0 N-CA-C 109.882 -1.287 . . . . 10.0 109.882 174.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -60.88 144.92 51.9 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.881 0.848 . . . . 10.0 112.153 -169.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mtm-85 -63.71 63.29 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 127.305 2.242 . . . . 10.0 110.806 169.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.46 -14.86 59.21 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.941 1.089 . . . . 10.0 113.941 -173.021 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.86 146.3 17.63 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 123.303 0.641 . . . . 10.0 109.738 169.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.0 p -155.07 156.48 35.95 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.79 -0.818 . . . . 10.0 108.79 -171.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.22 145.39 12.38 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.412 -1.075 . . . . 10.0 110.412 -169.152 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.86 140.85 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 125.903 1.681 . . . . 10.0 106.838 -172.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.8 mt -80.56 120.1 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-O 118.716 -0.659 . . . . 10.0 110.575 -174.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -128.51 154.37 20.01 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 124.263 0.935 . . . . 10.0 113.085 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 mm -64.75 146.21 13.37 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 C-N-CA 124.292 1.037 . . . . 10.0 112.254 -169.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.57 -17.47 1.73 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 116.231 1.937 . . . . 10.0 116.231 178.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.252 1.206 0 CA-C-O 117.693 -1.146 . . . . 10.0 110.683 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 108.383 -0.969 . . . . 10.0 108.383 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -170.13 -47.2 0.02 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 124.099 0.96 . . . . 10.0 109.785 178.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -138.51 125.76 21.59 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 125.256 1.422 . . . . 10.0 107.973 -169.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.02 162.58 35.09 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 124.545 1.138 . . . . 10.0 109.053 -172.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 m -115.74 172.94 3.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-O 121.611 0.719 . . . . 10.0 110.086 171.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.44 102.56 3.85 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 104.425 -2.435 . . . . 10.0 104.425 165.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 m -90.03 120.02 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 170.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.417 HD12 ' N ' ' B' ' 8' ' ' LEU . 4.8 mp -99.16 136.22 39.44 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 108.326 -0.99 . . . . 10.0 108.326 -177.011 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . 0.409 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 39.4 mtpt -145.45 160.26 41.86 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.659 -1.237 . . . . 10.0 107.659 169.392 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.07 -54.56 0.07 OUTLIER Glycine 0 N--CA 1.461 0.323 0 C-N-CA 120.522 -0.846 . . . . 10.0 113.669 169.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -72.06 -43.58 64.67 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 -174.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.84 -70.95 0.4 Allowed Glycine 0 CA--C 1.521 0.425 0 CA-C-N 114.223 -1.353 . . . . 10.0 109.86 169.656 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -57.62 -36.16 98.62 Favored 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 123.381 2.721 . . . . 10.0 111.389 172.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.95 101.69 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -117.79 106.91 13.52 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 124.633 1.173 . . . . 10.0 107.957 172.001 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.44 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -86.83 147.75 21.3 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 109.912 -1.275 . . . . 10.0 109.912 169.638 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 54' ' ' THR . 0.9 OUTLIER -149.56 76.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 N-CA-C 104.761 -2.311 . . . . 10.0 104.761 -175.851 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -97.44 146.15 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 124.744 1.218 . . . . 10.0 108.85 -178.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -126.11 125.17 42.1 Favored 'General case' 0 C--O 1.232 0.133 0 C-N-CA 126.669 1.988 . . . . 10.0 107.864 -175.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -112.69 105.57 13.76 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.406 1.482 . . . . 10.0 107.805 178.137 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -113.13 123.78 51.05 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 123.823 0.702 . . . . 10.0 111.486 175.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -95.18 97.78 10.15 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.332 1.453 . . . . 10.0 108.003 174.274 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? . . . . . 0 N--CA 1.448 -0.56 0 C-N-CA 126.275 1.83 . . . . 10.0 110.955 -175.001 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.852 0 N-CA-C 110.458 -1.057 . . . . 10.0 110.458 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.57 161.0 45.43 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.122 1.881 . . . . 10.0 109.073 171.487 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 14.1 t -87.44 112.28 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 N-CA-C 105.208 -2.145 . . . . 10.0 105.208 169.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -92.98 121.12 33.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.599 -1.63 . . . . 10.0 106.599 169.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.69 106.38 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.307 1.843 . . . . 10.0 106.495 177.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -127.64 152.87 47.13 Favored 'General case' 0 CA--C 1.522 -0.133 0 N-CA-C 113.461 0.912 . . . . 10.0 113.461 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.26 -150.31 21.54 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 108.2 -1.96 . . . . 10.0 108.2 172.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 22.6 t -155.14 158.31 38.79 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 119.598 -0.841 . . . . 10.0 112.299 -177.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.652 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -118.88 114.21 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 127.147 2.179 . . . . 10.0 108.76 169.806 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -100.27 142.87 31.16 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 168.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.43 -1.17 14.21 Favored Glycine 0 C--N 1.337 0.599 0 C-N-CA 124.597 1.094 . . . . 10.0 112.932 169.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 31.7 mt -80.78 175.98 10.21 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.875 0.845 . . . . 10.0 110.491 -178.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -93.11 150.77 20.28 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 68.9 tt0 -53.77 145.32 16.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.4 1.08 . . . . 10.0 110.824 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.4 -176.64 21.8 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.799 0.714 . . . . 10.0 111.882 176.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.8 mp -70.83 150.33 45.93 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.485 1.514 . . . . 10.0 111.87 -172.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -143.22 144.15 32.04 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 112.969 0.729 . . . . 10.0 112.969 178.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.515 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -37.19 115.82 0.34 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.405 2.431 . . . . 10.0 112.211 166.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.541 ' CZ ' HD12 ' B' ' 35' ' ' ILE . 2.0 m-85 -135.66 106.6 6.65 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.754 1.777 . . . . 10.0 110.592 172.179 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.75 171.35 18.37 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-N 115.376 -0.829 . . . . 10.0 109.885 178.142 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 12.3 m -99.93 147.16 7.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 112.952 -1.931 . . . . 10.0 107.106 167.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 22.7 m-70 -116.14 131.19 57.01 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 103.949 -2.612 . . . . 10.0 103.949 173.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -59.73 -48.78 80.32 Favored 'General case' 0 N--CA 1.45 -0.443 0 O-C-N 124.206 0.941 . . . . 10.0 111.643 -167.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.7 m-30 -80.01 148.28 31.18 Favored 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 118.386 -1.326 . . . . 10.0 108.324 175.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.72 35.89 4.29 Favored Glycine 0 N--CA 1.441 -1.021 0 N-CA-C 108.083 -2.007 . . . . 10.0 108.083 166.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.7 74.73 6.38 Favored 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 126.895 3.236 . . . . 10.0 107.318 171.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.479 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -76.63 -0.37 23.16 Favored 'General case' 0 N--CA 1.416 -2.133 0 CA-C-N 109.63 -3.441 . . . . 10.0 111.029 -173.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.657 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -32.08 -52.38 0.26 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 130.194 3.397 . . . . 10.0 112.932 175.526 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -21.97 47.45 Favored 'General case' 0 CA--C 1.529 0.147 0 N-CA-C 112.871 0.693 . . . . 10.0 112.871 -176.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.24 75.85 1.3 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -174.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 19.9 m 63.75 56.82 1.47 Allowed 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 123.716 0.806 . . . . 10.0 112.208 168.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -155.14 -58.19 0.1 Allowed 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 108.239 -1.023 . . . . 10.0 108.239 175.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.5 m -61.42 -26.63 67.99 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 122.376 0.27 . . . . 10.0 111.578 -173.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.02 -34.56 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.977 2.511 . . . . 10.0 112.734 168.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.97 155.97 9.24 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.144 -0.783 . . . . 10.0 111.144 166.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . 0.416 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 88.8 Cg_endo -75.92 58.83 5.6 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 123.566 2.844 . . . . 10.0 108.494 166.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.293 26.1 m170 75.2 -44.3 0.53 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 127.181 2.192 . . . . 10.0 109.519 -177.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . 0.416 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 2.8 m-85 51.61 47.62 24.45 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 126.461 1.904 . . . . 10.0 111.57 172.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -72.01 142.73 85.57 Favored Pre-proline 0 C--N 1.321 -0.638 0 C-N-CA 125.571 1.548 . . . . 10.0 112.987 178.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.92 -44.43 0.35 Allowed 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 123.623 2.882 . . . . 10.0 110.843 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 14.4 mt -68.96 88.13 0.38 Allowed 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.223 -1.399 . . . . 10.0 107.223 171.544 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -57.7 82.13 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.658 1.983 . . . . 10.0 111.25 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.68 -179.83 4.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 127.19 2.196 . . . . 10.0 108.126 177.588 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -111.1 107.89 17.41 Favored 'General case' 0 C--O 1.224 -0.244 0 N-CA-C 108.263 -1.014 . . . . 10.0 108.263 -177.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.522 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 83.1 t60 -12.09 98.23 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.439 0 C-N-CA 126.783 2.033 . . . . 10.0 113.892 -178.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.44 -175.54 14.11 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 106.916 -2.474 . . . . 10.0 106.916 176.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.32 -155.89 7.26 Favored Glycine 0 C--O 1.226 -0.376 0 N-CA-C 107.061 -2.416 . . . . 10.0 107.061 -177.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -67.22 1.45 2.95 Favored 'Trans proline' 0 CA--C 1.544 0.99 0 CA-C-N 119.69 1.745 . . . . 10.0 110.287 165.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 56.3 mmtt -89.8 -15.57 32.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.834 1.653 . . . . 10.0 110.416 171.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -133.81 178.53 6.87 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 119.832 1.196 . . . . 10.0 109.826 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -90.3 -32.41 16.53 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 169.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -95.14 43.52 1.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 122.299 1.047 . . . . 10.0 111.909 -169.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.58 144.31 17.72 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 115.849 -0.614 . . . . 10.0 110.48 168.47 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.522 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.2 m170 -68.95 -56.86 6.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 -173.175 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.4 p -173.74 -38.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 123.715 0.806 . . . . 10.0 111.429 -174.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -158.56 69.61 0.26 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 108.072 -2.011 . . . . 10.0 108.072 -169.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -122.92 94.4 4.26 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.401 -2.074 . . . . 10.0 105.401 -171.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 5.0 mt -72.07 -28.3 63.24 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . 0.412 ' CA ' HD11 ' B' ' 126' ' ' LEU . . . 88.39 -94.58 2.01 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 108.007 -2.037 . . . . 10.0 108.007 176.117 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -128.98 124.18 34.38 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.092 0.557 . . . . 10.0 110.531 -168.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.476 HG22 ' CD1' ' B' ' 45' ' ' PHE . 6.6 m -121.48 145.52 27.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.2 m -94.17 113.72 25.71 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 127.172 2.189 . . . . 10.0 111.97 -167.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.45 130.48 36.12 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 109.457 -0.571 . . . . 10.0 109.457 169.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -59.51 169.71 1.21 Allowed 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 125.098 1.359 . . . . 10.0 110.311 168.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.06 -32.29 34.03 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.035 1.334 . . . . 10.0 112.115 169.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -77.34 -1.4 29.75 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.3 0.64 . . . . 10.0 110.987 178.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.37 20.41 69.42 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 120.584 -1.323 . . . . 10.0 110.178 175.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.37 105.5 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 128.529 2.732 . . . . 10.0 106.604 -177.327 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.652 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -98.88 125.13 44.21 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 168.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 p-10 -88.52 122.7 32.27 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 127.052 2.141 . . . . 10.0 109.045 175.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 96.6 t -107.72 134.25 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 174.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.6 m -158.13 66.56 0.46 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.607 1.163 . . . . 10.0 109.695 169.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.59 156.07 5.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.277 -1.379 . . . . 10.0 107.277 -177.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -133.42 139.95 47.04 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.893 1.277 . . . . 10.0 109.946 175.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -147.29 159.14 44.01 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.071 -1.455 . . . . 10.0 107.071 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.66 14.49 4.04 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.423 1.889 . . . . 10.0 111.857 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -89.44 1.69 7.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 119.19 0.905 . . . . 10.0 109.523 169.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.465 HD13 ' H ' ' B' ' 104' ' ' ILE 0.264 0.0 OUTLIER -129.08 171.28 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 126.313 1.845 . . . . 10.0 111.612 -179.328 . . . . . . . . 4 4 . 1 . 012 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 6.2 m -163.56 147.13 10.31 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 107.462 -1.31 . . . . 10.0 107.462 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -62.38 -48.22 80.71 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 123.303 0.641 . . . . 10.0 109.706 -176.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.4 t . . . . . 0 N--CA 1.453 -0.296 0 C-N-CA 125.347 1.459 . . . . 10.0 107.469 169.66 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 22.3 t . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 115.809 1.781 . . . . 10.0 115.809 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 29.7 pt -71.67 -15.11 18.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 114.048 1.129 . . . . 10.0 114.048 -178.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.5 mm -46.51 127.65 2.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 CA-C-N 119.051 0.841 . . . . 10.0 110.173 172.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.27 -0.11 83.22 Favored Glycine 0 CA--C 1.532 1.137 0 CA-C-O 118.969 -0.906 . . . . 10.0 114.583 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -76.22 175.41 9.05 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 119.243 1.521 . . . . 10.0 108.507 169.402 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -121.7 125.99 47.9 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.362 0.665 . . . . 10.0 111.002 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -80.93 139.98 35.55 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 170.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 98.9 t -124.72 132.49 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 108.025 -1.102 . . . . 10.0 108.025 171.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.443 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 3.7 p -98.78 125.81 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.189 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 168.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.515 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.0 m170 -102.11 161.0 14.02 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 122.954 1.359 . . . . 10.0 114.022 -176.583 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . 0.574 ' HA ' HD22 ' B' ' 144' ' ' LEU . 62.7 tt0 -46.79 -56.73 5.76 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 128.031 2.532 . . . . 10.0 109.288 176.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -124.49 177.03 6.13 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.655 1.582 . . . . 10.0 110.355 -173.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.21 145.38 35.58 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 125.615 1.566 . . . . 10.0 110.401 176.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -85.38 157.39 20.53 Favored 'General case' 0 N--CA 1.457 -0.098 0 CA-C-O 121.392 0.615 . . . . 10.0 112.156 169.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -78.99 -11.31 60.0 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 115.078 -0.964 . . . . 10.0 111.278 174.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.412 HD11 ' CA ' ' B' ' 85' ' ' GLY . 3.8 mm? 52.93 57.04 6.76 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.887 1.275 . . . . 10.0 108.841 -174.202 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.93 -42.32 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 113.706 -1.588 . . . . 10.0 111.161 168.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.7 mtmt -80.53 42.57 0.61 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.684 0.794 . . . . 10.0 112.179 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -94.75 -20.04 30.03 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 127.922 2.677 . . . . 10.0 110.101 168.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.56 49.77 38.57 Favored Glycine 0 C--N 1.34 0.778 0 C-N-CA 124.314 0.959 . . . . 10.0 111.802 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -155.28 172.79 17.6 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 117.784 0.792 . . . . 10.0 108.875 176.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 8.6 tm-20 -52.19 -46.24 65.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 C-N-CA 123.351 0.66 . . . . 10.0 111.269 -177.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -70.06 -30.97 68.35 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.825 -0.607 . . . . 10.0 109.756 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.9 p -50.66 -41.36 55.43 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 119.287 0.949 . . . . 10.0 111.258 -177.706 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.7 t -86.91 -3.28 59.06 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 113.285 0.846 . . . . 10.0 113.285 -177.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 32.1 tttt -114.48 -57.26 2.29 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 127.424 2.29 . . . . 10.0 111.952 -166.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 6.1 p -132.31 7.19 4.21 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 118.453 -0.784 . . . . 10.0 111.041 168.184 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.23 -105.1 2.95 Favored Glycine 0 C--N 1.344 1.009 0 N-CA-C 108.91 -1.676 . . . . 10.0 108.91 -169.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.15 34.17 0.14 Allowed 'General case' 0 C--N 1.321 -0.65 0 O-C-N 121.095 -1.238 . . . . 10.0 108.342 177.453 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.63 -9.21 58.33 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.899 -1.046 . . . . 10.0 111.467 -169.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.31 -158.39 41.78 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 109.261 -1.535 . . . . 10.0 109.261 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.6 m -57.43 128.9 39.36 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-O 121.45 0.643 . . . . 10.0 109.822 -174.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.2 72.78 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 124.711 1.204 . . . . 10.0 111.132 169.463 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.574 HD22 ' HA ' ' B' ' 121' ' ' GLU . 10.0 tp -44.61 -38.0 3.99 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 128.036 2.535 . . . . 10.0 114.517 -174.303 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.443 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -162.32 158.98 24.9 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 178.515 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.8 165.29 36.63 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 122.471 -0.143 . . . . 10.0 110.906 -178.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.88 146.47 14.16 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 110.374 -1.091 . . . . 10.0 110.374 -172.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 64.4 t -100.46 138.76 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 N-CA-C 105.851 -1.907 . . . . 10.0 105.851 -174.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 38.5 mt -73.33 120.71 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 C-N-CA 122.524 0.33 . . . . 10.0 110.172 -173.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.56 134.35 10.85 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.095 1.331 . . . . 10.0 112.103 -172.482 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.71 137.0 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 125.604 1.562 . . . . 10.0 109.463 179.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.21 -48.15 1.1 Allowed 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 113.305 0.854 . . . . 10.0 113.305 -174.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 44.7 tt0 . . . . . 0 C--O 1.253 1.282 0 N-CA-C 108.782 -0.821 . . . . 10.0 108.782 -165.944 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 108.635 -0.876 . . . . 10.0 108.635 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.9 -6.77 55.44 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 118.52 0.6 . . . . 10.0 109.825 -174.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.93 156.66 42.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.028 0.531 . . . . 10.0 109.986 168.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.41 156.26 35.03 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 m -126.82 160.44 35.17 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 109.552 -0.536 . . . . 10.0 109.552 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.27 107.77 7.85 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 107.578 -1.268 . . . . 10.0 107.578 169.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.4 m -84.37 109.06 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 170.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mt -93.23 146.39 23.73 Favored 'General case' 0 C--O 1.224 -0.246 0 CA-C-O 117.97 -1.014 . . . . 10.0 108.434 -174.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.2 mtmt -164.78 158.93 18.04 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 120.081 1.31 . . . . 10.0 108.351 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.74 -51.05 0.1 OUTLIER Glycine 0 N--CA 1.461 0.365 0 C-N-CA 120.013 -1.089 . . . . 10.0 113.768 168.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -73.35 -44.17 59.27 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.975 -1.12 . . . . 10.0 107.975 -173.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.01 -71.44 0.35 Allowed Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 114.086 -1.416 . . . . 10.0 110.536 169.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -55.0 -39.91 88.55 Favored 'Trans proline' 0 N--CA 1.451 -1.028 0 C-N-CA 122.703 2.269 . . . . 10.0 110.72 172.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.739 HG13 HD12 ' A' ' 38' ' ' LEU . 97.7 t -58.52 112.91 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 C-N-CA 123.862 0.865 . . . . 10.0 109.83 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -131.0 109.23 10.37 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 122.752 0.421 . . . . 10.0 110.062 167.295 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.614 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -83.05 154.77 32.26 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.837 -0.905 . . . . 10.0 110.837 168.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.22 56.44 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 126.024 1.73 . . . . 10.0 106.858 -179.122 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.429 HD12 ' HA ' ' A' ' 18' ' ' ILE . 1.2 tp -67.25 145.46 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 O-C-N 121.473 -0.767 . . . . 10.0 109.494 -179.15 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -138.04 101.14 4.34 Favored 'General case' 0 CA--C 1.519 -0.22 0 C-N-CA 126.319 1.847 . . . . 10.0 109.429 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.441 ' CE1' ' HB ' ' A' ' 31' ' ' VAL . 15.7 m-30 -100.48 129.69 46.47 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.561 -1.274 . . . . 10.0 107.561 -177.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -129.38 152.22 49.18 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.574 0.749 . . . . 10.0 110.752 176.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -125.77 114.65 18.89 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.603 -1.629 . . . . 10.0 106.603 166.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 47.0 mmtt -61.34 -60.26 4.01 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 109.07 -0.715 . . . . 10.0 109.07 169.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -126.79 165.84 18.54 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.312 -2.107 . . . . 10.0 105.312 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.4 t -73.52 -10.96 60.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-O 121.516 0.674 . . . . 10.0 109.32 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.8 m120 -78.45 -19.65 52.7 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.194 0.998 . . . . 10.0 110.228 173.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.89 150.76 41.61 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.582 -1.007 . . . . 10.0 110.582 178.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -76.16 148.53 31.03 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 N-CA-C 106.078 -2.316 . . . . 10.0 106.078 166.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.6 t -75.22 100.13 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.9 mtpp -68.48 93.87 0.52 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 106.755 -1.572 . . . . 10.0 106.755 170.138 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.441 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 4.3 m -82.06 59.87 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 124.772 1.229 . . . . 10.0 108.853 -172.373 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -82.7 174.25 11.17 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 119.119 -1.032 . . . . 10.0 111.471 -168.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.11 -159.44 28.35 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.427 -1.469 . . . . 10.0 109.427 167.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 15.2 m -155.99 124.72 5.97 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 109.138 -0.69 . . . . 10.0 109.138 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.614 HG22 ' CA ' ' A' ' 16' ' ' GLY . 2.6 pt -93.1 143.5 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 106.505 -1.665 . . . . 10.0 106.505 165.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.16 119.1 17.37 Favored 'General case' 0 N--CA 1.45 -0.435 0 O-C-N 123.803 0.689 . . . . 10.0 110.91 171.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.27 14.24 1.81 Allowed Glycine 0 C--N 1.341 0.839 0 CA-C-O 118.849 -0.973 . . . . 10.0 114.967 168.37 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.739 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -97.03 179.49 4.92 Favored 'General case' 0 C--O 1.224 -0.269 0 CA-C-N 118.808 1.304 . . . . 10.0 108.397 174.245 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -75.55 174.26 9.93 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 119.6 -0.84 . . . . 10.0 110.885 170.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -63.85 177.29 0.77 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.078 1.751 . . . . 10.0 110.167 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.8 -174.35 40.89 Favored Glycine 0 N--CA 1.448 -0.55 0 O-C-N 121.32 -0.862 . . . . 10.0 112.987 167.323 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.08 147.77 49.59 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.672 1.189 . . . . 10.0 109.273 175.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -144.38 141.9 29.99 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 114.009 1.115 . . . . 10.0 114.009 -176.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.635 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -27.48 122.17 0.06 OUTLIER Glycine 0 C--N 1.343 0.925 0 C-N-CA 128.291 2.853 . . . . 10.0 114.0 166.427 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.75 107.06 3.13 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 119.575 1.687 . . . . 10.0 113.185 169.082 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.457 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -146.28 173.13 12.52 Favored 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 123.368 0.667 . . . . 10.0 110.903 178.505 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.0 t -89.97 -41.99 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 113.624 -1.625 . . . . 10.0 113.107 -168.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 61.29 157.56 0.04 OUTLIER 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 126.145 1.778 . . . . 10.0 114.24 -174.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -72.64 -64.89 0.87 Allowed 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 113.996 -1.456 . . . . 10.0 111.176 -177.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -77.79 149.76 34.4 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.025 0.441 . . . . 10.0 110.214 -173.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.18 -11.47 54.34 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.124 -1.591 . . . . 10.0 109.124 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.92 158.04 0.74 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.58 1.181 . . . . 10.0 111.992 171.601 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.534 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -151.17 28.78 0.66 Allowed 'General case' 0 N--CA 1.434 -1.262 0 CA-C-N 113.745 -1.571 . . . . 10.0 112.026 166.158 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.453 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.0 OUTLIER -59.12 -29.58 67.5 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 122.527 0.331 . . . . 10.0 110.425 173.643 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.56 -18.92 59.61 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 122.563 0.345 . . . . 10.0 111.302 176.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.42 82.08 0.27 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 110.923 -0.871 . . . . 10.0 110.923 -177.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m 33.56 58.18 0.53 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 127.499 2.32 . . . . 10.0 111.649 -177.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -136.06 -56.34 0.77 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 -170.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 t -126.3 43.78 3.01 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.015 -1.476 . . . . 10.0 107.015 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.82 65.15 1.34 Allowed 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 174.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.28 92.8 0.01 OUTLIER Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.816 1.198 . . . . 10.0 113.487 169.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -74.62 68.01 5.49 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 123.938 3.092 . . . . 10.0 113.374 -169.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.457 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 34.3 m170 65.34 77.13 0.31 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 128.52 2.728 . . . . 10.0 111.196 173.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -18.42 -60.72 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 128.504 2.722 . . . . 10.0 114.578 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.1 t30 4.49 86.55 0.04 OUTLIER Pre-proline 0 CA--C 1.54 0.577 0 C-N-CA 128.664 2.786 . . . . 10.0 114.676 -169.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -66.43 -35.9 28.9 Favored 'Trans proline' 0 N--CA 1.456 -0.701 0 C-N-CA 122.538 2.159 . . . . 10.0 111.551 -175.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.3 tt -74.25 66.74 1.32 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 108.181 -1.044 . . . . 10.0 108.181 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.7 t -31.86 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 127.467 2.307 . . . . 10.0 112.346 -174.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -131.06 170.0 15.11 Favored 'General case' 0 N--CA 1.444 -0.744 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -89.87 123.4 33.79 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 108.419 -0.956 . . . . 10.0 108.419 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 68.2 t60 -29.55 104.04 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 174.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.34 -170.33 12.68 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 108.503 -1.839 . . . . 10.0 108.503 176.036 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -135.08 -164.84 10.59 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-O 119.406 -0.664 . . . . 10.0 111.638 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -67.2 7.49 0.47 Allowed 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.042 1.828 . . . . 10.0 111.958 170.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -89.94 -29.27 18.61 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.787 -1.19 . . . . 10.0 107.787 169.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.67 177.69 4.57 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.396 1.079 . . . . 10.0 108.334 -168.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -110.99 -12.34 14.23 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.74 -1.118 . . . . 10.0 110.697 169.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -86.86 -0.67 56.87 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.051 0.94 . . . . 10.0 111.245 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -36.81 138.1 0.27 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 127.367 2.267 . . . . 10.0 112.217 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -82.13 60.86 5.11 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.073 -0.392 . . . . 10.0 110.05 -178.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.283 11.7 p 10.46 64.33 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 129.284 3.034 . . . . 10.0 114.507 -176.091 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.36 49.06 0.06 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 126.028 1.775 . . . . 10.0 109.583 -173.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -131.7 105.87 7.78 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 103.889 -2.634 . . . . 10.0 103.889 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -75.88 -13.32 60.26 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -166.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.37 -97.91 1.46 Allowed Glycine 0 C--O 1.219 -0.802 0 N-CA-C 108.006 -2.038 . . . . 10.0 108.006 -175.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -155.09 151.03 27.85 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 124.917 1.287 . . . . 10.0 108.599 -176.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.9 m -120.97 135.62 60.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 108.917 -0.771 . . . . 10.0 108.917 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -88.11 119.19 28.25 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 127.691 2.397 . . . . 10.0 110.594 -177.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.23 133.44 43.52 Favored 'General case' 0 CA--C 1.523 -0.095 0 C-N-CA 124.772 1.229 . . . . 10.0 111.064 176.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -61.02 169.57 1.93 Allowed 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.354 0.662 . . . . 10.0 110.146 168.243 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 -23.25 16.8 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.459 1.104 . . . . 10.0 112.898 170.055 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -17.69 60.8 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 110.29 -0.263 . . . . 10.0 110.29 177.215 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.8 13.89 66.14 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 110.524 -1.03 . . . . 10.0 110.524 -171.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.6 t -91.25 110.38 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.91 0 C-N-CA 126.973 2.109 . . . . 10.0 106.217 175.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.473 ' HB3' HG13 ' A' ' 35' ' ' ILE . . . -110.26 116.01 30.72 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 168.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -79.83 123.18 27.5 Favored 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 127.003 2.121 . . . . 10.0 108.09 171.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 29.6 t -108.41 129.06 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 106.86 -1.533 . . . . 10.0 106.86 178.39 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -155.97 64.09 0.58 Allowed 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.142 -1.058 . . . . 10.0 108.142 173.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 49.8 mt -102.13 153.47 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 N-CA-C 106.623 -1.621 . . . . 10.0 106.623 176.532 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -122.25 110.11 15.3 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.856 0.862 . . . . 10.0 110.75 176.246 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.23 129.18 37.25 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.212 1.005 . . . . 10.0 108.615 -177.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.2 t -119.05 44.83 2.23 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.134 0.974 . . . . 10.0 109.399 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -135.74 -43.09 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 124.05 0.94 . . . . 10.0 111.269 172.208 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.431 ' C ' HD12 ' A' ' 104' ' ' ILE 0.379 0.9 OUTLIER -87.46 161.01 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 CA-C-N 119.477 1.035 . . . . 10.0 111.956 169.948 . . . . . . . . 4 4 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.0 m -151.93 106.83 3.25 Favored 'General case' 0 C--N 1.341 0.214 0 C-N-CA 123.997 0.919 . . . . 10.0 109.413 -172.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 36.4 mt -37.79 -38.02 0.27 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.141 2.176 . . . . 10.0 115.326 -174.055 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 57.3 m -144.83 56.31 1.26 Allowed 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.229 -1.026 . . . . 10.0 108.229 170.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.32 -63.11 1.67 Allowed Glycine 0 C--N 1.335 0.483 0 N-CA-C 109.099 -1.6 . . . . 10.0 109.099 174.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -167.67 -53.38 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.434 1.894 . . . . 10.0 107.141 -178.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.61 -45.6 36.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.266 -1.334 . . . . 10.0 107.896 -173.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.0 t 53.77 173.64 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 125.844 1.658 . . . . 10.0 112.443 -175.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.7 pt -130.54 20.44 2.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 126.008 1.723 . . . . 10.0 108.961 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.9 mm -70.37 140.13 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.268 0.627 . . . . 10.0 109.593 169.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.37 32.42 84.12 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.298 0.952 . . . . 10.0 113.177 173.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -106.25 176.08 5.29 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.968 1.707 . . . . 10.0 107.919 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -124.52 108.52 12.2 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.285 -1.006 . . . . 10.0 108.285 -178.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.7 mp -80.75 138.18 36.29 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 107.36 -1.348 . . . . 10.0 107.36 177.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.406 HG12 ' CD2' ' A' ' 120' ' ' HIS . 64.5 t -117.62 129.59 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.975 0 N-CA-C 105.939 -1.875 . . . . 10.0 105.939 -178.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -99.35 110.35 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 102.851 -3.018 . . . . 10.0 102.851 169.455 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.635 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.4 m170 -91.41 156.66 17.57 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 122.591 1.186 . . . . 10.0 113.492 -170.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.59 -52.92 20.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 126.688 1.995 . . . . 10.0 109.957 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -110.1 170.85 7.81 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 124.183 0.993 . . . . 10.0 112.306 -172.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.22 140.9 57.44 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 114.113 -1.403 . . . . 10.0 109.3 173.089 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.522 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 0.0 OUTLIER -76.86 125.41 29.25 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 107.483 -1.302 . . . . 10.0 107.483 176.53 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -76.0 -9.74 58.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.761 0.425 . . . . 10.0 111.13 -177.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.6 mt 48.24 38.72 10.65 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.007 0.908 . . . . 10.0 109.924 -176.22 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.28 -15.29 63.6 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.707 1.622 . . . . 10.0 112.554 172.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ptpt -75.7 3.08 10.42 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.239 1.519 . . . . 10.0 112.716 -171.076 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.56 -22.13 76.48 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 169.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.1 35.9 50.49 Favored Glycine 0 CA--C 1.526 0.765 0 C-N-CA 123.89 0.757 . . . . 10.0 112.487 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -136.84 173.72 11.39 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 122.1 0.953 . . . . 10.0 110.058 175.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.6 tm-20 -46.08 -51.98 12.83 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.996 1.719 . . . . 10.0 111.221 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -73.05 -37.14 66.96 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.743 -0.598 . . . . 10.0 110.75 179.463 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -48.84 -43.5 38.67 Favored 'General case' 0 C--N 1.344 0.357 0 O-C-N 121.357 -0.84 . . . . 10.0 110.272 175.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -81.38 -5.3 57.73 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 119.147 -0.454 . . . . 10.0 111.65 -169.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.6 mtmt -114.15 -76.8 0.58 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.593 1.557 . . . . 10.0 110.726 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . 0.26 17.2 p -104.2 12.99 33.13 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 120.157 1.344 . . . . 10.0 113.042 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 28.9 69.12 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 119.351 0.978 . . . . 10.0 113.243 169.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 35.2 m120 49.57 21.25 0.59 Allowed 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 118.203 1.002 . . . . 10.0 113.003 -176.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 120' ' ' HIS . . . -70.75 -6.34 36.82 Favored 'General case' 0 C--O 1.221 -0.43 0 O-C-N 121.491 -0.756 . . . . 10.0 111.542 -171.348 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.45 162.71 15.05 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 109.919 -1.272 . . . . 10.0 109.919 174.431 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.6 t -81.41 58.78 3.76 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.688 0.795 . . . . 10.0 111.094 -169.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 45.72 58.81 4.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.311 1.445 . . . . 10.0 112.941 169.571 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.43 HD13 ' N ' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -69.15 -10.48 57.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 113.601 0.963 . . . . 10.0 113.601 -169.818 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.44 ' HB3' HG11 ' A' ' 14' ' ' VAL . . . -164.98 143.27 6.41 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.226 1.01 . . . . 10.0 108.584 172.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -157.01 166.3 33.72 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 122.83 0.452 . . . . 10.0 110.016 -172.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.53 158.25 29.7 Favored Glycine 0 C--N 1.332 0.34 0 N-CA-C 109.207 -1.557 . . . . 10.0 109.207 -178.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 30.5 t -105.91 137.5 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 106.823 -1.547 . . . . 10.0 106.823 -167.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.3 mt -75.85 125.35 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 118.161 0.437 . . . . 10.0 110.607 -176.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.06 149.52 18.13 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.59 1.09 . . . . 10.0 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.1 mt -56.35 137.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 124.305 1.042 . . . . 10.0 109.594 176.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.81 165.69 19.64 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 107.505 -1.295 . . . . 10.0 107.505 167.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 . . . . . 0 C--O 1.251 1.165 0 C-N-CA 124.997 1.319 . . . . 10.0 107.59 167.731 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 107.162 -1.421 . . . . 10.0 107.162 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.6 t -77.2 -48.52 17.39 Favored 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 119.137 0.88 . . . . 10.0 109.168 174.11 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.66 121.87 40.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 126.109 1.763 . . . . 10.0 107.441 -170.137 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -127.61 159.57 34.27 Favored 'General case' 0 CA--C 1.519 -0.249 0 C-N-CA 124.526 1.13 . . . . 10.0 109.239 177.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.1 t -117.41 156.15 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 123.761 0.824 . . . . 10.0 109.726 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.47 112.14 9.4 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.595 1.558 . . . . 10.0 108.514 169.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.534 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.7 OUTLIER -94.11 106.11 17.68 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 C-N-CA 122.857 0.463 . . . . 10.0 110.845 171.443 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.657 HD21 ' HB2' ' B' ' 117' ' ' LEU . 11.2 mt -86.82 127.67 35.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.396 1.079 . . . . 10.0 110.015 177.264 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -147.55 162.47 39.02 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.469 -1.308 . . . . 10.0 107.469 169.326 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.73 -53.71 0.08 OUTLIER Glycine 0 N--CA 1.461 0.303 0 C-N-CA 120.664 -0.779 . . . . 10.0 113.521 169.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -72.26 -44.04 63.43 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.461 -1.311 . . . . 10.0 107.461 -174.328 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.51 -70.88 0.4 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.149 -1.387 . . . . 10.0 110.073 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -57.34 -34.54 98.06 Favored 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 123.436 2.757 . . . . 10.0 111.366 172.078 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 73.8 t -64.58 109.78 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 108.386 -0.968 . . . . 10.0 108.386 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -129.03 118.21 22.17 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.33 1.052 . . . . 10.0 108.376 169.461 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.581 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -108.02 140.05 15.31 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 124.166 0.889 . . . . 10.0 111.373 173.113 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.453 ' CG2' HG22 ' A' ' 54' ' ' THR . 9.4 mt -137.03 72.41 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 N-CA-C 106.4 -1.704 . . . . 10.0 106.4 -169.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mm -95.55 138.55 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 115.749 -0.659 . . . . 10.0 109.74 -170.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -114.48 117.89 32.26 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.139 1.775 . . . . 10.0 108.338 -179.289 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -102.51 107.45 18.42 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.872 -1.159 . . . . 10.0 107.872 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -108.12 122.49 47.0 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 114.949 1.463 . . . . 10.0 114.949 173.568 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -82.52 115.61 21.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 101.715 -3.439 . . . . 10.0 101.715 162.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mtpm? . . . . . 0 N--CA 1.45 -0.455 0 N-CA-C 109.979 -0.378 . . . . 10.0 109.979 -178.644 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.894 0 N-CA-C 108.93 -1.668 . . . . 10.0 108.93 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -68.28 145.05 64.66 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 N-CA-C 108.131 -1.527 . . . . 10.0 108.131 169.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.78 108.67 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 N-CA-C 104.966 -2.235 . . . . 10.0 104.966 169.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.7 mtpp -90.2 113.56 25.37 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 169.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -101.64 111.26 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 106.977 -1.49 . . . . 10.0 106.977 179.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.1 p90 -126.38 167.63 15.28 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.323 0.582 . . . . 10.0 112.069 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.64 -151.37 23.12 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 107.159 -2.377 . . . . 10.0 107.159 169.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 33.5 t -155.18 158.72 39.38 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 120.222 -0.591 . . . . 10.0 110.222 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.581 HG22 ' CA ' ' B' ' 16' ' ' GLY . 1.5 pt -117.14 136.74 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 114.866 -1.061 . . . . 10.0 108.816 167.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 27.5 tptt -108.83 146.44 33.67 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 105.938 -1.875 . . . . 10.0 105.938 170.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.56 -7.07 39.07 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.421 -0.655 . . . . 10.0 113.71 169.524 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.07 175.04 2.22 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 118.348 1.074 . . . . 10.0 110.079 173.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -104.55 167.08 9.97 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 105.693 -1.965 . . . . 10.0 105.693 165.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 7.9 tm-20 -54.88 163.6 0.96 Allowed 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.904 0.881 . . . . 10.0 112.103 -169.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.36 -168.68 46.62 Favored Glycine 0 N--CA 1.445 -0.731 0 CA-C-O 122.012 0.785 . . . . 10.0 112.831 167.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -74.5 143.4 44.6 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.471 1.908 . . . . 10.0 110.606 -173.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -147.07 143.41 28.31 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 124.319 1.048 . . . . 10.0 112.27 -177.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.564 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -33.43 128.32 0.39 Allowed Glycine 0 C--N 1.339 0.73 0 C-N-CA 127.669 2.557 . . . . 10.0 112.351 168.279 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -149.74 110.86 4.38 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.09 -1.078 . . . . 10.0 108.09 166.74 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.04 170.82 16.93 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.437 0.637 . . . . 10.0 112.589 175.491 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 t -91.89 146.11 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 CA-C-N 112.143 -2.299 . . . . 10.0 106.966 169.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -129.41 147.1 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.29 1.436 . . . . 10.0 107.586 176.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.28 -68.06 0.22 Allowed 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.013 0.925 . . . . 10.0 110.6 -172.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -77.63 132.23 38.15 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.914 -1.143 . . . . 10.0 107.914 -169.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.07 -24.94 76.21 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 172.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.29 162.16 0.36 Allowed 'General case' 0 N--CA 1.447 -0.597 0 CA-C-O 123.031 1.396 . . . . 10.0 113.044 177.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.71 30.08 0.47 Allowed 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 114.185 -1.37 . . . . 10.0 111.759 172.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.4 -37.57 72.92 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.288 1.035 . . . . 10.0 112.535 -168.779 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.14 -21.17 54.53 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.014 0.525 . . . . 10.0 111.687 176.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.59 -155.83 16.06 Favored Glycine 0 N--CA 1.435 -1.372 0 N-CA-C 106.189 -2.765 . . . . 10.0 106.189 -166.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.43 54.33 0.44 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 127.214 2.206 . . . . 10.0 113.461 -168.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -161.24 -39.35 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 O-C-N 120.79 -1.194 . . . . 10.0 111.82 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 9.5 t -50.71 -30.28 13.43 Favored 'General case' 0 C--N 1.343 0.319 0 C-N-CA 124.307 1.043 . . . . 10.0 111.137 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.27 -36.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 127.247 2.219 . . . . 10.0 114.194 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.17 143.31 10.98 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 110.694 -0.962 . . . . 10.0 110.694 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -77.06 58.6 6.22 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 124.425 3.417 . . . . 10.0 112.882 -175.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.421 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 17.5 m170 61.0 48.85 6.16 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.738 2.415 . . . . 10.0 109.854 177.059 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -69.7 74.65 0.42 Allowed 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.931 0.872 . . . . 10.0 111.046 178.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -74.99 150.8 86.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 O-C-N 121.343 -0.848 . . . . 10.0 110.832 171.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -67.12 -45.11 4.21 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.631 2.221 . . . . 10.0 111.159 178.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.96 57.29 1.05 Allowed 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.53 0.732 . . . . 10.0 110.038 178.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 39.5 p -42.48 108.73 0.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.629 1.572 . . . . 10.0 110.935 -172.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 58.7 mtt180 -148.6 -172.08 4.01 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.792 -2.299 . . . . 10.0 104.792 -171.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -83.98 146.38 28.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 118.42 -1.312 . . . . 10.0 107.6 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -50.81 119.74 4.16 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 166.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.87 -134.66 4.34 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 108.103 -1.999 . . . . 10.0 108.103 177.051 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.53 -161.36 32.03 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 107.537 -2.225 . . . . 10.0 107.537 169.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -66.02 5.02 0.72 Allowed 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.519 1.479 . . . . 10.0 111.053 168.062 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.8 mtpm? -114.99 8.23 15.75 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.591 1.156 . . . . 10.0 111.412 172.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -126.04 169.16 13.03 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.018 -1.105 . . . . 10.0 108.018 165.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -89.45 -24.8 21.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.724 -0.843 . . . . 10.0 108.724 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -105.48 13.48 30.08 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 115.363 1.616 . . . . 10.0 115.363 -165.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -28.1 130.73 0.05 Allowed 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 127.547 2.339 . . . . 10.0 111.866 168.687 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -47.08 -68.38 0.2 Allowed 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.115 0.966 . . . . 10.0 110.83 -175.087 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.0 p -168.18 -50.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.193 0 N-CA-C 107.456 -1.313 . . . . 10.0 107.456 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.32 53.3 0.68 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.907 1.241 . . . . 10.0 110.504 179.279 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -91.84 92.91 8.58 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 105.817 -1.92 . . . . 10.0 105.817 169.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -73.67 -37.26 65.32 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.308 -1.738 . . . . 10.0 106.308 174.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.83 -104.28 2.73 Favored Glycine 0 N--CA 1.436 -1.328 0 N-CA-C 108.433 -1.867 . . . . 10.0 108.433 169.349 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -114.48 131.62 56.56 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.239 0.616 . . . . 10.0 110.191 -169.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -115.2 139.34 42.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 107.756 -1.202 . . . . 10.0 107.756 167.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -100.53 123.05 44.23 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 125.017 1.327 . . . . 10.0 110.244 -173.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.08 135.1 43.09 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 124.17 0.988 . . . . 10.0 110.514 179.331 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -58.99 168.8 1.18 Allowed 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.593 0.757 . . . . 10.0 110.213 167.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -50.58 -34.02 24.2 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.812 0.845 . . . . 10.0 110.767 169.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.0 t0 -79.37 0.71 28.03 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 120.859 0.361 . . . . 10.0 111.761 -178.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.25 13.83 82.36 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 120.733 -1.229 . . . . 10.0 110.695 177.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 45.2 t -89.73 103.33 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 C-N-CA 127.039 2.136 . . . . 10.0 106.29 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.548 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.66 120.92 41.1 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 168.23 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -81.45 117.64 22.05 Favored 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 126.479 1.911 . . . . 10.0 108.494 172.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 67.8 t -98.9 129.14 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.081 0 N-CA-C 106.553 -1.647 . . . . 10.0 106.553 175.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.8 p -157.91 68.29 0.5 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.678 0.791 . . . . 10.0 109.326 170.539 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.13 160.27 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.274 -1.75 . . . . 10.0 106.274 -177.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -135.7 148.01 48.72 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 121.755 -0.591 . . . . 10.0 111.055 169.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -133.14 160.98 35.65 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 125.408 1.483 . . . . 10.0 108.506 179.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.5 t -134.64 41.61 2.89 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.116 1.366 . . . . 10.0 111.933 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.8 p -132.43 -45.04 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 123.352 0.661 . . . . 10.0 110.315 167.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.06 154.16 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 121.843 0.83 . . . . 10.0 109.762 169.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.8 m -154.01 152.87 31.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.533 1.133 . . . . 10.0 108.458 168.477 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.87 -25.43 62.8 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.013 0.925 . . . . 10.0 110.137 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 16.2 t . . . . . 0 N--CA 1.453 -0.282 0 C-N-CA 124.456 1.102 . . . . 10.0 108.122 169.218 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t . . . . . 0 C--O 1.232 0.155 0 CA-C-O 121.484 0.659 . . . . 10.0 112.67 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 27.1 pt -63.17 -10.59 6.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 N-CA-C 113.984 1.105 . . . . 10.0 113.984 -169.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.7 mm -34.51 -45.71 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.271 0 C-N-CA 126.741 2.016 . . . . 10.0 114.833 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.78 14.43 57.53 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.363 0.982 . . . . 10.0 113.629 -173.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -90.68 175.89 6.86 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.688 1.195 . . . . 10.0 110.497 178.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -122.19 142.28 50.58 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 124.419 1.088 . . . . 10.0 109.747 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.657 ' HB2' HD21 ' B' ' 8' ' ' LEU . 1.7 mm? -101.5 154.96 18.37 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.248 -1.39 . . . . 10.0 107.248 168.032 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.11 137.54 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.064 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.465 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.5 OUTLIER -106.2 138.22 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.269 -2.123 . . . . 10.0 105.269 168.586 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.564 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.0 m170 -117.83 160.33 21.57 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 114.763 1.394 . . . . 10.0 114.763 -169.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 68.1 tt0 -45.19 -53.72 7.84 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.597 2.759 . . . . 10.0 109.949 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.5 mttt -124.52 175.35 7.21 Favored 'General case' 0 CA--C 1.518 -0.27 0 C-N-CA 125.286 1.434 . . . . 10.0 110.273 -170.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.28 139.03 35.67 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.513 0.725 . . . . 10.0 109.168 175.036 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -78.12 148.1 34.33 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 123.326 0.65 . . . . 10.0 110.484 169.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -78.1 10.12 3.18 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 124.986 1.314 . . . . 10.0 111.196 174.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 16.5 mt 46.16 41.27 8.4 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.223 1.409 . . . . 10.0 110.829 -179.073 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 104.59 -39.76 2.71 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 125.233 1.397 . . . . 10.0 112.538 177.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.5 ' HD3' ' H ' ' B' ' 128' ' ' LYS . 0.1 OUTLIER -79.9 37.34 0.36 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.176 1.39 . . . . 10.0 111.769 -167.64 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -95.57 -12.07 54.35 Favored Glycine 0 CA--C 1.523 0.564 0 C-N-CA 125.568 1.556 . . . . 10.0 111.671 177.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.99 38.18 23.88 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 123.892 0.758 . . . . 10.0 111.779 -175.369 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -124.75 155.58 39.09 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.3 tm-20 -52.58 -44.24 65.79 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 114.123 -1.399 . . . . 10.0 108.353 169.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -65.05 -40.01 94.11 Favored 'General case' 0 CA--C 1.541 0.606 0 O-C-N 121.608 -0.683 . . . . 10.0 112.049 171.056 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 9.1 p -57.2 -40.67 77.91 Favored 'General case' 0 C--N 1.347 0.467 0 CA-C-N 121.141 1.791 . . . . 10.0 111.249 -179.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.1 t -72.97 -18.27 61.38 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 119.953 -0.699 . . . . 10.0 112.515 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -103.74 -50.65 3.36 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.14 1.776 . . . . 10.0 112.799 -168.345 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.421 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 24.1 p -120.92 -10.92 9.02 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 118.584 -0.722 . . . . 10.0 112.896 171.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 92.94 -1.57 71.0 Favored Glycine 0 C--N 1.337 0.636 0 CA-C-O 118.784 -1.009 . . . . 10.0 112.388 -172.13 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 71.12 31.76 2.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.596 1.198 . . . . 10.0 111.297 177.388 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.11 6.32 2.24 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.43 1.092 . . . . 10.0 112.209 174.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.87 -162.38 53.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.279 -1.128 . . . . 10.0 110.279 172.045 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.3 m -56.83 129.16 40.2 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-O 121.571 0.7 . . . . 10.0 111.388 -168.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.62 73.73 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.881 1.273 . . . . 10.0 109.259 169.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -74.09 -12.71 60.68 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 113.79 1.033 . . . . 10.0 113.79 -169.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.465 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -160.98 144.45 13.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.09 0.471 . . . . 10.0 111.795 175.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -138.28 151.43 47.6 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 126.507 1.923 . . . . 10.0 108.327 -169.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . 0.521 ' N ' HD23 ' B' ' 8' ' ' LEU . . . -153.36 142.28 9.07 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 179.391 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.3 t -102.87 137.12 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 105.672 -1.973 . . . . 10.0 105.672 -175.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.524 HD11 HD21 ' B' ' 117' ' ' LEU . 5.5 mt -72.19 158.06 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 108.939 -0.763 . . . . 10.0 108.939 -179.144 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -166.97 154.84 25.55 Favored Glycine 0 CA--C 1.528 0.888 0 O-C-N 122.007 -0.433 . . . . 10.0 112.247 -173.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 92.1 mt -68.19 131.41 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 124.882 1.273 . . . . 10.0 109.432 -174.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.81 -12.24 1.13 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 115.993 1.849 . . . . 10.0 115.993 -173.159 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.274 0.0 OUTLIER . . . . . 0 C--O 1.254 1.3 0 C-N-CA 128.774 2.83 . . . . 10.0 116.471 -170.171 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.829 0 N-CA-C 108.03 -1.1 . . . . 10.0 108.03 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -155.99 -43.73 0.08 Allowed 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.525 0.602 . . . . 10.0 111.247 171.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -118.79 130.49 55.81 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 169.076 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.89 163.24 26.78 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.751 1.221 . . . . 10.0 108.422 176.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.498 ' CG1' ' HB2' ' B' ' 52' ' ' ASP . 2.0 m -143.24 163.71 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 118.235 0.471 . . . . 10.0 109.873 -177.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.5 110.43 6.83 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.707 1.254 . . . . 10.0 108.048 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.445 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.3 OUTLIER -82.61 119.88 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 N-CA-C 106.445 -1.687 . . . . 10.0 106.445 167.427 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.5 mt -98.52 135.51 39.97 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -157.54 159.72 37.45 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 120.564 1.529 . . . . 10.0 108.217 172.101 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 173.54 -40.32 0.14 Allowed Glycine 0 N--CA 1.461 0.304 0 C-N-CA 119.858 -1.163 . . . . 10.0 113.312 169.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -73.96 -47.3 38.44 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 107.589 -1.264 . . . . 10.0 107.589 -177.392 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.65 -73.08 0.31 Allowed Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.691 -1.364 . . . . 10.0 109.691 170.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -58.6 -39.6 81.35 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 123.126 2.551 . . . . 10.0 111.119 173.017 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.49 101.8 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 107.808 -1.182 . . . . 10.0 107.808 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -118.4 108.08 14.61 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 108.116 -1.068 . . . . 10.0 108.116 170.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.684 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -84.92 147.04 22.45 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 123.995 0.807 . . . . 10.0 111.556 169.008 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mt -140.72 82.2 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 N-CA-C 105.946 -1.872 . . . . 10.0 105.946 177.013 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.0 mm -89.92 138.96 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 C-N-CA 124.002 0.921 . . . . 10.0 108.956 177.161 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -130.47 126.65 37.46 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 125.693 1.597 . . . . 10.0 109.552 175.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -109.87 105.21 14.31 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.267 1.427 . . . . 10.0 109.368 177.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -86.26 134.32 33.77 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 120.034 -0.666 . . . . 10.0 110.81 167.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -135.07 82.84 1.98 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.642 2.377 . . . . 10.0 106.136 168.074 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.4 tttp -53.01 -51.03 62.97 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 125.793 1.637 . . . . 10.0 109.454 179.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 58.8 mt-10 -135.95 169.17 18.02 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 105.932 -1.877 . . . . 10.0 105.932 169.279 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.2 p -72.41 -10.0 59.24 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.992 -0.374 . . . . 10.0 109.992 170.098 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.5 m-80 -75.41 -24.79 57.17 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.519 -0.549 . . . . 10.0 109.519 170.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.33 129.0 9.3 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.29 -1.124 . . . . 10.0 110.29 -173.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -63.2 131.06 30.8 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 N-CA-C 105.957 -2.363 . . . . 10.0 105.957 168.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.2 t -78.0 107.88 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.154 -1.054 . . . . 10.0 108.154 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.62 96.39 3.55 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 170.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -83.6 106.61 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 N-CA-C 106.494 -1.669 . . . . 10.0 106.494 170.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.1 p90 -113.91 171.12 7.79 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.47 0.653 . . . . 10.0 109.901 172.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.94 170.11 41.09 Favored Glycine 0 N--CA 1.437 -1.256 0 C-N-CA 120.088 -1.053 . . . . 10.0 110.564 174.119 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.3 p -137.98 107.97 6.36 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.684 HG22 ' CA ' ' A' ' 16' ' ' GLY . 1.7 pt -90.8 145.22 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 167.383 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -140.05 147.58 40.54 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.37 -1.344 . . . . 10.0 107.37 175.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.25 -14.13 25.81 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.287 -0.729 . . . . 10.0 114.108 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.442 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.6 mp -74.27 179.48 4.49 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 118.692 1.246 . . . . 10.0 110.475 -179.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -95.97 169.02 10.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 165.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -58.21 168.29 1.09 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.981 1.312 . . . . 10.0 111.532 -172.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.93 -176.61 36.31 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-O 122.039 0.8 . . . . 10.0 112.671 167.349 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.65 142.49 51.6 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 124.539 1.136 . . . . 10.0 109.681 177.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -142.05 150.42 41.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 112.896 0.702 . . . . 10.0 112.896 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.613 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.78 123.85 1.21 Allowed Glycine 0 C--N 1.34 0.786 0 C-N-CA 127.382 2.42 . . . . 10.0 112.061 166.227 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -151.88 108.5 3.47 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 118.563 1.181 . . . . 10.0 108.997 168.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 174.59 12.21 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 120.876 0.37 . . . . 10.0 111.354 177.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 11.1 m -104.77 -18.38 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 O-C-N 125.658 1.849 . . . . 10.0 114.676 -168.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 57.29 175.76 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 125.322 1.449 . . . . 10.0 112.861 -177.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -72.62 -69.45 0.41 Allowed 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.561 -0.745 . . . . 10.0 109.855 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -92.02 176.92 6.33 Favored 'General case' 0 N--CA 1.454 -0.256 0 O-C-N 123.534 0.521 . . . . 10.0 111.279 -168.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.12 -22.75 11.36 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 125.477 1.513 . . . . 10.0 111.556 170.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -50.81 117.9 2.79 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-O 122.343 1.068 . . . . 10.0 111.935 -177.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -123.14 17.84 9.96 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.988 -1.006 . . . . 10.0 111.552 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -48.42 -41.77 30.2 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.176 1.79 . . . . 10.0 111.562 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.11 -21.62 46.38 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.225 1.01 . . . . 10.0 112.763 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.0 102.31 0.92 Allowed Glycine 0 CA--C 1.527 0.825 0 N-CA-C 108.392 -1.883 . . . . 10.0 108.392 -169.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.276 1.5 p 15.75 80.42 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 127.031 2.132 . . . . 10.0 113.819 -173.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -161.38 -54.99 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 107.541 -1.281 . . . . 10.0 107.541 179.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -65.59 -31.38 72.38 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 123.8 0.84 . . . . 10.0 110.99 -177.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.97 -6.76 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 129.024 2.93 . . . . 10.0 118.012 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.36 123.26 3.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.212 -1.155 . . . . 10.0 110.212 176.183 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.7 60.49 6.67 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.582 2.855 . . . . 10.0 110.765 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.7 m170 72.12 38.28 0.9 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 129.716 3.206 . . . . 10.0 112.584 172.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -74.53 67.94 1.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.386 0.994 . . . . 10.0 111.671 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.7 p-10 -58.97 154.71 36.92 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 123.947 0.899 . . . . 10.0 111.108 169.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.36 -46.15 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 122.656 2.238 . . . . 10.0 111.602 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 86.8 mt -75.53 59.79 1.15 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.266 0.627 . . . . 10.0 109.696 176.134 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -45.95 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.771 1.628 . . . . 10.0 111.558 -171.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -132.21 -176.54 4.11 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 107.237 -1.394 . . . . 10.0 107.237 -176.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.412 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 24.2 mttp -93.78 123.74 37.33 Favored 'General case' 0 N--CA 1.438 -1.068 0 C-N-CA 118.224 -1.39 . . . . 10.0 108.622 -169.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.432 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 85.9 t60 -35.2 112.53 0.16 Allowed 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 113.316 0.858 . . . . 10.0 113.316 178.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.03 -136.98 4.33 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 108.058 -2.017 . . . . 10.0 108.058 -178.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.06 -168.77 30.66 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 173.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -63.26 -2.8 4.25 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.025 1.817 . . . . 10.0 111.603 168.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -94.97 -19.92 19.81 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.265 1.026 . . . . 10.0 110.746 173.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -103.11 167.58 9.73 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -86.49 -31.99 21.02 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 107.322 -1.362 . . . . 10.0 107.322 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.412 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS 0.257 7.1 pt-20 -100.49 24.55 8.78 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 114.435 1.272 . . . . 10.0 114.435 -165.525 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.5 ptm180 -42.83 145.3 0.48 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 127.218 2.207 . . . . 10.0 110.346 168.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.432 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 30.9 m170 -67.61 -64.58 0.83 Allowed 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.52 0.676 . . . . 10.0 109.66 178.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.62 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.5 p -169.33 -91.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 105.472 -2.048 . . . . 10.0 105.472 173.358 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.62 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -80.51 56.32 4.7 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 111.04 -0.824 . . . . 10.0 111.04 174.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -90.9 83.16 5.64 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 103.342 -2.836 . . . . 10.0 103.342 166.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -65.26 -26.45 68.1 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 118.391 0.541 . . . . 10.0 109.821 -173.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 114.41 -89.08 0.5 Allowed Glycine 0 N--CA 1.44 -1.044 0 N-CA-C 108.082 -2.007 . . . . 10.0 108.082 169.428 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -155.52 124.82 6.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 -171.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.39 125.89 66.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 118.193 0.452 . . . . 10.0 110.84 178.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -78.82 112.01 15.54 Favored 'General case' 0 N--CA 1.444 -0.761 0 C-N-CA 127.554 2.341 . . . . 10.0 111.116 -177.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.74 134.79 34.16 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.863 0.465 . . . . 10.0 109.938 171.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -60.1 172.27 0.83 Allowed 'General case' 0 C--O 1.232 0.154 0 O-C-N 123.82 0.7 . . . . 10.0 109.441 168.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.5 pttm -48.67 -33.2 9.59 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.745 1.618 . . . . 10.0 109.793 173.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -79.1 -8.19 58.77 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 124.486 1.115 . . . . 10.0 110.812 -173.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.02 -0.26 86.01 Favored Glycine 0 C--N 1.338 0.678 0 N-CA-C 111.234 -0.746 . . . . 10.0 111.234 -174.247 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.5 t -78.43 105.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 106.776 -1.564 . . . . 10.0 106.776 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.53 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -106.23 117.47 34.12 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 169.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -80.37 118.05 21.67 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 127.123 2.169 . . . . 10.0 108.892 172.481 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.2 t -108.32 131.0 59.98 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.964 0 N-CA-C 106.862 -1.532 . . . . 10.0 106.862 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.2 p -157.36 86.81 0.95 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.455 0.702 . . . . 10.0 109.49 171.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.99 143.09 28.11 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 N-CA-C 107.991 -1.115 . . . . 10.0 107.991 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -111.61 129.5 56.06 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.816 -1.92 . . . . 10.0 105.816 167.069 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -140.54 117.69 11.26 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.5 p -87.15 49.42 1.81 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.891 1.676 . . . . 10.0 108.256 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 p -145.24 -51.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.478 -0.783 . . . . 10.0 109.433 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -51.11 132.36 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 122.926 0.49 . . . . 10.0 110.016 175.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.9 p -131.92 136.12 47.14 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.214 1.406 . . . . 10.0 108.551 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 50.1 mt -56.63 -42.69 79.3 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 169.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.8 t -146.07 128.88 16.3 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 149.54 69.4 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.771 -1.332 . . . . 10.0 109.771 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.7 t70 72.41 -60.25 0.53 Allowed 'General case' 0 CA--C 1.509 -0.633 0 C-N-CA 129.742 3.217 . . . . 10.0 109.482 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.7 m-70 -74.19 -44.71 52.3 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t 54.96 82.05 0.1 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.051 1.34 . . . . 10.0 111.714 173.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.5 pt -71.65 -18.16 19.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 O-C-N 120.999 -1.063 . . . . 10.0 112.699 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 16.2 mm -52.65 129.89 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 118.202 0.456 . . . . 10.0 110.156 172.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.58 22.57 77.06 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.684 -1.064 . . . . 10.0 113.644 175.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.9 mtt85 -89.08 175.75 7.26 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 118.235 1.018 . . . . 10.0 110.602 167.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -118.47 110.63 17.64 Favored 'General case' 0 C--N 1.347 0.486 0 N-CA-C 106.844 -1.539 . . . . 10.0 106.844 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mp -87.18 138.88 31.11 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.548 -0.908 . . . . 10.0 108.548 176.313 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 49.1 t -132.04 132.34 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.615 -1.254 . . . . 10.0 107.615 -173.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.487 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.5 OUTLIER -105.67 128.11 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 106.081 -1.822 . . . . 10.0 106.081 174.806 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.613 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.6 m170 -111.78 157.55 20.42 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 114.554 1.316 . . . . 10.0 114.554 -171.434 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -46.64 -59.52 2.97 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 127.572 2.349 . . . . 10.0 110.488 176.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 51.3 mttp -112.21 169.86 8.57 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.702 0.763 . . . . 10.0 112.042 -170.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.5 151.08 47.95 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 114.034 -1.439 . . . . 10.0 109.291 172.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -77.03 150.04 35.81 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 122.296 1.046 . . . . 10.0 110.944 172.649 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.476 ' HB3' ' CA ' ' A' ' 138' ' ' GLY . 4.4 t70 -79.04 -37.75 38.26 Favored 'General case' 0 N--CA 1.443 -0.824 0 C-N-CA 130.103 3.361 . . . . 10.0 110.596 172.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 48.5 mt 63.53 46.53 4.2 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.924 1.29 . . . . 10.0 111.656 178.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 79.64 10.24 86.0 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-N 115.23 -0.895 . . . . 10.0 114.703 167.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 26.8 mttm -97.06 -11.81 23.98 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 117.999 0.899 . . . . 10.0 112.18 -174.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.98 -21.45 69.68 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 125.124 1.345 . . . . 10.0 112.384 176.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.08 35.75 65.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.247 -0.741 . . . . 10.0 111.247 -177.215 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -129.89 169.94 14.56 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 173.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -52.43 -48.0 66.03 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 123.654 0.781 . . . . 10.0 109.628 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -58.98 -45.5 90.41 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 118.669 -0.682 . . . . 10.0 111.712 175.731 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.9 p -49.87 -43.59 49.32 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 109.206 -0.665 . . . . 10.0 109.206 177.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.1 t -84.3 -3.56 58.32 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -174.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 92.5 mttt -110.71 -69.58 0.86 Allowed 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.692 1.597 . . . . 10.0 111.85 -179.201 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -127.3 28.91 5.64 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 119.437 1.017 . . . . 10.0 109.935 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.476 ' CA ' ' HB3' ' A' ' 125' ' ' ASP . . . 66.84 -105.31 1.29 Allowed Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 107.519 -2.232 . . . . 10.0 107.519 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -157.3 42.6 0.33 Allowed 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 107.059 -1.46 . . . . 10.0 107.059 169.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.84 -12.38 53.87 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.606 0.762 . . . . 10.0 111.616 -175.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.81 -158.7 48.81 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.618 -1.393 . . . . 10.0 109.618 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.0 m -61.76 129.27 40.2 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 123.129 0.572 . . . . 10.0 111.599 -169.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -59.03 92.03 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.991 0.916 . . . . 10.0 109.661 169.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.4 mt -64.44 -41.58 96.49 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.444 -0.785 . . . . 10.0 111.309 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.487 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -152.0 148.89 28.26 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.731 0.301 . . . . 10.0 110.391 -172.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -124.24 146.68 48.58 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.679 1.591 . . . . 10.0 107.801 -169.426 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.85 156.65 27.03 Favored Glycine 0 CA--C 1.52 0.362 0 N-CA-C 108.545 -1.822 . . . . 10.0 108.545 168.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.8 t -119.69 134.91 61.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 -175.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.1 mt -75.66 138.44 20.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 CA-C-N 118.679 0.672 . . . . 10.0 111.014 -177.005 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -150.55 172.7 30.27 Favored Glycine 0 CA--C 1.53 0.984 0 N-CA-C 112.313 -0.315 . . . . 10.0 112.313 170.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 64.7 mt -72.79 142.4 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 125.194 1.397 . . . . 10.0 109.08 -169.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.421 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . . . -119.98 -48.22 2.36 Favored 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 123.4 0.68 . . . . 10.0 111.301 172.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 . . . . . 0 C--O 1.248 1.009 0 CA-C-O 116.685 -1.626 . . . . 10.0 110.026 -167.969 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.694 0 N-CA-C 105.631 -1.989 . . . . 10.0 105.631 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.24 76.88 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 120.055 1.298 . . . . 10.0 108.278 168.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.37 158.0 32.09 Favored 'General case' 0 C--O 1.242 0.667 0 C-N-CA 124.481 1.112 . . . . 10.0 109.576 168.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.14 158.51 41.93 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 127.04 2.136 . . . . 10.0 106.078 169.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 m -111.44 178.67 1.25 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 CA-C-N 118.365 0.53 . . . . 10.0 109.601 174.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.24 101.63 2.4 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 165.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.417 HG12 HG23 ' B' ' 17' ' ' ILE . 32.2 m -92.33 130.75 40.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 N-CA-C 107.863 -1.162 . . . . 10.0 107.863 172.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.448 HD12 ' N ' ' B' ' 8' ' ' LEU . 5.1 mp -110.05 155.7 21.51 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.32 1.048 . . . . 10.0 108.641 176.175 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.0 tttt -164.2 167.99 19.41 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 169.107 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.2 -48.42 0.1 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.047 -1.549 . . . . 10.0 112.29 168.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -76.08 -46.63 28.04 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 107.893 -1.151 . . . . 10.0 107.893 -177.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.76 -67.2 0.52 Allowed Glycine 0 CA--C 1.526 0.775 0 CA-C-N 114.483 -1.235 . . . . 10.0 110.604 178.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -62.5 -36.2 66.84 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 122.794 2.329 . . . . 10.0 110.68 171.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 89.2 t -72.82 113.91 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.93 134.13 27.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.764 -0.458 . . . . 10.0 109.764 166.199 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.52 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -101.96 154.38 18.71 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 124.635 1.112 . . . . 10.0 111.269 175.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.417 HG23 HG12 ' B' ' 7' ' ' VAL . 0.1 OUTLIER -153.31 81.5 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 -172.878 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -105.67 151.96 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 C-N-CA 125.216 1.407 . . . . 10.0 109.657 -175.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -126.17 118.4 25.13 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 127.199 2.199 . . . . 10.0 107.295 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -98.41 116.46 30.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 170.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -117.25 125.61 51.41 Favored 'General case' 0 N--CA 1.465 0.308 0 O-C-N 123.716 0.635 . . . . 10.0 112.61 169.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -81.34 106.49 13.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.404 -2.072 . . . . 10.0 105.404 169.079 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.0 tttt . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 124.869 1.268 . . . . 10.0 109.214 -171.497 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.995 0 N-CA-C 109.593 -1.403 . . . . 10.0 109.593 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -59.61 140.96 96.23 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.451 2.101 . . . . 10.0 108.292 174.085 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 p -79.89 103.56 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.537 0 N-CA-C 106.482 -1.673 . . . . 10.0 106.482 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.1 tttp -80.13 122.16 26.46 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 172.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.13 100.47 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 C-N-CA 127.566 2.346 . . . . 10.0 105.726 -178.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.8 p90 -125.56 155.71 40.24 Favored 'General case' 0 C--N 1.339 0.149 0 N-CA-C 112.986 0.735 . . . . 10.0 112.986 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.34 -145.86 13.68 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 106.383 -2.687 . . . . 10.0 106.383 173.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.5 p -157.35 168.16 28.18 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 118.798 -1.161 . . . . 10.0 111.998 177.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.613 HG12 ' HB3' ' B' ' 95' ' ' ALA . 1.8 pt -117.72 146.46 22.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 114.379 -1.282 . . . . 10.0 109.44 166.678 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.7 tptt -115.11 146.51 41.27 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 106.464 -1.68 . . . . 10.0 106.464 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.96 -10.1 37.27 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-O 119.538 -0.59 . . . . 10.0 114.073 168.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -62.0 174.45 0.87 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 118.181 0.99 . . . . 10.0 110.561 175.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -108.72 160.7 15.75 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 106.595 -1.631 . . . . 10.0 106.595 167.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -53.72 150.57 7.12 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.61 0.764 . . . . 10.0 111.962 -169.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.51 -172.64 23.19 Favored Glycine 0 CA--C 1.524 0.629 0 C-N-CA 123.496 0.569 . . . . 10.0 111.922 169.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -74.95 149.93 39.23 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.272 1.429 . . . . 10.0 111.594 -173.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -150.97 143.62 24.4 Favored 'General case' 0 C--N 1.342 0.24 0 N-CA-C 113.912 1.079 . . . . 10.0 113.912 -175.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.557 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -31.72 126.21 0.23 Allowed Glycine 0 C--N 1.341 0.808 0 C-N-CA 128.247 2.832 . . . . 10.0 112.38 166.019 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.464 ' CE1' HD12 ' B' ' 117' ' ' LEU . 0.1 OUTLIER -147.32 107.62 4.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 119.646 1.723 . . . . 10.0 109.887 167.303 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 176.54 9.75 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 109.718 -0.475 . . . . 10.0 109.718 174.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . 0.466 HG12 HD13 ' B' ' 117' ' ' LEU . 2.4 m -117.71 -15.48 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 125.134 1.521 . . . . 10.0 113.662 -173.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 58.15 171.7 0.05 Allowed 'General case' 0 C--N 1.345 0.412 0 CA-C-O 122.437 1.113 . . . . 10.0 111.661 175.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -72.37 -59.39 2.75 Favored 'General case' 0 N--CA 1.441 -0.885 0 O-C-N 121.507 -0.746 . . . . 10.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -87.04 156.62 19.68 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 121.831 -0.543 . . . . 10.0 109.546 -171.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.72 14.42 29.53 Favored Glycine 0 CA--C 1.524 0.62 0 C-N-CA 125.179 1.371 . . . . 10.0 110.754 177.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.498 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . 0.1 OUTLIER -93.77 175.23 6.81 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 121.918 0.866 . . . . 10.0 110.03 179.839 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.445 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -151.81 33.02 0.55 Allowed 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.055 -0.975 . . . . 10.0 111.165 169.241 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.23 -37.2 79.6 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.593 -0.692 . . . . 10.0 112.763 -168.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.57 -20.55 46.73 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 117.766 0.257 . . . . 10.0 111.146 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 123.72 -157.59 18.17 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 105.727 -2.949 . . . . 10.0 105.727 -167.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 2.8 t -65.27 7.72 0.19 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.06 1.744 . . . . 10.0 115.189 -169.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 62.2 m -97.74 -49.09 4.96 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 125.93 1.692 . . . . 10.0 108.544 -171.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.1 m -47.41 -39.96 16.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 126.326 1.85 . . . . 10.0 113.061 -166.482 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.89 -39.92 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 128.067 2.547 . . . . 10.0 113.929 168.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.3 162.84 15.23 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 121.44 -0.787 . . . . 10.0 111.951 167.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -86.7 37.94 0.54 Allowed 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.375 2.717 . . . . 10.0 111.885 -172.418 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 71.31 116.38 0.05 OUTLIER 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.38 2.272 . . . . 10.0 110.834 -170.271 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' B' ' 64' ' ' PHE . 0.0 OUTLIER -33.8 94.06 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 127.089 2.156 . . . . 10.0 113.268 165.922 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -105.69 32.71 0.05 OUTLIER Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 116.948 2.203 . . . . 10.0 116.948 -177.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -62.82 -55.88 0.73 Allowed 'Trans proline' 0 C--N 1.35 0.658 0 CA-C-N 122.951 2.09 . . . . 10.0 112.585 -172.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.03 41.88 0.45 Allowed 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.236 -0.915 . . . . 10.0 112.86 -176.308 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 88.0 p 17.41 69.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 128.48 2.712 . . . . 10.0 114.868 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.72 149.17 43.64 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 105.801 -1.926 . . . . 10.0 105.801 172.634 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 30.6 mttm -101.64 106.23 17.26 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 118.746 -0.645 . . . . 10.0 109.637 -168.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -2.33 87.46 0.0 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 126.596 1.959 . . . . 10.0 115.193 -178.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.49 -135.33 8.72 Favored Glycine 0 C--N 1.318 -0.465 0 N-CA-C 109.045 -1.622 . . . . 10.0 109.045 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.68 -168.82 37.88 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 107.467 -2.253 . . . . 10.0 107.467 173.039 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -65.25 -0.72 3.7 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 CA-C-N 119.561 1.68 . . . . 10.0 110.749 167.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.7 mtpm? -109.24 6.79 24.96 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 125.924 1.689 . . . . 10.0 111.0 175.476 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.99 174.14 10.95 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 165.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.3 -37.01 38.76 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.1 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -81.71 28.59 0.41 Allowed 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 125.433 1.493 . . . . 10.0 114.626 -165.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.67 134.89 41.61 Favored 'General case' 0 N--CA 1.456 -0.141 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 168.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -56.17 -66.43 0.43 Allowed 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.664 -0.495 . . . . 10.0 109.664 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 3.9 p -169.23 -46.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 O-C-N 124.262 0.976 . . . . 10.0 109.132 -176.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.79 53.67 0.79 Allowed Glycine 0 CA--C 1.536 1.379 0 CA-C-N 118.909 0.777 . . . . 10.0 111.865 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -89.38 99.35 12.36 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.655 -1.239 . . . . 10.0 107.655 172.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -70.49 -40.96 73.29 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.289 -1.375 . . . . 10.0 107.289 174.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.02 -93.42 1.03 Allowed Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 124.409 1.004 . . . . 10.0 112.266 168.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -127.66 123.69 36.14 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 123.779 0.832 . . . . 10.0 109.992 -168.06 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.3 m -119.95 150.31 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 N-CA-C 108.536 -0.913 . . . . 10.0 108.536 167.222 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -98.24 125.34 43.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.859 1.663 . . . . 10.0 109.204 -177.285 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.27 134.45 38.03 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 108.804 -0.813 . . . . 10.0 108.804 171.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.8 t0 -62.05 170.1 2.35 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 124.188 0.93 . . . . 10.0 109.565 167.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 9.4 pttm -52.19 -31.26 30.9 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 125.213 1.405 . . . . 10.0 111.246 173.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -81.91 -1.76 48.97 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.218 0.607 . . . . 10.0 111.386 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.37 9.32 86.65 Favored Glycine 0 C--N 1.339 0.717 0 O-C-N 120.787 -1.195 . . . . 10.0 111.216 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.3 t -80.62 106.11 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 126.2 1.8 . . . . 10.0 106.32 172.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.613 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -107.39 120.15 41.36 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.096 -1.076 . . . . 10.0 108.096 169.119 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -80.96 125.5 30.22 Favored 'General case' 0 N--CA 1.437 -1.112 0 C-N-CA 127.233 2.213 . . . . 10.0 109.762 176.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.2 t -111.03 133.71 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.957 0 C-N-CA 125.645 1.578 . . . . 10.0 108.105 175.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 96.9 p -157.63 57.61 0.49 Allowed 'General case' 0 C--O 1.235 0.303 0 C-N-CA 123.141 0.576 . . . . 10.0 111.207 169.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -93.38 144.52 9.3 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.287 0 N-CA-C 107.395 -1.335 . . . . 10.0 107.395 -172.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -90.98 128.13 36.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 167.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -107.06 100.93 10.38 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.278 -1.749 . . . . 10.0 106.278 166.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.77 24.14 4.33 Favored 'General case' 0 N--CA 1.44 -0.957 0 C-N-CA 126.688 1.995 . . . . 10.0 109.948 176.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 38.9 t -120.74 -55.86 3.31 Favored 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 -178.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.348 0.6 OUTLIER -94.3 178.03 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 C-N-CA 123.839 0.856 . . . . 10.0 113.266 -179.039 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 27.1 m -155.4 161.4 41.02 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 123.785 0.834 . . . . 10.0 110.109 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 92.5 mt -81.25 3.92 22.25 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 125.721 1.608 . . . . 10.0 112.456 -175.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 107.845 -1.168 . . . . 10.0 107.845 168.937 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 42.3 t . . . . . 0 N--CA 1.442 -0.868 0 N-CA-C 110.503 -0.184 . . . . 10.0 110.503 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 1.3 pt -79.04 57.53 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 122.372 1.082 . . . . 10.0 110.806 -171.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 19.4 mm -96.21 -37.8 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 C-N-CA 127.725 2.41 . . . . 10.0 110.474 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.75 49.92 0.81 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.563 -1.015 . . . . 10.0 110.563 -175.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.57 169.52 8.65 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.864 2.065 . . . . 10.0 108.746 175.108 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -122.91 103.37 8.57 Favored 'General case' 0 C--N 1.344 0.353 0 C-N-CA 124.837 1.255 . . . . 10.0 109.955 -177.026 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.466 HD13 HG12 ' B' ' 47' ' ' VAL . 1.1 mm? -61.85 134.57 56.86 Favored 'General case' 0 CA--C 1.52 -0.183 0 N-CA-C 108.152 -1.055 . . . . 10.0 108.152 169.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.45 132.78 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 107.924 -1.139 . . . . 10.0 107.924 176.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 m -108.27 134.43 50.15 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 O-C-N 124.282 0.989 . . . . 10.0 110.366 167.415 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.557 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.3 m170 -110.54 158.0 19.03 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -171.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -40.22 -57.18 1.77 Allowed 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 129.272 3.029 . . . . 10.0 111.192 173.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 mttm -123.85 175.18 7.06 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.902 1.281 . . . . 10.0 109.495 -175.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.17 149.56 33.72 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.766 0.826 . . . . 10.0 109.708 175.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -74.92 152.84 38.81 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.78 -1.193 . . . . 10.0 107.78 168.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -76.15 -5.79 48.28 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 124.591 1.182 . . . . 10.0 110.719 171.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 50.5 mt 51.03 58.15 5.87 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 124.32 1.048 . . . . 10.0 108.798 -177.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.42 -39.44 3.12 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 124.93 1.252 . . . . 10.0 111.261 169.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.8 mtmt -79.13 47.19 0.76 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.211 1.004 . . . . 10.0 111.373 -178.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.57 -22.31 10.48 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 126.891 2.186 . . . . 10.0 111.298 174.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.18 44.41 43.06 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.055 0.836 . . . . 10.0 112.784 176.58 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -151.49 172.84 15.35 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 108.797 -0.816 . . . . 10.0 108.797 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -51.75 -41.53 61.65 Favored 'General case' 0 N--CA 1.445 -0.72 0 C-N-CA 122.96 0.504 . . . . 10.0 111.652 -176.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -71.59 -25.0 62.0 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.33 -0.856 . . . . 10.0 111.891 178.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 36.8 p -59.96 -20.8 59.54 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 113.61 0.967 . . . . 10.0 113.61 -177.136 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.4 t -94.75 -12.81 26.47 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.622 0.646 . . . . 10.0 110.258 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -109.32 -65.96 1.1 Allowed 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 126.7 2.0 . . . . 10.0 111.514 -171.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.02 31.4 3.87 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 120.266 1.394 . . . . 10.0 110.857 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 65.04 -93.57 0.16 Allowed Glycine 0 C--N 1.343 0.933 0 N-CA-C 108.859 -1.696 . . . . 10.0 108.859 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -164.43 39.73 0.08 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.709 1.204 . . . . 10.0 108.402 167.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.04 -11.84 58.21 Favored 'General case' 0 N--CA 1.456 -0.167 0 N-CA-C 113.637 0.977 . . . . 10.0 113.637 -168.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.44 -165.22 53.64 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.427 -1.069 . . . . 10.0 110.427 177.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.3 t -57.02 130.9 48.1 Favored 'General case' 0 N--CA 1.447 -0.611 0 C-N-CA 123.812 0.845 . . . . 10.0 112.217 -168.082 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -64.21 76.61 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.107 1.363 . . . . 10.0 110.171 170.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.8 mt -53.78 -36.9 62.91 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 112.735 0.643 . . . . 10.0 112.735 -177.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 148.4 28.29 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 109.884 -0.413 . . . . 10.0 109.884 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 p -155.54 132.85 10.93 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.2 1.0 . . . . 10.0 108.911 -169.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.88 -162.02 10.82 Favored Glycine 0 CA--C 1.52 0.382 0 C-N-CA 123.84 0.733 . . . . 10.0 111.973 -173.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 7.1 t -138.9 153.18 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 104.684 -2.339 . . . . 10.0 104.684 168.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.3 mt -67.49 -88.17 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 123.784 0.834 . . . . 10.0 110.409 -169.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.33 134.02 8.07 Favored Glycine 0 CA--C 1.534 1.235 0 O-C-N 121.64 -0.662 . . . . 10.0 112.326 178.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 88.5 mt -72.31 144.97 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 125.143 1.377 . . . . 10.0 109.529 -176.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -124.21 -50.53 1.79 Allowed 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.974 0.909 . . . . 10.0 110.633 176.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 . . . . . 0 C--O 1.25 1.104 0 C-N-CA 125.011 1.324 . . . . 10.0 112.688 -171.931 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.1 t -104.55 -11.11 17.16 Favored 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.921 1.288 . . . . 10.0 110.605 -178.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 15.5 ptmt -155.22 160.77 41.1 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.76 168.44 22.93 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 126.871 2.068 . . . . 10.0 108.778 -177.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 m -126.37 169.23 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 C-N-CA 123.038 0.535 . . . . 10.0 110.825 175.261 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.51 107.68 6.07 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 107.132 -1.433 . . . . 10.0 107.132 165.466 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.469 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.6 OUTLIER -87.26 95.13 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 C-N-CA 123.549 0.74 . . . . 10.0 109.008 173.768 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -78.76 126.18 30.37 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 107.888 -1.153 . . . . 10.0 107.888 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.4 mptt -146.87 155.15 42.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 168.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.18 -65.91 0.03 OUTLIER Glycine 0 N--CA 1.46 0.272 0 C-N-CA 118.842 -1.646 . . . . 10.0 112.925 169.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -71.66 -43.74 65.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 107.205 -1.406 . . . . 10.0 107.205 -177.67 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 148.37 -71.1 0.32 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 114.324 -1.307 . . . . 10.0 111.351 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -56.71 -37.69 97.27 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 122.87 2.38 . . . . 10.0 112.078 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 m -72.23 87.19 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 108.529 -0.915 . . . . 10.0 108.529 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -104.19 108.36 19.69 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.097 -1.816 . . . . 10.0 106.097 -178.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.432 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -96.47 141.13 15.43 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.036 -0.826 . . . . 10.0 111.036 172.679 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.63 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.0 mt -139.37 81.83 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 -177.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -90.87 146.83 5.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 C-N-CA 123.529 0.732 . . . . 10.0 109.509 175.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -129.0 114.42 16.39 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.6 2.36 . . . . 10.0 107.331 177.199 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -93.74 115.65 28.08 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 172.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -117.87 137.8 52.54 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.804 0.729 . . . . 10.0 111.507 168.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -134.19 91.79 2.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.266 2.226 . . . . 10.0 106.235 -178.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -51.26 -38.66 53.86 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 125.581 1.552 . . . . 10.0 112.473 -168.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -152.23 -179.22 7.34 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 105.803 -1.925 . . . . 10.0 105.803 171.426 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.9 p -72.18 -18.96 61.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 118.14 0.427 . . . . 10.0 110.074 -178.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -83.81 -17.31 41.46 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 124.224 1.01 . . . . 10.0 109.438 175.286 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.63 147.84 30.01 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.647 -0.981 . . . . 10.0 110.647 175.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.26 170.99 15.85 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.443 2.095 . . . . 10.0 108.682 168.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.1 t -87.33 104.92 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 106.197 -1.779 . . . . 10.0 106.197 170.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -84.88 113.99 21.78 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 104.784 -2.302 . . . . 10.0 104.784 168.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.17 98.78 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.023 -1.473 . . . . 10.0 107.023 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.3 p90 -113.16 179.9 3.83 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.893 0.378 . . . . 10.0 110.705 174.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.74 -154.53 22.68 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.701 -2.16 . . . . 10.0 107.701 168.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 61.3 p -155.36 155.41 33.61 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 118.678 -1.209 . . . . 10.0 112.304 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.741 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -115.69 135.8 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 C-N-CA 126.229 1.812 . . . . 10.0 107.031 171.474 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -121.3 150.04 42.01 Favored 'General case' 0 CA--C 1.528 0.105 0 N-CA-C 107.354 -1.35 . . . . 10.0 107.354 170.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.77 -21.54 18.41 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-N 119.146 0.884 . . . . 10.0 114.161 175.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.5 mt -62.94 179.52 0.37 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 125.29 1.436 . . . . 10.0 111.652 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -103.75 175.54 5.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.777 -1.102 . . . . 10.0 108.107 166.092 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -64.28 169.73 4.36 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.054 0.942 . . . . 10.0 111.765 -171.054 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.76 -173.73 28.48 Favored Glycine 0 C--O 1.223 -0.583 0 C-N-CA 124.347 0.975 . . . . 10.0 111.841 167.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.88 148.73 47.48 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.854 0.862 . . . . 10.0 109.107 169.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.1 m-70 -141.53 143.46 33.78 Favored 'General case' 0 C--N 1.34 0.18 0 N-CA-C 113.718 1.007 . . . . 10.0 113.718 -177.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.798 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -18.14 116.41 0.01 OUTLIER Glycine 0 C--N 1.339 0.721 0 C-N-CA 129.104 3.24 . . . . 10.0 115.061 163.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -149.41 98.32 2.77 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 120.208 2.004 . . . . 10.0 114.609 174.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.464 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -144.85 170.85 15.34 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.649 0.78 . . . . 10.0 112.16 178.664 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.4 t -105.5 -28.09 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 128.355 2.662 . . . . 10.0 112.827 -168.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.5 m-70 63.03 176.08 0.15 Allowed 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.586 1.154 . . . . 10.0 112.451 178.362 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -92.47 -64.83 1.06 Allowed 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.582 -0.736 . . . . 10.0 110.855 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -79.21 148.92 32.08 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 119.174 -1.01 . . . . 10.0 109.615 -176.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.0 -25.71 33.56 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 109.797 -1.321 . . . . 10.0 109.797 169.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -62.06 166.57 4.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 123.093 1.425 . . . . 10.0 112.897 -176.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.434 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -162.56 21.55 0.1 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.482 -1.235 . . . . 10.0 113.137 -169.907 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.454 HG22 HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -52.44 -35.23 51.78 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 124.797 1.239 . . . . 10.0 111.823 -176.556 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.05 -19.79 53.62 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 122.892 0.477 . . . . 10.0 112.138 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.84 107.0 1.22 Allowed Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.741 -1.343 . . . . 10.0 109.741 -172.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.1 m 34.75 59.91 0.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.357 1.863 . . . . 10.0 112.046 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.5 m -153.77 -54.24 0.11 Allowed 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.577 -0.897 . . . . 10.0 108.577 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -51.19 -39.5 56.62 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.857 1.263 . . . . 10.0 110.768 -173.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -29.67 -38.51 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 128.526 2.73 . . . . 10.0 114.786 168.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.49 131.63 6.65 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.125 -1.19 . . . . 10.0 110.125 172.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.94 64.78 3.29 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.531 2.821 . . . . 10.0 112.36 174.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.472 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 11.6 m170 69.86 38.09 1.68 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 128.527 2.731 . . . . 10.0 111.926 168.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -73.19 26.64 0.06 Allowed 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 115.372 1.619 . . . . 10.0 115.372 -170.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -46.22 150.72 1.05 Allowed Pre-proline 0 CA--C 1.54 0.558 0 C-N-CA 125.0 1.32 . . . . 10.0 112.703 -170.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -52.88 -52.86 7.87 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.087 2.524 . . . . 10.0 112.348 -173.28 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -77.06 61.14 1.97 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.9 -0.778 . . . . 10.0 108.9 169.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.4 t -60.02 113.99 2.61 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 106.877 -1.527 . . . . 10.0 106.877 178.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.68 -81.13 0.41 Allowed 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 109.41 -0.589 . . . . 10.0 109.41 -175.227 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -145.53 150.67 36.85 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-O 122.31 1.053 . . . . 10.0 110.91 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 52.8 t60 -64.69 117.88 8.1 Favored 'General case' 0 N--CA 1.447 -0.623 0 C-N-CA 119.146 -1.021 . . . . 10.0 108.642 166.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.97 -132.45 2.58 Favored Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 107.465 -2.254 . . . . 10.0 107.465 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.1 -160.79 24.62 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 109.13 -1.588 . . . . 10.0 109.13 177.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -60.75 -6.91 6.52 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.767 1.645 . . . . 10.0 110.973 167.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -85.21 -27.54 26.03 Favored 'General case' 0 N--CA 1.445 -0.68 0 C-N-CA 124.529 1.132 . . . . 10.0 109.942 175.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -106.63 154.83 20.34 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.938 -1.134 . . . . 10.0 107.938 -173.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -85.37 -24.69 27.47 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 115.073 -0.967 . . . . 10.0 109.052 169.039 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -101.39 14.39 32.12 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.585 0.587 . . . . 10.0 112.585 -173.37 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -43.1 149.72 0.2 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.19 2.196 . . . . 10.0 110.181 171.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -77.46 48.86 0.68 Allowed 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.2 -0.937 . . . . 10.0 112.61 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 26.0 t 33.66 49.38 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 126.099 1.759 . . . . 10.0 110.561 -177.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.47 42.55 0.03 OUTLIER Glycine 0 CA--C 1.532 1.156 0 CA-C-N 116.11 -0.495 . . . . 10.0 114.014 -169.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -118.01 111.87 19.51 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 104.466 -2.42 . . . . 10.0 104.466 168.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.8 mt -79.51 -29.92 41.7 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 119.75 1.159 . . . . 10.0 108.783 174.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.49 -83.82 0.36 Allowed Glycine 0 C--O 1.221 -0.683 0 N-CA-C 111.22 -0.752 . . . . 10.0 111.22 167.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -155.64 143.5 19.78 Favored 'General case' 0 CA--C 1.517 -0.318 0 N-CA-C 107.909 -1.145 . . . . 10.0 107.909 -176.125 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -130.93 135.24 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 O-C-N 123.68 0.612 . . . . 10.0 110.299 174.353 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -79.31 108.46 12.84 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 127.232 2.213 . . . . 10.0 111.849 -175.024 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.54 130.17 35.3 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.21 1.404 . . . . 10.0 111.036 173.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -59.6 168.53 1.61 Allowed 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 124.311 1.007 . . . . 10.0 109.984 167.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -53.97 -29.83 44.5 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.754 0.821 . . . . 10.0 112.023 171.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.79 -3.57 42.03 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.033 0.382 . . . . 10.0 112.033 177.366 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.18 3.88 88.59 Favored Glycine 0 C--N 1.337 0.601 0 O-C-N 120.971 -1.08 . . . . 10.0 111.53 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.83 97.73 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 106.673 -1.603 . . . . 10.0 106.673 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.741 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -101.23 121.94 42.77 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 169.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -96.13 127.37 42.08 Favored 'General case' 0 C--N 1.329 -0.292 0 O-C-N 124.118 0.886 . . . . 10.0 109.377 174.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.7 t -108.81 139.53 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 C-N-CA 126.789 2.035 . . . . 10.0 108.934 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 95.4 p -156.39 70.35 0.66 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.694 1.198 . . . . 10.0 110.204 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 8.6 mm -106.53 167.45 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 C-N-CA 125.143 1.377 . . . . 10.0 109.303 -174.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 66.3 tt0 -155.35 123.16 5.71 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 127.224 2.21 . . . . 10.0 108.487 -170.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -155.74 158.23 37.85 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 104.37 -2.456 . . . . 10.0 104.37 173.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 15.1 p -106.14 -19.56 13.68 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 126.301 1.841 . . . . 10.0 111.751 -177.311 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 70.4 t -77.05 -38.68 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 -169.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.292 0.0 OUTLIER -76.19 54.43 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 C-N-CA 124.356 1.063 . . . . 10.0 112.3 178.677 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.93 145.03 52.21 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.229 1.012 . . . . 10.0 111.329 -169.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 76.0 mt -47.62 -52.84 16.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.352 0.596 . . . . 10.0 110.478 176.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.3 m -150.44 158.43 44.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 125.28 1.432 . . . . 10.0 107.354 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.9 -67.8 0.25 Allowed Glycine 0 C--N 1.335 0.492 0 N-CA-C 109.609 -1.396 . . . . 10.0 109.609 -176.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -155.82 -53.16 0.09 Allowed 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 126.904 2.082 . . . . 10.0 106.315 178.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.1 -37.62 64.09 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 114.197 -1.365 . . . . 10.0 108.771 -173.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.6 t 47.57 91.6 0.01 OUTLIER 'General case' 0 C--O 1.232 0.182 0 C-N-CA 127.112 2.165 . . . . 10.0 113.872 168.123 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 17.6 pt -68.13 -27.34 36.87 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 119.956 -0.697 . . . . 10.0 111.78 174.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -49.79 126.32 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 119.584 1.084 . . . . 10.0 109.911 175.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.74 14.68 79.35 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-O 118.457 -1.191 . . . . 10.0 114.424 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.507 ' HB2' HD12 ' A' ' 149' ' ' ILE . 5.8 mmt-85 -84.27 -179.46 7.2 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.092 1.357 . . . . 10.0 109.084 166.698 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -136.9 104.23 5.41 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -179.451 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.65 ' CD1' HD11 ' A' ' 149' ' ' ILE . 8.9 mp -72.82 146.08 46.53 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 108.3 -1.0 . . . . 10.0 108.3 173.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.2 t -129.04 131.89 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.18 0 N-CA-C 107.17 -1.419 . . . . 10.0 107.17 175.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.7 p -99.69 136.93 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 106.837 -1.542 . . . . 10.0 106.837 168.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.798 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 14.4 m-70 -114.74 160.7 19.09 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 114.516 1.302 . . . . 10.0 114.516 -173.141 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -60.39 -60.12 4.32 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 114.847 -1.07 . . . . 10.0 108.638 173.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -90.38 164.76 14.19 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.735 -0.786 . . . . 10.0 112.007 -170.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.47 147.76 37.66 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 106.951 -1.499 . . . . 10.0 106.951 169.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.52 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 27.7 m-20 -98.41 141.22 31.56 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 123.546 0.739 . . . . 10.0 109.441 -169.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 -72.32 -20.86 61.42 Favored 'General case' 0 N--CA 1.46 0.061 0 CA-C-O 120.822 0.344 . . . . 10.0 110.705 -173.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.5 mt 55.21 42.54 30.43 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 -167.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.98 -15.46 62.96 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 126.494 1.997 . . . . 10.0 113.194 171.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -76.88 -2.24 32.52 Favored 'General case' 0 CA--C 1.535 0.381 0 N-CA-C 114.443 1.275 . . . . 10.0 114.443 -167.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.17 -16.25 64.28 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 118.562 0.619 . . . . 10.0 111.983 174.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.01 40.89 67.2 Favored Glycine 0 CA--C 1.527 0.824 0 CA-C-N 117.981 0.89 . . . . 10.0 110.983 -178.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -128.3 161.91 28.29 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.477 -1.675 . . . . 10.0 106.477 177.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.403 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 3.0 tm-20 -53.34 -50.14 65.62 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.269 -1.382 . . . . 10.0 107.269 169.048 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -52.95 -44.25 66.95 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 115.382 -0.827 . . . . 10.0 112.11 172.494 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 23.1 p -57.4 -39.14 75.5 Favored 'General case' 0 N--CA 1.445 -0.677 0 O-C-N 120.449 -1.407 . . . . 10.0 110.763 -178.089 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.1 t -85.98 6.26 29.53 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 111.731 0.271 . . . . 10.0 111.731 -179.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.403 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 27.7 mmtp -106.75 -84.86 0.51 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.708 1.603 . . . . 10.0 109.241 171.306 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.472 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 2.9 p -95.47 -12.22 26.23 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 121.242 1.837 . . . . 10.0 112.841 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 80.58 32.97 32.34 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -168.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 53.69 44.69 29.33 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.376 1.088 . . . . 10.0 111.103 -178.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.13 -2.49 13.14 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.38 0.672 . . . . 10.0 112.256 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 94.95 -67.01 1.28 Allowed Glycine 0 C--N 1.336 0.556 0 O-C-N 120.921 -1.112 . . . . 10.0 111.215 169.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -166.89 175.21 7.86 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 -178.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -105.86 98.93 8.56 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.414 1.886 . . . . 10.0 106.981 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.437 ' N ' ' CD2' ' A' ' 144' ' ' LEU . 0.6 OUTLIER -84.93 -25.22 28.0 Favored 'General case' 0 C--O 1.232 0.178 0 C-N-CA 122.956 0.502 . . . . 10.0 110.963 -167.856 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 139.29 10.96 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.582 -0.896 . . . . 10.0 108.582 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 97.1 m -118.99 144.79 46.3 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.472 1.509 . . . . 10.0 107.657 -177.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.64 134.27 5.39 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.695 -0.962 . . . . 10.0 110.695 173.409 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -95.63 134.0 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 106.958 -1.497 . . . . 10.0 106.958 -170.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.65 HD11 ' CD1' ' A' ' 117' ' ' LEU . 9.4 mt -76.49 115.84 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 N-CA-C 110.517 -0.179 . . . . 10.0 110.517 -168.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.89 136.91 13.83 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.033 0.825 . . . . 10.0 111.515 -175.336 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 68.8 mt -54.7 138.44 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 C-N-CA 125.67 1.588 . . . . 10.0 108.433 173.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.57 -47.75 1.96 Allowed 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 123.265 0.626 . . . . 10.0 111.02 176.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.952 -1.975 . . . . 10.0 113.148 -174.245 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.923 0 CA-C-O 116.423 -1.751 . . . . 10.0 107.306 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . 0.254 1.9 t -141.0 -49.46 0.43 Allowed 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 120.493 1.497 . . . . 10.0 113.072 174.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -103.4 129.56 50.52 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 107.833 -1.173 . . . . 10.0 107.833 169.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.3 158.12 44.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 169.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.8 m -121.02 172.66 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.159 0 CA-C-N 117.89 0.314 . . . . 10.0 110.168 175.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.2 98.56 3.76 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.342 -1.355 . . . . 10.0 107.342 167.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.434 HG21 ' HB3' ' A' ' 53' ' ' ASN . 13.2 m -83.39 104.89 12.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.256 -1.016 . . . . 10.0 108.256 169.39 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.5 mt -92.71 145.2 24.6 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.011 -0.737 . . . . 10.0 109.011 -177.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 46.0 tttt -160.46 161.07 32.79 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 173.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.27 -51.01 0.05 OUTLIER Glycine 0 C--O 1.228 -0.271 0 CA-C-N 116.347 -0.388 . . . . 10.0 112.272 169.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.7 -45.78 34.87 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 -170.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.08 -67.85 0.54 Allowed Glycine 0 N--CA 1.442 -0.934 0 CA-C-N 113.672 -1.603 . . . . 10.0 110.292 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -56.25 -42.87 61.64 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.547 2.165 . . . . 10.0 110.543 171.117 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.434 HG13 HD11 ' B' ' 38' ' ' LEU . 53.9 t -63.66 114.13 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 -179.351 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.0 121.01 28.75 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.665 -1.605 . . . . 10.0 106.665 168.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.599 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -97.65 144.08 17.09 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 168.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.454 HG22 HG22 ' A' ' 54' ' ' THR . 1.3 mt -144.2 71.29 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.097 -1.446 . . . . 10.0 107.097 -176.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -94.1 141.58 14.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 O-C-N 122.042 -0.411 . . . . 10.0 109.938 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.7 m-80 -110.46 128.05 55.42 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 126.034 1.733 . . . . 10.0 109.48 171.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -109.4 98.01 7.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 174.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -105.24 124.18 49.09 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.599 0.714 . . . . 10.0 112.34 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 tt0 -91.36 99.18 12.19 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.201 1.801 . . . . 10.0 108.241 176.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.3 tttt . . . . . 0 N--CA 1.441 -0.887 0 C-N-CA 126.956 2.102 . . . . 10.0 110.17 179.857 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.68 0 N-CA-C 108.78 -1.728 . . . . 10.0 108.78 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -62.71 141.04 83.9 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 N-CA-C 108.097 -1.54 . . . . 10.0 108.097 170.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.4 t -87.19 109.39 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 105.322 -2.103 . . . . 10.0 105.322 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -76.93 113.18 14.35 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.645 -1.983 . . . . 10.0 105.645 168.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.47 102.19 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 171.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -120.73 154.71 35.25 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.202 0.525 . . . . 10.0 112.039 176.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.28 -168.59 36.58 Favored Glycine 0 N--CA 1.444 -0.831 0 N-CA-C 109.616 -1.393 . . . . 10.0 109.616 169.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.8 p -144.78 113.26 6.62 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 109.061 -0.718 . . . . 10.0 109.061 -169.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.599 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.4 pt -78.79 170.7 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.063 -1.088 . . . . 10.0 108.063 167.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -154.13 154.35 33.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.343 -0.984 . . . . 10.0 108.343 166.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.35 -15.62 32.6 Favored Glycine 0 CA--C 1.525 0.677 0 CA-C-O 119.139 -0.812 . . . . 10.0 114.08 177.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.453 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.7 mp -71.91 -179.21 2.62 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 118.757 1.278 . . . . 10.0 110.918 177.064 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -101.51 175.34 5.6 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.54 -0.911 . . . . 10.0 108.54 166.5 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -51.07 164.57 0.15 Allowed 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.23 2.212 . . . . 10.0 113.214 -173.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.76 -170.68 55.04 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 124.16 0.886 . . . . 10.0 114.008 165.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.96 141.76 54.86 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.127 1.771 . . . . 10.0 111.798 -175.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.4 m-70 -138.58 123.89 19.31 Favored 'General case' 0 C--N 1.339 0.115 0 C-N-CA 125.013 1.325 . . . . 10.0 109.847 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.42 127.83 1.75 Allowed Glycine 0 C--N 1.346 1.086 0 C-N-CA 126.839 2.161 . . . . 10.0 109.637 171.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.564 ' CE1' HG13 ' B' ' 87' ' ' VAL 0.274 0.3 OUTLIER -145.67 123.82 12.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 119.041 1.42 . . . . 10.0 112.406 168.139 . . . . . . . . 4 4 . 1 . 015 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.429 ' NE2' ' OD2' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -160.33 175.64 12.6 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.573 -0.74 . . . . 10.0 111.719 -174.264 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.2 m -88.72 153.43 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 O-C-N 125.697 1.873 . . . . 10.0 107.807 167.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 64.6 m-70 -134.72 95.04 3.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 108.329 -0.989 . . . . 10.0 108.329 177.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 24.43 -87.54 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 127.228 2.211 . . . . 10.0 114.24 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -78.87 161.76 26.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 122.734 1.254 . . . . 10.0 111.883 -169.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.44 -32.53 57.68 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 108.261 -1.936 . . . . 10.0 108.261 169.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -39.48 150.74 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 125.978 1.711 . . . . 10.0 113.929 176.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.469 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.6 OUTLIER -157.17 21.17 0.3 Allowed 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 113.882 -1.508 . . . . 10.0 113.081 178.527 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.63 HG23 ' CG2' ' A' ' 17' ' ' ILE . 6.0 m -41.69 -48.7 4.2 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.512 1.125 . . . . 10.0 113.093 -167.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.09 -25.36 47.53 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.891 0.876 . . . . 10.0 112.859 -176.393 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.17 104.15 2.6 Favored Glycine 0 CA--C 1.528 0.905 0 N-CA-C 109.544 -1.422 . . . . 10.0 109.544 -169.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 17.9 m 49.72 48.51 21.49 Favored 'General case' 0 N--CA 1.462 0.165 0 C-N-CA 125.474 1.51 . . . . 10.0 112.757 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -154.51 -55.86 0.1 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.6 m -50.56 -43.62 56.3 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.496 1.118 . . . . 10.0 111.45 -171.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.84 -51.47 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 128.005 2.522 . . . . 10.0 114.033 168.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.08 162.74 11.52 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.603 -1.399 . . . . 10.0 109.603 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -71.71 -164.68 0.17 Allowed 'Trans proline' 0 N--CA 1.447 -1.232 0 N-CA-C 105.019 -2.723 . . . . 10.0 105.019 163.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 34.1 m170 -81.47 53.55 2.12 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 119.288 -2.132 . . . . 10.0 109.72 -176.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -69.91 88.22 0.56 Allowed 'General case' 0 C--O 1.225 -0.225 0 CA-C-O 122.984 1.373 . . . . 10.0 109.383 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . 0.407 ' ND2' ' H ' ' B' ' 65' ' ' ASN . 4.9 p30 -96.34 151.2 37.95 Favored Pre-proline 0 C--N 1.325 -0.463 0 C-N-CA 127.236 2.214 . . . . 10.0 110.605 -176.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.4 -42.88 4.82 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.803 2.335 . . . . 10.0 111.282 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 77.0 mt -77.89 55.03 1.35 Allowed 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.829 0.852 . . . . 10.0 110.587 -178.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -38.28 101.77 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 126.752 2.021 . . . . 10.0 112.063 -171.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -140.38 -175.79 4.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.361 -1.348 . . . . 10.0 107.361 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -94.26 127.67 40.26 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -178.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -36.87 113.26 0.23 Allowed 'General case' 0 C--O 1.225 -0.207 0 O-C-N 123.639 0.587 . . . . 10.0 112.035 176.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.09 -137.09 5.65 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 177.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.409 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 168.44 -153.72 22.98 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.487 -2.245 . . . . 10.0 107.487 169.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -64.27 6.64 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.939 0 CA-C-N 120.635 2.217 . . . . 10.0 112.346 169.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.409 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.0 mmmt -121.4 12.26 10.84 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 126.978 2.111 . . . . 10.0 110.287 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -151.73 158.01 42.8 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 118.945 0.793 . . . . 10.0 108.919 168.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -79.39 -26.69 41.9 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 173.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -79.81 5.79 12.71 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 124.671 1.189 . . . . 10.0 112.82 -169.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt180 -35.23 120.75 0.55 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.796 1.639 . . . . 10.0 110.571 168.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.8 m170 -52.32 -53.55 43.0 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.506 1.122 . . . . 10.0 112.566 -170.057 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -178.03 -47.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 C-N-CA 125.667 1.587 . . . . 10.0 107.74 178.129 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.19 56.0 0.74 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.511 -1.435 . . . . 10.0 109.511 178.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -91.98 86.69 5.93 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 105.0 -2.222 . . . . 10.0 105.0 168.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . 0.516 ' HB3' ' CZ ' ' B' ' 45' ' ' PHE . 5.4 mp -72.98 -30.54 63.9 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 106.908 -1.516 . . . . 10.0 106.908 176.098 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.95 -93.18 0.86 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 124.687 1.137 . . . . 10.0 110.439 165.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 p30 -151.88 141.22 21.49 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.084 0.554 . . . . 10.0 110.021 -173.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.564 HG13 ' CE1' ' B' ' 45' ' ' PHE . 0.2 OUTLIER -128.6 138.87 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 C-N-CA 124.451 1.1 . . . . 10.0 111.677 179.219 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.4 m -79.17 115.05 18.6 Favored 'General case' 0 N--CA 1.437 -1.116 0 C-N-CA 128.821 2.849 . . . . 10.0 110.635 -177.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.7 134.17 38.94 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 123.855 0.862 . . . . 10.0 110.154 171.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -57.51 171.2 0.46 Allowed 'General case' 0 C--O 1.233 0.192 0 O-C-N 123.982 0.801 . . . . 10.0 109.634 167.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.63 -29.6 38.78 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 123.874 0.87 . . . . 10.0 110.955 173.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -79.08 -7.6 58.27 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.126 0.489 . . . . 10.0 111.203 -178.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.04 -0.24 72.25 Favored Glycine 0 C--N 1.338 0.684 0 O-C-N 121.195 -0.94 . . . . 10.0 111.001 -175.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 55.7 t -78.95 101.35 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 107.518 -1.289 . . . . 10.0 107.518 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.421 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -99.4 118.09 35.25 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.825 -1.176 . . . . 10.0 107.825 168.799 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.49 125.59 29.58 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 106.829 -1.545 . . . . 10.0 106.829 169.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 59.3 t -107.97 128.95 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 N-CA-C 105.385 -2.079 . . . . 10.0 105.385 169.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 73.0 m -152.72 59.85 0.8 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.798 0.839 . . . . 10.0 108.783 175.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.6 151.24 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 N-CA-C 108.138 -1.06 . . . . 10.0 108.138 -173.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -130.18 141.3 50.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.417 1.087 . . . . 10.0 109.155 170.292 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -149.27 161.03 42.84 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 29.7 p -122.6 4.89 9.55 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 127.237 2.215 . . . . 10.0 111.894 -172.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -84.14 -42.53 17.13 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 N-CA-C 107.699 -1.222 . . . . 10.0 107.699 177.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.283 0.0 OUTLIER -71.31 159.37 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 123.959 0.904 . . . . 10.0 113.228 172.378 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -160.04 155.0 24.59 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.202 -1.407 . . . . 10.0 107.202 170.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -82.14 55.88 2.98 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 108.129 -1.063 . . . . 10.0 108.129 169.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.5 t . . . . . 0 CA--C 1.542 0.648 0 C-N-CA 126.598 1.959 . . . . 10.0 108.666 177.246 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.3 t . . . . . 0 N--CA 1.455 -0.222 0 N-CA-C 115.575 1.694 . . . . 10.0 115.575 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 34.8 pt -73.51 6.2 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 N-CA-C 112.823 0.675 . . . . 10.0 112.823 171.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 9.1 mm -56.95 -67.13 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.311 0 CA-C-N 119.352 0.978 . . . . 10.0 111.458 -176.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -81.63 56.1 4.89 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 120.856 -1.152 . . . . 10.0 111.924 -175.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.1 mmt-85 -122.4 150.57 42.27 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.929 1.291 . . . . 10.0 107.957 176.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . 0.456 ' C ' HD12 ' B' ' 117' ' ' LEU . 1.1 m -92.24 129.26 38.23 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 104.065 -2.569 . . . . 10.0 104.065 168.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.456 HD12 ' C ' ' B' ' 116' ' ' THR . 10.9 mp -112.16 145.42 39.86 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.415 -0.957 . . . . 10.0 108.415 169.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.408 HG12 ' CD2' ' B' ' 120' ' ' HIS . 94.1 t -122.93 145.81 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 -171.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.501 HG13 ' HB3' ' B' ' 145' ' ' ALA . 1.5 p -117.2 122.74 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 C-N-CA 126.769 2.027 . . . . 10.0 106.473 169.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.408 ' CD2' HG12 ' B' ' 118' ' ' VAL . 10.2 m170 -105.29 167.22 9.87 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 115.722 1.749 . . . . 10.0 115.722 -168.463 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -59.29 -66.06 0.57 Allowed 'General case' 0 C--O 1.223 -0.29 0 C-N-CA 125.887 1.675 . . . . 10.0 110.186 174.155 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -107.06 177.71 4.77 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 118.817 0.735 . . . . 10.0 112.137 -169.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.08 144.13 48.81 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.683 1.193 . . . . 10.0 110.567 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.429 ' OD2' ' NE2' ' B' ' 46' ' ' HIS . 19.5 m-20 -89.59 149.36 22.88 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 109.091 -0.707 . . . . 10.0 109.091 168.039 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -76.76 -11.23 59.81 Favored 'General case' 0 N--CA 1.453 -0.289 0 O-C-N 124.73 1.269 . . . . 10.0 111.01 176.202 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 18.0 mt 57.37 40.05 27.8 Favored 'General case' 0 N--CA 1.457 -0.105 0 CA-C-N 118.26 0.482 . . . . 10.0 109.757 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 106.98 -33.41 6.43 Favored Glycine 0 CA--C 1.525 0.664 0 C-N-CA 125.325 1.44 . . . . 10.0 112.29 173.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.49 42.63 0.84 Allowed 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 118.471 1.135 . . . . 10.0 110.674 -169.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.71 -20.83 12.15 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.142 1.83 . . . . 10.0 111.743 -176.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.34 45.73 44.73 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 123.972 0.796 . . . . 10.0 112.554 178.477 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -152.03 172.43 16.29 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.444 0.622 . . . . 10.0 109.74 175.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 12.8 tm-20 -52.2 -43.78 64.37 Favored 'General case' 0 N--CA 1.443 -0.807 0 C-N-CA 123.699 0.799 . . . . 10.0 111.834 -176.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -72.43 -30.02 64.23 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.397 -0.815 . . . . 10.0 111.097 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 30.0 p -50.44 -40.42 50.4 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 119.419 1.009 . . . . 10.0 111.341 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -85.03 -13.79 49.4 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 123.793 0.683 . . . . 10.0 112.405 -175.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.2 ttmt -107.86 -48.75 3.34 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 126.841 2.056 . . . . 10.0 112.431 -166.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.9 p -131.93 -9.85 3.45 Favored 'General case' 0 C--O 1.224 -0.274 0 CA-C-O 116.794 -1.574 . . . . 10.0 112.258 169.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.0 -105.98 3.08 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 107.089 -2.404 . . . . 10.0 107.089 -166.394 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -171.81 21.53 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 115.187 1.551 . . . . 10.0 115.187 -176.702 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.09 -14.91 62.56 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 120.853 -1.154 . . . . 10.0 111.976 -178.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.53 -117.58 5.0 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.348 -1.901 . . . . 10.0 108.348 169.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 112.11 6.33 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 112.575 0.583 . . . . 10.0 112.575 -167.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.84 73.84 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.405 1.082 . . . . 10.0 109.938 166.172 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.9 mt -51.59 -45.2 63.07 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.783 0.66 . . . . 10.0 112.783 -175.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.501 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -151.27 156.82 41.62 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -168.047 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.0 p -163.4 170.13 17.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.951 -0.388 . . . . 10.0 109.951 -173.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.89 162.33 33.0 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.343 -1.503 . . . . 10.0 109.343 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.91 129.46 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 105.644 -1.984 . . . . 10.0 105.644 -176.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 22.6 mt -69.55 160.98 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 CA-C-N 118.773 0.715 . . . . 10.0 110.03 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.01 166.27 39.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 125.529 1.538 . . . . 10.0 109.919 -173.724 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 95.5 mt -74.29 134.56 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 C-N-CA 124.858 1.263 . . . . 10.0 109.785 -169.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.57 -35.25 3.59 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 112.795 0.665 . . . . 10.0 112.795 176.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.252 1.186 0 CA-C-O 116.953 -1.498 . . . . 10.0 108.893 174.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t -162.34 -43.77 0.04 OUTLIER 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 118.904 0.774 . . . . 10.0 110.795 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -118.41 138.52 52.39 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.34 155.68 49.13 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 124.148 0.905 . . . . 10.0 109.482 175.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -121.8 148.82 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 C-N-CA 125.618 1.567 . . . . 10.0 109.183 -176.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.33 100.85 4.36 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 108.022 -1.103 . . . . 10.0 108.022 167.131 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.481 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.2 m -79.51 100.99 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 109.055 -0.72 . . . . 10.0 109.055 171.571 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.9 mt -81.17 142.76 32.91 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -158.23 160.27 36.96 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 173.331 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -165.25 -60.68 0.02 OUTLIER Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.41 -0.424 . . . . 10.0 112.153 171.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -74.72 -45.86 41.39 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 106.644 -1.613 . . . . 10.0 106.644 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.69 -64.46 0.61 Allowed Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 114.021 -1.445 . . . . 10.0 111.203 -176.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -52.45 -42.74 59.33 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.06 1.84 . . . . 10.0 111.058 173.156 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.405 ' CG2' ' HB2' ' A' ' 145' ' ' ALA . 1.3 m -72.16 113.78 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.269 -1.011 . . . . 10.0 108.269 177.35 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -119.49 120.99 38.41 Favored 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 104.783 -2.303 . . . . 10.0 104.783 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.786 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -101.22 141.46 15.34 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.275 -1.93 . . . . 10.0 108.275 169.345 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.7 mt -137.16 67.26 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.069 -1.086 . . . . 10.0 108.069 -173.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.1 mm -77.06 133.86 29.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 109.4 -0.593 . . . . 10.0 109.4 -178.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -121.25 98.58 6.04 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.517 1.927 . . . . 10.0 107.6 -178.378 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.441 ' CD2' HG12 ' A' ' 31' ' ' VAL . 74.6 m-85 -81.27 128.79 34.19 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 118.155 -0.926 . . . . 10.0 108.616 177.612 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.77 122.21 43.81 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.619 0.768 . . . . 10.0 110.723 171.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -122.27 103.17 8.58 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.793 2.037 . . . . 10.0 106.483 168.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -61.77 -60.96 2.88 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 122.709 0.403 . . . . 10.0 110.467 -174.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -128.43 177.51 6.93 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 104.31 -2.478 . . . . 10.0 104.31 169.504 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.5 p -73.87 -17.17 61.08 Favored 'General case' 0 C--N 1.322 -0.594 0 O-C-N 122.114 -0.367 . . . . 10.0 110.578 -175.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.2 m-80 -79.2 -22.37 45.0 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.984 0.914 . . . . 10.0 109.461 172.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.64 124.73 18.83 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 109.91 -1.276 . . . . 10.0 109.91 179.325 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.92 141.95 86.34 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 N-CA-C 107.097 -1.924 . . . . 10.0 107.097 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 71.0 t -79.54 116.93 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 107.786 -1.19 . . . . 10.0 107.786 -169.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -88.91 108.4 19.53 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.122 -1.807 . . . . 10.0 106.122 177.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.441 HG12 ' CD2' ' A' ' 20' ' ' PHE . 18.6 m -101.32 90.59 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 125.328 1.451 . . . . 10.0 108.122 -177.756 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -101.49 167.5 10.11 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 122.03 0.919 . . . . 10.0 110.777 168.145 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.19 162.2 28.05 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.578 -1.409 . . . . 10.0 109.578 171.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.3 m -128.28 102.39 6.66 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 176.099 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.786 HG22 ' HA2' ' A' ' 16' ' ' GLY . 8.8 pt -77.08 176.32 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 N-CA-C 108.133 -1.062 . . . . 10.0 108.133 170.037 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.9 pttt -153.89 149.1 26.97 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 106.942 -1.503 . . . . 10.0 106.942 169.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.35 -24.24 12.7 Favored Glycine 0 C--N 1.338 0.654 0 CA-C-O 119.248 -0.751 . . . . 10.0 114.438 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.46 HD13 HD12 ' A' ' 35' ' ' ILE . 6.8 mp -65.56 175.92 1.66 Allowed 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 118.414 1.107 . . . . 10.0 111.063 -175.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -89.77 148.12 23.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.378 -0.828 . . . . 10.0 110.284 171.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -39.59 125.47 1.78 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.867 2.467 . . . . 10.0 110.938 174.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 121.42 -174.64 15.99 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 123.602 0.62 . . . . 10.0 112.961 171.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.64 151.91 44.45 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.806 1.642 . . . . 10.0 111.234 -178.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -148.27 143.3 26.86 Favored 'General case' 0 C--N 1.343 0.31 0 N-CA-C 113.524 0.935 . . . . 10.0 113.524 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.56 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.86 122.75 0.14 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.853 2.644 . . . . 10.0 110.917 165.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.92 106.41 4.42 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 119.989 1.894 . . . . 10.0 110.259 172.557 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -158.06 172.54 18.25 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-O 121.797 0.808 . . . . 10.0 111.764 -177.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 9.8 p -100.05 152.62 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-N 112.418 -2.174 . . . . 10.0 109.366 171.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -128.08 135.47 49.87 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 176.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -51.31 -61.77 2.03 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.318 1.447 . . . . 10.0 112.309 -168.323 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -83.9 147.79 27.31 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 119.539 -0.865 . . . . 10.0 109.516 -178.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.06 9.12 58.36 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 124.919 1.247 . . . . 10.0 111.321 170.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -67.56 98.45 0.68 Allowed 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 123.547 1.642 . . . . 10.0 110.907 -178.184 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.34 14.73 30.85 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 111.516 -2.584 . . . . 10.0 110.588 167.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.584 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -71.45 -40.95 70.0 Favored 'General case' 0 C--N 1.339 0.152 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 168.516 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -20.22 48.79 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.414 0.524 . . . . 10.0 112.414 170.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.02 78.83 1.37 Allowed Glycine 0 CA--C 1.529 0.909 0 N-CA-C 111.322 -0.711 . . . . 10.0 111.322 178.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.4 p 37.39 43.17 0.37 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 126.841 2.057 . . . . 10.0 114.292 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.2 m -133.14 -57.74 0.91 Allowed 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 105.682 -1.97 . . . . 10.0 105.682 -178.301 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -55.99 -29.05 59.7 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 122.823 0.449 . . . . 10.0 109.934 169.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.03 -27.7 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.564 1.545 . . . . 10.0 113.382 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.54 124.26 5.38 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-O 117.751 -1.583 . . . . 10.0 109.57 168.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -72.31 65.46 3.58 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.066 3.177 . . . . 10.0 111.69 176.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.6 m170 67.09 46.58 1.51 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 130.338 3.455 . . . . 10.0 111.868 176.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -70.48 64.68 0.28 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.194 0.597 . . . . 10.0 111.595 178.533 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -73.31 142.19 81.49 Favored Pre-proline 0 CA--C 1.533 0.292 0 O-C-N 120.154 -1.591 . . . . 10.0 109.102 172.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -57.94 -34.28 98.16 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.563 2.175 . . . . 10.0 111.591 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.45 -17.48 63.86 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.201 0.815 . . . . 10.0 113.201 177.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.4 t 20.75 81.93 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 127.495 2.318 . . . . 10.0 114.726 175.276 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.0 mtt180 -111.32 -84.73 0.57 Allowed 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 105.546 -2.02 . . . . 10.0 105.546 -177.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.09 160.56 41.07 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 109.131 -0.692 . . . . 10.0 109.131 167.557 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.0 t60 -56.74 126.68 27.94 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.316 -1.735 . . . . 10.0 106.316 165.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.39 -136.32 3.13 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 107.343 -2.303 . . . . 10.0 107.343 176.09 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 164.68 -150.64 18.98 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 108.982 -1.647 . . . . 10.0 108.982 169.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -68.11 19.22 0.13 Allowed 'Trans proline' 0 N--CA 1.453 -0.911 0 CA-C-N 119.77 1.785 . . . . 10.0 112.307 173.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 59.9 mttt -120.87 -11.66 8.92 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 118.161 -0.923 . . . . 10.0 111.243 169.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -143.6 118.44 9.93 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 104.856 -2.276 . . . . 10.0 104.856 -168.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 36.2 tp10 -75.11 -16.5 60.55 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 107.68 -1.23 . . . . 10.0 107.68 -171.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -82.56 11.11 6.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 C-N-CA 125.803 1.641 . . . . 10.0 111.991 175.656 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.8 ptt-85 -43.86 153.13 0.14 Allowed 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.76 1.624 . . . . 10.0 113.674 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -72.09 160.73 31.98 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 107.334 -1.358 . . . . 10.0 107.334 166.082 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.6 p -38.38 -47.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 125.358 1.463 . . . . 10.0 114.259 -172.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.74 55.0 0.76 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 123.396 0.522 . . . . 10.0 111.975 -177.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -82.47 93.5 7.26 Favored 'General case' 0 CA--C 1.528 0.126 0 N-CA-C 105.38 -2.082 . . . . 10.0 105.38 166.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -71.61 -28.94 64.14 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 106.79 -1.559 . . . . 10.0 106.79 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.63 -104.01 2.7 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 106.867 -2.493 . . . . 10.0 106.867 168.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -126.4 131.09 51.82 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.883 -1.155 . . . . 10.0 107.883 -169.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.98 135.58 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 119.076 0.853 . . . . 10.0 110.834 170.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.74 110.83 15.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.429 2.692 . . . . 10.0 110.51 -177.288 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.9 132.31 37.15 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.182 -0.673 . . . . 10.0 109.182 169.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -53.97 168.43 0.21 Allowed 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 125.047 1.339 . . . . 10.0 110.635 168.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 22.2 tttp -47.7 -35.43 9.64 Favored 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 125.654 1.582 . . . . 10.0 112.231 169.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -78.27 -9.84 59.4 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 121.203 0.525 . . . . 10.0 111.896 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.35 11.86 60.51 Favored Glycine 0 C--N 1.337 0.621 0 O-C-N 120.887 -1.133 . . . . 10.0 110.891 -177.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.3 t -92.19 103.92 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 125.749 1.62 . . . . 10.0 107.705 -178.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.43 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -98.88 121.72 41.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 109.052 -0.722 . . . . 10.0 109.052 169.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -84.6 86.16 7.34 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 127.528 2.331 . . . . 10.0 109.884 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.46 129.82 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.251 0 N-CA-C 105.67 -1.974 . . . . 10.0 105.67 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -158.18 72.06 0.61 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 122.986 0.514 . . . . 10.0 110.728 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -116.71 163.71 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.161 -1.792 . . . . 10.0 106.161 -178.016 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.66 144.85 39.83 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.571 0.623 . . . . 10.0 110.475 167.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -129.56 125.9 37.32 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 125.074 1.349 . . . . 10.0 110.205 -169.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 69.3 p -98.4 53.25 1.04 Allowed 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 107.172 -1.418 . . . . 10.0 107.172 169.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -157.24 -45.25 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 C-N-CA 124.085 0.954 . . . . 10.0 109.29 -175.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -74.23 145.09 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 167.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -133.08 157.15 46.0 Favored 'General case' 0 CA--C 1.528 0.124 0 N-CA-C 107.782 -1.192 . . . . 10.0 107.782 168.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.1 mt -95.39 -34.1 12.25 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 108.429 -0.952 . . . . 10.0 108.429 167.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.0 m -156.73 67.25 0.55 Allowed 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 124.486 1.114 . . . . 10.0 108.614 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -165.05 63.24 0.23 Allowed Glycine 0 C--N 1.333 0.365 0 N-CA-C 108.037 -2.025 . . . . 10.0 108.037 -179.313 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 69.75 -57.89 0.54 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 129.712 3.205 . . . . 10.0 109.532 -174.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -82.48 33.23 0.41 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 123.43 0.692 . . . . 10.0 111.416 -168.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.2 t -52.43 104.1 0.08 Allowed 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 126.618 1.967 . . . . 10.0 110.524 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 30.3 pt -86.06 23.55 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 C-N-CA 123.352 0.661 . . . . 10.0 111.787 171.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 20.8 mm -64.45 143.44 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 O-C-N 120.407 -1.433 . . . . 10.0 108.394 173.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.89 19.01 67.17 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-O 119.198 -0.779 . . . . 10.0 114.509 177.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.477 ' HD3' HD11 ' B' ' 151' ' ' ILE . 4.3 mmt-85 -88.29 176.4 7.24 Favored 'General case' 0 C--O 1.232 0.18 0 N-CA-C 107.76 -1.2 . . . . 10.0 107.76 167.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -121.08 132.66 55.01 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 106.841 -1.541 . . . . 10.0 106.841 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.9 mp -99.41 147.56 25.12 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.343 -1.354 . . . . 10.0 107.343 169.483 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.424 HG12 ' CD2' ' A' ' 120' ' ' HIS . 90.4 t -127.23 133.63 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.795 -1.557 . . . . 10.0 106.795 170.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.8 p -103.77 125.33 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.581 0 N-CA-C 103.913 -2.625 . . . . 10.0 103.913 167.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.56 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.2 m170 -105.56 160.6 15.05 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.052 1.406 . . . . 10.0 114.365 -168.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 -41.48 -58.15 1.99 Allowed 'General case' 0 N--CA 1.444 -0.773 0 C-N-CA 128.088 2.555 . . . . 10.0 109.702 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -124.81 176.96 6.26 Favored 'General case' 0 C--N 1.338 0.093 0 C-N-CA 125.791 1.636 . . . . 10.0 110.85 -174.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.69 135.92 33.34 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.143 0.977 . . . . 10.0 109.891 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.55 143.3 36.64 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.433 1.893 . . . . 10.0 111.897 177.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.75 19.95 0.26 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.986 1.314 . . . . 10.0 112.132 178.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 40.1 48.08 2.13 Favored 'General case' 0 C--O 1.226 -0.137 0 C-N-CA 126.25 1.82 . . . . 10.0 112.622 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 105.93 -11.31 45.09 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-O 118.781 -1.011 . . . . 10.0 113.437 173.113 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -120.96 40.6 3.52 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.743 0.771 . . . . 10.0 112.185 -166.276 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.28 -15.34 66.86 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 126.035 1.779 . . . . 10.0 112.323 173.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.7 49.19 78.88 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 118.417 1.109 . . . . 10.0 113.023 175.145 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.499 ' H ' ' HB2' ' A' ' 134' ' ' SER . 39.8 m-80 -161.12 167.63 25.88 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 127.35 2.26 . . . . 10.0 105.095 -177.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -46.31 -47.89 18.33 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.791 0.805 . . . . 10.0 111.026 172.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -56.74 -33.24 66.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.253 -0.885 . . . . 10.0 111.715 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.499 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 11.0 t -45.65 -46.59 14.71 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 125.064 1.346 . . . . 10.0 109.346 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.6 t -91.68 0.92 57.46 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 112.395 0.517 . . . . 10.0 112.395 -173.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -113.18 -81.64 0.59 Allowed 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 126.054 1.741 . . . . 10.0 110.537 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.4 p -111.23 22.82 14.78 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 121.176 1.807 . . . . 10.0 111.02 172.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 -88.51 0.41 Allowed Glycine 0 C--N 1.341 0.816 0 N-CA-C 109.932 -1.267 . . . . 10.0 109.932 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -173.77 40.17 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 125.895 1.678 . . . . 10.0 109.069 172.036 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.21 -4.18 9.73 Favored 'General case' 0 C--N 1.34 0.164 0 O-C-N 121.543 -0.723 . . . . 10.0 112.224 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.56 -166.99 53.85 Favored Glycine 0 N--CA 1.441 -0.987 0 N-CA-C 109.259 -1.537 . . . . 10.0 109.259 179.174 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.6 t -62.41 146.15 52.15 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 122.457 1.122 . . . . 10.0 111.324 -168.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.07 64.22 0.06 Allowed 'General case' 0 N--CA 1.444 -0.743 0 C-N-CA 126.837 2.055 . . . . 10.0 109.145 171.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.63 -19.16 64.64 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 113.206 0.817 . . . . 10.0 113.206 -168.721 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.405 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . . . -155.36 145.7 21.91 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.398 0.544 . . . . 10.0 110.129 172.369 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.9 m -146.85 158.51 43.93 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 123.852 0.861 . . . . 10.0 109.492 -167.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.92 167.09 36.5 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.472 -1.051 . . . . 10.0 110.472 175.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.8 t -116.28 142.01 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 107.398 -1.334 . . . . 10.0 107.398 -169.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 11.0 mt -80.03 113.68 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 123.291 0.636 . . . . 10.0 110.52 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.07 152.32 17.59 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.244 1.402 . . . . 10.0 111.728 -178.475 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 84.0 mt -73.55 141.32 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 124.562 1.145 . . . . 10.0 109.179 -178.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.69 -48.16 2.59 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 123.35 0.66 . . . . 10.0 110.764 176.28 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.1 tt0 . . . . . 0 C--O 1.25 1.125 0 C-N-CA 127.268 2.227 . . . . 10.0 112.146 -172.114 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 108.684 -0.858 . . . . 10.0 108.684 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . 0.498 HG23 ' HG3' ' B' ' 3' ' ' LYS . 15.0 t -91.46 -30.19 16.61 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 123.169 0.587 . . . . 10.0 111.149 -179.073 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . 0.498 ' HG3' HG23 ' B' ' 2' ' ' THR . 12.4 mtpt -124.44 127.9 48.21 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 124.882 1.273 . . . . 10.0 111.1 -175.527 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.01 155.47 49.93 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.957 0.503 . . . . 10.0 110.751 171.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.2 m -114.55 165.05 10.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.421 1.088 . . . . 10.0 109.346 171.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . 0.433 ' HB2' HG12 ' B' ' 149' ' ' ILE . . . -153.69 104.59 2.72 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 106.417 -1.697 . . . . 10.0 106.417 166.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -106.4 125.23 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 109.217 -0.66 . . . . 10.0 109.217 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.436 HD12 ' N ' ' B' ' 8' ' ' LEU . 4.1 mp -104.44 152.07 22.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.919 1.288 . . . . 10.0 109.352 -172.392 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . 0.409 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 44.8 tttt -160.0 162.64 34.34 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 169.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 175.0 -43.25 0.12 Allowed Glycine 0 C--O 1.228 -0.242 0 C-N-CA 119.768 -1.206 . . . . 10.0 113.682 168.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -74.22 -46.19 43.4 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.9 -72.37 0.33 Allowed Glycine 0 CA--C 1.52 0.348 0 N-CA-C 109.679 -1.368 . . . . 10.0 109.679 171.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -58.9 -39.23 83.17 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 123.211 2.607 . . . . 10.0 110.834 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.4 t -59.72 110.59 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -121.03 113.62 20.33 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 104.495 -2.409 . . . . 10.0 104.495 168.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.74 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -91.04 143.53 16.68 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 108.236 -1.946 . . . . 10.0 108.236 172.66 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.584 ' CG2' HG23 ' A' ' 54' ' ' THR . 3.0 mt -143.04 91.43 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 -176.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -104.31 138.66 28.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 C-N-CA 124.785 1.234 . . . . 10.0 109.29 178.081 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -122.84 122.35 38.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 126.38 1.872 . . . . 10.0 108.769 169.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -102.75 126.2 49.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 107.363 -1.347 . . . . 10.0 107.363 176.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -116.53 135.95 53.39 Favored 'General case' 0 C--O 1.233 0.203 0 O-C-N 123.759 0.662 . . . . 10.0 110.986 167.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.2 tt0 -119.52 114.15 21.83 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 106.095 -1.817 . . . . 10.0 106.095 168.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.4 mmpt? . . . . . 0 N--CA 1.453 -0.313 0 C-N-CA 123.912 0.885 . . . . 10.0 110.028 -169.828 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.21 0 N-CA-C 111.437 -0.665 . . . . 10.0 111.437 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_endo -62.63 159.45 36.8 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.874 2.383 . . . . 10.0 108.737 170.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 41.1 t -86.74 115.99 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.22 0 N-CA-C 105.325 -2.102 . . . . 10.0 105.325 169.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 38.8 tttp -92.07 112.45 24.39 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 168.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -94.44 100.66 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 C-N-CA 127.32 2.248 . . . . 10.0 106.484 176.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 23.3 p90 -112.77 171.32 7.6 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.304 0.573 . . . . 10.0 111.11 169.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.66 170.24 38.28 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.869 -0.892 . . . . 10.0 110.869 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.6 m -148.94 95.14 2.36 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.666 -1.605 . . . . 10.0 106.666 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.74 HG22 ' HA2' ' B' ' 16' ' ' GLY . 7.9 pt -75.8 176.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 108.725 -0.842 . . . . 10.0 108.725 173.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . 0.417 ' HE3' ' HB2' ' B' ' 36' ' ' LYS . 17.1 ptmt -156.57 164.8 37.77 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 163.285 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.69 -13.73 59.3 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 119.341 -0.7 . . . . 10.0 113.168 172.065 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.448 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.8 mp -69.71 176.69 3.42 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 118.568 1.184 . . . . 10.0 110.211 172.422 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.0 t -94.06 166.66 12.03 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 107.427 -1.324 . . . . 10.0 107.427 165.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.27 171.46 1.03 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.475 1.11 . . . . 10.0 112.21 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.18 179.89 39.64 Favored Glycine 0 C--N 1.334 0.428 0 C-N-CA 123.943 0.783 . . . . 10.0 112.074 168.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -66.99 142.6 57.19 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.632 0.773 . . . . 10.0 109.083 176.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.4 m-70 -139.68 151.79 46.19 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 123.087 0.555 . . . . 10.0 112.476 177.154 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.669 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -36.44 121.47 0.68 Allowed Glycine 0 C--N 1.341 0.822 0 C-N-CA 129.323 3.344 . . . . 10.0 110.883 166.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -149.59 115.21 5.58 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 119.335 1.567 . . . . 10.0 110.022 168.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.533 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.59 168.34 27.1 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-O 121.601 0.715 . . . . 10.0 111.406 176.401 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 7.7 m -93.28 148.88 4.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 111.957 -2.383 . . . . 10.0 105.389 166.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -121.91 153.55 38.3 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 174.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . 0.483 ' CD ' ' HA3' ' B' ' 61' ' ' GLY . 2.6 pm0 -40.1 -43.42 1.61 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 127.719 2.408 . . . . 10.0 115.403 -175.289 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -115.21 159.03 21.45 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 124.793 1.237 . . . . 10.0 109.264 -170.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.01 -7.71 63.96 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 126.009 1.766 . . . . 10.0 110.983 169.665 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -42.86 151.21 0.13 Allowed 'General case' 0 C--O 1.239 0.515 0 CA-C-O 123.174 1.464 . . . . 10.0 112.494 169.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.481 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -162.46 21.68 0.1 Allowed 'General case' 0 N--CA 1.437 -1.096 0 CA-C-N 112.485 -2.143 . . . . 10.0 111.997 167.955 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.83 -35.54 76.81 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.736 0.698 . . . . 10.0 110.821 -169.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.75 -17.6 55.54 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.602 1.161 . . . . 10.0 112.254 175.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.85 -173.2 17.25 Favored Glycine 0 N--CA 1.442 -0.909 0 N-CA-C 106.844 -2.502 . . . . 10.0 106.844 -167.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 60.1 m -66.53 69.96 0.07 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.311 1.444 . . . . 10.0 108.424 172.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -153.53 -53.04 0.1 Allowed 'General case' 0 N--CA 1.444 -0.774 0 O-C-N 120.693 -1.254 . . . . 10.0 109.617 -168.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.4 t -96.22 -1.26 48.55 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.874 0.87 . . . . 10.0 110.203 -178.069 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.31 47.3 0.37 Allowed 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.811 1.244 . . . . 10.0 112.225 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . 0.483 ' HA3' ' CD ' ' B' ' 49' ' ' GLU . . . 85.05 131.57 2.43 Favored Glycine 0 N--CA 1.44 -1.097 0 N-CA-C 117.479 1.752 . . . . 10.0 117.479 162.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -92.69 23.88 0.51 Allowed 'Trans proline' 0 CA--C 1.545 1.069 0 C-N-CA 123.135 2.557 . . . . 10.0 113.282 168.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.504 ' CD2' HG22 ' B' ' 137' ' ' THR . 21.1 m170 86.77 35.16 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 129.231 3.012 . . . . 10.0 112.352 176.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.24 70.34 0.16 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.319 1.048 . . . . 10.0 111.588 173.182 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -70.13 155.61 93.18 Favored Pre-proline 0 CA--C 1.536 0.413 0 C-N-CA 123.12 0.568 . . . . 10.0 109.965 170.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.57 -48.24 2.39 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 121.965 1.777 . . . . 10.0 110.815 176.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 tt -75.67 63.8 1.63 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.265 1.426 . . . . 10.0 109.205 -175.778 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -45.06 102.02 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 128.042 2.537 . . . . 10.0 113.143 -168.381 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.3 mtp85 -129.1 178.06 6.68 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 126.049 1.74 . . . . 10.0 108.027 175.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -111.94 56.98 0.64 Allowed 'General case' 0 C--O 1.226 -0.171 0 N-CA-C 113.12 0.785 . . . . 10.0 113.12 -167.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 67.8 t60 44.98 85.81 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 122.959 1.361 . . . . 10.0 114.069 175.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.65 -161.11 25.9 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 168.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.546 ' HA3' HD22 ' B' ' 126' ' ' LEU . . . -171.21 -152.99 8.6 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 107.043 -2.423 . . . . 10.0 107.043 173.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.42 8.44 0.12 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 120.15 1.975 . . . . 10.0 112.631 169.179 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.4 mttt -123.69 -0.49 8.58 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 117.419 -1.277 . . . . 10.0 113.066 175.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.32 163.55 32.71 Favored 'General case' 0 C--N 1.346 0.439 0 CA-C-N 120.629 1.559 . . . . 10.0 108.602 174.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -77.03 -30.29 55.67 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 177.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -76.58 26.07 0.13 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.651 1.58 . . . . 10.0 113.077 -166.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 18.1 mtm180 -47.58 129.5 13.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 107.392 -1.336 . . . . 10.0 107.392 168.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.1 m170 -67.67 -57.59 6.13 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 121.237 0.541 . . . . 10.0 109.932 176.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.8 p -163.82 -58.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 109.072 -0.714 . . . . 10.0 109.072 -176.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -137.23 62.91 0.58 Allowed Glycine 0 C--N 1.337 0.6 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 178.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -90.78 90.74 8.07 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.371 -1.344 . . . . 10.0 107.371 171.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.39 -25.5 57.68 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 121.352 0.596 . . . . 10.0 109.551 177.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . 0.559 ' CA ' HD21 ' B' ' 126' ' ' LEU . . . 80.98 -66.98 3.68 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 115.161 0.825 . . . . 10.0 115.161 167.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -137.93 109.29 6.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 118.677 -0.678 . . . . 10.0 109.249 -167.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -115.84 125.77 73.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 118.789 0.722 . . . . 10.0 110.451 169.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 10.9 m -81.35 97.51 7.74 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 128.325 2.65 . . . . 10.0 112.134 -171.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.64 132.77 39.6 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 123.824 0.849 . . . . 10.0 112.236 176.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -63.13 173.44 1.45 Allowed 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 125.308 1.443 . . . . 10.0 110.312 167.1 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.3 pttm -55.03 -30.5 59.68 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 123.766 0.827 . . . . 10.0 111.95 170.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.88 3.25 20.37 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.069 0.938 . . . . 10.0 110.953 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.47 -0.26 89.71 Favored Glycine 0 N--CA 1.441 -1.013 0 O-C-N 120.572 -1.33 . . . . 10.0 110.033 -174.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 67.0 t -78.33 94.79 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 108.414 -0.958 . . . . 10.0 108.414 -169.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -88.15 119.11 28.22 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 167.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -77.34 123.59 26.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.951 -1.5 . . . . 10.0 106.951 169.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 65.8 t -104.65 131.69 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 105.292 -2.114 . . . . 10.0 105.292 169.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -158.01 57.84 0.47 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 118.917 0.78 . . . . 10.0 111.815 177.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.6 151.61 12.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.166 0.986 . . . . 10.0 109.631 -169.279 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -109.1 141.99 40.48 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 126.068 1.747 . . . . 10.0 109.601 170.318 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -137.67 155.35 49.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 O-C-N 124.093 0.871 . . . . 10.0 109.413 173.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.5 p -128.07 58.37 1.52 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 126.86 2.064 . . . . 10.0 108.526 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -155.01 -44.5 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 C-N-CA 124.643 1.177 . . . . 10.0 108.888 174.096 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 33.6 mm -55.91 147.66 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 168.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.0 m -153.85 135.3 14.24 Favored 'General case' 0 C--O 1.233 0.22 0 N-CA-C 109.048 -0.723 . . . . 10.0 109.048 169.511 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -79.18 57.42 2.26 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.367 1.467 . . . . 10.0 108.492 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 15.5 t . . . . . 0 CA--C 1.536 0.432 0 C-N-CA 126.913 2.085 . . . . 10.0 110.416 -171.783 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.4 t . . . . . 0 C--O 1.238 0.492 0 N-CA-C 113.966 1.099 . . . . 10.0 113.966 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.2 pp -56.0 -30.29 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 166.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.7 mm -31.12 -36.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 C-N-CA 128.306 2.642 . . . . 10.0 115.234 169.495 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -104.56 28.95 12.86 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-O 118.711 -1.049 . . . . 10.0 112.784 -175.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -104.87 169.85 8.21 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 125.106 1.362 . . . . 10.0 110.176 177.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 18.4 m -108.26 127.7 54.08 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.696 1.598 . . . . 10.0 109.104 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.407 HD21 HD11 ' B' ' 149' ' ' ILE . 4.5 mm? -84.9 141.23 30.55 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 106.71 -1.589 . . . . 10.0 106.71 167.059 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.5 t -125.46 136.7 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 170.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.425 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 6.0 p -105.65 130.9 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 125.083 1.353 . . . . 10.0 107.583 169.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.669 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.3 m170 -114.68 157.84 22.59 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 115.75 1.759 . . . . 10.0 115.75 -171.298 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -37.11 -63.76 0.41 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 129.301 3.04 . . . . 10.0 111.078 169.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.5 mttt -117.93 175.32 5.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 C-N-CA 124.231 1.012 . . . . 10.0 110.131 -173.077 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -91.72 148.19 22.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.894 1.278 . . . . 10.0 109.478 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.533 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -75.04 143.35 43.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 112.053 0.39 . . . . 10.0 112.053 -178.786 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -80.64 -3.62 51.21 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 124.394 1.059 . . . . 10.0 110.791 166.564 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.559 HD21 ' CA ' ' B' ' 85' ' ' GLY . 71.1 mt 51.24 50.73 18.4 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 125.426 1.49 . . . . 10.0 111.218 170.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.37 -36.08 4.3 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-N 114.525 -1.216 . . . . 10.0 110.935 174.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.434 ' HD3' ' H ' ' B' ' 128' ' ' LYS . 0.2 OUTLIER -83.31 35.22 0.49 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 121.025 -1.279 . . . . 10.0 110.847 -173.844 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.92 -36.11 6.51 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 109.51 -1.436 . . . . 10.0 109.51 179.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.62 51.21 59.26 Favored Glycine 0 CA--C 1.529 0.938 0 N-CA-C 111.39 -0.684 . . . . 10.0 111.39 -171.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -142.66 171.7 13.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 104.605 -2.368 . . . . 10.0 104.605 170.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 24.4 mp0 -51.78 -48.11 63.91 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 120.726 -0.39 . . . . 10.0 110.379 174.328 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -53.08 -38.17 62.32 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.451 -0.34 . . . . 10.0 110.282 177.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.8 p -57.72 -30.01 65.19 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 118.013 -0.994 . . . . 10.0 112.513 -176.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -98.2 17.47 18.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.412 1.005 . . . . 10.0 109.834 -177.551 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -142.19 -69.74 0.35 Allowed 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 124.822 1.249 . . . . 10.0 110.38 -169.282 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.504 HG22 ' CD2' ' B' ' 63' ' ' HIS . 11.4 p -126.73 21.61 6.99 Favored 'General case' 0 CA--C 1.547 0.859 0 CA-C-N 119.653 1.115 . . . . 10.0 112.29 177.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 79.07 -88.07 1.18 Allowed Glycine 0 C--N 1.343 0.958 0 O-C-N 121.111 -0.993 . . . . 10.0 111.01 170.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.09 38.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 122.989 1.376 . . . . 10.0 107.934 174.34 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.76 -29.05 61.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 125.169 1.388 . . . . 10.0 109.607 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.95 -157.61 53.09 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 109.847 -1.301 . . . . 10.0 109.847 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 56.7 m -56.84 130.57 46.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 113.59 0.959 . . . . 10.0 113.59 -167.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.9 mtt85 -66.68 75.22 0.11 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.934 1.294 . . . . 10.0 110.654 172.695 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 55.1 mt -50.58 -40.19 51.77 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 118.349 0.522 . . . . 10.0 112.226 179.535 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.425 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -155.31 160.41 40.73 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 121.943 -0.473 . . . . 10.0 109.867 -177.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 p -159.42 166.46 30.99 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 109.982 -0.377 . . . . 10.0 109.982 -177.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.56 165.55 36.24 Favored Glycine 0 C--N 1.334 0.433 0 N-CA-C 110.689 -0.965 . . . . 10.0 110.689 -177.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.68 137.53 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 106.002 -1.851 . . . . 10.0 106.002 -171.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.433 HG12 ' HB2' ' B' ' 6' ' ' ALA . 16.7 mt -68.42 157.3 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 108.491 -0.929 . . . . 10.0 108.491 177.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -163.83 155.38 26.72 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 109.732 -1.347 . . . . 10.0 109.732 -176.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . 0.477 HD11 ' HD3' ' A' ' 115' ' ' ARG . 1.9 pp -90.32 125.84 43.16 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-N 118.475 1.138 . . . . 10.0 111.368 -173.1 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.75 -25.96 27.92 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.126 -0.984 . . . . 10.0 111.245 177.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.251 1.133 0 C-N-CA 125.837 1.655 . . . . 10.0 107.676 178.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.835 0 CA-C-O 118.253 -0.88 . . . . 10.0 108.636 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.31 -53.61 1.91 Allowed 'General case' 0 N--CA 1.463 0.175 0 C-N-CA 124.274 1.029 . . . . 10.0 110.828 -175.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -105.51 128.36 53.53 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.32 161.74 35.45 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.132 0.573 . . . . 10.0 109.665 172.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -125.94 153.45 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 125.71 1.604 . . . . 10.0 109.782 -179.202 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.73 127.53 21.98 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 108.251 -1.018 . . . . 10.0 108.251 165.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.648 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.9 m -115.36 83.7 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 C-N-CA 124.783 1.233 . . . . 10.0 110.772 -174.537 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.426 HD12 ' N ' ' A' ' 8' ' ' LEU . 2.7 mp -76.02 150.01 37.44 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.144 -0.972 . . . . 10.0 109.856 -169.069 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.429 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -165.96 155.24 11.81 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 -179.206 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.19 -46.2 0.18 Allowed Glycine 0 N--CA 1.463 0.477 0 C-N-CA 119.505 -1.331 . . . . 10.0 114.136 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -73.33 -45.35 55.74 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -175.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.71 -73.13 0.32 Allowed Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 170.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -56.75 -39.55 90.55 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.835 2.357 . . . . 10.0 110.996 172.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 98.4 t -62.97 106.54 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 CA-C-N 119.245 0.93 . . . . 10.0 108.507 -177.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.63 112.44 20.53 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 169.679 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.775 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -96.17 142.57 16.2 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 109.576 -1.41 . . . . 10.0 109.576 174.293 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -147.12 93.32 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 -172.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.4 mm -111.88 139.82 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 C-N-CA 125.582 1.553 . . . . 10.0 110.111 -175.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -118.32 122.45 42.9 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.943 1.697 . . . . 10.0 109.157 168.247 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -101.74 114.11 27.89 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 125.255 1.422 . . . . 10.0 107.259 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -120.6 112.68 19.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 122.154 0.978 . . . . 10.0 113.084 -179.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -82.29 104.8 12.86 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 106.307 -1.738 . . . . 10.0 106.307 168.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.3 -24.44 67.3 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 118.97 -0.538 . . . . 10.0 110.405 177.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -135.75 -161.22 1.13 Allowed 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.419 -0.586 . . . . 10.0 109.419 178.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 23.1 t -99.87 -7.68 25.02 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 119.363 -0.351 . . . . 10.0 110.355 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.9 m-80 -139.63 21.34 2.52 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.819 1.248 . . . . 10.0 108.969 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.98 161.8 42.09 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.278 -1.129 . . . . 10.0 110.278 -172.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -67.69 117.28 4.76 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 104.226 -3.029 . . . . 10.0 104.226 165.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.77 131.56 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 -174.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.1 mttt -101.53 122.74 44.37 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 106.541 -1.651 . . . . 10.0 106.541 174.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.1 m -119.73 111.93 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.82 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 -175.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -128.99 167.96 16.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 121.209 0.528 . . . . 10.0 109.988 -179.291 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.77 171.17 38.68 Favored Glycine 0 N--CA 1.437 -1.295 0 N-CA-C 110.009 -1.236 . . . . 10.0 110.009 -176.353 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.5 t -142.55 99.04 3.41 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 177.663 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.775 HG22 ' HA2' ' A' ' 16' ' ' GLY . 4.9 pt -79.51 156.26 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 C-N-CA 118.514 -1.275 . . . . 10.0 107.642 167.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.5 ptmt -141.9 164.6 29.76 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.519 -0.919 . . . . 10.0 108.519 164.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.66 -14.23 46.2 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-O 119.105 -0.831 . . . . 10.0 113.08 177.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.496 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.4 mp -70.77 176.9 3.88 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 118.566 1.183 . . . . 10.0 110.482 178.08 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -95.9 149.82 21.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.397 -0.82 . . . . 10.0 109.309 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -43.61 137.53 2.91 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.685 1.994 . . . . 10.0 111.58 -176.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 114.62 -172.87 14.49 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.881 0.753 . . . . 10.0 112.585 170.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.89 145.32 50.28 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 125.024 1.33 . . . . 10.0 110.908 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -147.9 143.58 27.48 Favored 'General case' 0 C--N 1.34 0.189 0 N-CA-C 113.099 0.777 . . . . 10.0 113.099 177.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.633 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -28.55 117.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 C-N-CA 127.842 2.639 . . . . 10.0 113.078 165.397 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -143.1 109.18 5.24 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 120.207 2.004 . . . . 10.0 110.873 169.046 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.78 171.79 19.77 Favored 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 115.438 -0.801 . . . . 10.0 110.765 178.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.9 m -89.45 163.39 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.514 -2.13 . . . . 10.0 106.895 166.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -124.47 158.23 33.32 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 124.857 1.263 . . . . 10.0 107.859 172.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -58.04 -41.3 82.95 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 123.994 0.918 . . . . 10.0 112.935 -169.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -107.41 174.65 5.79 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.034 0.934 . . . . 10.0 109.82 176.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.39 -9.96 14.14 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.236 1.874 . . . . 10.0 112.449 175.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -65.81 161.34 21.18 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 122.379 1.085 . . . . 10.0 110.949 -178.138 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -158.0 28.98 0.26 Allowed 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.445 -0.798 . . . . 10.0 112.289 -170.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.639 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -59.19 -36.43 75.35 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.569 -0.707 . . . . 10.0 112.368 -171.622 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.44 -17.54 56.2 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.178 0.591 . . . . 10.0 111.499 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.37 -156.25 15.73 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 104.664 -3.374 . . . . 10.0 104.664 -167.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 93.6 m -68.23 72.33 0.19 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 125.133 1.373 . . . . 10.0 110.174 177.033 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -158.56 -47.92 0.06 Allowed 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 123.564 0.746 . . . . 10.0 111.128 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -56.0 -35.17 66.5 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.27 1.028 . . . . 10.0 111.476 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.09 -28.86 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.482 3.113 . . . . 10.0 116.395 174.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.04 165.87 29.03 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 107.84 -2.104 . . . . 10.0 107.84 175.46 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -72.81 -141.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.347 0 N-CA-C 106.635 -2.102 . . . . 10.0 106.635 166.249 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -105.04 38.03 2.03 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 120.515 1.507 . . . . 10.0 111.556 179.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -72.18 73.17 0.93 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.848 1.658 . . . . 10.0 112.181 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 7.2 p-10 -61.12 151.43 75.44 Favored Pre-proline 0 CA--C 1.537 0.456 0 O-C-N 121.557 -0.715 . . . . 10.0 110.524 169.146 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -62.02 -43.55 24.22 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 122.571 2.181 . . . . 10.0 111.459 -178.338 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -77.06 60.4 1.84 Allowed 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 175.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 p -42.23 108.95 0.11 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 126.238 1.815 . . . . 10.0 111.762 -169.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -124.67 176.23 6.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 108.393 -0.965 . . . . 10.0 108.393 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -98.42 113.81 25.93 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -174.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.2 t60 -25.52 102.48 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 124.856 1.262 . . . . 10.0 113.894 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.81 -136.94 7.6 Favored Glycine 0 N--CA 1.443 -0.885 0 N-CA-C 107.975 -2.05 . . . . 10.0 107.975 178.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.03 -164.5 24.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 107.554 -2.219 . . . . 10.0 107.554 168.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -52.67 -18.27 8.44 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.14 1.894 . . . . 10.0 112.237 170.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.45 ' HZ1' ' CG ' ' A' ' 76' ' ' ASP . 0.0 OUTLIER -83.45 -33.36 25.66 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.025 0.93 . . . . 10.0 110.828 -177.424 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.45 ' CG ' ' HZ1' ' A' ' 75' ' ' LYS . 1.4 m-20 -98.04 175.14 6.22 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -171.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -89.42 -28.39 19.77 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 167.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -86.79 16.8 4.46 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 125.518 1.527 . . . . 10.0 113.156 -168.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.38 136.05 13.07 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.779 0.831 . . . . 10.0 109.729 168.399 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -71.77 -176.7 1.72 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 107.906 -1.146 . . . . 10.0 107.906 168.262 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.49 41.19 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 N-CA-C 113.754 1.02 . . . . 10.0 113.754 -175.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.82 56.71 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.237 -1.545 . . . . 10.0 109.237 172.166 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -98.01 95.89 7.78 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 169.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -80.16 -30.14 38.87 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.99 -102.02 1.89 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 107.954 -2.058 . . . . 10.0 107.954 168.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -132.34 114.0 13.87 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.998 1.319 . . . . 10.0 109.586 -167.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.5 m -103.6 137.2 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 C-N-CA 122.709 0.403 . . . . 10.0 110.192 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 92.1 m -83.27 105.47 14.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 127.13 2.172 . . . . 10.0 109.681 -177.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.75 131.07 35.21 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.253 0.621 . . . . 10.0 109.945 170.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -59.33 170.63 0.93 Allowed 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.13 1.372 . . . . 10.0 110.182 168.376 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 66.6 tttt -51.49 -35.27 39.42 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 125.925 1.69 . . . . 10.0 111.845 169.084 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -79.81 2.11 24.29 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 121.556 0.693 . . . . 10.0 111.292 177.293 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.34 -2.81 87.95 Favored Glycine 0 N--CA 1.445 -0.74 0 O-C-N 120.322 -1.487 . . . . 10.0 110.435 -178.312 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 69.5 t -75.67 103.99 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -170.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.595 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -104.23 115.25 30.06 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 108.43 -0.952 . . . . 10.0 108.43 173.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -79.16 125.44 29.45 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 114.44 -1.254 . . . . 10.0 108.107 173.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -106.28 128.67 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.397 0 N-CA-C 104.442 -2.429 . . . . 10.0 104.442 168.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.9 m -155.13 73.88 0.89 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 123.474 0.709 . . . . 10.0 110.028 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 15.8 mm -112.24 161.17 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 124.311 1.044 . . . . 10.0 111.29 -174.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -123.73 134.86 53.61 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 129.733 3.213 . . . . 10.0 107.047 169.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -145.68 144.17 30.24 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.505 -0.554 . . . . 10.0 109.505 175.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 5.1 p -109.57 18.72 20.02 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.311 1.844 . . . . 10.0 112.701 -174.24 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.8 t -126.38 -54.26 1.84 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.2 0 C-N-CA 125.595 1.558 . . . . 10.0 107.507 -177.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 10.9 mm -48.92 115.47 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 124.575 1.15 . . . . 10.0 109.086 172.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -114.51 116.78 29.37 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.897 0.879 . . . . 10.0 108.952 -176.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.97 -47.72 32.75 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 125.309 1.444 . . . . 10.0 109.647 176.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.4 m -149.13 164.39 34.83 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.137 -1.431 . . . . 10.0 107.137 174.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 134.27 -99.52 0.35 Allowed Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 107.211 -2.356 . . . . 10.0 107.211 -172.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -120.13 -49.2 2.3 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 124.653 1.181 . . . . 10.0 109.216 -168.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.03 -44.49 39.04 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 -177.315 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.1 t 46.97 76.14 0.11 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.994 1.717 . . . . 10.0 112.559 169.452 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 26.3 pt -59.77 -25.72 33.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 112.146 0.424 . . . . 10.0 112.146 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.1 mm -42.8 122.25 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 CA-C-N 119.068 0.849 . . . . 10.0 111.291 175.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.99 8.59 78.82 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 119.013 -0.881 . . . . 10.0 113.029 175.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.13 169.51 11.86 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.421 1.11 . . . . 10.0 108.499 168.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.92 141.37 36.67 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.862 0.865 . . . . 10.0 111.287 174.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.429 HD21 HD11 ' A' ' 149' ' ' ILE . 4.5 mm? -95.64 141.46 29.12 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.427 -1.323 . . . . 10.0 107.427 168.503 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.439 HG12 ' CD2' ' A' ' 120' ' ' HIS . 72.4 t -123.48 138.96 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 108.604 -0.887 . . . . 10.0 108.604 172.395 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.445 HG13 ' HB3' ' A' ' 145' ' ' ALA . 1.3 p -102.7 122.14 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 167.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.633 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.3 m-70 -104.88 160.29 15.12 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 115.207 1.558 . . . . 10.0 115.207 -173.036 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.34 -56.23 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 113.818 -1.537 . . . . 10.0 110.657 176.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 41.0 mttm -113.8 175.65 5.37 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-O 121.789 0.804 . . . . 10.0 111.918 -179.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.12 139.34 35.68 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.936 1.694 . . . . 10.0 109.051 172.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.14 164.63 24.81 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 121.843 0.83 . . . . 10.0 111.601 174.227 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -73.99 -16.56 61.07 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 114.618 -1.174 . . . . 10.0 110.54 -178.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 10.1 mt 52.13 46.68 26.19 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 -168.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.62 -13.29 67.05 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.65 2.072 . . . . 10.0 113.785 171.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.3 mtmp? -79.31 3.94 16.65 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 115.376 1.621 . . . . 10.0 115.376 -167.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.97 -33.15 51.26 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.493 1.042 . . . . 10.0 110.891 178.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.22 41.99 93.14 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 111.846 -0.502 . . . . 10.0 111.846 -173.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -132.96 170.34 15.49 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 124.684 1.194 . . . . 10.0 108.138 173.21 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -41.46 -55.66 2.76 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 125.497 1.519 . . . . 10.0 110.479 175.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 49.1 mp0 -56.43 -51.85 66.85 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 125.096 1.359 . . . . 10.0 110.311 176.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.6 p -51.46 -38.26 52.92 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 123.138 0.575 . . . . 10.0 111.009 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.91 -11.65 56.6 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 123.999 0.812 . . . . 10.0 111.307 -170.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -112.57 -48.84 2.98 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.829 1.251 . . . . 10.0 112.081 -172.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.7 p -137.05 23.65 3.03 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 120.289 1.404 . . . . 10.0 110.634 174.087 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.81 -113.79 6.19 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 106.065 -2.814 . . . . 10.0 106.065 -171.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 19.3 m-80 -157.95 44.05 0.32 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 107.258 -1.386 . . . . 10.0 107.258 174.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.84 -13.34 55.65 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 124.205 1.002 . . . . 10.0 112.313 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.6 -164.96 54.86 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 110.355 -1.098 . . . . 10.0 110.355 176.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.2 t -54.84 134.14 48.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 113.396 0.888 . . . . 10.0 113.396 -168.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -64.55 73.3 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.967 1.707 . . . . 10.0 109.432 168.308 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 39.8 mt -49.83 -39.3 38.31 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 118.383 0.538 . . . . 10.0 111.927 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.445 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -155.98 157.42 36.17 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.135 -0.691 . . . . 10.0 109.135 -177.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -157.08 162.3 39.47 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.415 -0.357 . . . . 10.0 110.531 -173.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.62 175.6 26.87 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.847 1.213 . . . . 10.0 110.088 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 13.6 t -122.04 140.81 44.82 Favored 'Isoleucine or valine' 0 C--N 1.343 0.298 0 CA-C-N 118.882 1.341 . . . . 10.0 107.422 -177.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.429 HD11 HD21 ' A' ' 117' ' ' LEU . 17.5 mt -75.82 119.56 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 123.76 0.824 . . . . 10.0 109.836 -176.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.97 148.9 17.89 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 125.428 1.49 . . . . 10.0 111.737 -178.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 89.0 mt -69.16 135.16 28.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.58 1.552 . . . . 10.0 110.163 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.02 -7.13 4.41 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 115.45 1.648 . . . . 10.0 115.45 -173.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.253 1.269 0 CA-C-O 117.528 -1.225 . . . . 10.0 110.199 -179.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.669 0 CA-C-O 118.272 -0.871 . . . . 10.0 109.043 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -78.19 -26.83 47.72 Favored 'General case' 0 C--O 1.224 -0.24 0 C-N-CA 123.345 0.658 . . . . 10.0 110.895 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 62.5 tttt -130.05 137.3 50.16 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.093 0.473 . . . . 10.0 111.068 176.257 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.29 161.17 36.17 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 125.129 1.372 . . . . 10.0 107.964 171.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -126.91 156.26 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 C-N-CA 125.184 1.394 . . . . 10.0 109.735 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . 0.423 ' HB1' HD11 ' B' ' 117' ' ' LEU . . . -138.85 112.31 8.2 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 168.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 11.6 m -100.41 128.65 52.22 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 108.31 -0.996 . . . . 10.0 108.31 171.004 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.18 145.35 31.64 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 123.917 0.887 . . . . 10.0 110.534 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -161.19 160.45 30.12 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.921 -1.141 . . . . 10.0 107.921 168.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.1 -45.58 0.12 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.982 -1.104 . . . . 10.0 113.285 169.107 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 -45.04 53.12 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.604 -1.258 . . . . 10.0 107.604 -175.588 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.37 -71.19 0.39 Allowed Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.644 -1.382 . . . . 10.0 109.644 170.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -57.86 -38.88 90.87 Favored 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 123.076 2.518 . . . . 10.0 111.095 171.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 92.2 t -61.47 103.05 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.035 0 N-CA-C 107.824 -1.176 . . . . 10.0 107.824 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -118.1 128.86 55.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.339 -1.356 . . . . 10.0 107.339 169.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.429 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -118.15 146.29 18.54 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 110.953 -0.859 . . . . 10.0 110.953 175.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.639 HG22 HG22 ' A' ' 54' ' ' THR . 1.5 mt -146.57 89.55 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 C-N-CA 125.634 1.573 . . . . 10.0 107.657 -176.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -102.5 139.25 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.744 1.618 . . . . 10.0 110.082 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -115.9 110.73 19.41 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 129.314 3.046 . . . . 10.0 107.366 176.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -95.02 114.64 26.47 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -112.47 122.34 47.42 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 118.64 0.655 . . . . 10.0 112.721 169.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 5.0 tp-100 -82.55 110.11 17.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.145 -2.168 . . . . 10.0 105.145 166.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt . . . . . 0 N--CA 1.442 -0.836 0 C-N-CA 130.429 3.492 . . . . 10.0 111.456 -179.963 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.04 151.05 86.97 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.458 1.439 . . . . 10.0 108.744 171.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 t -79.76 124.07 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.984 -2.599 . . . . 10.0 103.984 168.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -99.66 112.53 24.75 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.496 -1.668 . . . . 10.0 106.496 169.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -95.99 103.99 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.959 0 C-N-CA 127.08 2.152 . . . . 10.0 106.135 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -124.75 165.17 18.44 Favored 'General case' 0 C--O 1.223 -0.323 0 N-CA-C 112.648 0.61 . . . . 10.0 112.648 173.285 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.8 -156.63 27.1 Favored Glycine 0 N--CA 1.449 -0.494 0 N-CA-C 107.216 -2.354 . . . . 10.0 107.216 172.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 50.8 p -156.25 160.52 39.87 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.565 -1.254 . . . . 10.0 112.52 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.752 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -116.18 136.56 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 C-N-CA 126.197 1.799 . . . . 10.0 107.519 167.887 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 92' ' ' ASP . 0.1 OUTLIER -130.82 159.38 37.52 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.289 0.368 . . . . 10.0 110.452 167.276 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.14 -0.19 44.31 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.779 0.704 . . . . 10.0 113.22 -178.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.433 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.9 mp -85.02 175.62 8.93 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 118.0 0.9 . . . . 10.0 109.703 -178.308 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.5 t -90.89 154.45 19.47 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.913 -0.773 . . . . 10.0 108.913 168.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -51.22 145.32 8.14 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 126.536 1.935 . . . . 10.0 111.324 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.92 -170.49 21.84 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-O 121.593 0.552 . . . . 10.0 111.95 172.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -73.88 147.56 43.1 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.296 1.438 . . . . 10.0 112.535 -170.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -147.94 127.49 13.24 Favored 'General case' 0 C--N 1.341 0.218 0 N-CA-C 114.395 1.257 . . . . 10.0 114.395 -178.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.675 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -17.75 124.41 0.01 OUTLIER Glycine 0 C--N 1.342 0.89 0 C-N-CA 127.473 2.463 . . . . 10.0 114.489 164.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -147.18 106.17 3.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 119.863 1.832 . . . . 10.0 111.339 167.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.45 172.49 15.87 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.417 0.627 . . . . 10.0 111.165 175.206 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 19.5 m -96.91 153.92 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 112.632 -2.076 . . . . 10.0 108.479 168.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -134.49 135.47 42.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.005 2.122 . . . . 10.0 105.349 177.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -56.7 -48.36 77.87 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.896 0.748 . . . . 10.0 112.84 -168.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -78.42 112.66 15.68 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 118.126 -1.43 . . . . 10.0 108.486 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.74 -26.37 62.56 Favored Glycine 0 N--CA 1.44 -1.068 0 N-CA-C 109.534 -1.426 . . . . 10.0 109.534 167.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -34.37 109.12 0.07 Allowed 'General case' 0 CA--C 1.516 -0.364 0 C-N-CA 125.237 1.415 . . . . 10.0 111.343 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.648 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.7 OUTLIER -117.97 13.13 13.9 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 113.417 -1.719 . . . . 10.0 110.672 174.307 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.23 -39.84 67.14 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 119.102 0.864 . . . . 10.0 111.999 -168.314 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.88 -17.98 54.68 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.313 1.045 . . . . 10.0 113.027 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.23 76.07 1.11 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 108.269 -1.932 . . . . 10.0 108.269 -169.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.6 p 30.55 37.5 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 128.338 2.655 . . . . 10.0 116.177 -177.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.4 m -100.33 -50.25 3.99 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 -178.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.1 m -67.04 -14.73 63.18 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 126.378 1.871 . . . . 10.0 112.201 177.698 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.26 -26.74 0.35 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 127.228 2.211 . . . . 10.0 114.334 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 156.26 26.59 Favored Glycine 0 N--CA 1.438 -1.213 0 N-CA-C 109.002 -1.639 . . . . 10.0 109.002 169.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -69.31 -170.92 0.39 Allowed 'Trans proline' 0 N--CA 1.44 -1.65 0 N-CA-C 106.756 -2.055 . . . . 10.0 106.756 167.003 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 31.2 m170 -81.61 60.33 4.53 Favored 'General case' 0 CA--C 1.542 0.647 0 O-C-N 120.325 -1.485 . . . . 10.0 109.99 -172.398 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -70.85 75.52 0.62 Allowed 'General case' 0 C--O 1.223 -0.328 0 CA-C-N 118.917 0.781 . . . . 10.0 110.584 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -75.26 148.01 83.36 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.336 -0.853 . . . . 10.0 110.933 172.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.14 -42.97 12.32 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.57 2.18 . . . . 10.0 110.661 176.027 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.2 mt -75.87 54.77 0.84 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 123.806 0.843 . . . . 10.0 109.86 176.253 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.5 p -40.29 112.01 0.24 Allowed 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 125.787 1.635 . . . . 10.0 111.571 -172.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -142.34 178.4 7.6 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.42 -2.437 . . . . 10.0 104.42 -176.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -65.92 156.74 32.61 Favored 'General case' 0 N--CA 1.439 -0.977 0 C-N-CA 116.606 -2.038 . . . . 10.0 108.917 168.386 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -66.43 126.32 28.47 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 104.976 -2.231 . . . . 10.0 104.976 161.539 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.27 -133.21 3.07 Favored Glycine 0 N--CA 1.451 -0.35 0 N-CA-C 109.226 -1.55 . . . . 10.0 109.226 172.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.84 -155.08 23.19 Favored Glycine 0 C--O 1.226 -0.405 0 CA-C-O 118.028 -1.429 . . . . 10.0 109.53 174.64 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -64.88 2.37 1.37 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 CA-C-N 119.803 1.801 . . . . 10.0 112.155 172.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -95.18 -21.57 18.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 117.65 -1.167 . . . . 10.0 110.862 172.319 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -126.72 156.14 41.6 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 119.318 0.963 . . . . 10.0 109.817 -170.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -78.17 -32.79 50.31 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 106.885 -1.524 . . . . 10.0 106.885 167.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -88.01 57.17 4.18 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 125.553 1.541 . . . . 10.0 108.167 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 14.3 ptm180 -83.78 147.81 27.39 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 106.259 -1.756 . . . . 10.0 106.259 165.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -63.55 -57.95 8.52 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.481 1.037 . . . . 10.0 110.548 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.458 HG22 HG22 ' B' ' 104' ' ' ILE . 2.1 p 179.78 -99.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 104.883 -2.265 . . . . 10.0 104.883 -179.388 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.438 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -74.68 54.15 2.48 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.45 1.023 . . . . 10.0 112.417 172.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 70.0 m-20 -95.76 92.56 6.62 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.223 -2.51 . . . . 10.0 104.223 167.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 80.7 mt -89.44 38.84 0.92 Allowed 'General case' 0 CA--C 1.531 0.214 0 N-CA-C 107.983 -1.117 . . . . 10.0 107.983 177.195 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 32.91 -103.08 0.01 OUTLIER Glycine 0 C--N 1.341 0.84 0 C-N-CA 128.124 2.773 . . . . 10.0 112.206 -175.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -143.85 147.11 33.6 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.11 0.964 . . . . 10.0 109.769 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 32.4 m -113.15 139.04 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 125.095 1.358 . . . . 10.0 108.355 -174.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -83.41 122.47 28.54 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.273 0.629 . . . . 10.0 109.917 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.75 131.31 37.92 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.581 1.153 . . . . 10.0 109.255 171.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -56.15 169.36 0.41 Allowed 'General case' 0 N--CA 1.451 -0.41 0 O-C-N 124.486 1.116 . . . . 10.0 110.007 168.066 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 11.3 tttp -49.99 -35.46 24.56 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.284 1.434 . . . . 10.0 112.185 169.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 36' ' ' LYS . 36.1 t70 -79.47 0.31 30.04 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.275 0.559 . . . . 10.0 112.202 177.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.03 -1.0 86.54 Favored Glycine 0 C--N 1.337 0.623 0 O-C-N 120.394 -1.441 . . . . 10.0 110.698 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 56.0 t -77.15 97.71 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 107.443 -1.317 . . . . 10.0 107.443 -174.639 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.752 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -94.3 116.98 29.44 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 168.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -88.19 130.35 35.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.839 -1.171 . . . . 10.0 107.839 174.014 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.0 t -107.7 129.89 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.257 -2.127 . . . . 10.0 105.257 168.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -157.77 55.88 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 118.696 0.68 . . . . 10.0 110.957 175.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.58 143.68 17.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.466 -0.771 . . . . 10.0 110.222 -169.084 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -97.85 129.21 44.83 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 128.638 2.775 . . . . 10.0 107.049 168.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -143.23 134.0 25.26 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 109.454 -0.573 . . . . 10.0 109.454 -176.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.6 p -115.64 45.78 1.63 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.559 1.544 . . . . 10.0 110.011 -169.337 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.9 p -142.98 -46.79 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 122.634 0.374 . . . . 10.0 111.219 177.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.458 HG22 HG22 ' B' ' 81' ' ' VAL 0.31 0.0 OUTLIER -65.12 161.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 119.787 -0.765 . . . . 10.0 111.441 169.517 . . . . . . . . 4 4 . 1 . 017 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 20.3 m -146.32 165.47 29.17 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 169.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 83.4 mt -100.55 -18.52 16.59 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 123.138 0.575 . . . . 10.0 110.061 175.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 44.7 m . . . . . 0 N--CA 1.452 -0.344 0 C-N-CA 125.443 1.497 . . . . 10.0 107.189 174.358 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.7 t . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.481 -0.563 . . . . 10.0 109.481 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 24.5 pt -75.41 34.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.519 -0.738 . . . . 10.0 112.746 -177.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 38.2 mm -85.25 146.54 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 O-C-N 120.281 -1.512 . . . . 10.0 109.395 -175.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.85 24.21 69.78 Favored Glycine 0 CA--C 1.531 1.079 0 O-C-N 121.976 -0.452 . . . . 10.0 112.677 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -93.3 149.49 21.19 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 125.172 1.389 . . . . 10.0 107.347 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -87.47 139.96 30.01 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 168.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.423 HD11 ' HB1' ' B' ' 6' ' ' ALA . 0.0 OUTLIER -116.61 159.01 22.79 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 108.135 -1.061 . . . . 10.0 108.135 168.704 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 74.5 t -137.94 129.51 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 107.981 -1.118 . . . . 10.0 107.981 -172.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.409 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 3.0 p -94.52 122.65 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 105.929 -1.878 . . . . 10.0 105.929 167.035 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.675 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.7 m-70 -105.98 160.24 15.43 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 115.303 1.594 . . . . 10.0 115.303 -171.329 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -41.38 -60.94 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.069 2.948 . . . . 10.0 111.968 171.108 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -120.16 172.16 7.97 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.71 1.204 . . . . 10.0 113.166 -168.355 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.54 154.47 38.61 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 114.186 -1.37 . . . . 10.0 108.187 168.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -92.74 168.73 11.0 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 124.337 1.055 . . . . 10.0 111.034 -176.061 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.58 -20.99 59.72 Favored 'General case' 0 C--O 1.223 -0.336 0 C-N-CA 125.11 1.364 . . . . 10.0 108.278 175.049 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 49.8 mt 49.45 43.31 23.52 Favored 'General case' 0 C--N 1.341 0.237 0 C-N-CA 124.457 1.103 . . . . 10.0 109.998 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.51 33.17 80.48 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.087 -1.415 . . . . 10.0 113.174 178.142 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -75.4 0.08 18.18 Favored 'General case' 0 C--N 1.339 0.142 0 CA-C-N 118.913 1.357 . . . . 10.0 112.337 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.82 17.97 78.63 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.45 -1.46 . . . . 10.0 109.45 178.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.25 -26.08 74.32 Favored Glycine 0 N--CA 1.443 -0.834 0 N-CA-C 110.352 -1.099 . . . . 10.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 34.3 m-80 -156.07 163.14 40.03 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 118.067 0.933 . . . . 10.0 108.925 -168.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -56.23 -42.21 76.92 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 109.546 -0.539 . . . . 10.0 109.546 171.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -61.38 -23.96 66.15 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 112.635 0.606 . . . . 10.0 112.635 175.174 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.3 p -52.42 -39.32 60.83 Favored 'General case' 0 CA--C 1.512 -0.519 0 CA-C-N 118.556 0.617 . . . . 10.0 110.393 -172.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.7 t -90.17 -1.76 57.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 O-C-N 124.671 1.232 . . . . 10.0 111.67 -173.593 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -116.82 -48.93 2.64 Favored 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 126.769 2.028 . . . . 10.0 111.367 -168.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.7 p -135.43 -2.61 2.45 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 118.653 -0.689 . . . . 10.0 111.543 168.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 -106.38 3.19 Favored Glycine 0 N--CA 1.433 -1.52 0 N-CA-C 105.693 -2.963 . . . . 10.0 105.693 -166.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -168.79 30.55 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.22 1.01 . . . . 10.0 110.07 -173.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.19 -20.27 66.37 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.971 0.909 . . . . 10.0 113.277 -167.267 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.45 -160.69 53.25 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 110.394 -1.083 . . . . 10.0 110.394 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.5 m -55.57 130.8 44.38 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.074 0.94 . . . . 10.0 113.151 -167.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 60.6 mtt180 -69.23 68.25 0.19 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.129 1.771 . . . . 10.0 110.415 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 37.8 mt -54.41 -31.9 56.08 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 113.141 0.793 . . . . 10.0 113.141 -173.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.409 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -158.22 153.15 25.19 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 109.129 -0.693 . . . . 10.0 109.129 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.5 m -146.19 161.55 39.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 115.548 -0.751 . . . . 10.0 109.934 -166.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.36 172.78 34.81 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.089 -1.204 . . . . 10.0 110.089 176.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -122.4 135.32 62.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 9.1 mt -69.23 116.66 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 C-N-CA 122.983 0.513 . . . . 10.0 110.034 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.05 144.47 17.72 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 124.812 1.196 . . . . 10.0 110.526 -178.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 59.8 mt -65.77 144.56 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 N-CA-C 108.045 -1.094 . . . . 10.0 108.045 176.114 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.55 -43.05 3.06 Favored 'General case' 0 C--O 1.227 -0.124 0 CA-C-N 119.268 0.94 . . . . 10.0 111.923 170.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 117.088 -1.434 . . . . 10.0 110.854 179.029 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.656 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.6 t -154.77 -49.31 0.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 123.479 0.712 . . . . 10.0 109.501 173.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 ttmt -106.41 155.84 19.14 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.222 -1.77 . . . . 10.0 106.222 169.317 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.77 164.82 38.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 107.093 -1.447 . . . . 10.0 107.093 170.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -136.17 164.4 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 O-C-N 123.325 0.391 . . . . 10.0 110.854 -176.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.37 101.85 4.09 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.123 -1.065 . . . . 10.0 108.123 168.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.43 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.5 m -85.84 88.26 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 170.11 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -81.67 126.38 31.71 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.087 -0.708 . . . . 10.0 109.087 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 46.8 mtpt -140.8 160.41 40.11 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.05 -1.463 . . . . 10.0 107.05 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.07 -60.93 0.04 OUTLIER Glycine 0 C--O 1.229 -0.199 0 C-N-CA 120.808 -0.71 . . . . 10.0 112.745 169.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.99 -43.94 64.3 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 -176.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.82 -70.75 0.41 Allowed Glycine 0 CA--C 1.523 0.581 0 CA-C-N 114.23 -1.35 . . . . 10.0 110.446 169.542 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -58.16 -32.61 96.08 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 123.511 2.807 . . . . 10.0 111.665 173.483 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.0 t -67.22 93.75 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 N-CA-C 107.094 -1.447 . . . . 10.0 107.094 177.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -117.96 106.94 13.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.777 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -94.65 142.18 15.91 Favored Glycine 0 N--CA 1.441 -1.017 0 N-CA-C 109.171 -1.572 . . . . 10.0 109.171 169.204 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.611 HG22 HG23 ' B' ' 54' ' ' THR . 2.4 mt -143.77 58.66 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 -169.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.0 mm -79.74 137.28 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 115.688 -0.687 . . . . 10.0 109.328 -173.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -115.33 117.04 29.33 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.433 1.493 . . . . 10.0 108.024 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -102.74 122.88 45.36 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 177.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -118.37 144.61 45.77 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.675 0.671 . . . . 10.0 112.405 173.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -125.31 102.01 7.24 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 127.85 2.46 . . . . 10.0 106.594 167.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -49.74 -56.14 11.34 Favored 'General case' 0 C--N 1.338 0.098 0 C-N-CA 124.415 1.086 . . . . 10.0 109.931 172.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.56 178.54 6.99 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 105.128 -2.175 . . . . 10.0 105.128 171.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.0 t -72.31 -18.79 61.75 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.455 -0.202 . . . . 10.0 110.455 177.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -79.68 -19.38 49.15 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 123.673 0.789 . . . . 10.0 109.765 177.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.61 143.46 45.55 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.531 -1.028 . . . . 10.0 110.531 179.217 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.48 149.03 43.73 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.466 2.11 . . . . 10.0 107.648 168.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 t -79.58 100.34 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.404 ' NZ ' ' OE2' ' A' ' 100' ' ' GLU . 1.8 ttmp? -81.91 108.0 15.07 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.927 -1.508 . . . . 10.0 106.927 168.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.3 m -90.11 103.41 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 107.108 -1.441 . . . . 10.0 107.108 173.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.4 p90 -112.73 153.95 26.93 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-O 121.481 0.657 . . . . 10.0 112.61 173.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.47 179.37 41.28 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.637 -0.792 . . . . 10.0 111.274 169.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.4 p -131.67 103.94 6.65 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 -175.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.777 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.8 pt -79.8 140.99 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 169.178 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -118.28 149.84 40.46 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 169.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.55 -8.15 37.22 Favored Glycine 0 C--N 1.336 0.569 0 CA-C-O 119.534 -0.592 . . . . 10.0 113.354 170.071 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -60.97 176.68 0.39 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.915 0.864 . . . . 10.0 109.75 170.648 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -110.61 171.65 7.34 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 166.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -48.93 156.27 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.858 1.263 . . . . 10.0 112.816 -172.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.01 -169.93 46.84 Favored Glycine 0 N--CA 1.443 -0.858 0 CA-C-O 122.667 1.149 . . . . 10.0 113.848 166.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mp -69.86 141.78 53.16 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 126.246 1.818 . . . . 10.0 110.139 -177.321 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -142.54 151.98 42.15 Favored 'General case' 0 C--N 1.341 0.203 0 N-CA-C 114.132 1.16 . . . . 10.0 114.132 178.085 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.694 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.71 122.39 0.13 Allowed Glycine 0 C--N 1.34 0.783 0 C-N-CA 128.533 2.968 . . . . 10.0 112.709 164.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -156.14 107.22 2.46 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.206 1.503 . . . . 10.0 111.72 168.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.437 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -157.55 169.75 23.96 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 113.2 0.815 . . . . 10.0 113.2 -179.764 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.4 m -84.13 157.79 3.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 CA-C-N 112.694 -2.048 . . . . 10.0 109.929 169.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -142.14 140.15 32.35 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 126.58 1.952 . . . . 10.0 107.366 179.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -58.55 -59.72 4.94 Favored 'General case' 0 N--CA 1.446 -0.645 0 O-C-N 124.212 0.945 . . . . 10.0 111.249 -172.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -76.95 123.02 25.7 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 117.932 -1.507 . . . . 10.0 108.984 -169.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.05 -9.25 63.0 Favored Glycine 0 CA--C 1.535 1.317 0 N-CA-C 110.336 -1.106 . . . . 10.0 110.336 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -59.07 99.84 0.06 Allowed 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 122.371 1.081 . . . . 10.0 111.453 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -107.53 14.39 25.84 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 113.506 -1.679 . . . . 10.0 110.432 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.675 HG23 HG22 ' B' ' 17' ' ' ILE . 3.1 m -54.71 -35.51 63.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 120.065 1.302 . . . . 10.0 110.776 -177.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.72 -19.99 57.05 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.769 0.828 . . . . 10.0 112.392 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 133.05 -87.74 0.27 Allowed Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.432 1.492 . . . . 10.0 109.533 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 15.7 t -155.17 62.04 0.64 Allowed 'General case' 0 CA--C 1.529 0.162 0 O-C-N 122.067 -0.666 . . . . 10.0 109.705 -172.233 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -162.5 -49.92 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.557 -0.714 . . . . 10.0 110.175 -175.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.7 t -57.47 -19.98 27.77 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 123.941 0.896 . . . . 10.0 111.149 -178.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.82 -27.36 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.822 2.049 . . . . 10.0 113.589 168.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.48 170.69 33.17 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 108.071 -2.012 . . . . 10.0 108.071 168.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -81.5 -166.38 0.4 Allowed 'Trans proline' 0 N--CA 1.441 -1.582 0 N-CA-C 107.077 -1.932 . . . . 10.0 107.077 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.437 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.6 m170 -82.85 58.94 4.57 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 120.893 -1.129 . . . . 10.0 110.629 -174.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -71.99 74.18 0.9 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.949 0.88 . . . . 10.0 111.257 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 -74.92 153.11 86.84 Favored Pre-proline 0 CA--C 1.537 0.444 0 C-N-CA 124.292 1.037 . . . . 10.0 110.302 171.336 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.12 -43.54 11.23 Favored 'Trans proline' 0 N--CA 1.456 -0.712 0 C-N-CA 122.322 2.015 . . . . 10.0 111.019 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.6 51.21 0.73 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.401 0.68 . . . . 10.0 110.579 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 35.0 p -52.48 112.51 0.83 Allowed 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.247 1.019 . . . . 10.0 109.907 -174.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 30.1 mtt85 -136.93 -85.71 0.32 Allowed 'General case' 0 CA--C 1.511 -0.545 0 N-CA-C 106.953 -1.499 . . . . 10.0 106.953 -170.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -144.7 158.2 43.88 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-O 122.402 1.096 . . . . 10.0 109.361 167.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 67.3 t60 -73.13 120.46 18.79 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 162.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.5 -131.75 2.45 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 108.148 -1.981 . . . . 10.0 108.148 175.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.09 -149.2 7.87 Favored Glycine 0 C--O 1.226 -0.351 0 N-CA-C 109.106 -1.598 . . . . 10.0 109.106 169.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -64.92 3.71 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.863 0 CA-C-N 120.344 2.072 . . . . 10.0 111.656 169.112 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -92.35 -22.48 19.67 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 124.901 1.28 . . . . 10.0 110.611 172.09 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 59.6 t0 -117.18 152.77 34.09 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.118 -1.067 . . . . 10.0 108.118 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -79.2 -33.43 43.87 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.403 -1.271 . . . . 10.0 108.078 169.188 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -91.02 8.1 37.08 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.415 1.486 . . . . 10.0 111.606 -170.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.21 142.1 3.04 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.456 1.103 . . . . 10.0 110.478 176.109 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.7 m170 -59.73 -59.37 5.54 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.447 0.641 . . . . 10.0 110.342 -169.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.52 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.3 p -173.5 -98.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 104.586 -2.376 . . . . 10.0 104.586 177.469 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.52 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -79.1 58.38 4.34 Favored Glycine 0 CA--C 1.529 0.954 0 CA-C-N 118.776 0.716 . . . . 10.0 111.457 174.391 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -90.59 90.59 8.05 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 104.309 -2.478 . . . . 10.0 104.309 167.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 8.6 mt -70.79 -33.28 70.57 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.28 -76.53 0.51 Allowed Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 10.0 111.32 167.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -135.43 118.58 16.52 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 117.938 0.869 . . . . 10.0 109.45 -175.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.2 m -103.98 122.44 56.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 168.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 m -82.67 101.75 11.04 Favored 'General case' 0 N--CA 1.437 -1.107 0 C-N-CA 127.402 2.281 . . . . 10.0 109.507 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.64 130.24 35.33 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.251 0.62 . . . . 10.0 110.561 175.587 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -58.94 169.03 1.1 Allowed 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 124.215 0.947 . . . . 10.0 109.277 167.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 ptmm? -50.78 -32.4 19.76 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.539 1.535 . . . . 10.0 111.565 169.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.8 m-20 -78.28 -5.16 51.2 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.933 0.893 . . . . 10.0 111.321 -178.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.78 6.91 88.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 111.071 -0.811 . . . . 10.0 111.071 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.0 t -79.95 107.2 12.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.926 0 C-N-CA 126.532 1.933 . . . . 10.0 106.043 176.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.686 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -110.12 118.58 36.78 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 169.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -81.68 123.97 29.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 O-C-N 124.408 1.068 . . . . 10.0 108.461 172.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 99.4 t -112.38 130.44 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.238 0 C-N-CA 127.097 2.159 . . . . 10.0 106.365 177.043 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.3 p -156.11 65.34 0.57 Allowed 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.477 0.711 . . . . 10.0 109.458 174.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -96.63 156.9 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 -177.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.404 ' OE2' ' NZ ' ' A' ' 30' ' ' LYS . 8.5 tt0 -136.02 121.86 19.87 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 125.465 1.506 . . . . 10.0 109.38 -178.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -125.66 117.78 24.24 Favored 'General case' 0 C--O 1.232 0.174 0 C-N-CA 124.623 1.169 . . . . 10.0 108.6 -177.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -89.14 54.64 3.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 171.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.02 -53.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 C-N-CA 122.932 0.493 . . . . 10.0 110.245 -176.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -58.27 147.52 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 172.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.1 p -137.48 136.19 37.5 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.365 -0.379 . . . . 10.0 110.402 170.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -77.79 -35.08 51.91 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 107.862 -1.162 . . . . 10.0 107.862 168.511 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.7 m -151.39 130.58 12.73 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 103.534 -2.765 . . . . 10.0 103.534 168.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.33 -79.7 0.1 Allowed Glycine 0 C--N 1.331 0.302 0 N-CA-C 109.219 -1.552 . . . . 10.0 109.219 -169.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -147.22 -54.29 0.22 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.09 -1.055 . . . . 10.0 108.68 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -75.84 -36.99 59.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.372 -1.286 . . . . 10.0 108.633 -173.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.7 t 45.69 61.12 2.77 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.317 1.047 . . . . 10.0 110.326 169.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 25.5 pt -74.53 31.77 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.89 0.852 . . . . 10.0 112.956 -169.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.7 mm -81.76 123.82 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 C-N-CA 125.627 1.571 . . . . 10.0 107.912 -176.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.14 4.66 64.5 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 123.947 0.785 . . . . 10.0 111.541 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -83.58 171.05 13.71 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 168.189 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 2.4 m -119.12 140.7 49.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 108.245 -1.021 . . . . 10.0 108.245 -177.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.517 HD11 ' CG1' ' A' ' 149' ' ' ILE . 0.2 OUTLIER -113.43 164.25 13.85 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.61 0.641 . . . . 10.0 109.631 168.174 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -140.56 134.22 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 O-C-N 123.953 0.783 . . . . 10.0 109.345 -172.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.9 m -96.95 133.0 40.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 106.554 -1.647 . . . . 10.0 106.554 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.694 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m-70 -114.01 158.3 21.37 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 114.948 1.462 . . . . 10.0 114.948 -175.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -55.78 -47.16 77.55 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.246 1.819 . . . . 10.0 111.35 -179.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 79.3 mttt -112.46 163.39 14.51 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 119.121 0.873 . . . . 10.0 112.903 -175.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.76 152.78 30.32 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 124.697 1.199 . . . . 10.0 108.755 169.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.96 151.4 31.64 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-O 122.746 1.26 . . . . 10.0 112.292 -179.378 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.82 -29.54 44.83 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 112.133 -2.303 . . . . 10.0 109.448 170.633 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.0 mt 58.55 34.68 24.08 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 124.694 1.198 . . . . 10.0 111.893 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.1 -18.48 57.27 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 123.969 0.795 . . . . 10.0 111.768 170.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -74.77 -5.98 46.4 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 124.344 1.058 . . . . 10.0 111.941 -168.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.54 -28.99 70.59 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.362 -1.095 . . . . 10.0 110.362 168.217 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.76 43.46 54.15 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.512 -1.035 . . . . 10.0 110.512 -170.274 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -128.28 168.16 15.89 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.115 -1.069 . . . . 10.0 108.115 175.058 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -48.52 -50.24 32.69 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.076 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 58.8 mp0 -55.85 -54.13 48.26 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 125.805 1.642 . . . . 10.0 111.811 171.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.8 p -49.74 -44.98 48.87 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 109.389 -0.596 . . . . 10.0 109.389 -173.118 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.7 t -81.19 -1.64 45.51 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.503 0.557 . . . . 10.0 112.503 -171.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.7 mttt -112.68 -50.37 2.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 125.653 1.581 . . . . 10.0 112.128 -176.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.1 p -139.09 17.17 2.62 Favored 'General case' 0 C--N 1.34 0.174 0 CA-C-N 119.545 1.066 . . . . 10.0 111.817 173.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.07 -116.45 5.56 Favored Glycine 0 N--CA 1.436 -1.311 0 N-CA-C 103.794 -3.722 . . . . 10.0 103.794 -169.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -163.88 40.42 0.09 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.582 -1.636 . . . . 10.0 106.582 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.71 -4.47 37.65 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 124.06 0.944 . . . . 10.0 112.193 -170.539 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.72 -164.3 53.09 Favored Glycine 0 N--CA 1.446 -0.679 0 O-C-N 121.415 -0.803 . . . . 10.0 111.527 169.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.6 m -53.86 131.37 39.76 Favored 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 124.711 1.204 . . . . 10.0 114.019 -168.117 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 34.0 mtt180 -64.95 73.47 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.519 1.928 . . . . 10.0 111.168 174.248 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 43.1 mt -51.03 -35.67 35.5 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 112.642 0.608 . . . . 10.0 112.642 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.49 153.09 32.78 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 121.901 -0.5 . . . . 10.0 109.722 176.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.6 p -149.98 156.51 41.85 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 109.38 -0.6 . . . . 10.0 109.38 178.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.85 153.95 25.17 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.063 -0.815 . . . . 10.0 111.063 -176.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 84.6 t -102.88 139.86 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 105.967 -1.864 . . . . 10.0 105.967 -173.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.517 ' CG1' HD11 ' A' ' 117' ' ' LEU . 18.0 mt -74.91 110.31 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 122.843 0.457 . . . . 10.0 109.894 -175.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.61 141.92 15.38 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 124.237 0.922 . . . . 10.0 110.972 -177.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.8 mt -64.83 146.38 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.401 1.48 . . . . 10.0 110.523 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.59 165.57 29.97 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-O 122.564 1.173 . . . . 10.0 110.506 167.814 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 . . . . . 0 C--O 1.255 1.384 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 166.15 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 105.885 -1.894 . . . . 10.0 105.885 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.7 t -76.81 -46.62 24.21 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 119.996 1.271 . . . . 10.0 110.351 -168.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -127.36 128.3 45.64 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 124.321 1.048 . . . . 10.0 111.317 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.04 160.88 38.73 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 123.348 0.659 . . . . 10.0 109.591 168.742 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.13 162.09 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 124.129 0.972 . . . . 10.0 109.291 -178.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.41 102.75 3.88 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.703 -1.221 . . . . 10.0 107.703 169.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.414 HG12 HG23 ' B' ' 17' ' ' ILE . 1.5 m -85.12 111.88 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 N-CA-C 108.851 -0.796 . . . . 10.0 108.851 169.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mt -88.16 141.12 28.82 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.481 -0.933 . . . . 10.0 108.481 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -157.8 161.72 38.41 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.696 1.135 . . . . 10.0 108.14 171.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.59 -55.98 0.04 OUTLIER Glycine 0 C--N 1.329 0.166 0 N-CA-C 111.937 -0.465 . . . . 10.0 111.937 170.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.75 -45.78 41.65 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 -170.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.48 -66.19 0.57 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 113.676 -1.602 . . . . 10.0 110.786 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -57.81 -36.9 98.07 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.763 2.308 . . . . 10.0 111.071 172.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -67.52 109.9 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 108.472 -0.936 . . . . 10.0 108.472 174.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -126.57 112.25 15.3 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 106.381 -1.711 . . . . 10.0 106.381 168.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.636 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -96.39 145.28 17.75 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.718 -1.353 . . . . 10.0 109.718 171.091 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.675 HG22 HG23 ' A' ' 54' ' ' THR . 1.7 mt -145.62 87.63 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -169.801 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -105.99 145.33 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.204 0 C-N-CA 124.446 1.098 . . . . 10.0 110.253 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -121.06 126.33 49.57 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 127.078 2.151 . . . . 10.0 109.564 168.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -103.68 114.07 28.07 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 170.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -109.27 126.97 53.89 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 123.502 0.501 . . . . 10.0 111.333 169.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 -94.08 99.41 11.71 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 106.811 -1.552 . . . . 10.0 106.811 174.065 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.454 -0.243 0 C-N-CA 124.83 1.252 . . . . 10.0 109.928 -177.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.822 0 N-CA-C 110.073 -1.211 . . . . 10.0 110.073 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -66.12 150.54 85.06 Favored 'Trans proline' 0 N--CA 1.451 -1.029 0 C-N-CA 121.811 1.674 . . . . 10.0 108.426 169.648 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.11 121.0 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 N-CA-C 105.723 -1.954 . . . . 10.0 105.723 169.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.5 ttmp? -95.81 120.57 36.31 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 107.124 -1.436 . . . . 10.0 107.124 169.142 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -100.17 103.94 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 C-N-CA 126.824 2.049 . . . . 10.0 106.147 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -126.84 166.35 17.63 Favored 'General case' 0 CA--C 1.52 -0.198 0 N-CA-C 112.355 0.502 . . . . 10.0 112.355 177.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.18 -150.57 22.44 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 106.928 -2.469 . . . . 10.0 106.928 169.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.0 p -156.38 165.38 36.5 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.88 175.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.636 HG22 ' CA ' ' B' ' 16' ' ' GLY . 1.8 pp -113.67 173.19 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-N 115.298 -0.864 . . . . 10.0 108.868 167.261 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.8 tttt -144.03 142.04 30.44 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 106.492 -1.67 . . . . 10.0 106.492 164.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.03 -8.32 11.57 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 113.05 170.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.485 HD23 HD13 ' B' ' 35' ' ' ILE . 0.3 OUTLIER -67.37 177.73 1.79 Allowed 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.181 0.993 . . . . 10.0 111.037 177.464 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.1 t -110.77 152.85 26.13 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.724 -1.584 . . . . 10.0 106.724 168.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -53.52 150.78 6.41 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.437 0.695 . . . . 10.0 112.216 -168.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.67 -168.49 20.59 Favored Glycine 0 CA--C 1.523 0.567 0 C-N-CA 123.828 0.728 . . . . 10.0 111.295 173.726 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mp -78.16 138.87 38.92 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.335 1.454 . . . . 10.0 110.892 -172.192 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -142.02 131.91 24.39 Favored 'General case' 0 CA--C 1.521 -0.165 0 C-N-CA 124.376 1.07 . . . . 10.0 112.254 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.624 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -17.75 122.92 0.01 OUTLIER Glycine 0 C--N 1.343 0.918 0 C-N-CA 128.001 2.715 . . . . 10.0 113.161 167.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -148.76 106.3 3.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 119.198 1.499 . . . . 10.0 110.633 171.459 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.84 169.95 21.0 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.596 0.712 . . . . 10.0 111.393 177.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 9.3 p -90.6 145.88 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 CA-C-N 111.946 -2.388 . . . . 10.0 107.274 166.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -125.69 146.16 49.86 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.019 -1.845 . . . . 10.0 106.019 170.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . 0.51 ' CD ' ' HE ' ' B' ' 115' ' ' ARG . 29.7 tp10 -76.42 -31.5 57.94 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.295 -0.866 . . . . 10.0 111.887 -166.639 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -78.95 113.94 17.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.081 -1.081 . . . . 10.0 108.081 174.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.34 -15.6 68.18 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 167.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -42.89 148.47 0.25 Allowed 'General case' 0 C--N 1.343 0.305 0 C-N-CA 124.735 1.214 . . . . 10.0 111.716 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.43 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -158.24 16.54 0.22 Allowed 'General case' 0 N--CA 1.441 -0.925 0 C-N-CA 125.519 1.528 . . . . 10.0 111.564 169.917 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.611 HG23 HG22 ' A' ' 17' ' ' ILE . 3.1 m -54.95 -37.4 66.42 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 119.458 1.026 . . . . 10.0 111.469 -169.147 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.8 -22.23 46.57 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.409 1.084 . . . . 10.0 112.528 177.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 126.89 -167.01 19.46 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 106.246 -2.742 . . . . 10.0 106.246 -169.308 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m -72.65 53.28 0.32 Allowed 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 125.005 1.322 . . . . 10.0 107.877 169.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 88.9 m -120.83 -50.22 2.18 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 127.638 2.375 . . . . 10.0 108.245 -165.265 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 14.4 m -114.11 10.61 17.44 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.935 1.294 . . . . 10.0 112.226 -169.174 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -72.49 32.09 0.06 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.434 1.094 . . . . 10.0 113.721 -175.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.67 122.67 0.31 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.151 0.882 . . . . 10.0 112.667 168.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . 0.401 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 67.6 Cg_endo -77.33 60.79 7.14 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.13 2.553 . . . . 10.0 111.492 174.682 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 62.62 48.27 4.44 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.95 1.7 . . . . 10.0 110.235 173.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . 0.401 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 28.8 m-85 -71.03 62.21 0.29 Allowed 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.766 0.712 . . . . 10.0 111.373 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -65.58 142.36 98.25 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.291 -0.881 . . . . 10.0 111.303 -172.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.35 -41.61 6.52 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.723 2.282 . . . . 10.0 110.249 -177.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.75 55.16 1.04 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.166 0.986 . . . . 10.0 108.771 175.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.9 p -34.15 104.95 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 126.539 1.936 . . . . 10.0 111.859 -169.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.11 176.97 8.18 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 104.319 -2.475 . . . . 10.0 104.319 -173.166 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -69.78 154.28 42.2 Favored 'General case' 0 N--CA 1.435 -1.185 0 C-N-CA 117.148 -1.821 . . . . 10.0 107.994 169.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -65.72 118.29 9.38 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 104.717 -2.327 . . . . 10.0 104.717 159.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.79 -177.3 22.09 Favored Glycine 0 N--CA 1.435 -1.409 0 N-CA-C 106.699 -2.561 . . . . 10.0 106.699 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.65 -156.59 6.93 Favored Glycine 0 C--O 1.227 -0.294 0 N-CA-C 109.35 -1.5 . . . . 10.0 109.35 -177.423 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -65.48 1.66 2.0 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.323 1.349 . . . . 10.0 110.613 166.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -109.16 0.86 19.97 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 117.754 -1.117 . . . . 10.0 112.007 173.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -116.22 162.78 16.95 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 169.235 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -79.1 -39.79 32.8 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 167.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -110.55 63.53 0.61 Allowed 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 124.697 1.199 . . . . 10.0 111.65 -168.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -60.65 161.81 7.33 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.359 1.064 . . . . 10.0 109.728 166.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 15.5 m170 -66.49 -71.54 0.19 Allowed 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 113.062 0.764 . . . . 10.0 113.062 -174.095 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -166.79 -53.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 O-C-N 121.638 -0.664 . . . . 10.0 109.689 -173.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -131.48 60.47 0.68 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 171.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -112.15 90.5 3.36 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.074 -2.195 . . . . 10.0 105.074 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . 0.553 ' C ' HD12 ' B' ' 84' ' ' LEU . 0.3 OUTLIER -82.22 -30.38 30.83 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 106.362 -1.718 . . . . 10.0 106.362 -178.076 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.92 -83.96 0.36 Allowed Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 168.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -156.88 156.35 32.99 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 122.839 0.456 . . . . 10.0 111.101 -177.628 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.5 m -124.48 142.08 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 C-N-CA 125.289 1.435 . . . . 10.0 109.766 -174.339 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -85.71 103.1 14.19 Favored 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 129.433 3.093 . . . . 10.0 110.927 -172.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.48 136.12 36.25 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.861 -0.524 . . . . 10.0 109.844 169.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -65.93 172.49 3.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.733 1.613 . . . . 10.0 110.23 167.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.23 -23.48 66.69 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 122.771 0.428 . . . . 10.0 112.091 173.534 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -75.83 -3.05 33.0 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 120.864 0.364 . . . . 10.0 110.252 174.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.48 24.73 60.23 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 108.719 -1.752 . . . . 10.0 108.719 176.327 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.6 t -110.13 109.51 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 127.081 2.152 . . . . 10.0 106.904 -174.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.477 ' H ' ' CD1' ' B' ' 35' ' ' ILE . . . -102.17 120.19 40.04 Favored 'General case' 0 CA--C 1.513 -0.467 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 169.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -79.97 119.21 22.5 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 127.415 2.286 . . . . 10.0 108.8 170.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -103.68 130.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 C-N-CA 124.839 1.256 . . . . 10.0 107.754 177.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.9 p -158.42 83.02 0.83 Allowed 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 118.646 -0.693 . . . . 10.0 109.227 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.68 152.59 20.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 N-CA-C 107.553 -1.277 . . . . 10.0 107.553 179.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -126.81 137.01 53.13 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 126.014 1.726 . . . . 10.0 110.31 174.055 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.27 141.08 39.86 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.829 0.852 . . . . 10.0 109.513 177.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 18.6 p -106.3 22.91 14.97 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.363 1.465 . . . . 10.0 109.924 169.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 51.0 t -94.88 -15.21 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 C-N-CA 124.859 1.264 . . . . 10.0 109.479 -177.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.447 HD13 ' H ' ' B' ' 104' ' ' ILE . 0.0 OUTLIER -134.53 175.17 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 125.461 1.504 . . . . 10.0 112.42 -169.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -158.85 147.0 18.1 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 107.631 -1.248 . . . . 10.0 107.631 169.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -60.03 -50.61 73.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.727 -0.842 . . . . 10.0 108.727 -178.238 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 49.8 p . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 172.866 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.44 -0.956 0 CA-C-O 118.995 -0.526 . . . . 10.0 110.921 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 20.6 pt -67.75 -10.05 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 113.606 0.965 . . . . 10.0 113.606 -172.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . 0.418 HD12 HG23 ' B' ' 151' ' ' ILE . 21.2 mm -53.41 139.58 11.18 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 O-C-N 120.854 -1.153 . . . . 10.0 110.159 169.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.41 4.5 84.44 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.556 -1.136 . . . . 10.0 113.986 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . 0.51 ' HE ' ' CD ' ' B' ' 49' ' ' GLU . 27.7 mmt-85 -79.55 178.57 8.04 Favored 'General case' 0 C--N 1.342 0.239 0 CA-C-N 119.223 1.512 . . . . 10.0 109.542 168.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -124.69 135.54 53.13 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 106.454 -1.684 . . . . 10.0 106.454 178.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 7.9 mp -105.08 148.57 26.67 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.406 -1.331 . . . . 10.0 107.406 169.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.5 t -126.88 135.22 64.29 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 N-CA-C 107.429 -1.323 . . . . 10.0 107.429 178.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -102.91 121.0 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.883 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 169.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.624 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.0 m170 -106.12 162.6 13.48 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -169.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -47.95 -50.05 28.41 Favored 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 128.425 2.69 . . . . 10.0 112.477 174.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -128.49 171.97 11.58 Favored 'General case' 0 C--N 1.334 -0.086 0 C-N-CA 124.141 0.976 . . . . 10.0 112.225 -168.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.02 165.7 24.68 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.304 -0.862 . . . . 10.0 109.798 170.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.76 155.85 17.15 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.97 1.308 . . . . 10.0 111.637 -176.049 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -77.85 -15.3 59.15 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 114.731 -1.122 . . . . 10.0 110.254 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 73.2 mt 51.65 45.42 28.14 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 124.538 1.135 . . . . 10.0 110.335 172.179 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.19 27.85 73.26 Favored Glycine 0 N--CA 1.437 -1.246 0 CA-C-N 113.797 -1.547 . . . . 10.0 113.378 173.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -74.78 -3.84 34.06 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.295 1.548 . . . . 10.0 112.356 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.22 25.27 73.63 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 108.791 -1.724 . . . . 10.0 108.791 175.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -56.03 -30.15 56.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 170.601 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -155.87 167.84 29.12 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.59 -0.892 . . . . 10.0 108.59 -168.365 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.2 tm-20 -56.29 -46.27 79.83 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 108.511 -0.922 . . . . 10.0 108.511 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -59.04 -24.48 62.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 115.96 -0.564 . . . . 10.0 111.997 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 51.9 m -56.13 -32.63 64.41 Favored 'General case' 0 N--CA 1.444 -0.744 0 O-C-N 121.656 -0.653 . . . . 10.0 112.398 -177.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.6 t -93.46 7.73 43.38 Favored 'General case' 0 CA--C 1.534 0.339 0 O-C-N 123.52 0.512 . . . . 10.0 110.108 -174.074 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -128.69 -61.04 1.08 Allowed 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 126.678 1.991 . . . . 10.0 112.46 -174.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -135.71 31.03 3.09 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 120.69 1.586 . . . . 10.0 109.462 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 63.99 -97.59 0.23 Allowed Glycine 0 C--N 1.346 1.109 0 CA-C-O 123.79 1.772 . . . . 10.0 108.925 175.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.86 39.41 0.1 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 113.172 -1.514 . . . . 10.0 109.064 167.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.71 -12.95 52.25 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.713 0.805 . . . . 10.0 112.702 -169.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.75 -166.06 52.06 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 175.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -55.35 131.11 44.92 Favored 'General case' 0 N--CA 1.444 -0.771 0 C-N-CA 123.573 0.749 . . . . 10.0 111.935 -168.544 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -65.7 75.79 0.07 Allowed 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.603 0.761 . . . . 10.0 109.676 169.385 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 69.3 mt -45.37 -49.8 12.74 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.602 0.761 . . . . 10.0 110.726 177.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.56 155.86 36.96 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.495 -0.557 . . . . 10.0 109.495 -171.083 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -158.27 166.88 31.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.05 0.54 . . . . 10.0 109.572 -174.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.91 160.17 32.18 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 110.179 -1.169 . . . . 10.0 110.179 -173.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 57.4 t -109.25 138.38 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -171.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.7 mt -75.82 108.96 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 -177.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.5 135.19 12.23 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 109.957 -1.257 . . . . 10.0 109.957 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . 0.418 HG23 HD12 ' B' ' 113' ' ' ILE . 2.3 pt -75.42 127.25 36.89 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.231 0 CA-C-N 118.557 1.178 . . . . 10.0 108.604 174.189 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -75.39 -54.89 6.31 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 107.134 -1.432 . . . . 10.0 107.134 178.506 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.348 -0.834 . . . . 10.0 109.457 172.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 106.85 -1.537 . . . . 10.0 106.85 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 t -167.51 -38.01 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 124.055 0.942 . . . . 10.0 111.881 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 57.1 tttp -133.46 141.39 47.79 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 124.531 1.132 . . . . 10.0 109.843 178.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.66 169.53 21.36 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 126.487 1.915 . . . . 10.0 107.226 176.375 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.9 162.1 35.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 N-CA-C 109.526 -0.546 . . . . 10.0 109.526 -179.248 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.404 ' HB1' HD21 ' A' ' 8' ' ' LEU . . . -132.04 97.64 4.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.989 0.916 . . . . 10.0 108.951 175.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -83.73 106.0 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 N-CA-C 108.677 -0.86 . . . . 10.0 108.677 169.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.404 HD21 ' HB1' ' A' ' 6' ' ' ALA . 8.9 mt -100.14 140.68 34.02 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.63 -0.878 . . . . 10.0 108.63 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.9 ttmt -157.84 163.7 37.72 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.509 -1.293 . . . . 10.0 107.509 169.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.57 -53.14 0.06 OUTLIER Glycine 0 C--O 1.228 -0.255 0 C-N-CA 120.333 -0.937 . . . . 10.0 112.163 169.33 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -72.64 -45.34 59.49 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.329 -1.36 . . . . 10.0 107.329 -177.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.28 -71.09 0.41 Allowed Glycine 0 CA--C 1.524 0.619 0 CA-C-N 114.355 -1.293 . . . . 10.0 110.342 169.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -57.44 -34.8 98.56 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.462 2.775 . . . . 10.0 111.242 173.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.6 t -65.3 100.81 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.082 0 N-CA-C 107.335 -1.358 . . . . 10.0 107.335 175.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -119.5 116.23 25.67 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.568 1.147 . . . . 10.0 108.381 172.546 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.751 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.71 145.47 17.79 Favored Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 109.892 -1.283 . . . . 10.0 109.892 169.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.633 HG22 HG23 ' B' ' 54' ' ' THR . 1.2 mt -151.54 56.94 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.8 mm -80.82 140.23 16.95 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.041 0 O-C-N 121.587 -0.695 . . . . 10.0 110.011 -175.011 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -99.74 115.3 29.19 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.04 1.336 . . . . 10.0 108.298 170.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -92.56 110.38 21.8 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 105.486 -2.042 . . . . 10.0 105.486 170.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -131.17 146.6 52.4 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 119.084 0.856 . . . . 10.0 110.481 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.405 ' HB3' ' HA ' ' A' ' 29' ' ' VAL . 13.8 pt20 -148.24 16.21 1.05 Allowed 'General case' 0 C--N 1.342 0.274 0 N-CA-C 115.319 1.6 . . . . 10.0 115.319 -178.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? 74.23 -57.38 0.62 Allowed 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 125.595 1.558 . . . . 10.0 113.163 168.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.68 -157.26 0.8 Allowed 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 107.964 -1.124 . . . . 10.0 107.964 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -85.48 -23.08 27.94 Favored 'General case' 0 N--CA 1.45 -0.448 0 O-C-N 120.808 -1.182 . . . . 10.0 110.638 170.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -89.33 -21.27 23.21 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 123.985 0.914 . . . . 10.0 111.503 -173.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.56 151.76 51.68 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.619 -0.545 . . . . 10.0 112.356 -171.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -68.46 137.29 39.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.95 2.433 . . . . 10.0 108.842 169.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.405 ' HA ' ' HB3' ' A' ' 22' ' ' GLN . 0.3 OUTLIER -77.74 138.55 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 O-C-N 121.849 -0.532 . . . . 10.0 110.957 179.627 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -119.63 124.93 47.52 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.848 -1.538 . . . . 10.0 106.848 168.418 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.3 m -102.76 59.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 124.339 1.055 . . . . 10.0 109.094 -170.104 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.8 p90 -79.03 146.01 33.55 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 119.625 -0.83 . . . . 10.0 111.312 -172.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.39 -169.48 39.2 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.646 -0.981 . . . . 10.0 110.646 169.156 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.4 m -139.6 107.53 5.7 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.065 -0.717 . . . . 10.0 109.065 -170.411 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.751 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.2 pt -78.31 128.01 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 106.873 -1.529 . . . . 10.0 106.873 168.508 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 tttt -107.21 146.66 31.13 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.115 -1.439 . . . . 10.0 107.115 173.328 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -7.07 31.06 Favored Glycine 0 CA--C 1.522 0.528 0 CA-C-O 119.197 -0.779 . . . . 10.0 112.678 173.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.415 HD21 HD12 ' A' ' 35' ' ' ILE . 3.4 mm? -62.47 177.01 0.55 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.675 1.238 . . . . 10.0 109.284 168.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -113.53 157.06 22.51 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.961 -0.755 . . . . 10.0 108.961 170.039 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -48.9 123.67 7.41 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.062 1.345 . . . . 10.0 111.094 -171.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.66 -169.12 13.13 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 123.794 0.711 . . . . 10.0 112.347 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -77.3 146.77 36.61 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 126.12 1.768 . . . . 10.0 112.391 -170.448 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -149.48 144.0 26.03 Favored 'General case' 0 C--N 1.342 0.276 0 N-CA-C 114.049 1.129 . . . . 10.0 114.049 -178.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.595 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -33.15 126.24 0.34 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 127.145 2.307 . . . . 10.0 112.232 165.56 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.403 ' CD1' HD12 ' A' ' 84' ' ' LEU . 6.6 t80 -151.03 108.11 3.58 Favored 'General case' 0 C--O 1.238 0.486 0 CA-C-N 119.504 1.652 . . . . 10.0 109.561 167.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.94 174.44 13.62 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.148 0.975 . . . . 10.0 113.4 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.9 p -90.61 151.4 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 CA-C-N 112.028 -2.351 . . . . 10.0 108.038 168.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -127.59 142.69 51.29 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 106.931 -1.507 . . . . 10.0 106.931 171.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -37.24 -55.77 0.98 Allowed 'General case' 0 C--O 1.237 0.403 0 C-N-CA 127.535 2.334 . . . . 10.0 113.7 -170.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -106.34 169.31 8.59 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-O 122.367 1.079 . . . . 10.0 112.556 -171.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.42 -23.47 24.05 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 126.664 2.078 . . . . 10.0 109.771 169.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -43.39 120.41 1.9 Allowed 'General case' 0 C--N 1.346 0.417 0 CA-C-O 122.009 0.909 . . . . 10.0 109.863 170.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -134.75 11.9 3.69 Favored 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 125.942 1.697 . . . . 10.0 108.497 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.436 HG23 HG22 ' B' ' 17' ' ' ILE . 1.3 m -59.45 -33.64 71.54 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 119.031 0.832 . . . . 10.0 112.083 -168.216 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.39 -16.14 59.0 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.915 0.886 . . . . 10.0 112.33 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.26 62.92 0.56 Allowed Glycine 0 CA--C 1.521 0.462 0 N-CA-C 108.655 -1.778 . . . . 10.0 108.655 -172.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.6 p 41.31 39.6 1.02 Allowed 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 125.868 1.667 . . . . 10.0 114.122 171.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 16.3 m -108.13 -53.3 2.65 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.759 2.024 . . . . 10.0 105.584 -177.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.4 m -66.66 -15.46 63.5 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.525 1.93 . . . . 10.0 112.665 -175.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -50.06 -6.28 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.936 2.494 . . . . 10.0 115.715 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 105.8 123.41 5.16 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.117 -1.38 . . . . 10.0 110.372 170.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.59 60.16 5.78 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.595 2.863 . . . . 10.0 110.638 173.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.518 ' CD2' HG22 ' A' ' 137' ' ' THR . 20.9 m170 65.34 37.61 6.23 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 130.27 3.428 . . . . 10.0 111.897 179.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.1 m-30 -72.89 62.32 0.59 Allowed 'General case' 0 N--CA 1.468 0.462 0 O-C-N 121.196 -0.94 . . . . 10.0 110.628 175.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -74.1 152.66 88.49 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.247 -0.908 . . . . 10.0 111.146 -172.182 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -60.45 -42.67 39.09 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.435 2.756 . . . . 10.0 111.848 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.3 tp -77.91 59.08 2.04 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 123.781 0.832 . . . . 10.0 108.772 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 58.7 p -40.75 104.85 0.04 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.282 2.233 . . . . 10.0 112.128 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -137.62 175.11 9.88 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 126.403 1.881 . . . . 10.0 107.467 -177.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.15 113.93 27.42 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-N 118.952 0.796 . . . . 10.0 109.884 -174.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.0 t60 -30.18 101.55 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 114.593 1.331 . . . . 10.0 114.593 -171.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -114.44 -147.97 9.6 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 176.247 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.33 -148.65 5.64 Favored Glycine 0 C--N 1.332 0.334 0 CA-C-O 118.237 -1.313 . . . . 10.0 109.902 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -62.76 -3.76 4.95 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 CA-C-N 120.225 2.012 . . . . 10.0 111.946 169.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -85.0 -19.61 31.77 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 118.452 -0.785 . . . . 10.0 111.041 171.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -130.55 162.41 29.35 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 123.849 1.785 . . . . 10.0 112.875 -166.309 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -85.43 -24.06 27.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 112.879 -1.964 . . . . 10.0 108.261 166.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -86.34 7.79 24.11 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.532 1.533 . . . . 10.0 110.85 -174.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 33.9 ptt-85 -48.33 126.83 11.93 Favored 'General case' 0 C--N 1.342 0.263 0 N-CA-C 106.507 -1.664 . . . . 10.0 106.507 166.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m80 -50.57 -57.47 8.08 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.11 0.411 . . . . 10.0 112.11 -167.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.7 p -173.9 -45.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 124.711 1.205 . . . . 10.0 108.33 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.14 56.44 0.73 Allowed Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.681 -1.367 . . . . 10.0 109.681 175.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -97.5 97.25 8.92 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 106.001 -1.851 . . . . 10.0 106.001 169.058 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.403 HD12 ' CD1' ' A' ' 45' ' ' PHE . 14.0 mt -76.26 -27.11 56.58 Favored 'General case' 0 C--N 1.34 0.163 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 173.418 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.71 -104.17 3.07 Favored Glycine 0 N--CA 1.439 -1.128 0 N-CA-C 108.638 -1.785 . . . . 10.0 108.638 168.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -122.3 100.28 6.87 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.055 1.342 . . . . 10.0 109.48 -167.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.2 m -95.74 136.92 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 C-N-CA 122.855 0.462 . . . . 10.0 110.187 178.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.8 m -85.19 119.41 25.54 Favored 'General case' 0 N--CA 1.439 -0.985 0 C-N-CA 127.437 2.295 . . . . 10.0 108.819 -177.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.57 134.65 39.52 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 123.568 0.747 . . . . 10.0 109.627 169.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -62.62 169.86 2.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 O-C-N 124.412 1.07 . . . . 10.0 108.751 166.419 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.86 -21.63 64.84 Favored 'General case' 0 N--CA 1.445 -0.705 0 C-N-CA 124.192 0.997 . . . . 10.0 112.892 172.454 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.17 -4.68 45.86 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.036 0.446 . . . . 10.0 110.691 171.523 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.22 6.3 86.44 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 120.671 -1.268 . . . . 10.0 110.839 178.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.18 106.13 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 127.339 2.256 . . . . 10.0 107.332 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.432 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -103.43 116.47 32.47 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 167.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.28 104.17 10.65 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 126.812 2.045 . . . . 10.0 109.841 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.12 131.86 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 172.517 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.3 m -157.52 57.63 0.5 Allowed 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.495 1.118 . . . . 10.0 109.476 173.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.84 150.75 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.835 -1.543 . . . . 10.0 106.835 178.455 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -128.19 150.81 49.85 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 108.626 170.11 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.13 124.42 6.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 108.873 -0.788 . . . . 10.0 108.873 172.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 11.0 t -79.07 0.48 27.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.291 1.037 . . . . 10.0 112.196 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.41 -24.75 17.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 CA-C-N 119.579 1.081 . . . . 10.0 109.486 177.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.0 159.28 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 124.599 1.16 . . . . 10.0 111.003 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.8 m -152.72 144.93 23.89 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.281 -2.118 . . . . 10.0 105.281 174.632 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.6 mt -65.04 -8.55 16.7 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 123.95 0.9 . . . . 10.0 111.828 176.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.6 m -150.94 137.96 19.15 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.031 -1.47 . . . . 10.0 107.031 169.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.26 -66.25 0.14 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 109.018 -1.633 . . . . 10.0 109.018 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -167.71 -51.44 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 125.58 1.552 . . . . 10.0 107.981 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.96 -36.19 62.07 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 114.914 -1.039 . . . . 10.0 109.128 -169.194 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 30.9 t 38.98 70.66 0.2 Allowed 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 126.692 1.997 . . . . 10.0 112.263 167.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -56.67 -10.22 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 114.113 1.153 . . . . 10.0 114.113 177.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 mm -33.87 -52.95 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.327 1.451 . . . . 10.0 112.98 170.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -96.81 9.48 66.11 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-O 118.937 -0.924 . . . . 10.0 114.153 -174.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.94 156.46 21.18 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 118.525 1.162 . . . . 10.0 109.742 176.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 59.1 m -90.4 131.58 36.1 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.768 0.827 . . . . 10.0 109.627 168.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -99.87 145.61 27.58 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 167.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.8 t -137.46 136.34 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 123.516 0.726 . . . . 10.0 109.17 -176.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.35 142.08 17.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 O-C-N 124.579 1.175 . . . . 10.0 108.811 167.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.595 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.5 m170 -121.72 162.03 21.53 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.896 1.443 . . . . 10.0 114.896 -175.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -58.31 -50.87 72.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.266 1.427 . . . . 10.0 110.736 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -116.39 172.75 7.0 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 121.804 0.812 . . . . 10.0 112.203 -178.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.28 138.96 40.88 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 126.054 1.742 . . . . 10.0 108.981 174.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.36 164.76 25.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 122.232 1.015 . . . . 10.0 111.847 173.596 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.413 ' OD1' ' NZ ' ' A' ' 128' ' ' LYS . 25.6 t0 -74.82 -8.15 55.57 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 113.608 -1.633 . . . . 10.0 111.298 178.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 14.5 mt 46.8 41.18 10.05 Favored 'General case' 0 C--N 1.339 0.113 0 C-N-CA 124.484 1.114 . . . . 10.0 109.831 -177.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 72.05 19.64 78.53 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 118.313 -1.271 . . . . 10.0 114.765 171.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.413 ' NZ ' ' OD1' ' A' ' 125' ' ' ASP 0.251 8.7 mtmp? -77.13 10.65 2.25 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 119.803 1.801 . . . . 10.0 114.991 -176.073 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.72 29.0 61.98 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 109.185 -1.566 . . . . 10.0 109.185 168.196 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -53.19 -30.01 38.17 Favored Glycine 0 N--CA 1.436 -1.351 0 CA-C-O 118.132 -1.371 . . . . 10.0 110.321 167.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 174.61 178.85 0.13 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 106.7 -1.593 . . . . 10.0 106.7 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 37.5 mp0 -49.48 -41.29 40.12 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 112.876 0.695 . . . . 10.0 112.876 179.179 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 -64.33 -24.13 67.54 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 121.244 -0.91 . . . . 10.0 110.684 -178.481 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.413 ' HA ' ' HA2' ' A' ' 138' ' ' GLY . 55.1 m -45.3 -44.58 11.58 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 122.964 0.506 . . . . 10.0 110.286 175.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 t -84.7 -1.09 55.7 Favored 'General case' 0 CA--C 1.541 0.628 0 O-C-N 124.049 0.843 . . . . 10.0 112.147 -170.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.1 mttt -118.82 -73.65 0.64 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.955 1.302 . . . . 10.0 110.275 -173.386 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.518 HG22 ' CD2' ' A' ' 63' ' ' HIS . 7.1 p -121.56 26.83 8.56 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 120.164 -1.585 . . . . 10.0 110.242 171.544 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' A' ' 134' ' ' SER . . . 72.86 -91.57 0.6 Allowed Glycine 0 C--N 1.342 0.886 0 N-CA-C 109.934 -1.266 . . . . 10.0 109.934 174.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.38 39.12 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.195 1.398 . . . . 10.0 108.886 171.087 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.26 -16.61 62.49 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 121.473 -0.767 . . . . 10.0 112.77 -168.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.37 -162.59 54.66 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.102 -1.199 . . . . 10.0 110.102 175.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -51.9 126.77 19.14 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.036 1.334 . . . . 10.0 113.8 -168.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -64.7 72.89 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.229 1.812 . . . . 10.0 110.996 173.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.2 mt -51.12 -35.67 36.6 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 113.381 0.882 . . . . 10.0 113.381 -178.069 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 154.47 37.09 Favored 'General case' 0 CA--C 1.511 -0.555 0 O-C-N 121.61 -0.681 . . . . 10.0 109.948 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.6 p -153.24 153.7 33.21 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.583 -0.895 . . . . 10.0 108.583 -172.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.81 153.37 24.36 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 112.044 -0.422 . . . . 10.0 112.044 179.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 63.4 t -101.3 125.31 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.012 -2.218 . . . . 10.0 105.012 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.2 mt -68.55 164.93 2.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 CA-C-N 119.009 0.822 . . . . 10.0 110.403 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -160.5 150.66 20.84 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.576 1.56 . . . . 10.0 109.443 -172.136 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.3 mt -70.93 141.7 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.892 1.277 . . . . 10.0 109.023 -173.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.43 -46.51 2.87 Favored 'General case' 0 C--O 1.224 -0.268 0 C-N-CA 123.1 0.56 . . . . 10.0 110.674 170.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.7 tp60 . . . . . 0 C--O 1.25 1.107 0 C-N-CA 126.634 1.974 . . . . 10.0 112.082 -173.04 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.872 0 CA-C-O 117.571 -1.205 . . . . 10.0 108.993 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 t -61.27 -38.16 85.74 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 120.19 1.359 . . . . 10.0 108.852 172.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 36.9 tttt -132.03 156.35 46.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.447 1.499 . . . . 10.0 110.219 168.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.47 175.35 14.14 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 129.01 2.924 . . . . 10.0 106.504 166.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -133.6 179.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 118.677 0.671 . . . . 10.0 110.611 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.43 108.9 2.1 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.093 0.957 . . . . 10.0 109.189 165.039 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -95.17 124.28 47.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 122.959 0.503 . . . . 10.0 110.208 170.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -103.54 146.24 28.84 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 125.441 1.496 . . . . 10.0 110.275 176.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 5.4 tttm -161.73 158.61 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 169.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 179.86 -46.55 0.08 OUTLIER Glycine 0 N--CA 1.46 0.236 0 C-N-CA 118.927 -1.606 . . . . 10.0 113.638 169.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -72.59 -47.71 45.69 Favored 'General case' 0 N--CA 1.451 -0.375 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 -178.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.91 -73.84 0.29 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 114.331 -1.304 . . . . 10.0 109.845 171.115 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -59.07 -34.74 98.98 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.738 2.959 . . . . 10.0 111.18 174.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.5 t -62.2 114.04 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.12 -1.067 . . . . 10.0 108.12 176.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.87 118.6 22.97 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 106.339 -1.726 . . . . 10.0 106.339 168.589 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.679 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -102.47 141.12 15.14 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-O 118.598 -1.112 . . . . 10.0 110.48 174.42 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.436 HG22 HG23 ' A' ' 54' ' ' THR . 9.4 mt -139.78 94.2 0.77 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 C-N-CA 123.874 0.87 . . . . 10.0 109.063 -173.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.7 mm -105.71 139.77 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 C-N-CA 125.658 1.583 . . . . 10.0 112.623 -178.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -106.75 126.6 52.49 Favored 'General case' 0 C--N 1.34 0.179 0 N-CA-C 106.452 -1.685 . . . . 10.0 106.452 167.059 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -104.16 112.42 25.42 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 107.057 -1.46 . . . . 10.0 107.057 168.54 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -126.82 136.32 52.2 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 118.462 0.573 . . . . 10.0 112.35 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -105.48 112.76 25.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.62 1.568 . . . . 10.0 106.873 169.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.235 0.308 0 N-CA-C 111.93 0.344 . . . . 10.0 111.93 -177.023 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.025 0 CA-C-O 118.59 -1.117 . . . . 10.0 114.496 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -65.26 115.84 3.55 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 CA-C-N 119.834 1.817 . . . . 10.0 107.652 170.375 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t -77.27 84.65 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 105.31 -2.107 . . . . 10.0 105.31 175.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -74.35 117.4 16.12 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.024 -1.473 . . . . 10.0 107.024 179.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.42 58.77 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 C-N-CA 125.085 1.354 . . . . 10.0 108.121 -169.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.4 p90 -81.48 143.21 32.24 Favored 'General case' 0 C--N 1.341 0.209 0 C-N-CA 119.134 -1.026 . . . . 10.0 111.996 -176.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.81 -169.09 41.39 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.636 -1.269 . . . . 10.0 110.106 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 m -153.24 133.11 13.2 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.679 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.3 pt -103.63 147.72 9.53 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 N-CA-C 107.995 -1.113 . . . . 10.0 107.995 167.212 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -124.81 149.98 46.85 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 169.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.48 -6.7 36.24 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 123.428 0.537 . . . . 10.0 112.519 171.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.41 HD12 ' CG ' ' B' ' 43' ' ' HIS . 2.0 mm? -63.93 174.43 1.49 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.956 0.878 . . . . 10.0 109.965 169.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -101.76 170.81 7.92 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 105.898 -1.89 . . . . 10.0 105.898 165.414 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -59.84 166.67 2.52 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 118.661 0.664 . . . . 10.0 111.829 -171.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.49 -171.56 45.75 Favored Glycine 0 N--CA 1.446 -0.647 0 O-C-N 121.478 -0.764 . . . . 10.0 111.72 169.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -77.5 144.31 37.8 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.259 1.424 . . . . 10.0 111.224 -174.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . 0.41 ' CG ' HD12 ' B' ' 38' ' ' LEU . 89.7 m-70 -147.48 127.88 14.01 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.518 1.127 . . . . 10.0 112.633 -173.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.69 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -18.69 128.71 0.01 OUTLIER Glycine 0 C--N 1.342 0.881 0 C-N-CA 127.499 2.476 . . . . 10.0 114.179 165.739 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.75 104.94 3.23 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 118.605 1.203 . . . . 10.0 109.793 167.73 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.51 176.46 10.93 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 112.766 0.654 . . . . 10.0 112.766 176.385 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 23.4 m -89.82 158.69 2.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 113.601 -1.636 . . . . 10.0 108.626 168.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 74.8 m-70 -136.47 78.11 1.69 Allowed 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 123.586 0.755 . . . . 10.0 111.138 176.021 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.8 tt0 47.65 -94.42 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.792 1.237 . . . . 10.0 113.027 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -78.76 172.03 14.32 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.582 0.628 . . . . 10.0 110.01 -173.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.97 -23.1 23.74 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.553 -1.019 . . . . 10.0 110.553 170.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -37.71 135.07 0.64 Allowed 'General case' 0 C--N 1.343 0.306 0 C-N-CA 124.598 1.159 . . . . 10.0 110.863 170.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.427 HD21 HG21 ' B' ' 116' ' ' THR . 0.3 OUTLIER -146.05 23.99 1.33 Allowed 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 114.75 -1.114 . . . . 10.0 110.362 173.152 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.633 HG23 HG22 ' A' ' 17' ' ' ILE . 2.7 m -52.43 -36.83 55.34 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.065 0.848 . . . . 10.0 110.982 -173.513 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.56 -21.72 28.41 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.29 1.436 . . . . 10.0 113.697 177.178 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.48 101.92 1.45 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.813 1.197 . . . . 10.0 110.183 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.314 2.6 p 17.43 57.65 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 127.752 2.421 . . . . 10.0 114.151 -170.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.8 m -130.48 -61.9 0.94 Allowed 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.479 -2.045 . . . . 10.0 105.479 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 39.3 t -69.66 -35.68 75.38 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.009 1.324 . . . . 10.0 111.323 -178.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.88 -47.41 0.13 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 127.122 2.169 . . . . 10.0 114.181 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 138.5 172.54 12.6 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.243 -1.543 . . . . 10.0 109.243 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -78.67 -137.35 0.02 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.222 0 N-CA-C 104.156 -3.055 . . . . 10.0 104.156 166.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 27.3 m170 -100.99 50.68 0.86 Allowed 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 121.067 1.758 . . . . 10.0 109.557 170.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -71.79 80.05 0.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.169 0.985 . . . . 10.0 110.033 177.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.5 p-10 -80.15 156.31 74.26 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 125.474 1.509 . . . . 10.0 110.222 172.614 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -63.51 -50.1 3.75 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.489 2.126 . . . . 10.0 111.292 177.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.58 57.72 1.64 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.213 0.605 . . . . 10.0 109.887 179.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.9 p -51.35 114.21 1.16 Allowed 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.607 1.163 . . . . 10.0 109.999 -176.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.2 mtt-85 -131.33 -86.49 0.49 Allowed 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 104.996 -2.224 . . . . 10.0 104.996 -176.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 ptpp? -163.26 162.77 25.42 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 167.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 66.9 t60 -58.28 132.67 54.31 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 118.358 -1.337 . . . . 10.0 107.655 168.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.37 -133.23 2.64 Favored Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 169.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.507 ' HA3' HD13 ' B' ' 126' ' ' LEU . . . 163.51 -161.28 33.99 Favored Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 108.376 -1.89 . . . . 10.0 108.376 178.046 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.74 4.61 0.8 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.864 1.71 . . . . 10.0 111.928 168.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.567 ' HG3' HD12 ' B' ' 126' ' ' LEU . 9.9 mmmt -114.03 7.94 16.94 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 119.225 0.92 . . . . 10.0 110.481 170.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -125.93 163.09 23.74 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 119.733 1.151 . . . . 10.0 108.977 167.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -81.61 -30.06 33.02 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 169.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -119.65 61.5 0.83 Allowed 'General case' 0 N--CA 1.436 -1.168 0 CA-C-O 122.095 0.95 . . . . 10.0 110.859 -168.489 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . 0.442 HH12 ' CG ' ' B' ' 101' ' ' ASP . 0.3 OUTLIER -56.32 164.39 1.36 Allowed 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 114.393 -1.276 . . . . 10.0 108.697 164.833 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.6 m170 -65.99 -84.57 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 N-CA-C 108.569 -0.9 . . . . 10.0 108.569 169.36 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 49.2 t -149.82 -82.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 104.186 -2.524 . . . . 10.0 104.186 169.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.83 53.89 4.77 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.566 -0.614 . . . . 10.0 111.566 -178.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -93.9 98.78 11.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 104.39 -2.448 . . . . 10.0 104.39 168.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 37.1 mt -81.92 -36.26 28.26 Favored 'General case' 0 C--N 1.334 -0.095 0 N-CA-C 105.744 -1.947 . . . . 10.0 105.744 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.26 -92.06 0.64 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 106.717 -2.553 . . . . 10.0 106.717 169.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -155.82 155.73 33.5 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 122.793 0.437 . . . . 10.0 111.45 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.48 145.68 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 O-C-N 124.762 1.289 . . . . 10.0 108.507 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.0 m -93.43 110.42 21.98 Favored 'General case' 0 N--CA 1.436 -1.135 0 C-N-CA 128.497 2.719 . . . . 10.0 108.88 -172.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.3 135.59 33.49 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 123.771 0.828 . . . . 10.0 110.117 174.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -61.65 168.51 2.91 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 124.091 0.956 . . . . 10.0 109.107 166.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.78 -30.67 45.7 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.492 0.717 . . . . 10.0 111.079 172.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -78.68 1.6 22.36 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-O 121.25 0.548 . . . . 10.0 111.454 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.92 90.7 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 120.843 -1.161 . . . . 10.0 110.947 176.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.1 t -79.77 104.72 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.059 0 C-N-CA 127.09 2.156 . . . . 10.0 107.013 179.242 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.54 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -107.55 115.09 29.53 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 168.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.7 123.36 27.59 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 127.381 2.272 . . . . 10.0 108.622 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.0 t -110.79 131.43 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 C-N-CA 125.494 1.517 . . . . 10.0 107.279 178.804 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 93.0 p -156.98 59.14 0.52 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 123.316 0.646 . . . . 10.0 109.552 177.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.83 154.82 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -176.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -102.33 153.21 20.22 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 126.639 1.976 . . . . 10.0 107.382 170.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . 0.442 ' CG ' HH12 ' B' ' 79' ' ' ARG . 23.8 t0 -149.06 85.17 1.46 Allowed 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.583 0.706 . . . . 10.0 109.292 174.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.8 p -90.25 38.11 0.92 Allowed 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.81 0.844 . . . . 10.0 109.663 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 26.1 t -106.75 -46.19 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 107.444 -1.317 . . . . 10.0 107.444 176.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.406 ' CD1' ' H ' ' B' ' 104' ' ' ILE 0.261 0.0 OUTLIER -100.88 176.01 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 114.155 1.168 . . . . 10.0 114.155 175.465 . . . . . . . . 4 4 . 1 . 019 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -136.29 142.8 43.95 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.517 -1.66 . . . . 10.0 106.517 169.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -65.58 -25.72 67.54 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.131 0.573 . . . . 10.0 110.117 171.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.451 -0.408 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 170.275 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.9 t . . . . . 0 N--CA 1.443 -0.794 0 CA-C-O 118.356 -0.831 . . . . 10.0 109.301 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 12.5 pt -68.97 65.19 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.324 0 CA-C-O 122.786 1.279 . . . . 10.0 110.388 173.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.6 mm -110.61 151.73 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 129.117 2.967 . . . . 10.0 105.275 167.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 55.31 35.64 61.09 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 124.866 1.222 . . . . 10.0 113.746 171.382 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 83.7 mtt85 -113.96 154.62 27.28 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.305 1.842 . . . . 10.0 107.51 171.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . 0.427 HG21 HD21 ' B' ' 53' ' ' ASN . 90.2 m -86.06 133.95 33.86 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.01 0.924 . . . . 10.0 109.7 177.257 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -98.42 147.46 24.69 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 125.212 1.405 . . . . 10.0 107.297 166.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.57 141.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-N 118.563 0.62 . . . . 10.0 109.369 176.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.418 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 7.6 p -103.32 139.45 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 C-N-CA 124.575 1.15 . . . . 10.0 108.981 168.064 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.69 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.6 m-70 -115.91 164.25 14.69 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.814 1.413 . . . . 10.0 114.814 -175.268 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . 0.402 ' HB2' HD21 ' B' ' 144' ' ' LEU . 73.8 tt0 -59.43 -49.43 77.85 Favored 'General case' 0 C--N 1.343 0.293 0 C-N-CA 123.756 0.823 . . . . 10.0 110.438 178.607 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.2 mttt -121.24 175.56 6.06 Favored 'General case' 0 N--CA 1.462 0.169 0 N-CA-C 112.229 0.455 . . . . 10.0 112.229 -169.186 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.54 139.03 39.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.201 1.0 . . . . 10.0 109.332 173.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.67 144.1 30.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.059 0.944 . . . . 10.0 108.827 167.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -79.2 28.31 0.23 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 123.395 0.678 . . . . 10.0 111.236 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.567 HD12 ' HG3' ' B' ' 75' ' ' LYS . 6.6 mt 23.86 60.23 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 128.685 2.794 . . . . 10.0 112.157 -168.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 92.63 -35.58 4.0 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 126.192 1.853 . . . . 10.0 112.147 174.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.2 mtmm -84.46 44.15 1.02 Allowed 'General case' 0 CA--C 1.537 0.465 0 O-C-N 121.256 -1.144 . . . . 10.0 111.247 -170.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.44 -18.12 46.8 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 126.518 2.008 . . . . 10.0 110.159 169.371 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.15 35.82 91.41 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 123.965 0.793 . . . . 10.0 112.415 172.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -144.48 169.48 17.87 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 107.916 -1.142 . . . . 10.0 107.916 172.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -52.64 -47.4 67.09 Favored 'General case' 0 N--CA 1.444 -0.736 0 CA-C-O 121.805 0.812 . . . . 10.0 110.351 -177.44 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -65.36 -31.59 72.79 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 121.32 -0.863 . . . . 10.0 111.234 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 12.3 p -55.5 -42.14 74.03 Favored 'General case' 0 N--CA 1.447 -0.604 0 O-C-N 120.818 -1.176 . . . . 10.0 111.353 171.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.6 t -80.91 -24.16 38.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 119.835 -0.746 . . . . 10.0 111.202 -176.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 ttmm -80.81 -50.57 9.65 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 125.886 1.674 . . . . 10.0 111.533 -176.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 26.1 p -136.2 -15.18 1.72 Allowed 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 114.441 1.274 . . . . 10.0 114.441 176.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.53 3.07 55.43 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-O 118.286 -1.286 . . . . 10.0 113.884 -179.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 29.1 m120 73.23 26.97 2.02 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.101 1.45 . . . . 10.0 112.359 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.47 -2.29 13.48 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.272 -0.892 . . . . 10.0 113.298 176.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.0 -170.15 50.92 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 -175.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.51 169.66 2.87 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.167 0.987 . . . . 10.0 112.135 -177.01 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.79 115.96 18.82 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.85 2.06 . . . . 10.0 109.814 168.664 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.423 ' CD2' ' N ' ' B' ' 144' ' ' LEU . 0.4 OUTLIER -92.0 -36.84 13.18 Favored 'General case' 0 C--N 1.34 0.169 0 CA-C-N 119.753 1.16 . . . . 10.0 111.414 -176.263 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.418 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -148.36 149.78 32.4 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 176.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -118.63 142.44 47.64 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.796 1.638 . . . . 10.0 107.672 -168.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -137.06 161.19 25.14 Favored Glycine 0 C--N 1.331 0.265 0 N-CA-C 109.79 -1.324 . . . . 10.0 109.79 171.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -123.52 152.27 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 104.246 -2.501 . . . . 10.0 104.246 171.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.0 mt -67.41 -91.67 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 124.018 0.927 . . . . 10.0 111.625 -167.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.84 136.2 9.22 Favored Glycine 0 CA--C 1.532 1.112 0 N-CA-C 111.68 -0.568 . . . . 10.0 111.68 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 9.5 pt -85.34 146.78 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 C-N-CA 124.534 1.134 . . . . 10.0 110.122 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.87 -24.36 8.19 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.575 0.75 . . . . 10.0 112.8 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.88 0 C-N-CA 124.355 1.062 . . . . 10.0 108.195 -174.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.86 0 CA-C-O 117.89 -1.053 . . . . 10.0 109.158 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -116.81 -50.3 2.61 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 123.947 0.899 . . . . 10.0 112.304 -176.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -111.87 125.73 54.34 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 126.638 1.975 . . . . 10.0 108.825 -176.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 164.22 30.54 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.694 1.198 . . . . 10.0 108.286 170.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.4 m -139.04 164.46 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 C-N-CA 123.7 0.8 . . . . 10.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.66 118.72 15.38 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.644 -0.873 . . . . 10.0 108.644 168.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -92.34 110.23 22.57 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.33 -0.989 . . . . 10.0 108.33 168.248 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.424 HD12 ' N ' ' A' ' 8' ' ' LEU . 5.1 mp -95.0 144.86 25.35 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 108.731 -0.84 . . . . 10.0 108.731 177.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.2 mtmt -156.45 161.49 40.06 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 172.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.69 -51.59 0.09 OUTLIER Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.071 -1.061 . . . . 10.0 113.653 169.29 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.4 -44.57 62.3 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.49 -1.3 . . . . 10.0 107.49 -175.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.19 -71.01 0.4 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.684 -1.366 . . . . 10.0 109.684 169.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -58.06 -35.54 98.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 123.089 2.526 . . . . 10.0 111.273 172.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.3 t -64.65 107.33 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 178.264 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.45 104.87 10.0 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 172.489 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.807 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.37 137.1 14.15 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 176.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.424 ' CG2' HG22 ' B' ' 54' ' ' THR . 3.7 mt -139.08 87.93 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.282 0 N-CA-C 107.381 -1.34 . . . . 10.0 107.381 -175.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -99.75 141.64 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.16 0 C-N-CA 124.819 1.248 . . . . 10.0 110.059 -178.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -126.27 113.45 16.97 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.476 1.91 . . . . 10.0 108.569 175.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -93.51 115.02 27.53 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 126.367 1.867 . . . . 10.0 108.545 177.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -117.5 130.04 56.19 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.85 1.055 . . . . 10.0 113.85 171.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -105.2 111.88 24.8 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 104.545 -2.391 . . . . 10.0 104.545 166.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -65.0 -36.78 85.52 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.952 -0.468 . . . . 10.0 111.131 -172.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -137.6 -165.43 1.77 Allowed 'General case' 0 N--CA 1.436 -1.175 0 N-CA-C 104.521 -2.4 . . . . 10.0 104.521 171.508 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.0 t -78.6 -24.48 45.39 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 118.97 0.805 . . . . 10.0 110.206 173.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.6 m-80 -91.83 -17.88 24.65 Favored 'General case' 0 N--CA 1.448 -0.574 0 C-N-CA 124.648 1.179 . . . . 10.0 110.551 -175.26 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.22 144.82 41.74 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 178.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -63.63 156.87 54.62 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 N-CA-C 108.116 -1.532 . . . . 10.0 108.116 169.576 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 75.2 t -79.0 102.31 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 N-CA-C 106.036 -1.839 . . . . 10.0 106.036 175.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.2 mtpp -79.0 105.38 10.3 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 105.49 -2.041 . . . . 10.0 105.49 170.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -100.58 97.85 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 C-N-CA 125.421 1.488 . . . . 10.0 107.502 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.6 p90 -103.26 174.59 5.8 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.322 0.582 . . . . 10.0 110.205 169.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.07 170.93 37.97 Favored Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 110.79 -0.924 . . . . 10.0 110.79 177.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.6 t -136.82 96.39 3.31 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 177.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.807 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.6 pt -81.24 140.59 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 169.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.6 tttm -112.83 158.08 20.59 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 108.522 -0.918 . . . . 10.0 108.522 167.339 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.12 -7.27 58.57 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 123.579 0.609 . . . . 10.0 112.678 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -67.44 170.07 8.04 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 118.235 1.017 . . . . 10.0 109.86 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -103.65 153.33 20.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.688 -1.597 . . . . 10.0 106.688 167.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.6 143.88 4.72 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.25 1.02 . . . . 10.0 112.046 -170.497 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.48 -173.35 24.89 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 123.846 0.736 . . . . 10.0 112.269 171.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.26 145.27 54.41 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.594 1.957 . . . . 10.0 111.493 -175.162 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -146.31 141.25 27.1 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.398 1.079 . . . . 10.0 111.77 175.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.67 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -24.69 123.58 0.03 OUTLIER Glycine 0 C--N 1.344 1.008 0 C-N-CA 126.493 1.996 . . . . 10.0 112.219 165.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -144.55 104.54 4.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 119.735 1.767 . . . . 10.0 109.502 171.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.26 170.41 20.1 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 121.835 0.826 . . . . 10.0 111.557 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.4 m -88.54 149.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-N 112.139 -2.301 . . . . 10.0 106.259 167.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -120.6 128.08 52.7 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 103.782 -2.673 . . . . 10.0 103.782 169.049 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -58.54 -51.35 70.25 Favored 'General case' 0 N--CA 1.44 -0.932 0 O-C-N 124.99 1.431 . . . . 10.0 110.016 -168.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -79.55 137.84 37.29 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 -179.542 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.34 25.57 9.72 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.853 -0.899 . . . . 10.0 110.853 173.077 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.7 p30 -75.84 72.48 2.73 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 123.542 1.639 . . . . 10.0 109.317 170.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.471 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.6 OUTLIER -75.82 6.24 5.28 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 113.658 -1.61 . . . . 10.0 112.66 -173.853 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.543 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.1 OUTLIER -39.2 -44.26 1.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 128.207 2.603 . . . . 10.0 111.982 175.221 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.37 -19.97 48.89 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.247 1.019 . . . . 10.0 113.258 -177.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.79 87.13 1.47 Allowed Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.404 -1.079 . . . . 10.0 110.404 -177.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 m 52.31 29.14 6.38 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.417 1.487 . . . . 10.0 112.407 172.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.5 m -117.53 -54.83 2.34 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.295 -1.372 . . . . 10.0 107.295 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.1 m -77.01 -16.19 59.39 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 123.961 0.905 . . . . 10.0 112.579 -171.081 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -53.03 -12.88 0.38 Allowed 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.979 1.712 . . . . 10.0 115.234 -170.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.23 125.87 3.06 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 118.647 -1.085 . . . . 10.0 110.436 171.621 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -75.53 64.01 6.47 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.49 2.793 . . . . 10.0 111.732 179.326 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 26.7 m170 67.07 53.91 0.78 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 128.692 2.797 . . . . 10.0 111.108 175.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 -71.85 43.77 0.1 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 114.604 1.335 . . . . 10.0 114.604 -173.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -56.57 147.38 50.75 Favored Pre-proline 0 CA--C 1.54 0.568 0 O-C-N 120.817 -1.177 . . . . 10.0 112.565 -174.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -64.89 -43.03 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.81 2.34 . . . . 10.0 110.853 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 75.9 mt -76.69 54.6 0.98 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.484 0.714 . . . . 10.0 109.381 176.493 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.9 p -35.47 109.75 0.09 Allowed 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 126.019 1.727 . . . . 10.0 110.868 -173.074 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -131.71 -174.03 3.3 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 104.474 -2.417 . . . . 10.0 104.474 -170.126 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -82.39 159.02 23.1 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 106.262 -1.755 . . . . 10.0 106.262 169.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.7 t60 -59.04 123.5 16.79 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 106.826 -1.546 . . . . 10.0 106.826 162.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.93 -144.0 5.39 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 108.635 -1.786 . . . . 10.0 108.635 174.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.41 -163.39 29.72 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 109.746 -1.342 . . . . 10.0 109.746 169.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -63.99 3.68 0.69 Allowed 'Trans proline' 0 N--CA 1.455 -0.761 0 CA-C-N 119.763 1.782 . . . . 10.0 111.99 169.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 42.3 mmtt -100.19 -16.13 17.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.082 -0.961 . . . . 10.0 110.707 171.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -114.54 165.95 12.23 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 119.051 0.841 . . . . 10.0 109.901 -178.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -77.25 -38.61 50.72 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 105.431 -2.063 . . . . 10.0 105.431 167.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.277 1.5 pt-20 -103.48 49.89 0.82 Allowed 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 115.461 1.652 . . . . 10.0 115.461 -160.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -55.65 159.31 3.03 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 125.651 1.581 . . . . 10.0 108.799 167.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -66.69 -65.86 0.63 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.637 0.732 . . . . 10.0 109.619 168.372 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.534 HG13 ' H ' ' A' ' 82' ' ' GLY . 6.3 p -161.85 -69.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 N-CA-C 107.31 -1.367 . . . . 10.0 107.31 177.352 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.534 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -109.48 56.23 0.47 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 109.598 -1.401 . . . . 10.0 109.598 177.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -87.98 91.26 8.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 104.058 -2.571 . . . . 10.0 104.058 167.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.9 -32.36 69.28 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.1 -91.7 0.7 Allowed Glycine 0 N--CA 1.434 -1.485 0 N-CA-C 108.273 -1.931 . . . . 10.0 108.273 167.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -145.27 147.35 32.28 Favored 'General case' 0 N--CA 1.447 -0.596 0 O-C-N 123.818 0.364 . . . . 10.0 110.755 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.2 m -124.21 139.08 51.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 171.126 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 m -89.99 113.92 25.67 Favored 'General case' 0 N--CA 1.441 -0.888 0 C-N-CA 127.887 2.475 . . . . 10.0 107.711 -178.371 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.46 138.01 32.09 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 109.623 -0.51 . . . . 10.0 109.623 169.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -65.72 170.65 4.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.959 1.304 . . . . 10.0 109.658 168.13 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -50.69 -34.51 26.98 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.467 -0.788 . . . . 10.0 110.894 169.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -81.03 5.35 16.74 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.38 0.609 . . . . 10.0 112.039 -178.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.09 4.5 83.59 Favored Glycine 0 C--N 1.342 0.908 0 O-C-N 120.877 -1.139 . . . . 10.0 111.341 175.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.8 t -79.68 109.16 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.975 0 C-N-CA 127.76 2.424 . . . . 10.0 106.597 176.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.569 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -105.66 115.88 31.0 Favored 'General case' 0 CA--C 1.513 -0.459 0 N-CA-C 108.087 -1.079 . . . . 10.0 108.087 167.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -81.97 86.21 6.58 Favored 'General case' 0 N--CA 1.436 -1.157 0 C-N-CA 127.458 2.303 . . . . 10.0 109.294 179.143 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 32.9 t -75.72 131.94 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 N-CA-C 105.097 -2.186 . . . . 10.0 105.097 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -158.3 64.02 0.44 Allowed 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 122.995 0.518 . . . . 10.0 110.198 -175.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -111.47 158.6 11.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 106.948 -1.501 . . . . 10.0 106.948 -175.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -135.19 137.71 42.93 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 123.797 0.839 . . . . 10.0 109.942 168.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.39 147.43 43.4 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.124 0.97 . . . . 10.0 108.809 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 22.9 p -110.45 -2.14 16.7 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.076 1.75 . . . . 10.0 113.882 -172.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.9 p -97.22 -38.78 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 119.821 1.192 . . . . 10.0 109.081 172.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -65.22 136.91 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.953 -1.869 . . . . 10.0 105.953 167.158 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 25.2 m -154.86 132.42 11.28 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 108.943 -0.762 . . . . 10.0 108.943 -175.248 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -78.75 61.02 2.92 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.805 -1.183 . . . . 10.0 107.805 175.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.8 m -84.12 -119.27 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 123.81 0.844 . . . . 10.0 110.165 -174.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.96 -47.32 0.05 OUTLIER Glycine 0 CA--C 1.524 0.628 0 N-CA-C 107.91 -2.076 . . . . 10.0 107.91 -174.479 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -64.54 -59.32 4.44 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.899 0.88 . . . . 10.0 109.04 169.625 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.6 -39.05 58.53 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.276 -0.875 . . . . 10.0 108.658 -174.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.6 t 39.01 76.38 0.06 Allowed 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.525 1.53 . . . . 10.0 112.702 171.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pp -61.36 -26.94 40.84 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 115.899 -0.592 . . . . 10.0 110.382 168.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 32.2 mm -38.67 132.59 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 C-N-CA 126.003 1.721 . . . . 10.0 111.781 173.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.63 7.96 86.73 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-O 118.487 -1.174 . . . . 10.0 113.613 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 64.1 mtt85 -77.57 158.72 29.7 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 118.742 1.271 . . . . 10.0 109.673 169.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.82 115.5 27.52 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.111 -0.7 . . . . 10.0 109.111 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -83.97 138.27 33.21 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 170.028 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 71.9 t -125.34 137.09 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.99 -1.115 . . . . 10.0 107.99 178.033 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.06 132.95 46.99 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 105.542 -2.021 . . . . 10.0 105.542 166.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.67 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 8.5 m-70 -106.88 154.63 20.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 123.186 1.47 . . . . 10.0 114.623 -174.233 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -41.75 -61.92 1.0 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 128.398 2.679 . . . . 10.0 109.157 177.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mtmt -110.0 169.25 8.85 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 125.463 1.505 . . . . 10.0 111.84 -176.576 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.74 136.9 56.85 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.131 -1.395 . . . . 10.0 108.035 169.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 140' ' ' ALA . 0.0 OUTLIER -84.57 158.94 20.77 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 123.763 0.825 . . . . 10.0 110.169 170.687 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -104.02 17.06 24.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.07 0.948 . . . . 10.0 111.701 179.542 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 64.7 mt 43.56 40.72 2.99 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 119.269 0.941 . . . . 10.0 112.782 178.493 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.63 -4.16 53.7 Favored Glycine 0 C--N 1.336 0.565 0 CA-C-O 118.924 -0.931 . . . . 10.0 114.068 175.04 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mttt -118.01 30.69 7.1 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 118.136 0.968 . . . . 10.0 111.217 -166.162 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.65 -36.53 58.35 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 127.521 2.486 . . . . 10.0 110.907 171.674 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 72.45 43.68 44.38 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 111.179 -0.768 . . . . 10.0 111.179 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.461 ' H ' ' HB2' ' A' ' 134' ' ' SER . 12.2 m-80 -145.34 168.93 19.3 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 105.983 -1.858 . . . . 10.0 105.983 171.376 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.407 ' OE1' ' NZ ' ' A' ' 136' ' ' LYS . 15.8 tm-20 -52.57 -42.56 64.6 Favored 'General case' 0 N--CA 1.441 -0.899 0 CA-C-O 121.239 0.542 . . . . 10.0 110.958 177.627 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -63.49 -31.83 73.1 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.263 -0.898 . . . . 10.0 113.23 178.605 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.461 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 17.1 t -43.96 -48.4 8.61 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.226 1.01 . . . . 10.0 109.778 176.181 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 7.8 t -80.4 -3.72 50.82 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-O 118.333 -0.841 . . . . 10.0 112.134 -169.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.407 ' NZ ' ' OE1' ' A' ' 132' ' ' GLU . 41.9 mtmt -111.61 -79.41 0.58 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.317 1.447 . . . . 10.0 110.308 -177.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.9 p -105.94 1.85 27.0 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 120.13 1.332 . . . . 10.0 113.272 177.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.72 27.24 35.64 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-O 118.904 -0.942 . . . . 10.0 113.139 169.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.2 m120 59.36 21.9 10.25 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 118.382 1.091 . . . . 10.0 112.978 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.549 ' HB2' ' HB3' ' A' ' 124' ' ' ASP . . . -66.73 -10.6 48.68 Favored 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 124.897 1.279 . . . . 10.0 112.645 176.635 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.61 -161.83 51.68 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 110.268 -1.133 . . . . 10.0 110.268 177.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.8 m -58.74 139.97 55.47 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 124.129 0.972 . . . . 10.0 112.651 -167.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.13 68.16 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.813 1.245 . . . . 10.0 109.329 167.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . 0.261 0.4 OUTLIER -64.32 -17.04 63.29 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.616 0.969 . . . . 10.0 113.616 -169.144 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 150.92 24.9 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.099 -0.704 . . . . 10.0 109.099 168.094 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.5 p -153.72 165.35 36.25 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.39 0.276 . . . . 10.0 111.034 -177.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.0 -168.04 11.77 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.438 1.018 . . . . 10.0 111.559 -177.329 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 33.7 t -136.92 130.75 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 104.487 -2.412 . . . . 10.0 104.487 176.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -66.47 139.7 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-N 119.438 1.017 . . . . 10.0 110.815 178.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.6 146.67 18.58 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 124.829 1.204 . . . . 10.0 111.214 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 74.8 mt -68.83 152.26 9.63 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 177.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.36 -36.11 1.14 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 114.515 1.302 . . . . 10.0 114.515 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.121 0 N-CA-C 117.529 2.418 . . . . 10.0 117.529 -177.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . 0.451 ' C ' ' H ' ' B' ' 3' ' ' LYS . . . . . . . . 0 N--CA 1.474 0.74 0 CA-C-O 118.232 -0.89 . . . . 10.0 109.099 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . 0.421 HG22 ' O ' ' B' ' 1' ' ' ALA 0.282 9.2 t 70.62 -29.68 0.19 Allowed 'General case' 0 C--N 1.343 0.312 0 C-N-CA 131.397 3.879 . . . . 10.0 111.835 175.036 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . 0.451 ' H ' ' C ' ' B' ' 1' ' ' ALA . 61.3 tttt -152.15 131.37 12.77 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 126.288 1.835 . . . . 10.0 106.98 -168.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.59 165.96 25.85 Favored 'General case' 0 CA--C 1.522 -0.131 0 C-N-CA 124.476 1.11 . . . . 10.0 108.54 171.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.525 ' O ' HG23 ' B' ' 149' ' ' ILE . 7.7 m -131.38 179.97 3.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.395 0 C-N-CA 122.889 0.476 . . . . 10.0 110.563 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.27 110.66 3.74 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 124.459 1.104 . . . . 10.0 108.561 167.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.471 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.5 OUTLIER -96.88 92.23 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 C-N-CA 124.065 0.946 . . . . 10.0 109.419 171.748 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -80.32 137.82 36.64 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.197 0.999 . . . . 10.0 110.608 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.5 tttt -156.25 160.67 40.0 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.972 -1.122 . . . . 10.0 107.972 170.263 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.41 -50.06 0.05 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 121.333 -0.46 . . . . 10.0 112.215 171.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.26 -46.58 32.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 106.738 -1.578 . . . . 10.0 106.738 -173.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.94 -66.26 0.57 Allowed Glycine 0 CA--C 1.527 0.815 0 CA-C-N 113.891 -1.504 . . . . 10.0 110.382 -179.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -60.57 -35.41 90.14 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.964 2.442 . . . . 10.0 111.323 174.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.0 t -70.35 111.21 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 N-CA-C 107.582 -1.266 . . . . 10.0 107.582 175.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.74 110.04 11.83 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.88 -1.896 . . . . 10.0 105.88 168.626 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.738 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -97.79 133.37 11.32 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 110.012 -1.235 . . . . 10.0 110.012 179.02 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.543 ' CG2' HG22 ' A' ' 54' ' ' THR . 5.4 mt -137.57 87.77 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 108.252 -1.018 . . . . 10.0 108.252 -169.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -99.23 152.17 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.133 0 C-N-CA 124.672 1.189 . . . . 10.0 110.546 178.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 21.1 m-80 -134.43 121.57 21.29 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 128.457 2.703 . . . . 10.0 107.807 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -106.58 116.66 32.3 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 174.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.91 143.67 44.77 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.091 0.86 . . . . 10.0 112.861 169.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -93.69 94.02 8.35 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.617 1.567 . . . . 10.0 108.808 -176.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.2 tmtt? . . . . . 0 N--CA 1.445 -0.721 0 C-N-CA 126.369 1.868 . . . . 10.0 110.943 179.508 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.603 0 N-CA-C 106.93 -2.468 . . . . 10.0 106.93 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -66.48 148.79 84.34 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 121.841 1.694 . . . . 10.0 109.553 179.05 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.5 t -78.82 124.95 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 104.313 -2.477 . . . . 10.0 104.313 168.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -98.34 122.4 41.47 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 106.313 -1.736 . . . . 10.0 106.313 168.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.2 p -106.18 106.03 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 C-N-CA 127.708 2.403 . . . . 10.0 105.509 177.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -130.45 173.08 11.18 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 120.9 0.381 . . . . 10.0 110.844 179.042 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.76 -153.29 25.21 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 107.152 -2.379 . . . . 10.0 107.152 169.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 5.4 m -153.15 145.49 23.99 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 119.044 -1.063 . . . . 10.0 110.607 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.738 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.0 pt -111.97 136.75 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 CA-C-N 115.948 -0.569 . . . . 10.0 109.679 168.501 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.5 tptt -110.77 141.27 44.32 Favored 'General case' 0 N--CA 1.441 -0.922 0 N-CA-C 106.289 -1.745 . . . . 10.0 106.289 171.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.3 -6.37 23.16 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 123.757 0.694 . . . . 10.0 112.991 169.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -65.19 176.21 1.4 Allowed 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 118.147 0.974 . . . . 10.0 111.022 176.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -109.82 156.09 20.8 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 168.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -53.33 132.48 39.29 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.792 1.637 . . . . 10.0 111.443 -170.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 122.13 -173.2 15.81 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 118.724 0.693 . . . . 10.0 112.037 173.275 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.66 152.84 39.13 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.741 1.616 . . . . 10.0 110.756 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -150.31 147.73 27.98 Favored 'General case' 0 C--N 1.344 0.367 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -174.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.68 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -28.01 121.0 0.06 OUTLIER Glycine 0 C--N 1.34 0.784 0 C-N-CA 128.822 3.105 . . . . 10.0 113.14 161.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -153.73 101.31 2.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 119.712 1.756 . . . . 10.0 111.6 168.286 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.41 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -154.23 173.1 16.58 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 114.573 1.323 . . . . 10.0 114.573 -178.943 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 33.5 m -82.0 151.2 4.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 112.995 -1.912 . . . . 10.0 109.449 168.533 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -133.1 82.91 2.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.089 -1.078 . . . . 10.0 108.089 172.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 35.04 -80.8 0.0 OUTLIER 'General case' 0 C--O 1.239 0.506 0 C-N-CA 127.674 2.389 . . . . 10.0 115.135 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -77.84 173.78 11.75 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 122.043 0.925 . . . . 10.0 110.089 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -101.03 -19.53 16.71 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 125.152 1.358 . . . . 10.0 110.599 168.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.31 156.39 0.85 Allowed 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.802 1.241 . . . . 10.0 111.946 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.63 27.86 0.44 Allowed 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.322 -0.854 . . . . 10.0 111.822 169.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.424 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -55.06 -39.22 69.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.198 0.999 . . . . 10.0 111.624 -169.728 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.44 -23.71 42.96 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.055 0.942 . . . . 10.0 112.786 177.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.91 114.25 1.53 Allowed Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.829 -0.908 . . . . 10.0 110.829 -170.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 23.5 m 38.06 46.28 0.81 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 127.206 2.203 . . . . 10.0 115.529 169.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -153.31 -54.15 0.11 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 173.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 47.0 t -54.91 -38.61 67.82 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.479 1.112 . . . . 10.0 110.892 -173.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.97 -50.68 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 127.863 2.465 . . . . 10.0 114.487 170.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.01 157.19 9.61 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.299 -1.12 . . . . 10.0 110.299 177.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -74.76 -163.38 0.18 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 N-CA-C 105.395 -2.579 . . . . 10.0 105.395 165.026 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.412 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.9 m170 -81.03 48.66 1.13 Allowed 'General case' 0 CA--C 1.547 0.83 0 O-C-N 119.619 -1.925 . . . . 10.0 110.694 -176.411 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 m-30 -75.35 67.72 1.96 Allowed 'General case' 0 N--CA 1.466 0.341 0 O-C-N 120.936 -1.102 . . . . 10.0 110.332 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -66.19 154.64 89.66 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.408 -0.808 . . . . 10.0 109.919 170.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -76.46 49.68 2.72 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 123.572 2.848 . . . . 10.0 111.204 177.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -178.35 55.78 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 127.482 2.313 . . . . 10.0 105.677 -178.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.0 p -37.11 110.23 0.12 Allowed 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.8 1.24 . . . . 10.0 109.992 177.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -173.69 3.1 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 102.447 -3.168 . . . . 10.0 102.447 177.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -78.08 167.56 21.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 116.651 -2.019 . . . . 10.0 106.831 167.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -65.48 123.62 20.12 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 106.845 -1.539 . . . . 10.0 106.845 162.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.16 -142.05 4.42 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.458 -1.857 . . . . 10.0 108.458 173.605 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.15 -165.24 31.08 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.67 -1.628 . . . . 10.0 109.044 173.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -69.16 10.47 0.4 Allowed 'Trans proline' 0 CA--C 1.541 0.827 0 CA-C-N 119.923 1.861 . . . . 10.0 110.727 167.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -108.8 -1.16 19.48 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 124.84 1.256 . . . . 10.0 110.402 170.121 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -132.22 169.36 16.55 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 119.67 1.123 . . . . 10.0 109.007 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -78.71 -39.23 37.05 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 103.795 -2.669 . . . . 10.0 103.795 165.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -82.14 42.87 0.76 Allowed 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 114.117 1.154 . . . . 10.0 114.117 -165.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.32 159.29 18.33 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 124.006 0.922 . . . . 10.0 109.714 167.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -68.97 -79.91 0.05 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 169.111 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.509 HG13 ' H ' ' B' ' 82' ' ' GLY 0.25 8.6 p -149.18 -79.28 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 N-CA-C 107.175 -1.417 . . . . 10.0 107.175 167.923 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.509 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -86.43 62.52 4.28 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.258 -1.137 . . . . 10.0 110.258 178.415 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -101.55 100.45 10.87 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 105.714 -1.958 . . . . 10.0 105.714 169.065 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -73.73 -9.39 58.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 118.339 0.518 . . . . 10.0 111.452 -174.023 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.89 -99.7 2.34 Favored Glycine 0 N--CA 1.442 -0.94 0 N-CA-C 107.347 -2.301 . . . . 10.0 107.347 -176.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -148.17 144.97 28.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 -177.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.6 m -112.93 137.57 45.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 108.216 -1.031 . . . . 10.0 108.216 168.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -97.94 116.44 30.17 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.962 0.905 . . . . 10.0 109.582 -176.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.67 130.6 35.94 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.604 1.162 . . . . 10.0 109.15 174.572 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.05 168.11 3.47 Favored 'General case' 0 N--CA 1.448 -0.573 0 O-C-N 124.584 1.177 . . . . 10.0 109.824 168.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.9 tttp -47.76 -36.61 11.82 Favored 'General case' 0 N--CA 1.432 -1.327 0 C-N-CA 126.42 1.888 . . . . 10.0 111.468 168.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -79.84 1.04 28.49 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.992 0.517 . . . . 10.0 112.318 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.18 16.79 80.27 Favored Glycine 0 C--N 1.339 0.721 0 O-C-N 120.101 -1.624 . . . . 10.0 110.791 178.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 37.2 t -92.93 105.84 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 C-N-CA 126.513 1.925 . . . . 10.0 106.033 175.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.655 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -102.18 117.74 35.41 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 107.139 -1.43 . . . . 10.0 107.139 168.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -94.23 124.6 38.34 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.315 1.009 . . . . 10.0 108.279 177.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.99 134.53 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 C-N-CA 125.838 1.655 . . . . 10.0 108.421 -174.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -157.46 95.52 1.46 Allowed 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.719 1.207 . . . . 10.0 108.761 170.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 mp -123.59 145.36 30.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 108.105 -1.072 . . . . 10.0 108.105 176.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -106.06 135.28 47.8 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 128.691 2.797 . . . . 10.0 107.745 169.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -140.05 155.38 47.08 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 168.238 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.4 p -126.39 49.19 2.04 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.587 1.155 . . . . 10.0 109.771 174.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 p -133.33 -45.45 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.491 1.117 . . . . 10.0 110.246 172.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.32 131.81 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.298 -1.001 . . . . 10.0 108.298 169.575 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 67.8 m -125.37 112.71 16.64 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 170.078 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 18.1 mt -46.2 -41.52 12.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.193 1.397 . . . . 10.0 110.318 176.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 22.8 p . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 105.844 -1.91 . . . . 10.0 105.844 168.657 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 34.9 t . . . . . 0 N--CA 1.45 -0.473 0 CA-C-O 122.414 1.102 . . . . 10.0 109.922 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 3.6 pt -75.63 58.6 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.849 -0.797 . . . . 10.0 108.849 172.478 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 44.5 mm -108.84 -58.36 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.671 0.788 . . . . 10.0 109.176 -177.638 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -93.46 50.93 2.38 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 109.409 -1.477 . . . . 10.0 109.409 173.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.09 158.24 24.53 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.304 1.842 . . . . 10.0 107.401 177.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 67.1 m -108.68 119.07 38.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 127.042 2.137 . . . . 10.0 106.264 -178.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 62.6 mt -93.49 150.87 20.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 108.224 -1.028 . . . . 10.0 108.224 168.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 79.6 t -132.81 138.36 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 N-CA-C 108.159 -1.052 . . . . 10.0 108.159 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.85 136.76 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 168.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.68 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 9.4 m-70 -116.03 161.12 19.34 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -175.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . 0.418 ' HB2' HD21 ' B' ' 144' ' ' LEU . 53.6 tt0 -60.04 -50.11 75.0 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.217 -0.901 . . . . 10.0 109.677 177.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 92.6 mttt -104.53 163.3 12.56 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.927 0.714 . . . . 10.0 112.927 -168.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.93 157.02 34.29 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 114.301 -1.318 . . . . 10.0 108.991 172.191 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.483 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 47.2 m-20 -109.79 134.78 51.64 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 124.153 0.981 . . . . 10.0 109.243 -169.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -73.26 -24.56 60.47 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 124.861 1.264 . . . . 10.0 110.337 -174.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 59.64 42.87 16.5 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.52 -0.918 . . . . 10.0 108.52 -173.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.53 -53.12 1.02 Allowed Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 124.959 1.266 . . . . 10.0 110.971 170.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -79.29 49.88 1.02 Allowed 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.356 1.062 . . . . 10.0 113.072 -170.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -29.77 7.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 127.118 2.294 . . . . 10.0 110.593 169.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 75.81 18.71 79.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 118.978 -0.901 . . . . 10.0 112.395 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -111.65 160.22 17.45 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 105.947 -1.871 . . . . 10.0 105.947 168.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -50.26 -47.48 55.21 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.33 -1.304 . . . . 10.0 108.397 171.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -64.34 -37.43 87.47 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 112.915 0.709 . . . . 10.0 112.915 177.651 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.6 m -51.63 -45.47 63.3 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.336 1.425 . . . . 10.0 111.035 172.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.9 t -82.45 -22.51 35.2 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 111.922 0.341 . . . . 10.0 111.922 -173.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 25.2 ttmt -89.41 -46.89 8.39 Favored 'General case' 0 N--CA 1.439 -0.978 0 C-N-CA 125.225 1.41 . . . . 10.0 112.129 -177.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.412 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 30.7 p -133.44 -11.62 2.78 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 114.172 1.175 . . . . 10.0 114.172 178.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.22 15.72 37.5 Favored Glycine 0 C--O 1.221 -0.678 0 CA-C-O 118.982 -0.899 . . . . 10.0 112.15 -171.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 57.35 35.1 25.62 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.13 1.465 . . . . 10.0 111.233 -178.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.17 -13.59 62.1 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.515 1.926 . . . . 10.0 111.886 -178.435 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.89 -171.06 54.59 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 109.223 -1.551 . . . . 10.0 109.223 -169.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.1 m -52.52 166.12 0.21 Allowed 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 124.48 1.112 . . . . 10.0 113.071 -177.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -83.93 102.02 12.11 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 107.467 -1.308 . . . . 10.0 107.467 168.472 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.418 HD21 ' HB2' ' B' ' 121' ' ' GLU . 0.4 OUTLIER -71.61 -47.98 51.07 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.05 -1.092 . . . . 10.0 108.05 -177.642 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -143.49 144.54 32.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.094 -0.706 . . . . 10.0 109.094 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 39.0 m -126.71 147.98 49.91 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.669 -1.234 . . . . 10.0 107.669 -176.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.87 141.1 11.57 Favored Glycine 0 C--N 1.332 0.315 0 N-CA-C 108.834 -1.706 . . . . 10.0 108.834 172.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.71 136.8 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 N-CA-C 101.612 -3.477 . . . . 10.0 101.612 169.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.525 HG23 ' O ' ' B' ' 5' ' ' VAL . 68.5 mt -61.86 -81.41 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 CA-C-O 121.418 0.628 . . . . 10.0 110.285 -168.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.99 134.43 8.33 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.371 -0.691 . . . . 10.0 111.371 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.78 137.25 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.089 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 173.435 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.98 -70.08 0.54 Allowed 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 106.742 -1.577 . . . . 10.0 106.742 171.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 20.4 tm0? . . . . . 0 C--O 1.253 1.249 0 N-CA-C 104.827 -2.286 . . . . 10.0 104.827 167.266 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.62 0 N-CA-C 105.511 -2.033 . . . . 10.0 105.511 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.5 t -63.18 -30.62 71.73 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.978 1.263 . . . . 10.0 108.1 167.427 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.5 tmtm? -117.08 146.95 42.8 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 126.088 1.755 . . . . 10.0 108.675 177.562 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.06 177.04 11.78 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 125.829 1.652 . . . . 10.0 109.195 169.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.9 t -136.2 164.04 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 125.277 1.431 . . . . 10.0 108.749 -176.49 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.68 104.36 3.03 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.054 0.941 . . . . 10.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.5 m -93.47 127.99 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 109.322 -0.621 . . . . 10.0 109.322 176.389 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.93 137.28 47.92 Favored 'General case' 0 C--O 1.225 -0.218 0 C-N-CA 124.762 1.225 . . . . 10.0 108.559 -178.736 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 40.1 mtpt -146.22 164.93 30.71 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-N 120.69 1.586 . . . . 10.0 107.968 170.797 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.59 -60.24 0.04 OUTLIER Glycine 0 CA--C 1.511 -0.19 0 C-N-CA 120.377 -0.916 . . . . 10.0 112.291 169.701 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.64 -44.91 61.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 -177.647 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.9 -69.74 0.44 Allowed Glycine 0 CA--C 1.524 0.612 0 CA-C-N 114.296 -1.32 . . . . 10.0 110.887 172.78 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -57.3 -36.3 98.94 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 123.25 2.633 . . . . 10.0 111.263 174.971 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.8 t -65.62 97.56 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.117 -1.438 . . . . 10.0 107.117 175.323 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.56 105.86 11.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.138 0.975 . . . . 10.0 108.424 173.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.781 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -81.03 149.79 29.92 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 109.623 -1.391 . . . . 10.0 109.623 168.38 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -155.22 59.6 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 C-N-CA 125.925 1.69 . . . . 10.0 106.848 -168.939 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 mm -74.94 146.47 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 O-C-N 121.621 -0.675 . . . . 10.0 109.657 -179.27 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -118.9 124.53 47.32 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 126.711 2.004 . . . . 10.0 107.061 177.013 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -106.63 120.6 42.39 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 178.703 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.5 mp0 -125.73 117.8 24.23 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.33 0.652 . . . . 10.0 111.472 176.515 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -124.03 108.99 12.96 Favored 'General case' 0 C--O 1.227 -0.113 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 168.287 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.42 -50.92 68.53 Favored 'General case' 0 C--N 1.333 -0.117 0 O-C-N 121.749 -0.595 . . . . 10.0 110.671 -178.824 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -129.57 170.42 13.78 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 103.557 -2.757 . . . . 10.0 103.557 168.38 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 92.3 p -68.61 -19.75 64.46 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 123.837 0.855 . . . . 10.0 110.39 170.12 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -78.77 -14.83 59.06 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 123.321 0.649 . . . . 10.0 109.278 174.144 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.43 138.67 15.47 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.183 -1.567 . . . . 10.0 109.183 175.828 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -62.4 135.8 55.74 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 CA-C-N 119.414 1.607 . . . . 10.0 108.069 171.328 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.1 p -75.97 120.36 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.425 0 N-CA-C 107.545 -1.28 . . . . 10.0 107.545 -176.779 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.1 mtpt -91.52 109.68 20.98 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.942 -2.244 . . . . 10.0 104.942 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.3 m -104.77 88.82 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 178.768 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -97.33 170.94 8.73 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-O 121.75 0.786 . . . . 10.0 111.664 169.509 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.06 -169.15 38.84 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.51 -1.036 . . . . 10.0 110.51 172.025 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.9 p -147.15 102.35 3.49 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.908 -0.775 . . . . 10.0 108.908 -175.844 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.781 HG22 ' HA2' ' A' ' 16' ' ' GLY . 4.3 pt -78.44 130.8 35.69 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 N-CA-C 106.428 -1.694 . . . . 10.0 106.428 168.38 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 ptmt -118.73 136.17 54.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.708 -1.219 . . . . 10.0 107.708 173.864 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.95 -3.95 14.31 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.75 1.167 . . . . 10.0 112.979 179.676 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -66.35 176.97 1.61 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.625 1.212 . . . . 10.0 111.109 177.516 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.5 t -112.35 155.9 23.37 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 105.308 -2.108 . . . . 10.0 105.308 166.04 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -50.23 157.53 0.67 Allowed 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.29 1.036 . . . . 10.0 111.678 -170.365 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.51 -175.37 29.14 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 170.791 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -78.39 149.2 33.39 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.699 1.599 . . . . 10.0 110.695 -175.99 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.1 m-70 -144.39 137.63 27.21 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.516 0.726 . . . . 10.0 112.953 -175.586 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -40.96 122.07 2.16 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 126.574 2.035 . . . . 10.0 110.217 168.247 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -136.73 113.03 9.88 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.177 1.489 . . . . 10.0 107.925 169.799 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.69 174.69 13.2 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-O 122.247 1.022 . . . . 10.0 112.163 -179.158 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.0 t -96.32 143.9 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 CA-C-N 111.318 -2.674 . . . . 10.0 107.2 169.609 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 76.9 m-70 -123.39 126.4 46.75 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 103.643 -2.725 . . . . 10.0 103.643 172.55 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.5 tp10 -61.17 -42.76 99.14 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.184 -1.371 . . . . 10.0 112.746 -165.508 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -81.91 118.64 23.1 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 119.288 -0.965 . . . . 10.0 109.459 177.696 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.1 -13.89 16.19 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.707 2.575 . . . . 10.0 112.523 169.992 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -42.83 127.28 3.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 122.384 1.088 . . . . 10.0 111.173 168.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -137.39 23.12 2.96 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.521 164.854 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -66.71 -44.43 81.69 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 106.542 -1.651 . . . . 10.0 106.542 168.525 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.69 -21.92 44.08 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.335 -0.393 . . . . 10.0 111.55 173.062 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.58 71.49 1.31 Allowed Glycine 0 CA--C 1.528 0.848 0 C-N-CA 124.134 0.873 . . . . 10.0 111.28 173.015 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.291 23.2 p 43.12 48.98 5.5 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.665 1.186 . . . . 10.0 113.783 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 p -127.21 -66.95 0.86 Allowed 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 127.344 2.258 . . . . 10.0 105.354 173.072 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.1 m -79.05 -4.68 51.34 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 123.364 0.665 . . . . 10.0 112.56 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.7 -14.69 1.45 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.41 1.484 . . . . 10.0 112.925 173.377 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.22 131.55 6.89 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 108.847 -1.701 . . . . 10.0 108.847 170.071 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.403 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 70.3 Cg_endo -75.17 59.97 5.44 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.8 3.0 . . . . 10.0 110.38 172.247 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 23.3 m170 71.7 49.74 0.27 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 129.312 3.045 . . . . 10.0 111.275 175.435 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.403 ' CZ ' ' HD2' ' A' ' 62' ' ' PRO . 35.1 m-85 -72.21 38.12 0.07 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 115.258 1.577 . . . . 10.0 115.258 -173.344 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.27 151.15 0.57 Allowed Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.55 1.54 . . . . 10.0 113.107 169.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -66.02 -46.37 4.75 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.884 2.389 . . . . 10.0 111.953 179.544 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 71.1 mt -79.39 54.01 1.63 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.631 -0.668 . . . . 10.0 110.457 -177.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 40.0 p -55.5 109.2 0.52 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.537 1.135 . . . . 10.0 110.406 -173.826 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.4 mtt180 -121.29 -97.15 0.46 Allowed 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 -179.889 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.4 140.87 23.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 105.261 -2.126 . . . . 10.0 105.261 177.278 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -47.08 116.95 1.52 Allowed 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.654 -0.418 . . . . 10.0 110.991 169.402 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.48 -141.01 4.29 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 106.536 -2.626 . . . . 10.0 106.536 170.531 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.95 -147.51 8.1 Favored Glycine 0 C--O 1.227 -0.312 0 CA-C-O 118.644 -1.086 . . . . 10.0 111.229 175.267 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -68.27 14.93 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 120.041 1.921 . . . . 10.0 111.943 177.344 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.0 mmtt -104.68 -14.96 15.41 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 119.038 0.835 . . . . 10.0 110.042 169.805 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.33 177.34 7.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.337 1.065 . . . . 10.0 113.064 -165.049 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -98.64 -13.31 20.39 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 113.449 -1.705 . . . . 10.0 108.502 168.198 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.11 -16.26 56.97 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 124.735 1.214 . . . . 10.0 112.23 -168.598 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.28 135.88 2.47 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.596 1.158 . . . . 10.0 110.333 -169.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -73.66 61.99 0.76 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 123.405 0.682 . . . . 10.0 111.588 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.4 t 31.78 48.66 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 C-N-CA 126.872 2.069 . . . . 10.0 111.418 -174.511 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.22 42.0 0.05 OUTLIER Glycine 0 CA--C 1.531 1.062 0 CA-C-N 116.032 -0.531 . . . . 10.0 113.877 -178.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -97.07 100.42 11.92 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 103.617 -2.735 . . . . 10.0 103.617 166.049 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 27.5 mt -75.62 -24.86 56.53 Favored 'General case' 0 N--CA 1.462 0.174 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 177.865 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.94 -102.25 2.83 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.311 -1.916 . . . . 10.0 108.311 168.527 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -129.24 133.67 47.62 Favored 'General case' 0 CA--C 1.517 -0.311 0 C-N-CA 123.888 0.875 . . . . 10.0 112.176 -168.633 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.8 m -124.88 145.47 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.143 -1.799 . . . . 10.0 106.143 167.202 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -98.44 126.14 43.87 Favored 'General case' 0 C--O 1.225 -0.223 0 C-N-CA 124.851 1.261 . . . . 10.0 108.959 -178.025 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.52 134.46 34.35 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 172.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -67.17 172.45 4.67 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-O 121.592 0.71 . . . . 10.0 109.609 168.45 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.46 -32.2 4.91 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.39 2.276 . . . . 10.0 111.099 171.528 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -78.68 -11.34 59.97 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.855 0.359 . . . . 10.0 110.607 -175.804 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.06 15.67 69.17 Favored Glycine 0 C--N 1.339 0.75 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 -177.189 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.4 t -94.97 111.15 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 126.796 2.038 . . . . 10.0 105.921 175.162 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.536 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -106.02 120.24 41.28 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 168.734 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -78.53 131.08 36.66 Favored 'General case' 0 N--CA 1.429 -1.524 0 C-N-CA 125.906 1.682 . . . . 10.0 107.892 173.89 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.4 t -117.55 133.89 62.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.303 0 N-CA-C 106.235 -1.765 . . . . 10.0 106.235 179.459 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.5 p -157.45 70.42 0.6 Allowed 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 123.685 0.794 . . . . 10.0 109.554 175.554 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.43 153.22 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 179.406 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -137.35 123.16 20.02 Favored 'General case' 0 N--CA 1.443 -0.812 0 C-N-CA 125.557 1.543 . . . . 10.0 106.897 169.298 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -128.29 153.99 46.4 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.62 0.724 . . . . 10.0 109.051 -178.723 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 33.7 t -117.48 46.18 1.77 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.629 1.572 . . . . 10.0 110.043 -168.717 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.3 p -155.8 -46.13 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.132 0 N-CA-C 109.181 -0.674 . . . . 10.0 109.181 177.105 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 29.8 mm -56.35 142.22 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 123.49 0.716 . . . . 10.0 109.664 172.333 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.7 m -155.62 133.92 11.61 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 123.9 0.88 . . . . 10.0 108.758 171.671 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 82.7 mt -47.27 -55.21 9.11 Favored 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 126.914 2.086 . . . . 10.0 111.318 176.402 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.0 t -130.75 152.24 50.31 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 105.278 -2.119 . . . . 10.0 105.278 170.025 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.52 -84.77 0.12 Allowed Glycine 0 C--N 1.333 0.369 0 N-CA-C 110.058 -1.217 . . . . 10.0 110.058 -177.351 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -136.23 -53.47 0.74 Allowed 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 126.744 2.017 . . . . 10.0 107.5 -179.588 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -76.49 -31.15 57.57 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.117 -0.947 . . . . 10.0 108.57 -175.239 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 48.96 63.37 2.15 Favored 'General case' 0 N--CA 1.447 -0.594 0 C-N-CA 125.669 1.588 . . . . 10.0 109.372 177.109 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.315 1.1 tp -61.45 -18.77 19.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 C-N-CA 123.411 0.684 . . . . 10.0 112.112 -176.116 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.4 mm -48.75 135.79 5.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 118.812 0.733 . . . . 10.0 110.062 167.278 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.88 14.28 82.18 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.055 -0.858 . . . . 10.0 113.489 172.473 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.4 mmt-85 -84.02 175.43 9.54 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 167.898 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.3 m -108.36 122.27 46.64 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 177.003 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 6.5 mp -99.51 147.33 25.43 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-N 119.606 1.093 . . . . 10.0 108.535 171.058 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.6 t -131.18 135.93 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 N-CA-C 108.734 -0.839 . . . . 10.0 108.734 179.795 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 p -104.78 129.76 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 168.106 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 10.1 m-70 -111.12 158.86 18.39 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 114.994 1.479 . . . . 10.0 114.994 -169.672 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -46.42 -60.51 2.3 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.493 2.717 . . . . 10.0 110.903 171.369 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.2 mttp -117.27 165.61 13.24 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.104 0.478 . . . . 10.0 110.356 -172.917 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.39 140.8 54.21 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 168.854 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.03 153.75 32.06 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 108.837 -0.801 . . . . 10.0 108.837 168.264 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -78.59 10.73 2.97 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.118 0.967 . . . . 10.0 111.146 177.457 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.3 mt 38.94 51.35 1.85 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 125.151 1.38 . . . . 10.0 110.86 -170.334 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.94 -27.62 17.41 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-N 114.059 -1.428 . . . . 10.0 112.638 173.522 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -78.83 16.05 0.96 Allowed 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 113.66 0.985 . . . . 10.0 113.66 -168.42 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.93 -32.39 82.5 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 170.295 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 69.94 31.13 69.78 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 122.488 -0.419 . . . . 10.0 112.34 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.95 176.21 8.24 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 125.299 1.44 . . . . 10.0 107.545 173.338 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.406 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 2.6 tm-20 -59.51 -51.27 70.57 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 113.403 -1.726 . . . . 10.0 109.425 177.742 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -52.97 -43.9 66.74 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.565 1.146 . . . . 10.0 110.692 171.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.5 m -53.55 -46.59 70.28 Favored 'General case' 0 N--CA 1.441 -0.917 0 O-C-N 120.851 -1.156 . . . . 10.0 110.968 -179.118 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.5 t -77.65 -0.57 27.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 119.786 -0.766 . . . . 10.0 111.857 -177.121 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.406 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 90.6 mttt -113.91 -82.1 0.6 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.312 1.845 . . . . 10.0 111.197 -179.657 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . 0.299 2.0 p -105.95 11.84 31.24 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 120.738 1.608 . . . . 10.0 113.054 177.939 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.09 10.75 78.52 Favored Glycine 0 C--O 1.221 -0.699 0 CA-C-O 119.047 -0.863 . . . . 10.0 114.336 166.812 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 m120 65.7 26.35 11.42 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.594 1.197 . . . . 10.0 111.596 -176.863 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.59 -11.82 8.29 Favored 'General case' 0 CA--C 1.533 0.327 0 O-C-N 121.644 -0.66 . . . . 10.0 111.683 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.58 -140.32 21.74 Favored Glycine 0 N--CA 1.443 -0.852 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 168.495 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -70.72 118.23 13.25 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.23 0.538 . . . . 10.0 111.283 -168.359 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.41 76.55 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.734 1.214 . . . . 10.0 111.35 168.624 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 50.3 mt -52.12 -40.89 61.97 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.101 0.778 . . . . 10.0 113.101 -176.051 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 155.09 24.77 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 108.335 -0.987 . . . . 10.0 108.335 -171.579 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -167.15 166.07 15.18 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 116.049 -0.523 . . . . 10.0 109.626 -167.59 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.7 179.3 46.95 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.658 -0.782 . . . . 10.0 112.062 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 71.3 t -109.24 156.22 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 N-CA-C 104.978 -2.23 . . . . 10.0 104.978 -175.677 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.4 mt -75.07 -96.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 C-N-CA 123.656 0.782 . . . . 10.0 110.747 -168.478 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 106.28 130.85 6.68 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-O 121.917 0.732 . . . . 10.0 112.098 179.381 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 92.2 mt -72.18 141.25 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.689 0 C-N-CA 124.968 1.307 . . . . 10.0 108.968 179.083 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.11 -102.11 0.41 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 105.761 -1.94 . . . . 10.0 105.761 165.519 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 . . . . . 0 C--O 1.247 0.962 0 C-N-CA 131.033 3.733 . . . . 10.0 103.075 -171.237 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 106.267 -1.753 . . . . 10.0 106.267 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -160.49 -47.33 0.05 OUTLIER 'General case' 0 C--O 1.232 0.139 0 CA-C-N 118.89 0.768 . . . . 10.0 110.668 172.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -119.64 142.71 48.19 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 126.839 2.056 . . . . 10.0 107.691 173.877 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.44 155.51 45.86 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.118 0.967 . . . . 10.0 108.396 169.36 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -122.65 153.99 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 C-N-CA 123.873 0.869 . . . . 10.0 109.265 -175.181 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . 0.458 ' HB2' HG12 ' B' ' 149' ' ' ILE . . . -147.74 93.11 2.16 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 167.367 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.674 HG12 HG23 ' B' ' 17' ' ' ILE . 31.6 m -83.19 133.45 29.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 107.803 -1.184 . . . . 10.0 107.803 169.425 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mt -107.34 138.15 44.07 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.836 -1.172 . . . . 10.0 107.836 -177.507 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 36.5 mtpt -146.34 153.72 40.85 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 120.582 1.537 . . . . 10.0 107.545 169.518 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.51 -52.71 0.08 OUTLIER Glycine 0 N--CA 1.462 0.388 0 C-N-CA 119.217 -1.468 . . . . 10.0 114.171 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -72.68 -43.41 63.13 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.649 -1.241 . . . . 10.0 107.649 -172.065 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.74 -70.55 0.4 Allowed Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 114.055 -1.429 . . . . 10.0 110.032 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -54.91 -39.73 88.99 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.783 2.322 . . . . 10.0 110.879 170.817 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.477 HG13 HD12 ' B' ' 38' ' ' LEU . 94.7 t -58.65 107.54 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.246 0 CA-C-N 119.083 0.856 . . . . 10.0 109.157 179.688 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.04 92.2 3.68 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.744 -2.317 . . . . 10.0 104.744 168.676 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.704 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -78.44 152.19 37.35 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 109.401 -1.479 . . . . 10.0 109.401 177.045 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.674 HG23 HG12 ' B' ' 7' ' ' VAL . 0.0 OUTLIER -154.26 87.22 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -171.16 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.8 mm -96.56 142.18 14.35 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 C-N-CA 124.846 1.258 . . . . 10.0 109.464 174.872 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -127.64 119.31 25.61 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 125.38 1.472 . . . . 10.0 108.082 174.142 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -98.0 113.76 25.7 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.058 1.343 . . . . 10.0 107.5 173.409 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -117.89 136.06 53.7 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 119.133 0.878 . . . . 10.0 110.775 170.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 36.1 tt0 -126.54 81.15 1.98 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 124.638 1.175 . . . . 10.0 109.763 -176.102 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt . . . . . 0 N--CA 1.452 -0.359 0 C-N-CA 124.863 1.265 . . . . 10.0 111.963 -175.223 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.15 0 CA-C-O 118.565 -1.131 . . . . 10.0 114.48 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -71.17 108.18 2.28 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 N-CA-C 106.22 -2.261 . . . . 10.0 106.22 169.122 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 26.2 t -77.35 95.74 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.349 0 N-CA-C 105.374 -2.084 . . . . 10.0 105.374 174.612 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -76.33 96.63 4.02 Favored 'General case' 0 N--CA 1.444 -0.76 0 N-CA-C 105.594 -2.002 . . . . 10.0 105.594 174.516 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -92.58 90.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.751 0 N-CA-C 106.87 -1.53 . . . . 10.0 106.87 175.654 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -99.48 176.58 5.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 121.443 0.64 . . . . 10.0 109.4 169.428 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.15 173.58 40.32 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 110.016 -1.234 . . . . 10.0 110.016 176.206 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.6 m -149.52 89.55 1.64 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 -179.626 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.704 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.5 pt -77.38 150.46 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 174.313 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.8 pttt -136.96 126.05 24.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 O-C-N 124.288 0.992 . . . . 10.0 108.848 169.425 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.97 6.76 5.31 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-O 118.791 -1.005 . . . . 10.0 114.629 166.064 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.661 ' H ' HD13 ' B' ' 38' ' ' LEU . 0.0 OUTLIER -89.82 179.34 6.02 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-N 118.728 1.264 . . . . 10.0 108.62 172.443 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -81.09 175.12 10.94 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.348 -0.845 . . . . 10.0 111.011 172.175 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -63.23 169.72 3.38 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.426 1.49 . . . . 10.0 111.48 -174.616 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.94 -174.74 51.42 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 124.008 0.813 . . . . 10.0 113.256 167.376 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -66.19 143.0 57.53 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.795 1.638 . . . . 10.0 110.608 178.603 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -142.36 139.34 31.72 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 114.214 1.19 . . . . 10.0 114.214 -178.655 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.629 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.03 111.77 0.02 OUTLIER Glycine 0 C--N 1.342 0.883 0 C-N-CA 128.418 2.913 . . . . 10.0 114.208 165.493 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -138.57 102.95 4.73 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 120.376 2.088 . . . . 10.0 110.516 174.844 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.56 179.23 7.97 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.331 0.586 . . . . 10.0 111.829 -178.358 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 p -100.21 148.26 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 112.704 -2.044 . . . . 10.0 108.127 168.33 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -123.93 129.6 51.23 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.067 -2.568 . . . . 10.0 104.067 169.154 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -59.13 -44.73 92.04 Favored 'General case' 0 N--CA 1.441 -0.898 0 O-C-N 124.528 1.142 . . . . 10.0 112.363 -166.646 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -75.19 112.49 11.52 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 105.239 -2.134 . . . . 10.0 105.239 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -57.65 -33.51 67.45 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 109.503 -1.439 . . . . 10.0 109.503 168.798 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -35.93 146.34 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 125.253 1.421 . . . . 10.0 112.06 169.547 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -144.36 28.44 1.34 Allowed 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 115.261 -0.881 . . . . 10.0 111.406 176.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -49.12 -43.06 41.14 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 112.859 0.688 . . . . 10.0 112.859 -169.028 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -86.82 -23.5 25.32 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 113.378 0.881 . . . . 10.0 113.378 177.052 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.97 101.39 2.69 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.172 -1.571 . . . . 10.0 109.172 -170.273 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.289 26.3 p 11.5 49.62 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 129.633 3.173 . . . . 10.0 116.955 -168.673 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 42.4 m -120.84 -53.68 2.06 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 105.077 -2.194 . . . . 10.0 105.077 174.977 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.5 m -44.89 -40.45 6.29 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 126.158 1.783 . . . . 10.0 109.936 168.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.84 -25.25 0.09 Allowed 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 127.726 2.41 . . . . 10.0 114.999 176.934 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.41 155.79 29.45 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 108.572 -1.811 . . . . 10.0 108.572 169.35 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -68.5 -172.73 0.48 Allowed 'Trans proline' 0 N--CA 1.445 -1.352 0 N-CA-C 106.888 -2.005 . . . . 10.0 106.888 166.719 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -78.81 45.09 0.58 Allowed 'General case' 0 CA--C 1.542 0.649 0 O-C-N 119.743 -1.848 . . . . 10.0 112.047 -171.511 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.1 m-30 -72.55 68.22 0.8 Allowed 'General case' 0 C--O 1.221 -0.413 0 CA-C-N 119.846 1.203 . . . . 10.0 109.676 178.759 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -63.57 155.66 74.83 Favored Pre-proline 0 C--N 1.331 -0.226 0 N-CA-C 107.535 -1.283 . . . . 10.0 107.535 173.768 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -54.92 -27.95 56.47 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.097 1.865 . . . . 10.0 112.281 175.222 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -107.78 25.14 11.89 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.043 0.937 . . . . 10.0 111.815 177.189 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 44.7 p -40.98 117.79 0.9 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.646 1.179 . . . . 10.0 112.273 177.94 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -124.58 -88.89 0.59 Allowed 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 107.676 -1.231 . . . . 10.0 107.676 177.361 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.418 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 8.5 mtmp? -125.49 152.6 44.76 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 108.316 -0.994 . . . . 10.0 108.316 168.541 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 36.2 t60 -58.14 128.36 36.72 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 117.659 -1.617 . . . . 10.0 106.734 165.812 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.408 ' CA ' ' HB2' ' B' ' 76' ' ' ASP . . . -150.09 -141.16 3.35 Favored Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 109.905 -1.278 . . . . 10.0 109.905 -178.771 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.6 -147.52 11.43 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 107.95 -2.06 . . . . 10.0 107.95 169.976 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.05 12.94 0.2 Allowed 'Trans proline' 0 N--CA 1.452 -0.923 0 CA-C-N 120.114 1.957 . . . . 10.0 111.621 169.429 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -127.65 1.51 6.15 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.59 1.156 . . . . 10.0 111.737 176.502 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.42 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 0.2 OUTLIER -123.81 150.58 44.35 Favored 'General case' 0 C--N 1.34 0.168 0 N-CA-C 102.426 -3.175 . . . . 10.0 102.426 166.825 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -82.55 -17.74 43.9 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 121.646 -0.659 . . . . 10.0 109.832 174.705 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.9 pm0 -118.16 36.54 4.31 Favored 'General case' 0 N--CA 1.438 -1.056 0 C-N-CA 125.901 1.68 . . . . 10.0 111.579 -167.515 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -44.25 153.58 0.14 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.58 1.552 . . . . 10.0 109.578 168.937 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 38.4 m80 -60.9 -48.17 83.06 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 10.0 109.966 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.1 t 173.31 -75.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 C-N-CA 129.284 3.034 . . . . 10.0 105.059 166.082 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.03 59.06 5.02 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 179.305 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -106.08 95.07 5.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.557 -2.016 . . . . 10.0 105.557 169.322 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 43.6 mt -75.23 -33.87 61.39 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 106.741 -1.577 . . . . 10.0 106.741 175.632 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.51 -96.94 1.31 Allowed Glycine 0 N--CA 1.436 -1.337 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 169.442 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -132.42 136.14 46.56 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 122.863 0.465 . . . . 10.0 110.021 -169.518 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.5 m -122.24 140.3 46.54 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.955 -0.758 . . . . 10.0 108.955 169.488 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 9.4 m -81.93 119.25 23.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 127.457 2.303 . . . . 10.0 110.499 -177.159 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.4 130.46 44.53 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.984 1.314 . . . . 10.0 110.642 170.022 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -59.88 166.31 2.73 Favored 'General case' 0 N--CA 1.455 -0.222 0 O-C-N 124.069 0.855 . . . . 10.0 109.603 167.366 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 35.6 pttt -52.47 -30.5 30.18 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.804 1.241 . . . . 10.0 110.93 173.37 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -77.08 -9.52 58.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 117.676 0.216 . . . . 10.0 111.027 -178.148 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.54 10.57 67.54 Favored Glycine 0 C--N 1.34 0.774 0 O-C-N 121.092 -1.005 . . . . 10.0 111.038 -178.191 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.0 t -86.14 111.44 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 127.184 2.194 . . . . 10.0 106.466 175.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.577 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -114.61 120.71 41.1 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 118.715 0.689 . . . . 10.0 109.509 172.825 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -78.5 132.43 37.23 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 107.325 -1.361 . . . . 10.0 107.325 169.864 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.8 t -114.94 133.44 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 N-CA-C 104.777 -2.305 . . . . 10.0 104.777 169.063 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -156.73 62.8 0.52 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 118.174 0.443 . . . . 10.0 110.139 -178.731 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.69 152.85 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 N-CA-C 107.735 -1.209 . . . . 10.0 107.735 -173.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -136.6 139.22 41.95 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 123.798 0.839 . . . . 10.0 109.667 168.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -148.47 153.53 38.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.3 p -115.52 44.48 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 126.494 1.917 . . . . 10.0 109.549 177.403 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -111.69 -48.04 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 170.457 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 42.5 mm -65.1 148.49 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 108.007 -1.108 . . . . 10.0 108.007 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.4 m -157.29 120.97 4.16 Favored 'General case' 0 C--O 1.226 -0.134 0 N-CA-C 108.029 -1.1 . . . . 10.0 108.029 173.578 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.9 mp -59.62 -29.94 68.36 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.614 1.166 . . . . 10.0 111.955 -169.603 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.2 m . . . . . 0 N--CA 1.454 -0.227 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 176.096 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 7.1 t . . . . . 0 CA--C 1.531 0.247 0 CA-C-O 120.547 0.213 . . . . 10.0 111.176 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 mt 63.82 16.32 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 124.173 0.989 . . . . 10.0 110.721 174.104 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.8 mm -71.02 -56.1 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 124.478 1.111 . . . . 10.0 110.037 175.824 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.72 48.82 3.55 Favored Glycine 0 CA--C 1.526 0.758 0 O-C-N 120.617 -1.302 . . . . 10.0 112.501 -177.49 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.03 168.06 11.93 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 126.612 1.965 . . . . 10.0 108.692 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -114.21 141.11 47.95 Favored 'General case' 0 CA--C 1.515 -0.396 0 C-N-CA 124.654 1.181 . . . . 10.0 108.306 -172.07 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.8 mp -111.85 145.92 38.62 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.83 1.652 . . . . 10.0 108.474 172.489 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.9 t -131.71 136.06 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 178.278 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.405 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.4 p -97.57 120.17 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 105.838 -1.912 . . . . 10.0 105.838 168.007 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.629 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.2 m-70 -98.5 158.29 15.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 115.59 1.7 . . . . 10.0 115.59 -176.373 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -38.47 -66.18 0.29 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 129.834 3.254 . . . . 10.0 110.619 170.517 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -113.75 174.86 5.72 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 125.174 1.389 . . . . 10.0 110.319 -174.561 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.84 137.23 35.3 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.879 -1.055 . . . . 10.0 108.465 171.311 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.4 141.73 39.63 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.287 1.035 . . . . 10.0 109.284 169.892 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -78.45 24.51 0.27 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.375 0.67 . . . . 10.0 111.86 179.63 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.5 mt 36.64 51.6 0.91 Allowed 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.792 2.037 . . . . 10.0 111.7 -176.674 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.44 -32.03 6.6 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 125.594 1.569 . . . . 10.0 112.384 175.078 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.42 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 7.2 mttm -80.08 18.67 0.81 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.628 1.171 . . . . 10.0 113.222 -167.819 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.27 -18.73 75.29 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 109.531 -1.428 . . . . 10.0 109.531 167.109 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.78 40.19 92.52 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 124.402 1.001 . . . . 10.0 111.749 175.403 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -145.25 169.6 17.91 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.093 0.946 . . . . 10.0 109.583 173.643 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 13.0 tm-20 -46.83 -49.85 19.4 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.711 1.204 . . . . 10.0 110.139 -179.875 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 17.9 tp10 -71.35 -34.74 70.77 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 121.781 -0.574 . . . . 10.0 111.657 179.217 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.9 p -54.15 -43.63 70.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 120.715 -1.241 . . . . 10.0 110.799 172.149 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.272 5.6 t -77.81 -23.02 49.18 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 119.568 -0.853 . . . . 10.0 111.557 -173.627 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -84.71 -49.01 8.86 Favored 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 127.486 2.314 . . . . 10.0 112.525 -177.738 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 19.2 p -136.3 -15.04 1.71 Allowed 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 114.495 1.295 . . . . 10.0 114.495 175.556 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.76 3.9 52.18 Favored Glycine 0 C--N 1.339 0.707 0 CA-C-O 118.379 -1.234 . . . . 10.0 114.105 177.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 27.2 m120 72.18 25.26 2.95 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 118.573 1.186 . . . . 10.0 112.01 -177.788 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.34 -8.83 43.34 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.435 0.902 . . . . 10.0 113.435 179.356 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.93 -160.8 48.8 Favored Glycine 0 CA--C 1.524 0.608 0 O-C-N 121.029 -1.045 . . . . 10.0 111.536 172.622 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 m -60.63 134.69 57.33 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.7 1.2 . . . . 10.0 113.657 -167.675 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.9 84.92 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.524 1.529 . . . . 10.0 110.21 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 65.8 mt -58.02 -39.18 77.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.425 0.557 . . . . 10.0 112.094 -179.031 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.405 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -154.46 153.34 31.37 Favored 'General case' 0 CA--C 1.516 -0.334 0 O-C-N 121.683 -0.635 . . . . 10.0 110.655 -179.912 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.2 m -121.68 141.14 51.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.014 1.726 . . . . 10.0 108.556 -169.041 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.4 158.43 27.5 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 109.675 -1.37 . . . . 10.0 109.675 168.539 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.8 t -118.8 135.52 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 -179.838 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.458 HG12 ' HB2' ' B' ' 6' ' ' ALA . 59.8 mt -71.88 153.35 7.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 N-CA-C 108.658 -0.867 . . . . 10.0 108.658 176.808 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -164.77 151.24 20.15 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 109.099 -1.601 . . . . 10.0 109.099 -175.089 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.47 123.75 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 117.514 0.657 . . . . 10.0 109.768 -172.809 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.06 -26.26 39.74 Favored 'General case' 0 N--CA 1.446 -0.628 0 O-C-N 120.894 -1.129 . . . . 10.0 111.809 -173.276 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.428 -1.533 0 N-CA-C 103.918 -2.623 . . . . 10.0 103.918 -173.859 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.791 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -79.57 -38.91 33.02 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.194 0.598 . . . . 10.0 110.028 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -121.16 130.08 53.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.148 1.379 . . . . 10.0 107.331 -179.328 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.11 151.92 51.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.595 -0.891 . . . . 10.0 108.595 172.874 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.444 HG13 ' HB2' ' A' ' 152' ' ' ALA . 1.0 OUTLIER -109.24 170.52 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 123.115 0.566 . . . . 10.0 110.45 169.993 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -156.02 102.38 2.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 106.64 -1.615 . . . . 10.0 106.64 166.045 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.598 HG12 HG23 ' A' ' 17' ' ' ILE . 35.7 m -92.24 128.4 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 108.795 -0.817 . . . . 10.0 108.795 171.078 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.436 HD12 ' N ' ' A' ' 8' ' ' LEU . 4.2 mp -103.18 152.83 21.0 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 108.853 -0.795 . . . . 10.0 108.853 178.231 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 ttmt -161.16 162.24 31.31 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 108.044 -1.095 . . . . 10.0 108.044 169.52 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.37 -56.16 0.04 OUTLIER Glycine 0 C--N 1.33 0.21 0 N-CA-C 111.459 -0.657 . . . . 10.0 111.459 172.801 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.97 -45.89 39.12 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -174.769 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.88 -67.72 0.55 Allowed Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 113.739 -1.573 . . . . 10.0 110.338 -179.506 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -56.96 -38.77 95.19 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.914 2.409 . . . . 10.0 111.172 173.876 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -68.05 105.59 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.062 0 N-CA-C 107.033 -1.469 . . . . 10.0 107.033 175.255 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -124.57 120.63 32.49 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 108.601 -0.888 . . . . 10.0 108.601 169.384 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.457 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -90.49 150.96 21.08 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.452 -1.459 . . . . 10.0 109.452 169.36 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.852 HG22 HG23 ' B' ' 54' ' ' THR . 0.0 OUTLIER -156.37 82.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 105.491 -2.04 . . . . 10.0 105.491 -172.994 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.6 mm -104.62 145.03 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.39 1.076 . . . . 10.0 108.841 -178.561 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -122.91 122.78 39.43 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 127.161 2.185 . . . . 10.0 108.337 169.011 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -103.24 123.03 45.97 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 106.704 -1.591 . . . . 10.0 106.704 173.327 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -117.91 135.52 54.06 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 123.962 0.788 . . . . 10.0 113.126 169.553 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -123.82 100.02 6.56 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 127.42 2.288 . . . . 10.0 105.264 171.135 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 17.8 tttp -64.65 -62.63 1.46 Allowed 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 124.61 1.164 . . . . 10.0 109.392 -169.719 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -109.59 165.81 11.38 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 102.896 -3.001 . . . . 10.0 102.896 166.873 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.9 t -66.65 -21.54 66.11 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 -178.912 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.6 m-80 -76.76 -19.62 57.41 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.537 -0.756 . . . . 10.0 110.511 -179.595 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.55 140.82 32.57 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 109.862 -1.295 . . . . 10.0 109.862 -178.763 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -61.62 149.15 91.05 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 N-CA-C 107.041 -1.946 . . . . 10.0 107.041 168.877 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 t -79.29 113.68 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.087 0 N-CA-C 105.976 -1.861 . . . . 10.0 105.976 178.584 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -93.9 117.58 30.3 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 171.193 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -110.4 108.67 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 C-N-CA 126.817 2.047 . . . . 10.0 106.857 -175.558 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 20.8 p90 -127.49 163.11 24.84 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 112.103 0.408 . . . . 10.0 112.103 179.616 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.03 -147.37 18.32 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 106.917 -2.473 . . . . 10.0 106.917 170.144 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 52.2 p -157.96 164.78 36.49 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.065 -1.054 . . . . 10.0 112.551 178.617 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.632 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -116.45 121.53 67.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 C-N-CA 126.062 1.745 . . . . 10.0 106.668 166.628 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.61 54.78 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 175.025 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.14 -0.14 9.68 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.174 1.369 . . . . 10.0 113.539 178.537 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.26 178.38 2.87 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 118.394 1.097 . . . . 10.0 111.231 179.183 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -107.71 156.11 19.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.203 -1.777 . . . . 10.0 106.203 165.244 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -51.27 150.74 3.21 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.463 1.105 . . . . 10.0 112.347 -169.504 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.04 -171.36 23.49 Favored Glycine 0 C--N 1.336 0.558 0 N-CA-C 111.201 -0.76 . . . . 10.0 111.201 170.232 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.73 149.16 36.37 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.574 1.149 . . . . 10.0 111.363 -173.319 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -143.15 141.32 31.15 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.71 1.204 . . . . 10.0 112.502 -177.698 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.534 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -35.73 122.15 0.61 Allowed Glycine 0 C--N 1.341 0.86 0 C-N-CA 126.582 2.039 . . . . 10.0 112.878 166.303 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -143.43 115.42 8.32 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 120.085 1.942 . . . . 10.0 110.975 167.442 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.7 174.25 12.79 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 120.994 0.426 . . . . 10.0 111.787 -178.974 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 117' ' ' LEU . 1.1 m -113.47 82.24 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 126.036 1.735 . . . . 10.0 109.995 -179.656 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -56.8 141.31 44.91 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 122.292 1.044 . . . . 10.0 110.599 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -71.58 -53.21 14.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 112.045 -2.343 . . . . 10.0 110.456 -168.234 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.3 m-30 -76.49 110.09 10.75 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 175.154 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.42 48.71 1.22 Allowed Glycine 0 CA--C 1.531 1.051 0 N-CA-C 110.04 -1.224 . . . . 10.0 110.04 167.806 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.76 143.41 30.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.885 1.674 . . . . 10.0 106.825 170.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.468 ' HB3' HG21 ' B' ' 7' ' ' VAL . 1.1 m120 -139.5 2.13 2.0 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 126.344 1.858 . . . . 10.0 109.324 174.103 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.565 HG23 ' CG2' ' B' ' 17' ' ' ILE . 1.9 m -61.92 -30.36 70.84 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 120.098 1.317 . . . . 10.0 110.525 -170.111 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.18 -15.36 60.07 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.174 0.99 . . . . 10.0 112.047 176.136 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.14 76.55 1.33 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.57 -1.412 . . . . 10.0 109.57 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 74.0 m 47.56 45.66 17.63 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.53 1.132 . . . . 10.0 111.145 175.658 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.5 m -134.59 -52.5 0.81 Allowed 'General case' 0 N--CA 1.439 -0.995 0 N-CA-C 108.948 -0.76 . . . . 10.0 108.948 -168.863 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 t -99.5 21.04 12.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.425 0.528 . . . . 10.0 112.425 -170.28 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.12 3.52 0.85 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.15 0.98 . . . . 10.0 113.401 178.956 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.28 129.98 1.57 Allowed Glycine 0 CA--C 1.529 0.967 0 O-C-N 120.874 -1.141 . . . . 10.0 110.341 175.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.16 61.54 7.78 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 123.197 2.598 . . . . 10.0 110.556 178.605 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 28.9 m170 63.07 59.75 1.28 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 128.46 2.704 . . . . 10.0 110.858 177.581 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.1 m-85 -72.19 55.19 0.31 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.558 1.143 . . . . 10.0 113.892 -176.727 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -71.18 144.53 89.88 Favored Pre-proline 0 C--N 1.326 -0.437 0 C-N-CA 125.56 1.544 . . . . 10.0 113.18 -174.158 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -71.78 -37.87 4.75 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.283 2.655 . . . . 10.0 111.398 176.706 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.79 56.95 0.98 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.653 0.781 . . . . 10.0 110.533 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 67.9 p -42.06 94.85 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 126.676 1.99 . . . . 10.0 112.948 -169.58 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.2 mtt85 -121.14 172.15 8.18 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 126.129 1.772 . . . . 10.0 108.163 174.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 35.1 mtmm -102.0 106.32 17.22 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 -176.667 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -19.22 105.43 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.32 0 C-N-CA 126.71 2.004 . . . . 10.0 114.407 -171.024 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.424 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . -115.35 -146.45 8.89 Favored Glycine 0 N--CA 1.439 -1.101 0 C-N-CA 125.828 1.68 . . . . 10.0 109.467 176.541 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.98 -166.39 24.93 Favored Glycine 0 N--CA 1.45 -0.41 0 N-CA-C 108.587 -1.805 . . . . 10.0 108.587 171.603 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.4 -3.16 3.86 Favored 'Trans proline' 0 N--CA 1.454 -0.814 0 CA-C-N 119.87 1.835 . . . . 10.0 111.829 173.104 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -99.19 -17.35 18.19 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.592 0.757 . . . . 10.0 111.61 174.667 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.424 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 4.5 t70 -111.71 169.68 8.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.191 -1.041 . . . . 10.0 108.191 -179.138 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -80.8 -36.28 31.93 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.824 -1.547 . . . . 10.0 106.824 169.056 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 12.6 mt-10 -84.98 32.93 0.53 Allowed 'General case' 0 N--CA 1.442 -0.871 0 CA-C-O 122.646 1.213 . . . . 10.0 113.185 -166.02 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 ptm180 -66.68 133.65 50.65 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 170.091 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -66.56 -70.75 0.23 Allowed 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.461 0.648 . . . . 10.0 110.704 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 80.8 t -147.19 -105.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.038 -2.949 . . . . 10.0 103.038 177.729 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.34 62.8 4.52 Favored Glycine 0 CA--C 1.524 0.655 0 O-C-N 121.336 -0.852 . . . . 10.0 111.227 176.441 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -89.94 105.07 17.56 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 101.118 -3.66 . . . . 10.0 101.118 163.955 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -87.43 -37.29 17.14 Favored 'General case' 0 N--CA 1.461 0.109 0 N-CA-C 107.41 -1.33 . . . . 10.0 107.41 173.298 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.17 -95.68 1.26 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 123.448 0.547 . . . . 10.0 111.884 167.75 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -116.09 104.27 11.39 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.903 1.281 . . . . 10.0 111.304 -167.451 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.07 133.81 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 168.851 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 m -100.21 111.96 24.26 Favored 'General case' 0 N--CA 1.441 -0.895 0 C-N-CA 125.692 1.597 . . . . 10.0 109.07 -169.142 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.75 129.71 35.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.243 0.617 . . . . 10.0 110.912 179.123 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -57.33 170.86 0.46 Allowed 'General case' 0 C--O 1.233 0.224 0 O-C-N 124.778 1.299 . . . . 10.0 110.116 167.494 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.8 ptmm? -54.29 -30.56 51.26 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 114.676 -1.147 . . . . 10.0 111.189 172.14 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -78.87 -2.05 37.94 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.988 0.915 . . . . 10.0 111.439 -179.049 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.86 20.38 73.6 Favored Glycine 0 C--N 1.337 0.598 0 N-CA-C 110.625 -0.99 . . . . 10.0 110.625 179.204 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.16 102.43 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.954 0 N-CA-C 105.462 -2.051 . . . . 10.0 105.462 179.393 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.632 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -99.53 121.97 41.93 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.83 -1.174 . . . . 10.0 107.83 169.259 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -81.23 143.09 32.56 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.796 1.638 . . . . 10.0 109.347 173.597 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 85.4 t -117.79 129.84 73.59 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 N-CA-C 105.745 -1.946 . . . . 10.0 105.745 168.175 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 17.4 m -158.1 69.77 0.53 Allowed 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 124.515 1.126 . . . . 10.0 108.403 169.257 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -108.61 157.75 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -176.844 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -132.09 133.46 44.36 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 125.415 1.486 . . . . 10.0 108.691 170.892 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -136.26 135.07 38.7 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 108.288 -1.004 . . . . 10.0 108.288 -173.482 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 16.4 m -104.09 16.39 26.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.695 1.198 . . . . 10.0 111.729 -175.357 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.7 p -136.51 11.8 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 123.691 0.796 . . . . 10.0 110.33 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -113.95 136.13 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 103.11 -2.922 . . . . 10.0 103.11 169.905 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 11.5 m -139.53 123.68 17.9 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 123.358 0.663 . . . . 10.0 109.646 -178.223 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.1 mt -69.57 -31.6 69.88 Favored 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.985 0.914 . . . . 10.0 109.8 170.216 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 63.3 m -152.0 135.8 16.33 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.231 1.012 . . . . 10.0 108.339 170.666 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 164.59 -57.74 0.26 Allowed Glycine 0 C--N 1.333 0.391 0 N-CA-C 109.684 -1.367 . . . . 10.0 109.684 179.449 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -164.51 -50.06 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.694 1.998 . . . . 10.0 107.334 -178.129 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -74.37 -38.49 63.15 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.919 -1.037 . . . . 10.0 108.373 -169.597 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 45.5 t 42.03 55.14 3.9 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 126.486 1.914 . . . . 10.0 110.771 172.574 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.14 21.48 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 N-CA-C 113.873 1.064 . . . . 10.0 113.873 -168.626 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.7 mm -58.66 142.66 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 C-N-CA 125.33 1.452 . . . . 10.0 107.614 169.306 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.83 14.65 82.36 Favored Glycine 0 CA--C 1.534 1.245 0 CA-C-O 118.745 -1.031 . . . . 10.0 114.19 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.3 mmt180 -74.11 175.05 7.84 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 107.389 -1.338 . . . . 10.0 107.389 168.198 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -117.79 128.24 54.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.743 -1.206 . . . . 10.0 107.743 169.83 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.565 HD21 HD11 ' A' ' 149' ' ' ILE . 27.8 mt -98.42 142.73 29.68 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 107.953 -1.129 . . . . 10.0 107.953 174.317 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -131.09 132.33 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.324 -1.361 . . . . 10.0 107.324 178.191 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.31 123.66 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.254 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.044 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.534 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.2 m170 -101.01 161.55 13.51 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 114.465 1.283 . . . . 10.0 114.465 -173.956 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -56.21 -50.64 70.67 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 126.433 1.893 . . . . 10.0 110.967 178.441 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 48.8 mttm -112.35 163.44 14.4 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.421 0.629 . . . . 10.0 111.508 -171.104 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.37 141.23 42.72 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 114.628 -1.169 . . . . 10.0 108.773 172.172 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -76.45 148.15 37.44 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 108.56 -0.904 . . . . 10.0 108.56 174.768 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.86 -37.03 15.65 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 126.814 2.046 . . . . 10.0 109.757 -178.414 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 20.4 mt 66.48 36.88 4.84 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.788 0.835 . . . . 10.0 113.059 -176.742 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 111.58 -25.77 12.9 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 118.553 0.615 . . . . 10.0 114.435 165.35 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.252 0.0 OUTLIER -94.56 31.12 1.83 Allowed 'General case' 0 CA--C 1.543 0.69 0 N-CA-C 113.386 0.884 . . . . 10.0 113.386 -172.758 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.427 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -90.16 -12.21 62.02 Favored Glycine 0 C--N 1.343 0.938 0 C-N-CA 125.342 1.449 . . . . 10.0 112.06 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.62 44.95 47.62 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.252 0.929 . . . . 10.0 112.778 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -153.28 175.46 13.06 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.479 -0.934 . . . . 10.0 108.479 175.722 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -56.67 -40.16 75.03 Favored 'General case' 0 N--CA 1.437 -1.079 0 O-C-N 121.356 -0.84 . . . . 10.0 111.845 -175.31 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -63.13 -36.57 84.03 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 118.056 -0.973 . . . . 10.0 109.723 175.838 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.427 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 59.0 p -51.01 -42.89 60.7 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 119.62 1.1 . . . . 10.0 110.954 -172.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.252 12.3 t -81.93 -11.31 58.95 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 112.522 0.564 . . . . 10.0 112.522 -175.448 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -115.88 -58.45 2.11 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.532 1.533 . . . . 10.0 113.648 -170.266 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 16.9 p -128.98 10.84 5.96 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 120.449 1.477 . . . . 10.0 112.182 175.447 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.25 -97.01 2.17 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 125.401 1.477 . . . . 10.0 109.742 176.073 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -168.09 37.88 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 122.944 1.354 . . . . 10.0 107.706 178.864 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.11 -22.73 55.21 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 113.534 -1.667 . . . . 10.0 108.446 -173.803 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.82 -157.37 53.07 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 109.506 -1.438 . . . . 10.0 109.506 169.497 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.26 120.29 3.93 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 124.28 1.032 . . . . 10.0 113.229 -167.663 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -63.06 80.47 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.412 1.085 . . . . 10.0 109.939 171.229 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.8 mt -45.56 -52.68 10.14 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.343 0.592 . . . . 10.0 110.96 178.061 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.93 152.8 31.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.723 -0.672 . . . . 10.0 109.501 -168.623 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -147.13 161.06 41.65 Favored 'General case' 0 N--CA 1.447 -0.592 0 O-C-N 123.83 0.706 . . . . 10.0 111.009 -176.79 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.94 168.59 28.15 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 125.473 1.511 . . . . 10.0 109.413 -177.839 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.0 t -120.76 137.85 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 106.366 -1.716 . . . . 10.0 106.366 -178.84 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.565 HD11 HD21 ' A' ' 117' ' ' LEU . 6.9 mt -73.12 116.81 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.655 -0.498 . . . . 10.0 109.655 -177.451 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.25 154.25 17.08 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 111.331 -176.029 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.23 145.89 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 C-N-CA 124.763 1.225 . . . . 10.0 108.395 176.008 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.444 ' HB2' HG13 ' A' ' 5' ' ' VAL . . . -121.11 -25.99 5.2 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 113.58 0.956 . . . . 10.0 113.58 178.422 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.2 tp60 . . . . . 0 C--O 1.25 1.125 0 CA-C-O 117.074 -1.441 . . . . 10.0 107.153 -177.142 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.564 0 N-CA-C 106.534 -1.654 . . . . 10.0 106.534 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.2 t -156.83 -49.22 0.07 Allowed 'General case' 0 C--O 1.224 -0.242 0 CA-C-N 119.365 0.984 . . . . 10.0 110.957 169.161 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -124.01 122.23 37.35 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 125.13 1.372 . . . . 10.0 108.768 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -130.92 152.09 50.62 Favored 'General case' 0 CA--C 1.52 -0.184 0 C-N-CA 123.785 0.834 . . . . 10.0 109.523 170.019 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -118.38 161.15 17.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 C-N-CA 122.947 0.499 . . . . 10.0 111.091 178.022 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.9 110.4 5.78 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.165 -0.925 . . . . 10.0 108.561 167.859 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.468 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.6 m -96.95 108.48 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 124.246 1.019 . . . . 10.0 109.349 172.763 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.9 mt -92.17 131.56 37.31 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.527 -0.916 . . . . 10.0 108.527 -178.396 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -143.65 157.09 44.67 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.612 -1.255 . . . . 10.0 107.612 171.042 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.02 -60.91 0.05 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 121.157 -0.544 . . . . 10.0 113.045 169.35 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.25 -43.78 66.58 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 -177.318 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.58 -71.22 0.42 Allowed Glycine 0 CA--C 1.523 0.578 0 CA-C-N 114.358 -1.292 . . . . 10.0 110.631 168.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -57.1 -31.98 91.93 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 123.282 2.655 . . . . 10.0 111.313 171.757 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.417 HG13 HD11 ' B' ' 38' ' ' LEU . 93.5 t -67.97 94.5 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 107.118 -1.438 . . . . 10.0 107.118 177.334 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -115.55 112.4 22.14 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 105.91 -1.885 . . . . 10.0 105.91 178.591 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.677 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.07 139.62 14.59 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 172.182 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.565 ' CG2' HG23 ' A' ' 54' ' ' THR . 4.5 mt -140.77 95.85 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 108.286 -1.005 . . . . 10.0 108.286 -174.986 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -106.9 149.15 10.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 124.578 1.151 . . . . 10.0 113.011 -178.184 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -122.98 110.04 14.88 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.939 2.096 . . . . 10.0 108.24 168.749 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -86.97 108.2 18.73 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 170.821 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -109.3 113.41 26.22 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-O 121.395 0.616 . . . . 10.0 111.646 179.81 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -78.1 101.77 7.15 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 169.854 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 2.1 mmmp? . . . . . 0 CA--C 1.522 -0.103 0 C-N-CA 127.345 2.258 . . . . 10.0 109.72 177.511 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.961 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -61.88 144.02 96.27 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.491 2.127 . . . . 10.0 109.633 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 t -78.93 87.18 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.999 0 N-CA-C 106.417 -1.698 . . . . 10.0 106.417 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.4 mttm -67.08 108.19 2.55 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 106.854 -1.536 . . . . 10.0 106.854 169.012 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -110.03 108.87 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 125.624 1.569 . . . . 10.0 107.465 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 21.9 p90 -123.38 168.12 12.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.509 0.671 . . . . 10.0 110.123 173.408 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.46 -170.76 43.92 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 179.243 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.3 m -154.98 111.88 3.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -175.939 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.677 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.5 pt -84.22 175.19 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.573 -0.851 . . . . 10.0 110.115 169.703 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -149.98 156.35 41.56 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 166.675 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.52 -25.17 11.36 Favored Glycine 0 C--N 1.338 0.678 0 CA-C-O 119.372 -0.682 . . . . 10.0 114.154 171.039 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.502 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.4 mp -75.04 179.59 4.89 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 118.388 1.094 . . . . 10.0 111.513 -170.84 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.6 t -101.84 161.55 13.58 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.637 -0.875 . . . . 10.0 108.637 168.263 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -49.2 153.0 1.05 Allowed 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.192 1.797 . . . . 10.0 113.675 -169.292 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.43 179.55 39.43 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 124.607 1.099 . . . . 10.0 113.033 168.525 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 95.2 mt -49.49 137.71 14.61 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.119 1.768 . . . . 10.0 112.755 171.894 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -138.2 147.12 43.46 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 124.773 1.229 . . . . 10.0 112.048 171.351 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.694 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -18.65 118.5 0.01 OUTLIER Glycine 0 C--N 1.337 0.598 0 C-N-CA 127.835 2.636 . . . . 10.0 114.16 165.466 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -151.35 106.02 3.26 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 120.218 2.009 . . . . 10.0 112.909 167.296 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.418 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -151.07 168.39 24.76 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.655 -0.702 . . . . 10.0 111.269 176.504 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 16.7 m -86.7 155.09 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 112.21 -2.268 . . . . 10.0 107.06 166.681 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -126.09 152.91 45.23 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 173.243 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -59.7 -42.98 94.24 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 113.689 0.996 . . . . 10.0 113.689 -168.857 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -96.38 174.96 6.61 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.749 -0.834 . . . . 10.0 108.749 -177.193 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -111.35 10.8 28.64 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 125.418 1.485 . . . . 10.0 109.668 166.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.49 112.62 1.65 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 122.327 1.06 . . . . 10.0 109.067 176.772 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -120.56 9.97 10.99 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 114.244 -1.344 . . . . 10.0 108.305 168.006 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.852 HG23 HG22 ' A' ' 17' ' ' ILE . 15.5 m -67.59 -34.6 77.35 Favored 'General case' 0 C--N 1.344 0.359 0 C-N-CA 125.235 1.414 . . . . 10.0 108.625 171.02 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.41 -22.34 60.26 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.323 -0.399 . . . . 10.0 110.479 174.702 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.5 54.33 1.7 Allowed Glycine 0 C--N 1.34 0.761 0 C-N-CA 123.893 0.759 . . . . 10.0 111.557 172.083 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 37.5 m 59.76 28.96 18.51 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.03 0.932 . . . . 10.0 110.166 -176.136 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 38.7 m -112.09 -49.8 2.95 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 125.439 1.495 . . . . 10.0 107.147 -169.596 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 8.4 t -117.31 26.62 9.62 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 113.563 0.949 . . . . 10.0 113.563 -175.041 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.42 -7.57 6.97 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.701 1.001 . . . . 10.0 113.701 179.548 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.36 123.61 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.763 1.173 . . . . 10.0 111.052 172.856 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -81.34 55.86 5.78 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 123.074 2.516 . . . . 10.0 112.16 -172.154 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.418 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 16.1 m170 66.76 36.84 4.42 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 128.956 2.903 . . . . 10.0 111.78 176.192 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -76.99 71.66 3.5 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 120.692 1.587 . . . . 10.0 109.998 175.911 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -61.87 158.19 44.78 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 125.201 1.4 . . . . 10.0 110.208 169.31 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -62.91 -46.63 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.024 1.816 . . . . 10.0 111.153 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 69.9 mt -78.84 56.45 1.91 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 123.204 0.601 . . . . 10.0 110.309 -179.383 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -45.25 112.21 0.42 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.639 1.176 . . . . 10.0 110.775 -179.305 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.5 mtp85 -137.33 -97.83 0.2 Allowed 'General case' 0 CA--C 1.506 -0.74 0 N-CA-C 104.492 -2.41 . . . . 10.0 104.492 -175.624 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 50.7 mttp -144.38 164.72 29.98 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.706 -1.22 . . . . 10.0 107.706 166.733 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -66.47 120.65 13.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 106.59 -1.634 . . . . 10.0 106.59 164.641 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.23 -137.79 3.66 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 108.087 -2.005 . . . . 10.0 108.087 175.304 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.6 -160.63 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 109.422 -1.471 . . . . 10.0 109.422 173.493 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -65.41 4.45 0.77 Allowed 'Trans proline' 0 N--CA 1.454 -0.834 0 C-N-CA 122.15 1.9 . . . . 10.0 111.83 169.824 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 57.8 mmtt -94.31 -24.03 17.58 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-O 118.508 -0.758 . . . . 10.0 110.127 170.282 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -108.29 161.42 15.02 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-O 121.051 0.453 . . . . 10.0 111.176 -167.53 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -97.46 -9.72 26.71 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.134 -0.939 . . . . 10.0 109.585 174.15 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -123.05 28.5 7.16 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 119.32 -0.372 . . . . 10.0 110.645 -178.91 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . 0.437 HH12 ' CG ' ' B' ' 101' ' ' ASP . 14.9 ptt180 -50.38 154.53 1.24 Allowed 'General case' 0 C--N 1.344 0.354 0 C-N-CA 123.337 0.655 . . . . 10.0 109.879 169.217 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -65.78 -64.88 0.76 Allowed 'General case' 0 N--CA 1.453 -0.319 0 CA-C-O 121.552 0.691 . . . . 10.0 109.503 -178.534 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.713 HG13 ' H ' ' B' ' 82' ' ' GLY . 4.0 p -169.34 -93.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 105.602 -1.999 . . . . 10.0 105.602 176.195 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.713 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -78.94 58.98 4.27 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.479 -1.048 . . . . 10.0 110.479 173.905 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.83 98.93 10.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 102.306 -3.22 . . . . 10.0 102.306 165.951 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -78.26 10.77 2.76 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.24 0.473 . . . . 10.0 110.585 -175.571 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 81.12 -109.44 2.99 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 104.128 -3.589 . . . . 10.0 104.128 -175.28 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -159.53 149.78 18.97 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.354 -1.721 . . . . 10.0 106.354 -178.435 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.45 128.18 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 C-N-CA 123.18 0.592 . . . . 10.0 111.202 -171.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.87 97.52 5.3 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 126.676 1.99 . . . . 10.0 111.176 -174.412 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.33 134.36 39.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.071 -0.393 . . . . 10.0 110.482 173.066 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -61.91 169.0 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.874 0.845 . . . . 10.0 109.249 167.358 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 34.7 mtmt -48.06 -34.4 9.51 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.873 1.669 . . . . 10.0 111.395 169.331 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -78.16 -8.32 58.15 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.999 0.428 . . . . 10.0 112.077 -179.377 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.69 1.94 70.38 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 120.933 -1.104 . . . . 10.0 111.572 -176.102 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -84.81 101.39 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.115 0 C-N-CA 125.77 1.628 . . . . 10.0 108.007 -179.232 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.438 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -96.13 115.72 27.87 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 168.252 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -80.86 119.35 23.3 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 106.737 -1.579 . . . . 10.0 106.737 169.24 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 66.5 t -104.11 131.12 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -177.446 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.3 p -157.24 83.81 0.92 Allowed 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 174.033 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -115.18 159.46 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 105.088 -2.19 . . . . 10.0 105.088 176.325 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -133.52 133.19 41.85 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 109.103 -0.703 . . . . 10.0 109.103 168.082 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . 0.437 ' CG ' HH12 ' B' ' 79' ' ' ARG . 7.1 t0 -113.89 111.93 22.51 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 124.229 0.955 . . . . 10.0 109.377 -173.052 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.6 p -100.77 61.73 1.0 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.446 1.498 . . . . 10.0 107.079 -176.229 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.5 p -155.39 -47.07 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.145 0 N-CA-C 110.204 -0.295 . . . . 10.0 110.204 -173.006 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.355 0.0 OUTLIER -102.15 176.89 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.143 0 N-CA-C 113.622 0.971 . . . . 10.0 113.622 172.231 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 49.9 m -151.62 146.1 25.57 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 105.915 -1.883 . . . . 10.0 105.915 -179.723 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 29.0 mt -68.01 -14.7 63.18 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 117.948 0.34 . . . . 10.0 111.354 -175.615 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.8 m . . . . . 0 N--CA 1.451 -0.421 0 O-C-N 120.949 -1.094 . . . . 10.0 108.62 174.382 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 CA--C 1.534 0.335 0 N-CA-C 114.227 1.195 . . . . 10.0 114.227 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 36.7 pt -72.79 -11.86 15.22 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 C-N-CA 123.717 0.807 . . . . 10.0 112.45 176.854 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm -52.11 133.11 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 O-C-N 121.488 -0.758 . . . . 10.0 110.059 178.774 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.87 1.4 84.39 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 118.81 -0.995 . . . . 10.0 114.016 -178.749 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 57.2 mtt85 -85.92 175.94 8.35 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.719 1.759 . . . . 10.0 108.487 168.459 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.04 140.13 50.19 Favored 'General case' 0 CA--C 1.513 -0.467 0 C-N-CA 125.458 1.503 . . . . 10.0 108.512 179.101 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.502 HD11 ' CG1' ' B' ' 149' ' ' ILE . 1.5 mp -110.14 155.93 21.27 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 107.641 -1.244 . . . . 10.0 107.641 166.03 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.4 HG21 ' HD3' ' B' ' 143' ' ' ARG . 91.2 t -128.82 134.3 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.149 0 N-CA-C 106.695 -1.595 . . . . 10.0 106.695 -179.183 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.84 121.62 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.363 0 N-CA-C 105.71 -1.959 . . . . 10.0 105.71 166.865 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.694 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.5 m-70 -102.95 160.5 14.55 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 116.316 1.969 . . . . 10.0 116.316 -168.925 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -43.46 -56.73 3.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 129.085 2.954 . . . . 10.0 111.19 173.73 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 78.1 mttt -113.52 168.84 9.42 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 124.067 0.947 . . . . 10.0 113.352 -168.569 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.44 154.0 41.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 124.68 1.238 . . . . 10.0 108.641 169.822 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.45 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 13.0 m-20 -106.07 141.43 37.45 Favored 'General case' 0 N--CA 1.454 -0.243 0 O-C-N 123.902 0.751 . . . . 10.0 111.287 -168.6 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -74.54 -31.03 61.98 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 125.169 1.388 . . . . 10.0 110.195 -177.355 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 13.7 mt 60.62 50.57 5.59 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 122.618 1.199 . . . . 10.0 108.014 -176.005 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.68 -52.08 4.18 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 115.392 -0.822 . . . . 10.0 111.401 172.571 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 48.75 0.98 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.517 1.127 . . . . 10.0 112.249 -172.679 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.16 -26.97 7.14 Favored Glycine 0 CA--C 1.522 0.492 0 C-N-CA 127.936 2.684 . . . . 10.0 111.17 173.426 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.45 18.01 65.17 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-O 118.472 -1.182 . . . . 10.0 112.65 172.908 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -131.95 168.75 17.35 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-N 119.677 1.739 . . . . 10.0 108.277 168.361 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.45 -55.04 6.56 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.571 1.148 . . . . 10.0 108.878 178.042 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -63.62 -34.22 77.35 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 118.169 -0.919 . . . . 10.0 111.791 -175.674 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.3 m -49.16 -46.86 45.9 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 120.202 1.365 . . . . 10.0 110.804 169.301 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -89.3 -15.6 33.09 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.245 -0.883 . . . . 10.0 113.257 -170.549 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -98.07 -40.93 8.19 Favored 'General case' 0 N--CA 1.438 -1.062 0 C-N-CA 125.027 1.331 . . . . 10.0 111.773 179.146 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.4 p -136.28 -7.02 2.02 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 114.567 1.321 . . . . 10.0 114.567 175.086 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.83 17.14 52.96 Favored Glycine 0 C--O 1.221 -0.669 0 CA-C-O 118.463 -1.187 . . . . 10.0 112.306 -173.27 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 55.53 30.29 14.94 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.533 1.667 . . . . 10.0 111.765 178.76 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.59 54.8 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 125.979 1.712 . . . . 10.0 112.057 -175.323 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.33 54.81 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 110.595 -1.002 . . . . 10.0 110.595 174.605 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.2 m -55.6 139.63 43.75 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 123.966 0.906 . . . . 10.0 111.887 -168.354 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . 0.4 ' HD3' HG21 ' B' ' 118' ' ' VAL . 22.6 mtt85 -71.02 70.84 0.53 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.828 1.251 . . . . 10.0 110.06 176.684 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.3 tp -44.6 -36.2 2.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 127.84 2.456 . . . . 10.0 112.536 -176.673 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.28 151.13 17.05 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 172.959 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -146.7 164.82 31.5 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 109.914 -0.402 . . . . 10.0 109.914 177.129 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.64 -176.63 25.44 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.496 -1.042 . . . . 10.0 110.496 178.249 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.4 t -122.56 143.13 36.41 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 107.568 -1.271 . . . . 10.0 107.568 179.817 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.502 ' CG1' HD11 ' B' ' 117' ' ' LEU . 11.4 mt -78.38 112.42 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 124.1 0.96 . . . . 10.0 109.493 -179.066 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.69 146.12 16.52 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 178.2 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -79.96 119.02 28.57 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 177.22 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.56 -43.05 40.56 Favored 'General case' 0 C--O 1.221 -0.439 0 O-C-N 121.078 -1.014 . . . . 10.0 108.554 -176.038 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.946 0 C-N-CA 125.793 1.637 . . . . 10.0 110.815 170.577 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.836 0 CA-C-O 118.628 -0.701 . . . . 10.0 109.661 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.5 t -97.15 -32.71 11.81 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 124.982 1.313 . . . . 10.0 110.369 -178.295 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -148.25 151.62 35.77 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.344 -0.984 . . . . 10.0 108.344 -177.849 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.15 155.41 45.31 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 122.878 0.471 . . . . 10.0 110.548 176.401 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.636 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.1 p -126.84 151.4 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 C-N-CA 128.152 2.581 . . . . 10.0 107.028 -178.762 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.62 116.29 11.41 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.174 -2.158 . . . . 10.0 105.174 168.265 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.3 p -81.29 103.72 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 108.822 -0.807 . . . . 10.0 108.822 174.42 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.76 116.45 23.26 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.027 -1.101 . . . . 10.0 108.027 178.333 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -137.84 155.99 48.4 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 174.401 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -163.19 -66.28 0.02 OUTLIER Glycine 0 C--O 1.229 -0.18 0 CA-C-N 114.915 -1.039 . . . . 10.0 111.891 174.67 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.76 -43.91 57.64 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 -172.706 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.52 -67.66 0.53 Allowed Glycine 0 N--CA 1.443 -0.895 0 CA-C-N 113.481 -1.691 . . . . 10.0 110.525 179.779 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -58.23 -37.96 93.1 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.911 2.408 . . . . 10.0 111.142 174.617 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 94.4 t -64.54 96.81 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 176.425 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -120.35 123.1 42.27 Favored 'General case' 0 N--CA 1.446 -0.661 0 C-N-CA 125.104 1.361 . . . . 10.0 107.381 175.666 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.549 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -116.25 136.6 13.0 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 123.652 0.644 . . . . 10.0 112.168 175.363 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.428 ' CG2' HG22 ' B' ' 54' ' ' THR . 58.6 mt -124.56 74.09 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 -179.018 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -64.09 148.85 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.374 -0.83 . . . . 10.0 109.598 171.67 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -139.05 97.85 3.4 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 127.437 2.295 . . . . 10.0 107.548 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -89.79 118.87 29.7 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.781 -1.192 . . . . 10.0 107.781 171.301 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -104.8 130.88 52.83 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.838 0.745 . . . . 10.0 110.971 168.644 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -123.1 92.3 3.67 Favored 'General case' 0 C--N 1.341 0.217 0 C-N-CA 125.076 1.35 . . . . 10.0 109.102 171.759 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 11.0 mmtp -49.94 -60.91 2.48 Favored 'General case' 0 N--CA 1.46 0.072 0 C-N-CA 124.653 1.181 . . . . 10.0 111.054 175.804 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.0 176.65 8.57 Favored 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 105.604 -1.998 . . . . 10.0 105.604 171.2 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 t -74.72 -13.74 60.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 122.341 0.256 . . . . 10.0 110.708 177.229 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -88.25 -12.94 42.21 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 123.729 0.811 . . . . 10.0 109.794 174.434 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.14 119.54 4.98 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 109.357 -1.497 . . . . 10.0 109.357 178.573 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -60.83 127.73 23.37 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 N-CA-C 106.558 -2.132 . . . . 10.0 106.558 169.41 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -77.01 138.06 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 108.702 -0.851 . . . . 10.0 108.702 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.79 106.24 18.22 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 104.759 -2.311 . . . . 10.0 104.759 171.76 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 m -87.03 93.33 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 105.467 -2.049 . . . . 10.0 105.467 174.137 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -109.18 178.79 4.35 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-O 120.83 0.348 . . . . 10.0 111.219 173.721 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.58 -164.09 30.15 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 169.043 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.6 p -152.19 122.43 7.19 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 118.641 -0.695 . . . . 10.0 110.934 -169.383 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.629 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -100.88 136.6 31.73 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 105.891 -1.892 . . . . 10.0 105.891 166.325 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.44 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -130.14 160.05 34.96 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 168.809 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.7 -12.52 62.79 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 118.042 0.383 . . . . 10.0 113.208 -178.815 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 15.4 mt -68.2 -179.49 1.28 Allowed 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.872 0.869 . . . . 10.0 110.489 171.651 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -111.95 166.46 11.2 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 167.554 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -46.64 148.96 0.88 Allowed 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 127.359 2.264 . . . . 10.0 113.419 -169.534 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.65 -179.09 42.98 Favored Glycine 0 C--N 1.336 0.569 0 C-N-CA 124.235 0.922 . . . . 10.0 114.091 167.139 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.6 mt -52.38 137.9 28.23 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.878 1.671 . . . . 10.0 113.02 176.63 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 -135.31 141.57 45.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.439 1.095 . . . . 10.0 111.075 169.525 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.628 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -25.46 121.75 0.03 OUTLIER Glycine 0 C--N 1.344 0.992 0 CA-C-O 116.648 -2.195 . . . . 10.0 111.773 165.776 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -144.54 109.5 5.04 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 120.431 2.115 . . . . 10.0 111.053 169.768 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.09 175.02 11.36 Favored 'General case' 0 CA--C 1.512 -0.487 0 C-N-CA 123.572 0.749 . . . . 10.0 109.102 -179.612 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.88 98.29 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 113.595 -1.638 . . . . 10.0 109.653 179.448 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 20.4 m-70 -72.74 148.02 45.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 125.898 1.679 . . . . 10.0 109.681 -172.99 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -62.03 -55.72 26.34 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 123.958 0.786 . . . . 10.0 112.077 -173.435 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -87.92 150.6 23.38 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 119.258 -0.977 . . . . 10.0 109.583 177.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.98 32.92 5.57 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.098 -1.201 . . . . 10.0 110.098 168.414 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -79.8 70.22 6.28 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 123.251 1.5 . . . . 10.0 108.683 179.153 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.456 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.5 OUTLIER -73.98 5.5 4.19 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.557 -1.201 . . . . 10.0 113.519 -174.014 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.516 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -32.79 -50.75 0.27 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 129.607 3.163 . . . . 10.0 112.703 175.144 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.97 -20.4 45.6 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 113.517 0.932 . . . . 10.0 113.517 -174.572 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.25 71.24 0.89 Allowed Glycine 0 CA--C 1.524 0.62 0 N-CA-C 106.987 -2.445 . . . . 10.0 106.987 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.8 t 49.33 24.01 0.95 Allowed 'General case' 0 CA--C 1.529 0.145 0 N-CA-C 115.844 1.794 . . . . 10.0 115.844 171.356 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.5 m -94.27 -52.48 4.34 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -178.388 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.2 m -66.86 -25.36 66.38 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 125.359 1.464 . . . . 10.0 112.732 -169.332 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.43 -38.27 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.542 2.737 . . . . 10.0 113.73 173.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 152.71 9.61 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 111.299 -0.72 . . . . 10.0 111.299 167.713 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.85 57.28 6.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.414 2.076 . . . . 10.0 110.571 172.784 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 30.2 m170 71.56 -64.8 0.37 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 128.014 2.526 . . . . 10.0 108.875 -179.557 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.285 1.1 p90 26.02 49.32 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 129.845 3.258 . . . . 10.0 115.096 175.16 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -51.66 157.2 1.96 Allowed Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 114.438 -1.256 . . . . 10.0 111.057 169.415 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.14 -40.82 24.61 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 121.943 1.762 . . . . 10.0 111.054 -173.735 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mp -77.03 59.63 1.7 Allowed 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.532 -0.914 . . . . 10.0 108.532 169.134 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.3 p -60.95 106.87 0.63 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 107.942 -1.133 . . . . 10.0 107.942 -177.418 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -129.93 -87.64 0.51 Allowed 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 107.34 -1.356 . . . . 10.0 107.34 -169.857 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.3 mmtp -139.05 153.69 48.11 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 122.313 1.054 . . . . 10.0 109.573 169.076 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -70.42 119.78 15.1 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 105.742 -1.948 . . . . 10.0 105.742 162.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.26 -135.88 2.91 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 107.104 -2.398 . . . . 10.0 107.104 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.26 -147.73 6.21 Favored Glycine 0 C--O 1.226 -0.403 0 CA-C-O 117.965 -1.464 . . . . 10.0 109.677 171.65 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -67.13 7.78 0.43 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 119.818 1.809 . . . . 10.0 111.105 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -113.37 3.4 15.86 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 118.225 -0.893 . . . . 10.0 111.563 170.944 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -122.42 149.67 43.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.604 -1.628 . . . . 10.0 106.604 170.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -83.05 -24.77 32.63 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.65 -0.871 . . . . 10.0 108.65 171.189 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -113.3 26.2 10.65 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 125.242 1.417 . . . . 10.0 111.068 -168.665 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -47.62 161.54 0.09 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 128.589 2.756 . . . . 10.0 110.078 168.371 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -78.69 46.85 0.69 Allowed 'General case' 0 N--CA 1.463 0.216 0 O-C-N 120.575 -1.328 . . . . 10.0 112.318 -178.106 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.2 p 33.16 35.94 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 126.861 2.064 . . . . 10.0 113.595 -174.278 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 165.98 37.69 0.02 OUTLIER Glycine 0 CA--C 1.532 1.113 0 O-C-N 121.538 -0.726 . . . . 10.0 111.961 -169.246 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -113.71 108.15 16.72 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -81.33 -29.48 34.16 Favored 'General case' 0 N--CA 1.461 0.121 0 N-CA-C 107.557 -1.275 . . . . 10.0 107.557 169.033 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.16 -96.64 1.31 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 108.424 -1.871 . . . . 10.0 108.424 168.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -134.92 117.98 16.41 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 125.6 1.56 . . . . 10.0 106.905 -169.497 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 22.4 m -111.61 132.26 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 CA-C-N 118.553 0.615 . . . . 10.0 111.296 179.428 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.8 m -78.46 107.88 11.43 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.771 2.429 . . . . 10.0 112.468 -170.472 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.51 137.26 32.48 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.869 0.467 . . . . 10.0 111.309 174.225 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -62.18 174.6 0.87 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 122.009 0.909 . . . . 10.0 110.328 166.927 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.5 pttt -51.74 -32.48 30.68 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.516 1.927 . . . . 10.0 112.709 169.191 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.44 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 22.8 t70 -79.17 -10.46 59.83 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 122.14 0.971 . . . . 10.0 110.658 178.107 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.89 3.7 65.72 Favored Glycine 0 N--CA 1.431 -1.634 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 -171.898 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 26.4 t -75.55 95.65 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.095 0 N-CA-C 106.327 -1.731 . . . . 10.0 106.327 -172.461 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.629 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -98.21 113.17 25.01 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 169.052 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -81.78 115.14 20.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 C-N-CA 127.199 2.2 . . . . 10.0 108.832 175.191 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.2 133.31 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 176.406 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 72.7 p -158.52 80.88 0.81 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.963 0.905 . . . . 10.0 109.799 170.642 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -112.26 143.1 22.68 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 177.628 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -99.73 127.37 45.86 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.393 1.477 . . . . 10.0 107.564 169.372 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -133.7 156.15 48.45 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.601 0.715 . . . . 10.0 109.083 176.721 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.5 t -128.1 49.58 2.15 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 126.022 1.729 . . . . 10.0 109.015 -173.41 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -157.79 -39.42 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 123.361 0.664 . . . . 10.0 110.63 176.837 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 45.6 mm -59.92 116.53 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 169.887 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 48.5 m -131.34 119.29 21.51 Favored 'General case' 0 CA--C 1.528 0.115 0 C-N-CA 124.251 1.02 . . . . 10.0 108.417 178.396 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 59.1 mt -53.97 -38.39 64.97 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 125.108 1.363 . . . . 10.0 111.166 173.491 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.2 m -152.17 151.89 31.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.475 -0.935 . . . . 10.0 108.475 -176.095 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.3 -97.17 0.19 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.295 -1.922 . . . . 10.0 108.295 -174.825 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -122.31 -51.1 1.99 Allowed 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 127.066 2.146 . . . . 10.0 107.935 177.523 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.8 m-70 -73.56 -35.7 65.52 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 114.959 -1.019 . . . . 10.0 108.258 -169.695 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.4 t 42.47 61.47 2.02 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 125.839 1.656 . . . . 10.0 112.951 167.289 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.7 pp -68.71 -9.14 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 113.697 0.999 . . . . 10.0 113.697 -171.633 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 10.5 mm -47.09 133.37 3.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.957 -0.757 . . . . 10.0 108.957 168.893 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.3 -7.49 75.52 Favored Glycine 0 CA--C 1.533 1.156 0 CA-C-O 118.851 -0.972 . . . . 10.0 114.51 -178.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.7 mtp-105 -76.26 175.33 9.15 Favored 'General case' 0 CA--C 1.544 0.74 0 CA-C-N 119.843 1.821 . . . . 10.0 106.858 168.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -127.78 132.23 49.53 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 119.091 0.86 . . . . 10.0 112.006 -170.586 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.407 HD22 ' N ' ' A' ' 117' ' ' LEU . 3.6 mm? -85.23 148.29 26.16 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 123.997 0.919 . . . . 10.0 108.533 171.863 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 91.9 t -133.32 128.4 55.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.636 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -95.58 123.99 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 106.164 -1.791 . . . . 10.0 106.164 166.943 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.628 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.5 m-70 -98.86 159.72 14.76 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.963 1.468 . . . . 10.0 114.963 -172.805 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -40.47 -58.21 1.62 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 128.415 2.686 . . . . 10.0 110.362 172.385 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -121.44 170.97 9.13 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 113.865 1.061 . . . . 10.0 113.865 -168.209 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.29 136.69 58.13 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 113.938 -1.483 . . . . 10.0 109.072 172.673 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -76.93 148.68 36.22 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.77 0.795 . . . . 10.0 110.634 -179.877 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -81.82 -41.61 20.84 Favored 'General case' 0 N--CA 1.447 -0.625 0 C-N-CA 130.977 3.711 . . . . 10.0 108.955 -176.746 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 16.8 mt 61.29 43.85 10.33 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.451 0.7 . . . . 10.0 112.172 -178.049 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.01 19.55 77.21 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 113.991 0.356 . . . . 10.0 113.991 169.585 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -86.83 -21.8 26.21 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.534 1.133 . . . . 10.0 110.884 172.471 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -56.43 -30.02 58.02 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.777 0.703 . . . . 10.0 111.805 178.578 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.67 30.19 71.75 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.351 -1.1 . . . . 10.0 110.351 -176.124 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.4 166.6 12.46 Favored 'General case' 0 CA--C 1.511 -0.538 0 N-CA-C 108.594 -0.891 . . . . 10.0 108.594 173.006 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -48.67 -54.56 14.3 Favored 'General case' 0 N--CA 1.431 -1.389 0 C-N-CA 124.511 1.125 . . . . 10.0 108.517 176.006 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -51.6 -47.3 63.66 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 124.131 0.973 . . . . 10.0 112.2 173.644 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.9 p -52.67 -37.67 59.15 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 118.991 -0.528 . . . . 10.0 109.94 -179.223 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.251 14.8 t -90.67 0.57 57.35 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 113.807 1.04 . . . . 10.0 113.807 -179.26 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.99 -53.37 2.71 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.77 1.628 . . . . 10.0 112.596 -179.354 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.3 p -129.41 5.4 5.2 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 119.807 1.185 . . . . 10.0 111.862 171.342 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 81.52 -118.54 4.65 Favored Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 103.264 -3.934 . . . . 10.0 103.264 -167.181 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -168.81 39.14 0.03 OUTLIER 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 126.247 1.819 . . . . 10.0 107.789 -178.401 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.67 0.11 13.85 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.585 1.154 . . . . 10.0 111.792 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.15 -163.59 50.73 Favored Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 110.437 -1.065 . . . . 10.0 110.437 171.261 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.34 140.38 45.45 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.835 0.854 . . . . 10.0 111.798 -168.717 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -65.36 72.82 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.567 1.147 . . . . 10.0 110.068 169.709 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 6.0 tp -44.67 -45.53 9.75 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.991 1.716 . . . . 10.0 112.121 -175.685 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 145.93 20.19 Favored 'General case' 0 C--O 1.234 0.281 0 N-CA-C 108.199 -1.038 . . . . 10.0 108.199 -175.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 m -139.6 152.64 46.98 Favored 'General case' 0 CA--C 1.518 -0.259 0 C-N-CA 123.12 0.568 . . . . 10.0 109.974 -169.125 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -149.81 145.42 13.54 Favored Glycine 0 C--N 1.338 0.652 0 N-CA-C 110.536 -1.026 . . . . 10.0 110.536 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 23.8 t -102.07 138.04 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 106.335 -1.728 . . . . 10.0 106.335 -175.319 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 48.5 mt -76.04 107.74 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 N-CA-C 109.917 -0.401 . . . . 10.0 109.917 -173.457 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.8 164.52 12.04 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.574 1.559 . . . . 10.0 111.635 178.465 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.4 mt -64.37 143.67 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 C-N-CA 124.93 1.292 . . . . 10.0 111.495 -177.908 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -136.72 162.27 33.65 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.404 -1.332 . . . . 10.0 107.404 167.542 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 . . . . . 0 C--O 1.251 1.162 0 N-CA-C 104.256 -2.498 . . . . 10.0 104.256 166.884 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.49 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -105.54 -27.77 11.19 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 126.041 1.737 . . . . 10.0 111.743 170.009 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.8 tttt -131.05 137.06 48.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.846 0.859 . . . . 10.0 109.354 179.421 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.93 161.0 30.9 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 123.375 0.67 . . . . 10.0 110.083 170.792 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.6 t -120.45 154.66 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 C-N-CA 126.354 1.861 . . . . 10.0 108.874 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.46 108.57 4.77 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 167.86 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 53' ' ' ASN . 3.7 m -98.72 121.74 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 109.303 -0.629 . . . . 10.0 109.303 177.909 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.76 133.58 43.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.611 -0.709 . . . . 10.0 109.89 -175.266 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.3 mtpt -144.41 156.89 44.42 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 119.368 0.985 . . . . 10.0 109.153 167.447 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.47 -59.59 0.06 OUTLIER Glycine 0 N--CA 1.461 0.312 0 C-N-CA 119.696 -1.24 . . . . 10.0 113.861 169.776 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -71.12 -42.85 68.69 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -174.882 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.5 -70.05 0.41 Allowed Glycine 0 CA--C 1.523 0.532 0 CA-C-N 114.157 -1.383 . . . . 10.0 110.35 169.207 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.83 -36.82 99.0 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 123.338 2.692 . . . . 10.0 111.357 172.393 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.7 91.16 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 125.804 1.641 . . . . 10.0 107.802 177.098 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -117.82 112.39 20.33 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.205 1.402 . . . . 10.0 107.934 176.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.434 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -108.48 148.95 16.86 Favored Glycine 0 N--CA 1.432 -1.592 0 CA-C-N 114.137 -1.392 . . . . 10.0 111.328 -178.338 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.516 HG22 HG22 ' A' ' 54' ' ' THR . 1.2 mt -151.42 84.11 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.332 1.853 . . . . 10.0 107.107 -169.907 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.0 mm -97.01 149.89 4.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 C-N-CA 124.914 1.286 . . . . 10.0 110.566 179.708 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.18 111.66 11.62 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 128.901 2.88 . . . . 10.0 108.382 -178.031 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -98.29 111.02 23.5 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 117.435 -1.269 . . . . 10.0 107.845 172.948 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -108.77 108.55 19.41 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.365 0.984 . . . . 10.0 112.271 174.073 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -103.87 96.21 6.53 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.588 1.955 . . . . 10.0 107.153 174.442 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 65.6 mttt . . . . . 0 CA--C 1.518 -0.273 0 C-N-CA 123.946 0.898 . . . . 10.0 110.637 -169.052 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.022 0 N-CA-C 110.024 -1.231 . . . . 10.0 110.024 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.8 127.79 18.58 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 N-CA-C 107.045 -1.944 . . . . 10.0 107.045 169.832 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.5 p -76.46 85.81 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-O 122.432 1.11 . . . . 10.0 108.349 -174.36 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 mtpt -58.82 111.31 1.24 Allowed 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 169.607 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 p -102.07 101.87 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.754 0 C-N-CA 126.219 1.807 . . . . 10.0 106.395 -177.64 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -116.18 174.4 6.07 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 116.319 -0.401 . . . . 10.0 111.385 176.531 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.03 -156.01 26.72 Favored Glycine 0 C--N 1.331 0.264 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 169.294 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.2 p -149.71 146.56 27.29 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.451 0.644 . . . . 10.0 112.595 -172.373 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.616 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -120.95 115.41 46.75 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.329 0 C-N-CA 125.909 1.684 . . . . 10.0 108.693 169.774 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -102.49 143.1 32.63 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 169.746 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.72 9.35 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 124.562 1.077 . . . . 10.0 112.969 170.332 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 mt -87.77 -175.67 5.24 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.961 0.886 . . . . 10.0 110.571 -171.274 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -102.72 155.78 18.08 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 167.516 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -53.54 159.09 1.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.589 1.156 . . . . 10.0 111.793 -174.878 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.71 -177.15 35.59 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.717 0.675 . . . . 10.0 111.803 170.608 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -66.56 149.82 49.9 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 125.46 1.504 . . . . 10.0 112.373 -177.861 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.6 m-70 -146.8 142.28 27.56 Favored 'General case' 0 C--N 1.344 0.352 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -177.467 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.683 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -30.99 125.62 0.17 Allowed Glycine 0 C--N 1.343 0.943 0 C-N-CA 127.74 2.59 . . . . 10.0 113.03 165.679 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.67 105.12 2.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 119.343 1.572 . . . . 10.0 113.002 168.577 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.13 172.74 15.31 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.156 0.503 . . . . 10.0 111.501 179.64 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.0 m -93.99 149.93 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 113.156 -1.838 . . . . 10.0 108.408 169.299 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 24.2 m-70 -130.94 140.31 50.16 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.719 1.608 . . . . 10.0 106.888 174.795 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -52.76 -54.86 27.92 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 125.27 1.428 . . . . 10.0 112.327 -169.721 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -77.62 114.59 16.61 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -61.05 -32.16 79.29 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.261 -1.136 . . . . 10.0 110.261 172.257 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.636 ' HA ' HG11 ' A' ' 5' ' ' VAL . 25.3 t0 -32.16 125.35 0.29 Allowed 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 125.296 1.439 . . . . 10.0 112.548 172.282 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -129.69 11.36 5.7 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 113.967 -1.47 . . . . 10.0 111.401 176.628 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.428 HG22 ' CG2' ' A' ' 17' ' ' ILE . 8.2 p -37.17 -63.27 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 125.972 1.709 . . . . 10.0 113.309 -175.477 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -74.67 -16.03 60.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.444 -1.253 . . . . 10.0 111.89 -174.458 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 136.11 -75.57 0.4 Allowed Glycine 0 CA--C 1.521 0.464 0 N-CA-C 109.004 -1.638 . . . . 10.0 109.004 177.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 9.3 t -157.0 18.65 0.3 Allowed 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 112.734 0.642 . . . . 10.0 112.734 -172.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.0 p -99.07 -57.43 2.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 105.718 -1.956 . . . . 10.0 105.718 -176.527 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -55.64 -25.77 40.84 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.424 1.89 . . . . 10.0 111.81 -179.409 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.14 -29.64 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 127.953 2.501 . . . . 10.0 114.226 168.349 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.61 154.96 28.28 Favored Glycine 0 C--N 1.34 0.752 0 N-CA-C 109.359 -1.496 . . . . 10.0 109.359 170.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -74.12 -170.84 0.77 Allowed 'Trans proline' 0 N--CA 1.446 -1.315 0 N-CA-C 107.787 -1.659 . . . . 10.0 107.787 168.778 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.428 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.1 m170 -80.95 60.67 4.25 Favored 'General case' 0 CA--C 1.537 0.444 0 O-C-N 120.658 -1.276 . . . . 10.0 109.827 -177.079 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -73.67 72.71 1.48 Allowed 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 122.117 0.96 . . . . 10.0 109.698 174.408 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -73.16 135.06 79.99 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.636 -0.665 . . . . 10.0 110.042 173.271 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.18 -44.56 4.82 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 122.57 2.18 . . . . 10.0 110.867 -177.426 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.8 mt -72.63 67.85 0.8 Allowed 'General case' 0 C--O 1.225 -0.234 0 C-N-CA 123.481 0.712 . . . . 10.0 109.312 175.067 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 40.5 p -37.03 108.67 0.08 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 125.853 1.661 . . . . 10.0 111.054 -179.187 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.83 173.03 12.05 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 103.086 -2.931 . . . . 10.0 103.086 -170.568 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.418 ' NZ ' ' OE2' ' B' ' 78' ' ' GLU . 6.7 mptt -80.06 152.44 29.37 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 117.341 -1.743 . . . . 10.0 107.99 170.338 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.432 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 79.1 t60 -63.27 103.2 0.47 Allowed 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.398 -0.964 . . . . 10.0 108.398 165.596 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.37 -127.34 4.05 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.156 -1.977 . . . . 10.0 108.156 177.718 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.7 -163.83 32.47 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 108.377 -1.889 . . . . 10.0 108.377 173.346 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -63.29 -5.5 8.27 Favored 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 119.832 1.816 . . . . 10.0 110.793 167.499 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -87.53 -26.09 23.33 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 125.407 1.483 . . . . 10.0 110.076 175.131 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -98.94 158.36 15.7 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 106.798 -1.556 . . . . 10.0 106.798 179.299 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -79.0 -32.38 45.14 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 107.421 -1.326 . . . . 10.0 107.421 168.541 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . 0.418 ' OE2' ' NZ ' ' B' ' 70' ' ' LYS . 1.4 pt-20 -114.5 51.36 0.89 Allowed 'General case' 0 N--CA 1.447 -0.604 0 C-N-CA 124.26 1.024 . . . . 10.0 111.018 -168.684 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -61.43 164.53 5.58 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.589 1.556 . . . . 10.0 110.689 169.159 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.432 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 9.9 m170 -66.59 -63.09 1.14 Allowed 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.418 0.525 . . . . 10.0 112.418 -170.022 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 8.2 p -171.65 -47.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.19 0.996 . . . . 10.0 109.818 -178.092 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.59 72.28 0.37 Allowed Glycine 0 C--N 1.336 0.572 0 N-CA-C 107.149 -2.38 . . . . 10.0 107.149 176.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.05 98.11 5.83 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.497 -2.038 . . . . 10.0 105.497 -173.358 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 40.5 mt -80.72 5.92 14.35 Favored 'General case' 0 N--CA 1.463 0.177 0 C-N-CA 122.678 0.391 . . . . 10.0 111.774 -169.844 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 82.65 -106.36 2.73 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 107.475 -2.25 . . . . 10.0 107.475 -174.582 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -158.65 152.53 23.54 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.125 0.97 . . . . 10.0 110.248 -177.146 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -122.74 133.99 67.23 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 123.275 0.63 . . . . 10.0 110.174 -176.402 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -78.57 133.23 37.35 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 126.546 1.938 . . . . 10.0 109.266 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.29 132.56 50.41 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.548 1.939 . . . . 10.0 110.155 169.726 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -63.6 171.22 2.72 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.993 1.717 . . . . 10.0 111.145 168.733 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . 0.417 ' NZ ' ' OD1' ' B' ' 92' ' ' ASP . 17.9 pttp -49.07 -35.03 14.95 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 124.565 1.146 . . . . 10.0 110.647 169.535 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . 0.417 ' OD1' ' NZ ' ' B' ' 91' ' ' LYS . 0.1 OUTLIER -77.9 -3.15 40.28 Favored 'General case' 0 C--N 1.342 0.249 0 O-C-N 122.326 -0.234 . . . . 10.0 110.535 -175.919 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.68 22.88 78.75 Favored Glycine 0 N--CA 1.444 -0.797 0 N-CA-C 109.469 -1.452 . . . . 10.0 109.469 -175.289 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.0 t -96.21 106.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.86 0 C-N-CA 127.57 2.348 . . . . 10.0 105.093 173.438 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.616 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.44 125.05 48.03 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.287 -1.005 . . . . 10.0 108.287 169.341 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -94.68 121.33 36.15 Favored 'General case' 0 N--CA 1.435 -1.179 0 C-N-CA 127.838 2.455 . . . . 10.0 108.832 179.308 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 43.3 t -101.26 135.81 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 124.767 1.227 . . . . 10.0 108.147 177.326 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.26 72.43 0.62 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.945 1.298 . . . . 10.0 109.408 169.689 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -106.38 162.46 5.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 107.565 -1.272 . . . . 10.0 107.565 -179.036 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -146.13 136.46 23.87 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.584 1.554 . . . . 10.0 109.568 175.69 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -134.02 142.34 47.58 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.091 -1.818 . . . . 10.0 106.091 173.759 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 75.2 p -103.5 51.48 0.79 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.868 1.267 . . . . 10.0 107.811 174.228 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.32 -47.91 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.323 0.649 . . . . 10.0 110.377 -176.97 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.47 118.26 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 171.431 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.1 m -120.62 112.67 19.19 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 108.562 -0.903 . . . . 10.0 108.562 -176.658 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 77.4 mt -56.81 -43.97 81.51 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.457 0.646 . . . . 10.0 110.41 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.452 -0.345 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 -174.358 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t . . . . . 0 N--CA 1.45 -0.43 0 CA-C-O 122.957 1.36 . . . . 10.0 108.112 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 31.0 mm -73.57 -14.06 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 CA-C-N 113.543 -1.662 . . . . 10.0 112.228 -168.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.5 mm -51.48 147.32 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 N-CA-C 109.363 -0.606 . . . . 10.0 109.363 169.696 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.81 2.44 90.54 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 121.357 -0.84 . . . . 10.0 114.592 178.815 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 54.4 mmt-85 -77.58 163.31 26.37 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 118.914 1.357 . . . . 10.0 108.716 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.1 118.17 35.24 Favored 'General case' 0 C--N 1.34 0.153 0 N-CA-C 109.287 -0.634 . . . . 10.0 109.287 170.51 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.426 HD21 HD11 ' B' ' 149' ' ' ILE . 4.5 mm? -75.49 142.99 42.79 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.048 -1.464 . . . . 10.0 107.048 167.184 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.64 129.36 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.831 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.04 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.42 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.7 p -97.35 135.3 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.715 0 N-CA-C 107.96 -1.126 . . . . 10.0 107.96 169.275 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.683 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.8 m170 -115.02 159.72 20.46 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 116.465 2.024 . . . . 10.0 116.465 -175.891 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -48.92 -58.38 4.95 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 129.832 3.253 . . . . 10.0 111.932 177.071 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 54.8 mttp -111.93 173.46 6.35 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.966 0.906 . . . . 10.0 112.804 -169.874 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.05 136.04 35.26 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 126.524 1.929 . . . . 10.0 110.304 -179.165 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.69 144.22 32.42 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 113.362 0.875 . . . . 10.0 113.362 -169.558 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -74.9 -38.56 61.82 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.187 1.395 . . . . 10.0 109.206 177.855 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.8 mt 62.12 49.92 4.23 Favored 'General case' 0 C--N 1.337 0.054 0 C-N-CA 125.21 1.404 . . . . 10.0 110.006 -172.259 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 82.82 -45.58 3.45 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.562 1.077 . . . . 10.0 110.988 170.638 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.5 pttp -73.43 21.63 0.08 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.83 1.652 . . . . 10.0 112.72 -175.147 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -77.91 -32.71 43.99 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 126.475 1.988 . . . . 10.0 108.298 166.103 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.22 19.08 69.97 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.284 -0.731 . . . . 10.0 111.859 -179.124 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -112.07 162.27 15.59 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 104.839 -2.282 . . . . 10.0 104.839 169.215 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . 0.454 ' CD ' ' HZ1' ' B' ' 136' ' ' LYS . 15.6 tm-20 -60.92 -40.04 91.7 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 119.505 -0.878 . . . . 10.0 110.748 -169.849 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -69.12 -28.28 66.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 118.749 -0.643 . . . . 10.0 112.242 177.529 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -48.76 -47.47 41.64 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 119.68 1.127 . . . . 10.0 110.242 168.852 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.4 t -85.1 -10.15 57.15 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 118.461 -0.781 . . . . 10.0 112.711 -171.366 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.454 ' HZ1' ' CD ' ' B' ' 132' ' ' GLU . 1.1 ttmp? -100.61 -92.34 0.3 Allowed 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.69 1.596 . . . . 10.0 108.15 175.292 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.428 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 44.5 p -86.26 1.35 51.23 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 122.135 2.243 . . . . 10.0 112.744 -176.062 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.58 21.89 73.88 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 120.416 1.462 . . . . 10.0 110.79 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 61.72 19.92 10.93 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 119.577 1.688 . . . . 10.0 112.854 169.649 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -80.29 9.96 5.12 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 113.623 0.972 . . . . 10.0 113.623 -168.021 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.72 -165.07 53.94 Favored Glycine 0 N--CA 1.444 -0.781 0 O-C-N 121.252 -0.905 . . . . 10.0 111.502 170.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.5 m -59.3 135.63 57.71 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 124.1 0.96 . . . . 10.0 112.901 -167.705 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -67.23 86.99 0.16 Allowed 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 125.129 1.372 . . . . 10.0 110.276 174.042 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 58.5 mt -60.85 -35.12 75.76 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.827 0.676 . . . . 10.0 112.827 -177.19 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.42 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -158.39 154.35 26.81 Favored 'General case' 0 C--O 1.234 0.244 0 O-C-N 121.625 -0.672 . . . . 10.0 111.495 179.932 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -123.55 152.36 41.9 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 125.857 1.663 . . . . 10.0 109.088 -178.674 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.57 156.04 26.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.413 -1.075 . . . . 10.0 110.413 168.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 66.1 t -109.58 140.07 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 -175.588 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.426 HD11 HD21 ' B' ' 117' ' ' LEU . 27.6 mt -75.62 125.15 34.92 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-O 118.594 -0.717 . . . . 10.0 109.764 -178.622 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.81 162.76 24.48 Favored Glycine 0 CA--C 1.53 1.022 0 C-N-CA 124.383 0.992 . . . . 10.0 113.569 -178.573 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.8 mm -73.34 144.91 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.274 1.03 . . . . 10.0 111.226 -169.904 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.96 -47.2 2.18 Favored 'General case' 0 CA--C 1.51 -0.592 0 CA-C-N 118.45 0.568 . . . . 10.0 111.433 166.652 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 116.38 -1.771 . . . . 10.0 107.544 175.78 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.659 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.7 t -151.55 -48.44 0.11 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 119.12 0.873 . . . . 10.0 110.7 178.686 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 40.8 tttt -132.87 153.64 51.14 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.2 -1.778 . . . . 10.0 106.2 172.59 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.22 151.18 43.55 Favored 'General case' 0 CA--C 1.513 -0.46 0 N-CA-C 108.93 -0.767 . . . . 10.0 108.93 169.286 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.38 161.12 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 O-C-N 124.061 0.851 . . . . 10.0 110.223 172.464 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.432 ' CB ' HD12 ' A' ' 117' ' ' LEU . . . -147.41 98.96 3.07 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.206 -1.775 . . . . 10.0 106.206 165.703 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.481 HG21 ' HB3' ' B' ' 53' ' ' ASN . 7.5 m -93.29 98.02 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 122.844 0.458 . . . . 10.0 110.687 -179.204 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.415 HD12 ' N ' ' A' ' 8' ' ' LEU . 5.5 mp -79.6 136.26 36.8 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 121.227 -0.921 . . . . 10.0 109.833 -175.756 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -144.73 156.15 43.92 Favored 'General case' 0 C--N 1.341 0.212 0 C-N-CA 124.426 1.09 . . . . 10.0 108.344 168.346 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.6 -69.08 0.02 OUTLIER Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.185 -0.531 . . . . 10.0 112.166 169.252 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -74.24 -41.51 61.2 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 107.179 -1.415 . . . . 10.0 107.179 -175.656 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.91 -67.67 0.48 Allowed Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 114.996 -1.002 . . . . 10.0 111.588 176.969 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -55.15 -42.05 72.58 Favored 'Trans proline' 0 N--CA 1.45 -1.077 0 C-N-CA 121.972 1.782 . . . . 10.0 110.077 175.846 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.668 HG13 HD12 ' A' ' 38' ' ' LEU . 47.9 t -58.49 87.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 C-N-CA 126.182 1.793 . . . . 10.0 108.034 175.197 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.47 116.95 31.75 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.709 -1.96 . . . . 10.0 105.709 171.453 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.91 142.89 15.97 Favored Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 108.656 -1.778 . . . . 10.0 108.656 174.258 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.972 ' CG2' HG22 ' B' ' 54' ' ' THR . 7.1 mt -138.71 60.81 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 N-CA-C 107.357 -1.349 . . . . 10.0 107.357 -169.684 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.4 mm -77.87 133.56 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 N-CA-C 108.801 -0.814 . . . . 10.0 108.801 -176.072 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m-80 -122.44 105.11 9.87 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.203 2.201 . . . . 10.0 107.22 -176.805 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -89.1 136.44 33.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.499 1.12 . . . . 10.0 108.025 177.749 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -117.49 148.29 41.97 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 123.703 0.627 . . . . 10.0 110.701 168.191 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -122.46 107.14 11.69 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.7 1.6 . . . . 10.0 108.01 168.816 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -65.91 -59.2 4.08 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.974 0.91 . . . . 10.0 110.644 -178.492 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.1 mp0 -128.22 168.02 16.04 Favored 'General case' 0 N--CA 1.425 -1.725 0 N-CA-C 103.608 -2.738 . . . . 10.0 103.608 174.079 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.2 p -65.98 -25.74 67.24 Favored 'General case' 0 N--CA 1.44 -0.937 0 O-C-N 121.748 -0.595 . . . . 10.0 109.429 174.759 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -98.69 -6.33 29.85 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.207 1.403 . . . . 10.0 110.828 -173.361 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.63 144.57 21.4 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 -173.772 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -64.02 139.42 67.29 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 121.721 1.614 . . . . 10.0 108.101 170.525 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 m -93.12 142.51 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -176.861 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -108.06 123.21 48.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.298 -2.482 . . . . 10.0 104.298 166.606 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 m -108.99 103.45 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 105.916 -1.883 . . . . 10.0 105.916 -179.371 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 8.0 p90 -114.44 171.82 7.39 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 -176.298 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.65 -154.4 25.53 Favored Glycine 0 N--CA 1.447 -0.618 0 N-CA-C 108.537 -1.825 . . . . 10.0 108.537 169.076 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 m -153.54 150.24 28.5 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 117.124 0.462 . . . . 10.0 110.899 177.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.61 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -111.17 112.65 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 C-N-CA 127.356 2.263 . . . . 10.0 106.861 168.493 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.5 ptmt -121.73 90.3 3.28 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 112.214 0.45 . . . . 10.0 112.214 -178.276 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.65 32.35 0.02 OUTLIER Glycine 0 CA--C 1.52 0.406 0 CA-C-O 118.981 -0.9 . . . . 10.0 113.996 174.032 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.668 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -125.06 175.41 7.37 Favored 'General case' 0 C--O 1.224 -0.246 0 N-CA-C 108.237 -1.023 . . . . 10.0 108.237 177.144 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -75.6 168.54 19.81 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 118.83 0.741 . . . . 10.0 110.844 177.712 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 65.1 tt0 -61.02 173.3 0.81 Allowed 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.21 1.804 . . . . 10.0 111.288 -176.874 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.14 179.73 49.73 Favored Glycine 0 CA--C 1.522 0.52 0 C-N-CA 123.781 0.705 . . . . 10.0 112.017 168.897 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.0 mp -66.02 143.56 57.28 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.376 1.07 . . . . 10.0 110.275 178.449 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -140.39 146.5 38.45 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 113.384 0.883 . . . . 10.0 113.384 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.661 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -29.25 122.72 0.09 OUTLIER Glycine 0 C--N 1.341 0.851 0 C-N-CA 127.547 2.499 . . . . 10.0 112.269 165.25 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -150.62 106.01 3.37 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 120.034 1.917 . . . . 10.0 113.12 169.758 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.419 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.43 175.18 12.99 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.509 0.671 . . . . 10.0 112.803 -176.497 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.402 HG12 ' CD2' ' A' ' 117' ' ' LEU . 1.7 m -91.42 153.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 112.655 -2.066 . . . . 10.0 106.3 166.499 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.32 123.27 35.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 102.884 -3.006 . . . . 10.0 102.884 169.113 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -61.33 -35.03 76.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 114.894 1.442 . . . . 10.0 114.894 -164.571 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-30 -75.91 119.54 20.02 Favored 'General case' 0 C--N 1.342 0.251 0 C-N-CA 117.285 -1.766 . . . . 10.0 106.984 169.576 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.01 37.08 0.92 Allowed Glycine 0 CA--C 1.525 0.676 0 C-N-CA 125.041 1.305 . . . . 10.0 111.241 168.883 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -107.55 171.56 7.32 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 124.899 1.279 . . . . 10.0 107.697 177.459 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.439 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -161.1 25.65 0.14 Allowed 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 114.653 -1.158 . . . . 10.0 112.231 168.747 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.442 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.2 OUTLIER -55.39 -36.96 66.97 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.451 1.1 . . . . 10.0 111.253 -170.481 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.38 -19.6 55.95 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 124.022 0.929 . . . . 10.0 112.468 -179.695 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 87.04 97.87 0.85 Allowed Glycine 0 CA--C 1.528 0.866 0 N-CA-C 109.02 -1.632 . . . . 10.0 109.02 -169.698 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 59.2 m 43.11 55.17 4.67 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.032 1.733 . . . . 10.0 113.962 173.074 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.76 -49.62 0.08 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.078 0.551 . . . . 10.0 110.139 176.034 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 47.4 t -60.8 -28.89 69.12 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 122.44 0.296 . . . . 10.0 111.059 -173.314 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.42 -28.97 0.07 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 127.448 2.299 . . . . 10.0 115.156 179.758 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 134.26 8.41 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-O 118.449 -1.195 . . . . 10.0 110.528 170.994 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -78.46 62.24 8.14 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 123.211 2.607 . . . . 10.0 112.319 -174.315 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 14.0 m170 61.74 28.02 17.21 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.511 2.324 . . . . 10.0 110.581 177.372 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -53.72 -39.05 64.91 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 113.871 1.064 . . . . 10.0 113.871 -166.67 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 34.27 172.23 0.0 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 128.807 2.843 . . . . 10.0 115.518 -169.662 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -67.81 -65.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.349 0.573 0 O-C-N 118.621 -1.305 . . . . 10.0 110.849 -172.781 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.0 74.52 2.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 169.006 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 p -47.89 113.76 0.78 Allowed 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.048 0.939 . . . . 10.0 108.946 169.487 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 40.6 mtt180 -133.13 -167.06 1.85 Allowed 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 105.783 -1.932 . . . . 10.0 105.783 -178.465 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.81 137.54 33.66 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 118.046 -1.462 . . . . 10.0 110.304 -171.022 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 65.8 t60 -47.15 119.66 2.71 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 120.337 -0.545 . . . . 10.0 110.517 168.218 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.61 -143.76 4.22 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 108.636 -1.786 . . . . 10.0 108.636 177.583 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.61 -149.94 6.86 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-O 118.158 -1.357 . . . . 10.0 109.981 175.431 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 79.7 Cg_endo -69.27 14.68 0.22 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 122.162 1.908 . . . . 10.0 111.415 169.287 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.0 mtpm? -110.08 -10.78 14.67 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 124.616 1.166 . . . . 10.0 110.075 169.592 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -111.41 158.55 18.96 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.369 -1.345 . . . . 10.0 107.369 -179.176 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -79.41 -36.86 38.42 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.653 -1.24 . . . . 10.0 107.653 173.033 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -96.8 -49.7 4.96 Favored 'General case' 0 CA--C 1.498 -1.024 0 CA-C-O 121.453 0.644 . . . . 10.0 112.137 -166.3 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 7.1 ptp180 41.52 -141.4 0.09 Allowed 'General case' 0 N--CA 1.434 -1.253 0 CA-C-N 113.709 -1.587 . . . . 10.0 109.108 -169.478 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -112.12 44.56 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 O-C-N 120.611 -1.306 . . . . 10.0 108.073 166.511 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.9 t 37.8 38.96 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 124.081 0.953 . . . . 10.0 111.04 -167.596 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 70.69 0.02 OUTLIER Glycine 0 CA--C 1.533 1.195 0 O-C-N 121.541 -0.724 . . . . 10.0 112.431 -174.002 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -136.94 111.15 8.39 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 104.008 -2.59 . . . . 10.0 104.008 168.181 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 19.3 mt -72.19 -23.18 61.22 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 118.667 0.667 . . . . 10.0 109.225 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.11 -89.8 0.55 Allowed Glycine 0 N--CA 1.441 -1.025 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 167.042 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 m-20 -147.8 126.44 12.53 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -173.794 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.7 m -109.82 124.87 66.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 118.043 0.383 . . . . 10.0 110.097 176.293 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.1 m -79.51 111.39 15.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 127.245 2.218 . . . . 10.0 111.228 -176.825 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.56 129.75 34.75 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 123.176 0.59 . . . . 10.0 109.985 170.813 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -61.29 166.69 3.66 Favored 'General case' 0 N--CA 1.454 -0.272 0 O-C-N 124.574 1.171 . . . . 10.0 109.119 167.756 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.64 -26.0 54.92 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 123.91 0.884 . . . . 10.0 111.446 175.882 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -75.76 -10.62 59.59 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 120.583 0.23 . . . . 10.0 110.675 179.525 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.04 23.15 42.3 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.403 -1.079 . . . . 10.0 110.403 178.664 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.1 t -106.99 105.57 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.986 0 C-N-CA 128.359 2.664 . . . . 10.0 105.95 -178.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.61 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -102.83 121.46 42.52 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.668 -1.234 . . . . 10.0 107.668 168.635 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -92.32 132.63 36.56 Favored 'General case' 0 N--CA 1.434 -1.261 0 C-N-CA 127.188 2.195 . . . . 10.0 108.899 176.36 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -113.08 133.12 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.979 0 C-N-CA 125.298 1.439 . . . . 10.0 107.676 175.14 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.5 p -158.35 57.82 0.45 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.278 0.631 . . . . 10.0 110.688 169.651 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.79 155.15 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.101 0 N-CA-C 107.999 -1.112 . . . . 10.0 107.999 -173.986 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -122.2 156.41 33.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 124.746 1.218 . . . . 10.0 111.904 173.809 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -148.97 164.19 35.3 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.057 -1.428 . . . . 10.0 108.989 168.721 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.7 p -118.8 44.01 2.4 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 126.227 1.811 . . . . 10.0 110.364 -178.012 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.2 p -145.19 -43.46 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 118.255 0.48 . . . . 10.0 111.251 177.013 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.39 147.31 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.318 -1.364 . . . . 10.0 107.318 169.176 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.1 m -151.57 135.44 16.45 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.128 -1.064 . . . . 10.0 108.128 174.385 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -70.04 -38.16 75.77 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.832 0.853 . . . . 10.0 108.919 -179.593 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 22.6 m -137.75 130.22 29.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.74 -1.578 . . . . 10.0 106.74 170.335 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.91 -65.66 0.1 OUTLIER Glycine 0 C--N 1.333 0.369 0 N-CA-C 109.258 -1.537 . . . . 10.0 109.258 -177.941 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -163.06 -51.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.773 1.629 . . . . 10.0 107.703 -179.835 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -74.1 -41.59 61.4 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 114.38 -1.282 . . . . 10.0 108.091 -169.64 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.9 t 41.11 74.25 0.11 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 126.477 1.911 . . . . 10.0 111.702 174.858 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -68.22 -3.64 2.64 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 N-CA-C 112.932 0.716 . . . . 10.0 112.932 -179.682 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.1 mm -33.02 -44.34 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 126.453 1.901 . . . . 10.0 114.042 173.421 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.89 38.81 3.14 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 124.185 0.898 . . . . 10.0 112.515 -176.748 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -102.78 176.69 5.08 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.475 1.51 . . . . 10.0 111.643 170.046 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 4.7 m -119.1 131.22 55.9 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.952 2.101 . . . . 10.0 106.36 177.85 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.432 HD12 ' CB ' ' A' ' 6' ' ' ALA . 58.7 mt -103.9 148.35 26.26 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 125.28 1.432 . . . . 10.0 109.324 172.285 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.2 t -136.36 134.36 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 O-C-N 123.71 0.631 . . . . 10.0 109.364 -178.593 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.39 135.63 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 168.648 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.661 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.3 m170 -112.26 155.64 23.7 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 116.673 2.101 . . . . 10.0 116.673 -178.565 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -42.24 -62.93 0.83 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.779 3.231 . . . . 10.0 111.548 173.314 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 8.1 mtmt -106.89 172.41 6.84 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.993 1.317 . . . . 10.0 111.823 -177.298 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.4 150.96 39.76 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.994 -1.457 . . . . 10.0 109.605 172.459 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.419 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.3 m-20 -79.46 150.23 31.32 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.565 1.146 . . . . 10.0 112.495 177.317 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -74.36 -29.56 61.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.973 -1.467 . . . . 10.0 110.122 169.943 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 27.4 mt 54.97 44.27 28.53 Favored 'General case' 0 C--N 1.339 0.129 0 CA-C-O 121.847 0.832 . . . . 10.0 108.799 -167.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.38 -10.17 67.71 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 125.667 1.603 . . . . 10.0 113.151 173.204 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -78.33 -3.93 45.5 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 118.405 1.102 . . . . 10.0 113.117 -170.795 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.2 -38.62 95.94 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.813 -0.915 . . . . 10.0 110.813 175.152 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.43 33.45 81.88 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.114 -1.194 . . . . 10.0 110.114 -173.387 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -117.59 161.96 18.79 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 106.05 -1.833 . . . . 10.0 106.05 169.69 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -51.36 -48.87 62.36 Favored 'General case' 0 N--CA 1.428 -1.525 0 N-CA-C 108.721 -0.844 . . . . 10.0 108.721 170.773 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -59.04 -40.1 84.04 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.318 -0.401 . . . . 10.0 111.31 176.96 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 16.6 p -55.75 -40.15 72.16 Favored 'General case' 0 N--CA 1.443 -0.794 0 O-C-N 120.926 -1.109 . . . . 10.0 110.708 179.287 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -84.64 4.93 30.11 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 118.491 -0.766 . . . . 10.0 112.122 -178.265 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -112.83 -85.44 0.58 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.037 1.735 . . . . 10.0 110.091 175.022 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.4 p -111.43 30.87 6.56 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 121.088 1.767 . . . . 10.0 112.52 178.179 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.83 27.52 56.18 Favored Glycine 0 C--N 1.341 0.858 0 C-N-CA 123.757 0.694 . . . . 10.0 113.9 168.333 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 46.8 29.62 1.03 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.055 0.942 . . . . 10.0 113.01 -172.108 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.35 -4.57 18.77 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.228 -0.92 . . . . 10.0 112.24 -177.424 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.67 -161.92 50.17 Favored Glycine 0 N--CA 1.444 -0.812 0 O-C-N 121.129 -0.982 . . . . 10.0 111.315 169.212 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.1 m -55.12 128.39 33.57 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 114.644 -0.778 . . . . 10.0 112.842 -167.274 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 22.5 mtt85 -66.43 73.03 0.08 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.738 1.615 . . . . 10.0 109.758 172.078 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 35.1 mt -49.3 -36.82 21.94 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.595 1.158 . . . . 10.0 112.976 -175.722 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 152.1 24.72 Favored 'General case' 0 CA--C 1.513 -0.461 0 O-C-N 121.57 -0.706 . . . . 10.0 110.526 -177.877 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.0 m -130.87 145.66 52.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 124.821 1.326 . . . . 10.0 108.679 -175.661 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -135.48 141.28 12.46 Favored Glycine 0 C--N 1.332 0.314 0 N-CA-C 108.621 -1.792 . . . . 10.0 108.621 171.508 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -99.79 136.61 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 105.869 -1.9 . . . . 10.0 105.869 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.0 mt -72.09 158.93 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 -177.072 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -172.67 168.66 41.75 Favored Glycine 0 CA--C 1.527 0.787 0 O-C-N 121.379 -0.826 . . . . 10.0 111.737 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.7 mt -53.19 142.31 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 125.451 1.5 . . . . 10.0 111.534 -174.209 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.83 163.64 36.79 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.665 0.745 . . . . 10.0 109.489 166.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 . . . . . 0 C--O 1.256 1.405 0 N-CA-C 104.7 -2.333 . . . . 10.0 104.7 166.636 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.848 0 CA-C-O 117.997 -1.002 . . . . 10.0 108.432 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -165.21 -45.32 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.837 0.855 . . . . 10.0 110.208 178.346 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mttt -136.69 154.27 50.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 125.245 1.418 . . . . 10.0 109.248 169.711 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.59 164.43 30.23 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.366 1.466 . . . . 10.0 107.528 168.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -134.3 157.95 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 N-CA-C 109.327 -0.62 . . . . 10.0 109.327 -178.884 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.93 99.96 5.95 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.045 0.938 . . . . 10.0 109.502 172.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.439 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.2 OUTLIER -81.24 93.03 2.18 Favored 'Isoleucine or valine' 0 C--N 1.341 0.229 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 167.966 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mt -84.71 136.68 33.62 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.474 1.11 . . . . 10.0 108.561 -178.732 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -159.74 161.64 34.79 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.441 -1.318 . . . . 10.0 107.441 173.771 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.38 -44.82 0.11 Allowed Glycine 0 C--O 1.227 -0.331 0 C-N-CA 119.813 -1.184 . . . . 10.0 113.473 168.938 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -74.1 -45.17 50.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.721 -1.215 . . . . 10.0 107.721 -176.0 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 144.22 -71.36 0.38 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.636 -1.386 . . . . 10.0 109.636 171.487 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -59.1 -37.52 92.12 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.303 2.669 . . . . 10.0 111.14 171.768 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.419 HG13 HD11 ' B' ' 38' ' ' LEU . 58.4 t -58.93 111.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 108.538 -0.912 . . . . 10.0 108.538 178.094 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -125.96 127.86 46.6 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 105.598 -2.001 . . . . 10.0 105.598 167.949 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.528 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -114.12 135.46 12.5 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 108.765 -1.734 . . . . 10.0 108.765 170.505 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.442 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.6 mt -134.97 68.07 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 106.706 -1.591 . . . . 10.0 106.706 -173.836 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.4 mm -97.59 139.82 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 115.145 -0.934 . . . . 10.0 110.467 -170.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -107.39 130.52 54.79 Favored 'General case' 0 CA--C 1.527 0.095 0 C-N-CA 126.833 2.053 . . . . 10.0 109.168 -176.183 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -116.75 100.38 7.76 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.376 -1.342 . . . . 10.0 107.376 177.91 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.47 156.89 17.37 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.33 0.514 . . . . 10.0 110.973 175.637 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 34.5 tp60 -154.2 65.49 0.7 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.979 1.312 . . . . 10.0 109.851 -177.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? . . . . . 0 N--CA 1.432 -1.347 0 C-N-CA 124.86 1.264 . . . . 10.0 107.71 176.955 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.297 0 N-CA-C 115.419 0.928 . . . . 10.0 115.419 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.71 104.06 1.67 Allowed 'Trans proline' 0 N--CA 1.445 -1.361 0 N-CA-C 105.939 -2.369 . . . . 10.0 105.939 168.339 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 t -77.67 78.95 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.502 -2.036 . . . . 10.0 105.502 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.3 ttmm -69.83 109.57 4.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.385 -1.709 . . . . 10.0 106.385 169.046 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -90.84 102.61 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 105.413 -2.069 . . . . 10.0 105.413 173.852 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -119.56 150.59 40.02 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.92 -160.92 32.93 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 109.502 -1.439 . . . . 10.0 109.502 169.293 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.1 p -147.47 115.15 6.39 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 108.898 -0.779 . . . . 10.0 108.898 -173.542 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.528 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.3 pt -80.19 179.15 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 108.748 -0.834 . . . . 10.0 108.748 168.146 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . 0.445 ' NZ ' ' OD2' ' B' ' 92' ' ' ASP . 0.2 OUTLIER -155.86 159.86 39.71 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 107.472 -1.307 . . . . 10.0 107.472 164.034 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.06 -12.63 57.46 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-O 119.13 -0.817 . . . . 10.0 113.96 170.106 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.485 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.5 mp -70.65 176.65 4.0 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 119.036 1.418 . . . . 10.0 109.237 171.736 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -90.13 167.11 12.98 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.431 -0.951 . . . . 10.0 108.431 167.778 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -62.17 170.38 2.28 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.706 0.802 . . . . 10.0 111.734 -170.683 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.39 -174.23 33.45 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 124.317 0.96 . . . . 10.0 112.285 168.611 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -71.85 141.89 49.6 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.185 0.994 . . . . 10.0 109.409 175.761 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.82 148.92 41.34 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 114.7 1.37 . . . . 10.0 114.7 -179.368 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.553 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -36.85 127.05 1.09 Allowed Glycine 0 C--N 1.343 0.932 0 C-N-CA 127.649 2.547 . . . . 10.0 110.738 164.537 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.481 ' CD1' HD22 ' B' ' 84' ' ' LEU . 3.9 t80 -155.65 105.96 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 118.777 1.289 . . . . 10.0 109.055 168.485 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.05 175.34 14.1 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -178.2 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 29.0 m -90.04 151.58 3.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 113.771 -1.558 . . . . 10.0 110.265 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -142.42 137.75 30.61 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.592 1.557 . . . . 10.0 108.125 178.534 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -50.7 -57.14 9.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 114.944 1.461 . . . . 10.0 114.944 -169.103 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -78.46 123.13 26.7 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.92 -0.77 . . . . 10.0 108.92 -169.476 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.52 -30.53 77.88 Favored Glycine 0 CA--C 1.531 1.08 0 N-CA-C 107.444 -2.262 . . . . 10.0 107.444 165.6 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -45.81 142.58 2.46 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-O 123.303 1.525 . . . . 10.0 111.046 171.51 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.481 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -165.11 22.5 0.05 Allowed 'General case' 0 N--CA 1.434 -1.24 0 C-N-CA 126.05 1.74 . . . . 10.0 110.144 -169.573 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.972 HG22 ' CG2' ' A' ' 17' ' ' ILE . 1.3 p -53.16 -40.86 64.62 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 122.874 0.469 . . . . 10.0 112.11 -178.877 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.62 -18.31 54.7 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.227 0.611 . . . . 10.0 112.095 176.133 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.21 110.56 0.8 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.239 0.923 . . . . 10.0 111.986 -178.517 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.1 m 48.7 33.69 4.49 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.676 1.59 . . . . 10.0 112.336 172.492 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 22.3 m -138.18 -55.12 0.65 Allowed 'General case' 0 N--CA 1.437 -1.092 0 C-N-CA 126.296 1.838 . . . . 10.0 106.318 -173.591 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -67.04 -12.9 61.22 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.753 0.821 . . . . 10.0 111.722 178.041 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.31 -36.43 1.25 Allowed 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 126.961 2.104 . . . . 10.0 112.442 175.689 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.38 163.8 39.39 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 107.425 -2.27 . . . . 10.0 107.425 -178.644 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -74.73 -170.26 0.73 Allowed 'Trans proline' 0 N--CA 1.443 -1.463 0 C-N-CA 121.268 1.312 . . . . 10.0 109.252 172.2 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 38.3 m170 -78.6 58.7 2.29 Favored 'General case' 0 CA--C 1.538 0.515 0 O-C-N 121.269 -0.894 . . . . 10.0 110.572 -173.251 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -71.86 79.46 0.88 Allowed 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 123.096 1.427 . . . . 10.0 110.45 178.524 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . 0.44 ' HB3' HG22 ' B' ' 81' ' ' VAL . 15.3 p-10 -74.1 147.2 85.61 Favored Pre-proline 0 N--CA 1.445 -0.69 0 C-N-CA 125.015 1.326 . . . . 10.0 110.222 169.012 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -65.42 -43.53 10.5 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.319 2.013 . . . . 10.0 110.394 178.127 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 tt -78.14 56.82 1.71 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.024 0.93 . . . . 10.0 108.907 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 38.9 p -35.96 106.16 0.04 OUTLIER 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 126.055 1.742 . . . . 10.0 110.989 -173.098 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 2.8 ttt180 -133.29 -174.75 3.58 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 104.029 -2.582 . . . . 10.0 104.029 -178.919 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 22.3 mmtp -75.33 161.11 29.57 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 117.618 -1.633 . . . . 10.0 108.523 170.543 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -65.01 123.31 19.13 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 161.786 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.33 -138.42 4.03 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 108.209 -1.956 . . . . 10.0 108.209 171.687 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.25 -160.08 26.75 Favored Glycine 0 C--O 1.224 -0.502 0 N-CA-C 108.869 -1.692 . . . . 10.0 108.869 177.192 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -66.6 2.03 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 CA-C-N 119.544 1.672 . . . . 10.0 110.131 166.332 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 25.0 mmtt -107.9 6.16 27.05 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 125.598 1.559 . . . . 10.0 110.192 173.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.405 ' OD2' ' NZ ' ' B' ' 128' ' ' LYS . 1.9 t0 -141.48 155.89 45.8 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 119.565 1.075 . . . . 10.0 110.611 167.822 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tm-20 -79.36 -26.98 41.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.641 -1.614 . . . . 10.0 106.641 168.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -85.87 27.55 0.87 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.669 1.188 . . . . 10.0 111.732 -172.77 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 37.5 ptt-85 -63.72 150.41 44.5 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.208 1.003 . . . . 10.0 111.018 179.003 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -64.68 -70.61 0.22 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.781 0.433 . . . . 10.0 110.884 -177.659 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.471 HG23 ' H ' ' B' ' 82' ' ' GLY . 0.1 OUTLIER -165.83 -63.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.2 0 C-N-CA 126.01 1.724 . . . . 10.0 107.399 -175.938 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.471 ' H ' HG23 ' B' ' 81' ' ' VAL . . . -120.92 55.29 0.64 Allowed Glycine 0 C--N 1.335 0.497 0 N-CA-C 108.804 -1.718 . . . . 10.0 108.804 -176.002 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -93.03 90.45 6.92 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 105.152 -2.166 . . . . 10.0 105.152 169.282 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . 0.481 HD22 ' CD1' ' B' ' 45' ' ' PHE . 9.6 mp -65.8 -25.63 67.32 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 118.632 0.651 . . . . 10.0 110.84 -173.114 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.67 -94.11 0.58 Allowed Glycine 0 N--CA 1.436 -1.315 0 N-CA-C 107.872 -2.091 . . . . 10.0 107.872 172.845 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.2 m-20 -156.7 107.8 2.39 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.432 -0.581 . . . . 10.0 109.432 -169.621 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.2 m -89.12 122.71 40.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 CA-C-N 118.163 0.438 . . . . 10.0 110.401 -177.619 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.1 m -79.79 81.96 5.97 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 127.705 2.402 . . . . 10.0 112.55 -171.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -70.95 130.4 41.51 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 121.573 -0.704 . . . . 10.0 112.692 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -63.18 172.16 2.0 Allowed 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 125.479 1.511 . . . . 10.0 110.049 166.756 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.08 -28.85 59.32 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 124.2 1.0 . . . . 10.0 111.839 171.141 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . 0.445 ' OD2' ' NZ ' ' B' ' 36' ' ' LYS . 30.5 t70 -77.4 -2.88 37.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 122.261 1.029 . . . . 10.0 111.113 175.898 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.3 2.03 87.89 Favored Glycine 0 N--CA 1.44 -1.076 0 N-CA-C 109.959 -1.256 . . . . 10.0 109.959 -173.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.24 94.9 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 108.002 -1.11 . . . . 10.0 108.002 -171.572 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.23 118.74 29.14 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 166.76 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -78.16 117.69 19.68 Favored 'General case' 0 N--CA 1.433 -1.28 0 C-N-CA 126.005 1.722 . . . . 10.0 107.744 170.366 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 42.6 t -108.14 131.6 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.16 0 N-CA-C 106.735 -1.58 . . . . 10.0 106.735 -178.555 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.1 p -157.49 51.48 0.46 Allowed 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.394 0.678 . . . . 10.0 109.529 169.455 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -87.91 152.23 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -174.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -137.55 146.63 44.33 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.716 1.206 . . . . 10.0 109.986 -178.346 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -152.07 140.13 20.19 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 107.271 -1.381 . . . . 10.0 107.271 168.855 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 77.6 p -108.71 63.34 0.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 -174.265 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.3 p -151.97 -47.61 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 115.608 -0.724 . . . . 10.0 109.055 -177.751 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 20.9 mm -64.5 155.45 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 124.124 0.97 . . . . 10.0 110.058 172.734 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 28.8 t -150.69 147.28 27.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.717 -1.216 . . . . 10.0 107.717 168.367 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 68.2 mt -55.18 -30.61 60.25 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.995 -1.002 . . . . 10.0 109.82 167.085 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t . . . . . 0 N--CA 1.451 -0.383 0 N-CA-C 106.919 -1.511 . . . . 10.0 106.919 -179.312 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.532 0.267 0 CA-C-O 121.992 0.901 . . . . 10.0 109.576 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.295 0.0 OUTLIER -53.31 -28.26 14.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.23 -0.896 . . . . 10.0 113.218 -168.569 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.9 mm -27.13 -55.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 127.221 2.208 . . . . 10.0 114.045 173.776 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -83.67 4.69 81.39 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-O 118.493 -1.17 . . . . 10.0 115.08 -169.726 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 mmt180 -87.6 160.47 18.17 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.663 1.231 . . . . 10.0 111.95 -177.827 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 19.3 m -92.96 130.48 38.53 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 169.007 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -97.64 138.46 35.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 169.773 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 83.1 t -129.81 135.35 61.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 107.748 -1.204 . . . . 10.0 107.748 -177.336 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -103.05 145.99 11.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 123.897 0.879 . . . . 10.0 108.644 168.419 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.553 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 2.7 m170 -123.89 160.38 27.62 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 116.329 1.974 . . . . 10.0 116.329 -173.717 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.6 tt0 -43.07 -56.57 3.3 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.692 3.197 . . . . 10.0 111.918 172.827 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 76.0 mttt -117.3 170.02 9.02 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 123.599 0.76 . . . . 10.0 112.397 -169.29 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.9 149.7 47.54 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 114.003 -1.453 . . . . 10.0 109.458 173.701 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -80.58 146.21 31.35 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 123.881 0.872 . . . . 10.0 111.773 173.66 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -76.26 -27.97 56.9 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 124.235 0.959 . . . . 10.0 109.5 168.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 72.4 mt 62.04 53.01 3.1 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 123.058 1.408 . . . . 10.0 108.925 -174.923 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.28 -43.23 2.54 Favored Glycine 0 N--CA 1.445 -0.764 0 CA-C-N 112.561 -2.109 . . . . 10.0 110.637 173.581 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.405 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 13.1 mtmm -81.38 44.74 0.81 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.919 0.888 . . . . 10.0 112.392 -169.971 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.15 -22.7 14.44 Favored Glycine 0 CA--C 1.523 0.568 0 C-N-CA 125.921 1.724 . . . . 10.0 110.903 169.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.77 34.43 89.92 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 110.996 -0.841 . . . . 10.0 110.996 175.845 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -138.27 168.53 19.55 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.883 -1.525 . . . . 10.0 106.883 169.397 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.11 -48.53 73.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 116.038 -0.528 . . . . 10.0 109.865 -176.199 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -68.02 -26.4 65.87 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.006 -1.059 . . . . 10.0 110.935 178.977 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.0 p -56.92 -44.53 82.54 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 120.996 1.725 . . . . 10.0 110.544 171.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -83.92 -10.78 57.71 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.85 -0.595 . . . . 10.0 112.1 -173.75 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -103.33 -51.72 3.17 Favored 'General case' 0 N--CA 1.441 -0.905 0 C-N-CA 126.038 1.735 . . . . 10.0 112.319 -178.822 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.2 p -139.29 31.17 2.15 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.557 1.071 . . . . 10.0 112.461 176.045 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 58.23 25.87 57.98 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 118.723 0.692 . . . . 10.0 112.719 175.456 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 52.96 24.89 3.63 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 117.59 0.695 . . . . 10.0 112.585 -176.724 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.13 -4.26 9.67 Favored 'General case' 0 C--N 1.342 0.276 0 O-C-N 121.12 -0.988 . . . . 10.0 113.014 -173.32 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.03 -158.93 41.05 Favored Glycine 0 N--CA 1.446 -0.69 0 O-C-N 121.027 -1.045 . . . . 10.0 111.187 167.249 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 m -58.49 125.73 24.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.463 0.705 . . . . 10.0 111.767 -167.83 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -58.74 68.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.955 2.102 . . . . 10.0 111.864 172.048 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.7 mt -50.59 -36.93 37.26 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.898 -1.127 . . . . 10.0 113.714 -174.469 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -163.11 157.53 20.76 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 -170.823 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 23.6 p -161.76 168.29 23.47 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.96 -0.385 . . . . 10.0 109.96 -174.637 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.5 155.37 26.46 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.312 -1.515 . . . . 10.0 109.312 -176.44 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -107.94 131.25 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 105.776 -1.935 . . . . 10.0 105.776 -177.507 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 16.0 mt -79.48 165.95 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 118.818 0.736 . . . . 10.0 110.615 -179.782 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -169.13 170.92 42.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 127.875 2.655 . . . . 10.0 107.097 -177.065 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 20.3 mt -84.8 140.67 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 124.481 1.112 . . . . 10.0 110.1 -168.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -102.57 -114.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.903 -1.147 . . . . 10.0 107.903 167.44 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.252 1.227 0 C-N-CA 131.077 3.751 . . . . 10.0 106.136 172.297 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.799 0 CA-C-O 118.571 -0.728 . . . . 10.0 109.794 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 60.4 p -96.21 -63.89 1.1 Allowed 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 124.555 1.142 . . . . 10.0 110.001 -169.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -135.63 135.4 40.16 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 126.724 2.01 . . . . 10.0 107.857 -169.547 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -133.59 166.99 21.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.752 1.221 . . . . 10.0 110.119 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.73 162.12 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 125.803 1.641 . . . . 10.0 109.317 -179.015 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -149.89 90.72 1.71 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 106.204 -1.776 . . . . 10.0 106.204 166.631 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.704 HG21 ' HB3' ' B' ' 53' ' ' ASN . 3.7 m -77.37 118.97 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 170.915 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.6 mt -97.85 147.73 24.13 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 -178.947 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.06 162.56 17.95 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 168.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.43 -58.33 0.05 OUTLIER Glycine 0 C--O 1.227 -0.291 0 C-N-CA 121.09 -0.576 . . . . 10.0 112.057 169.861 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -72.98 -46.46 52.15 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.9 -69.81 0.51 Allowed Glycine 0 CA--C 1.527 0.796 0 CA-C-N 114.313 -1.312 . . . . 10.0 110.089 174.099 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -75.82 37.45 0.52 Allowed 'Trans proline' 0 CA--C 1.536 0.614 1 C-N-CA 125.69 4.26 . . . . 10.0 111.944 -179.884 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.8 t -149.01 100.38 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 C-N-CA 131.454 3.902 . . . . 10.0 100.537 178.603 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.72 116.04 22.39 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 106.032 -1.84 . . . . 10.0 106.032 -174.181 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.617 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.81 142.71 16.25 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 174.766 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.562 ' CG2' HG23 ' B' ' 54' ' ' THR . 6.3 mt -135.14 86.02 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.721 -1.214 . . . . 10.0 107.721 173.795 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -97.46 142.64 13.94 Favored 'Isoleucine or valine' 0 C--N 1.339 0.118 0 C-N-CA 124.028 0.931 . . . . 10.0 110.008 178.002 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -128.88 123.1 31.82 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 127.262 2.225 . . . . 10.0 109.511 174.353 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -105.23 116.87 32.68 Favored 'General case' 0 C--O 1.23 0.074 0 C-N-CA 125.294 1.437 . . . . 10.0 108.684 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 20.4 tt0 -105.58 134.71 48.24 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 118.666 0.666 . . . . 10.0 112.268 171.788 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 tp60 -109.71 99.36 8.54 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.672 1.989 . . . . 10.0 107.037 168.853 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 40.5 mmtt -58.72 -64.79 0.8 Allowed 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.752 -0.462 . . . . 10.0 109.752 175.469 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -124.13 164.62 19.09 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 104.657 -2.349 . . . . 10.0 104.657 169.453 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 t -71.47 -15.74 62.33 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 108.77 -0.826 . . . . 10.0 108.77 173.665 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.82 -24.31 44.55 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.021 0.529 . . . . 10.0 110.273 173.388 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.44 141.77 23.25 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 109.887 -1.285 . . . . 10.0 109.887 -176.825 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -62.56 142.21 89.16 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 CA-C-N 119.525 1.663 . . . . 10.0 107.866 169.252 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.5 t -77.92 125.77 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -174.731 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.1 mtmm -90.87 104.94 17.47 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.658 -1.238 . . . . 10.0 107.658 178.575 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 p -94.08 93.19 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 125.908 1.683 . . . . 10.0 107.555 174.264 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.9 p90 -102.28 175.07 5.64 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 121.207 0.527 . . . . 10.0 109.982 169.153 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.75 174.8 38.34 Favored Glycine 0 N--CA 1.441 -0.983 0 N-CA-C 111.367 -0.693 . . . . 10.0 111.367 176.892 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.0 p -145.69 102.78 3.72 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.239 -1.393 . . . . 10.0 107.239 178.751 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.617 HG22 ' HA2' ' A' ' 16' ' ' GLY . 7.5 pt -78.05 174.16 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 C-N-CA 118.878 -1.129 . . . . 10.0 108.099 169.225 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -154.83 144.17 21.22 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 168.808 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.6 -37.24 2.47 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-N 118.695 0.679 . . . . 10.0 113.957 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.518 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.1 mp -68.8 177.86 2.38 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.968 0.89 . . . . 10.0 112.651 -167.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.8 t -100.41 156.8 17.06 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.866 -0.606 . . . . 10.0 109.384 171.168 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -52.42 147.11 8.56 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.944 1.298 . . . . 10.0 112.191 -169.526 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.0 -172.12 17.68 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.124 0.869 . . . . 10.0 111.448 171.407 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -72.71 148.5 44.64 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.069 1.348 . . . . 10.0 110.855 -177.774 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -147.38 143.66 28.14 Favored 'General case' 0 C--N 1.338 0.067 0 C-N-CA 124.115 0.966 . . . . 10.0 112.314 -179.439 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.728 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -23.28 124.49 0.02 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.347 2.403 . . . . 10.0 114.062 165.301 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 20.1 t80 -149.25 106.5 3.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 119.286 1.543 . . . . 10.0 109.848 168.671 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.49 172.37 14.59 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.317 0.579 . . . . 10.0 111.04 174.102 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.4 p -112.82 120.93 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 CA-C-N 112.86 -1.973 . . . . 10.0 107.502 168.676 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -89.41 151.61 21.94 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.873 1.669 . . . . 10.0 108.223 -179.37 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -64.76 -57.01 10.08 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 114.798 -1.092 . . . . 10.0 110.473 -173.098 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -76.62 124.46 27.67 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.227 -1.397 . . . . 10.0 107.227 -173.403 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.07 -2.41 77.99 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.426 -0.652 . . . . 10.0 112.136 178.047 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -43.98 131.0 5.88 Favored 'General case' 0 C--N 1.344 0.343 0 CA-C-O 122.8 1.286 . . . . 10.0 112.525 175.289 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.621 ' HB3' HG21 ' B' ' 7' ' ' VAL . 2.9 m-80 -138.43 3.19 2.32 Favored 'General case' 0 N--CA 1.434 -1.232 0 CA-C-N 112.676 -2.056 . . . . 10.0 109.519 163.939 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.666 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -53.5 -40.09 65.12 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 125.063 1.345 . . . . 10.0 108.605 168.566 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.8 -15.12 59.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 116.041 -0.527 . . . . 10.0 111.976 178.223 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.75 75.5 0.99 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 109.092 -1.603 . . . . 10.0 109.092 -173.384 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t 38.78 48.87 1.41 Allowed 'General case' 0 C--O 1.231 0.105 0 C-N-CA 125.554 1.542 . . . . 10.0 114.448 177.311 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.4 m -127.76 -53.5 1.33 Allowed 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.996 -1.483 . . . . 10.0 106.996 -172.745 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.3 m -90.22 16.95 7.67 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.129 0.422 . . . . 10.0 111.527 173.758 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.56 -19.77 58.38 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.21 1.004 . . . . 10.0 111.032 169.379 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.3 135.85 7.98 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-O 119.017 -0.88 . . . . 10.0 111.232 168.578 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -73.39 66.04 4.5 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 123.244 2.63 . . . . 10.0 110.77 173.474 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 28.8 m170 71.81 -34.16 0.29 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 128.41 2.684 . . . . 10.0 112.664 175.385 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 43.42 25.9 0.09 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 128.308 2.643 . . . . 10.0 116.374 171.625 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -59.06 134.33 87.59 Favored Pre-proline 0 CA--C 1.534 0.354 0 N-CA-C 114.464 1.283 . . . . 10.0 114.464 -169.945 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -60.95 -37.49 76.47 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.565 2.177 . . . . 10.0 110.042 175.901 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 66.0 mt -63.05 2.8 0.29 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.748 1.219 . . . . 10.0 113.776 175.761 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 12.4 m 26.84 54.22 0.05 OUTLIER 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 128.293 2.637 . . . . 10.0 114.982 175.738 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtt85 -99.29 -179.15 4.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.572 1.149 . . . . 10.0 110.752 -172.983 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt -112.54 92.52 4.05 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.046 -0.724 . . . . 10.0 109.046 -174.643 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -5.88 97.16 0.01 OUTLIER 'General case' 0 C--O 1.223 -0.318 0 C-N-CA 128.255 2.622 . . . . 10.0 113.937 -176.916 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.41 -134.04 7.81 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.897 -1.681 . . . . 10.0 108.897 178.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.49 -170.33 40.43 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 106.915 -2.474 . . . . 10.0 106.915 171.498 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -63.59 -4.64 7.26 Favored 'Trans proline' 0 N--CA 1.455 -0.794 0 CA-C-N 119.867 1.834 . . . . 10.0 110.929 168.276 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -88.65 -24.06 22.88 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.313 1.045 . . . . 10.0 110.536 174.069 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.8 178.41 4.29 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 108.246 -1.02 . . . . 10.0 108.246 -178.262 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -92.81 -26.81 17.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 167.088 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.1 mm-40 -87.06 28.79 0.88 Allowed 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.391 -1.443 . . . . 10.0 112.436 -169.641 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.5 133.62 53.48 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.67 -1.233 . . . . 10.0 107.67 169.345 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.9 m170 -64.58 -57.92 7.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.823 -0.548 . . . . 10.0 112.007 -175.378 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.8 p -170.97 -43.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 C-N-CA 124.461 1.104 . . . . 10.0 109.065 -172.375 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -150.43 56.44 0.46 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 109.759 -1.336 . . . . 10.0 109.759 178.385 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -92.76 92.15 7.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 172.256 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.29 -36.69 63.78 Favored 'General case' 0 N--CA 1.461 0.1 0 N-CA-C 107.648 -1.242 . . . . 10.0 107.648 177.067 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.34 -98.66 1.23 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 110.833 -0.907 . . . . 10.0 110.833 167.859 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.3 m-80 -123.73 132.3 53.79 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.855 0.862 . . . . 10.0 111.274 -168.365 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.0 m -114.68 129.92 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 123.771 0.828 . . . . 10.0 109.14 168.072 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 28.2 m -86.81 104.09 15.85 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 127.651 2.381 . . . . 10.0 110.572 -174.857 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.03 33.49 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 122.825 0.45 . . . . 10.0 110.544 174.776 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -66.76 175.23 2.49 Favored 'General case' 0 CA--C 1.528 0.103 0 O-C-N 123.633 0.583 . . . . 10.0 109.728 167.661 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.13 -29.48 13.56 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.585 1.554 . . . . 10.0 111.746 172.38 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -79.42 -4.5 51.39 Favored 'General case' 0 N--CA 1.453 -0.301 0 O-C-N 123.226 0.329 . . . . 10.0 110.229 -177.779 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.8 9.28 86.94 Favored Glycine 0 C--N 1.337 0.635 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 -178.377 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 50.9 t -90.82 107.65 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.277 0 C-N-CA 126.149 1.78 . . . . 10.0 106.356 179.619 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.445 ' H ' HG12 ' A' ' 35' ' ' ILE . . . -102.85 118.52 37.02 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.579 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -79.24 112.2 16.23 Favored 'General case' 0 N--CA 1.434 -1.239 0 C-N-CA 125.927 1.691 . . . . 10.0 108.541 171.127 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.82 133.23 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.234 -1.765 . . . . 10.0 106.234 176.337 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -157.63 60.69 0.48 Allowed 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.861 -0.422 . . . . 10.0 109.861 -178.398 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 44.0 mt -115.46 154.69 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 107.97 -1.122 . . . . 10.0 107.97 -169.696 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -127.87 145.51 50.92 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.338 -0.615 . . . . 10.0 109.338 167.512 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 102' ' ' SER . 42.2 t0 -145.29 154.73 42.66 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 -178.752 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.406 ' N ' ' OD1' ' A' ' 101' ' ' ASP . 8.4 p -108.32 -9.35 15.49 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 128.145 2.578 . . . . 10.0 112.28 -174.28 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.6 p -79.6 -36.98 18.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.147 0 N-CA-C 107.602 -1.259 . . . . 10.0 107.602 -174.87 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.455 ' CD1' ' H ' ' A' ' 104' ' ' ILE 0.309 0.0 OUTLIER -79.51 150.24 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 124.714 1.206 . . . . 10.0 113.026 172.676 . . . . . . . . 4 4 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.6 m -157.28 133.56 9.7 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.089 0.956 . . . . 10.0 108.47 179.616 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.46 ' CD1' HD11 ' A' ' 113' ' ' ILE . 1.1 mm? -75.54 52.87 0.66 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.223 2.209 . . . . 10.0 108.394 175.13 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.2 t -88.38 -157.04 0.4 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.472 1.909 . . . . 10.0 110.204 -169.803 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.0 -53.65 0.13 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 128.177 2.799 . . . . 10.0 107.429 -178.302 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -64.99 -60.16 3.36 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.227 -0.657 . . . . 10.0 109.227 171.203 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -77.94 -28.35 49.54 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 115.903 -0.589 . . . . 10.0 110.228 -175.259 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t 13.32 78.63 0.01 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 128.3 2.64 . . . . 10.0 113.672 175.776 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -65.53 -16.19 19.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 112.04 0.385 . . . . 10.0 112.04 176.328 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.46 HD11 ' CD1' ' A' ' 106' ' ' LEU . 49.2 mm -46.39 137.64 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 C-N-CA 123.832 0.853 . . . . 10.0 110.318 169.981 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.08 -1.97 88.18 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.153 -1.36 . . . . 10.0 115.286 174.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.9 mtp85 -77.05 168.14 20.6 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.019 1.41 . . . . 10.0 107.364 169.122 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -106.6 120.86 43.07 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.48 0.582 . . . . 10.0 111.752 -174.902 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -77.22 145.72 37.42 Favored 'General case' 0 CA--C 1.517 -0.294 0 N-CA-C 108.337 -0.986 . . . . 10.0 108.337 168.698 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 86.8 t -131.93 132.49 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.899 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.145 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -104.48 134.8 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 N-CA-C 106.268 -1.753 . . . . 10.0 106.268 167.831 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.728 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 8.2 m-70 -112.67 156.95 21.88 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 115.794 1.776 . . . . 10.0 115.794 -170.906 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -43.25 -55.3 4.07 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.68 2.792 . . . . 10.0 112.155 171.597 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -115.55 162.8 16.69 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.784 0.834 . . . . 10.0 111.543 -169.675 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.87 153.86 42.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.877 -1.056 . . . . 10.0 109.129 170.103 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -93.51 144.41 25.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 C-N-CA 123.814 0.845 . . . . 10.0 110.75 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -76.7 -16.12 59.6 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-N 114.387 -1.279 . . . . 10.0 110.83 168.379 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.4 mt 53.23 40.57 31.48 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.178 0.991 . . . . 10.0 110.247 -172.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.77 -47.97 0.98 Allowed Glycine 0 C--N 1.337 0.59 0 C-N-CA 125.122 1.344 . . . . 10.0 111.023 169.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.42 51.97 1.75 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 122.035 -0.685 . . . . 10.0 112.466 -169.831 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.43 -38.62 5.85 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 124.786 1.184 . . . . 10.0 110.351 169.914 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.43 31.33 78.51 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 -169.451 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -114.21 157.42 22.7 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 106.067 -1.827 . . . . 10.0 106.067 169.236 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.414 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 4.8 tm-20 -51.75 -44.87 63.49 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.875 -1.057 . . . . 10.0 109.062 174.13 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -65.44 -34.08 77.44 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.162 0.985 . . . . 10.0 112.452 173.937 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 54.3 p -57.73 -35.99 71.45 Favored 'General case' 0 N--CA 1.448 -0.571 0 O-C-N 120.244 -1.535 . . . . 10.0 111.781 -175.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -84.65 -1.11 55.61 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 118.855 -0.593 . . . . 10.0 112.163 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 94.1 mttt -114.05 -56.13 2.43 Favored 'General case' 0 C--N 1.342 0.261 0 C-N-CA 124.628 1.171 . . . . 10.0 111.315 -176.523 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.8 p -120.17 -5.54 9.96 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.888 0.767 . . . . 10.0 113.061 175.929 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.03 33.65 Favored Glycine 0 C--N 1.342 0.889 0 CA-C-O 119.252 -0.749 . . . . 10.0 112.175 -177.465 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 62.12 23.79 14.09 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 118.317 1.059 . . . . 10.0 111.597 -177.694 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.27 -11.78 24.28 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 125.656 1.583 . . . . 10.0 112.013 -177.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.88 -157.28 48.61 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 172.926 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.2 m -61.39 133.93 56.35 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.875 0.87 . . . . 10.0 113.121 -167.495 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -66.25 71.39 0.07 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.968 1.307 . . . . 10.0 110.017 169.596 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.6 mt -55.85 -33.56 64.64 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 112.742 0.645 . . . . 10.0 112.742 -177.435 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.19 146.35 15.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.473 -0.566 . . . . 10.0 109.473 -175.749 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 18.1 m -148.51 161.25 42.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -169.855 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.07 -174.96 17.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.504 -0.639 . . . . 10.0 111.504 178.419 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 49.8 t -127.05 133.75 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 104.825 -2.287 . . . . 10.0 104.825 175.755 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 22.1 mt -69.37 117.46 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 108.903 -0.777 . . . . 10.0 108.903 177.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.83 141.86 16.7 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 110.611 -0.996 . . . . 10.0 110.611 -179.72 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.17 132.7 32.97 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 CA-C-N 119.353 1.577 . . . . 10.0 108.942 175.31 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.61 -26.27 50.5 Favored 'General case' 0 C--O 1.223 -0.342 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 167.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.253 1.278 0 C-N-CA 126.187 1.795 . . . . 10.0 109.318 169.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.706 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . 0.4 HG23 ' H ' ' B' ' 3' ' ' LYS . 8.8 t -150.76 -60.48 0.18 Allowed 'General case' 0 C--O 1.232 0.139 0 N-CA-C 108.958 -0.756 . . . . 10.0 108.958 176.135 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . 0.4 ' H ' HG23 ' B' ' 2' ' ' THR . 57.0 tttp -117.18 135.4 53.8 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 126.888 2.075 . . . . 10.0 106.852 174.904 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.85 161.7 34.88 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 125.253 1.421 . . . . 10.0 110.75 178.543 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 m -128.4 178.1 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 124.837 1.255 . . . . 10.0 110.042 -176.218 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -162.27 97.28 1.0 Allowed 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 125.368 1.467 . . . . 10.0 107.634 166.641 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.621 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.8 m -89.73 104.53 15.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.21 0.604 . . . . 10.0 110.818 173.765 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.7 mp -93.58 146.23 23.96 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.244 1.418 . . . . 10.0 110.176 178.195 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . 0.439 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 2.9 tttm -162.12 164.07 28.19 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 171.206 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.68 -47.65 0.14 Allowed Glycine 0 N--CA 1.462 0.398 0 C-N-CA 119.389 -1.386 . . . . 10.0 114.102 168.796 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -72.08 -45.73 59.58 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.141 -1.429 . . . . 10.0 107.141 -177.057 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.65 -75.17 0.28 Allowed Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 114.162 -1.381 . . . . 10.0 109.932 169.125 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -55.92 -39.22 92.49 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 123.511 2.808 . . . . 10.0 110.985 173.008 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.436 HG13 HD11 ' B' ' 38' ' ' LEU . 72.6 t -59.66 112.31 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 179.643 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.04 124.33 42.32 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 168.446 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.573 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -104.67 136.92 13.35 Favored Glycine 0 C--O 1.224 -0.494 0 N-CA-C 107.794 -2.122 . . . . 10.0 107.794 169.491 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.666 HG22 HG22 ' A' ' 54' ' ' THR . 3.0 mt -138.59 68.04 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -174.579 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 mm -89.05 151.89 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 N-CA-C 109.668 -0.493 . . . . 10.0 109.668 -173.503 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.24 143.89 48.04 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 126.617 1.967 . . . . 10.0 108.111 175.194 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -129.05 130.91 47.16 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 104.411 -2.44 . . . . 10.0 104.411 168.273 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -128.62 150.48 50.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 119.796 1.18 . . . . 10.0 110.402 172.375 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.58 97.59 5.12 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 178.392 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.515 -0.375 0 C-N-CA 123.978 0.911 . . . . 10.0 110.053 170.482 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.569 0 N-CA-C 109.397 -1.481 . . . . 10.0 109.397 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.27 129.94 24.12 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.808 2.338 . . . . 10.0 109.456 -177.499 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.1 t -79.87 111.52 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 N-CA-C 104.918 -2.253 . . . . 10.0 104.918 172.469 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -82.65 126.54 32.44 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 169.204 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -100.5 109.38 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 C-N-CA 126.37 1.868 . . . . 10.0 106.703 172.826 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.9 p90 -130.38 156.63 44.4 Favored 'General case' 0 C--O 1.226 -0.177 0 N-CA-C 113.504 0.927 . . . . 10.0 113.504 -179.729 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.65 -152.24 24.12 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 106.824 -2.511 . . . . 10.0 106.824 172.924 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 21.2 p -156.38 165.93 34.89 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 119.584 -0.846 . . . . 10.0 110.412 174.335 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.573 HG22 ' HA2' ' B' ' 16' ' ' GLY . 4.0 pt -107.01 179.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-N 114.344 -1.298 . . . . 10.0 109.424 165.366 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.19 163.17 40.54 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 124.689 1.196 . . . . 10.0 108.407 162.921 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.21 -17.12 44.69 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-O 119.315 -0.714 . . . . 10.0 113.155 172.626 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.482 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.4 mp -71.7 178.61 3.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.005 0.902 . . . . 10.0 110.194 173.708 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -97.4 170.45 9.05 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 166.408 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -60.03 170.69 1.15 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.203 1.001 . . . . 10.0 112.111 -171.341 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.95 -174.61 32.99 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 124.201 0.905 . . . . 10.0 112.08 168.461 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.24 146.78 50.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 123.834 0.854 . . . . 10.0 109.581 176.164 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -147.17 144.94 29.32 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 123.493 0.717 . . . . 10.0 111.703 178.558 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.66 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -34.79 120.5 0.39 Allowed Glycine 0 C--N 1.339 0.74 0 C-N-CA 127.738 2.59 . . . . 10.0 112.626 167.371 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.69 110.47 5.14 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-N 119.456 1.628 . . . . 10.0 109.458 168.306 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -146.57 170.65 16.46 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-O 121.718 0.771 . . . . 10.0 111.802 176.496 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.16 129.09 46.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 CA-C-N 111.146 -2.752 . . . . 10.0 105.647 168.193 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 41.5 m-70 -105.78 146.59 29.65 Favored 'General case' 0 CA--C 1.509 -0.611 0 N-CA-C 107.675 -1.231 . . . . 10.0 107.675 174.382 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 23.8 tp10 -66.64 -59.04 3.96 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.544 -1.207 . . . . 10.0 108.98 -172.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 22.2 m-30 -77.1 106.88 9.09 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 -175.222 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.68 42.8 1.31 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 124.592 1.091 . . . . 10.0 111.448 174.517 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.32 131.76 41.07 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 124.975 1.31 . . . . 10.0 108.241 177.057 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.704 ' HB3' HG21 ' A' ' 7' ' ' VAL . 1.2 m-80 -122.8 1.43 9.36 Favored 'General case' 0 N--CA 1.444 -0.755 0 C-N-CA 124.714 1.205 . . . . 10.0 110.28 168.968 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.562 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.18 -36.53 70.93 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.773 1.17 . . . . 10.0 108.792 178.194 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.38 -17.88 55.83 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.53 1.132 . . . . 10.0 112.965 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 77.61 0.77 Allowed Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.272 -0.731 . . . . 10.0 111.272 -178.273 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 34.8 m 50.96 34.36 10.46 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 124.754 1.222 . . . . 10.0 112.614 172.501 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 6.3 m -127.75 -57.43 1.26 Allowed 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -169.958 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 11.8 t -92.14 21.22 5.24 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 111.896 0.332 . . . . 10.0 111.896 179.166 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -68.1 -7.26 28.09 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.615 0.766 . . . . 10.0 111.949 176.285 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.47 127.66 2.19 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 109.704 -1.358 . . . . 10.0 109.704 174.132 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -74.81 65.42 5.88 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.517 2.811 . . . . 10.0 111.523 178.437 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.2 m170 59.98 55.83 3.64 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 128.382 2.673 . . . . 10.0 109.94 177.947 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -70.51 63.7 0.27 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.553 0.741 . . . . 10.0 112.393 -178.041 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -67.48 147.45 98.78 Favored Pre-proline 0 CA--C 1.532 0.27 0 O-C-N 121.642 -0.661 . . . . 10.0 110.858 -175.559 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -63.11 -49.44 4.88 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.245 1.963 . . . . 10.0 110.2 179.308 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.6 tt -81.41 59.64 4.12 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.358 0.663 . . . . 10.0 109.348 -177.852 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.0 t -14.96 97.31 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 128.411 2.684 . . . . 10.0 112.886 -176.806 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.59 168.58 10.88 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.423 1.089 . . . . 10.0 108.725 -175.807 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -108.24 105.91 15.84 Favored 'General case' 0 C--O 1.224 -0.26 0 N-CA-C 108.457 -0.942 . . . . 10.0 108.457 175.508 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 56.3 t60 -9.99 96.51 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 127.213 2.205 . . . . 10.0 115.482 -177.769 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.78 -141.1 10.37 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 173.658 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.03 -161.09 27.09 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 108.79 -1.724 . . . . 10.0 108.79 171.091 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -66.59 5.97 0.64 Allowed 'Trans proline' 0 N--CA 1.456 -0.704 0 CA-C-N 120.417 2.109 . . . . 10.0 111.889 174.106 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -103.56 -15.21 15.9 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 117.596 -1.193 . . . . 10.0 110.994 172.887 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.415 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 5.4 m-20 -131.36 162.25 30.53 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 119.164 0.893 . . . . 10.0 108.925 -167.855 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -78.61 -33.07 47.7 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.231 -1.396 . . . . 10.0 107.231 176.361 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -82.25 26.46 0.54 Allowed 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 125.431 1.493 . . . . 10.0 112.528 -167.108 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 36.2 ptt85 -64.58 134.35 54.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.304 -0.998 . . . . 10.0 108.304 173.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.5 m80 -58.86 -50.74 72.87 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 121.012 0.434 . . . . 10.0 111.088 -178.699 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 p -172.37 -105.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 104.06 -2.571 . . . . 10.0 104.06 177.864 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -77.54 57.36 3.78 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.864 0.756 . . . . 10.0 111.558 172.313 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -84.91 88.35 7.42 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 103.935 -2.616 . . . . 10.0 103.935 166.856 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 16.0 mt -71.72 -31.08 66.34 Favored 'General case' 0 N--CA 1.463 0.189 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -178.52 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.37 -102.54 2.57 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 109.82 -1.312 . . . . 10.0 109.82 167.571 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -121.05 104.11 9.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.603 1.161 . . . . 10.0 109.29 -167.201 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.1 m -94.66 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 118.725 0.693 . . . . 10.0 109.504 172.7 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 80.0 m -89.96 117.57 28.87 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 126.585 1.954 . . . . 10.0 108.908 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.82 134.6 43.55 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 124.536 1.135 . . . . 10.0 111.313 178.442 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -59.53 170.98 0.91 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 124.165 0.986 . . . . 10.0 110.811 166.769 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 28.3 mttm -52.06 -33.0 37.13 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.806 1.643 . . . . 10.0 112.453 169.183 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.45 -1.23 32.62 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-O 122.158 0.98 . . . . 10.0 111.307 176.601 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.41 0.89 84.24 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.052 -1.619 . . . . 10.0 109.052 -176.175 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.3 t -78.15 95.66 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -170.074 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.38 119.08 29.52 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 166.582 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.21 114.22 17.97 Favored 'General case' 0 N--CA 1.436 -1.163 0 C-N-CA 126.759 2.023 . . . . 10.0 108.971 171.95 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 91.8 t -98.11 131.23 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.705 -1.591 . . . . 10.0 106.705 174.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.6 p -157.76 57.69 0.49 Allowed 'General case' 0 CA--C 1.534 0.355 0 O-C-N 122.0 -0.437 . . . . 10.0 110.305 171.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.94 161.01 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 C-N-CA 124.784 1.234 . . . . 10.0 107.672 -170.892 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -130.54 146.25 52.03 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 124.625 1.17 . . . . 10.0 110.385 175.366 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 58.8 t0 -144.52 154.77 43.24 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.276 -1.009 . . . . 10.0 108.276 175.679 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 33.4 p -134.22 2.87 3.35 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 126.64 1.976 . . . . 10.0 112.544 -179.542 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.8 p -79.3 -31.84 14.62 Favored 'Isoleucine or valine' 0 C--N 1.343 0.324 0 CA-C-N 120.017 1.28 . . . . 10.0 107.891 169.948 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.402 ' C ' HD12 ' B' ' 104' ' ' ILE 0.273 0.7 OUTLIER -82.56 174.08 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 124.156 0.983 . . . . 10.0 111.556 169.423 . . . . . . . . 4 4 . 1 . 025 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 31.1 m -158.7 143.56 16.07 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 105.423 -2.066 . . . . 10.0 105.423 172.084 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 mt -75.5 -10.37 59.39 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.943 0.497 . . . . 10.0 112.335 -172.272 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 75.7 m . . . . . 0 N--CA 1.451 -0.414 0 C-N-CA 126.257 1.823 . . . . 10.0 106.43 173.242 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.0 t . . . . . 0 N--CA 1.453 -0.304 0 CA-C-O 121.444 0.64 . . . . 10.0 112.636 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.96 -7.61 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 112.802 0.667 . . . . 10.0 112.802 -176.704 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 41.0 mm -45.92 125.0 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 O-C-N 121.55 -0.719 . . . . 10.0 110.1 171.81 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.4 2.03 77.34 Favored Glycine 0 CA--C 1.527 0.81 0 CA-C-O 118.735 -1.036 . . . . 10.0 113.637 178.862 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -76.2 178.92 6.06 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 106.007 -1.849 . . . . 10.0 106.007 166.75 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -124.59 129.72 51.1 Favored 'General case' 0 CA--C 1.514 -0.438 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 -174.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.415 ' CD1' HD11 ' B' ' 149' ' ' ILE . 7.8 mp -96.97 139.72 32.57 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 171.37 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.4 t -123.17 129.8 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 O-C-N 124.605 1.191 . . . . 10.0 108.303 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.445 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.6 p -93.03 131.41 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.47 -1.308 . . . . 10.0 107.47 167.618 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.66 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.5 m170 -111.72 158.33 19.45 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.448 1.277 . . . . 10.0 114.448 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -56.6 -54.81 41.68 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 125.15 1.38 . . . . 10.0 110.98 178.757 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 43.7 mttm -109.44 176.11 5.2 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 118.686 0.676 . . . . 10.0 110.136 177.268 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.17 140.74 29.18 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.058 1.343 . . . . 10.0 108.515 176.781 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.69 152.63 35.66 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 123.297 0.639 . . . . 10.0 111.943 -177.362 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 51.2 m-20 -76.38 6.2 5.99 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 127.115 2.166 . . . . 10.0 111.491 178.899 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.7 mt 42.12 40.11 1.58 Allowed 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.369 1.868 . . . . 10.0 111.194 -173.137 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.24 -33.52 5.94 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-O 119.509 -0.606 . . . . 10.0 112.639 168.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.415 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 3.3 mppt? -80.42 40.84 0.51 Allowed 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 117.597 0.699 . . . . 10.0 110.974 -176.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . 0.519 ' HA3' ' CB ' ' B' ' 134' ' ' SER . . . -88.97 -30.22 15.31 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 124.806 1.193 . . . . 10.0 112.616 -173.317 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 94.63 6.95 60.57 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.793 -1.004 . . . . 10.0 114.751 170.391 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . 0.416 ' H ' ' HB2' ' B' ' 134' ' ' SER . 0.8 OUTLIER -141.39 175.47 9.64 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 119.844 1.822 . . . . 10.0 106.726 169.036 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -51.19 -58.52 5.93 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.742 1.217 . . . . 10.0 109.279 178.208 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -49.94 -52.47 33.11 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 123.109 1.433 . . . . 10.0 110.562 176.505 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . 0.519 ' CB ' ' HA3' ' B' ' 129' ' ' GLY . 0.2 OUTLIER -62.23 -4.8 1.93 Allowed 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 127.497 2.319 . . . . 10.0 113.27 179.979 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.24 15.01 6.72 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.731 0.813 . . . . 10.0 110.703 172.808 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmmm -122.22 -62.52 1.38 Allowed 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.727 2.011 . . . . 10.0 109.432 -178.56 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -113.71 16.1 18.64 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 119.513 1.052 . . . . 10.0 110.487 167.207 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.96 20.73 70.98 Favored Glycine 0 C--O 1.22 -0.764 0 C-N-CA 124.088 0.851 . . . . 10.0 113.2 168.81 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 60.03 24.74 13.94 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.327 1.064 . . . . 10.0 112.63 -179.76 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.74 -13.8 17.24 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.736 -0.603 . . . . 10.0 110.967 169.843 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.38 -158.87 42.23 Favored Glycine 0 N--CA 1.439 -1.11 0 N-CA-C 109.268 -1.533 . . . . 10.0 109.268 169.553 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -49.43 121.29 4.88 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 124.808 1.243 . . . . 10.0 112.635 -168.881 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 72.68 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.96 1.704 . . . . 10.0 108.983 169.232 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 52.8 mt -47.1 -41.27 16.97 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 124.317 1.047 . . . . 10.0 112.139 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.445 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -160.57 156.48 25.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 108.516 -0.92 . . . . 10.0 108.516 -171.351 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.8 p -162.33 168.78 21.68 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 108.897 -0.779 . . . . 10.0 108.897 -176.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.82 -175.18 17.75 Favored Glycine 0 N--CA 1.461 0.318 0 N-CA-C 111.229 -0.748 . . . . 10.0 111.229 -176.408 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 53.2 t -118.29 139.71 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 101.52 -3.511 . . . . 10.0 101.52 168.275 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.415 HD11 ' CD1' ' B' ' 117' ' ' LEU . 50.5 mt -59.32 -83.93 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 118.436 0.562 . . . . 10.0 110.33 -171.541 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.2 147.18 20.29 Favored Glycine 0 CA--C 1.52 0.363 0 O-C-N 121.724 -0.61 . . . . 10.0 112.65 178.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pt -73.6 154.31 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.393 -1.706 . . . . 10.0 106.393 168.15 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -52.91 6.43 Favored 'General case' 0 CA--C 1.512 -0.487 0 N-CA-C 106.078 -1.823 . . . . 10.0 106.078 169.748 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.252 1.187 0 O-C-N 126.328 2.268 . . . . 10.0 107.966 168.798 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.725 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.0 t -171.41 -43.43 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 124.468 1.107 . . . . 10.0 109.622 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -104.57 147.0 28.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 125.769 1.628 . . . . 10.0 107.639 171.006 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.0 157.96 37.05 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 168.543 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.403 ' CG2' ' HA ' ' B' ' 52' ' ' ASP . 3.5 m -130.16 177.61 6.47 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-O 121.642 0.734 . . . . 10.0 110.447 177.619 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.81 121.3 4.03 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 103.462 -2.792 . . . . 10.0 103.462 166.932 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.97 111.55 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 178.119 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.17 142.3 28.51 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 -171.164 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 mtpt -144.57 162.13 37.39 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 169.995 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.43 -65.75 0.02 OUTLIER Glycine 0 C--O 1.229 -0.198 0 CA-C-N 115.403 -0.817 . . . . 10.0 111.501 171.281 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.44 -45.45 46.33 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 106.597 -1.631 . . . . 10.0 106.597 -173.468 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.29 -65.46 0.59 Allowed Glycine 0 N--CA 1.444 -0.79 0 CA-C-N 113.431 -1.713 . . . . 10.0 110.866 -175.719 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -54.36 -38.97 89.17 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.579 2.186 . . . . 10.0 111.367 173.101 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.4 t -66.87 101.31 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.043 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 172.059 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -118.66 101.9 8.46 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.189 1.396 . . . . 10.0 107.709 171.278 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.875 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -83.89 148.36 24.55 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 125.13 1.348 . . . . 10.0 111.888 174.865 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.433 ' CG2' HG22 ' B' ' 54' ' ' THR . 0.8 OUTLIER -155.45 93.22 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 126.023 1.729 . . . . 10.0 106.463 -168.876 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.0 mm -86.49 151.18 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 C-N-CA 125.113 1.365 . . . . 10.0 109.767 179.045 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.1 m-80 -143.58 59.79 1.39 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.821 0.282 . . . . 10.0 111.725 179.402 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -47.68 120.91 3.63 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 117.559 -1.21 . . . . 10.0 109.417 -175.519 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -111.69 124.53 52.51 Favored 'General case' 0 C--O 1.233 0.2 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 176.506 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.2 tp60 -125.43 85.44 2.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.777 1.231 . . . . 10.0 109.055 172.058 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.15 -43.74 7.24 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 127.007 2.123 . . . . 10.0 112.309 -179.254 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -153.5 173.67 15.41 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 105.95 -1.87 . . . . 10.0 105.95 169.498 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 49.2 m -66.24 -19.55 65.86 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 122.943 0.497 . . . . 10.0 110.694 175.099 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -79.11 -15.54 58.0 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.423 0.689 . . . . 10.0 110.113 175.963 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.55 156.35 33.28 Favored Glycine 0 CA--C 1.532 1.101 0 O-C-N 122.145 -0.347 . . . . 10.0 112.964 -175.14 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -75.68 144.8 28.48 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 N-CA-C 105.727 -2.451 . . . . 10.0 105.727 165.911 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.2 t -78.94 127.17 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.521 -1.659 . . . . 10.0 106.521 179.467 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 mtmt -95.93 110.9 23.03 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.942 -0.762 . . . . 10.0 108.942 172.986 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.0 m -85.05 56.52 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 123.888 0.875 . . . . 10.0 110.788 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -40.24 139.28 0.75 Allowed 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 124.32 1.048 . . . . 10.0 112.947 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.73 131.93 4.52 Favored Glycine 0 N--CA 1.437 -1.258 0 N-CA-C 107.382 -2.287 . . . . 10.0 107.382 168.279 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.1 m -123.68 62.03 1.06 Allowed 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 106.654 -1.61 . . . . 10.0 106.654 172.06 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.875 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.2 pt -78.08 116.58 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.29 -1.004 . . . . 10.0 108.29 -176.541 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -99.37 141.07 32.62 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 107.722 -1.214 . . . . 10.0 107.722 172.537 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.53 -5.86 18.87 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 124.272 0.939 . . . . 10.0 112.211 173.907 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.44 173.2 4.22 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 118.494 1.147 . . . . 10.0 110.143 176.251 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.8 t -106.26 150.36 25.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.839 -1.541 . . . . 10.0 106.839 167.957 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -48.14 147.28 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.795 1.238 . . . . 10.0 110.299 -175.747 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.57 179.8 28.14 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.391 -1.083 . . . . 10.0 110.391 176.198 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.25 153.79 35.73 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.532 1.533 . . . . 10.0 111.404 -172.014 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -145.08 141.61 28.98 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 125.001 1.32 . . . . 10.0 110.535 -179.425 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.41 124.58 7.93 Favored Glycine 0 C--N 1.344 1.024 0 N-CA-C 107.308 -2.317 . . . . 10.0 107.308 166.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 57.4 t80 -145.7 118.72 8.79 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 118.851 1.326 . . . . 10.0 109.112 171.989 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -159.22 171.76 19.28 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.287 0.565 . . . . 10.0 110.103 -174.817 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -91.46 148.79 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 CA-C-N 112.757 -2.019 . . . . 10.0 106.972 168.027 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 62.1 m-70 -120.12 139.96 51.79 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.17 -1.789 . . . . 10.0 106.17 173.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -47.08 -57.35 5.16 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 124.609 1.193 . . . . 10.0 111.461 -171.872 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.38 136.76 33.33 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 109.559 -0.534 . . . . 10.0 109.559 -177.611 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.38 -8.6 86.93 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.421 -1.072 . . . . 10.0 110.421 167.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -47.78 144.63 3.25 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.63 1.205 . . . . 10.0 109.748 169.568 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -148.38 29.43 0.86 Allowed 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 114.585 -1.188 . . . . 10.0 110.393 172.75 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.401 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -58.41 -37.05 74.55 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 122.362 0.265 . . . . 10.0 111.609 -169.142 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.17 -23.51 40.98 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.652 0.781 . . . . 10.0 113.079 173.817 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.89 111.37 1.8 Allowed Glycine 0 CA--C 1.534 1.233 0 N-CA-C 110.178 -1.169 . . . . 10.0 110.178 -169.128 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.3 m 39.35 53.63 2.28 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 127.273 2.229 . . . . 10.0 114.07 170.901 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -156.17 -54.85 0.09 Allowed 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.526 -0.916 . . . . 10.0 108.526 178.569 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 m -61.39 -30.91 70.84 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.825 0.85 . . . . 10.0 112.127 -172.835 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.77 -30.31 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 129.188 2.995 . . . . 10.0 115.463 174.739 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.8 129.16 6.01 Favored Glycine 0 CA--C 1.524 0.633 0 CA-C-O 118.227 -1.318 . . . . 10.0 110.068 169.738 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.407 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 88.2 Cg_endo -73.91 65.92 5.0 Favored 'Trans proline' 0 CA--C 1.535 0.549 0 C-N-CA 124.21 3.273 . . . . 10.0 111.76 179.829 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 56.9 58.12 4.24 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.236 2.614 . . . . 10.0 109.395 179.925 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.407 ' CZ ' ' HD2' ' A' ' 62' ' ' PRO . 42.6 m-85 -68.0 74.39 0.2 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 122.112 0.958 . . . . 10.0 111.695 -179.366 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.463 ' H ' HD22 ' A' ' 65' ' ' ASN . 0.8 OUTLIER -85.73 126.39 66.26 Favored Pre-proline 0 C--N 1.323 -0.551 0 C-N-CA 126.306 1.842 . . . . 10.0 111.18 -178.494 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -68.04 -37.6 14.55 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.986 2.457 . . . . 10.0 110.668 -177.915 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 79.6 mt -76.72 52.47 0.83 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.212 0.605 . . . . 10.0 109.405 171.571 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -41.13 90.34 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 127.568 2.347 . . . . 10.0 113.817 -169.675 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -116.19 -164.0 0.94 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.843 1.257 . . . . 10.0 109.151 -174.592 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -116.18 108.49 16.21 Favored 'General case' 0 C--O 1.224 -0.284 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 -174.699 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.444 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 74.2 t60 -16.27 100.49 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.436 0 C-N-CA 126.11 1.764 . . . . 10.0 113.641 -179.218 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.47 -136.22 7.48 Favored Glycine 0 N--CA 1.449 -0.498 0 N-CA-C 108.022 -2.031 . . . . 10.0 108.022 -177.453 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 176.63 -165.39 35.61 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 108.262 -1.935 . . . . 10.0 108.262 169.195 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -67.64 12.85 0.19 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 121.751 1.634 . . . . 10.0 110.838 168.775 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.8 mmtp -104.52 -19.24 14.07 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 123.883 0.873 . . . . 10.0 108.89 172.286 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -119.7 167.19 12.29 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.375 -1.343 . . . . 10.0 107.375 -172.886 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -87.5 -24.57 24.05 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 172.106 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.313 1.8 pt-20 -107.36 40.95 1.58 Allowed 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 115.882 1.808 . . . . 10.0 115.882 -166.237 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.539 ' CD ' ' H ' ' A' ' 79' ' ' ARG . 0.3 OUTLIER -46.61 145.88 1.72 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.182 -1.372 . . . . 10.0 107.973 166.634 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.444 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 21.6 m170 -54.31 -58.81 5.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 109.276 -0.639 . . . . 10.0 109.276 169.202 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.1 p -168.42 -55.75 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 C-N-CA 124.477 1.111 . . . . 10.0 108.379 175.188 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -127.63 55.1 0.76 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.116 -1.194 . . . . 10.0 110.116 -176.564 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -86.45 97.62 10.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.784 -1.932 . . . . 10.0 105.784 169.433 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.559 HD13 ' C ' ' A' ' 84' ' ' LEU . 1.9 tm? -72.69 -39.91 66.66 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 105.265 -2.124 . . . . 10.0 105.265 171.817 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 106.59 -106.98 2.62 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 109.127 -1.589 . . . . 10.0 109.127 166.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -106.72 131.41 53.89 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.301 1.04 . . . . 10.0 110.083 -168.004 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -120.63 129.03 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.325 0.511 . . . . 10.0 109.63 168.426 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.9 t -96.93 132.73 42.41 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 124.328 1.051 . . . . 10.0 109.757 -177.218 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.4 140.09 35.14 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 122.913 0.485 . . . . 10.0 110.759 176.277 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.34 170.68 2.22 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.759 0.824 . . . . 10.0 109.487 168.236 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.27 -23.43 48.31 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 123.65 0.78 . . . . 10.0 113.1 169.689 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -77.18 -8.18 57.11 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 122.773 0.429 . . . . 10.0 111.726 173.932 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.68 18.76 67.39 Favored Glycine 0 C--N 1.34 0.781 0 N-CA-C 110.16 -1.176 . . . . 10.0 110.16 -178.895 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 36.2 t -98.89 110.26 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.627 2.371 . . . . 10.0 106.927 -179.364 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.453 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -101.31 121.82 42.58 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 119.054 0.843 . . . . 10.0 109.202 169.448 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -101.59 78.2 1.82 Allowed 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 128.427 2.691 . . . . 10.0 110.948 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.43 61.34 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 C-N-CA 124.452 1.101 . . . . 10.0 112.311 -169.228 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -90.77 55.63 3.01 Favored 'General case' 0 C--N 1.317 -0.845 0 O-C-N 121.251 -0.905 . . . . 10.0 108.726 -178.447 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.58 145.74 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 108.333 -0.988 . . . . 10.0 108.333 -174.144 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.86 139.54 35.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 126.477 1.911 . . . . 10.0 110.001 178.09 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.73 159.63 41.63 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 108.172 -1.047 . . . . 10.0 108.172 166.334 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 t -124.66 55.81 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 124.444 1.098 . . . . 10.0 109.236 176.976 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -148.66 -41.28 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 123.586 0.754 . . . . 10.0 110.854 175.84 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 49.7 mm -67.13 89.28 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 C-N-CA 124.372 1.069 . . . . 10.0 109.543 170.657 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.8 m -88.44 123.99 33.52 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.615 0.766 . . . . 10.0 109.933 172.509 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.7 mt -48.25 -55.71 9.83 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.108 0.963 . . . . 10.0 111.076 177.237 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.5 p -135.49 175.34 9.68 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 127.271 2.229 . . . . 10.0 107.826 -179.165 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 132.22 -92.55 0.28 Allowed Glycine 0 C--N 1.335 0.493 0 N-CA-C 109.114 -1.595 . . . . 10.0 109.114 176.362 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -125.03 -52.23 1.66 Allowed 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.423 1.889 . . . . 10.0 107.655 179.323 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -74.3 -37.41 63.64 Favored 'General case' 0 N--CA 1.457 -0.116 0 CA-C-N 114.717 -1.129 . . . . 10.0 108.26 -173.518 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t 44.4 65.99 0.95 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.824 1.65 . . . . 10.0 113.024 168.75 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -65.19 -19.18 25.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 113.252 0.834 . . . . 10.0 113.252 -174.161 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.0 mm -48.58 126.02 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 118.336 0.516 . . . . 10.0 109.706 172.653 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.34 1.52 55.68 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.77 -1.016 . . . . 10.0 113.779 -179.094 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.99 176.33 9.25 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 118.757 1.278 . . . . 10.0 109.984 169.179 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -113.13 140.57 47.79 Favored 'General case' 0 C--N 1.34 0.159 0 C-N-CA 124.505 1.122 . . . . 10.0 108.802 169.757 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -98.13 139.49 33.86 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.562 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.6 t -117.76 135.18 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 107.349 -1.352 . . . . 10.0 107.349 170.93 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.39 122.07 55.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 N-CA-C 106.04 -1.837 . . . . 10.0 106.04 167.579 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.2 m-70 -100.44 161.78 13.38 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.92 1.343 . . . . 10.0 114.225 -169.253 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.624 ' HA ' HD22 ' A' ' 144' ' ' LEU . 29.2 tt0 -53.85 -68.8 0.15 Allowed 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.641 2.376 . . . . 10.0 109.107 177.31 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 57.2 mttp -106.92 168.37 9.24 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 123.476 0.71 . . . . 10.0 111.164 -178.125 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.62 142.35 58.46 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.593 1.157 . . . . 10.0 109.528 171.322 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -81.93 144.3 31.04 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.359 0.599 . . . . 10.0 109.902 168.381 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -78.43 7.8 6.07 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.079 0.951 . . . . 10.0 110.972 175.555 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 33.4 mt 49.75 45.62 24.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 124.133 0.973 . . . . 10.0 109.668 -177.835 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.38 -31.46 8.03 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 114.943 -1.026 . . . . 10.0 111.188 174.876 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mtmm -84.23 42.34 0.88 Allowed 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.746 -0.855 . . . . 10.0 110.759 -170.108 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.85 -34.67 6.43 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 126.983 2.23 . . . . 10.0 109.999 176.719 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 58.64 47.9 87.64 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 111.73 -0.548 . . . . 10.0 111.73 -174.402 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -137.49 173.34 11.77 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.1 -1.815 . . . . 10.0 106.1 169.552 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -54.69 -54.05 46.82 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 109.195 -0.669 . . . . 10.0 109.195 173.502 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -58.71 -31.38 68.2 Favored 'General case' 0 C--N 1.344 0.359 0 O-C-N 121.396 -0.815 . . . . 10.0 112.502 179.452 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.3 p -51.18 -34.88 33.54 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 119.646 1.112 . . . . 10.0 110.461 178.276 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.3 t -98.34 11.13 39.02 Favored 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 113.549 0.944 . . . . 10.0 113.549 -179.793 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 73.3 mmtt -120.36 -54.67 2.08 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 125.299 1.44 . . . . 10.0 111.153 179.617 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -131.95 9.59 4.54 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 113.388 0.884 . . . . 10.0 113.388 171.92 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.14 16.18 61.32 Favored Glycine 0 C--O 1.221 -0.707 0 CA-C-O 119.216 -0.769 . . . . 10.0 113.366 173.063 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 69.36 17.75 8.1 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.188 0.994 . . . . 10.0 112.525 -177.121 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.08 -14.42 54.47 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 123.317 0.647 . . . . 10.0 112.005 176.553 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.87 -147.04 30.25 Favored Glycine 0 N--CA 1.442 -0.937 0 N-CA-C 109.816 -1.313 . . . . 10.0 109.816 169.848 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.3 m -61.07 121.31 12.14 Favored 'General case' 0 N--CA 1.444 -0.769 0 O-C-N 122.1 -0.647 . . . . 10.0 110.764 -168.74 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -56.24 71.25 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.866 1.666 . . . . 10.0 110.711 167.335 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.624 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.0 tp -45.91 -41.38 11.38 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 127.181 2.192 . . . . 10.0 112.925 -171.475 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.93 155.46 31.4 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.177 -1.046 . . . . 10.0 108.177 -175.78 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.1 p -164.12 170.85 15.89 Favored 'General case' 0 N--CA 1.454 -0.253 0 O-C-N 122.01 -0.431 . . . . 10.0 110.095 -176.705 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -166.95 -176.69 38.14 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.705 -1.358 . . . . 10.0 109.705 -177.629 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.89 143.28 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -169.717 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 61.0 mt -73.55 137.4 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 122.784 0.434 . . . . 10.0 110.536 -176.405 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.72 141.59 12.77 Favored Glycine 0 CA--C 1.529 0.906 0 C-N-CA 125.306 1.432 . . . . 10.0 111.272 -178.537 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 42.5 mt -57.05 139.04 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 125.212 1.405 . . . . 10.0 108.603 170.943 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.504 ' HB2' ' HB3' ' B' ' 52' ' ' ASP . . . -136.57 156.67 48.26 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.318 0.58 . . . . 10.0 109.887 172.032 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.287 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 165.667 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.68 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -14.68 60.79 Favored 'General case' 0 CA--C 1.527 0.062 0 CA-C-N 118.857 0.753 . . . . 10.0 110.679 176.439 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 45.4 tttt -151.4 148.26 27.9 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.723 -0.473 . . . . 10.0 109.723 169.528 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.73 165.97 25.85 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.295 1.438 . . . . 10.0 107.501 169.543 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.61 164.06 35.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 123.426 0.69 . . . . 10.0 109.168 176.039 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.15 111.63 10.47 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 169.238 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.1 m -86.88 100.5 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 169.95 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.403 HD22 HG13 ' B' ' 119' ' ' VAL . 10.3 mt -78.83 134.37 36.97 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 123.912 0.885 . . . . 10.0 109.423 176.348 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -158.6 162.19 37.31 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 169.302 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.5 -56.85 0.05 OUTLIER Glycine 0 N--CA 1.454 -0.125 0 N-CA-C 111.485 -0.646 . . . . 10.0 111.485 171.205 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.37 -45.72 45.13 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.486 -1.672 . . . . 10.0 106.486 -170.923 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.4 -65.92 0.57 Allowed Glycine 0 CA--C 1.526 0.753 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.734 -179.141 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -58.33 -36.8 97.26 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.913 2.409 . . . . 10.0 111.236 173.685 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.7 113.57 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.378 -0.971 . . . . 10.0 108.378 175.788 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.31 126.28 31.07 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.202 -1.036 . . . . 10.0 108.202 168.581 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.672 ' HA3' HG22 ' B' ' 35' ' ' ILE . . . -120.44 140.76 14.65 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-O 119.428 -0.651 . . . . 10.0 111.696 176.582 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.401 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 10.6 mt -135.37 75.24 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 -169.276 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.2 mm -92.25 139.65 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.819 -0.628 . . . . 10.0 110.023 -174.293 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -114.62 120.94 41.87 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 128.419 2.688 . . . . 10.0 108.02 -178.104 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.9 105.56 14.41 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.315 1.446 . . . . 10.0 107.576 178.838 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -100.57 150.54 22.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 118.414 0.552 . . . . 10.0 111.122 178.277 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 63.8 tp60 -142.24 102.31 4.08 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.7 2.0 . . . . 10.0 108.264 -179.057 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp . . . . . 0 N--CA 1.438 -1.069 0 C-N-CA 126.228 1.811 . . . . 10.0 110.879 -172.546 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.184 0 N-CA-C 111.943 -0.463 . . . . 10.0 111.943 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.18 154.34 61.94 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.418 2.079 . . . . 10.0 108.081 168.867 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 t -79.01 92.04 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 104.753 -2.314 . . . . 10.0 104.753 169.172 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 35.3 tttp -77.17 104.03 7.44 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 106.832 -1.544 . . . . 10.0 106.832 169.042 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -96.42 104.41 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 C-N-CA 126.566 1.946 . . . . 10.0 106.539 -179.352 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -122.24 163.03 20.33 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 112.693 0.627 . . . . 10.0 112.693 174.278 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.66 -154.15 25.33 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 106.866 -2.494 . . . . 10.0 106.866 169.666 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -155.14 160.55 41.02 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 120.134 -0.626 . . . . 10.0 110.198 176.705 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.672 HG22 ' HA3' ' B' ' 16' ' ' GLY . 1.8 pt -117.43 142.47 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.683 0 CA-C-N 114.262 -1.335 . . . . 10.0 109.557 167.475 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -117.35 149.54 40.32 Favored 'General case' 0 N--CA 1.443 -0.776 0 N-CA-C 106.864 -1.532 . . . . 10.0 106.864 168.385 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.04 -8.36 33.4 Favored Glycine 0 C--N 1.336 0.564 0 CA-C-O 119.34 -0.7 . . . . 10.0 112.731 171.395 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -62.15 175.36 0.73 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.198 0.999 . . . . 10.0 109.246 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.79 166.26 10.58 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 167.351 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -54.48 149.93 9.78 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.25 0.62 . . . . 10.0 111.469 -172.097 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.75 -168.6 31.81 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-O 121.763 0.646 . . . . 10.0 112.838 168.971 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.3 mp -75.26 144.8 42.37 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 126.824 2.05 . . . . 10.0 111.787 -169.652 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -147.85 145.08 28.57 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 113.813 1.042 . . . . 10.0 113.813 -177.322 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.637 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -28.22 128.41 0.07 OUTLIER Glycine 0 C--N 1.341 0.835 0 C-N-CA 127.284 2.373 . . . . 10.0 111.288 165.606 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -151.37 102.15 2.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 119.144 1.472 . . . . 10.0 111.675 169.861 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.446 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -150.57 170.07 20.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.764 0.653 . . . . 10.0 112.764 -179.83 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 24.2 m -97.4 -30.27 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 126.244 1.817 . . . . 10.0 113.986 -170.766 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 57.3 m-70 58.03 171.82 0.05 Allowed 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 122.905 1.336 . . . . 10.0 112.989 -177.571 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -83.25 -51.56 7.35 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 114.779 -1.101 . . . . 10.0 110.037 170.327 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -75.95 114.0 14.08 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 118.628 0.649 . . . . 10.0 109.669 -168.019 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.23 -31.71 81.75 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 107.824 -2.111 . . . . 10.0 107.824 165.792 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.504 ' HB3' ' HB2' ' A' ' 152' ' ' ALA . 1.7 p30 -58.82 161.46 4.83 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-O 123.251 1.5 . . . . 10.0 114.423 -176.551 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.14 21.68 0.08 Allowed 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 112.941 -1.936 . . . . 10.0 113.962 -168.128 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.433 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -58.31 -29.24 65.74 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 123.816 0.847 . . . . 10.0 111.75 -179.562 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.13 -15.95 59.35 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 122.909 0.484 . . . . 10.0 111.796 176.599 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.77 85.43 0.81 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 124.356 0.979 . . . . 10.0 111.049 178.521 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 65.5 m 37.6 47.53 0.8 Allowed 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 126.946 2.098 . . . . 10.0 112.146 -179.952 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -121.85 -54.89 1.92 Allowed 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 -169.659 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.0 t -128.34 54.81 1.72 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.021 0.928 . . . . 10.0 108.763 -177.472 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.02 49.97 0.45 Allowed 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 123.14 0.576 . . . . 10.0 110.399 172.149 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.0 125.92 0.13 Allowed Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.272 0.939 . . . . 10.0 111.448 172.346 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -77.46 47.39 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.86 0 C-N-CA 123.374 2.716 . . . . 10.0 112.605 179.607 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 60.76 47.79 7.64 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.931 2.492 . . . . 10.0 110.996 178.059 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -70.74 70.28 0.47 Allowed 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.886 0.85 . . . . 10.0 110.778 174.602 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . 0.414 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 4.9 p-10 -71.62 148.56 92.88 Favored Pre-proline 0 C--N 1.325 -0.467 0 C-N-CA 123.388 0.675 . . . . 10.0 112.709 -174.17 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -64.52 -46.61 6.93 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.975 2.45 . . . . 10.0 111.522 -179.722 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -78.89 48.9 0.87 Allowed 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.538 -0.726 . . . . 10.0 110.002 178.553 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 64.1 p -14.94 102.93 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 129.711 3.204 . . . . 10.0 113.466 -170.209 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 mtt85 -137.07 -179.77 5.91 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 118.612 0.642 . . . . 10.0 112.635 -170.635 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -111.79 102.09 10.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 105.753 -1.943 . . . . 10.0 105.753 -176.836 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.462 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.5 t60 -22.66 107.51 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.455 1.902 . . . . 10.0 114.185 -171.274 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.03 -149.55 8.38 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.964 -1.255 . . . . 10.0 109.964 176.652 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.96 -162.66 22.65 Favored Glycine 0 C--N 1.331 0.301 0 N-CA-C 108.51 -1.836 . . . . 10.0 108.51 -179.316 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -64.94 -6.69 13.26 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 121.367 1.378 . . . . 10.0 109.797 165.551 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 30.2 mmtt -101.89 2.43 38.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.82 1.648 . . . . 10.0 110.099 177.35 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 128' ' ' LYS . 3.7 t70 -129.32 170.98 12.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 N-CA-C 107.498 -1.297 . . . . 10.0 107.498 167.399 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -91.59 -27.17 18.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.426 -0.953 . . . . 10.0 108.426 169.186 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -102.89 39.3 1.57 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 122.831 1.301 . . . . 10.0 110.206 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.7 ptp180 -55.89 142.3 35.86 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 126.057 1.743 . . . . 10.0 108.941 169.664 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.462 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.0 m170 -64.98 -56.74 11.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 O-C-N 121.855 -0.528 . . . . 10.0 110.237 -175.181 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.515 HG13 ' H ' ' B' ' 82' ' ' GLY . 3.6 p -170.37 -68.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.992 -0.744 . . . . 10.0 108.992 176.908 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.515 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -118.2 67.91 0.34 Allowed Glycine 0 C--N 1.333 0.413 0 N-CA-C 107.522 -2.231 . . . . 10.0 107.522 -179.41 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -106.79 97.65 7.41 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.322 -2.473 . . . . 10.0 104.322 172.407 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 23.9 mt -82.09 22.94 0.75 Allowed 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.235 0.541 . . . . 10.0 110.56 -173.612 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.85 -104.85 2.36 Favored Glycine 0 N--CA 1.437 -1.287 0 N-CA-C 106.422 -2.671 . . . . 10.0 106.422 173.596 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -157.64 151.28 23.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.726 -1.213 . . . . 10.0 107.726 169.704 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.0 m -113.9 137.25 47.73 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 O-C-N 123.835 0.709 . . . . 10.0 109.547 -175.032 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 88.7 m -94.89 109.35 21.36 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 128.364 2.666 . . . . 10.0 108.491 -171.975 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.25 136.49 32.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 122.904 0.482 . . . . 10.0 110.205 174.845 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -57.56 171.51 0.44 Allowed 'General case' 0 C--O 1.235 0.298 0 O-C-N 124.079 0.862 . . . . 10.0 108.841 166.323 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 58.3 pttt -57.45 -29.04 63.87 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 123.541 0.736 . . . . 10.0 110.508 175.524 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -79.13 -0.64 32.54 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.785 0.834 . . . . 10.0 111.051 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.19 4.69 88.05 Favored Glycine 0 C--N 1.339 0.736 0 O-C-N 120.99 -1.069 . . . . 10.0 110.79 179.644 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.66 97.3 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 C-N-CA 126.128 1.771 . . . . 10.0 107.52 -178.008 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.461 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.72 118.83 37.75 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 108.367 -0.975 . . . . 10.0 108.367 169.192 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -82.15 129.13 34.74 Favored 'General case' 0 N--CA 1.437 -1.124 0 C-N-CA 126.856 2.062 . . . . 10.0 109.9 174.633 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.17 134.06 58.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 C-N-CA 125.907 1.683 . . . . 10.0 107.769 173.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 13.7 p -158.44 57.44 0.45 Allowed 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 112.804 0.668 . . . . 10.0 112.804 171.791 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.86 155.76 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.921 -0.77 . . . . 10.0 108.921 -172.075 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -116.47 99.25 7.05 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 126.546 1.938 . . . . 10.0 110.38 174.358 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -81.72 85.42 6.6 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.626 -1.249 . . . . 10.0 107.626 176.417 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 64.7 p -83.15 60.51 5.56 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 106.315 -1.735 . . . . 10.0 106.315 173.168 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.84 -47.77 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 O-C-N 123.356 0.41 . . . . 10.0 110.273 -170.9 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.325 0.0 OUTLIER -103.42 176.87 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 C-N-CA 123.74 0.816 . . . . 10.0 112.033 169.378 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -140.7 123.98 16.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.49 -29.57 50.51 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.358 1.463 . . . . 10.0 111.318 -179.031 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.4 m . . . . . 0 N--CA 1.452 -0.373 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 167.23 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.448 -0.529 0 CA-C-O 121.186 0.517 . . . . 10.0 111.818 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.95 20.17 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 124.796 1.238 . . . . 10.0 114.291 -174.477 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 17.9 mm -54.92 146.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 C-N-CA 125.538 1.535 . . . . 10.0 108.085 168.745 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.91 21.99 69.98 Favored Glycine 0 CA--C 1.533 1.169 0 CA-C-O 118.599 -1.111 . . . . 10.0 114.335 178.278 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.2 mmt180 -97.53 172.55 7.66 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 166.513 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -124.22 108.54 12.38 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.082 0.855 . . . . 10.0 111.454 -170.529 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.418 HD21 HD11 ' B' ' 149' ' ' ILE . 3.7 mm? -64.89 134.21 53.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 107.344 -1.354 . . . . 10.0 107.344 169.743 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.6 t -125.11 131.37 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 106.83 -1.544 . . . . 10.0 106.83 174.747 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.403 HG13 HD22 ' B' ' 8' ' ' LEU . 2.4 m -105.99 131.52 55.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 O-C-N 124.007 0.817 . . . . 10.0 110.084 169.466 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.637 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.3 m170 -113.04 163.5 14.62 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 114.813 1.412 . . . . 10.0 114.813 -170.583 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -51.31 -55.51 17.94 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 127.172 2.189 . . . . 10.0 109.468 -179.393 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -121.05 174.27 6.75 Favored 'General case' 0 CA--C 1.521 -0.154 0 C-N-CA 124.366 1.066 . . . . 10.0 112.228 -171.155 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.6 151.65 30.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.857 1.263 . . . . 10.0 110.06 -179.835 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.446 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -78.37 153.68 31.42 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 123.773 0.829 . . . . 10.0 111.799 175.733 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -76.31 -27.98 56.77 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 114.897 -1.047 . . . . 10.0 109.4 168.742 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 68.9 mt 59.52 52.04 6.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 123.669 1.7 . . . . 10.0 108.524 -172.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.65 -41.53 2.84 Favored Glycine 0 N--CA 1.443 -0.852 0 CA-C-N 111.655 -2.52 . . . . 10.0 111.489 169.171 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 19.1 mtmm -79.26 41.44 0.46 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.34 1.456 . . . . 10.0 112.47 -170.863 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.46 -15.73 34.07 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 126.653 2.073 . . . . 10.0 110.497 169.332 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.34 46.69 51.93 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 124.393 0.997 . . . . 10.0 111.951 -179.309 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.5 p30 -151.07 172.83 15.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 118.249 1.024 . . . . 10.0 109.883 176.216 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.3 tm-20 -55.18 -41.02 71.37 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.697 1.199 . . . . 10.0 110.915 -176.689 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 19.0 tp10 -71.42 -39.07 71.31 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 121.681 -0.637 . . . . 10.0 110.587 174.121 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.5 p -52.24 -43.92 64.56 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 118.451 0.569 . . . . 10.0 110.57 -176.376 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.3 t -74.92 -10.53 59.58 Favored 'General case' 0 CA--C 1.543 0.703 0 O-C-N 124.332 1.02 . . . . 10.0 113.058 -177.216 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.6 ttmt -115.21 -64.64 1.29 Allowed 'General case' 0 N--CA 1.436 -1.131 0 C-N-CA 126.973 2.109 . . . . 10.0 112.899 -168.878 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.5 p -126.46 17.01 7.63 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 120.048 1.295 . . . . 10.0 110.208 175.939 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.53 -105.7 1.91 Allowed Glycine 0 C--N 1.339 0.744 0 N-CA-C 106.952 -2.459 . . . . 10.0 106.952 -173.877 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -152.52 39.38 0.56 Allowed 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 170.009 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.22 -26.32 64.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.231 -0.895 . . . . 10.0 111.144 -177.03 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.48 -142.61 23.0 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 124.876 1.226 . . . . 10.0 110.379 170.707 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -69.16 134.96 49.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 -175.82 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . 0.401 ' NE ' ' H ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -63.07 120.84 12.21 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 106.414 -1.698 . . . . 10.0 106.414 167.758 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 31.9 mt -76.65 -60.43 2.35 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 169.547 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -139.18 163.17 33.14 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 122.974 0.51 . . . . 10.0 110.104 -174.03 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -154.15 163.71 39.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.353 -0.385 . . . . 10.0 110.443 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.33 149.1 18.22 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 109.418 -1.473 . . . . 10.0 109.418 -171.624 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -108.67 139.65 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 C-N-CA 124.916 1.286 . . . . 10.0 108.041 -169.065 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.418 HD11 HD21 ' B' ' 117' ' ' LEU . 19.0 mt -77.5 112.32 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 122.916 0.486 . . . . 10.0 109.966 -173.455 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.75 143.54 18.09 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.808 1.194 . . . . 10.0 112.21 -174.451 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.49 136.34 25.81 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.296 0 C-N-CA 126.315 1.846 . . . . 10.0 110.333 -175.758 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.74 -46.78 1.98 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.681 0.673 . . . . 10.0 111.759 177.821 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 . . . . . 0 C--O 1.25 1.103 0 CA-C-O 116.368 -1.777 . . . . 10.0 112.107 -169.443 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 108.411 -0.959 . . . . 10.0 108.411 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -80.06 -21.52 43.33 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.948 -1.13 . . . . 10.0 107.948 168.144 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.494 ' HZ3' ' C ' ' A' ' 153' ' ' GLN . 1.8 ttmp? -127.04 161.5 28.24 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.763 1.625 . . . . 10.0 107.868 179.078 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.24 164.28 38.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.435 -1.691 . . . . 10.0 106.435 168.337 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.41 ' O ' HG23 ' A' ' 149' ' ' ILE . 2.5 m -125.76 -179.9 2.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 118.08 0.4 . . . . 10.0 110.094 -179.429 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.71 108.37 2.9 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.852 -0.795 . . . . 10.0 108.852 165.207 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.47 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.3 m -92.91 115.53 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 171.282 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.7 mt -103.85 150.32 24.25 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.751 1.221 . . . . 10.0 109.224 -179.801 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.6 ttmt -163.12 159.83 23.57 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.721 1.146 . . . . 10.0 109.204 169.836 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.42 -56.35 0.02 OUTLIER Glycine 0 C--O 1.229 -0.197 0 N-CA-C 111.349 -0.7 . . . . 10.0 111.349 169.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -75.25 -45.85 37.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 106.575 -1.639 . . . . 10.0 106.575 -172.825 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.5 -64.85 0.6 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 113.859 -1.519 . . . . 10.0 110.902 -178.413 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -58.3 -41.29 67.86 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 122.512 2.142 . . . . 10.0 110.839 172.08 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -70.43 105.38 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.427 -1.694 . . . . 10.0 106.427 176.361 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.81 131.93 46.34 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.766 -0.827 . . . . 10.0 108.766 167.296 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.938 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -99.39 147.52 18.39 Favored Glycine 0 N--CA 1.441 -1.005 0 N-CA-C 109.658 -1.377 . . . . 10.0 109.658 174.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.624 HG22 HG23 ' B' ' 54' ' ' THR . 1.0 OUTLIER -150.81 81.8 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 105.355 -2.091 . . . . 10.0 105.355 -170.422 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -100.51 146.33 9.41 Favored 'Isoleucine or valine' 0 C--N 1.338 0.1 0 C-N-CA 125.091 1.356 . . . . 10.0 109.738 -178.283 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -126.0 117.15 22.65 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 127.502 2.321 . . . . 10.0 109.005 170.172 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -98.41 116.86 31.53 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 106.817 -1.549 . . . . 10.0 106.817 173.269 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -116.62 138.5 51.39 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 119.476 1.034 . . . . 10.0 112.948 171.18 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -114.35 85.37 2.22 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.728 2.011 . . . . 10.0 107.966 -178.176 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.42 ' NZ ' ' OE2' ' A' ' 100' ' ' GLU . 0.0 OUTLIER -46.07 -44.09 15.14 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.711 1.605 . . . . 10.0 111.366 -172.643 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -142.95 168.46 19.65 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 102.989 -2.967 . . . . 10.0 102.989 165.534 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.0 t -61.71 -29.17 69.93 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 174.525 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -81.09 -17.52 49.73 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 124.397 1.079 . . . . 10.0 110.783 -179.225 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.41 141.97 16.48 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 110.446 -1.062 . . . . 10.0 110.446 -171.174 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -63.55 136.48 54.6 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.078 1.852 . . . . 10.0 109.221 174.872 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.6 m -78.03 124.39 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -176.458 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 37.7 ttmt -88.11 116.48 26.33 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.759 -2.682 . . . . 10.0 103.759 167.591 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -97.51 104.19 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 171.258 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 21.2 p90 -112.88 167.65 10.33 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 116.129 -0.487 . . . . 10.0 110.086 176.473 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.36 176.15 42.51 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.878 -1.153 . . . . 10.0 111.688 178.33 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.6 t -144.84 99.17 3.3 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 107.775 -1.194 . . . . 10.0 107.775 177.252 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.938 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.4 pt -80.57 153.61 4.39 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.584 -1.265 . . . . 10.0 107.584 168.4 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.68 151.06 50.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 124.062 0.851 . . . . 10.0 109.085 167.83 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.65 -8.91 34.73 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.967 0.794 . . . . 10.0 113.541 175.443 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -61.06 176.27 0.44 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 122.301 1.048 . . . . 10.0 111.188 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -107.4 151.38 25.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 106.579 -1.638 . . . . 10.0 106.579 166.999 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -49.44 144.19 5.87 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.244 1.017 . . . . 10.0 111.717 -169.826 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.83 -168.01 21.18 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 123.685 0.659 . . . . 10.0 112.203 172.751 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -75.81 148.75 38.19 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.842 2.057 . . . . 10.0 111.768 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -147.6 134.24 19.9 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.477 1.111 . . . . 10.0 111.472 179.344 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.402 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -38.23 123.61 1.33 Allowed Glycine 0 C--N 1.345 1.076 0 C-N-CA 124.843 1.211 . . . . 10.0 111.02 168.337 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.516 ' HZ ' HG21 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -136.75 108.64 7.1 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 124.133 0.973 . . . . 10.0 109.37 176.397 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -155.57 174.4 15.32 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 121.788 0.804 . . . . 10.0 111.712 -178.101 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.7 m -102.35 144.65 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 CA-C-N 111.798 -2.456 . . . . 10.0 106.369 168.214 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -121.66 148.07 45.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 107.246 -1.39 . . . . 10.0 107.246 176.543 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.409 ' HB3' ' CE1' ' A' ' 64' ' ' PHE . 2.3 tp10 -59.43 -39.32 83.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 122.854 0.462 . . . . 10.0 112.213 -169.963 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -74.76 153.23 38.9 Favored 'General case' 0 CA--C 1.527 0.079 0 C-N-CA 118.358 -1.337 . . . . 10.0 109.561 177.205 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.58 -11.84 46.3 Favored Glycine 0 CA--C 1.54 1.602 0 N-CA-C 109.385 -1.486 . . . . 10.0 109.385 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -48.2 107.13 0.11 Allowed 'General case' 0 C--N 1.344 0.357 0 C-N-CA 126.653 1.981 . . . . 10.0 112.382 172.658 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -112.68 6.44 18.23 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 113.268 -1.787 . . . . 10.0 109.34 168.015 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.408 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -57.8 -39.92 78.7 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.254 1.021 . . . . 10.0 109.456 -178.91 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.5 -15.52 58.51 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.053 0.941 . . . . 10.0 112.699 177.622 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.48 -108.08 3.06 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 108.736 -1.746 . . . . 10.0 108.736 -173.13 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 60.9 m -131.0 43.7 3.06 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 124.307 1.043 . . . . 10.0 109.43 -173.215 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 55.3 m -130.18 -54.24 1.11 Allowed 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 125.796 1.638 . . . . 10.0 107.141 -171.748 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.9 t -80.75 4.61 18.36 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.265 0.555 . . . . 10.0 111.663 178.445 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.54 -25.87 7.52 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.871 1.268 . . . . 10.0 112.415 173.137 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.42 144.99 18.26 Favored Glycine 0 C--N 1.339 0.742 0 N-CA-C 110.576 -1.01 . . . . 10.0 110.576 173.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -80.07 57.74 6.65 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 CA-C-N 120.584 2.192 . . . . 10.0 111.399 179.649 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.477 ' CD2' HG22 ' A' ' 137' ' ' THR . 21.9 m170 71.77 -62.27 0.46 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 127.122 2.169 . . . . 10.0 108.211 -175.685 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.409 ' CE1' ' HB3' ' A' ' 49' ' ' GLU 0.343 3.1 p90 34.28 36.72 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 129.998 3.319 . . . . 10.0 116.85 174.635 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -45.29 152.24 0.64 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 129.837 3.255 . . . . 10.0 113.287 167.78 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -74.17 -48.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.493 2.795 . . . . 10.0 111.29 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 81.7 mt -68.82 83.44 0.3 Allowed 'General case' 0 C--N 1.339 0.145 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 172.839 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.7 p -69.54 64.65 0.18 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 126.628 1.971 . . . . 10.0 113.982 -169.358 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -87.73 -178.75 6.14 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.575 1.95 . . . . 10.0 109.779 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -111.43 84.98 2.04 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.188 0.518 . . . . 10.0 112.205 -169.356 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.451 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 64.8 t60 11.14 87.3 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 128.009 2.524 . . . . 10.0 114.627 175.791 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.26 -161.44 18.33 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 108.681 -1.767 . . . . 10.0 108.681 174.923 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.17 -155.88 6.73 Favored Glycine 0 C--O 1.224 -0.495 0 CA-C-O 117.671 -1.627 . . . . 10.0 110.512 170.106 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -64.91 -2.05 5.01 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 CA-C-N 120.756 2.278 . . . . 10.0 111.27 171.139 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 29.3 mtpt -88.41 -17.6 30.14 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.245 -0.884 . . . . 10.0 110.801 172.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -128.98 174.83 9.17 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 118.812 0.733 . . . . 10.0 109.482 -175.831 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -97.51 -15.05 20.73 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.707 0.803 . . . . 10.0 109.505 168.539 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 70.5 mm-40 -79.69 10.74 3.7 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.145 1.378 . . . . 10.0 112.78 178.712 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 16.4 ptt180 -51.65 127.56 20.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 166.995 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.451 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 21.3 m170 -65.7 -51.1 62.03 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 122.11 -0.369 . . . . 10.0 111.512 -169.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.6 p -166.94 -30.29 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 123.026 0.531 . . . . 10.0 111.804 -169.626 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.69 70.97 0.08 OUTLIER Glycine 0 C--N 1.334 0.442 0 N-CA-C 106.199 -2.761 . . . . 10.0 106.199 -176.557 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -116.58 91.11 3.49 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 -169.554 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp -72.86 -28.83 62.75 Favored 'General case' 0 CA--C 1.527 0.09 0 N-CA-C 107.314 -1.365 . . . . 10.0 107.314 -178.151 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.53 -87.78 0.77 Allowed Glycine 0 N--CA 1.44 -1.04 0 N-CA-C 106.493 -2.643 . . . . 10.0 106.493 172.12 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -140.98 149.38 41.71 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 122.884 0.473 . . . . 10.0 111.902 -176.414 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -129.32 143.41 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 105.506 -2.035 . . . . 10.0 105.506 168.093 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -95.48 121.58 37.31 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.357 1.863 . . . . 10.0 107.521 -176.285 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.14 137.4 32.37 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.721 -0.474 . . . . 10.0 109.721 171.208 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -67.5 173.25 4.25 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 126.193 1.797 . . . . 10.0 109.786 168.966 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -56.68 -24.36 48.28 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 124.75 1.22 . . . . 10.0 112.274 177.825 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -78.24 -17.61 56.48 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.092 -0.336 . . . . 10.0 110.092 179.527 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.28 7.74 69.39 Favored Glycine 0 C--N 1.338 0.647 0 N-CA-C 110.525 -1.03 . . . . 10.0 110.525 -171.86 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -80.7 119.54 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 N-CA-C 106.714 -1.587 . . . . 10.0 106.714 172.938 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.568 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -113.94 118.78 35.14 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 119.11 0.868 . . . . 10.0 108.691 169.482 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -79.2 117.35 20.14 Favored 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 126.366 1.866 . . . . 10.0 108.096 174.345 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 46.5 t -105.93 131.39 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 178.537 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 80.0 p -157.77 71.75 0.63 Allowed 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.735 0.814 . . . . 10.0 109.579 173.069 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.58 155.0 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 106.92 -1.511 . . . . 10.0 106.92 177.456 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.42 ' OE2' ' NZ ' ' A' ' 23' ' ' LYS . 26.3 tt0 -135.95 128.18 30.02 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 124.914 1.286 . . . . 10.0 108.276 174.742 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -136.7 152.8 50.78 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 124.046 0.842 . . . . 10.0 109.814 -177.601 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.4 p -118.68 48.75 1.39 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 127.484 2.314 . . . . 10.0 109.875 -171.068 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 14.6 p -155.34 -49.37 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 122.295 0.238 . . . . 10.0 110.655 173.002 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.99 119.48 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.663 -1.606 . . . . 10.0 106.663 170.617 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.09 85.79 2.3 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -176.038 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.2 pp -51.9 -10.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.603 1.561 . . . . 10.0 114.294 -177.961 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 24.9 t -148.36 137.01 21.55 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 103.953 -2.61 . . . . 10.0 103.953 168.862 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.78 -72.41 0.39 Allowed Glycine 0 C--N 1.334 0.421 0 N-CA-C 109.846 -1.301 . . . . 10.0 109.846 -176.526 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.45 -53.37 0.08 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 179.75 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -83.7 48.25 1.4 Allowed 'General case' 0 C--O 1.233 0.199 0 N-CA-C 109.269 -0.641 . . . . 10.0 109.269 -176.773 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.7 t -73.64 72.22 1.44 Allowed 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.072 1.349 . . . . 10.0 107.615 178.019 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.8 pt -72.2 39.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 126.251 1.821 . . . . 10.0 112.058 -177.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 44.2 mm -66.58 -47.5 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 125.246 1.418 . . . . 10.0 109.456 -178.445 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.77 51.3 3.74 Favored Glycine 0 CA--C 1.525 0.691 0 O-C-N 121.622 -0.674 . . . . 10.0 113.408 -175.053 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.29 145.81 46.72 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 -177.783 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 28.3 m -90.21 119.62 30.68 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 104.902 -2.259 . . . . 10.0 104.902 169.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.21 143.14 31.66 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -179.453 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 55.3 t -129.81 136.29 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 O-C-N 124.321 1.013 . . . . 10.0 109.405 -169.528 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.563 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.4 OUTLIER -105.96 119.32 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 N-CA-C 105.067 -2.198 . . . . 10.0 105.067 168.603 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.402 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 13.1 m-70 -99.19 161.45 13.62 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 113.823 1.045 . . . . 10.0 113.823 -169.563 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.609 ' HA ' HD22 ' A' ' 144' ' ' LEU . 0.5 OUTLIER -64.77 -53.06 53.03 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.685 -1.143 . . . . 10.0 108.483 -176.92 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -113.12 176.64 4.93 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.902 0.858 . . . . 10.0 111.987 -178.462 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.89 135.99 50.14 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.067 1.347 . . . . 10.0 111.19 -178.495 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -77.49 110.13 12.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 124.491 1.116 . . . . 10.0 108.507 173.757 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -80.36 58.41 3.11 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 123.196 0.31 . . . . 10.0 111.284 -179.379 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt -11.86 81.49 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 129.346 3.058 . . . . 10.0 115.384 -177.797 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 75.61 -7.48 25.76 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.927 -0.929 . . . . 10.0 113.812 168.779 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.7 pttp -116.03 27.34 9.33 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 118.4 1.1 . . . . 10.0 112.316 -174.458 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.23 -18.26 79.76 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.437 1.018 . . . . 10.0 111.273 170.662 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.83 44.33 98.01 Favored Glycine 0 CA--C 1.53 0.971 0 O-C-N 121.655 -0.909 . . . . 10.0 112.138 173.007 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.45 ' H ' ' HB2' ' A' ' 134' ' ' SER . 7.3 p30 -164.15 175.81 9.84 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 126.272 1.829 . . . . 10.0 106.821 177.913 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -56.0 -42.09 75.88 Favored 'General case' 0 N--CA 1.439 -1.023 0 CA-C-N 119.014 0.824 . . . . 10.0 111.906 -174.593 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -61.03 -28.79 69.31 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.813 -0.554 . . . . 10.0 110.179 -179.823 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.45 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 3.4 t -47.92 -46.02 31.43 Favored 'General case' 0 CA--C 1.519 -0.243 0 C-N-CA 124.228 1.011 . . . . 10.0 109.219 176.243 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -90.73 8.46 34.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 112.59 0.589 . . . . 10.0 112.59 -175.859 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.97 -81.19 0.63 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.045 1.338 . . . . 10.0 110.565 -178.918 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.477 HG22 ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -112.1 29.45 7.88 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 121.735 2.061 . . . . 10.0 111.537 174.091 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.95 -87.34 0.13 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 125.35 1.453 . . . . 10.0 110.823 179.012 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.404 ' ND2' HD21 ' A' ' 131' ' ' ASN . 0.4 OUTLIER -165.64 33.24 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 122.115 -0.638 . . . . 10.0 112.211 170.627 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.13 -13.42 61.94 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.586 0.587 . . . . 10.0 112.586 -174.014 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.61 -147.57 45.49 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.217 -1.953 . . . . 10.0 108.217 174.223 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -58.56 120.44 8.86 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 122.729 0.412 . . . . 10.0 111.765 -169.54 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.65 73.68 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.488 1.515 . . . . 10.0 111.623 168.04 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.609 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.7 tp -38.45 -49.74 1.49 Allowed 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.139 2.176 . . . . 10.0 113.894 -179.883 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.563 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -156.01 158.09 37.27 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -170.856 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 20.0 p -164.35 171.82 14.3 Favored 'General case' 0 N--CA 1.454 -0.247 0 O-C-N 121.759 -0.588 . . . . 10.0 111.222 -171.866 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -172.65 -161.39 23.0 Favored Glycine 0 N--CA 1.451 -0.334 0 N-CA-C 110.224 -1.15 . . . . 10.0 110.224 -178.894 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -133.0 154.66 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.392 -2.077 . . . . 10.0 105.392 -172.891 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.41 HG23 ' O ' ' A' ' 5' ' ' VAL . 2.8 mt -69.17 -85.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 123.613 0.765 . . . . 10.0 110.147 -169.301 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.54 132.92 7.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.151 -0.779 . . . . 10.0 111.151 179.645 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 58.1 mt -68.51 145.31 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 123.435 0.694 . . . . 10.0 110.069 -179.262 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.89 176.27 8.86 Favored 'General case' 0 N--CA 1.442 -0.856 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 164.732 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . 0.494 ' C ' ' HZ3' ' A' ' 3' ' ' LYS . 15.1 tt0 . . . . . 0 N--CA 1.44 -0.967 0 N-CA-C 106.213 -1.773 . . . . 10.0 106.213 167.889 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 N-CA-C 108.424 -0.954 . . . . 10.0 108.424 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.3 t -78.96 -14.58 59.13 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.436 0.695 . . . . 10.0 110.662 -178.149 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.0 ttmt -134.32 149.22 50.86 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 125.023 1.329 . . . . 10.0 107.774 -179.716 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.64 151.63 47.39 Favored 'General case' 0 CA--C 1.512 -0.505 0 C-N-CA 123.32 0.648 . . . . 10.0 109.382 169.48 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -106.62 154.63 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.223 0 O-C-N 124.741 1.276 . . . . 10.0 111.813 -172.576 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . 0.455 ' HB1' HD21 ' B' ' 8' ' ' LEU . . . -144.8 93.79 2.46 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 123.217 0.323 . . . . 10.0 111.449 169.28 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.3 m -81.65 103.54 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.365 0 N-CA-C 109.328 -0.619 . . . . 10.0 109.328 169.17 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.455 HD21 ' HB1' ' B' ' 6' ' ' ALA . 10.9 mt -97.36 127.37 43.26 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.336 1.054 . . . . 10.0 109.029 -177.796 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.3 mtpt -146.86 161.64 40.29 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 120.367 1.439 . . . . 10.0 108.66 173.76 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.31 -55.37 0.06 OUTLIER Glycine 0 N--CA 1.461 0.325 0 CA-C-N 115.798 -0.637 . . . . 10.0 113.318 168.63 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -72.63 -43.78 62.8 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 -176.477 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.12 -70.61 0.42 Allowed Glycine 0 CA--C 1.524 0.613 0 CA-C-N 114.334 -1.303 . . . . 10.0 109.923 170.075 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -58.27 -33.86 98.04 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.427 2.751 . . . . 10.0 111.291 172.044 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.9 t -65.01 100.62 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.637 -1.245 . . . . 10.0 107.637 176.179 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -124.55 108.29 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.606 1.562 . . . . 10.0 108.117 177.978 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.02 143.46 16.49 Favored Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 167.934 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.408 ' CG2' HG22 ' A' ' 54' ' ' THR . 2.4 mt -141.62 67.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.651 -1.611 . . . . 10.0 106.651 -179.797 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.06 148.96 4.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.476 0.655 . . . . 10.0 110.852 -174.926 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -123.53 119.31 29.56 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 125.703 1.601 . . . . 10.0 109.263 169.834 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -94.73 124.6 38.86 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 116.712 -1.614 . . . . 10.0 106.653 168.332 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -112.52 136.54 51.91 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 119.592 1.087 . . . . 10.0 111.184 165.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -89.27 112.71 23.84 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.025 -2.213 . . . . 10.0 105.025 168.471 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.9 mmpt? . . . . . 0 CA--C 1.513 -0.45 0 C-N-CA 125.649 1.58 . . . . 10.0 110.075 -171.554 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.046 0 N-CA-C 109.361 -1.496 . . . . 10.0 109.361 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -59.17 145.54 97.41 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.263 1.976 . . . . 10.0 109.132 175.731 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.7 t -87.76 114.55 26.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 105.22 -2.141 . . . . 10.0 105.22 174.811 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 10.9 ttmm -89.21 119.75 29.97 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 169.895 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -89.44 107.91 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 126.387 1.875 . . . . 10.0 106.397 169.593 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.0 p90 -126.3 164.63 20.61 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.886 0.851 . . . . 10.0 112.614 173.08 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.68 -152.93 24.43 Favored Glycine 0 N--CA 1.438 -1.208 0 N-CA-C 107.586 -2.205 . . . . 10.0 107.586 169.905 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 34.3 p -154.01 113.91 3.86 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 118.595 -0.717 . . . . 10.0 109.495 -169.956 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.615 ' CG1' ' HB3' ' B' ' 95' ' ' ALA . 2.8 pt -81.75 140.43 16.51 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 166.994 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -119.58 148.88 42.81 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 169.622 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.34 -5.85 41.76 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-O 119.365 -0.686 . . . . 10.0 113.652 174.965 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.34 176.8 2.12 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 118.584 1.192 . . . . 10.0 110.787 176.903 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -109.65 158.26 18.25 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 105.661 -1.977 . . . . 10.0 105.661 165.898 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -49.44 159.59 0.32 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.483 1.513 . . . . 10.0 112.487 -169.055 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.48 -172.94 35.04 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-O 121.786 0.659 . . . . 10.0 111.909 169.254 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -72.03 144.14 48.89 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.976 1.711 . . . . 10.0 110.207 -176.616 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -145.36 147.79 32.67 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.168 0.987 . . . . 10.0 113.036 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.639 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -20.37 117.73 0.01 OUTLIER Glycine 0 C--N 1.339 0.726 0 C-N-CA 129.36 3.362 . . . . 10.0 115.473 165.012 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -154.59 103.38 2.47 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.943 1.872 . . . . 10.0 111.541 170.736 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.446 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 2.2 m80 -133.6 -163.53 1.37 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 124.465 1.106 . . . . 10.0 111.188 179.415 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.2 p -116.66 -46.6 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 124.286 1.034 . . . . 10.0 112.045 -177.067 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 62.16 148.12 0.02 OUTLIER 'General case' 0 C--N 1.342 0.27 0 C-N-CA 125.589 1.556 . . . . 10.0 112.223 -171.595 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -75.31 -58.01 3.55 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 177.297 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -77.78 128.05 33.4 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 -172.797 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.91 -1.61 87.57 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.257 -1.537 . . . . 10.0 109.257 165.781 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -41.06 140.21 0.8 Allowed 'General case' 0 C--N 1.346 0.425 0 CA-C-N 117.982 0.891 . . . . 10.0 110.887 173.121 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.47 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -150.18 18.83 0.86 Allowed 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.512 -1.222 . . . . 10.0 111.328 167.455 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.624 HG23 HG22 ' A' ' 17' ' ' ILE . 0.7 OUTLIER -54.89 -35.97 64.68 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 118.903 0.774 . . . . 10.0 109.305 177.893 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.74 -21.45 44.48 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.347 1.459 . . . . 10.0 113.407 177.069 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.58 91.18 0.71 Allowed Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.444 -0.662 . . . . 10.0 111.444 -176.818 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 32.0 m 44.61 38.67 2.84 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.156 1.782 . . . . 10.0 112.625 176.414 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.2 m -133.33 -49.7 0.85 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.702 0.801 . . . . 10.0 109.25 -168.964 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -106.04 20.12 19.46 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.553 0.741 . . . . 10.0 110.265 -177.133 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.96 47.79 0.45 Allowed 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 124.438 1.095 . . . . 10.0 111.011 175.974 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.22 101.41 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 126.043 1.782 . . . . 10.0 113.683 168.455 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -68.15 72.7 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 123.635 2.89 . . . . 10.0 112.833 178.629 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.446 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 15.9 m170 58.55 45.69 15.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.237 3.415 . . . . 10.0 110.943 173.298 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -69.33 64.69 0.16 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 126.146 1.778 . . . . 10.0 111.692 177.919 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -82.9 154.22 67.56 Favored Pre-proline 0 C--N 1.32 -0.69 0 C-N-CA 126.067 1.747 . . . . 10.0 109.796 179.557 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.13 -52.03 0.54 Allowed 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.574 2.182 . . . . 10.0 111.447 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.2 mt -78.68 49.58 0.9 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.94 0.896 . . . . 10.0 110.584 -176.652 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.7 124.94 23.23 Favored 'General case' 0 N--CA 1.451 -0.4 0 O-C-N 122.024 -0.422 . . . . 10.0 111.096 -168.53 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.81 -75.22 0.32 Allowed 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 107.1 -1.444 . . . . 10.0 107.1 -172.503 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.7 mttt -149.26 164.77 33.89 Favored 'General case' 0 N--CA 1.422 -1.853 0 CA-C-N 114.871 -1.059 . . . . 10.0 108.583 169.317 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 76.3 t60 -71.6 126.82 30.68 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 105.165 -2.161 . . . . 10.0 105.165 162.873 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.05 -138.36 3.65 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 108.86 -1.696 . . . . 10.0 108.86 173.634 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.62 -160.87 25.98 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 107.884 -2.086 . . . . 10.0 107.884 173.414 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.51 1.36 2.66 Favored 'Trans proline' 0 CA--C 1.541 0.839 0 CA-C-N 119.819 1.81 . . . . 10.0 110.644 167.372 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -108.35 10.19 27.63 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 125.857 1.663 . . . . 10.0 109.8 173.905 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -135.47 161.44 35.47 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 165.571 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -77.59 -37.86 49.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 105.242 -2.133 . . . . 10.0 105.242 167.328 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -97.15 58.1 1.52 Allowed 'General case' 0 N--CA 1.446 -0.646 0 CA-C-O 121.718 0.77 . . . . 10.0 109.323 -169.614 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -70.37 154.01 42.37 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.521 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -67.66 -65.95 0.62 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.989 0.813 . . . . 10.0 109.39 177.831 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.751 HG13 ' H ' ' B' ' 82' ' ' GLY . 7.5 p -161.67 -90.46 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 170.664 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.751 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -84.12 69.31 3.36 Favored Glycine 0 CA--C 1.525 0.693 0 O-C-N 120.374 -1.454 . . . . 10.0 109.486 176.071 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -104.39 94.42 5.33 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 104.013 -2.588 . . . . 10.0 104.013 167.32 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -70.73 -34.1 71.55 Favored 'General case' 0 C--O 1.227 -0.114 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 -176.336 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 117.68 -85.96 0.4 Allowed Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 110.175 -1.17 . . . . 10.0 110.175 167.021 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -142.37 141.26 32.28 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.53 -0.915 . . . . 10.0 108.53 -177.627 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.3 m -114.63 135.65 53.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 166.891 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -104.23 117.97 35.5 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.75 0.82 . . . . 10.0 109.465 -171.666 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.26 134.54 34.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.08 -0.388 . . . . 10.0 110.327 -178.166 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -60.9 168.97 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.529 1.132 . . . . 10.0 109.579 167.695 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.9 -29.14 40.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.633 -0.712 . . . . 10.0 111.298 173.485 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -78.41 -9.26 59.22 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.003 0.521 . . . . 10.0 111.291 -178.704 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 10.06 73.74 Favored Glycine 0 C--N 1.341 0.807 0 O-C-N 121.099 -1.001 . . . . 10.0 111.101 -177.148 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.7 t -87.21 106.71 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 C-N-CA 126.273 1.829 . . . . 10.0 106.743 176.049 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.615 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -104.82 119.57 39.32 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.476 -0.935 . . . . 10.0 108.476 169.653 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -79.53 135.4 36.61 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.081 1.752 . . . . 10.0 108.454 175.088 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.52 132.53 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.454 1.502 . . . . 10.0 106.975 177.907 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 23.4 p -158.78 55.4 0.43 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.752 0.821 . . . . 10.0 111.79 168.821 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.0 mp -92.81 145.0 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 108.662 -0.866 . . . . 10.0 108.662 -174.536 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -101.67 126.33 48.5 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 126.814 2.046 . . . . 10.0 108.543 174.359 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -117.45 155.04 30.36 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.541 -0.911 . . . . 10.0 108.541 168.157 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.4 p -130.42 27.42 5.03 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 125.453 1.501 . . . . 10.0 111.989 -177.4 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.71 -40.54 1.32 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.894 0.77 . . . . 10.0 111.021 169.788 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.449 HD13 ' C ' ' B' ' 104' ' ' ILE 0.481 0.0 OUTLIER -69.38 158.07 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 119.895 1.225 . . . . 10.0 112.47 174.592 . . . . . . . . 4 4 . 1 . 027 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 40.5 m -153.95 121.69 5.93 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 120.937 -1.102 . . . . 10.0 109.805 -179.235 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.1 mt -68.2 -30.74 69.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.698 1.199 . . . . 10.0 110.598 -175.536 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 68.6 m . . . . . 0 N--CA 1.45 -0.458 0 N-CA-C 108.187 -1.042 . . . . 10.0 108.187 169.462 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.6 t . . . . . 0 N--CA 1.448 -0.547 0 CA-C-O 120.775 0.321 . . . . 10.0 111.022 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -69.77 37.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 C-N-CA 126.302 1.841 . . . . 10.0 111.844 -177.598 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 1.1 mp -56.07 -45.63 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 O-C-N 119.157 -2.214 . . . . 10.0 112.096 177.481 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.79 50.92 3.03 Favored Glycine 0 CA--C 1.534 1.251 0 CA-C-N 119.932 1.242 . . . . 10.0 114.244 -175.416 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -84.56 176.6 8.51 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 127.327 2.251 . . . . 10.0 109.784 170.123 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -135.85 99.19 4.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.35 -0.982 . . . . 10.0 108.35 169.114 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.74 129.65 42.04 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 105.565 -2.013 . . . . 10.0 105.565 167.625 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.16 129.4 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.24 -2.133 . . . . 10.0 105.24 169.168 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.507 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.3 OUTLIER -100.71 106.05 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.942 0 N-CA-C 104.868 -2.271 . . . . 10.0 104.868 170.997 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.639 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 12.0 m-70 -87.72 160.08 18.23 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 122.822 1.296 . . . . 10.0 114.258 -169.818 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . 0.664 ' HA ' HD22 ' B' ' 144' ' ' LEU . 52.0 tt0 -50.79 -56.55 11.58 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.839 2.056 . . . . 10.0 109.034 176.917 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -107.64 168.06 9.52 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.863 0.69 . . . . 10.0 112.863 -169.654 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.26 151.57 43.3 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 113.777 -1.556 . . . . 10.0 107.575 169.125 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.484 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 31.2 m-20 -100.94 132.36 46.38 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.235 -1.024 . . . . 10.0 108.235 -179.602 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -76.39 -12.68 60.1 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 124.857 1.263 . . . . 10.0 111.05 -176.796 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 15.4 mt 59.31 49.36 9.04 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 122.211 1.005 . . . . 10.0 109.04 177.39 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.4 -44.1 2.47 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 125.611 1.576 . . . . 10.0 110.445 174.645 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.7 mtmm -79.47 42.16 0.5 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.716 1.607 . . . . 10.0 112.518 -168.842 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.7 -17.77 27.36 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.281 2.372 . . . . 10.0 111.103 169.765 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.24 42.25 88.03 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.961 0.791 . . . . 10.0 111.777 178.861 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -145.94 166.38 26.2 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 169.929 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -52.23 -48.5 65.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 120.978 0.418 . . . . 10.0 110.143 -177.17 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -64.87 -30.45 71.45 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 119.225 -0.417 . . . . 10.0 110.427 -179.591 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 p -56.04 -35.33 66.77 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 120.146 1.339 . . . . 10.0 112.308 171.544 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -101.72 -14.73 17.23 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 118.294 0.497 . . . . 10.0 111.169 -170.515 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 53.9 mttt -88.0 -47.57 8.43 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 125.923 1.689 . . . . 10.0 111.256 173.715 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.404 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 44.7 p -134.09 -11.71 2.55 Favored 'General case' 0 CA--C 1.533 0.308 0 N-CA-C 115.057 1.502 . . . . 10.0 115.057 177.323 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.38 24.77 11.85 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 119.404 1.002 . . . . 10.0 112.978 -171.722 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 61.89 25.06 15.01 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 119.698 1.749 . . . . 10.0 111.432 179.316 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.73 -14.21 41.74 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 126.54 1.936 . . . . 10.0 112.5 -173.064 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.38 -160.22 52.98 Favored Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 108.776 -1.73 . . . . 10.0 108.776 172.434 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -55.29 130.54 42.74 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 109.24 -0.652 . . . . 10.0 109.24 -171.155 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.77 71.65 0.06 Allowed 'General case' 0 CA--C 1.543 0.708 0 O-C-N 121.667 -0.646 . . . . 10.0 110.274 172.198 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.664 HD22 ' HA ' ' B' ' 121' ' ' GLU . 11.7 tp -45.08 -35.78 3.25 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 128.118 2.567 . . . . 10.0 114.585 -172.858 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.507 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -165.77 159.18 15.9 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.049 -1.093 . . . . 10.0 108.049 -179.361 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.4 p -163.61 169.8 18.09 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.663 -0.495 . . . . 10.0 109.663 -178.045 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.12 -178.79 16.76 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 109.63 -1.388 . . . . 10.0 109.63 178.595 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 91.5 t -123.73 126.46 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 104.224 -2.51 . . . . 10.0 104.224 170.609 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.3 mt -81.72 152.08 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 CA-C-N 118.198 0.454 . . . . 10.0 110.787 -171.179 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -151.76 157.58 27.3 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 125.547 1.546 . . . . 10.0 111.059 -169.4 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.9 mt -54.12 140.27 11.33 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 C-N-CA 125.436 1.494 . . . . 10.0 111.806 172.64 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.72 170.17 16.23 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 107.492 -1.299 . . . . 10.0 107.492 165.759 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 . . . . . 0 C--O 1.25 1.096 0 N-CA-C 107.537 -1.283 . . . . 10.0 107.537 167.616 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.81 0 CA-C-O 117.971 -1.014 . . . . 10.0 108.952 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 t -105.47 -21.54 13.19 Favored 'General case' 0 C--O 1.223 -0.342 0 O-C-N 123.807 0.692 . . . . 10.0 110.503 176.897 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.74 172.5 13.2 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-O 121.368 0.604 . . . . 10.0 111.04 169.203 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.99 168.55 24.84 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 172.732 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -132.64 164.07 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.318 1.047 . . . . 10.0 109.284 176.771 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.01 116.87 10.97 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 167.898 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -95.66 102.77 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 124.542 1.137 . . . . 10.0 109.137 170.349 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -92.45 134.98 34.44 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.062 0.945 . . . . 10.0 109.703 -179.884 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt -145.38 162.44 37.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 168.797 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.95 -60.18 0.04 OUTLIER Glycine 0 C--O 1.229 -0.178 0 CA-C-N 115.393 -0.821 . . . . 10.0 112.542 172.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.37 -43.91 59.69 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 106.443 -1.688 . . . . 10.0 106.443 -171.532 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.25 -66.06 0.56 Allowed Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 113.713 -1.585 . . . . 10.0 110.097 177.65 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -58.54 -38.75 88.28 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 122.481 2.12 . . . . 10.0 111.276 172.297 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.1 t -64.44 108.17 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.691 -1.225 . . . . 10.0 107.691 178.363 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -122.6 116.27 23.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 105.452 -2.055 . . . . 10.0 105.452 168.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.765 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -100.38 131.29 10.52 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 175.858 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.492 ' CG2' HG23 ' B' ' 54' ' ' THR . 11.5 mt -133.19 89.57 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 107.111 -1.441 . . . . 10.0 107.111 -171.157 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.6 mm -104.17 141.88 18.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 124.396 1.078 . . . . 10.0 109.826 -178.665 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -126.5 119.42 27.11 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.939 2.095 . . . . 10.0 108.636 171.408 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -101.16 120.69 40.59 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 107.321 -1.362 . . . . 10.0 107.321 176.771 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -113.55 143.49 44.46 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 119.379 0.99 . . . . 10.0 112.832 172.214 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -127.42 97.33 4.85 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 128.166 2.586 . . . . 10.0 107.92 169.656 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.0 pttt -58.52 -48.14 81.82 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.287 1.035 . . . . 10.0 111.946 -176.255 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.76 166.61 24.29 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 104.38 -2.452 . . . . 10.0 104.38 168.14 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -65.21 -19.5 66.0 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 122.356 0.262 . . . . 10.0 110.893 179.891 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -80.66 -24.12 39.17 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 123.096 0.558 . . . . 10.0 110.499 176.617 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.41 155.1 53.39 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.645 -0.582 . . . . 10.0 111.645 -175.885 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -71.06 147.77 55.23 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 N-CA-C 106.155 -2.286 . . . . 10.0 106.155 165.56 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 t -79.61 128.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.04 0 N-CA-C 106.626 -1.62 . . . . 10.0 106.626 174.32 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -109.0 125.08 51.68 Favored 'General case' 0 C--O 1.233 0.234 0 N-CA-C 106.504 -1.665 . . . . 10.0 106.504 171.911 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.0 m -111.44 105.95 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.63 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 -176.5 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.5 p90 -117.13 168.54 10.2 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.25 0.548 . . . . 10.0 111.06 176.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.5 175.9 41.57 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.188 -1.006 . . . . 10.0 111.585 176.002 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 2.6 p -147.46 95.8 2.59 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 107.949 -1.13 . . . . 10.0 107.949 -177.098 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.765 HG22 ' HA2' ' A' ' 16' ' ' GLY . 8.4 pt -77.42 174.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.03 170.917 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -156.01 155.77 33.28 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.8 -17.23 33.0 Favored Glycine 0 CA--C 1.523 0.566 0 CA-C-O 119.411 -0.661 . . . . 10.0 113.824 173.326 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.505 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.3 mp -72.73 179.85 3.43 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 118.395 1.097 . . . . 10.0 110.354 178.362 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -95.81 175.78 6.38 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.586 -0.894 . . . . 10.0 108.586 166.404 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -63.6 176.54 0.85 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 124.633 1.173 . . . . 10.0 111.604 -172.024 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.04 -173.8 43.38 Favored Glycine 0 C--O 1.225 -0.438 0 C-N-CA 124.005 0.812 . . . . 10.0 112.563 167.345 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -77.22 140.7 40.18 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.332 1.453 . . . . 10.0 109.476 177.452 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -133.03 140.66 47.84 Favored 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 124.264 1.026 . . . . 10.0 112.366 -176.742 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -43.72 125.65 5.41 Favored Glycine 0 C--N 1.344 1.026 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 166.177 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -145.52 109.73 4.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 119.042 1.421 . . . . 10.0 109.025 171.122 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.22 173.12 17.32 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 113.74 1.015 . . . . 10.0 113.74 -174.139 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 33.3 m -88.0 154.37 3.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 113.629 -1.623 . . . . 10.0 109.578 171.246 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 -139.35 75.7 1.53 Allowed 'General case' 0 C--O 1.222 -0.37 0 C-N-CA 123.217 0.607 . . . . 10.0 112.122 -174.513 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 64.3 tt0 51.71 -87.22 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 125.301 1.44 . . . . 10.0 113.989 169.501 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -90.62 -172.34 3.37 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.537 -0.912 . . . . 10.0 108.537 -179.935 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -136.76 22.93 3.27 Favored Glycine 0 N--CA 1.452 -0.297 0 O-C-N 121.521 -0.737 . . . . 10.0 111.82 174.425 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -82.34 160.06 22.93 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 107.626 -1.25 . . . . 10.0 107.626 168.583 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.18 28.9 0.58 Allowed 'General case' 0 N--CA 1.448 -0.572 0 O-C-N 121.578 -0.701 . . . . 10.0 112.446 178.454 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.467 HG22 HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -49.7 -40.38 40.04 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.344 1.458 . . . . 10.0 112.373 -175.173 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -81.66 -24.31 36.37 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 123.391 0.676 . . . . 10.0 112.432 177.656 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.1 115.74 1.24 Allowed Glycine 0 CA--C 1.53 0.999 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 -169.512 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 64.2 m 42.27 53.37 4.47 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 125.629 1.572 . . . . 10.0 113.169 175.062 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -158.11 -56.98 0.07 Allowed 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 177.056 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -53.15 -45.34 68.38 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 124.909 1.284 . . . . 10.0 111.002 -169.233 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -53.59 0.18 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 127.039 2.136 . . . . 10.0 113.681 169.993 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.08 160.5 11.61 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.121 -1.192 . . . . 10.0 110.121 -176.838 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -74.02 -162.3 0.14 Allowed 'Trans proline' 0 N--CA 1.448 -1.169 0 N-CA-C 105.651 -2.48 . . . . 10.0 105.651 165.837 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -80.17 48.99 1.05 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 119.613 -1.93 . . . . 10.0 110.827 -175.386 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-30 -77.65 56.55 1.48 Allowed 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.935 1.35 . . . . 10.0 112.11 -176.632 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.4 HD21 ' CD2' ' A' ' 80' ' ' HIS . 1.8 p30 -59.83 148.52 75.92 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.81 1.244 . . . . 10.0 108.501 167.057 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.67 -48.59 8.75 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.693 2.262 . . . . 10.0 112.022 -174.285 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.19 57.65 1.46 Allowed 'General case' 0 CA--C 1.534 0.335 0 O-C-N 121.595 -0.69 . . . . 10.0 110.717 174.162 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.3 p -55.66 107.66 0.36 Allowed 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.842 1.257 . . . . 10.0 109.844 -179.705 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -119.45 -91.11 0.56 Allowed 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 -178.321 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -143.65 150.89 39.41 Favored 'General case' 0 N--CA 1.437 -1.095 0 CA-C-O 121.927 0.87 . . . . 10.0 109.81 169.012 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.5 t60 -57.79 120.96 9.35 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.643 -1.243 . . . . 10.0 107.643 165.699 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.73 -141.81 3.92 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 108.692 -1.763 . . . . 10.0 108.692 -177.96 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.492 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -174.17 -158.98 19.71 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 109.337 -1.505 . . . . 10.0 109.337 169.697 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -69.36 25.5 0.16 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 119.844 1.822 . . . . 10.0 111.173 168.739 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.492 ' H ' ' C ' ' A' ' 73' ' ' GLY . 71.7 mttt -123.96 -12.89 7.45 Favored 'General case' 0 N--CA 1.438 -1.028 0 C-N-CA 126.379 1.872 . . . . 10.0 109.787 171.942 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -135.96 129.11 31.65 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 104.842 -2.281 . . . . 10.0 104.842 -172.352 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -75.57 -22.19 57.21 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.243 -1.021 . . . . 10.0 108.243 -174.277 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -83.21 4.97 24.53 Favored 'General case' 0 N--CA 1.433 -1.323 0 C-N-CA 125.935 1.694 . . . . 10.0 111.122 -179.756 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.29 158.53 0.03 OUTLIER 'General case' 0 C--N 1.349 0.567 0 C-N-CA 124.53 1.132 . . . . 10.0 112.161 172.844 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.4 ' CD2' HD21 ' A' ' 65' ' ' ASN . 32.3 m170 -69.65 -103.81 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.689 -0.632 . . . . 10.0 109.359 176.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 88.0 t -126.7 -90.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 104.522 -2.399 . . . . 10.0 104.522 169.385 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -79.08 62.61 3.98 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.689 -0.565 . . . . 10.0 111.689 178.745 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -97.26 94.84 7.33 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 104.368 -2.456 . . . . 10.0 104.368 166.954 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -72.68 -7.46 50.54 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 117.913 0.324 . . . . 10.0 111.033 -174.229 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.27 -103.22 2.96 Favored Glycine 0 N--CA 1.44 -1.046 0 N-CA-C 105.006 -3.237 . . . . 10.0 105.006 -170.084 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -146.47 159.74 43.01 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 107.609 -1.256 . . . . 10.0 107.609 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.33 128.05 74.71 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 123.096 0.558 . . . . 10.0 110.575 170.422 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 m -79.68 114.08 18.33 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.758 2.823 . . . . 10.0 110.563 -178.889 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.16 46.51 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.298 1.039 . . . . 10.0 110.857 177.985 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -61.18 170.03 1.85 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 125.495 1.518 . . . . 10.0 109.096 166.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.95 -30.0 44.91 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.803 0.841 . . . . 10.0 111.408 176.723 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.1 -3.0 43.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 124.298 1.039 . . . . 10.0 110.863 -178.221 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.41 1.28 89.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.518 -1.033 . . . . 10.0 110.518 -175.633 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 62.1 t -79.47 103.53 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.288 0 N-CA-C 106.965 -1.495 . . . . 10.0 106.965 -176.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.405 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -100.95 118.67 37.44 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.825 -0.806 . . . . 10.0 108.825 169.213 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.2 110.01 15.21 Favored 'General case' 0 N--CA 1.434 -1.25 0 C-N-CA 126.265 1.826 . . . . 10.0 108.84 170.736 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.9 t -97.79 132.87 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 106.656 -1.609 . . . . 10.0 106.656 177.183 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.0 m -158.69 76.93 0.75 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.98 1.312 . . . . 10.0 109.863 169.799 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.7 161.13 3.83 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 177.505 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -142.51 130.85 22.24 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.65 1.98 . . . . 10.0 107.786 176.994 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -144.95 163.6 33.67 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.295 1.038 . . . . 10.0 108.959 179.126 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.4 p -125.36 51.39 1.7 Allowed 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.897 1.279 . . . . 10.0 109.876 176.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -142.69 -46.02 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.761 0.824 . . . . 10.0 110.762 174.475 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -63.29 139.74 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 169.339 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.3 m -126.74 156.19 41.55 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.941 0.877 . . . . 10.0 110.108 172.173 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -82.47 -29.54 30.53 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.75 0.82 . . . . 10.0 109.492 172.401 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.7 m -156.93 168.82 26.33 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 -174.599 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.32 -92.92 0.58 Allowed Glycine 0 C--N 1.333 0.407 0 N-CA-C 108.471 -1.852 . . . . 10.0 108.471 179.117 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -134.39 -51.64 0.81 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 125.72 1.608 . . . . 10.0 108.403 177.584 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -81.7 38.42 0.51 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.605 0.762 . . . . 10.0 110.145 -175.03 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.4 t -74.32 112.96 11.0 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 126.127 1.771 . . . . 10.0 108.627 -176.109 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 16.6 pt -81.87 11.49 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 173.16 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 30.9 mm -61.09 137.59 23.18 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 120.112 1.324 . . . . 10.0 109.925 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.56 87.01 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.0 -1.444 . . . . 10.0 114.707 172.544 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 29.5 mmt180 -83.93 171.13 13.31 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 168.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -105.4 136.48 44.87 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 124.677 1.191 . . . . 10.0 110.351 171.681 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.408 ' CD2' HD11 ' A' ' 149' ' ' ILE . 3.9 mm? -96.29 143.08 27.69 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 167.209 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.408 HG22 ' SG ' ' A' ' 146' ' ' CYS . 91.9 t -132.03 137.67 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.875 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 176.864 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.5 p -108.5 142.08 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.592 0 C-N-CA 124.996 1.318 . . . . 10.0 108.698 170.368 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -119.99 171.1 8.68 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.963 0.905 . . . . 10.0 113.143 -171.71 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -74.28 -46.83 38.75 Favored 'General case' 0 C--O 1.223 -0.323 0 C-N-CA 123.932 0.893 . . . . 10.0 111.669 -176.596 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -109.81 170.76 7.86 Favored 'General case' 0 CA--C 1.522 -0.113 0 C-N-CA 123.702 0.801 . . . . 10.0 113.015 -171.763 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.44 145.68 39.12 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.951 1.3 . . . . 10.0 108.777 174.134 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.53 164.47 24.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 122.167 0.984 . . . . 10.0 112.753 -178.208 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 63.9 m-20 -77.5 -22.4 51.28 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 112.625 -2.079 . . . . 10.0 109.631 167.082 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 40.2 mt 50.2 46.5 24.76 Favored 'General case' 0 C--N 1.341 0.232 0 CA-C-O 122.631 1.205 . . . . 10.0 108.354 -167.574 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.17 -32.79 4.76 Favored Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.125 -1.398 . . . . 10.0 112.247 177.765 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 25.4 mtmm -79.57 37.79 0.35 Allowed 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.672 1.189 . . . . 10.0 113.205 -168.535 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.8 -14.41 37.22 Favored Glycine 0 CA--C 1.526 0.778 0 C-N-CA 127.185 2.326 . . . . 10.0 110.036 169.419 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.17 43.07 32.75 Favored Glycine 0 C--N 1.34 0.781 0 C-N-CA 124.516 1.055 . . . . 10.0 112.081 -177.88 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -142.26 167.2 22.68 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 118.926 1.363 . . . . 10.0 109.221 173.088 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.403 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 1.7 tm-20 -37.5 -54.82 1.12 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 126.392 1.877 . . . . 10.0 111.374 176.531 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -72.2 -39.08 68.84 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.087 0.555 . . . . 10.0 110.739 179.927 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.8 p -53.04 -45.5 68.04 Favored 'General case' 0 N--CA 1.446 -0.635 0 O-C-N 120.893 -1.129 . . . . 10.0 110.589 -178.711 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.1 t -79.69 -2.45 42.92 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 118.744 -0.646 . . . . 10.0 111.799 -173.815 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.403 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 94.7 mttt -112.21 -71.07 0.77 Allowed 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.035 1.734 . . . . 10.0 110.811 -178.296 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.1 p -121.17 14.21 11.32 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 120.729 1.604 . . . . 10.0 112.841 177.462 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.46 21.08 78.7 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-O 119.236 -0.758 . . . . 10.0 113.473 168.752 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 50.75 24.83 1.85 Allowed 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 118.21 1.005 . . . . 10.0 112.202 -174.663 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.21 -7.55 47.59 Favored 'General case' 0 C--O 1.223 -0.323 0 O-C-N 121.41 -0.806 . . . . 10.0 111.554 -176.829 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 129.57 170.12 12.68 Favored Glycine 0 C--N 1.332 0.324 0 N-CA-C 110.199 -1.16 . . . . 10.0 110.199 169.674 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -82.38 54.85 2.71 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 123.029 0.532 . . . . 10.0 112.082 -169.058 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 42.66 72.87 0.16 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.057 1.343 . . . . 10.0 111.709 173.902 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -63.9 -36.4 83.82 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 123.041 0.537 . . . . 10.0 111.39 -169.185 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.06 138.22 14.65 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.904 -0.776 . . . . 10.0 108.904 -170.622 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.408 ' SG ' HG22 ' A' ' 118' ' ' VAL . 58.9 m -133.75 147.36 51.3 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.315 1.046 . . . . 10.0 109.678 -168.373 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.16 168.57 23.32 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.542 -1.023 . . . . 10.0 110.542 177.033 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 65.1 t -118.55 137.82 51.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 106.384 -1.71 . . . . 10.0 106.384 178.42 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.408 HD11 ' CD2' ' A' ' 117' ' ' LEU . 80.7 mt -73.96 126.18 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 118.099 0.409 . . . . 10.0 110.923 -176.297 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.65 145.61 18.63 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.365 -1.094 . . . . 10.0 110.365 176.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 47.9 mt -68.44 152.77 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 CA-C-N 119.358 1.579 . . . . 10.0 110.41 178.044 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.7 162.82 32.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 107.661 -1.237 . . . . 10.0 107.661 166.936 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.5 tt0 . . . . . 0 C--O 1.251 1.147 0 N-CA-C 106.338 -1.727 . . . . 10.0 106.338 169.603 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . 0.418 ' N ' ' O ' ' B' ' 153' ' ' GLN . . . . . . . . 0 N--CA 1.469 0.507 0 N-CA-C 109.134 -0.691 . . . . 10.0 109.134 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.3 t -94.94 -32.18 13.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.978 1.311 . . . . 10.0 110.913 174.965 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.2 ttmp? -124.61 138.9 54.28 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 124.471 1.108 . . . . 10.0 110.231 -177.862 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.59 159.54 42.04 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.159 1.384 . . . . 10.0 108.101 170.236 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -136.02 164.4 32.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 119.012 0.824 . . . . 10.0 110.307 177.41 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.88 118.91 18.49 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 124.7 1.2 . . . . 10.0 109.118 168.199 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -89.05 89.65 3.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 108.387 -0.968 . . . . 10.0 108.387 168.911 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mp -79.67 120.76 24.43 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 118.544 -0.741 . . . . 10.0 109.688 -179.752 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 22.7 mtpt -140.5 160.41 40.05 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 119.133 0.879 . . . . 10.0 109.207 171.802 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.52 -60.71 0.05 OUTLIER Glycine 0 N--CA 1.46 0.276 0 CA-C-N 114.87 -1.059 . . . . 10.0 113.071 170.923 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -71.24 -44.0 66.17 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 -176.748 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.14 -69.17 0.43 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-N 114.234 -1.348 . . . . 10.0 110.575 169.771 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -60.14 -32.32 94.43 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 123.714 2.943 . . . . 10.0 111.735 173.019 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.7 t -67.62 92.53 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 107.145 -1.428 . . . . 10.0 107.145 177.902 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -120.11 105.65 11.21 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 125.22 1.408 . . . . 10.0 107.822 -178.24 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.677 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.68 139.72 14.65 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 110.364 -1.094 . . . . 10.0 110.364 169.718 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.467 HG22 HG22 ' A' ' 54' ' ' THR . 6.5 mt -138.15 58.5 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 N-CA-C 105.552 -2.018 . . . . 10.0 105.552 -173.403 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.422 HD11 HG23 ' B' ' 35' ' ' ILE . 30.2 mm -81.96 134.8 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 114.879 -1.055 . . . . 10.0 109.39 -169.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -112.35 116.48 30.41 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.195 1.798 . . . . 10.0 108.973 -177.517 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -103.19 113.79 27.55 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 125.963 1.705 . . . . 10.0 107.759 -176.107 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -114.36 135.86 53.62 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.053 0.941 . . . . 10.0 111.524 -177.992 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -115.77 104.6 11.82 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 104.985 -2.228 . . . . 10.0 104.985 167.784 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.235 0.306 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -169.683 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.853 0 CA-C-O 117.562 -1.688 . . . . 10.0 115.372 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -66.1 145.45 79.03 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 CA-C-N 119.841 1.82 . . . . 10.0 107.625 170.867 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.37 97.43 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 106.196 -1.779 . . . . 10.0 106.196 173.542 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -79.09 102.42 8.41 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.504 -2.036 . . . . 10.0 105.504 168.895 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.93 101.12 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 C-N-CA 125.928 1.691 . . . . 10.0 107.822 -177.477 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -113.37 168.02 10.08 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.535 0.683 . . . . 10.0 111.867 169.88 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.55 178.37 32.51 Favored Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.642 -0.983 . . . . 10.0 110.642 168.886 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.5 p -124.33 102.06 7.49 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 108.593 -0.891 . . . . 10.0 108.593 -173.182 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.677 HG22 ' HA2' ' B' ' 16' ' ' GLY . 3.6 pt -81.78 133.99 28.03 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 108.219 -1.03 . . . . 10.0 108.219 168.852 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.9 tptt -108.09 148.83 29.28 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 170.069 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.67 -6.94 35.96 Favored Glycine 0 C--N 1.337 0.586 0 CA-C-O 119.563 -0.576 . . . . 10.0 113.47 169.348 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -66.43 175.93 2.06 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 118.276 1.038 . . . . 10.0 110.518 176.029 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -108.66 164.6 12.23 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 105.289 -2.115 . . . . 10.0 105.289 165.557 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -53.78 161.23 1.18 Allowed 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 113.11 0.782 . . . . 10.0 113.11 -169.041 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.12 -179.19 51.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 124.318 0.961 . . . . 10.0 112.085 169.049 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 mt -57.04 146.35 27.58 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.076 1.75 . . . . 10.0 112.921 175.501 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.5 m-70 -149.33 144.73 26.63 Favored 'General case' 0 C--N 1.339 0.149 0 C-N-CA 124.423 1.089 . . . . 10.0 113.439 -179.835 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.661 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.08 122.64 0.04 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 127.621 2.534 . . . . 10.0 113.243 166.515 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -152.37 105.52 3.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 119.059 1.429 . . . . 10.0 111.818 169.425 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.17 171.67 17.01 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 112.801 0.667 . . . . 10.0 112.801 -178.153 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.1 m -99.95 146.29 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 111.924 -2.398 . . . . 10.0 106.275 167.0 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -120.83 144.95 48.08 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 -179.437 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . 0.532 ' CG ' ' HA3' ' B' ' 61' ' ' GLY . 0.0 OUTLIER -6.73 -86.59 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.992 2.117 . . . . 10.0 116.593 170.978 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -102.14 171.86 7.24 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 119.737 1.153 . . . . 10.0 109.825 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.78 -25.71 52.28 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 117.63 -1.65 . . . . 10.0 111.234 174.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -40.16 113.04 0.32 Allowed 'General case' 0 C--N 1.342 0.278 0 CA-C-N 118.165 0.982 . . . . 10.0 111.448 178.064 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.33 20.85 12.96 Favored 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.748 -1.115 . . . . 10.0 109.972 167.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.492 HG23 ' CG2' ' A' ' 17' ' ' ILE . 4.2 m -55.44 -35.7 65.72 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 118.922 0.783 . . . . 10.0 110.49 -169.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.55 -21.35 45.27 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.803 1.241 . . . . 10.0 113.524 178.446 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.61 81.96 1.28 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 109.579 -1.408 . . . . 10.0 109.579 -174.056 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.327 25.7 p 18.73 55.51 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.914 2.086 . . . . 10.0 115.451 -167.88 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.6 m -112.87 -57.76 2.24 Favored 'General case' 0 N--CA 1.442 -0.848 0 N-CA-C 105.454 -2.054 . . . . 10.0 105.454 173.953 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.4 t -90.83 -4.0 56.95 Favored 'General case' 0 N--CA 1.443 -0.789 0 C-N-CA 124.724 1.21 . . . . 10.0 110.355 -178.323 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.38 41.51 0.14 Allowed 'General case' 0 C--N 1.341 0.239 0 C-N-CA 124.542 1.137 . . . . 10.0 112.787 -179.279 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . 0.532 ' HA3' ' CG ' ' B' ' 49' ' ' GLU . . . 88.35 125.93 2.47 Favored Glycine 0 N--CA 1.44 -1.077 0 N-CA-C 118.433 2.133 . . . . 10.0 118.433 162.168 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -81.5 55.85 5.73 Favored 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 121.646 1.564 . . . . 10.0 109.9 165.147 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.2 m170 66.17 -72.05 0.08 Allowed 'General case' 0 N--CA 1.461 0.099 0 C-N-CA 127.946 2.499 . . . . 10.0 111.034 -175.956 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 0.72 56.95 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 131.358 3.863 . . . . 10.0 116.076 -172.64 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -63.23 162.07 27.26 Favored Pre-proline 0 CA--C 1.538 0.487 0 CA-C-N 115.846 -0.616 . . . . 10.0 111.463 -172.499 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -53.7 -38.44 84.71 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 123.251 2.634 . . . . 10.0 112.985 179.531 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.45 -1.88 4.01 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 113.054 0.761 . . . . 10.0 113.054 176.596 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.3 p 22.34 89.83 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 129.436 3.094 . . . . 10.0 115.392 169.073 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -130.53 -168.92 2.05 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 179.461 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -103.98 128.91 51.53 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.216 -1.401 . . . . 10.0 107.216 177.047 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.411 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 78.3 t60 -42.88 109.27 0.13 Allowed 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 124.063 0.852 . . . . 10.0 112.061 -178.815 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.25 -155.84 9.5 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.1 -2.4 . . . . 10.0 107.1 169.667 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.24 -153.32 6.06 Favored Glycine 0 C--N 1.332 0.312 0 CA-C-N 118.371 1.085 . . . . 10.0 112.675 173.044 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -61.1 -9.47 12.46 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.241 1.961 . . . . 10.0 111.685 174.753 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -91.84 -18.65 23.51 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.609 1.164 . . . . 10.0 109.006 -179.101 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 20.8 m-20 -113.6 162.85 15.7 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 -169.308 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -92.07 -18.12 24.03 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.623 -1.171 . . . . 10.0 109.674 172.028 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -97.98 2.54 49.07 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 126.258 1.823 . . . . 10.0 112.49 -170.399 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -35.37 125.44 0.63 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.542 1.537 . . . . 10.0 109.447 169.037 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.411 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 18.5 m170 -47.05 -54.67 9.78 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.497 0.589 . . . . 10.0 112.242 -168.694 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -172.01 -40.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 C-N-CA 125.814 1.646 . . . . 10.0 108.404 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -149.27 68.67 0.34 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 109.395 -1.482 . . . . 10.0 109.395 174.413 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -97.05 103.59 15.54 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 105.099 -2.186 . . . . 10.0 105.099 168.65 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 28.1 mt -82.27 25.44 0.6 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 118.891 0.769 . . . . 10.0 111.433 -176.828 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 75.7 -113.13 3.81 Favored Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 174.43 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -158.6 128.78 5.95 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 -174.867 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 16.7 m -106.09 132.46 53.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 123.015 0.526 . . . . 10.0 110.422 -169.681 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 99.1 m -85.39 107.71 17.51 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 127.605 2.362 . . . . 10.0 110.308 -170.956 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.29 137.51 32.92 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 123.153 0.581 . . . . 10.0 110.338 171.981 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -65.9 172.02 3.96 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.818 1.247 . . . . 10.0 109.541 168.518 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.59 -28.41 63.6 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.117 0.484 . . . . 10.0 110.917 177.735 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -80.89 -0.5 39.39 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.899 0.88 . . . . 10.0 111.187 -178.255 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.34 80.35 Favored Glycine 0 C--N 1.339 0.737 0 O-C-N 120.74 -1.225 . . . . 10.0 110.808 176.942 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.7 t -91.62 108.71 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 C-N-CA 126.971 2.108 . . . . 10.0 105.642 174.816 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.567 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -106.76 118.61 37.13 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 119.189 0.904 . . . . 10.0 108.633 169.102 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -81.13 95.97 7.05 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 126.64 1.976 . . . . 10.0 108.285 172.586 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -78.77 131.92 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 105.626 -1.99 . . . . 10.0 105.626 170.916 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 6.7 p -157.8 60.03 0.48 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.814 0.845 . . . . 10.0 109.073 -179.629 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 30.1 mt -114.87 160.2 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.072 -1.455 . . . . 10.0 107.072 -169.743 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -138.77 135.74 34.97 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 109.725 -0.472 . . . . 10.0 109.725 168.846 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 16.6 t0 -117.2 101.62 8.6 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 -178.866 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 40.3 m -85.7 54.53 3.16 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 124.798 1.239 . . . . 10.0 108.471 -173.695 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 92.0 t -136.91 -54.33 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 -171.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.445 ' CD1' ' H ' ' B' ' 104' ' ' ILE 0.385 0.0 OUTLIER -88.19 175.37 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.384 0.674 . . . . 10.0 111.544 170.408 . . . . . . . . 4 4 . 1 . 028 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 56.0 m -157.83 97.2 1.54 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.418 -0.801 . . . . 10.0 109.882 -168.042 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.9 tp -37.88 -27.37 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 129.211 3.004 . . . . 10.0 116.37 -169.616 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 38.3 t . . . . . 0 N--CA 1.453 -0.296 0 C-N-CA 124.152 0.981 . . . . 10.0 109.743 176.544 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.8 t . . . . . 0 N--CA 1.442 -0.847 0 N-CA-C 110.318 -0.253 . . . . 10.0 110.318 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.2 pt 46.24 35.21 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.962 1.705 . . . . 10.0 113.774 177.87 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . 0.415 ' O ' ' HB ' ' B' ' 149' ' ' ILE . 11.5 mm -61.29 -71.19 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.452 0 C-N-CA 123.122 0.569 . . . . 10.0 110.012 -178.66 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.25 58.48 1.12 Allowed Glycine 0 CA--C 1.54 1.645 0 O-C-N 120.814 -1.179 . . . . 10.0 115.042 -177.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 30.7 mmt180 -103.77 161.47 13.9 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 127.161 2.185 . . . . 10.0 105.706 167.494 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.99 128.22 42.69 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 104.269 -2.493 . . . . 10.0 104.269 171.442 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 11.1 mp -108.26 151.27 26.18 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 109.084 -0.71 . . . . 10.0 109.084 172.292 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.427 HG11 ' CG ' ' B' ' 143' ' ' ARG . 93.7 t -137.77 138.41 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.948 0 N-CA-C 108.412 -0.958 . . . . 10.0 108.412 -175.377 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.406 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.7 p -104.12 131.49 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 168.154 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.661 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.2 m170 -113.7 159.8 19.31 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 116.433 2.012 . . . . 10.0 116.433 -170.692 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -43.79 -57.12 3.41 Favored 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 129.26 3.024 . . . . 10.0 112.133 176.09 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 75.0 mttt -118.67 171.31 8.28 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 124.198 0.999 . . . . 10.0 112.937 -168.581 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -80.24 138.64 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.647 1.579 . . . . 10.0 109.91 177.815 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.08 152.11 33.09 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -172.525 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -76.81 -30.16 56.29 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.624 1.97 . . . . 10.0 109.968 169.579 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 26.9 mt 54.4 49.88 17.43 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 124.115 0.966 . . . . 10.0 109.979 -172.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.06 -43.36 3.11 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.033 -0.827 . . . . 10.0 111.033 176.062 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 28.2 mtmm -76.64 30.3 0.13 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.617 1.967 . . . . 10.0 112.236 -172.142 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.54 -33.04 7.74 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 128.32 2.867 . . . . 10.0 109.474 168.647 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.34 21.68 77.42 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.001 -0.889 . . . . 10.0 112.104 -177.224 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -107.48 161.65 14.64 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 168.966 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 8.0 tm-20 -50.81 -51.67 48.63 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 114.957 -1.019 . . . . 10.0 108.279 172.448 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . 0.414 ' OE1' ' NZ ' ' B' ' 136' ' ' LYS . 7.2 tp10 -57.7 -40.51 79.65 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.812 0.671 . . . . 10.0 112.812 178.043 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -48.92 -50.09 36.97 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 119.9 1.227 . . . . 10.0 110.555 171.488 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -80.18 -19.63 46.63 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 112.983 0.734 . . . . 10.0 112.983 -174.23 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE1' ' B' ' 133' ' ' GLU . 2.5 ttmt -96.74 -42.76 7.84 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 124.957 1.303 . . . . 10.0 112.512 -173.403 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 60.7 p -135.14 -7.53 2.31 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 176.716 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.03 13.39 71.84 Favored Glycine 0 C--O 1.221 -0.662 0 CA-C-O 118.188 -1.34 . . . . 10.0 111.813 -170.039 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 64.81 19.54 11.87 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 120.18 1.99 . . . . 10.0 112.41 170.092 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.65 7.57 6.67 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.742 0.817 . . . . 10.0 112.525 -169.834 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.52 -166.81 52.69 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.453 -0.78 . . . . 10.0 111.262 173.075 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 50.2 m -60.36 141.79 55.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 113.522 0.934 . . . . 10.0 113.522 -168.505 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . 0.427 ' CG ' HG11 ' B' ' 118' ' ' VAL . 0.1 OUTLIER -60.38 97.19 0.05 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.85 1.66 . . . . 10.0 109.454 168.734 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 27.1 mt -72.64 -34.66 67.45 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 119.284 0.947 . . . . 10.0 111.989 178.51 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.406 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -152.15 149.05 28.35 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.887 -0.508 . . . . 10.0 110.476 176.257 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.74 142.14 46.41 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 126.991 2.116 . . . . 10.0 107.654 -176.439 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -140.88 160.96 26.74 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 109.176 -1.57 . . . . 10.0 109.176 168.944 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 51.8 t -119.23 131.45 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 104.52 -2.4 . . . . 10.0 104.52 174.181 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.415 ' HB ' ' O ' ' B' ' 113' ' ' ILE . 20.3 mt -73.35 146.81 10.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-N 119.332 0.969 . . . . 10.0 109.288 174.77 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.71 150.35 22.5 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 125.858 1.694 . . . . 10.0 109.053 179.603 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.0 pt -72.47 132.21 33.7 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.359 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 -176.11 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.68 -42.6 7.16 Favored 'General case' 0 CA--C 1.512 -0.519 0 C-N-CA 123.9 0.88 . . . . 10.0 109.932 173.281 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . 0.418 ' O ' ' N ' ' B' ' 1' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.433 -1.299 0 N-CA-C 105.17 -2.159 . . . . 10.0 105.17 176.327 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.881 0 N-CA-C 107.894 -1.15 . . . . 10.0 107.894 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.1 t -86.47 -16.47 36.97 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 166.625 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 47.5 tttt -131.88 164.54 25.86 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 125.603 1.561 . . . . 10.0 108.244 177.239 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -158.03 171.97 19.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 126.018 1.727 . . . . 10.0 106.689 168.537 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -133.05 173.93 14.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 107.702 -1.221 . . . . 10.0 107.702 171.246 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.46 113.24 6.05 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.302 -1.37 . . . . 10.0 107.302 165.46 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 5.8 m -92.62 120.32 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.623 -1.251 . . . . 10.0 107.623 168.141 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -100.13 131.7 45.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.861 -1.533 . . . . 10.0 106.861 179.289 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -141.78 158.73 43.45 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 106.325 -1.731 . . . . 10.0 106.325 167.766 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.25 -64.04 0.04 OUTLIER Glycine 0 N--CA 1.461 0.326 0 C-N-CA 119.393 -1.384 . . . . 10.0 113.685 168.772 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -72.7 -41.44 65.28 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.411 -1.329 . . . . 10.0 107.411 -172.927 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.03 -67.72 0.42 Allowed Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 114.173 -1.376 . . . . 10.0 111.667 169.443 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -57.8 -39.57 86.07 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.581 2.187 . . . . 10.0 111.367 179.002 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.18 118.88 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 107.902 -1.147 . . . . 10.0 107.902 179.645 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.63 104.09 8.49 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 103.548 -2.76 . . . . 10.0 103.548 168.702 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.72 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -86.23 142.27 18.82 Favored Glycine 0 N--CA 1.44 -1.086 0 N-CA-C 108.281 -1.928 . . . . 10.0 108.281 177.014 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.719 ' CG2' HG23 ' B' ' 54' ' ' THR . 5.2 mt -140.73 92.52 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 -174.248 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.7 mm -102.1 139.36 23.39 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 C-N-CA 124.487 1.115 . . . . 10.0 110.2 174.04 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -112.37 118.89 36.46 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 127.452 2.301 . . . . 10.0 106.88 168.601 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.535 ' CD2' HG12 ' A' ' 31' ' ' VAL . 4.6 m-85 -99.89 115.42 29.58 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 105.832 -1.914 . . . . 10.0 105.832 175.377 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -116.81 127.25 54.14 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 119.032 0.833 . . . . 10.0 110.444 170.002 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -79.8 88.16 5.25 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 106.236 -1.764 . . . . 10.0 106.236 174.562 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.23 -40.55 16.63 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 126.729 2.012 . . . . 10.0 112.099 -167.612 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -130.4 162.36 29.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 101.576 -3.49 . . . . 10.0 101.576 162.766 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.7 t -55.7 -33.36 64.11 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.738 -0.838 . . . . 10.0 108.738 173.518 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 30.3 m-80 -99.39 -2.15 36.93 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 125.749 1.62 . . . . 10.0 110.948 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.25 164.73 24.78 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.762 -0.935 . . . . 10.0 110.762 -170.804 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -61.95 149.57 89.74 Favored 'Trans proline' 0 N--CA 1.449 -1.125 0 C-N-CA 121.563 1.509 . . . . 10.0 108.29 169.477 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.0 t -86.11 122.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 -179.403 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.3 tttt -90.28 113.99 25.94 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 108.205 -1.035 . . . . 10.0 108.205 177.566 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.535 HG12 ' CD2' ' A' ' 20' ' ' PHE . 35.7 m -98.34 58.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 125.725 1.61 . . . . 10.0 108.395 -172.486 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.5 p90 -77.27 158.32 30.29 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 119.915 -0.714 . . . . 10.0 110.011 -175.281 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.02 179.9 48.21 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.968 179.145 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 20.4 m -150.41 96.39 2.39 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.503 -1.295 . . . . 10.0 107.503 -178.729 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.72 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.9 pt -77.65 154.76 5.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 170.908 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -138.82 146.97 41.93 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.266 -1.383 . . . . 10.0 107.266 169.317 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.09 -2.29 38.01 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.46 170.642 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.475 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.7 mp -72.31 178.83 3.7 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 119.398 1.599 . . . . 10.0 108.802 169.531 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 11.2 t -88.37 176.48 7.18 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 166.717 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 49.4 tt0 -64.02 169.69 4.15 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.04 0.936 . . . . 10.0 112.111 -172.311 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.12 -176.51 48.79 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 124.085 0.85 . . . . 10.0 113.079 167.15 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -62.42 150.85 38.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 123.815 0.846 . . . . 10.0 109.696 174.13 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -142.66 153.4 43.38 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 113.895 1.072 . . . . 10.0 113.895 176.614 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.6 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -39.54 125.02 2.1 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 127.542 2.496 . . . . 10.0 110.459 163.049 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.444 ' CD2' HG12 ' A' ' 119' ' ' VAL . 0.8 OUTLIER -149.73 105.85 3.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 119.823 1.811 . . . . 10.0 108.094 165.724 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -153.04 -179.99 8.18 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-O 121.844 0.83 . . . . 10.0 113.173 179.558 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.597 HG12 HD22 ' A' ' 117' ' ' LEU . 4.0 m -102.85 151.51 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 CA-C-N 113.219 -1.81 . . . . 10.0 110.345 174.116 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.85 133.4 45.89 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.276 1.83 . . . . 10.0 106.433 178.015 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.8 tp10 -62.41 -55.8 24.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 114.428 1.27 . . . . 10.0 114.428 -165.527 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 59.2 m-85 -77.66 144.94 36.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 117.612 -1.635 . . . . 10.0 108.243 179.652 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.38 20.8 48.35 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 172.684 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -80.67 70.73 7.47 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 125.765 2.698 . . . . 10.0 109.045 179.649 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.599 ' HB3' HG21 ' B' ' 7' ' ' VAL . 1.6 t-20 -69.33 -13.5 62.41 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 111.242 -2.708 . . . . 10.0 111.852 -174.056 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.54 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -27.69 -52.99 0.08 Allowed 'General case' 0 C--N 1.341 0.201 1 C-N-CA 131.92 4.088 . . . . 10.0 114.283 -175.799 . . . . . . . . 4 4 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.53 -14.77 59.58 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 124.068 0.947 . . . . 10.0 112.657 -172.518 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 107.1 52.96 0.71 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.925 -2.07 . . . . 10.0 107.925 -168.257 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 46.89 50.91 13.21 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.768 1.396 . . . . 10.0 114.768 169.784 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.2 p -111.79 -57.84 2.2 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 106.347 -1.723 . . . . 10.0 106.347 171.561 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.7 m -47.63 -33.19 6.41 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 127.167 2.187 . . . . 10.0 111.459 177.413 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -28.07 -39.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 128.666 2.786 . . . . 10.0 113.796 168.255 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.72 159.86 23.79 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 108.67 -1.772 . . . . 10.0 108.67 169.346 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -70.71 -170.25 0.44 Allowed 'Trans proline' 0 N--CA 1.445 -1.354 0 N-CA-C 107.585 -1.736 . . . . 10.0 107.585 167.5 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 36.9 m170 -78.89 55.93 1.83 Allowed 'General case' 0 CA--C 1.545 0.777 0 O-C-N 120.622 -1.299 . . . . 10.0 111.636 -170.121 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -74.88 64.47 1.29 Allowed 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 119.86 1.209 . . . . 10.0 112.275 -175.512 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.7 p-10 -57.6 155.37 21.1 Favored Pre-proline 0 CA--C 1.538 0.491 0 C-N-CA 123.283 0.633 . . . . 10.0 111.164 169.904 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -59.05 -45.8 26.05 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.534 2.156 . . . . 10.0 111.425 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -75.88 64.91 1.9 Allowed 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.116 -0.698 . . . . 10.0 109.116 174.725 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.9 p -42.04 113.76 0.47 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.685 1.194 . . . . 10.0 109.564 179.397 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.4 mtt-85 -145.97 -177.49 5.62 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 105.16 -2.163 . . . . 10.0 105.16 -169.88 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.4 mmtp -75.0 154.34 38.12 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 118.099 -1.44 . . . . 10.0 109.127 176.069 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -69.92 105.39 2.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 162.401 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.64 -140.65 6.85 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 107.909 -2.076 . . . . 10.0 107.909 173.822 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.7 -155.43 15.23 Favored Glycine 0 C--O 1.227 -0.309 0 CA-C-O 117.521 -1.711 . . . . 10.0 109.293 169.614 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -67.32 13.95 0.15 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 CA-C-N 120.378 2.089 . . . . 10.0 111.829 170.335 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 51.1 mttm -121.2 3.15 10.39 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-O 117.948 -1.025 . . . . 10.0 111.634 170.828 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -127.21 159.09 35.36 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 170.908 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -79.4 -32.52 42.97 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.639 -1.615 . . . . 10.0 106.639 167.017 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -82.89 28.48 0.49 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 124.58 1.152 . . . . 10.0 112.274 -168.643 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 164.08 11.97 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 119.839 1.199 . . . . 10.0 109.753 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -78.54 -67.58 0.73 Allowed 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.733 -0.604 . . . . 10.0 109.515 178.662 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -158.72 -116.35 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.827 -1.546 . . . . 10.0 106.827 -174.207 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -78.34 54.7 3.99 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-N 119.704 1.138 . . . . 10.0 111.012 178.749 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -79.46 92.3 5.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.735 -1.95 . . . . 10.0 105.735 170.014 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 29.1 mt -71.46 -21.7 61.92 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 118.755 -1.178 . . . . 10.0 108.204 175.325 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 83.13 -73.37 2.69 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.754 -1.338 . . . . 10.0 109.754 168.72 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -139.96 103.09 4.55 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 108.802 -0.814 . . . . 10.0 108.802 -169.412 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 23.9 m -109.09 129.53 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 119.068 0.849 . . . . 10.0 111.435 176.12 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -79.25 110.18 14.28 Favored 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 127.724 2.41 . . . . 10.0 112.371 -170.45 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.81 132.6 39.42 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 122.702 0.401 . . . . 10.0 110.154 169.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -53.5 166.98 0.24 Allowed 'General case' 0 CA--C 1.518 -0.258 0 O-C-N 124.093 0.871 . . . . 10.0 109.198 166.144 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -41.56 -43.19 2.64 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 126.324 1.85 . . . . 10.0 110.419 169.343 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.78 0.48 39.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.351 1.46 . . . . 10.0 110.948 -170.913 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.99 2.91 85.83 Favored Glycine 0 C--N 1.339 0.717 0 N-CA-C 111.408 -0.677 . . . . 10.0 111.408 178.116 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 33.1 t -78.97 106.5 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.376 -1.712 . . . . 10.0 106.376 -178.38 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.593 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -115.23 118.41 33.21 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 118.645 0.657 . . . . 10.0 109.638 176.541 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -79.73 126.68 31.26 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.526 1.93 . . . . 10.0 109.068 174.403 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -118.98 134.01 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.955 0 N-CA-C 107.319 -1.363 . . . . 10.0 107.319 175.548 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.8 p -156.62 59.75 0.55 Allowed 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 118.461 0.573 . . . . 10.0 110.872 174.457 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.11 153.48 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 -178.232 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -123.86 131.68 53.62 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 123.936 0.894 . . . . 10.0 108.908 169.398 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -120.57 147.95 44.51 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-O 121.639 0.733 . . . . 10.0 109.042 179.618 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.8 p -105.4 7.24 33.14 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.394 2.678 . . . . 10.0 111.865 -173.31 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.2 p -122.89 9.42 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.35 0.977 . . . . 10.0 110.763 179.525 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -108.45 150.03 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 105.944 -1.873 . . . . 10.0 105.944 176.773 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.7 m -146.29 152.69 39.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 169.939 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 55.4 mt -103.56 0.2 30.58 Favored 'General case' 0 C--O 1.237 0.437 0 C-N-CA 123.751 0.82 . . . . 10.0 111.66 -175.538 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.4 t -162.03 -172.38 3.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 126.472 1.909 . . . . 10.0 107.439 166.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 105.85 -69.87 0.23 Allowed Glycine 0 C--O 1.227 -0.336 0 C-N-CA 125.291 1.424 . . . . 10.0 110.307 167.302 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -162.69 -50.15 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 124.873 1.269 . . . . 10.0 107.611 -179.922 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -80.32 41.96 0.56 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.176 0.99 . . . . 10.0 109.034 179.449 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.5 t -81.4 83.8 6.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 126.076 1.75 . . . . 10.0 106.758 -171.773 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 20.8 pt -55.63 -21.61 10.42 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 113.649 0.981 . . . . 10.0 113.649 -170.172 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.417 ' CD1' ' H ' ' A' ' 113' ' ' ILE . 1.6 mp -14.04 -56.5 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 129.369 3.067 . . . . 10.0 115.139 174.866 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -87.7 6.6 83.19 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.208 -1.329 . . . . 10.0 114.812 -170.468 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.6 mpt_? -77.45 175.78 9.49 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.887 1.344 . . . . 10.0 108.751 174.014 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.41 ' C ' HD23 ' A' ' 117' ' ' LEU . 1.3 m -113.94 127.65 56.06 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.723 -1.584 . . . . 10.0 106.723 169.91 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.597 HD22 HG12 ' A' ' 47' ' ' VAL . 2.5 mt -102.86 152.73 20.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 118.754 0.707 . . . . 10.0 109.395 174.309 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.2 t -141.46 136.22 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 123.542 0.526 . . . . 10.0 110.178 -171.927 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.444 HG12 ' CD2' ' A' ' 45' ' ' PHE . 10.4 m -104.52 139.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 O-C-N 124.641 1.213 . . . . 10.0 109.201 164.13 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.6 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.5 m-70 -117.14 163.21 16.62 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 114.954 1.465 . . . . 10.0 114.954 -169.15 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -55.99 -54.66 42.19 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.693 -1.14 . . . . 10.0 110.103 178.032 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -111.31 173.4 6.36 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-O 121.305 0.574 . . . . 10.0 110.277 -178.231 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -96.19 136.82 36.15 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 125.24 1.416 . . . . 10.0 108.16 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.41 161.18 28.19 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 121.474 0.654 . . . . 10.0 111.943 -174.279 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -73.85 -15.5 61.16 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.763 -1.108 . . . . 10.0 110.809 -177.349 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mt 58.31 44.81 17.99 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.383 1.073 . . . . 10.0 108.292 -172.394 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.74 -15.65 59.45 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.96 1.267 . . . . 10.0 113.786 170.005 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -75.5 -4.46 39.89 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 114.838 1.421 . . . . 10.0 114.838 -166.548 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.51 -23.77 75.21 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-N 119.422 1.01 . . . . 10.0 110.65 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.34 18.74 50.95 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.812 -0.993 . . . . 10.0 114.429 179.267 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -116.92 176.66 5.02 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 119.474 1.637 . . . . 10.0 110.735 179.094 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -32.48 -61.76 0.25 Allowed 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 126.631 1.973 . . . . 10.0 112.186 171.396 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.88 -44.55 92.73 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.43 0.692 . . . . 10.0 111.529 178.536 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.8 m -49.24 -42.15 39.74 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 119.294 -0.384 . . . . 10.0 110.505 -176.06 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -87.18 -3.37 59.05 Favored 'General case' 0 N--CA 1.451 -0.386 0 O-C-N 124.32 1.013 . . . . 10.0 112.605 -172.464 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -114.53 -48.52 2.86 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.462 1.105 . . . . 10.0 111.521 -174.986 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 30.4 p -133.44 0.46 3.34 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 119.108 0.867 . . . . 10.0 112.286 171.658 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.75 -105.53 3.04 Favored Glycine 0 C--N 1.341 0.819 0 N-CA-C 107.289 -2.325 . . . . 10.0 107.289 -172.864 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.2 m-20 -167.52 43.44 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 125.298 1.439 . . . . 10.0 108.541 -179.477 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.43 -15.18 63.23 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.674 -0.641 . . . . 10.0 111.756 -177.636 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.17 -162.66 54.54 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 -176.742 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.1 m -62.25 149.52 41.67 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 113.736 1.013 . . . . 10.0 113.736 -170.043 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.2 74.59 0.69 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.161 2.584 . . . . 10.0 111.267 174.113 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.58 -27.32 67.62 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.187 -0.945 . . . . 10.0 113.361 -178.701 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.36 153.17 30.05 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 118.881 0.764 . . . . 10.0 110.392 171.737 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.0 p -155.52 155.64 33.77 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 123.081 0.552 . . . . 10.0 110.367 -168.482 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.92 162.64 30.56 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 124.054 0.835 . . . . 10.0 112.023 -174.727 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 62.1 t -122.64 66.85 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 105.263 -2.125 . . . . 10.0 105.263 -172.515 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.529 HD11 HD21 ' A' ' 117' ' ' LEU . 7.3 mm 30.44 -114.63 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 C-N-CA 127.1 2.16 . . . . 10.0 113.349 -173.737 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 126.61 102.5 1.25 Allowed Glycine 0 CA--C 1.531 1.045 0 N-CA-C 109.653 -1.379 . . . . 10.0 109.653 -169.536 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 56.3 mt -53.31 137.6 13.56 Favored 'Isoleucine or valine' 0 C--N 1.341 0.197 0 C-N-CA 124.151 0.98 . . . . 10.0 110.415 170.717 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.57 158.58 44.07 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 107.92 -1.141 . . . . 10.0 107.92 169.748 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.7 tt0 . . . . . 0 C--O 1.25 1.081 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 168.133 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.875 0 CA-C-O 118.538 -0.744 . . . . 10.0 109.62 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.7 t -90.57 -36.71 14.29 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.666 0.787 . . . . 10.0 110.705 169.951 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.3 tttp -127.44 124.15 37.77 Favored 'General case' 0 C--O 1.238 0.485 0 C-N-CA 125.798 1.639 . . . . 10.0 109.217 -171.814 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.11 155.92 49.89 Favored 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.741 0.816 . . . . 10.0 109.687 176.673 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.1 m -106.68 178.73 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 O-C-N 123.965 0.791 . . . . 10.0 109.94 176.944 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . 0.454 ' HB3' ' HB ' ' B' ' 18' ' ' ILE . . . -160.7 93.75 1.01 Allowed 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.35 1.46 . . . . 10.0 108.056 175.68 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.599 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.9 OUTLIER -92.41 95.09 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 C-N-CA 123.753 0.821 . . . . 10.0 110.722 179.453 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.401 HD22 HG23 ' B' ' 119' ' ' VAL . 1.6 mp -80.09 130.41 35.23 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 123.192 0.597 . . . . 10.0 109.41 175.938 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.34 158.99 44.44 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 106.211 -1.774 . . . . 10.0 106.211 168.938 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.48 -64.39 0.05 OUTLIER Glycine 0 CA--C 1.51 -0.231 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.967 169.311 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -70.34 -45.01 67.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 -178.831 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.11 -70.52 0.38 Allowed Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.425 -1.261 . . . . 10.0 110.784 169.571 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -57.12 -35.0 98.78 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 123.228 2.618 . . . . 10.0 111.821 175.81 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 37.4 t -68.63 89.24 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 C-N-CA 124.623 1.169 . . . . 10.0 107.986 179.033 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -113.12 116.22 29.51 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.109 -1.441 . . . . 10.0 107.109 -179.871 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.472 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -108.3 136.79 13.72 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.368 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.54 ' CG2' HG22 ' A' ' 54' ' ' THR . 7.8 mt -135.49 74.68 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 -175.286 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.454 ' HB ' ' HB3' ' B' ' 6' ' ' ALA . 28.7 mm -95.09 149.8 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 114.826 -1.079 . . . . 10.0 109.655 -172.347 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -126.37 114.6 18.43 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 126.775 2.03 . . . . 10.0 106.666 -170.57 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -102.36 115.54 30.78 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 106.229 -1.767 . . . . 10.0 106.229 176.559 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -119.24 137.51 53.61 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.085 0.772 . . . . 10.0 113.085 169.13 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -113.08 111.0 21.39 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 104.638 -2.356 . . . . 10.0 104.638 167.754 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? . . . . . 0 N--CA 1.445 -0.701 0 C-N-CA 125.554 1.542 . . . . 10.0 109.136 -176.117 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.891 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.02 163.16 39.67 Favored 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 123.051 2.501 . . . . 10.0 109.207 178.105 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -79.57 134.64 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 104.831 -2.285 . . . . 10.0 104.831 166.934 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 32.5 mttt -114.67 125.13 53.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 104.812 -2.292 . . . . 10.0 104.812 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -109.48 104.14 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 C-N-CA 126.404 1.882 . . . . 10.0 106.587 -178.072 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -126.16 159.46 32.88 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 112.728 0.64 . . . . 10.0 112.728 -178.029 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.99 -146.09 13.99 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 107.811 -2.116 . . . . 10.0 107.811 169.948 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 31.8 p -155.38 160.68 40.87 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 122.113 0.958 . . . . 10.0 112.044 175.033 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.75 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -110.92 145.42 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-N 113.25 -1.795 . . . . 10.0 107.509 166.871 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -125.15 142.97 51.17 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 107.167 -1.42 . . . . 10.0 107.167 168.834 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.22 0.57 20.69 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.082 0.849 . . . . 10.0 113.247 176.634 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.41 176.87 8.95 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 118.594 1.197 . . . . 10.0 110.321 -179.155 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -109.62 153.74 23.78 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.925 -1.88 . . . . 10.0 105.925 166.097 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.09 147.83 2.0 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.594 1.157 . . . . 10.0 112.315 -171.952 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.75 -173.22 18.25 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.05 0.833 . . . . 10.0 111.795 170.774 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -73.03 146.89 45.59 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.26 1.424 . . . . 10.0 110.594 -179.142 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -147.06 147.97 31.16 Favored 'General case' 0 C--N 1.342 0.25 0 N-CA-C 114.509 1.3 . . . . 10.0 114.509 -177.49 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.686 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.46 121.99 0.04 OUTLIER Glycine 0 C--N 1.339 0.738 0 C-N-CA 128.653 3.025 . . . . 10.0 114.501 164.587 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -152.72 109.2 3.42 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.665 1.233 . . . . 10.0 110.544 166.267 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.14 179.17 7.82 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.254 0.55 . . . . 10.0 112.193 173.098 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.4 m -116.56 134.24 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.066 -1.879 . . . . 10.0 106.848 166.02 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -110.91 152.99 26.1 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 125.268 1.427 . . . . 10.0 107.912 -178.701 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.23 -54.71 43.67 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.875 -0.602 . . . . 10.0 111.413 -172.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.51 111.96 13.79 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -169.189 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.57 -30.47 68.67 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.164 -1.174 . . . . 10.0 110.164 169.44 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -40.29 139.43 0.74 Allowed 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 124.788 1.235 . . . . 10.0 111.214 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -143.88 24.07 1.69 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 124.353 1.061 . . . . 10.0 112.551 169.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.719 HG23 ' CG2' ' A' ' 17' ' ' ILE . 3.6 m -61.82 -35.15 77.39 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.371 0.668 . . . . 10.0 110.748 -174.957 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.23 -16.45 59.82 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 122.215 -0.303 . . . . 10.0 111.582 176.103 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.39 -151.59 19.08 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 106.61 -2.596 . . . . 10.0 106.61 -169.656 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 1.8 m -69.26 67.63 0.19 Allowed 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 126.018 1.727 . . . . 10.0 111.298 -179.039 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -163.88 -53.16 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.317 1.847 . . . . 10.0 107.583 -179.299 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -39.16 -40.59 0.74 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 127.648 2.379 . . . . 10.0 111.235 174.132 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.81 -47.55 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.009 2.524 . . . . 10.0 114.062 168.28 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.08 152.24 26.45 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 110.424 -1.071 . . . . 10.0 110.424 173.512 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -79.13 46.94 2.34 Favored 'Trans proline' 0 CA--C 1.537 0.629 0 C-N-CA 124.379 3.386 . . . . 10.0 113.482 -171.065 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 57.14 58.03 4.19 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.1 1.76 . . . . 10.0 108.585 -175.825 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -66.77 75.64 0.11 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.769 0.795 . . . . 10.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -77.65 137.02 63.03 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.2 -0.938 . . . . 10.0 110.508 -177.52 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.06 -52.16 0.99 Allowed 'Trans proline' 0 N--CA 1.455 -0.752 0 C-N-CA 122.578 2.185 . . . . 10.0 111.132 -173.19 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mp -76.17 65.74 2.19 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 108.122 -1.066 . . . . 10.0 108.122 175.054 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 66.6 p -30.02 101.64 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.325 2.25 . . . . 10.0 114.021 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.2 mtp180 -139.85 177.7 7.77 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.072 0.949 . . . . 10.0 110.927 -174.729 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 67.2 mmtt -107.26 89.07 2.89 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 113.233 0.827 . . . . 10.0 113.233 -168.66 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.401 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 81.9 t60 5.73 92.85 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.23 0 C-N-CA 128.45 2.7 . . . . 10.0 114.849 179.219 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.24 -139.04 9.64 Favored Glycine 0 N--CA 1.442 -0.921 0 N-CA-C 110.144 -1.182 . . . . 10.0 110.144 178.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.03 -162.24 34.34 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 175.394 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.62 1.31 1.81 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 CA-C-N 120.055 1.927 . . . . 10.0 111.472 168.417 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.31 8.6 18.09 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.913 1.685 . . . . 10.0 110.516 176.4 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -142.03 169.62 17.24 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.442 1.019 . . . . 10.0 108.948 165.125 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -87.99 -22.6 24.17 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.235 -1.394 . . . . 10.0 107.235 167.996 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 -82.27 31.05 0.39 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 120.661 -1.274 . . . . 10.0 112.777 -176.526 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.6 132.7 54.77 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 172.898 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.401 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 16.9 m170 -63.17 -61.52 2.32 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 121.176 0.512 . . . . 10.0 110.538 -177.787 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.4 p -168.23 -56.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 -179.141 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.16 63.14 0.63 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 177.45 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.1 m-20 -92.7 95.5 9.6 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 104.101 -2.555 . . . . 10.0 104.101 167.528 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 9.2 mp -66.75 -26.61 67.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 118.828 0.74 . . . . 10.0 109.342 -176.713 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 116.9 -88.17 0.45 Allowed Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 108.106 -1.998 . . . . 10.0 108.106 168.631 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 38.5 m-80 -149.39 142.49 24.96 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.58 134.12 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 107.657 -1.238 . . . . 10.0 107.657 169.001 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -86.9 130.06 34.62 Favored 'General case' 0 C--O 1.226 -0.166 0 C-N-CA 123.978 0.911 . . . . 10.0 108.643 179.663 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.77 127.87 52.71 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.227 1.411 . . . . 10.0 109.43 175.247 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -61.29 167.71 3.04 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.888 1.368 . . . . 10.0 109.933 168.064 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -52.32 -30.8 30.11 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.681 1.192 . . . . 10.0 110.77 172.202 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -77.25 -7.73 56.42 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.035 0.379 . . . . 10.0 110.758 -177.541 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.14 17.01 73.02 Favored Glycine 0 C--N 1.34 0.788 0 N-CA-C 110.611 -0.995 . . . . 10.0 110.611 -178.497 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -94.54 119.29 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 C-N-CA 127.359 2.264 . . . . 10.0 105.434 172.532 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.75 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -115.82 126.6 54.21 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 123.706 0.802 . . . . 10.0 109.017 174.431 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -88.57 133.62 34.11 Favored 'General case' 0 N--CA 1.437 -1.096 0 C-N-CA 127.154 2.181 . . . . 10.0 109.567 178.936 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 50.1 t -113.97 130.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 C-N-CA 125.825 1.65 . . . . 10.0 108.228 174.624 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 78.1 p -157.78 73.81 0.71 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.132 0.973 . . . . 10.0 108.923 169.685 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.29 163.06 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 106.984 -1.487 . . . . 10.0 106.984 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -147.72 150.45 34.33 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 125.191 1.396 . . . . 10.0 109.933 174.333 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -155.32 159.28 39.84 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.323 -1.362 . . . . 10.0 107.323 172.881 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.2 p -104.81 -16.85 14.79 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 128.136 2.574 . . . . 10.0 112.281 179.053 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 4.5 p -78.34 -38.28 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 -176.387 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -70.64 154.72 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 C-N-CA 124.522 1.129 . . . . 10.0 107.978 168.771 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 11.1 m -153.77 163.28 40.28 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 172.088 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 79.2 mt -101.96 -11.06 19.24 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.797 0.839 . . . . 10.0 111.539 176.937 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.451 -0.38 0 C-N-CA 125.808 1.643 . . . . 10.0 107.239 169.498 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . 0.681 ' O ' HG23 ' B' ' 112' ' ' ILE . 13.6 t . . . . . 0 N--CA 1.438 -1.069 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.681 HG23 ' O ' ' B' ' 111' ' ' SER . 39.4 pt 162.87 -23.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.336 1 C-N-CA 133.226 4.61 . . . . 10.0 107.34 -171.482 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -43.25 120.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 118.854 0.752 . . . . 10.0 110.397 175.425 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 104.0 -6.55 47.53 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.786 -1.008 . . . . 10.0 113.781 179.025 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -77.1 154.64 33.1 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 118.309 1.055 . . . . 10.0 110.288 175.562 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 32.6 m -94.93 109.03 21.09 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.565 1.146 . . . . 10.0 109.183 178.553 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -79.57 147.92 31.94 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 167.272 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 65.3 t -142.63 132.87 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 C-N-CA 123.953 0.901 . . . . 10.0 109.551 -173.565 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.401 HG23 HD22 ' B' ' 8' ' ' LEU . 2.7 t -109.0 136.67 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.648 0 C-N-CA 126.173 1.789 . . . . 10.0 109.898 172.239 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.686 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.6 m-70 -117.52 158.68 24.13 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 116.466 2.024 . . . . 10.0 116.466 -171.179 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 57.8 tt0 -48.8 -53.06 20.72 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 129.836 3.254 . . . . 10.0 111.813 175.166 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -112.75 168.79 9.38 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 123.332 0.653 . . . . 10.0 111.876 -169.704 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.62 154.1 40.92 Favored 'General case' 0 N--CA 1.443 -0.82 0 O-C-N 125.016 1.448 . . . . 10.0 108.214 169.013 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -107.25 140.53 39.98 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 124.197 0.999 . . . . 10.0 109.032 -169.014 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -72.99 -28.99 62.71 Favored 'General case' 0 C--O 1.232 0.168 0 O-C-N 123.724 0.64 . . . . 10.0 109.803 -175.331 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.6 mt 59.86 50.95 6.4 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 107.896 -1.15 . . . . 10.0 107.896 -171.413 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 94.05 -39.33 2.94 Favored Glycine 0 CA--C 1.521 0.456 0 C-N-CA 126.189 1.852 . . . . 10.0 110.788 169.531 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 29.8 mtmm -80.91 39.79 0.51 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.004 0.922 . . . . 10.0 112.591 -169.485 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.18 -24.11 13.39 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 126.565 2.031 . . . . 10.0 110.262 169.186 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 59.94 36.11 89.15 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 123.732 0.682 . . . . 10.0 111.547 176.517 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -137.67 166.6 23.55 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 108.467 -0.938 . . . . 10.0 108.467 173.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -48.5 -47.4 38.79 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 124.363 1.065 . . . . 10.0 110.295 -178.586 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -70.48 -33.7 71.55 Favored 'General case' 0 N--CA 1.448 -0.549 0 O-C-N 121.922 -0.486 . . . . 10.0 111.671 179.417 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 26.6 p -55.69 -45.76 77.74 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 119.398 0.999 . . . . 10.0 110.435 177.274 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.5 t -76.3 -14.38 60.11 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.756 -0.656 . . . . 10.0 112.345 -171.728 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 10.5 ttmt -107.16 -49.34 3.29 Favored 'General case' 0 N--CA 1.434 -1.255 0 C-N-CA 125.987 1.715 . . . . 10.0 110.904 -172.141 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.03 23.77 2.58 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.972 0.806 . . . . 10.0 111.673 176.223 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 61.4 26.62 66.56 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 119.516 1.053 . . . . 10.0 111.951 177.983 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 57.16 23.19 8.32 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.286 1.043 . . . . 10.0 112.908 -178.798 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.58 -12.31 9.66 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 125.554 1.542 . . . . 10.0 114.045 -175.889 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.11 -162.92 52.93 Favored Glycine 0 N--CA 1.445 -0.765 0 O-C-N 121.029 -1.044 . . . . 10.0 110.849 172.193 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.4 m -56.19 128.32 35.04 Favored 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 124.097 0.959 . . . . 10.0 111.807 -167.96 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -73.48 98.78 2.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.45 1.1 . . . . 10.0 108.105 178.169 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 36.2 mt -79.24 -28.53 42.46 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.039 0.536 . . . . 10.0 112.024 -171.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.59 138.74 22.41 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.146 -0.687 . . . . 10.0 109.146 179.341 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -137.52 130.23 30.01 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 -178.185 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.24 -174.05 13.63 Favored Glycine 0 C--O 1.228 -0.235 0 N-CA-C 109.5 -1.44 . . . . 10.0 109.5 178.459 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.7 t -131.68 150.97 34.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 103.478 -2.786 . . . . 10.0 103.478 168.245 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.1 mt -60.12 -86.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.574 1.15 . . . . 10.0 111.534 -168.166 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.94 128.88 6.17 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 110.627 -0.989 . . . . 10.0 110.627 -179.01 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.6 pt -76.68 126.91 37.76 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 177.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.99 -45.68 12.86 Favored 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 108.533 -0.914 . . . . 10.0 108.533 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 . . . . . 0 C--O 1.253 1.262 0 CA-C-O 116.016 -1.945 . . . . 10.0 109.665 -176.064 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 106.331 -1.729 . . . . 10.0 106.331 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -88.81 -16.09 32.93 Favored 'General case' 0 C--O 1.228 -0.076 0 CA-C-N 119.917 1.235 . . . . 10.0 111.475 177.118 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -151.88 144.54 24.27 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.245 0.475 . . . . 10.0 112.261 177.792 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.2 160.62 37.28 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.832 1.653 . . . . 10.0 109.497 173.865 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 t -121.58 150.99 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 125.762 1.625 . . . . 10.0 109.93 179.502 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.55 100.59 5.01 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.782 1.233 . . . . 10.0 108.98 169.671 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -83.97 109.12 17.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 109.85 -0.426 . . . . 10.0 109.85 170.555 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -96.19 145.95 25.1 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.069 0.948 . . . . 10.0 109.316 177.419 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -157.89 164.53 36.82 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 107.89 -1.152 . . . . 10.0 107.89 171.227 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.07 -67.3 0.02 OUTLIER Glycine 0 C--O 1.229 -0.174 0 N-CA-C 111.574 -0.611 . . . . 10.0 111.574 171.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -75.99 -42.1 49.22 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 107.358 -1.349 . . . . 10.0 107.358 -176.557 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.98 -67.12 0.53 Allowed Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 114.851 -1.068 . . . . 10.0 111.615 -177.308 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -57.29 -41.69 70.5 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.157 1.904 . . . . 10.0 110.888 179.563 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -69.56 108.84 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 N-CA-C 107.176 -1.416 . . . . 10.0 107.176 176.843 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -120.48 117.51 27.84 Favored 'General case' 0 N--CA 1.437 -1.098 0 C-N-CA 126.049 1.74 . . . . 10.0 106.757 174.395 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.866 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.31 142.27 15.99 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 108.973 -1.651 . . . . 10.0 108.973 169.177 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.496 ' CG2' HG22 ' B' ' 54' ' ' THR . 2.3 mt -145.49 67.18 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 N-CA-C 106.049 -1.834 . . . . 10.0 106.049 -173.611 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.6 mm -90.91 135.51 26.53 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 CA-C-N 116.39 -0.368 . . . . 10.0 110.061 -172.4 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 m-80 -101.84 132.55 47.55 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 125.019 1.328 . . . . 10.0 108.708 175.589 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -116.18 87.41 2.68 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 126.626 1.97 . . . . 10.0 107.822 178.541 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -83.94 155.83 22.64 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-O 121.46 0.648 . . . . 10.0 111.169 175.68 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -145.23 99.16 3.27 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 126.068 1.747 . . . . 10.0 107.174 174.828 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.4 ptmt -62.31 -57.48 11.22 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 122.172 -0.33 . . . . 10.0 110.128 179.305 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -128.91 163.01 26.21 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 103.814 -2.661 . . . . 10.0 103.814 168.093 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.4 t -76.75 -4.59 44.19 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 119.172 0.897 . . . . 10.0 109.904 173.189 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -80.92 -21.86 40.15 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 124.452 1.101 . . . . 10.0 109.532 168.914 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.71 148.72 30.81 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 110.132 -1.187 . . . . 10.0 110.132 178.316 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -64.72 141.14 71.02 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 N-CA-C 107.803 -1.653 . . . . 10.0 107.803 169.245 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.8 t -78.3 83.12 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 174.241 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.0 tttt -63.33 111.58 2.34 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.915 -1.142 . . . . 10.0 107.915 171.429 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 18.1 m -91.62 121.67 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 N-CA-C 106.884 -1.524 . . . . 10.0 106.884 176.769 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 31.0 p90 -133.04 151.09 52.08 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 122.19 0.995 . . . . 10.0 113.145 170.5 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.08 -177.19 47.17 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 109.629 -1.388 . . . . 10.0 109.629 170.071 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.2 m -128.76 103.27 6.97 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.745 -1.206 . . . . 10.0 107.745 -173.551 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.866 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.7 pt -77.02 150.36 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.39 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 168.281 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.63 141.86 43.23 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.644 -0.502 . . . . 10.0 109.644 169.312 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.05 0.33 28.48 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.323 0.963 . . . . 10.0 112.899 175.76 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -65.12 176.05 1.41 Allowed 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 121.998 0.904 . . . . 10.0 109.669 169.922 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -98.92 167.1 10.95 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.649 -1.612 . . . . 10.0 106.649 164.95 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -58.19 169.08 0.89 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.398 1.079 . . . . 10.0 111.256 -171.251 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.94 -178.34 45.11 Favored Glycine 0 N--CA 1.448 -0.526 0 O-C-N 120.883 -1.136 . . . . 10.0 111.896 166.992 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.9 mp -70.63 153.3 42.99 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.283 1.433 . . . . 10.0 110.395 179.832 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -148.92 143.44 26.2 Favored 'General case' 0 C--N 1.34 0.185 0 N-CA-C 113.627 0.973 . . . . 10.0 113.627 -175.439 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.599 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.06 127.91 0.25 Allowed Glycine 0 C--N 1.34 0.777 0 C-N-CA 126.963 2.221 . . . . 10.0 111.644 164.391 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.39 103.48 2.33 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 119.744 1.772 . . . . 10.0 111.394 168.409 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.01 174.62 13.43 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 114.253 1.205 . . . . 10.0 114.253 -173.382 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.1 p -79.16 140.81 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 112.016 -2.356 . . . . 10.0 107.966 166.567 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.4 ' CD2' ' CG2' ' A' ' 118' ' ' VAL . 86.5 m-70 -126.17 100.5 6.35 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 102.875 -3.009 . . . . 10.0 102.875 163.861 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 6.89 -78.84 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 128.67 2.788 . . . . 10.0 116.017 178.773 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -81.69 162.22 23.08 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 119.166 0.894 . . . . 10.0 110.63 -171.098 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.01 -18.87 58.74 Favored Glycine 0 CA--C 1.524 0.61 0 O-C-N 121.306 -0.871 . . . . 10.0 110.956 170.91 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -65.34 162.82 16.76 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 122.275 1.036 . . . . 10.0 112.716 -170.268 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.424 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -161.58 17.91 0.11 Allowed 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 113.931 1.086 . . . . 10.0 113.931 -169.452 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.406 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -51.81 -37.89 53.52 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.489 1.116 . . . . 10.0 113.464 -169.003 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.22 -21.94 45.56 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 112.306 0.484 . . . . 10.0 112.306 179.485 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.61 100.9 2.65 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 -174.313 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 52.0 30.68 7.66 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 125.379 1.472 . . . . 10.0 114.502 169.147 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.8 m -133.79 -59.35 0.85 Allowed 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 106.816 -1.55 . . . . 10.0 106.816 -173.585 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.3 m -47.5 -46.12 26.96 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 126.5 1.92 . . . . 10.0 111.52 -169.469 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.88 -49.7 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 128.239 2.616 . . . . 10.0 114.975 169.4 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.12 171.37 12.95 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.769 -0.932 . . . . 10.0 110.769 173.094 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -79.45 -136.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 123.384 2.723 . . . . 10.0 106.092 166.022 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 18.1 m170 -106.29 50.35 0.78 Allowed 'General case' 0 CA--C 1.544 0.733 0 CA-C-N 121.67 2.032 . . . . 10.0 110.102 171.371 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -78.69 61.35 2.97 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.618 1.554 . . . . 10.0 110.218 174.591 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -61.94 155.97 59.97 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 127.581 2.353 . . . . 10.0 111.138 171.089 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.19 -58.28 0.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.228 2.618 . . . . 10.0 112.75 178.452 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -78.05 58.64 2.02 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.941 0.791 . . . . 10.0 110.509 -177.983 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.8 t -59.08 110.76 1.11 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 122.913 0.485 . . . . 10.0 109.752 -174.709 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 65.8 mtt180 -127.2 -90.08 0.53 Allowed 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 105.361 -2.089 . . . . 10.0 105.361 178.166 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.1 mttm -144.43 156.35 44.16 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.001 0.905 . . . . 10.0 108.812 169.999 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -63.29 120.2 11.11 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 118.493 -1.283 . . . . 10.0 107.804 166.656 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.12 -156.64 7.04 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 106.571 -2.612 . . . . 10.0 106.571 177.282 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -151.14 -159.35 8.79 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 118.442 1.121 . . . . 10.0 112.007 178.781 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -71.1 12.11 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 121.414 1.409 . . . . 10.0 109.466 165.724 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 37.5 mmtm -95.87 -24.78 16.28 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 169.704 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.426 ' OD1' ' NZ ' ' A' ' 128' ' ' LYS . 20.4 m-20 -115.56 171.27 7.83 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 -170.016 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -121.14 10.13 10.63 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.539 1.135 . . . . 10.0 110.279 171.394 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -109.16 6.47 24.85 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.515 1.126 . . . . 10.0 110.497 172.098 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -47.3 148.27 1.33 Allowed 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.531 1.532 . . . . 10.0 110.263 178.058 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -60.78 -64.11 1.07 Allowed 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 117.842 0.292 . . . . 10.0 111.185 -176.168 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.8 p -167.89 -51.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 C-N-CA 123.739 0.815 . . . . 10.0 109.266 174.552 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -136.51 47.96 0.94 Allowed Glycine 0 CA--C 1.526 0.741 0 C-N-CA 123.939 0.78 . . . . 10.0 111.327 -175.198 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -86.23 109.11 18.7 Favored 'General case' 0 CA--C 1.53 0.173 0 N-CA-C 105.068 -2.197 . . . . 10.0 105.068 168.395 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.3 mt -74.85 -14.57 60.69 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 118.607 0.639 . . . . 10.0 111.744 -170.94 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.61 -97.93 1.14 Allowed Glycine 0 N--CA 1.44 -1.048 0 N-CA-C 107.434 -2.267 . . . . 10.0 107.434 178.907 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -153.0 120.68 6.02 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 -172.317 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.1 m -102.53 147.27 9.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 N-CA-C 106.039 -1.838 . . . . 10.0 106.039 168.957 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -120.45 133.12 55.47 Favored 'General case' 0 C--N 1.334 -0.095 0 C-N-CA 123.426 0.69 . . . . 10.0 111.588 -173.358 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.75 132.75 48.69 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.244 1.018 . . . . 10.0 111.361 -175.025 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.04 172.74 0.53 Allowed 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 122.496 1.141 . . . . 10.0 110.319 167.778 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 mtmp? -63.15 -19.49 64.52 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 114.309 -1.314 . . . . 10.0 112.425 178.433 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -77.8 -20.31 53.47 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 122.35 0.26 . . . . 10.0 110.741 173.881 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.85 6.67 60.43 Favored Glycine 0 C--N 1.338 0.684 0 CA-C-O 118.749 -1.028 . . . . 10.0 110.685 -170.19 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 t -79.37 114.61 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 C-N-CA 125.502 1.521 . . . . 10.0 107.154 176.265 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.683 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -115.38 123.93 49.93 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.865 -0.791 . . . . 10.0 108.865 174.353 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -78.84 129.03 34.12 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.327 -0.99 . . . . 10.0 108.327 171.745 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.4 t -112.15 129.84 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 104.179 -2.526 . . . . 10.0 104.179 167.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.9 p -157.79 57.27 0.48 Allowed 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 123.025 0.53 . . . . 10.0 110.844 174.596 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.36 148.67 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 124.087 0.955 . . . . 10.0 109.024 -169.883 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -129.27 123.66 32.47 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.535 1.134 . . . . 10.0 110.243 174.253 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -127.61 107.15 9.67 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.823 1.649 . . . . 10.0 108.511 -177.653 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 45.2 p -85.22 58.54 5.09 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.823 2.049 . . . . 10.0 107.195 -171.294 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.3 p -142.07 -48.87 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 123.996 0.919 . . . . 10.0 109.307 -176.273 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.312 0.0 OUTLIER -79.91 174.65 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 N-CA-C 113.023 0.749 . . . . 10.0 113.023 174.933 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -167.88 155.0 8.17 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.994 1.318 . . . . 10.0 107.901 169.39 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 70.3 mt -62.29 -24.53 67.34 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 123.413 0.685 . . . . 10.0 111.214 -176.087 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.9 m -147.87 161.32 41.54 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.856 -1.905 . . . . 10.0 105.856 169.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 154.82 -74.57 0.24 Allowed Glycine 0 C--N 1.334 0.434 0 N-CA-C 109.925 -1.27 . . . . 10.0 109.925 -177.457 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -152.19 -53.69 0.12 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.768 2.027 . . . . 10.0 106.387 178.698 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -75.0 -38.6 61.54 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 114.069 -1.423 . . . . 10.0 108.507 -175.002 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.3 t 46.5 56.17 6.72 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.86 1.264 . . . . 10.0 110.309 169.401 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -66.77 6.92 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 N-CA-C 115.647 1.721 . . . . 10.0 115.647 -166.424 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.7 mm -57.41 142.02 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 167.103 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.95 19.21 79.77 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-O 118.916 -0.935 . . . . 10.0 114.033 175.129 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -79.81 175.87 10.24 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 106.779 -1.563 . . . . 10.0 106.779 166.035 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 16.5 m -111.64 131.92 54.94 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 103.302 -2.851 . . . . 10.0 103.302 169.467 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.422 HD12 ' HA ' ' A' ' 117' ' ' LEU . 0.5 OUTLIER -96.3 135.81 37.63 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 105.751 -1.944 . . . . 10.0 105.751 167.455 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.4 ' CG2' ' CD2' ' A' ' 48' ' ' HIS . 86.8 t -118.84 132.95 67.23 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.874 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 169.148 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.07 127.51 58.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.75 -1.945 . . . . 10.0 105.75 168.028 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.599 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.4 m-70 -103.69 159.13 15.88 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 123.529 1.633 . . . . 10.0 114.946 -169.835 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.687 ' HA ' HD22 ' A' ' 144' ' ' LEU . 10.6 tt0 -43.71 -60.73 1.66 Allowed 'General case' 0 N--CA 1.442 -0.873 0 C-N-CA 129.079 2.951 . . . . 10.0 110.041 172.62 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mtmm -115.93 175.4 5.56 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.912 1.285 . . . . 10.0 111.638 -171.897 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.57 149.54 32.99 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 125.938 1.695 . . . . 10.0 111.161 -176.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.462 ' OD1' ' HA2' ' A' ' 44' ' ' GLY . 1.9 m-20 -79.34 144.06 34.57 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.517 0.727 . . . . 10.0 112.567 175.502 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 m-20 -77.18 -35.55 55.74 Favored 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 124.781 1.301 . . . . 10.0 108.974 167.96 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 57.0 mt 66.55 48.8 1.43 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 125.439 1.496 . . . . 10.0 109.368 -167.689 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.83 50.21 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 125.243 1.402 . . . . 10.0 113.001 172.556 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.426 ' NZ ' ' OD1' ' A' ' 76' ' ' ASP . 18.1 mttm -78.82 -1.71 36.2 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.711 0.805 . . . . 10.0 111.273 -168.598 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.91 -26.58 73.2 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 109.087 -1.605 . . . . 10.0 109.087 166.387 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.32 39.25 82.1 Favored Glycine 0 C--N 1.341 0.856 0 N-CA-C 110.822 -0.911 . . . . 10.0 110.822 -179.544 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.9 m-80 -122.06 161.71 22.53 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 176.132 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.407 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 3.8 tm-20 -48.72 -45.5 39.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 113.388 -1.733 . . . . 10.0 108.781 171.038 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -64.76 -49.7 69.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.167 -0.47 . . . . 10.0 111.714 172.217 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.7 t -52.97 -44.72 67.36 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 120.552 -1.342 . . . . 10.0 110.65 -175.418 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.1 t -74.95 -5.98 46.8 Favored 'General case' 0 CA--C 1.538 0.492 0 O-C-N 123.186 0.304 . . . . 10.0 111.542 -174.955 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.407 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 87.9 mttt -102.83 -83.05 0.48 Allowed 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 126.578 1.951 . . . . 10.0 110.147 172.583 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.21 25.84 10.99 Favored 'General case' 0 C--N 1.345 0.391 0 CA-C-N 121.298 1.863 . . . . 10.0 112.988 -177.02 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 59.72 27.66 64.36 Favored Glycine 0 C--N 1.339 0.721 0 CA-C-N 118.942 0.792 . . . . 10.0 112.397 170.001 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.0 m-80 50.21 27.86 2.83 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 123.988 0.915 . . . . 10.0 112.689 -173.501 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.52 -3.85 9.85 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.527 -0.733 . . . . 10.0 112.243 179.694 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.35 -163.6 51.92 Favored Glycine 0 N--CA 1.443 -0.894 0 N-CA-C 110.866 -0.893 . . . . 10.0 110.866 169.192 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.8 m -56.98 142.22 42.58 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.5 0.667 . . . . 10.0 111.612 -169.248 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.0 mtp85 -68.9 64.79 0.12 Allowed 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 125.627 1.571 . . . . 10.0 109.681 175.357 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.687 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.9 tp -43.91 -35.11 1.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.669 1.988 . . . . 10.0 113.917 -174.537 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -162.53 159.06 24.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -162.16 168.15 22.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 -174.881 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.47 169.77 42.77 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 112.094 -0.402 . . . . 10.0 112.094 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.409 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 4.8 t -107.28 138.78 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 -171.304 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mt -80.11 136.58 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-N 118.0 0.364 . . . . 10.0 110.607 179.568 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.05 146.99 17.5 Favored Glycine 0 CA--C 1.53 0.984 0 C-N-CA 125.068 1.318 . . . . 10.0 110.81 176.977 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 10.8 pt -71.49 142.07 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.138 0 CA-C-N 117.82 0.81 . . . . 10.0 109.28 176.771 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.52 -19.71 8.05 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.282 1.433 . . . . 10.0 113.313 -176.372 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.9 tp60 . . . . . 0 C--O 1.254 1.298 0 C-N-CA 130.278 3.431 . . . . 10.0 117.278 -175.504 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 117.652 -1.166 . . . . 10.0 108.997 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.3 t -76.02 -37.35 58.51 Favored 'General case' 0 CA--C 1.516 -0.327 0 CA-C-N 120.217 1.371 . . . . 10.0 110.41 -178.767 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -124.54 136.44 53.99 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 123.377 0.671 . . . . 10.0 111.201 -171.561 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.36 165.5 28.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.146 1.378 . . . . 10.0 107.502 171.004 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.441 ' O ' HG23 ' B' ' 149' ' ' ILE . 7.9 m -128.32 -178.28 2.29 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 123.367 0.667 . . . . 10.0 110.114 178.904 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.39 110.97 4.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.774 1.23 . . . . 10.0 108.262 165.453 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.424 HG21 ' HB3' ' A' ' 53' ' ' ASN . 3.2 m -95.83 104.52 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 123.786 0.835 . . . . 10.0 109.615 170.633 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.413 HD12 ' N ' ' B' ' 8' ' ' LEU . 5.7 mp -95.06 135.57 36.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 124.026 0.93 . . . . 10.0 110.035 -177.947 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 43.2 mtpt -149.22 169.48 20.65 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 107.459 -1.312 . . . . 10.0 107.459 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.38 -72.6 0.04 OUTLIER Glycine 0 C--O 1.229 -0.201 0 CA-C-N 115.944 -0.571 . . . . 10.0 111.68 174.394 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -74.09 -41.29 61.91 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.15 -1.426 . . . . 10.0 107.15 -178.295 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.84 -65.92 0.58 Allowed Glycine 0 CA--C 1.526 0.759 0 C-N-CA 124.836 1.207 . . . . 10.0 110.498 -178.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -79.14 37.48 0.67 Allowed 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 124.874 3.716 . . . . 10.0 111.446 -175.282 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -148.74 108.11 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.534 0 N-CA-C 100.405 -3.924 . . . . 10.0 100.405 173.244 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.47 122.84 28.43 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 177.101 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.571 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -107.56 140.21 15.3 Favored Glycine 0 C--O 1.224 -0.508 0 N-CA-C 110.493 -1.043 . . . . 10.0 110.493 -179.745 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.406 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.6 mt -139.98 88.75 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.148 -1.427 . . . . 10.0 107.148 -174.317 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -100.23 146.52 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.13 0 C-N-CA 124.978 1.311 . . . . 10.0 111.288 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -123.99 121.3 34.91 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 127.056 2.142 . . . . 10.0 108.102 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -99.32 108.0 20.42 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.855 1.262 . . . . 10.0 107.999 171.761 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -105.13 139.08 40.34 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 119.039 0.836 . . . . 10.0 109.534 167.421 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -116.91 106.13 13.1 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.668 -1.604 . . . . 10.0 106.668 168.22 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt . . . . . 0 N--CA 1.424 -1.731 0 C-N-CA 125.343 1.457 . . . . 10.0 108.926 -178.317 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.163 0 CA-C-O 117.581 -1.677 . . . . 10.0 115.218 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -73.86 140.76 29.31 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 122.527 2.151 . . . . 10.0 108.77 175.091 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -85.81 99.5 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 107.212 -1.403 . . . . 10.0 107.212 173.754 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 60.4 mttm -79.3 109.06 13.29 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.489 -1.3 . . . . 10.0 107.489 174.093 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.39 97.21 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 126.446 1.899 . . . . 10.0 107.392 -178.153 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.7 p90 -116.18 171.31 7.89 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.245 0.545 . . . . 10.0 110.144 169.715 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.26 -165.41 36.59 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 111.126 -0.789 . . . . 10.0 111.126 170.069 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.3 m -154.68 107.86 2.84 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 108.876 -0.787 . . . . 10.0 108.876 -170.832 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.571 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.9 pt -79.87 177.71 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 108.869 -0.789 . . . . 10.0 108.869 169.01 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 tptt -153.5 153.88 33.29 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 170.858 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.17 -38.94 2.67 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 118.51 0.595 . . . . 10.0 111.622 169.728 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.519 ' H ' HD12 ' B' ' 38' ' ' LEU . 6.0 mp -64.14 177.0 0.87 Allowed 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 122.034 0.921 . . . . 10.0 111.664 -170.031 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -103.58 162.05 13.38 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.617 -0.719 . . . . 10.0 109.186 168.731 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -52.32 153.48 2.87 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 125.584 1.553 . . . . 10.0 112.18 -169.456 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.81 -173.41 20.04 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 123.517 0.58 . . . . 10.0 111.858 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -74.64 151.25 39.34 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.937 1.295 . . . . 10.0 110.364 -177.665 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -150.18 151.86 33.74 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 123.634 0.774 . . . . 10.0 112.605 -178.392 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.583 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -44.75 127.18 7.09 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 127.259 2.362 . . . . 10.0 110.96 165.985 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -154.73 111.17 3.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 119.038 1.419 . . . . 10.0 108.862 165.771 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.404 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -155.4 167.64 29.72 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-O 121.312 0.577 . . . . 10.0 111.466 179.285 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.0 m -86.51 149.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 112.504 -2.135 . . . . 10.0 106.563 168.014 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -117.57 164.01 15.58 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 123.014 0.526 . . . . 10.0 110.263 176.292 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -52.57 -54.41 33.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.162 0.985 . . . . 10.0 112.589 -176.025 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -106.54 -178.45 3.65 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 118.829 0.741 . . . . 10.0 109.381 178.219 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -139.47 13.41 3.22 Favored Glycine 0 C--N 1.333 0.382 0 O-C-N 122.109 -0.369 . . . . 10.0 113.461 176.093 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -67.13 153.31 43.98 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 107.276 -1.379 . . . . 10.0 107.276 167.188 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -149.13 22.53 0.96 Allowed 'General case' 0 N--CA 1.451 -0.421 0 O-C-N 121.649 -0.657 . . . . 10.0 112.189 -172.372 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.496 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -49.23 -38.42 26.46 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.758 2.023 . . . . 10.0 112.447 -177.489 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.2 -19.77 56.27 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 122.136 -0.353 . . . . 10.0 111.916 -178.278 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 125.9 -66.97 0.54 Allowed Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.309 -1.117 . . . . 10.0 110.309 -176.857 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 35.0 t -160.05 70.06 0.42 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 122.391 1.091 . . . . 10.0 110.625 -178.73 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -163.17 -50.73 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 125.282 1.433 . . . . 10.0 109.253 -174.235 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -48.8 -38.67 22.75 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 125.667 1.587 . . . . 10.0 111.447 -171.218 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.12 -41.54 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 128.662 2.785 . . . . 10.0 114.351 168.63 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.85 161.88 29.84 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 107.647 -2.181 . . . . 10.0 107.647 177.392 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -68.88 -143.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.547 1.132 0 C-N-CA 121.894 1.729 . . . . 10.0 109.615 169.783 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.6 m170 -104.17 42.91 1.14 Allowed 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.267 -1.52 . . . . 10.0 110.629 -179.665 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -73.31 71.98 1.26 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 120.601 1.546 . . . . 10.0 111.32 -179.707 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -62.56 155.06 70.76 Favored Pre-proline 0 CA--C 1.538 0.499 0 C-N-CA 124.218 1.007 . . . . 10.0 111.614 169.837 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.62 -47.95 2.54 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.282 1.988 . . . . 10.0 111.361 176.838 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.85 68.33 1.29 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.774 -0.579 . . . . 10.0 110.816 175.488 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 14.1 t -40.81 102.88 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.427 1.891 . . . . 10.0 111.782 -178.627 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.8 mtt85 -130.28 175.43 8.94 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 126.275 1.83 . . . . 10.0 108.863 177.07 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 62.0 mmtt -106.19 84.11 1.99 Allowed 'General case' 0 CA--C 1.531 0.227 0 CA-C-O 121.457 0.646 . . . . 10.0 112.473 -170.887 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 54.2 t60 13.79 88.39 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.433 2.293 . . . . 10.0 115.594 174.044 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -121.27 -164.6 12.37 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 126.985 2.231 . . . . 10.0 109.004 178.627 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.59 -154.88 15.24 Favored Glycine 0 C--O 1.227 -0.304 0 N-CA-C 106.973 -2.451 . . . . 10.0 106.973 -172.357 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -64.13 9.56 0.14 Allowed 'Trans proline' 0 CA--C 1.542 0.915 0 CA-C-N 120.119 1.96 . . . . 10.0 112.414 169.095 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.65 -31.33 11.27 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.738 1.215 . . . . 10.0 111.209 170.249 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -141.46 154.9 45.83 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-N 119.277 0.944 . . . . 10.0 110.445 -170.197 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 49.2 tt0 -75.87 -20.54 58.01 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.053 -1.091 . . . . 10.0 108.053 178.906 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -80.38 30.93 0.28 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.741 1.216 . . . . 10.0 112.096 -178.384 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -57.52 138.77 54.79 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.111 -0.993 . . . . 10.0 109.135 171.221 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -74.72 -61.03 2.02 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 179.776 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -156.42 -125.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 105.863 -1.903 . . . . 10.0 105.863 -174.444 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -74.4 69.96 1.66 Allowed Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.357 -1.097 . . . . 10.0 110.357 175.891 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -95.94 93.25 6.91 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 106.947 -1.501 . . . . 10.0 106.947 170.209 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.3 mt -65.19 -29.69 70.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.895 0.855 . . . . 10.0 108.987 178.814 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.87 -79.8 0.29 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 169.284 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . 0.484 HD22 ' HB1' ' B' ' 123' ' ' ALA . 23.6 m120 -144.17 108.07 4.71 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 118.185 -0.912 . . . . 10.0 108.627 -173.366 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.9 m -105.63 130.76 56.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 119.677 1.126 . . . . 10.0 111.924 -179.029 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -90.48 123.02 33.83 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 128.804 2.841 . . . . 10.0 111.269 -169.973 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.39 137.88 42.48 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 124.118 0.967 . . . . 10.0 111.411 177.198 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -62.08 171.65 1.69 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 124.325 1.05 . . . . 10.0 109.458 166.46 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.68 -28.96 58.38 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.554 0.742 . . . . 10.0 111.781 173.245 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -78.27 -3.94 45.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.336 0.588 . . . . 10.0 110.192 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.85 -0.63 82.61 Favored Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 110.257 -1.137 . . . . 10.0 110.257 -177.491 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.7 t -78.83 101.28 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 -173.154 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.49 117.19 30.39 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.45 -0.944 . . . . 10.0 108.45 168.392 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.37 106.84 12.69 Favored 'General case' 0 N--CA 1.435 -1.199 0 C-N-CA 126.814 2.046 . . . . 10.0 109.364 172.428 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 95.8 t -96.3 134.48 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.876 0 N-CA-C 106.964 -1.495 . . . . 10.0 106.964 178.626 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -158.22 79.09 0.82 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.382 0.673 . . . . 10.0 111.502 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -122.3 164.58 19.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 106.064 -1.828 . . . . 10.0 106.064 -179.419 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -138.1 145.0 41.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 121.469 -0.77 . . . . 10.0 111.498 168.743 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -109.62 104.15 13.12 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 125.769 1.628 . . . . 10.0 107.74 178.703 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 67.8 p -86.25 52.75 2.57 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 172.984 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 p -157.77 -49.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 C-N-CA 123.464 0.706 . . . . 10.0 109.325 -174.431 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 48.7 mm -66.58 155.46 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 108.704 -0.851 . . . . 10.0 108.704 169.845 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 41.3 m -153.13 137.35 16.51 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.232 -1.025 . . . . 10.0 108.232 174.455 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 34.5 mt -73.57 53.05 0.41 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.833 1.653 . . . . 10.0 111.459 177.28 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 CA--C 1.532 0.276 0 C-N-CA 127.942 2.497 . . . . 10.0 109.896 179.277 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.237 0.402 0 CA-C-O 122.085 0.945 . . . . 10.0 113.079 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.458 HD13 ' H ' ' B' ' 112' ' ' ILE . 0.1 OUTLIER -76.79 55.5 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-O 122.183 0.992 . . . . 10.0 109.518 167.439 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -117.75 -49.08 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 127.969 2.508 . . . . 10.0 108.295 178.659 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.04 10.25 71.47 Favored Glycine 0 CA--C 1.532 1.142 0 CA-C-O 119.193 -0.782 . . . . 10.0 112.794 -176.76 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -88.29 162.24 16.72 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 125.484 1.514 . . . . 10.0 108.892 178.678 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -103.84 140.24 37.92 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.505 0.722 . . . . 10.0 109.898 169.568 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.465 HD23 HG12 ' B' ' 149' ' ' ILE . 4.5 mm? -92.3 140.18 29.87 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 106.169 -1.789 . . . . 10.0 106.169 166.748 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 60.4 t -125.94 135.5 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 N-CA-C 107.563 -1.273 . . . . 10.0 107.563 174.736 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 8.6 p -105.39 129.68 57.88 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 106.216 -1.772 . . . . 10.0 106.216 169.109 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.583 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.5 m170 -113.31 157.75 21.42 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 115.13 1.53 . . . . 10.0 115.13 -169.362 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 58.3 tt0 -39.36 -63.24 0.57 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 128.518 2.727 . . . . 10.0 110.288 171.082 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 57.6 mttt -118.86 173.24 6.99 Favored 'General case' 0 CA--C 1.513 -0.461 0 C-N-CA 123.492 0.717 . . . . 10.0 109.685 -174.687 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . 0.484 ' HB1' HD22 ' B' ' 86' ' ' ASN . . . -92.41 148.78 21.84 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 179.309 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.643 ' HB2' ' CD2' ' B' ' 126' ' ' LEU . 0.9 OUTLIER -74.69 160.97 30.1 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.253 0.549 . . . . 10.0 111.675 -174.974 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.39 -28.53 61.14 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 114.624 -1.171 . . . . 10.0 110.152 174.855 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.643 ' CD2' ' HB2' ' B' ' 124' ' ' ASP . 2.8 mm? 62.57 56.95 1.93 Allowed 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 125.585 1.554 . . . . 10.0 109.847 -173.437 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 81.54 -40.57 2.61 Favored Glycine 0 CA--C 1.525 0.687 0 CA-C-N 113.971 -1.468 . . . . 10.0 111.78 168.115 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -77.13 49.29 0.67 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.048 1.339 . . . . 10.0 111.173 177.35 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.72 -32.67 4.69 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 126.226 1.869 . . . . 10.0 110.427 173.614 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.58 42.76 99.31 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.673 -0.971 . . . . 10.0 110.673 -171.761 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -132.76 163.35 29.21 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 106.607 -1.627 . . . . 10.0 106.607 173.338 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.57 -52.31 64.17 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 108.46 -0.941 . . . . 10.0 108.46 171.625 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -53.7 -33.54 55.85 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.216 -0.897 . . . . 10.0 112.416 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 21.0 p -52.15 -41.81 62.86 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-N 119.497 1.044 . . . . 10.0 110.649 179.21 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -85.01 -3.48 58.8 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-O 118.517 -0.754 . . . . 10.0 112.914 -178.97 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.95 -60.74 1.81 Allowed 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 126.291 1.836 . . . . 10.0 112.501 -174.223 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -136.25 23.77 3.24 Favored 'General case' 0 CA--C 1.547 0.827 0 CA-C-N 119.488 1.04 . . . . 10.0 110.483 175.447 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.16 -98.03 0.62 Allowed Glycine 0 C--N 1.342 0.91 0 N-CA-C 108.764 -1.734 . . . . 10.0 108.764 -177.461 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -165.34 43.57 0.08 Allowed 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 107.872 -1.158 . . . . 10.0 107.872 170.481 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.61 -19.69 64.01 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.396 0.678 . . . . 10.0 112.565 -174.13 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.01 -147.42 30.47 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 109.94 -1.264 . . . . 10.0 109.94 172.344 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.8 t -68.61 126.81 30.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.559 0.695 . . . . 10.0 110.64 -170.023 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.06 78.32 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.845 0.858 . . . . 10.0 110.604 169.502 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 56.5 mt -52.49 -40.17 62.05 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.922 -0.486 . . . . 10.0 112.11 179.331 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -149.13 145.65 27.3 Favored 'General case' 0 C--O 1.233 0.236 0 O-C-N 121.628 -0.67 . . . . 10.0 111.676 -179.574 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 m -123.72 147.9 47.06 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 126.686 1.995 . . . . 10.0 108.034 -178.224 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.61 141.95 10.82 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 109.761 -1.336 . . . . 10.0 109.761 171.598 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.409 ' HB ' ' HB ' ' A' ' 148' ' ' VAL . 95.8 t -89.8 150.57 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 102.894 -3.002 . . . . 10.0 102.894 172.646 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.465 HG12 HD23 ' B' ' 117' ' ' LEU . 90.4 mt -72.16 -88.03 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-O 121.474 0.654 . . . . 10.0 110.26 -167.566 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 99.87 132.69 7.82 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 124.329 0.966 . . . . 10.0 111.529 177.69 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 73.6 mt -63.31 147.75 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 125.155 1.382 . . . . 10.0 107.75 174.307 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.73 -32.81 4.43 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 113.466 0.913 . . . . 10.0 113.466 174.121 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . 0.412 HE21 ' C ' ' B' ' 153' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.898 0 N-CA-C 108.042 -1.096 . . . . 10.0 108.042 178.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.444 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.5 t -166.22 -41.08 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 127.159 2.184 . . . . 10.0 112.938 178.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -119.37 137.29 53.83 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.244 -1.761 . . . . 10.0 106.244 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -136.73 145.21 44.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.578 HG12 ' HB2' ' A' ' 152' ' ' ALA . 0.2 OUTLIER -134.99 150.04 29.59 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.236 0 N-CA-C 107.003 -1.481 . . . . 10.0 107.003 174.476 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.694 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -127.03 129.19 47.56 Favored 'General case' 0 CA--C 1.512 -0.499 0 C-N-CA 126.938 2.095 . . . . 10.0 105.457 168.068 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.444 HG12 HG23 ' A' ' 17' ' ' ILE . 35.1 m -98.78 121.89 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 168.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -97.16 149.23 22.23 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 119.095 0.861 . . . . 10.0 109.046 177.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.47 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 13.1 tttt -159.29 160.35 35.08 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 108.432 -0.951 . . . . 10.0 108.432 169.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.35 -53.68 0.06 OUTLIER Glycine 0 C--N 1.332 0.35 0 N-CA-C 111.684 -0.566 . . . . 10.0 111.684 170.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -74.1 -45.86 46.44 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.36 -67.75 0.54 Allowed Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.031 -1.441 . . . . 10.0 110.568 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -57.11 -42.94 58.13 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.451 2.101 . . . . 10.0 110.41 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.2 t -63.94 97.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 106.522 -1.658 . . . . 10.0 106.522 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -116.28 118.6 33.21 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.129 -1.434 . . . . 10.0 107.129 169.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.426 ' HA2' ' CG2' ' A' ' 35' ' ' ILE . . . -99.17 152.95 19.68 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 109.931 -1.268 . . . . 10.0 109.931 174.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.444 HG23 HG12 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -156.47 83.69 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 -172.166 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.612 HD12 ' HA3' ' A' ' 33' ' ' GLY . 1.1 tp -85.35 157.21 3.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 C-N-CA 125.166 1.387 . . . . 10.0 111.016 176.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.438 ' HB2' ' CD1' ' A' ' 32' ' ' TRP . 5.1 m120 -139.1 99.5 3.78 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 127.567 2.347 . . . . 10.0 106.621 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 m-30 -99.07 102.85 14.68 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 105.194 -2.15 . . . . 10.0 105.194 174.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -117.67 132.48 56.48 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 120.409 -0.516 . . . . 10.0 111.591 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -104.36 107.99 19.18 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.701 -1.222 . . . . 10.0 107.701 172.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.2 pttp -54.53 -40.84 69.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 122.955 0.502 . . . . 10.0 110.65 174.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -146.37 172.92 12.78 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 104.937 -2.246 . . . . 10.0 104.937 168.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 86.8 p -69.12 -20.8 64.05 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 124.13 0.972 . . . . 10.0 109.576 174.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -93.89 -3.06 52.42 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.822 -0.627 . . . . 10.0 111.119 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.18 144.8 18.18 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 173.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -61.36 149.7 88.29 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 N-CA-C 106.902 -1.999 . . . . 10.0 106.902 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.7 t -79.0 120.96 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 N-CA-C 104.754 -2.313 . . . . 10.0 104.754 176.178 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.6 tttt -83.24 113.26 20.56 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 105.558 -2.015 . . . . 10.0 105.558 169.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.7 m -97.31 59.14 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 C-N-CA 125.774 1.63 . . . . 10.0 107.975 -170.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.438 ' CD1' ' HB2' ' A' ' 19' ' ' ASN . 14.8 p90 -84.7 171.85 12.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 109.167 -0.679 . . . . 10.0 109.167 -171.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.612 ' HA3' HD12 ' A' ' 18' ' ' ILE . . . 169.12 175.25 38.3 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 119.823 -1.179 . . . . 10.0 112.489 178.247 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.3 p -149.03 85.18 1.46 Allowed 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 121.066 0.46 . . . . 10.0 111.972 -169.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.707 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -76.83 147.19 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 107.664 -1.235 . . . . 10.0 107.664 174.446 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.99 156.14 46.77 Favored 'General case' 0 C--O 1.232 0.157 0 O-C-N 124.102 0.876 . . . . 10.0 110.015 167.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.22 2.86 48.16 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 124.043 0.83 . . . . 10.0 114.52 177.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.45 HD12 ' N ' ' A' ' 38' ' ' LEU . 5.3 mp -87.75 176.64 7.3 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.542 1.137 . . . . 10.0 108.778 -177.27 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -91.06 172.71 8.38 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 165.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -64.33 176.02 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.226 1.01 . . . . 10.0 110.889 -172.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.63 175.46 48.42 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 124.137 0.875 . . . . 10.0 111.581 167.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.443 HD22 ' HB3' ' A' ' 86' ' ' ASN . 4.7 mt -62.24 147.58 47.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.332 -0.511 . . . . 10.0 110.173 171.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -133.59 147.03 51.48 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.637 0.775 . . . . 10.0 110.678 176.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.621 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -36.14 112.89 0.14 Allowed Glycine 0 CA--C 1.526 0.736 0 CA-C-O 116.105 -2.497 . . . . 10.0 113.445 164.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -137.08 107.65 6.53 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 121.522 2.661 . . . . 10.0 111.916 170.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.452 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -148.17 -178.99 6.6 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 113.783 1.031 . . . . 10.0 113.783 -175.442 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.7 p -91.5 -47.59 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 127.554 2.342 . . . . 10.0 114.506 -169.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 57.1 161.96 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 125.498 1.519 . . . . 10.0 112.431 -169.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -78.01 -67.85 0.69 Allowed 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.944 -0.571 . . . . 10.0 109.862 -176.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -78.63 146.27 34.21 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 119.954 -0.699 . . . . 10.0 109.432 -171.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -75.74 -28.42 61.09 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 108.905 -1.678 . . . . 10.0 108.905 169.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.3 145.68 1.62 Allowed 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.746 1.26 . . . . 10.0 113.995 -175.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -135.8 16.06 3.33 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 113.679 -1.6 . . . . 10.0 110.453 -178.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.424 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -58.08 -36.45 72.86 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 119.181 0.901 . . . . 10.0 112.477 -169.745 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.07 -17.71 58.54 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 111.778 0.288 . . . . 10.0 111.778 178.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 97.85 84.18 1.74 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.107 -1.597 . . . . 10.0 109.107 -173.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 94.2 m 48.81 57.13 6.71 Favored 'General case' 0 N--CA 1.464 0.228 0 C-N-CA 124.305 1.042 . . . . 10.0 111.391 175.268 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -157.66 -54.61 0.07 Allowed 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.6 p -54.73 -30.26 55.73 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 124.121 0.968 . . . . 10.0 111.023 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.26 -38.47 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 127.977 2.511 . . . . 10.0 113.995 167.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.75 170.06 20.17 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -79.29 -167.13 0.47 Allowed 'Trans proline' 0 N--CA 1.439 -1.679 0 N-CA-C 106.377 -2.201 . . . . 10.0 106.377 166.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.452 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.4 m170 -83.32 59.07 4.82 Favored 'General case' 0 CA--C 1.537 0.457 0 O-C-N 120.561 -1.337 . . . . 10.0 110.097 -175.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -76.61 51.66 0.76 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.6 1.191 . . . . 10.0 112.587 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -56.94 149.72 42.7 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 125.601 1.561 . . . . 10.0 111.008 168.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -67.96 -48.04 1.56 Allowed 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.652 2.235 . . . . 10.0 111.401 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.92 54.09 0.98 Allowed 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.743 -0.598 . . . . 10.0 111.103 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.6 t -58.63 100.85 0.07 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.048 0.939 . . . . 10.0 110.111 -174.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtt-85 -113.78 -90.47 0.52 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 105.857 -1.905 . . . . 10.0 105.857 -177.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -149.42 144.59 26.46 Favored 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 109.334 -0.617 . . . . 10.0 109.334 168.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -51.5 119.78 4.48 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 119.714 -0.794 . . . . 10.0 109.929 168.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.0 -129.48 1.97 Allowed Glycine 0 N--CA 1.451 -0.359 0 N-CA-C 107.513 -2.235 . . . . 10.0 107.513 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.53 -143.29 5.84 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 118.182 0.991 . . . . 10.0 111.03 169.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -68.83 1.26 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 CA-C-N 120.075 1.937 . . . . 10.0 110.228 168.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 31.2 mmtp -93.9 -15.96 24.47 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-O 117.844 -1.074 . . . . 10.0 110.494 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -127.61 161.38 28.98 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 119.255 0.934 . . . . 10.0 109.5 -171.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -84.28 -28.91 26.83 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -78.94 -11.52 60.0 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 124.465 1.106 . . . . 10.0 112.059 -169.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.4 ptp180 -33.45 138.46 0.07 Allowed 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 126.415 1.886 . . . . 10.0 114.596 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.4 m170 -69.5 177.17 3.03 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.562 -0.533 . . . . 10.0 109.562 169.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 p -72.85 39.32 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 125.525 1.53 . . . . 10.0 114.228 -172.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 48.03 0.04 OUTLIER Glycine 0 CA--C 1.524 0.655 0 O-C-N 120.597 -1.315 . . . . 10.0 111.526 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -85.0 102.81 13.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 104.92 -2.252 . . . . 10.0 104.92 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.7 mt -74.62 -32.19 62.23 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 107.073 -1.454 . . . . 10.0 107.073 169.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.82 -104.35 3.04 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 109.586 -1.406 . . . . 10.0 109.586 168.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.443 ' HB3' HD22 ' A' ' 42' ' ' LEU . 39.9 m-20 -126.4 105.79 9.02 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 126.743 2.017 . . . . 10.0 106.511 -167.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.63 134.67 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 123.411 0.684 . . . . 10.0 109.566 173.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.58 122.43 26.49 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.524 2.73 . . . . 10.0 112.809 -167.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.01 133.99 34.86 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.49 0.716 . . . . 10.0 109.255 169.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -60.76 171.53 1.15 Allowed 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.459 0.703 . . . . 10.0 110.001 168.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 pttt -47.54 -34.22 7.37 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.741 1.617 . . . . 10.0 111.311 171.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.8 -7.25 59.36 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 123.655 0.782 . . . . 10.0 111.166 -176.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.86 1.22 77.09 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.77 -0.932 . . . . 10.0 110.77 -175.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -77.19 103.87 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 -176.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.707 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -101.43 114.37 28.32 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 107.809 -1.182 . . . . 10.0 107.809 169.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -85.44 127.96 34.57 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 107.539 -1.282 . . . . 10.0 107.539 169.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 56.9 t -110.11 132.04 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 106.389 -1.708 . . . . 10.0 106.389 170.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -154.52 71.28 0.82 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.994 0.918 . . . . 10.0 108.955 170.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -114.62 159.01 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 105.603 -1.999 . . . . 10.0 105.603 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -130.95 142.44 50.35 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.854 0.861 . . . . 10.0 110.074 172.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -131.25 133.66 45.65 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.266 1.027 . . . . 10.0 109.683 -172.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 62.3 p -110.96 57.09 0.62 Allowed 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.373 1.869 . . . . 10.0 108.63 174.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 96.0 t -141.77 -61.73 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.14 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 -177.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.279 0.0 OUTLIER -60.68 170.94 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 N-CA-C 113.229 0.826 . . . . 10.0 113.229 174.83 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.6 m -145.5 111.97 5.8 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 121.498 -0.751 . . . . 10.0 109.286 175.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.2 tt -49.05 -44.89 42.11 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 126.09 1.756 . . . . 10.0 109.955 177.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -143.72 160.8 40.08 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 106.465 -1.679 . . . . 10.0 106.465 169.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.32 -95.96 0.2 Allowed Glycine 0 C--N 1.334 0.418 0 N-CA-C 109.349 -1.5 . . . . 10.0 109.349 -177.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -119.54 -51.69 2.28 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.265 1.826 . . . . 10.0 107.886 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -73.51 -37.31 65.72 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.681 -1.229 . . . . 10.0 107.681 -171.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 t 47.47 59.27 4.22 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.773 1.629 . . . . 10.0 108.078 169.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.2 pt -74.86 65.77 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 O-C-N 124.622 1.201 . . . . 10.0 110.121 -172.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.7 mm -110.64 -68.34 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 127.808 2.443 . . . . 10.0 108.33 -176.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.68 51.8 4.06 Favored Glycine 0 CA--C 1.531 1.092 0 O-C-N 121.221 -0.925 . . . . 10.0 112.086 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.4 ptm180 -112.36 162.16 15.85 Favored 'General case' 0 CA--C 1.53 0.173 0 C-N-CA 127.213 2.205 . . . . 10.0 107.168 176.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -109.61 104.72 13.79 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 118.565 0.621 . . . . 10.0 109.513 -179.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -64.47 131.02 45.94 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 106.695 -1.594 . . . . 10.0 106.695 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.2 t -122.5 132.59 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.522 ' CG1' ' HB3' ' A' ' 145' ' ' ALA . 1.7 p -94.56 122.35 45.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 105.829 -1.915 . . . . 10.0 105.829 166.154 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.621 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.9 m-70 -100.92 162.78 12.66 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.711 0.767 . . . . 10.0 112.631 174.002 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -64.58 -56.16 15.76 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.48 -0.782 . . . . 10.0 109.316 176.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -98.8 165.49 11.75 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 119.474 -0.89 . . . . 10.0 112.076 -168.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.7 147.15 53.04 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.801 -1.545 . . . . 10.0 107.792 169.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.432 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 6.7 m-20 -78.45 163.49 25.57 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.86 -0.793 . . . . 10.0 108.86 172.499 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.15 -10.38 59.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 113.736 -1.575 . . . . 10.0 110.781 168.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.5 mt 43.02 45.92 4.61 Favored 'General case' 0 C--N 1.343 0.32 0 C-N-CA 124.826 1.25 . . . . 10.0 109.856 -168.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.19 -21.83 44.01 Favored Glycine 0 CA--C 1.529 0.968 0 CA-C-N 113.713 -1.585 . . . . 10.0 113.728 170.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -77.48 0.78 21.45 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 115.543 1.682 . . . . 10.0 115.543 -165.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.89 -36.59 88.23 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.831 -0.907 . . . . 10.0 110.831 177.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.23 39.82 98.34 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 108.31 -1.916 . . . . 10.0 108.31 -169.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -128.39 164.46 22.64 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -54.79 -47.98 73.3 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.131 -0.941 . . . . 10.0 108.62 174.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -55.08 -39.61 69.47 Favored 'General case' 0 C--N 1.344 0.347 0 C-N-CA 123.283 0.633 . . . . 10.0 111.387 171.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.305 1.8 p -58.73 -36.06 73.7 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-O 118.138 -0.934 . . . . 10.0 111.733 -173.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.1 t -83.06 3.31 30.94 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.315 0.962 . . . . 10.0 112.541 178.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -118.6 -81.17 0.62 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.669 1.588 . . . . 10.0 110.511 -174.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.8 p -108.52 9.71 27.38 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 121.067 1.758 . . . . 10.0 111.43 175.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.1 -79.83 1.87 Allowed Glycine 0 C--N 1.342 0.891 0 O-C-N 120.708 -1.245 . . . . 10.0 110.0 176.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 178.71 36.87 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.684 1.993 . . . . 10.0 109.347 178.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.75 -14.29 61.96 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 123.832 0.853 . . . . 10.0 111.978 -169.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.02 -170.05 54.44 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 109.146 -1.582 . . . . 10.0 109.146 -169.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.4 m -55.06 165.0 0.74 Allowed 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 124.295 1.038 . . . . 10.0 112.667 -177.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -80.96 114.32 19.76 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 167.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.413 ' N ' ' CD2' ' A' ' 144' ' ' LEU . 1.1 mm? -84.5 -45.29 12.78 Favored 'General case' 0 C--N 1.333 -0.149 0 N-CA-C 108.396 -0.965 . . . . 10.0 108.396 -176.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.522 ' HB3' ' CG1' ' A' ' 119' ' ' VAL . . . -147.29 157.04 43.44 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 p -154.28 164.1 39.11 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 116.44 -0.345 . . . . 10.0 110.762 -176.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.86 150.8 22.43 Favored Glycine 0 C--N 1.336 0.531 0 C-N-CA 124.246 0.927 . . . . 10.0 110.916 -173.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.73 148.4 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 104.34 -2.467 . . . . 10.0 104.34 175.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.694 HG12 ' HB2' ' A' ' 6' ' ' ALA . 83.9 mt -76.66 -86.79 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 122.649 1.214 . . . . 10.0 109.169 -171.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.18 25.4 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.744 1.64 . . . . 10.0 115.257 170.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER 63.8 152.64 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 C-N-CA 124.283 1.033 . . . . 10.0 111.413 -173.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.578 ' HB2' HG12 ' A' ' 5' ' ' VAL . . . -113.36 -49.05 2.92 Favored 'General case' 0 CA--C 1.51 -0.592 0 O-C-N 120.456 -1.403 . . . . 10.0 110.316 169.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.433 -1.316 0 N-CA-C 106.047 -1.834 . . . . 10.0 106.047 -178.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.941 0 CA-C-O 118.01 -0.995 . . . . 10.0 108.886 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.5 t -95.15 -45.27 7.27 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.967 0.907 . . . . 10.0 111.952 -175.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.7 tttp -111.09 133.83 53.16 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.328 1.051 . . . . 10.0 109.011 176.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 166.82 23.73 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.12 1.368 . . . . 10.0 108.408 171.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.49 175.19 10.59 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 123.046 0.538 . . . . 10.0 109.767 175.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . 0.474 ' CB ' HD12 ' B' ' 117' ' ' LEU . . . -149.45 103.85 3.32 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 106.346 -1.724 . . . . 10.0 106.346 166.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 22.7 m -83.13 111.84 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 108.834 -0.802 . . . . 10.0 108.834 170.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.96 143.45 26.85 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.056 -1.09 . . . . 10.0 108.056 175.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . 0.402 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 46.5 tttt -163.73 163.76 24.01 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 108.097 -1.075 . . . . 10.0 108.097 170.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.61 -50.76 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 111.803 -0.519 . . . . 10.0 111.803 169.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.24 -47.16 20.9 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.106 -1.442 . . . . 10.0 107.106 -169.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.18 -61.1 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.919 -1.491 . . . . 10.0 111.785 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -62.74 -39.15 44.65 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 122.642 2.228 . . . . 10.0 110.89 170.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 68.1 t -77.6 115.03 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.553 1.141 . . . . 10.0 108.255 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -147.46 139.05 23.95 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 123.208 0.318 . . . . 10.0 110.605 166.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -107.66 153.53 16.79 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 110.15 -1.18 . . . . 10.0 110.15 169.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.424 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.0 mt -138.93 59.41 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 106.179 -1.786 . . . . 10.0 106.179 -176.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.1 mm -78.86 136.72 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-N 115.221 -0.9 . . . . 10.0 109.205 -169.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -108.71 117.13 33.39 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 127.329 2.252 . . . . 10.0 108.076 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.463 ' CE1' HD11 ' B' ' 117' ' ' LEU . 21.9 m-85 -101.15 111.18 23.32 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.256 -1.387 . . . . 10.0 107.256 175.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -118.03 133.26 56.08 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-O 121.358 0.599 . . . . 10.0 112.068 172.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -121.72 113.15 19.31 Favored 'General case' 0 N--CA 1.446 -0.646 0 N-CA-C 105.519 -2.03 . . . . 10.0 105.519 170.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 39.2 pttt -59.97 -29.66 68.58 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.3 1.04 . . . . 10.0 110.725 -175.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 53.6 mt-10 -132.35 179.95 5.81 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 103.853 -2.647 . . . . 10.0 103.853 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 34.3 m -87.43 -1.08 57.67 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 118.698 0.681 . . . . 10.0 109.858 173.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 35.0 m-80 -128.71 4.48 5.5 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 123.981 0.913 . . . . 10.0 112.179 -176.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.37 174.88 55.0 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 109.893 -1.283 . . . . 10.0 109.893 175.107 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -60.88 136.63 67.19 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 CA-C-N 119.735 1.767 . . . . 10.0 109.537 169.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.7 t -79.86 97.41 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 104.038 -2.579 . . . . 10.0 104.038 168.13 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . 0.266 71.2 tttt -82.84 112.63 19.83 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 172.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -95.48 101.45 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 C-N-CA 126.952 2.101 . . . . 10.0 105.855 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -121.23 160.94 22.82 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 112.325 0.491 . . . . 10.0 112.325 173.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.87 -152.48 24.14 Favored Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 170.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 40.1 t -155.72 151.49 27.41 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 120.211 -0.596 . . . . 10.0 110.321 177.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.439 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 0.9 OUTLIER -100.99 122.98 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 N-CA-C 107.433 -1.321 . . . . 10.0 107.433 165.836 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 20.9 ptmt -105.38 139.89 39.32 Favored 'General case' 0 N--CA 1.453 -0.296 0 O-C-N 123.891 0.744 . . . . 10.0 108.995 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.18 -5.52 15.48 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.417 1.008 . . . . 10.0 113.269 176.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -68.21 176.76 2.57 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 118.366 1.083 . . . . 10.0 111.09 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -108.54 161.03 15.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.28 -2.118 . . . . 10.0 105.28 165.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -52.03 160.43 0.73 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.636 1.174 . . . . 10.0 111.725 -169.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.84 -179.98 34.38 Favored Glycine 0 N--CA 1.447 -0.602 0 O-C-N 121.549 -0.719 . . . . 10.0 111.486 168.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.9 mp -68.62 149.01 49.64 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.735 1.614 . . . . 10.0 110.446 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -148.75 148.63 30.21 Favored 'General case' 0 C--O 1.233 0.198 0 C-N-CA 123.42 0.688 . . . . 10.0 112.432 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.684 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.4 121.29 0.2 Allowed Glycine 0 C--N 1.339 0.748 0 C-N-CA 127.941 2.686 . . . . 10.0 113.038 165.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -151.64 110.92 3.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 119.088 1.444 . . . . 10.0 110.044 167.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.521 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.2 OUTLIER -144.24 174.3 11.01 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-O 121.373 0.606 . . . . 10.0 111.888 178.131 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . 0.589 HG12 HH11 ' B' ' 115' ' ' ARG . 3.2 t -114.42 86.75 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 CA-C-N 112.599 -2.091 . . . . 10.0 107.981 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -67.66 149.99 49.31 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 124.876 1.27 . . . . 10.0 109.898 174.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -71.65 -59.6 2.67 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.136 -1.393 . . . . 10.0 110.412 -170.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -79.09 136.59 37.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 120.891 -0.323 . . . . 10.0 110.237 -171.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -54.75 -50.42 57.99 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 108.304 -1.918 . . . . 10.0 108.304 169.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -24.12 124.0 0.04 OUTLIER 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 128.069 2.547 . . . . 10.0 113.737 -173.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.92 11.99 2.65 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.63 -175.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.43 HG23 HG22 ' A' ' 17' ' ' ILE . 0.2 OUTLIER -51.41 -40.35 59.13 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 126.049 1.74 . . . . 10.0 111.389 -170.867 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.51 -20.73 46.51 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 124.703 1.201 . . . . 10.0 113.209 178.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.92 82.83 1.67 Allowed Glycine 0 CA--C 1.528 0.864 0 C-N-CA 124.67 1.129 . . . . 10.0 110.624 -178.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.9 m 53.22 21.1 2.09 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.382 1.473 . . . . 10.0 112.733 176.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -111.56 -42.29 3.89 Favored 'General case' 0 N--CA 1.437 -1.089 0 O-C-N 120.613 -1.304 . . . . 10.0 108.092 -168.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 70.3 m -92.14 -11.05 36.67 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 117.831 -1.08 . . . . 10.0 113.541 -168.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.35 2.01 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 128.597 2.759 . . . . 10.0 117.14 -174.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.2 119.24 2.25 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 109.482 -1.447 . . . . 10.0 109.482 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -76.52 64.12 7.31 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.483 2.789 . . . . 10.0 111.02 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 22.5 m170 69.53 53.62 0.41 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 128.752 2.821 . . . . 10.0 110.132 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -73.95 52.08 0.42 Allowed 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.306 1.042 . . . . 10.0 112.997 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -65.49 153.91 89.2 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 126.823 2.049 . . . . 10.0 111.62 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.8 -43.94 2.34 Favored 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 123.079 2.519 . . . . 10.0 111.955 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 67.3 mt -78.85 53.77 1.44 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.718 0.807 . . . . 10.0 110.363 -177.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.6 p -58.39 102.41 0.11 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.823 1.249 . . . . 10.0 110.337 -172.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 mtp85 -132.48 -87.88 0.44 Allowed 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 -171.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -145.13 155.61 43.41 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 121.689 0.757 . . . . 10.0 109.444 168.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.0 t60 -63.05 120.7 11.93 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 105.592 -2.003 . . . . 10.0 105.592 163.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -140.29 -136.44 3.34 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 107.602 -2.199 . . . . 10.0 107.602 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.36 -166.37 32.91 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.11 10.12 0.42 Allowed 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.607 1.538 . . . . 10.0 109.938 166.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 45.0 mmtt -97.28 -25.67 15.18 Favored 'General case' 0 N--CA 1.44 -0.927 0 C-N-CA 124.75 1.22 . . . . 10.0 107.818 173.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.415 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 23.1 m-20 -120.69 158.12 28.15 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.488 -1.671 . . . . 10.0 106.488 -169.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -80.66 -34.11 35.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.776 -1.194 . . . . 10.0 107.776 170.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -78.31 1.6 21.24 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 125.939 1.696 . . . . 10.0 113.311 -165.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -40.24 144.18 0.24 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.037 1.735 . . . . 10.0 111.694 174.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.4 m170 -61.52 -58.03 9.76 Favored 'General case' 0 C--O 1.224 -0.255 0 CA-C-O 120.989 0.424 . . . . 10.0 110.425 -175.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.555 HG13 ' H ' ' B' ' 82' ' ' GLY . 5.2 p -174.2 -69.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.457 -0.104 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 172.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.555 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -104.7 62.22 0.37 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 109.478 -1.449 . . . . 10.0 109.478 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -100.5 95.52 6.78 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 103.878 -2.638 . . . . 10.0 103.878 168.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.54 -17.87 64.81 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.694 0.679 . . . . 10.0 111.454 -171.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 107.24 -103.08 1.92 Allowed Glycine 0 N--CA 1.438 -1.228 0 N-CA-C 106.08 -2.808 . . . . 10.0 106.08 -176.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -147.65 139.11 23.78 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 -178.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 28.5 m -106.82 134.45 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.243 0 N-CA-C 105.914 -1.884 . . . . 10.0 105.914 169.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.2 t -109.13 126.21 52.99 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.527 -0.546 . . . . 10.0 109.527 -173.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.42 132.09 37.05 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 122.9 0.48 . . . . 10.0 110.773 -176.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -60.69 168.86 2.05 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 166.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -50.3 -29.26 9.35 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 126.387 1.875 . . . . 10.0 111.414 173.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -78.06 -11.88 59.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.967 0.507 . . . . 10.0 110.701 -177.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.29 20.59 48.34 Favored Glycine 0 C--N 1.338 0.694 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -103.66 107.31 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.838 0 C-N-CA 127.13 2.172 . . . . 10.0 106.115 -178.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.401 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -104.95 125.29 50.79 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 108.883 -0.784 . . . . 10.0 108.883 171.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -79.37 135.0 36.59 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.612 1.165 . . . . 10.0 109.807 175.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.26 129.83 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 127.145 2.178 . . . . 10.0 106.436 168.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.2 p -158.69 57.4 0.44 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.277 0.944 . . . . 10.0 112.726 176.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.4 152.38 12.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.954 0.902 . . . . 10.0 109.554 -169.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -99.27 112.21 24.42 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 10.0 109.708 167.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -79.13 71.41 5.62 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 104.89 -2.263 . . . . 10.0 104.89 169.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.09 54.37 2.75 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 127.011 2.124 . . . . 10.0 105.416 -174.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.5 t -148.0 -51.99 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 125.817 1.647 . . . . 10.0 109.393 -168.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.435 ' C ' HD12 ' B' ' 104' ' ' ILE 0.322 1.2 pp -113.37 -178.8 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 126.203 1.801 . . . . 10.0 112.683 -172.445 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 61.2 m -146.94 151.84 37.67 Favored 'General case' 0 C--O 1.232 0.172 0 O-C-N 121.052 -1.03 . . . . 10.0 110.78 -178.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 81.9 mt -70.39 -33.85 71.88 Favored 'General case' 0 N--CA 1.458 -0.047 0 C-N-CA 124.271 1.028 . . . . 10.0 110.891 -177.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.4 p -153.84 153.89 32.94 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 108.866 -0.79 . . . . 10.0 108.866 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.88 -100.92 0.5 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 106.497 -2.641 . . . . 10.0 106.497 -169.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -123.86 -44.82 2.05 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 125.444 1.498 . . . . 10.0 109.184 -169.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 12.1 m-70 -75.12 -41.83 57.64 Favored 'General case' 0 N--CA 1.456 -0.127 0 N-CA-C 108.05 -1.093 . . . . 10.0 108.05 -178.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 39.8 t 42.48 57.64 3.36 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 125.67 1.588 . . . . 10.0 113.581 167.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -71.19 -7.1 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 113.789 1.033 . . . . 10.0 113.789 -174.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.7 mm -52.14 127.71 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 109.17 -0.678 . . . . 10.0 109.17 173.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.78 -25.5 11.74 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.383 -0.687 . . . . 10.0 111.383 -175.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . 0.589 HH11 HG12 ' B' ' 47' ' ' VAL . 13.3 mtp-105 -72.05 161.8 30.37 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 119.094 1.447 . . . . 10.0 109.526 -169.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -111.03 131.77 54.78 Favored 'General case' 0 CA--C 1.514 -0.412 0 C-N-CA 124.53 1.132 . . . . 10.0 109.652 -167.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.474 HD12 ' CB ' ' B' ' 6' ' ' ALA . 26.4 mt -104.64 140.38 38.11 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.674 -0.861 . . . . 10.0 108.674 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 85.5 t -134.41 125.81 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.884 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 -175.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.407 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 2.3 p -90.35 129.02 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.772 -1.566 . . . . 10.0 106.772 167.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.684 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.8 m170 -106.54 157.12 17.91 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.076 1.139 . . . . 10.0 114.076 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -50.63 -51.84 45.18 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.667 1.587 . . . . 10.0 110.906 176.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -115.67 167.87 10.53 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-N 118.581 0.628 . . . . 10.0 111.593 -169.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.13 150.17 49.52 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.744 -1.116 . . . . 10.0 110.022 177.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.521 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.6 OUTLIER -79.16 135.16 36.73 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.204 1.002 . . . . 10.0 110.903 171.9 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -79.39 -15.83 57.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 124.621 1.201 . . . . 10.0 110.541 167.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 80.0 mt 58.86 46.11 14.37 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.234 1.014 . . . . 10.0 111.667 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.34 -51.76 1.24 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 110.22 -1.152 . . . . 10.0 110.22 173.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.415 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -82.21 48.77 1.3 Allowed 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 117.583 0.691 . . . . 10.0 112.099 -175.7 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.13 -38.52 5.67 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 108.648 -1.781 . . . . 10.0 108.648 169.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.54 33.26 16.95 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 178.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -130.61 165.08 23.55 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 105.83 -1.915 . . . . 10.0 105.83 168.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -50.38 -43.9 54.64 Favored 'General case' 0 N--CA 1.425 -1.724 0 CA-C-O 121.863 0.84 . . . . 10.0 108.796 171.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -65.7 -35.36 80.54 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-O 117.903 -1.046 . . . . 10.0 112.929 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 44.0 p -54.49 -46.28 73.39 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 120.987 1.721 . . . . 10.0 110.037 171.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -78.47 -13.65 59.74 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 118.11 -0.948 . . . . 10.0 113.162 -174.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.1 ttmm -103.92 -50.85 3.29 Favored 'General case' 0 N--CA 1.443 -0.778 0 C-N-CA 126.518 1.927 . . . . 10.0 112.51 -174.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 19.3 p -137.21 8.41 2.93 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 119.683 1.128 . . . . 10.0 113.658 174.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 88.23 20.56 48.65 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-O 118.577 -1.124 . . . . 10.0 113.215 174.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 6.9 m120 56.09 17.35 2.64 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 119.108 1.454 . . . . 10.0 112.244 -176.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.43 -11.69 58.43 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.007 0.923 . . . . 10.0 112.128 -174.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.97 -160.46 48.41 Favored Glycine 0 N--CA 1.441 -0.973 0 N-CA-C 111.104 -0.798 . . . . 10.0 111.104 168.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.8 m -51.6 125.27 14.26 Favored 'General case' 0 N--CA 1.439 -1.015 0 C-N-CA 124.622 1.169 . . . . 10.0 113.31 -168.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.5 mtm-85 -72.01 75.69 0.92 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 125.412 1.485 . . . . 10.0 109.595 176.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 70.2 mt -43.73 -49.08 8.02 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.997 0.919 . . . . 10.0 112.26 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.407 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -153.99 153.62 32.29 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.796 -0.816 . . . . 10.0 108.796 -168.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.06 166.12 34.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.58 -0.282 . . . . 10.0 110.805 -174.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.63 163.29 30.73 Favored Glycine 0 CA--C 1.523 0.563 0 C-N-CA 125.096 1.331 . . . . 10.0 109.856 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 37.6 t -120.94 136.58 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 106.088 -1.819 . . . . 10.0 106.088 -173.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 64.2 mt -70.52 130.42 34.71 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-N 118.175 0.443 . . . . 10.0 110.617 -177.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.64 141.98 13.24 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 124.254 0.93 . . . . 10.0 110.794 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -71.26 151.9 8.73 Favored 'Isoleucine or valine' 0 C--N 1.342 0.278 0 CA-C-N 118.44 1.12 . . . . 10.0 111.587 -178.323 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.3 -33.59 2.13 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 124.768 1.227 . . . . 10.0 113.267 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.063 0 CA-C-O 116.856 -1.545 . . . . 10.0 107.424 171.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.601 0 CA-C-O 118.863 -0.589 . . . . 10.0 110.059 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.9 t 125.01 -23.95 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 1 C-N-CA 131.942 4.097 . . . . 10.0 108.523 -174.309 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp -131.0 132.31 44.91 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 126.071 1.748 . . . . 10.0 108.124 169.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.54 168.75 18.66 Favored 'General case' 0 N--CA 1.462 0.149 0 C-N-CA 124.747 1.219 . . . . 10.0 109.443 169.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.413 ' O ' HG23 ' A' ' 149' ' ' ILE . 2.2 m -127.65 179.24 3.84 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.357 0 C-N-CA 124.177 0.991 . . . . 10.0 110.766 -174.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.81 114.77 2.64 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 106.879 -1.526 . . . . 10.0 106.879 164.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -98.66 96.26 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 C-N-CA 124.018 0.927 . . . . 10.0 110.21 172.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 mp -84.57 142.67 29.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.416 1.086 . . . . 10.0 110.023 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -153.2 165.06 36.85 Favored 'General case' 0 C--N 1.338 0.074 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 169.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.48 -59.65 0.04 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.391 -0.368 . . . . 10.0 113.268 169.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.19 -42.92 62.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -170.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.25 -66.51 0.53 Allowed Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 113.728 -1.578 . . . . 10.0 109.708 176.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -58.33 -39.95 79.77 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.62 2.213 . . . . 10.0 110.808 171.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.47 HG13 HD11 ' A' ' 38' ' ' LEU . 54.9 t -63.73 110.63 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 N-CA-C 108.134 -1.062 . . . . 10.0 108.134 178.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.18 132.01 51.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 168.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.687 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -114.28 134.03 11.49 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 109.47 -1.452 . . . . 10.0 109.47 174.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.43 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.9 mt -136.19 97.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 -170.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -102.52 152.24 5.74 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 C-N-CA 124.464 1.106 . . . . 10.0 110.979 -176.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -126.53 113.94 17.45 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 126.294 1.838 . . . . 10.0 107.714 169.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -96.94 100.01 11.54 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 172.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -110.65 118.73 36.99 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 120.436 -0.506 . . . . 10.0 111.594 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -90.73 103.61 16.29 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 105.752 -1.944 . . . . 10.0 105.752 172.222 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 27.1 mmmt -48.31 -57.56 5.82 Favored 'General case' 0 C--O 1.228 -0.071 0 C-N-CA 125.433 1.493 . . . . 10.0 110.811 -177.237 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.14 178.96 6.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 104.258 -2.497 . . . . 10.0 104.258 169.464 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -66.32 -26.98 67.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.594 0.712 . . . . 10.0 109.733 175.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -77.89 -22.68 49.39 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.507 -0.77 . . . . 10.0 109.815 177.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.8 144.75 22.24 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 110.779 -0.928 . . . . 10.0 110.779 -173.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -63.54 153.9 72.06 Favored 'Trans proline' 0 N--CA 1.449 -1.122 0 N-CA-C 107.237 -1.871 . . . . 10.0 107.237 168.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.4 p -77.21 117.24 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 N-CA-C 106.174 -1.787 . . . . 10.0 106.174 173.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 48.4 tttp -85.11 108.8 17.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 106.361 -1.718 . . . . 10.0 106.361 169.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -88.41 93.84 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.112 -1.811 . . . . 10.0 106.112 171.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.3 p90 -106.27 165.77 11.0 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 108.901 -0.777 . . . . 10.0 108.901 168.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.84 163.77 30.54 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -140.23 94.51 2.76 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.209 -1.034 . . . . 10.0 108.209 -175.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.687 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.7 pt -77.83 172.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 118.754 -1.179 . . . . 10.0 109.157 171.31 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -155.58 151.47 27.6 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 167.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.69 -18.97 19.38 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-O 118.83 -0.984 . . . . 10.0 114.036 174.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.47 HD11 HG13 ' A' ' 14' ' ' VAL . 6.8 mp -71.86 179.24 3.26 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 119.34 1.57 . . . . 10.0 111.672 -178.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -95.53 164.89 12.6 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.085 -1.08 . . . . 10.0 108.085 167.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -60.08 171.85 0.91 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.934 1.294 . . . . 10.0 112.892 -169.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.67 -173.08 43.33 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 123.879 0.752 . . . . 10.0 112.462 167.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -70.49 142.62 51.88 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.151 1.381 . . . . 10.0 110.017 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -144.13 147.46 33.75 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 123.64 0.776 . . . . 10.0 112.62 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.616 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.05 128.19 0.25 Allowed Glycine 0 C--N 1.341 0.853 0 C-N-CA 127.378 2.418 . . . . 10.0 111.589 165.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -153.79 106.32 2.86 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 118.904 1.352 . . . . 10.0 109.984 167.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.456 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -150.34 174.04 13.31 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 122.303 1.049 . . . . 10.0 113.686 -179.754 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.16 144.57 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 111.694 -2.503 . . . . 10.0 107.873 169.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.7 m-70 -128.14 138.95 52.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.085 -1.45 . . . . 10.0 107.085 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -50.64 -62.79 1.39 Allowed 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.974 1.31 . . . . 10.0 112.143 -169.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -80.22 130.24 35.08 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 119.624 -0.83 . . . . 10.0 109.294 -175.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.57 -13.74 71.63 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.313 -1.115 . . . . 10.0 110.313 167.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -46.37 144.84 1.94 Allowed 'General case' 0 C--N 1.345 0.387 0 CA-C-O 122.45 1.119 . . . . 10.0 109.697 168.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.424 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -153.82 15.6 0.49 Allowed 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.309 -1.314 . . . . 10.0 111.724 177.523 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.511 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -58.77 -34.29 71.26 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.331 0.969 . . . . 10.0 110.671 -174.044 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.67 -20.9 45.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.846 1.258 . . . . 10.0 113.062 175.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.22 97.59 1.36 Allowed Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.392 -1.083 . . . . 10.0 110.392 -170.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.288 20.9 p 15.36 60.27 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 128.597 2.759 . . . . 10.0 116.685 176.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 40.9 m -132.18 -61.77 0.86 Allowed 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 128.021 2.528 . . . . 10.0 105.172 174.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.6 m -57.25 -24.75 56.81 Favored 'General case' 0 C--N 1.34 0.156 0 C-N-CA 125.606 1.563 . . . . 10.0 111.667 176.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -41.89 -30.3 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 126.208 1.803 . . . . 10.0 112.502 168.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.93 125.66 5.62 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 109.845 -1.302 . . . . 10.0 109.845 169.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.6 66.95 3.78 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 124.096 3.197 . . . . 10.0 112.28 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 64.16 46.27 3.7 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 129.438 3.095 . . . . 10.0 111.227 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -70.85 69.79 0.47 Allowed 'General case' 0 CA--C 1.531 0.244 0 CA-C-O 121.759 0.79 . . . . 10.0 111.402 178.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.8 p-10 -68.61 152.1 96.86 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.306 -0.871 . . . . 10.0 109.206 169.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.19 -58.68 0.4 Allowed 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 122.26 1.974 . . . . 10.0 111.571 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -76.09 72.27 2.9 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 121.439 -0.788 . . . . 10.0 110.447 174.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.4 m -40.34 112.65 0.29 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.016 0.926 . . . . 10.0 110.699 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.92 -96.27 0.47 Allowed 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 176.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -149.39 155.86 41.13 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.988 0.899 . . . . 10.0 109.271 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 63.5 t60 -60.81 115.2 3.49 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 118.364 -1.334 . . . . 10.0 109.096 166.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.69 -137.4 3.49 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 107.935 -2.066 . . . . 10.0 107.935 176.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.26 -162.3 23.36 Favored Glycine 0 N--CA 1.45 -0.368 0 N-CA-C 109.03 -1.628 . . . . 10.0 109.03 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -61.56 -4.8 4.76 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 CA-C-N 119.585 1.692 . . . . 10.0 111.271 168.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -89.29 -26.81 20.94 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.724 1.21 . . . . 10.0 110.401 175.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 34.0 t0 -102.61 157.48 16.91 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 107.227 -1.398 . . . . 10.0 107.227 -178.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -80.6 -30.25 36.86 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.048 -1.093 . . . . 10.0 108.048 167.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -91.05 6.65 44.03 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.07 1.348 . . . . 10.0 113.419 -168.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -42.33 140.35 1.21 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.145 0.978 . . . . 10.0 110.835 178.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -60.27 -65.09 0.74 Allowed 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.852 0.835 . . . . 10.0 110.453 -171.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.714 HG13 ' H ' ' A' ' 82' ' ' GLY . 7.7 p -160.48 -87.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 105.336 -2.098 . . . . 10.0 105.336 171.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.714 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -88.38 59.95 4.06 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.311 -1.116 . . . . 10.0 110.311 178.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -96.15 91.53 5.97 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 104.916 -2.253 . . . . 10.0 104.916 168.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -66.88 -32.8 74.3 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 108.704 -0.85 . . . . 10.0 108.704 -175.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.45 -85.66 0.38 Allowed Glycine 0 N--CA 1.439 -1.13 0 N-CA-C 108.277 -1.929 . . . . 10.0 108.277 168.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 -150.76 135.78 17.56 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.161 -1.422 . . . . 10.0 107.161 -178.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -106.93 133.11 52.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 169.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -87.57 131.76 34.29 Favored 'General case' 0 C--O 1.224 -0.274 0 N-CA-C 108.208 -1.034 . . . . 10.0 108.208 176.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -107.11 135.9 47.86 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.029 0.932 . . . . 10.0 109.012 173.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -59.63 172.09 0.75 Allowed 'General case' 0 C--O 1.232 0.135 0 O-C-N 124.243 0.965 . . . . 10.0 109.912 167.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -47.39 -35.87 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 125.732 1.613 . . . . 10.0 110.387 170.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -79.69 -5.95 56.21 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.634 1.173 . . . . 10.0 110.723 -173.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 3.71 89.07 Favored Glycine 0 C--N 1.338 0.684 0 N-CA-C 111.101 -0.799 . . . . 10.0 111.101 -176.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.6 t -79.66 107.83 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 N-CA-C 106.465 -1.68 . . . . 10.0 106.465 179.05 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.453 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -105.39 120.93 42.83 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 108.829 -0.804 . . . . 10.0 108.829 169.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -79.81 114.8 19.0 Favored 'General case' 0 N--CA 1.434 -1.27 0 C-N-CA 125.849 1.659 . . . . 10.0 109.442 170.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.0 t -101.46 133.76 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 105.417 -2.068 . . . . 10.0 105.417 169.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 7.0 m -158.05 58.85 0.47 Allowed 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 118.969 0.804 . . . . 10.0 110.878 176.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.16 153.61 6.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 C-N-CA 124.001 0.92 . . . . 10.0 108.581 -174.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -123.08 136.27 54.74 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.395 1.478 . . . . 10.0 109.409 172.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -143.75 153.22 42.2 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.7 p -107.95 -26.47 10.69 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 127.148 2.179 . . . . 10.0 111.914 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.2 p -77.91 -45.15 28.08 Favored 'Isoleucine or valine' 0 C--N 1.342 0.27 0 N-CA-C 106.559 -1.645 . . . . 10.0 106.559 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -73.72 134.46 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 105.09 -2.189 . . . . 10.0 105.09 165.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -166.28 158.48 14.07 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 125.422 1.489 . . . . 10.0 108.117 -177.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.1 mt -60.59 -50.77 72.18 Favored 'General case' 0 N--CA 1.457 -0.08 0 CA-C-N 116.152 -0.477 . . . . 10.0 110.825 -171.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -120.1 -165.58 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.592 1.157 . . . . 10.0 108.28 172.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 97.77 62.65 0.89 Allowed Glycine 0 CA--C 1.524 0.608 0 C-N-CA 124.394 0.997 . . . . 10.0 111.198 169.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 t70 71.07 -57.54 0.6 Allowed 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 129.469 3.108 . . . . 10.0 109.334 -178.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -74.33 -39.96 62.5 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 -169.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.2 t 39.84 85.05 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 126.111 1.764 . . . . 10.0 113.012 167.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 35.7 pt -58.69 -22.7 21.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -177.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.5 mm -47.26 131.11 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 O-C-N 121.799 -0.563 . . . . 10.0 110.365 174.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.64 1.6 82.92 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 118.408 -1.218 . . . . 10.0 113.987 175.001 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mmt-85 -81.34 165.76 21.07 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.8 1.3 . . . . 10.0 111.348 171.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -100.7 130.51 46.75 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 105.309 -2.108 . . . . 10.0 105.309 169.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.7 mp -108.66 149.58 28.76 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.416 -0.957 . . . . 10.0 108.416 170.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 96.7 t -135.98 137.09 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.945 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 -173.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.6 p -108.19 138.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 168.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.616 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.6 m170 -116.22 161.16 19.4 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 115.641 1.719 . . . . 10.0 115.641 -170.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -43.33 -55.36 4.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 128.621 2.768 . . . . 10.0 110.046 177.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -124.21 174.41 7.7 Favored 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 125.065 1.346 . . . . 10.0 111.34 -169.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.25 148.86 45.06 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.667 1.187 . . . . 10.0 110.401 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.456 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.2 m-20 -78.59 147.33 33.74 Favored 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 124.145 0.978 . . . . 10.0 111.702 174.186 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -75.44 -30.23 59.93 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 114.372 -1.285 . . . . 10.0 109.675 169.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 29.9 mt 57.45 52.67 8.28 Favored 'General case' 0 C--N 1.339 0.13 0 N-CA-C 107.688 -1.227 . . . . 10.0 107.688 -167.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.42 -24.7 12.97 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-N 113.521 -1.672 . . . . 10.0 112.99 173.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -75.11 6.5 4.18 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 114.543 1.312 . . . . 10.0 114.543 -167.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.83 -16.6 79.27 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.057 0.836 . . . . 10.0 112.097 171.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.82 43.77 48.28 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 118.082 0.941 . . . . 10.0 111.801 -176.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -130.88 163.4 27.52 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 106.943 -1.503 . . . . 10.0 106.943 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -54.07 -49.54 68.8 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.16 -0.927 . . . . 10.0 108.502 169.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -56.95 -44.21 82.32 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 122.775 0.43 . . . . 10.0 110.519 173.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.3 p -56.3 -43.74 79.21 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 120.635 -1.29 . . . . 10.0 110.576 -178.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -82.24 2.12 33.37 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 118.848 -0.596 . . . . 10.0 112.071 -178.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.5 -75.84 0.61 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.328 1.851 . . . . 10.0 110.196 176.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 6.6 p -120.96 27.06 8.69 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 120.786 1.63 . . . . 10.0 113.371 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.2 27.99 70.01 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 121.811 -0.556 . . . . 10.0 113.771 167.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 47.65 30.06 1.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.816 0.808 . . . . 10.0 112.177 -173.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.18 -5.33 13.2 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.723 -0.61 . . . . 10.0 110.855 175.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.59 -156.06 36.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 109.806 -1.318 . . . . 10.0 109.806 168.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.3 m -59.86 131.95 52.45 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 109.497 -0.557 . . . . 10.0 109.497 -171.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.46 68.01 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 168.1 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.77 -27.45 67.99 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 -169.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.35 145.83 24.08 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-O 121.475 0.655 . . . . 10.0 109.278 -178.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 15.8 p -162.46 163.65 27.48 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-N 115.849 -0.614 . . . . 10.0 109.641 -167.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 179.6 36.23 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 110.588 -1.005 . . . . 10.0 110.588 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.88 148.12 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.675 0 N-CA-C 103.72 -2.696 . . . . 10.0 103.72 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.413 HG23 ' O ' ' A' ' 5' ' ' VAL . 3.9 mt -65.81 -87.7 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 C-N-CA 123.222 0.609 . . . . 10.0 111.203 -168.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.57 135.29 7.05 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.426 -0.669 . . . . 10.0 111.426 -178.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 62.3 mt -76.37 150.44 6.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 C-N-CA 125.132 1.373 . . . . 10.0 108.166 -176.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.14 -45.44 3.29 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 120.974 1.716 . . . . 10.0 112.006 169.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.3 tp60 . . . . . 0 C--O 1.252 1.219 0 C-N-CA 124.14 0.976 . . . . 10.0 109.772 -174.526 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.673 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.4 t -166.38 -46.88 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 124.486 1.114 . . . . 10.0 108.788 173.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -123.95 136.53 54.38 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.232 1.413 . . . . 10.0 109.165 -175.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 167.43 22.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 125.942 1.697 . . . . 10.0 107.803 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.49 168.88 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 118.488 0.585 . . . . 10.0 112.314 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.99 104.28 4.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 106.899 -1.519 . . . . 10.0 106.899 167.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.424 HG21 ' HB3' ' A' ' 53' ' ' ASN . 10.9 m -92.09 76.38 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 123.476 0.71 . . . . 10.0 109.212 175.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.5 mp -74.69 145.82 42.81 Favored 'General case' 0 N--CA 1.449 -0.521 0 O-C-N 121.299 -0.876 . . . . 10.0 109.263 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 161.4 19.77 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 107.992 -1.114 . . . . 10.0 107.992 -175.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.56 -58.37 0.04 OUTLIER Glycine 0 C--N 1.329 0.175 0 CA-C-N 115.628 -0.714 . . . . 10.0 111.579 169.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.21 -46.49 33.62 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 106.645 -1.613 . . . . 10.0 106.645 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.82 -68.37 0.51 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 113.383 -1.735 . . . . 10.0 110.729 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -59.89 -35.95 92.08 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.957 2.438 . . . . 10.0 111.424 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.408 HG13 HD11 ' B' ' 38' ' ' LEU . 96.5 t -68.71 99.74 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.141 0 N-CA-C 107.063 -1.458 . . . . 10.0 107.063 176.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -121.95 111.9 17.63 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.483 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -94.37 138.71 14.16 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 109.133 -1.587 . . . . 10.0 109.133 169.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.511 ' CG2' HG23 ' A' ' 54' ' ' THR . 6.5 mt -139.31 78.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 106.681 -1.6 . . . . 10.0 106.681 -177.022 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -102.59 148.88 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.143 -0.935 . . . . 10.0 109.59 -175.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -118.37 114.04 22.32 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.831 1.652 . . . . 10.0 108.223 171.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -86.09 99.28 11.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 175.083 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.37 153.3 21.85 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 123.964 0.79 . . . . 10.0 109.883 -178.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -158.84 86.9 0.85 Allowed 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.254 -0.647 . . . . 10.0 109.254 -173.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 2.0 ttpm? -147.14 83.48 1.57 Allowed 'General case' 0 N--CA 1.424 -1.755 0 CA-C-O 122.257 1.027 . . . . 10.0 109.74 -174.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.62 172.28 18.55 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 102.622 -3.103 . . . . 10.0 102.622 166.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 21.1 t -78.31 -11.3 59.93 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.796 -0.362 . . . . 10.0 110.616 175.683 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 -88.65 -18.79 27.21 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 124.08 0.952 . . . . 10.0 109.214 172.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 43.2 53.75 5.58 Favored Glycine 0 CA--C 1.532 1.126 0 C-N-CA 125.711 1.624 . . . . 10.0 114.723 178.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -67.0 151.44 82.03 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.371 2.048 . . . . 10.0 108.34 169.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.49 92.38 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 105.842 -1.91 . . . . 10.0 105.842 169.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttp -83.76 98.43 9.69 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -97.58 99.69 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.95 0 C-N-CA 125.628 1.571 . . . . 10.0 106.819 -174.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 13.3 p90 -117.16 165.54 13.29 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.528 0.68 . . . . 10.0 112.605 171.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.76 -150.04 21.97 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 106.922 -2.471 . . . . 10.0 106.922 169.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 28.6 p -156.04 166.41 33.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 119.352 -0.939 . . . . 10.0 110.931 173.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.483 HG22 ' HA2' ' B' ' 16' ' ' GLY . 4.7 pt -106.43 174.75 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.843 -1.071 . . . . 10.0 110.491 167.316 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt -140.4 152.15 45.51 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.552 2.341 . . . . 10.0 105.893 169.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.12 -25.09 14.66 Favored Glycine 0 C--N 1.338 0.653 0 N-CA-C 116.007 1.163 . . . . 10.0 116.007 167.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.528 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.3 mp -78.47 177.6 8.4 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 119.207 1.504 . . . . 10.0 110.945 -169.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.0 t -93.1 165.1 13.0 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 108.973 -0.751 . . . . 10.0 108.973 168.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -58.99 160.04 6.45 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.576 1.15 . . . . 10.0 111.45 -172.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.87 -170.24 29.06 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.626 -0.59 . . . . 10.0 111.626 169.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.77 148.6 42.39 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.405 1.082 . . . . 10.0 111.783 -172.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -144.42 141.74 29.84 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.215 1.006 . . . . 10.0 113.42 -177.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.512 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -38.2 126.48 1.6 Allowed Glycine 0 C--N 1.342 0.903 0 C-N-CA 126.803 2.144 . . . . 10.0 110.511 165.339 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -151.36 111.43 4.1 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.887 1.343 . . . . 10.0 108.295 168.083 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -153.76 168.33 26.66 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.978 0.894 . . . . 10.0 112.459 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 18.7 m -88.78 149.34 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 111.869 -2.423 . . . . 10.0 105.812 166.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -124.83 169.72 11.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.691 0.757 . . . . 10.0 109.309 169.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . 0.51 ' CG ' ' H ' ' B' ' 50' ' ' PHE . 0.8 OUTLIER 4.0 -113.68 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 130.503 3.521 . . . . 10.0 117.624 167.727 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . 0.51 ' H ' ' CG ' ' B' ' 49' ' ' GLU . 51.9 m-85 -95.29 -141.88 0.26 Allowed 'General case' 0 N--CA 1.434 -1.231 0 C-N-CA 127.96 2.504 . . . . 10.0 106.024 172.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.43 31.5 4.82 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 125.171 1.367 . . . . 10.0 110.875 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -70.5 158.55 35.88 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 119.685 1.742 . . . . 10.0 108.273 176.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -163.45 12.07 0.06 Allowed 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 126.288 1.835 . . . . 10.0 111.899 173.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.43 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -60.48 -31.63 70.65 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 119.904 1.229 . . . . 10.0 110.954 -173.048 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.03 -18.37 58.18 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.26 1.024 . . . . 10.0 111.887 176.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.83 -171.58 13.78 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 107.539 -2.225 . . . . 10.0 107.539 -169.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 84.7 m -70.43 70.04 0.41 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.826 -1.176 . . . . 10.0 107.826 169.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.14 -51.05 0.08 Allowed 'General case' 0 N--CA 1.448 -0.544 0 O-C-N 120.706 -1.246 . . . . 10.0 110.911 -169.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 10.7 t -98.96 -0.15 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.711 0.804 . . . . 10.0 110.076 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -70.46 60.02 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.821 1.648 . . . . 10.0 109.461 171.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . 0.463 ' HA3' ' HG2' ' B' ' 49' ' ' GLU . . . 80.24 130.42 0.89 Allowed Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 124.612 1.101 . . . . 10.0 115.227 164.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -87.84 42.49 0.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 123.279 2.653 . . . . 10.0 108.168 165.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' HG22 ' B' ' 137' ' ' THR . 15.1 m170 65.47 54.28 1.16 Allowed 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.993 2.517 . . . . 10.0 110.964 -172.237 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -69.37 70.27 0.26 Allowed 'General case' 0 N--CA 1.47 0.554 0 O-C-N 121.794 -0.566 . . . . 10.0 110.638 171.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -80.01 152.13 73.91 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.521 -0.737 . . . . 10.0 110.333 175.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.05 -48.57 1.29 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.601 2.201 . . . . 10.0 111.298 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 86.0 mt -77.5 59.49 1.92 Allowed 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -56.24 99.51 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 124.761 1.224 . . . . 10.0 110.172 -176.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.48 -89.89 0.53 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 105.517 -2.031 . . . . 10.0 105.517 -177.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -142.87 153.59 43.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.091 0.948 . . . . 10.0 110.286 168.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -64.85 123.24 18.88 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 165.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.41 -144.2 4.08 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 107.857 -2.097 . . . . 10.0 107.857 179.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.05 -153.37 10.42 Favored Glycine 0 N--CA 1.452 -0.296 0 N-CA-C 108.565 -1.814 . . . . 10.0 108.565 170.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -69.12 15.26 0.19 Allowed 'Trans proline' 0 CA--C 1.54 0.802 0 CA-C-N 119.519 1.66 . . . . 10.0 111.404 169.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 72.3 mttt -119.49 0.46 11.05 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.177 1.391 . . . . 10.0 110.791 169.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.4 t0 -118.03 156.48 28.51 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.264 -1.384 . . . . 10.0 107.264 172.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -79.3 -31.61 43.33 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 171.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -118.59 36.94 4.22 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 123.861 0.864 . . . . 10.0 112.466 -165.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.74 148.96 3.61 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 125.257 1.423 . . . . 10.0 110.66 169.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 26.0 m170 -55.26 -62.35 1.73 Allowed 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.161 0.584 . . . . 10.0 112.192 -171.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -172.35 -60.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.181 0 C-N-CA 124.32 1.048 . . . . 10.0 108.332 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.71 51.98 0.82 Allowed Glycine 0 C--N 1.337 0.613 0 N-CA-C 109.319 -1.513 . . . . 10.0 109.319 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -84.77 92.28 8.19 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.447 -2.797 . . . . 10.0 103.447 167.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.5 mt -63.06 -30.4 71.57 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 -173.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.55 -89.8 0.48 Allowed Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.607 -1.397 . . . . 10.0 109.607 166.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -151.79 100.73 2.7 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.332 -0.988 . . . . 10.0 108.332 -171.057 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -86.37 141.86 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 172.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -99.47 129.87 45.69 Favored 'General case' 0 C--O 1.224 -0.257 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.56 134.81 40.99 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.916 -0.772 . . . . 10.0 108.916 172.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -59.84 169.59 1.39 Allowed 'General case' 0 N--CA 1.451 -0.382 0 O-C-N 124.526 1.141 . . . . 10.0 110.045 167.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 61.8 pttt -50.41 -33.19 19.94 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 124.229 1.011 . . . . 10.0 110.876 169.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -78.53 -1.25 33.0 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 122.87 0.468 . . . . 10.0 111.409 -178.163 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.36 17.86 75.2 Favored Glycine 0 C--N 1.34 0.781 0 O-C-N 120.746 -1.221 . . . . 10.0 110.49 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.69 103.61 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 C-N-CA 126.439 1.896 . . . . 10.0 106.789 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.441 ' H ' HG12 ' B' ' 35' ' ' ILE . . . -98.35 121.64 40.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 167.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.46 117.79 20.74 Favored 'General case' 0 N--CA 1.436 -1.161 0 C-N-CA 126.579 1.951 . . . . 10.0 108.665 170.555 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 56.6 t -101.73 134.57 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 107.185 -1.413 . . . . 10.0 107.185 175.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -158.62 57.11 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.409 0.684 . . . . 10.0 111.263 175.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.71 158.2 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -172.182 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -130.73 90.72 2.95 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 126.762 2.025 . . . . 10.0 108.925 -176.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -84.46 83.78 7.88 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 63.1 p -78.73 60.31 2.74 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 105.87 -1.9 . . . . 10.0 105.87 169.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.3 t -143.22 -51.16 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 125.174 1.39 . . . . 10.0 107.704 -168.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.42 HD13 ' H ' ' B' ' 104' ' ' ILE 0.326 0.0 OUTLIER -118.91 165.12 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 113.656 0.984 . . . . 10.0 113.656 175.91 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.0 p -108.17 132.1 53.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.641 1.176 . . . . 10.0 109.646 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -69.83 -41.16 75.31 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.3 t -134.31 116.64 15.49 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 105.985 -1.857 . . . . 10.0 105.985 174.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.89 -66.33 0.09 OUTLIER Glycine 0 C--O 1.228 -0.242 0 N-CA-C 108.7 -1.76 . . . . 10.0 108.7 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -161.42 -48.66 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 113.581 -1.31 . . . . 10.0 109.263 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.63 -32.96 60.46 Favored 'General case' 0 N--CA 1.456 -0.147 0 CA-C-N 115.777 -0.647 . . . . 10.0 110.086 -168.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.9 t 33.65 75.1 0.05 Allowed 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 127.167 2.187 . . . . 10.0 112.25 168.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.9 pt -75.01 44.38 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 C-N-CA 123.752 0.821 . . . . 10.0 111.841 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 17.7 mm -78.25 -68.52 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 C-N-CA 125.685 1.594 . . . . 10.0 109.981 -174.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.42 52.31 3.05 Favored Glycine 0 CA--C 1.533 1.198 0 O-C-N 120.8 -1.187 . . . . 10.0 112.302 176.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.1 mmt85 -121.09 153.55 37.3 Favored 'General case' 0 C--O 1.233 0.192 0 C-N-CA 126.147 1.779 . . . . 10.0 110.614 -178.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 53.9 m -97.75 121.26 39.44 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.121 0.968 . . . . 10.0 109.587 177.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -98.24 144.33 27.79 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 125.916 1.686 . . . . 10.0 107.743 169.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 53.1 t -128.8 140.67 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 108.409 -0.96 . . . . 10.0 108.409 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 p -113.39 128.75 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 C-N-CA 125.666 1.586 . . . . 10.0 106.932 169.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.512 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.4 m170 -114.09 163.74 14.78 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 116.082 1.882 . . . . 10.0 116.082 -169.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -45.02 -59.1 2.76 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.602 2.761 . . . . 10.0 112.628 174.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -122.81 176.29 6.06 Favored 'General case' 0 CA--C 1.522 -0.134 0 C-N-CA 124.366 1.067 . . . . 10.0 113.317 -168.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.58 155.59 38.78 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.827 1.651 . . . . 10.0 111.094 176.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.5 146.86 24.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 124.8 1.24 . . . . 10.0 110.795 172.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -74.9 -32.88 61.94 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 114.849 -1.068 . . . . 10.0 109.321 170.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 52.2 mt 62.94 65.34 0.81 Allowed 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 123.265 1.507 . . . . 10.0 108.237 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.77 -51.11 4.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 112.945 -1.934 . . . . 10.0 111.726 170.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 38.3 mtmt -80.32 53.21 1.74 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.371 1.468 . . . . 10.0 111.591 -169.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.94 -3.71 23.11 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.208 1.861 . . . . 10.0 112.462 177.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.54 42.55 27.16 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.244 0.926 . . . . 10.0 112.797 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -135.98 158.32 44.69 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 107.577 -1.268 . . . . 10.0 107.577 176.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -54.15 -42.94 70.14 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 169.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -58.91 -44.39 91.26 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.983 -0.553 . . . . 10.0 112.175 170.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 10.1 p -56.19 -43.25 78.26 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 119.581 1.082 . . . . 10.0 111.22 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -71.24 -7.85 49.65 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-O 118.083 -0.961 . . . . 10.0 113.091 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -119.7 -65.65 1.14 Allowed 'General case' 0 N--CA 1.439 -1.008 0 C-N-CA 127.677 2.391 . . . . 10.0 113.141 -168.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.499 HG22 ' CD2' ' B' ' 63' ' ' HIS . 1.5 p -130.16 26.2 5.18 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.274 1.397 . . . . 10.0 109.908 177.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 68.32 -104.45 1.2 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 107.375 -2.29 . . . . 10.0 107.375 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -154.93 39.06 0.42 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 107.551 -1.278 . . . . 10.0 107.551 170.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.62 -12.48 23.38 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 123.527 0.731 . . . . 10.0 112.512 -171.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.96 -167.55 51.19 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 109.734 -1.346 . . . . 10.0 109.734 175.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 53.1 m -56.03 133.41 51.81 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 121.602 0.715 . . . . 10.0 111.729 -169.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 19.7 mtt180 -65.15 75.32 0.05 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.457 -0.792 . . . . 10.0 109.177 168.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.9 mt -47.56 -48.73 27.69 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.96 0.409 . . . . 10.0 109.986 177.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.15 152.54 37.46 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.414 0.626 . . . . 10.0 110.566 -172.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -148.42 167.71 24.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.595 -0.73 . . . . 10.0 109.308 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.0 148.66 19.75 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 109.592 -1.403 . . . . 10.0 109.592 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 75.1 t -101.35 124.26 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 N-CA-C 104.365 -2.457 . . . . 10.0 104.365 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 21.0 mt -67.75 157.74 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 CA-C-N 118.969 0.804 . . . . 10.0 110.454 -178.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -159.97 147.24 14.07 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.594 1.568 . . . . 10.0 110.423 -170.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 62.0 mt -69.15 135.41 28.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 C-N-CA 126.476 1.91 . . . . 10.0 110.452 -169.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -125.8 -48.4 1.64 Allowed 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.624 -0.673 . . . . 10.0 112.199 -178.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.254 1.294 0 C-N-CA 125.437 1.495 . . . . 10.0 110.517 -168.219 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 116.164 -1.874 . . . . 10.0 106.571 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -96.55 -33.77 11.69 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.773 1.169 . . . . 10.0 112.79 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -137.54 133.32 34.38 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 123.958 0.903 . . . . 10.0 111.615 -177.327 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.92 162.31 28.88 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.185 1.394 . . . . 10.0 109.457 173.243 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.2 t -124.31 154.89 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 125.784 1.634 . . . . 10.0 108.272 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.46 111.9 6.35 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 168.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.9 m -101.26 113.47 37.51 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.28 0.632 . . . . 10.0 110.945 -178.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -90.05 139.24 30.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 121.743 -0.598 . . . . 10.0 111.945 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -151.84 159.95 43.71 Favored 'General case' 0 N--CA 1.455 -0.197 0 N-CA-C 107.25 -1.389 . . . . 10.0 107.25 167.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.73 -56.68 0.06 OUTLIER Glycine 0 N--CA 1.461 0.351 0 C-N-CA 120.247 -0.978 . . . . 10.0 112.389 169.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -71.42 -44.5 64.76 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -178.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.3 -70.6 0.43 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.328 -1.305 . . . . 10.0 110.37 169.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -58.28 -33.12 97.35 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 123.528 2.819 . . . . 10.0 111.554 173.125 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.61 94.24 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 107.013 -1.477 . . . . 10.0 107.013 173.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -114.09 126.62 55.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.508 -1.293 . . . . 10.0 107.508 175.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -121.17 145.23 17.08 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 124.294 0.949 . . . . 10.0 111.045 -177.222 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.429 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 4.9 mt -146.42 84.22 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 106.555 -1.646 . . . . 10.0 106.555 -170.397 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.8 mm -95.46 142.74 13.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 C-N-CA 124.439 1.096 . . . . 10.0 108.571 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -124.3 127.63 47.93 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 125.957 1.703 . . . . 10.0 108.559 172.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.432 ' CD2' HG12 ' A' ' 31' ' ' VAL . 24.9 m-85 -106.43 112.92 26.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.424 -1.324 . . . . 10.0 107.424 176.6 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -105.26 127.42 52.93 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.601 0.637 . . . . 10.0 111.195 168.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -114.93 88.68 2.92 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.526 1.531 . . . . 10.0 107.288 169.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.5 pttp -59.58 -44.0 93.47 Favored 'General case' 0 N--CA 1.457 -0.09 0 C-N-CA 124.199 1.0 . . . . 10.0 110.279 -171.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -133.1 161.58 34.01 Favored 'General case' 0 N--CA 1.425 -1.704 0 N-CA-C 104.301 -2.481 . . . . 10.0 104.301 174.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.9 p -66.18 -18.96 65.68 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 121.505 0.669 . . . . 10.0 109.691 169.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 29.9 m120 -79.1 -21.52 46.56 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 124.828 1.251 . . . . 10.0 110.708 177.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.48 127.52 8.03 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 109.802 -1.319 . . . . 10.0 109.802 -174.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.63 131.39 29.36 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 N-CA-C 106.93 -1.988 . . . . 10.0 106.93 169.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.3 t -78.47 101.95 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -169.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -69.7 106.82 3.21 Favored 'General case' 0 N--CA 1.446 -0.667 0 N-CA-C 107.828 -1.175 . . . . 10.0 107.828 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.432 HG12 ' CD2' ' A' ' 20' ' ' PHE . 10.7 m -82.8 111.73 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 N-CA-C 106.265 -1.754 . . . . 10.0 106.265 169.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.8 p90 -122.38 168.0 12.61 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.245 0.545 . . . . 10.0 112.304 170.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.33 -152.51 24.57 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 107.738 -2.145 . . . . 10.0 107.738 169.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.3 p -156.17 155.54 32.65 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 119.306 -0.958 . . . . 10.0 112.527 -176.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.427 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -117.76 129.14 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 125.489 1.516 . . . . 10.0 107.92 168.868 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 48.1 tttp -110.08 148.32 31.95 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.73 1.612 . . . . 10.0 107.138 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.61 -10.02 25.92 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 123.796 0.712 . . . . 10.0 113.891 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.0 mt -73.04 179.25 3.87 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.335 1.054 . . . . 10.0 110.522 178.682 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.3 t -104.86 165.31 11.16 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 167.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -55.38 156.16 4.64 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.489 1.116 . . . . 10.0 113.195 -169.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.98 177.38 51.97 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.429 1.014 . . . . 10.0 112.669 169.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 84.9 mt -40.88 137.88 1.14 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.625 1.97 . . . . 10.0 114.74 175.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.21 150.68 44.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.631 1.572 . . . . 10.0 110.661 170.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.549 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -35.95 123.44 0.73 Allowed Glycine 0 C--N 1.338 0.651 0 CA-C-O 116.855 -2.08 . . . . 10.0 109.39 163.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -149.88 108.11 3.76 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 120.207 2.003 . . . . 10.0 109.205 167.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -154.22 175.47 13.45 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.503 0.668 . . . . 10.0 110.763 -176.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.97 156.63 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.639 0 CA-C-N 112.425 -2.171 . . . . 10.0 108.297 168.319 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -132.99 130.81 39.99 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 104.259 -2.497 . . . . 10.0 104.259 174.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -58.25 -53.08 62.37 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.162 0.914 . . . . 10.0 111.321 -168.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -77.04 135.93 38.66 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 118.388 -1.325 . . . . 10.0 107.71 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.07 -31.79 72.5 Favored Glycine 0 N--CA 1.441 -0.97 0 N-CA-C 109.59 -1.404 . . . . 10.0 109.59 169.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -36.35 126.86 0.8 Allowed 'General case' 0 C--N 1.341 0.216 0 C-N-CA 126.352 1.861 . . . . 10.0 112.761 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -130.48 9.94 5.17 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 114.445 -1.252 . . . . 10.0 110.894 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.442 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -54.61 -35.68 63.67 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.312 1.045 . . . . 10.0 112.112 -169.618 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.35 -17.17 58.47 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.197 0.599 . . . . 10.0 112.241 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.89 76.31 0.88 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 108.865 -1.694 . . . . 10.0 108.865 -177.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.84 6.52 0.91 Allowed 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.086 1.354 . . . . 10.0 113.312 176.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 45.1 m -98.72 -42.11 7.37 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 107.774 -1.195 . . . . 10.0 107.774 -169.029 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.93 -39.62 71.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 123.771 0.828 . . . . 10.0 111.022 -169.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.78 -25.2 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.754 3.621 . . . . 10.0 116.863 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.92 121.98 3.95 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.437 -1.465 . . . . 10.0 109.437 172.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.16 73.25 1.1 Allowed 'Trans proline' 0 CA--C 1.54 0.792 0 C-N-CA 123.596 2.864 . . . . 10.0 111.759 177.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 25.4 m170 61.09 46.84 7.79 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.624 3.17 . . . . 10.0 111.305 176.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -74.29 48.66 0.34 Allowed 'General case' 0 N--CA 1.467 0.39 0 O-C-N 121.799 -0.563 . . . . 10.0 111.993 178.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -63.62 149.45 92.42 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 121.36 -0.837 . . . . 10.0 108.804 178.037 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -54.23 -60.03 0.73 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 122.977 2.451 . . . . 10.0 111.879 -172.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.01 66.5 2.22 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.743 -0.598 . . . . 10.0 109.665 169.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t -59.1 102.5 0.13 Allowed 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.837 -1.172 . . . . 10.0 107.837 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.459 ' HE ' ' HA ' ' A' ' 78' ' ' GLU . 43.5 mtp85 -105.36 -89.9 0.42 Allowed 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 106.063 -1.828 . . . . 10.0 106.063 -176.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.2 mmtt -143.32 146.62 33.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.244 0.545 . . . . 10.0 109.664 168.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.0 t60 -55.99 121.57 9.64 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 117.976 -1.489 . . . . 10.0 107.6 165.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.71 -149.99 5.48 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.09 -150.97 8.17 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.265 -1.297 . . . . 10.0 110.675 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -70.05 17.37 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.849 1.699 . . . . 10.0 111.285 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.17 -19.33 16.49 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 108.017 -1.105 . . . . 10.0 108.017 168.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.28 -178.59 4.91 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.895 -1.15 . . . . 10.0 107.895 -168.204 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -116.39 -5.4 11.76 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 123.424 0.69 . . . . 10.0 110.734 170.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.459 ' HA ' ' HE ' ' A' ' 69' ' ' ARG . 0.8 OUTLIER -98.11 -2.88 39.04 Favored 'General case' 0 CA--C 1.517 -0.323 0 O-C-N 121.02 -1.05 . . . . 10.0 111.536 -174.258 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 9.6 ptt85 -28.76 129.83 0.07 Allowed 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.408 2.283 . . . . 10.0 111.019 167.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -59.52 151.99 22.95 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.968 -0.753 . . . . 10.0 108.968 172.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 94.5 t -59.5 89.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.955 -1.128 . . . . 10.0 107.955 171.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.64 28.58 3.42 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 125.724 1.631 . . . . 10.0 113.496 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -85.92 101.04 12.52 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 105.055 -2.202 . . . . 10.0 105.055 164.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.65 16.48 1.75 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 119.286 0.948 . . . . 10.0 110.83 173.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.03 -107.98 2.49 Favored Glycine 0 N--CA 1.434 -1.499 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 -179.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -155.94 144.59 20.27 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 106.646 -1.613 . . . . 10.0 106.646 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -120.77 135.99 59.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 C-N-CA 123.062 0.545 . . . . 10.0 109.867 -171.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -82.72 131.85 35.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 125.134 1.374 . . . . 10.0 109.616 -174.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.76 142.24 31.5 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 123.918 0.887 . . . . 10.0 110.897 170.07 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -60.93 167.43 2.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.473 1.109 . . . . 10.0 109.744 166.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.4 ptmt -54.1 -26.77 28.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.149 1.379 . . . . 10.0 112.184 173.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -75.9 -29.94 58.61 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 109.75 -0.463 . . . . 10.0 109.75 177.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 112.05 4.71 25.7 Favored Glycine 0 N--CA 1.446 -0.68 0 CA-C-O 118.626 -1.097 . . . . 10.0 111.216 -169.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.7 t -78.61 99.1 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 C-N-CA 125.069 1.347 . . . . 10.0 108.279 177.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 117.47 33.38 Favored 'General case' 0 CA--C 1.518 -0.264 0 N-CA-C 106.886 -1.524 . . . . 10.0 106.886 166.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -89.03 119.78 29.86 Favored 'General case' 0 N--CA 1.436 -1.142 0 C-N-CA 127.879 2.472 . . . . 10.0 109.106 177.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.6 t -105.15 135.06 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 C-N-CA 125.127 1.371 . . . . 10.0 107.787 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 88.9 p -159.72 69.74 0.43 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.309 0.855 . . . . 10.0 113.309 172.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 mp -123.96 143.19 38.08 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 124.53 1.132 . . . . 10.0 110.38 -170.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -116.28 149.84 38.57 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.942 2.097 . . . . 10.0 110.128 173.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -149.87 153.39 36.63 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 106.744 -1.576 . . . . 10.0 106.744 167.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 78.1 p -95.47 56.04 1.78 Allowed 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 125.395 1.478 . . . . 10.0 108.528 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 58.4 t -144.12 -53.18 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -176.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.7 mm -54.48 139.08 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 C-N-CA 124.022 0.929 . . . . 10.0 109.488 173.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.9 m -155.15 134.94 12.78 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 169.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.6 mt -55.85 -52.04 65.42 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.645 1.178 . . . . 10.0 110.436 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.0 t -140.52 -179.27 5.93 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.313 0.645 . . . . 10.0 109.514 176.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.85 -100.3 0.56 Allowed Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 106.22 -2.752 . . . . 10.0 106.22 -170.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -128.92 -49.77 1.23 Allowed 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 125.356 1.462 . . . . 10.0 108.356 -169.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.5 -41.07 48.32 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.888 -1.051 . . . . 10.0 108.867 -176.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t 38.71 89.81 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.391 2.276 . . . . 10.0 113.796 172.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pp -73.63 -15.31 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 112.534 0.568 . . . . 10.0 112.534 178.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.3 mm -50.12 122.63 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 O-C-N 121.188 -0.945 . . . . 10.0 110.412 174.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.44 5.43 56.94 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.466 1.032 . . . . 10.0 112.968 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.6 mpt_? -75.66 179.38 5.41 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.017 0.927 . . . . 10.0 109.533 169.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -129.72 141.56 50.87 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 173.284 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.659 HD11 HD11 ' A' ' 149' ' ' ILE . 6.1 mp -107.94 157.43 18.22 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.75 -0.833 . . . . 10.0 108.75 168.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -140.04 137.86 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 O-C-N 123.934 0.771 . . . . 10.0 109.206 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.4 m -103.25 134.56 44.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 O-C-N 124.473 1.108 . . . . 10.0 108.912 164.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.549 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.7 m170 -110.83 159.21 17.88 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 114.497 1.295 . . . . 10.0 114.497 -174.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.73 -50.05 73.37 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.973 1.309 . . . . 10.0 110.46 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -113.03 172.17 7.1 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.629 0.728 . . . . 10.0 112.366 -177.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.22 151.24 33.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.138 1.375 . . . . 10.0 109.503 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -79.49 147.04 32.38 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.207 0.447 . . . . 10.0 112.207 176.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -86.49 3.02 45.81 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.506 1.129 . . . . 10.0 111.637 168.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.4 mt 48.06 51.89 13.94 Favored 'General case' 0 CA--C 1.519 -0.238 0 C-N-CA 125.247 1.419 . . . . 10.0 111.859 170.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.38 -7.87 64.13 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 113.756 -1.565 . . . . 10.0 112.187 173.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -114.23 35.16 4.29 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.25 1.02 . . . . 10.0 110.691 -168.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -82.89 -23.55 55.3 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 126.124 1.821 . . . . 10.0 111.697 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.44 48.1 81.48 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-N 118.184 0.992 . . . . 10.0 111.547 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.517 ' H ' ' HB2' ' A' ' 134' ' ' SER . 37.3 m-80 -158.13 167.4 29.93 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 127.746 2.418 . . . . 10.0 105.734 -175.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -57.49 -44.51 85.01 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.627 0.727 . . . . 10.0 109.645 175.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -52.89 -31.15 38.16 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.788 0.835 . . . . 10.0 112.327 175.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.517 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 7.0 t -46.77 -47.14 20.86 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 124.054 0.942 . . . . 10.0 109.035 178.24 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.6 t -83.67 0.56 46.45 Favored 'General case' 0 CA--C 1.539 0.556 0 CA-C-O 118.35 -0.833 . . . . 10.0 112.714 -173.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -121.55 -83.02 0.66 Allowed 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.464 1.906 . . . . 10.0 111.897 -174.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.36 24.46 13.06 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 121.759 2.072 . . . . 10.0 110.662 174.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.89 -87.3 0.29 Allowed Glycine 0 C--N 1.34 0.793 0 C-N-CA 125.151 1.358 . . . . 10.0 110.027 175.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.22 34.08 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 125.233 1.413 . . . . 10.0 110.477 172.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.98 -9.76 56.28 Favored 'General case' 0 C--N 1.341 0.212 0 O-C-N 121.041 -1.037 . . . . 10.0 112.192 -172.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.77 -163.62 52.66 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 169.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -49.73 123.79 8.53 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.161 1.384 . . . . 10.0 113.428 -168.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -63.54 74.18 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.259 1.824 . . . . 10.0 110.734 173.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 52.7 mt -49.68 -36.81 26.3 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 113.189 0.811 . . . . 10.0 113.189 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.31 144.44 23.0 Favored 'General case' 0 CA--C 1.513 -0.442 0 O-C-N 121.711 -0.618 . . . . 10.0 109.418 178.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.9 p -132.37 152.16 51.56 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 124.206 0.941 . . . . 10.0 109.876 176.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.39 141.98 11.26 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.297 -1.121 . . . . 10.0 110.297 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.5 t -97.11 142.71 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 105.971 -1.863 . . . . 10.0 105.971 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.659 HD11 HD11 ' A' ' 117' ' ' LEU . 14.1 mt -79.29 136.7 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 N-CA-C 110.038 -0.356 . . . . 10.0 110.038 -176.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.84 145.49 17.34 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.75 1.167 . . . . 10.0 111.877 -175.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.3 mt -67.83 139.57 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 124.4 1.08 . . . . 10.0 108.362 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.9 -26.92 2.59 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 114.805 1.409 . . . . 10.0 114.805 -176.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.025 0 CA-C-O 117.61 -1.186 . . . . 10.0 111.84 -178.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.789 0 CA-C-O 116.73 -1.605 . . . . 10.0 107.134 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t -68.99 -18.83 64.11 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-N 120.533 1.515 . . . . 10.0 108.615 169.098 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.6 ptpt -144.39 162.27 36.9 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 120.831 0.348 . . . . 10.0 110.88 165.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -152.95 166.87 31.03 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 127.139 2.175 . . . . 10.0 107.645 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.71 162.79 36.46 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 C-N-CA 123.419 0.688 . . . . 10.0 111.014 -176.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.39 108.51 5.48 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.931 0.892 . . . . 10.0 109.307 168.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.1 m -82.5 81.81 1.53 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.485 0.714 . . . . 10.0 110.294 171.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -73.13 127.18 31.86 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.714 -0.847 . . . . 10.0 108.714 -171.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.6 mtmp? -147.54 160.36 42.71 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.324 -0.991 . . . . 10.0 108.324 -177.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.17 -57.51 0.06 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 120.479 -0.867 . . . . 10.0 112.928 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -72.65 -43.85 62.63 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 -175.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.02 -70.97 0.43 Allowed Glycine 0 CA--C 1.524 0.596 0 CA-C-N 114.273 -1.33 . . . . 10.0 110.078 171.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -56.46 -34.26 94.27 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.056 2.504 . . . . 10.0 111.28 172.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.8 t -66.83 100.63 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 176.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -122.35 109.52 14.52 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 174.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.642 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.56 134.86 11.98 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.751 -1.34 . . . . 10.0 109.751 169.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.442 ' CG2' HG23 ' A' ' 54' ' ' THR . 17.7 mt -129.55 67.66 0.34 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.153 0 N-CA-C 107.255 -1.387 . . . . 10.0 107.255 -174.273 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -89.25 137.92 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 114.611 -1.177 . . . . 10.0 109.735 -171.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -120.68 116.03 24.49 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.051 2.14 . . . . 10.0 107.97 -173.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -98.72 109.62 22.35 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 116.986 -1.483 . . . . 10.0 107.672 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -104.18 138.87 40.03 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 119.856 1.207 . . . . 10.0 112.592 169.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 40.2 tp60 -124.21 91.89 3.55 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 129.719 3.208 . . . . 10.0 107.288 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 59.0 tttt -155.21 86.47 1.1 Allowed 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 177.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -158.26 170.46 22.21 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 103.649 -2.723 . . . . 10.0 103.649 166.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 26.1 t -91.79 7.94 39.46 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 123.589 0.756 . . . . 10.0 109.84 171.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -112.44 -10.48 13.74 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 124.74 1.216 . . . . 10.0 109.236 168.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 54.76 35.77 58.48 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-O 117.21 -1.883 . . . . 10.0 116.279 173.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -68.26 128.27 17.17 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 CA-C-N 121.362 2.581 . . . . 10.0 106.174 168.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . 0.455 ' CG1' HD11 ' B' ' 104' ' ' ILE . 1.3 p -76.92 112.39 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.547 0 N-CA-C 105.968 -1.864 . . . . 10.0 105.968 169.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.5 tttt -85.77 107.19 17.5 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.994 -2.225 . . . . 10.0 104.994 172.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 p -95.48 96.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 C-N-CA 126.816 2.046 . . . . 10.0 105.733 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.0 p90 -117.65 169.04 9.89 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 121.827 0.822 . . . . 10.0 112.228 173.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.9 -157.26 27.2 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 106.959 -2.456 . . . . 10.0 106.959 169.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 p -149.24 160.3 43.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 176.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.642 HG22 ' HA2' ' B' ' 16' ' ' GLY . 1.5 pp -111.52 175.61 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 CA-C-N 114.69 -1.141 . . . . 10.0 109.393 167.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ptmt -143.83 141.43 30.35 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 106.185 -1.783 . . . . 10.0 106.185 166.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.02 -5.43 20.14 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.122 0.867 . . . . 10.0 114.734 170.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.607 HD23 HD13 ' B' ' 35' ' ' ILE . 0.6 OUTLIER -70.07 178.13 2.89 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 118.712 1.256 . . . . 10.0 111.502 -179.739 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.6 t -111.76 156.14 22.41 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 167.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -50.26 156.67 0.79 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.362 1.465 . . . . 10.0 113.073 -169.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.57 -169.24 32.61 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 123.422 0.534 . . . . 10.0 111.784 168.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -73.49 146.33 44.99 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 124.61 1.164 . . . . 10.0 111.135 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -143.2 151.19 40.34 Favored 'General case' 0 C--N 1.34 0.19 0 N-CA-C 113.684 0.994 . . . . 10.0 113.684 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.697 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.05 119.68 0.16 Allowed Glycine 0 C--N 1.339 0.714 0 C-N-CA 129.337 3.351 . . . . 10.0 113.662 166.408 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -152.4 112.48 4.02 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 120.047 1.923 . . . . 10.0 112.785 168.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.521 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 1.0 OUTLIER -142.22 173.1 11.83 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-O 121.645 0.736 . . . . 10.0 111.532 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 46.1 t -106.43 117.77 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 CA-C-N 111.927 -2.397 . . . . 10.0 104.691 168.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -92.81 148.61 21.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 172.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -60.1 -57.16 14.03 Favored 'General case' 0 N--CA 1.45 -0.475 0 CA-C-N 115.113 -0.949 . . . . 10.0 109.979 -171.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -77.67 148.49 34.98 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 108.91 -0.774 . . . . 10.0 108.91 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.55 -5.33 69.33 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 125.022 1.296 . . . . 10.0 110.15 166.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -40.7 143.03 0.38 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.805 1.242 . . . . 10.0 111.422 169.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.508 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -153.29 23.56 0.55 Allowed 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 113.89 -1.505 . . . . 10.0 111.359 168.309 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.429 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.83 -36.15 71.86 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 118.685 0.675 . . . . 10.0 110.865 -172.361 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.92 -22.98 39.23 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.673 1.189 . . . . 10.0 112.966 175.411 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.24 107.42 1.46 Allowed Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.251 0.929 . . . . 10.0 111.45 -174.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 28.7 m 33.45 55.55 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 127.557 2.343 . . . . 10.0 113.537 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -156.3 -54.81 0.08 Allowed 'General case' 0 N--CA 1.448 -0.568 0 O-C-N 121.439 -0.788 . . . . 10.0 108.955 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 52.5 m -79.77 -5.52 55.47 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.251 0.621 . . . . 10.0 112.43 -174.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.37 8.31 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.365 1.866 . . . . 10.0 114.829 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.26 113.21 0.99 Allowed Glycine 0 CA--C 1.528 0.862 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 175.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.02 69.17 3.12 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.909 2.406 . . . . 10.0 111.299 175.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.44 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 11.8 m170 70.52 43.29 0.79 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.605 2.762 . . . . 10.0 110.231 170.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -73.95 45.89 0.22 Allowed 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.738 1.215 . . . . 10.0 114.183 -175.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -51.76 155.81 2.73 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.19 1.396 . . . . 10.0 111.54 169.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.47 -51.21 0.76 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.538 2.158 . . . . 10.0 111.866 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . 0.579 HD23 ' H ' ' B' ' 67' ' ' LEU . 1.7 pt? -74.97 53.63 0.61 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.954 0.902 . . . . 10.0 112.7 -177.261 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -54.2 108.82 0.41 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 122.793 0.437 . . . . 10.0 110.133 -171.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 mtt180 -120.61 -91.74 0.55 Allowed 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 105.892 -1.892 . . . . 10.0 105.892 -174.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -148.23 157.11 43.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 168.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -62.02 116.78 5.2 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 117.869 -1.533 . . . . 10.0 107.643 164.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.56 -145.99 6.44 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 107.695 -2.162 . . . . 10.0 107.695 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.4 -164.76 18.09 Favored Glycine 0 C--N 1.33 0.225 0 N-CA-C 108.771 -1.732 . . . . 10.0 108.771 173.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.89 -1.19 3.9 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.983 1.788 . . . . 10.0 110.951 167.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -84.29 -29.35 26.48 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 123.803 0.841 . . . . 10.0 109.279 171.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -107.46 161.72 14.58 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 123.161 0.584 . . . . 10.0 109.483 -170.054 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -92.49 -9.11 42.59 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.512 0.725 . . . . 10.0 109.293 167.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -97.04 0.23 48.34 Favored 'General case' 0 N--CA 1.438 -1.05 0 CA-C-O 116.035 -1.936 . . . . 10.0 113.521 -176.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.8 137.32 0.65 Allowed 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 120.101 1.319 . . . . 10.0 110.57 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -59.32 -37.23 77.27 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 120.159 -0.616 . . . . 10.0 111.341 -170.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.42 HG13 ' H ' ' B' ' 82' ' ' GLY . 2.5 p -154.1 -61.23 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 106.61 -1.626 . . . . 10.0 106.61 172.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.42 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -116.46 -56.04 0.32 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 173.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 39.29 85.5 0.02 OUTLIER 'General case' 0 C--N 1.346 0.429 0 C-N-CA 126.325 1.85 . . . . 10.0 108.618 -167.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -49.79 -33.14 15.63 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.349 1.06 . . . . 10.0 112.749 -166.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 122.03 -89.13 0.42 Allowed Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 168.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -155.06 101.14 2.23 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.639 -0.875 . . . . 10.0 108.639 -170.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -83.6 128.83 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.137 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 174.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.3 t -90.83 130.33 36.8 Favored 'General case' 0 C--O 1.225 -0.2 0 N-CA-C 108.733 -0.84 . . . . 10.0 108.733 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.15 131.86 48.4 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 108.407 -0.961 . . . . 10.0 108.407 171.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -58.88 168.31 1.31 Allowed 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 124.246 0.966 . . . . 10.0 109.832 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -30.2 18.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.083 0.953 . . . . 10.0 111.3 170.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.71 -7.09 56.01 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 120.958 -0.297 . . . . 10.0 111.091 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.56 28.14 55.82 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.566 -1.413 . . . . 10.0 109.566 -178.197 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 34.9 t -107.7 115.48 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.862 0 N-CA-C 104.617 -2.364 . . . . 10.0 104.617 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.438 ' HB3' HG13 ' B' ' 35' ' ' ILE . . . -113.53 123.27 49.61 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 107.544 -1.28 . . . . 10.0 107.544 174.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -85.15 119.66 25.78 Favored 'General case' 0 N--CA 1.439 -1.009 0 C-N-CA 127.32 2.248 . . . . 10.0 109.044 174.14 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 93.9 t -105.12 133.76 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 C-N-CA 124.636 1.174 . . . . 10.0 107.848 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 84.5 p -158.91 72.29 0.56 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 123.564 0.746 . . . . 10.0 111.015 169.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -104.6 153.47 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -117.91 81.74 1.72 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 128.43 2.692 . . . . 10.0 108.103 -176.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -75.84 113.74 13.66 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.768 -1.938 . . . . 10.0 105.768 -176.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 15.1 m -108.48 35.58 3.13 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.819 -1.082 . . . . 10.0 109.963 -174.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.5 p -126.02 -43.07 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-O 118.538 -0.744 . . . . 10.0 110.622 171.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.619 HD13 ' C ' ' B' ' 104' ' ' ILE 0.361 0.0 OUTLIER -91.83 176.11 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 N-CA-C 113.707 1.002 . . . . 10.0 113.707 178.422 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 34.0 m -152.69 145.9 24.7 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 121.615 -0.678 . . . . 10.0 109.972 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -66.23 -18.14 65.17 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 124.159 0.984 . . . . 10.0 112.464 176.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.9 t -154.89 137.88 15.5 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.15 -61.91 0.19 Allowed Glycine 0 C--N 1.334 0.422 0 N-CA-C 110.739 -0.945 . . . . 10.0 110.739 179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -154.72 -51.9 0.09 Allowed 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 126.795 2.038 . . . . 10.0 106.662 -178.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -75.15 -42.33 56.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.311 -1.313 . . . . 10.0 108.568 -174.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 65.42 -59.77 0.27 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 125.926 1.69 . . . . 10.0 109.89 -170.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.32 0.2 OUTLIER 78.68 -40.22 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 125.264 1.426 . . . . 10.0 112.075 168.817 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.9 mm -24.23 127.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 128.086 2.554 . . . . 10.0 111.342 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 90.2 28.6 17.06 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-O 119.054 -0.859 . . . . 10.0 112.588 -170.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -81.03 176.31 9.93 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.705 -1.22 . . . . 10.0 107.705 166.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -128.66 123.3 32.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.554 -2.017 . . . . 10.0 105.554 167.044 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 mp -96.0 149.75 21.23 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.251 -1.389 . . . . 10.0 107.251 169.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 84.3 t -132.01 133.74 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.703 -1.591 . . . . 10.0 106.703 -174.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -104.34 122.95 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 N-CA-C 107.078 -1.453 . . . . 10.0 107.078 171.155 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.697 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.4 m-70 -105.43 157.44 17.35 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 115.893 1.812 . . . . 10.0 115.893 -171.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.1 tt0 -43.26 -57.5 2.96 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 128.279 2.632 . . . . 10.0 111.009 173.225 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -111.42 162.49 15.02 Favored 'General case' 0 CA--C 1.515 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.664 -170.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.13 140.41 58.79 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.888 1.275 . . . . 10.0 107.586 174.012 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.521 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 69.2 m-20 -77.34 132.79 38.76 Favored 'General case' 0 N--CA 1.441 -0.919 0 N-CA-C 108.579 -0.897 . . . . 10.0 108.579 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . 0.409 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 6.7 t0 -81.56 -4.22 55.42 Favored 'General case' 0 N--CA 1.448 -0.574 0 O-C-N 123.483 0.489 . . . . 10.0 110.81 174.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 37.6 mt 53.59 41.11 32.15 Favored 'General case' 0 N--CA 1.463 0.188 0 O-C-N 120.455 -1.403 . . . . 10.0 110.629 172.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.99 -29.87 9.35 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-O 119.072 -0.849 . . . . 10.0 113.089 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.409 ' NZ ' ' OD1' ' B' ' 125' ' ' ASP . 0.0 OUTLIER -78.59 10.1 3.49 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 120.054 1.927 . . . . 10.0 113.617 -169.721 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.41 -16.91 69.96 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.009 0.814 . . . . 10.0 112.003 173.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.88 31.55 76.48 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.52 0.581 . . . . 10.0 112.505 174.004 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -142.37 176.01 9.33 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 108.165 -1.05 . . . . 10.0 108.165 171.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -59.01 -45.93 89.46 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 116.219 -0.446 . . . . 10.0 110.637 -175.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -67.05 -26.01 66.54 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 120.937 -1.102 . . . . 10.0 110.324 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -52.09 -48.38 64.76 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 119.546 1.066 . . . . 10.0 110.301 168.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -86.8 -15.26 39.81 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 124.073 0.858 . . . . 10.0 111.851 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.8 ttmm -89.82 -48.56 7.17 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 125.416 1.486 . . . . 10.0 111.666 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.9 p -133.88 -14.49 2.41 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 114.98 1.474 . . . . 10.0 114.98 176.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.37 30.93 8.73 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 119.668 1.122 . . . . 10.0 112.797 -171.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 32.8 m120 50.82 34.74 10.73 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 119.21 1.505 . . . . 10.0 111.918 -177.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . 0.465 ' HB2' ' OD1' ' B' ' 124' ' ' ASP . . . -69.94 -11.71 61.08 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.764 1.226 . . . . 10.0 111.982 -173.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.91 -158.43 53.06 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 109.633 -1.387 . . . . 10.0 109.633 174.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 128.11 35.42 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.61 0.719 . . . . 10.0 110.643 -169.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.01 73.02 0.07 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 123.997 0.919 . . . . 10.0 109.663 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 79.2 mt -45.8 -41.83 11.46 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 124.726 1.211 . . . . 10.0 112.78 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.56 154.17 22.31 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 108.898 -0.778 . . . . 10.0 108.898 -171.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.3 p -156.01 164.53 38.33 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.834 -0.621 . . . . 10.0 109.907 -175.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.32 -176.09 14.34 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 -179.118 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.4 t -131.95 141.67 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 173.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 8.2 mt -70.78 115.52 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.441 0.564 . . . . 10.0 110.464 -177.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.71 136.72 13.7 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.696 1.141 . . . . 10.0 111.197 -178.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 83.1 mt -65.87 142.15 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 124.516 1.126 . . . . 10.0 109.993 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.03 -52.63 1.31 Allowed 'General case' 0 C--O 1.225 -0.204 0 C-N-CA 123.277 0.631 . . . . 10.0 110.957 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 13.3 tt0 . . . . . 0 C--O 1.25 1.114 0 CA-C-O 116.356 -1.783 . . . . 10.0 112.937 -172.489 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.757 0 N-CA-C 108.266 -1.013 . . . . 10.0 108.266 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -166.84 -42.97 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.77 1.228 . . . . 10.0 110.039 175.382 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.9 mtpm? -114.13 148.73 36.72 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 171.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.33 163.25 38.8 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.396 1.479 . . . . 10.0 107.725 177.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.43 HG22 ' HA ' ' B' ' 52' ' ' ASP . 0.7 OUTLIER -139.94 167.13 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 122.88 0.472 . . . . 10.0 110.718 -177.94 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.39 114.72 7.95 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 124.14 0.976 . . . . 10.0 108.393 167.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -94.1 118.74 40.75 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 123.832 0.853 . . . . 10.0 108.705 171.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt -104.9 140.89 37.47 Favored 'General case' 0 C--O 1.224 -0.237 0 CA-C-O 118.089 -0.957 . . . . 10.0 109.308 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt -148.42 162.13 40.2 Favored 'General case' 0 CA--C 1.519 -0.224 0 CA-C-N 120.312 1.415 . . . . 10.0 107.866 168.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.29 -72.44 0.02 OUTLIER Glycine 0 C--O 1.228 -0.237 0 CA-C-N 115.117 -0.947 . . . . 10.0 112.295 169.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.73 -41.48 62.48 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 106.972 -1.492 . . . . 10.0 106.972 -170.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.64 -61.39 0.56 Allowed Glycine 0 N--CA 1.441 -0.99 0 CA-C-N 113.697 -1.592 . . . . 10.0 112.401 175.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -55.3 -43.18 61.21 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 CA-C-N 119.12 1.46 . . . . 10.0 110.68 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.415 HG23 HD12 ' A' ' 38' ' ' LEU . 0.2 OUTLIER -64.63 117.51 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.985 0 N-CA-C 108.486 -0.931 . . . . 10.0 108.486 177.219 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.16 109.52 12.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.731 -2.322 . . . . 10.0 104.731 168.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.765 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.39 143.29 17.82 Favored Glycine 0 N--CA 1.437 -1.239 0 N-CA-C 109.181 -1.568 . . . . 10.0 109.181 175.477 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.434 ' CG2' ' CG2' ' B' ' 54' ' ' THR . 2.9 mt -143.11 86.87 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 -178.31 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.2 mm -97.95 145.46 9.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 C-N-CA 123.874 0.87 . . . . 10.0 109.599 177.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -126.13 143.38 51.15 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 125.321 1.448 . . . . 10.0 109.271 170.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -125.57 106.17 9.56 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 107.457 -1.312 . . . . 10.0 107.457 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -103.54 111.57 24.09 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 114.074 1.139 . . . . 10.0 114.074 176.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -78.75 95.06 5.23 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.297 -2.112 . . . . 10.0 105.297 165.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.7 mmmp? -56.14 -53.7 53.9 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 126.285 1.834 . . . . 10.0 109.741 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.78 -156.88 0.71 Allowed 'General case' 0 N--CA 1.434 -1.236 0 N-CA-C 104.111 -2.551 . . . . 10.0 104.111 168.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.36 -27.48 25.83 Favored 'General case' 0 N--CA 1.443 -0.789 0 O-C-N 122.131 -0.356 . . . . 10.0 110.06 169.141 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -108.23 -6.33 16.41 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.953 1.301 . . . . 10.0 111.314 -171.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.57 149.29 49.52 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.597 -1.001 . . . . 10.0 110.597 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -62.98 125.31 15.62 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 N-CA-C 107.392 -1.811 . . . . 10.0 107.392 169.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.8 t -79.34 103.15 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 106.647 -1.612 . . . . 10.0 106.647 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -67.97 112.49 5.0 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 105.858 -1.905 . . . . 10.0 105.858 167.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -95.62 104.99 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 105.61 -1.996 . . . . 10.0 105.61 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 19.9 p90 -112.48 164.18 13.59 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.238 0.542 . . . . 10.0 109.671 177.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -177.44 157.51 22.21 Favored Glycine 0 N--CA 1.434 -1.464 0 C-N-CA 119.946 -1.121 . . . . 10.0 110.506 176.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.6 p -128.54 86.37 2.44 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 106.853 -1.536 . . . . 10.0 106.853 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.765 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.2 pt -76.99 154.21 5.58 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 C-N-CA 117.736 -1.585 . . . . 10.0 107.271 168.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.1 ptmm? -145.79 119.77 9.38 Favored 'General case' 0 N--CA 1.446 -0.638 0 O-C-N 124.192 0.932 . . . . 10.0 109.242 172.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.28 8.43 4.98 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-O 118.802 -0.999 . . . . 10.0 114.442 166.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.739 HD13 ' H ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -83.07 179.0 7.87 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 107.201 -1.407 . . . . 10.0 107.201 168.795 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -77.9 167.06 22.1 Favored 'General case' 0 N--CA 1.453 -0.317 0 O-C-N 121.04 -1.038 . . . . 10.0 109.174 169.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -65.67 179.09 0.88 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.813 0.845 . . . . 10.0 112.051 -175.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.9 -171.01 44.32 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.211 -0.756 . . . . 10.0 111.211 169.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -76.24 140.46 41.61 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.184 1.394 . . . . 10.0 110.736 -177.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -140.92 139.64 34.36 Favored 'General case' 0 C--N 1.341 0.228 0 N-CA-C 113.907 1.076 . . . . 10.0 113.907 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.507 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.4 117.13 0.46 Allowed Glycine 0 C--N 1.341 0.852 0 C-N-CA 128.646 3.022 . . . . 10.0 111.945 166.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -135.65 109.18 7.93 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 120.005 1.903 . . . . 10.0 110.324 170.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.426 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -151.12 170.07 20.32 Favored 'General case' 0 CA--C 1.513 -0.462 0 C-N-CA 123.413 0.685 . . . . 10.0 110.372 176.679 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 34.2 m -105.39 -27.11 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 C-N-CA 127.048 2.139 . . . . 10.0 113.171 -169.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 24.9 m-70 61.09 165.18 0.08 Allowed 'General case' 0 C--N 1.342 0.244 0 C-N-CA 124.436 1.095 . . . . 10.0 112.92 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -75.99 -56.53 4.58 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 121.726 -0.609 . . . . 10.0 111.121 171.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -75.98 111.26 11.18 Favored 'General case' 0 C--N 1.341 0.216 0 C-N-CA 119.888 -0.725 . . . . 10.0 110.881 -169.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.3 -39.32 95.92 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 108.852 -1.699 . . . . 10.0 108.852 166.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -34.65 122.82 0.53 Allowed 'General case' 0 C--N 1.341 0.223 0 C-N-CA 125.638 1.575 . . . . 10.0 112.219 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -129.06 18.13 6.07 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 124.529 1.132 . . . . 10.0 111.354 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.633 HG23 ' CG2' ' B' ' 17' ' ' ILE . 2.8 m -54.21 -36.75 63.82 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 119.49 1.041 . . . . 10.0 111.036 -175.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.01 -22.04 53.69 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.386 0.674 . . . . 10.0 112.106 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.61 -163.15 18.61 Favored Glycine 0 N--CA 1.443 -0.891 0 N-CA-C 107.328 -2.309 . . . . 10.0 107.328 -169.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 90.5 m -74.69 49.56 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.202 1.401 . . . . 10.0 111.052 176.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -137.58 -45.83 0.55 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 126.493 1.917 . . . . 10.0 109.574 -177.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -47.99 -31.44 5.32 Favored 'General case' 0 C--N 1.341 0.239 0 C-N-CA 123.146 0.578 . . . . 10.0 111.219 171.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.89 -42.01 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 128.132 2.573 . . . . 10.0 114.639 169.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.43 150.33 26.76 Favored Glycine 0 C--N 1.339 0.7 0 N-CA-C 110.64 -0.984 . . . . 10.0 110.64 168.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -80.54 54.43 5.22 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.192 1.928 . . . . 10.0 111.079 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.474 ' CD2' HG22 ' A' ' 137' ' ' THR . 19.6 m170 65.6 -65.93 0.16 Allowed 'General case' 0 C--O 1.226 -0.183 0 C-N-CA 128.502 2.721 . . . . 10.0 111.468 -177.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.265 10.7 p90 36.08 23.4 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 130.594 3.558 . . . . 10.0 118.944 174.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -49.72 158.13 0.9 Allowed Pre-proline 0 CA--C 1.541 0.628 0 C-N-CA 125.98 1.712 . . . . 10.0 114.634 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -57.07 -45.01 38.77 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.583 2.855 . . . . 10.0 112.473 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 78.1 mt -75.1 58.21 0.88 Allowed 'General case' 0 C--N 1.343 0.284 0 N-CA-C 108.887 -0.782 . . . . 10.0 108.887 172.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -66.3 72.7 0.08 Allowed 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 128.748 2.819 . . . . 10.0 108.798 -176.697 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 mtt180 -92.16 -91.37 0.16 Allowed 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 105.231 -2.137 . . . . 10.0 105.231 -173.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.1 mttp -149.83 144.48 26.01 Favored 'General case' 0 N--CA 1.425 -1.7 0 N-CA-C 104.21 -2.515 . . . . 10.0 104.21 164.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -52.64 117.59 3.01 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 118.871 -1.131 . . . . 10.0 109.672 167.291 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.4 -154.72 7.9 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 107.037 -2.425 . . . . 10.0 107.037 175.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.407 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -162.92 -160.87 11.6 Favored Glycine 0 C--O 1.225 -0.413 0 N-CA-C 108.755 -1.738 . . . . 10.0 108.755 174.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -65.51 10.08 0.17 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 CA-C-N 120.864 2.332 . . . . 10.0 111.318 169.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.407 ' H ' ' C ' ' A' ' 73' ' ' GLY . 26.1 mmtp -107.36 -13.6 15.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 119.204 0.911 . . . . 10.0 109.065 175.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -140.82 140.5 34.69 Favored 'General case' 0 C--N 1.348 0.526 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 -169.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -76.13 -20.08 57.93 Favored 'General case' 0 C--N 1.332 -0.167 0 O-C-N 121.106 -0.996 . . . . 10.0 108.819 -169.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -77.18 -5.91 50.95 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 124.412 1.085 . . . . 10.0 111.962 -173.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -35.54 133.92 0.35 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.038 1.335 . . . . 10.0 112.862 -179.163 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -61.5 -79.7 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.246 0.545 . . . . 10.0 110.028 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -130.45 -91.42 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -108.93 52.39 0.65 Allowed Glycine 0 CA--C 1.521 0.421 0 N-CA-C 109.899 -1.28 . . . . 10.0 109.899 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.3 m-20 -72.37 93.64 1.54 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 105.759 -1.941 . . . . 10.0 105.759 168.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 26.6 mt -75.32 -29.42 60.01 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.407 ' HA2' HD21 ' A' ' 126' ' ' LEU . . . 99.73 -104.29 2.82 Favored Glycine 0 N--CA 1.439 -1.105 0 N-CA-C 110.559 -1.016 . . . . 10.0 110.559 168.133 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -125.67 101.02 6.69 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 125.713 1.605 . . . . 10.0 110.54 -167.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 5.0 m -110.04 140.19 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.616 0.766 . . . . 10.0 111.334 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.32 129.73 34.74 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 128.079 2.552 . . . . 10.0 112.416 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -110.16 134.48 52.16 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.342 1.457 . . . . 10.0 109.591 169.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -59.46 169.13 1.33 Allowed 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.015 1.326 . . . . 10.0 111.133 169.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 7.0 ptmt -47.52 -33.19 6.06 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.751 2.02 . . . . 10.0 111.348 172.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.69 -14.05 59.04 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 122.64 0.376 . . . . 10.0 111.13 -176.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.03 17.42 51.29 Favored Glycine 0 C--N 1.341 0.839 0 N-CA-C 110.44 -1.064 . . . . 10.0 110.44 -175.215 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.94 109.57 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 C-N-CA 126.645 1.978 . . . . 10.0 106.962 -179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.503 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -105.34 118.28 36.16 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.071 -0.715 . . . . 10.0 109.071 169.361 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -85.01 84.38 7.74 Favored 'General case' 0 N--CA 1.437 -1.119 0 C-N-CA 127.416 2.286 . . . . 10.0 109.327 174.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -75.86 129.57 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.307 0 N-CA-C 105.136 -2.172 . . . . 10.0 105.136 178.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -156.93 59.72 0.52 Allowed 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 122.869 0.467 . . . . 10.0 109.948 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.51 164.02 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -176.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -134.31 135.41 42.78 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.558 0.743 . . . . 10.0 111.215 169.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -131.1 131.11 43.94 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.973 1.309 . . . . 10.0 108.554 -175.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.5 p -98.31 24.2 7.52 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.851 0.86 . . . . 10.0 110.107 169.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.3 p -149.27 20.41 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.032 0.933 . . . . 10.0 110.722 -172.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -122.28 134.52 65.27 Favored 'Isoleucine or valine' 0 C--N 1.34 0.158 0 N-CA-C 102.591 -3.115 . . . . 10.0 102.591 169.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.5 m -146.73 125.77 12.85 Favored 'General case' 0 CA--C 1.527 0.074 0 CA-C-N 118.451 0.569 . . . . 10.0 109.699 -176.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.9 mp -54.53 -48.42 71.98 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.699 1.199 . . . . 10.0 110.52 177.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -137.02 176.35 8.79 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.549 1.54 . . . . 10.0 106.925 169.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.66 -97.25 0.4 Allowed Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 108.15 -1.98 . . . . 10.0 108.15 -176.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -121.96 -50.98 2.03 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 125.758 1.623 . . . . 10.0 108.461 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -73.5 -42.76 61.42 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.249 -1.389 . . . . 10.0 107.249 -171.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.4 t 47.19 54.88 8.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 126.004 1.722 . . . . 10.0 111.94 169.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.1 pt -60.01 -3.9 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 127.746 2.418 . . . . 10.0 115.222 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.3 mp -52.13 144.16 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 O-C-N 121.26 -0.9 . . . . 10.0 111.258 169.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.82 7.52 87.9 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.163 -0.798 . . . . 10.0 113.064 173.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -85.62 172.72 10.69 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.817 0.809 . . . . 10.0 109.123 170.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -122.43 104.64 9.53 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.908 0.883 . . . . 10.0 110.56 -175.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.467 ' CD2' HD11 ' A' ' 149' ' ' ILE . 3.8 mm? -62.42 130.14 43.88 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 108.261 -1.014 . . . . 10.0 108.261 172.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 51.2 t -119.64 132.65 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 169.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.473 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -100.99 121.86 52.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.245 -1.761 . . . . 10.0 106.245 169.913 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.507 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.2 m170 -106.32 164.16 12.25 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.364 1.246 . . . . 10.0 114.364 -173.625 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -45.13 -57.43 3.91 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 129.354 3.061 . . . . 10.0 111.476 174.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 61.2 mttt -126.17 175.32 7.86 Favored 'General case' 0 CA--C 1.522 -0.116 0 C-N-CA 124.552 1.141 . . . . 10.0 112.581 -169.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.89 152.57 41.4 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.051 1.341 . . . . 10.0 110.878 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -82.77 145.47 29.52 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 116.031 -0.531 . . . . 10.0 111.183 169.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -81.41 -16.07 53.24 Favored 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 125.025 1.453 . . . . 10.0 110.257 166.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.407 HD21 ' HA2' ' A' ' 85' ' ' GLY . 84.4 mt 57.37 64.14 1.68 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 122.721 1.248 . . . . 10.0 109.447 176.691 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.64 -41.41 3.07 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 114.714 -1.13 . . . . 10.0 110.937 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 29.1 mtmm -78.75 36.09 0.26 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.488 1.515 . . . . 10.0 112.341 -174.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.433 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -100.23 -7.27 52.45 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 127.252 2.358 . . . . 10.0 110.892 170.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 42.38 49.53 5.65 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.98 1.752 . . . . 10.0 114.009 177.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -153.29 172.56 16.83 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 169.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.0 mp0 -44.77 -50.64 10.02 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 123.021 0.528 . . . . 10.0 111.104 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.63 -28.36 66.83 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 118.694 -0.67 . . . . 10.0 111.035 -177.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.433 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 7.8 p -54.95 -37.6 66.66 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 119.902 1.228 . . . . 10.0 112.255 175.077 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.6 t -85.98 -0.26 55.03 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 123.348 0.405 . . . . 10.0 111.73 -178.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.1 mttt -111.71 -66.46 1.08 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.834 1.254 . . . . 10.0 111.125 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.474 HG22 ' CD2' ' A' ' 63' ' ' HIS . 0.8 OUTLIER -128.99 23.07 5.69 Favored 'General case' 0 CA--C 1.543 0.698 0 CA-C-N 119.434 1.015 . . . . 10.0 112.042 -175.569 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.6 -87.26 0.35 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -172.34 37.93 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 125.164 1.386 . . . . 10.0 109.073 169.055 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.09 -13.92 62.58 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -168.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.23 54.81 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.275 -1.13 . . . . 10.0 110.275 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -56.08 128.75 36.95 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 123.976 0.91 . . . . 10.0 112.038 -168.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.9 mtm105 -66.68 74.79 0.1 Allowed 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 124.956 1.302 . . . . 10.0 110.44 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 71.0 mt -46.88 -49.78 19.75 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.447 0.699 . . . . 10.0 111.881 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.473 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -151.65 155.63 38.75 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -169.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.17 165.07 37.47 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 122.564 0.346 . . . . 10.0 111.436 -175.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.78 170.16 38.23 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 125.339 1.447 . . . . 10.0 109.931 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 7.7 t -116.96 142.99 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 118.16 0.98 . . . . 10.0 108.693 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.467 HD11 ' CD2' ' A' ' 117' ' ' LEU . 41.2 mt -83.06 119.63 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.717 0 C-N-CA 123.728 0.811 . . . . 10.0 109.303 -176.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.17 159.75 24.13 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.775 -0.53 . . . . 10.0 111.775 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 55.6 mt -74.4 150.9 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 125.086 1.354 . . . . 10.0 110.415 -169.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.95 -106.59 0.38 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 167.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.922 1 C-N-CA 132.302 4.241 . . . . 10.0 102.72 -169.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.624 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.9 t -145.4 -51.81 0.26 Allowed 'General case' 0 CA--C 1.514 -0.418 0 C-N-CA 125.194 1.398 . . . . 10.0 108.482 176.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -110.24 145.81 36.71 Favored 'General case' 0 N--CA 1.44 -0.941 0 C-N-CA 126.567 1.947 . . . . 10.0 106.159 -172.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.57 149.6 30.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 172.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.5 m -129.69 161.31 39.51 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 O-C-N 123.718 0.636 . . . . 10.0 110.388 -176.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.16 105.11 4.03 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.418 -0.956 . . . . 10.0 108.418 170.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.02 91.85 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 170.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -77.36 143.59 38.61 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 108.309 -0.997 . . . . 10.0 108.309 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.14 165.14 32.23 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 107.959 -1.126 . . . . 10.0 107.959 173.027 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -168.67 -58.5 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 115.583 -0.735 . . . . 10.0 111.665 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.52 -45.23 47.17 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 -173.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.04 -68.28 0.52 Allowed Glycine 0 N--CA 1.445 -0.754 0 CA-C-N 113.75 -1.568 . . . . 10.0 110.288 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -57.84 -37.49 96.16 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.852 2.368 . . . . 10.0 111.068 174.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.26 102.76 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 N-CA-C 107.083 -1.451 . . . . 10.0 107.083 175.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -118.97 117.99 30.29 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 105.609 -1.997 . . . . 10.0 105.609 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.73 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -99.17 132.05 10.78 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 172.492 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.633 ' CG2' HG23 ' A' ' 54' ' ' THR . 6.5 mt -135.15 88.62 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 N-CA-C 107.01 -1.478 . . . . 10.0 107.01 -174.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -103.05 140.92 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 125.258 1.423 . . . . 10.0 109.659 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -124.87 112.47 16.68 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.047 1.739 . . . . 10.0 108.109 169.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -93.03 119.24 32.07 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.489 -1.301 . . . . 10.0 107.489 171.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -111.26 143.24 42.36 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 118.926 0.785 . . . . 10.0 111.447 168.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -92.6 118.14 30.7 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 103.909 -2.626 . . . . 10.0 103.909 166.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 79.3 mttt -55.1 -49.79 70.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.742 0.782 . . . . 10.0 109.412 171.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -130.21 -144.81 0.27 Allowed 'General case' 0 N--CA 1.432 -1.334 0 N-CA-C 105.454 -2.054 . . . . 10.0 105.454 -170.053 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.6 t -110.61 -12.55 14.33 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.275 0.56 . . . . 10.0 110.307 167.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -127.68 2.17 6.12 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.632 1.173 . . . . 10.0 110.999 -175.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.19 163.04 51.81 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 108.932 -1.667 . . . . 10.0 108.932 179.008 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -65.48 135.73 43.71 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.637 1.558 . . . . 10.0 108.446 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -78.23 107.22 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 105.775 -1.935 . . . . 10.0 105.775 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -77.11 108.91 10.53 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 106.284 -1.747 . . . . 10.0 106.284 170.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -85.85 105.99 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.754 -1.573 . . . . 10.0 106.754 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 25.3 p90 -113.99 163.81 14.64 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.444 0.64 . . . . 10.0 110.969 170.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 177.63 170.12 39.51 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.224 -0.75 . . . . 10.0 111.224 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.1 p -140.03 100.55 3.95 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.997 -1.483 . . . . 10.0 106.997 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.73 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.6 pt -78.12 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 C-N-CA 118.64 -1.224 . . . . 10.0 109.247 170.435 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -152.91 155.01 36.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 168.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.4 34.1 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 119.033 -0.87 . . . . 10.0 115.011 169.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.501 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.5 mp -72.45 177.79 4.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 118.934 1.367 . . . . 10.0 110.649 -177.141 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.25 161.56 15.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.295 -1.002 . . . . 10.0 108.295 168.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -55.74 163.34 1.42 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.227 1.011 . . . . 10.0 112.249 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.98 -175.37 33.66 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-O 121.863 0.702 . . . . 10.0 112.501 168.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -68.2 143.91 55.15 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.409 1.484 . . . . 10.0 109.999 -178.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -142.05 147.78 37.39 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 113.394 0.887 . . . . 10.0 113.394 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.63 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.38 125.5 0.27 Allowed Glycine 0 C--N 1.341 0.823 0 C-N-CA 127.738 2.59 . . . . 10.0 111.878 165.269 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -151.69 108.64 3.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 119.104 1.452 . . . . 10.0 110.473 166.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.498 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -147.66 172.29 14.29 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 122.407 1.099 . . . . 10.0 113.046 179.043 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.96 134.75 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.671 0 CA-C-N 111.191 -2.731 . . . . 10.0 106.418 169.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 47.1 m-70 -116.77 141.44 48.2 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 106.214 -1.773 . . . . 10.0 106.214 171.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -54.68 -52.23 63.03 Favored 'General case' 0 N--CA 1.451 -0.399 0 O-C-N 124.144 0.903 . . . . 10.0 111.915 -168.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -76.92 137.78 39.3 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 -175.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.62 12.51 51.78 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 124.381 0.991 . . . . 10.0 111.649 167.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.43 ' HA ' HG22 ' A' ' 5' ' ' VAL . 0.0 OUTLIER -79.69 174.76 11.26 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-O 121.864 0.84 . . . . 10.0 110.123 -179.503 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -165.3 30.56 0.06 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.552 -1.204 . . . . 10.0 112.641 168.625 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.434 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -63.41 -35.24 79.75 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 119.696 1.134 . . . . 10.0 112.423 -168.923 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.46 -20.75 50.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 118.06 0.391 . . . . 10.0 111.737 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.73 -160.43 13.2 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 105.852 -2.899 . . . . 10.0 105.852 -167.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 59.9 m -70.21 65.75 0.27 Allowed 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 126.321 1.848 . . . . 10.0 111.547 -175.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -153.38 -52.53 0.1 Allowed 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 124.446 1.098 . . . . 10.0 108.727 177.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 18.4 m -51.38 -34.94 36.52 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.205 1.002 . . . . 10.0 111.809 -177.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -26.8 -38.88 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.848 2.859 . . . . 10.0 114.47 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 110.39 139.69 8.3 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 110.285 -1.126 . . . . 10.0 110.285 169.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.27 55.54 4.65 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.61 3.54 . . . . 10.0 113.266 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 18.2 m170 62.88 48.58 3.94 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.418 2.287 . . . . 10.0 109.197 178.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -66.84 71.78 0.09 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.296 1.038 . . . . 10.0 111.68 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.0 p-10 -84.1 153.33 63.05 Favored Pre-proline 0 C--N 1.326 -0.45 0 O-C-N 121.212 -0.93 . . . . 10.0 111.84 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.66 -43.9 1.7 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.685 2.256 . . . . 10.0 111.447 176.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.0 mt -75.98 62.27 1.61 Allowed 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.711 0.805 . . . . 10.0 109.94 -178.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.2 p -40.28 99.87 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.423 1.889 . . . . 10.0 112.796 -173.087 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 14.2 mtp180 -140.26 177.71 7.8 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 126.058 1.743 . . . . 10.0 107.961 -175.27 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.5 mttt -110.66 82.47 1.6 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 112.218 0.451 . . . . 10.0 112.218 -168.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.459 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 69.1 t60 18.0 93.4 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 116.275 1.954 . . . . 10.0 116.275 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.07 -157.45 16.41 Favored Glycine 0 N--CA 1.441 -0.983 0 C-N-CA 125.223 1.392 . . . . 10.0 110.766 177.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . -165.86 -159.21 11.56 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 106.351 -2.699 . . . . 10.0 106.351 169.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -63.88 6.45 0.28 Allowed 'Trans proline' 0 CA--C 1.543 0.967 0 CA-C-N 120.665 2.233 . . . . 10.0 111.546 168.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.415 ' H ' ' C ' ' B' ' 73' ' ' GLY . 11.7 mmmt -114.15 5.88 16.1 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 125.59 1.556 . . . . 10.0 110.064 176.108 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -141.32 169.13 18.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 119.729 1.15 . . . . 10.0 109.342 167.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.71 -27.05 29.27 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 166.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.87 33.51 0.33 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 124.621 1.168 . . . . 10.0 113.217 -171.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.02 138.76 11.3 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 167.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.459 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 30.9 m80 -66.48 -62.45 1.46 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 118.16 -1.416 . . . . 10.0 108.611 169.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.4 p -164.45 -58.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 108.679 -0.86 . . . . 10.0 108.679 175.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.8 66.5 0.35 Allowed Glycine 0 C--N 1.334 0.471 0 N-CA-C 109.067 -1.613 . . . . 10.0 109.067 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -112.07 101.62 9.89 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.822 -1.918 . . . . 10.0 105.822 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 19.4 mt -72.65 -18.37 61.58 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.27 0.486 . . . . 10.0 112.195 -169.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 112.73 -95.44 0.78 Allowed Glycine 0 N--CA 1.443 -0.866 0 N-CA-C 106.781 -2.528 . . . . 10.0 106.781 -173.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -155.12 150.61 27.35 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.099 -1.075 . . . . 10.0 108.099 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.05 131.39 62.41 Favored 'Isoleucine or valine' 0 C--O 1.232 0.143 0 N-CA-C 107.332 -1.359 . . . . 10.0 107.332 168.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -95.22 119.12 33.18 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.006 0.522 . . . . 10.0 109.594 -176.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.96 133.54 38.61 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.707 1.203 . . . . 10.0 110.261 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -61.31 168.99 2.38 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.572 1.149 . . . . 10.0 109.215 166.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.18 -29.41 45.66 Favored 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 123.357 0.663 . . . . 10.0 111.385 172.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -77.63 -5.04 48.98 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 121.204 0.526 . . . . 10.0 111.423 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.0 3.17 88.0 Favored Glycine 0 C--N 1.338 0.694 0 O-C-N 120.785 -1.197 . . . . 10.0 111.067 -176.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.47 106.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.16 -1.422 . . . . 10.0 107.16 179.251 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.452 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -103.46 126.01 50.36 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 109.18 -0.674 . . . . 10.0 109.18 170.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -79.43 126.33 30.7 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 168.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 54.1 t -107.23 131.16 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 168.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 11.1 p -157.92 56.2 0.48 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 118.316 0.507 . . . . 10.0 111.152 176.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.93 152.05 4.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 C-N-CA 124.301 1.04 . . . . 10.0 109.055 -171.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -102.86 106.8 17.44 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 125.766 1.626 . . . . 10.0 108.865 174.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -80.11 77.58 6.81 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.103 -1.443 . . . . 10.0 107.103 175.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.1 m -80.61 50.03 1.26 Allowed 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -155.38 -48.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 C-N-CA 122.606 0.362 . . . . 10.0 110.994 -168.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.499 ' C ' HD12 ' B' ' 104' ' ' ILE 0.343 1.1 pp -104.22 177.09 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 C-N-CA 123.6 0.76 . . . . 10.0 112.24 178.482 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -138.12 138.92 39.15 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.848 -1.167 . . . . 10.0 107.848 171.209 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.88 -24.68 26.56 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.99 117.33 9.04 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 104.149 -2.538 . . . . 10.0 104.149 168.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.27 -67.91 0.09 OUTLIER Glycine 0 C--N 1.332 0.322 0 N-CA-C 108.257 -1.937 . . . . 10.0 108.257 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -156.99 -51.1 0.07 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 113.578 -1.311 . . . . 10.0 108.536 176.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -76.25 -23.14 54.48 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.206 -0.906 . . . . 10.0 110.312 -169.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 32.2 t 28.73 79.14 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 128.65 2.78 . . . . 10.0 111.306 178.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 8.1 pt -69.83 49.69 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 C-N-CA 125.783 1.633 . . . . 10.0 111.848 176.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -97.95 151.4 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 C-N-CA 126.5 1.92 . . . . 10.0 107.052 171.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 59.52 32.27 72.78 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.319 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 mmt-85 -105.34 170.44 7.88 Favored 'General case' 0 CA--C 1.536 0.424 0 N-CA-C 106.612 -1.625 . . . . 10.0 106.612 168.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.6 m -112.95 129.38 56.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 177.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.494 HD21 HD11 ' B' ' 149' ' ' ILE . 64.6 mt -102.07 141.57 34.71 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 107.806 -1.183 . . . . 10.0 107.806 173.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 67.8 t -129.39 133.32 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.084 -1.45 . . . . 10.0 107.084 -177.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -106.51 134.09 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 105.963 -1.866 . . . . 10.0 105.963 169.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.63 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.1 m170 -112.13 157.6 20.64 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 123.589 1.661 . . . . 10.0 114.63 -170.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . 0.475 ' N ' HD22 ' B' ' 144' ' ' LEU . 52.1 tt0 -45.79 -53.24 9.9 Favored 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 128.102 2.561 . . . . 10.0 110.041 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -119.58 175.56 5.79 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 125.084 1.354 . . . . 10.0 111.234 -172.27 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.91 149.68 37.69 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 124.667 1.187 . . . . 10.0 110.48 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.498 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.3 m-20 -77.13 135.62 38.57 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 123.325 0.65 . . . . 10.0 110.238 170.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.3 m-20 -77.13 -21.29 54.41 Favored 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 124.891 1.369 . . . . 10.0 109.72 168.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 76.9 mt 60.71 58.5 2.39 Favored 'General case' 0 C--N 1.342 0.253 0 CA-C-O 123.279 1.514 . . . . 10.0 109.387 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.36 -43.23 3.11 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 112.737 -2.029 . . . . 10.0 110.158 169.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 17.9 mtmm -78.24 44.28 0.49 Allowed 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.625 1.57 . . . . 10.0 111.821 -175.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.21 -33.82 7.47 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.574 2.035 . . . . 10.0 110.12 172.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.17 33.69 48.74 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 123.473 0.559 . . . . 10.0 112.278 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -145.11 165.5 28.08 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 105.905 -1.887 . . . . 10.0 105.905 174.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -55.08 -48.42 73.56 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-O 121.246 0.546 . . . . 10.0 110.068 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -59.86 -30.35 68.92 Favored 'General case' 0 N--CA 1.453 -0.312 0 O-C-N 121.69 -0.631 . . . . 10.0 111.726 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -51.84 -51.91 53.2 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 121.358 -0.838 . . . . 10.0 110.174 169.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.9 t -82.19 -10.74 59.05 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.841 -0.618 . . . . 10.0 112.105 -173.082 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.4 ttmm -100.17 -52.73 3.32 Favored 'General case' 0 N--CA 1.436 -1.143 0 C-N-CA 125.417 1.487 . . . . 10.0 111.506 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.0 p -140.05 31.18 1.99 Allowed 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.65 0.78 . . . . 10.0 112.2 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.23 19.65 64.28 Favored Glycine 0 C--N 1.339 0.706 0 CA-C-N 119.246 0.93 . . . . 10.0 112.29 174.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 53.62 26.14 5.52 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 117.915 0.858 . . . . 10.0 112.325 -173.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.37 0.78 3.53 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.698 -0.626 . . . . 10.0 112.455 -178.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.75 -165.18 47.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 109.918 -1.273 . . . . 10.0 109.918 168.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -54.19 134.11 44.5 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.61 0.719 . . . . 10.0 110.084 -172.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.04 67.59 0.07 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 169.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.475 HD22 ' N ' ' B' ' 121' ' ' GLU . 1.1 pt? -61.71 -25.18 67.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.815 0.672 . . . . 10.0 112.815 -168.174 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -154.33 148.68 26.08 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.133 0.492 . . . . 10.0 109.793 177.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 21.2 p -158.13 168.78 26.13 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.947 0.499 . . . . 10.0 109.958 -175.082 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -165.53 167.51 39.02 Favored Glycine 0 CA--C 1.528 0.844 0 N-CA-C 110.704 -0.959 . . . . 10.0 110.704 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 74.0 t -109.64 142.85 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.38 0 C-N-CA 125.48 1.512 . . . . 10.0 107.139 -169.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.494 HD11 HD21 ' B' ' 117' ' ' LEU . 67.7 mt -80.35 112.88 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 C-N-CA 122.492 0.317 . . . . 10.0 110.793 -172.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.05 145.39 17.66 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 124.691 1.138 . . . . 10.0 110.745 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 44.9 mt -62.89 148.52 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 124.473 1.109 . . . . 10.0 109.661 174.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.34 170.13 17.43 Favored 'General case' 0 N--CA 1.439 -0.983 0 CA-C-O 122.619 1.2 . . . . 10.0 110.84 168.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 . . . . . 0 C--O 1.25 1.082 0 C-N-CA 129.585 3.154 . . . . 10.0 103.097 165.132 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.803 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -156.35 -44.29 0.07 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 118.47 0.577 . . . . 10.0 110.955 172.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.5 ttpp -113.78 142.87 45.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 106.918 -1.512 . . . . 10.0 106.918 167.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.74 171.06 14.77 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.477 -1.305 . . . . 10.0 107.477 171.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -140.42 166.59 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 123.897 0.879 . . . . 10.0 110.235 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.68 112.37 5.36 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 168.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.448 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.4 m -97.59 114.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 173.124 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -103.51 137.2 41.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 -174.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.0 mtpt -146.33 165.39 29.44 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.924 1.238 . . . . 10.0 107.998 170.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.71 -58.81 0.04 OUTLIER Glycine 0 C--O 1.23 -0.096 0 CA-C-N 115.024 -0.989 . . . . 10.0 112.791 169.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.41 -44.91 49.82 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -171.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.48 -65.7 0.57 Allowed Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 113.601 -1.636 . . . . 10.0 110.659 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -59.0 -37.1 95.24 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.737 2.291 . . . . 10.0 111.315 174.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -67.33 106.58 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.007 0 N-CA-C 107.017 -1.475 . . . . 10.0 107.017 175.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -121.78 106.81 11.63 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.03 -1.841 . . . . 10.0 106.03 170.007 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.819 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -89.43 143.39 17.26 Favored Glycine 0 N--CA 1.434 -1.491 0 N-CA-C 109.66 -1.376 . . . . 10.0 109.66 173.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.634 HG22 HG23 ' B' ' 54' ' ' THR . 1.1 mt -150.22 84.56 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.207 -1.405 . . . . 10.0 107.207 -169.286 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.574 HD12 ' HA3' ' A' ' 33' ' ' GLY . 1.0 OUTLIER -96.19 145.43 8.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 C-N-CA 125.273 1.429 . . . . 10.0 110.963 175.815 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -128.95 117.49 21.05 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.942 2.097 . . . . 10.0 109.126 169.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -95.52 125.45 40.13 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.72 1.208 . . . . 10.0 108.862 178.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.53 132.99 53.62 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 125.121 1.368 . . . . 10.0 111.456 175.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -132.64 79.71 1.86 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 127.971 2.508 . . . . 10.0 106.045 168.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -56.12 -45.63 79.47 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 127.873 2.469 . . . . 10.0 110.658 -172.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -122.75 161.71 23.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 102.305 -3.22 . . . . 10.0 102.305 167.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -58.51 -30.27 66.92 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.473 -0.785 . . . . 10.0 109.073 174.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 m-80 -90.26 -9.13 49.1 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 124.892 1.277 . . . . 10.0 111.037 -174.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.29 138.8 27.01 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 109.308 -1.517 . . . . 10.0 109.308 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -59.82 135.46 63.68 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 N-CA-C 106.044 -2.329 . . . . 10.0 106.044 168.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 t -78.73 129.06 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.016 -1.476 . . . . 10.0 107.016 -170.244 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt -101.01 118.15 36.44 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.7 m -103.03 96.74 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 172.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -103.4 167.14 10.0 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 121.932 0.872 . . . . 10.0 110.613 168.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.574 ' HA3' HD12 ' A' ' 18' ' ' ILE . . . 176.03 -177.74 47.61 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.616 -0.802 . . . . 10.0 111.211 175.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.8 m -154.5 91.77 1.43 Allowed 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.774 -0.824 . . . . 10.0 108.774 -175.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.819 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.5 pt -78.96 151.68 4.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.511 0 CA-C-O 118.327 -0.844 . . . . 10.0 108.775 169.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.408 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -135.6 156.4 48.92 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 165.614 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.33 -10.13 39.21 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 123.836 0.731 . . . . 10.0 112.887 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -68.68 176.26 3.08 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 118.172 0.986 . . . . 10.0 109.641 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.1 t -105.32 150.41 25.21 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.451 -1.314 . . . . 10.0 107.451 167.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -50.86 146.11 6.34 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.115 0.966 . . . . 10.0 112.276 -169.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.3 -179.26 29.51 Favored Glycine 0 CA--C 1.528 0.85 0 C-N-CA 124.279 0.942 . . . . 10.0 112.128 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mt -57.85 148.72 24.5 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.133 2.173 . . . . 10.0 112.87 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -150.88 147.92 27.81 Favored 'General case' 0 CA--C 1.518 -0.254 0 C-N-CA 125.78 1.632 . . . . 10.0 112.18 176.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.621 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -33.17 125.36 0.33 Allowed Glycine 0 C--N 1.338 0.68 0 C-N-CA 126.462 1.982 . . . . 10.0 112.2 164.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -153.13 107.52 3.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 119.158 1.479 . . . . 10.0 110.279 166.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.4 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -154.93 169.52 23.85 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.67 0.748 . . . . 10.0 112.021 -179.214 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.1 m -84.72 153.18 3.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 112.663 -2.062 . . . . 10.0 107.715 168.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.91 148.43 50.49 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 107.536 -1.283 . . . . 10.0 107.536 171.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -35.91 -60.94 0.51 Allowed 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 126.576 1.95 . . . . 10.0 113.736 -170.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -98.8 161.14 13.8 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-O 121.925 0.869 . . . . 10.0 111.368 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.34 -22.88 28.25 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 126.46 1.981 . . . . 10.0 109.866 168.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -44.41 136.93 3.9 Favored 'General case' 0 C--N 1.342 0.243 0 C-N-CA 123.669 0.788 . . . . 10.0 110.275 169.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -141.51 21.1 2.2 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 10.0 111.439 -178.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.874 HG22 ' CG2' ' B' ' 17' ' ' ILE . 3.6 p -52.06 -39.01 59.03 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 113.961 1.096 . . . . 10.0 113.961 -174.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.04 -11.29 59.92 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.244 0.618 . . . . 10.0 111.619 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 118.66 -64.02 0.42 Allowed Glycine 0 C--O 1.225 -0.425 0 C-N-CA 126.052 1.787 . . . . 10.0 109.253 179.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.5 t -155.19 55.23 0.64 Allowed 'General case' 0 C--O 1.234 0.277 0 CA-C-O 121.789 0.804 . . . . 10.0 109.732 172.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -134.62 -46.47 0.74 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.7 0.8 . . . . 10.0 109.229 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.1 m -51.75 -29.34 18.34 Favored 'General case' 0 C--N 1.344 0.367 0 C-N-CA 123.886 0.874 . . . . 10.0 111.235 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.89 -42.27 0.08 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.748 2.419 . . . . 10.0 112.878 167.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.28 165.93 39.08 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -79.39 -164.86 0.3 Allowed 'Trans proline' 0 N--CA 1.444 -1.409 0 N-CA-C 107.353 -1.826 . . . . 10.0 107.353 169.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -80.25 46.54 0.83 Allowed 'General case' 0 CA--C 1.542 0.657 0 O-C-N 120.69 -1.256 . . . . 10.0 110.634 -176.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -75.31 70.08 2.19 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 119.352 0.978 . . . . 10.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -71.15 149.19 94.42 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 169.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -58.77 -47.12 19.7 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.407 2.071 . . . . 10.0 111.147 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.32 60.82 2.06 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 108.731 -0.841 . . . . 10.0 108.731 174.155 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.5 t -61.19 112.46 2.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 108.664 -0.865 . . . . 10.0 108.664 -178.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 75.4 mtt180 -105.82 -98.66 0.34 Allowed 'General case' 0 CA--C 1.512 -0.491 0 N-CA-C 106.157 -1.794 . . . . 10.0 106.157 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 16.9 pttt -158.81 144.97 16.84 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 104.982 -2.229 . . . . 10.0 104.982 169.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -47.33 121.78 4.12 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.366 0.603 . . . . 10.0 111.526 174.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.13 -156.13 6.69 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 106.235 -2.746 . . . . 10.0 106.235 169.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -148.34 -168.84 14.73 Favored Glycine 0 C--O 1.225 -0.43 0 CA-C-N 118.477 1.139 . . . . 10.0 113.464 -178.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -69.73 16.27 0.22 Allowed 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 123.416 2.744 . . . . 10.0 112.303 175.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -105.53 -29.24 10.3 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 126.4 1.88 . . . . 10.0 108.999 168.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -107.9 172.19 6.97 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 -169.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -89.41 -26.76 20.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 122.065 0.936 . . . . 10.0 109.351 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -78.6 -11.18 59.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 125.965 1.706 . . . . 10.0 114.692 -167.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.432 HH21 ' CG ' ' A' ' 101' ' ' ASP . 0.0 OUTLIER -34.69 129.17 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.699 1.2 . . . . 10.0 112.186 176.915 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -65.59 169.76 5.84 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 107.81 -1.182 . . . . 10.0 107.81 175.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.2 p -63.55 15.04 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 N-CA-C 115.864 1.801 . . . . 10.0 115.864 -169.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.51 55.91 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.621 0 N-CA-C 108.997 -1.641 . . . . 10.0 108.997 170.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -97.37 102.5 14.28 Favored 'General case' 0 N--CA 1.457 -0.109 0 N-CA-C 106.746 -1.575 . . . . 10.0 106.746 168.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -83.03 9.7 9.66 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 117.956 0.344 . . . . 10.0 111.49 -177.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 84.55 -100.18 2.35 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 107.536 -2.226 . . . . 10.0 107.536 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -145.57 157.57 43.96 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 107.287 -1.375 . . . . 10.0 107.287 174.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.3 m -112.48 126.12 69.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 109.02 -0.733 . . . . 10.0 109.02 169.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 70.1 m -94.72 101.53 13.38 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 127.518 2.327 . . . . 10.0 109.254 -170.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.7 141.64 37.75 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 122.373 -0.204 . . . . 10.0 111.113 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -69.5 173.77 5.61 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 127.343 2.257 . . . . 10.0 109.267 167.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -23.91 67.56 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.028 0.381 . . . . 10.0 112.028 174.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.408 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 32.7 t70 -78.21 -1.47 32.99 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 120.993 0.425 . . . . 10.0 111.226 173.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.23 1.11 89.58 Favored Glycine 0 C--N 1.339 0.732 0 O-C-N 120.679 -1.263 . . . . 10.0 110.51 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.3 t -77.41 105.66 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 -176.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.527 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -102.64 113.26 26.49 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.389 -0.967 . . . . 10.0 108.389 169.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.29 117.97 20.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 126.603 1.961 . . . . 10.0 107.91 173.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 26.4 t -105.89 135.86 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.114 0 N-CA-C 106.399 -1.704 . . . . 10.0 106.399 177.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -158.64 62.41 0.43 Allowed 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 123.649 0.779 . . . . 10.0 110.22 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -107.46 161.63 6.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -139.64 151.76 46.23 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.263 1.025 . . . . 10.0 109.404 167.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.432 ' CG ' HH21 ' A' ' 79' ' ' ARG . 25.0 t0 -146.97 152.43 38.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.645 -1.243 . . . . 10.0 107.645 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.9 p -105.66 -13.26 15.62 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.862 2.465 . . . . 10.0 112.154 -176.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -102.27 16.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 119.603 1.092 . . . . 10.0 110.315 179.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -118.05 142.79 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 104.714 -2.328 . . . . 10.0 104.714 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 91.8 p -142.44 149.8 39.74 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 172.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.2 mt -62.34 -41.17 98.35 Favored 'General case' 0 C--O 1.231 0.105 0 CA-C-N 119.025 0.83 . . . . 10.0 109.485 170.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.3 p -146.95 164.56 32.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.176 1.39 . . . . 10.0 108.947 -178.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 122.87 -105.0 0.91 Allowed Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 106.431 -2.668 . . . . 10.0 106.431 -169.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -126.68 -43.61 1.71 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.368 1.067 . . . . 10.0 110.362 -168.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 20.8 m-70 -73.7 -48.53 31.44 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 105.116 -2.179 . . . . 10.0 105.116 174.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.3 t 45.12 60.7 2.86 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 124.771 1.228 . . . . 10.0 113.214 167.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.8 pt -63.97 -11.43 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 113.339 0.866 . . . . 10.0 113.339 -175.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.1 mm -48.13 141.08 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 119.976 1.262 . . . . 10.0 110.923 170.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.44 16.98 75.9 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 125.074 1.321 . . . . 10.0 115.609 169.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 24.9 mmt-85 -84.65 165.61 17.79 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.917 1.358 . . . . 10.0 108.003 166.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 74.1 m -90.48 127.9 36.37 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 107.572 -1.27 . . . . 10.0 107.572 166.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.08 136.81 32.8 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 165.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.48 136.56 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.743 0 N-CA-C 107.075 -1.454 . . . . 10.0 107.075 171.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -105.25 134.53 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.166 -2.161 . . . . 10.0 105.166 167.038 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.621 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m-70 -114.11 158.13 21.68 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -170.32 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.418 ' N ' HD22 ' A' ' 144' ' ' LEU . 0.5 OUTLIER -58.67 -48.91 79.46 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 112.883 -1.962 . . . . 10.0 109.08 -174.735 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.9 mttm -110.76 175.05 5.57 Favored 'General case' 0 C--N 1.34 0.191 0 CA-C-O 121.492 0.663 . . . . 10.0 111.934 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.37 152.81 24.88 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.615 -1.175 . . . . 10.0 110.092 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.4 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.6 OUTLIER -76.75 149.11 36.34 Favored 'General case' 0 N--CA 1.443 -0.775 0 C-N-CA 123.782 0.833 . . . . 10.0 112.175 -179.382 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -79.06 -28.3 43.16 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 112.534 -2.121 . . . . 10.0 110.425 172.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 50.7 mt 50.57 48.47 22.53 Favored 'General case' 0 C--N 1.341 0.219 0 CA-C-O 122.349 1.071 . . . . 10.0 109.812 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.3 -11.06 70.9 Favored Glycine 0 CA--C 1.53 1.011 0 CA-C-N 113.907 -1.497 . . . . 10.0 114.086 169.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -81.57 -0.63 43.1 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.07 1.435 . . . . 10.0 114.078 -168.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.64 -22.44 79.01 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.75 38.86 65.33 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.345 -0.702 . . . . 10.0 111.345 -177.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -135.39 172.37 13.11 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 107.613 -1.254 . . . . 10.0 107.613 174.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -54.63 -47.89 72.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.424 0.631 . . . . 10.0 109.809 -178.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.27 -39.77 80.1 Favored 'General case' 0 C--O 1.236 0.353 0 O-C-N 121.516 -0.74 . . . . 10.0 111.707 176.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.3 p -53.28 -38.76 63.38 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 118.655 -0.688 . . . . 10.0 110.375 177.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.9 t -87.24 -7.83 57.46 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 123.703 0.627 . . . . 10.0 112.333 -177.217 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.9 mttt -103.17 -60.88 1.48 Allowed 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.215 -0.928 . . . . 10.0 111.277 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 14.3 p -135.55 17.4 3.35 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 118.677 0.671 . . . . 10.0 111.16 -177.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 75.93 -102.43 1.55 Allowed Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 107.453 -2.259 . . . . 10.0 107.453 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.7 m-20 -165.38 40.21 0.07 Allowed 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 124.933 1.293 . . . . 10.0 107.962 173.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.12 -11.95 61.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.519 0.728 . . . . 10.0 111.639 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.32 -163.33 54.63 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 109.61 -1.396 . . . . 10.0 109.61 174.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -51.05 133.98 26.87 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 124.258 1.023 . . . . 10.0 112.788 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.5 mtt180 -67.95 64.11 0.09 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.518 1.927 . . . . 10.0 108.592 171.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.449 HD22 ' C ' ' A' ' 120' ' ' HIS . 1.1 pt? -60.59 -22.92 64.25 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 112.971 0.73 . . . . 10.0 112.971 -168.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.12 148.5 22.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 109.323 -0.621 . . . . 10.0 109.323 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 17.7 p -163.25 168.97 19.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 110.109 -0.33 . . . . 10.0 110.109 -171.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.99 169.75 42.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.325 -0.71 . . . . 10.0 111.325 -176.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 96.6 t -109.87 145.55 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 106.271 -1.752 . . . . 10.0 106.271 -171.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 89.0 mt -74.6 138.22 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 110.403 -0.221 . . . . 10.0 110.403 -175.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.8 146.7 16.66 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.035 1.302 . . . . 10.0 110.308 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 80.4 mt -80.32 154.06 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.607 1.203 . . . . 10.0 109.17 177.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.88 -109.15 0.33 Allowed 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.326 -1.361 . . . . 10.0 107.326 167.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 1 C-N-CA 132.795 4.438 . . . . 10.0 102.843 -174.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 119.085 -0.483 . . . . 10.0 110.783 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.0 t -113.6 -13.19 12.76 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 124.105 0.962 . . . . 10.0 112.796 170.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -141.57 147.85 38.35 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 118.525 0.602 . . . . 10.0 109.718 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.99 156.55 47.11 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 123.984 0.914 . . . . 10.0 109.828 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -116.83 153.58 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 126.239 1.815 . . . . 10.0 109.044 172.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.86 97.99 3.55 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.924 -1.51 . . . . 10.0 106.924 166.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 m -77.86 121.63 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.111 -1.07 . . . . 10.0 108.111 170.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mt -103.16 130.32 50.3 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 117.85 -1.072 . . . . 10.0 108.769 -174.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 45.0 mtpt -145.46 160.01 42.23 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 120.236 1.38 . . . . 10.0 109.467 170.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.81 -71.26 0.01 OUTLIER Glycine 0 C--O 1.229 -0.177 0 CA-C-N 114.845 -1.07 . . . . 10.0 111.808 173.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.61 -43.64 54.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 106.865 -1.531 . . . . 10.0 106.865 -171.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.57 -65.5 0.57 Allowed Glycine 0 N--CA 1.443 -0.871 0 CA-C-N 113.299 -1.773 . . . . 10.0 111.27 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -54.57 -39.78 86.92 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.6 2.2 . . . . 10.0 111.019 173.262 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 64.9 t -66.33 99.49 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 107.729 -1.212 . . . . 10.0 107.729 173.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -124.61 123.0 39.11 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 125.169 1.388 . . . . 10.0 108.593 173.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.01 156.7 15.52 Favored Glycine 0 C--N 1.333 0.402 0 N-CA-C 111.872 -0.491 . . . . 10.0 111.872 171.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.874 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.2 mt -141.12 63.45 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 C-N-CA 124.466 1.106 . . . . 10.0 108.609 -172.489 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -78.22 141.09 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.073 0 O-C-N 121.502 -0.748 . . . . 10.0 110.138 -170.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.6 115.79 24.08 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 128.812 2.845 . . . . 10.0 108.156 -175.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -108.97 107.17 17.44 Favored 'General case' 0 C--N 1.333 -0.128 0 C-N-CA 124.411 1.084 . . . . 10.0 108.098 173.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 75.2 mt-10 -99.22 130.62 45.54 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 119.211 0.914 . . . . 10.0 112.064 169.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 tp60 -79.79 110.48 15.18 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 105.146 -2.168 . . . . 10.0 105.146 168.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mmmt -48.14 -67.79 0.24 Allowed 'General case' 0 CA--C 1.514 -0.423 0 C-N-CA 126.801 2.04 . . . . 10.0 110.0 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -123.57 -130.6 0.26 Allowed 'General case' 0 N--CA 1.421 -1.886 0 N-CA-C 103.957 -2.609 . . . . 10.0 103.957 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.6 t -93.23 -49.67 5.86 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.538 -1.282 . . . . 10.0 107.538 167.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -107.17 4.62 26.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.152 -1.386 . . . . 10.0 110.776 -170.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.91 152.8 50.71 Favored Glycine 0 CA--C 1.531 1.09 0 N-CA-C 108.699 -1.76 . . . . 10.0 108.699 173.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -60.51 140.04 89.31 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.297 1.998 . . . . 10.0 109.643 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 9.3 t -79.27 108.22 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.048 0 N-CA-C 105.569 -2.012 . . . . 10.0 105.569 175.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 56.1 mttm -83.52 119.05 24.22 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 105.126 -2.176 . . . . 10.0 105.126 168.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -105.79 111.15 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 177.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -129.15 170.9 12.97 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 120.79 0.329 . . . . 10.0 111.72 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.63 -153.25 25.17 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 107.787 -2.125 . . . . 10.0 107.787 172.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.7 156.52 35.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 117.656 0.728 . . . . 10.0 110.286 177.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.779 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -116.29 113.79 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 127.479 2.312 . . . . 10.0 106.894 167.782 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 1.3 pttt -96.58 136.43 37.11 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 108.413 -0.958 . . . . 10.0 108.413 168.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.95 0.27 9.03 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 124.892 1.234 . . . . 10.0 113.679 173.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -75.12 177.17 6.63 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 118.74 1.27 . . . . 10.0 110.785 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.0 t -107.76 149.75 27.81 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.706 -1.59 . . . . 10.0 106.706 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -44.87 140.72 2.45 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.811 1.644 . . . . 10.0 112.156 -172.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.75 -175.28 19.28 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 123.583 0.611 . . . . 10.0 112.18 171.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -70.91 147.59 48.61 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.305 1.442 . . . . 10.0 110.803 -174.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 81.9 m-70 -144.29 145.02 31.76 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.162 0.801 . . . . 10.0 113.162 178.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.667 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -27.7 125.0 0.06 OUTLIER Glycine 0 C--N 1.344 0.996 0 C-N-CA 127.039 2.257 . . . . 10.0 111.973 164.501 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -150.1 105.36 3.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 119.317 1.559 . . . . 10.0 112.085 168.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.08 171.25 18.16 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 122.054 0.931 . . . . 10.0 111.966 -178.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 8.0 m -92.31 149.0 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.789 -2.46 . . . . 10.0 106.694 167.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -120.64 131.44 54.61 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.069 -2.567 . . . . 10.0 104.069 169.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -60.47 -46.5 89.87 Favored 'General case' 0 N--CA 1.452 -0.334 0 O-C-N 124.315 1.009 . . . . 10.0 113.128 -165.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 11.5 m-30 -78.67 135.31 37.16 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 118.619 -1.232 . . . . 10.0 107.758 175.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.51 -41.26 98.0 Favored Glycine 0 CA--C 1.533 1.164 0 N-CA-C 107.918 -2.073 . . . . 10.0 107.918 166.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -29.48 101.31 0.02 OUTLIER 'General case' 0 C--N 1.344 0.369 0 C-N-CA 128.098 2.559 . . . . 10.0 113.933 -169.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.448 ' HB3' HG21 ' A' ' 7' ' ' VAL . 1.1 m-80 -107.67 14.54 25.52 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 113.836 -1.529 . . . . 10.0 111.297 173.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.634 HG23 HG22 ' A' ' 17' ' ' ILE . 0.8 OUTLIER -57.7 -33.05 67.98 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 120.453 1.479 . . . . 10.0 110.587 -176.594 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -20.0 51.19 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.049 1.34 . . . . 10.0 113.076 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.89 95.81 1.87 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.74 1.162 . . . . 10.0 110.439 -176.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 26.6 t 19.55 66.85 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.617 2.367 . . . . 10.0 114.219 -174.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.2 m -151.38 -52.09 0.13 Allowed 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 124.946 1.299 . . . . 10.0 107.741 -174.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 13.8 t -73.89 4.57 5.13 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.718 -0.614 . . . . 10.0 112.131 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.05 -22.36 66.8 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 124.938 1.295 . . . . 10.0 111.37 177.056 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.2 140.32 11.0 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 169.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -75.89 62.31 6.53 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.576 2.851 . . . . 10.0 111.102 176.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.0 m170 58.58 61.89 2.1 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 126.347 1.859 . . . . 10.0 109.123 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -68.66 71.47 0.21 Allowed 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 122.502 1.144 . . . . 10.0 111.843 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -74.96 152.88 86.7 Favored Pre-proline 0 C--N 1.32 -0.693 0 C-N-CA 127.664 2.385 . . . . 10.0 111.443 -178.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.74 163.49 38.05 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.564 2.176 . . . . 10.0 110.534 177.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . 0.29 0.2 OUTLIER 49.52 -96.5 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.745 1.618 . . . . 10.0 110.747 -169.676 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.3 m 172.59 94.8 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 128.079 2.552 . . . . 10.0 108.138 173.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -103.73 156.92 17.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 107.744 -1.206 . . . . 10.0 107.744 169.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 97.06 7.81 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.362 -0.352 . . . . 10.0 110.091 -172.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.552 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.6 t60 -10.17 96.1 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 C-N-CA 126.975 2.11 . . . . 10.0 114.072 -173.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -117.97 -162.14 12.25 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 108.971 -1.652 . . . . 10.0 108.971 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.29 -168.92 13.27 Favored Glycine 0 N--CA 1.449 -0.482 0 N-CA-C 110.521 -1.032 . . . . 10.0 110.521 175.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -67.45 11.39 0.22 Allowed 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.155 1.903 . . . . 10.0 112.302 175.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -101.24 -25.03 14.14 Favored 'General case' 0 N--CA 1.443 -0.814 0 C-N-CA 124.563 1.145 . . . . 10.0 108.896 169.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -107.85 170.88 7.72 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -169.284 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -86.03 -31.17 22.13 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 169.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -86.82 21.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 125.563 1.545 . . . . 10.0 113.062 -167.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.54 128.09 34.5 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 107.104 -1.443 . . . . 10.0 107.104 167.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.552 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 18.4 m170 -58.17 -68.09 0.28 Allowed 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.054 0.454 . . . . 10.0 111.096 -172.042 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.9 p -162.98 -51.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.456 -0.942 . . . . 10.0 108.456 -171.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -138.48 62.94 0.56 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 109.327 -1.509 . . . . 10.0 109.327 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -99.93 104.0 15.61 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 104.626 -2.361 . . . . 10.0 104.626 168.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -78.76 -2.97 42.02 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 119.235 0.925 . . . . 10.0 111.138 -175.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . 0.553 ' HA2' HD21 ' B' ' 126' ' ' LEU . . . 94.77 -98.92 2.36 Favored Glycine 0 N--CA 1.44 -1.039 0 N-CA-C 106.584 -2.606 . . . . 10.0 106.584 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -144.78 160.57 41.03 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 123.587 0.755 . . . . 10.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.55 132.03 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 105.495 -2.039 . . . . 10.0 105.495 166.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -94.83 118.12 31.25 Favored 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 108.656 -0.868 . . . . 10.0 108.656 -178.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.03 127.98 34.44 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 123.468 0.707 . . . . 10.0 109.135 175.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -61.94 167.06 4.04 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 124.453 1.096 . . . . 10.0 109.118 168.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -52.54 -28.88 22.61 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 126.022 1.729 . . . . 10.0 111.53 171.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -77.23 -10.86 59.69 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 118.115 0.416 . . . . 10.0 111.597 178.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.09 15.84 60.26 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 121.037 -1.04 . . . . 10.0 111.034 -177.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 43.0 t -97.43 106.82 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.889 2.076 . . . . 10.0 106.497 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.779 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -97.92 123.93 42.13 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.84 -1.17 . . . . 10.0 107.84 169.369 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -91.72 132.0 36.7 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 175.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -101.64 126.45 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 105.686 -1.968 . . . . 10.0 105.686 168.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 63.4 m -155.15 66.94 0.65 Allowed 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 125.001 1.32 . . . . 10.0 107.749 172.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -113.3 162.47 11.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 106.322 -1.733 . . . . 10.0 106.322 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -141.62 147.69 38.0 Favored 'General case' 0 N--CA 1.446 -0.672 0 O-C-N 121.36 -0.838 . . . . 10.0 111.06 168.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -132.75 137.11 46.74 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.92 1.288 . . . . 10.0 108.988 -175.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 1.7 p -108.79 56.75 0.62 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 125.615 1.566 . . . . 10.0 108.088 171.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.57 -61.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 N-CA-C 109.018 -0.734 . . . . 10.0 109.018 178.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.333 0.0 OUTLIER -70.41 169.55 1.41 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 112.74 0.644 . . . . 10.0 112.74 176.874 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 12.3 m -158.57 138.76 12.34 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 174.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 pp -81.75 -18.64 43.53 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.859 0.464 . . . . 10.0 110.232 172.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t -148.18 122.06 9.37 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 106.569 -1.641 . . . . 10.0 106.569 168.196 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.79 -62.04 0.1 Allowed Glycine 0 C--N 1.336 0.544 0 N-CA-C 109.645 -1.382 . . . . 10.0 109.645 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -164.01 -51.73 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 126.238 1.815 . . . . 10.0 107.094 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -74.26 -38.35 63.48 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 114.321 -1.309 . . . . 10.0 108.555 -170.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 14.2 t 49.83 70.85 0.45 Allowed 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.488 1.515 . . . . 10.0 110.943 171.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 44.5 pt -56.45 -14.78 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 N-CA-C 113.526 0.936 . . . . 10.0 113.526 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.5 mm -44.79 128.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 O-C-N 121.366 -0.834 . . . . 10.0 109.619 169.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.26 0.17 80.51 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.038 -0.868 . . . . 10.0 112.889 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -79.31 168.13 19.95 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.896 1.348 . . . . 10.0 109.152 168.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -112.31 124.81 53.28 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.72 0.808 . . . . 10.0 109.581 176.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.402 HD21 HD11 ' B' ' 149' ' ' ILE . 4.4 mm? -82.24 147.25 29.05 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.026 -1.101 . . . . 10.0 108.026 168.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 95.7 t -133.12 134.83 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.901 0 N-CA-C 108.217 -1.031 . . . . 10.0 108.217 168.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -103.47 129.95 54.61 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 105.754 -1.943 . . . . 10.0 105.754 167.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.667 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.9 m-70 -106.15 157.13 17.78 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 115.42 1.637 . . . . 10.0 115.42 -170.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -39.98 -56.62 1.79 Allowed 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 129.264 3.026 . . . . 10.0 110.623 173.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -119.79 168.35 11.17 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.176 0.991 . . . . 10.0 112.546 -169.244 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.81 129.13 38.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 113.98 -1.464 . . . . 10.0 109.129 170.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.419 ' CG ' HD23 ' B' ' 126' ' ' LEU . 62.4 t0 -77.77 108.26 10.87 Favored 'General case' 0 N--CA 1.442 -0.859 0 N-CA-C 107.347 -1.353 . . . . 10.0 107.347 171.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -78.97 3.38 17.33 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 111.676 0.251 . . . . 10.0 111.676 175.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.553 HD21 ' HA2' ' B' ' 85' ' ' GLY . 22.2 mt 59.79 -146.42 0.49 Allowed 'General case' 0 N--CA 1.419 -2.004 0 N-CA-C 105.97 -1.863 . . . . 10.0 105.97 -177.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 -14.28 77.26 Favored Glycine 0 C--N 1.304 -1.221 0 CA-C-N 114.351 -1.295 . . . . 10.0 112.244 -168.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -75.07 -1.27 22.13 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.413 1.107 . . . . 10.0 111.966 -169.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.36 -32.56 77.6 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 108.595 -1.802 . . . . 10.0 108.595 168.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 62.13 37.63 94.8 Favored Glycine 0 C--N 1.341 0.818 0 N-CA-C 111.267 -0.733 . . . . 10.0 111.267 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.66 175.34 9.26 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 105.176 -2.157 . . . . 10.0 105.176 170.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -45.82 -54.17 8.49 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 115.044 -0.98 . . . . 10.0 111.23 172.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -64.5 -34.68 78.78 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 119.777 -0.769 . . . . 10.0 111.162 -172.116 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -47.7 -40.0 18.99 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 124.116 0.967 . . . . 10.0 111.702 169.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 t -93.08 -4.04 53.11 Favored 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 119.658 1.117 . . . . 10.0 110.362 -170.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -110.44 -57.82 2.16 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 125.698 1.599 . . . . 10.0 110.922 -171.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.4 p -137.13 5.84 2.8 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.616 0.644 . . . . 10.0 112.563 175.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.69 32.18 57.6 Favored Glycine 0 C--N 1.341 0.848 0 CA-C-N 118.675 0.67 . . . . 10.0 114.37 172.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 63.2 m-20 57.78 19.61 5.78 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.794 0.838 . . . . 10.0 113.175 179.106 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.38 -4.04 20.42 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.128 -0.982 . . . . 10.0 112.945 -176.325 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.54 -164.14 53.99 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.679 -0.968 . . . . 10.0 110.679 172.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.78 141.73 43.28 Favored 'General case' 0 N--CA 1.445 -0.714 0 C-N-CA 123.696 0.798 . . . . 10.0 111.987 -168.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 25.7 mtm-85 -67.22 71.14 0.1 Allowed 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.62 1.568 . . . . 10.0 109.414 172.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 6.8 tp -43.54 -45.56 6.64 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 126.5 1.92 . . . . 10.0 112.212 -174.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -159.48 147.41 17.37 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 -173.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 9.5 m -141.09 157.27 45.53 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.296 -0.631 . . . . 10.0 109.296 -168.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.6 164.96 30.42 Favored Glycine 0 C--N 1.332 0.346 0 N-CA-C 110.219 -1.152 . . . . 10.0 110.219 175.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.02 135.94 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 108.045 -1.095 . . . . 10.0 108.045 -174.514 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.402 HD11 HD21 ' B' ' 117' ' ' LEU . 9.3 mt -75.33 107.13 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 N-CA-C 109.291 -0.633 . . . . 10.0 109.291 -174.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.12 154.97 16.38 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 125.799 1.666 . . . . 10.0 110.976 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 90.4 mt -73.27 140.3 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 124.301 1.04 . . . . 10.0 109.937 -175.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.98 -45.99 2.65 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.84 0.456 . . . . 10.0 111.567 169.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 mm100 . . . . . 0 N--CA 1.445 -0.683 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 179.381 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.974 0 CA-C-O 118.158 -0.925 . . . . 10.0 109.398 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.2 t -84.29 -13.46 52.42 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 119.661 1.119 . . . . 10.0 111.893 -176.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.5 ptpp? -152.6 157.86 41.62 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.499 0.666 . . . . 10.0 112.351 167.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.91 170.62 15.4 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 125.855 1.662 . . . . 10.0 109.635 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.5 150.12 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 C-N-CA 126.462 1.905 . . . . 10.0 110.302 -177.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.62 100.91 4.77 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.005 -1.48 . . . . 10.0 107.005 166.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.495 HG21 ' HB3' ' B' ' 53' ' ' ASN . 6.0 m -82.12 118.91 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 107.821 -1.177 . . . . 10.0 107.821 169.385 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -97.43 138.89 34.18 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.873 -1.158 . . . . 10.0 107.873 177.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.9 ttmt -156.76 162.85 39.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.34 -50.21 0.07 OUTLIER Glycine 0 C--O 1.228 -0.256 0 C-N-CA 120.303 -0.951 . . . . 10.0 112.963 169.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -73.31 -45.73 53.75 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.35 -71.48 0.4 Allowed Glycine 0 CA--C 1.524 0.599 0 CA-C-N 114.46 -1.245 . . . . 10.0 110.021 171.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -57.95 -33.82 97.61 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.496 2.798 . . . . 10.0 111.192 173.059 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.1 t -64.91 105.58 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 N-CA-C 107.915 -1.143 . . . . 10.0 107.915 174.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -124.01 110.64 15.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 106.167 -1.79 . . . . 10.0 106.167 173.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.703 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -91.59 144.38 17.14 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 109.362 -1.495 . . . . 10.0 109.362 169.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.538 ' CG2' HG22 ' B' ' 54' ' ' THR . 4.9 mt -140.1 80.46 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 106.26 -1.755 . . . . 10.0 106.26 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.7 mm -101.97 123.4 55.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 N-CA-C 109.557 -0.534 . . . . 10.0 109.557 -175.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 9.4 m-20 -85.63 151.29 24.01 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 109.268 -0.642 . . . . 10.0 109.268 169.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -126.33 91.53 3.39 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.231 -1.766 . . . . 10.0 106.231 169.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -84.27 138.72 32.78 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.175 0.99 . . . . 10.0 109.812 171.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -127.76 112.05 14.35 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 168.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.06 -56.4 11.72 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 122.7 1.238 . . . . 10.0 111.64 -170.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -139.97 170.39 15.95 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 103.657 -2.72 . . . . 10.0 103.657 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 91.8 p -65.0 -22.71 67.04 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.02 -0.536 . . . . 10.0 110.237 170.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -81.73 -11.75 58.9 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.763 0.825 . . . . 10.0 111.03 177.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.27 159.08 30.71 Favored Glycine 0 CA--C 1.532 1.116 0 O-C-N 121.929 -0.482 . . . . 10.0 112.073 -172.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -78.87 149.03 22.72 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 122.79 2.327 . . . . 10.0 107.889 167.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -76.6 94.38 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 171.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 mtpm? -73.95 97.7 2.88 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.538 -1.282 . . . . 10.0 107.538 169.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.6 m -85.45 115.01 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 107.261 -1.385 . . . . 10.0 107.261 173.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 23.8 p90 -129.9 160.26 34.08 Favored 'General case' 0 CA--C 1.516 -0.36 0 CA-C-O 121.756 0.789 . . . . 10.0 111.952 168.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.57 -173.45 45.41 Favored Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 109.552 -1.419 . . . . 10.0 109.552 173.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.8 t -142.43 118.75 10.84 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.683 -1.599 . . . . 10.0 106.683 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.703 HG22 ' HA2' ' A' ' 16' ' ' GLY . 1.5 pp -80.86 175.07 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 109.095 -0.706 . . . . 10.0 109.095 169.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -146.32 136.58 23.75 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 167.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.33 -5.12 15.31 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.937 0.779 . . . . 10.0 114.656 172.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.62 HD23 HD13 ' A' ' 35' ' ' ILE . 0.6 OUTLIER -69.09 176.46 3.19 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 119.147 1.473 . . . . 10.0 111.198 179.36 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -108.24 159.47 16.6 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.703 -1.962 . . . . 10.0 105.703 166.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -53.49 163.14 0.67 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.531 1.132 . . . . 10.0 112.935 -169.224 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.17 -174.39 50.84 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 123.962 0.791 . . . . 10.0 112.104 168.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 mp -63.26 144.48 56.9 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 125.233 1.413 . . . . 10.0 110.819 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -146.72 144.02 29.13 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 123.82 0.848 . . . . 10.0 111.352 174.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.644 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -24.87 121.98 0.03 OUTLIER Glycine 0 C--N 1.343 0.956 0 C-N-CA 128.242 2.829 . . . . 10.0 111.864 166.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.96 106.71 3.95 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 120.046 1.923 . . . . 10.0 109.728 171.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.456 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -156.46 172.39 18.62 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.56 0.695 . . . . 10.0 112.855 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.15 152.54 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-N 112.581 -2.099 . . . . 10.0 108.078 168.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 79.9 m-70 -126.2 152.69 45.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 170.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -49.31 -60.75 2.54 Favored 'General case' 0 N--CA 1.447 -0.576 0 O-C-N 124.202 0.938 . . . . 10.0 111.379 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -82.38 162.09 22.3 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 121.41 0.624 . . . . 10.0 110.141 -174.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.77 -6.59 52.26 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 167.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.41 172.52 9.31 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-O 122.588 1.185 . . . . 10.0 111.461 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.49 18.15 0.04 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 114.057 1.132 . . . . 10.0 114.057 -169.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.4 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.3 OUTLIER -50.41 -36.92 35.08 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.983 1.313 . . . . 10.0 113.713 -169.002 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.26 -21.38 49.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.393 0.677 . . . . 10.0 112.492 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.98 102.28 2.44 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 109.396 -1.481 . . . . 10.0 109.396 -172.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 96.2 m 37.27 60.78 1.01 Allowed 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 126.273 1.829 . . . . 10.0 112.161 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -157.76 -48.06 0.06 Allowed 'General case' 0 N--CA 1.443 -0.821 0 O-C-N 122.023 -0.423 . . . . 10.0 111.401 176.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -50.63 -35.76 32.03 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 125.092 1.357 . . . . 10.0 110.918 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.28 -36.31 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 128.347 2.659 . . . . 10.0 113.768 169.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.51 166.27 26.43 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 107.641 -2.183 . . . . 10.0 107.641 173.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -79.91 -162.77 0.19 Allowed 'Trans proline' 0 N--CA 1.441 -1.599 0 N-CA-C 105.476 -2.548 . . . . 10.0 105.476 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 44.4 m170 -81.49 53.88 2.2 Favored 'General case' 0 CA--C 1.541 0.609 0 O-C-N 120.38 -1.45 . . . . 10.0 110.716 -176.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.6 m-30 -73.09 71.59 1.13 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 123.273 1.511 . . . . 10.0 111.265 -178.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -78.44 141.51 61.28 Favored Pre-proline 0 N--CA 1.447 -0.583 0 C-N-CA 126.158 1.783 . . . . 10.0 109.642 169.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -79.21 47.77 2.61 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.874 2.383 . . . . 10.0 111.213 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -163.79 49.66 0.14 Allowed 'General case' 0 C--O 1.236 0.361 0 C-N-CA 124.761 1.224 . . . . 10.0 107.871 178.206 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.0 p -52.98 108.37 0.31 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.204 1.802 . . . . 10.0 111.57 -169.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -133.32 -173.2 3.14 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.107 -2.183 . . . . 10.0 105.107 169.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.401 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 6.9 mtmp? -85.71 136.63 33.28 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 118.549 -1.26 . . . . 10.0 107.804 -172.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.9 t60 -36.05 116.29 0.39 Allowed 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 123.251 0.621 . . . . 10.0 111.336 173.229 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.71 -134.2 4.92 Favored Glycine 0 N--CA 1.441 -1.015 0 N-CA-C 108.139 -1.984 . . . . 10.0 108.139 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.8 -165.81 31.74 Favored Glycine 0 N--CA 1.444 -0.804 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 169.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -57.52 -11.99 10.02 Favored 'Trans proline' 0 N--CA 1.451 -0.976 0 CA-C-N 119.345 1.572 . . . . 10.0 110.849 167.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.87 -33.98 18.35 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 125.223 1.409 . . . . 10.0 110.076 -177.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -107.45 168.54 9.17 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 108.677 -0.861 . . . . 10.0 108.677 -169.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -94.67 -18.88 20.91 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 124.346 1.058 . . . . 10.0 109.761 178.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.401 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -92.02 3.9 54.23 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.395 0.887 . . . . 10.0 113.395 -175.511 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 19.9 ptp180 -34.94 139.0 0.1 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 128.118 2.567 . . . . 10.0 112.272 171.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -71.22 -100.63 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.351 0.66 . . . . 10.0 111.96 -176.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.9 p -148.3 30.13 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.032 0.92 . . . . 10.0 110.228 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.5 47.83 0.02 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.479 -1.448 . . . . 10.0 109.479 -179.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -84.05 88.97 7.19 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 103.203 -2.888 . . . . 10.0 103.203 168.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 42.5 mt -71.3 -33.38 69.65 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 106.451 -1.685 . . . . 10.0 106.451 176.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.66 -97.19 1.34 Allowed Glycine 0 N--CA 1.44 -1.057 0 N-CA-C 108.815 -1.714 . . . . 10.0 108.815 167.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -132.67 129.06 38.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.655 1.182 . . . . 10.0 108.571 -172.195 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.8 m -113.52 141.65 28.7 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.573 -1.64 . . . . 10.0 106.573 168.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -93.13 133.65 36.1 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.738 -0.467 . . . . 10.0 109.738 -177.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.82 133.23 43.41 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.084 0.954 . . . . 10.0 108.848 172.053 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.416 ' OD2' ' NZ ' ' A' ' 91' ' ' LYS . 45.4 t0 -62.03 168.81 3.01 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.678 1.191 . . . . 10.0 108.438 167.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.416 ' NZ ' ' OD2' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -63.38 -19.16 64.41 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.047 0.451 . . . . 10.0 111.816 -179.22 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -77.45 -12.15 59.93 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 123.73 0.812 . . . . 10.0 110.589 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.87 26.88 43.58 Favored Glycine 0 C--N 1.344 0.979 0 N-CA-C 109.766 -1.334 . . . . 10.0 109.766 -178.696 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 37.7 t -109.08 116.31 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.007 2.523 . . . . 10.0 105.045 178.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -113.49 120.84 42.38 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 107.918 -1.141 . . . . 10.0 107.918 174.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -84.31 117.41 23.55 Favored 'General case' 0 N--CA 1.434 -1.258 0 C-N-CA 127.141 2.176 . . . . 10.0 108.767 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -102.4 131.88 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 p -159.53 75.91 0.66 Allowed 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 123.88 0.872 . . . . 10.0 110.804 171.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -116.37 147.23 19.89 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.037 0.935 . . . . 10.0 109.146 -176.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -107.14 104.71 14.42 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 126.449 1.9 . . . . 10.0 110.13 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -87.9 123.32 32.53 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 108.746 -0.835 . . . . 10.0 108.746 172.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.7 p -113.13 43.41 1.72 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.209 1.003 . . . . 10.0 110.21 177.511 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -138.62 -44.57 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 C-N-CA 123.289 0.636 . . . . 10.0 111.255 175.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.413 ' C ' HD12 ' A' ' 104' ' ' ILE 0.365 0.7 OUTLIER -87.85 175.19 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-N 119.342 0.973 . . . . 10.0 112.749 174.103 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 3.2 m -159.34 138.43 11.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 123.955 0.902 . . . . 10.0 109.007 172.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 pp -82.49 -14.75 54.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.552 0.741 . . . . 10.0 111.944 177.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.1 m -143.46 124.0 14.01 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 106.662 -1.607 . . . . 10.0 106.662 167.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.96 -59.63 0.2 Allowed Glycine 0 C--N 1.334 0.44 0 N-CA-C 109.638 -1.385 . . . . 10.0 109.638 175.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -166.89 -50.9 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 126.084 1.753 . . . . 10.0 107.465 -177.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -74.98 -36.02 62.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.669 -1.151 . . . . 10.0 108.879 -169.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t 42.41 61.93 1.86 Allowed 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 126.056 1.743 . . . . 10.0 110.99 169.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.57 32.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 113.194 0.812 . . . . 10.0 113.194 -175.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.0 mm -64.5 150.45 10.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 C-N-CA 125.969 1.708 . . . . 10.0 107.424 168.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.25 33.26 86.31 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 121.523 -0.736 . . . . 10.0 113.804 178.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -100.65 163.96 12.1 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 166.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.7 m -103.55 127.55 50.95 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-N 118.587 0.63 . . . . 10.0 111.106 170.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.14 139.64 30.26 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 106.498 -1.668 . . . . 10.0 106.498 166.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.404 HG12 ' CD2' ' A' ' 120' ' ' HIS . 93.0 t -122.88 138.67 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 172.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.1 p -105.69 134.72 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 104.96 -2.237 . . . . 10.0 104.96 166.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.644 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.5 m170 -113.67 161.36 17.57 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 114.506 1.298 . . . . 10.0 114.506 -172.355 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -57.73 -49.16 77.47 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 113.694 -1.594 . . . . 10.0 109.548 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -116.09 176.48 5.08 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.47 1.108 . . . . 10.0 111.812 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.1 146.55 23.57 Favored 'General case' 0 N--CA 1.451 -0.425 0 C-N-CA 125.375 1.47 . . . . 10.0 110.271 -177.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.456 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 3.9 m-20 -76.77 151.39 36.01 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.108 0.563 . . . . 10.0 110.612 178.114 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -89.54 16.58 7.48 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 114.836 -1.075 . . . . 10.0 109.878 166.227 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 69.9 mt 36.43 47.57 0.51 Allowed 'General case' 0 C--N 1.344 0.338 0 C-N-CA 127.19 2.196 . . . . 10.0 112.383 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.74 -47.37 1.05 Allowed Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 124.582 1.087 . . . . 10.0 111.851 176.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -83.23 44.27 0.93 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 124.999 1.32 . . . . 10.0 111.844 -168.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -81.98 -38.68 12.93 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.515 -1.434 . . . . 10.0 109.515 169.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.45 48.61 56.53 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 109.37 -1.492 . . . . 10.0 109.37 -170.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.7 m-80 -138.36 166.57 23.9 Favored 'General case' 0 CA--C 1.508 -0.652 0 N-CA-C 106.689 -1.597 . . . . 10.0 106.689 175.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 2.7 tm-20 -52.99 -46.52 68.36 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 114.712 -1.131 . . . . 10.0 108.843 171.042 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -57.1 -43.2 82.0 Favored 'General case' 0 C--N 1.343 0.305 0 CA-C-N 116.332 -0.395 . . . . 10.0 110.889 171.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . 0.297 2.1 p -59.21 -32.95 70.41 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -167.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -78.89 -8.05 58.5 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 118.592 -1.243 . . . . 10.0 112.276 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 89.5 mttt -116.68 -59.46 1.97 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.638 1.575 . . . . 10.0 111.834 -171.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.1 p -123.48 -4.66 8.26 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 119.318 0.963 . . . . 10.0 112.675 179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.19 -82.97 0.45 Allowed Glycine 0 CA--C 1.531 1.039 0 CA-C-N 119.386 0.994 . . . . 10.0 112.762 169.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.12 32.88 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 123.186 1.47 . . . . 10.0 108.343 177.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.64 -26.6 57.89 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.963 -1.471 . . . . 10.0 109.771 -167.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.13 -159.69 51.22 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 109.53 -1.428 . . . . 10.0 109.53 -177.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.0 t -58.49 139.26 55.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 113.136 0.791 . . . . 10.0 113.136 -168.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -65.05 65.72 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 126.764 2.025 . . . . 10.0 109.754 168.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.48 -19.2 61.77 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 113.904 1.076 . . . . 10.0 113.904 -172.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.22 150.89 25.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 122.81 0.444 . . . . 10.0 110.409 169.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.6 p -154.17 165.6 35.74 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.057 0.543 . . . . 10.0 110.049 -176.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -141.0 -172.0 12.82 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 123.434 0.54 . . . . 10.0 112.675 -177.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.7 t -136.79 136.52 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 107.648 -1.241 . . . . 10.0 107.648 172.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.0 mt -73.93 114.63 13.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 122.887 0.475 . . . . 10.0 110.402 -177.18 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.46 151.35 18.46 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 125.762 1.649 . . . . 10.0 111.461 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 83.8 mt -73.32 140.34 17.97 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 124.902 1.281 . . . . 10.0 109.855 -173.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.72 -45.47 2.89 Favored 'General case' 0 C--O 1.225 -0.222 0 O-C-N 121.069 -1.02 . . . . 10.0 111.74 173.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.25 1.09 0 C-N-CA 127.81 2.444 . . . . 10.0 109.203 -168.575 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.886 0 N-CA-C 108.708 -0.849 . . . . 10.0 108.708 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -70.93 -31.03 67.5 Favored 'General case' 0 C--O 1.226 -0.142 0 CA-C-N 119.27 0.941 . . . . 10.0 109.847 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.9 tttt -144.37 134.12 23.67 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.769 0.828 . . . . 10.0 109.395 -174.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 165.41 27.65 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.865 1.666 . . . . 10.0 107.768 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 m -126.13 171.1 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 118.339 0.518 . . . . 10.0 109.84 174.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.78 112.86 9.73 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.413 -1.328 . . . . 10.0 107.413 166.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 30.8 m -92.01 114.89 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 168.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.6 mt -100.56 135.65 41.67 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -158.13 157.43 32.73 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.862 1.21 . . . . 10.0 108.705 170.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.3 -52.17 0.04 OUTLIER Glycine 0 C--O 1.228 -0.269 0 C-N-CA 121.414 -0.422 . . . . 10.0 112.148 172.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.8 -45.95 40.1 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.609 -1.626 . . . . 10.0 106.609 -171.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.29 -67.06 0.55 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 113.711 -1.586 . . . . 10.0 110.461 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -56.97 -41.07 79.2 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.646 2.231 . . . . 10.0 110.68 172.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.8 t -65.94 105.83 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -123.02 117.98 26.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 169.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.646 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -101.83 141.63 15.36 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.358 -1.097 . . . . 10.0 110.358 172.383 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.4 HG22 ' CG2' ' A' ' 54' ' ' THR . 2.6 mt -143.13 81.13 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 106.476 -1.676 . . . . 10.0 106.476 -175.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.6 mm -102.72 151.37 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.324 1.049 . . . . 10.0 109.715 -173.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -121.48 119.93 33.43 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.939 2.095 . . . . 10.0 108.164 174.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -102.89 108.92 20.3 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.783 -1.562 . . . . 10.0 106.783 176.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -119.49 141.05 49.52 Favored 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.247 0.832 . . . . 10.0 113.247 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -118.39 119.18 33.82 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.332 -1.729 . . . . 10.0 106.332 166.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -154.95 40.27 0.43 Allowed 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 112.842 0.682 . . . . 10.0 112.842 -172.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.99 170.53 13.85 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 102.219 -3.252 . . . . 10.0 102.219 166.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 20.1 t -71.28 -21.83 62.03 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.108 0.48 . . . . 10.0 109.905 -178.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 15.4 m-80 -79.66 -12.63 59.81 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 123.165 0.586 . . . . 10.0 110.1 177.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 49.07 45.02 33.41 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-O 118.398 -1.223 . . . . 10.0 114.509 -177.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -65.63 136.59 46.72 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 107.191 -1.888 . . . . 10.0 107.191 172.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.49 105.19 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 106.028 -1.842 . . . . 10.0 106.028 174.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -97.49 112.85 24.52 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 173.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -111.99 113.59 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 125.126 1.37 . . . . 10.0 108.776 -173.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.5 p90 -132.65 170.82 14.67 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.874 0.368 . . . . 10.0 110.804 173.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.88 -147.92 18.84 Favored Glycine 0 N--CA 1.448 -0.52 0 N-CA-C 106.955 -2.458 . . . . 10.0 106.955 170.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 32.2 t -155.86 156.61 34.98 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 119.306 -0.958 . . . . 10.0 111.192 177.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.646 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.9 pt -117.08 153.68 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 N-CA-C 108.032 -1.099 . . . . 10.0 108.032 166.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -127.62 151.41 48.96 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 106.801 -1.555 . . . . 10.0 106.801 167.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.24 -14.44 15.93 Favored Glycine 0 C--N 1.336 0.542 0 CA-C-O 119.002 -0.888 . . . . 10.0 113.322 169.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.517 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.6 mp -76.4 176.84 7.84 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 118.652 1.226 . . . . 10.0 110.388 -177.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.6 t -91.59 152.76 20.13 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.596 -0.729 . . . . 10.0 109.348 169.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -45.34 143.98 1.58 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.109 1.764 . . . . 10.0 111.87 -176.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.72 -177.31 22.66 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 123.927 0.775 . . . . 10.0 112.159 171.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -71.69 153.55 41.97 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 125.347 1.459 . . . . 10.0 110.921 -177.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -149.34 146.93 27.77 Favored 'General case' 0 C--N 1.343 0.319 0 N-CA-C 113.959 1.096 . . . . 10.0 113.959 -177.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.711 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -31.48 114.26 0.07 OUTLIER Glycine 0 C--N 1.34 0.803 0 C-N-CA 128.379 2.895 . . . . 10.0 113.215 164.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.418 ' HZ ' HG21 ' B' ' 35' ' ' ILE . 1.5 m-85 -141.48 101.43 3.99 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 120.519 2.16 . . . . 10.0 109.353 173.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.509 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -151.17 170.15 20.16 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-O 121.749 0.785 . . . . 10.0 111.938 178.603 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.2 m -93.08 154.86 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.223 -2.262 . . . . 10.0 106.788 168.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 61.2 m-70 -126.58 135.87 51.81 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 170.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -50.92 -50.57 57.29 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 118.445 -0.788 . . . . 10.0 112.186 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -82.6 137.29 34.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 117.714 -1.594 . . . . 10.0 109.501 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.58 3.01 87.41 Favored Glycine 0 CA--C 1.533 1.204 0 C-N-CA 126.29 1.9 . . . . 10.0 112.147 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 p-10 -76.3 81.82 3.07 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-O 123.613 1.673 . . . . 10.0 110.181 -173.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.495 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.9 OUTLIER -75.31 9.75 1.94 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.488 -1.233 . . . . 10.0 113.732 -175.17 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.538 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -44.96 -45.94 10.79 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 127.734 2.414 . . . . 10.0 112.634 -170.818 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.86 -20.72 41.68 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.7 87.82 2.02 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 107.955 -2.058 . . . . 10.0 107.955 -168.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 16.88 54.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 127.987 2.515 . . . . 10.0 116.108 -169.221 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 17.0 m -125.97 -56.25 1.46 Allowed 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 105.69 -1.967 . . . . 10.0 105.69 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -47.74 -37.4 13.18 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.403 1.481 . . . . 10.0 110.708 169.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.14 -31.5 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 127.864 2.466 . . . . 10.0 115.257 169.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.27 148.64 18.98 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 109.517 -1.433 . . . . 10.0 109.517 169.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.51 -179.27 0.85 Allowed 'Trans proline' 0 N--CA 1.446 -1.305 0 N-CA-C 107.674 -1.702 . . . . 10.0 107.674 166.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 37.8 m170 -76.24 76.57 3.04 Favored 'General case' 0 CA--C 1.543 0.685 0 O-C-N 120.422 -1.424 . . . . 10.0 110.501 -169.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -71.46 69.44 0.59 Allowed 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 123.182 1.468 . . . . 10.0 112.417 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . 0.405 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 1.7 p30 -56.15 145.51 55.46 Favored Pre-proline 0 C--N 1.321 -0.649 0 C-N-CA 127.326 2.251 . . . . 10.0 112.155 168.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -74.79 167.74 26.41 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 122.106 1.871 . . . . 10.0 108.296 167.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 tp 62.46 -101.06 0.1 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 125.09 1.356 . . . . 10.0 108.041 -174.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 3.2 p 171.59 97.45 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.753 1.621 . . . . 10.0 110.263 -174.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 75.9 mtt180 -130.02 163.64 26.04 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 119.651 1.114 . . . . 10.0 110.346 176.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -113.44 55.32 0.71 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 124.648 1.179 . . . . 10.0 111.422 -168.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 65.3 t60 47.05 88.2 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 125.091 1.356 . . . . 10.0 114.646 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.06 -145.18 11.07 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.262 -1.336 . . . . 10.0 110.067 178.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.78 -173.96 32.1 Favored Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 109.152 -1.579 . . . . 10.0 109.152 176.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -55.22 -13.15 6.49 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 123.025 2.483 . . . . 10.0 112.434 173.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.2 mmtt -94.27 -30.25 14.65 Favored 'General case' 0 N--CA 1.444 -0.754 0 C-N-CA 125.189 1.396 . . . . 10.0 110.607 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -103.18 169.0 8.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -169.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -78.77 -33.52 46.33 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -77.14 18.14 0.41 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.309 1.043 . . . . 10.0 113.421 -165.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 20.2 ptp180 -64.55 117.22 7.05 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.106 -1.072 . . . . 10.0 108.106 -177.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.405 ' HB3' ' HB3' ' B' ' 65' ' ' ASN . 11.1 m170 -57.98 -60.96 2.92 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 120.824 0.345 . . . . 10.0 111.846 -170.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p -165.5 -47.09 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 -169.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -152.99 71.49 0.28 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 108.551 -1.82 . . . . 10.0 108.551 172.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -102.57 106.61 17.33 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 105.73 -1.952 . . . . 10.0 105.73 171.092 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.22 -12.07 60.03 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 111.7 -172.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.78 -98.26 1.56 Allowed Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 107.924 -2.071 . . . . 10.0 107.924 -178.301 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -156.28 146.96 21.82 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 107.099 -1.445 . . . . 10.0 107.099 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.7 m -122.08 131.95 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 107.208 -1.405 . . . . 10.0 107.208 169.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 63.0 m -90.89 107.26 19.07 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 126.298 1.839 . . . . 10.0 109.228 -172.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -77.82 130.33 36.54 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 110.172 -0.307 . . . . 10.0 110.172 172.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -61.85 170.1 2.22 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 124.274 1.03 . . . . 10.0 109.295 167.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -55.79 -29.08 59.09 Favored 'General case' 0 N--CA 1.433 -1.294 0 C-N-CA 125.884 1.674 . . . . 10.0 111.647 171.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -78.38 -1.67 34.55 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-O 121.163 0.506 . . . . 10.0 111.371 175.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.09 1.46 90.33 Favored Glycine 0 C--N 1.339 0.746 0 O-C-N 120.376 -1.452 . . . . 10.0 111.179 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 44.8 t -78.43 105.98 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 C-N-CA 126.929 2.092 . . . . 10.0 107.03 178.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.479 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -103.78 124.62 49.23 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 169.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -79.56 122.74 26.86 Favored 'General case' 0 N--CA 1.432 -1.338 0 C-N-CA 125.832 1.653 . . . . 10.0 107.816 169.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.4 t -101.92 128.85 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.208 0 N-CA-C 106.851 -1.537 . . . . 10.0 106.851 173.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.9 t -156.85 92.67 1.3 Allowed 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 169.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.3 mp -135.94 164.29 32.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 125.96 1.704 . . . . 10.0 106.542 -177.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -148.64 159.63 43.91 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.74 116.21 7.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.023 -0.732 . . . . 10.0 109.023 171.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 52.0 p -90.41 61.6 5.05 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 106.909 -1.515 . . . . 10.0 106.909 -171.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.16 -50.53 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 123.731 0.644 . . . . 10.0 110.068 -176.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -79.91 142.42 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.592 -1.262 . . . . 10.0 107.592 169.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 22.9 m -128.22 114.22 16.68 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.697 -1.594 . . . . 10.0 106.697 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mt -59.23 -4.34 0.53 Allowed 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 114.411 1.263 . . . . 10.0 114.411 -173.049 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.7 m -147.91 152.72 38.03 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.582 1.953 . . . . 10.0 107.558 177.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 117.91 -91.72 0.53 Allowed Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 106.515 -2.634 . . . . 10.0 106.515 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -135.81 -53.83 0.76 Allowed 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 125.515 1.526 . . . . 10.0 107.777 -169.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 -80.67 36.72 0.39 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.038 0.935 . . . . 10.0 110.49 -175.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 35.1 t -77.57 110.09 12.07 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 124.624 1.17 . . . . 10.0 107.963 -173.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 18.6 pt -83.98 23.42 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 122.957 0.503 . . . . 10.0 111.997 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.49 -73.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 CA-C-N 118.8 0.727 . . . . 10.0 111.268 -177.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.66 50.33 3.55 Favored Glycine 0 CA--C 1.532 1.133 0 O-C-N 120.642 -1.286 . . . . 10.0 112.546 -177.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.4 mmt-85 -110.3 152.38 26.24 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 124.832 1.253 . . . . 10.0 109.697 176.386 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.9 m -88.88 125.14 34.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.975 -0.75 . . . . 10.0 108.975 171.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -96.13 138.76 33.29 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 126.42 1.888 . . . . 10.0 107.7 170.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -126.44 135.67 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 N-CA-C 108.517 -0.919 . . . . 10.0 108.517 -177.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.459 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.2 OUTLIER -106.16 121.87 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 106.807 -1.553 . . . . 10.0 106.807 171.77 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.711 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.3 m-70 -105.63 158.12 16.93 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 123.75 1.738 . . . . 10.0 115.605 -171.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -43.82 -61.48 1.41 Allowed 'General case' 0 N--CA 1.442 -0.862 0 C-N-CA 129.738 3.215 . . . . 10.0 110.551 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.3 mttp -112.77 172.86 6.67 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.061 0.944 . . . . 10.0 111.395 -175.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.13 154.64 40.96 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.016 1.326 . . . . 10.0 110.571 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.509 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.0 OUTLIER -78.49 144.98 35.22 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 123.98 0.912 . . . . 10.0 111.578 174.083 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -76.27 -32.89 59.07 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 124.781 1.301 . . . . 10.0 109.349 168.057 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt 63.5 56.42 1.62 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 123.491 1.615 . . . . 10.0 109.572 -168.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.92 -47.96 3.44 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 113.582 -1.645 . . . . 10.0 111.341 165.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.19 44.97 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.8 1.64 . . . . 10.0 112.012 -173.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -10.83 50.08 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 126.263 1.887 . . . . 10.0 111.892 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.88 32.43 18.63 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.448 -0.64 . . . . 10.0 112.071 -174.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -113.66 152.34 30.56 Favored 'General case' 0 CA--C 1.506 -0.716 0 N-CA-C 105.65 -1.982 . . . . 10.0 105.65 171.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.8 tm-20 -50.54 -37.57 40.08 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 114.921 -1.036 . . . . 10.0 108.695 169.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 16.8 tp10 -70.81 -38.5 73.29 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 113.889 1.07 . . . . 10.0 113.889 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 76.7 p -57.67 -42.63 83.95 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 120.642 1.565 . . . . 10.0 110.456 -175.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 6.3 t -69.17 -10.3 57.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 113.109 0.781 . . . . 10.0 113.109 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 20.5 ttmt -113.71 -47.97 2.95 Favored 'General case' 0 N--CA 1.435 -1.204 0 C-N-CA 125.43 1.492 . . . . 10.0 112.347 -168.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 32.0 p -130.78 -2.87 4.14 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 113.016 0.747 . . . . 10.0 113.016 172.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.2 19.7 60.33 Favored Glycine 0 C--N 1.34 0.803 0 N-CA-C 110.809 -0.917 . . . . 10.0 110.809 -175.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 54.45 31.7 15.22 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 117.837 0.819 . . . . 10.0 111.718 176.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.47 7.26 4.62 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 123.906 0.882 . . . . 10.0 111.673 -176.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.85 -168.23 53.48 Favored Glycine 0 N--CA 1.444 -0.798 0 N-CA-C 110.065 -1.214 . . . . 10.0 110.065 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.8 t -67.4 158.32 32.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 122.582 1.182 . . . . 10.0 111.273 -169.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . 0.44 ' H ' ' NE ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -67.94 112.37 4.91 Favored 'General case' 0 N--CA 1.442 -0.857 0 C-N-CA 125.075 1.35 . . . . 10.0 107.966 170.69 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 29.0 mt -72.68 -55.71 6.4 Favored 'General case' 0 N--CA 1.458 -0.054 0 N-CA-C 109.098 -0.704 . . . . 10.0 109.098 170.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.459 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -138.34 156.6 47.47 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.858 -0.61 . . . . 10.0 110.273 -170.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.5 m -129.29 147.63 51.14 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.31 1.444 . . . . 10.0 108.805 -168.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -150.7 156.89 26.93 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.456 -1.458 . . . . 10.0 109.456 169.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 70.1 t -116.1 128.54 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 105.133 -2.173 . . . . 10.0 105.133 177.059 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.438 HD13 HG21 ' B' ' 149' ' ' ILE . 16.8 mt -69.03 156.93 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 CA-C-N 119.266 0.939 . . . . 10.0 110.06 176.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.02 160.91 32.47 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 124.995 1.283 . . . . 10.0 110.156 -176.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 96.0 mt -69.75 135.46 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.976 1.31 . . . . 10.0 109.478 -171.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.63 -47.1 2.44 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 123.366 0.666 . . . . 10.0 110.899 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 . . . . . 0 C--O 1.254 1.291 0 CA-C-O 117.809 -1.091 . . . . 10.0 111.031 -169.4 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.463 0 N-CA-C 110.161 -0.311 . . . . 10.0 110.161 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER 169.26 -41.06 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 129.861 3.264 . . . . 10.0 103.891 -167.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -106.39 132.35 52.52 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.243 -2.132 . . . . 10.0 105.243 166.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 163.05 33.97 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 107.526 -1.286 . . . . 10.0 107.526 169.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -124.28 176.51 5.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 C-N-CA 123.037 0.535 . . . . 10.0 109.998 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.77 117.13 5.68 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 118.504 0.593 . . . . 10.0 109.887 166.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -97.99 104.27 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 C-N-CA 124.609 1.164 . . . . 10.0 110.519 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mt -98.41 122.74 41.97 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.862 1.665 . . . . 10.0 109.517 -177.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -143.53 157.23 44.59 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 120.034 1.288 . . . . 10.0 108.513 173.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.26 -59.3 0.03 OUTLIER Glycine 0 N--CA 1.464 0.518 0 C-N-CA 120.317 -0.944 . . . . 10.0 113.005 169.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -70.93 -43.91 67.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.86 -71.45 0.38 Allowed Glycine 0 CA--C 1.521 0.451 0 CA-C-N 114.186 -1.37 . . . . 10.0 110.644 168.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -57.39 -33.36 96.13 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.786 2.99 . . . . 10.0 111.369 172.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 57.9 t -64.75 95.89 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.547 -1.279 . . . . 10.0 107.547 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 -120.58 111.27 17.45 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 125.684 1.594 . . . . 10.0 107.775 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.521 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -100.81 133.98 11.52 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-O 119.521 -0.6 . . . . 10.0 111.955 171.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.526 ' CG2' HG23 ' B' ' 54' ' ' THR . 8.7 mt -136.08 85.93 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 -172.39 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.55 152.8 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 C-N-CA 124.404 1.081 . . . . 10.0 111.136 -171.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -120.68 116.8 26.01 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 126.504 1.922 . . . . 10.0 108.905 170.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -91.5 99.34 12.3 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 174.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -97.39 117.86 32.58 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.775 0.798 . . . . 10.0 111.025 178.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.1 tp60 -117.61 97.31 5.8 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 127.895 2.478 . . . . 10.0 105.788 178.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.401 ' NZ ' ' OE2' ' A' ' 24' ' ' GLU . 4.8 mtmp? -59.08 -52.76 64.33 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 123.004 0.522 . . . . 10.0 110.377 -173.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.401 ' OE2' ' NZ ' ' A' ' 23' ' ' LYS . 2.0 mp0 -131.09 172.31 12.25 Favored 'General case' 0 N--CA 1.424 -1.748 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 173.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.9 t -71.49 -20.28 62.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 108.879 -0.785 . . . . 10.0 108.879 170.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . 0.306 0.0 OUTLIER -89.13 -5.43 57.78 Favored 'General case' 0 C--N 1.344 0.359 0 N-CA-C 113.401 0.889 . . . . 10.0 113.401 173.446 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.72 160.11 35.34 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 109.619 -1.393 . . . . 10.0 109.619 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -71.55 148.2 53.25 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 N-CA-C 107.592 -1.734 . . . . 10.0 107.592 168.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.3 t -78.39 110.92 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 105.39 -2.078 . . . . 10.0 105.39 173.275 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.2 102.86 15.58 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 171.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -98.92 99.7 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.415 -1.328 . . . . 10.0 107.415 179.497 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.8 p90 -118.15 166.87 12.06 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.566 0.698 . . . . 10.0 112.267 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.79 -150.3 21.81 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.07 -2.412 . . . . 10.0 107.07 171.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.7 t -155.23 152.87 29.84 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 119.773 -0.771 . . . . 10.0 110.914 -178.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.638 ' CG1' ' HB3' ' A' ' 95' ' ' ALA . 1.9 pt -110.63 142.85 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 115.215 -0.902 . . . . 10.0 108.616 166.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -118.81 148.85 42.41 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 169.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.71 -5.35 40.18 Favored Glycine 0 CA--C 1.525 0.664 0 CA-C-O 119.235 -0.759 . . . . 10.0 113.499 174.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -69.62 176.78 3.31 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 118.805 1.302 . . . . 10.0 110.122 177.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.1 t -104.75 167.83 9.46 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.319 -2.104 . . . . 10.0 105.319 165.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -57.07 166.38 1.07 Allowed 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.373 0.669 . . . . 10.0 111.254 -171.388 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.98 -177.17 42.94 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.286 -0.884 . . . . 10.0 112.375 168.56 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.0 mp -74.21 145.42 44.14 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 124.851 1.26 . . . . 10.0 110.093 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -144.91 145.36 31.53 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 124.177 0.991 . . . . 10.0 112.685 -175.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.65 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.48 125.97 0.28 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 126.695 2.093 . . . . 10.0 113.398 166.288 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -150.11 108.55 3.8 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.098 1.449 . . . . 10.0 108.253 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.25 173.0 12.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 122.732 1.253 . . . . 10.0 113.481 177.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 85.8 t -98.19 129.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 CA-C-N 111.03 -2.805 . . . . 10.0 105.487 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -105.8 139.72 39.93 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.194 -1.409 . . . . 10.0 107.194 170.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -58.1 -58.04 10.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 O-C-N 124.094 0.871 . . . . 10.0 110.214 -169.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -76.86 119.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.653 -1.61 . . . . 10.0 106.653 -171.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.74 46.81 2.94 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.523 -1.031 . . . . 10.0 110.523 171.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -108.89 118.72 37.53 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.929 1.291 . . . . 10.0 108.153 176.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.415 ' HB3' HG21 ' B' ' 7' ' ' VAL . 12.0 m120 -117.94 5.78 12.16 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.218 1.807 . . . . 10.0 109.988 178.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.42 HG23 ' CG2' ' B' ' 17' ' ' ILE . 1.3 m -57.07 -37.1 71.37 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 120.096 1.316 . . . . 10.0 111.667 -169.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -21.83 45.68 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.079 0.952 . . . . 10.0 112.682 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 143.85 -86.46 0.18 Allowed Glycine 0 CA--C 1.527 0.797 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 -172.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 24.1 p -170.78 43.29 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.152 0.981 . . . . 10.0 110.989 172.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 m -104.92 -49.31 3.52 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 m -50.18 -27.63 6.18 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 126.372 1.869 . . . . 10.0 111.641 174.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -37.16 -32.1 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 128.02 2.528 . . . . 10.0 113.848 168.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.32 126.64 5.2 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.277 -1.291 . . . . 10.0 109.95 170.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -72.4 65.34 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.81 0 C-N-CA 123.729 2.953 . . . . 10.0 112.268 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.7 m170 68.87 42.8 1.29 Allowed 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 129.773 3.229 . . . . 10.0 111.505 172.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -72.51 57.96 0.4 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.728 1.01 . . . . 10.0 113.728 -173.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.0 p-10 -68.3 159.57 79.95 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 118.968 0.804 . . . . 10.0 110.931 175.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -61.28 -47.68 11.55 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.216 1.944 . . . . 10.0 111.218 176.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 94.8 mt -78.1 59.05 2.12 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 109.301 -0.629 . . . . 10.0 109.301 177.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.0 t -58.97 95.64 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.417 1.087 . . . . 10.0 108.77 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.59 -96.57 0.41 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.796 -1.557 . . . . 10.0 106.796 -177.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.5 mttp -151.67 139.92 20.34 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 106.397 -1.705 . . . . 10.0 106.397 173.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.6 t60 -40.91 124.15 2.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 O-C-N 123.776 0.673 . . . . 10.0 110.903 170.401 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.15 -138.12 3.66 Favored Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 108.367 -1.893 . . . . 10.0 108.367 177.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.37 -165.94 33.35 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 107.342 -2.303 . . . . 10.0 107.342 169.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -62.54 -0.72 2.06 Favored 'Trans proline' 0 CA--C 1.542 0.878 0 CA-C-N 120.305 2.053 . . . . 10.0 110.948 167.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 61.0 mmtt -91.07 -24.62 19.98 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 124.409 1.084 . . . . 10.0 110.625 173.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.77 174.8 5.72 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -176.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -87.82 -32.15 19.19 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.969 -0.752 . . . . 10.0 108.969 170.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -82.25 2.0 33.99 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 115.032 1.493 . . . . 10.0 115.032 -165.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -41.54 137.36 1.59 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 125.639 1.575 . . . . 10.0 112.172 -177.12 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -71.88 -77.64 0.09 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.704 -0.798 . . . . 10.0 112.185 -170.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 p -161.41 58.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 121.324 -0.86 . . . . 10.0 109.46 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 106.94 50.55 0.83 Allowed Glycine 0 CA--C 1.523 0.533 0 N-CA-C 109.943 -1.263 . . . . 10.0 109.943 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -87.05 90.97 8.54 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 104.026 -2.583 . . . . 10.0 104.026 167.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.3 mt -70.3 -31.63 69.06 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 107.316 -1.364 . . . . 10.0 107.316 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 101.08 -106.43 3.08 Favored Glycine 0 N--CA 1.434 -1.44 0 N-CA-C 108.235 -1.946 . . . . 10.0 108.235 168.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -109.23 119.41 39.42 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.506 1.122 . . . . 10.0 110.388 -168.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.1 m -104.89 135.36 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 168.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 50.0 m -99.64 108.8 21.26 Favored 'General case' 0 N--CA 1.442 -0.858 0 C-N-CA 126.316 1.846 . . . . 10.0 109.641 -168.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.44 130.24 35.24 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.229 1.011 . . . . 10.0 110.748 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 45.4 t0 -66.26 170.71 5.52 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 123.956 0.902 . . . . 10.0 109.455 168.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -52.96 -26.99 16.91 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.872 1.669 . . . . 10.0 111.599 177.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -79.03 -15.52 58.11 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.349 1.059 . . . . 10.0 110.065 -175.299 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.81 74.21 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 110.991 -0.844 . . . . 10.0 110.991 -173.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.0 t -87.64 113.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 C-N-CA 126.338 1.855 . . . . 10.0 106.265 173.265 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.638 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -111.9 121.38 44.87 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 108.461 -0.94 . . . . 10.0 108.461 171.295 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -78.17 130.55 36.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 172.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 75.0 t -104.91 129.39 57.59 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.369 0 N-CA-C 105.15 -2.167 . . . . 10.0 105.15 169.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -156.93 66.95 0.53 Allowed 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 175.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.35 155.02 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 106.483 -1.673 . . . . 10.0 106.483 -175.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.37 138.36 38.2 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.929 0.492 . . . . 10.0 110.727 169.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.95 131.14 51.15 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.858 1.263 . . . . 10.0 108.789 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.4 p -95.96 42.75 1.09 Allowed 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.626 1.971 . . . . 10.0 108.424 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.3 -49.88 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 123.337 0.655 . . . . 10.0 109.644 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 33.7 mm -57.57 134.55 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 169.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.5 m -164.66 94.22 0.68 Allowed 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.668 0.787 . . . . 10.0 109.441 -176.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.631 HD13 ' H ' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -68.61 27.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.644 1.177 . . . . 10.0 113.839 175.328 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.9 p -157.8 113.4 2.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 121.275 -0.891 . . . . 10.0 110.32 -176.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 162.26 -54.1 0.31 Allowed Glycine 0 C--N 1.335 0.481 0 N-CA-C 110.688 -0.965 . . . . 10.0 110.688 169.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.75 -50.14 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 126.337 1.855 . . . . 10.0 107.475 -173.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 -74.42 -38.53 63.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.944 -1.025 . . . . 10.0 108.623 -169.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 40.53 62.2 1.42 Allowed 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.154 1.782 . . . . 10.0 110.01 172.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 24.3 pt -74.62 46.77 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.745 2.018 . . . . 10.0 111.77 -175.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.3 mm -72.49 -65.17 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 128.971 2.908 . . . . 10.0 108.207 172.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.75 47.52 3.07 Favored Glycine 0 CA--C 1.529 0.953 0 O-C-N 121.343 -0.848 . . . . 10.0 113.808 -169.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -89.65 174.63 7.64 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 125.105 1.362 . . . . 10.0 108.68 172.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 20.2 m -109.87 115.11 29.22 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.787 -2.301 . . . . 10.0 104.787 168.127 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.6 mp -97.94 151.78 19.92 Favored 'General case' 0 CA--C 1.512 -0.511 0 N-CA-C 108.296 -1.001 . . . . 10.0 108.296 175.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.7 t -143.16 136.89 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 O-C-N 123.837 0.711 . . . . 10.0 109.803 -170.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.8 m -105.89 140.35 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.952 1.301 . . . . 10.0 108.887 167.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.65 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m170 -120.66 159.13 25.94 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.49 2.033 . . . . 10.0 116.49 -172.234 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -39.46 -58.61 1.23 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 130.289 3.436 . . . . 10.0 111.886 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -123.17 168.34 12.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 124.679 1.192 . . . . 10.0 110.48 -171.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.76 137.66 55.61 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 108.308 -0.997 . . . . 10.0 108.308 169.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.84 144.12 37.27 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.191 -1.04 . . . . 10.0 108.191 168.193 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -78.14 25.04 0.23 Allowed 'General case' 0 CA--C 1.539 0.519 0 CA-C-O 121.133 0.492 . . . . 10.0 111.126 177.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 18.8 mt 30.53 45.82 0.03 OUTLIER 'General case' 0 C--N 1.34 0.162 0 C-N-CA 128.23 2.612 . . . . 10.0 112.629 -170.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.6 -45.53 1.3 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 124.623 1.106 . . . . 10.0 112.488 177.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -83.34 50.6 1.8 Allowed 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.092 0.957 . . . . 10.0 111.452 -169.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -87.45 -35.89 9.14 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 125.969 1.747 . . . . 10.0 110.022 172.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.27 38.7 71.56 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.865 -0.894 . . . . 10.0 110.865 -178.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 56.1 m-80 -130.8 163.74 26.7 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 106.769 -1.567 . . . . 10.0 106.769 169.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -53.31 -39.35 63.96 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.718 0.771 . . . . 10.0 109.592 173.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -67.14 -35.16 79.12 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.448 1.099 . . . . 10.0 112.934 173.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.4 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 60.0 p -56.31 -34.01 66.12 Favored 'General case' 0 N--CA 1.443 -0.776 0 O-C-N 120.029 -1.669 . . . . 10.0 112.033 -175.138 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -81.35 -1.98 47.44 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 118.738 -0.649 . . . . 10.0 112.139 -178.373 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -112.69 -82.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.263 1.825 . . . . 10.0 110.545 -177.025 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -109.6 25.45 11.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 120.725 1.602 . . . . 10.0 111.974 174.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.1 18.03 66.42 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.602 167.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 m120 62.24 23.54 13.93 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 118.085 0.943 . . . . 10.0 112.224 -171.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.03 -11.91 33.65 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.24 -0.913 . . . . 10.0 113.097 177.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.62 -161.2 46.1 Favored Glycine 0 CA--C 1.523 0.553 0 O-C-N 121.151 -0.968 . . . . 10.0 111.128 170.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.9 t -57.07 129.68 42.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 124.327 1.051 . . . . 10.0 113.135 -167.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.1 mtt85 -65.94 71.97 0.06 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.454 1.902 . . . . 10.0 111.404 175.152 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 51.7 mt -52.05 -33.4 38.68 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.286 1.034 . . . . 10.0 113.733 -177.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.81 147.18 26.96 Favored 'General case' 0 CA--C 1.512 -0.495 0 O-C-N 121.727 -0.608 . . . . 10.0 110.055 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.8 m -140.9 149.85 42.45 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 107.627 -1.249 . . . . 10.0 107.627 -170.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.58 36.42 Favored Glycine 0 CA--C 1.521 0.416 0 N-CA-C 111.397 -0.681 . . . . 10.0 111.397 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 52.9 t -115.23 154.68 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 103.145 -2.909 . . . . 10.0 103.145 171.082 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 8.3 mt -71.45 -90.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 123.51 0.724 . . . . 10.0 109.306 -169.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 108.06 125.61 5.3 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 81.2 mt -61.18 140.47 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 C-N-CA 125.686 1.594 . . . . 10.0 108.721 175.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.36 -38.84 4.57 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-N 119.525 1.057 . . . . 10.0 111.495 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? . . . . . 0 C--O 1.249 1.038 0 CA-C-O 117.308 -1.33 . . . . 10.0 109.899 178.22 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 106.458 -1.682 . . . . 10.0 106.458 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -88.1 -56.17 3.44 Favored 'General case' 0 N--CA 1.458 -0.027 0 O-C-N 124.293 0.995 . . . . 10.0 110.853 -174.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.07 138.79 49.73 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.415 1.086 . . . . 10.0 110.155 -176.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.48 162.64 33.99 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.63 0.772 . . . . 10.0 110.653 170.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 m -121.04 160.89 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.557 1.143 . . . . 10.0 109.617 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 95.82 2.9 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 107.556 -1.275 . . . . 10.0 107.556 166.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.415 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.7 m -82.15 108.48 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 169.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mt -93.99 137.8 32.8 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.968 -1.123 . . . . 10.0 107.968 178.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 tttt -156.58 159.03 38.12 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 119.912 1.233 . . . . 10.0 107.87 171.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.89 -47.91 0.04 OUTLIER Glycine 0 C--O 1.229 -0.2 0 C-N-CA 120.684 -0.769 . . . . 10.0 111.481 169.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.52 -46.43 26.59 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 -171.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.72 -69.0 0.52 Allowed Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 113.905 -1.498 . . . . 10.0 110.145 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -56.28 -44.04 50.23 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.311 2.007 . . . . 10.0 110.539 171.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.96 101.2 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.13 0 N-CA-C 107.228 -1.397 . . . . 10.0 107.228 -175.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -120.81 110.75 16.72 Favored 'General case' 0 N--CA 1.441 -0.921 0 N-CA-C 106.103 -1.814 . . . . 10.0 106.103 173.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.797 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -90.05 140.38 15.48 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.615 -1.794 . . . . 10.0 108.615 171.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.42 ' CG2' HG23 ' A' ' 54' ' ' THR . 4.0 mt -141.53 88.84 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 107.279 -1.378 . . . . 10.0 107.279 -173.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 mm -101.3 144.13 13.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 C-N-CA 123.576 0.75 . . . . 10.0 110.362 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -121.19 114.26 21.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 126.499 1.92 . . . . 10.0 108.266 168.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -98.19 106.4 18.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 mt-10 -107.54 123.86 49.07 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 112.789 0.662 . . . . 10.0 112.789 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -81.62 115.16 20.76 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 104.112 -2.551 . . . . 10.0 104.112 166.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -49.7 -54.15 20.46 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 123.954 0.902 . . . . 10.0 109.92 169.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -129.97 -136.6 0.22 Allowed 'General case' 0 N--CA 1.425 -1.684 0 N-CA-C 106.755 -1.572 . . . . 10.0 106.755 -176.097 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.4 t -108.42 -21.8 12.58 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-O 121.145 0.497 . . . . 10.0 110.689 168.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -127.32 6.7 6.39 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.548 1.139 . . . . 10.0 110.743 -176.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.98 169.06 54.72 Favored Glycine 0 CA--C 1.529 0.929 0 N-CA-C 108.862 -1.695 . . . . 10.0 108.862 174.184 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -65.7 132.18 29.94 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.5 1.467 . . . . 10.0 108.497 171.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.9 t -78.07 108.34 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 N-CA-C 104.778 -2.305 . . . . 10.0 104.778 169.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -79.62 109.74 14.29 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 105.275 -2.12 . . . . 10.0 105.275 169.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -96.67 97.07 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 106.328 -1.73 . . . . 10.0 106.328 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 20.5 p90 -108.76 164.37 12.44 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.163 0.506 . . . . 10.0 110.595 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.88 178.86 48.45 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 110.391 -1.084 . . . . 10.0 110.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -150.88 106.07 3.34 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.663 -0.866 . . . . 10.0 108.663 178.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.797 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.2 pt -79.9 173.15 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 119.55 -0.86 . . . . 10.0 109.738 173.123 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.0 pttt -150.85 153.36 35.22 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 168.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.82 -15.36 40.86 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-O 118.993 -0.893 . . . . 10.0 115.274 169.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.485 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.6 mp -75.33 179.66 5.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.943 1.372 . . . . 10.0 110.362 -177.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -91.56 174.95 7.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 166.018 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -62.25 175.09 0.78 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 124.391 1.076 . . . . 10.0 111.435 -173.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.44 -172.74 47.23 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 123.885 0.755 . . . . 10.0 112.588 166.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -75.89 142.78 42.02 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.425 1.49 . . . . 10.0 110.093 -178.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -137.39 143.25 41.84 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 114.753 1.39 . . . . 10.0 114.753 -175.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.658 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -32.04 124.95 0.24 Allowed Glycine 0 C--N 1.343 0.917 0 C-N-CA 127.262 2.363 . . . . 10.0 111.711 162.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.35 103.42 2.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 119.343 1.572 . . . . 10.0 109.949 170.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.515 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.79 173.98 15.7 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 113.806 1.039 . . . . 10.0 113.806 -176.91 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 m -85.26 151.99 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 CA-C-N 113.006 -1.906 . . . . 10.0 109.385 169.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -132.89 84.9 2.17 Favored 'General case' 0 C--O 1.221 -0.428 0 C-N-CA 124.756 1.222 . . . . 10.0 108.365 174.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 22.5 -83.96 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 128.046 2.539 . . . . 10.0 116.129 -176.025 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -76.76 179.06 6.31 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-O 121.555 0.693 . . . . 10.0 109.594 -169.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.69 -26.17 10.98 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.508 -1.037 . . . . 10.0 110.508 169.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -37.47 130.24 0.98 Allowed 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 125.502 1.521 . . . . 10.0 110.317 176.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -138.38 18.61 2.75 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 114.944 -1.026 . . . . 10.0 111.398 175.159 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.526 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -56.92 -35.76 69.41 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 118.362 0.528 . . . . 10.0 110.223 -178.197 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.95 -20.25 42.4 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 125.42 1.488 . . . . 10.0 113.515 176.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.29 99.12 1.04 Allowed Glycine 0 CA--C 1.531 1.065 0 N-CA-C 109.318 -1.513 . . . . 10.0 109.318 -169.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.9 p 3.94 61.6 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 128.555 2.742 . . . . 10.0 117.508 -169.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.1 m -135.33 -60.03 0.76 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.013 -1.847 . . . . 10.0 106.013 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 41.6 t -50.93 -34.52 28.92 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.736 0.814 . . . . 10.0 110.002 169.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.07 -47.52 0.28 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 126.29 1.836 . . . . 10.0 112.64 168.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 131.63 140.6 4.59 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.082 -0.844 . . . . 10.0 111.998 171.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . 0.403 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 89.0 Cg_endo -73.13 64.68 4.26 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.824 3.016 . . . . 10.0 110.501 169.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 30.3 m170 75.57 -44.31 0.52 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 129.781 3.232 . . . . 10.0 111.05 175.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . 0.403 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 27.8 m-85 31.13 59.4 0.26 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 127.75 2.42 . . . . 10.0 113.252 -174.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . 0.547 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 0.0 OUTLIER -55.34 146.23 43.32 Favored Pre-proline 0 C--N 1.324 -0.519 0 N-CA-C 113.441 0.904 . . . . 10.0 113.441 175.117 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.84 -47.54 0.34 Allowed 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.762 2.308 . . . . 10.0 110.832 177.172 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -81.71 56.57 3.07 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.821 0.848 . . . . 10.0 109.879 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -18.35 77.31 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.278 3.031 . . . . 10.0 116.48 -169.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt85 -116.53 -179.86 3.8 Favored 'General case' 0 CA--C 1.509 -0.598 0 C-N-CA 125.499 1.52 . . . . 10.0 109.84 173.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -114.59 89.4 3.09 Favored 'General case' 0 N--CA 1.439 -1.014 0 O-C-N 124.238 0.962 . . . . 10.0 112.755 -171.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.482 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 75.1 t60 12.83 89.19 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.174 2.19 . . . . 10.0 115.084 176.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -106.42 -141.69 10.45 Favored Glycine 0 C--N 1.318 -0.435 0 N-CA-C 108.721 -1.752 . . . . 10.0 108.721 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.67 -168.23 37.0 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 109.896 -1.281 . . . . 10.0 109.896 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -66.72 12.13 0.16 Allowed 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.224 1.95 . . . . 10.0 111.662 169.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 62.7 mmtt -107.55 -18.84 13.74 Favored 'General case' 0 N--CA 1.438 -1.025 0 C-N-CA 124.731 1.213 . . . . 10.0 109.541 173.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -135.54 162.75 31.8 Favored 'General case' 0 C--N 1.348 0.513 0 CA-C-N 118.766 0.712 . . . . 10.0 109.822 -167.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -82.62 -18.76 40.05 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 107.969 -1.123 . . . . 10.0 107.969 173.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -84.27 21.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.219 0 O-C-N 119.908 -1.745 . . . . 10.0 112.854 -169.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.01 138.04 5.4 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.54 1.136 . . . . 10.0 109.196 170.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.547 ' HB3' ' HB3' ' B' ' 65' ' ' ASN . 11.6 m170 -70.41 -65.61 0.71 Allowed 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 173.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.47 HG13 ' H ' ' B' ' 82' ' ' GLY . 7.8 p -174.42 -69.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.117 1.367 . . . . 10.0 108.248 -178.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.47 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -105.84 63.12 0.31 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 109.602 -1.399 . . . . 10.0 109.602 -175.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.8 95.3 5.51 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 105.774 -1.935 . . . . 10.0 105.774 178.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 26.1 mt -75.33 2.43 11.24 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 120.295 -0.562 . . . . 10.0 110.906 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 89.16 -95.63 2.12 Favored Glycine 0 N--CA 1.437 -1.25 0 N-CA-C 108.174 -1.97 . . . . 10.0 108.174 171.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.3 m-20 -156.17 113.56 3.23 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 118.622 -0.704 . . . . 10.0 109.258 -172.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.3 m -96.72 131.08 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 118.524 0.602 . . . . 10.0 110.215 177.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 14.4 m -87.21 108.64 19.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 127.85 2.46 . . . . 10.0 110.424 -173.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.8 133.17 34.34 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.156 0.583 . . . . 10.0 109.752 171.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -61.86 174.05 0.91 Allowed 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.939 0.876 . . . . 10.0 109.591 167.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -51.57 -29.88 18.83 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 125.244 1.418 . . . . 10.0 110.961 173.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.01 -9.55 59.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 123.35 0.66 . . . . 10.0 110.501 -175.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.07 7.14 83.98 Favored Glycine 0 C--N 1.339 0.745 0 N-CA-C 111.33 -0.708 . . . . 10.0 111.33 -177.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 47.5 t -90.02 114.18 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 126.144 1.778 . . . . 10.0 106.366 178.301 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.444 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -110.81 118.57 36.5 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 169.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -80.09 121.69 25.85 Favored 'General case' 0 N--CA 1.451 -0.393 0 O-C-N 124.886 1.366 . . . . 10.0 107.547 169.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 99.1 t -105.81 131.07 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 C-N-CA 125.928 1.691 . . . . 10.0 106.625 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.5 p -155.46 74.58 0.9 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 174.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.69 159.01 7.41 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -142.68 133.66 25.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 O-C-N 121.77 -0.581 . . . . 10.0 110.738 173.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -142.88 135.34 27.57 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.976 0.91 . . . . 10.0 109.543 -172.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 3.8 p -93.92 -10.52 33.52 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.17 1.388 . . . . 10.0 111.188 169.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -85.07 -15.75 10.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 123.916 0.886 . . . . 10.0 110.28 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -98.15 149.84 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 106.659 -1.608 . . . . 10.0 106.659 169.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.6 m -153.34 141.16 20.11 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 108.244 -1.021 . . . . 10.0 108.244 169.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -56.14 -50.04 72.24 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.886 0.874 . . . . 10.0 109.558 -178.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.3 m -136.21 161.93 34.38 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 124.862 1.265 . . . . 10.0 108.688 -178.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.29 -92.01 0.37 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 107.156 -2.378 . . . . 10.0 107.156 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -128.31 -46.09 1.35 Allowed 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 125.083 1.353 . . . . 10.0 109.21 -168.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -75.14 -36.4 61.58 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 107.609 -1.256 . . . . 10.0 107.609 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t 42.43 58.12 3.17 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 126.373 1.869 . . . . 10.0 114.514 166.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 28.1 pt -70.64 -12.16 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 N-CA-C 113.168 0.803 . . . . 10.0 113.168 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.4 mm -57.66 115.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 119.847 1.203 . . . . 10.0 110.208 171.334 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 102.69 2.6 49.79 Favored Glycine 0 C--N 1.336 0.546 0 C-N-CA 124.496 1.046 . . . . 10.0 111.804 173.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.77 148.8 31.32 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 117.845 0.822 . . . . 10.0 110.605 173.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 31.3 m -80.66 126.69 31.59 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.838 1.255 . . . . 10.0 108.091 168.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -103.48 145.47 29.95 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.305 1.442 . . . . 10.0 107.825 169.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 68.9 t -135.54 143.5 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 4.4 p -110.89 139.8 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 O-C-N 124.535 1.147 . . . . 10.0 108.679 169.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.658 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.6 m-70 -117.2 162.41 17.91 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 114.729 1.381 . . . . 10.0 114.729 -174.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . 0.424 ' HB2' HD21 ' B' ' 144' ' ' LEU . 62.4 tt0 -61.72 -51.11 69.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 114.888 -1.051 . . . . 10.0 109.789 178.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 88.4 mttt -109.65 170.18 8.23 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.51 0.671 . . . . 10.0 111.613 -168.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.21 148.77 45.23 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 114.278 -1.328 . . . . 10.0 109.078 178.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.515 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.7 OUTLIER -74.93 151.14 38.91 Favored 'General case' 0 N--CA 1.443 -0.775 0 N-CA-C 109.226 -0.657 . . . . 10.0 109.226 172.686 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -76.0 -38.35 57.45 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 112.713 -2.039 . . . . 10.0 108.936 172.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 62.8 mt 62.45 64.54 0.93 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 123.97 1.843 . . . . 10.0 108.061 -176.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 76.21 -38.49 1.38 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 112.136 -2.302 . . . . 10.0 116.14 167.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 11.9 mtmt -75.35 5.09 6.1 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.099 1.148 . . . . 10.0 114.099 -167.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.45 -34.93 90.14 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 108.388 -1.885 . . . . 10.0 108.388 166.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.71 25.61 51.77 Favored Glycine 0 C--N 1.341 0.827 0 N-CA-C 111.191 -0.764 . . . . 10.0 111.191 -176.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -108.2 172.88 6.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 106.928 -1.508 . . . . 10.0 106.928 170.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -57.1 -45.6 83.27 Favored 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 123.957 0.903 . . . . 10.0 109.277 -177.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 mp0 -52.96 -42.76 65.79 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.456 1.102 . . . . 10.0 109.992 173.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.12 -9.21 20.92 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 117.341 -1.314 . . . . 10.0 113.362 179.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.2 t -108.73 7.57 26.44 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 121.009 1.731 . . . . 10.0 110.627 173.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -127.05 -59.44 1.25 Allowed 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 124.909 1.284 . . . . 10.0 110.94 -170.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.7 p -140.63 22.42 2.33 Favored 'General case' 0 CA--C 1.544 0.736 0 CA-C-N 119.016 0.826 . . . . 10.0 112.008 176.37 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 78.03 -100.23 1.6 Allowed Glycine 0 C--N 1.341 0.857 0 N-CA-C 107.533 -2.227 . . . . 10.0 107.533 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -163.62 42.19 0.1 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 125.696 1.598 . . . . 10.0 107.6 169.075 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.43 -8.98 45.46 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.296 1.038 . . . . 10.0 113.009 -174.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.01 -171.34 55.13 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.669 -1.372 . . . . 10.0 109.669 -173.228 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -53.32 164.11 0.51 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 124.822 1.249 . . . . 10.0 112.004 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.25 114.25 19.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 168.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.425 ' N ' ' CD2' ' B' ' 144' ' ' LEU . 0.7 OUTLIER -84.63 -48.13 9.81 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 108.315 -0.994 . . . . 10.0 108.315 -177.716 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.64 141.17 39.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 116.208 -0.451 . . . . 10.0 110.121 -175.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.5 m -118.6 145.37 45.46 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 126.491 1.916 . . . . 10.0 108.297 -169.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.19 155.46 26.49 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.859 -1.296 . . . . 10.0 109.859 168.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 18.1 t -116.24 129.51 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 103.946 -2.613 . . . . 10.0 103.946 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.7 mt -65.93 133.65 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 119.188 0.904 . . . . 10.0 111.255 -177.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.04 143.38 16.15 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 109.338 -1.505 . . . . 10.0 109.338 173.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -80.94 128.21 38.89 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.346 0 CA-C-N 118.442 1.121 . . . . 10.0 108.622 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.33 -49.23 17.42 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 -175.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.8 tp60 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 117.218 -1.373 . . . . 10.0 109.527 175.195 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 108.466 -0.938 . . . . 10.0 108.466 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t -133.81 -49.09 0.82 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 124.061 0.944 . . . . 10.0 111.439 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -120.93 139.54 53.08 Favored 'General case' 0 C--O 1.235 0.31 0 C-N-CA 125.462 1.505 . . . . 10.0 109.371 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.87 164.12 36.23 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 173.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 m -123.72 179.57 2.7 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 O-C-N 123.469 0.481 . . . . 10.0 109.9 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.89 118.25 8.45 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 126.683 1.993 . . . . 10.0 107.631 164.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 m -97.23 86.81 1.6 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 124.211 1.005 . . . . 10.0 111.007 173.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.426 HD12 ' N ' ' A' ' 8' ' ' LEU . 5.7 mp -79.47 140.15 37.42 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 121.789 -0.569 . . . . 10.0 109.609 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.8 mtmt -152.35 163.65 39.06 Favored 'General case' 0 N--CA 1.456 -0.168 0 N-CA-C 106.622 -1.621 . . . . 10.0 106.622 170.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -166.4 -65.71 0.03 OUTLIER Glycine 0 C--N 1.33 0.249 0 C-N-CA 120.606 -0.806 . . . . 10.0 112.249 169.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -74.11 -42.1 60.59 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.08 -66.45 0.5 Allowed Glycine 0 N--CA 1.444 -0.796 0 CA-C-N 114.885 -1.052 . . . . 10.0 111.959 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.81 -41.24 71.76 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.89 1.727 . . . . 10.0 110.621 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.466 HG23 HD11 ' A' ' 38' ' ' LEU . 0.4 OUTLIER -68.0 109.47 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 N-CA-C 107.331 -1.359 . . . . 10.0 107.331 177.364 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -120.46 122.37 40.54 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.161 -2.163 . . . . 10.0 105.161 171.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.736 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -108.94 133.64 11.78 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 109.649 -1.38 . . . . 10.0 109.649 175.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.597 ' CG2' HG22 ' B' ' 54' ' ' THR . 2.2 mt -138.17 86.38 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -173.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.5 mm -95.57 143.33 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 C-N-CA 123.948 0.899 . . . . 10.0 109.111 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 32.7 m-80 -115.54 121.68 43.4 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 126.13 1.772 . . . . 10.0 108.721 168.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -102.28 98.11 8.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 125.862 1.665 . . . . 10.0 107.025 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -117.89 121.31 40.39 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.072 0.851 . . . . 10.0 113.109 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -94.05 105.49 17.49 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 125.867 1.667 . . . . 10.0 107.831 168.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.47 -42.76 61.83 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.795 0.838 . . . . 10.0 110.174 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -135.98 158.53 44.17 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 102.193 -3.262 . . . . 10.0 102.193 165.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 t -77.32 -3.87 42.19 Favored 'General case' 0 C--O 1.226 -0.135 0 CA-C-N 119.37 0.986 . . . . 10.0 109.817 173.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m120 -85.02 -24.6 28.12 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 125.182 1.393 . . . . 10.0 109.361 168.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.62 156.84 45.06 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 109.43 -1.468 . . . . 10.0 109.43 174.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -64.55 153.16 78.71 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 N-CA-C 108.006 -1.575 . . . . 10.0 108.006 169.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.8 p -79.14 121.14 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 N-CA-C 106.69 -1.596 . . . . 10.0 106.69 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -88.79 113.73 24.66 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.16 -1.793 . . . . 10.0 106.16 168.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 m -92.31 95.97 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.824 0 N-CA-C 105.555 -2.017 . . . . 10.0 105.555 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.7 p90 -106.97 161.8 14.4 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.178 0.513 . . . . 10.0 110.538 171.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.16 169.29 39.48 Favored Glycine 0 N--CA 1.438 -1.187 0 C-N-CA 120.055 -1.069 . . . . 10.0 110.63 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.0 t -139.37 95.75 2.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.992 -1.485 . . . . 10.0 106.992 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.736 HG22 ' HA2' ' A' ' 16' ' ' GLY . 6.4 pt -77.07 166.33 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.124 -1.065 . . . . 10.0 108.124 169.093 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -149.29 146.53 27.6 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 106.58 -1.637 . . . . 10.0 106.58 166.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.53 -4.93 24.73 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 123.921 0.772 . . . . 10.0 113.567 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.494 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.3 mp -73.23 177.93 4.8 Favored 'General case' 0 N--CA 1.444 -0.752 0 CA-C-N 118.117 0.959 . . . . 10.0 109.245 173.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 7.9 t -90.39 172.29 8.85 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.632 -0.877 . . . . 10.0 108.632 166.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.91 169.88 2.37 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.43 1.092 . . . . 10.0 110.837 -173.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.73 -178.92 41.26 Favored Glycine 0 N--CA 1.448 -0.503 0 O-C-N 121.428 -0.795 . . . . 10.0 112.843 167.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.6 mp -69.4 143.83 53.54 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.612 1.165 . . . . 10.0 109.779 176.04 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -142.61 139.49 31.31 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 123.381 0.672 . . . . 10.0 112.662 -176.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.627 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -26.84 117.94 0.04 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.106 2.289 . . . . 10.0 113.036 164.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.03 106.23 4.56 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 120.2 2.0 . . . . 10.0 110.095 170.03 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.422 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -148.48 172.06 15.09 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-O 121.174 0.512 . . . . 10.0 112.075 179.872 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.43 -44.57 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 C-N-CA 126.249 1.819 . . . . 10.0 113.429 -168.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 63.64 144.45 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 126.887 2.075 . . . . 10.0 112.074 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -67.0 -47.7 70.68 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.694 -0.854 . . . . 10.0 108.694 177.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -74.88 129.98 38.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 107.788 -1.19 . . . . 10.0 107.788 -169.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -88.75 -28.43 21.47 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 126.572 2.034 . . . . 10.0 110.695 175.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.59 176.43 0.65 Allowed 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 125.144 1.378 . . . . 10.0 112.819 -176.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -146.34 -64.41 0.3 Allowed 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.078 -1.419 . . . . 10.0 110.021 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.792 HG22 HG22 ' B' ' 17' ' ' ILE . 1.0 OUTLIER 46.54 -57.17 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.652 1 C-N-CA 133.211 4.604 . . . . 10.0 115.134 179.546 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . 0.293 . . -69.66 -37.05 76.57 Favored 'General case' 0 N--CA 1.437 -1.081 0 C-N-CA 127.763 2.425 . . . . 10.0 108.216 169.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.29 -143.76 14.96 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.233 -2.747 . . . . 10.0 106.233 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.3 t -78.8 39.35 0.35 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 122.178 0.99 . . . . 10.0 112.066 -172.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.4 m -111.27 -49.33 3.02 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 127.826 2.451 . . . . 10.0 106.811 -169.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 16.1 m -91.0 16.92 8.64 Favored 'General case' 0 N--CA 1.435 -1.224 0 C-N-CA 126.488 1.915 . . . . 10.0 110.113 -171.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.69 61.44 1.37 Allowed 'General case' 0 C--O 1.236 0.379 0 C-N-CA 124.101 0.96 . . . . 10.0 109.365 169.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 0.26 103.92 0.01 OUTLIER Glycine 0 C--N 1.335 0.488 1 C-N-CA 131.62 4.438 . . . . 10.0 111.087 166.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -73.04 73.5 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 122.752 2.301 . . . . 10.0 113.129 -168.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.461 ' CD2' HG22 ' A' ' 137' ' ' THR . 11.1 m170 71.82 36.2 1.24 Allowed 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 129.592 3.157 . . . . 10.0 110.749 170.008 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -73.62 60.02 0.66 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.451 1.1 . . . . 10.0 110.709 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -75.03 156.96 85.85 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 123.673 0.789 . . . . 10.0 110.181 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -65.43 -65.36 0.05 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.441 2.094 . . . . 10.0 111.5 -175.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.99 66.81 1.22 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.661 0.743 . . . . 10.0 109.975 172.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 113.74 3.3 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.401 -0.812 . . . . 10.0 109.557 178.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.6 mtt180 -116.8 -87.91 0.6 Allowed 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 103.298 -2.852 . . . . 10.0 103.298 -173.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtm -145.72 160.12 42.18 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 122.627 1.203 . . . . 10.0 108.702 167.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 42.7 t60 -62.2 127.27 30.59 Favored 'General case' 0 N--CA 1.439 -1.022 0 N-CA-C 105.364 -2.088 . . . . 10.0 105.364 163.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.89 -138.26 3.27 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 107.79 -2.124 . . . . 10.0 107.79 177.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.45 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.42 -158.39 22.26 Favored Glycine 0 N--CA 1.449 -0.444 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 169.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -65.98 10.58 0.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 CA-C-N 119.869 1.835 . . . . 10.0 110.945 168.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.45 ' H ' ' C ' ' A' ' 73' ' ' GLY . 1.9 mmmp? -108.68 -15.83 14.32 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.621 1.168 . . . . 10.0 109.257 177.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.419 ' OD2' ' NZ ' ' A' ' 128' ' ' LYS . 2.3 m-20 -141.32 132.13 25.85 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.617 -1.623 . . . . 10.0 106.617 -168.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -73.46 -22.58 60.14 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 -171.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -79.57 1.82 24.55 Favored 'General case' 0 N--CA 1.433 -1.313 0 C-N-CA 124.737 1.215 . . . . 10.0 111.579 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -42.15 142.97 0.65 Allowed 'General case' 0 C--N 1.346 0.445 0 C-N-CA 124.956 1.302 . . . . 10.0 112.436 177.305 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -59.49 -62.28 2.0 Allowed 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 121.238 0.542 . . . . 10.0 111.132 -173.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.438 HG13 ' H ' ' A' ' 82' ' ' GLY . 5.8 p -167.37 -64.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 179.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.438 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -122.04 60.26 0.56 Allowed Glycine 0 CA--C 1.522 0.503 0 N-CA-C 109.637 -1.385 . . . . 10.0 109.637 -179.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -92.37 90.97 7.45 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.672 -2.344 . . . . 10.0 104.672 168.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 40.4 mt -70.07 -31.49 69.11 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 173.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.1 -102.73 2.27 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 108.536 -1.825 . . . . 10.0 108.536 168.249 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 52.4 m-20 -124.51 124.22 41.81 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.686 1.194 . . . . 10.0 110.631 -168.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 16.2 m -111.1 137.71 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 N-CA-C 108.057 -1.09 . . . . 10.0 108.057 168.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 54.1 m -92.22 120.18 32.55 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.897 1.679 . . . . 10.0 108.667 -175.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.62 133.2 44.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 123.901 0.88 . . . . 10.0 110.508 176.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -59.38 170.97 0.87 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 123.589 0.755 . . . . 10.0 109.834 167.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.42 ' NZ ' ' OD1' ' A' ' 92' ' ' ASP . 12.6 pttp -47.37 -34.89 7.51 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.787 1.635 . . . . 10.0 110.403 171.016 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.42 ' OD1' ' NZ ' ' A' ' 91' ' ' LYS . 0.2 OUTLIER -79.48 -0.74 34.43 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 124.683 1.193 . . . . 10.0 111.438 -174.768 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.45 8.55 87.69 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 110.671 -0.972 . . . . 10.0 110.671 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.5 t -88.0 106.92 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 125.95 1.7 . . . . 10.0 106.614 -178.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.496 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -103.9 117.84 35.28 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 168.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.26 114.37 18.14 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 126.038 1.735 . . . . 10.0 108.654 172.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.2 t -107.24 133.43 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 178.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 94.9 p -156.62 59.21 0.55 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.264 0.625 . . . . 10.0 110.088 172.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.6 mt -96.43 157.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 106.767 -1.568 . . . . 10.0 106.767 -174.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -133.06 143.0 49.06 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.805 0.729 . . . . 10.0 111.057 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -127.09 124.14 38.52 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.274 1.43 . . . . 10.0 108.861 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 p -89.99 -8.89 50.57 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.352 1.461 . . . . 10.0 111.147 169.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.4 p -95.91 -39.23 9.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 124.331 1.052 . . . . 10.0 109.929 -174.081 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 mp -97.03 155.89 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 125.347 1.459 . . . . 10.0 108.514 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.6 m -157.63 156.39 31.74 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 108.281 -1.007 . . . . 10.0 108.281 -173.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -74.53 -23.04 58.75 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 120.919 0.39 . . . . 10.0 110.478 174.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.8 m -150.47 142.57 24.05 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.051 -1.462 . . . . 10.0 107.051 -177.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.73 -67.2 0.29 Allowed Glycine 0 C--N 1.334 0.427 0 N-CA-C 109.014 -1.634 . . . . 10.0 109.014 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -163.37 -51.36 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 126.398 1.879 . . . . 10.0 107.287 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.19 -28.29 59.97 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 114.755 -1.111 . . . . 10.0 110.241 -169.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.1 t 22.86 81.47 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 129.028 2.931 . . . . 10.0 111.814 172.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.8 pt -75.93 39.23 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 112.213 0.449 . . . . 10.0 112.213 -173.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -83.39 -48.61 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 124.899 1.28 . . . . 10.0 111.268 -171.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.79 46.02 1.32 Allowed Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.816 -0.914 . . . . 10.0 110.816 -175.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -111.13 162.02 15.35 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 125.201 1.4 . . . . 10.0 108.881 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -110.22 102.56 11.23 Favored 'General case' 0 C--N 1.347 0.476 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 179.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.82 134.98 40.24 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.514 -0.921 . . . . 10.0 108.514 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.408 HG12 ' CD2' ' A' ' 120' ' ' HIS . 61.9 t -124.11 131.74 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 O-C-N 123.911 0.757 . . . . 10.0 110.407 -172.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.445 HG13 HD21 ' A' ' 38' ' ' LEU . 1.8 t -98.19 123.37 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 128.416 2.686 . . . . 10.0 107.639 168.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.627 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.5 m-70 -109.94 157.54 19.15 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 115.868 1.803 . . . . 10.0 115.868 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -41.34 -65.13 0.47 Allowed 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 129.767 3.227 . . . . 10.0 111.73 171.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.1 mttp -112.28 175.41 5.44 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.861 0.865 . . . . 10.0 111.74 -172.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.61 147.91 37.29 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 114.005 -1.452 . . . . 10.0 109.72 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.422 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 4.5 m-20 -78.77 142.75 36.73 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 123.62 0.768 . . . . 10.0 110.659 171.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -78.53 -13.59 59.76 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.512 -1.222 . . . . 10.0 110.563 167.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 76.5 mt 61.62 42.86 10.56 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 125.474 1.51 . . . . 10.0 110.949 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.14 -5.94 56.12 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 124.262 0.934 . . . . 10.0 112.611 173.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.419 ' NZ ' ' OD2' ' A' ' 76' ' ' ASP . 11.9 mttt -110.65 35.79 3.35 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.752 0.821 . . . . 10.0 110.628 -167.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -84.09 -31.18 26.51 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.861 2.172 . . . . 10.0 111.901 178.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.61 48.41 84.7 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -176.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.481 ' H ' ' HB2' ' A' ' 134' ' ' SER . 14.8 m-80 -150.29 165.62 32.46 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.781 2.432 . . . . 10.0 106.289 -175.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -58.41 -47.65 83.23 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-O 121.588 0.709 . . . . 10.0 109.139 174.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -54.02 -30.92 49.54 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.979 1.312 . . . . 10.0 112.695 175.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.481 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 7.0 t -47.22 -47.46 24.43 Favored 'General case' 0 C--O 1.223 -0.307 0 C-N-CA 124.395 1.078 . . . . 10.0 108.412 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -88.24 10.19 20.46 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 118.751 -0.642 . . . . 10.0 112.55 -173.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -122.38 -94.39 0.5 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.455 1.902 . . . . 10.0 109.875 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.461 HG22 ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -101.85 25.04 9.08 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 121.353 1.888 . . . . 10.0 110.158 177.294 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.07 -91.32 0.44 Allowed Glycine 0 C--N 1.339 0.743 0 N-CA-C 108.886 -1.686 . . . . 10.0 108.886 177.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 m-80 -162.27 35.97 0.12 Allowed 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 126.428 1.891 . . . . 10.0 108.246 172.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.55 -9.92 55.95 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 121.219 -0.926 . . . . 10.0 112.116 -173.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.96 -167.92 53.82 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.862 -0.895 . . . . 10.0 110.862 174.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 58.4 p -59.12 139.34 56.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 122.308 1.051 . . . . 10.0 112.277 -168.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 40.2 mtt85 -66.76 74.84 0.11 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.526 1.131 . . . . 10.0 110.838 173.173 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.3 mt -47.31 -38.7 13.22 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 123.506 0.722 . . . . 10.0 112.09 176.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.8 157.17 40.38 Favored 'General case' 0 CA--C 1.514 -0.43 0 O-C-N 121.827 -0.546 . . . . 10.0 111.121 176.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -159.01 167.32 29.63 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.458 -0.337 . . . . 10.0 110.218 171.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.63 165.42 36.23 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 109.331 -1.508 . . . . 10.0 109.331 -176.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 92.9 t -105.53 146.95 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 103.018 -2.956 . . . . 10.0 103.018 -175.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . 0.3 5.0 mt -68.36 -86.88 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 CA-C-O 121.469 0.652 . . . . 10.0 112.46 -168.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 93.49 135.44 7.5 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.775 1.179 . . . . 10.0 112.699 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.1 mt -70.46 142.15 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 125.057 1.343 . . . . 10.0 109.357 -176.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.77 -45.22 2.29 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.077 0.951 . . . . 10.0 111.383 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.537 1.935 . . . . 10.0 113.266 -178.505 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 107.166 -1.42 . . . . 10.0 107.166 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -78.14 -50.44 11.99 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-O 122.299 1.047 . . . . 10.0 109.743 171.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -156.04 153.97 30.29 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.692 -1.14 . . . . 10.0 109.76 -169.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.4 151.47 48.58 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.074 0.949 . . . . 10.0 108.629 169.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.6 t -109.56 159.31 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 125.044 1.338 . . . . 10.0 110.099 174.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.99 97.17 3.01 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 124.31 1.044 . . . . 10.0 108.562 166.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.458 HG12 HG23 ' B' ' 17' ' ' ILE . 29.1 m -82.29 126.36 39.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -106.11 149.74 26.46 Favored 'General case' 0 CA--C 1.529 0.136 0 CA-C-O 117.914 -1.041 . . . . 10.0 108.351 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . 0.429 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 47.0 tttt -165.13 161.73 19.72 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 120.083 1.31 . . . . 10.0 108.679 170.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.42 -50.26 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 116.204 -0.453 . . . . 10.0 112.208 169.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -77.62 -46.34 22.41 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 -170.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 131.79 -61.7 0.66 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-N 113.928 -1.487 . . . . 10.0 111.303 -175.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -63.02 -39.68 38.6 Favored 'Trans proline' 0 N--CA 1.454 -0.811 0 C-N-CA 122.586 2.191 . . . . 10.0 110.79 169.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.97 115.34 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.114 -1.069 . . . . 10.0 108.114 -178.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.43 140.05 27.33 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-O 121.014 0.435 . . . . 10.0 110.091 165.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.486 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -108.07 157.28 15.43 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 125.256 1.408 . . . . 10.0 112.388 178.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.792 HG22 HG22 ' A' ' 54' ' ' THR . 0.3 OUTLIER -147.19 85.0 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 N-CA-C 106.29 -1.745 . . . . 10.0 106.29 -179.525 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.78 145.09 9.38 Favored 'Isoleucine or valine' 0 C--O 1.231 0.093 0 C-N-CA 124.062 0.945 . . . . 10.0 110.778 178.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -123.19 111.74 16.85 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 129.854 3.261 . . . . 10.0 106.928 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -101.09 103.22 14.3 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 79.0 mt-10 -96.38 137.1 35.95 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.139 0.881 . . . . 10.0 110.843 170.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -106.15 100.95 10.47 Favored 'General case' 0 CA--C 1.53 0.186 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 24.0 tttp -57.83 -50.56 72.88 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 125.959 1.704 . . . . 10.0 110.297 -176.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -145.17 169.63 17.81 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 104.167 -2.531 . . . . 10.0 104.167 179.068 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.4 t -75.26 -13.51 60.44 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 109.162 -0.681 . . . . 10.0 109.162 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -124.47 27.03 7.1 Favored 'General case' 0 N--CA 1.443 -0.823 0 C-N-CA 123.573 0.749 . . . . 10.0 109.904 169.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.24 151.69 23.77 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 172.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -62.83 130.15 28.47 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 N-CA-C 107.966 -1.59 . . . . 10.0 107.966 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.4 t -79.99 99.73 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 105.98 -1.859 . . . . 10.0 105.98 174.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -77.04 119.34 20.63 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 104.67 -2.344 . . . . 10.0 104.67 167.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -105.16 114.15 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 106.323 -1.732 . . . . 10.0 106.323 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -135.8 172.6 12.78 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 121.166 0.508 . . . . 10.0 111.831 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.59 -149.15 21.21 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 106.334 -2.706 . . . . 10.0 106.334 169.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.0 m -155.53 159.43 39.71 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 119.079 -1.048 . . . . 10.0 111.25 177.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.567 HG12 ' HB3' ' B' ' 95' ' ' ALA . 1.5 pt -117.28 147.1 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.772 -1.104 . . . . 10.0 108.565 166.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -126.07 138.72 53.73 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 124.38 1.05 . . . . 10.0 109.226 168.539 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.27 -8.05 10.47 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.972 1.272 . . . . 10.0 113.29 175.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -62.44 178.55 0.4 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.288 1.044 . . . . 10.0 112.237 177.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.2 t -115.0 156.72 24.57 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 106.897 -1.52 . . . . 10.0 106.897 167.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -46.95 143.95 2.71 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.583 1.553 . . . . 10.0 112.902 -169.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.24 -178.42 31.71 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 124.222 0.915 . . . . 10.0 111.887 171.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 10.6 mt -64.0 150.48 45.15 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.657 1.583 . . . . 10.0 112.71 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -146.11 148.57 32.75 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.681 1.192 . . . . 10.0 112.764 177.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.639 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -25.7 124.31 0.04 OUTLIER Glycine 0 C--N 1.341 0.852 0 C-N-CA 126.668 2.08 . . . . 10.0 112.616 166.473 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -148.91 98.9 2.91 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 119.888 1.844 . . . . 10.0 111.46 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.52 172.59 14.74 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 122.807 0.443 . . . . 10.0 111.151 -178.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.3 m -105.43 -24.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 115.826 1.787 . . . . 10.0 115.826 -167.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 62.39 175.22 0.14 Allowed 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 121.529 0.68 . . . . 10.0 112.568 177.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -81.09 -56.32 4.17 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.985 -0.552 . . . . 10.0 110.195 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -87.25 156.14 19.78 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.161 0.437 . . . . 10.0 110.158 -172.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.01 -19.26 22.23 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.036 -1.226 . . . . 10.0 110.036 169.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -63.38 160.43 16.11 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 122.556 1.17 . . . . 10.0 111.688 -176.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -153.79 16.66 0.51 Allowed 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.242 -0.89 . . . . 10.0 113.001 -171.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.597 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -45.53 -40.86 9.08 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 127.141 2.177 . . . . 10.0 112.707 -177.887 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.1 -18.56 57.88 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 111.915 0.339 . . . . 10.0 111.915 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.88 -66.2 0.56 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 109.474 -1.45 . . . . 10.0 109.474 -179.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 48.2 t -157.84 18.31 0.25 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.645 1.178 . . . . 10.0 110.584 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -98.87 -45.3 6.04 Favored 'General case' 0 N--CA 1.44 -0.931 0 O-C-N 120.184 -1.572 . . . . 10.0 108.695 -177.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -49.11 -39.71 29.44 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.438 1.495 . . . . 10.0 111.792 -169.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.46 -42.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 129.027 2.931 . . . . 10.0 114.205 168.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.33 163.24 28.43 Favored Glycine 0 N--CA 1.439 -1.113 0 N-CA-C 107.87 -2.092 . . . . 10.0 107.87 172.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -74.42 -169.29 0.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.547 0 N-CA-C 106.734 -2.064 . . . . 10.0 106.734 167.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 31.7 m170 -82.12 58.41 3.96 Favored 'General case' 0 CA--C 1.539 0.52 0 O-C-N 120.109 -1.62 . . . . 10.0 110.314 -174.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -76.51 59.66 1.51 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 123.06 1.41 . . . . 10.0 111.733 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -60.35 153.67 57.74 Favored Pre-proline 0 C--N 1.324 -0.516 0 C-N-CA 126.44 1.896 . . . . 10.0 110.965 169.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.77 -43.95 0.55 Allowed 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.686 2.257 . . . . 10.0 111.377 175.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 tt -79.3 62.77 3.75 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.175 0.99 . . . . 10.0 109.743 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 10.1 t -39.36 107.61 0.07 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.142 1.777 . . . . 10.0 113.368 -169.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.4 mtt180 -136.5 -174.07 3.59 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.422 1.489 . . . . 10.0 109.708 175.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.5 mmpt? -117.64 57.88 0.81 Allowed 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 113.975 1.102 . . . . 10.0 113.975 -167.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.402 ' CD2' ' CA ' ' B' ' 138' ' ' GLY . 63.5 t60 38.03 94.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 116.209 1.929 . . . . 10.0 116.209 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.6 -164.64 12.51 Favored Glycine 0 C--N 1.315 -0.61 0 N-CA-C 108.524 -1.83 . . . . 10.0 108.524 168.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -139.53 -162.4 9.1 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.143 -0.783 . . . . 10.0 111.143 171.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -69.81 10.32 0.51 Allowed 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.324 2.016 . . . . 10.0 111.569 176.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 84.3 mttt -101.28 -19.74 15.53 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.657 0.783 . . . . 10.0 109.174 170.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -125.67 -178.64 4.33 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 107.945 -1.132 . . . . 10.0 107.945 -167.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . 0.273 0.6 OUTLIER -110.43 -1.6 17.0 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 112.752 0.649 . . . . 10.0 112.752 167.918 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -77.61 -1.82 32.72 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 121.815 -0.553 . . . . 10.0 109.945 175.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 21.0 ptt-85 -42.25 124.43 2.8 Favored 'General case' 0 C--N 1.344 0.335 0 C-N-CA 124.965 1.306 . . . . 10.0 109.148 169.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -74.67 -54.3 7.67 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.574 -0.528 . . . . 10.0 109.574 -172.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.479 HG13 ' H ' ' B' ' 82' ' ' GLY . 6.6 p -165.02 -66.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.537 0.735 . . . . 10.0 109.157 176.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.479 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -118.7 77.01 0.3 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.663 -2.175 . . . . 10.0 107.663 178.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -119.54 97.97 5.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.99 -2.226 . . . . 10.0 104.99 178.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -83.13 23.06 0.9 Allowed 'General case' 0 CA--C 1.526 0.048 0 CA-C-O 120.962 0.41 . . . . 10.0 110.553 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 77.4 -109.93 2.91 Favored Glycine 0 N--CA 1.432 -1.615 0 N-CA-C 105.653 -2.979 . . . . 10.0 105.653 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -158.93 139.12 12.2 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.857 -1.164 . . . . 10.0 107.857 -178.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.3 m -108.46 130.49 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 123.535 0.734 . . . . 10.0 111.867 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -80.95 101.52 9.54 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.973 2.909 . . . . 10.0 111.488 -170.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.99 134.34 35.36 Favored 'General case' 0 N--CA 1.451 -0.398 0 O-C-N 121.866 -0.521 . . . . 10.0 109.733 170.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -61.9 167.57 3.68 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 122.033 0.921 . . . . 10.0 108.75 167.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 30.6 ttpt -49.87 -31.13 11.34 Favored 'General case' 0 N--CA 1.432 -1.358 0 C-N-CA 125.934 1.694 . . . . 10.0 111.964 169.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -77.03 -10.29 59.27 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.188 0.449 . . . . 10.0 111.258 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.2 12.11 66.03 Favored Glycine 0 C--N 1.34 0.797 0 O-C-N 120.993 -1.067 . . . . 10.0 110.798 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.2 t -92.6 111.48 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 C-N-CA 126.66 1.984 . . . . 10.0 106.311 176.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.567 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -108.53 121.6 45.31 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 108.489 -0.93 . . . . 10.0 108.489 169.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -82.64 123.06 28.91 Favored 'General case' 0 N--CA 1.434 -1.253 0 C-N-CA 126.893 2.077 . . . . 10.0 107.989 170.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.94 131.85 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.935 -1.505 . . . . 10.0 106.935 175.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.85 75.8 0.71 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.991 0.916 . . . . 10.0 109.583 169.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.9 164.31 3.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.589 -1.634 . . . . 10.0 106.589 179.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -137.49 138.9 40.19 Favored 'General case' 0 N--CA 1.451 -0.383 0 O-C-N 121.459 -0.776 . . . . 10.0 110.868 171.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.99 145.53 49.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 124.454 1.096 . . . . 10.0 108.558 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.2 p -120.1 16.71 12.44 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.12 1.368 . . . . 10.0 110.7 172.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -107.65 -49.23 7.93 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 124.362 1.065 . . . . 10.0 109.634 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.329 0.7 OUTLIER -67.82 170.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-O 121.206 0.527 . . . . 10.0 112.094 171.544 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 52.1 p -151.91 140.25 20.46 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.151 -1.055 . . . . 10.0 108.151 174.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.4 pp -85.85 -24.68 26.63 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 108.27 -1.011 . . . . 10.0 108.27 167.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m -148.54 120.9 8.44 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 105.433 -2.062 . . . . 10.0 105.433 166.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.33 -72.1 0.08 OUTLIER Glycine 0 C--O 1.227 -0.292 0 N-CA-C 108.715 -1.754 . . . . 10.0 108.715 -173.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -152.17 -53.0 0.12 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 113.641 -1.279 . . . . 10.0 108.003 176.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -75.71 -34.7 60.39 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-N 114.517 -1.22 . . . . 10.0 109.065 -170.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t 43.09 71.74 0.21 Allowed 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 125.709 1.604 . . . . 10.0 111.981 171.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 41.1 pt -66.4 1.53 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 113.619 0.97 . . . . 10.0 113.619 -178.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.8 mm -41.42 -40.88 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.302 0 C-N-CA 125.113 1.365 . . . . 10.0 113.783 177.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -105.5 25.59 24.1 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.82 1.2 . . . . 10.0 113.198 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.58 175.94 6.03 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.44 1.096 . . . . 10.0 110.439 174.31 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -123.71 107.98 12.04 Favored 'General case' 0 C--N 1.344 0.355 0 C-N-CA 124.554 1.142 . . . . 10.0 111.168 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -61.94 130.76 47.15 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 167.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.03 131.21 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 N-CA-C 107.504 -1.295 . . . . 10.0 107.504 173.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.445 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.8 OUTLIER -100.72 126.35 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.537 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.639 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.4 m170 -104.26 157.0 17.44 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 115.248 1.573 . . . . 10.0 115.248 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -47.48 -57.06 5.82 Favored 'General case' 0 N--CA 1.447 -0.614 0 C-N-CA 127.784 2.434 . . . . 10.0 110.657 177.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -107.53 170.84 7.73 Favored 'General case' 0 N--CA 1.463 0.199 0 C-N-CA 124.493 1.117 . . . . 10.0 112.478 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -75.28 149.93 38.67 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.558 1.543 . . . . 10.0 109.804 171.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.01 144.85 38.39 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 112.924 0.713 . . . . 10.0 112.924 177.101 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -78.32 -23.87 46.86 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.755 1.622 . . . . 10.0 109.259 167.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 48.9 mt 54.76 58.28 4.97 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 122.611 1.196 . . . . 10.0 109.693 -174.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.96 -47.31 3.82 Favored Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 113.996 -1.456 . . . . 10.0 112.505 167.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.91 42.39 0.38 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 118.026 0.913 . . . . 10.0 112.649 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.2 -22.82 26.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 127.122 2.296 . . . . 10.0 109.442 168.096 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.78 32.95 83.57 Favored Glycine 0 C--N 1.337 0.6 0 N-CA-C 110.975 -0.85 . . . . 10.0 110.975 176.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -135.67 162.94 31.32 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.132 -1.062 . . . . 10.0 108.132 172.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -45.87 -48.77 15.95 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 124.409 1.083 . . . . 10.0 110.02 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -70.46 -33.6 71.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.671 -0.643 . . . . 10.0 112.143 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.9 p -53.3 -44.26 68.2 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 119.374 0.988 . . . . 10.0 110.331 174.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.6 t -80.71 -19.18 45.66 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 112.852 0.686 . . . . 10.0 112.852 -173.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -101.41 -45.37 5.34 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 125.304 1.442 . . . . 10.0 112.666 -172.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 30.8 p -132.18 -1.97 3.59 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 119.211 0.914 . . . . 10.0 113.128 174.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . 0.402 ' CA ' ' CD2' ' B' ' 71' ' ' HIS . . . 88.89 22.97 36.95 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-O 118.601 -1.11 . . . . 10.0 112.241 -176.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 60.48 15.65 5.75 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 119.567 1.683 . . . . 10.0 112.056 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.98 3.13 5.7 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.103 -0.998 . . . . 10.0 112.438 -170.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.94 -168.55 54.76 Favored Glycine 0 N--CA 1.444 -0.813 0 N-CA-C 110.586 -1.006 . . . . 10.0 110.586 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.4 t -58.04 143.86 41.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 115.05 -0.575 . . . . 10.0 111.755 -169.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.9 mtm-85 -64.02 78.86 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.042 0.937 . . . . 10.0 110.02 168.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 5.7 tp -39.87 -55.37 2.0 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.234 1.813 . . . . 10.0 110.847 176.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.445 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -151.81 149.67 29.27 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.153 -0.684 . . . . 10.0 109.153 -173.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 12.6 m -128.48 153.78 46.79 Favored 'General case' 0 CA--C 1.522 -0.132 0 C-N-CA 125.477 1.511 . . . . 10.0 109.101 -173.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -133.57 169.95 22.56 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 108.964 -1.654 . . . . 10.0 108.964 167.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' A' ' 148' ' ' VAL . 17.2 t -117.83 132.44 67.64 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 105.408 -2.071 . . . . 10.0 105.408 169.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 71.4 mt -69.24 157.99 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.382 -0.97 . . . . 10.0 108.382 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.88 156.16 27.26 Favored Glycine 0 CA--C 1.528 0.891 0 O-C-N 121.249 -0.907 . . . . 10.0 111.731 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.7 mp -55.52 133.38 19.3 Favored 'Isoleucine or valine' 0 C--N 1.341 0.22 0 C-N-CA 125.618 1.567 . . . . 10.0 109.765 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -120.21 165.6 14.59 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.38 -1.341 . . . . 10.0 107.38 166.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 . . . . . 0 C--O 1.25 1.084 0 C-N-CA 125.939 1.695 . . . . 10.0 106.834 169.831 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 106.205 -1.776 . . . . 10.0 106.205 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.7 t -69.4 -14.34 62.85 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.496 1.044 . . . . 10.0 109.171 168.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.67 155.12 50.29 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 125.406 1.483 . . . . 10.0 107.481 168.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.04 158.24 44.03 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 125.483 1.513 . . . . 10.0 106.952 169.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -122.05 152.61 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 C-N-CA 123.529 0.732 . . . . 10.0 110.106 -178.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.557 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -127.8 97.23 4.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 125.099 1.359 . . . . 10.0 108.502 168.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.0 OUTLIER -79.64 109.25 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.13 -1.433 . . . . 10.0 107.13 167.427 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.3 mt -90.07 139.85 30.22 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.386 -1.339 . . . . 10.0 107.386 175.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.413 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 18.9 tttt -162.18 161.09 27.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 120.01 1.277 . . . . 10.0 108.388 170.191 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.42 -53.32 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.206 0 N-CA-C 111.66 -0.576 . . . . 10.0 111.66 170.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -75.72 -47.31 26.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 106.713 -1.588 . . . . 10.0 106.713 -171.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.53 -61.26 0.66 Allowed Glycine 0 CA--C 1.53 0.993 0 CA-C-N 113.822 -1.536 . . . . 10.0 111.807 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.14 -34.92 67.27 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 122.63 2.22 . . . . 10.0 111.23 172.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.0 t -75.58 110.1 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.176 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 176.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.21 129.69 38.08 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 123.448 0.699 . . . . 10.0 109.326 166.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.47 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -105.75 147.11 16.18 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 125.595 1.569 . . . . 10.0 109.559 171.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.448 HG22 HG22 ' B' ' 54' ' ' THR . 2.9 mt -140.82 59.68 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 -176.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm -78.95 140.27 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 N-CA-C 109.095 -0.705 . . . . 10.0 109.095 -172.446 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -116.61 110.52 18.63 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 126.939 2.096 . . . . 10.0 107.271 178.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -94.45 109.73 21.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 176.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.54 158.64 16.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.572 0.624 . . . . 10.0 112.127 170.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -155.61 83.23 1.04 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.818 2.047 . . . . 10.0 106.646 166.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 6.5 mmtp -52.13 -55.72 19.11 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 125.294 1.437 . . . . 10.0 110.503 -173.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -123.62 167.22 14.24 Favored 'General case' 0 N--CA 1.434 -1.264 0 N-CA-C 103.992 -2.595 . . . . 10.0 103.992 169.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -71.73 -14.58 62.06 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.885 -0.598 . . . . 10.0 109.917 173.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -79.8 -17.03 54.34 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 123.304 0.642 . . . . 10.0 109.314 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.67 140.98 23.17 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 178.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -62.06 153.35 69.74 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.118 1.879 . . . . 10.0 107.543 169.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.4 t -76.81 89.82 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.167 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 170.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.6 tmtp? -85.45 114.16 22.28 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 106.075 -1.824 . . . . 10.0 106.075 170.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.2 m -110.31 125.21 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 107.173 -1.417 . . . . 10.0 107.173 -174.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.7 p90 -134.46 164.78 26.69 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.118 0.485 . . . . 10.0 111.878 173.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.2 -148.67 19.52 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 107.827 -2.109 . . . . 10.0 107.827 170.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.5 t -155.31 150.77 27.22 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 116.973 0.387 . . . . 10.0 110.143 -176.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.47 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -113.49 111.51 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.268 0 C-N-CA 125.836 1.654 . . . . 10.0 106.611 165.551 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -95.93 137.33 35.15 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 108.073 -1.084 . . . . 10.0 108.073 170.151 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.78 -0.94 9.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 125.137 1.351 . . . . 10.0 112.585 173.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.04 174.96 7.89 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 118.453 1.126 . . . . 10.0 109.285 176.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -100.58 156.89 17.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.077 -1.823 . . . . 10.0 106.077 165.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -55.03 151.59 8.78 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.373 0.669 . . . . 10.0 111.834 -169.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.54 -178.93 26.56 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.115 0.864 . . . . 10.0 112.081 175.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -67.23 151.08 48.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.899 1.28 . . . . 10.0 111.355 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -151.02 153.77 35.77 Favored 'General case' 0 C--N 1.342 0.265 0 N-CA-C 113.577 0.955 . . . . 10.0 113.577 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.635 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -38.23 125.93 1.57 Allowed Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.693 2.568 . . . . 10.0 113.057 165.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -155.2 114.13 3.58 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.525 -1.287 . . . . 10.0 107.525 165.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 170.44 18.46 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 121.843 0.83 . . . . 10.0 111.582 174.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -115.33 127.28 72.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 104.251 -2.5 . . . . 10.0 104.251 168.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -167.52 175.16 7.31 Favored 'General case' 0 N--CA 1.451 -0.38 0 O-C-N 121.908 -0.495 . . . . 10.0 110.891 -168.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . 0.28 14.0 pt-20 50.3 -157.51 0.09 Allowed 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 126.279 2.237 . . . . 10.0 113.281 167.116 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.8 m-30 -82.64 -167.37 1.59 Allowed 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 109.247 -0.649 . . . . 10.0 109.247 177.086 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.37 -0.35 24.99 Favored Glycine 0 CA--C 1.536 1.347 0 C-N-CA 126.256 1.884 . . . . 10.0 112.975 174.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -75.0 83.0 2.24 Favored 'General case' 0 C--N 1.342 0.258 0 CA-C-N 119.737 1.768 . . . . 10.0 110.637 -176.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -79.51 8.41 6.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-N 115.282 -0.872 . . . . 10.0 113.077 177.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.518 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -42.53 -48.07 5.25 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 127.992 2.517 . . . . 10.0 113.376 -171.906 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.08 -26.74 39.49 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 123.206 0.602 . . . . 10.0 112.348 -179.305 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 137.99 -150.69 21.03 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 106.727 -2.549 . . . . 10.0 106.727 -169.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.8 m -80.23 33.16 0.28 Allowed 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 124.668 1.187 . . . . 10.0 112.273 -179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.8 m -125.24 -57.72 1.48 Allowed 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 108.646 -0.872 . . . . 10.0 108.646 -168.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 t -58.61 -39.79 81.46 Favored 'General case' 0 C--N 1.341 0.204 0 O-C-N 123.416 0.448 . . . . 10.0 110.935 -168.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.03 -41.69 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 127.387 2.275 . . . . 10.0 113.997 169.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.5 -162.93 19.65 Favored Glycine 0 C--N 1.34 0.779 0 N-CA-C 109.597 -1.401 . . . . 10.0 109.597 169.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -110.44 178.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.935 1 C-N-CA 125.558 4.172 . . . . 10.0 106.354 164.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.6 m170 -66.87 79.86 0.11 Allowed 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 120.088 1.313 . . . . 10.0 110.927 -176.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -105.85 53.93 0.7 Allowed 'General case' 0 N--CA 1.462 0.138 0 C-N-CA 127.262 2.225 . . . . 10.0 108.802 172.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -52.99 145.41 23.21 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 125.502 1.521 . . . . 10.0 110.772 168.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -64.98 -43.46 11.78 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 123.338 2.692 . . . . 10.0 111.243 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.4 68.68 0.55 Allowed 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.528 -0.915 . . . . 10.0 108.528 170.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.5 p -58.74 104.79 0.25 Allowed 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.381 1.073 . . . . 10.0 109.893 -175.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.1 mtt180 -141.55 -176.56 4.79 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 105.722 -1.955 . . . . 10.0 105.722 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.37 129.48 35.89 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 -177.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.446 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 76.1 t60 -44.92 112.13 0.4 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 122.558 0.343 . . . . 10.0 111.749 178.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.49 -147.66 6.52 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.03 -167.93 18.18 Favored Glycine 0 C--O 1.225 -0.451 0 CA-C-N 117.98 0.89 . . . . 10.0 111.567 179.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -68.36 16.09 0.16 Allowed 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.518 2.145 . . . . 10.0 112.398 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -110.39 -20.6 12.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 124.934 1.294 . . . . 10.0 110.25 169.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.67 162.65 16.94 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.754 -1.572 . . . . 10.0 106.754 -167.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -88.98 -21.85 23.31 Favored 'General case' 0 C--N 1.329 -0.32 0 O-C-N 121.629 -0.669 . . . . 10.0 109.877 178.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -83.4 -6.37 59.44 Favored 'General case' 0 N--CA 1.443 -0.813 0 C-N-CA 124.538 1.135 . . . . 10.0 111.474 -169.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -35.65 118.95 0.51 Allowed 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 126.145 1.778 . . . . 10.0 111.108 171.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.446 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 31.1 m170 -50.37 -50.66 50.75 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 115.828 1.788 . . . . 10.0 115.828 -167.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -178.25 -46.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 106.945 -1.502 . . . . 10.0 106.945 -174.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -153.45 62.33 0.38 Allowed Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -85.84 95.96 9.61 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 103.705 -2.702 . . . . 10.0 103.705 166.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -70.47 -10.42 59.1 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.578 0.626 . . . . 10.0 111.833 -171.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.85 -93.96 0.93 Allowed Glycine 0 N--CA 1.445 -0.744 0 N-CA-C 107.69 -2.164 . . . . 10.0 107.69 176.063 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -150.54 147.11 27.06 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 124.871 1.268 . . . . 10.0 107.79 -174.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.1 m -117.98 128.04 75.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 118.606 0.639 . . . . 10.0 109.755 169.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.7 m -90.19 95.11 10.04 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 127.267 2.227 . . . . 10.0 111.506 -169.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -69.63 128.5 36.68 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.778 -0.576 . . . . 10.0 111.654 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.1 171.8 5.25 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.123 1.369 . . . . 10.0 109.888 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 pttm -54.89 -29.35 55.62 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.218 1.007 . . . . 10.0 111.088 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -78.25 0.21 26.11 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.031 0.444 . . . . 10.0 111.213 178.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.45 17.59 79.81 Favored Glycine 0 C--N 1.339 0.734 0 O-C-N 120.654 -1.279 . . . . 10.0 110.766 178.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 18.3 t -97.68 103.34 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.734 0 C-N-CA 127.812 2.445 . . . . 10.0 106.356 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.404 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -97.33 118.42 33.77 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 168.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -79.42 141.87 36.45 Favored 'General case' 0 N--CA 1.425 -1.679 0 C-N-CA 124.643 1.177 . . . . 10.0 108.718 178.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 86.8 t -111.63 133.22 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 106.509 -1.663 . . . . 10.0 106.509 169.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.6 p -158.88 58.4 0.43 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.501 0.72 . . . . 10.0 111.512 170.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -101.3 152.73 5.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.897 0.879 . . . . 10.0 109.085 -171.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -112.01 127.94 56.03 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 126.568 1.947 . . . . 10.0 108.448 172.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -130.22 145.72 51.77 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-O 121.378 0.609 . . . . 10.0 111.001 169.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.8 t -133.07 64.66 1.61 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.089 2.156 . . . . 10.0 106.652 -178.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.01 -52.73 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.077 0 C-N-CA 123.672 0.789 . . . . 10.0 109.225 175.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.328 0.0 OUTLIER -78.84 174.82 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.145 0.497 . . . . 10.0 112.19 172.048 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 m -153.99 153.72 32.49 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.372 -1.714 . . . . 10.0 106.372 169.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 95.7 mt -68.45 -14.52 63.06 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.109 0.564 . . . . 10.0 111.602 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.4 m -151.75 157.21 41.7 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.056 -1.831 . . . . 10.0 106.056 169.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 151.84 -66.95 0.33 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 109.914 -1.274 . . . . 10.0 109.914 178.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -161.02 -51.74 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 126.298 1.839 . . . . 10.0 107.239 -178.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -73.79 -39.44 64.13 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.513 -1.222 . . . . 10.0 108.165 -169.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 17.8 t 35.53 74.86 0.06 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 127.559 2.344 . . . . 10.0 110.31 169.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 pt -76.36 46.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.986 0.914 . . . . 10.0 111.422 -173.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 35.1 mm -92.31 -86.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 124.936 1.295 . . . . 10.0 108.613 -171.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.23 50.57 2.76 Favored Glycine 0 CA--C 1.537 1.468 0 O-C-N 120.291 -1.506 . . . . 10.0 113.669 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 13.4 mmt-85 -101.05 175.63 5.53 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 126.195 1.798 . . . . 10.0 108.006 169.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 17.2 m -102.46 104.34 14.78 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.362 1.465 . . . . 10.0 107.086 172.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.02 144.65 40.74 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 105.428 -2.064 . . . . 10.0 105.428 168.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.7 t -134.69 139.03 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 N-CA-C 108.645 -0.872 . . . . 10.0 108.645 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -107.39 131.72 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 N-CA-C 106.039 -1.837 . . . . 10.0 106.039 167.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.635 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.8 m170 -114.8 158.89 21.27 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 115.693 1.738 . . . . 10.0 115.693 -169.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.2 tt0 -43.84 -57.31 3.34 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 129.035 2.934 . . . . 10.0 111.835 174.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -116.84 169.17 9.59 Favored 'General case' 0 CA--C 1.52 -0.182 0 N-CA-C 113.835 1.05 . . . . 10.0 113.835 -168.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.05 132.24 37.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.557 1.543 . . . . 10.0 109.829 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 125.956 1.702 . . . . 10.0 110.563 -175.058 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.6 -37.42 50.39 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 124.388 1.075 . . . . 10.0 109.859 174.252 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.0 mt 76.07 53.62 0.06 Allowed 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.916 2.086 . . . . 10.0 112.755 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.92 -25.2 22.87 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 115.509 0.964 . . . . 10.0 115.509 167.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mptt -75.82 -4.13 38.98 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 119.313 1.557 . . . . 10.0 112.56 -172.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.84 -29.41 64.66 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 109.076 -1.609 . . . . 10.0 109.076 168.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.29 41.02 99.39 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.273 -1.131 . . . . 10.0 110.273 -176.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -130.78 171.98 12.51 Favored 'General case' 0 CA--C 1.501 -0.94 0 N-CA-C 106.731 -1.581 . . . . 10.0 106.731 170.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 7.1 mp0 -40.22 -58.78 1.41 Allowed 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 10.0 110.109 168.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -50.1 -54.52 19.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 116.072 -0.513 . . . . 10.0 109.999 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.4 p -55.29 -44.46 75.73 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 120.022 -0.671 . . . . 10.0 110.313 -177.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -78.24 -7.75 57.52 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.622 1.169 . . . . 10.0 111.16 -173.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -109.36 -68.38 0.92 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.911 1.684 . . . . 10.0 111.38 -178.473 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -114.55 -6.95 12.82 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 121.456 1.934 . . . . 10.0 112.326 179.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.55 33.64 47.04 Favored Glycine 0 C--O 1.222 -0.606 0 CA-C-O 118.976 -0.902 . . . . 10.0 111.837 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 61.21 24.91 14.97 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 119.74 1.77 . . . . 10.0 112.189 176.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.7 -9.08 58.29 Favored 'General case' 0 CA--C 1.527 0.082 0 C-N-CA 123.544 0.738 . . . . 10.0 112.31 -177.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.21 -166.12 54.76 Favored Glycine 0 N--CA 1.447 -0.607 0 O-C-N 121.269 -0.894 . . . . 10.0 111.409 172.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.1 m -58.13 136.36 57.21 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.064 0.946 . . . . 10.0 113.078 -167.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -64.03 89.11 0.05 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.123 0.969 . . . . 10.0 109.191 168.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 62.0 mt -58.07 -51.46 69.61 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.848 -0.427 . . . . 10.0 109.848 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.413 ' HB1' ' C ' ' A' ' 9' ' ' LYS . . . -147.97 152.05 36.83 Favored 'General case' 0 N--CA 1.454 -0.261 0 O-C-N 122.273 -0.267 . . . . 10.0 110.371 -169.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 88.2 m -130.49 154.13 48.09 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 124.756 1.222 . . . . 10.0 109.539 -173.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -142.43 154.58 25.2 Favored Glycine 0 CA--C 1.519 0.328 0 N-CA-C 110.156 -1.178 . . . . 10.0 110.156 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 58.4 t -115.09 126.36 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 105.098 -2.186 . . . . 10.0 105.098 178.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.557 HG12 ' HB2' ' A' ' 6' ' ' ALA . 49.2 mt -78.71 147.7 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 108.895 -0.78 . . . . 10.0 108.895 -177.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -153.43 178.5 30.41 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.337 -1.105 . . . . 10.0 110.337 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -64.31 122.68 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 C-N-CA 124.477 1.111 . . . . 10.0 108.941 -177.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -116.89 148.84 40.96 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.761 -1.2 . . . . 10.0 107.761 168.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.016 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 167.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 119.111 -0.471 . . . . 10.0 110.174 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 t -81.77 -40.85 22.04 Favored 'General case' 0 C--O 1.226 -0.149 0 C-N-CA 124.217 1.007 . . . . 10.0 110.511 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 49.1 mttp -134.24 140.56 46.55 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 125.221 1.408 . . . . 10.0 109.192 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.43 152.89 47.42 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.017 0.927 . . . . 10.0 108.858 171.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -120.77 158.22 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 123.931 0.892 . . . . 10.0 110.153 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.47 101.94 4.49 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.427 -0.953 . . . . 10.0 108.427 168.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -79.64 105.97 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 108.692 -0.855 . . . . 10.0 108.692 169.666 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -91.86 128.13 37.58 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.364 -0.976 . . . . 10.0 108.364 -178.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -143.38 162.32 36.06 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 120.098 1.317 . . . . 10.0 108.494 170.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.67 -56.89 0.07 OUTLIER Glycine 0 N--CA 1.461 0.319 0 CA-C-N 115.077 -0.965 . . . . 10.0 113.146 169.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.47 -44.27 65.08 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 -177.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.4 -70.68 0.41 Allowed Glycine 0 CA--C 1.523 0.569 0 CA-C-N 114.319 -1.309 . . . . 10.0 110.323 169.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -59.13 -33.08 98.28 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 123.643 2.895 . . . . 10.0 111.515 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 65.2 t -67.06 95.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 177.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -117.69 101.15 8.1 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.522 -2.029 . . . . 10.0 105.522 178.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.938 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -85.47 142.04 19.28 Favored Glycine 0 N--CA 1.435 -1.401 0 N-CA-C 109.577 -1.409 . . . . 10.0 109.577 172.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.518 ' CG2' HG22 ' A' ' 54' ' ' THR . 2.2 mt -140.37 81.29 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 105.949 -1.871 . . . . 10.0 105.949 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -90.9 140.7 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 C-N-CA 123.892 0.877 . . . . 10.0 109.05 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 13.5 m-80 -126.44 114.7 18.52 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.044 1.338 . . . . 10.0 109.234 171.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -91.42 132.48 36.19 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 124.882 1.273 . . . . 10.0 108.248 174.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.6 156.38 24.8 Favored 'General case' 0 C--N 1.339 0.151 0 O-C-N 123.519 0.512 . . . . 10.0 111.874 169.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.59 135.0 55.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 102.519 -3.141 . . . . 10.0 102.519 162.063 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -76.04 -77.13 0.14 Allowed 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 170.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 62.1 mm-40 -99.98 -125.9 0.17 Allowed 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.923 1.689 . . . . 10.0 106.616 175.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 73.4 m -136.18 13.68 3.3 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 121.868 -0.52 . . . . 10.0 111.971 165.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -123.6 -2.82 8.35 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 124.894 1.278 . . . . 10.0 109.876 168.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.7 156.49 47.99 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 110.136 -1.186 . . . . 10.0 110.136 -178.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -66.29 125.22 13.64 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 123.021 2.48 . . . . 10.0 108.831 175.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 m -79.96 64.51 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 122.774 0.43 . . . . 10.0 110.382 -175.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.8 tttt -54.42 111.95 0.9 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.139 -0.689 . . . . 10.0 109.139 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -103.9 112.28 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 C-N-CA 127.412 2.285 . . . . 10.0 106.556 -176.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -106.14 171.43 7.35 Favored 'General case' 0 CA--C 1.511 -0.532 0 CA-C-O 121.847 0.832 . . . . 10.0 110.507 173.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.59 173.88 45.09 Favored Glycine 0 N--CA 1.436 -1.306 0 N-CA-C 110.124 -1.19 . . . . 10.0 110.124 174.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 19.5 m -145.75 90.19 1.97 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.565 -0.902 . . . . 10.0 108.565 -179.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.938 HG22 ' HA2' ' B' ' 16' ' ' GLY . 3.4 pt -79.93 146.93 6.97 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.497 0 N-CA-C 108.661 -0.866 . . . . 10.0 108.661 175.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -126.7 149.74 49.41 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 171.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.39 -5.87 49.18 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-O 119.415 -0.658 . . . . 10.0 113.665 174.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -63.47 177.69 0.65 Allowed 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 118.445 1.123 . . . . 10.0 110.599 173.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.1 t -115.25 168.09 10.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 105.687 -1.968 . . . . 10.0 105.687 165.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -46.57 156.84 0.16 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.785 1.634 . . . . 10.0 113.406 -170.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.14 -162.47 46.29 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-O 122.139 0.855 . . . . 10.0 113.376 166.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -79.7 141.32 36.51 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 125.873 1.669 . . . . 10.0 111.342 -170.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -139.72 145.39 38.26 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 114.504 1.298 . . . . 10.0 114.504 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.558 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -34.61 117.94 0.25 Allowed Glycine 0 C--N 1.343 0.95 0 C-N-CA 129.556 3.455 . . . . 10.0 114.569 167.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.451 ' HZ ' HG21 ' B' ' 35' ' ' ILE . 3.2 m-85 -141.37 109.23 5.71 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 120.012 1.906 . . . . 10.0 110.931 169.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.502 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -148.15 170.43 17.86 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 112.708 0.632 . . . . 10.0 112.708 178.66 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 m -116.69 79.1 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 C-N-CA 128.625 2.77 . . . . 10.0 111.247 -168.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 38.4 m-70 -79.23 142.69 36.02 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 124.802 1.241 . . . . 10.0 112.056 -171.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -62.47 -46.31 89.08 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 114.605 1.335 . . . . 10.0 114.605 -169.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -75.7 92.43 2.98 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.798 -2.667 . . . . 10.0 103.798 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.88 -27.13 74.14 Favored Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 128.103 2.764 . . . . 10.0 109.99 -176.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -52.57 175.88 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.777 0 CA-C-O 122.752 1.263 . . . . 10.0 110.78 167.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.537 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.4 OUTLIER -149.99 31.82 0.69 Allowed 'General case' 0 N--CA 1.431 -1.378 0 CA-C-N 114.603 -1.18 . . . . 10.0 112.809 168.815 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.448 HG22 HG22 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -51.78 -38.91 57.52 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.958 0.903 . . . . 10.0 111.084 -177.835 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.01 -18.08 54.24 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.84 1.256 . . . . 10.0 113.217 -179.425 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.09 85.56 0.62 Allowed Glycine 0 CA--C 1.533 1.161 0 N-CA-C 111.478 -0.649 . . . . 10.0 111.478 -176.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 71.4 m 44.11 39.36 2.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 128.008 2.523 . . . . 10.0 112.634 173.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -134.3 -54.32 0.85 Allowed 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 108.156 -1.053 . . . . 10.0 108.156 -169.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.7 m -90.56 34.31 0.89 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.109 0.563 . . . . 10.0 109.844 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -67.04 -23.18 65.86 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.401 1.08 . . . . 10.0 109.868 177.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.76 141.2 11.61 Favored Glycine 0 CA--C 1.533 1.172 0 N-CA-C 110.911 -0.876 . . . . 10.0 110.911 172.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -76.23 63.01 6.97 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.213 3.275 . . . . 10.0 113.202 -174.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 22.6 m170 63.26 44.04 5.87 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 126.697 1.999 . . . . 10.0 109.939 171.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -67.89 79.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 124.863 2.268 . . . . 10.0 111.351 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -81.89 147.15 57.54 Favored Pre-proline 0 C--N 1.318 -0.772 0 C-N-CA 126.396 1.878 . . . . 10.0 108.316 168.142 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -79.56 40.3 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 122.484 2.123 . . . . 10.0 111.775 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -162.84 37.68 0.1 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.787 0.835 . . . . 10.0 109.996 -176.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -42.31 100.05 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.599 1.56 . . . . 10.0 112.719 -170.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.57 -78.85 0.6 Allowed 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.284 -1.006 . . . . 10.0 108.284 -171.139 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -154.24 144.35 21.97 Favored 'General case' 0 N--CA 1.425 -1.678 0 CA-C-N 115.484 -0.78 . . . . 10.0 109.223 171.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -61.76 118.64 7.41 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 106.711 -1.589 . . . . 10.0 106.711 165.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.06 -146.19 6.25 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 107.743 -2.143 . . . . 10.0 107.743 175.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.53 -165.71 24.37 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 107.813 -2.115 . . . . 10.0 107.813 169.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -64.19 6.36 0.31 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.151 1.9 . . . . 10.0 112.207 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.407 ' HE2' ' HB2' ' B' ' 76' ' ' ASP . 0.0 OUTLIER -96.86 -29.99 13.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 118.997 0.817 . . . . 10.0 110.35 168.812 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.407 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 1.4 t70 -86.83 166.23 15.37 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 109.347 -0.612 . . . . 10.0 109.347 -174.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -86.18 -24.57 26.08 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 114.346 -1.297 . . . . 10.0 108.492 167.062 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -76.41 -93.78 0.02 OUTLIER 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 107.667 -1.234 . . . . 10.0 107.667 -173.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 28.5 mtm180 72.43 159.74 0.22 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 127.144 2.178 . . . . 10.0 108.644 -167.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.9 m170 -78.18 -48.63 15.45 Favored 'General case' 0 C--O 1.225 -0.208 0 C-N-CA 118.965 -1.094 . . . . 10.0 110.093 169.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.3 p -166.26 -51.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 N-CA-C 108.305 -0.998 . . . . 10.0 108.305 178.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.29 -76.28 0.9 Allowed Glycine 0 C--N 1.336 0.552 0 N-CA-C 109.019 -1.633 . . . . 10.0 109.019 171.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 41.42 78.58 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.792 1.237 . . . . 10.0 109.654 -169.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -20.97 64.96 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.939 0.348 . . . . 10.0 111.939 -168.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.91 -94.93 0.67 Allowed Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.027 -1.229 . . . . 10.0 110.027 167.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 33.2 m120 -155.61 106.45 2.51 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -168.647 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -99.24 130.6 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-N 119.773 1.17 . . . . 10.0 110.708 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -86.93 107.94 18.59 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 128.795 2.838 . . . . 10.0 110.945 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.88 131.51 36.47 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 122.857 0.463 . . . . 10.0 109.908 172.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . 0.407 ' OD2' ' NZ ' ' B' ' 91' ' ' LYS . 43.2 t0 -59.23 170.98 0.82 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.282 1.033 . . . . 10.0 109.806 168.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . 0.407 ' NZ ' ' OD2' ' B' ' 90' ' ' ASP . 12.4 pttm -51.36 -32.19 24.91 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 125.988 1.715 . . . . 10.0 110.584 175.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.36 -8.36 59.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 124.177 0.991 . . . . 10.0 110.963 -175.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.82 8.19 87.06 Favored Glycine 0 C--N 1.338 0.692 0 O-C-N 121.532 -0.73 . . . . 10.0 111.286 -177.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 50.0 t -80.18 114.92 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 N-CA-C 105.726 -1.953 . . . . 10.0 105.726 170.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.671 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -116.27 121.43 42.0 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 118.87 0.759 . . . . 10.0 109.006 170.021 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -83.0 121.78 27.45 Favored 'General case' 0 N--CA 1.433 -1.288 0 C-N-CA 126.404 1.881 . . . . 10.0 108.334 173.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 94.0 t -110.49 136.48 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 N-CA-C 106.543 -1.651 . . . . 10.0 106.543 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 18.7 m -157.77 64.97 0.47 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.071 1.349 . . . . 10.0 109.379 169.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 61.9 mt -101.97 156.35 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.859 1.263 . . . . 10.0 108.719 -171.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -144.81 140.48 28.46 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.645 1.578 . . . . 10.0 108.6 175.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -152.4 135.08 15.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 106.667 -1.605 . . . . 10.0 106.667 169.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.4 p -87.53 58.59 5.02 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.745 1.618 . . . . 10.0 107.916 -171.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 p -145.35 -46.53 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.918 -0.583 . . . . 10.0 109.677 -172.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 36.7 mm -66.8 143.04 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 N-CA-C 109.178 -0.675 . . . . 10.0 109.178 171.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 74.3 m -138.38 134.44 34.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 173.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -110.29 17.37 20.97 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.737 0.815 . . . . 10.0 110.59 172.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.17 156.5 34.32 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.131 -1.433 . . . . 10.0 107.131 173.409 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 93.67 55.38 1.54 Allowed Glycine 0 CA--C 1.525 0.689 0 O-C-N 123.743 0.652 . . . . 10.0 111.51 169.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 8.6 t70 71.02 -57.03 0.61 Allowed 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 129.663 3.185 . . . . 10.0 109.328 -178.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -82.64 48.31 1.3 Allowed 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 124.206 1.002 . . . . 10.0 109.53 -173.098 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -88.59 112.09 22.65 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 125.664 1.586 . . . . 10.0 107.983 -170.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.3 pt -69.73 13.87 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 114.095 1.146 . . . . 10.0 114.095 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 33.2 mm -55.74 135.12 19.22 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 O-C-N 120.627 -1.296 . . . . 10.0 108.063 172.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.74 11.66 73.62 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-O 118.132 -1.371 . . . . 10.0 113.855 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mmt-85 -79.38 161.84 25.93 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.242 1.521 . . . . 10.0 108.866 167.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.4 121.25 41.94 Favored 'General case' 0 C--N 1.345 0.394 0 C-N-CA 123.529 0.732 . . . . 10.0 109.99 171.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -84.37 132.37 34.6 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 107.218 -1.401 . . . . 10.0 107.218 167.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.1 t -116.51 137.43 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.792 -1.188 . . . . 10.0 107.792 169.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -104.76 123.99 59.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.558 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.2 m170 -107.69 159.09 16.74 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 116.582 2.067 . . . . 10.0 116.582 -172.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -41.45 -65.61 0.42 Allowed 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 129.631 3.173 . . . . 10.0 111.67 170.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.1 mttp -109.89 175.38 5.46 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 124.658 1.183 . . . . 10.0 111.559 -173.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.03 151.73 35.43 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 125.75 1.62 . . . . 10.0 109.903 175.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.502 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -77.53 154.64 32.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 122.901 0.48 . . . . 10.0 110.889 169.928 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 53.4 m-20 -76.27 -36.65 58.32 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.289 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 63.5 mt 64.26 56.32 1.35 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.99 1.376 . . . . 10.0 109.27 -170.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.15 -44.34 3.29 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-N 113.376 -1.738 . . . . 10.0 110.918 171.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -76.64 41.06 0.25 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.088 1.755 . . . . 10.0 112.919 -173.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -99.85 -17.83 24.46 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 125.838 1.685 . . . . 10.0 110.65 169.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.26 44.89 65.0 Favored Glycine 0 C--N 1.339 0.696 0 C-N-CA 123.861 0.743 . . . . 10.0 111.443 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -146.02 168.02 21.93 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.035 -1.098 . . . . 10.0 108.035 172.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.1 -42.55 76.97 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 116.144 -0.48 . . . . 10.0 109.88 -176.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -64.78 -40.37 95.15 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.502 -0.748 . . . . 10.0 110.825 175.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -50.8 -44.02 58.88 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 118.704 0.684 . . . . 10.0 110.449 -179.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -76.94 -8.26 57.06 Favored 'General case' 0 CA--C 1.542 0.662 0 CA-C-O 117.759 -1.115 . . . . 10.0 113.79 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 ttmm -114.87 -58.0 2.2 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 127.728 2.411 . . . . 10.0 113.072 -170.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 14.6 p -134.86 17.75 3.52 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.774 1.17 . . . . 10.0 110.784 175.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.12 -110.09 2.95 Favored Glycine 0 C--O 1.219 -0.81 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 -171.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -160.61 43.79 0.19 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 106.178 -1.786 . . . . 10.0 106.178 171.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.45 -14.76 62.66 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.787 -1.097 . . . . 10.0 112.194 -170.098 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.2 -163.5 54.53 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 110.48 -1.048 . . . . 10.0 110.48 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.7 m -56.94 130.41 45.85 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 123.929 0.891 . . . . 10.0 112.43 -168.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.58 73.36 0.06 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.809 1.644 . . . . 10.0 109.91 171.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 61.8 mt -50.96 -36.45 38.96 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.52 0.728 . . . . 10.0 112.116 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.31 159.59 28.7 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.971 -0.752 . . . . 10.0 108.971 -176.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -159.8 165.38 32.51 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.637 -0.505 . . . . 10.0 109.637 -177.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.31 167.73 35.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.421 -1.071 . . . . 10.0 110.421 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 15.9 t -115.41 138.67 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 107.233 -1.395 . . . . 10.0 107.233 -169.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.8 mt -73.18 109.82 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 110.212 -0.292 . . . . 10.0 110.212 -174.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.86 154.65 17.32 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 125.737 1.637 . . . . 10.0 110.373 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.1 mt -86.23 139.4 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 124.894 1.278 . . . . 10.0 108.815 -174.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -91.71 -114.71 0.08 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 106.071 -1.826 . . . . 10.0 106.071 167.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 . . . . . 0 C--O 1.248 1.006 0 C-N-CA 127.332 2.253 . . . . 10.0 105.014 166.937 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 107.416 -1.327 . . . . 10.0 107.416 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.2 t -158.45 -44.24 0.06 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.926 0.784 . . . . 10.0 111.328 177.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 11.7 tmtt? -131.78 134.04 45.39 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 123.68 0.792 . . . . 10.0 108.863 178.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.33 169.55 18.05 Favored 'General case' 0 C--O 1.232 0.184 0 C-N-CA 125.281 1.432 . . . . 10.0 109.936 -175.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -129.32 172.72 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 123.159 0.584 . . . . 10.0 112.236 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.72 107.47 4.46 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.826 1.25 . . . . 10.0 107.869 166.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -87.0 89.61 3.07 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-O 121.946 0.879 . . . . 10.0 109.111 172.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.65 HD21 ' HB3' ' A' ' 117' ' ' LEU . 9.1 mt -80.52 116.22 20.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.573 1.549 . . . . 10.0 109.443 -175.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -142.27 159.35 42.41 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.702 1.137 . . . . 10.0 108.35 173.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.62 -65.02 0.02 OUTLIER Glycine 0 N--CA 1.461 0.365 0 CA-C-N 115.249 -0.887 . . . . 10.0 112.216 169.338 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -72.15 -41.66 66.85 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 106.891 -1.522 . . . . 10.0 106.891 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.44 -64.26 0.55 Allowed Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.695 -1.059 . . . . 10.0 111.368 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -58.14 -37.91 93.61 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.056 1.837 . . . . 10.0 110.492 174.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.46 HG13 HD11 ' A' ' 38' ' ' LEU . 80.3 t -62.85 105.55 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 N-CA-C 107.644 -1.243 . . . . 10.0 107.644 174.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -124.02 118.98 28.22 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.089 -1.819 . . . . 10.0 106.089 171.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.536 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -107.87 130.53 10.15 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 109.725 -1.35 . . . . 10.0 109.725 170.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.595 ' CG2' HG23 ' B' ' 54' ' ' THR . 16.4 mt -128.29 72.04 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.15 -1.796 . . . . 10.0 106.15 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.14 147.19 6.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.288 -0.869 . . . . 10.0 110.447 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.03 106.24 8.74 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 126.78 2.032 . . . . 10.0 107.804 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -86.37 125.11 33.43 Favored 'General case' 0 N--CA 1.451 -0.425 0 CA-C-O 117.73 -1.129 . . . . 10.0 108.012 175.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -120.19 145.27 47.14 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 123.922 0.763 . . . . 10.0 110.963 167.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 tp60 -125.89 105.18 8.74 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 126.858 2.063 . . . . 10.0 107.036 169.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.77 -61.24 2.44 Favored 'General case' 0 C--N 1.339 0.15 0 C-N-CA 124.767 1.227 . . . . 10.0 110.24 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -134.01 167.48 20.53 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 104.552 -2.388 . . . . 10.0 104.552 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.7 t -69.41 -14.94 63.17 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 119.71 -0.186 . . . . 10.0 110.573 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -79.89 -18.02 51.68 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 123.386 0.675 . . . . 10.0 110.171 174.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.6 151.68 39.97 Favored Glycine 0 CA--C 1.53 0.997 0 N-CA-C 111.23 -0.748 . . . . 10.0 111.23 -176.097 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.23 146.66 40.94 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 N-CA-C 105.493 -2.541 . . . . 10.0 105.493 165.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t -76.65 119.35 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 N-CA-C 106.166 -1.791 . . . . 10.0 106.166 -179.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 18.0 mttp -90.97 110.57 21.83 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 106.432 -1.692 . . . . 10.0 106.432 176.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.13 106.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -128.85 169.96 13.95 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.744 0.783 . . . . 10.0 112.214 171.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.05 -153.09 24.77 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 106.592 -2.603 . . . . 10.0 106.592 169.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 27.5 t -156.06 155.98 33.58 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.54 -0.864 . . . . 10.0 109.464 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.536 HG22 ' CA ' ' A' ' 16' ' ' GLY . 3.1 pt -108.01 175.63 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 CA-C-N 115.153 -0.931 . . . . 10.0 110.082 167.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.2 ptmt -152.37 150.66 29.94 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.86 -15.57 33.99 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-O 118.985 -0.897 . . . . 10.0 114.566 171.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.533 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.1 mp -72.95 -179.67 3.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 118.948 1.374 . . . . 10.0 109.609 177.119 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -96.0 175.55 6.44 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.402 -0.962 . . . . 10.0 108.402 166.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -58.65 168.95 1.04 Allowed 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.676 1.19 . . . . 10.0 112.025 -172.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.37 -168.01 49.65 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-O 122.019 0.788 . . . . 10.0 112.909 167.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -71.26 146.13 49.15 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.762 1.625 . . . . 10.0 110.397 -176.363 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.07 152.69 35.21 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 113.125 0.787 . . . . 10.0 113.125 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.664 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.3 121.43 0.83 Allowed Glycine 0 C--N 1.339 0.727 0 C-N-CA 128.274 2.845 . . . . 10.0 111.069 165.239 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -155.68 106.21 2.48 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 106.558 -1.645 . . . . 10.0 106.558 169.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.07 170.6 17.42 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.876 0.846 . . . . 10.0 112.904 178.561 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.36 132.54 60.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 104.336 -2.468 . . . . 10.0 104.336 168.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 1.7 p80 -168.4 177.47 5.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 107.737 -1.208 . . . . 10.0 107.737 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 52.71 -167.75 0.05 Allowed 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 125.984 2.052 . . . . 10.0 116.157 162.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.75 159.42 19.77 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-O 121.593 0.711 . . . . 10.0 110.893 -175.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.01 -18.44 77.76 Favored Glycine 0 CA--C 1.523 0.565 0 C-N-CA 125.443 1.497 . . . . 10.0 110.308 168.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -50.61 140.6 14.03 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 122.723 1.249 . . . . 10.0 108.259 166.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -151.79 8.86 0.51 Allowed 'General case' 0 N--CA 1.412 -2.342 0 CA-C-N 113.5 -1.682 . . . . 10.0 109.889 -168.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.931 HG22 HG22 ' B' ' 17' ' ' ILE . 1.0 OUTLIER -41.45 -55.24 2.87 Favored 'General case' 0 C--N 1.343 0.29 0 C-N-CA 125.842 1.657 . . . . 10.0 114.425 -167.928 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.18 -18.37 57.84 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.836 0.454 . . . . 10.0 111.554 -173.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.72 78.63 1.38 Allowed Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.312 -1.115 . . . . 10.0 110.312 -175.305 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.2 m 70.24 35.3 2.12 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.989 1.315 . . . . 10.0 111.752 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -131.8 -57.51 0.98 Allowed 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 107.184 -1.413 . . . . 10.0 107.184 175.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.3 m -52.05 -43.14 63.64 Favored 'General case' 0 C--N 1.343 0.289 0 C-N-CA 123.913 0.885 . . . . 10.0 111.331 -170.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.11 -55.31 0.03 OUTLIER 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 128.35 2.66 . . . . 10.0 113.645 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 139.92 -154.18 23.68 Favored Glycine 0 CA--C 1.53 0.994 0 N-CA-C 110.533 -1.027 . . . . 10.0 110.533 175.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -122.21 -155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.54 0.811 1 C-N-CA 126.865 5.043 . . . . 10.0 105.85 165.049 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.573 ' CD2' HG22 ' A' ' 137' ' ' THR . 21.3 m170 -77.93 46.85 0.6 Allowed 'General case' 0 CA--C 1.548 0.896 0 O-C-N 118.587 -2.571 . . . . 10.0 112.113 177.436 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -77.51 60.9 2.18 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.923 1.289 . . . . 10.0 109.566 169.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -71.74 157.13 90.29 Favored Pre-proline 0 C--N 1.325 -0.457 0 C-N-CA 124.002 0.921 . . . . 10.0 108.67 171.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -56.17 -43.42 56.4 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 121.347 1.365 . . . . 10.0 109.478 169.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 68.2 mt -84.23 47.47 1.34 Allowed 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.831 -0.543 . . . . 10.0 111.232 173.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 p -61.29 91.39 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 107.407 -1.331 . . . . 10.0 107.407 166.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -113.36 -69.06 0.89 Allowed 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 104.183 -2.525 . . . . 10.0 104.183 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -154.64 161.33 41.63 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 106.171 -1.788 . . . . 10.0 106.171 167.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.8 t60 -72.48 129.07 37.48 Favored 'General case' 0 N--CA 1.44 -0.963 0 N-CA-C 105.194 -2.151 . . . . 10.0 105.194 163.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -150.03 -140.81 3.29 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 108.316 -1.913 . . . . 10.0 108.316 176.004 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . 179.33 -157.99 21.59 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.812 -2.115 . . . . 10.0 107.812 170.094 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -69.38 18.3 0.17 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 119.627 1.713 . . . . 10.0 111.326 169.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.402 ' H ' ' C ' ' A' ' 73' ' ' GLY . 30.4 mmtm -104.96 -21.03 13.36 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 124.753 1.221 . . . . 10.0 108.643 169.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.401 ' OD2' ' NZ ' ' A' ' 128' ' ' LYS . 4.8 m-20 -120.9 166.51 13.7 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.121 -1.807 . . . . 10.0 106.121 -171.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -79.32 -42.15 26.35 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 107.667 -1.235 . . . . 10.0 107.667 173.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -96.2 34.88 1.51 Allowed 'General case' 0 N--CA 1.441 -0.921 0 C-N-CA 127.53 2.332 . . . . 10.0 114.974 -161.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ptp180 -57.28 153.79 11.55 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.521 1.129 . . . . 10.0 110.867 174.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -72.97 159.21 34.03 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 118.9 -1.12 . . . . 10.0 108.497 168.064 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -38.91 -40.09 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 125.974 1.71 . . . . 10.0 114.397 -172.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.6 42.88 1.32 Allowed Glycine 0 C--N 1.338 0.664 0 CA-C-N 118.178 0.445 . . . . 10.0 112.641 179.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.0 89.48 5.34 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 106.619 -1.623 . . . . 10.0 106.619 167.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 21.4 mt -67.97 -37.71 81.86 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.15 -86.08 0.41 Allowed Glycine 0 N--CA 1.44 -1.051 0 CA-C-N 114.873 -1.058 . . . . 10.0 110.537 167.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -140.72 131.03 25.07 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 -172.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.0 m -115.24 137.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.944 -0.762 . . . . 10.0 108.944 169.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -85.19 131.92 34.36 Favored 'General case' 0 C--O 1.226 -0.168 0 C-N-CA 124.761 1.224 . . . . 10.0 109.485 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.05 138.47 45.35 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.37 1.468 . . . . 10.0 109.625 171.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -58.92 171.6 0.66 Allowed 'General case' 0 N--CA 1.456 -0.135 0 O-C-N 124.181 0.926 . . . . 10.0 109.191 167.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 27.5 pttt -45.91 -34.96 4.23 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 127.225 2.21 . . . . 10.0 110.852 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -82.53 -3.04 55.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.861 1.264 . . . . 10.0 110.83 -173.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.52 8.48 83.08 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.556 -1.017 . . . . 10.0 110.556 -177.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 73.5 t -87.83 98.82 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 107.289 -1.374 . . . . 10.0 107.289 -177.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.53 121.66 38.59 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 107.523 -1.288 . . . . 10.0 107.523 168.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -84.47 114.41 21.9 Favored 'General case' 0 N--CA 1.439 -1.003 0 C-N-CA 126.955 2.102 . . . . 10.0 108.202 169.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 87.9 t -102.05 131.36 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.672 -1.233 . . . . 10.0 107.672 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.6 p -157.97 88.95 0.98 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.392 1.077 . . . . 10.0 109.067 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -129.17 163.51 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 106.818 -1.549 . . . . 10.0 106.818 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -136.67 150.39 48.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 121.471 -0.768 . . . . 10.0 110.407 170.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -147.0 155.6 42.37 Favored 'General case' 0 N--CA 1.447 -0.608 0 O-C-N 124.551 1.157 . . . . 10.0 108.761 178.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 9.3 p -113.27 44.57 1.53 Allowed 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 127.583 2.353 . . . . 10.0 110.39 -173.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.8 p -142.59 -46.24 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 C-N-CA 123.624 0.77 . . . . 10.0 109.557 177.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 39.8 mm -54.73 110.33 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 169.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.4 m -120.82 105.16 10.45 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 124.386 1.074 . . . . 10.0 109.217 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 37.2 mt -58.15 -28.8 65.06 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.984 0.514 . . . . 10.0 111.935 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 m -150.29 160.79 43.45 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.869 -1.53 . . . . 10.0 106.869 174.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 66.1 0.4 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.333 -1.107 . . . . 10.0 110.333 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t70 71.53 -59.67 0.54 Allowed 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 129.557 3.143 . . . . 10.0 109.519 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.9 m-70 -76.49 -22.03 55.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.637 -0.71 . . . . 10.0 111.165 -169.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.1 t 26.43 78.26 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 128.358 2.663 . . . . 10.0 112.213 168.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -67.76 -6.36 5.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 112.599 0.592 . . . . 10.0 112.599 -174.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.5 mm -51.46 132.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 O-C-N 120.952 -1.092 . . . . 10.0 108.309 168.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.487 ' HA3' ' CG2' ' B' ' 113' ' ' ILE . . . 93.38 11.81 57.94 Favored Glycine 0 CA--C 1.523 0.577 0 CA-C-O 117.701 -1.611 . . . . 10.0 115.952 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -80.0 176.29 9.87 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 119.594 1.697 . . . . 10.0 108.554 167.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 99.7 m -106.54 121.46 44.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 125.095 1.358 . . . . 10.0 107.637 169.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.65 ' HB3' HD21 ' A' ' 8' ' ' LEU . 3.9 mm? -76.88 144.37 39.01 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 106.498 -1.667 . . . . 10.0 106.498 167.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.2 t -131.88 123.76 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 107.696 -1.224 . . . . 10.0 107.696 -176.021 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 11.7 t -104.49 137.83 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.664 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.9 m170 -124.89 157.65 35.44 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 114.553 1.316 . . . . 10.0 114.553 -174.138 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 68.7 tt0 -45.61 -55.92 5.78 Favored 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 128.833 2.853 . . . . 10.0 109.183 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 63.6 mttt -123.6 175.11 7.0 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.586 1.154 . . . . 10.0 110.751 -170.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.33 143.35 28.72 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 108.715 -0.846 . . . . 10.0 108.715 176.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -73.64 151.66 40.75 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.435 -0.58 . . . . 10.0 109.435 175.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -83.28 13.49 4.24 Favored 'General case' 0 N--CA 1.448 -0.529 0 O-C-N 124.355 1.034 . . . . 10.0 111.168 167.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 75.7 mt 45.58 46.6 11.21 Favored 'General case' 0 C--N 1.343 0.307 0 C-N-CA 125.513 1.525 . . . . 10.0 112.779 171.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 107.79 -21.88 29.08 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-N 115.724 -0.671 . . . . 10.0 112.119 173.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.401 ' NZ ' ' OD2' ' A' ' 76' ' ' ASP . 7.2 mtmm -112.26 43.89 1.53 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.056 1.343 . . . . 10.0 111.598 -168.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.49 -16.42 64.19 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.343 1.925 . . . . 10.0 112.435 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.33 47.9 88.31 Favored Glycine 0 CA--C 1.532 1.104 0 O-C-N 121.473 -1.016 . . . . 10.0 112.554 173.45 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.464 ' H ' ' HB2' ' A' ' 134' ' ' SER . 7.3 p30 -165.77 173.81 10.3 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 126.682 1.993 . . . . 10.0 106.094 177.259 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -56.9 -42.54 80.08 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 119.802 1.183 . . . . 10.0 111.24 -174.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -70.18 -18.32 63.19 Favored 'General case' 0 N--CA 1.454 -0.273 0 O-C-N 121.29 -0.881 . . . . 10.0 111.916 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.464 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 11.3 t -44.54 -43.53 8.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 C-N-CA 124.836 1.254 . . . . 10.0 109.549 170.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -93.79 5.95 49.96 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 112.411 0.523 . . . . 10.0 112.411 -174.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -117.87 -73.77 0.63 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.203 1.401 . . . . 10.0 110.286 179.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.573 HG22 ' CD2' ' A' ' 63' ' ' HIS . 1.4 p -111.87 7.81 20.2 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 120.213 1.369 . . . . 10.0 110.943 178.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.78 -90.15 1.06 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 108.413 -1.875 . . . . 10.0 108.413 -173.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.76 39.55 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 124.721 1.208 . . . . 10.0 109.872 176.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.35 -10.37 32.53 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 124.217 1.007 . . . . 10.0 112.745 -176.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.67 -168.01 53.34 Favored Glycine 0 N--CA 1.445 -0.743 0 O-C-N 121.059 -1.026 . . . . 10.0 110.736 178.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -59.68 138.99 57.58 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 123.781 0.832 . . . . 10.0 112.354 -168.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.8 mtm180 -68.18 69.32 0.14 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.714 1.206 . . . . 10.0 110.464 169.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.62 -9.16 32.77 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 113.654 0.983 . . . . 10.0 113.654 -178.024 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.38 143.4 17.68 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.47 0.708 . . . . 10.0 111.858 168.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 5.4 p -144.28 166.31 25.41 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.148 -0.686 . . . . 10.0 109.148 171.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.1 150.95 21.15 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 109.74 -1.344 . . . . 10.0 109.74 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.8 139.68 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 106.212 -1.773 . . . . 10.0 106.212 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.472 HD11 ' CD2' ' A' ' 117' ' ' LEU . 58.8 mt -76.84 127.34 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-O 119.555 -0.26 . . . . 10.0 110.937 -173.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -125.31 140.78 12.54 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 123.79 0.71 . . . . 10.0 111.882 -177.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 94.1 mt -68.29 140.96 18.2 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 C-N-CA 124.632 1.173 . . . . 10.0 108.699 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.21 -46.33 1.51 Allowed 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 112.348 0.499 . . . . 10.0 112.348 -176.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 . . . . . 0 C--O 1.248 0.986 0 CA-C-O 117.277 -1.344 . . . . 10.0 110.24 -167.896 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.556 0 N-CA-C 108.909 -0.774 . . . . 10.0 108.909 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -88.26 -15.74 35.04 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.865 1.266 . . . . 10.0 111.469 -175.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 31.2 tttp -130.18 135.44 48.17 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.142 1.377 . . . . 10.0 108.645 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.74 161.47 35.47 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.769 1.628 . . . . 10.0 108.843 169.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.1 t -117.98 152.86 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 C-N-CA 125.489 1.516 . . . . 10.0 110.163 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.47 94.96 3.28 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.416 1.887 . . . . 10.0 108.739 171.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.1 m -88.29 111.3 22.18 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 N-CA-C 109.368 -0.604 . . . . 10.0 109.368 172.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.4 mt -94.61 145.68 24.66 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 109.179 -0.674 . . . . 10.0 109.179 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.5 mtmt -166.72 159.28 13.76 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.533 1.133 . . . . 10.0 108.397 172.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.28 -48.7 0.11 Allowed Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.351 -0.928 . . . . 10.0 113.112 169.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -72.94 -45.96 55.15 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 107.548 -1.278 . . . . 10.0 107.548 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.04 -71.36 0.4 Allowed Glycine 0 CA--C 1.523 0.537 0 CA-C-N 114.323 -1.308 . . . . 10.0 109.909 170.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -58.18 -35.72 98.47 Favored 'Trans proline' 0 N--CA 1.453 -0.862 0 C-N-CA 123.156 2.57 . . . . 10.0 111.249 173.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.6 t -64.59 107.59 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 107.573 -1.269 . . . . 10.0 107.573 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -126.47 124.16 39.48 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 108.608 -0.886 . . . . 10.0 108.608 169.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.644 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -104.17 149.4 17.11 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 109.879 -1.289 . . . . 10.0 109.879 170.002 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.931 HG22 HG22 ' A' ' 54' ' ' THR . 1.5 mt -146.75 56.89 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 N-CA-C 107.251 -1.388 . . . . 10.0 107.251 -176.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mm -86.35 135.6 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.09 -0.707 . . . . 10.0 109.09 -169.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -103.23 115.76 31.18 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.249 1.82 . . . . 10.0 107.126 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -96.4 115.01 26.74 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.721 -1.585 . . . . 10.0 106.721 175.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -122.79 151.46 41.62 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 119.321 0.964 . . . . 10.0 112.699 172.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.6 tt0 -139.6 95.83 2.98 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.148 1.379 . . . . 10.0 108.733 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 68.6 tttt -143.2 83.42 1.79 Allowed 'General case' 0 N--CA 1.426 -1.626 0 C-N-CA 124.15 0.98 . . . . 10.0 109.3 178.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -157.66 170.14 23.06 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 102.701 -3.074 . . . . 10.0 102.701 165.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 16.0 t -71.91 -21.1 61.68 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 109.785 -0.45 . . . . 10.0 109.785 171.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 18.2 m-80 -88.05 -2.78 58.81 Favored 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 123.189 0.596 . . . . 10.0 111.062 -175.363 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.62 49.17 22.0 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-O 118.91 -0.939 . . . . 10.0 114.621 -176.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -68.57 116.33 4.36 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 107.3 -1.846 . . . . 10.0 107.3 169.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.8 t -79.37 99.94 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 N-CA-C 104.272 -2.492 . . . . 10.0 104.272 169.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -92.08 112.03 23.8 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 175.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -101.73 102.73 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.908 0 C-N-CA 126.631 1.972 . . . . 10.0 105.98 -174.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.1 p90 -125.14 160.76 28.37 Favored 'General case' 0 C--N 1.339 0.126 0 N-CA-C 112.683 0.623 . . . . 10.0 112.683 177.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.28 -157.64 27.38 Favored Glycine 0 N--CA 1.449 -0.44 0 N-CA-C 107.927 -2.069 . . . . 10.0 107.927 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -143.48 127.96 17.96 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 109.613 -0.514 . . . . 10.0 109.613 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.644 HG22 ' CA ' ' B' ' 16' ' ' GLY . 3.4 pt -90.14 139.84 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 N-CA-C 106.611 -1.626 . . . . 10.0 106.611 166.032 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.0 142.34 50.42 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 123.8 0.688 . . . . 10.0 109.437 171.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.98 -4.64 25.65 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.221 -0.766 . . . . 10.0 112.888 178.196 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -60.44 176.8 0.33 Allowed 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 118.676 1.238 . . . . 10.0 110.918 170.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.3 t -109.65 164.35 12.62 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 105.406 -2.072 . . . . 10.0 105.406 165.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -52.72 163.09 0.5 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.863 0.865 . . . . 10.0 112.974 -169.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.74 -171.59 47.26 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 123.745 0.688 . . . . 10.0 112.297 169.128 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -71.5 144.39 49.66 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.624 1.969 . . . . 10.0 110.961 -177.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -148.48 138.59 22.44 Favored 'General case' 0 C--N 1.342 0.244 0 N-CA-C 113.638 0.977 . . . . 10.0 113.638 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.736 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -20.26 120.87 0.01 OUTLIER Glycine 0 C--N 1.341 0.841 0 C-N-CA 129.134 3.254 . . . . 10.0 115.084 165.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.27 108.09 4.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 119.518 1.659 . . . . 10.0 109.827 168.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.559 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 2.0 m80 -139.5 179.88 6.3 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.607 0.718 . . . . 10.0 112.288 177.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 76.1 t -112.43 128.33 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 C-N-CA 127.173 2.189 . . . . 10.0 106.368 169.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 67.0 m-70 -109.42 138.42 45.8 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 125.589 1.555 . . . . 10.0 107.299 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -53.76 -57.73 9.79 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 124.189 0.996 . . . . 10.0 111.844 -169.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -80.06 135.2 36.29 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 118.109 -1.437 . . . . 10.0 109.59 -177.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.86 -19.76 79.56 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 109.827 -1.309 . . . . 10.0 109.827 168.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t0 -39.57 148.63 0.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 125.008 1.323 . . . . 10.0 112.48 175.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -153.88 20.06 0.52 Allowed 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.424 -1.262 . . . . 10.0 113.214 174.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.595 HG23 ' CG2' ' A' ' 17' ' ' ILE . 1.8 m -52.74 -38.04 60.27 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 119.389 0.995 . . . . 10.0 111.978 -171.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.41 -22.87 47.12 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.025 0.93 . . . . 10.0 113.007 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 96.05 111.39 2.65 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.056 -1.218 . . . . 10.0 110.056 -169.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.8 m 34.1 51.73 0.43 Allowed 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 127.816 2.446 . . . . 10.0 115.515 170.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.97 -46.18 0.05 Allowed 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 123.423 0.689 . . . . 10.0 110.032 173.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.8 t -57.09 -26.69 60.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.546 0.738 . . . . 10.0 111.333 -178.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.02 -32.52 0.09 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.032 2.133 . . . . 10.0 112.958 167.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.59 162.66 15.91 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 108.72 -1.752 . . . . 10.0 108.72 173.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . 0.443 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 44.5 Cg_endo -73.94 -134.05 0.01 OUTLIER 'Trans proline' 0 N--CA 1.437 -1.822 0 N-CA-C 103.986 -3.121 . . . . 10.0 103.986 165.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.412 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 16.4 m170 -110.18 40.18 2.0 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 120.322 -1.486 . . . . 10.0 109.42 -177.301 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . 0.443 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 0.0 OUTLIER -78.04 57.36 1.77 Allowed 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.061 0.846 . . . . 10.0 112.494 -179.506 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -54.38 167.04 0.61 Allowed Pre-proline 0 CA--C 1.541 0.597 0 C-N-CA 129.782 3.233 . . . . 10.0 112.175 173.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -93.87 19.53 0.76 Allowed 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.738 2.292 . . . . 10.0 111.744 -173.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -144.48 48.73 1.34 Allowed 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.156 1.383 . . . . 10.0 107.444 -171.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.3 p -40.61 107.17 0.07 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 126.716 2.006 . . . . 10.0 112.03 -169.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 45.3 mtp180 -147.56 177.96 8.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 104.98 -2.23 . . . . 10.0 104.98 -175.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -73.41 143.09 46.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 117.395 -1.722 . . . . 10.0 110.257 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.5 t60 -52.53 116.96 2.54 Favored 'General case' 0 CA--C 1.519 -0.216 0 N-CA-C 108.014 -1.106 . . . . 10.0 108.014 167.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.07 -178.84 22.69 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 106.659 -2.576 . . . . 10.0 106.659 178.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -151.77 -148.34 4.8 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 -174.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -65.58 -0.13 3.43 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 CA-C-N 119.386 1.593 . . . . 10.0 110.591 167.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -87.86 -27.17 22.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 118.798 0.726 . . . . 10.0 109.784 172.018 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -115.05 164.69 13.81 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.71 0.766 . . . . 10.0 111.315 -169.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -96.12 -9.0 31.78 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 124.855 1.262 . . . . 10.0 109.216 168.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 50.0 mm-40 -78.2 -81.32 0.1 Allowed 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 124.874 1.269 . . . . 10.0 109.953 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? 59.76 175.69 0.08 Allowed 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 114.634 -1.166 . . . . 10.0 110.722 -167.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -102.43 -59.81 1.64 Allowed 'General case' 0 CA--C 1.529 0.142 0 O-C-N 121.468 -0.77 . . . . 10.0 110.443 168.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.1 p -157.41 -55.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.146 0 C-N-CA 122.991 0.516 . . . . 10.0 109.698 -178.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.19 50.47 0.69 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.104 -1.598 . . . . 10.0 109.104 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -76.22 97.25 4.1 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 169.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 18.7 mt -75.26 -31.22 60.71 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 102.46 -95.94 1.35 Allowed Glycine 0 N--CA 1.438 -1.193 0 N-CA-C 108.063 -2.015 . . . . 10.0 108.063 171.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -135.72 137.0 41.28 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 112.115 0.413 . . . . 10.0 112.115 -168.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.0 m -119.46 143.83 29.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 108.423 -0.955 . . . . 10.0 108.423 168.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.06 134.75 34.55 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.828 1.651 . . . . 10.0 109.473 -178.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.43 134.38 49.67 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.721 1.208 . . . . 10.0 111.515 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -63.6 169.8 3.67 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.893 -0.78 . . . . 10.0 108.893 165.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.01 -25.48 30.43 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.592 1.157 . . . . 10.0 111.79 175.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -75.55 -11.06 59.95 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.838 0.351 . . . . 10.0 110.286 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.66 12.07 75.87 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 110.138 -1.185 . . . . 10.0 110.138 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.0 t -85.45 107.87 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 106.37 -1.715 . . . . 10.0 106.37 175.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.65 119.5 39.47 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 107.898 -1.149 . . . . 10.0 107.898 168.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -78.41 131.01 36.76 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.727 2.011 . . . . 10.0 108.432 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 38.6 t -117.65 131.46 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 C-N-CA 126.671 1.988 . . . . 10.0 106.64 -179.318 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 m -158.47 68.06 0.47 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 125.33 1.452 . . . . 10.0 109.196 170.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.1 mt -107.38 166.13 4.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 124.632 1.173 . . . . 10.0 108.283 -176.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.8 tt0 -152.68 125.27 8.28 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.714 1.606 . . . . 10.0 109.415 -169.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -140.29 136.24 33.08 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 170.222 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 68.5 p -105.4 60.33 0.67 Allowed 'General case' 0 N--CA 1.457 -0.124 0 N-CA-C 107.003 -1.48 . . . . 10.0 107.003 174.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 99.9 t -127.92 -56.71 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -177.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.504 ' CD1' ' H ' ' B' ' 104' ' ' ILE 0.301 0.0 OUTLIER -81.31 173.18 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 124.378 1.071 . . . . 10.0 112.226 170.555 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.9 m -147.65 171.35 15.75 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.229 -0.919 . . . . 10.0 108.744 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 61.1 mt -105.81 -18.65 13.99 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 124.796 1.238 . . . . 10.0 110.343 175.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 73.0 m -156.99 157.78 35.35 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 125.269 1.427 . . . . 10.0 107.243 174.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 129.47 -71.8 0.49 Allowed Glycine 0 C--N 1.334 0.428 0 N-CA-C 108.818 -1.713 . . . . 10.0 108.818 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -160.48 -49.97 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 125.981 1.712 . . . . 10.0 107.197 176.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -80.46 40.0 0.48 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.122 0.969 . . . . 10.0 110.205 -176.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 43.3 t -75.25 88.26 2.51 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 126.914 2.086 . . . . 10.0 108.862 -172.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 4.6 pt -78.35 45.76 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 O-C-N 121.349 -0.845 . . . . 10.0 112.618 -176.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . 0.487 ' CG2' ' HA3' ' A' ' 114' ' ' GLY . 1.3 mp -72.71 -63.83 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 O-C-N 121.599 -0.688 . . . . 10.0 110.299 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.76 48.71 3.54 Favored Glycine 0 CA--C 1.532 1.105 0 O-C-N 120.744 -1.223 . . . . 10.0 112.458 -178.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.04 166.17 10.81 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 127.064 2.146 . . . . 10.0 106.985 172.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -121.03 136.75 54.91 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.113 -1.069 . . . . 10.0 108.113 174.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.3 mp -103.07 147.3 27.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 173.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.5 t -123.69 134.82 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 106.884 -1.525 . . . . 10.0 106.884 174.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.2 p -101.29 121.29 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 169.111 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.736 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 9.6 m-70 -101.3 154.08 19.09 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 115.677 1.732 . . . . 10.0 115.677 -169.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -38.49 -61.03 0.74 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 128.715 2.806 . . . . 10.0 111.124 171.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 66.0 mttt -117.0 175.3 5.65 Favored 'General case' 0 CA--C 1.517 -0.322 0 C-N-CA 124.973 1.309 . . . . 10.0 109.916 -173.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.3 140.11 35.02 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 108.131 -1.062 . . . . 10.0 108.131 174.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.559 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -77.81 160.85 28.08 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 122.077 0.941 . . . . 10.0 111.592 170.477 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -74.78 -27.68 60.42 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 113.804 -1.544 . . . . 10.0 109.863 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 126' ' ' LEU . 3.9 mm? 61.05 63.29 1.28 Allowed 'General case' 0 CA--C 1.521 -0.149 0 C-N-CA 125.711 1.605 . . . . 10.0 107.782 -167.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 89.74 -52.49 3.64 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.299 168.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.8 pttp -78.62 55.71 1.7 Allowed 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.315 1.046 . . . . 10.0 112.421 -171.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.36 -34.22 4.85 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 125.387 1.47 . . . . 10.0 110.379 169.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 73.71 35.01 55.71 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.345 -1.102 . . . . 10.0 110.345 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -125.75 156.38 39.51 Favored 'General case' 0 CA--C 1.506 -0.717 0 N-CA-C 105.418 -2.068 . . . . 10.0 105.418 169.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.4 tt0 -49.23 -48.86 45.24 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 107.555 -1.276 . . . . 10.0 107.555 169.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -55.95 -41.73 75.14 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 114.648 -1.16 . . . . 10.0 111.959 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 23.2 p -58.61 -42.41 88.09 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 120.368 1.44 . . . . 10.0 111.183 178.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.9 t -78.5 -16.1 57.88 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 113.079 0.77 . . . . 10.0 113.079 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -102.21 -46.01 4.96 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 126.129 1.772 . . . . 10.0 112.889 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.412 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 29.4 p -127.07 -12.33 5.82 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.375 -0.828 . . . . 10.0 112.669 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 1.68 82.64 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-O 118.234 -1.314 . . . . 10.0 112.65 -169.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 69.24 29.71 4.51 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 119.95 1.875 . . . . 10.0 111.907 172.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.81 0.9 11.77 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 124.522 1.129 . . . . 10.0 112.552 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.93 -163.09 53.19 Favored Glycine 0 N--CA 1.445 -0.744 0 O-C-N 120.948 -1.095 . . . . 10.0 111.439 173.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -59.3 136.61 58.02 Favored 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.585 1.154 . . . . 10.0 114.005 -166.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -64.43 75.52 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.227 1.411 . . . . 10.0 109.822 168.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 47.8 mt -54.51 -37.88 65.87 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 118.655 0.661 . . . . 10.0 111.548 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.86 158.84 35.88 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -177.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -151.63 167.6 27.63 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.127 0.571 . . . . 10.0 109.543 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.26 147.43 16.92 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-O 118.446 -1.197 . . . . 10.0 110.361 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.2 t -96.64 127.5 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 N-CA-C 104.358 -2.46 . . . . 10.0 104.358 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.41 HG22 ' HA ' ' B' ' 113' ' ' ILE . 18.9 mt -70.16 158.02 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.055 0.843 . . . . 10.0 109.936 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -155.57 145.63 12.74 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.201 -1.16 . . . . 10.0 110.201 -172.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 98.6 mt -57.41 131.71 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 C-N-CA 126.335 1.854 . . . . 10.0 109.612 176.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -110.05 -44.37 3.79 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 118.85 0.75 . . . . 10.0 111.942 173.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.584 -2.151 . . . . 10.0 110.908 176.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.859 0 CA-C-O 118.698 -0.668 . . . . 10.0 109.276 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.8 t -165.11 -45.85 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.349 1.06 . . . . 10.0 109.919 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 20.0 ttmm -104.27 138.8 40.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.223 -1.769 . . . . 10.0 106.223 168.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.22 163.4 37.12 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 107.234 -1.395 . . . . 10.0 107.234 169.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -137.62 166.09 25.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-N 118.286 0.494 . . . . 10.0 110.171 -177.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.89 106.89 4.93 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.147 -1.057 . . . . 10.0 108.147 167.332 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.4 m -80.94 101.02 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 168.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mt -78.88 138.73 38.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.707 -0.849 . . . . 10.0 108.707 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.93 160.94 34.09 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.61 -0.885 . . . . 10.0 108.61 168.243 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.45 -60.73 0.03 OUTLIER Glycine 0 C--O 1.23 -0.144 0 N-CA-C 110.592 -1.003 . . . . 10.0 110.592 173.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -74.71 -45.14 46.25 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 139.53 -69.45 0.48 Allowed Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 114.731 -1.122 . . . . 10.0 111.331 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -55.58 -39.28 91.98 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 122.236 1.957 . . . . 10.0 111.062 -179.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.731 HG13 HD12 ' A' ' 38' ' ' LEU . 21.0 t -63.26 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 C-N-CA 129.064 2.946 . . . . 10.0 109.094 178.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -95.45 47.75 1.13 Allowed 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.92 1.288 . . . . 10.0 110.173 -167.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.407 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -58.77 150.73 34.87 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 121.142 -0.551 . . . . 10.0 114.041 -168.146 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.727 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.4 mt -136.63 89.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 106.31 -1.737 . . . . 10.0 106.31 -171.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.9 mm -96.24 136.74 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.139 0.576 . . . . 10.0 109.455 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -122.7 111.45 16.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 126.027 1.731 . . . . 10.0 107.522 172.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -92.85 118.74 31.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.2 1.4 . . . . 10.0 107.343 175.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -124.0 117.84 25.66 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 123.62 0.575 . . . . 10.0 111.161 175.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -101.13 102.57 13.53 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 105.876 -1.898 . . . . 10.0 105.876 168.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 2.3 mmmp? -54.32 -53.6 51.65 Favored 'General case' 0 C--N 1.338 0.108 0 C-N-CA 124.738 1.215 . . . . 10.0 110.821 -169.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.67 178.45 6.99 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 104.798 -2.297 . . . . 10.0 104.798 169.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 t -70.04 -20.37 63.25 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 110.311 -0.255 . . . . 10.0 110.311 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.8 m-80 -79.5 -21.88 44.72 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 123.742 0.817 . . . . 10.0 109.68 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.47 149.64 33.9 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.096 -0.802 . . . . 10.0 111.096 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -66.82 159.81 49.7 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 122.353 2.035 . . . . 10.0 107.597 168.176 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.29 96.33 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 105.93 -1.878 . . . . 10.0 105.93 174.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.9 mtpm? -71.98 100.6 2.51 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 106.42 -1.696 . . . . 10.0 106.42 172.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.54 97.7 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 125.52 1.528 . . . . 10.0 107.28 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 14.2 p90 -108.79 169.06 8.9 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 121.017 0.437 . . . . 10.0 110.606 169.299 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.57 -168.43 36.74 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.804 -0.518 . . . . 10.0 111.804 173.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 11.7 m -147.79 122.84 10.11 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.753 -0.223 . . . . 10.0 111.565 -177.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.436 ' HB ' HD11 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -99.53 95.42 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 C-N-CA 126.64 1.976 . . . . 10.0 107.449 169.471 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -106.0 102.45 11.88 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.009 0.524 . . . . 10.0 110.243 176.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.61 29.5 0.06 OUTLIER Glycine 0 C--N 1.334 0.463 0 CA-C-O 118.819 -0.989 . . . . 10.0 114.847 171.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.731 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -126.23 175.87 7.49 Favored 'General case' 0 C--O 1.223 -0.302 0 CA-C-N 118.329 1.065 . . . . 10.0 109.022 -177.827 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.3 t -75.52 160.42 30.2 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.933 0.788 . . . . 10.0 109.325 171.437 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -62.24 -176.4 0.1 Allowed 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.029 1.332 . . . . 10.0 112.74 -176.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.9 -177.65 46.48 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.059 -0.816 . . . . 10.0 111.059 171.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.27 150.29 46.54 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.904 0.882 . . . . 10.0 109.216 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 -144.55 149.05 35.2 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.359 0.664 . . . . 10.0 112.484 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.653 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.09 121.77 0.11 Allowed Glycine 0 C--N 1.34 0.774 0 C-N-CA 128.34 2.876 . . . . 10.0 112.215 165.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -149.56 107.53 3.72 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 120.045 1.923 . . . . 10.0 113.412 168.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.477 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -149.29 168.78 22.38 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 122.18 0.99 . . . . 10.0 112.747 177.777 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 43.5 t -95.36 143.34 12.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 111.186 -2.734 . . . . 10.0 105.964 168.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -125.58 152.24 45.36 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 125.022 1.329 . . . . 10.0 108.889 177.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -62.35 -55.82 24.34 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 123.621 0.768 . . . . 10.0 109.87 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -76.55 104.89 7.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.154 -1.795 . . . . 10.0 106.154 -170.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.57 -36.54 92.59 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 108.844 -1.702 . . . . 10.0 108.844 173.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -54.11 160.99 1.39 Allowed 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 122.735 1.255 . . . . 10.0 113.254 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.425 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -156.33 22.39 0.36 Allowed 'General case' 0 N--CA 1.438 -1.03 0 CA-C-N 114.206 -1.361 . . . . 10.0 114.506 -172.027 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.559 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.0 OUTLIER -48.94 -36.95 18.59 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.366 1.066 . . . . 10.0 111.387 174.529 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.6 -18.14 57.12 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.556 1.142 . . . . 10.0 112.854 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.52 84.15 0.57 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 123.686 0.66 . . . . 10.0 112.03 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.1 m 47.13 35.51 3.61 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.152 1.781 . . . . 10.0 112.378 174.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.5 m -129.44 -52.39 1.17 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 124.176 0.991 . . . . 10.0 108.396 -169.106 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.1 t -104.32 24.38 11.65 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.525 0.73 . . . . 10.0 109.394 178.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.29 46.51 0.62 Allowed 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 123.607 0.763 . . . . 10.0 110.68 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.15 100.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.1 0 C-N-CA 126.263 1.887 . . . . 10.0 113.919 168.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -68.61 73.79 0.89 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 123.523 2.815 . . . . 10.0 113.086 179.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 20.0 m170 60.64 44.24 11.67 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.365 3.466 . . . . 10.0 110.6 172.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -68.96 68.84 0.17 Allowed 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.917 1.287 . . . . 10.0 111.659 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -84.77 154.97 61.84 Favored Pre-proline 0 C--N 1.322 -0.621 0 C-N-CA 125.512 1.525 . . . . 10.0 109.593 177.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.23 -44.19 5.24 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 122.433 2.089 . . . . 10.0 111.564 178.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.14 53.55 0.99 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.753 0.821 . . . . 10.0 111.021 -178.113 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.6 t -47.34 114.23 0.83 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.086 0.954 . . . . 10.0 111.009 -169.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 54.6 mtt180 -151.69 178.0 9.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 105.458 -2.053 . . . . 10.0 105.458 -169.645 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.72 141.47 37.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 118.614 -1.235 . . . . 10.0 108.892 -177.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -44.98 118.04 1.53 Allowed 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 121.002 -0.279 . . . . 10.0 111.514 168.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.54 -141.64 4.32 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.461 -1.055 . . . . 10.0 110.461 179.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.32 -175.49 33.4 Favored Glycine 0 C--O 1.223 -0.591 0 CA-C-N 118.426 1.113 . . . . 10.0 113.562 -173.539 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -66.58 7.6 0.39 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.176 1.917 . . . . 10.0 111.09 168.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.7 mmtt -96.57 -22.47 17.04 Favored 'General case' 0 N--CA 1.435 -1.183 0 C-N-CA 124.422 1.089 . . . . 10.0 108.407 173.403 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -126.56 -172.61 2.67 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 112.476 0.547 . . . . 10.0 112.476 -168.301 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -115.1 -6.21 12.48 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.967 1.307 . . . . 10.0 111.071 -174.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -100.74 -14.34 18.1 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 124.646 1.178 . . . . 10.0 112.143 -178.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -26.09 114.65 0.06 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 125.929 1.691 . . . . 10.0 111.331 167.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -53.62 -53.11 56.53 Favored 'General case' 0 C--O 1.226 -0.14 0 CA-C-O 121.419 0.628 . . . . 10.0 111.718 -167.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.496 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.5 p -165.38 -103.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 104.376 -2.453 . . . . 10.0 104.376 170.192 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.496 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -76.49 59.39 3.31 Favored Glycine 0 CA--C 1.53 1.018 0 CA-C-N 119.098 0.863 . . . . 10.0 112.476 176.664 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -91.11 108.18 19.69 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 103.77 -2.678 . . . . 10.0 103.77 166.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -81.59 -19.9 40.96 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 118.446 0.566 . . . . 10.0 111.34 -172.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 115.03 -92.46 0.59 Allowed Glycine 0 C--O 1.217 -0.937 0 N-CA-C 107.51 -2.236 . . . . 10.0 107.51 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -155.19 159.52 40.18 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.911 -1.144 . . . . 10.0 107.911 -178.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.6 m -126.13 126.6 69.83 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 123.665 0.786 . . . . 10.0 110.283 170.203 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -80.11 124.47 28.79 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 127.025 2.13 . . . . 10.0 111.773 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.82 129.55 49.53 Favored 'General case' 0 C--O 1.234 0.243 0 C-N-CA 126.051 1.74 . . . . 10.0 109.58 170.031 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -64.98 172.14 3.09 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 123.985 0.803 . . . . 10.0 109.958 169.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -48.59 -34.61 11.86 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 126.586 1.954 . . . . 10.0 109.983 173.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -78.99 -6.53 56.55 Favored 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 123.943 0.897 . . . . 10.0 110.146 -172.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.13 21.18 71.23 Favored Glycine 0 C--N 1.339 0.738 0 N-CA-C 110.27 -1.132 . . . . 10.0 110.27 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.5 t -101.79 106.7 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 127.501 2.32 . . . . 10.0 105.266 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.412 ' HB3' HG13 ' A' ' 35' ' ' ILE . . . -101.9 120.39 40.32 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.092 -1.077 . . . . 10.0 108.092 169.391 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -88.77 134.72 33.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 107.475 -1.305 . . . . 10.0 107.475 169.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 90.1 t -109.68 131.78 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 104.705 -2.331 . . . . 10.0 104.705 168.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.9 m -154.79 68.5 0.71 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 124.158 0.983 . . . . 10.0 108.795 174.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -117.22 160.82 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 106.736 -1.579 . . . . 10.0 106.736 -174.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -132.01 123.91 28.25 Favored 'General case' 0 N--CA 1.446 -0.626 0 O-C-N 121.842 -0.536 . . . . 10.0 110.139 168.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -104.47 128.0 52.28 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.783 1.233 . . . . 10.0 109.403 -172.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.9 p -113.42 38.25 2.95 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.047 1.339 . . . . 10.0 110.867 177.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.53 -39.73 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 C-N-CA 123.644 0.778 . . . . 10.0 111.47 173.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.433 ' C ' HD12 ' A' ' 104' ' ' ILE 0.369 0.8 OUTLIER -90.27 175.66 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 119.566 1.076 . . . . 10.0 112.106 170.173 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 83.7 p -146.39 158.74 43.92 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.402 -0.811 . . . . 10.0 109.107 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.8 mp -89.82 -26.56 20.49 Favored 'General case' 0 N--CA 1.457 -0.077 0 C-N-CA 122.756 0.422 . . . . 10.0 110.493 170.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -155.9 46.51 0.47 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.188 0.449 . . . . 10.0 110.853 -172.035 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -151.92 70.44 0.3 Allowed Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.549 -1.82 . . . . 10.0 108.549 -178.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.8 t70 73.94 -52.32 0.69 Allowed 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 128.711 2.804 . . . . 10.0 111.21 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -75.3 -36.7 61.09 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -167.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.5 t 37.79 75.48 0.07 Allowed 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 125.694 1.598 . . . . 10.0 113.731 166.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.8 pt -61.98 -9.37 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 N-CA-C 114.133 1.16 . . . . 10.0 114.133 -177.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 39.1 mm -45.28 129.45 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 O-C-N 121.066 -1.022 . . . . 10.0 110.263 170.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.74 -3.41 86.89 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.5 -1.167 . . . . 10.0 114.116 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -78.26 175.67 9.99 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 119.101 1.451 . . . . 10.0 108.04 168.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -123.4 135.2 54.01 Favored 'General case' 0 C--N 1.338 0.105 0 C-N-CA 123.308 0.643 . . . . 10.0 110.151 171.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.542 HD21 HD11 ' A' ' 149' ' ' ILE . 3.6 mm? -89.53 147.22 24.09 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 107.64 -1.245 . . . . 10.0 107.64 168.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.4 t -129.27 131.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.2 -1.407 . . . . 10.0 107.2 169.254 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -102.97 133.18 47.46 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 N-CA-C 105.787 -1.931 . . . . 10.0 105.787 168.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.653 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.5 m-70 -111.52 157.67 20.07 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 114.839 1.422 . . . . 10.0 114.839 -170.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.574 ' HA ' HD22 ' A' ' 144' ' ' LEU . 52.0 tt0 -43.52 -52.46 6.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 128.598 2.759 . . . . 10.0 110.332 176.274 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -118.21 165.28 14.0 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 123.584 0.754 . . . . 10.0 110.915 -169.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -58.58 147.16 33.27 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.002 -0.999 . . . . 10.0 109.698 169.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.532 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 26.1 m-20 -79.49 130.56 35.52 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 124.459 1.104 . . . . 10.0 109.829 171.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.51 -16.66 59.59 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 123.876 0.735 . . . . 10.0 111.014 173.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.2 mt 55.6 49.74 15.89 Favored 'General case' 0 C--N 1.339 0.14 0 CA-C-O 122.251 1.024 . . . . 10.0 109.386 -173.105 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.52 -29.49 9.61 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.069 -1.423 . . . . 10.0 112.399 169.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt -77.06 9.94 2.68 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.731 1.011 . . . . 10.0 113.731 -168.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.07 -19.98 74.36 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 124.378 0.99 . . . . 10.0 111.86 172.469 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.79 42.51 68.9 Favored Glycine 0 C--N 1.343 0.944 0 N-CA-C 111.031 -0.828 . . . . 10.0 111.031 -176.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -131.51 159.09 39.16 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 106.139 -1.8 . . . . 10.0 106.139 177.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -50.68 -49.0 58.36 Favored 'General case' 0 N--CA 1.442 -0.841 0 CA-C-N 114.522 -1.217 . . . . 10.0 107.82 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -63.28 -33.67 76.02 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 115.376 -0.829 . . . . 10.0 112.41 175.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.9 p -59.43 -43.23 93.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 120.153 -1.592 . . . . 10.0 111.06 174.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -81.47 -21.04 39.02 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 122.973 0.171 . . . . 10.0 111.187 -174.115 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 15.6 mmtp -89.11 -49.3 6.83 Favored 'General case' 0 C--N 1.339 0.129 0 C-N-CA 124.781 1.232 . . . . 10.0 113.099 179.223 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 34.7 p -128.81 -18.08 3.89 Favored 'General case' 0 C--O 1.227 -0.125 0 N-CA-C 114.734 1.383 . . . . 10.0 114.734 177.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 106.55 26.26 5.97 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 119.452 1.024 . . . . 10.0 112.96 -176.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 58.64 21.6 8.93 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 118.349 1.074 . . . . 10.0 111.033 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.4 -5.36 35.93 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 123.965 0.906 . . . . 10.0 111.8 -169.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.84 -165.58 53.66 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.808 -1.317 . . . . 10.0 109.808 168.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 60.2 m -52.01 129.62 27.67 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-O 121.362 0.601 . . . . 10.0 110.037 -171.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.71 72.95 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.004 1.322 . . . . 10.0 110.414 171.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.574 HD22 ' HA ' ' A' ' 121' ' ' GLU . 6.5 tp -47.75 -35.2 9.48 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 128.202 2.601 . . . . 10.0 113.122 -172.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.93 157.09 25.87 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.73 -0.841 . . . . 10.0 108.73 172.549 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -145.31 163.32 34.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.047 -0.524 . . . . 10.0 109.714 177.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.18 147.32 15.39 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.495 -1.442 . . . . 10.0 109.495 -174.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 69.9 t -105.88 131.88 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 C-N-CA 126.142 1.777 . . . . 10.0 106.771 -169.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.542 HD11 HD21 ' A' ' 117' ' ' LEU . 8.2 mt -77.14 117.62 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.735 0 CA-C-N 117.884 0.311 . . . . 10.0 110.398 -174.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.45 158.87 14.1 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.572 1.082 . . . . 10.0 112.036 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.1 mt -64.74 142.56 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 125.309 1.444 . . . . 10.0 109.803 177.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.77 165.11 28.16 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.575 -1.269 . . . . 10.0 107.575 167.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.12 0 N-CA-C 105.023 -2.214 . . . . 10.0 105.023 167.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.551 0 N-CA-C 106.815 -1.55 . . . . 10.0 106.815 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.1 t -94.9 -35.1 12.17 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.558 1.143 . . . . 10.0 109.539 175.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -134.23 160.32 38.22 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 124.486 1.114 . . . . 10.0 110.467 -171.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.99 166.18 34.41 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 169.161 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -128.4 175.78 9.25 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.263 0 N-CA-C 107.739 -1.208 . . . . 10.0 107.739 171.175 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -143.04 122.61 13.24 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 124.064 0.946 . . . . 10.0 109.076 168.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.425 HG21 ' HB3' ' A' ' 53' ' ' ASN . 1.5 m -102.65 100.41 10.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 C-N-CA 124.482 1.113 . . . . 10.0 110.43 174.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.442 HD12 ' N ' ' B' ' 8' ' ' LEU . 5.7 mp -89.65 130.41 35.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.742 0.817 . . . . 10.0 109.188 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -144.62 162.68 36.04 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 119.529 1.059 . . . . 10.0 108.423 170.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -167.22 -61.37 0.03 OUTLIER Glycine 0 C--O 1.229 -0.208 0 CA-C-N 115.331 -0.85 . . . . 10.0 112.057 171.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -73.81 -44.64 55.19 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 106.544 -1.65 . . . . 10.0 106.544 -171.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.07 -65.57 0.59 Allowed Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 113.614 -1.63 . . . . 10.0 110.404 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -55.44 -38.75 93.67 Favored 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 122.644 2.23 . . . . 10.0 111.148 171.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 98.6 t -67.91 107.47 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 N-CA-C 108.058 -1.09 . . . . 10.0 108.058 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.04 107.7 10.67 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 125.662 1.585 . . . . 10.0 107.266 172.676 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.693 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -95.67 136.57 12.94 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.181 -0.768 . . . . 10.0 111.181 173.194 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.559 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.9 mt -140.75 89.58 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -102.39 149.77 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.087 0 C-N-CA 124.819 1.248 . . . . 10.0 110.753 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -119.57 133.39 55.68 Favored 'General case' 0 C--O 1.232 0.155 0 C-N-CA 127.639 2.376 . . . . 10.0 107.417 174.148 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -119.32 113.62 21.11 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 171.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -110.74 137.46 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 118.714 0.688 . . . . 10.0 111.478 167.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -96.93 113.92 25.5 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.655 -1.98 . . . . 10.0 105.655 167.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.7 tttt -57.64 -51.63 68.72 Favored 'General case' 0 N--CA 1.443 -0.775 0 C-N-CA 125.804 1.642 . . . . 10.0 109.672 -175.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 74.8 mt-10 -126.39 -139.11 0.27 Allowed 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 105.392 -2.077 . . . . 10.0 105.392 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 22.8 t -107.18 -12.05 15.47 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 120.12 1.327 . . . . 10.0 110.838 168.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -130.4 5.8 4.81 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 124.071 0.948 . . . . 10.0 110.901 176.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.01 148.57 43.09 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 108.164 -1.974 . . . . 10.0 108.164 171.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -59.59 149.18 83.92 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 122.63 2.22 . . . . 10.0 110.269 -177.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -88.99 108.1 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 105.913 -1.884 . . . . 10.0 105.913 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 40.4 tttt -88.39 116.86 26.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 105.886 -1.894 . . . . 10.0 105.886 168.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 p -92.56 103.22 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -123.28 152.41 41.4 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 112.63 0.604 . . . . 10.0 112.63 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.42 -150.86 22.07 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 106.556 -2.618 . . . . 10.0 106.556 172.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 44.7 t -155.98 154.62 31.38 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 118.86 -1.136 . . . . 10.0 110.733 -176.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.693 HG22 ' HA2' ' B' ' 16' ' ' GLY . 1.7 pt -113.89 141.38 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 114.91 -1.041 . . . . 10.0 109.614 167.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 tttm -118.81 141.28 48.78 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.81 -8.76 31.96 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 119.517 -0.602 . . . . 10.0 113.95 174.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.39 176.7 0.59 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 118.303 1.052 . . . . 10.0 111.601 175.121 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -112.7 154.04 26.75 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 105.656 -1.979 . . . . 10.0 105.656 165.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -48.95 154.38 0.74 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.869 1.267 . . . . 10.0 113.3 -168.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.97 -171.11 22.29 Favored Glycine 0 C--N 1.337 0.61 0 C-N-CA 123.84 0.733 . . . . 10.0 112.212 168.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -73.3 144.13 46.71 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.293 1.437 . . . . 10.0 109.782 -178.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -148.03 150.03 33.2 Favored 'General case' 0 C--N 1.34 0.187 0 N-CA-C 113.504 0.928 . . . . 10.0 113.504 -177.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.714 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -29.73 119.87 0.08 OUTLIER Glycine 0 C--N 1.339 0.731 0 C-N-CA 128.409 2.909 . . . . 10.0 113.847 165.088 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -153.77 110.92 3.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 118.72 1.26 . . . . 10.0 111.029 168.493 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -146.86 175.01 10.97 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-O 121.436 0.636 . . . . 10.0 110.382 177.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.9 m -103.1 155.62 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 104.903 -2.258 . . . . 10.0 104.903 166.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -138.58 154.98 48.73 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.845 1.258 . . . . 10.0 109.835 -173.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.7 tt0 -57.48 -64.62 0.83 Allowed 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.387 2.275 . . . . 10.0 112.387 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -77.06 105.92 8.44 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.887 -1.523 . . . . 10.0 106.887 -172.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.15 -23.9 66.61 Favored Glycine 0 CA--C 1.532 1.116 0 N-CA-C 108.995 -1.642 . . . . 10.0 108.995 167.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -46.38 152.43 0.44 Allowed 'General case' 0 N--CA 1.445 -0.699 0 C-N-CA 124.928 1.291 . . . . 10.0 111.682 168.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -152.21 24.46 0.63 Allowed 'General case' 0 N--CA 1.439 -1.007 0 CA-C-N 114.629 -1.169 . . . . 10.0 112.49 168.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.727 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -60.6 -25.41 66.22 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 121.783 -0.573 . . . . 10.0 110.292 176.878 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.57 -17.18 60.13 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 123.632 0.773 . . . . 10.0 111.149 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.05 73.71 0.9 Allowed Glycine 0 CA--C 1.527 0.795 0 N-CA-C 110.709 -0.956 . . . . 10.0 110.709 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 53.72 32.5 14.83 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.092 0.957 . . . . 10.0 112.534 170.201 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -122.4 -48.63 2.07 Favored 'General case' 0 N--CA 1.441 -0.923 0 C-N-CA 124.943 1.297 . . . . 10.0 108.317 -169.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.8 t -125.37 48.94 1.96 Allowed 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.58 -0.896 . . . . 10.0 108.58 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.81 50.62 0.72 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.603 0.761 . . . . 10.0 110.265 176.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 69.78 120.07 0.04 OUTLIER Glycine 0 CA--C 1.537 1.42 0 C-N-CA 124.947 1.261 . . . . 10.0 113.093 173.173 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -80.98 50.77 3.69 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 122.729 2.286 . . . . 10.0 112.817 -173.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.5 m170 62.33 100.33 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 127.966 2.507 . . . . 10.0 109.631 -175.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -27.38 -47.01 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 128.279 2.632 . . . . 10.0 115.725 -175.19 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 19.39 76.75 0.19 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 128.047 2.539 . . . . 10.0 116.011 -174.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.26 -50.63 2.61 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 121.128 1.218 . . . . 10.0 109.576 172.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 23.3 tp -77.58 75.9 4.12 Favored 'General case' 0 N--CA 1.453 -0.285 0 O-C-N 121.677 -0.64 . . . . 10.0 109.322 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.2 t -17.3 90.25 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 128.051 2.54 . . . . 10.0 114.241 174.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -135.34 164.77 26.99 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 126.721 2.008 . . . . 10.0 107.981 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -105.62 95.33 5.74 Favored 'General case' 0 C--O 1.224 -0.247 0 C-N-CA 122.897 0.479 . . . . 10.0 109.853 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.523 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 84.6 t60 2.16 94.84 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.406 0 C-N-CA 127.56 2.344 . . . . 10.0 115.254 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -100.91 -144.82 16.06 Favored Glycine 0 C--N 1.316 -0.582 0 N-CA-C 109.836 -1.306 . . . . 10.0 109.836 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.439 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 179.14 -165.82 34.95 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 106.749 -2.54 . . . . 10.0 106.749 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -65.28 7.25 0.31 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 CA-C-N 119.887 1.843 . . . . 10.0 111.169 167.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.439 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.8 mmmt -119.94 1.56 10.95 Favored 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 126.509 1.923 . . . . 10.0 110.775 178.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -143.34 159.68 41.92 Favored 'General case' 0 C--N 1.348 0.533 0 CA-C-N 120.709 1.595 . . . . 10.0 108.92 168.183 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.2 mm-40 -78.73 -22.0 47.2 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.588 -0.893 . . . . 10.0 108.588 177.09 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -87.14 34.13 0.68 Allowed 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.433 1.093 . . . . 10.0 111.713 -170.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.0 mtm180 -49.12 142.27 7.13 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.591 1.156 . . . . 10.0 108.254 169.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.523 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 24.4 m170 -75.74 -50.35 15.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.639 0.654 . . . . 10.0 110.367 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER 175.46 -19.88 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 126.949 2.1 . . . . 10.0 111.675 174.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -161.46 68.98 0.23 Allowed Glycine 0 C--N 1.338 0.642 0 N-CA-C 108.469 -1.852 . . . . 10.0 108.469 -169.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -127.58 94.79 4.06 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -168.342 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 7.1 mp -64.5 -35.9 82.44 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.468 -0.568 . . . . 10.0 109.468 -172.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.74 -88.14 0.41 Allowed Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 107.19 -2.364 . . . . 10.0 107.19 176.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . 0.41 ' ND2' ' H ' ' B' ' 124' ' ' ASP . 7.6 m120 -149.82 141.46 23.54 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.731 -1.211 . . . . 10.0 107.731 -172.227 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.5 m -116.52 135.5 56.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 118.443 0.565 . . . . 10.0 110.425 169.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 19.8 m -94.92 100.9 12.68 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 128.173 2.589 . . . . 10.0 110.584 -170.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.92 131.23 35.8 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.066 0.547 . . . . 10.0 110.645 174.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -64.92 168.92 5.74 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.919 1.688 . . . . 10.0 109.139 167.438 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.15 -32.03 33.93 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.488 1.115 . . . . 10.0 111.039 175.77 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -80.68 -2.0 44.88 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 124.445 1.098 . . . . 10.0 110.794 -176.372 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.83 82.72 Favored Glycine 0 C--N 1.34 0.762 0 O-C-N 121.158 -0.964 . . . . 10.0 110.86 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 62.8 t -90.37 104.12 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 106.069 -1.826 . . . . 10.0 106.069 176.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.628 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -102.61 122.68 44.88 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 107.61 -1.256 . . . . 10.0 107.61 169.531 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -89.7 124.75 34.88 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.305 1.042 . . . . 10.0 108.25 174.526 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 51.9 t -110.07 131.53 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.937 1.695 . . . . 10.0 107.529 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 95.2 p -156.53 60.8 0.55 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.174 0.589 . . . . 10.0 109.901 174.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.49 155.02 5.13 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 -173.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -131.56 142.37 49.9 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.575 0.75 . . . . 10.0 111.067 177.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -140.37 161.8 36.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.552 -1.648 . . . . 10.0 106.552 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 11.1 t -136.98 10.33 3.06 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 125.398 1.479 . . . . 10.0 112.893 175.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.9 p -89.19 -15.46 8.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 120.077 1.308 . . . . 10.0 109.628 174.294 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.29 1.0 OUTLIER -111.79 162.57 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 125.333 1.453 . . . . 10.0 112.05 175.578 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 16.2 m -148.66 147.5 29.0 Favored 'General case' 0 C--N 1.34 0.171 0 C-N-CA 124.087 0.955 . . . . 10.0 109.355 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.45 -21.25 66.2 Favored 'General case' 0 C--O 1.227 -0.113 0 C-N-CA 125.208 1.403 . . . . 10.0 111.35 176.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.7 t -156.73 -172.25 3.98 Favored 'General case' 0 N--CA 1.453 -0.299 0 O-C-N 121.293 -0.879 . . . . 10.0 109.674 171.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 112.45 -89.57 0.53 Allowed Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 107.377 -2.289 . . . . 10.0 107.377 172.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -123.58 -46.94 1.99 Allowed 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 125.232 1.413 . . . . 10.0 109.579 173.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -72.31 -42.91 64.91 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 107.37 -1.344 . . . . 10.0 107.37 -168.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 21.2 t 37.9 75.64 0.07 Allowed 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 127.353 2.261 . . . . 10.0 111.899 168.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 pt -74.29 55.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 C-N-CA 123.834 0.854 . . . . 10.0 111.281 176.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 43.5 mm -108.46 -49.3 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 125.848 1.659 . . . . 10.0 109.956 179.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -90.19 18.68 47.22 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.372 -0.682 . . . . 10.0 113.074 -174.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.7 mtt85 -99.64 179.73 4.45 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.115 1.366 . . . . 10.0 110.556 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -133.87 147.62 51.18 Favored 'General case' 0 CA--C 1.507 -0.688 0 C-N-CA 125.789 1.636 . . . . 10.0 106.726 -175.484 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.436 HD12 ' N ' ' B' ' 117' ' ' LEU . 7.7 mp -113.49 153.81 28.09 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.331 -0.988 . . . . 10.0 108.331 173.129 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.0 t -131.97 130.46 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -97.82 123.92 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.349 -1.723 . . . . 10.0 106.349 169.125 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.714 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.3 m-70 -105.06 155.04 19.35 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 115.857 1.799 . . . . 10.0 115.857 -172.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 59.3 tt0 -44.79 -53.35 7.51 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 128.139 2.576 . . . . 10.0 111.726 175.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -113.08 167.19 10.73 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.952 0.723 . . . . 10.0 112.952 -168.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -70.49 147.28 49.57 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 113.967 -1.469 . . . . 10.0 108.424 170.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.41 ' H ' ' ND2' ' B' ' 86' ' ' ASN . 14.6 m-20 -94.84 131.34 40.82 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -173.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -76.51 -17.42 59.28 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.36 1.064 . . . . 10.0 110.19 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 22.6 mt 57.74 56.6 4.72 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 122.513 1.149 . . . . 10.0 108.969 -179.363 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.1 -40.83 3.06 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 113.745 -1.57 . . . . 10.0 110.722 168.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 30.7 mtmt -79.01 48.99 0.89 Allowed 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.637 1.175 . . . . 10.0 110.81 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -112.07 -9.21 20.73 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 127.203 2.335 . . . . 10.0 112.377 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.7 37.73 43.1 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 123.951 0.786 . . . . 10.0 112.973 176.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 -134.0 157.87 44.97 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 106.359 -1.719 . . . . 10.0 106.359 174.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -54.86 -45.94 74.63 Favored 'General case' 0 N--CA 1.439 -0.999 0 CA-C-O 122.305 1.05 . . . . 10.0 108.207 170.207 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 24.0 tp10 -58.48 -33.83 70.23 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 121.185 -0.947 . . . . 10.0 112.978 173.084 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.0 p -56.51 -42.09 77.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 120.606 1.548 . . . . 10.0 111.074 172.118 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.3 t -82.78 -19.65 37.36 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 118.485 -0.769 . . . . 10.0 112.421 -178.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -90.86 -46.46 8.18 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 124.448 1.099 . . . . 10.0 112.128 -176.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 26.9 p -133.51 -9.26 2.86 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.098 1.147 . . . . 10.0 114.098 176.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.42 23.61 12.31 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 119.289 0.95 . . . . 10.0 112.546 -173.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 61.67 21.83 12.46 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 118.769 1.284 . . . . 10.0 111.248 -176.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.33 -7.76 20.99 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 125.592 1.557 . . . . 10.0 112.285 -171.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.18 -167.97 54.84 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.069 -1.212 . . . . 10.0 110.069 170.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 12.6 t -53.96 129.1 32.94 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 121.819 0.819 . . . . 10.0 110.862 -169.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.45 73.23 0.08 Allowed 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 124.049 0.94 . . . . 10.0 108.961 169.449 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 66.3 mt -47.14 -45.56 22.6 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.868 0.867 . . . . 10.0 111.676 -177.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.24 152.38 27.69 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 108.687 -0.857 . . . . 10.0 108.687 -169.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 17.1 p -161.42 165.26 29.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.855 -0.611 . . . . 10.0 109.485 -172.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.44 163.24 30.22 Favored Glycine 0 C--N 1.331 0.255 0 N-CA-C 110.162 -1.175 . . . . 10.0 110.162 -174.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -101.91 156.05 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 N-CA-C 104.05 -2.574 . . . . 10.0 104.05 169.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 77.9 mt -74.75 -94.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 N-CA-C 109.765 -0.457 . . . . 10.0 109.765 -169.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 112.92 135.95 6.48 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 124.626 1.108 . . . . 10.0 112.049 175.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 70.2 mt -62.48 138.63 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.106 1.363 . . . . 10.0 110.096 179.372 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.87 146.59 49.37 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.434 -1.321 . . . . 10.0 107.434 169.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 . . . . . 0 C--O 1.248 0.99 0 N-CA-C 106.195 -1.779 . . . . 10.0 106.195 169.295 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 t -172.37 -36.44 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.703 1.201 . . . . 10.0 112.077 -179.109 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 48.0 tttt -137.98 134.46 34.9 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 123.267 0.627 . . . . 10.0 110.357 -179.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.5 167.85 26.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.012 1.325 . . . . 10.0 108.849 -175.21 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -126.89 164.15 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 118.746 0.703 . . . . 10.0 110.519 170.071 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.74 112.31 11.27 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.285 1.434 . . . . 10.0 107.711 167.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.479 HG21 ' HB3' ' B' ' 53' ' ' ASN . 3.0 m -95.88 103.14 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 123.666 0.787 . . . . 10.0 110.216 177.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mt -87.77 107.83 18.84 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 118.637 -0.697 . . . . 10.0 110.038 -173.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -133.24 158.69 42.26 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 120.644 1.565 . . . . 10.0 108.453 175.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.71 -68.82 0.02 OUTLIER Glycine 0 N--CA 1.462 0.372 0 CA-C-N 114.818 -1.083 . . . . 10.0 112.342 170.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -72.37 -39.5 68.0 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.064 -1.458 . . . . 10.0 107.064 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.24 -60.48 0.56 Allowed Glycine 0 N--CA 1.443 -0.86 0 CA-C-O 118.476 -1.18 . . . . 10.0 112.608 170.241 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -60.62 -39.62 62.7 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 CA-C-N 119.198 1.499 . . . . 10.0 110.848 -177.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.437 HG12 ' H ' ' A' ' 14' ' ' VAL . 0.2 OUTLIER -70.66 115.32 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 177.322 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.84 103.95 7.78 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.413 -2.44 . . . . 10.0 104.413 170.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.75 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.38 145.79 19.19 Favored Glycine 0 N--CA 1.434 -1.452 0 N-CA-C 108.445 -1.862 . . . . 10.0 108.445 174.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.657 ' CG2' HG22 ' B' ' 54' ' ' THR . 3.3 mt -144.85 74.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -168.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 mm -87.45 128.8 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 N-CA-C 109.741 -0.466 . . . . 10.0 109.741 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -99.6 112.15 24.4 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 126.41 1.884 . . . . 10.0 107.752 173.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.421 ' CD2' HG12 ' A' ' 31' ' ' VAL . 25.7 m-85 -88.06 113.43 23.69 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 107.211 -1.403 . . . . 10.0 107.211 173.081 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -121.28 111.39 17.3 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 118.797 0.726 . . . . 10.0 111.272 168.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -99.53 91.54 4.95 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.129 -1.804 . . . . 10.0 106.129 168.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.48 -36.71 66.91 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.972 0.909 . . . . 10.0 112.939 -168.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.05 171.2 14.76 Favored 'General case' 0 N--CA 1.432 -1.362 0 N-CA-C 104.834 -2.284 . . . . 10.0 104.834 167.398 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.4 p -64.81 -24.65 67.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.235 0.54 . . . . 10.0 110.248 179.139 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -81.58 -19.29 42.29 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 115.221 -0.9 . . . . 10.0 110.259 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -82.02 154.48 33.71 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.617 -0.593 . . . . 10.0 111.617 -173.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_endo -67.36 146.8 76.37 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.71 2.274 . . . . 10.0 106.876 167.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.9 p -80.29 110.05 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 174.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -84.3 115.91 22.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.431 -0.952 . . . . 10.0 108.431 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.421 HG12 ' CD2' ' A' ' 20' ' ' PHE . 30.2 m -98.48 57.91 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 124.233 1.013 . . . . 10.0 108.73 -170.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 9.3 p90 -77.78 144.88 36.79 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 118.921 -1.112 . . . . 10.0 110.963 -175.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -175.88 172.04 45.06 Favored Glycine 0 N--CA 1.441 -0.976 0 O-C-N 121.24 -0.913 . . . . 10.0 110.89 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.8 t -128.58 107.91 10.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 178.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.758 ' CG1' ' HB3' ' A' ' 95' ' ' ALA . 2.7 pt -81.76 142.18 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 108.396 -0.964 . . . . 10.0 108.396 169.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.7 ptmm? -127.13 137.03 52.9 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.192 -1.04 . . . . 10.0 108.192 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.71 -1.92 27.52 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.075 0.845 . . . . 10.0 113.399 176.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -62.53 174.05 1.09 Allowed 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 122.132 0.968 . . . . 10.0 110.467 169.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -103.61 164.49 11.63 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 106.18 -1.785 . . . . 10.0 106.18 164.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -54.61 162.87 1.04 Allowed 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.576 0.751 . . . . 10.0 112.062 -172.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.72 -179.78 43.12 Favored Glycine 0 C--N 1.334 0.469 0 O-C-N 121.248 -0.908 . . . . 10.0 112.29 168.144 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.1 mt -66.55 142.22 57.58 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.059 0.943 . . . . 10.0 110.65 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -138.02 128.82 26.91 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 117.729 -1.129 . . . . 10.0 111.103 176.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.513 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -15.2 113.46 0.01 OUTLIER Glycine 0 C--N 1.347 1.148 0 CA-C-O 115.949 -2.584 . . . . 10.0 112.49 167.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -137.73 100.15 4.11 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 120.989 2.394 . . . . 10.0 109.91 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.413 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -156.73 169.84 23.79 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-O 122.04 0.924 . . . . 10.0 112.79 -174.075 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.8 t -96.81 141.14 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 111.566 -2.561 . . . . 10.0 107.729 177.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -116.28 168.58 10.0 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.178 0.991 . . . . 10.0 109.397 178.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -67.23 -72.51 0.16 Allowed 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.697 -0.683 . . . . 10.0 111.246 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.55 136.98 34.71 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 120.161 -0.616 . . . . 10.0 110.132 -169.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -66.87 -31.59 78.63 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 109.278 -1.529 . . . . 10.0 109.278 168.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -45.14 155.34 0.12 Allowed 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 122.837 1.303 . . . . 10.0 114.353 -175.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.17 15.37 0.82 Allowed 'General case' 0 N--CA 1.439 -0.985 0 CA-C-N 113.446 -1.707 . . . . 10.0 111.037 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.522 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -53.76 -43.07 68.88 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 120.266 1.394 . . . . 10.0 112.352 -167.676 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.59 -17.94 52.74 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.98 0.912 . . . . 10.0 112.65 -179.331 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.05 60.77 0.37 Allowed Glycine 0 CA--C 1.528 0.862 0 C-N-CA 124.468 1.033 . . . . 10.0 111.139 -177.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 61.24 18.65 9.35 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 114.513 1.301 . . . . 10.0 114.513 171.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.4 p -93.81 -57.53 2.53 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 176.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.4 m -49.91 -34.44 20.42 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.363 2.265 . . . . 10.0 111.853 -178.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -39.25 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 127.849 2.46 . . . . 10.0 112.078 168.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.74 154.02 28.63 Favored Glycine 0 N--CA 1.436 -1.339 0 N-CA-C 108.28 -1.928 . . . . 10.0 108.28 168.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -71.44 -164.95 0.17 Allowed 'Trans proline' 0 N--CA 1.442 -1.552 0 N-CA-C 107.269 -1.858 . . . . 10.0 107.269 167.295 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.413 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 50.4 m170 -79.84 62.75 4.17 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 120.596 -1.315 . . . . 10.0 109.951 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -75.28 67.28 1.86 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 123.702 1.715 . . . . 10.0 111.18 178.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -72.65 153.6 91.53 Favored Pre-proline 0 N--CA 1.448 -0.54 0 C-N-CA 128.205 2.602 . . . . 10.0 110.181 169.295 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.85 -40.2 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.767 2.312 . . . . 10.0 111.37 177.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mt -78.09 49.18 0.79 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.284 1.034 . . . . 10.0 110.442 -177.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.4 p -57.14 106.55 0.33 Allowed 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.417 1.087 . . . . 10.0 109.826 -170.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.4 mtt180 -134.7 -88.02 0.37 Allowed 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 106.562 -1.644 . . . . 10.0 106.562 -171.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.5 mmtp -140.71 155.39 46.48 Favored 'General case' 0 N--CA 1.438 -1.074 0 CA-C-O 122.695 1.236 . . . . 10.0 110.273 169.184 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 69.2 t60 -69.03 119.31 13.12 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 164.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.9 -138.24 3.81 Favored Glycine 0 N--CA 1.442 -0.919 0 N-CA-C 109.38 -1.488 . . . . 10.0 109.38 -175.645 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -176.94 -157.5 18.14 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 109.558 -1.417 . . . . 10.0 109.558 169.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -67.79 14.72 0.15 Allowed 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.158 1.905 . . . . 10.0 111.424 168.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.438 ' H ' ' C ' ' A' ' 73' ' ' GLY . 4.5 mtpm? -120.91 -6.93 9.54 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.626 1.571 . . . . 10.0 110.677 174.542 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -110.89 162.39 14.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 107.714 -1.217 . . . . 10.0 107.714 177.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.4 pm0 -98.74 -16.16 19.06 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 126.319 1.847 . . . . 10.0 109.866 169.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -105.39 6.9 32.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.852 1.661 . . . . 10.0 112.324 -174.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -35.52 149.81 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.575 1.95 . . . . 10.0 112.924 171.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -70.06 -100.42 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 112.47 0.545 . . . . 10.0 112.47 -178.312 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 p -151.64 25.06 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 O-C-N 120.606 -1.309 . . . . 10.0 110.392 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 157.36 51.33 0.01 OUTLIER Glycine 0 CA--C 1.522 0.483 0 N-CA-C 108.814 -1.715 . . . . 10.0 108.814 -173.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.55 99.74 11.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 105.346 -2.094 . . . . 10.0 105.346 169.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.7 mt -94.49 33.02 1.47 Allowed 'General case' 0 N--CA 1.461 0.122 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 172.143 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 46.09 -106.38 0.13 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 126.514 2.006 . . . . 10.0 111.025 -178.351 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -151.92 117.66 5.43 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 123.557 0.743 . . . . 10.0 110.439 -168.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -92.86 138.69 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 122.731 0.412 . . . . 10.0 110.83 -171.111 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.31 118.56 24.28 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 125.035 1.334 . . . . 10.0 110.493 -172.391 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.59 134.74 38.12 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 123.225 0.61 . . . . 10.0 109.847 173.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -57.92 167.57 1.16 Allowed 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.856 0.862 . . . . 10.0 109.025 167.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.11 -23.69 62.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.104 -0.498 . . . . 10.0 112.157 177.644 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -78.4 -13.09 60.0 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.266 0.627 . . . . 10.0 110.958 179.121 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.74 6.27 67.8 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.952 -0.859 . . . . 10.0 110.952 -176.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.9 t -81.49 108.1 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.516 1.927 . . . . 10.0 106.978 174.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.758 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -112.99 121.12 43.68 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 108.831 -0.803 . . . . 10.0 108.831 173.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -83.08 131.4 35.16 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 108.719 -0.845 . . . . 10.0 108.719 173.18 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.7 t -119.23 130.79 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 N-CA-C 104.815 -2.291 . . . . 10.0 104.815 168.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -155.75 57.78 0.61 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 118.655 0.661 . . . . 10.0 111.18 -177.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 71.6 mt -116.55 138.77 46.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.208 1.403 . . . . 10.0 109.824 -170.156 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -91.35 104.12 16.68 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 127.843 2.457 . . . . 10.0 109.121 172.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -81.34 116.48 21.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.009 -0.738 . . . . 10.0 109.009 175.256 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.8 p -111.3 46.46 1.09 Allowed 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 125.448 1.499 . . . . 10.0 109.68 174.081 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.23 -41.06 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.168 0 CA-C-O 118.157 -0.925 . . . . 10.0 110.543 175.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.407 0.0 OUTLIER -106.27 177.21 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-N 119.553 1.069 . . . . 10.0 113.549 169.501 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.6 t -146.23 153.71 40.92 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 108.112 -1.07 . . . . 10.0 108.112 -176.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 93.1 mt -69.77 -17.53 63.43 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.318 0.647 . . . . 10.0 110.801 173.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 18.3 t -151.15 150.55 30.79 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.536 0.607 . . . . 10.0 109.533 177.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.6 68.09 0.43 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.017 -1.233 . . . . 10.0 110.017 -179.079 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.8 t70 71.61 -56.67 0.63 Allowed 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 129.536 3.134 . . . . 10.0 109.847 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -78.15 -2.46 37.61 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 113.011 0.745 . . . . 10.0 113.011 -168.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.9 t -17.76 96.41 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 129.025 2.93 . . . . 10.0 112.523 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 29.2 pt -72.84 -3.58 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 N-CA-C 112.776 0.658 . . . . 10.0 112.776 -175.009 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.8 mm -52.54 130.28 13.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 O-C-N 121.092 -1.005 . . . . 10.0 108.493 169.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.92 8.71 87.67 Favored Glycine 0 CA--C 1.533 1.205 0 CA-C-O 118.67 -1.072 . . . . 10.0 114.22 -176.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -78.36 176.43 9.34 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 166.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -127.96 136.82 51.84 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 106.854 -1.535 . . . . 10.0 106.854 171.179 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.9 mp -107.61 158.07 17.55 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.183 -1.414 . . . . 10.0 107.183 168.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.1 t -132.27 136.79 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 107.487 -1.301 . . . . 10.0 107.487 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.3 125.19 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 103.674 -2.713 . . . . 10.0 103.674 167.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.513 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.0 m170 -106.37 164.37 12.08 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 120.207 1.367 . . . . 10.0 114.37 -171.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.39 -49.79 73.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 114.036 -1.438 . . . . 10.0 109.438 -175.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -117.97 173.05 6.99 Favored 'General case' 0 N--CA 1.456 -0.131 0 CA-C-O 122.425 1.107 . . . . 10.0 113.355 -174.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -73.57 143.28 46.5 Favored 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 113.475 -1.693 . . . . 10.0 109.646 169.454 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.13 156.3 36.11 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 123.851 0.861 . . . . 10.0 110.637 174.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 -85.35 8.92 16.98 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.414 -0.812 . . . . 10.0 109.968 166.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.4 mt 39.32 52.79 2.24 Favored 'General case' 0 C--N 1.344 0.369 0 C-N-CA 126.148 1.779 . . . . 10.0 110.782 -172.478 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.55 -26.24 24.68 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 113.642 -1.617 . . . . 10.0 112.59 173.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -78.97 24.37 0.31 Allowed 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 114.29 1.219 . . . . 10.0 114.29 -167.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.48 -38.41 38.29 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 108.49 -1.844 . . . . 10.0 108.49 169.034 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.84 47.8 58.7 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 109.431 -1.468 . . . . 10.0 109.431 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -152.17 164.08 38.06 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.544 -2.021 . . . . 10.0 105.544 176.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -44.74 -47.15 10.77 Favored 'General case' 0 N--CA 1.438 -1.055 0 C-N-CA 123.031 0.532 . . . . 10.0 111.344 -175.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.77 -34.56 71.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.453 -0.34 . . . . 10.0 110.176 -177.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -51.45 -44.44 62.36 Favored 'General case' 0 N--CA 1.446 -0.651 0 O-C-N 121.725 -0.61 . . . . 10.0 110.677 172.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.4 t -84.38 6.75 22.0 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.382 0.512 . . . . 10.0 112.382 -176.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -118.91 -75.62 0.58 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 125.594 1.557 . . . . 10.0 109.619 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 p -111.16 13.64 21.83 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 120.419 1.463 . . . . 10.0 113.689 175.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.66 -21.2 11.5 Favored Glycine 0 C--N 1.338 0.674 0 O-C-N 120.819 -1.176 . . . . 10.0 115.455 168.265 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 90.74 28.02 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 128.183 2.593 . . . . 10.0 110.097 -168.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.18 -2.2 1.28 Allowed 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.767 0.827 . . . . 10.0 112.686 169.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.11 -171.84 55.16 Favored Glycine 0 N--CA 1.443 -0.867 0 N-CA-C 109.882 -1.287 . . . . 10.0 109.882 174.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -60.88 144.92 51.9 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.881 0.848 . . . . 10.0 112.153 -169.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mtm-85 -63.71 63.29 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 127.305 2.242 . . . . 10.0 110.806 169.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.46 -14.86 59.21 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.941 1.089 . . . . 10.0 113.941 -173.021 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.86 146.3 17.63 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 123.303 0.641 . . . . 10.0 109.738 169.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.0 p -155.07 156.48 35.95 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.79 -0.818 . . . . 10.0 108.79 -171.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.22 145.39 12.38 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.412 -1.075 . . . . 10.0 110.412 -169.152 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.86 140.85 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 125.903 1.681 . . . . 10.0 106.838 -172.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.8 mt -80.56 120.1 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-O 118.716 -0.659 . . . . 10.0 110.575 -174.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -128.51 154.37 20.01 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 124.263 0.935 . . . . 10.0 113.085 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 mm -64.75 146.21 13.37 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 C-N-CA 124.292 1.037 . . . . 10.0 112.254 -169.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.57 -17.47 1.73 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 116.231 1.937 . . . . 10.0 116.231 178.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.252 1.206 0 CA-C-O 117.693 -1.146 . . . . 10.0 110.683 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 108.383 -0.969 . . . . 10.0 108.383 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.1 t -170.13 -47.2 0.02 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 124.099 0.96 . . . . 10.0 109.785 178.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -138.51 125.76 21.59 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 125.256 1.422 . . . . 10.0 107.973 -169.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.02 162.58 35.09 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 124.545 1.138 . . . . 10.0 109.053 -172.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 m -115.74 172.94 3.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-O 121.611 0.719 . . . . 10.0 110.086 171.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.44 102.56 3.85 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 104.425 -2.435 . . . . 10.0 104.425 165.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 m -90.03 120.02 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 170.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.417 HD12 ' N ' ' B' ' 8' ' ' LEU . 4.8 mp -99.16 136.22 39.44 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 108.326 -0.99 . . . . 10.0 108.326 -177.011 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . 0.409 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 39.4 mtpt -145.45 160.26 41.86 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.659 -1.237 . . . . 10.0 107.659 169.392 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -178.07 -54.56 0.07 OUTLIER Glycine 0 N--CA 1.461 0.323 0 C-N-CA 120.522 -0.846 . . . . 10.0 113.669 169.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -72.06 -43.58 64.67 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.6 -1.259 . . . . 10.0 107.6 -174.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.84 -70.95 0.4 Allowed Glycine 0 CA--C 1.521 0.425 0 CA-C-N 114.223 -1.353 . . . . 10.0 109.86 169.656 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -57.62 -36.16 98.62 Favored 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 123.381 2.721 . . . . 10.0 111.389 172.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.95 101.69 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.132 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -117.79 106.91 13.52 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 124.633 1.173 . . . . 10.0 107.957 172.001 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.44 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -86.83 147.75 21.3 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 109.912 -1.275 . . . . 10.0 109.912 169.638 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 54' ' ' THR . 0.9 OUTLIER -149.56 76.62 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 N-CA-C 104.761 -2.311 . . . . 10.0 104.761 -175.851 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -97.44 146.15 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 124.744 1.218 . . . . 10.0 108.85 -178.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -126.11 125.17 42.1 Favored 'General case' 0 C--O 1.232 0.133 0 C-N-CA 126.669 1.988 . . . . 10.0 107.864 -175.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -112.69 105.57 13.76 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.406 1.482 . . . . 10.0 107.805 178.137 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -113.13 123.78 51.05 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 123.823 0.702 . . . . 10.0 111.486 175.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -95.18 97.78 10.15 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.332 1.453 . . . . 10.0 108.003 174.274 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? -47.06 -61.88 1.67 Allowed 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 126.275 1.83 . . . . 10.0 110.955 -175.001 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -141.51 171.61 13.82 Favored 'General case' 0 N--CA 1.432 -1.37 0 N-CA-C 102.614 -3.106 . . . . 10.0 102.614 168.068 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.3 p -71.4 -15.62 62.37 Favored 'General case' 0 N--CA 1.445 -0.707 0 O-C-N 121.367 -0.833 . . . . 10.0 109.874 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 34.2 m120 -78.56 -26.6 45.63 Favored 'General case' 0 N--CA 1.441 -0.906 0 C-N-CA 123.59 0.756 . . . . 10.0 110.746 174.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.78 156.11 31.13 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.458 -1.057 . . . . 10.0 110.458 -177.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.57 161.0 45.43 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.122 1.881 . . . . 10.0 109.073 171.487 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 14.1 t -87.44 112.28 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 N-CA-C 105.208 -2.145 . . . . 10.0 105.208 169.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -92.98 121.12 33.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.599 -1.63 . . . . 10.0 106.599 169.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.69 106.38 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.307 1.843 . . . . 10.0 106.495 177.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -127.64 152.87 47.13 Favored 'General case' 0 CA--C 1.522 -0.133 0 N-CA-C 113.461 0.912 . . . . 10.0 113.461 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.26 -150.31 21.54 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 108.2 -1.96 . . . . 10.0 108.2 172.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 22.6 t -155.14 158.31 38.79 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 119.598 -0.841 . . . . 10.0 112.299 -177.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.652 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -118.88 114.21 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 127.147 2.179 . . . . 10.0 108.76 169.806 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -100.27 142.87 31.16 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 168.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.43 -1.17 14.21 Favored Glycine 0 C--N 1.337 0.599 0 C-N-CA 124.597 1.094 . . . . 10.0 112.932 169.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 31.7 mt -80.78 175.98 10.21 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.875 0.845 . . . . 10.0 110.491 -178.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -93.11 150.77 20.28 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.8 -1.185 . . . . 10.0 107.8 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 68.9 tt0 -53.77 145.32 16.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.4 1.08 . . . . 10.0 110.824 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.4 -176.64 21.8 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.799 0.714 . . . . 10.0 111.882 176.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 8.8 mp -70.83 150.33 45.93 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.485 1.514 . . . . 10.0 111.87 -172.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -143.22 144.15 32.04 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 112.969 0.729 . . . . 10.0 112.969 178.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.515 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -37.19 115.82 0.34 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.405 2.431 . . . . 10.0 112.211 166.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.541 ' CZ ' HD12 ' B' ' 35' ' ' ILE . 2.0 m-85 -135.66 106.6 6.65 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.754 1.777 . . . . 10.0 110.592 172.179 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.507 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -152.75 171.35 18.37 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-N 115.376 -0.829 . . . . 10.0 109.885 178.142 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 12.3 m -99.93 147.16 7.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 112.952 -1.931 . . . . 10.0 107.106 167.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 22.7 m-70 -116.14 131.19 57.01 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 103.949 -2.612 . . . . 10.0 103.949 173.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -59.73 -48.78 80.32 Favored 'General case' 0 N--CA 1.45 -0.443 0 O-C-N 124.206 0.941 . . . . 10.0 111.643 -167.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.7 m-30 -80.01 148.28 31.18 Favored 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 118.386 -1.326 . . . . 10.0 108.324 175.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.72 35.89 4.29 Favored Glycine 0 N--CA 1.441 -1.021 0 N-CA-C 108.083 -2.007 . . . . 10.0 108.083 166.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.7 74.73 6.38 Favored 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 126.895 3.236 . . . . 10.0 107.318 171.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.479 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -76.63 -0.37 23.16 Favored 'General case' 0 N--CA 1.416 -2.133 0 CA-C-N 109.63 -3.441 . . . . 10.0 111.029 -173.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.657 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -32.08 -52.38 0.26 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 130.194 3.397 . . . . 10.0 112.932 175.526 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.68 -21.97 47.45 Favored 'General case' 0 CA--C 1.529 0.147 0 N-CA-C 112.871 0.693 . . . . 10.0 112.871 -176.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.24 75.85 1.3 Allowed Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.132 -0.787 . . . . 10.0 111.132 -174.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 19.9 m 63.75 56.82 1.47 Allowed 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 123.716 0.806 . . . . 10.0 112.208 168.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -155.14 -58.19 0.1 Allowed 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 108.239 -1.023 . . . . 10.0 108.239 175.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.5 m -61.42 -26.63 67.99 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 122.376 0.27 . . . . 10.0 111.578 -173.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.02 -34.56 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.977 2.511 . . . . 10.0 112.734 168.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.97 155.97 9.24 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.144 -0.783 . . . . 10.0 111.144 166.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . 0.416 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 88.8 Cg_endo -75.92 58.83 5.6 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 123.566 2.844 . . . . 10.0 108.494 166.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.293 26.1 m170 75.2 -44.3 0.53 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 127.181 2.192 . . . . 10.0 109.519 -177.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . 0.416 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 2.8 m-85 51.61 47.62 24.45 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 126.461 1.904 . . . . 10.0 111.57 172.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -72.01 142.73 85.57 Favored Pre-proline 0 C--N 1.321 -0.638 0 C-N-CA 125.571 1.548 . . . . 10.0 112.987 178.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.92 -44.43 0.35 Allowed 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 123.623 2.882 . . . . 10.0 110.843 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 14.4 mt -68.96 88.13 0.38 Allowed 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.223 -1.399 . . . . 10.0 107.223 171.544 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -57.7 82.13 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.658 1.983 . . . . 10.0 111.25 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.68 -179.83 4.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 127.19 2.196 . . . . 10.0 108.126 177.588 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -111.1 107.89 17.41 Favored 'General case' 0 C--O 1.224 -0.244 0 N-CA-C 108.263 -1.014 . . . . 10.0 108.263 -177.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.522 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 83.1 t60 -12.09 98.23 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.439 0 C-N-CA 126.783 2.033 . . . . 10.0 113.892 -178.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.44 -175.54 14.11 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 106.916 -2.474 . . . . 10.0 106.916 176.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.32 -155.89 7.26 Favored Glycine 0 C--O 1.226 -0.376 0 N-CA-C 107.061 -2.416 . . . . 10.0 107.061 -177.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -67.22 1.45 2.95 Favored 'Trans proline' 0 CA--C 1.544 0.99 0 CA-C-N 119.69 1.745 . . . . 10.0 110.287 165.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 56.3 mmtt -89.8 -15.57 32.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.834 1.653 . . . . 10.0 110.416 171.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -133.81 178.53 6.87 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 119.832 1.196 . . . . 10.0 109.826 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -90.3 -32.41 16.53 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 169.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -95.14 43.52 1.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 122.299 1.047 . . . . 10.0 111.909 -169.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.58 144.31 17.72 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 115.849 -0.614 . . . . 10.0 110.48 168.47 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.522 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.2 m170 -68.95 -56.86 6.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 -173.175 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.4 p -173.74 -38.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 123.715 0.806 . . . . 10.0 111.429 -174.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -158.56 69.61 0.26 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 108.072 -2.011 . . . . 10.0 108.072 -169.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -122.92 94.4 4.26 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.401 -2.074 . . . . 10.0 105.401 -171.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 5.0 mt -72.07 -28.3 63.24 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 106.642 -1.614 . . . . 10.0 106.642 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . 0.412 ' CA ' HD11 ' B' ' 126' ' ' LEU . . . 88.39 -94.58 2.01 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 108.007 -2.037 . . . . 10.0 108.007 176.117 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -128.98 124.18 34.38 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.092 0.557 . . . . 10.0 110.531 -168.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.476 HG22 ' CD1' ' B' ' 45' ' ' PHE . 6.6 m -121.48 145.52 27.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 107.581 -1.266 . . . . 10.0 107.581 168.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.2 m -94.17 113.72 25.71 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 127.172 2.189 . . . . 10.0 111.97 -167.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -78.45 130.48 36.12 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 109.457 -0.571 . . . . 10.0 109.457 169.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -59.51 169.71 1.21 Allowed 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 125.098 1.359 . . . . 10.0 110.311 168.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.06 -32.29 34.03 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.035 1.334 . . . . 10.0 112.115 169.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -77.34 -1.4 29.75 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.3 0.64 . . . . 10.0 110.987 178.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.37 20.41 69.42 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 120.584 -1.323 . . . . 10.0 110.178 175.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.37 105.5 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 128.529 2.732 . . . . 10.0 106.604 -177.327 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.652 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -98.88 125.13 44.21 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 168.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 p-10 -88.52 122.7 32.27 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 127.052 2.141 . . . . 10.0 109.045 175.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 96.6 t -107.72 134.25 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 174.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.6 m -158.13 66.56 0.46 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.607 1.163 . . . . 10.0 109.695 169.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.59 156.07 5.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.277 -1.379 . . . . 10.0 107.277 -177.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -133.42 139.95 47.04 Favored 'General case' 0 CA--C 1.519 -0.245 0 C-N-CA 124.893 1.277 . . . . 10.0 109.946 175.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -147.29 159.14 44.01 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.071 -1.455 . . . . 10.0 107.071 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.66 14.49 4.04 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.423 1.889 . . . . 10.0 111.857 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -89.44 1.69 7.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 119.19 0.905 . . . . 10.0 109.523 169.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.465 HD13 ' H ' ' B' ' 104' ' ' ILE 0.264 0.0 OUTLIER -129.08 171.28 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 126.313 1.845 . . . . 10.0 111.612 -179.328 . . . . . . . . 4 4 . 1 . 012 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 6.2 m -163.56 147.13 10.31 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 107.462 -1.31 . . . . 10.0 107.462 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -62.38 -48.22 80.71 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 123.303 0.641 . . . . 10.0 109.706 -176.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.4 t -139.4 174.47 10.48 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 125.347 1.459 . . . . 10.0 107.469 169.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 128.56 -101.37 0.55 Allowed Glycine 0 N--CA 1.45 -0.374 0 N-CA-C 107.919 -2.073 . . . . 10.0 107.919 -171.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -120.22 -51.13 2.22 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 125.765 1.626 . . . . 10.0 108.282 178.085 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -73.75 -31.35 63.29 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 115.033 -0.985 . . . . 10.0 108.713 -171.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 22.3 t 33.43 72.21 0.09 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 127.994 2.517 . . . . 10.0 115.809 167.391 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 29.7 pt -71.67 -15.11 18.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.297 0 N-CA-C 114.048 1.129 . . . . 10.0 114.048 -178.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.5 mm -46.51 127.65 2.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 CA-C-N 119.051 0.841 . . . . 10.0 110.173 172.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.27 -0.11 83.22 Favored Glycine 0 CA--C 1.532 1.137 0 CA-C-O 118.969 -0.906 . . . . 10.0 114.583 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -76.22 175.41 9.05 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 119.243 1.521 . . . . 10.0 108.507 169.402 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -121.7 125.99 47.9 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.362 0.665 . . . . 10.0 111.002 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -80.93 139.98 35.55 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 107.388 -1.338 . . . . 10.0 107.388 170.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 98.9 t -124.72 132.49 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 108.025 -1.102 . . . . 10.0 108.025 171.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.443 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 3.7 p -98.78 125.81 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.189 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 168.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.515 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.0 m170 -102.11 161.0 14.02 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 122.954 1.359 . . . . 10.0 114.022 -176.583 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . 0.574 ' HA ' HD22 ' B' ' 144' ' ' LEU . 62.7 tt0 -46.79 -56.73 5.76 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 128.031 2.532 . . . . 10.0 109.288 176.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -124.49 177.03 6.13 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.655 1.582 . . . . 10.0 110.355 -173.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.21 145.38 35.58 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 125.615 1.566 . . . . 10.0 110.401 176.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.507 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.1 OUTLIER -85.38 157.39 20.53 Favored 'General case' 0 N--CA 1.457 -0.098 0 CA-C-O 121.392 0.615 . . . . 10.0 112.156 169.277 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -78.99 -11.31 60.0 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 115.078 -0.964 . . . . 10.0 111.278 174.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.412 HD11 ' CA ' ' B' ' 85' ' ' GLY . 3.8 mm? 52.93 57.04 6.76 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 124.887 1.275 . . . . 10.0 108.841 -174.202 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.93 -42.32 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 113.706 -1.588 . . . . 10.0 111.161 168.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.7 mtmt -80.53 42.57 0.61 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.684 0.794 . . . . 10.0 112.179 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -94.75 -20.04 30.03 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 127.922 2.677 . . . . 10.0 110.101 168.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.56 49.77 38.57 Favored Glycine 0 C--N 1.34 0.778 0 C-N-CA 124.314 0.959 . . . . 10.0 111.802 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -155.28 172.79 17.6 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 117.784 0.792 . . . . 10.0 108.875 176.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 8.6 tm-20 -52.19 -46.24 65.5 Favored 'General case' 0 N--CA 1.442 -0.859 0 C-N-CA 123.351 0.66 . . . . 10.0 111.269 -177.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -70.06 -30.97 68.35 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.825 -0.607 . . . . 10.0 109.756 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.9 p -50.66 -41.36 55.43 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 119.287 0.949 . . . . 10.0 111.258 -177.706 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.7 t -86.91 -3.28 59.06 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 113.285 0.846 . . . . 10.0 113.285 -177.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 32.1 tttt -114.48 -57.26 2.29 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 127.424 2.29 . . . . 10.0 111.952 -166.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 6.1 p -132.31 7.19 4.21 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 118.453 -0.784 . . . . 10.0 111.041 168.184 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.23 -105.1 2.95 Favored Glycine 0 C--N 1.344 1.009 0 N-CA-C 108.91 -1.676 . . . . 10.0 108.91 -169.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.15 34.17 0.14 Allowed 'General case' 0 C--N 1.321 -0.65 0 O-C-N 121.095 -1.238 . . . . 10.0 108.342 177.453 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.63 -9.21 58.33 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.899 -1.046 . . . . 10.0 111.467 -169.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.31 -158.39 41.78 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 109.261 -1.535 . . . . 10.0 109.261 169.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 67.6 m -57.43 128.9 39.36 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-O 121.45 0.643 . . . . 10.0 109.822 -174.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.2 72.78 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 124.711 1.204 . . . . 10.0 111.132 169.463 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.574 HD22 ' HA ' ' B' ' 121' ' ' GLU . 10.0 tp -44.61 -38.0 3.99 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 128.036 2.535 . . . . 10.0 114.517 -174.303 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.443 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -162.32 158.98 24.9 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 178.515 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -156.8 165.29 36.63 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 122.471 -0.143 . . . . 10.0 110.906 -178.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.88 146.47 14.16 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 110.374 -1.091 . . . . 10.0 110.374 -172.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 64.4 t -100.46 138.76 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 N-CA-C 105.851 -1.907 . . . . 10.0 105.851 -174.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 38.5 mt -73.33 120.71 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 C-N-CA 122.524 0.33 . . . . 10.0 110.172 -173.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.56 134.35 10.85 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.095 1.331 . . . . 10.0 112.103 -172.482 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.71 137.0 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.276 0 C-N-CA 125.604 1.562 . . . . 10.0 109.463 179.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.21 -48.15 1.1 Allowed 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 113.305 0.854 . . . . 10.0 113.305 -174.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 44.7 tt0 . . . . . 0 C--O 1.253 1.282 0 N-CA-C 108.782 -0.821 . . . . 10.0 108.782 -165.944 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 108.635 -0.876 . . . . 10.0 108.635 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.9 -6.77 55.44 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 118.52 0.6 . . . . 10.0 109.825 -174.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.93 156.66 42.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.028 0.531 . . . . 10.0 109.986 168.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.41 156.26 35.03 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 108.068 -1.086 . . . . 10.0 108.068 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 m -126.82 160.44 35.17 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 109.552 -0.536 . . . . 10.0 109.552 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.27 107.77 7.85 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 107.578 -1.268 . . . . 10.0 107.578 169.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.4 m -84.37 109.06 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 170.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mt -93.23 146.39 23.73 Favored 'General case' 0 C--O 1.224 -0.246 0 CA-C-O 117.97 -1.014 . . . . 10.0 108.434 -174.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.2 mtmt -164.78 158.93 18.04 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 120.081 1.31 . . . . 10.0 108.351 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.74 -51.05 0.1 OUTLIER Glycine 0 N--CA 1.461 0.365 0 C-N-CA 120.013 -1.089 . . . . 10.0 113.768 168.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -73.35 -44.17 59.27 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.975 -1.12 . . . . 10.0 107.975 -173.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.01 -71.44 0.35 Allowed Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 114.086 -1.416 . . . . 10.0 110.536 169.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -55.0 -39.91 88.55 Favored 'Trans proline' 0 N--CA 1.451 -1.028 0 C-N-CA 122.703 2.269 . . . . 10.0 110.72 172.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.739 HG13 HD12 ' A' ' 38' ' ' LEU . 97.7 t -58.52 112.91 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 C-N-CA 123.862 0.865 . . . . 10.0 109.83 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -131.0 109.23 10.37 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 122.752 0.421 . . . . 10.0 110.062 167.295 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.614 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -83.05 154.77 32.26 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.837 -0.905 . . . . 10.0 110.837 168.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.22 56.44 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 126.024 1.73 . . . . 10.0 106.858 -179.122 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.429 HD12 ' HA ' ' A' ' 18' ' ' ILE . 1.2 tp -67.25 145.46 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 O-C-N 121.473 -0.767 . . . . 10.0 109.494 -179.15 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -138.04 101.14 4.34 Favored 'General case' 0 CA--C 1.519 -0.22 0 C-N-CA 126.319 1.847 . . . . 10.0 109.429 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.441 ' CE1' ' HB ' ' A' ' 31' ' ' VAL . 15.7 m-30 -100.48 129.69 46.47 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.561 -1.274 . . . . 10.0 107.561 -177.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -129.38 152.22 49.18 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.574 0.749 . . . . 10.0 110.752 176.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -125.77 114.65 18.89 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.603 -1.629 . . . . 10.0 106.603 166.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 47.0 mmtt -61.34 -60.26 4.01 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 109.07 -0.715 . . . . 10.0 109.07 169.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -126.79 165.84 18.54 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.312 -2.107 . . . . 10.0 105.312 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.4 t -73.52 -10.96 60.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-O 121.516 0.674 . . . . 10.0 109.32 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.8 m120 -78.45 -19.65 52.7 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.194 0.998 . . . . 10.0 110.228 173.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.89 150.76 41.61 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.582 -1.007 . . . . 10.0 110.582 178.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -76.16 148.53 31.03 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 N-CA-C 106.078 -2.316 . . . . 10.0 106.078 166.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.6 t -75.22 100.13 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.9 mtpp -68.48 93.87 0.52 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 106.755 -1.572 . . . . 10.0 106.755 170.138 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.441 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 4.3 m -82.06 59.87 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 124.772 1.229 . . . . 10.0 108.853 -172.373 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -82.7 174.25 11.17 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 119.119 -1.032 . . . . 10.0 111.471 -168.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.11 -159.44 28.35 Favored Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 109.427 -1.469 . . . . 10.0 109.427 167.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 15.2 m -155.99 124.72 5.97 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 109.138 -0.69 . . . . 10.0 109.138 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.614 HG22 ' CA ' ' A' ' 16' ' ' GLY . 2.6 pt -93.1 143.5 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 106.505 -1.665 . . . . 10.0 106.505 165.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.16 119.1 17.37 Favored 'General case' 0 N--CA 1.45 -0.435 0 O-C-N 123.803 0.689 . . . . 10.0 110.91 171.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.27 14.24 1.81 Allowed Glycine 0 C--N 1.341 0.839 0 CA-C-O 118.849 -0.973 . . . . 10.0 114.967 168.37 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.739 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -97.03 179.49 4.92 Favored 'General case' 0 C--O 1.224 -0.269 0 CA-C-N 118.808 1.304 . . . . 10.0 108.397 174.245 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -75.55 174.26 9.93 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 119.6 -0.84 . . . . 10.0 110.885 170.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -63.85 177.29 0.77 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.078 1.751 . . . . 10.0 110.167 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.8 -174.35 40.89 Favored Glycine 0 N--CA 1.448 -0.55 0 O-C-N 121.32 -0.862 . . . . 10.0 112.987 167.323 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.08 147.77 49.59 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.672 1.189 . . . . 10.0 109.273 175.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 65.1 m-70 -144.38 141.9 29.99 Favored 'General case' 0 C--O 1.234 0.246 0 N-CA-C 114.009 1.115 . . . . 10.0 114.009 -176.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.635 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -27.48 122.17 0.06 OUTLIER Glycine 0 C--N 1.343 0.925 0 C-N-CA 128.291 2.853 . . . . 10.0 114.0 166.427 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.75 107.06 3.13 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 119.575 1.687 . . . . 10.0 113.185 169.082 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.457 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -146.28 173.13 12.52 Favored 'General case' 0 CA--C 1.516 -0.329 0 C-N-CA 123.368 0.667 . . . . 10.0 110.903 178.505 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.0 t -89.97 -41.99 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 113.624 -1.625 . . . . 10.0 113.107 -168.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 61.29 157.56 0.04 OUTLIER 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 126.145 1.778 . . . . 10.0 114.24 -174.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -72.64 -64.89 0.87 Allowed 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 113.996 -1.456 . . . . 10.0 111.176 -177.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -77.79 149.76 34.4 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.025 0.441 . . . . 10.0 110.214 -173.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.18 -11.47 54.34 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.124 -1.591 . . . . 10.0 109.124 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.92 158.04 0.74 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.58 1.181 . . . . 10.0 111.992 171.601 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.534 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -151.17 28.78 0.66 Allowed 'General case' 0 N--CA 1.434 -1.262 0 CA-C-N 113.745 -1.571 . . . . 10.0 112.026 166.158 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.453 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.0 OUTLIER -59.12 -29.58 67.5 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 122.527 0.331 . . . . 10.0 110.425 173.643 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.56 -18.92 59.61 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 122.563 0.345 . . . . 10.0 111.302 176.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.42 82.08 0.27 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 110.923 -0.871 . . . . 10.0 110.923 -177.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m 33.56 58.18 0.53 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 127.499 2.32 . . . . 10.0 111.649 -177.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -136.06 -56.34 0.77 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 -170.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 t -126.3 43.78 3.01 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.015 -1.476 . . . . 10.0 107.015 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.82 65.15 1.34 Allowed 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 174.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.28 92.8 0.01 OUTLIER Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.816 1.198 . . . . 10.0 113.487 169.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -74.62 68.01 5.49 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 123.938 3.092 . . . . 10.0 113.374 -169.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.457 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 34.3 m170 65.34 77.13 0.31 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 128.52 2.728 . . . . 10.0 111.196 173.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -18.42 -60.72 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 128.504 2.722 . . . . 10.0 114.578 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.1 t30 4.49 86.55 0.04 OUTLIER Pre-proline 0 CA--C 1.54 0.577 0 C-N-CA 128.664 2.786 . . . . 10.0 114.676 -169.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -66.43 -35.9 28.9 Favored 'Trans proline' 0 N--CA 1.456 -0.701 0 C-N-CA 122.538 2.159 . . . . 10.0 111.551 -175.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.3 tt -74.25 66.74 1.32 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 108.181 -1.044 . . . . 10.0 108.181 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.7 t -31.86 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 127.467 2.307 . . . . 10.0 112.346 -174.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -131.06 170.0 15.11 Favored 'General case' 0 N--CA 1.444 -0.744 0 N-CA-C 106.836 -1.542 . . . . 10.0 106.836 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -89.87 123.4 33.79 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 108.419 -0.956 . . . . 10.0 108.419 -173.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 68.2 t60 -29.55 104.04 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 113.396 0.887 . . . . 10.0 113.396 174.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.34 -170.33 12.68 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 108.503 -1.839 . . . . 10.0 108.503 176.036 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -135.08 -164.84 10.59 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-O 119.406 -0.664 . . . . 10.0 111.638 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -67.2 7.49 0.47 Allowed 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.042 1.828 . . . . 10.0 111.958 170.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -89.94 -29.27 18.61 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 107.787 -1.19 . . . . 10.0 107.787 169.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.67 177.69 4.57 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.396 1.079 . . . . 10.0 108.334 -168.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -110.99 -12.34 14.23 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.74 -1.118 . . . . 10.0 110.697 169.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -86.86 -0.67 56.87 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.051 0.94 . . . . 10.0 111.245 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -36.81 138.1 0.27 Allowed 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 127.367 2.267 . . . . 10.0 112.217 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -82.13 60.86 5.11 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.073 -0.392 . . . . 10.0 110.05 -178.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.283 11.7 p 10.46 64.33 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 129.284 3.034 . . . . 10.0 114.507 -176.091 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.36 49.06 0.06 OUTLIER Glycine 0 CA--C 1.532 1.129 0 C-N-CA 126.028 1.775 . . . . 10.0 109.583 -173.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -131.7 105.87 7.78 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 103.889 -2.634 . . . . 10.0 103.889 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -75.88 -13.32 60.26 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -166.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.37 -97.91 1.46 Allowed Glycine 0 C--O 1.219 -0.802 0 N-CA-C 108.006 -2.038 . . . . 10.0 108.006 -175.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -155.09 151.03 27.85 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 124.917 1.287 . . . . 10.0 108.599 -176.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.9 m -120.97 135.62 60.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 108.917 -0.771 . . . . 10.0 108.917 167.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -88.11 119.19 28.25 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 127.691 2.397 . . . . 10.0 110.594 -177.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.23 133.44 43.52 Favored 'General case' 0 CA--C 1.523 -0.095 0 C-N-CA 124.772 1.229 . . . . 10.0 111.064 176.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -61.02 169.57 1.93 Allowed 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.354 0.662 . . . . 10.0 110.146 168.243 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 -23.25 16.8 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.459 1.104 . . . . 10.0 112.898 170.055 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -17.69 60.8 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 110.29 -0.263 . . . . 10.0 110.29 177.215 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.8 13.89 66.14 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 110.524 -1.03 . . . . 10.0 110.524 -171.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.6 t -91.25 110.38 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.91 0 C-N-CA 126.973 2.109 . . . . 10.0 106.217 175.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.473 ' HB3' HG13 ' A' ' 35' ' ' ILE . . . -110.26 116.01 30.72 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 168.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -79.83 123.18 27.5 Favored 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 127.003 2.121 . . . . 10.0 108.09 171.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 29.6 t -108.41 129.06 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 106.86 -1.533 . . . . 10.0 106.86 178.39 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -155.97 64.09 0.58 Allowed 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.142 -1.058 . . . . 10.0 108.142 173.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 49.8 mt -102.13 153.47 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 N-CA-C 106.623 -1.621 . . . . 10.0 106.623 176.532 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -122.25 110.11 15.3 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.856 0.862 . . . . 10.0 110.75 176.246 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.23 129.18 37.25 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.212 1.005 . . . . 10.0 108.615 -177.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.2 t -119.05 44.83 2.23 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.134 0.974 . . . . 10.0 109.399 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.1 p -135.74 -43.09 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 124.05 0.94 . . . . 10.0 111.269 172.208 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.431 ' C ' HD12 ' A' ' 104' ' ' ILE 0.379 0.9 OUTLIER -87.46 161.01 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 CA-C-N 119.477 1.035 . . . . 10.0 111.956 169.948 . . . . . . . . 4 4 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.0 m -151.93 106.83 3.25 Favored 'General case' 0 C--N 1.341 0.214 0 C-N-CA 123.997 0.919 . . . . 10.0 109.413 -172.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 36.4 mt -37.79 -38.02 0.27 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.141 2.176 . . . . 10.0 115.326 -174.055 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 57.3 m -144.83 56.31 1.26 Allowed 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.229 -1.026 . . . . 10.0 108.229 170.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.32 -63.11 1.67 Allowed Glycine 0 C--N 1.335 0.483 0 N-CA-C 109.099 -1.6 . . . . 10.0 109.099 174.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -167.67 -53.38 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.434 1.894 . . . . 10.0 107.141 -178.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.61 -45.6 36.52 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.266 -1.334 . . . . 10.0 107.896 -173.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.0 t 53.77 173.64 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 125.844 1.658 . . . . 10.0 112.443 -175.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 11.7 pt -130.54 20.44 2.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 126.008 1.723 . . . . 10.0 108.961 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.9 mm -70.37 140.13 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.268 0.627 . . . . 10.0 109.593 169.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.37 32.42 84.12 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.298 0.952 . . . . 10.0 113.177 173.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -106.25 176.08 5.29 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.968 1.707 . . . . 10.0 107.919 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -124.52 108.52 12.2 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.285 -1.006 . . . . 10.0 108.285 -178.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.7 mp -80.75 138.18 36.29 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 107.36 -1.348 . . . . 10.0 107.36 177.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.406 HG12 ' CD2' ' A' ' 120' ' ' HIS . 64.5 t -117.62 129.59 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.975 0 N-CA-C 105.939 -1.875 . . . . 10.0 105.939 -178.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -99.35 110.35 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 102.851 -3.018 . . . . 10.0 102.851 169.455 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.635 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.4 m170 -91.41 156.66 17.57 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 122.591 1.186 . . . . 10.0 113.492 -170.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.59 -52.92 20.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 126.688 1.995 . . . . 10.0 109.957 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -110.1 170.85 7.81 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 124.183 0.993 . . . . 10.0 112.306 -172.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.22 140.9 57.44 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 114.113 -1.403 . . . . 10.0 109.3 173.089 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.522 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 0.0 OUTLIER -76.86 125.41 29.25 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 107.483 -1.302 . . . . 10.0 107.483 176.53 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -76.0 -9.74 58.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.761 0.425 . . . . 10.0 111.13 -177.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.6 mt 48.24 38.72 10.65 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.007 0.908 . . . . 10.0 109.924 -176.22 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.28 -15.29 63.6 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.707 1.622 . . . . 10.0 112.554 172.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ptpt -75.7 3.08 10.42 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.239 1.519 . . . . 10.0 112.716 -171.076 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.56 -22.13 76.48 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 169.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 53.1 35.9 50.49 Favored Glycine 0 CA--C 1.526 0.765 0 C-N-CA 123.89 0.757 . . . . 10.0 112.487 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -136.84 173.72 11.39 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 122.1 0.953 . . . . 10.0 110.058 175.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.6 tm-20 -46.08 -51.98 12.83 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.996 1.719 . . . . 10.0 111.221 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -73.05 -37.14 66.96 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.743 -0.598 . . . . 10.0 110.75 179.463 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.6 p -48.84 -43.5 38.67 Favored 'General case' 0 C--N 1.344 0.357 0 O-C-N 121.357 -0.84 . . . . 10.0 110.272 175.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -81.38 -5.3 57.73 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 119.147 -0.454 . . . . 10.0 111.65 -169.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.6 mtmt -114.15 -76.8 0.58 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.593 1.557 . . . . 10.0 110.726 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . 0.26 17.2 p -104.2 12.99 33.13 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 120.157 1.344 . . . . 10.0 113.042 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 28.9 69.12 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 119.351 0.978 . . . . 10.0 113.243 169.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 35.2 m120 49.57 21.25 0.59 Allowed 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 118.203 1.002 . . . . 10.0 113.003 -176.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 120' ' ' HIS . . . -70.75 -6.34 36.82 Favored 'General case' 0 C--O 1.221 -0.43 0 O-C-N 121.491 -0.756 . . . . 10.0 111.542 -171.348 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.45 162.71 15.05 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 109.919 -1.272 . . . . 10.0 109.919 174.431 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.6 t -81.41 58.78 3.76 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.688 0.795 . . . . 10.0 111.094 -169.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 45.72 58.81 4.03 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.311 1.445 . . . . 10.0 112.941 169.571 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.43 HD13 ' N ' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -69.15 -10.48 57.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 113.601 0.963 . . . . 10.0 113.601 -169.818 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.44 ' HB3' HG11 ' A' ' 14' ' ' VAL . . . -164.98 143.27 6.41 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.226 1.01 . . . . 10.0 108.584 172.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -157.01 166.3 33.72 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 122.83 0.452 . . . . 10.0 110.016 -172.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.53 158.25 29.7 Favored Glycine 0 C--N 1.332 0.34 0 N-CA-C 109.207 -1.557 . . . . 10.0 109.207 -178.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 30.5 t -105.91 137.5 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 106.823 -1.547 . . . . 10.0 106.823 -167.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.3 mt -75.85 125.35 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 118.161 0.437 . . . . 10.0 110.607 -176.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.06 149.52 18.13 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.59 1.09 . . . . 10.0 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.1 mt -56.35 137.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 124.305 1.042 . . . . 10.0 109.594 176.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.81 165.69 19.64 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 107.505 -1.295 . . . . 10.0 107.505 167.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 . . . . . 0 C--O 1.251 1.165 0 C-N-CA 124.997 1.319 . . . . 10.0 107.59 167.731 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 107.162 -1.421 . . . . 10.0 107.162 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.6 t -77.2 -48.52 17.39 Favored 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 119.137 0.88 . . . . 10.0 109.168 174.11 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.66 121.87 40.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 126.109 1.763 . . . . 10.0 107.441 -170.137 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -127.61 159.57 34.27 Favored 'General case' 0 CA--C 1.519 -0.249 0 C-N-CA 124.526 1.13 . . . . 10.0 109.239 177.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.1 t -117.41 156.15 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 123.761 0.824 . . . . 10.0 109.726 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.47 112.14 9.4 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.595 1.558 . . . . 10.0 108.514 169.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.534 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.7 OUTLIER -94.11 106.11 17.68 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 C-N-CA 122.857 0.463 . . . . 10.0 110.845 171.443 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.657 HD21 ' HB2' ' B' ' 117' ' ' LEU . 11.2 mt -86.82 127.67 35.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.396 1.079 . . . . 10.0 110.015 177.264 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -147.55 162.47 39.02 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.469 -1.308 . . . . 10.0 107.469 169.326 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.73 -53.71 0.08 OUTLIER Glycine 0 N--CA 1.461 0.303 0 C-N-CA 120.664 -0.779 . . . . 10.0 113.521 169.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -72.26 -44.04 63.43 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.461 -1.311 . . . . 10.0 107.461 -174.328 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.51 -70.88 0.4 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.149 -1.387 . . . . 10.0 110.073 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -57.34 -34.54 98.06 Favored 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 123.436 2.757 . . . . 10.0 111.366 172.078 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 73.8 t -64.58 109.78 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 108.386 -0.968 . . . . 10.0 108.386 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -129.03 118.21 22.17 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.33 1.052 . . . . 10.0 108.376 169.461 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.581 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -108.02 140.05 15.31 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 124.166 0.889 . . . . 10.0 111.373 173.113 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.453 ' CG2' HG22 ' A' ' 54' ' ' THR . 9.4 mt -137.03 72.41 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 N-CA-C 106.4 -1.704 . . . . 10.0 106.4 -169.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mm -95.55 138.55 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 115.749 -0.659 . . . . 10.0 109.74 -170.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -114.48 117.89 32.26 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.139 1.775 . . . . 10.0 108.338 -179.289 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -102.51 107.45 18.42 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.872 -1.159 . . . . 10.0 107.872 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -108.12 122.49 47.0 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 114.949 1.463 . . . . 10.0 114.949 173.568 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -82.52 115.61 21.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 101.715 -3.439 . . . . 10.0 101.715 162.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.3 mtpm? -62.26 -40.98 98.0 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.979 -0.378 . . . . 10.0 109.979 -178.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 65.0 mt-10 -137.26 -145.06 0.2 Allowed 'General case' 0 N--CA 1.428 -1.558 0 N-CA-C 105.79 -1.93 . . . . 10.0 105.79 -170.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 25.8 t -103.39 -19.91 14.26 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 110.207 -0.294 . . . . 10.0 110.207 168.182 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -129.1 11.64 6.01 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.07 0.948 . . . . 10.0 110.791 -174.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.12 166.76 51.89 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.93 -1.668 . . . . 10.0 108.93 175.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -68.28 145.05 64.66 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 N-CA-C 108.131 -1.527 . . . . 10.0 108.131 169.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.78 108.67 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.143 0 N-CA-C 104.966 -2.235 . . . . 10.0 104.966 169.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 18.7 mtpp -90.2 113.56 25.37 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 104.652 -2.351 . . . . 10.0 104.652 169.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -101.64 111.26 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 106.977 -1.49 . . . . 10.0 106.977 179.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.1 p90 -126.38 167.63 15.28 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.323 0.582 . . . . 10.0 112.069 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.64 -151.37 23.12 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 107.159 -2.377 . . . . 10.0 107.159 169.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 33.5 t -155.18 158.72 39.38 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 120.222 -0.591 . . . . 10.0 110.222 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.581 HG22 ' CA ' ' B' ' 16' ' ' GLY . 1.5 pt -117.14 136.74 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 CA-C-N 114.866 -1.061 . . . . 10.0 108.816 167.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 27.5 tptt -108.83 146.44 33.67 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 105.938 -1.875 . . . . 10.0 105.938 170.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.56 -7.07 39.07 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.421 -0.655 . . . . 10.0 113.71 169.524 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.07 175.04 2.22 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 118.348 1.074 . . . . 10.0 110.079 173.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -104.55 167.08 9.97 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 105.693 -1.965 . . . . 10.0 105.693 165.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 7.9 tm-20 -54.88 163.6 0.96 Allowed 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.904 0.881 . . . . 10.0 112.103 -169.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.36 -168.68 46.62 Favored Glycine 0 N--CA 1.445 -0.731 0 CA-C-O 122.012 0.785 . . . . 10.0 112.831 167.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -74.5 143.4 44.6 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.471 1.908 . . . . 10.0 110.606 -173.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -147.07 143.41 28.31 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 124.319 1.048 . . . . 10.0 112.27 -177.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.564 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -33.43 128.32 0.39 Allowed Glycine 0 C--N 1.339 0.73 0 C-N-CA 127.669 2.557 . . . . 10.0 112.351 168.279 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -149.74 110.86 4.38 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.09 -1.078 . . . . 10.0 108.09 166.74 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.04 170.82 16.93 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.437 0.637 . . . . 10.0 112.589 175.491 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 22.2 t -91.89 146.11 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 CA-C-N 112.143 -2.299 . . . . 10.0 106.966 169.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -129.41 147.1 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.29 1.436 . . . . 10.0 107.586 176.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.28 -68.06 0.22 Allowed 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.013 0.925 . . . . 10.0 110.6 -172.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -77.63 132.23 38.15 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 107.914 -1.143 . . . . 10.0 107.914 -169.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.07 -24.94 76.21 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 109.249 -1.54 . . . . 10.0 109.249 172.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.29 162.16 0.36 Allowed 'General case' 0 N--CA 1.447 -0.597 0 CA-C-O 123.031 1.396 . . . . 10.0 113.044 177.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.71 30.08 0.47 Allowed 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 114.185 -1.37 . . . . 10.0 111.759 172.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.4 -37.57 72.92 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.288 1.035 . . . . 10.0 112.535 -168.779 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.14 -21.17 54.53 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.014 0.525 . . . . 10.0 111.687 176.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.59 -155.83 16.06 Favored Glycine 0 N--CA 1.435 -1.372 0 N-CA-C 106.189 -2.765 . . . . 10.0 106.189 -166.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.43 54.33 0.44 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 127.214 2.206 . . . . 10.0 113.461 -168.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -161.24 -39.35 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 O-C-N 120.79 -1.194 . . . . 10.0 111.82 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 9.5 t -50.71 -30.28 13.43 Favored 'General case' 0 C--N 1.343 0.319 0 C-N-CA 124.307 1.043 . . . . 10.0 111.137 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -34.27 -36.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 127.247 2.219 . . . . 10.0 114.194 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.17 143.31 10.98 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 110.694 -0.962 . . . . 10.0 110.694 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -77.06 58.6 6.22 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 124.425 3.417 . . . . 10.0 112.882 -175.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.421 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 17.5 m170 61.0 48.85 6.16 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.738 2.415 . . . . 10.0 109.854 177.059 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -69.7 74.65 0.42 Allowed 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.931 0.872 . . . . 10.0 111.046 178.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -74.99 150.8 86.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 O-C-N 121.343 -0.848 . . . . 10.0 110.832 171.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -67.12 -45.11 4.21 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.631 2.221 . . . . 10.0 111.159 178.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.96 57.29 1.05 Allowed 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.53 0.732 . . . . 10.0 110.038 178.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 39.5 p -42.48 108.73 0.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.629 1.572 . . . . 10.0 110.935 -172.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 58.7 mtt180 -148.6 -172.08 4.01 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.792 -2.299 . . . . 10.0 104.792 -171.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -83.98 146.38 28.02 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 118.42 -1.312 . . . . 10.0 107.6 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -50.81 119.74 4.16 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.795 -1.187 . . . . 10.0 107.795 166.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.87 -134.66 4.34 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 108.103 -1.999 . . . . 10.0 108.103 177.051 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.53 -161.36 32.03 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 107.537 -2.225 . . . . 10.0 107.537 169.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -66.02 5.02 0.72 Allowed 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.519 1.479 . . . . 10.0 111.053 168.062 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.8 mtpm? -114.99 8.23 15.75 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.591 1.156 . . . . 10.0 111.412 172.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -126.04 169.16 13.03 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.018 -1.105 . . . . 10.0 108.018 165.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -89.45 -24.8 21.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.724 -0.843 . . . . 10.0 108.724 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -105.48 13.48 30.08 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 115.363 1.616 . . . . 10.0 115.363 -165.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -28.1 130.73 0.05 Allowed 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 127.547 2.339 . . . . 10.0 111.866 168.687 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -47.08 -68.38 0.2 Allowed 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.115 0.966 . . . . 10.0 110.83 -175.087 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.0 p -168.18 -50.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.193 0 N-CA-C 107.456 -1.313 . . . . 10.0 107.456 171.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.32 53.3 0.68 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.907 1.241 . . . . 10.0 110.504 179.279 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -91.84 92.91 8.58 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 105.817 -1.92 . . . . 10.0 105.817 169.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -73.67 -37.26 65.32 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.308 -1.738 . . . . 10.0 106.308 174.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.83 -104.28 2.73 Favored Glycine 0 N--CA 1.436 -1.328 0 N-CA-C 108.433 -1.867 . . . . 10.0 108.433 169.349 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -114.48 131.62 56.56 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.239 0.616 . . . . 10.0 110.191 -169.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.3 m -115.2 139.34 42.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 107.756 -1.202 . . . . 10.0 107.756 167.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -100.53 123.05 44.23 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 125.017 1.327 . . . . 10.0 110.244 -173.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.08 135.1 43.09 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 124.17 0.988 . . . . 10.0 110.514 179.331 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -58.99 168.8 1.18 Allowed 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.593 0.757 . . . . 10.0 110.213 167.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -50.58 -34.02 24.2 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.812 0.845 . . . . 10.0 110.767 169.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.0 t0 -79.37 0.71 28.03 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 120.859 0.361 . . . . 10.0 111.761 -178.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.25 13.83 82.36 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 120.733 -1.229 . . . . 10.0 110.695 177.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 45.2 t -89.73 103.33 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 C-N-CA 127.039 2.136 . . . . 10.0 106.29 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.548 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.66 120.92 41.1 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.092 -1.447 . . . . 10.0 107.092 168.23 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -81.45 117.64 22.05 Favored 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 126.479 1.911 . . . . 10.0 108.494 172.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 67.8 t -98.9 129.14 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.081 0 N-CA-C 106.553 -1.647 . . . . 10.0 106.553 175.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.8 p -157.91 68.29 0.5 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.678 0.791 . . . . 10.0 109.326 170.539 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.13 160.27 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.274 -1.75 . . . . 10.0 106.274 -177.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -135.7 148.01 48.72 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 121.755 -0.591 . . . . 10.0 111.055 169.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -133.14 160.98 35.65 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 125.408 1.483 . . . . 10.0 108.506 179.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 2.5 t -134.64 41.61 2.89 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.116 1.366 . . . . 10.0 111.933 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.8 p -132.43 -45.04 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 123.352 0.661 . . . . 10.0 110.315 167.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.06 154.16 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 121.843 0.83 . . . . 10.0 109.762 169.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.8 m -154.01 152.87 31.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.533 1.133 . . . . 10.0 108.458 168.477 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.87 -25.43 62.8 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.013 0.925 . . . . 10.0 110.137 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 16.2 t -131.6 179.91 5.77 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.456 1.102 . . . . 10.0 108.122 169.218 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.95 -71.47 0.48 Allowed Glycine 0 C--N 1.332 0.349 0 C-N-CA 124.873 1.225 . . . . 10.0 110.227 170.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -158.27 -52.22 0.07 Allowed 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 126.5 1.92 . . . . 10.0 106.72 -176.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -74.3 -32.28 62.81 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 114.277 -1.329 . . . . 10.0 108.995 -174.009 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 23.3 t 25.2 76.28 0.02 OUTLIER 'General case' 0 C--N 1.344 0.338 0 C-N-CA 128.191 2.596 . . . . 10.0 112.67 169.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 27.1 pt -63.17 -10.59 6.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 N-CA-C 113.984 1.105 . . . . 10.0 113.984 -169.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 5.7 mm -34.51 -45.71 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.271 0 C-N-CA 126.741 2.016 . . . . 10.0 114.833 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.78 14.43 57.53 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.363 0.982 . . . . 10.0 113.629 -173.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -90.68 175.89 6.86 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.688 1.195 . . . . 10.0 110.497 178.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -122.19 142.28 50.58 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 124.419 1.088 . . . . 10.0 109.747 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.657 ' HB2' HD21 ' B' ' 8' ' ' LEU . 1.7 mm? -101.5 154.96 18.37 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.248 -1.39 . . . . 10.0 107.248 168.032 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.11 137.54 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 106.296 -1.742 . . . . 10.0 106.296 169.064 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.465 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.5 OUTLIER -106.2 138.22 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.269 -2.123 . . . . 10.0 105.269 168.586 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.564 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.0 m170 -117.83 160.33 21.57 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 114.763 1.394 . . . . 10.0 114.763 -169.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 68.1 tt0 -45.19 -53.72 7.84 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.597 2.759 . . . . 10.0 109.949 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 69.5 mttt -124.52 175.35 7.21 Favored 'General case' 0 CA--C 1.518 -0.27 0 C-N-CA 125.286 1.434 . . . . 10.0 110.273 -170.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.28 139.03 35.67 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.513 0.725 . . . . 10.0 109.168 175.036 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -78.12 148.1 34.33 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 123.326 0.65 . . . . 10.0 110.484 169.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -78.1 10.12 3.18 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 124.986 1.314 . . . . 10.0 111.196 174.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 16.5 mt 46.16 41.27 8.4 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.223 1.409 . . . . 10.0 110.829 -179.073 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 104.59 -39.76 2.71 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 125.233 1.397 . . . . 10.0 112.538 177.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.5 ' HD3' ' H ' ' B' ' 128' ' ' LYS . 0.1 OUTLIER -79.9 37.34 0.36 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.176 1.39 . . . . 10.0 111.769 -167.64 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -95.57 -12.07 54.35 Favored Glycine 0 CA--C 1.523 0.564 0 C-N-CA 125.568 1.556 . . . . 10.0 111.671 177.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 48.99 38.18 23.88 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 123.892 0.758 . . . . 10.0 111.779 -175.369 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -124.75 155.58 39.09 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 107.149 -1.426 . . . . 10.0 107.149 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 15.3 tm-20 -52.58 -44.24 65.79 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 114.123 -1.399 . . . . 10.0 108.353 169.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -65.05 -40.01 94.11 Favored 'General case' 0 CA--C 1.541 0.606 0 O-C-N 121.608 -0.683 . . . . 10.0 112.049 171.056 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 9.1 p -57.2 -40.67 77.91 Favored 'General case' 0 C--N 1.347 0.467 0 CA-C-N 121.141 1.791 . . . . 10.0 111.249 -179.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.1 t -72.97 -18.27 61.38 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 119.953 -0.699 . . . . 10.0 112.515 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -103.74 -50.65 3.36 Favored 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 126.14 1.776 . . . . 10.0 112.799 -168.345 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.421 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 24.1 p -120.92 -10.92 9.02 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 118.584 -0.722 . . . . 10.0 112.896 171.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 92.94 -1.57 71.0 Favored Glycine 0 C--N 1.337 0.636 0 CA-C-O 118.784 -1.009 . . . . 10.0 112.388 -172.13 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 71.12 31.76 2.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.596 1.198 . . . . 10.0 111.297 177.388 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.11 6.32 2.24 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.43 1.092 . . . . 10.0 112.209 174.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.87 -162.38 53.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.279 -1.128 . . . . 10.0 110.279 172.045 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.3 m -56.83 129.16 40.2 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-O 121.571 0.7 . . . . 10.0 111.388 -168.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.62 73.73 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.881 1.273 . . . . 10.0 109.259 169.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -74.09 -12.71 60.68 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 113.79 1.033 . . . . 10.0 113.79 -169.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.465 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -160.98 144.45 13.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.09 0.471 . . . . 10.0 111.795 175.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -138.28 151.43 47.6 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 126.507 1.923 . . . . 10.0 108.327 -169.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . 0.521 ' N ' HD23 ' B' ' 8' ' ' LEU . . . -153.36 142.28 9.07 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 179.391 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.3 t -102.87 137.12 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 105.672 -1.973 . . . . 10.0 105.672 -175.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.524 HD11 HD21 ' B' ' 117' ' ' LEU . 5.5 mt -72.19 158.06 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 108.939 -0.763 . . . . 10.0 108.939 -179.144 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -166.97 154.84 25.55 Favored Glycine 0 CA--C 1.528 0.888 0 O-C-N 122.007 -0.433 . . . . 10.0 112.247 -173.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 92.1 mt -68.19 131.41 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 124.882 1.273 . . . . 10.0 109.432 -174.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.81 -12.24 1.13 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 115.993 1.849 . . . . 10.0 115.993 -173.159 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.274 0.0 OUTLIER . . . . . 0 C--O 1.254 1.3 0 C-N-CA 128.774 2.83 . . . . 10.0 116.471 -170.171 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.829 0 N-CA-C 108.03 -1.1 . . . . 10.0 108.03 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -155.99 -43.73 0.08 Allowed 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.525 0.602 . . . . 10.0 111.247 171.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -118.79 130.49 55.81 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 169.076 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -129.89 163.24 26.78 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.751 1.221 . . . . 10.0 108.422 176.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.498 ' CG1' ' HB2' ' B' ' 52' ' ' ASP . 2.0 m -143.24 163.71 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 118.235 0.471 . . . . 10.0 109.873 -177.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.5 110.43 6.83 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.707 1.254 . . . . 10.0 108.048 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.445 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.3 OUTLIER -82.61 119.88 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 N-CA-C 106.445 -1.687 . . . . 10.0 106.445 167.427 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.5 mt -98.52 135.51 39.97 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 107.723 -1.214 . . . . 10.0 107.723 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -157.54 159.72 37.45 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 120.564 1.529 . . . . 10.0 108.217 172.101 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 173.54 -40.32 0.14 Allowed Glycine 0 N--CA 1.461 0.304 0 C-N-CA 119.858 -1.163 . . . . 10.0 113.312 169.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -73.96 -47.3 38.44 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 107.589 -1.264 . . . . 10.0 107.589 -177.392 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.65 -73.08 0.31 Allowed Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.691 -1.364 . . . . 10.0 109.691 170.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -58.6 -39.6 81.35 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 123.126 2.551 . . . . 10.0 111.119 173.017 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.49 101.8 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 107.808 -1.182 . . . . 10.0 107.808 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -118.4 108.08 14.61 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 108.116 -1.068 . . . . 10.0 108.116 170.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.684 ' CA ' HG22 ' A' ' 35' ' ' ILE . . . -84.92 147.04 22.45 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 123.995 0.807 . . . . 10.0 111.556 169.008 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mt -140.72 82.2 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 N-CA-C 105.946 -1.872 . . . . 10.0 105.946 177.013 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.0 mm -89.92 138.96 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 C-N-CA 124.002 0.921 . . . . 10.0 108.956 177.161 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -130.47 126.65 37.46 Favored 'General case' 0 C--O 1.232 0.142 0 C-N-CA 125.693 1.597 . . . . 10.0 109.552 175.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -109.87 105.21 14.31 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 125.267 1.427 . . . . 10.0 109.368 177.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -86.26 134.32 33.77 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 120.034 -0.666 . . . . 10.0 110.81 167.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -135.07 82.84 1.98 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.642 2.377 . . . . 10.0 106.136 168.074 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.4 tttp -53.01 -51.03 62.97 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 125.793 1.637 . . . . 10.0 109.454 179.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 58.8 mt-10 -135.95 169.17 18.02 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 105.932 -1.877 . . . . 10.0 105.932 169.279 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.2 p -72.41 -10.0 59.24 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 109.992 -0.374 . . . . 10.0 109.992 170.098 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.5 m-80 -75.41 -24.79 57.17 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.519 -0.549 . . . . 10.0 109.519 170.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.33 129.0 9.3 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.29 -1.124 . . . . 10.0 110.29 -173.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -63.2 131.06 30.8 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 N-CA-C 105.957 -2.363 . . . . 10.0 105.957 168.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.2 t -78.0 107.88 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.154 -1.054 . . . . 10.0 108.154 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.62 96.39 3.55 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 170.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -83.6 106.61 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 N-CA-C 106.494 -1.669 . . . . 10.0 106.494 170.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 10.1 p90 -113.91 171.12 7.79 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.47 0.653 . . . . 10.0 109.901 172.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.94 170.11 41.09 Favored Glycine 0 N--CA 1.437 -1.256 0 C-N-CA 120.088 -1.053 . . . . 10.0 110.564 174.119 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.3 p -137.98 107.97 6.36 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.684 HG22 ' CA ' ' A' ' 16' ' ' GLY . 1.7 pt -90.8 145.22 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 167.383 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -140.05 147.58 40.54 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 107.37 -1.344 . . . . 10.0 107.37 175.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.25 -14.13 25.81 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.287 -0.729 . . . . 10.0 114.108 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.442 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.6 mp -74.27 179.48 4.49 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 118.692 1.246 . . . . 10.0 110.475 -179.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -95.97 169.02 10.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 107.822 -1.177 . . . . 10.0 107.822 165.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -58.21 168.29 1.09 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.981 1.312 . . . . 10.0 111.532 -172.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.93 -176.61 36.31 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-O 122.039 0.8 . . . . 10.0 112.671 167.349 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.65 142.49 51.6 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 124.539 1.136 . . . . 10.0 109.681 177.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -142.05 150.42 41.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 112.896 0.702 . . . . 10.0 112.896 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.613 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -37.78 123.85 1.21 Allowed Glycine 0 C--N 1.34 0.786 0 C-N-CA 127.382 2.42 . . . . 10.0 112.061 166.227 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -151.88 108.5 3.47 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 118.563 1.181 . . . . 10.0 108.997 168.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.22 174.59 12.21 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 120.876 0.37 . . . . 10.0 111.354 177.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 11.1 m -104.77 -18.38 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 O-C-N 125.658 1.849 . . . . 10.0 114.676 -168.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 57.29 175.76 0.05 OUTLIER 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 125.322 1.449 . . . . 10.0 112.861 -177.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -72.62 -69.45 0.41 Allowed 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.561 -0.745 . . . . 10.0 109.855 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -92.02 176.92 6.33 Favored 'General case' 0 N--CA 1.454 -0.256 0 O-C-N 123.534 0.521 . . . . 10.0 111.279 -168.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.12 -22.75 11.36 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 125.477 1.513 . . . . 10.0 111.556 170.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -50.81 117.9 2.79 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-O 122.343 1.068 . . . . 10.0 111.935 -177.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -123.14 17.84 9.96 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.988 -1.006 . . . . 10.0 111.552 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -48.42 -41.77 30.2 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.176 1.79 . . . . 10.0 111.562 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.11 -21.62 46.38 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.225 1.01 . . . . 10.0 112.763 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.0 102.31 0.92 Allowed Glycine 0 CA--C 1.527 0.825 0 N-CA-C 108.392 -1.883 . . . . 10.0 108.392 -169.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.276 1.5 p 15.75 80.42 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 127.031 2.132 . . . . 10.0 113.819 -173.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -161.38 -54.99 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 107.541 -1.281 . . . . 10.0 107.541 179.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -65.59 -31.38 72.38 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 123.8 0.84 . . . . 10.0 110.99 -177.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.97 -6.76 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 129.024 2.93 . . . . 10.0 118.012 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.36 123.26 3.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.212 -1.155 . . . . 10.0 110.212 176.183 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.7 60.49 6.67 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.582 2.855 . . . . 10.0 110.765 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 21.7 m170 72.12 38.28 0.9 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 129.716 3.206 . . . . 10.0 112.584 172.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -74.53 67.94 1.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.386 0.994 . . . . 10.0 111.671 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 13.7 p-10 -58.97 154.71 36.92 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 123.947 0.899 . . . . 10.0 111.108 169.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.36 -46.15 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 122.656 2.238 . . . . 10.0 111.602 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 86.8 mt -75.53 59.79 1.15 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.266 0.627 . . . . 10.0 109.696 176.134 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -45.95 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.771 1.628 . . . . 10.0 111.558 -171.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -132.21 -176.54 4.11 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 107.237 -1.394 . . . . 10.0 107.237 -176.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.412 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 24.2 mttp -93.78 123.74 37.33 Favored 'General case' 0 N--CA 1.438 -1.068 0 C-N-CA 118.224 -1.39 . . . . 10.0 108.622 -169.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.432 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 85.9 t60 -35.2 112.53 0.16 Allowed 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 113.316 0.858 . . . . 10.0 113.316 178.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.03 -136.98 4.33 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 108.058 -2.017 . . . . 10.0 108.058 -178.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.06 -168.77 30.66 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 173.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -63.26 -2.8 4.25 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.025 1.817 . . . . 10.0 111.603 168.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -94.97 -19.92 19.81 Favored 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.265 1.026 . . . . 10.0 110.746 173.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -103.11 167.58 9.73 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -86.49 -31.99 21.02 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 107.322 -1.362 . . . . 10.0 107.322 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.412 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS 0.257 7.1 pt-20 -100.49 24.55 8.78 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 114.435 1.272 . . . . 10.0 114.435 -165.525 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.5 ptm180 -42.83 145.3 0.48 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 127.218 2.207 . . . . 10.0 110.346 168.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.432 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 30.9 m170 -67.61 -64.58 0.83 Allowed 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.52 0.676 . . . . 10.0 109.66 178.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.62 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.5 p -169.33 -91.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 105.472 -2.048 . . . . 10.0 105.472 173.358 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.62 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -80.51 56.32 4.7 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 111.04 -0.824 . . . . 10.0 111.04 174.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -90.9 83.16 5.64 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 103.342 -2.836 . . . . 10.0 103.342 166.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -65.26 -26.45 68.1 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 118.391 0.541 . . . . 10.0 109.821 -173.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 114.41 -89.08 0.5 Allowed Glycine 0 N--CA 1.44 -1.044 0 N-CA-C 108.082 -2.007 . . . . 10.0 108.082 169.428 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -155.52 124.82 6.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.741 -1.207 . . . . 10.0 107.741 -171.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.39 125.89 66.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 118.193 0.452 . . . . 10.0 110.84 178.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -78.82 112.01 15.54 Favored 'General case' 0 N--CA 1.444 -0.761 0 C-N-CA 127.554 2.341 . . . . 10.0 111.116 -177.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.74 134.79 34.16 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.863 0.465 . . . . 10.0 109.938 171.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -60.1 172.27 0.83 Allowed 'General case' 0 C--O 1.232 0.154 0 O-C-N 123.82 0.7 . . . . 10.0 109.441 168.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.5 pttm -48.67 -33.2 9.59 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.745 1.618 . . . . 10.0 109.793 173.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -79.1 -8.19 58.77 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 124.486 1.115 . . . . 10.0 110.812 -173.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.02 -0.26 86.01 Favored Glycine 0 C--N 1.338 0.678 0 N-CA-C 111.234 -0.746 . . . . 10.0 111.234 -174.247 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 53.5 t -78.43 105.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 106.776 -1.564 . . . . 10.0 106.776 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.53 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -106.23 117.47 34.12 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 169.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -80.37 118.05 21.67 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 127.123 2.169 . . . . 10.0 108.892 172.481 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.2 t -108.32 131.0 59.98 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.964 0 N-CA-C 106.862 -1.532 . . . . 10.0 106.862 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.2 p -157.36 86.81 0.95 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.455 0.702 . . . . 10.0 109.49 171.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.99 143.09 28.11 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 N-CA-C 107.991 -1.115 . . . . 10.0 107.991 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -111.61 129.5 56.06 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.816 -1.92 . . . . 10.0 105.816 167.069 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -140.54 117.69 11.26 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.355 -0.98 . . . . 10.0 108.355 179.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.5 p -87.15 49.42 1.81 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.891 1.676 . . . . 10.0 108.256 -169.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 p -145.24 -51.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.478 -0.783 . . . . 10.0 109.433 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -51.11 132.36 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 122.926 0.49 . . . . 10.0 110.016 175.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.9 p -131.92 136.12 47.14 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.214 1.406 . . . . 10.0 108.551 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 50.1 mt -56.63 -42.69 79.3 Favored 'General case' 0 C--N 1.341 0.199 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 169.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.8 t -146.07 128.88 16.3 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 104.991 -2.225 . . . . 10.0 104.991 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 149.54 69.4 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.771 -1.332 . . . . 10.0 109.771 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.7 t70 72.41 -60.25 0.53 Allowed 'General case' 0 CA--C 1.509 -0.633 0 C-N-CA 129.742 3.217 . . . . 10.0 109.482 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.7 m-70 -74.19 -44.71 52.3 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 107.692 -1.225 . . . . 10.0 107.692 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t 54.96 82.05 0.1 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.051 1.34 . . . . 10.0 111.714 173.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.5 pt -71.65 -18.16 19.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 O-C-N 120.999 -1.063 . . . . 10.0 112.699 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 16.2 mm -52.65 129.89 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 118.202 0.456 . . . . 10.0 110.156 172.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.58 22.57 77.06 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.684 -1.064 . . . . 10.0 113.644 175.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.9 mtt85 -89.08 175.75 7.26 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 118.235 1.018 . . . . 10.0 110.602 167.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -118.47 110.63 17.64 Favored 'General case' 0 C--N 1.347 0.486 0 N-CA-C 106.844 -1.539 . . . . 10.0 106.844 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mp -87.18 138.88 31.11 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.548 -0.908 . . . . 10.0 108.548 176.313 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 49.1 t -132.04 132.34 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 107.615 -1.254 . . . . 10.0 107.615 -173.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.487 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.5 OUTLIER -105.67 128.11 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 106.081 -1.822 . . . . 10.0 106.081 174.806 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.613 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.6 m170 -111.78 157.55 20.42 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 114.554 1.316 . . . . 10.0 114.554 -171.434 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -46.64 -59.52 2.97 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 127.572 2.349 . . . . 10.0 110.488 176.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 51.3 mttp -112.21 169.86 8.57 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.702 0.763 . . . . 10.0 112.042 -170.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.5 151.08 47.95 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 114.034 -1.439 . . . . 10.0 109.291 172.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -77.03 150.04 35.81 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 122.296 1.046 . . . . 10.0 110.944 172.649 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.476 ' HB3' ' CA ' ' A' ' 138' ' ' GLY . 4.4 t70 -79.04 -37.75 38.26 Favored 'General case' 0 N--CA 1.443 -0.824 0 C-N-CA 130.103 3.361 . . . . 10.0 110.596 172.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 48.5 mt 63.53 46.53 4.2 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.924 1.29 . . . . 10.0 111.656 178.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 79.64 10.24 86.0 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-N 115.23 -0.895 . . . . 10.0 114.703 167.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 26.8 mttm -97.06 -11.81 23.98 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 117.999 0.899 . . . . 10.0 112.18 -174.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.98 -21.45 69.68 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 125.124 1.345 . . . . 10.0 112.384 176.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.08 35.75 65.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.247 -0.741 . . . . 10.0 111.247 -177.215 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -129.89 169.94 14.56 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 173.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -52.43 -48.0 66.03 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 123.654 0.781 . . . . 10.0 109.628 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -58.98 -45.5 90.41 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 118.669 -0.682 . . . . 10.0 111.712 175.731 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.9 p -49.87 -43.59 49.32 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 109.206 -0.665 . . . . 10.0 109.206 177.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.1 t -84.3 -3.56 58.32 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -174.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 92.5 mttt -110.71 -69.58 0.86 Allowed 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.692 1.597 . . . . 10.0 111.85 -179.201 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -127.3 28.91 5.64 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 119.437 1.017 . . . . 10.0 109.935 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.476 ' CA ' ' HB3' ' A' ' 125' ' ' ASP . . . 66.84 -105.31 1.29 Allowed Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 107.519 -2.232 . . . . 10.0 107.519 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -157.3 42.6 0.33 Allowed 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 107.059 -1.46 . . . . 10.0 107.059 169.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.84 -12.38 53.87 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.606 0.762 . . . . 10.0 111.616 -175.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.81 -158.7 48.81 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.618 -1.393 . . . . 10.0 109.618 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.0 m -61.76 129.27 40.2 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 123.129 0.572 . . . . 10.0 111.599 -169.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -59.03 92.03 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.991 0.916 . . . . 10.0 109.661 169.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.4 mt -64.44 -41.58 96.49 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.444 -0.785 . . . . 10.0 111.309 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.487 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -152.0 148.89 28.26 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.731 0.301 . . . . 10.0 110.391 -172.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -124.24 146.68 48.58 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.679 1.591 . . . . 10.0 107.801 -169.426 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.85 156.65 27.03 Favored Glycine 0 CA--C 1.52 0.362 0 N-CA-C 108.545 -1.822 . . . . 10.0 108.545 168.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 53.8 t -119.69 134.91 61.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 106.243 -1.762 . . . . 10.0 106.243 -175.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.1 mt -75.66 138.44 20.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 CA-C-N 118.679 0.672 . . . . 10.0 111.014 -177.005 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -150.55 172.7 30.27 Favored Glycine 0 CA--C 1.53 0.984 0 N-CA-C 112.313 -0.315 . . . . 10.0 112.313 170.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 64.7 mt -72.79 142.4 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 125.194 1.397 . . . . 10.0 109.08 -169.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.421 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . . . -119.98 -48.22 2.36 Favored 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 123.4 0.68 . . . . 10.0 111.301 172.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 . . . . . 0 C--O 1.248 1.009 0 CA-C-O 116.685 -1.626 . . . . 10.0 110.026 -167.969 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.694 0 N-CA-C 105.631 -1.989 . . . . 10.0 105.631 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.24 76.88 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 120.055 1.298 . . . . 10.0 108.278 168.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.37 158.0 32.09 Favored 'General case' 0 C--O 1.242 0.667 0 C-N-CA 124.481 1.112 . . . . 10.0 109.576 168.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.14 158.51 41.93 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 127.04 2.136 . . . . 10.0 106.078 169.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 m -111.44 178.67 1.25 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 CA-C-N 118.365 0.53 . . . . 10.0 109.601 174.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.24 101.63 2.4 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 107.475 -1.306 . . . . 10.0 107.475 165.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.417 HG12 HG23 ' B' ' 17' ' ' ILE . 32.2 m -92.33 130.75 40.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 N-CA-C 107.863 -1.162 . . . . 10.0 107.863 172.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.448 HD12 ' N ' ' B' ' 8' ' ' LEU . 5.1 mp -110.05 155.7 21.51 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.32 1.048 . . . . 10.0 108.641 176.175 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.0 tttt -164.2 167.99 19.41 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 169.107 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 177.2 -48.42 0.1 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.047 -1.549 . . . . 10.0 112.29 168.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -76.08 -46.63 28.04 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 107.893 -1.151 . . . . 10.0 107.893 -177.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 138.76 -67.2 0.52 Allowed Glycine 0 CA--C 1.526 0.775 0 CA-C-N 114.483 -1.235 . . . . 10.0 110.604 178.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -62.5 -36.2 66.84 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 122.794 2.329 . . . . 10.0 110.68 171.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 89.2 t -72.82 113.91 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.93 134.13 27.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.764 -0.458 . . . . 10.0 109.764 166.199 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.52 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -101.96 154.38 18.71 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 124.635 1.112 . . . . 10.0 111.269 175.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.417 HG23 HG12 ' B' ' 7' ' ' VAL . 0.1 OUTLIER -153.31 81.5 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 106.277 -1.749 . . . . 10.0 106.277 -172.878 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 31.2 mm -105.67 151.96 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 C-N-CA 125.216 1.407 . . . . 10.0 109.657 -175.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -126.17 118.4 25.13 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 127.199 2.199 . . . . 10.0 107.295 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -98.41 116.46 30.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 170.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -117.25 125.61 51.41 Favored 'General case' 0 N--CA 1.465 0.308 0 O-C-N 123.716 0.635 . . . . 10.0 112.61 169.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -81.34 106.49 13.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.404 -2.072 . . . . 10.0 105.404 169.079 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.0 tttt -56.81 -43.63 81.19 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 124.869 1.268 . . . . 10.0 109.214 -171.497 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -130.43 -167.42 1.82 Allowed 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 103.0 -2.963 . . . . 10.0 103.0 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.7 m -79.0 -26.4 43.28 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 119.902 1.228 . . . . 10.0 109.412 172.494 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -111.88 -5.22 14.39 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 124.369 1.068 . . . . 10.0 111.799 -176.3 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.49 151.3 52.16 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 109.593 -1.403 . . . . 10.0 109.593 177.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -59.61 140.96 96.23 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.451 2.101 . . . . 10.0 108.292 174.085 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 p -79.89 103.56 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.537 0 N-CA-C 106.482 -1.673 . . . . 10.0 106.482 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 45.1 tttp -80.13 122.16 26.46 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 106.209 -1.774 . . . . 10.0 106.209 172.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.13 100.47 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 C-N-CA 127.566 2.346 . . . . 10.0 105.726 -178.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.8 p90 -125.56 155.71 40.24 Favored 'General case' 0 C--N 1.339 0.149 0 N-CA-C 112.986 0.735 . . . . 10.0 112.986 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.34 -145.86 13.68 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 106.383 -2.687 . . . . 10.0 106.383 173.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.5 p -157.35 168.16 28.18 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 118.798 -1.161 . . . . 10.0 111.998 177.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.613 HG12 ' HB3' ' B' ' 95' ' ' ALA . 1.8 pt -117.72 146.46 22.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 114.379 -1.282 . . . . 10.0 109.44 166.678 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.7 tptt -115.11 146.51 41.27 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 106.464 -1.68 . . . . 10.0 106.464 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.96 -10.1 37.27 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-O 119.538 -0.59 . . . . 10.0 114.073 168.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -62.0 174.45 0.87 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 118.181 0.99 . . . . 10.0 110.561 175.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -108.72 160.7 15.75 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 106.595 -1.631 . . . . 10.0 106.595 167.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -53.72 150.57 7.12 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.61 0.764 . . . . 10.0 111.962 -169.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.51 -172.64 23.19 Favored Glycine 0 CA--C 1.524 0.629 0 C-N-CA 123.496 0.569 . . . . 10.0 111.922 169.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -74.95 149.93 39.23 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.272 1.429 . . . . 10.0 111.594 -173.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -150.97 143.62 24.4 Favored 'General case' 0 C--N 1.342 0.24 0 N-CA-C 113.912 1.079 . . . . 10.0 113.912 -175.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.557 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -31.72 126.21 0.23 Allowed Glycine 0 C--N 1.341 0.808 0 C-N-CA 128.247 2.832 . . . . 10.0 112.38 166.019 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.464 ' CE1' HD12 ' B' ' 117' ' ' LEU . 0.1 OUTLIER -147.32 107.62 4.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 119.646 1.723 . . . . 10.0 109.887 167.303 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 176.54 9.75 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 109.718 -0.475 . . . . 10.0 109.718 174.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . 0.466 HG12 HD13 ' B' ' 117' ' ' LEU . 2.4 m -117.71 -15.48 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 125.134 1.521 . . . . 10.0 113.662 -173.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 58.15 171.7 0.05 Allowed 'General case' 0 C--N 1.345 0.412 0 CA-C-O 122.437 1.113 . . . . 10.0 111.661 175.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -72.37 -59.39 2.75 Favored 'General case' 0 N--CA 1.441 -0.885 0 O-C-N 121.507 -0.746 . . . . 10.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -87.04 156.62 19.68 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 121.831 -0.543 . . . . 10.0 109.546 -171.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.72 14.42 29.53 Favored Glycine 0 CA--C 1.524 0.62 0 C-N-CA 125.179 1.371 . . . . 10.0 110.754 177.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.498 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . 0.1 OUTLIER -93.77 175.23 6.81 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 121.918 0.866 . . . . 10.0 110.03 179.839 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.445 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -151.81 33.02 0.55 Allowed 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.055 -0.975 . . . . 10.0 111.165 169.241 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.23 -37.2 79.6 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.593 -0.692 . . . . 10.0 112.763 -168.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.57 -20.55 46.73 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 117.766 0.257 . . . . 10.0 111.146 175.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 123.72 -157.59 18.17 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 105.727 -2.949 . . . . 10.0 105.727 -167.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 2.8 t -65.27 7.72 0.19 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 126.06 1.744 . . . . 10.0 115.189 -169.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 62.2 m -97.74 -49.09 4.96 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 125.93 1.692 . . . . 10.0 108.544 -171.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.1 m -47.41 -39.96 16.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 126.326 1.85 . . . . 10.0 113.061 -166.482 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.89 -39.92 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 128.067 2.547 . . . . 10.0 113.929 168.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.3 162.84 15.23 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 121.44 -0.787 . . . . 10.0 111.951 167.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -86.7 37.94 0.54 Allowed 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.375 2.717 . . . . 10.0 111.885 -172.418 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 71.31 116.38 0.05 OUTLIER 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.38 2.272 . . . . 10.0 110.834 -170.271 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' B' ' 64' ' ' PHE . 0.0 OUTLIER -33.8 94.06 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 127.089 2.156 . . . . 10.0 113.268 165.922 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -105.69 32.71 0.05 OUTLIER Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 116.948 2.203 . . . . 10.0 116.948 -177.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -62.82 -55.88 0.73 Allowed 'Trans proline' 0 C--N 1.35 0.658 0 CA-C-N 122.951 2.09 . . . . 10.0 112.585 -172.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.03 41.88 0.45 Allowed 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.236 -0.915 . . . . 10.0 112.86 -176.308 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 88.0 p 17.41 69.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 128.48 2.712 . . . . 10.0 114.868 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.72 149.17 43.64 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 105.801 -1.926 . . . . 10.0 105.801 172.634 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 30.6 mttm -101.64 106.23 17.26 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 118.746 -0.645 . . . . 10.0 109.637 -168.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.4 t60 -2.33 87.46 0.0 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 126.596 1.959 . . . . 10.0 115.193 -178.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.49 -135.33 8.72 Favored Glycine 0 C--N 1.318 -0.465 0 N-CA-C 109.045 -1.622 . . . . 10.0 109.045 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.68 -168.82 37.88 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 107.467 -2.253 . . . . 10.0 107.467 173.039 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -65.25 -0.72 3.7 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 CA-C-N 119.561 1.68 . . . . 10.0 110.749 167.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 4.7 mtpm? -109.24 6.79 24.96 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 125.924 1.689 . . . . 10.0 111.0 175.476 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.99 174.14 10.95 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 165.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.3 -37.01 38.76 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 107.402 -1.332 . . . . 10.0 107.402 169.1 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -81.71 28.59 0.41 Allowed 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 125.433 1.493 . . . . 10.0 114.626 -165.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.67 134.89 41.61 Favored 'General case' 0 N--CA 1.456 -0.141 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 168.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -56.17 -66.43 0.43 Allowed 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.664 -0.495 . . . . 10.0 109.664 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 3.9 p -169.23 -46.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 O-C-N 124.262 0.976 . . . . 10.0 109.132 -176.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.79 53.67 0.79 Allowed Glycine 0 CA--C 1.536 1.379 0 CA-C-N 118.909 0.777 . . . . 10.0 111.865 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -89.38 99.35 12.36 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.655 -1.239 . . . . 10.0 107.655 172.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -70.49 -40.96 73.29 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.289 -1.375 . . . . 10.0 107.289 174.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.02 -93.42 1.03 Allowed Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 124.409 1.004 . . . . 10.0 112.266 168.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -127.66 123.69 36.14 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 123.779 0.832 . . . . 10.0 109.992 -168.06 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.3 m -119.95 150.31 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 N-CA-C 108.536 -0.913 . . . . 10.0 108.536 167.222 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -98.24 125.34 43.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.859 1.663 . . . . 10.0 109.204 -177.285 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.27 134.45 38.03 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 108.804 -0.813 . . . . 10.0 108.804 171.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.8 t0 -62.05 170.1 2.35 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 124.188 0.93 . . . . 10.0 109.565 167.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 9.4 pttm -52.19 -31.26 30.9 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 125.213 1.405 . . . . 10.0 111.246 173.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -81.91 -1.76 48.97 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.218 0.607 . . . . 10.0 111.386 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.37 9.32 86.65 Favored Glycine 0 C--N 1.339 0.717 0 O-C-N 120.787 -1.195 . . . . 10.0 111.216 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 39.3 t -80.62 106.11 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 126.2 1.8 . . . . 10.0 106.32 172.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.613 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -107.39 120.15 41.36 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.096 -1.076 . . . . 10.0 108.096 169.119 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -80.96 125.5 30.22 Favored 'General case' 0 N--CA 1.437 -1.112 0 C-N-CA 127.233 2.213 . . . . 10.0 109.762 176.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.2 t -111.03 133.71 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.957 0 C-N-CA 125.645 1.578 . . . . 10.0 108.105 175.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 96.9 p -157.63 57.61 0.49 Allowed 'General case' 0 C--O 1.235 0.303 0 C-N-CA 123.141 0.576 . . . . 10.0 111.207 169.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -93.38 144.52 9.3 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.287 0 N-CA-C 107.395 -1.335 . . . . 10.0 107.395 -172.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -90.98 128.13 36.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 107.471 -1.307 . . . . 10.0 107.471 167.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -107.06 100.93 10.38 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.278 -1.749 . . . . 10.0 106.278 166.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.77 24.14 4.33 Favored 'General case' 0 N--CA 1.44 -0.957 0 C-N-CA 126.688 1.995 . . . . 10.0 109.948 176.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 38.9 t -120.74 -55.86 3.31 Favored 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 -178.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.348 0.6 OUTLIER -94.3 178.03 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 C-N-CA 123.839 0.856 . . . . 10.0 113.266 -179.039 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 27.1 m -155.4 161.4 41.02 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 123.785 0.834 . . . . 10.0 110.109 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 92.5 mt -81.25 3.92 22.25 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 125.721 1.608 . . . . 10.0 112.456 -175.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.9 t -157.93 -169.48 2.84 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 107.845 -1.168 . . . . 10.0 107.845 168.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 111.32 -85.09 0.38 Allowed Glycine 0 C--N 1.333 0.374 0 N-CA-C 109.114 -1.594 . . . . 10.0 109.114 168.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -136.66 -49.61 0.65 Allowed 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 125.935 1.694 . . . . 10.0 107.899 174.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -72.43 -35.02 68.21 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 107.838 -1.171 . . . . 10.0 107.838 -171.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 42.3 t 31.95 67.13 0.15 Allowed 'General case' 0 N--CA 1.442 -0.868 0 C-N-CA 128.271 2.629 . . . . 10.0 110.503 167.669 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 1.3 pt -79.04 57.53 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 122.372 1.082 . . . . 10.0 110.806 -171.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 19.4 mm -96.21 -37.8 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 C-N-CA 127.725 2.41 . . . . 10.0 110.474 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.75 49.92 0.81 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.563 -1.015 . . . . 10.0 110.563 -175.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.57 169.52 8.65 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.864 2.065 . . . . 10.0 108.746 175.108 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -122.91 103.37 8.57 Favored 'General case' 0 C--N 1.344 0.353 0 C-N-CA 124.837 1.255 . . . . 10.0 109.955 -177.026 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.466 HD13 HG12 ' B' ' 47' ' ' VAL . 1.1 mm? -61.85 134.57 56.86 Favored 'General case' 0 CA--C 1.52 -0.183 0 N-CA-C 108.152 -1.055 . . . . 10.0 108.152 169.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.45 132.78 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 107.924 -1.139 . . . . 10.0 107.924 176.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 m -108.27 134.43 50.15 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 O-C-N 124.282 0.989 . . . . 10.0 110.366 167.415 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.557 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.3 m170 -110.54 158.0 19.03 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -171.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -40.22 -57.18 1.77 Allowed 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 129.272 3.029 . . . . 10.0 111.192 173.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 mttm -123.85 175.18 7.06 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.902 1.281 . . . . 10.0 109.495 -175.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.17 149.56 33.72 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.766 0.826 . . . . 10.0 109.708 175.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -74.92 152.84 38.81 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.78 -1.193 . . . . 10.0 107.78 168.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -76.15 -5.79 48.28 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 124.591 1.182 . . . . 10.0 110.719 171.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 50.5 mt 51.03 58.15 5.87 Favored 'General case' 0 C--N 1.342 0.271 0 C-N-CA 124.32 1.048 . . . . 10.0 108.798 -177.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.42 -39.44 3.12 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 124.93 1.252 . . . . 10.0 111.261 169.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.8 mtmt -79.13 47.19 0.76 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.211 1.004 . . . . 10.0 111.373 -178.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.57 -22.31 10.48 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 126.891 2.186 . . . . 10.0 111.298 174.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.18 44.41 43.06 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.055 0.836 . . . . 10.0 112.784 176.58 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -151.49 172.84 15.35 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 108.797 -0.816 . . . . 10.0 108.797 174.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -51.75 -41.53 61.65 Favored 'General case' 0 N--CA 1.445 -0.72 0 C-N-CA 122.96 0.504 . . . . 10.0 111.652 -176.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -71.59 -25.0 62.0 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.33 -0.856 . . . . 10.0 111.891 178.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 36.8 p -59.96 -20.8 59.54 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 113.61 0.967 . . . . 10.0 113.61 -177.136 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 7.4 t -94.75 -12.81 26.47 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.622 0.646 . . . . 10.0 110.258 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -109.32 -65.96 1.1 Allowed 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 126.7 2.0 . . . . 10.0 111.514 -171.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.02 31.4 3.87 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 120.266 1.394 . . . . 10.0 110.857 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 65.04 -93.57 0.16 Allowed Glycine 0 C--N 1.343 0.933 0 N-CA-C 108.859 -1.696 . . . . 10.0 108.859 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -164.43 39.73 0.08 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.709 1.204 . . . . 10.0 108.402 167.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.04 -11.84 58.21 Favored 'General case' 0 N--CA 1.456 -0.167 0 N-CA-C 113.637 0.977 . . . . 10.0 113.637 -168.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.44 -165.22 53.64 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.427 -1.069 . . . . 10.0 110.427 177.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.3 t -57.02 130.9 48.1 Favored 'General case' 0 N--CA 1.447 -0.611 0 C-N-CA 123.812 0.845 . . . . 10.0 112.217 -168.082 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -64.21 76.61 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.107 1.363 . . . . 10.0 110.171 170.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 50.8 mt -53.78 -36.9 62.91 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 112.735 0.643 . . . . 10.0 112.735 -177.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 148.4 28.29 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 109.884 -0.413 . . . . 10.0 109.884 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 p -155.54 132.85 10.93 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.2 1.0 . . . . 10.0 108.911 -169.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.88 -162.02 10.82 Favored Glycine 0 CA--C 1.52 0.382 0 C-N-CA 123.84 0.733 . . . . 10.0 111.973 -173.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 7.1 t -138.9 153.18 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 104.684 -2.339 . . . . 10.0 104.684 168.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.3 mt -67.49 -88.17 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 123.784 0.834 . . . . 10.0 110.409 -169.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.33 134.02 8.07 Favored Glycine 0 CA--C 1.534 1.235 0 O-C-N 121.64 -0.662 . . . . 10.0 112.326 178.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 88.5 mt -72.31 144.97 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 125.143 1.377 . . . . 10.0 109.529 -176.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -124.21 -50.53 1.79 Allowed 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.974 0.909 . . . . 10.0 110.633 176.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 . . . . . 0 C--O 1.25 1.104 0 C-N-CA 125.011 1.324 . . . . 10.0 112.688 -171.931 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.1 t -104.55 -11.11 17.16 Favored 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.921 1.288 . . . . 10.0 110.605 -178.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 15.5 ptmt -155.22 160.77 41.1 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.76 168.44 22.93 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 126.871 2.068 . . . . 10.0 108.778 -177.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 m -126.37 169.23 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 C-N-CA 123.038 0.535 . . . . 10.0 110.825 175.261 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.51 107.68 6.07 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 107.132 -1.433 . . . . 10.0 107.132 165.466 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.469 HG21 ' HB3' ' B' ' 53' ' ' ASN . 0.6 OUTLIER -87.26 95.13 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 C-N-CA 123.549 0.74 . . . . 10.0 109.008 173.768 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.4 mt -78.76 126.18 30.37 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 107.888 -1.153 . . . . 10.0 107.888 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.4 mptt -146.87 155.15 42.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 106.539 -1.652 . . . . 10.0 106.539 168.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.18 -65.91 0.03 OUTLIER Glycine 0 N--CA 1.46 0.272 0 C-N-CA 118.842 -1.646 . . . . 10.0 112.925 169.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -71.66 -43.74 65.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 107.205 -1.406 . . . . 10.0 107.205 -177.67 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 148.37 -71.1 0.32 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 114.324 -1.307 . . . . 10.0 111.351 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -56.71 -37.69 97.27 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 122.87 2.38 . . . . 10.0 112.078 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 m -72.23 87.19 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 108.529 -0.915 . . . . 10.0 108.529 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -104.19 108.36 19.69 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.097 -1.816 . . . . 10.0 106.097 -178.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.432 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -96.47 141.13 15.43 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.036 -0.826 . . . . 10.0 111.036 172.679 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.63 ' CG2' HG23 ' B' ' 54' ' ' THR . 9.0 mt -139.37 81.83 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 -177.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -90.87 146.83 5.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 C-N-CA 123.529 0.732 . . . . 10.0 109.509 175.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -129.0 114.42 16.39 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.6 2.36 . . . . 10.0 107.331 177.199 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -93.74 115.65 28.08 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 172.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -117.87 137.8 52.54 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.804 0.729 . . . . 10.0 111.507 168.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -134.19 91.79 2.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.266 2.226 . . . . 10.0 106.235 -178.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -51.26 -38.66 53.86 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 125.581 1.552 . . . . 10.0 112.473 -168.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -152.23 -179.22 7.34 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 105.803 -1.925 . . . . 10.0 105.803 171.426 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.9 p -72.18 -18.96 61.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 118.14 0.427 . . . . 10.0 110.074 -178.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -83.81 -17.31 41.46 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 124.224 1.01 . . . . 10.0 109.438 175.286 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.63 147.84 30.01 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 110.647 -0.981 . . . . 10.0 110.647 175.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.26 170.99 15.85 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.443 2.095 . . . . 10.0 108.682 168.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.1 t -87.33 104.92 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 106.197 -1.779 . . . . 10.0 106.197 170.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -84.88 113.99 21.78 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 104.784 -2.302 . . . . 10.0 104.784 168.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.17 98.78 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.023 -1.473 . . . . 10.0 107.023 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.3 p90 -113.16 179.9 3.83 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.893 0.378 . . . . 10.0 110.705 174.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.74 -154.53 22.68 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.701 -2.16 . . . . 10.0 107.701 168.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 61.3 p -155.36 155.41 33.61 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 118.678 -1.209 . . . . 10.0 112.304 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.741 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -115.69 135.8 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 C-N-CA 126.229 1.812 . . . . 10.0 107.031 171.474 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -121.3 150.04 42.01 Favored 'General case' 0 CA--C 1.528 0.105 0 N-CA-C 107.354 -1.35 . . . . 10.0 107.354 170.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.77 -21.54 18.41 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-N 119.146 0.884 . . . . 10.0 114.161 175.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.5 mt -62.94 179.52 0.37 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 125.29 1.436 . . . . 10.0 111.652 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -103.75 175.54 5.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.777 -1.102 . . . . 10.0 108.107 166.092 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -64.28 169.73 4.36 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.054 0.942 . . . . 10.0 111.765 -171.054 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.76 -173.73 28.48 Favored Glycine 0 C--O 1.223 -0.583 0 C-N-CA 124.347 0.975 . . . . 10.0 111.841 167.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.88 148.73 47.48 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.854 0.862 . . . . 10.0 109.107 169.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.1 m-70 -141.53 143.46 33.78 Favored 'General case' 0 C--N 1.34 0.18 0 N-CA-C 113.718 1.007 . . . . 10.0 113.718 -177.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.798 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -18.14 116.41 0.01 OUTLIER Glycine 0 C--N 1.339 0.721 0 C-N-CA 129.104 3.24 . . . . 10.0 115.061 163.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -149.41 98.32 2.77 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 120.208 2.004 . . . . 10.0 114.609 174.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.464 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -144.85 170.85 15.34 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.649 0.78 . . . . 10.0 112.16 178.664 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.4 t -105.5 -28.09 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 C-N-CA 128.355 2.662 . . . . 10.0 112.827 -168.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 71.5 m-70 63.03 176.08 0.15 Allowed 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.586 1.154 . . . . 10.0 112.451 178.362 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -92.47 -64.83 1.06 Allowed 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.582 -0.736 . . . . 10.0 110.855 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -79.21 148.92 32.08 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 119.174 -1.01 . . . . 10.0 109.615 -176.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.0 -25.71 33.56 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 109.797 -1.321 . . . . 10.0 109.797 169.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -62.06 166.57 4.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 123.093 1.425 . . . . 10.0 112.897 -176.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.434 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -162.56 21.55 0.1 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.482 -1.235 . . . . 10.0 113.137 -169.907 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.454 HG22 HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -52.44 -35.23 51.78 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 124.797 1.239 . . . . 10.0 111.823 -176.556 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.05 -19.79 53.62 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 122.892 0.477 . . . . 10.0 112.138 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.84 107.0 1.22 Allowed Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.741 -1.343 . . . . 10.0 109.741 -172.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.1 m 34.75 59.91 0.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.357 1.863 . . . . 10.0 112.046 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.5 m -153.77 -54.24 0.11 Allowed 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.577 -0.897 . . . . 10.0 108.577 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -51.19 -39.5 56.62 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.857 1.263 . . . . 10.0 110.768 -173.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -29.67 -38.51 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 128.526 2.73 . . . . 10.0 114.786 168.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.49 131.63 6.65 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.125 -1.19 . . . . 10.0 110.125 172.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.94 64.78 3.29 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.531 2.821 . . . . 10.0 112.36 174.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.472 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 11.6 m170 69.86 38.09 1.68 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 128.527 2.731 . . . . 10.0 111.926 168.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -73.19 26.64 0.06 Allowed 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 115.372 1.619 . . . . 10.0 115.372 -170.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -46.22 150.72 1.05 Allowed Pre-proline 0 CA--C 1.54 0.558 0 C-N-CA 125.0 1.32 . . . . 10.0 112.703 -170.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -52.88 -52.86 7.87 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.087 2.524 . . . . 10.0 112.348 -173.28 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -77.06 61.14 1.97 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 108.9 -0.778 . . . . 10.0 108.9 169.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.4 t -60.02 113.99 2.61 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 106.877 -1.527 . . . . 10.0 106.877 178.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.68 -81.13 0.41 Allowed 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 109.41 -0.589 . . . . 10.0 109.41 -175.227 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -145.53 150.67 36.85 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-O 122.31 1.053 . . . . 10.0 110.91 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 52.8 t60 -64.69 117.88 8.1 Favored 'General case' 0 N--CA 1.447 -0.623 0 C-N-CA 119.146 -1.021 . . . . 10.0 108.642 166.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.97 -132.45 2.58 Favored Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 107.465 -2.254 . . . . 10.0 107.465 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.1 -160.79 24.62 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 109.13 -1.588 . . . . 10.0 109.13 177.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -60.75 -6.91 6.52 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.767 1.645 . . . . 10.0 110.973 167.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -85.21 -27.54 26.03 Favored 'General case' 0 N--CA 1.445 -0.68 0 C-N-CA 124.529 1.132 . . . . 10.0 109.942 175.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -106.63 154.83 20.34 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.938 -1.134 . . . . 10.0 107.938 -173.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -85.37 -24.69 27.47 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 115.073 -0.967 . . . . 10.0 109.052 169.039 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -101.39 14.39 32.12 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.585 0.587 . . . . 10.0 112.585 -173.37 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -43.1 149.72 0.2 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.19 2.196 . . . . 10.0 110.181 171.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -77.46 48.86 0.68 Allowed 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.2 -0.937 . . . . 10.0 112.61 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 26.0 t 33.66 49.38 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 126.099 1.759 . . . . 10.0 110.561 -177.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.47 42.55 0.03 OUTLIER Glycine 0 CA--C 1.532 1.156 0 CA-C-N 116.11 -0.495 . . . . 10.0 114.014 -169.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -118.01 111.87 19.51 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 104.466 -2.42 . . . . 10.0 104.466 168.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.8 mt -79.51 -29.92 41.7 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 119.75 1.159 . . . . 10.0 108.783 174.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.49 -83.82 0.36 Allowed Glycine 0 C--O 1.221 -0.683 0 N-CA-C 111.22 -0.752 . . . . 10.0 111.22 167.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -155.64 143.5 19.78 Favored 'General case' 0 CA--C 1.517 -0.318 0 N-CA-C 107.909 -1.145 . . . . 10.0 107.909 -176.125 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -130.93 135.24 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 O-C-N 123.68 0.612 . . . . 10.0 110.299 174.353 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -79.31 108.46 12.84 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 127.232 2.213 . . . . 10.0 111.849 -175.024 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.54 130.17 35.3 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.21 1.404 . . . . 10.0 111.036 173.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -59.6 168.53 1.61 Allowed 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 124.311 1.007 . . . . 10.0 109.984 167.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -53.97 -29.83 44.5 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.754 0.821 . . . . 10.0 112.023 171.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.79 -3.57 42.03 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.033 0.382 . . . . 10.0 112.033 177.366 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.18 3.88 88.59 Favored Glycine 0 C--N 1.337 0.601 0 O-C-N 120.971 -1.08 . . . . 10.0 111.53 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.83 97.73 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 106.673 -1.603 . . . . 10.0 106.673 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.741 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -101.23 121.94 42.77 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.635 -1.246 . . . . 10.0 107.635 169.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -96.13 127.37 42.08 Favored 'General case' 0 C--N 1.329 -0.292 0 O-C-N 124.118 0.886 . . . . 10.0 109.377 174.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 47.7 t -108.81 139.53 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 C-N-CA 126.789 2.035 . . . . 10.0 108.934 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 95.4 p -156.39 70.35 0.66 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.694 1.198 . . . . 10.0 110.204 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 8.6 mm -106.53 167.45 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 C-N-CA 125.143 1.377 . . . . 10.0 109.303 -174.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 66.3 tt0 -155.35 123.16 5.71 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 127.224 2.21 . . . . 10.0 108.487 -170.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -155.74 158.23 37.85 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 104.37 -2.456 . . . . 10.0 104.37 173.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 15.1 p -106.14 -19.56 13.68 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 126.301 1.841 . . . . 10.0 111.751 -177.311 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 70.4 t -77.05 -38.68 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.872 -1.529 . . . . 10.0 106.872 -169.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.292 0.0 OUTLIER -76.19 54.43 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 C-N-CA 124.356 1.063 . . . . 10.0 112.3 178.677 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.93 145.03 52.21 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.229 1.012 . . . . 10.0 111.329 -169.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 76.0 mt -47.62 -52.84 16.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.352 0.596 . . . . 10.0 110.478 176.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.3 m -150.44 158.43 44.15 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 125.28 1.432 . . . . 10.0 107.354 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.9 -67.8 0.25 Allowed Glycine 0 C--N 1.335 0.492 0 N-CA-C 109.609 -1.396 . . . . 10.0 109.609 -176.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -155.82 -53.16 0.09 Allowed 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 126.904 2.082 . . . . 10.0 106.315 178.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.1 -37.62 64.09 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 114.197 -1.365 . . . . 10.0 108.771 -173.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.6 t 47.57 91.6 0.01 OUTLIER 'General case' 0 C--O 1.232 0.182 0 C-N-CA 127.112 2.165 . . . . 10.0 113.872 168.123 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 17.6 pt -68.13 -27.34 36.87 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 119.956 -0.697 . . . . 10.0 111.78 174.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -49.79 126.32 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 119.584 1.084 . . . . 10.0 109.911 175.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.74 14.68 79.35 Favored Glycine 0 CA--C 1.534 1.28 0 CA-C-O 118.457 -1.191 . . . . 10.0 114.424 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.507 ' HB2' HD12 ' A' ' 149' ' ' ILE . 5.8 mmt-85 -84.27 -179.46 7.2 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.092 1.357 . . . . 10.0 109.084 166.698 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -136.9 104.23 5.41 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -179.451 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.65 ' CD1' HD11 ' A' ' 149' ' ' ILE . 8.9 mp -72.82 146.08 46.53 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 108.3 -1.0 . . . . 10.0 108.3 173.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.2 t -129.04 131.89 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.18 0 N-CA-C 107.17 -1.419 . . . . 10.0 107.17 175.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.7 p -99.69 136.93 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 N-CA-C 106.837 -1.542 . . . . 10.0 106.837 168.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.798 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 14.4 m-70 -114.74 160.7 19.09 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 114.516 1.302 . . . . 10.0 114.516 -173.141 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -60.39 -60.12 4.32 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 114.847 -1.07 . . . . 10.0 108.638 173.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -90.38 164.76 14.19 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.735 -0.786 . . . . 10.0 112.007 -170.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.47 147.76 37.66 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 106.951 -1.499 . . . . 10.0 106.951 169.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.52 ' OD2' ' HA2' ' A' ' 44' ' ' GLY . 27.7 m-20 -98.41 141.22 31.56 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 123.546 0.739 . . . . 10.0 109.441 -169.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 32.0 m-20 -72.32 -20.86 61.42 Favored 'General case' 0 N--CA 1.46 0.061 0 CA-C-O 120.822 0.344 . . . . 10.0 110.705 -173.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.5 mt 55.21 42.54 30.43 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 -167.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.98 -15.46 62.96 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 126.494 1.997 . . . . 10.0 113.194 171.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -76.88 -2.24 32.52 Favored 'General case' 0 CA--C 1.535 0.381 0 N-CA-C 114.443 1.275 . . . . 10.0 114.443 -167.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.17 -16.25 64.28 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 118.562 0.619 . . . . 10.0 111.983 174.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 54.01 40.89 67.2 Favored Glycine 0 CA--C 1.527 0.824 0 CA-C-N 117.981 0.89 . . . . 10.0 110.983 -178.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -128.3 161.91 28.29 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.477 -1.675 . . . . 10.0 106.477 177.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.403 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 3.0 tm-20 -53.34 -50.14 65.62 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.269 -1.382 . . . . 10.0 107.269 169.048 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -52.95 -44.25 66.95 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 115.382 -0.827 . . . . 10.0 112.11 172.494 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 23.1 p -57.4 -39.14 75.5 Favored 'General case' 0 N--CA 1.445 -0.677 0 O-C-N 120.449 -1.407 . . . . 10.0 110.763 -178.089 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.1 t -85.98 6.26 29.53 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 111.731 0.271 . . . . 10.0 111.731 -179.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.403 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 27.7 mmtp -106.75 -84.86 0.51 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.708 1.603 . . . . 10.0 109.241 171.306 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.472 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 2.9 p -95.47 -12.22 26.23 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 121.242 1.837 . . . . 10.0 112.841 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 80.58 32.97 32.34 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.303 -1.119 . . . . 10.0 110.303 -168.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 53.69 44.69 29.33 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.376 1.088 . . . . 10.0 111.103 -178.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.13 -2.49 13.14 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.38 0.672 . . . . 10.0 112.256 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 94.95 -67.01 1.28 Allowed Glycine 0 C--N 1.336 0.556 0 O-C-N 120.921 -1.112 . . . . 10.0 111.215 169.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -166.89 175.21 7.86 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 -178.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -105.86 98.93 8.56 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.414 1.886 . . . . 10.0 106.981 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.437 ' N ' ' CD2' ' A' ' 144' ' ' LEU . 0.6 OUTLIER -84.93 -25.22 28.0 Favored 'General case' 0 C--O 1.232 0.178 0 C-N-CA 122.956 0.502 . . . . 10.0 110.963 -167.856 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 139.29 10.96 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.582 -0.896 . . . . 10.0 108.582 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 97.1 m -118.99 144.79 46.3 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.472 1.509 . . . . 10.0 107.657 -177.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.64 134.27 5.39 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.695 -0.962 . . . . 10.0 110.695 173.409 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -95.63 134.0 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 106.958 -1.497 . . . . 10.0 106.958 -170.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.65 HD11 ' CD1' ' A' ' 117' ' ' LEU . 9.4 mt -76.49 115.84 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 N-CA-C 110.517 -0.179 . . . . 10.0 110.517 -168.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.89 136.91 13.83 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.033 0.825 . . . . 10.0 111.515 -175.336 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 68.8 mt -54.7 138.44 14.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 C-N-CA 125.67 1.588 . . . . 10.0 108.433 173.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.57 -47.75 1.96 Allowed 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 123.265 0.626 . . . . 10.0 111.02 176.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 . . . . . 0 C--O 1.249 1.058 0 CA-C-O 115.952 -1.975 . . . . 10.0 113.148 -174.245 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.923 0 CA-C-O 116.423 -1.751 . . . . 10.0 107.306 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . 0.254 1.9 t -141.0 -49.46 0.43 Allowed 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 120.493 1.497 . . . . 10.0 113.072 174.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -103.4 129.56 50.52 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 107.833 -1.173 . . . . 10.0 107.833 169.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.3 158.12 44.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 169.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.8 m -121.02 172.66 7.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.159 0 CA-C-N 117.89 0.314 . . . . 10.0 110.168 175.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.2 98.56 3.76 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.342 -1.355 . . . . 10.0 107.342 167.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.434 HG21 ' HB3' ' A' ' 53' ' ' ASN . 13.2 m -83.39 104.89 12.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.256 -1.016 . . . . 10.0 108.256 169.39 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 12.5 mt -92.71 145.2 24.6 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.011 -0.737 . . . . 10.0 109.011 -177.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 46.0 tttt -160.46 161.07 32.79 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 173.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.27 -51.01 0.05 OUTLIER Glycine 0 C--O 1.228 -0.271 0 CA-C-N 116.347 -0.388 . . . . 10.0 112.272 169.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.7 -45.78 34.87 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 106.934 -1.506 . . . . 10.0 106.934 -170.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.08 -67.85 0.54 Allowed Glycine 0 N--CA 1.442 -0.934 0 CA-C-N 113.672 -1.603 . . . . 10.0 110.292 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -56.25 -42.87 61.64 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 122.547 2.165 . . . . 10.0 110.543 171.117 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.434 HG13 HD11 ' B' ' 38' ' ' LEU . 53.9 t -63.66 114.13 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.066 0 N-CA-C 108.648 -0.871 . . . . 10.0 108.648 -179.351 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.0 121.01 28.75 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 106.665 -1.605 . . . . 10.0 106.665 168.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.599 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -97.65 144.08 17.09 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 108.149 -1.98 . . . . 10.0 108.149 168.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.454 HG22 HG22 ' A' ' 54' ' ' THR . 1.3 mt -144.2 71.29 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.097 -1.446 . . . . 10.0 107.097 -176.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -94.1 141.58 14.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 O-C-N 122.042 -0.411 . . . . 10.0 109.938 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.7 m-80 -110.46 128.05 55.42 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 126.034 1.733 . . . . 10.0 109.48 171.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -109.4 98.01 7.49 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 174.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -105.24 124.18 49.09 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.599 0.714 . . . . 10.0 112.34 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 tt0 -91.36 99.18 12.19 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.201 1.801 . . . . 10.0 108.241 176.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.42 ' CE ' ' OE2' ' B' ' 24' ' ' GLU . 28.3 tttt -53.95 -54.29 40.99 Favored 'General case' 0 N--CA 1.441 -0.887 0 C-N-CA 126.956 2.102 . . . . 10.0 110.17 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . 0.42 ' OE2' ' CE ' ' B' ' 23' ' ' LYS . 35.3 mt-10 -138.08 161.86 35.68 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 102.45 -3.167 . . . . 10.0 102.45 -178.214 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 m -69.58 -19.33 63.67 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 119.304 0.957 . . . . 10.0 110.138 -174.347 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -114.42 7.49 16.31 Favored 'General case' 0 N--CA 1.437 -1.095 0 O-C-N 124.916 1.385 . . . . 10.0 110.822 177.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.62 152.66 32.27 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 108.78 -1.728 . . . . 10.0 108.78 178.082 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -62.71 141.04 83.9 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 N-CA-C 108.097 -1.54 . . . . 10.0 108.097 170.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 37.4 t -87.19 109.39 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 N-CA-C 105.322 -2.103 . . . . 10.0 105.322 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 24.9 ttmt -76.93 113.18 14.35 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.645 -1.983 . . . . 10.0 105.645 168.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.6 p -90.47 102.19 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 105.649 -1.982 . . . . 10.0 105.649 171.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -120.73 154.71 35.25 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.202 0.525 . . . . 10.0 112.039 176.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.28 -168.59 36.58 Favored Glycine 0 N--CA 1.444 -0.831 0 N-CA-C 109.616 -1.393 . . . . 10.0 109.616 169.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 35.8 p -144.78 113.26 6.62 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 109.061 -0.718 . . . . 10.0 109.061 -169.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.599 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.4 pt -78.79 170.7 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.063 -1.088 . . . . 10.0 108.063 167.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -154.13 154.35 33.43 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.343 -0.984 . . . . 10.0 108.343 166.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.35 -15.62 32.6 Favored Glycine 0 CA--C 1.525 0.677 0 CA-C-O 119.139 -0.812 . . . . 10.0 114.08 177.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.453 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.7 mp -71.91 -179.21 2.62 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 118.757 1.278 . . . . 10.0 110.918 177.064 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -101.51 175.34 5.6 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.54 -0.911 . . . . 10.0 108.54 166.5 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -51.07 164.57 0.15 Allowed 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.23 2.212 . . . . 10.0 113.214 -173.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.76 -170.68 55.04 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 124.16 0.886 . . . . 10.0 114.008 165.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.96 141.76 54.86 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.127 1.771 . . . . 10.0 111.798 -175.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.4 m-70 -138.58 123.89 19.31 Favored 'General case' 0 C--N 1.339 0.115 0 C-N-CA 125.013 1.325 . . . . 10.0 109.847 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -38.42 127.83 1.75 Allowed Glycine 0 C--N 1.346 1.086 0 C-N-CA 126.839 2.161 . . . . 10.0 109.637 171.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.564 ' CE1' HG13 ' B' ' 87' ' ' VAL 0.274 0.3 OUTLIER -145.67 123.82 12.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 119.041 1.42 . . . . 10.0 112.406 168.139 . . . . . . . . 4 4 . 1 . 015 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.429 ' NE2' ' OD2' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -160.33 175.64 12.6 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.573 -0.74 . . . . 10.0 111.719 -174.264 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.2 m -88.72 153.43 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 O-C-N 125.697 1.873 . . . . 10.0 107.807 167.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 64.6 m-70 -134.72 95.04 3.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 108.329 -0.989 . . . . 10.0 108.329 177.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 24.43 -87.54 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 127.228 2.211 . . . . 10.0 114.24 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -78.87 161.76 26.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 122.734 1.254 . . . . 10.0 111.883 -169.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.44 -32.53 57.68 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 108.261 -1.936 . . . . 10.0 108.261 169.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -39.48 150.74 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 125.978 1.711 . . . . 10.0 113.929 176.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.469 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.6 OUTLIER -157.17 21.17 0.3 Allowed 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 113.882 -1.508 . . . . 10.0 113.081 178.527 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.63 HG23 ' CG2' ' A' ' 17' ' ' ILE . 6.0 m -41.69 -48.7 4.2 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.512 1.125 . . . . 10.0 113.093 -167.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.09 -25.36 47.53 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.891 0.876 . . . . 10.0 112.859 -176.393 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.17 104.15 2.6 Favored Glycine 0 CA--C 1.528 0.905 0 N-CA-C 109.544 -1.422 . . . . 10.0 109.544 -169.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 17.9 m 49.72 48.51 21.49 Favored 'General case' 0 N--CA 1.462 0.165 0 C-N-CA 125.474 1.51 . . . . 10.0 112.757 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -154.51 -55.86 0.1 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 2.6 m -50.56 -43.62 56.3 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.496 1.118 . . . . 10.0 111.45 -171.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.84 -51.47 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 128.005 2.522 . . . . 10.0 114.033 168.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.08 162.74 11.52 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.603 -1.399 . . . . 10.0 109.603 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -71.71 -164.68 0.17 Allowed 'Trans proline' 0 N--CA 1.447 -1.232 0 N-CA-C 105.019 -2.723 . . . . 10.0 105.019 163.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 34.1 m170 -81.47 53.55 2.12 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 119.288 -2.132 . . . . 10.0 109.72 -176.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -69.91 88.22 0.56 Allowed 'General case' 0 C--O 1.225 -0.225 0 CA-C-O 122.984 1.373 . . . . 10.0 109.383 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . 0.407 ' ND2' ' H ' ' B' ' 65' ' ' ASN . 4.9 p30 -96.34 151.2 37.95 Favored Pre-proline 0 C--N 1.325 -0.463 0 C-N-CA 127.236 2.214 . . . . 10.0 110.605 -176.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.4 -42.88 4.82 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.803 2.335 . . . . 10.0 111.282 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 77.0 mt -77.89 55.03 1.35 Allowed 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.829 0.852 . . . . 10.0 110.587 -178.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 47.1 t -38.28 101.77 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 126.752 2.021 . . . . 10.0 112.063 -171.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -140.38 -175.79 4.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.361 -1.348 . . . . 10.0 107.361 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -94.26 127.67 40.26 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.764 -1.569 . . . . 10.0 106.764 -178.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -36.87 113.26 0.23 Allowed 'General case' 0 C--O 1.225 -0.207 0 O-C-N 123.639 0.587 . . . . 10.0 112.035 176.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.09 -137.09 5.65 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 108.783 -1.727 . . . . 10.0 108.783 177.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.409 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 168.44 -153.72 22.98 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 107.487 -2.245 . . . . 10.0 107.487 169.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -64.27 6.64 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.939 0 CA-C-N 120.635 2.217 . . . . 10.0 112.346 169.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.409 ' H ' ' C ' ' B' ' 73' ' ' GLY . 10.0 mmmt -121.4 12.26 10.84 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 126.978 2.111 . . . . 10.0 110.287 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -151.73 158.01 42.8 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 118.945 0.793 . . . . 10.0 108.919 168.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -79.39 -26.69 41.9 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 107.529 -1.286 . . . . 10.0 107.529 173.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -79.81 5.79 12.71 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 124.671 1.189 . . . . 10.0 112.82 -169.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt180 -35.23 120.75 0.55 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.796 1.639 . . . . 10.0 110.571 168.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.8 m170 -52.32 -53.55 43.0 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.506 1.122 . . . . 10.0 112.566 -170.057 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.3 p -178.03 -47.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 C-N-CA 125.667 1.587 . . . . 10.0 107.74 178.129 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.19 56.0 0.74 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.511 -1.435 . . . . 10.0 109.511 178.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -91.98 86.69 5.93 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 105.0 -2.222 . . . . 10.0 105.0 168.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . 0.516 ' HB3' ' CZ ' ' B' ' 45' ' ' PHE . 5.4 mp -72.98 -30.54 63.9 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 106.908 -1.516 . . . . 10.0 106.908 176.098 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.95 -93.18 0.86 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 124.687 1.137 . . . . 10.0 110.439 165.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 p30 -151.88 141.22 21.49 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.084 0.554 . . . . 10.0 110.021 -173.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.564 HG13 ' CE1' ' B' ' 45' ' ' PHE . 0.2 OUTLIER -128.6 138.87 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 C-N-CA 124.451 1.1 . . . . 10.0 111.677 179.219 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.4 m -79.17 115.05 18.6 Favored 'General case' 0 N--CA 1.437 -1.116 0 C-N-CA 128.821 2.849 . . . . 10.0 110.635 -177.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -95.7 134.17 38.94 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 123.855 0.862 . . . . 10.0 110.154 171.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -57.51 171.2 0.46 Allowed 'General case' 0 C--O 1.233 0.192 0 O-C-N 123.982 0.801 . . . . 10.0 109.634 167.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.63 -29.6 38.78 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 123.874 0.87 . . . . 10.0 110.955 173.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -79.08 -7.6 58.27 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.126 0.489 . . . . 10.0 111.203 -178.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.04 -0.24 72.25 Favored Glycine 0 C--N 1.338 0.684 0 O-C-N 121.195 -0.94 . . . . 10.0 111.001 -175.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 55.7 t -78.95 101.35 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 107.518 -1.289 . . . . 10.0 107.518 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.421 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -99.4 118.09 35.25 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.825 -1.176 . . . . 10.0 107.825 168.799 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.49 125.59 29.58 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 106.829 -1.545 . . . . 10.0 106.829 169.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 59.3 t -107.97 128.95 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 N-CA-C 105.385 -2.079 . . . . 10.0 105.385 169.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 73.0 m -152.72 59.85 0.8 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.798 0.839 . . . . 10.0 108.783 175.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.6 151.24 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 N-CA-C 108.138 -1.06 . . . . 10.0 108.138 -173.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -130.18 141.3 50.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.417 1.087 . . . . 10.0 109.155 170.292 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -149.27 161.03 42.84 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 105.903 -1.888 . . . . 10.0 105.903 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 29.7 p -122.6 4.89 9.55 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 127.237 2.215 . . . . 10.0 111.894 -172.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.7 p -84.14 -42.53 17.13 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 N-CA-C 107.699 -1.222 . . . . 10.0 107.699 177.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.283 0.0 OUTLIER -71.31 159.37 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 123.959 0.904 . . . . 10.0 113.228 172.378 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -160.04 155.0 24.59 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.202 -1.407 . . . . 10.0 107.202 170.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -82.14 55.88 2.98 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 108.129 -1.063 . . . . 10.0 108.129 169.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.5 t -73.83 -159.0 0.07 Allowed 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.598 1.959 . . . . 10.0 108.666 177.246 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -120.96 -51.89 0.25 Allowed Glycine 0 CA--C 1.528 0.903 0 C-N-CA 128.466 2.936 . . . . 10.0 107.662 173.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -65.77 -58.25 6.09 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 125.902 1.681 . . . . 10.0 108.908 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -81.8 -38.32 25.74 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.639 -0.71 . . . . 10.0 109.979 -176.147 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.3 t 3.39 109.43 0.0 OUTLIER 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 129.489 3.115 . . . . 10.0 115.575 177.217 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 34.8 pt -73.51 6.2 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 N-CA-C 112.823 0.675 . . . . 10.0 112.823 171.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 9.1 mm -56.95 -67.13 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.311 0 CA-C-N 119.352 0.978 . . . . 10.0 111.458 -176.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -81.63 56.1 4.89 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 120.856 -1.152 . . . . 10.0 111.924 -175.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.1 mmt-85 -122.4 150.57 42.27 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.929 1.291 . . . . 10.0 107.957 176.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . 0.456 ' C ' HD12 ' B' ' 117' ' ' LEU . 1.1 m -92.24 129.26 38.23 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 104.065 -2.569 . . . . 10.0 104.065 168.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.456 HD12 ' C ' ' B' ' 116' ' ' THR . 10.9 mp -112.16 145.42 39.86 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.415 -0.957 . . . . 10.0 108.415 169.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.408 HG12 ' CD2' ' B' ' 120' ' ' HIS . 94.1 t -122.93 145.81 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 108.345 -0.983 . . . . 10.0 108.345 -171.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.501 HG13 ' HB3' ' B' ' 145' ' ' ALA . 1.5 p -117.2 122.74 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 C-N-CA 126.769 2.027 . . . . 10.0 106.473 169.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.408 ' CD2' HG12 ' B' ' 118' ' ' VAL . 10.2 m170 -105.29 167.22 9.87 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 115.722 1.749 . . . . 10.0 115.722 -168.463 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -59.29 -66.06 0.57 Allowed 'General case' 0 C--O 1.223 -0.29 0 C-N-CA 125.887 1.675 . . . . 10.0 110.186 174.155 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -107.06 177.71 4.77 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 118.817 0.735 . . . . 10.0 112.137 -169.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.08 144.13 48.81 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.683 1.193 . . . . 10.0 110.567 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.429 ' OD2' ' NE2' ' B' ' 46' ' ' HIS . 19.5 m-20 -89.59 149.36 22.88 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 109.091 -0.707 . . . . 10.0 109.091 168.039 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -76.76 -11.23 59.81 Favored 'General case' 0 N--CA 1.453 -0.289 0 O-C-N 124.73 1.269 . . . . 10.0 111.01 176.202 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 18.0 mt 57.37 40.05 27.8 Favored 'General case' 0 N--CA 1.457 -0.105 0 CA-C-N 118.26 0.482 . . . . 10.0 109.757 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 106.98 -33.41 6.43 Favored Glycine 0 CA--C 1.525 0.664 0 C-N-CA 125.325 1.44 . . . . 10.0 112.29 173.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.49 42.63 0.84 Allowed 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 118.471 1.135 . . . . 10.0 110.674 -169.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -101.71 -20.83 12.15 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 126.142 1.83 . . . . 10.0 111.743 -176.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.34 45.73 44.73 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 123.972 0.796 . . . . 10.0 112.554 178.477 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -152.03 172.43 16.29 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.444 0.622 . . . . 10.0 109.74 175.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 12.8 tm-20 -52.2 -43.78 64.37 Favored 'General case' 0 N--CA 1.443 -0.807 0 C-N-CA 123.699 0.799 . . . . 10.0 111.834 -176.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -72.43 -30.02 64.23 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.397 -0.815 . . . . 10.0 111.097 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 30.0 p -50.44 -40.42 50.4 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 119.419 1.009 . . . . 10.0 111.341 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -85.03 -13.79 49.4 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 123.793 0.683 . . . . 10.0 112.405 -175.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.2 ttmt -107.86 -48.75 3.34 Favored 'General case' 0 N--CA 1.434 -1.236 0 C-N-CA 126.841 2.056 . . . . 10.0 112.431 -166.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.9 p -131.93 -9.85 3.45 Favored 'General case' 0 C--O 1.224 -0.274 0 CA-C-O 116.794 -1.574 . . . . 10.0 112.258 169.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.0 -105.98 3.08 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 107.089 -2.404 . . . . 10.0 107.089 -166.394 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -171.81 21.53 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 115.187 1.551 . . . . 10.0 115.187 -176.702 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.09 -14.91 62.56 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 120.853 -1.154 . . . . 10.0 111.976 -178.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.53 -117.58 5.0 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.348 -1.901 . . . . 10.0 108.348 169.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 112.11 6.33 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 112.575 0.583 . . . . 10.0 112.575 -167.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.84 73.84 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.405 1.082 . . . . 10.0 109.938 166.172 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.9 mt -51.59 -45.2 63.07 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.783 0.66 . . . . 10.0 112.783 -175.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.501 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -151.27 156.82 41.62 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -168.047 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.0 p -163.4 170.13 17.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.951 -0.388 . . . . 10.0 109.951 -173.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.89 162.33 33.0 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 109.343 -1.503 . . . . 10.0 109.343 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.91 129.46 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 105.644 -1.984 . . . . 10.0 105.644 -176.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 22.6 mt -69.55 160.98 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 CA-C-N 118.773 0.715 . . . . 10.0 110.03 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -168.01 166.27 39.32 Favored Glycine 0 CA--C 1.526 0.754 0 C-N-CA 125.529 1.538 . . . . 10.0 109.919 -173.724 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 95.5 mt -74.29 134.56 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 C-N-CA 124.858 1.263 . . . . 10.0 109.785 -169.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.57 -35.25 3.59 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 112.795 0.665 . . . . 10.0 112.795 176.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.252 1.186 0 CA-C-O 116.953 -1.498 . . . . 10.0 108.893 174.508 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t -162.34 -43.77 0.04 OUTLIER 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 118.904 0.774 . . . . 10.0 110.795 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -118.41 138.52 52.39 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.528 -1.286 . . . . 10.0 107.528 167.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.34 155.68 49.13 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 124.148 0.905 . . . . 10.0 109.482 175.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -121.8 148.82 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 C-N-CA 125.618 1.567 . . . . 10.0 109.183 -176.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.33 100.85 4.36 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 108.022 -1.103 . . . . 10.0 108.022 167.131 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.481 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.2 m -79.51 100.99 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 109.055 -0.72 . . . . 10.0 109.055 171.571 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.9 mt -81.17 142.76 32.91 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -158.23 160.27 36.96 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 173.331 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -165.25 -60.68 0.02 OUTLIER Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.41 -0.424 . . . . 10.0 112.153 171.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -74.72 -45.86 41.39 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 106.644 -1.613 . . . . 10.0 106.644 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.69 -64.46 0.61 Allowed Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 114.021 -1.445 . . . . 10.0 111.203 -176.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -52.45 -42.74 59.33 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.06 1.84 . . . . 10.0 111.058 173.156 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.405 ' CG2' ' HB2' ' A' ' 145' ' ' ALA . 1.3 m -72.16 113.78 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.269 -1.011 . . . . 10.0 108.269 177.35 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -119.49 120.99 38.41 Favored 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 104.783 -2.303 . . . . 10.0 104.783 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.786 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -101.22 141.46 15.34 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.275 -1.93 . . . . 10.0 108.275 169.345 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.7 mt -137.16 67.26 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.069 -1.086 . . . . 10.0 108.069 -173.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.1 mm -77.06 133.86 29.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 109.4 -0.593 . . . . 10.0 109.4 -178.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -121.25 98.58 6.04 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.517 1.927 . . . . 10.0 107.6 -178.378 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.441 ' CD2' HG12 ' A' ' 31' ' ' VAL . 74.6 m-85 -81.27 128.79 34.19 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 118.155 -0.926 . . . . 10.0 108.616 177.612 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.77 122.21 43.81 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.619 0.768 . . . . 10.0 110.723 171.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -122.27 103.17 8.58 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.793 2.037 . . . . 10.0 106.483 168.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -61.77 -60.96 2.88 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 122.709 0.403 . . . . 10.0 110.467 -174.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -128.43 177.51 6.93 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 104.31 -2.478 . . . . 10.0 104.31 169.504 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.5 p -73.87 -17.17 61.08 Favored 'General case' 0 C--N 1.322 -0.594 0 O-C-N 122.114 -0.367 . . . . 10.0 110.578 -175.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.2 m-80 -79.2 -22.37 45.0 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.984 0.914 . . . . 10.0 109.461 172.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.64 124.73 18.83 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 109.91 -1.276 . . . . 10.0 109.91 179.325 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.92 141.95 86.34 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 N-CA-C 107.097 -1.924 . . . . 10.0 107.097 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 71.0 t -79.54 116.93 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 107.786 -1.19 . . . . 10.0 107.786 -169.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -88.91 108.4 19.53 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.122 -1.807 . . . . 10.0 106.122 177.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.441 HG12 ' CD2' ' A' ' 20' ' ' PHE . 18.6 m -101.32 90.59 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 125.328 1.451 . . . . 10.0 108.122 -177.756 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -101.49 167.5 10.11 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 122.03 0.919 . . . . 10.0 110.777 168.145 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.19 162.2 28.05 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.578 -1.409 . . . . 10.0 109.578 171.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.3 m -128.28 102.39 6.66 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 106.401 -1.703 . . . . 10.0 106.401 176.099 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.786 HG22 ' HA2' ' A' ' 16' ' ' GLY . 8.8 pt -77.08 176.32 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 N-CA-C 108.133 -1.062 . . . . 10.0 108.133 170.037 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.9 pttt -153.89 149.1 26.97 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 106.942 -1.503 . . . . 10.0 106.942 169.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.35 -24.24 12.7 Favored Glycine 0 C--N 1.338 0.654 0 CA-C-O 119.248 -0.751 . . . . 10.0 114.438 169.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.46 HD13 HD12 ' A' ' 35' ' ' ILE . 6.8 mp -65.56 175.92 1.66 Allowed 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 118.414 1.107 . . . . 10.0 111.063 -175.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -89.77 148.12 23.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.378 -0.828 . . . . 10.0 110.284 171.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -39.59 125.47 1.78 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.867 2.467 . . . . 10.0 110.938 174.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 121.42 -174.64 15.99 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 123.602 0.62 . . . . 10.0 112.961 171.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.64 151.91 44.45 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.806 1.642 . . . . 10.0 111.234 -178.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -148.27 143.3 26.86 Favored 'General case' 0 C--N 1.343 0.31 0 N-CA-C 113.524 0.935 . . . . 10.0 113.524 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.56 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.86 122.75 0.14 Allowed Glycine 0 C--N 1.341 0.839 0 C-N-CA 127.853 2.644 . . . . 10.0 110.917 165.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -143.92 106.41 4.42 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 119.989 1.894 . . . . 10.0 110.259 172.557 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.443 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -158.06 172.54 18.25 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-O 121.797 0.808 . . . . 10.0 111.764 -177.922 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 9.8 p -100.05 152.62 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-N 112.418 -2.174 . . . . 10.0 109.366 171.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -128.08 135.47 49.87 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 176.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -51.31 -61.77 2.03 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.318 1.447 . . . . 10.0 112.309 -168.323 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -83.9 147.79 27.31 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 119.539 -0.865 . . . . 10.0 109.516 -178.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.06 9.12 58.36 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 124.919 1.247 . . . . 10.0 111.321 170.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -67.56 98.45 0.68 Allowed 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 123.547 1.642 . . . . 10.0 110.907 -178.184 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.34 14.73 30.85 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 111.516 -2.584 . . . . 10.0 110.588 167.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.584 HG23 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -71.45 -40.95 70.0 Favored 'General case' 0 C--N 1.339 0.152 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 168.516 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.23 -20.22 48.79 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.414 0.524 . . . . 10.0 112.414 170.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.02 78.83 1.37 Allowed Glycine 0 CA--C 1.529 0.909 0 N-CA-C 111.322 -0.711 . . . . 10.0 111.322 178.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.4 p 37.39 43.17 0.37 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 126.841 2.057 . . . . 10.0 114.292 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.2 m -133.14 -57.74 0.91 Allowed 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 105.682 -1.97 . . . . 10.0 105.682 -178.301 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -55.99 -29.05 59.7 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 122.823 0.449 . . . . 10.0 109.934 169.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.03 -27.7 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.564 1.545 . . . . 10.0 113.382 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.54 124.26 5.38 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-O 117.751 -1.583 . . . . 10.0 109.57 168.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -72.31 65.46 3.58 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.066 3.177 . . . . 10.0 111.69 176.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.6 m170 67.09 46.58 1.51 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 130.338 3.455 . . . . 10.0 111.868 176.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -70.48 64.68 0.28 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.194 0.597 . . . . 10.0 111.595 178.533 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -73.31 142.19 81.49 Favored Pre-proline 0 CA--C 1.533 0.292 0 O-C-N 120.154 -1.591 . . . . 10.0 109.102 172.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -57.94 -34.28 98.16 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.563 2.175 . . . . 10.0 111.591 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.45 -17.48 63.86 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 113.201 0.815 . . . . 10.0 113.201 177.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.4 t 20.75 81.93 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 127.495 2.318 . . . . 10.0 114.726 175.276 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.0 mtt180 -111.32 -84.73 0.57 Allowed 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 105.546 -2.02 . . . . 10.0 105.546 -177.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.09 160.56 41.07 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 109.131 -0.692 . . . . 10.0 109.131 167.557 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.0 t60 -56.74 126.68 27.94 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.316 -1.735 . . . . 10.0 106.316 165.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -143.39 -136.32 3.13 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 107.343 -2.303 . . . . 10.0 107.343 176.09 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 164.68 -150.64 18.98 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 108.982 -1.647 . . . . 10.0 108.982 169.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -68.11 19.22 0.13 Allowed 'Trans proline' 0 N--CA 1.453 -0.911 0 CA-C-N 119.77 1.785 . . . . 10.0 112.307 173.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 59.9 mttt -120.87 -11.66 8.92 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 118.161 -0.923 . . . . 10.0 111.243 169.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -143.6 118.44 9.93 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 104.856 -2.276 . . . . 10.0 104.856 -168.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 36.2 tp10 -75.11 -16.5 60.55 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 107.68 -1.23 . . . . 10.0 107.68 -171.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -82.56 11.11 6.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 C-N-CA 125.803 1.641 . . . . 10.0 111.991 175.656 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.8 ptt-85 -43.86 153.13 0.14 Allowed 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.76 1.624 . . . . 10.0 113.674 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -72.09 160.73 31.98 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 107.334 -1.358 . . . . 10.0 107.334 166.082 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.6 p -38.38 -47.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 125.358 1.463 . . . . 10.0 114.259 -172.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -132.74 55.0 0.76 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 123.396 0.522 . . . . 10.0 111.975 -177.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -82.47 93.5 7.26 Favored 'General case' 0 CA--C 1.528 0.126 0 N-CA-C 105.38 -2.082 . . . . 10.0 105.38 166.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -71.61 -28.94 64.14 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 106.79 -1.559 . . . . 10.0 106.79 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.63 -104.01 2.7 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 106.867 -2.493 . . . . 10.0 106.867 168.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -126.4 131.09 51.82 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.883 -1.155 . . . . 10.0 107.883 -169.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.98 135.58 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 119.076 0.853 . . . . 10.0 110.834 170.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.74 110.83 15.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.429 2.692 . . . . 10.0 110.51 -177.288 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.9 132.31 37.15 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.182 -0.673 . . . . 10.0 109.182 169.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -53.97 168.43 0.21 Allowed 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 125.047 1.339 . . . . 10.0 110.635 168.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 22.2 tttp -47.7 -35.43 9.64 Favored 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 125.654 1.582 . . . . 10.0 112.231 169.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -78.27 -9.84 59.4 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 121.203 0.525 . . . . 10.0 111.896 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.35 11.86 60.51 Favored Glycine 0 C--N 1.337 0.621 0 O-C-N 120.887 -1.133 . . . . 10.0 110.891 -177.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.3 t -92.19 103.92 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 125.749 1.62 . . . . 10.0 107.705 -178.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.43 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -98.88 121.72 41.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 109.052 -0.722 . . . . 10.0 109.052 169.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -84.6 86.16 7.34 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 127.528 2.331 . . . . 10.0 109.884 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.46 129.82 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.251 0 N-CA-C 105.67 -1.974 . . . . 10.0 105.67 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -158.18 72.06 0.61 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 122.986 0.514 . . . . 10.0 110.728 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -116.71 163.71 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.161 -1.792 . . . . 10.0 106.161 -178.016 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -138.66 144.85 39.83 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 118.571 0.623 . . . . 10.0 110.475 167.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -129.56 125.9 37.32 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 125.074 1.349 . . . . 10.0 110.205 -169.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 69.3 p -98.4 53.25 1.04 Allowed 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 107.172 -1.418 . . . . 10.0 107.172 169.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -157.24 -45.25 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 C-N-CA 124.085 0.954 . . . . 10.0 109.29 -175.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -74.23 145.09 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 167.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -133.08 157.15 46.0 Favored 'General case' 0 CA--C 1.528 0.124 0 N-CA-C 107.782 -1.192 . . . . 10.0 107.782 168.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.1 mt -95.39 -34.1 12.25 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 108.429 -0.952 . . . . 10.0 108.429 167.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.0 m -156.73 67.25 0.55 Allowed 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 124.486 1.114 . . . . 10.0 108.614 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -165.05 63.24 0.23 Allowed Glycine 0 C--N 1.333 0.365 0 N-CA-C 108.037 -2.025 . . . . 10.0 108.037 -179.313 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 69.75 -57.89 0.54 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 129.712 3.205 . . . . 10.0 109.532 -174.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -82.48 33.23 0.41 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 123.43 0.692 . . . . 10.0 111.416 -168.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.2 t -52.43 104.1 0.08 Allowed 'General case' 0 N--CA 1.442 -0.84 0 C-N-CA 126.618 1.967 . . . . 10.0 110.524 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 30.3 pt -86.06 23.55 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 C-N-CA 123.352 0.661 . . . . 10.0 111.787 171.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 20.8 mm -64.45 143.44 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 O-C-N 120.407 -1.433 . . . . 10.0 108.394 173.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.89 19.01 67.17 Favored Glycine 0 CA--C 1.531 1.062 0 CA-C-O 119.198 -0.779 . . . . 10.0 114.509 177.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.477 ' HD3' HD11 ' B' ' 151' ' ' ILE . 4.3 mmt-85 -88.29 176.4 7.24 Favored 'General case' 0 C--O 1.232 0.18 0 N-CA-C 107.76 -1.2 . . . . 10.0 107.76 167.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -121.08 132.66 55.01 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 106.841 -1.541 . . . . 10.0 106.841 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.9 mp -99.41 147.56 25.12 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.343 -1.354 . . . . 10.0 107.343 169.483 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.424 HG12 ' CD2' ' A' ' 120' ' ' HIS . 90.4 t -127.23 133.63 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 N-CA-C 106.795 -1.557 . . . . 10.0 106.795 170.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.8 p -103.77 125.33 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.581 0 N-CA-C 103.913 -2.625 . . . . 10.0 103.913 167.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.56 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.2 m170 -105.56 160.6 15.05 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.052 1.406 . . . . 10.0 114.365 -168.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 -41.48 -58.15 1.99 Allowed 'General case' 0 N--CA 1.444 -0.773 0 C-N-CA 128.088 2.555 . . . . 10.0 109.702 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -124.81 176.96 6.26 Favored 'General case' 0 C--N 1.338 0.093 0 C-N-CA 125.791 1.636 . . . . 10.0 110.85 -174.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.69 135.92 33.34 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.143 0.977 . . . . 10.0 109.891 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.443 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.2 OUTLIER -78.55 143.3 36.64 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.433 1.893 . . . . 10.0 111.897 177.787 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.75 19.95 0.26 Allowed 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.986 1.314 . . . . 10.0 112.132 178.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 40.1 48.08 2.13 Favored 'General case' 0 C--O 1.226 -0.137 0 C-N-CA 126.25 1.82 . . . . 10.0 112.622 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 105.93 -11.31 45.09 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-O 118.781 -1.011 . . . . 10.0 113.437 173.113 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -120.96 40.6 3.52 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.743 0.771 . . . . 10.0 112.185 -166.276 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -85.28 -15.34 66.86 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 126.035 1.779 . . . . 10.0 112.323 173.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.7 49.19 78.88 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 118.417 1.109 . . . . 10.0 113.023 175.145 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.499 ' H ' ' HB2' ' A' ' 134' ' ' SER . 39.8 m-80 -161.12 167.63 25.88 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 127.35 2.26 . . . . 10.0 105.095 -177.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -46.31 -47.89 18.33 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.791 0.805 . . . . 10.0 111.026 172.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -56.74 -33.24 66.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.253 -0.885 . . . . 10.0 111.715 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.499 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 11.0 t -45.65 -46.59 14.71 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 125.064 1.346 . . . . 10.0 109.346 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 13.6 t -91.68 0.92 57.46 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 112.395 0.517 . . . . 10.0 112.395 -173.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -113.18 -81.64 0.59 Allowed 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 126.054 1.741 . . . . 10.0 110.537 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.4 p -111.23 22.82 14.78 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 121.176 1.807 . . . . 10.0 111.02 172.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.3 -88.51 0.41 Allowed Glycine 0 C--N 1.341 0.816 0 N-CA-C 109.932 -1.267 . . . . 10.0 109.932 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -173.77 40.17 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 125.895 1.678 . . . . 10.0 109.069 172.036 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.21 -4.18 9.73 Favored 'General case' 0 C--N 1.34 0.164 0 O-C-N 121.543 -0.723 . . . . 10.0 112.224 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.56 -166.99 53.85 Favored Glycine 0 N--CA 1.441 -0.987 0 N-CA-C 109.259 -1.537 . . . . 10.0 109.259 179.174 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.6 t -62.41 146.15 52.15 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 122.457 1.122 . . . . 10.0 111.324 -168.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.07 64.22 0.06 Allowed 'General case' 0 N--CA 1.444 -0.743 0 C-N-CA 126.837 2.055 . . . . 10.0 109.145 171.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.63 -19.16 64.64 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 113.206 0.817 . . . . 10.0 113.206 -168.721 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.405 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . . . -155.36 145.7 21.91 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.398 0.544 . . . . 10.0 110.129 172.369 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.9 m -146.85 158.51 43.93 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 123.852 0.861 . . . . 10.0 109.492 -167.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.92 167.09 36.5 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.472 -1.051 . . . . 10.0 110.472 175.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.8 t -116.28 142.01 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 107.398 -1.334 . . . . 10.0 107.398 -169.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 11.0 mt -80.03 113.68 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 123.291 0.636 . . . . 10.0 110.52 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -118.07 152.32 17.59 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.244 1.402 . . . . 10.0 111.728 -178.475 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 84.0 mt -73.55 141.32 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 124.562 1.145 . . . . 10.0 109.179 -178.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.69 -48.16 2.59 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 123.35 0.66 . . . . 10.0 110.764 176.28 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.1 tt0 . . . . . 0 C--O 1.25 1.125 0 C-N-CA 127.268 2.227 . . . . 10.0 112.146 -172.114 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 108.684 -0.858 . . . . 10.0 108.684 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . 0.498 HG23 ' HG3' ' B' ' 3' ' ' LYS . 15.0 t -91.46 -30.19 16.61 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 123.169 0.587 . . . . 10.0 111.149 -179.073 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . 0.498 ' HG3' HG23 ' B' ' 2' ' ' THR . 12.4 mtpt -124.44 127.9 48.21 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 124.882 1.273 . . . . 10.0 111.1 -175.527 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.01 155.47 49.93 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.957 0.503 . . . . 10.0 110.751 171.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.2 m -114.55 165.05 10.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 C-N-CA 124.421 1.088 . . . . 10.0 109.346 171.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . 0.433 ' HB2' HG12 ' B' ' 149' ' ' ILE . . . -153.69 104.59 2.72 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 106.417 -1.697 . . . . 10.0 106.417 166.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -106.4 125.23 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 109.217 -0.66 . . . . 10.0 109.217 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.436 HD12 ' N ' ' B' ' 8' ' ' LEU . 4.1 mp -104.44 152.07 22.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.919 1.288 . . . . 10.0 109.352 -172.392 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . 0.409 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 44.8 tttt -160.0 162.64 34.34 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 169.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 175.0 -43.25 0.12 Allowed Glycine 0 C--O 1.228 -0.242 0 C-N-CA 119.768 -1.206 . . . . 10.0 113.682 168.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -74.22 -46.19 43.4 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.9 -72.37 0.33 Allowed Glycine 0 CA--C 1.52 0.348 0 N-CA-C 109.679 -1.368 . . . . 10.0 109.679 171.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -58.9 -39.23 83.17 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 123.211 2.607 . . . . 10.0 110.834 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 79.4 t -59.72 110.59 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -121.03 113.62 20.33 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 104.495 -2.409 . . . . 10.0 104.495 168.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.74 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -91.04 143.53 16.68 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 108.236 -1.946 . . . . 10.0 108.236 172.66 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.584 ' CG2' HG23 ' A' ' 54' ' ' THR . 3.0 mt -143.04 91.43 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 107.746 -1.205 . . . . 10.0 107.746 -176.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -104.31 138.66 28.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 C-N-CA 124.785 1.234 . . . . 10.0 109.29 178.081 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -122.84 122.35 38.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 126.38 1.872 . . . . 10.0 108.769 169.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -102.75 126.2 49.78 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 107.363 -1.347 . . . . 10.0 107.363 176.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -116.53 135.95 53.39 Favored 'General case' 0 C--O 1.233 0.203 0 O-C-N 123.759 0.662 . . . . 10.0 110.986 167.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 26.2 tt0 -119.52 114.15 21.83 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 106.095 -1.817 . . . . 10.0 106.095 168.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.4 mmpt? -65.11 -53.85 38.95 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 123.912 0.885 . . . . 10.0 110.028 -169.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -125.62 -156.98 0.76 Allowed 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 104.775 -2.305 . . . . 10.0 104.775 177.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 29.1 m -95.11 -18.94 20.54 Favored 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 120.43 -0.508 . . . . 10.0 110.653 167.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -81.74 -34.38 30.53 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 123.876 0.87 . . . . 10.0 110.389 179.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.76 151.57 52.39 Favored Glycine 0 CA--C 1.533 1.21 0 N-CA-C 111.437 -0.665 . . . . 10.0 111.437 -176.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_endo -62.63 159.45 36.8 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.874 2.383 . . . . 10.0 108.737 170.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 41.1 t -86.74 115.99 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.22 0 N-CA-C 105.325 -2.102 . . . . 10.0 105.325 169.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 38.8 tttp -92.07 112.45 24.39 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 168.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -94.44 100.66 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 C-N-CA 127.32 2.248 . . . . 10.0 106.484 176.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 23.3 p90 -112.77 171.32 7.6 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.304 0.573 . . . . 10.0 111.11 169.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.66 170.24 38.28 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.869 -0.892 . . . . 10.0 110.869 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.6 m -148.94 95.14 2.36 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.666 -1.605 . . . . 10.0 106.666 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.74 HG22 ' HA2' ' B' ' 16' ' ' GLY . 7.9 pt -75.8 176.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 108.725 -0.842 . . . . 10.0 108.725 173.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . 0.417 ' HE3' ' HB2' ' B' ' 36' ' ' LYS . 17.1 ptmt -156.57 164.8 37.77 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 109.01 -0.737 . . . . 10.0 109.01 163.285 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.69 -13.73 59.3 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 119.341 -0.7 . . . . 10.0 113.168 172.065 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.448 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.8 mp -69.71 176.69 3.42 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 118.568 1.184 . . . . 10.0 110.211 172.422 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.0 t -94.06 166.66 12.03 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 107.427 -1.324 . . . . 10.0 107.427 165.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.27 171.46 1.03 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.475 1.11 . . . . 10.0 112.21 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.18 179.89 39.64 Favored Glycine 0 C--N 1.334 0.428 0 C-N-CA 123.943 0.783 . . . . 10.0 112.074 168.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -66.99 142.6 57.19 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.632 0.773 . . . . 10.0 109.083 176.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.4 m-70 -139.68 151.79 46.19 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 123.087 0.555 . . . . 10.0 112.476 177.154 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.669 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -36.44 121.47 0.68 Allowed Glycine 0 C--N 1.341 0.822 0 C-N-CA 129.323 3.344 . . . . 10.0 110.883 166.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -149.59 115.21 5.58 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 119.335 1.567 . . . . 10.0 110.022 168.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.533 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -154.59 168.34 27.1 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-O 121.601 0.715 . . . . 10.0 111.406 176.401 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 7.7 m -93.28 148.88 4.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 111.957 -2.383 . . . . 10.0 105.389 166.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -121.91 153.55 38.3 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 174.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . 0.483 ' CD ' ' HA3' ' B' ' 61' ' ' GLY . 2.6 pm0 -40.1 -43.42 1.61 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 127.719 2.408 . . . . 10.0 115.403 -175.289 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -115.21 159.03 21.45 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 124.793 1.237 . . . . 10.0 109.264 -170.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.01 -7.71 63.96 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 126.009 1.766 . . . . 10.0 110.983 169.665 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -42.86 151.21 0.13 Allowed 'General case' 0 C--O 1.239 0.515 0 CA-C-O 123.174 1.464 . . . . 10.0 112.494 169.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.481 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -162.46 21.68 0.1 Allowed 'General case' 0 N--CA 1.437 -1.096 0 CA-C-N 112.485 -2.143 . . . . 10.0 111.997 167.955 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.83 -35.54 76.81 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 118.736 0.698 . . . . 10.0 110.821 -169.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.75 -17.6 55.54 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.602 1.161 . . . . 10.0 112.254 175.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.85 -173.2 17.25 Favored Glycine 0 N--CA 1.442 -0.909 0 N-CA-C 106.844 -2.502 . . . . 10.0 106.844 -167.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 60.1 m -66.53 69.96 0.07 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.311 1.444 . . . . 10.0 108.424 172.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -153.53 -53.04 0.1 Allowed 'General case' 0 N--CA 1.444 -0.774 0 O-C-N 120.693 -1.254 . . . . 10.0 109.617 -168.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.4 t -96.22 -1.26 48.55 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.874 0.87 . . . . 10.0 110.203 -178.069 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.31 47.3 0.37 Allowed 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.811 1.244 . . . . 10.0 112.225 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . 0.483 ' HA3' ' CD ' ' B' ' 49' ' ' GLU . . . 85.05 131.57 2.43 Favored Glycine 0 N--CA 1.44 -1.097 0 N-CA-C 117.479 1.752 . . . . 10.0 117.479 162.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -92.69 23.88 0.51 Allowed 'Trans proline' 0 CA--C 1.545 1.069 0 C-N-CA 123.135 2.557 . . . . 10.0 113.282 168.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.504 ' CD2' HG22 ' B' ' 137' ' ' THR . 21.1 m170 86.77 35.16 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 129.231 3.012 . . . . 10.0 112.352 176.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.24 70.34 0.16 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.319 1.048 . . . . 10.0 111.588 173.182 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -70.13 155.61 93.18 Favored Pre-proline 0 CA--C 1.536 0.413 0 C-N-CA 123.12 0.568 . . . . 10.0 109.965 170.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.57 -48.24 2.39 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 121.965 1.777 . . . . 10.0 110.815 176.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 tt -75.67 63.8 1.63 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.265 1.426 . . . . 10.0 109.205 -175.778 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -45.06 102.02 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 128.042 2.537 . . . . 10.0 113.143 -168.381 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.3 mtp85 -129.1 178.06 6.68 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 126.049 1.74 . . . . 10.0 108.027 175.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -111.94 56.98 0.64 Allowed 'General case' 0 C--O 1.226 -0.171 0 N-CA-C 113.12 0.785 . . . . 10.0 113.12 -167.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 67.8 t60 44.98 85.81 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 122.959 1.361 . . . . 10.0 114.069 175.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -102.65 -161.11 25.9 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 168.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.546 ' HA3' HD22 ' B' ' 126' ' ' LEU . . . -171.21 -152.99 8.6 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 107.043 -2.423 . . . . 10.0 107.043 173.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.42 8.44 0.12 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 120.15 1.975 . . . . 10.0 112.631 169.179 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.4 mttt -123.69 -0.49 8.58 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 117.419 -1.277 . . . . 10.0 113.066 175.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.32 163.55 32.71 Favored 'General case' 0 C--N 1.346 0.439 0 CA-C-N 120.629 1.559 . . . . 10.0 108.602 174.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -77.03 -30.29 55.67 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 177.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -76.58 26.07 0.13 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.651 1.58 . . . . 10.0 113.077 -166.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 18.1 mtm180 -47.58 129.5 13.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 107.392 -1.336 . . . . 10.0 107.392 168.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.1 m170 -67.67 -57.59 6.13 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 121.237 0.541 . . . . 10.0 109.932 176.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.8 p -163.82 -58.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 109.072 -0.714 . . . . 10.0 109.072 -176.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -137.23 62.91 0.58 Allowed Glycine 0 C--N 1.337 0.6 0 N-CA-C 109.209 -1.556 . . . . 10.0 109.209 178.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -90.78 90.74 8.07 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.371 -1.344 . . . . 10.0 107.371 171.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.39 -25.5 57.68 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 121.352 0.596 . . . . 10.0 109.551 177.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . 0.559 ' CA ' HD21 ' B' ' 126' ' ' LEU . . . 80.98 -66.98 3.68 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 115.161 0.825 . . . . 10.0 115.161 167.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -137.93 109.29 6.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 118.677 -0.678 . . . . 10.0 109.249 -167.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.0 m -115.84 125.77 73.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 118.789 0.722 . . . . 10.0 110.451 169.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 10.9 m -81.35 97.51 7.74 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 128.325 2.65 . . . . 10.0 112.134 -171.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.64 132.77 39.6 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 123.824 0.849 . . . . 10.0 112.236 176.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -63.13 173.44 1.45 Allowed 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 125.308 1.443 . . . . 10.0 110.312 167.1 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.3 pttm -55.03 -30.5 59.68 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 123.766 0.827 . . . . 10.0 111.95 170.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.88 3.25 20.37 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.069 0.938 . . . . 10.0 110.953 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.47 -0.26 89.71 Favored Glycine 0 N--CA 1.441 -1.013 0 O-C-N 120.572 -1.33 . . . . 10.0 110.033 -174.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 67.0 t -78.33 94.79 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 N-CA-C 108.414 -0.958 . . . . 10.0 108.414 -169.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -88.15 119.11 28.22 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 167.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -77.34 123.59 26.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.951 -1.5 . . . . 10.0 106.951 169.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 65.8 t -104.65 131.69 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 105.292 -2.114 . . . . 10.0 105.292 169.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 10.1 p -158.01 57.84 0.47 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 118.917 0.78 . . . . 10.0 111.815 177.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.6 151.61 12.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 C-N-CA 124.166 0.986 . . . . 10.0 109.631 -169.279 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -109.1 141.99 40.48 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 126.068 1.747 . . . . 10.0 109.601 170.318 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -137.67 155.35 49.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 O-C-N 124.093 0.871 . . . . 10.0 109.413 173.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.5 p -128.07 58.37 1.52 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 126.86 2.064 . . . . 10.0 108.526 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -155.01 -44.5 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 C-N-CA 124.643 1.177 . . . . 10.0 108.888 174.096 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 33.6 mm -55.91 147.66 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 168.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.0 m -153.85 135.3 14.24 Favored 'General case' 0 C--O 1.233 0.22 0 N-CA-C 109.048 -0.723 . . . . 10.0 109.048 169.511 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -79.18 57.42 2.26 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.367 1.467 . . . . 10.0 108.492 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 15.5 t -83.2 -168.35 2.05 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 126.913 2.085 . . . . 10.0 110.416 -171.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -124.49 -51.93 0.19 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 127.896 2.665 . . . . 10.0 107.469 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -65.24 -58.89 4.83 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 109.776 -0.453 . . . . 10.0 109.776 169.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -76.92 -38.33 53.65 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 108.048 -1.093 . . . . 10.0 108.048 -173.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.4 t 37.18 69.13 0.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 127.009 2.124 . . . . 10.0 113.966 169.574 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.2 pp -56.0 -30.29 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.34 -0.985 . . . . 10.0 108.34 166.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.7 mm -31.12 -36.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 C-N-CA 128.306 2.642 . . . . 10.0 115.234 169.495 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -104.56 28.95 12.86 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-O 118.711 -1.049 . . . . 10.0 112.784 -175.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -104.87 169.85 8.21 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 125.106 1.362 . . . . 10.0 110.176 177.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 18.4 m -108.26 127.7 54.08 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.696 1.598 . . . . 10.0 109.104 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.407 HD21 HD11 ' B' ' 149' ' ' ILE . 4.5 mm? -84.9 141.23 30.55 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 106.71 -1.589 . . . . 10.0 106.71 167.059 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 92.5 t -125.46 136.7 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 170.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.425 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 6.0 p -105.65 130.9 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 125.083 1.353 . . . . 10.0 107.583 169.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.669 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.3 m170 -114.68 157.84 22.59 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 115.75 1.759 . . . . 10.0 115.75 -171.298 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -37.11 -63.76 0.41 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 129.301 3.04 . . . . 10.0 111.078 169.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 61.5 mttt -117.93 175.32 5.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 C-N-CA 124.231 1.012 . . . . 10.0 110.131 -173.077 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -91.72 148.19 22.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.894 1.278 . . . . 10.0 109.478 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.533 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -75.04 143.35 43.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 112.053 0.39 . . . . 10.0 112.053 -178.786 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -80.64 -3.62 51.21 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 124.394 1.059 . . . . 10.0 110.791 166.564 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.559 HD21 ' CA ' ' B' ' 85' ' ' GLY . 71.1 mt 51.24 50.73 18.4 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 125.426 1.49 . . . . 10.0 111.218 170.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.37 -36.08 4.3 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-N 114.525 -1.216 . . . . 10.0 110.935 174.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.434 ' HD3' ' H ' ' B' ' 128' ' ' LYS . 0.2 OUTLIER -83.31 35.22 0.49 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 121.025 -1.279 . . . . 10.0 110.847 -173.844 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.92 -36.11 6.51 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 109.51 -1.436 . . . . 10.0 109.51 179.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.62 51.21 59.26 Favored Glycine 0 CA--C 1.529 0.938 0 N-CA-C 111.39 -0.684 . . . . 10.0 111.39 -171.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -142.66 171.7 13.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 104.605 -2.368 . . . . 10.0 104.605 170.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 24.4 mp0 -51.78 -48.11 63.91 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 120.726 -0.39 . . . . 10.0 110.379 174.328 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -53.08 -38.17 62.32 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.451 -0.34 . . . . 10.0 110.282 177.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.8 p -57.72 -30.01 65.19 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 118.013 -0.994 . . . . 10.0 112.513 -176.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -98.2 17.47 18.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.412 1.005 . . . . 10.0 109.834 -177.551 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -142.19 -69.74 0.35 Allowed 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 124.822 1.249 . . . . 10.0 110.38 -169.282 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.504 HG22 ' CD2' ' B' ' 63' ' ' HIS . 11.4 p -126.73 21.61 6.99 Favored 'General case' 0 CA--C 1.547 0.859 0 CA-C-N 119.653 1.115 . . . . 10.0 112.29 177.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 79.07 -88.07 1.18 Allowed Glycine 0 C--N 1.343 0.958 0 O-C-N 121.111 -0.993 . . . . 10.0 111.01 170.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -170.09 38.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 122.989 1.376 . . . . 10.0 107.934 174.34 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.76 -29.05 61.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 125.169 1.388 . . . . 10.0 109.607 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.95 -157.61 53.09 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 109.847 -1.301 . . . . 10.0 109.847 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 56.7 m -56.84 130.57 46.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 113.59 0.959 . . . . 10.0 113.59 -167.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.9 mtt85 -66.68 75.22 0.11 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.934 1.294 . . . . 10.0 110.654 172.695 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 55.1 mt -50.58 -40.19 51.77 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 118.349 0.522 . . . . 10.0 112.226 179.535 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.425 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -155.31 160.41 40.73 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 121.943 -0.473 . . . . 10.0 109.867 -177.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 p -159.42 166.46 30.99 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 109.982 -0.377 . . . . 10.0 109.982 -177.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.56 165.55 36.24 Favored Glycine 0 C--N 1.334 0.433 0 N-CA-C 110.689 -0.965 . . . . 10.0 110.689 -177.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.68 137.53 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 106.002 -1.851 . . . . 10.0 106.002 -171.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.433 HG12 ' HB2' ' B' ' 6' ' ' ALA . 16.7 mt -68.42 157.3 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 N-CA-C 108.491 -0.929 . . . . 10.0 108.491 177.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -163.83 155.38 26.72 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 109.732 -1.347 . . . . 10.0 109.732 -176.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . 0.477 HD11 ' HD3' ' A' ' 115' ' ' ARG . 1.9 pp -90.32 125.84 43.16 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-N 118.475 1.138 . . . . 10.0 111.368 -173.1 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.75 -25.96 27.92 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.126 -0.984 . . . . 10.0 111.245 177.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.251 1.133 0 C-N-CA 125.837 1.655 . . . . 10.0 107.676 178.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.835 0 CA-C-O 118.253 -0.88 . . . . 10.0 108.636 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.31 -53.61 1.91 Allowed 'General case' 0 N--CA 1.463 0.175 0 C-N-CA 124.274 1.029 . . . . 10.0 110.828 -175.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -105.51 128.36 53.53 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -137.32 161.74 35.45 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.132 0.573 . . . . 10.0 109.665 172.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -125.94 153.45 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 125.71 1.604 . . . . 10.0 109.782 -179.202 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -139.73 127.53 21.98 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 108.251 -1.018 . . . . 10.0 108.251 165.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.648 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.9 m -115.36 83.7 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 C-N-CA 124.783 1.233 . . . . 10.0 110.772 -174.537 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.426 HD12 ' N ' ' A' ' 8' ' ' LEU . 2.7 mp -76.02 150.01 37.44 Favored 'General case' 0 N--CA 1.452 -0.369 0 O-C-N 121.144 -0.972 . . . . 10.0 109.856 -169.069 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.429 ' C ' ' HB1' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -165.96 155.24 11.81 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 107.527 -1.286 . . . . 10.0 107.527 -179.206 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.19 -46.2 0.18 Allowed Glycine 0 N--CA 1.463 0.477 0 C-N-CA 119.505 -1.331 . . . . 10.0 114.136 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -73.33 -45.35 55.74 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -175.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.71 -73.13 0.32 Allowed Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 109.32 -1.512 . . . . 10.0 109.32 170.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -56.75 -39.55 90.55 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.835 2.357 . . . . 10.0 110.996 172.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 98.4 t -62.97 106.54 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 CA-C-N 119.245 0.93 . . . . 10.0 108.507 -177.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.63 112.44 20.53 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 106.014 -1.847 . . . . 10.0 106.014 169.679 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.775 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -96.17 142.57 16.2 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 109.576 -1.41 . . . . 10.0 109.576 174.293 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -147.12 93.32 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 107.593 -1.262 . . . . 10.0 107.593 -172.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.4 mm -111.88 139.82 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 C-N-CA 125.582 1.553 . . . . 10.0 110.111 -175.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -118.32 122.45 42.9 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.943 1.697 . . . . 10.0 109.157 168.247 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -101.74 114.11 27.89 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 125.255 1.422 . . . . 10.0 107.259 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -120.6 112.68 19.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 122.154 0.978 . . . . 10.0 113.084 -179.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -82.29 104.8 12.86 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 106.307 -1.738 . . . . 10.0 106.307 168.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.3 -24.44 67.3 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 118.97 -0.538 . . . . 10.0 110.405 177.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -135.75 -161.22 1.13 Allowed 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.419 -0.586 . . . . 10.0 109.419 178.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 23.1 t -99.87 -7.68 25.02 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 119.363 -0.351 . . . . 10.0 110.355 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.9 m-80 -139.63 21.34 2.52 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.819 1.248 . . . . 10.0 108.969 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.98 161.8 42.09 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.278 -1.129 . . . . 10.0 110.278 -172.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -67.69 117.28 4.76 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 N-CA-C 104.226 -3.029 . . . . 10.0 104.226 165.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.77 131.56 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 -174.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.1 mttt -101.53 122.74 44.37 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 106.541 -1.651 . . . . 10.0 106.541 174.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.1 m -119.73 111.93 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.82 0 N-CA-C 105.572 -2.01 . . . . 10.0 105.572 -175.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -128.99 167.96 16.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 121.209 0.528 . . . . 10.0 109.988 -179.291 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.77 171.17 38.68 Favored Glycine 0 N--CA 1.437 -1.295 0 N-CA-C 110.009 -1.236 . . . . 10.0 110.009 -176.353 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.5 t -142.55 99.04 3.41 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 177.663 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.775 HG22 ' HA2' ' A' ' 16' ' ' GLY . 4.9 pt -79.51 156.26 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 C-N-CA 118.514 -1.275 . . . . 10.0 107.642 167.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.5 ptmt -141.9 164.6 29.76 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.519 -0.919 . . . . 10.0 108.519 164.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.66 -14.23 46.2 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-O 119.105 -0.831 . . . . 10.0 113.08 177.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.496 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.4 mp -70.77 176.9 3.88 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 118.566 1.183 . . . . 10.0 110.482 178.08 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -95.9 149.82 21.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.397 -0.82 . . . . 10.0 109.309 169.066 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -43.61 137.53 2.91 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.685 1.994 . . . . 10.0 111.58 -176.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 114.62 -172.87 14.49 Favored Glycine 0 CA--C 1.526 0.772 0 C-N-CA 123.881 0.753 . . . . 10.0 112.585 170.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.89 145.32 50.28 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 125.024 1.33 . . . . 10.0 110.908 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -147.9 143.58 27.48 Favored 'General case' 0 C--N 1.34 0.189 0 N-CA-C 113.099 0.777 . . . . 10.0 113.099 177.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.633 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -28.55 117.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 C-N-CA 127.842 2.639 . . . . 10.0 113.078 165.397 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -143.1 109.18 5.24 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 120.207 2.004 . . . . 10.0 110.873 169.046 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.492 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -156.78 171.79 19.77 Favored 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 115.438 -0.801 . . . . 10.0 110.765 178.573 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.9 m -89.45 163.39 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 112.514 -2.13 . . . . 10.0 106.895 166.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -124.47 158.23 33.32 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 124.857 1.263 . . . . 10.0 107.859 172.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -58.04 -41.3 82.95 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 123.994 0.918 . . . . 10.0 112.935 -169.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -107.41 174.65 5.79 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.034 0.934 . . . . 10.0 109.82 176.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.39 -9.96 14.14 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.236 1.874 . . . . 10.0 112.449 175.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -65.81 161.34 21.18 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 122.379 1.085 . . . . 10.0 110.949 -178.138 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -158.0 28.98 0.26 Allowed 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.445 -0.798 . . . . 10.0 112.289 -170.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.639 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -59.19 -36.43 75.35 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.569 -0.707 . . . . 10.0 112.368 -171.622 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.44 -17.54 56.2 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.178 0.591 . . . . 10.0 111.499 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.37 -156.25 15.73 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 104.664 -3.374 . . . . 10.0 104.664 -167.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 93.6 m -68.23 72.33 0.19 Allowed 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 125.133 1.373 . . . . 10.0 110.174 177.033 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -158.56 -47.92 0.06 Allowed 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 123.564 0.746 . . . . 10.0 111.128 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 m -56.0 -35.17 66.5 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.27 1.028 . . . . 10.0 111.476 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.09 -28.86 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.482 3.113 . . . . 10.0 116.395 174.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.04 165.87 29.03 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 107.84 -2.104 . . . . 10.0 107.84 175.46 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -72.81 -141.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.347 0 N-CA-C 106.635 -2.102 . . . . 10.0 106.635 166.249 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -105.04 38.03 2.03 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 120.515 1.507 . . . . 10.0 111.556 179.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -72.18 73.17 0.93 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.848 1.658 . . . . 10.0 112.181 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 7.2 p-10 -61.12 151.43 75.44 Favored Pre-proline 0 CA--C 1.537 0.456 0 O-C-N 121.557 -0.715 . . . . 10.0 110.524 169.146 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -62.02 -43.55 24.22 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 122.571 2.181 . . . . 10.0 111.459 -178.338 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 tt -77.06 60.4 1.84 Allowed 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 108.503 -0.925 . . . . 10.0 108.503 175.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 p -42.23 108.95 0.11 Allowed 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 126.238 1.815 . . . . 10.0 111.762 -169.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -124.67 176.23 6.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 108.393 -0.965 . . . . 10.0 108.393 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -98.42 113.81 25.93 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 108.559 -0.904 . . . . 10.0 108.559 -174.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.2 t60 -25.52 102.48 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 124.856 1.262 . . . . 10.0 113.894 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.81 -136.94 7.6 Favored Glycine 0 N--CA 1.443 -0.885 0 N-CA-C 107.975 -2.05 . . . . 10.0 107.975 178.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.03 -164.5 24.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 107.554 -2.219 . . . . 10.0 107.554 168.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -52.67 -18.27 8.44 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.14 1.894 . . . . 10.0 112.237 170.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.45 ' HZ1' ' CG ' ' A' ' 76' ' ' ASP . 0.0 OUTLIER -83.45 -33.36 25.66 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.025 0.93 . . . . 10.0 110.828 -177.424 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.45 ' CG ' ' HZ1' ' A' ' 75' ' ' LYS . 1.4 m-20 -98.04 175.14 6.22 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 -171.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -89.42 -28.39 19.77 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 107.72 -1.215 . . . . 10.0 107.72 167.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -86.79 16.8 4.46 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 125.518 1.527 . . . . 10.0 113.156 -168.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.38 136.05 13.07 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.779 0.831 . . . . 10.0 109.729 168.399 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -71.77 -176.7 1.72 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 107.906 -1.146 . . . . 10.0 107.906 168.262 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.49 41.19 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 N-CA-C 113.754 1.02 . . . . 10.0 113.754 -175.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.82 56.71 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.237 -1.545 . . . . 10.0 109.237 172.166 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -98.01 95.89 7.78 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 107.049 -1.463 . . . . 10.0 107.049 169.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -80.16 -30.14 38.87 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 105.99 -102.02 1.89 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 107.954 -2.058 . . . . 10.0 107.954 168.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -132.34 114.0 13.87 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.998 1.319 . . . . 10.0 109.586 -167.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.5 m -103.6 137.2 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 C-N-CA 122.709 0.403 . . . . 10.0 110.192 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 92.1 m -83.27 105.47 14.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 127.13 2.172 . . . . 10.0 109.681 -177.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.75 131.07 35.21 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.253 0.621 . . . . 10.0 109.945 170.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -59.33 170.63 0.93 Allowed 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 125.13 1.372 . . . . 10.0 110.182 168.376 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 66.6 tttt -51.49 -35.27 39.42 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 125.925 1.69 . . . . 10.0 111.845 169.084 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -79.81 2.11 24.29 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 121.556 0.693 . . . . 10.0 111.292 177.293 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.34 -2.81 87.95 Favored Glycine 0 N--CA 1.445 -0.74 0 O-C-N 120.322 -1.487 . . . . 10.0 110.435 -178.312 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 69.5 t -75.67 103.99 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -170.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.595 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -104.23 115.25 30.06 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 108.43 -0.952 . . . . 10.0 108.43 173.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -79.16 125.44 29.45 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 114.44 -1.254 . . . . 10.0 108.107 173.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -106.28 128.67 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.397 0 N-CA-C 104.442 -2.429 . . . . 10.0 104.442 168.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.9 m -155.13 73.88 0.89 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 123.474 0.709 . . . . 10.0 110.028 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 15.8 mm -112.24 161.17 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 124.311 1.044 . . . . 10.0 111.29 -174.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -123.73 134.86 53.61 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 129.733 3.213 . . . . 10.0 107.047 169.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -145.68 144.17 30.24 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.505 -0.554 . . . . 10.0 109.505 175.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 5.1 p -109.57 18.72 20.02 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.311 1.844 . . . . 10.0 112.701 -174.24 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.8 t -126.38 -54.26 1.84 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.2 0 C-N-CA 125.595 1.558 . . . . 10.0 107.507 -177.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 10.9 mm -48.92 115.47 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 C-N-CA 124.575 1.15 . . . . 10.0 109.086 172.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 44.0 m -114.51 116.78 29.37 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 123.897 0.879 . . . . 10.0 108.952 -176.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.97 -47.72 32.75 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 125.309 1.444 . . . . 10.0 109.647 176.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.4 m -149.13 164.39 34.83 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 107.137 -1.431 . . . . 10.0 107.137 174.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 134.27 -99.52 0.35 Allowed Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 107.211 -2.356 . . . . 10.0 107.211 -172.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -120.13 -49.2 2.3 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 124.653 1.181 . . . . 10.0 109.216 -168.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -76.03 -44.49 39.04 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 106.957 -1.497 . . . . 10.0 106.957 -177.315 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.1 t 46.97 76.14 0.11 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.994 1.717 . . . . 10.0 112.559 169.452 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 26.3 pt -59.77 -25.72 33.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 112.146 0.424 . . . . 10.0 112.146 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.1 mm -42.8 122.25 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 CA-C-N 119.068 0.849 . . . . 10.0 111.291 175.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.99 8.59 78.82 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-O 119.013 -0.881 . . . . 10.0 113.029 175.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.13 169.51 11.86 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.421 1.11 . . . . 10.0 108.499 168.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.92 141.37 36.67 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.862 0.865 . . . . 10.0 111.287 174.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.429 HD21 HD11 ' A' ' 149' ' ' ILE . 4.5 mm? -95.64 141.46 29.12 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.427 -1.323 . . . . 10.0 107.427 168.503 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.439 HG12 ' CD2' ' A' ' 120' ' ' HIS . 72.4 t -123.48 138.96 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 108.604 -0.887 . . . . 10.0 108.604 172.395 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.445 HG13 ' HB3' ' A' ' 145' ' ' ALA . 1.3 p -102.7 122.14 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 105.806 -1.924 . . . . 10.0 105.806 167.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.633 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.3 m-70 -104.88 160.29 15.12 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 115.207 1.558 . . . . 10.0 115.207 -173.036 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.34 -56.23 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 113.818 -1.537 . . . . 10.0 110.657 176.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 41.0 mttm -113.8 175.65 5.37 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-O 121.789 0.804 . . . . 10.0 111.918 -179.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.12 139.34 35.68 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.936 1.694 . . . . 10.0 109.051 172.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.492 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -78.14 164.63 24.81 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 121.843 0.83 . . . . 10.0 111.601 174.227 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -73.99 -16.56 61.07 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 114.618 -1.174 . . . . 10.0 110.54 -178.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 10.1 mt 52.13 46.68 26.19 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 -168.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.62 -13.29 67.05 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.65 2.072 . . . . 10.0 113.785 171.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.3 mtmp? -79.31 3.94 16.65 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 115.376 1.621 . . . . 10.0 115.376 -167.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.97 -33.15 51.26 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.493 1.042 . . . . 10.0 110.891 178.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.22 41.99 93.14 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 111.846 -0.502 . . . . 10.0 111.846 -173.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -132.96 170.34 15.49 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 124.684 1.194 . . . . 10.0 108.138 173.21 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -41.46 -55.66 2.76 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 125.497 1.519 . . . . 10.0 110.479 175.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 49.1 mp0 -56.43 -51.85 66.85 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 125.096 1.359 . . . . 10.0 110.311 176.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 18.6 p -51.46 -38.26 52.92 Favored 'General case' 0 CA--C 1.508 -0.641 0 C-N-CA 123.138 0.575 . . . . 10.0 111.009 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.91 -11.65 56.6 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 123.999 0.812 . . . . 10.0 111.307 -170.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -112.57 -48.84 2.98 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.829 1.251 . . . . 10.0 112.081 -172.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.7 p -137.05 23.65 3.03 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 120.289 1.404 . . . . 10.0 110.634 174.087 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.81 -113.79 6.19 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 106.065 -2.814 . . . . 10.0 106.065 -171.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 19.3 m-80 -157.95 44.05 0.32 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 107.258 -1.386 . . . . 10.0 107.258 174.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.84 -13.34 55.65 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 124.205 1.002 . . . . 10.0 112.313 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.6 -164.96 54.86 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 110.355 -1.098 . . . . 10.0 110.355 176.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.2 t -54.84 134.14 48.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 113.396 0.888 . . . . 10.0 113.396 -168.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -64.55 73.3 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.967 1.707 . . . . 10.0 109.432 168.308 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 39.8 mt -49.83 -39.3 38.31 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 118.383 0.538 . . . . 10.0 111.927 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.445 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -155.98 157.42 36.17 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.135 -0.691 . . . . 10.0 109.135 -177.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -157.08 162.3 39.47 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.415 -0.357 . . . . 10.0 110.531 -173.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -147.62 175.6 26.87 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.847 1.213 . . . . 10.0 110.088 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 13.6 t -122.04 140.81 44.82 Favored 'Isoleucine or valine' 0 C--N 1.343 0.298 0 CA-C-N 118.882 1.341 . . . . 10.0 107.422 -177.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.429 HD11 HD21 ' A' ' 117' ' ' LEU . 17.5 mt -75.82 119.56 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 123.76 0.824 . . . . 10.0 109.836 -176.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.97 148.9 17.89 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 125.428 1.49 . . . . 10.0 111.737 -178.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 89.0 mt -69.16 135.16 28.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.58 1.552 . . . . 10.0 110.163 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.02 -7.13 4.41 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 115.45 1.648 . . . . 10.0 115.45 -173.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.253 1.269 0 CA-C-O 117.528 -1.225 . . . . 10.0 110.199 -179.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.669 0 CA-C-O 118.272 -0.871 . . . . 10.0 109.043 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -78.19 -26.83 47.72 Favored 'General case' 0 C--O 1.224 -0.24 0 C-N-CA 123.345 0.658 . . . . 10.0 110.895 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 62.5 tttt -130.05 137.3 50.16 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.093 0.473 . . . . 10.0 111.068 176.257 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.29 161.17 36.17 Favored 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 125.129 1.372 . . . . 10.0 107.964 171.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 t -126.91 156.26 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 C-N-CA 125.184 1.394 . . . . 10.0 109.735 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . 0.423 ' HB1' HD11 ' B' ' 117' ' ' LEU . . . -138.85 112.31 8.2 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 107.196 -1.409 . . . . 10.0 107.196 168.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 11.6 m -100.41 128.65 52.22 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 108.31 -0.996 . . . . 10.0 108.31 171.004 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.18 145.35 31.64 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 123.917 0.887 . . . . 10.0 110.534 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -161.19 160.45 30.12 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.921 -1.141 . . . . 10.0 107.921 168.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.1 -45.58 0.12 Allowed Glycine 0 C--O 1.228 -0.257 0 C-N-CA 119.982 -1.104 . . . . 10.0 113.285 169.107 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 -45.04 53.12 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.604 -1.258 . . . . 10.0 107.604 -175.588 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.37 -71.19 0.39 Allowed Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.644 -1.382 . . . . 10.0 109.644 170.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -57.86 -38.88 90.87 Favored 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 123.076 2.518 . . . . 10.0 111.095 171.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 92.2 t -61.47 103.05 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.035 0 N-CA-C 107.824 -1.176 . . . . 10.0 107.824 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -118.1 128.86 55.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.339 -1.356 . . . . 10.0 107.339 169.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.429 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -118.15 146.29 18.54 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 110.953 -0.859 . . . . 10.0 110.953 175.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.639 HG22 HG22 ' A' ' 54' ' ' THR . 1.5 mt -146.57 89.55 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 C-N-CA 125.634 1.573 . . . . 10.0 107.657 -176.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.8 mm -102.5 139.25 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.744 1.618 . . . . 10.0 110.082 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -115.9 110.73 19.41 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 129.314 3.046 . . . . 10.0 107.366 176.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -95.02 114.64 26.47 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -112.47 122.34 47.42 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 118.64 0.655 . . . . 10.0 112.721 169.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 5.0 tp-100 -82.55 110.11 17.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.145 -2.168 . . . . 10.0 105.145 166.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt -39.18 -69.7 0.12 Allowed 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 130.429 3.492 . . . . 10.0 111.456 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 11.4 mp0 -127.42 -116.06 0.26 Allowed 'General case' 0 N--CA 1.423 -1.824 0 O-C-N 124.3 1.0 . . . . 10.0 109.088 -178.097 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 12.0 m -121.2 -15.57 8.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 112.26 0.467 . . . . 10.0 112.26 170.013 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -134.67 12.47 3.72 Favored 'General case' 0 N--CA 1.456 -0.138 0 C-N-CA 123.991 0.916 . . . . 10.0 109.975 179.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.97 166.58 48.78 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 108.96 -1.656 . . . . 10.0 108.96 176.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -64.04 151.05 86.97 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.458 1.439 . . . . 10.0 108.744 171.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 t -79.76 124.07 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.984 -2.599 . . . . 10.0 103.984 168.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -99.66 112.53 24.75 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.496 -1.668 . . . . 10.0 106.496 169.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -95.99 103.99 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.959 0 C-N-CA 127.08 2.152 . . . . 10.0 106.135 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.1 p90 -124.75 165.17 18.44 Favored 'General case' 0 C--O 1.223 -0.323 0 N-CA-C 112.648 0.61 . . . . 10.0 112.648 173.285 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.8 -156.63 27.1 Favored Glycine 0 N--CA 1.449 -0.494 0 N-CA-C 107.216 -2.354 . . . . 10.0 107.216 172.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 50.8 p -156.25 160.52 39.87 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.565 -1.254 . . . . 10.0 112.52 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.752 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -116.18 136.56 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 C-N-CA 126.197 1.799 . . . . 10.0 107.519 167.887 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 92' ' ' ASP . 0.1 OUTLIER -130.82 159.38 37.52 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.289 0.368 . . . . 10.0 110.452 167.276 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.14 -0.19 44.31 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.779 0.704 . . . . 10.0 113.22 -178.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.433 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.9 mp -85.02 175.62 8.93 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 118.0 0.9 . . . . 10.0 109.703 -178.308 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.5 t -90.89 154.45 19.47 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.913 -0.773 . . . . 10.0 108.913 168.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -51.22 145.32 8.14 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 126.536 1.935 . . . . 10.0 111.324 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.92 -170.49 21.84 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-O 121.593 0.552 . . . . 10.0 111.95 172.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -73.88 147.56 43.1 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.296 1.438 . . . . 10.0 112.535 -170.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -147.94 127.49 13.24 Favored 'General case' 0 C--N 1.341 0.218 0 N-CA-C 114.395 1.257 . . . . 10.0 114.395 -178.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.675 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -17.75 124.41 0.01 OUTLIER Glycine 0 C--N 1.342 0.89 0 C-N-CA 127.473 2.463 . . . . 10.0 114.489 164.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -147.18 106.17 3.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 119.863 1.832 . . . . 10.0 111.339 167.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.45 172.49 15.87 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.417 0.627 . . . . 10.0 111.165 175.206 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 19.5 m -96.91 153.92 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 112.632 -2.076 . . . . 10.0 108.479 168.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -134.49 135.47 42.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.005 2.122 . . . . 10.0 105.349 177.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -56.7 -48.36 77.87 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 123.896 0.748 . . . . 10.0 112.84 -168.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -78.42 112.66 15.68 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 118.126 -1.43 . . . . 10.0 108.486 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.74 -26.37 62.56 Favored Glycine 0 N--CA 1.44 -1.068 0 N-CA-C 109.534 -1.426 . . . . 10.0 109.534 167.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -34.37 109.12 0.07 Allowed 'General case' 0 CA--C 1.516 -0.364 0 C-N-CA 125.237 1.415 . . . . 10.0 111.343 169.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.648 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.7 OUTLIER -117.97 13.13 13.9 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 113.417 -1.719 . . . . 10.0 110.672 174.307 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.23 -39.84 67.14 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 119.102 0.864 . . . . 10.0 111.999 -168.314 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.88 -17.98 54.68 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.313 1.045 . . . . 10.0 113.027 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.23 76.07 1.11 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 108.269 -1.932 . . . . 10.0 108.269 -169.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.6 p 30.55 37.5 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 128.338 2.655 . . . . 10.0 116.177 -177.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 20.4 m -100.33 -50.25 3.99 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 105.046 -2.205 . . . . 10.0 105.046 -178.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.1 m -67.04 -14.73 63.18 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 126.378 1.871 . . . . 10.0 112.201 177.698 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -44.26 -26.74 0.35 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 127.228 2.211 . . . . 10.0 114.334 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 156.26 26.59 Favored Glycine 0 N--CA 1.438 -1.213 0 N-CA-C 109.002 -1.639 . . . . 10.0 109.002 169.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -69.31 -170.92 0.39 Allowed 'Trans proline' 0 N--CA 1.44 -1.65 0 N-CA-C 106.756 -2.055 . . . . 10.0 106.756 167.003 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 31.2 m170 -81.61 60.33 4.53 Favored 'General case' 0 CA--C 1.542 0.647 0 O-C-N 120.325 -1.485 . . . . 10.0 109.99 -172.398 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -70.85 75.52 0.62 Allowed 'General case' 0 C--O 1.223 -0.328 0 CA-C-N 118.917 0.781 . . . . 10.0 110.584 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -75.26 148.01 83.36 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.336 -0.853 . . . . 10.0 110.933 172.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.14 -42.97 12.32 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.57 2.18 . . . . 10.0 110.661 176.027 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.2 mt -75.87 54.77 0.84 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 123.806 0.843 . . . . 10.0 109.86 176.253 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.5 p -40.29 112.01 0.24 Allowed 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 125.787 1.635 . . . . 10.0 111.571 -172.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -142.34 178.4 7.6 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.42 -2.437 . . . . 10.0 104.42 -176.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -65.92 156.74 32.61 Favored 'General case' 0 N--CA 1.439 -0.977 0 C-N-CA 116.606 -2.038 . . . . 10.0 108.917 168.386 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -66.43 126.32 28.47 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 104.976 -2.231 . . . . 10.0 104.976 161.539 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -138.27 -133.21 3.07 Favored Glycine 0 N--CA 1.451 -0.35 0 N-CA-C 109.226 -1.55 . . . . 10.0 109.226 172.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.84 -155.08 23.19 Favored Glycine 0 C--O 1.226 -0.405 0 CA-C-O 118.028 -1.429 . . . . 10.0 109.53 174.64 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -64.88 2.37 1.37 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 CA-C-N 119.803 1.801 . . . . 10.0 112.155 172.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -95.18 -21.57 18.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 117.65 -1.167 . . . . 10.0 110.862 172.319 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -126.72 156.14 41.6 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 119.318 0.963 . . . . 10.0 109.817 -170.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -78.17 -32.79 50.31 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 106.885 -1.524 . . . . 10.0 106.885 167.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -88.01 57.17 4.18 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 125.553 1.541 . . . . 10.0 108.167 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 14.3 ptm180 -83.78 147.81 27.39 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 106.259 -1.756 . . . . 10.0 106.259 165.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -63.55 -57.95 8.52 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.481 1.037 . . . . 10.0 110.548 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.458 HG22 HG22 ' B' ' 104' ' ' ILE . 2.1 p 179.78 -99.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 104.883 -2.265 . . . . 10.0 104.883 -179.388 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.438 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -74.68 54.15 2.48 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.45 1.023 . . . . 10.0 112.417 172.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 70.0 m-20 -95.76 92.56 6.62 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 104.223 -2.51 . . . . 10.0 104.223 167.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 80.7 mt -89.44 38.84 0.92 Allowed 'General case' 0 CA--C 1.531 0.214 0 N-CA-C 107.983 -1.117 . . . . 10.0 107.983 177.195 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 32.91 -103.08 0.01 OUTLIER Glycine 0 C--N 1.341 0.84 0 C-N-CA 128.124 2.773 . . . . 10.0 112.206 -175.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -143.85 147.11 33.6 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.11 0.964 . . . . 10.0 109.769 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 32.4 m -113.15 139.04 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 125.095 1.358 . . . . 10.0 108.355 -174.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -83.41 122.47 28.54 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.273 0.629 . . . . 10.0 109.917 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.75 131.31 37.92 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.581 1.153 . . . . 10.0 109.255 171.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -56.15 169.36 0.41 Allowed 'General case' 0 N--CA 1.451 -0.41 0 O-C-N 124.486 1.116 . . . . 10.0 110.007 168.066 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 11.3 tttp -49.99 -35.46 24.56 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.284 1.434 . . . . 10.0 112.185 169.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 36' ' ' LYS . 36.1 t70 -79.47 0.31 30.04 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.275 0.559 . . . . 10.0 112.202 177.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.03 -1.0 86.54 Favored Glycine 0 C--N 1.337 0.623 0 O-C-N 120.394 -1.441 . . . . 10.0 110.698 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 56.0 t -77.15 97.71 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 107.443 -1.317 . . . . 10.0 107.443 -174.639 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.752 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -94.3 116.98 29.44 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 168.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -88.19 130.35 35.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.839 -1.171 . . . . 10.0 107.839 174.014 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.0 t -107.7 129.89 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 105.257 -2.127 . . . . 10.0 105.257 168.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 12.2 p -157.77 55.88 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 118.696 0.68 . . . . 10.0 110.957 175.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -107.58 143.68 17.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.466 -0.771 . . . . 10.0 110.222 -169.084 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -97.85 129.21 44.83 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 128.638 2.775 . . . . 10.0 107.049 168.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -143.23 134.0 25.26 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 109.454 -0.573 . . . . 10.0 109.454 -176.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.6 p -115.64 45.78 1.63 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.559 1.544 . . . . 10.0 110.011 -169.337 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.9 p -142.98 -46.79 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 122.634 0.374 . . . . 10.0 111.219 177.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.458 HG22 HG22 ' B' ' 81' ' ' VAL 0.31 0.0 OUTLIER -65.12 161.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 119.787 -0.765 . . . . 10.0 111.441 169.517 . . . . . . . . 4 4 . 1 . 017 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 20.3 m -146.32 165.47 29.17 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 107.912 -1.144 . . . . 10.0 107.912 169.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 83.4 mt -100.55 -18.52 16.59 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 123.138 0.575 . . . . 10.0 110.061 175.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 44.7 m -156.3 164.47 38.28 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.443 1.497 . . . . 10.0 107.189 174.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 119.53 -95.11 0.59 Allowed Glycine 0 C--N 1.333 0.385 0 N-CA-C 108.378 -1.889 . . . . 10.0 108.378 -178.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -131.79 -52.29 0.99 Allowed 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 126.056 1.743 . . . . 10.0 107.966 176.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -81.85 37.13 0.47 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.645 0.778 . . . . 10.0 110.489 -170.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.7 t -74.81 93.12 2.58 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 127.261 2.224 . . . . 10.0 109.481 -169.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 24.5 pt -75.41 34.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.519 -0.738 . . . . 10.0 112.746 -177.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 38.2 mm -85.25 146.54 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 O-C-N 120.281 -1.512 . . . . 10.0 109.395 -175.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.85 24.21 69.78 Favored Glycine 0 CA--C 1.531 1.079 0 O-C-N 121.976 -0.452 . . . . 10.0 112.677 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -93.3 149.49 21.19 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 125.172 1.389 . . . . 10.0 107.347 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.1 m -87.47 139.96 30.01 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 105.66 -1.978 . . . . 10.0 105.66 168.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.423 HD11 ' HB1' ' B' ' 6' ' ' ALA . 0.0 OUTLIER -116.61 159.01 22.79 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 108.135 -1.061 . . . . 10.0 108.135 168.704 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 74.5 t -137.94 129.51 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 107.981 -1.118 . . . . 10.0 107.981 -172.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.409 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 3.0 p -94.52 122.65 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 105.929 -1.878 . . . . 10.0 105.929 167.035 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.675 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.7 m-70 -105.98 160.24 15.43 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 115.303 1.594 . . . . 10.0 115.303 -171.329 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -41.38 -60.94 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.069 2.948 . . . . 10.0 111.968 171.108 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -120.16 172.16 7.97 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.71 1.204 . . . . 10.0 113.166 -168.355 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.54 154.47 38.61 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 114.186 -1.37 . . . . 10.0 108.187 168.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -92.74 168.73 11.0 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 124.337 1.055 . . . . 10.0 111.034 -176.061 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.58 -20.99 59.72 Favored 'General case' 0 C--O 1.223 -0.336 0 C-N-CA 125.11 1.364 . . . . 10.0 108.278 175.049 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 49.8 mt 49.45 43.31 23.52 Favored 'General case' 0 C--N 1.341 0.237 0 C-N-CA 124.457 1.103 . . . . 10.0 109.998 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.51 33.17 80.48 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.087 -1.415 . . . . 10.0 113.174 178.142 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -75.4 0.08 18.18 Favored 'General case' 0 C--N 1.339 0.142 0 CA-C-N 118.913 1.357 . . . . 10.0 112.337 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.82 17.97 78.63 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.45 -1.46 . . . . 10.0 109.45 178.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.25 -26.08 74.32 Favored Glycine 0 N--CA 1.443 -0.834 0 N-CA-C 110.352 -1.099 . . . . 10.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 34.3 m-80 -156.07 163.14 40.03 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 118.067 0.933 . . . . 10.0 108.925 -168.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 11.0 tm-20 -56.23 -42.21 76.92 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 109.546 -0.539 . . . . 10.0 109.546 171.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -61.38 -23.96 66.15 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 112.635 0.606 . . . . 10.0 112.635 175.174 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.3 p -52.42 -39.32 60.83 Favored 'General case' 0 CA--C 1.512 -0.519 0 CA-C-N 118.556 0.617 . . . . 10.0 110.393 -172.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.7 t -90.17 -1.76 57.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 O-C-N 124.671 1.232 . . . . 10.0 111.67 -173.593 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -116.82 -48.93 2.64 Favored 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 126.769 2.028 . . . . 10.0 111.367 -168.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.7 p -135.43 -2.61 2.45 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 118.653 -0.689 . . . . 10.0 111.543 168.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.71 -106.38 3.19 Favored Glycine 0 N--CA 1.433 -1.52 0 N-CA-C 105.693 -2.963 . . . . 10.0 105.693 -166.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -168.79 30.55 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.22 1.01 . . . . 10.0 110.07 -173.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.19 -20.27 66.37 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.971 0.909 . . . . 10.0 113.277 -167.267 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.45 -160.69 53.25 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 110.394 -1.083 . . . . 10.0 110.394 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.5 m -55.57 130.8 44.38 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.074 0.94 . . . . 10.0 113.151 -167.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 60.6 mtt180 -69.23 68.25 0.19 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.129 1.771 . . . . 10.0 110.415 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 37.8 mt -54.41 -31.9 56.08 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 113.141 0.793 . . . . 10.0 113.141 -173.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.409 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -158.22 153.15 25.19 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 109.129 -0.693 . . . . 10.0 109.129 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.5 m -146.19 161.55 39.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 115.548 -0.751 . . . . 10.0 109.934 -166.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.36 172.78 34.81 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.089 -1.204 . . . . 10.0 110.089 176.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -122.4 135.32 62.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 9.1 mt -69.23 116.66 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 C-N-CA 122.983 0.513 . . . . 10.0 110.034 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.05 144.47 17.72 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 124.812 1.196 . . . . 10.0 110.526 -178.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 59.8 mt -65.77 144.56 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 N-CA-C 108.045 -1.094 . . . . 10.0 108.045 176.114 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.55 -43.05 3.06 Favored 'General case' 0 C--O 1.227 -0.124 0 CA-C-N 119.268 0.94 . . . . 10.0 111.923 170.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 117.088 -1.434 . . . . 10.0 110.854 179.029 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.656 0 N-CA-C 107.501 -1.296 . . . . 10.0 107.501 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.6 t -154.77 -49.31 0.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 123.479 0.712 . . . . 10.0 109.501 173.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 ttmt -106.41 155.84 19.14 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.222 -1.77 . . . . 10.0 106.222 169.317 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -154.77 164.82 38.25 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 107.093 -1.447 . . . . 10.0 107.093 170.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.6 m -136.17 164.4 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 O-C-N 123.325 0.391 . . . . 10.0 110.854 -176.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.37 101.85 4.09 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.123 -1.065 . . . . 10.0 108.123 168.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.43 HG21 ' HB3' ' B' ' 53' ' ' ASN . 2.5 m -85.84 88.26 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 170.11 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mp -81.67 126.38 31.71 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.087 -0.708 . . . . 10.0 109.087 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 46.8 mtpt -140.8 160.41 40.11 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.05 -1.463 . . . . 10.0 107.05 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.07 -60.93 0.04 OUTLIER Glycine 0 C--O 1.229 -0.199 0 C-N-CA 120.808 -0.71 . . . . 10.0 112.745 169.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.99 -43.94 64.3 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 107.355 -1.35 . . . . 10.0 107.355 -176.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.82 -70.75 0.41 Allowed Glycine 0 CA--C 1.523 0.581 0 CA-C-N 114.23 -1.35 . . . . 10.0 110.446 169.542 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -58.16 -32.61 96.08 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 123.511 2.807 . . . . 10.0 111.665 173.483 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.0 t -67.22 93.75 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 N-CA-C 107.094 -1.447 . . . . 10.0 107.094 177.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -117.96 106.94 13.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.777 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -94.65 142.18 15.91 Favored Glycine 0 N--CA 1.441 -1.017 0 N-CA-C 109.171 -1.572 . . . . 10.0 109.171 169.204 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.611 HG22 HG23 ' B' ' 54' ' ' THR . 2.4 mt -143.77 58.66 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 -169.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.0 mm -79.74 137.28 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 115.688 -0.687 . . . . 10.0 109.328 -173.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -115.33 117.04 29.33 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.433 1.493 . . . . 10.0 108.024 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -102.74 122.88 45.36 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.663 -1.236 . . . . 10.0 107.663 177.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -118.37 144.61 45.77 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.675 0.671 . . . . 10.0 112.405 173.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -125.31 102.01 7.24 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 127.85 2.46 . . . . 10.0 106.594 167.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -49.74 -56.14 11.34 Favored 'General case' 0 C--N 1.338 0.098 0 C-N-CA 124.415 1.086 . . . . 10.0 109.931 172.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.56 178.54 6.99 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 105.128 -2.175 . . . . 10.0 105.128 171.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.0 t -72.31 -18.79 61.75 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.455 -0.202 . . . . 10.0 110.455 177.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -79.68 -19.38 49.15 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 123.673 0.789 . . . . 10.0 109.765 177.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.61 143.46 45.55 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 110.531 -1.028 . . . . 10.0 110.531 179.217 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.48 149.03 43.73 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.466 2.11 . . . . 10.0 107.648 168.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 t -79.58 100.34 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.404 ' NZ ' ' OE2' ' A' ' 100' ' ' GLU . 1.8 ttmp? -81.91 108.0 15.07 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.927 -1.508 . . . . 10.0 106.927 168.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.3 m -90.11 103.41 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 107.108 -1.441 . . . . 10.0 107.108 173.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.4 p90 -112.73 153.95 26.93 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-O 121.481 0.657 . . . . 10.0 112.61 173.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.47 179.37 41.28 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.637 -0.792 . . . . 10.0 111.274 169.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.4 p -131.67 103.94 6.65 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.346 -0.983 . . . . 10.0 108.346 -175.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.777 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.8 pt -79.8 140.99 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 N-CA-C 108.18 -1.044 . . . . 10.0 108.18 169.178 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -118.28 149.84 40.46 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 169.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.55 -8.15 37.22 Favored Glycine 0 C--N 1.336 0.569 0 CA-C-O 119.534 -0.592 . . . . 10.0 113.354 170.071 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -60.97 176.68 0.39 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.915 0.864 . . . . 10.0 109.75 170.648 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -110.61 171.65 7.34 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 166.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -48.93 156.27 0.52 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.858 1.263 . . . . 10.0 112.816 -172.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.01 -169.93 46.84 Favored Glycine 0 N--CA 1.443 -0.858 0 CA-C-O 122.667 1.149 . . . . 10.0 113.848 166.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mp -69.86 141.78 53.16 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 126.246 1.818 . . . . 10.0 110.139 -177.321 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -142.54 151.98 42.15 Favored 'General case' 0 C--N 1.341 0.203 0 N-CA-C 114.132 1.16 . . . . 10.0 114.132 178.085 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.694 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -30.71 122.39 0.13 Allowed Glycine 0 C--N 1.34 0.783 0 C-N-CA 128.533 2.968 . . . . 10.0 112.709 164.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -156.14 107.22 2.46 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.206 1.503 . . . . 10.0 111.72 168.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.464 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -157.55 169.75 23.96 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 113.2 0.815 . . . . 10.0 113.2 -179.764 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.4 m -84.13 157.79 3.62 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 CA-C-N 112.694 -2.048 . . . . 10.0 109.929 169.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -142.14 140.15 32.35 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 126.58 1.952 . . . . 10.0 107.366 179.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -58.55 -59.72 4.94 Favored 'General case' 0 N--CA 1.446 -0.645 0 O-C-N 124.212 0.945 . . . . 10.0 111.249 -172.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -76.95 123.02 25.7 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 117.932 -1.507 . . . . 10.0 108.984 -169.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.05 -9.25 63.0 Favored Glycine 0 CA--C 1.535 1.317 0 N-CA-C 110.336 -1.106 . . . . 10.0 110.336 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -59.07 99.84 0.06 Allowed 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 122.371 1.081 . . . . 10.0 111.453 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -107.53 14.39 25.84 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 113.506 -1.679 . . . . 10.0 110.432 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.675 HG23 HG22 ' B' ' 17' ' ' ILE . 3.1 m -54.71 -35.51 63.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 120.065 1.302 . . . . 10.0 110.776 -177.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.72 -19.99 57.05 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.769 0.828 . . . . 10.0 112.392 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 133.05 -87.74 0.27 Allowed Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.432 1.492 . . . . 10.0 109.533 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 15.7 t -155.17 62.04 0.64 Allowed 'General case' 0 CA--C 1.529 0.162 0 O-C-N 122.067 -0.666 . . . . 10.0 109.705 -172.233 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -162.5 -49.92 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.557 -0.714 . . . . 10.0 110.175 -175.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.7 t -57.47 -19.98 27.77 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 123.941 0.896 . . . . 10.0 111.149 -178.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -39.82 -27.36 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.822 2.049 . . . . 10.0 113.589 168.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.48 170.69 33.17 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 108.071 -2.012 . . . . 10.0 108.071 168.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -81.5 -166.38 0.4 Allowed 'Trans proline' 0 N--CA 1.441 -1.582 0 N-CA-C 107.077 -1.932 . . . . 10.0 107.077 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.437 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 38.6 m170 -82.85 58.94 4.57 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 120.893 -1.129 . . . . 10.0 110.629 -174.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -71.99 74.18 0.9 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.949 0.88 . . . . 10.0 111.257 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 -74.92 153.11 86.84 Favored Pre-proline 0 CA--C 1.537 0.444 0 C-N-CA 124.292 1.037 . . . . 10.0 110.302 171.336 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.12 -43.54 11.23 Favored 'Trans proline' 0 N--CA 1.456 -0.712 0 C-N-CA 122.322 2.015 . . . . 10.0 111.019 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.6 51.21 0.73 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.401 0.68 . . . . 10.0 110.579 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 35.0 p -52.48 112.51 0.83 Allowed 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.247 1.019 . . . . 10.0 109.907 -174.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 30.1 mtt85 -136.93 -85.71 0.32 Allowed 'General case' 0 CA--C 1.511 -0.545 0 N-CA-C 106.953 -1.499 . . . . 10.0 106.953 -170.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -144.7 158.2 43.88 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-O 122.402 1.096 . . . . 10.0 109.361 167.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 67.3 t60 -73.13 120.46 18.79 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 106.152 -1.796 . . . . 10.0 106.152 162.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.5 -131.75 2.45 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 108.148 -1.981 . . . . 10.0 108.148 175.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.09 -149.2 7.87 Favored Glycine 0 C--O 1.226 -0.351 0 N-CA-C 109.106 -1.598 . . . . 10.0 109.106 169.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -64.92 3.71 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.863 0 CA-C-N 120.344 2.072 . . . . 10.0 111.656 169.112 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -92.35 -22.48 19.67 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 124.901 1.28 . . . . 10.0 110.611 172.09 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 59.6 t0 -117.18 152.77 34.09 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.118 -1.067 . . . . 10.0 108.118 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -79.2 -33.43 43.87 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.403 -1.271 . . . . 10.0 108.078 169.188 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -91.02 8.1 37.08 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.415 1.486 . . . . 10.0 111.606 -170.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.21 142.1 3.04 Favored 'General case' 0 C--N 1.343 0.291 0 C-N-CA 124.456 1.103 . . . . 10.0 110.478 176.109 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.7 m170 -59.73 -59.37 5.54 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.447 0.641 . . . . 10.0 110.342 -169.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.52 HG13 ' H ' ' A' ' 82' ' ' GLY . 2.3 p -173.5 -98.43 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 104.586 -2.376 . . . . 10.0 104.586 177.469 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.52 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -79.1 58.38 4.34 Favored Glycine 0 CA--C 1.529 0.954 0 CA-C-N 118.776 0.716 . . . . 10.0 111.457 174.391 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -90.59 90.59 8.05 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 104.309 -2.478 . . . . 10.0 104.309 167.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 8.6 mt -70.79 -33.28 70.57 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.28 -76.53 0.51 Allowed Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 10.0 111.32 167.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -135.43 118.58 16.52 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 117.938 0.869 . . . . 10.0 109.45 -175.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.2 m -103.98 122.44 56.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 108.764 -0.828 . . . . 10.0 108.764 168.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 m -82.67 101.75 11.04 Favored 'General case' 0 N--CA 1.437 -1.107 0 C-N-CA 127.402 2.281 . . . . 10.0 109.507 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.64 130.24 35.33 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 123.251 0.62 . . . . 10.0 110.561 175.587 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -58.94 169.03 1.1 Allowed 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 124.215 0.947 . . . . 10.0 109.277 167.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.5 ptmm? -50.78 -32.4 19.76 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.539 1.535 . . . . 10.0 111.565 169.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.8 m-20 -78.28 -5.16 51.2 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.933 0.893 . . . . 10.0 111.321 -178.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.78 6.91 88.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 111.071 -0.811 . . . . 10.0 111.071 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.0 t -79.95 107.2 12.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.926 0 C-N-CA 126.532 1.933 . . . . 10.0 106.043 176.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.686 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -110.12 118.58 36.78 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 108.393 -0.966 . . . . 10.0 108.393 169.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -81.68 123.97 29.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 O-C-N 124.408 1.068 . . . . 10.0 108.461 172.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 99.4 t -112.38 130.44 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.238 0 C-N-CA 127.097 2.159 . . . . 10.0 106.365 177.043 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.3 p -156.11 65.34 0.57 Allowed 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.477 0.711 . . . . 10.0 109.458 174.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -96.63 156.9 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 -177.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.404 ' OE2' ' NZ ' ' A' ' 30' ' ' LYS . 8.5 tt0 -136.02 121.86 19.87 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 125.465 1.506 . . . . 10.0 109.38 -178.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -125.66 117.78 24.24 Favored 'General case' 0 C--O 1.232 0.174 0 C-N-CA 124.623 1.169 . . . . 10.0 108.6 -177.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -89.14 54.64 3.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 106.578 -1.638 . . . . 10.0 106.578 171.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.02 -53.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 C-N-CA 122.932 0.493 . . . . 10.0 110.245 -176.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.7 mp -58.27 147.52 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 N-CA-C 107.616 -1.253 . . . . 10.0 107.616 172.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.1 p -137.48 136.19 37.5 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.365 -0.379 . . . . 10.0 110.402 170.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.8 mt -77.79 -35.08 51.91 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 107.862 -1.162 . . . . 10.0 107.862 168.511 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 48.7 m -151.39 130.58 12.73 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 103.534 -2.765 . . . . 10.0 103.534 168.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.33 -79.7 0.1 Allowed Glycine 0 C--N 1.331 0.302 0 N-CA-C 109.219 -1.552 . . . . 10.0 109.219 -169.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -147.22 -54.29 0.22 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.09 -1.055 . . . . 10.0 108.68 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -75.84 -36.99 59.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.372 -1.286 . . . . 10.0 108.633 -173.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.7 t 45.69 61.12 2.77 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.317 1.047 . . . . 10.0 110.326 169.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 25.5 pt -74.53 31.77 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.89 0.852 . . . . 10.0 112.956 -169.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 34.7 mm -81.76 123.82 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 C-N-CA 125.627 1.571 . . . . 10.0 107.912 -176.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.14 4.66 64.5 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 123.947 0.785 . . . . 10.0 111.541 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -83.58 171.05 13.71 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 168.189 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 2.4 m -119.12 140.7 49.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 108.245 -1.021 . . . . 10.0 108.245 -177.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.517 HD11 ' CG1' ' A' ' 149' ' ' ILE . 0.2 OUTLIER -113.43 164.25 13.85 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.61 0.641 . . . . 10.0 109.631 168.174 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 92.8 t -140.56 134.22 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 O-C-N 123.953 0.783 . . . . 10.0 109.345 -172.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.9 m -96.95 133.0 40.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 106.554 -1.647 . . . . 10.0 106.554 165.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.694 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 5.0 m-70 -114.01 158.3 21.37 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 114.948 1.462 . . . . 10.0 114.948 -175.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -55.78 -47.16 77.55 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 126.246 1.819 . . . . 10.0 111.35 -179.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 79.3 mttt -112.46 163.39 14.51 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 119.121 0.873 . . . . 10.0 112.903 -175.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.76 152.78 30.32 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 124.697 1.199 . . . . 10.0 108.755 169.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.464 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.5 OUTLIER -78.96 151.4 31.64 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-O 122.746 1.26 . . . . 10.0 112.292 -179.378 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.82 -29.54 44.83 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 112.133 -2.303 . . . . 10.0 109.448 170.633 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 70.0 mt 58.55 34.68 24.08 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 124.694 1.198 . . . . 10.0 111.893 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.1 -18.48 57.27 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 123.969 0.795 . . . . 10.0 111.768 170.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -74.77 -5.98 46.4 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 124.344 1.058 . . . . 10.0 111.941 -168.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.54 -28.99 70.59 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.362 -1.095 . . . . 10.0 110.362 168.217 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.76 43.46 54.15 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.512 -1.035 . . . . 10.0 110.512 -170.274 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -128.28 168.16 15.89 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.115 -1.069 . . . . 10.0 108.115 175.058 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -48.52 -50.24 32.69 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 113.953 -1.476 . . . . 10.0 109.076 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 58.8 mp0 -55.85 -54.13 48.26 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 125.805 1.642 . . . . 10.0 111.811 171.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.8 p -49.74 -44.98 48.87 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 109.389 -0.596 . . . . 10.0 109.389 -173.118 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.7 t -81.19 -1.64 45.51 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 112.503 0.557 . . . . 10.0 112.503 -171.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 88.7 mttt -112.68 -50.37 2.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 125.653 1.581 . . . . 10.0 112.128 -176.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.1 p -139.09 17.17 2.62 Favored 'General case' 0 C--N 1.34 0.174 0 CA-C-N 119.545 1.066 . . . . 10.0 111.817 173.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.07 -116.45 5.56 Favored Glycine 0 N--CA 1.436 -1.311 0 N-CA-C 103.794 -3.722 . . . . 10.0 103.794 -169.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -163.88 40.42 0.09 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.582 -1.636 . . . . 10.0 106.582 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.71 -4.47 37.65 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 124.06 0.944 . . . . 10.0 112.193 -170.539 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.72 -164.3 53.09 Favored Glycine 0 N--CA 1.446 -0.679 0 O-C-N 121.415 -0.803 . . . . 10.0 111.527 169.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.6 m -53.86 131.37 39.76 Favored 'General case' 0 N--CA 1.442 -0.839 0 C-N-CA 124.711 1.204 . . . . 10.0 114.019 -168.117 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 34.0 mtt180 -64.95 73.47 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.519 1.928 . . . . 10.0 111.168 174.248 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 43.1 mt -51.03 -35.67 35.5 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 112.642 0.608 . . . . 10.0 112.642 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -152.49 153.09 32.78 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 121.901 -0.5 . . . . 10.0 109.722 176.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.6 p -149.98 156.51 41.85 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 109.38 -0.6 . . . . 10.0 109.38 178.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.85 153.95 25.17 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.063 -0.815 . . . . 10.0 111.063 -176.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 84.6 t -102.88 139.86 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 105.967 -1.864 . . . . 10.0 105.967 -173.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.517 ' CG1' HD11 ' A' ' 117' ' ' LEU . 18.0 mt -74.91 110.31 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 122.843 0.457 . . . . 10.0 109.894 -175.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.61 141.92 15.38 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 124.237 0.922 . . . . 10.0 110.972 -177.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 48.8 mt -64.83 146.38 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.401 1.48 . . . . 10.0 110.523 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.59 165.57 29.97 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-O 122.564 1.173 . . . . 10.0 110.506 167.814 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 . . . . . 0 C--O 1.255 1.384 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 166.15 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 105.885 -1.894 . . . . 10.0 105.885 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.7 t -76.81 -46.62 24.21 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 119.996 1.271 . . . . 10.0 110.351 -168.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -127.36 128.3 45.64 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 124.321 1.048 . . . . 10.0 111.317 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.04 160.88 38.73 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 123.348 0.659 . . . . 10.0 109.591 168.742 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.13 162.09 39.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 C-N-CA 124.129 0.972 . . . . 10.0 109.291 -178.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.41 102.75 3.88 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.703 -1.221 . . . . 10.0 107.703 169.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.414 HG12 HG23 ' B' ' 17' ' ' ILE . 1.5 m -85.12 111.88 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 N-CA-C 108.851 -0.796 . . . . 10.0 108.851 169.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mt -88.16 141.12 28.82 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.481 -0.933 . . . . 10.0 108.481 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -157.8 161.72 38.41 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.696 1.135 . . . . 10.0 108.14 171.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.59 -55.98 0.04 OUTLIER Glycine 0 C--N 1.329 0.166 0 N-CA-C 111.937 -0.465 . . . . 10.0 111.937 170.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.75 -45.78 41.65 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.65 -1.611 . . . . 10.0 106.65 -170.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.48 -66.19 0.57 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 113.676 -1.602 . . . . 10.0 110.786 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -57.81 -36.9 98.07 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.763 2.308 . . . . 10.0 111.071 172.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -67.52 109.9 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.197 0 N-CA-C 108.472 -0.936 . . . . 10.0 108.472 174.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -126.57 112.25 15.3 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 106.381 -1.711 . . . . 10.0 106.381 168.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.636 ' CA ' HG22 ' B' ' 35' ' ' ILE . . . -96.39 145.28 17.75 Favored Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.718 -1.353 . . . . 10.0 109.718 171.091 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.675 HG22 HG23 ' A' ' 54' ' ' THR . 1.7 mt -145.62 87.63 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 107.629 -1.248 . . . . 10.0 107.629 -169.801 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.0 mm -105.99 145.33 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.204 0 C-N-CA 124.446 1.098 . . . . 10.0 110.253 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -121.06 126.33 49.57 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 127.078 2.151 . . . . 10.0 109.564 168.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -103.68 114.07 28.07 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 106.593 -1.632 . . . . 10.0 106.593 170.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -109.27 126.97 53.89 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 123.502 0.501 . . . . 10.0 111.333 169.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 -94.08 99.41 11.71 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 106.811 -1.552 . . . . 10.0 106.811 174.065 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -50.31 -63.19 1.19 Allowed 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 124.83 1.252 . . . . 10.0 109.928 -177.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -143.6 167.26 22.67 Favored 'General case' 0 N--CA 1.435 -1.208 0 N-CA-C 102.244 -3.243 . . . . 10.0 102.244 167.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.3 m -74.49 -10.07 59.2 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 118.545 0.611 . . . . 10.0 110.038 174.473 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 32.6 m120 -78.58 -24.53 45.44 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 124.055 0.942 . . . . 10.0 110.508 172.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.77 159.14 26.61 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 110.073 -1.211 . . . . 10.0 110.073 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -66.12 150.54 85.06 Favored 'Trans proline' 0 N--CA 1.451 -1.029 0 C-N-CA 121.811 1.674 . . . . 10.0 108.426 169.648 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.11 121.0 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 N-CA-C 105.723 -1.954 . . . . 10.0 105.723 169.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.5 ttmp? -95.81 120.57 36.31 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 107.124 -1.436 . . . . 10.0 107.124 169.142 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -100.17 103.94 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 C-N-CA 126.824 2.049 . . . . 10.0 106.147 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -126.84 166.35 17.63 Favored 'General case' 0 CA--C 1.52 -0.198 0 N-CA-C 112.355 0.502 . . . . 10.0 112.355 177.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.18 -150.57 22.44 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 106.928 -2.469 . . . . 10.0 106.928 169.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.0 p -156.38 165.38 36.5 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.88 175.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.636 HG22 ' CA ' ' B' ' 16' ' ' GLY . 1.8 pp -113.67 173.19 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-N 115.298 -0.864 . . . . 10.0 108.868 167.261 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.8 tttt -144.03 142.04 30.44 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 106.492 -1.67 . . . . 10.0 106.492 164.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.03 -8.32 11.57 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 113.05 170.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.485 HD23 HD13 ' B' ' 35' ' ' ILE . 0.3 OUTLIER -67.37 177.73 1.79 Allowed 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.181 0.993 . . . . 10.0 111.037 177.464 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.1 t -110.77 152.85 26.13 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.724 -1.584 . . . . 10.0 106.724 168.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -53.52 150.78 6.41 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.437 0.695 . . . . 10.0 112.216 -168.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.67 -168.49 20.59 Favored Glycine 0 CA--C 1.523 0.567 0 C-N-CA 123.828 0.728 . . . . 10.0 111.295 173.726 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.4 mp -78.16 138.87 38.92 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.335 1.454 . . . . 10.0 110.892 -172.192 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -142.02 131.91 24.39 Favored 'General case' 0 CA--C 1.521 -0.165 0 C-N-CA 124.376 1.07 . . . . 10.0 112.254 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.624 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -17.75 122.92 0.01 OUTLIER Glycine 0 C--N 1.343 0.918 0 C-N-CA 128.001 2.715 . . . . 10.0 113.161 167.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -148.76 106.3 3.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 119.198 1.499 . . . . 10.0 110.633 171.459 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.84 169.95 21.0 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.596 0.712 . . . . 10.0 111.393 177.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 9.3 p -90.6 145.88 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 CA-C-N 111.946 -2.388 . . . . 10.0 107.274 166.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -125.69 146.16 49.86 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.019 -1.845 . . . . 10.0 106.019 170.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . 0.51 ' CD ' ' HE ' ' B' ' 115' ' ' ARG . 29.7 tp10 -76.42 -31.5 57.94 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.295 -0.866 . . . . 10.0 111.887 -166.639 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -78.95 113.94 17.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.081 -1.081 . . . . 10.0 108.081 174.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.34 -15.6 68.18 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 167.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -42.89 148.47 0.25 Allowed 'General case' 0 C--N 1.343 0.305 0 C-N-CA 124.735 1.214 . . . . 10.0 111.716 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.43 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -158.24 16.54 0.22 Allowed 'General case' 0 N--CA 1.441 -0.925 0 C-N-CA 125.519 1.528 . . . . 10.0 111.564 169.917 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.611 HG23 HG22 ' A' ' 17' ' ' ILE . 3.1 m -54.95 -37.4 66.42 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 119.458 1.026 . . . . 10.0 111.469 -169.147 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.8 -22.23 46.57 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.409 1.084 . . . . 10.0 112.528 177.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 126.89 -167.01 19.46 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 106.246 -2.742 . . . . 10.0 106.246 -169.308 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 61.4 m -72.65 53.28 0.32 Allowed 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 125.005 1.322 . . . . 10.0 107.877 169.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 88.9 m -120.83 -50.22 2.18 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 127.638 2.375 . . . . 10.0 108.245 -165.265 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 14.4 m -114.11 10.61 17.44 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.935 1.294 . . . . 10.0 112.226 -169.174 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -72.49 32.09 0.06 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.434 1.094 . . . . 10.0 113.721 -175.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.67 122.67 0.31 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.151 0.882 . . . . 10.0 112.667 168.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . 0.401 ' HD2' ' CZ ' ' B' ' 64' ' ' PHE . 67.6 Cg_endo -77.33 60.79 7.14 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.13 2.553 . . . . 10.0 111.492 174.682 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 14.7 m170 62.62 48.27 4.44 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.95 1.7 . . . . 10.0 110.235 173.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . 0.401 ' CZ ' ' HD2' ' B' ' 62' ' ' PRO . 28.8 m-85 -71.03 62.21 0.29 Allowed 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.766 0.712 . . . . 10.0 111.373 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -65.58 142.36 98.25 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.291 -0.881 . . . . 10.0 111.303 -172.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.35 -41.61 6.52 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.723 2.282 . . . . 10.0 110.249 -177.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.75 55.16 1.04 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.166 0.986 . . . . 10.0 108.771 175.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.9 p -34.15 104.95 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 126.539 1.936 . . . . 10.0 111.859 -169.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.11 176.97 8.18 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 104.319 -2.475 . . . . 10.0 104.319 -173.166 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -69.78 154.28 42.2 Favored 'General case' 0 N--CA 1.435 -1.185 0 C-N-CA 117.148 -1.821 . . . . 10.0 107.994 169.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -65.72 118.29 9.38 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 104.717 -2.327 . . . . 10.0 104.717 159.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.79 -177.3 22.09 Favored Glycine 0 N--CA 1.435 -1.409 0 N-CA-C 106.699 -2.561 . . . . 10.0 106.699 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -145.65 -156.59 6.93 Favored Glycine 0 C--O 1.227 -0.294 0 N-CA-C 109.35 -1.5 . . . . 10.0 109.35 -177.423 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -65.48 1.66 2.0 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.323 1.349 . . . . 10.0 110.613 166.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -109.16 0.86 19.97 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 117.754 -1.117 . . . . 10.0 112.007 173.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -116.22 162.78 16.95 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.403 -1.703 . . . . 10.0 106.403 169.235 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -79.1 -39.79 32.8 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 167.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -110.55 63.53 0.61 Allowed 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 124.697 1.199 . . . . 10.0 111.65 -168.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -60.65 161.81 7.33 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.359 1.064 . . . . 10.0 109.728 166.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 15.5 m170 -66.49 -71.54 0.19 Allowed 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 113.062 0.764 . . . . 10.0 113.062 -174.095 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -166.79 -53.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 O-C-N 121.638 -0.664 . . . . 10.0 109.689 -173.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -131.48 60.47 0.68 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 106.995 -2.442 . . . . 10.0 106.995 171.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -112.15 90.5 3.36 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.074 -2.195 . . . . 10.0 105.074 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . 0.553 ' C ' HD12 ' B' ' 84' ' ' LEU . 0.3 OUTLIER -82.22 -30.38 30.83 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 106.362 -1.718 . . . . 10.0 106.362 -178.076 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 121.92 -83.96 0.36 Allowed Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 106.189 -2.764 . . . . 10.0 106.189 168.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -156.88 156.35 32.99 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 122.839 0.456 . . . . 10.0 111.101 -177.628 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 34.5 m -124.48 142.08 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 C-N-CA 125.289 1.435 . . . . 10.0 109.766 -174.339 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -85.71 103.1 14.19 Favored 'General case' 0 N--CA 1.437 -1.079 0 C-N-CA 129.433 3.093 . . . . 10.0 110.927 -172.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.48 136.12 36.25 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.861 -0.524 . . . . 10.0 109.844 169.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -65.93 172.49 3.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.733 1.613 . . . . 10.0 110.23 167.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.23 -23.48 66.69 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 122.771 0.428 . . . . 10.0 112.091 173.534 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -75.83 -3.05 33.0 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 120.864 0.364 . . . . 10.0 110.252 174.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.48 24.73 60.23 Favored Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 108.719 -1.752 . . . . 10.0 108.719 176.327 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.6 t -110.13 109.51 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 127.081 2.152 . . . . 10.0 106.904 -174.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.477 ' H ' ' CD1' ' B' ' 35' ' ' ILE . . . -102.17 120.19 40.04 Favored 'General case' 0 CA--C 1.513 -0.467 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 169.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.0 p-10 -79.97 119.21 22.5 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 127.415 2.286 . . . . 10.0 108.8 170.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -103.68 130.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 C-N-CA 124.839 1.256 . . . . 10.0 107.754 177.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.9 p -158.42 83.02 0.83 Allowed 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 118.646 -0.693 . . . . 10.0 109.227 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.68 152.59 20.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 N-CA-C 107.553 -1.277 . . . . 10.0 107.553 179.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -126.81 137.01 53.13 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 126.014 1.726 . . . . 10.0 110.31 174.055 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.27 141.08 39.86 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.829 0.852 . . . . 10.0 109.513 177.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 18.6 p -106.3 22.91 14.97 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.363 1.465 . . . . 10.0 109.924 169.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 51.0 t -94.88 -15.21 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 C-N-CA 124.859 1.264 . . . . 10.0 109.479 -177.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.447 HD13 ' H ' ' B' ' 104' ' ' ILE . 0.0 OUTLIER -134.53 175.17 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 125.461 1.504 . . . . 10.0 112.42 -169.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 3.9 m -158.85 147.0 18.1 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 107.631 -1.248 . . . . 10.0 107.631 169.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -60.03 -50.61 73.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.727 -0.842 . . . . 10.0 108.727 -178.238 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 49.8 p -131.39 155.26 47.58 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 107.391 -1.337 . . . . 10.0 107.391 172.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 144.9 -101.84 0.26 Allowed Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 107.537 -2.225 . . . . 10.0 107.537 -169.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -128.08 -50.89 1.32 Allowed 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 125.466 1.506 . . . . 10.0 108.7 -167.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -75.7 -42.24 51.5 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.184 -1.413 . . . . 10.0 107.184 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 25.0 t 52.23 66.91 1.07 Allowed 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 126.87 2.068 . . . . 10.0 110.921 168.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 20.6 pt -67.75 -10.05 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 N-CA-C 113.606 0.965 . . . . 10.0 113.606 -172.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . 0.418 HD12 HG23 ' B' ' 151' ' ' ILE . 21.2 mm -53.41 139.58 11.18 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 O-C-N 120.854 -1.153 . . . . 10.0 110.159 169.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.41 4.5 84.44 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.556 -1.136 . . . . 10.0 113.986 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . 0.51 ' HE ' ' CD ' ' B' ' 49' ' ' GLU . 27.7 mmt-85 -79.55 178.57 8.04 Favored 'General case' 0 C--N 1.342 0.239 0 CA-C-N 119.223 1.512 . . . . 10.0 109.542 168.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.8 m -124.69 135.54 53.13 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 106.454 -1.684 . . . . 10.0 106.454 178.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 7.9 mp -105.08 148.57 26.67 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.406 -1.331 . . . . 10.0 107.406 169.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.5 t -126.88 135.22 64.29 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 N-CA-C 107.429 -1.323 . . . . 10.0 107.429 178.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -102.91 121.0 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.883 0 N-CA-C 107.014 -1.476 . . . . 10.0 107.014 169.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.624 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.0 m170 -106.12 162.6 13.48 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -169.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -47.95 -50.05 28.41 Favored 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 128.425 2.69 . . . . 10.0 112.477 174.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -128.49 171.97 11.58 Favored 'General case' 0 C--N 1.334 -0.086 0 C-N-CA 124.141 0.976 . . . . 10.0 112.225 -168.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.02 165.7 24.68 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.304 -0.862 . . . . 10.0 109.798 170.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.76 155.85 17.15 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.97 1.308 . . . . 10.0 111.637 -176.049 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -77.85 -15.3 59.15 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 114.731 -1.122 . . . . 10.0 110.254 168.466 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 73.2 mt 51.65 45.42 28.14 Favored 'General case' 0 CA--C 1.519 -0.225 0 C-N-CA 124.538 1.135 . . . . 10.0 110.335 172.179 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.19 27.85 73.26 Favored Glycine 0 N--CA 1.437 -1.246 0 CA-C-N 113.797 -1.547 . . . . 10.0 113.378 173.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -74.78 -3.84 34.06 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.295 1.548 . . . . 10.0 112.356 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.22 25.27 73.63 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 108.791 -1.724 . . . . 10.0 108.791 175.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -56.03 -30.15 56.86 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 170.601 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -155.87 167.84 29.12 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.59 -0.892 . . . . 10.0 108.59 -168.365 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 14.2 tm-20 -56.29 -46.27 79.83 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 108.511 -0.922 . . . . 10.0 108.511 168.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -59.04 -24.48 62.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 115.96 -0.564 . . . . 10.0 111.997 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 51.9 m -56.13 -32.63 64.41 Favored 'General case' 0 N--CA 1.444 -0.744 0 O-C-N 121.656 -0.653 . . . . 10.0 112.398 -177.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.6 t -93.46 7.73 43.38 Favored 'General case' 0 CA--C 1.534 0.339 0 O-C-N 123.52 0.512 . . . . 10.0 110.108 -174.074 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -128.69 -61.04 1.08 Allowed 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 126.678 1.991 . . . . 10.0 112.46 -174.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -135.71 31.03 3.09 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 120.69 1.586 . . . . 10.0 109.462 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 63.99 -97.59 0.23 Allowed Glycine 0 C--N 1.346 1.109 0 CA-C-O 123.79 1.772 . . . . 10.0 108.925 175.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.86 39.41 0.1 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 113.172 -1.514 . . . . 10.0 109.064 167.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.71 -12.95 52.25 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.713 0.805 . . . . 10.0 112.702 -169.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.75 -166.06 52.06 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 175.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -55.35 131.11 44.92 Favored 'General case' 0 N--CA 1.444 -0.771 0 C-N-CA 123.573 0.749 . . . . 10.0 111.935 -168.544 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -65.7 75.79 0.07 Allowed 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 123.603 0.761 . . . . 10.0 109.676 169.385 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 69.3 mt -45.37 -49.8 12.74 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.602 0.761 . . . . 10.0 110.726 177.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.56 155.86 36.96 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.495 -0.557 . . . . 10.0 109.495 -171.083 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -158.27 166.88 31.24 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.05 0.54 . . . . 10.0 109.572 -174.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.91 160.17 32.18 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 110.179 -1.169 . . . . 10.0 110.179 -173.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 57.4 t -109.25 138.38 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.529 -1.656 . . . . 10.0 106.529 -171.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.7 mt -75.82 108.96 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 -177.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.5 135.19 12.23 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 109.957 -1.257 . . . . 10.0 109.957 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . 0.418 HG23 HD12 ' B' ' 113' ' ' ILE . 2.3 pt -75.42 127.25 36.89 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.231 0 CA-C-N 118.557 1.178 . . . . 10.0 108.604 174.189 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -75.39 -54.89 6.31 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 107.134 -1.432 . . . . 10.0 107.134 178.506 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.348 -0.834 . . . . 10.0 109.457 172.1 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 106.85 -1.537 . . . . 10.0 106.85 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 t -167.51 -38.01 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 124.055 0.942 . . . . 10.0 111.881 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 57.1 tttp -133.46 141.39 47.79 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 124.531 1.132 . . . . 10.0 109.843 178.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.66 169.53 21.36 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 126.487 1.915 . . . . 10.0 107.226 176.375 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.9 162.1 35.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 N-CA-C 109.526 -0.546 . . . . 10.0 109.526 -179.248 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.404 ' HB1' HD21 ' A' ' 8' ' ' LEU . . . -132.04 97.64 4.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.989 0.916 . . . . 10.0 108.951 175.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -83.73 106.0 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 N-CA-C 108.677 -0.86 . . . . 10.0 108.677 169.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.404 HD21 ' HB1' ' A' ' 6' ' ' ALA . 8.9 mt -100.14 140.68 34.02 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.63 -0.878 . . . . 10.0 108.63 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.9 ttmt -157.84 163.7 37.72 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.509 -1.293 . . . . 10.0 107.509 169.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.57 -53.14 0.06 OUTLIER Glycine 0 C--O 1.228 -0.255 0 C-N-CA 120.333 -0.937 . . . . 10.0 112.163 169.33 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -72.64 -45.34 59.49 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.329 -1.36 . . . . 10.0 107.329 -177.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.28 -71.09 0.41 Allowed Glycine 0 CA--C 1.524 0.619 0 CA-C-N 114.355 -1.293 . . . . 10.0 110.342 169.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -57.44 -34.8 98.56 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.462 2.775 . . . . 10.0 111.242 173.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.6 t -65.3 100.81 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.082 0 N-CA-C 107.335 -1.358 . . . . 10.0 107.335 175.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -119.5 116.23 25.67 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.568 1.147 . . . . 10.0 108.381 172.546 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.751 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.71 145.47 17.79 Favored Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 109.892 -1.283 . . . . 10.0 109.892 169.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.633 HG22 HG23 ' B' ' 54' ' ' THR . 1.2 mt -151.54 56.94 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 107.045 -1.465 . . . . 10.0 107.045 -170.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.8 mm -80.82 140.23 16.95 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.041 0 O-C-N 121.587 -0.695 . . . . 10.0 110.011 -175.011 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -99.74 115.3 29.19 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.04 1.336 . . . . 10.0 108.298 170.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -92.56 110.38 21.8 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 105.486 -2.042 . . . . 10.0 105.486 170.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -131.17 146.6 52.4 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 119.084 0.856 . . . . 10.0 110.481 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.405 ' HB3' ' HA ' ' A' ' 29' ' ' VAL . 13.8 pt20 -148.24 16.21 1.05 Allowed 'General case' 0 C--N 1.342 0.274 0 N-CA-C 115.319 1.6 . . . . 10.0 115.319 -178.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? 74.23 -57.38 0.62 Allowed 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 125.595 1.558 . . . . 10.0 113.163 168.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.68 -157.26 0.8 Allowed 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 107.964 -1.124 . . . . 10.0 107.964 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.1 t -85.48 -23.08 27.94 Favored 'General case' 0 N--CA 1.45 -0.448 0 O-C-N 120.808 -1.182 . . . . 10.0 110.638 170.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -89.33 -21.27 23.21 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 123.985 0.914 . . . . 10.0 111.503 -173.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -65.56 151.76 51.68 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.619 -0.545 . . . . 10.0 112.356 -171.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -68.46 137.29 39.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.95 2.433 . . . . 10.0 108.842 169.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.405 ' HA ' ' HB3' ' A' ' 22' ' ' GLN . 0.3 OUTLIER -77.74 138.55 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 O-C-N 121.849 -0.532 . . . . 10.0 110.957 179.627 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -119.63 124.93 47.52 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 106.848 -1.538 . . . . 10.0 106.848 168.418 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.3 m -102.76 59.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 124.339 1.055 . . . . 10.0 109.094 -170.104 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.8 p90 -79.03 146.01 33.55 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 119.625 -0.83 . . . . 10.0 111.312 -172.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.39 -169.48 39.2 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.646 -0.981 . . . . 10.0 110.646 169.156 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.4 m -139.6 107.53 5.7 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.065 -0.717 . . . . 10.0 109.065 -170.411 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.751 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.2 pt -78.31 128.01 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 N-CA-C 106.873 -1.529 . . . . 10.0 106.873 168.508 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 tttt -107.21 146.66 31.13 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 107.115 -1.439 . . . . 10.0 107.115 173.328 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -7.07 31.06 Favored Glycine 0 CA--C 1.522 0.528 0 CA-C-O 119.197 -0.779 . . . . 10.0 112.678 173.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.415 HD21 HD12 ' A' ' 35' ' ' ILE . 3.4 mm? -62.47 177.01 0.55 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.675 1.238 . . . . 10.0 109.284 168.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.8 t -113.53 157.06 22.51 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.961 -0.755 . . . . 10.0 108.961 170.039 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -48.9 123.67 7.41 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.062 1.345 . . . . 10.0 111.094 -171.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.66 -169.12 13.13 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 123.794 0.711 . . . . 10.0 112.347 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -77.3 146.77 36.61 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 126.12 1.768 . . . . 10.0 112.391 -170.448 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -149.48 144.0 26.03 Favored 'General case' 0 C--N 1.342 0.276 0 N-CA-C 114.049 1.129 . . . . 10.0 114.049 -178.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.595 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -33.15 126.24 0.34 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 127.145 2.307 . . . . 10.0 112.232 165.56 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.403 ' CD1' HD12 ' A' ' 84' ' ' LEU . 6.6 t80 -151.03 108.11 3.58 Favored 'General case' 0 C--O 1.238 0.486 0 CA-C-N 119.504 1.652 . . . . 10.0 109.561 167.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.5 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -151.94 174.44 13.62 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.148 0.975 . . . . 10.0 113.4 179.329 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.9 p -90.61 151.4 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.554 0 CA-C-N 112.028 -2.351 . . . . 10.0 108.038 168.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -127.59 142.69 51.29 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 106.931 -1.507 . . . . 10.0 106.931 171.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -37.24 -55.77 0.98 Allowed 'General case' 0 C--O 1.237 0.403 0 C-N-CA 127.535 2.334 . . . . 10.0 113.7 -170.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -106.34 169.31 8.59 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-O 122.367 1.079 . . . . 10.0 112.556 -171.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.42 -23.47 24.05 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 126.664 2.078 . . . . 10.0 109.771 169.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -43.39 120.41 1.9 Allowed 'General case' 0 C--N 1.346 0.417 0 CA-C-O 122.009 0.909 . . . . 10.0 109.863 170.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -134.75 11.9 3.69 Favored 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 125.942 1.697 . . . . 10.0 108.497 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.436 HG23 HG22 ' B' ' 17' ' ' ILE . 1.3 m -59.45 -33.64 71.54 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 119.031 0.832 . . . . 10.0 112.083 -168.216 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.39 -16.14 59.0 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.915 0.886 . . . . 10.0 112.33 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.26 62.92 0.56 Allowed Glycine 0 CA--C 1.521 0.462 0 N-CA-C 108.655 -1.778 . . . . 10.0 108.655 -172.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.6 p 41.31 39.6 1.02 Allowed 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 125.868 1.667 . . . . 10.0 114.122 171.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 16.3 m -108.13 -53.3 2.65 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.759 2.024 . . . . 10.0 105.584 -177.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.4 m -66.66 -15.46 63.5 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.525 1.93 . . . . 10.0 112.665 -175.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -50.06 -6.28 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.936 2.494 . . . . 10.0 115.715 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 105.8 123.41 5.16 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.117 -1.38 . . . . 10.0 110.372 170.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.59 60.16 5.78 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.595 2.863 . . . . 10.0 110.638 173.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.518 ' CD2' HG22 ' A' ' 137' ' ' THR . 20.9 m170 65.34 37.61 6.23 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 130.27 3.428 . . . . 10.0 111.897 179.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.1 m-30 -72.89 62.32 0.59 Allowed 'General case' 0 N--CA 1.468 0.462 0 O-C-N 121.196 -0.94 . . . . 10.0 110.628 175.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -74.1 152.66 88.49 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.247 -0.908 . . . . 10.0 111.146 -172.182 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -60.45 -42.67 39.09 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.435 2.756 . . . . 10.0 111.848 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.3 tp -77.91 59.08 2.04 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 123.781 0.832 . . . . 10.0 108.772 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 58.7 p -40.75 104.85 0.04 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.282 2.233 . . . . 10.0 112.128 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -137.62 175.11 9.88 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 126.403 1.881 . . . . 10.0 107.467 -177.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.15 113.93 27.42 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-N 118.952 0.796 . . . . 10.0 109.884 -174.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.0 t60 -30.18 101.55 0.02 OUTLIER 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 114.593 1.331 . . . . 10.0 114.593 -171.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -114.44 -147.97 9.6 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 108.858 -1.697 . . . . 10.0 108.858 176.247 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.33 -148.65 5.64 Favored Glycine 0 C--N 1.332 0.334 0 CA-C-O 118.237 -1.313 . . . . 10.0 109.902 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -62.76 -3.76 4.95 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 CA-C-N 120.225 2.012 . . . . 10.0 111.946 169.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -85.0 -19.61 31.77 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 118.452 -0.785 . . . . 10.0 111.041 171.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -130.55 162.41 29.35 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 123.849 1.785 . . . . 10.0 112.875 -166.309 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -85.43 -24.06 27.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 112.879 -1.964 . . . . 10.0 108.261 166.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -86.34 7.79 24.11 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.532 1.533 . . . . 10.0 110.85 -174.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 33.9 ptt-85 -48.33 126.83 11.93 Favored 'General case' 0 C--N 1.342 0.263 0 N-CA-C 106.507 -1.664 . . . . 10.0 106.507 166.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m80 -50.57 -57.47 8.08 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.11 0.411 . . . . 10.0 112.11 -167.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.7 p -173.9 -45.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 124.711 1.205 . . . . 10.0 108.33 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.14 56.44 0.73 Allowed Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.681 -1.367 . . . . 10.0 109.681 175.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -97.5 97.25 8.92 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 106.001 -1.851 . . . . 10.0 106.001 169.058 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.403 HD12 ' CD1' ' A' ' 45' ' ' PHE . 14.0 mt -76.26 -27.11 56.58 Favored 'General case' 0 C--N 1.34 0.163 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 173.418 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.71 -104.17 3.07 Favored Glycine 0 N--CA 1.439 -1.128 0 N-CA-C 108.638 -1.785 . . . . 10.0 108.638 168.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -122.3 100.28 6.87 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.055 1.342 . . . . 10.0 109.48 -167.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.2 m -95.74 136.92 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 C-N-CA 122.855 0.462 . . . . 10.0 110.187 178.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.8 m -85.19 119.41 25.54 Favored 'General case' 0 N--CA 1.439 -0.985 0 C-N-CA 127.437 2.295 . . . . 10.0 108.819 -177.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.57 134.65 39.52 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 123.568 0.747 . . . . 10.0 109.627 169.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -62.62 169.86 2.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 O-C-N 124.412 1.07 . . . . 10.0 108.751 166.419 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.86 -21.63 64.84 Favored 'General case' 0 N--CA 1.445 -0.705 0 C-N-CA 124.192 0.997 . . . . 10.0 112.892 172.454 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.17 -4.68 45.86 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.036 0.446 . . . . 10.0 110.691 171.523 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.22 6.3 86.44 Favored Glycine 0 C--N 1.339 0.738 0 O-C-N 120.671 -1.268 . . . . 10.0 110.839 178.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.18 106.13 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 127.339 2.256 . . . . 10.0 107.332 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.432 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -103.43 116.47 32.47 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 167.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.28 104.17 10.65 Favored 'General case' 0 N--CA 1.435 -1.181 0 C-N-CA 126.812 2.045 . . . . 10.0 109.841 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.12 131.86 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 172.517 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.3 m -157.52 57.63 0.5 Allowed 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 124.495 1.118 . . . . 10.0 109.476 173.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.84 150.75 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.835 -1.543 . . . . 10.0 106.835 178.455 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -128.19 150.81 49.85 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 108.626 170.11 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.13 124.42 6.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 108.873 -0.788 . . . . 10.0 108.873 172.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 11.0 t -79.07 0.48 27.77 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.291 1.037 . . . . 10.0 112.196 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.41 -24.75 17.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 CA-C-N 119.579 1.081 . . . . 10.0 109.486 177.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.0 159.28 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 124.599 1.16 . . . . 10.0 111.003 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.8 m -152.72 144.93 23.89 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.281 -2.118 . . . . 10.0 105.281 174.632 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.6 mt -65.04 -8.55 16.7 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 123.95 0.9 . . . . 10.0 111.828 176.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.6 m -150.94 137.96 19.15 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.031 -1.47 . . . . 10.0 107.031 169.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.26 -66.25 0.14 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 109.018 -1.633 . . . . 10.0 109.018 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -167.71 -51.44 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 125.58 1.552 . . . . 10.0 107.981 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -74.96 -36.19 62.07 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 114.914 -1.039 . . . . 10.0 109.128 -169.194 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 30.9 t 38.98 70.66 0.2 Allowed 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 126.692 1.997 . . . . 10.0 112.263 167.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -56.67 -10.22 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 114.113 1.153 . . . . 10.0 114.113 177.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 mm -33.87 -52.95 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.327 1.451 . . . . 10.0 112.98 170.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -96.81 9.48 66.11 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-O 118.937 -0.924 . . . . 10.0 114.153 -174.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.94 156.46 21.18 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 118.525 1.162 . . . . 10.0 109.742 176.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 59.1 m -90.4 131.58 36.1 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 123.768 0.827 . . . . 10.0 109.627 168.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -99.87 145.61 27.58 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 167.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.8 t -137.46 136.34 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 123.516 0.726 . . . . 10.0 109.17 -176.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.35 142.08 17.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 O-C-N 124.579 1.175 . . . . 10.0 108.811 167.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.595 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 3.5 m170 -121.72 162.03 21.53 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.896 1.443 . . . . 10.0 114.896 -175.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -58.31 -50.87 72.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.266 1.427 . . . . 10.0 110.736 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -116.39 172.75 7.0 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-O 121.804 0.812 . . . . 10.0 112.203 -178.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.28 138.96 40.88 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 126.054 1.742 . . . . 10.0 108.981 174.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.5 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -77.36 164.76 25.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 122.232 1.015 . . . . 10.0 111.847 173.596 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.413 ' OD1' ' NZ ' ' A' ' 128' ' ' LYS . 25.6 t0 -74.82 -8.15 55.57 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 113.608 -1.633 . . . . 10.0 111.298 178.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 14.5 mt 46.8 41.18 10.05 Favored 'General case' 0 C--N 1.339 0.113 0 C-N-CA 124.484 1.114 . . . . 10.0 109.831 -177.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 72.05 19.64 78.53 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 118.313 -1.271 . . . . 10.0 114.765 171.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.413 ' NZ ' ' OD1' ' A' ' 125' ' ' ASP 0.251 8.7 mtmp? -77.13 10.65 2.25 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 119.803 1.801 . . . . 10.0 114.991 -176.073 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.72 29.0 61.98 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 109.185 -1.566 . . . . 10.0 109.185 168.196 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -53.19 -30.01 38.17 Favored Glycine 0 N--CA 1.436 -1.351 0 CA-C-O 118.132 -1.371 . . . . 10.0 110.321 167.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 174.61 178.85 0.13 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 106.7 -1.593 . . . . 10.0 106.7 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 37.5 mp0 -49.48 -41.29 40.12 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 112.876 0.695 . . . . 10.0 112.876 179.179 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 -64.33 -24.13 67.54 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 121.244 -0.91 . . . . 10.0 110.684 -178.481 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.413 ' HA ' ' HA2' ' A' ' 138' ' ' GLY . 55.1 m -45.3 -44.58 11.58 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 122.964 0.506 . . . . 10.0 110.286 175.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 t -84.7 -1.09 55.7 Favored 'General case' 0 CA--C 1.541 0.628 0 O-C-N 124.049 0.843 . . . . 10.0 112.147 -170.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.1 mttt -118.82 -73.65 0.64 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.955 1.302 . . . . 10.0 110.275 -173.386 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.518 HG22 ' CD2' ' A' ' 63' ' ' HIS . 7.1 p -121.56 26.83 8.56 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 120.164 -1.585 . . . . 10.0 110.242 171.544 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' A' ' 134' ' ' SER . . . 72.86 -91.57 0.6 Allowed Glycine 0 C--N 1.342 0.886 0 N-CA-C 109.934 -1.266 . . . . 10.0 109.934 174.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -173.38 39.12 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.195 1.398 . . . . 10.0 108.886 171.087 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.26 -16.61 62.49 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 121.473 -0.767 . . . . 10.0 112.77 -168.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.37 -162.59 54.66 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.102 -1.199 . . . . 10.0 110.102 175.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -51.9 126.77 19.14 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.036 1.334 . . . . 10.0 113.8 -168.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -64.7 72.89 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.229 1.812 . . . . 10.0 110.996 173.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.2 mt -51.12 -35.67 36.6 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 113.381 0.882 . . . . 10.0 113.381 -178.069 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.04 154.47 37.09 Favored 'General case' 0 CA--C 1.511 -0.555 0 O-C-N 121.61 -0.681 . . . . 10.0 109.948 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.6 p -153.24 153.7 33.21 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.583 -0.895 . . . . 10.0 108.583 -172.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.81 153.37 24.36 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 112.044 -0.422 . . . . 10.0 112.044 179.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 63.4 t -101.3 125.31 55.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.012 -2.218 . . . . 10.0 105.012 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.2 mt -68.55 164.93 2.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 CA-C-N 119.009 0.822 . . . . 10.0 110.403 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -160.5 150.66 20.84 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.576 1.56 . . . . 10.0 109.443 -172.136 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 61.3 mt -70.93 141.7 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.892 1.277 . . . . 10.0 109.023 -173.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.43 -46.51 2.87 Favored 'General case' 0 C--O 1.224 -0.268 0 C-N-CA 123.1 0.56 . . . . 10.0 110.674 170.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.7 tp60 . . . . . 0 C--O 1.25 1.107 0 C-N-CA 126.634 1.974 . . . . 10.0 112.082 -173.04 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.872 0 CA-C-O 117.571 -1.205 . . . . 10.0 108.993 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 t -61.27 -38.16 85.74 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 120.19 1.359 . . . . 10.0 108.852 172.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 36.9 tttt -132.03 156.35 46.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.447 1.499 . . . . 10.0 110.219 168.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.47 175.35 14.14 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 129.01 2.924 . . . . 10.0 106.504 166.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 m -133.6 179.49 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 118.677 0.671 . . . . 10.0 110.611 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -158.43 108.9 2.1 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.093 0.957 . . . . 10.0 109.189 165.039 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -95.17 124.28 47.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 122.959 0.503 . . . . 10.0 110.208 170.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -103.54 146.24 28.84 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 125.441 1.496 . . . . 10.0 110.275 176.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 5.4 tttm -161.73 158.61 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 169.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 179.86 -46.55 0.08 OUTLIER Glycine 0 N--CA 1.46 0.236 0 C-N-CA 118.927 -1.606 . . . . 10.0 113.638 169.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -72.59 -47.71 45.69 Favored 'General case' 0 N--CA 1.451 -0.375 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 -178.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.91 -73.84 0.29 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 114.331 -1.304 . . . . 10.0 109.845 171.115 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -59.07 -34.74 98.98 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.738 2.959 . . . . 10.0 111.18 174.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.5 t -62.2 114.04 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.12 -1.067 . . . . 10.0 108.12 176.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.87 118.6 22.97 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 106.339 -1.726 . . . . 10.0 106.339 168.589 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.679 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -102.47 141.12 15.14 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-O 118.598 -1.112 . . . . 10.0 110.48 174.42 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.436 HG22 HG23 ' A' ' 54' ' ' THR . 9.4 mt -139.78 94.2 0.77 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 C-N-CA 123.874 0.87 . . . . 10.0 109.063 -173.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.7 mm -105.71 139.77 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 C-N-CA 125.658 1.583 . . . . 10.0 112.623 -178.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -106.75 126.6 52.49 Favored 'General case' 0 C--N 1.34 0.179 0 N-CA-C 106.452 -1.685 . . . . 10.0 106.452 167.059 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -104.16 112.42 25.42 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 107.057 -1.46 . . . . 10.0 107.057 168.54 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -126.82 136.32 52.2 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 118.462 0.573 . . . . 10.0 112.35 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -105.48 112.76 25.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.62 1.568 . . . . 10.0 106.873 169.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.23 34.95 1.34 Allowed 'General case' 0 C--O 1.235 0.308 0 N-CA-C 111.93 0.344 . . . . 10.0 111.93 -177.023 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -142.9 166.35 24.88 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 104.903 -2.258 . . . . 10.0 104.903 169.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 29.4 t -91.28 14.98 12.93 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 109.031 -0.729 . . . . 10.0 109.031 -173.365 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -112.62 7.61 18.84 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 123.832 0.853 . . . . 10.0 108.892 167.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.57 47.13 23.65 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.59 -1.117 . . . . 10.0 114.496 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -65.26 115.84 3.55 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 CA-C-N 119.834 1.817 . . . . 10.0 107.652 170.375 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t -77.27 84.65 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 105.31 -2.107 . . . . 10.0 105.31 175.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -74.35 117.4 16.12 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.024 -1.473 . . . . 10.0 107.024 179.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.42 58.77 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 C-N-CA 125.085 1.354 . . . . 10.0 108.121 -169.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 9.4 p90 -81.48 143.21 32.24 Favored 'General case' 0 C--N 1.341 0.209 0 C-N-CA 119.134 -1.026 . . . . 10.0 111.996 -176.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.81 -169.09 41.39 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.636 -1.269 . . . . 10.0 110.106 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.1 m -153.24 133.11 13.2 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.811 -0.811 . . . . 10.0 108.811 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.679 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.3 pt -103.63 147.72 9.53 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 N-CA-C 107.995 -1.113 . . . . 10.0 107.995 167.212 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -124.81 149.98 46.85 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 106.356 -1.72 . . . . 10.0 106.356 169.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.48 -6.7 36.24 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 123.428 0.537 . . . . 10.0 112.519 171.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.41 HD12 ' CG ' ' B' ' 43' ' ' HIS . 2.0 mm? -63.93 174.43 1.49 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.956 0.878 . . . . 10.0 109.965 169.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.7 t -101.76 170.81 7.92 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 105.898 -1.89 . . . . 10.0 105.898 165.414 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -59.84 166.67 2.52 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 118.661 0.664 . . . . 10.0 111.829 -171.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.49 -171.56 45.75 Favored Glycine 0 N--CA 1.446 -0.647 0 O-C-N 121.478 -0.764 . . . . 10.0 111.72 169.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -77.5 144.31 37.8 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.259 1.424 . . . . 10.0 111.224 -174.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . 0.41 ' CG ' HD12 ' B' ' 38' ' ' LEU . 89.7 m-70 -147.48 127.88 14.01 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.518 1.127 . . . . 10.0 112.633 -173.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.69 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -18.69 128.71 0.01 OUTLIER Glycine 0 C--N 1.342 0.881 0 C-N-CA 127.499 2.476 . . . . 10.0 114.179 165.739 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.75 104.94 3.23 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 118.605 1.203 . . . . 10.0 109.793 167.73 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.51 176.46 10.93 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 112.766 0.654 . . . . 10.0 112.766 176.385 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 23.4 m -89.82 158.69 2.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 113.601 -1.636 . . . . 10.0 108.626 168.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 74.8 m-70 -136.47 78.11 1.69 Allowed 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 123.586 0.755 . . . . 10.0 111.138 176.021 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.8 tt0 47.65 -94.42 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.792 1.237 . . . . 10.0 113.027 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -78.76 172.03 14.32 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.582 0.628 . . . . 10.0 110.01 -173.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.97 -23.1 23.74 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.553 -1.019 . . . . 10.0 110.553 170.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -37.71 135.07 0.64 Allowed 'General case' 0 C--N 1.343 0.306 0 C-N-CA 124.598 1.159 . . . . 10.0 110.863 170.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.427 HD21 HG21 ' B' ' 116' ' ' THR . 0.3 OUTLIER -146.05 23.99 1.33 Allowed 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 114.75 -1.114 . . . . 10.0 110.362 173.152 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.633 HG23 HG22 ' A' ' 17' ' ' ILE . 2.7 m -52.43 -36.83 55.34 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.065 0.848 . . . . 10.0 110.982 -173.513 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.56 -21.72 28.41 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.29 1.436 . . . . 10.0 113.697 177.178 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 92.48 101.92 1.45 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.813 1.197 . . . . 10.0 110.183 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.314 2.6 p 17.43 57.65 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 127.752 2.421 . . . . 10.0 114.151 -170.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.8 m -130.48 -61.9 0.94 Allowed 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.479 -2.045 . . . . 10.0 105.479 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 39.3 t -69.66 -35.68 75.38 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.009 1.324 . . . . 10.0 111.323 -178.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -31.88 -47.41 0.13 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 127.122 2.169 . . . . 10.0 114.181 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 138.5 172.54 12.6 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.243 -1.543 . . . . 10.0 109.243 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -78.67 -137.35 0.02 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.222 0 N-CA-C 104.156 -3.055 . . . . 10.0 104.156 166.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 27.3 m170 -100.99 50.68 0.86 Allowed 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 121.067 1.758 . . . . 10.0 109.557 170.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -71.79 80.05 0.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 122.169 0.985 . . . . 10.0 110.033 177.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.5 p-10 -80.15 156.31 74.26 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 125.474 1.509 . . . . 10.0 110.222 172.614 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -63.51 -50.1 3.75 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.489 2.126 . . . . 10.0 111.292 177.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.9 mt -77.58 57.72 1.64 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.213 0.605 . . . . 10.0 109.887 179.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 31.9 p -51.35 114.21 1.16 Allowed 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.607 1.163 . . . . 10.0 109.999 -176.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.2 mtt-85 -131.33 -86.49 0.49 Allowed 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 104.996 -2.224 . . . . 10.0 104.996 -176.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.7 ptpp? -163.26 162.77 25.42 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 106.34 -1.726 . . . . 10.0 106.34 167.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 66.9 t60 -58.28 132.67 54.31 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 118.358 -1.337 . . . . 10.0 107.655 168.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.37 -133.23 2.64 Favored Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 108.116 -1.994 . . . . 10.0 108.116 169.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.507 ' HA3' HD13 ' B' ' 126' ' ' LEU . . . 163.51 -161.28 33.99 Favored Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 108.376 -1.89 . . . . 10.0 108.376 178.046 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.74 4.61 0.8 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.864 1.71 . . . . 10.0 111.928 168.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.567 ' HG3' HD12 ' B' ' 126' ' ' LEU . 9.9 mmmt -114.03 7.94 16.94 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 119.225 0.92 . . . . 10.0 110.481 170.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -125.93 163.09 23.74 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 119.733 1.151 . . . . 10.0 108.977 167.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -81.61 -30.06 33.02 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 106.987 -1.486 . . . . 10.0 106.987 169.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -119.65 61.5 0.83 Allowed 'General case' 0 N--CA 1.436 -1.168 0 CA-C-O 122.095 0.95 . . . . 10.0 110.859 -168.489 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . 0.442 HH12 ' CG ' ' B' ' 101' ' ' ASP . 0.3 OUTLIER -56.32 164.39 1.36 Allowed 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 114.393 -1.276 . . . . 10.0 108.697 164.833 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 25.6 m170 -65.99 -84.57 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 N-CA-C 108.569 -0.9 . . . . 10.0 108.569 169.36 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 49.2 t -149.82 -82.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 104.186 -2.524 . . . . 10.0 104.186 169.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.83 53.89 4.77 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.566 -0.614 . . . . 10.0 111.566 -178.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -93.9 98.78 11.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 104.39 -2.448 . . . . 10.0 104.39 168.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 37.1 mt -81.92 -36.26 28.26 Favored 'General case' 0 C--N 1.334 -0.095 0 N-CA-C 105.744 -1.947 . . . . 10.0 105.744 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.26 -92.06 0.64 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 106.717 -2.553 . . . . 10.0 106.717 169.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -155.82 155.73 33.5 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 122.793 0.437 . . . . 10.0 111.45 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.48 145.68 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 O-C-N 124.762 1.289 . . . . 10.0 108.507 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.0 m -93.43 110.42 21.98 Favored 'General case' 0 N--CA 1.436 -1.135 0 C-N-CA 128.497 2.719 . . . . 10.0 108.88 -172.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.3 135.59 33.49 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 123.771 0.828 . . . . 10.0 110.117 174.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -61.65 168.51 2.91 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 124.091 0.956 . . . . 10.0 109.107 166.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.78 -30.67 45.7 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.492 0.717 . . . . 10.0 111.079 172.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -78.68 1.6 22.36 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-O 121.25 0.548 . . . . 10.0 111.454 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.92 90.7 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 120.843 -1.161 . . . . 10.0 110.947 176.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.1 t -79.77 104.72 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.059 0 C-N-CA 127.09 2.156 . . . . 10.0 107.013 179.242 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.54 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -107.55 115.09 29.53 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 107.843 -1.169 . . . . 10.0 107.843 168.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -79.7 123.36 27.59 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 127.381 2.272 . . . . 10.0 108.622 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.0 t -110.79 131.43 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 C-N-CA 125.494 1.517 . . . . 10.0 107.279 178.804 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 93.0 p -156.98 59.14 0.52 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 123.316 0.646 . . . . 10.0 109.552 177.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -99.83 154.82 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -176.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -102.33 153.21 20.22 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 126.639 1.976 . . . . 10.0 107.382 170.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . 0.442 ' CG ' HH12 ' B' ' 79' ' ' ARG . 23.8 t0 -149.06 85.17 1.46 Allowed 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.583 0.706 . . . . 10.0 109.292 174.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.8 p -90.25 38.11 0.92 Allowed 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.81 0.844 . . . . 10.0 109.663 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 26.1 t -106.75 -46.19 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 107.444 -1.317 . . . . 10.0 107.444 176.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.406 ' CD1' ' H ' ' B' ' 104' ' ' ILE 0.261 0.0 OUTLIER -100.88 176.01 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 114.155 1.168 . . . . 10.0 114.155 175.465 . . . . . . . . 4 4 . 1 . 019 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -136.29 142.8 43.95 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 106.517 -1.66 . . . . 10.0 106.517 169.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -65.58 -25.72 67.54 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.131 0.573 . . . . 10.0 110.117 171.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.1 p -140.76 118.94 12.0 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 170.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.04 -63.04 0.05 OUTLIER Glycine 0 C--N 1.333 0.41 0 N-CA-C 109.024 -1.63 . . . . 10.0 109.024 -177.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -163.04 -51.87 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 125.877 1.671 . . . . 10.0 107.489 177.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -74.33 -38.61 63.23 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 114.413 -1.267 . . . . 10.0 108.621 -169.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.9 t 47.76 75.36 0.13 Allowed 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 126.166 1.786 . . . . 10.0 109.301 169.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 12.5 pt -68.97 65.19 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.324 0 CA-C-O 122.786 1.279 . . . . 10.0 110.388 173.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.6 mm -110.61 151.73 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 C-N-CA 129.117 2.967 . . . . 10.0 105.275 167.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 55.31 35.64 61.09 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 124.866 1.222 . . . . 10.0 113.746 171.382 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 83.7 mtt85 -113.96 154.62 27.28 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 126.305 1.842 . . . . 10.0 107.51 171.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . 0.427 HG21 HD21 ' B' ' 53' ' ' ASN . 90.2 m -86.06 133.95 33.86 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.01 0.924 . . . . 10.0 109.7 177.257 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -98.42 147.46 24.69 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 125.212 1.405 . . . . 10.0 107.297 166.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.57 141.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-N 118.563 0.62 . . . . 10.0 109.369 176.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.418 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 7.6 p -103.32 139.45 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 C-N-CA 124.575 1.15 . . . . 10.0 108.981 168.064 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.69 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.6 m-70 -115.91 164.25 14.69 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.814 1.413 . . . . 10.0 114.814 -175.268 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . 0.402 ' HB2' HD21 ' B' ' 144' ' ' LEU . 73.8 tt0 -59.43 -49.43 77.85 Favored 'General case' 0 C--N 1.343 0.293 0 C-N-CA 123.756 0.823 . . . . 10.0 110.438 178.607 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.2 mttt -121.24 175.56 6.06 Favored 'General case' 0 N--CA 1.462 0.169 0 N-CA-C 112.229 0.455 . . . . 10.0 112.229 -169.186 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.54 139.03 39.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.201 1.0 . . . . 10.0 109.332 173.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.67 144.1 30.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.059 0.944 . . . . 10.0 108.827 167.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -79.2 28.31 0.23 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 123.395 0.678 . . . . 10.0 111.236 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.567 HD12 ' HG3' ' B' ' 75' ' ' LYS . 6.6 mt 23.86 60.23 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 128.685 2.794 . . . . 10.0 112.157 -168.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 92.63 -35.58 4.0 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 126.192 1.853 . . . . 10.0 112.147 174.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.2 mtmm -84.46 44.15 1.02 Allowed 'General case' 0 CA--C 1.537 0.465 0 O-C-N 121.256 -1.144 . . . . 10.0 111.247 -170.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.44 -18.12 46.8 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 126.518 2.008 . . . . 10.0 110.159 169.371 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.15 35.82 91.41 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 123.965 0.793 . . . . 10.0 112.415 172.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -144.48 169.48 17.87 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 107.916 -1.142 . . . . 10.0 107.916 172.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -52.64 -47.4 67.09 Favored 'General case' 0 N--CA 1.444 -0.736 0 CA-C-O 121.805 0.812 . . . . 10.0 110.351 -177.44 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -65.36 -31.59 72.79 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 121.32 -0.863 . . . . 10.0 111.234 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 12.3 p -55.5 -42.14 74.03 Favored 'General case' 0 N--CA 1.447 -0.604 0 O-C-N 120.818 -1.176 . . . . 10.0 111.353 171.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.6 t -80.91 -24.16 38.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 119.835 -0.746 . . . . 10.0 111.202 -176.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 ttmm -80.81 -50.57 9.65 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 125.886 1.674 . . . . 10.0 111.533 -176.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 26.1 p -136.2 -15.18 1.72 Allowed 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 114.441 1.274 . . . . 10.0 114.441 176.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.53 3.07 55.43 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-O 118.286 -1.286 . . . . 10.0 113.884 -179.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 29.1 m120 73.23 26.97 2.02 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.101 1.45 . . . . 10.0 112.359 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.47 -2.29 13.48 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.272 -0.892 . . . . 10.0 113.298 176.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.0 -170.15 50.92 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 109.769 -1.332 . . . . 10.0 109.769 -175.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.51 169.66 2.87 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.167 0.987 . . . . 10.0 112.135 -177.01 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.79 115.96 18.82 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.85 2.06 . . . . 10.0 109.814 168.664 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.423 ' CD2' ' N ' ' B' ' 144' ' ' LEU . 0.4 OUTLIER -92.0 -36.84 13.18 Favored 'General case' 0 C--N 1.34 0.169 0 CA-C-N 119.753 1.16 . . . . 10.0 111.414 -176.263 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.418 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -148.36 149.78 32.4 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 176.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -118.63 142.44 47.64 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.796 1.638 . . . . 10.0 107.672 -168.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -137.06 161.19 25.14 Favored Glycine 0 C--N 1.331 0.265 0 N-CA-C 109.79 -1.324 . . . . 10.0 109.79 171.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -123.52 152.27 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 104.246 -2.501 . . . . 10.0 104.246 171.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 56.0 mt -67.41 -91.67 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 124.018 0.927 . . . . 10.0 111.625 -167.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.84 136.2 9.22 Favored Glycine 0 CA--C 1.532 1.112 0 N-CA-C 111.68 -0.568 . . . . 10.0 111.68 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 9.5 pt -85.34 146.78 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 C-N-CA 124.534 1.134 . . . . 10.0 110.122 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -115.87 -24.36 8.19 Favored 'General case' 0 N--CA 1.462 0.166 0 C-N-CA 123.575 0.75 . . . . 10.0 112.8 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.88 0 C-N-CA 124.355 1.062 . . . . 10.0 108.195 -174.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.86 0 CA-C-O 117.89 -1.053 . . . . 10.0 109.158 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -116.81 -50.3 2.61 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 123.947 0.899 . . . . 10.0 112.304 -176.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -111.87 125.73 54.34 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 126.638 1.975 . . . . 10.0 108.825 -176.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 164.22 30.54 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.694 1.198 . . . . 10.0 108.286 170.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.4 m -139.04 164.46 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 C-N-CA 123.7 0.8 . . . . 10.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -136.66 118.72 15.38 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.644 -0.873 . . . . 10.0 108.644 168.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -92.34 110.23 22.57 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.33 -0.989 . . . . 10.0 108.33 168.248 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.424 HD12 ' N ' ' A' ' 8' ' ' LEU . 5.1 mp -95.0 144.86 25.35 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 108.731 -0.84 . . . . 10.0 108.731 177.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 15.2 mtmt -156.45 161.49 40.06 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 107.307 -1.368 . . . . 10.0 107.307 172.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.69 -51.59 0.09 OUTLIER Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.071 -1.061 . . . . 10.0 113.653 169.29 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.4 -44.57 62.3 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.49 -1.3 . . . . 10.0 107.49 -175.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.19 -71.01 0.4 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 109.684 -1.366 . . . . 10.0 109.684 169.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -58.06 -35.54 98.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 123.089 2.526 . . . . 10.0 111.273 172.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.3 t -64.65 107.33 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 N-CA-C 107.749 -1.204 . . . . 10.0 107.749 178.264 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -121.45 104.87 10.0 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 172.489 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.807 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -88.37 137.1 14.15 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 109.273 -1.531 . . . . 10.0 109.273 176.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.424 ' CG2' HG22 ' B' ' 54' ' ' THR . 3.7 mt -139.08 87.93 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.282 0 N-CA-C 107.381 -1.34 . . . . 10.0 107.381 -175.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -99.75 141.64 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.16 0 C-N-CA 124.819 1.248 . . . . 10.0 110.059 -178.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -126.27 113.45 16.97 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.476 1.91 . . . . 10.0 108.569 175.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -93.51 115.02 27.53 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 126.367 1.867 . . . . 10.0 108.545 177.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -117.5 130.04 56.19 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.85 1.055 . . . . 10.0 113.85 171.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -105.2 111.88 24.8 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 104.545 -2.391 . . . . 10.0 104.545 166.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -65.0 -36.78 85.52 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.952 -0.468 . . . . 10.0 111.131 -172.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -137.6 -165.43 1.77 Allowed 'General case' 0 N--CA 1.436 -1.175 0 N-CA-C 104.521 -2.4 . . . . 10.0 104.521 171.508 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.0 t -78.6 -24.48 45.39 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 118.97 0.805 . . . . 10.0 110.206 173.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.6 m-80 -91.83 -17.88 24.65 Favored 'General case' 0 N--CA 1.448 -0.574 0 C-N-CA 124.648 1.179 . . . . 10.0 110.551 -175.26 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.22 144.82 41.74 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 178.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -63.63 156.87 54.62 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 N-CA-C 108.116 -1.532 . . . . 10.0 108.116 169.576 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 75.2 t -79.0 102.31 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 N-CA-C 106.036 -1.839 . . . . 10.0 106.036 175.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.2 mtpp -79.0 105.38 10.3 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 105.49 -2.041 . . . . 10.0 105.49 170.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -100.58 97.85 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 C-N-CA 125.421 1.488 . . . . 10.0 107.502 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.6 p90 -103.26 174.59 5.8 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.322 0.582 . . . . 10.0 110.205 169.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.07 170.93 37.97 Favored Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 110.79 -0.924 . . . . 10.0 110.79 177.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.6 t -136.82 96.39 3.31 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.957 -1.498 . . . . 10.0 106.957 177.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.807 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.6 pt -81.24 140.59 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 169.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.6 tttm -112.83 158.08 20.59 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 108.522 -0.918 . . . . 10.0 108.522 167.339 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.12 -7.27 58.57 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 123.579 0.609 . . . . 10.0 112.678 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -67.44 170.07 8.04 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 118.235 1.017 . . . . 10.0 109.86 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -103.65 153.33 20.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.688 -1.597 . . . . 10.0 106.688 167.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.6 143.88 4.72 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.25 1.02 . . . . 10.0 112.046 -170.497 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.48 -173.35 24.89 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 123.846 0.736 . . . . 10.0 112.269 171.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.26 145.27 54.41 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.594 1.957 . . . . 10.0 111.493 -175.162 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -146.31 141.25 27.1 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 124.398 1.079 . . . . 10.0 111.77 175.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.67 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -24.69 123.58 0.03 OUTLIER Glycine 0 C--N 1.344 1.008 0 C-N-CA 126.493 1.996 . . . . 10.0 112.219 165.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -144.55 104.54 4.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 119.735 1.767 . . . . 10.0 109.502 171.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -152.26 170.41 20.1 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 121.835 0.826 . . . . 10.0 111.557 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.4 m -88.54 149.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-N 112.139 -2.301 . . . . 10.0 106.259 167.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -120.6 128.08 52.7 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 103.782 -2.673 . . . . 10.0 103.782 169.049 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -58.54 -51.35 70.25 Favored 'General case' 0 N--CA 1.44 -0.932 0 O-C-N 124.99 1.431 . . . . 10.0 110.016 -168.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -79.55 137.84 37.29 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 -179.542 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.34 25.57 9.72 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.853 -0.899 . . . . 10.0 110.853 173.077 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.7 p30 -75.84 72.48 2.73 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 123.542 1.639 . . . . 10.0 109.317 170.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.471 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.6 OUTLIER -75.82 6.24 5.28 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 113.658 -1.61 . . . . 10.0 112.66 -173.853 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.543 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.1 OUTLIER -39.2 -44.26 1.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 128.207 2.603 . . . . 10.0 111.982 175.221 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.37 -19.97 48.89 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.247 1.019 . . . . 10.0 113.258 -177.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.79 87.13 1.47 Allowed Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.404 -1.079 . . . . 10.0 110.404 -177.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 m 52.31 29.14 6.38 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.417 1.487 . . . . 10.0 112.407 172.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.5 m -117.53 -54.83 2.34 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.295 -1.372 . . . . 10.0 107.295 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.1 m -77.01 -16.19 59.39 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 123.961 0.905 . . . . 10.0 112.579 -171.081 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -53.03 -12.88 0.38 Allowed 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.979 1.712 . . . . 10.0 115.234 -170.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.23 125.87 3.06 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 118.647 -1.085 . . . . 10.0 110.436 171.621 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -75.53 64.01 6.47 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.49 2.793 . . . . 10.0 111.732 179.326 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 26.7 m170 67.07 53.91 0.78 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 128.692 2.797 . . . . 10.0 111.108 175.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 -71.85 43.77 0.1 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 114.604 1.335 . . . . 10.0 114.604 -173.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 12.2 p-10 -56.57 147.38 50.75 Favored Pre-proline 0 CA--C 1.54 0.568 0 O-C-N 120.817 -1.177 . . . . 10.0 112.565 -174.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -64.89 -43.03 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.81 2.34 . . . . 10.0 110.853 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 75.9 mt -76.69 54.6 0.98 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.484 0.714 . . . . 10.0 109.381 176.493 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 44.9 p -35.47 109.75 0.09 Allowed 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 126.019 1.727 . . . . 10.0 110.868 -173.074 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -131.71 -174.03 3.3 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 104.474 -2.417 . . . . 10.0 104.474 -170.126 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -82.39 159.02 23.1 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 106.262 -1.755 . . . . 10.0 106.262 169.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 51.7 t60 -59.04 123.5 16.79 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 106.826 -1.546 . . . . 10.0 106.826 162.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.93 -144.0 5.39 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 108.635 -1.786 . . . . 10.0 108.635 174.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.41 -163.39 29.72 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 109.746 -1.342 . . . . 10.0 109.746 169.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -63.99 3.68 0.69 Allowed 'Trans proline' 0 N--CA 1.455 -0.761 0 CA-C-N 119.763 1.782 . . . . 10.0 111.99 169.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 42.3 mmtt -100.19 -16.13 17.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.082 -0.961 . . . . 10.0 110.707 171.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -114.54 165.95 12.23 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 119.051 0.841 . . . . 10.0 109.901 -178.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -77.25 -38.61 50.72 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 105.431 -2.063 . . . . 10.0 105.431 167.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.277 1.5 pt-20 -103.48 49.89 0.82 Allowed 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 115.461 1.652 . . . . 10.0 115.461 -160.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -55.65 159.31 3.03 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 125.651 1.581 . . . . 10.0 108.799 167.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -66.69 -65.86 0.63 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.637 0.732 . . . . 10.0 109.619 168.372 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.534 HG13 ' H ' ' A' ' 82' ' ' GLY . 6.3 p -161.85 -69.0 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 N-CA-C 107.31 -1.367 . . . . 10.0 107.31 177.352 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.534 ' H ' HG13 ' A' ' 81' ' ' VAL . . . -109.48 56.23 0.47 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 109.598 -1.401 . . . . 10.0 109.598 177.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -87.98 91.26 8.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 104.058 -2.571 . . . . 10.0 104.058 167.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.9 -32.36 69.28 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 106.237 -1.764 . . . . 10.0 106.237 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.1 -91.7 0.7 Allowed Glycine 0 N--CA 1.434 -1.485 0 N-CA-C 108.273 -1.931 . . . . 10.0 108.273 167.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -145.27 147.35 32.28 Favored 'General case' 0 N--CA 1.447 -0.596 0 O-C-N 123.818 0.364 . . . . 10.0 110.755 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 21.2 m -124.21 139.08 51.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.832 -1.173 . . . . 10.0 107.832 171.126 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 m -89.99 113.92 25.67 Favored 'General case' 0 N--CA 1.441 -0.888 0 C-N-CA 127.887 2.475 . . . . 10.0 107.711 -178.371 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.46 138.01 32.09 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 109.623 -0.51 . . . . 10.0 109.623 169.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -65.72 170.65 4.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.959 1.304 . . . . 10.0 109.658 168.13 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -50.69 -34.51 26.98 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.467 -0.788 . . . . 10.0 110.894 169.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -81.03 5.35 16.74 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.38 0.609 . . . . 10.0 112.039 -178.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.09 4.5 83.59 Favored Glycine 0 C--N 1.342 0.908 0 O-C-N 120.877 -1.139 . . . . 10.0 111.341 175.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.8 t -79.68 109.16 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.975 0 C-N-CA 127.76 2.424 . . . . 10.0 106.597 176.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.569 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -105.66 115.88 31.0 Favored 'General case' 0 CA--C 1.513 -0.459 0 N-CA-C 108.087 -1.079 . . . . 10.0 108.087 167.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -81.97 86.21 6.58 Favored 'General case' 0 N--CA 1.436 -1.157 0 C-N-CA 127.458 2.303 . . . . 10.0 109.294 179.143 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 32.9 t -75.72 131.94 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 N-CA-C 105.097 -2.186 . . . . 10.0 105.097 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -158.3 64.02 0.44 Allowed 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 122.995 0.518 . . . . 10.0 110.198 -175.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -111.47 158.6 11.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 106.948 -1.501 . . . . 10.0 106.948 -175.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -135.19 137.71 42.93 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 123.797 0.839 . . . . 10.0 109.942 168.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.39 147.43 43.4 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.124 0.97 . . . . 10.0 108.809 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 22.9 p -110.45 -2.14 16.7 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.076 1.75 . . . . 10.0 113.882 -172.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.9 p -97.22 -38.78 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 119.821 1.192 . . . . 10.0 109.081 172.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -65.22 136.91 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.953 -1.869 . . . . 10.0 105.953 167.158 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 25.2 m -154.86 132.42 11.28 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 108.943 -0.762 . . . . 10.0 108.943 -175.248 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -78.75 61.02 2.92 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.805 -1.183 . . . . 10.0 107.805 175.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.8 m -84.12 -119.27 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 123.81 0.844 . . . . 10.0 110.165 -174.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.96 -47.32 0.05 OUTLIER Glycine 0 CA--C 1.524 0.628 0 N-CA-C 107.91 -2.076 . . . . 10.0 107.91 -174.479 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -64.54 -59.32 4.44 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.899 0.88 . . . . 10.0 109.04 169.625 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -75.6 -39.05 58.53 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.276 -0.875 . . . . 10.0 108.658 -174.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.6 t 39.01 76.38 0.06 Allowed 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.525 1.53 . . . . 10.0 112.702 171.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pp -61.36 -26.94 40.84 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 115.899 -0.592 . . . . 10.0 110.382 168.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 32.2 mm -38.67 132.59 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 C-N-CA 126.003 1.721 . . . . 10.0 111.781 173.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.63 7.96 86.73 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-O 118.487 -1.174 . . . . 10.0 113.613 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 64.1 mtt85 -77.57 158.72 29.7 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 118.742 1.271 . . . . 10.0 109.673 169.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.82 115.5 27.52 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.111 -0.7 . . . . 10.0 109.111 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -83.97 138.27 33.21 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 170.028 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 71.9 t -125.34 137.09 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.99 -1.115 . . . . 10.0 107.99 178.033 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -102.06 132.95 46.99 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 105.542 -2.021 . . . . 10.0 105.542 166.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.67 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 8.5 m-70 -106.88 154.63 20.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 123.186 1.47 . . . . 10.0 114.623 -174.233 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -41.75 -61.92 1.0 Allowed 'General case' 0 N--CA 1.442 -0.867 0 C-N-CA 128.398 2.679 . . . . 10.0 109.157 177.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mtmt -110.0 169.25 8.85 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 125.463 1.505 . . . . 10.0 111.84 -176.576 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -65.74 136.9 56.85 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.131 -1.395 . . . . 10.0 108.035 169.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 140' ' ' ALA . 0.0 OUTLIER -84.57 158.94 20.77 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 123.763 0.825 . . . . 10.0 110.169 170.687 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -104.02 17.06 24.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 124.07 0.948 . . . . 10.0 111.701 179.542 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 64.7 mt 43.56 40.72 2.99 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 119.269 0.941 . . . . 10.0 112.782 178.493 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 101.63 -4.16 53.7 Favored Glycine 0 C--N 1.336 0.565 0 CA-C-O 118.924 -0.931 . . . . 10.0 114.068 175.04 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mttt -118.01 30.69 7.1 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 118.136 0.968 . . . . 10.0 111.217 -166.162 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.65 -36.53 58.35 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 127.521 2.486 . . . . 10.0 110.907 171.674 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 72.45 43.68 44.38 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 111.179 -0.768 . . . . 10.0 111.179 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.461 ' H ' ' HB2' ' A' ' 134' ' ' SER . 12.2 m-80 -145.34 168.93 19.3 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 105.983 -1.858 . . . . 10.0 105.983 171.376 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.407 ' OE1' ' NZ ' ' A' ' 136' ' ' LYS . 15.8 tm-20 -52.57 -42.56 64.6 Favored 'General case' 0 N--CA 1.441 -0.899 0 CA-C-O 121.239 0.542 . . . . 10.0 110.958 177.627 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -63.49 -31.83 73.1 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.263 -0.898 . . . . 10.0 113.23 178.605 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.461 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 17.1 t -43.96 -48.4 8.61 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.226 1.01 . . . . 10.0 109.778 176.181 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 7.8 t -80.4 -3.72 50.82 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-O 118.333 -0.841 . . . . 10.0 112.134 -169.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.407 ' NZ ' ' OE1' ' A' ' 132' ' ' GLU . 41.9 mtmt -111.61 -79.41 0.58 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.317 1.447 . . . . 10.0 110.308 -177.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.9 p -105.94 1.85 27.0 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 120.13 1.332 . . . . 10.0 113.272 177.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.72 27.24 35.64 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-O 118.904 -0.942 . . . . 10.0 113.139 169.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.2 m120 59.36 21.9 10.25 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 118.382 1.091 . . . . 10.0 112.978 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.549 ' HB2' ' HB3' ' A' ' 124' ' ' ASP . . . -66.73 -10.6 48.68 Favored 'General case' 0 N--CA 1.462 0.168 0 C-N-CA 124.897 1.279 . . . . 10.0 112.645 176.635 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.61 -161.83 51.68 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 110.268 -1.133 . . . . 10.0 110.268 177.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.8 m -58.74 139.97 55.47 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 124.129 0.972 . . . . 10.0 112.651 -167.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.13 68.16 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.813 1.245 . . . . 10.0 109.329 167.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . 0.261 0.4 OUTLIER -64.32 -17.04 63.29 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.616 0.969 . . . . 10.0 113.616 -169.144 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 150.92 24.9 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.099 -0.704 . . . . 10.0 109.099 168.094 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.5 p -153.72 165.35 36.25 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.39 0.276 . . . . 10.0 111.034 -177.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.0 -168.04 11.77 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.438 1.018 . . . . 10.0 111.559 -177.329 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 33.7 t -136.92 130.75 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 104.487 -2.412 . . . . 10.0 104.487 176.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -66.47 139.7 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 CA-C-N 119.438 1.017 . . . . 10.0 110.815 178.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.6 146.67 18.58 Favored Glycine 0 CA--C 1.528 0.89 0 C-N-CA 124.829 1.204 . . . . 10.0 111.214 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 74.8 mt -68.83 152.26 9.63 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 108.376 -0.972 . . . . 10.0 108.376 177.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.36 -36.11 1.14 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 114.515 1.302 . . . . 10.0 114.515 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.121 0 N-CA-C 117.529 2.418 . . . . 10.0 117.529 -177.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . 0.451 ' C ' ' H ' ' B' ' 3' ' ' LYS . . . . . . . . 0 N--CA 1.474 0.74 0 CA-C-O 118.232 -0.89 . . . . 10.0 109.099 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . 0.421 HG22 ' O ' ' B' ' 1' ' ' ALA 0.282 9.2 t 70.62 -29.68 0.19 Allowed 'General case' 0 C--N 1.343 0.312 0 C-N-CA 131.397 3.879 . . . . 10.0 111.835 175.036 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . 0.451 ' H ' ' C ' ' B' ' 1' ' ' ALA . 61.3 tttt -152.15 131.37 12.77 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 126.288 1.835 . . . . 10.0 106.98 -168.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.59 165.96 25.85 Favored 'General case' 0 CA--C 1.522 -0.131 0 C-N-CA 124.476 1.11 . . . . 10.0 108.54 171.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.525 ' O ' HG23 ' B' ' 149' ' ' ILE . 7.7 m -131.38 179.97 3.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.395 0 C-N-CA 122.889 0.476 . . . . 10.0 110.563 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.27 110.66 3.74 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 124.459 1.104 . . . . 10.0 108.561 167.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.471 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.5 OUTLIER -96.88 92.23 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 C-N-CA 124.065 0.946 . . . . 10.0 109.419 171.748 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mp -80.32 137.82 36.64 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.197 0.999 . . . . 10.0 110.608 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.5 tttt -156.25 160.67 40.0 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.972 -1.122 . . . . 10.0 107.972 170.263 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.41 -50.06 0.05 OUTLIER Glycine 0 C--O 1.229 -0.213 0 C-N-CA 121.333 -0.46 . . . . 10.0 112.215 171.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.26 -46.58 32.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 106.738 -1.578 . . . . 10.0 106.738 -173.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.94 -66.26 0.57 Allowed Glycine 0 CA--C 1.527 0.815 0 CA-C-N 113.891 -1.504 . . . . 10.0 110.382 -179.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -60.57 -35.41 90.14 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.964 2.442 . . . . 10.0 111.323 174.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.0 t -70.35 111.21 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 N-CA-C 107.582 -1.266 . . . . 10.0 107.582 175.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.74 110.04 11.83 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 105.88 -1.896 . . . . 10.0 105.88 168.626 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.738 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -97.79 133.37 11.32 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 110.012 -1.235 . . . . 10.0 110.012 179.02 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.543 ' CG2' HG22 ' A' ' 54' ' ' THR . 5.4 mt -137.57 87.77 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 108.252 -1.018 . . . . 10.0 108.252 -169.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -99.23 152.17 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.133 0 C-N-CA 124.672 1.189 . . . . 10.0 110.546 178.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 21.1 m-80 -134.43 121.57 21.29 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 128.457 2.703 . . . . 10.0 107.807 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -106.58 116.66 32.3 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 174.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.91 143.67 44.77 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.091 0.86 . . . . 10.0 112.861 169.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -93.69 94.02 8.35 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.617 1.567 . . . . 10.0 108.808 -176.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 11.2 tmtt? -44.51 -61.33 1.58 Allowed 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 126.369 1.868 . . . . 10.0 110.943 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -145.21 176.35 9.6 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 104.459 -2.423 . . . . 10.0 104.459 170.458 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 23.1 t -86.8 -2.29 58.44 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.976 -0.379 . . . . 10.0 109.976 174.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 29.5 m-80 -130.28 35.4 4.09 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 124.251 1.02 . . . . 10.0 108.4 169.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -126.87 160.16 21.13 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 106.93 -2.468 . . . . 10.0 106.93 170.466 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -66.48 148.79 84.34 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 121.841 1.694 . . . . 10.0 109.553 179.05 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.5 t -78.82 124.95 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 104.313 -2.477 . . . . 10.0 104.313 168.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -98.34 122.4 41.47 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 106.313 -1.736 . . . . 10.0 106.313 168.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.2 p -106.18 106.03 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 C-N-CA 127.708 2.403 . . . . 10.0 105.509 177.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 22.5 p90 -130.45 173.08 11.18 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 120.9 0.381 . . . . 10.0 110.844 179.042 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.76 -153.29 25.21 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 107.152 -2.379 . . . . 10.0 107.152 169.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 5.4 m -153.15 145.49 23.99 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 119.044 -1.063 . . . . 10.0 110.607 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.738 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.0 pt -111.97 136.75 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 CA-C-N 115.948 -0.569 . . . . 10.0 109.679 168.501 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.5 tptt -110.77 141.27 44.32 Favored 'General case' 0 N--CA 1.441 -0.922 0 N-CA-C 106.289 -1.745 . . . . 10.0 106.289 171.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.3 -6.37 23.16 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 123.757 0.694 . . . . 10.0 112.991 169.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -65.19 176.21 1.4 Allowed 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 118.147 0.974 . . . . 10.0 111.022 176.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -109.82 156.09 20.8 Favored 'General case' 0 CA--C 1.531 0.229 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 168.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -53.33 132.48 39.29 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.792 1.637 . . . . 10.0 111.443 -170.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 122.13 -173.2 15.81 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 118.724 0.693 . . . . 10.0 112.037 173.275 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.66 152.84 39.13 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.741 1.616 . . . . 10.0 110.756 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -150.31 147.73 27.98 Favored 'General case' 0 C--N 1.344 0.367 0 N-CA-C 116.06 1.874 . . . . 10.0 116.06 -174.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.68 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -28.01 121.0 0.06 OUTLIER Glycine 0 C--N 1.34 0.784 0 C-N-CA 128.822 3.105 . . . . 10.0 113.14 161.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -153.73 101.31 2.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 119.712 1.756 . . . . 10.0 111.6 168.286 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.41 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -154.23 173.1 16.58 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 114.573 1.323 . . . . 10.0 114.573 -178.943 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 33.5 m -82.0 151.2 4.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 112.995 -1.912 . . . . 10.0 109.449 168.533 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 -133.1 82.91 2.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.089 -1.078 . . . . 10.0 108.089 172.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 64.0 tt0 35.04 -80.8 0.0 OUTLIER 'General case' 0 C--O 1.239 0.506 0 C-N-CA 127.674 2.389 . . . . 10.0 115.135 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -77.84 173.78 11.75 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 122.043 0.925 . . . . 10.0 110.089 -173.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -101.03 -19.53 16.71 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 125.152 1.358 . . . . 10.0 110.599 168.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.31 156.39 0.85 Allowed 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 124.802 1.241 . . . . 10.0 111.946 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.63 27.86 0.44 Allowed 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.322 -0.854 . . . . 10.0 111.822 169.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.424 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -55.06 -39.22 69.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.198 0.999 . . . . 10.0 111.624 -169.728 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.44 -23.71 42.96 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.055 0.942 . . . . 10.0 112.786 177.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.91 114.25 1.53 Allowed Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.829 -0.908 . . . . 10.0 110.829 -170.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 23.5 m 38.06 46.28 0.81 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 127.206 2.203 . . . . 10.0 115.529 169.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -153.31 -54.15 0.11 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.79 -1.189 . . . . 10.0 107.79 173.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 47.0 t -54.91 -38.61 67.82 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.479 1.112 . . . . 10.0 110.892 -173.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -24.97 -50.68 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 127.863 2.465 . . . . 10.0 114.487 170.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.01 157.19 9.61 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.299 -1.12 . . . . 10.0 110.299 177.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -74.76 -163.38 0.18 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 N-CA-C 105.395 -2.579 . . . . 10.0 105.395 165.026 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.412 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.9 m170 -81.03 48.66 1.13 Allowed 'General case' 0 CA--C 1.547 0.83 0 O-C-N 119.619 -1.925 . . . . 10.0 110.694 -176.411 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 m-30 -75.35 67.72 1.96 Allowed 'General case' 0 N--CA 1.466 0.341 0 O-C-N 120.936 -1.102 . . . . 10.0 110.332 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -66.19 154.64 89.66 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.408 -0.808 . . . . 10.0 109.919 170.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -76.46 49.68 2.72 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 123.572 2.848 . . . . 10.0 111.204 177.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -178.35 55.78 0.01 OUTLIER 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 127.482 2.313 . . . . 10.0 105.677 -178.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.0 p -37.11 110.23 0.12 Allowed 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.8 1.24 . . . . 10.0 109.992 177.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -173.69 3.1 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 102.447 -3.168 . . . . 10.0 102.447 177.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -78.08 167.56 21.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 116.651 -2.019 . . . . 10.0 106.831 167.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -65.48 123.62 20.12 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 106.845 -1.539 . . . . 10.0 106.845 162.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.16 -142.05 4.42 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.458 -1.857 . . . . 10.0 108.458 173.605 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -175.15 -165.24 31.08 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.67 -1.628 . . . . 10.0 109.044 173.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -69.16 10.47 0.4 Allowed 'Trans proline' 0 CA--C 1.541 0.827 0 CA-C-N 119.923 1.861 . . . . 10.0 110.727 167.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -108.8 -1.16 19.48 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 124.84 1.256 . . . . 10.0 110.402 170.121 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -132.22 169.36 16.55 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 119.67 1.123 . . . . 10.0 109.007 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -78.71 -39.23 37.05 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 103.795 -2.669 . . . . 10.0 103.795 165.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -82.14 42.87 0.76 Allowed 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 114.117 1.154 . . . . 10.0 114.117 -165.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.32 159.29 18.33 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 124.006 0.922 . . . . 10.0 109.714 167.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -68.97 -79.91 0.05 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 107.203 -1.406 . . . . 10.0 107.203 169.111 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.509 HG13 ' H ' ' B' ' 82' ' ' GLY 0.25 8.6 p -149.18 -79.28 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 N-CA-C 107.175 -1.417 . . . . 10.0 107.175 167.923 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.509 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -86.43 62.52 4.28 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.258 -1.137 . . . . 10.0 110.258 178.415 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -101.55 100.45 10.87 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 105.714 -1.958 . . . . 10.0 105.714 169.065 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -73.73 -9.39 58.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 118.339 0.518 . . . . 10.0 111.452 -174.023 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.89 -99.7 2.34 Favored Glycine 0 N--CA 1.442 -0.94 0 N-CA-C 107.347 -2.301 . . . . 10.0 107.347 -176.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -148.17 144.97 28.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.606 -0.887 . . . . 10.0 108.606 -177.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.6 m -112.93 137.57 45.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 108.216 -1.031 . . . . 10.0 108.216 168.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -97.94 116.44 30.17 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.962 0.905 . . . . 10.0 109.582 -176.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.67 130.6 35.94 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.604 1.162 . . . . 10.0 109.15 174.572 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.05 168.11 3.47 Favored 'General case' 0 N--CA 1.448 -0.573 0 O-C-N 124.584 1.177 . . . . 10.0 109.824 168.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 2.9 tttp -47.76 -36.61 11.82 Favored 'General case' 0 N--CA 1.432 -1.327 0 C-N-CA 126.42 1.888 . . . . 10.0 111.468 168.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -79.84 1.04 28.49 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.992 0.517 . . . . 10.0 112.318 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.18 16.79 80.27 Favored Glycine 0 C--N 1.339 0.721 0 O-C-N 120.101 -1.624 . . . . 10.0 110.791 178.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 37.2 t -92.93 105.84 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 C-N-CA 126.513 1.925 . . . . 10.0 106.033 175.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.655 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -102.18 117.74 35.41 Favored 'General case' 0 CA--C 1.514 -0.428 0 N-CA-C 107.139 -1.43 . . . . 10.0 107.139 168.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -94.23 124.6 38.34 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 124.315 1.009 . . . . 10.0 108.279 177.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.99 134.53 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 C-N-CA 125.838 1.655 . . . . 10.0 108.421 -174.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -157.46 95.52 1.46 Allowed 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.719 1.207 . . . . 10.0 108.761 170.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 mp -123.59 145.36 30.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 108.105 -1.072 . . . . 10.0 108.105 176.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -106.06 135.28 47.8 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 128.691 2.797 . . . . 10.0 107.745 169.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -140.05 155.38 47.08 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 168.238 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.4 p -126.39 49.19 2.04 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.587 1.155 . . . . 10.0 109.771 174.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 p -133.33 -45.45 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.491 1.117 . . . . 10.0 110.246 172.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -63.32 131.81 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.298 -1.001 . . . . 10.0 108.298 169.575 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 67.8 m -125.37 112.71 16.64 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 106.352 -1.721 . . . . 10.0 106.352 170.078 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 18.1 mt -46.2 -41.52 12.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.193 1.397 . . . . 10.0 110.318 176.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 22.8 p -132.54 118.48 19.3 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 105.844 -1.91 . . . . 10.0 105.844 168.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.49 -59.74 0.06 OUTLIER Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.344 -1.102 . . . . 10.0 110.344 178.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -165.29 -51.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 125.195 1.398 . . . . 10.0 107.977 -176.166 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -73.88 -40.24 63.35 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 114.3 -1.318 . . . . 10.0 108.098 -169.332 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 34.9 t 42.51 70.07 0.32 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 125.47 1.508 . . . . 10.0 109.922 172.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 3.6 pt -75.63 58.6 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.849 -0.797 . . . . 10.0 108.849 172.478 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 44.5 mm -108.84 -58.36 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.671 0.788 . . . . 10.0 109.176 -177.638 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -93.46 50.93 2.38 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 109.409 -1.477 . . . . 10.0 109.409 173.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.09 158.24 24.53 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.304 1.842 . . . . 10.0 107.401 177.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 67.1 m -108.68 119.07 38.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 C-N-CA 127.042 2.137 . . . . 10.0 106.264 -178.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 62.6 mt -93.49 150.87 20.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 108.224 -1.028 . . . . 10.0 108.224 168.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 79.6 t -132.81 138.36 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 N-CA-C 108.159 -1.052 . . . . 10.0 108.159 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.85 136.76 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 106.615 -1.624 . . . . 10.0 106.615 168.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.68 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 9.4 m-70 -116.03 161.12 19.34 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -175.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . 0.418 ' HB2' HD21 ' B' ' 144' ' ' LEU . 53.6 tt0 -60.04 -50.11 75.0 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.217 -0.901 . . . . 10.0 109.677 177.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 92.6 mttt -104.53 163.3 12.56 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 112.927 0.714 . . . . 10.0 112.927 -168.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.93 157.02 34.29 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 114.301 -1.318 . . . . 10.0 108.991 172.191 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.483 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 47.2 m-20 -109.79 134.78 51.64 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 124.153 0.981 . . . . 10.0 109.243 -169.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -73.26 -24.56 60.47 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 124.861 1.264 . . . . 10.0 110.337 -174.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 59.64 42.87 16.5 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.52 -0.918 . . . . 10.0 108.52 -173.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.53 -53.12 1.02 Allowed Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 124.959 1.266 . . . . 10.0 110.971 170.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -79.29 49.88 1.02 Allowed 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.356 1.062 . . . . 10.0 113.072 -170.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.38 -29.77 7.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 127.118 2.294 . . . . 10.0 110.593 169.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 75.81 18.71 79.48 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 118.978 -0.901 . . . . 10.0 112.395 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -111.65 160.22 17.45 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 105.947 -1.871 . . . . 10.0 105.947 168.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -50.26 -47.48 55.21 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.33 -1.304 . . . . 10.0 108.397 171.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -64.34 -37.43 87.47 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 112.915 0.709 . . . . 10.0 112.915 177.651 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.6 m -51.63 -45.47 63.3 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.336 1.425 . . . . 10.0 111.035 172.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.9 t -82.45 -22.51 35.2 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 111.922 0.341 . . . . 10.0 111.922 -173.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 25.2 ttmt -89.41 -46.89 8.39 Favored 'General case' 0 N--CA 1.439 -0.978 0 C-N-CA 125.225 1.41 . . . . 10.0 112.129 -177.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.412 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 30.7 p -133.44 -11.62 2.78 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 114.172 1.175 . . . . 10.0 114.172 178.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.22 15.72 37.5 Favored Glycine 0 C--O 1.221 -0.678 0 CA-C-O 118.982 -0.899 . . . . 10.0 112.15 -171.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 57.35 35.1 25.62 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.13 1.465 . . . . 10.0 111.233 -178.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.17 -13.59 62.1 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 126.515 1.926 . . . . 10.0 111.886 -178.435 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.89 -171.06 54.59 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 109.223 -1.551 . . . . 10.0 109.223 -169.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 11.1 m -52.52 166.12 0.21 Allowed 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 124.48 1.112 . . . . 10.0 113.071 -177.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -83.93 102.02 12.11 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 107.467 -1.308 . . . . 10.0 107.467 168.472 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.418 HD21 ' HB2' ' B' ' 121' ' ' GLU . 0.4 OUTLIER -71.61 -47.98 51.07 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.05 -1.092 . . . . 10.0 108.05 -177.642 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -143.49 144.54 32.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.094 -0.706 . . . . 10.0 109.094 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 39.0 m -126.71 147.98 49.91 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.669 -1.234 . . . . 10.0 107.669 -176.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.87 141.1 11.57 Favored Glycine 0 C--N 1.332 0.315 0 N-CA-C 108.834 -1.706 . . . . 10.0 108.834 172.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.71 136.8 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 N-CA-C 101.612 -3.477 . . . . 10.0 101.612 169.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.525 HG23 ' O ' ' B' ' 5' ' ' VAL . 68.5 mt -61.86 -81.41 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 CA-C-O 121.418 0.628 . . . . 10.0 110.285 -168.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.99 134.43 8.33 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.371 -0.691 . . . . 10.0 111.371 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.78 137.25 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.089 0 N-CA-C 107.697 -1.223 . . . . 10.0 107.697 173.435 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.98 -70.08 0.54 Allowed 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 106.742 -1.577 . . . . 10.0 106.742 171.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 20.4 tm0? . . . . . 0 C--O 1.253 1.249 0 N-CA-C 104.827 -2.286 . . . . 10.0 104.827 167.266 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.62 0 N-CA-C 105.511 -2.033 . . . . 10.0 105.511 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.5 t -63.18 -30.62 71.73 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.978 1.263 . . . . 10.0 108.1 167.427 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.5 tmtm? -117.08 146.95 42.8 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 126.088 1.755 . . . . 10.0 108.675 177.562 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.06 177.04 11.78 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 125.829 1.652 . . . . 10.0 109.195 169.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.9 t -136.2 164.04 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 125.277 1.431 . . . . 10.0 108.749 -176.49 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.68 104.36 3.03 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 124.054 0.941 . . . . 10.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.5 m -93.47 127.99 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 109.322 -0.621 . . . . 10.0 109.322 176.389 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.93 137.28 47.92 Favored 'General case' 0 C--O 1.225 -0.218 0 C-N-CA 124.762 1.225 . . . . 10.0 108.559 -178.736 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 40.1 mtpt -146.22 164.93 30.71 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-N 120.69 1.586 . . . . 10.0 107.968 170.797 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.59 -60.24 0.04 OUTLIER Glycine 0 CA--C 1.511 -0.19 0 C-N-CA 120.377 -0.916 . . . . 10.0 112.291 169.701 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.64 -44.91 61.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 107.431 -1.322 . . . . 10.0 107.431 -177.647 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.9 -69.74 0.44 Allowed Glycine 0 CA--C 1.524 0.612 0 CA-C-N 114.296 -1.32 . . . . 10.0 110.887 172.78 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -57.3 -36.3 98.94 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 123.25 2.633 . . . . 10.0 111.263 174.971 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.8 t -65.62 97.56 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.117 -1.438 . . . . 10.0 107.117 175.323 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.56 105.86 11.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.138 0.975 . . . . 10.0 108.424 173.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.781 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -81.03 149.79 29.92 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 109.623 -1.391 . . . . 10.0 109.623 168.38 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -155.22 59.6 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 C-N-CA 125.925 1.69 . . . . 10.0 106.848 -168.939 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 mm -74.94 146.47 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 O-C-N 121.621 -0.675 . . . . 10.0 109.657 -179.27 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -118.9 124.53 47.32 Favored 'General case' 0 N--CA 1.447 -0.619 0 C-N-CA 126.711 2.004 . . . . 10.0 107.061 177.013 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -106.63 120.6 42.39 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.086 -1.079 . . . . 10.0 108.086 178.703 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.5 mp0 -125.73 117.8 24.23 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.33 0.652 . . . . 10.0 111.472 176.515 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -124.03 108.99 12.96 Favored 'General case' 0 C--O 1.227 -0.113 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 168.287 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.42 -50.92 68.53 Favored 'General case' 0 C--N 1.333 -0.117 0 O-C-N 121.749 -0.595 . . . . 10.0 110.671 -178.824 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -129.57 170.42 13.78 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 103.557 -2.757 . . . . 10.0 103.557 168.38 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 92.3 p -68.61 -19.75 64.46 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 123.837 0.855 . . . . 10.0 110.39 170.12 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -78.77 -14.83 59.06 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 123.321 0.649 . . . . 10.0 109.278 174.144 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.43 138.67 15.47 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.183 -1.567 . . . . 10.0 109.183 175.828 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -62.4 135.8 55.74 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 CA-C-N 119.414 1.607 . . . . 10.0 108.069 171.328 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.1 p -75.97 120.36 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.425 0 N-CA-C 107.545 -1.28 . . . . 10.0 107.545 -176.779 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.1 mtpt -91.52 109.68 20.98 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.942 -2.244 . . . . 10.0 104.942 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.3 m -104.77 88.82 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 N-CA-C 107.408 -1.33 . . . . 10.0 107.408 178.768 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -97.33 170.94 8.73 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-O 121.75 0.786 . . . . 10.0 111.664 169.509 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.06 -169.15 38.84 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.51 -1.036 . . . . 10.0 110.51 172.025 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.9 p -147.15 102.35 3.49 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.908 -0.775 . . . . 10.0 108.908 -175.844 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.781 HG22 ' HA2' ' A' ' 16' ' ' GLY . 4.3 pt -78.44 130.8 35.69 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 N-CA-C 106.428 -1.694 . . . . 10.0 106.428 168.38 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 ptmt -118.73 136.17 54.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.708 -1.219 . . . . 10.0 107.708 173.864 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.95 -3.95 14.31 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.75 1.167 . . . . 10.0 112.979 179.676 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -66.35 176.97 1.61 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.625 1.212 . . . . 10.0 111.109 177.516 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.5 t -112.35 155.9 23.37 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 105.308 -2.108 . . . . 10.0 105.308 166.04 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -50.23 157.53 0.67 Allowed 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.29 1.036 . . . . 10.0 111.678 -170.365 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.51 -175.37 29.14 Favored Glycine 0 N--CA 1.448 -0.504 0 N-CA-C 111.153 -0.779 . . . . 10.0 111.153 170.791 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -78.39 149.2 33.39 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.699 1.599 . . . . 10.0 110.695 -175.99 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.1 m-70 -144.39 137.63 27.21 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.516 0.726 . . . . 10.0 112.953 -175.586 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -40.96 122.07 2.16 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 126.574 2.035 . . . . 10.0 110.217 168.247 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -136.73 113.03 9.88 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.177 1.489 . . . . 10.0 107.925 169.799 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.69 174.69 13.2 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-O 122.247 1.022 . . . . 10.0 112.163 -179.158 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.0 t -96.32 143.9 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 CA-C-N 111.318 -2.674 . . . . 10.0 107.2 169.609 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 76.9 m-70 -123.39 126.4 46.75 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 103.643 -2.725 . . . . 10.0 103.643 172.55 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.5 tp10 -61.17 -42.76 99.14 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.184 -1.371 . . . . 10.0 112.746 -165.508 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -81.91 118.64 23.1 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 119.288 -0.965 . . . . 10.0 109.459 177.696 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.1 -13.89 16.19 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.707 2.575 . . . . 10.0 112.523 169.992 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -42.83 127.28 3.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 122.384 1.088 . . . . 10.0 111.173 168.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -137.39 23.12 2.96 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 113.861 -1.518 . . . . 10.0 108.521 164.854 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -66.71 -44.43 81.69 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 106.542 -1.651 . . . . 10.0 106.542 168.525 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.69 -21.92 44.08 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.335 -0.393 . . . . 10.0 111.55 173.062 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.58 71.49 1.31 Allowed Glycine 0 CA--C 1.528 0.848 0 C-N-CA 124.134 0.873 . . . . 10.0 111.28 173.015 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . 0.291 23.2 p 43.12 48.98 5.5 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.665 1.186 . . . . 10.0 113.783 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 p -127.21 -66.95 0.86 Allowed 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 127.344 2.258 . . . . 10.0 105.354 173.072 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.1 m -79.05 -4.68 51.34 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 123.364 0.665 . . . . 10.0 112.56 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.7 -14.69 1.45 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 125.41 1.484 . . . . 10.0 112.925 173.377 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.22 131.55 6.89 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 108.847 -1.701 . . . . 10.0 108.847 170.071 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.403 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 70.3 Cg_endo -75.17 59.97 5.44 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.8 3.0 . . . . 10.0 110.38 172.247 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 23.3 m170 71.7 49.74 0.27 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 129.312 3.045 . . . . 10.0 111.275 175.435 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.403 ' CZ ' ' HD2' ' A' ' 62' ' ' PRO . 35.1 m-85 -72.21 38.12 0.07 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 115.258 1.577 . . . . 10.0 115.258 -173.344 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.27 151.15 0.57 Allowed Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 125.55 1.54 . . . . 10.0 113.107 169.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -66.02 -46.37 4.75 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.884 2.389 . . . . 10.0 111.953 179.544 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 71.1 mt -79.39 54.01 1.63 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.631 -0.668 . . . . 10.0 110.457 -177.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 40.0 p -55.5 109.2 0.52 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.537 1.135 . . . . 10.0 110.406 -173.826 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.4 mtt180 -121.29 -97.15 0.46 Allowed 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.819 -1.178 . . . . 10.0 107.819 -179.889 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.4 140.87 23.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 105.261 -2.126 . . . . 10.0 105.261 177.278 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -47.08 116.95 1.52 Allowed 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.654 -0.418 . . . . 10.0 110.991 169.402 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -135.48 -141.01 4.29 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 106.536 -2.626 . . . . 10.0 106.536 170.531 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.95 -147.51 8.1 Favored Glycine 0 C--O 1.227 -0.312 0 CA-C-O 118.644 -1.086 . . . . 10.0 111.229 175.267 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -68.27 14.93 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 120.041 1.921 . . . . 10.0 111.943 177.344 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.0 mmtt -104.68 -14.96 15.41 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 119.038 0.835 . . . . 10.0 110.042 169.805 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.33 177.34 7.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 122.337 1.065 . . . . 10.0 113.064 -165.049 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -98.64 -13.31 20.39 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 113.449 -1.705 . . . . 10.0 108.502 168.198 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.11 -16.26 56.97 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 124.735 1.214 . . . . 10.0 112.23 -168.598 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.28 135.88 2.47 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.596 1.158 . . . . 10.0 110.333 -169.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -73.66 61.99 0.76 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 123.405 0.682 . . . . 10.0 111.588 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.4 t 31.78 48.66 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 C-N-CA 126.872 2.069 . . . . 10.0 111.418 -174.511 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.22 42.0 0.05 OUTLIER Glycine 0 CA--C 1.531 1.062 0 CA-C-N 116.032 -0.531 . . . . 10.0 113.877 -178.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -97.07 100.42 11.92 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 103.617 -2.735 . . . . 10.0 103.617 166.049 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 27.5 mt -75.62 -24.86 56.53 Favored 'General case' 0 N--CA 1.462 0.174 0 N-CA-C 107.984 -1.117 . . . . 10.0 107.984 177.865 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.94 -102.25 2.83 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.311 -1.916 . . . . 10.0 108.311 168.527 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -129.24 133.67 47.62 Favored 'General case' 0 CA--C 1.517 -0.311 0 C-N-CA 123.888 0.875 . . . . 10.0 112.176 -168.633 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.8 m -124.88 145.47 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.143 -1.799 . . . . 10.0 106.143 167.202 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -98.44 126.14 43.87 Favored 'General case' 0 C--O 1.225 -0.223 0 C-N-CA 124.851 1.261 . . . . 10.0 108.959 -178.025 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.52 134.46 34.35 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 172.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -67.17 172.45 4.67 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-O 121.592 0.71 . . . . 10.0 109.609 168.45 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.46 -32.2 4.91 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.39 2.276 . . . . 10.0 111.099 171.528 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -78.68 -11.34 59.97 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.855 0.359 . . . . 10.0 110.607 -175.804 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.06 15.67 69.17 Favored Glycine 0 C--N 1.339 0.75 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 -177.189 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 42.4 t -94.97 111.15 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 C-N-CA 126.796 2.038 . . . . 10.0 105.921 175.162 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.536 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -106.02 120.24 41.28 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 168.734 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -78.53 131.08 36.66 Favored 'General case' 0 N--CA 1.429 -1.524 0 C-N-CA 125.906 1.682 . . . . 10.0 107.892 173.89 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 42.4 t -117.55 133.89 62.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.303 0 N-CA-C 106.235 -1.765 . . . . 10.0 106.235 179.459 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.5 p -157.45 70.42 0.6 Allowed 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 123.685 0.794 . . . . 10.0 109.554 175.554 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.43 153.22 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 N-CA-C 106.761 -1.57 . . . . 10.0 106.761 179.406 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -137.35 123.16 20.02 Favored 'General case' 0 N--CA 1.443 -0.812 0 C-N-CA 125.557 1.543 . . . . 10.0 106.897 169.298 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -128.29 153.99 46.4 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.62 0.724 . . . . 10.0 109.051 -178.723 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 33.7 t -117.48 46.18 1.77 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.629 1.572 . . . . 10.0 110.043 -168.717 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.3 p -155.8 -46.13 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.132 0 N-CA-C 109.181 -0.674 . . . . 10.0 109.181 177.105 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 29.8 mm -56.35 142.22 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 C-N-CA 123.49 0.716 . . . . 10.0 109.664 172.333 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.7 m -155.62 133.92 11.61 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 123.9 0.88 . . . . 10.0 108.758 171.671 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 82.7 mt -47.27 -55.21 9.11 Favored 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 126.914 2.086 . . . . 10.0 111.318 176.402 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.0 t -130.75 152.24 50.31 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 105.278 -2.119 . . . . 10.0 105.278 170.025 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.52 -84.77 0.12 Allowed Glycine 0 C--N 1.333 0.369 0 N-CA-C 110.058 -1.217 . . . . 10.0 110.058 -177.351 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -136.23 -53.47 0.74 Allowed 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 126.744 2.017 . . . . 10.0 107.5 -179.588 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -76.49 -31.15 57.57 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.117 -0.947 . . . . 10.0 108.57 -175.239 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.8 t 48.96 63.37 2.15 Favored 'General case' 0 N--CA 1.447 -0.594 0 C-N-CA 125.669 1.588 . . . . 10.0 109.372 177.109 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.315 1.1 tp -61.45 -18.77 19.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 C-N-CA 123.411 0.684 . . . . 10.0 112.112 -176.116 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.4 mm -48.75 135.79 5.51 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 118.812 0.733 . . . . 10.0 110.062 167.278 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.88 14.28 82.18 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.055 -0.858 . . . . 10.0 113.489 172.473 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.4 mmt-85 -84.02 175.43 9.54 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 167.898 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.3 m -108.36 122.27 46.64 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 105.84 -1.911 . . . . 10.0 105.84 177.003 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 6.5 mp -99.51 147.33 25.43 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-N 119.606 1.093 . . . . 10.0 108.535 171.058 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 89.6 t -131.18 135.93 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 N-CA-C 108.734 -0.839 . . . . 10.0 108.734 179.795 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 p -104.78 129.76 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 106.048 -1.834 . . . . 10.0 106.048 168.106 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 10.1 m-70 -111.12 158.86 18.39 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 114.994 1.479 . . . . 10.0 114.994 -169.672 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -46.42 -60.51 2.3 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.493 2.717 . . . . 10.0 110.903 171.369 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.2 mttp -117.27 165.61 13.24 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-O 121.104 0.478 . . . . 10.0 110.356 -172.917 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.39 140.8 54.21 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.881 -1.155 . . . . 10.0 107.881 168.854 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.03 153.75 32.06 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 108.837 -0.801 . . . . 10.0 108.837 168.264 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -78.59 10.73 2.97 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.118 0.967 . . . . 10.0 111.146 177.457 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.3 mt 38.94 51.35 1.85 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 125.151 1.38 . . . . 10.0 110.86 -170.334 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.94 -27.62 17.41 Favored Glycine 0 CA--C 1.529 0.933 0 CA-C-N 114.059 -1.428 . . . . 10.0 112.638 173.522 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -78.83 16.05 0.96 Allowed 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 113.66 0.985 . . . . 10.0 113.66 -168.42 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.93 -32.39 82.5 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 170.295 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 69.94 31.13 69.78 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 122.488 -0.419 . . . . 10.0 112.34 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.95 176.21 8.24 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 125.299 1.44 . . . . 10.0 107.545 173.338 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.406 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 2.6 tm-20 -59.51 -51.27 70.57 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 113.403 -1.726 . . . . 10.0 109.425 177.742 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -52.97 -43.9 66.74 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.565 1.146 . . . . 10.0 110.692 171.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.5 m -53.55 -46.59 70.28 Favored 'General case' 0 N--CA 1.441 -0.917 0 O-C-N 120.851 -1.156 . . . . 10.0 110.968 -179.118 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.5 t -77.65 -0.57 27.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 119.786 -0.766 . . . . 10.0 111.857 -177.121 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.406 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 90.6 mttt -113.91 -82.1 0.6 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.312 1.845 . . . . 10.0 111.197 -179.657 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . 0.299 2.0 p -105.95 11.84 31.24 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 120.738 1.608 . . . . 10.0 113.054 177.939 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 73.09 10.75 78.52 Favored Glycine 0 C--O 1.221 -0.699 0 CA-C-O 119.047 -0.863 . . . . 10.0 114.336 166.812 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 m120 65.7 26.35 11.42 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.594 1.197 . . . . 10.0 111.596 -176.863 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.59 -11.82 8.29 Favored 'General case' 0 CA--C 1.533 0.327 0 O-C-N 121.644 -0.66 . . . . 10.0 111.683 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.58 -140.32 21.74 Favored Glycine 0 N--CA 1.443 -0.852 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 168.495 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -70.72 118.23 13.25 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.23 0.538 . . . . 10.0 111.283 -168.359 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.41 76.55 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.734 1.214 . . . . 10.0 111.35 168.624 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 50.3 mt -52.12 -40.89 61.97 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.101 0.778 . . . . 10.0 113.101 -176.051 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.02 155.09 24.77 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 108.335 -0.987 . . . . 10.0 108.335 -171.579 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -167.15 166.07 15.18 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 116.049 -0.523 . . . . 10.0 109.626 -167.59 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.7 179.3 46.95 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.658 -0.782 . . . . 10.0 112.062 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 71.3 t -109.24 156.22 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 N-CA-C 104.978 -2.23 . . . . 10.0 104.978 -175.677 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.4 mt -75.07 -96.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 C-N-CA 123.656 0.782 . . . . 10.0 110.747 -168.478 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 106.28 130.85 6.68 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-O 121.917 0.732 . . . . 10.0 112.098 179.381 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 92.2 mt -72.18 141.25 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.689 0 C-N-CA 124.968 1.307 . . . . 10.0 108.968 179.083 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -112.11 -102.11 0.41 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 105.761 -1.94 . . . . 10.0 105.761 165.519 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 . . . . . 0 C--O 1.247 0.962 0 C-N-CA 131.033 3.733 . . . . 10.0 103.075 -171.237 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 106.267 -1.753 . . . . 10.0 106.267 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -160.49 -47.33 0.05 OUTLIER 'General case' 0 C--O 1.232 0.139 0 CA-C-N 118.89 0.768 . . . . 10.0 110.668 172.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -119.64 142.71 48.19 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 126.839 2.056 . . . . 10.0 107.691 173.877 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.44 155.51 45.86 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.118 0.967 . . . . 10.0 108.396 169.36 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -122.65 153.99 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.925 0 C-N-CA 123.873 0.869 . . . . 10.0 109.265 -175.181 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . 0.458 ' HB2' HG12 ' B' ' 149' ' ' ILE . . . -147.74 93.11 2.16 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.94 -1.133 . . . . 10.0 107.94 167.367 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.674 HG12 HG23 ' B' ' 17' ' ' ILE . 31.6 m -83.19 133.45 29.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 N-CA-C 107.803 -1.184 . . . . 10.0 107.803 169.425 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mt -107.34 138.15 44.07 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 107.836 -1.172 . . . . 10.0 107.836 -177.507 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 36.5 mtpt -146.34 153.72 40.85 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 120.582 1.537 . . . . 10.0 107.545 169.518 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.51 -52.71 0.08 OUTLIER Glycine 0 N--CA 1.462 0.388 0 C-N-CA 119.217 -1.468 . . . . 10.0 114.171 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -72.68 -43.41 63.13 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.649 -1.241 . . . . 10.0 107.649 -172.065 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.74 -70.55 0.4 Allowed Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 114.055 -1.429 . . . . 10.0 110.032 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -54.91 -39.73 88.99 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.783 2.322 . . . . 10.0 110.879 170.817 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.477 HG13 HD12 ' B' ' 38' ' ' LEU . 94.7 t -58.65 107.54 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.246 0 CA-C-N 119.083 0.856 . . . . 10.0 109.157 179.688 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.04 92.2 3.68 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 104.744 -2.317 . . . . 10.0 104.744 168.676 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.704 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -78.44 152.19 37.35 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 109.401 -1.479 . . . . 10.0 109.401 177.045 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.674 HG23 HG12 ' B' ' 7' ' ' VAL . 0.0 OUTLIER -154.26 87.22 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 107.142 -1.429 . . . . 10.0 107.142 -171.16 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.8 mm -96.56 142.18 14.35 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 C-N-CA 124.846 1.258 . . . . 10.0 109.464 174.872 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -127.64 119.31 25.61 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 125.38 1.472 . . . . 10.0 108.082 174.142 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -98.0 113.76 25.7 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.058 1.343 . . . . 10.0 107.5 173.409 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -117.89 136.06 53.7 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 119.133 0.878 . . . . 10.0 110.775 170.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 36.1 tt0 -126.54 81.15 1.98 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 124.638 1.175 . . . . 10.0 109.763 -176.102 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -130.92 73.85 1.57 Allowed 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 124.863 1.265 . . . . 10.0 111.963 -175.223 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -157.05 172.02 19.42 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 104.192 -2.522 . . . . 10.0 104.192 166.172 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.9 t -96.81 16.37 19.41 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 124.014 0.926 . . . . 10.0 108.646 179.522 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -117.19 4.18 12.66 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.122 0.969 . . . . 10.0 109.855 169.658 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 49.96 45.95 41.27 Favored Glycine 0 CA--C 1.532 1.15 0 CA-C-O 118.565 -1.131 . . . . 10.0 114.48 -177.682 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -71.17 108.18 2.28 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 N-CA-C 106.22 -2.261 . . . . 10.0 106.22 169.122 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 26.2 t -77.35 95.74 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.349 0 N-CA-C 105.374 -2.084 . . . . 10.0 105.374 174.612 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -76.33 96.63 4.02 Favored 'General case' 0 N--CA 1.444 -0.76 0 N-CA-C 105.594 -2.002 . . . . 10.0 105.594 174.516 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -92.58 90.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.751 0 N-CA-C 106.87 -1.53 . . . . 10.0 106.87 175.654 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.3 p90 -99.48 176.58 5.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 121.443 0.64 . . . . 10.0 109.4 169.428 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.15 173.58 40.32 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 110.016 -1.234 . . . . 10.0 110.016 176.206 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 17.6 m -149.52 89.55 1.64 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.198 -1.038 . . . . 10.0 108.198 -179.626 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.704 HG22 ' HA2' ' B' ' 16' ' ' GLY . 2.5 pt -77.38 150.46 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 174.313 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.8 pttt -136.96 126.05 24.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 O-C-N 124.288 0.992 . . . . 10.0 108.848 169.425 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.97 6.76 5.31 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-O 118.791 -1.005 . . . . 10.0 114.629 166.064 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.661 ' H ' HD13 ' B' ' 38' ' ' LEU . 0.0 OUTLIER -89.82 179.34 6.02 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-N 118.728 1.264 . . . . 10.0 108.62 172.443 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -81.09 175.12 10.94 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.348 -0.845 . . . . 10.0 111.011 172.175 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -63.23 169.72 3.38 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.426 1.49 . . . . 10.0 111.48 -174.616 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.94 -174.74 51.42 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 124.008 0.813 . . . . 10.0 113.256 167.376 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -66.19 143.0 57.53 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.795 1.638 . . . . 10.0 110.608 178.603 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -142.36 139.34 31.72 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 114.214 1.19 . . . . 10.0 114.214 -178.655 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.629 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.03 111.77 0.02 OUTLIER Glycine 0 C--N 1.342 0.883 0 C-N-CA 128.418 2.913 . . . . 10.0 114.208 165.493 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -138.57 102.95 4.73 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 120.376 2.088 . . . . 10.0 110.516 174.844 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.525 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -148.56 179.23 7.97 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.331 0.586 . . . . 10.0 111.829 -178.358 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 p -100.21 148.26 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 112.704 -2.044 . . . . 10.0 108.127 168.33 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -123.93 129.6 51.23 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.067 -2.568 . . . . 10.0 104.067 169.154 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -59.13 -44.73 92.04 Favored 'General case' 0 N--CA 1.441 -0.898 0 O-C-N 124.528 1.142 . . . . 10.0 112.363 -166.646 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -75.19 112.49 11.52 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 105.239 -2.134 . . . . 10.0 105.239 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -57.65 -33.51 67.45 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 109.503 -1.439 . . . . 10.0 109.503 168.798 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -35.93 146.34 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 125.253 1.421 . . . . 10.0 112.06 169.547 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -144.36 28.44 1.34 Allowed 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 115.261 -0.881 . . . . 10.0 111.406 176.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -49.12 -43.06 41.14 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 112.859 0.688 . . . . 10.0 112.859 -169.028 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -86.82 -23.5 25.32 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 113.378 0.881 . . . . 10.0 113.378 177.052 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.97 101.39 2.69 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 109.172 -1.571 . . . . 10.0 109.172 -170.273 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.289 26.3 p 11.5 49.62 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 129.633 3.173 . . . . 10.0 116.955 -168.673 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 42.4 m -120.84 -53.68 2.06 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 105.077 -2.194 . . . . 10.0 105.077 174.977 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.5 m -44.89 -40.45 6.29 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 126.158 1.783 . . . . 10.0 109.936 168.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.84 -25.25 0.09 Allowed 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 127.726 2.41 . . . . 10.0 114.999 176.934 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.41 155.79 29.45 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 108.572 -1.811 . . . . 10.0 108.572 169.35 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -68.5 -172.73 0.48 Allowed 'Trans proline' 0 N--CA 1.445 -1.352 0 N-CA-C 106.888 -2.005 . . . . 10.0 106.888 166.719 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -78.81 45.09 0.58 Allowed 'General case' 0 CA--C 1.542 0.649 0 O-C-N 119.743 -1.848 . . . . 10.0 112.047 -171.511 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 23.1 m-30 -72.55 68.22 0.8 Allowed 'General case' 0 C--O 1.221 -0.413 0 CA-C-N 119.846 1.203 . . . . 10.0 109.676 178.759 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -63.57 155.66 74.83 Favored Pre-proline 0 C--N 1.331 -0.226 0 N-CA-C 107.535 -1.283 . . . . 10.0 107.535 173.768 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -54.92 -27.95 56.47 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.097 1.865 . . . . 10.0 112.281 175.222 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -107.78 25.14 11.89 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.043 0.937 . . . . 10.0 111.815 177.189 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 44.7 p -40.98 117.79 0.9 Allowed 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.646 1.179 . . . . 10.0 112.273 177.94 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -124.58 -88.89 0.59 Allowed 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 107.676 -1.231 . . . . 10.0 107.676 177.361 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.418 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 8.5 mtmp? -125.49 152.6 44.76 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 108.316 -0.994 . . . . 10.0 108.316 168.541 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 36.2 t60 -58.14 128.36 36.72 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 117.659 -1.617 . . . . 10.0 106.734 165.812 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.408 ' CA ' ' HB2' ' B' ' 76' ' ' ASP . . . -150.09 -141.16 3.35 Favored Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 109.905 -1.278 . . . . 10.0 109.905 -178.771 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.6 -147.52 11.43 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 107.95 -2.06 . . . . 10.0 107.95 169.976 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.05 12.94 0.2 Allowed 'Trans proline' 0 N--CA 1.452 -0.923 0 CA-C-N 120.114 1.957 . . . . 10.0 111.621 169.429 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -127.65 1.51 6.15 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 124.59 1.156 . . . . 10.0 111.737 176.502 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.42 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 0.2 OUTLIER -123.81 150.58 44.35 Favored 'General case' 0 C--N 1.34 0.168 0 N-CA-C 102.426 -3.175 . . . . 10.0 102.426 166.825 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -82.55 -17.74 43.9 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 121.646 -0.659 . . . . 10.0 109.832 174.705 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.9 pm0 -118.16 36.54 4.31 Favored 'General case' 0 N--CA 1.438 -1.056 0 C-N-CA 125.901 1.68 . . . . 10.0 111.579 -167.515 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -44.25 153.58 0.14 Allowed 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.58 1.552 . . . . 10.0 109.578 168.937 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 38.4 m80 -60.9 -48.17 83.06 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 10.0 109.966 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.1 t 173.31 -75.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 C-N-CA 129.284 3.034 . . . . 10.0 105.059 166.082 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.03 59.06 5.02 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.617 -0.993 . . . . 10.0 110.617 179.305 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -106.08 95.07 5.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.557 -2.016 . . . . 10.0 105.557 169.322 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 43.6 mt -75.23 -33.87 61.39 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 106.741 -1.577 . . . . 10.0 106.741 175.632 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.51 -96.94 1.31 Allowed Glycine 0 N--CA 1.436 -1.337 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 169.442 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -132.42 136.14 46.56 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 122.863 0.465 . . . . 10.0 110.021 -169.518 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.5 m -122.24 140.3 46.54 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.955 -0.758 . . . . 10.0 108.955 169.488 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 9.4 m -81.93 119.25 23.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 127.457 2.303 . . . . 10.0 110.499 -177.159 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.4 130.46 44.53 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.984 1.314 . . . . 10.0 110.642 170.022 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -59.88 166.31 2.73 Favored 'General case' 0 N--CA 1.455 -0.222 0 O-C-N 124.069 0.855 . . . . 10.0 109.603 167.366 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 35.6 pttt -52.47 -30.5 30.18 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.804 1.241 . . . . 10.0 110.93 173.37 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -77.08 -9.52 58.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 117.676 0.216 . . . . 10.0 111.027 -178.148 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.54 10.57 67.54 Favored Glycine 0 C--N 1.34 0.774 0 O-C-N 121.092 -1.005 . . . . 10.0 111.038 -178.191 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.0 t -86.14 111.44 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 127.184 2.194 . . . . 10.0 106.466 175.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.577 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -114.61 120.71 41.1 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 118.715 0.689 . . . . 10.0 109.509 172.825 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -78.5 132.43 37.23 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 107.325 -1.361 . . . . 10.0 107.325 169.864 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 57.8 t -114.94 133.44 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 N-CA-C 104.777 -2.305 . . . . 10.0 104.777 169.063 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -156.73 62.8 0.52 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 118.174 0.443 . . . . 10.0 110.139 -178.731 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -110.69 152.85 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 N-CA-C 107.735 -1.209 . . . . 10.0 107.735 -173.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -136.6 139.22 41.95 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 123.798 0.839 . . . . 10.0 109.667 168.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -148.47 153.53 38.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 107.362 -1.347 . . . . 10.0 107.362 174.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.3 p -115.52 44.48 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 126.494 1.917 . . . . 10.0 109.549 177.403 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -111.69 -48.04 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 170.457 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 42.5 mm -65.1 148.49 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 N-CA-C 108.007 -1.108 . . . . 10.0 108.007 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.4 m -157.29 120.97 4.16 Favored 'General case' 0 C--O 1.226 -0.134 0 N-CA-C 108.029 -1.1 . . . . 10.0 108.029 173.578 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.9 mp -59.62 -29.94 68.36 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.614 1.166 . . . . 10.0 111.955 -169.603 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.2 m -149.88 66.81 0.98 Allowed 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 176.096 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.03 -72.43 1.17 Allowed Glycine 0 C--N 1.333 0.364 0 N-CA-C 108.628 -1.789 . . . . 10.0 108.628 177.203 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -152.03 -57.84 0.15 Allowed 'General case' 0 N--CA 1.44 -0.926 0 C-N-CA 127.462 2.305 . . . . 10.0 107.435 -167.646 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -85.25 -32.37 22.61 Favored 'General case' 0 N--CA 1.445 -0.7 0 C-N-CA 125.632 1.573 . . . . 10.0 108.826 -179.207 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 7.1 t 70.77 -51.21 0.68 Allowed 'General case' 0 C--N 1.342 0.277 0 C-N-CA 127.504 2.322 . . . . 10.0 111.176 178.221 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 mt 63.82 16.32 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 124.173 0.989 . . . . 10.0 110.721 174.104 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.8 mm -71.02 -56.1 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 124.478 1.111 . . . . 10.0 110.037 175.824 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.72 48.82 3.55 Favored Glycine 0 CA--C 1.526 0.758 0 O-C-N 120.617 -1.302 . . . . 10.0 112.501 -177.49 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -121.03 168.06 11.93 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 126.612 1.965 . . . . 10.0 108.692 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -114.21 141.11 47.95 Favored 'General case' 0 CA--C 1.515 -0.396 0 C-N-CA 124.654 1.181 . . . . 10.0 108.306 -172.07 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 4.8 mp -111.85 145.92 38.62 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 125.83 1.652 . . . . 10.0 108.474 172.489 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 88.9 t -131.71 136.06 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 107.835 -1.172 . . . . 10.0 107.835 178.278 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.405 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.4 p -97.57 120.17 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 105.838 -1.912 . . . . 10.0 105.838 168.007 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.629 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.2 m-70 -98.5 158.29 15.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 115.59 1.7 . . . . 10.0 115.59 -176.373 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -38.47 -66.18 0.29 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 129.834 3.254 . . . . 10.0 110.619 170.517 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -113.75 174.86 5.72 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 125.174 1.389 . . . . 10.0 110.319 -174.561 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -81.84 137.23 35.3 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.879 -1.055 . . . . 10.0 108.465 171.311 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.525 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -77.4 141.73 39.63 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.287 1.035 . . . . 10.0 109.284 169.892 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -78.45 24.51 0.27 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.375 0.67 . . . . 10.0 111.86 179.63 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.5 mt 36.64 51.6 0.91 Allowed 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 126.792 2.037 . . . . 10.0 111.7 -176.674 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.44 -32.03 6.6 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 125.594 1.569 . . . . 10.0 112.384 175.078 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.42 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 7.2 mttm -80.08 18.67 0.81 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.628 1.171 . . . . 10.0 113.222 -167.819 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.27 -18.73 75.29 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 109.531 -1.428 . . . . 10.0 109.531 167.109 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 57.78 40.19 92.52 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 124.402 1.001 . . . . 10.0 111.749 175.403 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -145.25 169.6 17.91 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.093 0.946 . . . . 10.0 109.583 173.643 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 13.0 tm-20 -46.83 -49.85 19.4 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 124.711 1.204 . . . . 10.0 110.139 -179.875 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 17.9 tp10 -71.35 -34.74 70.77 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 121.781 -0.574 . . . . 10.0 111.657 179.217 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.9 p -54.15 -43.63 70.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 120.715 -1.241 . . . . 10.0 110.799 172.149 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.272 5.6 t -77.81 -23.02 49.18 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 119.568 -0.853 . . . . 10.0 111.557 -173.627 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -84.71 -49.01 8.86 Favored 'General case' 0 N--CA 1.441 -0.912 0 C-N-CA 127.486 2.314 . . . . 10.0 112.525 -177.738 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 19.2 p -136.3 -15.04 1.71 Allowed 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 114.495 1.295 . . . . 10.0 114.495 175.556 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.76 3.9 52.18 Favored Glycine 0 C--N 1.339 0.707 0 CA-C-O 118.379 -1.234 . . . . 10.0 114.105 177.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 27.2 m120 72.18 25.26 2.95 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 118.573 1.186 . . . . 10.0 112.01 -177.788 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.34 -8.83 43.34 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.435 0.902 . . . . 10.0 113.435 179.356 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.93 -160.8 48.8 Favored Glycine 0 CA--C 1.524 0.608 0 O-C-N 121.029 -1.045 . . . . 10.0 111.536 172.622 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 m -60.63 134.69 57.33 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.7 1.2 . . . . 10.0 113.657 -167.675 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.9 84.92 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.524 1.529 . . . . 10.0 110.21 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 65.8 mt -58.02 -39.18 77.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 118.425 0.557 . . . . 10.0 112.094 -179.031 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.405 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -154.46 153.34 31.37 Favored 'General case' 0 CA--C 1.516 -0.334 0 O-C-N 121.683 -0.635 . . . . 10.0 110.655 -179.912 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 8.2 m -121.68 141.14 51.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.014 1.726 . . . . 10.0 108.556 -169.041 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.4 158.43 27.5 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 109.675 -1.37 . . . . 10.0 109.675 168.539 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.8 t -118.8 135.52 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 -179.838 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.458 HG12 ' HB2' ' B' ' 6' ' ' ALA . 59.8 mt -71.88 153.35 7.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 N-CA-C 108.658 -0.867 . . . . 10.0 108.658 176.808 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -164.77 151.24 20.15 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 109.099 -1.601 . . . . 10.0 109.099 -175.089 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.47 123.75 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 117.514 0.657 . . . . 10.0 109.768 -172.809 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.06 -26.26 39.74 Favored 'General case' 0 N--CA 1.446 -0.628 0 O-C-N 120.894 -1.129 . . . . 10.0 111.809 -173.276 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.428 -1.533 0 N-CA-C 103.918 -2.623 . . . . 10.0 103.918 -173.859 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.791 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -79.57 -38.91 33.02 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.194 0.598 . . . . 10.0 110.028 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -121.16 130.08 53.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.148 1.379 . . . . 10.0 107.331 -179.328 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.11 151.92 51.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.595 -0.891 . . . . 10.0 108.595 172.874 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.444 HG13 ' HB2' ' A' ' 152' ' ' ALA . 1.0 OUTLIER -109.24 170.52 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 123.115 0.566 . . . . 10.0 110.45 169.993 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -156.02 102.38 2.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 106.64 -1.615 . . . . 10.0 106.64 166.045 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.598 HG12 HG23 ' A' ' 17' ' ' ILE . 35.7 m -92.24 128.4 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 108.795 -0.817 . . . . 10.0 108.795 171.078 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.436 HD12 ' N ' ' A' ' 8' ' ' LEU . 4.2 mp -103.18 152.83 21.0 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 108.853 -0.795 . . . . 10.0 108.853 178.231 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 ttmt -161.16 162.24 31.31 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 108.044 -1.095 . . . . 10.0 108.044 169.52 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.37 -56.16 0.04 OUTLIER Glycine 0 C--N 1.33 0.21 0 N-CA-C 111.459 -0.657 . . . . 10.0 111.459 172.801 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -74.97 -45.89 39.12 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 106.661 -1.607 . . . . 10.0 106.661 -174.769 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 133.88 -67.72 0.55 Allowed Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 113.739 -1.573 . . . . 10.0 110.338 -179.506 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -56.96 -38.77 95.19 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.914 2.409 . . . . 10.0 111.172 173.876 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -68.05 105.59 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.062 0 N-CA-C 107.033 -1.469 . . . . 10.0 107.033 175.255 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -124.57 120.63 32.49 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 108.601 -0.888 . . . . 10.0 108.601 169.384 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.457 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -90.49 150.96 21.08 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 109.452 -1.459 . . . . 10.0 109.452 169.36 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.852 HG22 HG23 ' B' ' 54' ' ' THR . 0.0 OUTLIER -156.37 82.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 105.491 -2.04 . . . . 10.0 105.491 -172.994 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.6 mm -104.62 145.03 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.39 1.076 . . . . 10.0 108.841 -178.561 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -122.91 122.78 39.43 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 127.161 2.185 . . . . 10.0 108.337 169.011 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -103.24 123.03 45.97 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 106.704 -1.591 . . . . 10.0 106.704 173.327 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -117.91 135.52 54.06 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 123.962 0.788 . . . . 10.0 113.126 169.553 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -123.82 100.02 6.56 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 127.42 2.288 . . . . 10.0 105.264 171.135 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 17.8 tttp -64.65 -62.63 1.46 Allowed 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 124.61 1.164 . . . . 10.0 109.392 -169.719 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -109.59 165.81 11.38 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 102.896 -3.001 . . . . 10.0 102.896 166.873 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.9 t -66.65 -21.54 66.11 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.918 -0.771 . . . . 10.0 108.918 -178.912 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.6 m-80 -76.76 -19.62 57.41 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.537 -0.756 . . . . 10.0 110.511 -179.595 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.55 140.82 32.57 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 109.862 -1.295 . . . . 10.0 109.862 -178.763 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -61.62 149.15 91.05 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 N-CA-C 107.041 -1.946 . . . . 10.0 107.041 168.877 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 t -79.29 113.68 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.087 0 N-CA-C 105.976 -1.861 . . . . 10.0 105.976 178.584 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -93.9 117.58 30.3 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 105.696 -1.964 . . . . 10.0 105.696 171.193 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -110.4 108.67 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 C-N-CA 126.817 2.047 . . . . 10.0 106.857 -175.558 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 20.8 p90 -127.49 163.11 24.84 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 112.103 0.408 . . . . 10.0 112.103 179.616 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.03 -147.37 18.32 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 106.917 -2.473 . . . . 10.0 106.917 170.144 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 52.2 p -157.96 164.78 36.49 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.065 -1.054 . . . . 10.0 112.551 178.617 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.632 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -116.45 121.53 67.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 C-N-CA 126.062 1.745 . . . . 10.0 106.668 166.628 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.61 54.78 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 108.291 -1.003 . . . . 10.0 108.291 175.025 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.14 -0.14 9.68 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.174 1.369 . . . . 10.0 113.539 178.537 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.26 178.38 2.87 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 118.394 1.097 . . . . 10.0 111.231 179.183 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -107.71 156.11 19.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.203 -1.777 . . . . 10.0 106.203 165.244 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -51.27 150.74 3.21 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.463 1.105 . . . . 10.0 112.347 -169.504 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.04 -171.36 23.49 Favored Glycine 0 C--N 1.336 0.558 0 N-CA-C 111.201 -0.76 . . . . 10.0 111.201 170.232 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -76.73 149.16 36.37 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.574 1.149 . . . . 10.0 111.363 -173.319 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -143.15 141.32 31.15 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.71 1.204 . . . . 10.0 112.502 -177.698 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.534 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -35.73 122.15 0.61 Allowed Glycine 0 C--N 1.341 0.86 0 C-N-CA 126.582 2.039 . . . . 10.0 112.878 166.303 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -143.43 115.42 8.32 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 120.085 1.942 . . . . 10.0 110.975 167.442 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -149.7 174.25 12.79 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 120.994 0.426 . . . . 10.0 111.787 -178.974 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 117' ' ' LEU . 1.1 m -113.47 82.24 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 126.036 1.735 . . . . 10.0 109.995 -179.656 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -56.8 141.31 44.91 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 122.292 1.044 . . . . 10.0 110.599 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -71.58 -53.21 14.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 112.045 -2.343 . . . . 10.0 110.456 -168.234 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 22.3 m-30 -76.49 110.09 10.75 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 106.652 -1.61 . . . . 10.0 106.652 175.154 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.42 48.71 1.22 Allowed Glycine 0 CA--C 1.531 1.051 0 N-CA-C 110.04 -1.224 . . . . 10.0 110.04 167.806 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.76 143.41 30.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.885 1.674 . . . . 10.0 106.825 170.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.468 ' HB3' HG21 ' B' ' 7' ' ' VAL . 1.1 m120 -139.5 2.13 2.0 Favored 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 126.344 1.858 . . . . 10.0 109.324 174.103 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.565 HG23 ' CG2' ' B' ' 17' ' ' ILE . 1.9 m -61.92 -30.36 70.84 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 120.098 1.317 . . . . 10.0 110.525 -170.111 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.18 -15.36 60.07 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.174 0.99 . . . . 10.0 112.047 176.136 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.14 76.55 1.33 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.57 -1.412 . . . . 10.0 109.57 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 74.0 m 47.56 45.66 17.63 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.53 1.132 . . . . 10.0 111.145 175.658 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.5 m -134.59 -52.5 0.81 Allowed 'General case' 0 N--CA 1.439 -0.995 0 N-CA-C 108.948 -0.76 . . . . 10.0 108.948 -168.863 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 t -99.5 21.04 12.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 112.425 0.528 . . . . 10.0 112.425 -170.28 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.12 3.52 0.85 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.15 0.98 . . . . 10.0 113.401 178.956 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.28 129.98 1.57 Allowed Glycine 0 CA--C 1.529 0.967 0 O-C-N 120.874 -1.141 . . . . 10.0 110.341 175.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.16 61.54 7.78 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 123.197 2.598 . . . . 10.0 110.556 178.605 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 28.9 m170 63.07 59.75 1.28 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 128.46 2.704 . . . . 10.0 110.858 177.581 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.1 m-85 -72.19 55.19 0.31 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.558 1.143 . . . . 10.0 113.892 -176.727 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -71.18 144.53 89.88 Favored Pre-proline 0 C--N 1.326 -0.437 0 C-N-CA 125.56 1.544 . . . . 10.0 113.18 -174.158 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -71.78 -37.87 4.75 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.283 2.655 . . . . 10.0 111.398 176.706 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.79 56.95 0.98 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.653 0.781 . . . . 10.0 110.533 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 67.9 p -42.06 94.85 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 126.676 1.99 . . . . 10.0 112.948 -169.58 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.2 mtt85 -121.14 172.15 8.18 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 126.129 1.772 . . . . 10.0 108.163 174.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.408 ' NZ ' ' OE2' ' A' ' 78' ' ' GLU . 35.1 mtmm -102.0 106.32 17.22 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.018 -1.104 . . . . 10.0 108.018 -176.667 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -19.22 105.43 0.02 OUTLIER 'General case' 0 C--O 1.223 -0.32 0 C-N-CA 126.71 2.004 . . . . 10.0 114.407 -171.024 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.424 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . -115.35 -146.45 8.89 Favored Glycine 0 N--CA 1.439 -1.101 0 C-N-CA 125.828 1.68 . . . . 10.0 109.467 176.541 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.98 -166.39 24.93 Favored Glycine 0 N--CA 1.45 -0.41 0 N-CA-C 108.587 -1.805 . . . . 10.0 108.587 171.603 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -62.4 -3.16 3.86 Favored 'Trans proline' 0 N--CA 1.454 -0.814 0 CA-C-N 119.87 1.835 . . . . 10.0 111.829 173.104 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -99.19 -17.35 18.19 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 123.592 0.757 . . . . 10.0 111.61 174.667 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.424 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 4.5 t70 -111.71 169.68 8.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.191 -1.041 . . . . 10.0 108.191 -179.138 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -80.8 -36.28 31.93 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 106.824 -1.547 . . . . 10.0 106.824 169.056 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.408 ' OE2' ' NZ ' ' A' ' 70' ' ' LYS . 12.6 mt-10 -84.98 32.93 0.53 Allowed 'General case' 0 N--CA 1.442 -0.871 0 CA-C-O 122.646 1.213 . . . . 10.0 113.185 -166.02 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 ptm180 -66.68 133.65 50.65 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.43 -1.322 . . . . 10.0 107.43 170.091 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -66.56 -70.75 0.23 Allowed 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.461 0.648 . . . . 10.0 110.704 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 80.8 t -147.19 -105.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.038 -2.949 . . . . 10.0 103.038 177.729 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.34 62.8 4.52 Favored Glycine 0 CA--C 1.524 0.655 0 O-C-N 121.336 -0.852 . . . . 10.0 111.227 176.441 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -89.94 105.07 17.56 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 101.118 -3.66 . . . . 10.0 101.118 163.955 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 12.4 mt -87.43 -37.29 17.14 Favored 'General case' 0 N--CA 1.461 0.109 0 N-CA-C 107.41 -1.33 . . . . 10.0 107.41 173.298 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.17 -95.68 1.26 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 123.448 0.547 . . . . 10.0 111.884 167.75 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -116.09 104.27 11.39 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 124.903 1.281 . . . . 10.0 111.304 -167.451 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.07 133.81 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 168.851 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 m -100.21 111.96 24.26 Favored 'General case' 0 N--CA 1.441 -0.895 0 C-N-CA 125.692 1.597 . . . . 10.0 109.07 -169.142 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.75 129.71 35.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 123.243 0.617 . . . . 10.0 110.912 179.123 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -57.33 170.86 0.46 Allowed 'General case' 0 C--O 1.233 0.224 0 O-C-N 124.778 1.299 . . . . 10.0 110.116 167.494 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.8 ptmm? -54.29 -30.56 51.26 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 114.676 -1.147 . . . . 10.0 111.189 172.14 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -78.87 -2.05 37.94 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.988 0.915 . . . . 10.0 111.439 -179.049 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.86 20.38 73.6 Favored Glycine 0 C--N 1.337 0.598 0 N-CA-C 110.625 -0.99 . . . . 10.0 110.625 179.204 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.16 102.43 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.954 0 N-CA-C 105.462 -2.051 . . . . 10.0 105.462 179.393 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.632 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -99.53 121.97 41.93 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.83 -1.174 . . . . 10.0 107.83 169.259 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -81.23 143.09 32.56 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.796 1.638 . . . . 10.0 109.347 173.597 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 85.4 t -117.79 129.84 73.59 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 N-CA-C 105.745 -1.946 . . . . 10.0 105.745 168.175 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 17.4 m -158.1 69.77 0.53 Allowed 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 124.515 1.126 . . . . 10.0 108.403 169.257 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -108.61 157.75 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 106.875 -1.528 . . . . 10.0 106.875 -176.844 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -132.09 133.46 44.36 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 125.415 1.486 . . . . 10.0 108.691 170.892 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -136.26 135.07 38.7 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 108.288 -1.004 . . . . 10.0 108.288 -173.482 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 16.4 m -104.09 16.39 26.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.695 1.198 . . . . 10.0 111.729 -175.357 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.7 p -136.51 11.8 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 123.691 0.796 . . . . 10.0 110.33 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -113.95 136.13 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 103.11 -2.922 . . . . 10.0 103.11 169.905 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 11.5 m -139.53 123.68 17.9 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 123.358 0.663 . . . . 10.0 109.646 -178.223 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.1 mt -69.57 -31.6 69.88 Favored 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.985 0.914 . . . . 10.0 109.8 170.216 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 63.3 m -152.0 135.8 16.33 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.231 1.012 . . . . 10.0 108.339 170.666 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 164.59 -57.74 0.26 Allowed Glycine 0 C--N 1.333 0.391 0 N-CA-C 109.684 -1.367 . . . . 10.0 109.684 179.449 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -164.51 -50.06 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.694 1.998 . . . . 10.0 107.334 -178.129 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -74.37 -38.49 63.15 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.919 -1.037 . . . . 10.0 108.373 -169.597 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 45.5 t 42.03 55.14 3.9 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 126.486 1.914 . . . . 10.0 110.771 172.574 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.14 21.48 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 N-CA-C 113.873 1.064 . . . . 10.0 113.873 -168.626 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 21.7 mm -58.66 142.66 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 C-N-CA 125.33 1.452 . . . . 10.0 107.614 169.306 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.83 14.65 82.36 Favored Glycine 0 CA--C 1.534 1.245 0 CA-C-O 118.745 -1.031 . . . . 10.0 114.19 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.3 mmt180 -74.11 175.05 7.84 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 107.389 -1.338 . . . . 10.0 107.389 168.198 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -117.79 128.24 54.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.743 -1.206 . . . . 10.0 107.743 169.83 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.565 HD21 HD11 ' A' ' 149' ' ' ILE . 27.8 mt -98.42 142.73 29.68 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 107.953 -1.129 . . . . 10.0 107.953 174.317 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 93.5 t -131.09 132.33 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 N-CA-C 107.324 -1.361 . . . . 10.0 107.324 178.191 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.31 123.66 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.254 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.044 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.534 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 6.2 m170 -101.01 161.55 13.51 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 114.465 1.283 . . . . 10.0 114.465 -173.956 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -56.21 -50.64 70.67 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 126.433 1.893 . . . . 10.0 110.967 178.441 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 48.8 mttm -112.35 163.44 14.4 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.421 0.629 . . . . 10.0 111.508 -171.104 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.37 141.23 42.72 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 114.628 -1.169 . . . . 10.0 108.773 172.172 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -76.45 148.15 37.44 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 108.56 -0.904 . . . . 10.0 108.56 174.768 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.86 -37.03 15.65 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 126.814 2.046 . . . . 10.0 109.757 -178.414 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 20.4 mt 66.48 36.88 4.84 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.788 0.835 . . . . 10.0 113.059 -176.742 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 111.58 -25.77 12.9 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 118.553 0.615 . . . . 10.0 114.435 165.35 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.252 0.0 OUTLIER -94.56 31.12 1.83 Allowed 'General case' 0 CA--C 1.543 0.69 0 N-CA-C 113.386 0.884 . . . . 10.0 113.386 -172.758 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.427 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -90.16 -12.21 62.02 Favored Glycine 0 C--N 1.343 0.938 0 C-N-CA 125.342 1.449 . . . . 10.0 112.06 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 50.62 44.95 47.62 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.252 0.929 . . . . 10.0 112.778 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -153.28 175.46 13.06 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.479 -0.934 . . . . 10.0 108.479 175.722 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -56.67 -40.16 75.03 Favored 'General case' 0 N--CA 1.437 -1.079 0 O-C-N 121.356 -0.84 . . . . 10.0 111.845 -175.31 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -63.13 -36.57 84.03 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 118.056 -0.973 . . . . 10.0 109.723 175.838 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.427 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 59.0 p -51.01 -42.89 60.7 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 119.62 1.1 . . . . 10.0 110.954 -172.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.252 12.3 t -81.93 -11.31 58.95 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 112.522 0.564 . . . . 10.0 112.522 -175.448 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -115.88 -58.45 2.11 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.532 1.533 . . . . 10.0 113.648 -170.266 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 16.9 p -128.98 10.84 5.96 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 120.449 1.477 . . . . 10.0 112.182 175.447 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.25 -97.01 2.17 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 125.401 1.477 . . . . 10.0 109.742 176.073 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -168.09 37.88 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 122.944 1.354 . . . . 10.0 107.706 178.864 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.11 -22.73 55.21 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 113.534 -1.667 . . . . 10.0 108.446 -173.803 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.82 -157.37 53.07 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 109.506 -1.438 . . . . 10.0 109.506 169.497 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.26 120.29 3.93 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 124.28 1.032 . . . . 10.0 113.229 -167.663 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -63.06 80.47 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.412 1.085 . . . . 10.0 109.939 171.229 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.8 mt -45.56 -52.68 10.14 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.343 0.592 . . . . 10.0 110.96 178.061 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -153.93 152.8 31.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.723 -0.672 . . . . 10.0 109.501 -168.623 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.4 p -147.13 161.06 41.65 Favored 'General case' 0 N--CA 1.447 -0.592 0 O-C-N 123.83 0.706 . . . . 10.0 111.009 -176.79 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.94 168.59 28.15 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 125.473 1.511 . . . . 10.0 109.413 -177.839 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.0 t -120.76 137.85 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 106.366 -1.716 . . . . 10.0 106.366 -178.84 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.565 HD11 HD21 ' A' ' 117' ' ' LEU . 6.9 mt -73.12 116.81 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.655 -0.498 . . . . 10.0 109.655 -177.451 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.25 154.25 17.08 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.808 1.194 . . . . 10.0 111.331 -176.029 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.23 145.89 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 C-N-CA 124.763 1.225 . . . . 10.0 108.395 176.008 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.444 ' HB2' HG13 ' A' ' 5' ' ' VAL . . . -121.11 -25.99 5.2 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 113.58 0.956 . . . . 10.0 113.58 178.422 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.2 tp60 . . . . . 0 C--O 1.25 1.125 0 CA-C-O 117.074 -1.441 . . . . 10.0 107.153 -177.142 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.564 0 N-CA-C 106.534 -1.654 . . . . 10.0 106.534 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.2 t -156.83 -49.22 0.07 Allowed 'General case' 0 C--O 1.224 -0.242 0 CA-C-N 119.365 0.984 . . . . 10.0 110.957 169.161 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -124.01 122.23 37.35 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 125.13 1.372 . . . . 10.0 108.768 178.71 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -130.92 152.09 50.62 Favored 'General case' 0 CA--C 1.52 -0.184 0 C-N-CA 123.785 0.834 . . . . 10.0 109.523 170.019 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -118.38 161.15 17.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 C-N-CA 122.947 0.499 . . . . 10.0 111.091 178.022 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.9 110.4 5.78 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.165 -0.925 . . . . 10.0 108.561 167.859 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.468 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.6 m -96.95 108.48 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 C-N-CA 124.246 1.019 . . . . 10.0 109.349 172.763 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.9 mt -92.17 131.56 37.31 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.527 -0.916 . . . . 10.0 108.527 -178.396 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -143.65 157.09 44.67 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.612 -1.255 . . . . 10.0 107.612 171.042 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.02 -60.91 0.05 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 121.157 -0.544 . . . . 10.0 113.045 169.35 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.25 -43.78 66.58 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 107.341 -1.355 . . . . 10.0 107.341 -177.318 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.58 -71.22 0.42 Allowed Glycine 0 CA--C 1.523 0.578 0 CA-C-N 114.358 -1.292 . . . . 10.0 110.631 168.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -57.1 -31.98 91.93 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 123.282 2.655 . . . . 10.0 111.313 171.757 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.417 HG13 HD11 ' B' ' 38' ' ' LEU . 93.5 t -67.97 94.5 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 107.118 -1.438 . . . . 10.0 107.118 177.334 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -115.55 112.4 22.14 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 105.91 -1.885 . . . . 10.0 105.91 178.591 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.677 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.07 139.62 14.59 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 172.182 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.565 ' CG2' HG23 ' A' ' 54' ' ' THR . 4.5 mt -140.77 95.85 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 108.286 -1.005 . . . . 10.0 108.286 -174.986 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -106.9 149.15 10.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 124.578 1.151 . . . . 10.0 113.011 -178.184 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -122.98 110.04 14.88 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.939 2.096 . . . . 10.0 108.24 168.749 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -86.97 108.2 18.73 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 170.821 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -109.3 113.41 26.22 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-O 121.395 0.616 . . . . 10.0 111.646 179.81 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -78.1 101.77 7.15 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 169.854 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.409 ' NZ ' ' OE2' ' B' ' 24' ' ' GLU . 2.1 mmmp? -42.32 -66.4 0.36 Allowed 'General case' 0 CA--C 1.522 -0.103 0 C-N-CA 127.345 2.258 . . . . 10.0 109.72 177.511 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . 0.409 ' OE2' ' NZ ' ' B' ' 23' ' ' LYS . 16.5 mp0 -120.8 -169.87 1.9 Allowed 'General case' 0 N--CA 1.423 -1.809 0 N-CA-C 102.211 -3.255 . . . . 10.0 102.211 167.961 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 9.8 t -75.94 -29.79 58.44 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 118.163 -1.415 . . . . 10.0 109.024 173.012 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -97.1 -15.44 20.97 Favored 'General case' 0 N--CA 1.446 -0.631 0 C-N-CA 124.379 1.072 . . . . 10.0 111.777 -175.205 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.39 158.94 52.12 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 110.066 -1.214 . . . . 10.0 110.066 -179.734 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -61.88 144.02 96.27 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.491 2.127 . . . . 10.0 109.633 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 t -78.93 87.18 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.999 0 N-CA-C 106.417 -1.698 . . . . 10.0 106.417 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.4 mttm -67.08 108.19 2.55 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 106.854 -1.536 . . . . 10.0 106.854 169.012 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -110.03 108.87 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 125.624 1.569 . . . . 10.0 107.465 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 21.9 p90 -123.38 168.12 12.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.509 0.671 . . . . 10.0 110.123 173.408 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.46 -170.76 43.92 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 110.022 -1.231 . . . . 10.0 110.022 179.243 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 16.3 m -154.98 111.88 3.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.043 -0.725 . . . . 10.0 109.043 -175.939 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.677 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.5 pt -84.22 175.19 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.573 -0.851 . . . . 10.0 110.115 169.703 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -149.98 156.35 41.56 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 166.675 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.52 -25.17 11.36 Favored Glycine 0 C--N 1.338 0.678 0 CA-C-O 119.372 -0.682 . . . . 10.0 114.154 171.039 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.502 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.4 mp -75.04 179.59 4.89 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 118.388 1.094 . . . . 10.0 111.513 -170.84 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 7.6 t -101.84 161.55 13.58 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.637 -0.875 . . . . 10.0 108.637 168.263 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -49.2 153.0 1.05 Allowed 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.192 1.797 . . . . 10.0 113.675 -169.292 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.43 179.55 39.43 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 124.607 1.099 . . . . 10.0 113.033 168.525 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 95.2 mt -49.49 137.71 14.61 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.119 1.768 . . . . 10.0 112.755 171.894 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -138.2 147.12 43.46 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 124.773 1.229 . . . . 10.0 112.048 171.351 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.694 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -18.65 118.5 0.01 OUTLIER Glycine 0 C--N 1.337 0.598 0 C-N-CA 127.835 2.636 . . . . 10.0 114.16 165.466 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -151.35 106.02 3.26 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 120.218 2.009 . . . . 10.0 112.909 167.296 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.418 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -151.07 168.39 24.76 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.655 -0.702 . . . . 10.0 111.269 176.504 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 16.7 m -86.7 155.09 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 112.21 -2.268 . . . . 10.0 107.06 166.681 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -126.09 152.91 45.23 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 173.243 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -59.7 -42.98 94.24 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 113.689 0.996 . . . . 10.0 113.689 -168.857 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -96.38 174.96 6.61 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.749 -0.834 . . . . 10.0 108.749 -177.193 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -111.35 10.8 28.64 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 125.418 1.485 . . . . 10.0 109.668 166.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.49 112.62 1.65 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 122.327 1.06 . . . . 10.0 109.067 176.772 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -120.56 9.97 10.99 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 114.244 -1.344 . . . . 10.0 108.305 168.006 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.852 HG23 HG22 ' A' ' 17' ' ' ILE . 15.5 m -67.59 -34.6 77.35 Favored 'General case' 0 C--N 1.344 0.359 0 C-N-CA 125.235 1.414 . . . . 10.0 108.625 171.02 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.41 -22.34 60.26 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.323 -0.399 . . . . 10.0 110.479 174.702 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.5 54.33 1.7 Allowed Glycine 0 C--N 1.34 0.761 0 C-N-CA 123.893 0.759 . . . . 10.0 111.557 172.083 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 37.5 m 59.76 28.96 18.51 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.03 0.932 . . . . 10.0 110.166 -176.136 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 38.7 m -112.09 -49.8 2.95 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 125.439 1.495 . . . . 10.0 107.147 -169.596 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 8.4 t -117.31 26.62 9.62 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 113.563 0.949 . . . . 10.0 113.563 -175.041 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.42 -7.57 6.97 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.701 1.001 . . . . 10.0 113.701 179.548 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.36 123.61 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.763 1.173 . . . . 10.0 111.052 172.856 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -81.34 55.86 5.78 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 123.074 2.516 . . . . 10.0 112.16 -172.154 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.418 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 16.1 m170 66.76 36.84 4.42 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 128.956 2.903 . . . . 10.0 111.78 176.192 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -76.99 71.66 3.5 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 120.692 1.587 . . . . 10.0 109.998 175.911 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -61.87 158.19 44.78 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 125.201 1.4 . . . . 10.0 110.208 169.31 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -62.91 -46.63 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.024 1.816 . . . . 10.0 111.153 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 69.9 mt -78.84 56.45 1.91 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 123.204 0.601 . . . . 10.0 110.309 -179.383 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.2 m -45.25 112.21 0.42 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.639 1.176 . . . . 10.0 110.775 -179.305 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.5 mtp85 -137.33 -97.83 0.2 Allowed 'General case' 0 CA--C 1.506 -0.74 0 N-CA-C 104.492 -2.41 . . . . 10.0 104.492 -175.624 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 50.7 mttp -144.38 164.72 29.98 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.706 -1.22 . . . . 10.0 107.706 166.733 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -66.47 120.65 13.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 106.59 -1.634 . . . . 10.0 106.59 164.641 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.23 -137.79 3.66 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 108.087 -2.005 . . . . 10.0 108.087 175.304 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.6 -160.63 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 109.422 -1.471 . . . . 10.0 109.422 173.493 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -65.41 4.45 0.77 Allowed 'Trans proline' 0 N--CA 1.454 -0.834 0 C-N-CA 122.15 1.9 . . . . 10.0 111.83 169.824 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 57.8 mmtt -94.31 -24.03 17.58 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-O 118.508 -0.758 . . . . 10.0 110.127 170.282 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -108.29 161.42 15.02 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-O 121.051 0.453 . . . . 10.0 111.176 -167.53 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -97.46 -9.72 26.71 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.134 -0.939 . . . . 10.0 109.585 174.15 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -123.05 28.5 7.16 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 119.32 -0.372 . . . . 10.0 110.645 -178.91 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . 0.437 HH12 ' CG ' ' B' ' 101' ' ' ASP . 14.9 ptt180 -50.38 154.53 1.24 Allowed 'General case' 0 C--N 1.344 0.354 0 C-N-CA 123.337 0.655 . . . . 10.0 109.879 169.217 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -65.78 -64.88 0.76 Allowed 'General case' 0 N--CA 1.453 -0.319 0 CA-C-O 121.552 0.691 . . . . 10.0 109.503 -178.534 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.713 HG13 ' H ' ' B' ' 82' ' ' GLY . 4.0 p -169.34 -93.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 105.602 -1.999 . . . . 10.0 105.602 176.195 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.713 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -78.94 58.98 4.27 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.479 -1.048 . . . . 10.0 110.479 173.905 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.83 98.93 10.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 102.306 -3.22 . . . . 10.0 102.306 165.951 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -78.26 10.77 2.76 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 118.24 0.473 . . . . 10.0 110.585 -175.571 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 81.12 -109.44 2.99 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 104.128 -3.589 . . . . 10.0 104.128 -175.28 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -159.53 149.78 18.97 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.354 -1.721 . . . . 10.0 106.354 -178.435 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.45 128.18 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 C-N-CA 123.18 0.592 . . . . 10.0 111.202 -171.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.87 97.52 5.3 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 126.676 1.99 . . . . 10.0 111.176 -174.412 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -76.33 134.36 39.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.071 -0.393 . . . . 10.0 110.482 173.066 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -61.91 169.0 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.874 0.845 . . . . 10.0 109.249 167.358 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 34.7 mtmt -48.06 -34.4 9.51 Favored 'General case' 0 N--CA 1.435 -1.207 0 C-N-CA 125.873 1.669 . . . . 10.0 111.395 169.331 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -78.16 -8.32 58.15 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.999 0.428 . . . . 10.0 112.077 -179.377 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.69 1.94 70.38 Favored Glycine 0 C--N 1.339 0.701 0 O-C-N 120.933 -1.104 . . . . 10.0 111.572 -176.102 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 53.1 t -84.81 101.39 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.115 0 C-N-CA 125.77 1.628 . . . . 10.0 108.007 -179.232 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.438 ' HB3' ' CD1' ' B' ' 35' ' ' ILE . . . -96.13 115.72 27.87 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 107.333 -1.358 . . . . 10.0 107.333 168.252 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -80.86 119.35 23.3 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 106.737 -1.579 . . . . 10.0 106.737 169.24 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 66.5 t -104.11 131.12 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 -177.446 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.3 p -157.24 83.81 0.92 Allowed 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 174.033 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -115.18 159.46 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 105.088 -2.19 . . . . 10.0 105.088 176.325 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -133.52 133.19 41.85 Favored 'General case' 0 N--CA 1.441 -0.876 0 N-CA-C 109.103 -0.703 . . . . 10.0 109.103 168.082 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . 0.437 ' CG ' HH12 ' B' ' 79' ' ' ARG . 7.1 t0 -113.89 111.93 22.51 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 124.229 0.955 . . . . 10.0 109.377 -173.052 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.6 p -100.77 61.73 1.0 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.446 1.498 . . . . 10.0 107.079 -176.229 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.5 p -155.39 -47.07 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.145 0 N-CA-C 110.204 -0.295 . . . . 10.0 110.204 -173.006 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.355 0.0 OUTLIER -102.15 176.89 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.143 0 N-CA-C 113.622 0.971 . . . . 10.0 113.622 172.231 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 49.9 m -151.62 146.1 25.57 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 105.915 -1.883 . . . . 10.0 105.915 -179.723 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 29.0 mt -68.01 -14.7 63.18 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 117.948 0.34 . . . . 10.0 111.354 -175.615 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.8 m -145.65 158.72 43.82 Favored 'General case' 0 N--CA 1.451 -0.421 0 O-C-N 120.949 -1.094 . . . . 10.0 108.62 174.382 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.21 -101.08 0.56 Allowed Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 106.167 -2.773 . . . . 10.0 106.167 -169.761 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -129.56 -47.37 1.17 Allowed 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 125.455 1.502 . . . . 10.0 109.199 -168.885 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 36.1 m-70 -75.44 -39.56 58.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 115.158 -0.928 . . . . 10.0 109.133 -170.472 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 11.4 t 21.35 92.84 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 128.868 2.867 . . . . 10.0 114.227 172.142 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 36.7 pt -72.79 -11.86 15.22 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 C-N-CA 123.717 0.807 . . . . 10.0 112.45 176.854 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm -52.11 133.11 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 O-C-N 121.488 -0.758 . . . . 10.0 110.059 178.774 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 78.87 1.4 84.39 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 118.81 -0.995 . . . . 10.0 114.016 -178.749 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 57.2 mtt85 -85.92 175.94 8.35 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.719 1.759 . . . . 10.0 108.487 168.459 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.04 140.13 50.19 Favored 'General case' 0 CA--C 1.513 -0.467 0 C-N-CA 125.458 1.503 . . . . 10.0 108.512 179.101 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.502 HD11 ' CG1' ' B' ' 149' ' ' ILE . 1.5 mp -110.14 155.93 21.27 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 107.641 -1.244 . . . . 10.0 107.641 166.03 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.4 HG21 ' HD3' ' B' ' 143' ' ' ARG . 91.2 t -128.82 134.3 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.149 0 N-CA-C 106.695 -1.595 . . . . 10.0 106.695 -179.183 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.84 121.62 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.363 0 N-CA-C 105.71 -1.959 . . . . 10.0 105.71 166.865 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.694 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 7.5 m-70 -102.95 160.5 14.55 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 116.316 1.969 . . . . 10.0 116.316 -168.925 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -43.46 -56.73 3.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 129.085 2.954 . . . . 10.0 111.19 173.73 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 78.1 mttt -113.52 168.84 9.42 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 124.067 0.947 . . . . 10.0 113.352 -168.569 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.44 154.0 41.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 124.68 1.238 . . . . 10.0 108.641 169.822 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.45 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 13.0 m-20 -106.07 141.43 37.45 Favored 'General case' 0 N--CA 1.454 -0.243 0 O-C-N 123.902 0.751 . . . . 10.0 111.287 -168.6 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -74.54 -31.03 61.98 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 125.169 1.388 . . . . 10.0 110.195 -177.355 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 13.7 mt 60.62 50.57 5.59 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-O 122.618 1.199 . . . . 10.0 108.014 -176.005 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 87.68 -52.08 4.18 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 115.392 -0.822 . . . . 10.0 111.401 172.571 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 48.75 0.98 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.517 1.127 . . . . 10.0 112.249 -172.679 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.16 -26.97 7.14 Favored Glycine 0 CA--C 1.522 0.492 0 C-N-CA 127.936 2.684 . . . . 10.0 111.17 173.426 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.45 18.01 65.17 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-O 118.472 -1.182 . . . . 10.0 112.65 172.908 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -131.95 168.75 17.35 Favored 'General case' 0 CA--C 1.515 -0.403 0 CA-C-N 119.677 1.739 . . . . 10.0 108.277 168.361 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.45 -55.04 6.56 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.571 1.148 . . . . 10.0 108.878 178.042 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -63.62 -34.22 77.35 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 118.169 -0.919 . . . . 10.0 111.791 -175.674 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 5.3 m -49.16 -46.86 45.9 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 120.202 1.365 . . . . 10.0 110.804 169.301 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -89.3 -15.6 33.09 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.245 -0.883 . . . . 10.0 113.257 -170.549 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -98.07 -40.93 8.19 Favored 'General case' 0 N--CA 1.438 -1.062 0 C-N-CA 125.027 1.331 . . . . 10.0 111.773 179.146 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.4 p -136.28 -7.02 2.02 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 114.567 1.321 . . . . 10.0 114.567 175.086 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.83 17.14 52.96 Favored Glycine 0 C--O 1.221 -0.669 0 CA-C-O 118.463 -1.187 . . . . 10.0 112.306 -173.27 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 55.53 30.29 14.94 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.533 1.667 . . . . 10.0 111.765 178.76 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.59 54.8 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 125.979 1.712 . . . . 10.0 112.057 -175.323 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.59 -164.33 54.81 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 110.595 -1.002 . . . . 10.0 110.595 174.605 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.2 m -55.6 139.63 43.75 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 123.966 0.906 . . . . 10.0 111.887 -168.354 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . 0.4 ' HD3' HG21 ' B' ' 118' ' ' VAL . 22.6 mtt85 -71.02 70.84 0.53 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.828 1.251 . . . . 10.0 110.06 176.684 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.3 tp -44.6 -36.2 2.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 127.84 2.456 . . . . 10.0 112.536 -176.673 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.28 151.13 17.05 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.504 -0.925 . . . . 10.0 108.504 172.959 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -146.7 164.82 31.5 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 109.914 -0.402 . . . . 10.0 109.914 177.129 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.64 -176.63 25.44 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.496 -1.042 . . . . 10.0 110.496 178.249 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.4 t -122.56 143.13 36.41 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 107.568 -1.271 . . . . 10.0 107.568 179.817 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.502 ' CG1' HD11 ' B' ' 117' ' ' LEU . 11.4 mt -78.38 112.42 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 124.1 0.96 . . . . 10.0 109.493 -179.066 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.69 146.12 16.52 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.205 -1.158 . . . . 10.0 110.205 178.2 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -79.96 119.02 28.57 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.827 -0.805 . . . . 10.0 108.827 177.22 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.56 -43.05 40.56 Favored 'General case' 0 C--O 1.221 -0.439 0 O-C-N 121.078 -1.014 . . . . 10.0 108.554 -176.038 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.946 0 C-N-CA 125.793 1.637 . . . . 10.0 110.815 170.577 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.836 0 CA-C-O 118.628 -0.701 . . . . 10.0 109.661 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.5 t -97.15 -32.71 11.81 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 124.982 1.313 . . . . 10.0 110.369 -178.295 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -148.25 151.62 35.77 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.344 -0.984 . . . . 10.0 108.344 -177.849 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.15 155.41 45.31 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 122.878 0.471 . . . . 10.0 110.548 176.401 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.636 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.1 p -126.84 151.4 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 C-N-CA 128.152 2.581 . . . . 10.0 107.028 -178.762 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -138.62 116.29 11.41 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.174 -2.158 . . . . 10.0 105.174 168.265 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.3 p -81.29 103.72 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 N-CA-C 108.822 -0.807 . . . . 10.0 108.822 174.42 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.76 116.45 23.26 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.027 -1.101 . . . . 10.0 108.027 178.333 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -137.84 155.99 48.4 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 174.401 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -163.19 -66.28 0.02 OUTLIER Glycine 0 C--O 1.229 -0.18 0 CA-C-N 114.915 -1.039 . . . . 10.0 111.891 174.67 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.76 -43.91 57.64 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 -172.706 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.52 -67.66 0.53 Allowed Glycine 0 N--CA 1.443 -0.895 0 CA-C-N 113.481 -1.691 . . . . 10.0 110.525 179.779 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -58.23 -37.96 93.1 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.911 2.408 . . . . 10.0 111.142 174.617 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 94.4 t -64.54 96.81 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 107.263 -1.384 . . . . 10.0 107.263 176.425 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -120.35 123.1 42.27 Favored 'General case' 0 N--CA 1.446 -0.661 0 C-N-CA 125.104 1.361 . . . . 10.0 107.381 175.666 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.549 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -116.25 136.6 13.0 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 123.652 0.644 . . . . 10.0 112.168 175.363 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.428 ' CG2' HG22 ' B' ' 54' ' ' THR . 58.6 mt -124.56 74.09 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.525 -1.657 . . . . 10.0 106.525 -179.018 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -64.09 148.85 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.374 -0.83 . . . . 10.0 109.598 171.67 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -139.05 97.85 3.4 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 127.437 2.295 . . . . 10.0 107.548 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -89.79 118.87 29.7 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.781 -1.192 . . . . 10.0 107.781 171.301 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -104.8 130.88 52.83 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.838 0.745 . . . . 10.0 110.971 168.644 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -123.1 92.3 3.67 Favored 'General case' 0 C--N 1.341 0.217 0 C-N-CA 125.076 1.35 . . . . 10.0 109.102 171.759 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 11.0 mmtp -49.94 -60.91 2.48 Favored 'General case' 0 N--CA 1.46 0.072 0 C-N-CA 124.653 1.181 . . . . 10.0 111.054 175.804 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.0 176.65 8.57 Favored 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 105.604 -1.998 . . . . 10.0 105.604 171.2 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 t -74.72 -13.74 60.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 122.341 0.256 . . . . 10.0 110.708 177.229 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -88.25 -12.94 42.21 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 123.729 0.811 . . . . 10.0 109.794 174.434 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.14 119.54 4.98 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 109.357 -1.497 . . . . 10.0 109.357 178.573 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -60.83 127.73 23.37 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 N-CA-C 106.558 -2.132 . . . . 10.0 106.558 169.41 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -77.01 138.06 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 108.702 -0.851 . . . . 10.0 108.702 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.79 106.24 18.22 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 104.759 -2.311 . . . . 10.0 104.759 171.76 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.2 m -87.03 93.33 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 105.467 -2.049 . . . . 10.0 105.467 174.137 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -109.18 178.79 4.35 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-O 120.83 0.348 . . . . 10.0 111.219 173.721 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.58 -164.09 30.15 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 111.24 -0.744 . . . . 10.0 111.24 169.043 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.6 p -152.19 122.43 7.19 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 118.641 -0.695 . . . . 10.0 110.934 -169.383 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.629 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -100.88 136.6 31.73 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 105.891 -1.892 . . . . 10.0 105.891 166.325 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.44 ' NZ ' ' OD2' ' A' ' 92' ' ' ASP . 0.2 OUTLIER -130.14 160.05 34.96 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 168.809 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.7 -12.52 62.79 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-N 118.042 0.383 . . . . 10.0 113.208 -178.815 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 15.4 mt -68.2 -179.49 1.28 Allowed 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.872 0.869 . . . . 10.0 110.489 171.651 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -111.95 166.46 11.2 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 109.042 -0.725 . . . . 10.0 109.042 167.554 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -46.64 148.96 0.88 Allowed 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 127.359 2.264 . . . . 10.0 113.419 -169.534 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.65 -179.09 42.98 Favored Glycine 0 C--N 1.336 0.569 0 C-N-CA 124.235 0.922 . . . . 10.0 114.091 167.139 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.6 mt -52.38 137.9 28.23 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.878 1.671 . . . . 10.0 113.02 176.63 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 -135.31 141.57 45.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.439 1.095 . . . . 10.0 111.075 169.525 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.628 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -25.46 121.75 0.03 OUTLIER Glycine 0 C--N 1.344 0.992 0 CA-C-O 116.648 -2.195 . . . . 10.0 111.773 165.776 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -144.54 109.5 5.04 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 120.431 2.115 . . . . 10.0 111.053 169.768 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.09 175.02 11.36 Favored 'General case' 0 CA--C 1.512 -0.487 0 C-N-CA 123.572 0.749 . . . . 10.0 109.102 -179.612 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.88 98.29 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 113.595 -1.638 . . . . 10.0 109.653 179.448 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 20.4 m-70 -72.74 148.02 45.04 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 125.898 1.679 . . . . 10.0 109.681 -172.99 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -62.03 -55.72 26.34 Favored 'General case' 0 N--CA 1.45 -0.427 0 O-C-N 123.958 0.786 . . . . 10.0 112.077 -173.435 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -87.92 150.6 23.38 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 119.258 -0.977 . . . . 10.0 109.583 177.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -114.98 32.92 5.57 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.098 -1.201 . . . . 10.0 110.098 168.414 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -79.8 70.22 6.28 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 123.251 1.5 . . . . 10.0 108.683 179.153 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.456 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.5 OUTLIER -73.98 5.5 4.19 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.557 -1.201 . . . . 10.0 113.519 -174.014 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.516 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -32.79 -50.75 0.27 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 129.607 3.163 . . . . 10.0 112.703 175.144 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.97 -20.4 45.6 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 113.517 0.932 . . . . 10.0 113.517 -174.572 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.25 71.24 0.89 Allowed Glycine 0 CA--C 1.524 0.62 0 N-CA-C 106.987 -2.445 . . . . 10.0 106.987 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.8 t 49.33 24.01 0.95 Allowed 'General case' 0 CA--C 1.529 0.145 0 N-CA-C 115.844 1.794 . . . . 10.0 115.844 171.356 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.5 m -94.27 -52.48 4.34 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 105.567 -2.012 . . . . 10.0 105.567 -178.388 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.2 m -66.86 -25.36 66.38 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 125.359 1.464 . . . . 10.0 112.732 -169.332 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.43 -38.27 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.542 2.737 . . . . 10.0 113.73 173.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 152.71 9.61 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 111.299 -0.72 . . . . 10.0 111.299 167.713 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.85 57.28 6.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.414 2.076 . . . . 10.0 110.571 172.784 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 30.2 m170 71.56 -64.8 0.37 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 128.014 2.526 . . . . 10.0 108.875 -179.557 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . 0.285 1.1 p90 26.02 49.32 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 129.845 3.258 . . . . 10.0 115.096 175.16 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -51.66 157.2 1.96 Allowed Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 114.438 -1.256 . . . . 10.0 111.057 169.415 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.14 -40.82 24.61 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 121.943 1.762 . . . . 10.0 111.054 -173.735 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mp -77.03 59.63 1.7 Allowed 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 108.532 -0.914 . . . . 10.0 108.532 169.134 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.3 p -60.95 106.87 0.63 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 107.942 -1.133 . . . . 10.0 107.942 -177.418 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -129.93 -87.64 0.51 Allowed 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 107.34 -1.356 . . . . 10.0 107.34 -169.857 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.3 mmtp -139.05 153.69 48.11 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-O 122.313 1.054 . . . . 10.0 109.573 169.076 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -70.42 119.78 15.1 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 105.742 -1.948 . . . . 10.0 105.742 162.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -145.26 -135.88 2.91 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 107.104 -2.398 . . . . 10.0 107.104 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -174.26 -147.73 6.21 Favored Glycine 0 C--O 1.226 -0.403 0 CA-C-O 117.965 -1.464 . . . . 10.0 109.677 171.65 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -67.13 7.78 0.43 Allowed 'Trans proline' 0 N--CA 1.452 -0.925 0 CA-C-N 119.818 1.809 . . . . 10.0 111.105 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 73.6 mttt -113.37 3.4 15.86 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 118.225 -0.893 . . . . 10.0 111.563 170.944 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -122.42 149.67 43.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.604 -1.628 . . . . 10.0 106.604 170.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -83.05 -24.77 32.63 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.65 -0.871 . . . . 10.0 108.65 171.189 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -113.3 26.2 10.65 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 125.242 1.417 . . . . 10.0 111.068 -168.665 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -47.62 161.54 0.09 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 128.589 2.756 . . . . 10.0 110.078 168.371 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -78.69 46.85 0.69 Allowed 'General case' 0 N--CA 1.463 0.216 0 O-C-N 120.575 -1.328 . . . . 10.0 112.318 -178.106 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.2 p 33.16 35.94 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 126.861 2.064 . . . . 10.0 113.595 -174.278 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 165.98 37.69 0.02 OUTLIER Glycine 0 CA--C 1.532 1.113 0 O-C-N 121.538 -0.726 . . . . 10.0 111.961 -169.246 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -113.71 108.15 16.72 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 105.425 -2.065 . . . . 10.0 105.425 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -81.33 -29.48 34.16 Favored 'General case' 0 N--CA 1.461 0.121 0 N-CA-C 107.557 -1.275 . . . . 10.0 107.557 169.033 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.16 -96.64 1.31 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 108.424 -1.871 . . . . 10.0 108.424 168.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -134.92 117.98 16.41 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 125.6 1.56 . . . . 10.0 106.905 -169.497 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 22.4 m -111.61 132.26 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 CA-C-N 118.553 0.615 . . . . 10.0 111.296 179.428 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.8 m -78.46 107.88 11.43 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.771 2.429 . . . . 10.0 112.468 -170.472 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.51 137.26 32.48 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.869 0.467 . . . . 10.0 111.309 174.225 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -62.18 174.6 0.87 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 122.009 0.909 . . . . 10.0 110.328 166.927 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.5 pttt -51.74 -32.48 30.68 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.516 1.927 . . . . 10.0 112.709 169.191 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.44 ' OD2' ' NZ ' ' A' ' 36' ' ' LYS . 22.8 t70 -79.17 -10.46 59.83 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-O 122.14 0.971 . . . . 10.0 110.658 178.107 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.89 3.7 65.72 Favored Glycine 0 N--CA 1.431 -1.634 0 N-CA-C 110.052 -1.219 . . . . 10.0 110.052 -171.898 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 26.4 t -75.55 95.65 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.095 0 N-CA-C 106.327 -1.731 . . . . 10.0 106.327 -172.461 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.629 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -98.21 113.17 25.01 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 169.052 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -81.78 115.14 20.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 C-N-CA 127.199 2.2 . . . . 10.0 108.832 175.191 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.2 133.31 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 176.406 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 72.7 p -158.52 80.88 0.81 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.963 0.905 . . . . 10.0 109.799 170.642 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -112.26 143.1 22.68 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 177.628 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -99.73 127.37 45.86 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.393 1.477 . . . . 10.0 107.564 169.372 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -133.7 156.15 48.45 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.601 0.715 . . . . 10.0 109.083 176.721 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 3.5 t -128.1 49.58 2.15 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 126.022 1.729 . . . . 10.0 109.015 -173.41 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 p -157.79 -39.42 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 123.361 0.664 . . . . 10.0 110.63 176.837 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 45.6 mm -59.92 116.53 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.459 -0.941 . . . . 10.0 108.459 169.887 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 48.5 m -131.34 119.29 21.51 Favored 'General case' 0 CA--C 1.528 0.115 0 C-N-CA 124.251 1.02 . . . . 10.0 108.417 178.396 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 59.1 mt -53.97 -38.39 64.97 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 125.108 1.363 . . . . 10.0 111.166 173.491 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.2 m -152.17 151.89 31.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 108.475 -0.935 . . . . 10.0 108.475 -176.095 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.3 -97.17 0.19 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.295 -1.922 . . . . 10.0 108.295 -174.825 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -122.31 -51.1 1.99 Allowed 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 127.066 2.146 . . . . 10.0 107.935 177.523 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.8 m-70 -73.56 -35.7 65.52 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 114.959 -1.019 . . . . 10.0 108.258 -169.695 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.4 t 42.47 61.47 2.02 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 125.839 1.656 . . . . 10.0 112.951 167.289 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.7 pp -68.71 -9.14 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 113.697 0.999 . . . . 10.0 113.697 -171.633 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 10.5 mm -47.09 133.37 3.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.957 -0.757 . . . . 10.0 108.957 168.893 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.3 -7.49 75.52 Favored Glycine 0 CA--C 1.533 1.156 0 CA-C-O 118.851 -0.972 . . . . 10.0 114.51 -178.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.7 mtp-105 -76.26 175.33 9.15 Favored 'General case' 0 CA--C 1.544 0.74 0 CA-C-N 119.843 1.821 . . . . 10.0 106.858 168.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -127.78 132.23 49.53 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 119.091 0.86 . . . . 10.0 112.006 -170.586 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.407 HD22 ' N ' ' A' ' 117' ' ' LEU . 3.6 mm? -85.23 148.29 26.16 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 123.997 0.919 . . . . 10.0 108.533 171.863 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 91.9 t -133.32 128.4 55.36 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.636 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -95.58 123.99 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 106.164 -1.791 . . . . 10.0 106.164 166.943 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.628 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.5 m-70 -98.86 159.72 14.76 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.963 1.468 . . . . 10.0 114.963 -172.805 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -40.47 -58.21 1.62 Allowed 'General case' 0 N--CA 1.447 -0.579 0 C-N-CA 128.415 2.686 . . . . 10.0 110.362 172.385 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -121.44 170.97 9.13 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 113.865 1.061 . . . . 10.0 113.865 -168.209 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.29 136.69 58.13 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 113.938 -1.483 . . . . 10.0 109.072 172.673 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -76.93 148.68 36.22 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.77 0.795 . . . . 10.0 110.634 -179.877 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -81.82 -41.61 20.84 Favored 'General case' 0 N--CA 1.447 -0.625 0 C-N-CA 130.977 3.711 . . . . 10.0 108.955 -176.746 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 16.8 mt 61.29 43.85 10.33 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.451 0.7 . . . . 10.0 112.172 -178.049 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.01 19.55 77.21 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 113.991 0.356 . . . . 10.0 113.991 169.585 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -86.83 -21.8 26.21 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.534 1.133 . . . . 10.0 110.884 172.471 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -56.43 -30.02 58.02 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.777 0.703 . . . . 10.0 111.805 178.578 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.67 30.19 71.75 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.351 -1.1 . . . . 10.0 110.351 -176.124 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.4 166.6 12.46 Favored 'General case' 0 CA--C 1.511 -0.538 0 N-CA-C 108.594 -0.891 . . . . 10.0 108.594 173.006 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -48.67 -54.56 14.3 Favored 'General case' 0 N--CA 1.431 -1.389 0 C-N-CA 124.511 1.125 . . . . 10.0 108.517 176.006 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -51.6 -47.3 63.66 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 124.131 0.973 . . . . 10.0 112.2 173.644 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.9 p -52.67 -37.67 59.15 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 118.991 -0.528 . . . . 10.0 109.94 -179.223 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.251 14.8 t -90.67 0.57 57.35 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 113.807 1.04 . . . . 10.0 113.807 -179.26 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -111.99 -53.37 2.71 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.77 1.628 . . . . 10.0 112.596 -179.354 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.3 p -129.41 5.4 5.2 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 119.807 1.185 . . . . 10.0 111.862 171.342 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 81.52 -118.54 4.65 Favored Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 103.264 -3.934 . . . . 10.0 103.264 -167.181 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -168.81 39.14 0.03 OUTLIER 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 126.247 1.819 . . . . 10.0 107.789 -178.401 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.67 0.11 13.85 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.585 1.154 . . . . 10.0 111.792 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.15 -163.59 50.73 Favored Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 110.437 -1.065 . . . . 10.0 110.437 171.261 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.3 m -56.34 140.38 45.45 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 123.835 0.854 . . . . 10.0 111.798 -168.717 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -65.36 72.82 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.567 1.147 . . . . 10.0 110.068 169.709 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 6.0 tp -44.67 -45.53 9.75 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.991 1.716 . . . . 10.0 112.121 -175.685 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.88 145.93 20.19 Favored 'General case' 0 C--O 1.234 0.281 0 N-CA-C 108.199 -1.038 . . . . 10.0 108.199 -175.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 m -139.6 152.64 46.98 Favored 'General case' 0 CA--C 1.518 -0.259 0 C-N-CA 123.12 0.568 . . . . 10.0 109.974 -169.125 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -149.81 145.42 13.54 Favored Glycine 0 C--N 1.338 0.652 0 N-CA-C 110.536 -1.026 . . . . 10.0 110.536 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 23.8 t -102.07 138.04 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 106.335 -1.728 . . . . 10.0 106.335 -175.319 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 48.5 mt -76.04 107.74 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 N-CA-C 109.917 -0.401 . . . . 10.0 109.917 -173.457 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.8 164.52 12.04 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.574 1.559 . . . . 10.0 111.635 178.465 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.4 mt -64.37 143.67 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 C-N-CA 124.93 1.292 . . . . 10.0 111.495 -177.908 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -136.72 162.27 33.65 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 107.404 -1.332 . . . . 10.0 107.404 167.542 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 . . . . . 0 C--O 1.251 1.162 0 N-CA-C 104.256 -2.498 . . . . 10.0 104.256 166.884 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.49 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 10.0 t -105.54 -27.77 11.19 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 126.041 1.737 . . . . 10.0 111.743 170.009 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 71.8 tttt -131.05 137.06 48.98 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.846 0.859 . . . . 10.0 109.354 179.421 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.93 161.0 30.9 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 123.375 0.67 . . . . 10.0 110.083 170.792 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 3.6 t -120.45 154.66 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 C-N-CA 126.354 1.861 . . . . 10.0 108.874 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.46 108.57 4.77 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.33 -1.359 . . . . 10.0 107.33 167.86 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 53' ' ' ASN . 3.7 m -98.72 121.74 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 109.303 -0.629 . . . . 10.0 109.303 177.909 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.76 133.58 43.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 118.611 -0.709 . . . . 10.0 109.89 -175.266 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.3 mtpt -144.41 156.89 44.42 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 119.368 0.985 . . . . 10.0 109.153 167.447 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -175.47 -59.59 0.06 OUTLIER Glycine 0 N--CA 1.461 0.312 0 C-N-CA 119.696 -1.24 . . . . 10.0 113.861 169.776 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -71.12 -42.85 68.69 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -174.882 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.5 -70.05 0.41 Allowed Glycine 0 CA--C 1.523 0.532 0 CA-C-N 114.157 -1.383 . . . . 10.0 110.35 169.207 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.83 -36.82 99.0 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 123.338 2.692 . . . . 10.0 111.357 172.393 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.7 91.16 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.11 0 C-N-CA 125.804 1.641 . . . . 10.0 107.802 177.098 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -117.82 112.39 20.33 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 125.205 1.402 . . . . 10.0 107.934 176.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.434 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -108.48 148.95 16.86 Favored Glycine 0 N--CA 1.432 -1.592 0 CA-C-N 114.137 -1.392 . . . . 10.0 111.328 -178.338 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.516 HG22 HG22 ' A' ' 54' ' ' THR . 1.2 mt -151.42 84.11 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.332 1.853 . . . . 10.0 107.107 -169.907 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.0 mm -97.01 149.89 4.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 C-N-CA 124.914 1.286 . . . . 10.0 110.566 179.708 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.18 111.66 11.62 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 128.901 2.88 . . . . 10.0 108.382 -178.031 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -98.29 111.02 23.5 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 117.435 -1.269 . . . . 10.0 107.845 172.948 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 63.1 mt-10 -108.77 108.55 19.41 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.365 0.984 . . . . 10.0 112.271 174.073 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -103.87 96.21 6.53 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.588 1.955 . . . . 10.0 107.153 174.442 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 65.6 mttt -59.19 -50.22 74.85 Favored 'General case' 0 CA--C 1.518 -0.273 0 C-N-CA 123.946 0.898 . . . . 10.0 110.637 -169.052 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -135.13 171.56 14.25 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 102.755 -3.054 . . . . 10.0 102.755 -176.524 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.5 p -71.92 -18.25 62.04 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 119.174 0.897 . . . . 10.0 109.467 173.893 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -78.93 -19.35 52.01 Favored 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 123.606 0.763 . . . . 10.0 110.796 172.397 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.21 123.1 9.19 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 110.024 -1.231 . . . . 10.0 110.024 -175.876 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.8 127.79 18.58 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 N-CA-C 107.045 -1.944 . . . . 10.0 107.045 169.832 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 12.5 p -76.46 85.81 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-O 122.432 1.11 . . . . 10.0 108.349 -174.36 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 mtpt -58.82 111.31 1.24 Allowed 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 105.692 -1.966 . . . . 10.0 105.692 169.607 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 p -102.07 101.87 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.754 0 C-N-CA 126.219 1.807 . . . . 10.0 106.395 -177.64 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -116.18 174.4 6.07 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 116.319 -0.401 . . . . 10.0 111.385 176.531 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.03 -156.01 26.72 Favored Glycine 0 C--N 1.331 0.264 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 169.294 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.2 p -149.71 146.56 27.29 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.451 0.644 . . . . 10.0 112.595 -172.373 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.616 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -120.95 115.41 46.75 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.329 0 C-N-CA 125.909 1.684 . . . . 10.0 108.693 169.774 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.0 tttt -102.49 143.1 32.63 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 108.37 -0.974 . . . . 10.0 108.37 169.746 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.72 9.35 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 124.562 1.077 . . . . 10.0 112.969 170.332 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 mt -87.77 -175.67 5.24 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.961 0.886 . . . . 10.0 110.571 -171.274 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 8.9 t -102.72 155.78 18.08 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 167.516 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -53.54 159.09 1.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.589 1.156 . . . . 10.0 111.793 -174.878 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.71 -177.15 35.59 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 123.717 0.675 . . . . 10.0 111.803 170.608 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -66.56 149.82 49.9 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 125.46 1.504 . . . . 10.0 112.373 -177.861 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.6 m-70 -146.8 142.28 27.56 Favored 'General case' 0 C--N 1.344 0.352 0 N-CA-C 114.267 1.21 . . . . 10.0 114.267 -177.467 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.683 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -30.99 125.62 0.17 Allowed Glycine 0 C--N 1.343 0.943 0 C-N-CA 127.74 2.59 . . . . 10.0 113.03 165.679 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.67 105.12 2.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 119.343 1.572 . . . . 10.0 113.002 168.577 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.13 172.74 15.31 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.156 0.503 . . . . 10.0 111.501 179.64 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 6.0 m -93.99 149.93 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 113.156 -1.838 . . . . 10.0 108.408 169.299 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 24.2 m-70 -130.94 140.31 50.16 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.719 1.608 . . . . 10.0 106.888 174.795 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -52.76 -54.86 27.92 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 125.27 1.428 . . . . 10.0 112.327 -169.721 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -77.62 114.59 16.61 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -61.05 -32.16 79.29 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.261 -1.136 . . . . 10.0 110.261 172.257 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.636 ' HA ' HG11 ' A' ' 5' ' ' VAL . 25.3 t0 -32.16 125.35 0.29 Allowed 'General case' 0 CA--C 1.509 -0.602 0 C-N-CA 125.296 1.439 . . . . 10.0 112.548 172.282 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -129.69 11.36 5.7 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 113.967 -1.47 . . . . 10.0 111.401 176.628 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.428 HG22 ' CG2' ' A' ' 17' ' ' ILE . 8.2 p -37.17 -63.27 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 125.972 1.709 . . . . 10.0 113.309 -175.477 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -74.67 -16.03 60.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.444 -1.253 . . . . 10.0 111.89 -174.458 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 136.11 -75.57 0.4 Allowed Glycine 0 CA--C 1.521 0.464 0 N-CA-C 109.004 -1.638 . . . . 10.0 109.004 177.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 9.3 t -157.0 18.65 0.3 Allowed 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 112.734 0.642 . . . . 10.0 112.734 -172.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 4.0 p -99.07 -57.43 2.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 105.718 -1.956 . . . . 10.0 105.718 -176.527 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -55.64 -25.77 40.84 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.424 1.89 . . . . 10.0 111.81 -179.409 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.14 -29.64 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 127.953 2.501 . . . . 10.0 114.226 168.349 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.61 154.96 28.28 Favored Glycine 0 C--N 1.34 0.752 0 N-CA-C 109.359 -1.496 . . . . 10.0 109.359 170.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -74.12 -170.84 0.77 Allowed 'Trans proline' 0 N--CA 1.446 -1.315 0 N-CA-C 107.787 -1.659 . . . . 10.0 107.787 168.778 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.428 ' CE1' ' HA ' ' B' ' 137' ' ' THR . 27.1 m170 -80.95 60.67 4.25 Favored 'General case' 0 CA--C 1.537 0.444 0 O-C-N 120.658 -1.276 . . . . 10.0 109.827 -177.079 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -73.67 72.71 1.48 Allowed 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 122.117 0.96 . . . . 10.0 109.698 174.408 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -73.16 135.06 79.99 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.636 -0.665 . . . . 10.0 110.042 173.271 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.18 -44.56 4.82 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 122.57 2.18 . . . . 10.0 110.867 -177.426 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 85.8 mt -72.63 67.85 0.8 Allowed 'General case' 0 C--O 1.225 -0.234 0 C-N-CA 123.481 0.712 . . . . 10.0 109.312 175.067 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 40.5 p -37.03 108.67 0.08 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 125.853 1.661 . . . . 10.0 111.054 -179.187 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.83 173.03 12.05 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 103.086 -2.931 . . . . 10.0 103.086 -170.568 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.418 ' NZ ' ' OE2' ' B' ' 78' ' ' GLU . 6.7 mptt -80.06 152.44 29.37 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 117.341 -1.743 . . . . 10.0 107.99 170.338 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.432 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 79.1 t60 -63.27 103.2 0.47 Allowed 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.398 -0.964 . . . . 10.0 108.398 165.596 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.37 -127.34 4.05 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.156 -1.977 . . . . 10.0 108.156 177.718 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.7 -163.83 32.47 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 108.377 -1.889 . . . . 10.0 108.377 173.346 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -63.29 -5.5 8.27 Favored 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 119.832 1.816 . . . . 10.0 110.793 167.499 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -87.53 -26.09 23.33 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 125.407 1.483 . . . . 10.0 110.076 175.131 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -98.94 158.36 15.7 Favored 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 106.798 -1.556 . . . . 10.0 106.798 179.299 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -79.0 -32.38 45.14 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 107.421 -1.326 . . . . 10.0 107.421 168.541 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . 0.418 ' OE2' ' NZ ' ' B' ' 70' ' ' LYS . 1.4 pt-20 -114.5 51.36 0.89 Allowed 'General case' 0 N--CA 1.447 -0.604 0 C-N-CA 124.26 1.024 . . . . 10.0 111.018 -168.684 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -61.43 164.53 5.58 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.589 1.556 . . . . 10.0 110.689 169.159 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.432 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 9.9 m170 -66.59 -63.09 1.14 Allowed 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.418 0.525 . . . . 10.0 112.418 -170.022 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 8.2 p -171.65 -47.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.19 0.996 . . . . 10.0 109.818 -178.092 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.59 72.28 0.37 Allowed Glycine 0 C--N 1.336 0.572 0 N-CA-C 107.149 -2.38 . . . . 10.0 107.149 176.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.05 98.11 5.83 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 105.497 -2.038 . . . . 10.0 105.497 -173.358 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 40.5 mt -80.72 5.92 14.35 Favored 'General case' 0 N--CA 1.463 0.177 0 C-N-CA 122.678 0.391 . . . . 10.0 111.774 -169.844 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 82.65 -106.36 2.73 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 107.475 -2.25 . . . . 10.0 107.475 -174.582 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -158.65 152.53 23.54 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.125 0.97 . . . . 10.0 110.248 -177.146 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -122.74 133.99 67.23 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 123.275 0.63 . . . . 10.0 110.174 -176.402 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -78.57 133.23 37.35 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 126.546 1.938 . . . . 10.0 109.266 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.29 132.56 50.41 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.548 1.939 . . . . 10.0 110.155 169.726 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -63.6 171.22 2.72 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.993 1.717 . . . . 10.0 111.145 168.733 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . 0.417 ' NZ ' ' OD1' ' B' ' 92' ' ' ASP . 17.9 pttp -49.07 -35.03 14.95 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 124.565 1.146 . . . . 10.0 110.647 169.535 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.417 ' OD1' ' NZ ' ' B' ' 91' ' ' LYS . 0.1 OUTLIER -77.9 -3.15 40.28 Favored 'General case' 0 C--N 1.342 0.249 0 O-C-N 122.326 -0.234 . . . . 10.0 110.535 -175.919 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.68 22.88 78.75 Favored Glycine 0 N--CA 1.444 -0.797 0 N-CA-C 109.469 -1.452 . . . . 10.0 109.469 -175.289 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.0 t -96.21 106.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.86 0 C-N-CA 127.57 2.348 . . . . 10.0 105.093 173.438 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.616 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.44 125.05 48.03 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.287 -1.005 . . . . 10.0 108.287 169.341 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -94.68 121.33 36.15 Favored 'General case' 0 N--CA 1.435 -1.179 0 C-N-CA 127.838 2.455 . . . . 10.0 108.832 179.308 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 43.3 t -101.26 135.81 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 C-N-CA 124.767 1.227 . . . . 10.0 108.147 177.326 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 79.8 p -158.26 72.43 0.62 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.945 1.298 . . . . 10.0 109.408 169.689 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -106.38 162.46 5.23 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 107.565 -1.272 . . . . 10.0 107.565 -179.036 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -146.13 136.46 23.87 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.584 1.554 . . . . 10.0 109.568 175.69 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -134.02 142.34 47.58 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.091 -1.818 . . . . 10.0 106.091 173.759 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 75.2 p -103.5 51.48 0.79 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.868 1.267 . . . . 10.0 107.811 174.228 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.32 -47.91 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.323 0.649 . . . . 10.0 110.377 -176.97 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.47 118.26 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 171.431 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.1 m -120.62 112.67 19.19 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 108.562 -0.903 . . . . 10.0 108.562 -176.658 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 77.4 mt -56.81 -43.97 81.51 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 121.457 0.646 . . . . 10.0 110.41 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.0 m -156.5 83.5 0.97 Allowed 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 106.68 -1.6 . . . . 10.0 106.68 -174.358 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -147.65 -61.53 0.01 OUTLIER Glycine 0 C--N 1.334 0.435 0 N-CA-C 111.062 -0.815 . . . . 10.0 111.062 -170.328 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -153.95 -52.88 0.1 Allowed 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 126.02 1.728 . . . . 10.0 106.827 -175.799 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -77.57 -34.95 53.52 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.868 -1.16 . . . . 10.0 107.868 -175.218 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 6.9 t 56.14 61.48 2.73 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 125.135 1.374 . . . . 10.0 108.112 173.084 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 31.0 mm -73.57 -14.06 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 CA-C-N 113.543 -1.662 . . . . 10.0 112.228 -168.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.5 mm -51.48 147.32 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 N-CA-C 109.363 -0.606 . . . . 10.0 109.363 169.696 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 81.81 2.44 90.54 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 121.357 -0.84 . . . . 10.0 114.592 178.815 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 54.4 mmt-85 -77.58 163.31 26.37 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 118.914 1.357 . . . . 10.0 108.716 168.626 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.1 118.17 35.24 Favored 'General case' 0 C--N 1.34 0.153 0 N-CA-C 109.287 -0.634 . . . . 10.0 109.287 170.51 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.426 HD21 HD11 ' B' ' 149' ' ' ILE . 4.5 mm? -75.49 142.99 42.79 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.048 -1.464 . . . . 10.0 107.048 167.184 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.64 129.36 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.831 0 N-CA-C 108.043 -1.095 . . . . 10.0 108.043 172.04 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.42 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.7 p -97.35 135.3 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.715 0 N-CA-C 107.96 -1.126 . . . . 10.0 107.96 169.275 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.683 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.8 m170 -115.02 159.72 20.46 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 116.465 2.024 . . . . 10.0 116.465 -175.891 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -48.92 -58.38 4.95 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 129.832 3.253 . . . . 10.0 111.932 177.071 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 54.8 mttp -111.93 173.46 6.35 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.966 0.906 . . . . 10.0 112.804 -169.874 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.05 136.04 35.26 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 126.524 1.929 . . . . 10.0 110.304 -179.165 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.69 144.22 32.42 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 113.362 0.875 . . . . 10.0 113.362 -169.558 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -74.9 -38.56 61.82 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 125.187 1.395 . . . . 10.0 109.206 177.855 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.8 mt 62.12 49.92 4.23 Favored 'General case' 0 C--N 1.337 0.054 0 C-N-CA 125.21 1.404 . . . . 10.0 110.006 -172.259 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 82.82 -45.58 3.45 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.562 1.077 . . . . 10.0 110.988 170.638 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 18.5 pttp -73.43 21.63 0.08 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.83 1.652 . . . . 10.0 112.72 -175.147 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -77.91 -32.71 43.99 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 126.475 1.988 . . . . 10.0 108.298 166.103 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.22 19.08 69.97 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.284 -0.731 . . . . 10.0 111.859 -179.124 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -112.07 162.27 15.59 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 104.839 -2.282 . . . . 10.0 104.839 169.215 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . 0.454 ' CD ' ' HZ1' ' B' ' 136' ' ' LYS . 15.6 tm-20 -60.92 -40.04 91.7 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 119.505 -0.878 . . . . 10.0 110.748 -169.849 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -69.12 -28.28 66.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-O 118.749 -0.643 . . . . 10.0 112.242 177.529 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -48.76 -47.47 41.64 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 119.68 1.127 . . . . 10.0 110.242 168.852 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.4 t -85.1 -10.15 57.15 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 118.461 -0.781 . . . . 10.0 112.711 -171.366 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.454 ' HZ1' ' CD ' ' B' ' 132' ' ' GLU . 1.1 ttmp? -100.61 -92.34 0.3 Allowed 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.69 1.596 . . . . 10.0 108.15 175.292 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.428 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 44.5 p -86.26 1.35 51.23 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 122.135 2.243 . . . . 10.0 112.744 -176.062 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 76.58 21.89 73.88 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 120.416 1.462 . . . . 10.0 110.79 -167.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 61.72 19.92 10.93 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 119.577 1.688 . . . . 10.0 112.854 169.649 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -80.29 9.96 5.12 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 113.623 0.972 . . . . 10.0 113.623 -168.021 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.72 -165.07 53.94 Favored Glycine 0 N--CA 1.444 -0.781 0 O-C-N 121.252 -0.905 . . . . 10.0 111.502 170.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.5 m -59.3 135.63 57.71 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 124.1 0.96 . . . . 10.0 112.901 -167.705 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -67.23 86.99 0.16 Allowed 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 125.129 1.372 . . . . 10.0 110.276 174.042 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 58.5 mt -60.85 -35.12 75.76 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.827 0.676 . . . . 10.0 112.827 -177.19 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.42 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -158.39 154.35 26.81 Favored 'General case' 0 C--O 1.234 0.244 0 O-C-N 121.625 -0.672 . . . . 10.0 111.495 179.932 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -123.55 152.36 41.9 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 125.857 1.663 . . . . 10.0 109.088 -178.674 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.57 156.04 26.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.413 -1.075 . . . . 10.0 110.413 168.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 66.1 t -109.58 140.07 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 -175.588 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.426 HD11 HD21 ' B' ' 117' ' ' LEU . 27.6 mt -75.62 125.15 34.92 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-O 118.594 -0.717 . . . . 10.0 109.764 -178.622 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -133.81 162.76 24.48 Favored Glycine 0 CA--C 1.53 1.022 0 C-N-CA 124.383 0.992 . . . . 10.0 113.569 -178.573 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.8 mm -73.34 144.91 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 124.274 1.03 . . . . 10.0 111.226 -169.904 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.96 -47.2 2.18 Favored 'General case' 0 CA--C 1.51 -0.592 0 CA-C-N 118.45 0.568 . . . . 10.0 111.433 166.652 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 116.38 -1.771 . . . . 10.0 107.544 175.78 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.659 0 N-CA-C 106.625 -1.62 . . . . 10.0 106.625 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.7 t -151.55 -48.44 0.11 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 119.12 0.873 . . . . 10.0 110.7 178.686 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 40.8 tttt -132.87 153.64 51.14 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.2 -1.778 . . . . 10.0 106.2 172.59 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.22 151.18 43.55 Favored 'General case' 0 CA--C 1.513 -0.46 0 N-CA-C 108.93 -0.767 . . . . 10.0 108.93 169.286 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.38 161.12 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 O-C-N 124.061 0.851 . . . . 10.0 110.223 172.464 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.432 ' CB ' HD12 ' A' ' 117' ' ' LEU . . . -147.41 98.96 3.07 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.206 -1.775 . . . . 10.0 106.206 165.703 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.481 HG21 ' HB3' ' B' ' 53' ' ' ASN . 7.5 m -93.29 98.02 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 122.844 0.458 . . . . 10.0 110.687 -179.204 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.415 HD12 ' N ' ' A' ' 8' ' ' LEU . 5.5 mp -79.6 136.26 36.8 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 121.227 -0.921 . . . . 10.0 109.833 -175.756 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -144.73 156.15 43.92 Favored 'General case' 0 C--N 1.341 0.212 0 C-N-CA 124.426 1.09 . . . . 10.0 108.344 168.346 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.6 -69.08 0.02 OUTLIER Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.185 -0.531 . . . . 10.0 112.166 169.252 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -74.24 -41.51 61.2 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 107.179 -1.415 . . . . 10.0 107.179 -175.656 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.91 -67.67 0.48 Allowed Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 114.996 -1.002 . . . . 10.0 111.588 176.969 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -55.15 -42.05 72.58 Favored 'Trans proline' 0 N--CA 1.45 -1.077 0 C-N-CA 121.972 1.782 . . . . 10.0 110.077 175.846 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.668 HG13 HD12 ' A' ' 38' ' ' LEU . 47.9 t -58.49 87.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 C-N-CA 126.182 1.793 . . . . 10.0 108.034 175.197 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.47 116.95 31.75 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 105.709 -1.96 . . . . 10.0 105.709 171.453 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.91 142.89 15.97 Favored Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 108.656 -1.778 . . . . 10.0 108.656 174.258 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.972 ' CG2' HG22 ' B' ' 54' ' ' THR . 7.1 mt -138.71 60.81 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 N-CA-C 107.357 -1.349 . . . . 10.0 107.357 -169.684 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.4 mm -77.87 133.56 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 N-CA-C 108.801 -0.814 . . . . 10.0 108.801 -176.072 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m-80 -122.44 105.11 9.87 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.203 2.201 . . . . 10.0 107.22 -176.805 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -89.1 136.44 33.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.499 1.12 . . . . 10.0 108.025 177.749 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -117.49 148.29 41.97 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 123.703 0.627 . . . . 10.0 110.701 168.191 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -122.46 107.14 11.69 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.7 1.6 . . . . 10.0 108.01 168.816 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -65.91 -59.2 4.08 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.974 0.91 . . . . 10.0 110.644 -178.492 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 27.1 mp0 -128.22 168.02 16.04 Favored 'General case' 0 N--CA 1.425 -1.725 0 N-CA-C 103.608 -2.738 . . . . 10.0 103.608 174.079 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.2 p -65.98 -25.74 67.24 Favored 'General case' 0 N--CA 1.44 -0.937 0 O-C-N 121.748 -0.595 . . . . 10.0 109.429 174.759 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -98.69 -6.33 29.85 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.207 1.403 . . . . 10.0 110.828 -173.361 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.63 144.57 21.4 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 -173.772 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -64.02 139.42 67.29 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 121.721 1.614 . . . . 10.0 108.101 170.525 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 m -93.12 142.51 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 108.587 -0.894 . . . . 10.0 108.587 -176.861 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -108.06 123.21 48.35 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 104.298 -2.482 . . . . 10.0 104.298 166.606 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 m -108.99 103.45 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 105.916 -1.883 . . . . 10.0 105.916 -179.371 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 8.0 p90 -114.44 171.82 7.39 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 -176.298 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.65 -154.4 25.53 Favored Glycine 0 N--CA 1.447 -0.618 0 N-CA-C 108.537 -1.825 . . . . 10.0 108.537 169.076 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 m -153.54 150.24 28.5 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 117.124 0.462 . . . . 10.0 110.899 177.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.61 HG12 ' HB3' ' A' ' 95' ' ' ALA . 0.0 OUTLIER -111.17 112.65 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.676 0 C-N-CA 127.356 2.263 . . . . 10.0 106.861 168.493 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.5 ptmt -121.73 90.3 3.28 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 112.214 0.45 . . . . 10.0 112.214 -178.276 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.65 32.35 0.02 OUTLIER Glycine 0 CA--C 1.52 0.406 0 CA-C-O 118.981 -0.9 . . . . 10.0 113.996 174.032 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.668 HD12 HG13 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -125.06 175.41 7.37 Favored 'General case' 0 C--O 1.224 -0.246 0 N-CA-C 108.237 -1.023 . . . . 10.0 108.237 177.144 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.7 t -75.6 168.54 19.81 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 118.83 0.741 . . . . 10.0 110.844 177.712 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 65.1 tt0 -61.02 173.3 0.81 Allowed 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.21 1.804 . . . . 10.0 111.288 -176.874 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.14 179.73 49.73 Favored Glycine 0 CA--C 1.522 0.52 0 C-N-CA 123.781 0.705 . . . . 10.0 112.017 168.897 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.0 mp -66.02 143.56 57.28 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.376 1.07 . . . . 10.0 110.275 178.449 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 80.0 m-70 -140.39 146.5 38.45 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 113.384 0.883 . . . . 10.0 113.384 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.661 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -29.25 122.72 0.09 OUTLIER Glycine 0 C--N 1.341 0.851 0 C-N-CA 127.547 2.499 . . . . 10.0 112.269 165.25 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -150.62 106.01 3.37 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 120.034 1.917 . . . . 10.0 113.12 169.758 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.419 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.43 175.18 12.99 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.509 0.671 . . . . 10.0 112.803 -176.497 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.402 HG12 ' CD2' ' A' ' 117' ' ' LEU . 1.7 m -91.42 153.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 112.655 -2.066 . . . . 10.0 106.3 166.499 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -127.32 123.27 35.94 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 102.884 -3.006 . . . . 10.0 102.884 169.113 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -61.33 -35.03 76.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 114.894 1.442 . . . . 10.0 114.894 -164.571 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-30 -75.91 119.54 20.02 Favored 'General case' 0 C--N 1.342 0.251 0 C-N-CA 117.285 -1.766 . . . . 10.0 106.984 169.576 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.01 37.08 0.92 Allowed Glycine 0 CA--C 1.525 0.676 0 C-N-CA 125.041 1.305 . . . . 10.0 111.241 168.883 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -107.55 171.56 7.32 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 124.899 1.279 . . . . 10.0 107.697 177.459 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.439 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.4 OUTLIER -161.1 25.65 0.14 Allowed 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 114.653 -1.158 . . . . 10.0 112.231 168.747 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.442 ' CG2' HG22 ' B' ' 17' ' ' ILE . 0.2 OUTLIER -55.39 -36.96 66.97 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.451 1.1 . . . . 10.0 111.253 -170.481 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.38 -19.6 55.95 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 124.022 0.929 . . . . 10.0 112.468 -179.695 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 87.04 97.87 0.85 Allowed Glycine 0 CA--C 1.528 0.866 0 N-CA-C 109.02 -1.632 . . . . 10.0 109.02 -169.698 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 59.2 m 43.11 55.17 4.67 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.032 1.733 . . . . 10.0 113.962 173.074 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.76 -49.62 0.08 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.078 0.551 . . . . 10.0 110.139 176.034 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 47.4 t -60.8 -28.89 69.12 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 122.44 0.296 . . . . 10.0 111.059 -173.314 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -40.42 -28.97 0.07 Allowed 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 127.448 2.299 . . . . 10.0 115.156 179.758 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.57 134.26 8.41 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-O 118.449 -1.195 . . . . 10.0 110.528 170.994 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -78.46 62.24 8.14 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 123.211 2.607 . . . . 10.0 112.319 -174.315 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 14.0 m170 61.74 28.02 17.21 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.511 2.324 . . . . 10.0 110.581 177.372 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -53.72 -39.05 64.91 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 113.871 1.064 . . . . 10.0 113.871 -166.67 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 34.27 172.23 0.0 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 128.807 2.843 . . . . 10.0 115.518 -169.662 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -67.81 -65.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.349 0.573 0 O-C-N 118.621 -1.305 . . . . 10.0 110.849 -172.781 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.0 74.52 2.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 108.182 -1.044 . . . . 10.0 108.182 169.006 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 p -47.89 113.76 0.78 Allowed 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.048 0.939 . . . . 10.0 108.946 169.487 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 40.6 mtt180 -133.13 -167.06 1.85 Allowed 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 105.783 -1.932 . . . . 10.0 105.783 -178.465 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.81 137.54 33.66 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 118.046 -1.462 . . . . 10.0 110.304 -171.022 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 65.8 t60 -47.15 119.66 2.71 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 120.337 -0.545 . . . . 10.0 110.517 168.218 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.61 -143.76 4.22 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 108.636 -1.786 . . . . 10.0 108.636 177.583 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.61 -149.94 6.86 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-O 118.158 -1.357 . . . . 10.0 109.981 175.431 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 79.7 Cg_endo -69.27 14.68 0.22 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 122.162 1.908 . . . . 10.0 111.415 169.287 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.0 mtpm? -110.08 -10.78 14.67 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 124.616 1.166 . . . . 10.0 110.075 169.592 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -111.41 158.55 18.96 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.369 -1.345 . . . . 10.0 107.369 -179.176 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -79.41 -36.86 38.42 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.653 -1.24 . . . . 10.0 107.653 173.033 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -96.8 -49.7 4.96 Favored 'General case' 0 CA--C 1.498 -1.024 0 CA-C-O 121.453 0.644 . . . . 10.0 112.137 -166.3 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 7.1 ptp180 41.52 -141.4 0.09 Allowed 'General case' 0 N--CA 1.434 -1.253 0 CA-C-N 113.709 -1.587 . . . . 10.0 109.108 -169.478 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -112.12 44.56 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 O-C-N 120.611 -1.306 . . . . 10.0 108.073 166.511 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.9 t 37.8 38.96 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 124.081 0.953 . . . . 10.0 111.04 -167.596 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 70.69 0.02 OUTLIER Glycine 0 CA--C 1.533 1.195 0 O-C-N 121.541 -0.724 . . . . 10.0 112.431 -174.002 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -136.94 111.15 8.39 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 104.008 -2.59 . . . . 10.0 104.008 168.181 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 19.3 mt -72.19 -23.18 61.22 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 118.667 0.667 . . . . 10.0 109.225 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 111.11 -89.8 0.55 Allowed Glycine 0 N--CA 1.441 -1.025 0 N-CA-C 109.895 -1.282 . . . . 10.0 109.895 167.042 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 m-20 -147.8 126.44 12.53 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.325 -0.991 . . . . 10.0 108.325 -173.794 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.7 m -109.82 124.87 66.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 118.043 0.383 . . . . 10.0 110.097 176.293 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.1 m -79.51 111.39 15.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 127.245 2.218 . . . . 10.0 111.228 -176.825 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.56 129.75 34.75 Favored 'General case' 0 CA--C 1.518 -0.257 0 C-N-CA 123.176 0.59 . . . . 10.0 109.985 170.813 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -61.29 166.69 3.66 Favored 'General case' 0 N--CA 1.454 -0.272 0 O-C-N 124.574 1.171 . . . . 10.0 109.119 167.756 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.64 -26.0 54.92 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 123.91 0.884 . . . . 10.0 111.446 175.882 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -75.76 -10.62 59.59 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 120.583 0.23 . . . . 10.0 110.675 179.525 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.04 23.15 42.3 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.403 -1.079 . . . . 10.0 110.403 178.664 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 43.1 t -106.99 105.57 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.986 0 C-N-CA 128.359 2.664 . . . . 10.0 105.95 -178.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.61 ' HB3' HG12 ' A' ' 35' ' ' ILE . . . -102.83 121.46 42.52 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.668 -1.234 . . . . 10.0 107.668 168.635 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -92.32 132.63 36.56 Favored 'General case' 0 N--CA 1.434 -1.261 0 C-N-CA 127.188 2.195 . . . . 10.0 108.899 176.36 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.5 t -113.08 133.12 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.979 0 C-N-CA 125.298 1.439 . . . . 10.0 107.676 175.14 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.5 p -158.35 57.82 0.45 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.278 0.631 . . . . 10.0 110.688 169.651 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -104.79 155.15 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.101 0 N-CA-C 107.999 -1.112 . . . . 10.0 107.999 -173.986 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -122.2 156.41 33.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 124.746 1.218 . . . . 10.0 111.904 173.809 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -148.97 164.19 35.3 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.057 -1.428 . . . . 10.0 108.989 168.721 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.7 p -118.8 44.01 2.4 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 126.227 1.811 . . . . 10.0 110.364 -178.012 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.2 p -145.19 -43.46 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 118.255 0.48 . . . . 10.0 111.251 177.013 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.39 147.31 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.318 -1.364 . . . . 10.0 107.318 169.176 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.1 m -151.57 135.44 16.45 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.128 -1.064 . . . . 10.0 108.128 174.385 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -70.04 -38.16 75.77 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.832 0.853 . . . . 10.0 108.919 -179.593 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 22.6 m -137.75 130.22 29.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.74 -1.578 . . . . 10.0 106.74 170.335 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.91 -65.66 0.1 OUTLIER Glycine 0 C--N 1.333 0.369 0 N-CA-C 109.258 -1.537 . . . . 10.0 109.258 -177.941 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -163.06 -51.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.773 1.629 . . . . 10.0 107.703 -179.835 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.1 m-70 -74.1 -41.59 61.4 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 114.38 -1.282 . . . . 10.0 108.091 -169.64 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.9 t 41.11 74.25 0.11 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 126.477 1.911 . . . . 10.0 111.702 174.858 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -68.22 -3.64 2.64 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 N-CA-C 112.932 0.716 . . . . 10.0 112.932 -179.682 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.1 mm -33.02 -44.34 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 126.453 1.901 . . . . 10.0 114.042 173.421 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -109.89 38.81 3.14 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 124.185 0.898 . . . . 10.0 112.515 -176.748 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -102.78 176.69 5.08 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.475 1.51 . . . . 10.0 111.643 170.046 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 4.7 m -119.1 131.22 55.9 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.952 2.101 . . . . 10.0 106.36 177.85 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.432 HD12 ' CB ' ' A' ' 6' ' ' ALA . 58.7 mt -103.9 148.35 26.26 Favored 'General case' 0 CA--C 1.513 -0.48 0 C-N-CA 125.28 1.432 . . . . 10.0 109.324 172.285 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.2 t -136.36 134.36 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 O-C-N 123.71 0.631 . . . . 10.0 109.364 -178.593 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.39 135.63 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 N-CA-C 107.537 -1.282 . . . . 10.0 107.537 168.648 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.661 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 4.3 m170 -112.26 155.64 23.7 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 116.673 2.101 . . . . 10.0 116.673 -178.565 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -42.24 -62.93 0.83 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.779 3.231 . . . . 10.0 111.548 173.314 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 8.1 mtmt -106.89 172.41 6.84 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.993 1.317 . . . . 10.0 111.823 -177.298 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -74.4 150.96 39.76 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.994 -1.457 . . . . 10.0 109.605 172.459 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.419 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.3 m-20 -79.46 150.23 31.32 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.565 1.146 . . . . 10.0 112.495 177.317 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -74.36 -29.56 61.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.973 -1.467 . . . . 10.0 110.122 169.943 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 27.4 mt 54.97 44.27 28.53 Favored 'General case' 0 C--N 1.339 0.129 0 CA-C-O 121.847 0.832 . . . . 10.0 108.799 -167.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.38 -10.17 67.71 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 125.667 1.603 . . . . 10.0 113.151 173.204 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -78.33 -3.93 45.5 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 118.405 1.102 . . . . 10.0 113.117 -170.795 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -61.2 -38.62 95.94 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.813 -0.915 . . . . 10.0 110.813 175.152 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.43 33.45 81.88 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.114 -1.194 . . . . 10.0 110.114 -173.387 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -117.59 161.96 18.79 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 106.05 -1.833 . . . . 10.0 106.05 169.69 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -51.36 -48.87 62.36 Favored 'General case' 0 N--CA 1.428 -1.525 0 N-CA-C 108.721 -0.844 . . . . 10.0 108.721 170.773 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -59.04 -40.1 84.04 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.318 -0.401 . . . . 10.0 111.31 176.96 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 16.6 p -55.75 -40.15 72.16 Favored 'General case' 0 N--CA 1.443 -0.794 0 O-C-N 120.926 -1.109 . . . . 10.0 110.708 179.287 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -84.64 4.93 30.11 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 118.491 -0.766 . . . . 10.0 112.122 -178.265 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -112.83 -85.44 0.58 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.037 1.735 . . . . 10.0 110.091 175.022 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.4 p -111.43 30.87 6.56 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 121.088 1.767 . . . . 10.0 112.52 178.179 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.83 27.52 56.18 Favored Glycine 0 C--N 1.341 0.858 0 C-N-CA 123.757 0.694 . . . . 10.0 113.9 168.333 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 46.8 29.62 1.03 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.055 0.942 . . . . 10.0 113.01 -172.108 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.35 -4.57 18.77 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.228 -0.92 . . . . 10.0 112.24 -177.424 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.67 -161.92 50.17 Favored Glycine 0 N--CA 1.444 -0.812 0 O-C-N 121.129 -0.982 . . . . 10.0 111.315 169.212 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.1 m -55.12 128.39 33.57 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 114.644 -0.778 . . . . 10.0 112.842 -167.274 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 22.5 mtt85 -66.43 73.03 0.08 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.738 1.615 . . . . 10.0 109.758 172.078 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 35.1 mt -49.3 -36.82 21.94 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.595 1.158 . . . . 10.0 112.976 -175.722 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 152.1 24.72 Favored 'General case' 0 CA--C 1.513 -0.461 0 O-C-N 121.57 -0.706 . . . . 10.0 110.526 -177.877 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 74.0 m -130.87 145.66 52.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 124.821 1.326 . . . . 10.0 108.679 -175.661 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -135.48 141.28 12.46 Favored Glycine 0 C--N 1.332 0.314 0 N-CA-C 108.621 -1.792 . . . . 10.0 108.621 171.508 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -99.79 136.61 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 105.869 -1.9 . . . . 10.0 105.869 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 5.0 mt -72.09 158.93 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 N-CA-C 108.86 -0.792 . . . . 10.0 108.86 -177.072 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -172.67 168.66 41.75 Favored Glycine 0 CA--C 1.527 0.787 0 O-C-N 121.379 -0.826 . . . . 10.0 111.737 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 45.7 mt -53.19 142.31 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 125.451 1.5 . . . . 10.0 111.534 -174.209 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.83 163.64 36.79 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.665 0.745 . . . . 10.0 109.489 166.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 . . . . . 0 C--O 1.256 1.405 0 N-CA-C 104.7 -2.333 . . . . 10.0 104.7 166.636 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.848 0 CA-C-O 117.997 -1.002 . . . . 10.0 108.432 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -165.21 -45.32 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.837 0.855 . . . . 10.0 110.208 178.346 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mttt -136.69 154.27 50.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 125.245 1.418 . . . . 10.0 109.248 169.711 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.59 164.43 30.23 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.366 1.466 . . . . 10.0 107.528 168.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -134.3 157.95 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.524 -0.055 0 N-CA-C 109.327 -0.62 . . . . 10.0 109.327 -178.884 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.93 99.96 5.95 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.045 0.938 . . . . 10.0 109.502 172.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.439 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.2 OUTLIER -81.24 93.03 2.18 Favored 'Isoleucine or valine' 0 C--N 1.341 0.229 0 N-CA-C 108.265 -1.013 . . . . 10.0 108.265 167.966 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mt -84.71 136.68 33.62 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.474 1.11 . . . . 10.0 108.561 -178.732 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -159.74 161.64 34.79 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.441 -1.318 . . . . 10.0 107.441 173.771 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 176.38 -44.82 0.11 Allowed Glycine 0 C--O 1.227 -0.331 0 C-N-CA 119.813 -1.184 . . . . 10.0 113.473 168.938 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -74.1 -45.17 50.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.721 -1.215 . . . . 10.0 107.721 -176.0 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 144.22 -71.36 0.38 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.636 -1.386 . . . . 10.0 109.636 171.487 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -59.1 -37.52 92.12 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.303 2.669 . . . . 10.0 111.14 171.768 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.419 HG13 HD11 ' B' ' 38' ' ' LEU . 58.4 t -58.93 111.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 108.538 -0.912 . . . . 10.0 108.538 178.094 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -125.96 127.86 46.6 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 105.598 -2.001 . . . . 10.0 105.598 167.949 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.528 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -114.12 135.46 12.5 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 108.765 -1.734 . . . . 10.0 108.765 170.505 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.442 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.6 mt -134.97 68.07 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 106.706 -1.591 . . . . 10.0 106.706 -173.836 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.4 mm -97.59 139.82 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 115.145 -0.934 . . . . 10.0 110.467 -170.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -107.39 130.52 54.79 Favored 'General case' 0 CA--C 1.527 0.095 0 C-N-CA 126.833 2.053 . . . . 10.0 109.168 -176.183 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -116.75 100.38 7.76 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 107.376 -1.342 . . . . 10.0 107.376 177.91 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.47 156.89 17.37 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.33 0.514 . . . . 10.0 110.973 175.637 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 34.5 tp60 -154.2 65.49 0.7 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.979 1.312 . . . . 10.0 109.851 -177.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -142.04 92.64 2.46 Favored 'General case' 0 N--CA 1.432 -1.347 0 C-N-CA 124.86 1.264 . . . . 10.0 107.71 176.955 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -153.02 -170.12 3.53 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 103.557 -2.757 . . . . 10.0 103.557 166.709 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 29.2 m -89.92 -9.21 49.72 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 118.141 0.428 . . . . 10.0 111.055 174.843 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -128.68 8.94 5.87 Favored 'General case' 0 CA--C 1.529 0.15 0 C-N-CA 123.756 0.822 . . . . 10.0 111.355 -169.703 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 41.93 55.05 4.22 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 124.71 1.148 . . . . 10.0 115.419 179.637 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.71 104.06 1.67 Allowed 'Trans proline' 0 N--CA 1.445 -1.361 0 N-CA-C 105.939 -2.369 . . . . 10.0 105.939 168.339 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 t -77.67 78.95 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.502 -2.036 . . . . 10.0 105.502 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 17.3 ttmm -69.83 109.57 4.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.385 -1.709 . . . . 10.0 106.385 169.046 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.5 p -90.84 102.61 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 105.413 -2.069 . . . . 10.0 105.413 173.852 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.3 p90 -119.56 150.59 40.02 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.92 -160.92 32.93 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 109.502 -1.439 . . . . 10.0 109.502 169.293 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 29.1 p -147.47 115.15 6.39 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 108.898 -0.779 . . . . 10.0 108.898 -173.542 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.528 HG22 ' HA2' ' B' ' 16' ' ' GLY . 5.3 pt -80.19 179.15 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 108.748 -0.834 . . . . 10.0 108.748 168.146 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . 0.445 ' NZ ' ' OD2' ' B' ' 92' ' ' ASP . 0.2 OUTLIER -155.86 159.86 39.71 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 107.472 -1.307 . . . . 10.0 107.472 164.034 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.06 -12.63 57.46 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-O 119.13 -0.817 . . . . 10.0 113.96 170.106 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.485 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.5 mp -70.65 176.65 4.0 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 119.036 1.418 . . . . 10.0 109.237 171.736 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.0 t -90.13 167.11 12.98 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 108.431 -0.951 . . . . 10.0 108.431 167.778 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -62.17 170.38 2.28 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.706 0.802 . . . . 10.0 111.734 -170.683 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.39 -174.23 33.45 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 124.317 0.96 . . . . 10.0 112.285 168.611 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -71.85 141.89 49.6 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.185 0.994 . . . . 10.0 109.409 175.761 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 -140.82 148.92 41.34 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 114.7 1.37 . . . . 10.0 114.7 -179.368 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.553 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -36.85 127.05 1.09 Allowed Glycine 0 C--N 1.343 0.932 0 C-N-CA 127.649 2.547 . . . . 10.0 110.738 164.537 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.481 ' CD1' HD22 ' B' ' 84' ' ' LEU . 3.9 t80 -155.65 105.96 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 118.777 1.289 . . . . 10.0 109.055 168.485 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.49 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -156.05 175.34 14.1 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 113.893 1.072 . . . . 10.0 113.893 -178.2 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 29.0 m -90.04 151.58 3.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 113.771 -1.558 . . . . 10.0 110.265 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -142.42 137.75 30.61 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.592 1.557 . . . . 10.0 108.125 178.534 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -50.7 -57.14 9.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 114.944 1.461 . . . . 10.0 114.944 -169.103 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -78.46 123.13 26.7 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.92 -0.77 . . . . 10.0 108.92 -169.476 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.52 -30.53 77.88 Favored Glycine 0 CA--C 1.531 1.08 0 N-CA-C 107.444 -2.262 . . . . 10.0 107.444 165.6 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -45.81 142.58 2.46 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-O 123.303 1.525 . . . . 10.0 111.046 171.51 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.481 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -165.11 22.5 0.05 Allowed 'General case' 0 N--CA 1.434 -1.24 0 C-N-CA 126.05 1.74 . . . . 10.0 110.144 -169.573 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.972 HG22 ' CG2' ' A' ' 17' ' ' ILE . 1.3 p -53.16 -40.86 64.62 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 122.874 0.469 . . . . 10.0 112.11 -178.877 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.62 -18.31 54.7 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.227 0.611 . . . . 10.0 112.095 176.133 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.21 110.56 0.8 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.239 0.923 . . . . 10.0 111.986 -178.517 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 25.1 m 48.7 33.69 4.49 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.676 1.59 . . . . 10.0 112.336 172.492 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 22.3 m -138.18 -55.12 0.65 Allowed 'General case' 0 N--CA 1.437 -1.092 0 C-N-CA 126.296 1.838 . . . . 10.0 106.318 -173.591 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.2 m -67.04 -12.9 61.22 Favored 'General case' 0 C--N 1.341 0.236 0 C-N-CA 123.753 0.821 . . . . 10.0 111.722 178.041 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -42.31 -36.43 1.25 Allowed 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 126.961 2.104 . . . . 10.0 112.442 175.689 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.38 163.8 39.39 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 107.425 -2.27 . . . . 10.0 107.425 -178.644 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -74.73 -170.26 0.73 Allowed 'Trans proline' 0 N--CA 1.443 -1.463 0 C-N-CA 121.268 1.312 . . . . 10.0 109.252 172.2 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 38.3 m170 -78.6 58.7 2.29 Favored 'General case' 0 CA--C 1.538 0.515 0 O-C-N 121.269 -0.894 . . . . 10.0 110.572 -173.251 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -71.86 79.46 0.88 Allowed 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 123.096 1.427 . . . . 10.0 110.45 178.524 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . 0.44 ' HB3' HG22 ' B' ' 81' ' ' VAL . 15.3 p-10 -74.1 147.2 85.61 Favored Pre-proline 0 N--CA 1.445 -0.69 0 C-N-CA 125.015 1.326 . . . . 10.0 110.222 169.012 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -65.42 -43.53 10.5 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 122.319 2.013 . . . . 10.0 110.394 178.127 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 tt -78.14 56.82 1.71 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.024 0.93 . . . . 10.0 108.907 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 38.9 p -35.96 106.16 0.04 OUTLIER 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 126.055 1.742 . . . . 10.0 110.989 -173.098 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 2.8 ttt180 -133.29 -174.75 3.58 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 104.029 -2.582 . . . . 10.0 104.029 -178.919 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 22.3 mmtp -75.33 161.11 29.57 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 117.618 -1.633 . . . . 10.0 108.523 170.543 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -65.01 123.31 19.13 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 106.601 -1.629 . . . . 10.0 106.601 161.786 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.33 -138.42 4.03 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 108.209 -1.956 . . . . 10.0 108.209 171.687 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.25 -160.08 26.75 Favored Glycine 0 C--O 1.224 -0.502 0 N-CA-C 108.869 -1.692 . . . . 10.0 108.869 177.192 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -66.6 2.03 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 CA-C-N 119.544 1.672 . . . . 10.0 110.131 166.332 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 25.0 mmtt -107.9 6.16 27.05 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 125.598 1.559 . . . . 10.0 110.192 173.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.405 ' OD2' ' NZ ' ' B' ' 128' ' ' LYS . 1.9 t0 -141.48 155.89 45.8 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 119.565 1.075 . . . . 10.0 110.611 167.822 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tm-20 -79.36 -26.98 41.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.641 -1.614 . . . . 10.0 106.641 168.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -85.87 27.55 0.87 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.669 1.188 . . . . 10.0 111.732 -172.77 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 37.5 ptt-85 -63.72 150.41 44.5 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.208 1.003 . . . . 10.0 111.018 179.003 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -64.68 -70.61 0.22 Allowed 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.781 0.433 . . . . 10.0 110.884 -177.659 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.471 HG23 ' H ' ' B' ' 82' ' ' GLY . 0.1 OUTLIER -165.83 -63.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.2 0 C-N-CA 126.01 1.724 . . . . 10.0 107.399 -175.938 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.471 ' H ' HG23 ' B' ' 81' ' ' VAL . . . -120.92 55.29 0.64 Allowed Glycine 0 C--N 1.335 0.497 0 N-CA-C 108.804 -1.718 . . . . 10.0 108.804 -176.002 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -93.03 90.45 6.92 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 105.152 -2.166 . . . . 10.0 105.152 169.282 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . 0.481 HD22 ' CD1' ' B' ' 45' ' ' PHE . 9.6 mp -65.8 -25.63 67.32 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 118.632 0.651 . . . . 10.0 110.84 -173.114 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 118.67 -94.11 0.58 Allowed Glycine 0 N--CA 1.436 -1.315 0 N-CA-C 107.872 -2.091 . . . . 10.0 107.872 172.845 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.2 m-20 -156.7 107.8 2.39 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.432 -0.581 . . . . 10.0 109.432 -169.621 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.2 m -89.12 122.71 40.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 CA-C-N 118.163 0.438 . . . . 10.0 110.401 -177.619 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.1 m -79.79 81.96 5.97 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 127.705 2.402 . . . . 10.0 112.55 -171.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -70.95 130.4 41.51 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 121.573 -0.704 . . . . 10.0 112.692 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -63.18 172.16 2.0 Allowed 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 125.479 1.511 . . . . 10.0 110.049 166.756 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.08 -28.85 59.32 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 124.2 1.0 . . . . 10.0 111.839 171.141 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.445 ' OD2' ' NZ ' ' B' ' 36' ' ' LYS . 30.5 t70 -77.4 -2.88 37.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 122.261 1.029 . . . . 10.0 111.113 175.898 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.3 2.03 87.89 Favored Glycine 0 N--CA 1.44 -1.076 0 N-CA-C 109.959 -1.256 . . . . 10.0 109.959 -173.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 25.2 t -78.24 94.9 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 N-CA-C 108.002 -1.11 . . . . 10.0 108.002 -171.572 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.23 118.74 29.14 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 166.76 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -78.16 117.69 19.68 Favored 'General case' 0 N--CA 1.433 -1.28 0 C-N-CA 126.005 1.722 . . . . 10.0 107.744 170.366 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 42.6 t -108.14 131.6 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.16 0 N-CA-C 106.735 -1.58 . . . . 10.0 106.735 -178.555 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.1 p -157.49 51.48 0.46 Allowed 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.394 0.678 . . . . 10.0 109.529 169.455 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -87.91 152.23 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 N-CA-C 107.296 -1.372 . . . . 10.0 107.296 -174.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -137.55 146.63 44.33 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.716 1.206 . . . . 10.0 109.986 -178.346 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -152.07 140.13 20.19 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 107.271 -1.381 . . . . 10.0 107.271 168.855 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 77.6 p -108.71 63.34 0.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 107.685 -1.228 . . . . 10.0 107.685 -174.265 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.3 p -151.97 -47.61 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 115.608 -0.724 . . . . 10.0 109.055 -177.751 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 20.9 mm -64.5 155.45 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 124.124 0.97 . . . . 10.0 110.058 172.734 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 28.8 t -150.69 147.28 27.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.717 -1.216 . . . . 10.0 107.717 168.367 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 68.2 mt -55.18 -30.61 60.25 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.995 -1.002 . . . . 10.0 109.82 167.085 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t -153.57 109.11 3.23 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 106.919 -1.511 . . . . 10.0 106.919 -179.312 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.37 -63.53 0.01 OUTLIER Glycine 0 C--N 1.333 0.373 0 N-CA-C 109.746 -1.342 . . . . 10.0 109.746 -177.858 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -156.37 -53.57 0.08 Allowed 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 126.721 2.008 . . . . 10.0 106.185 178.373 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -75.36 -36.84 60.91 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 113.998 -1.455 . . . . 10.0 108.758 -174.322 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.2 t 56.74 63.26 2.0 Allowed 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.083 0.953 . . . . 10.0 109.576 169.936 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.295 0.0 OUTLIER -53.31 -28.26 14.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.23 -0.896 . . . . 10.0 113.218 -168.569 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.9 mm -27.13 -55.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 127.221 2.208 . . . . 10.0 114.045 173.776 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -83.67 4.69 81.39 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-O 118.493 -1.17 . . . . 10.0 115.08 -169.726 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 mmt180 -87.6 160.47 18.17 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.663 1.231 . . . . 10.0 111.95 -177.827 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 19.3 m -92.96 130.48 38.53 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 107.479 -1.304 . . . . 10.0 107.479 169.007 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -97.64 138.46 35.0 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.513 -1.292 . . . . 10.0 107.513 169.773 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 83.1 t -129.81 135.35 61.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 107.748 -1.204 . . . . 10.0 107.748 -177.336 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -103.05 145.99 11.53 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 123.897 0.879 . . . . 10.0 108.644 168.419 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.553 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 2.7 m170 -123.89 160.38 27.62 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 116.329 1.974 . . . . 10.0 116.329 -173.717 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 62.6 tt0 -43.07 -56.57 3.3 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 129.692 3.197 . . . . 10.0 111.918 172.827 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 76.0 mttt -117.3 170.02 9.02 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 123.599 0.76 . . . . 10.0 112.397 -169.29 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.9 149.7 47.54 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 114.003 -1.453 . . . . 10.0 109.458 173.701 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.49 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 1.2 m-20 -80.58 146.21 31.35 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 123.881 0.872 . . . . 10.0 111.773 173.66 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -76.26 -27.97 56.9 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 124.235 0.959 . . . . 10.0 109.5 168.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 72.4 mt 62.04 53.01 3.1 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 123.058 1.408 . . . . 10.0 108.925 -174.923 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.28 -43.23 2.54 Favored Glycine 0 N--CA 1.445 -0.764 0 CA-C-N 112.561 -2.109 . . . . 10.0 110.637 173.581 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.405 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 13.1 mtmm -81.38 44.74 0.81 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.919 0.888 . . . . 10.0 112.392 -169.971 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.15 -22.7 14.44 Favored Glycine 0 CA--C 1.523 0.568 0 C-N-CA 125.921 1.724 . . . . 10.0 110.903 169.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 63.77 34.43 89.92 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 110.996 -0.841 . . . . 10.0 110.996 175.845 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -138.27 168.53 19.55 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 106.883 -1.525 . . . . 10.0 106.883 169.397 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.11 -48.53 73.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 116.038 -0.528 . . . . 10.0 109.865 -176.199 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -68.02 -26.4 65.87 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.006 -1.059 . . . . 10.0 110.935 178.977 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 24.0 p -56.92 -44.53 82.54 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 120.996 1.725 . . . . 10.0 110.544 171.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 11.1 t -83.92 -10.78 57.71 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.85 -0.595 . . . . 10.0 112.1 -173.75 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.5 ttmm -103.33 -51.72 3.17 Favored 'General case' 0 N--CA 1.441 -0.905 0 C-N-CA 126.038 1.735 . . . . 10.0 112.319 -178.822 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.2 p -139.29 31.17 2.15 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.557 1.071 . . . . 10.0 112.461 176.045 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 58.23 25.87 57.98 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 118.723 0.692 . . . . 10.0 112.719 175.456 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 52.96 24.89 3.63 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 117.59 0.695 . . . . 10.0 112.585 -176.724 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.13 -4.26 9.67 Favored 'General case' 0 C--N 1.342 0.276 0 O-C-N 121.12 -0.988 . . . . 10.0 113.014 -173.32 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.03 -158.93 41.05 Favored Glycine 0 N--CA 1.446 -0.69 0 O-C-N 121.027 -1.045 . . . . 10.0 111.187 167.249 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 m -58.49 125.73 24.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.463 0.705 . . . . 10.0 111.767 -167.83 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -58.74 68.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.955 2.102 . . . . 10.0 111.864 172.048 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 49.7 mt -50.59 -36.93 37.26 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.898 -1.127 . . . . 10.0 113.714 -174.469 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -163.11 157.53 20.76 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 108.7 -0.852 . . . . 10.0 108.7 -170.823 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 23.6 p -161.76 168.29 23.47 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.96 -0.385 . . . . 10.0 109.96 -174.637 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.5 155.37 26.46 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.312 -1.515 . . . . 10.0 109.312 -176.44 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -107.94 131.25 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 105.776 -1.935 . . . . 10.0 105.776 -177.507 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 16.0 mt -79.48 165.95 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 118.818 0.736 . . . . 10.0 110.615 -179.782 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -169.13 170.92 42.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 127.875 2.655 . . . . 10.0 107.097 -177.065 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 20.3 mt -84.8 140.67 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 C-N-CA 124.481 1.112 . . . . 10.0 110.1 -168.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -102.57 -114.21 0.21 Allowed 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.903 -1.147 . . . . 10.0 107.903 167.44 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.252 1.227 0 C-N-CA 131.077 3.751 . . . . 10.0 106.136 172.297 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.799 0 CA-C-O 118.571 -0.728 . . . . 10.0 109.794 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 60.4 p -96.21 -63.89 1.1 Allowed 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 124.555 1.142 . . . . 10.0 110.001 -169.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -135.63 135.4 40.16 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 126.724 2.01 . . . . 10.0 107.857 -169.547 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -133.59 166.99 21.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 124.752 1.221 . . . . 10.0 110.119 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.73 162.12 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 125.803 1.641 . . . . 10.0 109.317 -179.015 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -149.89 90.72 1.71 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 106.204 -1.776 . . . . 10.0 106.204 166.631 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.704 HG21 ' HB3' ' B' ' 53' ' ' ASN . 3.7 m -77.37 118.97 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 107.845 -1.169 . . . . 10.0 107.845 170.915 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.6 mt -97.85 147.73 24.13 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 108.136 -1.061 . . . . 10.0 108.136 -178.947 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.06 162.56 17.95 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 168.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -174.43 -58.33 0.05 OUTLIER Glycine 0 C--O 1.227 -0.291 0 C-N-CA 121.09 -0.576 . . . . 10.0 112.057 169.861 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -72.98 -46.46 52.15 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 135.9 -69.81 0.51 Allowed Glycine 0 CA--C 1.527 0.796 0 CA-C-N 114.313 -1.312 . . . . 10.0 110.089 174.099 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -75.82 37.45 0.52 Allowed 'Trans proline' 0 CA--C 1.536 0.614 1 C-N-CA 125.69 4.26 . . . . 10.0 111.944 -179.884 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.8 t -149.01 100.38 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 C-N-CA 131.454 3.902 . . . . 10.0 100.537 178.603 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.72 116.04 22.39 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 106.032 -1.84 . . . . 10.0 106.032 -174.181 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.617 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.81 142.71 16.25 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 109.463 -1.455 . . . . 10.0 109.463 174.766 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.562 ' CG2' HG23 ' B' ' 54' ' ' THR . 6.3 mt -135.14 86.02 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.721 -1.214 . . . . 10.0 107.721 173.795 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -97.46 142.64 13.94 Favored 'Isoleucine or valine' 0 C--N 1.339 0.118 0 C-N-CA 124.028 0.931 . . . . 10.0 110.008 178.002 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -128.88 123.1 31.82 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 127.262 2.225 . . . . 10.0 109.511 174.353 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -105.23 116.87 32.68 Favored 'General case' 0 C--O 1.23 0.074 0 C-N-CA 125.294 1.437 . . . . 10.0 108.684 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 20.4 tt0 -105.58 134.71 48.24 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 118.666 0.666 . . . . 10.0 112.268 171.788 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 tp60 -109.71 99.36 8.54 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.672 1.989 . . . . 10.0 107.037 168.853 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 40.5 mmtt -58.72 -64.79 0.8 Allowed 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.752 -0.462 . . . . 10.0 109.752 175.469 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -124.13 164.62 19.09 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 104.657 -2.349 . . . . 10.0 104.657 169.453 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 t -71.47 -15.74 62.33 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 108.77 -0.826 . . . . 10.0 108.77 173.665 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.82 -24.31 44.55 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.021 0.529 . . . . 10.0 110.273 173.388 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.44 141.77 23.25 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 109.887 -1.285 . . . . 10.0 109.887 -176.825 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -62.56 142.21 89.16 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 CA-C-N 119.525 1.663 . . . . 10.0 107.866 169.252 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.5 t -77.92 125.77 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.004 -1.48 . . . . 10.0 107.004 -174.731 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.1 mtmm -90.87 104.94 17.47 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.658 -1.238 . . . . 10.0 107.658 178.575 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 p -94.08 93.19 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 125.908 1.683 . . . . 10.0 107.555 174.264 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 16.9 p90 -102.28 175.07 5.64 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 121.207 0.527 . . . . 10.0 109.982 169.153 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 169.75 174.8 38.34 Favored Glycine 0 N--CA 1.441 -0.983 0 N-CA-C 111.367 -0.693 . . . . 10.0 111.367 176.892 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.0 p -145.69 102.78 3.72 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.239 -1.393 . . . . 10.0 107.239 178.751 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.617 HG22 ' HA2' ' A' ' 16' ' ' GLY . 7.5 pt -78.05 174.16 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.189 0 C-N-CA 118.878 -1.129 . . . . 10.0 108.099 169.225 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -154.83 144.17 21.22 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 106.305 -1.739 . . . . 10.0 106.305 168.808 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 126.6 -37.24 2.47 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-N 118.695 0.679 . . . . 10.0 113.957 178.309 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.518 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.1 mp -68.8 177.86 2.38 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.968 0.89 . . . . 10.0 112.651 -167.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.8 t -100.41 156.8 17.06 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.866 -0.606 . . . . 10.0 109.384 171.168 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -52.42 147.11 8.56 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.944 1.298 . . . . 10.0 112.191 -169.526 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.0 -172.12 17.68 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.124 0.869 . . . . 10.0 111.448 171.407 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -72.71 148.5 44.64 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.069 1.348 . . . . 10.0 110.855 -177.774 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -147.38 143.66 28.14 Favored 'General case' 0 C--N 1.338 0.067 0 C-N-CA 124.115 0.966 . . . . 10.0 112.314 -179.439 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.728 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -23.28 124.49 0.02 OUTLIER Glycine 0 C--N 1.341 0.856 0 C-N-CA 127.347 2.403 . . . . 10.0 114.062 165.301 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 20.1 t80 -149.25 106.5 3.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 119.286 1.543 . . . . 10.0 109.848 168.671 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.49 172.37 14.59 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.317 0.579 . . . . 10.0 111.04 174.102 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.4 p -112.82 120.93 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 CA-C-N 112.86 -1.973 . . . . 10.0 107.502 168.676 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -89.41 151.61 21.94 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.873 1.669 . . . . 10.0 108.223 -179.37 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -64.76 -57.01 10.08 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 114.798 -1.092 . . . . 10.0 110.473 -173.098 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -76.62 124.46 27.67 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.227 -1.397 . . . . 10.0 107.227 -173.403 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.07 -2.41 77.99 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.426 -0.652 . . . . 10.0 112.136 178.047 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -43.98 131.0 5.88 Favored 'General case' 0 C--N 1.344 0.343 0 CA-C-O 122.8 1.286 . . . . 10.0 112.525 175.289 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.621 ' HB3' HG21 ' B' ' 7' ' ' VAL . 2.9 m-80 -138.43 3.19 2.32 Favored 'General case' 0 N--CA 1.434 -1.232 0 CA-C-N 112.676 -2.056 . . . . 10.0 109.519 163.939 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.666 HG22 HG22 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -53.5 -40.09 65.12 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 125.063 1.345 . . . . 10.0 108.605 168.566 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.8 -15.12 59.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 116.041 -0.527 . . . . 10.0 111.976 178.223 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.75 75.5 0.99 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 109.092 -1.603 . . . . 10.0 109.092 -173.384 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t 38.78 48.87 1.41 Allowed 'General case' 0 C--O 1.231 0.105 0 C-N-CA 125.554 1.542 . . . . 10.0 114.448 177.311 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.4 m -127.76 -53.5 1.33 Allowed 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.996 -1.483 . . . . 10.0 106.996 -172.745 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.3 m -90.22 16.95 7.67 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.129 0.422 . . . . 10.0 111.527 173.758 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.56 -19.77 58.38 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.21 1.004 . . . . 10.0 111.032 169.379 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.3 135.85 7.98 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-O 119.017 -0.88 . . . . 10.0 111.232 168.578 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -73.39 66.04 4.5 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 123.244 2.63 . . . . 10.0 110.77 173.474 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 28.8 m170 71.81 -34.16 0.29 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 128.41 2.684 . . . . 10.0 112.664 175.385 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 43.42 25.9 0.09 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 128.308 2.643 . . . . 10.0 116.374 171.625 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -59.06 134.33 87.59 Favored Pre-proline 0 CA--C 1.534 0.354 0 N-CA-C 114.464 1.283 . . . . 10.0 114.464 -169.945 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -60.95 -37.49 76.47 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.565 2.177 . . . . 10.0 110.042 175.901 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 66.0 mt -63.05 2.8 0.29 Allowed 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.748 1.219 . . . . 10.0 113.776 175.761 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 12.4 m 26.84 54.22 0.05 OUTLIER 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 128.293 2.637 . . . . 10.0 114.982 175.738 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtt85 -99.29 -179.15 4.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.572 1.149 . . . . 10.0 110.752 -172.983 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt -112.54 92.52 4.05 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.046 -0.724 . . . . 10.0 109.046 -174.643 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -5.88 97.16 0.01 OUTLIER 'General case' 0 C--O 1.223 -0.318 0 C-N-CA 128.255 2.622 . . . . 10.0 113.937 -176.916 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.41 -134.04 7.81 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.897 -1.681 . . . . 10.0 108.897 178.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.49 -170.33 40.43 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 106.915 -2.474 . . . . 10.0 106.915 171.498 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -63.59 -4.64 7.26 Favored 'Trans proline' 0 N--CA 1.455 -0.794 0 CA-C-N 119.867 1.834 . . . . 10.0 110.929 168.276 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -88.65 -24.06 22.88 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.313 1.045 . . . . 10.0 110.536 174.069 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.8 178.41 4.29 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 108.246 -1.02 . . . . 10.0 108.246 -178.262 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -92.81 -26.81 17.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 167.088 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.1 mm-40 -87.06 28.79 0.88 Allowed 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.391 -1.443 . . . . 10.0 112.436 -169.641 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.5 133.62 53.48 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.67 -1.233 . . . . 10.0 107.67 169.345 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.9 m170 -64.58 -57.92 7.79 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.823 -0.548 . . . . 10.0 112.007 -175.378 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.8 p -170.97 -43.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 C-N-CA 124.461 1.104 . . . . 10.0 109.065 -172.375 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -150.43 56.44 0.46 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 109.759 -1.336 . . . . 10.0 109.759 178.385 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -92.76 92.15 7.82 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.935 -1.506 . . . . 10.0 106.935 172.256 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.29 -36.69 63.78 Favored 'General case' 0 N--CA 1.461 0.1 0 N-CA-C 107.648 -1.242 . . . . 10.0 107.648 177.067 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.34 -98.66 1.23 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 110.833 -0.907 . . . . 10.0 110.833 167.859 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.3 m-80 -123.73 132.3 53.79 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.855 0.862 . . . . 10.0 111.274 -168.365 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.0 m -114.68 129.92 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 123.771 0.828 . . . . 10.0 109.14 168.072 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 28.2 m -86.81 104.09 15.85 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 127.651 2.381 . . . . 10.0 110.572 -174.857 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.03 33.49 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 122.825 0.45 . . . . 10.0 110.544 174.776 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -66.76 175.23 2.49 Favored 'General case' 0 CA--C 1.528 0.103 0 O-C-N 123.633 0.583 . . . . 10.0 109.728 167.661 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.13 -29.48 13.56 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.585 1.554 . . . . 10.0 111.746 172.38 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -79.42 -4.5 51.39 Favored 'General case' 0 N--CA 1.453 -0.301 0 O-C-N 123.226 0.329 . . . . 10.0 110.229 -177.779 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.8 9.28 86.94 Favored Glycine 0 C--N 1.337 0.635 0 N-CA-C 110.855 -0.898 . . . . 10.0 110.855 -178.377 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 50.9 t -90.82 107.65 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.277 0 C-N-CA 126.149 1.78 . . . . 10.0 106.356 179.619 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.445 ' H ' HG12 ' A' ' 35' ' ' ILE . . . -102.85 118.52 37.02 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.226 -1.398 . . . . 10.0 107.226 168.579 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -79.24 112.2 16.23 Favored 'General case' 0 N--CA 1.434 -1.239 0 C-N-CA 125.927 1.691 . . . . 10.0 108.541 171.127 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.82 133.23 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.234 -1.765 . . . . 10.0 106.234 176.337 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.4 p -157.63 60.69 0.48 Allowed 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.861 -0.422 . . . . 10.0 109.861 -178.398 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 44.0 mt -115.46 154.69 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 107.97 -1.122 . . . . 10.0 107.97 -169.696 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -127.87 145.51 50.92 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.338 -0.615 . . . . 10.0 109.338 167.512 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 102' ' ' SER . 42.2 t0 -145.29 154.73 42.66 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 106.862 -1.533 . . . . 10.0 106.862 -178.752 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.406 ' N ' ' OD1' ' A' ' 101' ' ' ASP . 8.4 p -108.32 -9.35 15.49 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 128.145 2.578 . . . . 10.0 112.28 -174.28 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.6 p -79.6 -36.98 18.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.147 0 N-CA-C 107.602 -1.259 . . . . 10.0 107.602 -174.87 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.455 ' CD1' ' H ' ' A' ' 104' ' ' ILE 0.309 0.0 OUTLIER -79.51 150.24 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 124.714 1.206 . . . . 10.0 113.026 172.676 . . . . . . . . 4 4 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.6 m -157.28 133.56 9.7 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.089 0.956 . . . . 10.0 108.47 179.616 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.46 ' CD1' HD11 ' A' ' 113' ' ' ILE . 1.1 mm? -75.54 52.87 0.66 Allowed 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.223 2.209 . . . . 10.0 108.394 175.13 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.2 t -88.38 -157.04 0.4 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 126.472 1.909 . . . . 10.0 110.204 -169.803 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.0 -53.65 0.13 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 128.177 2.799 . . . . 10.0 107.429 -178.302 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -64.99 -60.16 3.36 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.227 -0.657 . . . . 10.0 109.227 171.203 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -77.94 -28.35 49.54 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 115.903 -0.589 . . . . 10.0 110.228 -175.259 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t 13.32 78.63 0.01 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 128.3 2.64 . . . . 10.0 113.672 175.776 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -65.53 -16.19 19.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 112.04 0.385 . . . . 10.0 112.04 176.328 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.46 HD11 ' CD1' ' A' ' 106' ' ' LEU . 49.2 mm -46.39 137.64 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 C-N-CA 123.832 0.853 . . . . 10.0 110.318 169.981 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.08 -1.97 88.18 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.153 -1.36 . . . . 10.0 115.286 174.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.9 mtp85 -77.05 168.14 20.6 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.019 1.41 . . . . 10.0 107.364 169.122 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -106.6 120.86 43.07 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.48 0.582 . . . . 10.0 111.752 -174.902 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -77.22 145.72 37.42 Favored 'General case' 0 CA--C 1.517 -0.294 0 N-CA-C 108.337 -0.986 . . . . 10.0 108.337 168.698 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 86.8 t -131.93 132.49 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.899 0 N-CA-C 107.678 -1.23 . . . . 10.0 107.678 170.145 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -104.48 134.8 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 N-CA-C 106.268 -1.753 . . . . 10.0 106.268 167.831 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.728 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 8.2 m-70 -112.67 156.95 21.88 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 115.794 1.776 . . . . 10.0 115.794 -170.906 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -43.25 -55.3 4.07 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.68 2.792 . . . . 10.0 112.155 171.597 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -115.55 162.8 16.69 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 123.784 0.834 . . . . 10.0 111.543 -169.675 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -67.87 153.86 42.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.877 -1.056 . . . . 10.0 109.129 170.103 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -93.51 144.41 25.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 C-N-CA 123.814 0.845 . . . . 10.0 110.75 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -76.7 -16.12 59.6 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-N 114.387 -1.279 . . . . 10.0 110.83 168.379 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 36.4 mt 53.23 40.57 31.48 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 124.178 0.991 . . . . 10.0 110.247 -172.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.77 -47.97 0.98 Allowed Glycine 0 C--N 1.337 0.59 0 C-N-CA 125.122 1.344 . . . . 10.0 111.023 169.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.42 51.97 1.75 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 122.035 -0.685 . . . . 10.0 112.466 -169.831 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -91.43 -38.62 5.85 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 124.786 1.184 . . . . 10.0 110.351 169.914 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.43 31.33 78.51 Favored Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 -169.451 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -114.21 157.42 22.7 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 106.067 -1.827 . . . . 10.0 106.067 169.236 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.414 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 4.8 tm-20 -51.75 -44.87 63.49 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.875 -1.057 . . . . 10.0 109.062 174.13 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -65.44 -34.08 77.44 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.162 0.985 . . . . 10.0 112.452 173.937 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 54.3 p -57.73 -35.99 71.45 Favored 'General case' 0 N--CA 1.448 -0.571 0 O-C-N 120.244 -1.535 . . . . 10.0 111.781 -175.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -84.65 -1.11 55.61 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 118.855 -0.593 . . . . 10.0 112.163 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 94.1 mttt -114.05 -56.13 2.43 Favored 'General case' 0 C--N 1.342 0.261 0 C-N-CA 124.628 1.171 . . . . 10.0 111.315 -176.523 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.8 p -120.17 -5.54 9.96 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.888 0.767 . . . . 10.0 113.061 175.929 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.03 33.65 Favored Glycine 0 C--N 1.342 0.889 0 CA-C-O 119.252 -0.749 . . . . 10.0 112.175 -177.465 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 62.12 23.79 14.09 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 118.317 1.059 . . . . 10.0 111.597 -177.694 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.27 -11.78 24.28 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 125.656 1.583 . . . . 10.0 112.013 -177.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.88 -157.28 48.61 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.945 -1.262 . . . . 10.0 109.945 172.926 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.2 m -61.39 133.93 56.35 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.875 0.87 . . . . 10.0 113.121 -167.495 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -66.25 71.39 0.07 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.968 1.307 . . . . 10.0 110.017 169.596 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 44.6 mt -55.85 -33.56 64.64 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 112.742 0.645 . . . . 10.0 112.742 -177.435 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -160.19 146.35 15.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.473 -0.566 . . . . 10.0 109.473 -175.749 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 18.1 m -148.51 161.25 42.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.872 -0.788 . . . . 10.0 108.872 -169.855 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.07 -174.96 17.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.504 -0.639 . . . . 10.0 111.504 178.419 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 49.8 t -127.05 133.75 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 104.825 -2.287 . . . . 10.0 104.825 175.755 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 22.1 mt -69.37 117.46 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 108.903 -0.777 . . . . 10.0 108.903 177.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.83 141.86 16.7 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 110.611 -0.996 . . . . 10.0 110.611 -179.72 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -74.17 132.7 32.97 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 CA-C-N 119.353 1.577 . . . . 10.0 108.942 175.31 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.61 -26.27 50.5 Favored 'General case' 0 C--O 1.223 -0.342 0 N-CA-C 108.535 -0.913 . . . . 10.0 108.535 167.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.253 1.278 0 C-N-CA 126.187 1.795 . . . . 10.0 109.318 169.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.706 0 N-CA-C 106.985 -1.487 . . . . 10.0 106.985 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . 0.4 HG23 ' H ' ' B' ' 3' ' ' LYS . 8.8 t -150.76 -60.48 0.18 Allowed 'General case' 0 C--O 1.232 0.139 0 N-CA-C 108.958 -0.756 . . . . 10.0 108.958 176.135 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . 0.4 ' H ' HG23 ' B' ' 2' ' ' THR . 57.0 tttp -117.18 135.4 53.8 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 126.888 2.075 . . . . 10.0 106.852 174.904 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.85 161.7 34.88 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 125.253 1.421 . . . . 10.0 110.75 178.543 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 m -128.4 178.1 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 124.837 1.255 . . . . 10.0 110.042 -176.218 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -162.27 97.28 1.0 Allowed 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 125.368 1.467 . . . . 10.0 107.634 166.641 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.621 HG21 ' HB3' ' A' ' 53' ' ' ASN . 2.8 m -89.73 104.53 15.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.21 0.604 . . . . 10.0 110.818 173.765 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.7 mp -93.58 146.23 23.96 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.244 1.418 . . . . 10.0 110.176 178.195 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . 0.439 ' C ' ' HB1' ' B' ' 145' ' ' ALA . 2.9 tttm -162.12 164.07 28.19 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.531 -1.285 . . . . 10.0 107.531 171.206 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.68 -47.65 0.14 Allowed Glycine 0 N--CA 1.462 0.398 0 C-N-CA 119.389 -1.386 . . . . 10.0 114.102 168.796 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -72.08 -45.73 59.58 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 107.141 -1.429 . . . . 10.0 107.141 -177.057 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 147.65 -75.17 0.28 Allowed Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 114.162 -1.381 . . . . 10.0 109.932 169.125 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -55.92 -39.22 92.49 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 123.511 2.808 . . . . 10.0 110.985 173.008 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.436 HG13 HD11 ' B' ' 38' ' ' LEU . 72.6 t -59.66 112.31 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.21 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 179.643 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.04 124.33 42.32 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 106.82 -1.548 . . . . 10.0 106.82 168.446 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.573 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -104.67 136.92 13.35 Favored Glycine 0 C--O 1.224 -0.494 0 N-CA-C 107.794 -2.122 . . . . 10.0 107.794 169.491 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.666 HG22 HG22 ' A' ' 54' ' ' THR . 3.0 mt -138.59 68.04 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 N-CA-C 107.816 -1.179 . . . . 10.0 107.816 -174.579 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 mm -89.05 151.89 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 N-CA-C 109.668 -0.493 . . . . 10.0 109.668 -173.503 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -120.24 143.89 48.04 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 126.617 1.967 . . . . 10.0 108.111 175.194 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -129.05 130.91 47.16 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 104.411 -2.44 . . . . 10.0 104.411 168.273 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -128.62 150.48 50.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 119.796 1.18 . . . . 10.0 110.402 172.375 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.58 97.59 5.12 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 107.589 -1.263 . . . . 10.0 107.589 178.392 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -42.8 -57.51 2.75 Favored 'General case' 0 CA--C 1.515 -0.375 0 C-N-CA 123.978 0.911 . . . . 10.0 110.053 170.482 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 15.0 mp0 -134.15 178.71 6.75 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 128.892 2.877 . . . . 10.0 103.461 168.378 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 22.6 t -94.2 13.8 22.15 Favored 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.221 -0.659 . . . . 10.0 109.221 170.366 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -149.18 28.15 0.83 Allowed 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 125.435 1.494 . . . . 10.0 110.199 -173.311 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -141.45 174.94 22.68 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.397 -1.481 . . . . 10.0 109.397 -172.893 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.27 129.94 24.12 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.808 2.338 . . . . 10.0 109.456 -177.499 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.1 t -79.87 111.52 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 N-CA-C 104.918 -2.253 . . . . 10.0 104.918 172.469 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -82.65 126.54 32.44 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.601 -1.259 . . . . 10.0 107.601 169.204 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 p -100.5 109.38 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 C-N-CA 126.37 1.868 . . . . 10.0 106.703 172.826 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.9 p90 -130.38 156.63 44.4 Favored 'General case' 0 C--O 1.226 -0.177 0 N-CA-C 113.504 0.927 . . . . 10.0 113.504 -179.729 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.65 -152.24 24.12 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 106.824 -2.511 . . . . 10.0 106.824 172.924 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 21.2 p -156.38 165.93 34.89 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 119.584 -0.846 . . . . 10.0 110.412 174.335 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.573 HG22 ' HA2' ' B' ' 16' ' ' GLY . 4.0 pt -107.01 179.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-N 114.344 -1.298 . . . . 10.0 109.424 165.366 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.19 163.17 40.54 Favored 'General case' 0 N--CA 1.437 -1.083 0 C-N-CA 124.689 1.196 . . . . 10.0 108.407 162.921 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.21 -17.12 44.69 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-O 119.315 -0.714 . . . . 10.0 113.155 172.626 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.482 HD12 ' N ' ' B' ' 38' ' ' LEU . 6.4 mp -71.7 178.61 3.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.005 0.902 . . . . 10.0 110.194 173.708 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -97.4 170.45 9.05 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.463 -0.94 . . . . 10.0 108.463 166.408 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -60.03 170.69 1.15 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.203 1.001 . . . . 10.0 112.111 -171.341 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.95 -174.61 32.99 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 124.201 0.905 . . . . 10.0 112.08 168.461 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -70.24 146.78 50.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 123.834 0.854 . . . . 10.0 109.581 176.164 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -147.17 144.94 29.32 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 123.493 0.717 . . . . 10.0 111.703 178.558 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.66 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -34.79 120.5 0.39 Allowed Glycine 0 C--N 1.339 0.74 0 C-N-CA 127.738 2.59 . . . . 10.0 112.626 167.371 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.69 110.47 5.14 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-N 119.456 1.628 . . . . 10.0 109.458 168.306 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.55 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.1 OUTLIER -146.57 170.65 16.46 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-O 121.718 0.771 . . . . 10.0 111.802 176.496 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.16 129.09 46.73 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 CA-C-N 111.146 -2.752 . . . . 10.0 105.647 168.193 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 41.5 m-70 -105.78 146.59 29.65 Favored 'General case' 0 CA--C 1.509 -0.611 0 N-CA-C 107.675 -1.231 . . . . 10.0 107.675 174.382 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 23.8 tp10 -66.64 -59.04 3.96 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.544 -1.207 . . . . 10.0 108.98 -172.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 22.2 m-30 -77.1 106.88 9.09 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 107.28 -1.378 . . . . 10.0 107.28 -175.222 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.68 42.8 1.31 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 124.592 1.091 . . . . 10.0 111.448 174.517 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.32 131.76 41.07 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 124.975 1.31 . . . . 10.0 108.241 177.057 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.704 ' HB3' HG21 ' A' ' 7' ' ' VAL . 1.2 m-80 -122.8 1.43 9.36 Favored 'General case' 0 N--CA 1.444 -0.755 0 C-N-CA 124.714 1.205 . . . . 10.0 110.28 168.968 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.562 HG23 ' CG2' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -57.18 -36.53 70.93 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.773 1.17 . . . . 10.0 108.792 178.194 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.38 -17.88 55.83 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.53 1.132 . . . . 10.0 112.965 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 77.61 0.77 Allowed Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.272 -0.731 . . . . 10.0 111.272 -178.273 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 34.8 m 50.96 34.36 10.46 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 124.754 1.222 . . . . 10.0 112.614 172.501 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 6.3 m -127.75 -57.43 1.26 Allowed 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 107.041 -1.466 . . . . 10.0 107.041 -169.958 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 11.8 t -92.14 21.22 5.24 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 111.896 0.332 . . . . 10.0 111.896 179.166 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -68.1 -7.26 28.09 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.615 0.766 . . . . 10.0 111.949 176.285 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.47 127.66 2.19 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 109.704 -1.358 . . . . 10.0 109.704 174.132 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -74.81 65.42 5.88 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.517 2.811 . . . . 10.0 111.523 178.437 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.2 m170 59.98 55.83 3.64 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 128.382 2.673 . . . . 10.0 109.94 177.947 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -70.51 63.7 0.27 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.553 0.741 . . . . 10.0 112.393 -178.041 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -67.48 147.45 98.78 Favored Pre-proline 0 CA--C 1.532 0.27 0 O-C-N 121.642 -0.661 . . . . 10.0 110.858 -175.559 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -63.11 -49.44 4.88 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.245 1.963 . . . . 10.0 110.2 179.308 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 1.6 tt -81.41 59.64 4.12 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.358 0.663 . . . . 10.0 109.348 -177.852 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.0 t -14.96 97.31 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 128.411 2.684 . . . . 10.0 112.886 -176.806 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.59 168.58 10.88 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.423 1.089 . . . . 10.0 108.725 -175.807 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -108.24 105.91 15.84 Favored 'General case' 0 C--O 1.224 -0.26 0 N-CA-C 108.457 -0.942 . . . . 10.0 108.457 175.508 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 56.3 t60 -9.99 96.51 0.01 OUTLIER 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 127.213 2.205 . . . . 10.0 115.482 -177.769 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.78 -141.1 10.37 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 173.658 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.03 -161.09 27.09 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 108.79 -1.724 . . . . 10.0 108.79 171.091 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -66.59 5.97 0.64 Allowed 'Trans proline' 0 N--CA 1.456 -0.704 0 CA-C-N 120.417 2.109 . . . . 10.0 111.889 174.106 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -103.56 -15.21 15.9 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 117.596 -1.193 . . . . 10.0 110.994 172.887 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.415 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 5.4 m-20 -131.36 162.25 30.53 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 119.164 0.893 . . . . 10.0 108.925 -167.855 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -78.61 -33.07 47.7 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.231 -1.396 . . . . 10.0 107.231 176.361 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -82.25 26.46 0.54 Allowed 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 125.431 1.493 . . . . 10.0 112.528 -167.108 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 36.2 ptt85 -64.58 134.35 54.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.304 -0.998 . . . . 10.0 108.304 173.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.5 m80 -58.86 -50.74 72.87 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 121.012 0.434 . . . . 10.0 111.088 -178.699 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 p -172.37 -105.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 104.06 -2.571 . . . . 10.0 104.06 177.864 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -77.54 57.36 3.78 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.864 0.756 . . . . 10.0 111.558 172.313 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -84.91 88.35 7.42 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 103.935 -2.616 . . . . 10.0 103.935 166.856 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 16.0 mt -71.72 -31.08 66.34 Favored 'General case' 0 N--CA 1.463 0.189 0 N-CA-C 107.946 -1.131 . . . . 10.0 107.946 -178.52 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.37 -102.54 2.57 Favored Glycine 0 N--CA 1.439 -1.109 0 N-CA-C 109.82 -1.312 . . . . 10.0 109.82 167.571 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -121.05 104.11 9.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.603 1.161 . . . . 10.0 109.29 -167.201 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 22.1 m -94.66 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 118.725 0.693 . . . . 10.0 109.504 172.7 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 80.0 m -89.96 117.57 28.87 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 126.585 1.954 . . . . 10.0 108.908 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.82 134.6 43.55 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 124.536 1.135 . . . . 10.0 111.313 178.442 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -59.53 170.98 0.91 Allowed 'General case' 0 CA--C 1.528 0.107 0 C-N-CA 124.165 0.986 . . . . 10.0 110.811 166.769 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 28.3 mttm -52.06 -33.0 37.13 Favored 'General case' 0 N--CA 1.435 -1.182 0 C-N-CA 125.806 1.643 . . . . 10.0 112.453 169.183 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.45 -1.23 32.62 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-O 122.158 0.98 . . . . 10.0 111.307 176.601 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.41 0.89 84.24 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.052 -1.619 . . . . 10.0 109.052 -176.175 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.3 t -78.15 95.66 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 108.021 -1.103 . . . . 10.0 108.021 -170.074 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.38 119.08 29.52 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.026 -1.472 . . . . 10.0 107.026 166.582 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -79.21 114.22 17.97 Favored 'General case' 0 N--CA 1.436 -1.163 0 C-N-CA 126.759 2.023 . . . . 10.0 108.971 171.95 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 91.8 t -98.11 131.23 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 106.705 -1.591 . . . . 10.0 106.705 174.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.6 p -157.76 57.69 0.49 Allowed 'General case' 0 CA--C 1.534 0.355 0 O-C-N 122.0 -0.437 . . . . 10.0 110.305 171.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.94 161.01 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 C-N-CA 124.784 1.234 . . . . 10.0 107.672 -170.892 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -130.54 146.25 52.03 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 124.625 1.17 . . . . 10.0 110.385 175.366 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 58.8 t0 -144.52 154.77 43.24 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 108.276 -1.009 . . . . 10.0 108.276 175.679 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 33.4 p -134.22 2.87 3.35 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 126.64 1.976 . . . . 10.0 112.544 -179.542 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.8 p -79.3 -31.84 14.62 Favored 'Isoleucine or valine' 0 C--N 1.343 0.324 0 CA-C-N 120.017 1.28 . . . . 10.0 107.891 169.948 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.402 ' C ' HD12 ' B' ' 104' ' ' ILE 0.273 0.7 OUTLIER -82.56 174.08 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 124.156 0.983 . . . . 10.0 111.556 169.423 . . . . . . . . 4 4 . 1 . 025 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 31.1 m -158.7 143.56 16.07 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 105.423 -2.066 . . . . 10.0 105.423 172.084 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.4 mt -75.5 -10.37 59.39 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.943 0.497 . . . . 10.0 112.335 -172.272 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 75.7 m -155.71 178.51 10.17 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 126.257 1.823 . . . . 10.0 106.43 173.242 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.67 -65.13 0.31 Allowed Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.777 -0.929 . . . . 10.0 110.777 169.373 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -161.21 -48.81 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 125.425 1.49 . . . . 10.0 108.068 -173.509 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -72.59 -39.78 67.09 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 107.073 -1.454 . . . . 10.0 107.073 -173.007 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 5.0 t 23.86 69.83 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 128.694 2.798 . . . . 10.0 112.636 167.116 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.96 -7.61 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 112.802 0.667 . . . . 10.0 112.802 -176.704 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 41.0 mm -45.92 125.0 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 O-C-N 121.55 -0.719 . . . . 10.0 110.1 171.81 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.4 2.03 77.34 Favored Glycine 0 CA--C 1.527 0.81 0 CA-C-O 118.735 -1.036 . . . . 10.0 113.637 178.862 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -76.2 178.92 6.06 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 106.007 -1.849 . . . . 10.0 106.007 166.75 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -124.59 129.72 51.1 Favored 'General case' 0 CA--C 1.514 -0.438 0 N-CA-C 106.907 -1.516 . . . . 10.0 106.907 -174.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.415 ' CD1' HD11 ' B' ' 149' ' ' ILE . 7.8 mp -96.97 139.72 32.57 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 107.171 -1.418 . . . . 10.0 107.171 171.37 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 97.4 t -123.17 129.8 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 O-C-N 124.605 1.191 . . . . 10.0 108.303 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.445 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.6 p -93.03 131.41 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 107.47 -1.308 . . . . 10.0 107.47 167.618 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.66 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.5 m170 -111.72 158.33 19.45 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 114.448 1.277 . . . . 10.0 114.448 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -56.6 -54.81 41.68 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 125.15 1.38 . . . . 10.0 110.98 178.757 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 43.7 mttm -109.44 176.11 5.2 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 118.686 0.676 . . . . 10.0 110.136 177.268 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -93.17 140.74 29.18 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.058 1.343 . . . . 10.0 108.515 176.781 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.55 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.0 OUTLIER -76.69 152.63 35.66 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 123.297 0.639 . . . . 10.0 111.943 -177.362 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 51.2 m-20 -76.38 6.2 5.99 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 127.115 2.166 . . . . 10.0 111.491 178.899 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.7 mt 42.12 40.11 1.58 Allowed 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.369 1.868 . . . . 10.0 111.194 -173.137 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 110.24 -33.52 5.94 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-O 119.509 -0.606 . . . . 10.0 112.639 168.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.415 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 3.3 mppt? -80.42 40.84 0.51 Allowed 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 117.597 0.699 . . . . 10.0 110.974 -176.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . 0.519 ' HA3' ' CB ' ' B' ' 134' ' ' SER . . . -88.97 -30.22 15.31 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 124.806 1.193 . . . . 10.0 112.616 -173.317 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 94.63 6.95 60.57 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.793 -1.004 . . . . 10.0 114.751 170.391 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . 0.416 ' H ' ' HB2' ' B' ' 134' ' ' SER . 0.8 OUTLIER -141.39 175.47 9.64 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 119.844 1.822 . . . . 10.0 106.726 169.036 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -51.19 -58.52 5.93 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 124.742 1.217 . . . . 10.0 109.279 178.208 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -49.94 -52.47 33.11 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 123.109 1.433 . . . . 10.0 110.562 176.505 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . 0.519 ' CB ' ' HA3' ' B' ' 129' ' ' GLY . 0.2 OUTLIER -62.23 -4.8 1.93 Allowed 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 127.497 2.319 . . . . 10.0 113.27 179.979 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.24 15.01 6.72 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.731 0.813 . . . . 10.0 110.703 172.808 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmmm -122.22 -62.52 1.38 Allowed 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.727 2.011 . . . . 10.0 109.432 -178.56 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.9 p -113.71 16.1 18.64 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 119.513 1.052 . . . . 10.0 110.487 167.207 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.96 20.73 70.98 Favored Glycine 0 C--O 1.22 -0.764 0 C-N-CA 124.088 0.851 . . . . 10.0 113.2 168.81 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 60.03 24.74 13.94 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.327 1.064 . . . . 10.0 112.63 -179.76 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.74 -13.8 17.24 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.736 -0.603 . . . . 10.0 110.967 169.843 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.38 -158.87 42.23 Favored Glycine 0 N--CA 1.439 -1.11 0 N-CA-C 109.268 -1.533 . . . . 10.0 109.268 169.553 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -49.43 121.29 4.88 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 124.808 1.243 . . . . 10.0 112.635 -168.881 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 72.68 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.96 1.704 . . . . 10.0 108.983 169.232 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 52.8 mt -47.1 -41.27 16.97 Favored 'General case' 0 N--CA 1.463 0.216 0 C-N-CA 124.317 1.047 . . . . 10.0 112.139 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.445 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -160.57 156.48 25.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 108.516 -0.92 . . . . 10.0 108.516 -171.351 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.8 p -162.33 168.78 21.68 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 108.897 -0.779 . . . . 10.0 108.897 -176.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -144.82 -175.18 17.75 Favored Glycine 0 N--CA 1.461 0.318 0 N-CA-C 111.229 -0.748 . . . . 10.0 111.229 -176.408 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 53.2 t -118.29 139.71 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 101.52 -3.511 . . . . 10.0 101.52 168.275 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.415 HD11 ' CD1' ' B' ' 117' ' ' LEU . 50.5 mt -59.32 -83.93 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 118.436 0.562 . . . . 10.0 110.33 -171.541 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 92.2 147.18 20.29 Favored Glycine 0 CA--C 1.52 0.363 0 O-C-N 121.724 -0.61 . . . . 10.0 112.65 178.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pt -73.6 154.31 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.393 -1.706 . . . . 10.0 106.393 168.15 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -52.91 6.43 Favored 'General case' 0 CA--C 1.512 -0.487 0 N-CA-C 106.078 -1.823 . . . . 10.0 106.078 169.748 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.252 1.187 0 O-C-N 126.328 2.268 . . . . 10.0 107.966 168.798 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.725 0 N-CA-C 108.004 -1.11 . . . . 10.0 108.004 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.0 t -171.41 -43.43 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 124.468 1.107 . . . . 10.0 109.622 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -104.57 147.0 28.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 125.769 1.628 . . . . 10.0 107.639 171.006 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.0 157.96 37.05 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 107.102 -1.444 . . . . 10.0 107.102 168.543 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.403 ' CG2' ' HA ' ' B' ' 52' ' ' ASP . 3.5 m -130.16 177.61 6.47 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-O 121.642 0.734 . . . . 10.0 110.447 177.619 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.81 121.3 4.03 Favored 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 103.462 -2.792 . . . . 10.0 103.462 166.932 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.97 111.55 34.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 107.206 -1.405 . . . . 10.0 107.206 178.119 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.17 142.3 28.51 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 -171.164 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 42.1 mtpt -144.57 162.13 37.39 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.379 -1.341 . . . . 10.0 107.379 169.995 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.43 -65.75 0.02 OUTLIER Glycine 0 C--O 1.229 -0.198 0 CA-C-N 115.403 -0.817 . . . . 10.0 111.501 171.281 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.44 -45.45 46.33 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 106.597 -1.631 . . . . 10.0 106.597 -173.468 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.29 -65.46 0.59 Allowed Glycine 0 N--CA 1.444 -0.79 0 CA-C-N 113.431 -1.713 . . . . 10.0 110.866 -175.719 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -54.36 -38.97 89.17 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.579 2.186 . . . . 10.0 111.367 173.101 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.4 t -66.87 101.31 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.043 0 N-CA-C 107.5 -1.296 . . . . 10.0 107.5 172.059 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -118.66 101.9 8.46 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.189 1.396 . . . . 10.0 107.709 171.278 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.875 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -83.89 148.36 24.55 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 125.13 1.348 . . . . 10.0 111.888 174.865 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.433 ' CG2' HG22 ' B' ' 54' ' ' THR . 0.8 OUTLIER -155.45 93.22 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 126.023 1.729 . . . . 10.0 106.463 -168.876 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.0 mm -86.49 151.18 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 C-N-CA 125.113 1.365 . . . . 10.0 109.767 179.045 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.1 m-80 -143.58 59.79 1.39 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.821 0.282 . . . . 10.0 111.725 179.402 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -47.68 120.91 3.63 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 117.559 -1.21 . . . . 10.0 109.417 -175.519 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -111.69 124.53 52.51 Favored 'General case' 0 C--O 1.233 0.2 0 N-CA-C 108.697 -0.853 . . . . 10.0 108.697 176.506 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.2 tp60 -125.43 85.44 2.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.777 1.231 . . . . 10.0 109.055 172.058 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.15 -43.74 7.24 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 127.007 2.123 . . . . 10.0 112.309 -179.254 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -153.5 173.67 15.41 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 105.95 -1.87 . . . . 10.0 105.95 169.498 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 49.2 m -66.24 -19.55 65.86 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 122.943 0.497 . . . . 10.0 110.694 175.099 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -79.11 -15.54 58.0 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.423 0.689 . . . . 10.0 110.113 175.963 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.55 156.35 33.28 Favored Glycine 0 CA--C 1.532 1.101 0 O-C-N 122.145 -0.347 . . . . 10.0 112.964 -175.14 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -75.68 144.8 28.48 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 N-CA-C 105.727 -2.451 . . . . 10.0 105.727 165.911 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.2 t -78.94 127.17 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.521 -1.659 . . . . 10.0 106.521 179.467 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 mtmt -95.93 110.9 23.03 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.942 -0.762 . . . . 10.0 108.942 172.986 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.0 m -85.05 56.52 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 123.888 0.875 . . . . 10.0 110.788 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -40.24 139.28 0.75 Allowed 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 124.32 1.048 . . . . 10.0 112.947 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -144.73 131.93 4.52 Favored Glycine 0 N--CA 1.437 -1.258 0 N-CA-C 107.382 -2.287 . . . . 10.0 107.382 168.279 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.1 m -123.68 62.03 1.06 Allowed 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 106.654 -1.61 . . . . 10.0 106.654 172.06 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.875 HG22 ' HA2' ' A' ' 16' ' ' GLY . 5.2 pt -78.08 116.58 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.29 -1.004 . . . . 10.0 108.29 -176.541 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -99.37 141.07 32.62 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 107.722 -1.214 . . . . 10.0 107.722 172.537 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.53 -5.86 18.87 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 124.272 0.939 . . . . 10.0 112.211 173.907 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -67.44 173.2 4.22 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 118.494 1.147 . . . . 10.0 110.143 176.251 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 9.8 t -106.26 150.36 25.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 106.839 -1.541 . . . . 10.0 106.839 167.957 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -48.14 147.28 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.795 1.238 . . . . 10.0 110.299 -175.747 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.57 179.8 28.14 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.391 -1.083 . . . . 10.0 110.391 176.198 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.25 153.79 35.73 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.532 1.533 . . . . 10.0 111.404 -172.014 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -145.08 141.61 28.98 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 125.001 1.32 . . . . 10.0 110.535 -179.425 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.41 124.58 7.93 Favored Glycine 0 C--N 1.344 1.024 0 N-CA-C 107.308 -2.317 . . . . 10.0 107.308 166.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 57.4 t80 -145.7 118.72 8.79 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 118.851 1.326 . . . . 10.0 109.112 171.989 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -159.22 171.76 19.28 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.287 0.565 . . . . 10.0 110.103 -174.817 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -91.46 148.79 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 CA-C-N 112.757 -2.019 . . . . 10.0 106.972 168.027 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 62.1 m-70 -120.12 139.96 51.79 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 106.17 -1.789 . . . . 10.0 106.17 173.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -47.08 -57.35 5.16 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 124.609 1.193 . . . . 10.0 111.461 -171.872 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.38 136.76 33.33 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 109.559 -0.534 . . . . 10.0 109.559 -177.611 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.38 -8.6 86.93 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.421 -1.072 . . . . 10.0 110.421 167.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -47.78 144.63 3.25 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 122.63 1.205 . . . . 10.0 109.748 169.568 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -148.38 29.43 0.86 Allowed 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 114.585 -1.188 . . . . 10.0 110.393 172.75 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.401 ' CG2' ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -58.41 -37.05 74.55 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 122.362 0.265 . . . . 10.0 111.609 -169.142 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.17 -23.51 40.98 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.652 0.781 . . . . 10.0 113.079 173.817 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.89 111.37 1.8 Allowed Glycine 0 CA--C 1.534 1.233 0 N-CA-C 110.178 -1.169 . . . . 10.0 110.178 -169.128 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 35.3 m 39.35 53.63 2.28 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 127.273 2.229 . . . . 10.0 114.07 170.901 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.1 m -156.17 -54.85 0.09 Allowed 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.526 -0.916 . . . . 10.0 108.526 178.569 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 14.8 m -61.39 -30.91 70.84 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.825 0.85 . . . . 10.0 112.127 -172.835 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -33.77 -30.31 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 129.188 2.995 . . . . 10.0 115.463 174.739 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.8 129.16 6.01 Favored Glycine 0 CA--C 1.524 0.633 0 CA-C-O 118.227 -1.318 . . . . 10.0 110.068 169.738 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.407 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 88.2 Cg_endo -73.91 65.92 5.0 Favored 'Trans proline' 0 CA--C 1.535 0.549 0 C-N-CA 124.21 3.273 . . . . 10.0 111.76 179.829 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 29.0 m170 56.9 58.12 4.24 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.236 2.614 . . . . 10.0 109.395 179.925 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.407 ' CZ ' ' HD2' ' A' ' 62' ' ' PRO . 42.6 m-85 -68.0 74.39 0.2 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 122.112 0.958 . . . . 10.0 111.695 -179.366 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.463 ' H ' HD22 ' A' ' 65' ' ' ASN . 0.8 OUTLIER -85.73 126.39 66.26 Favored Pre-proline 0 C--N 1.323 -0.551 0 C-N-CA 126.306 1.842 . . . . 10.0 111.18 -178.494 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -68.04 -37.6 14.55 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.986 2.457 . . . . 10.0 110.668 -177.915 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 79.6 mt -76.72 52.47 0.83 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.212 0.605 . . . . 10.0 109.405 171.571 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -41.13 90.34 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 127.568 2.347 . . . . 10.0 113.817 -169.675 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -116.19 -164.0 0.94 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.843 1.257 . . . . 10.0 109.151 -174.592 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -116.18 108.49 16.21 Favored 'General case' 0 C--O 1.224 -0.284 0 N-CA-C 107.865 -1.161 . . . . 10.0 107.865 -174.699 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.444 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 74.2 t60 -16.27 100.49 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.436 0 C-N-CA 126.11 1.764 . . . . 10.0 113.641 -179.218 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -109.47 -136.22 7.48 Favored Glycine 0 N--CA 1.449 -0.498 0 N-CA-C 108.022 -2.031 . . . . 10.0 108.022 -177.453 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 176.63 -165.39 35.61 Favored Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 108.262 -1.935 . . . . 10.0 108.262 169.195 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -67.64 12.85 0.19 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 121.751 1.634 . . . . 10.0 110.838 168.775 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.8 mmtp -104.52 -19.24 14.07 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 123.883 0.873 . . . . 10.0 108.89 172.286 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -119.7 167.19 12.29 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.375 -1.343 . . . . 10.0 107.375 -172.886 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -87.5 -24.57 24.05 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 108.49 -0.93 . . . . 10.0 108.49 172.106 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . 0.313 1.8 pt-20 -107.36 40.95 1.58 Allowed 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 115.882 1.808 . . . . 10.0 115.882 -166.237 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.539 ' CD ' ' H ' ' A' ' 79' ' ' ARG . 0.3 OUTLIER -46.61 145.88 1.72 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.182 -1.372 . . . . 10.0 107.973 166.634 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.444 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 21.6 m170 -54.31 -58.81 5.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 109.276 -0.639 . . . . 10.0 109.276 169.202 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.1 p -168.42 -55.75 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 C-N-CA 124.477 1.111 . . . . 10.0 108.379 175.188 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -127.63 55.1 0.76 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.116 -1.194 . . . . 10.0 110.116 -176.564 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -86.45 97.62 10.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.784 -1.932 . . . . 10.0 105.784 169.433 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.559 HD13 ' C ' ' A' ' 84' ' ' LEU . 1.9 tm? -72.69 -39.91 66.66 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 105.265 -2.124 . . . . 10.0 105.265 171.817 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 106.59 -106.98 2.62 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 109.127 -1.589 . . . . 10.0 109.127 166.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -106.72 131.41 53.89 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.301 1.04 . . . . 10.0 110.083 -168.004 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.1 m -120.63 129.03 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.325 0.511 . . . . 10.0 109.63 168.426 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.9 t -96.93 132.73 42.41 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 124.328 1.051 . . . . 10.0 109.757 -177.218 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.4 140.09 35.14 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 122.913 0.485 . . . . 10.0 110.759 176.277 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.34 170.68 2.22 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 123.759 0.824 . . . . 10.0 109.487 168.236 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.27 -23.43 48.31 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 123.65 0.78 . . . . 10.0 113.1 169.689 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -77.18 -8.18 57.11 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 122.773 0.429 . . . . 10.0 111.726 173.932 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.68 18.76 67.39 Favored Glycine 0 C--N 1.34 0.781 0 N-CA-C 110.16 -1.176 . . . . 10.0 110.16 -178.895 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 36.2 t -98.89 110.26 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.627 2.371 . . . . 10.0 106.927 -179.364 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.453 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -101.31 121.82 42.58 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 119.054 0.843 . . . . 10.0 109.202 169.448 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -101.59 78.2 1.82 Allowed 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 128.427 2.691 . . . . 10.0 110.948 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.43 61.34 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 C-N-CA 124.452 1.101 . . . . 10.0 112.311 -169.228 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -90.77 55.63 3.01 Favored 'General case' 0 C--N 1.317 -0.845 0 O-C-N 121.251 -0.905 . . . . 10.0 108.726 -178.447 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.58 145.74 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 108.333 -0.988 . . . . 10.0 108.333 -174.144 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.86 139.54 35.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 126.477 1.911 . . . . 10.0 110.001 178.09 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.73 159.63 41.63 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 108.172 -1.047 . . . . 10.0 108.172 166.334 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.1 t -124.66 55.81 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 124.444 1.098 . . . . 10.0 109.236 176.976 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.2 p -148.66 -41.28 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 123.586 0.754 . . . . 10.0 110.854 175.84 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 49.7 mm -67.13 89.28 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 C-N-CA 124.372 1.069 . . . . 10.0 109.543 170.657 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.8 m -88.44 123.99 33.52 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.615 0.766 . . . . 10.0 109.933 172.509 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.7 mt -48.25 -55.71 9.83 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.108 0.963 . . . . 10.0 111.076 177.237 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.5 p -135.49 175.34 9.68 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 127.271 2.229 . . . . 10.0 107.826 -179.165 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 132.22 -92.55 0.28 Allowed Glycine 0 C--N 1.335 0.493 0 N-CA-C 109.114 -1.595 . . . . 10.0 109.114 176.362 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -125.03 -52.23 1.66 Allowed 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.423 1.889 . . . . 10.0 107.655 179.323 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -74.3 -37.41 63.64 Favored 'General case' 0 N--CA 1.457 -0.116 0 CA-C-N 114.717 -1.129 . . . . 10.0 108.26 -173.518 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 25.8 t 44.4 65.99 0.95 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.824 1.65 . . . . 10.0 113.024 168.75 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.9 pp -65.19 -19.18 25.19 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 N-CA-C 113.252 0.834 . . . . 10.0 113.252 -174.161 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.0 mm -48.58 126.02 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 118.336 0.516 . . . . 10.0 109.706 172.653 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.34 1.52 55.68 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.77 -1.016 . . . . 10.0 113.779 -179.094 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.99 176.33 9.25 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 118.757 1.278 . . . . 10.0 109.984 169.179 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -113.13 140.57 47.79 Favored 'General case' 0 C--N 1.34 0.159 0 C-N-CA 124.505 1.122 . . . . 10.0 108.802 169.757 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -98.13 139.49 33.86 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 106.297 -1.742 . . . . 10.0 106.297 168.562 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 88.6 t -117.76 135.18 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 N-CA-C 107.349 -1.352 . . . . 10.0 107.349 170.93 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.39 122.07 55.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 N-CA-C 106.04 -1.837 . . . . 10.0 106.04 167.579 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.2 m-70 -100.44 161.78 13.38 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.92 1.343 . . . . 10.0 114.225 -169.253 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.624 ' HA ' HD22 ' A' ' 144' ' ' LEU . 29.2 tt0 -53.85 -68.8 0.15 Allowed 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.641 2.376 . . . . 10.0 109.107 177.31 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 57.2 mttp -106.92 168.37 9.24 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 123.476 0.71 . . . . 10.0 111.164 -178.125 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.62 142.35 58.46 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.593 1.157 . . . . 10.0 109.528 171.322 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -81.93 144.3 31.04 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.359 0.599 . . . . 10.0 109.902 168.381 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -78.43 7.8 6.07 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.079 0.951 . . . . 10.0 110.972 175.555 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 33.4 mt 49.75 45.62 24.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 124.133 0.973 . . . . 10.0 109.668 -177.835 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 98.38 -31.46 8.03 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 114.943 -1.026 . . . . 10.0 111.188 174.876 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 21.7 mtmm -84.23 42.34 0.88 Allowed 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.746 -0.855 . . . . 10.0 110.759 -170.108 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -93.85 -34.67 6.43 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 126.983 2.23 . . . . 10.0 109.999 176.719 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 58.64 47.9 87.64 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 111.73 -0.548 . . . . 10.0 111.73 -174.402 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -137.49 173.34 11.77 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.1 -1.815 . . . . 10.0 106.1 169.552 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -54.69 -54.05 46.82 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 109.195 -0.669 . . . . 10.0 109.195 173.502 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -58.71 -31.38 68.2 Favored 'General case' 0 C--N 1.344 0.359 0 O-C-N 121.396 -0.815 . . . . 10.0 112.502 179.452 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.3 p -51.18 -34.88 33.54 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 119.646 1.112 . . . . 10.0 110.461 178.276 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.3 t -98.34 11.13 39.02 Favored 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 113.549 0.944 . . . . 10.0 113.549 -179.793 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 73.3 mmtt -120.36 -54.67 2.08 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 125.299 1.44 . . . . 10.0 111.153 179.617 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -131.95 9.59 4.54 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 113.388 0.884 . . . . 10.0 113.388 171.92 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 87.14 16.18 61.32 Favored Glycine 0 C--O 1.221 -0.707 0 CA-C-O 119.216 -0.769 . . . . 10.0 113.366 173.063 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 69.36 17.75 8.1 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.188 0.994 . . . . 10.0 112.525 -177.121 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.08 -14.42 54.47 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 123.317 0.647 . . . . 10.0 112.005 176.553 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.87 -147.04 30.25 Favored Glycine 0 N--CA 1.442 -0.937 0 N-CA-C 109.816 -1.313 . . . . 10.0 109.816 169.848 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.3 m -61.07 121.31 12.14 Favored 'General case' 0 N--CA 1.444 -0.769 0 O-C-N 122.1 -0.647 . . . . 10.0 110.764 -168.74 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -56.24 71.25 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.866 1.666 . . . . 10.0 110.711 167.335 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.624 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.0 tp -45.91 -41.38 11.38 Favored 'General case' 0 N--CA 1.443 -0.799 0 C-N-CA 127.181 2.192 . . . . 10.0 112.925 -171.475 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.93 155.46 31.4 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 108.177 -1.046 . . . . 10.0 108.177 -175.78 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.1 p -164.12 170.85 15.89 Favored 'General case' 0 N--CA 1.454 -0.253 0 O-C-N 122.01 -0.431 . . . . 10.0 110.095 -176.705 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -166.95 -176.69 38.14 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.705 -1.358 . . . . 10.0 109.705 -177.629 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.89 143.28 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 106.699 -1.593 . . . . 10.0 106.699 -169.717 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 61.0 mt -73.55 137.4 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 122.784 0.434 . . . . 10.0 110.536 -176.405 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.72 141.59 12.77 Favored Glycine 0 CA--C 1.529 0.906 0 C-N-CA 125.306 1.432 . . . . 10.0 111.272 -178.537 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 42.5 mt -57.05 139.04 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 C-N-CA 125.212 1.405 . . . . 10.0 108.603 170.943 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.504 ' HB2' ' HB3' ' B' ' 52' ' ' ASP . . . -136.57 156.67 48.26 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-O 121.318 0.58 . . . . 10.0 109.887 172.032 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.287 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 165.667 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.68 0 N-CA-C 107.605 -1.257 . . . . 10.0 107.605 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -14.68 60.79 Favored 'General case' 0 CA--C 1.527 0.062 0 CA-C-N 118.857 0.753 . . . . 10.0 110.679 176.439 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 45.4 tttt -151.4 148.26 27.9 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.723 -0.473 . . . . 10.0 109.723 169.528 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.73 165.97 25.85 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.295 1.438 . . . . 10.0 107.501 169.543 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -131.61 164.06 35.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 123.426 0.69 . . . . 10.0 109.168 176.039 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -134.15 111.63 10.47 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 169.238 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.1 m -86.88 100.5 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 109.232 -0.655 . . . . 10.0 109.232 169.95 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.403 HD22 HG13 ' B' ' 119' ' ' VAL . 10.3 mt -78.83 134.37 36.97 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 123.912 0.885 . . . . 10.0 109.423 176.348 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -158.6 162.19 37.31 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 169.302 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -173.5 -56.85 0.05 OUTLIER Glycine 0 N--CA 1.454 -0.125 0 N-CA-C 111.485 -0.646 . . . . 10.0 111.485 171.205 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.37 -45.72 45.13 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 106.486 -1.672 . . . . 10.0 106.486 -170.923 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.4 -65.92 0.57 Allowed Glycine 0 CA--C 1.526 0.753 0 CA-C-N 113.6 -1.636 . . . . 10.0 110.734 -179.141 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -58.33 -36.8 97.26 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.913 2.409 . . . . 10.0 111.236 173.685 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.7 113.57 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.378 -0.971 . . . . 10.0 108.378 175.788 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.31 126.28 31.07 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.202 -1.036 . . . . 10.0 108.202 168.581 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.672 ' HA3' HG22 ' B' ' 35' ' ' ILE . . . -120.44 140.76 14.65 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-O 119.428 -0.651 . . . . 10.0 111.696 176.582 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.401 ' CG2' ' CG2' ' A' ' 54' ' ' THR . 10.6 mt -135.37 75.24 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 -169.276 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 35.2 mm -92.25 139.65 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.819 -0.628 . . . . 10.0 110.023 -174.293 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -114.62 120.94 41.87 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 128.419 2.688 . . . . 10.0 108.02 -178.104 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.9 105.56 14.41 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.315 1.446 . . . . 10.0 107.576 178.838 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -100.57 150.54 22.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 118.414 0.552 . . . . 10.0 111.122 178.277 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 63.8 tp60 -142.24 102.31 4.08 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 126.7 2.0 . . . . 10.0 108.264 -179.057 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp -65.18 -54.98 21.44 Favored 'General case' 0 N--CA 1.438 -1.069 0 C-N-CA 126.228 1.811 . . . . 10.0 110.879 -172.546 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -140.17 169.75 17.11 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 102.475 -3.157 . . . . 10.0 102.475 178.492 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 3.2 p -68.02 -18.31 64.67 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 120.71 1.596 . . . . 10.0 109.928 179.577 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 35.0 m120 -77.56 -19.21 56.04 Favored 'General case' 0 N--CA 1.441 -0.9 0 C-N-CA 123.792 0.837 . . . . 10.0 111.415 178.511 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.1 154.85 52.94 Favored Glycine 0 CA--C 1.533 1.184 0 N-CA-C 111.943 -0.463 . . . . 10.0 111.943 -174.54 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.18 154.34 61.94 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.418 2.079 . . . . 10.0 108.081 168.867 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 t -79.01 92.04 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 104.753 -2.314 . . . . 10.0 104.753 169.172 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 35.3 tttp -77.17 104.03 7.44 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 106.832 -1.544 . . . . 10.0 106.832 169.042 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -96.42 104.41 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 C-N-CA 126.566 1.946 . . . . 10.0 106.539 -179.352 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -122.24 163.03 20.33 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 112.693 0.627 . . . . 10.0 112.693 174.278 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.66 -154.15 25.33 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 106.866 -2.494 . . . . 10.0 106.866 169.666 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -155.14 160.55 41.02 Favored 'General case' 0 N--CA 1.446 -0.649 0 C-N-CA 120.134 -0.626 . . . . 10.0 110.198 176.705 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.672 HG22 ' HA3' ' B' ' 16' ' ' GLY . 1.8 pt -117.43 142.47 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.683 0 CA-C-N 114.262 -1.335 . . . . 10.0 109.557 167.475 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -117.35 149.54 40.32 Favored 'General case' 0 N--CA 1.443 -0.776 0 N-CA-C 106.864 -1.532 . . . . 10.0 106.864 168.385 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.04 -8.36 33.4 Favored Glycine 0 C--N 1.336 0.564 0 CA-C-O 119.34 -0.7 . . . . 10.0 112.731 171.395 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -62.15 175.36 0.73 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.198 0.999 . . . . 10.0 109.246 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.79 166.26 10.58 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 106.974 -1.491 . . . . 10.0 106.974 167.351 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -54.48 149.93 9.78 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.25 0.62 . . . . 10.0 111.469 -172.097 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.75 -168.6 31.81 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-O 121.763 0.646 . . . . 10.0 112.838 168.971 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.3 mp -75.26 144.8 42.37 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 126.824 2.05 . . . . 10.0 111.787 -169.652 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -147.85 145.08 28.57 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 113.813 1.042 . . . . 10.0 113.813 -177.322 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.637 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -28.22 128.41 0.07 OUTLIER Glycine 0 C--N 1.341 0.835 0 C-N-CA 127.284 2.373 . . . . 10.0 111.288 165.606 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -151.37 102.15 2.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 119.144 1.472 . . . . 10.0 111.675 169.861 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.446 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -150.57 170.07 20.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.764 0.653 . . . . 10.0 112.764 -179.83 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 24.2 m -97.4 -30.27 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 126.244 1.817 . . . . 10.0 113.986 -170.766 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 57.3 m-70 58.03 171.82 0.05 Allowed 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 122.905 1.336 . . . . 10.0 112.989 -177.571 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -83.25 -51.56 7.35 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 114.779 -1.101 . . . . 10.0 110.037 170.327 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -75.95 114.0 14.08 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 118.628 0.649 . . . . 10.0 109.669 -168.019 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.23 -31.71 81.75 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 107.824 -2.111 . . . . 10.0 107.824 165.792 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.504 ' HB3' ' HB2' ' A' ' 152' ' ' ALA . 1.7 p30 -58.82 161.46 4.83 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-O 123.251 1.5 . . . . 10.0 114.423 -176.551 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.14 21.68 0.08 Allowed 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 112.941 -1.936 . . . . 10.0 113.962 -168.128 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.433 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -58.31 -29.24 65.74 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 123.816 0.847 . . . . 10.0 111.75 -179.562 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.13 -15.95 59.35 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 122.909 0.484 . . . . 10.0 111.796 176.599 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.77 85.43 0.81 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 124.356 0.979 . . . . 10.0 111.049 178.521 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 65.5 m 37.6 47.53 0.8 Allowed 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 126.946 2.098 . . . . 10.0 112.146 -179.952 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.8 m -121.85 -54.89 1.92 Allowed 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 107.954 -1.128 . . . . 10.0 107.954 -169.659 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.0 t -128.34 54.81 1.72 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 124.021 0.928 . . . . 10.0 108.763 -177.472 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.02 49.97 0.45 Allowed 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 123.14 0.576 . . . . 10.0 110.399 172.149 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.0 125.92 0.13 Allowed Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.272 0.939 . . . . 10.0 111.448 172.346 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -77.46 47.39 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.86 0 C-N-CA 123.374 2.716 . . . . 10.0 112.605 179.607 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 60.76 47.79 7.64 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.931 2.492 . . . . 10.0 110.996 178.059 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -70.74 70.28 0.47 Allowed 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.886 0.85 . . . . 10.0 110.778 174.602 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . 0.414 ' HB3' ' HB3' ' B' ' 80' ' ' HIS . 4.9 p-10 -71.62 148.56 92.88 Favored Pre-proline 0 C--N 1.325 -0.467 0 C-N-CA 123.388 0.675 . . . . 10.0 112.709 -174.17 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -64.52 -46.61 6.93 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.975 2.45 . . . . 10.0 111.522 -179.722 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -78.89 48.9 0.87 Allowed 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.538 -0.726 . . . . 10.0 110.002 178.553 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 64.1 p -14.94 102.93 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 129.711 3.204 . . . . 10.0 113.466 -170.209 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 mtt85 -137.07 -179.77 5.91 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 118.612 0.642 . . . . 10.0 112.635 -170.635 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -111.79 102.09 10.4 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 105.753 -1.943 . . . . 10.0 105.753 -176.836 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.462 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 86.5 t60 -22.66 107.51 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.455 1.902 . . . . 10.0 114.185 -171.274 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -120.03 -149.55 8.38 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.964 -1.255 . . . . 10.0 109.964 176.652 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.96 -162.66 22.65 Favored Glycine 0 C--N 1.331 0.301 0 N-CA-C 108.51 -1.836 . . . . 10.0 108.51 -179.316 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -64.94 -6.69 13.26 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 121.367 1.378 . . . . 10.0 109.797 165.551 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 30.2 mmtt -101.89 2.43 38.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.82 1.648 . . . . 10.0 110.099 177.35 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.423 ' OD2' ' NZ ' ' B' ' 128' ' ' LYS . 3.7 t70 -129.32 170.98 12.95 Favored 'General case' 0 N--CA 1.443 -0.799 0 N-CA-C 107.498 -1.297 . . . . 10.0 107.498 167.399 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -91.59 -27.17 18.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.426 -0.953 . . . . 10.0 108.426 169.186 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -102.89 39.3 1.57 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 122.831 1.301 . . . . 10.0 110.206 -169.124 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 5.7 ptp180 -55.89 142.3 35.86 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 126.057 1.743 . . . . 10.0 108.941 169.664 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.462 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 25.0 m170 -64.98 -56.74 11.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 O-C-N 121.855 -0.528 . . . . 10.0 110.237 -175.181 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.515 HG13 ' H ' ' B' ' 82' ' ' GLY . 3.6 p -170.37 -68.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.992 -0.744 . . . . 10.0 108.992 176.908 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.515 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -118.2 67.91 0.34 Allowed Glycine 0 C--N 1.333 0.413 0 N-CA-C 107.522 -2.231 . . . . 10.0 107.522 -179.41 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -106.79 97.65 7.41 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 104.322 -2.473 . . . . 10.0 104.322 172.407 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 23.9 mt -82.09 22.94 0.75 Allowed 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.235 0.541 . . . . 10.0 110.56 -173.612 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.85 -104.85 2.36 Favored Glycine 0 N--CA 1.437 -1.287 0 N-CA-C 106.422 -2.671 . . . . 10.0 106.422 173.596 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -157.64 151.28 23.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.726 -1.213 . . . . 10.0 107.726 169.704 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.0 m -113.9 137.25 47.73 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 O-C-N 123.835 0.709 . . . . 10.0 109.547 -175.032 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 88.7 m -94.89 109.35 21.36 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 128.364 2.666 . . . . 10.0 108.491 -171.975 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.25 136.49 32.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 122.904 0.482 . . . . 10.0 110.205 174.845 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -57.56 171.51 0.44 Allowed 'General case' 0 C--O 1.235 0.298 0 O-C-N 124.079 0.862 . . . . 10.0 108.841 166.323 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 58.3 pttt -57.45 -29.04 63.87 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 123.541 0.736 . . . . 10.0 110.508 175.524 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -79.13 -0.64 32.54 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.785 0.834 . . . . 10.0 111.051 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.19 4.69 88.05 Favored Glycine 0 C--N 1.339 0.736 0 O-C-N 120.99 -1.069 . . . . 10.0 110.79 179.644 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.66 97.3 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.052 0 C-N-CA 126.128 1.771 . . . . 10.0 107.52 -178.008 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.461 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -101.72 118.83 37.75 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 108.367 -0.975 . . . . 10.0 108.367 169.192 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -82.15 129.13 34.74 Favored 'General case' 0 N--CA 1.437 -1.124 0 C-N-CA 126.856 2.062 . . . . 10.0 109.9 174.633 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.17 134.06 58.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 C-N-CA 125.907 1.683 . . . . 10.0 107.769 173.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 13.7 p -158.44 57.44 0.45 Allowed 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 112.804 0.668 . . . . 10.0 112.804 171.791 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -97.86 155.76 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.921 -0.77 . . . . 10.0 108.921 -172.075 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -116.47 99.25 7.05 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 126.546 1.938 . . . . 10.0 110.38 174.358 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -81.72 85.42 6.6 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.626 -1.249 . . . . 10.0 107.626 176.417 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 64.7 p -83.15 60.51 5.56 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 106.315 -1.735 . . . . 10.0 106.315 173.168 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.84 -47.77 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 O-C-N 123.356 0.41 . . . . 10.0 110.273 -170.9 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.325 0.0 OUTLIER -103.42 176.87 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 C-N-CA 123.74 0.816 . . . . 10.0 112.033 169.378 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -140.7 123.98 16.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.49 -29.57 50.51 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.358 1.463 . . . . 10.0 111.318 -179.031 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.4 m -140.1 135.73 32.84 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.085 -1.82 . . . . 10.0 106.085 167.23 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.01 -64.2 0.19 Allowed Glycine 0 C--N 1.333 0.393 0 N-CA-C 108.819 -1.713 . . . . 10.0 108.819 -175.096 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -166.4 -50.38 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 125.979 1.712 . . . . 10.0 107.872 -179.787 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 -74.73 -36.65 62.65 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.858 -1.064 . . . . 10.0 109.527 -169.278 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 7.5 t 31.43 73.61 0.06 Allowed 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.68 2.392 . . . . 10.0 111.818 169.723 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.95 20.17 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 124.796 1.238 . . . . 10.0 114.291 -174.477 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 17.9 mm -54.92 146.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 C-N-CA 125.538 1.535 . . . . 10.0 108.085 168.745 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.91 21.99 69.98 Favored Glycine 0 CA--C 1.533 1.169 0 CA-C-O 118.599 -1.111 . . . . 10.0 114.335 178.278 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.2 mmt180 -97.53 172.55 7.66 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 106.808 -1.553 . . . . 10.0 106.808 166.513 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -124.22 108.54 12.38 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 119.082 0.855 . . . . 10.0 111.454 -170.529 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.418 HD21 HD11 ' B' ' 149' ' ' ILE . 3.7 mm? -64.89 134.21 53.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 107.344 -1.354 . . . . 10.0 107.344 169.743 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 64.6 t -125.11 131.37 72.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 106.83 -1.544 . . . . 10.0 106.83 174.747 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.403 HG13 HD22 ' B' ' 8' ' ' LEU . 2.4 m -105.99 131.52 55.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 O-C-N 124.007 0.817 . . . . 10.0 110.084 169.466 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.637 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 5.3 m170 -113.04 163.5 14.62 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 114.813 1.412 . . . . 10.0 114.813 -170.583 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -51.31 -55.51 17.94 Favored 'General case' 0 N--CA 1.441 -0.889 0 C-N-CA 127.172 2.189 . . . . 10.0 109.468 -179.393 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -121.05 174.27 6.75 Favored 'General case' 0 CA--C 1.521 -0.154 0 C-N-CA 124.366 1.066 . . . . 10.0 112.228 -171.155 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.6 151.65 30.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.857 1.263 . . . . 10.0 110.06 -179.835 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.446 ' CG ' ' HE2' ' B' ' 46' ' ' HIS . 0.9 OUTLIER -78.37 153.68 31.42 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 123.773 0.829 . . . . 10.0 111.799 175.733 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -76.31 -27.98 56.77 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 114.897 -1.047 . . . . 10.0 109.4 168.742 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 68.9 mt 59.52 52.04 6.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 123.669 1.7 . . . . 10.0 108.524 -172.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 91.65 -41.53 2.84 Favored Glycine 0 N--CA 1.443 -0.852 0 CA-C-N 111.655 -2.52 . . . . 10.0 111.489 169.171 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.423 ' NZ ' ' OD2' ' B' ' 76' ' ' ASP . 19.1 mtmm -79.26 41.44 0.46 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.34 1.456 . . . . 10.0 112.47 -170.863 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.46 -15.73 34.07 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 126.653 2.073 . . . . 10.0 110.497 169.332 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 51.34 46.69 51.93 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 124.393 0.997 . . . . 10.0 111.951 -179.309 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.5 p30 -151.07 172.83 15.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 118.249 1.024 . . . . 10.0 109.883 176.216 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.3 tm-20 -55.18 -41.02 71.37 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.697 1.199 . . . . 10.0 110.915 -176.689 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 19.0 tp10 -71.42 -39.07 71.31 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 121.681 -0.637 . . . . 10.0 110.587 174.121 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.5 p -52.24 -43.92 64.56 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 118.451 0.569 . . . . 10.0 110.57 -176.376 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 14.3 t -74.92 -10.53 59.58 Favored 'General case' 0 CA--C 1.543 0.703 0 O-C-N 124.332 1.02 . . . . 10.0 113.058 -177.216 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 21.6 ttmt -115.21 -64.64 1.29 Allowed 'General case' 0 N--CA 1.436 -1.131 0 C-N-CA 126.973 2.109 . . . . 10.0 112.899 -168.878 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 2.5 p -126.46 17.01 7.63 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 120.048 1.295 . . . . 10.0 110.208 175.939 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.53 -105.7 1.91 Allowed Glycine 0 C--N 1.339 0.744 0 N-CA-C 106.952 -2.459 . . . . 10.0 106.952 -173.877 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -152.52 39.38 0.56 Allowed 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 107.156 -1.424 . . . . 10.0 107.156 170.009 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.22 -26.32 64.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.231 -0.895 . . . . 10.0 111.144 -177.03 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.48 -142.61 23.0 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 124.876 1.226 . . . . 10.0 110.379 170.707 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 3.9 m -69.16 134.96 49.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 -175.82 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . 0.401 ' NE ' ' H ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -63.07 120.84 12.21 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 106.414 -1.698 . . . . 10.0 106.414 167.758 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 31.9 mt -76.65 -60.43 2.35 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 108.274 -1.009 . . . . 10.0 108.274 169.547 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -139.18 163.17 33.14 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 122.974 0.51 . . . . 10.0 110.104 -174.03 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.1 p -154.15 163.71 39.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.353 -0.385 . . . . 10.0 110.443 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.33 149.1 18.22 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 109.418 -1.473 . . . . 10.0 109.418 -171.624 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -108.67 139.65 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 C-N-CA 124.916 1.286 . . . . 10.0 108.041 -169.065 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.418 HD11 HD21 ' B' ' 117' ' ' LEU . 19.0 mt -77.5 112.32 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 122.916 0.486 . . . . 10.0 109.966 -173.455 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.75 143.54 18.09 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.808 1.194 . . . . 10.0 112.21 -174.451 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.49 136.34 25.81 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.296 0 C-N-CA 126.315 1.846 . . . . 10.0 110.333 -175.758 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -123.74 -46.78 1.98 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.681 0.673 . . . . 10.0 111.759 177.821 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 . . . . . 0 C--O 1.25 1.103 0 CA-C-O 116.368 -1.777 . . . . 10.0 112.107 -169.443 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.674 0 N-CA-C 108.411 -0.959 . . . . 10.0 108.411 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -80.06 -21.52 43.33 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 107.948 -1.13 . . . . 10.0 107.948 168.144 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.494 ' HZ3' ' C ' ' A' ' 153' ' ' GLN . 1.8 ttmp? -127.04 161.5 28.24 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.763 1.625 . . . . 10.0 107.868 179.078 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -153.24 164.28 38.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.435 -1.691 . . . . 10.0 106.435 168.337 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.41 ' O ' HG23 ' A' ' 149' ' ' ILE . 2.5 m -125.76 -179.9 2.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 118.08 0.4 . . . . 10.0 110.094 -179.429 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -154.71 108.37 2.9 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.852 -0.795 . . . . 10.0 108.852 165.207 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.47 HG21 ' HB3' ' B' ' 53' ' ' ASN . 1.3 m -92.91 115.53 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.057 -0.72 . . . . 10.0 109.057 171.282 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.7 mt -103.85 150.32 24.25 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.751 1.221 . . . . 10.0 109.224 -179.801 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.6 ttmt -163.12 159.83 23.57 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.721 1.146 . . . . 10.0 109.204 169.836 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.42 -56.35 0.02 OUTLIER Glycine 0 C--O 1.229 -0.197 0 N-CA-C 111.349 -0.7 . . . . 10.0 111.349 169.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -75.25 -45.85 37.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 106.575 -1.639 . . . . 10.0 106.575 -172.825 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.5 -64.85 0.6 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 113.859 -1.519 . . . . 10.0 110.902 -178.413 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -58.3 -41.29 67.86 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 122.512 2.142 . . . . 10.0 110.839 172.08 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -70.43 105.38 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.953 0 N-CA-C 106.427 -1.694 . . . . 10.0 106.427 176.361 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.81 131.93 46.34 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.766 -0.827 . . . . 10.0 108.766 167.296 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.938 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -99.39 147.52 18.39 Favored Glycine 0 N--CA 1.441 -1.005 0 N-CA-C 109.658 -1.377 . . . . 10.0 109.658 174.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.624 HG22 HG23 ' B' ' 54' ' ' THR . 1.0 OUTLIER -150.81 81.8 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 105.355 -2.091 . . . . 10.0 105.355 -170.422 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.1 mm -100.51 146.33 9.41 Favored 'Isoleucine or valine' 0 C--N 1.338 0.1 0 C-N-CA 125.091 1.356 . . . . 10.0 109.738 -178.283 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -126.0 117.15 22.65 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 127.502 2.321 . . . . 10.0 109.005 170.172 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -98.41 116.86 31.53 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 106.817 -1.549 . . . . 10.0 106.817 173.269 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -116.62 138.5 51.39 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 119.476 1.034 . . . . 10.0 112.948 171.18 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -114.35 85.37 2.22 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.728 2.011 . . . . 10.0 107.966 -178.176 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.42 ' NZ ' ' OE2' ' A' ' 100' ' ' GLU . 0.0 OUTLIER -46.07 -44.09 15.14 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.711 1.605 . . . . 10.0 111.366 -172.643 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -142.95 168.46 19.65 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 102.989 -2.967 . . . . 10.0 102.989 165.534 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.0 t -61.71 -29.17 69.93 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.315 -0.624 . . . . 10.0 109.315 174.525 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.6 m-80 -81.09 -17.52 49.73 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 124.397 1.079 . . . . 10.0 110.783 -179.225 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.41 141.97 16.48 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 110.446 -1.062 . . . . 10.0 110.446 -171.174 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -63.55 136.48 54.6 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.078 1.852 . . . . 10.0 109.221 174.872 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.6 m -78.03 124.39 36.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.006 0 N-CA-C 107.814 -1.18 . . . . 10.0 107.814 -176.458 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 37.7 ttmt -88.11 116.48 26.33 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.759 -2.682 . . . . 10.0 103.759 167.591 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.6 p -97.51 104.19 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 N-CA-C 106.382 -1.71 . . . . 10.0 106.382 171.258 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 21.2 p90 -112.88 167.65 10.33 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 116.129 -0.487 . . . . 10.0 110.086 176.473 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 174.36 176.15 42.51 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.878 -1.153 . . . . 10.0 111.688 178.33 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.6 t -144.84 99.17 3.3 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 107.775 -1.194 . . . . 10.0 107.775 177.252 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.938 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.4 pt -80.57 153.61 4.39 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.599 0 N-CA-C 107.584 -1.265 . . . . 10.0 107.584 168.4 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.68 151.06 50.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 124.062 0.851 . . . . 10.0 109.085 167.83 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.65 -8.91 34.73 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.967 0.794 . . . . 10.0 113.541 175.443 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -61.06 176.27 0.44 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 122.301 1.048 . . . . 10.0 111.188 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -107.4 151.38 25.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 106.579 -1.638 . . . . 10.0 106.579 166.999 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -49.44 144.19 5.87 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.244 1.017 . . . . 10.0 111.717 -169.826 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.83 -168.01 21.18 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 123.685 0.659 . . . . 10.0 112.203 172.751 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -75.81 148.75 38.19 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.842 2.057 . . . . 10.0 111.768 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -147.6 134.24 19.9 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.477 1.111 . . . . 10.0 111.472 179.344 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.402 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -38.23 123.61 1.33 Allowed Glycine 0 C--N 1.345 1.076 0 C-N-CA 124.843 1.211 . . . . 10.0 111.02 168.337 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.516 ' HZ ' HG21 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -136.75 108.64 7.1 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 124.133 0.973 . . . . 10.0 109.37 176.397 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -155.57 174.4 15.32 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 121.788 0.804 . . . . 10.0 111.712 -178.101 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.7 m -102.35 144.65 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.714 0 CA-C-N 111.798 -2.456 . . . . 10.0 106.369 168.214 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -121.66 148.07 45.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 107.246 -1.39 . . . . 10.0 107.246 176.543 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.409 ' HB3' ' CE1' ' A' ' 64' ' ' PHE . 2.3 tp10 -59.43 -39.32 83.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 122.854 0.462 . . . . 10.0 112.213 -169.963 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -74.76 153.23 38.9 Favored 'General case' 0 CA--C 1.527 0.079 0 C-N-CA 118.358 -1.337 . . . . 10.0 109.561 177.205 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.58 -11.84 46.3 Favored Glycine 0 CA--C 1.54 1.602 0 N-CA-C 109.385 -1.486 . . . . 10.0 109.385 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -48.2 107.13 0.11 Allowed 'General case' 0 C--N 1.344 0.357 0 C-N-CA 126.653 1.981 . . . . 10.0 112.382 172.658 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -112.68 6.44 18.23 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 113.268 -1.787 . . . . 10.0 109.34 168.015 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.408 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -57.8 -39.92 78.7 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.254 1.021 . . . . 10.0 109.456 -178.91 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.5 -15.52 58.51 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.053 0.941 . . . . 10.0 112.699 177.622 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.48 -108.08 3.06 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 108.736 -1.746 . . . . 10.0 108.736 -173.13 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 60.9 m -131.0 43.7 3.06 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 124.307 1.043 . . . . 10.0 109.43 -173.215 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 55.3 m -130.18 -54.24 1.11 Allowed 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 125.796 1.638 . . . . 10.0 107.141 -171.748 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.9 t -80.75 4.61 18.36 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.265 0.555 . . . . 10.0 111.663 178.445 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -51.54 -25.87 7.52 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.871 1.268 . . . . 10.0 112.415 173.137 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.42 144.99 18.26 Favored Glycine 0 C--N 1.339 0.742 0 N-CA-C 110.576 -1.01 . . . . 10.0 110.576 173.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -80.07 57.74 6.65 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 CA-C-N 120.584 2.192 . . . . 10.0 111.399 179.649 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.477 ' CD2' HG22 ' A' ' 137' ' ' THR . 21.9 m170 71.77 -62.27 0.46 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 127.122 2.169 . . . . 10.0 108.211 -175.685 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.409 ' CE1' ' HB3' ' A' ' 49' ' ' GLU 0.343 3.1 p90 34.28 36.72 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 129.998 3.319 . . . . 10.0 116.85 174.635 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -45.29 152.24 0.64 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 129.837 3.255 . . . . 10.0 113.287 167.78 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -74.17 -48.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.493 2.795 . . . . 10.0 111.29 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 81.7 mt -68.82 83.44 0.3 Allowed 'General case' 0 C--N 1.339 0.145 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 172.839 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.7 p -69.54 64.65 0.18 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 126.628 1.971 . . . . 10.0 113.982 -169.358 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -87.73 -178.75 6.14 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 126.575 1.95 . . . . 10.0 109.779 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt -111.43 84.98 2.04 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-O 121.188 0.518 . . . . 10.0 112.205 -169.356 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.451 ' HB2' ' CE1' ' A' ' 80' ' ' HIS . 64.8 t60 11.14 87.3 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 128.009 2.524 . . . . 10.0 114.627 175.791 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -110.26 -161.44 18.33 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 108.681 -1.767 . . . . 10.0 108.681 174.923 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.17 -155.88 6.73 Favored Glycine 0 C--O 1.224 -0.495 0 CA-C-O 117.671 -1.627 . . . . 10.0 110.512 170.106 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -64.91 -2.05 5.01 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 CA-C-N 120.756 2.278 . . . . 10.0 111.27 171.139 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 29.3 mtpt -88.41 -17.6 30.14 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.245 -0.884 . . . . 10.0 110.801 172.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -128.98 174.83 9.17 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 118.812 0.733 . . . . 10.0 109.482 -175.831 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -97.51 -15.05 20.73 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.707 0.803 . . . . 10.0 109.505 168.539 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 70.5 mm-40 -79.69 10.74 3.7 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.145 1.378 . . . . 10.0 112.78 178.712 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 16.4 ptt180 -51.65 127.56 20.84 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 106.669 -1.604 . . . . 10.0 106.669 166.995 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.451 ' CE1' ' HB2' ' A' ' 71' ' ' HIS . 21.3 m170 -65.7 -51.1 62.03 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 122.11 -0.369 . . . . 10.0 111.512 -169.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.6 p -166.94 -30.29 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 123.026 0.531 . . . . 10.0 111.804 -169.626 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.69 70.97 0.08 OUTLIER Glycine 0 C--N 1.334 0.442 0 N-CA-C 106.199 -2.761 . . . . 10.0 106.199 -176.557 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -116.58 91.11 3.49 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 104.816 -2.29 . . . . 10.0 104.816 -169.554 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp -72.86 -28.83 62.75 Favored 'General case' 0 CA--C 1.527 0.09 0 N-CA-C 107.314 -1.365 . . . . 10.0 107.314 -178.151 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 99.53 -87.78 0.77 Allowed Glycine 0 N--CA 1.44 -1.04 0 N-CA-C 106.493 -2.643 . . . . 10.0 106.493 172.12 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -140.98 149.38 41.71 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 122.884 0.473 . . . . 10.0 111.902 -176.414 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 m -129.32 143.41 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 105.506 -2.035 . . . . 10.0 105.506 168.093 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -95.48 121.58 37.31 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.357 1.863 . . . . 10.0 107.521 -176.285 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.14 137.4 32.37 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.721 -0.474 . . . . 10.0 109.721 171.208 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -67.5 173.25 4.25 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 126.193 1.797 . . . . 10.0 109.786 168.966 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -56.68 -24.36 48.28 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 124.75 1.22 . . . . 10.0 112.274 177.825 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -78.24 -17.61 56.48 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.092 -0.336 . . . . 10.0 110.092 179.527 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.28 7.74 69.39 Favored Glycine 0 C--N 1.338 0.647 0 N-CA-C 110.525 -1.03 . . . . 10.0 110.525 -171.86 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -80.7 119.54 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 N-CA-C 106.714 -1.587 . . . . 10.0 106.714 172.938 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.568 ' HB3' HD11 ' A' ' 35' ' ' ILE . . . -113.94 118.78 35.14 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 119.11 0.868 . . . . 10.0 108.691 169.482 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -79.2 117.35 20.14 Favored 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 126.366 1.866 . . . . 10.0 108.096 174.345 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 46.5 t -105.93 131.39 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.728 -1.582 . . . . 10.0 106.728 178.537 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 80.0 p -157.77 71.75 0.63 Allowed 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.735 0.814 . . . . 10.0 109.579 173.069 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.58 155.0 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 106.92 -1.511 . . . . 10.0 106.92 177.456 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.42 ' OE2' ' NZ ' ' A' ' 23' ' ' LYS . 26.3 tt0 -135.95 128.18 30.02 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 124.914 1.286 . . . . 10.0 108.276 174.742 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -136.7 152.8 50.78 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 124.046 0.842 . . . . 10.0 109.814 -177.601 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.4 p -118.68 48.75 1.39 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 127.484 2.314 . . . . 10.0 109.875 -171.068 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 14.6 p -155.34 -49.37 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 122.295 0.238 . . . . 10.0 110.655 173.002 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.5 mp -55.99 119.48 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.663 -1.606 . . . . 10.0 106.663 170.617 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.09 85.79 2.3 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 107.309 -1.367 . . . . 10.0 107.309 -176.038 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.2 pp -51.9 -10.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.603 1.561 . . . . 10.0 114.294 -177.961 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 24.9 t -148.36 137.01 21.55 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 103.953 -2.61 . . . . 10.0 103.953 168.862 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 141.78 -72.41 0.39 Allowed Glycine 0 C--N 1.334 0.421 0 N-CA-C 109.846 -1.301 . . . . 10.0 109.846 -176.526 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.45 -53.37 0.08 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 106.889 -1.523 . . . . 10.0 106.889 179.75 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -83.7 48.25 1.4 Allowed 'General case' 0 C--O 1.233 0.199 0 N-CA-C 109.269 -0.641 . . . . 10.0 109.269 -176.773 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.7 t -73.64 72.22 1.44 Allowed 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 125.072 1.349 . . . . 10.0 107.615 178.019 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.8 pt -72.2 39.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 126.251 1.821 . . . . 10.0 112.058 -177.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 44.2 mm -66.58 -47.5 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 125.246 1.418 . . . . 10.0 109.456 -178.445 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.77 51.3 3.74 Favored Glycine 0 CA--C 1.525 0.691 0 O-C-N 121.622 -0.674 . . . . 10.0 113.408 -175.053 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.29 145.81 46.72 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.734 -1.21 . . . . 10.0 107.734 -177.783 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 28.3 m -90.21 119.62 30.68 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 104.902 -2.259 . . . . 10.0 104.902 169.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.21 143.14 31.66 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 108.361 -0.977 . . . . 10.0 108.361 -179.453 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 55.3 t -129.81 136.29 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 O-C-N 124.321 1.013 . . . . 10.0 109.405 -169.528 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.563 HG13 ' HB3' ' A' ' 145' ' ' ALA . 0.4 OUTLIER -105.96 119.32 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 N-CA-C 105.067 -2.198 . . . . 10.0 105.067 168.603 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.402 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 13.1 m-70 -99.19 161.45 13.62 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 113.823 1.045 . . . . 10.0 113.823 -169.563 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.609 ' HA ' HD22 ' A' ' 144' ' ' LEU . 0.5 OUTLIER -64.77 -53.06 53.03 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.685 -1.143 . . . . 10.0 108.483 -176.92 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -113.12 176.64 4.93 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.902 0.858 . . . . 10.0 111.987 -178.462 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -69.89 135.99 50.14 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.067 1.347 . . . . 10.0 111.19 -178.495 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -77.49 110.13 12.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 124.491 1.116 . . . . 10.0 108.507 173.757 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -80.36 58.41 3.11 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 123.196 0.31 . . . . 10.0 111.284 -179.379 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.1 mt -11.86 81.49 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 129.346 3.058 . . . . 10.0 115.384 -177.797 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 75.61 -7.48 25.76 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.927 -0.929 . . . . 10.0 113.812 168.779 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.7 pttp -116.03 27.34 9.33 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 118.4 1.1 . . . . 10.0 112.316 -174.458 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.23 -18.26 79.76 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.437 1.018 . . . . 10.0 111.273 170.662 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.83 44.33 98.01 Favored Glycine 0 CA--C 1.53 0.971 0 O-C-N 121.655 -0.909 . . . . 10.0 112.138 173.007 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.45 ' H ' ' HB2' ' A' ' 134' ' ' SER . 7.3 p30 -164.15 175.81 9.84 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 126.272 1.829 . . . . 10.0 106.821 177.913 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -56.0 -42.09 75.88 Favored 'General case' 0 N--CA 1.439 -1.023 0 CA-C-N 119.014 0.824 . . . . 10.0 111.906 -174.593 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -61.03 -28.79 69.31 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.813 -0.554 . . . . 10.0 110.179 -179.823 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.45 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 3.4 t -47.92 -46.02 31.43 Favored 'General case' 0 CA--C 1.519 -0.243 0 C-N-CA 124.228 1.011 . . . . 10.0 109.219 176.243 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.0 t -90.73 8.46 34.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 112.59 0.589 . . . . 10.0 112.59 -175.859 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.97 -81.19 0.63 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.045 1.338 . . . . 10.0 110.565 -178.918 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.477 HG22 ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -112.1 29.45 7.88 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 121.735 2.061 . . . . 10.0 111.537 174.091 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.95 -87.34 0.13 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 125.35 1.453 . . . . 10.0 110.823 179.012 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.404 ' ND2' HD21 ' A' ' 131' ' ' ASN . 0.4 OUTLIER -165.64 33.24 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 122.115 -0.638 . . . . 10.0 112.211 170.627 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.13 -13.42 61.94 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.586 0.587 . . . . 10.0 112.586 -174.014 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.61 -147.57 45.49 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 108.217 -1.953 . . . . 10.0 108.217 174.223 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.3 m -58.56 120.44 8.86 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 122.729 0.412 . . . . 10.0 111.765 -169.54 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.65 73.68 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.488 1.515 . . . . 10.0 111.623 168.04 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.609 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.7 tp -38.45 -49.74 1.49 Allowed 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.139 2.176 . . . . 10.0 113.894 -179.883 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.563 ' HB3' HG13 ' A' ' 119' ' ' VAL . . . -156.01 158.09 37.27 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.652 -1.24 . . . . 10.0 107.652 -170.856 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 20.0 p -164.35 171.82 14.3 Favored 'General case' 0 N--CA 1.454 -0.247 0 O-C-N 121.759 -0.588 . . . . 10.0 111.222 -171.866 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -172.65 -161.39 23.0 Favored Glycine 0 N--CA 1.451 -0.334 0 N-CA-C 110.224 -1.15 . . . . 10.0 110.224 -178.894 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.6 t -133.0 154.66 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.392 -2.077 . . . . 10.0 105.392 -172.891 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.41 HG23 ' O ' ' A' ' 5' ' ' VAL . 2.8 mt -69.17 -85.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 123.613 0.765 . . . . 10.0 110.147 -169.301 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 98.54 132.92 7.81 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.151 -0.779 . . . . 10.0 111.151 179.645 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 58.1 mt -68.51 145.31 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 123.435 0.694 . . . . 10.0 110.069 -179.262 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.89 176.27 8.86 Favored 'General case' 0 N--CA 1.442 -0.856 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 164.732 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . 0.494 ' C ' ' HZ3' ' A' ' 3' ' ' LYS . 15.1 tt0 . . . . . 0 N--CA 1.44 -0.967 0 N-CA-C 106.213 -1.773 . . . . 10.0 106.213 167.889 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.636 0 N-CA-C 108.424 -0.954 . . . . 10.0 108.424 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.3 t -78.96 -14.58 59.13 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.436 0.695 . . . . 10.0 110.662 -178.149 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.0 ttmt -134.32 149.22 50.86 Favored 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 125.023 1.329 . . . . 10.0 107.774 -179.716 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -138.64 151.63 47.39 Favored 'General case' 0 CA--C 1.512 -0.505 0 C-N-CA 123.32 0.648 . . . . 10.0 109.382 169.48 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -106.62 154.63 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.223 0 O-C-N 124.741 1.276 . . . . 10.0 111.813 -172.576 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . 0.455 ' HB1' HD21 ' B' ' 8' ' ' LEU . . . -144.8 93.79 2.46 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 123.217 0.323 . . . . 10.0 111.449 169.28 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.3 m -81.65 103.54 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.365 0 N-CA-C 109.328 -0.619 . . . . 10.0 109.328 169.17 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.455 HD21 ' HB1' ' B' ' 6' ' ' ALA . 10.9 mt -97.36 127.37 43.26 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.336 1.054 . . . . 10.0 109.029 -177.796 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 44.3 mtpt -146.86 161.64 40.29 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 120.367 1.439 . . . . 10.0 108.66 173.76 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.31 -55.37 0.06 OUTLIER Glycine 0 N--CA 1.461 0.325 0 CA-C-N 115.798 -0.637 . . . . 10.0 113.318 168.63 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -72.63 -43.78 62.8 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.63 -1.248 . . . . 10.0 107.63 -176.477 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 142.12 -70.61 0.42 Allowed Glycine 0 CA--C 1.524 0.613 0 CA-C-N 114.334 -1.303 . . . . 10.0 109.923 170.075 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -58.27 -33.86 98.04 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.427 2.751 . . . . 10.0 111.291 172.044 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 88.9 t -65.01 100.62 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.637 -1.245 . . . . 10.0 107.637 176.179 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -124.55 108.29 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 C-N-CA 125.606 1.562 . . . . 10.0 108.117 177.978 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.02 143.46 16.49 Favored Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.949 -1.26 . . . . 10.0 109.949 167.934 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.408 ' CG2' HG22 ' A' ' 54' ' ' THR . 2.4 mt -141.62 67.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.651 -1.611 . . . . 10.0 106.651 -179.797 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.06 148.96 4.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.476 0.655 . . . . 10.0 110.852 -174.926 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -123.53 119.31 29.56 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 125.703 1.601 . . . . 10.0 109.263 169.834 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -94.73 124.6 38.86 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 116.712 -1.614 . . . . 10.0 106.653 168.332 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -112.52 136.54 51.91 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 119.592 1.087 . . . . 10.0 111.184 165.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -89.27 112.71 23.84 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.025 -2.213 . . . . 10.0 105.025 168.471 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 1.9 mmpt? -55.29 -58.11 9.04 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 125.649 1.58 . . . . 10.0 110.075 -171.554 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 80.4 mt-10 -122.67 -130.42 0.27 Allowed 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 105.146 -2.168 . . . . 10.0 105.146 176.969 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 19.8 t -103.69 -36.82 7.74 Favored 'General case' 0 N--CA 1.446 -0.662 0 O-C-N 123.288 0.368 . . . . 10.0 110.015 167.989 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -111.83 -1.41 15.57 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 124.298 1.039 . . . . 10.0 111.282 -175.279 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.42 156.75 53.43 Favored Glycine 0 CA--C 1.531 1.046 0 N-CA-C 109.361 -1.496 . . . . 10.0 109.361 175.622 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -59.17 145.54 97.41 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.263 1.976 . . . . 10.0 109.132 175.731 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 25.7 t -87.76 114.55 26.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 105.22 -2.141 . . . . 10.0 105.22 174.811 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 10.9 ttmm -89.21 119.75 29.97 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.831 -1.174 . . . . 10.0 107.831 169.895 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.4 p -89.44 107.91 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 C-N-CA 126.387 1.875 . . . . 10.0 106.397 169.593 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 18.0 p90 -126.3 164.63 20.61 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.886 0.851 . . . . 10.0 112.614 173.08 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 154.68 -152.93 24.43 Favored Glycine 0 N--CA 1.438 -1.208 0 N-CA-C 107.586 -2.205 . . . . 10.0 107.586 169.905 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 34.3 p -154.01 113.91 3.86 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 118.595 -0.717 . . . . 10.0 109.495 -169.956 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.615 ' CG1' ' HB3' ' B' ' 95' ' ' ALA . 2.8 pt -81.75 140.43 16.51 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 107.611 -1.255 . . . . 10.0 107.611 166.994 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -119.58 148.88 42.81 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 107.64 -1.244 . . . . 10.0 107.64 169.622 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.34 -5.85 41.76 Favored Glycine 0 CA--C 1.525 0.71 0 CA-C-O 119.365 -0.686 . . . . 10.0 113.652 174.965 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.34 176.8 2.12 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 118.584 1.192 . . . . 10.0 110.787 176.903 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -109.65 158.26 18.25 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 105.661 -1.977 . . . . 10.0 105.661 165.898 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -49.44 159.59 0.32 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.483 1.513 . . . . 10.0 112.487 -169.055 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.48 -172.94 35.04 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-O 121.786 0.659 . . . . 10.0 111.909 169.254 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -72.03 144.14 48.89 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.976 1.711 . . . . 10.0 110.207 -176.616 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -145.36 147.79 32.67 Favored 'General case' 0 C--N 1.34 0.182 0 C-N-CA 124.168 0.987 . . . . 10.0 113.036 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.639 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -20.37 117.73 0.01 OUTLIER Glycine 0 C--N 1.339 0.726 0 C-N-CA 129.36 3.362 . . . . 10.0 115.473 165.012 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -154.59 103.38 2.47 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 119.943 1.872 . . . . 10.0 111.541 170.736 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.446 ' CG ' ' CE1' ' B' ' 63' ' ' HIS . 2.2 m80 -133.6 -163.53 1.37 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 124.465 1.106 . . . . 10.0 111.188 179.415 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.2 p -116.66 -46.6 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 124.286 1.034 . . . . 10.0 112.045 -177.067 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 62.16 148.12 0.02 OUTLIER 'General case' 0 C--N 1.342 0.27 0 C-N-CA 125.589 1.556 . . . . 10.0 112.223 -171.595 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -75.31 -58.01 3.55 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 108.575 -0.898 . . . . 10.0 108.575 177.297 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.6 m-30 -77.78 128.05 33.4 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 -172.797 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.91 -1.61 87.57 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.257 -1.537 . . . . 10.0 109.257 165.781 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -41.06 140.21 0.8 Allowed 'General case' 0 C--N 1.346 0.425 0 CA-C-N 117.982 0.891 . . . . 10.0 110.887 173.121 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.47 ' HB3' HG21 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -150.18 18.83 0.86 Allowed 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.512 -1.222 . . . . 10.0 111.328 167.455 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.624 HG23 HG22 ' A' ' 17' ' ' ILE . 0.7 OUTLIER -54.89 -35.97 64.68 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 118.903 0.774 . . . . 10.0 109.305 177.893 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.74 -21.45 44.48 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.347 1.459 . . . . 10.0 113.407 177.069 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.58 91.18 0.71 Allowed Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.444 -0.662 . . . . 10.0 111.444 -176.818 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 32.0 m 44.61 38.67 2.84 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.156 1.782 . . . . 10.0 112.625 176.414 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.2 m -133.33 -49.7 0.85 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.702 0.801 . . . . 10.0 109.25 -168.964 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -106.04 20.12 19.46 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 123.553 0.741 . . . . 10.0 110.265 -177.133 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.96 47.79 0.45 Allowed 'General case' 0 C--O 1.225 -0.193 0 C-N-CA 124.438 1.095 . . . . 10.0 111.011 175.974 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 56.22 101.41 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 C-N-CA 126.043 1.782 . . . . 10.0 113.683 168.455 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -68.15 72.7 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 123.635 2.89 . . . . 10.0 112.833 178.629 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.446 ' CE1' ' CG ' ' B' ' 46' ' ' HIS . 15.9 m170 58.55 45.69 15.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.237 3.415 . . . . 10.0 110.943 173.298 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -69.33 64.69 0.16 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 126.146 1.778 . . . . 10.0 111.692 177.919 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -82.9 154.22 67.56 Favored Pre-proline 0 C--N 1.32 -0.69 0 C-N-CA 126.067 1.747 . . . . 10.0 109.796 179.557 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.13 -52.03 0.54 Allowed 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.574 2.182 . . . . 10.0 111.447 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.2 mt -78.68 49.58 0.9 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.94 0.896 . . . . 10.0 110.584 -176.652 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.7 124.94 23.23 Favored 'General case' 0 N--CA 1.451 -0.4 0 O-C-N 122.024 -0.422 . . . . 10.0 111.096 -168.53 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.81 -75.22 0.32 Allowed 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 107.1 -1.444 . . . . 10.0 107.1 -172.503 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 86.7 mttt -149.26 164.77 33.89 Favored 'General case' 0 N--CA 1.422 -1.853 0 CA-C-N 114.871 -1.059 . . . . 10.0 108.583 169.317 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 76.3 t60 -71.6 126.82 30.68 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 105.165 -2.161 . . . . 10.0 105.165 162.873 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.05 -138.36 3.65 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 108.86 -1.696 . . . . 10.0 108.86 173.634 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.62 -160.87 25.98 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 107.884 -2.086 . . . . 10.0 107.884 173.414 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.51 1.36 2.66 Favored 'Trans proline' 0 CA--C 1.541 0.839 0 CA-C-N 119.819 1.81 . . . . 10.0 110.644 167.372 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -108.35 10.19 27.63 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 125.857 1.663 . . . . 10.0 109.8 173.905 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -135.47 161.44 35.47 Favored 'General case' 0 N--CA 1.439 -1.0 0 N-CA-C 108.36 -0.978 . . . . 10.0 108.36 165.571 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -77.59 -37.86 49.54 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 105.242 -2.133 . . . . 10.0 105.242 167.328 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -97.15 58.1 1.52 Allowed 'General case' 0 N--CA 1.446 -0.646 0 CA-C-O 121.718 0.77 . . . . 10.0 109.323 -169.614 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -70.37 154.01 42.37 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 108.394 -0.965 . . . . 10.0 108.394 166.521 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -67.66 -65.95 0.62 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.989 0.813 . . . . 10.0 109.39 177.831 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.751 HG13 ' H ' ' B' ' 82' ' ' GLY . 7.5 p -161.67 -90.46 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 106.561 -1.644 . . . . 10.0 106.561 170.664 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.751 ' H ' HG13 ' B' ' 81' ' ' VAL . . . -84.12 69.31 3.36 Favored Glycine 0 CA--C 1.525 0.693 0 O-C-N 120.374 -1.454 . . . . 10.0 109.486 176.071 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -104.39 94.42 5.33 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 104.013 -2.588 . . . . 10.0 104.013 167.32 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -70.73 -34.1 71.55 Favored 'General case' 0 C--O 1.227 -0.114 0 N-CA-C 107.88 -1.156 . . . . 10.0 107.88 -176.336 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 117.68 -85.96 0.4 Allowed Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 110.175 -1.17 . . . . 10.0 110.175 167.021 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -142.37 141.26 32.28 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.53 -0.915 . . . . 10.0 108.53 -177.627 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.3 m -114.63 135.65 53.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 106.602 -1.629 . . . . 10.0 106.602 166.891 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -104.23 117.97 35.5 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 123.75 0.82 . . . . 10.0 109.465 -171.666 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.26 134.54 34.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 O-C-N 122.08 -0.388 . . . . 10.0 110.327 -178.166 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -60.9 168.97 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.529 1.132 . . . . 10.0 109.579 167.695 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.9 -29.14 40.67 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.633 -0.712 . . . . 10.0 111.298 173.485 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -78.41 -9.26 59.22 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.003 0.521 . . . . 10.0 111.291 -178.704 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.68 10.06 73.74 Favored Glycine 0 C--N 1.341 0.807 0 O-C-N 121.099 -1.001 . . . . 10.0 111.101 -177.148 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 41.7 t -87.21 106.71 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 C-N-CA 126.273 1.829 . . . . 10.0 106.743 176.049 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.615 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -104.82 119.57 39.32 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 108.476 -0.935 . . . . 10.0 108.476 169.653 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -79.53 135.4 36.61 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.081 1.752 . . . . 10.0 108.454 175.088 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.52 132.53 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.181 0 C-N-CA 125.454 1.502 . . . . 10.0 106.975 177.907 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 23.4 p -158.78 55.4 0.43 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.752 0.821 . . . . 10.0 111.79 168.821 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.0 mp -92.81 145.0 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 108.662 -0.866 . . . . 10.0 108.662 -174.536 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -101.67 126.33 48.5 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 126.814 2.046 . . . . 10.0 108.543 174.359 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -117.45 155.04 30.36 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.541 -0.911 . . . . 10.0 108.541 168.157 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 4.4 p -130.42 27.42 5.03 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 125.453 1.501 . . . . 10.0 111.989 -177.4 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.71 -40.54 1.32 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.894 0.77 . . . . 10.0 111.021 169.788 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.449 HD13 ' C ' ' B' ' 104' ' ' ILE 0.481 0.0 OUTLIER -69.38 158.07 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 119.895 1.225 . . . . 10.0 112.47 174.592 . . . . . . . . 4 4 . 1 . 027 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 40.5 m -153.95 121.69 5.93 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 120.937 -1.102 . . . . 10.0 109.805 -179.235 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.1 mt -68.2 -30.74 69.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.698 1.199 . . . . 10.0 110.598 -175.536 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 68.6 m -149.35 148.82 29.96 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 108.187 -1.042 . . . . 10.0 108.187 169.462 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 165.82 -58.62 0.24 Allowed Glycine 0 C--N 1.334 0.419 0 N-CA-C 108.856 -1.698 . . . . 10.0 108.856 -179.258 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -166.56 -49.82 0.03 OUTLIER 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 126.218 1.807 . . . . 10.0 107.757 -179.088 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -75.45 -39.87 58.24 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.98 -1.009 . . . . 10.0 109.035 -169.505 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 36.6 t 40.9 54.44 3.19 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.91 1.684 . . . . 10.0 111.022 175.242 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -69.77 37.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.607 0 C-N-CA 126.302 1.841 . . . . 10.0 111.844 -177.598 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 1.1 mp -56.07 -45.63 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 O-C-N 119.157 -2.214 . . . . 10.0 112.096 177.481 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.79 50.92 3.03 Favored Glycine 0 CA--C 1.534 1.251 0 CA-C-N 119.932 1.242 . . . . 10.0 114.244 -175.416 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -84.56 176.6 8.51 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 127.327 2.251 . . . . 10.0 109.784 170.123 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.2 m -135.85 99.19 4.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.35 -0.982 . . . . 10.0 108.35 169.114 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.74 129.65 42.04 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 105.565 -2.013 . . . . 10.0 105.565 167.625 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.16 129.4 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 105.24 -2.133 . . . . 10.0 105.24 169.168 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.507 HG13 ' HB3' ' B' ' 145' ' ' ALA . 0.3 OUTLIER -100.71 106.05 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.942 0 N-CA-C 104.868 -2.271 . . . . 10.0 104.868 170.997 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.639 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 12.0 m-70 -87.72 160.08 18.23 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 122.822 1.296 . . . . 10.0 114.258 -169.818 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . 0.664 ' HA ' HD22 ' B' ' 144' ' ' LEU . 52.0 tt0 -50.79 -56.55 11.58 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.839 2.056 . . . . 10.0 109.034 176.917 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -107.64 168.06 9.52 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.863 0.69 . . . . 10.0 112.863 -169.654 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.26 151.57 43.3 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 113.777 -1.556 . . . . 10.0 107.575 169.125 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.484 ' OD2' ' HA2' ' B' ' 44' ' ' GLY . 31.2 m-20 -100.94 132.36 46.38 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.235 -1.024 . . . . 10.0 108.235 -179.602 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -76.39 -12.68 60.1 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 124.857 1.263 . . . . 10.0 111.05 -176.796 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 15.4 mt 59.31 49.36 9.04 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 122.211 1.005 . . . . 10.0 109.04 177.39 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 93.4 -44.1 2.47 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 125.611 1.576 . . . . 10.0 110.445 174.645 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.7 mtmm -79.47 42.16 0.5 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.716 1.607 . . . . 10.0 112.518 -168.842 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.7 -17.77 27.36 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.281 2.372 . . . . 10.0 111.103 169.765 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.24 42.25 88.03 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 123.961 0.791 . . . . 10.0 111.777 178.861 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -145.94 166.38 26.2 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 106.88 -1.526 . . . . 10.0 106.88 169.929 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -52.23 -48.5 65.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 120.978 0.418 . . . . 10.0 110.143 -177.17 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -64.87 -30.45 71.45 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 119.225 -0.417 . . . . 10.0 110.427 -179.591 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 p -56.04 -35.33 66.77 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 120.146 1.339 . . . . 10.0 112.308 171.544 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -101.72 -14.73 17.23 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 118.294 0.497 . . . . 10.0 111.169 -170.515 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 53.9 mttt -88.0 -47.57 8.43 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 125.923 1.689 . . . . 10.0 111.256 173.715 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.404 ' HA ' ' CE1' ' B' ' 63' ' ' HIS . 44.7 p -134.09 -11.71 2.55 Favored 'General case' 0 CA--C 1.533 0.308 0 N-CA-C 115.057 1.502 . . . . 10.0 115.057 177.323 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.38 24.77 11.85 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 119.404 1.002 . . . . 10.0 112.978 -171.722 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 61.89 25.06 15.01 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 119.698 1.749 . . . . 10.0 111.432 179.316 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.73 -14.21 41.74 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 126.54 1.936 . . . . 10.0 112.5 -173.064 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.38 -160.22 52.98 Favored Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 108.776 -1.73 . . . . 10.0 108.776 172.434 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -55.29 130.54 42.74 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 109.24 -0.652 . . . . 10.0 109.24 -171.155 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.77 71.65 0.06 Allowed 'General case' 0 CA--C 1.543 0.708 0 O-C-N 121.667 -0.646 . . . . 10.0 110.274 172.198 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.664 HD22 ' HA ' ' B' ' 121' ' ' GLU . 11.7 tp -45.08 -35.78 3.25 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 128.118 2.567 . . . . 10.0 114.585 -172.858 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.507 ' HB3' HG13 ' B' ' 119' ' ' VAL . . . -165.77 159.18 15.9 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.049 -1.093 . . . . 10.0 108.049 -179.361 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 13.4 p -163.61 169.8 18.09 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.663 -0.495 . . . . 10.0 109.663 -178.045 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.12 -178.79 16.76 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 109.63 -1.388 . . . . 10.0 109.63 178.595 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 91.5 t -123.73 126.46 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 104.224 -2.51 . . . . 10.0 104.224 170.609 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.3 mt -81.72 152.08 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 CA-C-N 118.198 0.454 . . . . 10.0 110.787 -171.179 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -151.76 157.58 27.3 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 125.547 1.546 . . . . 10.0 111.059 -169.4 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 29.9 mt -54.12 140.27 11.33 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 C-N-CA 125.436 1.494 . . . . 10.0 111.806 172.64 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -134.72 170.17 16.23 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 107.492 -1.299 . . . . 10.0 107.492 165.759 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 . . . . . 0 C--O 1.25 1.096 0 N-CA-C 107.537 -1.283 . . . . 10.0 107.537 167.616 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.81 0 CA-C-O 117.971 -1.014 . . . . 10.0 108.952 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 t -105.47 -21.54 13.19 Favored 'General case' 0 C--O 1.223 -0.342 0 O-C-N 123.807 0.692 . . . . 10.0 110.503 176.897 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.74 172.5 13.2 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-O 121.368 0.604 . . . . 10.0 111.04 169.203 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -151.99 168.55 24.84 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.622 -1.251 . . . . 10.0 107.622 172.732 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -132.64 164.07 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.318 1.047 . . . . 10.0 109.284 176.771 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.01 116.87 10.97 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 107.812 -1.181 . . . . 10.0 107.812 167.898 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -95.66 102.77 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 124.542 1.137 . . . . 10.0 109.137 170.349 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -92.45 134.98 34.44 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 124.062 0.945 . . . . 10.0 109.703 -179.884 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt -145.38 162.44 37.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 108.101 -1.074 . . . . 10.0 108.101 168.797 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.95 -60.18 0.04 OUTLIER Glycine 0 C--O 1.229 -0.178 0 CA-C-N 115.393 -0.821 . . . . 10.0 112.542 172.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -73.37 -43.91 59.69 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 106.443 -1.688 . . . . 10.0 106.443 -171.532 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.25 -66.06 0.56 Allowed Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 113.713 -1.585 . . . . 10.0 110.097 177.65 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -58.54 -38.75 88.28 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 122.481 2.12 . . . . 10.0 111.276 172.297 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.1 t -64.44 108.17 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.691 -1.225 . . . . 10.0 107.691 178.363 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -122.6 116.27 23.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 105.452 -2.055 . . . . 10.0 105.452 168.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.765 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -100.38 131.29 10.52 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 175.858 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.492 ' CG2' HG23 ' B' ' 54' ' ' THR . 11.5 mt -133.19 89.57 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 107.111 -1.441 . . . . 10.0 107.111 -171.157 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.6 mm -104.17 141.88 18.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 124.396 1.078 . . . . 10.0 109.826 -178.665 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -126.5 119.42 27.11 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.939 2.095 . . . . 10.0 108.636 171.408 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -101.16 120.69 40.59 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 107.321 -1.362 . . . . 10.0 107.321 176.771 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -113.55 143.49 44.46 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 119.379 0.99 . . . . 10.0 112.832 172.214 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -127.42 97.33 4.85 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 128.166 2.586 . . . . 10.0 107.92 169.656 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 39.0 pttt -58.52 -48.14 81.82 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.287 1.035 . . . . 10.0 111.946 -176.255 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.76 166.61 24.29 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 104.38 -2.452 . . . . 10.0 104.38 168.14 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.0 t -65.21 -19.5 66.0 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 122.356 0.262 . . . . 10.0 110.893 179.891 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -80.66 -24.12 39.17 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 123.096 0.558 . . . . 10.0 110.499 176.617 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -69.41 155.1 53.39 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.645 -0.582 . . . . 10.0 111.645 -175.885 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -71.06 147.77 55.23 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 N-CA-C 106.155 -2.286 . . . . 10.0 106.155 165.56 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 t -79.61 128.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.04 0 N-CA-C 106.626 -1.62 . . . . 10.0 106.626 174.32 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -109.0 125.08 51.68 Favored 'General case' 0 C--O 1.233 0.234 0 N-CA-C 106.504 -1.665 . . . . 10.0 106.504 171.911 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.0 m -111.44 105.95 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.63 0 N-CA-C 106.894 -1.521 . . . . 10.0 106.894 -176.5 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 24.5 p90 -117.13 168.54 10.2 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.25 0.548 . . . . 10.0 111.06 176.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.5 175.9 41.57 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.188 -1.006 . . . . 10.0 111.585 176.002 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 2.6 p -147.46 95.8 2.59 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 107.949 -1.13 . . . . 10.0 107.949 -177.098 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.765 HG22 ' HA2' ' A' ' 16' ' ' GLY . 8.4 pt -77.42 174.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 C-N-CA 119.402 -0.919 . . . . 10.0 109.03 170.917 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -156.01 155.77 33.28 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 107.027 -1.472 . . . . 10.0 107.027 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.8 -17.23 33.0 Favored Glycine 0 CA--C 1.523 0.566 0 CA-C-O 119.411 -0.661 . . . . 10.0 113.824 173.326 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.505 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.3 mp -72.73 179.85 3.43 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 118.395 1.097 . . . . 10.0 110.354 178.362 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.4 t -95.81 175.78 6.38 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.586 -0.894 . . . . 10.0 108.586 166.404 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -63.6 176.54 0.85 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 124.633 1.173 . . . . 10.0 111.604 -172.024 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.04 -173.8 43.38 Favored Glycine 0 C--O 1.225 -0.438 0 C-N-CA 124.005 0.812 . . . . 10.0 112.563 167.345 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -77.22 140.7 40.18 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.332 1.453 . . . . 10.0 109.476 177.452 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -133.03 140.66 47.84 Favored 'General case' 0 N--CA 1.464 0.245 0 C-N-CA 124.264 1.026 . . . . 10.0 112.366 -176.742 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -43.72 125.65 5.41 Favored Glycine 0 C--N 1.344 1.026 0 N-CA-C 108.317 -1.913 . . . . 10.0 108.317 166.177 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -145.52 109.73 4.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 119.042 1.421 . . . . 10.0 109.025 171.122 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.22 173.12 17.32 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 113.74 1.015 . . . . 10.0 113.74 -174.139 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 33.3 m -88.0 154.37 3.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 113.629 -1.623 . . . . 10.0 109.578 171.246 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 -139.35 75.7 1.53 Allowed 'General case' 0 C--O 1.222 -0.37 0 C-N-CA 123.217 0.607 . . . . 10.0 112.122 -174.513 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 64.3 tt0 51.71 -87.22 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 125.301 1.44 . . . . 10.0 113.989 169.501 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -90.62 -172.34 3.37 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 108.537 -0.912 . . . . 10.0 108.537 -179.935 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -136.76 22.93 3.27 Favored Glycine 0 N--CA 1.452 -0.297 0 O-C-N 121.521 -0.737 . . . . 10.0 111.82 174.425 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -82.34 160.06 22.93 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 107.626 -1.25 . . . . 10.0 107.626 168.583 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.18 28.9 0.58 Allowed 'General case' 0 N--CA 1.448 -0.572 0 O-C-N 121.578 -0.701 . . . . 10.0 112.446 178.454 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.467 HG22 HG22 ' B' ' 17' ' ' ILE . 0.1 OUTLIER -49.7 -40.38 40.04 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.344 1.458 . . . . 10.0 112.373 -175.173 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -81.66 -24.31 36.37 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 123.391 0.676 . . . . 10.0 112.432 177.656 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.1 115.74 1.24 Allowed Glycine 0 CA--C 1.53 0.999 0 N-CA-C 109.76 -1.336 . . . . 10.0 109.76 -169.512 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 64.2 m 42.27 53.37 4.47 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 125.629 1.572 . . . . 10.0 113.169 175.062 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -158.11 -56.98 0.07 Allowed 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.957 -1.127 . . . . 10.0 107.957 177.056 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -53.15 -45.34 68.38 Favored 'General case' 0 C--N 1.34 0.176 0 C-N-CA 124.909 1.284 . . . . 10.0 111.002 -169.233 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -30.56 -53.59 0.18 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 127.039 2.136 . . . . 10.0 113.681 169.993 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.08 160.5 11.61 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.121 -1.192 . . . . 10.0 110.121 -176.838 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -74.02 -162.3 0.14 Allowed 'Trans proline' 0 N--CA 1.448 -1.169 0 N-CA-C 105.651 -2.48 . . . . 10.0 105.651 165.837 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -80.17 48.99 1.05 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 119.613 -1.93 . . . . 10.0 110.827 -175.386 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.2 m-30 -77.65 56.55 1.48 Allowed 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.935 1.35 . . . . 10.0 112.11 -176.632 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.4 HD21 ' CD2' ' A' ' 80' ' ' HIS . 1.8 p30 -59.83 148.52 75.92 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.81 1.244 . . . . 10.0 108.501 167.057 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.67 -48.59 8.75 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.693 2.262 . . . . 10.0 112.022 -174.285 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.19 57.65 1.46 Allowed 'General case' 0 CA--C 1.534 0.335 0 O-C-N 121.595 -0.69 . . . . 10.0 110.717 174.162 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.3 p -55.66 107.66 0.36 Allowed 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.842 1.257 . . . . 10.0 109.844 -179.705 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -119.45 -91.11 0.56 Allowed 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.105 -1.443 . . . . 10.0 107.105 -178.321 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -143.65 150.89 39.41 Favored 'General case' 0 N--CA 1.437 -1.095 0 CA-C-O 121.927 0.87 . . . . 10.0 109.81 169.012 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.5 t60 -57.79 120.96 9.35 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.643 -1.243 . . . . 10.0 107.643 165.699 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -142.73 -141.81 3.92 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 108.692 -1.763 . . . . 10.0 108.692 -177.96 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.492 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -174.17 -158.98 19.71 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 109.337 -1.505 . . . . 10.0 109.337 169.697 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -69.36 25.5 0.16 Allowed 'Trans proline' 0 CA--C 1.541 0.864 0 CA-C-N 119.844 1.822 . . . . 10.0 111.173 168.739 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.492 ' H ' ' C ' ' A' ' 73' ' ' GLY . 71.7 mttt -123.96 -12.89 7.45 Favored 'General case' 0 N--CA 1.438 -1.028 0 C-N-CA 126.379 1.872 . . . . 10.0 109.787 171.942 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -135.96 129.11 31.65 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 104.842 -2.281 . . . . 10.0 104.842 -172.352 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -75.57 -22.19 57.21 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.243 -1.021 . . . . 10.0 108.243 -174.277 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -83.21 4.97 24.53 Favored 'General case' 0 N--CA 1.433 -1.323 0 C-N-CA 125.935 1.694 . . . . 10.0 111.122 -179.756 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -42.29 158.53 0.03 OUTLIER 'General case' 0 C--N 1.349 0.567 0 C-N-CA 124.53 1.132 . . . . 10.0 112.161 172.844 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.4 ' CD2' HD21 ' A' ' 65' ' ' ASN . 32.3 m170 -69.65 -103.81 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.689 -0.632 . . . . 10.0 109.359 176.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 88.0 t -126.7 -90.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 104.522 -2.399 . . . . 10.0 104.522 169.385 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -79.08 62.61 3.98 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.689 -0.565 . . . . 10.0 111.689 178.745 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -97.26 94.84 7.33 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 104.368 -2.456 . . . . 10.0 104.368 166.954 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -72.68 -7.46 50.54 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 117.913 0.324 . . . . 10.0 111.033 -174.229 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.27 -103.22 2.96 Favored Glycine 0 N--CA 1.44 -1.046 0 N-CA-C 105.006 -3.237 . . . . 10.0 105.006 -170.084 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -146.47 159.74 43.01 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 107.609 -1.256 . . . . 10.0 107.609 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.33 128.05 74.71 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 123.096 0.558 . . . . 10.0 110.575 170.422 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 m -79.68 114.08 18.33 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.758 2.823 . . . . 10.0 110.563 -178.889 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.16 46.51 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.298 1.039 . . . . 10.0 110.857 177.985 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -61.18 170.03 1.85 Allowed 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 125.495 1.518 . . . . 10.0 109.096 166.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.95 -30.0 44.91 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.803 0.841 . . . . 10.0 111.408 176.723 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.1 -3.0 43.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 124.298 1.039 . . . . 10.0 110.863 -178.221 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.41 1.28 89.38 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.518 -1.033 . . . . 10.0 110.518 -175.633 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 62.1 t -79.47 103.53 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.288 0 N-CA-C 106.965 -1.495 . . . . 10.0 106.965 -176.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.405 ' HB3' ' CD1' ' A' ' 35' ' ' ILE . . . -100.95 118.67 37.44 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.825 -0.806 . . . . 10.0 108.825 169.213 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.2 110.01 15.21 Favored 'General case' 0 N--CA 1.434 -1.25 0 C-N-CA 126.265 1.826 . . . . 10.0 108.84 170.736 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 57.9 t -97.79 132.87 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 106.656 -1.609 . . . . 10.0 106.656 177.183 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.0 m -158.69 76.93 0.75 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.98 1.312 . . . . 10.0 109.863 169.799 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.7 161.13 3.83 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.52 -1.289 . . . . 10.0 107.52 177.505 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -142.51 130.85 22.24 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.65 1.98 . . . . 10.0 107.786 176.994 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -144.95 163.6 33.67 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.295 1.038 . . . . 10.0 108.959 179.126 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.4 p -125.36 51.39 1.7 Allowed 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.897 1.279 . . . . 10.0 109.876 176.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.5 p -142.69 -46.02 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.761 0.824 . . . . 10.0 110.762 174.475 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.6 mp -63.29 139.74 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 106.608 -1.627 . . . . 10.0 106.608 169.339 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 22.3 m -126.74 156.19 41.55 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.941 0.877 . . . . 10.0 110.108 172.173 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -82.47 -29.54 30.53 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.75 0.82 . . . . 10.0 109.492 172.401 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.7 m -156.93 168.82 26.33 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.634 -1.247 . . . . 10.0 107.634 -174.599 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.32 -92.92 0.58 Allowed Glycine 0 C--N 1.333 0.407 0 N-CA-C 108.471 -1.852 . . . . 10.0 108.471 179.117 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -134.39 -51.64 0.81 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 125.72 1.608 . . . . 10.0 108.403 177.584 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -81.7 38.42 0.51 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.605 0.762 . . . . 10.0 110.145 -175.03 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 33.4 t -74.32 112.96 11.0 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 126.127 1.771 . . . . 10.0 108.627 -176.109 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 16.6 pt -81.87 11.49 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 112.121 0.415 . . . . 10.0 112.121 173.16 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 30.9 mm -61.09 137.59 23.18 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 120.112 1.324 . . . . 10.0 109.925 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.56 87.01 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.0 -1.444 . . . . 10.0 114.707 172.544 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 29.5 mmt180 -83.93 171.13 13.31 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 107.165 -1.42 . . . . 10.0 107.165 168.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -105.4 136.48 44.87 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 124.677 1.191 . . . . 10.0 110.351 171.681 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.408 ' CD2' HD11 ' A' ' 149' ' ' ILE . 3.9 mm? -96.29 143.08 27.69 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 167.209 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.408 HG22 ' SG ' ' A' ' 146' ' ' CYS . 91.9 t -132.03 137.67 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.875 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 176.864 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.5 p -108.5 142.08 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.592 0 C-N-CA 124.996 1.318 . . . . 10.0 108.698 170.368 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -119.99 171.1 8.68 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.963 0.905 . . . . 10.0 113.143 -171.71 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -74.28 -46.83 38.75 Favored 'General case' 0 C--O 1.223 -0.323 0 C-N-CA 123.932 0.893 . . . . 10.0 111.669 -176.596 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -109.81 170.76 7.86 Favored 'General case' 0 CA--C 1.522 -0.113 0 C-N-CA 123.702 0.801 . . . . 10.0 113.015 -171.763 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -76.44 145.68 39.12 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.951 1.3 . . . . 10.0 108.777 174.134 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.53 164.47 24.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 122.167 0.984 . . . . 10.0 112.753 -178.208 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 63.9 m-20 -77.5 -22.4 51.28 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-N 112.625 -2.079 . . . . 10.0 109.631 167.082 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 40.2 mt 50.2 46.5 24.76 Favored 'General case' 0 C--N 1.341 0.232 0 CA-C-O 122.631 1.205 . . . . 10.0 108.354 -167.574 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.17 -32.79 4.76 Favored Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.125 -1.398 . . . . 10.0 112.247 177.765 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 25.4 mtmm -79.57 37.79 0.35 Allowed 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.672 1.189 . . . . 10.0 113.205 -168.535 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -98.8 -14.41 37.22 Favored Glycine 0 CA--C 1.526 0.778 0 C-N-CA 127.185 2.326 . . . . 10.0 110.036 169.419 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 49.17 43.07 32.75 Favored Glycine 0 C--N 1.34 0.781 0 C-N-CA 124.516 1.055 . . . . 10.0 112.081 -177.88 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -142.26 167.2 22.68 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 118.926 1.363 . . . . 10.0 109.221 173.088 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.403 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 1.7 tm-20 -37.5 -54.82 1.12 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 126.392 1.877 . . . . 10.0 111.374 176.531 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -72.2 -39.08 68.84 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.087 0.555 . . . . 10.0 110.739 179.927 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.8 p -53.04 -45.5 68.04 Favored 'General case' 0 N--CA 1.446 -0.635 0 O-C-N 120.893 -1.129 . . . . 10.0 110.589 -178.711 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.1 t -79.69 -2.45 42.92 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 118.744 -0.646 . . . . 10.0 111.799 -173.815 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.403 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 94.7 mttt -112.21 -71.07 0.77 Allowed 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.035 1.734 . . . . 10.0 110.811 -178.296 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.1 p -121.17 14.21 11.32 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 120.729 1.604 . . . . 10.0 112.841 177.462 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.46 21.08 78.7 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-O 119.236 -0.758 . . . . 10.0 113.473 168.752 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 50.75 24.83 1.85 Allowed 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 118.21 1.005 . . . . 10.0 112.202 -174.663 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.21 -7.55 47.59 Favored 'General case' 0 C--O 1.223 -0.323 0 O-C-N 121.41 -0.806 . . . . 10.0 111.554 -176.829 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 129.57 170.12 12.68 Favored Glycine 0 C--N 1.332 0.324 0 N-CA-C 110.199 -1.16 . . . . 10.0 110.199 169.674 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 6.6 m -82.38 54.85 2.71 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 123.029 0.532 . . . . 10.0 112.082 -169.058 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 42.66 72.87 0.16 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.057 1.343 . . . . 10.0 111.709 173.902 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -63.9 -36.4 83.82 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 123.041 0.537 . . . . 10.0 111.39 -169.185 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -156.06 138.22 14.65 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.904 -0.776 . . . . 10.0 108.904 -170.622 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.408 ' SG ' HG22 ' A' ' 118' ' ' VAL . 58.9 m -133.75 147.36 51.3 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 124.315 1.046 . . . . 10.0 109.678 -168.373 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.16 168.57 23.32 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.542 -1.023 . . . . 10.0 110.542 177.033 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 65.1 t -118.55 137.82 51.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 106.384 -1.71 . . . . 10.0 106.384 178.42 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.408 HD11 ' CD2' ' A' ' 117' ' ' LEU . 80.7 mt -73.96 126.18 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 118.099 0.409 . . . . 10.0 110.923 -176.297 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -114.65 145.61 18.63 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.365 -1.094 . . . . 10.0 110.365 176.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 47.9 mt -68.44 152.77 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 CA-C-N 119.358 1.579 . . . . 10.0 110.41 178.044 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.7 162.82 32.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 107.661 -1.237 . . . . 10.0 107.661 166.936 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.5 tt0 . . . . . 0 C--O 1.251 1.147 0 N-CA-C 106.338 -1.727 . . . . 10.0 106.338 169.603 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . 0.418 ' N ' ' O ' ' B' ' 153' ' ' GLN . . . . . . . . 0 N--CA 1.469 0.507 0 N-CA-C 109.134 -0.691 . . . . 10.0 109.134 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.3 t -94.94 -32.18 13.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.978 1.311 . . . . 10.0 110.913 174.965 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 2.2 ttmp? -124.61 138.9 54.28 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 124.471 1.108 . . . . 10.0 110.231 -177.862 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.59 159.54 42.04 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.159 1.384 . . . . 10.0 108.101 170.236 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -136.02 164.4 32.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 119.012 0.824 . . . . 10.0 110.307 177.41 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.88 118.91 18.49 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 124.7 1.2 . . . . 10.0 109.118 168.199 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -89.05 89.65 3.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 108.387 -0.968 . . . . 10.0 108.387 168.911 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 mp -79.67 120.76 24.43 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 118.544 -0.741 . . . . 10.0 109.688 -179.752 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 22.7 mtpt -140.5 160.41 40.05 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 119.133 0.879 . . . . 10.0 109.207 171.802 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.52 -60.71 0.05 OUTLIER Glycine 0 N--CA 1.46 0.276 0 CA-C-N 114.87 -1.059 . . . . 10.0 113.071 170.923 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -71.24 -44.0 66.17 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 107.474 -1.306 . . . . 10.0 107.474 -176.748 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 143.14 -69.17 0.43 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-N 114.234 -1.348 . . . . 10.0 110.575 169.771 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -60.14 -32.32 94.43 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 123.714 2.943 . . . . 10.0 111.735 173.019 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.7 t -67.62 92.53 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.028 0 N-CA-C 107.145 -1.428 . . . . 10.0 107.145 177.902 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -120.11 105.65 11.21 Favored 'General case' 0 N--CA 1.443 -0.776 0 C-N-CA 125.22 1.408 . . . . 10.0 107.822 -178.24 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.677 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -96.68 139.72 14.65 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 110.364 -1.094 . . . . 10.0 110.364 169.718 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.467 HG22 HG22 ' A' ' 54' ' ' THR . 6.5 mt -138.15 58.5 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 N-CA-C 105.552 -2.018 . . . . 10.0 105.552 -173.403 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.422 HD11 HG23 ' B' ' 35' ' ' ILE . 30.2 mm -81.96 134.8 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 114.879 -1.055 . . . . 10.0 109.39 -169.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -112.35 116.48 30.41 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 126.195 1.798 . . . . 10.0 108.973 -177.517 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -103.19 113.79 27.55 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 125.963 1.705 . . . . 10.0 107.759 -176.107 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -114.36 135.86 53.62 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.053 0.941 . . . . 10.0 111.524 -177.992 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -115.77 104.6 11.82 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 104.985 -2.228 . . . . 10.0 104.985 167.784 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.51 30.74 0.74 Allowed 'General case' 0 C--O 1.235 0.306 0 N-CA-C 114.118 1.155 . . . . 10.0 114.118 -169.683 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -131.25 166.55 20.93 Favored 'General case' 0 N--CA 1.432 -1.357 0 N-CA-C 101.779 -3.415 . . . . 10.0 101.779 167.591 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 22.7 t -77.01 -14.56 59.82 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 109.471 -0.566 . . . . 10.0 109.471 178.321 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -78.49 -15.08 59.01 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 119.828 -0.749 . . . . 10.0 109.308 169.163 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.08 43.53 17.93 Favored Glycine 0 CA--C 1.528 0.853 0 C-N-CA 126.076 1.798 . . . . 10.0 115.372 -178.436 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -66.1 145.45 79.03 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 CA-C-N 119.841 1.82 . . . . 10.0 107.625 170.867 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.2 t -79.37 97.43 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 106.196 -1.779 . . . . 10.0 106.196 173.542 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -79.09 102.42 8.41 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.504 -2.036 . . . . 10.0 105.504 168.895 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -101.93 101.12 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 C-N-CA 125.928 1.691 . . . . 10.0 107.822 -177.477 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.2 p90 -113.37 168.02 10.08 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.535 0.683 . . . . 10.0 111.867 169.88 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.55 178.37 32.51 Favored Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.642 -0.983 . . . . 10.0 110.642 168.886 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.5 p -124.33 102.06 7.49 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 108.593 -0.891 . . . . 10.0 108.593 -173.182 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.677 HG22 ' HA2' ' B' ' 16' ' ' GLY . 3.6 pt -81.78 133.99 28.03 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 108.219 -1.03 . . . . 10.0 108.219 168.852 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 29.9 tptt -108.09 148.83 29.28 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 106.725 -1.583 . . . . 10.0 106.725 170.069 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.67 -6.94 35.96 Favored Glycine 0 C--N 1.337 0.586 0 CA-C-O 119.563 -0.576 . . . . 10.0 113.47 169.348 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -66.43 175.93 2.06 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 118.276 1.038 . . . . 10.0 110.518 176.029 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -108.66 164.6 12.23 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 105.289 -2.115 . . . . 10.0 105.289 165.557 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -53.78 161.23 1.18 Allowed 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 113.11 0.782 . . . . 10.0 113.11 -169.041 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.12 -179.19 51.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 124.318 0.961 . . . . 10.0 112.085 169.049 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 mt -57.04 146.35 27.58 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.076 1.75 . . . . 10.0 112.921 175.501 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 78.5 m-70 -149.33 144.73 26.63 Favored 'General case' 0 C--N 1.339 0.149 0 C-N-CA 124.423 1.089 . . . . 10.0 113.439 -179.835 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.661 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.08 122.64 0.04 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 127.621 2.534 . . . . 10.0 113.243 166.515 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -152.37 105.52 3.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 119.059 1.429 . . . . 10.0 111.818 169.425 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -151.17 171.67 17.01 Favored 'General case' 0 CA--C 1.511 -0.549 0 N-CA-C 112.801 0.667 . . . . 10.0 112.801 -178.153 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.1 m -99.95 146.29 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 111.924 -2.398 . . . . 10.0 106.275 167.0 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -120.83 144.95 48.08 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 -179.437 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . 0.532 ' CG ' ' HA3' ' B' ' 61' ' ' GLY . 0.0 OUTLIER -6.73 -86.59 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.992 2.117 . . . . 10.0 116.593 170.978 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -102.14 171.86 7.24 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 119.737 1.153 . . . . 10.0 109.825 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.78 -25.71 52.28 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 117.63 -1.65 . . . . 10.0 111.234 174.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -40.16 113.04 0.32 Allowed 'General case' 0 C--N 1.342 0.278 0 CA-C-N 118.165 0.982 . . . . 10.0 111.448 178.064 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.33 20.85 12.96 Favored 'General case' 0 N--CA 1.436 -1.136 0 CA-C-N 114.748 -1.115 . . . . 10.0 109.972 167.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.492 HG23 ' CG2' ' A' ' 17' ' ' ILE . 4.2 m -55.44 -35.7 65.72 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 118.922 0.783 . . . . 10.0 110.49 -169.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.55 -21.35 45.27 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.803 1.241 . . . . 10.0 113.524 178.446 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.61 81.96 1.28 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 109.579 -1.408 . . . . 10.0 109.579 -174.056 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . 0.327 25.7 p 18.73 55.51 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.914 2.086 . . . . 10.0 115.451 -167.88 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.6 m -112.87 -57.76 2.24 Favored 'General case' 0 N--CA 1.442 -0.848 0 N-CA-C 105.454 -2.054 . . . . 10.0 105.454 173.953 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.4 t -90.83 -4.0 56.95 Favored 'General case' 0 N--CA 1.443 -0.789 0 C-N-CA 124.724 1.21 . . . . 10.0 110.355 -178.323 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.38 41.51 0.14 Allowed 'General case' 0 C--N 1.341 0.239 0 C-N-CA 124.542 1.137 . . . . 10.0 112.787 -179.279 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . 0.532 ' HA3' ' CG ' ' B' ' 49' ' ' GLU . . . 88.35 125.93 2.47 Favored Glycine 0 N--CA 1.44 -1.077 0 N-CA-C 118.433 2.133 . . . . 10.0 118.433 162.168 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -81.5 55.85 5.73 Favored 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 121.646 1.564 . . . . 10.0 109.9 165.147 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.2 m170 66.17 -72.05 0.08 Allowed 'General case' 0 N--CA 1.461 0.099 0 C-N-CA 127.946 2.499 . . . . 10.0 111.034 -175.956 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 0.72 56.95 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 131.358 3.863 . . . . 10.0 116.076 -172.64 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -63.23 162.07 27.26 Favored Pre-proline 0 CA--C 1.538 0.487 0 CA-C-N 115.846 -0.616 . . . . 10.0 111.463 -172.499 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -53.7 -38.44 84.71 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 123.251 2.634 . . . . 10.0 112.985 179.531 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.45 -1.88 4.01 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 113.054 0.761 . . . . 10.0 113.054 176.596 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.3 p 22.34 89.83 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 129.436 3.094 . . . . 10.0 115.392 169.073 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -130.53 -168.92 2.05 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.282 -1.748 . . . . 10.0 106.282 179.461 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -103.98 128.91 51.53 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.216 -1.401 . . . . 10.0 107.216 177.047 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.411 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 78.3 t60 -42.88 109.27 0.13 Allowed 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 124.063 0.852 . . . . 10.0 112.061 -178.815 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.25 -155.84 9.5 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.1 -2.4 . . . . 10.0 107.1 169.667 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.24 -153.32 6.06 Favored Glycine 0 C--N 1.332 0.312 0 CA-C-N 118.371 1.085 . . . . 10.0 112.675 173.044 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -61.1 -9.47 12.46 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.241 1.961 . . . . 10.0 111.685 174.753 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -91.84 -18.65 23.51 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.609 1.164 . . . . 10.0 109.006 -179.101 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' B' ' 128' ' ' LYS . 20.8 m-20 -113.6 162.85 15.7 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 108.665 -0.865 . . . . 10.0 108.665 -169.308 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -92.07 -18.12 24.03 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.623 -1.171 . . . . 10.0 109.674 172.028 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -97.98 2.54 49.07 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 126.258 1.823 . . . . 10.0 112.49 -170.399 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -35.37 125.44 0.63 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.542 1.537 . . . . 10.0 109.447 169.037 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.411 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 18.5 m170 -47.05 -54.67 9.78 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.497 0.589 . . . . 10.0 112.242 -168.694 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -172.01 -40.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 C-N-CA 125.814 1.646 . . . . 10.0 108.404 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -149.27 68.67 0.34 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 109.395 -1.482 . . . . 10.0 109.395 174.413 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -97.05 103.59 15.54 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 105.099 -2.186 . . . . 10.0 105.099 168.65 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 28.1 mt -82.27 25.44 0.6 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 118.891 0.769 . . . . 10.0 111.433 -176.828 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 75.7 -113.13 3.81 Favored Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 106.695 -2.562 . . . . 10.0 106.695 174.43 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -158.6 128.78 5.95 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 -174.867 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 16.7 m -106.09 132.46 53.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 123.015 0.526 . . . . 10.0 110.422 -169.681 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 99.1 m -85.39 107.71 17.51 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 127.605 2.362 . . . . 10.0 110.308 -170.956 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.29 137.51 32.92 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 123.153 0.581 . . . . 10.0 110.338 171.981 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -65.9 172.02 3.96 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 124.818 1.247 . . . . 10.0 109.541 168.518 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.59 -28.41 63.6 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.117 0.484 . . . . 10.0 110.917 177.735 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -80.89 -0.5 39.39 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.899 0.88 . . . . 10.0 111.187 -178.255 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.34 80.35 Favored Glycine 0 C--N 1.339 0.737 0 O-C-N 120.74 -1.225 . . . . 10.0 110.808 176.942 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 30.7 t -91.62 108.71 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 C-N-CA 126.971 2.108 . . . . 10.0 105.642 174.816 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.567 ' HB3' ' CG1' ' B' ' 35' ' ' ILE . . . -106.76 118.61 37.13 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 119.189 0.904 . . . . 10.0 108.633 169.102 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -81.13 95.97 7.05 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 126.64 1.976 . . . . 10.0 108.285 172.586 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -78.77 131.92 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 105.626 -1.99 . . . . 10.0 105.626 170.916 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 6.7 p -157.8 60.03 0.48 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.814 0.845 . . . . 10.0 109.073 -179.629 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 30.1 mt -114.87 160.2 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 N-CA-C 107.072 -1.455 . . . . 10.0 107.072 -169.743 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -138.77 135.74 34.97 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 109.725 -0.472 . . . . 10.0 109.725 168.846 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 16.6 t0 -117.2 101.62 8.6 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 108.104 -1.073 . . . . 10.0 108.104 -178.866 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 40.3 m -85.7 54.53 3.16 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 124.798 1.239 . . . . 10.0 108.471 -173.695 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 92.0 t -136.91 -54.33 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 108.023 -1.103 . . . . 10.0 108.023 -171.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.445 ' CD1' ' H ' ' B' ' 104' ' ' ILE 0.385 0.0 OUTLIER -88.19 175.37 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 C-N-CA 123.384 0.674 . . . . 10.0 111.544 170.408 . . . . . . . . 4 4 . 1 . 028 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 56.0 m -157.83 97.2 1.54 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.418 -0.801 . . . . 10.0 109.882 -168.042 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.9 tp -37.88 -27.37 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 129.211 3.004 . . . . 10.0 116.37 -169.616 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 38.3 t -153.09 45.43 0.67 Allowed 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.152 0.981 . . . . 10.0 109.743 176.544 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -141.04 62.13 0.54 Allowed Glycine 0 C--N 1.337 0.611 0 N-CA-C 109.422 -1.471 . . . . 10.0 109.422 -178.907 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 7.6 t70 68.98 -55.32 0.55 Allowed 'General case' 0 CA--C 1.52 -0.193 0 C-N-CA 129.673 3.189 . . . . 10.0 109.303 -171.31 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -81.42 45.83 0.9 Allowed 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 124.551 1.14 . . . . 10.0 110.156 -174.038 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 29.8 t -67.39 -44.49 78.78 Favored 'General case' 0 N--CA 1.442 -0.847 0 C-N-CA 126.879 2.071 . . . . 10.0 110.318 -172.947 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 7.2 pt 46.24 35.21 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.962 1.705 . . . . 10.0 113.774 177.87 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . 0.415 ' O ' ' HB ' ' B' ' 149' ' ' ILE . 11.5 mm -61.29 -71.19 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.452 0 C-N-CA 123.122 0.569 . . . . 10.0 110.012 -178.66 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.25 58.48 1.12 Allowed Glycine 0 CA--C 1.54 1.645 0 O-C-N 120.814 -1.179 . . . . 10.0 115.042 -177.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 30.7 mmt180 -103.77 161.47 13.9 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 127.161 2.185 . . . . 10.0 105.706 167.494 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -95.99 128.22 42.69 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 104.269 -2.493 . . . . 10.0 104.269 171.442 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 11.1 mp -108.26 151.27 26.18 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 109.084 -0.71 . . . . 10.0 109.084 172.292 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.427 HG11 ' CG ' ' B' ' 143' ' ' ARG . 93.7 t -137.77 138.41 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.948 0 N-CA-C 108.412 -0.958 . . . . 10.0 108.412 -175.377 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.406 ' CG1' ' HB3' ' B' ' 145' ' ' ALA . 1.7 p -104.12 131.49 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 106.914 -1.513 . . . . 10.0 106.914 168.154 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.661 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 4.2 m170 -113.7 159.8 19.31 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 116.433 2.012 . . . . 10.0 116.433 -170.692 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -43.79 -57.12 3.41 Favored 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 129.26 3.024 . . . . 10.0 112.133 176.09 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 75.0 mttt -118.67 171.31 8.28 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 124.198 0.999 . . . . 10.0 112.937 -168.581 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -80.24 138.64 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.647 1.579 . . . . 10.0 109.91 177.815 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.08 152.11 33.09 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -172.525 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -76.81 -30.16 56.29 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.624 1.97 . . . . 10.0 109.968 169.579 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 26.9 mt 54.4 49.88 17.43 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 124.115 0.966 . . . . 10.0 109.979 -172.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.06 -43.36 3.11 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.033 -0.827 . . . . 10.0 111.033 176.062 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' B' ' 76' ' ' ASP . 28.2 mtmm -76.64 30.3 0.13 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.617 1.967 . . . . 10.0 112.236 -172.142 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.54 -33.04 7.74 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 128.32 2.867 . . . . 10.0 109.474 168.647 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.34 21.68 77.42 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.001 -0.889 . . . . 10.0 112.104 -177.224 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -107.48 161.65 14.64 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 168.966 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 8.0 tm-20 -50.81 -51.67 48.63 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 114.957 -1.019 . . . . 10.0 108.279 172.448 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . 0.414 ' OE1' ' NZ ' ' B' ' 136' ' ' LYS . 7.2 tp10 -57.7 -40.51 79.65 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.812 0.671 . . . . 10.0 112.812 178.043 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 1.6 m -48.92 -50.09 36.97 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 119.9 1.227 . . . . 10.0 110.555 171.488 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -80.18 -19.63 46.63 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 112.983 0.734 . . . . 10.0 112.983 -174.23 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.414 ' NZ ' ' OE1' ' B' ' 133' ' ' GLU . 2.5 ttmt -96.74 -42.76 7.84 Favored 'General case' 0 N--CA 1.445 -0.717 0 C-N-CA 124.957 1.303 . . . . 10.0 112.512 -173.403 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 60.7 p -135.14 -7.53 2.31 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.326 0.861 . . . . 10.0 113.326 176.716 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.03 13.39 71.84 Favored Glycine 0 C--O 1.221 -0.662 0 CA-C-O 118.188 -1.34 . . . . 10.0 111.813 -170.039 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 64.81 19.54 11.87 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 120.18 1.99 . . . . 10.0 112.41 170.092 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.65 7.57 6.67 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.742 0.817 . . . . 10.0 112.525 -169.834 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.52 -166.81 52.69 Favored Glycine 0 N--CA 1.445 -0.729 0 O-C-N 121.453 -0.78 . . . . 10.0 111.262 173.075 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 50.2 m -60.36 141.79 55.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 113.522 0.934 . . . . 10.0 113.522 -168.505 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . 0.427 ' CG ' HG11 ' B' ' 118' ' ' VAL . 0.1 OUTLIER -60.38 97.19 0.05 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.85 1.66 . . . . 10.0 109.454 168.734 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 27.1 mt -72.64 -34.66 67.45 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 119.284 0.947 . . . . 10.0 111.989 178.51 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.406 ' HB3' ' CG1' ' B' ' 119' ' ' VAL . . . -152.15 149.05 28.35 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.887 -0.508 . . . . 10.0 110.476 176.257 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.74 142.14 46.41 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 126.991 2.116 . . . . 10.0 107.654 -176.439 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -140.88 160.96 26.74 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 109.176 -1.57 . . . . 10.0 109.176 168.944 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 51.8 t -119.23 131.45 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 104.52 -2.4 . . . . 10.0 104.52 174.181 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.415 ' HB ' ' O ' ' B' ' 113' ' ' ILE . 20.3 mt -73.35 146.81 10.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-N 119.332 0.969 . . . . 10.0 109.288 174.77 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.71 150.35 22.5 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 125.858 1.694 . . . . 10.0 109.053 179.603 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.0 pt -72.47 132.21 33.7 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.359 0 N-CA-C 109.2 -0.667 . . . . 10.0 109.2 -176.11 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.68 -42.6 7.16 Favored 'General case' 0 CA--C 1.512 -0.519 0 C-N-CA 123.9 0.88 . . . . 10.0 109.932 173.281 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . 0.418 ' O ' ' N ' ' B' ' 1' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.433 -1.299 0 N-CA-C 105.17 -2.159 . . . . 10.0 105.17 176.327 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.881 0 N-CA-C 107.894 -1.15 . . . . 10.0 107.894 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.1 t -86.47 -16.47 36.97 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 107.454 -1.313 . . . . 10.0 107.454 166.625 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 47.5 tttt -131.88 164.54 25.86 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 125.603 1.561 . . . . 10.0 108.244 177.239 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -158.03 171.97 19.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 126.018 1.727 . . . . 10.0 106.689 168.537 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -133.05 173.93 14.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 107.702 -1.221 . . . . 10.0 107.702 171.246 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.46 113.24 6.05 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 107.302 -1.37 . . . . 10.0 107.302 165.46 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 5.8 m -92.62 120.32 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.623 -1.251 . . . . 10.0 107.623 168.141 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -100.13 131.7 45.92 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 106.861 -1.533 . . . . 10.0 106.861 179.289 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -141.78 158.73 43.45 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 106.325 -1.731 . . . . 10.0 106.325 167.766 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.25 -64.04 0.04 OUTLIER Glycine 0 N--CA 1.461 0.326 0 C-N-CA 119.393 -1.384 . . . . 10.0 113.685 168.772 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -72.7 -41.44 65.28 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.411 -1.329 . . . . 10.0 107.411 -172.927 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.03 -67.72 0.42 Allowed Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 114.173 -1.376 . . . . 10.0 111.667 169.443 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -57.8 -39.57 86.07 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.581 2.187 . . . . 10.0 111.367 179.002 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.18 118.88 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.024 0 N-CA-C 107.902 -1.147 . . . . 10.0 107.902 179.645 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.63 104.09 8.49 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 103.548 -2.76 . . . . 10.0 103.548 168.702 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.72 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -86.23 142.27 18.82 Favored Glycine 0 N--CA 1.44 -1.086 0 N-CA-C 108.281 -1.928 . . . . 10.0 108.281 177.014 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.719 ' CG2' HG23 ' B' ' 54' ' ' THR . 5.2 mt -140.73 92.52 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 N-CA-C 108.318 -0.993 . . . . 10.0 108.318 -174.248 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.7 mm -102.1 139.36 23.39 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 C-N-CA 124.487 1.115 . . . . 10.0 110.2 174.04 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -112.37 118.89 36.46 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 127.452 2.301 . . . . 10.0 106.88 168.601 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.535 ' CD2' HG12 ' A' ' 31' ' ' VAL . 4.6 m-85 -99.89 115.42 29.58 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 105.832 -1.914 . . . . 10.0 105.832 175.377 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -116.81 127.25 54.14 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 119.032 0.833 . . . . 10.0 110.444 170.002 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -79.8 88.16 5.25 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 106.236 -1.764 . . . . 10.0 106.236 174.562 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.23 -40.55 16.63 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 126.729 2.012 . . . . 10.0 112.099 -167.612 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -130.4 162.36 29.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 101.576 -3.49 . . . . 10.0 101.576 162.766 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.7 t -55.7 -33.36 64.11 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.738 -0.838 . . . . 10.0 108.738 173.518 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 30.3 m-80 -99.39 -2.15 36.93 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 125.749 1.62 . . . . 10.0 110.948 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.25 164.73 24.78 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.762 -0.935 . . . . 10.0 110.762 -170.804 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -61.95 149.57 89.74 Favored 'Trans proline' 0 N--CA 1.449 -1.125 0 C-N-CA 121.563 1.509 . . . . 10.0 108.29 169.477 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.0 t -86.11 122.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 N-CA-C 106.398 -1.704 . . . . 10.0 106.398 -179.403 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.3 tttt -90.28 113.99 25.94 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 108.205 -1.035 . . . . 10.0 108.205 177.566 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.535 HG12 ' CD2' ' A' ' 20' ' ' PHE . 35.7 m -98.34 58.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 125.725 1.61 . . . . 10.0 108.395 -172.486 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.5 p90 -77.27 158.32 30.29 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 119.915 -0.714 . . . . 10.0 110.011 -175.281 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 178.02 179.9 48.21 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.968 179.145 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 20.4 m -150.41 96.39 2.39 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.503 -1.295 . . . . 10.0 107.503 -178.729 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.72 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.9 pt -77.65 154.76 5.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 N-CA-C 108.02 -1.104 . . . . 10.0 108.02 170.908 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -138.82 146.97 41.93 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 107.266 -1.383 . . . . 10.0 107.266 169.317 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.09 -2.29 38.01 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.95 -0.917 . . . . 10.0 114.46 170.642 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.475 HD12 ' N ' ' A' ' 38' ' ' LEU . 6.7 mp -72.31 178.83 3.7 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 119.398 1.599 . . . . 10.0 108.802 169.531 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 11.2 t -88.37 176.48 7.18 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.726 -0.842 . . . . 10.0 108.726 166.717 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 49.4 tt0 -64.02 169.69 4.15 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.04 0.936 . . . . 10.0 112.111 -172.311 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.12 -176.51 48.79 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 124.085 0.85 . . . . 10.0 113.079 167.15 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -62.42 150.85 38.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 123.815 0.846 . . . . 10.0 109.696 174.13 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -142.66 153.4 43.38 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 113.895 1.072 . . . . 10.0 113.895 176.614 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.6 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -39.54 125.02 2.1 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 127.542 2.496 . . . . 10.0 110.459 163.049 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.444 ' CD2' HG12 ' A' ' 119' ' ' VAL . 0.8 OUTLIER -149.73 105.85 3.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 119.823 1.811 . . . . 10.0 108.094 165.724 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.469 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -153.04 -179.99 8.18 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-O 121.844 0.83 . . . . 10.0 113.173 179.558 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.597 HG12 HD22 ' A' ' 117' ' ' LEU . 4.0 m -102.85 151.51 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 CA-C-N 113.219 -1.81 . . . . 10.0 110.345 174.116 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.85 133.4 45.89 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.276 1.83 . . . . 10.0 106.433 178.015 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.8 tp10 -62.41 -55.8 24.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 114.428 1.27 . . . . 10.0 114.428 -165.527 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 59.2 m-85 -77.66 144.94 36.98 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 117.612 -1.635 . . . . 10.0 108.243 179.652 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.38 20.8 48.35 Favored Glycine 0 N--CA 1.442 -0.941 0 N-CA-C 110.482 -1.047 . . . . 10.0 110.482 172.684 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -80.67 70.73 7.47 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 125.765 2.698 . . . . 10.0 109.045 179.649 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.599 ' HB3' HG21 ' B' ' 7' ' ' VAL . 1.6 t-20 -69.33 -13.5 62.41 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 111.242 -2.708 . . . . 10.0 111.852 -174.056 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.54 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.3 OUTLIER -27.69 -52.99 0.08 Allowed 'General case' 0 C--N 1.341 0.201 1 C-N-CA 131.92 4.088 . . . . 10.0 114.283 -175.799 . . . . . . . . 4 4 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.53 -14.77 59.58 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 124.068 0.947 . . . . 10.0 112.657 -172.518 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 107.1 52.96 0.71 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 107.925 -2.07 . . . . 10.0 107.925 -168.257 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 25.3 p 46.89 50.91 13.21 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.768 1.396 . . . . 10.0 114.768 169.784 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.2 p -111.79 -57.84 2.2 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 106.347 -1.723 . . . . 10.0 106.347 171.561 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.7 m -47.63 -33.19 6.41 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 127.167 2.187 . . . . 10.0 111.459 177.413 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -28.07 -39.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 128.666 2.786 . . . . 10.0 113.796 168.255 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.72 159.86 23.79 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 108.67 -1.772 . . . . 10.0 108.67 169.346 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -70.71 -170.25 0.44 Allowed 'Trans proline' 0 N--CA 1.445 -1.354 0 N-CA-C 107.585 -1.736 . . . . 10.0 107.585 167.5 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 36.9 m170 -78.89 55.93 1.83 Allowed 'General case' 0 CA--C 1.545 0.777 0 O-C-N 120.622 -1.299 . . . . 10.0 111.636 -170.121 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -74.88 64.47 1.29 Allowed 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 119.86 1.209 . . . . 10.0 112.275 -175.512 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.7 p-10 -57.6 155.37 21.1 Favored Pre-proline 0 CA--C 1.538 0.491 0 C-N-CA 123.283 0.633 . . . . 10.0 111.164 169.904 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -59.05 -45.8 26.05 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.534 2.156 . . . . 10.0 111.425 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -75.88 64.91 1.9 Allowed 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.116 -0.698 . . . . 10.0 109.116 174.725 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.9 p -42.04 113.76 0.47 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.685 1.194 . . . . 10.0 109.564 179.397 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.4 mtt-85 -145.97 -177.49 5.62 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 105.16 -2.163 . . . . 10.0 105.16 -169.88 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.4 mmtp -75.0 154.34 38.12 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 118.099 -1.44 . . . . 10.0 109.127 176.069 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -69.92 105.39 2.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 107.447 -1.316 . . . . 10.0 107.447 162.401 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.64 -140.65 6.85 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 107.909 -2.076 . . . . 10.0 107.909 173.822 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.7 -155.43 15.23 Favored Glycine 0 C--O 1.227 -0.309 0 CA-C-O 117.521 -1.711 . . . . 10.0 109.293 169.614 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -67.32 13.95 0.15 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 CA-C-N 120.378 2.089 . . . . 10.0 111.829 170.335 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 51.1 mttm -121.2 3.15 10.39 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-O 117.948 -1.025 . . . . 10.0 111.634 170.828 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -127.21 159.09 35.36 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 170.908 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -79.4 -32.52 42.97 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.639 -1.615 . . . . 10.0 106.639 167.017 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -82.89 28.48 0.49 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 124.58 1.152 . . . . 10.0 112.274 -168.643 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.37 164.08 11.97 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 119.839 1.199 . . . . 10.0 109.753 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -78.54 -67.58 0.73 Allowed 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.733 -0.604 . . . . 10.0 109.515 178.662 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -158.72 -116.35 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 106.827 -1.546 . . . . 10.0 106.827 -174.207 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -78.34 54.7 3.99 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-N 119.704 1.138 . . . . 10.0 111.012 178.749 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -79.46 92.3 5.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 105.735 -1.95 . . . . 10.0 105.735 170.014 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 29.1 mt -71.46 -21.7 61.92 Favored 'General case' 0 N--CA 1.463 0.197 0 C-N-CA 118.755 -1.178 . . . . 10.0 108.204 175.325 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 83.13 -73.37 2.69 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 109.754 -1.338 . . . . 10.0 109.754 168.72 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -139.96 103.09 4.55 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 108.802 -0.814 . . . . 10.0 108.802 -169.412 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 23.9 m -109.09 129.53 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 119.068 0.849 . . . . 10.0 111.435 176.12 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 m -79.25 110.18 14.28 Favored 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 127.724 2.41 . . . . 10.0 112.371 -170.45 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.81 132.6 39.42 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 122.702 0.401 . . . . 10.0 110.154 169.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -53.5 166.98 0.24 Allowed 'General case' 0 CA--C 1.518 -0.258 0 O-C-N 124.093 0.871 . . . . 10.0 109.198 166.144 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -41.56 -43.19 2.64 Favored 'General case' 0 N--CA 1.442 -0.827 0 C-N-CA 126.324 1.85 . . . . 10.0 110.419 169.343 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.78 0.48 39.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.351 1.46 . . . . 10.0 110.948 -170.913 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.99 2.91 85.83 Favored Glycine 0 C--N 1.339 0.717 0 N-CA-C 111.408 -0.677 . . . . 10.0 111.408 178.116 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 33.1 t -78.97 106.5 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.376 -1.712 . . . . 10.0 106.376 -178.38 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.593 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -115.23 118.41 33.21 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 118.645 0.657 . . . . 10.0 109.638 176.541 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -79.73 126.68 31.26 Favored 'General case' 0 N--CA 1.432 -1.357 0 C-N-CA 126.526 1.93 . . . . 10.0 109.068 174.403 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -118.98 134.01 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.955 0 N-CA-C 107.319 -1.363 . . . . 10.0 107.319 175.548 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 97.8 p -156.62 59.75 0.55 Allowed 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 118.461 0.573 . . . . 10.0 110.872 174.457 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -106.11 153.48 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 -178.232 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -123.86 131.68 53.62 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 123.936 0.894 . . . . 10.0 108.908 169.398 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -120.57 147.95 44.51 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-O 121.639 0.733 . . . . 10.0 109.042 179.618 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.8 p -105.4 7.24 33.14 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 128.394 2.678 . . . . 10.0 111.865 -173.31 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.2 p -122.89 9.42 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.35 0.977 . . . . 10.0 110.763 179.525 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 mp -108.45 150.03 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 105.944 -1.873 . . . . 10.0 105.944 176.773 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 14.7 m -146.29 152.69 39.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.845 -0.798 . . . . 10.0 108.845 169.939 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 55.4 mt -103.56 0.2 30.58 Favored 'General case' 0 C--O 1.237 0.437 0 C-N-CA 123.751 0.82 . . . . 10.0 111.66 -175.538 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.4 t -162.03 -172.38 3.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 126.472 1.909 . . . . 10.0 107.439 166.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 105.85 -69.87 0.23 Allowed Glycine 0 C--O 1.227 -0.336 0 C-N-CA 125.291 1.424 . . . . 10.0 110.307 167.302 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -162.69 -50.15 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 124.873 1.269 . . . . 10.0 107.611 -179.922 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -80.32 41.96 0.56 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.176 0.99 . . . . 10.0 109.034 179.449 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.5 t -81.4 83.8 6.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 C-N-CA 126.076 1.75 . . . . 10.0 106.758 -171.773 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 20.8 pt -55.63 -21.61 10.42 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 113.649 0.981 . . . . 10.0 113.649 -170.172 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.417 ' CD1' ' H ' ' A' ' 113' ' ' ILE . 1.6 mp -14.04 -56.5 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 129.369 3.067 . . . . 10.0 115.139 174.866 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -87.7 6.6 83.19 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.208 -1.329 . . . . 10.0 114.812 -170.468 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.6 mpt_? -77.45 175.78 9.49 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.887 1.344 . . . . 10.0 108.751 174.014 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.41 ' C ' HD23 ' A' ' 117' ' ' LEU . 1.3 m -113.94 127.65 56.06 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 106.723 -1.584 . . . . 10.0 106.723 169.91 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.597 HD22 HG12 ' A' ' 47' ' ' VAL . 2.5 mt -102.86 152.73 20.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 118.754 0.707 . . . . 10.0 109.395 174.309 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.2 t -141.46 136.22 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 123.542 0.526 . . . . 10.0 110.178 -171.927 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.444 HG12 ' CD2' ' A' ' 45' ' ' PHE . 10.4 m -104.52 139.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 O-C-N 124.641 1.213 . . . . 10.0 109.201 164.13 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.6 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.5 m-70 -117.14 163.21 16.62 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 114.954 1.465 . . . . 10.0 114.954 -169.15 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -55.99 -54.66 42.19 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.693 -1.14 . . . . 10.0 110.103 178.032 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -111.31 173.4 6.36 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-O 121.305 0.574 . . . . 10.0 110.277 -178.231 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -96.19 136.82 36.15 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 125.24 1.416 . . . . 10.0 108.16 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.469 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -77.41 161.18 28.19 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 121.474 0.654 . . . . 10.0 111.943 -174.279 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -73.85 -15.5 61.16 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.763 -1.108 . . . . 10.0 110.809 -177.349 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mt 58.31 44.81 17.99 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.383 1.073 . . . . 10.0 108.292 -172.394 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.74 -15.65 59.45 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.96 1.267 . . . . 10.0 113.786 170.005 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -75.5 -4.46 39.89 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 114.838 1.421 . . . . 10.0 114.838 -166.548 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -68.51 -23.77 75.21 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-N 119.422 1.01 . . . . 10.0 110.65 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.34 18.74 50.95 Favored Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.812 -0.993 . . . . 10.0 114.429 179.267 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -116.92 176.66 5.02 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 119.474 1.637 . . . . 10.0 110.735 179.094 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -32.48 -61.76 0.25 Allowed 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 126.631 1.973 . . . . 10.0 112.186 171.396 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.88 -44.55 92.73 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.43 0.692 . . . . 10.0 111.529 178.536 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 10.8 m -49.24 -42.15 39.74 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 119.294 -0.384 . . . . 10.0 110.505 -176.06 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.3 t -87.18 -3.37 59.05 Favored 'General case' 0 N--CA 1.451 -0.386 0 O-C-N 124.32 1.013 . . . . 10.0 112.605 -172.464 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -114.53 -48.52 2.86 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.462 1.105 . . . . 10.0 111.521 -174.986 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 30.4 p -133.44 0.46 3.34 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 119.108 0.867 . . . . 10.0 112.286 171.658 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 86.75 -105.53 3.04 Favored Glycine 0 C--N 1.341 0.819 0 N-CA-C 107.289 -2.325 . . . . 10.0 107.289 -172.864 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.2 m-20 -167.52 43.44 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 125.298 1.439 . . . . 10.0 108.541 -179.477 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.43 -15.18 63.23 Favored 'General case' 0 CA--C 1.533 0.312 0 O-C-N 121.674 -0.641 . . . . 10.0 111.756 -177.636 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.17 -162.66 54.54 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.215 -1.154 . . . . 10.0 110.215 -176.742 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.1 m -62.25 149.52 41.67 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 113.736 1.013 . . . . 10.0 113.736 -170.043 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.2 74.59 0.69 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.161 2.584 . . . . 10.0 111.267 174.113 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.58 -27.32 67.62 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.187 -0.945 . . . . 10.0 113.361 -178.701 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.36 153.17 30.05 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 118.881 0.764 . . . . 10.0 110.392 171.737 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.0 p -155.52 155.64 33.77 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 123.081 0.552 . . . . 10.0 110.367 -168.482 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.92 162.64 30.56 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 124.054 0.835 . . . . 10.0 112.023 -174.727 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 62.1 t -122.64 66.85 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 105.263 -2.125 . . . . 10.0 105.263 -172.515 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.529 HD11 HD21 ' A' ' 117' ' ' LEU . 7.3 mm 30.44 -114.63 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 C-N-CA 127.1 2.16 . . . . 10.0 113.349 -173.737 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 126.61 102.5 1.25 Allowed Glycine 0 CA--C 1.531 1.045 0 N-CA-C 109.653 -1.379 . . . . 10.0 109.653 -169.536 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 56.3 mt -53.31 137.6 13.56 Favored 'Isoleucine or valine' 0 C--N 1.341 0.197 0 C-N-CA 124.151 0.98 . . . . 10.0 110.415 170.717 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -137.57 158.58 44.07 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 107.92 -1.141 . . . . 10.0 107.92 169.748 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 23.7 tt0 . . . . . 0 C--O 1.25 1.081 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 168.133 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.875 0 CA-C-O 118.538 -0.744 . . . . 10.0 109.62 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 4.7 t -90.57 -36.71 14.29 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.666 0.787 . . . . 10.0 110.705 169.951 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 47.3 tttp -127.44 124.15 37.77 Favored 'General case' 0 C--O 1.238 0.485 0 C-N-CA 125.798 1.639 . . . . 10.0 109.217 -171.814 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.11 155.92 49.89 Favored 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.741 0.816 . . . . 10.0 109.687 176.673 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.1 m -106.68 178.73 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 O-C-N 123.965 0.791 . . . . 10.0 109.94 176.944 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . 0.454 ' HB3' ' HB ' ' B' ' 18' ' ' ILE . . . -160.7 93.75 1.01 Allowed 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.35 1.46 . . . . 10.0 108.056 175.68 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.599 HG21 ' HB3' ' A' ' 53' ' ' ASN . 0.9 OUTLIER -92.41 95.09 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 C-N-CA 123.753 0.821 . . . . 10.0 110.722 179.453 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.401 HD22 HG23 ' B' ' 119' ' ' VAL . 1.6 mp -80.09 130.41 35.23 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 123.192 0.597 . . . . 10.0 109.41 175.938 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.34 158.99 44.44 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 106.211 -1.774 . . . . 10.0 106.211 168.938 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -172.48 -64.39 0.05 OUTLIER Glycine 0 CA--C 1.51 -0.231 0 C-N-CA 119.109 -1.52 . . . . 10.0 111.967 169.311 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -70.34 -45.01 67.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 107.047 -1.464 . . . . 10.0 107.047 -178.831 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.11 -70.52 0.38 Allowed Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.425 -1.261 . . . . 10.0 110.784 169.571 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -57.12 -35.0 98.78 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 123.228 2.618 . . . . 10.0 111.821 175.81 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 37.4 t -68.63 89.24 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 C-N-CA 124.623 1.169 . . . . 10.0 107.986 179.033 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -113.12 116.22 29.51 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 107.109 -1.441 . . . . 10.0 107.109 -179.871 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.472 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -108.3 136.79 13.72 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 109.902 -1.279 . . . . 10.0 109.902 173.368 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.54 ' CG2' HG22 ' A' ' 54' ' ' THR . 7.8 mt -135.49 74.68 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 106.414 -1.699 . . . . 10.0 106.414 -175.286 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.454 ' HB ' ' HB3' ' B' ' 6' ' ' ALA . 28.7 mm -95.09 149.8 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 CA-C-N 114.826 -1.079 . . . . 10.0 109.655 -172.347 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -126.37 114.6 18.43 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 126.775 2.03 . . . . 10.0 106.666 -170.57 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -102.36 115.54 30.78 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 106.229 -1.767 . . . . 10.0 106.229 176.559 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -119.24 137.51 53.61 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.085 0.772 . . . . 10.0 113.085 169.13 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -113.08 111.0 21.39 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 104.638 -2.356 . . . . 10.0 104.638 167.754 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? -56.25 -70.81 0.1 Allowed 'General case' 0 N--CA 1.445 -0.701 0 C-N-CA 125.554 1.542 . . . . 10.0 109.136 -176.117 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 23.0 mp0 -107.14 -133.38 0.33 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 107.133 -1.432 . . . . 10.0 107.133 176.487 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.3 m -136.86 15.32 3.09 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.195 0.521 . . . . 10.0 112.049 166.545 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -115.57 -22.97 8.98 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 124.803 1.241 . . . . 10.0 109.536 167.351 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.01 156.44 53.22 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 108.873 -1.691 . . . . 10.0 108.873 169.181 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -72.02 163.16 39.67 Favored 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 123.051 2.501 . . . . 10.0 109.207 178.105 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -79.57 134.64 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 104.831 -2.285 . . . . 10.0 104.831 166.934 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 32.5 mttt -114.67 125.13 53.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 104.812 -2.292 . . . . 10.0 104.812 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.9 p -109.48 104.14 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 C-N-CA 126.404 1.882 . . . . 10.0 106.587 -178.072 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -126.16 159.46 32.88 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 112.728 0.64 . . . . 10.0 112.728 -178.029 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.99 -146.09 13.99 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 107.811 -2.116 . . . . 10.0 107.811 169.948 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 31.8 p -155.38 160.68 40.87 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 122.113 0.958 . . . . 10.0 112.044 175.033 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.75 HG12 ' HB3' ' B' ' 95' ' ' ALA . 0.0 OUTLIER -110.92 145.42 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-N 113.25 -1.795 . . . . 10.0 107.509 166.871 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -125.15 142.97 51.17 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 107.167 -1.42 . . . . 10.0 107.167 168.834 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.22 0.57 20.69 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.082 0.849 . . . . 10.0 113.247 176.634 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.41 176.87 8.95 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 118.594 1.197 . . . . 10.0 110.321 -179.155 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 6.3 t -109.62 153.74 23.78 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.925 -1.88 . . . . 10.0 105.925 166.097 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -48.09 147.83 2.0 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.594 1.157 . . . . 10.0 112.315 -171.952 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.75 -173.22 18.25 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.05 0.833 . . . . 10.0 111.795 170.774 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -73.03 146.89 45.59 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.26 1.424 . . . . 10.0 110.594 -179.142 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 62.8 m-70 -147.06 147.97 31.16 Favored 'General case' 0 C--N 1.342 0.25 0 N-CA-C 114.509 1.3 . . . . 10.0 114.509 -177.49 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.686 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -26.46 121.99 0.04 OUTLIER Glycine 0 C--N 1.339 0.738 0 C-N-CA 128.653 3.025 . . . . 10.0 114.501 164.587 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -152.72 109.2 3.42 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.665 1.233 . . . . 10.0 110.544 166.267 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.14 179.17 7.82 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.254 0.55 . . . . 10.0 112.193 173.098 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.4 m -116.56 134.24 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.066 -1.879 . . . . 10.0 106.848 166.02 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -110.91 152.99 26.1 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 125.268 1.427 . . . . 10.0 107.912 -178.701 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.23 -54.71 43.67 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.875 -0.602 . . . . 10.0 111.413 -172.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.51 111.96 13.79 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.613 -0.884 . . . . 10.0 108.613 -169.189 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.57 -30.47 68.67 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.164 -1.174 . . . . 10.0 110.164 169.44 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -40.29 139.43 0.74 Allowed 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 124.788 1.235 . . . . 10.0 111.214 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -143.88 24.07 1.69 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 124.353 1.061 . . . . 10.0 112.551 169.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.719 HG23 ' CG2' ' A' ' 17' ' ' ILE . 3.6 m -61.82 -35.15 77.39 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.371 0.668 . . . . 10.0 110.748 -174.957 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.23 -16.45 59.82 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 122.215 -0.303 . . . . 10.0 111.582 176.103 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.39 -151.59 19.08 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 106.61 -2.596 . . . . 10.0 106.61 -169.656 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 1.8 m -69.26 67.63 0.19 Allowed 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 126.018 1.727 . . . . 10.0 111.298 -179.039 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -163.88 -53.16 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.317 1.847 . . . . 10.0 107.583 -179.299 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -39.16 -40.59 0.74 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 127.648 2.379 . . . . 10.0 111.235 174.132 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.81 -47.55 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.009 2.524 . . . . 10.0 114.062 168.28 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.08 152.24 26.45 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 110.424 -1.071 . . . . 10.0 110.424 173.512 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -79.13 46.94 2.34 Favored 'Trans proline' 0 CA--C 1.537 0.629 0 C-N-CA 124.379 3.386 . . . . 10.0 113.482 -171.065 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 16.8 m170 57.14 58.03 4.19 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.1 1.76 . . . . 10.0 108.585 -175.825 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -66.77 75.64 0.11 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.769 0.795 . . . . 10.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -77.65 137.02 63.03 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 121.2 -0.938 . . . . 10.0 110.508 -177.52 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.06 -52.16 0.99 Allowed 'Trans proline' 0 N--CA 1.455 -0.752 0 C-N-CA 122.578 2.185 . . . . 10.0 111.132 -173.19 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mp -76.17 65.74 2.19 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 108.122 -1.066 . . . . 10.0 108.122 175.054 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 66.6 p -30.02 101.64 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.325 2.25 . . . . 10.0 114.021 -172.877 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.2 mtp180 -139.85 177.7 7.77 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.072 0.949 . . . . 10.0 110.927 -174.729 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 67.2 mmtt -107.26 89.07 2.89 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 113.233 0.827 . . . . 10.0 113.233 -168.66 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.401 ' HB2' ' CE1' ' B' ' 80' ' ' HIS . 81.9 t60 5.73 92.85 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.23 0 C-N-CA 128.45 2.7 . . . . 10.0 114.849 179.219 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -105.24 -139.04 9.64 Favored Glycine 0 N--CA 1.442 -0.921 0 N-CA-C 110.144 -1.182 . . . . 10.0 110.144 178.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.03 -162.24 34.34 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 106.636 -2.586 . . . . 10.0 106.636 175.394 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.62 1.31 1.81 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 CA-C-N 120.055 1.927 . . . . 10.0 111.472 168.417 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.31 8.6 18.09 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.913 1.685 . . . . 10.0 110.516 176.4 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -142.03 169.62 17.24 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.442 1.019 . . . . 10.0 108.948 165.125 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -87.99 -22.6 24.17 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.235 -1.394 . . . . 10.0 107.235 167.996 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 -82.27 31.05 0.39 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 120.661 -1.274 . . . . 10.0 112.777 -176.526 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.6 132.7 54.77 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.255 -1.017 . . . . 10.0 108.255 172.898 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.401 ' CE1' ' HB2' ' B' ' 71' ' ' HIS . 16.9 m170 -63.17 -61.52 2.32 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 121.176 0.512 . . . . 10.0 110.538 -177.787 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.4 p -168.23 -56.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 N-CA-C 107.147 -1.427 . . . . 10.0 107.147 -179.141 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -133.16 63.14 0.63 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 109.844 -1.302 . . . . 10.0 109.844 177.45 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.1 m-20 -92.7 95.5 9.6 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 104.101 -2.555 . . . . 10.0 104.101 167.528 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 9.2 mp -66.75 -26.61 67.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 118.828 0.74 . . . . 10.0 109.342 -176.713 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 116.9 -88.17 0.45 Allowed Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 108.106 -1.998 . . . . 10.0 108.106 168.631 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 38.5 m-80 -149.39 142.49 24.96 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 108.195 -1.039 . . . . 10.0 108.195 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.58 134.12 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 N-CA-C 107.657 -1.238 . . . . 10.0 107.657 169.001 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -86.9 130.06 34.62 Favored 'General case' 0 C--O 1.226 -0.166 0 C-N-CA 123.978 0.911 . . . . 10.0 108.643 179.663 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -104.77 127.87 52.71 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.227 1.411 . . . . 10.0 109.43 175.247 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -61.29 167.71 3.04 Favored 'General case' 0 N--CA 1.453 -0.306 0 O-C-N 124.888 1.368 . . . . 10.0 109.933 168.064 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -52.32 -30.8 30.11 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.681 1.192 . . . . 10.0 110.77 172.202 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -77.25 -7.73 56.42 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.035 0.379 . . . . 10.0 110.758 -177.541 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.14 17.01 73.02 Favored Glycine 0 C--N 1.34 0.788 0 N-CA-C 110.611 -0.995 . . . . 10.0 110.611 -178.497 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 42.1 t -94.54 119.29 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 C-N-CA 127.359 2.264 . . . . 10.0 105.434 172.532 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.75 ' HB3' HG12 ' B' ' 35' ' ' ILE . . . -115.82 126.6 54.21 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 123.706 0.802 . . . . 10.0 109.017 174.431 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -88.57 133.62 34.11 Favored 'General case' 0 N--CA 1.437 -1.096 0 C-N-CA 127.154 2.181 . . . . 10.0 109.567 178.936 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 50.1 t -113.97 130.98 67.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 C-N-CA 125.825 1.65 . . . . 10.0 108.228 174.624 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 78.1 p -157.78 73.81 0.71 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.132 0.973 . . . . 10.0 108.923 169.685 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.29 163.06 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 106.984 -1.487 . . . . 10.0 106.984 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -147.72 150.45 34.33 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 125.191 1.396 . . . . 10.0 109.933 174.333 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -155.32 159.28 39.84 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.323 -1.362 . . . . 10.0 107.323 172.881 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 5.2 p -104.81 -16.85 14.79 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 128.136 2.574 . . . . 10.0 112.281 179.053 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 4.5 p -78.34 -38.28 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 N-CA-C 108.585 -0.894 . . . . 10.0 108.585 -176.387 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 1.3 mp -70.64 154.72 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 C-N-CA 124.522 1.129 . . . . 10.0 107.978 168.771 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 11.1 m -153.77 163.28 40.28 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 106.962 -1.495 . . . . 10.0 106.962 172.088 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 79.2 mt -101.96 -11.06 19.24 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.797 0.839 . . . . 10.0 111.539 176.937 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.5 m -148.94 139.48 22.58 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.808 1.643 . . . . 10.0 107.239 169.498 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 178.54 -61.06 0.08 OUTLIER Glycine 0 C--O 1.227 -0.331 0 N-CA-C 107.296 -2.322 . . . . 10.0 107.296 171.017 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -169.71 -52.69 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 127.321 2.249 . . . . 10.0 106.804 174.102 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -78.39 -41.34 33.48 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 114.399 -1.273 . . . . 10.0 108.52 -174.506 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . 0.681 ' O ' HG23 ' B' ' 112' ' ' ILE . 13.6 t 49.86 -105.75 0.19 Allowed 'General case' 0 N--CA 1.438 -1.069 0 C-N-CA 125.637 1.575 . . . . 10.0 108.182 -169.55 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.681 HG23 ' O ' ' B' ' 111' ' ' SER . 39.4 pt 162.87 -23.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.336 1 C-N-CA 133.226 4.61 . . . . 10.0 107.34 -171.482 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -43.25 120.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 118.854 0.752 . . . . 10.0 110.397 175.425 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 104.0 -6.55 47.53 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.786 -1.008 . . . . 10.0 113.781 179.025 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -77.1 154.64 33.1 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 118.309 1.055 . . . . 10.0 110.288 175.562 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 32.6 m -94.93 109.03 21.09 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.565 1.146 . . . . 10.0 109.183 178.553 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -79.57 147.92 31.94 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 167.272 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 65.3 t -142.63 132.87 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 C-N-CA 123.953 0.901 . . . . 10.0 109.551 -173.565 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.401 HG23 HD22 ' B' ' 8' ' ' LEU . 2.7 t -109.0 136.67 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.648 0 C-N-CA 126.173 1.789 . . . . 10.0 109.898 172.239 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.686 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 6.6 m-70 -117.52 158.68 24.13 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 116.466 2.024 . . . . 10.0 116.466 -171.179 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 57.8 tt0 -48.8 -53.06 20.72 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 129.836 3.254 . . . . 10.0 111.813 175.166 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -112.75 168.79 9.38 Favored 'General case' 0 CA--C 1.515 -0.4 0 C-N-CA 123.332 0.653 . . . . 10.0 111.876 -169.704 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.62 154.1 40.92 Favored 'General case' 0 N--CA 1.443 -0.82 0 O-C-N 125.016 1.448 . . . . 10.0 108.214 169.013 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -107.25 140.53 39.98 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 124.197 0.999 . . . . 10.0 109.032 -169.014 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -72.99 -28.99 62.71 Favored 'General case' 0 C--O 1.232 0.168 0 O-C-N 123.724 0.64 . . . . 10.0 109.803 -175.331 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 14.6 mt 59.86 50.95 6.4 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 107.896 -1.15 . . . . 10.0 107.896 -171.413 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 94.05 -39.33 2.94 Favored Glycine 0 CA--C 1.521 0.456 0 C-N-CA 126.189 1.852 . . . . 10.0 110.788 169.531 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 29.8 mtmm -80.91 39.79 0.51 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.004 0.922 . . . . 10.0 112.591 -169.485 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.18 -24.11 13.39 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 126.565 2.031 . . . . 10.0 110.262 169.186 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 59.94 36.11 89.15 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 123.732 0.682 . . . . 10.0 111.547 176.517 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -137.67 166.6 23.55 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 108.467 -0.938 . . . . 10.0 108.467 173.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -48.5 -47.4 38.79 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 124.363 1.065 . . . . 10.0 110.295 -178.586 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -70.48 -33.7 71.55 Favored 'General case' 0 N--CA 1.448 -0.549 0 O-C-N 121.922 -0.486 . . . . 10.0 111.671 179.417 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 26.6 p -55.69 -45.76 77.74 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 119.398 0.999 . . . . 10.0 110.435 177.274 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.5 t -76.3 -14.38 60.11 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.756 -0.656 . . . . 10.0 112.345 -171.728 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 10.5 ttmt -107.16 -49.34 3.29 Favored 'General case' 0 N--CA 1.434 -1.255 0 C-N-CA 125.987 1.715 . . . . 10.0 110.904 -172.141 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.03 23.77 2.58 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 118.972 0.806 . . . . 10.0 111.673 176.223 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 61.4 26.62 66.56 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 119.516 1.053 . . . . 10.0 111.951 177.983 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 57.16 23.19 8.32 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.286 1.043 . . . . 10.0 112.908 -178.798 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.58 -12.31 9.66 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 125.554 1.542 . . . . 10.0 114.045 -175.889 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.11 -162.92 52.93 Favored Glycine 0 N--CA 1.445 -0.765 0 O-C-N 121.029 -1.044 . . . . 10.0 110.849 172.193 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 5.4 m -56.19 128.32 35.04 Favored 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 124.097 0.959 . . . . 10.0 111.807 -167.96 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -73.48 98.78 2.85 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.45 1.1 . . . . 10.0 108.105 178.169 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 36.2 mt -79.24 -28.53 42.46 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.039 0.536 . . . . 10.0 112.024 -171.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -148.59 138.74 22.41 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 109.146 -0.687 . . . . 10.0 109.146 179.341 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -137.52 130.23 30.01 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 107.136 -1.431 . . . . 10.0 107.136 -178.185 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -128.24 -174.05 13.63 Favored Glycine 0 C--O 1.228 -0.235 0 N-CA-C 109.5 -1.44 . . . . 10.0 109.5 178.459 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 4.7 t -131.68 150.97 34.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 103.478 -2.786 . . . . 10.0 103.478 168.245 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.1 mt -60.12 -86.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.574 1.15 . . . . 10.0 111.534 -168.166 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 97.94 128.88 6.17 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 110.627 -0.989 . . . . 10.0 110.627 -179.01 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 5.6 pt -76.68 126.91 37.76 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.166 0 N-CA-C 108.963 -0.754 . . . . 10.0 108.963 177.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.99 -45.68 12.86 Favored 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 108.533 -0.914 . . . . 10.0 108.533 169.954 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 . . . . . 0 C--O 1.253 1.262 0 CA-C-O 116.016 -1.945 . . . . 10.0 109.665 -176.064 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 106.331 -1.729 . . . . 10.0 106.331 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -88.81 -16.09 32.93 Favored 'General case' 0 C--O 1.228 -0.076 0 CA-C-N 119.917 1.235 . . . . 10.0 111.475 177.118 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -151.88 144.54 24.27 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.245 0.475 . . . . 10.0 112.261 177.792 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.2 160.62 37.28 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 125.832 1.653 . . . . 10.0 109.497 173.865 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 t -121.58 150.99 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 125.762 1.625 . . . . 10.0 109.93 179.502 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.55 100.59 5.01 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.782 1.233 . . . . 10.0 108.98 169.671 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -83.97 109.12 17.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 109.85 -0.426 . . . . 10.0 109.85 170.555 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.5 mt -96.19 145.95 25.1 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.069 0.948 . . . . 10.0 109.316 177.419 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -157.89 164.53 36.82 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 107.89 -1.152 . . . . 10.0 107.89 171.227 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -161.07 -67.3 0.02 OUTLIER Glycine 0 C--O 1.229 -0.174 0 N-CA-C 111.574 -0.611 . . . . 10.0 111.574 171.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -75.99 -42.1 49.22 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 107.358 -1.349 . . . . 10.0 107.358 -176.557 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.98 -67.12 0.53 Allowed Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 114.851 -1.068 . . . . 10.0 111.615 -177.308 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -57.29 -41.69 70.5 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 122.157 1.904 . . . . 10.0 110.888 179.563 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -69.56 108.84 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 N-CA-C 107.176 -1.416 . . . . 10.0 107.176 176.843 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -120.48 117.51 27.84 Favored 'General case' 0 N--CA 1.437 -1.098 0 C-N-CA 126.049 1.74 . . . . 10.0 106.757 174.395 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.866 ' HA2' HG22 ' A' ' 35' ' ' ILE . . . -95.31 142.27 15.99 Favored Glycine 0 N--CA 1.444 -0.812 0 N-CA-C 108.973 -1.651 . . . . 10.0 108.973 169.177 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.496 ' CG2' HG22 ' B' ' 54' ' ' THR . 2.3 mt -145.49 67.18 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 N-CA-C 106.049 -1.834 . . . . 10.0 106.049 -173.611 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.6 mm -90.91 135.51 26.53 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 CA-C-N 116.39 -0.368 . . . . 10.0 110.061 -172.4 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 m-80 -101.84 132.55 47.55 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 125.019 1.328 . . . . 10.0 108.708 175.589 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -116.18 87.41 2.68 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 126.626 1.97 . . . . 10.0 107.822 178.541 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -83.94 155.83 22.64 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-O 121.46 0.648 . . . . 10.0 111.169 175.68 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -145.23 99.16 3.27 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 126.068 1.747 . . . . 10.0 107.174 174.828 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.4 ptmt -62.31 -57.48 11.22 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 122.172 -0.33 . . . . 10.0 110.128 179.305 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -128.91 163.01 26.21 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 103.814 -2.661 . . . . 10.0 103.814 168.093 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.4 t -76.75 -4.59 44.19 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 119.172 0.897 . . . . 10.0 109.904 173.189 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -80.92 -21.86 40.15 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 124.452 1.101 . . . . 10.0 109.532 168.914 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.71 148.72 30.81 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 110.132 -1.187 . . . . 10.0 110.132 178.316 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -64.72 141.14 71.02 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 N-CA-C 107.803 -1.653 . . . . 10.0 107.803 169.245 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.8 t -78.3 83.12 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 106.191 -1.781 . . . . 10.0 106.191 174.241 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 56.0 tttt -63.33 111.58 2.34 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.915 -1.142 . . . . 10.0 107.915 171.429 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 18.1 m -91.62 121.67 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 N-CA-C 106.884 -1.524 . . . . 10.0 106.884 176.769 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 31.0 p90 -133.04 151.09 52.08 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 122.19 0.995 . . . . 10.0 113.145 170.5 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.08 -177.19 47.17 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 109.629 -1.388 . . . . 10.0 109.629 170.071 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.2 m -128.76 103.27 6.97 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 107.745 -1.206 . . . . 10.0 107.745 -173.551 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.866 HG22 ' HA2' ' A' ' 16' ' ' GLY . 3.7 pt -77.02 150.36 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.39 0 N-CA-C 106.351 -1.722 . . . . 10.0 106.351 168.281 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.63 141.86 43.23 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.644 -0.502 . . . . 10.0 109.644 169.312 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.05 0.33 28.48 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.323 0.963 . . . . 10.0 112.899 175.76 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -65.12 176.05 1.41 Allowed 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 121.998 0.904 . . . . 10.0 109.669 169.922 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.0 t -98.92 167.1 10.95 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 106.649 -1.612 . . . . 10.0 106.649 164.95 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -58.19 169.08 0.89 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.398 1.079 . . . . 10.0 111.256 -171.251 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.94 -178.34 45.11 Favored Glycine 0 N--CA 1.448 -0.526 0 O-C-N 120.883 -1.136 . . . . 10.0 111.896 166.992 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.9 mp -70.63 153.3 42.99 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.283 1.433 . . . . 10.0 110.395 179.832 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -148.92 143.44 26.2 Favored 'General case' 0 C--N 1.34 0.185 0 N-CA-C 113.627 0.973 . . . . 10.0 113.627 -175.439 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.599 ' HA3' ' HB2' ' A' ' 120' ' ' HIS . . . -32.06 127.91 0.25 Allowed Glycine 0 C--N 1.34 0.777 0 C-N-CA 126.963 2.221 . . . . 10.0 111.644 164.391 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -155.39 103.48 2.33 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 119.744 1.772 . . . . 10.0 111.394 168.409 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.527 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -152.01 174.62 13.43 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 114.253 1.205 . . . . 10.0 114.253 -173.382 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.1 p -79.16 140.81 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 112.016 -2.356 . . . . 10.0 107.966 166.567 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.4 ' CD2' ' CG2' ' A' ' 118' ' ' VAL . 86.5 m-70 -126.17 100.5 6.35 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 102.875 -3.009 . . . . 10.0 102.875 163.861 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 6.89 -78.84 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 128.67 2.788 . . . . 10.0 116.017 178.773 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -81.69 162.22 23.08 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 119.166 0.894 . . . . 10.0 110.63 -171.098 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.01 -18.87 58.74 Favored Glycine 0 CA--C 1.524 0.61 0 O-C-N 121.306 -0.871 . . . . 10.0 110.956 170.91 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -65.34 162.82 16.76 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-O 122.275 1.036 . . . . 10.0 112.716 -170.268 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.424 ' HB3' HG21 ' B' ' 7' ' ' VAL . 0.3 OUTLIER -161.58 17.91 0.11 Allowed 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 113.931 1.086 . . . . 10.0 113.931 -169.452 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.406 HG22 ' CG2' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -51.81 -37.89 53.52 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.489 1.116 . . . . 10.0 113.464 -169.003 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.22 -21.94 45.56 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 112.306 0.484 . . . . 10.0 112.306 179.485 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.61 100.9 2.65 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 110.575 -1.01 . . . . 10.0 110.575 -174.313 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.9 t 52.0 30.68 7.66 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 125.379 1.472 . . . . 10.0 114.502 169.147 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.8 m -133.79 -59.35 0.85 Allowed 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 106.816 -1.55 . . . . 10.0 106.816 -173.585 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.3 m -47.5 -46.12 26.96 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 126.5 1.92 . . . . 10.0 111.52 -169.469 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -23.88 -49.7 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 128.239 2.616 . . . . 10.0 114.975 169.4 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.12 171.37 12.95 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.769 -0.932 . . . . 10.0 110.769 173.094 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -79.45 -136.22 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 123.384 2.723 . . . . 10.0 106.092 166.022 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 18.1 m170 -106.29 50.35 0.78 Allowed 'General case' 0 CA--C 1.544 0.733 0 CA-C-N 121.67 2.032 . . . . 10.0 110.102 171.371 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -78.69 61.35 2.97 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.618 1.554 . . . . 10.0 110.218 174.591 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -61.94 155.97 59.97 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 127.581 2.353 . . . . 10.0 111.138 171.089 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.19 -58.28 0.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.228 2.618 . . . . 10.0 112.75 178.452 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 5.4 mp -78.05 58.64 2.02 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.941 0.791 . . . . 10.0 110.509 -177.983 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.8 t -59.08 110.76 1.11 Allowed 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 122.913 0.485 . . . . 10.0 109.752 -174.709 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 65.8 mtt180 -127.2 -90.08 0.53 Allowed 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 105.361 -2.089 . . . . 10.0 105.361 178.166 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 64.1 mttm -144.43 156.35 44.16 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.001 0.905 . . . . 10.0 108.812 169.999 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -63.29 120.2 11.11 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 118.493 -1.283 . . . . 10.0 107.804 166.656 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -147.12 -156.64 7.04 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 106.571 -2.612 . . . . 10.0 106.571 177.282 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -151.14 -159.35 8.79 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 118.442 1.121 . . . . 10.0 112.007 178.781 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -71.1 12.11 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 121.414 1.409 . . . . 10.0 109.466 165.724 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 37.5 mmtm -95.87 -24.78 16.28 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 108.009 -1.108 . . . . 10.0 108.009 169.704 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.426 ' OD1' ' NZ ' ' A' ' 128' ' ' LYS . 20.4 m-20 -115.56 171.27 7.83 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 107.965 -1.124 . . . . 10.0 107.965 -170.016 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -121.14 10.13 10.63 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.539 1.135 . . . . 10.0 110.279 171.394 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -109.16 6.47 24.85 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.515 1.126 . . . . 10.0 110.497 172.098 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ptp85 -47.3 148.27 1.33 Allowed 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.531 1.532 . . . . 10.0 110.263 178.058 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -60.78 -64.11 1.07 Allowed 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 117.842 0.292 . . . . 10.0 111.185 -176.168 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.8 p -167.89 -51.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.226 -0.165 0 C-N-CA 123.739 0.815 . . . . 10.0 109.266 174.552 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -136.51 47.96 0.94 Allowed Glycine 0 CA--C 1.526 0.741 0 C-N-CA 123.939 0.78 . . . . 10.0 111.327 -175.198 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -86.23 109.11 18.7 Favored 'General case' 0 CA--C 1.53 0.173 0 N-CA-C 105.068 -2.197 . . . . 10.0 105.068 168.395 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 54.3 mt -74.85 -14.57 60.69 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 118.607 0.639 . . . . 10.0 111.744 -170.94 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 108.61 -97.93 1.14 Allowed Glycine 0 N--CA 1.44 -1.048 0 N-CA-C 107.434 -2.267 . . . . 10.0 107.434 178.907 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -153.0 120.68 6.02 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.188 -1.412 . . . . 10.0 107.188 -172.317 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.1 m -102.53 147.27 9.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 N-CA-C 106.039 -1.838 . . . . 10.0 106.039 168.957 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -120.45 133.12 55.47 Favored 'General case' 0 C--N 1.334 -0.095 0 C-N-CA 123.426 0.69 . . . . 10.0 111.588 -173.358 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.75 132.75 48.69 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.244 1.018 . . . . 10.0 111.361 -175.025 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.04 172.74 0.53 Allowed 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 122.496 1.141 . . . . 10.0 110.319 167.778 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 mtmp? -63.15 -19.49 64.52 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 114.309 -1.314 . . . . 10.0 112.425 178.433 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -77.8 -20.31 53.47 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 122.35 0.26 . . . . 10.0 110.741 173.881 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.85 6.67 60.43 Favored Glycine 0 C--N 1.338 0.684 0 CA-C-O 118.749 -1.028 . . . . 10.0 110.685 -170.19 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 t -79.37 114.61 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 C-N-CA 125.502 1.521 . . . . 10.0 107.154 176.265 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.683 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -115.38 123.93 49.93 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.865 -0.791 . . . . 10.0 108.865 174.353 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -78.84 129.03 34.12 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.327 -0.99 . . . . 10.0 108.327 171.745 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 92.4 t -112.15 129.84 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 104.179 -2.526 . . . . 10.0 104.179 167.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.9 p -157.79 57.27 0.48 Allowed 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 123.025 0.53 . . . . 10.0 110.844 174.596 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.36 148.67 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 124.087 0.955 . . . . 10.0 109.024 -169.883 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -129.27 123.66 32.47 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.535 1.134 . . . . 10.0 110.243 174.253 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -127.61 107.15 9.67 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.823 1.649 . . . . 10.0 108.511 -177.653 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 45.2 p -85.22 58.54 5.09 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.823 2.049 . . . . 10.0 107.195 -171.294 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.3 p -142.07 -48.87 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 C-N-CA 123.996 0.919 . . . . 10.0 109.307 -176.273 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . 0.312 0.0 OUTLIER -79.91 174.65 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 N-CA-C 113.023 0.749 . . . . 10.0 113.023 174.933 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -167.88 155.0 8.17 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 124.994 1.318 . . . . 10.0 107.901 169.39 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 70.3 mt -62.29 -24.53 67.34 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 123.413 0.685 . . . . 10.0 111.214 -176.087 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.9 m -147.87 161.32 41.54 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.856 -1.905 . . . . 10.0 105.856 169.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 154.82 -74.57 0.24 Allowed Glycine 0 C--N 1.334 0.434 0 N-CA-C 109.925 -1.27 . . . . 10.0 109.925 -177.457 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -152.19 -53.69 0.12 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.768 2.027 . . . . 10.0 106.387 178.698 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -75.0 -38.6 61.54 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 114.069 -1.423 . . . . 10.0 108.507 -175.002 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.3 t 46.5 56.17 6.72 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.86 1.264 . . . . 10.0 110.309 169.401 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -66.77 6.92 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 N-CA-C 115.647 1.721 . . . . 10.0 115.647 -166.424 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.7 mm -57.41 142.02 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 108.077 -1.083 . . . . 10.0 108.077 167.103 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.95 19.21 79.77 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-O 118.916 -0.935 . . . . 10.0 114.033 175.129 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -79.81 175.87 10.24 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 106.779 -1.563 . . . . 10.0 106.779 166.035 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 16.5 m -111.64 131.92 54.94 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 103.302 -2.851 . . . . 10.0 103.302 169.467 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.422 HD12 ' HA ' ' A' ' 117' ' ' LEU . 0.5 OUTLIER -96.3 135.81 37.63 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 105.751 -1.944 . . . . 10.0 105.751 167.455 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.4 ' CG2' ' CD2' ' A' ' 48' ' ' HIS . 86.8 t -118.84 132.95 67.23 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.874 0 N-CA-C 105.27 -2.122 . . . . 10.0 105.27 169.148 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.5 p -104.07 127.51 58.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.75 -1.945 . . . . 10.0 105.75 168.028 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.599 ' HB2' ' HA3' ' A' ' 44' ' ' GLY . 7.4 m-70 -103.69 159.13 15.88 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 123.529 1.633 . . . . 10.0 114.946 -169.835 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.687 ' HA ' HD22 ' A' ' 144' ' ' LEU . 10.6 tt0 -43.71 -60.73 1.66 Allowed 'General case' 0 N--CA 1.442 -0.873 0 C-N-CA 129.079 2.951 . . . . 10.0 110.041 172.62 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 36.7 mtmm -115.93 175.4 5.56 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.912 1.285 . . . . 10.0 111.638 -171.897 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -78.57 149.54 32.99 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 125.938 1.695 . . . . 10.0 111.161 -176.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.527 ' CG ' ' HE2' ' A' ' 46' ' ' HIS . 1.9 m-20 -79.34 144.06 34.57 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.517 0.727 . . . . 10.0 112.567 175.502 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 m-20 -77.18 -35.55 55.74 Favored 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 124.781 1.301 . . . . 10.0 108.974 167.96 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 57.0 mt 66.55 48.8 1.43 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 125.439 1.496 . . . . 10.0 109.368 -167.689 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.83 50.21 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 125.243 1.402 . . . . 10.0 113.001 172.556 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.426 ' NZ ' ' OD1' ' A' ' 76' ' ' ASP . 18.1 mttm -78.82 -1.71 36.2 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.711 0.805 . . . . 10.0 111.273 -168.598 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -66.91 -26.58 73.2 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 109.087 -1.605 . . . . 10.0 109.087 166.387 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 56.32 39.25 82.1 Favored Glycine 0 C--N 1.341 0.856 0 N-CA-C 110.822 -0.911 . . . . 10.0 110.822 -179.544 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.9 m-80 -122.06 161.71 22.53 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 106.636 -1.616 . . . . 10.0 106.636 176.132 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.407 ' OE2' ' NZ ' ' A' ' 136' ' ' LYS . 3.8 tm-20 -48.72 -45.5 39.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 113.388 -1.733 . . . . 10.0 108.781 171.038 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -64.76 -49.7 69.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.167 -0.47 . . . . 10.0 111.714 172.217 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.7 t -52.97 -44.72 67.36 Favored 'General case' 0 N--CA 1.447 -0.586 0 O-C-N 120.552 -1.342 . . . . 10.0 110.65 -175.418 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.1 t -74.95 -5.98 46.8 Favored 'General case' 0 CA--C 1.538 0.492 0 O-C-N 123.186 0.304 . . . . 10.0 111.542 -174.955 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.407 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 87.9 mttt -102.83 -83.05 0.48 Allowed 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 126.578 1.951 . . . . 10.0 110.147 172.583 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.21 25.84 10.99 Favored 'General case' 0 C--N 1.345 0.391 0 CA-C-N 121.298 1.863 . . . . 10.0 112.988 -177.02 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 59.72 27.66 64.36 Favored Glycine 0 C--N 1.339 0.721 0 CA-C-N 118.942 0.792 . . . . 10.0 112.397 170.001 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.0 m-80 50.21 27.86 2.83 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 123.988 0.915 . . . . 10.0 112.689 -173.501 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.52 -3.85 9.85 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.527 -0.733 . . . . 10.0 112.243 179.694 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.35 -163.6 51.92 Favored Glycine 0 N--CA 1.443 -0.894 0 N-CA-C 110.866 -0.893 . . . . 10.0 110.866 169.192 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.8 m -56.98 142.22 42.58 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.5 0.667 . . . . 10.0 111.612 -169.248 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.0 mtp85 -68.9 64.79 0.12 Allowed 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 125.627 1.571 . . . . 10.0 109.681 175.357 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.687 HD22 ' HA ' ' A' ' 121' ' ' GLU . 11.9 tp -43.91 -35.11 1.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.669 1.988 . . . . 10.0 113.917 -174.537 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -162.53 159.06 24.37 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.627 -0.879 . . . . 10.0 108.627 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -162.16 168.15 22.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.731 -0.47 . . . . 10.0 109.731 -174.881 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.47 169.77 42.77 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 112.094 -0.402 . . . . 10.0 112.094 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.409 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 4.8 t -107.28 138.78 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.469 -1.678 . . . . 10.0 106.469 -171.304 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mt -80.11 136.58 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-N 118.0 0.364 . . . . 10.0 110.607 179.568 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -129.05 146.99 17.5 Favored Glycine 0 CA--C 1.53 0.984 0 C-N-CA 125.068 1.318 . . . . 10.0 110.81 176.977 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 10.8 pt -71.49 142.07 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.138 0 CA-C-N 117.82 0.81 . . . . 10.0 109.28 176.771 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -119.52 -19.71 8.05 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.282 1.433 . . . . 10.0 113.313 -176.372 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.9 tp60 . . . . . 0 C--O 1.254 1.298 0 C-N-CA 130.278 3.431 . . . . 10.0 117.278 -175.504 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 117.652 -1.166 . . . . 10.0 108.997 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 1.3 t -76.02 -37.35 58.51 Favored 'General case' 0 CA--C 1.516 -0.327 0 CA-C-N 120.217 1.371 . . . . 10.0 110.41 -178.767 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -124.54 136.44 53.99 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 123.377 0.671 . . . . 10.0 111.201 -171.561 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.36 165.5 28.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.146 1.378 . . . . 10.0 107.502 171.004 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.441 ' O ' HG23 ' B' ' 149' ' ' ILE . 7.9 m -128.32 -178.28 2.29 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 123.367 0.667 . . . . 10.0 110.114 178.904 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -151.39 110.97 4.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.774 1.23 . . . . 10.0 108.262 165.453 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.424 HG21 ' HB3' ' A' ' 53' ' ' ASN . 3.2 m -95.83 104.52 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 123.786 0.835 . . . . 10.0 109.615 170.633 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.413 HD12 ' N ' ' B' ' 8' ' ' LEU . 5.7 mp -95.06 135.57 36.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 124.026 0.93 . . . . 10.0 110.035 -177.947 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 43.2 mtpt -149.22 169.48 20.65 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 107.459 -1.312 . . . . 10.0 107.459 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.38 -72.6 0.04 OUTLIER Glycine 0 C--O 1.229 -0.201 0 CA-C-N 115.944 -0.571 . . . . 10.0 111.68 174.394 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -74.09 -41.29 61.91 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 107.15 -1.426 . . . . 10.0 107.15 -178.295 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 132.84 -65.92 0.58 Allowed Glycine 0 CA--C 1.526 0.759 0 C-N-CA 124.836 1.207 . . . . 10.0 110.498 -178.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -79.14 37.48 0.67 Allowed 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 124.874 3.716 . . . . 10.0 111.446 -175.282 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -148.74 108.11 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.534 0 N-CA-C 100.405 -3.924 . . . . 10.0 100.405 173.244 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.47 122.84 28.43 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 106.904 -1.517 . . . . 10.0 106.904 177.101 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.571 ' HA2' HG22 ' B' ' 35' ' ' ILE . . . -107.56 140.21 15.3 Favored Glycine 0 C--O 1.224 -0.508 0 N-CA-C 110.493 -1.043 . . . . 10.0 110.493 -179.745 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.406 ' CG2' HG22 ' A' ' 54' ' ' THR . 3.6 mt -139.98 88.75 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.148 -1.427 . . . . 10.0 107.148 -174.317 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 mp -100.23 146.52 8.92 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.13 0 C-N-CA 124.978 1.311 . . . . 10.0 111.288 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -123.99 121.3 34.91 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 127.056 2.142 . . . . 10.0 108.102 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -99.32 108.0 20.42 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 124.855 1.262 . . . . 10.0 107.999 171.761 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -105.13 139.08 40.34 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 119.039 0.836 . . . . 10.0 109.534 167.421 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -116.91 106.13 13.1 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.668 -1.604 . . . . 10.0 106.668 168.22 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt -152.19 79.13 1.24 Allowed 'General case' 0 N--CA 1.424 -1.731 0 C-N-CA 125.343 1.457 . . . . 10.0 108.926 -178.317 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -158.45 165.05 35.56 Favored 'General case' 0 N--CA 1.434 -1.265 0 N-CA-C 102.647 -3.094 . . . . 10.0 102.647 165.063 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 10.2 t -72.32 -18.3 61.78 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 121.372 0.606 . . . . 10.0 109.446 170.565 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 14.0 m-80 -79.95 -10.42 59.77 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.656 -0.498 . . . . 10.0 109.656 173.582 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 47.71 44.76 23.91 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-O 117.581 -1.677 . . . . 10.0 115.218 -178.64 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -73.86 140.76 29.31 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 122.527 2.151 . . . . 10.0 108.77 175.091 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.9 t -85.81 99.5 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 107.212 -1.403 . . . . 10.0 107.212 173.754 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 60.4 mttm -79.3 109.06 13.29 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.489 -1.3 . . . . 10.0 107.489 174.093 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.39 97.21 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 126.446 1.899 . . . . 10.0 107.392 -178.153 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.7 p90 -116.18 171.31 7.89 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.245 0.545 . . . . 10.0 110.144 169.715 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.26 -165.41 36.59 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 111.126 -0.789 . . . . 10.0 111.126 170.069 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 20.3 m -154.68 107.86 2.84 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 108.876 -0.787 . . . . 10.0 108.876 -170.832 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.571 HG22 ' HA2' ' B' ' 16' ' ' GLY . 6.9 pt -79.87 177.71 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 108.869 -0.789 . . . . 10.0 108.869 169.01 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 4.3 tptt -153.5 153.88 33.29 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 105.207 -2.146 . . . . 10.0 105.207 170.858 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.17 -38.94 2.67 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 118.51 0.595 . . . . 10.0 111.622 169.728 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.519 ' H ' HD12 ' B' ' 38' ' ' LEU . 6.0 mp -64.14 177.0 0.87 Allowed 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 122.034 0.921 . . . . 10.0 111.664 -170.031 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.9 t -103.58 162.05 13.38 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.617 -0.719 . . . . 10.0 109.186 168.731 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -52.32 153.48 2.87 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 125.584 1.553 . . . . 10.0 112.18 -169.456 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.81 -173.41 20.04 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 123.517 0.58 . . . . 10.0 111.858 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -74.64 151.25 39.34 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.937 1.295 . . . . 10.0 110.364 -177.665 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -150.18 151.86 33.74 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 123.634 0.774 . . . . 10.0 112.605 -178.392 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.583 ' HA3' ' HB2' ' B' ' 120' ' ' HIS . . . -44.75 127.18 7.09 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 127.259 2.362 . . . . 10.0 110.96 165.985 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -154.73 111.17 3.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 119.038 1.419 . . . . 10.0 108.862 165.771 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.404 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 0.0 OUTLIER -155.4 167.64 29.72 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-O 121.312 0.577 . . . . 10.0 111.466 179.285 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.0 m -86.51 149.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 112.504 -2.135 . . . . 10.0 106.563 168.014 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -117.57 164.01 15.58 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 123.014 0.526 . . . . 10.0 110.263 176.292 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -52.57 -54.41 33.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.162 0.985 . . . . 10.0 112.589 -176.025 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -106.54 -178.45 3.65 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 118.829 0.741 . . . . 10.0 109.381 178.219 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -139.47 13.41 3.22 Favored Glycine 0 C--N 1.333 0.382 0 O-C-N 122.109 -0.369 . . . . 10.0 113.461 176.093 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -67.13 153.31 43.98 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 107.276 -1.379 . . . . 10.0 107.276 167.188 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -149.13 22.53 0.96 Allowed 'General case' 0 N--CA 1.451 -0.421 0 O-C-N 121.649 -0.657 . . . . 10.0 112.189 -172.372 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.496 HG22 ' CG2' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -49.23 -38.42 26.46 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 126.758 2.023 . . . . 10.0 112.447 -177.489 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.2 -19.77 56.27 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 122.136 -0.353 . . . . 10.0 111.916 -178.278 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 125.9 -66.97 0.54 Allowed Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.309 -1.117 . . . . 10.0 110.309 -176.857 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 35.0 t -160.05 70.06 0.42 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 122.391 1.091 . . . . 10.0 110.625 -178.73 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -163.17 -50.73 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 125.282 1.433 . . . . 10.0 109.253 -174.235 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -48.8 -38.67 22.75 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 125.667 1.587 . . . . 10.0 111.447 -171.218 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -27.12 -41.54 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 128.662 2.785 . . . . 10.0 114.351 168.63 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.85 161.88 29.84 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 107.647 -2.181 . . . . 10.0 107.647 177.392 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -68.88 -143.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.547 1.132 0 C-N-CA 121.894 1.729 . . . . 10.0 109.615 169.783 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 26.6 m170 -104.17 42.91 1.14 Allowed 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.267 -1.52 . . . . 10.0 110.629 -179.665 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 22.5 m-85 -73.31 71.98 1.26 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 120.601 1.546 . . . . 10.0 111.32 -179.707 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -62.56 155.06 70.76 Favored Pre-proline 0 CA--C 1.538 0.499 0 C-N-CA 124.218 1.007 . . . . 10.0 111.614 169.837 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.62 -47.95 2.54 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.282 1.988 . . . . 10.0 111.361 176.838 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.85 68.33 1.29 Allowed 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.774 -0.579 . . . . 10.0 110.816 175.488 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 14.1 t -40.81 102.88 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.427 1.891 . . . . 10.0 111.782 -178.627 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.8 mtt85 -130.28 175.43 8.94 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 126.275 1.83 . . . . 10.0 108.863 177.07 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 62.0 mmtt -106.19 84.11 1.99 Allowed 'General case' 0 CA--C 1.531 0.227 0 CA-C-O 121.457 0.646 . . . . 10.0 112.473 -170.887 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 54.2 t60 13.79 88.39 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 127.433 2.293 . . . . 10.0 115.594 174.044 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -121.27 -164.6 12.37 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 126.985 2.231 . . . . 10.0 109.004 178.627 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.59 -154.88 15.24 Favored Glycine 0 C--O 1.227 -0.304 0 N-CA-C 106.973 -2.451 . . . . 10.0 106.973 -172.357 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -64.13 9.56 0.14 Allowed 'Trans proline' 0 CA--C 1.542 0.915 0 CA-C-N 120.119 1.96 . . . . 10.0 112.414 169.095 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -100.65 -31.33 11.27 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.738 1.215 . . . . 10.0 111.209 170.249 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -141.46 154.9 45.83 Favored 'General case' 0 C--N 1.347 0.459 0 CA-C-N 119.277 0.944 . . . . 10.0 110.445 -170.197 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 49.2 tt0 -75.87 -20.54 58.01 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.053 -1.091 . . . . 10.0 108.053 178.906 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -80.38 30.93 0.28 Allowed 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.741 1.216 . . . . 10.0 112.096 -178.384 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -57.52 138.77 54.79 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.111 -0.993 . . . . 10.0 109.135 171.221 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -74.72 -61.03 2.02 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 108.166 -1.05 . . . . 10.0 108.166 179.776 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -156.42 -125.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 105.863 -1.903 . . . . 10.0 105.863 -174.444 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -74.4 69.96 1.66 Allowed Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.357 -1.097 . . . . 10.0 110.357 175.891 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -95.94 93.25 6.91 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 106.947 -1.501 . . . . 10.0 106.947 170.209 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.3 mt -65.19 -29.69 70.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.895 0.855 . . . . 10.0 108.987 178.814 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 104.87 -79.8 0.29 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.195 -1.562 . . . . 10.0 109.195 169.284 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . 0.484 HD22 ' HB1' ' B' ' 123' ' ' ALA . 23.6 m120 -144.17 108.07 4.71 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 118.185 -0.912 . . . . 10.0 108.627 -173.366 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.9 m -105.63 130.76 56.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-N 119.677 1.126 . . . . 10.0 111.924 -179.029 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.5 m -90.48 123.02 33.83 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 128.804 2.841 . . . . 10.0 111.269 -169.973 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.39 137.88 42.48 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 124.118 0.967 . . . . 10.0 111.411 177.198 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -62.08 171.65 1.69 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 124.325 1.05 . . . . 10.0 109.458 166.46 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.68 -28.96 58.38 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.554 0.742 . . . . 10.0 111.781 173.245 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -78.27 -3.94 45.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.336 0.588 . . . . 10.0 110.192 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.85 -0.63 82.61 Favored Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 110.257 -1.137 . . . . 10.0 110.257 -177.491 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 52.7 t -78.83 101.28 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 107.267 -1.383 . . . . 10.0 107.267 -173.154 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.49 117.19 30.39 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.45 -0.944 . . . . 10.0 108.45 168.392 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -80.37 106.84 12.69 Favored 'General case' 0 N--CA 1.435 -1.199 0 C-N-CA 126.814 2.046 . . . . 10.0 109.364 172.428 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 95.8 t -96.3 134.48 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.876 0 N-CA-C 106.964 -1.495 . . . . 10.0 106.964 178.626 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -158.22 79.09 0.82 Allowed 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.382 0.673 . . . . 10.0 111.502 172.67 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.8 mp -122.3 164.58 19.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 106.064 -1.828 . . . . 10.0 106.064 -179.419 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -138.1 145.0 41.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 121.469 -0.77 . . . . 10.0 111.498 168.743 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -109.62 104.15 13.12 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 125.769 1.628 . . . . 10.0 107.74 178.703 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 67.8 p -86.25 52.75 2.57 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 106.855 -1.535 . . . . 10.0 106.855 172.984 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 p -157.77 -49.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 C-N-CA 123.464 0.706 . . . . 10.0 109.325 -174.431 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 48.7 mm -66.58 155.46 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 108.704 -0.851 . . . . 10.0 108.704 169.845 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 41.3 m -153.13 137.35 16.51 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.232 -1.025 . . . . 10.0 108.232 174.455 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 34.5 mt -73.57 53.05 0.41 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.833 1.653 . . . . 10.0 111.459 177.28 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.6 m -87.16 -165.24 1.24 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 127.942 2.497 . . . . 10.0 109.896 179.277 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -106.2 -25.61 6.33 Favored Glycine 0 CA--C 1.527 0.82 0 C-N-CA 125.093 1.33 . . . . 10.0 111.725 176.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -70.15 -56.98 5.48 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 126.029 1.731 . . . . 10.0 108.31 -175.03 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -87.02 -39.32 15.76 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.176 -1.375 . . . . 10.0 109.174 178.126 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 31.81 79.76 0.02 OUTLIER 'General case' 0 C--O 1.237 0.402 0 C-N-CA 126.223 1.809 . . . . 10.0 113.079 178.969 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.458 HD13 ' H ' ' B' ' 112' ' ' ILE . 0.1 OUTLIER -76.79 55.5 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-O 122.183 0.992 . . . . 10.0 109.518 167.439 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.7 mm -117.75 -49.08 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 127.969 2.508 . . . . 10.0 108.295 178.659 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.04 10.25 71.47 Favored Glycine 0 CA--C 1.532 1.142 0 CA-C-O 119.193 -0.782 . . . . 10.0 112.794 -176.76 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -88.29 162.24 16.72 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 125.484 1.514 . . . . 10.0 108.892 178.678 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 1.3 m -103.84 140.24 37.92 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.505 0.722 . . . . 10.0 109.898 169.568 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.465 HD23 HG12 ' B' ' 149' ' ' ILE . 4.5 mm? -92.3 140.18 29.87 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 106.169 -1.789 . . . . 10.0 106.169 166.748 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 60.4 t -125.94 135.5 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.851 0 N-CA-C 107.563 -1.273 . . . . 10.0 107.563 174.736 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 8.6 p -105.39 129.68 57.88 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 106.216 -1.772 . . . . 10.0 106.216 169.109 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.583 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 3.5 m170 -113.31 157.75 21.42 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 115.13 1.53 . . . . 10.0 115.13 -169.362 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 58.3 tt0 -39.36 -63.24 0.57 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 128.518 2.727 . . . . 10.0 110.288 171.082 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 57.6 mttt -118.86 173.24 6.99 Favored 'General case' 0 CA--C 1.513 -0.461 0 C-N-CA 123.492 0.717 . . . . 10.0 109.685 -174.687 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . 0.484 ' HB1' HD22 ' B' ' 86' ' ' ASN . . . -92.41 148.78 21.84 Favored 'General case' 0 N--CA 1.444 -0.768 0 N-CA-C 108.16 -1.052 . . . . 10.0 108.16 179.309 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.643 ' HB2' ' CD2' ' B' ' 126' ' ' LEU . 0.9 OUTLIER -74.69 160.97 30.1 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.253 0.549 . . . . 10.0 111.675 -174.974 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.39 -28.53 61.14 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 114.624 -1.171 . . . . 10.0 110.152 174.855 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.643 ' CD2' ' HB2' ' B' ' 124' ' ' ASP . 2.8 mm? 62.57 56.95 1.93 Allowed 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 125.585 1.554 . . . . 10.0 109.847 -173.437 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 81.54 -40.57 2.61 Favored Glycine 0 CA--C 1.525 0.687 0 CA-C-N 113.971 -1.468 . . . . 10.0 111.78 168.115 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -77.13 49.29 0.67 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.048 1.339 . . . . 10.0 111.173 177.35 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -102.72 -32.67 4.69 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 126.226 1.869 . . . . 10.0 110.427 173.614 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 60.58 42.76 99.31 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.673 -0.971 . . . . 10.0 110.673 -171.761 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -132.76 163.35 29.21 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 106.607 -1.627 . . . . 10.0 106.607 173.338 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.57 -52.31 64.17 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 108.46 -0.941 . . . . 10.0 108.46 171.625 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -53.7 -33.54 55.85 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-O 118.216 -0.897 . . . . 10.0 112.416 175.516 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 21.0 p -52.15 -41.81 62.86 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-N 119.497 1.044 . . . . 10.0 110.649 179.21 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -85.01 -3.48 58.8 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-O 118.517 -0.754 . . . . 10.0 112.914 -178.97 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.95 -60.74 1.81 Allowed 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 126.291 1.836 . . . . 10.0 112.501 -174.223 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.6 p -136.25 23.77 3.24 Favored 'General case' 0 CA--C 1.547 0.827 0 CA-C-N 119.488 1.04 . . . . 10.0 110.483 175.447 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 70.16 -98.03 0.62 Allowed Glycine 0 C--N 1.342 0.91 0 N-CA-C 108.764 -1.734 . . . . 10.0 108.764 -177.461 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -165.34 43.57 0.08 Allowed 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 107.872 -1.158 . . . . 10.0 107.872 170.481 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.61 -19.69 64.01 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.396 0.678 . . . . 10.0 112.565 -174.13 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.01 -147.42 30.47 Favored Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 109.94 -1.264 . . . . 10.0 109.94 172.344 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.8 t -68.61 126.81 30.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-O 121.559 0.695 . . . . 10.0 110.64 -170.023 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.06 78.32 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.845 0.858 . . . . 10.0 110.604 169.502 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 56.5 mt -52.49 -40.17 62.05 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.922 -0.486 . . . . 10.0 112.11 179.331 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -149.13 145.65 27.3 Favored 'General case' 0 C--O 1.233 0.236 0 O-C-N 121.628 -0.67 . . . . 10.0 111.676 -179.574 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 m -123.72 147.9 47.06 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 126.686 1.995 . . . . 10.0 108.034 -178.224 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -143.61 141.95 10.82 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 109.761 -1.336 . . . . 10.0 109.761 171.598 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.409 ' HB ' ' HB ' ' A' ' 148' ' ' VAL . 95.8 t -89.8 150.57 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 102.894 -3.002 . . . . 10.0 102.894 172.646 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.465 HG12 HD23 ' B' ' 117' ' ' LEU . 90.4 mt -72.16 -88.03 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-O 121.474 0.654 . . . . 10.0 110.26 -167.566 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . 99.87 132.69 7.82 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 124.329 0.966 . . . . 10.0 111.529 177.69 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 73.6 mt -63.31 147.75 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 125.155 1.382 . . . . 10.0 107.75 174.307 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.73 -32.81 4.43 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 113.466 0.913 . . . . 10.0 113.466 174.121 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . 0.412 HE21 ' C ' ' B' ' 153' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.898 0 N-CA-C 108.042 -1.096 . . . . 10.0 108.042 178.66 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' B' B ' 154' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' B' B ' 155' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_